FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Teping, F
   Fischer, G
   Huelser, M
   Sippl, C
   Linsler, S
   Knosp, E
   Wadiura, L
   Oertel, J
AF Teping, Fritz
   Fischer, Gerrit
   Huelser, Matthias
   Sippl, Christoph
   Linsler, Stefan
   Knosp, Engelbert
   Wadiura, Lisa
   Oertel, Joachim
TI A New Clip Generation for Microsurgical Treatment of Intracranial
   Aneurysms-The First Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm clip; Clipping; D-Clip; Intracranial aneurysm; Lazic;
   Neurovascular surgery
ID ASSISTED BRAIN SURGERY; TRIAL ISAT; SYSTEM
AB OBJECTIVE: Considerable effort has been made in order to reduce surgical invasiveness while maintaining optimal exploiting of the operative space in aneurysm surgery. One aspect of this evolution is represented by the Lazic (Peter Lazic GmbH, Tuttlingen, Germany) aneurysm clip system. The purpose of this study was to illustrate the new generation clip system in practiced aneurysm surgery.
   METHODS: A retrospective analysis of all aneurysm surgeries in our departments between December 2015 and January 2018 using the new D-Clip system was performed. Evaluation included standardized retrospective review of the main surgeon, the nursing staff, as well as an analysis of surgical video documentation by objective reviewers.
   RESULTS: Forty-five patients with 50 intracranial aneurysms underwent surgical clipping using the D-Clip system. A total of 64 permanent and 19 temporary D-Clips were applied. Nine clips needed to be replaced. All aneurysms could be occluded totally. Surgeons considered handling and manoeuvrability of clip application as feasible and good in all cases (100%), even under impaired visibility circumstances (14%). Objective video analysis revealed comparable results. Nursing staff scored handling and practicability of D-Clips equivalent to the preceding L-Clip generation. There were no intra-operative complications. Surgery-related postoperative morbidity was 6.7%.
   CONCLUSIONS: The new D-Clip system combines an attenuated design for minimally invasive clipping procedures with traditional mechanisms of common clip systems. It therefore appears to be highly versatile in the context of variable different aneurysm morphologies and locations while maintaining high standard surgical safety and efficacy.
C1 [Teping, Fritz; Fischer, Gerrit; Huelser, Matthias; Sippl, Christoph; Linsler, Stefan; Oertel, Joachim] Saarland Univ, Med Ctr, Dept Neurosurg, Homburg, Germany.
   [Knosp, Engelbert; Wadiura, Lisa] Med Univ Vienna, Dept Neurosurg, Vienna, Austria.
RP Fischer, G (reprint author), Saarland Univ, Med Ctr, Dept Neurosurg, Homburg, Germany.
EM gerrit.fischer@gmx.de
CR Brown MA, 2017, J NEUROSURG, V126, P819, DOI 10.3171/2016.2.JNS152059
   Fischer G, 2012, NEUROSURGERY, V70, P184, DOI 10.1227/NEU.0b013e3182376a36
   Fischer G, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820934ca
   Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008
   Gnanalingham KK, 2006, CLIN NEUROL NEUROSUR, V108, P117, DOI 10.1016/j.clineuro.2005.11.001
   He L, 2016, WORLD NEUROSURG, V96, P454, DOI 10.1016/j.wneu.2016.09.053
   Krammer MJ, 2010, NEUROSURGERY, V66, pONSE336, DOI 10.1227/01.NEU.0000369644.26132.56
   Linsler S, 2017, WORLD NEUROSURG, V104, P601, DOI 10.1016/j.wneu.2017.05.023
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Perneczky A, 1998, NEUROL MED-CHIR, V38, P33, DOI 10.2176/nmc.38.suppl_33
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Reisch R, 2014, WORLD NEUROSURG, V82, pS130, DOI 10.1016/j.wneu.2014.07.038
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
NR 18
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E160
EP E165
DI 10.1016/j.wneu.2019.06.023
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200021
PM 31203069
DA 2020-05-12
ER

PT J
AU Tobin, MK
   Gragnaniello, C
   Sun, FW
   Rangwala, SD
   Birk, DM
   Neckrysh, S
AF Tobin, Matthew K.
   Gragnaniello, Cristian
   Sun, Felicia Wang
   Rangwala, Shivani D.
   Birk, Daniel M.
   Neckrysh, Sergey
TI Safety and Efficacy of Skipping C7 Instrumentation in Posterior
   Cervicothoracic Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Posterior spinal fusion; Spinal instrumentation; Spine
   surgery; Surgical approach; Surgical outcome; Thoracic spine
ID CERVICAL-SPINE SURGERY; CLINICAL-IMPLICATIONS; EARLY COMPLICATIONS;
   FIXATION
AB OBJECTIVE: To analyze the safety and efficacy of skipping instrumentation at the C7 vertebra during posterior cervicothoracic fusions.
   METHODS: This is a retrospective chart review of 53 patients who underwent multilevel posterior cervical fusion between 2010 and 2015. of 53 patients, 7 patients were instrumented at C7, serving as the control group, whereas the remaining 46 patients were not. Evaluation of efficacy was based on intraoperative complications, operative time, estimated blood loss, significant long-term complications, and radiographic evidence of fusion.
   RESULTS: Skipping the C7 level resulted in a significant reduction in estimated blood loss (321 +/- 214 mL in the C7 bridge group vs. 531 +/- 365 mL in the control group) and an insignificant, but decreased, reduction in operative time (155 +/- 70 minutes in the C7 bridge group vs. 194 +/- 66 minutes in the control group). Two intraoperative complications were noted in the C7 group, and 1 intraoperative complication was noted in the control group. In addition, patients skipped at C7 maintained sagittal balance with fusion rates similar to control patients at follow-up. No significant long-term complications were found in both groups.
   CONCLUSIONS: Skipping C7 in a multilevel posterior cervicothoracic fusion demonstrates significantly reduced estimated blood loss and faster operative times compared with the control group. In addition, postoperative assessment yielded similar rates of fusion in both groups. Serious negative outcomes of skipping C7 were not found in this retrospective study. Our study results illustrate the clinical benefits of skipping instrumentation at C7 to minimize surgical risk in patients undergoing posterior cervical fusion across the cervicothoracic junction.
C1 [Tobin, Matthew K.; Gragnaniello, Cristian; Sun, Felicia Wang; Rangwala, Shivani D.; Birk, Daniel M.; Neckrysh, Sergey] Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA.
RP Neckrysh, S (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA.
EM neckrysh@uic.edu
CR Bayoumi AB, 2018, WORLD NEUROSURG, V111, P216, DOI 10.1016/j.wneu.2017.12.026
   Bhatia NN., 2009, SEMIN SPINE SURG, V21, P177
   Campbell PG, 2010, WORLD NEUROSURG, V74, P363, DOI 10.1016/j.wneu.2010.05.034
   Deen HG, 2006, NEUROSURGERY, V59, P1062, DOI 10.1227/01.NEU.0000245592.54204.D0
   Denaro L, 2010, PITFALLS IN CERVICAL SPINE SURGERY: AVOIDANCE AND MANAGEMENT OF COMPLICATIONS, P109, DOI 10.1007/978-3-540-85019-9_9
   Keskin F, 2015, J CRANIOVERTEBRAL JU, V6, P30, DOI 10.4103/0974-8237.151590
   Memtsoudis SG, 2011, CLIN ORTHOP RELAT R, V469, P649, DOI 10.1007/s11999-010-1549-4
   Nagashima K, 2019, J CLIN NEUROSCI, V63, P106, DOI 10.1016/j.jocn.2019.01.029
   Oglesby M, 2013, SPINE, V38, P1226, DOI 10.1097/BRS.0b013e31828be75d
   Peng CW, 2009, SPINE J, V9, P70, DOI 10.1016/j.spinee.2008.03.006
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Shamji MF, 2009, SPINE J, V9, P31, DOI 10.1016/j.spinee.2008.07.005
   Tatsumi RL, 2007, SPINE, V32, P1072, DOI 10.1097/01.brs.0000261490.90956.2b
   Tetreault L, 2016, NEUROSURGERY, V79, P33, DOI 10.1227/NEU.0000000000001151
   Wang MC, 2007, SPINE, V32, P342, DOI 10.1097/01.brs.0000254120.25411.ae
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E68
EP E73
DI 10.1016/j.wneu.2019.05.201
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200009
PM 31154099
DA 2020-05-12
ER

PT J
AU Tokunaga, K
   Hatano, T
   Nakahara, I
   Ishii, A
   Higashi, E
   Kamata, T
   Funakoshi, Y
   Hashikawa, T
   Takita, W
   Chihara, H
   Ando, M
   Sadamasa, N
   Kitazono, T
   Nagata, I
AF Tokunaga, Keisuke
   Hatano, Taketo
   Nakahara, Ichiro
   Ishii, Akira
   Higashi, Eiji
   Kamata, Takahiko
   Funakoshi, Yusuke
   Hashikawa, Takuro
   Takita, Wataru
   Chihara, Hideo
   Ando, Mitsushige
   Sadamasa, Nobutake
   Kitazono, Takanari
   Nagata, Izumi
TI Factors Associated with Postprocedural Diffusion-Weighted
   Imaging-Positive Lesions in Endovascular Treatment for Unruptured
   Cerebral Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Diffusion-weighted imaging; Endovascular treatment
ID DETACHABLE COIL EMBOLIZATION; INTRACRANIAL ANEURYSMS; ARTERY ANEURYSMS;
   SILENT EMBOLISM; FLOW DIVERSION; COMPLICATIONS; PIPELINE; RESISTANCE;
   MRI
AB BACKGROUND: In endovascular treatment for cerebral aneurysms, the appearance of asymptomatic thromboembolic lesions detected by postprocedural diffusion-weighted imaging (DWI) can be a surrogate marker for estimating the potential risk of symptomatic thromboembolism. The aim of this study was to clarify factors associated with postprocedural DWI-positive lesions in endovascular treatment for unruptured cerebral aneurysms.
   METHODS: Patients with untreated unruptured cerebral aneurysms undergoing endovascular treatment were consecutively enrolled. Treatment techniques were classified into simple coiling, balloon-assisted coiling, stent-assisted coiling, and flow-diverter placement. Head magnetic resonance imaging was performed within 3 months before and 24 hours after the procedure to assess the appearance of DWI-positive lesions.
   RESULTS: Among 376 aneurysms in 355 patients that were analyzed, 232 (61.7%) had postprocedural DWI-positive lesions. In univariate analyses, age (P = 0.001), dome size (P < 0.001), neck size (P < 0.001), treatment technique (P = 0.029), and total procedural time (P < 0.001) were significantly associated with postprocedural DWI-positive lesions. In the multiple logistic regression model, older age (odds ratio, 1.33; 95% confidence interval, 1.10-1.60; P = 0.003; per decade), flow-diverter placement (odds ratio, 4.93; 95% confidence interval, 1.33-20.92; P = 0.016; compared with simple coiling), and longer procedural time (odds ratio, 1.66; 95% confidence interval, 1.26-2.21; P < 0.001; per hour) were associated with postprocedural DWI-positive lesions.
   CONCLUSIONS: Older age, flow-diverter placement, and longer procedural time were associated with postprocedural DWI-positive lesions in endovascular treatment for unruptured cerebral aneurysms.
C1 [Tokunaga, Keisuke; Hatano, Taketo; Higashi, Eiji; Kamata, Takahiko; Funakoshi, Yusuke; Hashikawa, Takuro; Takita, Wataru; Chihara, Hideo; Ando, Mitsushige; Sadamasa, Nobutake; Nagata, Izumi] Kokura Mem Hosp, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
   [Nakahara, Ichiro] Fujita Hlth Univ, Sch Med, Dept Comprehens Strokol, Toyoake, Aichi, Japan.
   [Ishii, Akira] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan.
   [Kitazono, Takanari] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan.
RP Tokunaga, K (reprint author), Kokura Mem Hosp, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
EM keisuketokunaga@hotmail.co.jp
OI Tokunaga, Keisuke/0000-0002-0701-3635; Higashi,
   Eiji/0000-0002-3461-9149; Chihara, Hideo/0000-0001-8767-6617
CR Albayram S, 2004, AM J NEURORADIOL, V25, P1768
   Altay T, 2011, J NEUROINTERV SURG, V3, P147, DOI 10.1136/jnis.2010.003616
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Bendszus M, 1999, LANCET, V354, P1594, DOI 10.1016/S0140-6736(99)07083-X
   Biondi A, 2000, AM J NEURORADIOL, V21, P957
   Bond KM, 2017, AM J NEURORADIOL, V38, P304, DOI 10.3174/ajnr.A4989
   Brooks NP, 2008, J NEUROSURG, V108, P1095, DOI 10.3171/JNS/2008/108/6/1095
   Cronqvist M, 2005, NEURORADIOLOGY, V47, P855, DOI 10.1007/s00234-005-1408-2
   Fischer S, 2014, NEUROSURGERY, V75, P364, DOI 10.1227/NEU.0000000000000431
   Grunwald IQ, 2006, NEUROSURGERY, V58, P612, DOI 10.1227/01.NEU.0000204101.00996.D9
   Hahnemann ML, 2014, J NEUROINTERV SURG, V6, P461, DOI 10.1136/neurintsurg-2013-010820
   Iosif C, 2018, J NEUROSURG, V128, P982, DOI 10.3171/2016.11.JNS161020
   Ishibashi T, 2009, STROKE, V40, P313, DOI 10.1161/STROKEAHA.108.521674
   Kang DH, 2013, STROKE, V44, P789, DOI 10.1161/STROKEAHA.112.669853
   Kim B, 2014, AM J NEURORADIOL, V35, P1786, DOI 10.3174/ajnr.A3955
   Kim MS, 2016, AM J NEURORADIOL, V37, P1099, DOI 10.3174/ajnr.A4777
   Park JC, 2016, J NEUROSURG, V124, P777, DOI 10.3171/2015.3.JNS142835
   Rahme RJ, 2014, NEUROL RES, V36, P383, DOI 10.1179/1743132814Y.0000000317
   Rordorf G, 2001, AM J NEURORADIOL, V22, P5
   Seino Y, 2010, J DIABETES INVEST, V1, P1, DOI 10.1111/j.2040-1124.2010.00005.x
   Soeda A, 2003, AM J NEURORADIOL, V24, P2035
   Soeda A, 2003, AM J NEURORADIOL, V24, P127
   Topcuoglu OM, 2016, WORLD NEUROSURG, V87, P317, DOI 10.1016/j.wneu.2015.11.073
   Vendrell JF, 2013, EUR J RADIOL, V82, P671, DOI 10.1016/j.ejrad.2012.11.030
   Yavuz K, 2014, AM J NEURORADIOL, V35, P529, DOI 10.3174/ajnr.A3692
   Zanaty M, 2014, NEURORADIOLOGY, V56, P381, DOI 10.1007/s00234-014-1339-x
NR 26
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E457
EP E462
DI 10.1016/j.wneu.2019.06.114
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200057
PM 31247348
DA 2020-05-12
ER

PT J
AU Tomatis, A
   Trevisi, G
   Boido, B
   Perez, R
   Benech, CA
AF Tomatis, Alberto
   Trevisi, Gianluca
   Boido, Beatrice
   Perez, Rosa
   Benech, Carlo Alberto
TI Surgical Outcomes and Their Correlation with Increasing Surgical
   Experience in a Series of 250 Ruptured or Unruptured Aneurysms
   Undergoing Microsurgical Clipping
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Intracranial aneurysm; Learning curve;
   Subarachnoid hemorrhage; Surgical clipping; Surgical experience;
   Unruptured aneurysm
ID INTRACRANIAL ANEURYSMS; ENDOVASCULAR COILING; SACCULAR ANEURYSMS;
   CEREBRAL ANEURYSM; NATURAL-HISTORY; MANAGEMENT; SAFETY; TRIAL
AB BACKGROUND: The development of endovascular techniques has offered extraordinary therapeutic opportunities to treat intracranial aneurysms. However, mainly for anterior circulation aneurysms, no clear superiority of these techniques compared with microsurgical clipping has been shown in terms of morbidity, mortality, aneurysm occlusion rate, and long-term protection from recanalization and rebleeding. We reviewed the data from a retrospective case series to determine the clinical and radiological outcomes of clipped ruptured and unruptured aneurysm to analyze the relationship between increasing surgical experience and operative time, recovery time, and clinical outcomes.
   METHODS: A total of 250 consecutive aneurysms in 221 patients had been treated from June 2009 to June 2015. The postoperative complications, recovery time (only for the unruptured group), operative time, clinical outcomes, and aneurysm occlusion rate at 3 months were analyzed for both ruptured and unruptured aneurysms. Linear regression was used to analyze the relationship between surgical experience and the operative time, recovery time, and clinical outcomes.
   RESULTS: The complication rate was very low in the unruptured cases (117 patients), with 100% of patients in good clinical status at 3 months. In the ruptured cases (104 patients), the presenting neurological status significantly influenced the postoperative outcomes. Complete obliteration found on the 3-month digital subtraction angiogram was obtained for 96.6% of the treated aneurysms in both groups. A significant correlation was found between surgical experience and both the operative time and recovery time.
   CONCLUSIONS: In a subset of patients (aneurysm located in the anterior circulation and <12 mm), microsurgical clipping appeared to be as safe as endovascular treatment and can obtain a very high complete occlusion rate. Increasing surgical experience improved the operative time and recovery time, with a trend toward improvement of the clinical outcomes.
C1 [Tomatis, Alberto; Trevisi, Gianluca] Osped Spirito Santo, Neurosurg Unit, Pescara, Italy.
   [Boido, Beatrice; Perez, Rosa; Benech, Carlo Alberto] Clin Fornaca Sessant, Dept Neurosurg, Turin, Italy.
RP Tomatis, A (reprint author), Osped Spirito Santo, Neurosurg Unit, Pescara, Italy.
EM albertotommy.tomatis@gmail.com
CR Akiyama Y, 2010, CEREBROVASC DIS, V30, P491, DOI 10.1159/000317087
   Alreshidi M, 2018, NEUROSURGERY, V83, P879, DOI 10.1093/neuros/nyx623
   Bekelis K, 2016, J NEUROINTERV SURG, V8, P913, DOI 10.1136/neurintsurg-2015-011890
   Bekelis K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137946
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Bruneau M, 2016, NEUROSURGERY, V78, P47, DOI 10.1227/NEU.0000000000000991
   Crobeddu E, 2013, AM J NEURORADIOL, V34, P266, DOI 10.3174/ajnr.A3032
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   Ferns SP, 2009, STROKE, V40, pE523, DOI 10.1161/STROKEAHA.109.553099
   Hsu CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151805
   Jo KI, 2015, NEUROSURG REV, V38, P677, DOI 10.1007/s10143-015-0642-2
   Johnston SC, 2008, STROKE, V39, P120, DOI 10.1161/STROKEAHA.107.495747
   Komotar RJ, 2008, NEUROSURGERY, V62, P183, DOI 10.1227/01.NEU.0000311076.64109.2E
   Komotar RJ, 2008, NEUROSURGERY, V62, P93
   Korja M, 2014, STROKE, V45, P1958, DOI 10.1161/STROKEAHA.114.005318
   Kosty JA, 2019, BRIT J NEUROSURG, V33, P322, DOI 10.1080/02688697.2018.1527286
   Lawton MT, 2005, NEUROSURGERY, V57, P9, DOI 10.1227/01.NEU.0000163082.20941.EF
   Matano F, 2016, WORLD NEUROSURG, V85, P169, DOI 10.1016/j.wneu.2015.08.068
   MCCORMICK WF, 1970, J NEUROSURG, V33, P422, DOI 10.3171/jns.1970.33.4.0422
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Nanda A, 2017, WORLD NEUROSURG, V100, P85, DOI 10.1016/j.wneu.2016.12.099
   Nussbaum ES, 2007, SURG NEUROL, V67, P457, DOI 10.1016/j.surneu.2006.08.069
   O'Neill AH, 2017, J NEUROINTERV SURG, V9, P761, DOI 10.1136/neurintsurg-2016-012629
   Petr O, 2015, ACTA NEUROCHIR, V157, P1623, DOI 10.1007/s00701-015-2500-y
   Ruan CH, 2015, BRIT J NEUROSURG, V29, P485, DOI 10.3109/02688697.2015.1023771
   Shigematsu T, 2013, STROKE, V44, P2735, DOI 10.1161/STROKEAHA.111.000609
   Song J, 2015, ACTA NEUROCHIR, V157, P1303, DOI 10.1007/s00701-015-2460-2
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   Spetzler RF, 2018, J NEUROSURG, V128, P120, DOI 10.3171/2016.9.JNS161301
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   van Lindert EJ, 2001, SURG NEUROL, V56, P151, DOI 10.1016/S0090-3019(01)00547-X
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   White PM, 2011, LANCET, V377, P1655, DOI 10.1016/S0140-6736(11)60408-X
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E542
EP E550
DI 10.1016/j.wneu.2019.06.150
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200067
PM 31254710
DA 2020-05-12
ER

PT J
AU Torres, YC
   Alves-Leon, SV
   Lima, MA
AF Torres, Yasmine C.
   Alves-Leon, Soniza V.
   Lima, Marco A.
TI Frequency of Pseudotumoral Central Nervous System Lesions in an Oncology
   Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Demyelinating; Tumefactive
ID BRAIN-TUMORS; DIAGNOSIS
AB BACKGROUND: Brain tumors are frequent in clinical practice and associated with high morbidity and mortality. However, many diseases can present as tumefactive lesions and mimic neoplastic lesions. We aimed to determine the frequency of pseudotumoral central nervous system lesions referred to an oncology center and the frequency of the tumor mimickers.
   METHODS: This was a retrospective study at the National Institute of Cancer, Rio de Janeiro, Brazil. Medical charts of patients admitted to the Neurosurgery and Pediatrics services from 2007 to 2011 were reviewed. Clinical and radiologic features of cases initially diagnosed with primary central nervous system tumors but received a final diagnosis of pseudotumoral disease were recorded.
   RESULTS: Among 891 patients referred as primary brain tumors, 38 cases had pseudotumoral lesions (4.3%). Most were adults (63%), with mean age of 29.4 years, and women (60.5%). Most frequent symptoms were headache (28.9%), motor signs (23.7%), and seizures (15.8%). Mean time from initial symptoms to diagnosis was 12.2 months. Lesions were single in 84.2% of patients, had contrast enhancement in 45.6%, and surrounding edema in 17.4%. Twenty patients (52,6%) underwent biopsy. Systemic autoimmune diseases were the most frequent etiologies (28.9%), followed by idiopathic inflammatory demyelinating diseases, infections, and vascular abnormalities (15.8% each). Good outcome with no major deficits was observed in 60.5% cases.
   CONCLUSIONS: The frequency of pseudotumoral lesions in an oncology reference center was low. Young women were most affected, and lesions were associated more frequently with systemic autoimmune diseases. Prompt recognition is important to avoid unnecessary treatment, because most patients had a good outcome.
C1 [Torres, Yasmine C.] Inst Nacl Canc, Rio De Janeiro, Brazil.
   [Alves-Leon, Soniza V.] Univv Fed Estado Rio jAiro;, Rio De Janeiro, Brazil.
   [Alves-Leon, Soniza V.; Lima, Marco A.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Lima, Marco A.] Fundacao Oswaldo Cruz Rio, Rio De Janeiro, Brazil.
RP Lima, MA (reprint author), Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
EM masdlima@gmail.com
CR Al-Okaili RN, 2007, RADIOLOGY, V243, P539, DOI 10.1148/radiol.2432060493
   Al-Okaili RN, 2006, RADIOGRAPHICS, V26, pS173, DOI 10.1148/rg.26si065513
   [Anonymous], 1999, J Natl Cancer Inst, V91, P1535
   Arismendi-Morillo GJ, 2004, REV NEUROLOGIA, V38, P427
   Bradley David, 2013, Pract Neurol, V13, P359, DOI 10.1136/practneurol-2013-000652
   Coffey KC, 2012, CLIN PEDIATR, V51, P1115, DOI 10.1177/0009922812448955
   Cunliffe CH, 2009, ARCH PATHOL LAB MED, V133, P101, DOI 10.1043/1543-2165-133.1.101
   Dagher AP, 1996, NEURORADIOLOGY, V38, P560
   Dombrowski KE, 2011, BRIT J NEUROSURG, V25, P249, DOI 10.3109/02688697.2010.544784
   Fairweather D, 2008, AM J PATHOL, V173, P600, DOI 10.2353/ajpath.2008.071008
   Fallah A, 2010, CAN J SURG, V53, P69
   Huisman Thierry A G M, 2009, Cancer Imaging, V9 Spec No A, pS10, DOI 10.1102/1470-7330.2009.9003
   Kirby S, 2014, NEUROL CLIN, V32, P423, DOI 10.1016/j.ncl.2013.11.006
   Lee M, 1998, NEUROSURGERY, V43, P788, DOI 10.1097/00006123-199810000-00034
   Omuro AMP, 2006, LANCET NEUROL, V5, P937, DOI 10.1016/S1474-4422(06)70597-X
   Pobereskin LH, 2000, J NEUROL NEUROSUR PS, V69, P464, DOI 10.1136/jnnp.69.4.464
   Spalice A, 2010, CURR NEUROPHARMACOL, V8, P135, DOI 10.2174/157015910791233141
   Uematsu Y, 2010, BRAIN TUMOR PATHOL, V27, P71, DOI 10.1007/s10014-010-0266-8
   VanLandingham M, 2010, CHILD NERV SYST, V26, P655, DOI 10.1007/s00381-009-1045-x
   VAZQUEZBARQUERO A, 1994, CEPHALALGIA, V14, P270, DOI 10.1046/j.1468-2982.1994.1404270.x
   Villa A, 2016, ACTA NEUROL BELG, V116, P627, DOI 10.1007/s13760-016-0615-4
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E333
EP E337
DI 10.1016/j.wneu.2019.06.083
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200039
PM 31228702
DA 2020-05-12
ER

PT J
AU Tu, Q
   Ding, HW
   Chen, H
   Miao, QJ
   Yang, X
   Li, K
   Zhang, K
   Wu, ZH
   Tang, Y
   Xia, H
   Xu, JZ
AF Tu, Qiang
   Ding, Huan-wen
   Chen, Hu
   Miao, Qiu-ju
   Yang, Xuan
   Li, Kang
   Zhang, Kai
   Wu, Zeng-hui
   Tang, Yong
   Xia, Hong
   Xu, Jian-zhong
TI Three-Dimensional-Printed Individualized Guiding Templates for Surgical
   Correction of Severe Kyphoscoliosis Secondary to Ankylosing Spondylitis:
   Outcomes of 9 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing; Ankylosing spondylitis; Computer-aided design;
   Kyphoscoliosis; Template
ID THORACOLUMBAR KYPHOSIS SECONDARY; OSTEOTOMY; LUMBAR
AB OBJECTIVE: To report the outcomes of severe kyphoscoliosis secondary to ankylosing spondylitis (AS) corrected with 3D-printed individualized guiding templates.
   METHODS: Computed tomography (CT) data of patients with severe kyphoscoliosis secondary to AS were used to reconstruct 3D models of the spine and to develop a surgical plan. An asymmetric wedge pedicle subtraction osteotomy (PSO) was simulated using medical computer design software. Before the actual surgery, continual surgical simulations were performed until the most suitable one was obtained, and personalized guiding templates were manufactured for the anticipated PSO. During operation, the osteotomy plane and trajectories for the pedicle screws were positioned by the designed patient-specific 3D-printed guiding templates.
   RESULTS: In this study, we reviewed 9 patients who underwent correction of kyphoscoliosis using a 3D-printed individualized guiding template and were followed for a median of 21.4 months (range, 9-36 months). The average correction at the site of osteotomy was 65.9 degrees. No patient experienced severe complications, such as misplaced pedicle screws or neurologic complications. At the last follow-up, no patient exhibited implant dysfunction on radiography.
   CONCLUSIONS: Preoperative surgical simulation using 3D-printed templates is a viable technique that enables surgery to meet both patient- and surgeon-specific requirements for correction of severe thoracolumbar kyphoscoliosis. These 3D-printed templates can guide the performance of planned PSO to provide functional restoration of severe kyphoscoliosis secondary to AS.
C1 [Tu, Qiang; Tang, Yong; Xu, Jian-zhong] Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Tu, Qiang; Yang, Xuan; Li, Kang; Zhang, Kai; Wu, Zeng-hui; Xia, Hong] Gen Hosp Southern Theatre Command PLA, Dept Orthoped Surg, Guangzhou, Guangdong, Peoples R China.
   [Ding, Huan-wen; Miao, Qiu-ju] South China Univ Technol, Sch Med, Guangzhou, Guangdong, Peoples R China.
   [Chen, Hu] South China Univ Technol, Sch Clin Med 1, Dept Orthoped, Guangzhou, Guangdong, Peoples R China.
RP Xu, JZ (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Orthoped, Chongqing, Peoples R China.
EM xujzspine@126.com
OI Tu, qiang/0000-0003-2339-4009
FU Military Medical Science and Technology Youth Cultivation Program
   Incubation Project [19QNP040]; Science and Technology Planning Project
   of Guangzhou City [201904010349]
FX This study was supported by grants from the Military Medical Science and
   Technology Youth Cultivation Program Incubation Project (19QNP040) and
   the Science and Technology Planning Project of Guangzhou City
   (201904010349).
CR Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   Diao WY, 2018, CLIN NEUROL NEUROSUR, V172, P39, DOI 10.1016/j.clineuro.2018.06.026
   Ding HW, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-331
   Kaneyama S, 2014, J NEUROSURG-SPINE, V21, P231, DOI 10.3171/2014.3.SPINE13730
   Kim KT, 2015, CLIN ORTHOP SURG, V7, P330, DOI 10.4055/cios.2015.7.3.330
   Merc M, 2013, ARCH ORTHOP TRAUM SU, V133, P893, DOI 10.1007/s00402-013-1755-0
   Paiva WS, 2007, ARQ NEURO-PSIQUIAT, V65, P443, DOI 10.1590/S0004-282X2007000300015
   Pijpker PAJ, 2018, WORLD NEUROSURG, V119, P113, DOI 10.1016/j.wneu.2018.07.219
   Qian BP, 2013, SPINE, V38, pE1669, DOI 10.1097/BRS.0000000000000021
   Qiao M, 2018, WORLD NEUROSURG, V117, pE475, DOI 10.1016/j.wneu.2018.06.053
   Sugawara T, 2013, J NEUROSURG-SPINE, V19, P185, DOI 10.3171/2013.4.SPINE121059
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Xu W, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1703-1
   Zhang YQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006414
   Zheng GQ, 2014, SPINE, V39, P1055, DOI 10.1097/BRS.0000000000000346
NR 15
TC 0
Z9 0
U1 5
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E961
EP E970
DI 10.1016/j.wneu.2019.07.047
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200120
PM 31302275
DA 2020-05-12
ER

PT J
AU Tyagi, G
   Srinivas, D
   Nanjaiah, ND
   Purushottam, M
   Somanna, S
   Santosh, V
   Jain, S
AF Tyagi, Gaurav
   Srinivas, Dwarakanath
   Nanjaiah, Nandakumar Dalavaikodihalli
   Purushottam, Meera
   Somanna, Sampath
   Santosh, Vani
   Jain, Sanjeev
TI Gene Expression in Intracranial Aneurysms-Comparison Analysis of
   Aneurysmal Walls and Extracranial Arteries with Real-Time Polymerase
   Chain Reaction and Immunohistochemistry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alpha-1 antitrypsin; Aneurysm; Aneurysm genetics; Cathepsin B (CTSB);
   Collagen 1A2 (COL1A2); Immunohistochemistry; Intracranial aneurysms;
   PCR; Tissue inhibitor of metalloproteinase 4 (TIMP4)
ID MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; RISK-FACTORS; CATHEPSIN-B;
   DEFICIENCY; PROFILES; PCR
AB BACKGROUND: This study was aimed at evaluating the gene expression levels of 4 genes in the intracranial aneurysm wall and comparing them with extracranial arteries. The analysis was done using real-time polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC). Also, a correlation of the differential genetic expression was done with various patient clinical and radiologic factors.
   METHODS: The quantitative assessment of ribonucleic acid levels was done with RT-PCR and was validated with IHC. The genes studied were collagen 1A2 (COL1A2), tissue inhibitor of metalloproteinase 4 (TIMP4), cathepsin B (CTSB), and alpha-1 antitrypsin (alpha-1 AT). The analysis was done on 24 aneurysm sacs and superficial temporal/occipital artery samples from patients undergoing surgical clipping.
   RESULTS: The mean fold change of COL1A2 in the aneurysm sample was 8.89, that of TIMP4 was 10.16, that of CTSB was 1.02, and that of alpha-1 ATwas 1.46 when compared with normal control vessel on PCR. On semiquantitative IHC, COL1A2 was 94.44%, alpha-1 AT was 77.8% overexpressed, CTSB was positive in 50%, and the expression of TIMP4 was 94.4% underexpressed in aneurysmal walls. There was no statistically significant correlation between patient profile and gene expression.
   CONCLUSIONS: On RT-PCR and IHC analysis, COL1A2and alpha-1 AT were overexpressed, CTSB was marginally overexpressed, and TIMP4 had equivocal expression in the aneurysmal sac when compared with the normal extracranial vessel. This is the first study of its kind in the Indian population with the largest sample size on live human patients.
C1 [Tyagi, Gaurav; Srinivas, Dwarakanath; Somanna, Sampath] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Nanjaiah, Nandakumar Dalavaikodihalli] Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore, Karnataka, India.
   [Santosh, Vani] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India.
   [Jain, Sanjeev] Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Bangalore, Karnataka, India.
   [Purushottam, Meera] Natl Inst Mental Hlth & Neurosci, Mol Genet Lab, Bangalore, Karnataka, India.
RP Srinivas, D (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM dwarakaneuro@yahoo.com
OI Purushottam, Meera/0000-0002-4000-268X; Kandregula,
   Sandeep/0000-0001-9392-3143
CR Aoki T, 2008, STROKE, V39, P2603, DOI 10.1161/STROKEAHA.107.513648
   Babu RA, 2016, NEUROL INDIA, V64, P663, DOI 10.4103/0028-3886.185350
   BAKER CJ, 1995, NEUROSURGERY, V37, P56, DOI 10.1227/00006123-199507000-00008
   BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Eagleton MJ, 2006, J SURG RES, V135, P345, DOI 10.1016/j.jss.2006.03.026
   Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8
   Gan Q, 2017, MED SCI MONITOR, V23, P3240, DOI 10.12659/MSM.902327
   Giannotta SL, 1998, NEUROSURGERY, V43, P26, DOI 10.1097/00006123-199807000-00014
   Jin DS, 2007, SURG NEUROL, V68, P11, DOI 10.1016/j.sumeu.2007.02.060
   Koskivirta I, 2006, HISTOCHEM CELL BIOL, V126, P335, DOI 10.1007/s00418-006-0163-8
   Krischek B, 2008, NEUROSCIENCE, V154, P1398, DOI 10.1016/j.neuroscience.2008.04.049
   Krischek B, 2008, ADV TECH STAND NEURO, V33, P131, DOI 10.1007/978-3-211-72283-1_3
   Krischek B, 2006, J HUM GENET, V51, P587, DOI 10.1007/s10038-006-0407-4
   Li L, 2009, EUR NEUROL, V62, P330, DOI 10.1159/000236911
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marchese E, 2010, J BIOL REG HOMEOS AG, V24, P185
   McGough E, 2016, NEUROLOGY, V86
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Pera J, 2010, STROKE, V41, P224, DOI 10.1161/STROKEAHA.109.562009
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789
   Ruigrok YM, 2008, STROKE, V39, P1049, DOI 10.1161/STROKEAHA.107.497305
   Schievink WI, 1996, J NEUROSURG, V84, P781, DOI 10.3171/jns.1996.84.5.0781
   SCHIEVINK WI, 1994, LANCET, V343, P452, DOI 10.1016/S0140-6736(94)92693-X
   Shi CB, 2009, STROKE, V40, P1252, DOI 10.1161/STROKEAHA.108.532036
   StJean P, 1996, HUM HERED, V46, P92
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   Winn HR, 2002, J NEUROSURG, V96, P43, DOI 10.3171/jns.2002.96.1.0043
   Yu Nian-zu, 2010, Zhonghua Wai Ke Za Zhi, V48, P457
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E117
EP E126
DI 10.1016/j.wneu.2019.06.002
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200016
PM 31371266
DA 2020-05-12
ER

PT J
AU van der Steen, WE
   Marquering, HA
   Boers, AMM
   Ramos, LA
   van den Berg, R
   Vergouwen, MDI
   Majoie, CBLM
   Coert, BA
   Vandertop, WP
   Verbaan, D
   Roos, YBWEM
AF van der Steen, Wessel E.
   Marquering, Henk A.
   Boers, Anna M. M.
   Ramos, Lucas A.
   van den Berg, Rene
   Vergouwen, Mervyn D. I.
   Majoie, Charles B. L. M.
   Coert, Bert A.
   Vandertop, William P.
   Verbaan, Dagmar
   Roos, Yvo B. W. E. M.
TI Predicting Delayed Cerebral Ischemia with Quantified Aneurysmal
   Subarachnoid Blood Volume
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed cerebral ischemia; Prediction model; Subarachnoid hemorrhage;
   Total blood volume
ID HEMORRHAGE; VASOSPASM; ASSOCIATION; SCALES
AB BACKGROUND: The amount of blood detected on brain computed tomography scan is frequently used in prediction models for delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (aSAH). These models, which include coarse grading scales to assess the amount of blood, have only moderate predictive value. Therefore, we aimed to develop a predictive model for DCI including automatically quantified total blood volume (TBV).
   METHODS: We included patients from a prospective aSAH registry. TBV was assessed with an automatic hemorrhage quantification algorithm. The outcome measure was clinical deterioration due to DCI. Clinical and radiologic variables were included in a logistic regression model The final model was selected by bootstrapped backward selection and internally validated by assessing the optimism-corrected R-2 value, c-statistic, and calibration plot. The c-statistic of the TBV model was compared with models that used the (modified) Fisher scale instead.
   RESULTS: We included 369 patients. After backward selection, only TBV was included in the final model. The internally validated R-2 value was 6%, and the c-statistic was 0.64. The c-statistic of the TBV model was higher than both the Fisher scale model (0.56; P < 0.001) and the modified Fisher scale model (0.58; P < 0.05).
   CONCLUSIONS: In our registry, only TBV independently predicted DCI. TBV discriminated better than the (modified) Fisher scale, but still had only moderate value for predicting DCI. Our findings suggest that other factors need to be identified to achieve better accuracy for predicting DCI.
C1 [van der Steen, Wessel E.; Marquering, Henk A.; van den Berg, Rene; Majoie, Charles B. L. M.] Univ Amsterdam, Amsterdam UMC, Dept Radiol & Nucl Med, Amsterdam, Netherlands.
   [van der Steen, Wessel E.; Roos, Yvo B. W. E. M.] Univ Amsterdam, Amsterdam UMC, Dept Neurol, Amsterdam, Netherlands.
   [van der Steen, Wessel E.; Coert, Bert A.; Vandertop, William P.; Verbaan, Dagmar] Univ Amsterdam, Amsterdam UMC, Neurosurg Ctr Amsterdam, Amsterdam, Netherlands.
   [van der Steen, Wessel E.; Marquering, Henk A.; Boers, Anna M. M.; Ramos, Lucas A.] Univ Amsterdam, Amsterdam UMC, Dept Biomed Engn & Phys, Amsterdam, Netherlands.
   [Boers, Anna M. M.] Univ Twente, Dept Robot & Mech, Enschede, Netherlands.
   [Ramos, Lucas A.] Univ Amsterdam, Amsterdam UMC, Dept Clin Epidemiol Biostatist & Bioinformat, Amsterdam, Netherlands.
   [Vergouwen, Mervyn D. I.] Univ Utrecht, Univ Med Ctr, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.
RP van der Steen, WE (reprint author), Univ Amsterdam, Amsterdam UMC, Dept Radiol & Nucl Med, Amsterdam, Netherlands.; van der Steen, WE (reprint author), Univ Amsterdam, Amsterdam UMC, Dept Neurol, Amsterdam, Netherlands.; van der Steen, WE (reprint author), Univ Amsterdam, Amsterdam UMC, Neurosurg Ctr Amsterdam, Amsterdam, Netherlands.; van der Steen, WE (reprint author), Univ Amsterdam, Amsterdam UMC, Dept Biomed Engn & Phys, Amsterdam, Netherlands.
EM w.e.vandersteen@amc.uva.nl
FU NutsOhra [1403-023]
FX This study was funded by NutsOhra (Grant 1403-023).
CR Ahn SH, 2018, NEUROSURGERY, V83, P137, DOI 10.1093/neuros/nyx364
   Al-Mufti F, 2019, NEUROSURGERY, V84, P397, DOI 10.1093/neuros/nyy045
   Boers AM, 2014, AM J NEURORADIOL, V35, P2279, DOI 10.3174/ajnr.A4042
   de Rooij NK, 2013, STROKE, V44, P1288, DOI 10.1161/STROKEAHA.113.001125
   de Rooij NK, 2013, STROKE, V44, P43, DOI 10.1161/STROKEAHA.112.674291
   Dupont SA, 2009, NEUROCRIT CARE, V11, P71, DOI 10.1007/s12028-009-9227-7
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Fragata I, 2017, STROKE, V48, P2091, DOI 10.1161/STROKEAHA.117.016811
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   Germans MR, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-143
   HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061
   HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250
   Kramer AH, 2008, J NEUROSURG, V109, P199, DOI 10.3171/JNS/2008/109/8/0199
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Manoel ALD, 2015, STROKE, V46, P1826, DOI 10.1161/STROKEAHA.115.008728
   Musoro JZ, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-116
   Steyerberg E, 2009, CLIN PREDICTION MODE
   Stienen MN, 2018, STROKE, V49, P333, DOI 10.1161/STROKEAHA.117.019328
   van Buuren S, 2012, FLEXIBLE IMPUTATION
   van der Steen WE, 2018, AM J NEURORADIOL, V39, P1059, DOI 10.3174/ajnr.A5626
   van der Zande JJ, 2011, AM J NEURORADIOL, V32, P271, DOI 10.3174/ajnr.A2287
   van Norden AGW, 2006, J NEUROL, V253, P1217, DOI 10.1007/s00415-006-0205-0
   Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74
   Vergouwen MDI, 2016, NEUROLOGY, V86, P59, DOI 10.1212/WNL.0000000000002239
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015
   Zijlstra IA, 2016, AM J NEURORADIOL, V37, P1588, DOI 10.3174/ajnr.A4771
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E613
EP E619
DI 10.1016/j.wneu.2019.06.170
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200077
PM 31260850
DA 2020-05-12
ER

PT J
AU Vlasak, A
   Okechi, H
   Horinek, D
   Albright, AL
AF Vlasak, Ales
   Okechi, Humphrey
   Horinek, Daniel
   Albright, A. Leland
TI Pediatric Ventriculoperitoneal Shunts Revision Rate and Costs in
   High-Volume sub-Saharan Department
SO WORLD NEUROSURGERY
LA English
DT Article
DE Africa; Costs; Hydrocephalus; Revision rate; Ventriculoperitoneal shunt
ID UNITED-STATES; HYDROCEPHALUS; INFECTIONS; FAILURES; OUTCOMES; CHILDREN;
   SURGERY
AB BACKGROUND: Ventriculoperitoneal shunt (VPS) placement is one of the most common neurosurgical procedures. VPSs are associated with high costs, which predominantly arise from relatively high complication and revision rates. It is reasonable to assume that revision rates in developing countries would be higher. In this study we report the single-institution revision rates and costs from a high-volume department in sub-Saharan Africa.
   METHODS: A pediatric neurosurgical database was studied in the extent of 5 years. The 30-day shunt failure rate, overall revision rate, and costs were calculated, and results were compared with previously published studies from developed countries.
   RESULTS: In the selected time period 1840 VPS surgeries were performed, of which 592 were shunt revisions (32.14%). The majority of revision surgeries was performed in the first year- 501 (representing 84.63%); second year, 64; third year, 21; fourth year, 6; and fifth year, 2. The overall shunt revision rate was 28.94% with a 30-day revision rate of 14.58%. During the course of the study, costs of VPS surgery, the shunt, and daily ward charges did not change significantly. The average total charge for VPS insertion was 60,000 KES (586 USD), VPS removal 30,000 KES (293 USD), and VPS revision 50,000 KES (489 USD).
   CONCLUSIONS: This retrospective study proves that VPSs, with their known complication risks, can be performed in a sub-Saharan missionary hospital with acceptable costs and results that are comparable with those achieved in some Western hospitals. Keys to those outcomes include high volume and a highly experienced team.
C1 [Vlasak, Ales; Horinek, Daniel; Albright, A. Leland] Motol Univ Hosp, Fac Med 2, Dept Neurosurg, Prague, Czech Republic.
   [Okechi, Humphrey] AC Kijabe Hosp, Pediat Neurosurg, Kijabe, Kenya.
RP Vlasak, A (reprint author), Motol Univ Hosp, Fac Med 2, Dept Neurosurg, Prague, Czech Republic.
EM ales.vlasak@fnmotol.cz
CR Al-Tamimi YZ, 2014, NEUROSURGERY, V74, P29, DOI 10.1227/NEU.0000000000000196
   Berry JG, 2008, NEUROSURGERY, V62, P445, DOI 10.1227/01.neu.0000316012.20797.04
   COCHRANE D, 1995, PEDIATR NEUROSURG, V23, P14, DOI 10.1159/000120930
   Cochrane DD, 2003, PEDIATR NEUROSURG, V38, P295, DOI 10.1159/000070413
   Dewan MC, J NEUROSURG, DOI [10.3171/2017, DOI 10.3171/2017]
   Gathura E, 2010, J NEUROSURG-PEDIATR, V6, P329, DOI 10.3171/2010.7.PEDS09543
   Kahle KT, 2016, LANCET, V387, P788, DOI 10.1016/S0140-6736(15)60694-8
   Kausch W, 1908, ARCH KLIN CHIR, V87, P709
   Lam SK, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14454
   Lifshutz JI, 2001, NEUROSURG FOCUS, V11, P2
   LIPTAK GS, 1986, PEDIATR NEUROSCI, V12, P289
   McCullough DC, 1990, HYDROCEPHALUS, P1
   McGirt MJ, 2002, PEDIATR NEUROSURG, V36, P248, DOI 10.1159/000058428
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Mwang'Ombe NJM, 2000, E AFR MED J, V77, P386
   Ochieng' N, 2015, J NEUROSURG-PEDIATR, V15, P150, DOI 10.3171/2014.10.PEDS14178
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096
   Simon TD, 2008, J NEUROS-PEDIATR, V1, P131, DOI 10.3171/PED/2008/1/2/131
   Tuli S, 2000, J NEUROSURG, V92, P31, DOI 10.3171/jns.2000.92.1.0031
   Warf BC, 2012, J NEUROSURG-PEDIATR, V10, P463, DOI 10.3171/2012.9.PEDS1236
   Warf BC, 2013, CHILD NERV SYST, V29, P935, DOI 10.1007/s00381-013-2072-1
NR 22
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1000
EP E1003
DI 10.1016/j.wneu.2019.07.059
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200123
PM 31306836
DA 2020-05-12
ER

PT J
AU Wang, CY
   Zhang, XY
   Liu, JH
   Shan, Z
   Li, SY
   Zhao, FD
AF Wang, Chongyan
   Zhang, Xuyang
   Liu, Junhui
   Shan, Zhi
   Li, Shengyun
   Zhao, Fengdong
TI Percutaneous kyphoplasty: Risk Factors for Recollapse of Cemented
   Vertebrae
SO WORLD NEUROSURGERY
LA English
DT Article
DE Kyphotic angle; Percutaneous kyphoplasty; Re-collapse; Vertebral height
ID BALLOON-KYPHOPLASTY; COMPRESSION FRACTURES; DISTRIBUTION PATTERN; HEIGHT
   RESTORATION; VERTEBROPLASTY; BODY; DEFORMITY; RECOMPRESSION; SPINE
AB INTRODUCTION: Percutaneous kyphoplasty can offer pain relief and restoration of vertebral height immediately after the procedure; however, little is known about how many vertebrae recollapse during follow-up or why recollapse occurs. In the present study, we define recollapse of a treated vertebra, assess how common it is following percutaneous kyphoplasty, and investigate risk factors for the condition.
   METHODS: In total, 203 consecutive patients who underwent percutaneous kyphoplasty were reviewed after an average 12.7 months to assess what proportion of cementaugmented vertebrae had recollapsed. Potential risk factors for recollapse included age, gender, body weight, body height, body mass index, treated level, duration of symptoms, follow-up duration, preoperative T-scores, surgical approach, the intravertebral cleft, contact of polymethyl methacrylate (PMMA) with endplates, cement volume, cement leakage, and midline vertebral body height. Stepwise multivariate linear regression was conducted to predict recollapse as quantified by midline vertebral height loss.
   RESULTS: Overall, 38.9% of the augmented vertebrae recollapsed. In the recollapse group, the average midline vertebral height ratio and kyphotic angles statistically significantly changed during follow-up (P < 0.05). Pain scores decreased immediately after percutaneous kyphoplasty and generally remained low at follow-up. Significant predictors of midline vertebral height loss at follow-up included presence of an intravertebral cleft, postoperative vertebral height, and non-PMMA-endplate-contact. Together, these factors accounted for 28% of the variability in midline height loss.
   CONCLUSIONS: Benefits of percutaneous kyphoplasty are partly offset by subsequent recollapse. Recollapse is greater if there is an intravertebral cleft, non-PMMAendplate-contact and an increase in the post vertebral height.
C1 [Wang, Chongyan; Zhang, Xuyang; Liu, Junhui; Shan, Zhi; Li, Shengyun; Zhao, Fengdong] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
RP Zhao, FD (reprint author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
EM zhaodong68@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81871796, 81672208, 81802192, 81802188]; Zhejiang
   Medical Science and Technology Project [2016ZDB006]
FX This study was supported by National Natural Science Foundation of China
   [Grant Numbers 81871796, 81672208, 81802192, 81802188]; Zhejiang Medical
   Science and Technology Project [Grant Numbers 2016ZDB006]. There are no
   conflicts of interests for the authors of this manuscript.
CR Berlemann U, 2004, EUR SPINE J, V13, P496, DOI 10.1007/s00586-004-0691-7
   Borgen TT, 2019, BONE, V122, P14, DOI 10.1016/j.bone.2019.02.008
   Chen LA, 2011, SPINE, V36, P534, DOI 10.1097/BRS.0b013e3181f99d70
   Chen YJ, 2012, EUR J RADIOL, V81, P558, DOI 10.1016/j.ejrad.2011.02.034
   Chung HJ, 2008, INT ORTHOP, V32, P817, DOI 10.1007/s00264-007-0439-1
   Crespo-Sanjuan J, 2017, WORLD NEUROSURG, V105, P137, DOI 10.1016/j.wneu.2017.05.142
   DOLAN P, 1994, J BIOMECH, V27, P1237, DOI 10.1016/0021-9290(94)90277-1
   Gao C, 2018, ACTA RADIOL, V59, P577, DOI 10.1177/0284185117725368
   Garfin SR, 2001, SPINE, V26, P1511, DOI 10.1097/00007632-200107150-00002
   Ha KY, 2013, ASIAN SPINE J, V7, P294, DOI 10.4184/asj.2013.7.4.294
   Heo DH, 2009, OSTEOPOROSIS INT, V20, P473, DOI 10.1007/s00198-008-0682-3
   Kasperk C, 2005, J BONE MINER RES, V20, P604, DOI 10.1359/JBMR.041203
   Kim HW, 2010, J KOREAN NEUROSURG S, V47, P278, DOI 10.3340/jkns.2010.47.4.278
   Kim KH, 2012, J SPINAL DISORD TECH, V25, P338, DOI 10.1097/BSD.0b013e318224a6e6
   Kim MJ, 2006, SPINE, V31, P2079, DOI 10.1097/01.brs.0000231714.15876.76
   Kim YY, 2010, EUR SPINE J, V19, P1907, DOI 10.1007/s00586-010-1479-6
   Krueger A, 2013, CLIN BIOMECH, V28, P725, DOI 10.1016/j.clinbiomech.2013.06.007
   Lamparello NA, 2016, J RADIOL CASE REP, V10, P40, DOI 10.3941/jrcr.v10i7.2806
   Landham PR, 2015, SPINE, V40, P902, DOI 10.1097/BRS.0000000000000905
   Landham PR, 2015, SPINE J, V15, P721, DOI 10.1016/j.spinee.2014.11.017
   Leslie-Mazwi T, 2006, J NEUROSURG-SPINE, V4, P270, DOI 10.3171/spi.2006.4.3.270
   Li XG, 2014, OSTEOPOROSIS INT, V25, P1647, DOI 10.1007/s00198-014-2626-4
   Li XG, 2012, J SPINAL DISORD TECH, V25, P142, DOI 10.1097/BSD.0b013e318213c113
   Lin DS, 2017, CLIN SPINE SURG, V30, pE270, DOI 10.1097/BSD.0000000000000204
   Liu JT, 2015, J NEUROSURG-SPINE, V23, P94, DOI 10.3171/2014.11.SPINE14579
   McKiernan F, 2003, ARTHRITIS RHEUM-US, V48, P1414, DOI 10.1002/art.10984
   Niu JJ, 2015, ACTA RADIOL, V56, P1380, DOI 10.1177/0284185114556016
   Oberkircher L, 2014, J SPINAL DISORD TECH, V27, P283, DOI 10.1097/BSD.0b013e3182aab205
   Ohba T, 2013, EUR SPINE J, V22, pS341, DOI 10.1007/s00586-012-2414-9
   Oka M, 2005, ACAD RADIOL, V12, P992, DOI 10.1016/j.acra.2005.05.003
   Piazzolla Andrea, 2011, Musculoskelet Surg, V95, P141, DOI 10.1007/s12306-011-0130-y
   Rollinghoff M, 2009, MINIM INVAS NEUROSUR, V52, P233, DOI 10.1055/s-0029-1243631
   Sasani M, 2009, PAIN PRACT, V9, P141, DOI 10.1111/j.1533-2500.2008.00250.x
   Shim J, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1215-4
   Tanigawa N, 2007, AM J ROENTGENOL, V189, pW348, DOI 10.2214/AJR.07.2186
   Trout AT, 2006, AM J NEURORADIOL, V27, P1586
   Wang G, 2010, J BONE JOINT SURG BR, V92B, P1553, DOI 10.1302/0301-620X.92B11.24671
   Wu XJ, 2018, J ORTHOP SCI, V23, P39, DOI 10.1016/j.jos.2017.09.010
   Xu C, 2014, AM J NEURORADIOL, V35, P202, DOI 10.3174/ajnr.A3617
   Yoon ST, 2005, J SPINAL DISORD TECH, V18, pS129, DOI 10.1097/00024720-200502001-00020
   Zhang CG, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008895
   Zhao FD, 2009, BONE, V44, P372, DOI 10.1016/j.bone.2008.10.048
   Zhao Feng-dong, 2006, Zhonghua Wai Ke Za Zhi, V44, P1132
   Zoarski GH, 2002, J VASC INTERV RADIOL, V13, P139, DOI 10.1016/S1051-0443(07)61930-7
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E307
EP E315
DI 10.1016/j.wneu.2019.06.071
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200036
PM 31226459
DA 2020-05-12
ER

PT J
AU Wang, HW
   Li, XP
   Yin, YH
   Li, T
   Yu, XG
AF Wang, Hua-wei
   Li, Xue-ping
   Yin, Yi-heng
   Li, Teng
   Yu, Xin-guang
TI Change of Anatomical Location of the Internal Carotid Artery Relative to
   the Atlas with Congenital Occipitalization and the Relevant Clinical
   Implications
SO WORLD NEUROSURGERY
LA English
DT Article
DE C1-C2 fixation; Craniovertebral junction; Internal carotid artery;
   Lateral mass; Malformation; Occipitalization of the atlas
ID LATERAL MASS SCREW; DIRECT POSTERIOR REDUCTION; BASILAR INVAGINATION;
   ATLANTOAXIAL DISLOCATION; CRANIOVERTEBRAL JUNCTION;
   MORPHOMETRIC-ANALYSIS; FIXATION; DISTRACTION; PLACEMENT; STABILIZATION
AB INTRODUCTION: The occipitalization of the atlas (OA) is always associated with multiplanar dislocation and olisthy of the C1 over C2 facets, which may change the anatomical relationship between the internal carotid artery (ICA) and the atlas. The purpose of this current study is to identify the location of the ICA relative to the anterior aspect of the atlas in patients with OA and define the clinical implications for screw placement.
   METHODS: We retrospectively reviewed the computed tomography angiography data of 86 patients with OA and 86 control subjects. Several parameters were also measured to quantitatively evaluate the mutual relationship.
   RESULTS: In the OA group, 25.6% of ICAs were located in area 3 and 74.4% in area 2, whereas the percentages were 57.4% and 42.6%, respectively, in the control group. There were 73 (42.4%) ICAs in which the shortest distance between the dorsal surface of the ICA and the ventral cortex of the atlas was less than 4 mm in the OA group and only 50 (29.1%) in the control group. The ideal angulation of C1 screw trajectory was about 5 degrees more medial in the OA group than that in the control group (P < 0.01).
   CONCLUSIONS: The risk of ICA injury is much higher in OA patients than in non-OA patients during the C1 screw placement. A mean medial angulation about 20 degrees will permit a long and safe screw purchase, but should be individualized. We recommend careful preoperative computed tomography angiography evaluation in all patients before surgery.
C1 [Wang, Hua-wei; Yin, Yi-heng; Li, Teng; Yu, Xin-guang] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Xue-ping] Chinese Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China.
RP Yu, XG (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xinguang_yu@263.net
FU Beijing Science and Technology Nova Program Project [Z171100001117106];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571350]; National Key R&D Program of China
   [2018YFC1002500]
FX This research was supported by the Beijing Science and Technology Nova
   Program Project (No: Z171100001117106), the National Natural Science
   Foundation of China (No: 81571350) and the National Key R&D Program of
   China (No: 2018YFC1002500).
CR Bogaerde MV, 2007, CLIN NEUROL NEUROSUR, V109, P466, DOI 10.1016/j.clineuro.2007.02.008
   Chandra PS, 2014, OPER NEUROSURG, V10, P621, DOI 10.1227/NEU.0000000000000470
   Chandra PS, 2013, NEUROSURGERY, V72, P1040, DOI 10.1227/NEU.0b013e31828bf342
   Currier BL, 2003, SPINE, V28, pE461, DOI 10.1097/01.BRS.0000092385.19307.9E
   Currier BL, 2008, SPINE, V33, P635, DOI 10.1097/BRS.0b013e318166e083
   Cyr SJ, 2008, SPINE J, V8, P661, DOI 10.1016/j.spinee.2007.02.008
   DOHERTY BJ, 1994, SPINE, V19, P2497, DOI 10.1097/00007632-199411001-00001
   Eck JC, 2007, J SPINAL DISORD TECH, V20, P505, DOI 10.1097/BSD.0b013e318031af8b
   Estillore RP, 2011, SPINE J, V11, P316, DOI 10.1016/j.spinee.2011.03.009
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Goel A, 2004, SPINE, V29, pE520, DOI 10.1097/01.brs.0000144827.17054.35
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Guo SL, 2014, EUR SPINE J, V23, P1666, DOI 10.1007/s00586-014-3409-5
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Jian FZ, 2012, CLIN NEUROL NEUROSUR, V114, P590, DOI 10.1016/j.clineuro.2011.12.017
   Jian FZ, 2010, NEUROSURGERY, V66, P678, DOI 10.1227/01.NEU.0000367632.45384.5A
   Kim MS, 2016, EUR SPINE J, V25, P103, DOI 10.1007/s00586-015-3848-7
   Li LF, 2012, J SPINAL DISORD TECH, V25, P77, DOI 10.1097/BSD.0b013e31820f8afb
   Li LF, 2012, J CLIN NEUROSCI, V19, P49, DOI 10.1016/j.jocn.2011.03.036
   Murakami S, 2008, SPINE, V33, P2581, DOI 10.1097/BRS.0b013e318186b2fd
   RUPP SM, 1983, BRIT J ANAESTH, V55, pS67
   Salunke P, 2018, CLIN NEUROL NEUROSUR, V171, P85, DOI 10.1016/j.clineuro.2018.05.024
   Salunke P, 2016, CLIN NEUROL NEUROSUR, V145, P19, DOI 10.1016/j.clineuro.2016.04.001
   Salunke P, 2015, J NEUROSURG-SPINE, V23, P294, DOI 10.3171/2014.12.SPINE14310
   Salunke P, 2015, CLIN NEUROL NEUROSUR, V131, P47, DOI 10.1016/j.clineuro.2015.01.025
   Sardhara J, 2018, NEUROSURGERY, V82, P525, DOI 10.1093/neuros/nyx196
   Simsek S, 2009, NEUROSURGERY, V65, P1154, DOI 10.1227/01.NEU.0000351779.58845.62
   Srivastava AK, 2017, NEUROL INDIA, V65, P1068, DOI 10.4103/neuroindia.NI_819_17
   Wang HW, 2019, WORLD NEUROSURG, V121, pE1, DOI 10.1016/j.wneu.2018.08.016
   Wang MY, 2004, NEUROSURGERY, V54, P1436, DOI 10.1227/01.NEU.0000124753.74864.07
   Wang SL, 2009, SPINE, V34, P2838, DOI 10.1097/BRS.0b013e3181b4fb8b
   Yin YH, 2016, NEUROSURGERY, V78, P391, DOI 10.1227/NEU.0000000000001026
   Yin YH, 2014, SPINE, V39, P2013, DOI 10.1097/BRS.0000000000000611
   Yin YH, 2012, SPINE, V37, pE170, DOI 10.1097/BRS.0b013e318227efe7
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E505
EP E512
DI 10.1016/j.wneu.2019.06.138
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200063
PM 31254707
DA 2020-05-12
ER

PT J
AU Wang, XQ
   Zhuang, HX
   Zhang, LX
   Chen, X
   Niu, CS
   Zhao, M
AF Wang, Xue-qi
   Zhuang, Hong-xia
   Zhang, Li-xiang
   Chen, Xia
   Niu, Chao-shi
   Zhao, Mei
TI Nomogram for Predicting Postoperative Delirium After Deep Brain
   Stimulation Surgery for Parkinson's Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Nomograms; Parkinson's disease; Postoperative
   delirium
ID NONMOTOR SYMPTOMS SCALE; DYSFUNCTION; VALIDATION; SYSTEM; COST
AB OBJECTIVE: The purpose of the present study was to construct a nomogram for postoperative delirium (POD) after deep brain stimulation (DBS) surgery in patients with Parkinson's disease (PD).
   METHODS: The present study retrospectively enrolled 165 patients with PD who had undergone DBS surgery. The patients were assessed using the Confusion Assessment Method for the Intensive Care Unit and were divided into 2 groups: the delirium group and nondelirium group. The nomogram for POD after DBS surgery was constructed from the results of univariate analysis and multivariate logistic analysis of the influencing factors for POD after DBS surgery.
   RESULTS: Univariate analysis revealed that the preoperative length of stay and the presence of preoperative brain atrophy, preoperative pulmonary inflammation, and postoperative cerebral edema were statistically significant. The results from the nonmotor symptoms scale for PD, mini-mental state examination, PD sleep scale, and unified PD rating scale III were also statistically significant (P < 0.05). Multivariate logistic regression analysis showed that the unified PD rating scale III (odds ratio [OR], 2.284; 95% confidence interval [CI], 1.614-3.232), nonmotor symptoms scale for PD (OR, 8.191; 95% CI, 5.629-11.917), PD sleep scale (OR, 0.058; 95% CI, 0.05-0.067), preoperative length of stay (OR, 1.230; 95% CI, 1.053-1.437), and preoperative brain atrophy (OR, 3.912; 95% CI, 3.5-4.255) were independent factors that influenced the occurrence of POD after DBS surgery. A nomogram model was constructed using these indicators. The model predicted an area under the receiver operating characteristic curve after DBS surgery of 0.870 (95% CI, 0.808-0.918), sensitivity of 74.19%, and specificity of 91.54%.
   CONCLUSIONS: The present study has presented a reliable and useful nomogram that can accurately predict the occurrence of POD after DBS surgery in patients with PD. This tool is easy to use and could assist physicians during the therapeutic decision-making process.
C1 [Wang, Xue-qi; Zhao, Mei] Anhui Med Univ, Nursing Sch, Hefei, Anhui, Peoples R China.
   [Wang, Xue-qi; Zhuang, Hong-xia; Zhang, Li-xiang; Chen, Xia; Niu, Chao-shi] Univ Sci & Technol China, Dept Neurosurg, Affiliated Hosp 1, Hefei, Anhui, Peoples R China.
   [Wang, Xue-qi; Zhuang, Hong-xia; Zhang, Li-xiang; Chen, Xia; Niu, Chao-shi] Univ Sci & Technol China, Div Life Sci & Med, Hefei, Anhui, Peoples R China.
RP Zhao, M (reprint author), Anhui Med Univ, Nursing Sch, Hefei, Anhui, Peoples R China.
EM zhaomei2019@163.com
FU Nursing School of Anhui Medical University; Department of Neurosurgery,
   First Affiliated Hospital of University of Science and Technology of
   China
FX The present study was supported by the Nursing School of Anhui Medical
   University and Department of Neurosurgery, First Affiliated Hospital of
   University of Science and Technology of China.
CR Akunne A, 2012, AGE AGEING, V41, P285, DOI 10.1093/ageing/afr147
   Bhattacharya B, 2017, J SURG RES, V207, P223, DOI 10.1016/j.jss.2016.08.084
   Carlson JD, 2014, J CLIN NEUROSCI, V21, P1192, DOI 10.1016/j.jocn.2013.12.007
   Chaudhuri KR, 2007, MOVEMENT DISORD, V22, P1901, DOI 10.1002/mds.21596
   Cozac VV, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00132
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Inouye SK, 2014, ANN INTERN MED, V160, P526, DOI 10.7326/M13-1927
   INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941
   Jain FA, 2011, PSYCHOSOMATICS, V52, P410, DOI 10.1016/j.psym.2011.03.011
   Kim MS, 2016, J NEURAL TRANSM, V123, P589, DOI 10.1007/s00702-016-1555-0
   Lange M, 2015, J NEUROL SCI, V355, P168, DOI 10.1016/j.jns.2015.06.012
   Lucke JA, 2019, EUR J EMERG MED, V26, P428, DOI 10.1097/MEJ.0000000000000587
   Radziunas A, 2020, BRAIN IMAGING BEHAV, V14, P62, DOI 10.1007/s11682-018-9971-4
   Serrano-Duenas M, 2005, PARKINSONISM RELAT D, V11, P387, DOI 10.1016/j.parkreldis.2005.05.002
   Silverstein JH, 2007, ANESTHESIOLOGY, V106, P622, DOI 10.1097/00000542-200703000-00026
   Tanaka M, 2018, WORLD NEUROSURG, V114, pE518, DOI 10.1016/j.wneu.2018.03.021
   Vardy ERLC, 2015, J NEUROL, V262, P2401, DOI 10.1007/s00415-015-7760-1
   Wang G, 2009, CLIN NEUROL NEUROSUR, V111, P523, DOI 10.1016/j.clineuro.2009.02.005
   Weaver F. M., 2009, CURRENT NEUROLOGY NE, V9, P266, DOI DOI 10.1007/S11910-009-0039-0
   Weinrebe W, 2016, Z GERONTOL GERIATR, V49, P52, DOI 10.1007/s00391-015-0871-6
   Zhu K B, 2016, Zhonghua Xin Xue Guan Bing Za Zhi, V44, P338, DOI 10.3760/cma.j.issn.0253-3758.2016.04.012
NR 21
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E551
EP E557
DI 10.1016/j.wneu.2019.06.151
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200068
PM 31254699
DA 2020-05-12
ER

PT J
AU Ward, M
   Ward, B
   Abraham, M
   Nicheporuck, A
   Elkattawy, O
   Herschman, Y
   Mammis, A
   Liu, JK
   Paskhover, B
AF Ward, Max
   Ward, Brittany
   Abraham, Mickey
   Nicheporuck, Alexis
   Elkattawy, Omar
   Herschman, Yehuda
   Mammis, Antonios
   Liu, James K.
   Paskhover, Boris
TI Thy educational Quality of Neurosurgical Resources on YouTube
SO WORLD NEUROSURGERY
LA English
DT Article
DE DISCERN; Most viewed; Neurosurgery; Quality; Relevance; YouTube
ID INFORMATION
AB BACKGROUND: YouTube has rapidly become one of the most widely accessed educational platforms of our time. Over 1 billion hours of YouTube content are viewed every day, including neurosurgical videos. To date, there has never been a qualitative analysis of neurosurgical content on YouTube.
   METHODS: By evaluating the search interest of neurosurgical terms via Google Trends, we selected 8 search terms to assess on YouTube. For each term, we selected the top 20 videos, 10 when sorting by view count and 10 when sorting by relevance. Using the DISCERN criteria, we evaluated 131 unique YouTube videos to assess bias and overall educational quality. In addition, we categorized each video based on its intended utility and the credentials of the video's commentator. The number of views, average DISCERN scores, and bias scores were compared between search terms and between video categories.
   RESULTS: There were 131 unique and 29 duplicate videos. The videos received 143,538,363 combined views (1,104,141 average). The average video age was 4.6 years (range, 66 days to 12.5 years). The term "brain surgery" received the most total views (62,339,885), with an average DISCERN score of 1.65 overall and 2 for bias. The average DISCERN score was 2.02 overall and 2.39 for bias. There were 45 advertisements for either hospitals, physicians, or companies, totaling 18,052,873 views and averaging a DISCERN score of 2.04.
   CONCLUSIONS: YouTube is a frequently viewed but biased source for neurosurgical information. Advertisements are frequently disguised as educational material, and few videos provide references or sources for their information.
C1 [Herschman, Yehuda; Mammis, Antonios; Liu, James K.] Facial Plast & Reconstruct Surg, Dept Neurol Surg, Newark, NJ USA.
   [Paskhover, Boris] Facial Plast & Reconstruct Surg, Dept Otolaryngol, Newark, NJ USA.
   [Ward, Max; Ward, Brittany; Abraham, Mickey; Nicheporuck, Alexis; Elkattawy, Omar] Rutgers New Jersey Med Sch, Newark, NJ 07103 USA.
RP Ward, M (reprint author), Rutgers New Jersey Med Sch, Newark, NJ 07103 USA.
EM Mw731@njms.rutgers.edu
OI WARD, MAX/0000-0003-1279-4920
CR American Association of Neurological Surgeons, NEUR COND TREATM
   Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105
   MANTEL N, 1975, BIOMETRICS, V31, P727, DOI 10.2307/2529555
   McCool ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139895
   Samuel N, 2017, WORLD NEUROSURG, V105, P394, DOI 10.1016/j.wneu.2017.05.111
   Socialbakers, MUST KNOW INFL TREND
   Ward B, 2018, JAMA FACIAL PLAST SU, V20, P333, DOI 10.1001/jamafacial.2018.0009
   Ward M, 2020, PEDIATR NEUROL, V103, P84, DOI 10.1016/j.pediatrneurol.2019.04.001
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E660
EP E665
DI 10.1016/j.wneu.2019.06.184
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200083
PM 31276855
DA 2020-05-12
ER

PT J
AU Werner, JM
   Kuhl, S
   Ulrich, K
   Krischek, B
   Stavrinou, P
   Goldbrunner, R
   Timmer, M
AF Werner, Jan-Michael
   Kuhl, Saskia
   Ulrich, Katharina
   Krischek, Boris
   Stavrinou, Pantelis
   Goldbrunner, Roland
   Timmer, Marco
TI Expression of CD40 Correlates Negatively with Overall and
   Progression-Free Survival of LOW- and High-Grade Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE CD40; CD40L; Glioblastoma; Glioma; Low-grade glioma; Prognosis; TNF
   receptor
ID MONOCLONAL-ANTIBODY; CANCER CELLS; CARCINOMA; PLATELETS; LIGAND; GROWTH
AB BACKGROUND: Low-grade gliomas (LGGs) are known to progress to glioblastoma (GBM), decreasing the chances of survival. The tumor necrosis factor receptor CD40 and its ligand CD40L have shown value as biomarkers for GBM. The present study evaluated the role of CD40/CD40L in LGG and GBM in differentiating isocitrate dehydrogenase (IDH) wild-type and IDH-mutant GBM.
   METHODS: The present study was based on patient-derived samples (74 grade II gliomas, 36 grade III gliomas, and 40 cases of GBM) and expression analysis using real-time polymerase chain reaction. Open-access data from The Cancer Genome Atlas (TCGA) and the strong cohorts of TCGA data sets "brain lower grade glioma" and "glioblastoma" were used to run the analysis on mRNA expression as a validation data set.
   RESULTS: We found that patients with LGG and CD40 overexpression experienced shorter progression-free survival (43 vs. 29 months; hazard ratio, 0.5715; P = 0.0262) and overall survival (116 vs. 54 months; hazard ratio, 0.3431; P < 0.0001). Consistently, relapsed grade II glioma showed greater CD40 expression compared with primary grade II glioma (P = 0.0028). Just as with LGG, CD40 was a negative marker for overall survival in GBM (12 vs. 10 months; hazard ratio, 0.5178; P = 0.0491). In this context, we found greater CD40 expression in IDH wild-type GBM than in IDH-mutant GBM. The data obtained from TCGA supported our findings, with similar results for PFS and OS in LGG and GBM. CD40L expression showed no correlation with the survival data.
   CONCLUSION: High CD40 expression showed a significant correlation with poor outcomes for both LGG and GBM and was overexpressed in IDH wild-type GBM.
C1 [Werner, Jan-Michael; Kuhl, Saskia; Krischek, Boris; Stavrinou, Pantelis; Goldbrunner, Roland; Timmer, Marco] Univ Cologne, Fac Med, Ctr Neurosurg, Lab Neurooncol & Expt Neurosurg,Dept Gen Neurosur, Cologne, Germany.
   [Werner, Jan-Michael] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany.
   Univ Cologne, Univ Hosp Cologne, Cologne, Germany.
   [Ulrich, Katharina] German Ctr Neurodegenerat Dis, Bonn, Germany.
   [Timmer, Marco] Max Planck Inst Metab Res, Cologne, Germany.
RP Timmer, M (reprint author), Univ Cologne, Fac Med, Ctr Neurosurg, Lab Neurooncol & Expt Neurosurg,Dept Gen Neurosur, Cologne, Germany.; Timmer, M (reprint author), Max Planck Inst Metab Res, Cologne, Germany.
EM marco.timmer@uk-koeln.de
OI Werner, Jan-Michael/0000-0001-7147-4594
FU German Foundation for Young Adults with Cancer
FX The present study was supported by the German Foundation for Young
   Adults with Cancer.
CR Bensinger W, 2012, BRIT J HAEMATOL, V159, P58, DOI 10.1111/j.1365-2141.2012.09251.x
   Buchner K, 2003, J PATHOL, V201, P288, DOI 10.1002/path.1425
   Bugajska U, 2002, J NATL CANCER I, V94, P1381
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen JC, 2016, INT J HEAT MASS TRAN, V95, P1, DOI 10.1016/j.ijheatmasstransfer.2015.11.067
   Chonan M, 2015, NEURO-ONCOLOGY, V17, P1453, DOI 10.1093/neuonc/nov090
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gormand F, 1999, SCAND J IMMUNOL, V49, P355
   Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393
   Hirano A, 1999, BLOOD, V93, P2999
   Hussein M, 2010, HAEMATOL-HEMATOL J, V95, P845, DOI 10.3324/haematol.2009.008003
   Iida T, 2010, SURGERY, V148, P925, DOI 10.1016/j.surg.2010.02.004
   Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377
   Li R, 2009, INT J MOL SCI, V10, P3900, DOI 10.3390/ijms10093900
   Loskog A, 2016, BRIT J CANCER, V114, P872, DOI 10.1038/bjc.2016.42
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Matsumura Y, 2016, ANTICANCER RES, V36, P4467, DOI 10.21873/anticanres.10991
   Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Qin LJ, 2016, BIOMED PHARMACOTHER, V79, P166, DOI 10.1016/j.biopha.2016.01.006
   Reuss DE, 2015, ACTA NEUROPATHOL, V130, P407, DOI 10.1007/s00401-015-1454-8
   Shibahara I, 2012, INT J CLIN ONCOL, V17, P551, DOI 10.1007/s10147-011-0323-2
   Shoji T, 2016, NEURO-ONCOLOGY, V18, P1120, DOI 10.1093/neuonc/now023
   Vonderheide RH, 2007, CLIN CANCER RES, V13, P1083, DOI 10.1158/1078-0432.CCR-06-1893
   Walker PR, 2015, NEURO-ONCOLOGY, V17, P1428, DOI 10.1093/neuonc/nov138
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
   Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805
   Wischhusen J, 2005, J NEUROIMMUNOL, V162, P28, DOI 10.1016/j.jneuroim.2005.01.005
   Zhou Y, 2016, CANCER IMMUNOL IMMUN, V65, P919, DOI 10.1007/s00262-016-1847-0
   Zhou Y, 2012, CANCER IMMUNOL IMMUN, V61, P1735, DOI 10.1007/s00262-011-1194-0
NR 30
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E17
EP E25
DI 10.1016/j.wneu.2019.05.112
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200004
PM 31125770
DA 2020-05-12
ER

PT J
AU Wright, CH
   Wright, J
   Alonso, A
   Raghavan, A
   Momotaz, H
   Burant, C
   Zhou, XF
   Selman, W
   Sajatovic, M
   Hoffer, A
AF Wright, Christina Huang
   Wright, James
   Alonso, Andrea
   Raghavan, Alankrita
   Momotaz, Hasina
   Burant, Christopher
   Zhou, Xiaofei
   Selman, Warren
   Sajatovic, Martha
   Hoffer, Alan
TI Subdural Hematoma in Patients with Hematologic Malignancies: An Outcome
   Analysis and Examination of Risk Factors of Operative and Nonoperative
   Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hematologic malignancy; Myelodysplastic syndrome; Subdural hematoma
ID ADVERSE PERIOPERATIVE OUTCOMES; CHRONIC MYELOID-LEUKEMIA; INTRACRANIAL
   HEMORRHAGE; CHEMOTHERAPY; PREVALENCE; MORTALITY; ADULTS
AB BACKGROUND: Patients with hematologic disorders who present with subdural hematomas (SDH) present a surgical decision-making challenge. Because of intrinsic coagulopathy, platelet dysfunction, and immunosuppression, surgical intervention poses a unique set of risks.
   OBJECTIVE: To describe a clinical sample of patients with hematologic disorders and concurrent SDH, to compare baseline and outcome variables, including complication rates and survival, in surgical versus nonsurgical management, and to identify clinical variables that may predict outcomes.
   METHODS: A 12-year retrospective case-control study was carried out of 50 adult patients with hematologic malignancies and SDH. Patients underwent surgical evacuation for SDH. Controls did not. Outcomes included discharge disposition, Glasgow Outcome Scale score, 30-day mortality, and overall survival. Complications included seizure, reoperation, and readmission. A Fisher exact test or chi(2) analysis compared categorical variables; continuous outcomes were compared with a Student t test. A Kaplan-Meier survival analysis was performed and multivariable Cox logistic regression evaluated variables associated with overall mortality.
   RESULTS: Surgical and nonsurgical groups differed only by Glasgow Coma Scale score, with slightly lower Glasgow Coma Scale scores in the surgical group. Complication rates did not differ; however, the 30-day reoperation rate was 35% for the surgical cohort. Overall, seizure incidence was 18%, readmission was 30%, 30-day mortality was 38%, median survival was 140.5 days, and 75% had a Glasgow Outcome Scale score of 1-3 at censorship. Increased age, low hemoglobin levels, and low platelet levels were associated with increased risk of mortality.
   CONCLUSIONS: Low platelet and hemoglobin levels are consistent markers of poor prognosis and surgical intervention, either as a proxy of or as a cause for clinical deterioration, is associated with increased mortality risk.
C1 [Wright, Christina Huang; Wright, James; Zhou, Xiaofei; Selman, Warren; Hoffer, Alan] Univ Hosp Cleveland Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA.
   [Sajatovic, Martha] Univ Hosp Cleveland Med Ctr, Dept Neurol & Psychiat, Cleveland, OH USA.
   [Sajatovic, Martha] Univ Hosp Cleveland Med Ctr, Neurol & Behav Outcomes Ctr, Cleveland, OH USA.
   [Wright, Christina Huang; Wright, James; Alonso, Andrea; Raghavan, Alankrita; Zhou, Xiaofei; Selman, Warren; Hoffer, Alan] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Momotaz, Hasina] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
   [Burant, Christopher] Case Western Reserve Univ, Mandel Sch Appl Social Sci, Cleveland, OH 44106 USA.
RP Wright, CH (reprint author), Univ Hosp Cleveland Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA.
EM christina.wright@uhhospitals.org
CR Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550
   Bower H, 2016, J CLIN ONCOL, V34, P2851, DOI 10.1200/JCO.2015.66.2866
   Brunner AM, 2013, CANCER-AM CANCER SOC, V119, P2620, DOI 10.1002/cncr.28106
   Chandler FL, 2018, ONCOL NURS FORUM, V45, P177, DOI 10.1188/18.ONF.177-186
   Chen CY, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-97
   Chern JJ, 2011, J NEUROSURG, V115, P268, DOI 10.3171/2011.4.JNS101784
   Dayyani F, 2011, AM J HEMATOL, V86, P546, DOI 10.1002/ajh.22031
   Delord M, 2018, LEUKEMIA RES, V69, P94, DOI 10.1016/j.leukres.2018.04.008
   FENAUX P, 1993, BLOOD, V82, P3241
   Gonzalez-Duarte Alejandra, 2008, J Stroke Cerebrovasc Dis, V17, P204, DOI 10.1016/j.jstrokecerebrovasdis.2008.02.008
   Ichikawa K, 2016, INT J HEMATOL, V104, P612, DOI 10.1007/s12185-016-2072-5
   JOURDAN E, 1995, BRIT J HAEMATOL, V89, P527, DOI 10.1111/j.1365-2141.1995.tb08358.x
   Krok-Schoen JL, 2018, CANCER MED-US, V7, P3425, DOI 10.1002/cam4.1461
   LIEBERMAN A, 1978, STROKE, V9, P18, DOI 10.1161/01.STR.9.1.18
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402
   MINETTE SE, 1989, MAYO CLIN PROC, V64, P637, DOI 10.1016/S0025-6196(12)65340-3
   Najima Y, 2009, AM J HEMATOL, V84, P298, DOI 10.1002/ajh.21382
   Navi BB, 2010, NEUROLOGY, V74, P494, DOI 10.1212/WNL.0b013e3181cef837
   Newman JM, 2018, J KNEE SURG, V31, P291, DOI 10.1055/s-0037-1603335
   Newman JM, 2017, J ARTHROPLASTY, V32, P2436, DOI 10.1016/j.arth.2017.03.002
   Openshaw H, 2008, BONE MARROW TRANSPL, V41, P791, DOI 10.1038/sj.bmt.1705971
   Owattanapanich Weerapat, 2016, Journal of the Medical Association of Thailand, V99, P15
   Pulte D, 2016, BLOOD, V128, P2409
   Pulte D, 2008, HAEMATOLOGICA, V93, P594, DOI 10.3324/haematol.12304
   Reichman J, 2012, NEUROSURGERY, V71, P74, DOI 10.1227/NEU.0b013e3182517938
   Schwarz F, 2015, CLIN NEUROL NEUROSUR, V138, P66, DOI 10.1016/j.clineuro.2015.08.002
   Sommer SP, 2011, EUR J CARDIO-THORAC, V40, P173, DOI 10.1016/j.ejcts.2010.10.031
   U. S. Census Bureau, 2017, AG NAT PROJ NUMB CHI
   Ureshino H, 2016, INTERNAL MED, V55, P2703, DOI 10.2169/internalmedicine.55.6966
   Zhang XH, 2016, ANN HEMATOL, V95, P1637, DOI 10.1007/s00277-016-2767-y
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1061
EP E1069
DI 10.1016/j.wneu.2019.07.079
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200131
PM 31323408
DA 2020-05-12
ER

PT J
AU Wu, DL
   Wang, HW
   Hu, P
   Xu, WJ
   Liu, J
AF Wu, Deluo
   Wang, Hongwei
   Hu, Pan
   Xu, Weijie
   Liu, Jun
TI The Postoperative Prognosis of Thoracic Ossification of the Ligamentum
   Flavum can be Described by a Novel Method: The Thoracic Ossification of
   the Ligamentum Flavum Score
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ligamentum flavum; Ossification; Postoperative prognosis; Score;
   Thoracic
ID POSTERIOR LONGITUDINAL LIGAMENT; SURGICAL-TREATMENT; RETROSPECTIVE
   ANALYSIS; CLINICAL-FEATURES; MYELOPATHY; COMPLICATIONS; OUTCOMES; SPINE;
   DECOMPRESSION; COMPRESSION
AB OBJECTIVE: To create an available thoracic ossification of the ligamentum flavum (TOLF) score as a rudimentary predictor for the postoperative prognosis of TOLF.
   METHODS: A retrospective review was conducted for all patients with TOLF who received surgical decompression from April 2012 to February 2019. The TOLF score consists of 5 components, namely, the age at surgery (1-3 points), diabetes mellitus (1 point), preoperative duration of symptoms (1-2 points), spinal canal axial remnant area ratio (0-2 points), and intramedullary signal change on magnetic resonance imaging (1 point). The scores of all patients were calculated and analyzed for their correlation with the postoperative recovery ratio. In addition, intraoperative blood loss, urinary catheter indwelling time, cerebrospinal fluid leakage, and postoperative neurologic deterioration were also measured.
   RESULTS: A total of 64 patients were included. The mean TOLF score at the final follow-up was 4.6 points in the excellent group (20 patients), 5.0 points in the good group (29 patients), and 7.3 points in the poor group (15 patients). A higher TOLF score predicts lower postoperative recovery ratio (P = 0.000), longer urinary catheter indwelling time (P = 0.023), and higher incidence of postoperative neurologic deterioration (P = 0.000). However, no correlation was identified between the TOLF score and intraoperative blood loss (P = 0.755) or cerebrospinal fluid leakage (P = 0.911).
   CONCLUSIONS: The TOLF score is a novel and rudimentary scoring system that describes the predictive factors that indicate the postoperative prognosis of TOLF.
C1 [Wu, Deluo; Wang, Hongwei; Liu, Jun] Chinese PLA, Shenyang Mil Area Command, Gen Hosp, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
   [Wu, Deluo] Dalian Med Univ, Grad Sch, Dalian, Liaoning, Peoples R China.
   [Hu, Pan] Chinese Med Hosp Dianjiang Cty, Dept Orthoped, Chongqing, Peoples R China.
   [Xu, Weijie] Jinzhou Med Univ, Grad Sch, Jinzhou, Liaoning, Peoples R China.
RP Liu, J (reprint author), Chinese PLA, Shenyang Mil Area Command, Gen Hosp, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
EM junliu_gh@163.com
CR Aizawa T, 2006, J NEUROSURG-SPINE, V5, P514, DOI 10.3171/spi.2006.5.6.514
   Akhaddar A, 2002, JOINT BONE SPINE, V69, P319, DOI 10.1016/S1297-319X(02)00400-1
   Ando K, 2012, J NEUROSURG-SPINE, V16, P147, DOI 10.3171/2011.10.SPINE11296
   Braddock R, 2002, PEDIATR RES, V51, P647, DOI 10.1203/00006450-200205000-00017
   Chang UK, 2001, SPINAL CORD, V39, P362, DOI 10.1038/sj.sc.3101174
   Chen ZQ, 2015, ORTHOP SURG, V7, P208, DOI 10.1111/os.12190
   Gao R, 2013, SPINE J, V13, P1032, DOI 10.1016/j.spinee.2013.02.034
   Guo JJ, 2010, SPINE, V35, P51, DOI 10.1097/BRS.0b013e3181b3f779
   Hou XF, 2018, SPINAL CORD, V56, P301, DOI 10.1038/s41393-017-0040-4
   Inamasu J, 2009, J NEUROSURG SCI, V53, P93
   Inamasu J, 2006, J NEUROSURG-SPINE, V5, P133, DOI 10.3171/spi.2006.5.2.133
   Ito T, 1996, SPINE, V21, P827, DOI 10.1097/00007632-199604010-00010
   Kawaguchi Y, 2013, SPINE J, V13, P1095, DOI 10.1016/j.spinee.2013.03.001
   KOJIMA T, 1992, INT ORTHOP, V16, P75
   Lang N, 2013, EUR SPINE J, V22, P857, DOI 10.1007/s00586-012-2492-8
   Lee BJ, 2019, EUR SPINE J, V28, P1846, DOI 10.1007/s00586-018-5750-6
   Li WJ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0672-5
   Li Z, 2016, SPINAL CORD, V54, P188, DOI 10.1038/sc.2015.139
   Luo JQ, 2017, J ORTHOP RES, V35, P1058, DOI 10.1002/jor.23302
   Miyakoshi N, 2003, J NEUROSURG, V99, P251, DOI 10.3171/spi.2003.99.3.0251
   Onishi E, 2016, SPINE, V41, pE1356, DOI 10.1097/BRS.0000000000001622
   Onishi E, 2016, CLIN SPINE SURG, V29, pE389, DOI 10.1097/BSD.0000000000000059
   Osman NS, 2018, SPINE, V43, pE842, DOI 10.1097/BRS.0000000000002563
   Payer M, 2000, J NEUROSURG, V92, P105, DOI 10.3171/spi.2000.92.1.0105
   Sanghvi AV, 2011, EUR SPINE J, V20, P205, DOI 10.1007/s00586-010-1423-9
   Setter SM, 2003, ANN PHARMACOTHER, V37, P1858, DOI 10.1345/aph.1D002
   Sun JC, 2014, J CLIN NEUROSCI, V21, P2102, DOI 10.1016/j.jocn.2014.02.027
   Tang CYK, 2017, EUR SPINE J, V26, P2598, DOI 10.1007/s00586-017-5078-7
   Wang H, 2017, J CLIN NEUROSCI, V45, P83, DOI 10.1016/j.jocn.2017.07.008
   Wang T, 2018, TURK NEUROSURG, V28, P616, DOI 10.5137/1019-5149.JTN.20391-17.1
   Wang T, 2017, CLIN SPINE SURG, V30, pE7, DOI 10.1097/BSD.0000000000000213
   Yukawa Y, 2007, SPINE, V32, P1675, DOI 10.1097/BRS.0b013e318074d62e
   Zhou SY, 2018, WORLD NEUROSURG, V110, pE1025, DOI 10.1016/j.wneu.2017.11.164
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E47
EP E53
DI 10.1016/j.wneu.2019.05.185
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200006
PM 31152889
DA 2020-05-12
ER

PT J
AU Wu, HH
   Wang, GC
   Sun, LW
   Chang, KS
   Yang, JS
   Chu, L
   Chen, CM
AF Wu, Hsuan-Han
   Wang, Guan-Chyuan
   Sun, Li-Wei
   Chang, Kai-Sheng
   Yang, Jun-Song
   Chu, Lei
   Chen, Chien-Min
TI Symptomatic Lumbar Juxtafacet Cyst Treated by Full Endoscopic Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Full endoscopic technique; Interlaminar; JFC; Juxtafacet
   cyst; Transfacet; Transforaminal; Translaminar
ID SYNOVIAL CYSTS; JOINT CYSTS; MANAGEMENT
AB BACKGROUND: Juxtafacet cysts (JFCs) include both synovial and ganglion cysts adjacent to a spinal facet joint or arising from the ligamentum flavum of the spinal facet joints. Various treatments have been proposed; however, a surgical approach appears to be most effective. The aim of this study was to review patients with lumbar JFCs treated using a full endoscopic approach and elaborate the details of the surgical routes and techniques and their merits and pitfalls.
   METHODS: All patients with lumbar JFCs underwent complete endoscopic cyst removal. Muscle power, visual analog scale score, modified MacNab criteria score, and magnetic resonance imaging were assessed during follow-up.
   RESULTS: The study enrolled 8 patients. Five patients received an interlaminar approach, 2 patients received a transforaminal approach, and 1 patient received a transfacet approach. Visual analog scale scores decreased from a mean of 7.75 (range, 5-10) before surgery to 0.625 (range, 0-2) after surgery, and modified MacNab criteria score ranged from good to excellent after surgery. No neurologic injuries were observed.
   CONCLUSIONS: JFCs could be effectively treated by full endoscopic surgery. The type of approach should be based on the anatomic site of the lesion and the condition of the patient. The interlaminar approach is appropriate for cysts located in the lower segment with larger interlaminar space. The transforaminal or transfacet approach is preferred for patients for whom general anesthesia is a high risk.
C1 [Wu, Hsuan-Han; Sun, Li-Wei; Chang, Kai-Sheng; Chen, Chien-Min] Changhua Christian Hosp, Dept Surg, Div Neurosurg, Changhua, Taiwan.
   [Wang, Guan-Chyuan] Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Dept Neurosurg, Hualien, Taiwan.
   [Sun, Li-Wei] Chung Shan Med Univ, Inst Biochem Microbiol & Immunol, Taichung, Taiwan.
   [Yang, Jun-Song] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spinal Surg, Xian, Shaanxi, Peoples R China.
   [Chu, Lei] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped, Chongqing, Peoples R China.
   [Chen, Chien-Min] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.
   [Chen, Chien-Min] Dayeh Univ, Coll Nursing & Hlth Sci, Changhua, Taiwan.
RP Chen, CM (reprint author), Changhua Christian Hosp, Dept Surg, Div Neurosurg, Changhua, Taiwan.; Chen, CM (reprint author), Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.; Chen, CM (reprint author), Dayeh Univ, Coll Nursing & Hlth Sci, Changhua, Taiwan.
EM 96015@cch.org.tw
OI Wang, Guan-Chyuan/0000-0003-2815-7846
CR Boody BS, 2016, J AM ACAD ORTHOP SUR, V24, P829, DOI 10.5435/JAAOS-D-14-00461
   CAMERON SE, 1992, SPINE, V17, P1528, DOI 10.1097/00007632-199212000-00019
   Campbell RJ, 2017, WORLD NEUROSURG, V98, P492, DOI 10.1016/j.wneu.2016.11.044
   Choudhri Haroon Fiaz, 2006, Neurosurg Focus, V20, pE1
   Epstein Nancy E, 2012, Surg Neurol Int, V3, pS157, DOI 10.4103/2152-7806.98576
   Hatgis J, 2017, CUREUS, V9, DOI 10.7759/cureus.1318
   HSU KY, 1995, SPINE, V20, P80, DOI 10.1097/00007632-199501000-00015
   KAO CC, 1968, J NEUROSURG, V29, P168, DOI 10.3171/jns.1968.29.2.0168
   Komp M, 2014, SURG INNOV, V21, P605, DOI 10.1177/1553350614525668
   Lyons MK, 2000, J NEUROSURG, V93, P53, DOI 10.3171/spi.2000.93.1.0053
   ONOFRIO BM, 1988, NEUROSURGERY, V22, P642, DOI 10.1227/00006123-198804000-00004
   Sabo RA, 1996, J NEUROSURG, V85, P560, DOI 10.3171/jns.1996.85.4.0560
   Soren A, 1966, Clin Orthop Relat Res, V48, P173
   Wu HH, 2018, WORLD NEUROSURG, V116, P35, DOI 10.1016/j.wneu.2018.05.018
   YARDE WL, 1995, SURG NEUROL, V43, P459, DOI 10.1016/0090-3019(95)80090-4
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E598
EP E604
DI 10.1016/j.wneu.2019.06.168
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200075
PM 31260849
DA 2020-05-12
ER

PT J
AU Wu, LF
   Zhao, WB
   Rajah, GB
   Wu, D
   Chen, J
   Zhang, Z
   Wu, CJ
   Li, CH
   Duan, JG
   An, H
   Che, RW
   Jiang, F
   Ding, YC
   Ji, XM
AF Wu, Longfei
   Zhao, Wenbo
   Rajah, Gary B.
   Wu, Di
   Chen, Jian
   Zhang, Zhen
   Wu, Chuanjie
   Li, Chuanhui
   Duan, Jiangang
   An, Hong
   Che, Ruiwen
   Jiang, Fang
   Ding, Yuchuan
   Ji, Xunming
TI Postinterventional Sedation Worsens Functional Outcomes in Patients with
   Acute Ischemic Stroke Treated with Endovascular Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular therapy; Functional outcome; Large-vessel occlusion;
   Postinterventional sedation; Stroke
ID HEALTH-CARE PROFESSIONALS; LONG-TERM MORTALITY; CONSCIOUS SEDATION;
   GENERAL-ANESTHESIA; EARLY MANAGEMENT; THROMBECTOMY; METAANALYSIS;
   GUIDELINES; CLASSIFICATION; INTUBATION
AB BACKGROUND: Postinterventional sedation is commonly used in clinical practice to ensure patient safety and comfort. Although sedation or anesthesia during thrombectomy has been well studied, the association between postinterventional sedation and functional outcomes in endovascularly treated patients with acute ischemic stroke (AIS) has yet to be investigated. We describe the association between postinterventional sedation and functional outcomes in patients with AIS treated with endovascular therapy (EVT).
   METHODS: This observational study was based on a prospective registry. Patients with AIS treated with EVT from January 2013 to August 2017 at Xuanwu Hospital, Capital Medical University were included. Patients receiving postinterventional sedation were compared with patients not receiving sedation. The primary outcome was the 3 months modified Rankin Scale score.
   RESULTS: A total of 268 patients were eligible for study: 112 patients (41.8%) receiving postinterventional sedation and 156 patients (58.2%) without sedation. At 3 months follow-up, the median modified Rankin Scale score was 4 (interquartile range, 3-6) in the sedation group and 2 (interquartile range, 1-4) in the nonsedation group (P < 0.001). Multivariable regression analysis suggested that the need for postinterventional sedation was associated with unfavorable outcomes, with an odds ratio of 0.20 for functional independence (95% confidence interval [CI], 0.078-0.487; P < 0.901), 0.06 for freedom from disability (95% CI, 0.017 0/28, P < 0.001), and 8.37 for death (95% CI, 2.196-31.889; P = 0.002).
   CONCLUSIONS: Postinterventional sedation worsens functional outcomes in patients with AIS with large-vessel occlusions treated with EVT. Whether the sedation is a causative factor or a surrogate for poor functional outcomes remains to be determined.
C1 [Wu, Longfei; Zhao, Wenbo; Wu, Di; Zhang, Zhen; Wu, Chuanjie; Duan, Jiangang; An, Hong; Che, Ruiwen; Jiang, Fang] Capital Med Univ, Dept Neurol, Xuanwu Hosp, Beijing, Peoples R China.
   [Wu, Longfei; Wu, Di; An, Hong] Capital Med Univ, China Amer Inst Neurosci, Xuanwu Hosp, Beijing, Peoples R China.
   [Chen, Jian; Li, Chuanhui; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI USA.
   [Rajah, Gary B.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY USA.
   [Rajah, Gary B.] Gates Vasc Inst Kaleida Hlth, Dept Neurosurg, Buffalo, NY USA.
RP Ji, XM (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM jixm@ccmu.edu.cn
FU Cheung Kong (Chang Jiang) Scholars Program [T51]; National Key Research
   and Development Program of China [2016YFC1301502]; National Science
   Foundation of ChinaNational Natural Science Foundation of China
   [81601006]; Beijing Municipal Administration of Hospitals Clinical
   Medicine Development of Special Funding Support [ZYLX201706]
FX This study was funded by Cheung Kong (Chang Jiang) Scholars Program
   (T51), National Key Research and Development Program of China
   (2016YFC1301502), the National Science Foundation of China (81601006),
   and Beijing Municipal Administration of Hospitals Clinical Medicine
   Development of Special Funding Support (ZYLX201706).
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Al-Mufti F, 2017, J INTENSIVE CARE MED, V32, P373, DOI 10.1177/0885066616656361
   Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Bembenek J, 2011, J THROMB THROMBOLYS, V32, P96, DOI 10.1007/s11239-010-0548-3
   Campbell BCV, 2018, LANCET NEUROL, V17, P47, DOI 10.1016/S1474-4422(17)30407-6
   Campbell BCV, 2016, STROKE, V47, P798, DOI 10.1161/STROKEAHA.115.012360
   Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Hassan AE, 2012, NEUROCRIT CARE, V16, P246, DOI 10.1007/s12028-011-9638-0
   Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152
   Jadhav AP, 2017, JAMA NEUROL, V74, P704, DOI 10.1001/jamaneurol.2017.0192
   Leslie-Mazwi T, 2017, J NEUROINTERV SURG, V9, P1258, DOI 10.1136/neurintsurg-2017-013270
   Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872
   Mullen E, 2018, STROKE, V49
   Munsch F, 2016, STROKE, V47, P66, DOI 10.1161/STROKEAHA.115.011242
   Nii K, 2018, NEUROL MED-CHIR, V58, P79, DOI 10.2176/nmc.oa.2017-0188
   Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Savitz SI, 2017, STROKE, V48, P3413, DOI 10.1161/STROKEAHA.117.017283
   Schonenberger S, 2016, JAMA-J AM MED ASSOC, V316, P1986, DOI 10.1001/jama.2016.16623
   Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138
   Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2
   Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC
   Simonsen CZ, 2018, JAMA NEUROL, V75, P470, DOI 10.1001/jamaneurol.2017.4474
   Von der Brelie C, 2017, WORLD NEUROSURG, V97, P374, DOI 10.1016/j.wneu.2016.09.121
   von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049
   Whalin MK, 2017, AM J NEURORADIOL, V38, P294, DOI 10.3174/ajnr.A4992
   Zaidat OO, 2013, STROKE, V44, P2650, DOI 10.1161/STROKEAHA.113.001972
NR 30
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E794
EP E803
DI 10.1016/j.wneu.2019.06.227
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200101
PM 31295591
DA 2020-05-12
ER

PT J
AU Yahya, N
   Manan, HA
AF Yahya, Noorazrul
   Manan, Hanani A.
TI Utilisation of Diffusion Tensor Imaging in Intracranial Radiotherapy and
   Radiosurgery Planning for White Matter Dose Optimization: A Systematic
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diffusion tensor imaging; Radiosurgery; Radiotherapy; Treatment planning
ID RADIATION-INDUCED CHANGES; GAMMA-KNIFE RADIOSURGERY;
   ARTERIOVENOUS-MALFORMATION; STEREOTACTIC RADIOSURGERY; CORTICOSPINAL
   TRACT; PYRAMIDAL TRACT; TRACTOGRAPHY; INTEGRATION; BRAIN; MRI
AB BACKGROUND: Diffusion tensor imaging (DTI), which visualizes white matter tracts, can be integrated to optimize intracranial radiation therapy (RT) and radiosurgery (RS) treatment planning. This study aimed to systematically review the integration of DTI for dose optimization in terms of evidence of dose improvement, clinical parameter changes, and clinical outcome in RT/RS treatment planning.
   METHODS: PubMed and Scopus electronic databases were searched based on the guidelines established by PRISMA to obtain studies investigating the integration of DTI in intracranial RT/RS treatment planning. References and citations from Google Scholar were also extracted. Eligible studies were extracted for information on changes in dose distribution, treatment parameters, and outcome after DTI integration.
   RESULTS: Eighteen studies were selected for inclusion with 406 patients (median study size, 19; range: 2-144). Dose distribution, with or without DTI integration, described changes of treatment parameters, and the reported outcome of treatment were compared in 12, 7, and 10 studies, respectively. Dose distributions after DTI integration improved in all studies. Delivery time or monitor unit was higher after integration. In studies with long-term follow-up (median, >12 months), neurologic deficits were significantly fewer in patients with DTI integration.
   CONCLUSIONS: Integrating DTI into RT/RS treatment planning improved dose distribution, with higher treatment delivery time or monitor unit as a potential drawback. Fewer neurologic deficits were found with DTI integration.
C1 [Yahya, Noorazrul] Natl Univ Malaysia, Fac Hlth Sci, Diagnost Imaging & Radiotherapy, Kuala Lumpur, Malaysia.
   [Manan, Hanani A.] Univ Kebangsaan Malaysia, Med Ctr, Dept Radiol, Funct Image Proc Lab, Kuala Lumpur, Malaysia.
RP Yahya, N (reprint author), Natl Univ Malaysia, Fac Hlth Sci, Diagnost Imaging & Radiotherapy, Kuala Lumpur, Malaysia.
EM azrulyahya@ukm.edu.my
OI Yahya, Noorazrul/0000-0002-2736-6489
FU National University of Malaysia [GGPM-2017-095]
FX This study was funded by the National University of Malaysia
   (GGPM-2017-095).
CR Abdul Maman H, 2018, J SAINS KESIHAT MALA, V16, P85, DOI DOI 10.17576/JSKM-2018-1602-11
   Agarwal A, 2013, J NEURO-ONCOL, V112, P413, DOI 10.1007/s11060-013-1070-1
   Altabella L, 2018, PHYS MEDICA, V55, P127, DOI 10.1016/j.ejmp.2018.10.004
   Andrade-Souza YM, 2005, NEUROSURGERY, V56, P56, DOI 10.1227/01.NEU.0000145797.35968.ED
   Aoyama H, 2004, INT J RADIAT ONCOL, V58, P1177, DOI 10.1016/j.ijrobp.2003.08.034
   Aoyama H, 2003, RADIOTHER ONCOL, V68, P27, DOI 10.1016/S0167-8140(03)00032-X
   Baro V, 2019, WORLD NEUROSURG, V125, P24, DOI 10.1016/j.wneu.2019.01.099
   Berberat J, 2014, STRAHLENTHER ONKOL, V190, P939, DOI 10.1007/s00066-014-0676-3
   Bowden G, 2014, STEREOT FUNCT NEUROS, V92, P103, DOI 10.1159/000358271
   Chang Z, 2014, TECHNOL CANCER RES T, V13, P21, DOI 10.7785/tcrt.2012.500358
   Conti A, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12414
   Essayed WI, 2017, NEUROIMAGE-CLIN, V15, P659, DOI 10.1016/j.nicl.2017.06.011
   Foroni RI, 2010, RADIOSURG, V7, P128, DOI 10.1159/000288725
   FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304
   Gavin CG, 2016, J NEUROSURG, V125, P139, DOI 10.3171/2016.8.GKS161032
   Hey Spencer Phillips, 2015, AMA J Ethics, V17, P1108, DOI 10.1001/journalofethics.2015.17.12.ecas1-1512
   Hope TR, 2015, J MAGN RESON IMAGING, V41, P414, DOI 10.1002/jmri.24533
   Hou ZG, 2018, WORLD NEUROSURG, V113, pE561, DOI 10.1016/j.wneu.2018.02.095
   Igaki H, 2014, REP PRACT ONCOL RADI, V19, P310, DOI 10.1016/j.rpor.2014.01.002
   Kawasaki K, 2017, RADIOL PHYS TECHNOL, V10, P507, DOI 10.1007/s12194-017-0411-8
   Kim MS, 2018, J NEURORADIOLOGY, V45, P310, DOI 10.1016/j.neurad.2017.12.022
   Kinoshita M, 2010, J NEURO-ONCOL, V96, P409, DOI 10.1007/s11060-009-9979-0
   Kitahara S, 2005, AM J NEURORADIOL, V26, P2200
   Koga T, 2009, ACTA NEUROCHIR, V151, P465, DOI 10.1007/s00701-009-0279-4
   Koga T, 2012, INT J RADIAT ONCOL, V83, P129, DOI 10.1016/j.ijrobp.2011.05.036
   Koga T, 2012, INT J RADIAT ONCOL, V82, P799, DOI 10.1016/j.ijrobp.2010.11.046
   Koivula L, 2016, MED PHYS, V43, P4634, DOI 10.1118/1.4958677
   Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091
   Ma LJ, 2014, INT J COMPUT ASS RAD, V9, P1079, DOI 10.1007/s11548-014-1001-4
   Makale MT, 2017, NAT REV NEUROL, V13, P52, DOI 10.1038/nrneurol.2016.185
   Maruyama K, 2005, J NEUROSURG, V102, P673, DOI 10.3171/jns.2005.102.4.0673
   Maruyama K, 2008, INT J RADIAT ONCOL, V70, P1330, DOI 10.1016/j.ijrobp.2007.08.010
   Maruyama K, 2009, J NEUROSURG, V111, P520, DOI 10.3171/2008.4.17521
   Maruyania K, 2007, J NEUROSURG, V107, P721, DOI 10.3171/JNS-07/10/0721
   Mitrasinovic S, 2019, J CLIN NEUROSCI, V59, P12, DOI 10.1016/j.jocn.2018.09.029
   Mohamad M, 2017, J PHYS CONF SER, V851, DOI 10.1088/1742-6596/851/1/012016
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nagesh V, 2008, INT J RADIAT ONCOL, V70, P1002, DOI 10.1016/j.ijrobp.2007.08.020
   Nakamura JL, 2001, INT J RADIAT ONCOL, V51, P1313, DOI 10.1016/S0360-3016(01)01757-6
   Nattabi Haliimah A, 2017, Acad Radiol, DOI 10.1016/j.acra.2017.09.002
   Nazem-Zadeh MR, 2012, MED PHYS, V39, P5603, DOI 10.1118/1.4745560
   Pantelis E, 2010, INT J RADIAT ONCOL, V78, P257, DOI 10.1016/j.ijrobp.2009.10.064
   Piper RJ, 2018, J NEURO-ONCOL, V139, P77, DOI 10.1007/s11060-018-2843-3
   Pollock BE, 2017, NEUROSURGERY, V81, P928, DOI 10.1093/neuros/nyx010
   Price SJ, 2016, J MAGN RESON IMAGING, V43, P487, DOI 10.1002/jmri.24996
   Gomes JGR, 2016, J NEUROSURG, V125, P129, DOI 10.3171/2016.7.GKS161553
   Schmidt MA, 2015, PHYS MED BIOL, V60, pR323, DOI 10.1088/0031-9155/60/22/R323
   Schwendner MJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00424
   Shuto T, 2018, J NEUROSURG, V129, P86, DOI 10.3171/2018.7.GKS181378
   Sun L, 2017, TECHNOL CANCER RES T, V16, P850, DOI 10.1177/1533034617705283
   Thorwarth D, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150056
   Wang ML, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0364-1
   Welzel T, 2008, AM J NEURORADIOL, V29, P379, DOI 10.3174/ajnr.A0797
   Wen R, 2019, WORLD NEUROSURG, V123, P371, DOI 10.1016/j.wneu.2018.12.046
   Yahya N, 2018, ASIA-PAC J CLIN ONCO, V14, pe543, DOI 10.1111/ajco.12831
   Yahya N, 2018, STRAHLENTHER ONKOL, V194, P780, DOI 10.1007/s00066-018-1303-5
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E188
EP E198
DI 10.1016/j.wneu.2019.06.027
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200024
PM 31326352
DA 2020-05-12
ER

PT J
AU Yamagami, K
   Kurogi, R
   Kurogi, A
   Nishimura, K
   Onozuka, D
   Ren, N
   Kada, A
   Nishimura, A
   Arimura, K
   Ido, K
   Mizoguchi, M
   Sakamoto, T
   Kayama, T
   Suzuki, M
   Arai, H
   Hagihara, A
   Iihara, K
AF Yamagami, Keitaro
   Kurogi, Ryota
   Kurogi, Ai
   Nishimura, Kunihiro
   Onozuka, Daisuke
   Ren, Nice
   Kada, Akiko
   Nishimura, Ataru
   Arimura, Koichi
   Ido, Keisuke
   Mizoguchi, Masahiro
   Sakamoto, Tetsuya
   Kayama, Takamasa
   Suzuki, Michiyasu
   Arai, Hajime
   Hagihara, Akihito
   Iihara, Koji
CA J-ASPECT Study Collaborators
TI The Influence of Age on the Outcomes of Traumatic Brain Injury: Findings
   from a Japanese Nationwide Survey (J-ASPECT Study-Traumatic Brain
   Injury)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aging; Hospital mortality; Prognosis; Subdural hematoma; Traumatic brain
   injury
ID CLINICAL-VARIABLES; HOSPITAL VOLUME; IMPACT; GENDER; COMA; CARE
AB BACKGROUND: The epidemiology of patients with traumatic brain injury (TBI) has changed dramatically over recent decades as a result of rapid advances in aging societies. We assessed the influence of age on outcomes of patients with TBI and sought to identify prognostic factors for in-hospital mortality of TBI among elderly patients.
   METHODS: Using a nationwide database, we analyzed data from 5651 patients with TBI. Univariate analysis was conducted to compare patient demographics, neurologic status on admission, radiologic findings, systemic complication rates, length of hospital stay, in-hospital mortality, and home discharge rates between elderly and nonelderly groups. Multivariable analysis was conducted to determine prognostic factors for in-hospital mortality among elderly patients.
   RESULTS: Overall in-hospital mortality was significantly higher in elderly patients (12.8% vs. 19.3%; P < 0.001). Inhospital mortality of elderly patients with mild TBI increased significantly at >7 days after admission, whereas that of elderly patients with moderate or severe TBI was significantly higher immediately after admission. Age (odds ratio [OR], 1.62; P = 0.024), male sex (OR, 1.30; P = 0.004), Japan Coma Scale score on admission (OR, 5.95, P < 0.001), and incidence of acute subdural hematoma (OR, 1.89; P < 0.001) were associated with in-hospital mortality in elderly patients with TBI.
   CONCLUSIONS: Elderly patients with TBI showed significantly higher in-hospital mortality. Delayed increases in in-hospital mortality were observed among elderly patients with mild TBI. Level of consciousness on admission was the strongest predictor of in-hospital mortality among elderly patients.
C1 [Yamagami, Keitaro; Kurogi, Ryota; Kurogi, Ai; Ren, Nice; Nishimura, Ataru; Arimura, Koichi; Ido, Keisuke; Mizoguchi, Masahiro; Iihara, Koji] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Nishimura, Kunihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Med, Suita, Osaka, Japan.
   [Onozuka, Daisuke; Hagihara, Akihito] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Commun, Fukuoka, Fukuoka, Japan.
   [Kada, Akiko] Natl Hosp Org Nagoya Med Ctr, Dept Clin Res Management, Nagoya, Aichi, Japan.
   [Sakamoto, Tetsuya] Teikyo Univ, Sch Med, Dept Emergency Med, Tokyo, Japan.
   [Kayama, Takamasa] Yamagata Univ, Fac Med, Dept Adv Canc Sci, Yamagata, Japan.
   [Suzuki, Michiyasu] Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan.
   [Arai, Hajime] Juntendo Univ, Grad Sch Med, Dept Neurosurg, Tokyo, Japan.
RP Iihara, K (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM kiihara@ns.med.kyushu-u.ac.jp
RI Onozuka, Daisuke/F-5067-2014
OI Onozuka, Daisuke/0000-0001-9596-9188; Kinoshita,
   Manabu/0000-0001-7923-6902; Ota, Takahiro/0000-0002-5108-6719; arimura,
   koichi/0000-0003-2455-9506
FU Japanese Ministry of Health, Labor and WelfareMinistry of Health, Labour
   and Welfare, Japan [H28-Shinkin-Ippan-001]; Japan Agency for Medical
   Research and DevelopmentJapan Agency for Medical Research and
   Development (AMED) [17ek0210088h0001, 18ek0210088h0002, JP18ek0210088];
   KAKENHI grant from the Japan Society for the Promotion of Science
   [25293314, 18H02914]
FX J-ASPECT Study (principal investigator: K. I.) was supported by
   Grantsin-Aid from the Japanese Ministry of Health, Labor and Welfare
   (H28-Shinkin-Ippan-001). This research is partially supported by the
   Japan Agency for Medical Research and Development (17ek0210088h0001,
   18ek0210088h0002, JP18ek0210088) and a KAKENHI grant (25293314,
   18H02914) from the Japan Society for the Promotion of Science. The
   funding sources had no role in the study design, data collection, data
   analysis, data interpretation, or writing of the report. The
   corresponding author had full access to all the data in the study and
   had the final responsibility for the decision to submit for publication.
CR Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4
   Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354
   Bobeff EJ, 2019, WORLD NEUROSURG, V128, pE129, DOI 10.1016/j.wneu.2019.04.060
   Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315
   Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450
   Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8
   Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539
   Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032
   Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4
   HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858
   Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666
   Hukkelhoven CWPM, 2000, J NEUROL NEUROSUR PS, V68, P396
   Iihara K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096819
   Iihara K, 2014, J STROKE CEREBROVASC, V23, P1001, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.016
   Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059
   Karibe H, 2017, NEUROL MED-CHIR, V57, P418, DOI 10.2176/nmc.st.2017-0058
   Kurogi R, 2018, J NEUROSURG, V128, P1318, DOI 10.3171/2016.12.JNS161039
   Kurogi R, 2018, NEUROLOGY, V90, pE1143, DOI 10.1212/WNL.0000000000005207
   Lee JJ, 2018, J NEUROSURG, V128, P236, DOI 10.3171/2016.5.JNS16255
   Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422
   Leyens L, 2017, GENET EPIDEMIOL, V41, P51, DOI 10.1002/gepi.22012
   LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256
   Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5
   Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028
   Nakamura K, 2016, CIRC J, V80, P2289, DOI 10.1253/circj.CJ-16-0973
   Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567
   Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291
   Shigematsu K, 2013, BMJ OPEN, V3, P10
   Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165
   Suehiro E, 2019, WORLD NEUROSURG, V127, pE1221, DOI 10.1016/j.wneu.2019.04.108
   Suehiro E, 2011, WORLD NEUROSURG, V75, P563, DOI 10.1016/j.wneu.2010.09.013
   Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1
   Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577
   Wada T, 2017, INJURY, V48, P1423, DOI 10.1016/j.injury.2017.05.003
   Yasunaga H, 2005, INT HEART J, V46, P855, DOI 10.1536/ihj.46.855
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E26
EP E46
DI 10.1016/j.wneu.2019.05.140
PG 21
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200005
PM 31132488
DA 2020-05-12
ER

PT J
AU Yamahata, H
   Yamaguchi, S
   Osanai, T
   Takeda, M
   Mitsuhara, T
   Mori, M
   Tanaka, S
   Yonenaga, M
   Taguchi, A
   Watanabe, Y
   Abiko, M
   Seki, T
   Sasamori, T
   Arita, K
   Yoshimoto, K
AF Yamahata, Hitoshi
   Yamaguchi, Satoshi
   Osanai, Toshiya
   Takeda, Masaaki
   Mitsuhara, Takafumi
   Mori, Masanao
   Tanaka, Shunichi
   Yonenaga, Masanori
   Taguchi, Akira
   Watanabe, Yosuke
   Abiko, Masaru
   Seki, Toshitaka
   Sasamori, Toru
   Arita, Kazunori
   Yoshimoto, Koji
TI Cauda Equina Occupation Ratio as a New Imaging Parameter for the
   Evaluation of Spinal Dural Arteriovenous Fistulae
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cauda equina; Diagnosis; Magnetic resonance imaging; Occupation ratio;
   Spinal dural arteriovenous fistulae
ID CLINICAL-FEATURES; MALFORMATIONS; MRI; SURGERY
AB BACKGROUND: Because spinal dural arteriovenous fistulae (SDAVF) are rare and their clinical presentation is nonspecific, they are often overlooked during diagnostic evaluations. Typical magnetic resonance imaging (MRI) findings are intramedullary T2-weighted signal hyper-intensity and perimedullary flow voids. There are few reports on the characteristic signs of the cauda equina. We assessed the significance of a new imaging parameter, the cauda equina occupation ratio (CEOR), for the evaluation of SDAVF.
   METHODS: We retrospectively analyzed the clinical charts and radiological findings of 20 SDAVF patients treated at our institutions. We evaluated sagittal T2-weighted MRI scans and assessed the CEOR, the occupation ratio of the cauda equina compared to the sagittal diameter of the corresponding lumbar spinal canal. The controls were 21 age- and sex-matched subjects.
   RESULTS: Of the 20 SDAVF, 10 were at the thoracic and 10 at the lumbar spine. There was no significant difference between the preoperative CEOR and the spinal level of the fistulae or the neurological signs. On preoperative MRI scans, the mean CEOR was 56.0 +/- 7.8; postoperatively, it was 37.1 +/- 7.4 (P = 0.000). The preoperative CEOR was significantly larger in SDAVF patients than in the controls (P = 0.000); postoperatively, it was smaller than in the controls (P = 0.14).
   CONCLUSIONS: The preoperative CEOR was larger in patients with SDAVF than in the controls. It normalized after successful occlusion of the fistula. Our findings indicate that the CEOR is a useful parameter for the pre-and postoperative evaluation of SDAVF.
C1 [Yamahata, Hitoshi; Mori, Masanao; Tanaka, Shunichi; Yonenaga, Masanori; Arita, Kazunori; Yoshimoto, Koji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
   [Yamaguchi, Satoshi] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Osanai, Toshiya; Seki, Toshitaka; Sasamori, Toru] Hokkaido Univ, Grad Sch Med, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Takeda, Masaaki; Mitsuhara, Takafumi; Taguchi, Akira; Watanabe, Yosuke; Abiko, Masaru] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Hiroshima, Japan.
RP Yamahata, H (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
EM yamahata-nsu@umin.net
RI Osanai, Toshiya/AAF-3011-2020
CR Aghakhani N, 2008, STROKE, V39, P2756, DOI 10.1161/STROKEAHA.108.517037
   AMINOFF MJ, 1974, J NEUROL SCI, V23, P255, DOI 10.1016/0022-510X(74)90229-9
   AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211
   Atkinson JLD, 2001, MAYO CLIN PROC, V76, P1120, DOI 10.4065/76.11.1120
   BOWEN BC, 1995, AM J NEURORADIOL, V16, P2029
   Brinjikji W, 2018, AM J NEURORADIOL, V39, P1953, DOI 10.3174/ajnr.A5784
   Cenzato M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1218
   Chen CJ, 2002, EUR J RADIOL, V44, P152, DOI 10.1016/S0720-048X(02)00010-4
   Endo T, 2018, WORLD NEUROSURG, V110, pE383, DOI 10.1016/j.wneu.2017.11.002
   GILBERTSON JR, 1995, AM J NEURORADIOL, V16, P2049
   Gioppo A, 2018, J NEUROINTERV SURG, V10, P415, DOI 10.1136/neurintsurg-2017-013307
   HASSLER W, 1989, J NEUROSURG, V70, P360, DOI 10.3171/jns.1989.70.3.0360
   Horikoshi T, 2000, SURG NEUROL, V53, P243, DOI 10.1016/S0090-3019(99)00168-8
   ISU T, 1989, NEUROSURGERY, V24, P919, DOI 10.1227/00006123-198906000-00023
   Jablawi F, 2018, AM J NEURORADIOL, V39, P392, DOI 10.3174/ajnr.A5497
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Jones B V, 1997, J Spinal Cord Med, V20, P43
   Kaufmann TJ, 2011, J NEUROSURG-SPINE, V14, P548, DOI 10.3171/2010.11.SPINE10178
   KENDALL BE, 1977, NEURORADIOLOGY, V13, P181, DOI 10.1007/BF00344211
   KOENIG E, 1989, J NEUROL, V236, P260, DOI 10.1007/BF00314453
   Kohno M, 1997, SURG NEUROL, V48, P352, DOI 10.1016/S0090-3019(97)88195-5
   Krings T, 2007, NEUROIMAG CLIN N AM, V17, P57, DOI 10.1016/j.nic.2007.01.001
   LANE JI, 1994, AM J NEURORADIOL, V15, P1317
   LARSSON EM, 1991, AM J NEURORADIOL, V12, P739
   Lee TT, 1998, NEUROSURGERY, V43, P242, DOI 10.1097/00006123-199808000-00032
   Mascalchi M, 2001, RADIOLOGY, V219, P346, DOI 10.1148/radiology.219.2.r01ap26346
   MERLAND JJ, 1980, J NEURORADIOLOGY, V7, P271
   MOURIER KL, 1989, ACTA NEUROCHIR, V100, P136, DOI 10.1007/BF01403601
   Muralidharan R, 2011, SPINE, V36, pE1641, DOI 10.1097/BRS.0b013e31821352dd
   Nagata S, 2006, SURG NEUROL, V65, P563, DOI 10.1016/j.surneu.2005.09.018
   Namba K, 2016, NEUROL MED-CHIR, V56, P310, DOI 10.2176/nmc.ra.2016-0006
   NDIAYE M, 1984, J NEURORADIOLOGY, V11, P327
   OLDFIELD EH, 1983, J NEUROSURG, V59, P1019, DOI 10.3171/jns.1983.59.6.1019
   Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821
   Schick U, 2003, EUR SPINE J, V12, P350, DOI 10.1007/s00586-002-0487-6
   Shinoyama M, 2010, WORLD NEUROSURG, V73, P401, DOI 10.1016/j.wneu.2010.01.003
   Song JK, 2001, J NEUROSURG, V94, P199, DOI 10.3171/spi.2001.94.2.0199
   SYMON L, 1984, J NEUROSURG, V60, P238, DOI 10.3171/jns.1984.60.2.0238
   TERWEY B, 1989, J COMPUT ASSIST TOMO, V13, P30, DOI 10.1097/00004728-198901000-00006
   Toossi S, 2012, NEUROLOGY, V79, P25, DOI 10.1212/WNL.0b013e3182582f07
   Wang DH, 2013, SPINE, V38, pE546, DOI 10.1097/BRS.0b013e31828a38c4
   WILLINSKY RA, 1995, AM J NEURORADIOL, V16, P2063
   Yen PPW, 2014, J NEUROSURG-SPINE, V21, P837, DOI 10.3171/2014.7.SPINE13797
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1020
EP E1027
DI 10.1016/j.wneu.2019.07.069
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200126
PM 31306848
DA 2020-05-12
ER

PT J
AU Yang, L
   Li, WH
   Zhao, YJ
   Zhong, S
   Wang, XH
   Jiang, SS
   Cheng, Y
   Xu, HY
   Zhao, G
AF Yang, Liu
   Li, Weihang
   Zhao, Yingjing
   Zhong, Sheng
   Wang, Xinhui
   Jiang, Shanshan
   Cheng, Ye
   Xu, Haiyang
   Zhao, Gang
TI Computational Study of Novel Natural Inhibitors Targeting
   O-6-Methylguanine-DNA Methyltransferase
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discovery Studio; Inhibitor; O-6-Benzylguanine (O-6-BG);
   O-6-methylguanine-DNA methyltransferase (MGMT); Virtual screening
ID HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; PROGNOSTIC VALUE;
   INACTIVATION; MGMT; DNA; O-6-BENZYLGUANINE; CHEMOTHERAPY; METHYLATION;
   SENSITIVITY; RESISTANCE
AB OBJECTIVE: To screen ideal lead compounds from a drug library (ZINC15 database) with potential inhibition effect against O-6-methylguanine-DNA methyltransferase (MGMT) to contribute to medication design and refinement.
   METHODS: A series of computer-aided virtual screening techniques were used to identify potential inhibitors of MGMT. Structure-based virtual screening by LibDock was carried out to calculate LibDock scores, followed by absorption, distribution, metabolism, and excretion and toxicity predictions. Molecule docking was employed to demonstrate binding affinity and mechanism between the selected ligands and MGMT protein. Molecular dynamics simulation was performed to evaluate stability of the ligand-MGMT complex under natural circumstances.
   RESULTS: Two novel natural compounds, ZINC000008220033 and ZINC000001529323, from the ZINC15 database were found to bind with MGMT with a higher binding affinity together with more favorable interaction energy. Also, they were predicted to have less rodent carcinogenicity, Ames mutagenicity, and developmental toxicity potential as well as noninhibition with cytochrome P-450 2D6. Molecular dynamics simulation analysis demonstrated that the 2 complexes ZINC000008220033-MGMT and ZINC000001529323-MGMT had more favorable potential energy compared with reference ligand O-6-benzylguanine, and they could exist stably in the natural environment.
   CONCLUSIONS: This study elucidated that ZINC000008220033 and ZINC000001529323 were ideal lead compounds with potential inhibition targeting to MGMT protein. These compounds were selected as safe drug candidates and may contribute a solid basis for MGMT target medication design and improvement.
C1 [Zhong, Sheng; Xu, Haiyang; Zhao, Gang] First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Wang, Xinhui] First Hosp Jilin Univ, Dept Oncol, Changchun, Jilin, Peoples R China.
   [Yang, Liu] Jilin Univ, Dept Ultrasound, China Japan Union Hosp, Changchun, Jilin, Peoples R China.
   [Li, Weihang; Zhao, Yingjing] Jilin Univ, Coll Clin Med, Changchun, Jilin, Peoples R China.
   [Jiang, Shanshan] Jilin Univ, Coll Pharm, Changchun, Jilin, Peoples R China.
   [Zhong, Sheng] Harvard Med Sch, Dept Surg, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Cheng, Ye] Capital Med Univ, Dept Neurosurg, Xuan Wu Hosp, Beijing, Peoples R China.
RP Xu, HY (reprint author), First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM xuhaiyang_jdyy@126.com
CR BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2
   Binabaj MM, 2018, J CELL PHYSIOL, V233, P378, DOI 10.1002/jcp.25896
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chamberlain MC, 2010, EXPERT REV NEUROTHER, V10, P547, DOI 10.1586/ERN.10.14
   CRONE TM, 1995, CARCINOGENESIS, V16, P1687, DOI 10.1093/carcin/16.8.1687
   CRONE TM, 1993, CANCER RES, V53, P4750
   Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719
   DOLAN ME, 1994, CANCER RES, V54, P5123
   Edara S, 1996, CANCER RES, V56, P5571
   Encell LP, 1999, NAT BIOTECHNOL, V17, P143
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Kalani K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074761
   Kelner MJ, 2008, CANCER CHEMOTH PHARM, V63, P19, DOI 10.1007/s00280-008-0703-0
   Kyrtopoulos SA, 1997, CANCER DETECT PREV, V21, P391
   Li J. W. -H., 2011, Biomeditsinskaya Khimiya, V57, P148
   Liu LL, 2006, CLIN CANCER RES, V12, P328, DOI 10.1158/1078-0432.CCR-05-2543
   MICETICH KC, 1992, J NATL CANCER I, V84, P256, DOI 10.1093/jnci/84.4.256
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   MOSCHEL RC, 1992, J MED CHEM, V35, P4486, DOI 10.1021/jm00101a028
   Newman DJ, 2016, PHARMACOL THERAPEUT, V162, P1, DOI 10.1016/j.pharmthera.2015.12.002
   Perazzoli G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140131
   Preusser M, 2011, ANN NEUROL, V70, P9, DOI 10.1002/ana.22425
   Rao SN, 2007, J CHEM INF MODEL, V47, P2159, DOI 10.1021/ci6004299
   RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x
   Sarvagalla S, 2015, J COMPUT AID MOL DES, V29, P89, DOI 10.1007/s10822-014-9807-2
   Toraih EA, 2019, INT J BIOL MARKER, V34, P69, DOI 10.1177/1724600818814459
   Tubbs JL, 2007, DNA REPAIR, V6, P1100, DOI 10.1016/j.dnarep.2007.03.011
   van den Bent MJ, 2003, J CLIN ONCOL, V21, P2525, DOI 10.1200/JCO.2003.12.015
   Wang W, 2018, J CELL BIOCHEM, V119, P723, DOI 10.1002/jcb.26236
   Xu-Welliver M, 1998, CANCER RES, V58, P1936
   Zhao R, 2018, CHEM REAGENT, V40
NR 31
TC 2
Z9 2
U1 6
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E294
EP E306
DI 10.1016/j.wneu.2019.05.264
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200035
PM 31203065
DA 2020-05-12
ER

PT J
AU Yuan, W
   Zhu, Y
AF Yuan, Wei
   Zhu, Yue
TI Posterior Revision Surgery for Cervical Open-Door Laminoplasty Because
   of Poor Expansion of the Spinal Canal
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Laminoplasty; Myelopathy; Posterior approach; Revision
   surgery
ID TERM-FOLLOW-UP; ANTERIOR DECOMPRESSION; SPONDYLOTIC MYELOPATHY;
   REOPERATION RATES; OSSIFICATION; FUSION; CLOSURE; LAMINA; OUTCOMES;
   DISEASE
AB OBJECTIVE: Few studies have addressed the causes of poor expansion of the spinal canal after open-door laminoplasty (ODL) that require revision surgery. The aim of this study is to identify the reasons of poor expansion of the spinal canal after ODL and to discuss the surgical methods and clinical outcomes of the posterior revision surgery.
   METHODS: All patients who underwent posterior revision surgery because of poor expansion of the spinal canal after ODL were retrospectively reviewed at our spine center. Clinical data, radiologic findings, method of surgical revision, interval between surgeries, Japanese Orthopaedic Association (JOA) score, and complications were analyzed.
   RESULTS: We identified 16 patients that underwent posterior revision surgery because of poor expansion of the spinal canal after ODL. The main causes of poor expansion of the spinal canal included inadequate expansion degree of the spinal canal (75%, 12/16) and improper expansion range of the spinal canal (25%, 4/16). Revision surgery was performed with posterior ODL, laminectomy and fusion (LCF), or laminectomy of responsible lamina. The interval between the initial procedure and revision surgery was 72.2 months (range, 0.5-168 months). The mean JOA score was restored from 10.6 (range, 8-13) to 14.3 (range, 13-17) after the revision surgery.
   CONCLUSIONS: The main causes of poor expansion of the spinal canal after ODL were inadequate expansion degree of the spinal canal and improper expanded range of the spinal canal. Posterior revision surgeries, such as ODL, LCF, and laminectomy of responsible lamina, could guarantee fine clinical results.
C1 [Yuan, Wei; Zhu, Yue] China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
RP Zhu, Y (reprint author), China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
EM zhuyuedr@163.com
OI yuan, wei/0000-0003-4012-4350
FU National Key Research and Development Program of China [2017YFC1104903]
FX This study was supported by the National Key Research and Development
   Program of China (2017YFC1104903).
CR Bayerl S, 2013, CLIN NEUROL NEUROSUR, V115, P1966, DOI 10.1016/j.clineuro.2013.05.031
   Chen HC, 2008, J SPINAL DISORD TECH, V21, P387, DOI 10.1097/BSD.0b013e318157c699
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Highsmith JM, 2011, J NEUROSURG-SPINE, V14, P619, DOI 10.3171/2011.1.SPINE10206
   HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   Hirabayashi K, 1999, CLIN ORTHOP RELAT R, P35
   Hirai T, 2018, J ORTHOP SCI, V23, P32, DOI 10.1016/j.jos.2017.07.012
   ITOH T, 1985, SPINE, V10, P729, DOI 10.1097/00007632-198510000-00007
   Kawaguchi Y, 2014, SPINE J, V14, P955, DOI 10.1016/j.spinee.2013.07.457
   Komura S, 2011, ARCH ORTHOP TRAUM SU, V131, P1177, DOI 10.1007/s00402-010-1248-3
   Lee CH, 2017, SPINE, V42, P887, DOI 10.1097/BRS.0000000000001933
   Lin JH, 2016, SPINE J, V16, P1428, DOI 10.1016/j.spinee.2016.08.017
   Liu G, 2009, SPINE, V34, P2760, DOI 10.1097/BRS.0b013e3181b11ee1
   Liu XZ, 2014, ORTHOPEDICS, V37, pE117, DOI 10.3928/01477447-20140124-12
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   Matsumoto M, 2012, SPINE, V37, P1288, DOI 10.1097/BRS.0b013e3182498434
   Matsumoto M, 2008, J NEUROSURG-SPINE, V9, P530, DOI 10.3171/SPI.2008.4.08176
   Odate S, 2017, J NEUROSURG-SPINE, V26, P466, DOI 10.3171/2016.9.SPINE16430
   Park MS, 2016, SPINE, V41, P1484, DOI 10.1097/BRS.0000000000001581
   Sakaura H, 2005, SPINE, V30, P756, DOI 10.1097/01.brs.0000157415.79713.7e
   Satomi K, 2001, Spine J, V1, P26, DOI 10.1016/S1529-9430(01)00008-0
   Shamji MF, 2013, SPINE, V38, pS195, DOI 10.1097/BRS.0b013e3182a7eb27
   Shigematsu H, 2015, SPINE J, V15, pE7, DOI 10.1016/j.spinee.2013.11.048
   Takagi Hiroshi, 2002, J Orthop Sci, V7, P495, DOI 10.1007/s007760200086
   Wada K, 2014, J ORTHOP SCI, V19, P511, DOI 10.1007/s00776-012-0299-4
   Wang HQ, 2011, SPINE J, V11, P832, DOI 10.1016/j.spinee.2011.07.026
   Yonenobu K, 2001, SPINE, V26, P1890, DOI 10.1097/00007632-200109010-00014
   Yoon ST, 2013, SPINE, V38, pS232, DOI 10.1097/BRS.0b013e3182a7eb55
   Yuan W, 2015, CLIN NEUROL NEUROSUR, V134, P17, DOI 10.1016/j.clineuro.2015.04.004
   Zhang H, 2015, J SPINAL DISORD TECH, V28, P89, DOI 10.1097/BSD.0b013e3182695295
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E90
EP E97
DI 10.1016/j.wneu.2019.05.240
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200012
PM 31173916
DA 2020-05-12
ER

PT J
AU Yuk, CD
   Kim, TH
   Park, MS
   Kim, SW
   Chang, HG
   Kim, JH
   Ahn, JH
   Chang, IB
   Song, JH
   Oh, JK
AF Yuk, Chang Duk
   Kim, Tae Hwan
   Park, Moon Soo
   Kim, Seok Woo
   Chang, Ho Geun
   Kim, Ji Hee
   Ahn, Jun Hyong
   Chang, In Bok
   Song, Joon Ho
   Oh, Jae Keun
TI Cervical Cord Compression and Whole-Spine Sagittal Balance:
   Retrospective Study Using Whole-Spine Magnetic Resonance Imaging and
   Cervical Cord Compression Index
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical cord compression index; Sagittal vertical axis; Whole spine
   sagittal balance; Whole spine sagittal T2 scout magnetic resonance
   imaging
ID ALIGNMENT; PREVALENCE; DEGENERATION; SURGERY
AB OBJECTIVE: We sought to investigate the relationship nen cervical cord compression and factors related to whole-spine sagittal balance.
   METHODS: This retrospective single-center study Aided patients who visited our clinic for the evaluation of lumbar pathology including trauma and degeneration. Patients aged 60- 89 years who underwent whole-spine sagittal T2 scout magnetic resonance imaging and whole-spine radiograph between 2014 and 2018 were included in our study. We consecutively enrolled 100 patients for our study without any prejudice. We collected data on patient characteristics, diagnosis, cervical cord compression index (CCI), sagittal vertical axis (C7-81, C2-7), and other parameters related to sagittal balance such as pelvic incidence minus lumbar lordosis. Pearson correlation coefficients were calculated to compare CCI with each whole-spine sagittal balance parameter.
   RESULTS: Of the 100 patients, 44 were men. The mean u s e was 74.21 years. On the basis of Pearson correlation coefficients, CCI showed the strongest positive linear correlation with C7-S1 sagittal vertical axis (r = 0.688; P < 0.01), followed by the C2-7 sagittal vertical axis (r = 0.563; P < 0.01).
   CONCLUSIONS: Cervical cord compression is more likely to develop in patients with sagittal imbalance. It is important to use whole-spine T2 scout magnetic resonance imaging to analyze CCI in these patients.
C1 [Yuk, Chang Duk; Kim, Ji Hee; Ahn, Jun Hyong; Chang, In Bok; Song, Joon Ho; Oh, Jae Keun] Hallym Univ, Sacred Heart Hosp, Dept Neurosurg, Anyang, South Korea.
   [Kim, Tae Hwan; Park, Moon Soo; Kim, Seok Woo; Chang, Ho Geun] Hallym Univ, Sacred Heart Hosp, Dept Orthoped, Anyang, South Korea.
RP Oh, JK (reprint author), Hallym Univ, Sacred Heart Hosp, Dept Neurosurg, Anyang, South Korea.
EM ohjaekeun@gmail.com
CR Aoki Y, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0676-1
   Bae J, 2018, NEUROSPINE, V15, P18, DOI 10.14245/ns.1836022.011
   Chatley A, 2009, J NEUROSURG-SPINE, V11, P562, DOI 10.3171/2009.6.SPINE091
   Fujimori T, 2017, CLIN SPINE SURG, V30, pE423, DOI 10.1097/BSD.0000000000000327
   Goh S, 2000, RHEUMATOLOGY, V39, P310, DOI 10.1093/rheumatology/39.3.310
   Kang Kyung Tag, 2017, Korean J Spine, V14, P41, DOI 10.14245/kjs.2017.14.2.41
   Kim HS, 2018, EUR SPINE J, V27, P2023, DOI 10.1007/s00586-018-5634-9
   Lee SH, 2010, SPINE, V35, P2057, DOI 10.1097/BRS.0b013e3181f4588a
   Liang C, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1164-y
   Mac-Thiong Jean-Marc, 2009, Spine (Phila Pa 1976), V34, pE519, DOI 10.1097/BRS.0b013e3181a9c7ad
   Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929
   Park JH, 2013, J KOREAN NEUROSURG S, V53, P356, DOI 10.3340/jkns.2013.53.6.356
   Sawamura M, 2016, NEUROL CLIN NEUROSCI, V4, P182, DOI 10.1111/ncn3.12059
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Schwab F, 2005, SPINE, V30, P1082, DOI 10.1097/01.brs.0000160842.43482.cd
   Shimizu T, 2019, SPINE, V44, P1049, DOI 10.1097/BRS.0000000000003007
   Teraguchi M, 2014, OSTEOARTHR CARTILAGE, V22, P104, DOI 10.1016/j.joca.2013.10.019
   Vedantam R, 1998, SPINE, V23, P211, DOI 10.1097/00007632-199801150-00012
   Wu JC, 2018, NEUROSPINE, V15, P33, DOI 10.14245/ns.1836084.042
   Zhang L, 2012, CHIN J TRAUMATOL, V15, P36, DOI 10.3760/cma.j.issn.1008-1275.2012.01.008
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E709
EP E714
DI 10.1016/j.wneu.2019.06.198
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200090
PM 31279106
DA 2020-05-12
ER

PT J
AU Zakaria, HM
   Mansour, T
   Telemi, E
   Xiao, SJ
   Bazydlo, M
   Schultz, L
   Nerenz, D
   Perez-Cruet, M
   Seyfried, D
   Aleem, IS
   Easton, R
   Schwalb, JM
   Abdulhak, M
   Chang, V
AF Zakaria, Hesham Mostafa
   Mansour, Tarek
   Telemi, Edvin
   Xiao, Shujie
   Bazydlo, Michael
   Schultz, Lonni
   Nerenz, David
   Perez-Cruet, Miguelangelo
   Seyfried, Donald
   Aleem, Ilyas S.
   Easton, Richard
   Schwalb, Jason M.
   Abdulhak, Muwaffak
   Chang, Victor
TI Patient Demographic and Surgical Factors that Affect Completion of
   Patient-Reported Outcomes 90 Days and 1 Year After Spine Surgery:
   Analysis from the Michigan Spine Surgery Improvement Collaborative
   (MSSIC)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Demographics; Lumbar spine surgery; Patient-reported outcomes;
   Prospective study; Quality improvement; Spondylolisthesis; Spondylosis
ID NATIONWIDE INPATIENT SAMPLE; UNITED-STATES; QUALITY IMPROVEMENT;
   FOLLOW-UP; PERIOPERATIVE COMPLICATIONS; ADMINISTRATIVE DATABASES;
   TRENDS; HOSPITALIZATION; LIMITATIONS; REGISTRY
AB BACKGROUND: The Michigan Spine Surgery improvement Collaborative is a statewide multicenter quality improvement registry. Because missing data can affect registry results, we used MSSIC to find demographic and surgical characteristics that affect the completion of patient-reported outcomes (PROs) at 90 days and 1 year.
   METHODS: A total of 24,404 patients who had lumbar surgery (17,813 patients) or cervical surgery (6591 patients) were included. Multivariate logistic regression models of patient disease were constructed to identify risk factors for failure to complete scheduled PRO surveys.
   RESULTS: Patients >= 65 years old and female patients were both more likely to respond at 90 days and 1 year. Increasing education was associated with greater response rate at 90 days and 1 year. Whites and African Americans had no differences in response rates. Calling provided the highest response rate at 90 days and 1 year. For cervical spine patients, only discharge to rehabilitation increased completion rates, at 90 days but not 1 year. For lumbar spine patients, spondylolisthesis or stenosis (vs. herniated disc) had a greater response rate at 1 year. Patients with leg (vs. back) pain had a greater response only at 1 year. Patients with multilevel surgery had an increased response at 1 year. Patients who underwent fusion were more likely to respond at 90 days, but not 1 year. Discharge to rehabilitation increased response at 90 days and 1 year.
   CONCLUSIONS: A multivariate analysis from a multi-center prospective database identified surgical factors that affect PRO follow-up, up to 1 year. This information can be helpful for imputing missing PRO data and could be used to strengthen data derived from large prospective databases.
C1 [Zakaria, Hesham Mostafa; Mansour, Tarek; Telemi, Edvin; Xiao, Shujie; Bazydlo, Michael; Schultz, Lonni; Nerenz, David; Seyfried, Donald; Schwalb, Jason M.; Abdulhak, Muwaffak; Chang, Victor] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
   [Perez-Cruet, Miguelangelo] William Beaumont Hosp, Dept Neurosurg, Royal Oak, MI 48072 USA.
   [Aleem, Ilyas S.] Univ Michigan, Dept Orthoped, Ann Arbor, MI 48109 USA.
   [Easton, Richard] Oakland Univ, Dept Orthopaed Surg, Beaumont Hlth, William Beaumont Sch Med, Rochester, MI 48063 USA.
RP Chang, V (reprint author), Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
EM vchang1@hfhs.org
OI Mansour, Tarek R./0000-0003-0758-3387
FU Blue Cross and Blue Shield of Michigan; Blue Care Network as part of the
   BCBSM Value Partnerships program
FX We thank Sue MacPhee-Gray for editorial assistance. Although Blue Cross
   Blue Shield of Michigan and MSSIC work collaboratively, the opinions,
   beliefs, and viewpoints expressed by the authors do not necessarily
   reflect the opinions, beliefs, and viewpoints of BCBSM or any of its
   employees. Support for MSSIC is provided by Blue Cross and Blue Shield
   of Michigan and Blue Care Network as part of the BCBSM Value
   Partnerships program.
CR Alluri RK, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.49
   Asher AL, 2014, SPINE, V39, pS106, DOI 10.1097/BRS.0000000000000579
   Basques BA, 2017, CLIN ORTHOP RELAT R, V475, P2893, DOI 10.1007/s11999-016-5175-7
   Bekelis K, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.8.FOCUS15354
   Bekkers S, 2014, CLIN ORTHOP RELAT R, V472, P3441, DOI 10.1007/s11999-014-3836-y
   Bernstein DN, 2017, GLOB SPINE J, V7, P213, DOI 10.1177/2192568217694151
   Birkmeyer NJO, 2006, NEW ENGL J MED, V354, P864, DOI 10.1056/NEJMsb053364
   Birkmeyer NJO, 2005, SURGERY, V138, P815, DOI 10.1016/j.surg.2005.06.037
   Bohl DD, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01490
   Bohl DD, 2014, CLIN ORTHOP RELAT R, V472, P1672, DOI 10.1007/s11999-014-3559-0
   Breakwell LM, 2015, BONE JOINT J, V97B, P871, DOI 10.1302/0301-620X.97B7.35391
   Brueton VC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003835
   Buckland AJ, 2017, SPINE, V42, P1248, DOI 10.1097/BRS.0000000000002064
   Chang V, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15370
   Daffner SD, 2013, GLOB SPINE J, V3, P15, DOI 10.1055/s-0033-1337120
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Eaker S, 1998, AM J EPIDEMIOL, V147, P74
   Englesbe MJ, 2007, ANN SURG, V246, P1100, DOI 10.1097/SLA.0b013e31815c3fe5
   Epstein AM, 2009, NEW ENGL J MED, V360, P1457, DOI 10.1056/NEJMe0901006
   Gerling MC, 2017, SPINE, V42, P1559, DOI 10.1097/BRS.0000000000002196
   Golinvaux NS, 2014, SPINE J, V14, P2923, DOI 10.1016/j.spinee.2014.04.025
   Golinvaux NS, 2014, SPINE, V39, P2019, DOI 10.1097/BRS.0000000000000598
   Gologorsky Y, 2014, J NEUROSURG-SPINE, V21, P984, DOI 10.3171/2014.8.SPINE131113
   Gologorsky Y, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1459
   Grauer JN, 2015, CLIN ORTHOP RELAT R, V473, P1537, DOI 10.1007/s11999-015-4223-z
   Greenwald AS, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.01174
   Hackbarth G, 2008, NEW ENGL J MED, V359, P3, DOI 10.1056/NEJMp0803749
   Karhade AV, 2018, NEUROSURGERY, V83, P333, DOI 10.1093/neuros/nyx408
   Leckie S, 2016, GLOB SPINE J, V6, P640, DOI 10.1055/s-0035-1570089
   Leong KC, 2006, FAM PRACT, V23, P699, DOI 10.1093/fampra/cml044
   Lurie JD, 2015, SPINE, V40, P63, DOI 10.1097/BRS.0000000000000731
   Missios S, 2015, J CLIN NEUROSCI, V22, P1632, DOI 10.1016/j.jocn.2015.05.005
   Murray DW, 1997, J BONE JOINT SURG BR, V79B, P254, DOI 10.1302/0301-620X.79B2.6975
   Norvell DC, 2016, GLOB SPINE J, V6, P519, DOI 10.1055/s-0036-1584928
   Passias PG, 2017, SPINE J, V17, P1633, DOI 10.1016/j.spinee.2017.05.018
   Rajaee SS, 2014, BONE JOINT J, V96B, P807, DOI 10.1302/0301-620X.96B6.31149
   Richesson R, 2010, ADV EXP MED BIOL, V686, P87, DOI 10.1007/978-90-481-9485-8_6
   Schoenfeld AJ, 2011, J BONE JOINT SURG AM, V93A, P1577, DOI 10.2106/JBJS.J.01048
   Sebastian AS, 2017, CLIN SPINE SURG, V30, P27, DOI 10.1097/BSD.0000000000000496
   Sebastian AS, 2016, CLIN SPINE SURG, V29, P427
   Share DA, 2011, HEALTH AFFAIR, V30, P636, DOI 10.1377/hlthaff.2010.0526
   Sielatycki JA, 2015, SPINE, V40, P1934, DOI 10.1097/BRS.0000000000001101
   Sivasubramaniam V, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009011
   Solberg TK, 2011, ACTA ORTHOP, V82, P56, DOI 10.3109/17453674.2010.548024
   TAYLOR VM, 1994, SPINE, V19, P1207, DOI 10.1097/00007632-199405310-00002
   Tee JW, 2012, GLOB SPINE J, V2, P71, DOI 10.1055/s-0032-1319772
   Tolonen H, 2006, EUR J EPIDEMIOL, V21, P409, DOI 10.1007/s10654-006-9019-8
   Veeravagu A, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1669
   Waljee JF, 2014, HAND CLIN, V30, P335, DOI 10.1016/j.hcl.2014.05.003
   Yoshihara H, 2015, SPINE J, V15, P265, DOI 10.1016/j.spinee.2014.09.026
NR 50
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E259
EP E271
DI 10.1016/j.wneu.2019.06.058
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200033
PM 31207366
DA 2020-05-12
ER

PT J
AU Zhang, B
   Yan, R
   Lu, J
   Ma, ZZ
   Zhang, XH
   Li, LB
   Gao, J
   Xia, L
   Zhang, K
   Zhang, FF
   Liu, Y
   Shi, JG
AF Zhang, Bin
   Yan, Ran
   Lu, Jun
   Ma, Zhenzhen
   Zhang, Xuhui
   Li, Leiben
   Gao, Jie
   Xia, Lei
   Zhang, Ke
   Zhang, Feifei
   Liu, Yang
   Shi, Jiangang
TI Metabolic Changes in Serum in the Rat Model of Cauda Equina Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomarker; Cauda equina injury; Metabolomics; UHPLC/Q-TOF-MS
ID IMPROVE; BRAIN
AB OBJECTIVE: To identify the potent metabolic biomarkers of cauda equina injury (CEI).
   METHODS: A total of 50 Sprague-Dawley rats were used to establish the CEI model in this study. The serum was collected at 12 hours, 1 day, 2 days, and 7 days after surgery. Ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry was performed to analyze metabolic changes in the serum of the CEI rats from different groups. The differences between the metabolic profiles of the rats in 5 groups were analyzed using partial least squares discriminant analysis (PLS-DA).
   RESULTS: Metabolic profiling revealed significant differences between the sham operated and other groups. A total of 57 potential CEI metabolite biomarkers were identified between the sham operated group and the model groups at the different time points. Principal component analysis and PLS-DA analyses revealed clear segregation between CEI versus sham operation group. These potential biomarkers appear in 15 metabolic pathways.
   CONCLUSIONS: Using metabolomic analysis, we were able to identify the novel serum biomarkers of CEI that may be relevant to the diagnosis and prognosis of CEI. In addition, our pathway analysis provides important insights into the etiology of CEI and a basis for clinical diagnosis, locating biomarkers in the early stages of the pathological process.
C1 [Zhang, Bin; Shi, Jiangang] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Surg, Spine Ctr, Shanghai, Peoples R China.
   [Yan, Ran] Hlth Co, Unit PLA 32145, Xinxiang, Henan, Peoples R China.
   [Lu, Jun] Second Mil Med Univ, Shanghai Changhai Hosp, Dept Anesthesiol, Shanghai, Peoples R China.
   [Ma, Zhenzhen; Zhang, Xuhui; Li, Leiben; Gao, Jie; Xia, Lei; Zhang, Ke; Zhang, Feifei; Liu, Yang] 83 Army Hosp, Dept Orthoped, Xinxiang, Henan, Peoples R China.
RP Liu, Y (reprint author), 83 Army Hosp, Dept Orthoped, Xinxiang, Henan, Peoples R China.
EM lymys@163.com
FU National Scientific Foundation of ChinaNational Natural Science
   Foundation of China [81802186, 81871828, 81650031]
FX The work was supported by the National Scientific Foundation of China
   (81802186, 81871828, and 81650031).
CR Altura BM, 2002, BRAIN RES BULL, V58, P271, DOI 10.1016/S0361-9230(02)00772-4
   COHEN MS, 1991, J BONE JOINT SURG BR, V73, P381
   Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268
   Figueroa JD, 2013, NEUROSCIENCE, V255, P1, DOI 10.1016/j.neuroscience.2013.09.012
   Figueroa JD, 2013, J NEUROTRAUM, V30, P853, DOI 10.1089/neu.2012.2718
   Gao SY, 2015, J ETHNOPHARMACOL, V166, P323, DOI 10.1016/j.jep.2015.03.025
   Korse NS, 2017, EUR SPINE J, V26, P894, DOI 10.1007/s00586-017-4943-8
   Liu Y, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.03.072
   Peng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093736
   Rahman A, 2009, CURR NEUROPHARMACOL, V7, P207, DOI 10.2174/157015909789152119
   Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310
   Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1
   Sun JC, 2014, SPINE, V39, P596, DOI 10.1097/BRS.0000000000000079
   Tarulli Andrew W, 2015, Continuum (Minneap Minn), V21, P146, DOI 10.1212/01.CON.0000461090.09736.45
   Thakur JD, 2017, SPINE J, V17, P1435, DOI 10.1016/j.spinee.2017.04.023
   Todd NV, 2015, BONE JOINT J, V97B, P1390, DOI 10.1302/0301-620X.97B10.35922
   Wu YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38718
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1051
EP E1060
DI 10.1016/j.wneu.2019.07.077
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200130
PM 31323400
DA 2020-05-12
ER

PT J
AU Zhang, JS
   Hua, W
   Zhang, X
   Quan, K
   Song, JP
   Li, PL
   Chen, L
AF Zhang, Jinsen
   Hua, Wei
   Zhang, Xin
   Quan, Kai
   Song, Jianping
   Li, Peiliang
   Chen, Liang
TI Pure Endoscopic Surgery via Subtemporal Extradural Keyhole Approach for
   Middle Cranial Fossa Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Middle cranial fossa tumor; Subtemporal extradural approach
ID ORBITOZYGOMATIC INFRATEMPORAL APPROACH; PETROCLIVAL MENINGIOMAS; SKULL
   BASE; SUPRASELLAR; EXPERIENCE; RESECTION; REGION
AB OBJECTIVE: Extradural subtemporal keyhole approach could provide adequate removal for some specific middle skull base tumors. The combination of endoscopy and keyhole technique might further help to minimize the complications and provide optimal surgical visualization , Here, a series of attempts with endoscopy by mini-invasive subtemporal extradural approach for 5 middle skull base tumors were successfully achieved.
   METHODS: From November 2015 to November 2018, resetions of 5 cases of middle cranial fossa tumors were performed with pure endoscopy via subtemporal extradural keyhole approach. Patient medical records, imaging data, surgical procedures, pathology results, and follow-up outcomes were collected and analyzed.
   RESULTS: Adequate extradural subtemporal space was successfully established for endoscopy, and tumor resection was performed. Postoperative pathology confirmed cholesteatoma, cholesterol granuloma, schwannoma, granuloma, and osteoblastoma, respectively. Two patients with osteoblastoma and granuloma received subtotal resection, and the other 3 achieved total resection. One patient suffered from brain edema and was relieved after systematic mannitol treatment. No other complications were observed, and no progression was found during follow-up.
   CONCLUSIONS: This exploratory series demonstrated safety and effectiveness of pure endoscopic surgery via subtemporal extradural route for satisfactory middle cranial base tumor resection.
C1 [Zhang, Jinsen; Hua, Wei; Zhang, Xin; Quan, Kai; Song, Jianping; Li, Peiliang; Chen, Liang] Fudan Univ, Dept Neurosurg, Huashan Hosp, Shanghai, Peoples R China.
RP Chen, L (reprint author), Fudan Univ, Dept Neurosurg, Huashan Hosp, Shanghai, Peoples R China.
EM chenlianghs@126.com
FU Shanghai Committee of Science and TechnologyShanghai Science &
   Technology Committee [15441904500]; Shanghai Municipal Science and
   Technology Major Project [2018SHZDZX03]
FX Writing and publication work of this article was supported by Shanghai
   Committee of Science and Technology (No. 15441904500), and Shanghai
   Municipal Science and Technology Major Project (No. 2018SHZDZX03).
CR Aziz KMA, 2000, NEUROSURGERY, V47, P139, DOI 10.1097/00006123-200007000-00030
   Bambakidis NC, 2008, NEUROSURGERY, V62, P1182, DOI [10.1227/01.NEU.0000280119.36270.BA, 10.1227/01.neu.0000333784.04435.65]
   BAUER BL, 1994, ACT NEUR S, V61, P1
   Ding ZM, 2017, WORLD NEUROSURG, V101, P606, DOI 10.1016/j.wneu.2017.02.052
   Fischer G, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820934ca
   Gu Y, 2016, ACTA NEUROCHIR, V158, P2155, DOI 10.1007/s00701-016-2895-0
   HAKUBA A, 1986, SURG NEUROL, V26, P271, DOI 10.1016/0090-3019(86)90161-8
   Jeon C, 2019, J NEUROSURG, V131, P1126, DOI 10.3171/2018.6.JNS181099
   Komatsu F, 2013, WORLD NEUROSURG, V80, P591, DOI 10.1016/j.wneu.2012.12.018
   LEE JP, 1993, ACTA NEUROL SCAND, V87, P403
   Lemole GM, 2003, J NEUROSURG, V99, P924, DOI 10.3171/jns.2003.99.5.0924
   Leonetti JP, 2008, OTOL NEUROTOL, V29, P380, DOI 10.1097/mao.0b013e31816021a3
   Mafee M F, 1994, Neuroimaging Clin N Am, V4, P561
   McLaughlin N, 2013, J NEUROSURG, V118, P613, DOI 10.3171/2012.11.JNS112020
   Pichierri A, 2010, NEUROSURGERY, V67, P29, DOI 10.1227/01.NEU.0000383131.72001.9E
   Rak R, 2004, NEUROSURGERY, V54, P876, DOI 10.1227/01.NEU.0000115151.52925.37
   Rehder R, 2017, WORLD NEUROSURG, V103, P114, DOI 10.1016/j.wneu.2017.02.054
   Schroeder HWS, 2004, J NEUROSURG, V101, P227, DOI 10.3171/jns.2004.101.2.0227
   Shigeno T, 1999, SURG NEUROL, V52, P81, DOI 10.1016/S0090-3019(99)00047-6
   Shou XF, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0767-0
   Taniguchi M, 1997, NEUROSURGERY, V41, P592, DOI 10.1097/00006123-199709000-00017
   Wang H, 2010, ACTA NEUROCHIR, V152, P1933, DOI 10.1007/s00701-010-0800-9
   Wang H, 2009, SURG NEUROL, V72, P124, DOI 10.1016/j.surneu.2008.08.002
   Wang XD, 2016, J CRANIOFAC SURG, V27, pE240, DOI 10.1097/SCS.0000000000002437
   WILSON DH, 1971, J NEUROSURG, V34, P102, DOI 10.3171/jns.1971.34.1.0102
   Xiao XR, 2013, NEUROSURG REV, V36, P587, DOI 10.1007/s10143-013-0484-8
   Youssef AS, 2012, ACTA NEUROCHIR, V154, P1275, DOI 10.1007/s00701-012-1370-9
   Zhu W, 2008, MINIM INVAS NEUROSUR, V51, P95, DOI 10.1055/s-2007-1022551
   Zhu W, 2007, MINIM INVAS NEUROSUR, V50, P106, DOI 10.1055/s-2007-984384
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E487
EP E497
DI 10.1016/j.wneu.2019.06.131
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200061
PM 31254695
DA 2020-05-12
ER

PT J
AU Zhao, YY
   Chen, SH
   Hao, Z
   Zhu, HX
   Xing, ZL
   Li, MH
AF Zhao, Ye-Yu
   Chen, Si-Hai
   Hao, Zheng
   Zhu, Hua-Xin
   Xing, Ze-Long
   Li, Mei-Hua
TI A Nomogram for Predicting Individual Prognosis of Patients with
   Low-Grade Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Low-grade glioma; Nomogram; Prognosis; SEER
ID CENTRAL-NERVOUS-SYSTEM; TUMOR LOCATION; ADULT PATIENTS; ASTROCYTOMA;
   SURVIVAL; CANCER; OLIGODENDROGLIOMA; CLASSIFICATION; ASSOCIATION; IDH1
AB OBJECTIVE: The present study aimed to develop and evaluate a nomogram for predicting the overall survival (OS) of patients with low-grade glioma (LGG).
   METHODS: Patients with LGG diagnosed from 1973 to 2013 were identified using the Surveillance, Epidemiology, and End Results (SEER) database. A total of 3732 patients were randomly divided into a training set (n = 2612) and a validation set (n = 1120). Univariate and multivariate Cox regression analyses of the clinical variables were performed to screen for significant prognostic factors. Next, a nomogram that included significant prognostic variables was formulated to predict for LGG. Harrell's concordance index (C-index) and calibration plots were formulated to evaluate the reliability and accuracy of the nomogram using bootstrapping according to the internal (training set) and external (validation set) validity.
   RESULTS: A nomogram was developed to predict the 5-and 9-year OS rates using 7 variables in the training set: age, tumor site, sex, marital status, histological type, tumor size, and surgery (P < 0.05). The C-index for internal validation, which the nomogram used to predict OS according to the training set, was 0.777 (range, 0.763-0.791), and the C-index for external validation (validation set) was 0.776 (range, 0.754-0.797). The results of the calibration plots showed that the actual observation and prediction values obtained by the nomogram had good consistency between the 2 sets.
   CONCLUSIONS: We have developed a ready-to-use nomogram model that includes clinical characteristics to predict OS. The nomogram might provide consultation and risk assessments for subsequent treatment of patients with LGG.
C1 [Zhao, Ye-Yu; Chen, Si-Hai; Hao, Zheng; Zhu, Hua-Xin; Xing, Ze-Long; Li, Mei-Hua] Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
   [Chen, Si-Hai] Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China.
RP Li, MH (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
EM limeihua2000@sina.com
OI Hao, Zheng/0000-0001-5760-1278
CR Abern MR, 2012, UROL ONCOL-SEMIN ORI, V30, P487, DOI 10.1016/j.urolonc.2010.03.005
   Alattar AA, 2019, WORLD NEUROSURG, V121, pE411, DOI 10.1016/j.wneu.2018.09.124
   Ali FS, 2018, CANCER TREAT REV, V65, P33, DOI 10.1016/j.ctrv.2018.02.007
   Baine MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017014
   Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7
   Buckner JC, 2016, NEW ENGL J MED, V374, P1344, DOI 10.1056/NEJMoa1500925
   Bush NAO, 2016, J ONCOL PRACT, V12, P1235, DOI 10.1200/JOP.2016.018622
   Chung Caroline, 2015, CNS Oncol, V4, P325, DOI 10.2217/cns.15.25
   Dahlrot RH, 2013, J NEURO-ONCOL, V114, P309, DOI 10.1007/s11060-013-1186-3
   Hollon T, 2015, SEMIN RADIAT ONCOL, V25, P181, DOI 10.1016/j.semradonc.2015.02.007
   Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282
   Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791
   Iwamoto FM, 2008, J NEURO-ONCOL, V88, P293, DOI 10.1007/s11060-008-9563-z
   Jia ZZ, 2013, J CLIN NEUROSCI, V20, P1110, DOI 10.1016/j.jocn.2012.09.019
   Kim YH, 2010, AM J PATHOL, V177, P2708, DOI 10.2353/ajpath.2010.100680
   Kujas M, 2005, ANN NEUROL, V58, P322, DOI 10.1002/ana.20543
   Lee JY, 2018, ACTA RADIOL, V59, P723, DOI 10.1177/0284185117728981
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   McDonald JM, 2005, CANCER-AM CANCER SOC, V104, P1468, DOI 10.1002/cncr.21338
   Nabors LB, 2017, J NATL COMPR CANC NE, V15, P1331, DOI 10.6004/jnccn.2017.0166
   Narang J, 2011, J NEURO-ONCOL, V102, P287, DOI 10.1007/s11060-010-0317-3
   Paldor I, 2016, J CLIN NEUROSCI, V34, P117, DOI 10.1016/j.jocn.2016.05.016
   Pignatti F, 2002, J CLIN ONCOL, V20, P2076, DOI 10.1200/JCO.2002.08.121
   Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3
   Sanai N, 2010, J NEUROSURG, V112, P1, DOI 10.3171/2009.6.JNS0952
   Shariat SF, 2008, CLIN CANCER RES, V14, P4400, DOI 10.1158/1078-0432.CCR-07-4713
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Sonoda Y, 2015, BRAIN TUMOR PATHOL, V32, P99, DOI 10.1007/s10014-014-0211-3
   van den Bent MJ, 2005, LANCET, V366, P985, DOI 10.1016/S0140-6736(05)67070-5
   van Veelen MLC, 1998, J NEUROL NEUROSUR PS, V64, P581, DOI 10.1136/jnnp.64.5.581
   Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E605
EP E612
DI 10.1016/j.wneu.2019.06.169
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200076
PM 31319188
DA 2020-05-12
ER

PT J
AU Zheng, X
   Zhang, J
   Dong, L
   Li, FY
   Sun, GC
   Zhao, Y
   Liu, YY
   Xu, BN
AF Zheng, Xuan
   Zhang, Jun
   Dong, Li
   Li, Fangye
   Sun, Guochen
   Zhao, Yue
   Liu, Yuyang
   Xu, Bainan
TI A Preliminary Investigation Report on Using Probabilistic Fiber
   Tractography to Track Human Auditory Pathways
SO WORLD NEUROSURGERY
LA English
DT Article
DE Auditory pathways; Diffusion tensor imaging; Hearing rehabilitation;
   Probabilistic fiber tracking
ID DIFFUSION TENSOR TRACTOGRAPHY; COCHLEAR IMPLANTATION; WHITE-MATTER;
   REGION; IDENTIFICATION; ORGANIZATION; VALIDATION; CORTEX; NERVE
AB BACKGROUND: Diffusion tensor imaging is currently the only noninvasive way to map subcortical white matter tractography. Radiologists and neurologists often fail to reconstruct the complex auditory pathways when applying the most commonly used approach, deterministic fiber tracking, as this method is limited in spatial and angular resolution. A different fiber-tracking method involving a probabilistic approach could partly compensate for these limitations. We investigated efficiency and potential usefulness of probabilistic fiber tracking in depicting human auditory pathways in healthy individuals and patients with unilateral vestibular schwannoma (VS).
   METHODS: Eight healthy volunteers and 14 patients with unilateral VS underwent diffusion tensor imaging. Probabilistic fiber tracking of the auditory pathways for each subject was carried out using FSL software. Tracking rate, reliability of results, fiber volume, fiber length, and fractional anisotropy values were considered in assessing reliability and sensitivity of this method. Fiber length and fiber volume were analyzed separately for the healthy group and VS group.
   RESULTS: Good tracking sensitivity and consistency were shown in healthy subjects and patients with VS. For fiber length, the 8 healthy subjects exhibited significant between-sides differences, whereas the 14 patients with VS showed no such difference. For fiber volume, there was a statistically significant difference between groups, as the patients with VS displayed a smaller fiber volume on the nontumor side. Fractional anisotropy values revealed no significant autologous or between-group differences. These results match results of previous anatomic and neurologic studies.
   CONCLUSIONS: The auditory pathway can be depicted well by probabilistic fiber tracking. This method can compensate in part for weaknesses of the widely used deterministic tractography approach in depicting fine and complicated subcortical fibers.
C1 [Zheng, Xuan; Zhang, Jun; Dong, Li; Li, Fangye; Sun, Guochen; Zhao, Yue; Liu, Yuyang; Xu, Bainan] Chinese PLA 301 Hosp, Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Xu, BN (reprint author), Chinese PLA 301 Hosp, Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM bnxu301@163.com
CR Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018
   Bizzi A, 2008, RADIOLOGY, V248, P579, DOI 10.1148/radiol.2482071214
   CAMPAIN R, 1976, BRAIN LANG, V3, P318, DOI 10.1016/0093-934X(76)90026-2
   CODE RA, 1985, J COMP NEUROL, V242, P485, DOI 10.1002/cne.902420404
   Feigl GC, 2014, WORLD NEUROSURG, V81, P144, DOI 10.1016/j.wneu.2013.01.004
   Fernandez-Miranda JC, 2012, NEUROSURGERY, V71, P430, DOI 10.1227/NEU.0b013e3182592faa
   GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312
   GALABURDA AM, 1983, J COMP NEUROL, V221, P169, DOI 10.1002/cne.902210206
   Gerganov VM, 2011, J NEUROSURG, V115, P1087, DOI 10.3171/2011.7.JNS11495
   Hackett TA, 2001, J COMP NEUROL, V441, P197, DOI 10.1002/cne.1407
   Javad F, 2014, NEUROIMAGE, V84, P562, DOI 10.1016/j.neuroimage.2013.09.007
   Jellison BJ, 2004, AM J NEURORADIOL, V25, P356
   Kondziolka Douglas, 2002, Curr Treat Options Neurol, V4, P157, DOI 10.1007/s11940-002-0024-2
   Kovacs S, 2006, INVEST RADIOL, V41, P87, DOI 10.1097/01.rli.0000189637.42344.09
   Kwon HG, 2013, J NEUROL NEUROSUR PS, V84, P1073, DOI 10.1136/jnnp-2013-305111
   Lerner A, 2014, WORLD NEUROSURG, V82, P96, DOI 10.1016/j.wneu.2013.07.083
   Lustig LR, 2006, OTOL NEUROTOL, V27, P512, DOI 10.1097/00129492-200606000-00013
   Malcolm JG, 2009, LECT NOTES COMPUT SC, V5761, P894
   Matsumoto R, 2008, J NEUROL, V255, P1703, DOI 10.1007/s00415-008-0005-9
   Matthew LC, 2005, OTOL NEUROTOL, V33, P853
   Neary WJ, 2010, J LARYNGOL OTOL, V124, P720, DOI 10.1017/S0022215110000460
   O'Donnell LJ, 2015, SCHIZOPHR RES, V161, P133, DOI 10.1016/j.schres.2014.09.007
   O'Donnell LJ, 2013, NEUROIMAGE, V80, P283, DOI 10.1016/j.neuroimage.2013.04.066
   Otto SR, 2008, OTOL NEUROTOL, V29, P1147, DOI 10.1097/MAO.0b013e31818becb4
   Rademacher J, 2001, NEUROIMAGE, V13, P669, DOI 10.1006/nimg.2000.0714
   Rueckriegel SM, 2016, AM J NEURORADIOL, V37, P1610, DOI 10.3174/ajnr.A4833
   Skorpil M, 2011, MAGN RESON IMAGING, V29, P289, DOI 10.1016/j.mri.2010.07.004
   Vermeire K, 2009, AUDIOL NEURO-OTOL, V14, P163, DOI 10.1159/000171478
   Wallace MN, 2002, EXP BRAIN RES, V143, P499, DOI 10.1007/s00221-002-1014-z
   Wang YX, 2014, PROC CVPR IEEE, P3051, DOI 10.1109/CVPR.2014.390
   Yeh FC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080713
   Yeh FC, 2010, IEEE T MED IMAGING, V29, P1626, DOI 10.1109/TMI.2010.2045126
   Yoshino M, 2015, INT J COMPUT ASS RAD, V10, P383, DOI 10.1007/s11548-014-1129-2
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E1
EP E8
DI 10.1016/j.wneu.2019.03.066
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200002
PM 30885875
DA 2020-05-12
ER

PT J
AU Zhou, QS
   Chen, X
   Xu, L
   Li, S
   Du, CZ
   Sun, X
   Wang, B
   Zhu, ZZ
   Qiu, Y
AF Zhou, Qing-shuang
   Chen, Xi
   Xu, Liang
   Li, Song
   Du, Chang-zhi
   Sun, Xu
   Wang, Bin
   Zhu, Ze-zhang
   Qiu, Yong
TI Does Vertebral End Plate Morphology Affect Cage Subsidence After
   Transforaminal Lumbar Interbody Fusion?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cage subsidence; End plate morphology; Lumbar alignment;
   Patient-reported outcomes; TLIF
ID BONE-MINERAL DENSITY; DISC-DEGENERATION; ALIGNMENT; SHAPE
AB OBJECTIVE: To investigate the effect of end plate morphology on cage subsidence and to compare the surgical outcomes among patients with different vertebral end plate morphologies.
   METHODS: We reviewed a series of consecutive patients from January 2009 to January 2016 who had undergone monosegment L4/5 transforaminal lumbar interbody fusion (TLIF) with a follow-up >2 years. The enrolled patients were divided into 3 groups based on the preoperative vertebral end plate morphology on T1-weighed sagittal magnetic resonance scans: concave group (C group), flat group (F group), and irregular group (Ir group). Lumbar lordosis (LL), segmental lordosis (SL), and disc height (DH) were measured on the plain image at each follow-up, and three-dimensional computed tomography (3D-CT) was obtained at 1 year follow-up to evaluate the cage subsidence and solid fusion.
   RESULTS: A total of 145 consecutive patients (41 males and 104 females) were included in this study, with a mean follow-up of 33.8 +/- 12.3 months. The age was significantly older in the Ir group than in the C group or F group (P < 0.05). Cage subsidence was detected in 23 patients (15.9%) at 1 year follow-up through 3D-CT. The incidence of cage subsidence was significantly higher in the Ir group than in the F group or C group (P < 0.05). Patients in the Ir group had significant loss of DH, SL, and LL at the latest follow-up, compared with those in the C group and F group (P < 0.05). Patients with cage subsidence had a significantly older age (P < 0.05). The presence of cage subsidence was associated with end plate morphology as shown by logistic regression analysis (P < 0.05). Before surgery, Oswestry Disability Index and visual analog scale back pain scores were significantly higher in the Ir group than in the C and F groups (P < 0.05). After surgery and until the latest follow-up, each group experienced significant improvement in contrast to preoperative scores regardless of end plate morphology (P < 0.05).
   CONCLUSIONS: Morphology of the end plate plays an important role in the development of cage subsidence after TLIF surgery. Fused segments with irregular end plates are prone to cage subsidence. Although cage subsidence does not affect short-term clinical outcomes, measures should be taken to prevent cage subsidence-related loss of SL and total LL.
C1 [Zhou, Qing-shuang; Chen, Xi; Du, Chang-zhi; Sun, Xu; Wang, Bin; Zhu, Ze-zhang; Qiu, Yong] Nanjing Med Univ, Drum Tower Hosp Clin Coll, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
   [Xu, Liang; Li, Song] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
RP Sun, X (reprint author), Nanjing Med Univ, Drum Tower Hosp Clin Coll, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
EM drsunxu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81772422]; Natural Science Foundation of Jiangsu
   ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural
   Science Foundation of Jiangsu Province [BE2017606, BK20170126]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81772422) and the Natural Science Foundation of
   Jiangsu Province (BE2017606 and BK20170126).
CR Abbushi A, 2009, EUR SPINE J, V18, P1621, DOI 10.1007/s00586-009-1036-3
   Aoki Y, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0676-1
   Beutler William J, 2003, Spine J, V3, P289, DOI 10.1016/S1529-9430(03)00061-5
   Challier V, 2017, SPINE, V42, P531, DOI 10.1097/BRS.0000000000001857
   Chen X, 2018, WORLD NEUROSURG, V114, pE293, DOI 10.1016/j.wneu.2018.02.175
   Cho JH, 2017, SPINE J, V17, P1794, DOI 10.1016/j.spinee.2017.05.029
   Feng ZY, 2018, SPINE, V43, P919, DOI 10.1097/BRS.0000000000002450
   Grant JP, 2002, J ORTHOP RES, V20, P1115, DOI 10.1016/S0736-0266(02)00039-6
   Hey HWD, 2017, SPINE, V42, P1447, DOI 10.1097/BRS.0000000000002131
   Hey HWD, 2017, SPINE J, V17, P183, DOI 10.1016/j.spinee.2016.08.026
   Hou Y, 2012, SPINE J, V12, P249, DOI 10.1016/j.spinee.2012.01.021
   Kim MC, 2013, J SPINAL DISORD TECH, V26, P87, DOI 10.1097/BSD.0b013e318237b9b1
   [孔令豪 Kong Linghao], 2016, [中国表面工程, China Surface Engineering], V29, P87
   Li YW, 2014, SPINE, V39, pE1035, DOI 10.1097/BRS.0000000000000419
   Makanji H, 2018, EUR SPINE J, V27, P1868, DOI 10.1007/s00586-018-5544-x
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Moon MS, 2018, CLIN ORTHOP SURG, V10, P322, DOI 10.4055/cios.2018.10.3.322
   Oh KW, 2017, CLIN SPINE SURG, V30, pE683, DOI 10.1097/BSD.0000000000000315
   Pappou IP, 2007, SPINE J, V7, P32, DOI 10.1016/j.spinee.2006.02.029
   Park MK, 2019, SPINE J, V19, P437, DOI 10.1016/j.spinee.2018.08.007
   Polikeit A, 2003, EUR SPINE J, V12, P556, DOI 10.1007/s00586-003-0556-5
   Pye SR, 2006, ANN RHEUM DIS, V65, P234, DOI 10.1136/ard.2005.038224
   Rade M, 2018, SPINE, V43, P412, DOI 10.1097/BRS.0000000000002352
   Rao Prashanth J, 2017, J Spine Surg, V3, P168, DOI 10.21037/jss.2017.05.03
   Suh PB, 2017, J AM ACAD ORTHOP SUR, V25, P160, DOI 10.5435/JAAOS-D-16-00390
   Uehara M, 2019, SPINE J, V19, P349, DOI 10.1016/j.spinee.2018.06.346
   Yang JJ, 2011, CLIN ORTHOP SURG, V3, P16, DOI 10.4055/cios.2011.3.1.16
NR 27
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD OCT
PY 2019
VL 130
BP E694
EP E701
DI 10.1016/j.wneu.2019.06.195
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JB0MH
UT WOS:000488248200088
PM 31279113
DA 2020-05-12
ER

PT J
AU Cheung, W
   Russo, C
   Maher, S
   Malik, R
   Slapeta, J
AF Cheung, Wesley
   Russo, Candace
   Maher, Simone
   Malik, Richard
   Slapeta, Jan
TI Successful use of secnidazole to manage a giardiosis outbreak in a
   shelter
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Giardia duodenalis; Antigen; Secnidazole; Treatment; Canine; Clinical
   signs
ID DUODENALIS INFECTION; DOGS; CATS; GIARDIASIS; METRONIDAZOLE; PREVALENCE;
   UPDATE; EPIDEMIOLOGY; EFFICACY; RISK
AB Giardia duodenalis is a common parasite in dogs in shelters where new introductions, including numerous juvenile individuals, are ongoing. A safe and effective single dose parasiticide is highly desirable for shelters experiencing disease caused by G. duodenalis (giardiosis). Secnidazole is an efficacious, low-cost medication used for the treatment of giardiosis in humans and has the advantage of requiring only a single oral dose. The aim of this study was to determine retrospectively the effectiveness of secnidazole on dogs of all ages during an outbreak of giardiosis in a shelter. Patients recruited into this retrospective study were divided into two groups. Group A consisted of adult dogs and weaned dogs ( > 10 weeks-of-age). Group B was comprised of puppies ( < 10 weeks-of-age). Giardiosis resolved in all 14 patients in Group A within 13 days following a single oral dose of secnidazole (30 mg/kg). There were no individuals with both gastrointestinal signs and a positive G. duodenalis antigen test at the time of the first and second follow-up examination. For the young puppies in Group B, giardiosis was reduced by 90% (9/10) within 22 days following two consecutive doses of secnidazole (30 mg/kg; 2 weeks apart). No adverse reactions were observed in any patients treated with secnidazole. Secnidazole is an effective and easily administered drug for the treatment of clinical canine giardiosis.
C1 [Cheung, Wesley; Slapeta, Jan] Univ Sydney, Fac Sci, Sydney Sch Vet Sci, Sydney, NSW, Australia.
   [Cheung, Wesley; Russo, Candace] Anim Welf League NSW, Kemps Creek, NSW, Australia.
   [Maher, Simone; Malik, Richard] Univ Sydney, Ctr Vet Educ, Sydney, NSW 2006, Australia.
RP Slapeta, J (reprint author), Univ Sydney, Lab Vet & Mol Parasitol, Sydney Sch Vet Sci, Fac Sci, Sydney, NSW 2006, Australia.
EM jan.slapeta@sydney.edu.au
OI Slapeta, Jan/0000-0003-1459-9117
CR Almirall Pedro, 2011, J Parasitol Res, V2011, P636857, DOI 10.1155/2011/636857
   Backhed F, 2015, CELL HOST MICROBE, V17, P852, DOI 10.1016/j.chom.2015.05.012
   Ballweber LR, 2010, TRENDS PARASITOL, V26, P180, DOI 10.1016/j.pt.2010.02.005
   Barr SC, 1998, AM J VET RES, V59, P1134
   Beatty JK, 2017, INT J PARASITOL, V47, P311, DOI 10.1016/j.ijpara.2016.11.010
   Bouzid M, 2015, VET PARASITOL, V207, P181, DOI 10.1016/j.vetpar.2014.12.011
   Bowman DD, 2009, PARASITOL RES, V105, pS125, DOI 10.1007/s00436-009-1503-0
   Buddington RK, 2003, AM J VET RES, V64, P646, DOI 10.2460/ajvr.2003.64.646
   Caylor KB, 2001, J AM ANIM HOSP ASSOC, V37, P258, DOI 10.5326/15473317-37-3-258
   Da Silva AS, 2011, PARASITOL INT, V60, P429, DOI 10.1016/j.parint.2011.06.024
   Dingsdag SA, 2018, J ANTIMICROB CHEMOTH, V73, P265, DOI 10.1093/jac/dkx351
   Dinnage JD, 2009, J FELINE MED SURG, V11, P816, DOI 10.1016/j.jfms.2009.03.001
   DOW SW, 1989, J AM VET MED ASSOC, V195, P365
   Edinboro CH, 2004, PREV VET MED, V62, P89, DOI 10.1016/j.prevetmed.2003.10.001
   Efstratiou A, 2017, WATER RES, V114, P14, DOI 10.1016/j.watres.2017.01.036
   Einarsson E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004571
   Feng YY, 2011, CLIN MICROBIOL REV, V24, P110, DOI 10.1128/CMR.00033-10
   Gillis JC, 1996, DRUGS, V51, P621, DOI 10.2165/00003495-199651040-00007
   GRAY SF, 1994, EPIDEMIOL INFECT, V113, P95, DOI 10.1017/S0950268800051505
   Gruffydd-Jones T, 2013, J FELINE MED SURG, V15, P650, DOI 10.1177/1098612X13489232
   Guard BC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175718
   Holt DE, 2010, JAVMA-J AM VET MED A, V237, P71, DOI 10.2460/javma.237.1.71
   Hoque M. Ekramul, 2002, International Journal of Infectious Diseases, V6, P191, DOI 10.1016/S1201-9712(02)90110-4
   Hoque ME, 2003, EPIDEMIOL INFECT, V131, P655, DOI 10.1017/S0950268803008598
   Hunter PR, 2005, INT J PARASITOL, V35, P1181, DOI 10.1016/j.ijpara.2005.07.009
   Jenkins EK, 2016, AM J VET RES, V77, P906, DOI 10.2460/ajvr.77.8.906
   Karahalli C, 2017, MAGY ALLATORVOSOK, V139, P621
   Meggiolaro MN, 2019, VET PARASITOL, V266, P12, DOI 10.1016/j.vetpar.2018.12.009
   Mueller NT, 2015, TRENDS MOL MED, V21, P109, DOI 10.1016/j.molmed.2014.12.002
   Olson ME, 2010, CAN VET J, V51, P640
   Palmer CS, 2008, VET PARASITOL, V151, P181, DOI 10.1016/j.vetpar.2007.10.015
   Raza A, 2018, ANIMALS-BASEL, V8, DOI 10.3390/ani8070108
   Rossignol JF, 2010, EXP PARASITOL, V124, P45, DOI 10.1016/j.exppara.2009.07.005
   Scorza AV, 2004, J FELINE MED SURG, V6, P157, DOI 10.1016/j.jfms.2003.11.007
   Slapeta J, 2015, INT J PARASITOL, V45, P585, DOI 10.1016/j.ijpara.2015.04.001
   Sommer MF, 2018, VET PARASITOL, V249, P49, DOI 10.1016/j.vetpar.2017.11.006
   Tangtrongsup S, 2010, TOP COMPANION ANIM M, V25, P155, DOI 10.1053/j.tcam.2010.07.003
   Tysnes KR, 2014, TRENDS PARASITOL, V30, P520, DOI 10.1016/j.pt.2014.08.007
   Uiterwijk M, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3014-2
   Upjohn M, 2010, VET PARASITOL, V172, P341, DOI 10.1016/j.vetpar.2010.05.010
   Volpato A, 2018, EXP PARASITOL, V189, P16, DOI 10.1016/j.exppara.2018.04.008
   Warburton A R, 1994, Commun Dis Rep CDR Rev, V4, pR32
   Yassour M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad0917
   Zajac AM, 1998, AM J VET RES, V59, P61
NR 44
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108911
DI 10.1016/j.vetpar.2019.08.005
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200003
PM 31499401
DA 2020-05-12
ER

PT J
AU Chontananarth, T
   Parawat, J
AF Chontananarth, Thapana
   Parawat, Janjura
TI Development of Cytochrome B, a new candidate gene for a high accuracy
   detection of Fasciola eggs in fecal specimens
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola gigantica; Cytochrome B; Species-specific primer;
   Epidemiological mapping
ID PHYLOGENETIC ANALYSIS; MOLECULAR CHARACTERIZATION; RIBOSOMAL DNA; PCR
   ASSAY; HEPATICA; GIGANTICA; MITOCHONDRIAL; NUCLEAR; TRICLABENDAZOLE;
   IDENTIFICATION
AB Fasciolosis among domestic ruminants has resulted in a decrease in the production of milk products and has occasionally led to the deaths of young ruminants due to of acute infections. This study aimed to discriminate between the eggs of Fasciola gigantica and other trematode eggs in samples collected from ruminant feces specimens using PCR-based methods with the new candidate gene Cytochrome B (CYTB). A species-specific primer was developed with a high degree of sensitivity (3.285 pg). The primer was able to amplify the F. gigantica genomic DNA and there were no positive results with the other related trematodes (Paramphistomum sp., Orthocoelium sp., Fischoederius sp., Calicophoron sp., Echinostoma revolutum, E. cinetorchis, E. ilocanum and Isthmiophora hortensis), freshwater snails (Lymnaea auricularia, Bithynia siamensis, Indoplanorbis exustus, Melanoides tuberculata, Tarebia granifera) or definitive hosts (Bos primigenius and Bubalus bubalis). The minimum concentration of DNA from eggs that could be give a positive result was 3.285 pg. Moreover, the results of the study confirmed the existence of F. gigantica in Nakhon Pathom Province with a high prevalence (28.57%) and revealed the area of infection through epidemiological mapping. Thus, the species-specific primer and epidemiological data in this study may be helpful for use in epidemiological studies, phylogenetic studies and veterinary studies in the future.
C1 [Chontananarth, Thapana; Parawat, Janjura] Srinakharinwirot Univ, Fac Sci, Dept Biol, Appl Parasitol Res Lab, Bangkok, Thailand.
   [Chontananarth, Thapana] Srinakharinwirot Univ, Ctr Excellence Anim Plant & Parasit Biotechnol, Bangkok, Thailand.
RP Chontananarth, T (reprint author), Srinakharinwirot Univ, Fac Sci, Dept Biol, Appl Parasitol Res Lab, Bangkok, Thailand.
EM thapana@g.swu.ac.th
FU Srinakharinwirot University, Thailand [037/2561]
FX We greatly acknowledge Srinakharinwirot University, Thailand for
   providing funding and relevant facilities (Research Grant No. 037/2561).
   Additionally, we would like to thank Mr. Simon McIver for his assistance
   in editing this manuscript.
CR Ai L, 2010, ANN TROP MED PARASIT, V104, P65, DOI 10.1179/136485910X12607012373713
   Ali ME, 2015, FOOD CHEM, V177, P214, DOI 10.1016/j.foodchem.2014.12.098
   Ali ME, 2014, FOOD ANAL METHOD, V7, P234, DOI 10.1007/s12161-013-9672-y
   ALLEN AVH, 1970, J CLIN PATHOL, V23, P545, DOI 10.1136/jcp.23.6.545
   Ashrafi K, 2014, TRAVEL MED INFECT DI, V12, P636, DOI 10.1016/j.tmaid.2014.09.006
   Bazsalovicsova E, 2010, HELMINTHOLOGIA, V47, P76, DOI 10.2478/s11687-010-0011-1
   Blasco-Costa I, 2016, SYST PARASITOL, V93, P295, DOI 10.1007/s11230-016-9631-2
   Bless PJ, 2015, ACTA TROP, V141, P295, DOI 10.1016/j.actatropica.2014.09.007
   Chaichanasak P, 2012, PARASITOL INT, V61, P545, DOI 10.1016/j.parint.2012.03.009
   Chaudhry U, 2016, J HELMINTHOL, V90, P206, DOI 10.1017/S0022149X15000176
   Demerdash ZA, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-176
   Bargues MD, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1589-z
   Dorchies P, 2006, P 24 WORLD BUIATR C, P1
   EDUARDO S L, 1980, Systematic Parasitology, V1, P203, DOI 10.1007/BF00009846
   Elkhatam A, 2016, INT J SCI RES SCI TE, V2, P188
   Gaasenbeek CPH, 2001, VET PARASITOL, V95, P37, DOI 10.1016/S0304-4017(00)00413-1
   Hanna REB, 2015, VET PARASITOL, V207, P34, DOI 10.1016/j.vetpar.2014.11.016
   Hanna R, 2015, PATHOGENS, V4, P431, DOI 10.3390/pathogens4030431
   Hayashi K, 2016, J VET MED SCI, V78, P1529, DOI 10.1292/jvms.16-0126
   Ichikawa-Seki M, 2017, PARASITOLOGY, V144, P206, DOI 10.1017/S003118201600161X
   Ichikawa-Seki M, 2017, PARASITOL INT, V66, P893, DOI 10.1016/j.parint.2016.10.010
   Ichikawa-Seki M, 2016, PARASITOL INT, V65, P171, DOI 10.1016/j.parint.2015.11.010
   Kaewpitoon Natthawut, 2015, Asian Pac J Cancer Prev, V16, P6825
   Monteiro L, 1997, J CLIN MICROBIOL, V35, P995, DOI 10.1128/JCM.35.4.995-998.1997
   OVEREND DJ, 1995, AUST VET J, V72, P275, DOI 10.1111/j.1751-0813.1995.tb03546.x
   Raina O.K., 2015, Journal of Parasitic Diseases, V39, P27, DOI 10.1007/s12639-013-0276-7
   Rast L, 2017, ANIM PROD SCI, V57, P141, DOI 10.1071/AN141032
   Sanabria REF, 2008, HELMINTHOLOGIA, V45, P64, DOI 10.2478/s11687-008-0012-5
   Shoriki T, 2016, PARASITOL INT, V65, P180, DOI 10.1016/j.parint.2015.12.002
   Staats M, 2016, ANAL BIOANAL CHEM, V408, P4615, DOI 10.1007/s00216-016-9595-8
   Stevanovic J, 2016, J INVERTEBR PATHOL, V139, P6, DOI 10.1016/j.jip.2016.07.001
   Swarnakar G., 2014, International Journal of Current Microbiology and Applied Sciences, V3, P32
   Umur Sinasi, 2018, Vet Parasitol Reg Stud Reports, V13, P1, DOI 10.1016/j.vprsr.2018.02.008
   Valadas SYOB, 2016, EXP PARASITOL, V164, P71, DOI 10.1016/j.exppara.2016.02.008
   Wannasan A, 2014, EXP PARASITOL, V146, P64, DOI 10.1016/j.exppara.2014.09.006
   Xu WP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120210
   Yamaguti S, 1958, SYSTEMA HELMINIHUM, VI
   Zhao YY, 2017, J HELMINTHOL, V91, P255, DOI [10.1017/S0022149X16000183, 10.1017/s0022149x16000183]
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108922
DI 10.1016/j.vetpar.2019.108922
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200006
PM 31539665
DA 2020-05-12
ER

PT J
AU Escareno-Diaz, S
   Alonso-Diaz, MA
   de Gives, PM
   Castillo-Gallegos, E
   von Son-de Fernex, E
AF Escareno-Diaz, S.
   Alonso-Diaz, M. A.
   Mendoza de Gives, P.
   Castillo-Gallegos, E.
   von Son-de Fernex, E.
TI Anthelmintic-like activity of polyphenolic compounds and their
   interactions against the cattle nematode Cooperia punctata
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Polyphenolic compounds; Phytochemicals; Synergism; Gastrointestinal
   nematodes; Ruminant; Novel approaches
ID GASTROINTESTINAL NEMATODES; HYDROLYZABLE TANNINS; PARASITIC NEMATODES;
   PLANT-EXTRACTS; EXSHEATHMENT; BIOCHEMISTRY; FLAVONOIDS; IVERMECTIN;
   KAEMPFEROL; RESISTANCE
AB Polyphenolic compounds (PCs) have been proposed as one of the most bioactive group of secondary metabolites occurring in nature and have been associated to anthelmintic (AH)-like activity of plants against cattle nematodes. However, little is known regarding their synergetic / antagonistic interactions. This study assessed the in vitro AH-like activity of commercial PCs: quercetin, caffeic acid, rutin and coumarin, and their combinations against the egg hatching and larval exsheathment of Cooperia punctata; one of the most prevalent nematodes affecting grazing cattle in tropical regions. The molecules selected for the in vitro analysis were identified as bioactive phytochemicals of plants through bio-guided fractionation in previous studies. To estimate mean effective concentrations (EC50) five increasing concentrations were used for both Egg hatching inhibition assay (EHIA) and larval exsheathment inhibition assay (LEIA) (0.6-9.8 mg mL(-1) and 0.15-2.4 mg mL(-1), respectively). From the four molecules, only rutin did not affect egg hatching; while quercetin, showed no bioactivity against eggs or larvae (P > 0.766 and P > 0.621, respectively). Best-fit EC50 estimated through the EHIA was considered for PCs classification as bioactive (coumarin and caffeic acid) and non-bioactive (quercetin and rutin). Phytochemical interactions were subsequently assessed combining bioactive:non-bioactive PCs (8:2 ratio), and the nature of their interaction was classified using the fractional inhibitory concentration index (FICindex). Combinations had a highly synergistic interaction against larval exsheathment (FICindex < 0.5) except for coumarin:rutin against egg hatching (FICindex > 0.5). Quercetin and rutin acted as PCs AH-like activity enhancers, reducing EC50 of bioactive molecules in a range of 43%-64% and 68%-83% for EHIA and LEIA, respectively. A linear relationship between low molecular weight of molecules and ovicidal activity was observed; where, molecules with lower molecular weight displayed better-fit EC50 for ovicidal activity. Furthermore, coumarin and caffeic acid bioactivity against free-living stages of C. punctata makes them suitable candidates as markers for anthelmintic-like activity in bioactive forages. Combinations used through this investigation showed a potent anthelmintic-like activity against free-living forms of C. punctata, representing a first step towards the identification of promising alternatives for nematode control.
C1 [Escareno-Diaz, S.] Univ Autonoma Zacatecas, Ctr Hist, Zacatecas Ctr, Jardin Juarez 147, Zacatecas 98000, Zac, Mexico.
   [Alonso-Diaz, M. A.; Castillo-Gallegos, E.; von Son-de Fernex, E.] Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Ctr Ensenanza Invest & Extens Ganaderia Trop, Km 5-5 Carretera Fed Tlapacoyan Martinez de Torre, Martinez De La Torre 93600, Veracruz, Mexico.
   [Mendoza de Gives, P.] INIFAP, CENID Parasitol Vet, Carretera Fed Cuernavaca Cuautla 8534, Jiutepec 62550, Morelos, Mexico.
RP von Son-de Fernex, E (reprint author), Univ Nacl Autonoma Mexico, Fac Med Vet & Zootecnia, Ctr Ensenanza Invest & Extens Ganaderia Trop, Km 5-5 Carretera Fed Tlapacoyan Martinez de Torre, Martinez De La Torre 93600, Veracruz, Mexico.
EM elkevsf@hotmail.com
RI Castillo-Gallegos, Epigmenio/I-8965-2018
OI Castillo-Gallegos, Epigmenio/0000-0002-2850-9795
FU DGAPA-UNAM through the Research PAPIIT Project [IA210917]
FX This work was supported by DGAPA-UNAM through the Research PAPIIT
   Project No. IA210917.
CR Alonso-Diaz MA, 2008, VET PARASITOL, V153, P313, DOI 10.1016/j.vetpar.2008.01.042
   Alonso-Diaz MA, 2015, VET PARASITOL, V212, P439, DOI 10.1016/j.vetpar.2015.07.023
   Anwar J, 2012, PHARMACOL BIOCHEM BE, V103, P386, DOI 10.1016/j.pbb.2012.09.006
   Brunet S, 2006, J AGR FOOD CHEM, V54, P7481, DOI 10.1021/jf0610007
   Cassano A, 2017, COORDIN CHEM REV, V351, P45, DOI 10.1016/j.ccr.2017.06.013
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   Corticelli B, 1963, ACTA MED VET NAPOLI, V9
   Dubey S., 2013, CHRONICLES YOUNG SCI, V4, P153
   Engstrom MT, 2016, J AGR FOOD CHEM, V64, P840, DOI 10.1021/acs.jafc.5b05691
   Engstrom MT, 2015, J AGR FOOD CHEM, V63, P4068, DOI 10.1021/acs.jafc.5b00595
   FETTERER RH, 1993, VET PARASITOL, V46, P103, DOI 10.1016/0304-4017(93)90051-N
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gullon B, 2017, TRENDS FOOD SCI TECH, V67, P220, DOI 10.1016/j.tifs.2017.07.008
   Heckler RP, 2014, VET PARASITOL, V205, P638, DOI 10.1016/j.vetpar.2014.08.002
   Hoste H, 2015, VET PARASITOL, V212, P5, DOI 10.1016/j.vetpar.2015.06.026
   Hoste H, 2012, VET PARASITOL, V186, P18, DOI 10.1016/j.vetpar.2011.11.042
   Rodriguez-Vivas RI, 2017, REV MEX CIENC PECU, V8, P61, DOI 10.22319/rmcp.v8i1.4305
   Jakobek L, 2015, FOOD CHEM, V175, P556, DOI 10.1016/j.foodchem.2014.12.013
   Katiki LM, 2013, VET PARASITOL, V192, P218, DOI 10.1016/j.vetpar.2012.09.030
   Klongsiriwet C, 2015, INT J PARASITOL-DRUG, V5, P127, DOI 10.1016/j.ijpddr.2015.06.001
   Louvandini H, 2009, VET PARASITOL, V163, P47, DOI 10.1016/j.vetpar.2009.04.021
   Mandery K, 2010, BIOCHEM PHARMACOL, V80, P1746, DOI 10.1016/j.bcp.2010.08.008
   Minakov I., 2017, PHENOLIC COMPOUNDS B, P1, DOI [DOI 10.5772/66368, 10.5772/66368]
   Mirunalini S., 2011, International Journal of PharmTech Research, V3, P1693
   Mor V, 2015, MBIO, V6, DOI 10.1128/mBio.00647-15
   Nakamura H, 2018, J TAIWAN INST CHEM E, V90, P18, DOI 10.1016/j.jtice.2017.11.016
   Novobilsky A, 2011, VET PARASITOL, V182, P213, DOI 10.1016/j.vetpar.2011.06.003
   Qiang Z, 2011, THESIS
   Ramos F, 2016, INT J PARASITOL-DRUG, V6, P93, DOI 10.1016/j.ijpddr.2016.02.002
   Ramunke S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200390
   Sanhueza L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172273
   Selway J W, 1986, Prog Clin Biol Res, V213, P521
   Spiegler V, 2017, NAT PROD REP, V34, P627, DOI 10.1039/c6np00126b
   Stromberg BE, 2012, VET PARASITOL, V183, P284, DOI 10.1016/j.vetpar.2011.07.030
   Sutherland IA, 2011, TRENDS PARASITOL, V27, P176, DOI 10.1016/j.pt.2010.11.008
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Tsimogiannis D., 2019, POLYPHENOLS PLANTS, P263, DOI 10.1016/B978-0-12-813768-0.0002
   Vargas-Magana JJ, 2014, VET PARASITOL, V206, P322, DOI 10.1016/j.vetpar.2014.10.008
   von Son-de Fernex E, 2017, EXP PARASITOL, V178, P1, DOI 10.1016/j.exppara.2017.04.013
   von Son-de Fernex E, 2015, VET PARASITOL, V214, P89, DOI 10.1016/j.vetpar.2015.10.005
   Wang TY, 2018, ASIAN J PHARM SCI, V13, P12, DOI 10.1016/j.ajps.2017.08.004
   Yang XJ, 2014, J INTEGR PLANT BIOL, V56, P979, DOI 10.1111/jipb.12212
NR 42
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108909
DI 10.1016/j.vetpar.2019.08.003
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200011
PM 31586699
DA 2020-05-12
ER

PT J
AU Escotte-Binet, S
   Da Silva, AM
   Cances, B
   Aubert, D
   Dubey, J
   La Carbona, S
   Villena, I
   Poulle, ML
AF Escotte-Binet, Sandie
   Da Silva, Abdou Malik
   Cances, Benjamin
   Aubert, Dominique
   Dubey, Jitender
   La Carbona, Stephanie
   Villena, Isabelle
   Poulle, Marie-Lazarine
TI A rapid and sensitive method to detect Toxoplasma gondii oocysts in soil
   samples
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Soil contamination; Dispersion solution; Sucrose flotation; Density
   gradients; Toxoplasma gondii; qPCR detection
ID CRYPTOSPORIDIUM-PARVUM OOCYSTS; SPATIAL-DISTRIBUTION;
   ENVIRONMENTAL-FACTORS; PROTOZOAN PARASITES; TOXOCARA-CANIS; DNA;
   CONTAMINATION; TRANSMISSION; INFECTIVITY; DIAGNOSIS
AB Documenting the extent of soil contamination by Toxoplasma gondii oocysts is a key issue to prevent the worldwide infection caused by this protozoan. Our aim was to improve the practicability and sensitivity of a low-cost method to detect T. gondii DNA in soil samples developed a few years ago. Various parameters of the reference protocol were modified to determine their effect on the detection of T. gondii DNA in soil samples ("natural soil" and "sand") spiked with oocysts. We tested i) filtration using stomacher bags, ii) Tween 80, Tween 20, SDS and Triton X100 as dispersion solutions, iii) sucrose solution, zinc chloride solution, Optiprep and Percoll as density gradients, iv) freeze/thaw versus mechanical grinding as lysis methods, and v) Qiagen versus Fastprep as extraction kits The optimized protocol is quicker and easier to use than the previous one, and includes the following items: 0.1% Tween80/PBS for dispersion, sucrose solution for flotation, mechanical grinding, and FastDNA spin kit for extraction. It accurately detects T. gondii DNA in both fresh and frozen soil samples and displays a detection limit below 1 oocyst/g of fresh soil.
C1 [Escotte-Binet, Sandie; Da Silva, Abdou Malik; Aubert, Dominique; Villena, Isabelle; Poulle, Marie-Lazarine] Univ Reims, ESCAPE EA 7510, CAP SANTE, F-51097 Reims, France.
   [Cances, Benjamin] Univ Reims, GEGENAA EA 3795, CONDORCET, F-51097 Reims, France.
   [Aubert, Dominique; Villena, Isabelle] CHU Reims, Hop Maison Blanche, Ctr Natl Reference Toxoplasmose, CRB Toxoplasma,Lab Parasitol Mycol, F-51097 Reims, France.
   [Dubey, Jitender] ARS, USDA, Beltsville Agr Res Ctr, Anim Parasit Dis Lab, Bldg 1001, Beltsville, MD 20705 USA.
   [La Carbona, Stephanie] ACTALIA, Food Safety Dept, 310 Rue Popielujko, F-50000 St Lo, France.
   [Poulle, Marie-Lazarine] Univ Reims, CERFE, F-08240 Boult Aux Bois, France.
RP Poulle, ML (reprint author), Univ Reims, CERFE, F-08240 Boult Aux Bois, France.
EM sandie.escotte@univ-reims.fr; abdou_malik.da_silva@univ-fcomte.fr;
   benjamin.cances@univ-reims.fr; daubert@chu-reims.fr; dubey@ars.usda.gov;
   s.lacarbona@actalia.eu; ivillena@chu-reims.fr;
   marie-lazarine.poulle@univ-reims.fr
RI Aubert, dominique/AAH-5854-2019
OI Escotte-Binet, Sandie/0000-0002-5959-1533
CR Afonso E, 2008, INT J PARASITOL, V38, P1017, DOI 10.1016/j.ijpara.2008.01.004
   Caradonna T, 2017, FOOD MICROBIOL, V67, P67, DOI 10.1016/j.fm.2017.06.006
   Cheun HI, 2003, J APPL MICROBIOL, V95, P728, DOI 10.1046/j.1365-2672.2003.02038.x
   Dubey JP, 2006, VET PARASITOL, V140, P69, DOI 10.1016/j.vetpar.2006.03.018
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL, P336
   Dumetre A, 2003, FEMS MICROBIOL REV, V27, P651, DOI 10.1016/S0168-6445(03)00071-8
   Dumetre A, 2013, P NATL ACAD SCI USA, V110, P11535, DOI 10.1073/pnas.1308425110
   Elwin K, 2014, J MED MICROBIOL, V63, P38, DOI 10.1099/jmm.0.066050-0
   Elwin K, 2012, J MICROBIOL METH, V89, P38, DOI 10.1016/j.mimet.2012.02.006
   FRENKEL JK, 1975, AM J TROP MED HYG, V24, P439, DOI 10.4269/ajtmh.1975.24.439
   Gotteland C, 2014, VET PARASITOL, V205, P629, DOI 10.1016/j.vetpar.2014.08.003
   Highmore CJ, 2017, MICROB BIOTECHNOL, V10, P969, DOI 10.1111/1751-7915.12737
   Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x
   Hohweyer J, 2016, FOOD MICROBIOL, V57, P36, DOI 10.1016/j.fm.2016.01.002
   Kuczynska E, 1999, APPL ENVIRON MICROB, V65, P2820
   Lass A, 2012, EUR J CLIN MICROBIOL, V31, P1101, DOI 10.1007/s10096-011-1414-8
   Lass A, 2009, EUR J CLIN MICROBIOL, V28, P599, DOI 10.1007/s10096-008-0681-5
   Lelu M, 2012, APPL ENVIRON MICROB, V78, P5127, DOI 10.1128/AEM.00246-12
   Lelu M, 2011, VET PARASITOL, V183, P59, DOI 10.1016/j.vetpar.2011.06.018
   Lindqvist R, 1997, INT J FOOD MICROBIOL, V37, P73, DOI 10.1016/S0168-1605(97)00054-8
   Liu JA, 2010, J MICROBIOL, V48, P728, DOI 10.1007/s12275-010-0139-1
   Mawdsley JL, 1996, BIOL FERT SOILS, V21, P30, DOI 10.1007/BF00335990
   Mizgajska H, 2001, Wiad Parazytol, V47, P399
   Mizgajska-Wiktor H, 2017, VET PARASITOL, V234, P1, DOI 10.1016/j.vetpar.2016.12.011
   Munoz-Zanzi C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-837
   NUNES CM, 1994, VET PARASITOL, V53, P269, DOI 10.1016/0304-4017(94)90190-2
   Petersen HH, 2012, APPL ENVIRON MICROB, V78, P5994, DOI 10.1128/AEM.07829-11
   Reischl U, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-7
   Schick M.J, 1966, NONIONIC SURFACTANTS, P1085
   Schluter D, 2014, INT J MED MICROBIOL, V304, P917, DOI 10.1016/j.ijmm.2014.09.002
   Schrader C, 2012, J APPL MICROBIOL, V113, P1014, DOI 10.1111/j.1365-2672.2012.05384.x
   Simon JA, 2017, INT J PARASITOL, V47, P357, DOI 10.1016/j.ijpara.2017.01.004
   Slifko TR, 2000, INT J PARASITOL, V30, P1379, DOI 10.1016/S0020-7519(00)00128-4
   VanWormer E, 2013, COMP IMMUNOL MICROB, V36, P217, DOI 10.1016/j.cimid.2012.10.006
   VEIT P, 1995, PARASITOLOGY, V110, P79, DOI 10.1017/S0031182000081075
   Yan C, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1432-6
   Yang WL, 2009, APPL ENVIRON MICROB, V75, P3477, DOI 10.1128/AEM.00285-09
   Zilberman A, 2009, WATER AIR SOIL POLL, V203, P325, DOI 10.1007/s11270-009-0015-y
NR 38
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108904
DI 10.1016/j.vetpar.2019.07.012
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200008
PM 31557695
DA 2020-05-12
ER

PT J
AU Hanna, REB
   Moffett, D
   Robinson, MW
   Jura, WGZO
   Brennan, GP
   Fairweather, I
   Threadgold, LT
AF Hanna, R. E. B.
   Moffett, D.
   Robinson, M. W.
   Jura, W. G. Z. O.
   Brennan, G. P.
   Fairweather, I
   Threadgold, L. T.
TI Fasciola gigantica: Ultrastructural cytochemistry of the tegumental
   surface in newly-excysted metacercariae and in vitro-penetrated juvenile
   flukes informs a concept of parasite defence at the interface with the
   host
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola gigantica; In vitro excystment and gut-penetration; Tegumental
   ultrastructure and cytochemistry; Glycocalyx; Parasite defence; Innate
   and acquired immunity
ID HEPATICA; RESISTANCE; INFECTION; IMMUNITY; GLYCOCALYX; MOLECULES;
   PLANARIAN; MIGRATION; ANTIBODY; SHEEP
AB Cytochemical staining techniques were carried out en bloc with in vitro excysted and gut-penetrated Fasciola gigantica larvae in order to visualise the glycocalyx of the tegument, a structure which comprises the parasite component of the host-parasite interface, yet is incompletely preserved by conventional fixation and preparation techniques for electron microscopy. Positive reactivity with ruthenium red and periodic acid-thiocarbohydrazine-osmium (PATCO) techniques revealed that the glycocalyx is polyanionic and carbohydrate-rich throughout its depth. It comprises a trilaminate arrangement, with a thin dense zone and fibrillar layer closely apposed to the outer aspect of the apical plasma membrane, invested by an irregular thick mucopolysaccharide capsule. The latter, not recorded in adult flukes, may represent a specific adaptation to facilitate invasion in the face of host immunity, and may also protect the parasite surface from the action of host- and parasite-derived proteases. Early in the invasion of a naive host, the glycocalyx may be partly responsible for triggering the responses of innate immunity, while later in infection, or when an anamnestic response is initiated in an immunocompetent host, the antibodies and activated lymphocytes of specific acquired immunity are invoked to interact with the parasite surface. The cytochemical properties of the glycocalyx, together with its potential for dynamic turnover due to exocytosis of the T0 tegumental secretory bodies, are likely to aid neutralisation of potentially damaging immune effectors and ensure their removal from the vicinity of the parasite by sloughing in complex with glycocalyx components.
C1 [Hanna, R. E. B.; Moffett, D.] AFBI, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland.
   [Robinson, M. W.; Brennan, G. P.; Fairweather, I; Threadgold, L. T.] Queens Univ Belfast, Sch Biol Sci, Belfast BT9 5DL, Antrim, North Ireland.
   [Jura, W. G. Z. O.] Maseno Univ, Dept Zool, Maseno, Kenya.
RP Hanna, REB (reprint author), AFBI, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland.
EM bob.hanna@afbini.gov.uk
FU Biotechnology and Biological Sciences Research Council
   (BBSRC)Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/L019612/1, BB/N017757/1]
FX Our thanks are due to Mr R. Ogola and Ms E. Wairimu of the Department of
   Parasitology, East African Veterinary Research Organisation, Muguga,
   Kenya, for expert technical assistance. Thanks are also due to Ms N.
   Dobson (Librarian, QUB/AFBI) and Mr C. Mason (Photographer, AFBI) for
   assistance and advice. No external funding was obtained for this work.
   M.W.R. was supported by grants (BB/L019612/1 and BB/N017757/1) from the
   Biotechnology and Biological Sciences Research Council (BBSRC).
CR AHMAD M, 1988, ZOOL ANZ, V220, P59
   Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992
   Andrews SJ, 1999, FASCIOLOSIS, P1
   BENNETT CE, 1975, EXP PARASITOL, V38, P38, DOI 10.1016/0014-4894(75)90036-3
   BENNETT CE, 1975, EXP PARASITOL, V37, P426, DOI 10.1016/0014-4894(75)90013-2
   Cameron TC, 2017, INT J PARASITOL, V47, P555, DOI 10.1016/j.ijpara.2017.02.004
   Cwiklinski K, 2019, ADV PARASIT, V104, P113, DOI 10.1016/bs.apar.2019.01.001
   Dalton JP, 2013, VET PARASITOL, V195, P272, DOI 10.1016/j.vetpar.2013.04.008
   Dangprasert T, 2001, J HELMINTHOL, V75, P43, DOI 10.1079/JOH200041
   Escudero ED, 2011, J PROTEOMICS, V74, P1534, DOI 10.1016/j.jprot.2011.05.024
   de la Torre-Escudero E, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007087
   DIXON KE, 1964, NATURE, V202, P1240, DOI 10.1038/2021240b0
   DOYLE JJ, 1971, RES VET SCI, V12, P527
   Fairweather I, 1999, FASCIOLOSIS, P47
   Hanna REB, 2019, VET PARASITOL, V265, P38, DOI 10.1016/j.vetpar.2018.11.019
   HANNA REB, 1980, EXP PARASITOL, V50, P155, DOI 10.1016/0014-4894(80)90017-X
   HANNA REB, 1977, RES VET SCI, V22, P339, DOI 10.1016/S0034-5288(18)33259-4
   HANNA REB, 1980, EXP PARASITOL, V50, P103, DOI 10.1016/0014-4894(80)90012-0
   HANNA REB, 1988, RES VET SCI, V44, P237, DOI 10.1016/S0034-5288(18)30847-6
   Hayat M.A., 1989, PRINCIPLES TECHNIQUE, P208
   Hayes MJ, 2017, BIOL OPEN, V6, P571, DOI 10.1242/bio.024554
   Jackson JA, 2009, IMMUNOLOGY, V126, P18, DOI 10.1111/j.1365-2567.2008.03010.x
   Kumar V, 2018, ROBBINS BASIC PATHOL, P57
   McGee C, 1996, J ZOOL, V240, P563, DOI 10.1111/j.1469-7998.1996.tb05306.x
   McVeigh P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29673-3
   Mulcahy G, 1999, FASCIOLOSIS, P341
   Pearse A.G.E., 1985, HISTOCHEMISTRY THEOR, V2, P675
   Piedrafita D, 2010, PARASITE IMMUNOL, V32, P572, DOI 10.1111/j.1365-3024.2010.01223.x
   Pleasance J, 2011, PARASITE IMMUNOL, V33, P495, DOI 10.1111/j.1365-3024.2011.01305.x
   Pleasance J, 2011, VET PARASITOL, V178, P264, DOI 10.1016/j.vetpar.2011.01.037
   Rambourg A, 1971, Int Rev Cytol, V31, P57
   Ravida A, 2016, MOL CELL PROTEOMICS, V15, P3139, DOI 10.1074/mcp.M116.059774
   Roberts JA, 1997, VET PARASITOL, V68, P69, DOI 10.1016/S0304-4017(96)01027-8
   Roberts JA, 1997, VET PARASITOL, V73, P215, DOI 10.1016/S0304-4017(97)00119-2
   ROGAN MT, 1984, EXP PARASITOL, V57, P248, DOI 10.1016/0014-4894(84)90098-5
   Sobhon P., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P387
   Spithill TW, 1999, FASCIOLOSIS, P377
   Spithill TW, 1999, FASCIOLOSIS, P465
   Suvarna S.K., 2019, BANCROFTS THEORY PRA, P176
   THREADGOLD LT, 1976, EXP PARASITOL, V39, P119, DOI 10.1016/0014-4894(76)90019-9
   THREADGOLD LT, 1978, EXP PARASITOL, V46, P300, DOI 10.1016/0014-4894(78)90143-1
   Varki A, 2009, ESSENTIALS GLYCOBIOL
NR 42
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108923
DI 10.1016/j.vetpar.2019.108923
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200007
PM 31542719
DA 2020-05-12
ER

PT J
AU Parody, N
   Cacheiro-Llaguno, C
   Osuna, C
   Renshaw-Calderon, A
   Alonso, C
   Carnes, J
AF Parody, Nuria
   Cacheiro-Llaguno, Cristina
   Osuna, Cristina
   Renshaw-Calderon, Ana
   Alonso, Carlos
   Carnes, Jeronimo
TI Circulating immune complexes levels correlate with the progression of
   canine leishmaniosis in naturally infected dogs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Biomarkers; Canine leishmaniosis; Circulating immune complexes;
   Leishmania infantum
ID ANTIGEN-ANTIBODY COMPLEXES; DISEASE-ACTIVITY; VISCERAL LEISHMANIASIS;
   HUMAN SERA; INFANTUM; NEPHRITIS; SIZE; SERODIAGNOSIS; SPECIMENS;
   DIAGNOSIS
AB Dogs are the main domestic reservoir of Leishmania infantum, and in cases of uncontrolled infection, a strong humoral immune response is elicited, which is inefficient against the parasites. Previous studies have suggested that an adequate antigen/antibody ratio, with a moderate prevalence of antigens with respect to the antibodies, could result in the formation of circulating immune complexes (CIC) in canine leishmaniosis (CanL). Deposition of these complexes in tissues has been associated with vasculitis, uveitis, arthritis, dermatitis and especially glomerulonephritis and renal failure. However, little is known about the relationship between the presence of CIC and disease progression. The aim of this study was to evaluate serum CIC level and its correlation with disease severity in infected dogs with different stages of disease and non-infected animals as a control. A total of 60 dogs were included in the study, classified according to the proposed LeishVet classification criteria: healthy non-infected (n = 13); healthy infected (n = 12); sick stage I (n = 9); sick stage II (n = 17); sick stage III (n = 8); and sick stage IV (n = 1). CIC were isolated from serum samples using a modified polyethylene glycol precipitation method, and their levels measured by ELISA and bicinchoninic acid protein assay. A nanoparticle tracking analysis was performed to investigate the relationship between the molecular size distribution of the CIC and disease progression. In conclusion, the results confirmed a positive association between CIC levels, their molecular size and disease progression that suggests a potential use of CIC as biomarkers of CanL.
C1 [Parody, Nuria; Cacheiro-Llaguno, Cristina; Osuna, Cristina; Carnes, Jeronimo] Labs LETI SL, R&D Dept, Madrid, Spain.
   [Renshaw-Calderon, Ana; Alonso, Carlos] Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid, Spain.
RP Carnes, J (reprint author), Labs LETI SL, R&D Dept, Madrid, Spain.
EM jcarnes@leti.com
OI Carnes, Jeronimo/0000-0003-4050-2577
CR ABRASS CK, 1980, ARTHRITIS RHEUM-US, V23, P273, DOI 10.1002/art.1780230302
   Aresu L, 2013, VET PATHOL, V50, P753, DOI 10.1177/0300985812459336
   BERNSTEIN KA, 1994, CLIN EXP IMMUNOL, V98, P60
   Brunner M, 2001, J CLIN MICROBIOL, V39, P3213, DOI 10.1128/JCM.39.9.3213-3221.2001
   Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262
   COCHRANE CG, 1968, J EXP MED, V127, P137, DOI 10.1084/jem.127.1.137
   Costa FAL, 2003, VET PATHOL, V40, P677, DOI 10.1354/vp.40-6-677
   Dantas-Torres F, 2007, VET PARASITOL, V149, P139, DOI 10.1016/j.vetpar.2007.07.007
   Dantas-Torres F, 2006, VET PARASITOL, V140, P54, DOI 10.1016/j.vetpar.2006.03.008
   DIGEON M, 1977, J IMMUNOL METHODS, V16, P165, DOI 10.1016/0022-1759(77)90051-5
   dos Santos JP, 2013, REV BRAS PARASITOL V, V22, P420, DOI 10.1590/S1984-29612013000300017
   Elshafie AI, 2007, J IMMUNOL, V178, P5383, DOI 10.4049/jimmunol.178.8.5383
   Fernandez-Cotrina J, 2013, VET PARASITOL, V192, P118, DOI 10.1016/j.vetpar.2012.10.002
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Galvez R, 2010, VET PARASITOL, V169, P327, DOI 10.1016/j.vetpar.2009.11.025
   Goedvolk CA, 2003, ARCH DIS CHILD, V88, P927, DOI 10.1136/adc.88.10.927
   HAY FC, 1976, CLIN EXP IMMUNOL, V24, P396
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Jaiswal P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192302
   Jamal F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182474
   Koraka P, 2003, J CLIN MICROBIOL, V41, P4154, DOI 10.1128/JCM.41.9.4154-4159.2003
   Korolevskaya LB, 2014, DOKL BIOCHEM BIOPHYS, V457, P134, DOI 10.1134/S160767291404005X
   Koutinas AF, 2014, VET PATHOL, V51, P527, DOI 10.1177/0300985814521248
   LEVINSKY RJ, 1977, LANCET, V1, P564
   LEVINSKY RJ, 1977, CLIN EXP IMMUNOL, V29, P428
   Lopez R, 1996, J VET MED B, V43, P469, DOI 10.1111/j.1439-0450.1996.tb00342.x
   LUCENA R, 1994, J VET MED A, V41, P48, DOI 10.1111/j.1439-0442.1994.tb00064.x
   MAGEED RA, 1991, ANN RHEUM DIS, V50, P231, DOI 10.1136/ard.50.4.231
   Maia C, 2008, VET PARASITOL, V158, P274, DOI 10.1016/j.vetpar.2008.07.028
   Maia C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00302
   MANCIANTI F, 1988, AM J VET RES, V49, P1409
   MANCIANTI F, 1989, Parassitologia (Rome), V31, P213
   MANNIK M, 1980, J INVEST DERMATOL, V74, P333, DOI 10.1111/1523-1747.ep12543582
   MARCUSSEN N, 1989, APMIS, V97, P1137, DOI 10.1111/j.1699-0463.1989.tb00529.x
   Margarito JM, 1998, J VET MED B, V45, P263, DOI 10.1111/j.1439-0450.1998.tb00793.x
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501
   Miro G, 2007, PARASITOL RES, V101, P253, DOI 10.1007/s00436-007-0497-8
   Nangaku Masaomi, 2005, Clin Exp Nephrol, V9, P183, DOI 10.1007/s10157-005-0357-8
   NIETO CG, 1992, VET PARASITOL, V45, P33, DOI 10.1016/0304-4017(92)90025-5
   NYDEGGER UE, 1980, CRC CR REV CL LAB SC, V12, P123, DOI 10.3109/10408368009108728
   Nydegger UE, 2007, ANN NY ACAD SCI, V1109, P66, DOI 10.1196/annals.1398.009
   Ordeix L, 2005, VET DERMATOL, V16, P187, DOI 10.1111/j.1365-3164.2005.00454.x
   PAGANELLI R, 1981, CLIN EXP IMMUNOL, V46, P44
   Paltrinieri S, 2010, JAVMA-J AM VET MED A, V236, P1184, DOI 10.2460/javma.236.11.1184
   Park Hae-Sim, 1998, Korean Journal of Internal Medicine, V13, P51
   Plevraki K, 2006, J VET INTERN MED, V20, P228, DOI 10.1892/0891-6640(2006)20[228:EOATOT]2.0.CO;2
   POLI A, 1991, NEPHRON, V57, P444, DOI 10.1159/000186348
   RAJA A, 1995, J LAB CLIN MED, V125, P581
   Reis AB, 2009, VET IMMUNOL IMMUNOP, V128, P87, DOI 10.1016/j.vetimm.2008.10.307
   Requena JM, 2000, VET IMMUNOL IMMUNOP, V76, P269, DOI 10.1016/S0165-2427(00)00221-X
   Rigo RS, 2013, REV INST MED TROP SP, V55, P113, DOI 10.1590/S0036-46652013000200008
   Roura X, 2013, VET J, V198, P43, DOI 10.1016/j.tvjl.2013.04.001
   Sengupta K, 2002, J HEALTH POPUL NUTR, V20, P215
   Sheerin NS, 2006, J AM SOC NEPHROL, V17, P686, DOI 10.1681/ASN.2004070515
   SOBEL AT, 1975, J EXP MED, V142, P139, DOI 10.1084/jem.142.1.139
   Solano-Gallego L, 2003, CLIN DIAGN LAB IMMUN, V10, P849, DOI 10.1128/CDLI.10.5.849-855.2003
   Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022
   Solano-Gallego L, 2017, TRENDS PARASITOL, V33, P706, DOI 10.1016/j.pt.2017.06.004
   Solano-Gallego L, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-86
   TAFURI WL, 1989, REV I MED TROP, V31, P139, DOI 10.1590/S0036-46651989000300002
   Thanadetsuntorn C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20947-4
   Thomas BN, 2012, BIOMARK INSIGHTS, V7, P81, DOI 10.4137/BMI.S9624
   TUNG KSK, 1981, CLIN EXP IMMUNOL, V43, P615
   Tuzun E, 2004, J IMMUNOL, V172, P5743, DOI 10.4049/jimmunol.172.9.5743
   Urbaniak-Kujda D, 1996, Pol Tyg Lek, V51, P303
   Willen L, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006607
   Zatelli A, 2003, AM J VET RES, V64, P558, DOI 10.2460/ajvr.2003.64.558
NR 68
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108921
DI 10.1016/j.vetpar.2019.108921
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200005
PM 31536867
DA 2020-05-12
ER

PT J
AU Pires, H
   Martins, M
   Matos, AC
   Cardoso, L
   Monteiro, F
   Roque, N
   Nunes, T
   Gottstein, B
   Cortes, H
AF Pires, Humberto
   Martins, Manuel
   Matos, Ana Cristina
   Cardoso, Luis
   Monteiro, Fernando
   Roque, Natalia
   Nunes, Telmo
   Gottstein, Bruno
   Cortes, Helder
TI Geospatial analysis applied to seroepidemiological survey of canine
   leishmaniosis in east-central Portugal
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Dogs; Epidemiology; GIS; Leishmania; Portugal; Serology
ID CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; ENVIRONMENTAL-FACTORS;
   IRAN; PREVALENCE; PROVINCE; VECTOR
AB Despite the high prevalence of canine Leishmania infantum infection in Portugal, significant differences associated with different risk factors can be found between geographically contiguous areas. In this study, a geographical area within the central region of Portugal (municipalities of Proenca-a-Nova, Macho and Vila de Rei) was investigated. An epidemiological survey involved the analysis by an indirect enzyme-linked immunosorbent assay of serum samples collected during the anti-rabies vaccination campaign from 282 dogs. Geospatial analysis showed the distribution of geospatial prevalence of leishmaniosis and has delimited two areas (clusters) with a statistically significant higher risk of seropositivity in dogs (p = 0.003 and p = 0.027, for clusters 1 and 2, respectively). The highest seroprevalence (56.0%; CI: 41.2-70.0) was found in Vila de Rei. Five land occupation types showed a possible influence on the geographic distribution of seropositivity, with statistically significant differences between seropositive and seronegative dogs. Land occupied by temporary irrigated crops (p = 0.026), olive groves (p = 0.013), complex cultural systems and parcelling (p = 0.021), open forests, logging and new plantations (p = 0.043) and watercourses (p = 0.012) influenced the geographical distribution of canine Leishmania infection. Seropositive dogs had a greater average area of occupied land (i.e. open forests, logging and new plantations) than the seronegative ones (3.1439 km(2) versus 2.5650 km(2), respectively; p = 0.043).
C1 [Pires, Humberto; Martins, Manuel; Matos, Ana Cristina; Roque, Natalia] Sch Agr, Polytech Inst Castelo Branco, P-6000084 Castelo Branco, Portugal.
   [Martins, Manuel; Matos, Ana Cristina; Roque, Natalia] Polytech Inst Castelo Branco, QRural Qual Life Rural World Res Unit, Castelo Branco, Portugal.
   [Matos, Ana Cristina] Polytech Inst Castelo Branco, CERNAS Res Ctr Nat Resources Environm & Soc, Castelo Branco, Portugal.
   [Cardoso, Luis] Univ Tras Os Montes & Alto Douro UTAD, CECAV Anim & Vet Res Ctr, Dept Vet Sci, Vila Real, Portugal.
   [Monteiro, Fernando] Municipal Macao, Macao, Portugal.
   [Nunes, Telmo] Univ Lisbon, Fac Vet Med, CIISA Ctr Interdisciplinary Res Anim Hlth, Lisbon, Portugal.
   [Gottstein, Bruno] Univ Bern, Vetsuisse Fac, Inst Parasitol, Dept Infect Dis & Pathobiol, Bern, Switzerland.
   [Cortes, Helder] Univ Evora, Inst Mediterranean Agr & Environm Sci ICAAM, Nucleo Mitra, Evora, Portugal.
RP Matos, AC (reprint author), Sch Agr, Polytech Inst Castelo Branco, P-6000084 Castelo Branco, Portugal.
EM acmatos@ipcb.pt
RI ; Matos, Ana/K-6664-2013; Cardoso, Luis/J-8310-2013
OI Cortes, Helder/0000-0003-4644-2165; Nunes, Telmo/0000-0003-4388-5366;
   Matos, Ana/0000-0001-9709-862X; Cardoso, Luis/0000-0002-6145-7560
CR Antoniou M, 2013, EUROSURVEILLANCE, V18, P54, DOI 10.2807/1560-7917.ES2013.18.30.20540
   Aparicio C, 2004, REV SAUDE PUBL, V38, P511, DOI 10.1590/S0034-89102004000400005
   Brancal H.A.C., 2009, P 6 C PORT BOARD VET
   Caetano M., 2007, PORTUGAL CORINE LAND
   Campino LM, 2002, WORLD CL PARASITES, V4, P45
   Direcao-Geral do Territorio, 2017, CAT SERV DAD GEOGR
   Direcao-Geral do Territorio D, 2016, ESP TECN CART US OC
   Dujardin JC, 2008, EMERG INFECT DIS, V14, P1013, DOI 10.3201/eid1407.071589
   Elnaiem DEA, 2003, AM J TROP MED HYG, V68, P10, DOI 10.4269/ajtmh.2003.68.1.0680010
   Franco AO, 2011, PARASITOLOGY, V138, P1878, DOI 10.1017/S003118201100148X
   Golpayegani AA, 2018, J ARTHROPOD-BORNE DI, V12, P41
   Mokhtari M, 2016, ACTA TROP, V163, P90, DOI 10.1016/j.actatropica.2016.08.002
   Mollalo A., 2014, Asian Pacific Journal of Tropical Disease, V4, P176, DOI 10.1016/S2222-1808(14)60500-4
   Pereira S, 2017, ACTA TROP, V174, P45, DOI 10.1016/j.actatropica.2017.06.020
   Ramezankhani R, 2017, SPAT SPATIO-TEMPORAL, V21, P57, DOI 10.1016/j.sste.2017.03.003
   Ready PD, 2010, EUROSURVEILLANCE, V15, P29
   Rempel RS, 2012, PATCH ANAL PATCH GRI
   Saraiva L, 2008, ESCUDOS FAUNA FLEBOT
   Shirzadi MR, 2015, J ARTHROPOD-BORNE DI, V9, P148
   Signorini M, 2014, GEOSPATIAL HEALTH, V9, P193, DOI 10.4081/gh.2014.16
   Silva A.C., 2010, THESIS
   World Health Organization, 2019, LEISHMANIASIS
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108930
DI 10.1016/j.vetpar.2019.108930
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200012
PM 31586700
DA 2020-05-12
ER

PT J
AU Ribeiro, VM
   Miranda, JB
   Marcelino, AP
   de Andrade, HM
   Reis, IA
   Cardoso, MS
   Gontijo, CMF
   Paz, GF
AF Ribeiro, Vitor Marcio
   Miranda, Julia Bahia
   Marcelino, Andreza Pain
   de Andrade, Helida Monteiro
   Reis, Ilka Afonso
   Cardoso, Mariana Santos
   Ferreira Gontijo, Celia Maria
   Paz, Gustavo Fontes
TI Performance of different serological tests in the diagnosis of natural
   infection by Leishmania infantum in dogs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Canine leishmaniasis; Serological diagnosis; Rapid tests; Enzyme-linked
   immunosorbent assay; Indirect immunofluorescence assay
ID CANINE VISCERAL LEISHMANIASIS; CVL RAPID TEST; CHROMATOGRAPHIC
   IMMUNOASSAY; SERODIAGNOSIS; VALIDATION; ASSAY; SPP.
AB Visceral leishmaniasis (VL) is a zoonosis caused by the parasite Leishmania infant um and the dog is its main reservoir in rural and urban areas. The diagnosis of infection is mainly based on the presence of anti-Leishmania IgG antibodies in the serum of infected dogs. In this study, the sensitivity and specificity of qualitative rapid tests (RTs) dual path platform (DPP) Bio-Manguinhos, rapid enzyme-linked immunosorbent assay (ELISA) IDEXX, Kalazar Detect and ALERE, as well as quantitative ELISA Bio-Manguinhos and in-house indirect immunofluorescence assay (IFA) tests were analyzed in sera from infected and uninfected dogs. Serial dilutions of the in-house IFA were compared with RTs and ELISA Bio-Manguinhos. The results showed that none of the tests reached 100% sensitivity and specificity. There was no statistical difference between the analyzed RTs. The most sensitive test was the DPP Bio-Manguinhos (97.9%), while the rapid ELISA IDEXX showed higher specificity (100%). In the treatment setting of infected and/or diseased animals, quantitative tests for monitoring the evolution of antibody titers are required, which indicates the maintenance of in-house IFA in animal handling. Furthermore, we demonstrate that the RTs present higher sensitivity in serum samples with superior antibody titers obtained in the in-house IFA. However, the RTs exhibited false negatives in samples with low titers of antibodies. Among the RTs, only the DPP Bio-Manguinhos presented better performance in this situation. Therefore, the use of RTs for the diagnosis of VL in dogs with low titers of antibodies, such as asymptomatic, should be carefully evaluated.
C1 [Ribeiro, Vitor Marcio] Santo Agostinho Hosp Vet, BR-30180003 Belo Horizonte, MG, Brazil.
   [Ribeiro, Vitor Marcio] Pontificia Univ Catolica Minas Gerais, Escola Vet, BR-32604115 Betim, Brazil.
   [Ribeiro, Vitor Marcio; Miranda, Julia Bahia; Ferreira Gontijo, Celia Maria; Paz, Gustavo Fontes] Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Estudos Leishmanioses, BR-30190002 Belo Horizonte, MG, Brazil.
   [Marcelino, Andreza Pain] Fundacao Ezequiel Dias, Div Epidemiol & Controle Doencas, Serv Doencas Parasitarias, BR-30510010 Belo Horizonte, MG, Brazil.
   [de Andrade, Helida Monteiro; Cardoso, Mariana Santos] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Parasitol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Reis, Ilka Afonso] Univ Fed Minas Gerais, Inst Ciencias Exatas, Dept Estat, BR-31270901 Belo Horizonte, MG, Brazil.
RP Ribeiro, VM (reprint author), Pontificia Univ Catolica Minas Gerais, Escola Vet, BR-32604115 Betim, Brazil.; Ribeiro, VM; Paz, GF (reprint author), Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Estudos Leishmanioses, BR-30190002 Belo Horizonte, MG, Brazil.
EM ribeirovm@yahoo.com.br; gustavo.paz@fiocruz.br
RI Reis, Ilka Afonso/AAG-8007-2019
OI Reis, Ilka Afonso/0000-0001-7199-8590; ribeiro,
   vitor/0000-0002-2046-1192
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [401975/2012-6]; Programa de Apoio a Pesquisa (PAPES VI) da
   Fundacao Oswaldo Cruz (FIOCRUZ) [407529/2012-8]
FX We acknowledge Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG), Programa de Excelencia em PesquisaPROEP, Centro de Pesquisas
   Rene Rachou (CPqRR), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) grant number 401975/2012-6 and Programa de Apoio a
   Pesquisa (PAPES VI) da Fundacao Oswaldo Cruz (FIOCRUZ) grant
   number407529/2012-8. CMF Gontijo is research fellow of CNPq.
CR Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X
   Alves Waneska Alexandre, 2004, Cad. Saúde Pública, V20, P259, DOI 10.1590/S0102-311X2004000100043
   Athanasiou LV, 2014, J VET DIAGN INVEST, V26, P286, DOI 10.1177/1040638714523614
   CamargO M. E., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P117
   Coura-Vital W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091009
   Dantas-Torres F, 2018, VET J, V234, P102, DOI 10.1016/j.tvjl.2018.02.007
   de Assis J, 2010, REV BRAS PARASITOL V, V19, P17, DOI 10.1590/S1984-29612010000100005
   de Mendonca IL, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759039, 10.1590/s1678-9946201759039]
   de Souza JA, 2016, VET PARASITOL, V225, P114, DOI 10.1016/j.vetpar.2016.06.011
   Ferroglio E, 2007, VET PARASITOL, V144, P162, DOI 10.1016/j.vetpar.2006.09.017
   Figueiredo F.B., 2010, REV INST MED TROP SP, V52, P4
   Fiocruz, 2008, EIE LEISHM VISC CAN
   Garcia L, 2004, J CLIN MICROBIOL, V42, P2294, DOI 10.1128/JCM.42.5.2294-2297.2004
   Gomes YM, 2008, VET J, V175, P45, DOI 10.1016/j.tvjl.2006.10.019
   Grimaldi G, 2012, T ROY SOC TROP MED H, V106, P54, DOI 10.1016/j.trstmh.2011.10.001
   Krawczak FD, 2015, REV SOC BRAS MED TRO, V48, P64, DOI 10.1590/0037-8682-0291-2014
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Laurenti MD, 2014, VET PARASITOL, V205, P444, DOI 10.1016/j.vetpar.2014.09.002
   Lemos E.M., 2003, REV SOC BRAS MED S2, V36
   Lemos EM, 2008, ACTA TROP, V107, P205, DOI 10.1016/j.actatropica.2008.04.023
   Lira RA, 2006, VET PARASITOL, V137, P11, DOI 10.1016/j.vetpar.2005.12.020
   Madeira MD, 2006, VET PARASITOL, V138, P366, DOI 10.1016/j.vetpar.2006.01.059
   Maia C, 2008, VET PARASITOL, V158, P274, DOI 10.1016/j.vetpar.2008.07.028
   Marcelino A.P, 2015, INSTRUCOES REALIZACA, P15
   Marcondes M, 2011, VET PARASITOL, V175, P15, DOI 10.1016/j.vetpar.2010.09.036
   Ministerio da Saude B., 2014, MAN VIG CONTR LEISHM, P120
   Oliveira E, 2016, VET PARASITOL, V221, P9, DOI 10.1016/j.vetpar.2016.02.006
   Paz GF, 2018, ACTA TROP, V182, P198, DOI 10.1016/j.actatropica.2018.03.018
   Peixoto HM, 2015, TROP MED INT HEALTH, V20, P334, DOI 10.1111/tmi.12429
   Quinnell RJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001992
   Ribeiro V.M, 2016, ANN CLIN CYTOL PATHO, V2
   Ribeiro V.M., 2009, 4 WORLD C LEISHM 200
   Schubach EYP, 2014, T ROY SOC TROP MED H, V108, P568, DOI 10.1093/trstmh/tru109
   Solano-Gallego L, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-86
   WHO, 2010, WHO TECH REP SER, V949, P1
NR 35
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108920
DI 10.1016/j.vetpar.2019.08.014
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200004
PM 31493694
DA 2020-05-12
ER

PT J
AU Rizk, MA
   El-Sayed, SA
   El-Khodery, S
   Yokoyama, N
   Igarashi, I
AF Rizk, Mohamed Abdo
   El-Sayed, Shimaa Abd El-Salam
   El-Khodery, Sabry
   Yokoyama, Naoaki
   Igarashi, Ikuo
TI Discovering the in vitro potent inhibitors against Babesia and Theileria
   parasites by repurposing the Malaria Box: A review
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Babesia; Theileria; Malaria Box; Drug discovery; In vitro
ID DRUG; APICOPLAST; GROWTH; EQUI; PIROPLASMS; DIVERGENS; IDENTIFICATION;
   VALIDATION; VETERINARY; INFECTION
AB There is an innovative approach to discovering and developing novel potent and safe anti-Babesia and anti-Theileria agents for the control of animal piroplasmosis. Large-scale screening of 400 compounds from a Malaria Box (a treasure trove of 400 diverse compounds with antimalarial activity has been established by Medicines for Malaria Venture) against the in vitro growth of bovine Babesia and equine Babesia and Theileria parasites was performed, and the data were published in a brief with complete dataset from 236 screens of the Malaria Box compounds. Therefore, in this review, we explored and discussed in detail the in vitro inhibitory effects of 400 antimalarial compounds (200 drug-like and 200 probe-like) from the Malaria Box against Babesia (B.) bovis, B. bigemina, B. caballi, and Theileria (T.) equi. Seventeen hits were the most interesting with regard to bovine Babesia parasites, with mean selectivity indices (SIs) greater than 300 and half maximal inhibitory concentration (IC(50)s) ranging from 50 to 410 nM. The most interesting compounds with regard to equine Babesia and Theileria parasites were MMV020490 and MMV020275, with mean SIs > 258.68 and > 251.55, respectively, and IC(50)s ranging from 76 to 480 nM. Ten novel anti-B. bovis, anti-B. bigemina, anti-T. equi, and anti-B. caballi hits, MMV666093, MMV396794, MMV006706, MMV665941, MMV085203, MMV396693, MMV006787, MMV073843, MMV007092, and MMV665875, with nanomole levels of IC50 were identified. The most interesting hits were MMV396693, MMV073843, MMV666093, and MMV665875, with mean SIs greater than 307.8 and IC(50)s ranging from 43 to 630 nM for both bovine Babesia and equine Babesia and Theileria parasites. Screening the Malaria Box against the in vitro growth of Babesia and Theileria parasites helped with the discovery of new drugs than those traditionally used, diminazene aceturate and imidocarb dipropionate, and indicated the potential of the Malaria Box in finding new, potent antibabesial drugs.
C1 [Rizk, Mohamed Abdo; El-Sayed, Shimaa Abd El-Salam; Yokoyama, Naoaki; Igarashi, Ikuo] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
   [Rizk, Mohamed Abdo; El-Khodery, Sabry] Mansoura Univ, Dept Internal Med & Infect Dis, Fac Vet Med, Mansoura 35516, Egypt.
   [El-Sayed, Shimaa Abd El-Salam] Mansoura Univ, Dept Biochem & Chem Nutr, Fac Vet Med, Mansoura 35516, Egypt.
RP Igarashi, I (reprint author), Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
EM igarcpmi@obihiro.ac.jp
RI Rizk, Mohamed Abdo/J-7232-2019; El-khodery, Sabry A/S-8175-2018
OI Rizk, Mohamed Abdo/0000-0002-5250-6172; El-khodery, Sabry
   A/0000-0002-0545-5827
FU Medicines for Malaria Venture MMV Challenge Grant; Japan Society for the
   Promotion of Science (JSPS)Ministry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   Science [P18091]
FX This study was supported financially by the Medicines for Malaria
   Venture MMV Challenge Grant. Mohamed Abdo Rizk is supported by a
   research grant fellowship for young scientists from the Japan Society
   for the Promotion of Science (JSPS) (ID No. P18091).
CR Abd El-Salam El-Sayed S, 2017, PARASITOL INT, V66, P721, DOI 10.1016/j.parint.2017.07.004
   Abdulla S, 2008, LANCET, V372, P1819, DOI 10.1016/S0140-6736(08)61492-0
   AbouLaila M, 2014, VET PARASITOL, V204, P104, DOI 10.1016/j.vetpar.2014.05.023
   AbouLaila M, 2012, ANTIMICROB AGENTS CH, V56, P3196, DOI 10.1128/AAC.05488-11
   Allsopp MTEP, 2007, VET PARASITOL, V148, P130, DOI 10.1016/j.vetpar.2007.05.017
   Avarzed A, 1997, J VET MED SCI, V59, P479, DOI 10.1292/jvms.59.479
   Aykul S, 2016, ANAL BIOCHEM, V508, P97, DOI 10.1016/j.ab.2016.06.025
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Barbrook AC, 2006, TRENDS PLANT SCI, V11, P101, DOI 10.1016/j.tplants.2005.12.004
   Bennett TN, 2004, ANTIMICROB AGENTS CH, V48, P1807, DOI 10.1128/AAC.48.5.1807-1810.2004
   Bessoff K, 2014, ANTIMICROB AGENTS CH, V58, P2731, DOI 10.1128/AAC.02641-13
   Bork S, 2004, ANTIMICROB AGENTS CH, V48, P236, DOI 10.1128/AAC.48.1.236-241.2004
   Boyom FF, 2014, ANTIMICROB AGENTS CH, V58, P5848, DOI 10.1128/AAC.02541-14
   Criado A, 2006, VET PARASITOL, V142, P238, DOI 10.1016/j.vetpar.2006.07.004
   Criado-Fornelio A, 2003, VET PARASITOL, V113, P189, DOI 10.1016/S0304-4017(03)00078-5
   Dalgliesh R. J., 1993, Immunology and molecular biology of parasitic infections., P352
   DOCAMPO R, 1990, DRUG METAB REV, V22, P161, DOI 10.3109/03602539009041083
   El-Sayed Shimaa Abd El-Salam, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P977, DOI 10.1016/j.apjtb.2015.09.001
   Flower DR, 1999, J MOL GRAPH MODEL, V17, P238
   Food Security and Public Health 2011. Institute for Internal Cooperation in Animal Biologics, 2011, BOV BAB
   Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107
   Gloor M, 2001, DERMATOLOGY, V203, P325, DOI 10.1159/000051782
   Gomes LI, 2012, EXP PARASITOL, V131, P175, DOI 10.1016/j.exppara.2012.03.021
   Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099
   Guswanto A, 2014, ANTIMICROB AGENTS CH, V58, P4713, DOI 10.1128/AAC.00022-14
   He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330
   HINES SA, 1992, MOL BIOCHEM PARASIT, V55, P85, DOI 10.1016/0166-6851(92)90129-8
   Hotzel I, 1997, MOL BIOCHEM PARASIT, V90, P479, DOI 10.1016/S0166-6851(97)00182-5
   Ingram-Sieber K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002610
   Jang JW, 2014, SCI WORLD J, V2014, P536723
   Johnson JD, 2007, ANTIMICROB AGENTS CH, V51, P1926, DOI 10.1128/AAC.01607-06
   Kondo Shigemi, 2006, Kansenshogaku Zasshi, V80, P651
   Kouam MK, 2010, INFECT GENET EVOL, V10, P1013, DOI 10.1016/j.meegid.2010.06.014
   Kuttler KL., 1981, BABESIOSIS, P25
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Maley AM, 2013, EXP DERMATOL, V22, P775, DOI 10.1111/exd.12257
   Meister S, 2011, SCIENCE, V334, P1372, DOI 10.1126/science.1211936
   Moretti A, 2010, VET J, V184, P346, DOI 10.1016/j.tvjl.2009.03.021
   Mosqueda J, 2012, CURR MED CHEM, V19, P1504, DOI 10.2174/092986712799828355
   Omar MA, 2016, EXP PARASITOL, V161, P62, DOI 10.1016/j.exppara.2015.12.016
   Pritchett J. C, 2014, HUMAN HERPESVIRUSES, P311, DOI 10.1016/b978-0-444-62703-2.00019-7
   Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205
   Rishton G.M, 1997, REACTIVE COMPOUNDS I, V2
   Rizk MA, 2018, INFECT DRUG RESIST, V11, P1605, DOI 10.2147/IDR.S159519
   Rizk MA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13052-5
   Rizk MA, 2017, EXP PARASITOL, V179, P43, DOI 10.1016/j.exppara.2017.06.003
   Rizk MA, 2016, VET PARASITOL, V227, P93, DOI 10.1016/j.vetpar.2016.07.032
   Rizk MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125276
   Rodriquez RI, 1996, VET PARASITOL, V62, P35, DOI 10.1016/0304-4017(95)00850-0
   Salama AA, 2014, PARASITOL RES, V113, P275, DOI 10.1007/s00436-013-3654-2
   Salama AA, 2013, VET PARASITOL, V191, P1, DOI 10.1016/j.vetpar.2012.08.022
   Scoles GA, 2015, ANNU REV ENTOMOL, V60, P561, DOI 10.1146/annurev-ento-010814-021110
   Spangenberg T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062906
   Suarez CE, 2011, VET PARASITOL, V180, P109, DOI 10.1016/j.vetpar.2011.05.032
   Sullivan M, 2000, MOL BIOCHEM PARASIT, V109, P17, DOI 10.1016/S0166-6851(00)00226-7
   Tayebwa DS, 2018, TICKS TICK-BORNE DIS, V9, P1192, DOI 10.1016/j.ttbdis.2018.04.019
   Tuvshintulga B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14304-0
   Uilenberg G, 2006, VET PARASITOL, V138, P3, DOI 10.1016/j.vetpar.2006.01.035
   Vaishnava S, 2006, MOL MICROBIOL, V61, P1380, DOI 10.1111/j.1365-2958.2006.05343.x
   van Dooren GG, 2005, MOL MICROBIOL, V57, P405, DOI 10.1111/j.1365-2958.2005.04699.x
   Van Voorhis WC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005763
   VANVIANEN PH, 1990, AM J TROP MED HYG, V43, P602, DOI 10.4269/ajtmh.1990.43.602
   Vial HJ, 2006, VET PARASITOL, V138, P147, DOI 10.1016/j.vetpar.2006.01.048
   Waldman SA, 2002, ANN ALLERG ASTHMA IM, V89, P7, DOI 10.1016/S1081-1206(10)61904-7
   Wise LN, 2013, J VET INTERN MED, V27, P1334, DOI 10.1111/jvim.12168
   Zanet S, 2017, VET PARASITOL, V236, P38, DOI 10.1016/j.vetpar.2017.01.003
   Zintl A, 2003, CLIN MICROBIOL REV, V16, P622, DOI 10.1128/CMR.16.4.622-636.2003
NR 67
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108895
DI 10.1016/j.vetpar.2019.07.003
PG 10
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200002
PM 31494399
DA 2020-05-12
ER

PT J
AU Salusbury, I
AF Salusbury, Ian
TI Publisher's Note
SO VETERINARY PARASITOLOGY
LA English
DT Editorial Material
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
DI 10.1016/S0304-4017(19)30224-9
PG 1
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200001
OA Bronze
DA 2020-05-12
ER

PT J
AU Shi, HF
   Duan, LS
   Liu, F
   Hu, Y
   Shi, ZR
   Chen, XY
   Yang, H
   Yan, BL
   Yao, LG
AF Shi, Hongfei
   Duan, Lisha
   Liu, Fei
   Hu, Yun
   Shi, Zhaorong
   Chen, Xiaoying
   Yang, Huan
   Yan, Baolong
   Yao, Lunguang
TI Rhipicephalus (Boophilus) microplus ticks as reservoir and vector of
   'Candidates Mycoplasma haemobos' in China
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE 'Candidates Mycoplasma haemobos'; Transmission; Rhipicephalus
   (Boophilus) microplus; China
ID HEMOPLASMA INFECTION; MOLECULAR-DETECTION; CATTLE; PREVALENCE; WENYONII;
   DNA
AB 'Candidatus Mycoplasma haemobos' is an emerging pathogen in the genus Mycoplasma. The Rhipicephalus (Boophilus) microplus tick has been suspected to be the vector of 'C. M. haemobos'. To determine the role of R. (B.) microplus in transmission of 'C. M. haemobos', we tested the competence of R. (B.) microplus larvae to acquire 'C. M. haemobos' from positive female ticks and to serve as a 'C. M. haemobos' vector in mice. Using PCR and sequencing, we also analyzed the epidemic strains of 'C. M. haemobos' among R. (B.) microplus ticks collected from goats and sheep in southern Henan Province, central China. Our results identified three epidemic strains of 'C. M. haemobos', and the positive female ticks naturally infected could pass 'C. M. haemobos' at egg and larval stages. Furthermore, 'C. M. haemobos' infected larvae could transmit the pathogens to mice during feeding, and the negative larvae could acquire 'C. M. haemobos' from infected mice. Our study shows that R. (B.) microplus ticks could serve as a vector and reservoir of 'C. M. haemobos'.
C1 [Shi, Hongfei; Duan, Lisha; Liu, Fei; Hu, Yun; Shi, Zhaorong; Chen, Xiaoying; Yang, Huan; Yao, Lunguang] Nanyang Normal Univ, China UK NYNU RRes Joint Lab Insect Biol, Henan Prov Engn Lab Insects Bioreactor, Nanyang, Peoples R China.
   [Yan, Baolong] Wenzhou Med Univ, Sch Basic Med Sci, Dept Parasitol, Wenzhou, Peoples R China.
RP Shi, HF; Yao, LG (reprint author), Nanyang Normal Univ, China UK NYNU RRes Joint Lab Insect Biol, Henan Prov Engn Lab Insects Bioreactor, Nanyang, Peoples R China.; Yan, BL (reprint author), Wenzhou Med Univ, Sch Basic Med Sci, Dept Parasitol, Wenzhou, Peoples R China.
EM 77956479@qq.com; 1982ybllog@163.com; lunguangyao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31371381, 31902263]; Henan Provincial Scientific
   and technological research project [182102110084, 162102110046]; Nanyang
   Normal University (CN) [15081]
FX The National Natural Science Foundation of China (Grant no. 31371381 and
   31902263), the Henan Provincial Scientific and technological research
   project (Grant nos. 182102110084 and 162102110046) and Nanyang Normal
   University (CN) (Grant no. 15081) supported this study.
CR Ade J, 2018, VET MICROBIOL, V220, P1, DOI 10.1016/j.vetmic.2018.04.028
   Ayling RD, 2012, VET REC, V170, DOI 10.1136/vr.100636
   Chen Z, 2010, EXP APPL ACAROL, V51, P393, DOI 10.1007/s10493-010-9335-2
   DAVEY RB, 1981, ANN ENTOMOL SOC AM, V74, P331, DOI 10.1093/aesa/74.3.331
   Fujihara Y, 2011, J VET MED SCI, V73, P1653, DOI 10.1292/jvms.11-0269
   Girotto A, 2012, REV BRAS PARASITOL V, V21, P342, DOI 10.1590/S1984-29612012000300034
   Hartelt K, 2008, PARASITOL RES, V103, pS109, DOI 10.1007/s00436-008-1059-4
   Hellenbrand W, 2005, TIERAERZTL PRAX G N, V33, P5
   Hornok S, 2011, VET MICROBIOL, V152, P411, DOI 10.1016/j.vetmic.2011.04.031
   Hornok S, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1403-6
   Jiang M., 2014, STUDY INFECT TRANSMI
   Johnson KA, 2016, AM J VET RES, V77, P881
   Lappin MR, 2006, J FELINE MED SURG, V8, P85, DOI 10.1016/j.jfms.2005.08.003
   Ma C., 2006, EPIDEMIOLOGY CONTROL
   MANGOLD AJ, 1993, VET PARASITOL, V51, P143, DOI 10.1016/0304-4017(93)90205-2
   Martinez-Ocampo F, 2016, GENOME ANNOUNC, V4
   Meli ML, 2010, J CLIN MICROBIOL, V48, P3563, DOI 10.1128/JCM.02224-09
   Neimark H, 1997, FEMS MICROBIOL LETT, V156, P287, DOI 10.1111/j.1574-6968.1997.tb12742.x
   Oliveira MCS, 2005, VET PARASITOL, V130, P61, DOI 10.1016/j.vetpar.2005.03.007
   REHACEK J, 1968, B WORLD HEALTH ORGAN, V39, P974
   Santos NJR, 2018, COMP IMMUNOL MICROB, V56, P27, DOI 10.1016/j.cimid.2017.12.003
   Sasaoka F, 2013, J VET MED SCI, V75, P361, DOI 10.1292/jvms.12-0349
   Shang Z. S., 2014, J HENAN U SCI TECHNO, V35, P73
   Shi HF, 2019, TRANSBOUND EMERG DIS, V66, P22, DOI 10.1111/tbed.13021
   Su QL, 2010, TROP ANIM HEALTH PRO, V42, P1805, DOI 10.1007/s11250-010-9640-0
   Tagawa M, 2008, VET MICROBIOL, V132, P177, DOI 10.1016/j.vetmic.2008.05.006
   Taroura S, 2005, J VET MED SCI, V67, P1277, DOI 10.1292/jvms.67.1277
   Wang P., 2011, ANIM HUSBANDRY VET M, V43, P22
   Wu S., 2013, J HENAN I SCI TECHNO, V41, P54
   Yu PF, 2016, ACTA TROP, V158, P181, DOI 10.1016/j.actatropica.2016.02.027
   Zhao Qi, 2015, Zhongguo Meijieshengwuxue Ji Kongzhi Zazhi, V26, P75
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108929
DI 10.1016/j.vetpar.2019.108929
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200010
PM 31568995
DA 2020-05-12
ER

PT J
AU Tzelos, T
   Morgan, ER
   Easton, S
   Hodgkinson, JE
   Matthews, JB
AF Tzelos, Thomas
   Morgan, Eric R.
   Easton, Stephanie
   Hodgkinson, Jane E.
   Matthews, Jacqueline B.
TI A survey of the level of horse owner uptake of evidence-based
   anthelmintic treatment protocols for equine helminth control in the UK
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Helminths; Equine; Questionnaire; Anthelmintics; Anthelmintic
   resistance; Faecal egg count tests
ID PARASITE CONTROL PRACTICES; EGG REAPPEARANCE PERIOD; SMALL STRONGYLES;
   REDUCED ACTIVITY; FIELD-TESTS; IVERMECTIN; MOXIDECTIN; RESISTANCE;
   QUESTIONNAIRE; FARMS
AB Interval treatment control programmes used widely in equine helminth control have favoured the development of anthelmintic resistance worldwide. Best practice guidelines have been designed to address resistance and include the requirement for improved pasture hygiene to break helminth transmission cycles, along with anthelmintic application informed by the results of diagnostic tests to reduce selection pressure for resistance. Using an online questionnaire, this study examined uptake of measures recommended in these guidelines by UK horse owners. The survey comprised 58 questions spanning grazing management, anthelmintic use and use of faecal egg count (FEC) testing to inform treatment decisions. Analysis was carried out using a combination of Chi-square and Mann-Whitney tests. In total, 705 owners responded and, following specific exclusion criteria, the responses of 652 individuals were analysed. The majority of the respondents owned < 20 horses on private premises or livery yards in England. The main outputs of the survey were as follows. Overall, 60.9% of respondents used FEC tests to inform the requirement to administer anthelmintics, with macrocyclic lactones the most frequently-used anthelmintics. Of the respondents, 38% obtained advice on anthelmintic choice from their veterinarians; however, many respondents (43.8%) purchased anthelmintics via the internet. Encouragingly, 74.4% of respondents stated that they practiced good pasture hygiene by removing dung from pasture. Generally, there were differences between the responses of participants who based anthelmintic treatments on FEC testing (targeted treatments; TT) and those who practiced calendar-based anthelmintic treatments (interval treatments; IT). Briefly, the "key" findings from the Chi-square analysis included higher levels of satisfaction with the level of knowledge about equine parasites/parasitic diseases and higher levels of concern about anthelmintic resistance from TT-respondents compared to IT-participants. Confusion on the interpretation of quarantine recommendations was identified in this study group and there was poor uptake of testing for anthelmintic effectiveness. Overall, compared to previous reports, this study indicated improved engagement of UK horse owners with some helminth control practices recommended to reduce the spread of anthelmintic resistance. However, a proportion of respondents did not utilise these practices and there were still important gaps in the use of appropriate quarantine and efficacy testing. These identified gaps must be taken into consideration in knowledge dissemination activities in the future.
C1 [Tzelos, Thomas; Easton, Stephanie; Matthews, Jacqueline B.] Moredun Res Inst, Pentlands Sci Pk, Edinburgh EH26 0PZ, Midlothian, Scotland.
   [Tzelos, Thomas] Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.
   [Morgan, Eric R.] Queens Univ, Sch Biol Sci, Belfast BT9 7BL, Antrim, North Ireland.
   [Hodgkinson, Jane E.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 7ZJ, Merseyside, England.
RP Tzelos, T (reprint author), Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland.
EM thomas.tzelos@roslin.ed.ac.uk
OI Morgan, Eric/0000-0002-5999-7728
FU Horse Trust [G4014]
FX This work was supported by funding from The Horse Trust (Project Grant
   Reference: G4014). The authors would like to thank the respondents for
   completing the survey and the equine veterinary practices for promoting
   the survey.
CR Allison K, 2011, VET REC, V168, P483, DOI 10.1136/vr.d731
   BETA, 2015, NAT EQ SURV OV REP
   Bolwell CF, 2015, VET PARASITOL, V209, P62, DOI 10.1016/j.vetpar.2015.02.011
   Canever RJ, 2013, VET PARASITOL, V194, P35, DOI 10.1016/j.vetpar.2012.12.020
   Corbett CJ, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-48
   DRUDGE JH, 1966, J AM VET MED ASSOC, V148, P378
   Easton S, 2016, PREV VET MED, V135, P17, DOI 10.1016/j.prevetmed.2016.10.017
   Fritzen B, 2010, EQUINE VET J, V42, P79, DOI 10.2746/042516409X471485
   Geurden T, 2014, VET PARASITOL, V204, P291, DOI 10.1016/j.vetpar.2014.04.013
   HERD RP, 1986, EQUINE VET J, V18, P447, DOI 10.1111/j.2042-3306.1986.tb03684.x
   HERD RP, 1993, VET PARASITOL, V48, P327, DOI 10.1016/0304-4017(93)90166-K
   Hinney B, 2011, PARASITOL RES, V109, P1625, DOI 10.1007/s00436-011-2434-0
   Hohwu L, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2595
   Kaplan RM, 2010, EQUINE VET EDUC, V22, P306, DOI 10.1111/j.2042-3292.2010.00084.x
   Kaplan RM, 2002, VET RES, V33, P491, DOI 10.1051/vetres:2002035
   Lester HE, 2014, EQUINE VET J, V46, P139, DOI 10.1111/evj.12199
   Lind EO, 2007, ACTA VET SCAND, V49, DOI 10.1186/1751-0147-49-25
   Lyons ET, 2013, PARASITOL RES, V112, P889, DOI 10.1007/s00436-012-3098-0
   Lyons ET, 2009, PARASITOL RES, V104, P569, DOI 10.1007/s00436-008-1231-x
   Lyons ET, 2011, PARASITOL RES, V108, P355, DOI 10.1007/s00436-010-2068-7
   Lyons ET, 2010, PARASITOL RES, V107, P1495, DOI 10.1007/s00436-010-2025-5
   Matthews JB, 2008, EQUINE VET EDUC, V20, P552, DOI 10.2746/095777308X363912
   Matthews JB, 2014, INT J PARASITOL-DRUG, V4, P310, DOI 10.1016/j.ijpddr.2014.10.003
   McArthur CL, 2015, VET PARASITOL, V212, P292, DOI 10.1016/j.vetpar.2015.06.019
   Nielsen MK, 2014, VET PARASITOL, V204, P64, DOI 10.1016/j.vetpar.2013.10.016
   Nielsen MK, 2014, VET PARASITOL, V202, P95, DOI 10.1016/j.vetpar.2014.03.020
   O'Meara B, 2002, VET PARASITOL, V109, P101, DOI 10.1016/S0304-4017(02)00249-2
   Peregrine AS, 2014, VET PARASITOL, V201, P1, DOI 10.1016/j.vetpar.2014.01.004
   Proudman C, 2000, IN PRACTICE, V22, P90
   Raza A, 2019, PARASITOLOGY, V146, P425, DOI 10.1017/S0031182018001786
   REID SWJ, 1995, EQUINE VET J, V27, P127, DOI 10.1111/j.2042-3306.1995.tb03048.x
   Reinemeyer CR, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-S2-S8
   Relf VE, 2012, EQUINE VET J, V44, P466, DOI 10.1111/j.2042-3306.2011.00493.x
   Relf VE, 2014, INT J PARASITOL, V44, P507, DOI 10.1016/j.ijpara.2014.03.006
   Robert M, 2015, EQUINE VET J, V47, P694, DOI 10.1111/evj.12344
   Rosanowski SM, 2016, EQUINE VET J, V48, P387, DOI 10.1111/evj.12558
   Rossano MG, 2010, VET PARASITOL, V173, P349, DOI 10.1016/j.vetpar.2010.07.001
   Salle G, 2015, VET REC OPEN, V2
   Sangster NC, 2001, VET PARASITOL, V98, P89, DOI 10.1016/S0304-4017(01)00425-3
   SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989
   Stratford CH, 2014, EQUINE VET J, V46, P25, DOI 10.1111/evj.12101
   Traversa D, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-S2-S2
   Tzelos T, 2017, VET PARASITOL, V237, P70, DOI 10.1016/j.vetpar.2017.02.018
   Tzelos T, 2016, IN PRACTICE, V38, P489, DOI 10.1136/inp.i5287
   van Doorn DCK, 2014, VET PARASITOL, V206, P246, DOI 10.1016/j.vetpar.2014.10.004
   Vineer HR, 2017, PREV VET MED, V144, P66, DOI 10.1016/j.prevetmed.2017.05.002
   von Samson-Himmelstjerna G, 2007, VET PARASITOL, V144, P74, DOI 10.1016/j.vetpar.2006.09.036
   von Samson-Himmelstjerna G, 2012, VET PARASITOL, V185, P2, DOI 10.1016/j.vetpar.2011.10.010
NR 48
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD OCT
PY 2019
VL 274
AR UNSP 108926
DI 10.1016/j.vetpar.2019.108926
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JI1GF
UT WOS:000493213200009
PM 31563583
DA 2020-05-12
ER

PT J
AU Anothaisintawee, T
   Genuino, AJ
   Thavorncharoensap, M
   Youngkong, S
   Rattanavipapong, W
   Meeyai, A
   Chaikledkaew, U
AF Anothaisintawee, Thunyarat
   Genuino, Anne Julienne
   Thavorncharoensap, Montarat
   Youngkong, Sitaporn
   Rattanavipapong, Waranya
   Meeyai, Aronrag
   Chaikledkaew, Usa
TI Cost-effectiveness modelling studies of all preventive measures against
   rabies: A systematic review
SO VACCINE
LA English
DT Review
DE Rabies; Vaccine; Prevention and control; Cost-effectiveness model;
   Economic evaluation; Systematic review
ID POSTEXPOSURE PROPHYLAXIS; VACCINATION; THRESHOLDS; COVERAGE; NDJAMENA;
   DOGS
AB Rabies is one of the most feared infectious diseases worldwide, predominantly occurring in Asia and Africa where rabies is endemic in domestic dog populations. Whereas previous studies have demonstrated mass dog vaccination and post-exposure prophylaxis (PEP) as the most effective control strategies, successful rabies elimination has yet to be realized as these recognized effective interventions continue to face challenges of limited accessibility. In the light of new evidence towards improving programmatic feasibility and clinical practice in rabies control especially among endemic countries, a systematic review was undertaken to identify cost-effectiveness modelling studies of rabies preventive measures and to provide a critical review of published evidence through comparative evaluation and model quality assessment, and a synthesis of key findings based thereon. Our search through MEDLINE and SCOPUS identified a total of 17 studies which mostly focused on estimating the impact of increasing PEP and pre-exposure prophylaxis (PrEP) access, human rabies elimination scenarios using mass dog vaccinations only or complemented with PEP strategy. While no significant methodological inconsistency across studies was identified and the extent of reporting is generally high, we note several points for quality and internal validity improvement. Assessment of modelling approach showed that decision tree models had similar pathways. The results of the studies suggest that interventions would be cost-effective at the cost-effectiveness threshold of 1 to 3 times per capita Gross Domestic Product (GDP) as recommended by the Commission on Macroeconomics and Health's GDP based thresholds, compared with no intervention in rabies endemic countries. When compared across studies which reported incremental cost-effectiveness ratio (ICER) as cost per QALY gained or DALY averted in international dollars adjusted by purchasing power parity conversion rate, PEP vaccination yields less cost per DALY averted or QALY gained due to one year-horizon assessment compared to canine vaccination at 4- or 10-year-time horizon. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Anothaisintawee, Thunyarat] Ramathibodi Hosp, Fac Med, Dept Family Med, 270 Rama 6 Rd, Bangkok 10400, Thailand.
   [Anothaisintawee, Thunyarat; Rattanavipapong, Waranya] Minist Publ Hlth, HITAP, Dept Hlth, 6th Floor,6th Bldg,Tiwanon Rd, Muang 11000, Nonthaburi, Thailand.
   [Anothaisintawee, Thunyarat; Genuino, Anne Julienne; Thavorncharoensap, Montarat; Youngkong, Sitaporn; Meeyai, Aronrag; Chaikledkaew, Usa] Mahidol Univ, Hlth Technol Assessment Postgrad Program, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.
   [Thavorncharoensap, Montarat; Youngkong, Sitaporn; Chaikledkaew, Usa] Mahidol Univ, Fac Pharm, Dept Pharm, Social Adm Pharm Excellence Res SAPER Unit, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.
   [Meeyai, Aronrag] Mahidol Univ, Fac Publ Hlth, Dept Epidemiol, 420-1 Ratchawithi Rd, Bangkok 10400, Thailand.
RP Chaikledkaew, U (reprint author), Mahidol Univ, Fac Pharm, Dept Pharm, Social Adm Pharm Excellence Res SAPER Unit, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.
EM thunyarat.ano@mahidol.ac.th; montharat.tha@mahidol.ac.th;
   sitaporn.you@mahidol.edu; waranya.r@hitap.net;
   aronrag.coo@mahidol.ac.th; usa.chi@mahidol.ac.th
OI Meeyai, Aronrag/0000-0002-2359-1574
FU World Health Organization (WHO)World Health Organization; Health
   Intervention and Technology Assessment Program (HITAP), Department of
   Health, Ministry of Public Health, Nonthaburi, Thailand; Thailand
   Research Fund under the senior research scholar on Health Technology
   Assessment [RTA5980011]; Bureau of Health Policy and Strategy, Ministry
   of Public Health; Bill & Melinda Gates FoundationGates Foundation; UK's
   Department for International Development; Rockefeller Foundation
   [OPP124589]
FX This work was supported by grants from the World Health Organization
   (WHO) and Health Intervention and Technology Assessment Program (HITAP),
   Department of Health, Ministry of Public Health, Nonthaburi, Thailand.
   HITAP is funded by the Thailand Research Fund under the senior research
   scholar on Health Technology Assessment [grant numbers RTA5980011] and
   the Bureau of Health Policy and Strategy, Ministry of Public Health.
   HITAP's International Unit is part of the iDSI to provide technical
   assistance on health intervention and technology assessment to
   governments in low-and middle-income countries. The iDSI is funded by
   the Bill & Melinda Gates Foundation; the UK's Department for
   International Development and the Rockefeller Foundation [grant numbers
   OPP124589]. The findings, interpretations and conclusions expressed in
   this article do not necessarily reflect the views of the aforementioned
   funding agencies. We would like to thank Professor Ben Cooper for
   providing useful comments and suggestions on this paper.
CR Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Bilinski AM, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.1211
   Chaikledkaew U, 2017, REPORT EPIDEMIOLOGIC
   Coleman PG, 1996, VACCINE, V14, P185, DOI 10.1016/0264-410X(95)00197-9
   Costa GB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197330
   Drummond M, 2005, METHODS EC EVALUATIO
   Dumas FR, 2015, VACCINE, V33, P2367, DOI 10.1016/j.vaccine.2015.02.075
   Fitzpatrick MC, 2016, P NATL ACAD SCI USA, V113, P14574, DOI 10.1073/pnas.1604975113
   Fitzpatrick MC, 2014, ANN INTERN MED, V160, P91, DOI 10.7326/M13-0542
   FRERICHS RR, 1975, MANAGE SCI, V22, P411, DOI 10.1287/mnsc.22.4.411
   Frey J, 2013, TROP MED INT HEALTH, V18, P1555, DOI 10.1111/tmi.12202
   Hasler B, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003270
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hampson K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000982
   Hatam N, 2014, J RES HEALTH SCI, V14, P122
   Husereau D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1049
   Kasempimolporn S, 2008, DEV BIOLOGICALS, V131, P137
   Kayali U, 2003, B WORLD HEALTH ORGAN, V81, P739
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Knobel DL, 2005, B WHO, V83
   LeGuerrier P, 1996, VACCINE, V14, P167, DOI 10.1016/0264-410X(95)00110-M
   Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206
   Shim E, 2009, VACCINE, V27, P7167, DOI 10.1016/j.vaccine.2009.09.027
   Strady C, 2001, VACCINE, V19, P1416, DOI 10.1016/S0264-410X(00)00368-6
   Varghese L, 2017, HLTH EC MODEL RABIES
   Wera E., 2016, TRANSBOUND EMERG DIS
   World Health Organization, 2010, RAB VACC WHO POS PAP
   World Health Organization, 2001, MACROECONOMICS HLTH
   Zinsstag J, 2009, P NATL ACAD SCI USA, V106, P14996, DOI 10.1073/pnas.0904740106
NR 29
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A146
EP A153
DI 10.1016/j.vaccine.2018.11.071
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500023
PM 30554795
OA Other Gold
DA 2020-05-12
ER

PT J
AU Bharti, OK
   Thakur, B
   Rao, R
AF Bharti, Omesh Kumar
   Thakur, Baldev
   Rao, Ranjna
TI Wound-only injection of rabies immunoglobulin (RIG) saves lives and
   costs less than a dollar per patient by "pooling strategy"
SO VACCINE
LA English
DT Article
DE Rabies; Low cost; Rabies lmmunoglobulins; Post exposure prophylaxis
AB Since 2008, we in Himachal Pradesh have used a "pooling strategy" to help patients save money by pooling vials of antirabies vaccine at a centralized hospital and sharing them using the intradermal technique. In 2014, there was an acute shortage of rabies immunoglobulins (RIG) and two patients died after four injections of rabies vaccine were administered without RIG, which was not commercially available. After an extensive literature review and technical and ethical committee clearances, in June 2014 we started to infiltrate equine RIG (eRIG) into wound/s only without the recommended systemic intramuscular (IM) injection. WHO recommended this technique in 2018. During the four-year period June 2014 to June 2018, 7506 of 10,830 patients exposed to suspected rabid animals were injected with eRIG in and around the wounds in a single clinic at DDU Hospital Shimla without any adverse outcomes. The average volume of eRIG used per patient was 0.75 mL and cost US$ 0.75. Of the 80% of patients who were followed up, all were healthy at the end of a year, including 26 patients bitten by laboratory-confirmed rabid dogs. The reaction rate after PEP administration also declined significantly. Since February 2018, Himachal has started following the new WHO recommendations on PEP regimens of three intradermal antirabies vaccines instead of four, thereby saving hundreds of vaccine vials that became useful during shortages of rabies vaccine in India. To date, more than 700 vaccine vials have been saved in a single clinic at DDU hospital during the past 6 months alone. Not giving PEP to patients who have consumed raw milk from a suspected rabid cow has also saved 62 vials. Currently, 90 "pooling centers" have been established for sharing of vaccine and eRIG vials in Himachal State, generating huge savings that have enabled the government to provide PEP free of charge to all. The new WHO guidelines are a positive step towards a rabies-free world by 2030. (C) 2019 Published by Elsevier Ltd.
C1 [Bharti, Omesh Kumar] State Inst Hlth & Family Welf, Shimla 171009, Himachal Prades, India.
   [Thakur, Baldev] Govt Himachal Pradesh, Directorate Hlth, Kasumpti 171009, Shimla, India.
   [Rao, Ranjna] DDU Hosp, Anti Rabies Clin & Res Ctr, Shimla 171009, India.
RP Bharti, OK (reprint author), State Inst Hlth & Family Welf, Shimla 171009, Himachal Prades, India.
EM bhartiomesh@yahoo.com
CR Abela-Ridder B., 1012 WHO TRS
   Anderson DC, 2007, ASIAN BIOMED, V1, P103
   Bharti OK, 2017, HUM VACC IMMUNOTHER, V13, P762, DOI 10.1080/21645515.2016.1255834
   Bharti OK, 2016, HUM VACC IMMUNOTHER, V12, P837, DOI 10.1080/21645515.2015.1085142
   Bharti Omesh Kumar OK, 2012, WORLD J VACCINES, V2, P121
   Chomchay P, 2000, J TRAVEL MED, V7, P187
   DEAN DJ, 1963, B WORLD HEALTH ORGAN, V28, P477
   Florence Cliquet, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/NRDP.2017.9117091, DOI 10.1038/NRDP.2017.9117091]
   Hampson K, 2015, PLOS NEGL TROP DIS
   Hueffer Karsten, RABIES VIRUS MODIFIE
   Kumar Bharti Omesh, 2016, J TRAVEL MED, V23, DOI [10.1093/itm/taw028, DOI 10.1093/ITM/TAW028]
   Kumar Gohil Hemant, 2018, APCRI J, VXX
   Mani RS, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw007
   Ranasinghe Shamithri, THESIS
   Servat A, 2003, VACCINE, V22, P244, DOI 10.1016/S0264-410X(03)00559-0
   Wilde H., 2009, Journal of Infectious Diseases and Antimicrobial Agents, V26, P63
   Wilde H, 1996, CLIN INFECT DIS, V22, P228, DOI 10.1093/clinids/22.2.228
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A128
EP A131
DI 10.1016/j.vaccine.2019.07.087
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500020
PM 31395454
OA Other Gold
DA 2020-05-12
ER

PT J
AU Changalucha, J
   Steenson, R
   Grieve, E
   Cleaveland, S
   Lembo, T
   Lushasi, K
   Mchau, G
   Mtema, Z
   Sambo, M
   Nanai, A
   Govella, NJ
   Dilip, A
   Sikana, L
   Ventura, F
   Hampson, K
AF Changalucha, Joel
   Steenson, Rachel
   Grieve, Eleanor
   Cleaveland, Sarah
   Lembo, Tiziana
   Lushasi, Kennedy
   Mchau, Geofrey
   Mtema, Zacharia
   Sambo, Maganga
   Nanai, Alphoncina
   Govella, Nicodem J.
   Dilip, Angel
   Sikana, Lwitiko
   Ventura, Francesco
   Hampson, Katie
TI The need to improve access to rabies post-exposure vaccines: Lessons
   from Tanzania
SO VACCINE
LA English
DT Article
DE Post-exposure prophylaxis; Dog-mediated rabies; Rabies prevention;
   Canine rabies; lmmunoglobulin; Intradermal; Intramuscular; Vaccine
   regimen; Supply chain; Procurement
ID REAL-TIME; DOG BITES; PROPHYLAXIS; COST; VACCINATION; REGIMEN; BURDEN;
   ASSAY
AB Background: Rabies is preventable through prompt administration of post-exposure prophylaxis (PEP) to exposed persons, but PEP access is limited in many rabies-endemic countries. We investigated how access to PEP can be improved to better prevent human rabies.
   Methods: Using data from different settings in Tanzania, including contact tracing (2,367 probable rabies exposures identified) and large-scale mobile phone-based surveillance (24,999 patient records), we estimated the incidence of rabies exposures and bite-injuries, and examined health seeking and health outcomes in relation to PEP access. We used surveys and qualitative interviews with stakeholders within the health system to further characterise PEP supply and triangulate these findings.
   Results: Incidence of bite-injury patients was related to dog population sizes, with higher incidence in districts with lower human:dog ratios and urban centres. A substantial percentage (25%) of probable rabies exposures did not seek care due to costs and limited appreciation of risk. Upon seeking care a further 15% of probable rabies exposed persons did not obtain PEP due to shortages, cost barriers or misadvice. Of those that initiated PEP, 46% did not complete the course. If no PEP was administered, the risk of developing rabies following a probable rabies exposure was high (0.165), with bites to the head carrying most risk. Decentralized and free PEP increased the probability that patients received PEP and reduced delays in initiating PEP. No major difficulties were encountered by health workers whilst switching to dose-sparing ID administration of PEP. Health infrastructure also includes sufficient cold chain capacity to support improved PEP provision. However, high costs to governments and patients currently limits the supply chain and PEP access. The cost barrier was exacerbated by decentralization of budgets, with priority given to purchase of cheaper medicines for other conditions. Reactive procurement resulted in limited and unresponsive PEP supply, increasing costs and risks to bite victims.
   Conclusion: PEP access could be improved and rabies deaths reduced through ring-fenced procurement, switching to dose-sparing ID regimens and free provision of PEP. (C) 2018 Published by Elsevier Ltd.
C1 [Changalucha, Joel; Lushasi, Kennedy; Mtema, Zacharia; Sambo, Maganga; Govella, Nicodem J.; Dilip, Angel; Sikana, Lwitiko] Ifakara Hlth Inst, POB 78373, Dar Es Salaam, Tanzania.
   [Steenson, Rachel; Cleaveland, Sarah; Lembo, Tiziana; Sambo, Maganga; Ventura, Francesco; Hampson, Katie] Univ Glasgow, Boyd Orr Ctr Populat & Ecosyst Hlth, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.
   [Grieve, Eleanor] Univ Glasgow, Inst Hlth & Wellbeing, HEHTA, 1 Lilybank Gardens, Glasgow, Lanark, Scotland.
   [Mchau, Geofrey] Minist Hlth Community Dev Gender Elderly & Childr, POB 573, Dodoma, Tanzania.
   [Nanai, Alphoncina] WHO, Tanzania Country Off, POB 9292, Dar Es Salaam, Tanzania.
RP Changalucha, J (reprint author), Ifakara Hlth Inst, POB 78373, Dar Es Salaam, Tanzania.
EM jchangalucha@ihi.or.tz
RI Ventura, Francesco/AAN-2158-2020
OI Ventura, Francesco/0000-0002-1584-2433; Changalucha,
   Joel/0000-0003-0758-2480; Mchau, Geofrey/0000-0002-4640-0486; Hampson,
   Katie/0000-0001-5392-6884; Steenson, Rachel/0000-0002-1579-6596
FU Wellcome TrustWellcome Trust [095787/Z/11/Z, 207569/Z/17/Z,
   106824/Z/15/Z]; Bill and Melinda Gates FoundationGates Foundation; UBS
   Optimus Foundation; WHO country office; MoHCDGEC
FX KH and JC were supported by the Wellcome Trust (095787/Z/11/Z,
   207569/Z/17/Z and 106824/Z/15/Z). The Bill and Melinda Gates Foundation
   funded rabies control and prevention activities in Southern Tanzania and
   the UBS Optimus Foundation (http://www.ubs.com/optimus-foundation)
   funded surveillance. We also acknowledge the support from the MoHCDGEC
   and WHO country office for their support in enabling this survey,
   COSTECH and NIMR for research permissions, health facility staff and
   local communities for participating in data collection and supporting
   research activities.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   Amenyah J, 2005, TANZANIA INTEGRATED
   Atun RA, 2008, WHO EUR MIN C HLTH S
   Dodet B, 2008, VACCINE, V26, P6344, DOI 10.1016/j.vaccine.2008.09.003
   Eggerbauer E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004776
   Etheart MD, 2017, LANCET GLOB HEALTH, V5, pE1017, DOI 10.1016/S2214-109X(17)30321-2
   Hampson K, 2016, BIORXIV, V096883, P1, DOI [10.1101/096883, DOI 10.1101/096883]
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2019, VACCINE, V37, pA166, DOI 10.1016/j.vaccine.2018.11.010
   Hampson K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000982
   Hampson K, 2009, PLOS BIOL, V7, P462, DOI 10.1371/journal.pbio.1000053
   Hayman DTS, 2011, J VIROL METHODS, V177, P87, DOI 10.1016/j.jviromet.2011.07.002
   Kamoltham T, 2003, B WORLD HEALTH ORGAN, V81, P375
   Khawplod P, 2006, VACCINE, V24, P3084, DOI 10.1016/j.vaccine.2006.01.051
   Lechenne M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005010
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Macha J, 2012, HEALTH POLICY PLANN, V27, pi46, DOI 10.1093/heapol/czs024
   Mallewa M, 2007, EMERG INFECT DIS, V13, P136, DOI 10.3201/eid1301.060810
   Mamdani M, 2004, REPROD HEALTH MATTER, V12, P138, DOI 10.1016/S0968-8080(04)24135-0
   Mikkelsen-Lopez I, 2014, HEALTH SYST, V3, P74, DOI 10.1057/hs.2013.14
   Ministry of Health and Social Welfare, 2013, STAND TREATM GUID ST
   [Ministry of Health and Social Welfare Tanzania Mainland], 2015, NAT HLTH POL 2015
   Ministry of Health CD Ministry of Health-MoH/Zanzibar National Bureau of Statistics-NBS/Tanzania Office of Chief Government Statistician-OCGS/Zanzibar ICF, 2016, TANZ DEM HLTH SURV M
   Ministry of Health [Tanzania Mainland]. Expanded Program on Immunization, 2010, EXP PROGR IMM TANZ M
   Mpolya EA, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00021
   Mtema Z, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002002
   National Bureau of Statistics, 2013, 2012 POP HOUS CENS P
   Quiambao BP, 2005, VACCINE, V23, P1709, DOI 10.1016/j.vaccine.2004.09.027
   Ritchie J, 1994, ANAL QUALITATIVE DAT
   Rysava K, 2019, VACCINE, V37, pA64, DOI 10.1016/j.vaccine.2018.11.066
   Sambo M, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00033
   Sambo M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002510
   Shim E, 2009, VACCINE, V27, P7167, DOI 10.1016/j.vaccine.2009.09.027
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tenzin, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001391
   Undurraga EA, 2017, AM J TROP MED HYG, V96, P1307, DOI 10.4269/ajtmh.16-0785
   Wakeley PR, 2005, J CLIN MICROBIOL, V43, P2786, DOI 10.1128/JCM.43.6.2786-2792.2005
   Warrell MJ, 2004, LANCET, V363, P959, DOI 10.1016/S0140-6736(04)15792-9
   World Health Organization, 2018, RAB VACC WHO POS PAP, P18
   World Health Organization, 2018, EXP CONS RAB 3 REP
NR 40
TC 10
Z9 10
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A45
EP A53
DI 10.1016/j.vaccine.2018.08.086
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500009
PM 30309746
OA Other Gold, Green Published, Green Accepted
DA 2020-05-12
ER

PT J
AU Denis, M
   Knezevic, I
   Wilde, H
   Hemachudha, T
   Briggs, D
   Knopf, L
AF Denis, Martine
   Knezevic, Ivana
   Wilde, Henry
   Hemachudha, Thiravat
   Briggs, Deborah
   Knopf, Lea
TI An overview of the immunogenicity and effectiveness of current human
   rabies vaccines administered by intradermal route
SO VACCINE
LA English
DT Review
DE Rabies vaccines; Intradermal route; Immunogenicity; Pre-exposure
   prophylaxis; Post-exposure prophylaxis
ID EMBRYO CELL VACCINE; POSTEXPOSURE PROPHYLAXIS; ANTIBODY-RESPONSE;
   OPEN-LABEL; SAFETY; REGIMEN; IMMUNOGLOBULIN; PVRV; POTENCY; 4-SITE
AB Pre- as well as post-exposure prophylaxis plays an important role in controlling the number of deaths associated with human rabies. Rabies vaccines, classically injected intramuscularly, are now also administered by intradermal (ID) route. Vaccines to be administered by the ID route should meet the same quality, safety and efficacy specifications as vaccines for intramuscular (IM) use.
   The aim of this paper is to provide information based on publicly available data regarding the ID use of rabies vaccines and to identify potential needs for further analysis of the potency, immunogenicity and effectiveness of rabies vaccines administered by this route.
   A first literature search, focused on the immunogenicity of rabies vaccines given by ID route, identified 338 publications in the period 1997-2018, 40 of which were included in our analyses. A second search investigating the effectiveness of ID vaccination resulted in 371 hits for the period 2007-2018, of which 13 suitable publications were retained.
   The immunogenicity of current rabies vaccines was analyzed in 3 ways: proportion of subjects reaching the antibody threshold of 0.5 IU/ml after ID vaccination, relationship between potency and immunogenicity of the vaccine given intradermally, and comparison of antibody responses after IM or ID vaccination. Overall, vaccines administered intradermally were found immunogenic. Post-exposure prophylaxis by ID route appeared at least as immunogenic as by IM regimens. By contrast, ID pre-exposure prophylaxis trended towards lower antibody titers than IM vaccination, but the observation was not associated with any clinical relevance.
   Vaccine effectiveness was assessed by investigating survival after exposure. Data from more than 30,000 patients who sought rabies post-exposure prophylaxis did not indicate that current vaccines administered by ID route lack efficacy.
   These results support current recommendations for ID vaccination against rabies. However, published data on ID performance were associated with significant weaknesses that future research should better address. (C) 2018 Published by Elsevier Ltd.
C1 [Knezevic, Ivana] WHO, Dept Essential Med & Hlth Prod, Norms & Stand Biol, Geneva, Switzerland.
   [Wilde, Henry] Chulalongkorn Univ, Fac Med, Bangkok, Thailand.
   [Hemachudha, Thiravat] Chulalongkorn Univ, Fac Med, World Hlth Org Collaborating Ctr Res & Training V, Bangkok, Thailand.
   [Briggs, Deborah] Kansas State Univ, Coll Vet Med, Manhattan, KS 66506 USA.
   [Knopf, Lea] WHO, Dept Control Neglected Trop Dis, Neglected Zoonot Dis, Geneva, Switzerland.
RP Denis, M (reprint author), 22 Ave Madrid, F-06400 Cannes, France.
EM martinejdenis@gmail.com
OI Knopf, Lea/0000-0001-5927-5285; Knezevic, Ivana/0000-0002-6441-7601
CR Ambrozaitis A, 2006, VACCINE, V24, P4116, DOI 10.1016/j.vaccine.2006.02.036
   Angsuwatcharakon P, 2018, EXPERT REV VACCINES, V17, P185, DOI 10.1080/14760584.2018.1421074
   [Anonymous], 1992, WHO TECH REP SER, P1
   [Anonymous], 2005, WHO TECHN REP SER, V931
   [Anonymous], 2005, TECHNICAL REPORT SER, V941, P83
   BARTH R, 1988, VACCINE, V6, P369, DOI 10.1016/0264-410X(88)90185-5
   Behera T. R., 2011, Journal of Communicable Diseases, V43, P31
   Beran J, 2005, VACCINE, V23, P3902, DOI 10.1016/j.vaccine.2005.03.007
   Bharti OK, 2017, HUM VACC IMMUNOTHER, V13, P762, DOI 10.1080/21645515.2016.1255834
   Bharti OK, 2016, HUM VACC IMMUNOTHER, V12, P837, DOI 10.1080/21645515.2015.1085142
   Bose A, 2016, VACCINE, V34, P4820, DOI 10.1016/j.vaccine.2016.08.005
   Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693
   Chowdhury Fazle-Rabbi, 2015, Recent Pat Antiinfect Drug Discov, V10, P30
   CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q
   Cunha RS, 2010, REV SAUDE PUBL, V44, P548, DOI 10.1590/s0034-89102010005000005
   Dodet B, 2011, BIOLOGICALS, V39, P444, DOI 10.1016/j.biologicals.2011.08.002
   Giesen A, 2015, EXPERT REV VACCINES, V14, P351, DOI 10.1586/14760584.2015.1011134
   Gowda VK, 2014, J PEDIATR NEUROSCI, V9, P154, DOI 10.4103/1817-1745.139328
   Gozdas HT, 2015, AM J EMERG MED, V33, P594, DOI 10.1016/j.ajem.2015.01.037
   Jaijaroensup W, 1999, J TRAVEL MED, V6, P234, DOI 10.1111/j.1708-8305.1999.tb00524.x
   Jain RS, 2015, AM J EMERG MED, V33
   Jonker EFF, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax033
   Khawplod P, 2006, VACCINE, V24, P3084, DOI 10.1016/j.vaccine.2006.01.051
   Khawplod P, 2002, CLIN INFECT DIS, V35, P1562, DOI 10.1086/344954
   Khawplod P, 2002, VACCINE, V20, P2240, DOI 10.1016/S0264-410X(02)00111-1
   Khawplod P, 2002, J TRAVEL MED, V9, P153, DOI 10.2310/7060.2002.23189
   Khawplod P, 2012, VACCINE, V30, P2918, DOI 10.1016/j.vaccine.2011.12.028
   Kulkarni PS, 2013, VACCINE, V31, P2719, DOI [10.1016/j.vaccine.2013.03.050, 10.1016/j.vaccine.201]
   Lang J, 1999, T ROY SOC TROP MED H, V93, P208, DOI 10.1016/S0035-9203(99)90309-7
   Laurent PE, 2010, VACCINE, V28, P5850, DOI 10.1016/j.vaccine.2010.06.062
   Madhusudana S. N., 2002, International Journal of Infectious Diseases, V6, P210, DOI 10.1016/S1201-9712(02)90113-X
   Madhusudana SN, 2006, HUM VACCINES, V2, P200, DOI 10.4161/hv.2.5.3197
   Madhusudana SN, 2004, INT J INFECT DIS, V8, P175, DOI 10.1016/j.ijid.2003.07.001
   Madhusudana SN, 2001, NATL MED J INDIA, V14, P145
   Magpantay RL, 2010, ASIAN BIOMED, V4, P61, DOI 10.2478/abm-2010-0007
   Masthi N. R. R., 2014, Asian Pacific Journal of Tropical Disease, V4, pS486
   Miranda EA, 2014, PHILLIPPINE J INT ME, V52, P7
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Narayana DHA, 2014, HUM VACC IMMUNOTHER, V10, P120, DOI 10.4161/hv.26456
   Pengsaa K, 2009, PEDIATR INFECT DIS J, V28, P335, DOI 10.1097/INF.0b013e3181906351
   Quiambao BP, 2009, VACCINE, V27, P7162, DOI 10.1016/j.vaccine.2009.09.036
   Quiambao BP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000243
   Quiambao BP, 2005, VACCINE, V23, P1709, DOI 10.1016/j.vaccine.2004.09.027
   Rabies WHO, 2018, WEEKLY EPIDEMIOL REC, V16, P201
   Ravish HS, 2014, HUM VACC IMMUNOTHER, V10, P2433, DOI 10.4161/hv.29403
   Ravish HS, 2014, HUM VACC IMMUNOTHER, V10, P1354, DOI 10.4161/hv.28064
   Recuenco S, 2017, VACCINE, V35, P4315, DOI 10.1016/j.vaccine.2017.06.083
   Salahuddin N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004448
   Sampath G, 2010, VACCINE, V28, P4086, DOI 10.1016/j.vaccine.2010.03.064
   Saraya A, 2010, VACCINE, V28, P4553, DOI 10.1016/j.vaccine.2010.04.090
   Satapathy DM., 2011, INT J PHARM BIO SCI, V2, P147
   Shantavasinkul P, 2010, CLIN INFECT DIS, V51, P1070, DOI 10.1086/656585
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P77, DOI 10.1086/649873
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Shiota S, 2008, VACCINE, V26, P6441, DOI 10.1016/j.vaccine.2008.08.068
   Sirikwin S, 2009, VACCINE, V27, P4350, DOI 10.1016/j.vaccine.2009.03.027
   Sudarshan MK, 2005, CURR THER RES CLIN E, V66, P323, DOI 10.1016/j.curtheres.2005.08.009
   Sudarshan MK, 2010, HUM VACCINES, V6, P562, DOI 10.4161/hv.6.7.11934
   Sudarshan MK, 2012, HUM VACC IMMUNOTHER, V8, P1077, DOI 10.4161/hv.20471
   Tantawichien T, 2001, CLIN INFECT DIS, V33, pE122, DOI 10.1086/324087
   Tantawichien T, 2014, EXPERT REV VACCINES, V13, P1593, DOI 10.1586/14760584.2014.971764
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Tinsa F, 2015, BMJ CASE REP, V14
   Toovey Stephen, 2007, Travel Med Infect Dis, V5, P327, DOI 10.1016/j.tmaid.2007.07.004
   Warrell MJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000224
   Wongsaroj P, 2013, VACCINE, V31, P1748, DOI 10.1016/j.vaccine.2013.01.035
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
   Yanagisawa N, 2012, J INFECT CHEMOTHER, V18, P66, DOI 10.1007/s10156-011-0286-2
NR 68
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A99
EP A106
DI 10.1016/j.vaccine.2018.11.072
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500017
PM 30551985
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fooks, AR
   Banyard, AC
   Ertl, HCJ
AF Fooks, Anthony R.
   Banyard, Ashley C.
   Ertl, Hildegund C. J.
TI New human rabies vaccines in the pipeline
SO VACCINE
LA English
DT Article
DE Pre-exposure prophylaxis (or PrEP); Post-exposure prophylaxis (PEP);
   Rabies immune globulin (RIG); Correlates of protection
ID REPLICATION-DEFECTIVE ADENOVIRUS; VIRUS GLYCOPROTEIN; IMMUNE-RESPONSES;
   NONHUMAN-PRIMATES; NEUTRALIZING ANTIBODY; DNA VACCINATION;
   RHESUS-MONKEYS; GENE GUN; RECOMBINANT; IMMUNOGENICITY
AB Rabies remains endemic in more than 150 countries. In 99% of human cases, rabies virus is transmitted by dogs. The disease, which is nearly always fatal, is preventable by vaccines given either before and/or after exposure to a rabid animal. Numerous factors including the high cost of vaccines, the relative complexity of post-exposure vaccination protocols requiring multiple doses of vaccine, which in cases of severe exposure have to be combined with a rabies immune globulin, lack of access to health care, and insufficient surveillance contribute to the estimated 59,000 human deaths caused by rabies each year. New, less expensive and more immunogenic rabies vaccines are needed together with improved surveillance and dog rabies control to reduce the death toll of human rabies. Here, we discuss new rabies vaccines that are in clinical and pre-clinical testing and evaluate their potential to replace current vaccines. (C) 2018 Published by Elsevier Ltd.
C1 [Fooks, Anthony R.; Banyard, Ashley C.] Anim & Plant Hlth Agcy, Weybridge, Surrey, England.
   [Ertl, Hildegund C. J.] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
RP Ertl, HCJ (reprint author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
EM Tony.Fooks@apha.gov.uk; Ashley.Banyard@apha.gov.uk; ertl@wistar.org
CR Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3
   Alcock R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000490
   Amarasinghe GK, 2018, ARCH VIROL, V163, P2283, DOI 10.1007/s00705-018-3814-x
   Badrane H, 2001, J VIROL, V75, P3268, DOI 10.1128/JVI.75.7.3268-3276.2001
   Bahloul C, 1998, VACCINE, V16, P417, DOI 10.1016/S0264-410X(97)00204-1
   Boland TA, 2014, ANN NEUROL, V75, P155, DOI 10.1002/ana.24016
   Brookes SM, 2006, DEV BIOLOGICALS, V125, P185
   Brooks SA, 2004, MOL BIOTECHNOL, V28, P241, DOI 10.1385/MB:28:3:241
   Brown D, 2008, VACCINE, V26, P3909, DOI 10.1016/j.vaccine.2008.04.081
   CADOZ M, 1992, LANCET, V339, P1429, DOI 10.1016/0140-6736(92)92027-D
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Cenna J, 2009, J INFECT DIS, V200, P1251, DOI 10.1086/605949
   Chen ZH, 2013, J VIROL, V87, P2986, DOI 10.1128/JVI.02886-12
   Chulasugandha P, 2006, VACCINE, V24, P1478, DOI 10.1016/j.vaccine.2005.03.059
   Dorfmeier CL, 2013, J VIROL, V87, P9217, DOI 10.1128/JVI.00995-13
   Farina SF, 2001, J VIROL, V75, P11603, DOI 10.1128/JVI.75.23.11603-11613.2001
   Fernandez-Nunez EG, 2015, BIOTECHNOL LETT, V37, P1153, DOI 10.1007/s10529-015-1787-3
   Fontana D, 2014, VACCINE, V32, P2799, DOI 10.1016/j.vaccine.2014.02.031
   Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91
   Fooks AR, 2014, VACCINE, V32, P2020, DOI 10.1016/j.vaccine.2014.02.065
   Fooks AR, 2000, CURR OPIN MOL THER, V2, P80
   Galesi ALL, 2008, CYTOTECHNOLOGY, V57, P73, DOI 10.1007/s10616-008-9139-y
   GALLETTI R, 1995, VACCINE, V13, P197, DOI 10.1016/0264-410X(95)93136-W
   Ge JY, 2011, J VIROL, V85, P8241, DOI 10.1128/JVI.00519-11
   Gonin P, 1996, VACCINE, V14, P1083, DOI 10.1016/0264-410X(95)00226-Q
   Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hemachudha Thiravat, 2003, International Journal of Infectious Diseases, V7, P76, DOI 10.1016/S1201-9712(03)90046-4
   Hicks DJ, 2012, CLIN EXP IMMUNOL, V169, P199, DOI 10.1111/j.1365-2249.2012.04592.x
   Horowitz A, 2010, J IMMUNOL, V185, P2808, DOI 10.4049/jimmunol.1000844
   Hosokawa-Muto J, 2006, MICROBIOL IMMUNOL, V50, P187, DOI 10.1111/j.1348-0421.2006.tb03785.x
   Ito N, 2005, MICROBIOL IMMUNOL, V49, P973, DOI 10.1111/j.1348-0421.2005.tb03692.x
   Johnson N, 2010, VACCINE, V28, P3896, DOI 10.1016/j.vaccine.2010.03.039
   Jorritsma SHT, 2016, VACCINE, V34, P5488, DOI 10.1016/j.vaccine.2016.09.062
   Kalimuddin S, 2017, VACCINE, V35, P7127, DOI 10.1016/j.vaccine.2017.10.097
   Kessels JA, 2017, B WORLD HEALTH ORGAN, V95, P210, DOI 10.2471/BLT.16.173039
   Kumar BD, 2013, INDIAN J MED RES, V137, P1072
   Lodmell DL, 2001, VACCINE, V20, P838, DOI 10.1016/S0264-410X(01)00392-9
   Lodmell DL, 2002, VACCINE, V20, P2221, DOI 10.1016/S0264-410X(02)00143-3
   Loza-Rubio E, 2008, DEV BIOLOGICALS, V131, P477
   Ma CS, 2017, IMMUNOLOGY, V152, P382, DOI 10.1111/imm.12793
   Malerczyk C, 2009, VACCINE, V27, P5320, DOI 10.1016/j.vaccine.2009.06.095
   Mansfield KL, 2008, J NEUROVIROL, V14, P218, DOI 10.1080/13550280802008297
   MCGARVEY PB, 1995, BIO-TECHNOL, V13, P1484, DOI 10.1038/nbt1295-1484
   McKimmie CS, 2005, BIOCHEM BIOPH RES CO, V336, P925, DOI 10.1016/j.bbrc.2005.08.209
   Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P7310, DOI 10.1073/pnas.93.14.7310
   MERIGAN TC, 1984, ANN NEUROL, V16, P82, DOI 10.1002/ana.410160116
   Miao L, 2017, VIRAL IMMUNOL, V30, P727, DOI 10.1089/vim.2017.0093
   Morimoto K, 2005, VIRUS RES, V111, P61, DOI 10.1016/j.virusres.2005.03.011
   Nicholson SM, 2016, LAB ANIMAL, V45, P128, DOI 10.1038/laban.988
   Pancharoen C, 2001, SCAND J INFECT DIS, V33, P390, DOI 10.1080/003655401750174183
   Papp Z, 1999, VACCINE, V17, P933, DOI 10.1016/S0264-410X(98)00279-5
   PASTORET PP, 1988, VET REC, V123, P481, DOI 10.1136/vr.123.19.481
   Plotkin SA, 2000, CLIN INFECT DIS, V30, P4, DOI 10.1086/313632
   PREHAUD C, 1989, VIROLOGY, V173, P390, DOI 10.1016/0042-6822(89)90551-5
   Ray NB, 1997, VACCINE, V15, P892, DOI 10.1016/S0264-410X(96)00281-2
   Rojas-Anaya E, 2009, TRANSGENIC RES, V18, P911, DOI 10.1007/s11248-009-9278-8
   Rupprecht CE, 2001, NEW ENGL J MED, V345, P582, DOI 10.1056/NEJMoa010560
   Sakamoto S, 1999, VACCINE, V17, P205, DOI 10.1016/S0264-410X(98)00196-0
   Shankar SK, 2012, ANN INDIAN ACAD NEUR, V15, P221, DOI 10.4103/0972-2327.99728
   Tatsis N, 2007, BLOOD, V110, P1916, DOI 10.1182/blood-2007-02-062117
   TAYLOR J, 1991, VACCINE, V9, P190, DOI 10.1016/0264-410X(91)90152-V
   THRAENHART O, 1994, CLIN IMMUNOL IMMUNOP, V71, P287, DOI 10.1006/clin.1994.1088
   Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1
   van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568
   Vellinga J, 2014, HUM GENE THER, V25, P318, DOI 10.1089/hum.2014.007
   Wang X, 2008, VACCINE, V26, P5135, DOI 10.1016/j.vaccine.2008.03.088
   WARRELL DA, 1976, T ROY SOC TROP MED H, V70, P188, DOI 10.1016/0035-9203(76)90037-7
   WARRELL MJ, 1989, BMJ-BRIT MED J, V299, P830, DOI 10.1136/bmj.299.6703.830
   Weyer J, 2007, VACCINE, V25, P4213, DOI 10.1016/j.vaccine.2007.02.084
   WHO, 2005, WHO TECH REP SER, V931, P1
   WHO, 2017, WHO TECH REP SER, V1004, P1
   Wilde H, 1999, J TRAVEL MED, V6, P238, DOI 10.1111/j.1708-8305.1999.tb00525.x
   Wilde H, 2007, VACCINE, V25, P7605, DOI 10.1016/j.vaccine.2007.08.054
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Wojczyk BS, 1996, PROTEIN EXPRES PURIF, V7, P183, DOI 10.1006/prep.1996.0026
   Wu XF, 2011, EXPERT REV VACCINES, V10, P1597, DOI [10.1586/erv.11.140, 10.1586/ERV.11.140]
   WUNNER WH, 1985, ANN INST PASTEUR VIR, V136E, P353, DOI 10.1016/S0769-2617(85)80127-1
   Xiang ZQ, 2014, VIROLOGY, V450, P243, DOI 10.1016/j.virol.2013.12.029
   Xiang ZQ, 2006, EMERG INFECT DIS, V12, P1596, DOI 10.3201/eid1210.060078
   XIANG ZQ, 1995, VIROLOGY, V209, P569, DOI 10.1006/viro.1995.1289
   Xiang ZQ, 1995, VIROLOGY, V214, P398, DOI 10.1006/viro.1995.0049
   Xiao XX, 2016, ARCH VIROL, V161, P685, DOI 10.1007/s00705-015-2704-8
   Yendo ACA, 2016, VACCINE, V34, P2305, DOI 10.1016/j.vaccine.2016.03.070
   Yuan ZG, 2008, VACCINE, V26, P1314, DOI 10.1016/j.vaccine.2007.12.050
   Yusibov V, 2002, VACCINE, V20, P3155, DOI 10.1016/S0264-410X(02)00260-8
   Zeiler FA, 2016, CAN J NEUROL SCI, V43, P44, DOI 10.1017/cjn.2015.331
NR 87
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A140
EP A145
DI 10.1016/j.vaccine.2018.08.039
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500022
PM 30153997
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Gongal, G
   Sampath, G
AF Gongal, Gyanendra
   Sampath, Gadey
TI Introduction of intradermal rabies vaccination - A paradigm shift in
   improving post-exposure prophylaxis in Asia
SO VACCINE
LA English
DT Article
DE Rabies; Asia; Post-exposure prophylaxis; Vaccine; Intradermal;
   Intramuscular
ID ANTIBODY-RESPONSE
AB The cost of cell culture vaccines for intramuscular administration limits their widespread use in many areas where rabies is present. The innovation of cost-effective multi-site intradermal (ID) vaccination technique was an impetus for high burden countries to phase out production and use of rabies vaccine of nerve tissue origin in public hospitals in subsequent years. The WHO Expert Committee in 1991 recommended intradermal application of modern rabies vaccines for post-exposure prophylaxis. There are many challenges in promotion of ID schedule. Poor patient compliance due to the need for several clinic visits is one of the drawbacks of the presently recommended ID rabies vaccination regimens. A series of clinical trial and field observations in past 3 decade have generated enough evidence-based information to recommend one week ID schedule. Off label use of commercially available human rabies vaccine for ID administration is an issue. The national authority should consider revision of ID vaccination schedule in line with new WHO guidelines. (C) 2018 Published by Elsevier Ltd.
C1 [Gongal, Gyanendra] WHO Reg Off South East Asia, New Delhi, India.
   [Sampath, Gadey] Inst Prevent Med, Hyderabad, India.
RP Gongal, G (reprint author), WHO Reg Off South East Asia, New Delhi, India.
EM gn_gongal@yahoo.com
FU World Health OrganizationWorld Health Organization [001]
CR Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693
   Gongal Gyanendra, 2011, Adv Prev Med, V2011, P383870, DOI 10.4061/2011/383870
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Kopel E, 2012, EMERG INFECT DIS, V18, P1493, DOI 10.3201/eid1809.111833
   Madhusudana SN, 2014, EXPERT REV VACCINES, V13, P641, DOI 10.1586/14760584.2014.901893
   Teunissen MBM, 2012, CURR TOP MICROBIOL, V351, P25, DOI 10.1007/82_2011_169
   WARRELL MJ, 1984, LANCET, V1, P874
   WHO, 2018, TRS1012 WHO
   WHO, WHOCDSNTDNZD201804
   WHO, 1995, REP WHO CONS INTR AP
   WHO expert committee on rabies, 1992, WHO EXP COMM RAB TEC, V824
   WHO expert consultation on rabies, 2005, WHO TECH REP SER WHO, V931
   WHO Expert Consultation on Rabies, 2013, WHO TECH REP SER, V982
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
NR 14
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A94
EP A98
DI 10.1016/j.vaccine.2018.08.034
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500016
PM 30150166
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hampson, K
   Abela-Ridder, B
   Bharti, O
   Knopf, L
   Lechenne, M
   Mindekem, R
   Tarantola, A
   Zinsstag, J
   Trotter, C
AF Hampson, Katie
   Abela-Ridder, Bernadette
   Bharti, Omesh
   Knopf, Lea
   Lechenne, Monique
   Mindekem, Rolande
   Tarantola, Arnaud
   Zinsstag, Jakob
   Trotter, Caroline
TI Modelling to inform prophylaxis regimens to prevent human rabies
SO VACCINE
LA English
DT Article
DE Post-exposure prophylaxis; Pre-exposure prophylaxis; Expanded program on
   immunization; Rabies immunoglobulin; lntradermal; Intramuscular;
   Regimen; Dose-sparing
ID POSTEXPOSURE PROPHYLAXIS; DOG BITES; VACCINE; COST; IMMUNOGLOBULIN
AB Background: The Strategic Advisory Group of Experts (SAGE) Working Group on rabies vaccines and immunoglobulins was established in 2016 to develop practical and feasible recommendations for prevention of human rabies. To support the SAGE agenda we developed models to compare the relative costs and potential benefits of rabies prevention strategies.
   Methods: We examined Post-Exposure Prophylaxis (PEP) regimens, protocols for administration of Rabies Immunoglobulin (RIG) and inclusion of rabies Pre-Exposure Prophylaxis (PrEP) within the Expanded Programme on Immunization (EPI). For different PEP regimens, clinic throughputs and consumables for vaccine administration, we evaluated the cost per patient treated, costs to patients and potential to treat more patients given limited vaccine availability.
   Results: We found that intradermal (ID) vaccination reduces the volume of vaccine used in all settings, is less costly and has potential to mitigate vaccine shortages. Specifically, the abridged 1-week 2-site ID regimen was the most cost-effective PEP regimen, even in settings with low numbers of bite patients presenting to clinics. We found advantages of administering RIG to the wound(s) only, using considerably less product than when the remaining dose is injected intramuscularly distant to the wound(s). We found that PrEP as part of the EPI programme would be substantially more expensive than use of PEP and dog vaccination in prevention of human rabies.
   Conclusions: These modeling insights inform WHO recommendations for use of human rabies vaccines and biologicals. Specifically, the 1-week 2-site ID regimen is recommended as it is less costly and treats many more patients when vaccine is in short supply. If available, RIG should be administered at the wound only. PrEP is highly unlikely to be an efficient use of resources and should therefore only be considered in extreme circumstances, where the incidence of rabies exposures is extremely high. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Hampson, Katie] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.
   [Abela-Ridder, Bernadette; Knopf, Lea] Dept Control Neglected Trop Dis, CH-1121 Geneva 27, Switzerland.
   [Bharti, Omesh] State Inst Hlth & Family Welf, Shimla, Himachal Prades, India.
   [Lechenne, Monique; Zinsstag, Jakob] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland.
   [Lechenne, Monique; Zinsstag, Jakob] Univ Basel, Peterspl 1, CH-4003 Basel, Switzerland.
   [Mindekem, Rolande] CSSI, Ndjamena, Chad.
   [Tarantola, Arnaud] Inst Pasteur Cambodge, Epidemiol & Publ Hlth Unit, Phnom Penh, Cambodia.
   [Trotter, Caroline] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Madingley Rd, Cambridge CB3 0ES, England.
RP Hampson, K (reprint author), Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.
EM katie.hampson@glasgow.ac.uk; abelab@who.int; bhartiomesh@yahoo.com;
   knopfl@who.int; Monique.lechenne@swissph.ch; mrola2002@yahoo.fr;
   atarantola@pasteur.nc; jakob.zinsstag@unibas.ch; clt56@cam.ac.uk
RI Tarantola, Arnaud/D-2149-2015; Bharti, Omesh Kumar/AAG-2946-2019
OI Tarantola, Arnaud/0000-0002-6946-7958; Bharti, Omesh
   Kumar/0000-0001-5178-1503; Lechenne, Monique/0000-0003-0370-3978;
   Hampson, Katie/0000-0001-5392-6884; Knopf, Lea/0000-0001-5927-5285;
   Trotter, Caroline/0000-0003-4000-2708
FU WHOWorld Health Organization; Wellcome TrustWellcome Trust
   [207569/Z/17/Z]; Afrique One ASPIRE - Wellcome Trust
FX We are grateful for valuable discussions with the WHO SAGE working group
   and IVIR-AC. This work is supported by a grant from WHO to the
   Universities of Glasgow and Cambridge. KH is supported by the Wellcome
   Trust (207569/Z/17/Z). ML was supported by Afrique One ASPIRE funded by
   the Wellcome Trust. We thank Rachel Steenson for assistance with data
   preparation.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P729
   Bharti OK, 2017, HUM VACC IMMUNOTHER, V13, P762, DOI 10.1080/21645515.2016.1255834
   Bharti OK, 2016, HUM VACC IMMUNOTHER, V12, P837, DOI 10.1080/21645515.2015.1085142
   Both L, 2012, LANCET INFECT DIS, V12, P397, DOI 10.1016/S1473-3099(11)70340-1
   Changalucha J, 2019, VACCINE, V37, pA45, DOI 10.1016/j.vaccine.2018.08.086
   Chulasugandha P, 2006, VACCINE, V24, P1478, DOI 10.1016/j.vaccine.2005.03.059
   Etheart MD, 2017, LANCET GLOBAL HLTH
   Grout L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-193
   Hampson K., 2015, PLOS NEGLECT TROP D, V9, P4, DOI DOI 10.1371/J0URNAL.PNTD.0003709.E0003709
   Hampson K, 2016, BIORXIV
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000982
   Hemachudha T., 1989, HDB CLIN NEUROLOGY
   Hickling JK, 2011, B WORLD HEALTH ORGAN, V89, P221, DOI 10.2471/BLT.10.079426
   Kamoltham T, 2002, VACCINE, V20, P3272, DOI 10.1016/S0264-410X(02)00299-2
   Kessels JA, 2017, B WORLD HEALTH ORGAN, V95, P210, DOI 10.2471/BLT.16.173039
   Khawplod P, 2006, VACCINE, V24, P3084, DOI 10.1016/j.vaccine.2006.01.051
   Lechenne M, 2017, CHAD TROP MED INFECT, V2, P43, DOI [10.3390/tropicalmed2030043, DOI 10.3390/TROPICALMED2030043]
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.13710:m11W, pntd 0000511e511
   Mallewa M, 2007, EMERG INFECT DIS, V13, P136, DOI 10.3201/eid1301.060810
   Mindekem R, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00038
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Ponsich A, 2016, ACTA TROP, V160, P62, DOI 10.1016/j.actatropica.2016.04.015
   Quiambao BP, 2005, VACCINE, V23, P1709, DOI 10.1016/j.vaccine.2004.09.027
   Rajeev M, 2019, VACCINE, V37, pA35, DOI 10.1016/j.vaccine.2018.11.011
   Ren JP, 2015, CLIN VACCINE IMMUNOL, V22, P1, DOI 10.1128/CVI.00531-14
   Rupprecht Charles E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Sambo M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002510
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Shim E, 2009, VACCINE, V27, P7167, DOI 10.1016/j.vaccine.2009.09.027
   Sudarshan MK, 2012, HUM VACC IMMUNOTHER, V8, P1077, DOI 10.4161/hv.20471
   Tarantola A, 2019, VACCINE, V37, pA118, DOI 10.1016/j.vaccine.2018.10.054
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Ugolini G, 2018, CURR OPIN INFECT DIS, V31, P93, DOI 10.1097/QCO.0000000000000420
   VODOPIJA I, 1988, REV INFECT DIS, V10, pS758
   Warrell MJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000224
   WHO, 1984, WHO EXP COMM RAB 7 R
   World Health Organization, 1992, WHO TECHN REP SER
   World Health Organization, 2018, WHO TECHN REP SER, V1012
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 42
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A166
EP A173
DI 10.1016/j.vaccine.2018.11.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500025
PM 30528846
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Ives, A
   Dieuzy-Labaye, I
   Abela-Ridder, B
AF Ives, Annette
   Dieuzy-Labaye, Isabelle
   Abela-Ridder, Bernadette
TI Global characteristics of the rabies biologics market in 2017
SO VACCINE
LA English
DT Article
DE Rabies; Vaccine; Immunoglobulins; Market analysis; Monoclonal
   antibodies; Post-exposure prophylaxis
AB In 2017, the World Health Organization, the World Organisation for Animal Health, the Food and Agriculture Organization of the United Nations and the Global Alliance for Rabies control developed a strategic plan to end human rabies deaths by 2030.
   A survey for manufacturing capacity and product characteristics of rabies biologics was conducted to inform this process. Twenty-three of 42 manufacturers, responded, giving a market capacity for 2017 of 90 million vials for human vaccines, 2.5 million vials for rabies immunoglobulins, 2 million vials for monoclonal antibodies and 181 million vials for dog vaccines.
   Production capacity could be increased by many manufacturers but was limited by country demand, lack of long-term planning and restricted market expansion. Should countries implement national rabies elimination programmes where biologic needs are forecasted and production lead times respected, manufacturers can meet future supply needs towards global elimination of human dog-mediated rabies deaths. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Ives, Annette; Abela-Ridder, Bernadette] WHO, Dept Control Neglected Trop Dis, Ave Appia 20, CH-1211 Geneva, Switzerland.
   [Dieuzy-Labaye, Isabelle] World Org Anim Hlth, 12 Rue Prony, F-75017 Paris, France.
RP Ives, A (reprint author), WHO, Dept Control Neglected Trop Dis, Ave Appia 20, CH-1211 Geneva, Switzerland.
EM annette.ives@gmail.com; i.dieuzy-labaye@oie.int; abelab@who.int
OI Ives, Annette/0000-0002-7407-960X
FU World Health OrganizationWorld Health Organization [001]
CR Abela-Ridder B, 2016, B WORLD HEALTH ORGAN, V94, P635, DOI 10.2471/BLT.16.183012
   GAVI, 2018, VACC INV STRAT
   GAVI, 2018, REP BOARD 6 7 JUN 20
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Rupprecht Charles, 2017, F1000Res, V6, P184, DOI 10.12688/f1000research.10416.1
   Wallace RM, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00009
   Warrell MJ, 2012, TRAVEL MED INFECT DI, V10, P1, DOI 10.1016/j.tmaid.2011.12.005
   WHO, 2018, WKLY EPIDEMIOL REC, V16, P93
   WHO, 2002, GETT START VACC VIAL
   WHO, 2017, WHO FACT SHEET RAB
   WHO, 2017, BACKGR PAP PROP REV
   World Health Organization, 2018, ZER 30 GLOB STRAT PL
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A73
EP A76
DI 10.1016/j.vaccine.2018.10.012
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500012
PM 30420115
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Kessels, J
   Tarantola, A
   Salahuddin, N
   Blumberg, L
   Knopf, L
AF Kessels, Joss
   Tarantola, Arnaud
   Salahuddin, Naseem
   Blumberg, Lucille
   Knopf, Lea
TI Rabies post-exposure prophylaxis: A systematic review on abridged
   vaccination schedules and the effect of changing administration routes
   during a single course
SO VACCINE
LA English
DT Review
DE Rabies; Post-exposure prophylaxis; Updated WHO position; Systematic
   literature review; Vaccine
ID IMMUNOGENICITY; SAFETY; VACCINES; CHILDREN; REGIMEN
AB Rabies is a fatal zoonotic disease preventable through timely and adequate post-exposure prophylaxis (PEP) to potentially exposed persons i.e. wound washing and antisepsis, a series of intradermal (ID) or intramuscular (IM) rabies vaccinations, and rabies immunoglobulin in WHO category III exposures. The 2010 WHO position on rabies vaccines recommended PEP schedules requiring up to 5 clinic visits over the course of approximately one month. Abridged schedules with less doses have potential to save costs, increase patient compliance, and thereby improve equitable access to life-saving PEP for at-risk populations. We systematically reviewed new evidence since that considered for the 2010 position paper to evaluate (i) the immunogenicity and effectiveness of PEP schedules of reduced dose and duration; (ii) new evidence on effective PEP protocols for special populations; and (iii) the effect of changing routes of administration (ID or IM) during a single course of PEP. Our search identified a total of 14 relevant studies. The identified studies supported a reduction in dose or duration of rabies PEP schedules. The 1-week, 2-site ID PEP schedule was found to be most advantageous, as it was safe, immunogenic, supported by clinical outcome data and involved the least direct costs (i.e. cost of vaccine) compared to other schedules. To supplement this evidence, as yet unpublished additional data were reviewed to support the strength of the recommendations.
   Evidence suggests that changes in the rabies vaccine product and/or the route of administration during PEP is possible. Few studies have evaluated PEP schedules in persons with suspect or confirmed rabies exposures. Gaps exist in understanding the safety and immunogenicity of novel PEP schedules in special populations such as infants and immunocompromised individuals. Available data indicate that administering rabies vaccines during pregnancy is safe and effective. (C) 2019 Published by Elsevier Ltd.
C1 [Kessels, Joss; Knopf, Lea] WHO, Dept Control Neglected Trop Dis, Geneva, Switzerland.
   [Tarantola, Arnaud] Inst Pasteur Nouvelle Caledonie, Unite Epidemiol, Noumea, New Caledonia.
   [Tarantola, Arnaud] Inst Pasteur Cambodge, Unite Epidemiol & Sante Publ, Phnom Penh, Cambodia.
   [Salahuddin, Naseem] Indus Hosp Karachi, Karachi, Pakistan.
   [Blumberg, Lucille] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa.
RP Knopf, L (reprint author), WHO, Dept Control Neglected Trop Dis, Geneva, Switzerland.
EM lea4knopf@gmail.com
RI Tarantola, Arnaud/D-2149-2015
OI Tarantola, Arnaud/0000-0002-6946-7958; Knopf, Lea/0000-0001-5927-5285
FU World Health OrganizationWorld Health Organization [001]
CR Aguemon CT, 2016, VACCINE, V34, P1752, DOI 10.1016/j.vaccine.2016.02.065
   Ambrozaitis A, 2006, VACCINE, V24, P4116, DOI 10.1016/j.vaccine.2006.02.036
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P425
   Changalucha J, 2019, VACCINE, V37, pA45, DOI 10.1016/j.vaccine.2018.08.086
   de Martino M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060894
   DEAN DJ, 1963, B WORLD HEALTH ORGAN, V28, P477
   Farquhar C, 2009, PEDIATR INFECT DIS J, V28, P295, DOI 10.1097/INF.0b013e3181903ed3
   Garg S, 2016, CLIN INFECT DIS, V62, P383, DOI 10.1093/cid/civ884
   Hampson K, 2019, VACCINE, V37, pA166, DOI 10.1016/j.vaccine.2018.11.010
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hampson K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000982
   Huang GH, 2014, HUM VACC IMMUNOTHER, V10, P114, DOI 10.4161/hv.26264
   Huang GH, 2013, HUM VACC IMMUNOTHER, V9, P177, DOI 10.4161/hv.22377
   Li AJ, 2019, VACCINE, V37, pA14, DOI 10.1016/j.vaccine.2018.10.011
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Neels P, 2017, VACCINE, V35, P2329, DOI 10.1016/j.vaccine.2017.02.056
   Pancharoen C, 2001, SCAND J INFECT DIS, V33, P390, DOI 10.1080/003655401750174183
   Quiambao B, 2008, APCRI J, VX, P15
   Rahimi P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139171
   Ravish HS, 2014, HUM VACC IMMUNOTHER, V10, P1354, DOI 10.4161/hv.28064
   Salahuddin N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004448
   Sambo M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003310
   Seo YB, 2016, HUM VACC IMMUNOTHER, V12, P478, DOI 10.1080/21645515.2015.1076599
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127
   Sirikwin S, 2009, VACCINE, V27, P4350, DOI 10.1016/j.vaccine.2009.03.027
   Sudarshan MK, 2006, NATL MED J INDIA, V19, P192
   Sudarshan MK, 2012, HUM VACC IMMUNOTHER, V8, P1077, DOI 10.4161/hv.20471
   Tanisaro T, 2010, VACCINE, V28, P2385, DOI 10.1016/j.vaccine.2010.01.003
   Tarantola A, 2019, VACCINE, V37, pA88, DOI 10.1016/j.vaccine.2018.10.103
   Tarantola A, 2019, VACCINE, V37, pA118, DOI 10.1016/j.vaccine.2018.10.054
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Thisyakorn U, 2001, VACCINE, V19, P1534, DOI 10.1016/S0264-410X(00)00322-4
   Warrell MJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000224
   WHO Expert Consultation on Rabies, 2018, WHO TECHN SER, V1012
   World Health Organization, 2017, SAG M OCT
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
   World Health Organization, 2017, IMM BAS IMM SER MOD
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
   Zaidi SMA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002574
NR 41
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A107
EP A117
DI 10.1016/j.vaccine.2019.01.041
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500018
PM 30737043
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Li, AJ
   Sreenivasan, N
   Siddiqi, UR
   Tahmina, S
   Penjor, K
   Sovann, L
   Gunesekera, A
   Blanton, JD
   Knopf, L
   Hyde, TB
AF Li, Anyie J.
   Sreenivasan, Nandini
   Siddiqi, Umme Ruman
   Tahmina, Sanya
   Penjor, Kinley
   Sovann, Ly
   Gunesekera, Amila
   Blanton, Jesse D.
   Knopf, Lea
   Hyde, Terri B.
TI Descriptive assessment of rabies post-exposure prophylaxis procurement,
   distribution, monitoring, and reporting in four Asian countries:
   Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018
SO VACCINE
LA English
DT Article
DE Rabies virus; Human rabies; Rabies post-exposure prophylaxis; Rabies
   vaccine
AB Background: There are approximately 35,000 human deaths from rabies in Asia annually. Rabies can be prevented through timely post-exposure prophylaxis (PEP) consisting of wound washing, rabies vaccine, and in some cases, rabies immunoglobulin (RIG). However, access to rabies PEP often remains limited to urban areas and is cost-prohibitive. There is little information on procurement, distribution, monitoring, and reporting of rabies PEP.
   Methods: We interviewed key informants in the public sector from various levels in Bangladesh, Bhutan, Cambodia, and Sri Lanka between March 2017 and May 2018 using a descriptive assessment tool to obtain information on procurement, distribution, monitoring, and reporting of rabies PEP. These four countries in Asia were chosen to showcase a range of rabies PEP systems. National rabies focal points were interviewed in each country and focal points helped identify additional key informants at lower levels.
   Results: A total of 22 key informants were interviewed at various levels (central level to health facility level) including national rabies focal points in each country. Each country has a unique system for managing rabies PEP procurement, distribution, monitoring, and reporting. There are varying levels of PEP access for those with potential rabies exposures. Rabies PEP is available in select health facilities throughout the country in Bangladesh, Bhutan, and Sri Lanka. In Cambodia, rabies PEP is limited to two urban centers. The availability of RIG in all four countries is limited. In these four countries, most aspects of the rabies PEP distribution system operate independently of systems for other vaccines. However, in Bhutan, rabies PEP and Expanded Programme on Immunization (EPI) vaccines share cold chain space in some locations at the lowest level. All countries have a monitoring system in place, but there is limited reporting of data, particularly to the central level.
   Conclusion: Systems to procure, deliver, monitor, and report on rabies PEP are variable across countries. Sharing information on practices more widely among countries can help programs to increase access to this life-saving treatment. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Sreenivasan, Nandini; Blanton, Jesse D.; Hyde, Terri B.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Siddiqi, Umme Ruman; Tahmina, Sanya] Directorate Gen Hlth Serv, Dis Control Unit, Communicable Dis Control, Dhaka, Bangladesh.
   [Penjor, Kinley] Minist Hlth, Dept Med Serv, Dewathang Mil Hosp, Thimphu, Bhutan.
   [Sovann, Ly] Minist Hlth, Communicable Dis Control Dept, Phnom Penh, Cambodia.
   [Gunesekera, Amila] Minist Hlth, Colombo, Sri Lanka.
   [Knopf, Lea] WHO, Geneva, Switzerland.
RP Li, AJ (reprint author), 1600 Clifton Rd NE,Mailstop H24-2, Atlanta, GA 30329 USA.
EM yrw5@cdc.gov
RI Gunesekera, Amila/AAF-2195-2020; Penjor, Kinley/AAF-1023-2020
OI Penjor, Kinley/0000-0001-9529-4096; Knopf, Lea/0000-0001-5927-5285
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U36OE000002]; Association of Schools and Programs of Public Health
   (ASPPH); Public Health Institute (PHI); CDCUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [NU2GGH002093-01-00]
FX This publication was supported by Cooperative Agreement Number
   U36OE000002 from the Centers for Disease Control and Prevention (CDC)
   and the Association of Schools and Programs of Public Health (ASPPH) and
   NU2GGH002093-01-00 from the CDC and the Public Health Institute (PHI).
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the CDC, the Department of
   Health and Human Services, ASPPH, or PHI.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   [Anonymous], 2013, 982 WHO
   ASEAN, 2015, ASEAN RAB EL STRAT
   De Silva AP, 2017, B WORLD HEALTH ORGAN, V95, P646, DOI 10.2471/BLT.16.188060
   Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91
   Gavi, 2018, COUNTR EL SUPP
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hossain M, 2012, EPIDEMIOL INFECT, V140, P1964, DOI 10.1017/S095026881100272X
   Hossain M, 2011, VACCINE, V29, P1036, DOI 10.1016/j.vaccine.2010.11.052
   KARUNANAYAKE D, 1999, PLOS NEGLECT TROP D, V8, pE3205
   Khawplod P, 2002, CLIN INFECT DIS, V35, P1562, DOI 10.1086/344954
   Kularatne SAM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1394-5
   Lavan RP, 2017, VACCINE, V35, P1668, DOI 10.1016/j.vaccine.2017.02.014
   Lionel Harischandra P A, 2016, WHO South East Asia J Public Health, V5, P113, DOI 10.4103/2224-3151.206247
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Ministry of Health Bangladesh, 2010, NAT GUID RAB PROPH I
   Ministry of Health Bhutan, 2017, ANN HLTH B
   Ministry of Health Bhutan, 2014, NAT GUID MAN RAB
   Mondal SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104435
   Mu TT, 2017, AM J TROP MED HYG, V97, P989, DOI 10.4269/ajtmh.17-0198
   National Statistics Bureau, 2017, NAT STAT BUR STAT YB
   Seneviratne S, 2017, WEEKLY EPIDEMIOLOGIC, P44
   Tarantola A, 2017, AM J EPIDEMIOL
   Tenzin, 2011, VACCINE, V29, P4094, DOI 10.1016/j.vaccine.2011.03.106
   Tenzin T, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003784
   Warrell MJ, 2012, TRAVEL MED INFECT DI, V10, P1, DOI 10.1016/j.tmaid.2011.12.005
   WHO, 2012, STRAT FRAM EL HUM RA
   WHO, 2010, WKLY EPIDEMIOL REC, V85, P309
   Wilde H, 2002, CLIN INFECT DIS, V34, P477, DOI 10.1086/324628
   Wilde H, 2017, VACCINE, V35, P2293, DOI 10.1016/j.vaccine.2017.03.001
   World Health Organization, 2014, BANGL TACK RAB MASS
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
   2015, LANCET LONDON ENGLAN, V386, P2446
NR 33
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A14
EP A19
DI 10.1016/j.vaccine.2018.10.011
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500005
PM 30314908
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Nguyen, HTT
   Le, NDT
   Pham, TN
   Urabe, MI
   Afriyie, DO
   Otsu, S
   Tran, DN
   Tran, HGT
   Nguyen, HV
   Le, H
   Tran, CH
AF Nguyen, Huong T. T.
   Le, Nhan D. T.
   Pham, Thach N.
   Urabe, Maho, I
   Afriyie, Doris O.
   Otsu, Satoko
   Tran, Duong N.
   Tran, Huong G. T.
   Nguyen, Hoang, V
   Le, Ha T.
   Tran, Cuc H.
TI Evaluation of Vietnam's post-exposure prophylaxis delivery system, 2017
SO VACCINE
LA English
DT Article
DE Rabies; Canine; Human; Vaccine; Post-exposure prophylaxis;
   Immunoglobulin; Vietnam
AB Background: Canine-mediated human rabies deaths typically occur in poor and rural populations with limited access to rabies biologics: vaccine and immunoglobulin. A critical aspect of reducing rabies deaths is understanding how these countries procure, deliver, and forecast rabies biologics. Vietnam is one of the few endemic countries where biologics is widely available. However, a formal evaluation of its current rabies biologics distribution system has not been conducted.
   Methods: In 2017, we conducted a formal evaluation of Vietnam's rabies biologics distribution system. Our goals were (1) to identify centers providing rabies biologics (2) identify costs to the patient and centers and (3) assess the rabies biologic procurement and delivery system at eligible district and provincial centers (provides and orders biologics for itself and other centers directly from the manufacture). To conduct the formal evaluation, we developed a standardized survey that was distributed to centers.
   Results: Of the 780 designated rabies biologics centers in Vietnam, 659 (84%) of them provide rabies immunoglobulin (eRIG), vaccine, or both. Of the 177 eligible centers, 90% (160) responded to the survey. The average costs to patients were $8.45 (range: 5.43-12.77) for one dose of IM injection, $13.90 (range: 11.86-16.71) for domestic eRIG, and $23 (21.11-27.11) for imported eRIG. Respondents reported experiencing delays in receiving vaccine in 50 centers and eRIG in 14 centers within the past year. Respondents stated their top three challenges in providing biologics were: delays or shortages from manufactures, lack of funds to pay for biologics, and the high cost of biologics.
   Conclusions and relevance: Despite the wide availability of biologics in Vietnam, more work is needed to provide affordable and reliable supply of biologics to patients. This includes the expansion of ID injection use throughout the country to lower vaccine demand, and decrease the costs to centers and patients. Furthermore, a more coordinated effort to share biologics among centers, possibly through a more centralized system at the provincial level may alleviate delays and shortages. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Nguyen, Huong T. T.; Pham, Thach N.; Tran, Duong N.; Nguyen, Hoang, V] Minist Hlth, Natl Inst Hyg & Epidemiol, 1 Yersin St, Hanoi, Vietnam.
   [Le, Nhan D. T.] Inst Publ Hlth, 159 Hung Phu St,8 Ward,8 Dist, Hcmc, Vietnam.
   [Le, Nhan D. T.] Minist Hlth, Field Epidemiol Training Program, 135 Nui Tow St, Hanoi, Vietnam.
   [Urabe, Maho, I; Otsu, Satoko] WHO, Representat Off Vietnam, 304 Kim Ma St, Hanoi, Vietnam.
   [Afriyie, Doris O.] US Ctr Dis Control & Prevent Country Off Vietnam, 2 Ngo Quyen, Hanoi, Vietnam.
   [Tran, Huong G. T.] Minist Hlth, Int Cooperat Dept, 138A Clang Vo, Hanoi, Vietnam.
   [Le, Ha T.] Hanoi Med Univ, 1 Ton Tung, Hanoi, Vietnam.
   [Tran, Cuc H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA USA.
   [Tran, Cuc H.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd, Atlanta, GA USA.
RP Nguyen, HTT (reprint author), Minist Hlth, Natl Inst Hyg & Epidemiol, 1 Yersin St, Hanoi, Vietnam.
EM ntth1@nihe.org.vn
FU Gavi Learning Agenda, Switzerland via the WHO Neglected Tropical
   Diseases Department, Switzerland
FX This funding was supported through the Gavi Learning Agenda, Switzerland
   via the WHO Neglected Tropical Diseases Department, Switzerland.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   Amparo ACB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200873
   [Anonymous], 2013, HIST VACC INV STRAT
   Dimaano EM, 2011, INT J INFECT DIS, V15, pE495, DOI 10.1016/j.ijid.2011.03.023
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Li AJ, 2019, VACCINE, V37, pA14, DOI 10.1016/j.vaccine.2018.10.011
   Minghui R, 2018, LANCET GLOBAL HLTH
   Ministry of Agriculture and Rural Development and Ministry of Health, 2016, NAT PROGR RAB CONTR
   Ministry of Agriculture and Rural Development (MARD) Ministry of Health (MoH), 2016, NAT PROGR RAB CONTR
   Ministry of Health, 2014, GUID HUM RAB SURV PR
   Nguyen HIT, 2018, OIE SCI TECH REV, V38, P1
   Sreenivasan N, 2018, VACCINE
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tran CH, 2018, PLOS NEGLECT T UNPUB
   Tran CH, 2019, VACCINE, V37, pA54, DOI 10.1016/j.vaccine.2019.01.030
   Wilde H, 2016, VACCINE, V34, P187, DOI 10.1016/j.vaccine.2015.11.036
   World Health Organization, 2018, WHO TECH REP SER
   World Health Organization, 2018, PREQ VACC
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A20
EP A27
DI 10.1016/j.vaccine.2019.02.041
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500006
PM 31235373
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Rajeev, M
   Edosoa, G
   Hanitriniaina, C
   Andriamandimby, SF
   Guis, H
   Ramiandrasoa, R
   Ratovoson, R
   Randrianasolo, L
   Andriamananjara, M
   Heraud, JM
   Baril, L
   Metcalf, CJE
   Hampson, K
AF Rajeev, Malavika
   Edosoa, Glenn
   Hanitriniaina, Chantal
   Andriamandimby, Soa Fy
   Guis, Helene
   Ramiandrasoa, Ravo
   Ratovoson, Rila
   Randrianasolo, Laurence
   Andriamananjara, Mamitiana
   Heraud, Jean-Michel
   Baril, Laurence
   Metcalf, C. Jessica E.
   Hampson, Katie
TI Healthcare utilization, provisioning of post-exposure prophylaxis, and
   estimation of human rabies burden in Madagascar
SO VACCINE
LA English
DT Article
DE Disease burden; Contact tracing; Rabies surveillance; Intradermal;
   Post-exposure treatment; Canine rabies
ID DOG BITES; MANAGEMENT
AB In Madagascar, dog-mediated rabies has been endemic for over a century, however there is little data on its incidence or impact. We collected data over a 16-month period on provisioning of post-exposure prophylaxis (PEP) at a focal clinic in the Moramanga District and determined the rabies status of biting animals using clinical and laboratory diagnosis. We find that animal rabies cases are widespread, and clinic-based triage and investigation are effective ways to increase detection of rabies exposures and to rule out non-cases. A high proportion of rabies-exposed persons from Moramanga sought (84%) and completed PEP (90% of those that initiated PEP), likely reflecting the access and free provisioning of PEP in the district. Current clinic vial sharing practices demonstrate the potential for intradermal administration of PEP in endemic African settings, reducing vaccine use by 50% in comparison to intramuscular administration. A high proportion of PEP demand was attributed to rabies cases, with approximately 20% of PEP administered to probable rabies exposures and an additional 20% to low-to-no risk contacts with confirmed/probable animal or human cases. Using a simplified decision tree and our data on rabies exposure status and health-seeking behavior, we estimated an annual incidence of 42-110 rabies exposures and 1-3 deaths per 100,000 persons annually. Extrapolating to Madagascar, we estimate an annual burden of 282-745 human rabies deaths with current PEP provisioning averting 1499-3958 deaths each year. Data from other clinics and districts are needed to improve these estimates, particularly given that PEP availability is currently limited to only 31 clinics in the country. A combined strategy of mass dog vaccination, enhanced surveillance, and expanded access to PEP along with more judicious guidelines for administration could effectively reduce and eventually eliminate the burden of rabies in Madagascar. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Rajeev, Malavika; Metcalf, C. Jessica E.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Edosoa, Glenn] Minist Re St Publ, Serv Lutte Malad Epidem & Negligees, Antananarivo, Madagascar.
   [Hanitriniaina, Chantal] Univ Antananarivo, Fac Sci, Ment Zool & Biodiversit Anim, Antananarivo, Madagascar.
   [Andriamandimby, Soa Fy; Heraud, Jean-Michel] Inst Pasteur Madagascar, Virol Unit, Antananarivo, Madagascar.
   [Guis, Helene; Ratovoson, Rila; Randrianasolo, Laurence; Baril, Laurence] Inst Pasteur Madagascar, Epidemiol & Clin Res Unit, Antananarivo, Madagascar.
   [Ramiandrasoa, Ravo] Inst Pasteur Madagascar, Vaccinat Ctr, Antananarivo, Madagascar.
   [Guis, Helene] CIRAD, UMR ASTRE, Antananarivo, Madagascar.
   [Guis, Helene] Univ Montpellier, INRA, CIRAD, ASTRE, Montpellier, France.
   [Andriamananjara, Mamitiana] Minist Charge Agr & Elevage, Direct Serv Vet, Antananarivo, Madagascar.
   [Hampson, Katie] Univ Glasgow, Boyd Orr Ctr Populat & Ecosyst Hlth, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.
RP Rajeev, M (reprint author), Princeton Univ, 106D Guyot Hall, Princeton, NJ 08540 USA.
EM mrajeev@princeton.edu
RI Heraud, Jean-Michel/AAD-8056-2019; Heraud, Jean-Michel/O-1464-2013
OI Heraud, Jean-Michel/0000-0003-1107-0859; Heraud,
   Jean-Michel/0000-0003-1107-0859; Hampson, Katie/0000-0001-5392-6884;
   Ratovoson, Rila/0000-0002-3867-6343; Glenn, Edosoa/0000-0002-5301-5906;
   Rajeev, Malavika/0000-0001-6030-4995; Baril,
   Laurence/0000-0003-2346-883X
FU Center for Health and Wellbeing; Department of Ecology and Evolutionary
   Biology at Princeton UniversityPrinceton University; NSFNational Science
   Foundation (NSF); Wellcome TrustWellcome Trust [207569/Z/17/Z]
FX We would like to thank all staff and officials at the Moramanga ARMC and
   other hospitals in the district, the local veterinarians, livestock
   officers, the local presidents and town officials, and the National
   Rabies Laboratory who were integral to this work. We are grateful to
   staff and officials at IPM, the Ministry of Public Health, and the
   Department of Veterinary Services for their support and technical
   assistance. In particular, we thank Jean Hyacinthe Randrianarisoa,
   Ranaivoarimanana, Fierenantsoa Randriamahatana, Esther Noiarisaona,
   Girard Razafitrimo, Cara Brook, Amy Winter, Christian Ranaivoson, John
   Friar, and Amy Wesolowski. This work was funded by grants from the
   Center for Health and Wellbeing and the Department of Ecology and
   Evolutionary Biology at Princeton University to CJEM and MR. MR is
   supported by an NSF Graduate Research Fellowship. KH is supported by the
   Wellcome Trust (207569/Z/17/Z).
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   Andriamandimby SF, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-77
   [Anonymous], 2018, WHO WKLY EPIDEMIOL R
   Beyene TJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192313
   Changalucha J, 2019, VACCINE, V37, pA45, DOI 10.1016/j.vaccine.2018.08.086
   Dacheux L, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004812
   Etheart MD, 2017, LANCET GLOB HEALTH, V5, pE1017, DOI 10.1016/S2214-109X(17)30321-2
   Frey J, 2013, TROP MED INT HEALTH, V18, P1555, DOI 10.1111/tmi.12202
   Gogtay NJ, 2014, INDIAN J MED RES, V139, P459
   Hampson K, 2016, BIORXIV, V096883, P1, DOI [10.1101/096883, DOI 10.1101/096883]
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hampson K, 2009, PLOS BIOL, V7, P462, DOI 10.1371/journal.pbio.1000053
   Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Lechenne Monique, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2030043
   Linard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031743
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Mbilo C, 2017, ACTA TROP, V175, P100, DOI 10.1016/j.actatropica.2016.06.003
   Medley Alexandra M, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2020014
   Meslin F.-X., 1996, LAB TECHNIQUES RABIE
   Rasolonjatovo FS., 2017, THESIS, P1
   Reynes J-M, 2011, ADV PREV MED, V2011, DOI [10.4061/2011/727821727821, DOI 10.4061/2011/727821727821]
   Salomao C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005787
   Sambo M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003310
   Sudarshan MK, 2007, INT J INFECT DIS, V11, P29, DOI 10.1016/j.ijid.2005.10.007
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tenzin, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001391
   Tenzin, 2011, VACCINE, V29, P4094, DOI 10.1016/j.vaccine.2011.03.106
   Tepsumethanon Veera, 2005, Journal of the Medical Association of Thailand, V88, P419
   Tricou V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004433
   Tschopp R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004471
   Undurraga EA, 2017, AM J TROP MED HYG, V96, P1307, DOI 10.4269/ajtmh.16-0785
   Wallace RM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004245
   WHO, 2013, WHO TECH REP SER, V982, P1
   Youla A S, 2014, Bull Soc Pathol Exot, V107, P18, DOI 10.1007/s13149-013-0321-x
NR 36
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A35
EP A44
DI 10.1016/j.vaccine.2018.11.011
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500008
PM 30509692
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Rattanavipapong, W
   Thavorncharoensap, M
   Youngkong, S
   Genuino, AJ
   Anothaisintawee, T
   Chaikledkaew, U
   Meeyai, A
AF Rattanavipapong, Waranya
   Thavorncharoensap, Montarat
   Youngkong, Sitaporn
   Genuino, Anne Julienne
   Anothaisintawee, Thunyarat
   Chaikledkaew, Usa
   Meeyai, Aronrag
TI The impact of transmission dynamics of rabies control: Systematic review
SO VACCINE
LA English
DT Review
DE Rabies; Prevention and control; Vaccine; Transmission dynamics;
   Mathematical model; Systematic review
ID METAPOPULATION DYNAMICS; VACCINATION; DOGS
AB The public health and economic burden of rabies has led to major intersectoral initiatives worldwide to reduce its burden. Over the last decade, the impact of rabies prevention and control programmes in real-world settings has become increasingly evident, especially in countries where most rabies exposures and deaths occur, but they have yet to successfully eradicate rabies due to limited access to health care services.
   We aimed to systematically review published transmission dynamic modelling studies of rabies in both humans and dogs with a focus on studies which estimated the epidemiological and economic impact of different preventive measures. The findings are intended to inform the World Health Organization's (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) to improve programmatic feasibility and clinical practice in rabies.
   Medline and Scopus were systematically searched for peer-reviewed articles which were published up to 14th June 2017. In addition, studies identified from a meeting of the WHO Expert Consultation on Rabies on 26-28th April 2017 in Bangkok, Thailand were added, resulting in 19 articles which were included in the review. Results from the disease modelling indicated that the basic reproduction number was low (less than 2 in all but one study). All studies found that rabies control through canine vaccination was likely to be effective in terms of reducing the incidence of rabies in dogs and/or humans, with most studies suggesting 70% annual coverage was adequate. Vaccine coverage, dog density and birth rate were identified as crucial factors influencing the effectiveness of the interventions. In conclusion, the findings from this review suggest that rabies control through canine vaccination is likely to be effective in reducing the incidence of rabies. Vaccine coverage, dog density and canine birth rate were identified as critical factors influencing the effectiveness of vaccination interventions. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Rattanavipapong, Waranya; Anothaisintawee, Thunyarat] Minist Publ Hlth, HITAP, Dept Hlth, 6th Floor,6th Bldg,Tiwanon Rd, Muang 11000, Nonthaburi, Thailand.
   [Thavorncharoensap, Montarat; Youngkong, Sitaporn; Genuino, Anne Julienne; Anothaisintawee, Thunyarat; Chaikledkaew, Usa; Meeyai, Aronrag] Mahidol Univ, Hlth Technol Assessment Postgrad Program, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.
   [Thavorncharoensap, Montarat; Youngkong, Sitaporn; Chaikledkaew, Usa] Mahidol Univ, Fac Pharm, Dept Pharm, Social Adm Pharm Excellence Res SAPER Unit, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.
   [Anothaisintawee, Thunyarat] Ramathibodi Hosp, Fac Med, Dept Family Med, 270 Rama 6 Rd, Bangkok 10400, Thailand.
   [Meeyai, Aronrag] Mahidol Univ, Fac Publ Hlth, Dept Epidemiol, 420-1 Ratchawithi Rd, Bangkok 10400, Thailand.
RP Meeyai, A (reprint author), Mahidol Univ, Fac Publ Hlth, Dept Epidemiol, 420-1 Ratchawithi Rd, Bangkok 10400, Thailand.
EM aronrag.coo@mahidol.ac.th
OI Meeyai, Aronrag/0000-0002-2359-1574
FU World Health Organization (WHO)World Health Organization; Thailand
   Research Fund under the senior research scholar on Health Technology
   Assessment [RTA5980011]; Bureau of Health Policy and Strategy, Ministry
   of Public Health; Bill & Melinda Gates FoundationGates Foundation; UK
   Department for International Development; Rockefeller Foundation; Health
   Intervention and Technology Assessment Program (HITAP), Department of
   Health, Ministry of Public Health, Nonthaburi, Thailand
FX This work was supported by grants from the World Health Organization
   (WHO) and Health Intervention and Technology Assessment Program (HITAP),
   Department of Health, Ministry of Public Health, Nonthaburi, Thailand.
   HITAP is funded by the Thailand Research Fund under the senior research
   scholar on Health Technology Assessment [grant numbers RTA5980011] and
   the Bureau of Health Policy and Strategy, Ministry of Public Health.
   HITAP is part of the International Decision Support Initiative (iDSI),
   which supports countries to get the best value for money from health
   spending. iDSI receives funding from the Bill & Melinda Gates
   Foundation, the UK Department for International Development, and
   Rockefeller Foundation. The findings, interpretations and conclusions
   expressed in this article do not necessarily reflect the views of the
   aforementioned funding agencies. Thanks also to Ben Cooper for
   illuminating discussions and help with Figure 2.
CR Beyer HL, 2012, VACCINE, V30, P1014, DOI 10.1016/j.vaccine.2011.12.052
   Beyer HL, 2011, P ROY SOC B-BIOL SCI, V278, P2182, DOI 10.1098/rspb.2010.2312
   Bhunu CP, 2011, INT J BIOMATH, V4, P379, DOI 10.1142/S1793524511001283
   Bilinski AM, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.1211
   Carroll MJ, 2010, WILDLIFE RES, V37, P676, DOI 10.1071/WR10027
   Coleman PG, 1996, VACCINE, V14, P185, DOI 10.1016/0264-410X(95)00197-9
   Durr S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003876
   Fitzpatrick MC, 2016, P NATL ACAD SCI USA, V113, P14574, DOI 10.1073/pnas.1604975113
   Fitzpatrick MC, 2014, ANN INTERN MED, V160, P91, DOI 10.7326/M13-0542
   Fitzpatrick MC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001796
   FRERICHS RR, 1975, MANAGE SCI, V22, P411, DOI 10.1287/mnsc.22.4.411
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hampson K, 2009, PLOS BIOL, V7, P462, DOI 10.1371/journal.pbio.1000053
   Hou Q, 2012, J THEOR BIOL, V300, P39, DOI 10.1016/j.jtbi.2012.01.006
   Kitala PM, 2002, EPIDEMIOL INFECT, V129, P215, DOI 10.1017/S0950268802006957
   Sparkes J, 2016, PREV VET MED, V131, P127, DOI 10.1016/j.prevetmed.2016.07.015
   Townsend SE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002372
   Wera E., 2016, TRANSBOUND EMERG DIS
   WHO Expert Consultation on Rabies, 2013, WHO TECH REP SER, V982
   World Health Organization, 2013, WHO EXP CONS RAB
   Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014525
   Zinsstag J, 2009, P NATL ACAD SCI USA, V106, P14996, DOI 10.1073/pnas.0904740106
NR 22
TC 1
Z9 1
U1 6
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A154
EP A165
DI 10.1016/j.vaccine.2018.11.035
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500024
PM 30528329
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rupprecht, CE
   Kuzmin, IV
   Yale, G
   Nagarajan, T
   Meslin, FX
AF Rupprecht, Charles E.
   Kuzmin, Ivan, V
   Yale, Gowri
   Nagarajan, Thirumeni
   Meslin, Francois-Xavier
TI Priorities in applied research to ensure programmatic success in the
   global elimination of canine rabies
SO VACCINE
LA English
DT Article
DE Canine vaccination; Disease elimination; Human prophylaxis; Lyssavirus;
   Rabies; Risk assessment; Surveillance; Veterinary biologics; Viral
   diagnosis; Zoonosis
ID PROTECTIVE IMMUNE-RESPONSE; ORAL VACCINATION; VIRUS; DOGS;
   IMMUNOGLOBULIN; PROPHYLAXIS; PREVENTION; ANTIBODY; STRAIN; SAFETY
AB The elimination of human rabies mediated by dogs is attainable in concept, based upon current sensitive and specific diagnostic methods, existing safe and effective human and veterinary vaccines and a sound virological, pathological and epidemiological understanding of the disease. Globally, all developed countries achieved this goal. Regionally, major progress occurred throughout the Americas. However, less advancement is evident in Africa and Asia. Our objective was to concentrate upon those salient improvements to extant tools and methods over the next five years which could assist and simplify the task for both those developing countries that have already begun the process, as well as other localities in the earlier stages of consideration. We considered several categories of applied research which could be accomplished in the short term, based upon the available scientific evidence and recent recommendations from subject matter experts and key opinion leaders, focused upon perceived major limitations to prior program success. Areas of concentration included: laboratory-based surveillance, pathogen detection and characterization; human rabies prophylaxis; veterinary biologics; implementation of canine vaccination; and oral vaccination of free-ranging community dogs. Further real-time application in these core areas with proven techniques and technology would simplify attaining not only the global goal focused subtly upon human mortality, but the actual elimination of canine rabies as well. (C) 2019 Elsevier Ltd.
C1 [Rupprecht, Charles E.] LYSSA LLC, Cumming, GA 30040 USA.
   [Kuzmin, Ivan, V] USDA, APHIS, VS, STAS,NVSL, Ames, IA 50010 USA.
   [Yale, Gowri] Mission Rabies, Panaji 403002, Goa, India.
   [Nagarajan, Thirumeni] Biol E Ltd, Hyderabad 500033, India.
RP Rupprecht, CE (reprint author), LYSSA LLC, Cumming, GA 30040 USA.
EM charleserupprechtii@gmail.com
RI Rupprecht, Charles/AAI-1544-2020
CR Amarasinghe GK, 2018, ARCH VIROL
   Begeman L, 2018, LANCET INFECT DIS, V18, pE147, DOI 10.1016/S1473-3099(17)30574-1
   Belo VS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144830
   Bender Scott, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2020017
   Bharti OK, 2017, HUM VACC IMMUNOTHER, V13, P762, DOI 10.1080/21645515.2016.1255834
   Brown CM, 2016, JAVMA-J AM VET MED A, V248, P505, DOI 10.2460/javma.248.5.505
   Cardoso FMC, 2017, ACTA VIROL, V61, P231, DOI 10.4149/av_2017_301
   Chen T, 2018, BIOMED ENVIRON SCI, V31, P146, DOI 10.3967/bes2018.017
   Cliquet F, 2018, VET RES, V49, DOI 10.1186/s13567-018-0554-6
   Darkaoui S, 2014, CLIN EXP VACCINE RES, V3, P220, DOI 10.7774/cevr.2014.3.2.220
   de Carvalho MF, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006271
   Eggerbauer E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004776
   Elser JL, 2018, TRANSBOUND EMERG DIS, V65, P135, DOI 10.1111/tbed.12637
   Evans JS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030130
   Feng Y, 2018, J VIROL METHODS
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Gibson AD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200942
   Gibson AD, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1320-2
   Gigante CM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197074
   Gogtay NJ, 2018, CLIN INFECT DIS, V66, P387, DOI 10.1093/cid/cix791
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hanna K, 2018, CLIN PHARMACOL-ADV A, V10, P79, DOI 10.2147/CPAA.S166454
   Hutton ARJ, 2018, INT J PHARMACEUT, V541, P56, DOI 10.1016/j.ijpharm.2018.02.031
   Jacoby E, 2015, VACCINE, V33, P4699, DOI 10.1016/j.vaccine.2015.03.062
   Jochmans D, 2019, VACCINE, V37, P4660, DOI 10.1016/j.vaccine.2017.12.051
   Kasemsuwan Suwicha, 2018, Vet Sci, V5, DOI 10.3390/vetsci5020047
   Lankester FJ, 2016, VACCINE, V34, P5504, DOI 10.1016/j.vaccine.2016.10.015
   Lechenne M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005010
   Lechenne M, 2016, VACCINE, V34, P571, DOI 10.1016/j.vaccine.2015.11.033
   Maki J, 2017, VET RES, V48, DOI 10.1186/s13567-017-0459-9
   Martins RD, 2015, CONTEMP CLIN TRIALS, V41, P1, DOI 10.1016/j.cct.2014.11.014
   Neevel AMG, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006387
   Okayasu H, 2017, J INFECT DIS, V216, pS161, DOI 10.1093/infdis/jix038
   Ren MH, 2018, LANCET GLOB HEALTH, V6, pE828, DOI 10.1016/S2214-109X(18)30302-4
   Rupprecht Charles, 2017, F1000Res, V6, P184, DOI 10.12688/f1000research.10416.1
   Rupprecht CE, 2015, FUTURE VIROL, V10, P517, DOI 10.2217/FVL.15.26
   Sambo M, 2014, PLOS NEGLECT TROP D, V8, P4
   Shinwari MW, 2014, VET MICROBIOL, V173, P224, DOI 10.1016/j.vetmic.2014.07.029
   Shuai L, 2015, ANTIVIR RES, V121, P9, DOI 10.1016/j.antiviral.2015.06.011
   Smith TG, 2019, VACCINE, V37, P4743, DOI 10.1016/j.vaccine.2017.09.096
   Tarantola Arnaud, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2020005
   Taylor LH, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00109
   Troupin C, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006041
   Ugolini G, 2018, CURR OPIN INFECT DIS, V31, P93, DOI 10.1097/QCO.0000000000000420
   Undurraga EA, 2017, AM J TROP MED HYG, V96, P1307, DOI 10.4269/ajtmh.16-0785
   Vos A, 2018, VACCINE, V36, P811, DOI 10.1016/j.vaccine.2017.12.076
   WHO, 2015, RAG GLOB C GEN 10 11
   World Health Organization, 2018, VACCINE
   World Health Organization, 2018, TECHNICAL REPORT SER, V1012
   Zhugunissov K, 2017, ARCH VIROL, V162, P3363, DOI 10.1007/s00705-017-3499-6
NR 50
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A77
EP A84
DI 10.1016/j.vaccine.2019.01.015
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500013
PM 30685249
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rysava, K
   Miranda, ME
   Zapatos, R
   Lapiz, S
   Rances, P
   Miranda, LM
   Roces, MC
   Friar, J
   Townsend, SE
   Hampson, K
AF Rysava, K.
   Miranda, M. E.
   Zapatos, R.
   Lapiz, S.
   Rances, P.
   Miranda, L. M.
   Roces, M. C.
   Friar, J.
   Townsend, S. E.
   Hampson, K.
TI On the path to rabies elimination: The need for risk assessments to
   improve administration of post-exposure prophylaxis
SO VACCINE
LA English
DT Article
DE Post-exposure vaccination; Dog-mediated rabies; Rabies prevention;
   Dose-sparing; Immunoglobulin; Intradermal; Intramuscular; Integrated
   Bite Case Management; IBCM; One Health; Risk assessment; Surveillance;
   Freedom from disease; Verification
ID DOG BITES; SURVEILLANCE
AB Background: Costs of rabies post-exposure prophylaxis (PEP) often remain high in regions where rabies has been controlled in dogs, presenting a challenge for sustaining rabies elimination programmes. We investigated the potential for bite patient risk assessments to improve PEP provision and surveillance in settings approaching elimination of dog-mediated rabies.
   Methods: We conducted a longitudinal study of patients presenting to animal bite treatment centres (ABTCs) on the island province of Bohol in the Philippines to investigate the health status of biting dogs and to quantify current expenditure on PEP.
   Results: Incidence of bite patients presenting to ABTCs was high (>300/100,000 persons/year) and increasing, resulting in substantial health provider costs. Over $142,000 was spent on PEP in 2013 for a population of 1.3 million. From follow up of 3820 bite patients we found that >92% were bitten by healthy dogs (alive 14 days after the bite) and just 1.4% were bitten by probable or confirmed rabid dogs. The status of dogs that bit 6% of patients could not be determined. During the course of investigations of bites by suspect dogs, we were able to obtain samples for case confirmation, identify exposed persons who had not sought PEP as well as in-contact dogs at risk of developing rabies. We calculate that expenditure on PEP could at least be halved through more judicious approaches to provision of PEP, based on the histories of biting animals determined through risk assessments with bite patients.
   Conclusions: We conclude that a One Health approach to surveillance based on Integrated Bite Case Management could improve the sustainability and effectiveness of rabies elimination programmes while also improving patient care by identifying those genuinely in need of lifesaving PEP. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Rysava, K.; Hampson, K.] Univ Warwick, Sch Life Sci, Zeeman Inst Syst Biol & Infect Dis Epidemiol Res, Coventry, W Midlands, England.
   [Rysava, K.; Townsend, S. E.; Hampson, K.] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.
   [Miranda, M. E.] Alumni Fdn Inc, Field Epidemiol Training Program, Quezon City, Philippines.
   [Miranda, M. E.; Miranda, L. M.; Roces, M. C.] Global Alliance Rabies Control Inc, Laguna, Philippines.
   [Zapatos, R.; Rances, P.] Prov Hlth Off, Tagbilaran City, Philippines.
   [Lapiz, S.] Off Prov Veterinarian, Tagbilaran City, Philippines.
   [Miranda, L. M.] Asian Dev Bank, Manila, Philippines.
   [Friar, J.] Wise Monkey Fdn, Washington, DC USA.
RP Hampson, K (reprint author), Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.
EM katie.hampson@glasgow.ac.uk
OI Hampson, Katie/0000-0001-5392-6884
FU Wellcome TrustWellcome Trust [082715/B/07/Z, 095787/Z/11/Z]
FX This work was supported by the Wellcome Trust (082715/B/07/Z and
   095787/Z/11/Z to KH). We are grateful to the Global Alliance for Rabies
   Control, the health and veterinary staff and local communities from
   Bohol Province who participated in this study.
CR Ahmed K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003645
   Amparo ACB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199186
   Bamaiyi PH., 2015, J VET ADV, V5
   Barroga TR, 2018, ZOONOSES PUBLIC HLTH, V65, P805, DOI 10.1111/zph.12502
   Bourhy H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005525
   CUTTS FT, 1993, B WORLD HEALTH ORGAN, V71, P633
   Vilas VJD, 2017, FRONT VET SCI, V4, DOI [10.3389/fvets.2017.00004, 10.3389/fvets.2017.0004]
   Department of Health, 2012, NAT RAB PREV CONTR P
   Etheart MD, 2017, LANCET GLOB HEALTH, V5, pE1017, DOI 10.1016/S2214-109X(17)30321-2
   Fahrion AS, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00103
   Hampson K, 2016, BIORXIV
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Lankester F, 2014, SCIENCE, V345, P1562, DOI 10.1126/science.1256306
   Lapiz SMD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001891
   Lechenne Monique, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2030043
   Lee HS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194943
   Lembo T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000626
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Medley AM, 2017, TROP MED INFECT DIS, V2
   Miranda LM, 2017, TRANSBOUND EMERG DIS, V64, P121, DOI 10.1111/tbed.12350
   Murphy Trudy V., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Vigilato MAN, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0143
   Nel LH, 2013, EMERG INFECT DIS, V19, P529, DOI 10.3201/eid1904.120185
   PHE, 2014, RAB RISK ASS POST TR
   Rabies WHO, 2018, WEEKLY EPIDEMIOL REC, V16, P201
   Rajeev M, 2019, VACCINE, V37, pA35, DOI 10.1016/j.vaccine.2018.11.011
   Suseno PP, 2012, INT C EM INF DIS
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Tenzin, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001391
   Tepsumethanon Veera, 2005, Journal of the Medical Association of Thailand, V88, P419
   Tohma K, 2016, INFECT GENET EVOL, V38, P22, DOI 10.1016/j.meegid.2015.12.001
   Townsend SE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002372
   Townsend SE, 2013, COMP IMMUNOL MICROB, V36, P249, DOI 10.1016/j.cimid.2012.10.008
   Undurraga EA, 2017, AM J TROP MED HYG, V96, P1307, DOI 10.4269/ajtmh.16-0785
   Valenzuela LM, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00054
   Vitasek J, 2004, VET MED-CZECH, V49, P171, DOI 10.17221/5692-VETMED
   Wertheim HFL, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000044
   WHO, 2005, MAK SURV WORK MOD 1
   WHO, 2014, 6 M INT COORD GROUP
   WHO Expert Consultation on Rabies, 2018, WHO TECHN REP SER, V1012
   Windiyaningsih Caecilia, 2004, Journal of the Medical Association of Thailand, V87, P1389
   Zinsstag J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6984
NR 43
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A64
EP A72
DI 10.1016/j.vaccine.2018.11.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500011
PM 30573356
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Sparrow, E
   Torvaldsen, S
   Newall, AT
   Wood, JG
   Sheikh, M
   Kieny, MP
   Abela-Ridder, B
AF Sparrow, Erin
   Torvaldsen, Siranda
   Newall, Anthony T.
   Wood, James G.
   Sheikh, Mohamud
   Kieny, Marie Paule
   Abela-Ridder, Bernadette
TI Recent advances in the development of monoclonal antibodies for rabies
   post exposure prophylaxis: A review of the current status of the
   clinical development pipeline
SO VACCINE
LA English
DT Review
DE Rabies Monoclonal antibodies; Post-exposure prophylaxis; Passive
   immunization; lmmunoglobulins; Research and development
ID POSTEXPOSURE PROPHYLAXIS; VIRUS; SAFETY; IMMUNOGENICITY; COMBINATION;
   VACCINE; IMMUNOGLOBULIN; PREVENTION; GLOBULIN; SERUM
AB Despite successful control in many parts of the world, rabies virus continues to result in tens of thousands of deaths each year. Death from rabies can be prevented by timely and appropriate post exposure prophylaxis including wound cleaning and administration of vaccine and rabies immunoglobulin. Currently, rabies immunoglobulin is derived from the blood plasma of horses or humans and has several limitations relating to supply, cost and quality. Monoclonal antibodies produced through recombinant DNA technologies could potentially overcome these limitations. The first anti-rabies monoclonal antibody has recently gained regulatory approval in India and there are several other candidates being evaluated in clinical trials. Given the advances in the field, rabies monoclonal antibodies have been recently considered by the World Health Organization's Strategic Advisory Group of Experts on Immunization and included in updated WHO immunization policy recommendations for rabies published in April 2018. This article reviews the current landscape of the clinical trial development of anti-rabies monoclonal antibodies and the historical clinical trial pathways followed for blood-derived rabies immunoglobulin before discussing challenges in the clinical evaluation, regulatory approval, uptake and monitoring of these products. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Sparrow, Erin; Abela-Ridder, Bernadette] WHO, Geneva, Switzerland.
   [Sparrow, Erin; Torvaldsen, Siranda; Newall, Anthony T.; Wood, James G.; Sheikh, Mohamud] UNSW Sydney, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [Torvaldsen, Siranda] Univ Sydney, Clin & Populat Perinatal Hlth Res, Northern Clin Sch, Sydney, NSW, Australia.
   [Kieny, Marie Paule] INSERM, Paris, France.
RP Sparrow, E (reprint author), WHO, Geneva, Switzerland.
EM sparrowe@who.int
OI Wood, James/0000-0002-0122-4482; Newall, Anthony/0000-0003-0836-1065;
   Sparrow, Erin/0000-0003-3912-2550
FU European UnionEuropean Union (EU)
FX This document was produced with the financial assistance of the European
   Union. The views expressed herein can in no way be taken to reflect the
   official opinion of the European Union.
CR Aniwth Huluvadi S, 2018, INDIAN J COMMUNITY H, V30
   [Anonymous], 2017, BAKCGR PAP PROP REV
   [Anonymous], 2017, WHO M MON ANT RAB EV
   [Anonymous], 2017, WKLY EPIDEMIOL REC, V92, P729
   [Anonymous], 1990, REP 6 WHO CONS MON 2, P6
   [Anonymous], 2002, WHO CONS RAB MON ANT
   [Anonymous], 2007, REP CONS M
   AOKI FY, 1989, J BIOL STAND, V17, P91, DOI 10.1016/0092-1157(89)90032-2
   Bakker ABH, 2008, VACCINE, V26, P5922, DOI 10.1016/j.vaccine.2008.08.050
   Bakker ABH, 2005, J VIROL, V79, P9062, DOI 10.1128/JVI.79.14.9062-9068.2005
   BALTAZARD M, 1955, Bull World Health Organ, V13, P747
   Both L, 2012, LANCET INFECT DIS, V12, P397, DOI 10.1016/S1473-3099(11)70340-1
   Bourhy H, 2009, EUROSURVEILLANCE, V14
   Chao TY, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006133
   Conn P. Michael, ANIMAL MODELS STUDY, P938
   De Benedictis P, 2016, EMBO MOL MED, V8, P407, DOI 10.15252/emmm.201505986
   de Carvalho MF, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006271
   Franka R, 2017, TROP MED INFECT DIS, V2
   Freuling CM, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0142
   Gholami A.F.A., 2014, J MED MICROBIOL INFE, V2, P1
   Gogtay N, 2012, VACCINE, V30, P7315, DOI 10.1016/j.vaccine.2012.09.027
   Gogtay NJ, 2017, CLIN INFECT DIS
   Goudsmit J, 2006, J INFECT DIS, V193, P796, DOI 10.1086/500470
   HABEL K, 1955, Bull World Health Organ, V13, P773
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hanlon CA, 2001, VACCINE, V19, P3834, DOI 10.1016/S0264-410X(01)00135-9
   Kelley B, 2009, MABS-AUSTIN, V1, P443, DOI 10.4161/mabs.1.5.9448
   Khawplod P, 2002, CLIN INFECT DIS, V35, P1562, DOI 10.1086/344954
   Kreindel SM, 1998, PUBLIC HEALTH REP, V113, P247
   Kuzmina NA, 2013, J ANTIVIR ANTIRETROV, V5, P2, DOI DOI 10.4172/JAA.1000061
   Lang J, 1998, BIOLOGICALS, V26, P7, DOI 10.1006/biol.1997.0117
   Lang J, 1998, ACTA TROP, V70, P317, DOI 10.1016/S0001-706X(98)00038-2
   LIN FT, 1988, REV INFECT DIS, V10, pS766
   Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8
   Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363
   Marissen WE, 2005, J VIROL, V79, P4672, DOI 10.1128/JVI.79.8.4672-4678.2005
   Muller T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000542
   Nagarajan T, 2014, ANTIBODY TECHNOL J, V4, P1, DOI DOI 10.2147/ANTI.S33533
   Nigg AJ, 2009, PHARMACOTHERAPY, V29, P1182, DOI 10.1592/phco.29.10.1182
   SELIMOV MA, 1978, ZH MIKROB EPID IMMUN, P105
   Tenzin, 2012, VACCINE, V31, P260, DOI 10.1016/j.vaccine.2012.05.023
   The Clinical Trials Registry India (CTRI), CTRI201707009038
   The Clinical Trials Registry India (CTRI), CTRI201506005838
   The Clinical Trials Registry India (CTRI), CTRI201110002060
   Warrell MJ, 2012, TRAVEL MED INFECT DI, V10, P1, DOI 10.1016/j.tmaid.2011.12.005
   WHO, 2018, WEEKLY EPIDEMIOLOGIC, P12
   WHO, 2015, GLOB EL DOG MED HUM
   Wilde H, 2002, CLIN INFECT DIS, V34, P477, DOI 10.1086/324628
NR 48
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A132
EP A139
DI 10.1016/j.vaccine.2018.11.004
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500021
PM 30503659
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sreenivasan, N
   Li, A
   Shiferaw, M
   Tran, CH
   Wallace, R
   Blanton, J
   Knopf, L
   Abela-Ridder, B
   Hyde, T
   Siddiqi, UR
   Tahmina, S
   Penjor, K
   Sovann, L
   Doeurn, Y
   Sim, K
   Houssiere, V
   Tejiokem, M
   Mindekem, R
   Yu, L
   Wenwu, Y
   Benie, J
   Tetchi, M
   Tiembre, I
   Deressa, A
   Haile, A
   Hurisa, B
   Yawson, NA
   Ohene, SA
   Sudarshan, MK
   Narayana, A
   Mwatondo, A
   Thumbi, SM
   Edosoa, G
   Baril, L
   Ramiandrasoa, R
   Rajeev, M
   Fofana, MS
   Traore, A
   Matchaya, M
   Bailey, JLB
   Yale, G
   Dolgorkhand, A
   Tsogbadrakh, N
   Ochirpurev, A
   Shrestha, K
   Balami, J
   Qureshi, H
   Salahuddin, N
   Villalon, E
   Blumberg, L
   Gunesekara, A
   Changalucha, J
   Nguyen, H
AF Sreenivasan, N.
   Li, A.
   Shiferaw, M.
   Tran, C. H.
   Wallace, R.
   Blanton, J.
   Knopf, L.
   Abela-Ridder, B.
   Hyde, T.
   Siddiqi, U. R.
   Tahmina, S.
   Penjor, K.
   Sovann, L.
   Doeurn, Y.
   Sim, K.
   Houssiere, V
   Tejiokem, M.
   Mindekem, R.
   Yu, L.
   Wenwu, Y.
   Benie, J.
   Tetchi, M.
   Tiembre, I
   Deressa, A.
   Haile, A.
   Hurisa, B.
   Yawson, N. A.
   Ohene, S. A.
   Sudarshan, M. K.
   Narayana, A.
   Mwatondo, A.
   Thumbi, S. M.
   Edosoa, G.
   Baril, L.
   Ramiandrasoa, R.
   Rajeev, M.
   Fofana, M. S.
   Traore, A.
   Matchaya, M.
   Bailey, J. L. Burdon
   Yale, G.
   Dolgorkhand, A.
   Tsogbadrakh, N.
   Ochirpurev, A.
   Shrestha, K.
   Balami, J.
   Qureshi, H.
   Salahuddin, N.
   Villalon, E.
   Blumberg, L.
   Gunesekara, A.
   Changalucha, Joel
   Nguyen, H.
CA Working Grp Rabies PEP Logistics
TI Overview of rabies post-exposure prophylaxis access, procurement and
   distribution in selected countries in Asia and Africa, 2017-2018
SO VACCINE
LA English
DT Article
DE Human rabies; Rabies post-exposure prophylaxis; Rabies vaccine access
ID INACTIVATED POLIOVIRUS VACCINE
AB Background: Rabies is a neglected zoonotic disease with a global burden of approximately 59,000 human deaths a year. Once clinical symptoms appear, rabies is almost invariably fatal; however, with timely and appropriate post-exposure prophylaxis (PEP) consisting of wound washing, vaccine, and in some cases rabies immunoglobulin (RIG), the disease is almost entirely preventable. Access to PEP is limited in many countries, and when available, is often very expensive.
   Methods: We distributed a standardized assessment tool electronically to a convenience sample of 25 low- and middle-income countries in Asia and Africa to collect information on rabies PEP procurement, forecasting, distribution, monitoring and reporting. Information was collected from national rabies focal points, focal points at the World Health Organization (WHO) country offices, and others involved in procurement, logistics and distribution of PEP. Because RIG was limited in availability or unavailable in many countries, the assessment focused on vaccine. Data were collected between January 2017 and May 2018.
   Results: We received responses from key informants in 23 countries: 11 countries in Asia and 12 countries in Africa. In 9 of 23 (39%) countries, rabies vaccine was provided for free in the public sector and was consistently available. In 10 (43%) countries, all or some patients were required to pay for the vaccine in the public sector, with the cost of a single dose ranging from US$ 6.60 to US$ 20/dose. The primary reason for the high cost of the vaccine for patients was a lack of funding at the central level to subsidize vaccine costs. In the remaining 4 (17%) countries, vaccine was provided for free but was often unavailable so patients were required to purchase it instead. The majority of countries used the intramuscular route for vaccine administration and only 5 countries exclusively used the dose-sparing intradermal (ID) route. Half (11/22; 50%) of all countries assessed had a standardized distribution system for PEP, separate from the systems used for routine childhood vaccines, and almost half used separate storage facilities at both central and health facility levels. Approximately half (9/22; 41%) of all countries assessed reported having regular weekly, monthly or quarterly reporting on rabies vaccination.
   Conclusions: While all countries in our assessment had rabies vaccines available in the public sector to some extent, barriers to access include the high cost of the vaccine to the government as well as to patients. Countries should be encouraged to use ID administration as this would provide access to rabies vaccine for many more people with the same number of vaccine vials. In addition, standardized monitoring and reporting of vaccine utilization should be encouraged, in order to improve data on PEP needs. (C) 2019 Published by Elsevier Ltd.
C1 [Sreenivasan, N.; Shiferaw, M.; Tran, C. H.; Wallace, R.; Blanton, J.; Hyde, T.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Li, A.] PHI CDC Global Hlth Fellowship, Atlanta, GA USA.
   [Li, A.] ASPPH CDC Allen Rosenfield Global Hlth Fellowship, Atlanta, GA USA.
   [Knopf, L.; Abela-Ridder, B.] WHO, Geneva, Switzerland.
   [Siddiqi, U. R.; Tahmina, S.] Directorate Gen Hlth Serv, Dis Control Unit, Communicable Dis Control, Dhaka, Bangladesh.
   [Penjor, K.] Minist Hlth, Dept Med Serv, Dewathang Mil Hosp, Thimphu, Bhutan.
   [Sovann, L.; Doeurn, Y.; Sim, K.] Minist Hlth, Communicable Dis Control Dept, Phnom Penh, Cambodia.
   [Houssiere, V] WHO, Phnom Penh, Cambodia.
   [Tejiokem, M.] Ctr Pasteur Cameroun, Yaounde, Cameroon.
   [Mindekem, R.] Minist Sante Publ, Ndjamena, Chad.
   [Yu, L.; Wenwu, Y.] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Benie, J.; Tetchi, M.; Tiembre, I] Inst Natl Hyg Publ Cote DIvoire, Abidjan, Cote Ivoire.
   [Deressa, A.; Haile, A.; Hurisa, B.] Ethiopian Publ Hlth Inst, Addis Ababa, Ethiopia.
   [Yawson, N. A.] Minist Hlth, Accra, Ghana.
   [Ohene, S. A.] WHO, Accra, Ghana.
   [Sudarshan, M. K.] APCRI, Bangalore, Karnataka, India.
   [Narayana, A.] KIMS, Dept Community Med, Bangalore, Karnataka, India.
   [Mwatondo, A.] Minist Hlth, Zoonot Dis Unit, Nairobi, Kenya.
   [Thumbi, S. M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
   [Thumbi, S. M.] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Edosoa, G.] Minist Sante Publ, Antananarivo, Madagascar.
   [Baril, L.; Ramiandrasoa, R.] Inst Pasteur Madagascar, Antananarivo, Madagascar.
   [Rajeev, M.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Fofana, M. S.] Direct Natl Sante, Bamako, Mali.
   [Traore, A.] Lab Cent Vet, Bamako, Mali.
   [Matchaya, M.] Minist Hlth, Lilongwe, Malawi.
   [Bailey, J. L. Burdon; Yale, G.] Mission Rabies, Cranborne, England.
   [Dolgorkhand, A.] Minist Hlth, Ulan Bator, Mongolia.
   [Tsogbadrakh, N.] Natl Ctr Zoonot Dis, Ulan Bator, Mongolia.
   [Ochirpurev, A.] WHO, Ulan Bator, Mongolia.
   [Shrestha, K.] Himalayan Coll Agr Sci & Technol, Kathmandu, Nepal.
   [Balami, J.] Fed Minist Hlth, Dept Publ Hlth, Abuja, Nigeria.
   [Qureshi, H.] Pakistan Hlth Res Council, Islamabad, Pakistan.
   [Salahuddin, N.] Indus Hosp, Karachi, Pakistan.
   [Villalon, E.] Dept Hlth, Natl Rabies Prevent & Control Program, Manila, Philippines.
   [Blumberg, L.] Natl Inst Communicable Dis, Ctr Emerging Zoonot & Parasit Dis, Johannesburg, South Africa.
   [Gunesekara, A.] Minist Hlth, Colombo, Sri Lanka.
   [Changalucha, Joel] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Nguyen, H.] Minist Hlth, Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
RP Sreenivasan, N (reprint author), Global Immunizat Div, 1600 Clifton Rd NE,Mailstop H24-2, Atlanta, GA 30333 USA.
EM vii2@cdc.gov
RI Penjor, Kinley/AAF-1023-2020
OI Penjor, Kinley/0000-0001-9529-4096; Glenn, Edosoa/0000-0002-5301-5906;
   Knopf, Lea/0000-0001-5927-5285; Rajeev, Malavika/0000-0001-6030-4995;
   Changalucha, Joel/0000-0003-0758-2480
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U360E000002]; Association of Schools and Programs of Public Health
   (ASPPH); Public Health Institute (PHI); CDCUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [NU2GGH002093-01-00]
FX This publication was supported by Cooperative Agreement Number
   U360E000002 from the Centers for Disease Control and Prevention (CDC)
   and the Association of Schools and Programs of Public Health (ASPPH) and
   NU2GGH002093-01-00 from the CDC and the Public Health Institute (PHI).
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the CDC, the Department of
   Health and Human Services, ASPPH, or PHI.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   [Anonymous], 2015, LANCET, V386, P2446, DOI 10.1016/S0140-6736(15)01287-8
   [Anonymous], 2013, 982 WHO
   Estivariz CF, 2017, J INFECT DIS, V216, pS122, DOI 10.1093/infdis/jiw510
   Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91
   Gavi, 2013, HIST VACCINE INVESTM
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Lavan RP, 2017, VACCINE, V35, P1668, DOI 10.1016/j.vaccine.2017.02.014
   Okayasu H, 2017, J INFECT DIS, V216, pS161, DOI 10.1093/infdis/jix038
   Pervaiz A, 2017, MMWR-MORBID MORTAL W, V66, P1295, DOI 10.15585/mmwr.mm6647a4
   Salahuddin N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004448
   Sambo M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002510
   Shiferaw ML, 2017, EMERG INFECT DIS, V23, pS71, DOI 10.3201/eid2313.170601
   Sudarshan MK, 2006, NATL MED J INDIA, V19, P192
   WHO, 2018, WHO PREQ VACC
   WHO, 2017, BACKGR PAP PROP REV
   Wilde H, 2017, VACCINE, V35, P2293, DOI 10.1016/j.vaccine.2017.03.001
   World Health Organization, 2018, 1012 WHO
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A6
EP A13
DI 10.1016/j.vaccine.2019.04.024
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500004
PM 31471150
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tarantola, A
   Tejiokem, MC
   Briggs, DJ
AF Tarantola, Arnaud
   Tejiokem, Mathurin Cyrille
   Briggs, Deborah J.
TI Evaluating new rabies post-exposure prophylaxis (PEP) regimens or
   vaccines
SO VACCINE
LA English
DT Review
DE Rabies vaccines; Post-exposure prophylaxis; IPC PEP regimen; Vaccine
   evaluation
ID ANTIBODY-RESPONSE; ANTIRABIES VACCINE; CELL VACCINE; IMMUNIZATION;
   SCHEDULE; DESIGN; SAFETY; IMMUNOGENICITY; IMMUNOGLOBULIN; ELIMINATION
AB The development of human rabies vaccines has evolved dramatically from the first crude nerve tissue vaccine produced then administered in the presence of Louis Pasteur in 1885. New cell culture technology has enabled highly potent and well-tolerated rabies vaccines to be produced that have reduced the volume and number of doses required to save human lives after exposure. However, these highly potent vaccines are still unaffordable to many patients living at risk of exposure on a daily basis. The cost of post-exposure prophylaxis (PEP) is not only related to the direct cost of rabies biologicals and equipment but is also associated with indirect costs that patients incur as a result of travel, loss of work time (income loss), and accommodation over the period of time that a PEP regimen requires to be completed. This paper summarizes the particular criteria that the SAGE Working Group and WHO personnel reviewed as part of the evaluation process for recommending the new one-week intradermal vaccination regimen (2-2-2-0-0) for rabies post-exposure prophylaxis. These criteria included: Cost-effectiveness; evaluation of number of doses; seroconversion after vaccination; efficacy; safety; and patient follow-up. (C) 2018 Published by Elsevier Ltd.
C1 [Tarantola, Arnaud] Inst Pasteur Nouvelle Caledonie, Unite Epidemiol, Noumea, New Caledonia.
   [Tejiokem, Mathurin Cyrille] Ctr Pasteur Cameroun, Serv Epidemiol & Sante Publ, Yaounde, Cameroon.
   [Briggs, Deborah J.] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
RP Briggs, DJ (reprint author), Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
EM atarantola@pasteur.nc; tejiokem@pasteur-yaounde.org; briggs@vet.ksu.edu
RI Tarantola, Arnaud/D-2149-2015
OI Tarantola, Arnaud/0000-0002-6946-7958
CR Abazeed ME, 2007, EMERG INFECT DIS, V13, P1966, DOI 10.3201/eid1312.070157
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P425
   [Anonymous], 1984, WHO TECH REP SER, P1
   [Anonymous], 2017, REPL ANN 1 WHO TECHN, V924, P1
   [Anonymous], 2018, GUID CLIN EV VACC, P1
   [Anonymous], 2017, WHO TECHN REP SER, V924, P503
   [Anonymous], 2017, IEEE T POWER SYSTEMS, VPP, P1, DOI DOI 10.13155/46607
   [Anonymous], 2018, WHO EXP CONS RAB 3 R, P183
   ARYA SC, 1990, VACCINE, V8, P410, DOI 10.1016/0264-410X(90)90123-4
   BERNARD KW, 1985, AM J TROP MED HYG, V34, P633
   Briggs DJ, 2000, B WORLD HEALTH ORGAN, V78, P693
   Brown D, 2011, ADV PREV MED, V2011
   Brown D, 2008, VACCINE, V26, P3909, DOI 10.1016/j.vaccine.2008.04.081
   Chu Haitao, 2004, Clin Trials, V1, P306, DOI 10.1191/1740774504cn025oa
   CHUTIVONGSE S, 1990, LANCET, V335, P896, DOI 10.1016/0140-6736(90)90488-Q
   Concato J, 2013, AM J RESP CRIT CARE, V187, P1167, DOI 10.1164/rccm.201303-0521OE
   D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425
   Dacheux Laurent, 2011, Infectious Disorders - Drug Targets, V11, P251
   Dietzschold B, 2008, FUTURE VIROL, V3, P481, DOI 10.2217/17460794.3.5.481
   Duong V, 2016, INT J INFECT DIS, V46, P107, DOI 10.1016/j.ijid.2016.03.016
   Elser JL, 2018, TRANSBOUND EMERG DIS, V65, P135, DOI 10.1111/tbed.12637
   FUENZALIDA E, 1972, B WORLD HEALTH ORGAN, V46, P561
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hur K, 2002, HLTH SERVICES OUTCOM, V1, P5, DOI DOI 10.1023/A:1021594923546
   Kammer AR, 2002, HYBRIDOMA HYBRIDOM, V21, P123, DOI 10.1089/153685902317401726
   Kamoltham Thavatchai, 2011, Adv Prev Med, V2011, P403201, DOI 10.4061/2011/403201
   Khawplod P, 2006, VACCINE, V24, P3084, DOI 10.1016/j.vaccine.2006.01.051
   Lang J, 2009, J TROP PEDIATRICS, V55, P26, DOI 10.1093/tropej/fmm100
   Lie RK, 2004, J MED ETHICS, V30, P190, DOI 10.1136/jme.2003.006031
   MADHUSUDANA SN, 1988, INDIAN J MED RES, V87, P1
   Mauri L, 2017, NEW ENGL J MED, V377, P1357, DOI 10.1056/NEJMra1510063
   McMillan JR, 2004, J MED ETHICS, V30, P204, DOI 10.1136/jme.2002.001263
   Millum J, 2013, CONTEMP CLIN TRIALS, V36, P510, DOI 10.1016/j.cct.2013.09.003
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101
   Peng J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005049
   Ramos JM, 2015, ANN AGR ENV MED, V22, P76, DOI 10.5604/12321966.1141372
   Ravish HS, 2014, HUM VACC IMMUNOTHER, V10, P319, DOI 10.4161/hv.26756
   Ren JP, 2015, CLIN VACCINE IMMUNOL, V22, P1, DOI 10.1128/CVI.00531-14
   Rupprecht Charles, 2017, F1000Res, V6, P184, DOI 10.12688/f1000research.10416.1
   Rupprecht Charles E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Rupprecht CE, 2009, VACCINE, V27, P7141, DOI 10.1016/j.vaccine.2009.09.029
   Sampath G, 2017, HUM VACC IMMUNOTHER, P1
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Shi JF, 2010, VACCINE, V28, P2573, DOI [10.1016/j.vaccine.2010.08.082, 10.1016/j.vaccine.2010.01.051]
   Shwiff SA, 2016, TRANSBOUND EMERG DIS, V63, P408, DOI 10.1111/tbed.12283
   Strady C, 2009, T ROY SOC TROP MED H, V103, P1159, DOI 10.1016/j.trstmh.2009.03.007
   Sudarshan M K, 1999, Indian J Public Health, V43, P76
   Sudarshan MK, 2012, HUM VACC IMMUNOTHER, V8, P1077, DOI 10.4161/hv.20471
   Suraweera W, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001847
   Suwansrinon K, 2006, VACCINE, V24, P3878, DOI 10.1016/j.vaccine.2006.02.027
   Tarantola A, 2019, VACCINE, V37, pA118, DOI 10.1016/j.vaccine.2018.10.054
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tarantola Arnaud, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2020005
   Tarantola A, 2016, TROP MED INT HEALTH, V21, P564, DOI 10.1111/tmi.12670
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   TAYLOR DN, 1984, LANCET, V1, P1405
   VODOPIJA I, 1988, VACCINE, V6, P283, DOI 10.1016/0264-410X(88)90225-3
   Wang J, 2017, HUM VACC IMMUNOTHER, V13, P144, DOI 10.1080/21645515.2016.1230260
   Warrell MJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000224
   WARRELL MJ, 1985, LANCET, V1, P1059
   WHO, 2005, WHO TECH REP SER, V931, P1
   WHO, 2013, WHO TECH REP SER, V982, P1
   Wu XF, 2011, EXPERT REV VACCINES, V10, P1597, DOI [10.1586/erv.11.140, 10.1586/ERV.11.140]
   Zhang XW, 2011, CLIN VACCINE IMMUNOL, V18, P1477, DOI 10.1128/CVI.05090-11
   2018, WKLY EPIDEMIOL REC, V16, P201
NR 67
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A88
EP A93
DI 10.1016/j.vaccine.2018.10.103
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500015
PM 30471958
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tarantola, A
   Ly, S
   Chan, M
   In, S
   Peng, Y
   Hing, C
   Taing, CN
   Phoen, C
   Ly, S
   Cauchemez, S
   Buchy, P
   Dussart, P
   Bourhy, H
   Mary, JY
AF Tarantola, Arnaud
   Ly, Sowath
   Chan, Malen
   In, Sotheary
   Peng, Yiksing
   Hing, Chanthy
   Taing, Chun Navy
   Phoen, Chandara
   Ly, Sovann
   Cauchemez, Simon
   Buchy, Philippe
   Dussart, Philippe
   Bourhy, Herve
   Mary, Jean-Yves
TI Intradermal rabies post-exposure prophylaxis can be abridged with no
   measurable impact on clinical outcome in Cambodia, 2003-2014
SO VACCINE
LA English
DT Article
DE Rabies; Post-exposure prophylaxis; Survival; Intradermal; Abridged
   regimens, Vaccine
ID DOG BITES; VACCINE; IMMUNOGENICITY; REGIMEN
AB Rabies causes 60,000 deaths worldwide annually. Rabies post-exposure prophylaxis is highly effective but often geographically and financially beyond reach in endemic developing countries. We conducted a retrospective study on clinical outcome at >= 6 months in 3318 Cambodians who received intradermal Vero cell vaccine post-exposure prophylaxis after a bite by a rabid or sick-looking but untested dog in 2003-2014. An external expert panel examined verbal autopsy reports to identify rabies deaths. 1739 (93.65%) persons bitten by rabid- and 1066 (72.96%) bitten by sick-looking but untested dogs were traced and 513 were lost to follow-up. Among the former, 1591 (91.49%) and 129 (7.42%) patients referred for 4+ and 3 post-exposure prophylaxis sessions, respectively. Three persons died of probable rabies so that the overall percentage of survival was 99.83% (95% exact confidence interval: 99.49-99.96%) in post-exposure prophylaxis recipients bitten by confirmed rabid dogs. No significant difference was found in survival among patients who received 3 vs. 4+ sessions (with or without rabies immunoglobin). The power of the study, however, was limited. The current four sessions/one month intradermal regimen can be reduced to a three sessions/one week at no detectable added risk to patients, with the limitation of study power at 49%. A clinical follow-up system should be adopted by rabies prevention centers, especially to monitor implementation of an abridged course. The Institut Pasteur in Cambodia regimen will improve vaccine equity by treating 33% more patients with available doses, reduce direct cost of vaccination, transportation and other indirect costs to vaccinees. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Tarantola, Arnaud; Ly, Sowath; Chan, Malen; In, Sotheary; Peng, Yiksing; Hing, Chanthy; Taing, Chun Navy; Phoen, Chandara] Inst Pasteur Cambodge, Epidemiol & Publ Hlth Unit, 5 Bvd Monivong,BP 983, Phnom Penh, Cambodia.
   [Tarantola, Arnaud] Inst Pasteur Nouvelle Caledonie, Epidemiol Unit, Noumea, New Caledonia.
   [Ly, Sovann] Minist Hlth, Ctr Communicable Dis Control, Phnom Penh, Cambodia.
   [Cauchemez, Simon] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Math Modelling Infect Dis Unit, CNRS,UMR2000 Genom Evolut Modelisat & Sante GEMS, F-75015 Paris, France.
   [Buchy, Philippe] GlaxoSmithKline, Vaccines R&D, Singapore, Singapore.
   [Dussart, Philippe] Inst Pasteur Cambodge, Virol Unit, Phnom Penh, Cambodia.
   [Bourhy, Herve] WHO Collaborating Ctr Reference & Res Rabies, Inst Pasteur, Lyssavirus Dynam & Host Adaptat Unit, Paris, France.
   [Mary, Jean-Yves] Univ Paris Diderot Paris 7, INSERM, Ctr Rech Epidemiol & Stat, Sorbonne Paris Cite,Hop St Louis,UMR 1153, Paris, France.
RP Tarantola, A (reprint author), Inst Pasteur Cambodge, Epidemiol & Publ Hlth Unit, 5 Bvd Monivong,BP 983, Phnom Penh, Cambodia.
EM arnaud.tarantola@pasteur.fr
RI Tarantola, Arnaud/D-2149-2015; Dussart, Philippe/P-4152-2014
OI Tarantola, Arnaud/0000-0002-6946-7958; Dussart,
   Philippe/0000-0002-1931-3037
FU Institut Pasteur
FX Institut Pasteur.
CR AGRESTI A, 1992, STAT SCI, V7, P131, DOI DOI 10.1214/SS/1177011454
   ANDERSON LJ, 1984, ANN INTERN MED, V100, P728, DOI 10.7326/0003-4819-100-5-728
   Asian Development Bank, CAMBODIA COUNTRY POV
   Chandramohan D, 1998, TROP MED INT HEALTH, V3, P436, DOI 10.1046/j.1365-3156.1998.00255.x
   Department of Measurement and Health Information Systems, 2004, WHO TECHN CONS VERB, P45
   Dimaano EM, 2011, INT J INFECT DIS, V15, pE495, DOI 10.1016/j.ijid.2011.03.023
   Dodet B, 2009, VACCINE, V27, P5027, DOI [10.1016/j.vaccine.2009.06.030, 10.1016/j.vaccine.2009.02.012]
   Duong V, 2016, INT J INFECT DIS, V46, P107, DOI 10.1016/j.ijid.2016.03.016
   Giesen A, 2015, EXPERT REV VACCINES, V14, P351, DOI 10.1586/14760584.2015.1011134
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   HIRJI KF, 1991, STAT MED, V10, P1137, DOI 10.1002/sim.4780100713
   Khawplod P, 2002, CLIN INFECT DIS, V35, P1562, DOI 10.1086/344954
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Narayana A, 2015, HUM VACC IMMUNOTHER, V11, P1748, DOI 10.1080/21645515.2015.1048938
   National Institute of Statistics/Cambodia, 2015, CAMB DEM HLTH SURV 2
   Ponsich A, 2016, ACTA TROP, V160, P62, DOI 10.1016/j.actatropica.2016.04.015
   Putra AAG, 2013, EMERG INFECT DIS, V19, P648, DOI 10.3201/eid1904.120380
   Quiambao BP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000243
   Quiambao BP, 2005, VACCINE, V23, P1709, DOI 10.1016/j.vaccine.2004.09.027
   Ren JP, 2015, CLIN VACCINE IMMUNOL, V22, P1, DOI 10.1128/CVI.00531-14
   Robertson K, 2010, VACCINE, V28, P6523, DOI 10.1016/j.vaccine.2010.06.102
   Salahuddin N, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004448
   Shantavasinkul P, 2010, CLIN INFECT DIS, V50, P56, DOI 10.1086/649211
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tarantola Arnaud, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2020005
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Tohma K, 2016, INFECT GENET EVOL, V38, P22, DOI 10.1016/j.meegid.2015.12.001
   Toovey Stephen, 2007, Travel Med Infect Dis, V5, P327, DOI 10.1016/j.tmaid.2007.07.004
   Weyer J, 2016, S AFR J INFECT DIS, V31, P1
   WHO, 2013, WHO TECHN REP SER, V982
   Wilde H, 1996, CLIN INFECT DIS, V22, P228, DOI 10.1093/clinids/22.2.228
   Wilde H, 2007, VACCINE, V25, P7605, DOI 10.1016/j.vaccine.2007.08.054
   Windiyaningsih Caecilia, 2004, Journal of the Medical Association of Thailand, V87, P1389
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 35
TC 7
Z9 7
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A118
EP A127
DI 10.1016/j.vaccine.2018.10.054
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500019
PM 30454946
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Tran, CH
   Afriyie, DO
   Pham, TN
   Otsu, S
   Urabe, M
   Dang, AD
   Tran, HGT
   Nguyen, HV
   Le, H
   Nguyen, HTT
AF Tran, Cuc H.
   Afriyie, Doris O.
   Pham, Thach N.
   Otsu, Satoko
   Urabe, Maho
   Dang, Anh D.
   Tran, Huong G. T.
   Nguyen, Hoang, V
   Le, Ha T.
   Nguyen, Huong T. T.
TI Rabies post-exposure prophylaxis initiation and adherence among patients
   in Vietnam, 2014-2016
SO VACCINE
LA English
DT Article
DE Rabies; Canine; Human; Vaccine; Post-exposure prophylaxis;
   lmmunoglobulin
ID ANIMAL BITE; DOG BITES; DETERMINANTS; PROVINCE; HAITI
AB Background: Adhering to post-exposure prophylaxis (PEP): wound treatment, vaccine, and rabies immunoglobulin (RIG) is a crucial step in preventing rabies mortality. When PEP is widely available, a lack of adherence to the recommended treatment guidelines can also lead to death. Our objective was to understand characteristics associated with adherence to the vaccine regimen and RIG in Vietnam.
   Methods: We obtained individual-level data on PEP adherence from registries at 10 sites located in five provinces. From these registries, we extracted epidemiologic characteristics of patients including the timing of PEP initiation and completion. We used descriptive analyses and logistic regression to examine patient characteristics associated with initiation and completion of RIG and vaccine. Based on reported rabies mortality, the government defined provincial rabies burden as medium-burden (<5 and >2 deaths) and high-burden (>= 5 deaths).
   Results: During 2014-2016, 15,646 patients received PEP in our study. Among 14,296 vaccinated patients, only 41.4% (5847) completed their five-dose intramuscular (IM) injections and 81.6% (133) of patients completed their eight-dose intradermal (ID) injections. Approximately 26% of patients received RIG. Patient characteristics associated with vaccine completion were females (44%), <15 years of age (44%), category 1 exposure (68%, bite location on leg (46%), bite from bat (56%), bite from a healthy animal (45%), high-burden province (86%), and district preventive center (49%). Disparities were revealed among provinces, with high-burden provinces having highest (86%) and lowest (7%) vaccine completion rates.
   Conclusions and relevance: Vietnam has made tremendous progress towards reducing the burden of rabies. However, despite the wide availability of PEP, we found relatively low rates of vaccine completion. Our findings suggest provider training and patient education is needed to ensure appropriate treatment is completed. Moreover, our data suggest changes to information reported through the national surveillance system for monitoring good clinical practice for rabies prevention and control. Published by Elsevier Ltd.
C1 [Tran, Cuc H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Tran, Cuc H.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Afriyie, Doris O.] US Ctr Dis Control & Prevent Country Off Vietnam, 2 Ngo Quyen, Hanoi, Vietnam.
   [Pham, Thach N.; Dang, Anh D.; Nguyen, Hoang, V; Nguyen, Huong T. T.] Minist Hlth, Natl Inst Hyg & Epidemiol, 1 Yersin St, Hanoi, Vietnam.
   [Otsu, Satoko; Urabe, Maho] WHO, Representat Fice Vietnam, 304 Kim Ma St, Hanoi, Vietnam.
   [Tran, Huong G. T.] Minist Hlth, Int Cooperat Dept, 138A Giang Vo, Hanoi, Vietnam.
   [Le, Ha T.] Hanoi Med Univ, 1 Ton That Tung, Hanoi, Vietnam.
RP Tran, CH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA.
EM ywj0@cdc.gov
FU Gavi Learning Agenda via the WHO Neglected Tropical Diseases Department
FX This funding was supported through the Gavi Learning Agenda via the WHO
   Neglected Tropical Diseases Department.
CR Alabi Olaniran, 2014, Pan Afr Med J, V18 Suppl 1, P12, DOI 10.11694/pamj.supp.2014.18.1.4341
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Esmaeilzadeh Firooz, 2017, J Prev Med Public Health, V50, P210, DOI 10.3961/jpmph.17.027
   Etheart MD, 2017, LANCET GLOB HEALTH, V5, pE1017, DOI 10.1016/S2214-109X(17)30321-2
   Ghannad MS, 2012, ARCH IRAN MED, V15, P356, DOI 012156/AIM.008
   Gongal Gyanendra, 2011, Adv Prev Med, V2011, P383870, DOI 10.4061/2011/383870
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Joseph J, 2013, VACCINE, V32, P74, DOI 10.1016/j.vaccine.2013.10.067
   Kassiri H, 2014, J ACUTE DIS, V3, P51, DOI 10.1016/S2221-6189(14)60011-1
   Khazaei Salman, 2014, Med J Islam Repub Iran, V28, P158
   Kilic B, 2006, INT J INFECT DIS, V10, P248, DOI 10.1016/j.ijid.2005.05.010
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Liu QY, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005663
   Mazigo HD, 2010, J GLOB INFECT DIS, V2, P216, DOI 10.4103/0974-777X.68530
   Ministry of Agriculture and Rural Development (MARD) Ministry of Health (MoH), 2016, NAT PROGR RAB CONTR
   Ogundare EO, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.81.7360
   Tarantola A, 2018, AM J EPIDEMIOL, V187, P306, DOI 10.1093/aje/kwx234
   Tarantola A, 2015, J TRAVEL MED, V22, P348, DOI 10.1111/jtm.12228
   Tenzin, 2011, VACCINE, V29, P4094, DOI 10.1016/j.vaccine.2011.03.106
   Tepsumethanon Saowaluck, 2007, Travel Med Infect Dis, V5, P189, DOI 10.1016/j.tmaid.2006.07.001
   Tiembre I, 1990, B SOC PATHOL EXOT, V2013, P272
   Tran CH, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006955
   Tran CH, 2018, EMERG INFECT DIS, V24, P156, DOI 10.3201/eid2401.161555
   Vietnam Ministry of Health, 2014, GUID HUM RAB SURV PR
   Wallace RM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004245
   Wheelock A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113503
   World Health Organization, 2018, WORLD MAL REP 2018, P1
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 28
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A54
EP A63
DI 10.1016/j.vaccine.2019.01.030
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500010
PM 30723063
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wambura, G
   Mwatondo, A
   Muturi, M
   Nasimiyu, C
   Wentworth, D
   Hampson, K
   Bichanga, P
   Tabu, C
   Juma, S
   Ngere, I
   Thumbi, SM
AF Wambura, Gati
   Mwatondo, Athman
   Muturi, Mathew
   Nasimiyu, Carolyne
   Wentworth, Diorbhail
   Hampson, Katie
   Bichanga, Philet
   Tabu, Collins
   Juma, Samuel
   Ngere, Isaac
   Thumbi, S. M.
TI Rabies vaccine and immunoglobulin supply and logistics: Challenges and
   opportunities for rabies elimination in Kenya
SO VACCINE
LA English
DT Article
DE Rabies; Vaccines; PEP; Immunoglobulins; Kenya
ID CANINE RABIES
AB Prompt provision of post-exposure-prophylaxis (PEP) including vaccines and rabies immunoglobulin (RIG) to persons bitten by suspect rabid dogs is a key strategy to eliminating human deaths from dog-mediated rabies in Kenya by 2030. We assessed the availability, forecasting and supply chain logistics for rabies PEP in Kenya, compared with the system used for vaccines in the expanded program of immunization (routine vaccines). Semi-structured questionnaires capturing data on forecasting, procurement, distribution, cold chain and storage, monitoring and reporting for routine vaccines and rabies vaccines and RIG were administered to 35 key personnel at the national, county, sub-county and health facility levels in five counties. Results showed large variability in PEP availability (stockouts ranged from 3 to 36?weeks per year) with counties implementing rabies elimination activities having shorter stockouts. PEP is administered intramuscularly using the 5-dose Essen regimen (day 0, 3, 7, 14 and 28). PEP costs to bite patients were reported to range from 10 to 15 US dollars per dose; RIG was seldom available. A less robust supply and logistics infrastructure is used for rabies PEP compared to routine vaccines. Forecasting and monitoring mechanisms for rabies PEP was poor in the study counties. The supply of vaccines from the national to the sub-national level is mainly through two government agencies and a private agency. Since government decentralization, the National Vaccine and Immunization Program has remained as the main supplier of the routine vaccines, playing a lesser role in the supply of rabies biologicals. Adoption of the dose-saving intradermal route for PEP administration, reduction of PEP costs to patients, and placing rabies vaccines within the routine vaccines supply and logistics system would significantly improve PEP availability and accessibility to persons at risk of rabies; a critical step to achieving elimination of human deaths from rabies. (C) 2019 Published by Elsevier Ltd.
C1 [Wambura, Gati; Thumbi, S. M.] Kenya Med Inst Res, Ctr Global Hlth Res, Kisumu, Kenya.
   [Mwatondo, Athman; Muturi, Mathew; Nasimiyu, Carolyne] Minist Hlth, Zoonot Dis Unit, Nairobi, Kenya.
   [Mwatondo, Athman; Muturi, Mathew; Nasimiyu, Carolyne] Minist Agr Livestock & Fisheries, Nairobi, Kenya.
   [Wentworth, Diorbhail; Hampson, Katie] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow, Lanark, Scotland.
   [Bichanga, Philet] Minist Hlth, Cty Govt Makueni, Nairobi, Kenya.
   [Tabu, Collins; Juma, Samuel] Minist Hlth, Natl Vaccines & Immunizat Program, Nairobi, Kenya.
   [Ngere, Isaac; Thumbi, S. M.] Washington State Univ, Global Hlth Program, Nairobi, Kenya.
   [Thumbi, S. M.] Washington State Univ, Rabies Free Africa, Pullman, WA 99164 USA.
   [Thumbi, S. M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
RP Thumbi, SM (reprint author), Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
EM thumbi.mwangi@wsu.edu
OI Wambura, Gati/0000-0002-3137-2355; Hampson, Katie/0000-0001-5392-6884
FU Wellcome TrustWellcome Trust [110330/Z/15/Z, 207569/Z/17/Z]; World
   Health OrganizationWorld Health Organization [2017/694169-1]
FX SM Thumbi and K Hampson receive funding support from the Wellcome Trust
   (Grant numbers 110330/Z/15/Z and 207569/Z/17/Z respectively). The World
   Health Organization provided funding support for the study (grant number
   2017/694169-1) under the GAVI learning agenda for rabies.
CR Abela-Ridder B, 2016, LANCET GLOB HEALTH, V4, pE780, DOI 10.1016/S2214-109X(16)30245-5
   Assi TM, 2012, VACCINE, V30, P4517, DOI 10.1016/j.vaccine.2012.04.041
   Bharti OK, 2015, SUCCESS STORY LOW CO, P129
   Bitek A, A HUNDRED YEARS OF R
   Briggs DJ, 2012, CURR OPIN VIROL, V2, P309, DOI 10.1016/j.coviro.2012.03.007
   Cleaveland S, 2018, PROOF OF CONCEPT OF, V37
   Davlin SL, 2012, VACCINE, V30, P3492, DOI 10.1016/j.vaccine.2012.03.069
   Dimaano EM, 2011, INT J INFECT DIS, V15, pE495, DOI 10.1016/j.ijid.2011.03.023
   Dodet B, 2014, VACCINE, V32, P2017, DOI 10.1016/j.vaccine.2013.12.031
   Hampson K, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000339
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Jibat T, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003447
   Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360
   Lankester F, 2014, SCIENCE, V345, P1562, DOI 10.1126/science.1256306
   Lembo T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000626
   Levin A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101114
   Neevel AMG, 2017, ZOONOSES PUBLIC HLTH, P1, DOI [10.1111/zph.12357, DOI 10.1111/ZPH.12357]
   Permpalung N, 2013, VACCINE, V31, P4079, DOI 10.1016/j.vaccine.2013.06.083
   Scott TP, 2015, ANTIVIR RES, V124, P93, DOI 10.1016/j.antiviral.2015.10.002
   Scott TP, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00018
   Wallace RM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004245
   WHO Rabies Modelling Consortium, 2019, POT EFF IMPR PROV RA, V19, DOI [10.1016/S1473-3099(18)30512-7, DOI 10.1016/S1473-3099(18)30512-7]
   Wilde H, 2017, VACCINE, V35, P2293, DOI 10.1016/j.vaccine.2017.03.001
   World Hlth Org, 2018, VACCINE, V36, P5500, DOI 10.1016/j.vaccine.2018.06.061
   ZDU, 2014, STRAT PLAN EL HUM RA
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A28
EP A34
DI 10.1016/j.vaccine.2019.05.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500007
PM 31326251
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Wentworth, D
   Hampson, K
   Thumbi, SM
   Mwatondo, A
   Wambura, G
   Chng, NR
AF Wentworth, Diorbhail
   Hampson, Katie
   Thumbi, Samuel M.
   Mwatondo, Athman
   Wambura, Gati
   Chng, Nai Rui
TI A social justice perspective on access to human rabies vaccines
SO VACCINE
LA English
DT Article
AB Rabies kills tens of thousands of people every year despite being entirely vaccine preventable. Key global health actors have launched a country-driven plan to achieve zero human deaths from dog-mediated rabies by 2030 worldwide. This partnership has recently been strengthened by Gavi, the Vaccine Alliance's decision to invest in human rabies vaccines for post-exposure prophylaxis (PEP). While nation states are key to rabies elimination, the importance of Gavi's role cannot be understated. Unlike any other actor, Gavi can directly address an otherwise intractable market failure in the inadequate supply of rabies PEP. In this commentary, we employ the Capabilities Approach to identify the barriers to PEP access that lead to this market failure and, as a result, unnecessary deaths and suffering. We show the role that Gavi can play in reducing exposure of PEP supply to market forces as a matter of social justice, and hence redress the inequity underlying human rabies deaths. (C) 2019 Published by Elsevier Ltd.
C1 [Wentworth, Diorbhail; Chng, Nai Rui] Univ Glasgow, Coll Social Sci, Inst Hlth & Wellbeing, Glasgow G12 8QQ, Lanark, Scotland.
   [Hampson, Katie] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.
   [Thumbi, Samuel M.; Wambura, Gati] Kenya Med Inst Res, Ctr Global Hlth Res, Kisumu, Kenya.
   [Thumbi, Samuel M.] Washington State Univ, Global Hlth Program, Nairobi, Kenya.
   [Thumbi, Samuel M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.
   [Mwatondo, Athman] Minist Hlth, Zoonot Dis Unit, Nairobi, Kenya.
   [Mwatondo, Athman] Minist Agr Livestock & Fisheries, Nairobi, Kenya.
RP Chng, NR (reprint author), Univ Glasgow, Coll Social Sci, Inst Hlth & Wellbeing, Glasgow G12 8QQ, Lanark, Scotland.
EM nairui.chng@glasgow.ac.uk
OI Wambura, Gati/0000-0002-3137-2355; Hampson, Katie/0000-0001-5392-6884
FU Wellcome TrustWellcome Trust [207569/Z/17/Z, 110330/Z/15/Z]
FX KH and STM are supported by the Wellcome Trust (207569/Z/17/Z and
   110330/Z/15/Z).
CR Acharya AK, 2013, WORLD BANK RES OBSER
   Alkire S, 2004, LANCET, V364, P1069, DOI 10.1016/S0140-6736(04)17063-3
   Changalucha J, 2019, VACCINE, V37, pA45, DOI 10.1016/j.vaccine.2018.08.086
   Cleaveland S, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0168
   Dye C, 2018, SCIENCE, V359, P1337, DOI 10.1126/science.aaq1081
   Hampson K, 2019, VACCINE, V37, pA166, DOI 10.1016/j.vaccine.2018.11.010
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Lankester F, 2014, SCIENCE, V345, P1562, DOI 10.1126/science.1256306
   Li AJ, 2019, VACCINE, V37, pA14, DOI 10.1016/j.vaccine.2018.10.011
   Ly S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000511
   Mindekem R, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00038
   Rajeev M, 2018, VACCINE
   Robeyns I., 2005, J HUMAN DEV, V6, P93, DOI DOI 10.1080/146498805200034266
   Ruger J. P., 2009, HLTH SOCIAL JUSTICE
   Sen A., 1980, TANNER LECT HUMAN VA, VI, P196
   Sen Amartya, 1993, QUALITY LIFE, P30, DOI DOI 10.1093/0198287976.003.0003
   Sofeu CL, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006597
   Tarantola A, 2019, VACCINE, V37, pA118, DOI 10.1016/j.vaccine.2018.10.054
   Tichenor M, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3347
   Waithaka Dennis, 2018, Wellcome Open Res, V3, P2, DOI 10.12688/wellcomeopenres.13393.2
   Wambura G, 2019, VACCINE, V37, pA28, DOI 10.1016/j.vaccine.2019.05.035
   WARRELL MJ, 1983, LANCET, V2, P301
   WHO rabies modeling consortium, 2018, LANCET INFECT DIS, V18, P30512
   World Health Organization, 2018, ZER 30 GLOB STRAT PL
   World Health Organization (WHO), 2018, WKLY EPIDEMIOL REC, V93, P201, DOI DOI 10.1016/J.VACCINE.2010.08.082
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 3
PY 2019
VL 37
SU 1
BP A3
EP A5
DI 10.1016/j.vaccine.2019.01.065
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF8FD
UT WOS:000491619500003
PM 30952501
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Noad, RJ
   Simpson, K
   Fooks, AR
   Hewson, R
   Gilbert, SC
   Stevens, MP
   Hosie, MJ
   Prior, J
   Kinsey, AM
   Entrican, G
   Simpson, A
   Whitty, CJM
   Carroll, MW
AF Noad, Rob J.
   Simpson, Karl
   Fooks, Anthony R.
   Hewson, Roger
   Gilbert, Sarah C.
   Stevens, Mark P.
   Hosie, Margaret J.
   Prior, Joann
   Kinsey, Anna M.
   Entrican, Gary
   Simpson, Andrew
   Whitty, Christopher J. M.
   Carroll, Miles W.
TI UK vaccines network: Mapping priority pathogens of epidemic potential
   and vaccine pipeline developments
SO VACCINE
LA English
DT Article
DE Vaccine; Epidemic; Priority; Pathogen; Outbreak; UKVN
ID EBOLA-VIRUS DISEASE; DOUBLE-BLIND; HEMORRHAGIC-FEVER; HEALTHY-ADULTS;
   OPEN-LABEL; RING VACCINATION; CLINICAL-TRIAL; RENAL SYNDROME;
   SIERRA-LEONE; SAFETY
AB During the 2013-2016 Ebola outbreak in West Africa an expert panel was established on the instructions of the UK Prime Minister to identify priority pathogens for outbreak diseases that had the potential to cause future epidemics. A total of 13 priority pathogens were identified, which led to the prioritisation of spending in emerging diseases vaccine research and development from the UK. This meeting report summarises the process used to develop the UK pathogen priority list, compares it to lists generated by other organisations (World Health Organisation, National Institutes of Allergy and Infectious Diseases) and summarises clinical progress towards the development of vaccines against priority diseases. There is clear technical progress towards the development of vaccines. However, the availability of these vaccines will be dependent on sustained funding for clinical trials and the preparation of clinically acceptable manufactured material during inter-epidemic periods.
C1 [Noad, Rob J.] Royal Vet Coll, Pathobiol & Populat Sci, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.
   [Simpson, Karl] JKS Biosci Ltd, 2 Midanbury Court,44 Midanbury Lane, Southampton SO18 4HF, Hants, England.
   [Fooks, Anthony R.] Anim & Plant Hlth Agcy, Weybridge, Surrey, England.
   [Hewson, Roger; Simpson, Andrew; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
   [Gilbert, Sarah C.] Univ Oxford, Jenner Inst, Old Rd Campus Res Bldg, Oxford OX3 7DQ, England.
   [Stevens, Mark P.] Univ Edinburgh, Sch Vet Studies, Roslin Inst & Royal Dick, Easter Bush EH25 9RG, Midlothian, Scotland.
   [Hosie, Margaret J.] Univ Glasgow, Ctr Virus Res, MRC, Coll Vet Med & Life Sci, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.
   [Prior, Joann] Dstl Porton Down, CBR Div, Porton Down SP3 4DZ, Wilts, England.
   [Kinsey, Anna M.] MRC, One Kemble St, London WC2B 4AN, England.
   [Entrican, Gary] Pentlands Sci Pk, Moredun Res Inst, Near Edinburgh, Penicuik EH26 0PZ, Midlothian, Scotland.
   [Whitty, Christopher J. M.] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
RP Carroll, MW (reprint author), Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
EM rnoad@rvc.ac.uk; Karl.simpson@jksbioscience.co.uk;
   Tony.Fooks@apha.gsi.gov.uk; sarah.gilbert@ndm.ox.ac.uk;
   Mark.Stevens@roslin.ed.ac.uk; margaret.hosie@glas-gow.ac.uk;
   jlprior@dstl.gsi.gov.uk; anna.kinsey@mrc.ukri.org;
   Gary.Entrican@moredun.ac.uk; Andrew.simpson@phe.gov.uk;
   christopher.whitty@lshtm.ac.uk; miles.car-roll@phe.gov.uk
OI Fooks, Anthony/0000-0002-3243-6154; Noad, Rob/0000-0002-0279-8461
CR Agnandji ST, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002402
   Allen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00923-8
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   Bond KA, 2017, VACCINE, V35, P7084, DOI 10.1016/j.vaccine.2017.10.088
   Carter RJ, 2018, J INFECT DIS, V217, pS16, DOI 10.1093/infdis/jix657
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   Coffey LL, 2014, VIROLOGY, V448, P146, DOI 10.1016/j.virol.2013.09.026
   Coltart CEM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0297
   Dowall SD, 2017, VACCINE, V35, P6015, DOI 10.1016/j.vaccine.2017.05.031
   Enria L, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3799-x
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Friedrich BM, 2012, VIRUSES-BASEL, V4, P1619, DOI 10.3390/v4091619
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   Geldenhuys M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194527
   Gilroy N, 2001, AUST NZ J PUBL HEAL, V25, P362, DOI 10.1111/j.1467-842X.2001.tb00595.x
   Goordial J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02594
   Gsell PS, 2017, LANCET INFECT DIS, V17, P1276, DOI 10.1016/S1473-3099(17)30541-8
   Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108
   Hadinegoro SR, EFFICACY LONG TERM S, DOI [10.1056/NEJMoa1506223, DOI 10.1056/NEJMOA1506223]
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Higgs ES, 2017, CURR TOP MICROBIOL, V411, P229, DOI 10.1007/82_2017_53
   Hossmann S, 2017, VACCINE, DOI [10.1016/j.vaccine201709094, DOI 10.1016/J.VACCINE201709094]
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061
   Kennedy SB, 2017, NEW ENGL J MED, V377, P1438, DOI 10.1056/NEJMoa1614067
   Kummervold PE, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4618-8
   Li Z, 2017, HUM VACC IMMUNOTHER, V13, P802, DOI 10.1080/21645515.2016.1253645
   Lo MM, 2015, ONDERSTEPOORT J VET, V82, DOI [10.4102/OJVR.V82I1.857, 10.4102/ojvr.v82i1.857]
   Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9
   Mooney T, 2018, CLIN TRIALS, V15, P436, DOI 10.1177/1740774518780678
   Njenga MK, 2015, PLOS NEGLECT TROP D, P9, DOI [10.1371/journalpntd.0003550e0003550, DOI 10.1371/JOURNALPNTD.0003550E0003550]
   Pittman PR, 2016, VACCINE, V34, P523, DOI 10.1016/j.vaccine.2015.11.078
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996
   Ramsauer K, 2015, LANCET INFECT DIS, V15, P519, DOI 10.1016/S1473-3099(15)70043-5
   RDC, 2018, EBOLA RDC EV RIP EP
   Russell JA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23641-7
   Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1
   Song JY, 2016, VACCINE, V34, P1289, DOI 10.1016/j.vaccine.2016.01.031
   Stremlau MH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003631
   Walter MC, 2017, J BIOTECHNOL, V250, P16, DOI 10.1016/j.jbiotec.2016.12.006
   Warimwe GM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20617
   WHO, 2015, BLUEPR R D PREP RESP
   Williamson ED, 2009, VACCINE, V27, pD56, DOI 10.1016/j.vaccine.2009.07.068
   World Health Organization, 2018, WKLY EPIDEMIOL REC, V23, P329
   Zheng Y, 2018, INFECT DIS-NOR, V50, P21, DOI 10.1080/23744235.2017.1353704
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/s0140-6736(16)32617-4, 10.1016/S0140-6736(16)32617-4]
NR 49
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6241
EP 6247
DI 10.1016/j.vaccine.2019.09.009
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100001
PM 31522809
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Blackman, MA
   Marchionni, MA
   Gilly, J
   Hepburn, M
   Innis, BL
   Barrett, ADT
   Kester, KE
   Mascola, JR
   Cummings, JF
   Monath, TP
   Cassetti, MC
   Kim, JH
   Saville, M
   Thomas, SJ
AF Blackman, Marcia A.
   Marchionni, Mark A.
   Gilly, John
   Hepburn, Matthew
   Innis, Bruce L.
   Barrett, Alan D. T.
   Kester, Kent E.
   Mascola, John R.
   Cummings, James F.
   Monath, Thomas P.
   Cassetti, M. Cristina
   Kim, Jerome H.
   Saville, Melanie
   Thomas, Stephen J.
TI Summit proceedings: Biomedical countermeasure development for emerging
   vector-borne viral diseases
SO VACCINE
LA English
DT Article
ID ENCEPHALITIS; PROTECTION
AB Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current "gaps," and prospect what could be done to improve our position. Herein we describe the summit proceedings, "Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases," held October 2-3, 2018, at the Trudeau Institute in Saranac Lake, NY.
C1 [Blackman, Marcia A.; Marchionni, Mark A.; Gilly, John] Trudeau Inst, Saranac Lake, NY USA.
   [Hepburn, Matthew] DARPA, Biol Technol Off, Arlington, VA USA.
   [Innis, Bruce L.] PATH, Washington, DC USA.
   [Barrett, Alan D. T.] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX 77555 USA.
   [Barrett, Alan D. T.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Kester, Kent E.] Sanofi Pasteur, Swiftwater, PA USA.
   [Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Cummings, James F.] ICON Govt & Publ Hlth Solut, Washington, DC USA.
   [Monath, Thomas P.] Crozet BioPharma LLC, Devens, MA USA.
   [Cassetti, M. Cristina] NIAID, Virol Branch, Div Microbiol & Infect Dis, NIH, Rockville, MD USA.
   [Kim, Jerome H.] Int Vaccine Inst, Seoul, South Korea.
   [Saville, Melanie] CEPI, London, England.
   [Thomas, Stephen J.] SUNY Upstate Med Univ, Div Infect Dis, Syracuse, NY 13210 USA.
RP Thomas, SJ (reprint author), SUNY Upstate Med Univ, Div Infect Dis, Syracuse, NY 13210 USA.
RI Kester, Kent/AAF-8235-2020
OI Kester, Kent/0000-0002-5056-0802
FU Trudeau Institute; State University of New York Upstate Medical
   University
FX We thank Dr. Atsuo Kuki, President and Director, and the scientists and
   staff at the Trudeau Institute for the use of the Institute's facilities
   and their hard work and dedication to convene and host this Summit
   meeting. Financial support for the meeting was provided by the Trudeau
   Institute and the State University of New York Upstate Medical
   University. This research did not receive any specific grant from
   funding agencies in the public, commercial, or not-for-profit sectors.
   We thank Tina Lupone for sharing her detailed meeting notes, which were
   instrumental in putting together this meeting review. We thank all the
   attendees for their vigorous discussion: Wataru Akahata-VLP
   Therapeutics, Frances Burghouwt-Oviawe-Janssen Global, Holly
   Chanatry-State University of New York Upstate Medical University,
   Claudia Christian-FHI 360, Beth-Ann Coller-Merck and Company, Aravinda
   deSilvaUniversity of North Carolina, Diane
   Epperson-Booze/Allen/Hamilton, Thomas Friedrich-University of Wisconsin,
   Richard Jarman-Walter Reed Army Institute of Research, Viral Diseases
   Branch, David Kaslow-PATH Center for Vaccine Innovation and Access, Mark
   Kristiansen-Cormac Life Sciences, LLC, Atsuo KukiTrudeau Institute,
   Kathleen Lanzer-Trudeau Institute, Christina Lupone-State University of
   New York Upstate Medical University, Christian Mandl-Themis Bioscience,
   Joel Maslow-GeneOne Life Science, Kristopher Paolino-State University of
   New York Upstate Medical University, Steven Projan-Beat the Reaper, LLC,
   Katrin Ramsauer-Themis Bioscience, William Reiley-Trudeau Institute,
   Christine Roberts-GeneOne Life Science, Alan Rothman-University of Rhode
   Island, Rajni Samavedam-Booz/Allen/Hamilton, Alexander Schmidt-Bill and
   Melinda Gates Medical Research Institute, Mark Schmitt-State University
   of New York Upstate Medical University, Peter Sifuna-US Army Medical
   Research DirectorateKenya, Jonathan Smith-PaxVax, Inc., Saravanan
   Thangamani-State University of New York Upstate Medical University,
   Marnix Van Loock-Janssen Global, David Vaughn-Bill and Melinda Gates
   Foundation, Benjamin Wizel-GlaxoSmithKline, and In-Kyu
   Yoon-International Vaccine Institute.
CR [Anonymous], SHATT LECT
   CDC centers for disease control and prevention, EB
   Diakite I, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004866
   Graham BS, 2018, NAT IMMUNOL, V19, P20, DOI 10.1038/s41590-017-0007-9
   Henao-Restrepo AM, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3740
   Li R, 2017, PROTEIN CELL, V8, P823, DOI 10.1007/s13238-017-0479-2
   Li XF, 2013, J GEN VIROL, V94, P2700, DOI 10.1099/vir.0.059436-0
   Li Y, 2014, ORGANOGENESIS, V10, P159, DOI 10.4161/org.28918
   Li Y, 2017, CELL STEM CELL, V20, P385, DOI 10.1016/j.stem.2016.11.017
   Partidos CD, 2012, VACCINE, V30, P4638, DOI 10.1016/j.vaccine.2012.04.099
   Petrovsky N, 2013, J VIROL, V87, P10324, DOI 10.1128/JVI.00480-13
   Sun EC, 2013, VET MICROBIOL, V166, P145, DOI 10.1016/j.vetmic.2013.05.026
   Szaba FM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006994
   Zeitlin L, 2016, P NATL ACAD SCI USA, V113, P4458, DOI 10.1073/pnas.1600996113
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6248
EP 6254
DI 10.1016/j.vaccine.2019.08.061
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100002
PM 31500964
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Cherian, T
   Morales, KF
   Mantel, C
   Lambach, P
   Al Awaidy, S
   Bresee, JS
   Chunsuttiwat, S
   Coulibaly, D
   Feng, LZ
   Hale, R
   Maltezou, HC
   Moore, K
   Nguyen-Van-Tam, J
   Omer, S
   Poland, G
   Wicker, S
   Lagos, R
   Madhi, S
   Bino, S
   Bodeker, B
   Chu, SY
   Hamid, S
   Lafond, K
   Neufeind, J
   Wang, SS
   Atuhebwe, PL
   Gould, P
   Heffelfinger, J
   Jorgensen, P
   Mosina, L
   Ropero-Alvarez, AM
   Quamrul, H
   Desai, S
   Egloff, R
   Goldin, S
   Ivanov, I
   Marti, M
   Moen, A
   Perut, M
   Steulet, C
   Morales, K
AF Cherian, Thomas
   Morales, Kathleen F.
   Mantel, Carsten
   Lambach, Philipp
   Al Awaidy, Salah
   Bresee, Joseph S.
   Chunsuttiwat, Supamit
   Coulibaly, Daouda
   Feng, Luzhao
   Hale, Rachel
   Maltezou, Helena C.
   Moore, Kelly
   Nguyen-Van-Tam, Jonathan
   Omer, Saad
   Poland, Gregory
   Wicker, Sabine
   Lagos, Rosanna
   Madhi, Shabir
   Bino, Silvia
   Boedeker, Birte
   Chu, Susan Y.
   Hamid, Sara
   Lafond, Kathryn
   Neufeind, Julia
   Wang, Susan
   Atuhebwe, Phionah Lynn
   Gould, Philip
   Heffelfinger, James
   Jorgensen, Pernille
   Mosina, Liudmila
   Ropero-Alvarez, Alba Maria
   Quamrul, Hassan
   Desai, Shalini
   Egloff, Rola
   Goldin, Shoshanna
   Ivanov, Ivan
   Marti, Melanie
   Moen, Ann
   Perut, Marc
   Steulet, Claudia
   Morales, Kathleen
CA Independent Expert Advisory Grp IE
TI Factors and considerations for establishing and improving seasonal
   influenza vaccination of health workers: Report from a WHO meeting,
   January 16-17, Berlin, Germany
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Health workers
ID CARE WORKERS; PREVENTABLE DISEASES; ATTITUDES; COVERAGE; CHALLENGES;
   PERSONNEL; IMMUNIZATION; PRESENTEEISM; RATIONALE; MORTALITY
AB Health workers represent an important target group for seasonal influenza vaccination because of their increased risk of infection as well as the risk of transmitting infection to vulnerable patients in the health care setting. Moreover, seasonal vaccination of health workers contributes to pandemic preparedness. However, many countries, especially in Africa and Asia, do not have policies for health worker influenza vaccination. In countries where such policies exist, vaccination coverage is often low. The World Health Organization (WHO) is developing a manual to guide the introduction of seasonal influenza vaccination of health workers. An Independent External Advisory Group (IEAG) that is advising WHO on the content of the manual met to discuss issues that are relevant and often unique to health worker vaccination. This meeting report summarizes the main issues that were discussed and the outcomes of the discussion. The issues include policy considerations, including the evidence in support of health worker vaccination; categorization and prioritization of health workers; the choice of vaccination strategy; its integration into broader health worker vaccination and occupational health policies; planning and management of vaccination, particularly the approaches for communication and demand generation; and the challenges with monitoring and evaluation of health worker vaccination, especially in low and middle-income countries.
C1 [Cherian, Thomas; Mantel, Carsten] MMGH Consulting, Zurich, Switzerland.
   [Morales, Kathleen F.] Sierra Strategy Grp, Evian Les Bains, France.
   [Lambach, Philipp] WHO, Dept Immunizat Vaccines & Biol IVB, Geneva, Switzerland.
   [Mantel, Carsten] Robert Koch Inst, Immunizat Unit, Berlin, Germany.
   [Al Awaidy, Salah] Dept Communicable Dis, Muscat, Oman.
   [Bresee, Joseph S.; Chu, Susan Y.; Lafond, Kathryn; Wang, Susan] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Chunsuttiwat, Supamit] Minist Publ Hlth, Div Communicable Dis, Bangkok, Thailand.
   [Coulibaly, Daouda] CDI, Abidjan, Cote Ivoire.
   [Feng, Luzhao] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.
   [Hale, Rachel] Cardiff Univ, Cardiff, S Glam, Wales.
   [Maltezou, Helena C.] Hellen Ctr Dis Control & Prevent, Athens, Greece.
   [Moore, Kelly] Tennessee Dept Hlth, Tennessee Immunizat Program, Nashville, TN USA.
   [Nguyen-Van-Tam, Jonathan] Dept Hlth & Social Care, London, England.
   [Nguyen-Van-Tam, Jonathan] Univ Nottingham, Nottingham, England.
   [Omer, Saad; Hamid, Sara] Emory Univ, Atlanta, GA 30322 USA.
   [Poland, Gregory] Mayo Clin & Mayo Fdn, Vaccine Res Grp, Rochester, MN USA.
   [Wicker, Sabine] Univ Hosp, Frankfurt, Germany.
   [Lagos, Rosanna] Hosp Ninos Roberto Rio, Ctr Vacunas Desarrollo, Santiago, Chile.
   [Madhi, Shabir] Univ Witwatersrand, Johannesburg, South Africa.
   [Bino, Silvia] Inst Publ Hlth, Tirana, Albania.
   [Boedeker, Birte; Neufeind, Julia] Robert Koch Inst, Berlin, Germany.
   [Atuhebwe, Phionah Lynn] African Reg Off, Brazzaville, Rep Congo.
   [Gould, Philip] South East Asia Reg Off, New Delhi, India.
   [Heffelfinger, James] Western Pacific Reg Off, Manila, Philippines.
   [Jorgensen, Pernille; Mosina, Liudmila] European Reg Off, Copenhagen, Denmark.
   [Ropero-Alvarez, Alba Maria] Reg Off Amer, Washington, DC USA.
   [Quamrul, Hassan] Reg Off Eastern Mediterranean, Cairo, Egypt.
   [Desai, Shalini; Steulet, Claudia] WHO, Immunizat Vaccines & Biol, Geneva, Switzerland.
   [Egloff, Rola; Perut, Marc] WHO, Initiat Vaccine Res, Geneva, Switzerland.
   [Goldin, Shoshanna; Moen, Ann] WHO, Influenza Preparedness & Response, Geneva, Switzerland.
   [Ivanov, Ivan] WHO, Publ Hlth Environm & Social Determinant, Geneva, Switzerland.
   [Marti, Melanie] WHO, SAGE Secretariat Immunizat Vaccines & Biol, Geneva, Switzerland.
   [Morales, Kathleen] Sierra Strategy Grp, Evian Les Baines, France.
RP Lambach, P (reprint author), WHO, Dept Immunizat Vaccines & Biol, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland.
EM lambachp@who.int
RI Hale, Rachel/AAF-2242-2019; Awaidy, Salah Al/AAF-5884-2020
OI Hale, Rachel/0000-0003-4248-0391; Awaidy, Salah Al/0000-0001-5112-3893;
   Lambach, Philipp/0000-0003-0105-8899
FU World Health Organization's Initiative for Vaccine Research; Centers for
   Disease Control and Prevention (CDC)United States Department of Health &
   Human ServicesCenters for Disease Control & Prevention - USA
   [U50CK000431]
FX This study was funded by a grant from the World Health Organization's
   Initiative for Vaccine Research. The authors would like to acknowledge
   the contributions of the Centers for Disease Control and Prevention
   (CDC), which provides financial support to the World Health Organization
   Initiative for Vaccine Research (U50CK000431).
CR Ahmed F, 2014, CLIN INFECT DIS, V58, P50, DOI 10.1093/cid/cit580
   Amodio E, 2014, J HOSP INFECT, V86, P182, DOI 10.1016/j.jhin.2014.01.005
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], 2015, TAIL IMM PROGR SEAS
   [Anonymous], 2017, EVALUATION INFLUENZA
   [Anonymous], 2014, PRINC CONS ADD VACC
   [Anonymous], 2018, INFL VACC POST EV MA
   [Anonymous], 2018, SEAS INFL VACC UPT H
   [Anonymous], 2018, FIELD GUID QUAL RES
   Betsch C, 2014, VACCINE, V32, P4478, DOI 10.1016/j.vaccine.2014.06.046
   Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2
   Bodeker B, OKAPII STUDIE ONLINE
   Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P68
   Chiu S, 2017, AM J INFECT CONTROL, V45, P1254, DOI 10.1016/j.ajic.2017.04.008
   De Serres G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0163586
   Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685
   Jenkin D.C., 2019, VACCINE X, V2
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Kuster SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026239
   Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a
   Lietz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162061
   MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042
   Maltezou HC, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030047
   Maltezou HC, 2014, VACCINE, V32, P4813, DOI 10.1016/j.vaccine.2014.05.046
   Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P66, DOI 10.1016/j.ajic.2012.01.028
   Maltezou HC, 2012, J INFECTION, V64, P319, DOI 10.1016/j.jinf.2011.12.004
   Mihigo R, 2012, J INFECT DIS, V206, pS22, DOI 10.1093/infdis/jis535
   Mossad SB, 2017, INFECT CONT HOSP EP, V38, P966, DOI 10.1017/ice.2017.91
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Ottenberg AL, 2011, AM J PUBLIC HEALTH, V101, P212, DOI 10.2105/AJPH.2009.190751
   Patel MS, 2018, NAT HUM BEHAV, V2, P720, DOI 10.1038/s41562-018-0445-x
   Patel MS, 2018, NEW ENGL J MED, V378, P214, DOI 10.1056/NEJMp1712984
   Pitts SI, 2014, AM J PREV MED, V47, P330, DOI 10.1016/j.amepre.2014.05.035
   Poland CM, 2011, VACCINE, V29, P6145, DOI 10.1016/j.vaccine.2011.07.131
   Poland GA, 2011, ANN RESP MED, V2
   Rebmann T, 2016, J SCH NURS, V32, P407, DOI 10.1177/1059840516637651
   Rhudy LM, 2010, WORLDV EVID-BASED NU, V7, P111, DOI 10.1111/j.1741-6787.2010.00190.x
   Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Sullivan SJ, 2009, EXPERT REV VACCINES, V8, P1469, DOI 10.1586/ERV.09.118
   Swift MD, 2017, AM J PUBLIC HEALTH, V107, pS168, DOI [10.2105/AJPH.2017.303953, 10.2105/ajph.2017.303953]
   Talbot TR, 2010, INFECT CONT HOSP EP, V31, P987, DOI 10.1086/656558
   Thaler RH, 2009, NUDGE IMPROVING DECI
   Thomas RE, 2010, VACCINE, V29, P344, DOI 10.1016/j.vaccine.2010.09.085
   Tilburt JC, 2008, VACCINE, V26, pD27, DOI 10.1016/j.vaccine.2008.07.068
   To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003
   WHO/UNICEF, 2017, JOINT REP FORM
   Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849
   Wilson KE, 2019, AM J INFECT CONTROL, DOI [10.1016/j.ajjc.2018.10.024, DOI 10.1016/J.AJJC.2018.10.024]
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   World Health Organization, GLOB INFL STRAT 2019
   Yang J S, 2018, Zhonghua Liu Xing Bing Xue Za Zhi, V39, P1066, DOI 10.3760/cma.j.issn.0254-6450.2018.08.010
   Yuen CYS, 2014, J PERINAT NEONAT NUR, V28, P261, DOI 10.1097/JPN.0000000000000068
   Zhang WQ, 2017, VACCINE, V35, P851, DOI 10.1016/j.vaccine.2016.12.056
NR 58
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6255
EP 6261
DI 10.1016/j.vaccine.2019.07.079
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100003
PM 31500965
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Willer, DO
   Oostvogels, L
   Cunningham, AL
   Gervais, P
   Gorfinkel, I
   Kim, JH
   Talarico, C
   Wascotte, V
   Zahaf, T
   Colindres, R
   Schuind, A
AF Willer, David O.
   Oostvogels, Lidia
   Cunningham, Anthony L.
   Gervais, Pierre
   Gorfinkel, Iris
   Kim, Joon Hyung
   Talarico, Carla
   Wascotte, Valentine
   Zahaf, Toufik
   Colindres, Romulo
   Schuind, Anne
CA ZOE 50 70 Study Grp
TI Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex,
   geographic region, and geographic ancestry/ethnicity: A post-hoc
   analysis of the ZOE-50 and ZOE-70 randomized trials
SO VACCINE
LA English
DT Article
DE Recombinant zoster vaccine; Efficacy; Herpes zoster; Sex; Region;
   Geographic ancestry/ethnicity
ID HERPES-ZOSTER; SUBUNIT VACCINE
AB Background: Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity.
   Methods: In 2 randomized clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months apart. In this post-hoc analysis, we investigate efficacy of RZV against HZ and postherpetic neuralgia (PHN) by sex, geographic region, and geographic ancestry/ethnicity in >= 50-year-olds (ZOE-50: NCT01165177) and >= 70-year-olds (pooled data from ZOE-50 and ZOE-70: NCT01165229).
   Results: Vaccine efficacy against HZ or PHN was similar in women and men. Across geographic regions, efficacy against HZ ranged between 95.7 and 97.2% in >= 50-year-olds, and between 87.3% and 95.1% in >= 70-year-olds; efficacy against PHN ranged between 86.8 and 100% in >= 70-year-olds. Across ancestral/ethnic groups, efficacy ranged between 88.1 and 100% against HZ and between 65.9 and 100% against PHN in >= 70-year-olds.
   Conclusions: While the ZOE-50/70 studies were not powered or pre-designed for these post-hoc analyses, RZV appears efficacious against HZ and PHN irrespective of sex, region, or geographic ancestry/ethnicity. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Willer, David O.] GSK, 7333 Mississauga Rd, Mississauga, ON, Canada.
   [Oostvogels, Lidia; Wascotte, Valentine; Zahaf, Toufik] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Cunningham, Anthony L.] Westmead Inst Med Res, 176 Hawkesbury Rd, Westmead, NSW 2145, Australia.
   [Cunningham, Anthony L.] Univ Sydney, 133 Castlereagh St, Sydney, NSW 2000, Australia.
   [Gervais, Pierre] Q&T Res Sherbrooke Inc, 2185 King W, Sherbrooke, PQ, Canada.
   [Gorfinkel, Iris] PrimeHlth Clin Res, 1849 Yonge St,Suite 516, Toronto, ON, Canada.
   [Kim, Joon Hyung; Talarico, Carla; Colindres, Romulo; Schuind, Anne] GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
   [Oostvogels, Lidia] CureVac AG, Tubingen, Germany.
RP Willer, DO (reprint author), GSK, 7333 Mississauga Rd, Mississauga, ON, Canada.
EM david.o.willer@gsk.com; cornelia.oostvogels@orange.fr;
   tony.cunningham@sydney.edu.au; pierre.gervais@qtresearch.com;
   i.gor@outlook.com; joon-hyung.k.kim@gsk.com; carla.a.talarico@gsk.com;
   valentine.v.wascotte@gsk.com; toufik.zahaf@gsk.com;
   romcolindres@hotmail.com; anne.a.schuind@gsk.com
OI Diez-Domingo, Javier/0000-0003-1008-3922; Smetana,
   Jan/0000-0002-4566-3356
FU GlaxoSmithKline Biologicals SA, Rixensart, Belgium
FX This work was sponsored by GlaxoSmithKline Biologicals SA, Rixensart,
   Belgium. GlaxoSmithKline Biologicals SA was involved in all stages of
   the conduct and analysis of the studies. GlaxoSmithKline Biologicals SA
   covered the costs associated with the development and the publishing of
   the present manuscript.
CR Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Dagnew AF, 2018, ID WEEK
   de la Serna J, 2018, BMT TAND M
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Hales CM, 2013, ANN INTERN MED, V159, P739, DOI 10.7326/0003-4819-159-11-201312030-00006
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009
   Kawai K, 2015, INT J INFECT DIS, V34, P126, DOI 10.1016/j.ijid.2015.03.022
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   Lopez-Fauqued M, 2019, VACCINE, V37, P2482, DOI 10.1016/j.vaccine.2019.03.043
   National Advisory Committee on Immunization, UPD REC US HERP ZOST
   RKI, EPIDEMIOLOGICAL B
   Schmader KE, 2007, CLIN J PAIN, V23, P490, DOI 10.1097/AJP.0b013e318065b6c9
   Schmidt-Chanasit J, 2011, INFECT GENET EVOL, V11, P1, DOI 10.1016/j.meegid.2010.08.014
   Yawn BP, 2013, NEUROLOGY, V81, P928, DOI 10.1212/WNL.0b013e3182a3516e
NR 16
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6262
EP 6267
DI 10.1016/j.vaccine.2019.09.028
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100004
PM 31537443
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wu, WD
   Cao, LS
   Zheng, JS
   Cao, L
   Cui, J
   Xiao, QY
AF Wu, Wendi
   Cao, Lingsheng
   Zheng, Jingshan
   Cao, Lei
   Cui, Jian
   Xiao, Qiyou
TI Immunization information system status in China, 2017
SO VACCINE
LA English
DT Article
DE Immunization Information Systems; Immunization registries
ID UNITED-STATES; PROGRESS; RATES
AB Immunization Information Systems (IIS) are computerized population-based systems with individual-level vaccination-related information used to help ensure protection from vaccine preventable diseases. The Chinese Center for Diseases Control and Prevention (China CDC) conducted a survey of the 32 mainland China provincial CDCs to determine IIS coverage and implementation of key functions: individual vaccination records, vaccine management, cold-chain management, and school entry vaccination status verification. Twenty-seven IISs collectively managed 252 million immunization records, 43.8% for children under 6 years; 20 could exchange records with other IISs. The within-province duplicate-record rate varied from 0.3% to 4.0%, but compared with National Statistical Bureau's census estimates, 138.0% of births from 2012 to 2017 were represented in the IISs, implying significant across-province record duplication. China CDC should consider developing a national-level IIS center for data exchange and analysis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Wendi; Cao, Lingsheng; Zheng, Jingshan; Cao, Lei; Cui, Jian; Xiao, Qiyou] Chinese Ctr Dis Control & Prevent, Natl Immunizat Programme, Beijing, Peoples R China.
RP Cao, LS (reprint author), Chinese Ctr Dis Control & Prevent, Natl Immunizat Programme, Immunizat Serv Div, 27 Nanwei Rd, Beijing 100050, Peoples R China.
EM caols@chinacdc.cn
OI WU, Wendi/0000-0002-0327-6497
CR Cardemil C, 2013, MMWR-MORBID MORTAL W, V62, P1005
   Center for Health Statistics and Information National Health and Family Planning Commission, 2013, AN REP NAT HLTH SERV
   Derrough T, 2017, EUROSURVEILLANCE, V22, P10, DOI [10.2807/1560-7917.ES.2017.22.17.30519, 10.2807/1560-7917.es.2017.22.17.30519]
   Guo BA, 2013, VACCINE, V31, P603, DOI 10.1016/j.vaccine.2012.11.051
   Li Q, 2014, INT J ENV RES PUB HE, V11, P2713, DOI 10.3390/ijerph110302713
   Martin DW, 2015, J PUBLIC HEALTH MAN, V21, P296, DOI 10.1097/PHH.0000000000000040
   Murthy N, 2017, MMWR-MORBID MORTAL W, V66, P1178, DOI 10.15585/mmwr.mm6643a4
   National Bureau of Statistics of the People's Republic of China, ANN DAT BIRTH RAT
   National Health Commission of the People's Republic of China, 2016, STANDARD OPERATION O
   Ronveaux O, 2009, REV PANAM SALUD PUBL, V26, P153, DOI 10.1590/S1020-49892009000800008
   Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6268
EP 6270
DI 10.1016/j.vaccine.2019.08.070
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100005
PM 31526621
DA 2020-05-12
ER

PT J
AU Chow, EPF
   Danielewski, JA
   Murray, GL
   Fehler, G
   Chen, MY
   Bradshaw, CS
   Garland, SM
   Fairley, CK
AF Chow, Eric P. F.
   Danielewski, Jennifer A.
   Murray, Gerald L.
   Fehler, Glenda
   Chen, Marcus Y.
   Bradshaw, Catriona S.
   Garland, Suzanne M.
   Fairley, Christopher K.
TI Anal human papillomavirus infections in young unvaccinated men who have
   sex with men attending a sexual health clinic for HPV vaccination in
   Melbourne, Australia
SO VACCINE
LA English
DT Article
DE Vaccine; HPV; Gay men; Vaccination; MSM; Catch-up program; Human
   papillomavirus; Homosexual; Anal; Cancer; Prevention
ID PREVALENCE; PENILE
AB The Victorian Government introduced a time-limited quadrivalent human papillomavirus (HPV) vaccination catch-up program targeting gay and bisexual men who have sex with men (MSM) aged up to 26 years in 2017. As of 2017, men aged >= 20 years were not eligible for the school-based HPV vaccination program. This study examined the prevalence of anal HPV among 496 MSM aged 20-26 years before they received the first dose of the HPV vaccine at the Melbourne Sexual Health Centre, Australia. More than half (56.5%) had any high-risk HPV genotypes detected in the anus. Almost half (43.1%) had at least one quadrivalent HPV vaccine-preventable genotype (6, 11, 16 or 18) and one-fifth (21.0%) had HPV 16 detected in the anus. These findings suggest that a targeted catch-up HPV vaccination program for MSM is still beneficial to protect against high-risk HPV genotypes associated with anal cancer, as well as low-risk HPV genotypes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chow, Eric P. F.; Fehler, Glenda; Chen, Marcus Y.; Bradshaw, Catriona S.; Fairley, Christopher K.] Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Chow, Eric P. F.; Chen, Marcus Y.; Bradshaw, Catriona S.; Fairley, Christopher K.] Monash Univ, Fac Med Nursing & Hlth Sci, Cent Clin Sch, Melbourne, Vic, Australia.
   [Danielewski, Jennifer A.; Murray, Gerald L.; Garland, Suzanne M.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Danielewski, Jennifer A.; Murray, Gerald L.] Royal Womens Hosp, Ctr Womens Infect Dis Res, Parkville, Vic, Australia.
   [Garland, Suzanne M.] Univ Melbourne, Dept Obstet Gynaecol, Parkville, Vic, Australia.
RP Chow, EPF (reprint author), Melbourne Sexual Hlth Ctr, 580 Swanston St, Carlton, Vic 3053, Australia.
EM eric.chow@monash.edu; jennifer.danielewski@mcri.edu.au;
   gerald.murray@mcri.edu.au; gfehler@mshc.org.au; mchen@mshc.org.au;
   cbradshaw@mshc.org.au; suzanne.garland@thewomens.org.au;
   cfairley@mshc.org.au
RI Chow, Eric P.F./W-6684-2019
OI Chow, Eric P.F./0000-0003-1766-0657; Murray, Gerald/0000-0003-3330-4433
FU Australian National Health and Medical Research CouncilNational Health
   and Medical Research Council of Australia [568971]
FX This study was funded by the Australian National Health and Medical
   Research Council Program Grant (number 568971).
CR Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   Chow EPF, 2018, SEX HEALTH, V15, P350, DOI 10.1071/SH18024
   Chow EPF, 2017, LANCET INFECT DIS, V17, P68, DOI 10.1016/S1473-3099(16)30116-5
   Chow EPF, 2015, LANCET INFECT DIS, V15, P1314, DOI 10.1016/S1473-3099(15)00055-9
   Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813
   Fairley CK, 2017, SEX HEALTH, V14, P123, DOI 10.1071/SH16067
   Green A, 2018, LANCET, V392, P374, DOI 10.1016/S0140-6736(18)31728-8
   Lin A, 2017, CLIN INFECT DIS, V64, P580, DOI 10.1093/cid/ciw845
   Machalek DA, 2017, J INFECT DIS, V215, P202, DOI 10.1093/infdis/jiw530
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   McGrath L, 2019, SEX TRANSM INFECT, V95, P181, DOI 10.1136/sextrans-2018-053619
   Ong JJ, 2018, SEX TRANSM DIS, DOI [10.1097/OLO.0000000000000958, DOI 10.1097/OLO.0000000000000958]
   Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737
   Prue G, 2018, MED ACCESS POINT CAR, V2
   Ucciferri C, 2018, J MED VIROL, V90, P358, DOI 10.1002/jmv.24943
   van Aar F, 2013, AIDS, V27, P2921, DOI 10.1097/01.aids.0000432541.67409.3c
   Zhang L, 2017, VACCINE, V35, P4923, DOI 10.1016/j.vaccine.2017.07.078
   Zou HC, 2015, LANCET INFECT DIS, V15, P65, DOI 10.1016/S1473-3099(14)70994-6
   Zou HC, 2014, J INFECT DIS, V209, P642, DOI 10.1093/infdis/jit626
NR 19
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6271
EP 6275
DI 10.1016/j.vaccine.2019.08.066
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100006
PM 31521414
DA 2020-05-12
ER

PT J
AU Sastre-Canton, M
   Perez-Vilar, S
   Vilata-Corell, JJ
   Diez-Domingo, J
AF Sastre-Canton, Macrina
   Perez-Vilar, Silvia
   Jose Vilata-Corell, Juan
   Diez-Domingo, Javier
TI Prevalence of oral human papillomavirus infection among university
   students in Valencia, Spain
SO VACCINE
LA English
DT Article
DE Oral human papillomavirus; Prevalence; Persistence; Clearance; Young
   adult; Oropharynx
ID SQUAMOUS-CELL CARCINOMA; HPV INFECTION; EPIDEMIOLOGY; MUCOSA; ADULTS;
   WOMEN; HEAD
AB Human papillomavirus (HPV) infection contributes to the pathogenesis of oropharyngeal squamous cell carcinomas. We estimated prevalence and six-month persistence of oral HPV infections among university students ages 18-25 years living in Valencia, Spain, during the 2012-2013 academic year. Participants provided oral rinse samples; HPV-positive subjects provided a follow-up sample. The study included 543 students; 70 (12.9%) women had received HPV vaccination. Prevalence among vaccinees and non-vaccinees were 10.0% (95% CI: 4.1-19.5%) and 6.8% (95% CI: 4.7-9.4%), respectively. All HPV infections among vaccinees were non-typeable genotypes; 59.4% of non-vaccinees had high-risk genotype infections. Follow-up samples were obtained from 36 participants: one vaccinee (whose specimen was non-typeable) and seven non-vaccinees were found to be HPV positive. Among non-vaccinees, six-month persistence was 10.3% (95% CI: 2.2-27.4%); all persistent infections were with high-risk genotypes. Our results, although subject to study limitations, may support the need to implement new public health strategies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sastre-Canton, Macrina; Perez-Vilar, Silvia; Diez-Domingo, Javier] FISABIO Publ Hlth, Fdn Promot Hlth & Biomed Res, Vaccine Res Dept, Valencia, Spain.
   [Jose Vilata-Corell, Juan] Hosp Gen Univ, Dermatol Unit, Valencia, Spain.
RP Sastre-Canton, M (reprint author), Ronda de Narcis Monturiol 11, Valencia 46980, Spain.
EM Macrina_Sastre@edwards.com
RI Perez-Vilar, Silvia/H-4372-2016
OI Perez-Vilar, Silvia/0000-0003-1272-1502; Diez-Domingo,
   Javier/0000-0003-1008-3922
CR Antonsson A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091761
   Canadas MP, 2004, J CLIN MICROBIOL, V42, P1330, DOI 10.1128/JCM.42.3.1330-1332.2004
   Castellsague X, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-74
   Curado MP, 2013, CURR OPIN ONCOL, V25, P229, DOI 10.1097/CCO.0b013e32835ff48c
   D'Souza G, 2014, CANCERS, V6, P1691, DOI 10.3390/cancers6031691
   de Matos LL, 2015, BRAZ J OTORHINOLAR, V81, P554, DOI 10.1016/j.bjorl.2015.04.001
   Edelstein ZR, 2012, SEX TRANSM DIS, V39, P860, DOI 10.1097/OLQ.0b013e318269d098
   Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025
   Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101
   Hang D, 2014, CANCER EPIDEM BIOMAR, V23, P2101, DOI 10.1158/1055-9965.EPI-14-0084
   Hirth JM, 2017, VACCINE, V35, P3446, DOI 10.1016/j.vaccine.2017.05.025
   Kreimer AR, 2011, CANCER EPIDEM BIOMAR, V20, P172, DOI 10.1158/1055-9965.EPI-10-0682
   Kurose K, 2004, ORAL SURG ORAL MED O, V98, P91, DOI 10.1016/j.tripleo.2003.12.029
   Llamas-Martinez S, 2008, ANTICANCER RES, V28, P3733
   Louvanto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053413
   Mourad M, 2017, J ORAL MAXIL SURG, V75, P2562, DOI 10.1016/j.joms.2017.05.008
   Pickard RKL, 2012, SEX TRANSM DIS, V39, P559, DOI 10.1097/OLQ.0b013e31824f1c65
   Rautava J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042171
   Safaeian M, 2007, J CLIN MICROBIOL, V45, P1447, DOI 10.1128/JCM.02580-06
   Sastre-Canton Macrina, 2015, 8 C SPAN VACC ASS CO
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6276
EP 6281
DI 10.1016/j.vaccine.2019.08.058
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100007
PM 31515148
DA 2020-05-12
ER

PT J
AU Zeevat, F
   van der Schans, J
   Boersma, WG
   Boersma, C
   Postma, MJ
AF Zeevat, F.
   van der Schans, J.
   Boersma, W. G.
   Boersma, C.
   Postma, M. J.
TI Cost-effectiveness analysis on elderly pneumococcal vaccination in the
   Netherlands: Challenging the Dutch Health Council's advice
SO VACCINE
LA English
DT Article
DE Elderly pneumococcal vaccination; Polysaccharide vaccine; Conjugated
   vaccine; Cost-effectiveness; The Netherlands; Dutch Health Council
   advice
ID CONJUGATE VACCINE
AB Recently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conventional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for the conjugated vaccine. We argue that using the same data and methods as presented by the Health Council, a different perspective on the results leads to a conclusion that not only the polysaccharide but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness modelling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the conjugated vaccine seems cost-effective; i.e. well below the threshold of (sic)20,000 per quality-adjusted life year, reflecting the most stringent threshold used for vaccines in the Netherlands. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Zeevat, F.; van der Schans, J.; Boersma, C.; Postma, M. J.] Univ Groningen, Univ Med Ctr, Dept Hlth Sci, Groningen, Netherlands.
   [Boersma, W. G.] Nortwest Clin, Dept Lung Dis, Alkmaar, Netherlands.
   [Postma, M. J.] Univ Groningen, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ, Groningen, Netherlands.
   [Postma, M. J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Groningen, Netherlands.
RP Zeevat, F (reprint author), Univ Groningen, Univ Med Ctr, Dept Hlth Sci, Groningen, Netherlands.
EM f.zeevat@rug.nl
OI Zeevat, Florian/0000-0001-6427-4172
CR Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Dutch Health Council (Gezondheidsraad), 2018, VACC OUD TEG PNEUM
   European Centre for Disease Prevention and Controle (ECDC), 2017, VACC SCHED ALL COUNT
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Houweling H, 2010, VACCINE, V28, P2924, DOI 10.1016/j.vaccine.2010.02.021
   Immunisation and High Consequence Infectious Diseases Team Global and Public Health Group, 2018, CONS COST EFF METH V
   ISPOR, 2018, PHARM GUID WORLD
   Kuchenbecker U, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197905
   Mangen MJJ, 2015, EUR RESPIR J, V46, P1407, DOI 10.1183/13993003.00325-2015
   National Health Care Institute [Internet], MED
   Rozenbaum MH, 2010, CLIN THER, V32, P1517, DOI 10.1016/j.clinthera.2010.06.016
   Tan SS, 2012, INT J TECHNOL ASSESS, V28, P152, DOI 10.1017/S0266462312000062
   The Dutch Healthcare Authority, 2014, KOST VACC CA 300 607
   Thorrington D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192640
   Versteegh M.M., 2016, IMTA DIS BURDEN CALC
   Willem L, 2018, HUM VACC IMMUNOTHER, V14, P1218, DOI 10.1080/21645515.2018.1428507
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6282
EP 6284
DI 10.1016/j.vaccine.2019.08.051
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100008
PM 31515151
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Acosta, D
   Hendrickx, S
   McKune, S
AF Acosta, Daniel
   Hendrickx, Saskia
   McKune, Sarah
TI The livestock vaccine supply chain: Why it matters and how it can help
   eradicate peste des petits Ruminants, based on findings in Karamoja,
   Uganda
SO VACCINE
LA English
DT Review
DE Livestock vaccine; PPR; Peste des petits ruminants; Supply Chain;
   Logistics; Karamoja; One Health; Gender; Vaccine Distribution
AB Understanding factors that hinder vaccination, including logistical and social constraints, is critical to finding the most effective approach for the global eradication of peste des petits ruminants (PPR). Vaccination projects should analyze the supply chain and take it into consideration when planning and creating a vaccination strategy. Adequate supply chain management of the PPR vaccine could lead to reduced cost, increased availability, and the construction of a data platform for other livestock vaccines. Integrating the supply chain of PPR vaccine with other veterinary or health commodities could reduce cost, as well as increase uptake. The use of a thermostable vaccine could potentially have a positive impact on the eradication of PPR in remote areas, such as the Karamoja subregion in Uganda, as it did with rinderpest across Sub Saharan Africa. In terms of vaccine delivery, the use of community animal health workers (CAHWs) could be beneficial in certain areas, such as the Karamoja subregion of Uganda, by alleviating supply chain constraints in the last-mile delivery, as well as increasing coverage and uptake. A gendered approach to livestock vaccines should also be considered, as decision-making power regarding livestock vaccination is gendered in many various contexts. The PPR eradication strategy-as well as other livestock vaccination programs-would be more effective and efficient if the supply chain management were considered as a key component in the process and efforts tailored, accordingly. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Acosta, Daniel] Univ Florida, Dept Anim Sci, Feed Future Innovat Lab Livestock Syst, Inst Food & Agr Sci, Gainesville, FL 32611 USA.
   [Hendrickx, Saskia] Univ Florida, Inst Food & Agr Sci, Feed Future Innovat Lab Livestock Syst, Gainesville, FL 32611 USA.
   [Hendrickx, Saskia] Univ Florida, Inst Food & Agr Sci, Dept Anim Sci, Gainesville, FL 32611 USA.
   [McKune, Sarah] Univ Florida, Dept Environm & Global Hlth, Feed Future Innovat Lab Livestock Syst, Gainesville, FL USA.
   [McKune, Sarah] Univ Florida, Ctr African Studies, Gainesville, FL USA.
RP Acosta, D (reprint author), Univ Florida, Dept Anim Sci, Feed Future Innovat Lab Livestock Syst, Inst Food & Agr Sci, Gainesville, FL 32611 USA.
EM daniel.acosta@ufl.edu
OI Acosta, Daniel/0000-0002-8043-4065
CR Admassu B., 2003, PRIM ANIM HEALTHC 21, P1
   Ahuja V, 2004, REV SCI TECH OIE, V23, P33, DOI 10.20506/rst.23.1.1464
   Alders RG, 2007, DEV BIOLOGICALS, V130, P73
   Andrew J, 1996, P FAO TECHN CONS GLO
   Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011
   Assi TM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-425
   Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090
   Bugeza J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179110
   Catley A, 1998, EXCH ORG BEHAV TEACH
   Chanamuto N. J. C., 2015, Gender and Development, V23, P515, DOI 10.1080/13552074.2015.1096041
   Gitonga PN, 2016, SMALL RUMINANT HUSBA
   Greter H, 2014, ONDERSTEPOORT J VET, V2012, P2
   Hadush A, 2015, MAJOR CONSTRAINTS VE, V12, P5
   International Monetary Fund, 2015, WORL EC FIN SURV REG
   Kaufmann JR, 2011, HEALTH AFFAIR, V30, P1113, DOI 10.1377/hlthaff.2011.0368
   Kiara H, 2017, DELIVERY ANIMAL HLTH
   Lakshminarasimhan C, 2017, SUB SAHARAN AFRICA H
   Lee BY, 2008, CLIN INFECT DIS, V46, P1139, DOI 10.1086/529441
   Lee BY, 2017, VACCINE, V35, P4475, DOI 10.1016/j.vaccine.2017.05.096
   Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036
   Lee BY, 2012, VACCINE, V30, P5637, DOI 10.1016/j.vaccine.2012.06.087
   Leyland T., 2014, COMMUNITY BASED ANIM
   Lloyd J, 2017, VACCINE, V35, P2115, DOI 10.1016/j.vaccine.2016.11.097
   Luter N, 2017, VACCINE, V35, P3897, DOI 10.1016/j.vaccine.2017.04.087
   Mariner JC, 2012, SCIENCE, V337, P1309, DOI 10.1126/science.1223805
   Metcalf CJE, 2015, EPIDEMIOL INFECT, V143, P1457, DOI 10.1017/S0950268814001988
   Milstien J, 1997, VACCINE, V15, P1358, DOI 10.1016/S0264-410X(97)00053-4
   Ministere D'Elevage, 2015, SERV VET PRIV PROX
   Normile D, 2008, SCIENCE, V319, P1606, DOI 10.1126/science.319.5870.1606
   OIE and FAO, 2015, GLOB STRAT CONTR ERR
   PATH, 2016, IMM SUPPL CHAIN POL
   Roeder P, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0139
   Schelling E, 2007, EMERG INFECT DIS, V13, P373, DOI 10.3201/eid1303.060391
   Waithanji E, ROLE GENDER OTHER SO
   Waithanji E., 2015, DEV PRACTICE GENDERE, P4524
   World Health Organization, 2014, IMM SUPPL CHAIN LOG
   Yadav P, 2014, VACCINE, V32, P6725, DOI 10.1016/j.vaccine.2014.10.001
   Yisehak K., 2008, S W ETHIOPIA LIVEST
NR 38
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6285
EP 6290
DI 10.1016/j.vaccine.2019.09.011
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100009
PM 31526623
OA Other Gold
DA 2020-05-12
ER

PT J
AU Torres, JR
   Falleiros-Arlant, LH
   Gessner, BD
   Delrieu, I
   Avila-Aguero, ML
   Giambernardino, HIG
   Mascarenas, A
   Brea, J
   Torres, CN
   Castellanos-Martinez, JM
AF Torres, J. R.
   Falleiros-Arlant, L. H.
   Gessner, B. D.
   Delrieu, I
   Avila-Aguero, M. L.
   Giambernardino, H. I. G.
   Mascarenas, A.
   Brea, J.
   Torres, C. N.
   Castellanos-Martinez, J. M.
TI Updated recommendations of the International Dengue Initiative expert
   group for CYD-TDV vaccine implementation in Latin America
SO VACCINE
LA English
DT Review
DE Dengue vaccine; Latin America; Updated recommendations; International
   Dengue Initiative
ID DISEASE; VIRUS
AB Dengue disease represents a large and growing global threat to public health, causing a significant burden to health systems of endemic countries. For countries considering vaccination as part of their Integrated Management Strategy for Prevention and Control of Dengue, the World Health Organization currently recommends the first licensed dengue vaccine, CYD-TDV for: individuals aged 9 years or above from populations with high transmission rates, based on either seroprevalence criteria or pre-vaccination screening strategies, and for persons with confirmed prior exposure to infection in moderate to lower transmission settings. This paper describes the main conclusions of the Sixth Meeting of the International Dengue Initiative (IDI) held in June 2018, following release of a new product label by the manufacturer, updated WHO-SAGE recommendations, additional scientific evidence on vaccine performance, and reports of experiences by implementing countries. Considerations were made regarding the need for improving the quality of epidemiological and surveillance data in the region to help define the convenience of either of the two vaccination strategies recommended by WHO-SAGE. Extensive discussion was dedicated to the pros and cons of implementing either of such strategies in Latin America. Although, in general, a seroprevalence-based approach was preferred in high transmission settings, when cost-effectivity is favorable pre-vaccination screening is a convenient alternative. Cost-effectiveness evaluations can assist with the decisions by public health authorities of whether to introduce a vaccine. Where implemented, vaccine introduction should be part of a public health strategy that includes the participation of multiple sectors of society, incorporating input from scientific societies, ministries of heath, and civil society, while ensuring a robust communication program. (C) 2019 Published by Elsevier Ltd.
C1 [Torres, J. R.] Univ Cent Venezuela, Trop Med Inst, Infect Dis Sect, Caracas, Venezuela.
   [Falleiros-Arlant, L. H.] Univ Metropolitana Santos, Fac Med, Dept Salud Ninos, Santos, SP, Brazil.
   [Gessner, B. D.] Agence Med Prevent, Ferney Voltaire, Ferney Voltaire, France.
   [Delrieu, I] Sci & Technol Hlth EpiLinks, St Genis Pouilly, France.
   [Avila-Aguero, M. L.] Hosp Nacl Ninos Dr Carlos Saenz Herrera, CCSS San, Serv Infectol, San Jose, Costa Rica.
   [Avila-Aguero, M. L.] Yale Univ, CIDMA, New Haven, CT USA.
   [Giambernardino, H. I. G.] Hosp Pequeno Principe, Dept Inmunizac & Control Infecc, Curitiba, Parana, Brazil.
   [Mascarenas, A.] Univ Autonoma Nuevo Leon, Hosp Univ Jose & Gonzalez, Dept Pediat Infect Dis, San Nicolas De Los Garza, Nuevo Leon, Mexico.
   [Brea, J.] Ctr Med UCE, Santo Domingo, Dominican Rep.
   [Torres, C. N.] Univ Bosque, Cafettor Med, Bogota, Colombia.
   [Castellanos-Martinez, J. M.] Secretatia Salud, Hosp Reg Alta Especialidad Bajio, Leon Guanajuato, Mexico.
RP Torres, JR (reprint author), Univ Cent Venezuela, Trop Med Inst, Infect Dis Sect, Caracas, Venezuela.
EM torresj@iname.com; luizahfc@terra.com.br; idelrieu@epilinks.net;
   heloisa.ihle@hpp.org.br; catorres@uniandes.edu.co
RI Avila-Aguero, Maria L./AAK-5086-2020; Belaunzaran-Zamudio, Pablo
   Francisco/T-4085-2019
OI Avila-Aguero, Maria L./0000-0002-1979-0431
CR [Anonymous], 2018, SAGE WORKING GROUP D
   [Anonymous], 2016, SAGE WORKING GROUP D
   Arredondo-Garcia JL, 2018, CLIN MICROBIOL INFEC, V24, P755, DOI 10.1016/j.cmi.2018.01.018
   Beatty ME, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000890
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bonaparte M, 2018, PEDIATR ASUNCION, V45, P86
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   Direccion General de Vigilancia de la Salud, B EPIDEMIOLOGICO
   Duong V, 2015, P NATL ACAD SCI USA, V112, P14688, DOI 10.1073/pnas.1508114112
   Espana G, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007482
   Flasche S, 2019, LANCET INFECT DIS, V19, P465, DOI 10.1016/S1473-3099(19)30167-7
   Gessner BD, 2016, VACCINE, V34, P2397, DOI 10.1016/j.vaccine.2016.03.017
   Giamberardino HIG, 2018, 21 EUR SOC CLIN VIR
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Harenberg A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004830
   Hashim A, 2015, VACCINE, V33, P753, DOI 10.1016/j.vaccine.2014.12.033
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Laoprasopwattana K, 2005, J INFECT DIS, V192, P510, DOI 10.1086/431520
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Len-Maldonado L, 2019, HUM VACC IMMUNOTHER, V15, P1986, DOI 10.1080/21645515.2019.1619401
   Lewis EN, 2007, PEDIATRICS, V120, P467, DOI 10.1542/peds.2007-0167
   Libraty DH, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000171
   Luo R, 2019, CLIN MICROBIOL INFEC, V25, P659, DOI 10.1016/j.cmi.2019.01.002
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Murgue B, 2010, MICROBES INFECT, V12, P113, DOI 10.1016/j.micinf.2009.11.006
   Olivera-Botello G, 2016, J INFECT DIS, V214, P994, DOI 10.1093/infdis/jiw297
   PAHO, PLIISA HLTH INF PLAT
   Parana Governo do Estado, PAR ENC CICL OF VAC
   Perez F, 2019, TROP MED INT HEALTH, V24, P442, DOI 10.1111/tmi.13200
   Rodriguez-Barraquer I, 2019, LANCET INFECT DIS, V19, P132, DOI 10.1016/S1473-3099(18)30799-0
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Sarti E, 2016, INT J INFECT DIS, V44, P44, DOI 10.1016/j.ijid.2016.01.015
   Secretaria da Saude de Parana Ministerio de Sadde de Brasil, VAC DENG PERG RESP
   Shepard DS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003306
   Soo KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154760
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Subsecretaria de Prevencion y Promocion de la Salud, 2017, LIN VAC DENG
   UNICEF-PNUD-Banco Mundial-OMS, 2009, DENG GUIAS DIAGN TRA
   Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128
   Watts DM, 1999, LANCET, V354, P1431, DOI 10.1016/S0140-6736(99)04015-5
   WHO, TOP 10 THREATS PUBL
   WHO, 2017, INF VACC PROGR GUID
   WHO, DENG SEV DENG DENG C
   WHO, 2018, WEEKLY EPIDEMIOLOGIC, V93, P389
   Wilder-Smith A, 2019, VACCINE, V37, P5137, DOI 10.1016/j.vaccine.2019.07.016
NR 45
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6291
EP 6298
DI 10.1016/j.vaccine.2019.09.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100010
PM 31515144
DA 2020-05-12
ER

PT J
AU Chan, J
   Nguyen, CD
   Dunne, EM
   Mulholland, EK
   Mungun, T
   Pomat, WS
   Rafai, E
   Satzke, C
   Weinberger, DM
   Russell, FM
AF Chan, Jocelyn
   Nguyen, Cattram D.
   Dunne, Eileen M.
   Mulholland, E. Kim
   Mungun, Tuya
   Pomat, William S.
   Rafai, Eric
   Satzke, Catherine
   Weinberger, Daniel M.
   Russell, Fiona M.
TI Using pneumococcal carriage studies to monitor vaccine impact in low-
   and middle-income countries
SO VACCINE
LA English
DT Review
DE Pneumococcal vaccines; Nasopharyngeal carriage; Low- and middle-income
   countries
ID THAN 5 YEARS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE;
   NASOPHARYNGEAL CARRIAGE; HAEMOPHILUS-INFLUENZAE; SEROTYPE DISTRIBUTION;
   DOSING SCHEDULES; TEMPORAL-CHANGES; CHILDREN; DISEASE
AB Pneumococcal disease is a leading cause of childhood mortality, globally. The pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide. However there are few studies evaluating PCV impacts in low- and middle-income countries (LMIC) because measuring the impact of PCV on pneumococcal disease in LMICs is challenging. We review the role of pneumococcal carriage studies for the evaluation of PCVs in LM1C5 and discuss optimal methods for conducting these studies. Fifteen carriage studies from 13 LMICs quantified the effects of PCV on carriage, and identified replacement carriage serotypes in the post-PCV era. Ten studies reported on the indirect effects of PCV on carriage. Results can be used to inform cost-effectiveness evaluations, guide policy decisions on dosing and product, and monitor equity in program implementation. Critically, we highlight gaps in our understanding of serotype replacement disease in LMICs and identify priorities for research to address this gap. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Chan, Jocelyn; Nguyen, Cattram D.; Dunne, Eileen M.; Mulholland, E. Kim; Satzke, Catherine; Russell, Fiona M.] Murdoch Childrens Res Inst, New Vaccines Grp, Melbourne, Vic, Australia.
   [Chan, Jocelyn; Nguyen, Cattram D.; Dunne, Eileen M.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Mulholland, E. Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Mungun, Tuya] Minist Hlth, NCCD, Ulaanbaatar, Mongolia.
   [Pomat, William S.] Papua New Guinea Inst Med Res, Infect & Immun Unit, Goroka, Papua N Guinea.
   [Pomat, William S.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA, Australia.
   [Rafai, Eric] Minist Hlth & Med Serv, Suva, Fiji.
   [Satzke, Catherine] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia.
   [Weinberger, Daniel M.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Russell, Fiona M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia.
RP Chan, J (reprint author), Murdoch Childrens Res Inst, New Vaccines Grp, 50 Flemington Rd, Parkville, Vic, Australia.; Russell, FM (reprint author), Univ Melbourne, Dept Paediat, 50 Flemington Rd, Parkville, Vic, Australia.
EM jocelyn.chan@mcri.edu.au; fmruss@unimelb.edu.au
RI ; Satzke, Catherine/D-6501-2013
OI Dunne, Eileen/0000-0001-5542-0780; Satzke,
   Catherine/0000-0003-3164-8849; Weinberger, Daniel/0000-0003-1178-8086
FU National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia; Yale University (Fox Fellowship);
   Australian GovernmentAustralian Government
FX Thank you to Claire von Mollendorf for providing an advance copy of a
   submitted manuscript for this review. FMR and CS are supported by
   National Health and Medical Research Council fellowships. JC is
   supported by scholarships from Yale University (Fox Fellowship) and the
   Australian Government.
CR Abu Seir R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206927
   Adebanjo T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199363
   Adegbola RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103293
   Andrade AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098128
   Anh DD, 2007, TOHOKU J EXP MED, V213, P167, DOI 10.1620/tjem.213.167
   Baggett HC, 2017, CLIN INFECT DIS, V64, pS317, DOI 10.1093/cid/cix100
   Balsells E, 2018, J INFECTION, DOI [10.1016/J.jjinf.2018.06.004, DOI 10.1016/J.JJINF.2018.06.004]
   Bojang A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129649
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Centers for Disease Control and Prevention (CDC), STREPT LAB RES PROT
   Chan J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021512
   Collins DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082280
   Conklin L, 2014, PEDIATR INFECT DIS J, V33, pS109, DOI 10.1097/INF.0000000000000078
   Danino D, 2018, CLIN INFECT DIS
   De Waroux OL, 2015, PEDIATR INFECT DIS J, V34, P858, DOI 10.1097/INF.0000000000000717
   de Waroux OL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086136
   Deutscher M, 2012, J EPIDEMIOL GLOB HEA, V2, P73, DOI 10.1016/j.jegh.2012.03.001
   Driscoll AJ, 2017, CLIN INFECT DIS, V64, pS368, DOI 10.1093/cid/cix101
   Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8
   Egere U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049143
   Fadlyana E, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0058-1
   Fan RR, 2016, EMERG INFECT DIS, V22, P1996, DOI 10.3201/eid2211.160902
   Flasche S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0882-9
   Flasche S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001839
   Flasche S, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004173
   Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083
   Greenberg D, 2011, PEDIATR INFECT DIS J, V30, P227, DOI 10.1097/INF.0b013e3181f87802
   Halloran ME, 1999, EPIDEMIOL REV, V21, P73, DOI 10.1093/oxfordjournals.epirev.a017990
   HALLORAN ME, 1991, EPIDEMIOLOGY, V2, P331, DOI 10.1097/00001648-199109000-00004
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   Hammitt LL, 2006, J INFECT DIS, V193, P1487, DOI 10.1086/503805
   Hammitt LL, 2018, INT S PNEUM PNEUM DI
   Hanke CR, 2016, PEDIATR INFECT DIS J, V35, P432, DOI 10.1097/INF.0000000000001030
   Hanquet G, 2013, VACCINE, V31, P5634, DOI 10.1016/j.vaccine.2013.07.006
   Haraldsson A, 2018, LANCET GLOB HEALTH, V6, pE1264, DOI 10.1016/S2214-109X(18)30489-3
   Heinsbroek E, 2018, VACCINE, V36, P7369, DOI 10.1016/j.vaccine.2018.10.021
   Heinsbroek E, 2016, AM J EPIDEMIOL, V183, P70, DOI 10.1093/aje/kwv134
   Hill PC, 2010, CLIN INFECT DIS, V50, P1468, DOI 10.1086/652443
   Howard LM, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx161
   Huong TTV, 2011, PEDIATR INFECT DIS J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Ikuse T, 2018, EPIDEMIOL INFECT, V146, DOI 10.1017/S0950268818002133
   International Vaccine Access Center (IVAC), 2018, VIEW HUB
   International Vaccine Access Center; U.S. Centers for Disease Control and Prevention; University of College London; Agence de Medecine Preventive; World Health Organization HQ; Pan-American Health Organization, 2017, PNEUM CONJ VACC PCV
   Jayasinghe S, 2018, CLIN INFECT DIS, V67, P367, DOI 10.1093/cid/ciy129
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Kandasamy R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114286
   Klugman KP, P NATL ACAD SCI US, P12896
   Lai J, 2013, BMC INFECT DIS, V13, P1
   Levy C, 2020, CLIN INFECT DIS, V70, P446, DOI 10.1093/cid/ciz221
   Lewnard JA, 2019, LANCET INFECT DIS, P3099, DOI [10.1016/51473-3049(18)30660-1, DOI 10.1016/51473-3049(18)30660-1]
   Lo SW, 2019, LANCET INFECT DIS, V19, P759, DOI 10.1016/S1473-3099(19)30297-X
   Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS161, DOI 10.1097/INF.0000000000000084
   Lourenco J, 2018, BIORXIV
   Moore HC, 2012, J EPIDEMIOL COMMUN H, V66, P489, DOI 10.1136/jech.2010.122762
   Negash AA, 2019, OPEN FORUM INFECT DI, P6, DOI [10.1093/ofidinfz259, DOI 10.1093/OFIDINFZ259]
   Numminen E, 2015, SCI REP-UK, V5, DOI 10.1038/srep11344
   Nunes MC, 2013, PEDIATR INFECT DIS J, V32, pE192, DOI 10.1097/INF.0b013e31828683a3
   Nzenze SA, 2017, AM J EPIDEMIOL, V186, P435, DOI 10.1093/aje/kwx048
   Nzenze SA, 2015, J INFECT DIS, V212, P1082, DOI 10.1093/infdis/jiv167
   Nzenze SA, 2013, PEDIATR INFECT DIS J, V32, P1270, DOI 10.1097/01.inf.0000435805.25366.64
   Ojal J, 2017, VACCINE, V35, P4561, DOI 10.1016/j.vaccine.2017.07.019
   Parra EL, 2013, VACCINE, V31, P4033, DOI 10.1016/j.vaccine.2013.04.074
   Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697
   Reis JN, 2008, J INFECTION, V57, P204, DOI 10.1016/j.jinf.2008.06.017
   Roca A, 2012, CLIN INFECT DIS, V55, P816, DOI 10.1093/cid/cis554
   Roca A, 2015, VACCINE, V33, P7144, DOI 10.1016/j.vaccine.2015.11.012
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Rozenbaum MH, 2010, VACCINE, V28, P2367, DOI 10.1016/j.vaccine.2010.01.005
   Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077
   Satzke C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001903
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Schillberg E, 2014, CLIN INFECT DIS, V59, P651, DOI 10.1093/cid/ciu366
   Scott JR, 2012, J INFECT DIS, V205, P280, DOI 10.1093/infdis/jir730
   Seir R, 2018, BIORXIV
   Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Southern J, 2018, PLOS ONE, V16, P1
   Soysal A, 2016, VACCINE, V34, P3894, DOI 10.1016/j.vaccine.2016.05.043
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Tokarz R, 2013, J CLIN MICROBIOL, V51, P995, DOI 10.1128/JCM.02974-12
   Tricarico S, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0030-5
   Usuf E, 2019, CLIN INFECT DIS, V68, P1512, DOI 10.1093/cid/ciy726
   von Mollendorf C, 2019, VACCINE, V37, P4068, DOI 10.1016/j.vaccine.2019.05.078
   von Mollendorf C, 2015, PEDIATR INFECT DIS J, V34, P27, DOI 10.1097/INF.0000000000000484
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Weinberger DM, 2019, AM J EPIDEMIOL, V188, P160, DOI 10.1093/aje/kwy219
   Weinberger DM, 2013, AM J EPIDEMIOL, V178, P1488, DOI 10.1093/aje/kwt156
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Weinberger DM, 2011, EPIDEMIOLOGY, V22, P199, DOI 10.1097/EDE.0b013e3182087634
   Whitney CG, 2018, CLIN INFECT DIS, V67, P375, DOI 10.1093/cid/ciy135
   WHO, 2018, WHO IB VPD ROT SURV
   World Health Organization, 2018, SUBN IMM COV DAT
   World Health Organization, 2012, MEAS IMP STREPT PNEU, DOI [10.1038/nmat3063, DOI 10.1038/NMAT3063]
   Yildirim I, 2015, PEDIATRICS, V135, P495, DOI 10.1542/peds.2014-2426
   Yildirim I, 2010, VACCINE, V29, P283, DOI 10.1016/j.vaccine.2010.10.032
NR 95
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6299
EP 6309
DI 10.1016/j.vaccine.2019.08.073
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100011
PM 31500968
OA Other Gold
DA 2020-05-12
ER

PT J
AU McLaughlin, JM
   Jiang, Q
   Gessner, BD
   Swerdlow, DL
   Sings, HL
   Isturiz, RE
   Jodar, L
AF McLaughlin, John M.
   Jiang, Qin
   Gessner, Bradford D.
   Swerdlow, David L.
   Sings, Heather L.
   Isturiz, Raul E.
   Jodar, Luis
TI Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia
   in adults: A systematic review and pooled analysis
SO VACCINE
LA English
DT Review
DE Serotype 3; Community-acquired pneumonia (CAP); Effectiveness; Efficacy;
   13-valent pneumococcal conjugate vaccine (PCV13); Pooled analysis;
   Adults; Elderly
ID COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL
   CARRIAGE; RACIAL DISPARITIES; UNITED-STATES; DISEASE; 13-VALENT;
   EPIDEMIOLOGY; CHILDREN; EFFICACY
AB Background: Serotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.
   Methods: We performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.
   Results: Two published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged >= 65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2-75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7-76.9%]). No heterogeneity was observed.
   Conclusions: Currently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged >= 65 years. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [McLaughlin, John M.; Jiang, Qin; Gessner, Bradford D.; Swerdlow, David L.; Sings, Heather L.; Isturiz, Raul E.; Jodar, Luis] Pfizer Vaccines, Collegeville, PA 19426 USA.
RP McLaughlin, JM (reprint author), Pfizer Vaccines, Pneumococcal Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM john.mclaughlin@pfizer.com
FU Pfizer Inc.Pfizer
FX This study was sponsored by Pfizer Inc.
CR Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   Azarian T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006966
   Black SB, 2001, PEDIATR INFECT DIS J, V20, P1105, DOI 10.1097/00006454-200112000-00002
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Centers for Disease Control and Prevention Active Bacterial Core Surveillance Emerging Infections Program Network, 1997, ABC REP STREPT PNEUM
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P893
   Dagan R, 2016, VACCINE, V34, P4313, DOI 10.1016/j.vaccine.2016.06.075
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   DAVIDSON M, 1994, J INFECT DIS, V170, P368, DOI 10.1093/infdis/170.2.368
   De Serres G, 2013, EUROSURVEILLANCE, P18
   Dominguez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183191
   French N, 2016, MALAWI MED J, V28, P115, DOI 10.1056/NEJMoa0903029
   Gessner BD, 2019, VACCINE, V37, P5777, DOI 10.1016/j.vaccine.2018.05.097
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Haber M, 2015, EPIDEMIOL INFECT, V143, P1417, DOI 10.1017/S0950268814002179
   Hanquet G, 2018, THORAX
   Huang SS, 2009, PEDIATRICS, V124, pE1, DOI 10.1542/peds.2008-3099
   Huijts SM, 2018, CLIN MICROBIOL INFEC, V24, P764, DOI 10.1016/j.cmi.2017.10.006
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443
   Kieninger DM, 2010, VACCINE, V28, P4192, DOI 10.1016/j.vaccine.2010.04.008
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043
   Lipsitch M, 2016, INT J EPIDEMIOL, V45, P2060, DOI 10.1093/ije/dyw124
   Lopardo G, 2018, SOC ARG MED 26 C NAC
   Matanock A., 2018, ADVISORY COMMITTEE I
   McLaughlin JM, 2019, HUM VACC IMMUNOTHER, V15, P584, DOI 10.1080/21645515.2018.1538611
   McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312
   Miller E, 2011, VACCINE, V29, P9127, DOI 10.1016/j.vaccine.2011.09.112
   Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7
   Moore MR, 2014, UPDATE EFFECTIVENESS
   Ojal J, 2017, VACCINE, V35, P4652, DOI 10.1016/j.vaccine.2017.05.088
   Pemiciaro S, 2018, 28 ECCMID
   Pfizer Inc, 2015, RESP FDA STN 125324
   Pilishvili T, 2018, 11 INT S PNEUM PNEUM
   Pilishvili T., 2018, IMPACT PCV13 INVASIV
   Pilishvili T., 2019, FEB 2019 ACIP M
   Pilishvili T., 2018, ADVISORY COMMITTEE I
   Poehling KA, 2006, JAMA-J AM MED ASSOC, V295, P1668, DOI 10.1001/jama.295.14.1668
   Prato R, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019034
   Pride MW, 2012, CLIN VACCINE IMMUNOL, V19, P1131, DOI 10.1128/CVI.00064-12
   Principi N, 2015, HUM VACC IMMUNOTHER, V11, P1494, DOI 10.1080/21645515.2015.1033600
   Ramani RR, 2004, AM J PUBLIC HEALTH, V94, P958, DOI 10.2105/AJPH.94.6.958
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Savulescu C., 2016, ESCAIDE
   Schwartz LM, 2017, VACCINE, V35, P184, DOI 10.1016/j.vaccine.2016.10.077
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920
   Spicer JO, 2014, PEDIATR INFECT DIS J, V33, P158, DOI 10.1097/INF.0000000000000025
   Suaya JA, 2018, VACCINE, V36, P1477, DOI 10.1016/j.vaccine.2018.01.049
   van der Linden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161257
   Vila-Corcoles A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3096-7
   Webber C, 2017, VACCINE, V35, P1266, DOI 10.1016/j.vaccine.2017.01.032
   Weinberger R, 2016, VACCINE, V34, P2062, DOI 10.1016/j.vaccine.2016.02.043
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Wortham JM, 2014, CLIN INFECT DIS, V58, P1250, DOI 10.1093/cid/ciu108
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6310
EP 6316
DI 10.1016/j.vaccine.2019.08.059
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100012
PM 31522807
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wiyeh, AB
   Cooper, S
   Jaca, A
   Mavundza, E
   Ndwandwe, D
   Wiysonge, CS
AF Wiyeh, Alison B.
   Cooper, Sara
   Jaca, Anelisa
   Mavundza, Edison
   Ndwandwe, Duduzile
   Wiysonge, Charles S.
TI Social media and HPV vaccination: Unsolicited public comments on a
   Facebook post by the Western Cape Department of Health provide insights
   into determinants of vaccine hesitancy in South Africa
SO VACCINE
LA English
DT Article
DE HPV vaccine; Vaccine hesitancy; Vaccine acceptance; South Africa; Social
   media
ID HUMAN-PAPILLOMAVIRUS VACCINE; ACCEPTABILITY; KNOWLEDGE; ATTITUDES;
   AWARENESS; IMPACT
AB On the 4 February 2019, the Western Cape Department of Health's Facebook page announced the implementation of a school-based vaccination campaign aimed to administer the first doses of human papillomavirus (HPV) vaccine in public schools to Grade 4 girls who are nine years old. This announcement was met with a flurry of social media responses posted on the campaign's Facebook page. This study identifies determinants of vaccine hesitancy amongst responses provided by social media users to this post. On 8 March 2019, we conducted a qualitative study including all 157 comments to the Facebook post. The post had 659 'emotion' reactions: 574 "likes", 62 "loves", 21 "angry faces", 2 "laughs", 2 "wows" and 1 "sad face". An overwhelming majority (636/659 i.e. 97%) of reactions were favourable to the HPV vaccination campaign. Out of the 157 comments, we judged 52 (33%) of them to be 'hesitant', suggesting that people with negative reactions though few in number, were more likely to be vocal deniers. Concern around the safety of HPV vaccines including effects on reproductive health was the most common theme identified. Other emerging themes included: risk of cervical cancer perceived as being low, issues around consent, concerns that girls are being used for research, questionable vaccine effectiveness, use of the school-based strategy for the campaign, risk-benefits calculations of HPV vaccination and constraints such as stock-outs. Knowing someone who had been affected or being at risk of cervical cancer, having knowledge about the causes of cervical cancer, confidence in the effectiveness and safety of the vaccine, knowing the vaccine was being used in high income settings, and having strong recommendations from the World Health Organisation and key actors seemed to increase the willingness to accept the vaccine. The magnitude and causes of HPV vaccine hesitancy need to be investigated to ensure the success of this programme. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wiyeh, Alison B.; Cooper, Sara; Jaca, Anelisa; Mavundza, Edison; Ndwandwe, Duduzile; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.
   [Wiysonge, Charles S.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Stellenbosch, South Africa.
   [Wiysonge, Charles S.] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa.
RP Wiyeh, AB (reprint author), South African Med Res Council, Cochrane South Africa, POB 19070,Francie van Zijl Dr, ZA-7505 Tygerberg, South Africa.
EM wberiliy@yahoo.co.uk; sara.cooper@mrc.ac.za; Anelisa.jaca@mrc.ac.za;
   Edison.mavundza@mrc.ac.za; Duduzile.ndwandwe@mrc.ac.za;
   charles.wiysonge@mrc.ac.za
RI Wiysonge, Charles/AAF-2845-2019; DE Ndwandwe, Duduzile/L-2296-2013
OI Wiysonge, Charles/0000-0002-1273-4779; Ndwandwe,
   Duduzile/0000-0001-7129-3865; Wiyeh, Alison Beriliy/0000-0003-0417-3948
FU South African Medical Research Council; National Research Foundation of
   South AfricaNational Research Foundation - South Africa [106035]
FX This work was supported by the South African Medical Research Council
   and the National Research Foundation of South Africa grant number
   106035. The views expressed in this article are those of the authors,
   and do not necessarily reflect the views of Cochrane South Africa, the
   South African Medical Research Council, or any other institution with
   which the authors are affiliated.
CR Arbyn M, 2018, EXPERT REV VACCINES, V17, P1085, DOI 10.1080/14760584.2018.1548282
   Ashrafi GH, 2016, PATHOGENESIS HUMAN P
   Basch CH, 2019, HUM VACC IMMUNOTHER, V15, P1476, DOI 10.1080/21645515.2018.1560774
   Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008
   Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601
   Bingham A, 2009, ARCH PEDIAT ADOL MED, V163, P455, DOI 10.1001/archpediatrics.2009.50
   Bloem P, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002325
   Buller DB, 2019, HUM VACC IMMUNOTHER, V15, P1479, DOI 10.1080/21645515.2019.1581555
   Cooper S, 2018, HUM VACCIN IMMUNOTHE
   De Vincenzo R, 2014, IN J WOMENS HEALTH, V6, P999, DOI 10.2147/IJWH.S50365
   Delany-Moretlwe S, 2018, GLOB HEALTH-SCI PRAC, V6, P425, DOI 10.9745/GHSP-D-18-00090
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Francis SA, 2011, VACCINE, V29, P8760, DOI 10.1016/j.vaccine.2011.07.116
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Green J, 2004, QUALITATIVE METHODS, P262
   Harries J, 2009, VACCINE, V27, P38, DOI 10.1016/j.vaccine.2008.10.033
   Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2
   Karafillakis E, 2019, HUM VACC IMMUNOTHER
   Katagwa VN, 2014, EUR J CANCER PREV, V23, P294, DOI 10.1097/CEJ.0000000000000021
   Katz IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072094
   LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   LATSUZBAIA A, 2018, COCHRANE DB SYST REV, V6, DOI DOI 10.1128/GENOMEA.00114-18
   Liu XX, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0708-8
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Muhwezi WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106686
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Ngcobo N J, 2018, S Afr Med J, V109, P13, DOI 10.7196/SAMJ.2018.v109i1.13723
   Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543
   Paul P, 2015, INFLUENCES PARENTAL
   Perlman S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090912
   Remes P, 2012, VACCINE, V30, P5363, DOI 10.1016/j.vaccine.2012.06.025
   Turiho Andrew Kampikaho, 2017, BMC Res Notes, V10, P431, DOI 10.1186/s13104-017-2749-8
   WHO, 2017, WKLY EPIDEMIOL REC
   WHO Europe, 2017, BEST PRACT GUID RESP
   Wiyeh AB, 2018, EXPERT REV VACCINES, V17, P1063, DOI 10.1080/14760584.2018.1549994
   World Health Organization (WHO), 2018, BACKGR PAP SAGE DEL
NR 37
TC 1
Z9 1
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6317
EP 6323
DI 10.1016/j.vaccine.2019.09.019
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100013
PM 31521412
DA 2020-05-12
ER

PT J
AU Mokomane, M
   Esona, MD
   Bowen, MD
   Tate, JE
   Steenhoff, AP
   Lechiile, K
   Gaseitsiwe, S
   Seheri, LM
   Magagula, NB
   Weldegebriel, G
   Pernica, JM
   Mwenda, JM
   Kasvosve, I
   Parashar, UD
   Goldfarb, DM
AF Mokomane, M.
   Esona, M. D.
   Bowen, M. D.
   Tate, J. E.
   Steenhoff, A. P.
   Lechiile, K.
   Gaseitsiwe, S.
   Seheri, L. M.
   Magagula, N. B.
   Weldegebriel, G.
   Pernica, J. M.
   Mwenda, J. M.
   Kasvosve, I
   Parashar, U. D.
   Goldfarb, D. M.
TI Diversity of Rotavirus Strains Circulating in Botswana before and after
   introduction of the Monovalent Rotavirus Vaccine
SO VACCINE
LA English
DT Article
DE Rotarix; G3P[8] genotype; Botswana; Acute gastroenteritis; Multiplexed
   one-step genotyping
ID EQUINE-LIKE; GASTROENTERITIS; CHILDREN; DIARRHEA; IMPACT;
   IDENTIFICATION; SURVEILLANCE; REASSORTMENT; MORTALITY; PATHOGENS
AB Background: Globally, rotavirus is the leading cause of acute gastroenteritis (AGE) in children aged <5 years. Botswana introduced the monovalent rotavirus vaccine (Rotarix) in July 2012. To study the impact of this vaccine on rotavirus genotypes circulating in Botswana, a comparison of the genotypes pre-vaccination (2011-2012) and post-vaccination (2013-2018) periods was conducted.
   Subjects and methods: Residual samples from 284 children <5 years of age that tested positive for rotavirus by enzyme immunoassay were genotyped. One hundred and five samples were from the pre-vaccination period and 179 were from the post-vaccination period. Genotyping was performed using two multiplexed one-step reverse transcription polymerase chain reaction (RT-PCR) assays for the amplification and genotyping of rotavirus VP7 (G) and VP4 (P) genes.
   Results: Prior to vaccine introduction, the predominant rotavirus circulating genotypes were G9P[8] (n = 63, 60%) and G1P[8] (n = 22, 21%). During the vaccine period, G2P[4] was the predominant genotype (n = 49, 28%), followed by G9P[8] (n = 40, 22%) and G1P[8] (n = 33, 18.5%). There was a significant decline in the prevalence of G9P[8] (p = 0.001) in the post-vaccination period. There was also a notable decline in G1P[8]. A spike in G2P[4] was observed in 2013, one year post-vaccine introduction. Rotavirus strain G3P [4] (n = 8) was only detected in the post-vaccine introduction period. In 2018 there was a marked increase in genotype G3P[8] (p = 0.0003).
   Conclusions: The distribution of circulating rotavirus genotypes in Botswana changed after vaccine implementation. Further studies are needed to examine whether these changes are related to vaccination or simply represent natural secular variation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mokomane, M.] Univ Botswana, Fac Hlth Sci, Dept Med Lab Sci, Private Bag UB, Gaborone 00712, Botswana.
   [Mokomane, M.; Kasvosve, I] Botswana Natl Hlth Lab, Gaborone, Botswana.
   [Esona, M. D.; Bowen, M. D.; Tate, J. E.; Parashar, U. D.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Steenhoff, A. P.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Lechiile, K.] Botswana UPenn Partnership, Gaborone, Botswana.
   [Gaseitsiwe, S.] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
   [Seheri, L. M.; Magagula, N. B.] Sefako Makgatho Hlth Sci Univ, Diarrhoeal Pathogens Res Unit, WHO Reg Rotavirus Reference Lab, Ga Rankuwa, South Africa.
   [Weldegebriel, G.] WHO IST East & Southern Africa, Harare, Zimbabwe.
   [Pernica, J. M.] McMaster Univ, Hamilton, ON, Canada.
   [Mwenda, J. M.] WHO African Reg Off, Immunizat Vaccines & Dev Cluster, African Rotavirus Surveillance Network, Brazzaville, Rep Congo.
   [Goldfarb, D. M.] Univ British Columbia, Vancouver, BC, Canada.
RP Mokomane, M (reprint author), Univ Botswana, Fac Hlth Sci, Dept Med Lab Sci, Private Bag UB, Gaborone 00712, Botswana.
EM mbafana@gov.bw
OI Goldfarb, David/0000-0003-0835-9504; Bowen, Michael/0000-0002-2564-3083
FU Grand Challenges Canada [0009-02-01-01-02]
FX Funds for this project were received from Grand Challenges Canada (grant
   0009-02-01-01-02).
CR African Rotavirus Surveillance Network, UNPUB
   Aladin F, 2010, J CLIN VIROL, V47, P340, DOI 10.1016/j.jcv.2010.01.004
   Bar-Zen N, 2015, LANCET INFECT DIS, V15, P422, DOI 10.1016/S1473-3099(14)71060-6
   Binka FN, 2003, TROP MED INT HEALTH, V8, P840
   Burnett E, 2016, FUTURE VIROL, V11, P699, DOI 10.2217/fvl-2016-0082
   Cowley D, 2016, J GEN VIROL, V97, P403, DOI 10.1099/jgv.0.000352
   Creek TL, 2010, JAIDS-J ACQ IMM DEF, V53, P14, DOI 10.1097/QAI.0b013e3181bdf676
   Donato CM, 2014, INFECT GENET EVOL, V28, P434, DOI 10.1016/j.meegid.2014.08.009
   Doro R, 2014, INFECT GENET EVOL, V28, P446, DOI 10.1016/j.meegid.2014.08.017
   Enane LA, 2016, CLIN INFECT DIS, V62, pS168, DOI 10.1093/cid/civ1210
   Esona MD, 2015, J VIROL METHODS, V223, P96, DOI 10.1016/j.jviromet.2015.07.012
   Esona MD, 2010, J INFECT DIS, V202, pS205, DOI 10.1086/653575
   Estes M. K., 2007, FIELDS VIROLOGY, P1917
   Gastanaduy PA, 2016, CLIN INFECT DIS, V62, pS161, DOI 10.1093/cid/civ1207
   Gentsch JR, 2005, J INFECT DIS, V192, pS146, DOI 10.1086/431499
   GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992
   Goldfarb DM, 2014, J CLIN MICROBIOL, V52, P3922, DOI 10.1128/JCM.01894-14
   GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990
   Groome MJ, 2014, LANCET INFECT DIS, V14, P1096, DOI 10.1016/S1473-3099(14)70940-5
   Gurgel RQ, 2007, EMERG INFECT DIS, V13, P1571, DOI 10.3201/eid1310.070412
   Kasule M, 2003, TROP MED INT HEALTH, V8, P1137, DOI 10.1046/j.1360-2276.2003.01141.x
   Khandoker N, 2018, J MED VIROL, V90, P1040, DOI 10.1002/jmv.25067
   Kirkwood CD, 2010, J INFECT DIS, V202, pS43, DOI 10.1086/653548
   Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1
   Malasao R, 2015, VIRUS GENES, V50, P129, DOI 10.1007/s11262-014-1135-z
   Matthijnssens J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36841
   Medici MC, 2016, INFECT GENET EVOL, V40, P253, DOI 10.1016/j.meegid.2016.03.013
   Mokomane M, 2018, PEDIATR INFECT DIS J, V37, pE58, DOI [10.1097/INF.0000000000001828, 10.1097/inf.0000000000001828]
   Mokomane M, 2016, DIAGN MICR INFEC DIS, V86, P141, DOI 10.1016/j.diagmicrobio.2016.07.007
   Rega.kuleuven.be, 2019, ROT CLASS WORK GROUP
   Rivera R, 2013, INT J INFECT DIS, V17, pE762, DOI 10.1016/j.ijid.2013.03.016
   Roczo-Farkas S, 2018, J INFECT DIS, V218, P546, DOI 10.1093/infdis/jiy197
   Guerra SFS, 2016, J GEN VIROL, V97, P3131, DOI 10.1099/jgv.0.000626
   Seheri L M, 2018, Vaccine, V36, P7222, DOI 10.1016/j.vaccine.2017.11.068
   Shulman LM, 2011, EMERG INFECT DIS, V17, P44, DOI 10.3201/eid1701.101132
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Welch H, 2013, PEDIATR INFECT DIS J, V32, P570, DOI 10.1097/INF.0b013e3182847295
   World Health Organization, 2009, MAN ROT DET CHAR MET
NR 38
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6324
EP 6328
DI 10.1016/j.vaccine.2019.09.022
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100014
PM 31530468
DA 2020-05-12
ER

PT J
AU Tan, HY
   Lai, E
   Kunasekaran, M
   Chughtai, AA
   Trent, M
   Poulos, CJ
   MacIntyre, CR
AF Tan, Hao Yi
   Lai, Elisa
   Kunasekaran, Mohana
   Chughtai, Abrar A.
   Trent, Mallory
   Poulos, Christopher J.
   MacIntyre, Chandini R.
TI Prevalence and predictors of influenza vaccination among residents of
   long-term care facilities
SO VACCINE
LA English
DT Article
DE Influenza; Aged care; Long term care facilities; Outbreaks; Ageing
ID IMMUNIZATION; DETERMINANTS; OUTBREAKS; BARRIERS
AB Influenza is a respiratory illness which results in significant morbidity and mortality, especially in the older population. Older people living in Long-Term Care Facilities (LTCFs) have a significantly higher risk of infection and complications from influenza. Influenza vaccine is considered the best strategy to prevent infection in high-risk populations. In Australia, the Communicable Diseases Network Australia (CNDA) suggests a vaccination coverage rate of 95% in both staff and residents(1). This study aims to measure the vaccination coverage rates for residents in LTCFs and identify predictors of vaccination uptake for these individuals.
   This study was conducted in nine LTCFs in four sites from March to September 2018. This was done via medical record reviews for residents over 65 years old in these LTCFs, collecting information such as vaccination status, age, gender, ethnicity and occupation. Simple and multivariable logistic regression was used to calculate the Odds Ratio (OR) to determine significant predictors of influenza vaccination uptake.
   The overall vaccination rate among LTCF residents was 83.6%. Significant predictors of vaccination were LTCF location, ethnicity and previous year vaccination status. Residents in LTCF Site D were less likely to be vaccinated compared to Site A (OR 0.11, 95% Cl 0.02-0.61), non-Caucasians were less likely to get vaccinated (OR 0.09, 95% CI 0.01-0.67), and residents who refused the 2017 vaccine were less likely to be vaccinated (OR 0.04, 95% CI 0.01-0.15).
   Compared with previous Australian studies on LTCF vaccination rates, the overall vaccination rate was high in these LTCFs (83.6% versus 66-84%), but it varied across different sites. Reasons for varying vaccination rates should be explored further - for example, lower rates in non-Caucasians with diverse cultural backgrounds. Better understanding the causes of under-vaccination can help improve vaccination programs in LTCFs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tan, Hao Yi; Lai, Elisa; Chughtai, Abrar A.; Poulos, Christopher J.] Univ New South Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW, Australia.
   [Kunasekaran, Mohana; Trent, Mallory; MacIntyre, Chandini R.] Univ New South Wales, Kirby Inst, UNSW Med, Biosecur Program, Sydney, NSW, Australia.
   [Poulos, Christopher J.] HammondCare, Sydney, NSW, Australia.
RP Trent, M (reprint author), Univ New South Wales, Kirby Inst, UNSW Med, Biosecur Program, Sydney, NSW, Australia.
EM mallory.trent@unsw.edu.au
FU NHMRC Principal Research FellowshipNational Health and Medical Research
   Council of Australia [1137582]
FX The authors thank the staff at the four participating LTCF5 for their
   assistance with the study. Your help has been greatly valued. CR
   Maclntyre is supported by a NHMRC Principal Research Fellowship, grant
   number 1137582.
CR Australian Government Department of Health, 2017, 2017 INFL SEAS AUSTR
   Australian Government Department of Health, 2019, MAND INFL FLU VACC P
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Barrett SC, 2019, J RACIAL ETHN HEALTH, V6, P153, DOI 10.1007/s40615-018-0510-1
   Bates AS, 1998, PEDIATRICS, V101, P591, DOI 10.1542/peds.101.4.591
   Booy R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046509
   Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089
   Bush Kym A, 2004, Commun Dis Intell Q Rep, V28, P396
   Centers for Disease Control and Prevention, 2019, PEOPL HIGH RISK FLU
   Demicheli V, 2018, COCHRANE DB SYST REV, P2
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x
   Egede LE, 2003, AM J PUBLIC HEALTH, V93, P2074, DOI 10.2105/AJPH.93.12.2074
   Elias C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4556-5
   European Centre for Disease Prevention and Control, 2018, FACTSH SEAS INFL
   Fiscella K, 2002, MED CARE, V40, P52, DOI 10.1097/00005650-200201000-00007
   Gaillat J, 2009, EUR J CLIN MICROBIOL, V28, P1077, DOI 10.1007/s10096-009-0751-3
   Gilbert GL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012562
   Halliday L, 2003, AUST NZ J PUBL HEAL, V27, P70, DOI 10.1111/j.1467-842X.2003.tb00383.x
   Hebert PL, 2005, HEALTH SERV RES, V40, P517, DOI 10.1111/j.1475-6773.2005.0e371.x
   Helbert M., 2016, IMMUNOLOGY MED STUDE
   Hendry A, 2018, NSW ANN IMMUN COVERA, V2016
   International Monetary Fund, 2018, WORLD EC OUTLOOK
   Jain A, 2017, VACCINE, V35, P2315, DOI 10.1016/j.vaccine.2017.03.013
   Jean Li-Kim-Moy, 2016, COMMUN DIS INTELL, V40
   Lansbury LE, 2017, INFLUENZA OTHER RESP
   Lester RT, 2003, INFECT CONT HOSP EP, V24, P839, DOI 10.1086/502146
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Martinez-Baz I, 2012, PREV MED, V55, P246, DOI 10.1016/j.ypmed.2012.06.020
   Monto AS, 2004, CLIN INFECT DIS, V39, P459, DOI 10.1086/422646
   Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0
   Rosewell A, 2010, EPIDEMIOL INFECT, V138, P1126, DOI 10.1017/S0950268809991440
   Sayers G, 2013, EPIDEMIOL INFECT, V141, P357, DOI 10.1017/S0950268812000659
   Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455
   Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199
   Sheikh-Mohammed M, 2006, MED J AUSTRALIA, V185, P594, DOI 10.5694/j.1326-5377.2006.tb00721.x
   Simonsen L, 2007, LANCET INFECT DIS, V7, P658, DOI 10.1016/S1473-3099(07)70236-0
   Stephenson I, 2002, OCCUP MED-OXFORD, V52, P241, DOI 10.1093/occmed/52.5.241
   Stohr K, 2002, LANCET INFECT DIS, V2, P517, DOI 10.1016/S1473-3099(02)00366-3
   SYPSA V, 2009, EUROSURVEILLANCE, V14, P2
   Takayama M, 2012, PREV MED, V54, P358, DOI 10.1016/j.ypmed.2012.03.008
   Talbot HK, 2017, INFECT DIS CLIN N AM, V31, P757, DOI 10.1016/j.idc.2017.07.005
   Winston CA, 2006, J AM GERIATR SOC, V54, P303, DOI 10.1111/j.1532-5415.2005.00585.x
NR 44
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6329
EP 6335
DI 10.1016/j.vaccine.2019.09.021
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100015
PM 31526622
DA 2020-05-12
ER

PT J
AU Wiley, KE
   Walker, J
   Lower, T
   Massey, PD
   Durrheim, DN
   Khandaker, G
AF Wiley, Kerrie E.
   Walker, Jacina
   Lower, Tony
   Massey, Peter D.
   Durrheim, David N.
   Khandaker, Gulam
TI Australian beef industry worker's knowledge, attitudes and practices
   regarding Q fever: A pilot study
SO VACCINE
LA English
DT Article
DE Attitudes; Australia; Beef farmer; Q fever; Vaccine; Zoonosis
ID VACCINATION
AB Background: Q fever is a vaccine-preventable zoonotic infection with potentially severe health outcomes and high economic costs that affects agricultural workers, including beef and cattle industry workers, however this population historically have sub-optimal vaccine uptake.
   Objective: To gather quantitative and qualitative pilot data from Australian beef industry workers on their knowledge, attitudes and practices around Q fever and Q fever vaccination.
   Methods: A mixed methods approach was used to ascertain the Q fever disease risk perception and vaccination behavior of a purposive convenience sample of beef industry workers attending an industry expo in Rockhampton, Queensland, Australia between May 7th and 9th, 2018.
   Results: The quantitative survey response rate was 83% (n = 86). More than 70% of respondents reported exposure to known Q fever risk factors. Eighty six percent were aware of Q fever, the self-reported uptake of Q fever vaccine was 27% and 9% reported undertaking testing which showed evidence of previous infection. Five main themes emerged from the qualitative data: "Finding the time" among other life priorities to attend a doctor for a vaccine; "Employer responsibility" to provide the vaccine; "My doctor knows me" and could suggest Q fever vaccination; "Assigning Risk" across a range of attitudes, including thinking it would not happen to them, 'fatalism', and knowing the danger but taking the risk anyway; and "The Need for Outreach" vaccine delivery services in their communities.
   Significance: These data suggest that a coordinated public health approach to testing and vaccine provision, coupled with an awareness campaign among regional doctors to prompt them to routinely ask patients about their Q fever risk and vaccination history, should form part of a broad approach to Q fever control and prevention. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wiley, Kerrie E.] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Walker, Jacina; Khandaker, Gulam] Cent Queensland Hosp & Hlth Serv, Publ Hlth Unit, Rockhampton, Qld, Australia.
   [Lower, Tony] Univ Sydney, Fac Med & Hlth, Sch Rural Hlth Dubbo, Sydney, NSW, Australia.
   [Massey, Peter D.] Hunter New England Populat Hlth, Newcastle, NSW, Australia.
   [Durrheim, David N.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
RP Wiley, KE (reprint author), Univ Sydney, Room 127 Edward Ford Bldg A27, Sydney, NSW, Australia.
EM Kerrie.Wiley@sydney.edu.au
CR Armitage CJ, 2000, PSYCHOL HEALTH, V15, P173, DOI 10.1080/08870440008400299
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, Q FEV AUSTR IMM HDB
   Australian Technical Advisory Group on Immunisation (ATAGI), 2017, AUSTR IMM HDB
   Barnard M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182266
   Beef Australia, 2018, BEEF AUSTR ROCKH ROC
   Bond KA, 2016, EPIDEMIOL INFECT, V144, P1129, DOI 10.1017/S0950268815002368
   Boyatzis R. E., 1998, TRANSFORMING QUALITA
   Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038
   Communicable Diseases Branch Health Protection New South Wales (NSW), 2018, Q FEV EARL DIAGN VAC
   Dixon J, 2000, Aust J Rural Health, V8, P254, DOI 10.1046/j.1440-1584.2000.00327.x
   Eastwood K, 2018, AUST J GEN PRACT, V47, P112
   Eldin C, 2017, CLIN MICROBIOL REV, V30, P115, DOI 10.1128/CMR.00045-16
   Gidding HF, 2009, VACCINE, V27, P2037, DOI 10.1016/j.vaccine.2009.02.007
   Guatteo R, 2011, VET MICROBIOL, V149, P1, DOI 10.1016/j.vetmic.2010.10.007
   Kermode M, 2003, AUST NZ J PUBL HEAL, V27, P390, DOI 10.1111/j.1467-842X.2003.tb00415.x
   Krassan Covan E., 2010, SAGE HDB GROUNDED TH, P68
   Lower T, 2017, AUST J RURAL HEALTH, V25, P306, DOI 10.1111/ajr.12346
   Mori M, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-017-0248-y
   Morse JM, 2010, SAGE HDB GROUNDED TH, P235
   Queensland Health, 2011, SURV NOT COND Q FEV
   Sivabalan P, 2017, ONE HEALTH-AMSTERDAM, V3, P51, DOI 10.1016/j.onehlt.2017.03.002
   Sloan-Gardner TS, 2017, EPIDEMIOL INFECT, V145, P787, DOI 10.1017/S0950268816002843
   Thomas S, 2018, VACCINE, V36, P2596, DOI 10.1016/j.vaccine.2018.03.072
   Tozer SJ, 2014, ZOONOSES PUBLIC HLTH, V61, P105, DOI 10.1111/zph.12051
   van Asseldonk MAPM, 2013, PREV VET MED, V112, P27, DOI 10.1016/j.prevetmed.2013.06.002
   WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278-6133.7.4.355
   Wiley KE, 2013, VACCINE, V31, P3972, DOI 10.1016/j.vaccine.2013.06.015
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6336
EP 6341
DI 10.1016/j.vaccine.2019.09.020
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100016
PM 31526617
DA 2020-05-12
ER

PT J
AU Gil-Prieto, R
   Walter, S
   San-Roman-Montero, J
   Marin-Garcia, P
   Gonzalez-Escalada, A
   Gil-de-Miguel, A
AF Gil-Prieto, Ruth
   Walter, Stefan
   San-Roman-Montero, Jesus
   Marin-Garcia, Patricia
   Gonzalez-Escalada, Alba
   Gil-de-Miguel, Angel
TI Paediatric hospitalizations due to whooping cough in Spain (1997-2017)
SO VACCINE
LA English
DT Article
DE Whooping cough; Pertussis; Vaccine; Spain; Epidemiology;
   Hospitalizations
ID ACELLULAR PERTUSSIS-VACCINE; IMMUNIZATION; IMPACT; TRANSMISSION;
   INFECTIONS; STRATEGIES; DIPHTHERIA; RESURGENCE; TETANUS; BURDEN
AB This epidemiological survey estimates the burden of whooping cough in infants up to 12 months old in Spain during a twenty-one-year period (1997-2017). The survey was conducted by reviewing data from the Spanish Surveillance System for Hospital Data. All hospitalizations due to whooping cough for infants, reported during the 1997-2017 period, were analysed. Codes were selected from the International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 033.0-033.9. To explore the latest national outbreak and the implementation of vaccination in pregnant women, analyses were stratified to compare the following periods: 1997-2010, 2011-2015 and 2016-2017. A total of 13,352 hospital discharges for whooping cough in infants up to 12 months old were reported. A total of 6850 discharges in the period 1997-2010, 5271 in the period 2011-2015 and 1231 in 2016-2017 were identified. The annual hospitalization rate prior to 2011 was 131.02 cases per 100,000 infants; in 2011-2015, the rate was significantly higher (250.13 cases per 100,000 infants) and in 2016-2017 it decreased (157.69 cases per 100,000 infants). Most of the cases (n = 11,446) occurred in infants under 4 months of age, with hospitalization rates of 328.80, 670.81 and 385.84 cases per 100,000 infants up to 4 months of age in the periods 1997-2010, 2011-2015 and 2016-17, respectively. Thirty-four deaths occurred in the period 1997-2010, 36 in the period 2011-2015 and 4 in 2016-2017. All of the deaths occurred in infants under 4 months old. The case fatality rate did not vary significantly across the study periods. Whooping cough infections concentrate in infants up to 4 months of age in Spain. Public health measures such as vaccination of pregnant women, caregivers, health care professionals and relatives, especially young parents, could reduce the hospitalization burden during the current outbreak. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Gil-Prieto, Ruth; Gil-de-Miguel, Angel] Rey Juan Carlos Univ, Area Prevent Med & Publ Hlth, Avda Atenas S-N, Madrid 28922, Spain.
   [Walter, Stefan] Hosp Univ Getafe, Fdn Invest, Madrid, Spain.
   [Walter, Stefan] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
   [San-Roman-Montero, Jesus] Rey Juan Carlos Univ, Area Med, Madrid, Spain.
   [Marin-Garcia, Patricia] Rey Juan Carlos Univ, Area Med Immunol, Madrid, Spain.
   [Gonzalez-Escalada, Alba] Rey Juan Carlos Univ, Area Med Microbiol, Madrid, Spain.
RP Gil-Prieto, R (reprint author), Rey Juan Carlos Univ, Area Prevent Med & Publ Hlth, Avda Atenas S-N, Madrid 28922, Spain.
EM ruth.gil@urjc.es
FU Sanofi Pasteur Spain
FX This research study is part of the research activities of the "Cathedra
   in Vaccines Research from Rey Juan Carlos University", which is
   sponsored by Sanofi Pasteur Spain.
CR Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   [Anonymous], COB VAC
   Barlow RS, 2014, CLIN INFECT DIS, V58, P1523, DOI 10.1093/cid/ciu156
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Centers for Disease Control and Prevention, PERT OUTBR TRENDS
   Cherry JD, 2012, NEW ENGL J MED, V367, P785, DOI 10.1056/NEJMp1209051
   Crespo I, 2015, PLOS ONE, V10
   Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925
   Ghaswalla P, 2019, AM J PREV MED, V57, pE87, DOI 10.1016/j.amepre.2019.04.013
   Prieto RG, 2009, VACCINE, V27, P2669, DOI 10.1016/j.vaccine.2009.02.063
   Gil-Prieto R, 2014, VACCINE, V32, P277, DOI 10.1016/j.vaccine.2013.11.008
   Gil-Prieto R, 2011, VACCINE, V29, P5765, DOI 10.1016/j.vaccine.2011.05.089
   Gil-Prieto R, 2009, HUM VACCINES, V5, P748, DOI 10.4161/hv.5.11.9792
   Hoshi S, 2018, VACCINE, V36, P5133, DOI 10.1016/j.vaccine.2018.07.026
   Fernandez-Cano MI, 2014, ENFERM INFEC MICR CL, V32, P638, DOI 10.1016/j.eimc.2013.11.006
   Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850
   Lavine JS, 2012, VACCINE, V30, P544, DOI 10.1016/j.vaccine.2011.11.065
   Maria de Viarce Torres de Mier Noemi Lopez-Pereajosefa Masa Calles y la Red Nacional de Vigilancia Epidemiologica (RENAVE), 2018, SIT TOS FER ESP 1998
   *MIN SAN CONS, 1996, [No title captured], P375
   Peiro S, 1999, REV NEUROLOGIA, V29, P651, DOI 10.33588/rn.2907.99330
   Perrett K, 2017, PEDIATR DRUGS, V19, P313, DOI 10.1007/s40272-017-0231-7
   Rivero Cuadrado A, 2000, REV FUENTES ESTADIST, V49, P18
   Santos JM, 2008, VACUNAS, V9, P50
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Shapiro ED, 2012, JAMA-J AM MED ASSOC, V308, P2149, DOI 10.1001/jama.2012.65031
   Sizaire V, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.32.20875
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Tan TN, 2015, PEDIATR INFECT DIS J, V34, pE222, DOI 10.1097/INF.0000000000000795
   Van Bellinghen LA, 2018, HUM VACC IMMUNOTHER, V17, P1
   van der Maas NAT, 2013, VACCINE, V31, P4541, DOI 10.1016/j.vaccine.2013.07.060
   Winter K, 2018, PEDIATR INFECT DIS J, V37, P324, DOI 10.1097/INF.0000000000001761
   Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P13
   Wymann MN, 2011, VACCINE, V29, P2058, DOI 10.1016/j.vaccine.2011.01.017
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6342
EP 6347
DI 10.1016/j.vaccine.2019.09.017
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100017
PM 31526619
OA Other Gold
DA 2020-05-12
ER

PT J
AU Burnett, EM
   Francois, J
   Sreenivasan, N
   Wannemuehler, K
   Faye, PC
   Tohme, RA
   Delly, P
   Deslouches, YG
   Etheart, MD
   Dismer, AM
   Patel, R
   Date, K
AF Burnett, Eleanor M.
   Francois, Jeannot
   Sreenivasan, Nandini
   Wannemuehler, Kathleen
   Faye, Papa Coumba
   Tohme, Rania A.
   Delly, Patrick
   Deslouches, Yves Gaston
   Etheart, Melissa D.
   Dismer, Amber Marie
   Patel, Roopal
   Date, Kashmira
TI Oral cholera vaccination coverage after the first global stockpile
   deployment in Haiti, 2014
SO VACCINE
LA English
DT Article
DE Cholera; Cholera vaccine; Diarrhea
ID IMMUNIZATION DATA; POPULATION; QUALITY
AB Introduction: In 2014, an oral cholera vaccine (OCV) campaign targeting 185,314 persons aged >= 1 years was conducted in 3 departments via fixed post and door-to-door strategies. This was the first use of the global OCV stockpile in Haiti.
   Methods: We conducted a multi-stage cluster survey to assess departmental OCV coverage. Target population estimates were projected from the 2003 Haiti population census with adjustments for population growth and estimated proportion of pregnant women. In the three departments, we sampled 30/106 enumeration areas (EAs) in Artibonite, 30/244 EAs in Centre, and 20/29 EAs in Ouest; 20 households were systematically sampled in each EA. Household and individual interviews using a standard questionnaire were conducted in each selected household; data on OCV receipt were obtained from vaccination card or verbal report. We calculated OCV campaign coverage estimates and 95% confidence intervals (CIs) accounting for survey design.
   Results: Overall two-dose OCV coverage was 70% (95% CI: 60, 79), 63% (95% CI: 55, 71), and 44% (95% CI: 35, 53) in Artibonite, Centre, and Ouest, respectively. Two-dose coverage was higher in the 1-4 years age group than among those >= 15 years in Artibonite (difference: 11%; 95% CI: 5%, 17%) and Ouest (difference: 12%; 95% CI: 3, 20). A higher percentage of children aged 5-14 years received both recommended doses than did those >= 15 years (Artibonite: 14% (95% CI: 8%, 19%) difference; Centre: 11% difference (95% CI: 5%, 17%); Ouest: 10% difference (95% CI: 2%, 17%). The most common reason for not receiving any OCV dose was being absent during the campaign or not having heard about vaccination activities.
   Conclusions: While coverage estimates in Artibonite and Centre were comparable with other OCV campaigns in Haiti and elsewhere, inadequate social mobilization and outdated population estimates might have contributed to lower coverage in Ouest. Published by Elsevier Ltd.
C1 [Burnett, Eleanor M.; Wannemuehler, Kathleen; Tohme, Rania A.; Date, Kashmira] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA.
   [Francois, Jeannot; Delly, Patrick; Deslouches, Yves Gaston] Minist Publ Hlth & Populat, DELR, Port Au Prince, Haiti.
   [Sreenivasan, Nandini] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA.
   [Faye, Papa Coumba] Pan Amer Hlth Org, Port Au Prince, Haiti.
   [Etheart, Melissa D.; Patel, Roopal] Ctr Dis Control & Prevent, Port Au Prince, Haiti.
   [Dismer, Amber Marie] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA 30329 USA.
RP Burnett, EM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30329 USA.
EM wwg7@cdc.gov
FU Pan-American Health Organization
FX We would like to acknowledge the Pan-American Health Organization for
   funding this evaluation; Barbara Marston, Terri Hyde, Eric Mintz,
   Jacqueline Gindler for their support and insightful comments; Michel
   Cayemittes, Heloine Gerard, Josue Michaud and the interview teams with
   Institut Haitien de l'Enfance for their excellent field work; and
   Kristen Renneker, Brian Chu, Alex Pavluck with Task Force for Global
   Health for mobile data collection support.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P214
   Azman AS, 2016, EMERG INFECT DIS, V22, P1067, DOI 10.3201/eid2206.151592
   Baltazar CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198592
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Bosch-Capblanch X, 2009, TROP MED INT HEALTH, V14, P2, DOI 10.1111/j.1365-3156.2008.02181.x
   Burnett E, 2014, VACCINE
   Childs L, 2016, AM J TROP MED HYG, V95, P1305, DOI 10.4269/ajtmh.16-0555
   Cholera, 2015, WEEKLY EPIDEMIOLOGIC
   Dunkle SE, 2014, J INFECT DIS, V210, pS523, DOI 10.1093/infdis/jiu373
   Ivers LC, 2015, LANCET GLOB HEALTH, V3, pE162, DOI 10.1016/S2214-109X(14)70368-7
   Ivers LC, 2013, AM J TROP MED HYG, V89, P617, DOI 10.4269/ajtmh.13-0183
   Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021
   Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680
   Luquero FJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002465
   Phares CR, 2016, VACCINE, V34, P128, DOI 10.1016/j.vaccine.2015.10.112
   Population MSedl, 2012, NAT PLAN EL CHOL HAI
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Ronveaux O, 2005, B WORLD HEALTH ORGAN, V83, P503
   Rouzier V, 2013, AM J TROP MED HYG, V89, P671, DOI 10.4269/ajtmh.13-0171
   Sauvageot D, 2017, VACCINE, V35, P5194, DOI 10.1016/j.vaccine.2017.07.104
   Severe K, 2016, AM J TROP MED HYG, V94, P1136, DOI 10.4269/ajtmh.15-0700
   Tohme RA, 2015, EMERG INFECT DIS, V21, P984, DOI 10.3201/eid2106.141797
NR 23
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6348
EP 6355
DI 10.1016/j.vaccine.2019.09.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100018
PM 31521413
DA 2020-05-12
ER

PT J
AU Smiley, MA
   Sanford, DC
   Triplett, CA
   Callahan, D
   Frolov, V
   Look, J
   Ruiz, C
   Reece, JJ
   Miles, A
   Ruiz, E
   Ionin, B
   Shearer, JD
   Savransky, V
AF Smiley, M. Autumn
   Sanford, Daniel C.
   Triplett, Cheryl A.
   Callahan, Daniel
   Frolov, Vladimir
   Look, Jee
   Ruiz, Christian
   Reece, Joshua J.
   Miles, Aaron
   Ruiz, Ericka
   Ionin, Boris
   Shearer, Jeffry D.
   Savransky, Vladimir
TI Comparative immunogenicity and efficacy of thermostable (lyophilized)
   and liquid formulation of anthrax vaccine candidate AV7909
SO VACCINE
LA English
DT Article
DE Anthrax vaccine; CPG 7909; Lyophilized vaccine; Immunogenicity;
   Efficacy; Thermostable; Toxin neutralizing antibodies
ID INHALATIONAL ANTHRAX; DNA; ANTIGEN
AB The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for a postexposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the anthrax vaccine adsorbed (AVA) (Emergent BioSolutions Inc., Lansing, MI) bulk drug substance adjuvanted with the immunostimulatory oligodeoxynucleotide (ODN) compound, CPG 7909. The addition of CPG 7909 to AVA enhances both the magnitude and the kinetics of antibody responses in animals and human subjects, making AV7909 a suitable next-generation vaccine for use in a PEP setting. Emergent has produced a thermostable (lyophilized) formulation of AV7909 vaccine utilizing drying technology. The purpose of the study described here was to assess the immunogenicity and efficacy of the lyophilized formulation of the AV7909 vaccine candidate as compared with the liquid formulation in the guinea pig general-use prophylaxis (GUP) model. The study also provides initial information on the relationship between the immune response induced by the thermostable formulation of the vaccine, as measured by the toxin neutralization assay (TNA), and animal survival following lethal anthrax aerosol challenge. Results demonstrated that there were no significant differences in the immunogenicity or efficacy of lyophilized AV7909 against lethal anthrax spore aerosol challenge in the guinea pig model as compared to liquid AV7909. For both vaccine formulations, logistic regression modeling showed that the probability of survival increased as the pre-challenge antibody levels increased. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Smiley, M. Autumn; Sanford, Daniel C.; Triplett, Cheryl A.] Battelle Biomed Res Ctr, 1425 Plain City Georgesville Rd,JM7, West Jefferson, OH 43162 USA.
   [Callahan, Daniel; Frolov, Vladimir; Look, Jee; Ruiz, Christian; Reece, Joshua J.; Miles, Aaron; Ruiz, Ericka; Ionin, Boris; Shearer, Jeffry D.; Savransky, Vladimir] Emergent BioSolut Inc, 300 Profess Dr, Gaithersburg, MD 20879 USA.
RP Savransky, V (reprint author), Emergent BioSolut Inc, 300 Profess Dr, Gaithersburg, MD 20879 USA.
EM savranskyv@ebsi.com
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272201400038C]
FX This work was funded by contract HHSN272201400038C from the National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health, Department of Health and Human Services.
CR Bann JG, 2004, NATURE, V430, P843, DOI 10.1038/430843a
   Brossier F, 2001, TOXICON, V39, P1747, DOI 10.1016/S0041-0101(01)00161-1
   CDC, 2008, ACIP SUMM REP
   Chen DX, 2009, HUM VACCINES, V5, P26, DOI 10.4161/hv.5.1.6494
   Clapp T, 2014, VACCINE, V32, P3765, DOI 10.1016/j.vaccine.2014.05.037
   Davis HL, 1998, J IMMUNOL, V160, P870
   Diminsky D, 1999, VACCINE, V18, P3, DOI 10.1016/S0264-410X(99)00149-8
   GUYTON AC, 1947, AM J PHYSIOL, V150, P70
   HENDERSON D. W., 1956, JOUR HYG, V54, P28
   Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063
   Ionin B, 2013, CLIN VACCINE IMMUNOL, V20, P1016, DOI 10.1128/CVI.00099-13
   Kao LM, 2006, ANTIMICROB AGENTS CH, V50, P3535, DOI 10.1128/AAC.00090-06
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Kurzatkowski W, 2013, BIOLOGICALS, V41, P71, DOI 10.1016/j.biologicals.2011.10.011
   Li H, 2008, J IMMUNOL METHODS, V333, P89, DOI 10.1016/j.jim.2008.01.007
   Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931
   Look J, 2014, Temperature stable vaccine formulations, Patent No. [WO/2014/004578, 2014004578]
   Maa YF, 2003, J PHARM SCI-US, V92, P319, DOI 10.1002/jps.10294
   Milstein J, 2006, WHOIVB0610
   Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849
   Savransky V, 2017, VACCINE, V35, P4952, DOI 10.1016/j.vaccine.2017.07.076
   Savransky V, 2013, INFECT IMMUN, V81, P1152, DOI 10.1128/IAI.01289-12
   World Health Organization, 1980, WKLY EPIDEM REC, V55, P386
   World Health Organization (WHO), 2006, TEMP SENS VACC
NR 24
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6356
EP 6361
DI 10.1016/j.vaccine.2019.09.015
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100019
PM 31530467
DA 2020-05-12
ER

PT J
AU Du, LP
   Yu, XM
   Hou, LT
   Zhang, D
   Zhang, YP
   Qiao, XW
   Hou, JB
   Chen, J
   Zheng, QS
AF Du, Luping
   Yu, Xiaoming
   Hou, Liting
   Zhang, Dong
   Zhang, Yuanpeng
   Qiao, Xuwen
   Hou, Jibo
   Chen, Jin
   Zheng, Qisheng
TI Identification of mechanisms conferring an enhanced immune response in
   mice induced by CVC1302-adjuvanted killed serotype O foot-and-mouth
   virus vaccine
SO VACCINE
LA English
DT Article
DE FMDV; CVC1302; Local mechanism; Injection sites; Draining lymph nodes;
   Mice
ID B-CELL ACTIVATION; GERMINAL-CENTERS; T-CELLS; MONOCYTE; DIFFERENTIATION;
   EXPRESSION; MIGRATION; COMPLEX; LLT1; NMI
AB The adjuvant CVC1302 was previously shown to efficiently enhance the immunogenicity of killed footand-mouth disease virus (FMDV) in mice and piglets. However, the underlining mechanism of action of CVC1302 remains unclear, especially at local injection sites and draining lymph nodes. Since the FMDV vaccine is administrated intramuscularly in field settings, we studied local immune responses to FMDV following intramuscular injection in mice, and found that CVC1302-adjuvanted killed FMDV (KV-CVC1302) induced secretion of several chemokines in murine muscle tissues, including MCP-1, MIP-1 alpha, and mIP-1 beta. The number of monocytes recruited to the site of injection was significantly higher in mice immunized with KV-CVC1302 compared with mice immunized with killed FMDV alone (MV). iTAQ-based quantitative proteomic assays were additionally employed to explore the molecular mechanisms of CVC1302 action in the draining lymph nodes. A total of 35 proteins were identified as being differentially expressed among the control group, KV-immunized group and KV-CVC1302-immunized group at 10 days post immunization (dpi). Proteins exhibiting differential expression were mainly involved in signal transduction, apoptosis, endocytosis and innate immune responses. Pathway analysis demonstrated that AMPK, phospholipase D, cAMP, Rapt, and MAPK signaling pathways were potentially induced by the immunopotentiator CVC1302. Understanding the local mechanism of CVC1302 action at injection sites and draining lymph nodes will provide new insights into the development of FMDV vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Du, Luping; Yu, Xiaoming; Hou, Liting; Zhang, Yuanpeng; Qiao, Xuwen; Hou, Jibo; Chen, Jin; Zheng, Qisheng] Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing 210014, Jiangsu, Peoples R China.
   [Du, Luping; Yu, Xiaoming; Hou, Liting; Zhang, Yuanpeng; Qiao, Xuwen; Hou, Jibo; Chen, Jin; Zheng, Qisheng] Jiangsu Acad Agr Sci, Natl Res Ctr Engn & Technol Vet Biol, Nanjing 210014, Jiangsu, Peoples R China.
   [Du, Luping; Yu, Xiaoming; Hou, Liting; Zhang, Yuanpeng; Qiao, Xuwen; Hou, Jibo; Chen, Jin; Zheng, Qisheng] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.
   [Du, Luping; Yu, Xiaoming; Hou, Liting; Zhang, Yuanpeng; Qiao, Xuwen; Hou, Jibo; Chen, Jin; Zheng, Qisheng] Minist Sci & Technol Nanjing, Jiangsu Key Lab Food Qual, Nanjing 210014, Jiangsu, Peoples R China.
   [Du, Luping; Yu, Xiaoming; Hou, Liting; Zhang, Yuanpeng; Qiao, Xuwen; Hou, Jibo; Chen, Jin; Zheng, Qisheng] Minist Sci & Technol Nanjing, Safety State Key Lab Cultivat Base, Nanjing 210014, Jiangsu, Peoples R China.
   [Zhang, Dong] Shandong Prov Ctr Anim Dis Control & Prevent, Jinan 250022, Shandong, Peoples R China.
RP Chen, J; Zheng, QS (reprint author), Jiangsu Acad Agr Sci, Inst Vet Immunol & Engn, Nanjing 210014, Jiangsu, Peoples R China.
EM chenjin_abc@163.com; immun_tech@163.com
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [31802220]
FX This work was supported by the National Natural Sciences Foundation of
   China (31802220). We thank Liwen Bianji, Edanz Editing China
   (www.liwenbianii.cnlac), for editing the English text of a draft of this
   manuscript.
CR Adema GJ, 2009, IMMUNOL LETT, V122, P128, DOI 10.1016/j.imlet.2008.11.017
   BARTELING SJ, 1991, VACCINE, V9, P75, DOI 10.1016/0264-410X(91)90261-4
   Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Busby Theodore, 2017, Cell Logist, V7, pe1308900, DOI 10.1080/21592799.2017.1308900
   Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651
   Chen J, 2018, VACCINE, V36, P7929, DOI 10.1016/j.vaccine.2018.11.012
   Coppotelli G, 2018, INNOVATION AGING, V2, P387
   Cox SJ, 2009, VET RES, V40, DOI 10.1051/vetres:2008051
   Das A, 2015, VIROLOGY, V485, P383, DOI 10.1016/j.virol.2015.08.013
   Du LP, 2017, VACCINE, V35, P7088, DOI 10.1016/j.vaccine.2017.10.094
   Du LP, 2017, SCI REP-UK, V7, DOI 10.1038/srep41886
   Dupont N, 2017, INT REV CEL MOL BIO, V328, P1, DOI 10.1016/bs.ircmb.2016.08.001
   Dupuis M, 2001, EUR J IMMUNOL, V31, P2910, DOI 10.1002/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3
   Eberlein J, 2010, J CLIN INVEST, V120, P907, DOI 10.1172/JCI40645
   Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779
   Germain C, 2011, J BIOL CHEM, V286, P37964, DOI 10.1074/jbc.M111.285312
   Golde WT, 2005, VACCINE, V23, P5775, DOI 10.1016/j.vaccine.2005.07.043
   Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004
   Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015
   Kanda T, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0694-8
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Llibre A, 2016, J IMMUNOL, V196, P2085, DOI 10.4049/jimmunol.1502462
   Maglione PJ, 2015, ANN NY ACAD SCI, V1356, P1, DOI 10.1111/nyas.12763
   Mathew SO, 2016, ONCOTARGET, V7, P68650, DOI 10.18632/oncotarget.11896
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Puri C, 2013, CELL, V154, P1285, DOI 10.1016/j.cell.2013.08.044
   Rodriguez LL, 2011, EXPERT REV VACCINES, V10, P377, DOI [10.1586/ERV.11.4, 10.1586/erv.11.4]
   Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039
   Rohrbach TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140870
   Rubtsov AV, 2008, J IMMUNOL, V180, P3882, DOI 10.4049/jimmunol.180.6.3882
   Sajadi SMA, 2013, ARCH PATHOL LAB MED, V137, P1674, DOI 10.5858/arpa.2012-0415-OA
   Schenten D, 2011, ADV IMMUNOL, V109, P87, DOI 10.1016/B978-0-12-387664-5.00003-0
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402
   Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572
   Slattery ML, 2011, MUTAT RES-FUND MOL M, V706, P13, DOI 10.1016/j.mrfmmm.2010.10.005
   Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943
   Thomas EC, 2018, BIOCHEM J, V475, P2969, DOI 10.1042/BCJ20180475
   Wang J, 2013, J IMMUNOL, V191, P3393, DOI 10.4049/jimmunol.1300740
   Webster CP, 2016, EMBO J, V35, P1656, DOI 10.15252/embj.201694401
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Xu XT, 2017, CELL PHYSIOL BIOCHEM, V44, P1949, DOI 10.1159/000485885
   Yu YF, 2018, J CANCER, V9, P2953, DOI 10.7150/jca.25542
   Yuan HX, 2013, AUTOPHAGY, V9, P1983, DOI 10.4161/auto.26058
   Zhao YG, 2018, CURR BIOL, V28, P1234, DOI 10.1016/j.cub.2018.03.002
NR 47
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6362
EP 6370
DI 10.1016/j.vaccine.2019.09.014
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100020
PM 31526618
DA 2020-05-12
ER

PT J
AU Kuczkowska, K
   Overland, L
   Rocha, SDC
   Eijsink, VGH
   Mathiesen, G
AF Kuczkowska, Katarzyna
   Overland, Lise
   Rocha, Sergio D. C.
   Eijsink, Vincent G. H.
   Mathiesen, Geir
TI Comparison of eight Lactobacillus species for delivery of
   surface-displayed mycobacterial antigen
SO VACCINE
LA English
DT Article
DE Lactobacillus; Vaccine; Tuberculosis; Immunogenicity
ID INDUCIBLE GENE-EXPRESSION; LACTIC-ACID BACTERIA; TUBERCULOSIS VACCINE;
   GENOME SEQUENCE; PLANTARUM; CELLS; TRANSFORMATION; VECTORS;
   ELECTROPORATION; IMMUNIZATION
AB Lactobacillus spp. comprise a large group of Gram-positive lactic acid bacteria with varying physiological, ecological and immunomodulatory properties that are widely exploited by mankind, primarily in food production and as health-promoting probiotics. Recent years have shown increased interest in using lactobacilli for delivery of vaccines, mainly due to their ability to skew the immune system towards proinflammatory responses. We have compared the potential of eight Lactobacillus species, L. plantarum, L. brevis, L. curvatus, L. rhamnosus, L. sakei, L. gasseri, L. acidophilus and L. reuteri, as immunogenic carriers of the Ag85B-ESAT-6 antigen from Mycobacterium tuberculosis. Surface-display of the antigen was achieved in L. plantarum, L. brevis, L. gasseri and L. reuteri and these strains were further analyzed in terms of their in vitro and in vivo immunogenicity. All strains activated human dendritic cells in vitro. Immunization of mice using a homologous prime-boost regimen comprising a primary subcutaneous immunization followed by three intranasal boosters, led to slightly elevated IgG levels in serum in most strains, and, importantly, to significantly increased levels of antigen-specific mucosal IgA. Cellular immunity was assessed by studying antigen-specific T cell responses in splenocytes, which did not reveal proliferation as assessed by the expression of Ki67, but which showed clear antigen-specific IFN-gamma and IL-17 responses for some of the groups. Taken together, the present results indicate that L. plantarum and L. brevis are the most promising carriers of TB vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kuczkowska, Katarzyna; Overland, Lise; Rocha, Sergio D. C.; Eijsink, Vincent G. H.; Mathiesen, Geir] Norwegian Univ Life Sci NMBU, Fac Chem Biotechnol & Food Sci, POB 5003, N-1432 As, Norway.
RP Kuczkowska, K (reprint author), Norwegian Univ Life Sci NMBU, Fac Chem Biotechnol & Food Sci, POB 5003, N-1432 As, Norway.
EM katarzyna.kuczkowska@nmbu.no
OI Eijsink, Vincent/0000-0002-9220-8743
FU Globvac program of the Research Council of Norway [234502]
FX This work was funded by the Globvac program of the Research Council of
   Norway [grant number 234502].
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   Agger EM, 2001, VACCINE, V19, P2298, DOI 10.1016/S0264-410X(00)00519-3
   AHRNE S, 1992, CURR MICROBIOL, V24, P199, DOI 10.1007/BF01579282
   AUKRUST T, 1992, FOOD RES INT, V25, P253, DOI 10.1016/0963-9969(92)90121-K
   Azcarate-Peril MA, 2008, APPL ENVIRON MICROB, V74, P4610, DOI 10.1128/AEM.00054-08
   Batista FD, 2000, EMBO J, V19, P513, DOI 10.1093/emboj/19.4.513
   BLOKSMA N, 1979, CLIN EXP IMMUNOL, V37, P367
   Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R
   Chowdhury MYE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094051
   Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171
   Claesson MJ, 2007, FEMS MICROBIOL LETT, V269, P22, DOI 10.1111/j.1574-6968.2006.00596.x
   Copland A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00346
   de Vries MC, 2006, INT DAIRY J, V16, P1018, DOI 10.1016/j.idairyj.2005.09.003
   Dong HL, 2012, BRIT J NUTR, V108, P459, DOI 10.1017/S0007114511005824
   Fletcher HA, 2016, T ROY SOC TROP MED H, V110, P212, DOI 10.1093/trstmh/trw016
   Fredriksen L, 2012, APPL ENVIRON MICROB, V78, P5864, DOI 10.1128/AEM.01227-12
   LeBlanc JG, 2013, FEMS MICROBIOL LETT, V344, P1, DOI 10.1111/1574-6968.12159
   Nguyen HM, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0570-z
   HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989
   Ibnou-Zekri N, 2003, INFECT IMMUN, V71, P428, DOI 10.1128/IAI.71.1.428-436.2003
   Kankainen M, 2009, P NATL ACAD SCI USA, V106, P17193, DOI 10.1073/pnas.0908876106
   Karlskas IL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091125
   Kawana K, 2014, VACCINE, V32, P6233, DOI 10.1016/j.vaccine.2014.09.020
   Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100
   Komatsu A, 2018, VACCINE, V36, P3423, DOI 10.1016/j.vaccine.2018.05.009
   Kuczkowska K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01588
   Kuczkowska K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176401
   Kuczkowska K, 2017, APPL ENVIRON MICROB, V83, DOI [10.1128/AEM.02782-16, 10.1128/aem.02782-16]
   Kuczkowska K, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0360-z
   LeCureux JS, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00061-18
   Lee YK, 2000, APPL ENVIRON MICROB, V66, P3692, DOI 10.1128/AEM.66.9.3692-3697.2000
   Lin RQ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00417
   Maassen CBM, 2000, VACCINE, V18, P2613, DOI 10.1016/S0264-410X(99)00378-3
   Mileti E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007056
   Mohamadzadeh M, 2005, P NATL ACAD SCI USA, V102, P2880, DOI 10.1073/pnas.0500098102
   Mohamadzadeh M, 2010, FUTURE MICROBIOL, V5, P1289, DOI 10.2217/FMB.10.78
   Mustafa AD, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0461-y
   Patten DA, 2013, MICROBIOL-SGM, V159, P1535, DOI 10.1099/mic.0.064717-0
   Poecheim J, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030032
   Ribelles P, 2013, APPL MICROBIOL BIOT, V97, P1231, DOI 10.1007/s00253-012-4575-1
   Soborg C, 2014, EUR RESPIR J, V44, P540, DOI 10.1183/09031936.00170913
   Sorvig E, 2005, MICROBIOL-SGM, V151, P2439, DOI 10.1099/mic.0.28084-0
   Sorvig E, 2003, FEMS MICROBIOL LETT, V229, P119, DOI 10.1016/S0378-1097(03)00798-5
   Spertini F, 2015, LANCET RESP MED, V3, P953, DOI 10.1016/S2213-2600(15)00435-X
   Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880
   Szatraj K, 2017, J APPL MICROBIOL, V123, P325, DOI 10.1111/jam.13446
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004
   van Dissel JT, 2011, VACCINE, V29, P2100, DOI 10.1016/j.vaccine.2010.12.135
   Wells JM, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S17
   Wu CM, 2007, FEMS IMMUNOL MED MIC, V50, P354, DOI 10.1111/j.1574-695X.2007.00255.x
   Wyszynska A, 2015, APPL MICROBIOL BIOT, V99, P2967, DOI [10.1007/s00253-015-6498-0, 10.1007/s00253-015-6569-2]
   Yang WT, 2018, APPL MICROBIOL BIOT, V102, P5077, DOI 10.1007/s00253-018-8924-6
NR 53
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6371
EP 6379
DI 10.1016/j.vaccine.2019.09.012
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100021
PM 31526620
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Li, XR
   Yang, YK
   Wang, RB
   An, FL
   Zhang, YD
   Nie, JQ
   Ahamada, H
   Liu, XX
   Liu, CL
   Deng, Y
   Bai, ZH
   Li, Y
   Liu, XR
AF Li, Xin-Ran
   Yang, Yan-Kun
   Wang, Rong-Bin
   An, Fang-Lan
   Zhang, Yun-De
   Nie, Jian-Qi
   Ahamada, Hadji
   Liu, Xiu-Xia
   Liu, Chun-Li
   Deng, Yu
   Bai, Zhong-Hu
   Li, Ye
   Liu, Xue-Rong
TI A scale-down model of 4000-L cell culture process for inactivated
   foot-and-mouth disease vaccine production
SO VACCINE
LA English
DT Article
DE Scale-down model; FMD vaccine; Cell culture; CFD simulation; QbD
ID VIRUS; GROWTH; PERFORMANCE; BIOPROCESS; STRESS; LINE; 3-L
AB The anticipated increasing demand for inactivated foot-and-mouth (FMD) disease vaccine calls for its larger production capacity, while development of a large-scale process typically requires high running cost and has very limited experimental throughput at manufacturing scale. Thus, an economic scale-down model of representing a large-scale process becomes necessary and essential. In this study, we used a systematic approach to establish a scale-down model representing a 4000-L culture process for FMD vaccine production by suspension BHK-21 cells. In detail, we firstly compared hydrodynamic properties of three bioreactors (14-L, 800-L and 4000-L) under three different conditions (equivalent mixing time, equivalent shear stress and equivalent volumetric power). We figured out equivalent volumetric power (P/V) potentially as an appropriate scale-down strategy, since it resulted in comparable calculated hydrodynamic parameters among three bioreactors. Next, we used computational fluid dynamics (CFD) simulation to provide more details about hydrodynamic environments inside the bioreactors, which supports the reliability of this scale-down strategy. Finally, we compared cell growth, metabolites, vaccine productivity and product quality attributes during FMD vaccine production by BHK-21 cells and observed very close performances among three bioreactors, which once again demonstrates the robustness of this scale-down model. This scale-down strategy can be applied to study variations and critical quality attributes (CQAs) in the resultant production process based on quality by design (QbD) principles, aiming at further more efficient optimization of vaccine production. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Xin-Ran; Yang, Yan-Kun; Nie, Jian-Qi] Jiangnan Univ, Sch Biotechnol, Key Lab Ind Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
   [Li, Xin-Ran; Yang, Yan-Kun; Nie, Jian-Qi; Liu, Xiu-Xia; Liu, Chun-Li; Deng, Yu; Bai, Zhong-Hu; Li, Ye] Jiangnan Univ, Natl Engn Lab Cereal Fermentat Technol, Wuxi 214122, Jiangsu, Peoples R China.
   [Yang, Yan-Kun; Wang, Rong-Bin; Ahamada, Hadji; Bai, Zhong-Hu] Jiangnan Univ, Sch Biotechnol, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
   [Wang, Rong-Bin; Ahamada, Hadji; Liu, Xiu-Xia; Liu, Chun-Li; Deng, Yu; Bai, Zhong-Hu] Jiangnan Univ, Jiangsu Prov Res Ctr Bioact Prod Proc Technol, Wuxi 214122, Jiangsu, Peoples R China.
   [An, Fang-Lan; Zhang, Yun-De; Liu, Xue-Rong] China Agr Vet Biol Sci & Technol Co Ltd, Lanzhou 730046, Gansu, Peoples R China.
RP Bai, ZH; Li, Y; Liu, XR (reprint author), Jiangnan Univ, Natl Engn Lab Cereal Fermentat Technol, Wuxi 214122, Jiangsu, Peoples R China.
EM baizhonghu@jiangnan.edu.cn; yeli0622@jiangnan.edu.cn; lxr0931@126.com
RI Yang, Yankun/AAJ-3032-2020
OI Yang, Yankun/0000-0003-4815-6832
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31570034]; National First-class Discipline Program
   of Light Industry Technology and Engineering [LITE2018-24]; Opening
   Project of the Key Laboratory of Industrial Biotechnology, Ministry of
   Education [KLIB-KF201802]; Collaborative Innovation Center of Jiangsu
   Modern Industrial Fermentation; 111 ProjectMinistry of Education, China
   - 111 Project [111-2-06]; Priority Academic Program Development of
   Jiangsu Higher Education Institutions; Achievements Transformation
   Project of Gansu Province [17ZD4CA010]; Research Innovation Program for
   College Graduates of Jiangsu Province [KYLX16_0807]
FX This work was supported by the National Natural Science Foundation of
   China (31570034), the National First-class Discipline Program of Light
   Industry Technology and Engineering (LITE2018-24), the Opening Project
   of the Key Laboratory of Industrial Biotechnology, Ministry of Education
   (KLIB-KF201802), the Collaborative Innovation Center of Jiangsu Modern
   Industrial Fermentation, the 111 Project (111-2-06), the Priority
   Academic Program Development of Jiangsu Higher Education Institutions,
   and the Achievements Transformation Project of Gansu Province
   (17ZD4CA010), Research Innovation Program for College Graduates of
   Jiangsu Province (KYLX16_0807).
CR ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0
   Ahuja S, 2015, BIOTECHNOL PROGR, V31, P1370, DOI 10.1002/btpr.2134
   Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0
   Barteling SJ, 2002, REV SCI TECH OIE, V21, P577, DOI 10.20506/rst.21.3.1361
   Brucato A, 2000, CHEM ENG SCI, V55, P291, DOI 10.1016/S0009-2509(99)00324-3
   CAPSTICK PB, 1962, NATURE, V195, P1163, DOI 10.1038/1951163a0
   Chalmers JM, 2000, INST PHYS CONF SER, P41
   De Rueda CB, 2015, EPIDEMIOL INFECT, V143, P2279, DOI 10.1017/S0950268814003033
   Delvigne F, 2017, MICROB BIOTECHNOL, V10, P1267, DOI 10.1111/1751-7915.12803
   Farrell P, 2015, VACCINE, V33, P6752, DOI 10.1016/j.vaccine.2015.10.071
   FAYET MT, 1971, ANN I PASTEUR PARIS, V121, P107
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004
   Haringa C, 2017, CHEM ENG SCI, P175
   Harris CK, 1996, CHEM ENG SCI, V51, P1569, DOI 10.1016/0009-2509(96)00021-8
   HINZE JO, 1975, TURBULENCE
   Lee TS, 2009, VACCINE, V27, P6439, DOI 10.1016/j.vaccine.2009.06.058
   Li XR, 2019, J PHARM SCI-US, V108, P2288, DOI 10.1016/j.xphs.2019.02.004
   Lombard M, 2007, REV SCI TECH OIE, V26, P29, DOI 10.20506/rst.26.1.1724
   Marks DM, 2003, CYTOTECHNOLOGY, V42, P21, DOI 10.1023/A:1026103405618
   Mccoy R, 2010, BIOTECHNOL BIOENG, V106, P584, DOI 10.1002/bit.22716
   MOWAT GN, 1962, NATURE, V194, P253, DOI 10.1038/194253a0
   Nienow AW, 2006, CYTOTECHNOLOGY, V50, P9, DOI 10.1007/s10616-006-9005-8
   Nienow AW, 2013, CHEM ENG RES DES, V91, P2265, DOI 10.1016/j.cherd.2013.04.002
   Noorman H, 2011, BIOTECHNOL J, V6, P934, DOI 10.1002/biot.201000406
   Pope S. B., 2000, TURBULENT FLOWS
   Rao G, 2009, BIOTECHNOL BIOENG, V104, P841, DOI 10.1002/bit.22566
   RIET K, 1991, BASIC BIOREACTOR DES
   Rimmelzwaan GF, 1998, J VIROL METHODS, V74, P57, DOI 10.1016/S0166-0934(98)00071-8
   SANFORD KK, 1948, J NATL CANCER I, V9, P229
   Sieck JB, 2013, J BIOTECHNOL, V164, P41, DOI 10.1016/j.jbiotec.2012.11.012
   Thomassen YE, 2013, BIOTECHNOL BIOENG, V110, P1354, DOI 10.1002/bit.24798
   Vallee H, 1925, RECH MED VET, V101, P297
   Wold S, 2008, BATCH PROCESSES MODE
   Xing ZZ, 2009, BIOTECHNOL BIOENG, V103, P733, DOI 10.1002/bit.22287
   Yang JD, 2007, BIOTECHNOL BIOENG, V98, P141, DOI 10.1002/bit.21413
NR 36
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6380
EP 6389
DI 10.1016/j.vaccine.2019.09.013
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100022
PM 31519448
DA 2020-05-12
ER

PT J
AU Quattrocchi, A
   Mereckiene, J
   Fitzgerald, M
   Cotter, S
AF Quattrocchi, A.
   Mereckiene, J.
   Fitzgerald, M.
   Cotter, S.
TI Determinants of influenza and pertussis vaccine uptake in pregnant women
   in Ireland: A cross-sectional survey in 2017/18 influenza season
SO VACCINE
LA English
DT Article
DE Pregnant women; Vaccine; Campaign; Influenza; Pertussis; Socio-economic
   status
ID TDAP VACCINATION; VIRUS INFECTION; UNITED-STATES; OUTCOMES; RISK;
   COVERAGE; CHILDREN
AB In Ireland seasonal influenza and pertussis vaccination during pregnancy is recommended and every year national campaigns are organised to raise awareness and improve uptake. We estimated influenza and pertussis vaccine uptake and identified factors associated with vaccination status in pregnant women in 2017/18.
   We conducted a face-to-face omnibus survey, with quota sampling, among women aged 18-55 years and collected socio-demographic characteristics, self-reported vaccination status, awareness of vaccine campaigns, and attitudes towards vaccination. Sample was weighted to ensure representativeness with the target population. We performed univariate and multivariable logistic regression analyses on survey data.
   Overall, 241 pregnant women were enrolled. Influenza and pertussis vaccine uptake was 61.7% and 49.9%, respectively. Awareness of vaccine campaign and socio-economic status (SES) were associated with both influenza and pertussis vaccine uptake. The association between SES and uptake of vaccines differed by awareness. Women aware of the influenza vaccine campaign and with mid and low SES were less likely to be vaccinated, compared to those with high SES (aOR = 0.46; 95%CI: 0.22-0.97; aOR = 0.27; 95%CI: 0.12-0.60, respectively); women not aware of the pertussis vaccine campaign and with mid and low SES were less likely to be vaccinated, compared to those aware and with high SES (aOR = 0.15; 95%CI: 0.04-0.48; aOR = 0.05; 95%CI: 0.01-0.24, respectively).
   General practitioner (GP) recommendation was the main reason for receiving influenza vaccine (39.2%), and 71.8% of women were recommended pertussis vaccination from their GPs.
   The survey reports moderate uptake of vaccines among pregnant women, inequalities in uptake by SES and identifies GPs as primary source for vaccine recommendation. We recommend multifaceted campaigns, by engaging GPs, to target all socio-economic groups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Quattrocchi, A.; Mereckiene, J.; Fitzgerald, M.; Cotter, S.] Hlth Protect Surveillance Ctr, Dublin, Ireland.
   [Quattrocchi, A.] European Programme Intervent Epidemiol Training, Stockholm, Sweden.
RP Mereckiene, J (reprint author), Hlth Protect Surveillance Ctr, Dublin, Ireland.
EM jolita.mereckiene@hse.ie
OI Quattrocchi, Annalisa/0000-0002-5764-6721
FU Health Services Executive-Health Protection Surveillance Centre
FX The study was funded by the Health Services Executive-Health Protection
   Surveillance Centre.
CR Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Barrett T, 2018, BJGP OPEN, V3
   Bisset KA, 2018, VACCINE, V36, P2751, DOI 10.1016/j.vaccine.2018.04.013
   Bodeker B, 2014, VACCINE, V32, P4131, DOI 10.1016/j.vaccine.2014.06.007
   Centers for Disease Control and Prevention (CDC), PERT WHOOP COUGH
   Cleary BJ, 2014, EUR J OBSTET GYN R B, V178, P163, DOI 10.1016/j.ejogrb.2014.04.015
   Crosby D A, 2016, Ir Med J, V109, P449
   Dabrera G, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.45.20959
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   European Centre for Disease Prevention and Control, 2014, EXP CONS PERT BARC 2
   European Centre for Disease Prevention and Control, 2018, ANN EP REP 2016
   European Centre for Disease Prevention and Control, 2018, SEAS INFL VACC ANT U
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028
   Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210
   Health Protection Surveillance Centre, 2018, INFL SURV REP WEEK 2
   HSE Health Protection Surveillance Centre, 2017, INFL OTH SEAS RESP V
   HSE Health Protection Surveillance Centre, 2018, PERT IR 2017
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Mak DB, 2015, AUST NZ J OBSTET GYN, V55, P131, DOI 10.1111/ajo.12292
   Marshall H, 2016, HUM VACC IMMUNOTHER, V12, P848, DOI 10.1080/21645515.2015.1127485
   Mc Hugh SM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1356-7
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Mohammed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197867
   Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033
   National Immunisation Advisory Committe, 2011, REV NAT IMM ADV COMM
   National Immunisation Office, IMM
   O'Shea A, 2018, BJGP OPEN, V3, P2
   Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441
   Peebles PJ, 2011, INFLUENZA OTHER RESP, V5, P25, DOI 10.1111/j.1750-2659.2010.00166.x
   Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255
   Public Health England, HLTH PROTECTION REPO, V12
   Public Health England, 2018, SEAS INFL VACC UPT G
   Puleston RL, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14550-01
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Regan AK, 2016, VACCINE, V34, P3649, DOI 10.1016/j.vaccine.2016.05.032
   Regan AK, 2016, CLIN INFECT DIS, V62, P1221, DOI 10.1093/cid/ciw082
   Royal College of Physicians of Ireland, 2016, IMM GUID IR
   Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867
   Sukumaran L, 2015, JAMA-J AM MED ASSOC, V314, P1581, DOI 10.1001/jama.2015.12790
   Tozzi AE, 2005, CAN MED ASSOC J, V172, P509, DOI 10.1503/cmaj.1040766
   Tuells J, 2018, REV ESP QUIM, V31, P344
   Ugezu C, 2018, HUM VACC IMMUNOTHER, V14, P978, DOI 10.1080/21645515.2017.1419110
   WHO, 2016, VACCINE, V34, P1423, DOI 10.1016/j.vaccine.2015.10.136
   *WHO, WHO REC SURV STAND P
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   World Health Organization, 2012, BACKGR PAP INFL VACC
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6390
EP 6396
DI 10.1016/j.vaccine.2019.09.008
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100023
PM 31515147
DA 2020-05-12
ER

PT J
AU Umthong, S
   Dunn, JR
   Cheng, HH
AF Umthong, Supawadee
   Dunn, John R.
   Cheng, Hans H.
TI Towards a mechanistic understanding of the synergistic response induced
   by bivalent Marek's disease vaccines to prevent lymphomas
SO VACCINE
LA English
DT Article
DE Marek's disease; Marek's disease virus; Protective synergy; Bivalent
   vaccine; Bursa
ID VIRUS-INFECTED LYMPHOCYTES; TURKEY HERPESVIRUS; FIELD TRIALS;
   VACCINATION; BURSA; PROTECTION; SEROTYPE-2; EPITHELIUM; FABRICIUS;
   EVOLUTION
AB Background: Marek's disease (MD) is a lymphoproliferative disease of chickens caused by Marek's disease virus (MDV), an oncogenic alpha-herpesvirus. Since 1970, MD has been controlled by widespread vaccination; however, more effective MD vaccines are needed to counter more virulent MDV strains. The bivalent vaccine combination of SB-1 and herpesvirus of turkey (HVT) strain FC126 has been widely used. Nonetheless, the mechanism(s) underlying this synergistic effect has not been investigated.
   Methods: Three experiments were conducted where SB-1 or HVT were administered as monovalent or bivalent vaccines to newly hatched chickens, then challenged five days later with MDV. In Experiment 1, levels of MDV replication in PBMCs were measured over time, and tumor incidence and vaccinal protection determined. In Experiment 2, MDV and vaccine strains replication levels in lymphoid organs were measured at 1, 5,10, and 14 days post-challenge (DPC). In Experiment 3, to verify that the bursa was necessary for HVT protection, a subset of chicks were bursectomized and these birds plus controls were similarly vaccinated and challenged, and the levels of vaccinal protection determined.
   Results: The efficacy of bivalent SB-1 + HVT surpasses that of either SB-1 or HVT monovalent vaccines in controlling the level of pathogenic MDV in PBMCs until the end of the study, and this correlated with the ability to inhibit tumor formation. SB-1 replication in the spleen increased from 1 to 14 DPC, while HVT replicated only in the bursa at 1 DPC. The bursa was necessary for immune protection induced by HVT vaccine.
   Conclusion: Synergy of SB-1 and HVT vaccines is due to additive influences of the individual vaccines acting at different times and target organs. And the bursa is vital for HVT to replicate and induce immune protection. (C) 2019 Published by Elsevier Ltd.
C1 [Umthong, Supawadee] Michigan State Univ, Microbiol & Mol Genet Program, E Lansing, MI 48824 USA.
   [Umthong, Supawadee; Dunn, John R.; Cheng, Hans H.] ARS, USDA, US Natl Poultry Res Ctr, Avian Dis & Oncol Lab, E Lansing, MI 48823 USA.
RP Cheng, HH (reprint author), ARS, USDA, US Natl Poultry Res Ctr, Avian Dis & Oncol Lab, E Lansing, MI 48823 USA.
EM Hans.Cheng@USDA.GOV
FU Development and Promotion of Science and Technology Talents Project
   (DPST), Thailand
FX Partial support for this project was provided by the Development and
   Promotion of Science and Technology Talents Project (DPST), Thailand.
CR Abdul-Careem MF, 2007, VACCINE, V25, P424, DOI 10.1016/j.vaccine.2006.08.006
   Atkins KE, 2013, EVOLUTION, V67, P851, DOI 10.1111/j.1558-5646.2012.01803.x
   Bacon LD, 2000, POULTRY SCI, V79, P1082, DOI 10.1093/ps/79.8.1082
   Baigent SJ, 1998, J GEN VIROL, V79, P2795, DOI 10.1099/0022-1317-79-11-2795
   Bertzbach LD, 2018, P NATL ACAD SCI USA, V115, P11603, DOI 10.1073/pnas.1813964115
   Bublot M, 2004, VACCINATION MAREKS D, P168
   CALNEK BW, 1970, AVIAN DIS, V14, P219, DOI 10.2307/1588466
   Calnek BW, 2001, CURR TOP MICROBIOL, V255, P25
   CALNEK BW, 1984, INT J CANCER, V33, P389, DOI 10.1002/ijc.2910330318
   CALNEK BW, 1983, AVIAN DIS, V27, P844, DOI 10.2307/1590330
   DEBOER GF, 1986, AVIAN DIS, V30, P276, DOI 10.2307/1590529
   DOLFI A, 1988, J ANAT, V156, P17
   Gimeno IM, 2008, VACCINE, V26, pC31, DOI 10.1016/j.vaccine.2008.04.009
   Gimeno IM, 2012, AVIAN DIS, V56, P295, DOI 10.1637/9930-091311-Reg.1
   KODAMA H, 1979, AVIAN PATHOL, V8, P33, DOI 10.1080/03079457908418325
   MORROW C, 2004, MAREKS DIS EVOLVING, P49, DOI DOI 10.1016/B978-012088379-0/50009-8
   Nair V, 2005, VET J, V170, P175, DOI 10.1016/j.tvjl.2004.05.009
   NAUKKARINEN A, 1978, ANAT REC, V191, P415, DOI 10.1002/ar.1091910403
   Osterrieder N, 2006, NAT REV MICROBIOL, V4, P283, DOI 10.1038/nrmicro1382
   Osterrieder N, 2004, MAREKS DIS EVOLVING, P17
   Payne L N, 1976, Int Rev Exp Pathol, V16, P59
   POWELL PC, 1980, AVIAN PATHOL, V9, P193, DOI 10.1080/03079458008418403
   Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198
   RENNIE M, 1980, AVIAN PATHOL, V9, P557, DOI 10.1080/03079458008418443
   SCHAT KA, 1981, INFECT IMMUN, V31, P199, DOI 10.1128/IAI.31.1.199-207.1981
   SCHAT KA, 1978, INFECT IMMUN, V22, P225, DOI 10.1128/IAI.22.1.225-232.1978
   SHEK WR, 1983, JNCI-J NATL CANCER I, V70, P485
   WITTER RL, 1985, POULTRY SCI, V64, P2280, DOI 10.3382/ps.0642280
   WITTER RL, 1992, AVIAN PATHOL, V21, P601, DOI 10.1080/03079459208418881
   WITTER RL, 1976, AVIAN DIS, V20, P676, DOI 10.2307/1589448
   WITTER RL, 1987, AVIAN DIS, V31, P752, DOI 10.2307/1591027
   WITTER RL, 1984, AVIAN PATHOL, V13, P75, DOI 10.1080/03079458408418510
   WITTER RL, 1994, AVIAN DIS, V38, P800, DOI 10.2307/1592117
NR 33
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6397
EP 6404
DI 10.1016/j.vaccine.2019.09.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100024
PM 31515142
DA 2020-05-12
ER

PT J
AU Govasli, ML
   Diaz, Y
   Puntervoll, P
AF Govasli, Morten L.
   Diaz, Yuleima
   Puntervoll, Pal
TI Virus-like particle-display of the enterotoxigenic Escherichia coli
   heat-stable toxoid STh-A14T elicits neutralizing antibodies in mice
SO VACCINE
LA English
DT Article
DE ETEC; Enterotoxin; Heat-stable toxin; ST; Subunit vaccine; Virus-like
   particles
ID GLOBAL BURDEN; CYCLASE-C; VACCINE; PROTEIN; DISEASE; TOXIN; DIVERSITY;
   CHILDREN; DIARRHEA; INFANTS
AB Enterotoxigenic Escherichia coli (ETEC) causes diarrhoea by secreting enterotoxins into the small intestine. Human ETEC strains may secrete any combination of three enterotoxins: the heat-labile toxin (LT) and the heat-stable toxins (ST), of which there are two variants, called human ST (STh) and porcine ST (STp). Strains expressing STh, either alone or in combination with LT and/or STp, are among the four most important diarrhoea-causing pathogens affecting children in low- and middle-income countries. ST is therefore an attractive target for ETEC vaccine development. To produce a safe ST-based vaccine, several challenges must be solved. ST must be rendered immunogenic and non-toxic, and antibodies elicited by an ST vaccine should neutralize ST but not cross-react with the endogenous ligands uroguanylin and guanylin. Virus-like particles (VLPs) tend to be highly immunogenic and are increasingly being used as carriers for presenting heterologous antigens in new vaccines. In this study, we have coupled native STh and the STh-A14T toxoid to the coat protein of Acinetobacter phage AP205 by using the SpyCatcher system and immunized mice with these VLPs without the use of adjuvants. We found that both STs were efficiently coupled to the VLP, that both the STh and STh-A14T VLPs were immunogenic in mice, and that the resulting serum antibodies could completely neutralize the toxic activities of native STh. The serum antibodies showed a high degree of immunological cross-reaction to STp, while there was little or no unwanted cross-reaction to uroguanylin and guanylin. Moreover, compared to native STh, the STh-A14T mutation did not seem to negatively impact the immunogenicity of the construct or the neutralizing ability of the resulting sera. Taken together, these findings demonstrate that VLPs are suitable carriers for making STs immunogenic, and that the STh-A14T-coupled AP205 VLP represents a promising ETEC vaccine candidate. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Govasli, Morten L.; Diaz, Yuleima; Puntervoll, Pal] NORCE Norwegian Res Ctr, Postboks 22 Nygardstangen, N-5838 Bergen, Norway.
   [Puntervoll, Pal] Univ Bergen, Ctr Int Hlth, Dept Global Publ Hlth & Primary Care, Postboks 7804, N-5020 Bergen, Norway.
   [Govasli, Morten L.] UCL, Div Infect & Immun, London, England.
RP Puntervoll, P (reprint author), NORCE Norwegian Res Ctr, Postboks 22 Nygardstangen, N-5838 Bergen, Norway.
EM pal.puntervoll@norceresearch.no
OI Puntervoll, Pal/0000-0003-0093-7816
FU Research Council of Norway through the Global Health and Vaccination
   Research Programme (GLOBVAC) [234364]; PATH, USA [102290-002]; Meltzer
   Research Fund, Norway
FX We thank Dr. Mark Howarth and Dr. Karl D. Brune for providing the
   plasmid encoding AP205-SpyC as well as for scientific discussion
   regarding the VLP platform. Synthetic STh was a kind gift from Dr. Yves
   -Marie Coic and Dr. Laurence Mulard, Institute Pasteur, Paris, France.
   The MALDI-MS analysis was performed at the Proteomics core facility,
   Department of Biosciences, University of Oslo, Norway. We thank Dr.
   Ephrem Debebe Zegeye, Dr. Hans Steinsland, Dr. Halvor Sommerfelt, Dr.
   Oyvind Halskau, Dr. Oyvind Stromland for reviewing the manuscript. The
   research leading to these results was supported by the Research Council
   of Norway through the Global Health and Vaccination Research Programme
   (GLOBVAC) [grant number 234364], by PATH, USA [grant number 102290-002],
   and by The Meltzer Research Fund, Norway [grant to Govasli].
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Arshad N, 2012, FEBS LETT, V586, P2835, DOI 10.1016/j.febslet.2012.07.028
   BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784
   Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Brierley SM, 2012, CURR OPIN PHARMACOL, V12, P632, DOI 10.1016/j.coph.2012.10.005
   Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432
   Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234
   DEMOL P, 1985, J MED MICROBIOL, V20, P69, DOI 10.1099/00222615-20-1-69
   DIAZ Y, 2019, INFECT IMMUN, V87, DOI DOI 10.1128/1A1.000G9-19
   Diemert DJ, 2006, CLIN MICROBIOL REV, V19, P583, DOI 10.1128/CMR.00052-05
   DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671
   Fischer Walker Christa L, 2012, BMC Public Health, V12, P220, DOI 10.1186/1471-2458-12-220
   Frederick DR, 2018, MUCOSAL IMMUNOL, V11, P549, DOI 10.1038/mi.2017.70
   Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001
   Govasli ML, 2018, TOXINS, V10, DOI 10.3390/toxins10070274
   He HH, 2012, J INNOV OPT HEAL SCI, V5, DOI 10.1142/S1793545812500174
   Jain NK, 2015, ADV DRUG DELIVER REV, V93, P42, DOI 10.1016/j.addr.2014.10.023
   Jegerlehner A, 2002, EUR J IMMUNOL, V32, P3305, DOI 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
   Jeong H, 2017, J MICROBIOL, V55, P220, DOI 10.1007/s12275-017-7058-3
   Kapust RB, 2002, BIOCHEM BIOPH RES CO, V294, P949, DOI 10.1016/S0006-291X(02)00574-0
   Klint JK, 2013, PLOS ONE, P8, DOI [10.1371/journalpane0063865, DOI 10.1371/JOURNALPANE0063865]
   KLIPSTEIN FA, 1983, INFECT IMMUN, V40, P924, DOI 10.1128/IAI.40.3.924-929.1983
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Liu J, 2016, LANCET, V388, P1291, DOI 10.1016/S0140-6736(16)31529-X
   Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P142
   Naylor C, 2015, EBIOMEDICINE, V2, P1759, DOI 10.1016/j.ebiom.2015.09.036
   PATH BIO ventures for Global Health, 2011, CAS INV ENT ESCH COL, P1
   Platts-Mills JA, 2015, LANCET GLOB HEALTH, p[3, 00181], DOI 10.1016/S2214-109X/15)00181-5
   Qadri F, 2007, INFECT IMMUN, V75, P3961, DOI 10.1128/IAI.00459-07
   Ritz C, 2005, J STAT SOFTW, V12, P1
   Svennerholm AM, 2008, EXPERT REV VACCINES, V7, P795, DOI 10.1586/14760584.7.6.795
   Taxt A, 2010, INFECT IMMUN, V78, P1824, DOI 10.1128/IAI.01397-09
   Taxt AM, 2016, INFECT IMMUN, V84, P1239, DOI 10.1128/IAI.01225-15
   Taxt AM, 2014, INFECT IMMUN, V82, P2913, DOI 10.1128/IAI.01749-14
   Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Yan D, 2015, APPL MICROBIOL BIOT, V99, P10415, DOI 10.1007/s00253-015-7000-8
   Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109
   Zegeye ED, 2019, HUM VACC IMMUNOTHER, V15, P1379, DOI 10.1080/21645515.2018.1496768
NR 43
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6405
EP 6414
DI 10.1016/j.vaccine.2019.09.004
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100025
PM 31515145
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lopes, JLS
   Oliveira, DCA
   Utescher, CLA
   Quintilio, W
   Tenorio, ECN
   Oliveira, CLP
   Fantini, MCA
   Rasmussen, MK
   Bordallo, HN
   Sant'Anna, OA
   Botosso, VF
AF Lopes, J. L. S.
   Oliveira, D. C. A.
   Utescher, C. L. A.
   Quintilio, W.
   Tenorio, E. C. N.
   Oliveira, C. L. P.
   Fantini, M. C. A.
   Rasmussen, M. K.
   Bordallo, H. N.
   Sant'Anna, O. A.
   Botosso, V. F.
TI Antigenic and physicochemical characterization of Hepatitis B surface
   protein under extreme temperature and pH conditions
SO VACCINE
LA English
DT Article
DE Hepatitis B; HBsAg antigenicity; Thermal stability; pH stability
ID SMALL-ANGLE SCATTERING; CIRCULAR-DICHROISM SPECTROSCOPY; VIRUS-LIKE
   PARTICLE; X-RAY-SCATTERING; SECONDARY STRUCTURE; MESOPOROUS SILICA;
   ADJUVANT; EXTRACTION; STABILITY; LYSOZYME
AB Hepatitis B virus causes acute and chronic infections in millions of people worldwide and, since 1982, a vaccine with 95% effectiveness has been available for immunization. The main component of the recombinant hepatitis B vaccine is the surface antigen protein (HBsAg). In this work, the effect of pH, ionic strength and temperature on the native state of the HBsAg antigen were studied by a combination of biophysical methods that included small angle X-ray scattering, synchrotron radiation circular dichroism, fluorescence and surface plasmon resonance spectroscopies, as well as in vivo and in vitro potency assays. The native conformation, morphology, radius of gyration, and antigenic properties of the HBsAg antigen demonstrate high stability to pH treatment, especially in the pH range employed in all stages of HBsAg vaccine production and storage. The HBsAg protein presents thermal melting point close to 56 degrees C, reaching a more unfolded state after crossing this point, but it only experiences loss of vaccine potency and antigenic properties at 100 degrees C. Interestingly, a 6-month storage period does not affect vaccine stability, and the results are similar when the protein is kept under refrigerated conditions or at room temperature (20 degrees C). At frozen temperatures, large aggregates (>200 nm) are formed and possibly cause loss of HBsAg content, but that does not affect the in vivo assay. Furthermore, HBsAg has a well-ordered secondary structure content that is not affected when the protein is formulated with silica SBA-15, targeting the oral delivery of the vaccine. The combined results from all the characterization techniques employed in this study showed the high stability of the antigen at different storage temperature and extreme values of pH. These findings are important for considering the delivery of HBsAg to the immune system via an oral vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lopes, J. L. S.; Oliveira, C. L. P.; Fantini, M. C. A.] Univ Sao Paulo, Inst Phys, Sao Paulo, Brazil.
   [Oliveira, D. C. A.; Utescher, C. L. A.; Quintilio, W.; Tenorio, E. C. N.; Sant'Anna, O. A.; Botosso, V. F.] Butantan Inst, Sao Paulo, Brazil.
   [Rasmussen, M. K.; Bordallo, H. N.] Univ Copenhagen, Niels Bohr Inst, Copenhagen, Denmark.
   [Rasmussen, M. K.] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark.
   [Bordallo, H. N.] European Spallat Source, Lund, Sweden.
RP Lopes, JLS (reprint author), Rua Matao 1371, BR-05508090 Sao Paulo, Brazil.
EM zeluiz@if.usp.br
RI Fantini, Marcia/AAH-7808-2020; Quintilio, Wagner/B-3748-2014; Bordallo,
   Heloisa N./I-6836-2012; Oliveira, Cristiano L P/B-4403-2008; Oliveira,
   Denise C A/F-3321-2019; Lopes, Jose/D-3213-2012
OI Fantini, Marcia/0000-0001-6862-8716; Quintilio,
   Wagner/0000-0002-3382-8184; Bordallo, Heloisa N./0000-0003-0750-0553;
   Oliveira, Cristiano L P/0000-0002-3426-6507; Oliveira, Denise C
   A/0000-0002-1454-3490; Lopes, Jose/0000-0003-1281-0521
FU National Council for Scientific and Technological Development
   (CNPq/Bra211) [406429/2016-2]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/17844-8, 2018/19546-7]; Danish Agency for Science, Technology and
   Innovation (International Network Programme) [5132-00054B]
FX Authors are grateful for grants 406429/2016-2 from National Council for
   Scientific and Technological Development (CNPq/Bra211) to JLSL, and the
   beamline access to the AU-CD beamline on ASTRID2 at ISA Synchrotron
   (Aarhus, Denmark) to JLSL. The authors would like to acknowledge Dr. Ana
   Maria Moro for the kind support to SPR experiments. Thanks are due to
   the Sao Paulo Research Foundation (FAPESP) for the financial support
   (grants 2017/17844-8 and 2018/19546-7) and to The Danish Agency for
   Science, Technology and Innovation (International Network Programme
   -Ref. number: 5132-00054B). CLPO, JLSL, MCAF and OAS are CNPq fellows.
   This research is under the scope of the International Patents
   W007/030901, IN 248654, ZA 2008/02277, KR 1089400, MX 297263, HK
   1124791, JP 5091863, CN 101287491B, CA 2621373, US 8642258 B2, EP
   1942934 B1 and BR PI 0503817-0.
CR Almeida NL, 2004, COLLOID SURFACE B, V38, P67, DOI 10.1016/j.colsurfb.2004.08.004
   Braun LJ, 2009, VACCINE, V27, P4609, DOI 10.1016/j.vaccine.2009.05.069
   Carman WF, 1997, J VIRAL HEPATITIS, V4, P11, DOI 10.1111/j.1365-2893.1997.tb00155.x
   Carvalho LV, 2010, VACCINE, V28, P7829, DOI 10.1016/j.vaccine.2010.09.087
   Chen DX, 2009, HUM VACCINES, V5, P26, DOI 10.4161/hv.5.1.6494
   Chen Y, 2015, VACCINE, V33, P4300, DOI 10.1016/j.vaccine.2015.03.078
   Dinda AK, 2016, VACCINE, V34, P3076, DOI 10.1016/j.vaccine.2016.04.084
   Erickson HP, 2009, BIOL PROCED ONLINE, V11, P32, DOI 10.1007/s12575-009-9008-x
   Farhadian A, 2015, HUM VACC IMMUNOTHER, V11, P2811, DOI 10.1080/21645515.2015.1053663
   Garcia-Bennett AE, 2011, NANOMEDICINE-UK, V6, P867, DOI [10.2217/nnm.11.82, 10.2217/NNM.11.82]
   Garnier J, 1996, METHOD ENZYMOL, V266, P540
   GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879
   GLATTER O, 1977, ACTA PHYS AUSTRIACA, V47, P83
   Greiner VJ, 2014, VACCINE, V32, P1049, DOI 10.1016/j.vaccine.2014.01.012
   Hayden CA, 2015, VACCINE, V33, P2881, DOI 10.1016/j.vaccine.2015.04.080
   Hayden CA, 2014, VACCINE, V32, P1240, DOI 10.1016/j.vaccine.2014.01.037
   Hirai M, 1998, J PHYS CHEM B, V102, P1308, DOI 10.1021/jp9713367
   Huang XY, 2014, NANOMATER NANOTECHNO, V4, DOI 10.5772/58290
   Hutin Y, 2018, B WORLD HEALTH ORGAN, P96, DOI [10.2471/BLT1/1215210, DOI 10.2471/BLT.18.1215210]
   ISHIZAKA S, 1990, J HEPATOL, V11, P326, DOI 10.1016/0168-8278(90)90216-E
   Jameson D. M., 2014, INTRO FLUORESCENCE
   Jezek J, 2009, HUM VACCINES, V5, P529, DOI 10.4161/hv.5.8.8600
   Kikhney AG, 2015, FEBS LETT, V589, P2570, DOI 10.1016/j.febslet.2015.08.027
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lang R, 2009, DRUG DEV IND PHARM, V35, P83, DOI 10.1080/03639040802192806 
   Lees JG, 2006, BIOINFORMATICS, V22, P1955, DOI 10.1093/bioinformatics/btl327
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUBECK MD, 1989, P NATL ACAD SCI USA, V86, P6763, DOI 10.1073/pnas.86.17.6763
   Luna Expedito José de Albuquerque, 2009, Rev. Saúde Pública, V43, P1014, DOI 10.1590/S0034-89102009000600013
   Mariano-Neto F, 2014, J PHYS D APPL PHYS, V47, DOI 10.1088/0022-3727/47/42/425402
   Mercuri LP, 2006, SMALL, V2, P254, DOI 10.1002/smll.200500274
   Miles AJ, 2018, PROTEIN SCI, V27, P1717, DOI 10.1002/pro.3474
   MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016
   Mulder AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033235
   Oliveira CLP, 2011, CURRENT TRENDS XRAY, DOI [10.5772/30730, DOI 10.5772/30730]
   Organization WH, 2016, GLOB HLTH SECT STRAT
   Rahikkala A, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800020
   Rasmussen MK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42645-5
   Scaramuzzi K, 2016, NANOMED-NANOTECHNOL, V12, P2241, DOI 10.1016/j.nano.2016.06.003
   SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X
   Smith ML, 2002, BIOTECHNOL PROGR, V18, P538, DOI 10.1021/bp010169w
   Soares E, 2018, INT J PHARMACEUT, V535, P261, DOI 10.1016/j.ijpharm.2017.11.009
   Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880
   Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6
   VANDAMME P, 1992, VACCINE, V10, P366, DOI 10.1016/0264-410X(92)90064-Q
   Wallace BA, 2009, MODERN TECHNIQUES CI, P231
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   World Health Organization, 2017, WEEKL EP REC NO 27
   World Heathy Organization, 2016, SYST REV MON HEP B V
   World Hlth Org, 2019, VACCINE, V37, P223, DOI 10.1016/j.vaccine.2017.07.046
   Zhang Q, 2014, J COLLOID INTERF SCI, V434, P113, DOI 10.1016/j.jcis.2014.07.035
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao QJ, 2006, HUM VACCINES, V2, P174, DOI 10.4161/hv.2.4.3015
   2013, WHO TECHN REP SER, V978, P1
NR 55
TC 0
Z9 0
U1 7
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6415
EP 6425
DI 10.1016/j.vaccine.2019.09.005
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100026
PM 31519445
DA 2020-05-12
ER

PT J
AU Xu, J
   Hiramatsu, R
   Suhaimi, H
   Kato, T
   Fujimoto, A
   Tokiwa, T
   Ike, K
   Park, EY
AF Xu, Jian
   Hiramatsu, Rikito
   Suhaimi, Hamizah
   Kato, Tatsuya
   Fujimoto, Akari
   Tokiwa, Toshihiro
   Ike, Kazunori
   Park, Enoch Y.
TI Neospora caninum antigens displaying virus-like particles as a bivalent
   vaccine candidate against neosporosis
SO VACCINE
LA English
DT Article
DE Neospora caninum; Neosporosis; Virus-like particle; Display; Silkworm;
   Bacmid
ID SILKWORM LARVAE; SURFACE PROTEIN; INFECTION; IDENTIFICATION; EXPRESSION;
   TACHYZOITES; PROTECTION; FUSION; CATTLE; MODEL
AB Neospora caninum is a causative and transmissible agent of dog and bovine neosporosis. The resulting reproductive failures in infected cattle lead to significant economic losses worldwide. However, there is no satisfactory treatment or vaccine currently available to combat this pathogen. Thus, the development of appropriate vaccines to manage its infection and transmission is urgently needed. In this study, we expressed Rous sarcoma virus-like particles (RSV-LP) that displayed dual N. caninum antigens in silkworms. The antigen candidates are modified by adding a transmembrane domain of GP64 protein from Bombyx mori nucleopolyhedrovirus (BmNPV) to the C-terminus of surface antigen 1 (NcSAG1) and SAG1-related sequence 2 (NcSRS2). The NcSRS2 alone or the NcSAG1/NcSRS2 bivalent form displaying RSV-LPs were purified using sucrose density gradient centrifugation. These purified VLPs were then used for immunizations in gerbils, Meriones unguiculatus, to evaluate the anti-N. caninum effects in vivo. The results demonstrated that antigens displaying RSV-LPs in immunized gerbils produced the antigen-specific antibody, leading to a relatively lower parasite load after infections of N. caninum. To the best of our knowledge, this is the first study to present an RSV-LP vaccine displaying bivalent antigens from neosporosis. Taken together, our strategy suggests that silkworm-expressed virus-like particles (VLPs) are promising bivalent vaccine candidates against N. caninum infections. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Jian; Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Res Inst Green Sci & Technol, Lab Biotechnol, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.
   [Hiramatsu, Rikito; Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Grad Sch Integrated Sci & Technol, Lab Biotechnol, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.
   [Suhaimi, Hamizah; Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Grad Sch Sci & Technol, Lab Biotechnol, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.
   [Fujimoto, Akari; Tokiwa, Toshihiro; Ike, Kazunori] Nippon Vet & Life Univ, Lab Vet Parasitol, Musashino, Tokyo 1808602, Japan.
RP Park, EY (reprint author), Shizuoka Univ, Res Inst Green Sci & Technol, Lab Biotechnol, Suruga Ku, 836 Ohya, Shizuoka 4228529, Japan.
EM xu.jian@shizuoka.ac.jp; rikito_hiramatsu@yahoo.co.jp;
   noor.hamizah.binsuhaimi.16@shizuoka.ac.jp; kato.tatsuya@shizuoka.ac.jp;
   tokiwa@nvlu.ac.jp; ike-k@nvlu.ac.jp; park.enoch@shizuoka.ac.jp
RI Xu, Jian/G-6684-2015; Kato, Tatsuya/E-3095-2010
OI Xu, Jian/0000-0003-1816-4129; Kato, Tatsuya/0000-0001-7990-2557
FU Japan Society for the Promotion of Science (JSPS)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science; KAKENHIMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H02544]
FX This project was financially supported by the Japan Society for the
   Promotion of Science (JSPS) and the KAKENHI Grant-in-Aid for Scientific
   Research (A) (Grant No. 16H02544).
CR Aguado-Martinez A, 2009, VACCINE, V27, P7331, DOI 10.1016/j.vaccine.2009.09.050
   Baszler TV, 2008, CLIN VACCINE IMMUNOL, V15, P659, DOI 10.1128/CVI.00436-07
   Berger I, 2015, BIOENGINEERED, V6, P316, DOI 10.1080/21655979.2015.1104433
   BJERKAS I, 1984, Z PARASITENKD, V70, P271, DOI 10.1007/BF00942230
   Debache K, 2009, INT J PARASITOL, V39, P1373, DOI 10.1016/j.ijpara.2009.04.006
   Deo VK, 2013, J BIOTECHNOL, V165, P69, DOI 10.1016/j.jbiotec.2013.02.013
   Dong JH, 2014, J BIOSCI BIOENG, V117, P351, DOI 10.1016/j.jbiosc.2013.09.003
   Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031
   DUBEY JP, 1988, J AM VET MED ASSOC, V192, P1269
   Fernandez-Garia A, 2006, MOL BIOCHEM PARASIT, V146, P89, DOI 10.1016/j.molbiopara.2005.08.019
   Frey S, 2018, CURR OPIN BIOTECH, V52, P80, DOI 10.1016/j.copbio.2018.03.003
   Gomez-Sebastian S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096562
   Goodswen SJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00332
   Goodswen SJ, 2013, INFECT GENET EVOL, V13, P133, DOI 10.1016/j.meegid.2012.08.012
   Hemphill A, 1996, INFECT IMMUN, V64, P4279, DOI 10.1128/IAI.64.10.4279-4287.1996
   Kato T, 2015, MOL BIOTECHNOL, V57, P145, DOI 10.1007/s12033-014-9810-9
   LINDSAY DS, 1994, AM J VET RES, V55, P976
   LINDSAY DS, 1990, J PARASITOL, V76, P177, DOI 10.2307/3283010
   Makela AR, 2006, ADV VIRUS RES, V68, P91, DOI 10.1016/S0065-3527(06)68003-2
   Mansilla FC, 2016, PARASITE IMMUNOL, V38, P663, DOI 10.1111/pim.12354
   McAllister MM, 1998, INT J PARASITOL, V28, P1473, DOI 10.1016/S0020-7519(98)00138-6
   Monney T, 2011, ANIMALS-BASEL, V1, P306, DOI 10.3390/ani1030306
   Monney T, 2014, EXP PARASITOL, V140, P52, DOI 10.1016/j.exppara.2014.02.015
   Nishikawa Y, 2000, INT J PARASITOL, V30, P51, DOI 10.1016/S0020-7519(99)00162-9
   Nishikawa Y, 2017, J VET MED SCI, V79, P1374, DOI 10.1292/jvms.17-0285
   Otsuki T, 2013, VET PARASITOL, V192, P284, DOI 10.1016/j.vetpar.2012.09.038
   Park EY, 2008, BIOTECHNOL APPL BIOC, V49, P135, DOI 10.1042/BA20070098
   Pastor-Fernandez I, 2015, VET PARASITOL, V207, P203, DOI 10.1016/j.vetpar.2014.12.009
   Qian WF, 2015, PARASITOL INT, V64, P597, DOI 10.1016/j.parint.2015.08.002
   Ramamoorthy S, 2005, VET PARASITOL, V127, P111, DOI 10.1016/j.vetpar.2004.09.016
   Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022
   Risco-Castillo V, 2011, PARASITOLOGY, V138, P1832, DOI 10.1017/S0031182011001351
   Schneider IC, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700345
   Sinnott FA, 2017, VET PARASITOL, V239, P19, DOI 10.1016/j.vetpar.2017.04.008
   Sokolenko S, 2012, BIOTECHNOL ADV, V30, P766, DOI 10.1016/j.biotechadv.2012.01.009
   Song PX, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2147-1
   Staska LM, 2005, INFECT IMMUN, V73, P1321, DOI 10.1128/IAI.73.3.1321-1329.2005
   Tsuji Y, 2011, J BIOTECHNOL, V155, P185, DOI 10.1016/j.jbiotec.2011.07.008
   van Oers MM, 2011, J INVERTEBR PATHOL, V107, pS3, DOI 10.1016/j.jip.2011.05.001
   Williams DJL, 2007, INFECT IMMUN, V75, P1343, DOI 10.1128/IAI.00777-06
   Ybanez RHD, 2016, PARASITOL INT, V65, P319, DOI 10.1016/j.parint.2016.03.009
   Yoshimoto M, 2015, J BIOSCI BIOENG, V120, P715, DOI 10.1016/j.jbiosc.2015.04.002
   Zhao QJ, 2013, TRENDS BIOTECHNOL, V31, P654, DOI 10.1016/j.tibtech.2013.09.002
NR 43
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6426
EP 6434
DI 10.1016/j.vaccine.2019.09.002
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100027
PM 31515150
DA 2020-05-12
ER

PT J
AU Wang, LY
   Chen, CF
   Wu, TW
   Lai, SK
   Chu, CC
   Lin, HH
AF Wang, Li-Yu
   Chen, Chuen-Fei
   Wu, Tzu-Wei
   Lai, Sheng-Kai
   Chu, Chen-Chung
   Lin, Hans Hsienhong
TI Response to hepatitis B vaccination is co-determined by HLA-DPA1
   and-DPB1
SO VACCINE
LA English
DT Article
DE Human leukocyte antigen-DP; Hepatitis B vaccination; Biomarker; Genetic
   association study; Immunity
ID LONG-TERM EFFICACY; IMMUNE-RESPONSES; BOOSTER; INFECTION; MOTHERS;
   IMPACT; BORN
AB Background and aims: No report explored the combined effects of HLA-DPA1 and -DPB1 with long-term response to hepatitis B (HB) vaccination (HBVac). The specific aims of the study were to assess the combined effects and relative contributions of DPA1 and DPB1 genes.
   Methods: The cases were 152 adolescents who had undetectable (<1.0 mIU/mL) post-booster anti-HBs titers and the controls were adolescents who had residual anti-HBs >= 10 mIU/mL at aged 16 years (n = 207) or had detectable (>= 1.0 mIU/mL) anti-HBs titers after booster HBVac (n = 481). HLA-DPA1 and -DPB1 genotypes were determined by sequence-based typing.
   Results: HLA-DPA1*01:03:01 was correlated with lower ORs of undetectable anti-HBs titers, while - DPA1*02:02:02 and -DPB1*05:01 :01 were correlated with higher ORs. The ORs for HLA-DPA1*01 :03:01-DPB1*05:01:01 and DPA1*02:02:02-DPB1*protective combinatory types were significantly less than 1.0. As compared with subjects who had no protective allele, the adjusted ORs (95% CI) were 0.545 (0.328-0.906), 0.350 (0.174-0.702), and 0.122 (0.058-0.257), for subjects who had protective alleles on DPA1 only, DPB1 only, and both genes, respectively. Analyses of amino acid polymorphisms showed that subjects who carried Arg81-Pro158-Val191-Pro259 alpha + Met234 beta and GIn62-Arg82 alpha + Met234 beta combinations had 4.3-to-4.6 folds of risks.
   Conclusion: Both DPA1 and DPB1 genes contribute to the persistence of immunological response to primary infantile HBVac. The effects of HLA-DP risk alleles were dominated by the protective alleles and there were significant gene-gene interactions. Our findings provide evidences for the design of more potent HB vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Li-Yu; Chen, Chuen-Fei; Wu, Tzu-Wei] Mackay Med Coll, Dept Med, 46,Sec 3,Jhong Jheng Rd, New Taipei 252, Taiwan.
   [Wang, Li-Yu] Mackay Med Coll, Inst Biomed Sci, New Taipei, Taiwan.
   [Lai, Sheng-Kai; Chu, Chen-Chung] Mackay Mem Hosp, Med Res Dept, 45 Ming Sheng Rd, New Taipei 251, Taiwan.
   [Lai, Sheng-Kai] Natl Taiwan Univ, Inst Mol Med, Coll Med, Taipei, Taiwan.
   [Lin, Hans Hsienhong] Buddhist Tzu Chi Gen Hosp, Dept Gastroenterol, Taipei Branch, New Taipei, Taiwan.
RP Wang, LY (reprint author), Mackay Med Coll, Dept Med, 46,Sec 3,Jhong Jheng Rd, New Taipei 252, Taiwan.; Chu, CC (reprint author), Mackay Mem Hosp, Med Res Dept, 45 Ming Sheng Rd, New Taipei 251, Taiwan.
EM yannbo@mmc.edu.tw; chucc@mmh.org.tw
FU Mackay Medical College [1051B15, 1071B18]; Ministry of Science and
   Technology, the Executive Yuan, Taiwan [MOST-104-2314-B-715-002-MY3]
FX This study was supported from grants from Mackay Medical College [grant
   number 1051B15 and 1071B18] and the Ministry of Science and Technology,
   the Executive Yuan, Taiwan [grant number MOST-104-2314-B-715-002-MY3,
   2016-2018]. The funding agencies played no role in the work.
CR BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0
   Chang MH, 2009, JNCI-J NATL CANCER I, V101, P1348, DOI 10.1093/jnci/djp288
   Dai SD, 2010, P NATL ACAD SCI USA, V107, P7425, DOI 10.1073/pnas.1001772107
   Hadler SC, 2013, VACCINE, V31, pJ66, DOI 10.1016/j.vaccine.2013.03.043
   Hu YH, 2018, ONCOL LETT, V16, P4297, DOI 10.3892/ol.2018.9144
   Huang LM, 1999, HEPATOLOGY, V29, P954, DOI 10.1002/hep.510290349
   Jan CF, 2010, HEPATOLOGY, V51, P1547, DOI 10.1002/hep.23543
   Kamatani Y, 2009, NAT GENET, V41, P591, DOI 10.1038/ng.348
   Kusano S, 2014, J MOL BIOL, V426, P3016, DOI 10.1016/j.jmb.2014.06.020
   LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5
   Li JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025777
   Lu CY, 2008, J INFECT DIS, V197, P1419, DOI 10.1086/587695
   Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Ni YH, 2016, CLIN GASTROENTEROL H, V14, P1324, DOI 10.1016/j.cgh.2016.04.030
   Nishida N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039175
   Romano L, 2011, DIGEST LIVER DIS, V43, pS2, DOI 10.1016/S1590-8658(10)60685-8
   ROZEMULLER EH, 1995, TISSUE ANTIGENS, V45, P57, DOI 10.1111/j.1399-0039.1995.tb02415.x
   Thio CL, 2015, LANCET INFECT DIS, V15, P981, DOI 10.1016/S1473-3099(15)00158-9
   Wang LY, 2006, VACCINE, V24, P4427, DOI 10.1016/j.vaccine.2005.12.069
   Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292
   Wu TW, 2015, J GASTROEN HEPATOL, V30, P891, DOI 10.1111/jgh.12845
   Wu TW, 2013, HUM GENET, V132, P1131, DOI 10.1007/s00439-013-1320-5
   Wu TW, 2013, HEPATOLOGY, V57, P38, DOI 10.1002/hep.25988
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6435
EP 6440
DI 10.1016/j.vaccine.2019.09.001
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100028
PM 31515149
DA 2020-05-12
ER

PT J
AU Fougere, Y
   El Houss, S
   Suris, JC
   Rouvenaz-Defago, S
   Miletto, D
   Von der Weid, L
   Willen, F
   Williams-Smith, JA
   Gehri, M
   Crisinel, PA
AF Fougere, Yves
   El Houss, Samir
   Suris, Joan-Carles
   Rouvenaz-Defago, Sylvie
   Miletto, Damien
   Von der Weid, Lucie
   Willen, Fanny
   Williams-Smith, Joanne Anesta
   Gehri, Mario
   Crisinel, Pierre Alex
TI Single doses of diphtheria-tetanus-pertussis and poliomyelitis vaccines
   are sufficient to generate a booster-type response to tetanus in most
   migrant children
SO VACCINE
LA English
DT Article
DE Migrant children; Vaccination catch-up; Tetanus
ID HB-PRP-T; HEXAVALENT VACCINE; IMMUNOGENICITY; COUNTRIES
AB Background: Immunization coverage for three doses of the diphtheria-tetanus-pertussis and poliomyelitis vaccines in infants is high worldwide, therefore despite the lack of documentation of past vaccinations, most migrant children do not require complete revaccination. Our strategy was to administer a single dose of a tetanus toxoid containing vaccine (TTCV) to migrant children followed by anti-tetanus toxoid (TT) serology to determine whether additional vaccine doses were required. Our goal was to estimate the basic TTCV coverage and to identify potential determinants of the vaccination response.
   Methods: Newly arrived migrant children were prospectively enrolled between October 2014 and August 2017. We included patients aged 1-18 years with no proof of past vaccinations who accepted a single dose of TTCV. Anti-TT serology was performed after 4-6 weeks, and an anti-TT level >= 1 IU/mL was considered a booster-type antibody response with no need for additional doses of TTCV. Potential determinants of the vaccination response were identified using univariate and multivariate linear regression analyses.
   Results: Two hundred and eight children were eligible for analysis. The mean age of the children was 9 (+/- 4.5) years and 100 (48%) were female. The majority (n =129, 62%) of the children came from the WHO Eastern Mediterranean region. Only three patients (1.4%) required additional vaccine doses. A Syrian origin (p < 0.001) and direct arrival primarily by airplane into Switzerland without transiting through other European countries (p = 0.029) associated with higher anti-TT levels in a multivariate regression model (multiple r2 = 0.210, p < 0.001).
   Conclusion: A single dose of TTCV is enough to generate long-term protection in most migrant children. In the context of high basic vaccination coverage, the strategy, which consists of administration of a single dose of TTCV followed by anti-TT serology, can be considered where serotesting is available and economical. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fougere, Yves; El Houss, Samir; Suris, Joan-Carles; Rouvenaz-Defago, Sylvie; Miletto, Damien; Von der Weid, Lucie; Willen, Fanny; Williams-Smith, Joanne Anesta; Gehri, Mario] Lausanne Univ Hosp, Dept Women Mother Child, Serv Pediat, Lausanne, Switzerland.
   [Crisinel, Pierre Alex] Lausanne Univ Hosp, Dept Women Mother Child, Unit Pediat Infect Dis & Vaccinol, Lausanne, Switzerland.
RP Fougere, Y (reprint author), Lausanne Univ Hosp, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.
EM yves.fougere@chuv.ch
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P53
   [Anonymous], 2016, CATCH UP IMM REF AS
   Bernhard S, 2016, PAEDIATRICA, V27, P1
   de la Fuente IG, 2013, PEDIATR INFECT DIS J, V32, P274, DOI 10.1097/INF.0b013e3182748f0b
   Fougere Y, 2018, VACCINE, V36, P4501, DOI 10.1016/j.vaccine.2018.06.010
   Gowin E, 2016, MEDICINE, V49, P49
   Hosseinpoor AR, 2016, LANCET GLOB HEALTH, V4, pE617, DOI 10.1016/S2214-109X(16)30141-3
   Institut Virion/Serion Gmbh, SERION ELISA CLASS T, P1
   Jablonka A, 2017, INFECTION, V45, P157, DOI 10.1007/s15010-016-0934-7
   Lopez P, 2017, PEDIATR INFECT DIS J, V36, pE272, DOI 10.1097/INF.0000000000001682
   Madhi SA, 2019, HUM VACC IMMUNOTHER, V15, P658, DOI 10.1080/21645515.2018.1546524
   Ministry of Health New Zealand, 2017, APP 2 PLANN IMM CATC, P613
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Office federal de la sante publique Commission federale pour les vaccinations, 2018, PLAN VACC SUISS 2018
   Pavlopoulou ID, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0888-7
   Prymula R, 2018, PEDIATR INFECT DIS J, V37, P823, DOI 10.1097/INF.0000000000002109
   Public Health England, 2016, VACC IND UNC INC IMM
   Ravensbergen SJ, 2019, TRAVEL MED INFECT DI, V27, P33, DOI 10.1016/j.tmaid.2018.10.011
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Tregnaghi MW, 2011, PEDIATR INFECT DIS J, V30, pE88, DOI 10.1097/INF.0b013e318212eb80
   UNICEF World Health Organisation, 2013, ICCM EV REV S S SUMM, P1
   Van der Meeren O, 2012, VACCINE, V30, P2710, DOI 10.1016/j.vaccine.2012.02.024
   Vesikari T, 2017, PEDIATR INFECT DIS J, V36, P87, DOI 10.1097/INF.0000000000001358
   Vie le Sage F, 2014, RATTRAPAGE VACCINATI, P1
   WHO, 2018, GLOB TUB REP 2018, P1, DOI DOI 10.1126/SCIENCE.1223389
   WHO, 2018, SUMM ASS, P1
   World Health Organization, 2018, IMM BAS IMM SER, P1
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6441
EP 6446
DI 10.1016/j.vaccine.2019.08.089
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100029
PM 31522805
DA 2020-05-12
ER

PT J
AU Ihara, H
   Kikuchi, K
   Taniguchi, H
   Fujita, S
   Tsuruta, Y
   Kato, M
   Mitsuishi, Y
   Tajima, K
   Kodama, Y
   Takahashi, F
   Takahashi, K
   Azuma, N
AF Ihara, Hiroaki
   Kikuchi, Kan
   Taniguchi, Hiromi
   Fujita, Shogo
   Tsuruta, Yuki
   Kato, Motoyasu
   Mitsuishi, Yoichiro
   Tajima, Ken
   Kodama, Yuzo
   Takahashi, Fumiyuki
   Takahashi, Kazuhisa
   Azuma, Nakanobu
TI 23-valent pneumococcal polysaccharide vaccine improves survival in
   dialysis patients by preventing cardiac events
SO VACCINE
LA English
DT Article
DE 23-valent pneumococcal polysaccharide vaccine; Dialysis; Cardiac events
ID MYOCARDIAL-INFARCTION; ACUTE INFECTION; ASSOCIATION; PNEUMONIA;
   MORTALITY; STROKE; ADULTS; RISK
AB Background: Immunodeficient patients are recommended to receive pneumococcal vaccination. However, there is limited evidence showing effectiveness of the polysaccharide vaccine. Polysaccharide vaccination has shown an association with cardiovascular event risk reduction. We assessed the efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in relation to the risk of hospitalization and death due to pneumonia and acute cardiac events.
   Methods: The medical records of all dialysis patients attending our 8 study centers in 2010 were studied, and we selected 1038 consecutive patients. One-to-one propensity score matching was used to correct for potential selection bias in a PPSV23-vaccinated group versus a non-vaccinated group, and a total of 510 patients were identified for outcome analysis. Time to first admission, or deaths due to all-cause pneumonia or cardiac events until 2015 were compared between both groups.
   Results: The all-cause death rate was significantly decreased in the PPSV23-vaccinated group, (hazard ratio [HR] 0.62, 95% confidence interval [CI]; 0.46-0.83, P = 0.002). All-cause death was considered to be a competing risk for the other outcomes. Further outcomes were evaluated by competing risk analysis adjusting for mortality. There was no statistically significant difference in the hospitalization rate for pneumonia; however, the hospitalization rate due to cardiac events was significantly lower in the PPSV23-vaccinated group than in the non-vaccinated group (HR 0.44, 95% CI; 0.20-0.96, P = 0.040). There was no statistically significant difference in the death rate due to pneumonia; however, the rate of cardiac death was significantly lower in the PPSV23-vaccinated group than in the non-vaccinated group (HR 0.36, 95% CI; 0.18-0.71, P = 0.003).
   Conclusions: The PPSV23 vaccination is associated with a good prognosis and a low-risk of cardiac events in dialysis patients; however, there was no evidence indicating enhanced protective efficacy against pneumonia, suggesting the PPSV23 vaccination might improve the prognosis by directly preventing cardiovascular events. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Ihara, Hiroaki; Kato, Motoyasu; Mitsuishi, Yoichiro; Tajima, Ken; Kodama, Yuzo; Takahashi, Fumiyuki; Takahashi, Kazuhisa] Juntendo Univ, Fac Med, Dept Resp Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
   [Ihara, Hiroaki; Kato, Motoyasu; Mitsuishi, Yoichiro; Tajima, Ken; Kodama, Yuzo; Takahashi, Fumiyuki; Takahashi, Kazuhisa] Juntendo Univ, Fac Med, Res Inst Dis Old Ages, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
   [Ihara, Hiroaki; Taniguchi, Hiromi; Fujita, Shogo; Azuma, Nakanobu] Tokatsu Clin Hosp, 865-2 Hinokuchi, Matsudo, Chiba 2710067, Japan.
   [Kikuchi, Kan] Shimoochiai Clin, Dept Kidney & Dialysis, Shinjuku Ku, 2-1-6 Shimo Ochiai, Tokyo 1610033, Japan.
   [Tsuruta, Yuki] Tsuruta Itabashi Clin, Dept Kidney & Dialysis, Kita Ku, 7-5-7 Takinogawa, Tokyo 1140023, Japan.
RP Ihara, H (reprint author), Juntendo Univ, Dept Resp Med, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.
EM h-ihara@juntendo.ac.jp
CR Akman OE, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-88
   Austrian R, 1976, Trans Assoc Am Physicians, V89, P184
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Caligiuri G, 2007, J AM COLL CARDIOL, V50, P540, DOI 10.1016/j.jacc.2006.11.054
   Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7
   Corrales-Medina VF, 2009, MEDICINE, V88, P154, DOI 10.1097/MD.0b013e3181a692f0
   COSIO FG, 1981, KIDNEY INT, V20, P254, DOI 10.1038/ki.1981.128
   Dominguez A, 2005, CLIN INFECT DIS, V40, P1250, DOI 10.1086/429236
   French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1
   Fuchshuber A, 1996, NEPHROL DIAL TRANSPL, V11, P468
   Gilbertson DT, 2011, NEPHROL DIAL TRANSPL, V26, P2934, DOI 10.1093/ndt/gfq853
   Hung IFN, 2010, CLIN INFECT DIS, V51, P1007, DOI 10.1086/656587
   Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678
   KHAN IH, 1993, KIDNEY INT, V43, pS143
   Kobayashi M, 2015, MMWR-MORBID MORTAL W, V64, P944, DOI 10.15585/mmwr.mm6434a4
   Lamontagne F, 2008, CAN MED ASSOC J, V179, P773, DOI 10.1503/cmaj.070221
   Mahmoodi M, 2009, EUR CYTOKINE NETW, V20, P69, DOI 10.1684/ecn.2009.0153
   Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3
   Musher DM, 2007, CLIN INFECT DIS, V45, P158, DOI 10.1086/518849
   Musher DM, 2006, CLIN INFECT DIS, V43, P1004, DOI 10.1086/507699
   Pourfarziani V, 2008, ANN TRANSPL, V13, P43
   Ren S, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2015-000247
   Sarnak MJ, 2001, CHEST, V120, P1883, DOI 10.1378/chest.120.6.1883
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613
   Suthers B, 2012, VACCINE, V30, P3983, DOI 10.1016/j.vaccine.2012.03.084
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6447
EP 6453
DI 10.1016/j.vaccine.2019.08.088
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100030
PM 31526624
OA Other Gold
DA 2020-05-12
ER

PT J
AU Elaish, M
   Xia, M
   Ngunjiri, JM
   Ghorbani, A
   Jang, H
   Mahesh, KC
   Abundo, MC
   Dhakal, S
   Gourapura, R
   Jiang, X
   Lee, CW
AF Elaish, Mohamed
   Xia, Ming
   Ngunjiri, John M.
   Ghorbani, Amir
   Jang, Hyesun
   Mahesh, K. C.
   Abundo, Michael C.
   Dhakal, Santosh
   Gourapura, Renukaradhya
   Jiang, Xi
   Lee, Chang-Won
TI Protective immunity against influenza virus challenge by norovirus P
   particle-M2e and HA2-AtCYN vaccines in chickens
SO VACCINE
LA English
DT Article
DE Avian influenza virus; Universal influenza vaccine; M2e vaccine; HA2
   vaccine; Avian influenza vaccines
ID A VIRUS; FUSION PROTEIN; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODIES;
   CROSS-PROTECTION; HEMAGGLUTININ; VACCINATION; MUCOSAL; MICE; M2E
AB Development of a broadly reactive influenza vaccine that can provide protection against emerging type A influenza viruses is a big challenge. We previously demonstrated that a vaccine displaying the extracellular domain of the matrix protein 2 (M2e) on the surface loops of norovirus P-particle (M2eP) can partially protect chickens against several subtypes of avian influenza viruses. In the current study, a chimeric vaccine containing a conserved peptide from the subunit 2 of hemagglutinin (HA) glycoprotein (HA2) and Arabidopsis thaliana cyanase protein (AtCYN) (HA2-AtCYN vaccine) was evaluated in 2-weeks-old chickens. Depending on the route of administration, the HA2-AtCYN vaccine was shown to induce various levels of HA2-specific IgA in tears as well as serum IgG, which were associated with partial protection of chickens against tracheal shedding of a low pathogenicity H5N2 challenge virus. Furthermore, intranasal administration with a combination of HA2-AtCYN and M2eP vaccines resulted in enhanced protection compared to each vaccine alone. Simultaneous intranasal administration of the vaccines did not interfere with secretory IgA induction by each vaccine. Additionally, significantly higher M2eP-specific proliferative responses were observed in peripheral blood mononuclear cells of all M2eP-vaccinated groups when compared with the mock-vaccinated group. Although tripling the number of M2e copies did not enhance the protective efficacy of the chimeric vaccine, it significantly reduced immunodominance of P-particle epitopes without affecting the robustness of M2e-specific immune responses. Taken together, our data suggests that mucosal immunization of chickens with combinations of mechanistically different cross-subtype-conserved vaccines has the potential to enhance the protective efficacy against influenza virus challenge. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Elaish, Mohamed; Ngunjiri, John M.; Ghorbani, Amir; Jang, Hyesun; Mahesh, K. C.; Abundo, Michael C.; Dhakal, Santosh; Gourapura, Renukaradhya; Lee, Chang-Won] Ohio State Univ, Ohio Agr Res & Dev Ctr, Food Anim Hlth Res Program, Wooster, OH 44691 USA.
   [Elaish, Mohamed] Cairo Univ, Fac Vet Med, Poultry Dis Dept, Cairo, Egypt.
   [Xia, Ming; Jiang, Xi] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.
   [Ghorbani, Amir; Jang, Hyesun; Mahesh, K. C.; Abundo, Michael C.; Dhakal, Santosh; Gourapura, Renukaradhya; Lee, Chang-Won] Ohio State Univ, Coll Vet Med, Dept Vet Prevent Med, Columbus, OH 43210 USA.
RP Lee, CW (reprint author), 1680 Madison Ave, Wooster, OH 44691 USA.
EM lee.2854@osu.edu
OI Dhakal, Santosh/0000-0002-4494-8608; Ghorbani, Amir/0000-0001-8511-1727
FU Agriculture and Food Research Initiative Competitive Grant from the USDA
   National Institute of Food and Agriculture [2013-67015-20476]
FX The authors would like to thank Dr. Juliette Hanson, Megan Strother,
   Rachel Root (deceased), Sara Tallmadge, Dennis Hartzler, and Ronna Wood
   for assistance with animal care. This study was supported by Agriculture
   and Food Research Initiative Competitive Grant no. 2013-67015-20476 from
   the USDA National Institute of Food and Agriculture.
CR Ameghi A, 2016, VIRAL IMMUNOL, V29, P228, DOI 10.1089/vim.2015.0050
   Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107
   Capua I, 2008, ZOONOSES PUBLIC HLTH, V55, P2, DOI 10.1111/j.1863-2378.2007.01081.x
   Dabaghian M, 2014, VET MICROBIOL, V174, P116, DOI 10.1016/j.vetmic.2014.09.009
   De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004
   De Filette M, 2006, VACCINE, V24, P6597, DOI 10.1016/j.vaccine.2006.05.082
   Du LY, 2010, MICROBES INFECT, V12, P280, DOI 10.1016/j.micinf.2010.01.001
   Ebrahimi SM, 2012, VIROLOGY, V430, P63, DOI 10.1016/j.virol.2012.04.015
   Ebrahimi SM, 2010, MOL BIOL REP, V37, P2877, DOI 10.1007/s11033-009-9846-2
   El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147
   Elaish M, 2015, VACCINE, V33, P4901, DOI 10.1016/j.vaccine.2015.07.049
   Elaish M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171174
   Eliasson DG, 2008, VACCINE, V26, P1243, DOI 10.1016/j.vaccine.2007.12.027
   Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007
   Gerhard W, 2006, EMERG INFECT DIS, V12, P569, DOI 10.3201/eid1204.051020
   Ghorbani A, 2019, VACCINE, V37, P1356, DOI 10.1016/j.vaccine.2019.01.037
   Guo Y, 2017, MICROBES INFECT, V19, P641, DOI 10.1016/j.micinf.2017.08.010
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Jang H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195285
   Jang H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156603
   Janulikova J, 2012, ACTA VIROL, V56, P169, DOI 10.4149/av_2012_03_169
   Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598
   Kong XF, 2004, INT IMMUNOPHARMACOL, V4, P975, DOI 10.1016/j.intimp.2004.03.008
   Krammer F, 2016, CURR OPIN VIROL, V17, P95, DOI 10.1016/j.coviro.2016.02.002
   Krammer F, 2015, CURR TOP MICROBIOL, V386, P301, DOI 10.1007/82_2014_408
   Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007
   Krammer F, 2012, J VIROL, V86, P10302, DOI 10.1128/JVI.01336-12
   Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014
   Lee Jong-Soo, 2013, J Virol Methods, V194, P280, DOI 10.1016/j.jviromet.2013.08.022
   Lei H, 2015, ARCH VIROL, V160, P3011, DOI 10.1007/s00705-015-2587-8
   Liu WL, 2004, VACCINE, V23, P366, DOI 10.1016/j.vaccine.2004.05.028
   Luhtala M, 1997, EUR J IMMUNOL, V27, P189, DOI 10.1002/eji.1830270128
   Mozdzanowska K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-118
   Neirynck S, 1999, NAT MED, V5, P1157
   Oxford JS, 2013, BRIT J CLIN PHARMACO, V76, P210, DOI 10.1111/bcp.12146
   Pedersen Janice C., 2008, V436, P53, DOI 10.1007/978-1-59745-279-3_8
   Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annure, 10.1146/annurev-med-120611-145115]
   Prabhu N, 2009, J VIROL, V83, P2553, DOI 10.1128/JVI.02165-08
   Qian D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018300
   Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123
   Roose K, 2009, DRUG NEWS PERSPECT, V22, P80, DOI 10.1358/dnp.2009.22.2.1334451
   Rue CA, 2011, J GEN VIROL, V92, P931, DOI 10.1099/vir.0.025486-0
   Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y
   Schotsaert M, 2009, EXPERT REV VACCINES, V8, P499, DOI [10.1586/erv.09.6, 10.1586/ERV.09.6]
   Scorza FB, 2016, VACCINE, V34, P2926, DOI 10.1016/j.vaccine.2016.03.085
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Smialek M, 2011, POL J VET SCI, V14, P291, DOI 10.2478/v10181-011-0047-2
   Song JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014538
   Song JM, 2011, P NATL ACAD SCI USA, V108, P757, DOI 10.1073/pnas.1012199108
   Song L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00326
   Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002
   Spackman E, 2014, VET J, V202, P408, DOI 10.1016/j.tvjl.2014.09.017
   Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10
   Stepanova LA, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0433-5
   Stropkovska A, 2009, ACTA VIROL, V53, P15, DOI 10.4149/av_2009_01_15
   Swayne DE, 2014, ECOHEALTH, V11, P94, DOI 10.1007/s10393-013-0861-3
   Swayne DE, 2012, EXPERT REV VACCINES, V11, P877, DOI 10.1586/ERV.12.60
   Swayne DE, 2017, DIS POULTRY, P181
   Tan GS, 2012, J VIROL, V86, P6179, DOI 10.1128/JVI.00469-12
   Tan M, 2005, J VIROL, V79, P14017, DOI 10.1128/JVI.79.22.14017-14030.2005
   Tan M, 2008, VIROLOGY, V382, P115, DOI 10.1016/j.virol.2008.08.047
   Tan M, 2012, NANOMEDICINE-UK, V7, P889, DOI [10.2217/NNM.12.62, 10.2217/nnm.12.62]
   Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10
   van Riet E, 2012, VACCINE, V30, P5893, DOI 10.1016/j.vaccine.2012.04.109
   Vareckova E, 2003, ACTA VIROL, V47, P229
   Walsh MA, 2000, STRUCTURE, V8, P505, DOI 10.1016/S0969-2126(00)00134-9
   Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107
   Wiersma LCM, 2015, VACCINES, V3, P239, DOI 10.3390/vaccines3020239
   Wright PF, 2011, AM J REPROD IMMUNOL, V65, P248, DOI 10.1111/j.1600-0897.2010.00954.x
   Xia M, 2011, VACCINE, V29, P7670, DOI 10.1016/j.vaccine.2011.07.139
   Yang WT, 2017, APPL MICROBIOL BIOT, V101, P8475, DOI 10.1007/s00253-017-8600-2
   Zhang XT, 2011, INTERVIROLOGY, V54, P290, DOI 10.1159/000319440
   Zhang Z, 2017, VET MICROBIOL, V203, P143, DOI 10.1016/j.vetmic.2017.03.004
   Zhao GY, 2010, VACCINE, V28, P7233, DOI 10.1016/j.vaccine.2010.08.049
NR 74
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6454
EP 6462
DI 10.1016/j.vaccine.2019.08.082
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100031
PM 31506195
DA 2020-05-12
ER

PT J
AU Wangchuk, S
   Nogareda, F
   Tshering, N
   Khandu, L
   Pelden, S
   Wannemuehler, K
   Wangdi, S
   Wangchuk, U
   Mulders, M
   Tamang, T
   Patel, MK
AF Wangchuk, Sonam
   Nogareda, Francisco
   Tshering, Namgay
   Khandu, Lekey
   Pelden, Sonam
   Wannemuehler, Kathleen
   Wangdi, Sonam
   Wangchuk, Ugyen
   Mulders, Mick
   Tamang, Tshewang
   Patel, Minal K.
TI Measles and rubella immunity in the population of Bhutan, 2017
SO VACCINE
LA English
DT Article
DE Measles; Rubella; Seroprevalence; Bhutan
ID VACCINATION; FAILURE
AB Background: In 2017, measles elimination was verified in Bhutan, and the country appears to have sufficiently high vaccination coverage to achieve rubella elimination. However, a measles and rubella serosurvey was conducted to find if any hidden immunity gaps existed that could threaten Bhutan's elimination status.
   Methods: A nationwide, three-stage, cluster seroprevalence survey was conducted among individuals aged 1-4, 5-17, and >20 years in 2017. Demographic information and children's vaccination history were collected, and a blood specimen was drawn. Serum was tested for measles and rubella immunoglobulin G (IgG). Frequencies, weighted proportions, and prevalence ratios for measles and rubella seropositivity were calculated by demographic and vaccination history, taking into account the study design.
   Results: Of the 1325 individuals tested, 1045 (81%, 95% CI 78%-85%) were measles IgG seropositive, and 1290 (97%, 95% CI 95%-99%) were rubella IgG seropositive. Rubella IgG seropositivity was high in all three age strata, but only 47% of those aged 5-17 years were measles IgG seropositive. Additionally, only 41% of those aged 5-17 years who had documented receipt of two doses of measles- or measles-rubella-containing vaccine were seropositive for measles IgG, but almost all these children were rubella IgG seropositive.
   Conclusions: An unexpected measles immunity gap was identified among children 5-17 years of age. It is unclear why this immunity gap exists; however, it could have led to a large outbreak and threatened sustaining of measles elimination in Bhutan. Based on this finding, a mass vaccination campaign was conducted to close the immunity gap. (C) 2019 Published by Elsevier Ltd.
C1 [Wangchuk, Sonam; Pelden, Sonam] Royal Govt Bhutan, Royal Ctr Dis Control, Minist Hlth, Serbithang, Thimphu, Bhutan.
   [Nogareda, Francisco] C Juan de Austria 13, Madrid 28010, Spain.
   [Tshering, Namgay; Khandu, Lekey; Wangdi, Sonam; Wangchuk, Ugyen; Tamang, Tshewang] Royal Govt Bhutan, Minist Hlth, POB 726, Kawajangsa, Thimphu, Bhutan.
   [Wannemuehler, Kathleen] Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Mulders, Mick; Patel, Minal K.] WHO, Expanded Programme Immunizat, 20 Ave Appia, CH-1211 Geneva, Switzerland.
RP Patel, MK (reprint author), WHO, Expanded Programme Immunizat, 20 Ave Appia, CH-1211 Geneva, Switzerland.
EM swangchuk@health.gov.bt; chesconogareda@hotmail.com;
   ntshering@health.gov.bt; lkhandu@health.gov.bt; spelden@health.gov.bt;
   kpw9@cdc.gov; wangdis@who.int; WANGCHUKU@who.int; muldersm@who.int;
   ttamang@health.gov.bt; patelm@who.int
FU Bill and Melinda Gates FoundationGates Foundation
FX Funding for this study was provided by the Bill and Melinda Gates
   Foundation.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   [Anonymous], 2018, 7 M VACC PREV DIS LA
   Breakwell L, 2015, MMWR-MORBID MORTAL W, V64, P1088, DOI 10.15585/mmwr.mm6438a7
   Cohen BJ, 2006, J VIROL METHODS, V131, P209, DOI 10.1016/j.jviromet.2005.08.001
   Cutts FT, 2016, TROP MED INT HEALTH, V21, P1086, DOI 10.1111/tmi.12737
   Durrheim DN, 2018, VACCINE, V36, P4001, DOI 10.1016/j.vaccine.2018.04.036
   Durrheim DN, 2016, NEW ENGL J MED, V375, P1392, DOI 10.1056/NEJMe1610620
   Durrheim DN, 2014, VACCINE, V32, P6880, DOI 10.1016/j.vaccine.2014.10.061
   Fowotade A, 2015, J Immunoassay Immunochem, V36, P195, DOI 10.1080/15321819.2014.920713
   Hachiya M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194931
   Hales CM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw064
   Kang HJ, 2017, VACCINE, V35, P4126, DOI 10.1016/j.vaccine.2017.06.058
   Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089
   Patel MK, 2019, LANCET GLOB HEALTH, V7, pE313, DOI 10.1016/S2214-109X(18)30492-3
   Sa Machado R, 2018, EUROSURVEILLANCE, V2018, P23
   WHO, WHO VACCINEPREVENTAB
   World Health Organization, 2018, WKLY EPIDEMIOL REC, V93, P544
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World health organization regional office for South-East Asia, 2017, BHUT MALD EL MEASL
   World health organization regional office of South-East Asia, 2018, DPR KOR TIM LEST EL
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6463
EP 6469
DI 10.1016/j.vaccine.2019.08.085
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100032
PM 31500970
DA 2020-05-12
ER

PT J
AU Bernstein, DI
   Cardin, RD
   Bravo, FJ
   Hamouda, T
   Pullum, DA
   Cohen, G
   Bitko, V
   Fattom, A
AF Bernstein, David, I
   Cardin, Rhonda D.
   Bravo, Fernando J.
   Hamouda, Tarek
   Pullum, Derek A.
   Cohen, Gary
   Bitko, Vira
   Fattom, Ali
TI Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as
   a prophylactic and therapeutic vaccine using the guinea pig model of
   genital herpes
SO VACCINE
LA English
DT Article
DE Herpes simplex virus type 2; Genital herpes; Vaccine; NanoVax;
   Nanoemulsion
ID SIMPLEX-VIRUS TYPE-2; SEXUALLY-TRANSMITTED INFECTIONS; HIV ACQUISITION;
   UNITED-STATES; PROTECTS; IMMUNIZATION; INCREASES; IMMUNITY; INSIGHTS;
   CELLS
AB Genital herpes is a sexually transmitted disease representing a major global health concern. Currently, there is no approved vaccine and existing antiviral therapies exhibit limited efficacy. Herein, we describe an intranasal (IN) vaccine comprised of HSV-2 surface glycoproteins gD2 and gB2 formulated in a nanoemulsion adjuvant (NE01-gD2/gB2). Using the HSV-2 genital herpes guinea pig model, we demonstrate that IN NE01-gD2/gB2 induces higher levels of neutralizing antibody compared to a monovalent IN NE01-gD2 vaccine, but less than an intramuscular (IM) Alum/MPL-gD2 vaccine. Following intravaginal (IVag) challenge with HSV-2, the group immunized with IN NE01-gD2/gB2 exhibited significantly reduced acute and recurrent disease scores compared to placebo recipients. Significantly, latent virus was only detected in the dorsal root ganglia of 1 of 12 IN NE01-gD2/gB2-vaccinated animals compared to 11 of 12 placebo recipient. In the therapeutic model, IN NE01-gD2/gB2 immunized guinea pigs exhibited a significant reduction in the recurrent lesions scores (64%, p < 0.01), number of animal days with disease (64%, p < 0.01), number of animals with viral shedding (50%, p < 0.04) and reduction in virus positive vaginal swabs (56%, p < 0.04), These data suggests that the treatment may be effective in treating chronic disease and minimizing virus transmission. These results warrant advancing the development of IN NE01-gD2/gB2 as both a prophylactic and therapeutic vaccine against HSV-2. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bernstein, David, I; Cardin, Rhonda D.; Bravo, Fernando J.; Pullum, Derek A.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Hamouda, Tarek; Bitko, Vira; Fattom, Ali] BlueWillow Biol, Ann Arbor, MI USA.
   [Cohen, Gary] Univ Penn, Philadelphia, PA 19104 USA.
RP Bernstein, DI (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.; Fattom, A (reprint author), 2311 Green Rd,Suite A, Ann Arbor, MI 48105 USA.
EM david.bernstein@cchmc.org; ali.fattom@bluewillow.com
FU National Institute of Allergy and Infectious Diseases/National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [HHSN272201700017I,
   HHSN27200003]; Cincinnati Children Hospital Medical Center (CCHMC)
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases/National Institutes of Health Contract No.
   HHSN272201700017I and HHSN27200003 to Cincinnati Children Hospital
   Medical Center (CCHMC).
CR Anjuere F, 2012, CLIN MICROBIOL INFEC, V18, P117, DOI 10.1111/j.1469-0691.2012.03995.x
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   Bernstein DI, 2019, VACCINE, V37, P61, DOI 10.1016/j.vaccine.2018.11.042
   Bernstein David I, 2014, Antivir Chem Chemother, V23, P189, DOI 10.3851/IMP2499
   Bernstein DI, 2011, VACCINE, V29, P2071, DOI 10.1016/j.vaccine.2011.01.005
   Bernstein DI, 2010, VACCINE, V28, P3748, DOI 10.1016/j.vaccine.2009.10.025
   Bielinska AU, 2008, CLIN VACCINE IMMUNOL, V15, P348, DOI 10.1128/CVI.00440-07
   Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148
   Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07
   Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Brugha R, 1997, INT J EPIDEMIOL, V26, P698, DOI 10.1093/ije/26.4.698
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331
   Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7
   Freeman EE, 2007, SEX TRANSM INFECT, V83, pI17, DOI 10.1136/sti.2006.023549
   Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4
   Hensel MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02257-16
   Hofstetter AM, 2014, CURR OPIN INFECT DIS, V27, P75, DOI 10.1097/QCO.0000000000000029
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Johnson KE, 2009, AIDS, V23, P1807, DOI 10.1097/QAD.0b013e32832efdf1
   Johnston C, 2016, VACCINE, V34, P2948, DOI 10.1016/j.vaccine.2015.12.076
   Koelle DM, 2008, ANNU REV MED, V59, P381, DOI 10.1146/annurev.med.59.061606.095540
   Lindell DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021823
   Looker KJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114989
   Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346
   Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954
   Masese L, 2015, AIDS, V29, P1077, DOI 10.1097/QAD.0000000000000646
   Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5
   Owusu-Edusei K, 2013, SEX TRANSM DIS, V40, P197, DOI 10.1097/OLQ.0b013e318285c6d2
   Passmore C, 2014, HUM VACC IMMUNOTHER, V10, P615, DOI 10.4161/hv.27383
   Rebbapragada A, 2007, AIDS, V21, P589, DOI 10.1097/QAD.0b013e328012b896
   Roth K, 2013, MICROB PATHOGENESIS, V58, P45, DOI 10.1016/j.micpath.2012.11.001
   Schiffer JT, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000193
   Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522
   STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914
   Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205
   Thompson C, 2011, ADV EXP MED BIOL, V697, P221, DOI 10.1007/978-1-4419-7185-2_15
   Tronstein E, 2011, JAMA-J AM MED ASSOC, V305, P1441, DOI 10.1001/jama.2011.420
   Wang SH, 2019, VACCINE, V37, P1591, DOI 10.1016/j.vaccine.2019.02.002
   Whitley RJ, 2001, LANCET, V357, P1513, DOI 10.1016/S0140-6736(00)04638-9
   Xu F., 2010, Morbidity and Mortality Weekly Report, V59, P456
   Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110
NR 42
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6470
EP 6477
DI 10.1016/j.vaccine.2019.08.077
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100033
PM 31515143
DA 2020-05-12
ER

PT J
AU Salmon, DA
   Limaye, RJ
   Dudley, MZ
   Oloko, OK
   Church-Balin, C
   Ellingson, MK
   Spina, CI
   Brewer, SE
   Orenstein, WA
   Halsey, NA
   Chamberlain, AT
   Bednarczyk, RA
   Malik, FA
   Frew, PM
   O'Leary, ST
   Omer, SB
AF Salmon, Daniel A.
   Limaye, Rupali J.
   Dudley, Matthew Z.
   Oloko, Oladeji K.
   Church-Balin, Cathy
   Ellingson, Mallory K.
   Spina, Christine, I
   Brewer, Sarah E.
   Orenstein, Walter A.
   Halsey, Neal A.
   Chamberlain, Allison T.
   Bednarczyk, Robert A.
   Malik, Fauzia A.
   Frew, Paula M.
   O'Leary, Sean T.
   Omer, Saad B.
TI MomsTalkShots: An individually tailored educational application for
   maternal and infant vaccines
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Technology; Vaccine uptake
ID SCHOOL IMMUNIZATION REQUIREMENTS; NONMEDICAL EXEMPTIONS; PARENTAL
   REFUSAL; VACCINATION; PERTUSSIS; HESITANCY; RISK; CONSEQUENCES;
   INFECTION; ATTITUDES
AB Introduction: The development and initial assessment in a clinical setting of a theory-driven, individually tailored educational application (app), MomsTalkShots, focused on increasing uptake of maternal and infant vaccines is described.
   Methods: MomsTalkShots algorithmically tailored videos based on parent needs to deliver an intervention that was specifically responsive to individual vaccine attitudes, beliefs and intentions, demographics, and source credibility. MomsTalkShots was evaluated among 1103 pregnant women recruited from 23 geographically and socio-demographically diverse obstetrician-gynecologist offices in Georgia and Colorado in 2017. Self-reported information needs were assessed pre-and post-videos and participants self-reported factors related to usability and analyzed in 2018.
   Results: The vast majority of women reported MomsTalkShots was helpful (95%), trustworthy (94%), interesting (97%) and clear to understand (99%), none of which varied by demographics or parity. Reported usability was slightly lower among vaccine hesitant women, yet the majority reported MomsTalkShots was helpful (91%), trustworthy (85%), interesting (97%) and clear (99%). The majority of women (72%) who did not have enough vaccine information pre-videos reported enough information post-videos.
   Conclusions: MomsTalkShots was designed to provide individually tailored vaccine information to pregnant women from a population with varied vaccine intentions, confidence and vaccine concerns. MomsTalkShots was extremely well-received among pregnant women, even among women who were initially vaccine hesitant and did not intend to vaccinate themselves and their infants according to the recommended immunization schedule. Next steps include evaluation to assess impact on vaccine uptake and expansion to adolescent and adult vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salmon, Daniel A.; Limaye, Rupali J.; Dudley, Matthew Z.; Oloko, Oladeji K.; Halsey, Neal A.] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room W5035, Baltimore, MD 21205 USA.
   [Salmon, Daniel A.; Limaye, Rupali J.; Dudley, Matthew Z.; Halsey, Neal A.] Johns Hopkins Univ, Inst Vaccine Safety, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Limaye, Rupali J.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Church-Balin, Cathy] Johns Hopkins Univ, Ctr Commun Programs, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Ellingson, Mallory K.; Bednarczyk, Robert A.; Malik, Fauzia A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Spina, Christine, I; Brewer, Sarah E.; O'Leary, Sean T.] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus,13199 E Montview Blvd,Suite, Aurora, CO 80045 USA.
   [Spina, Christine, I; Brewer, Sarah E.; O'Leary, Sean T.] Childrens Hosp, 13199 E Montview Blvd,Suite 300,Mail Stop F443, Aurora, CO 80045 USA.
   [Brewer, Sarah E.] Univ Colorado, Sch Med, Dept Family Med, Anschutz Med Campus,12631 East 17th Ave AO1,3rd, Aurora, CO 80045 USA.
   [O'Leary, Sean T.] Univ Colorado, Dept Pediat, Anschutz Med Campus,13123 E 16th Ave,B065, Aurora, CO 80045 USA.
   [Orenstein, Walter A.; Chamberlain, Allison T.; Bednarczyk, Robert A.; Omer, Saad B.] Emory Univ, Sch Med, Dept Med, 100 Woodruff Circle, Atlanta, GA 30322 USA.
   [Orenstein, Walter A.; Bednarczyk, Robert A.; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Emory Vaccine Ctr, 201 Dowman Dr, Atlanta, GA 30322 USA.
   [Frew, Paula M.] Univ Nevada, Sch Community Hlth Sci, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.
   [Frew, Paula M.] Univ Nevada, Off Res & Econ Dev, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.
   [Frew, Paula M.] Univ Nevada, Populat Hlth & Hlth Equ Initiat, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.
RP Salmon, DA (reprint author), Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room W5035, Baltimore, MD 21205 USA.
EM dsalmon1@jhu.edu
RI Brewer, Sarah/AAG-7535-2019; Chamberlain, Allison T./AAA-3835-2019;
   Bednarczyk, Robert/L-9403-2017
OI Chamberlain, Allison T./0000-0001-6009-537X; Bednarczyk,
   Robert/0000-0002-6812-0928; Brewer, Sarah E./0000-0003-0063-6626;
   Limaye, Rupali/0000-0002-3883-9720
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 AI110482]
FX This work was supported in part by the National Institutes of Health
   [grant number R01 AI110482]. The funder had no role in the design and
   conduct of the study; collection, management, analysis, or
   interpretation of the data; or preparation, review or approval of the
   manuscript.
CR Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878
   Bednarczyk Robert A, 2018, Prev Med Rep, V11, P131, DOI 10.1016/j.pmedr.2018.06.009
   CDC, MAT VACC COV
   Daley MF, 2018, AM J PREV MED, V55, P44, DOI 10.1016/j.amepre.2018.04.010
   Dempsey AF, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.0016
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dudley MZ, 2019, OBSTET GYNECOL UNPUB
   Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146
   Fiebelkorn AP, 2010, J INFECT DIS, V202, P1520, DOI 10.1086/656914
   Frew PM, 2018, HUM VACC IMMUNOTHER, V14, P1548, DOI 10.1080/21645515.2018.1425116
   Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117
   Glanz JM, 2011, VACCINE, V29, P994, DOI 10.1016/j.vaccine.2010.11.085
   Glanz JM, 2010, ARCH PEDIAT ADOL MED, V164, P66, DOI 10.1001/archpediatrics.2009.244
   Glanz JM, 2009, PEDIATRICS, V123, P1446, DOI 10.1542/peds.2008-2150
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199
   Hunt E., 2008, Morbidity and Mortality Weekly Report, V57, P169
   Kahan DM, 17 CCP
   Keane MT, 2005, VACCINE, V23, P2486, DOI 10.1016/j.vaccine.2004.10.026
   Kennedy AM, 2011, HLTH AFF MILLWOOD, V30, P1
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757
   Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263
   Opel D, 2013, PEDIATRICS, V132, P1
   Opel DJ, 2015, AM J PUBLIC HEALTH, V105, P1998, DOI 10.2105/AJPH.2014.302425
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Petty R.E., 1986, ADV EXPT SOCIAL PSYC, P1, DOI DOI 10.1016/S0065-2601(08)60214-2
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Salmon DA, 1999, JAMA-J AM MED ASSOC, V282, P47, DOI 10.1001/jama.282.1.47
   Salmon DA, 2000, JAMA-J AM MED ASSOC, V283, P2241
   Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   WHO, MEASL EUR REC NUMB B
   World Health Organization, 10 THREATS GLOB HLTH
NR 37
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6478
EP 6485
DI 10.1016/j.vaccine.2019.08.080
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100034
PM 31506192
DA 2020-05-12
ER

PT J
AU Syiroj, ATR
   Pardosi, JF
   Heywood, AE
AF Syiroj, Agung Taufiqur Rokhman
   Pardosi, Jerico Franciscus
   Heywood, Anita E.
TI Exploring parents' reasons for incomplete childhood immunisation in
   Indonesia
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Immunisation; Parental decision-making; Vaccination;
   Indonesia
ID VACCINE HESITANCY; PUBLISHED LITERATURE; ATTITUDES; CHILDREN; COUNTRIES
AB Introduction: Immunisation is one of the most successful interventions for controlling infectious diseases but relies on continuous high coverage. Parental vaccine refusal and logistical barriers to access are threats to the success of immunisation programs, with resultant population immunity gaps leading to outbreaks of vaccine-preventable diseases. In Indonesia, coverage of childhood vaccines is suboptimal, with poor coverage of diphtheria-tetanus-pertussis vaccine leading to a large diphtheria outbreak in 2017.
   Methods: To explore the underlying parents' reasons for incomplete childhood immunisation in Indonesia, semi-structured interviews were conducted in Tangerang Selatan, Banten Province, Indonesia. Sixteen purposively selected primary carers of partially and unimmunised children were interviewed. Transcripts were coded and analysed using inductive thematic analysis.
   Results: Parental reasons were categorised into three interrelated themes of belief barriers, safety concerns, and issues of trust and misinformation. Stark differences were evident in reasons provided by carers of unimmunised children compared to partially immunised children. For parents of unimmunised children, Islamic beliefs, belief in the strength of natural immunity, and the use of alternative medicines strongly influenced behaviours. Safety concerns, issues of trust including distrust in the government, misinformation, and trust in information obtained through social networks were also prominent. In contrast, concerns about mild side-effects and logistical barriers outweighed beliefs among carers of partially immunised children.
   Conclusions: Our findings highlight the complexities in decision making for parents who decide not to vaccinate their children. In the Indonesian context, public health education and engagement of religious leaders to bridge the gap between religious beliefs and vaccine acceptance are needed to address vaccine refusal. Future research on the influence of social networks on vaccine hesitancy in the Indonesian context is also warranted. For parents of partially vaccinated children, interventions should focus on barriers of access to community health staff to encourage timely schedule completion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Syiroj, Agung Taufiqur Rokhman] Natl Populat & Family Planning Board, East Jakarta, East Java Provi, Indonesia.
   [Pardosi, Jerico Franciscus] Queensland Univ Technol, Fac Hlth, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia.
   [Syiroj, Agung Taufiqur Rokhman; Pardosi, Jerico Franciscus; Heywood, Anita E.] Univ New South Wales, Fac Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [Pardosi, Jerico Franciscus] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia.
RP Syiroj, ATR (reprint author), Kesemen 024-006, Kab Sidoarjo, Jawa Timur, Indonesia.
EM Agungtaufiqur@gmail.com
RI Syiroj, Agung/AAF-2798-2019
OI Heywood, Anita/0000-0003-4400-7960
FU Lembaga Pengelola Dana Pendidikan (LPDP), Indonesia Endowment Fund for
   Education [FR232018130388]
FX This work was supported by Lembaga Pengelola Dana Pendidikan (LPDP),
   Indonesia Endowment Fund for Education (FR232018130388,2018).
CR [Anonymous], 2011, Wkly Epidemiol Rec, V86, P509
   Banten Provincial Health Office, 2013, PROF KES PROV BANT T
   Banten Provincial Health Office, 2012, HLTH PROF BANT PROV
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Busse JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022737
   Bystrom E, 2014, VACCINE, V32, P6752, DOI 10.1016/j.vaccine.2014.10.011
   Cassell JA, 2006, PUBLIC HEALTH, V120, P783, DOI 10.1016/j.puhe.2006.03.011
   CDC, 2018, MEASL CAS OUTBR
   Center PR, 2010, MUSL POP IND
   Downey L, 2010, MATERN CHILD HLTH J, V14, P922, DOI 10.1007/s10995-009-0519-5
   Dube E, 2016, QUAL HEALTH RES, V26, P411, DOI 10.1177/1049732315573207
   ecdc, 2018, MEASL OUTBR STILL ON
   Enkel SL, 2018, VACCINE, V36, P6459, DOI 10.1016/j.vaccine.2017.09.088
   Eriksson A, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-48
   Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692
   Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1
   Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074
   Gross K, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1716-3
   Harjaningrum AT, 2013, VACCINE, V31, P1516, DOI 10.1016/j.vaccine.2013.01.007
   Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1183
   Healy CM, 2011, PEDIATRICS, V127, pS127, DOI 10.1542/peds.2010-1722S
   Husada D, 2017, OPEN FORUM INFECT S1, V4, pS244
   Jones L, 2010, PREV MED, V50, P148, DOI 10.1016/j.ypmed.2009.12.001
   Kennedy A, 2011, PEDIATRICS, V127, pS92, DOI 10.1542/peds.2010-1722N
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Leach M, 2008, B WORLD HEALTH ORGAN, V86, P418, DOI 10.2471/BLT.08.054726
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Ministry of Health, 2018, PEM OPT KLB DIFT BIS
   Ministry of Health, 2013, RIS KES DAS RISKESDA
   Ministry of Health, 2017, IM EF CEG DIFT
   Ministry of Health, 2017, IN MANK KLB DIFT
   MUI, 2018, PENGG VAKS MR, V33
   MUI, 2016, FATW PEN IM
   National Institute of Health Research and Development, 2010, 2010 BAS HLTH RES
   NEW SJ, 1991, SOC SCI MED, V33, P509, DOI 10.1016/0277-9536(91)90333-8
   Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Reich JA, 2016, SOC SCI MED, V157, P103, DOI 10.1016/j.socscimed.2016.04.001
   Seale H, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1187-3
   Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243
   Smith MJ, 2010, PEDIATR ANN, V39, P476, DOI 10.3928/00904481-20100726-05
   Soewarta Kosen, 2013, LANCET, V381, pS75, DOI [10.1016/S0140-6736(13)61329-x, DOI 10.1016/S0140-6736(13)61329-X]
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Turner N., 2004, NZ MED J, V117
   WHO, 2001, JUD PROH IMP SUBST F
   WHO, 2018, IMM COV
   WHO, 2014, STRATEGIES ADDRESSIN
   WHO and UNICEF, 2017, WHO UNICEF EST DTP3
   Wulandari D, 2017, INDONESIAN J MED SCI, V4, P44
NR 49
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6486
EP 6493
DI 10.1016/j.vaccine.2019.08.081
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100035
PM 31522808
DA 2020-05-12
ER

PT J
AU Connochie, D
   Tingler, RC
   Bauermeister, JA
AF Connochie, Daniel
   Tingler, Ryan C.
   Bauermeister, Jose A.
TI Young men who have sex with men's awareness, acceptability, and
   willingness to participate in HIV vaccine trials: Results from a
   nationwide online pilot study
SO VACCINE
LA English
DT Article
DE HIV; Men who have sex with men; Prevention; Acceptability; Sexual
   minority
ID KNOWLEDGE; PREVENTION; ATTITUDES; BELIEFS; RISK
AB Background: New cases of human immunodeficiency virus (HIV) among young men who have sex with men (YMSM) underscore the need to examine their willingness to use biomedical prevention methods, including an acceptable and efficacious HIV vaccine. We examined whether YMSM's vaccine altruism and vaccine-related socials concerns factors were associated with HIV vaccine acceptability across two vaccine efficacy scenarios, and their awareness and willingness to participate in HIV vaccine research.
   Methods: This secondary analysis uses data from a mHealth trial with YMSM at heightened HIV risk (N =137; 50% racial/ethnic minority; M = 21.7 years). Most YMSM (91.2%) had tested for HIV, and 17.5% (N = 24) reported a prior STI. We used paired-samples t-test to compare differences in efficacy acceptability (50% vs 85%), followed by multivariable regressions examining whether vaccine attitudes (altruism and social concerns) were associated with vaccine acceptability and awareness and willingness to participate in HIV vaccine trials. We controlled for age, education, race/ethnicity, prior HIV testing, and STI diagnosis in our analyses.
   Results: Acceptability for the HIV vaccine with 85% efficacy (M = 8.86; SD = 1.76) was greater than acceptability in the 50% efficacy scenario (M = 7.60; SD = 2.58). Altruistic attitudes were associated with greater vaccine acceptability at 50% (beta = 0.62) and 85% (beta = 0.59) efficacy. Higher educational attainment was negatively associated with a vaccine with 50% efficacy (beta = -0.20, but not for 85% efficacy. Greater vaccine-related social concerns were negatively associated with HIV vaccine research awareness (AOR = 0.38 (95% CI: 0.22, 0.67). Willingness to participate in a HIV vaccine trial was positively associated with age (p = 0.18) and altruism (beta = 0.60), and negatively associated with education (beta = -0.21).
   Conclusions: YMSM find HIV vaccines as an acceptable prevention modality and are willing to participate in HIV vaccine trials. Findings highlight the need to consider YMSM's altruistic and social concerns attitudes in HIV vaccine research and explore how to leverage these attitudes in research campaigns. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Connochie, Daniel; Tingler, Ryan C.; Bauermeister, Jose A.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, 418 Curie Blvd,Rm 235L, Philadelphia, PA 19104 USA.
RP Connochie, D (reprint author), 418 Curie Blvd,Suite 235L, Philadelphia, PA 19104 USA.
EM dconno@upenn.edu
RI ; Bauermeister, Jose/X-8960-2018
OI Tingler, Ryan/0000-0002-4601-7401; Bauermeister,
   Jose/0000-0002-9276-2306
FU US National Institutes of Health (NIH)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R34 MH101997]
FX This research was sponsored by the US National Institutes of Health
   (NIH), under R34 MH101997. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of
   NIH.
CR Alio AP, 2014, J GAY LESBIAN SOC SE, V26, P336, DOI 10.1080/10538720.2014.924892
   Allen MA, 2005, JAIDS-J ACQ IMM DEF, V40, P617, DOI 10.1097/01.qai.0000174655.63653.38
   Arnold MP, 2014, AM J PUBLIC HEALTH, V104, pE112, DOI 10.2105/AJPH.2014.301893
   Atujuna M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191251
   Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110
   Bauermeister Jose Arturo, 2017, JMIR Res Protoc, V6, pe141, DOI 10.2196/resprot.7965
   Castillo-Mancilla JR, 2014, HIV CLIN TRIALS, V15, P14, DOI 10.1310/hct1501-14
   CDC, 2017, HIV SURV REP 2016, V28
   Chimoyi L, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4355-z
   Doshi M, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4395-4
   Fauci AB, 2018, P HIV RES PREV RES I
   Lee SJ, 2014, VACCINE, V32, P5013, DOI 10.1016/j.vaccine.2014.07.018
   Lee SJ, 2008, AIDS CARE, V20, P1161, DOI 10.1080/09540120701855375
   Nel A, 2016, NEW ENGL J MED, V375, P2133, DOI 10.1056/NEJMoa1602046
   Newman PA, 2006, VACCINE, V24, P2094, DOI 10.1016/j.vaccine.2005.11.013
   Newman PA, 2010, AIDS, V24, P1749, DOI 10.1097/QAD.0b013e32833adbe8
   Newman PA, 2009, HEALTH EDUC BEHAV, V36, P321, DOI 10.1177/1090198107305078
   Nodin N, 2008, AIDS CARE, V20, P106, DOI 10.1080/09540120701449096
   Ravert RD, 2009, AM J HEALTH BEHAV, V33, P391
   Richardson S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181702
   Zimet G, 1996, J ADOLESCENT HEALTH, V18, P148, DOI 10.1016/1054-139X(96)81209-2
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6494
EP 6499
DI 10.1016/j.vaccine.2019.08.076
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100036
PM 31522806
DA 2020-05-12
ER

PT J
AU Keitel, WA
   Potter, GE
   Diemert, D
   Bethony, J
   El Sahly, HM
   Kennedy, JK
   Patel, SM
   Plieskatt, JL
   Jones, W
   Deye, G
   Bottazzi, ME
   Hotez, PJ
   Atmar, RL
AF Keitel, W. A.
   Potter, G. E.
   Diemert, D.
   Bethony, J.
   El Sahly, H. M.
   Kennedy, J. K.
   Patel, S. M.
   Plieskatt, J. L.
   Jones, W.
   Deye, G.
   Bottazzi, M. E.
   Hotez, P. J.
   Atmar, R. L.
TI A phase 1 study of the safety, reactogenicity, and immunogenicity of a
   Schistosoma mansoni vaccine with or without glucopyranosyl lipid A
   aqueous formulation (GLA-AF) in healthy adults from a non-endemic area
SO VACCINE
LA English
DT Article
DE Schistosomiasis; Schistosoma mansoni (Sm); Sm tetraspanin 2 (Sm-TSP-2);
   Immune responses; Immunization; Glucopyranosyl lipid A; Adjuvant
ID PREVALENCE; HOOKWORM
AB Background: Schistosomiasis caused by Schistosoma mansoni (Sm) is a chronic, debilitating and potentially deadly neglected tropical disease. The licensure of a vaccine to prevent schistosomiasis would represent a major breakthrough in public health.
   Methods: The safety and immunogenicity of a candidate Sm vaccine were assessed in this phase I, double-blind, dose-escalation trial. Seventy-two healthy Sm-naive 18-50 year olds were randomized to receive 3 doses similar to 8 weeks apart of saline placebo, or 10 mu g, 30 mu g, or 100 mu g of recombinant Sm-Tetraspanin-2 vaccine formulated on aluminum hydroxide adjuvant (Sm-TSP-2/Al) with or without 5 mu g of glucopyranosyl lipid A aqueous formulation (GLA-AF). Clinical and serologic responses were assessed for 1 year after dose 3.
   Results: Vaccines were safe and well-tolerated. The most common reactions were injection site tenderness and pain, and headache and fatigue. Tenderness and pain were more frequent in groups receiving vaccine with GLA-AF than placebo (p = 0.0036 and p = 0.0014, respectively). Injection site reactions among those given Sm-TSP-2/Al with GLA-AF lasted 1.22 and 1.33 days longer than those receiving Sm-TSP-2/Al without GLA-AF or placebo (p < 0.001 for both).
   Dose- and adjuvant-related increases in serum IgG against Sm-TSP-2 were observed. Peak IgG levels occurred 14 days after dose 3. Seroresponse frequencies were low among recipients of Sm-TSP-2/Al without GLA-AF, but higher among subjects receiving 30 mu g or 100 mu g of Sm-TSP-2/Al with GLA-AF. More seroresponses were observed among those given 30 mu g or 100 mu g of Sm-TSP-2/Al with GLA-AF compared to placebo (p = 0.023 and p < 0.001, respectively). Seroresponse frequencies were 0%, 30%, 50%, and 89%, respectively, among those given placebo, or 10 mu g, 30 mu g or 100 mu g of Sm-TSP-2/Al with GLA-AF, suggesting a dose-response relationship for Sm-TSP-2/Al with GLA-AF (p = 0.0001).
   Conclusions: Sm-TSP-2/Al with or without GLA-AF was safe and well tolerated in a Sm-naive population. A vaccine like the one under development may represent our best hope to eliminating this neglected tropical disease. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Keitel, W. A.; El Sahly, H. M.; Patel, S. M.; Bottazzi, M. E.; Hotez, P. J.; Atmar, R. L.] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA.
   [Keitel, W. A.; El Sahly, H. M.; Patel, S. M.; Bottazzi, M. E.; Hotez, P. J.; Atmar, R. L.] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA.
   [Keitel, W. A.; El Sahly, H. M.; Patel, S. M.; Bottazzi, M. E.; Hotez, P. J.; Atmar, R. L.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Potter, G. E.; Kennedy, J. K.] Emmes Corp, Rockville, MD USA.
   [Diemert, D.; Bethony, J.; Plieskatt, J. L.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
   [Jones, W.; Deye, G.] NIAID, DMID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Bottazzi, M. E.; Hotez, P. J.] Baylor Coll Med, Dept Pediat, Texas Childrens Hosp, Ctr Vaccine Dev, Houston, TX 77030 USA.
RP Keitel, WA (reprint author), One Baylor Plaza BCM280, Houston, TX 77030 USA.
EM wkeitel@bcm.edu
OI Kennedy, Jessie/0000-0003-0557-5789
FU NIAID/NIH/Health and Human Services [HHSN272200800002C,
   HHSN2722013000151, HHSN272201500002C]; Texas Children's Center for
   Vaccine Development
FX This work was supported in whole or in part with federal funds from the
   NIAID/NIH/Health and Human Services under Contract Numbers
   HHSN272200800002C, HHSN2722013000151 (Baylor College of Medicine);
   HHSN272201500002C (Emmes); and by intramural funding from Texas
   Children's Center for Vaccine Development.
CR ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Brant SV, 2009, J HELMINTHOL, V83, P191, DOI 10.1017/S0022149X09308020
   Brelsford JB, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005385
   Broker M, 2017, VACCINE, V35, P3286, DOI 10.1016/j.vaccine.2017.04.078
   BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381
   Cheng WQ, 2013, HUM VACC IMMUNOTHER, V9, P2351, DOI 10.4161/hv.25788
   Curti E, 2013, HUM VACC IMMUNOTHER, V9, P2342, DOI 10.4161/hv.25787
   Diemert DJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005574
   Hotez PJ, 2008, EXPERT REV VACCINES, V7, P745, DOI 10.1586/14760584.7.6.745
   Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000485
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Jariwala AR, 2010, EXPERT REV VACCINES, V9, P1219, DOI 10.1586/ERV.10.107
   Jia XY, 2014, J BIOL CHEM, V289, P7151, DOI 10.1074/jbc.M113.531558
   Lammie Patrick J, 2007, PLoS Negl Trop Dis, V1, pe71, DOI 10.1371/journal.pntd.0000071
   Mader P, 2018, CHEMMEDCHEM, DOI [10.1002/cmdc.201800572.1, DOI 10.1002/CMDC.201800572.1]
   McManus DP, 2008, CLIN MICROBIOL REV, V21, P225, DOI 10.1128/CMR.00046-07
   Merrifield M, 2016, VACCINE, V34, P2988, DOI 10.1016/j.vaccine.2016.03.079
   Scaria PV, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0121-9
   Steinmann P, 2006, LANCET INFECT DIS, V6, P411, DOI 10.1016/S1473-3099(06)70521-7
   STIRATELLI R, 1984, BIOMETRICS, V40, P961, DOI 10.2307/2531147
   Stylianou A, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2227-0
   Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430
   Tran MH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000840
   van der Werf MJ, 2003, T ROY SOC TROP MED H, V97, P373, DOI 10.1016/S0035-9203(03)90057-5
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Wang LH, 2018, PARASITOL RES, V117, P3625, DOI 10.1007/s00436-018-6063-8
   World Health Organization, 2018, WKLY EPIDEMIOL REC, P681
NR 27
TC 3
Z9 3
U1 11
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6500
EP 6509
DI 10.1016/j.vaccine.2019.08.075
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100037
PM 31515141
DA 2020-05-12
ER

PT J
AU Gomes, RR
   Antunes, DE
   dos Santos, DF
   Sabino, EFP
   Oliveira, DB
   Goulart, IMB
AF Gomes, Rafaela Resende
   Antunes, Douglas Eulalio
   dos Santos, Diogo Fernandes
   Pipi Sabino, Elaine Favaro
   Oliveira, Dulcineia Bernardes
   Bernardes Goulart, Isabela Maria
TI BCG vaccine and leprosy household contacts: Protective effect and
   probability to becoming sick during follow-up
SO VACCINE
LA English
DT Article
DE Leprosy; Bacillus Calmette-Guerin vaccine; Household contacts; Survival
   curve; Relative risk
ID CALMETTE-GUERIN BCG; MYCOBACTERIUM-LEPRAE; RISK-FACTORS; SURVEILLANCE;
   PREVENTION
AB Background: Immunoprophylaxis with Bacillus Calmette-Guerin (BCG) vaccine is still the most effective intervention in the prevention of leprosy among household contacts (HHCs) of leprosy patients.
   Methods: A retrospective cohort study using data of 5.061 HHCs for a period of 16 years (follow-up of 7 years per leprosy HHCs), evaluating the occurrence of disease as the main outcome and the presence or absence of BCG scars verified at the first evaluation. Statistical analyzes were performed using the relative risk, hazard ratio and survival curves by Kaplan-Meier test.
   Results: A total of 92 contacts sickened, of which 41.3% (38/92) in the first year and 58.7% (54/92) in the course of the other years of follow-up. Of those who became sick, 62% (57/92) developed borderline tuberculoid (BT). The additional protective effect occurred for those who had 2 BCG scars at the first follow-up assessment (Relative Risk: 0.41; p = 0.007) when compared to those not previously exposed to the vaccine. The number of BCG scars examined at the first assessment (t(0) = time zero) affected the occurrence of the outcome evidenced by the difference in survival curves throughout the follow-up (Log Rank, p = 0.041; Breslow, p = 0.012; Tarone-Ware, p = 0.020). Leprosy HHCs with 0 BCG scar at time zero (t(0)) have a shorter survival time (average time of 22 months between t(0) and outcome) when compared to those with 2 BCG scars (average time of 36 months between t(0) and outcome).
   Conclusions: Vaccination of healthy individuals without signs and symptoms of leprosy is extremely important because BCG vaccine has an additional protective effect in those cases with 2 BCG scars throughout follow-up. Reducing the risk of leprosy HHCs becoming sick depends on preventive actions such as immunoprophylaxis and index cases treatment. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gomes, Rafaela Resende; Antunes, Douglas Eulalio; dos Santos, Diogo Fernandes; Pipi Sabino, Elaine Favaro; Oliveira, Dulcineia Bernardes; Bernardes Goulart, Isabela Maria] Univ Fed Uberlandia, Clin Hosp, Natl Reference Ctr Sanit Dermatol & Leprosy, BR-38413018 Uberlandia, MG, Brazil.
   [Antunes, Douglas Eulalio; dos Santos, Diogo Fernandes; Pipi Sabino, Elaine Favaro; Bernardes Goulart, Isabela Maria] Univ Fed Uberlandia, Sch Med, Postgrad Program Hlth Sci, BR-38400902 Uberlandia, MG, Brazil.
RP Antunes, DE (reprint author), CREDESH HC UFU, Natl Reference Ctr Sanit Dermatol & Leprosy, Av Aspirante Mega 77, BR-38413018 Uberlandia, MG, Brazil.
EM credsh@hc.ufu.br
FU CNN [CNPq-465669/2014-0]; FAPEMIGMinas Gerais State Research Foundation
   (FAPEMIG) [FAPEMIG-CBB-APQ-03613-17]
FX This work was supported by CNN [Grant numbers, CNPq-465669/2014-0] and
   FAPEMIG, [Grant numbers, FAPEMIG-CBB-APQ-03613-17]. We declare that the
   funding sources had no involvement for the conduct of the research
   and/or preparation of the article.
CR Altman DG, 1998, BRIT MED J, V317, P468
   Anjum V, 2015, LEPROSY REV, V86, P383
   Araujo S, 2016, CLIN INFECT DIS, V63, P1412, DOI 10.1093/cid/ciw570
   Araujo S, 2015, REV SOC BRAS MED TRO, V48, P739, DOI 10.1590/0037-8682-0245-2015
   de Oliveira MBB, 2016, AN BRAS DERMATOL, V91, P196, DOI 10.1590/abd1806-4841.20163661
   Bazan-Furini R, 2011, MEM I OSWALDO CRUZ, V106, P536, DOI 10.1590/S0074-02762011000500003
   CONVIT J, 1992, LANCET, V339, P446, DOI 10.1016/0140-6736(92)91056-E
   Duppre NC, 2008, T ROY SOC TROP MED H, V102, P631, DOI 10.1016/j.trstmh.2008.04.015
   Duthie MS, 2011, HUM VACCINES, V7, P1172, DOI 10.4161/hv.7.11.16848
   Fine PEM, 1997, AM J EPIDEMIOL, V146, P91, DOI 10.1093/oxfordjournals.aje.a009195
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Gillini L, 2017, PLOS NEGLECT TROP D, P11, DOI [10.1371/.jourrktontd.0005399e0005399, DOI 10.1371/.JOURRKTONTD.0005399E0005399]
   Goulart IMB, 2008, CLIN VACCINE IMMUNOL, V15, P101, DOI 10.1128/CVI.00372-07
   Hacker MD, 2012, MEM I OSWALDO CRUZ, V107, P49, DOI 10.1590/S0074-02762012000900009
   Kerr-Pontes LRS, 2006, INT J EPIDEMIOL, V35, P994, DOI 10.1093/ije/dyl072
   LeGrand A, 1997, LEPROSY REV, V68, P203
   Lombardi C, 1996, Bull Pan Am Health Organ, V30, P24
   Martinez AN, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002655
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI 10.1586/ERV.09.161
   MULIYIL J, 1991, INT J LEPROSY, V59, P229
   OREGE PA, 1993, INT J LEPROSY, V61, P542
   Richardus RA, 2015, VACCINE, V33, P1562, DOI 10.1016/j.vaccine.2015.02.017
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Rodrigues LC, 2007, VACCINE, V25, P6842, DOI 10.1016/j.vaccine.2007.07.032
   Romero-Montoya M, 2017, PLOS NEGLECT TROP D, P11, DOI [10.1371/j.pitrnalpntd000537ie0005325, DOI 10.1371/J.PITRNALPNTD000537IE0005325]
   Sasaki S, 2001, MICROBIOL IMMUNOL, V45, P729, DOI [10.1111/j.i.1348-0421.2001.tb01.308.x, DOI 10.1111/J.I.1348-0421.2001.TB01.308.X]
   Setia MS, 2006, LANCET INFECT DIS, V6, P162, DOI 10.1016/S1473-3099(06)70412-1
   Shen Jian-ping, 2005, Chinese Medical Sciences Journal, V20, P77
   Texier L, 1975, Med Cutan Ibero Lat Am, V3, P381
   WHO, 2017, WKLY EPIDEMIOL REC, V93, P444
   World Health Organization, 2018, Vaccine, V36, P3408, DOI 10.1016/j.vaccine.2018.03.009
   Zodpey SP, 2005, PUBLIC HEALTH, V119, P209, DOI 10.1016/j.puhe.2004.04.007
   Zodpey SP, 1999, LEPROSY REV, V70, P287
NR 33
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6510
EP 6517
DI 10.1016/j.vaccine.2019.08.067
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100038
PM 31500969
DA 2020-05-12
ER

PT J
AU Gabriel, MA
   Dare, E
   Meunier, SM
   Campbell, JL
   Sasges, MR
   Aucoin, MG
AF Gabriel, Michelle A.
   Dare, Emma
   Meunier, Sarah M.
   Campbell, J. Larry
   Sasges, Michael R.
   Aucoin, Marc G.
TI Ultraviolet irradiation of trypsin, lysozyme and beta-galactosidase: how
   does UVC affect these enzymes when used as a secondary barrier against
   adventitious agents?
SO VACCINE
LA English
DT Article
DE Ultraviolet light; Irradiation; Trypsin; Disinfection
ID PORCINE CIRCOVIRUS; CELL-CULTURES; VIRUS INACTIVATION; MANUFACTURE;
   RESISTANCE; REDUCTION; OXIDATION; SERA
AB Trypsin is one of the essential raw materials used in the manufacturing of biopharmaceutical products. As an animal derived product, it can potentially carry a serious risk of contamination with adventitious agents that can result in production shut down and lost product. To mitigate these risks, several methods are currently being used in the industry to remove contamination including physical and chemical methods. Ultraviolet-C (UVC) light is known to inactivate adventitious agents that are resistant to physical and chemical methods and could be a secondary barrier strategy. In this study, we investigated the effect of UVC irradiation on the activity and structure of trypsin. Extreme doses of UVC light were applied to trypsin using a collimated beam apparatus. The effect of UVC light on trypsin enzymatic activity was measured using a colorimetric activity assay and the effect on structure was analyzed by spectrophotometry, gel electrophoresis, and mass spectrometry. To broaden the scope, the effect of UVC light on the activity of two additional enzymes, lysozyme and il-galactosidase, was also examined. At high doses of UVC light, changes to protein structure and protein fragmentation resulted in decreased trypsin activity. However, minimal damage was observed at doses applicable to inactivating adventitious agents, making UVC a feasible treatment for viral inactivation of trypsin products. (C) 2019 Published by Elsevier Ltd.
C1 [Gabriel, Michelle A.; Dare, Emma; Meunier, Sarah M.; Aucoin, Marc G.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
   [Gabriel, Michelle A.; Sasges, Michael R.] Trojan Technol, London, ON, Canada.
   [Campbell, J. Larry] SCIEX Ltd, Concord, ON, Canada.
RP Aucoin, MG (reprint author), Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
EM marc.aucoin@uwaterloo.ca
OI Aucoin, Marc/0000-0001-9393-5558
FU MITACS Elevate Postdoctoral Fellowship; NSERC Collaborative Research and
   Development grantNatural Sciences and Engineering Research Council of
   Canada [CRDPJ-484833-2015]
FX This work was supported in part by the generous contribution of SCIEX in
   the form of LC-MS, PeakView and BioPharmaView software. This work was
   made possible by a MITACS Elevate Postdoctoral Fellowship to MAG and an
   NSERC Collaborative Research and Development grant [grant number
   CRDPJ-484833-2015] to MGA.
CR Ainsworth E, 2009, VIRUS SHUTS GENZYME
   Amano M, 2014, ANAL CHEM, V86, P7536, DOI 10.1021/ac501300m
   Aranha H., 2011, CONTRACT PHARM, P82
   Baylis SA, 2011, VACCINE, V29, P690, DOI 10.1016/j.vaccine.2010.11.028
   Bolton JR, 2003, J ENVIRON ENG-ASCE, V129, P209, DOI 10.1061/(ASCE)0733-9372(2003)129:3(209)
   Brandt T, 2011, J MOL BIOL, V405, P1170, DOI 10.1016/j.jmb.2010.11.038
   BURKE M, 1969, BIOCHEM J, V114, P535, DOI 10.1042/bj1140535
   Chen Joseph, 2012, PDA J Pharm Sci Technol, V66, P580, DOI 10.5731/pdajpst.2012.00892
   Di Cera E, 2009, IUBMB LIFE, V61, P510, DOI 10.1002/iub.186
   Drexler HG, 2002, CYTOTECHNOLOGY, V39, P75, DOI 10.1023/A:1022913015916
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   European Medicines Agency, 2015, GUID US PORC TRYPS U
   FUKUNAGA Y, 1982, J BIOCHEM-TOKYO, V92, P129, DOI 10.1093/oxfordjournals.jbchem.a133909
   Goetschalckx S, 2014, AM PHARM REV, V17, P48
   Lackner C, 2014, VACCINE, V32, P2056, DOI 10.1016/j.vaccine.2014.02.011
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langer ES, 2016, GENETIC ENG BIOTECHN, V36
   Ma WZ, 2005, BIOPHYS J, V89, P1183, DOI 10.1529/biophysj.104.057158
   Marcus-Sekura C, 2011, BIOLOGICALS, V39, P359, DOI 10.1016/j.biologicals.2011.08.003
   Marques EF, 2017, J MASS SPECTROM, V52, P739, DOI 10.1002/jms.3983
   Masschelein W. J., 2002, ULTRAVIOLET LIGHT WA
   Meunier SM, 2017, J IND MICROBIOL BIOT, V44, P893, DOI 10.1007/s10295-017-1917-0
   Moody Mark, 2011, PDA J Pharm Sci Technol, V65, P580, DOI 10.5731/pdajpst.2011.00824
   NEMEC HW, 1977, RADIAT ENVIRON BIOPH, V14, P137, DOI 10.1007/BF01332149
   Nims RW, 2011, BIOLOGICALS, V39, P370, DOI 10.1016/j.biologicals.2011.05.003
   Pastoret PP, 2010, BIOLOGICALS, V38, P332, DOI 10.1016/j.biologicals.2010.02.015
   Petricciani J, 2014, BIOLOGICALS, V42, P223, DOI 10.1016/j.biologicals.2014.07.003
   de Oliveira TFP, 2016, BIOLOGICALS, V44, P53, DOI 10.1016/j.biologicals.2015.12.003
   de Oliveira TFP, 2013, BIOLOGICALS, V41, P407, DOI 10.1016/j.biologicals.2013.08.005
   Plavsic M, 2014, BIOPROCESS J, V13, P6
   Plavsic ZM, 2001, BIOPHARM-APPL T BIO, V14, P32
   Prazeres DMF, 2016, PHARM BIOPROCESS, V4, P95
   Purtle DR, 2006, VALIDATED GAMMA RADI
   Qiu YC, 2013, BIOTECHNOL BIOENG, V110, P1342, DOI 10.1002/bit.24791
   Rasband W.S., 1997, IMAGEJ
   Remington K., 2014, 17 PLAN WORKSH WASH
   Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2
   Rockoff JD, 2010, WALL STREET J, V11
   Saltzman J., 2017, SANOFI GENZYME ISSUE
   Skrine Jim, 2011, PDA J Pharm Sci Technol, V65, P599, DOI 10.5731/pdajpst.2011.00823
   Vaidya V, 2018, VACCINE, V36, P4215, DOI 10.1016/j.vaccine.2018.06.008
   Victoria JG, 2010, J VIROL, V84, P6033, DOI 10.1128/JVI.02690-09
   Wang ECW, 1997, PROTEIN ENG, V10, P405, DOI 10.1093/protein/10.4.405
   Wang J, 2004, VOX SANG, V86, P230, DOI 10.1111/j.0042-9007.2004.00485.x
   Welch J, 2006, TRANSFUSION, V46, P1951, DOI 10.1111/j.1537-2995.2006.01003.x
   Wu LZ, 2008, J MOL STRUCT, V882, P101, DOI 10.1016/j.molstruc.2007.09.016
NR 46
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6518
EP 6525
DI 10.1016/j.vaccine.2019.08.063
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100039
PM 31519446
DA 2020-05-12
ER

PT J
AU Nakamura, K
   Harada, Y
   Takahashi, H
   Trusheim, H
   Bernhard, R
   Hamamoto, I
   Hirata-Saito, A
   Ogane, T
   Mizuta, K
   Konomi, N
   Konomi, Y
   Asanuma, H
   Odagiri, T
   Tashiro, M
   Yamamoto, N
AF Nakamura, Kazuya
   Harada, Yuichi
   Takahashi, Hitoshi
   Trusheim, Heidi
   Bernhard, Roth
   Hamamoto, Itsuki
   Hirata-Saito, Asumi
   Ogane, Teruko
   Mizuta, Katsumi
   Konomi, Nami
   Konomi, Yasushi
   Asanuma, Hideki
   Odagiri, Takato
   Tashiro, Masato
   Yamamoto, Norio
TI Systematic evaluation of suspension MDCK cells, adherent MDCK cells, and
   LLC-MK2 cells for preparing influenza vaccine seed virus
SO VACCINE
LA English
DT Article
DE Influenza vaccine seed virus; Suspension culture; Madin-Darby canine
   kidney cell line; Genetic and antigenic stability
ID SEASONAL INFLUENZA; A VIRUS; ADVENTITIOUS AGENTS; CLINICAL SPECIMENS;
   RISK-ASSESSMENT; B VIRUS; HEMAGGLUTININ; GLYCOSYLATION; LINE;
   SURVEILLANCE
AB Suspension Madin-Darby canine kidney (MDCK) cells (MDCK-N), adherent MDCK cells (MDCK-C), and adherent rhesus monkey kidney LLC-MK2 cells (LLC-MK2D) were systematically evaluated for the preparation of influenza vaccine seed viruses for humans on the basis of primary virus isolation efficiency, growth ability, genetic stability of the hemagglutinin (HA) and neuraminidase (NA) genes, and antigenic properties in hemagglutination inhibition (HI) test of each virus isolate upon further passages. All the subtypes/lineages of influenza viruses (A(H1N1), A(H1N1)pdm09, A(H3N2), B-Victoria, and B-Yamagata) were successfully isolated from clinical specimens by using MDCK-N and MDCK-C, whereas LLC-MK2D did not support virus replication well. Serial passages of A(H1N1) viruses in MDCK-N and MDCK-C induced genetic mutations of HA that resulted in moderate antigenic changes in the HI test. All A(H1N1)pdm09 isolates from MDCK-C acquired amino acid substitutions at the site from K153 to N156 of the HA protein, which resulted in striking antigenic alteration. In contrast, only 30% of MDCK-N isolates showed amino acid changes at this site. The frequency of MDCK-N isolates with less than two-fold reduction in the HI titer was as high as 70%. A(H3N2) and B-Yamagata isolates showed high antigenic stability and no specific amino acid substitution during passages in MDCK-N and MDCK-C. B-Victoria isolates from MDCK-N and MDCK-C acquired genetic changes at HA glycosylation sites that greatly affected their antigenicity. When these cell isolates were applied to passages in hen eggs, A (H1N1), B-Victoria, and B-Yamagata viruses grew well in eggs, while none of the cell isolates of A (H3N2) viruses did. Thus, we demonstrate that MDCK-N might be useful for the preparation of influenza vaccine seed viruses. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Nakamura, Kazuya; Harada, Yuichi; Takahashi, Hitoshi; Hamamoto, Itsuki; Asanuma, Hideki; Odagiri, Takato; Tashiro, Masato; Yamamoto, Norio] Natl Inst Infect Dis, Influenza Virus Res Ctr, 4-7-1 Gakuen, Tokyo 2080011, Japan.
   [Trusheim, Heidi; Bernhard, Roth] Novartis Vaccines & Diagnost GmbH, Emil von Behring Str 76, D-35041 Marburg, Germany.
   [Hirata-Saito, Asumi; Ogane, Teruko] Tochigi Prefectural Inst Publ Hlth & Environm Sci, 2145-13 Shimokamoto Cho, Utsunomiya, Tochigi 3291196, Japan.
   [Mizuta, Katsumi] Yamagata Prefectural Inst Publ Hlth, 1-6-6 Tokamachi, Yamagata, Yamagata 9900031, Japan.
   [Konomi, Nami; Konomi, Yasushi] Jinjikai Takahashi Clin, 4595 Iwai, Bando City, Ibaraki 3060631, Japan.
   [Yamamoto, Norio] Juntendo Univ, Grad Sch Med, Dept Infect Control Sci, Bunkyo Ku, 2-1-1 Hongo, Tokyo 2080011, Japan.
   [Trusheim, Heidi] IDT Biol GmbH, Pharmapk, D-06861 Dessau Rosslau, Germany.
   [Bernhard, Roth] GSK Vaccines GmbH, Emil von Behring Str 76, D-35041 Marburg, Germany.
RP Yamamoto, N (reprint author), Natl Inst Infect Dis, Influenza Virus Res Ctr, 4-7-1 Gakuen, Tokyo 2080011, Japan.
EM nyamamo@juntendo.ac.jp
FU National Institute of Biomedical InnovationNational Institute of
   Biomedical Innovation [08-16]; Ministry of Health, Labour and
   WelfareMinistry of Health, Labour and Welfare, Japan
   [h23-shinkou-shitei-021]; Japan Agency for Medical Research and
   DevelopmentJapan Agency for Medical Research and Development (AMED)
   [JP18fk0108212, JP18fk0108124]
FX We thank the staff at the National Institute of Infectious Diseases,
   Japan; Novartis Vaccines & Diagnostics GmbH & Co.; and the Prefectural
   Institutes of Public Health at Yamagata and Tochigi for their
   assistance. This work was supported, in part, by a grant from the
   National Institute of Biomedical Innovation to M.T., T.O., N.Y., H.A.,
   I.H., H.T., Y.H., and K.N. [grant no. 08-16]; a grant from the Ministry
   of Health, Labour and Welfare to M.T., T.O., N.Y., H. A., I.H., H.T.,
   Y.H., and K.N [grant no. h23-shinkou-shitei-021]; and grants from the
   Japan Agency for Medical Research and Development to N.Y. and H.A.
   [grant nos. JP18fk0108212 and JP18fk0108124]. The content of this
   manuscript is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institute of
   Infectious Diseases, Japan
CR Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z
   Brown Stephen W, 2010, PDA J Pharm Sci Technol, V64, P419
   Chen ZY, 2008, VACCINE, V26, P361, DOI 10.1016/j.vaccine.2007.11.013
   Donis RO, 2014, VACCINE, V32, P6583, DOI 10.1016/j.vaccine.2014.06.045
   Doroshenko A, 2009, EXPERT REV VACCINES, V8, P679, DOI 10.1586/ERV.09.31
   EVANS AS, 1982, YALE J BIOL MED, V55, P391
   Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459
   Genzel Y, 2014, VACCINE, V32, P2770, DOI 10.1016/j.vaccine.2014.02.016
   Govorkova EA, 1996, J VIROL, V70, P5519, DOI 10.1128/JVI.70.8.5519-5524.1996
   GOVORKOVA EA, 1995, J INFECT DIS, V172, P250, DOI 10.1093/infdis/172.1.250
   Gregersen JP, 2008, VACCINE, V26, P3332, DOI 10.1016/j.vaccine.2008.03.075
   Gregersen JP, 2008, VACCINE, V26, P3297, DOI 10.1016/j.vaccine.2008.03.076
   Gregersen JP, 2011, FUTURE MICROBIOL, V6, P143, DOI 10.2217/FMB.10.161
   Hamamoto I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059892
   Hartgroves LCS, 2010, VACCINE, V28, P2973, DOI 10.1016/j.vaccine.2010.02.012
   HULL RN, 1962, J EXP MED, V115, P903, DOI 10.1084/jem.115.5.903
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   MEYER WJ, 1993, VIROLOGY, V196, P130, DOI 10.1006/viro.1993.1461
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Nakamura K, 2016, VACCINE, V34, P328, DOI 10.1016/j.vaccine.2015.11.050
   Nakauchi M, 2011, J VIROL METHODS, V171, P156, DOI 10.1016/j.jviromet.2010.10.018
   Pau MG, 2001, VACCINE, V19, P2716, DOI 10.1016/S0264-410X(00)00508-9
   Ping JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9148
   ROBERTSON JS, 1991, J GEN VIROL, V72, P2671, DOI 10.1099/0022-1317-72-11-2671
   ROBERTSON JS, 1990, VIROLOGY, V179, P35, DOI 10.1016/0042-6822(90)90270-2
   ROCHA EP, 1993, J GEN VIROL, V74, P2513, DOI 10.1099/0022-1317-74-11-2513
   Rodig JV, 2013, BIOTECHNOL BIOENG, V110, P1691, DOI 10.1002/bit.24834
   Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486
   Roth B, 2012, VACCINE, V30, P517, DOI 10.1016/j.vaccine.2011.11.063
   Saito T, 2004, J MED VIROL, V74, P336, DOI 10.1002/jmv.20178
   SCHEPETIUK SK, 1993, J VIROL METHODS, V42, P241, DOI 10.1016/0166-0934(93)90036-Q
   SCHILD GC, 1983, NATURE, V303, P706, DOI 10.1038/303706a0
   Stevens J, 2010, J VIROL, V84, P8287, DOI 10.1128/JVI.00058-10
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   Taubenberger JK, 2001, PHILOS T ROY SOC B, V356, P1829, DOI 10.1098/rstb.2001.1020
   TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572
   WHO, 2019, CUM NUMB CONF HUM CA
   WHO, 2018, HUM INF AV INFL A H7
   Widjaja L, 2006, VIROLOGY, V350, P137, DOI 10.1016/j.virol.2006.02.020
NR 39
TC 2
Z9 3
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6526
EP 6534
DI 10.1016/j.vaccine.2019.08.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100040
PM 31500967
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chen, JY
   Wu, CM
   Liao, CM
   Chen, KC
   You, CC
   Wang, YW
   Huang, C
   Chien, MS
AF Chen, Jing-Yuan
   Wu, Chi-Ming
   Liao, Chih-Ming
   Chen, Kun-Chao
   You, Chia-Chin
   Wang, Yu-Wen
   Huang, Chienjin
   Chien, Maw-Sheng
TI The impact of porcine circovirus associated diseases on live attenuated
   classical swine fever vaccine in field farm applications
SO VACCINE
LA English
DT Article
DE Porcine circovirus associated diseases; Classical swine fever live
   attenuated vaccine; Subunit porcine circovirus type 2 vaccine;
   Vaccination-challenge model; Concurrent infection
ID MULTISYSTEMIC WASTING SYNDROME; RESPIRATORY SYNDROME VIRUS;
   LINKED-IMMUNOSORBENT-ASSAY; TYPE-2 PCV2; PIGS; INFECTION; ANTIBODIES;
   SAMPLES; PMWS; REPRODUCTION
AB Porcine circovirus associated diseases (PCVADs) are among the most important diseases affecting the worldwide swine industry. Vaccination against porcine circovirus type 2 (PCV2) infection has been utilized for disease control and effectively reduces clinical signs of PCVADs. To evaluate the efficacy of the PCV2 vaccine in field farms, we conducted a trial using conventional pigs immunized with the subunit PCV2 vaccine followed by PCV2 challenge. Immunized pigs demonstrated lower serum viral loads, less viral antigen staining in lymph nodes, and higher average daily weight gain, confirming the protective efficacy of the vaccine. However, low levels of PCV2 infection were still detected in vaccinated pigs after challenge, suggesting that the PCV2 vaccine was unable to eradicate the virus, which could lead to asymptomatic PCV2 subclinical infection (PCV2-SI) in pig farms. Additionally, PCV2 infection is a risk factor for impaired pig immune response development during the weaning to growth stages, which is a crucial period to receive vaccines against classical swine fever (CSF). Therefore, the impact of PCV2-SI or PCV2-systemic disease (PCV2-SD) on live attenuated CSF vaccine was investigated. After PCV2 challenge, there was no difference in levels of classical swine fever virus (CSFV) neutralizing antibodies (NA) between pigs with PCV2-SD and PCV2-SI, suggesting that the efficacy of CSF vaccine was compromised. Moreover, results of long-term monitoring of CSFV NA titers in PCV2-SI pigs with minimized interference by maternally-derived antibodies suggested that serum PCV2 viral loads greater than 10(2) copies/mL may compromise the efficacy of CSF vaccine. Overall, a conventional pig model was established to demonstrate the impaired efficacy of the subunit PCV2 vaccine and its impact on the CSF vaccine in vaccination-challenge trials. Additionally, the impaired efficacy of the PCV2 vaccine resulted in increased PCV2-SI, eventually leading to compromised the live attenuated CSF vaccine induced NA response in field farm applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Jing-Yuan; Chien, Maw-Sheng] Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Vet Pathobiol, 145 Xingda Rd, Taichung 40227, Taiwan.
   [Wu, Chi-Ming; Liao, Chih-Ming; Chen, Kun-Chao; You, Chia-Chin; Wang, Yu-Wen; Chien, Maw-Sheng] Natl Chung Hsing Univ, Grad Inst Microbiol & Publ Hlth, Coll Vet Med, 145 Xingda Rd, Taichung 40227, Taiwan.
   [Huang, Chienjin] Natl Chung Hsing Univ, Res Ctr Anim Med, 145 Xingda Rd, Taichung 40227, Taiwan.
RP Huang, C; Chien, MS (reprint author), Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Vet Pathobiol, 145 Xingda Rd, Taichung 40227, Taiwan.
EM cjhuang@dragon.nchu.edu.tw; mschien@dragon.nchu.edu.tw
OI Chen, Jing-Yuan/0000-0001-8021-2369
CR Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002
   Alarcon P, 2013, PREV VET MED, V110, P88, DOI 10.1016/j.prevetmed.2013.02.010
   Blome S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040086
   Brunborg IM, 2004, J VIROL METHODS, V122, P171, DOI 10.1016/j.jviromet.2004.08.014
   Brunborg IM, 2010, ACTA VET SCAND, V52, DOI 10.1186/1751-0147-52-22
   Chae C, 2012, VET J, V194, P151, DOI 10.1016/j.tvjl.2012.06.031
   Cortey M, 2011, J VET DIAGN INVEST, V23, P233, DOI 10.1177/104063871102300206
   Eddicks M, 2015, VET MICROBIOL, V176, P337, DOI 10.1016/j.vetmic.2015.01.013
   Feng HY, 2014, ANAL BIOCHEM, V447, P49, DOI 10.1016/j.ab.2013.10.030
   Fort M, 2007, VET MICROBIOL, V125, P244, DOI 10.1016/j.vetmic.2007.06.004
   Franzo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep39458
   Graham SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029310
   Grasland B, 2005, VET RES, V36, P685, DOI 10.1051/vetres:2005024
   Grau-Roma L, 2009, VET MICROBIOL, V135, P272, DOI 10.1016/j.vetmic.2008.10.007
   Huang YL, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-115
   Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099
   Kennedy S, 2000, J COMP PATHOL, V122, P9, DOI 10.1053/jcpa.1999.0337
   Kristensen CS, 2011, PREV VET MED, V98, P250, DOI 10.1016/j.prevetmed.2010.11.015
   Kwon T, 2017, VIRUS RES, V228, P24, DOI 10.1016/j.virusres.2016.11.015
   Li H, 2003, VET MICROBIOL, V95, P295, DOI 10.1016/S0378-1135(03)00158-5
   Maes D, 2012, VET J, V194, P9, DOI 10.1016/j.tvjl.2012.06.029
   McNair I, 2004, J VET DIAGN INVEST, V16, P164, DOI 10.1177/104063870401600214
   Oh Y, 2014, VET MICROBIOL, V172, P371, DOI 10.1016/j.vetmic.2014.05.028
   Opriessnig T, 2017, VACCINE, V35, P248, DOI 10.1016/j.vaccine.2016.11.085
   Opriessnig T, 2012, VIRUS RES, V164, P20, DOI 10.1016/j.virusres.2011.09.014
   Park C, 2014, CLIN VACCINE IMMUNOL, V21, P399, DOI 10.1128/CVI.00768-13
   Patterson AR, 2011, J VET DIAGN INVEST, V23, P206, DOI 10.1177/104063871102300203
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rose N, 2017, PORCINE HEALTH MANAG, V3, DOI 10.1186/s40813-017-0053-6
   Segales J, 2015, EXPERT REV VACCINES, V14, P473, DOI 10.1586/14760584.2015.983084
   Segales J, 2012, VIRUS RES, V164, P10, DOI 10.1016/j.virusres.2011.10.007
   Seo HW, 2014, ARCH VIROL, V159, P3107, DOI 10.1007/s00705-014-2164-6
   Seo HW, 2014, VET J, V200, P65, DOI 10.1016/j.tvjl.2014.02.002
   Suradhat S, 2007, VET MICROBIOL, V119, P1, DOI 10.1016/j.vetmic.2006.10.003
   Suradhat S, 2006, VACCINE, V24, P2634, DOI 10.1016/j.vaccine.2005.12.010
   TERPSTRA C, 1988, VET MICROBIOL, V16, P123, DOI 10.1016/0378-1135(88)90036-3
   van Oirschot JT, 2003, VET MICROBIOL, V96, P367, DOI 10.1016/j.vetmic.2003.09.008
   Wang XL, 2016, VET MICROBIOL, V197, P68, DOI 10.1016/j.vetmic.2016.11.007
   Xiao CT, 2016, VET MICROBIOL, V197, P72, DOI 10.1016/j.vetmic.2016.11.009
   Xiao CT, 2012, J VIROL, V86, P12469, DOI 10.1128/JVI.02345-12
   Xu L, 2018, VIRAL IMMUNOL, V31, P34, DOI 10.1089/vim.2017.0010
   Yang S, 2018, TRANSBOUND EMERG DIS, V65, pe383, DOI 10.1111/tbed.12768
NR 42
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6535
EP 6542
DI 10.1016/j.vaccine.2019.08.039
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100041
PM 31500966
DA 2020-05-12
ER

PT J
AU Arya, DP
   Said, MA
   Izurieta, HS
   Perez-Vilar, S
   Zinderman, C
   Wernecke, M
   Alexander, M
   White, T
   Su, IH
   Lufkin, B
   MaCurdy, T
   Kelman, J
   Forshee, R
AF Arya, Deepa P.
   Said, Maria A.
   Izurieta, Hector S.
   Perez-Vilar, Silvia
   Zinderman, Craig
   Wernecke, Michael
   Alexander, Michael
   White, Taylor
   Su, I-Hsuan
   Lufkin, Bradley
   MaCurdy, Thomas
   Kelman, Jeffrey
   Forshee, Richard
TI Surveillance for Guillain-Barre syndrome after 2015-2016 and 2016-2017
   influenza vaccination of Medicare beneficiaries
SO VACCINE
LA English
DT Article
DE Influenza; Flu; Vaccine; Immunization; Guillain-Barre syndrome; High
   dose influenza vaccine
ID POPULATION; VACCINES; ASSOCIATION; SAFETY; OLDER; RISK
AB Background: Guillain-Barre syndrome (GBS) is a serious acute demyelinating disease, an increased risk of which was found after the 1976 swine flu vaccinations. The U.S. Food and Drug Administration, in collaboration with the Centers for Medicare & Medicaid Services, has been conducting active surveillance for GBS after influenza vaccinations of Medicare Fee-For-Service beneficiaries since 2009.
   Methods: We conducted active surveillance for CBS claims in the 2015-2016 and 2016-2017 influenza seasons using the Updating Sequential Probability Ratio Test (USPRT) to monitor for signals of GBS risk. We performed self-controlled risk interval (SCRI) analyses at the end of both seasons, including chart confirmation in the 2015-2016 season, to estimate the odds ratio of GBS risk. We used 1-42 and 8-21 days post-vaccination as primary and secondary risk windows, respectively, and 43-84 days post-vaccination as the control window.
   Results: Over 13 million beneficiaries were vaccinated in each season. USPRT found a low magnitude signal for GBS in both seasons. SCRI analyses did not find excess GBS risk following any influenza vaccine for days 1-42 post-vaccination in either season. In the 2015-2016 season, for the 8-21 day window, our chart-confirmation showed an attributable GBS risk of 0.87 (95% CI: 0.16, 1.49) and 1.68 (95% Cl: 0.69, 2.41) cases per million vaccinees after all seasonal and high dose (HD) vaccines, respectively, an elevated GBS risk for beneficiaries aged >= 75 years following all seasonal vaccines (OR: 2.25; 95% CI: 1.15, 4.39) and HD vaccine (OR: 3.67, 95% CI: 1.52, 8.85), and an elevated GBS risk for males who received seasonal vaccines (OR: 2.18; 95% CI: 1.15, 4.15) and HD vaccine (OR: 3.33; 95% CI: 1.35, 8.20). The finding of elevated CBS risk with advancing age and in males is consistent with literature; however, a distinction between HD and SD was a new finding. In the 2016-17 season, for the 8-21 day window, attributed cases showed an attributable GBS risk of 0.87 (95% CI: 0.03, 1.61) and 1.11 (95% CI: 0.00, 2.01) cases per million vaccinees after all seasonal and HD vaccines, respectively. We found no excess GBS risk for standard dose vaccines in the 8-21 day window in either season.
   Conclusions: Our primary analysis finding of no excess GBS risk during both seasons was reassuring. The slightly elevated GBS risk, although in the expected range, in the 8-21 day window after all seasonal and high dose vaccines, but not after standard dose vaccines is hypothesis-generating because the difference may be due to vaccine factors such as antigen amount or strains in various seasons or due to host factors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Arya, Deepa P.; Said, Maria A.; Izurieta, Hector S.; Perez-Vilar, Silvia; Zinderman, Craig; Forshee, Richard] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.
   [Wernecke, Michael; Alexander, Michael; White, Taylor; Su, I-Hsuan; Lufkin, Bradley; MaCurdy, Thomas] Acumen LLC, Burlingame, CA USA.
   [MaCurdy, Thomas] Stanford Univ, Stanford, CA 94305 USA.
   [Kelman, Jeffrey] Ctr Medicare, Washington, DC USA.
   [Kelman, Jeffrey] Ctr Medicaid Serv, Washington, DC USA.
   [Arya, Deepa P.; Said, Maria A.; Izurieta, Hector S.; Perez-Vilar, Silvia; Zinderman, Craig; Forshee, Richard] US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
   [Said, Maria A.] Natl Pk Serv, Washington, DC 20240 USA.
   [Alexander, Michael] UBER, Washington, DC USA.
   [White, Taylor] Qlik, Los Angeles, CA USA.
   [Su, I-Hsuan] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.
RP Arya, DP (reprint author), US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM deepa.arya@fda.hhs.gov
RI Perez-Vilar, Silvia/H-4372-2016
OI Perez-Vilar, Silvia/0000-0003-1272-1502
FU U.S. Food and Drug Administration; Centers for Medicare & Medicaid
   Services
FX This work did not receive any grant from funding agencies in the public,
   commercial, or not-for-profit sectors. This study was funded through an
   interagency agreement between the U.S. Food and Drug Administration and
   the Centers for Medicare & Medicaid Services.
CR Blum S, 2014, J PERIPHER NERV SYST, V19, P88, DOI 10.1111/jns5.12074
   BREMAN JG, 1984, AM J EPIDEMIOL, V119, P880, DOI 10.1093/oxfordjournals.aje.a113810
   Burwen DR, 2012, AM J PUBLIC HEALTH, V102, P1921, DOI 10.2105/AJPH.2011.300510
   Burwen DR, 2010, AM J PREV MED, V39, P296, DOI 10.1016/j.amepre.2010.05.022
   Centers for Disease Control and Prevention, 2017, GUILL BARR SYNDR FLU
   Centers for Medicare & Medicaid Services, 2018, MED PROGR GEN INF
   Centers for Medicare & Medicaid Services, 2019, CMS STAT REF BOOKL
   Dahlgren FS, 2018, INFLUENZA OTHER RESP, V12, P465, DOI 10.1111/irv.12552
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Dodd CN, 2013, VACCINE, V31, P4448, DOI 10.1016/j.vaccine.2013.06.032
   Franks R, 2014, STAT ANAL DATA MIN, V7, P368, DOI 10.1002/sam.11234
   Haber P, 2009, DRUG SAFETY, V32, P309, DOI 10.2165/00002018-200932040-00005
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4
   Juurlink DN, 2006, ARCH INTERN MED, V166, P2217, DOI 10.1001/archinte.166.20.2217
   Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X
   LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809
   Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501
   Perez-Vilar S, 2019, VACCINE, V37, P3856, DOI 10.1016/j.vaccine.2019.05.041
   Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051
   Principi N, 2019, VACCINE, V37, P5544, DOI 10.1016/j.vaccine.2018.05.119
   Romio S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082222
   SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973
   Salemi S, 2010, INT REV IMMUNOL, V29, P247, DOI 10.3109/08830181003746304
   Salmon DA, 2013, LANCET, V381, P1461, DOI 10.1016/S0140-6736(12)62189-8
   Sandhu SK, 2017, VACCINE, V35, P2986, DOI 10.1016/j.vaccine.2017.03.087
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   U.S. Food and Drug Administration, 2018, VACC LIC US US
   Vellozzi C, 2014, CLIN INFECT DIS, V58, P1149, DOI 10.1093/cid/ciu005
   Wakerley BR, 2013, EXPERT REV CLIN IMMU, V9, P627, DOI 10.1586/1744666X.2013.811119
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
NR 37
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6543
EP 6549
DI 10.1016/j.vaccine.2019.08.045
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100042
PM 31515146
DA 2020-05-12
ER

PT J
AU Honemann, M
   Martin, D
   Pietsch, C
   Maier, M
   Bergs, S
   Bieck, E
   Liebert, UG
AF Hoenemann, M.
   Martin, D.
   Pietsch, C.
   Maier, M.
   Bergs, S.
   Bieck, E.
   Liebert, U. G.
TI Influenza B virus infections in Western Saxony, Germany in three
   consecutive seasons between 2015 and 2018: Analysis of molecular and
   Crook for clinical features
SO VACCINE
LA English
DT Article
DE Influenza; Influenza B; Epidemiology; Molecular epidemiology;
   Yamagata-like strains; Victoria-like strains; Seasonal frequency
ID VACCINE EFFECTIVENESS; UNITED-STATES; MUTATION; LINEAGE; AGE
AB Background: The impact of annual influenza epidemics and prevailing strains varies worldwide and regional. The majority of vaccines used contained two influenza A strains and only one influenza B strain (trivalent vaccine).
   Aim: The aim of the study was to compare laboratory confirmed influenza B cases during three consecutive years with respect to vaccination history, clinical symptoms and molecular virology.
   Methods: Partial HA gene sequences were analyzed for lineage determination and complete HA sequence in cases with reported vaccination and in fatal cases. Clinical data were retrieved from patient charts.
   Findings: During the 2015/16 season, 75 influenza B cases were retrieved; 11 in 2016/17, and 274 in 2017/18. The frequency of Yamagata-lineage strains increased from 7.6% to 100%. No difference was detected in the relative frequency of co-morbidities in season 2017/18. 37.7% of the adult patients and 4.5% of pediatric patients were vaccinated against influenza.
   Interpretation: Phylogenetically, Yamagata strains clustered similarly in 2017/2018 when compared to the previous two influenza seasons. While the relative frequency of influenza B cases differed, the clinical symptoms remained similar.
   Conclusion: World Health Organization recommendations for the use of tetravalent vaccines that contain two influenza B strains (Yamagata and Victoria) in addition to the two influenza A strains (H1N1 and H3N2) should be implemented in national vaccination guidelines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hoenemann, M.; Martin, D.; Pietsch, C.; Maier, M.; Bergs, S.; Liebert, U. G.] Univ Leipzig, Inst Virol, Johannisallee 30, D-04103 Leipzig, Germany.
   [Bieck, E.] Kreiskrankenhaus Torgau J Kentmann gGmbH, D-04860 Torgau, Germany.
RP Honemann, M (reprint author), Univ Leipzig, Inst Virol, Johannisallee 30, D-04103 Leipzig, Germany.
EM Mario.Hoenemann@medizin.uni-leipzig.de
OI Honemann, Mario/0000-0001-7517-402X
FU Association of Sponsors and Friends of Leipzig University (Vereinigung
   von Forderern und Freunden der Universitat Leipzig)
FX This research was partially supported by the Association of Sponsors and
   Friends of Leipzig University (Vereinigung von Forderern and Freunden
   der Universitat Leipzig).
CR an der Heiden M, 2017, INFLUENZA OTHER RESP, V11, P110, DOI 10.1111/irv.12434
   Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522
   Anton A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.02.007
   Bailey ES, 2018, EVOL MED PUBLIC HLTH, P192, DOI 10.1093/emph/eoy013
   Belshe RB, 2010, VACCINE, V28, P2149, DOI 10.1016/j.vaccine.2009.11.068
   Bouvier NM, 2008, VACCINE S4, V26, P53
   Caini S, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3181-y
   Caini S, 2018, INFLUENZA OTHER RESP, V12, P780, DOI 10.1111/irv.12575
   Dolin R, 2013, J INFECT DIS, V208, P539, DOI 10.1093/infdis/jit264
   eCDC, REP 2017 18 INFL SEA
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Greer AL, 2010, EPIDEMIOL INFECT, V138, P1542, DOI 10.1017/S0950268810000579
   Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003
   Hirano D, 2018, J IMMUNOL RES, DOI 10.1155/2018/7251793
   Katinger D, 2004, ARCH VIROL, V149, P173, DOI 10.1007/s00705-003-0203-9
   Kuo SM, 2016, J FORMOS MED ASSOC, V115, P510, DOI 10.1016/j.jfma.2016.01.017
   Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224
   Liu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08165-y
   Machado A, 2018, PULMONOLOGY, V24, P260, DOI 10.1016/j.pulmoe.2018.05.004
   Modin D, 2018, CIRCULATION
   Nobusawa E, 2006, J VIROL, V80, P3675, DOI 10.1128/JVI.80.7.3675-3678.2006
   Pan YD, 2016, VACCINE, V34, P4610, DOI 10.1016/j.vaccine.2016.07.015
   Pebody R, 2016, EUROSURVEILLANCE, V21, P41, DOI 10.2807/1560-7917.ES.2016.21.38.30348
   Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118
   Quandelacy TM, 2014, AM J EPIDEMIOL, V179, P156, DOI 10.1093/aje/kwt235
   Ray GT, 2018, CLIN INFECT DIS
   Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369
   Robert Koch Institut (RKI), SEAS INFL REP
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Skowronski DM, 2014, J INFECT DIS, V210, P126, DOI 10.1093/infdis/jiu048
   Suptawiwat O, 2017, VIROLOGY, V502, P84, DOI 10.1016/j.virol.2016.12.015
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   Vijaykrishna D, 2015, ELIFE, V4, DOI 10.7554/eLife.05055
   World Health Organization, 2019, WHO INF MOL DET INFL
   Yasugi M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003150
NR 36
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6550
EP 6557
DI 10.1016/j.vaccine.2019.08.027
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100043
PM 31521415
OA Green Published
DA 2020-05-12
ER

PT J
AU Vestjens, SMT
   Sanders, EAM
   Vlaminckx, BJ
   de Melker, HE
   van der Ende, A
   Knol, MJ
AF Vestjens, Stefan M. T.
   Sanders, Elisabeth A. M.
   Vlaminckx, Bart J.
   de Melker, Hester E.
   van der Ende, Arie
   Knol, Mirjam J.
TI Twelve years of pneumococcal conjugate vaccination in the Netherlands:
   Impact on incidence and clinical outcomes of invasive pneumococcal
   disease
SO VACCINE
LA English
DT Article
DE Invasive pneumococcal disease; 10-valent pneumococcal vaccination;
   Clinical outcome; National immunisation programme; The Netherlands
ID ENGLAND; CHILDREN; WALES
AB Introduction: In 2006, the Netherlands introduced the 7-valent pneumococcal conjugate vaccine (PCV7) in their national immunisation programme. In 2011, PCV7 was replaced by the 10-valent vaccine (PCV10). We report on the impact of PCV on invasive pneumococcal disease (IPD) incidence, clinical syndromes and patient outcomes.
   Methods: Pneumococcal isolates of hospitalised IPD patients between June 2004 and May 2018 were obtained from nine sentinel laboratories, covering 25% of the Dutch population. All isolates were serotyped. IPD incidence and clinical outcome were determined before and after introduction of PCV7 and after the switch to PCV10, stratified by age and serotype.
   Results: Compared to before PCV7 introduction, significant declines in IPD incidence were observed in 2016-2018 in children <5 years (69%), 18-49 year olds (31%) and >= 65 year olds (19%). Compared to before PCV10 introduction, the IPD incidence in 2016-2018 declined in children <5 years (RR:0.68, 95%CI:0.42-1.11), 5-17 year olds (RR:0.58, 95%CI:0.29-1.14) and 18-49 year olds (RR:0.72, 95%CI:0.57-0.90), but not in 50-64 year olds (RR:0.94, 95%CI:0.81-1.10) and >= 65 year olds (RR:1.04, 95%CI:0.0.93-1.15). While the case fatality rate (CFR) decreased from 16.2% pre-PCV to 13.4% post-PCV10 (RR:0.83, 95%CI:0.70-0.99), the switch to PCV10 had no further impact on CFR (RR:1.14, 95%CI:0.96-1.36).
   Conclusion: Twelve years of PCV in the Netherlands has resulted in a sustained reduction of IPD incidence in children and younger adults. The switch from PCV7 to PCV10 did not have additional impact on the IPD incidence in older adults and CFR due to emerging non-vaccine serotypes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vestjens, Stefan M. T.; Vlaminckx, Bart J.] St Antonius Hosp, Dept Med Microbiol & Immunol, Koekoekslaan 1,POB 2500, NL-3430 EM Nieuwegein, Netherlands.
   [Sanders, Elisabeth A. M.; de Melker, Hester E.; Knol, Mirjam J.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control Netherlands CIb, Bilthoven, Netherlands.
   [Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands.
   [van der Ende, Arie] Univ Amsterdam, Dept Med Microbiol, Amsterdam UMC, Amsterdam, Netherlands.
   [van der Ende, Arie] Univ Amsterdam, Netherlands Reference Lab Bacterial Meningitis, Amsterdam UMC, Amsterdam, Netherlands.
RP Vestjens, SMT (reprint author), St Antonius Hosp, Dept Med Microbiol & Immunol, Koekoekslaan 1,POB 2500, NL-3430 EM Nieuwegein, Netherlands.; Knol, MJ (reprint author), Natl Inst Publ Hlth & Environm, POB 1, NL-3720 BA Bilthoven, Netherlands.
EM s.vestjens@antoniusziekenhuis.nl; mirjam.knol@rivm.nl
FU European Centre for Disease Prevention and Control (SplDnet project);
   European Comission (Horizon 2020, I-MOVE+)
FX This work was supported by the European Centre for Disease Prevention
   and Control (SplDnet project) and the European Comission (Horizon 2020,
   I-MOVE+).
CR AUSTRIAN R, 1976, MT SINAI J MED, V43, P699
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   ClinicalTrials.gov, TRIAL EV SAF IMM 20
   ClinicalTrials.gov, STUD EV SAF TOL IMM
   Desmet S, 2018, LANCET INFECT DIS, V18, P830, DOI 10.1016/S1473-3099(18)30346-3
   European Center for Disease Prevention and Control (ECDC), VACC SCHED ALL COUNT
   European Centre for Disease Prevention and Control (ECDC), DIS FACTSH PNEUM DIS
   Hanquet G, 2018, THORAX, DOI [10.1136/thoraxjn1-2018-211767thoraxjnI-2018-211767, DOI 10.1136/THORAXJN1-2018-211767THORAXJNI-2018-211767]
   Health Council of the Netherlands, 2003, PNEUM VACC ELD AD RI
   Health Council of the Netherlands, 2018, PNEUM VACC ELD AD AD
   Izurieta P, 2018, EXPERT REV VACCINES, V17, P479, DOI 10.1080/14760584.2018.1413354
   Knol MJ, 2015, EMERG INFECT DIS, V21, P2040, DOI 10.3201/eid2111.140780
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Ladhani SN, 2013, EMERG INFECT DIS, V19, P61, DOI 10.3201/eid1901.120741
   Makwana A, 2018, PEDIATR INFECT DIS J, V37, P697, DOI 10.1097/INF.0000000000001845
   Medication and medical tools Information Project (GIP), 2018, NUMB DDS AG GEND ATC
   National Institute for Public Health and the Environment (RIVM), 2018, IMM COV ANN REP NAT
   Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685
   Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001
   Rodenburg GD, 2010, EMERG INFECT DIS, V16, P816, DOI 10.3201/eid1605.091223
   Thorrington D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192640
   van Deursen AMM, 2012, EMERG INFECT DIS, V18, P1729, DOI 10.3201/eid1811.120329
   Wagenvoort GHJ, 2016, VACCINE, V34, P1077, DOI 10.1016/j.vaccine.2015.12.066
   World Health Organization, 2018, WHO VACC PREV DIS MO
   World Health Organization (WHO), 2014, VACC DIS PNEUM DIS
   World Health Organization (WHO), 2019, WKLY EPIDEMIOL REC
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6558
EP 6565
DI 10.1016/j.vaccine.2019.08.025
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100044
PM 31500963
DA 2020-05-12
ER

PT J
AU Chen, XX
   Wagner, AL
   Zheng, XB
   Xie, JY
   Boulton, ML
   Chen, KY
   Ren, H
   Lu, YH
AF Chen, Xiang-Xiang
   Wagner, Abram L.
   Zheng, Xu-Bin
   Xie, Jia-Yu
   Boulton, Matthew L.
   Chen, Kai-Yun
   Ren, Hong
   Lu, Yi-Han
TI Hepatitis E vaccine in China: Public health professional perspectives on
   vaccine promotion and strategies for control
SO VACCINE
LA English
DT Article
DE China; Hepatitis E; Vaccination introduction; Stakeholders analysis;
   Qualitative research
ID E VIRUS-INFECTION; GLOBAL BURDEN; DISEASE; IMPACT; TRUST
AB Background: A hepatitis E (HepE) vaccine was developed and released in China in 2011. Uptake is currently very limited. The aims of this study were to characterize what public health professionals thought about promoting the HepE vaccine in Shanghai, China, and to develop realistic goals for the HepE vaccine based on this information.
   Methods: Public health professionals from Shanghai and other jurisdictions of China were contacted to participate in in-depth qualitative interviews between October 2017 and August 2018. Participants were asked about their perception of the HepE vaccine roll-out. Codes were initially based on the structure of the questionnaire. Subsequently, similar ideas were further developed into themes based on what was present in the transcript data.
   Results: Thirty-five individuals participated. Major topics of discussion included (1) clarifying the roles and responsibilities of private and public institutions in promoting and marketing the HepE vaccine, (2) identifying what methods of promotion were most efficient, and, (3) endeavoring to formulate a reasonable and realistic goal, if any, for HepE prevention and control in China. Participants emphasized that public sector sources can be trusted sources of information (although the private vaccination company can also be useful in disseminating information) and social media such as WeChat can be good ways to disseminate articles (although netizens may be worried about the spread of fake news). Vaccine promotion is restrained given limited levels of knowledge in the government, hospitals, and public health vaccination centers.
   Conclusion: Successful promotion and use of this vaccine in China, even in limited settings (for instance, certain workplaces, or certain groups) could provide additional information on long-term safety and could promote its adoption in other regions of the world where HepE has high morbidity among pregnant women and other populations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Xiang-Xiang; Zheng, Xu-Bin; Lu, Yi-Han] Fudan Univ, Dept Epidemiol, Key Lab Publ Hlth Safety, Sch Publ Hlth,Minist Educ, Fosun Tower Room 513,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
   [Wagner, Abram L.; Xie, Jia-Yu; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Boulton, Matthew L.] Univ Michigan, Dept Internal Med, Div Infect Dis, Med Sch, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Chen, Kai-Yun; Ren, Hong] Shanghai Municipal Ctr Dis Control & Prevent, Dept Viral Hepatitis Control & Prevent, Shanghai 200336, Peoples R China.
RP Lu, YH (reprint author), Fudan Univ, Dept Epidemiol, Key Lab Publ Hlth Safety, Sch Publ Hlth,Minist Educ, Fosun Tower Room 513,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
EM xx_chen16@fudan.edu.cn; awag@umich.edu; xiejy@umich.edu;
   mboulton@umich.edu; chenkaiyun@scdc.sh.cn; renhong@scdc.sh.cn;
   luyihan@fudan.edu.cn
OI Lu, Yihan/0000-0003-4651-9433; Wagner, Abram/0000-0003-4691-7802
FU Fulbright Fellowship; University of Michigan Office of Global Public
   Health; Shanghai Municipal Health Commission [2018-40117]; China
   National Natural Science FundsNational Natural Science Foundation of
   China [81370081]
FX Research reported in this publication was supported by a Fulbright
   Fellowship (ALW), by an award through the University of Michigan Office
   of Global Public Health (JYX), by a grant from Shanghai Municipal Health
   Commission (grant #2018-40117, HR), and through the China National
   Natural Science Funds (grant #81370081, YHL). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the study funders.
CR Ames H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183721
   [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   [Anonymous], 2012, NINTH REPORT OF THE, P1021, DOI [10.1016/13978-0-12-384684-6.00087-2, DOI 10.1016/13978-0-12-384684-6.00087-2]
   BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Clark A., 2007, CBS NEWS
   Dalton HR, 2009, NEW ENGL J MED, V361, P1025, DOI 10.1056/NEJMc0903778
   Emerson SU, 2003, REV MED VIROL, V13, P145, DOI 10.1002/rmv.384
   Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P
   Hu XJ, 2012, VACCINE, V30, P5721, DOI 10.1016/j.vaccine.2012.07.007
   Huang XY, 2019, ZOONOSES PUBLIC HLTH, V66, P155, DOI 10.1111/zph.12548
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Kamar N, 2008, NEW ENGL J MED, V358, P811, DOI 10.1056/NEJMoa0706992
   Khuroo MS, 2016, WORLD J GASTROENTERO, V22, P7030, DOI 10.3748/wjg.v22.i31.7030
   Klepac P, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0137
   Kmush BL, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz144
   Kmush BL, 2015, EXPERT REV ANTI-INFE, V13, P41, DOI 10.1586/14787210.2015.981158
   Labrique AB, 2012, EMERG INFECT DIS, V18, P1401, DOI 10.3201/eid1809.120241
   Lim HJ, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-97
   Navaneethan U, 2008, LIVER INT, V28, P1190, DOI 10.1111/j.1478-3231.2008.01840.x
   Nie JB, 2018, DEV WORLD BIOETH, V18, P4, DOI 10.1111/dewb.12172
   Packard RM, 2016, A HISTORY OF GLOBAL
   Schmeer K., 1999, GUIDELINES FOR CONDU
   Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7
   Sun IY, 2013, SOC SCI RES, V42, P1737, DOI 10.1016/j.ssresearch.2013.08.002
   The National Institute of Allergy and Infectious Diseases, 2018, NIAID EMERGING INFEC
   The Strategic Advisory Group of Experts (SAGE), 2018, 2018 ASSESSMENT REPO
   WHO, 2015, WKLY EPIDEMIOL REC, P185
   Wu X, 2016, HUM VACC IMMUNOTHER, V12, P2603, DOI 10.1080/21645515.2016.1184806
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhang S, THE DELETED WECHAT P
   Zhang XY, 2016, INT J INFECT DIS, V48, P7, DOI 10.1016/j.ijid.2016.04.010
   Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
   2016, LANCET, V388, P438, DOI DOI 10.1016/S0140-6716/16131706-%
NR 37
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6566
EP 6572
DI 10.1016/j.vaccine.2019.07.067
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100045
PM 31353258
DA 2020-05-12
ER

PT J
AU Sakurai, A
   Ogawa, T
   Matsumoto, J
   Kihira, T
   Fukushima, S
   Miyata, I
   Shimizu, H
   Itamura, S
   Ouchi, K
   Hamada, A
   Tani, K
   Okabe, N
   Yamaguchi, T
AF Sakurai, Akira
   Ogawa, Takashi
   Matsumoto, Jun
   Kihira, Tetsunari
   Fukushima, Shinji
   Miyata, Ippei
   Shimizu, Hideaki
   Itamura, Shigeyuki
   Ouchi, Kazunobu
   Hamada, Atsuro
   Tani, Kenzaburo
   Okabe, Nobuhiko
   Yamaguchi, Teruhide
TI Regulatory aspects of quality and safety for live recombinant viral
   vaccines against infectious diseases in Japan
SO VACCINE
LA English
DT Article
ID BACKBONE STANDARDIZED TEMPLATE; EBOLA-VIRUS DISEASE; KEY CONSIDERATIONS;
   RING VACCINATION; GUINEA
AB Recombinant viral vaccines expressing antigens of pathogenic microbes (e.g., HIV, Ebola virus, and malaria) have been designed to overcome the insufficient immune responses induced by the conventional vaccines. Our knowledge of and clinical experience with the new recombinant viral vaccines are insufficient, and a clear regulatory pathway is needed for the further development and evaluation of recombinant viral vaccines. In 2018, the research group supported by the Ministry of Health, Labour and Welfare, Japan (MHLW) published a concept paper to address the development of recombinant viral vaccines against infectious diseases. Herein we summarize the concept paper-which explains the Japanese regulatory concerns about recombinant viral vaccines-and provide a focus of discussion about the development of recombinant viral vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sakurai, Akira; Ogawa, Takashi; Matsumoto, Jun; Kihira, Tetsunari] Pharmaceut & Med Devices Agcy, Off Vaccines & Blood Prod, Chiyoda Ku, Shin Kasumigaseki Bldg,3-3-2 Kasumigaseki, Tokyo 1000013, Japan.
   [Fukushima, Shinji; Hamada, Atsuro] Tokyo Med Univ Hosp, Travellers Med Ctr, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.
   [Miyata, Ippei; Ouchi, Kazunobu] Kawasaki Med Sch, Dept Pediat, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.
   [Shimizu, Hideaki; Okabe, Nobuhiko] Kawasaki City Inst Publ Hlth, Life Sci & Environm LiSE Res Ctr, Kawasaki Ku, 2F,3-25-13 Tono Machi, Kawasaki, Kanagawa 2100821, Japan.
   [Itamura, Shigeyuki] Natl Inst Infect Dis, 4-7-1 Gakuen, Musashimurayama, Tokyo 2080011, Japan.
   [Tani, Kenzaburo] Univ Tokyo, Inst Med Sci, Project Div ALA Adv Med Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
   [Yamaguchi, Teruhide] Nihon Pharmaceut Univ, Div Pharmacol, 10281 Komuro, Ina, Saitama 3620806, Japan.
RP Sakurai, A (reprint author), Pharmaceut & Med Devices Agcy, Off Vaccines & Blood Prod, Chiyoda Ku, Shin Kasumigaseki Bldg,3-3-2 Kasumigaseki, Tokyo 1000013, Japan.
EM sakurai-akira@pmda.go.jp; ogawa-takashi@pmda.go.jp;
   matsumoto-jun@pmda.go.jp; kihira-tetsunari@pmda.go.jp;
   fuku789@tokyo-med.ac.jp; miyata.kkcl@gmail.com;
   shimizu-h@city.kawasaki.jp; sitamura@nih.go.jp;
   kouchi@med.kawasaki-m.ac.jp; a-hamada@tokyo-med.ac.jp;
   k-tani@ims.u-tokyo.ac.jp; okaben-n@city.kawasaki.jp;
   t-yamaguchi@nichiyaku.ac.jp
OI Fukushima, Shinji/0000-0002-0918-610X
FU Ministry of Health, Labour and Welfare, JapanMinistry of Health, Labour
   and Welfare, Japan
FX This review was supported by a grant-aid from the Ministry of Health,
   Labour and Welfare, Japan.
CR Appaiahgari MB, 2010, EXPERT REV VACCINES, V9, P1371, DOI [10.1586/erv.10.139, 10.1586/ERV.10.139]
   Bray M, 2003, CLIN INFECT DIS, V36, P766, DOI 10.1086/374244
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Chen RT, 2015, VACCINE, V33, P73, DOI 10.1016/j.vaccine.2014.09.035
   CHMP, 2010, EMACHMPVVVP141697200
   Clarke DK, 2016, VACCINE, V34, P6597, DOI 10.1016/j.vaccine.2016.06.071
   Condit RC, 2016, VACCINE, V34, P6610, DOI 10.1016/j.vaccine.2016.04.060
   Eckart RE, 2004, J AM COLL CARDIOL, V44, P201, DOI 10.1016/j.jacc.2004.05.004
   Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594
   Gsell PS, 2017, LANCET INFECT DIS, V17, P1276, DOI 10.1016/S1473-3099(17)30541-8
   Gudmundsdotter L, 2009, VACCINE, V27, P4468, DOI 10.1016/j.vaccine.2009.05.018
   Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094
   Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   ICH, 2009, GEN PRINC ADDR VIR V
   ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use), 2006, GEN PRINC ADDR RISK
   Kochhar S, 2019, VACCINE, V37, P5796, DOI 10.1016/j.vaccine.2018.08.085
   MHLW, 2010, GUID NONCL STUD PREV
   MHLW, 2010, GUID CLIN STUD PREV
   Monath TP, 2015, VACCINE, V33, P62, DOI 10.1016/j.vaccine.2014.10.004
   Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184
   Ramezanpour B, 2016, VACCINE, V34, P6436, DOI 10.1016/j.vaccine.2016.06.059
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   RWRG, CONC PAP
   Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001
NR 25
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 8
PY 2019
VL 37
IS 43
BP 6573
EP 6579
DI 10.1016/j.vaccine.2019.08.031
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JF9EH
UT WOS:000491685100046
PM 31506194
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sun, Q
   Du, M
   Li, XX
   Guo, XQ
   Liu, AX
   Chen, GJ
   Yang, LY
AF Sun, Qiang
   Du, Mei
   Li, Xingxun
   Guo, Xuqiang
   Liu, Aixian
   Chen, Guangjin
   Yang, Lanying
TI Study on ethane hydrate formation/dissociation in a sub-millimeter sized
   capillary
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ethane hydrate; Sub-millimeter sized capillary; Hydrate memory effect;
   Degree of subcooling; Bridge effect
ID GAS HYDRATE; NATURAL-GAS; SHENHU AREA; WATER; SEA
AB Study on the gas hydrates in porous medium has great significance to the formation, accumulation and exploitation of natural gas hydrate (NGH). Consequently, we investigated the formation/dissociation of ethane hydrate in a sub-millimeter sized capillary in this work, and observed the appearance and kinetic rate during the hydrate formation/dissociation process. The dissociation equilibria of ethane hydrate in capillary was measured first, then the influences of hydrate memory effect (dissociation temperature and time) and degree of subcooling on ethane hydrate formation were obtained, respectively. The results demonstrate that hydrate forms more difficultly in capillary than in conventional macro-reactor because of the fluid resistance effect and poor mass transfer of gas-liquid. The appearance and formation kinetics of ethane hydrate are greatly influenced by the memory effect and subcooling degree. The morphology of ethane hydrate formation on the bubble surface in water bulk phase shows that "bridge effect" occurs during the hydrate formation and growth in capillary. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Qiang; Du, Mei; Li, Xingxun; Chen, Guangjin; Yang, Lanying] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Guo, Xuqiang; Liu, Aixian] China Univ Petr Beijing Karamay, Dept Engn, Sinkang 834000, Peoples R China.
RP Sun, Q (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.; Guo, XQ (reprint author), China Univ Petr Beijing Karamay, Dept Engn, Sinkang 834000, Peoples R China.
EM sunq@cup.edu.cn; guoxq@cup.edu.cn
OI Guo, Xuqiang/0000-0001-5198-9064; Sun, Qiang/0000-0002-9336-7375
FU Science Foundation of China University of Petroleum, Beijing
   [2462017BJB05, 2462016YJRC005, 2462018BJC004]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21306226, RCYJ2017A-02-001, RCYJ2017A-03-001]
FX This work was supported by Science Foundation of China University of
   Petroleum, Beijing (2462017BJB05, 2462016YJRC005, and 2462018BJC004),
   National Natural Science Foundation of China (21306226), Science
   Foundation of CUPBK (RCYJ2017A-02-001, RCYJ2017A-03-001), which are
   greatly acknowledged.
CR Beltran JG, 2010, CRYST GROWTH DES, V10, P4339, DOI 10.1021/cg1003098
   Boswell R, 2011, ENERG ENVIRON SCI, V4, P1206, DOI 10.1039/c0ee00203h
   Chen GJ, 2008, GAS HYDRATE SCI TECH
   Chen XY, 2018, FUEL, V234, P358, DOI 10.1016/j.fuel.2018.07.030
   Chong ZR, 2017, ENRGY PROCED, V143, P780, DOI 10.1016/j.egypro.2017.12.762
   Clarke MA, 1999, IND ENG CHEM RES, V38, P2485, DOI 10.1021/ie980625u
   Collett T. S., 2014, P 8 INT C GAS HYDR B
   Daniel-David D, 2015, CHEM ENG SCI, V132, P118, DOI 10.1016/j.ces.2015.04.015
   Dicharry C, 2013, CHEM ENG SCI, V98, P88, DOI 10.1016/j.ces.2013.05.015
   ENGLEZOS P, 1993, IND ENG CHEM RES, V32, P1251, DOI 10.1021/ie00019a001
   Kida M, 2019, MAR PETROL GEOL, V108, P471, DOI 10.1016/j.marpetgeo.2018.10.012
   Kim HJ, 2013, MAR PETROL GEOL, V47, P214, DOI 10.1016/j.marpetgeo.2013.05.019
   Lee JD, 2005, CHEM ENG SCI, V60, P4203, DOI 10.1016/j.ces.2005.03.003
   Li G, 2019, CHEM ENG SCI, V193, P1, DOI 10.1016/j.ces.2018.08.055
   Li XS, 2016, APPL ENERG, V172, P286, DOI 10.1016/j.apenergy.2016.03.101
   Liu CL, 2015, J GEOCHEM EXPLOR, V152, P67, DOI 10.1016/j.gexplo.2015.02.002
   Liu J, 2017, MAR PETROL GEOL, V88, P225, DOI 10.1016/j.marpetgeo.2017.08.014
   Makogon Y. F., 1972, EXPRESS INF, V11, P1
   Makogon Y. F., 1981, P 4 CAN PERM C CALG
   Makogon YF, 1981, HYDRATES NATURAL GAS
   de Banos MLM, 2015, CHEM ENG SCI, V123, P564, DOI 10.1016/j.ces.2014.11.018
   RIPMEESTER JA, 1990, J PHYS CHEM-US, V94, P8773, DOI 10.1021/j100388a006
   Satyavani N, 2015, J NAT GAS SCI ENG, V25, P317, DOI 10.1016/j.jngse.2015.05.010
   Sefidroodi H, 2013, CHEM ENG SCI, V87, P133, DOI 10.1016/j.ces.2012.10.018
   Siazik J, 2017, PROCEDIA ENGINEER, V192, P782, DOI 10.1016/j.proeng.2017.06.135
   Sloan ED, 2008, CHEM IND-SER, V119, pXIX
   Touil A, 2017, LANGMUIR, V33, P10965, DOI 10.1021/acs.langmuir.7b02121
   Wang JL, 2018, MAR PETROL GEOL, V92, P895, DOI 10.1016/j.marpetgeo.2018.03.020
   Wang PF, 2017, CHEM ENG SCI, V168, P344, DOI 10.1016/j.ces.2017.04.036
   Wei JG, 2018, MAR PETROL GEOL, V98, P622, DOI 10.1016/j.marpetgeo.2018.07.028
   Zhao JF, 2015, J NAT GAS SCI ENG, V26, P330, DOI 10.1016/j.jngse.2015.06.031
NR 31
TC 2
Z9 2
U1 16
U2 92
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 1
EP 9
DI 10.1016/j.ces.2019.05.024
PG 9
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700001
DA 2020-05-12
ER

PT J
AU Wang, D
   Zhu, GL
   Li, Z
   Xue, MC
   Xia, CG
AF Wang, Dan
   Zhu, Gangli
   Li, Zhen
   Xue, Machen
   Xia, Chungu
TI Conceptual design of production of eco-friendly polyoxymethylene
   dimethyl ethers catalyzed by acid functionalized ionic liquids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polyoxymethylene dimethyl ethers; Clean diesel additives; Conceptual
   process design; Physicochemical properties; Acid functionalized ionic
   liquids; Blockage prevention
ID DIESEL ADDITIVES; METHANOL; DIMETHOXYMETHANE; PERFORMANCE; KINETICS;
   METHYLAL; ENGINE
AB As the clean fuel additives, polyoxymethylene dimethyl ethers (DMMn) could significantly reduce carbonaceous particulate matters and volatile organic pollutants in the exhaust gas. Large scale production in a green route would be crucial if the DMMn tailored diesel was applied to the abatement of widespread PM air pollution. In the production, heavy components usually should be separated, recycled, decomposed and re-reacted to gain the aimed products, which would significantly increase complexity and energy consumption of the process. And fatally, it also might cause blockage of units and pipelines. In this work, to prevent blockage, the facile and robust process producing DMMn was conceptually designed basing on physicochemical properties researches. The process exempting from recycle of heavy components and de-heavy column was proposed according to cold-flow properties. Both energy consumption and fixed capital investment can be saved. The reaction kinetic model, which was described in the form of power law functions, showed good consistency for both propagation and depolymerization reactions. Flash points of diesel blends were also measured for determining specification of light components. This work shows it is feasible that DMMn can be produced from dimethoxy methane and trioxane in the presence of acid functionalized ionic liquids in large scale. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Dan; Zhu, Gangli; Li, Zhen; Xue, Machen; Xia, Chungu] Chinese Acad Sci, Suzhou Res Inst LICP, LICP, State Key Lab Oxo Synth & Select Oxidat, Lanzhou 730000, Gansu, Peoples R China.
   [Xue, Machen] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
RP Zhu, GL; Xia, CG (reprint author), Chinese Acad Sci, Suzhou Res Inst LICP, LICP, State Key Lab Oxo Synth & Select Oxidat, Lanzhou 730000, Gansu, Peoples R China.
EM zhugl@licp.cas.cn; cgxia@licp.cas.cn
FU National Key Research and Development Program of China [2018YFB0604801];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21773270, 21673259]; Youth Innovation Promotion
   Association CAS [2018453]; Suzhou Science and Technology Bureau of
   Applied Foundation Research Project [SYG201628]
FX This research was financially supported by the National Key Research and
   Development Program of China (Grant No. 2018YFB0604801), the National
   Natural Science Foundation of China (Grant Nos. 21773270, 21673259) and
   the Youth Innovation Promotion Association CAS (No. 2018453). Supports
   from the Suzhou Science and Technology Bureau of Applied Foundation
   Research Project (SYG201628) are also gratefully acknowledged.
CR ARVIDSON M, 1987, J MOL CATAL, V41, P391, DOI 10.1016/0304-5102(87)80118-9
   Baranton S, 2013, ELECTROCHIM ACTA, V108, P350, DOI 10.1016/j.electacta.2013.06.138
   BOYD RH, 1961, J POLYM SCI, V50, P133, DOI 10.1002/pol.1961.1205015316
   Burger J, 2013, CHEM ENG RES DES, V91, P2648, DOI 10.1016/j.cherd.2013.05.023
   Burger J, 2013, CHEM ENG SCI, V99, P118, DOI 10.1016/j.ces.2013.05.049
   Burger J, 2012, IND ENG CHEM RES, V51, P12751, DOI 10.1021/ie301490q
   Burger J, 2010, FUEL, V89, P3315, DOI 10.1016/j.fuel.2010.05.014
   Claxton LD, 2015, MUTAT RES-REV MUTAT, V763, P30, DOI 10.1016/j.mrrev.2014.09.002
   Deutz S, 2018, ENERG ENVIRON SCI, V11, P331, DOI 10.1039/c7ee01657c
   Devaux D, 2011, ELECTROCHIM ACTA, V56, P1460, DOI 10.1016/j.electacta.2010.10.088
   DIPPR, 2009, 801 DIPPR BRIGH U DE
   Douglas J. M., 1988, CONCEPTUAL DESIGN CH, P75
   Gao XC, 2012, CHINESE J CATAL, V33, P1389, DOI 10.3724/SP.J.1088.2012.20337
   GMEHLING J, 1993, IND ENG CHEM RES, V32, P178, DOI 10.1021/ie00013a024
   Hartl M, 2015, FUEL, V153, P328, DOI 10.1016/j.fuel.2015.03.012
   Hesterberg TW, 2005, CRIT REV TOXICOL, V35, P379, DOI 10.1080/10408440590950542
   Kakinurna K, 2014, ACS APPL MATER INTER, V6, P22138, DOI 10.1021/am505553b
   Lautenschutz L, 2016, FUEL, V173, P129, DOI 10.1016/j.fuel.2016.01.060
   Li DH, 2016, FUEL, V186, P235, DOI 10.1016/j.fuel.2016.08.082
   Li HJ, 2015, APPL CATAL B-ENVIRON, V165, P466, DOI 10.1016/j.apcatb.2014.10.033
   Liu HY, 2015, ENERGY, V88, P793, DOI 10.1016/j.energy.2015.05.088
   Luyben WL, 2013, DISTILLATION DESIGN AND CONTROL USING ASPEN(TM) SIMULATION, 2ND EDITION, P1, DOI 10.1002/9781118510193
   Masel RH, 2013, IND ENG CHEM RES, V52, P5172, DOI 10.1021/ie3033735
   Pascall A, 2013, CAN J CHEM ENG, V91, P1001, DOI 10.1002/cjce.21813
   Pellegrini L., 2012, 1 SAE, P1053
   Schmitz N, 2017, IND ENG CHEM RES, V56, P11519, DOI 10.1021/acs.iecr.7b02314
   Schmitz N, 2016, FUEL, V185, P67, DOI 10.1016/j.fuel.2016.07.085
   Thenert K, 2016, ANGEW CHEM INT EDIT, V55, P12266, DOI 10.1002/anie.201606427
   Wang D, 2019, FUEL, V237, P833, DOI 10.1016/j.fuel.2018.10.014
   Wang D, 2018, CHEM ENG J, V334, P2616, DOI 10.1016/j.cej.2017.11.181
   Wang D, 2017, J MOL LIQ, V234, P403, DOI 10.1016/j.molliq.2017.03.105
   Wang F, 2015, J MOL CATAL A-CHEM, V408, P228, DOI 10.1016/j.molcata.2015.07.028
   Wang H, 2017, CATAL TODAY, V298, P263, DOI 10.1016/j.cattod.2017.01.041
   Wang RY, 2016, CATAL SCI TECHNOL, V6, P993, DOI 10.1039/c5cy01854d
   Wasserscheid P, 2000, ANGEW CHEM INT EDIT, V39, P3772, DOI 10.1002/1521-3773(20001103)39:21<3772::AID-ANIE3772>3.0.CO;2-5
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Wu JB, 2015, GREEN CHEM, V17, P2353, DOI 10.1039/c4gc02510e
   Wu Q, 2015, RSC ADV, V5, P57968, DOI 10.1039/c5ra08360e
   Wu Q, 2014, IND ENG CHEM RES, V53, P16254, DOI 10.1021/ie502409t
   Wu YJ, 2016, IND ENG CHEM RES, V55, P1859, DOI 10.1021/acs.iecr.5b04177
   Xia C., 2012, Patent No. [US2014114092-A1, 2014114092]
   Xia C., 2015, Patent No. [2015103134110, CN2015103134110]
   Xue ZZ, 2017, RSC ADV, V7, P20300, DOI 10.1039/c7ra02678a
   Xue ZZ, 2017, ENERG FUEL, V31, P279, DOI 10.1021/acs.energyfuels.6b02255
   Zhang JQ, 2014, IND ENG CHEM RES, V53, P13589, DOI 10.1021/ie501231a
   Zhang XL, 2016, BIOMASS BIOENERG, V90, P7, DOI 10.1016/j.biombioe.2016.03.032
   Zhang XL, 2014, ENRGY PROCED, V61, P1921, DOI 10.1016/j.egypro.2014.12.242
   Zhao YP, 2013, J ENERGY CHEM, V22, P833, DOI 10.1016/S2095-4956(14)60261-8
   Zheng YY, 2015, CHEM ENG SCI, V134, P758, DOI 10.1016/j.ces.2015.05.067
   Zheng YY, 2015, CHEM ENG J, V278, P183, DOI 10.1016/j.cej.2014.10.056
   Zheng YY, 2013, CHEM ENG TECHNOL, V36, P1951, DOI 10.1002/ceat.201300360
   Zhu GL, 2017, J CHROMATOGR A, V1513, P194, DOI 10.1016/j.chroma.2017.07.036
NR 52
TC 2
Z9 2
U1 20
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 10
EP 21
DI 10.1016/j.ces.2019.05.017
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700002
DA 2020-05-12
ER

PT J
AU Gong, HJ
   Zhang, H
   Xu, L
   Li, YJ
   Dong, MZ
AF Gong, Houjian
   Zhang, Hao
   Xu, Long
   Li, Yajun
   Dong, Mingzhe
TI Effects of cosolvent on dissolution behaviors of PVAc in supercritical
   CO2: A molecular dynamics study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molecular dynamics simulation; PVAc; scCO(2); Dissolubility; Cosolvents
ID PRESSURE PHASE-BEHAVIOR; CARBON-DIOXIDE; POLY(VINYL ACETATE); BINARY;
   ETHANOL; CO2-PHILICITY; SYSTEMS; EQUILIBRIUM; SOLUBILITY; SOLVATION
AB The dissolution behavior of polymers in CO2 has become increasingly important to the applications of CO2 in industry. Experimental results showed that PVAc could be dissolved in CO2 at a high pressure. When cosolvents such as ethanol, acetic acid, and ethyl acetate were present in the system, the transition points could be decreased with the increase in cosolvent concentration. In this work, the influence mechanisms of cosolvents on dissolution behaviors of PVAc in supercritical CO2 were investigated by molecular dynamics simulation methods. First, the cohesive energy and solubility parameters of PVAc, cosolvents and CO2 were analyzed. Compared with CO2, the mixtures of CO2 and cosolvents have closer solubility parameters with PVAc to enhance the dissolubility of PVAc within them. Moreover, the mechanism of PVAc dissolution in CO2 and the effects of cosolvents on decreasing the transition points were investigated. The Lewis acid-Lewis base (LA-LB) interactions between 0 atoms in PVAc and C atoms in CO2 are the main influencing factors of PVAc dissolution in CO2. The presence of cosolvent can generate new interactions, such as hydrogen bonding and LA-LB interactions, which have different influences on the LA-LB interactions between PVAc and CO2. Ethanol and ethyl acetate have no great influence on these LA-LB interactions, while acetic acid exerts considerable influence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gong, Houjian; Zhang, Hao; Xu, Long; Li, Yajun] China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Shandong, Peoples R China.
   [Gong, Houjian; Zhang, Hao; Xu, Long; Li, Yajun] China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
   [Dong, Mingzhe] Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
RP Gong, HJ (reprint author), China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Shandong, Peoples R China.; Gong, HJ (reprint author), China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
EM gonghoujian@upc.edu.cn
OI Xu, Long/0000-0003-1859-6538; Gong, Houjian/0000-0002-3304-1605
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51774310]; Natural Science Foundation of Shandong Province of
   ChinaNatural Science Foundation of Shandong Province [ZR2019MEE058];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [17CX05005, 18CX02165A]
FX We gratefully acknowledge financial support from the Natural Science
   Foundation of China (Grant No. 51774310), Natural Science Foundation of
   Shandong Province of China (No. ZR2019MEE058), and the Fundamental
   Research Funds for the Central Universities (No. 17CX05005, 18CX02165A).
CR Bachu S, 2004, SPE DOE S IMPR OIL R
   Baradie B, 2004, MACROMOLECULES, V37, P7799, DOI 10.1021/ma049384u
   Beckman EJ, 2004, CHEM COMMUN, P1885, DOI 10.1039/b404406c
   Bray CL, 2010, MACROMOLECULES, V43, P9426, DOI 10.1021/ma1016055
   Bulgarevich DS, 2002, IND ENG CHEM RES, V41, P2074, DOI 10.1021/ie0106332
   Byun HS, 2006, IND ENG CHEM RES, V45, P3373, DOI 10.1021/ie0507070
   Dardin A, 1998, J PHYS CHEM B, V102, P1775, DOI 10.1021/jp972127p
   Drohmann C, 2002, J SUPERCRIT FLUID, V22, P103, DOI 10.1016/S0896-8446(01)00111-5
   EASTOE J, 2006, ANGEW CHEM, V118, P3757
   Gornert M, 2008, J SUPERCRIT FLUID, V46, P218, DOI 10.1016/j.supflu.2008.02.009
   Gross J, 2001, IND ENG CHEM RES, V40, P1244, DOI 10.1021/ie0003887
   Gupta AP, 2005, SPE ANN TECHN C EXH
   Hoogenboom R, 2008, SOFT MATTER, V4, P103, DOI 10.1039/b712771e
   Hu DD, 2016, J SUPERCRIT FLUID, V118, P96, DOI 10.1016/j.supflu.2016.07.024
   Hu DD, 2015, J PHYS CHEM B, V119, P12490, DOI 10.1021/acs.jpcb.5b08393
   Hu DD, 2015, J PHYS CHEM B, V119, P3194, DOI 10.1021/jp5130052
   Huang ZH, 2000, MACROMOLECULES, V33, P5437, DOI 10.1021/ma992043+
   Joung SN, 2001, FLUID PHASE EQUILIBR, V185, P219, DOI 10.1016/S0378-3812(01)00472-1
   Kazarian SG, 1996, J AM CHEM SOC, V118, P1729, DOI 10.1021/ja950416q
   Lalanne P, 2004, J PHYS CHEM A, V108, P2617, DOI 10.1021/jp037802b
   Liu S, 2009, IND ENG CHEM RES, V48, P7821, DOI 10.1021/ie900598w
   Matsuyama K, 2006, FLUID PHASE EQUILIBR, V249, P173, DOI 10.1016/j.fluid.2006.09.023
   MERTSCH R, 1994, MACROMOLECULES, V27, P3289, DOI 10.1021/ma00090a023
   Ozkan IA, 2005, FLUID PHASE EQUILIBR, V228, P487, DOI 10.1016/j.fluid.2004.09.035
   Raveendran P, 2002, J AM CHEM SOC, V124, P12590, DOI 10.1021/ja0174635
   Shen Z, 2003, POLYMER, V44, P1491, DOI 10.1016/S0032-3861(03)00020-X
   Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v
   Tan B, 2005, J AM CHEM SOC, V127, P8938, DOI 10.1021/ja052508d
   Tan B, 2009, MACROMOLECULES, V42, P7945, DOI 10.1021/ma901458a
   Wu JL, 2002, J APPL POLYM SCI, V85, P1938, DOI 10.1002/app.10754
   XIONG Y, 1994, J APPL POLYM SCI, V53, P1179, DOI 10.1002/app.1994.070530905
   Xu WH, 2009, J PHYS CHEM B, V113, P4781, DOI 10.1021/jp810193b
   Zhu T., 2017, J CHEM ENG DATA
   Zhu T, 2018, FLUID PHASE EQUILIBR, V458, P264, DOI 10.1016/j.fluid.2017.11.029
NR 34
TC 1
Z9 1
U1 12
U2 52
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 22
EP 30
DI 10.1016/j.ces.2019.05.023
PG 9
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700003
DA 2020-05-12
ER

PT J
AU Zhang, BQ
   Kobayashi, N
   Itaya, Y
   Ono, K
   Suami, A
AF Zhang, Baiqiang
   Kobayashi, Nobusuke
   Itaya, Yoshinori
   Ono, Kyosuke
   Suami, Akira
TI Optical emission spectroscopy diagnostics of DBD plasma with particles
   in a two-dimensional spouted bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE DBD plasma; Two-dimensional spouted bed; Fluidization behavior; Optical
   emission spectral characteristic; Emission intensity
ID FLUIDIZED-BED; BEHAVIOR
AB To gain an insight into the effect of fluidization behavior of particles on the characteristic of plasma in a plasma-enhanced spouted bed, we investigated the changes of plasma optical emission spectroscopy (OES) with fluidized particles in this paper. Fluidization experiments under the irradiation of a dielectric barrier discharge (DBD) plasma generator were performed in a two-dimensional spouted bed. Essential operation parameters, such as particle type, applied voltage, gas velocity, and particle number were changed. The pressure drop of particles, emission intensity (El) of plasma, and high-speed camera images of plasma pattern were measured. As the results, the fluidization behavior of particles had been changed by the plasma irradiation, especially for polypropylene (PP) particles. The emission spectra of argon (Ar) plasma had been changed significantly with particles. The emission intensities of the Ar I transition lines were increased, and Ar II lines were decreased with PP particles compared to the case of no particle. The emission intensity of Ar I lines was enhanced with the applied voltage regardless of the addition of particles. The emission intensity changed with a gas velocity versus particle numbers was identified with the fluidization behavior, that emission intensity was increased at first and then decreased. The gas velocities corresponded to the highest value of emission intensity with various particle number were similar to the trend of the changes of minimum spouted velocity. The electrical conductivity and color of particles may affect the difference of pressure drop and detected emission intensity for two kinds of particles. Our research extends the knowledge of the relationship between fluidization behavior and plasma optical characteristic. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Baiqiang; Kobayashi, Nobusuke; Itaya, Yoshinori; Ono, Kyosuke; Suami, Akira] Gifu Univ, Environm & Renewable Energy Syst, Gifu, Japan.
RP Zhang, BQ (reprint author), Gifu Univ, Environm & Renewable Energy Syst, Gifu, Japan.
EM zbq415@gmail.com
FU JSPS KAKENHI GrantMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP17K06906];
   China Scholarship CouncilChina Scholarship Council [201606860009]
FX The financial support in the author's laboratory received from a JSPS
   KAKENHI Grant (No. JP17K06906) is gratefully acknowledged. We also
   recognize the financial support from the China Scholarship Council
   through a Ph.D. scholarship (No. 201606860009) to Baiqiang Zhang.
CR [Anonymous], 2018, NIST AT SPECTR DAT L
   Benard N, 2014, EXP FLUIDS, V55, DOI 10.1007/s00348-014-1846-x
   Corke TC, 2007, PROG AEROSP SCI, V43, P193, DOI 10.1016/j.paerosci.2007.06.001
   Erfani R, 2015, ACTA ASTRONAUT, V109, P132, DOI 10.1016/j.actaastro.2014.12.016
   Gao J, 2018, NANO RES, V11, P1470, DOI 10.1007/s12274-017-1764-3
   Gibalov VI, 2000, J PHYS D APPL PHYS, V33, P2618, DOI 10.1088/0022-3727/33/20/315
   Gryczka O, 2008, CHEM ENG SCI, V63, P791, DOI 10.1016/j.ces.2007.10.023
   Karches M, 1999, SURF COAT TECH, V116, P879, DOI 10.1016/S0257-8972(99)00194-2
   Krause B, 2016, AIP CONF PROC, V1779, DOI 10.1063/1.4965494
   Lam SK, 2000, J PHYS D APPL PHYS, V33, P242, DOI 10.1088/0022-3727/33/3/310
   Li SZ, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3223848
   Malyshev MV, 1997, J VAC SCI TECHNOL A, V15, P550, DOI 10.1116/1.580682
   MATHUR K, 1974, SPOUTED BEDS
   MATSUKATA M, 1994, INT J MULTIPHAS FLOW, V20, P763, DOI 10.1016/0301-9322(94)90044-2
   MOROOKA S, 1988, J CHEM ENG JPN, V21, P41, DOI 10.1252/jcej.21.41
   Nozaki T, 2002, PLASMA SOURCES SCI T, V11, P431, DOI 10.1088/0963-0252/11/4/310
   Olenici-Craciunescu SB, 2011, SPECTROCHIM ACTA B, V66, P268, DOI 10.1016/j.sab.2011.03.005
   Olenici-Craciunescu SB, 2009, SPECTROCHIM ACTA B, V64, P1253, DOI 10.1016/j.sab.2009.10.001
   Pajkic Z, 2009, SURF COAT TECH, V203, P3168, DOI 10.1016/j.surfcoat.2009.03.047
   Pavon S, 2007, J PHYS D APPL PHYS, V40, P1733, DOI 10.1088/0022-3727/40/6/021
   Pissinati R, 2003, EUR J PHARM BIOPHARM, V55, P313, DOI 10.1016/S0939-6411(03)00002-X
   Rehman NU, 2008, PHYS LETT A, V372, P1462, DOI 10.1016/j.physleta.2007.09.052
   Sathiyamoorthy D, 2010, J PHYS CONF SER, V208, DOI 10.1088/1742-6596/208/1/012120
   Shao XJ, 2011, IEEE T PLASMA SCI, V39, P3095, DOI 10.1109/TPS.2011.2160569
   Song LH, 2011, KOREAN J CHEM ENG, V28, P627, DOI 10.1007/s11814-010-0390-5
   Wang JJ, 2013, PROG AEROSP SCI, V62, P52, DOI 10.1016/j.paerosci.2013.05.003
   Wang Q, 2009, CATAL TODAY, V148, P275, DOI 10.1016/j.cattod.2009.08.008
   Wei GD, 2011, IEEE T PLASMA SCI, V39, P1842, DOI 10.1109/TPS.2011.2159810
   Zaplotnik R, 2014, EPL-EUROPHYS LETT, V106, DOI 10.1209/0295-5075/106/25001
   Zhang BQ, 2019, POWDER TECHNOL, V343, P309, DOI 10.1016/j.powtec.2018.11.044
   Zhang JF, 2009, CHINESE PHYS LETT, V26, DOI 10.1088/0256-307X/26/3/035203
   Zhu XB, 2015, CATAL TODAY, V256, P108, DOI 10.1016/j.cattod.2015.01.028
NR 32
TC 1
Z9 1
U1 9
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 31
EP 40
DI 10.1016/j.ces.2019.05.019
PG 10
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700004
DA 2020-05-12
ER

PT J
AU de Klerk, DN
   Govender, I
   Mainza, AN
AF de Klerk, D. N.
   Govender, I
   Mainza, A. N.
TI Geometric features of tumbling mill flows: A positron emission particle
   tracking investigation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PEPT; Charge features; Alpha hull method; Tumbling mills; Lifter bars
ID MOTION; BEHAVIOR
AB Positron emission particle tracking (PEPT) allows for the in situ tracking of particles (rocks, balls, slurry) in experimental tumbling mills. For sufficiently long tracking times, the trajectory fields can be cast into time averages per unit volume of kinematic and dynamical information which constitute the key ingredients for fundamental modelling of tumbling mills. Central to this objective is the accurate delineation of geometric features making up the tumbling mill in the azimuthal plane. To this end, algorithms for extracting bulk features of the media (free surface, equilibrium surface, centre of circulation, toe and shoulder positions) are presented. These algorithms are then employed to compare results from dry, batch experiments spanning a wide range of mill speeds, lifter heights and lifter angles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [de Klerk, D. N.; Mainza, A. N.] Univ Cape Town, Ctr Minerals Res, ZA-7701 Rondebosch, South Africa.
   [Govender, I] Univ KwaZulu Natal, Sch Engn, ZA-4041 Glenwood, South Africa.
RP Govender, I (reprint author), Univ KwaZulu Natal, Sch Engn, ZA-4041 Glenwood, South Africa.
EM indresan.govender@gmail.com
CR Bbosa LS, 2011, MINER ENG, V24, P319, DOI 10.1016/j.mineng.2010.10.005
   Bickell M, 2012, NUCL INSTRUM METH A, V682, P36, DOI 10.1016/j.nima.2012.04.037
   Chou HT, 2009, GRANUL MATTER, V11, P13, DOI 10.1007/s10035-008-0118-y
   Cleary PW, 2001, INT J MINER PROCESS, V63, P79, DOI 10.1016/S0301-7516(01)00037-0
   EDELSBRUNNER H, 1983, IEEE T INFORM THEORY, V29, P551, DOI 10.1109/TIT.1983.1056714
   Govender I, 2017, J PHYS D APPL PHYS, V50, DOI 10.1088/1361-6463/aa5125
   Govender I, 2011, MINER ENG, V24, P225, DOI 10.1016/j.mineng.2010.08.009
   Govender I, 2011, MINER ENG, V24, P230, DOI 10.1016/j.mineng.2010.08.010
   Govender I, 2017, AICHE J, V63, P903, DOI 10.1002/aic.15453
   HAWKESWORTH MR, 1986, NUCL INSTRUM METH A, V253, P145, DOI 10.1016/0168-9002(86)91138-1
   Jain N, 2002, PHYS FLUIDS, V14, P572, DOI 10.1063/1.1431244
   Kallon DVV, 2011, MINER ENG, V24, P282, DOI 10.1016/j.mineng.2010.09.006
   Maleki-Moghaddam M., 2013, MIN ENG, V10, P166
   McBride A, 2004, ENG COMPUTATION, V21, P119, DOI 10.1108/02644400410519703
   Mellmann J, 2001, POWDER TECHNOL, V118, P251, DOI 10.1016/S0032-5910(00)00402-2
   MORRELL S, 1992, T I MIN METALL C, V101, pC25
   Morrell S., 1993, THESIS
   Morrison AJ, 2016, CHEM ENG SCI, V152, P186, DOI 10.1016/j.ces.2016.06.022
   NAKAGAWA M, 1993, EXP FLUIDS, V16, P54, DOI 10.1007/BF00188507
   Orpe AV, 2007, J FLUID MECH, V571, P1, DOI 10.1017/S002211200600320X
   Orpe AV, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.031302
   Parker DJ, 1997, CHEM ENG SCI, V52, P2011, DOI 10.1016/S0009-2509(97)00030-4
   PARKER DJ, 1993, NUCL INSTRUM METH A, V326, P592, DOI 10.1016/0168-9002(93)90864-E
   Powell MS, 2004, MINER ENG, V17, P1099, DOI 10.1016/j.mineng.2004.06.022
   RAJCHENBACH J, 1990, PHYS REV LETT, V65, P2221, DOI 10.1103/PhysRevLett.65.2221
   ROGOVIN Z, 1989, MINER METALL PROC, V6, P18
   Rose H., 1956, P I MECH ENG, V170, P793
   Rose H., 1956, P I MECH ENG, V170, P784
   Rose H., 1956, P I MECH ENG, V170, P773
   ROSE HE, 1957, TREATISE INTERNAL ME
   Santomaso AC, 2003, CHEM ENG RES DES, V81, P936, DOI 10.1205/026387603322482176
   Sichalwe K, 2011, MINER ENG, V24, P276, DOI 10.1016/j.mineng.2010.08.027
   Taberlet N, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.050301
   Wildman RD, 2000, PHYS REV E, V62, P3826, DOI 10.1103/PhysRevE.62.3826
   Yang Z, 2006, NUCL INSTRUM METH A, V564, P332, DOI 10.1016/j.nima.2006.04.054
   Yin ZX, 2017, MATERIALS, V10, DOI 10.3390/ma10080882
   ZIK O, 1994, PHYS REV LETT, V73, P644, DOI 10.1103/PhysRevLett.73.644
NR 37
TC 0
Z9 0
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 41
EP 49
DI 10.1016/j.ces.2019.05.020
PG 9
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700005
DA 2020-05-12
ER

PT J
AU Bettermann, S
   Stuhr, R
   Moritz, HU
   Pauer, W
AF Bettermann, Sven
   Stuhr, Robin
   Moritz, Hans-Ulrich
   Pauer, Werner
TI Customizable 3D-printed stirrers for investigation, optimization and
   scale-up processes of batch emulsion copolymerizations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Additive manufacturing; 3D-printed stirrer; Emulsion copolymerization;
   Scale-manufacturing concept,scale-up process; Online monitoring
ID OF-THE-ART; CHEMICAL-SYNTHESIS; HEAT-TRANSFER; POLYMERIZATION;
   REACTIONWARE; FLOW; MECHANISM; REACTORS; DEVICES
AB Diverse and cost-effective polyamide stirrers, printed by fused deposition modeling, were used in a 0.5 L reaction calorimeter (Mettler Toledo RC1e) to principally investigate the suitability and performance of 3D-printed stirrers. Thermal-initiated batch emulsion copolymerizations of styrene and butyl acrylate were successfully carried out with monomer contents between 20 and 40 wt% and temperatures in the range of 60 to 85 degrees C. Further, precisely adjusted stirrers were designed and fabricated based on a constant volume related power input for scale-up processes in a 10 L batch reactor. This scale-manufacturing concept enables a time-effective and inexpensive access to versatile and tailor-made 3D-printed stirrers, even for the implementation in already existing reaction systems. Inline turbidity was used as online monitoring tool to detect the mixing characteristics and control the course of emulsion polymerization processes. Analytical results of the 10 L resembled those of the 0.5 L scale and proved our main objective to produce comparable droplet dispersions (+/- 2 nm). The resulting emulsions from 0.5 and 10 L scale were stable with Zeta potential values down to -90 mV. Neither product adhesion on nor deformation of the 3D-printed stirrers were found even at higher temperatures, monomer contents or scale-up processes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bettermann, Sven; Stuhr, Robin; Moritz, Hans-Ulrich; Pauer, Werner] Univ Hamburg, Inst Tech & Macromol Chem, Bundesstr 45, D-20146 Hamburg, Germany.
RP Pauer, W (reprint author), Univ Hamburg, Inst Tech & Macromol Chem, Bundesstr 45, D-20146 Hamburg, Germany.
EM werner.pauer@um-hamburg.de
CR Ambrosi A, 2016, CHEM SOC REV, V45, P2740, DOI 10.1039/c5cs00714c
   Anderson KB, 2013, ANAL CHEM, V85, P5622, DOI 10.1021/ac4009594
   Anderson NG, 2001, ORG PROCESS RES DEV, V5, P613, DOI 10.1021/op0100605
   Arjmandi N, 2012, ANAL CHEM, V84, P8490, DOI 10.1021/ac300705z
   Au AK, 2016, ANGEW CHEM INT EDIT, V55, P3862, DOI 10.1002/anie.201504382
   BADYGA J, 1995, CHEM ENG J BIOCH ENG, V58, P183, DOI 10.1016/0923-0467(95)02982-6
   Bettermann S, 2018, CHEM ENG J, V338, P311, DOI 10.1016/j.cej.2018.01.038
   Bhattacharjee N, 2016, LAB CHIP, V16, P1720, DOI 10.1039/c6lc00163g
   Bloch D, 2017, MACROMOL REACT ENG, V11, DOI 10.1002/mren.201600063
   Capel AJ, 2013, LAB CHIP, V13, P4583, DOI 10.1039/c3lc50844g
   Crump S. S., 1992, APPARATUS METHOD CRE, Patent No. 5,121,329
   Dimitrov D, 2006, RAPID PROTOTYPING J, V12, P136, DOI 10.1108/13552540610670717
   Dragone V, 2013, BEILSTEIN J ORG CHEM, V9, P951, DOI 10.3762/bjoc.9.109
   Drumright RE, 2000, ADV MATER, V12, P1841, DOI 10.1002/1521-4095(200012)12:23<1841::AID-ADMA1841>3.0.CO;2-E
   Engelis NG, 2017, NAT CHEM, V9, P171, DOI [10.1038/nchem.2634, 10.1038/NCHEM.2634]
   Fan WJ, 2018, ANGEW CHEM INT EDIT, V57, P962, DOI 10.1002/anie.201710754
   Gowers SAN, 2015, ANAL CHEM, V87, P7763, DOI 10.1021/acs.analchem.5b01353
   Gupta B, 2007, PROG POLYM SCI, V32, P455, DOI 10.1016/j.progpolymsci.2007.01.005
   He Y, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7070108
   Ho J, 2018, GREEN CHEM, V20, P1899, DOI 10.1039/c8gc00130h
   Jia ZX, 2016, J APPL POLYM SCI, V133, DOI 10.1002/app.43014
   Kazenwadel F, 2016, ENG LIFE SCI, V16, P560, DOI 10.1002/elsc.201600007
   Kitson PJ, 2018, SCIENCE, V359, P314, DOI 10.1126/science.aao3466
   Kitson PJ, 2016, NAT PROTOC, V11, P920, DOI 10.1038/nprot.2016.041
   Kitson PJ, 2014, ANGEW CHEM INT EDIT, V53, P12723, DOI 10.1002/anie.201402654
   Kitson PJ, 2013, CHEM SCI, V4, P3099, DOI 10.1039/c3sc51253c
   Kitson PJ, 2012, LAB CHIP, V12, P3267, DOI 10.1039/c2lc40761b
   Kockmann N, 2011, CHEM ENG PROCESS, V50, P1017, DOI 10.1016/j.cep.2011.05.021
   Kockmann N, 2011, CHEM ENG J, V167, P718, DOI 10.1016/j.cej.2010.08.089
   Kohut-Svelko N, 2009, J POLYM SCI POL CHEM, V47, P2917, DOI 10.1002/pola.23362
   Kurt SK, 2015, CHEM ENG TECHNOL, V38, P1122, DOI 10.1002/ceat.201400515
   Letellier B, 2002, CHEM ENG SCI, V57, P4617, DOI 10.1016/S0009-2509(02)00371-8
   Ligon SC, 2017, CHEM REV, V117, P10212, DOI 10.1021/acs.chemrev.7b00074
   Lucking TH, 2015, ENG LIFE SCI, V15, P51, DOI 10.1002/elsc.201400093
   Luo JZ, 2016, CHEM ENG SCI, V155, P386, DOI 10.1016/j.ces.2016.08.010
   Maier M, 2018, ANGEW CHEM INT EDIT, V57, P5539, DOI 10.1002/anie.201711072
   Mao ZS, 2017, CHINESE J CHEM ENG, V25, P381, DOI 10.1016/j.cjche.2016.09.012
   Maschio G, 1999, CHEM ENG SCI, V54, P3273, DOI 10.1016/S0009-2509(98)90318-9
   Nomura M, 2005, ADV POLYM SCI, V175, P1, DOI 10.1007/b100116
   Ostolska I, 2014, COLLOID POLYM SCI, V292, P2453, DOI 10.1007/s00396-014-3276-y
   Parekh DP, 2016, LAB CHIP, V16, P1812, DOI 10.1039/c6lc00198j
   Parra-Cabrera C, 2018, CHEM SOC REV, V47, P209, DOI 10.1039/c7cs00631d
   Perreira AC, 2017, POLYM CHEM-UK, V8, P1233, DOI 10.1039/c6py01742h
   Pham DT, 1998, INT J MACH TOOL MANU, V38, P1257, DOI 10.1016/S0890-6955(97)00137-5
   RICHARDS JR, 1989, J APPL POLYM SCI, V37, P2727, DOI 10.1002/app.1989.070370923
   Rossi S, 2018, CHEMCATCHEM, V10, P1512, DOI 10.1002/cctc.201701619
   Sanchez-Silva L, 2010, J MICROENCAPSUL, V27, P583, DOI 10.3109/02652048.2010.501394
   Shepherd JNH, 2011, ADV FUNCT MATER, V21, P47, DOI 10.1002/adfm.201001746
   Symes MD, 2012, NAT CHEM, V4, P349, DOI [10.1038/NCHEM.1313, 10.1038/nchem.1313]
   Thickett SC, 2007, POLYMER, V48, P6965, DOI 10.1016/j.polymer.2007.09.031
   Truong NP, 2016, POLYM CHEM-UK, V7, P430, DOI 10.1039/c5py01467k
   Waheed S, 2016, LAB CHIP, V16, P1993, DOI 10.1039/c6lc00284f
   Wang X, 2017, COMPOS PART B-ENG, V110, P442, DOI 10.1016/j.compositesb.2016.11.034
   Yazdi AA, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1715-4
   Yuen PK, 2016, BIOMICROFLUIDICS, V10, DOI 10.1063/1.4958909
   Zhu WJ, 2015, CHEM ENG J, V276, P249, DOI 10.1016/j.cej.2015.04.084
NR 56
TC 2
Z9 2
U1 9
U2 49
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 50
EP 62
DI 10.1016/j.ces.2019.05.026
PG 13
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700006
DA 2020-05-12
ER

PT J
AU Setekleiv, AE
   Knuutila, HK
AF Setekleiv, A. Eddie
   Knuutila, Hanna K.
TI Experimental investigation of inlet vane design and performance in
   hydrocarbon systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase flow; Re-entrainment; Breakup; Scrubber; Inlet vane; Souder
   Brown equation
ID DROPLET
AB Separation efficiencies for a scrubber inlet vane section was investigated using a natural gas hydrocarbon system at 20, 50 and 85 bars. Several design features were investigated such as diameter of inlet pipe, vane design, separator vessel diameter. In addition the effect of liquid rate was examined. The study finds that pipe diameter, column diameter, liquid rate and fluid properties of the inlet vane affect separation efficiencies. This is a result of several different fluid mechanical processes which affect the droplet size distribution into the separation vessel. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Setekleiv, A. Eddie; Knuutila, Hanna K.] Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
RP Knuutila, HK (reprint author), Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
EM hanna.knuutila@ntnu.no
OI Knuutila, Hanna Katariina/0000-0003-2057-1743
FU Norwegian Research Council (NFR)Research Council of Norway [206989];
   Cameron Process Systems; Conoco Phillips Norge; Exxon Mobile Upstream
   Research Company; FMC Technologies; GE Oil Gas; Pall Europe Ltd.;
   Peerless Europa; Shell Technology Norway; Statoil ASA; Sulzer Chemtech
FX The authors would like to thank the Norwegian Research Council (NFR),
   project No. 206989, and industrial sponsors, consisting of Cameron
   Process Systems, Conoco Phillips Norge, Exxon Mobile Upstream Research
   Company, FMC Technologies, GE Oil & Gas, Pall Europe Ltd., Peerless
   Europa, Shell Technology Norway, Statoil ASA and Sulzer Chemtech for
   making this research possible as well as helping with design and
   interpretation of data.
CR Austrheim T., 2006, THESIS
   Austrheim T, 2007, ENERG FUEL, V21, P2969, DOI 10.1021/ef070109t
   CHEN CY, 1955, CHEM REV, V55, P595, DOI 10.1021/cr50003a004
   Chesters A., 1991, T I CHEM ENG-LOND, V69A, P259
   Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601
   Hagesaether L., 2002, THESIS
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   ISHII M, 1975, AICHE J, V21, P308, DOI 10.1002/aic.690210212
   KATAOKA I, 1983, J FLUID ENG-T ASME, V105, P230, DOI 10.1115/1.3240969
   Lin S.P., 2003, BREAKUP LIQUID SHEET
   Marmottant PH, 2004, J FLUID MECH, V498, P73, DOI 10.1017/S0022112003006529
   NORSOK, 2001, P100 NORSOK
   Patruno LE, 2010, CHEM ENG SCI, V65, P5272, DOI 10.1016/j.ces.2010.06.038
   PENELOUX A, 1982, FLUID PHASE EQUILIBR, V8, P7, DOI 10.1016/0378-3812(82)80002-2
   Saunders M, 1934, IND ENG CHEM, V26, P98
   Setekleiv AE, 2014, FUEL, V120, P98, DOI 10.1016/j.fuel.2013.11.059
   Setekleiv AE, 2012, CHEM ENG SCI, V68, P624, DOI 10.1016/j.ces.2011.10.027
   Setekleiv E., 2016, OFFSH TECHN C HOUST
   Soave G., 1961, CHEM ENG SCI, V71, P135
   TSOURIS C, 1994, AICHE J, V40, P395, DOI 10.1002/aic.690400303
   Weinaug CF, 1943, IND ENG CHEM, V35, P239, DOI 10.1021/ie50398a028
NR 21
TC 0
Z9 0
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 63
EP 95
DI 10.1016/j.ces.2019.04.052
PG 33
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700007
DA 2020-05-12
ER

PT J
AU Thosar, AU
   Agarwal, H
   Govarthan, S
   Lele, AK
AF Thosar, Aniket U.
   Agarwal, Harshal
   Govarthan, S.
   Lele, Ashish K.
TI Comprehensive analytical model for polarization curve of a PEM fuel cell
   and experimental validation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PEMFC; Fuel cell equation; Polarization curve; Modelling
ID CATHODE CATALYST LAYER; ISOTHERMAL 2-DIMENSIONAL MODEL; OXYGEN REDUCTION
   KINETICS; MASS-TRANSPORT; MATHEMATICAL-MODEL; FLOW CHANNEL; RESISTANCE;
   PERFORMANCE; ELECTRODES; MEMBRANES
AB The kinetics of cathodic oxygen reduction reaction (ORR) in a proton exchange membrane fuel cell (PEMFC) is significantly modulated by the resistances for transport of reactants to the catalytic sites offered by different components of the fuel cell. This modulation governs the polarization curve of the PEMFC. Consequently, the various operating, geometric and material parameters of the fuel cell dictate the polarization curve. The effects of these parameters on the polarization curve over the entire range of current density, from zero to limiting current, can be predicted using detailed numerical simulations, which are however expensive. Analytical models, although simple can capture the essential details of physico-chemical processes occurring inside a PEMFC and are significantly inexpensive. In this article, we derive an analytical equation of the polarization curve which is valid over the entire range of current density. Specifically, the representative situation of a humidified low temperature PEMFC is considered wherein oxygen transport resistance in the cathode catalyst layer (CCL) is encountered at lower current density than proton transport resistance in the CCL. A novel experimental methodology is illustrated to confirm that this is indeed the case. Next, we elucidate a procedure to determine in-situ oxygen diffusion coefficients in the various domains of an operational PEMFC. Finally, it is shown that the analytical polarization curve predicted using these parameters is in excellent agreement with the experimental and numerically simulated polarization curves over the entire range of current density. The significance of this work is that the analytical model relates the performance of a PEMFC to all operating and geometric parameters as well as the average transport and kinetic properties of the materials used in its different components, without the need for computationally expensive numerical simulations. The model can therefore provide useful insights for enhancing the performance of PEMFC in different regimes of current density as well as for diagnostic purposes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Thosar, Aniket U.; Agarwal, Harshal] CSIR, Acad Sci & Innovat Res AcSIR, NCL, Pune, Maharashtra, India.
   [Thosar, Aniket U.] CSIR, Natl Chem Lab, Pune, Maharashtra, India.
   [Agarwal, Harshal; Govarthan, S.] CSIR, Cent Electrochem Res Inst, CSIR Madras Complex, Chennai, Tamil Nadu, India.
   [Lele, Ashish K.] Reliance Ind Ltd, Navi Mumbai, India.
RP Lele, AK (reprint author), Reliance Ind Ltd, Navi Mumbai, India.
EM Ashish.Lele@ril.com
FU CSIR-NMITLI program on PEM fuel cells; CSIRCouncil of Scientific &
   Industrial Research (CSIR) - India
FX PAuthors acknowledge CSIR-NMITLI program on PEM fuel cells for financial
   assistance. AUT thanks CSIR for Senior Research fellowship. Authors also
   acknowledge N Nagaraju, Karthika P., Sudeshna Sarmah and Dr. S D Bhat
   from CECRI for providing membrane electrode assembly.
CR Andronie A, 2019, PROCEDIA MANUF, V32, P810, DOI 10.1016/j.promfg.2019.02.289
   Baker DR, 2009, J ELECTROCHEM SOC, V156, pB991, DOI 10.1149/1.3152226
   BERNARDI DM, 1991, AICHE J, V37, P1151, DOI 10.1002/aic.690370805
   Beuscher U, 2006, J ELECTROCHEM SOC, V153, pA1788, DOI 10.1149/1.2218760
   Buchi FN, 1996, J ELECTROCHEM SOC, V143, P927, DOI 10.1149/1.1836560
   Cetinbas FC, 2013, J ELECTROCHEM SOC, V160, pF750, DOI 10.1149/2.017308jes
   Chen GY, 2017, INT J HYDROGEN ENERG, V42, P29960, DOI 10.1016/j.ijhydene.2017.06.229
   Chevalier S, 2018, RENEW ENERG, V125, P738, DOI 10.1016/j.renene.2018.02.120
   Cimenti M, 2010, ECS TRANSACTIONS, V28, P147, DOI 10.1149/1.3502346
   COMSOL Multiphysics, 2017, BATT FUEL CELLS MOD
   Cussler E. L., 2009, DIFFUSION MASS TRANS
   Eikerling M, 1998, J ELECTROANAL CHEM, V453, P89, DOI 10.1016/S0022-0728(98)00214-9
   Epting WK, 2012, ADV FUNCT MATER, V22, P555, DOI 10.1002/adfm.201101525
   FERRELL RT, 1967, J CHEM ENG DATA, V12, P111, DOI 10.1021/je60032a036
   Haji S, 2011, RENEW ENERG, V36, P451, DOI 10.1016/j.renene.2010.07.007
   Han IS, 2017, INT J HYDROGEN ENERG, V42, P7023, DOI 10.1016/j.ijhydene.2017.01.131
   Han IS, 2016, KOREAN J CHEM ENG, V33, P3121, DOI 10.1007/s11814-016-0157-8
   Harvey D, 2008, J POWER SOURCES, V179, P209, DOI 10.1016/j.jpowsour.2007.12.077
   Jaouen F, 2002, J ELECTROCHEM SOC, V149, pA437, DOI 10.1149/1.1456916
   Khajeh-Hosseini-Dalasm N, 2012, ELECTROCHIM ACTA, V60, P55, DOI 10.1016/j.electacta.2011.10.099
   Kreuer KD, 2001, J MEMBRANE SCI, V185, P29, DOI 10.1016/S0376-7388(00)00632-3
   Kulikovsky AA, 2014, ELECTROCHIM ACTA, V130, P826, DOI 10.1016/j.electacta.2014.03.131
   Kulikovsky AA, 2011, ELECTROCHEM COMMUN, V13, P1395, DOI 10.1016/j.elecom.2011.08.019
   Kulikovsky AA, 2010, ELECTROCHIM ACTA, V55, P6391, DOI 10.1016/j.electacta.2010.06.053
   Kulikovsky AA, 2002, ELECTROCHEM COMMUN, V4, P318, DOI 10.1016/S1388-2481(02)00275-8
   Kulikovsky AA, 2004, ELECTROCHEM COMMUN, V6, P729, DOI 10.1016/j.elecom.2004.05.015
   Larminie James, 2003, FUEL CELL SYSTEMS EX
   Liu YX, 2009, J ELECTROCHEM SOC, V156, pB970, DOI 10.1149/1.3143965
   Makharia R, 2005, J ELECTROCHEM SOC, V152, pA970, DOI 10.1149/1.1888367
   Mann RF, 2000, J POWER SOURCES, V86, P173, DOI 10.1016/S0378-7753(99)00484-X
   Marquis J, 2013, CHEM ENG SCI, V102, P151, DOI 10.1016/j.ces.2013.08.003
   Mashio T., 2007, ECS T, V11, P529
   Neyerlin KC, 2006, J ELECTROCHEM SOC, V153, pA1955, DOI 10.1149/1.2266294
   Neyerlin KC, 2005, J ELECTROCHEM SOC, V152, pA1073, DOI 10.1149/1.1897368
   Nonoyama N, 2011, J ELECTROCHEM SOC, V158, pB416, DOI 10.1149/1.3546038
   Perry ML, 1998, J ELECTROCHEM SOC, V145, P5, DOI 10.1149/1.1838202
   Reshetenko TV, 2014, J ELECTROCHEM SOC, V161, pF1089, DOI 10.1149/2.1021410jes
   Sambandam S, 2010, PHYS CHEM CHEM PHYS, V12, P6140, DOI 10.1039/b921916a
   SPRINGER TE, 1993, J ELECTROCHEM SOC, V140, P3513, DOI 10.1149/1.2221120
   Sun W, 2005, ELECTROCHIM ACTA, V50, P3359, DOI 10.1016/j.electacta.2004.12.009
   Thosar AU, 2019, CHEM ENG SCI, V196, P166, DOI 10.1016/j.ces.2018.10.048
   Thosar AU, 2018, CHEM ENG SCI, V190, P333, DOI 10.1016/j.ces.2018.06.025
   Wang Y, 2011, APPL ENERG, V88, P981, DOI 10.1016/j.apenergy.2010.09.030
   Weber AZ, 2014, J ELECTROCHEM SOC, V161, pF1254, DOI 10.1149/2.0751412jes
   Yu HR, 2018, J ELECTROCHEM SOC, V165, pF272, DOI 10.1149/2.0261805jes
NR 45
TC 2
Z9 2
U1 21
U2 115
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 96
EP 117
DI 10.1016/j.ces.2019.05.022
PG 22
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700008
DA 2020-05-12
ER

PT J
AU Ahamed, F
   Song, HS
   Ooi, CW
   Ho, YK
AF Ahamed, Firnaaz
   Song, Hyun-Seob
   Ooi, Chien Wei
   Ho, Yong Kuen
TI Modelling heterogeneity in cellulose properties predicts the slowdown
   phenomenon during enzymatic hydrolysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Enzymatic hydrolysis; Cellulose; Mechanistic modelling; Population
   balance model; Cellulose morphology
ID PORE-SIZE DISTRIBUTION; CHAIN-END SCISSION; POPULATION BALANCE;
   MECHANISTIC MODEL; CELLOBIOHYDROLASE-I; KINETIC-MODEL; SUBSTRATE;
   SACCHARIFICATION; DEPOLYMERIZATION; BIOETHANOL
AB Fine control of the enzymatic hydrolysis of cellulose is challenging due to complex process dynamics. Rate of conversion of cellulose to valuable monomeric products is often significantly slowed down after an initial rapid but short-lived phase. Underlying mechanisms for this process have yet to be fully understood and as a result poorly represented in existing models. Here, we propose a new modelling platform termed Multi-Layered Population Balance Model (ML-PBM), which enables various key aspects of cellulose enzymatic hydrolysis occurring over the entire breakdown process to be captured. As a core component for predicting the slowdown phenomenon, the ML-PBM properly accounts for heterogeneity in cellulose crystallinity and chain lengths across the structural layers of cellulose particles with different morphologies. Beyond a decent quantitative fit to highly nonlinear dynamic experimental data collected across different conditions, the ML-PBM reveals that the rate slowdown phenomenon is potentially due to heterogeneity in cellulose properties coupled with cellulose morphology. Equipped with the unification of various process fundamentals, the ML-PBM is a rational framework with the potential to facilitate sound cellulose engineering. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ahamed, Firnaaz; Ooi, Chien Wei; Ho, Yong Kuen] Monash Univ Malaysia, Chem Engn Discipline, Sch Engn, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
   [Song, Hyun-Seob] Pacific Northwest Natl Lab, Biol Sci Div, Richland, WA 99352 USA.
   [Ho, Yong Kuen] Monash Univ Malaysia, Monash Ind Palm Oil Educ & Res Platform, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
RP Ho, YK (reprint author), Monash Univ Malaysia, Chem Engn Discipline, Sch Engn, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
EM ho.yongkuen@monash.edu
RI Ahamed, Firnaaz/V-3757-2019
OI Ahamed, Firnaaz/0000-0002-9251-5516
CR Bansal P, 2009, BIOTECHNOL ADV, V27, P833, DOI 10.1016/j.biotechadv.2009.06.005
   Bezerra RMF, 2004, APPL BIOCHEM BIOTECH, V112, P173, DOI 10.1385/ABAB:112:3:173
   Bezerra RMF, 2006, APPL BIOCHEM BIOTECH, V134, P27, DOI 10.1385/ABAB:134:1:27
   Binod P, 2010, BIORESOURCE TECHNOL, V101, P4767, DOI 10.1016/j.biortech.2009.10.079
   Bommarius AS, 2008, METAB ENG, V10, P370, DOI 10.1016/j.ymben.2008.06.008
   Brun R, 2001, WATER RESOUR RES, V37, P1015, DOI 10.1029/2000WR900350
   Chakraborty S, 2010, IND ENG CHEM RES, V49, P10818, DOI 10.1021/ie100466h
   Chundawat SPS, 2011, ANNU REV CHEM BIOMOL, V2, P121, DOI 10.1146/annurev-chembioeng-061010-114205
   Cohen R, 2005, APPL ENVIRON MICROB, V71, P2412, DOI 10.1128/AEM.71.5.2412-2417.2005
   Cruys-Bagger N, 2013, BIOCHEMISTRY-US, V52, P8938, DOI 10.1021/bi401210n
   Desai SG, 1997, BIOTECHNOL BIOENG, V56, P650, DOI 10.1002/(SICI)1097-0290(19971220)56:6<650::AID-BIT8>3.0.CO;2-M
   Eibinger M, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0463-8
   Engel P, 2012, BIOTECHNOL BIOFUELS, V5, DOI 10.1186/1754-6834-5-77
   Eriksson T, 2002, APPL BIOCHEM BIOTECH, V101, P41, DOI 10.1385/ABAB:101:1:41
   EVANS R, 1989, J APPL POLYM SCI, V37, P3291, DOI 10.1002/app.1989.070371202
   Bezerra RMF, 2011, APPL BIOCHEM BIOTECH, V165, P178, DOI 10.1007/s12010-011-9242-y
   Gaikwad A, 2018, CHEM ENG COMMUN, V205, P47, DOI 10.1080/00986445.2017.1371015
   Gaikwad A, 2013, IND ENG CHEM RES, V52, P3988, DOI 10.1021/ie301234b
   Gao DH, 2013, P NATL ACAD SCI USA, V110, P10922, DOI 10.1073/pnas.1213426110
   GRETHLEIN HE, 1985, BIO-TECHNOL, V3, P155, DOI 10.1038/nbt0285-155
   Griggs AJ, 2012, BIOTECHNOL BIOENG, V109, P665, DOI 10.1002/bit.23355
   Griggs AJ, 2012, BIOTECHNOL BIOENG, V109, P676, DOI 10.1002/bit.23354
   Hall M, 2010, FEBS J, V277, P1571, DOI 10.1111/j.1742-4658.2010.07585.x
   Ho YK, 2018, CAN J CHEM ENG, V96, P800, DOI 10.1002/cjce.22957
   Ho YK, 2018, CHEM ENG SCI, V176, P329, DOI 10.1016/j.ces.2017.10.027
   Ho YK, 2015, IND ENG CHEM RES, V54, P10228, DOI 10.1021/acs.iecr.5b01667
   Ho YK, 2015, BIOTECHNOL BIOENG, V112, P2084, DOI 10.1002/bit.25616
   Ho YK, 2014, CHEM ENG SCI, V116, P601, DOI 10.1016/j.ces.2014.05.035
   Hosseini SA, 2011, BIOMASS BIOENERG, V35, P3841, DOI 10.1016/j.biombioe.2011.04.026
   Hosseini SA, 2011, BIOMASS BIOENERG, V35, P3830, DOI 10.1016/j.biombioe.2011.04.029
   Huron M, 2016, BIOTECHNOL BIOENG, V113, P1011, DOI 10.1002/bit.25873
   Igarashi K, 2009, J BIOL CHEM, V284, P36186, DOI 10.1074/jbc.M109.034611
   Jacobsen SE, 2000, APPL BIOCHEM BIOTECH, V84-6, P81, DOI 10.1385/ABAB:84-86:1-9:81
   Jeoh T, 2007, BIOTECHNOL BIOENG, V98, P112, DOI 10.1002/bit.21408
   Jeoh T, 2017, BIOTECHNOL BIOENG, V114, P1369, DOI 10.1002/bit.26277
   Kadam KL, 2004, BIOTECHNOL PROGR, V20, P698, DOI 10.1021/bp034316x
   Kadam KL, 2003, BIORESOURCE TECHNOL, V88, P17, DOI 10.1016/S0960-8524(02)00269-9
   Keshwani DR, 2009, BIORESOURCE TECHNOL, V100, P1515, DOI 10.1016/j.biortech.2008.09.035
   Kirse C, 2015, COMPUT CHEM ENG, V73, P154, DOI 10.1016/j.compchemeng.2014.11.008
   Kumar D., 2016, ENZYMATIC HYDROLYSIS
   Kumar D, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-63
   Larsson PT, 1997, CARBOHYD RES, V302, P19, DOI 10.1016/S0008-6215(97)00130-4
   Lebaz N, 2016, CHEM ENG SCI, V149, P322, DOI 10.1016/j.ces.2016.04.029
   Lebaz N, 2016, CHEM ENG SCI, V149, P306, DOI 10.1016/j.ces.2016.04.018
   Lebaz N, 2015, CAN J CHEM ENG, V93, P276, DOI 10.1002/cjce.22088
   LEVI M. P., 1967, CARBOHYD RES, V5, P351, DOI 10.1016/S0008-6215(00)80513-3
   Levine SE, 2010, BIOTECHNOL BIOENG, V107, P37, DOI 10.1002/bit.22789
   Luterbacher JS, 2015, BIOTECHNOL BIOENG, V112, P21, DOI 10.1002/bit.25329
   Luterbacher JS, 2013, BIOTECHNOL BIOENG, V110, P127, DOI 10.1002/bit.24614
   LYND LR, 1991, SCIENCE, V251, P1318, DOI 10.1126/science.251.4999.1318
   Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002
   Maurer SA, 2013, J COLLOID INTERF SCI, V394, P498, DOI 10.1016/j.jcis.2012.12.022
   Medve J, 1998, BIOTECHNOL BIOENG, V59, P621, DOI 10.1002/(SICI)1097-0290(19980905)59:5&lt;621::AID-BIT13&gt;3.0.CO;2-C
   Nag A, 2015, BIOTECHNOL PROGR, V31, P1237, DOI 10.1002/btpr.2122
   Nill J, 2018, PROCESS BIOCHEM, V74, P108, DOI 10.1016/j.procbio.2018.07.006
   Niu HX, 2016, BIOCHEM ENG J, V105, P455, DOI 10.1016/j.bej.2015.10.017
   Olsson L., 2004, POLYSACCHARIDES STRU, P957
   OSullivan AC, 1997, CELLULOSE, V4, P173, DOI 10.1023/A:1018431705579
   Peri S, 2007, BIOTECHNOL PROGR, V23, P626, DOI 10.1021/bp060322s
   Pino MS, 2018, CHEM ENG J, V347, P119, DOI 10.1016/j.cej.2018.04.057
   Praestgaard E, 2011, FEBS J, V278, P1547, DOI 10.1111/j.1742-4658.2011.08078.x
   Rosenau T, 2006, ADV POLYM SCI, V205, P153, DOI 10.1007/12_098
   Samejima M, 1997, CARBOHYD RES, V305, P281, DOI 10.1016/S0008-6215(97)10034-9
   Shang BZ, 2013, J BIOL CHEM, V288, P29081, DOI 10.1074/jbc.M113.497412
   Pino MS, 2019, CARBOHYD POLYM, V211, P349, DOI 10.1016/j.carbpol.2019.01.111
   Song HS, 2012, BIOETHANOL, P173
   Talebnia F, 2010, BIORESOURCE TECHNOL, V101, P4744, DOI 10.1016/j.biortech.2009.11.080
   TANAKA M, 1988, BIOTECHNOL BIOENG, V32, P698, DOI 10.1002/bit.260320515
   Teeri TT, 1997, TRENDS BIOTECHNOL, V15, P160, DOI 10.1016/S0167-7799(97)01032-9
   Tervasmaki P, 2017, BIORESOURCE TECHNOL, V227, P112, DOI 10.1016/j.biortech.2016.12.054
   Wyman C., 2004, POLYSACCHARIDES STRU, P995, DOI DOI 10.1201/9781420030822.CH43
   Zhang LB, 2017, SCI REP-UK, V7, DOI 10.1038/srep44319
   Zhang S, 1999, BIOTECHNOL BIOENG, V66, P35, DOI 10.1002/(SICI)1097-0290(1999)66:1&lt;35::AID-BIT3&gt;3.0.CO;2-G
   Zhang YHP, 2004, BIOTECHNOL BIOENG, V88, P797, DOI 10.1002/bit.20282
NR 74
TC 1
Z9 1
U1 1
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 118
EP 133
DI 10.1016/j.ces.2019.05.028
PG 16
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700009
DA 2020-05-12
ER

PT J
AU Fan, C
   Guo, SM
   Jin, H
AF Fan, Chao
   Guo, Simao
   Jin, Hui
TI Numerical study on coal gasification in supercritical water fluidized
   bed and exploration of complete gasification under mild temperature
   conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supercritical water gasification; Fluidized bed; Field distribution;
   Alkali salt catalyst; Reactor optimization
ID HYDROGEN-PRODUCTION; STEAM GASIFICATION; CATALYTIC GASIFICATION; BIOMASS
   GASIFICATION; HEAT-TRANSFER; REACTOR; K2CO3; PARTICLE; KINETICS; WASTES
AB Supercritical water fluidized bed is a promising reactor for the industrial application of the technology of supercritical water gasification of coal. In this work, a numerical model of lignite gasification in SCWFB considering flow, heat transfer and gasification reaction was established, and the Euler-Lagrange method and RNG k-epsilon model were used. Through this model, the multi-field distribution characteristics and developing rules were studied under wide temperature range. A low-temperature zone with uneven circumferential temperature distribution was found below the feed inlet, and the average residence time decreased with the increase of reactor temperature. Steam reforming of solid residual carbon was the bottleneck of complete gasification, and the alkali salt catalyst can accelerate its reaction rate and cause the reaction zone to move to the lower fluidization section. Besides, the simulated results show that the extension of the reactor length was an effective means to improve the carbon gasification efficiency, and the increase of the feed inlet height can avoid the blockage of distributor. Based on both the catalyst addition and reactor structure optimization, a scheme was proposed where the complete gasification of lignite at 750 degrees C was achieved with H-2 promotion promoted. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fan, Chao; Guo, Simao; Jin, Hui] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn SKLMF, 28 Xianning West Rd, Xian 710049, Shaanxi, Peoples R China.
   [Guo, Simao] China Acad Engn Phys, Inst Nucl Phys & Chem, Mianyang 621900, Sichuan, Peoples R China.
RP Jin, H (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn SKLMF, 28 Xianning West Rd, Xian 710049, Shaanxi, Peoples R China.
EM jinhui@mail.xjtu.edu.cn
RI Jin, Hui/N-9892-2014
OI Jin, Hui/0000-0001-9216-7921
FU National Key R&D Program of China [2016YFB0600100]
FX This work was financially supported by the National Key R&D Program of
   China [Grant number 2016YFB0600100].
CR Bai B, 2019, RENEW ENERG, V135, P32, DOI 10.1016/j.renene.2018.11.092
   Bo Y., 2007, J ENVIRON SCI, V19, P1424
   Brunner G, 2009, J SUPERCRIT FLUID, V47, P373, DOI 10.1016/j.supflu.2008.09.002
   Chen YA, 2013, INT J HYDROGEN ENERG, V38, P12991, DOI 10.1016/j.ijhydene.2013.03.165
   Jarana MBG, 2008, J SUPERCRIT FLUID, V46, P329, DOI 10.1016/j.supflu.2008.03.002
   Ge ZW, 2014, INT J HYDROGEN ENERG, V39, P19583, DOI 10.1016/j.ijhydene.2014.09.119
   GORBATY YE, 1995, J PHYS CHEM-US, V99, P5336, DOI 10.1021/j100015a016
   Guo LJ, 2015, J SUPERCRIT FLUID, V96, P144, DOI 10.1016/j.supflu.2014.09.023
   Guo SM, 2013, J SUPERCRIT FLUID, V78, P95, DOI 10.1016/j.supflu.2013.03.025
   Guo Y, 2010, RENEW SUST ENERG REV, V14, P334, DOI 10.1016/j.rser.2009.08.012
   Jin H., 2018, J POROUS MED, V21, P1319
   Jin H, 2018, J SUPERCRIT FLUID, V136, P102, DOI 10.1016/j.supflu.2018.02.016
   Jin H, 2017, ENERG CONVERS MANAGE, V145, P214, DOI 10.1016/j.enconman.2017.04.102
   Jin H, 2016, THERM SCI, V20, pS895, DOI 10.2298/TSCI16S3895J
   Jin H, 2015, ENERG FUEL, V29, P8053, DOI 10.1021/acs.energyfuels.5b02014
   Jin H, 2016, J SUPERCRIT FLUID, V107, P526, DOI 10.1016/j.supflu.2015.06.028
   Kopyscinski J, 2014, FUEL, V128, P210, DOI 10.1016/j.fuel.2014.03.014
   Lan RH, 2014, ENERG FUEL, V28, P6911, DOI 10.1021/ef502050p
   Li YL, 2010, INT J HYDROGEN ENERG, V35, P3036, DOI 10.1016/j.ijhydene.2009.07.023
   Lu YJ, 2008, INT J HYDROGEN ENERG, V33, P6066, DOI 10.1016/j.ijhydene.2008.07.082
   Lu YJ, 2016, APPL THERM ENG, V93, P200, DOI 10.1016/j.applthermaleng.2015.09.026
   Lu YJ, 2015, CHEM ENG RES DES, V104, P164, DOI 10.1016/j.cherd.2015.08.005
   Lu YJ, 2015, APPL THERM ENG, V88, P297, DOI 10.1016/j.applthermaleng.2014.09.052
   Lu YJ, 2014, CHEM ENG SCI, V117, P283, DOI 10.1016/j.ces.2014.06.032
   Lu YJ, 2013, INT J MULTIPHAS FLOW, V49, P78, DOI 10.1016/j.ijmultiphaseflow.2012.10.005
   Matsumura Y, 2004, INT J HYDROGEN ENERG, V29, P701, DOI 10.1016/j.ijhydene.2003.09.005
   Nanda S, 2016, ENERG CONVERS MANAGE, V110, P296, DOI 10.1016/j.enconman.2015.11.060
   Su XH, 2016, ENERG FUEL, V30, P9028, DOI 10.1021/acs.energyfuels.6b01557
   Su XH, 2015, CHEM ENG SCI, V134, P737, DOI 10.1016/j.ces.2015.05.034
   Su XH, 2015, INT J HYDROGEN ENERG, V40, P7424, DOI 10.1016/j.ijhydene.2015.02.110
   Wagner W, 2000, J ENG GAS TURB POWER, V122, P150, DOI 10.1115/1.483186
   Wang J, 2010, FUEL, V89, P310, DOI 10.1016/j.fuel.2009.09.001
   Wang J, 2009, FUEL, V88, P1572, DOI 10.1016/j.fuel.2008.12.017
   Wang T, 2003, FUEL, V82, P2267, DOI 10.1016/S0016-2361(03)00167-4
   Weingartner H, 2005, ANGEW CHEM INT EDIT, V44, P2672, DOI 10.1002/anie.200462468
   Yao L, 2017, INT J HYDROGEN ENERG, V42, P7857, DOI 10.1016/j.ijhydene.2017.03.009
   Zhao X, 2019, INT J HEAT MASS TRAN, V133, P718, DOI 10.1016/j.ijheatmasstransfer.2018.12.164
NR 37
TC 6
Z9 6
U1 21
U2 70
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 134
EP 145
DI 10.1016/j.ces.2019.05.041
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700010
DA 2020-05-12
ER

PT J
AU Cao, J
   Song, T
   Wang, XJ
   Zhu, YJ
   Wang, SS
   Zhao, MT
   Miao, YJ
   Zhang, J
AF Cao, Jie
   Song, Tao
   Wang, Xiujun
   Zhu, Yuejun
   Wang, Shanshan
   Zhao, Mitao
   Miao, Yungjing
   Zhang, Jian
TI Studies on the rheological properties of amphiphilic nanosilica and a
   partially hydrolyzed polyacrylamide hybrid for enhanced oil recovery
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE HPAM; Amphiphilic nanosilica; Polymer flooding; Enhanced oil recovery;
   Heat and salt resistance
ID AMINO-FUNCTIONALIZED NANOSILICA; ACRYLAMIDE-BASED POLYMER; SILICA
   NANOPARTICLES; THERMAL-STABILITY; RAMAN-SPECTROSCOPY; IONS AFFECT;
   WATER; BEHAVIOR; MORPHOLOGY; PHASE
AB Because amide groups can be easily hydrolyzed to carboxyl groups at high temperature, polyacrylamide (PAM) and its derivatives cannot be applied to high temperature and salinity reservoirs. To solve this problem, a new kind of surface modified nanosilica with different functional groups, including amine and octyl groups, was prepared in this article. Benefiting from its structure, the viscosity of the nanosilica/polymer solution increased by 26.08% when the degree of hydrolysis was high (degree of hydrolysis 47.5%, to simulate the HPAM solution after experiencing long-term flooding), whereas the viscosity of the nanosilica/polymer solution only increased by 0.26% when the degree of hydrolysis was low (degree of hydrolysis 17.8%, to simulate the HPAM solution at the beginning of polymer flooding). In core flooding experiments, the polymer/nanosilica hybrid solution exhibited a higher oil recovery factor (17.30%) than the polymer solution (5.00%). Enhanced oil recovery (EOR) mechanisms were systematically investigated by carrying out rheological measurements, visualization tests of polymer flooding, and interfacial activity and long-term stability analyses. The excellent performance of the nanosilica/polymer solution could be attributed to the high interfacial activity of nanosilica and the strong electrostatic and hydrophobic interactions between nanosilica and polymer chains. These results indicate that the nanosilica/polymer hybrid solution could be an effective oil-displacing agent. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cao, Jie; Song, Tao; Zhao, Mitao; Miao, Yungjing] China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
   [Cao, Jie; Song, Tao; Zhao, Mitao; Miao, Yungjing] China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Shandong, Peoples R China.
   [Wang, Xiujun; Zhu, Yuejun; Wang, Shanshan; Zhang, Jian] State Key Lab Offshore Oil Exploitat, Beijing 100027, Peoples R China.
   [Wang, Xiujun; Zhu, Yuejun; Wang, Shanshan; Zhang, Jian] CNOOC Res Inst Co Ltd, Beijing 100027, Peoples R China.
RP Cao, J (reprint author), China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.; Zhang, J (reprint author), State Key Lab Offshore Oil Exploitat, Beijing 100027, Peoples R China.
EM jcao@upc.edu.cu; zhangjian@cnooc.com.cn
RI Song, Tao/AAB-8036-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874347, 21607174, U1762212]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [17CX02053]; Shandong Provincial Natural Science
   Foundation, ChinaNatural Science Foundation of Shandong Province
   [ZR2019MEE037]
FX The authors appreciate the financial support from the National Natural
   Science Foundation of China (51874347, 21607174 and U1762212), the
   Fundamental Research Funds for the Central Universities (17CX02053), and
   the Shandong Provincial Natural Science Foundation, China
   (ZR2019MEE037).
CR Ahmadi MA, 2016, PETROL SCI TECHNOL, V34, P1048, DOI 10.1080/10916466.2016.1148052
   Ahmed M, 2013, J PHYS CHEM B, V117, P16479, DOI 10.1021/jp4100697
   Bagwe RP, 2006, LANGMUIR, V22, P4357, DOI 10.1021/la052797j
   Bera A, 2016, J NAT GAS SCI ENG, V34, P1284, DOI 10.1016/j.jngse.2016.08.023
   Bradna B, 1997, ACTA POLYM, V48, P446, DOI 10.1002/actp.1997.010481005
   Cao J, 2018, RSC ADV, V8, P38056, DOI 10.1039/c8ra07076h
   Cao J, 2018, ENERG FUEL, V32, P246, DOI 10.1021/acs.energyfuels.7b03053
   Clarke A, 2016, SPE J, V21, P675, DOI 10.2118/174654-PA
   Cui J, 2017, COLLOID SURFACE A, V529, P346, DOI 10.1016/j.colsurfa.2017.05.090
   Delshad M., 2008, MECH INTERPRETATION
   Deng YJ, 2006, COLLOID SURFACE A, V281, P82, DOI 10.1016/j.colsurfa.2006.02.030
   Diasty E., 2015, SPE N AFR TECHN C EX
   Dugas V, 2011, LANGMUIR, V27, P14188, DOI 10.1021/la2029438
   Feng YJ, 2005, POLYMER, V46, P9283, DOI 10.1016/j.polymer.2005.07.054
   Fletcher A., 2010, SPE IMPR OIL REC S T
   Hribar B, 2002, J AM CHEM SOC, V124, P12302, DOI 10.1021/ja026014h
   Hu ZL, 2017, IND ENG CHEM RES, V56, P3456, DOI 10.1021/acs.iecr.6b05036
   Huang XB, 2019, MATER LETT, V248, P146, DOI 10.1016/j.matlet.2019.04.005
   Ikushima Y, 1998, CHEM PHYS, V238, P455, DOI 10.1016/S0301-0104(98)00339-5
   Jia H, 2019, CHEM ENG SCI, V202, P75, DOI 10.1016/j.ces.2019.03.036
   Karimi A., 2016, ENERG FUEL, V26, P1028
   Kennedy JRM, 2015, MAT SCI ENG C-MATER, V48, P347, DOI 10.1016/j.msec.2014.12.040
   Levin DB, 2011, SPE RESERV EVAL ENG, V14, P281, DOI 10.2118/129879-PA
   Li H, 2010, J CHROMATOGR A, V1217, P7448, DOI 10.1016/j.chroma.2010.09.050
   Lu HS, 2010, J MACROMOL SCI A, V47, P602, DOI 10.1080/10601321003742105
   Ma H, 2008, PHYS CHEM CHEM PHYS, V10, P2207, DOI 10.1039/b718427c
   Maghzi A, 2014, FUEL, V123, P123, DOI 10.1016/j.fuel.2014.01.017
   Maurya NK, 2017, J TAIWAN INST CHEM E, V70, P319, DOI 10.1016/j.jtice.2016.10.021
   McElwee J, 2005, J COLLOID INTERF SCI, V285, P551, DOI 10.1016/j.jcis.2004.12.006
   Muggeridge A, 2014, PHILOS T R SOC A, V372, DOI 10.1098/rsta.2012.0320
   Okay O, 2007, MACROMOLECULES, V40, P3378, DOI 10.1021/ma062929v
   OLEA AF, 1989, MACROMOLECULES, V22, P1165, DOI 10.1021/ma00193a029
   ONG SW, 1992, CHEM PHYS LETT, V191, P327, DOI 10.1016/0009-2614(92)85309-X
   Oweini R., 2009, J MOL STRUCT, V4, P3
   Patel CM, 2015, PARTICUL SCI TECHNOL, V33, P240, DOI 10.1080/02726351.2014.978425
   Portehault D, 2006, COLLOID SURFACE A, V278, P26, DOI 10.1016/j.colsurfa.2005.11.089
   Qiao B, 2015, APPL SURF SCI, V351, P646, DOI 10.1016/j.apsusc.2015.05.174
   Rezaei A, 2016, J MOL LIQ, V222, P1148, DOI 10.1016/j.molliq.2016.08.004
   Schmatz J, 2017, SPE J, V22, P1374, DOI 10.2118/180049-PA
   SCOGGINS MW, 1979, SOC PETROL ENG J, V19, P151, DOI 10.2118/7664-PA
   Sheng JJ, 2015, J CAN PETROL TECHNOL, V54, P116, DOI 10.2118/174541-PA
   Sheng JJ, 2013, ASIA-PAC J CHEM ENG, V8, P555, DOI 10.1002/apj.1696
   Shokrlu YH, 2014, J PETROL SCI ENG, V119, P210, DOI 10.1016/j.petrol.2014.05.012
   TAYLOR KC, 1994, J PETROL SCI ENG, V12, P9, DOI 10.1016/0920-4105(94)90003-5
   Terpilowski K, 2015, J IND ENG CHEM, V30, P71, DOI 10.1016/j.jiec.2015.05.003
   Valle-Vigon P, 2012, APPL SURF SCI, V261, P574, DOI 10.1016/j.apsusc.2012.08.059
   Wang D., 2011, SPE ENH OIL REC C KU
   Wang Demin, 2000, ACTA PETROLEI SINICA, V21, P45, DOI DOI 10.7623/SYXB
   Wasan DT, 2003, NATURE, V423, P156, DOI 10.1038/nature01591
   Wisniewska M, 2010, J THERM ANAL CALORIM, V101, P753, DOI 10.1007/s10973-010-0888-4
   Wu YN, 2019, IND ENG CHEM RES, V58, P3707, DOI 10.1021/acs.iecr.8b06057
   Zheng C, 2017, COLLOID SURFACE A, V524, P169, DOI 10.1016/j.colsurfa.2017.04.026
   Zhu DY, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40282
NR 53
TC 7
Z9 7
U1 26
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 146
EP 155
DI 10.1016/j.ces.2019.05.034
PG 10
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700011
DA 2020-05-12
ER

PT J
AU Xu, XM
   Li, XB
   Zhou, QS
   Qi, TG
   Zhou, KC
   Liu, GH
   Peng, ZH
AF Xu, Xiangming
   Li, Xiaobin
   Zhou, Qiusheng
   Qi, Tiangui
   Zhou, Kechao
   Liu, Guihua
   Peng, Zhihong
TI Equilibrium WO3 concentration in the Ca2+-(NH4)(2)CO3-(NH4)(2)
   WO4-NH3-H2O system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermodynamics; Leaching; Ammonium tungstate solution; Ammoniacal
   ammonium carbonate solution; CaWO4; CaCO3
ID VAPOR-LIQUID-EQUILIBRIA; TUNGSTEN-CONTAINING MATERIALS; AMMONIUM
   CARBONATE SOLUTION; GIBBS FREE-ENERGY; CALCIUM-CARBONATE; SULFURIC-ACID;
   SCHEELITE CONCENTRATE; OSMOTIC COEFFICIENTS; AQUEOUS-SOLUTIONS; CO2
   CAPTURE
AB The Ca2+-(NH4)(2)CO3-(NH4)(2)WO4-NH3-H2O system is a typical system in tungsten extractive metallurgy used in the preparation and purification of ammonium tungstate solution. To determine an appropriate solution composition to optimize these processes, a thermodynamic model combined with the Pitzer activity equations was developed. This model allowed us to predict the dependence of the equilibrium WO3 concentration on the compositions of the solution in the Ca2+-(NH4)(2)CO3-(NH4)(2)WO4-NH3-H2O system. Thermodynamic analyses clarified the stable regions of CaCO3 and CaWO4 in the Ca2+-(NH4)(2)CO3-(NH4)(2)WO4-NH3-H2O system and indicated that increasing both the total NH3 and total CO2 concentrations is beneficial for increasing the equilibrium WO3 concentration. The experimental results confirm that the thermodynamic model offers a means of predicting the equilibrium concentrations of species in the system. Furthermore, the equilibrium WO3 concentrations of the solution of the Ca2+-(NH4)(2)CO3-(NH4)(2)WO4-NH3-H2O system at 298.15 K have been predicted at different total CO2 concentrations, as well as different total NH3 to total CO2 concentration ratios. Thus, the findings of this study will not only help determine the appropriate composition of the leaching system for preparing ammonium tungstate solutions, but also provide a reference for purifying ammonium tungstate solutions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Xiangming; Zhou, Kechao] Cent S Univ, Powder Met Res Inst, Changsha 410083, Hunan, Peoples R China.
   [Xu, Xiangming; Li, Xiaobin; Zhou, Qiusheng; Qi, Tiangui; Liu, Guihua; Peng, Zhihong] Cent S Univ, Sch Met & Environm, Changsha 410083, Hunan, Peoples R China.
RP Li, XB; Zhou, QS (reprint author), Cent S Univ, Sch Met & Environm, Changsha 410083, Hunan, Peoples R China.
EM x.b.li@csu.edu.cn; qszhou@csu.edu.cn
RI ZHOU, Qiusheng/L-1904-2018
OI ZHOU, Qiusheng/0000-0003-0159-0041
FU China Postdoctoral Science Foundation, ChinaChina Postdoctoral Science
   Foundation [2017M622603]; Postdoctoral Foundation of Central South
   University, China [140050011]; National Natural Science Foundation of
   China, ChinaNational Natural Science Foundation of China [51874372]
FX This work was supported by the China Postdoctoral Science Foundation,
   China (2017M622603), the Postdoctoral Foundation of Central South
   University, China (No. 140050011), and the National Natural Science
   Foundation of China, China (No. 51874372).
CR Ahn CK, 2011, INT J GREENH GAS CON, V5, P1606, DOI 10.1016/j.ijggc.2011.09.007
   Chen T, 2006, CHEM ENG SCI, V61, P5318, DOI 10.1016/j.ces.2006.04.007
   Ding Z., 2004, RARE MET CEMENT CARB, V3, P8
   EDWARDS TJ, 1978, AICHE J, V24, P966, DOI 10.1002/aic.690240605
   Gaur RPS, 2006, JOM-US, V58, P45, DOI 10.1007/s11837-006-0082-0
   HARVIE CE, 1984, GEOCHIM COSMOCHIM AC, V48, P723, DOI 10.1016/0016-7037(84)90098-X
   Hosoda N, 2003, MACROMOLECULES, V36, P6449, DOI 10.1021/ma025869b
   Jun K., 2009, J PHYS CONDENS MATT, V21
   KAWAZUISHI K, 1987, IND ENG CHEM RES, V26, P1482, DOI 10.1021/ie00067a036
   Konopacka-Lyskawa D, 2017, MATER CHEM PHYS, V193, P13, DOI 10.1016/j.matchemphys.2017.01.060
   Krop J, 1999, FLUID PHASE EQUILIBR, V163, P209, DOI 10.1016/S0378-3812(99)00225-3
   Lassner E., 1999, TUNGSTEN PROPERTIES
   Li H.G., 2010, TUNGSTEN METALLURGY
   Li JT, 2016, HYDROMETALLURGY, V163, P55, DOI 10.1016/j.hydromet.2016.03.009
   Li J, 2011, GEOCHIM COSMOCHIM AC, V75, P4351, DOI 10.1016/j.gca.2011.05.019
   Li XB, 2018, T NONFERR METAL SOC, V28, P1456, DOI 10.1016/S1003-6326(18)64784-3
   Li XB, 2017, HYDROMETALLURGY, V171, P106, DOI 10.1016/j.hydromet.2017.05.005
   Li XB, 2016, INT J REFRACT MET H, V60, P82, DOI 10.1016/j.ijrmhm.2016.07.007
   Li XB, 2016, INT J REFRACT MET H, V57, P93, DOI 10.1016/j.ijrmhm.2016.01.007
   Li XB, 2015, INT J REFRACT MET H, V52, P151, DOI 10.1016/j.ijrmhm.2015.06.003
   [刘明 Liu Ming], 2013, [过程工程学报, The Chinese Journal of Process Engineering], V13, P292
   MARCUS Y, 1994, BIOPHYS CHEM, V51, P111, DOI 10.1016/0301-4622(94)00051-4
   MARCUS Y, 1991, J CHEM SOC FARADAY T, V87, P2995, DOI 10.1039/ft9918702995
   Martins JP, 1996, HYDROMETALLURGY, V42, P221, DOI 10.1016/0304-386X(95)00099-3
   OSSEOASARE K, 1982, METALL TRANS B, V13, P555, DOI 10.1007/BF02650012
   Pitzer KS, 1974, J SOLUTION CHEM, V3, P539, DOI 10.1007/BF00648138
   PITZER KS, 1973, J PHYS CHEM-US, V77, P2300, DOI 10.1021/j100638a009
   PITZER KS, 1973, J PHYS CHEM-US, V77, P268, DOI 10.1021/j100621a026
   PLUMMER LN, 1982, GEOCHIM COSMOCHIM AC, V46, P1011, DOI 10.1016/0016-7037(82)90056-4
   Prah J, 2011, J CRYST GROWTH, V324, P229, DOI 10.1016/j.jcrysgro.2011.03.020
   Qin F, 2011, INT J GREENH GAS CON, V5, P405, DOI 10.1016/j.ijggc.2010.04.005
   Rodriguez-Ruiz I, 2018, CHEM ENG SCI, V183, P20, DOI 10.1016/j.ces.2018.03.007
   Schilde C, 2013, CHEM ENG SCI, V94, P127, DOI 10.1016/j.ces.2013.02.042
   Shen LT, 2018, J CLEAN PROD, V197, P690, DOI 10.1016/j.jclepro.2018.06.256
   Simoes MC, 2018, IND ENG CHEM RES, V57, P2346, DOI 10.1021/acs.iecr.7b04250
   Simoes MC, 2016, J CHEM ENG DATA, V61, P2536, DOI 10.1021/acs.jced.6b00236
   Speight J.G., 2005, LANGES HDB CHEM
   Srivastava SC, 1996, B MATER SCI, V19, P331, DOI 10.1007/BF02744670
   VADASDI K, 1995, INT J REFRACT MET H, V13, P45, DOI 10.1016/0263-4368(94)00032-8
   Villeneuve K, 2018, CHEM ENG SCI, V190, P345, DOI 10.1016/j.ces.2018.06.016
   Wan LS, 2015, HYDROMETALLURGY, V154, P17, DOI 10.1016/j.hydromet.2015.03.010
   Wan LS, 2015, INT J REFRACT MET H, V48, P301, DOI 10.1016/j.ijrmhm.2014.09.023
   WEN NP, 1995, J PHYS CHEM-US, V99, P359, DOI 10.1021/j100001a054
   Xu XM, 2019, HYDROMETALLURGY, V184, P55, DOI 10.1016/j.hydromet.2018.12.026
   Xu Y, 2014, INT J GREENH GAS CON, V31, P113, DOI 10.1016/j.ijggc.2014.09.018
   YATIRAJAM V, 1975, TALANTA, V22, P760, DOI 10.1016/0039-9140(75)80221-9
   Zhao Q, 2011, IND ENG CHEM RES, V50, P5316, DOI 10.1021/ie1010178
   Zhao Z. W., 2014, U.S. Patent, Patent No. 8771617
   Zhao ZW, 2011, HYDROMETALLURGY, V108, P152, DOI 10.1016/j.hydromet.2011.03.004
NR 49
TC 0
Z9 0
U1 5
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 156
EP 163
DI 10.1016/j.ces.2019.05.038
PG 8
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700012
DA 2020-05-12
ER

PT J
AU Li, GP
   Qi, RH
   Zhang, LZ
AF Li, Guo-Pei
   Qi, Rong-hui
   Zhang, Li-Zhi
TI Performance study of a solar-assisted hollow-fiber-membrane-based air
   humidification-dehumidification desalination system: Effects of membrane
   properties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Desalination; Solar-assisted; Hollow fiber membrane; Heat and moisture
   transfer; Membrane characteristics
ID DISTILLATION-BASED DESALINATION; MASS-TRANSFER; THERMAL EFFICIENCY;
   COMPOSITE MEMBRANE; HEAT-EXCHANGERS; CHALLENGES; EQUATIONS; ENERGY;
   SCALE; COST
AB Hollow-fiber membrane humidifiers were used in solar-assisted and membrane-based air humidification-dehumidification desalination systems (SMHDD) because of their greater packing density and thus better transfer efficiency. A dynamic mathematical model containing the major components of this system was established, including the membrane humidifier, dehumidifier and solar heating unit. The model was validated with test data from an experimental platform where three kinds of membranes with different membrane thickness, heat conductivity, etc., were tested. To understand the role of membrane characteristics in the proposed desalination system, the effects of the membrane moisture diffusivity (D-m), heat conductivity (lambda(m)), membrane thickness (delta(m)) and membrane area (A(tot)) on the system performance were analyzed numerically. Of the three factors, D-m and A(tot) show the most significant effect on the accumulated freshwater production (AP) and coefficient of performance (COP), and the effects of delta(m) on the system performance are far less pronounced than that of D-m and delta(m). In summary, membranes with higher moisture diffusivity and smaller thickness can improve system performance without much attention to the heat conductivity. However, further raising D-m above 3.0 x 10(6) m(2)/s has a slight benefit to the performance improvement. Findings in this paper are useful in guiding the preparation of membranes used for application-scale membrane-based desalination systems operating in real-world environmental conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Guo-Pei; Qi, Rong-hui; Zhang, Li-Zhi] South China Univ Technol, Sch Chem & Chem Engn, Educ Minist, Key Lab Enhanced Heat Transfer & Energy Conservat, Guangzhou 510640, Guangdong, Peoples R China.
   [Zhang, Li-Zhi] South China Univ Technol, State Key Lab Subtrop Bldg Sci, Guangzhou 510640, Guangdong, Peoples R China.
RP Zhang, LZ (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Educ Minist, Key Lab Enhanced Heat Transfer & Energy Conservat, Guangzhou 510640, Guangdong, Peoples R China.
EM Lzzhang@scut.edu.ch
FU National Key Research and Development Program [2017YFE0116100]; Key
   Project of Science and Technology Program of Guangzhou, China
   [201904020027]; National Science Fund for Distinguished Young Scholars
   of ChinaNational Natural Science Foundation of ChinaNational Science
   Fund for Distinguished Young Scholars [51425601]
FX This project is supported by the National Key Research and Development
   Program, No. 2017YFE0116100. It is also supported by the Key Project of
   Science and Technology Program of Guangzhou, China, No. 201904020027 and
   by the National Science Fund for Distinguished Young Scholars of China,
   No. 51425601.
CR Al-Obaidani S, 2008, J MEMBRANE SCI, V323, P85, DOI 10.1016/j.memsci.2008.06.006
   Ali MI, 2012, DESALINATION, V306, P60, DOI 10.1016/j.desal.2012.07.043
   Alklaibi AM, 2005, DESALINATION, V171, P111, DOI 10.1016/j.desal.2004.03.024
   Charfi K, 2010, DESALINATION, V259, P84, DOI 10.1016/j.desal.2010.04.028
   Comakli K, 2012, ENERG CONVERS MANAGE, V63, P112, DOI 10.1016/j.enconman.2012.01.031
   Ding ZW, 2005, DESALINATION, V172, P27, DOI 10.1016/j.desal.2004.06.195
   Duffle J. A., 1974, SOLAR ENERGY THERMAL
   ElDessouky H, 1995, DESALINATION, V103, P271, DOI 10.1016/0011-9164(95)00080-1
   Ghaffour N, 2013, DESALINATION, V309, P197, DOI 10.1016/j.desal.2012.10.015
   GNIELINSKI V, 1976, INT CHEM ENG, V16, P359
   Guttman I., 1965, INTRO ENG STAT
   JENNINGS SG, 1988, J AEROSOL SCI, V19, P159, DOI 10.1016/0021-8502(88)90219-4
   Karanikola V, 2015, J MEMBRANE SCI, V483, P15, DOI 10.1016/j.memsci.2015.02.010
   Khayet M, 2012, DESALINATION, V287, P138, DOI 10.1016/j.desal.2011.09.017
   Khayet M, 2000, J MEMBRANE SCI, V165, P261, DOI 10.1016/S0376-7388(99)00236-7
   Lawson KW, 1997, J MEMBRANE SCI, V124, P1, DOI 10.1016/S0376-7388(96)00236-0
   Li B, 2005, J MEMBRANE SCI, V257, P60, DOI 10.1016/j.memsci.2004.08.040
   Li GP, 2017, INT J HEAT MASS TRAN, V111, P123, DOI 10.1016/j.ijheatmasstransfer.2017.03.107
   Li GP, 2016, APPL ENERG, V177, P393, DOI 10.1016/j.apenergy.2016.05.113
   Li L, 2016, J MEMBRANE SCI, V513, P280, DOI 10.1016/j.memsci.2016.04.015
   Li ZH, 2014, APPL SURF SCI, V317, P338, DOI 10.1016/j.apsusc.2014.07.080
   Misdan N, 2012, DESALINATION, V287, P228, DOI 10.1016/j.desal.2011.11.001
   Mistry KH, 2010, INT J THERM SCI, V49, P1837, DOI 10.1016/j.ijthermalsci.2010.05.002
   Narayan GP, 2013, INT J HEAT MASS TRAN, V58, P740, DOI 10.1016/j.ijheatmasstransfer.2012.11.035
   Rahimi-Ahar Z, 2018, DESALINATION, V437, P73, DOI 10.1016/j.desal.2018.03.002
   Raudensky M., 2016, P HEAT TRANSF 14 SIM, V106, P95
   Sayyaadi H, 2010, APPL ENERG, V87, P1122, DOI 10.1016/j.apenergy.2009.05.023
   Song LM, 2007, IND ENG CHEM RES, V46, P2307, DOI 10.1021/ie0609968
   Song LM, 2010, IND ENG CHEM RES, V49, P11961, DOI 10.1021/ie100375b
   Sparrow BS, 2003, DESALINATION, V159, P161, DOI 10.1016/S0011-9164(03)90068-3
   Thiel GP, 2013, DESALINATION, V314, P50, DOI 10.1016/j.desal.2012.12.025
   Tomaszewska M, 2000, J MEMBRANE SCI, V166, P149, DOI 10.1016/S0376-7388(99)00263-X
   Yamali C, 2008, DESALINATION, V220, P538, DOI 10.1016/j.desal.2007.01.054
   Yildirim C, 2014, ENERG CONVERS MANAGE, V86, P568, DOI 10.1016/j.enconman.2014.06.016
   Zamen M, 2014, DESALINATION, V332, P1, DOI 10.1016/j.desal.2013.10.018
   Zarkadas DM, 2004, IND ENG CHEM RES, V43, P8093, DOI 10.1021/ie040143k
   Zhang JH, 2010, J MEMBRANE SCI, V349, P295, DOI 10.1016/j.memsci.2009.11.056
   Zhang LZ, 2018, CHEM ENG SCI, V192, P61, DOI 10.1016/j.ces.2018.07.019
   Zhang LZ, 2017, DESALINATION, V404, P200, DOI 10.1016/j.desal.2016.11.002
   Zhang LZ, 2006, ENERGY, V31, P1228, DOI 10.1016/j.energy.2005.05.027
NR 40
TC 4
Z9 4
U1 15
U2 72
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 164
EP 179
DI 10.1016/j.ces.2019.05.040
PG 16
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700013
DA 2020-05-12
ER

PT J
AU Jin, WJ
   van Ommen, JR
   Kleijn, CR
AF Jin, Wenjie
   van Ommen, J. Ruud
   Kleijn, Chris R.
TI Moving reaction fronts in fractal nanoparticle agglomerates
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Self-limiting surface reaction; Knudsen diffusion; Nanoparticle
   agglomerate; Atomic layer deposition
ID ATOMIC LAYER DEPOSITION; RANDOM-WALK SIMULATION; CATALYST PORE;
   DIFFUSION; TRANSPORT; CONFORMALITY; RATES
AB Self-limiting gas-surface reactions lead to reaction fronts that penetrate nanoporous materials with a finite speed. We present a closed form theoretical model, validated against molecular simulations, that shows the influence of the fractal scaling law on the time needed to fully penetrate fractal agglomerates of nanoparticles. For very large agglomerate sizes, this penetration time scales with the number of particles N in the agglomerate as NDf-1/Df. The penetration time for agglomerates with fractal dimensions D-f < 3 may therefore be orders of magnitude smaller than for non-fractal porous materials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jin, Wenjie; van Ommen, J. Ruud; Kleijn, Chris R.] Delft Univ Technol, Dept Chem Engn, Van Der Maasweg 9, NL-2629 HZ Delft, Netherlands.
RP Kleijn, CR (reprint author), Delft Univ Technol, Dept Chem Engn, Van Der Maasweg 9, NL-2629 HZ Delft, Netherlands.
EM c.r.kleijn@tudelft.nl
RI van Ommen, J. Ruud/A-4119-2009
OI van Ommen, J. Ruud/0000-0001-7884-0323
FU NanoNextNL, a micro and nanotechnology consortium of the government of
   the Netherlands and 130 partners
FX This work is supported by NanoNextNL, a micro and nanotechnology
   consortium of the government of the Netherlands and 130 partners.
CR Ackerman DM, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.228301
   Aris R., 1975, OXFORD STUDIES PHYS, V1
   Berson A, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.026310
   Bird GA, 1998, COMPUT MATH APPL, V35, P1, DOI 10.1016/S0898-1221(97)00254-X
   Ca P., 2013, PHYS REV LETT, V110
   CHASSAING E, 1994, J ELECTROCHEM SOC, V141, P2711, DOI 10.1149/1.2059188
   CLAUSING P, 1971, J VAC SCI TECHNOL, V8, P636, DOI 10.1116/1.1316379
   COPPENS MO, 1995, CHEM ENG SCI, V50, P1027, DOI 10.1016/0009-2509(94)00479-B
   Coppens MO, 1997, FRACTALS, V5, P493, DOI 10.1142/S0218348X97000395
   COPPENS MO, 1994, CHEM ENG SCI, V49, P4897
   de Martin L, 2014, CHEM ENG SCI, V112, P79, DOI 10.1016/j.ces.2014.03.024
   Dendooven J, 2009, J ELECTROCHEM SOC, V156, pP63, DOI 10.1149/1.3072694
   Derjaguin B., 1946, CR ACAD SCI URSS, V53, P623
   Detavernier C, 2011, CHEM SOC REV, V40, P5242, DOI 10.1039/c1cs15091j
   Filippov AV, 2000, J COLLOID INTERF SCI, V229, P261, DOI 10.1006/jcis.2000.7027
   Gavrilov C, 1997, AICHE J, V43, P1691, DOI 10.1002/aic.690430706
   George SM, 2010, CHEM REV, V110, P111, DOI 10.1021/cr900056b
   GIONA AR, 1992, CHEM ENG SCI, V47, P2623, DOI 10.1016/0009-2509(92)87103-W
   Go JY, 2007, J SOLID STATE ELECTR, V11, P323, DOI [10.1007/s10008-006-0108-0, 10.1007/s10008-005-0084-9]
   Gordon RG, 2003, CHEM VAPOR DEPOS, V9, P73, DOI 10.1002/cvde.200390005
   GUTFRAIND R, 1992, CHEM ENG SCI, V47, P4425, DOI 10.1016/0009-2509(92)85120-Z
   KARGER J, 1992, DIFFUSION ZEOLITES O
   Kim HW, 2013, SCIENCE, V342, P91, DOI 10.1126/science.1236098
   King DM, 2012, POWDER TECHNOL, V221, P13, DOI 10.1016/j.powtec.2011.12.020
   Knoops HCM, 2010, J ELECTROCHEM SOC, V157, pG241, DOI 10.1149/1.3491381
   Knudsen M., 1908, Annalen der Physik, V28, P75
   Kuijpers KR, 2014, COMPUT PHYS COMMUN, V185, P841, DOI 10.1016/j.cpc.2013.12.003
   Lankhorst AM, 2007, SURF COAT TECH, V201, P8842, DOI 10.1016/j.surfcoat.2007.04.079
   LINDENBERG K, 1991, J STAT PHYS, V65, P1269, DOI 10.1007/BF01049612
   LU BL, 1993, J CHEM PHYS, V98, P6472, DOI 10.1063/1.464812
   Malek K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.125505
   Malek K, 2003, J CHEM PHYS, V119, P2801, DOI 10.1063/1.1584652
   MEAKIN P, 1991, PHYS REV A, V43, P2993, DOI 10.1103/PhysRevA.43.2993
   Milina M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4922
   PAVLOVITCH A, 1991, PHYSICA A, V176, P206, DOI 10.1016/0378-4371(91)90288-N
   ROSNER DE, 1994, AICHE J, V40, P1167, DOI 10.1002/aic.690400708
   SAPOVAL B, 1993, PHYS REV E, V48, P3333, DOI 10.1103/PhysRevE.48.3333
   Sato H, 2014, SCIENCE, V343, P167, DOI 10.1126/science.1246423
   Scanlon TJ, 2010, COMPUT FLUIDS, V39, P2078, DOI 10.1016/j.compfluid.2010.07.014
   Schwager T, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.218002
   Skorupski K, 2014, PHYSICA A, V404, P106, DOI 10.1016/j.physa.2014.02.072
   Thiele EW, 1939, IND ENG CHEM, V31, P916, DOI 10.1021/ie50355a027
   Van Bui H, 2017, CHEM COMMUN, V53, P45, DOI 10.1039/c6cc05568k
   Wang G, 2007, CHEM ENG SCI, V62, P5110, DOI 10.1016/j.ces.2007.01.046
   WITTEN TA, 1981, PHYS REV LETT, V47, P1400, DOI 10.1103/PhysRevLett.47.1400
   Zalc JM, 2004, CHEM ENG SCI, V59, P2947, DOI 10.1016/j.ces.2004.04.028
NR 46
TC 0
Z9 0
U1 2
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 180
EP 186
DI 10.1016/j.ces.2019.05.027
PG 7
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700014
DA 2020-05-12
ER

PT J
AU Ramezani, R
   Mazinani, S
   Di Felice, R
AF Ramezani, Rouzbeh
   Mazinani, Saeed
   Di Felice, Renzo
TI A comprehensive kinetic and thermodynamic study of CO2 absorption in
   blends of monoethanolamine and potassium lysinate: Experimental and
   modeling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kent-Eisenberg; Thermodynamic modeling; Kinetic study; CO2 capture;
   Amino acid
ID CARBON-DIOXIDE ABSORPTION; MIXED AQUEOUS-SOLUTIONS; EQUILIBRIUM
   SOLUBILITY; N-METHYLDIETHANOLAMINE; PHYSICAL-PROPERTIES; CORROSION RATE;
   L-PROLINATE; NONAQUEOUS SOLUTIONS; REACTIVE ABSORPTION; GAS SOLUBILITIES
AB In this work, a kinetic and thermodynamic study of CO2 absorption in blends of monoethanolamine (MEA) and potassium lysinate (K-Lys) solutions was carried out at low CO2 partial pressures and temperatures (303-323 K). The CO2 loading capacity, density and viscosity of MEA + K-Lys solutions were measured. A modified Kent-Eisenberg model was applied to predict the CO2 loading capacity and also to determine the reaction equilibrium constants for the MEA + K-Lys system. The results showed that the model predictions are in excellent agreement with the experimental data. In order to study the reaction kinetics between CO2 and the MEA + K-Lys solution, the values of the reaction rate constant, the overall reaction kinetic constant, reaction order, physical solubility and CO2 diffusivity were determined. Finally, the absorption performance of the MEA + K-Lys system was compared with other common CO2 absorbents in terms of absorption heat, CO2 loading capacity and absorption rate. It was found that MEA + K-Lys has a better performance compared to other absorbents which makes it an attractive alternative to alkanolamines for CO2 capture. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ramezani, Rouzbeh; Di Felice, Renzo] Univ Genoa, Dept Civil Chem & Environm Engn, Via Opera Pia 15, I-16145 Genoa, Italy.
   [Mazinani, Saeed] Katholieke Univ Leuven, Dept Chem Engn, Proc Engn Sustainable Syst, Leuven, Belgium.
RP Ramezani, R (reprint author), Univ Genoa, Dept Civil Chem & Environm Engn, Via Opera Pia 15, I-16145 Genoa, Italy.
EM rouzbeh.ramezani@edu.unige.it
RI MAZINANI, SAEED/AAD-2592-2019; Ramezani, Rouzbeh/K-6564-2017
OI Ramezani, Rouzbeh/0000-0002-9234-4470
CR Aboudheir A, 2003, CHEM ENG SCI, V58, P5195, DOI 10.1016/j.ces.2003.08.014
   Arias AM, 2016, J CLEAN PROD, V115, P315, DOI 10.1016/j.jclepro.2015.12.056
   Arshad MW, 2014, J CHEM ENG DATA, V59, P764, DOI 10.1021/je400886w
   Benamor A, 2016, J NAT GAS SCI ENG, V33, P186, DOI 10.1016/j.jngse.2016.04.063
   Bhosale RR, 2016, IND ENG CHEM RES, V55, P5238, DOI 10.1021/acs.iecr.5b04398
   BLAUWHOFF PMM, 1984, CHEM ENG SCI, V39, P207, DOI 10.1016/0009-2509(84)80021-4
   Bougie F, 2012, J CHEM ENG DATA, V57, P635, DOI 10.1021/je200731v
   CAPLOW M, 1968, J AM CHEM SOC, V90, P6795, DOI 10.1021/ja01026a041
   Carson JK, 2000, J CHEM THERMODYN, V32, P1285
   Chang YC, 2013, J CHEM THERMODYN, V64, P106, DOI 10.1016/j.jct.2013.05.005
   Choi SY, 2014, IND ENG CHEM RES, V53, P14451, DOI 10.1021/ie502434m
   Chung PY, 2010, J CHEM THERMODYN, V42, P802, DOI 10.1016/j.jct.2010.02.005
   CLARKE JKA, 1964, IND ENG CHEM FUND, V3, P239, DOI 10.1021/i160011a012
   DANCKWERTS PV, 1979, CHEM ENG SCI, V34, P443, DOI 10.1016/0009-2509(79)85087-3
   DANCKWERTS PV, 1970, GAS LIQUID REACTIONS
   Dash SK, 2016, INT J GREENH GAS CON, V44, P227, DOI 10.1016/j.ijggc.2015.11.007
   Dash SK, 2011, FLUID PHASE EQUILIBR, V307, P166, DOI 10.1016/j.fluid.2011.05.009
   Dash SK, 2011, CHEM ENG SCI, V66, P3223, DOI 10.1016/j.ces.2011.02.028
   El Hadri N, 2017, APPL ENERG, V185, P1433, DOI 10.1016/j.apenergy.2016.03.043
   Fouad WA, 2012, IND ENG CHEM RES, V51, P6591, DOI 10.1021/ie202612k
   Fu KY, 2014, IND ENG CHEM RES, V53, P4413, DOI 10.1021/ie403259g
   Garg S, 2017, CHEM ENG RES DES, V118, P121, DOI 10.1016/j.cherd.2016.12.013
   Haider MB, 2016, J MOL LIQ, V224, P1025, DOI 10.1016/j.molliq.2016.10.044
   Haji-Sulaiman MZ, 1998, CHEM ENG RES DES, V76, P961, DOI 10.1205/026387698525603
   Horng SY, 2002, IND ENG CHEM RES, V41, P257, DOI 10.1021/ie010671l
   Hu GP, 2016, INT J GREENH GAS CON, V53, P28, DOI 10.1016/j.ijggc.2016.07.020
   Hwang SJ, 2016, INT J GREENH GAS CON, V49, P250, DOI 10.1016/j.ijggc.2016.03.011
   Jansen D, 2015, INT J GREENH GAS CON, V40, P167, DOI 10.1016/j.ijggc.2015.05.028
   JOU FY, 1982, IND ENG CHEM PROC DD, V21, P539, DOI 10.1021/i200019a001
   Kierzkowska-Pawlak H, 2017, INT J GREENH GAS CON, V57, P134, DOI 10.1016/j.ijggc.2016.12.019
   Kierzkowska-Pawlak H, 2015, INT J GREENH GAS CON, V37, P76, DOI 10.1016/j.ijggc.2015.03.002
   Kim M, 2012, IND ENG CHEM RES, V51, P2570, DOI 10.1021/ie201609b
   Kumar G, 2012, J CHEM ENG DATA, V57, P670, DOI 10.1021/je200647j
   LADDHA SS, 1981, CHEM ENG SCI, V36, P228, DOI 10.1016/0009-2509(81)80074-7
   LEE JI, 1976, J APPL CHEM BIOTECHN, V26, P541
   LEE JIL, 1972, J CHEM ENG DATA, V17, P465, DOI 10.1021/je60055a015
   Li H, 2014, INT J GREENH GAS CON, V31, P25, DOI 10.1016/j.ijggc.2014.09.012
   LI MH, 1993, FLUID PHASE EQUILIBR, V85, P129, DOI 10.1016/0378-3812(93)80008-B
   Liao CH, 2002, CHEM ENG SCI, V57, P4569, DOI 10.1016/S0009-2509(02)00395-0
   Lin CY, 2009, J TAIWAN INST CHEM E, V40, P403, DOI 10.1016/j.jtice.2008.11.002
   LITTEL RJ, 1991, CHEM ENG SCI, V46, P3308, DOI 10.1016/0009-2509(91)85036-W
   Lu BH, 2013, ENERG FUEL, V27, P6002, DOI 10.1021/ef400976j
   Luo X, 2017, J CHEM ENG DATA, V62, P129, DOI 10.1021/acs.jced.6b00504
   Majchrowicz ME, 2012, CHEM ENG SCI, V72, P35, DOI 10.1016/j.ces.2011.12.014
   Majchrowicz ME, 2014, IND ENG CHEM RES, V53, P11460, DOI 10.1021/ie501083v
   Mazinani S, 2015, FLUID PHASE EQUILIBR, V396, P28, DOI 10.1016/j.fluid.2015.03.031
   Mazinani S, 2011, J CHEM ENG DATA, V56, P3163, DOI 10.1021/je2002418
   Mondal BK, 2017, IND ENG CHEM RES, V56, P14902, DOI 10.1021/acs.iecr.7b02744
   Mondal BK, 2017, FLUID PHASE EQUILIBR, V437, P118, DOI 10.1016/j.fluid.2017.01.020
   Mondal BK, 2017, GREENH GASES, V7, P202, DOI 10.1002/ghg.1653
   Mondal BK, 2015, FLUID PHASE EQUILIBR, V402, P102, DOI 10.1016/j.fluid.2015.05.033
   Mukherjee S, 2018, ENERG FUEL, V32, P3668, DOI 10.1021/acs.energyfuels.7b03743
   Nwaoha C, 2017, CHEM ENG SCI, V170, P26, DOI 10.1016/j.ces.2017.03.025
   Park SH, 2002, IND ENG CHEM RES, V41, P1658, DOI 10.1021/ie010252o
   Paul S, 2009, CHEM ENG SCI, V64, P1618, DOI 10.1016/j.ces.2008.12.034
   Penders-van Elk N. J. M. C., 2015, CHEM ENG J, V259, P682, DOI DOI 10.1016/J.CEJ.2014.08.001
   PINSENT BRW, 1956, T FARADAY SOC, V52, P1512, DOI 10.1039/tf9565201512
   Portugal AF, 2008, CHEM ENG SCI, V63, P3493, DOI 10.1016/j.ces.2008.04.017
   Posey ML, 1996, GAS SEP PURIF, V10, P181, DOI 10.1016/0950-4214(96)00019-9
   Puxty G, 2011, ENVIRON SCI TECHNOL, V45, P2398, DOI 10.1021/es1022784
   Ramazani R, 2016, INT J GREENH GAS CON, V45, P27, DOI 10.1016/j.ijggc.2015.12.003
   Ramazani R, 2016, SEP SCI TECHNOL, V51, P327, DOI 10.1080/01496395.2015.1088027
   Ramazani R, 2015, PROCESS SAF ENVIRON, V98, P325, DOI 10.1016/j.psep.2015.09.003
   Ramazani R, 2016, INT J GREENH GAS CON, V51, P29, DOI 10.1016/j.ijggc.2016.05.005
   Ramezani R., 2018, OPEN CHEM ENG J, V12, P67
   Ramezani R, 2018, KOREAN J CHEM ENG, V35, P2065, DOI 10.1007/s11814-018-0123-8
   Ramezani R, 2018, J ENVIRON CHEM ENG, V6, P3262, DOI 10.1016/j.jece.2018.05.019
   Ramezani R, 2017, J NAT GAS SCI ENG, V45, P599, DOI 10.1016/j.jngse.2017.06.028
   Ramezani R, 2017, INT J GREENH GAS CON, V62, P61, DOI 10.1016/j.ijggc.2017.04.012
   Rho SW, 1997, J CHEM ENG DATA, V42, P1161, DOI 10.1021/je970097d
   Samanta A, 2012, IND ENG CHEM RES, V51, P1438, DOI 10.1021/ie200686q
   Sanchez LMG, 2011, CHEM ENG J, V166, P1104, DOI 10.1016/j.cej.2010.12.016
   Sema T, 2011, IND ENG CHEM RES, V50, P14008, DOI 10.1021/ie2008345
   Shaikh MS, 2015, CHEM ENG RES DES, V102, P378, DOI 10.1016/j.cherd.2015.07.003
   Shaikh MS, 2013, J CHEM ENG DATA, V58, P634, DOI 10.1021/je301091z
   SHEN KP, 1992, J CHEM ENG DATA, V37, P96, DOI 10.1021/je00005a025
   Shen SF, 2017, J CHEM THERMODYN, V115, P209, DOI 10.1016/j.jct.2017.07.041
   Shen SF, 2016, ENERG FUEL, V30, P6585, DOI 10.1021/acs.energyfuels.6b01092
   Shen SF, 2016, ENVIRON SCI TECHNOL, V50, P2054, DOI 10.1021/acs.est.5b04515
   Shen SF, 2015, FLUID PHASE EQUILIBR, V399, P40, DOI 10.1016/j.fluid.2015.04.021
   Singto S, 2016, SEP PURIF TECHNOL, V167, P97, DOI 10.1016/j.seppur.2016.05.002
   Song HJ, 2012, INT J GREENH GAS CON, V11, P64, DOI 10.1016/j.ijggc.2012.07.019
   Song JH, 1996, J CHEM ENG DATA, V41, P497, DOI 10.1021/je9502758
   Sun WC, 2005, CHEM ENG SCI, V60, P503, DOI 10.1016/j.ces.2004.08.012
   Sutar PN, 2013, CHEM ENG SCI, V100, P234, DOI 10.1016/j.ces.2012.11.038
   Thee H, 2014, INT J GREENH GAS CON, V20, P212, DOI 10.1016/j.ijggc.2013.10.027
   Tong DL, 2013, CHEM ENG SCI, V101, P851, DOI 10.1016/j.ces.2013.05.034
   VERSTEEG GF, 1988, J CHEM ENG DATA, V33, P29, DOI 10.1021/je00051a011
   Versteeg GF, 1996, CHEM ENG COMMUN, V144, P113, DOI 10.1080/00986449608936450
   Wagner M, 2013, J CHEM ENG DATA, V58, P883, DOI 10.1021/je301030z
   Wang T, 2017, CHEM ENG J, V314, P123, DOI 10.1016/j.cej.2016.12.129
   Weisenberger S, 1996, AICHE J, V42, P298, DOI 10.1002/aic.690420130
   Xiao J, 2000, CHEM ENG SCI, V55, P161, DOI 10.1016/S0009-2509(99)00303-6
   Ying JR, 2013, IND ENG CHEM RES, V52, P2548, DOI 10.1021/ie303450u
   Zarogiannis T, 2016, J CLEAN PROD, V136, P159, DOI 10.1016/j.jclepro.2016.04.110
   Zhang R, 2017, APPL ENERG, V205, P1002, DOI 10.1016/j.apenergy.2017.08.130
   Zhao BT, 2016, RENEW SUST ENERG REV, V65, P44, DOI 10.1016/j.rser.2016.06.059
   Zhao Y, 2017, ENERG FUEL, V31, P14033, DOI 10.1021/acs.energyfuels.7b02800
   Zhao Y, 2017, J CHEM THERMODYN, V111, P100, DOI 10.1016/j.jct.2017.03.024
NR 99
TC 1
Z9 1
U1 9
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 187
EP 202
DI 10.1016/j.ces.2019.05.039
PG 16
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700015
DA 2020-05-12
ER

PT J
AU Zhao, MW
   Wang, RY
   Dai, CL
   Wu, XP
   Wu, YR
   Dai, YJ
   Wu, YN
AF Zhao, Mingwei
   Wang, Ruoyu
   Dai, Caili
   Wu, Xuepeng
   Wu, Youran
   Dai, Yingjie
   Wu, Yining
TI Adsorption behaviour of surfactant-nanoparticles at the gas-liquid
   interface: Influence of the alkane chain length
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Alkane chain; Nanoparticles; Foam stability; Molecular simulation
ID SILICA NANOPARTICLES; COLLOIDAL PARTICLES; POROUS-MEDIA; FOAM;
   STABILITY; WATER; ENERGY; WETTABILITY; BUBBLES; MIXTURE
AB Silica nanoparticles (NPs) have shown tremendous application potential as stabilising agents in foams. The adsorption of cationic surfactants on the surface of NPs through electrostatic interactions forms integrated surfactant-NP compounds and endows the NPs with surfactancy. The aim of this study was to investigate the influence of the alkane chain length of cationic surfactants on NP surfactancy and foam stability. The results demonstrate that the surface tension decreases and dilational elasticity modulus increases with surfactant chain length. Simultaneously, coalescence of bubbles is markedly suppressed and the stability of surfactant-NP foams is enhanced in static and dynamic tests. With a coarse-grained molecular dynamics simulation (CGMD), it was found that the surfactant-NP complexes evolve into an asymmetric Janus structure at the gas-liquid interface from their symmetric configuration in the aqueous phase. In addition, the resistance force during the pulling of a NP away from the interface increases with surfactant chain length. The simulation results imply that surfactant-NPs have a high surfactancy and the adsorption stability is improved with increasing surfactant chain length, which is in good agreement with the experimental results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Mingwei; Wang, Ruoyu; Dai, Caili; Wu, Yining] China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Shandong, Peoples R China.
   [Zhao, Mingwei; Wang, Ruoyu; Dai, Caili; Wu, Youran; Dai, Yingjie; Wu, Yining] China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
   [Wu, Xuepeng] SRIPE, Beijing 100101, Peoples R China.
RP Dai, CL; Wu, YN (reprint author), China Univ Petr East China, Minist Educ, Key Lab Unconvent Oil & Gas Dev, Qingdao 266580, Shandong, Peoples R China.; Dai, CL; Wu, YN (reprint author), China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
EM daicl@upc.edu.cn; wuyining@126.com
OI Dai, Cai li/0000-0002-7477-8865
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1663206, 51704313, 51874337]; Chang Jiang Scholars
   ProgramProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [T2014152]; Climb Taishan Scholar Program in
   Shandong Province [tspd20161004]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [15CX08003A, 18CX02028A]
FX The work was supported by the National Natural Science Foundation of
   China (U1663206, 51704313, 51874337), Chang Jiang Scholars Program
   (T2014152), the Climb Taishan Scholar Program in Shandong Province
   (tspd20161004) and the Fundamental Research Funds for the Central
   Universities (15CX08003A, 18CX02028A).
CR Almobarky M.A., 2017, CARB MAN TECHN C HOU
   Alvarez NJ, 2012, LANGMUIR, V28, P8052, DOI 10.1021/la300737p
   AlYousef ZA, 2018, J COLLOID INTERF SCI, V511, P365, DOI 10.1016/j.jcis.2017.09.051
   And O.P., 1996, LANGMUIR, V12, P4808
   [Anonymous], 2015, SOFT MATTER, V11, P6245
   [Anonymous], 1907, J CHEM SOC T, V91, P2001
   Asghari AK, 2016, FOOD HYDROCOLLOID, V53, P311, DOI 10.1016/j.foodhyd.2015.09.007
   Azmin M, 2012, MAT SCI ENG C-MATER, V32, P2654, DOI 10.1016/j.msec.2012.06.019
   Bera A, 2013, APPL SURF SCI, V284, P87, DOI 10.1016/j.apsusc.2013.07.029
   Binks BP, 2007, PHYS CHEM CHEM PHYS, V9, P6298, DOI 10.1039/b716587k
   Binks B.P., 2010, ANGEW CHEM INT EDIT, V44, P3722
   Binks BP, 2007, LANGMUIR, V23, P3626, DOI 10.1021/la0634600
   Binks BP, 2002, LANGMUIR, V18, P1270, DOI 10.1021/la011420k
   Binks BP, 2000, LANGMUIR, V16, P8622, DOI 10.1021/la000189s
   Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0
   Bird JC, 2010, NATURE, V465, P759, DOI 10.1038/nature09069
   Carn F, 2009, LANGMUIR, V25, P7847, DOI 10.1021/la900414q
   Corbala-Robles L, 2016, WATER RES, V95, P340, DOI 10.1016/j.watres.2016.03.031
   Cui ZG, 2008, COLLOID SURFACE A, V329, P67, DOI 10.1016/j.colsurfa.2008.06.049
   Curschellas C, 2012, SOFT MATTER, V8, P11620, DOI 10.1039/c2sm26446c
   Dai CL, 2018, CHEM ENG SCI, V179, P73, DOI 10.1016/j.ces.2018.01.005
   Du K, 2010, LANGMUIR, V26, P12518, DOI 10.1021/la100497h
   Du ZP, 2003, LANGMUIR, V19, P3106, DOI 10.1021/la034042n
   Engelhardt K, 2012, LANGMUIR, V28, P7780, DOI 10.1021/la301368v
   Francesca R., 2006, J PHYS CHEM B, V110, P19543
   Gunes DZ, 2017, LANGMUIR, V33, P1563, DOI 10.1021/acs.langmuir.6b04141
   Guo F, 2016, FUEL, V186, P430, DOI 10.1016/j.fuel.2016.08.058
   Harkins WD, 1919, J AM CHEM SOC, V41, P499, DOI 10.1021/ja01461a003
   Hu Z, 2015, J COLLOID INTERF SCI, V439, P139, DOI 10.1016/j.jcis.2014.10.034
   Kamand S.I., 1999, J COLLOID INTERF SCI, V213, P329
   Legrand J, 2005, LANGMUIR, V21, P64, DOI 10.1021/la047649s
   Liu X., 2017, ANGEW CHEM, V129, P12768
   Ma C, 2010, PROCEEDINGS OF THE ASME DYNAMIC SYSTEMS AND CONTROL CONFERENCE 2010, VOL 1, P1
   Ma K, 2012, SOFT MATTER, V8, P10669, DOI 10.1039/c2sm25833a
   Matteo Cocuzza, 2012, American Journal of Applied Sciences, V9, P784
   Mehta RN, 2015, APPL NANOSCI, V5, P891, DOI 10.1007/s13204-014-0385-3
   Metin CO, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1246-1
   Osei-Bonsu K, 2017, FUEL, V203, P403, DOI 10.1016/j.fuel.2017.04.114
   Rio E, 2014, ADV COLLOID INTERFAC, V205, P74, DOI 10.1016/j.cis.2013.10.023
   Saigal T, 2010, LANGMUIR, V26, P15200, DOI 10.1021/la1027898
   San-Miguel A, 2012, LANGMUIR, V28, P12038, DOI 10.1021/la302224v
   Toor A, 2018, ACS NANO, V12, P2365, DOI 10.1021/acsnano.7b07635
   Wu YN, 2019, IND ENG CHEM RES, V58, P3707, DOI 10.1021/acs.iecr.8b06057
   Wu YN, 2018, LANGMUIR, V34, P8015, DOI 10.1021/acs.langmuir.8b01187
   Wu YN, 2017, J PETROL SCI ENG, V153, P283, DOI 10.1016/j.petrol.2017.04.015
   Yang J, 2007, PHYS CHEM CHEM PHYS, V9, P6327, DOI 10.1039/b709624k
NR 46
TC 6
Z9 6
U1 34
U2 127
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 203
EP 211
DI 10.1016/j.ces.2019.05.033
PG 9
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700016
DA 2020-05-12
ER

PT J
AU Sun, X
   Zhu, CY
   Fu, TT
   Ma, YG
   Li, HZ
AF Sun, Xin
   Zhu, Chunying
   Fu, Taotao
   Ma, Youguang
   Li, Huai Z.
TI Breakup dynamics of elastic droplet and stretching of polymeric filament
   in a T-junction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidics; Multi-phase flow; Polymer solution; Viscoelastic droplet;
   Interface breakup
ID VISCOELASTIC THREAD; DILUTE-SOLUTIONS; MICROCAPSULES; MICROCHANNEL;
   RUPTURE
AB Dynamics of elastic droplet breakup and stretching of polymeric filaments in a microfluidic T-junction are investigated experimentally. Through comparisons between cases of Newtonian droplet and a series of viscoelastic droplets with similar shear viscosity, the effect of elasticity on breakup dynamic of droplet is especially focused. Four sequential stages of droplet breakup in a microfluidic T-junction are observed: (I) squeezing, (II) transition, (III) pinch-off and (IV) filament rupture stages. For former three stages (I-III), dynamic behaviors of viscoelastic droplets with lower molecular weight (M w = 1 x 10(5) g/mol and 3 x 10(5) g/mol) and Newtonian droplet are similar, while for viscoelastic droplet with higher molecular weight (M-w =1 x 10(6) g/mol), the spatial obstruction of previous filaments accelerates the shrinkage of droplet neck. Additionally, the transformation of dominant force from inertial to capillary force leads to the variation of scaling laws describing the neck evolution. For filament rupture stages (IV), with extension of polymer molecules chain, the elastocapillary balance contributes to the exponential thinning of the polymeric filament, while the width of thread neck decreases linearly with the time for Newtonian droplet. Furthermore, more effort has been devoted to investigate the stretching dynamic of filament. The stretching rate of filament is independent of elasticity, but proportional to two-phase flow rates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Xin; Zhu, Chunying; Fu, Taotao; Ma, Youguang] Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Li, Huai Z.] Univ Lorraine, Lab React & Proc Engn, CNRS, 1 Rue Grandville,BP 20451, F-54001 Nancy, France.
RP Zhu, CY; Ma, YG (reprint author), Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
EM zhchy971@tju.edu.cn; ygma@tju.edu.cn
RI Li, Huai/S-2162-2019
OI Li, Huai/0000-0001-7129-6660; Fu, Taotao/0000-0003-1881-1509
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21576186, 21776200, 91634105]; aid of Opening
   Project of State Key Laboratory of Chemical Engineering [SKL-ChE-17B02]
FX The financial supports for this project from the National Natural
   Science Foundation of China (No. 21576186, 21776200, 91634105), the aid
   of Opening Project of State Key Laboratory of Chemical Engineering (No.
   SKL-ChE-17B02) are gratefully acknowledged.
CR Agarwal P, 2013, LAB CHIP, V13, P4525, DOI 10.1039/c3lc50678a
   Amarouchene Y, 2001, PHYS REV LETT, V86, P3558, DOI 10.1103/PhysRevLett.86.3558
   Chen YP, 2017, J FLUID MECH, V819, P401, DOI 10.1017/jfm.2017.181
   Chen Z, 2019, CHEM ENG SCI, V202, P1, DOI 10.1016/j.ces.2019.03.016
   Christopher GF, 2009, J RHEOL, V53, P663, DOI 10.1122/1.3086871
   Clasen C, 2006, J RHEOL, V50, P849, DOI 10.1122/1.2357595
   Du W, 2017, AICHE J, V63, P5196, DOI 10.1002/aic.15834
   Du W, 2016, CHEM ENG SCI, V153, P255, DOI 10.1016/j.ces.2016.07.038
   Entov VM, 1997, J NON-NEWTON FLUID, V72, P31, DOI 10.1016/S0377-0257(97)00022-0
   Fu TT, 2014, AICHE J, V60, P1920, DOI 10.1002/aic.14377
   Han WB, 2019, CHEM ENG RES DES, V145, P213, DOI 10.1016/j.cherd.2019.03.002
   Han WB, 2018, AUST J CHEM, V71, P957, DOI 10.1071/CH18320
   Hoang DA, 2013, J FLUID MECH, V717, DOI 10.1017/jfm.2013.18
   Huerre A, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.064501
   Husny J, 2006, J NON-NEWTON FLUID, V137, P121, DOI 10.1016/j.jnnfm.2006.03.007
   Jullien MC, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3170983
   Lee W, 2011, MACROMOL MATER ENG, V296, P203, DOI 10.1002/mame.201000302
   Leshansky AM, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.264502
   Leshansky AM, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3078515
   Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503
   Liu J, 2017, ACCOUNTS CHEM RES, V50, P208, DOI 10.1021/acs.accounts.6b00429
   Menetrier-Deremble L, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.035303
   Min KI, 2014, LAB CHIP, V14, P3987, DOI 10.1039/c4lc00700j
   Oliveira MSN, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1949197
   Petschacher C, 2013, POLYM CHEM-UK, V4, P2342, DOI 10.1039/c3py20939c
   Rothbauer M, 2018, LAB CHIP, V18, P249, DOI 10.1039/c7lc00815e
   Roumpea E, 2017, AICHE J, V63, P3599, DOI 10.1002/aic.15704
   Saint Vincent MRD, 2012, J FLUID MECH, V692, P499, DOI 10.1017/jfm.2011.550
   Steinhaus B, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2747660
   Sun X, 2018, CHEM ENG SCI, V188, P158, DOI 10.1016/j.ces.2018.05.027
   Tan TB, 2018, J FOOD ENG, V238, P188, DOI 10.1016/j.jfoodeng.2018.06.026
   Tirtaatmadja V, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2190469
   Vladisavljevic GT, 2012, MICROFLUID NANOFLUID, V13, P151, DOI 10.1007/s10404-012-0948-0
NR 33
TC 0
Z9 0
U1 23
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 212
EP 223
DI 10.1016/j.ces.2019.05.030
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700017
DA 2020-05-12
ER

PT J
AU Chen, CH
   Hallmark, B
   Davidson, JF
AF Chen, C-H
   Hallmark, B.
   Davidson, J. F.
TI The motion and shape of a bubble in highly viscous liquid flowing
   through an orifice
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Two-phase flow; Bubble deformation; Geometric theory; Viscous flows;
   Multipass rheometer
ID DROP DEFORMATION; CUSP FORMATION; SHEAR; FLUID; RHEOLOGY; CONCRETE;
   BREAKUP; MAGMAS
AB Experiments and theory concern the behaviour of a small bubble carried through an orifice by a very viscous liquid. The liquid was polybutene oil, of viscosity about 70 Pa s, i.e. 70,000 times that of water. The Reynolds number of the flow is substantially less than one, hence the flow pattern is approximately radial flowing into, and away from, the orifice. These flow patterns have profound effects on the shape of an entrained bubble. On the upstream side, the acceleration of the liquid, as it approaches the orifice, causes elongation of the bubble since the front of the bubble moves faster than the back. On the downstream side, the reverse occurs: the back of the bubble moves fast than the front. Thus the height of the bubble diminishes as it moves away from the orifice, leading to the formation of a 'crescent-moon' shape. The shape of these bubbles can be predicted by considering the motion of a droplet of the same liquid replacing the bubble: the resulting geometric theory gives good predictions of bubble deformation approaching the orifice and of 'crescent-moon' formation downstream of the orifice. (C) 2019 Published by Elsevier Ltd.
C1 [Chen, C-H; Hallmark, B.; Davidson, J. F.] Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
RP Hallmark, B (reprint author), Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM bh206@cam.ac.uk
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/N00230X/1]
FX The work was supported by EPSRC contract number EP/N00230X/1. The
   authors are grateful to P.J. Davidson, who initiated the project.
CR Amran YHM, 2015, CONSTR BUILD MATER, V101, P990, DOI 10.1016/j.conbuildmat.2015.10.112
   BENTLEY BJ, 1986, J FLUID MECH, V167, P241, DOI 10.1017/S0022112086002811
   COLLISHAW PG, 1994, J MATER SCI, V29, P2261, DOI 10.1007/BF00363413
   Dawson G, 2015, PROC IUTAM, V16, P22, DOI 10.1016/j.piutam.2015.03.004
   de Chaumont F, 2011, I S BIOMED IMAGING, P234, DOI 10.1109/ISBI.2011.5872395
   Delgado-Gonzalo R, 2015, IEEE SIGNAL PROC MAG, V32, P41, DOI 10.1109/MSP.2014.2344552
   Drenckhan W, 2015, ADV COLLOID INTERFAC, V224, P1, DOI 10.1016/j.cis.2015.05.004
   Dufour A, 2011, IEEE T IMAGE PROCESS, V20, P1925, DOI 10.1109/TIP.2010.2099125
   Eaves D., 2004, HDB POLYM FOAMS
   GRACE HP, 1982, CHEM ENG COMMUN, V14, P225, DOI 10.1080/00986448208911047
   Hallmark B, 2019, CHEM ENG SCI, V206, P272, DOI 10.1016/j.ces.2019.04.043
   Hill C, 2017, ADV COLLOID INTERFAC, V247, P496, DOI 10.1016/j.cis.2017.05.013
   HINCH EJ, 1980, J FLUID MECH, V98, P305, DOI 10.1017/S0022112080000171
   Kameda M, 2008, FLUID DYN RES, V40, P576, DOI 10.1016/j.fluiddyn.2007.12.010
   Khayat RE, 2000, INT J MULTIPHAS FLOW, V26, P17, DOI 10.1016/S0301-9322(98)00083-4
   KOPFSILL AR, 1988, PHYS FLUIDS, V31, P18, DOI 10.1063/1.866566
   LEWANDOWSKI FY, 1994, J NON-NEWTON FLUID, V52, P233, DOI 10.1016/0377-0257(94)80053-7
   MACKLEY MR, 1995, J RHEOL, V39, P1293, DOI 10.1122/1.550637
   Mader HM, 2013, J VOLCANOL GEOTH RES, V257, P135, DOI 10.1016/j.jvolgeores.2013.02.014
   Mezzenga R, 2005, NAT MATER, V4, P729, DOI 10.1038/nmat1496
   Mora CF, 2000, CEMENT CONCRETE RES, V30, P351, DOI 10.1016/S0008-8846(99)00259-8
   Narsimhan G, 2018, ANNU REV FOOD SCI T, V9, P45, DOI 10.1146/annurev-food-030216-030009
   Ostwald W., 1897, Z PHYS CHEM, V22, P189
   Pozrikidis C, 1998, J FLUID MECH, V357, P29, DOI 10.1017/S0022112097007866
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   RALLISON JM, 1984, ANNU REV FLUID MECH, V16, P45, DOI 10.1146/annurev.fl.16.010184.000401
   RICHARDS.S, 1973, J FLUID MECH, V58, P115, DOI 10.1017/S0022112073002168
   RICHARDSON JF, 1954, CHEM ENG SCI, V3, P65, DOI 10.1016/0009-2509(54)85015-9
   Rust AC, 2003, J VOLCANOL GEOTH RES, V122, P111, DOI 10.1016/S0377-0273(02)00487-0
   Rust AC, 2002, J COLLOID INTERF SCI, V249, P476, DOI 10.1006/jcis.2002.8292
   Sauzade M, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.034202
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shikhmurzaev YD, 1998, J FLUID MECH, V359, P313, DOI 10.1017/S0022112098008532
   Siegel M, 2000, J FLUID MECH, V412, P227, DOI 10.1017/S002211200000834X
   Stegeman Y.W., 2008, CAN J CHEM ENG, V80, P1
   STONE HA, 1994, ANNU REV FLUID MECH, V26, P65, DOI 10.1146/annurev.fluid.26.1.65
   Torres MD, 2015, J FOOD ENG, V146, P129, DOI 10.1016/j.jfoodeng.2014.09.012
   VOORHEES PW, 1985, J STAT PHYS, V38, P231, DOI 10.1007/BF01017860
   Wallis G. B., 1974, International Journal of Multiphase Flow, V1, P491, DOI 10.1016/0301-9322(74)90003-2
   Wang J., 2009, RHEOLOGY FOAMING POL
   WILLIAMS DJ, 1992, CVGIP-IMAG UNDERSTAN, V55, P14, DOI 10.1016/1049-9660(92)90003-L
NR 41
TC 0
Z9 0
U1 9
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 224
EP 234
DI 10.1016/j.ces.2019.05.021
PG 11
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700018
DA 2020-05-12
ER

PT J
AU Kashanj, S
   Kebriaee, A
AF Kashanj, S.
   Kebriaee, A.
TI The effects of different jet velocities and axial misalignment on the
   liquid sheet of two colliding jets
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Colliding jets; Droplets size distribution; Jet velocity; Liquid sheet;
   Misaligned jets
ID THICKNESS DISTRIBUTION; IMPINGEMENT; COLLISION
AB This experimental study investigated the patterns and characteristics of the liquid sheet formed by two axial misaligned colliding jets and two colliding jets with different velocities. The tests were limited to the low Reynolds number region, 100 < Re < 400, of two Newtonian colliding jets (a glycerol-water mixture). This range of Reynolds number includes the triple-chain, double-chain, closed-rim, and open-rim regimes. In the case of misaligned collision, it was found that an open-rim pattern, called trigonous liquid sheet, was formed for a specific measured degree of skewness in the triple-chain, double-chain, and closed-rim regimes. In the case of colliding with different velocities, two effects were observed, including the rotation of the liquid sheet in the direction of the jets axis and the deformation of the liquid sheet. A cancer-like instability, similar to what has been observed in two identical viscoelastic colliding jets, was also captured in the central region of the liquid sheet in the case of different velocities. This instability confirmed the sheet-driven mechanism of the fishbone pattern formation. In addition, the quantitative measurement of the geometrical characteristics of the liquid sheet and the droplets size distribution of the fishbone pattern were comprehensively discussed for different Reynolds numbers, skewness factors, and velocity ratios in the cases of two misaligned jets and different velocities of the two jets. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kashanj, S.; Kebriaee, A.] Sharif Univ Technol, Aerosp Engn Dept, Tehran, Iran.
RP Kebriaee, A (reprint author), Sharif Univ Technol, Aerosp Engn Dept, Tehran, Iran.
EM kebriaee@sharif.ir
FU center of research assistance of Sharif University of Technology
   [G950411]
FX The authors thank "Arsin Tabesh Negran Fannavar" Company for their
   sincere cooperation and the availability of PhotoFreezer v2.5. Financial
   support from the center of research assistance of Sharif University of
   Technology (Grant No. G950411) is also gratefully acknowledged.
CR Ahmed M, 2008, EXP FLUIDS, V44, P125, DOI 10.1007/s00348-007-0381-4
   Ahmed M, 2009, J FLUID ENG-T ASME, V131, DOI 10.1115/1.3026729
   ArsinTNF A. T. N. F., 2017, ENL BRIGHT LIGHT
   Ashgriz N, 2011, HANDBOOK OF ATOMIZATION AND SPRAYS: THEORY AND APPLICATIONS, P1, DOI 10.1007/978-1-4419-7264-4
   Bailardi G., 2010, P 23 EUR C LIQ AT SP
   Blaisot JB, 2005, EXP FLUIDS, V39, P977, DOI 10.1007/s00348-005-0026-4
   Bremond N, 2006, J FLUID MECH, V549, P273, DOI 10.1017/S0022112005007962
   Bush JWM, 2004, J FLUID MECH, V511, P285, DOI 10.1017/S002211200400967X
   Chen X., 2011, ARXIV11103356
   Chen XD, 2014, J COMPUT PHYS, V269, P22, DOI 10.1016/j.jcp.2014.02.035
   Choo YJ, 2002, PHYS FLUIDS, V14, P622, DOI 10.1063/1.1429250
   Choo YJ, 2001, EXP FLUIDS, V31, P56, DOI 10.1007/s003480000258
   DOMBROWSKI N, 1962, CHEM ENG SCI, V17, P291, DOI 10.1016/0009-2509(62)85008-8
   Dombrowski N., 1964, STUDY SPRAYS FORMED
   Gadgil HP, 2009, ATOMIZATION SPRAY, V19, P1, DOI 10.1615/AtomizSpr.v19.i1.10
   Halls B., 2015, 27 ILASS AM C RAYL N
   HASSON D, 1964, AICHE J, V10, P752, DOI 10.1002/aic.690100533
   Heidmann M. F., 1957, STUDY SPRAYS FORMED
   Jung SJ, 2011, J NON-NEWTON FLUID, V166, P297, DOI 10.1016/j.jnnfm.2010.12.006
   Jung SJ, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3373513
   Kebriaee A., 2018, ATOM SPRAYS, V28
   Kebriaee A., 2018, ATOMIZATION SPRAY, V22
   Lai W.-H., 2005, ATOM SPRAYS, V15
   Lefebvre A.H., 2017, ATOMIZATION SPRAYS
   Li R, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2338064
   Lu JK, 2014, CHEM ENG SCI, V119, P182, DOI 10.1016/j.ces.2014.08.024
   Miller E, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.1984099
   Panao MRO, 2014, EXP THERM FLUID SCI, V58, P170, DOI 10.1016/j.expthermflusci.2014.07.003
   Panao MRO, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4774347
   Pizziol B, 2018, EXP THERM FLUID SCI, V96, P303, DOI 10.1016/j.expthermflusci.2018.03.019
   Sanjay V, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4998288
   Shi Z.-H., 2018, AICHE J
   Soni A, 2018, CHEM ENG SCI, V191, P67, DOI 10.1016/j.ces.2018.06.055
   Yamamura K, 2011, CHEM ENG SCI, V66, P1844, DOI 10.1016/j.ces.2011.01.017
   Yang LJ, 2014, J PROPUL POWER, V30, P1016, DOI 10.2514/1.B35105
   Yasuda N, 2010, P ROY SOC A-MATH PHY, V466, P3501, DOI 10.1098/rspa.2010.0144
   Zhao F, 2017, J PROPUL POWER, V33, P1260, DOI 10.2514/1.B36438
   Zhao F, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031869
NR 38
TC 0
Z9 0
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 235
EP 248
DI 10.1016/j.ces.2019.05.015
PG 14
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700019
DA 2020-05-12
ER

PT J
AU Zheng, P
   Li, TS
   Chi, KB
   Xiao, CK
   Wang, XL
   Fan, JY
   Duan, AJ
   Xu, CM
AF Zheng, Peng
   Li, Tianshu
   Chi, Kebin
   Xiao, Chengkun
   Wang, Xilong
   Fan, Jiyuan
   Duan, Aijun
   Xu, Chunming
TI DFT insights into the direct desulfurization pathways of DBT and
   4,6-DMDBT catalyzed by Co-promoted and Ni-promoted MoS2 corner sites
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrodesulfurization; Density functional theory; Corner sites;
   Dibenzothiophene; 4,6-Dimethyldibenzothiophene
ID DENSITY-FUNCTIONAL THEORY; THIOPHENE HYDRODESULFURIZATION MECHANISM;
   ACTIVE PHASE; ADSORPTION; MOLECULES; 4,6-DIMETHYLDIBENZOTHIOPHENE;
   DIBENZOTHIOPHENE; SELECTIVITY; SOLIDS; EXAFS
AB The direct desulfurization (DDS) mechanisms of DBT and 4,6-DMDBT over the different Co-promoted and Ni-promoted MoS2 corner sites were systematically investigated using DFT calculations. Innovatively, the adsorption processes of both sulfur-containing compounds were evaluated by dispersion corrected methods (DFT-D) firstly. After that, the effect of corner vacancy on the direct desulfurization mechanism was discussed in detail. And the results showed that single corner vacancy provided sufficient support for the DDS reaction of DBT, while double corner vacancies revealed necessary for the adsorption and subsequent C-S bond scission of 4,6-DMDBT. However, based on the DFT calculations, the formation energy of the double vacancies was relatively high, which was considered to be present at a very low possibility under the hydrodesulfurization (HDS) condition, thus the DDS activity of 4,6-DMDBT was relatively low. Compared to CoMoS, it could also be found that the corner vacancy of NiMoS showed more superiorities, not only in the contributions to the C-S bond cleavages of DBT and 4,6-DMDBT but also in the generation and regeneration processes of active sites. Consequently, the barriers of C-S bond cleavages over NiMoS corner sites were as low as 1.16 and 1.22 eV for DBT and 4,6-DMDBT, respectively. Furthermore, the formation energy of the single corner vacancy over NiMoS was 0.78 eV. The relative DFT researches provided atomic-scale insights into the catalytic cycle and the role of corner vacancy in the HDS reaction on Co/Ni-promoted catalysts, which were of significance for the design of highly active Mo-based HDS catalysts. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zheng, Peng; Xiao, Chengkun; Wang, Xilong; Fan, Jiyuan; Duan, Aijun; Xu, Chunming] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Li, Tianshu; Chi, Kebin] PetroChina Co Ltd, Petrochem Res Inst, Beijing 102206, Peoples R China.
RP Duan, AJ; Xu, CM (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
EM duanaijun@cup.edu.cn; xcm@cup.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676298, 21878330, U1463207, 21503152]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21676298, 21878330, U1463207 and 21503152).
CR BOUWENS SMAM, 1991, J PHYS CHEM-US, V95, P123, DOI 10.1021/j100154a028
   BOUWENS SMAM, 1990, CATAL LETT, V5, P273, DOI 10.1007/BF00764672
   Cristol S, 2006, J CATAL, V239, P145, DOI 10.1016/j.jcat.2006.01.015
   DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452
   Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015
   Ding SJ, 2017, J CATAL, V345, P24, DOI 10.1016/j.jcat.2016.11.011
   Gronborg SS, 2016, J CATAL, V344, P121, DOI 10.1016/j.jcat.2016.09.004
   Gutierrez OY, 2011, J CATAL, V281, P50, DOI 10.1016/j.jcat.2011.04.001
   HALGREN TA, 1977, CHEM PHYS LETT, V49, P225, DOI 10.1016/0009-2614(77)80574-5
   Huang YC, 2016, J PHYS CHEM C, V120, P12012, DOI 10.1021/acs.jpcc.6b02769
   Humbert S, 2016, J CATAL, V333, P78, DOI 10.1016/j.jcat.2015.10.016
   Krebs E, 2008, CATAL TODAY, V130, P160, DOI 10.1016/j.cattod.2007.06.081
   Krebs E, 2008, J CATAL, V260, P276, DOI 10.1016/j.jcat.2008.09.026
   Lauritsen JV, 2015, J CATAL, V328, P49, DOI 10.1016/j.jcat.2014.12.034
   Lauritsen JV, 2004, J CATAL, V224, P94, DOI 10.1016/j.jcat.2004.02.009
   Li HP, 2016, AICHE J, V62, P2087, DOI 10.1002/aic.15161
   LOUWERS SPA, 1992, J CATAL, V133, P94, DOI 10.1016/0021-9517(92)90188-N
   Moses PG, 2007, J CATAL, V248, P188, DOI 10.1016/j.jcat.2007.02.028
   Moses PG, 2009, J CATAL, V268, P201, DOI 10.1016/j.jcat.2009.09.016
   Nikulshin PA, 2014, J CATAL, V312, P152, DOI 10.1016/j.jcat.2014.01.014
   Oyama ST, 2009, J CATAL, V268, P209, DOI 10.1016/j.jcat.2009.09.018
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671
   Prodhomme PY, 2011, J CATAL, V280, P178, DOI 10.1016/j.jcat.2011.03.017
   Rangarajan S, 2017, ACS CATAL, V7, P501, DOI 10.1021/acscatal.6b02735
   Rangarajan S, 2015, AICHE J, V61, P4036, DOI 10.1002/aic.15025
   Saric M, 2018, J CATAL, V358, P131, DOI 10.1016/j.jcat.2017.12.001
   Saric M, 2017, PHYS CHEM CHEM PHYS, V19, P2017, DOI 10.1039/c6cp06881b
   Song CS, 2003, CATAL TODAY, V86, P211, DOI 10.1016/S0920-5861(03)00412-7
   Topsoe H, 2007, APPL CATAL A-GEN, V322, P3, DOI 10.1016/j.apcata.2007.01.002
   Tuxen AK, 2012, J CATAL, V295, P146, DOI 10.1016/j.jcat.2012.08.004
   Walton AS, 2013, J CATAL, V308, P306, DOI 10.1016/j.jcat.2013.08.017
   Wang HM, 2009, J CATAL, V264, P31, DOI 10.1016/j.jcat.2009.03.011
   Weber T, 2008, CATAL TODAY, V130, P170, DOI 10.1016/j.cattod.2007.06.078
   Zheng P, 2017, CHEM ENG SCI, V164, P292, DOI 10.1016/j.ces.2017.02.037
   Zhu HY, 2011, ACS CATAL, V1, P1498, DOI 10.1021/cs2002548
   Zhu YY, 2014, ANGEW CHEM INT EDIT, V53, P10723, DOI 10.1002/anie.201405690
NR 37
TC 0
Z9 0
U1 21
U2 86
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 249
EP 260
DI 10.1016/j.ces.2019.05.032
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700020
DA 2020-05-12
ER

PT J
AU Tarasenko, A
AF Tarasenko, Alexander
TI The general theory of diffusion in a mixture of molecules coadsorbed on
   a homogeneous two-dimensional lattice
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multicomponent diffusion; Non-equilibrium statistical mechanics; Lattice
   gas systems; Monte Carlo methods
ID SURFACE-DIFFUSION; MULTICOMPONENT DIFFUSION; COLLECTIVE DIFFUSION;
   BINARY DIFFUSION; COEFFICIENTS; STATE; SIMULATIONS; ZEOLITE; MODELS;
   GASES
AB The diffusion in the multicomponent mixture of molecules coadsorbed on a surface with a square symmetry of the adsorption sites is investigated in the framework of a lattice gas model by a theoretical approach and the Monte Carlo simulations. Using the approach based on the theory of the non-equilibrium statistical operator I have derived the systems of equations describing the diffusion of the molecules in the Fickian and Onsager forms and obtained the analytical expressions for the Fickian diffusivities. These expressions are derived taking into account the lateral interactions between the molecules and the interactions of the activated molecules in the saddle points of the lattice potential relief with their surroundings. The diffusion equations in the Fickian representation exactly coincide with the corresponding classical counterparts, but the Onsager-like transport equations differ from their standard lore. In the new Onsager representation the migration of the diffusants is controlled only by the gradients of their own chemical potentials and the cross terms are absent. The Monte Carlo simulations have been used to test the correctness of the new expressions. There is a very good coincidence between the analytical and numerical data in the whole coverage region and in the wide range of the lateral interactions. The lateral interactions substantially influence on the behavior of the thermodynamic quantities and the Fickian diffusivities. These results demonstrate that the classical description in the Onsager presentation is not universal and cannot be applied for some lattice gas systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tarasenko, Alexander] AS CR, Inst Phys, Na Slovance 1999-2, Prague 18221, Czech Republic.
   [Tarasenko, Alexander] Palacky Univ, Fac Sci, Joint Lab Opt, 17 Listopadu 12, Olomouc 77146, Czech Republic.
RP Tarasenko, A (reprint author), AS CR, Inst Phys, Na Slovance 1999-2, Prague 18221, Czech Republic.
EM taras@fzu.cz
RI Tarasenko, Alexander/G-5644-2014
OI Tarasenko, Alexander/0000-0001-7788-1078
FU MSMT CRMinistry of Education, Youth & Sports - Czech Republic [MEYS
   "SAFMAT" LM2015088, LO1409, 02.1.01/0.0/0.0/17_049/0008422]
FX This work has been supported by the projects MEYS "SAFMAT" LM2015088 and
   LO1409 and by the project CZ. 02.1.01/0.0/0.0/17_049/0008422 of the MSMT
   CR. The author acknowledges Professor Felix Nieto for his valuable help
   in the preparation of the reference list.
CR Ala-Nissila T, 2002, ADV PHYS, V51, P949, DOI 10.1080/00018730110107902
   ALEXANDROWICZ Z, 1976, J STAT PHYS, V14, P1, DOI 10.1007/BF01020131
   Baron P., 2017, REACTION RATE THEORY
   Benes NE, 2002, CHEM ENG SCI, V57, P2673, DOI 10.1016/S0009-2509(02)00154-9
   CHUMAK AA, 1980, SURF SCI, V91, P694, DOI 10.1016/0039-6028(80)90360-X
   Curtiss CF, 1999, IND ENG CHEM RES, V38, P2515, DOI 10.1021/ie9901123
   Curtiss CF, 1996, P NATL ACAD SCI USA, V93, P7440, DOI 10.1073/pnas.93.15.7440
   Cussler E., 1976, MULTICOMPONENT DIFFU
   Danani A, 1997, INT J MOD PHYS B, V11, P2217, DOI 10.1142/S0217979297001155
   Evans MG, 1935, T FARADAY SOC, V31, P0875, DOI 10.1039/tf9353100875
   Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604
   FERRANDO R, 1992, SURF SCI, V265, P273, DOI 10.1016/0039-6028(92)90507-3
   Forster D., 1975, HYDRODYNAMIC FLUCTUA
   Herm ZR, 2013, SCIENCE, V340, P960, DOI 10.1126/science.1234071
   Karger J., 2012, DIFFUSION NANOPOROUS
   Keil FJ, 2000, REV CHEM ENG, V16, P71
   Kizilyalli M, 1999, PURE APPL CHEM, V71, P1307, DOI 10.1351/pac199971071307
   KRISHNA R, 1990, CHEM ENG SCI, V45, P1779, DOI 10.1016/0009-2509(90)87055-W
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Krylov SY, 1999, SURF SCI, V420, P233, DOI 10.1016/S0039-6028(98)00836-X
   Lam SH, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2221312
   LANE JE, 1965, CAN J CHEMISTRY, V43, P1812, DOI 10.1139/v65-239
   LOMBARDO SJ, 1991, SURF SCI REP, V13, P1
   MA YH, 1977, IND ENG CHEM FUND, V16, P44, DOI 10.1021/i160061a011
   Maceiras DB, 2002, LANGMUIR, V18, P7393, DOI 10.1021/la025972u
   Manzi SJ, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.062104
   Marcelin R, 1915, ANN PHYS, V3, P120, DOI [DOI 10.1051/ANPHYS/191509030120, 10.1051/anphys/191509030120]
   Mazenko G. F., 1983, SURFACE MOBILITIES S
   METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114
   Newman J, 2009, CHEM ENG SCI, V64, P4796, DOI 10.1016/j.ces.2009.07.002
   NEWMAN MEJ, 1999, MONTE CARLO METHODS
   Onsager L, 1931, PHYS REV, V38, P2265, DOI 10.1103/PhysRev.38.2265
   REED DA, 1981, SURF SCI, V102, P588, DOI 10.1016/0039-6028(81)90048-0
   Reichl L. E., 1998, MODERN COURSE STAT P
   Sanborn MJ, 2001, AICHE J, V47, P2032, DOI 10.1002/aic.690470914
   Sanborn MJ, 2000, SEP PURIF TECHNOL, V20, P1, DOI 10.1016/S1383-5866(00)00067-8
   Sholl DS, 2006, LANGMUIR, V22, P3707, DOI 10.1021/la053405b
   Sirkar K.K., 2014, SEPARATION MOL MACRO
   Skoulidas AI, 2003, J MEMBRANE SCI, V227, P123, DOI 10.1016/j.memsci.2003.08.021
   Skoulidas AI, 2003, LANGMUIR, V19, P7977, DOI 10.1021/la034759a
   Tarasenko A, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.085401
   Tarasenko A, 2019, SEP PURIF TECHNOL, V224, P421, DOI 10.1016/j.seppur.2019.05.003
   Tarasenko A, 2018, PHYSICA E, V95, P37, DOI 10.1016/j.physe.2017.09.005
   Tarasenko A, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4945607
   Tarasenko A, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4890370
   TAYLOR R, 1993, MULTICOMPONENT MASS
   THEODOROU DN, 1996, COMPREHENSIVE SUPRAM, V7, P507
   UEBING C, 1991, J CHEM PHYS, V95, P7626, DOI 10.1063/1.461336
   van Kampen NG, 2007, NORTH-HOLL PERS LIBR, P1
   Viljoen EC, 1997, LANGMUIR, V13, P1001, DOI 10.1021/la950782n
   YANG RT, 1991, CHEM ENG SCI, V46, P3089, DOI 10.1016/0009-2509(91)85012-M
   ZHDANOV VP, 1988, SURF SCI, V194, P1
   Zubarev D. N., 1962, SOV PHYS DOKL, V6, P776
NR 53
TC 0
Z9 0
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 261
EP 271
DI 10.1016/j.ces.2019.05.031
PG 11
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700021
DA 2020-05-12
ER

PT J
AU Hallmark, B
   Chen, CH
   Davidson, JF
AF Hallmark, B.
   Chen, C-H
   Davidson, J. F.
TI Experimental and simulation studies of the shape and motion of an air
   bubble contained in a highly viscous liquid flowing through an orifice
   constriction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multipass rheometer; Two-phase flow; Bubble motion; Volume of fluid
   method; OpenFOAM; Viscosity averaging rules
ID NUMERICAL-SIMULATION; MULTIPASS RHEOMETER; MULTIPHASE FLOWS; CUSP
   FORMATION; SHEAR; CRYSTALLIZATION; POLYETHYLENE; DEFORMATION;
   MICROCHANNELS; EQUATIONS
AB This paper reports an experimental and computational study on the shape and motion of an air bubble, contained in a highly viscous Newtonian liquid, as it passes through a rectangular channel having a con- striction orifice. The magnitude of the viscosity ratios, lambda, and capillary numbers, Ca, explored is high: 5.5 x 10(5) < lambda < 3.9 x 10(6) and 2.9 < Ca < 35.9 respectively. A multipass rheometer is used for the experimental work: air bubbles are suspended in 10 Pa s and 70 Pa s polybutene viscosity standards and passed through an orifice-plate geometry constructed within an optical flow-cell. High levels of bubble distortion are observed, including bubbles that resemble 'crescent moons'. Simulation work is carried out using an implementation of the volume of fluid method in the freely-available finite-volume computational fluid dynamics code OpenFOAM. Quantitative data pertaining to the motion and shape of the bubble was extracted from both the experimental and simulation work. Initially, a good match between numerical simulation and experimental work could not be obtained: this problem was alleviated by changing the viscosity averaging method from an arithmetic mean to a logarithmically-weighted arithmetic mean. Medium- and high-resolution simulations using this new viscosity averaging method were able to match experimental data with coefficients of determination, R-2, typically 0.898 < / R-2 < 0.985. (C) 2019 Published by Elsevier Ltd.
C1 [Hallmark, B.; Chen, C-H; Davidson, J. F.] Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
RP Hallmark, B (reprint author), Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM bh206@cam.ac.uk
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/N00230X/1]
FX Thanks are due to Dr Jie Li for useful discussions, Mr Greville Wild and
   his team for hosting the Linux cluster at the West Cambridge Data
   Centre, and Mr Peter Davidson for initiating the project. Funding is
   gratefully acknowledged from the EPSRC, grant EP/N00230X/1. EP/N00230X/1
CR Afkhami S, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4817374
   Amran YHM, 2015, CONSTR BUILD MATER, V101, P990, DOI 10.1016/j.conbuildmat.2015.10.112
   Ayachit U., 2015, PARAVIEW GUIDE UPDAT
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Carvajal D, 2015, CHEM ENG TECHNOL, V38, P473, DOI 10.1002/ceat.201400449
   Chen G, 2014, NOTICES AMS, V61, P354, DOI DOI 10.1090/NOTI/201404
   Chung T. J., 2002, COMPUTATIONAL FLUID
   Collis MW, 2005, J NON-NEWTON FLUID, V128, P29, DOI 10.1016/j.jnnfm.2005.02.010
   COLLISHAW PG, 1994, J MATER SCI, V29, P2261, DOI 10.1007/BF00363413
   COURANT R, 1967, IBM J RES DEV, V11, P215, DOI 10.1147/rd.112.0215
   de Chaumont F, 2011, I S BIOMED IMAGING, P234, DOI 10.1109/ISBI.2011.5872395
   Dufour A, 2011, IEEE T IMAGE PROCESS, V20, P1925, DOI 10.1109/TIP.2010.2099125
   Harvie DJE, 2006, APPL MATH MODEL, V30, P1056, DOI 10.1016/j.apm.2005.08.015
   HINCH EJ, 1980, J FLUID MECH, V98, P305, DOI 10.1017/S0022112080000171
   Hoang DA, 2013, COMPUT FLUIDS, V86, P28, DOI 10.1016/j.compfluid.2013.06.024
   Hua J, 2008, J COMPUT PHYS, V227, P3358, DOI 10.1016/j.jcp.2007.12.002
   Hua J, 2007, J COMPUT PHYS, V222, P769, DOI 10.1016/j.jcp.2006.08.008
   ISSA RI, 1986, J COMPUT PHYS, V62, P40, DOI 10.1016/0021-9991(86)90099-9
   Kameda M, 2008, FLUID DYN RES, V40, P576, DOI 10.1016/j.fluiddyn.2007.12.010
   Khayat RE, 2000, INT J MULTIPHAS FLOW, V26, P17, DOI 10.1016/S0301-9322(98)00083-4
   Khodaparast S, 2015, MICROFLUID NANOFLUID, V19, P209, DOI 10.1007/s10404-015-1566-4
   Klostermann J, 2013, INT J NUMER METH FL, V71, P960, DOI 10.1002/fld.3692
   KOPFSILL AR, 1988, PHYS FLUIDS, V31, P18, DOI 10.1063/1.866566
   KVALSETH TO, 1985, AM STAT, V39, P279, DOI 10.2307/2683704
   LAFAURIE B, 1994, J COMPUT PHYS, V113, P134, DOI 10.1006/jcph.1994.1123
   Lee K, 2001, CHEM ENG SCI, V56, P5653, DOI 10.1016/S0009-2509(01)00153-1
   Lorstad D, 2004, J COMPUT PHYS, V200, P153, DOI 10.1016/j.jcp.2004.04.001
   Mackley MR, 2011, J NON-NEWTON FLUID, V166, P421, DOI 10.1016/j.jnnfm.2011.01.007
   MACKLEY MR, 1995, J RHEOL, V39, P1293, DOI 10.1122/1.550637
   Mackley MR, 2000, J MATER SCI, V35, P5247, DOI 10.1023/A:1004824924912
   Mader HM, 2013, J VOLCANOL GEOTH RES, V257, P135, DOI 10.1016/j.jvolgeores.2013.02.014
   Mezzenga R, 2005, NAT MATER, V4, P729, DOI 10.1038/nmat1496
   Mora CF, 2000, CEMENT CONCRETE RES, V30, P351, DOI 10.1016/S0008-8846(99)00259-8
   Nekouei M, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4978801
   Ohta M, 2005, INT J MULTIPHAS FLOW, V31, P223, DOI 10.1016/j.ijmultiphaseflow.2004.12.001
   Ostwald W., 1897, Z PHYS CHEM, V22, P189
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   PATANKAR SV, 1972, INT J HEAT MASS TRAN, V15, P1787, DOI 10.1016/0017-9310(72)90054-3
   Pellegrini F, 1997, LECT NOTES COMPUT SC, V1225, P370
   PELLEGRINI F, 1994, PROCEEDINGS OF THE SCALABLE HIGH-PERFORMANCE COMPUTING CONFERENCE, P486, DOI 10.1109/SHPCC.1994.296682
   Pozrikidis C, 1998, J FLUID MECH, V357, P29, DOI 10.1017/S0022112097007866
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   RALLISON JM, 1984, ANNU REV FLUID MECH, V16, P45, DOI 10.1146/annurev.fl.16.010184.000401
   Ranganathan M, 1999, J RHEOL, V43, P443, DOI 10.1122/1.550990
   RICHARDSON JF, 1954, CHEM ENG SCI, V3, P65, DOI 10.1016/0009-2509(54)85015-9
   Rust AC, 2002, J COLLOID INTERF SCI, V249, P476, DOI 10.1006/jcis.2002.8292
   Sargent M., 2018, THESIS
   Scelsi L, 2008, RHEOL ACTA, V47, P895, DOI 10.1007/s00397-008-0278-z
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shikhmurzaev YD, 1998, J FLUID MECH, V359, P313, DOI 10.1017/S0022112098008532
   Siegel M, 2000, J FLUID MECH, V412, P227, DOI 10.1017/S002211200000834X
   So KK, 2011, J COMPUT PHYS, V230, P5155, DOI 10.1016/j.jcp.2011.03.011
   Sonwai S, 2006, J AM OIL CHEM SOC, V83, P583, DOI 10.1007/s11746-006-1243-6
   Taha T, 2006, CHEM ENG SCI, V61, P665, DOI 10.1016/j.ces.2005.07.023
   Thompson MJ, 2001, J RHEOL, V45, P1341, DOI 10.1122/1.1410371
   Tuladhar TR, 2004, CHEM ENG SCI, V59, P5997, DOI 10.1016/j.ces.2004.07.054
   VOORHEES PW, 1985, J STAT PHYS, V38, P231, DOI 10.1007/BF01017860
   Wallis G. B., 1974, International Journal of Multiphase Flow, V1, P491, DOI 10.1016/0301-9322(74)90003-2
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   WILLIAMS DJ, 1992, CVGIP-IMAG UNDERSTAN, V55, P14, DOI 10.1016/1049-9660(92)90003-L
   Worner M, 2012, MICROFLUID NANOFLUID, V12, P841, DOI 10.1007/s10404-012-0940-8
NR 61
TC 1
Z9 1
U1 7
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 272
EP 288
DI 10.1016/j.ces.2019.04.043
PG 17
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700022
DA 2020-05-12
ER

PT J
AU Altree-Williams, A
   Brugger, J
   Pring, A
   Bedrikovetsky, P
AF Altree-Williams, A.
   Brugger, J.
   Pring, A.
   Bedrikovetsky, P.
TI Coupled reactive flow and dissolution with changing reactive surface and
   porosity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactive flow; Mineral dissolution; Porous media; Mathematical model;
   Exact solution; Reactive surface
ID POROUS-MEDIA; FILTRATION FUNCTION; PARTICLE-TRACKING; BATCH DISSOLUTION;
   MASS-TRANSFER; TRANSPORT; MODEL; WATER; PERMEABILITY; SUSPENSIONS
AB Mineral dissolution flows in porous media occur in numerous industrial and natural processes. We investigate the effects of varying rock-liquid interface on mineral dissolution transport in porous media. The one-dimensional mineral-dissolution flow problem that accounts for varying reacting interface and porosity is essentially non-linear. However, a novel exact solution is derived. The exact solution reveals a four-zone structure of the flow pattern with typical mineral concentration curves in all zones. The exact solution allows for a simplified inverse solver, facilitating determination of the surface function from laboratory reactive flow tests. Accounting for surface area evolution in the governing system of equations allows for significant improvement of matching the experimental data if compared with the constant-surface model. Moreover, the comparison between the analytical model and laboratory data reveals high agreement. The values of equilibrium mineral concentration as obtained from the matching and by thermodynamic calculations exhibit close agreement. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Altree-Williams, A.; Bedrikovetsky, P.] Univ Adelaide, Adelaide, SA 5005, Australia.
   [Brugger, J.] Monash Univ, Clayton, Vic 3800, Australia.
   [Pring, A.] Flinders Univ S Australia, Bedford Pk, SA 5042, Australia.
RP Bedrikovetsky, P (reprint author), Univ Adelaide, Adelaide, SA 5005, Australia.
EM pavel.russia@gmail.com
RI Brugger, Joel/C-7113-2008
OI Brugger, Joel/0000-0003-1510-5764
FU Australian Research CouncilAustralian Research Council [DP140102765,
   LP150100626, LP160101497]
FX The authors are grateful to Eng. T. Russell and A/Prof. Yung Ngothai
   (The University of Adelaide) for fruitful and encouraging discussions.
   Many thanks are due to David H. Levin (Murphy, NC, USA) who provided
   professional English-language editing of this article. The authors thank
   Australian Research Council for grants DP140102765, LP150100626 and
   LP160101497.
CR Alexeev A, 2015, TRANSPORT POROUS MED, V106, P545, DOI 10.1007/s11242-014-0413-5
   Altree-Williams A, 2018, TRANSPORT POROUS MED, V124, P655, DOI 10.1007/s11242-018-1088-0
   Altree-Williams A, 2017, ACS EARTH SPACE CHEM, V1, P89, DOI 10.1021/acsearthspacechem.6b00012
   Altree-Williams A, 2015, EARTH-SCI REV, V150, P628, DOI 10.1016/j.earscirev.2015.08.013
   Alvarez AC, 2006, INVERSE PROBL, V22, P69, DOI 10.1088/0266-5611/22/1/005
   Alvarez AC, 2007, TRANSPORT POROUS MED, V70, P43, DOI 10.1007/s11242-006-9082-3
   Appelo CAJ, 2004, GEOCHEMISTRY GROUNDW
   Battiato I, 2011, J CONTAM HYDROL, V120-21, P18, DOI 10.1016/j.jconhyd.2010.05.005
   Battiato I, 2011, ADV WATER RESOUR, V34, P1140, DOI 10.1016/j.advwatres.2011.01.012
   Bedrikovetsky P, 2008, TRANSPORT POROUS MED, V75, P335, DOI 10.1007/s11242-008-9228-6
   Bedrikovetsky P, 2013, MATH THEORY OIL GAS
   Bedrikovetsky P, 2017, CHEM ENG J, V330, P1148, DOI 10.1016/j.cej.2017.08.031
   Bedrikovetsky P, 2011, TRANSPORT POROUS MED, V86, P383, DOI 10.1007/s11242-010-9626-4
   Bethke C., 2018, CHEMPLUGIN USERS GUI
   BOX JC, 1986, HYDROMETALLURGY, V16, P77, DOI 10.1016/0304-386X(86)90053-8
   Burnham K.P., 2003, MODEL SELECTION MULT
   Chrysikopoulos CV, 2014, ENVIRON SCI TECHNOL, V48, P6805, DOI 10.1021/es501295n
   Cohen D, 2017, CHEM ENG SCI, V166, P101, DOI 10.1016/j.ces.2017.03.032
   Coleman TF, 1996, SIAM J OPTIMIZ, V6, P418, DOI 10.1137/0806023
   Colon CFJ, 2004, GEOCHIM COSMOCHIM AC, V68, P805, DOI 10.1016/j.gca.2003.06.002
   Courant R, 1989, METHODS MATH PHYS
   Dagan G, 2013, ADV WATER RESOUR, V51, P67, DOI 10.1016/j.advwatres.2011.12.017
   Datta-Gupta A, 2007, STREAMLINE SIMULATIO
   Ding BB, 2018, CHEM ENG SCI, V175, P1, DOI 10.1016/j.ces.2017.09.033
   Eberts SM, 2012, HYDROGEOL J, V20, P263, DOI 10.1007/s10040-011-0810-6
   Fischer C, 2018, P NATL ACAD SCI USA, V115, P897, DOI 10.1073/pnas.1711254115
   Fogler HS, 2006, ELEMENTS CHEM REACTI
   Hayek M, 2015, TRANSPORT POROUS MED, V107, P403, DOI 10.1007/s11242-014-0445-x
   Hayek M, 2012, WATER RESOUR RES, V48, DOI 10.1029/2011WR011663
   Hayek M, 2011, WATER RESOUR RES, V47, DOI 10.1029/2010WR010321
   Hussain F, 2012, TRANSPORT POROUS MED, V92, P187, DOI 10.1007/s11242-011-9897-4
   James SC, 2001, CHEM ENG SCI, V56, P6535, DOI 10.1016/S0009-2509(01)00344-X
   Jung YJ, 2017, COMPUT GEOSCI-UK, V108, P2, DOI 10.1016/j.cageo.2016.09.009
   Katzourakis VE, 2018, WATER RESOUR RES, V54, P3841, DOI 10.1029/2017WR021996
   Katzourakis VE, 2015, J CONTAM HYDROL, V181, P102, DOI 10.1016/j.jconhyd.2015.05.010
   Lake L.W., 2014, FUNDAMENTALS ENHANCE
   Landau L D, 1987, FLUID MECH
   LASAGA AC, 1998, PR S GEOCH, P3
   LICHTNER PC, 1988, GEOCHIM COSMOCHIM AC, V52, P143, DOI 10.1016/0016-7037(88)90063-4
   Lichtner PC, 2003, STOCH ENV RES RISK A, V17, P419, DOI 10.1007/s00477-003-0163-3
   Luquot L, 2014, TRANSPORT POROUS MED, V101, P507, DOI 10.1007/s11242-013-0257-4
   Luttge A, 2019, CHEM GEOL, V504, P216, DOI 10.1016/j.chemgeo.2018.11.016
   Maikov IL, 2007, CHEM ENG SCI, V62, P1388, DOI 10.1016/j.ces.2006.11.038
   Mikolajczyk G, 2018, CHEM ENG SCI, V175, P257, DOI 10.1016/j.ces.2017.09.054
   MILLERO FJ, 1984, GEOCHIM COSMOCHIM AC, V48, P1141, DOI 10.1016/0016-7037(84)90205-9
   Noiriel C, 2009, CHEM GEOL, V265, P160, DOI 10.1016/j.chemgeo.2009.01.032
   Olajire AA, 2013, J PETROL SCI ENG, V109, P364, DOI 10.1016/j.petrol.2013.03.013
   Parkhurst D.L., 2013, DESCRIPTION INPUT EX
   Petersen J, 2016, HYDROMETALLURGY, V165, P206, DOI 10.1016/j.hydromet.2015.09.001
   Polyanin A., 1994, METHODS MODELING EQU
   Polyanin A.D., 2012, HDB NONLINEAR PARTIA, pxxxvi+876
   Polyanin A. D., 2006, HDB MATH ENG SCI
   Polyanin AD, 2004, THEOR FOUND CHEM EN+, V38, P622, DOI 10.1007/s11236-005-0035-2
   Prausnitz JM, 1998, MOL THERMODYNAMICS F
   Putnis A, 2002, MINERAL MAG, V66, P689, DOI 10.1180/0026461026650056
   Putnis A, 2015, REV MINERAL GEOCHEM, V80, P1, DOI 10.2138/rmg.2015.80.01
   Putnis A, 2009, REV MINERAL GEOCHEM, V70, P87, DOI 10.2138/rmg.2009.70.3
   Reverberi AP, 2002, CHEM ENG SCI, V57, P3733, DOI 10.1016/S0009-2509(02)00244-0
   Robb L., 2013, INTRO ORE FORMING PR
   Sadeghi A, 2018, CHEM ENG SCI, V176, P180, DOI 10.1016/j.ces.2017.10.038
   Schechter R. S., 1992, OIL WELL STIMULATION
   Scheibe TD, 2015, GROUNDWATER, V53, P38, DOI 10.1111/gwat.12179
   Shampine L. F., 2005, Applied Numerical Analysis and Computational Mathematics, V2, P346, DOI 10.1002/anac.200510025
   Shampine LE, 2005, APPL MATH LETT, V18, P1134, DOI 10.1016/j.aml.2004.11.007
   Shapiro AA, 2008, CHEM ENG J, V142, P14, DOI 10.1016/j.cej.2007.11.006
   Shapiro AA, 2007, PHYSICA A, V375, P81, DOI 10.1016/j.physa.2006.08.033
   SHARMA MM, 1987, AICHE J, V33, P1636, DOI 10.1002/aic.690331007
   SHARMA MM, 1987, AICHE J, V33, P1654, DOI 10.1002/aic.690331009
   Sinclair L, 2015, HYDROMETALLURGY, V157, P306, DOI 10.1016/j.hydromet.2015.08.022
   Siuliukina N, 2018, WATER RESOUR RES, V54, P61, DOI 10.1002/2017WR020867
   Sorbie KS, 2018, TRANSPORT POROUS MED, V123, P271, DOI 10.1007/s11242-018-1040-3
   Spiess Andrej-Nikolai, 2010, BMC Pharmacology, V10, P6, DOI 10.1186/1471-2210-10-6
   Stepanek V, 2018, CHEM ENG SCI, V191, P410, DOI 10.1016/j.ces.2018.07.003
   Tartakovsky DM, 2011, J CONTAM HYDROL, V120-21, P129, DOI 10.1016/j.jconhyd.2010.08.009
   Tartakovsky DM, 2009, WATER RESOUR RES, V45, DOI 10.1029/2008WR007383
   Tikhonov AN, 1963, EQUATIONS MATH PHYS
   Truesdale VW, 2018, ENVIRON CHEM, V15, P113, DOI 10.1071/EN17199
   Truesdale VW, 2015, AQUAT GEOCHEM, V21, P365, DOI 10.1007/s10498-015-9265-z
   Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482
   Yang L, 2017, CHEM ENG SCI, V169, P106, DOI 10.1016/j.ces.2016.12.003
   You ZJ, 2014, CHEM ENG J, V258, P374, DOI 10.1016/j.cej.2014.07.051
   Yuan H., 2012, COLLOIDS CLASSIFICAT
   Yuan H, 2010, CHEM ENG J, V162, P974, DOI 10.1016/j.cej.2010.07.003
   Zhang H, 2018, INT J NONLIN MECH, V105, P27, DOI 10.1016/j.ijnonlinmec.2018.07.007
   Zhou K, 2017, CHEM ENG SCI, V167, P288, DOI 10.1016/j.ces.2017.04.026
NR 85
TC 0
Z9 0
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 289
EP 304
DI 10.1016/j.ces.2019.05.016
PG 16
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700023
DA 2020-05-12
ER

PT J
AU Chen, CH
   Perera, A
   Jackson, P
   Hallmark, B
   Davidson, JF
AF Chen, C-H
   Perera, A.
   Jackson, P.
   Hallmark, B.
   Davidson, J. F.
TI The distortion of a horizontal soap film due to the impact of a falling
   sphere
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Foams; Thin liquid films; Froth flotation; Bubbles; Liquid menisci
ID ATTACHMENT; PARTICLES; COLLAPSE
AB A horizontal soap film is established in vertical tube a few centimetres in diameter. A metal sphere, 1-2 mm diameter, is dropped onto the film, whose distortion is observed by means of a high speed camera. The film wraps partly around the sphere, detaching at a circle which moves up the sphere as it falls.
   The shape of the film at successive radii, bigger than the radius of contact, was predicted from theory relying on the proposition that if both sides of the film are open to atmosphere, there can be no pressure difference across it. The pressure difference across a film is proportional to (surface tension)/(radius of curvature); hence it follows that the radii of curvature in two planes, perpendicular to each other and to the film surface, must be equal and opposite. This proposition gives equations predicting the shape, in reasonable agreement with experiment.
   This theory is compared with the theory of catenoids, first studied by Euler in 1744. Catenoid theory gives exactly the same results as the 'radius of curvature' theory presented here. A simple energy conservation argument shows that the two theories are compatible and agree with a published photograph of a soap film catenoid. (C) 2019 Published by Elsevier Ltd.
C1 [Chen, C-H; Perera, A.; Jackson, P.; Hallmark, B.; Davidson, J. F.] Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
RP Hallmark, B (reprint author), Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM bh206@cam.ac.uk
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/N00230X/1]
FX The work was supported by EPSRC contract number EP/N00230X/1. The
   authors are grateful to P.J. Davidson, who initiated the project.
CR Albijanic B, 2014, MINER ENG, V65, P187, DOI 10.1016/j.mineng.2014.06.008
   CHOPP DL, 1993, [No title captured], V2, P235
   Colding TH, 2006, P NATL ACAD SCI USA, V103, P11106, DOI 10.1073/pnas.0510379103
   Courbin L, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2336102
   Craik ADD, 2010, J ENG MATH, V67, P95, DOI 10.1007/s10665-009-9298-7
   CRYER SA, 1992, J COLLOID INTERF SCI, V154, P276, DOI 10.1016/0021-9797(92)90101-Q
   Davies IT, 2018, P ROY SOC A-MATH PHY, V474, DOI 10.1098/rspa.2018.0533
   Davies IT, 2012, J RHEOL, V56, P473, DOI 10.1122/1.3687415
   Dierkes U, 2010, GRUNDLEHR MATH WISS, V339, pXI, DOI 10.1007/978-3-642-11698-8
   Euler L., 1744, CURVIS ELASTICIS MET
   Gilet T, 2009, J FLUID MECH, V625, P167, DOI 10.1017/S0022112008005442
   Gullberg J., 1997, EUR J PHYS, V31, P357
   Kim I, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.026313
   Kirstetter G, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.036303
   Le Goff A, 2008, EPL-EUROPHYS LETT, V84, DOI 10.1209/0295-5075/84/36001
   Lee J, 2016, GEOTECH SP, P1, DOI 10.1061/9780784480090
   Morris G, 2012, MINER ENG, V33, P87, DOI 10.1016/j.mineng.2011.09.015
   Morris G., 2010, EFFECTS HYDROPHOBICI
   Morris G, 2015, CURR OPIN COLLOID IN, V20, P98, DOI 10.1016/j.cocis.2015.03.001
   Morris GDM, 2014, INT J MINER PROCESS, V131, P1, DOI 10.1016/j.minpro.2014.07.004
   Oldfather W.A., 1933, ISIS, V20, P72, DOI [10.1086/346767, DOI 10.1086/346767]
   Oprea J., 2000, MATH SOAP FILMS EXPL
   ORR FM, 1975, J FLUID MECH, V67, P723, DOI 10.1017/S0022112075000572
   Perez J., 2017, NOT AM MATH SOC, V64, P347
   Plateau J., 1873, EXPT THEORETICAL STA, V1
   Robinson ND, 2001, J COLLOID INTERF SCI, V241, P448, DOI 10.1006/jcis.2001.7717
   Salkin L, 2014, AM J PHYS, V82, P839, DOI 10.1119/1.4879541
   Schoen H. A., 1970, NASATND5541
   Seiwert J, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.094501
   Stechemesser H, 1999, INT J MINER PROCESS, V56, P117, DOI 10.1016/S0301-7516(98)00045-3
   Stogin BB, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat3276
   TAYLOR GI, 1973, J FLUID MECH, V58, P625, DOI 10.1017/S0022112073002375
   Verrelli DI, 2011, CHEM ENG SCI, V66, P5910, DOI 10.1016/j.ces.2011.08.016
NR 33
TC 0
Z9 0
U1 5
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 305
EP 314
DI 10.1016/j.ces.2019.04.041
PG 10
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700024
DA 2020-05-12
ER

PT J
AU Zelin, J
   Regenhardt, SA
   Meyer, CI
   Duarte, HA
   Sebastian, V
   Marchi, AJ
AF Zelin, Juan
   Regenhardt, Silvina A.
   Meyer, Camilo, I
   Duarte, Hernan A.
   Sebastian, Victor
   Marchi, Alberto J.
TI Selective aqueous-phase hydrogenation of D-fructose into D-mannitol
   using a highly efficient and reusable Cu-Ni/SiO2 catalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE D-fructose; D-mannitol; Cu-Ni catalysts; Selective hydrogenation; Metal
   nanoparticles; Catalyst deactivation
ID COPPER; NANOPARTICLES; NICKEL; WATER
AB D-fructose hydrogenation in aqueous phase, at 373 K and 40 bar, was performed using monometallic and bimetallic Cu-Ni/SiO2 catalysts prepared by precipitation-deposition at controlled pH, without any type of co-catalysts and/or additives in solution. The precursors and catalysts were characterized by X-ray diffraction (XRD), N-2 physisorption at 77 K, temperature programmed reduction (TPR), scanning transmission electron microscopy (STEM), energy dispersive X-ray spectroscopy (EDS) analysis, temperature programmed desorption of H-2 (H-2-TPD) and X-ray photoelectron spectroscopy (XPS). The characterization of the mono and bimetallic samples showed that metal phase is composed of nanoparticles highly dispersed on SiO2 surface. It was also found evidence that a Cu-Ni like-alloy forms in the bimetallic sample. Precisely, the best catalytic performance was obtained with the bimetallic catalyst. This was attributed to a synergistic effect between Cu and Ni, favored by the intimate contact between both elements, which was reached from the Cu-Ni coprecipitation at controlled pH over SiO2. In a three cycles experiment performed with CuNi/SiO2, partial catalyst deactivation was observed. The original activity could be recovered by ex-situ reduction under H-2 flow. By temperature programmed oxidation (TPO), it was found that this deactivation is due to surface carbon species strongly chemisorbed on the metallic phase. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zelin, Juan; Regenhardt, Silvina A.; Meyer, Camilo, I; Duarte, Hernan A.; Marchi, Alberto J.] UNL CONICET, Catalysis Sci & Engn Res Grp GICIC, INCAPE, Colectora Ruta Nacl 168,Km 0, RA-3000 Santa Fe, Argentina.
   [Sebastian, Victor] Univ Zaragoza, Aragon Inst Nanosci INA, Dept Chem Engn, Campus Rio Ebro Edificio I D, Zaragoza 50018, Spain.
   [Sebastian, Victor] CIBER Bioingn Biomat & Nanomed CIBER BBN, C Monforte de Lemos 3-5,Pabellon 11, Madrid 28029, Spain.
RP Marchi, AJ (reprint author), UNL CONICET, Catalysis Sci & Engn Res Grp GICIC, INCAPE, Colectora Ruta Nacl 168,Km 0, RA-3000 Santa Fe, Argentina.
EM amarchi@fiq.unl.edu.ar
OI /0000-0002-6873-5244; Duarte, Hernan Antonio/0000-0003-3946-3785;
   Regenhardt, Silvina/0000-0002-6660-999X
FU Universidad Nacional del Litoral (UNL) from Argentina [CAI+D
   50020150100078LI]; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET) from ArgentinaConsejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET) [PIP 2015-17]; Agencia Nacional de
   Promocion Cientifica y Tecnologica (ANPCyT) from ArgentinaANPCyT [PICT
   1892, PICT 3521]; VI National R&D&i Plan 2008-2011 - Instituto de Salud
   Carlos IIIInstituto de Salud Carlos III; European Regional Development
   FundEuropean Union (EU)
FX We thank to Universidad Nacional del Litoral (UNL, CAI+D
   50020150100078LI), Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET, PIP 2015-17) and Agencia Nacional de Promocion
   Cientifica y Tecnologica (ANPCyT, PICT 1892, PICT 3521) from Argentina
   for the financial support, and to LMA-INA-UNIZAR, Spain, for the
   transmission electronic microscopy analyses. CIBER-BBN is an initiative
   funded by the VI National R&D&i Plan 2008-2011 financed by the Instituto
   de Salud Carlos III with assistance from the European Regional
   Development Fund. Thanks are given to the ANPCyT for the purchase of the
   SPECS multitechnique analysis instrument (PME 8-2003).
CR Ahmed MJ, 2011, J TAIWAN INST CHEM E, V42, P114, DOI 10.1016/j.jtice.2010.03.011
   Ang ML, 2016, CATAL SCI TECHNOL, V6, P3394, DOI 10.1039/c5cy01885d
   Argueta-Figueroa L, 2014, PROG NAT SCI-MATER, V24, P321, DOI 10.1016/j.pnsc.2014.07.002
   Ban I, 2011, J MAGN MAGN MATER, V323, P2254, DOI 10.1016/j.jmmm.2011.04.004
   Bertone ME, 2015, APPL CATAL A-GEN, V503, P135, DOI 10.1016/j.apcata.2015.07.013
   Climent MJ, 2011, GREEN CHEM, V13, P520, DOI 10.1039/c0gc00639d
   Corma A, 2007, CHEM REV, V107, P2411, DOI 10.1021/cr050989d
   Flood AE, 1996, CARBOHYD RES, V288, P45, DOI 10.1016/0008-6215(96)00099-7
   Geffen N, 2006, J MEMBRANE SCI, V286, P45, DOI 10.1016/j.memsci.2006.09.019
   Ghoreishi SM, 2009, TRENDS FOOD SCI TECH, V20, P263, DOI 10.1016/j.tifs.2009.03.006
   Heinen AW, 2000, CARBOHYD RES, V328, P449, DOI 10.1016/S0008-6215(00)00146-4
   Heinen AW, 2001, CARBOHYD RES, V330, P381, DOI 10.1016/S0008-6215(00)00297-4
   Imhof P., 2013, CATALYTIC PROCESS DE
   Kohantorabi M, 2017, IND ENG CHEM RES, V56, P1159, DOI 10.1021/acs.iecr.6b04208
   Kuusisto J, 2005, CHEM ENG J, V115, P93, DOI 10.1016/j.cej.2005.09.020
   Liaw BJ, 2010, CHEM ENG J, V157, P140, DOI 10.1016/j.cej.2009.11.020
   Lichtenthaler FW, 2002, ACCOUNTS CHEM RES, V35, P728, DOI 10.1021/ar010071i
   Lu MH, 2019, IND ENG CHEM RES, V58, P1513, DOI 10.1021/acs.iecr.8b04517
   Majewski AJ, 2013, INT J HYDROGEN ENERG, V38, P14531, DOI 10.1016/j.ijhydene.2013.09.017
   MAKKEE M, 1985, CARBOHYD RES, V138, P225, DOI 10.1016/0008-6215(85)85106-5
   Marchi AJ, 1996, APPL CATAL A-GEN, V142, P375, DOI 10.1016/0926-860X(96)00087-7
   Meyer CI, 2009, APPL CATAL A-GEN, V367, P122, DOI 10.1016/j.apcata.2009.07.041
   MOSSER C, 1992, CLAY CLAY MINER, V40, P593, DOI 10.1346/CCMN.1992.0400514
   Naghash AR, 2006, CHEM MATER, V18, P2480, DOI 10.1021/cm051910o
   Ohrem HL, 2014, PHARM DEV TECHNOL, V19, P257, DOI 10.3109/10837450.2013.775154
   Ostgard D.J., 2007, CHEM IND
   Rodrigues EL, 2005, APPL CATAL A-GEN, V294, P197, DOI 10.1016/j.apcata.2005.07.029
   Smeds S, 1996, APPL CATAL A-GEN, V144, P177, DOI 10.1016/0926-860X(96)00103-2
   Toukoniitty B, 2005, IND ENG CHEM RES, V44, P9370, DOI 10.1021/ie050190s
   Villaverde MM, 2013, CATAL TODAY, V213, P87, DOI 10.1016/j.cattod.2013.02.031
   Zelin J, 2017, CHEM ENG J, V319, P48, DOI 10.1016/j.cej.2017.02.127
   Zhang J, 2013, CHEM ENG SCI, V99, P171, DOI 10.1016/j.ces.2013.06.002
   Zhong JS, 2017, J NON-CRYST SOLIDS, V462, P17, DOI 10.1016/j.jnoncrysol.2017.02.005
NR 33
TC 3
Z9 3
U1 19
U2 148
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 315
EP 326
DI 10.1016/j.ces.2019.05.042
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700025
DA 2020-05-12
ER

PT J
AU Domaschke, M
   Strunz, L
   Peukert, W
AF Domaschke, Maximilian
   Strunz, Lea
   Peukert, Wolfgang
TI Single-step aerosol synthesis of oxygen-deficient blue titania
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogenated titania; Blue titania; Magneli phases; Aerosol synthesis;
   Process engineering
ID PARTICLE GENERATION; GAS-PHASE; TIO2; NANOPARTICLES; PHOTOCATALYSIS;
   VACANCY; ENERGY
AB We present a novel approach for the single-step, continuous aerosol synthesis of blue, oxygen-deficient titania in a hot-wall reactor operated under reducing conditions by adding hydrogen. The precursor titanium(IV) tetraisopropoxide is evaporated in a bubbler and consecutively carried into the reactor by a nitrogen stream where it undergoes thermal decomposition. According to X-ray diffraction analysis, several reduced titania states, among them the Magneli phases Ti4O7 and Ti5O9, are formed via the intermediates anatase and rutile. By slight modifications in the reactor setup both nanoparticles in the size range from 20 to 50 nm with high surface area and well-defined spherical submicron particles of 100 to 160 nm diameter can be produced. In particular, crystallographically phase-pure Ti4O7 is formed at high reactor temperatures. The presented synthesis process is scalable and poses an attractive alternative for the multi-step synthesis of oxygen deficient titania nanoparticles that is currently done via batch-wise annealing. Such nanoparticles are attractive material in the field of photocatalysis. They can be used for both water splitting to produce hydrogen and the decomposition of organic pollutants. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Domaschke, Maximilian; Strunz, Lea; Peukert, Wolfgang] FAU Erlangen Numberg, Inst Particle Technol LFG, Cauerstr 4, D-91058 Erlangen, Germany.
RP Peukert, W (reprint author), FAU Erlangen Numberg, Inst Particle Technol LFG, Cauerstr 4, D-91058 Erlangen, Germany.
EM wolfgang.peukert@fau.de
FU German Research Council (DFG)German Research Foundation (DFG)
FX The financial support from German Research Council (DFG) within the
   framework of its Excellence Initiative for the Cluster of Excellence
   "Engineering of Advanced Materials" (www.eam.fau.de) is thankfully
   acknowledged.
CR ANDERSSON S, 1956, NATURWISSENSCHAFTEN, V43, P495, DOI 10.1007/BF00632520
   Arif AF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03509-y
   Artelt C, 2006, CHEM ENG SCI, V61, P18, DOI 10.1016/j.ces.2004.12.053
   Carp O, 2004, PROG SOLID STATE CH, V32, P33, DOI 10.1016/j.progsolidstchem.2004.08.001
   Chen XB, 2011, SCIENCE, V331, P746, DOI 10.1126/science.1200448
   DAUDE N, 1977, PHYS REV B, V15, P3229, DOI 10.1103/PhysRevB.15.3229
   Dhumal SY, 2009, APPL CATAL B-ENVIRON, V86, P145, DOI 10.1016/j.apcatb.2008.08.014
   Domaschke M, 2019, ACS CATAL, V9, P3627, DOI 10.1021/acscatal.9b00578
   Domaschke M, 2018, J AEROSOL SCI, V126, P133, DOI 10.1016/j.jaerosci.2018.09.004
   Fujishima A, 2008, SURF SCI REP, V63, P515, DOI 10.1016/j.surfrep.2008.10.001
   Goudeli E, 2015, LANGMUIR, V31, P1320, DOI 10.1021/la504296z
   Groschel M, 2012, CHEM ENG SCI, V73, P181, DOI 10.1016/j.ces.2012.01.035
   Gutsch A., 2002, KONA, V20, P24
   Jiang XD, 2012, J PHYS CHEM C, V116, P22619, DOI 10.1021/jp307573c
   Kirchhof MJ, 2012, J AEROSOL SCI, V45, P26, DOI 10.1016/j.jaerosci.2011.10.006
   Kruis FE, 1998, J AEROSOL SCI, V29, P511, DOI 10.1016/S0021-8502(97)10032-5
   Liu N, 2015, NANO LETT, V15, P6815, DOI 10.1021/acs.nanolett.5b02663
   Liu X., 2016, ADV ENERGY MATER, V6, DOI DOI 10.1002/AENM.201600452
   Nakamura I, 2000, J MOL CATAL A-CHEM, V161, P205, DOI 10.1016/S1381-1169(00)00362-9
   Nakaso K, 2003, CHEM ENG SCI, V58, P3327, DOI 10.1016/S0009-2509(03)00213-6
   OKUYAMA K, 1989, CHEM ENG SCI, V44, P1369, DOI 10.1016/0009-2509(89)85010-9
   OKUYAMA K, 1990, AICHE J, V36, P409, DOI 10.1002/aic.690360310
   OTTO E, 1994, PART PART SYST CHAR, V11, P359, DOI 10.1002/ppsc.19940110502
   TANG H, 1994, J APPL PHYS, V75, P2042, DOI 10.1063/1.356306
   Teleki A, 2009, PHYS CHEM CHEM PHYS, V11, P3742, DOI 10.1039/b821590a
   Walsh FC, 2010, ELECTROCHIM ACTA, V55, P6342, DOI 10.1016/j.electacta.2010.05.011
   Wergen L, 2019, J AEROSOL SCI, V128, P50, DOI 10.1016/j.jaerosci.2018.11.013
NR 27
TC 2
Z9 2
U1 18
U2 88
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 327
EP 334
DI 10.1016/j.ces.2019.05.044
PG 8
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700026
DA 2020-05-12
ER

PT J
AU Sharma, P
   Bhattacharya, A
   Basu, S
AF Sharma, Pooja
   Bhattacharya, Atmadeep
   Basu, Saptarshi
TI Formation of hollow and solid carbon spheres in thermally stressed jet
   fuel in the low temperature autoxidation regime
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon sphere; Jet A-1; Nanostructures; Deposit; Thermal stressing;
   Ostwald ripening
ID GRAPHENE NANOSHEETS; POLLUTANT SOOT; DEGRADATION; DEPOSITS
AB We report the formation of hollow and solid carbon spheres and spherical nanostructures by self-assembly through thermal stressing of jet fuel (Jet A-1) in the autoxidation temperature range. The characterization of Jet A-1 deposits was conducted by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) with energy dispersive x-ray spectroscopy (EDS). Additionally, high resolution mass spectrometry with electro spray ionization source (ESI-MS) have been used to identify large molecular weight compounds in the mass range 350 Da to 1000 Da in the thermally stressed fuel. Fourier transform infrared (FTIR) spectroscopy analysis revealed oxygenated functional groups in the jet fuel treated by flask tests. Compositional analysis of deposit by TEM EDS and scanning transmission electron microscopy (STEM) and a high-angle annular dark field (HAADF) detector identified multiple trace metallic elements such as Cu, Fe, Zn, Sn, Mg, Al and heteroatoms S, N, 0. Hollow carbon sphere formation was due to the catalytic activity of trace metals. Spherical particle growth in this method also appeared to follow Ostwald ripening mechanism. Simple flask static tests in the low temperature regime with jet fuel as hydrocarbon source without externally added catalysts thus is a novel method for hollow and solid carbon sphere synthesis and presented in this paper. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sharma, Pooja; Bhattacharya, Atmadeep; Basu, Saptarshi] Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Karnataka, India.
RP Basu, S (reprint author), Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Karnataka, India.
EM sbasu@iisc.ac.in
RI Bhattacharya, Atmadeep/AAH-6157-2019
OI Bhattacharya, Atmadeep/0000-0001-7980-8341
CR Adams RK, 2013, ENERG FUEL, V27, P2390, DOI 10.1021/ef3015298
   [Anonymous], AV TURB FUEL JET A 1
   Christie S, 2012, ENVIRON SCI TECHNOL, V46, P6393, DOI 10.1021/es300301k
   Commodo M, 2011, ENERG FUEL, V25, P2142, DOI 10.1021/ef2002102
   Deshmukh AA, 2010, MAT SCI ENG R, V70, P1, DOI 10.1016/j.mser.2010.06.017
   Eser S, 2000, CARBON, V38, P1512, DOI 10.1016/S0008-6223(00)00112-3
   Eser S, 2006, IND ENG CHEM RES, V45, P8946, DOI 10.1021/ie060968p
   Ham H, 2014, SCI REP-UK, V4, DOI 10.1038/srep03579
   HARDY DR, 1990, ENERG FUEL, V4, P270, DOI 10.1021/ef00021a009
   Huneck S., 1996, IDENTIFICATION LICHE, DOI [10.1007/978-3-642-85243-5_3, DOI 10.1007/978-3-642-85243-5_3]
   Kabana CG, 2011, ENERG FUEL, V25, P5145, DOI 10.1021/ef200964z
   Kosanic M, 2014, EXCLI J, V13, P1226
   Li SJ, 2016, J MATER CHEM A, V4, P12686, DOI 10.1039/c6ta03802f
   Liu J, 2015, NAT MATER, V14, P763, DOI [10.1038/NMAT4317, 10.1038/nmat4317]
   Liu J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3798
   Lu AH, 2011, ANGEW CHEM INT EDIT, V50, P11765, DOI 10.1002/anie.201105486
   Mohan AR, 2010, IND ENG CHEM RES, V49, P2722, DOI 10.1021/ie901283r
   Rankovic B, 2015, LICHEN SECONDARY MET, P1, DOI [DOI 10.1007/978-3-319-13374-4_1, 10.1007/978-3-319-13374-4_1.]
   Sharma P., 2018, ARXIV180511675PHYSIC
   Sharon M., 1998, CARBON N Y, DOI [10.1016/S0008-6223(98)00060-8, DOI 10.1016/S0008-6223(98)00060-8]
   Singh A, 2017, ACS SUSTAIN CHEM ENG, V5, P8860, DOI 10.1021/acssuschemeng.7b01645
   Srinivasan V, 2019, SENSOR ACTUAT B-CHEM, V282, P972, DOI 10.1016/j.snb.2018.11.144
   Tripathi KM, 2016, ACS SUSTAIN CHEM ENG, V4, P6399, DOI 10.1021/acssuschemeng.6b01045
   Venkataraman R, 2008, IND ENG CHEM RES, V47, P9351, DOI 10.1021/ie801007r
   Wang ZL, 1996, J PHYS CHEM-US, V100, P17725, DOI 10.1021/jp962762f
   Zeiger M, 2016, J MATER CHEM A, V4, P3172, DOI 10.1039/c5ta08295a
   Zhang J, 2016, MATER TODAY, V19, P382, DOI 10.1016/j.mattod.2015.11.008
NR 27
TC 1
Z9 1
U1 6
U2 83
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 335
EP 347
DI 10.1016/j.ces.2019.05.045
PG 13
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700027
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Sitaraman, H
   Danes, N
   Lischeske, JJ
   Stickel, JJ
   Sprague, MA
AF Sitaraman, Hariswaran
   Danes, Nicholas
   Lischeske, James J.
   Stickel, Jonathan J.
   Sprague, Michael A.
TI Coupled CFD and chemical-kinetics simulations of cellulosic-biomass
   enzymatic hydrolysis: Mathematical-model development and validation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Enzymatic hydrolysis; Computational fluid dynamics; Physics sub-cycling;
   Chemical kinetics; Finite element method
ID SIMULTANEOUS SACCHARIFICATION; MECHANISTIC MODEL; CELLULASE;
   FERMENTATION; ETHANOL; SOLIDS; LIGNIN; LIGNOCELLULOSES; HEMICELLULOSE;
   ADSORPTION
AB Computational simulations of cellulosic-biomass enzymatic hydrolysis using a computational-fluid-dynamics (CFD) model coupled to a chemical-kinetics model are presented in this work. A time-step sub-cycling strategy was used to circumvent large disparities in time scales with respect to transport physics and chemical kinetics. The unknown reaction and transport parameters in the mathematical model were first fit to two canonical experiments: a well-mixed case that was limited by reaction kinetics and a settled-solids case that was limited by transport. The model was then validated against a benchtop experiment for an intermediate-mixing scenario, for which simulation results were in reasonable agreement with experimentally measured cellulose conversions. Settling of cellulose particles and diffusion of enzymes determine overall conversion rates for lower mixing rates, while reaction rates dominate conversion at higher mixing rates for which greater homogenization of substrates is achieved. (C) 2019 Published by Elsevier Ltd.
C1 [Sitaraman, Hariswaran; Danes, Nicholas] Natl Renewable Energy Lab, Computat Sci Ctr, 15013 Denver West Pkwy, Golden, CO 80401 USA.
   [Danes, Nicholas] Colorado Sch Mines, Dept Appl Math & Stat, Golden, CO 80401 USA.
   [Lischeske, James J.] Natl Renewable Energy Lab, Natl Bioenergy Ctr, 15013 Denver West Pkwy, Golden, CO 80401 USA.
   [Stickel, Jonathan J.] Natl Renewable Energy Lab, Biosci Ctr, 15013 Denver West Pkwy, Golden, CO 80401 USA.
   [Sprague, Michael A.] Natl Renewable Energy Lab, Natl Wind Technol Ctr, 15013 Denver West Pkwy, Golden, CO 80401 USA.
RP Sitaraman, H (reprint author), Natl Renewable Energy Lab, Computat Sci Ctr, 15013 Denver West Pkwy, Golden, CO 80401 USA.
EM hariswaran.sitaraman@nrel.gov
OI Stickel, Jonathan/0000-0003-0276-3506
FU U.S. Department of Energy (DOE)United States Department of Energy (DOE)
   [DE-AC36-08GO28308]; U.S. Department of Energy, Office of Energy
   Efficiency and Renewable Energy's Bioenergy Technologies Office;
   National Science FoundationNational Science Foundation (NSF)
   [DMS-1551229]
FX This work was authored by the National Renewable Energy Laboratory
   (NREL), operated by Alliance for Sustainable Energy, LLC, for the U.S.
   Department of Energy (DOE) under Contract No. DE-AC36-08GO28308. We
   acknowledge funding provided by U.S. Department of Energy, Office of
   Energy Efficiency and Renewable Energy's Bioenergy Technologies Office.
   Co-author, Nicholas Danes, acknowledges funding provided by the National
   Science Foundation under Grant No. DMS-1551229 for performing part of
   this research. This work also utilized the supercomputingre sources at
   NREL for which we are deeply grateful. The views expressed in the
   article do not necessarily represent the views of the DOE or the U.S.
   Government. The U.S. Government retains and the publisher, by accepting
   the article for publication, acknowledges that the U.S. Government
   retains a nonexclusive, paid-up, irrevocable, worldwide license to
   publish or reproduce the published form of this work, or allow others to
   do so, for U.S. Government purposes.
CR Bansal P, 2012, BIORESOURCE TECHNOL, V107, P243, DOI 10.1016/j.biortech.2011.12.063
   BATES RL, 1963, IND ENG CHEM PROC DD, V2, P310, DOI 10.1021/i260008a011
   Carvajal D, 2012, IND ENG CHEM RES, V51, P7518, DOI 10.1021/ie201673t
   Crawford NC, 2016, CHEM ENG SCI, V144, P310, DOI 10.1016/j.ces.2016.01.028
   Fischer P, 2008, J PHYS CONF SER, V125, P12076, DOI 10.1088/1742-6596/125/1/012076
   Gan Q, 2003, PROCESS BIOCHEM, V38, P1003, DOI 10.1016/S0032-9592(02)00220-0
   Huff G. F., 1976, U.S. Patent, Patent No. [3,990,945, 3990945]
   Levine SE, 2010, BIOTECHNOL BIOENG, V107, P37, DOI 10.1002/bit.22789
   Lou HM, 2018, BIORESOURCE TECHNOL, V249, P1, DOI 10.1016/j.biortech.2017.07.066
   Lou HM, 2013, BIORESOURCE TECHNOL, V146, P478, DOI 10.1016/j.biortech.2013.07.115
   Martin C, 2007, ENZYME MICROB TECH, V40, P426, DOI 10.1016/j.enzmictec.2006.07.015
   Mussatto SI, 2008, ENZYME MICROB TECH, V43, P124, DOI 10.1016/j.enzmictec.2007.11.006
   Nag A, 2015, BIOTECHNOL PROGR, V31, P1237, DOI 10.1002/btpr.2122
   Nguyenhuynh T, 2017, J ENG SCI TECHNOL, V12, P1129
   Ohgren K, 2007, BIORESOURCE TECHNOL, V98, P2503, DOI 10.1016/j.biortech.2006.09.003
   PHILIPPIDIS GP, 1993, BIOTECHNOL BIOENG, V41, P846, DOI 10.1002/bit.260410903
   Roche CM, 2009, BIOTECHNOL BIOFUELS, V2, DOI 10.1186/1754-6834-2-28
   Roche CM, 2009, BIOTECHNOL BIOENG, V104, P290, DOI 10.1002/bit.22381
   Russ DC, 2015, CHEM ENG TECHNOL, V38, P53, DOI 10.1002/ceat.201400327
   Seo DJ, 2011, BIORESOURCE TECHNOL, V102, P9605, DOI 10.1016/j.biortech.2011.07.034
   Shao XJ, 2010, BIOPROC BIOSYST ENG, V33, P485, DOI 10.1007/s00449-009-0357-2
   Shao X, 2009, BIOTECHNOL BIOENG, V102, P66, DOI 10.1002/bit.22047
   Sitaraman H, 2012, J PHYS D APPL PHYS, V45, DOI 10.1088/0022-3727/45/18/185201
   Sprague MA, 2018, CHEM ENG SCI, V182, P108, DOI 10.1016/j.ces.2018.02.030
   Stewart PS, 2003, J BACTERIOL, V185, P1485, DOI 10.1128/JB.185.5.1485-1491.2003
   Stickel JJ, 2018, J CHEM TECHNOL BIOT, V93, P2181, DOI 10.1002/jctb.5559
   Stickel JJ, 2014, BIOPROCESSING OF RENEWABLE RESOURCES TO COMMODITY BIOPRODUCTS, P77
   Syamlal M., 1993, DOEMETC951013
   Yanez R, 2006, PROCESS BIOCHEM, V41, P1244, DOI 10.1016/j.procbio.2005.12.020
   Zhang J, 2010, BIOTECHNOL BIOENG, V105, P718, DOI 10.1002/bit.22593
   Zhang YHP, 2004, BIOTECHNOL BIOENG, V88, P797, DOI 10.1002/bit.20282
NR 31
TC 1
Z9 1
U1 7
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 348
EP 360
DI 10.1016/j.ces.2019.05.025
PG 13
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700028
DA 2020-05-12
ER

PT J
AU Noorithaya, AV
   Bishop, C
   Sarkar, P
   Khinas, JG
   Glasser, BJ
AF Noorithaya, Anusha, V
   Bishop, Cody
   Sarkar, Prateek
   Khinas, Johannes G.
   Glasser, Benjamin J.
TI Drying of supported catalysts for high metal concentrations: A reduced
   parameter model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supported catalysts; Catalyst manufacturing; Drying; Metal
   redistribution; Preparation of catalysts; Impregnation
ID SURFACE-TENSION; IMPREGNATION; VISCOSITY; DENSITY; NICKEL; PROFILE;
   SILICA; IMPACT; STEP
AB Supported catalysts are widely used in many industries. Manufacturing these catalysts is complex and manufacturing processes are influenced by many interdependent parameters. Although the performance and activity of catalysts are the most critical properties, their structures and design are also critical to their effectiveness. Previous work has shown that drying of catalysts can lead to the redistribution of metal and this in turn can affect the performance of the catalyst. At the same time, drying processes are often designed and scaled up by trial-and-error so it is desirable to have predictive models of the drying process. Previous experimental and modeling work has shown how the adsorption (of metal on the catalyst support) can significantly influence metal distributions at lower concentrations. It was also observed that at higher concentrations, adsorption was no longer the controlling factor, and solution properties began to control the metal distribution characteristics. Solution properties like density, viscosity, surface tension and volume ratio of metal all change as the metal concentration increases and these properties can in turn affect the distribution of metal during drying. In previous work, a drying model was developed that takes into account six different parameters to account for changes in solution properties as the concentration of metal increased. In this work, we carry out a parametric analysis, for nickel nitrate hexahydrate on a gamma-alumina support, to investigate the relative importance of these parameters in accounting for metal redistribution during drying at high concentrations. A detailed analysis on each of the solution parameters, in terms of the drying rate and redistribution of metal, showed that only three of the parameters were important: the volume ratio of metal, the vapor pressure, and the solubility of the metal in the solution. Based on this, we have created a reduced parameter model with fewer parameters. This model can be used for different metal precursors without doing multiple expensive and time-consuming experiments. We tested this reduced parameter model using a new metal precursor (cobalt nitrate hexahydrate) on the same support, and modeling and experimental results for the new metal precursor are presented in this paper. We show that the reduced parameter model does not show appreciably different results from the more complex drying model and the results are in qualitative agreement with the experimental results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Noorithaya, Anusha, V; Bishop, Cody; Sarkar, Prateek; Glasser, Benjamin J.] Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA.
   [Khinas, Johannes G.] Graz Univ Technol, Res Ctr Pharmaceut Engn, Inffeldgasse 13, A-8010 Graz, Austria.
   [Khinas, Johannes G.] Graz Univ Technol, Inst Proc & Particle Engn, Inffeldgasse 13, A-8010 Graz, Austria.
RP Glasser, BJ (reprint author), Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA.
EM bglasser@rutgers.edu
FU Rutgers Catalyst Manufacturing Consortium
FX We wish to acknowledge financial support for this work from the Rutgers
   Catalyst Manufacturing Consortium.
CR Auvray X, 2018, CATALYSTS, V8, DOI 10.3390/catal8090348
   Bender E, 1981, CHEM INGENIEUR TECHN, V53, P225
   Buffle J, 2007, ENVIRON SCI TECHNOL, V41, P7609, DOI 10.1021/es070702p
   Cherne III F. J., 1998, CALCULATION VISCOSIT
   Debacq M, 2013, CHEM ENG SCI, V104, P586, DOI 10.1016/j.ces.2013.09.037
   DEUFLHARD P, 1987, NUMER MATH, V51, P501, DOI 10.1007/BF01400352
   Dominguez CM, 2013, APPL CATAL B-ENVIRON, V140, P663, DOI 10.1016/j.apcatb.2013.04.068
   Emady HN, 2016, CHEM ENG SCI, V152, P45, DOI 10.1016/j.ces.2016.05.022
   Ertl G, 2008, HDB HETEROGENEOUS CA
   HANSEN FK, 1991, J COLLOID INTERF SCI, V141, P1, DOI 10.1016/0021-9797(91)90296-K
   Irving J. B., 1977, VISCOSITIES BINARY L
   JAIN SK, 1980, J CHEM ENG DATA, V25, P36, DOI 10.1021/je60084a006
   Jiao L, 2008, J CATAL, V260, P342, DOI 10.1016/j.jcat.2008.09.023
   Kim HW, 2009, INT J HYDROGEN ENERG, V34, P3351, DOI 10.1016/j.ijhydene.2009.02.036
   Knijff L. M., 1993, THESIS
   KNIJFF LM, 1991, STUD SURF SCI CATAL, V63, P165
   KOMIYAMA M, 1980, J CATAL, V63, P35, DOI 10.1016/0021-9517(80)90058-5
   KRISHNA R, 1987, CHEM ENG J BIOCH ENG, V35, P75, DOI 10.1016/0300-9467(87)80002-3
   Laliberte M, 2004, J CHEM ENG DATA, V49, P1141, DOI 10.1021/je0498659
   Laliberte M, 2007, J CHEM ENG DATA, V52, P321, DOI 10.1021/je0604075
   Laliberte M, 2009, J CHEM ENG DATA, V54, P1725, DOI 10.1021/je8008123
   LEE SY, 1985, CATAL REV, V27, P207, DOI 10.1080/01614948508064737
   Lekhal A, 2004, CHEM ENG SCI, V59, P1063, DOI 10.1016/j.ces.2003.12.009
   Lekhal A, 2001, IND ENG CHEM RES, V40, P3989, DOI 10.1021/ie010126k
   Lekhal A, 2001, CHEM ENG SCI, V56, P4473, DOI 10.1016/S0009-2509(01)00120-8
   Liu LC, 2018, CHEM REV, V118, P4981, DOI 10.1021/acs.chemrev.7b00776
   Liu X, 2008, CHEM ENG SCI, V63, P4517, DOI 10.1016/j.ces.2008.06.013
   Liu X, 2014, IND ENG CHEM RES, V53, P5792, DOI 10.1021/ie500099c
   Liu X, 2012, CHEM ENG SCI, V79, P187, DOI 10.1016/j.ces.2012.05.046
   Liu X, 2010, IND ENG CHEM RES, V49, P2649, DOI 10.1021/ie9014606
   Mehrabadi BAT, 2017, ADV CATAL, V61, P1, DOI 10.1016/bs.acat.2017.10.001
   MONNERY WD, 1995, CAN J CHEM ENG, V73, P3, DOI 10.1002/cjce.5450730103
   Morbidelli M., 2005, CATALYST DESIGN OPTI
   Munnik P, 2015, CHEM REV, V115, P6687, DOI 10.1021/cr500486u
   NEIMARK AV, 1981, IND ENG CHEM PROD RD, V20, P439, DOI 10.1021/i300003a006
   Njeng ASB, 2015, POWDER TECHNOL, V269, P554, DOI 10.1016/j.powtec.2014.03.066
   Njeng ASB, 2018, EXP THERM FLUID SCI, V91, P197, DOI 10.1016/j.expthermflusci.2017.10.024
   Papageorgiou P, 1996, J CATAL, V158, P439, DOI 10.1006/jcat.1996.0045
   Paredes IJ, 2018, CHEM ENG SCI, V191, P56, DOI 10.1016/j.ces.2018.06.044
   Pinna F, 1998, CATAL TODAY, V41, P129, DOI 10.1016/S0920-5861(98)00043-1
   SANTHANAM N, 1994, CATAL TODAY, V21, P141, DOI 10.1016/0920-5861(94)80040-5
   Takahashi R, 2002, PHYS CHEM CHEM PHYS, V4, P3800, DOI 10.1039/b202024f
   Van Den Berg G. H., 1979, STUDIES SURFACE SCI, V3, P265
   van Dillen AJ, 2003, J CATAL, V216, P257, DOI 10.1016/S0021-9517(02)00130-6
   van Haandel L, 2016, CHEMCATCHEM, V8, P1367, DOI 10.1002/cctc.201501347
   Wong A, 2017, SCIENCE, V358, P1427, DOI 10.1126/science.aao6538
NR 46
TC 0
Z9 0
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 361
EP 374
DI 10.1016/j.ces.2019.05.014
PG 14
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700029
DA 2020-05-12
ER

PT J
AU Huang, ZQ
   Zhang, C
   Jiang, M
   Wang, HZ
   Zhou, Q
AF Huang, Zheqing
   Zhang, Chi
   Jiang, Ming
   Wang, Huizhi
   Zhou, Qiang
TI Effects of particle velocity fluctuations on inter-phase heat transfer
   in gas-solid flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Direct numerical simulations; Granular temperature; Heat transfer;
   Nusselt number
ID DIRECT NUMERICAL-SIMULATION; GRANULAR TEMPERATURE; PACKED-BEDS; DRAG
   FORCE; REYNOLDS; MASS; ARRAYS; MODEL; SUSPENSIONS; MULTISCALE
AB Heat transfer in gas-solid flows has been numerically investigated via an immersed boundary-thermal lattice Boltzmann method. Stationary random assemblies of spheres are adopted in the simulations. The effect of particle velocity fluctuations whose magnitude is represented by the so-called granular temperature is accounted for by implementing velocity fluctuations obeying the isotropic Maxwellian distribution on spheres. It is found that particle fluctuations enhance the heat transfer between the gas and solid phases. This enhancement increases with increasing granular temperature-based Reynolds number and becomes less significant as the particle Reynolds number and the solid volume fraction increase. It is also found that the Nusselt numbers on individual particles follow the Log-Normal distribution at both zero and finite granular temperature conditions. The long tail of this distribution is caused by the existence of a non-negligible portion of the domain with fast local gas velocities that could significantly promote heat transfer. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Huang, Zheqing; Zhang, Chi; Jiang, Ming; Wang, Huizhi; Zhou, Qiang] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
   [Zhou, Qiang] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
   [Huang, Zheqing; Zhang, Chi; Jiang, Ming; Wang, Huizhi] Xi An Jiao Tong Univ, Shaanxi Key Lab Energy Chem Proc Intensificat, Xian 710049, Shaanxi, Peoples R China.
RP Zhou, Q (reprint author), Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.; Zhou, Q (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM zhou.590@mail.xjtu.edu.cn
RI Zhou, Qiang/B-1568-2015
OI Zhou, Qiang/0000-0002-1190-6030
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11602190, 91634114]; Natural Science Foundation of
   Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research
   FundsNatural Science Foundation of Jiangsu Province [BK20160390];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities
FX The authors would like to thank the National Natural Science Foundation
   of China (11602190, 91634114) and the Natural Science Foundation of
   Jiangsu Province for Youth (BK20160390) for the financial support. The
   author are also grateful to the support by "the Fundamental Research
   Funds for the Central Universities".
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Biggs MJ, 2008, GRANUL MATTER, V10, P63, DOI 10.1007/s10035-007-0077-8
   Campbell CS, 2006, POWDER TECHNOL, V162, P208, DOI 10.1016/j.powtec.2005.12.008
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Deen NG, 2014, CHEM ENG SCI, V116, P645, DOI 10.1016/j.ces.2014.05.036
   Derksen JJ, 2008, AICHE J, V54, P1741, DOI 10.1002/aic.11519
   Din XD, 1997, PHYS FLUIDS, V9, P3915, DOI 10.1063/1.869490
   Esteghamatian A, 2018, INT J MULTIPHAS FLOW, V99, P363, DOI 10.1016/j.ijmultiphaseflow.2017.11.003
   Feng ZG, 1998, J HEAT TRANS-T ASME, V120, P674, DOI 10.1115/1.2824336
   Feng ZG, 2000, INT J HEAT MASS TRAN, V43, P219, DOI 10.1016/S0017-9310(99)00133-7
   Feng ZG, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031690
   Feng ZG, 2014, POWDER TECHNOL, V262, P62, DOI 10.1016/j.powtec.2014.04.019
   Feng ZG, 2014, J HEAT TRANS-T ASME, V136, DOI 10.1115/1.4026307
   Fullmer WD, 2017, ANNU REV FLUID MECH, V49, P485, DOI 10.1146/annurev-fluid-010816-060028
   Garzo V, 2016, PHYS REV E, V93, DOI 10.1103/PhysRevE.93.012905
   Gopalan B, 2013, POWDER TECHNOL, V242, P13, DOI 10.1016/j.powtec.2013.01.046
   Guardo A, 2006, CHEM ENG SCI, V61, P4341, DOI 10.1016/j.ces.2006.02.011
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Hadinoto K, 2009, INT J MULTIPHAS FLOW, V35, P129, DOI 10.1016/j.ijmultiphaseflow.2008.10.003
   Hill RJ, 2001, J FLUID MECH, V448, P213, DOI 10.1017/S0022112001005948
   Huang ZQ, 2017, POWDER TECHNOL, V321, P435, DOI 10.1016/j.powtec.2017.08.035
   Kempe T, 2012, J COMPUT PHYS, V231, P3663, DOI 10.1016/j.jcp.2012.01.021
   Koch DL, 2001, ANNU REV FLUID MECH, V33, P619, DOI 10.1146/annurev.fluid.33.1.619
   Kriebitzsch SHL, 2013, CHEM ENG SCI, V91, P1, DOI 10.1016/j.ces.2012.12.038
   Li JH, 2018, ANNU REV CHEM BIOMOL, V9, P41, DOI 10.1146/annurev-chembioeng-060817-084249
   Luo K, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.066709
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   Muller CR, 2008, POWDER TECHNOL, V184, P241, DOI 10.1016/j.powtec.2007.11.046
   Municchi F, 2017, INT J HEAT MASS TRAN, V111, P171, DOI 10.1016/j.ijheatmasstransfer.2017.03.122
   Nijemeisland M., 2000, THESIS
   Peng Y, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.026701
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Rice JA, 1995, MATH STAT DATA ANAL
   Seta T, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.063304
   Shi Y, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.066310
   Singhal A, 2017, CHEM ENG J, V314, P27, DOI 10.1016/j.cej.2016.12.124
   Sun B, 2015, INT J HEAT MASS TRAN, V86, P898, DOI 10.1016/j.ijheatmasstransfer.2015.03.046
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   Tang Y, 2016, CHEM ENG SCI, V143, P166, DOI 10.1016/j.ces.2015.12.026
   Tang YL, 2016, AICHE J, V62, P1958, DOI 10.1002/aic.15197
   Tartan M, 2004, AICHE J, V50, P1760, DOI 10.1002/aic.10192
   Tavassoli H, 2013, INT J MULTIPHAS FLOW, V57, P29, DOI 10.1016/j.ijmultiphaseflow.2013.06.009
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Tenneti S, 2011, INT J MULTIPHAS FLOW, V37, P1072, DOI 10.1016/j.ijmultiphaseflow.2011.05.010
   Tenneti S, 2016, J FLUID MECH, V788, P695, DOI 10.1017/jfm.2015.693
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
   Wylie JJ, 2003, J FLUID MECH, V480, P95, DOI 10.1017/S0022112002003531
   Zhou Q, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4927552
   Zhou Q, 2015, J FLUID MECH, V765, P396, DOI 10.1017/jfm.2014.732
   Zhou Q, 2014, J COMPUT PHYS, V268, P269, DOI 10.1016/j.jcp.2014.02.038
   Zhou ZY, 2009, AICHE J, V55, P868, DOI 10.1002/aic.11823
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
NR 54
TC 1
Z9 1
U1 3
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 375
EP 386
DI 10.1016/j.ces.2019.05.047
PG 12
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700030
DA 2020-05-12
ER

PT J
AU Zhang, ZN
   Wang, ZY
   Liu, H
   Gao, YH
   Li, H
   Sun, BJ
AF Zhang, Zhennan
   Wang, Zhiyuan
   Liu, Hui
   Gao, Yonghai
   Li, Hao
   Sun, Baojiang
TI Experimental study on bubble and droplet entrainment in vertical churn
   and annular flows and their relationship
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble entrainment; Droplet entrainment; Churn flow; Annular flow;
   High-speed camera
ID 2-PHASE FLOW; LIQUID-FILM; GAS; MODEL; WAVES; MECHANISM; CRITERIA; ONSET
AB Bubble and droplet entrainment plays an important role in the mass transfer between the liquid film and the gas core in churn and annular flow. In this work, bubble and droplet entrainments in vertical churn and annular flows are systematically studied in an air-water two-phase vertical flow experiment using a high-speed camera. The results show that there are three kinds of bubble entrainment and five kinds of droplet entrainment in churn and annular flows. The entrainment can be categorized as primary entrainment and secondary entrainment. The primary entrainment includes one kind of bubble entrainment, which is a large wave roll and overturn, and three kinds of droplet entrainment, which are shearing-off of waves containing bubbles, bag break-up of waves, and ligament break-up of waves. The secondary entrainment includes two kinds of bubble entrainment, which are synchronized bubble entrainment along with droplet entrainment and droplets from the gas core impacting the liquid film, and two kinds of droplet entrainment, which are droplets impacting the liquid film and the burst of bubbles. With the flow pattern transition from churn to annular flow, the dominant bubble entrainment changes from large wave roll and overturn to the synchronized bubble entrainment along with droplet entrainment accompanied by a decreasing intensity. The dominant droplet entrainment changes from shearing-off of waves containing bubbles to ligament break-up of waves with the intensity first decreasing and then increasing. There is a close relationship between bubble entrainment and droplet entrainment. The entrained bubbles reduce the strength of large-scale waves and facilitate the shearing-off of waves. A small number of droplets are entrained due to the burst of residual bubbles in the liquid film. Droplets that are generated by bag or ligament break-up of waves can directly impact the nearby liquid film, leading to synchronous bubble entrainment. A small number of bubbles can be entrapped by droplets from the gas core impacting the liquid film. The primary entrainment intensity is significantly greater than that of the secondary entrainment. With the transition from churn to annular flow, the change in the primary entrainment intensity determines the variety of the secondary entrainment intensity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Zhennan; Wang, Zhiyuan; Liu, Hui; Gao, Yonghai; Li, Hao; Sun, Baojiang] China Univ Petr East China, Sch Petr Engn, 66 Changjiang West Rd, Qingdao 266580, Shandong, Peoples R China.
   [Zhang, Zhennan] China Univ Petr East China, Shandong Prov Key Lab Oil & Gas Storage & Transpo, Qingdao 266555, Shandong, Peoples R China.
RP Sun, BJ (reprint author), China Univ Petr East China, Sch Petr Engn, 66 Changjiang West Rd, Qingdao 266580, Shandong, Peoples R China.
EM sunbj1128@126.com
FU National Natural Science Foundation-Outstanding Youth Foundation
   [51622405]; 973 ProgramNational Basic Research Program of China
   [2015CB251200]; National Science and Technology Major Project
   [2016ZX05028-001-03]; Natural Science Foundation of Shandong Provence
   [JQ201716]; National Engineering Laboratory for Testing and Detection
   Technology of Subsea Equipments
FX This work was supported by the National Natural Science
   Foundation-Outstanding Youth Foundation (51622405), the 973 Program
   (2015CB251200), the National Science and Technology Major Project
   (2016ZX05028-001-03), the Natural Science Foundation of Shandong
   Provence (JQ201716) and the National Engineering Laboratory for Testing
   and Detection Technology of Subsea Equipments.
CR Alekseenko SV, 2014, INT J MULTIPHAS FLOW, V67, P122, DOI 10.1016/j.ijmultiphaseflow.2014.07.009
   Alipchenkov VM, 2004, INT J HEAT MASS TRAN, V47, P5323, DOI 10.1016/j.ijheatmasstransfer.2004.07.011
   Azzopardi B. J., 1983, MECH ENTRAINMENT ANN
   Azzopardi BJ, 2004, INT J MULTIPHAS FLOW, V30, P89, DOI 10.1016/j.ijmultiphaseflow.2003.11.001
   Azzopardi BJ, 1997, INT J MULTIPHAS FLOW, V23, P1
   Berna C, 2014, PROG NUCL ENERG, V74, P14, DOI 10.1016/j.pnucene.2014.01.018
   Cherdantsev AV, 2018, AIP CONF PROC, V1939, DOI 10.1063/1.5027318
   Cherdantsev AV, 2014, INT J MULTIPHAS FLOW, V67, P52, DOI 10.1016/j.ijmultiphaseflow.2014.08.003
   Cioncolini A, 2010, INT J MULTIPHAS FLOW, V36, P293, DOI 10.1016/j.ijmultiphaseflow.2009.11.011
   Crowe CT, 2005, MULTIPHASE FLOW HDB
   Dasgupta A, 2017, EXP THERM FLUID SCI, V81, P147, DOI 10.1016/j.expthermflusci.2016.10.012
   Durve AP, 2012, CHEM ENG SCI, V73, P140, DOI 10.1016/j.ces.2012.01.030
   Hann DB, 2018, INT J MULTIPHAS FLOW, V108, P181, DOI 10.1016/j.ijmultiphaseflow.2018.07.001
   Hewitt G, 1970, ANNULAR 2 PHASE FLOW
   Hewitt GF, 2012, ENERG FUEL, V26, P4067, DOI 10.1021/ef3002422
   Isaenkov SV, 2019, INT J MULTIPHAS FLOW, V111, P62, DOI 10.1016/j.ijmultiphaseflow.2018.11.010
   ISHII M, 1975, AICHE J, V21, P308, DOI 10.1002/aic.690210212
   ISHII M, 1989, INT J HEAT MASS TRAN, V32, P1835, DOI 10.1016/0017-9310(89)90155-5
   Kataoka I, 2000, INT J HEAT MASS TRAN, V43, P1573, DOI 10.1016/S0017-9310(99)00236-7
   Kumar P, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4954999
   Kunugi T., 2017, NUCL ENG DES, P45
   Liu L, 2017, CHEM ENG SCI, V164, P279, DOI 10.1016/j.ces.2017.02.023
   MISHIMA K, 1984, INT J HEAT MASS TRAN, V27, P723
   Miwa S, 2018, CHEM ENG SCI, V181, P251, DOI 10.1016/j.ces.2018.01.037
   Pan L, 2002, INT J MULTIPHAS FLOW, V28, P363, DOI 10.1016/S0301-9322(01)00073-8
   Patruno LE, 2010, CHEM ENG SCI, V65, P5272, DOI 10.1016/j.ces.2010.06.038
   Patruno LE, 2009, CHEM ENG SCI, V64, P1362, DOI 10.1016/j.ces.2008.11.023
   Pham SH, 2015, INT J MULTIPHAS FLOW, V70, P35, DOI 10.1016/j.ijmultiphaseflow.2014.11.010
   Pham SH, 2014, INT J MULTIPHAS FLOW, V59, P135, DOI 10.1016/j.ijmultiphaseflow.2013.11.004
   Rodriguez DJ, 2004, INT J MULTIPHAS FLOW, V30, P565, DOI 10.1016/j.ijmultiphaseflow.2004.04.011
   Salque G, 2013, INT J MULTIPHAS FLOW, V51, P87, DOI 10.1016/j.ijmultiphaseflow.2012.11.002
   Sawant P, 2008, NUCL ENG DES, V238, P1342, DOI 10.1016/j.nucengdes.2007.10.005
   Schubring D, 2010, INT J MULTIPHAS FLOW, V36, P815, DOI 10.1016/j.ijmultiphaseflow.2010.05.007
   TAITEL Y, 1980, AICHE J, V26, P345, DOI 10.1002/aic.690260304
   Tekavcic M, 2018, CHEM ENG SCI, V175, P231, DOI 10.1016/j.ces.2017.09.050
   van Nimwegen AT, 2015, INT J MULTIPHAS FLOW, V71, P133, DOI 10.1016/j.ijmultiphaseflow.2014.03.008
   Van't Westende J. M. C., 2008, DROPLETS ANNULAR DIS
   Wang K, 2017, CHEM ENG SCI, V164, P270, DOI 10.1016/j.ces.2017.02.028
   Wang K, 2013, CHEM ENG SCI, V104, P1045, DOI 10.1016/j.ces.2013.10.028
   Wang K, 2013, CHEM ENG SCI, V104, P638, DOI 10.1016/j.ces.2013.09.022
   WOODMANS.DE, 1969, CHEM ENG SCI, V24, P299, DOI 10.1016/0009-2509(69)80038-2
   Wua B, 2017, CHEM ENG J, V326, P350, DOI 10.1016/j.cej.2017.05.135
   Xie ZH, 2017, CHEM ENG SCI, V166, P303, DOI 10.1016/j.ces.2017.04.015
   Zhang JQ, 2012, CHEM ENG SCI, V68, P151, DOI 10.1016/j.ces.2011.09.019
NR 44
TC 0
Z9 0
U1 12
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 387
EP 400
DI 10.1016/j.ces.2019.05.005
PG 14
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700031
DA 2020-05-12
ER

PT J
AU Kaiser, M
   Freund, H
AF Kaiser, Markus
   Freund, Hannsjoerg
TI A multimodular pseudoheterogeneous model framework for optimal design of
   catalytic reactors exemplified by methanol synthesis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactor design; Optimization; Heterogeneous model; Intrapellet
   diffusion; Modular framework; Methanol synthesis
ID PRESSURE-DROP; KINETIC-MODEL; HEAT-TRANSFER; TRANSPORT; DIFFUSION;
   METHODOLOGY; PACKINGS
AB Model-based design of chemical reactors via dynamic optimization can be performed using a recently developed approach called Multi-Level Reactor Design (MLRD). As a start, the MLRD method, its extensions and applications over the last ten years are reviewed compactly. In the main part of this contribution, a further extension to the model framework applied within this method allowing for the rigorous consideration of intrapellet transport processes in heterogeneously catalyzed systems is introduced. Accordingly, a system of coupled differential equations describing the mass and energy balance of both, reactor and catalyst pellet is set up. Balance equations are kept strictly distinguished from kinetic approaches, leaving the latter to be easily exchangeable. This leads to a multimodular model structure used to incorporate different models for diffusion flux, heat transport and pressure drop. The type of the extended model structure is "pseudoheterogeneous", i.e., the domain in which chemical reactions take place is shifted from a commonly applied pseudohomogeneous mixed phase to the catalyst interior while a solid phase on reactor scale is not modelled. Applying the extended and modularized method to methanol synthesis as a case study reveals considerable concentration and temperature gradients inside the catalyst. These are neglected implicitly in pseudohomogeneous approaches which can lead to a violation of the allowed range of operating conditions for a given catalyst. The extended MLRD model framework using a pseudoheterogeneous model overcomes this drawback and allows for apparatus independent reactor design while meeting process specific constraints in both the bulk gas and the catalyst phase. Further, a systematic investigation applying 27 combinations of diffusion flux, heat transport and pressure drop models reveals that a certain performance can be reached with any combination, while the deduced reactor design differs significantly. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kaiser, Markus; Freund, Hannsjoerg] Friedrich Alexander Univ Erlangen Nurnberg FAU, Lehrstuhl Chem Reakt Tech, Egerlandstr 3, D-91058 Erlangen, Germany.
RP Freund, H (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Lehrstuhl Chem Reakt Tech, Egerlandstr 3, D-91058 Erlangen, Germany.
EM hannsjoerg.freund@fau.de
OI Kaiser, Markus/0000-0002-8228-7310
FU German Research Foundation (DFG)German Research Foundation (DFG); Air
   Liquide
FX The authors gratefully acknowledge funding of the German Research
   Foundation (DFG), which, within the framework of its "Excellence
   Initiative", supports the Cluster of Excellence "Engineering of Advanced
   Materials" at the Friedrich-Alexander-Universitat Erlangen-Nurnberg
   (www.eam.fau.de). Furthermore, the authors gratefully acknowledge the
   financial support of Air Liquide within a collaboration. Especially, the
   authors thank Robert Frind (Air Liquide), Timm Schuhmann (Air Liquide)
   and Sebastian Werner (CLARIANT) for fruitful discussions.
CR [Anonymous], 2006, VDI WARMEATLAS
   Ascher Uri M, 1998, COMPUTER METHODS ORD, V61
   ASKGAARD TS, 1995, J CATAL, V156, P229, DOI 10.1006/jcat.1995.1250
   Bauer R., 1977, VERFAHRENSTECHNIK, V11, P605
   Biegler LT, 2007, CHEM ENG PROCESS, V46, P1043, DOI 10.1016/j.cep.2006.06.021
   Butcher J.C., 2016, NUMERICAL METHODS OR
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   Eisfeld B, 2001, CHEM ENG SCI, V56, P4321, DOI 10.1016/S0009-2509(00)00533-9
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   EVANS RB, 1961, J CHEM PHYS, V35, P2076, DOI 10.1063/1.1732211
   Fick A, 1855, POGGENDORFFS ANN PHY, V170, P59, DOI DOI 10.1002/ANDP.18551700105
   Finlayson B. A., 2000, MATH CHEM ENG
   Finlayson BA, 1980, NONLINEAR ANAL CHEM
   FOURER R, 2002, AMPL BOOK
   Freund H., 2007, THESIS
   Freund H., 2010, CHEM-ING-TECH, V83, P420
   Freund H, 2008, CHEM ENG PROCESS, V47, P2051, DOI 10.1016/j.cep.2008.07.011
   Froment G. F., 2011, CHEM REACTOR ANAL DE
   FULLER EN, 1969, J PHYS CHEM-US, V73, P3679, DOI 10.1021/j100845a020
   Gmehling J., 2012, CHEM THERMODYNAMICS
   GRAAF GH, 1986, CHEM ENG SCI, V41, P2883, DOI 10.1016/0009-2509(86)80019-7
   GRAAF GH, 1990, CHEM ENG SCI, V45, P773, DOI 10.1016/0009-2509(90)85001-T
   GRAAF GH, 1988, CHEM ENG SCI, V43, P3185, DOI 10.1016/0009-2509(88)85127-3
   Henkel T., 2011, THESIS
   Hentschel B, 2014, CHEM ENG SCI, V115, P69, DOI 10.1016/j.ces.2013.09.046
   Hentschel B, 2014, CHEM ENG SCI, V115, P58, DOI 10.1016/j.ces.2013.03.051
   Hiller H., 2006, ULLMANNS ENCY IND CH
   Jackson R., 1977, TRANSPORT POROUS CAT, V4
   Jeschar R., 1964, ARCH EISENHUTTENWES, V35, P91, DOI 10.1002/srin.196402300
   Kaiser NM, 2018, CHEM ENG J, V335, P1018, DOI 10.1016/j.cej.2017.09.051
   Kaiser NM, 2016, COMPUT CHEM ENG, V94, P45, DOI 10.1016/j.compchemeng.2016.06.008
   Kameswaran S, 2008, COMPUT OPTIM APPL, V41, P81, DOI 10.1007/s10589-007-9098-9
   Kerkhof PJAM, 1996, CHEM ENG J, V64, P319, DOI 10.1016/S0923-0467(96)03121-1
   Klein O., 2001, THESIS
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Lanczos C, 1938, J MATH PHYS, V17, P123, DOI DOI 10.1002/SAPM1938171123
   LI C, 1977, CHEM ENG SCI, V32, P1055, DOI 10.1016/0009-2509(77)80143-7
   MARTIN H, 1993, CHEM-ING-TECH, V65, P1468, DOI 10.1002/cite.330651206
   Maussner J, 2018, CHEM ENG SCI, V183, P329, DOI 10.1016/j.ces.2018.02.002
   Maussner J, 2017, CHEM ENG SCI, V171, P495, DOI 10.1016/j.ces.2017.06.005
   Nilles M., 1991, FORTSCHR BER VDI, V3
   Ott J., 2012, ULLMANNS ENCY IND CH
   Passler F, 2018, CHEM-ING-TECH, V90, P852, DOI 10.1002/cite.201700124
   Peschel A., 2012, CHEM ENG J
   Peschel A, 2012, CHEM ENG J, V188, P126, DOI 10.1016/j.cej.2012.01.123
   Peschel A, 2011, CHEM ENG SCI, V66, P6453, DOI 10.1016/j.ces.2011.08.054
   Peschel A, 2010, IND ENG CHEM RES, V49, P10535, DOI 10.1021/ie100476q
   Pietschak A, 2018, CHEM ENG RES DES, V137, P60, DOI 10.1016/j.cherd.2018.06.043
   Poling B. E., 2001, PROPERTIES GASES LIQ, V5
   Radau R., 1880, J MATH PURE APPL, V6, P283
   REICHELT W, 1972, CHEM-ING-TECH, V44, P1068, DOI 10.1002/cite.330441806
   SKRZYPEK J, 1995, CHEM ENG J BIOCH ENG, V58, P101, DOI 10.1016/0923-0467(94)02955-5
   SKRZYPEK J, 1991, CHEM ENG SCI, V46, P2809, DOI 10.1016/0009-2509(91)85150-V
   SOAVE G, 1972, CHEM ENG SCI, V27, P1197, DOI 10.1016/0009-2509(72)80096-4
   SPECCHIA V, 1980, CHEM ENG COMMUN, V4, P361, DOI 10.1080/00986448008935916
   Taylor R., 1993, MULTICOMPONENT MASS, V2
   Tsotsas E., 2013, VDI WARMEATLAS, P1517, DOI [10.1007/978-3-642-19981-3_102, DOI 10.1007/978-3-642-19981-3_102]
   Tsotsas E., 2013, VDI WARMEATLAS, P651
   VandenBussche KM, 1996, J CATAL, V161, P1
   VELDSINK JW, 1995, CHEM ENG J BIOCH ENG, V57, P115, DOI 10.1016/0923-0467(94)02929-6
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Wachter A., 2002, THESIS
   Wachter A., 2009, DAGST SEM P
   Wesselingh J.A., 2000, MASS TRANSFER MULTIC
   Xie MQ, 2018, CHEM ENG PROCESS, V124, P174, DOI 10.1016/j.cep.2017.11.012
   Xie MQ, 2018, CHEM ENG PROCESS, V123, P280, DOI 10.1016/j.cep.2017.11.011
   Xie MQ, 2018, CHEM ENG SCI, V175, P405, DOI 10.1016/j.ces.2017.10.010
   Young JB, 2005, INT J HEAT MASS TRAN, V48, P5338, DOI 10.1016/j.ijheatmasstransfer.2005.07.034
   ZEHNER P, 1970, CHEM-ING-TECH, V42, P933, DOI 10.1002/cite.330421408
   ZHAVORONKOV NM, 1949, ZH FIZ KHIM+, V23, P342
NR 70
TC 3
Z9 3
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 401
EP 423
DI 10.1016/j.ces.2019.04.036
PG 23
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700032
DA 2020-05-12
ER

PT J
AU Park, JE
   Lee, H
   Oh, SH
   Kang, SY
   Choi, I
   Cho, YH
   Sung, YE
AF Park, Ji Eun
   Lee, Hyunjoon
   Oh, Seung-Hyeon
   Kang, Sun Young
   Choi, Insoo
   Cho, Yong-Hun
   Sung, Yung-Eun
TI Electrodeposited mesh-type dimensionally stable anode for oxygen
   evolution reaction in acidic and alkaline media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dimensionally stable anode; Oxygen evolution electrode; Ruthenium oxide;
   Iridium oxide; Electrodeposition
ID TAFEL LINES; THIN-FILMS; WATER; CATALYSTS; IRIDIUM; NI;
   ELECTROCATALYSTS; CONVERSION; REDUCTION; STORAGE
AB A mesh-type dimensionally stable anode (DSA) consisting of ruthenium and iridium with low catalyst loading was prepared as an oxygen evolution reaction catalyst in acidic and alkaline media. The electrodeposition (ED) conditions, i.e., applied current density and total cycle number, and ED solutions with different precursor ratios of ruthenium to iridium are examined to fabricate various DSAs with a uniform thickness, and the effect of the iridium content on the catalytic activity is investigated. Among various DSA electrodes, the DSA electrode without iridium exhibits the highest activity and stability in the acidic medium owing to the high ratio of ruthenium. Conversely, the DSA electrode obtained using the ED solution with the ratio of 8:2 exhibits the highest performance in the alkaline medium. This is because the DSA electrode without iridium showed low stability, which is attributed to the dissolution of ruthenium oxide in the alkaline medium. In addition, two large-scale DSA electrodes optimized in the acidic and alkaline electrolytes show excellent performance, indicating the feasibility of the application of this electrode in practical electrolysis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Park, Ji Eun; Lee, Hyunjoon; Sung, Yung-Eun] Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 08826, South Korea.
   [Park, Ji Eun; Lee, Hyunjoon; Sung, Yung-Eun] Inst for Basic Sci Korea, Ctr Nanoparticle Res, Seoul 08826, South Korea.
   [Oh, Seung-Hyeon; Kang, Sun Young; Cho, Yong-Hun] Kangwon Natl Univ, Dept Chem Engn, Samcheok 25913, Gangwon Do, South Korea.
   [Choi, Insoo] Kangwon Natl Univ, Div Energy Engn, Samcheok 25913, Gangwon Do, South Korea.
RP Sung, YE (reprint author), Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 08826, South Korea.; Cho, YH (reprint author), Kangwon Natl Univ, Dept Chem Engn, Samcheok 25913, Gangwon Do, South Korea.
EM yhun00@kangwon.ac.kr; ysung@snu.ac.kr
OI Park, Ji Eun/0000-0002-3109-0518
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2016R1D1A3B03934752]; Korea
   Electric Power Corporation [R16VA08]; 2018 Research Grant (PoINT) from
   Kangwon National University;  [IBS-R006-A2]
FX This work was supported by Project Code IBS-R006-A2 in Korea. Y.-H. C.
   acknowledges financial support from the Basic Science Research Program
   (2016R1D1A3B03934752) through the National Research Foundation of Korea
   (NRF), which is funded by the Ministry of Education. This research was
   also supported by Korea Electric Power Corporation (Grant number:
   R16VA08). This study was supported by 2018 Research Grant (PoINT) from
   Kangwon National University.
CR Antolini E, 2014, ACS CATAL, V4, P1426, DOI 10.1021/cs4011875
   Audichon T, 2014, INT J HYDROGEN ENERG, V39, P16785, DOI 10.1016/j.ijhydene.2014.07.170
   Benson EE, 2009, CHEM SOC REV, V38, P89, DOI 10.1039/b804323j
   Bicelli LP, 2008, INT J ELECTROCHEM SC, V3, P356
   Browne MP, 2016, CHEMELECTROCHEM, V3, P1847, DOI 10.1002/celc.201600370
   Cherevko S, 2016, CATAL TODAY, V262, P170, DOI 10.1016/j.cattod.2015.08.014
   Choe S, 2018, APPL CATAL B-ENVIRON, V226, P289, DOI 10.1016/j.apcatb.2017.12.037
   CIPRIS D, 1976, J ELECTROANAL CHEM, V73, P125, DOI 10.1016/0368-1874(76)87034-7
   Cook TR, 2010, CHEM REV, V110, P6474, DOI 10.1021/cr100246c
   Delplancke J. L., 2003, ELECTROCHIM ACTA, V48, P1131
   Devilliers D, 2010, ELECTROCHIM ACTA, V55, P8207, DOI 10.1016/j.electacta.2010.01.098
   Fabbri E, 2014, CATAL SCI TECHNOL, V4, P3800, DOI 10.1039/c4cy00669k
   Fang YH, 2010, J AM CHEM SOC, V132, P18214, DOI 10.1021/ja1069272
   Godwin I. J., 2013, ECS Transactions, V53, P21, DOI 10.1149/05323.0021ecst
   Gong M, 2013, J AM CHEM SOC, V135, P8452, DOI 10.1021/ja4027715
   Gorlin Y, 2010, J AM CHEM SOC, V132, P13612, DOI 10.1021/ja104587v
   Gui Z, 2015, PHYS CHEM CHEM PHYS, V17, P15173, DOI 10.1039/c5cp01814e
   Han JH, 2010, CHEM MATER, V22, P5700, DOI 10.1021/cm101694g
   Pham HH, 2015, ADV NAT SCI-NANOSCI, V6, DOI 10.1088/2043-6262/6/2/025015
   Hu JM, 2004, INT J HYDROGEN ENERG, V29, P791, DOI 10.1016/j.ijhydene.2003.09.007
   Jovic VD, 2006, ELECTROCHIM ACTA, V51, P5468, DOI 10.1016/j.electacta.2006.02.022
   Lee Y, 2012, J PHYS CHEM LETT, V3, P399, DOI 10.1021/jz2016507
   Ma W, 2015, ACS NANO, V9, P1977, DOI 10.1021/nn5069836
   Mattos-Costa FI, 1998, ELECTROCHIM ACTA, V44, P1515, DOI 10.1016/S0013-4686(98)00275-8
   McCrory CCL, 2015, J AM CHEM SOC, V137, P4347, DOI 10.1021/ja510442p
   McCrory CCL, 2013, J AM CHEM SOC, V135, P16977, DOI 10.1021/ja407115p
   Reier T, 2012, ACS CATAL, V2, P1765, DOI 10.1021/cs3003098
   Salvatore DA, 2017, J MATER CHEM A, V5, P1575, DOI 10.1039/c6ta09094j
   Song F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5477
   Suen NT, 2017, CHEM SOC REV, V46, P337, DOI 10.1039/c6cs00328a
   Tahir M, 2017, NANO ENERGY, V37, P136, DOI 10.1016/j.nanoen.2017.05.022
   Takasu Y, 2010, J APPL ELECTROCHEM, V40, P1789, DOI 10.1007/s10800-010-0137-3
   Tilley SD, 2010, ANGEW CHEM INT EDIT, V49, P6405, DOI 10.1002/anie.201003110
   Tsuji E, 2011, ELECTROCHIM ACTA, V56, P2009, DOI 10.1016/j.electacta.2010.11.062
   Turner JA, 2004, SCIENCE, V305, P972, DOI 10.1126/science.1103197
   VUKOVIC M, 1987, J APPL ELECTROCHEM, V17, P737, DOI 10.1007/BF01007809
   Xia ZH, 2016, NAT ENERGY, V1, P1, DOI 10.1038/NENERGY.2016.155
   Xu LK, 2009, ELECTROCHIM ACTA, V54, P1820, DOI 10.1016/j.electacta.2008.10.004
   Zeng Y, 2007, CERAM INT, V33, P1087, DOI 10.1016/j.ceramint.2006.03.025
   Zhao Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3390
NR 40
TC 1
Z9 1
U1 19
U2 113
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 424
EP 431
DI 10.1016/j.ces.2019.05.048
PG 8
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700033
DA 2020-05-12
ER

PT J
AU Liu, F
   Lv, JS
   Zhang, B
   Yang, ZN
AF Liu, Feng
   Lv, Jinsheng
   Zhang, Bo
   Yang, Zhucnang
TI Nonlinear stability analysis of Ledinegg instability under constant
   external driving force
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flow instability; Ledinegg instability; Nonlinear stability; Dynamic
   analysis; Two-phase flow; Supercritical flow
ID PRESSURE-DROP OSCILLATIONS; 2-PHASE FLOW; HYDROCARBON FUEL; HEATED
   CHANNELS; CIRCULATION; ONSET; GENERATION; TUBE
AB Nonlinear stability analysis that is based on a numerical phase portrait is performed to investigate excursive instability, which is a type of Ledinegg instability, under a constant external driving force. The lumped parameter system model consists of time-dependent nonlinear ordinary differential equations, and the dynamic analysis from the lumped model agrees well with the results of previous research. A global phase portrait of excursive instability is constructed in the phase space of mass flux vs. pressure drop. The trajectories in the phase portrait accurately describe the excursive process. An initiation boundary that passes through OFI, the maximum point of the internal characteristic curve and the unstable equilibrium solution is observed and developed with a versatile expression for each operating condition. The critical margin of the perturbation intensities is quantitatively determined by the initiation boundary to evaluate the effects of perturbation intensities on the system stability. The results demonstrate that the effects of small and large perturbation intensities are different. Although a system can maintain stability under small perturbations, flow instability possibly occurs with large perturbations imposed on the system. In addition, the hysteresis phenomenon in the system with two parallel channels is observed under a constant external driving force. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Feng; Zhang, Bo; Yang, Zhucnang] Key Lab Complex Energy Convers & Utilizat, Dalian, Liaoning, Peoples R China.
   [Liu, Feng; Zhang, Bo; Yang, Zhucnang] Dalian Univ Technol, Sch Energy & Power Engn, Dalian, Peoples R China.
   [Lv, Jinsheng] Shandong Univ Technol, Sch Transportat & Vehicle Engn, Zibo, Peoples R China.
RP Zhang, B (reprint author), Key Lab Complex Energy Convers & Utilizat, Dalian, Liaoning, Peoples R China.
EM zhangbo@dlut.edu.cn
OI Zhang, Bo/0000-0002-7803-6973
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [51876020]
FX This work was supported by the National Nature Science Foundation of
   China (No. 51876020).
CR Ambrosini W., 2006, 14 INT C NUCL ENG, V2, P889
   Ambrosini W, 2008, NUCL ENG DES, V238, P1917, DOI 10.1016/j.nucengdes.2007.09.008
   Ambrosini W, 2007, NUCL ENG DES, V237, P1164, DOI 10.1016/j.nucengdes.2007.01.006
   Ambrosini W, 2009, NUCL ENG DES, V239, P2952, DOI 10.1016/j.nucengdes.2009.09.010
   BOURE JA, 1973, NUCL ENG DES, V25, P165, DOI 10.1016/0029-5493(73)90043-5
   Chen Y, 2016, APPL THERM ENG, V98, P628, DOI 10.1016/j.applthermaleng.2015.12.088
   Chiapero EM, 2013, INT J MULTIPHAS FLOW, V56, P15, DOI 10.1016/j.ijmultiphaseflow.2013.05.010
   Crespi F, 2017, APPL ENERG, V195, P152, DOI 10.1016/j.apenergy.2017.02.048
   Ghione A, 2017, INT J HEAT MASS TRAN, V105, P464, DOI 10.1016/j.ijheatmasstransfer.2016.10.012
   Huang H, 2002, AIAA PAPER, V3871, P2002
   Kakac S, 2008, INT J HEAT MASS TRAN, V51, P399, DOI 10.1016/j.ijheatmasstransfer.2007.09.026
   Khalil H. K., 2002, NONLINEAR SYSTEMS, P36
   Koji A., 1971, B JSME, V14, P837
   Ledinegg M., 1938, Waerme, V61, P891
   Li XF, 2011, APPL THERM ENG, V31, P2360, DOI 10.1016/j.applthermaleng.2011.03.036
   Liu GX, 2017, APPL ENERG, V205, P813, DOI 10.1016/j.apenergy.2017.08.132
   Maulbetsch J.S., 1965, STUDY SYSTEM INDUCED, P1
   Mawasha PR, 2001, INT J HEAT FLUID FL, V22, P643, DOI 10.1016/S0142-727X(01)00115-1
   Natan S, 2003, INT J MULTIPHAS FLOW, V29, P1669, DOI 10.1016/j.ijmultiphaseflow.2003.07.002
   OZAWA M, 1979, B JSME, V22, P1113
   PADKI MM, 1992, INT J HEAT MASS TRAN, V35, P525, DOI 10.1016/0017-9310(92)90287-3
   Pandey V, 2017, CHEM ENG SCI, V168, P204, DOI 10.1016/j.ces.2017.04.041
   Ruspini LC, 2010, J NAT GAS SCI ENG, V2, P211, DOI 10.1016/j.jngse.2010.08.003
   Schulenberg T, 2013, NUCL ENG DES, V264, P231, DOI 10.1016/j.nucengdes.2012.08.040
   Stenning A. H., 1964, J BASIC ENG, V86, P213, DOI DOI 10.1115/1.3653038
   Taitel Y, 2011, INT J MULTIPHAS FLOW, V37, P469, DOI 10.1016/j.ijmultiphaseflow.2011.01.002
   Van Oevelen T, 2017, INT J HEAT MASS TRAN, V107, P557, DOI 10.1016/j.ijheatmasstransfer.2016.11.050
   Wang HL, 2013, APPL THERM ENG, V51, P1144, DOI 10.1016/j.applthermaleng.2012.10.007
   Wang H, 2015, ACTA ASTRONAUT, V117, P296, DOI 10.1016/j.actaastro.2015.08.009
   Xia GL, 2016, NUCL ENG DES, V305, P604, DOI 10.1016/j.nucengdes.2016.04.016
   Yang ZQ, 2018, APPL THERM ENG, V135, P504, DOI 10.1016/j.applthermaleng.2018.02.092
   Yang ZQ, 2018, APPL THERM ENG, V129, P62, DOI 10.1016/j.applthermaleng.2017.10.009
   Yu ZT, 2016, INT J HEAT MASS TRAN, V98, P438, DOI 10.1016/j.ijheatmasstransfer.2016.03.047
   Yuncu H., 1990, HEAT TRANSFER ENG, V11, P45
   Zhang TJ, 2011, INT J MULTIPHAS FLOW, V37, P84, DOI 10.1016/j.ijmultiphaseflow.2010.07.003
   Zhang TJ, 2009, INT J HEAT MASS TRAN, V52, P5661, DOI 10.1016/j.ijheatmasstransfer.2009.09.008
   Zhou WX, 2014, APPL THERM ENG, V71, P34, DOI 10.1016/j.applthermaleng.2014.06.002
NR 37
TC 1
Z9 1
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 432
EP 445
DI 10.1016/j.ces.2019.05.035
PG 14
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700034
DA 2020-05-12
ER

PT J
AU Naskar, M
   Rana, K
   Chatterjee, D
   Dhara, T
   Sultana, R
   Sarkar, D
AF Naskar, Mithu
   Rana, Keka
   Chatterjee, Deepangsu
   Dhara, Trina
   Sultana, Ruhi
   Sarkar, Debasish
TI Design, performance characterization and hydrodynamic modeling of
   intermeshed spinning basket membrane (ISBM) module
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shear enhanced module; Intermeshed spinning basket; Permeate flux; Flux
   regeneration; Computational fluid dynamics; Energy budget
ID OVERLAPPING CERAMIC MEMBRANES; CROSS-FLOW ULTRAFILTRATION; BOVINE
   SERUM-ALBUMIN; DYNAMIC FILTRATION; CONCENTRATION POLARIZATION;
   ROTATING-DISKS; FLUX DECLINE; MICROFILTRATION; SHEAR; SYSTEMS
AB Dynamic Shear Enhanced (DSE) membrane modules have been established as effective replacement of classical cross flow devices, especially in treatment of high fouling feed solutions. Nevertheless, even with latest modifications, no DSE module is able to regenerate permeate flux without intermittent chemical/ hydrodynamic membrane cleaning. In this article, we have presented the design, performance characterization and primary CFD modeling of a DSE module with rapid on-line membrane washing facility along with high permeate production rate even in treatment of extremely fouling feed solution. Present device, named as Intermeshed Spinning Basket Membrane (ISBM) module, consists of two intermeshed counter rotating baskets, with flat sheet rectangular membranes fitted on alternate sides of their radial arms. Maximum permeate flux was evaluated to be as high as 2.4 x 10 (4) m(3) m(-2) s(-1) at moderate transmembrane pressure and rotational speed (588 kPa and 52.36 rad s(-1)). High rate of flux regeneration (>85% of start-up flux), even after 11 h of filtration run and moderately high flux (2.6 x 10 (6) m(3) m(-2) s(-1)) for concentrated feed solution (10.5 kg m(-3)) clearly establish the novelty of present design. Irrespective of low packing density, outcomes of this investigation suggests viable commercial use of ISBM module in treatment of extremely fouling feed solutions, for which other standard membrane units are apprehended to be inoperative. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Naskar, Mithu; Chatterjee, Deepangsu; Dhara, Trina; Sultana, Ruhi; Sarkar, Debasish] Univ Calcutta, Dept Chem Engn, Kolkata 700009, India.
   [Rana, Keka] Haldia Inst Technol, Dept Chem Engn, Haldia 721631, W Bengal, India.
RP Sarkar, D (reprint author), Univ Calcutta, Dept Chem Engn, Kolkata 700009, India.
EM debasish.sarkarcuce@gmail.com
CR Abdulgader H.A., 2013, SEP PURIF TECHNOL, V116, P253, DOI DOI 10.1016/J.SEPPUR.2013.05.052
   Al Akoum O, 2002, J MEMBRANE SCI, V197, P37
   Antony A, 2011, J MEMBRANE SCI, V383, P1, DOI 10.1016/j.memsci.2011.08.054
   Armbruster S, 2018, J MEMBRANE SCI, V554, P156, DOI 10.1016/j.memsci.2018.02.015
   Bacchin P, 2004, J MEMBRANE SCI, V228, P237, DOI 10.1016/j.memsci.2003.10.012
   Bae TH, 2005, J MEMBRANE SCI, V266, P1, DOI 10.1016/j.memsci.2005.08.014
   Bird R. B., 2005, TRANSPORT PHENOMENON
   Blanpain-Avet P, 2009, J MEMBRANE SCI, V337, P153, DOI 10.1016/j.memsci.2009.03.033
   BOUCHARD CR, 1994, J MEMBRANE SCI, V97, P215, DOI 10.1016/0376-7388(94)00164-T
   BOWEN WR, 1995, J MEMBRANE SCI, V101, P153, DOI 10.1016/0376-7388(94)00295-A
   Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906
   Choi H, 2005, J MEMBRANE SCI, V248, P189, DOI 10.1016/j.memsci.2004.08.027
   Dakshinamoorthy D, 2004, J LOSS PREVENT PROC, V17, P355, DOI 10.1016/j.jlp.2004.06.007
   Ding LH, 2006, J MEMBRANE SCI, V276, P232, DOI 10.1016/j.memsci.2005.09.051
   Diskin B., 2009, 47 AIAA AER SCI M, V2009, P597
   Dresch M, 2001, SEP PURIF TECHNOL, V22-3, P181, DOI 10.1016/S1383-5866(00)00128-3
   FIELD RW, 1995, J MEMBRANE SCI, V100, P259, DOI 10.1016/0376-7388(94)00265-Z
   Gao W, 2011, DESALINATION, V272, P1, DOI 10.1016/j.desal.2011.01.051
   Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013
   Glover G. C., 2013, CHEM ENG J, V127, P11
   GRACE HP, 1956, AICHE J, V2, P307, DOI 10.1002/aic.690020307
   He G, 2007, J MEMBRANE SCI, V300, P63, DOI 10.1016/j.memsci.2007.05.005
   Hermans P.H., 1936, J SOC CHEM IND T, V55T, P1
   Herrero C, 1997, J COLLOID INTERF SCI, V187, P344, DOI 10.1006/jcis.1996.4662
   HOLESCHOVSKY UB, 1991, AICHE J, V37, P1219, DOI 10.1002/aic.690370811
   Hsiao RC, 2011, MEMBR WATER TREAT, V2, P91, DOI 10.12989/mwt.2011.2.2.091
   Jaffrin MY, 2008, J MEMBRANE SCI, V324, P7, DOI 10.1016/j.memsci.2008.06.050
   Jaffrin MY, 2012, CURR OPIN CHEM ENG, V1, P171, DOI 10.1016/j.coche.2012.01.002
   Jahoda M, 2007, CHEM ENG RES DES, V85, P616, DOI 10.1205/cherd06183
   Jamaly S, 2014, DESALINATION, V354, P30, DOI 10.1016/j.desal.2014.09.017
   Jiang SX, 2017, SCI TOTAL ENVIRON, V595, P567, DOI 10.1016/j.scitotenv.2017.03.235
   Kang GD, 2014, J MEMBRANE SCI, V463, P145, DOI 10.1016/j.memsci.2014.03.055
   Kaya R, 2014, DESALINATION, V351, P109, DOI 10.1016/j.desal.2014.07.033
   Kim S, 2005, DESALINATION, V186, P111, DOI 10.1016/j.desal.2005.05.017
   KRONER KH, 1988, J MEMBRANE SCI, V36, P85, DOI 10.1016/0376-7388(88)80009-7
   Ladner DA, 2010, J MEMBRANE SCI, V356, P33, DOI 10.1016/j.memsci.2010.03.024
   Landazuri AC, 2016, J AEROSOL SCI, V95, P54, DOI 10.1016/j.jaerosci.2016.01.004
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Lee Y, 1998, J MEMBRANE SCI, V149, P181, DOI 10.1016/S0376-7388(98)00177-X
   Luo JQ, 2013, J MEMBRANE SCI, V435, P120, DOI 10.1016/j.memsci.2013.01.057
   Montgomery D.C., 2008, DESIGN ANAL EXPT
   Nicolaisen B, 2003, DESALINATION, V153, P355, DOI 10.1016/S0011-9164(02)01127-X
   Nunes S. P., 2006, MEMBRANE TECHNOLOGY
   Piry A, 2008, J MEMBRANE SCI, V325, P887, DOI 10.1016/j.memsci.2008.09.025
   Prakash M., 2003, 3 INT C CFD MIN PROC, P183
   ROCK G, 1986, TRANSFUSION, V26, P269, DOI 10.1046/j.1537-2995.1986.26386209385.x
   Sarkar A, 2012, J CHEM TECHNOL BIOT, V87, P1121, DOI 10.1002/jctb.3728
   Sarkar A, 2012, DESALINATION, V292, P53, DOI 10.1016/j.desal.2012.02.009
   Sarkar D, 2012, SEP PURIF TECHNOL, V94, P23, DOI 10.1016/j.seppur.2012.03.034
   Sarkar D, 2011, CHEM ENG SCI, V66, P2554, DOI 10.1016/j.ces.2011.02.056
   She QH, 2016, J MEMBRANE SCI, V499, P201, DOI 10.1016/j.memsci.2015.10.040
   SHIH TH, 1995, COMPUT FLUIDS, V24, P227, DOI 10.1016/0045-7930(94)00032-T
   Shirazi S, 2010, DESALINATION, V250, P236, DOI 10.1016/j.desal.2009.02.056
   Sun SK, 2017, VACUUM, V137, P195, DOI 10.1016/j.vacuum.2017.01.005
   Tamamidis P, 1996, J COMPUT PHYS, V124, P1, DOI 10.1006/jcph.1996.0041
   Vadi PK, 2001, J MEMBRANE SCI, V189, P69, DOI 10.1016/S0376-7388(01)00396-9
   Wang YQ, 2006, J MEMBRANE SCI, V286, P228, DOI 10.1016/j.memsci.2006.09.040
   Zhang WX, 2015, IND ENG CHEM RES, V54, P2843, DOI 10.1021/ie504848m
   Zhang WX, 2015, SEP PURIF TECHNOL, V141, P160, DOI 10.1016/j.seppur.2014.11.041
NR 59
TC 0
Z9 0
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 446
EP 462
DI 10.1016/j.ces.2019.05.049
PG 17
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700035
DA 2020-05-12
ER

PT J
AU Franken, D
   Ahmed, Z
   Eckels, S
   Eckels, S
   Bindra, H
AF Franken, Daniel
   Ahmed, Zayed
   Eckels, Seth
   Eckels, Steven
   Bindra, Hitesh
TI Impact of dissolved salts on two-phase flow and boiling heat transfer in
   a natural circulation loop
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Seawater; Flow oscillations; Natural circulation; Two-phase flow
ID BUBBLE COALESCENCE; BINARY-MIXTURES; WATER
AB Two-phase natural circulation and boiling experiments are conducted in this study with artificial seawater as a heat transfer fluid or process coolant. This experimental work is focused on understanding the role of dissolved salts in water on the steady state two-phase natural circulation flow rates. Mass flow rates were measured at different heat flux levels with artificial seawater, deionized water and tap water in the experimental loop. It was found that the average quasi-steady state mass flow rates were the same at any particular heat flux level regardless of the fluid being used. Artificial seawater coolant exhibited more stable natural circulation at higher heat flux as compared to the other two coolants. Mass flow measurements recorded at 2 s intervals show that magnitude of flow oscillations are much higher in case of tap water and deionized water. Also, high speed camera images revealed that the bubble departure diameters are smaller in seawater compared to tap or deionized water. This can be attributed to the increased local wettability due to the presence of dissolved salts in the fluid. Visual observations of the riser section showed that bubble coalescence and formation of slugs is inhibited in the seawater. These observations also explain the reduced pressure drop across test section when seawater was used as a coolant. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Franken, Daniel; Ahmed, Zayed; Eckels, Seth; Eckels, Steven; Bindra, Hitesh] Kansas State Univ, Dept Mech & Nucl Engn, Manhattan, KS 66506 USA.
RP Bindra, H (reprint author), Kansas State Univ, Dept Mech & Nucl Engn, Manhattan, KS 66506 USA.
EM hbindra@ksu.edu
FU U.S. Department of Energy, Nuclear Energy University Program
   [DE-NE0008690]; Department of Energy, Office of Nuclear Energy,
   Integrated University Program Graduate FellowshipUnited States
   Department of Energy (DOE)
FX The work presented was supported by the U.S. Department of Energy,
   Nuclear Energy University Program, under Award Number DE-NE0008690.
   First author acknowledges the support of Department of Energy, Office of
   Nuclear Energy, Integrated University Program Graduate Fellowship.
CR [Anonymous], 2012, PROPERTIES WATER STE
   Atkinson MJ, 1998, J AQUARICULTURE AQUA, V8, P39
   Besagni G, 2017, CHEM ENG RES DES, V118, P170, DOI 10.1016/j.cherd.2016.12.012
   Bindra H., 2010, THESIS
   Bindra H, 2012, COLLOID SURFACE A, V397, P85, DOI 10.1016/j.colsurfa.2012.01.038
   CRAIG VSJ, 1993, J PHYS CHEM-US, V97, P10192, DOI 10.1021/j100141a047
   Firouzi M, 2015, ADV COLLOID INTERFAC, V222, P305, DOI 10.1016/j.cis.2014.07.005
   Franco A, 2012, MICROGRAVITY SCI TEC, V24, P165, DOI 10.1007/s12217-011-9281-6
   GREIF R, 1988, J HEAT TRANS-T ASME, V110, P1243, DOI 10.1115/1.3250624
   Helali AB, 2011, ENERG CONVERS MANAGE, V52, P2288, DOI 10.1016/j.enconman.2010.11.025
   HOSPETI NB, 1969, AICHE J, V15, P214, DOI 10.1002/aic.690150217
   Hsu SH, 2015, INT J HEAT MASS TRAN, V86, P65, DOI 10.1016/j.ijheatmasstransfer.2015.02.049
   Jamialahmadi M, 2004, INT J HEAT MASS TRAN, V47, P729, DOI 10.1016/j.ijheatmasstransfer.2003.07.025
   Kakac S., 1983, ADV 2 PHASE FLOW HEA
   Kandlikar SG, 1998, J HEAT TRANS-T ASME, V120, P380, DOI 10.1115/1.2824260
   Kandlikar SG, 1998, J HEAT TRANS-T ASME, V120, P388, DOI 10.1115/1.2824262
   LESSARD RR, 1971, IND ENG CHEM FUND, V10, P260, DOI 10.1021/i160038a012
   Merlino RL, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2338790
   Nam Y, 2011, INT J HEAT MASS TRAN, V54, P1572, DOI 10.1016/j.ijheatmasstransfer.2010.11.031
   Nayar KG, 2016, DESALINATION, V390, P1, DOI 10.1016/j.desal.2016.02.024
   Raghupathi P. A., 2017, ASME C NAN MICR MIN, P1
   Rusydi A. F, 2018, IOP C SERIES EARTH E, V118, P1
   Sarafraz MM, 2014, AIN SHAMS ENG J, V5, P553, DOI 10.1016/j.asej.2013.11.006
   Sharqawy M. H., 2013, THERMOPHYSICAL PROPE, V16
   Slauenwhite DE, 1999, J GEOPHYS RES-OCEANS, V104, P3265, DOI 10.1029/1998JC900064
   Takata Y, 2005, ENERGY, V30, P209, DOI 10.1016/j.energy.2004.05.004
   Vassallo P., 2006, 2 PHASE FRICTIONAL P
   Wua B, 2017, CHEM ENG J, V326, P350, DOI 10.1016/j.cej.2017.05.135
   Zuber N., 1965, AMSE J HEAT TRANSFER
   ZVIRIN Y, 1982, NUCL ENG DES, V67, P203, DOI 10.1016/0029-5493(82)90142-X
NR 30
TC 0
Z9 0
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 463
EP 470
DI 10.1016/j.ces.2019.05.046
PG 8
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700036
DA 2020-05-12
ER

PT J
AU Moshkovich, Y
   Levy, Y
   Sher, E
AF Moshkovich, Yahav
   Levy, Yeshayahou
   Sher, Eran
TI Theoretical criteria for homogeneous flash boiling atomization
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID SPRAY FORMATION; BINARY-MIXTURE; WATER
AB When a liquid at a high pressure is driven out through an orifice to below its saturation pressure, flash-boiling of the homogeneous nucleation type may occur, resulting in high quality liquid atomization. This is one of the most effective means of generating a fine and narrow-dispersed spray. The occurrence of flash boiling atomization involves kinetic stability problems that are characterized by two criteria that include a minimal initial liquid temperature and a minimal rate of pressure drop. In this work, we analyze, and suggest analytical expressions for these two criteria. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moshkovich, Yahav; Levy, Yeshayahou; Sher, Eran] Technion Israel Inst Technol, IL-32000 Haifa, Israel.
RP Moshkovich, Y (reprint author), Technion Israel Inst Technol, IL-32000 Haifa, Israel.
EM yahavmoshko@gmail.com
FU Technion-IIT; Minerva Research Center (Max Planck Society)
   [AZ5746940764]
FX The authors acknowledge the financial support of the Technion-IIT and
   Minerva Research Center (Max Planck Society Contract AZ5746940764)
   towards initialization of this work.
CR ABUAF N, 1983, J HEAT TRANS-T ASME, V105, P379, DOI 10.1115/1.3245589
   ALAMGIR M, 1981, J HEAT TRANS-T ASME, V103, P52, DOI 10.1115/1.3244429
   AVEDISIAN CT, 1985, J PHYS CHEM REF DATA, V14, P695, DOI 10.1063/1.555734
   Bar-Kohany T, 2016, ATOMIZATION SPRAY, V26, P1259, DOI 10.1615/AtomizSpr.2016015626
   BARTAK J, 1990, INT J MULTIPHAS FLOW, V16, P789, DOI 10.1016/0301-9322(90)90004-3
   Carey V.P., 2008, LIQUID VAPOR PHASE C
   Carey V. P., 1992, LIQUID VAPOR PHASE C
   ELIAS E, 1993, J HEAT TRANS-T ASME, V115, P231, DOI 10.1115/1.2910654
   HUTCHERSON MN, 1983, J HEAT TRANS-T ASME, V105, P694, DOI 10.1115/1.3245650
   Levy M, 2016, ATOMIZATION SPRAY, V26, P1241, DOI 10.1615/AtomizSpr.2016014272
   Levy M, 2014, APPL THERM ENG, V73, P416, DOI 10.1016/j.applthermaleng.2014.08.008
   MIKIC BB, 1970, INT J HEAT MASS TRAN, V13, P657, DOI 10.1016/0017-9310(70)90040-2
   PARK BS, 1994, ATOMIZATION SPRAY, V4, P159, DOI 10.1615/AtomizSpr.v4.i2.30
   Rashkovan A, 2006, ATOMIZATION SPRAY, V16, P615, DOI 10.1615/AtomizSpr.v16.i6.20
   Rayleigh, 1917, PHILOS MAG, V34, P94, DOI 10.1080/14786440808635681
   SHER E, 1977, IND ENG CHEM PROC DD, V16, P237, DOI 10.1021/i260062a014
   Sher E, 2008, PROG ENERG COMBUST, V34, P417, DOI 10.1016/j.pecs.2007.05.001
   Skripov VP, 1974, METASTABLE LIQUIDS
   Sonntag R.E., 1966, FUNDAMENTALS STAT TH
   Wu B., 1981, STUDY NONEQUILIBRIUM, V2
   Zeigerson-Katz M, 1998, ATOMIZATION SPRAY, V8, P255, DOI 10.1615/AtomizSpr.v8.i3.20
   Zhou ZF, 2012, INT J HEAT MASS TRAN, V55, P4460, DOI 10.1016/j.ijheatmasstransfer.2012.04.021
NR 22
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 471
EP 475
DI 10.1016/j.ces.2019.06.001
PG 5
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700037
DA 2020-05-12
ER

PT J
AU Mizutani, HM
   Saito, T
AF Mizutani, Hiroya Muramatsu
   Saito, Takayuki
TI Innovative use of low-frequency ultrasound for particle
   separation/classification: Forces acting on a single particle held in
   water of 20-kHz-ultrasound pressure fields in transition states under
   control of the acoustic pressure amplitude
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE kHz-ultrasound; Acoustic cavitation-oriented bubble; Separation;
   Particle image velocimetry
ID BUBBLE
AB We have developed a unique particle-separation technique based on size that uses kHz-band ultrasound irradiation in water. Dispersed-millimeter-size particles in dissolved-gases water form themselves into a spherically flocculated particle swarm (SFPS). With the changes of ultrasound irradiation properties, the particles are separated according to their sizes. We previously investigated the characteristics of an SFPS and elucidated its formation mechanism. To achieve an efficient and precise particle-separation technique, the forces acting on the particles during the transition state of the ultrasound modulation must be determined, but it is difficult to clarify the forces acting on each particle. Herein, we experimentally and systematically investigated the forces acting on a single particle trapped in the sound pressure field. We discuss nine types of forces acting on the particle and the bubble adhering to its surface. Under the static state, the particle buoyancy was counterbalanced with the acoustic radiation force acting on the acoustic cavitation-oriented bubbles (ACOBs). We examined two types of amplitude change: a gradual amplitude change of the input power of a transducer, and a step-like amplitude change. The results revealed that the particle motion depends on a subtle balance between the acoustic radiation force acting on the ACOBs and unsteady fluid-dynamical forces acting on the particle. We also demonstrate the classification of particles by diameter by controlling the transition state of the amplitude change of the ultra-sound input power. We conclude that the gradual amplitude change provided an efficient and precise classification of particles by their diameters. (C) 2019 Published by Elsevier Ltd.
C1 [Mizutani, Hiroya Muramatsu] Shizuoka Univ, Grad Sch Sci & Technol, Naka Ku, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328561, Japan.
   [Saito, Takayuki] Shizuoka Univ, Res Inst Green Sci & Technol, Naka Ku, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328561, Japan.
RP Saito, T (reprint author), Shizuoka Univ, Res Inst Green Sci & Technol, Naka Ku, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328561, Japan.
EM muramatsu.hiroya.15@shizuoka.ac.jp; saito.takayuki@shizuoka.ac.jp
FU Japan Society for the Promotion of Science (JSPS)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science
FX This study was promoted and financially supported by Category 'A' of the
   Grants-in-Aid for Scientific Research, Japan Society for the Promotion
   of Science (JSPS). We thank the JSPS for its help. We declare no
   conflicts of interest.
CR Clift R., 1978, BUBBLES DROPS PARTIC
   Gor'Kov L.P., 1962, SOV PHYS DOKL, V6, P773, DOI DOI 10.1039/C004504G
   Kozuka T, 2007, JPN J APPL PHYS 1, V46, P4948, DOI 10.1143/JJAP.46.4948
   Matula TJ, 1997, J ACOUST SOC AM, V102, P1522, DOI 10.1121/1.420065
   Mitome H, 2001, JPN J APPL PHYS 1, V40, P3484, DOI 10.1143/JJAP.40.3484
   Mizushima Y, 2013, CHEM ENG SCI, V93, P395, DOI 10.1016/j.ces.2013.02.028
   Muramatsu H, 2018, AICHE J, V64, P1564, DOI 10.1002/aic.16039
   Muramatsu H, 2017, CHEM ENG SCI, V170, P195, DOI 10.1016/j.ces.2017.03.040
   Muramatsu H, 2015, J PHYS CONF SER, V656, DOI 10.1088/1742-6596/656/1/012117
   Ochiai Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097590
   Parajuli D, 2016, J ENVIRON RADIOACTIV, V151, P233, DOI 10.1016/j.jenvrad.2015.10.014
   Saito T, 2010, CHEM ENG J, V158, P39, DOI 10.1016/j.cej.2008.07.021
   Woodside SM, 1997, AICHE J, V43, P1727, DOI 10.1002/aic.690430710
   Yanai S, 2017, ADV INTELL SYST, V519, P183, DOI 10.1007/978-3-319-46490-9_26
NR 14
TC 0
Z9 0
U1 4
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 476
EP 488
DI 10.1016/j.ces.2019.04.053
PG 13
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700038
DA 2020-05-12
ER

PT J
AU Liu, P
   Chen, MM
   Ma, YQ
   Hu, C
   Zhang, QG
   Zhu, AM
   Liu, QL
AF Liu, Peng
   Chen, Mengmeng
   Ma, Yiqiang
   Hu, Chuan
   Zhang, Qiugen
   Zhu, Aimei
   Liu, Qinglin
TI A hydrophobic pervaporation membrane with hierarchical microporosity for
   high-efficient dehydration of alcohols
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pervaporation; Organic dehydration; Polymeric membrane; Polymer of
   intrinsic microporosity
ID COMPOSITE MEMBRANES; POLYIMIDE MEMBRANES; MOLECULAR-SIEVE;
   NEXT-GENERATION; SEPARATION; PIM-1; POLYMER; ETHANOL; PERMEABILITY;
   PERFORMANCE
AB Pervaporation is a promising membrane technology for separation of aqueous organic solution particularly azeotrope and close-boiling point compounds. However, most of pervaporation membranes are based on hydrophilic polymers that suffer decline of separation performance due to their swelling in aqueous solution. Here we present a copolymer synthetic strategy for preparation of hydrophobic polymer pervaporation membrane with hierarchical porosity via uniting both rigid and flexible segments. The synthesized membrane has well-defined micropores and high free volume faction of 8.03% with cavity size of 0.476 nm, and demonstrate exceptional performance with high permeability and selectivity for dehydration of alcohols. In the pervaporation of ethanol-water azeotrope, the membrane displays the high permeabtion flux of 74.6 mu m kg m(-2) h(-1) and water selectivity of 34 (separation factor of 732) at 30 degrees C. The developed strategy has excellent potential for synthesizing copolymers for high-efficient pervaporation membranes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Peng; Chen, Mengmeng; Ma, Yiqiang; Hu, Chuan; Zhang, Qiugen; Zhu, Aimei; Liu, Qinglin] Xiamen Univ, Coll Chem & Chem Engn, Dept Chem & Biochem Engn, Xiamen 361005, Fujian, Peoples R China.
RP Zhang, QG (reprint author), Xiamen Univ, Coll Chem & Chem Engn, Dept Chem & Biochem Engn, Xiamen 361005, Fujian, Peoples R China.
EM gzhang@xmu.edu.cn
RI Liu, Qing Lin/L-6776-2013
OI Liu, Qing Lin/0000-0002-8324-6764; Zhang, Qiu Gen/0000-0003-0998-1506
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [21676220, 21736009, 21878253]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [20720170032]
FX This work was supported by the National Nature Science Foundation of
   China (No. 21676220, 21736009 and 21878253) and the Fundamental Research
   Funds for the Central Universities (No. 20720170032).
CR Budd PM, 2004, ADV MATER, V16, P456, DOI 10.1002/adma.200306053
   Carta M, 2013, SCIENCE, V339, P303, DOI 10.1126/science.1228032
   Castro-Munoz R, 2019, J MEMBRANE SCI, V582, P423, DOI 10.1016/j.memsci.2019.03.076
   Chapman PD, 2008, J MEMBRANE SCI, V318, P5, DOI 10.1016/j.memsci.2008.02.061
   Chen MM, 2018, J IND ENG CHEM, V63, P296, DOI 10.1016/j.jiec.2018.02.030
   Chen SH, 2009, EUR POLYM J, V45, P1293, DOI 10.1016/j.eurpolymj.2008.11.030
   Cheng XX, 2017, J MEMBRANE SCI, V541, P329, DOI 10.1016/j.memsci.2017.07.009
   Deng YH, 2016, ANGEW CHEM INT EDIT, V55, P12793, DOI 10.1002/anie.201607014
   Fan HW, 2014, ANGEW CHEM INT EDIT, V53, P5578, DOI 10.1002/anie.201309534
   Gao L, 2017, J MEMBRANE SCI, V529, P207, DOI 10.1016/j.memsci.2017.02.008
   Gimenes ML, 2007, J MEMBRANE SCI, V295, P71, DOI 10.1016/j.memsci.2007.02.036
   Gin DL, 2011, SCIENCE, V332, P674, DOI 10.1126/science.1203771
   Holst JR, 2010, NAT CHEM, V2, P915, DOI [10.1038/NCHEM.873, 10.1038/nchem.873]
   Kanse NG, 2017, MATER TODAY-PROC, V4, P10520, DOI 10.1016/j.matpr.2017.06.412
   Khoonsap S, 2017, J MEMBRANE SCI, V544, P287, DOI 10.1016/j.memsci.2017.09.035
   Koros WJ, 2017, NAT MATER, V16, P289, DOI [10.1038/NMAT4805, 10.1038/nmat4805]
   Li LQ, 2016, AICHE J, V62, P2813, DOI 10.1002/aic.15234
   Li WB, 2015, CHEM ENG SCI, V135, P232, DOI 10.1016/j.ces.2015.04.011
   Li X, 2017, CHEM SOC REV, V46, P7124, DOI 10.1039/c7cs00575j
   Li YF, 2015, CHEM SOC REV, V44, P103, DOI 10.1039/c4cs00215f
   Liu L, 2018, J MEMBRANE SCI, V553, P63, DOI 10.1016/j.memsci.2018.02.021
   Liu XL, 2011, ANGEW CHEM INT EDIT, V50, P10636, DOI 10.1002/anie.201104383
   Mahdi T, 2015, SEP PURIF REV, V44, P308, DOI 10.1080/15422119.2014.963607
   McKeown NB, 2005, CHEM-EUR J, V11, P2610, DOI 10.1002/chem.200400860
   McKeown NB, 2006, CHEM SOC REV, V35, P675, DOI 10.1039/b600349d
   Namboodiri VV, 2007, J MEMBRANE SCI, V306, P209, DOI 10.1016/j.memsci.2007.08.050
   Le NL, 2012, J MEMBRANE SCI, V415, P109, DOI 10.1016/j.memsci.2012.04.042
   Ong YK, 2016, PROG POLYM SCI, V57, P1, DOI 10.1016/j.progpolymsci.2016.02.003
   Ong YK, 2012, CHEM ENG SCI, V79, P41, DOI 10.1016/j.ces.2012.05.013
   Park HB, 2017, SCIENCE, V356, DOI 10.1126/science.aab0530
   Paul DR, 2012, SCIENCE, V335, P413, DOI 10.1126/science.1216923
   Praptowidodo VS, 2005, J MOL STRUCT, V739, P207, DOI 10.1016/j.molstruc.2004.04.035
   Qiao ZA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4705
   Rafik M, 2003, POLYM INT, V52, P1222, DOI 10.1002/pi.1260
   Richter H, 2017, ANGEW CHEM INT EDIT, V56, P7760, DOI 10.1002/anie.201701851
   Smuleac V, 2010, J MEMBRANE SCI, V352, P41, DOI 10.1016/j.memsci.2010.01.058
   Song QL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5813
   Varoon K, 2011, SCIENCE, V334, P72, DOI 10.1126/science.1208891
   Wu XM, 2016, AICHE J, V62, P842, DOI 10.1002/aic.15077
   Wu XM, 2016, J CHEM ENG DATA, V61, P579, DOI 10.1021/acs.jced.5b00731
   Xu YM, 2018, SEP PURIF TECHNOL, V193, P165, DOI 10.1016/j.seppur.2017.11.004
   Yong WF, 2017, J MEMBRANE SCI, V523, P430, DOI 10.1016/j.memsci.2016.10.021
   Zhang QG, 2013, RSC ADV, V3, P1855, DOI 10.1039/c2ra21827e
NR 43
TC 2
Z9 2
U1 26
U2 97
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 489
EP 498
DI 10.1016/j.ces.2019.05.057
PG 10
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700039
DA 2020-05-12
ER

PT J
AU Ge, YL
   Fu, KX
   Zhao, Q
   Ji, N
   Song, CF
   Ma, DG
   Liu, QL
AF Ge, Yunli
   Fu, Kaixuan
   Zhao, Qian
   Ji, Na
   Song, Chunfeng
   Ma, Degang
   Liu, Qingling
TI Performance study of modified Pt catalysts for the complete oxidation of
   acetone
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalytic oxidation; VOCs; Pt; Cerium
ID VOLATILE ORGANIC-COMPOUNDS; ZIRCONIA MIXED OXIDES; LOW-TEMPERATURE; DEEP
   OXIDATION; GOLD CATALYSTS; COMBUSTION; VOCS; SO2
AB Low temperature catalytic oxidation (LTCO) is an effective method of treatment for low concentrations of volatile organic compounds (VOCs) that uses efficient catalysts to reduce reaction activation energy and to improve reaction rates. A series of modified Pt catalysts (Pt-Ce, Pt-Zr) were successfully prepared, and they were used as catalysts for acetone oxidation. Several methods such as X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), transmission electron microscopy (TEM) and Hydrogen-temperatureprogrammed reduction (H-2-TPR) have been used to explore the reaction mechanisms between catalysts and acetone. The results show that Ce-modified Pt catalysts (Pt-Ce/TiO2) display excellent performance for acetone oxidation, and the T-50 (temperature at 50% conversion rate) and T-90 of Pt-Ce/TiO2 are 210 degrees C and 236 degrees C, respectively. The XPS results show that the amount of Pt-0 (metal) in the Pt-Ce/TiO2 was significantly higher than that in the Pt/TiO2. The addition of Ce favors the formation of more Pt-0 (metal) on the catalyst surface, which accelerates the acetone oxidation. It can be concluded that the additional Pt nanoparticles exposed to the catalyst surface accelerated the process of acetone oxidation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ge, Yunli; Fu, Kaixuan; Zhao, Qian; Ji, Na; Song, Chunfeng; Liu, Qingling] Tianjin Univ, Sch Environm Sci & Technol, Tianjin Key Lab Indoor Air Environm Qual Control, Tianjin 300350, Peoples R China.
   [Ge, Yunli; Fu, Kaixuan; Zhao, Qian; Ji, Na; Song, Chunfeng; Ma, Degang; Liu, Qingling] Tianjin Univ, Sch Mech Engn, State Key Lab Engines, Tianjin 300350, Peoples R China.
RP Liu, QL (reprint author), Tianjin Univ, Sch Environm Sci & Technol, Tianjin Key Lab Indoor Air Environm Qual Control, Tianjin 300350, Peoples R China.
EM liuql@tju.edu.cn
RI LIU, Qingling/A-9197-2011
OI LIU, Qingling/0000-0002-5058-883X
FU National Key R&D Program of China [2016YFC0205300]; National Engineering
   Laboratory for Mobile Source Emission Control Technology of China
   [NELMS2017A03]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21503144]; Tianjin Research Program
   of Application Foundation and Advanced Technology [15JCQNJC08500,
   16JCQNJC05400]; Major science and technology project for ecological
   environment management in Tianjin [18ZXSZSF00210]
FX The project is financially supported by National Key R&D Program of
   China (Project No. 2016YFC0205300), National Engineering Laboratory for
   Mobile Source Emission Control Technology of China (NELMS2017A03), and
   National Natural Science Foundation of China (No. 21503144), the Tianjin
   Research Program of Application Foundation and Advanced Technology (No.
   15JCQNJC08500, No. 16JCQNJC05400). Major science and technology project
   for ecological environment management in Tianjin (18ZXSZSF00210).
CR Abdelouahab-Reddam Z, 2015, APPL CATAL A-GEN, V494, P87, DOI 10.1016/j.apcata.2015.01.026
   An NH, 2014, RSC ADV, V4, P38250, DOI 10.1039/c4ra05646a
   Arnold F, 1997, GEOPHYS RES LETT, V24, P57, DOI 10.1029/96GL03693
   Azalim S, 2013, CHEM ENG J, V223, P536, DOI 10.1016/j.cej.2013.03.017
   Boltic Z, 2013, J CLEAN PROD, V44, P123, DOI 10.1016/j.jclepro.2013.01.004
   Burgos N, 2002, APPL CATAL B-ENVIRON, V38, P251, DOI 10.1016/S0926-3373(01)00294-6
   Corma A, 2008, CHEM SOC REV, V37, P2096, DOI 10.1039/b707314n
   de Rivas B, 2007, J MOL CATAL A-CHEM, V278, P181, DOI 10.1016/j.molcata.2007.09.006
   Diaz E, 2006, J CHROMATOGR A, V1116, P230, DOI 10.1016/j.chroma.2006.03.043
   Everaert K, 2004, J HAZARD MATER, V109, P113, DOI 10.1016/j.jhazmat.2004.03.019
   Fernandez C, 2014, APPL CATAL B-ENVIRON, V156, P202, DOI 10.1016/j.apcatb.2014.03.023
   Frances Rico, 2016, APPL CATAL B-ENVIRON, V180, P169
   Gelin P, 2002, APPL CATAL B-ENVIRON, V39, P1, DOI 10.1016/S0926-3373(02)00076-0
   Gonzalez ID, 2010, CATAL TODAY, V149, P372, DOI 10.1016/j.cattod.2009.07.100
   Gutierrez-Ortiz JI, 2004, APPL CATAL A-GEN, V269, P147, DOI 10.1016/j.apcata.2004.04.014
   HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405
   Hazlett M. J., 2016, APPL CATAL B-ENVIRON
   Hu CQ, 2009, CHEM ENG J, V152, P583, DOI 10.1016/j.cej.2009.05.033
   Hua-Fei H.E., 2012, ENV SCI, V32, P2271
   Huang HB, 2015, CATAL SCI TECHNOL, V5, P2649, DOI 10.1039/c4cy01733a
   Huang HF, 2015, J ENVIRON SCI, V33, P135, DOI 10.1016/j.jes.2014.10.026
   KIM KS, 1971, J AM CHEM SOC, V93, P6296, DOI 10.1021/ja00752a065
   Lahousse C, 1998, J CATAL, V178, P214, DOI 10.1006/jcat.1998.2148
   Li N, 2013, APPL CATAL B-ENVIRON, V142, P523, DOI 10.1016/j.apcatb.2013.05.068
   Li TY, 2011, APPL CATAL B-ENVIRON, V103, P143, DOI 10.1016/j.apcatb.2011.01.020
   Li WB, 2009, CATAL TODAY, V148, P81, DOI 10.1016/j.cattod.2009.03.007
   Lin BF, 2018, ELECTROCHIM ACTA, V290, P55, DOI 10.1016/j.electacta.2018.09.006
   Lin LY, 2015, CHEM ENG J, V264, P835, DOI 10.1016/j.cej.2014.12.042
   Lin SY, 2014, CHEM ENG J, V247, P42, DOI 10.1016/j.cej.2014.03.015
   Liotta LF, 2010, APPL CATAL B-ENVIRON, V100, P403, DOI 10.1016/j.apcatb.2010.08.023
   Lv HF, 2014, NANOSCALE, V6, P5063, DOI 10.1039/c4nr00402g
   Ma Y, 2008, ACTA PHYS-CHIM SIN, V24, P1132, DOI 10.1016/S1872-1508(08)60047-9
   Navarro RM, 2006, APPL CATAL A-GEN, V297, P60, DOI 10.1016/j.apcata.2005.08.036
   Panagiotopoulou P, 2007, CATAL TODAY, V127, P319, DOI 10.1016/j.cattod.2007.05.010
   Scire S, 2012, APPL CATAL B-ENVIRON, V125, P222, DOI 10.1016/j.apcatb.2012.05.047
   Sharma S, 2011, J SOLID STATE ELECTR, V15, P2185, DOI 10.1007/s10008-011-1402-z
   Solsona B, 2011, APPL CATAL B-ENVIRON, V101, P388, DOI 10.1016/j.apcatb.2010.10.008
   Spivey J. J., 1989, J AM CHEM SOC, V26, P2165
   Tang WX, 2015, SCI CHINA PHYS MECH, V58, DOI 10.1007/s11433-015-5746-8
   Wang CY, 2011, CATAL TODAY, V174, P70, DOI 10.1016/j.cattod.2011.02.025
   Wu XD, 2012, J HAZARD MATER, V225, P146, DOI 10.1016/j.jhazmat.2012.05.011
   Xu F, 2017, ELECTROCHIM ACTA, V229, P253, DOI 10.1016/j.electacta.2017.01.154
   Xu F, 2013, ELECTROCHIM ACTA, V112, P304, DOI 10.1016/j.electacta.2013.08.141
   Yang M, 2012, J NAT GAS CHEM, V21, P76, DOI 10.1016/S1003-9953(11)60336-8
   Yang P, 2015, APPL CATAL B-ENVIRON, V162, P227, DOI 10.1016/j.apcatb.2014.06.048
   Zhang MQ, 1997, APPL CATAL B-ENVIRON, V13, P123, DOI 10.1016/S0926-3373(96)00097-5
NR 46
TC 1
Z9 1
U1 24
U2 118
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 499
EP 506
DI 10.1016/j.ces.2019.05.051
PG 8
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700040
DA 2020-05-12
ER

PT J
AU Farhadian, A
   Varfolomeev, MA
   Kudbanov, A
   Gallyamova, SR
AF Farhadian, Abdolreza
   Varfolomeev, Mikhail A.
   Kudbanov, Arman
   Gallyamova, Svetlana R.
TI A new class of promising biodegradable kinetic/anti-agglomerant methane
   hydrate inhibitors based on castor oil
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methane hydrate; Vegetable oil; Kinetic hydrate inhibitor;
   Anti-agglomerant; Biodegradability; Flow assurance; Differential
   scanning calorimeter
ID CRYSTAL-GROWTH; PERFORMANCE; SERIES
AB This study is devoted to the evaluation of vegetable oils (in this case castor oil) as an inexpensive, sustainable, environment-friendly, natural and promising resource to design/synthesis efficient kinetic/anti-agglomerant methane hydrate inhibitors. The castor-based waterborne polyurea/urethanes (CWPUUs) were synthesized on the basis of the waterborne technique. The high-pressure autoclave cell and high-pressure micro-differential scanning calorimeter (HP-mu DSC) using methane gas were applied to evaluate the inhibition performance of CWPUUs as an inhibitor for methane gas hydrate formation. The results of gas uptake tests confirm that the CWPUUs show high efficiency as kinetic hydrate inhibitors (KHIs). The CWPUUs with similar to 3.2 and 6.8 kD molecular weight delayed the onset time of methane hydrate formation by a factor of 26.8 and 13 times and reduced the methane hydrate growth rate by a factor of 3.8 and 2.5 times in comparison with pure water. The results were further confirmed through DSC measurements, in which the usage of CWPUUs with similar to 3.2 and 6.8 kD molecular weight decreased the mean onset temperature of methane hydrate formation on 6.1 and 4.7 degrees C compared to pure water, respectively. Additives of CWPUUs (1 wt % solution) increased the mean onset time of methane hydrate formation from 2.3 h for pure water to 8.7 and 6.4 h. CWPUUs also demonstrated the thermodynamic inhibition by decreasing the melting temperature of methane hydrates comparing to the pure water system. On the other hand, the torque measurements were used to assess anti-agglomerant performance of CWPUUs. During the methane hydrate formation in the presence of CWPUUs, the torque changes remained constant that suggests the hydrate particles stayed separate without aggregation. Moreover, synthesized CWPUUs can be related to biodegradable substances because their BOD5/CODcr value measured in this work is equal to 0.389. Hence, the application of CWPPUs can be a prospective option for delaying the onset time/temperature of hydrate formation, reducing hydrate growth rate and preventing agglomeration of hydrate particles, and this strategy refers to the terms of green chemistry. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Farhadian, Abdolreza; Varfolomeev, Mikhail A.; Kudbanov, Arman] Kazan Fed Univ, Dept Phys Chem, Kremlevskaya Str 18, Kazan 420008, Russia.
   [Farhadian, Abdolreza; Varfolomeev, Mikhail A.; Kudbanov, Arman] Kazan Fed Univ, Dept Petr Engn, Kremlevskaya Str 18, Kazan 420008, Russia.
   [Gallyamova, Svetlana R.] Fed Ctr Toxicol Radiol & Biol Safety, FGBI, Kazan, Russia.
RP Varfolomeev, MA (reprint author), Kazan Fed Univ, Dept Petr Engn, Kremlevskaya Str 18, Kazan 420008, Russia.
EM mikhail.varfolomeev@kpfu.ru
RI Varfolomeev, Mikhail A./N-1824-2014
OI Varfolomeev, Mikhail A./0000-0001-8578-6257; Farhadian,
   Abdolreza/0000-0002-7566-5184
FU Russian Foundation for Basic ResearchRussian Foundation for Basic
   Research (RFBR) [N 18-05-70121]
FX This work was supported by the Russian Foundation for Basic Research
   Project N 18-05-70121. It has been partly carried out on the basis of
   the Russian Government Program of Competitive Growth of Kazan Federal
   University.
CR Cha M, 2013, J PHYS CHEM A, V117, P13988, DOI 10.1021/jp408346z
   Clark J.H., 2011, DEGRAD APPL
   Dalmazzone D, 2009, CHEM ENG SCI, V64, P2020, DOI 10.1016/j.ces.2009.01.028
   Daraboina N, 2013, ENERG FUEL, V27, P5779, DOI 10.1021/ef401042h
   Daraboina N, 2011, ENERG FUEL, V25, P4398, DOI 10.1021/ef200814z
   Del Villano L, 2010, CHEM ENG SCI, V65, P5366, DOI 10.1016/j.ces.2010.06.033
   Desroches M, 2012, POLYM REV, V52, P38, DOI 10.1080/15583724.2011.640443
   Dong SB, 2017, FUEL, V210, P713, DOI 10.1016/j.fuel.2017.08.096
   Farhadian A, 2019, IND ENG CHEM RES, V58, P7752, DOI 10.1021/acs.iecr.9b00803
   Farhadian A, 2018, POLYM DEGRAD STABIL, V155, P111, DOI 10.1016/j.polymdegradstab.2018.07.010
   Gulbrandsen AC, 2017, ENERG FUEL, V31, P8505, DOI 10.1021/acs.energyfuels.6b03487
   Islam MR, 2014, J APPL POLYM SCI, V131, DOI [10.1002/APP.40787, 10.1002/app.40787]
   Karaaslan U, 2000, ENERG FUEL, V14, P1103, DOI 10.1021/ef000069s
   Karak N, 2012, WOODHEAD PUBL MATER, P1
   Ke W, 2016, ENERG FUEL, V30, P10015, DOI 10.1021/acs.energyfuels.6b02739
   Kelland M., 2014, PRODUCTION CHEM OIL
   Kelland M.A., 2008, International Pat, Patent No. [WO/2008/023989, 2008023989]
   Kelland MA, 2006, CHEM ENG SCI, V61, P4290, DOI 10.1016/j.ces.2006.02.016
   Kelland MA, 2016, ENERG FUEL, V30, P3934, DOI 10.1021/acs.energyfuels.6b00386
   Lee JD, 2006, CHEM ENG SCI, V61, P1368, DOI 10.1016/j.ces.2005.08.009
   Leinweber D., 2007, International Pat, Patent No. [WO/2007/054226, 2007054226]
   Lin H, 2017, ENERG FUEL, V31, P3843, DOI 10.1021/acs.energyfuels.7b00019
   Mady MF, 2015, ENERG FUEL, V29, P678, DOI 10.1021/ef502489d
   Magnusson CD, 2015, ENERG FUEL, V29, P2336, DOI 10.1021/acs.energyfuels.5b00222
   Maisonneuve L, 2013, POLYM CHEM-UK, V4, P5472, DOI 10.1039/c3py00791j
   Moradpour H, 2011, FUEL, V90, P3343, DOI 10.1016/j.fuel.2011.06.038
   Omrani I, 2016, EUR POLYM J, V82, P220, DOI 10.1016/j.eurpolymj.2016.07.021
   Perrin A, 2013, CHEM SOC REV, V42, P1996, DOI 10.1039/c2cs35340g
   Reyes FT, 2015, ENERG FUEL, V29, P4774, DOI 10.1021/acs.energyfuels.5b00628
   Reyes FT, 2015, ENERG FUEL, V29, P695, DOI 10.1021/ef502539u
   Reyes FT, 2014, ENERG FUEL, V28, P6889, DOI 10.1021/ef501779p
   Saikia T, 2016, J PETROL SCI ENG, V147, P647, DOI 10.1016/j.petrol.2016.09.022
   Sharifi H, 2015, J CHEM ENG DATA, V60, P336, DOI 10.1021/je500591q
   Sharifi H, 2014, CRYST GROWTH DES, V14, P2923, DOI 10.1021/cg500218q
   Sloan ED, 1998, IND ENG CHEM RES, V37, P3124, DOI 10.1021/ie970902h
   Sohn YH, 2015, CHEM ENG SCI, V126, P711, DOI 10.1016/j.ces.2015.01.016
   Talaghat MR, 2014, J NAT GAS SCI ENG, V18, P7, DOI 10.1016/j.jngse.2014.01.013
   Tariq M, 2014, IND ENG CHEM RES, V53, P17855, DOI 10.1021/ie503559k
   Roux MV, 2008, J PHYS CHEM REF DATA, V37, P1855, DOI 10.1063/1.2955570
   Xiao CW, 2009, CHEM ENG SCI, V64, P1522, DOI 10.1016/j.ces.2008.12.031
   XU S, 2016, SCI REP, V6, P1
   Yang JH, 2011, CHEM ENG SCI, V66, P278, DOI 10.1016/j.ces.2010.10.025
   Zanota ML, 2005, ENERG FUEL, V19, P584, DOI 10.1021/ef040064l
   Zeng H, 2006, J AM CHEM SOC, V128, P2844, DOI 10.1021/ja0548182
NR 44
TC 3
Z9 3
U1 8
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 507
EP 517
DI 10.1016/j.ces.2019.05.055
PG 11
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700041
DA 2020-05-12
ER

PT J
AU Huang, CF
   Xu, M
   Huai, XL
AF Huang, Caifeng
   Xu, Min
   Huai, Xiulan
TI Experimental investigation on thermodynamic and kinetic of calcium
   hydroxide dehydration with hexagonal boron nitride doping for
   thermochemical energy storage
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermochemical energy storage; Calcium hydroxide; Hexagonal boron
   nitride doping; Non-isothermal kinetic; Cycle stability
ID HEAT-STORAGE; CYCLING STABILITY; BED REACTOR; CAO/CA(OH)(2); SYSTEM;
   PERFORMANCE; MAGNESIUM; ENHANCEMENT; REHYDRATION; COMPOSITES
AB Thermochemical heat storage is a promising candidate due to its high energy densities and the possibility of long-term storage in the areas of waste heat recovery and renewable energy utilization. In this work, hexagonal boron nitride (HBN)-doped calcium hydroxide has been prepared by ultrasonic and mechanical agitation. Thermodynamics, kinetic and cycling stability of HBN-doped composites as well as the pure calcium hydroxide are investigated by thermogravimetric analysis, differential scanning calorimetry, thermal constant analyzer and scanning electron microscope. The obtained results show that the thermal conductivity of the materials has been improved with HBN doping, and the dehydration enthalpy of HBN-doped composites has also been slightly enhanced in comparison to that of the pure calcium hydroxide. In addition, the pre-exponential factor and activation energy associated to the suitable kinetic models are derived for dehydration of both pure and an optimal mass content of 15 wt% HBN-doped composite. Moreover, the results of cycling stability texts indicate that HBN-doped composite shows the improved multicycle activity in comparison to the pure compound. After ten dehydration/rehydration cycles, a 67% of the rehydration conversion remains for HBN-doped composite, exhibiting competitive heat storage capacity with energy density of more than 1000 kJ/kg. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Huang, Caifeng; Xu, Min; Huai, Xiulan] Chinese Acad Sci, Inst Engn Thermophys, Beijing 100190, Peoples R China.
   [Huang, Caifeng; Xu, Min; Huai, Xiulan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Xu, M (reprint author), Chinese Acad Sci, Inst Engn Thermophys, Beijing 100190, Peoples R China.
EM xumin@iet.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51836009, 51776202]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 51836009 and 51776202).
CR Abedin AH, 2012, ENERGY, V41, P83, DOI 10.1016/j.energy.2011.06.034
   ACHAR BNN, 1966, P INT CLAY C JERUSAL, V1, P67
   Alva G, 2018, ENERGY, V144, P341, DOI 10.1016/j.energy.2017.12.037
   Angerer M, 2018, ENERGY REP, V4, P507, DOI 10.1016/j.egyr.2018.07.005
   Benitez-Guerrero M, 2018, APPL ENERG, V210, P108, DOI 10.1016/j.apenergy.2017.10.109
   BROWN DR, 1992, J SOL ENERG-T ASME, V114, P212, DOI 10.1115/1.2930008
   Chen XY, 2018, ENERG CONVERS MANAGE, V177, P792, DOI 10.1016/j.enconman.2018.10.011
   Chen XY, 2018, ENERGY, V155, P128, DOI 10.1016/j.energy.2018.05.016
   COATS AW, 1964, NATURE, V201, P68, DOI 10.1038/201068a0
   Criado YA, 2016, SOL ENERGY, V135, P800, DOI 10.1016/j.solener.2016.06.056
   Criado YA, 2014, IND ENG CHEM RES, V53, P12594, DOI 10.1021/ie404246p
   Dai L, 2018, APPL THERM ENG, V133, P261, DOI 10.1016/j.applthermaleng.2018.01.059
   Han R, 2018, APPL ENERG, V231, P412, DOI 10.1016/j.apenergy.2018.09.142
   IRABIEN A, 1990, IND ENG CHEM RES, V29, P1599, DOI 10.1021/ie00104a004
   Ishitobi H, 2013, APPL THERM ENG, V50, P1639, DOI 10.1016/j.applthermaleng.2011.07.020
   Kenisarin M, 2007, RENEW SUST ENERG REV, V11, P1913, DOI 10.1016/j.rser.2006.05.005
   Lipp A., 1989, Journal of the European Ceramic Society, V5, P3, DOI 10.1016/0955-2219(89)90003-4
   Mastronardo E, 2016, APPL ENERG, V181, P232, DOI 10.1016/j.apenergy.2016.08.041
   Myagmarjav O, 2014, APPL THERM ENG, V63, P170, DOI 10.1016/j.applthermaleng.2013.10.045
   Pardo P, 2014, SOL ENERGY, V107, P605, DOI 10.1016/j.solener.2014.06.010
   Pardo P, 2014, RENEW SUST ENERG REV, V32, P591, DOI 10.1016/j.rser.2013.12.014
   Prieto C, 2016, RENEW SUST ENERG REV, V60, P909, DOI 10.1016/j.rser.2015.12.364
   Sakata K, 2013, SCI REP-UK, V3, DOI 10.1038/srep03243
   Sakellariou KG, 2017, SOL ENERGY, V146, P65, DOI 10.1016/j.solener.2017.02.013
   Schaube F, 2013, CHEM ENG RES DES, V91, P856, DOI 10.1016/j.cherd.2012.09.020
   Schaube F, 2012, THERMOCHIM ACTA, V538, P9, DOI 10.1016/j.tca.2012.03.003
   Schaube F, 2011, J SOL ENERG-T ASME, V133, DOI 10.1115/1.4004245
   Schmidt M, 2014, APPL THERM ENG, V62, P553, DOI 10.1016/j.applthermaleng.2013.09.020
   SHARP JH, 1969, ANAL CHEM, V41, P2060, DOI 10.1021/ac50159a046
   Shkatulov A, 2015, ENERGY, V85, P667, DOI 10.1016/j.energy.2015.04.004
   Shkatulov A, 2012, ENERGY, V44, P1028, DOI 10.1016/j.energy.2012.04.045
   Tatsidjodoung P, 2013, RENEW SUST ENERG REV, V18, P327, DOI 10.1016/j.rser.2012.10.025
   Tian Y, 2013, APPL ENERG, V104, P538, DOI 10.1016/j.apenergy.2012.11.051
   Vyazovkin S, 2011, THERMOCHIM ACTA, V520, P1, DOI 10.1016/j.tca.2011.03.034
   Xu M, 2017, J PHYS CHEM C, V121, P3025, DOI 10.1021/acs.jpcc.6b08615
   Yan J, 2016, APPL ENERG, V175, P277, DOI 10.1016/j.apenergy.2016.05.038
   Yan J, 2015, CHEM ENG SCI, V138, P86, DOI 10.1016/j.ces.2015.07.053
   Yan J, 2014, CHEM ENG SCI, V117, P293, DOI 10.1016/j.ces.2014.07.007
   Yan T, 2015, RENEW SUST ENERG REV, V43, P13, DOI 10.1016/j.rser.2014.11.015
   Yuan Y, 2018, ENERG CONVERS MANAGE, V174, P8, DOI 10.1016/j.enconman.2018.08.021
   Zamengo M, 2014, APPL THERM ENG, V64, P339, DOI 10.1016/j.applthermaleng.2013.12.036
   Zhang H, 2013, APPL ENERG, V112, P956, DOI 10.1016/j.apenergy.2013.02.019
   Zhang HL, 2016, PROG ENERG COMBUST, V53, P1, DOI 10.1016/j.pecs.2015.10.003
NR 43
TC 4
Z9 4
U1 18
U2 89
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD OCT 12
PY 2019
VL 206
BP 518
EP 526
DI 10.1016/j.ces.2019.06.002
PG 9
WC Engineering, Chemical
SC Engineering
GA ID6ZV
UT WOS:000471831700042
DA 2020-05-12
ER

PT J
AU Evans-Gilbert, T
   Lewis-Bell, KN
   Figueroa, JP
AF Evans-Gilbert, Tracy
   Lewis-Bell, Karen N.
   Figueroa, J. Peter
TI The Caribbean Immunization Technical Advisory Group (CITAG); A unique
   NITAG
SO VACCINE
LA English
DT Article
DE National Immunization Technical Advisory Group (NITAG); Evidence-based
   policy; Decision-making; Health policy; Capacity building; Routine
   immunization
AB The Global Vaccine Action Plan 2011-2020 called for all countries to establish a National Immunization Technical Advisory Group (NITAG) by 2020. The Caribbean, with its unique geographical context of 22 countries/territories, had limited technical expertise to establish individual NITAGs in small countries. The Caribbean Immunization Technical Advisory Group (CITAG) was launched in 2018. This paper describes the Caribbean context for a common framework for policy and evidence-based decision-making for immunization. Challenges in immunization in the region are reviewed and potential solutions are outlined. A recent decline in immunization rates in the Caribbean, along with outbreaks of vaccine-preventable diseases globally, places the region, a premier tourist destination, in a vulnerable position. The CITAG aims to strengthen the policy and evidence-based decision-making process for immunization to enable the Caribbean to remain at the forefront of vaccine-preventable disease elimination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Evans-Gilbert, Tracy] Cornwall Reg Hosp, Dept Pediat, Montego Bay, Jamaica.
   [Lewis-Bell, Karen N.] Pan Amer Hlth Org, Kingston, Jamaica.
   [Figueroa, J. Peter] Univ West Indies, Dept Community Hlth & Psychiat, Kingston, Jamaica.
RP Evans-Gilbert, T (reprint author), Cornwall Reg Hosp, Dept Pediat, Montego Bay, Jamaica.
EM tracy.gilbert@wrha.gov.jm; lewisbek@paho.org; peter.figueroa10@gmail.com
OI Evans-Gilbert, Tracy/0000-0001-7929-4387
CR Adjagba A, 2017, VACCINE, V35, P3007, DOI 10.1016/j.vaccine.2017.04.039
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Global Vaccine Action Plan, 2018, SECR ANN REP 2018
   Howard N, 2018, HUM VACC IMMUNOTHER, V14, P1539, DOI 10.1080/21645515.2018.1444321
   NITAG Resource Centre, 2019, 3 GLOB NITAG M
   Pan American Health Organization, 2018, 33 CAR M EPI MAN POR
   Smith H, CARIBBEAN EPIDEMIOLO
   Supporting Independent Immunization Advisory Committee, 2017, PREV CONFL INT NITAG
   van Zandvoort K, 2019, VACCINE, V37, P430, DOI 10.1016/j.vaccine.2018.11.070
   WHO, 2013, GLOB VACC ACT PLAN G
   World Health Organization, 2008, NAT IMM TECHN ADV GR
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6584
EP 6587
DI 10.1016/j.vaccine.2019.09.032
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300002
PM 31537448
DA 2020-05-12
ER

PT J
AU Eto, A
   Fujita, M
   Nishiyama, Y
   Saito, T
   Molina, DM
   Morikawa, S
   Saijo, M
   Shinmura, Y
   Kanatani, Y
AF Eto, Akiko
   Fujita, Masanori
   Nishiyama, Yasumasa
   Saito, Tomoya
   Molina, Douglas M.
   Morikawa, Shigeru
   Saijo, Masayuki
   Shinmura, Yasuhiko
   Kanatani, Yasuhiro
TI Profiling of the antibody response to attenuated LC16m8 smallpox vaccine
   using protein array analysis
SO VACCINE
LA English
DT Article
DE Smallpox vaccine; LC16m8; Antibody profiling; Protein array; Human
ID IMMUNE-RESPONSE; IMMUNOGENICITY; SAFETY
AB Concerns about bioterrorism and outbreaks of zoonotic orthopoxvirus require safe and efficacious smallpox vaccines. We previously reported the clinical efficacy and safety profiles of LC16m8, a live, attenuated, cell culture-derived, smallpox vaccine, examined in over 3000 healthy Japanese adults with various vaccination histories. In this study, serum of approximately 200 subjects pre and post LC16m8 vaccination were subjected to a vaccinia virus-specific protein array to evaluate the proteome-wide immunogenicity. The relationships between antigen-specific antibodies and plaque reduction neutralization titers were analyzed. LC16m8 induced antibodies to multiple vaccinia antigens in primary-vaccinated individuals and yielded effective booster responses in previously vaccinated individuals, demonstrating similar antibody profiles to those reported for other vaccinia virus strains. Several immunodominant antigens were indicated to be important for neutralization of the intracellular mature virion. The similarity of antibody profiles between LC16m8 and other smallpox vaccine strains supports the immunogenicity and protective efficacy of LC16m8. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Eto, Akiko; Saito, Tomoya; Kanatani, Yasuhiro] Natl Inst Publ Hlth, Dept Hlth Crisis Management, 2-3-6 Minami, Wako, Saitama 3510197, Japan.
   [Fujita, Masanori] Natl Def Med Coll, Div Environm Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.
   [Nishiyama, Yasumasa] Japan Self Def Forces Cent Hosp, Hlth Care Ctr, Setagaya Ku, 1-2-24 Ikeziri, Tokyo 1548532, Japan.
   [Molina, Douglas M.] Antigen Discovery Inc, Irvine, CA USA.
   [Morikawa, Shigeru] Natl Inst Infect Dis, Dept Vet Sci, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.
   [Saijo, Masayuki] Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.
   [Shinmura, Yasuhiko] KM Biol Co Ltd, Kumamoto 8608568, Japan.
   [Nishiyama, Yasumasa] Minist Def, Bur Personnel & Educ, Hlth & Med Div, Shinjuku Ku, 5-1 Ichigaya Honmura Cho, Tokyo 1628860, Japan.
   [Morikawa, Shigeru] Okayama Univ Sci, Fac Vet Med, 1-3 Ikoinooka, Imabari City, Ehime 7948555, Japan.
RP Kanatani, Y (reprint author), Tokai Univ, Dept Clin Pharmacol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
EM kanatani.yasuhiro.f@tokai.ac.jp
OI Saijo, Masayuki/0000-0001-5458-7298; Kanatani,
   Yasuhiro/0000-0001-5790-4084
FU Ministry of Health, Labour and Welfare of Japan (Research on Publicly
   Essential Drugs and Medical Devices)Ministry of Health, Labour and
   Welfare, Japan [KHC1216]; Ministry of Health, Labour and Welfare of
   Japan (Research on Emerging and Re-emerging infectious diseases)Ministry
   of Health, Labour and Welfare, Japan [H26-Shinko-Shitei-002]
FX This work was supported by the Ministry of Health, Labour and Welfare of
   Japan (Research on Publicly Essential Drugs and Medical Devices, grant
   number KHC1216, and Research on Emerging and Re-emerging infectious
   diseases, H26-Shinko-Shitei-002).
CR Benhnia MREI, 2008, J VIROL, V82, P3751, DOI 10.1128/JVI.02244-07
   Condit RC, 2006, ADV VIRUS RES, V66, P31, DOI 10.1016/S0065-3527(06)66002-8
   Davies DH, 2008, J VIROL, V82, P652, DOI 10.1128/JVI.01706-07
   Davies DH, 2005, P NATL ACAD SCI USA, V102, P547, DOI 10.1073/pnas.0408782102
   Empig C, 2006, VACCINE, V24, P3686, DOI 10.1016/j.vaccine.2005.03.029
   Eto A, 2015, VACCINE, V33, P6106, DOI 10.1016/j.vaccine.2015.07.111
   Gilchuk I, 2016, CELL, V167, P684, DOI 10.1016/j.cell.2016.09.049
   Davies DH, 2007, PROTEOMICS, V7, P1678, DOI 10.1002/pmic.200600926
   Johnson BF, 2011, J GEN VIROL, V92, P2405, DOI 10.1099/vir.0.034207-0
   Kennedy JS, 2011, J INFECT DIS, V204, P1395, DOI 10.1093/infdis/jir527
   Meseda CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067984
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   Nishiyama Y, 2015, VACCINE, V33, P6120, DOI 10.1016/j.vaccine.2015.09.067
   Saijo M, 2006, J VIROL, V80, P5179, DOI 10.1128/JVI.02642-05
   Saito T, 2009, J DISASTER RES, V4, P329, DOI 10.20965/jdr.2009.p0329
   Saito T, 2009, JAMA-J AM MED ASSOC, V301, P1025, DOI 10.1001/jama.2009.289
   Tan XL, 2012, CLIN VACCINE IMMUNOL, V19, P418, DOI 10.1128/CVI.05521-11
   Townsend MB, 2013, J VIROL, V87, P900, DOI 10.1128/JVI.02089-12
   WHO, 2014, WKLY EPIDEMIOL REC, V89, P1
   Wim Z, 2013, 2013 FOURTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS DESIGN AND ENGINEERING APPLICATIONS, P718, DOI 10.1109/ISDEA.2013.572
NR 20
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6588
EP 6593
DI 10.1016/j.vaccine.2019.09.006
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300003
PM 31540810
DA 2020-05-12
ER

PT J
AU Karras, J
   Dube, E
   Danchin, M
   Kaufman, J
   Seale, H
AF Karras, Joshua
   Dube, Eve
   Danchin, Margie
   Kaufman, Jessica
   Seale, Holly
TI A scoping review examining the availability of dialogue-based resources
   to support healthcare providers engagement with vaccine hesitant
   individuals
SO VACCINE
LA English
DT Review
DE Childhood vaccination; Parents; Vaccination decisions; Vaccine
   hesitancy; Vaccine refusal; Healthcare providers; Tools; Communication
ID COMMUNICATION; DETERMINANTS; STRATEGIES
AB Background: There is growing attention around the need to improve the confidence and skills of healthcare providers to assist them in completing the complex task of communicating to vaccine hesitant parents and other individuals. While interventions have been developed and evaluated in a research setting, there is uncertainty regarding the public availability. This study aimed to examine the current landscape regarding the availability of online dialogue- based interventions which aim to support vaccination conversations.
   Methods: A scoping review was undertaken to identify and appraise the availability and accessibility of dialogue-based interventions. A dialogue-based intervention was defined as a strategy aiming to improve an individual's confidence and communication skills to engage with and respond to vaccine hesitant individuals. Two approaches were utilised to identify relevant interventions and resources. Firstly, the European Centre for Disease Prevention and Control Catalogue of Interventions was assessed to identify interventions that met the definition. Secondarily, a Google search (in English only) was conducted using key words, that reflected the strategy that healthcare providers may use to identify resources.
   Results: We identified a total of 31 dialogue-based interventions, of which 29 were reviewed. The interventions were all text based and instructional in nature. Twenty-two were suitable for healthcare providers, as well as non-clinical immunisation spokespersons to use. Of issue, was that in many instances it was common to find the resource located on the fifth to tenth page of search entries, and usually disguised under seemingly non-descript and nonspecific titles. Lastly, not all resources were available for free and not all could be accessed directly from the site.
   Conclusions: Findings suggest that while there have been numerous interventions developed to support healthcare providers to communicate with vaccine hesitant parents/individuals, there are fundamental issues with accessing the materials in a timely and convenient way. Having a central repository or website (which links to the interventions) would not only assistant healthcare providers to have an improved comprehension of the different interventions available but also would theoretically increase the utilisation by providers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Karras, Joshua; Seale, Holly] Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
   [Dube, Eve] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Quebec City, PQ, Canada.
   [Dube, Eve] Univ Laval, Axe Malad Infect & Immunitaires, Ctr Rech, CHU Quebec, Quebec City, PQ, Canada.
   [Danchin, Margie] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia.
   [Danchin, Margie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Danchin, Margie; Kaufman, Jessica] Murdoch Childrens Res Inst, Vaccine & Immunisat Res Grp, Parkville, Vic, Australia.
   [Kaufman, Jessica] La Trobe Univ, Sch Psychol & Publ Hlth, Ctr Hlth Commun & Participat, Bundoora, Vic, Australia.
   [Kaufman, Jessica] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia.
RP Seale, H (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Ave, Kensington, NSW 2033, Australia.
EM h.seale@unsw.edu.au
OI Seale, Holly/0000-0002-1877-5395
CR Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI DOI 10.1080/1364557032000119616
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Berg SA, 2008, J WORKPLACE LEARN, V20, P229, DOI 10.1108/13665620810871097
   Biasio LR, 2016, HUM VACC IMMUNOTHER, V12, P2984, DOI 10.1080/21645515.2016.1198456
   Brown VB, 2016, J COMMUN HEALTH, V41, P265, DOI 10.1007/s10900-015-0092-3
   Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038
   Chitika, 2013, VAL GOOGL RES POS
   Davis K, 2009, INT J NURS STUD, V46, P1386, DOI 10.1016/j.ijnurstu.2009.02.010
   DiMatteo MR, 1998, WESTERN J MED, V168, P328
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   European Centre for Disease Prevention and Control, 2017, CAT INT ADDR VACC HE
   Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P
   Gagneur A, 2018, VACCINE, V36, P6553, DOI 10.1016/j.vaccine.2017.10.049
   Gagneur A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5724-y
   Glanz JM, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002227
   Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P1755, DOI 10.4161/hv.25085
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Kaufman J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub2
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Newcombe J, 2014, VACCINE, V32, P6364, DOI 10.1016/j.vaccine.2014.06.044
   Newcombe JP, 2017, J PAEDIATR CHILD H, V53, P711, DOI 10.1111/jpc.13406
   Opel DJ, 2015, AM J PUBLIC HEALTH, V105, P1998, DOI 10.2105/AJPH.2014.302425
   Winefield HR, 2000, MED EDUC, V34, P90, DOI 10.1046/j.1365-2923.2000.00463.x
NR 23
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6594
EP 6600
DI 10.1016/j.vaccine.2019.09.039
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300004
PM 31540811
DA 2020-05-12
ER

PT J
AU Fisher, MP
   Gurfinkel, D
   Szilagyi, PG
   Saville, A
   Albertin, C
   Breck, A
   Valderrama, R
   Kempe, A
AF Fisher, Michael P.
   Gurfinkel, Dennis
   Szilagyi, Peter G.
   Saville, Alison
   Albertin, Christina
   Breck, Abigail
   Valderrama, Rebecca
   Kempe, Allison
TI Supporting and sustaining centralized reminder/recall for immunizations:
   Qualitative insights from stakeholders
SO VACCINE
LA English
DT Article
DE Centralized reminder/recall; Immunizations; Immunization information
   system; Immunization registry; Vaccination
ID INFLUENZA VACCINATION REMINDERS; YOUNG-CHILDREN; POPULATION; ATTITUDES;
   SYSTEMS; RATES; URBAN
AB Centralized reminder/recall (C-R/R) is an evidence-based strategy for increasing vaccination rates that uses a population-level database such as a state immunization information system (IIS) to send notifications across large geographic areas. IISs are usually based in state public health departments, which could initiate C-R/R. While C-R/R is a promising strategy, the factors influencing its initiation and sustainment are not clear. Utilizing qualitative content analysis methodology and interviews with key stakeholders involved in or knowledgeable about C-R/R, we examined the characteristics of these initiatives and factors influencing their success. We identified and spoke with managers and senior leaders across IISs, health plans, health systems, pharmaceutical companies, and advocacy organizations and focused especially on C-R/R activities within IISs. Several considerations were determined important to C-R/R success: decision-making, stakeholder buy-in, partnerships, funding, data and technology, evaluation, and message content. Salient barriers were costs and lack of funding, poor contact data quality (i.e. telephone number, home address), and messaging that is either overly broad or too specific. Pertinent facilitators of C-R/R included notifying health providers in advance of an initiative, conducting a rigorous post-reminder/recall evaluation, and engaging a range of partners. Partnerships were important to stakeholders for multiple reasons including technical assistance, resource sharing, and sharing of best practices. Overall, our results illustrate the many opportunities to advance C-R/R through further collaboration within and across public health departments and potentially via public-private partnerships. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fisher, Michael P.; Gurfinkel, Dennis; Saville, Alison; Kempe, Allison] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Sch Med, Aurora, CO 80045 USA.
   [Fisher, Michael P.; Gurfinkel, Dennis; Saville, Alison; Kempe, Allison] Childrens Hosp Colorado, Aurora, CO USA.
   [Fisher, Michael P.] Univ Colorado, Dept Med, Sch Med, Aurora, CO 80045 USA.
   [Szilagyi, Peter G.; Albertin, Christina; Breck, Abigail; Valderrama, Rebecca] Univ Calif Los Angeles, Dept Pediat, UCLA Mattel Childrens Hosp, Los Angeles, CA 90024 USA.
   [Kempe, Allison] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO 80045 USA.
RP Gurfinkel, D (reprint author), Univ Colorado, ACCORDS, Sch Med, Childrens Hosp Colorado, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA.
EM Michael.p.fisher@CUAnschutz.edu; Dennis.gurfinkel@CUAnschutz.edu;
   PSzilagyi@mednet.ucla.edu; Alison.saville@CUAnschutz.edu;
   Christina.albertin@urmc.rochester.edu; Abreck@mednet.ucla.edu;
   Allison.kempe@childrenscolorado.org
FU National Institutes of Health (NIH) under National Institute of Allergy
   and Infectious Diseases [R01Al114903]; National Institutes of Health
   (NIH) under National Cancer InstituteUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R01CA187707]
FX This work was supported by the National Institutes of Health (NIH) under
   two awards: National Institute of Allergy and Infectious Diseases grant
   number R01Al114903 and National Cancer Institute grant number
   R01CA187707. The findings do not necessarily represent the NIH and are
   only the author's viewpoints.
CR Albright K, 2017, VACCINE, V35, P7292, DOI 10.1016/j.vaccine.2017.11.001
   Albright K, 2014, ACAD PEDIATR, V14, P62, DOI 10.1016/j.acap.2013.09.003
   Centers for Disease Control and Prevention, 2019, IMM INF SYST ANN REP
   Centers for Disease Control and Prevention, 2019, Q IIS SENT SIT
   Centers for Disease Control and Prevention, 2017, IMM INF SYST
   Centers for Disease Control and Prevention, 2019, CONT IIS IMM REC
   Charmaz K., 2014, CONSTRUCTING GROUNDE
   Dombkowski KJ, 2014, AM J PUBLIC HEALTH, V104, pE39, DOI 10.2105/AJPH.2013.301662
   Dombkowski KJ, 2012, AM J PREV MED, V42, P71, DOI 10.1016/j.amepre.2011.09.028
   Federal Communications Commission, 2018, FCC ACT ROB TEL
   Gianfredi V, 2019, HUM VACC IMMUNOTHER, V15, P2508, DOI 10.1080/21645515.2019.1599675
   Gurfinkel D, 2019, PED AC SOC ANN M BAL
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Hurley LP, 2018, AM J PREV MED, V55, P231, DOI 10.1016/j.amepre.2018.04.022
   Institute of Medicine, 2015, PRIM CAR PUBL HLTH E
   Jacobson Vann JC, 2018, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD003941.PUB3/FULL
   Kempe A, 2017, ACAD PEDIATR, V17, P330, DOI 10.1016/j.acap.2016.11.016
   Kempe A, 2015, JAMA PEDIATR, V169, P365, DOI 10.1001/jamapediatrics.2014.3670
   Kempe A, 2013, AM J PUBLIC HEALTH, V103, P1116, DOI 10.2105/AJPH.2012.301035
   Martin DW, 2015, J PUBLIC HEALTH MAN, V21, P296, DOI 10.1097/PHH.0000000000000040
   Meyer AM, 2012, J PUBLIC HEALTH MAN, V18, P535, DOI 10.1097/PHH.0b013e31825ce928
   Modeling of Immunization Registry Operations Work Group, 2009, REM REC IMM INF SYST
   Roberts JR, 2018, VACCINE, V36, P2788, DOI 10.1016/j.vaccine.2018.03.088
   Saville AW, 2018, ACAD PEDIATR, V18, P873, DOI 10.1016/j.acap.2018.07.003
   Saville AW, 2016, ACAD PEDIATR, V16, P50, DOI 10.1016/j.acap.2015.09.002
   Saville AW, 2014, ACAD PEDIATR, V14, P249, DOI 10.1016/j.acap.2014.02.003
   Schell SF, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-15
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   The Community Guide, 2017, VACC PROGR CLIENT RE
NR 29
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6601
EP 6608
DI 10.1016/j.vaccine.2019.09.055
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300005
PM 31562003
DA 2020-05-12
ER

PT J
AU Hajizadeh, M
AF Hajizadeh, Mohammad
TI Decomposing socioeconomic inequality in child vaccination in the Gambia,
   the Kyrgyz Republic and Namibia
SO VACCINE
LA English
DT Article
DE Socioeconomic status; Inequalities; Child vaccination; Determinants;
   Developing country
ID CONCENTRATION INDEX; IMMUNIZATION; DETERMINANTS; MALNUTRITION;
   INDICATORS; INFLUENZA; COVERAGE; REASONS
AB Extant work suggested pro-rich distribution of vaccination coverage in low- and middle-income countries (LMICs). However, the current literature also suggested pro-poor distribution of vaccination in some countries, including the Gambia, the Kyrgyz Republic and Namibia. This study aimed to explain socioeconomic inequalities in the completion rate of the four-core vaccines (i.e., Bacille Calmette-Guerin [BCC], diphtheria-tetanus-pertussis [DTP, 3 doses], Polio [3 doses] and Measles vaccines) in the three aforementioned countries. We used the most recent available Demographic Health Surveys (DHS) to measure vaccination completion rates among children (aged 0-59 months, n = 16,752) in the three countries. The normalized concentration index (C-n) was used to quantify and decompose socioeconomic inequalities in vaccination coverage in each country. The negative values of the C-n index suggested that children belong to lower socioeconomic status groups were more likely to be immunized than their higher socioeconomic status counterparts in the Gambia (C-n = -0.101, 95% confidence interval [CI]: -0.128 to -0.074), the Kyrgyz Republic (C-n = -0.097, 95% CI: -0.13 to -0.063) and Namibia (C-n = -0.161, 95% CI: -0.199 to -0.124). The decomposition analysis of the C-n suggested that the difference in child vaccination completion rates between rural and urban areas was the main factor contributing to the concentration of child vaccination among the poor in the Gambia and Namibia. The concentration of child vaccination among the poor in the Kyrgyz Republic was chiefly determined by household wealth. These results suggest that there should be strategies to improve child immunization uptake among urban children in the Gambia and Namibia. Since household wealth was the main factor contributing to the observed pro-poor distribution of child vaccination in the Kyrgyz Republic, further studies are required to understand the reasons for lower vaccination rate among the wealthy children in order to implement the most effective strategies to increase child vaccination uptake. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hajizadeh, Mohammad] Dalhousie Univ, Fac Hlth, Sch Hlth Adm, Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3H 4R2, Canada.
RP Hajizadeh, M (reprint author), Dalhousie Univ, Fac Hlth, Sch Hlth Adm, Sir Charles Tupper Med Bldg,5850 Coll St, Halifax, NS B3H 4R2, Canada.
EM m.hajizadeh@dal.ca
OI Hajizadeh, Mohammad/0000-0002-4591-8531
CR AbdelSalam HHM, 2004, CLIN PEDIATR, V43, P83, DOI 10.1177/000992280404300111
   Abebe DS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1075
   African Health Observatory, 2018, COMPR AN PROF GAMB
   Akkazieva B, 2009, KYRGYZSTAN CASE STUD
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   [Anonymous], 2014, B WORLD HEALTH ORGAN, V92, P314, DOI 10.2471/BLT.14.020514
   Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Bardenheier B, 2004, ARCH PEDIAT ADOL MED, V158, P569, DOI 10.1001/archpedi.158.6.569
   Bondy JN, 2009, VACCINE, V27, P169, DOI 10.1016/j.vaccine.2008.08.042
   Bugvi AS, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-232
   Chen Z, 2009, J HEALTH ECON, V28, P169, DOI 10.1016/j.jhealeco.2008.09.004
   Branco FLCC, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0118-y
   Demographic and Health Survey, 1996, SAMPL MAN
   Erreygers G, 2009, J HEALTH ECON, V28, P504, DOI 10.1016/j.jhealeco.2008.02.003
   Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692
   Gemson D H, 1988, J Community Health, V13, P53, DOI 10.1007/BF01321480
   Hajizadeh M, 2018, J EPIDEMIOL COMMUN H, V72, P719, DOI 10.1136/jech-2017-210296
   Hajizadeh M, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/1475-9276-13-18
   Hak E, 2005, VACCINE, V23, P3103, DOI 10.1016/j.vaccine.2005.01.074
   Harmanci H, 2003, PUBLIC HEALTH, V117, P54, DOI 10.1016/S0033-3506(02)00015-X
   Ibraimova A, 2011, HLTH SYSTEMS TRANSIT, V13, P1
   Kakwani N, 1997, J ECONOMETRICS, V77, P87, DOI 10.1016/S0304-4076(96)01807-6
   Khan MMH, 2011, B WORLD HEALTH ORGAN, V89, P583, DOI 10.2471/BLT.11.087429
   King NB, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5774
   Lindley MC, 2006, AM J PREV MED, V31, P281, DOI 10.1016/j.amepre.2006.06.025
   Machingaidze S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001405
   Matsumura T, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-59
   Mayer-Foulkes D, 2005, RACIAL ETHNIC HLTH I
   Mazumdar S, 2010, ASIAN POPUL STUD, V6, P307, DOI 10.1080/17441730.2010.512763
   Ministry of Health, 2015, EHEALTH KYRG REP STR
   O'Donnell OA, 2008, ANAL HLTH EQUITY USI
   O'Donnell O, 2016, STATA J, V16, P112, DOI 10.1177/1536867X1601600112
   Payne S, 2014, HEALTH POLICY PLANN, V29, P193, DOI 10.1093/heapol/czt004
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Rutstein S. O., 2004, DHS COMP REPORTS
   Rutstein SO, 2006, GUIDE DHS STAT DEMOG
   Sherif HEL, 2010, PATIENT SATISFACTION
   Shrivastwa N, 2015, AM J PREV MED, V49, pS435, DOI 10.1016/j.amepre.2015.05.008
   Singleton JA, 2005, AM J PREV MED, V29, P412, DOI 10.1016/j.amepre.2005.08.012
   Sissoko D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106528
   Soares RR, 2007, POPUL DEV REV, V33, P247, DOI 10.1111/j.1728-4457.2007.00169.x
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Wagstaff A, 2005, HEALTH ECON, V14, P429, DOI 10.1002/hec.953
   Wagstaff A, 2003, J ECONOMETRICS, V112, P207, DOI 10.1016/S0304-4076(02)00161-6
   World Bank, 2019, WORLD DEV IND DAT GL
   World Health Organization, 2018, REG OFF AFR
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   ZERE E, 2007, INT J EQUITY HEALTH, V7, DOI DOI 10.1186/1475-9,76-6-1
   Zere E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-252
NR 50
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6609
EP 6616
DI 10.1016/j.vaccine.2019.09.054
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300006
PM 31558326
DA 2020-05-12
ER

PT J
AU Guclu, OA
   Demirci, H
   Ocakoglu, G
   Guclu, Y
   Uzaslan, E
   Karadag, M
AF Guclu, Ozge Aydin
   Demirci, Hakan
   Ocakoglu, Gokhan
   Guclu, Yasin
   Uzaslan, Esra
   Karadag, Mehmet
TI Relationship of pneumococcal and influenza vaccination frequency with
   health literacy in the rural population in Turkey
SO VACCINE
LA English
DT Article
DE Pneumococcal vaccine; Influenza vaccine; Health literacy
ID OLDER; MANAGEMENT; PHYSICIANS; BEHAVIORS; ADULTS; RATES; RISK
AB Introduction: Vaccines have been shown to prevent illness, disability and death from vaccine-preventable diseases. The purpose of our study was to analyze the influenza and pneumococcal vaccination status of patients, the factors that influence the uptake of influenza/pneumococcal vaccination and the effects of health literacy (HL) on vaccination.
   Materials and methods: In this cross-sectional study, demographic characteristics, comorbid diseases and the pneumococcal and influenza vaccination status in previous years were recorded for each patient. The Turkish version of the European Health Literacy Survey Questionnaire (HLS-EU-Q47) was used to assess HL.
   Results: A total of 350 patients were enrolled in the study. A total of 6.3% of patients had received both vaccines. 20% of subjects were vaccinated with influenza vaccine and 11.1% of the subjects were vaccinated with pneumococcal vaccine. Overall HL was insufficient for 70.9%, problematic for 20.6%, sufficient for 7.1% and excellent for 14.2% of patients. Patients who had pneumococcal and influenza vaccination had higher disease prevention HL scores (p = 0.013, p = 0.001; respectively).
   Discussion: An insufficient HL level was found to be much higher than previous studies. It was observed that an increase in disease prevention HL was associated with a rise in the rate of pneumococcal and influenza vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guclu, Ozge Aydin] Boyabat 75th Year State Hosp, Dept Pulm Dis, Sinop, Turkey.
   [Demirci, Hakan] Univ Hlth Sci, Dept Family Med, Bursa Yuksek Ihtisas Training & Res Hosp, Bursa, Turkey.
   [Ocakoglu, Gokhan] Uludag Univ, Dept Biostat, Fac Med, Bursa, Turkey.
   [Guclu, Yasin] Boyabat Community Hlth Ctr, Dept Family Med, Sinop, Turkey.
   [Uzaslan, Esra; Karadag, Mehmet] Uludag Univ, Fac Med, Dept Pulm Dis, Bursa, Turkey.
RP Demirci, H (reprint author), Bursa Yuksek Ihtisas Training & Res Hosp, Family Med, Bursa, Turkey.
EM hakan.demirci@sbu.edu.tr
RI Guclu, Ozge Aydin/AAG-9930-2019
OI Guclu, Ozge Aydin/0000-0003-1005-3205; Demirci,
   Hakan/0000-0003-0434-4807
CR Abacigil F, 2018, HLTH PROMOT INT
   Akin L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157657
   Andrew MK, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-36
   Aranha ANF, 2018, AM J MANAG CARE, V24, P428
   Baker DW, 2002, AM J PUBLIC HEALTH, V92, P1278, DOI 10.2105/AJPH.92.8.1278
   Bennett IM, 2009, ANN FAM MED, V7, P204, DOI 10.1370/afm.940
   Biberoglu K, 2006, ACTUAL MED, V14, P18
   Bostock S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1602
   Bridges CB, 2013, MMWR-MORBID MORTAL W, V62, P9
   Cetinoglu ED, 2017, HUM VACC IMMUNOTHER, V13, P2072, DOI 10.1080/21645515.2017.1339851
   Chiauzzi E, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0319-2
   Ciblak MA, 2013, VACCINE, V31, P518, DOI 10.1016/j.vaccine.2012.11.022
   Dernegi Turk Toraks, 2009, TURK THORAC J S9, V10, P1
   Feinberg I, 2015, UNDERSTANDING HLTH I
   Kamal Khalid M, 2003, J Am Pharm Assoc (2003), V43, P403, DOI 10.1331/154434503321831120
   Kaya A, 2017, ALLERGOL IMMUNOPATH, V45, P240, DOI 10.1016/j.aller.2016.08.003
   Kickbusch IS, 2001, HEALTH PROMOT INT, V16, P289, DOI 10.1093/heapro/16.3.289
   Mackey LM, 2016, MED DECIS MAKING, V36, P741, DOI 10.1177/0272989X16638330
   Moran MB, 2017, J IMMIGR MINOR HEALT, V19, P790, DOI 10.1007/s10903-016-0428-9
   Ratzan SC, 2011, VACCINE LITERACY NEW
   Satman I, 2013, HUM VACC IMMUNOTHER, V9, P2618, DOI 10.4161/hv.25826
   Song JY, 2015, CLIN VACCINE IMMUNOL, V22, P229, DOI 10.1128/CVI.00673-14
   Sorensen K, 2017, STUD HEALTH TECHNOL, V240, P3, DOI 10.3233/978-1-61499-790-0-3
   White S, 2008, AM J HEALTH BEHAV, V32, P227
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6617
EP 6623
DI 10.1016/j.vaccine.2019.09.049
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300007
PM 31542263
DA 2020-05-12
ER

PT J
AU Gelinas, JF
   Azizi, H
   Kiesslich, S
   Lanthier, S
   Perdersen, J
   Chahal, PS
   Ansorge, S
   Kobinger, G
   Gilbert, R
   Kamen, AA
AF Gelinas, Jean-Francois
   Azizi, Hiva
   Kiesslich, Sascha
   Lanthier, Stephane
   Perdersen, Jannie
   Chahal, Parminder S.
   Ansorge, Sven
   Kobinger, Gary
   Gilbert, Renald
   Kamen, Amine A.
TI Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF
   cells
SO VACCINE
LA English
DT Article
DE rVSV-ZEBOV; Ebola; Vaccine; Production; HEK 293SF; Serum-free;
   Suspension
ID VESICULAR STOMATITIS-VIRUS; LENTIVIRAL VECTOR PRODUCTION; TRANSIENT
   TRANSFECTION; HEALTHY-ADULTS; DOUBLE-BLIND; HUMAN INFECTION; EBOLA
   VACCINE; SIERRA-LEONE; SCALE-UP; SAFETY
AB Ebola virus disease is an urgent international priority. Promising results for several vaccine candidates have been reported in non-human primate studies and clinical trials with the most promising being the rVSV-ZEBOV vaccine. In this study, we sought to produce rVSV-ZEBOV in HEK 293SF cells in suspension and serum-free media. The purpose of this study was to establish a process using the HEK 293SF production platform, optimise the production titre, demonstrate scalability and the efficiency of the generated material to elicit an immune reaction in an animal model. Critical process parameters were evaluated to maximize production yield and process robustness and the following operating conditions: 1-2 x 10(6) cells/mL grown in HyClone HyCell TransFx-H media infected at an MOl of 0.001 with a temperature shift to 34 degrees C during the production phase and a harvest of the product after 48 h. Using these conditions, scalability in a 3.5 L controlled bioreactor was shown reaching a titre of 1.19 x 10(8) TCID50/mL at the peak of production, the equivalent of 4165 doses of vaccine per litre. The produced virus was shown to be thermostable in the culture media and, when concentrated, purified and administered to mice, demonstrated the ability to induce a ZEBOV-specific immune response. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Gelinas, Jean-Francois; Kiesslich, Sascha; Gilbert, Renald; Kamen, Amine A.] McGill Univ, Dept Bioengn, 3480 Univ, Montreal, PQ H3A 0E9, Canada.
   [Azizi, Hiva; Perdersen, Jannie; Kobinger, Gary] Univ Laval, Ctr Rech Infectiol, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Lanthier, Stephane; Chahal, Parminder S.; Ansorge, Sven; Gilbert, Renald] Natl Res Council Canada, Human Hlth Therapeut, Montreal, PQ, Canada.
RP Kamen, AA (reprint author), McGill Univ, Dept Bioengn, 3480 Univ, Montreal, PQ H3A 0E9, Canada.
EM amine.kamen@mcgill.ca
RI ; Gelinas, Jean-Francois/F-5882-2010
OI Kamen, Amine/0000-0001-9110-8815; Gelinas,
   Jean-Francois/0000-0003-3454-5781
FU Canadian Institutes of Health Research GrantCanadian Institutes of
   Health Research (CIHR) [OW 152411]; Natural Sciences and Engineering
   Research Council of Canada (NSERC)Natural Sciences and Engineering
   Research Council of Canada; Fonds de Recherche du Quebec -Sante (FRQS)
FX We thank Melanie Leclerc and Nathalie Coulombe from the National
   Research Council Canada who performed the virus purification for the
   samples used in animal studies and Julien Robitaille, also from the
   National Research Council Canada, who performed data extraction for the
   bioreactor. This research was funded by the Canadian Institutes of
   Health Research Grant OW 152411. JFG is funded by a Natural Sciences and
   Engineering Research Council of Canada (NSERC) postdoctoral fellowship.
   SK is funded by a doctoral scholarship from the Fonds de Recherche du
   Quebec -Sante (FRQS). The funding sources had no involvement in the
   study design, in the collection, analysis and interpretation of data, in
   the writing of the report or in the decision to submit the article for
   publication.
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   [Anonymous], 2019, PREL RES EFF RVSV ZE
   Ansorge S, 2009, J GENE MED, V11, P868, DOI 10.1002/jgm.1370
   Ausubel LJ, 2011, HUM GENE THER, V22, P489, DOI 10.1089/hum.2010.159
   Blue JT, 2016, VACCINE TECHNOLOGY, VVI
   Broussau S, 2008, MOL THER, V16, P500, DOI 10.1038/sj.mt.6300383
   Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001
   Chahal PS, 2014, J VIROL METHODS, V196, P163, DOI 10.1016/j.jviromet.2013.10.038
   Clarke DK, 2006, SPRINGER SEMIN IMMUN, V28, P239, DOI 10.1007/s00281-006-0042-3
   Cote J, 1998, BIOTECHNOL BIOENG, V59, P567, DOI 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.3.CO;2-Z
   Cotton WE, 1926, J AM VET MED ASSOC, V69, P313
   Dolzhikova IV, 2017, HUM VACC IMMUNOTHER, V13, P613, DOI 10.1080/21645515.2016.1238535
   Elahi SM, 2019, J BIOTECHNOL, V289, P144, DOI 10.1016/j.jbiotec.2018.11.023
   ElSherif MS, 2017, CAN MED ASSOC J, V189, pE819, DOI 10.1503/cmaj.170074
   Emmerling VV, 2016, BIOTECHNOL J, V11, P290, DOI 10.1002/biot.201500176
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   FIELDS BN, 1967, NEW ENGL J MED, V277, P889, DOI 10.1056/NEJM196711092771901
   Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004
   Gilbert R, 2018, MOL THER, V26, P153
   GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59
   Gross L, 2018, INT J INFECT DIS, V74, P83, DOI 10.1016/j.ijid.2018.06.022
   HANSON RP, 1950, J LAB CLIN MED, V36, P754
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Heppner DG, 2017, LANCET INFECT DIS, V17, P854, DOI 10.1016/S1473-3099(17)30313-4
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   JOHNSON KM, 1966, AM J TROP MED HYG, V15, P244, DOI 10.4269/ajtmh.1966.15.244
   Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258
   Manceur AP, 2017, HUM GENE THER METHOD, V28, P330, DOI 10.1089/hgtb.2017.086
   Nadeau I, 2003, BIOTECHNOL ADV, V20, P475, DOI 10.1016/S0734-9750(02)00030-7
   Nadeau I, 2000, BIOTECHNOL PROGR, V16, P872, DOI 10.1021/bp000098l
   Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003
   Rabinovich S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106597
   Racine T, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0179-2
   Ramsburg E, 2004, J VIROL, V78, P3930, DOI 10.1128/JVI.78.8.3930-3940.2004
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998
   Samai M, 2018, J INFECT DIS, V217, pS6, DOI 10.1093/infdis/jiy020
   Shen CF, 2019, VACCINE
   Shen CF, 2016, VACCINE, V34, P3381, DOI 10.1016/j.vaccine.2016.04.090
   Smither SJ, 2013, J VIROL METHODS, V193, P565, DOI 10.1016/j.jviromet.2013.05.015
   STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051
   TESH RB, 1969, AM J EPIDEMIOL, V90, P255, DOI 10.1093/oxfordjournals.aje.a121068
   Timm A, 2012, VIROLOGY, V424, P11, DOI 10.1016/j.virol.2011.12.005
   Venereo-Sanchez A, 2016, VACCINE, V34, P3371, DOI 10.1016/j.vaccine.2016.04.089
   Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   World Health Organization, 2016, SIT REP EB VIR DIS 1
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/s0140-6736(16)32617-4, 10.1016/S0140-6736(16)32617-4]
   Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0
NR 49
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6624
EP 6632
DI 10.1016/j.vaccine.2019.09.044
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300008
PM 31548015
OA Other Gold
DA 2020-05-12
ER

PT J
AU Detoc, M
   Launay, O
   Duale, C
   Mutter, C
   Le Huec, JC
   Lenzi, N
   Lucht, F
   Gagneux-Brunon, A
   Botelho-Nevers, E
AF Detoc, M.
   Launay, O.
   Duale, C.
   Mutter, C.
   Le Huec, J-C
   Lenzi, N.
   Lucht, F.
   Gagneux-Brunon, A.
   Botelho-Nevers, E.
TI Barriers and motivations for participation in preventive vaccine
   clinical trials: Experience of 5 clinical research sites
SO VACCINE
LA English
DT Article
DE Vaccine; Vaccine clinical trial; Motivations; Barriers; Participation;
   Recruitment
ID RANDOMIZED CONTROLLED-TRIALS; RECRUITMENT
AB Recruitment in preventive vaccine trials (PVT) is challenging due to common barriers to clinical research and lack of vaccine confidence. Identifying determinants of participation can help to improve recruitment. A prospective survey was conducted in 5 French clinical investigational sites. People asked to participate in a PVT were given a questionnaire whether they decided to participate or not in the trial. A total of 341 people answered the survey: 210 accepting and 131 declining to participate in a PVT. Acceptors were significantly younger (38.5 vs 54.9 years old), more likely to be involved in early phase trials, had a higher level of education (p < 0.005) and a significantly better general opinion concerning vaccines (92.3% versus 72.3%, p < 0.005) compared with those who declined. Factors associated with acceptance or refusal were evaluated in 224 people in the 4 sites where both groups were included. In a multivariate analysis, three factors: older age, having heard about PVT through multiple sources and financial incentives were significantly associated with refusal to participate in the PVT. A generally favourable opinion of vaccines was associated with acceptance. The main motivation for participation was altruism (93.2%) whereas fear of side effects was at the forefront of the barriers (36.6%). Information given by the physician was a key point for decision-making in 70.2% of those who accepted. In brief, vaccine hesitancy may decrease recruitment in PVTs; reinforcing altruism and quality of information given are key points in acceptance of participation in PVT. (C) 2019 Published by Elsevier Ltd.
C1 [Detoc, M.; Lucht, F.; Gagneux-Brunon, A.; Botelho-Nevers, E.] Univ Hosp St Etienne, Clin Trial Ctr, INSERM CIC 1408, F-42055 St Etienne, France.
   [Detoc, M.; Lucht, F.; Gagneux-Brunon, A.; Botelho-Nevers, E.] Univ Lyon, Med Sch St Etienne, GIMAP, EA3064, Lyon, France.
   [Detoc, M.; Launay, O.; Duale, C.; Mutter, C.; Lenzi, N.; Lucht, F.; Gagneux-Brunon, A.; Botelho-Nevers, E.] INSERM, F CRIN, Innovat Clin Res Network Vaccinol I REIVAC, Paris, France.
   [Launay, O.] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Launay, O.] Hop Cochin Broca Hotel Dieu, AP HP, INSERM, CIC Cochin Pasteur,CIC 1417, Paris, France.
   [Duale, C.] CHU Clermont Ferrand, Ctr Pharmacol Clin INSERM CIC1405, Clermont Ferrand, France.
   [Mutter, C.] CHU Strasbourg, CIC Inserm 1434, Strasbourg, France.
   [Le Huec, J-C] Univ Bordeaux, Unite Rachis, Polyclin Bordeaux Nord Aquitaine, Deterca Lab, 15 Rue Boucher, F-33000 Bordeaux, France.
RP Botelho-Nevers, E (reprint author), Univ Hosp St Etienne, Clin Trial Ctr, INSERM CIC 1408, F-42055 St Etienne, France.; Botelho-Nevers, E (reprint author), Univ Lyon, Med Sch St Etienne, GIMAP, EA3064, Lyon, France.; Botelho-Nevers, E (reprint author), INSERM, F CRIN, Innovat Clin Res Network Vaccinol I REIVAC, Paris, France.
EM elisabeth.botelho-nevers@chu-st-etienne.fr
RI Schmidt-Mutter, Catherine/K-1088-2016; Botelho-Nevers,
   Elisabeth/H-2063-2019
OI Schmidt-Mutter, Catherine/0000-0002-8154-117X; Botelho-Nevers,
   Elisabeth/0000-0003-2773-7750
CR Benkimoun P., 2016, ESSAI CLIN MORTEL RE
   Buchbinder SP, 1999, J ACQ IMMUN DEF SYND, V2004, P604
   Cobb EM, 2014, CTS-CLIN TRANSL SCI, V7, P145, DOI 10.1111/cts.12142
   Costas L, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-28
   Detoc M, 2017, EXPERT REV VACCINES, V16, P467, DOI 10.1080/14760584.2017.1297706
   Detoc M, 2019, HUM VACC IMMUNOTHER, V15, P2969, DOI 10.1080/21645515.2019.1625646
   Gagneux-Brunon A, 2018, EXPERT REV VACCINES, V17, P421, DOI 10.1080/14760584.2018.1470507
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   Harrington L, 2017, VACCINE, V35, P6598, DOI 10.1016/j.vaccine.2017.10.041
   Hwang TJ, 2016, HEALTH AFFAIR, V35, P219, DOI 10.1377/hlthaff.2015.1073
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Lazcano-Ponce E, 2001, ARCH MED RES, V32, P243, DOI 10.1016/S0188-4409(01)00277-6
   McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9
   Newman PA, 2011, AM J PUBLIC HEALTH, V101, P1749, DOI 10.2105/AJPH.2011.300208
   Raheja D, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081743
   Ramsey TM, 2016, CLIN TRIALS, V13, P319, DOI 10.1177/1740774516631735
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Rikin S, 2017, CONT CLIN TRIAL COMM, V7, P122, DOI 10.1016/j.conctc.2017.06.010
   Ross S, 1999, J CLIN EPIDEMIOL, V52, P1143, DOI 10.1016/S0895-4356(99)00141-9
   Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115
   Sojka BN, 2008, VOX SANG, V94, P56, DOI 10.1111/j.1423-0410.2007.00990.x
   Tramm R, 2013, J CLIN NURS, V22, P2436, DOI 10.1111/jocn.12145
   van den Bogert CA, 2017, J CLIN EPIDEMIOL, V88, P140, DOI 10.1016/j.jclinepi.2017.05.001
   World Health Organization [Internet], IMM
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 25
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6633
EP 6639
DI 10.1016/j.vaccine.2019.09.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300009
PM 31543417
DA 2020-05-12
ER

PT J
AU Yitbarek, A
   Astill, J
   Hodgins, DC
   Parkinson, J
   Nagy, E
   Sharif, S
AF Yitbarek, Alexander
   Astill, Jake
   Hodgins, Douglas C.
   Parkinson, John
   Nagy, Eva
   Sharif, Shayan
TI Commensal gut microbiota can modulate adaptive immune responses in
   chickens vaccinated with whole inactivated avian influenza virus subtype
   H9N2
SO VACCINE
LA English
DT Article
DE Gut microbiota; Chicken; Whole inactivated influenza vaccine; H9N2
ID BROILER-CHICKENS; SEASONAL INFLUENZA; DOUBLE-BLIND; BACTERIA;
   QUANTIFICATION; MICROFLORA; EXPRESSION; PROBIOTICS; EVOLUTION; INTESTINE
AB Variations in the composition of commensal gut microbiota have been reported to be major contributors to differences in responses to vaccination among individuals. In chickens, there is limited information on the role of gut microbiota in responses to vaccination. The current study studied the role of gut microbiota in cell- and antibody-mediated immune responses to vaccination with a whole inactivated avian influenza virus, subtype H9N2. A total of 166 one-day-old specific pathogen free layer chickens (SPF) were randomly assigned to treatments, where a combination of antibiotic depletion, and probiotics (a combination of five Lactobacillus species) or fecal microbial transplant (FMT) reconstitution were used to study the dynamics of cell- and antibody-mediated immune responses to primary and secondary vaccinations at days 15 and 29 of age, respectively. Overall, at days 7 and 14 post primary vaccination (p.p. v.), administration of probiotics to non-depleted chickens resulted in significantly higher mean hemagglutination (HI) titre compared to antibiotic treated chickens. Furthermore, at day 21 p.p.v., chickens treated with probiotics or FMT post-antibiotic treatment showed a significantly higher mean HI titre compared to non-depleted chickens treated with probiotics. At day 7 p.p.v., a significantly higher virus specific IgM and IgG titres were observed in non-depleted chickens administered with probiotics compared to antibiotic depleted chickens, and a significantly higher IgG titre was observed in chickens treated with FMT following antibiotic treatment compared to only antibiotic treatment. Analysis of interferon gamma expression in splenocytes to assess cell-mediated immune responses showed a significantly lower expression in antibiotic-treated chickens compared to non-depleted chickens and FMT reconstituted chickens. Taken together, the current study suggests that shifts in the composition of gut microbiota of chickens may result in changes in cell- and antibody-mediated immune responses to vaccination against influenza viruses. Further studies will be needed to highlight the mechanisms involved in this modulation. (C) 2019 Published by Elsevier Ltd.
C1 [Yitbarek, Alexander; Astill, Jake; Hodgins, Douglas C.; Nagy, Eva; Sharif, Shayan] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
   [Parkinson, John] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3G4, Canada.
   [Parkinson, John] Hosp Sick Children, Res Inst, Div Mol Struct & Funct, Toronto, ON M5G 1X8, Canada.
   [Parkinson, John] Univ Toronto, Dept Biochem & Mol Genet, Toronto, ON M5S 1A8, Canada.
RP Sharif, S (reprint author), Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.
EM shayan@uoguelph.ca
OI Yitbarek, Alexander/0000-0002-3500-0305
FU Canadian Poultry Research Council-Agriculture and Agri-Food Canada
   Cluster; Natural Sciences and Engineering Research Council of
   CanadaNatural Sciences and Engineering Research Council of Canada;
   Ontario Ministry of Agriculture, Food and Rural Affairs; University of
   Guelph's Food from Thought initiative; Ontario Veterinary College
   Scholarship; Queen Elizabeth II Graduate Scholarship in Science
   Technology; Canadian Poultry Research Council Scholarship; Canada First
   Research Excellence Fund
FX The authors wish to acknowledge the staff at the Animal Isolation Unit.
   Funding was partly provided by the Canadian Poultry Research Council
   -Agriculture and Agri -Food Canada Cluster, Natural Sciences and
   Engineering Research Council of Canada, and the Ontario Ministry of
   Agriculture, Food and Rural Affairs. This research is supported in part
   by the University of Guelph's Food from Thought initiative, thanks to
   funding from the Canada First Research Excellence Fund. Alexander
   Yitbarek was the recipient of the Ontario Veterinary College
   Scholarship, Queen Elizabeth II Graduate Scholarship in Science &
   Technology and the Canadian Poultry Research Council Scholarship.
CR Alizadeh M, 2017, POULTRY SCI, V96, P58, DOI 10.3382/ps/pew244
   Astill J, 2018, VACCINE, V36, P3908, DOI 10.1016/j.vaccine.2018.05.093
   Barjesteh N, 2015, VACCINE, V33, P4843, DOI 10.1016/j.vaccine.2015.07.070
   Beckmann L, 2006, J BASIC MICROB, V46, P175, DOI 10.1002/jobm.200510107
   Brisbin JT, 2011, CLIN VACCINE IMMUNOL, V18, P1447, DOI 10.1128/CVI.05100-11
   Capua I, 2004, AVIAN PATHOL, V33, P393, DOI 10.1080/03079450410001724085
   COLE JR, 1967, APPL MICROBIOL, V15, P1229, DOI 10.1128/AEM.15.5.1229-1234.1967
   Davidson LE, 2011, EUR J CLIN NUTR, V65, P501, DOI 10.1038/ejcn.2010.289
   De Gregoris TB, 2011, J MICROBIOL METH, V86, P351, DOI 10.1016/j.mimet.2011.06.010
   Dunkley KD, 2007, POULTRY SCI, V86, P801, DOI 10.1093/ps/86.5.801
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Gu M, 2014, VET MICROBIOL, V174, P309, DOI 10.1016/j.vetmic.2014.09.029
   Guan JW, 2015, AVIAN DIS, V59, P263, DOI 10.1637/10972-110714-Reg
   Haghighi HR, 2006, CLIN VACCINE IMMUNOL, V13, P975, DOI 10.1128/CVI.00161-06
   Haghighi HR, 2005, CLIN DIAGN LAB IMMUN, V12, P1387, DOI 10.1128/CDLI.12.12.1387-1392.2005
   Kato LM, 2014, IMMUNOL REV, V260, P67, DOI 10.1111/imr.12185
   Kawamoto S, 2014, IMMUNITY, V41, P152, DOI 10.1016/j.immuni.2014.05.016
   Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075
   Kim M, 2016, CELL HOST MICROBE, V20, P202, DOI 10.1016/j.chom.2016.07.001
   Lee YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/science.1195568
   Li M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00692
   Lin YP, 2000, P NATL ACAD SCI USA, V97, P9654, DOI 10.1073/pnas.160270697
   Lynn DJ, 2018, J LEUKOCYTE BIOL, V103, P225, DOI 10.1189/jlb.5MR0617-216R
   McCracken VJ, 1999, PROBIOTICS: A CRITICAL REVIEW, P85
   Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067
   Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009
   Olivares M, 2007, NUTRITION, V23, P254, DOI 10.1016/j.nut.2007.01.004
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Qu A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002945
   Rinttila T, 2004, J APPL MICROBIOL, V97, P1166, DOI 10.1111/j.1365-2672.2004.02409.x
   Rizzardini G, 2012, BRIT J NUTR, V107, P876, DOI 10.1017/S000711451100420X
   Sergeant MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091941
   Shakouri MD, 2009, J ANIM PHYSIOL AN N, V93, P647, DOI 10.1111/j.1439-0396.2008.00852.x
   Shi JZ, 2013, CHINESE SCI BULL, V58, P1857, DOI 10.1007/s11434-013-5873-4
   Singh SM, 2016, VACCINE, V34, P4807, DOI 10.1016/j.vaccine.2016.08.009
   Singh SM, 2015, VACCINE, V33, P3947, DOI 10.1016/j.vaccine.2015.06.043
   Sommer F, 2013, NAT REV MICROBIOL, V11, P227, DOI 10.1038/nrmicro2974
   St Paul M, 2011, VET IMMUNOL IMMUNOP, V144, P228, DOI 10.1016/j.vetimm.2011.09.004
   Sun YP, 2010, VET MICROBIOL, V146, P215, DOI 10.1016/j.vetmic.2010.05.010
   Suthar MS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000757
   van der Wielen PWJJ, 2000, APPL ENVIRON MICROB, V66, P2536, DOI 10.1128/AEM.66.6.2536-2540.2000
   Wan HQ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002923
   Yitbarek A, 2012, POULTRY SCI, V91, P1105, DOI 10.3382/ps.2011-02109
   Yitbarek A, 2018, BENEF MICROBES, P1
   Yitbarek A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31613-0
   Zeng MY, 2016, IMMUNITY, V44, P647, DOI 10.1016/j.immuni.2016.02.006
   Zhang K, 2013, VIRUS RES, V175, P52, DOI 10.1016/j.virusres.2013.04.004
   Zhang ZJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1932-1
NR 49
TC 0
Z9 0
U1 7
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6640
EP 6647
DI 10.1016/j.vaccine.2019.09.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300010
PM 31542262
DA 2020-05-12
ER

PT J
AU Groom, HC
   Smith, N
   Irving, SA
   Koppolu, P
   Vazquez-Benitez, G
   Kharbanda, EO
   Daley, MF
   Donahue, JG
   Getahun, D
   Jackson, LA
   Klein, NP
   McCarthy, NL
   Nordin, JD
   Panagiotakopoulos, L
   Naleway, AL
AF Groom, Holly C.
   Smith, Ning
   Irving, Stephanie A.
   Koppolu, Padma
   Vazquez-Benitez, Gabriela
   Kharbanda, Elyse O.
   Daley, Matthew F.
   Donahue, James G.
   Getahun, Darios
   Jackson, Lisa A.
   Klein, Nicola P.
   McCarthy, Natalie L.
   Nordin, James D.
   Panagiotakopoulos, Lakshmi
   Naleway, Allison L.
TI Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine
   Safety Datalink study
SO VACCINE
LA English
DT Article
DE Vaccination; Hepatitis A; Pregnancy; Vaccine safety; Maternal
   immunization
ID VERTICAL TRANSMISSION; UNITED-STATES; BIRTH; GUIDELINES; OUTCOMES;
   PRETERM
AB Introduction: Infection with hepatitis A virus (HAV) during pregnancy, although uncommon, is associated with gestational complications and pre-term labor. Hepatitis A vaccine (HepA) is recommended for anyone at increased risk for contracting hepatitis A, including women at risk who are also pregnant. Limited data are available on the safety of maternal HepA vaccination.
   Objectives: Assess the frequency of maternal HepA receipt and evaluate the potential association between maternal vaccination and pre-specified maternal and infant safety outcomes.
   Methods: A retrospective cohort of pregnancies in the Vaccine Safety Datalink (VSD) resulting in live births from 2004 through 2015 was included. Pregnancies with HepA exposure were compared to those with other vaccine exposures, and to those with no vaccine exposures. Risk factors for contracting hepatitis A were identified up to one-year prior to or during the pregnancy using ICD-9 codes. Maternal and fetal adverse events were evaluated according to maternal HepA exposure status. Adjusted odds ratio (OR) were used to describe the association.
   Results: Among 666,233 pregnancies in the study period, HepA was administered at a rate of 1.7 per 1000 (n = 1140), most commonly within the first six weeks of pregnancy. Less than 3% of those exposed to HepA during pregnancy had an ICD-confirmed risk factor. There were no significant associations between HepA exposure during pregnancy and gestational hypertension, gestational diabetes, pre-eclampsia/eclampsia, cesarean delivery, pre-term delivery, and low birthweight. There was a statistically significant association between HepA exposure during pregnancy and small-for-gestational age (SGA) infants (aOR 1.32, [95% CI 1.09, 1.60], p = 0.004).
   Conclusions: The rate of maternal HepA vaccination was low and rarely due to documented risk factors for vaccination. HepA vaccination during pregnancy was not associated with an increased risk for a range of adverse events examined among pregnancies resulting in live births, but an identified association between maternal HepA and SGA infant outcomes, while likely due to unmeasured confounding, warrants further exploration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Groom, Holly C.; Smith, Ning; Irving, Stephanie A.; Koppolu, Padma; Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
   [Vazquez-Benitez, Gabriela; Kharbanda, Elyse O.; Nordin, James D.] HealthPartners Inst, Minneapolis, MN USA.
   [Daley, Matthew F.] Kaiser Permanente Colorado, Inst Hlth Res, Aurora, CO USA.
   [Donahue, James G.] Marshfield Clin Res Inst, Marshfield, WI USA.
   [Getahun, Darios] Kaiser Permanente Southern Calif, Res & Evaluat, Pasadena, CA USA.
   [Jackson, Lisa A.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
   [McCarthy, Natalie L.; Panagiotakopoulos, Lakshmi] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA.
RP Groom, HC (reprint author), 3800 N Interstate Ave, Portland, OR 97218 USA.
EM Holly.c.groom@kpchr.org
OI Nordin, James/0000-0002-3359-5843; Daley, Matthew/0000-0003-1309-4096;
   Groom, Holly/0000-0003-2866-9788; Irving, Stephanie/0000-0001-7437-6797
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2012-53584]; Findings and conclusions of this study are those of
   the authors and do not necessarily represent the official position of
   the Centers for Disease Control and Prevention
FX Funding for this study was provided by the Centers for Disease Control
   and Prevention, Contract 200-2012-53584. Findings and conclusions of
   this study are those of the authors and do not necessarily represent the
   official position of the Centers for Disease Control and Prevention. We
   would like to acknowledge the contributions of Project Managers and Data
   Managers from participating VSD sites. We would also like to extend our
   appreciation to Dr. Noele Nelson, the Acting Branch Chief in CDC's
   Division of Viral Hepatitis, for her review of, and contributions to,
   the final manuscript.
CR Ananth CV, 2009, EARLY HUM DEV, V85, P653, DOI 10.1016/j.earlhumdev.2009.09.004
   Ananth CV, 2004, EPIDEMIOLOGY, V15, P28, DOI 10.1097/01.ede.0000100288.37475.19
   [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   Antony KM, 2017, OBSTET GYNECOL SURV, V72, P97, DOI 10.1097/OGX.0000000000000398
   Bridges CB, 2013, MMWR-MORBID MORTAL W, V62, P9
   Elinav E, 2006, GASTROENTEROLOGY, V130, P1129, DOI 10.1053/j.gastro.2006.01.007
   Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Groom HC, 2018, VACCINE, V36, P6111, DOI 10.1016/j.vaccine.2018.08.074
   Herrero R, 2008, VACCINE, V26, P4795, DOI 10.1016/j.vaccine.2008.07.002
   Joseph KS, 2001, AM J EPIDEMIOL, V153, P110, DOI 10.1093/aje/153.2.110
   Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046
   Kharbanda EO, 2013, OBSTET GYNECOL, V122, P659, DOI 10.1097/AOG.0b013e3182a1118a
   Kourtis AP, 2014, NEW ENGL J MED, V371, P1077, DOI 10.1056/NEJMc1408436
   Kuhberger Anton, 2015, BMC Res Notes, V8, P84, DOI 10.1186/s13104-015-1020-4
   Leikin E, 1996, OBSTET GYNECOL, V88, P690, DOI 10.1016/0029-7844(96)00259-1
   Magriples U, 1998, SEMIN PERINATOL, V22, P112, DOI 10.1016/S0146-0005(98)80043-8
   McCowan L, 2009, BEST PRACT RES CL OB, V23, P779, DOI 10.1016/j.bpobgyn.2009.06.003
   McCowan LM, 2018, AM J OBSTET GYNECOL, V218, pS855, DOI 10.1016/j.ajog.2017.12.004
   McDuffie RS, 1999, AM J OBSTET GYNECOL, V180, P1031, DOI 10.1016/S0002-9378(99)70678-2
   McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073
   Mieske K, 2010, J TRAVEL MED, V17, P48, DOI 10.1111/j.1708-8305.2009.00369.x
   Naleway AL, 2013, VACCINE, V31, P2898, DOI 10.1016/j.vaccine.2013.03.069
   Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6
   Panagiotou OA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4358
   Rogerson SJ, 2010, ADV EXP MED BIOL, V659, P139, DOI 10.1007/978-1-4419-0981-7_12
   Saito M, 2018, EXPERT OPIN DRUG SAF, V17, P1129, DOI 10.1080/14740338.2018.1535593
   Savitz DA, 2002, EPIDEMIOL REV, V24, P91, DOI 10.1093/epirev/mxf006
   Schlaudecker EP, 2017, VACCINE, V35, P6518, DOI 10.1016/j.vaccine.2017.01.040
   Sukumaran L, 2015, OBSTET GYNECOL, V126, P1069, DOI 10.1097/AOG.0000000000001066
   TANAKA I, 1995, LANCET, V345, P397, DOI 10.1016/S0140-6736(95)90389-5
   Vazquez-Benitez G, 2016, AM J EPIDEMIOL, V184, P176, DOI 10.1093/aje/kww043
   WATSON JC, 1993, J INFECT DIS, V167, P567, DOI 10.1093/infdis/167.3.567
   Wilcox AJ, 2001, INT J EPIDEMIOL, V30, P1233, DOI 10.1093/ije/30.6.1233
   Zheteyeva Y, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.027
NR 34
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6648
EP 6655
DI 10.1016/j.vaccine.2019.09.043
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300011
PM 31548013
DA 2020-05-12
ER

PT J
AU Kwon, YM
   Lee, Y
   Kim, KH
   Jung, YJ
   Li, Z
   Jeeva, S
   Lee, S
   Moore, ML
   Kang, SM
AF Kwon, Young-Man
   Lee, Youri
   Kim, Ki Hye
   Jung, Yu Jin
   Li, Zhuo
   Jeeva, Subbiah
   Lee, Sujin
   Moore, Martin L.
   Kang, Sang-Moo
TI Antigenicity and immunogenicity of unique prefusion-mimic F proteins
   presented on enveloped virus-like particles
SO VACCINE
LA English
DT Article
DE RSV; RSV F protein; Prefusion; Post-fusion transition; VLP; P27
ID RESPIRATORY SYNCYTIAL-VIRUS; FUSION-GLYCOPROTEIN VACCINE; 2 DISTINCT
   SITES; COTTON RATS; PULMONARY HISTOPATHOLOGY; RSV; PROTECTION;
   INFECTION; ACTIVATION; ANTIBODIES
AB Pre-fusion stabilizing mutations (DS-Cav1) in soluble fusion (F) proteins of human respiratory syncytial virus (RSV) were previously reported. Here we investigated the antigenic and immunogenic properties of pre-fusion like RSV F proteins on enveloped virus-like particles (VLP). Additional mutations were introduced to DS-Cav1(F-dcmTM VLP); fusion peptide deletion and cleavage mutation site 1 (F1d-dcmTM VLP) or both sites (F12d-dcmTM VLP). F1d-dcmTM VLP and F12d-dcmTM VLP displayed higher reactivity against pre-fusion specific site empty set and antigenic site I and II specific monoclonal antibodies, compared to FdcmTM VLP with DS-Cav1 only. Mice immunized with F1d-dcmTM VLP and F12d-dcmTM VLP induced higher levels of DS-Cav1 pre-fusion specific IgG antibodies, RSV neutralizing activity titers, and effective lung viral clearance after challenge. These results suggest that cleavage site mutations and fusion peptide deletion in addition to DS-Cav1 mutations have contributed to structural stabilization of pre-fusion like F conformation on enveloped VLP, capable of inducing high levels of pre-fusion F specific and RSV neutralizing antibodies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kwon, Young-Man; Lee, Youri; Kim, Ki Hye; Jung, Yu Jin; Li, Zhuo; Jeeva, Subbiah; Kang, Sang-Moo] Georgia State Univ, Ctr Inflammat Immun & Infect, Inst Biomed Sci, Atlanta, GA 30303 USA.
   [Lee, Sujin] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA USA.
   [Lee, Sujin] Childrens Healthcare Atlanta, Atlanta, GA USA.
   [Moore, Martin L.] Meissa Vaccines Inc, San Francisco, CA USA.
RP Kang, SM (reprint author), Georgia State Univ, Ctr Inflammat Immun & Infect, Inst Biomed Sci, Atlanta, GA 30303 USA.
EM skang24@gsu.edu
OI Kang, SAng Moo/0000-0001-6198-331X
FU National Institutes of Health (NIH)/National Institute of Allergy and
   Infectious Diseases (NIAID)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI093772, AI105170, AI134132]
FX This work was supported by National Institutes of Health (NIH)/National
   Institute of Allergy and Infectious Diseases (NIAID) grants AI093772
   (SMK), AI105170 (SMK), and AI134132 (SMK). The authors express thanks to
   Dr. EH Lee for providing palivizumab and acknowledge the provision of
   RSV F purified proteins in post-fusion and pre-fusion conformation, and
   5C4 monoclonal antibody from Dr. B Graham (Vaccine Research Center,
   NIAID, NIH).
CR Blais N, 2017, J VIROL, V91, DOI 10.1128/JVI.02437-16
   Cardenas Silvia, 2005, Expert Rev Anti Infect Ther, V3, P719, DOI 10.1586/14787210.3.5.719
   CONNORS M, 1992, VACCINE, V10, P475, DOI 10.1016/0264-410X(92)90397-3
   Cullen LM, 2019, VACCINES-BASEL, V15, P1
   Cullen LM, 2015, J VIROL, V89, P6835, DOI 10.1128/JVI.00384-15
   Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376
   Gilbert BE, 2018, VACCINE, V36, P8069, DOI 10.1016/j.vaccine.2018.10.073
   Gilman MSA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09807-5
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   Gonzalez-Reyes L, 2001, P NATL ACAD SCI USA, V98, P9859, DOI 10.1073/pnas.151098198
   Graham BS, 2017, CURR OPIN VIROL, V23, P107, DOI 10.1016/j.coviro.2017.03.012
   Graham BS, 2015, CURR OPIN IMMUNOL, V35, P30, DOI 10.1016/j.coi.2015.04.005
   HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693
   Hosken N, 2017, VACCINE, V35, P3082, DOI 10.1016/j.vaccine.2017.04.053
   Joyce MG, 2016, NAT STRUCT MOL BIOL, V23, P811, DOI 10.1038/nsmb.3267
   Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108
   Kim KH, 2015, J VIROL, V89, P11692, DOI 10.1128/JVI.02018-15
   Kim MC, 2013, MOL THER, V21, P485, DOI 10.1038/mt.2012.246
   Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143
   Krzyzaniak MA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003309
   Kwon YM, 2014, ANTIVIR RES, V104, P1, DOI 10.1016/j.antiviral.2014.01.008
   Lee S, 2014, ANTIVIR RES, V111, P129, DOI 10.1016/j.antiviral.2014.09.005
   Lee Y, 2017, HUM VACC IMMUNOTHER, V13, P2594, DOI 10.1080/21645515.2017.1362514
   Magro M, 2012, P NATL ACAD SCI USA, V109, P3089, DOI 10.1073/pnas.1115941109
   Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5
   McGinnes LW, 2011, J VIROL, V85, P366, DOI 10.1128/JVI.01861-10
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11
   Melero JA, 2017, VACCINE, V35, P461, DOI 10.1016/j.vaccine.2016.09.045
   Meyerholz DK, 2009, TOXICOL PATHOL, V37, P249, DOI 10.1177/0192623308329342
   Murawski MR, 2010, J VIROL, V84, P1110, DOI 10.1128/JVI.01709-09
   MURPHY BR, 1990, VACCINE, V8, P497, DOI 10.1016/0264-410X(90)90253-I
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Ngwuta JO, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4241
   Palomo C, 2016, J VIROL, V90, P5485, DOI 10.1128/JVI.00338-16
   Phan SI, 2017, J VIROL, V91
   Quan FS, 2011, J INFECT DIS, V204, P987, DOI 10.1093/infdis/jir474
   Raghunandan R, 2014, VACCINE, V32, P6485, DOI 10.1016/j.vaccine.2014.09.030
   Rigter A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071072
   Ruiz-Arguello MB, 2004, J GEN VIROL, V85, P3677, DOI 10.1099/vir.0.80318-0
   Ruiz-Arguello MB, 2002, VIROLOGY, V298, P317, DOI 10.1006/viro.2002.1497
   Schneider-Ohrum K, 2017, J VIROL, V91, DOI 10.1128/JVI.02180-16
   Smith G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050852
   SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127
   STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0
   Stokes KL, 2013, J VIROL, V87, P10070, DOI 10.1128/JVI.01347-13
   Walsh EE, 2018, J INFECT DIS, V218, P208, DOI 10.1093/infdis/jiy106
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Welch BD, 2012, P NATL ACAD SCI USA, V109, P16672, DOI 10.1073/pnas.1213802109
   Widjaja I, 2016, J VIROL, V90, P5965, DOI 10.1128/JVI.00235-16
   Widjaja I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130829
   Zhang L, 2018, VACCINE, V36, P8119, DOI 10.1016/j.vaccine.2018.10.032
   Zimmer G, 2001, J BIOL CHEM, V276, P31642, DOI 10.1074/jbc.M102633200
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6656
EP 6664
DI 10.1016/j.vaccine.2019.09.041
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300012
PM 31542260
DA 2020-05-12
ER

PT J
AU Teo, LM
   Smith, HE
   Lwin, MO
   Tang, WE
AF Teo, L. M.
   Smith, H. E.
   Lwin, M. O.
   Tang, W. E.
TI Attitudes and perception of influenza vaccines among older people in
   Singapore: A qualitative study
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Elderly; Older adults; Barriers; Motivators; Travel;
   Healthcare workers; Misconceptions; Singapore
ID VACCINATION; COMMUNITY; KNOWLEDGE; BELIEFS; CHINA
AB Background: Despite recommendations for influenza vaccination of people aged 65 and above, uptake rate of influenza vaccines remains low.
   This study aims to understand barriers and motivators behind older adult's decision on influenza vaccination.
   Methods: Face to face interviews with participants aged 65 and above were conducted and audio recorded in Geylang polyclinic in Singapore. Thematic content analysis was used to organise the data.
   Results: 15 older adults were interviewed, aged between 66 and 85 years old. 6 were vaccine refusers, 3 defaulters and 6 acceptors.
   A perceived lack of vulnerability, fear of side effects, and trivialisation of influenza were common reasons for not taking the vaccine. Encouragement from family and friends, travel and previous positive vaccination experiences were motivators for getting vaccinated. Healthcare workers played a role in influencing many of the participants' decision-making. Common misconceptions included vaccines considered as necessary only before travel and as a cure rather than prevention. Most participants exhibited ambivalence, giving reasons both for and against vaccine uptake.
   Discussion: Most older adults do not perceive influenza as a potentially serious disease nor trust in influenza vaccines' efficacy. Misconceptions played a significant role in vaccine decline. Novel findings include the importance of the family unit in decision making, prioritization of chronic health problems over vaccination and misconception that vaccines are only needed when travelling out of country. Healthcare workers and family members appear to be important influencers in the decision making of older adults and should be actively engaged in future health promotion initiatives. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Teo, L. M.; Smith, H. E.] Nanyang Technol Univ, Lee Kong Chian Sch Med, 11 Mandalay Rd, Singapore 308232, Singapore.
   [Lwin, M. O.] Nanyang Technol Univ, Wee Kim Wee Sch Commun & Informat, Singapore, Singapore.
   [Tang, W. E.] Natl Healthcare Grp Polyclin, Clin Res Unit, Singapore, Singapore.
RP Smith, HE (reprint author), Nanyang Technol Univ, Lee Kong Chian Sch Med, 11 Mandalay Rd, Singapore 308232, Singapore.
EM h.e.smith@ntu.edu.sg
RI Smith, Helen/M-2449-2016
OI Smith, Helen/0000-0003-1883-6124
FU Nanyang Technological University under the Undergraduate Research
   Experience on CAmpus (URECA) programme
FX We wish to acknowledge the funding for this project from Nanyang
   Technological University under the Undergraduate Research Experience on
   CAmpus (URECA) programme.
CR Ang LW, 2017, EPIDEMIOL INFECT, V145, P775, DOI 10.1017/S0950268816002491
   Ang LW, 2014, EMERG INFECT DIS, V20, P1652, DOI 10.3201/eid2010.131768
   Chow A, 2006, EMERG INFECT DIS, V12, P114, DOI 10.3201/eid1201.050826
   Cornford CS, 1999, BRIT J GEN PRACT, V49, P281
   FRANK JW, 1985, CAN MED ASSOC J, V132, P371
   Goh C.N., ANN REPORT FY 2015
   Ho ZJM, 2010, J PAIN SYMPTOM MANAG, V40, P932, DOI 10.1016/j.jpainsymman.2010.06.010
   Lang PO, 2012, CLIN INTERV AGING, V7, P55, DOI 10.2147/CIA.S25215
   Leo YS, 2010, EMERG INFECT DIS, V16, P103, DOI 10.3201/eid1601.091164
   Lim P.L., 2012, BRIDGING GAP PREDISC
   Low MSF, 2017, VACCINE, V35, P6096, DOI 10.1016/j.vaccine.2017.09.060
   Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7
   Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444
   Ministry of Health Singapore, DIS COND INFL
   Nichol KL, 2007, NEW ENGL J MED, V357, P1373, DOI 10.1056/NEJMoa070844
   OECD, 2019, INFL VACC RAT IND, DOI [10.1787/e452582e-en, DOI 10.1787/E452582E-EN]
   Santos AJ, 2017, EPIDEMIOL INFECT, V145, P1786, DOI 10.1017/S0950268817000814
   Song Y, 2017, VACCINE, V35, P4060, DOI 10.1016/j.vaccine.2017.06.054
   Sundaram N, 2018, VACCINE, V36, P1996, DOI 10.1016/j.vaccine.2018.02.102
   Tan EK, 2010, SINGAP MED J, V51, P623
   Weir R, 2004, INT CONGR SER, V1263, P276, DOI 10.1016/j.ics.2004.02.122
   Wilder-Smith Annelies, 2006, Travel Med Infect Dis, V4, P53, DOI 10.1016/j.tmaid.2005.04.004
   Yi B, 2018, HUM VACC IMMUNOTHER, V14, P947, DOI 10.1080/21645515.2017.1403704
   Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00698-9
NR 24
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6665
EP 6672
DI 10.1016/j.vaccine.2019.09.037
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300013
PM 31542261
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Donahue, JG
   Kieke, BA
   King, JP
   Mascola, MA
   Shimabukuro, TT
   DeStefano, F
   Hanson, KE
   McClure, DL
   Olaiya, O
   Glanz, JM
   Hechter, RC
   Irving, SA
   Jackson, LA
   Klein, NP
   Naleway, AL
   Weintraub, ES
   Belongia, EA
AF Donahue, James G.
   Kieke, Burney A.
   King, Jennifer P.
   Mascola, Maria A.
   Shimabukuro, Tom T.
   DeStefano, Frank
   Hanson, Kayla E.
   McClure, David L.
   Olaiya, Oluwatosin
   Glanz, Jason M.
   Hechter, Rulin C.
   Irving, Stephanie A.
   Jackson, Lisa A.
   Klein, Nicola P.
   Naleway, Allison L.
   Weintraub, Eric S.
   Belongia, Edward A.
TI Inactivated influenza vaccine and spontaneous abortion in the Vaccine
   Safety Datalink in 2012-13, 2013-14, and 2014-15
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Spontaneous abortion; Influenza; Pregnancy
ID IMMUNIZATION PRACTICES ACIP; PREGNANCY BIRTH-DEFECTS; UNITED-STATES;
   FETAL-DEATH; ADVISORY-COMMITTEE; SEASONAL INFLUENZA; PRETERM DELIVERY;
   VIRUS VACCINE; WOMEN; RECOMMENDATIONS
AB Introduction: A recent study reported an association between inactivated influenza vaccine (IIV) and spontaneous abortion (SAB), but only among women who had also been vaccinated in the previous influenza season. We sought to estimate the association between IIV administered in three recent influenza seasons and SAB among women who were and were not vaccinated in the previous influenza season.
   Methods: We conducted a case-control study over three influenza seasons (2012-13, 2013-14, 2014-15) in the Vaccine Safety Datalink (VSD). Cases (women with SAB) and controls (women with live births) were matched on VSD site, date of last menstrual period, age group, and influenza vaccination status in the previous influenza season. Of 1908 presumptive cases identified from the electronic record, 1236 were included in the main analysis. Administration of IIV was documented in several risk windows, including 1-28, 29-56, and >56 days before the SAB date.
   Results: Among 627 matched pairs vaccinated in the previous season, no association was found between vaccination in the 1-28 day risk window and SAB (adjusted odds ratio (aOR) 0.9; 95% confidence interval (CI) 0.6-1.5). The season-specific aOR ranged from 0.5 to 1.7 with all Cis including the null value of 1.0. Similarly, no association was found among women who were not vaccinated in the previous season; the season-specific aOR in the 1-28 day risk window ranged from 0.6 to 0.7 and the 95% CI included 1.0 in each season. There was no association found between SAB and influenza vaccination in the other risk windows, or when vaccine receipt was analyzed relative to date of conception.
   Conclusion: During these seasons we found no association between IIV and SAB, including among women vaccinated in the previous season. These findings lend support to current recommendations for influenza vaccination at any time during pregnancy, including the first trimester. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Donahue, James G.; Kieke, Burney A.; King, Jennifer P.; Hanson, Kayla E.; McClure, David L.; Olaiya, Oluwatosin; Belongia, Edward A.] Marshfield Clin Res Inst, ML-2,1000 N Oak Ave, Marshfield, WI 54449 USA.
   [Mascola, Maria A.] Marshfield Clin Fdn Med Res & Educ, Dept Obstet & Gynecol, 1000 N Oak Ave, Marshfield, WI 54449 USA.
   [Shimabukuro, Tom T.; DeStefano, Frank; Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS V18-4, Atlanta, GA 30329 USA.
   [Glanz, Jason M.] Kaiser Permanente Colorado, 10065 E Harvard Ave,Suite 300, Denver, CO 80231 USA.
   [Hechter, Rulin C.] Kaiser Permanente Southern Calif, 100 S Los Robles Ave 2nd Floor, Pasadena, CA 91101 USA.
   [Irving, Stephanie A.; Naleway, Allison L.] Kaiser Permanente Northwest, 3800 N Interstate Ave, Portland, OR 97227 USA.
   [Jackson, Lisa A.] Kaiser Permanente Washington, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
RP Donahue, JG (reprint author), Marshfield Clin Res Inst, ML-2,1000 N Oak Ave, Marshfield, WI 54449 USA.
EM donahue.james@mcrf.mfldclin.edu; kieke.burney@marshfieldresearch.org;
   king.jennifer@marshfieldresearch.org;
   mascola.maria@marshfieldclinic.org; ayv6@cdc.gov; fxd1@cdc.gov;
   hanson.kayla@marshfieldresearch.org;
   mcclure.david@marshfieldresearch.org;
   olaiya.oluwatosin@marshfieldresearch.org; jason.m.glanz@kp.org;
   rulin.c.hechter@kp.org; stephanie.a.irving@kpchr.org;
   lisa.a.jackson@kp.org; Nicola.Klein@kp.org; Allison.Naleway@kpchr.org;
   eiw8@cdc.gov; belongia.edward@marshfieldclinic.org
OI Irving, Stephanie/0000-0001-7437-6797; Belongia,
   Edward/0000-0001-7478-0415
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2012-53587-0007]
FX This work was supported by a contract (200-2012-53587-0007) from the
   Centers for Disease Control and Prevention. CDC scientists participated
   in the design and conduct of the study, analysis and interpretation of
   the data, and preparation, review, and approval of the manuscript for
   publication. The findings and conclusions in this report are those of
   the authors and do not necessarily represent the official position of
   the Centers for Disease Control and Prevention.
CR American College of Obstetricians and Gynecologists Committee on Obstetric Practice, 2010, Obstet Gynecol, V116, P1006, DOI 10.1097/AOG.0b013e3181fae845
   [Anonymous], 1997, MMWR Recomm Rep, V46, P1
   Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H
   Bednarczyk RA, 2012, AM J OBSTET GYNECOL, V207, pS38, DOI 10.1016/j.ajog.2012.07.002
   BOWKER AH, 1948, J AM STAT ASSOC, V43, P572, DOI 10.2307/2280710
   Bratton KN, 2015, CLIN INFECT DIS, V60, pE11, DOI 10.1093/cid/ciu915
   Chambers CD, 2016, VACCINE, V34, P4443, DOI 10.1016/j.vaccine.2016.06.054
   Chambers CD, 2013, VACCINE, V31, P5026, DOI 10.1016/j.vaccine.2013.08.097
   Christian LM, 2013, AM J REPROD IMMUNOL, V70, P45, DOI 10.1111/aji.12117
   Christian LM, 2011, VACCINE, V29, P8982, DOI 10.1016/j.vaccine.2011.09.039
   Christiansen OB, 2006, SEMIN FETAL NEONAT M, V11, P302, DOI 10.1016/j.siny.2006.03.001
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Doubilet PM, 2013, SEMIN PERINATOL, V37, P307, DOI 10.1053/j.semperi.2013.06.006
   Fell DB, 2015, BJOG-INT J OBSTET GY, V122, P17, DOI 10.1111/1471-0528.12977
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Fell Deshayne B, 2012, Am J Public Health, V102, pe33, DOI 10.2105/AJPH.2011.300606
   Giles ML, 2019, HUM VACC IMMUNOTHER, V15, P687, DOI 10.1080/21645515.2018.1540807
   Greenland S, 1997, AM J EPIDEMIOL, V146, P883
   Grohskopf Lisa, 2012, Morbidity and Mortality Weekly Report, V61, P613
   Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691
   Grohskopf LA, 2013, MMWR RECOMM REP, V62, P1
   Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210
   Harper Scott A., 2004, Morbidity and Mortality Weekly Report, V53, P1
   Hastie T., 2001, ELEMENTS STAT LEARNI
   Hospital Infection Control Practices Advisory Committee (HICPAC), 1995, MMWR-MORBID MORTAL W, V44, P1
   Hutcheon JA, 2016, AM J EPIDEMIOL, V184, P227, DOI 10.1093/aje/kww048
   Irving SA, 2013, OBSTET GYNECOL, V121, P159, DOI [10.1097/AOG.0b013e318279f56f, http://10.1097/AOG.0b013e318279f56f]
   Kay AW, 2014, P NATL ACAD SCI USA, V111, P14506, DOI 10.1073/pnas.1416569111
   Kharbanda EO, 2017, J PEDIATR-US, V187, P234, DOI 10.1016/j.jpeds.2017.04.039
   LEHMANN EL, 1975, NONPARAMETRICS STAT
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813
   McMillan M, 2015, VACCINE, V33, P2108, DOI 10.1016/j.vaccine.2015.02.068
   McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996
   Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047
   Moro PL, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.050
   Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033
   Munoz FM, 2012, AM J OBSTET GYNECOL, V207, pS33, DOI 10.1016/j.ajog.2012.06.072
   Munoz FM, 2005, AM J OBSTET GYNECOL, V192, P1098, DOI 10.1016/j.ajog.2004.12.019
   Naleway AL, 2013, VACCINE, V31, P2898, DOI 10.1016/j.vaccine.2013.03.069
   Newsome Kimberly, 2011, Morbidity and Mortality Weekly Report, V60, P1193
   Pasternak B, BMJ-BRIT MED J, V344, pe2794, DOI DOI 10.1136/BMJ.E2794
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Rasmussen SA, 2012, CLIN OBSTET GYNECOL, V55, P487, DOI 10.1097/GRF.0b013e31824df23e
   Sammon CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051734
   Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479
   Tamma PD, 2009, AM J OBSTET GYNECOL, V201, P547, DOI 10.1016/j.ajog.2009.09.034
   Tulandi T., 2013, UPTODATE
   WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1
   Zhang C, 2018, INT J GYNECOL OBSTET, V141, P141, DOI 10.1002/ijgo.12394
NR 49
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6673
EP 6681
DI 10.1016/j.vaccine.2019.09.035
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300014
PM 31540812
OA Other Gold
DA 2020-05-12
ER

PT J
AU Alashkar, F
   Vance, C
   Herich-Terhurne, D
   Turki, AT
   Schmitz, C
   Bommer, M
   Huttmann, A
   Duhrsen, U
   Vogel, U
   Roth, A
AF Alashkar, Ferras
   Vance, Colin
   Herich-Terhuerne, Dorte
   Turki, Amin T.
   Schmitz, Christine
   Bommer, Martin
   Huettmann, Andreas
   Duehrsen, Ulrich
   Vogel, Ulrich
   Roeth, Alexander
TI Serologic response to meningococcal vaccination in patients with cold
   agglutinin disease (CAD) in the novel era of complement inhibition
SO VACCINE
LA English
DT Article
DE Cold agglutinin disease (CAD); Eculizumab; N. meningitidis
ID NEISSERIA-MENINGITIDIS; ECULIZUMAB
AB Cold agglutinin disease (CAD) is a rare, potentially life-threatening acquired autoimmune hemolytic anemia characterized by hemagglutination and hemolysis due to immunoglobulin-mediated (usually [OAK) classic complement pathway activation. Complement inhibition (CI) represents a novel treatment option to control hemolysis. Due to CI patients (pts) are susceptible to encapsulated bacteria e.g. N. meningitidis. Therefore, meningococcal vaccination on CI is mandatory. In this study serologic response to the tetravalent conjugate vaccine Menveo (R) was analyzed in CAD pts on eculizumab treatment (DECADE trial) using rabbit serum as complement source (rSBA). Protective rSBA titers varied for meningococcal serogroups and over time reflecting an early decline to even non-protective rSBA titers. These data highlight the importance of serologic analyses under chronic CI. Currently, re-vaccination with a tetravalent meningococcal conjugate vaccine every 3 years is recommended on chronic CI. However, re-vaccination on CI might further rely on serologic analyses, implying even early booster vaccinations similar to adults with (functional) asplenia. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Alashkar, Ferras; Herich-Terhuerne, Dorte; Schmitz, Christine; Huettmann, Andreas; Duehrsen, Ulrich; Roeth, Alexander] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol, Hufelandstr 55, D-45147 Essen, Germany.
   [Vance, Colin] Rhein Westfalisches Inst Wirtschaftsforsch, Essen, Germany.
   [Turki, Amin T.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Bone Marrow Transplantat, Essen, Germany.
   [Bommer, Martin] Univ Ulm, Dept Internal Med 3, Ulm, Germany.
   [Bommer, Martin] Alb Fils Kliniken, Dept Hematol Oncol Infect Dis & Palliat Care, Goppingen, Germany.
   [Vogel, Ulrich] Univ Wurzburg, Reference Ctr Meningococci & Haemophilus Influenz, Inst Hyg & Microbiol, Wurzburg, Germany.
RP Roth, A (reprint author), Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol, Hufelandstr 55, D-45147 Essen, Germany.
EM alexander.roeth@uk-essen.de
OI Turki, Amin/0000-0003-1347-3360; Roth, Alexander/0000-0003-4414-7699;
   Alashkar, Ferras/0000-0001-7530-8892; Huttmann,
   Andreas/0000-0003-2230-3873
FU Alexion PharmaceuticalsFukuda Foundation for Medical TechnologyKayamori
   FoundationKayamori Foundation of Informational Science
   AdvancementSENSHIN Medical Research FoundationSasagawa Scientific
   Research GrantMukai Science and Technology Foundation
FX The DECADE trial was supported by Alexion Pharmaceuticals, which
   provided research funding to A.R. We would like to thank PD Dr. H. Claus
   at the Institute for Hygiene and Microbiology at the University of
   Wtirzburg, Wtirzburg for thorough review of this manuscript.
CR Alashkar F, 2017, ANN HEMATOL, V96, P589, DOI 10.1007/s00277-017-2924-y
   Balmer Paul, 2004, Expert Rev Vaccines, V3, P77, DOI 10.1586/14760584.3.1.77
   Berentsen S, 2006, HAEMATOLOGICA, V91, P460
   Berentsen S, 2018, BRIT J HAEMATOL, V181, P320, DOI 10.1111/bjh.15109
   Berentsen S, 2016, HEMATOL-AM SOC HEMAT, P226, DOI 10.1182/asheducation-2016.1.226
   Bonanni P, 2017, HUM VACC IMMUNOTHER, V13, P359, DOI 10.1080/21645515.2017.1264797
   Campbell H, 2018, GUIDANCE PUBLIC HLTH
   Elias J, 2013, J OCCUP MED TOXICOL, V8, DOI 10.1186/1745-6673-8-4
   Gackler A, 2020, NEPHROL DIAL TRANSPL, V35, P298, DOI 10.1093/ndt/gfy225
   Gill CJ, 2011, VACCINE, V30, P29, DOI 10.1016/j.vaccine.2011.10.068
   Hellerud BC, 2010, INFECT IMMUN, V78, P802, DOI 10.1128/IAI.01044-09
   Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17
   Jones S., 2016, MECH RESPONSIBLE DIF
   Koch-Institut R, 2018, EP B R KOCH I AUSG 3
   Lewis LA, 2014, VIRULENCE, V5, P98, DOI 10.4161/viru.26515
   McNamara LA, 2017, MMWR-MORBID MORTAL W, V66, P734, DOI 10.15585/mmwr.mm6627e1
   Mullins M, 2017, BLOOD ADV, V1, P839, DOI 10.1182/bloodadvances.2017004390
   Nazi I, 2013, BLOOD, V122, P1946, DOI 10.1182/blood-2013-04-494096
   Roth A, 2018, BLOOD ADV, V2, P2543, DOI 10.1182/bloodadvances.2018024190
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6682
EP 6687
DI 10.1016/j.vaccine.2019.09.033
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300015
PM 31562002
DA 2020-05-12
ER

PT J
AU Opriessnig, T
   Castro, AMMG
   Karuppanan, AK
   Gauger, PC
   Halbur, PG
   Matzinger, SR
   Meng, XJ
AF Opriessnig, Tanja
   Castro, Alessandra M. M. G.
   Karuppanan, Anbu K.
   Gauger, Phillip C.
   Halbur, Patrick G.
   Matzinger, Shannon R.
   Meng, Xiang-Jin
TI A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is
   effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model
SO VACCINE
LA English
DT Article
DE Porcine circovirus (PCV); PCV2b; Coinfection; Vaccination; Conventional
   pig model
ID MULTISYSTEMIC WASTING SYNDROME; MYCOPLASMA-HYOPNEUMONIAE;
   GENETIC-CHARACTERIZATION; ANTIBODY-RESPONSES; 2A-BASED VACCINE; PCV2;
   INFECTION; DISEASE; TRANSMISSION; REVEALS
AB Porcine circovirus type 2 (PCV2) is one of the major swine pathogens causing high economic losses due to PCV2-associated disease (PCVAD). PCV2 infection is not only immunosuppressive by damaging lymphoid tissues but is also exacerbated by co-infections with other pathogens including Mycoplasma hyopneumoniae. While PCV2 can be divided into several genotypes, currently only PCV2a, PCV2b and PCV2d are globally prevalent and considered of major importance. Most commercial PCV2 vaccines are based on PCV2a isolates; however, the high prevalence of PCV2b and PCV2d in the global pig population is raising concerns among pig veterinarians. The objective of this study was to evaluate the efficacy of an experimental PCV2b-based subunit vaccine in a combined PCV2b and M. hyopneumoniae coinfection model. Briefly, a total of 49 PCV2- and M. hyopneumoniae-free 3-week-old pigs were randomly divided into four groups: A non-vaccinated, non-infected NEG-CONTROL group, a non-vaccinated, PCV2b-infected, POS-CONTROL group, and two vaccinated and PCV2b-infected groups (SINGLE-VAC, DUAL-VAC). SINGLE-VAC and DUAL-VAC pigs were vaccinated at 3 weeks of age and DUAL-VAC pigs received a booster dose at 5 weeks of age. All pigs, except NEG-CONTROLS, were experimentally infected with M. hyopneumoniae 28 days after initial vaccination and challenged with PCV2b one week later. The pigs were necropsied 21 days after PCV2b challenge. Prior to PCV2b challenge, both vaccinated groups had detectable humoral and cell-medicated immune responses to PCV2. Vaccination significantly reduced PCV2b viremia and also reduced or eliminated PCV2-associated lymphoid lesions compared to the POS-CONTROL pigs. Under the study conditions, an experimental PCV2b vaccine protected conventional growing pigs against PCV2b viremia and associated lesions in a coinfection model with some advantages of the two-dose regimen versus the one dose regimen. Both protocols induced neutralizing antibodies against PCV2a and PCV2d prior to challenge. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Opriessnig, Tanja] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja; Karuppanan, Anbu K.; Gauger, Phillip C.; Halbur, Patrick G.] Iowa State Univ, Dept Vet Diagnost & Prod Anim Med, Coll Vet Med, Ames, IA USA.
   [Castro, Alessandra M. M. G.] Ctr Univ Fac Metropolitana Unidas, Vet, Real Parque, Sao Paulo, SP, Brazil.
   [Matzinger, Shannon R.; Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
RP Opriessnig, T (reprint author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.; Opriessnig, T (reprint author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
EM Tanja.Opriessnig@roslin.ed.ac.uk
RI Opriessnig, Tanja/F-2984-2012
OI Opriessnig, Tanja/0000-0001-9642-0904; Karuppannan, Anbu
   Kumar/0000-0003-3020-4867
FU Ourofino Sal de Animal Ltda, Cravinhos, SP, Brazil; Roslin Institute
   Strategic Programme Control of Infectious Diseases [BBS/E/D/20002173,
   BBS/E/D/20002174]
FX This work was supported by a grant through Ourofino Sal de Animal Ltda,
   Cravinhos, SP, Brazil. We would also like to acknowledge Biotechnology
   and Biological Sciences Research Council (BBSRC) support of the Roslin
   Institute Strategic Programme Control of Infectious Diseases
   (BBS/E/D/20002173 and BBS/E/D/20002174).
CR Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002
   Alarcon P, 2013, PREV VET MED, V110, P88, DOI 10.1016/j.prevetmed.2013.02.010
   Bao F, 2018, TRANSBOUND EMERG DIS, V65, P432, DOI 10.1111/tbed.12721
   Carman S, 2006, CAN VET J, V47, P761
   Davies B, 2016, VIRUS RES, V217, P32, DOI 10.1016/j.virusres.2016.02.010
   Dupont K, 2008, VET MICROBIOL, V128, P56, DOI 10.1016/j.vetmic.2007.09.016
   Eddicks M, 2015, VET MICROBIOL, V176, P337, DOI 10.1016/j.vetmic.2015.01.013
   Fenaux M, 2000, J CLIN MICROBIOL, V38, P2494, DOI 10.1128/JCM.38.7.2494-2503.2000
   Franzo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208585
   Franzo G, 2015, VET MICROBIOL, V178, P158, DOI 10.1016/j.vetmic.2015.05.003
   Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724
   Neto JCG, 2014, VET MICROBIOL, V174, P163, DOI 10.1016/j.vetmic.2014.08.008
   Halbur PG, 1996, VET PATHOL, V33, P159, DOI 10.1177/030098589603300205
   Harding JCS, 2004, VET MICROBIOL, V98, P131, DOI 10.1016/j.vetmic.2003.10.013
   Harmon KM, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.01315-15
   Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099
   Liu JK, 2018, PEERJ, V6, DOI 10.7717/peerj.4476
   Opriessnig T, 2008, J GEN VIROL, V89, P2482, DOI 10.1099/vir.0.2008/001081-0
   Opriessnig T, 2004, VET PATHOL, V41, P624, DOI 10.1354/vp.41-6-624
   Opriessnig T, 2011, THERIOGENOLOGY, V76, P351, DOI 10.1016/j.theriogenology.2011.02.014
   Opriessnig T, 2003, VET PATHOL, V40, P521, DOI 10.1354/vp.40-5-521
   Opriessnig T, 2007, J VET DIAGN INVEST, V19, P591, DOI 10.1177/104063870701900601
   Opriessnig T, 2017, VACCINE, V35, P248, DOI 10.1016/j.vaccine.2016.11.085
   Opriessnig T, 2014, VACCINE, V32, P230, DOI 10.1016/j.vaccine.2013.11.010
   Opriessnig T, 2013, VET MICROBIOL, V163, P177, DOI 10.1016/j.vetmic.2012.12.019
   Opriessnig T, 2013, VACCINE, V31, P487, DOI 10.1016/j.vaccine.2012.11.030
   Opriessnig T, 2012, VIRUS RES, V164, P20, DOI 10.1016/j.virusres.2011.09.014
   Ouyang T, 2019, VIRUSES, V11
   Park KH, 2019, VET MICROBIOL, V231, P87, DOI 10.1016/j.vetmic.2019.03.002
   Patterson A. R., 2010, Animal Health Research Reviews, V11, P217, DOI 10.1017/S1466252310000162
   Rose N, 2016, VACCINE, V34, P3738, DOI 10.1016/j.vaccine.2016.06.005
   ROSS RF, 1984, AM J VET RES, V45, P1899
   Salgado RL, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00163-14
   Seo HW, 2014, ARCH VIROL, V159, P3107, DOI 10.1007/s00705-014-2164-6
   Seo HW, 2014, VACCINE, V32, P2480, DOI 10.1016/j.vaccine.2014.02.088
   Sorden SD, 1999, J VET DIAGN INVEST, V11, P528, DOI 10.1177/104063879901100607
   TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0
   Wellenberg GJ, 2000, VET QUART, V22, P167, DOI 10.1080/01652176.2000.9695049
   Worsfold CS, 2015, J GEN VIROL, V96, P2743, DOI 10.1099/vir.0.000206
   Xiao CT, 2015, J GEN VIROL, V96, P1830, DOI 10.1099/vir.0.000100
   Xiao CT, 2012, J VIROL, V86, P12469, DOI 10.1128/JVI.02345-12
   Yao J, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1859-z
NR 42
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6688
EP 6695
DI 10.1016/j.vaccine.2019.09.029
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300016
PM 31537445
DA 2020-05-12
ER

PT J
AU Kumru, OS
   Saleh-Birdjandi, S
   Antunez, LR
   Sayeed, E
   Robinson, D
   van den Worm, S
   Diemer, GS
   Perez, W
   Caposio, P
   Fruh, K
   Joshi, SB
   Volkin, DB
AF Kumru, Ozan S.
   Saleh-Birdjandi, Soraia
   Antunez, Lorena R.
   Sayeed, Eddy
   Robinson, David
   van den Worm, Sjoerd
   Diemer, Geoffrey S.
   Perez, Wilma
   Caposio, Patrizia
   Frueh, Klaus
   Joshi, Sangeeta B.
   Volkin, David B.
TI Stabilization and formulation of a recombinant Human Cytomegalovirus
   vector for use as a candidate HIV-1 vaccine
SO VACCINE
LA English
DT Article
DE HIV vaccine; Cytomegalovirus; Formulation; Freeze-thaw; Stability;
   Excipient
ID HIGHLY PATHOGENIC SIV; COLD CHAIN; IONIC-STRENGTH; VIRUS; STABILITY;
   IMMUNOGENICITY; MECHANISMS; EXPRESSION; SAFETY; GENES
AB Live attenuated viral vaccine/vector candidates are inherently unstable and infectivity titer losses can readily occur without defining appropriate formulations, storage conditions and clinical handling practices. During initial process development of a candidate vaccine against HIV-1 using a recombinant Human Cytomegalovirus vector (rHCMV-1), large vector titer losses were observed after storage at 4 degrees C and after undergoing freeze-thaw. Thus, the goal of this work was to develop candidate frozen liquid formulations of rHCMV-1 with improved freeze-thaw and short-term liquid stability for potential use in early clinical trials. To this end, a virus stability screening protocol was developed including use of a rapid, in vitro cell-based immunofluorescence focus assay to quantitate viral titers. A library of similar to 50 pharmaceutical excipients (from various known classes of additives) were evaluated for their effect on vector stability after freeze-thaw cycling or incubation at 4 degrees C for several days. Certain additives including sugars and polymers (e.g., trehalose, sucrose, sorbitol, hydrolyzed gelatin, dextran 40) as well as removal of NaCl (lower ionic strength) protected rHCMV-1 against freeze-thaw mediated losses in viral titers. Optimized solution conditions (e.g., solution pH, buffers and sugar type) slowed the rate of rHCMV-1 titer losses in the liquid state at 4 degrees C. After evaluating various excipient combinations, three new candidate formulations were designed and rHCMV-1 stability was benchmarked against both the currently-used and a previously reported formulation. The new candidate formulations were significantly more stable in terms of reducing rHCMV-1 titer losses after 5 freeze-thaw cycles or incubation at 4 degrees C for 30 days. This case study highlights the utility of semi-empirical design of frozen liquid formulations of a live viral vaccine candidate, where protection against infectivity titer losses due to freeze-thaw and short-term liquid storage are sufficient to enable more rapid initiation of early clinical trials. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kumru, Ozan S.; Saleh-Birdjandi, Soraia; Antunez, Lorena R.; Joshi, Sangeeta B.; Volkin, David B.] Univ Kansas, Vaccine Analyt & Formulat Ctr, Dept Pharmaceut Chem, Lawrence, KS 66047 USA.
   [Sayeed, Eddy] Int AIDS Vaccine Initiat, 125 Broad St,9th Floor, New York, NY 10004 USA.
   [Robinson, David] Robinson Vaccines & Biol LLC, New York, NY USA.
   [van den Worm, Sjoerd; Diemer, Geoffrey S.; Perez, Wilma; Caposio, Patrizia; Frueh, Klaus] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW185th Ave, Beaverton, OR 97006 USA.
   [Robinson, David] Bill & Melinda Gates Fdn, 500 Fifth Ave North, Seattle, WA 98109 USA.
   [van den Worm, Sjoerd] Batavia Biosci, Zernikedreef 16, NL-2333 CL Leiden, Netherlands.
   [Diemer, Geoffrey S.] Vir Biotechnol, 4640 SW Macadam Ave, Portland, OR 97239 USA.
RP Volkin, DB (reprint author), Multidisciplinary Res Bldg,2030 Becker Dr, Lawrence, KS 66047 USA.
EM volkin@ku.edu
FU Bill and Melinda Gates FoundationGates Foundation
FX This work was funded by the Bill and Melinda Gates Foundation.
CR Abad-Fernandez M, 2019, CURR OPIN HIV AIDS, V14, P137, DOI [10.1097/COH.0000000000000524, 10.1097/coh.0000000000000524]
   Anderholm KM, 2016, DRUGS, V76, P1625, DOI 10.1007/s40265-016-0653-5
   Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P1, DOI 10.2277/ 0521827140
   Barouch DH, 2014, NAT REV MICROBIOL, V12, P765, DOI 10.1038/nrmicro3360
   Bernstein HH, 2007, PEDIATRICS, V119, pE1299, DOI 10.1542/peds.2006-2283
   Bresnahan WA, 2000, P NATL ACAD SCI USA, V97, P14506, DOI 10.1073/pnas.97.26.14506
   Burke CJ, 1999, CRIT REV THER DRUG, V16, P1
   Cantrell SR, 2006, J VIROL, V80, P6188, DOI 10.1128/JVI.02676-05
   Caposio P, 2019, CHARACTERIZATI UNPUB
   Dolan A, 2004, J GEN VIROL, V85, P1301, DOI 10.1099/vir.0.79888-0
   Fu T-M, 2019, European Patent Specification, Patent No. [EP325170081, 325170081]
   GALDIERO F, 1979, ARCH VIROL, V59, P99, DOI 10.1007/BF01317899
   Hahn G, 2004, J VIROL, V78, P10023, DOI 10.1128/JVI.78.18.10023-10033.2004
   Hansen LJJ, 2015, VACCINE, V33, P5507, DOI 10.1016/j.vaccine.2015.08.085
   Hansen SG, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2607
   Hansen SG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210252
   Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473
   Hansen SG, 2016, SCIENCE, V351, P714, DOI 10.1126/science.aac9475
   Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519
   Hansen SG, 2013, SCIENCE, V340, P940, DOI 10.1126/science.1237874
   Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003
   Harrington KJ, 2017, ONCOTARGETS THER, V10, P3867, DOI 10.2147/OTT.S133699
   Kamerzell TJ, 2011, ADV DRUG DELIVER REV, V63, P1118, DOI 10.1016/j.addr.2011.07.006
   Kartoglu U, 2014, EXPERT REV VACCINES, V13, P843, DOI 10.1586/14760584.2014.923761
   Keefer MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041936
   Knezevic I, 2009, BIOLOGICALS, V37, P357, DOI 10.1016/j.biologicals.2009.08.004
   Kumru OS, 2018, J PHARM SCI-US, V107, P2764, DOI 10.1016/j.xphs.2018.07.010
   Kumru OS, 2015, J PHARM SCI-US, V104, P485, DOI 10.1002/jps.24211
   Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007
   Liska Vladimir, 2007, J Immune Based Ther Vaccines, V5, P4, DOI 10.1186/1476-8518-5-4
   Lloyd J, 2017, VACCINE, V35, P2115, DOI 10.1016/j.vaccine.2016.11.097
   Marshall E, 2019, SCI TRANSL MED
   Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052
   McVoy MA, 2013, CLIN INFECT DIS, V57, pS196, DOI 10.1093/cid/cit587
   Murphy E, 2003, P NATL ACAD SCI USA, V100, P14976, DOI 10.1073/pnas.2136652100
   Olsen D, 2005, PROTEIN EXPRES PURIF, V40, P346, DOI 10.1016/j.pep.2004.11.016
   Patel A, 2018, VACCINE, V36, P3169, DOI 10.1016/j.vaccine.2017.04.086
   PIERCE JS, 1974, J VIROL, V13, P1030, DOI 10.1128/JVI.13.5.1030-1036.1974
   Reisinger KS, 2019, VACCINE, V37, P5788, DOI 10.1016/j.vaccine.2018.01.089
   Rexroad J, 2006, J PHARM SCI-US, V95, P237, DOI 10.1002/jps.20496
   Rodrigues GA, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-018-2554-7
   Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287
   Varnum SM, 2004, J VIROL, V78, P10960, DOI 10.1128/JVI.78.20.10960-10966.2004
   VONKA V, 1966, J BACTERIOL, V91, P221, DOI 10.1128/JB.91.1.221-226.1966
   Wan Y, 2018, J PHARM SCI-US, V107, P1540, DOI 10.1016/j.xphs.2018.01.027
   Wiggan O, 2011, VACCINE, V29, P7456, DOI 10.1016/j.vaccine.2011.07.054
   Wolfe J, 2001, INT J REFRIG, V24, P438, DOI 10.1016/S0140-7007(00)00027-X
NR 47
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6696
EP 6706
DI 10.1016/j.vaccine.2019.09.027
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300017
PM 31548012
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Cutrell, JB
   Drechsler, H
   Bedimo, R
   Alvarez, CA
   Mansi, IA
AF Cutrell, James B.
   Drechsler, Henning
   Bedimo, Roger
   Alvarez, Carlos A.
   Mansi, Ishak A.
TI Statin use and medically attended acute respiratory illness among
   influenza vaccine recipients
SO VACCINE
LA English
DT Article
DE Statin; Influenza vaccine; Medically attended acute respiratory illness
ID MORTALITY; VIRUS; TRIALS; RISK
AB Background: Previous studies have suggested that statins decrease influenza vaccine effectiveness and increase risk of medically attended acute respiratory illness (MAARI).
   Objectives: To examine the association of incident statin use and MAARI in a cohort of influenza vaccine recipients.
   Methods: This retrospective cohort study evaluated influenza vaccine recipients within the Tricare population. The primary outcome compared MAARI incidence during the follow-up period in a propensity score-matched cohort of incident statin users and statin non-users. Secondary analysis included propensity score-adjusted comparisons between incident statin users and statin non-users in the entire cohort and prespecified sub-cohorts with and without comorbidities. The propensity score was derived from 72 variables encompassing demographics, medical history, comorbidities, medication use, and healthcare utilization.
   Results: MAARI incidence in statin users was similar to non-users in the propensity score-matched cohort (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.84-1.01). In contrast, statin users with lower comorbidity had lower OR for MAARI compared to non-users (Charlson Score zero cohort: 0.85 [CI 0.74-0.98]; No Diabetes cohort: 0.88 [CI 0.80-0.96]).
   Conclusion: Incident statin use was not associated with increased MAARI incidence and may be associated with lower incidence of MAARI in those with less comorbidity. This study thus offers reassurance regarding the effectiveness of the influenza vaccine in statin users. Published by Elsevier Ltd.
C1 [Cutrell, James B.; Drechsler, Henning; Bedimo, Roger; Mansi, Ishak A.] VA North Texas Hlth Care Syst, Med Serv, Dallas, TX 75216 USA.
   [Cutrell, James B.; Drechsler, Henning; Bedimo, Roger] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Infect Dis & Geog Med, Dallas, TX USA.
   [Alvarez, Carlos A.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, 5920 Forest Pk, Dallas, TX USA.
   [Alvarez, Carlos A.; Mansi, Ishak A.] Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, Dallas, TX 75390 USA.
   [Mansi, Ishak A.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
RP Mansi, IA (reprint author), VA North Texas Hlth Care Syst, 4500 S Lancaster Rd, Dallas, TX 75216 USA.
EM James.Cutrell@va.gov; Henning.Drechsler@va.gov; Roger.Bedimo@va.gov;
   Carlos.Alvarez@ttuhsc.edu; ishak.mansi@va.gov
FU UT Southwestern Center for Patient-Centered Outcomes Research [AHRQ R24
   HS022418]; VA Health Services Research and Development ServiceUS
   Department of Veteran Affairs [IK6 HX002608-01]
FX This work was supported in part by resources from the North Texas VA
   Healthcare System, University of Texas Southwestern Medical Center,
   Dallas, TX, and the UT Southwestern Center for Patient-Centered Outcomes
   Research (AHRQ R24 HS022418) and VA Health Services Research and
   Development Service (IK6 HX002608-01).
CR Abeles AM, 2006, ARTHRITIS RHEUM-US, V54, P393, DOI 10.1002/art.21521
   Atmar RL, 2016, J INFECT DIS, V213, P1211, DOI 10.1093/infdis/jiv459
   Baxter R, 2010, VACCINE, V28, P7267, DOI 10.1016/j.vaccine.2010.08.088
   Belongia EA, 2009, J INFECT DIS, V199, P159, DOI 10.1086/595861
   Black S, 2016, J INFECT DIS, V213, P1224, DOI 10.1093/infdis/jiv456
   Brassard P, 2017, PHARMACOEPIDEM DR S, V26, P63, DOI 10.1002/pds.4112
   Brett SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018120
   Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Elixhauser A, 2012, CLIN CLASSIFICATIONS
   FDA Drug Safety Communication, 2011, NEW RESTR CONTR DOS
   Frost FJ, 2007, CHEST, V131, P1006, DOI 10.1378/chest.06-1997
   Hak E, 2005, ARCH INTERN MED, V165, P274, DOI 10.1001/archinte.165.3.274
   Halloran ME, 2003, AM J EPIDEMIOL, V158, P305, DOI 10.1093/aje/kwg163
   Hansen BB, 2004, J AM STAT ASSOC, V99, P609, DOI 10.1198/016214504000000647
   Hansen BB, 2008, STAT SCI, V23, P219, DOI 10.1214/08-STS254
   Havers FP, 2018, CLIN INFECT DIS
   Ho DE, 2007, POLIT ANAL, V15, P199, DOI 10.1093/pan/mpl013
   Ho Daniel E., 2011, J STAT SOFTW, V42, P1, DOI DOI 10.18637/JSS.V042.I08
   Izurieta HS, 2018, CLIN INFECT DIS, V67, P378, DOI 10.1093/cid/ciy100
   Kugler J, 2011, MILITARY HLTH SYSTEM
   Kwong JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008087
   Lilly SM, 2014, AM J CARDIOL, V114, P1035, DOI 10.1016/j.amjcard.2014.07.010
   Luhrman S, 2008, INTERFACE CONTROL DO
   Mann DM, 2010, ANN PHARMACOTHER, V44, P1410, DOI 10.1345/aph.1P150
   Mansi I, 2015, AM J MED SCI, V350, P330, DOI 10.1097/MAJ.0000000000000527
   Mansi I, 2013, EXPERT OPIN DRUG SAF, V12, P327, DOI 10.1517/14740338.2013.779667
   Mascitelli L, 2016, J INFECT DIS, V213, P1857, DOI 10.1093/infdis/jiw055
   McLean HQ, 2016, J INFECT DIS, V214, P1150, DOI 10.1093/infdis/jiw335
   Omer SB, 2016, J INFECT DIS, V213, P1216, DOI 10.1093/infdis/jiv457
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Thoemmes F, PROPENSITY SCORE MAT
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Vandermeer ML, 2012, J INFECT DIS, V205, P13, DOI 10.1093/infdis/jir695
   Walsh EE, 2012, J INFECT DIS, V205, P1, DOI 10.1093/infdis/jir693
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6707
EP 6713
DI 10.1016/j.vaccine.2019.09.024
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300018
PM 31543418
DA 2020-05-12
ER

PT J
AU Lin, YL
   Lin, Z
   He, F
   Hu, ZJ
   Zimet, GD
   Alias, H
   Wong, L
AF Lin, Yulan
   Lin, Zheng
   He, Fei
   Hu, Zhijian
   Zimet, Gregory D.
   Alias, Haridah
   Wong, Li Ping
TI Factors influencing intention to obtain the HPV vaccine and
   acceptability of 2-, 4-and 9-valent HPV vaccines: A study of
   undergraduate female health sciences students in Fujian, China
SO VACCINE
LA English
DT Article
DE HPV vaccination; Female students; China; Acceptance of 2-, 4-and
   9-valent HPV vaccines
ID HUMAN-PAPILLOMAVIRUS VACCINE; CERVICAL-CANCER; WOMEN
AB Background: Little research has been conducted on the intention to obtain HPV vaccine now that the vaccine is approved for use in China. Acceptance of the three HPV vaccines, which differ in valency and price, has never been investigated.
   Methods: An online cross-sectional survey assessing female undergraduate students' intention to obtain the HPV vaccine and their acceptability of 2-, 4- and 9-valent HPV vaccines (2vHPV, 4vHPV, and 9vHPV, respectively).
   Results: Of a total of 997 complete responses, 55.2% reported intent to obtain the HPV vaccine. Some of the significant factors exerting influence on intent to obtain HPV vaccination were high knowledge score (OR =1.469, 95% CI:1.087-1.987), perceived high risk of HPV infection (OR =1.466, 95%CI:1.017-2.114), perception of no serious side effects (OR = 1.562, 95%CI:1.150-2.121), and mass media exposure to HPV vaccination information (OR = 2.196, 95%CI:1.625-2.966). Socioeconomic status indicators did not significantly influence intent to obtain the HPV vaccine. A higher proportion of respondents were willing to pay for 2vHPV (78.6%) and 4vHPV (68.0%) compared with 9vHPV (49.3%). Socioeconomic status indicators were the strongest correlates of acceptability for all the three vaccines. Exposure to mass media reporting about HPV vaccination is the factor which exerts the most influence on acceptance of 9vHPV after socioeconomic status indicators.
   Conclusions: It is important to improve knowledge and health beliefs, and to establish a mass media marketing strategy to promote HPV vaccination in order to enhance HPV vaccine uptake. Undergraduate female students should be provided with detailed information about the different valency vaccine choices to help them make informed decisions about immunization. (C) 2019 Published by Elsevier Ltd.
C1 [Lin, Yulan; Lin, Zheng; He, Fei; Hu, Zhijian] Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fujian Prov Key Lab Environm Factors & Canc, Fuzhou 350108, Fujian, Peoples R China.
   [Lin, Yulan; Lin, Zheng; He, Fei; Hu, Zhijian] Fujian Med Univ, Minist Educ Gastrointestinal Canc, Key Lab, Fuzhou 350108, Fujian, Peoples R China.
   [Zimet, Gregory D.] Indiana Univ, Sch Med, Dept Pediat, 410 W,10th St,HS 1001, Indianapolis, IN 46202 USA.
   [Alias, Haridah] Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia.
   [Wong, Li Ping] Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia.
RP Hu, ZJ (reprint author), Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fujian Prov Key Lab Environm Factors & Canc, Fuzhou 350108, Fujian, Peoples R China.; Wong, L (reprint author), Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia.
EM huzhijian@fjmu.edu.cn; wonglp@ummc.edu.my
RI Lin, Yulan/AAL-8091-2020; Wong, Li Ping/B-2782-2010
OI Wong, Li Ping/0000-0002-0107-0532; Lin, Yulan/0000-0002-4208-9408;
   Zimet, Gregory/0000-0003-3835-937X; Lin, Zheng/0000-0001-5242-716X
FU Natural Science Foundation of Fujian Province - Fujian Science and
   Technology Committee, China [2018J01825]; Cultivation Program for
   Distinguished Young Scholar in Fujian Province University - Education
   Department of Fujian Province, China [20178020]; Fujian Medical
   University's Research Foundation for Talented Scholars - Fujian Medical
   University, China [XRCZX2017012]; National Key R&D Program of China -
   Ministry of Education of the People's Republic of China [2017YFC0907100]
FX This work was supported by the following grants: 1) Natural Science
   Foundation of Fujian Province (Grant No. 2018J01825), funded by Fujian
   Science and Technology Committee, China; 2) Cultivation Program for
   Distinguished Young Scholar in Fujian Province University (Grant No.
   20178020), funded by The Education Department of Fujian Province, China;
   3) Fujian Medical University's Research Foundation for Talented Scholars
   (Grant No. XRCZX2017012), funded by Fujian Medical University, China;
   and 4) National Key R&D Program of China (Grant No. 2017YFC0907100),
   funded by Ministry of Education of the People's Republic of China.
CR Baloch Z, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903370
   Becker M.H., 1974, HLTH ED MONOGRAPHS, V2, P324, DOI DOI 10.1177/109019817400200401
   Buang SN, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4602
   Champion VL, 2008, HLTH BEHAV HLTH ED T, P45
   Chen LH, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818775356
   Cheung T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198615
   Ferris DG, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3947
   Geng Y, 2019, HUM VACC IMMUNOTHER, V15, P1884, DOI 10.1080/21645515.2019.1611159
   He JY, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0619-8
   Hoque ME, 2013, ASIAN PAC J CANCER P, V14, P4865, DOI 10.7314/APJCP.2013.14.8.4865
   Hosmer DW, 1989, APPL LOGISTIC REGRES
   Palmer T, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1161
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   SLOMSKI A, 2015, JAMA-J AM MED ASSOC, V313, P1609, DOI DOI 10.1001/JAMA
   Song BB, 2017, CHINESE J CANCER RES, V29, P471, DOI 10.21147/j.issn.1000-9604.2017.06.01
   Wang J, 2019, HUM VACC IMMUNOTHER, V15, P1889, DOI 10.1080/21645515.2019.1578598
   Wang SM, 2014, ASIAN PAC J CANCER P, V15, P3239, DOI 10.7314/APJCP.2014.15.7.3239
   Wang T, 2015, CHINESE MED J-PEKING, V128, P3298, DOI 10.4103/0366-6999.171420
   Wong LP, 2019, HUM VACC IMMUNOTHER, V15, P1533, DOI 10.1080/21645515.2019.1611157
   Zhang J, 2018, CHIN J DIS CONTR PRE, V22, p[99, 105]
   Zhang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-2045-8
   Zhao FH, 2019, LANCET, V393, P969, DOI 10.1016/S0140-6736(18)32849-6
   Zhao XL, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e30
   Zhou HL, 2018, J INFECTION, V76, P522, DOI 10.1016/j.jinf.2018.02.008
   Zhou M, 2019, HUM VACC IMMUNOTHER, V15, P1688, DOI 10.1080/21645515.2018.1547605
NR 25
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6714
EP 6723
DI 10.1016/j.vaccine.2019.09.026
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300019
PM 31548016
DA 2020-05-12
ER

PT J
AU Abdi, I
   Menzies, R
   Seale, H
AF Abdi, Ikram
   Menzies, Robert
   Seale, Holly
TI Barriers and facilitators of immunisation in refugees and migrants in
   Australia: an east-African case study
SO VACCINE
LA English
DT Article
DE Immunisation; Refugees; Migrants; Africa; Barriers; Vaccine
ID HEALTH-CARE; CHALLENGES; REMINDERS; CHILDREN; ACCESS; IMPACT
AB Background: Immunisation programs available in low and middle-income countries include fewer vaccines in comparison to Australia's National Immunisation Program. As a result, refugees and migrants may have a heightened risk of being inadequately immunised upon arrival to Australia. Several studies have suggested that East African immigrants have low vaccination coverage. As such, the aim of this study was to explore the underlying attitudes, barriers and facilitators to immunisation in east African communities in two states of Australia: New South Wales and Victoria.
   Methods: A qualitative study involving 17 semi-structured, in-depth interviews were undertaken with East African refugees and migrants living in two states of Australia: New South Wales and Victoria. These refugees and migrants were from four key East African countries: Kenya, Somalia, Ethiopia and South Sudan. Thematic analysis was undertaken to analyse and interpret the results.
   Results: Language barriers, low risk perception and a lack of education were the key barriers identified by participants. Facilitators mentioned included the development of resources in participants' languages and the implementation of reminder systems consistently across all GP practices. There was also a unanimous agreement amongst participants that community organisations need to play a greater role in the dissemination of information about immunisation.
   Conclusions: Further research needs to be undertaken with regards to how education about immunisation is delivered and disseminated to refugee and migrant communities. Current findings also support the need to improve the health literacy of refugees and migrants by providing culturally and linguistically appropriate resources in participants' respective languages. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abdi, Ikram; Menzies, Robert; Seale, Holly] Univ New South Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW 2052, Australia.
RP Abdi, I (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, UNSW Med, Sydney, NSW 2052, Australia.
EM i.abdi@unsw.edu.au; r.menzies@unsw.edu.au; h.seale@unsw.edu.au
OI Menzies, Rob/0000-0003-3833-5765; Seale, Holly/0000-0002-1877-5395;
   Abdi, Ikram/0000-0003-0636-3200
CR Zoni AC, 2019, HUM VACC IMMUNOTHER, V15, P102, DOI 10.1080/21645515.2018.1520585
   EPI team of Somalia, 2011, EXP PROGR IMM MULT P
   Health A.G.D.o, 2017, FREE CATCH UP VACC R
   Health A.G.-D.o, FREE CATCH UP VACC 1
   Kpozehouen E, 2017, AUST NZ J PUBL HEAL, V41, P118, DOI 10.1111/1753-6405.12602
   LaFond A., 1993, DEV PRACTICE, V3, P27
   Lawn S.t. C. Joy, 2006, WHO BEHALF PARTNERSH
   Leder K, 2006, CLIN INFECT DIS, V43, P1185, DOI 10.1086/507893
   Lee SK, 2013, HEALTH PROMOT J AUST, V24, P98, DOI 10.1071/HE12919
   Mahimbo A, 2017, VACCINE, V35, P5148, DOI 10.1016/j.vaccine.2017.08.002
   McKeary M, 2010, J REFUG STUD, V23, P523, DOI 10.1093/jrs/feq038
   McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3
   Menzies RI, 2017, MED J AUSTRALIA, V206, P1, DOI 10.5694/mja16.00811
   Mupandawana ET, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0209-x
   Murray Sally B, 2005, Aust Health Rev, V29, P25
   NCIRS, 2017, NO JAB NO PAY
   Neale A, 2007, AUST NZ J PUBL HEAL, V31, P333, DOI 10.1111/j.1753-6405.2007.00081.x
   Paxton GA, 2011, J PAEDIATR CHILD H, V47, P888, DOI 10.1111/j.1440-1754.2011.02099.x
   Refugee Health Network, 2016, CATCH UP IMM REF AS
   Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120
   Sackey DM, 2018, INT J INTEGR CARE, V18, DOI 10.5334/ijic.s1079
   Schmitt HJ, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-11
   Seale H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1479-1
   Sheikh-Mohammed M, 2006, MED J AUSTRALIA, V185, P594, DOI 10.5694/j.1326-5377.2006.tb00721.x
   Skull SA, 2008, J IMMIGR MINOR HEALT, V10, P263, DOI 10.1007/s10903-007-9071-9
   Smith J, 2009, HEALTH PROMOT J AUST, V20, P77
   STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426
   Stockwell MS, 2012, AM J PUBLIC HEALTH, V102, pE15, DOI 10.2105/AJPH.2011.300331
   Tomlinson N, 2013, DIVERS EQUAL HLTH CA, V10, P101
   UNESCO, 2014, MIGR MIGR
   UNHCR (UN High Comm. Refug.), 2010, CONV PROT REL STAT R
   van der Veen YJJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-674
   Vivier PM, 2000, ARCH PEDIAT ADOL MED, V154, P1243, DOI 10.1001/archpedi.154.12.1243
   (WHO), 2018, WHO 3 DOS DIPHTH TOX
   Wilson L, 2018, VACCINE, V36, P1055, DOI 10.1016/j.vaccine.2018.01.025
   Wolff ER, 2014, J AM BOARD FAM MED, V27, P458, DOI 10.3122/jabfm.2014.04.130275
NR 36
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6724
EP 6729
DI 10.1016/j.vaccine.2019.09.025
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300020
PM 31537444
DA 2020-05-12
ER

PT J
AU Rieckmann, A
   Meyle, KD
   Rod, NH
   Baker, JL
   Benn, CS
   Aaby, P
   Sorup, S
AF Rieckmann, Andreas
   Meyle, Kathrine Damm
   Rod, Naja Hulvej
   Baker, Jennifer Lyn
   Benn, Christine Stabell
   Aaby, Peter
   Sorup, Signe
TI Smallpox and BCG vaccination in childhood and cutaneous malignant
   melanoma in Danish adults followed from 18 to 49 years
SO VACCINE
LA English
DT Article
DE Bacillus Calmette-Guerin vaccine; Cancer; Cutaneous malignant melanoma;
   Heterologous immunity; Non-specific effects of vaccines; Smallpox
   vaccine; Vaccinia
ID VACCINIA; COHORT; RISK; IMMUNOTHERAPY; REGISTER
AB Background: Early smallpox and Bacillus Calmette-Guerin (BCG) vaccinations have been associated with reduced risk of cutaneous malignant melanoma (CMM). We assessed the association between pre-school smallpox vaccination and early-school BCG vaccination and CMM in a young Danish population.
   Methods: We conducted a register-based case-cohort study of individuals growing up during the phase-out period of smallpox and BCG vaccination in Denmark (born 1965-1976) utilising the decrease in vaccination during this period. Information on childhood vaccinations and potential confounders from Copenhagen school health records were linked with nationwide registers on cancer (CMM diagnoses), migrations and deaths by personal identification numbers.
   Results: The individuals were followed from age 18 until 31/12/2014 (maximum age at end of follow-up, 49 years). 188 cases of CMM occurred in the background population of 46,239 individuals; 172 CMM cases (91%) had full information and were analysed. The adjusted hazard ratio (HR) for CMM by BCG and/or smallpox vaccination compared with neither vaccine was 1.29 (95% confidence interval (CI) 0.72-2.31). For smallpox vaccination only, HR = 1.23 (95% CI 0.53-2.86) for BCG vaccination only, HR = 1.13 (95% CI 0.61-2.09) and for both smallpox and BCG vaccination, HR =1.75 (95% CI 0.87-3.48) compared with none of these. Vaccination below the age of one year gave similar results.
   Conclusions: We found no strong beneficial effect of smallpox and BCG vaccination against CMM among young adult Danes and with broad confidence intervals our data alone could be compatible with both modest preventive effects, no effects, and modest harmful effects. Our estimates do not contradict a potential modest beneficial effect of neonatal vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rieckmann, Andreas; Sorup, Signe] Statens Serum Inst, Bandim Hlth Project, Res Ctr Vitamins & Vaccines CVIVA, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
   [Rieckmann, Andreas; Benn, Christine Stabell] Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, OPEN, Odense, Denmark.
   [Rieckmann, Andreas; Rod, Naja Hulvej] Univ Copenhagen, Dept Publ Hlth, Sect Epidemiol, Copenhagen, Denmark.
   [Meyle, Kathrine Damm; Baker, Jennifer Lyn] Bispebjerg & Frederiksberg Hosp, Ctr Clin Res & Prevent, Copenhagen, Denmark.
   [Baker, Jennifer Lyn] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Sect Metab Genet, Copenhagen, Denmark.
   [Aaby, Peter] Indepth Network, Band Hlth Project, Apartado 861, Bissau, Guinea Bissau.
   [Sorup, Signe] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark.
RP Rieckmann, A (reprint author), Statens Serum Inst, Bandim Hlth Project, Res Ctr Vitamins & Vaccines CVIVA, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM anri@ssi.dk
OI Rieckmann, Andreas/0000-0001-8695-2376; Sorup,
   Signe/0000-0003-1942-683X; Aaby, Peter/0000-0001-8331-1389
FU Danish National Research Foundation (DNRF)Danmarks Grundforskningsfond
   [DNRF108]; Danish Cancer SocietyDanish Cancer Society
   [R146-A9534-16-52]; Danish Council for Independent ResearchDet Frie
   Forskningsrad (DFF) [DFF - 4183-00316]; European Research Council under
   the European UnionEuropean Research Council (ERC) [281419]
FX The Danish National Research Foundation (DNRF) supports the Research
   Center for Vitamins and Vaccines [DNRF108]. AR was funded by the Danish
   Cancer Society [R146-A9534-16-52]. SS holds a grant from the Danish
   Council for Independent Research [DFF - 4183-00316]. KDM and JLB were
   funded by the European Research Council under the European Union's
   Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no.
   281419 to JLB.
CR Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041
   Baker JL, 2011, SCAND J PUBLIC HEALT, V39, P87, DOI 10.1177/1403494810390727
   Baker JL, 2009, INT J EPIDEMIOL, V38, P656, DOI 10.1093/ije/dyn164
   Barlow WE, 1999, J CLIN EPIDEMIOL, V52, P1165, DOI 10.1016/S0895-4356(99)00102-X
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Bay C, 2015, CANCER EPIDEMIOL, V39, P1, DOI 10.1016/j.canep.2014.10.010
   Benn CS, 2016, EBIOMEDICINE, V10, P312, DOI 10.1016/j.ebiom.2016.07.016
   FENNER F, 1988, SMALLPOX ITS ERADICA
   Gandini S, 2016, J DERMATOL SCI, V84, P137, DOI 10.1016/j.jdermsci.2016.07.009
   Gjerstorff ML, 2011, SCAND J PUBLIC HEALT, V39, P42, DOI 10.1177/1403494810393562
   Grange J, 2009, MED J AUST
   GRANGE JM, 1990, TUBERCLE, V71, P61, DOI 10.1016/0041-3879(90)90063-E
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   HUNTERCRAIG I, 1970, BMJ-BRIT MED J, V2, P512, DOI 10.1136/bmj.2.5708.512
   Jensen CB, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008628
   Krone B, 2005, EUR J CANCER, V41, P104, DOI 10.1016/j.ejca.2004.08.010
   Krone B, 2003, EUR J CANCER, V39, P2372, DOI 10.1016/S0959-8049(03)00625-7
   Krone B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-595
   Mastrangelo G, 2009, VACCINE, V27, P588, DOI 10.1016/j.vaccine.2008.10.076
   Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965
   Pedersen SA, 2018, EPIDEMIOLOGY, V29, P442, DOI 10.1097/EDE.0000000000000802
   Pfahlberg A, 2002, J INVEST DERMATOL, V119, P570, DOI 10.1046/j.1523-1747.2002.00643.x
   Plesner A M, 1994, Ugeskr Laeger, V156, P7497
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Rieckmann A, 2016, INT J EPIDEMIOL, V46
   ROENIGK HH, 1974, ARCH DERMATOL, V109, P668, DOI 10.1001/archderm.109.5.668
   ROSENBERG SA, 1976, MED CLIN N AM, V60, P419, DOI 10.1016/S0025-7125(16)31889-2
   Rosenthal S R, 1986, Dev Biol Stand, V58 ( Pt A), P401
   Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37
   Sorup S, 2011, INT J EPIDEMIOL, V40, P955, DOI 10.1093/ije/dyr063
   Stewart JH, 2011, EXPERT REV ANTICANC, V11, P1671, DOI [10.1586/era.11.163, 10.1586/ERA.11.163]
   TAN JKL, 1993, J DERMATOL SURG ONC, V19, P985, DOI 10.1111/j.1524-4725.1993.tb00989.x
   The National Health Service of Denmark, MED REP KINGD DENM 1
   Vallgarda S., 2003, FOLKESUNDHED SOM POL
   VANGINNEKEN V, 2016, J FISHSCI COM, V10, P1
   Xue XN, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-88
NR 36
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6730
EP 6736
DI 10.1016/j.vaccine.2019.09.023
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300021
PM 31537447
DA 2020-05-12
ER

PT J
AU Small, RD
   Ozol-Godfrey, A
   Yan, LH
AF Small, Robert D.
   Ozol-Godfrey, Ayca
   Yan, Lihan
TI On the use of nonparametric tests for comparing immunological Reverse
   Cumulative distribution curves (RCDCs)
SO VACCINE
LA English
DT Article
DE Distribution; Normality assumption; Rank-based test; Survival; Vaccine
ID ANTIBODY CONCENTRATIONS; VACCINE; IMMUNOGENICITY; COMBINATION
AB Reverse Cumulative Distribution Curves (RCDCs) have proven to be a useful tool in summarizing immune response profiles in vaccine studies since their introduction by Reed, Meade, and Steinhoff (RMS) (1995). They are able to display virtually all of the treatment data and characterize summary statistics such as means or even their confidence intervals (CIs) that might be obscure. RMS mentioned their similarity to survival curves often used to summarize time-to-event data which are usually not normally distributed. The RCDCs, while intuitively pleasing and useful, contain important properties which allow for more powerful statistical applications. In this paper, we will suggest several widely used rank-based tests to compare the curves in the context of vaccine studies. These rank-based tests allow for comparisons between treatments, for stratified analyses, weighted analyses, and other modifications that make them the alternative of parametric analyses without the normality assumptions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Small, Robert D.] RDS Stat Consulting LLC, Tampa, FL USA.
   [Ozol-Godfrey, Ayca] Sunovion Pharmaceut Inc, Marlborough, MA 01752 USA.
   [Yan, Lihan] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
RP Ozol-Godfrey, A (reprint author), Sunovion Pharmaceut Inc, Marlborough, MA 01752 USA.
EM ayca.ozol-godfrey@sunovion.com
CR Ball LK, 2001, CLIN INFECT DIS, V33, pS299, DOI 10.1086/322578
   de Bruyn G, 2016, VACCINE, V34, P2170, DOI 10.1016/j.vaccine.2016.03.028
   Gorse GJ, 2015, VACCINE, V33, P1151, DOI 10.1016/j.vaccine.2015.01.025
   HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991
   Henckaerts I, 2006, CLIN VACCINE IMMUNOL, V13, P356, DOI 10.1128/CVI.13.3.356-360.2006
   HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510
   Kalbfleisch J. D., 2002, STAT ANAL FAILURE TI
   Lachenbruch P A, 2004, J Biopharm Stat, V14, P275, DOI 10.1081/BIP-120037179
   Lehmann EL, 2009, J NONPARAMETR STAT, V21, P397, DOI 10.1080/10485250902842727
   Mehrotra DV, 2010, AM STAT, V64, P121, DOI 10.1198/tast.2010.08121
   Nauta J, 2010, STATISTICS IN CLINICAL VACCINE TRIALS, P1, DOI 10.1007/978-3-642-14691-6_1
   Nauta JJP, 2009, BIOLOGICALS, V37, P216, DOI 10.1016/j.biologicals.2009.02.002
   O'Brien KL, 2007, J INFECT DIS, V196, P104, DOI 10.1086/518438
   REED GF, 1995, PEDIATRICS, V96, P600
   Saul A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000850
   SCHOENFELD D, 1981, BIOMETRIKA, V68, P316, DOI 10.2307/2335833
   Schuerman L, 2011, CLIN VACCINE IMMUNOL, V18, P2161, DOI 10.1128/CVI.05313-11
   TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156
   VANELTEREN P, 1960, B INT STATIST INST, V37, P351
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6737
EP 6742
DI 10.1016/j.vaccine.2019.09.007
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300022
PM 31537446
DA 2020-05-12
ER

PT J
AU Giles, ML
   Buttery, J
   Davey, MA
   Wallace, E
AF Giles, Michelle L.
   Buttery, Jim
   Davey, Mary-Ann
   Wallace, Euan
TI Pregnant women's knowledge and attitude to maternal vaccination
   including group B streptococcus and respiratory syncytial virus vaccines
SO VACCINE
LA English
DT Article
DE Vaccine; Immunisation; RSV; GBS; Pregnant
ID ACELLULAR PERTUSSIS VACCINATION; INFLUENZA IMMUNIZATION;
   CLINICAL-TRIALS; SYSTEMATIC ANALYSIS; DISEASE WORLDWIDE; YOUNG-CHILDREN;
   HEALTHY WOMEN; INFANTS; SAFETY; TETANUS
AB Background: Maternal immunisation is an important strategy to reduce neonatal mortality and morbidity. New maternal vaccines such as Respiratory Syncytial Virus (RSV) and Group B streptococcus (GBS) are in development and/or clinical trials. However, little is known about pregnant women's knowledge about these diseases.
   Methods: Women attending antenatal clinics in Melbourne, Australia were invited to complete a questionnaire collecting demographic information, past vaccination history, understanding of risk of GBS and RSV disease in pregnancy and likelihood to accept these theoretical vaccines in the future.
   Findings: 495 women (48% born outside of Australia, from 48 different countries) completed the questionnaire. A large number of women had never heard of GBS (63%) or RSV (83%). Women over 35 years, born in Australia and women who had more than one child were more likely to have heard of GBS or RSV (p < 0.001). Women who had received influenza or pertussis vaccine in pregnancy were more likely to accept a RSV or GBS vaccine (p < 0.001).
   Conclusions: This study has shown that knowledge of GBS and RSV is poor. However, when provided with information about the two diseases, acceptance of a hypothetical vaccine for both diseases was high. This study highlights the enormous amount of work that needs to be done in educating pregnant women about the seriousness of these two diseases if a future vaccine is ever to be accepted and high coverage achieved among the target population. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Giles, Michelle L.; Davey, Mary-Ann; Wallace, Euan] Monash Univ, Ritchie Ctr, Monash Med Ctr, Dept Obstet & Gynaecol, 246 Clayton Rd, Clayton, Vic 3168, Australia.
   [Giles, Michelle L.] Monash Hlth, Womens & Childrens Hlth, 246 Clayton Rd, Clayton, Vic 3168, Australia.
   [Buttery, Jim] Monash Univ, Sch Publ Hlth & Prevent Med, 246 Clayton Rd, Clayton, Vic 3168, Australia.
   [Buttery, Jim] Monash Univ, Dept Pediat, 246 Clayton Rd, Clayton, Vic 3168, Australia.
   [Giles, Michelle L.; Buttery, Jim] Monash Hlth, Monash Immunisat, 246 Clayton Rd, Clayton, Vic 3168, Australia.
RP Giles, ML (reprint author), Monash Univ, Ritchie Ctr, Monash Med Ctr, Dept Obstet & Gynaecol, 246 Clayton Rd, Clayton, Vic 3168, Australia.
EM michelle.giles@monash.edu
OI Giles, Michelle/0000-0003-3007-1822
CR Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559
   [Anonymous], 2018, IMM PREGN WOM
   [Anonymous], 2013, AUSTR IMM HDB
   [Anonymous], 2018, UPD IMM PREGN TET TO
   Baker CJ, 1999, J INFECT DIS, V179, P142, DOI 10.1086/314574
   Baker CJ, 2004, J INFECT DIS, V189, P1103, DOI 10.1086/382193
   Baker CJ, 2003, VACCINE, V21, P3468, DOI 10.1016/S0264-410X(03)00353-0
   Baker CJ, 2003, J INFECT DIS, V188, P66, DOI 10.1086/375536
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Bellido-Blasco J, 2017, EURO SURVEIL, V22
   Byrne L, 2018, ARCH DIS CHILD, V103, P224, DOI 10.1136/archdischild-2016-311802
   Centers for Disease Control and Prevention, 2013, UPD REC US TET TOX R
   Centers for Disease Control and Prevention, 2010, MMWR, V59
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Dempsey AF, 2014, VACCINE, V32, P2463, DOI 10.1016/j.vaccine.2014.02.089
   Edmond KM, 2012, LANCET, V379, P547, DOI 10.1016/S0140-6736(11)61651-6
   Fleming JA, 2018, VACCINE, V36, P4054, DOI 10.1016/j.vaccine.2018.05.096
   Heyderman RS, 2016, LANCET INFECT DIS, V16, P546, DOI 10.1016/S1473-3099(15)00484-3
   Jones CE, 2016, VACCINE, V34, P5998, DOI 10.1016/j.vaccine.2016.07.032
   Jones CE, 2016, VACCINE, V34, P6007, DOI 10.1016/j.vaccine.2016.07.007
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Krishnaswamy S, 2018, HUM VACC IMMUNOTHER, V14, P1591, DOI 10.1080/21645515.2018.1445455
   Krishnaswamy S, 2017, EUR J OBSTET GYN R B, V216, P159, DOI 10.1016/j.ejogrb.2017.07.031
   Le Doare K, 2017, CLIN INFECT DIS, V65, pS143, DOI 10.1093/cid/cix654
   Leroux-Roels G, 2016, VACCINE, V34, P1786, DOI 10.1016/j.vaccine.2016.02.044
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P857, DOI 10.1080/21645515.2015.1101524
   Madhi SA, 2016, LANCET INFECT DIS, V16, P923, DOI 10.1016/S1473-3099(16)00152-3
   Maertens K, 2016, VACCINE, V34, P5785, DOI 10.1016/j.vaccine.2016.09.055
   Malek A, 1996, AM J REPROD IMMUNOL, V36, P248
   McQuaid F, 2018, ACTA OBSTET GYN SCAN, V97, P330, DOI 10.1111/aogs.13288
   McQuaid F, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010790
   Moreno-Perez D, 2017, ANALESDEPEDIATRIA, V88, pe9
   Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Public Health England, 2017, PERT VACC PROGR PREG
   Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/ror.0.0040081
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Wiley KE, 2015, QUAL HEALTH RES, V25, P360, DOI 10.1177/1049732314551061
   Winter K, 2017, CLIN INFECT DIS, V64, P9, DOI 10.1093/cid/ciw633
   World Health Organization, 2012, WEEKLY EPIDEMIOLOGIC, P201
   World health organization, 2017, MAT NEON TET EL
   2012, EV THREAT ANT RES, P1
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6743
EP 6749
DI 10.1016/j.vaccine.2019.08.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300023
PM 31540809
DA 2020-05-12
ER

PT J
AU Mostafapour, M
   Meyer, SB
   Scholer, A
AF Mostafapour, Mehrnaz
   Meyer, Samantha B.
   Scholer, Abigail
TI Exploring the effect of risk and benefit information provision on
   vaccination decision-making
SO VACCINE
LA English
DT Article
DE Perceived risk; Perceived benefit; Information; Vaccination
ID WEB 2.0; PREDICTORS
AB In the era in which people are bombarded with misinformation about vaccination, research regarding the degree to which various types of risk or benefit information affect perceptions of vaccines and intentions to vaccinate is critical. The present research utilizes a robust methodology to quantify the extent to which risk and benefit information affects vaccination intentions. Our work demonstrates an inverse relationship between the perceived risks and benefits of a vaccine. By providing information about either risks or benefits of a vaccine, our findings suggest that we can change one's perception of both the risks and benefits of the vaccine. Considering that the main cognitive barriers to vaccination are related to concerns about efficacy and safety, our results suggest that vaccine messages can be framed to address the audience's main concerns, whether it be about the low efficacy of the vaccine or its safety, knowing that both frames would carry similar outcomes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mostafapour, Mehrnaz; Meyer, Samantha B.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
   [Scholer, Abigail] Univ Waterloo, Dept Psychol, Waterloo, ON, Canada.
RP Mostafapour, M (reprint author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
EM M3mostaf@uwaterloo.ca; samantha.meyer@uwaterloo.ca;
   ascholer@uwaterloo.ca
FU Office of Research Ethics at the University of Waterloo [21792]
FX This research received ethics clearance from the Office of Research
   Ethics at the University of Waterloo under the file number 21792. There
   was no conflict of interest between the researchers conducting this
   research or the source of funding and the subject of the research.
CR ALHAKAMI AS, 1994, RISK ANAL, V14, P1085, DOI 10.1111/j.1539-6924.1994.tb00080.x
   Attwell K, 2017, J BIOETHIC INQ, V14, P65, DOI 10.1007/s11673-016-9756-7
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Bond L, 1998, AUST NZ J PUBL HEAL, V22, P441, DOI 10.1111/j.1467-842X.1998.tb01411.x
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Chapman GB, 1999, PREV MED, V29, P249, DOI 10.1006/pmed.1999.0535
   Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118
   Finucane ML, 2000, J BEHAV DECIS MAKING, V13, P1, DOI 10.1002/(SICI)1099-0771(200001/03)13:1<1::AID-BDM333>3.0.CO;2-S
   Finucane ML, 2000, AFFECT HEURISTIC JUD, V17, P1
   Hobson-West P, 2003, HEALTH RISK SOC, V5, P273, DOI 10.1080/13698570310001606978
   Hochbaum G, 1952, HLTH BELIEF MODEL, DOI [10.1037/10519-035, DOI 10.1037/10519-035]
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Kevin Kunzmann, 2017, MD MAGAZINE
   Myers MG, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P255, DOI 10.1016/B978-0-12-369408-9.00017-2
   Osgood C. E., 1957, MEASUREMENT MEANING
   Slovic P., 1987, SCIENCE
   Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0
   Witteman HO, 2012, VACCINE, V30, P3734, DOI 10.1016/j.vaccine.2011.12.039
   World Health Organization, 2013, 6 COMM MISC IMM
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 22
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6750
EP 6759
DI 10.1016/j.vaccine.2019.08.083
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300024
PM 31558328
DA 2020-05-12
ER

PT J
AU McNeil, MM
   Paradowska-Stankiewicz, I
   Miller, ER
   Marquez, PL
   Seshadri, S
   Collins, LC
   Cano, MV
AF McNeil, Michael M.
   Paradowska-Stankiewicz, Iwona
   Miller, Elaine R.
   Marquez, Paige L.
   Seshadri, Srihari
   Collins, Limone C., Jr.
   Cano, Maria, V
TI Adverse events following adenovirus type 4 and type 7 vaccine, live,
   oral in the Vaccine Adverse Event Reporting System (VAERS), United
   States, October 2011-July 2018
SO VACCINE
LA English
DT Article
DE Adverse event; Epidemiology; Adenovirus vaccine; Surveillance; Vaccine
   safety; Hereditary Neuropathy with Liability to Pressure Palsy
ID ACUTE RESPIRATORY-DISEASE; GUILLAIN-BARRE-SYNDROME; US MILITARY
   RECRUITS; LARGE EPIDEMIC; DOUBLE-BLIND; SAFETY; ILLNESS; SURVEILLANCE;
   INFECTIONS; GUIDELINES
AB Background: In March 2011, the U.S. Food and Drug Administration licensed adenovirus type 4 and type 7 vaccine, live, oral (Barr Labs, Inc.) (adenovirus vaccine) for use in military personnel 17 through 50 years of age. The vaccine was first universally administered to U.S. military recruits in October 2011. We investigated adverse event (AE) reports following the adenovirus vaccine submitted to the Vaccine Adverse Event Reporting System (VAERS).
   Methods: We searched the VAERS database for U.S. reports among persons who received adenovirus vaccine during October 2011 through July 2018 including participants in a military observational study. We reviewed all serious reports and accompanying medical records. We compared the proportion of serious reports in a proxy military recruit population and reviewed all reports of suspected allergic reactions following adenovirus vaccination.
   Results: During the analytic period, VAERS received 100 reports following adenovirus vaccination; 39 (39%) were classified as serious and of these, 17 (44%) were from the observational study. One death was reported. Males accounted for 72% of reports. Median age of vaccinees was 19 years (range 17-32). The most frequently reported serious AEs were Guillain Barre syndrome (GBS) (n = 12) and anaphylaxis (n = 8); of these, two GBS and all the anaphylaxis reports were reported in the observational study. Reports documented concurrent receipt of multiple other vaccines (95%) and penicillin G (IM Pen G) or other antibiotics (50%).
   Conclusions: The reporting rate for serious AEs was higher than with other vaccines administered in the comparison military recruit population (39% vs 18%); however, we identified no unexpected or concerning pattern of adenovirus vaccine AEs, Co-administration of vaccines and IM Pen G was commonly reported in this military population. These exposures may have contributed to the GBS and anaphylaxis outcomes observed with the adenovirus vaccine. Future adenovirus vaccine safety studies in a population without these co-administrations would be helpful in clarifying the vaccine's safety profile. Published by Elsevier Ltd.
C1 [McNeil, Michael M.; Paradowska-Stankiewicz, Iwona; Miller, Elaine R.; Marquez, Paige L.; Cano, Maria, V] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Div Healthcare Qual Promot, NCZEID, Atlanta, GA 30329 USA.
   [Seshadri, Srihari; Collins, Limone C., Jr.] Def Hlth Agcy, Immunizat Healthcare Div, Publ Hlth Div, Falls Church, VA 22042 USA.
   [Paradowska-Stankiewicz, Iwona] Natl Inst Publ Hlth, Natl Inst Hyg, Warsaw, Poland.
RP McNeil, MM (reprint author), CDC, 1600 Clifton Rd NE,MS V18-4, Atlanta, GA 30329 USA.
EM mmm2@cdc.gov
FU CDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA
FX This study was supported solely by the CDC and no external funding was
   secured.
CR Adenoviruses Foy H., 1997, VIRAL INFECT HUMANS, P119
   [Anonymous], 2014, BUMEDINST 6220 8B RE
   Bhattacharya S, 2010, J ADV PHARM TECHNOL, V1, P11
   Chance PF, 2006, NEUROMOL MED, V8, P159, DOI 10.1385/NMM:8:1:159
   Choudhry A, 2016, VACCINE, V34, P4558, DOI 10.1016/j.vaccine.2016.07.033
   DUDDING BA, 1973, AM J EPIDEMIOL, V97, P187, DOI 10.1093/oxfordjournals.aje.a121499
   Food and Drug Administration, 1997, FED REGISTER, V62, P52252
   Food and Drug Administration, AD TYP 4 TYP 7 VACC
   Gray GC, 2000, CLIN INFECT DIS, V31, P663, DOI 10.1086/313999
   Gray GC, 2007, CLIN INFECT DIS, V45, P1120, DOI 10.1086/522188
   HILLEMAN MR, 1957, AM J HYG, V66, P29, DOI 10.1093/oxfordjournals.aje.a119882
   Horowitz SH, 2004, J NEUROL NEUROSUR PS, V75, P1629, DOI 10.1136/jnnp.2003.029314
   Kolavic-Gray SA, 2002, CLIN INFECT DIS, V35, P808, DOI 10.1086/342573
   Kuschner RA, 2013, VACCINE, V31, P2963, DOI 10.1016/j.vaccine.2013.04.035
   Lyons A, 2008, VACCINE, V26, P2890, DOI 10.1016/J.vaccine.2008.03.037
   McNeill KM, 2000, EMERG INFECT DIS, V6, P415, DOI 10.3201/eid0604.000419
   PACINI DL, 1987, J INFECT DIS, V156, P920, DOI 10.1093/infdis/156.6.920
   Perugula Malathi, 2017, J Clin Neuromuscul Dis, V18, P228, DOI 10.1097/CND.0000000000000145
   Potter RN, 2012, EMERG INFECT DIS, V18, P507, DOI 10.3201/eid1803.111238
   Radin JM, 2014, CLIN INFECT DIS, V59, P962, DOI 10.1093/cid/ciu507
   Rhee EG, 2009, DOUGLAS BENNETTS PRI, P1797
   Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   Russell KL, 2006, VACCINE, V24, P2835, DOI 10.1016/j.vaccine.2005.12.062
   Ryan MAK, 2002, CLIN INFECT DIS, V34, P577, DOI 10.1086/338471
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6760
EP 6767
DI 10.1016/j.vaccine.2019.08.087
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300025
PM 31548014
DA 2020-05-12
ER

PT J
AU Costantino, V
   Trent, M
   MacIntyre, CR
AF Costantino, Valentina
   Trent, Mallory
   MacIntyre, C. Raina
TI Modelling of optimal timing for influenza vaccination as a function of
   intraseasonal waning of immunity and vaccine coverage
SO VACCINE
LA English
DT Article
DE Vaccine efficacy waning; Influenza control; Vaccine effectiveness;
   Outbreak response; Vaccination timing
ID PROTECTION; AUSTRALIA; DURATION; EFFICACY; DISEASE; SEASONS; COST
AB The influenza season in Australia usually peaks in August. Vaccination is recommended beginning in March-April. Recent studies suggest that vaccine effectiveness may wane over a given influenza season, leading to reduced effectiveness at the peak of the season. We aimed to quantify how changes in timing of influenza vaccination and declining vaccine coverage could change the percentages of prevented cases.
   Results from a systematic review were used to inform calculation of a waning function over time from vaccination. Age specific notification data and vaccine effectiveness and coverage estimates from 2007 to 2016 (2009 influenza pandemic year excluded) were used to model a new notification series where vaccine effectiveness is shifted in time to account for delayed vaccination by month from March to August. A sensitivity analysis was done on possible vaccine coverage changes and considering time gap between vaccine uptake and recommendation.
   Delaying vaccination from March to end of May prevents more cases over a season, but the variation in cases prevented by month of vaccination is not large. If delaying vaccination results in missed or forgotten vaccination and decrease coverage, delaying vaccination could have a net negative impact. Furthermore, considering a time gap between recommendation and uptake, earlier recommendation is more effective in preventing cases. The results are sensitive to assumptions of intra-seasonal waning of effectiveness. More research is required on intra-seasonal vaccine effectiveness waning and the effect of delayed vaccination on overall uptake to inform any potential changes to current vaccine scheduling recommendations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Costantino, Valentina; Trent, Mallory; MacIntyre, C. Raina] Univ New South Wales, Fac Med, Kirby Inst, Biosecur Program, Sydney, NSW, Australia.
   [MacIntyre, C. Raina] Arizona State Univ, Coll Publ Serv & Community Solut, Tempe, AZ 85287 USA.
RP Costantino, V (reprint author), Unit 4-81a Birriga Rd, Sydney, NSW 2023, Australia.
EM v.costantino@unsw.edu.au; mallory.trent@unsw.edu.au;
   r.macintyre@unsw.edu.au
FU Seqirus Australia
FX This research has been funded from Seqirus Australia, the funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Australian Government Department of Health, 2017, NAT IMM PROGR SCHED
   Australian Government Department of Health, 2015, AUSTR IMM HDB
   Australian Government Department of Health, 2017, INFL SEAS AUSTR SUMM
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052
   BERTOLAZZI M, 2019, PLOS ONE, V11, DOI DOI 10.3390/FI11080173
   Carville KS, 2015, VACCINE, V33, P341, DOI 10.1016/j.vaccine.2014.11.019
   Center for Disease Control and Prevention, 2017, INFL SEAS VACC COV R
   Chen C, 2018, VACCINE, V36, P1265, DOI 10.1016/j.vaccine.2018.01.052
   Dey A, 2016, COMMUN DIS INTELL, V40, pS1
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816
   Fielding JE, 2016, VACCINE, V34, P4905, DOI 10.1016/j.vaccine.2016.08.067
   Fisman DN, 2017, LANCET PUBLIC HEALTH, V2, pE57, DOI 10.1016/S2468-2667(17)30004-X
   Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078
   Kelly HA, 2013, INFLUENZA OTHER RESP, V7, P729, DOI 10.1111/irv.12018
   Kissling E, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.16.30201
   Kissling E, 2013, EURO SURVEILL, V18
   Lee VJ, 2018, INFLUENZA OTHER RESP, V12, P3, DOI 10.1111/irv.12533
   Li-Kim-Moy J, 2016, COMMUN DIS INTELL, V40, pE482
   Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064
   Muscatello DJ, 2017, WEST PAC SURVEILL RE, V8, DOI 10.5365/wpsar.2017.8.2.002
   Newall AT, 2008, VACCINE, V26, P2135, DOI 10.1016/j.vaccine.2008.01.051
   Newall AT, 2008, VACCINE, V26, P6818, DOI 10.1016/j.vaccine.2008.09.086
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pebody RG, 2013, EURO SURVEIL, V18
   Petrie JG, 2016, J INFECT DIS, V214, P1142, DOI 10.1093/infdis/jiw105
   Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035
   Qazi U, 2019, VACCINE, V37, P4618, DOI 10.1016/j.vaccine.2018.01.044
   Radin JM, 2016, VACCINE, V34, P3907, DOI 10.1016/j.vaccine.2016.05.034
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Sharma S, 2017, COMMUN DIS INTELL, V41, pE49
   Sheridan SL, 2018, MED J AUSTRALIA, V209, P110, DOI 10.5694/mja18.00334
   Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226
   Ss G, 2014, J MED VIROL, V86, P1017
   Sullivan SG, 2016, EPIDEMIOL INFECT, V144, P2317, DOI 10.1017/S0950268816000819
   Sullivan SG, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.43.17-00707
   Surveillance W.P.R.G.I., 2012, PLOS ONE, V7
   World Health Organization, 2018, INFL SEAS FACT SHEET
   Young B, 2018, J INFECT DIS, V217, P731, DOI 10.1093/infdis/jix632
   Young B, 2017, VACCINE, V35, P212, DOI 10.1016/j.vaccine.2016.11.013
NR 41
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6768
EP 6775
DI 10.1016/j.vaccine.2019.08.069
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300026
PM 31521411
DA 2020-05-12
ER

PT J
AU Asada, H
AF Asada, Hideo
TI VZV-specific cell-mediated immunity, but not humoral immunity,
   correlates inversely with the incidence of herpes zoster and the
   severity of skin symptoms and zoster-associated pain: The SHEZ study
SO VACCINE
LA English
DT Review
ID VARICELLA-ZOSTER; POSTHERPETIC NEURALGIA; ADHERENCE HEMAGGLUTINATION;
   VIRUS-ANTIGEN; ANTIBODY; RESPONSES; PATHOGENESIS; PREVENTION; VACCINE;
   ADULTS
AB Onset of herpes zoster (HZ) is thought to be related to a decline in cell-mediated immunity (CMI). However, until recently, there have been no large-scale prospective studies on the relationship between varicella-zoster virus (VZV)-specific CMI and the onset and severity of HZ. The Japanese researchers conducted a cohort study on VZV immunity in a population living on an island cluster, Shozu County in Japan, and examined the people who developed HZ during a follow-up period of three years to clarify the relationship between the onset and severity of HZ and immunity. In this study, they focused on the relationship between cell-mediated and humoral immunity and the onset and severity of HZ. CMI was measured by VZV skin test, and humoral immunity was assessed with serological tests for VZV-specific antibodies. A total of 12,522 people over the age of 50 were enrolled in this study, and 401 registrants were diagnosed as HZ. VZV-specific CMI assessed by VZV skin test showed a significant inverse relationship with the incidence of HZ and the severity of skin lesions and acute and subacute pain, and with the occurrence of postherpetic neuralgia. In contrast, VZV-specific antibody titer was not associated with the incidence and severity of HZ. These results suggest that VZV-specific CMI, but not humoral immunity, plays a key role in controlling the onset of HZ, the severity of skin lesions, and zoster-associated pain. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Asada, Hideo] Nara Med Univ, Dept Dermatol, Sch Med, Nara, Japan.
RP Asada, H (reprint author), Nara Med Univ, Dept Dermatol, Sch Med, Nara, Japan.
FU Japanese Ministry of Health, Labour and WelfareMinistry of Health,
   Labour and Welfare, Japan [KHC1102]; Research Foundation for Microbial
   Diseases of Osaka University
FX This work was supported by Grants-in-Aid for Scientific Research from
   the Japanese Ministry of Health, Labour and Welfare for Research on
   Publicly Essential Drugs and Medical Devices (fiscal year 2008-2010)
   [KHC1102] and for Public-private Sector Joint Research on Publicly
   Essential Drugs (fiscal year 2011-2012) [KHC1102], as well as research
   funds from the Research Foundation for Microbial Diseases of Osaka
   University.
CR Asada H, 2013, J DERMATOL SCI, V69, P243, DOI 10.1016/j.jdermsci.2012.10.015
   Ban J, 2017, EPIDEMIOL INFECT, V145, P1270, DOI 10.1017/S0950268816003174
   BERGER R, 1981, INFECT IMMUN, V32, P24, DOI 10.1128/IAI.32.1.24-27.1981
   BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291
   Coplan PM, 2004, J PAIN, V5, P344, DOI 10.1016/j.jpain.2004.06.001
   GERSHON AA, 1976, P SOC EXP BIOL MED, V151, P762, DOI 10.3181/00379727-151-39302
   GROSE C, 1981, PEDIATRICS, V68, P735
   Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Imoto K, 2015, J DERMATOL SCI, V79, P235, DOI 10.1016/j.jdermsci.2015.05.011
   KALTER ZG, 1977, J INFECT DIS, V135, P1010, DOI 10.1093/infdis/135.6.1010
   Ku CC, 2005, J VIROL, V79, P2651, DOI 10.1128/JVI.79.5.2651-2658.2005
   Mims C, 1984, VIRAL PATHOGENESIS I
   Nakamura Y, 2016, J AM ACAD DERMATOL, V75, P950, DOI 10.1016/j.jaad.2016.05.037
   Okuno Y, 2013, EPIDEMIOL INFECT, V141, P706, DOI 10.1017/S0950268812002671
   Okuno Y, 2014, J CLIN THERAPEUT MED, V30, P905
   Opstelten W, 2007, PAIN, V132, pS52, DOI 10.1016/j.pain.2007.02.004
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   PROVOST PJ, 1991, VACCINE, V9, P111, DOI 10.1016/0264-410X(91)90266-9
   Sadaoka K, 2008, J INFECT DIS, V198, P1327, DOI 10.1086/592219
   Shirane R, 2017, J MED VIROL, V89, P313, DOI 10.1002/jmv.24629
   Takahashi M, 2003, VACCINE, V21, P3845, DOI 10.1016/S0264-410X(03)00303-7
   Takao Y, 2018, AM J EPIDEMIOL, V187, P251, DOI 10.1093/aje/kwx249
   Takao Y, 2015, J EPIDEMIOL, V25, P617, DOI 10.2188/jea.JE20140210
   Takao Y, 2012, J EPIDEMIOL, V22, P167, DOI 10.2188/jea.JE20110035
   Tang HM, 2012, J CLIN VIROL, V55, P46, DOI 10.1016/j.jcv.2012.06.008
   Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9
   Toyama N, 2009, J MED VIROL, V81, P2053, DOI 10.1002/jmv.21599
   Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611
   YAMADA A, 1979, BIKEN J, V22, P55
NR 30
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 16
PY 2019
VL 37
IS 44
BP 6776
EP 6781
DI 10.1016/j.vaccine.2019.09.031
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JK5OS
UT WOS:000494893300027
PM 31543415
DA 2020-05-12
ER

PT J
AU Silveira, MM
   McBride, AJ
   Trotter, CL
AF Silveira, Marcelle Moura
   McBride, Alan Ja
   Trotter, Caroline L.
TI Health impact and cost-effectiveness of introducing the vaccine
   (Bexsero) against MenB disease into the Brazilian immunization programme
SO VACCINE
LA English
DT Article
DE Meningococcal disease serogroup B; Vaccination program;
   Cost-effectiveness; Brazil
ID B MENINGOCOCCAL DISEASE; EPIDEMIOLOGIC IMPACT; MENINGITIS; INFANTS
AB Invasive meningococcal disease (IMD) is associated with a high mortality and severe sequelae. The aim of the present study was to evaluate the potential cost-effectiveness of the Bexsero vaccine in Brazil. We used a cohort model to compare routine vaccination against MenB disease with no vaccination. Epidemiological and cost estimates were obtained from the Brazilian Health Information System. The cost per disability-adjusted life year (DALY) averted and incremental cost-effectiveness ratio (ICER) was estimated assuming a 3-dose vaccination schedule, at R$90 ( pound 20.50) per vaccine dose, 82.0% vaccine efficacy against MenB disease and a vaccine uptake of 90.0%. We estimated that 1,527 MenB cases would be prevented and 78 deaths averted. This strategy would cost R$ 762,381, 000 ( pound 174,059,503) with a R$ 4,364,280 ( pound 996,410) reduction in disease treatment costs. However, at an ICER of 372,256 ( pound 84,990) per DALY averted, a vaccination programme is unlikely to be cost-effective. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Silveira, Marcelle Moura; McBride, Alan Ja] Univ Fed Pelotas, Technol Dev Ctr, Biotechnol Unit, Pelotas, RS, Brazil.
   [McBride, Alan Ja] Minist Hlth, Oswaldo Cruz Fdn, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Silveira, Marcelle Moura; Trotter, Caroline L.] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Cambridge, England.
RP Silveira, MM (reprint author), Univ Fed Pelotas, Biotechnol Unit, Campus Univ S-N, BR-96010900 Pelotas, RS, Brazil.
EM marcellemsilveira@gmail.com
RI McBride, Alan/D-4106-2012
OI McBride, Alan/0000-0001-9682-540X; Trotter, Caroline/0000-0003-4000-2708
FU Brazilian CAPES/PDSE [88881.136034/2017-01]
FX This work was supported by Brazilian CAPES/PDSE [MMS, grant number
   88881.136034/2017-01].
CR Andrade AL, 2017, VACCINE, V35, P2025, DOI 10.1016/j.vaccine.2017.03.010
   Christensen H, 2017, VACCINE, V35, P208, DOI 10.1016/j.vaccine.2016.11.076
   Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004
   Sartori AMC, 2016, VACCINE, V34, P1531, DOI 10.1016/j.vaccine.2016.02.026
   de Soarez PC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130217
   de Soarez PC, 2011, VALUE HEALTH, V14, P1019, DOI 10.1016/j.jval.2011.05.045
   Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7
   Gasparini R, 2016, HUM VACC IMMUNOTHER, V12, P2148, DOI 10.1080/21645515.2016.1160177
   Lecocq H, 2016, VACCINE, V34, P2240, DOI 10.1016/j.vaccine.2016.03.020
   Lemos APS, 2006, J MED MICROBIOL, V55, P751, DOI 10.1099/jmm.0.46451-0
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Pouwels KB, 2013, HUM VACC IMMUNOTHER, V9, P1129, DOI 10.4161/hv.23888
   Ruttimann RW, 2014, PEDIATR INFECT DIS J, V33, P284, DOI 10.1097/INF.0000000000000228
   Safadi MA, 2015, EXPERT REV VACCINES, V14, P505, DOI 10.1586/14760584.2015.979799
   Safadi MAP, 2017, VACCINE, V35, P2052, DOI 10.1016/j.vaccine.2017.03.002
   Sartori AMC, 2012, VACCINE, V30, P7489, DOI 10.1016/j.vaccine.2012.10.056
   Strelow VL, 2016, ARQ NEURO-PSIQUIAT, V74, P875, DOI [10.1590/0004-282x20160143, 10.1590/0004-282X20160143]
   Tirani M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123383
   Toneatto D, 2017, EXPERT REV VACCINES, V16, P433, DOI 10.1080/14760584.2017.1308828
   Trotter CL, 2006, MED DECIS MAKING, V26, P38, DOI 10.1177/0272989X05284109
   Tu HAT, 2014, VACCINE, V32, P5436, DOI 10.1016/j.vaccine.2014.07.096
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6783
EP 6786
DI 10.1016/j.vaccine.2019.09.062
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800001
PM 31570182
DA 2020-05-12
ER

PT J
AU van Zandvoort, K
   Checchi, F
   Diggle, E
   Eggo, RM
   Gadroen, K
   Mulholland, K
   McGowan, CR
   de Waroux, OL
   Rao, VB
   Satzke, C
   Flasche, S
AF van Zandvoort, Kevin
   Checchi, Francesco
   Diggle, Emma
   Eggo, Rosalind M.
   Gadroen, Kartini
   Mulholland, Kim
   McGowan, Catherine R.
   de Waroux, Olivier le Polain
   Rao, V. Bhargavi
   Satzke, Catherine
   Flasche, Stefan
TI Pneumococcal conjugate vaccine use during humanitarian crises
SO VACCINE
LA English
DT Review
DE Pneumococcal conjugate vaccine; Humanitarian crises; Humanitarian
   health; Refugees; Internally displaced people; Vaccination strategy;
   Pneumonia
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; COST-EFFECTIVENESS; CHILDREN; REFUGEE;
   EPIDEMIOLOGY; EMERGENCIES; POPULATIONS; PREVENTION
AB Streptococcus pneumoniae is a common human commensal that causes a sizeable part of the overall childhood mortality in low income settings. Populations affected by humanitarian crises are at especially high risk, because a multitude of risk factors that are enhanced during crises increase pneumococcal transmission and disease severity. Pneumococcal conjugate vaccines (PCVs) provide effective protection and have been introduced into the majority of routine childhood immunisation programmes globally, though several barriers have hitherto limited their uptake during humanitarian crises. When PCV coverage cannot be sustained during crises or when PCV has not been part of routine programmes, mass vaccination campaigns offer a quick acting and programmatically feasible bridging solution until services can be restored. However, we currently face a paucity of evidence on which to base the structure of such campaigns. We believe that, now that PCV can be procured at a substantially reduced price through the Humanitarian Mechanism, this lack of information is a remaining hurdle to PCV use in humanitarian crises. Considering the difficulties in conducting research in crises, we propose an evidence generation pathway consisting of primary data collection in combination with mathematical modelling followed by quasiexperimental evaluation of a PCV intervention, which can inform on optimal vaccination strategies that consider age targeting, dosing regimens and impact duration. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [van Zandvoort, Kevin; Checchi, Francesco; Eggo, Rosalind M.; Mulholland, Kim; de Waroux, Olivier le Polain; Flasche, Stefan] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [van Zandvoort, Kevin; Eggo, Rosalind M.; de Waroux, Olivier le Polain; Flasche, Stefan] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London, England.
   [Diggle, Emma; McGowan, Catherine R.] Save Children UK, London, England.
   [Gadroen, Kartini] Med Sans Frontieres, Amsterdam, Netherlands.
   [Gadroen, Kartini] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands.
   [Mulholland, Kim; Satzke, Catherine] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Vic, Australia.
   [McGowan, Catherine R.] London Sch Hyg & Trop Med, Dept Publ Hlth Environm & Soc, London, England.
   [de Waroux, Olivier le Polain] UK Publ Hlth Rapid Support Team, London, England.
   [Rao, V. Bhargavi] Med Sans Frontieres MSF UK, Manson Unit, London, England.
   [de Waroux, Olivier le Polain] Publ Hlth England, London, England.
RP van Zandvoort, K (reprint author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
EM Kevin.Van-Zandvoort@lshtm.ac.uk
RI Satzke, Catherine/D-6501-2013
OI Satzke, Catherine/0000-0003-3164-8849; Eggo, Rosalind
   M/0000-0002-0362-6717; van Zandvoort, Kevin/0000-0002-7770-0537;
   McGowan, Catherine/0000-0001-6941-6539; le Polain de Waroux,
   Olivier/0000-0003-3458-2945
FU Elrha's Research for Health in Humanitarian Crises (R2HC) Programme; UK
   Government (DFID); Wellcome TrustWellcome Trust; UK National Institute
   for Health Research (NIHR)National Institute for Health Research (NIHR);
   Sir Henry Dale Fellowship - Wellcome Trust [208812/Z/17/Z]; Sir Henry
   Dale Fellowship - Royal Society [208812/Z/17/Z]; HDR UK Innovation
   Fellowship [MR/S003975/1]; Australian NHMRC Career Development
   FellowshipNational Health and Medical Research Council of Australia
   [1087957]; Veski Inspiring Women Fellowship; Victorian Government's
   Operational Infrastructure Support Program; National Institute for
   Health ResearchNational Institute for Health Research (NIHR); Department
   of Health and Social Care
FX KvZ, FC, CS and KM are supported by Elrha's Research for Health in
   Humanitarian Crises (R2HC) Programme, which aims to improve health
   outcomes by strengthening the evidence base for public health
   interventions in humanitarian crises. The R2HC programme is funded by
   the UK Government (DFID), the Wellcome Trust, and the UK National
   Institute for Health Research (NIHR).; SF was supported by a Sir Henry
   Dale Fellowship jointly funded by the Wellcome Trust and Royal Society
   (grant number 208812/Z/17/Z). RME acknowledges funding from an HDR UK
   Innovation Fellowship (grant MR/S003975/1).; CS is supported by an
   Australian NHMRC Career Development Fellowship (1087957) and a Veski
   Inspiring Women Fellowship. MCRI is supported by the Victorian
   Government's Operational Infrastructure Support Program.; The UK Public
   Health Rapid Support Team is funded by the National Institute for Health
   Research and the Department of Health and Social Care. The views
   expressed are those of the authors and not necessarily those of the NIHR
   or DHSC.
CR Ager A, 2014, SCIENCE, V345, P1290, DOI 10.1126/science.1254164
   Akramuzzaman SM, 2000, AM J EPIDEMIOL, V151, P723, DOI 10.1093/oxfordjournals.aje.a010267
   Althouse BM, 2017, EPIDEMIOL INFECT, V145, P2750, DOI 10.1017/S095026881700125X
   Andrejko K, 2017, WHO TECHNICAL EXPERT
   Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527
   Bellos A., 2012, VACCINATION HUMANITA
   Bellos Anna, 2010, Confl Health, V4, P3, DOI 10.1186/1752-1505-4-3
   Bernal JAL, 2019, CLIN INFECT DIS, V68, P1769, DOI 10.1093/cid/ciy906
   Blanchet K, 2017, LANCET, V390, P2287, DOI 10.1016/S0140-6736(16)30768-1
   Bruhn CAW, 2017, P NATL ACAD SCI USA, V114, P1524, DOI 10.1073/pnas.1612833114
   Checchi F, 2007, PUBLIC HLTH CRISIS A
   Checchi F, 2017, LANCET, V390, P2297, DOI 10.1016/S0140-6736(17)30702-X
   Choi YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043418
   Close RM, 2016, VACCINE, V34, P4649, DOI 10.1016/j.vaccine.2016.08.025
   Cohuet S, 2017, BIORXIV101101121665, V18, DOI [10.1101/121665, DOI 10.1101/121665]
   Coldiron ME, 2018, EMERG INFECT DIS, V24, P1720, DOI 10.3201/eid2409.171058
   Collins DA, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0038-x
   Cooper BS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006807
   Crellen Thomas, 2018, Wellcome Open Res, V3, P134, DOI 10.12688/wellcomeopenres.14868.2
   Croicu M, 2017, UCDP GED CODEBOOK VE
   Lima EJD, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0695-6
   de Lima Pereira Alan, 2018, PLoS Curr, V10, DOI 10.1371/currents.dis.bb5f22928e631dff9a80377309381feb
   De Waroux OL, 2018, HUM VACC IMMUNOTHER, V14, P1939, DOI 10.1080/21645515.2018.1467201
   De Waroux OL, 2015, PEDIATR INFECT DIS J, V34, P858, DOI 10.1097/INF.0000000000000717
   Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529
   Dueger EL, 2008, INT J INFECT DIS, V12, P289, DOI 10.1016/j.ijid.2007.09.001
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   File TM, 2008, CLIN INFECT DIS, V47, pS157, DOI 10.1086/591398
   Finger F, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1288-7
   Finger F, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002509
   Flasche S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0882-9
   Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181
   Gargano LM, 2017, VACCINE, V35, P435, DOI 10.1016/j.vaccine.2016.11.070
   Gargano LM, 2015, PREHOSP DISASTER MED, V30, P402, DOI 10.1017/S1049023X15004781
   Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0
   Grabenstein JD, 2018, PLOTKINS VACCINES
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   Havumaki J, 2019, EPIDEMIOLOGY, DOI [10.1101/514406, DOI 10.1101/514406]
   Heudtlass P, 2016, CONFL HEALTH, V10, DOI 10.1186/s13031-016-0082-9
   Heymann DL, 2006, CURR TOP MICROBIOL, V304, P1
   Klugman KP, 2014, LANCET GLOB HEALTH, V2, pE365, DOI 10.1016/S2214-109X(14)70241-4
   Klugman KP, 2018, PNEUMOCOCCAL CONJUGA
   Kucharski AJ, 2016, EMERG INFECT DIS, V22, P105, DOI 10.3201/eid2201.151410
   Lam E, 2015, HUM VACC IMMUNOTHER, V11, P2627, DOI 10.1080/21645515.2015.1096457
   Leaning J, 2001, LANCET, V357, P1432, DOI 10.1016/S0140-6736(00)04572-4
   Loughlin AM, 2014, PEDIATR INFECT DIS J, V33, P504, DOI 10.1097/INF.0000000000000279
   Medecins Sans Frontieres, 2016, NIG THER WER HARDL A
   Medecins Sans Frontieres, 2018, A7139 MED SANS FRONT
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Muthumbi E, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0041-2
   Nnadi C, 2017, J INFECT DIS, V216, pS368, DOI 10.1093/infdis/jix175
   Ojal J, 2019, LANCET GLOB HEALTH, V7, pE644, DOI 10.1016/S2214-109X(18)30562-X
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Petrosillo N, 2002, EUR J CLIN MICROBIOL, V21, P181, DOI 10.1007/s10096-001-0689-6
   Peyraud N, 2018, B WORLD HEALTH ORGAN, V96, P540, DOI 10.2471/BLT.17.204321
   Ravelo JL, 2015, DEVEX
   Reisman J, 2014, J PEDIATR INFECT DIS, V3, P104, DOI 10.1093/jpids/pit069
   SELWYN BJ, 1990, REV INFECT DIS, V12, pS870
   Silaba M, 2019, LANCET GLOB HEALTH, V7, pE337, DOI 10.1016/S2214-109X(18)30491-1
   Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10
   Singer M, 2008, CLIN INFECT DIS, V47, pS216, DOI 10.1086/591407
   Small C, 1950, J IMMUNOL BALTIM MD, V2010, P2048
   Stacey HL, 2019, HUM VACC IMMUNOTHER, V15, P530, DOI 10.1080/21645515.2018.1532249
   Sundberg R, 2013, J PEACE RES, V50, P523, DOI 10.1177/0022343313484347
   Tedijanto C, 2018, P NATL ACAD SCI USA, V115, pE11988, DOI 10.1073/pnas.1810840115
   Temple B, 2019, LANCET INFECT DIS, V19, P497, DOI 10.1016/S1473-3099(18)30734-5
   Thomas SL, 2004, BRIT MED BULL, V69, P115, DOI 10.1093/bmb/ldh009
   Toole MJ, 1997, ANNU REV PUBL HEALTH, V18, P283, DOI 10.1146/annurev.publhealth.18.1.283
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Unicef, 2018, UPD HUM MECH
   United Nations High Commissioner for Refugees, 2018, POP STAT DAT DEM
   Universite catholique de Louvain CRED, 2019, EM DAT EM EV DAT
   Varon E, 2000, CLIN INFECT DIS, V31, P477, DOI 10.1086/313981
   Weinberger DM, 2019, AM J EPIDEMIOL, V188, P160, DOI 10.1093/aje/kwy219
   World Health Organization, 2009, PER INT ROUT IMM
   World Health Organization, 2019, WKLY EPIDEMIOL REC, V94, P85
   World Health Organization, 2017, HUM MECH
   World Health Organization, 2018, OFF COUNTR REP COV E
   World Health Organization, 2017, VACC AC HUM EM FRAM
   World Health Organization, 2019, GLOB ROUT IMM STRAT
   Zhou H, 2012, EMERG INFECT DIS, V18, P294, DOI 10.3201/eid1802.102025
   Zivich PN, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0055-4
NR 82
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6787
EP 6792
DI 10.1016/j.vaccine.2019.09.038
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800002
PM 31562004
OA Other Gold, Green Published, Green Accepted
DA 2020-05-12
ER

PT J
AU Gidengil, C
   Chen, C
   Parker, AM
   Nowak, S
   Matthews, L
AF Gidengil, Courtney
   Chen, Christine
   Parker, Andrew M.
   Nowak, Sarah
   Matthews, Luke
TI Beliefs around childhood vaccines in the United States: A systematic
   review
SO VACCINE
LA English
DT Review
DE Vaccine beliefs; Vaccine hesitancy; Childhood vaccines; Systematic
   review
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HPV VACCINE; DECISION-MAKING;
   AFRICAN-AMERICAN; INFLUENZA VACCINATION; PARENTAL ACCEPTANCE; ADOLESCENT
   GIRLS; ATTITUDES; IMMUNIZATION; PERCEPTIONS
AB Background: While childhood vaccines are safe and effective, some parents remain hesitant to vaccinate their children, which has led to outbreaks of vaccine preventable diseases. The goal of this systematic review was to identify and summarize the range of beliefs around childhood vaccines elicited using open-ended questions, which are better suited for discovering beliefs compared to closed-ended questions.
   Methods: PubMed, Embase, and PsycINFO were searched using keywords for childhood vaccines, decision makers, beliefs, and attitudes to identify studies that collected primary data using a variety of open-ended questions regarding routine childhood vaccine beliefs in the United States. Study designs, population characteristics, vaccine types, and vaccine beliefs were abstracted. We conducted a qualitative analysis to conceptualize beliefs into themes and generated descriptive statistics.
   Results: Of 1727 studies identified, 71 were included, focusing largely on parents (including in general, and those who were vaccine hesitant or at risk of hesitancy). Seven themes emerged: Adverse effects was most prominent, followed by mistrust, perceived lack of necessity, pro-vaccine opinions, skepticism about effectiveness, desire for autonomy, and morality concerns. The most commonly described beliefs included that vaccines can cause illnesses; a child's immune system can be overwhelmed if receiving too many vaccines at once; vaccines contain harmful ingredients; younger children are more susceptible to vaccine adverse events; the purpose of vaccines is profit-making; and naturally developed immunity is better than that acquired from vaccines. Nearly a third of the studies exclusively assessed minority populations, and more than half of the studies examined beliefs only regarding HPV vaccine.
   Conclusions: Few studies used open-ended questions to elicit beliefs about vaccines. Many of the studies that did so, focused on HPV vaccine. Concerns about vaccine safety were the most commonly stated beliefs about childhood vaccines, likely because studies were designed to capture barriers and challenges to vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gidengil, Courtney; Matthews, Luke] RAND Corp, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA.
   [Gidengil, Courtney] Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
   [Chen, Christine] Frederick S Pardee RAND Grad Sch, 1776 Main St, Santa Monica, CA 90401 USA.
   [Chen, Christine; Nowak, Sarah] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
   [Parker, Andrew M.] RAND Corp, 4570 Fifth Ave 600, Pittsburgh, PA 15213 USA.
RP Gidengil, C (reprint author), RAND Corp, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA.
EM gidengil@rand.org; cchen@rand.org; parker@rand.org; snowak@rand.org;
   lmatthew@rand.org
OI Parker, Andrew/0000-0001-7511-0894
FU NIH/NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R21HD087749]
FX This research was supported by NIH/NICHD grant R21HD087749.
CR Alexander AB, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-192
   Allen JD, 2012, J ONCOL, DOI 10.1155/2012/401979
   [Anonymous], 2017, HLTH US 2016 CHARTB
   Bahta Lynn, 2015, Minn Med, V98, P33
   Bair RM, 2008, J PEDIATR ADOL GYNEC, V21, P329, DOI 10.1016/j.jpag.2008.02.007
   Bardenheier B, 2004, ARCH PEDIAT ADOL MED, V158, P569, DOI 10.1001/archpedi.158.6.569
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Blaisdell LL, 2016, MED DECIS MAKING, V36, P479, DOI 10.1177/0272989X15607855
   Brawner BM, 2013, HEALTH PROMOT PRACT, V14, P624, DOI 10.1177/1524839912462389
   Brunson EK, 2015, GLOB PEDIAT HLTH, V2
   Cates JR, 2012, PERSPECT SEX REPRO H, V44, P39, DOI 10.1363/4403912
   Centers for Disease Control and Prevention, 2017, REC IMM SCHED CHILDR
   Children's Hospital of Philadelphia, 2014, VACC HIST VACC AV TI
   Constantine NA, 2007, J ADOLESCENT HEALTH, V40, P108, DOI 10.1016/j.jadohealth.2006.10.007
   Dailey PM, 2017, J CANCER EDUC, V32, P516, DOI 10.1007/s13187-015-0959-0
   Dela Cruz MRI, 2017, J CANCER EDUC, V32, P613, DOI 10.1007/s13187-016-1009-2
   Do H, 2009, ASIAN PAC J CANCER P, V10, P339
   Downs JS, 2008, VACCINE, V26, P1595, DOI 10.1016/j.vaccine.2008.01.011
   Faasse K, 2016, VACCINE, V34, P5808, DOI 10.1016/j.vaccine.2016.09.029
   Fishbein M., 2011, PREDICTING CHANGING
   Fontenot HB, 2015, J ADOLESCENT HEALTH, V57, P595, DOI 10.1016/j.jadohealth.2015.09.003
   Fredrickson DD, 2004, FAM MED, V36, P431
   Galbraith-Gyan KV, 2019, ETHNIC HEALTH, V24, P323, DOI 10.1080/13557858.2017.1332758
   Garg R, 2017, MATERN CHILD HLTH J
   Gazmararian JA, 2010, CLIN PEDIATR, V49, P1018, DOI 10.1177/0009922810373946
   Getrich CM, 2014, ETHNIC HEALTH, V19, P47, DOI 10.1080/13557858.2013.857767
   Goff SL, 2011, VACCINE, V29, P7343, DOI 10.1016/j.vaccine.2011.07.082
   Gostin LO, 2011, JAMA-J AM MED ASSOC, V306, P1699, DOI 10.1001/jama.2011.1525
   Gowda C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-509
   Griffioen AM, 2012, CLIN PEDIATR, V51, P560, DOI 10.1177/0009922812443732
   Gullion JS, 2008, PUBLIC HEALTH NURS, V25, P401, DOI 10.1111/j.1525-1446.2008.00724.x
   Gust DA, 2007, HLTH ED RES, V23, P499
   Hansen CE, 2016, J CANCER EDUC, V31, P147, DOI 10.1007/s13187-014-0788-6
   Herbert NL, 2013, HEALTH EDUC RES, V28, P663, DOI 10.1093/her/cyt060
   Hughes CC, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-74
   Hull PC, 2014, GYNECOL ONCOL, V132, pS13, DOI 10.1016/j.ygyno.2014.01.046
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Joseph NP, 2012, WOMEN HEALTH ISS, V22, pE571, DOI 10.1016/j.whi.2012.09.003
   Katz IT, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3529-4
   Katz ML, 2009, VACCINE, V27, P3945, DOI 10.1016/j.vaccine.2009.04.040
   Luque JS, 2012, RURAL REMOTE HEALTH, V12, P1
   Luthy KE, 2013, J SCH NURS, V29, P95, DOI 10.1177/1059840512455365
   Luthy KE, 2012, J SCH NURS, V28, P153, DOI 10.1177/1059840511426578
   Luthy KE, 2010, PUBLIC HEALTH NURS, V27, P25, DOI 10.1111/j.1525-1446.2009.00823.x
   Maertens JA, 2017, J HEALTH COMMUN, V22, P285, DOI 10.1080/10810730.2016.1275890
   Maglione MA, 2014, PEDIATRICS, V134, P325, DOI 10.1542/peds.2014-1079
   McCauley MM, 2012, ACAD PEDIATR, V12, P375, DOI 10.1016/j.acap.2012.06.007
   Meleo-Erwin Z, 2017, HUM VACC IMMUNOTHER, V13, P1895, DOI 10.1080/21645515.2017.1321182
   Mendel-Van Alstyne JA, 2017, VACCINE
   Middleman AB, 2012, HUM VACC IMMUNOTHER, V8, P1395, DOI 10.4161/hv.21575
   Miller MK, 2014, J COMMUN HEALTH, V39, P835, DOI 10.1007/s10900-014-9858-2
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Morales-Campos DY, 2013, J ADOLESCENT HEALTH, V52, pS69, DOI 10.1016/j.jadohealth.2012.09.020
   Mullins TLK, 2015, VACCINE, V33, P3907, DOI 10.1016/j.vaccine.2015.06.060
   Niccolai LM, 2014, SEX HEALTH, V11, P274, DOI 10.1071/SH14047
   Nodulman JA, 2015, J SCHOOL HEALTH, V85, P289, DOI 10.1111/josh.12253
   Olshen E, 2005, J ADOLESCENT HEALTH, V37, P248, DOI 10.1016/j.jadohealth.2005.05.016
   Perkins RB, 2016, HUM VACC IMMUNOTHER, V12, P1528, DOI 10.1080/21645515.2015.1118594
   Perkins RB, 2014, PEDIATRICS, V134, pE666, DOI 10.1542/peds.2014-0442
   Perkins RB, 2013, CLIN PEDIATR, V52, P231, DOI 10.1177/0009922812473775
   Reich JA, 2014, GENDER SOC, V28, P679, DOI 10.1177/0891243214532711
   Rendle KA, 2017, QUAL HEALTH RES, V27, P1380, DOI 10.1177/1049732316664499
   ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803
   Roncancio AM, 2017, HEALTH EDUC RES, V32, P96, DOI 10.1093/her/cyw055
   Roncancio AM, 2019, J HEALTH PSYCHOL, V24, P453, DOI 10.1177/1359105316676627
   Saada A, 2015, CLIN PEDIATR, V54, P236, DOI 10.1177/0009922814548838
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Schmidt-Grimminger D, 2013, J CANCER EDUC, V28, P357, DOI 10.1007/s13187-013-0468-y
   Senier L, 2008, SOCIOL INQ, V78, P207, DOI 10.1111/j.1475-682X.2008.00235.x
   Shui I, 2005, J NATL MED ASSOC, V97, P657
   Sobo EJ, 2016, MED ANTHROPOL, V35, P529, DOI 10.1080/01459740.2016.1145219
   Sobo EJ, 2016, SOC SCI MED, V165, P187, DOI 10.1016/j.socscimed.2016.06.015
   Sobo EJ, 2015, MED ANTHROPOL Q, V29, P381, DOI 10.1111/maq.12214
   Thompson VLS, 2012, J HEALTH CARE POOR U, V23, P290, DOI 10.1353/hpu.2012.0007
   Vercruysse J, 2016, HUM VACC IMMUNOTHER, V12, P1606, DOI 10.1080/21645515.2016.1140289
   Viens LJ, 2016, MMWR MORB MORTAL WKL, V65
   Wakefield AJ, 1998, RETRACTED ILEAL LYMP
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
   Wang E, 2015, VACCINE, V33, P6703, DOI 10.1016/j.vaccine.2015.10.090
   Warner EL, 2015, J COMMUN HEALTH, V40, P387, DOI 10.1007/s10900-014-9949-0
   Wenger OK, 2011, PEDIATRICS, V128, P79, DOI 10.1542/peds.2009-2599
   Wentzell E, 2016, FAM COMMUNITY HEALTH, V39, P310, DOI 10.1097/FCH.0000000000000102
   Westrick SC, 2017, PAPILLOMAVIRUS RES, V3, P24, DOI 10.1016/j.pvr.2016.12.003
   White MD, 2014, TRANSL ANDROL UROL, V3, P429, DOI 10.3978/j.issn.2223-4683.2014.11.02
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
   Wilson R, 2013, J IMMIGR MINOR HEALT, V15, P747, DOI 10.1007/s10903-012-9749-5
   Wilson T, 2000, J Pediatr Health Care, V14, P117, DOI 10.1016/S0891-5245(00)70022-8
   Zell ER, 2000, PUBLIC HEALTH REP, V115, P65, DOI 10.1093/phr/115.1.65
NR 88
TC 0
Z9 0
U1 14
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6793
EP 6802
DI 10.1016/j.vaccine.2019.08.068
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800003
PM 31562000
DA 2020-05-12
ER

PT J
AU Goodman, RM
   Bridges, CB
   Kim, D
   Pike, J
   Rose, A
   Prosser, LA
   Hutton, DW
AF Goodman, Robert M.
   Bridges, Carolyn B.
   Kim, David
   Pike, Jamison
   Rose, Angela
   Prosser, Lisa A.
   Hutton, David W.
TI Billing and payment of commercial and Medicaid health plan adult
   vaccination claims in Michigan since the Affordable Care Act
SO VACCINE
LA English
DT Article
DE Insurance reimbursement; Adult vaccination
ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS; PERSPECTIVE
AB Background: Provider concern regarding insurance non-payment for vaccines is a common barrier to provision of adult immunizations. We examined current adult vaccination billing and payment associated with two managed care populations to identify reasons for non-payment of immunization insurance claims.
   Methods: We assessed administrative data from 2014 to 2015 from Blue Care Network of Michigan, a nonprofit health maintenance organization, and Blue Cross Complete of Michigan, a Medicaid managed care plan, to determine rates of and reasons for non-payment of adult vaccination claims across patient-care settings, insurance plans, and vaccine types. We compared commercial and Medicaid payment rates to Medicare payment rates and examined patient cost sharing.
   Results: Pharmacy-submitted claims for adult vaccine doses were almost always paid (commercial 98.5%; Medicaid 100%). As the physician office accounted for the clear majority (79% commercial; 69% Medicaid) of medical (non-pharmacy) vaccination services, we limited further analyses of both commercial and Medicaid medical claims to the physician office setting. In the physician office setting, rates of payment were high with commercial rates of payment (97.9%) greater than Medicaid rates (91.6%). Reasons for non-payment varied, but generally related to the complexity of adult vaccine recommendations (patient diagnosis does not match recommendations) or insurance coverage (complex contracts, multiple insurance payers). Vaccine administration services were also generally paid. Commercial health plan payments were greater for both vaccine dose and vaccine administration than Medicare payments; Medicaid paid a higher amount for the vaccine dose, but less for vaccine administration than Medicare. Patients generally had very low (commercial) or no (Medicaid) cost-sharing for vaccination.
   Conclusions: Adult vaccine dose claims were usually paid. Medicaid generally had higher rates of nonpayment than commercial insurance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Goodman, Robert M.] Blue Cross Blue Shield Michigan, Blue Care Network, Southfield, MI USA.
   [Bridges, Carolyn B.; Kim, David; Pike, Jamison] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Respirator Dis, Immunizat Serv Div, Atlanta, GA USA.
   [Bridges, Carolyn B.] Berry Technol Solut Inc, Peachtree City, GA USA.
   [Rose, Angela; Prosser, Lisa A.; Hutton, David W.] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Hutton, DW (reprint author), 1415 Washington Hts,M3525 SPH 2, Ann Arbor, MI 48109 USA.
EM dwhutton@umich.edu
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5-U01-IP-000965-03]
FX This research was supported as part of a cooperative agreement with the
   Centers for Disease Control and Prevention (CDC), 5-U01-IP-000965-03.
   CDC co-authors had a role in study design, interpretation of the data,
   the writing of the report, and the decision to submit for publishing.
   However, the findings and conclusions in this report are those of the
   authors and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention.
CR Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
   Claxton G, 2014, HEALTH AFFAIR, V33, P1851, DOI 10.1377/hlthaff.2014.0792
   Coleman Margaret S, 2009, Pediatrics, V124 Suppl 5, pS472, DOI 10.1542/peds.2009-1542G
   Coleman MS, 2005, VACCINE, V23, P915, DOI 10.1016/j.vaccine.2004.07.028
   Folaranmi T, 2015, MMWR-MORBID MORTAL W, V64, P608
   Hurley LP, 2018, J AM BOARD FAM MED, V31, P94, DOI 10.3122/jabfm.2018.01.170216
   Hurley LP, 2017, VACCINE, V35, P647, DOI 10.1016/j.vaccine.2016.12.007
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Lindley MC, 2018, VACCINE, V36, P1093, DOI 10.1016/j.vaccine.2018.01.015
   National Adult and Influenza Immunization Summit, 2018, COD BILL AD VACC
   O'Leary ST, 2014, PEDIATRICS, V133, P367, DOI 10.1542/peds.2013-2637
   Patton ME, 2017, MMWR-MORBID MORTAL W, V66, P509, DOI 10.15585/mmwr.mm6619a6
   Shen A, 2019, VACCINE, V37, P792, DOI 10.1016/j.vaccine.2018.12.045
   Sommers BD, 2009, J GEN INTERN MED, V24, P1, DOI 10.1007/s11606-008-0792-9
   Stewart AM, 2015, VACCINE, V33, P5801, DOI 10.1016/j.vaccine.2015.09.014
   Swartz K, 2015, HEALTH AFFAIR, V34, P1180, DOI 10.1377/hlthaff.2014.1204
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6803
EP 6813
DI 10.1016/j.vaccine.2019.09.042
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800004
PM 31585724
DA 2020-05-12
ER

PT J
AU Wallace, AS
   Peetosutan, K
   Untung, A
   Ricardo, M
   Yosephine, P
   Wannemuehler, K
   Brown, DW
   McFarland, DA
   Orenstein, WA
   Rosenberg, ES
   Omer, SB
   Daniels, D
AF Wallace, Aaron S.
   Peetosutan, Kenny
   Untung, Andi
   Ricardo, Marisa
   Yosephine, Prima
   Wannemuehler, Kathleen
   Brown, David W.
   McFarland, Deborah A.
   Orenstein, Walter A.
   Rosenberg, Eli S.
   Omer, Saad B.
   Daniels, Danni
TI Home-based records and vaccination appointment stickers as parental
   reminders to reduce vaccination dropout in Indonesia: A
   cluster-randomized controlled trial
SO VACCINE
LA English
DT Article
DE Vaccination; Indonesia; Vaccination reminder
ID TIMELINESS; ATTITUDES
AB Introduction: Limited evidence is available about the effectiveness of strategies to remind caregivers when to bring children back for future vaccinations in low- and middle-income country settings. We evaluated the effectiveness of two reminder strategies based on home-based vaccination records (HBR) in Indonesia.
   Methods: In this cluster-randomized controlled trial involving 3616 children <1 year of age, 90 health facilities were randomly assigned to either a control group or one of two intervention groups: (1) HBR-only group, where healthcare workers provided an HBR to any child without an HBR during a vaccination visit and instructed the caregiver to keep it at home between visits, or (2) HBR + sticker group, where, in addition to HBR provision, healthcare workers placed vaccination appointment reminder stickers on the HBR. The primary outcome was receipt of the third dose of diphtheria-tetanus-pertussis-con taming vaccine (DTPcv3) within 7 months and the secondary outcome was receipt of a timely DTPcv3 dose.
   Results: Control group DTPcv3 coverage was 81%. In intention-to-treat analysis, neither intervention group had significantly different DTPcv3 coverage compared with the control group (RR = 0.94, 95% confidence interval [CI] 0.87; 1.02 for HBR-only group; RR = 0.97, 95% CI 0.90; 1.04 for HBR + sticker group) by study end. However, children in the HBR + sticker group were 50% more likely to have received a DTPcv3 vaccination (RR =1.46, 95% CI 1.02, 2.09) within 60 days of DTPcv1 vaccination, compared with children in the control group; children in the HBR-only group were not more likely to have done so (RR =1.05, 95% CI 0.71, 1.55).
   Discussion: Reminder stickers had an immediate effect on coverage by improving the proportion of children who received a timely DTPcv3 dose but no effect on the proportion who received DTPcv3 after 7 months. Coupling reminder stickers with strategies to address other reasons why children do not return for vaccination visits should be further explored. Published by Elsevier Ltd.
C1 [Wallace, Aaron S.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Wallace, Aaron S.; Wannemuehler, Kathleen; Daniels, Danni] US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
   [Peetosutan, Kenny] UNICEF, Maternal & Child Hlth Team, Jakarta, Indonesia.
   [Untung, Andi] Minist Hlth, Hlth Commun Team, Jakarta, Indonesia.
   [Ricardo, Marisa] UNICEF, Maternal & Child Hlth Team, Addis Ababa, Ethiopia.
   [Yosephine, Prima] Minist Hlth, Natl Immunizat Program, Jakarta, Indonesia.
   [McFarland, Deborah A.; Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA.
   [Orenstein, Walter A.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Rosenberg, Eli S.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Albany, NY 12222 USA.
   [Brown, David W.] Brown Consulting Grp Int LLC, Cornelius, NC 28031 USA.
RP Wallace, AS (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA.
EM awallace@cdc.gov
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001863]; Intramural CDC HHS
   [CC999999]
CR Akmatov MK, 2008, VACCINE, V26, P3805, DOI 10.1016/j.vaccine.2008.05.031
   [Anonymous], 2018, EST STRENGTH IMM 2 Y
   Curran D, 2016, PEDIATR INFECT DIS J, V35, P542, DOI 10.1097/INF.0000000000001071
   DHS, 2012, IND DEM HLTH SURV 20
   Grant C, 2004, NZ MED J, V117, P4
   Gust DA, 2004, PEDIATRICS, V114, pE16, DOI 10.1542/peds.114.1.e16
   Gust DA, 2005, AM J PREV MED, V29, P105, DOI 10.1016/j.amepre.2005.04.010
   Harvey H, 2015, VACCINE, V33, P2862, DOI 10.1016/j.vaccine.2015.04.085
   Jacobson Vann JC, 2005, PATIENT REMINDER REC
   Kolos V, 2007, VACCINE, V25, P588, DOI 10.1016/j.vaccine.2006.08.022
   Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y
   Osaki K, 2018, INDONESIA J PUBLIC H
   Oyolta A, 2016, INTERVENTIONS IMPROV
   Oyolta A, 2012, EVIDENCE BASED CHILD, V7, P959
   Siedler A, 2002, PEDIATR INFECT DIS J, V21, P826, DOI 10.1097/00006454-200209000-00008
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   Usman HR, 2011, TROP MED INT HEALTH, V16, P334, DOI 10.1111/j.1365-3156.2010.02698.x
   Usman HR, 2009, VACCINE, V27, P467, DOI 10.1016/j.vaccine.2008.10.048
   Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3
   Wallace AS, 2014, VACCINE, V32, P5301, DOI 10.1016/j.vaccine.2014.07.076
   World Health Organization, 2015, PRACT GUID DES US PR
NR 21
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6814
EP 6823
DI 10.1016/j.vaccine.2019.09.040
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800005
PM 31564451
DA 2020-05-12
ER

PT J
AU Maruyama, J
   Mateer, EJ
   Manning, JT
   Sattler, R
   Seregin, AV
   Bukreyeva, N
   Jones, FR
   Balint, JP
   Gabitzsch, ES
   Huang, C
   Paessler, S
AF Maruyama, Junki
   Mateer, Elizabeth J.
   Manning, John T.
   Sattler, Rachel
   Seregin, Alexey, V
   Bukreyeva, Natalya
   Jones, Frank R.
   Balint, Joseph P.
   Gabitzsch, Elizabeth S.
   Huang, Cheng
   Paessler, Slobodan
TI Adenoviral vector-based vaccine is fully protective against lethal Lassa
   fever challenge in Hartley guinea pigs
SO VACCINE
LA English
DT Article
DE Lassa virus; Lassa fever; Vaccine; Adenovirus vector
ID ANTIBODY-MEDIATED NEUTRALIZATION; IMMUNE-RESPONSES; ENVELOPE
   GLYCOPROTEIN; VIRUS-INFECTION; AD5 E1; E2B; EPIDEMIOLOGY; GENERATION;
   INDUCTION; OUTBREAK
AB Lassa virus (LASV), the causative agent of Lassa fever (LF), was first identified in 1969. Since then, outbreaks in the endemic countries of Nigeria, Liberia, and Sierra Leone occur on an annual basis resulting in a case-fatality rate of 15-70% in hospitalized patients. There is currently no licensed vaccine and there are limited animal models to test vaccine efficacy. An estimated 37.7 million people are at risk of contracting LASV; therefore, there is an urgent need for the development of a safe, effective vaccine against LASV infection. The LF endemic countries are also inflicted with HIV, Ebola, and malaria infections. The safety in immunocompromised populations must be considered in LASV vaccine development. The novel adenovirus vector-based platform, Ad5 (E1-,E2b-) has been used in clinical trial protocols for treatment of immunocompromised individuals, has been shown to exhibit high stability, low safety risk in humans, and induces a strong cell-mediated and pro-inflammatory immune response even in the presence of pre-existing adenovirus immunity. To this nature, our lab has developed an Ad5 (E1-,E2b-) vectorbased vaccine expressing the LASV-NP or LASV-GPC. We found that guinea pigs vaccinated with two doses of Ad5 (E1-,E2b-) LASV-NP and Ad5 (E1-,E2b-) LASV-GPC were protected against lethal LASV challenge. The Ad5 (E1-,E2b-) LASV-NP and LASV-GPC vaccine represents a potential vaccine candidate against LF. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Maruyama, Junki; Mateer, Elizabeth J.; Manning, John T.; Sattler, Rachel; Seregin, Alexey, V; Bukreyeva, Natalya; Huang, Cheng; Paessler, Slobodan] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Jones, Frank R.; Balint, Joseph P.; Gabitzsch, Elizabeth S.] Etub Corp, Seattle, WA USA.
   [Seregin, Alexey, V] Takeda, Boston, MA USA.
RP Paessler, S (reprint author), Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA.
EM slpaessl@utmb.edu
RI Maruyama, Junki/M-4735-2019
OI Maruyama, Junki/0000-0003-0088-4793
FU UTMB Pathology Core and Animal Resources Center (ARC); Japan Society for
   the Promotion of Science (JSPS)Ministry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   Science; National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [T32
   AI0075256]
FX We would like to thank the UTMB Pathology Core and Animal Resources
   Center (ARC). J.M. is supported by Japan Society for the Promotion of
   Science (JSPS). E.J.M is supported by the National Institutes of Health
   [T32 AI0075256]
CR Abreu-Mota T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06741-w
   Ajayi IO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188128
   Baize S, 2004, J IMMUNOL, V172, P2861, DOI 10.4049/jimmunol.172.5.2861
   Baize S, 2009, J VIROL, V83, P5890, DOI 10.1128/JVI.01948-08
   Balint JP, 2015, CANCER IMMUNOL IMMUN, V64, P977, DOI 10.1007/s00262-015-1706-4
   Buba MI, 2018, AM J PUBLIC HEALTH, V108, P262, DOI [10.2105/AJPH.2017.304186, 10.2105/ajph.2017.304186]
   BUCHMEIER MJ, 2006, FIELDS VIROLOGY
   Burri DJ, 2012, VIRUSES-BASEL, V4, P2162, DOI 10.3390/v4102162
   Burri DJ, 2012, J VIROL, V86, P4935, DOI 10.1128/JVI.00024-12
   De Vuyst H, 2013, VACCINE, V31, pF32, DOI 10.1016/j.vaccine.2012.07.092
   Djomand G, 2014, CURR OPIN HIV AIDS, V9, P506, DOI 10.1097/COH.0000000000000090
   Flatz L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000836
   Gabitzsch ES, 2011, CANCER GENE THER, V18, P326, DOI 10.1038/cgt.2010.82
   Gabitzsch ES, 2015, ONCOTARGET, V6, P31344, DOI 10.18632/oncotarget.5181
   Gabitzsch ES, 2012, VACCINE, V30, P7265, DOI 10.1016/j.vaccine.2012.09.058
   Gabitzsch ES, 2011, VACCINE, V29, P8101, DOI 10.1016/j.vaccine.2011.08.038
   Gabitzsch ES, 2010, CANCER IMMUNOL IMMUN, V59, P1131, DOI 10.1007/s00262-010-0847-8
   Gabitzsch ES, 2009, VACCINE, V27, P6394, DOI 10.1016/j.vaccine.2009.06.028
   Gabitzsch ES, 2009, IMMUNOL LETT, V122, P44, DOI 10.1016/j.imlet.2008.11.003
   Gehre F, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0704-5
   Geisbert TW, 2018, LANCET INFECT DIS, V18, P594, DOI 10.1016/S1473-3099(18)30116-6
   Gunther S, 2001, MED MICROBIOL IMMUN, V189, P225, DOI 10.1007/s004300100061
   Hallam HJ, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0049-5
   Hastie KM, 2017, SCIENCE, V356, P923, DOI 10.1126/science.aam7260
   Jones FR, 2011, VACCINE, V29, P7020, DOI 10.1016/j.vaccine.2011.07.073
   Koma T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004969
   Mahmutovic S, 2015, CELL HOST MICROBE, V18, P705, DOI 10.1016/j.chom.2015.11.005
   Manning JT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00020
   Maruyama J, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00428-19
   Mateer EJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006187
   MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104
   McElroy AK, 2017, J INFECT DIS, V215, P1862, DOI 10.1093/infdis/jix201
   Morse MA, 2013, CANCER IMMUNOL IMMUN, V62, P1293, DOI 10.1007/s00262-013-1400-3
   Mylne AQN, 2015, T ROY SOC TROP MED H, V109, P483, DOI 10.1093/trstmh/trv047
   Osada T, 2009, CANCER GENE THER, V16, P673, DOI 10.1038/cgt.2009.17
   Prescott JB, 2017, NAT REV IMMUNOL, V17, P195, DOI 10.1038/nri.2016.138
   Richmond JK, 2003, BRIT MED J, V327, P1271, DOI 10.1136/bmj.327.7426.1271
   Robinson JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11544
   Russier M, 2012, VIRUSES-BASEL, V4, P2766, DOI 10.3390/v4112766
   Shaffer JG, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002748
   Shehu NY, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00232
   ter Meulen J, 2004, VIROLOGY, V321, P134, DOI 10.1016/j.virol.2003.12.013
   ter Meulen J, 2000, J VIROL, V74, P2186, DOI 10.1128/JVI.74.5.2186-2192.2000
   Warner BM, 2018, DRUG DES DEV THER, V12, P2519, DOI 10.2147/DDDT.S147276
   Yun NE, 2016, J VIROL, V90, P2920, DOI 10.1128/JVI.02948-15
   Yun NE, 2013, J VIROL, V87, P10908, DOI 10.1128/JVI.01433-13
   Yun NE, 2012, VIRUSES-BASEL, V4, P2031, DOI 10.3390/v4102031
NR 47
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6824
EP 6831
DI 10.1016/j.vaccine.2019.09.030
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800006
PM 31561999
DA 2020-05-12
ER

PT J
AU Widdice, LE
   Bernstein, DI
   Franco, EL
   Ding, LL
   Brown, DR
   Ermel, AC
   Higgins, L
   Kahn, JA
AF Widdice, Lea E.
   Bernstein, David, I
   Franco, Eduardo L.
   Ding, Lili
   Brown, Darron R.
   Ermel, Aaron C.
   Higgins, Lisa
   Kahn, Jessica A.
TI Decline in vaccine-type human papillomavirus prevalence in young men
   from a Midwest metropolitan area of the United States over the six years
   after vaccine introduction
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Male; Prevalence; Vaccine; Herd protection;
   Effectiveness
ID GENITAL HUMAN-PAPILLOMAVIRUS; HERD-IMMUNITY; HPV; INFECTION; WOMEN;
   PROGRAM; PROTECTION; SCOTLAND; FEMALE
AB Purpose: The aim of this study was to determine changes in human papillomavirus (HPV) prevalence among young men from a Midwest metropolitan area over the six years after vaccine introduction, including HPV prevalence in men overall, in vaccinated men to examine vaccine impact and in unvaccinated men to examine herd protection. An exploratory aim was to examine associations between number of vaccine doses and HPV prevalence.
   Methods: Men aged 14-26 years reporting male-female and/or male-male sexual contact were recruited from a primary care clinic, sexually transmitted disease clinic, and community setting during two waves of data collection: 2013-2014 (N = 400) and 2016-2017 (N = 347). Participants completed a questionnaire and were tested for penile, scrotal and anal HPV. Changes in prevalence of any (>= 1 type) and vaccine-type HPV (HPV6, 11, 16, and/or 18) were examined using propensity score weighted logistic regression. Associations between number of doses and HPV infection were determined using chi-square tests and logistic regression.
   Results: The proportion of men with a history of >= 1 HPV vaccine doses increased from 23% to 44% (p < 0.001) from waves 1 to 2. After propensity score weighting, infection with >= 1 vaccine-type HPV significantly decreased among all men (29% to 20%; 31% decrease; odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.44-0.88) and unvaccinated men (32% to 21%; 36% decrease; OR = 0.56, 95%Cl = 0.34-0.86); there was a non-significant decrease (21%) among vaccinated men. Associations between number of doses and HPV prevalence were not statistically significant.
   Conclusions: Prevalence of vaccine-type HPV decreased among all, vaccinated, and unvaccinated men six years after HPV vaccine recommendation, supporting vaccine impact and herd protection. Decreases in vaccine-type HPV in all men appear to be due to decreases in unvaccinated men, suggesting that the full impact of vaccination has yet to be realized. Continued monitoring and efforts to vaccinate men prior to sexual initiation are warranted. (C) 2019 Published by Elsevier Ltd.
C1 [Widdice, Lea E.; Bernstein, David, I; Ding, Lili; Higgins, Lisa; Kahn, Jessica A.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
   [Widdice, Lea E.; Higgins, Lisa; Kahn, Jessica A.] Cincinnati Childrens Hosp Med Ctr, Div Adolescent & Transit Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Bernstein, David, I] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Franco, Eduardo L.] McGill Univ, Fac Med, Dept Oncol, 5100 Maisonneuve Blvd West,Suite 720, Montreal, PQ H4A 3T2, Canada.
   [Franco, Eduardo L.] McGill Univ, Fac Med, Dept Epidemiol & Biostat, 5100 Maisonneuve Blvd West,Suite 720, Montreal, PQ H4A 3T2, Canada.
   [Ding, Lili] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Brown, Darron R.; Ermel, Aaron C.] Indiana Univ Sch Med, Dept Med, 635 Barnhill Dr,Van Nuys Med Sci Bldg,Suite 224, Indianapolis, IN 46202 USA.
   [Brown, Darron R.; Ermel, Aaron C.] Indiana Univ Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,Van Nuys Med Sci Bldg,Suite 224, Indianapolis, IN 46202 USA.
RP Widdice, LE (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Adolescent & Transit Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM lea.widdice@cchmc.org; david.bernstein@cchmc.org;
   eduardo.franco@mcgill.ca; lili.ding@cchmc.org; darbrow@iu.edu;
   aermel@iu.edu; lisa.higgins@cchmc.org; Jessica.kahn@cchmc.org
OI Kahn, Jessica/0000-0002-6313-4976
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI073713, R01 AI104709];  [UL1
   TR001425]
FX Funding for this study was provided by R01 AI073713 and R01 AI104709
   from NIAID (Jessica Kahn, PI). Research reported in this publication was
   supported by the National Center for Advancing Translational Sciences of
   the National Institutes of Health under Award Number UL1 TR001425. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Berenson AB, 2017, OBSTET GYNECOL, V130, P693, DOI 10.1097/AOG.0000000000002193
   Cameron RL, 2016, EMERG INFECT DIS, V22, P56, DOI 10.3201/eid2201.150736
   Carozzi F, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2945-8
   Chandler E, 2018, J ADOLESCENT HEALTH, V63, P43, DOI 10.1016/j.jadohealth.2018.01.005
   Chow EPF, 2017, LANCET INFECT DIS, V17, P68, DOI 10.1016/S1473-3099(16)30116-5
   Covert C, 2019, HUM VACC IMMUNOTHER, P1
   Ding LL, 2017, VACCINE, V35, P7217, DOI 10.1016/j.vaccine.2017.11.005
   Food and Drug Administration, 2011, HIGHL PRESCR INF
   Gargano JW, 2017, J INFECT DIS, V215, P1070, DOI 10.1093/infdis/jix057
   Giuliano AR, 2007, J INFECT DIS, V196, P1146, DOI 10.1086/521629
   Gray P, 2018, INT J CANCER, V142, P2491, DOI 10.1002/ijc.31281
   Kahn JA, 2008, OBSTET GYNECOL, V111, P1103, DOI 10.1097/AOG.0b013e31817051fa
   Kahn JA, 2016, CLIN INFECT DIS, V63, P1281, DOI 10.1093/cid/ciw533
   Kahn JA, 2012, PEDIATRICS, V130, pE249, DOI 10.1542/peds.2011-3587
   Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1
   Liu ZY, 2018, J INFECT DIS, V217, P767, DOI 10.1093/infdis/jix588
   Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075
   Machalek DA, 2017, J INFECT DIS, V215, P202, DOI 10.1093/infdis/jiw530
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   Merikukka M, 2011, INT J CANCER, V128, P1114, DOI 10.1002/ijc.25675
   Mesher D, 2016, EMERG INFECT DIS, V22, P1732, DOI 10.3201/eid2210.160675
   Shin HR, 2004, J INFECT DIS, V190, P468, DOI 10.1086/421279
   Smith MA, 2011, VACCINE, V29, P9112, DOI 10.1016/j.vaccine.2011.02.091
   Spinner C, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1902
   Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2
   Thomas R, 2016, AM J MENS HLTH
   Tota JE, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw300
   Widdice LE, 2012, ARCH PEDIAT ADOL MED, V166, P774, DOI 10.1001/archpediatrics.2012.586
   Winer RL, 2003, AM J EPIDEMIOL, V157, P218, DOI 10.1093/aje/kwf180
   Yang ZH, 2014, AM J EPIDEMIOL, V180, P1066, DOI 10.1093/aje/kwu267
NR 31
TC 0
Z9 0
U1 6
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6832
EP 6841
DI 10.1016/j.vaccine.2019.08.052
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800007
PM 31582269
DA 2020-05-12
ER

PT J
AU Nayak, MK
   Banerjee, A
   Sarkar, R
   Mitra, S
   Dutta, K
   Ganguly, N
   Ghosh, C
   Kumar, CPG
   Niyogi, P
   Panda, S
   Dutta, S
   Chawla-Sarkar, M
AF Nayak, Mukti Kant
   Banerjee, Anindita
   Sarkar, Rakesh
   Mitra, Suvrotoa
   Dutta, Kunal
   Ganguly, Nupur
   Ghosh, Chandradipa
   Kumar, C. P. Girish
   Niyogi, Prabal
   Panda, Samiran
   Dutta, Shanta
   Chawla-Sarkar, Mamta
TI Genetic characterization of group-A rotaviruses among children in
   eastern India during 2014-2016: Phylodynamics of co-circulating
   genotypes
SO VACCINE
LA English
DT Article
DE Group-A rotavirus; Acute diarrhea; Genotypic dynamicity; Genetic drift;
   Phylogenetic analysis; Vaccine
ID HERD-IMMUNITY; VACCINE; DIARRHEA; STRAINS; BOVINE; SURVEILLANCE; IMPACT;
   PREVALENCE; DIVERSITY; EFFICACY
AB Background: Group-A human rotaviruses (GARV) are among the major cause of childhood diarrhea worldwide. In lieu of monitoring the circulatory GARV strains and underscoring the burden of GARV related hospitalization, a systematic surveillance was conducted in three hospitals of eastern India. In this hospital-based diarrheal disease surveillance (2014-2016), GARV was the most common cause of acute infantile gastroenteritis. The strains were genotyped and characterized to understand their prevalence and phylodynamics prior to the introduction of vaccine in eastern India.
   Materials and methods: A total of 3652 stool samples were screened from children (<= 5 years) hospitalized with acute diarrhea during 2014-2016. Initial screening for VP6 antigen was done by ELISA. GARV positive samples were genotyped by multiplex semi-nested PCR and DNA sequencing and phylogenetic analyses were based on the capsid proteins VP4 and VP7.
   Results: Of 3652 samples, 1817 (49.8%) were GARV positive. G1, G2, G3 and G9 in conjunction with P[4], P [6]and P[8]genotypes were seen to co-circulate in the population. A sharp deflection from G1 to G3 occurred since 2016; upsurge of G9 strains was seen in alternate years, whereas G2 strains had a low frequency. All the circulating genotypes depicted a low phylogenetic relatedness to the vaccine strains. Differences in antigenic epitopes of VP4 and VP7 proteins in local strains were seen when compared to the vaccine strains. A significant difference in the degree of dehydration, duration of mean hospital stay and frequency of vomiting/24 h between GARV positive and negative children was evident.
   Conclusion: The study provides a relevant set of base-line data on high burden of rotaviral gastroenteritis and the varied genotypic diversity among children prior to the introduction of GARV vaccine in this endemic region. Continuous monitoring during post-vaccination era will be required to assess the impact of vaccination in this region. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nayak, Mukti Kant; Banerjee, Anindita; Sarkar, Rakesh; Mitra, Suvrotoa; Dutta, Shanta; Chawla-Sarkar, Mamta] ICMR NICED, Kolkata, India.
   [Ganguly, Nupur; Niyogi, Prabal] Inst Child Hlth, Kolkata, India.
   [Dutta, Kunal; Ghosh, Chandradipa] Vidyasagar Univ, Medinipur, India.
   [Kumar, C. P. Girish] ICMR Natl Inst Epidemiol, Chennai, Tamil Nadu, India.
   [Panda, Samiran] ICMR Natl AIDS Res Inst, Pune, Maharashtra, India.
   [Nayak, Mukti Kant] BB Coll, Kuchai, Odisha, India.
RP Chawla-Sarkar, M (reprint author), Natl Inst Cholera & Enter Dis, Div Virol, P-33,CIT Rd,Scheme XM, Kolkata 700010, W Bengal, India.
EM chawlasarkar.m@icmr.gov.in
OI Dutta, Kunal/0000-0002-0818-8787
FU Indian Council of Medical Research (ICMR), New Delhi, IndiaIndian
   Council of Medical Research (ICMR)
FX This work was supported by financial assistance from the Indian Council
   of Medical Research (ICMR), New Delhi, India. Papiya De and Suman Das
   are hereby acknowledged for their support in the laboratory during
   processing of stool samples.
CR Aliabadi N, 2016, CLIN MICROBIOL INFEC, V22, pS128, DOI 10.1016/j.cmi.2016.03.007
   Babji S, 2018, VACCINE, V36, P7816, DOI 10.1016/j.vaccine.2017.08.035
   Banerjee A, 2018, INFECT GENET EVOL, V63, P158, DOI 10.1016/j.meegid.2018.05.026
   Banyai K, 2012, VACCINE, V30, pA122, DOI 10.1016/j.vaccine.2011.09.111
   Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS213, DOI 10.1093/cid/civ1183
   Bar-Zen N, 2015, LANCET INFECT DIS, V15, P422, DOI 10.1016/S1473-3099(14)71060-6
   Bennett A, 2016, VACCINE, V34, P4351, DOI 10.1016/j.vaccine.2016.07.001
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Chandrahasen C, 2010, J MED VIROL, V82, P897, DOI 10.1002/jmv.21739
   Ciarlet M, 2002, VIRUS GENES, V24, P107, DOI 10.1023/A:1014512314545
   Clark A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183392
   Cunliffe NA, 2001, EMERG INFECT DIS, DOI [10.3201/eid0705.017521, DOI 10.3201/EID0705.017521]
   Das S, 2002, J CLIN MICROBIOL, V40, P146, DOI 10.1128/JCM.40.1.146-149.2002
   Estes M, 2007, FIELDS VIROLOGY
   Gastanaduy PA, 2013, PEDIATRICS, V131, pE1115, DOI 10.1542/peds.2012-2797
   Gouvea V, 1994, J CLIN MICROBIOL, V32, P1834
   Groome MJ, 2014, LANCET INFECT DIS, V14, P1096, DOI 10.1016/S1473-3099(14)70940-5
   Hull JJ, 2011, PEDIATR INFECT DIS J, V30, pS42, DOI 10.1097/INF.0b013e3181fefd78
   Iyoha O, 2015, NIGER J CLIN PRACT, V18, P48, DOI 10.4103/1119-3077.146978
   John J, 2014, VACCINE, V32, pA5, DOI 10.1016/j.vaccine.2014.03.004
   Kang G, 2013, VACCINE, V31, P2879, DOI 10.1016/j.vaccine.2013.04.030
   Kirkwood CD, 2011, PEDIATR INFECT DIS J, V30, pS48, DOI 10.1097/INF.0b013e3181fefd90
   Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014
   Kumar A, 2016, INDIAN PEDIATR, V53, P607, DOI 10.1007/s13312-016-0896-y
   Leite JPG, 1996, ARCH VIROL, V141, P2365, DOI 10.1007/BF01718637
   Luchs A, 2014, J CLIN VIROL, DOI [10.1016/j.jcv2013.11.001, DOI 10.1016/J.JCV2013.11.001]
   Mandal P, 2016, ARCH VIROL, V161, P2773, DOI 10.1007/s00705-016-2969-6
   Martella V, 2010, VET MICROBIOL, V140, P246, DOI 10.1016/j.vetmic.2009.08.028
   Mast TC, 2015, PEDIATR INFECT DIS J, V34, P615, DOI 10.1097/INF.0000000000000702
   Matthijnssens J, 2012, CURR OPIN VIROL, V2, P426, DOI 10.1016/j.coviro.2012.04.007
   Matthijnssens J, 2009, FUTURE MICROBIOL, V4, P1303, DOI 10.2217/FMB.09.96
   McDonald SM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000634
   Mukherjee A, 2013, J MED VIROL, V85, P537, DOI 10.1002/jmv.23483
   Mukherjee A, 2012, INFECT GENET EVOL, V12, P467, DOI 10.1016/j.meegid.2011.11.007
   Mukherjee A, 2010, INFECT GENET EVOL, V10, P311, DOI 10.1016/j.meegid.2010.01.002
   Mullick S, 2014, VACCINE, V32, pA20, DOI 10.1016/j.vaccine.2014.03.018
   Nirwati H, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1724-5
   Nokes DJ, 2010, J INFECT DIS, V202, pS180, DOI 10.1086/653566
   Pollard SL, 2015, VACCINE, V33, P3795, DOI 10.1016/j.vaccine.2015.06.064
   Reesu R, 2013, INTERVIROLOGY, V56, P134, DOI 10.1159/000342219
   Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994
   Steele AD, 2003, VACCINE, V21, P354, DOI 10.1016/S0264-410X(02)00615-1
   TANIGUCHI K, 1992, EPIDEMIOL INFECT, V109, P303, DOI 10.1017/S0950268800050263
   Tate JE, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1082
   Thongprachum A, 2013, INFECT GENET EVOL, V13, P168, DOI 10.1016/j.meegid.2012.09.010
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Wang YH, 2009, J MED VIROL, V81, P382, DOI 10.1002/jmv.21387
   Zaman K, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002282
   Zeller M, 2010, VACCINE, V28, P7507, DOI 10.1016/j.vaccine.2010.09.004
NR 49
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2019
VL 37
IS 45
BP 6842
EP 6856
DI 10.1016/j.vaccine.2019.06.062
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JI1GB
UT WOS:000493212800008
PM 31543416
DA 2020-05-12
ER

PT J
AU Martinez, MP
   Magnoli, AP
   Pereyra, MLG
   Cavaglieri, L
AF Martinez, M. P.
   Magnoli, A. P.
   Gonzalez Pereyra, M. L.
   Cavaglieri, L.
TI Probiotic bacteria and yeasts adsorb aflatoxin M-1 in milk and degrade
   it to less toxic AFM(1)-metabolites
SO TOXICON
LA English
DT Article
DE Probiotics; Adsorption/degradation; Aflatoxin M-1; AFM(1)-metabolites;
   Milk
ID LACTIC-ACID BACTERIA; SACCHAROMYCES-CEREVISIAE STRAINS; IRANIAN WHITE;
   BREAST-MILK; DETOXIFICATION; LACTOBACILLUS; MYCOTOXINS; ADSORPTION;
   EFFICIENCY; ABILITY
AB The presence of contaminants such as aflatoxins (AFs) in dairy products constitutes a serious risk to the health of consumers, especially children who are most sensitive to the adverse effects of AFs. The presence of Aflatoxin M-1 (AFM(1)) in milk is a public health problem since dairy products are massively consumed worldwide. The aim of the present work was to select microorganisms capable of reducing AFM(1) entry into the food chain through adsorption/degradation strategies. Moreover, the toxicity of AFM(1) degradation products was evaluated. All tested strains had the capacity to adsorb 19%-61% AFM(1) in milk. These strains also had the ability to degrade AFM(1) into metabolites less toxic than the original toxin. Moreover, this is the first study to report harmless and probiotic Pediococcus pentosaceus and Kluveromyces marxianus have the ability to adsorb and degrade AFM(1) to less toxic metabolites in milk.
C1 [Martinez, M. P.; Magnoli, A. P.; Gonzalez Pereyra, M. L.; Cavaglieri, L.] Univ Nacl Rio Cuarto, Dept Microbiol & Inmunol, Fac Ciencias Exactas Fis Quim & Nat, Ruta N 36 Km 601, RA-5800 Cordoba, Argentina.
   [Martinez, M. P.; Magnoli, A. P.; Gonzalez Pereyra, M. L.; Cavaglieri, L.] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
RP Cavaglieri, L (reprint author), Univ Nacl Rio Cuarto, Dept Microbiol & Inmunol, Ruta 36 Km,601, RA-5800 Cordoba, Argentina.
EM lcavaglieri@exa.unrc.edu.ar
FU CONICET, ArgentinaConsejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET) [PIP 2013-2016 GI 11220120100156]; FonCyT,
   ArgentinaFONCyT [PICT 2033/15]
FX This work was supported by: CONICET, Argentina [grant number PIP
   2013-2016 GI 11220120100156] and FonCyT, Argentina [grant number PICT
   2033/15].
CR ABDELMOTILIB NM, 2018, EUROPEAN J NUTR FOOD, V8, P83, DOI DOI 10.9734/EJNFS/2018/39486
   Alonso VA, 2013, J APPL MICROBIOL, V115, P637, DOI 10.1111/jam.12178
   Armando MR, 2012, J APPL MICROBIOL, V113, P256, DOI 10.1111/j.1365-2672.2012.05331.x
   Bovo F, 2013, FOOD BIOPROCESS TECH, V6, P2230, DOI 10.1007/s11947-011-0770-9
   Campagnollo FB, 2016, FOOD CONTROL, V68, P310, DOI 10.1016/j.foodcont.2016.04.007
   CAST Council for Agricultural Science and Technology, 2003, MYCOTOXINS RISKS PLA
   Corassin CH, 2013, FOOD CONTROL, V31, P80, DOI 10.1016/j.foodcont.2012.09.033
   Diaz-Vergara L, 2017, FOOD ADDIT CONTAM A, V34, P750, DOI 10.1080/19440049.2017.1290830
   Dogi CA, 2013, J APPL MICROBIOL, V114, P1650, DOI 10.1111/jam.12173
   Dogi CA, 2011, FOOD ADDIT CONTAM A, V28, P1705, DOI 10.1080/19440049.2011.605771
   DURACKOVA Z, 1977, Zentralblatt fuer Bakteriologie Parasitenkunde Infektionskrankheiten und Hygiene Zweite Naturwissenschaftliche Abteilung Allgemeine Landwirtschaftliche und Technische Mikrobiologie, V132, P294
   Elsanhoty RM, 2014, FOOD CONTROL, V43, P129, DOI 10.1016/j.foodcont.2014.03.002
   Fallah AA, 2010, FOOD CONTROL, V21, P1478, DOI 10.1016/j.foodcont.2010.04.017
   Fallah AA, 2009, FOOD CHEM TOXICOL, V47, P1872, DOI 10.1016/j.fct.2009.04.042
   Fink-Gremmels J, 2008, VET J, V176, P84, DOI 10.1016/j.tvjl.2007.12.034
   Fochesato AS, 2019, J APPL MICROBIOL, V126, P223, DOI 10.1111/jam.14101
   Foroughi M, 2019, J FOOD PROCESS PRES, V43, DOI 10.1111/jfpp.13876
   Foroughi M, 2018, J FOOD SCI, V83, P2008, DOI 10.1111/1750-3841.14100
   Gao X, 2011, EUR FOOD RES TECHNOL, V232, P957, DOI 10.1007/s00217-011-1463-3
   Gomez-Mascaraque LG, 2016, J FUNCT FOODS, V26, P290, DOI 10.1016/j.jff.2016.08.006
   Pereyra MLG, 2014, J APPL MICROBIOL, V117, P824, DOI 10.1111/jam.12552
   Pereyra MLG, 2011, J SCI FOOD AGR, V91, P1474, DOI 10.1002/jsfa.4336
   Gonzalez PML, 2008, J APPL MICROBIOL, V104, P1034, DOI DOI 10.1111/J.1365-2672.2007.03634.X
   Gurbay A, 2010, FOOD CHEM TOXICOL, V48, P314, DOI 10.1016/j.fct.2009.10.016
   Iannacone J.J., 2016, REV TOXICOL, V33, P31
   IARC-WHO, 2002, MON EV CARC RISK CHE
   International Agency for Research on Cancer (IARC) International Agency for Research on Cancer-World Health Organization, 1993, MON EV CARC RISK HUM
   Jard G, 2011, FOOD ADDIT CONTAM A, V28, P1590, DOI 10.1080/19440049.2011.595377
   Kabak B, 2008, J ENVIRON SCI HEAL B, V43, P617, DOI 10.1080/03601230802234740
   Kamkar A, 2008, FOOD CHEM TOXICOL, V46, P2236, DOI 10.1016/j.fct.2008.02.028
   Khaneghah AM, 2017, CURR NUTR FOOD SCI, V13, P78, DOI 10.2174/1573401313666170102162930
   Maxim LD, 2016, INHAL TOXICOL, V28, P591, DOI 10.1080/08958378.2016.1240727
   Mohan A., 2015, ENCAPSULATION HIDROL, P79270
   Moudgil V, 2013, J ENVIRON PATHOL TOX, V32, P165, DOI 10.1615/JEnvironPatholToxicolOncol.2013007166
   Patel A., 2017, ACT DIN IND LACT DEM
   Pereyra C., 2016, C 8 C BRAS MIC
   Martinez MP, 2017, FOOD ADDIT CONTAM A, V34, P2118, DOI 10.1080/19440049.2017.1371854
   Poloni V, 2015, FOOD ADDIT CONTAM A, V32, P970, DOI 10.1080/19440049.2015.1024761
   Polychronaki N, 2007, FOOD CHEM TOXICOL, V45, P1210, DOI 10.1016/j.fct.2007.01.001
   Rahaie S, 2012, INT J FOOD SCI TECH, V47, P1647, DOI 10.1111/j.1365-2621.2012.03015.x
   Garcia GR, 2018, ARCH TOXICOL, V92, P983, DOI 10.1007/s00204-017-2083-x
   Sarlak Z, 2017, FOOD CONTROL, V71, P152, DOI 10.1016/j.foodcont.2016.06.037
   Serrano-Nino JC, 2013, FOOD CONTROL, V31, P202, DOI 10.1016/j.foodcont.2012.09.023
   Zhao LH, 2011, J APPL MICROBIOL, V110, P147, DOI 10.1111/j.1365-2672.2010.04867.x
NR 44
TC 0
Z9 0
U1 6
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 1
EP 7
DI 10.1016/j.toxicon.2019.10.001
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700001
PM 31610179
DA 2020-05-12
ER

PT J
AU Wang, X
   Yu, H
   Fang, HT
   Zhao, Y
   Jin, YC
   Shen, JL
   Zhou, CH
   Zhou, YF
   Fu, YR
   Wang, JM
   Zhang, J
AF Wang, Xin
   Yu, Hao
   Fang, Hengtong
   Zhao, Yun
   Jin, Yongcheng
   Shen, Jinglin
   Zhou, Changhai
   Zhou, Yongfeng
   Fu, Yurong
   Wang, Junmei
   Zhang, Jing
TI Transcriptional profiling of zearalenone-induced inhibition of IPEC-J2
   cell proliferation
SO TOXICON
LA English
DT Article
DE Zearalenone; IPEC-J2 cells; Cell cycle; RNA-Seq
ID DNA-REPLICATION; MYCOTOXINS; DETOXIFICATION; MODULATION; ACTIVATION;
   EXPRESSION; APOPTOSIS; EXPOSURE; GPR30; CYCLE
AB Mounting evidence has shown that zearalenone (ZEA) can have toxic effects on the intestinal epithelial cells (IECs) of mammals and humans, but the mechanism of ZEA-induced toxicity on IECs is unclear. The aim of this study was to reveal the mechanism of action of ZEA on intestinal epithelial cells via RNA-seq technology. We measured the effects of ZEA on the viability and lactate dehydrogenase (LDH) activity of the pig intestinal epithelial cell line J2 (IPEC-J2). The results showed ZEA can decrease the IPEC-J2 cell viability and increase LDH activity. Appropriate treatment concentrations were determined (40 mu M ZEA) to study the toxic effect of ZEA on IPEC-J2. The results showed that 40 mu M ZEA significantly inhibited IPEC-J2 proliferation and arrested the cell cycle at the G2/M phase. A total of 783 differentially expressed genes (DEGs) were identified after ZEA treatment. KEGG pathway analysis revealed that PERK regulates gene expression, Toll-like receptor cascades signaling pathway, mitosis, mitotic metaphase and anaphase, DNA replication and G2/M checkpoints, were involved in the cell cycle pathway. Eleven key genes involved in G2/M checkpoints were validated by qPCR. Thus, these data highlighted that ZEA caused abnormalities in the G2/M transition in IPEC-J2 cells by altering the cell cycle signaling pathway, thereby inhibiting cell proliferation and inducing injury in IECs. And the study will contribute to get the molecular mechanisms of ZEA inhibition of IECs cell proliferation.
C1 [Wang, Xin; Yu, Hao; Fang, Hengtong; Zhao, Yun; Jin, Yongcheng; Shen, Jinglin; Zhou, Changhai; Zhou, Yongfeng; Fu, Yurong; Wang, Junmei; Zhang, Jing] Jilin Univ, Coll Anim Sci, 5333 Xian Rd, Changchun, Jilin, Peoples R China.
RP Zhang, J (reprint author), Jilin Univ, Coll Anim Sci, 5333 Xian Rd, Changchun, Jilin, Peoples R China.
EM jing_zhang99@jlu.edu.cn
OI Jin, YongCheng/0000-0002-3462-3674; Yu, Hao/0000-0002-2833-6441; zhou,
   yong feng/0000-0002-0506-4113
FU Jilin Scientific and Technological Development Program [20170307018NY,
   20190301034NY]; Special Project of the Province-University
   Coconstructing Program of Jilin Province [SXGJXX2017-4]; Jilin Modern
   Agricultural Technology Demonstration and Extension Project
FX This research was financially supported by the Jilin Scientific and
   Technological Development Program (20170307018NY, 20190301034NY), the
   Special Project of the Province-University Coconstructing Program of
   Jilin Province (SXGJXX2017-4), and the Jilin Modern Agricultural
   Technology Demonstration and Extension Project. The funders had no role
   in the study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abid-Essefi S, 2003, TOXICOLOGY, V192, P237, DOI 10.1016/S0300-483X(03)00329-9
   Adesso S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121343
   Aiko V, 2015, J BIOSCIENCES, V40, P943, DOI 10.1007/s12038-015-9569-6
   Allen K.J., 2013, APPL ENVIRON MICROB, V79, P2225
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Bonfield JK, 2014, BIOINFORMATICS, V30, P2818, DOI 10.1093/bioinformatics/btu390
   Cheraghi S, 2015, TOXICON, V106, P108, DOI 10.1016/j.toxicon.2015.09.018
   Chimento A, 2010, MOL CELL ENDOCRINOL, V320, P136, DOI 10.1016/j.mce.2010.01.035
   Cortinovis C, 2013, THERIOGENOLOGY, V80, P557, DOI 10.1016/j.theriogenology.2013.06.018
   De Boer L, 2008, ONCOGENE, V27, P4261, DOI 10.1038/onc.2008.74
   Du JL, 2014, MOL BIOSYST, V10, P2441, DOI 10.1039/c4mb00287c
   Early A, 2004, PHILOS T R SOC B, V359, P31, DOI 10.1098/rstb.2003.1362
   Enyiukwu D., 2018, GREENER J EPIDEMIOL, V6, DOI [10.15580/gjeph.2018.1.010818004, DOI 10.15580/GJEPH.2018.1.010818004]
   Erenpreisa Jekaterina, 2001, Cancer Cell Int, V1, P1, DOI 10.1186/1475-2867-1-1
   Fan WT, 2018, CHEMOSPHERE, V190, P272, DOI 10.1016/j.chemosphere.2017.09.145
   Fan WT, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21944
   Gajecka M, 2017, MOLECULES, V22, DOI 10.3390/molecules22010018
   Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177
   Grenier B, 2013, TOXINS, V5, P396, DOI 10.3390/toxins5020396
   Jeong SH, 2010, TOX RESEARCH, V26, P301, DOI 10.5487/TR.2010.26.4.301
   Jose P., 2010, CURR PHARM DES, V16
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Maresca M, 2010, TOXICON, V56, P282, DOI 10.1016/j.toxicon.2010.04.016
   Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070
   Nilsson Hoffmann, 2000, PROGR CELL CYCLE RES
   Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608
   Qingwei M., 2014, PLOS ONE, V9
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Signorini ML, 2012, FOOD CHEM TOXICOL, V50, P250, DOI 10.1016/j.fct.2011.09.036
   Soares RRG, 2018, ANALYST, V143, P1015, DOI [10.1039/c7an01762f, 10.1039/C7AN01762F]
   Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017
   Tsaniras SC, 2014, SEMIN CELL DEV BIOL, V30, P174, DOI 10.1016/j.semcdb.2014.03.013
   Wan LYM, 2014, TOXICOL SCI, V139, P83, DOI 10.1093/toxsci/kfu019
   Wan LYM, 2013, TOXICOL LETT, V220, P238, DOI 10.1016/j.toxlet.2013.05.003
   Wang X, 2018, FOOD AGR IMMUNOL, V29, P1002, DOI 10.1080/09540105.2018.1503233
   Wild CP, 2010, CARCINOGENESIS, V31, P71, DOI 10.1093/carcin/bgp264
   Yu S.M., 2014, PLOS ONE, V9
   Zhang KZ, 2018, ECOTOX ENVIRON SAFE, V153, P135, DOI 10.1016/j.ecoenv.2018.01.005
   Zheng WL, 2018, TOXINS, V10, DOI 10.3390/toxins10050184
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
NR 42
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 8
EP 14
DI 10.1016/j.toxicon.2019.10.004
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700002
PM 31614155
DA 2020-05-12
ER

PT J
AU Kaur, M
   Dubey, A
   Khatri, M
   Sehrawat, S
AF Kaur, Manpreet
   Dubey, Abhishek
   Khatri, Madhu
   Sehrawat, Sharvan
TI Secretory PLA2 specific single domain antibody neutralizes Russell viper
   venom induced cellular and organismal toxicity
SO TOXICON
LA English
DT Article
DE Phage display; Monoclonal Ab; sdAb; VHH; RVV envenoming
AB Despite continued destruction of human lives by snakebites, appreciable improvements in immunotherapies have not been made. We selected and characterized venom-specific single domain antibodies (sdAbs) from a constructed phage display library of camelid variable region of heavy chain of the heavy chain antibodies (V(H)Hs). Secretory phospholipase A2-specific sdAbs neutralized venom-induced toxicity in vim and in vivo. Such monoclonal sdAbs could serve as an alternative to help manage snakebites to save lives.
C1 [Kaur, Manpreet; Dubey, Abhishek; Sehrawat, Sharvan] Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Sect 81 SAS Nagar Knowledge City,PO Manauli, Mohali 140306, Punjab, India.
   [Khatri, Madhu] Panjab Univ Chandigarh, Univ Inst Engn & Technol, Chandigarh 160014, India.
RP Sehrawat, S (reprint author), Indian Inst Sci Educ & Res Mohali, Dept Biol Sci, Sect 81 SAS Nagar Knowledge City,PO Manauli, Mohali 140306, Punjab, India.
EM sharvan@iisermohali.ac.in
FU IISER Mohali; Department of Biotechnology (DBT), Govt of IndiaDepartment
   of Biotechnology (DBT) India [BT/PR20283/BBE/117/258/2016]; MHRD-STARS;
   Council of Scientific and Industrial Research (CSIR), Govt of
   IndiaCouncil of Scientific & Industrial Research (CSIR) - India
FX The study was funded partly by the intramural grant from IISER Mohali,
   extramural grant from Department of Biotechnology (DBT), Govt of India
   (BT/PR20283/BBE/117/258/2016) and MHRD-STARS to SS. MK received
   fellowship from the Council of Scientific and Industrial Research
   (CSIR), Govt of India.
CR Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175
   Casewell NR, 2014, P NATL ACAD SCI USA, V111, P9205, DOI 10.1073/pnas.1405484111
   Chippaux JP, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0127-6
   Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602
   Engmark M., 2017, PLOS NEGLECTED TROP, V11
   Evazalipour M, 2012, HYBRIDOMA, V31, P424, DOI 10.1089/hyb.2012.0048
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Jayawardana S, 2018, J MULTIDISCIP HEALTH, V11, P279, DOI 10.2147/JMDH.S126648
   Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113
   Kang TS, 2011, FEBS J, V278, P4544, DOI 10.1111/j.1742-4658.2011.08115.x
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Kini RM, 1997, VENOM PHOSPHOLIPASE, P1
   LoVecchio F, 2003, WILD ENVIRON MED, V14, P220, DOI 10.1580/1080-6032(2003)14[220:SSFAOA]2.0.CO;2
   Maggi M, 2017, PROTEIN EXPRES PURIF, V136, P39, DOI 10.1016/j.pep.2017.02.007
   McIlwain S, 2014, J PROTEOME RES, V13, P4488, DOI 10.1021/pr500741y
   Sehrawat S, 2006, VET IMMUNOL IMMUNOP, V111, P139, DOI 10.1016/j.vetimm.2005.11.004
   't Hoen PAC, 2012, ANAL BIOCHEM, V421, P622, DOI 10.1016/j.ab.2011.11.005
NR 18
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 15
EP 18
DI 10.1016/j.toxicon.2019.10.240
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700003
PM 31689425
DA 2020-05-12
ER

PT J
AU Kara, M
   Gurcay, E
   Aydin, G
   Kaymak, B
   Sekizkardes, M
   Akinci, A
   Uluduz, D
   Ozcakar, L
AF Kara, Murat
   Gurcay, Eda
   Aydin, Gulumser
   Kaymak, Bayram
   Sekizkardes, Merve
   Akinci, Aysen
   Uluduz, Derya
   Ozcakar, Levent
TI Botulinum toxin injections to cranial sutures for chronic migraine
   Rewinding the technique using ultrasound imaging
SO TOXICON
LA English
DT Article
DE Headache; Pain; Ultrasonography; Intervention
ID MENINGEAL NOCICEPTORS; ONABOTULINUMTOXINA; SAFETY; BLIND
AB The treatment of chronic migraine headache is quite challenging and new alternatives are still being explored for its management. Onabotulinum toxin A (BoNT-A) applied into extracranial muscles has been shown to inhibit the release of acetylcholine and local nociceptive peptides at the sensory nerve endings. As the highest concentration of extracranial pain fibers are located at/nearby the sutures, extracranial applications of BoTN-A are suggested to be performed to sutures rather than into the head and neck muscles in the treatment of chronic migraine. Moreover, in an animal study, BoTN-A is found to be more effective for decreasing the chemosensitivity of meningeal nociceptors when the total dose is injected along the sutures in comparison to being divided into sutures and cranial muscles. Of note, since BoNT-A injections performed with the blind/nontargeted technique have lower effectivity and several complications (muscle weakness, ptosis, facial paresis, etc.), the use of ultrasound guidance for targeting the cranial sutures is definitely expected to provide technical ease, better pain relief and toxin tolerance in chronic migraine.
C1 [Kara, Murat; Kaymak, Bayram; Akinci, Aysen; Ozcakar, Levent] Hacettepe Univ, Dept Phys & Rehabil Med, Med Sch, Ankara, Turkey.
   [Gurcay, Eda] Gaziler Training & Res Hosp, Dept Phys & Rehabil Med, Ankara, Turkey.
   [Aydin, Gulumser] Yildirim Beyazit Univ, Dept Phys & Rehabil Med, Med Sch, Ankara, Turkey.
   [Sekizkardes, Merve] Istanbul Phys & Rehabil Med Training & Res Hosp, Dept Phys & Rehabil Med, Istanbul, Turkey.
   [Uluduz, Derya] Istanbul Univ Cerrahpasa, Dept Neurol, Med Sch, Istanbul, Turkey.
RP Sekizkardes, M (reprint author), Istanbul Phys & Rehabil Med Training & Res Hosp, Dept Phys & Rehabil Med, Istanbul, Turkey.
EM merve.sekizkardes@gmail.com
RI Aydin, Gulumser/AAC-3912-2020
CR Aoki KR, 2011, PARKINSONISM RELAT D, V17, pS28, DOI 10.1016/j.parkreldis.2011.06.013
   Aurora SK, 2014, ACTA NEUROL SCAND, V129, P61, DOI 10.1111/ane.12171
   Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
   Blumenfeld A, 2010, HEADACHE, V50, P1406, DOI 10.1111/j.1526-4610.2010.01766.x
   Blumenfeld AM, 2017, HEADACHE, V57, P766, DOI 10.1111/head.13074
   Burstein R, 2014, CEPHALALGIA, V34, P853, DOI 10.1177/0333102414527648
   Guyuron B, 2015, PLAST RECONSTR SURG, V135, P1109, DOI 10.1097/PRS.0000000000001102
   Kara M, 2018, ACTA NEUROL SCAND, V138, P99, DOI 10.1111/ane.12939
   Kara M, 2019, AM J PHYS MED REHAB, V98, pE98, DOI 10.1097/PHM.0000000000001120
   Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049
   Lee HJ, 2015, TOXINS, V7, P2629, DOI 10.3390/toxins7072629
   Matharu M, 2017, CEPHALALGIA, V37, P1384, DOI 10.1177/0333102417724150
   Natoli JL, 2010, CEPHALALGIA, V30, P599, DOI 10.1111/j.1468-2982.2009.01941.x
   Ozcakar L, 2016, AM J PHYS MED REHAB, V95, P158, DOI 10.1097/PHM.0000000000000377
   Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102
   Schueler M, 2013, PAIN, V154, P1622, DOI 10.1016/j.pain.2013.04.040
   Williamson DJ, 2001, MICROSC RES TECHNIQ, V53, P167, DOI 10.1002/jemt.1081
   Zhang XC, 2016, CEPHALALGIA, V36, P875, DOI 10.1177/0333102416636843
NR 18
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 19
EP 22
DI 10.1016/j.toxicon.2019.10.239
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700004
PM 31654680
DA 2020-05-12
ER

PT J
AU Rodriguez-Abarca, S
   Corrales, G
   Chacon, D
   Guevara, M
   Esquivel, C
   Arroyo, C
   Gomez, A
AF Rodriguez-Abarca, Sylvia
   Corrales, Greivin
   Chacon, Danilo
   Guevara, Maricruz
   Esquivel, Carolina
   Arroyo, Cynthia
   Gomez, Aaron
TI Morphological alterations caused by manual venom extraction on the main
   venom gland of Bothrops asper and Crotalus simus snakes (Serpentes:
   Viperidae): Long-term implications for antivenom production
SO TOXICON
LA English
DT Article
DE Snake venom glands; Histopathology; Defective venom yield; Main venom
   gland alterations
ID PROTEIN-SYNTHESIS; MYOTOXINS; JARARACA; STORAGE; COST
AB The only scientifically validated treatment for snakebite envenomation is the administration of antivenoms. For their production, small quantities of snake venom are injected in animals to elicit a specific antibody response. Snakes are kept in captivity, and their venom is regularly extracted to assure antivenom access. It has already been reported that the pressure exerted upon the venom gland during this extraction can cause tissue damage and fibrosis, leading to a decrease in the venom yield. We described the histopathology of venom glands for B. asper and C. simus snakes used for antivenom production. Based on these reported tissue abnormalities, we quantify the tissue injury by a generated damage-SCORE and fibrosis. A variety of histopathological damages were found such as fibrosis, edema, necrosis, hemorrhage, and formation of anomalous structures, especially in C. simus, which is more prone to suffer severe damage. The level and severity of the damage depend on the frequency and the number of venom extractions. Furthermore, we design an experimental intensive venom extraction scheme with which we could confirm the causality of these effects. In addition to the histopathological damages, the LD50 and biochemical venom composition were also affected giving experimental evidence that the venom extraction not only causes tissue damage but also affects the composition stability and toxicity of the venom. In order to produce quality and effective antivenoms, an improvement of the management of snake collections could be established, such as rotation groups to assure the quality of the venom yielded.
C1 [Rodriguez-Abarca, Sylvia; Corrales, Greivin; Chacon, Danilo; Gomez, Aaron] Univ Costa Rica, Inst Clodomiro Picado, Serpentario, Apto 11501-2060, San Jose, Costa Rica.
   [Rodriguez-Abarca, Sylvia] Univ Nacl, Fac Ciencias Exactas & Nat, Escuela Ciencias Biol, Apto 86-3000, Heredia, Costa Rica.
   [Guevara, Maricruz] Univ Tecn Nacl, Fac Med Vet, Alajuela, Costa Rica.
   [Esquivel, Carolina] Univ Nacl, Fac Ciencias Exactas & Nat, Lab Biol Trop, Escuela Ciencias Biol, Apto 86-3000, Heredia, Costa Rica.
   [Arroyo, Cynthia] Univ Costa Rica, Fac Microbiol, Dept Anal Clin, Apto 11501-2060, San Jose, Costa Rica.
   [Arroyo, Cynthia] Aix Marseille Univ, CIML, CNRS, INSERM, Marseille, France.
RP Gomez, A (reprint author), Univ Costa Rica, Inst Clodomiro Picado, Serpentario, Apto 11501-2060, San Jose, Costa Rica.
EM sylviaele10@gmail.com; greivin.corraleschaves@ucr.ac.cr;
   danilo.chacon@ucr.ac.cr; mguevarasoto@gmail.com;
   caroesquiveldobles@gmail.com; carroyoportilla@gmail.com;
   aaron.gomez@ucr.ac.cr
OI Esquivel, Carolina/0000-0002-8284-1545
FU Vicerrectoria de Investigacion, Universidad de Costa Rica [741-B7-107]
FX This study was partially supported by Vicerrectoria de Investigacion,
   Universidad de Costa Rica, grant #741-B7-107. This manuscript is part of
   the requirements to achieve a Degree in Tropical Biology by S.
   Rodriguez-Abarca. The authors also thank Randall Arguedas Porras, DVM,
   MSc for all the chirurgical procedures performed; and Arturo Chang
   Castillo, BSc, for the help and assistance during the biochemical
   analysis.
CR Alape-Giron A, 2008, J PROTEOME RES, V7, P3556, DOI 10.1021/pr800332p
   Alape-Giron A, 2009, TOXICON, V54, P938, DOI 10.1016/j.toxicon.2009.06.011
   Angulo Y, 2009, TOXICON, V54, P949, DOI 10.1016/j.toxicon.2008.12.014
   ASHLEY BD, 1968, TOXICON, V5, P267, DOI 10.1016/0041-0101(68)90118-9
   Bielli M., 2014, Journal of Herpetological Medicine and Surgery, V24, P43, DOI 10.5818/1529-9651-24.1.43
   Brown N, 2010, TOXICON, V55, P1405, DOI 10.1016/j.toxicon.2010.02.012
   Burki T, 2018, LANCET, V391, P2311, DOI 10.1016/S0140-6736(18)31314-X
   Calvete JJ, 2009, J PROTEOME RES, V8, P3055, DOI 10.1021/pr900249q
   Chulasugandha P, 2003, J TOXICOL-TOXIN REV, V22, P1, DOI 10.1081/TXR-120019561
   CIOMS (Council of International Organizations of Medical Sciences), 1986, INT GUID PRINC BIOM
   DELUCCA FL, 1974, TOXICON, V12, P361, DOI 10.1016/0041-0101(74)90003-8
   Durban J, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-234
   Fry G.B, 2015, VENOMOUS REPTILES TH, P606
   Giannotti KC, 2013, TOXICON, V70, P32, DOI 10.1016/j.toxicon.2013.03.019
   Gibbs HL, 2011, J PROTEOMICS, V74, P2169, DOI 10.1016/j.jprot.2011.06.013
   GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Habib AG, 2018, TOXICON, V150, P115, DOI 10.1016/j.toxicon.2018.05.009
   Harrison RA, 2003, TOXICON, V41, P441, DOI 10.1016/S0041-0101(02)00360-4
   Kasturiratne A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005647
   Kilkenny C., 2010, VET CLIN PATH, V41, P27
   KOCHVA E, 1966, COPEIA, P506, DOI 10.2307/1441074
   Lalloo DG, 2003, J TOXICOL-CLIN TOXIC, V41, P277, DOI 10.1081/CLT-120021113
   Leon G, 2016, TOXINOLOGY, P425, DOI 10.1007/978-94-007-6416-3_24
   Luna MS, 2013, J PROTEOMICS, V94, P460, DOI 10.1016/j.jprot.2013.10.026
   MACKESSY SP, 1991, J MORPHOL, V208, P109, DOI 10.1002/jmor.1052080106
   MACKESSY SP, 1988, COPEIA, P92, DOI 10.2307/1445927
   Mackessy SP, 2006, ZOOL ANZ, V245, P147, DOI 10.1016/j.jcz.2006.01.003
   Gutierrez JM, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-7
   Gutierrez JM, 2011, B MALARIOL SALUD AMB, V51, P1
   Gutierrez JM, 2011, BIOLOGICALS, V39, P129, DOI 10.1016/j.biologicals.2011.02.005
   MARSH N, 1974, TOXICON, V12, P621, DOI 10.1016/0041-0101(74)90196-2
   McCue MD, 2006, COPEIA, P818, DOI 10.1643/0045-8511(2006)6[818:COPVIT]2.0.CO;2
   Moura-da-Silva AM, 2012, TOXICON, V60, P280, DOI 10.1016/j.toxicon.2012.03.026
   MOURADASILVA AM, 1991, TOXICON, V29, P713, DOI 10.1016/0041-0101(91)90063-W
   Munekiyo SA, 2005, TOXICON, V45, P255, DOI 10.1016/j.toxicon.2004.10.009
   Munekiyo SM, 1998, COMP BIOCHEM PHYS B, V119, P119, DOI 10.1016/S0305-0491(97)00294-0
   Murphy J.B, 1978, MAINTENANCE RATTLESN
   Castro EN, 2013, J PROTEOMICS, V87, P103, DOI 10.1016/j.jprot.2013.05.024
   Nunez V, 2009, J PROTEOMICS, V73, P57, DOI 10.1016/j.jprot.2009.07.013
   ORON U, 1973, J CELL BIOL, V56, P177, DOI 10.1083/jcb.56.1.177
   ORON U, 1978, BIOCHEM J, V174, P733, DOI 10.1042/bj1740733
   Sakai F, 2012, TOXICON, V59, P393, DOI 10.1016/j.toxicon.2011.12.012
   Sanchez E, 2006, APPL HERPETOL, V3, P1, DOI [10.1163/157075406775247067, DOI 10.1163/157075406775247067]
   SCHENBERG S, 1970, TOXICON, V8, P152
   Solano G, 2010, BIOLOGICALS, V38, P577, DOI 10.1016/j.biologicals.2010.05.006
   Teixeira CFP, 2003, TOXICON, V42, P947, DOI 10.1016/j.toxicon.2003.11.006
   Warrell DA, 2010, LANCET, V375, P77, DOI 10.1016/S0140-6736(09)61754-2
   *WHO, 2010, WHO GUID PROD CONTR
   WHO (World Health Organization), 2019, SNAK ENV STRAT PREV
   WILLEMSE GT, 1979, TOXICON, V17, P37, DOI 10.1016/0041-0101(79)90253-8
NR 51
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 23
EP 32
DI 10.1016/j.toxicon.2019.10.242
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700005
PM 31689424
DA 2020-05-12
ER

PT J
AU Huang, YH
   Du, QD
   Craik, DJ
AF Huang, Yen-Hua
   Du, Qingdan
   Craik, David J.
TI Cyclotides: Disulfide-rich peptide toxins in plants
SO TOXICON
LA English
DT Review
DE Cyclotides; Stability; Insecticidal peptide; Cytotoxicity; Cell
   penetrating peptide; Applications
ID CYSTINE KNOT MOTIF; ANTI-HIV ACTIVITY; KALATA B1; CYCLIC PEPTIDE;
   CYCLOVIOLACIN O2; CIRCULAR PROTEIN; CYTOTOXIC CYCLOTIDES;
   OLDENLANDIA-AFFINIS; VIOLA-ODORATA; MACROCYCLIC POLYPEPTIDES
AB Cyclotides are a plant-derived family of peptides that comprise approximately 30 amino acid residues, a cyclic backbone and a cystine knot. Due to their unique structure, cyclotides are exceptionally stable to heat or proteolytic degradation and are tolerant to amino acid substitutions in their backbone loops between conserved cysteine residues. Their toxicity to insect pests and their make-up of natural amino acids has led to their applications in eco-friendly crop protection. Furthermore, their stability and cell penetrating properties make cyclotides ideal scaffolds for bioactive epitope grafting. This article gives a brief overview of cyclotide discovery, characterization, distribution, synthesis and mode of action mechanisms. We focus on their toxicities to insect pests and their medical and agricultural applications.
C1 [Huang, Yen-Hua; Du, Qingdan; Craik, David J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
RP Craik, DJ (reprint author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
EM d.craik@imb.uq.edu.au
RI Craik, David/B-1695-2010
OI Craik, David/0000-0003-0007-6796; Du, Qingdan/0000-0002-1165-3766
FU Australian Research CouncilAustralian Research Council [DP150100443];
   National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia [APP1084965, APP1060225]
FX Work in our laboratory on cyclotides is funded by grants from the
   Australian Research Council (DP150100443) and the National Health and
   Medical Research Council (APP1084965 and APP1060225). DJC is an
   Australian Research Council Laureate Fellow (FL150100146).
CR Alvarez CA, 2018, MOLECULES, V23, DOI 10.3390/molecules23040952
   Alvarez CA, 2018, MOLECULES, V23, DOI 10.3390/molecules23051033
   Balaraman S, 2018, J CELL BIOCHEM, V119, P3999, DOI 10.1002/jcb.26557
   Barbeta BL, 2008, P NATL ACAD SCI USA, V105, P1221, DOI 10.1073/pnas.0710338104
   Barry DG, 2004, STRUCTURE, V12, P85, DOI 10.1016/j.str.2003.11.019
   Barry DG, 2003, BIOCHEMISTRY-US, V42, P6688, DOI 10.1021/bi027323n
   Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l
   Burman R., 2011, BIOCHIM BIOPHYS ACTA, V2665, P1808
   Burman R, 2010, BIOPOLYMERS, V94, P626, DOI 10.1002/bip.21408
   Burman R, 2010, PHYTOCHEMISTRY, V71, P13, DOI 10.1016/j.phytochem.2009.09.023
   Camarero JA, 2007, CHEMBIOCHEM, V8, P1363, DOI 10.1002/cbic.200700183
   Camarero JA, 2017, BIOORG MED CHEM LETT, V27, P5089, DOI 10.1016/j.bmcl.2017.10.051
   Cao P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030793
   Cascales L, 2011, J BIOL CHEM, V286, P36932, DOI 10.1074/jbc.M111.264424
   Chen B, 2005, J BIOL CHEM, V280, P22395, DOI 10.1074/jbc.M501737200
   Cheneval O, 2014, J ORG CHEM, V79, P5538, DOI 10.1021/jo500699m
   Chiche L, 2004, CURR PROTEIN PEPT SC, V5, P341, DOI 10.2174/1389203043379477
   Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r
   Clark RJ, 2010, BIOPOLYMERS, V94, P414, DOI 10.1002/bip.21372
   Colgrave ML, 2008, CHEMBIOCHEM, V9, P1939, DOI 10.1002/cbic.200800174
   Colgrave ML, 2008, BIOCHEMISTRY-US, V47, P5581, DOI 10.1021/bi800223y
   Colgrave ML, 2010, ANTIMICROB AGENTS CH, V54, P2160, DOI 10.1128/AAC.01306-09
   Colgrave ML, 2009, ACTA TROP, V109, P163, DOI 10.1016/j.actatropica.2008.11.003
   Colgrave ML, 2004, BIOCHEMISTRY-US, V43, P5965, DOI 10.1021/bi049711q
   Conlan BF, 2012, J BIOL CHEM, V287, P28037, DOI 10.1074/jbc.M112.347823
   Contreras J, 2011, J CONTROL RELEASE, V155, P134, DOI 10.1016/j.jconrel.2011.08.030
   Cowper B, 2013, CHEMBIOCHEM, V14, P809, DOI 10.1002/cbic.201300105
   Craik DJ, 2018, BIOORGAN MED CHEM, V26, P2727, DOI 10.1016/j.bmc.2017.08.005
   Craik DJ, 2017, CURR OPIN CHEM BIOL, V38, P8, DOI 10.1016/j.cbpa.2017.01.018
   Craik DJ, 2013, J PEPT SCI, V19, P393, DOI 10.1002/psc.2523
   Craik DJ, 2012, TOXINS, V4, P139, DOI 10.3390/toxins4020139
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4
   Daly NL, 2006, BIOCHEM J, V393, P619, DOI 10.1042/BJ20051371
   Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200
   Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b
   Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007
   Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276
   Daly NL, 2011, EUR BIOPHYS J BIOPHY, V40, P359, DOI 10.1007/s00249-011-0672-9
   Daly NL, 2010, AUST J CHEM, V63, P771, DOI 10.1071/CH10007
   Daly NL, 2009, ADV DRUG DELIVER REV, V61, P918, DOI 10.1016/j.addr.2009.05.003
   DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629
   de Veer SJ, 2017, ACCOUNTS CHEM RES, V50, P1557, DOI 10.1021/acs.accounts.7b00157
   Du JQ, 2019, J NAT PROD, V82, P293, DOI 10.1021/acs.jnatprod.8b00716
   Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200
   Fensterseifer ICM, 2015, PEPTIDES, V63, P38, DOI 10.1016/j.peptides.2014.10.019
   Giang KTN, 2013, J BIOL CHEM, V288, P3370, DOI 10.1074/jbc.M112.415356
   Gilding EK, 2016, NEW PHYTOL, V210, P717, DOI 10.1111/nph.13789
   Goransson U, 2004, J NAT PROD, V67, P1287, DOI 10.1021/np0499719
   Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878
   Goransson U, 2012, J BIOL CHEM, V287, P27001, DOI 10.1074/jbc.R111.300129
   Gould A, 2017, CHEMBIOCHEM, V18, P1350, DOI 10.1002/cbic.201700153
   Gould A, 2011, CURR PHARM DESIGN, V17, P4294, DOI 10.2174/138161211798999438
   GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400
   GRAN L, 1973, LLOYDIA, V36, P174
   Gran L., 1970, MEDD NOR FARM SELSK, V12, P173
   Gran L, 2008, CHEM BIODIVERS, V5, P2014, DOI 10.1002/cbdv.200890184
   Greenwood KP, 2007, INT J BIOCHEM CELL B, V39, P2252, DOI 10.1016/j.biocel.2007.06.016
   Gruber CW, 2008, PLANT CELL, V20, P2471, DOI 10.1105/tpc.108.062331
   Gruber CW, 2010, BIOPOLYMERS, V94, P565, DOI 10.1002/bip.21414
   Grundemann C, 2019, INT J PEPT RES THER, V25, P9, DOI 10.1007/s10989-018-9701-1
   Grundemann C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068016
   Grundemann C, 2012, J NAT PROD, V75, P167, DOI 10.1021/np200722w
   Gunasekera S, 2013, INT J PEPT RES THER, V19, P43, DOI 10.1007/s10989-012-9331-y
   GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064
   Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r
   Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r
   Harris KS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10199
   Hellinger R, 2015, J NAT PROD, V78, P1073, DOI 10.1021/np501061t
   Henriques ST, 2017, BIOCHEMISTRY-US, V56, P669, DOI 10.1021/acs.biochem.6b01212
   Henriques ST, 2015, CHEM BIOL, V22, P1087, DOI 10.1016/j.chembiol.2015.07.012
   Henriques ST, 2014, CHEMBIOCHEM, V15, P1956, DOI 10.1002/cbic.201402144
   Henriques ST, 2012, J BIOL CHEM, V287, P33629, DOI 10.1074/jbc.M112.372011
   Henriques ST, 2012, ACS CHEM BIOL, V7, P626, DOI 10.1021/cb200395f
   Henriques ST, 2011, J BIOL CHEM, V286, P24231, DOI 10.1074/jbc.M111.253393
   Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756
   Herrmann A, 2008, PHYTOCHEMISTRY, V69, P939, DOI 10.1016/j.phytochem.2007.10.023
   Huang YH, 2010, J BIOL CHEM, V285, P10797, DOI 10.1074/jbc.M109.089854
   Huang YH, 2009, J BIOL CHEM, V284, P20699, DOI 10.1074/jbc.M109.003384
   Ireland DC, 2008, BIOPOLYMERS, V90, P51, DOI 10.1002/bip.20886
   Ireland DC, 2006, BIOCHEM J, V400, P1, DOI 10.1042/BJ20060627
   Ireland DC, 2006, J MOL BIOL, V357, P1522, DOI 10.1016/j.jmb.2006.01.051
   Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04669-9
   Jagadish K, 2015, ANGEW CHEM INT EDIT, V54, P8390, DOI 10.1002/anie.201501186
   Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898
   Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h
   Jia XY, 2014, J BIOL CHEM, V289, P6627, DOI 10.1074/jbc.M113.539262
   Kamimori H, 2005, ANAL BIOCHEM, V337, P149, DOI 10.1016/j.ab.2004.10.028
   Kan M. -W., 2018, CYCLIC PEPTIDES BIOO, P302
   Kimura RH, 2006, ANGEW CHEM INT EDIT, V45, P973, DOI 10.1002/anie.200503882
   Koehbach J, 2013, P NATL ACAD SCI USA, V110, P21183, DOI 10.1073/pnas.1311183110
   Koehbach J, 2013, BIOPOLYMERS, V100, P438, DOI 10.1002/bip.22328
   Koltay A, 2005, INT J PEPT RES THER, V11, P99, DOI 10.1007/s10989-004-1722-2
   Kwon S, 2018, ACS CHEM BIOL, V13, P2973, DOI 10.1021/acschembio.8b00653
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   Malik SZ, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00684-17, 10.1128/aac.00684-17]
   Mulvenna JR, 2005, STRUCTURE, V13, P691, DOI 10.1016/j.str.2005.02.013
   Mylne JS, 2012, PLANT CELL, V24, P2765, DOI 10.1105/tpc.112.099085
   Nguyen GKT, 2014, NAT CHEM BIOL, V10, P732, DOI [10.1038/nchembio.1586, 10.1038/NCHEMBIO.1586]
   Noonan J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091938
   Nourse A, 2004, J BIOL CHEM, V279, P562, DOI 10.1074/jbc.M306826200
   Oren Z, 1998, BIOPOLYMERS, V47, P451
   Parsley NC, 2018, PHYTOCHEMISTRY, V152, P61, DOI 10.1016/j.phytochem.2018.04.014
   Pinto MEF, 2018, J NAT PROD, V81, P1203, DOI 10.1021/acs.jnatprod.7b00969
   Plan MR, 2010, BIOPOLYMERS, V94, P647, DOI 10.1002/bip.21409
   Plan MRR, 2008, J AGR FOOD CHEM, V56, P5237, DOI 10.1021/jf800302f
   Plan MRR, 2007, CHEMBIOCHEM, V8, P1001, DOI 10.1002/cbic.200700097
   Poth AG, 2013, BIOPOLYMERS, V100, P480, DOI 10.1002/bip.22284
   Poth AG, 2012, J BIOL CHEM, V287, P27033, DOI 10.1074/jbc.M112.370841
   Poth AG, 2011, P NATL ACAD SCI USA, V108, P10127, DOI 10.1073/pnas.1103660108
   Poth AG, 2011, ACS CHEM BIOL, V6, P345, DOI 10.1021/cb100388j
   Pranting M, 2010, J ANTIMICROB CHEMOTH, V65, P1964, DOI 10.1093/jac/dkq220
   Qu HO, 2017, AUST J CHEM, V70, P152, DOI 10.1071/CH16589
   Quimbar P, 2013, J BIOL CHEM, V288, P13885, DOI 10.1074/jbc.M113.460030
   Rehm FBH, 2019, P NATL ACAD SCI USA, V116, P7831, DOI 10.1073/pnas.1901807116
   Rosengren KJ, 2013, BIOPOLYMERS, V100, P453, DOI 10.1002/bip.22269
   Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200
   SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002
   Saska I, 2007, J BIOL CHEM, V282, P29721, DOI 10.1074/jbc.M705185200
   SCHOPKE T, 1993, SCI PHARM, V61, P145
   Shenkarev ZO, 2008, J INORG BIOCHEM, V102, P1246, DOI 10.1016/j.jinorgbio.2008.01.018
   Shenkarev ZO, 2006, FEBS J, V273, P2658, DOI 10.1111/j.1742-4658.2006.05282.x
   Simonsen SM, 2008, J BIOL CHEM, V283, P9805, DOI 10.1074/jbc.M709303200
   Slazak B, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01296
   Svangard E, 2004, J NAT PROD, V67, P144, DOI 10.1021/np030101l
   Svangard E, 2007, J NAT PROD, V70, P643, DOI 10.1021/np070007v
   Taichi M, 2013, ORG LETT, V15, P2620, DOI 10.1021/ol400801k
   Tam JP, 1998, PROTEIN SCI, V7, P1583, DOI 10.1002/pro.5560070712
   Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913
   Tang J, 2010, PEPTIDES, V31, P1434, DOI 10.1016/j.peptides.2010.05.004
   Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790
   Wang CK, 2018, NAT CHEM BIOL, V14, P417, DOI 10.1038/s41589-018-0039-y
   Wang CK, 2014, ANGEW CHEM INT EDIT, V53, P11236, DOI 10.1002/anie.201406563
   Wang CK, 2012, J BIOL CHEM, V287, P43884, DOI 10.1074/jbc.M112.421198
   Wang CK, 2009, BIOPHYS J, V97, P1471, DOI 10.1016/j.bpj.2009.06.032
   Wang CK, 2009, J BIOL CHEM, V284, P10672, DOI 10.1074/jbc.M900021200
   Wang CKL, 2008, NUCLEIC ACIDS RES, V36, pD206, DOI 10.1093/nar/gkm953
   Wang CKL, 2008, J NAT PROD, V71, P47, DOI 10.1021/np070393g
   Wang CKL, 2011, BIOCHEMISTRY-US, V50, P4077, DOI 10.1021/bi2004153
   Weidmann J, 2016, J EXP BOT, V67, P4801, DOI 10.1093/jxb/erw210
   WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002
   Zenoni S, 2011, PLANT J, V68, P11, DOI 10.1111/j.1365-313X.2011.04661.x
NR 142
TC 1
Z9 1
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 33
EP 44
DI 10.1016/j.toxicon.2019.10.244
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700006
PM 31682883
DA 2020-05-12
ER

PT J
AU dos Reis, VP
   Tavares, MNM
   Rego, CMA
   Ferreira, AAFE
   Setubal, SD
   Soares, AM
   Zamuner, SR
   Zuliani, JP
AF dos Reis, Valdison Pereira
   Macedo Tavares, Maria Naiara
   Alves Rego, Cristina Matiele
   Augusto Ferreira e Ferreira, Alex
   Setubal, Sulamita da Silva
   Soares, Andreimar Martins
   Zamuner, Stella Regina
   Zuliani, Juliana Pavan
TI Light emitting diode (LED) photobiomodulation therapy on murine
   macrophage exposed to Bothropstoxin-I and Bothropstoxin-II myotoxins
SO TOXICON
LA English
DT Article
DE Bothrops jararacussu venom; Bothropstoxins; Macrophages; Light emitting
   diode
ID LEVEL LASER THERAPY; ASPER SNAKE-VENOM; PHOSPHOLIPASES A(2); LIPID
   DROPLETS; NITRIC-OXIDE; MUSCLE; INHIBITOR; ASP-49; LYS-49; ROLES
AB The light-emitting diode (LED) is considered a therapeutic tool due to its anti-inflammatory, analgesic, and wound-healing effects, which occur through angiogenesis, decrease in IL-1 beta and IL-6 secretion, and acceleration of the cicatricial process. Snakebites are an important public health problem in tropical regions of the world. LED treatment is a therapeutic tool associated with serum therapy used to minimize the local effects of snakebites, including decrease in creatine kinase (CK) and lactate dehydrogenase (LDH) concentrations, myonecrosis, and inflammatory and haemorrhagic responses. In this study, we analysed the photobiomodulation effect of LED on the activation of murine macrophages induced by BthTX-I or BthTX-II isolated from Bothrops jararacussu venom. Photobiomodulation caused an increase in mitochondrial metabolism and a considerable decrease in cytotoxicity in murine macrophages. Moreover, it induced a decrease in reactive oxygen species and nitrogen liberation. However, photobiomodulation caused an increase in macrophage phagocytic capacity and lipid droplet formation. The results of this study corroborated with those of others in an unprecedented way and provide a better understanding of the mechanism of action of photobiomodulation, besides offering a coadjuvant action treatment for the local effects of snakebites, not achieved with serum therapy alone.
C1 [dos Reis, Valdison Pereira; Macedo Tavares, Maria Naiara; Alves Rego, Cristina Matiele; Augusto Ferreira e Ferreira, Alex; Setubal, Sulamita da Silva; Zuliani, Juliana Pavan] FIOCRUZ Rondonia, Lab Imunol Celular Aplicada Saude, Rua Beira,7671 BR364,Km 3,5, BR-76812245 Porto Velho, RO, Brazil.
   [Soares, Andreimar Martins; Zuliani, Juliana Pavan] Univ Fed Rondonia, UNIR, Ctr Estudos Biomol Aplicadas Saude, CEBio,Dept Med, Porto Velho, RO, Brazil.
   [Soares, Andreimar Martins; Zuliani, Juliana Pavan] FIOCRUZ Rondonia, Porto Velho, RO, Brazil.
   [Soares, Andreimar Martins] UNISL, Ctr Univ Sao Lucas, Porto Velho, RO, Brazil.
   [Zamuner, Stella Regina] Univ Nove Julho, UNINOVE, Sao Paulo, SP, Brazil.
RP Zuliani, JP (reprint author), FIOCRUZ Rondonia, Lab Imunol Celular Aplicada Saude, Rua Beira,7671 BR364,Km 3,5, BR-76812245 Porto Velho, RO, Brazil.
EM juliana.zuliani@fiocruz.br
RI Zamuner, Stella/C-3132-2012
OI Zamuner, Stella/0000-0002-4694-7617
FU Conselho Nacional de Desenvolvimento Cientffico e TecnolOgico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [482562/2010-2, 479316-2013-6, 301809/2011-9, 306672/2014-6];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Instituto Nacional de Ciencia e Tecnologia em Toxinas
   (INCTTox); Fundacao de Amparo a Pesquisa do Estado de Rondonia (FAPERO);
   CAPES (FAPERO)CAPES
FX The authors express their gratitude to Conselho Nacional de
   Desenvolvimento Cientffico e TecnolOgico (CNPq), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Instituto Nacional
   de Ciencia e Tecnologia em Toxinas (INCTTox) and Fundacao de Amparo a
   Pesquisa do Estado de Rondonia (FAPERO) for the financial support. The
   authors thank the Program for Technological Development in Tools for
   Health-PDTIS-FIOCRUZ for the use of their facilities and Programa
   Pesquisa para o SUS (PP-SUS). This study was supported by grants
   (482562/2010-2 and 479316-2013-6) from Conselho Nacional de
   Desenvolvimento Cientffico e Tecnologico (CNPq). Juliana Pavan Zuliani
   was a recipient of productivity grant 301809/2011-9 and 306672/2014-6
   from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq) and Valdison Pereira dos Reis was the beneficiary of CAPES
   (FAPERO) by Master's fellowship.
CR Lins RDAU, 2010, AN BRAS DERMATOL, V85, P849, DOI 10.1590/S0365-05962010000600011
   Arrese Estela L, 2014, Lipid Insights, V7, P7
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Barbosa AM, 2010, J VENOM ANIM TOXINS, V16, P470, DOI 10.1590/S1678-91992010000300014
   Barbosa AM, 2008, TOXICON, V51, P1236, DOI 10.1016/j.toxicon.2008.02.007
   Barbosa AM, 2009, PHOTOMED LASER SURG, V27, P591, DOI 10.1089/pho.2008.2296
   Bartos A, 2016, J BIOPHOTONICS, V9, P1125, DOI 10.1002/jbio.201500209
   Franco ATB, 2016, LASER MED SCI, V31, P1017, DOI 10.1007/s10103-016-1941-8
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   BULTRON E, 1993, TOXICON, V31, P217, DOI 10.1016/0041-0101(93)90289-U
   Carces A.S, 2012, LASER BAIXA POTENCIA
   Doin-Silva R, 2009, PHOTOCHEM PHOTOBIOL, V85, P63, DOI 10.1111/j.1751-1097.2008.00397.x
   dos Santos AS, 2018, INT J BIOL MACROMOL, V107, P2020, DOI 10.1016/j.ijbiomac.2017.10.076
   Dourado DM, 2003, LASER SURG MED, V33, P352, DOI 10.1002/lsm.10237
   ElSayed SO, 1996, LASER SURG MED, V19, P433, DOI 10.1002/(SICI)1096-9101(1996)19:4<433::AID-LSM8>3.0.CO;2-T
   Fuma S, 2015, MOL VIS, V21, P883
   Furtado JL, 2014, BIOMED RES INT, DOI 10.1155/2014/683123
   Gao Qiang, 2015, Front Cell Dev Biol, V3, P49, DOI 10.3389/fcell.2015.00049
   Giannotti KC, 2013, BIOMED RES INT, DOI 10.1155/2013/807982
   Silva LMG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152890
   Guzzo ML, 2000, TOXICON, V38, P1535, DOI 10.1016/S0041-0101(00)00087-8
   HAAS AF, 1990, J INVEST DERMATOL, V94, P822, DOI 10.1111/1523-1747.ep12874679
   HOMSIBRANDEBURGO MI, 1988, TOXICON, V26, P615, DOI 10.1016/0041-0101(88)90244-9
   KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651
   Leiguez E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093741
   Leiguez E, 2011, J LEUKOCYTE BIOL, V90, P155, DOI 10.1189/jlb.0510263
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x
   Lomonte B, 1999, TOXICON, V37, P145, DOI 10.1016/S0041-0101(98)00171-8
   LOMONTE B, 1994, TOXICON, V32, P41, DOI 10.1016/0041-0101(94)90020-5
   MOURADASILVA AM, 1991, TOXICON, V29, P713, DOI 10.1016/0041-0101(91)90063-W
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nadur-Andrade N, 2014, PHOTOBIOL PHOTOBIOL, V10, P311
   Nadur-Andrade N, 2012, LASER MED SCI, V27, P65, DOI 10.1007/s10103-011-0914-1
   Pontes A.S, 2016, TOXICON, V1, P119
   Pontes AS, 2016, TOXICON, V119, P106, DOI 10.1016/j.toxicon.2016.05.013
   Saka HA, 2012, ANNU REV CELL DEV BI, V28, P411, DOI 10.1146/annurev-cellbio-092910-153958
   Schindl A, 2000, J INVEST MED, V48, P312
   Setubal SS, 2011, J VENOM ANIM TOXINS, V17, P430, DOI 10.1590/S1678-91992011000400010
   Setubal SD, 2013, TOXICON, V76, P143, DOI 10.1016/j.toxicon.2013.09.019
   Singh SB, 2000, ARCH BIOCHEM BIOPHYS, V375, P289, DOI 10.1006/abbi.1999.1672
   Soares AM, 2004, CURR ORG CHEM, V8, P1677, DOI 10.2174/1385272043369610
   Souza L.G, 2011, CLIN EXP MED LETT, V52, P26
   SOUZA LG, 2011, [No title captured], V52, P97
   Silva DFT, 2012, PHOTOCHEM PHOTOBIOL, V88, P1211, DOI 10.1111/j.1751-1097.2012.01166.x
   Vallochi AL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01022
   Walther TC, 2012, ANNU REV BIOCHEM, V81, P687, DOI 10.1146/annurev-biochem-061009-102430
   Welte MA, 2015, CURR BIOL, V25, pR470, DOI 10.1016/j.cub.2015.04.004
   Xavier CV, 2017, INT J BIOL MACROMOL, V105, P1117, DOI 10.1016/j.ijbiomac.2017.07.140
   Zamuner SR, 2001, TOXICON, V39, P1505, DOI 10.1016/S0041-0101(01)00123-4
   Zuliani JP, 2005, TOXICON, V46, P523, DOI 10.1016/j.toxicon.2005.06.017
   Zuliani JP, 2005, TOXICON, V45, P335, DOI 10.1016/j.toxicon.2004.11.004
   Zuliani JP, 2018, INT J BIOL MACROMOL, V113, P575, DOI 10.1016/j.ijbiomac.2018.02.158
   Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7
NR 53
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 45
EP 52
DI 10.1016/j.toxicon.2019.10.243
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700007
PM 31693915
DA 2020-05-12
ER

PT J
AU Riffault-Valois, L
   Wattez, C
   Langrand, J
   Boucaud-Maitre, D
   Gaslonde, T
   Colas, C
   Nossin, E
   Blateau, A
   Michel, S
   Cachet, X
AF Riffault-Valois, Ludivine
   Wattez, Camille
   Langrand, Jerome
   Boucaud-Maitre, Denis
   Gaslonde, Thomas
   Colas, Cyril
   Nossin, Emmanuel
   Blateau, Alain
   Michel, Sylvie
   Cachet, Xavier
TI Health risk associated with the oral consumption of "Chiniy-tref", a
   traditional medicinal preparation used in Martinique (French West
   Indies): Qualitative and quantitative analyses of aristolochic acids
   contained therein
SO TOXICON
LA English
DT Article
DE "Chiniy-tref"; Traditional medicine; Aristolochic acids; Phytochemical
   profile; Probable daily intakes; Aristolochic acid nephropathy
AB "Chiniy-tree" (CT) is a traditional preparation used in folk medicine in Martinique Island (French West Indies) that is nowadays mainly taken orally to prevent or act against any "manifestation of evil". CT is easily prepared at home by macerating larvae of the endemic swallowtail Battus polydamas (ssp.) cebriones (Dalman, 1823), sometimes accompanied by a leaf of its host-plant Aristolochia trilobata L., in commercial rum. We have previously reported the detection of nephrotoxic and carcinogenic aristolochic acids (AM) I and II in CT, leading the Regional Health Agency (ARS) of Martinique to issue an alert regarding the potential risks associated with its consumption in 2015. In order to complete the toxicity risk assessment for oral consumption of CT, a full qualitative analysis of AAs and their analogues (AAAs) was performed, as well as a quantitative determination of the major AM, namely AM I and II. The phytochemical profiling of AAAs present in CT, that also corresponds to that of B. polydamas cebriones larvae feeding on A. trilobata, has been established for the first time by ultra-high performance liquid chromatography/electrospray ionization quadrupole time of-flight tandem mass spectrometry. AM I and II were quantified in a small panel of tinctures by using a validated UHPLC/UV method, allowing us to estimate the probable daily intakes of these toxins by CT consumers. The results proved the existence of a real risk of renal toxicity and carcinogenicity associated with the chronic oral consumption of CT in Martinique, and more generally of similar "snake bottles" throughout the Caribbean.
C1 [Riffault-Valois, Ludivine; Wattez, Camille; Gaslonde, Thomas; Michel, Sylvie; Cachet, Xavier] Univ Paris 05, Fac Pharm Paris, Sorbonne Paris Cite, UMR CiTCoM CNRS 8038, F-75006 Paris, France.
   [Langrand, Jerome] Hop Lariboisiere Fernand Widal, AP HP, Ctr Antipoison Paris, F-75010 Paris, France.
   [Boucaud-Maitre, Denis] Ctr Hosp Basse Terre, Dispositif Toxicovigilance Antilles, F-97100 Basse Terre, Guadeloupe, France.
   [Boucaud-Maitre, Denis] CHU Guadeloupe, Direct Rech Clin & Innovat, F-97110 Pointe A Pitre, Guadeloupe, France.
   [Colas, Cyril] Univ Orleans, Inst Chim Organ & Analyt, ICOA UMR 7311, CNRS, F-45071 Orleans, France.
   [Colas, Cyril] Ctr Biophys Mol, CBM UPR 4301, CNRS, F-45071 Orleans, France.
   [Nossin, Emmanuel] Pharm Prechotaine, F-97250 Le Precheur, Martinique, France.
   [Blateau, Alain] Agence Reg Sante Martin, F-97200 Fort De France, Martinique, France.
RP Cachet, X (reprint author), Univ Paris 05, Fac Pharm Paris, Sorbonne Paris Cite, UMR CiTCoM CNRS 8038, F-75006 Paris, France.
EM xavier.cachet@parisdescartes.fr
OI COLAS, Cyril/0000-0003-1651-6813
FU "Agence Regional de Sante Martinique" (France) [CF02122015]
FX The Authors thank O. Thoison (Institut de Chimie des Substances
   Naturelles CNRS) for her technical support; C. Locatelli-Jouans (ARS
   Martinique), C. Bottai, J. Kai and K. Ma Chou (Faculte de Pharmacie de
   Paris) for their substantial help in the preparation of this manuscript;
   F. Achille (Collections vegetales du Museum National d'Histoire
   Naturelle) for providing the herbal reference standard of A. trilobata
   (Voucher number C87793-63) and the "Agence Regional de Sante Martinique"
   (France) for financial support (ARS Martinique grant CF02122015).
CR Abdullah R, 2017, FOOD ADDIT CONTAM A, V34, P135, DOI 10.1080/19440049.2016.1266098
   Bhattacharjee P, 2017, TOXICON, V138, P1, DOI 10.1016/j.toxicon.2017.08.003
   Bin Bae J, 2019, AGING DIS, V10, P1, DOI 10.14336/AD.2018.0123
   Bocquillon-Limousin H, 1891, PLANTES ALEXITERES A, P13
   Boos J, 1986, J TRINIDAD TOBAGO FI, P48
   Cachet X, 2016, TOXICON, V114, P28, DOI 10.1016/j.toxicon.2016.02.013
   Chan CK, 2019, TOXICS, V7, DOI 10.3390/toxics7010014
   Chen CJ, 2018, INT J CANCER, V143, P1578, DOI 10.1002/ijc.31544
   Ebrahimi M, 2018, INTERDISCIP SCI, V10, P400, DOI 10.1007/s12539-016-0197-0
   Grollman AP, 2009, ADV MOLEC TOXICOL, V3, P211, DOI 10.1016/S1872-0854(09)00007-1
   Hall D., 2017, EENY62 U FLOR
   Heinrich M, 2009, J ETHNOPHARMACOL, V125, P108, DOI 10.1016/j.jep.2009.05.028
   Hoang ML, 2016, CANCER EPIDEM BIOMAR, V25, P1600, DOI 10.1158/1055-9965.EPI-16-0219
   IARC, 2012, IARC MONOGR EVAL C A, p[347, 100A]
   [ICH I.H.T. Guideline], 2005, VAL AN PROC TEXT MET, P1
   Lans C, 2001, BMC Complement Altern Med, V1, P10, DOI 10.1186/1472-6882-1-10
   Martinique A.R.S, 2015, MISE GARDE TOXICITE
   Michl J, 2016, J NAT PROD, V79, P30, DOI 10.1021/acs.jnatprod.5b00556
   Moretti C., 1991, ENCY MED NAT PHYTOTH, P1
   Nault LC, 2019, SEMIN LIVER DIS, V39, P334, DOI 10.1055/s-0039-1685516
   Ng AWT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan6446
   NOSSIN E, 2008, [No title captured], V42, P37
   NOSSIN E, 2006, [No title captured], V38, P23
   Nossin E., 2017, ETHNOPHARMACOLOGIA, V57, P79
   Poon SL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0161-3
   Priestap HA, 2012, BIOCHEM SYST ECOL, V40, P126, DOI 10.1016/j.bse.2011.10.006
   Rufz E., 1859, ENQUETE SERPENT MART, P12
NR 27
TC 1
Z9 1
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD OCT 25
PY 2019
VL 172
BP 53
EP 60
DI 10.1016/j.toxicon.2019.10.241
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JU8SB
UT WOS:000501938700008
PM 31704310
DA 2020-05-12
ER

PT J
AU Buffin, S
   Peubez, I
   Barriere, F
   Nicolai, MC
   Tapia, T
   Dhir, V
   Forma, E
   Seve, N
   Legastelois, I
AF Buffin, Sophie
   Peubez, Isabelle
   Barriere, Fabienne
   Nicolai, Marie-Claire
   Tapia, Tenekua
   Dhir, Vipra
   Forma, Eric
   Seve, Nicolas
   Legastelois, Isabelle
TI Influenza A and B virus-like particles produced in mammalian cells are
   highly immunogenic and induce functional antibodies
SO VACCINE
LA English
DT Article
DE Influenza; Virus-like particle; Vaccine; Transient transfection;
   Neuraminidase inhibition
ID TRANSIENT TRANSFECTION; VACCINE; NEURAMINIDASE; CULTURE; QUANTIFICATION;
   HEMAGGLUTININ; GENERATION; RESPONSES; PROTEINS; PLATFORM
AB Influenza virus-like particles (VLPs) represent an attractive alternative to traditional influenza vaccine formulations. Influenza VLPs mimic the natural virus while lacking the genetic material, are easily recognized by the immune system, and are considered safe. The use of a mammalian cell platform offers many advantages for VLP production, such as flexibility and the same glycosylation patterns as a human virus. In this study, the influenza VLPs containing hemagglutinin (HA), neuraminidase (NA) and matrix M1 proteins were expressed in CHO-K1, Vero or 293 T cell lines using transient transfection. After production in 3L bioreactor and purification, extensive characterization was performed on two batches of VLPs produced in 293 T, the best cell line for VLP expression; one batch expressed the HA and NA genes from A/Hong Kong/4801/2014 (H3N2) strain and the other, HA and NA genes from B/Phuket/3073/2013. Characterizations provided evidence that mammalian VLPs closely emulate the exterior of authentic virus particles in terms of both antigen presentation and biological properties. The two VLPs produced contained more NA proteins on their surface with a HA:NA ratio around 1:1 than influenza viruses which present a HA:NA ratio of around 4:1. Immunogenicity studies in BALB/c mice demonstrated that the VLPs, administered intra-muscularly, were highly immunogenic at low doses, with the induction of functional antibodies against HA and NA. Immunogenicity was also shown in a human in vitro model (MIMIC (R) system). In conclusion, we believe that influenza vaccines made of VLPs produced in mammalian cell lines, constitute a potential alternative to the classical influenza vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Buffin, Sophie; Peubez, Isabelle; Barriere, Fabienne; Nicolai, Marie-Claire; Forma, Eric; Seve, Nicolas; Legastelois, Isabelle] Sanofi Pasteur, Res & Dev, Marcy Letoile, France.
   [Tapia, Tenekua; Dhir, Vipra] Sanofi Pasteur, VaxDesign Campus,2501 Discovery Dr Suite 300, Orlando, FL 32826 USA.
RP Buffin, S (reprint author), Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.
EM sophie.buffin@sanofi.com; isabelle.peubez@sanofi.com;
   fabienne.barriere@sanofi.com; marie-claire.nicolai@sanofi.com;
   tenekua.tapia@sanofi.com; vipra.dhir@sanofi.com; eric.forma@sanofi.com;
   nicolas.seve@sanofi.com; isabelle.legastelois@sanofi.com
CR ANANTHANARAYAN R, 1960, Bull World Health Organ, V22, P409
   Barrett PN, 2009, EXPERT REV VACCINES, V8, P607, DOI [10.1586/erv.09.19, 10.1586/ERV.09.19]
   Bialas KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050595
   Bodewes R, 2010, EXPERT REV VACCINES, V9, P59, DOI 10.1586/ERV.09.148
   Burlaud-Gaillard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093573
   Cervera L, 2018, METHODS MOL BIOL, V1674, P117, DOI 10.1007/978-1-4939-7312-5_10
   Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001
   Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690
   Chlanda P, 2015, J VIROL, V89, P8957, DOI 10.1128/JVI.00592-15
   Cohen M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-321
   Cotter CR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003831
   Couch RB, 2012, VACCINE, V31, P190, DOI 10.1016/j.vaccine.2012.10.065
   Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003
   Dauner A, 2017, VACCINE, V35, P5487, DOI 10.1016/j.vaccine.2017.03.099
   Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]
   E56 Committee, GUID MEAS PART SIZ D, DOI [10.1520/E2834-12R18, DOI 10.1520/E2834-12R18]
   Ehrlich HJ, 2012, VACCINE, V30, P4377, DOI 10.1016/j.vaccine.2011.11.114
   Garg H, 2017, J VIROL, V91, DOI 10.1128/JVI.00834-17
   Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100
   Getie-Kebtie M, 2013, INFLUENZA OTHER RESP, V7, P521, DOI 10.1111/irv.12001
   Gutierrez-Granados S, 2018, CRIT REV BIOTECHNOL, V38, P918, DOI 10.1080/07388551.2017.1419459
   Hofmann I, 2015, BIOTECHNOL BIOENG, V112, P2505, DOI 10.1002/bit.25670
   Hu CMJ, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-016-0321-6
   Kramberger P, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-265
   Lai JCC, 2010, J GEN VIROL, V91, P2322, DOI 10.1099/vir.0.019935-0
   Li F, 2010, MABS-AUSTIN, V2, P466, DOI 10.4161/mabs.2.5.12720
   Lopez-Macias C, 2011, VACCINE, V29, P7826, DOI 10.1016/j.vaccine.2011.07.099
   Lorenzo MMG, 2013, CHEST, V143, P502, DOI 10.1378/chest.12-1711
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Maegawa K, 2018, ARCH VIROL, V163, P2787, DOI 10.1007/s00705-018-3941-4
   Manini I, 2015, EXPERT REV VACCINES, V14, P789, DOI 10.1586/14760584.2015.1039520
   Medina J, 2014, J VIROL METHODS, V196, P25, DOI 10.1016/j.jviromet.2013.09.007
   Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014
   Nachbagauer R, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030047
   Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annure, 10.1146/annurev-med-120611-145115]
   Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008
   Pion C, 2014, VACCINE, V32, P5570, DOI 10.1016/j.vaccine.2014.07.092
   Rajendran M, 2017, MBIO, V8, DOI [10.1128/mbio.02281-16, 10.1128/mBio.02281-16]
   Schanen BC, 2008, J IMMUNOL METHODS, V335, P53, DOI 10.1016/j.jim.2008.02.021
   Shaw ML, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000085
   Singh I, 2012, DISRUPTIVE SCI TECHN, V1, P28, DOI DOI 10.1089/DST.2012.0006
   Stepanenko AA, 2015, GENE, V569, P182, DOI 10.1016/j.gene.2015.05.065
   Stohr Klaus, 2012, Methods Mol Biol, V865, P147, DOI 10.1007/978-1-61779-621-0_9
   Thompson CM, 2015, BMC BIOTECHNOL, V15
   Tretyakova I, 2016, VIROLOGY, V487, P163, DOI 10.1016/j.virol.2015.10.007
   Venereo-Sanchez A, 2019, VACCINE, V37, P7100, DOI 10.1016/j.vaccine.2019.07.057
   Venereo-Sanchez A, 2017, VACCINE, V35, P4220, DOI 10.1016/j.vaccine.2017.06.024
   Venereo-Sanchez A, 2016, VACCINE, V34, P3371, DOI 10.1016/j.vaccine.2016.04.089
   Vernay O, 2019, J VIROL METHODS, DOI [10.1016/J.jviromet2019.01.001, DOI 10.1016/J.JVIROMET2019.01.001]
   Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056
   Wu CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011285
NR 51
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6857
EP 6867
DI 10.1016/j.vaccine.2019.09.057
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000001
PM 31590935
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kirtland, KA
   Lin, X
   Kroger, AT
   Myerburg, S
   Rodgers, L
AF Kirtland, Karen A.
   Lin, Xia
   Kroger, Andrew T.
   Myerburg, Stuart
   Rodgers, Loren
TI Frequency and cost of live vaccines administered too soon after prior
   live vaccine in children aged 12 months through 6 years, 2014-2017
SO VACCINE
LA English
DT Article
DE Live vaccines; Vaccination errors; Children; Immunization information
   systems
ID IMMUNIZATION INFORMATION-SYSTEMS; UNITED-STATES; ADVISORY-COMMITTEE;
   SEASONAL INFLUENZA; VARICELLA VACCINE; RECOMMENDATIONS; PREVENTION;
   MEASLES; MUMPS; RUBELLA
AB Objective: To identify number of children who received live vaccines outside recommended intervals between doses and calculate corrective revaccination costs.
   Methods: We analyzed >1.6 million vaccination records for children aged 12 months through 6 years from six immunization information system (IIS) Sentinel Sites from 2014-15 when live attenuated influenza vaccine (LAIV, FluMist (R) Quadrivalent) was recommended for use, and from 2016-17, when not recommended for use. Depending on the vaccine, insufficient intervals between live vaccine doses are less than 24 or 28 days from a preceding live vaccine dose. Private and public purchase costs of vaccines were used to determine revaccination costs of live vaccine doses administered during the live vaccine conflict interval. Measles, mumps, rubella (MMR), varicella, combined MMRV, and LAIV were live vaccines evaluated in this study.
   Results: Among 946,659 children who received at least one live vaccine dose from 2014-15, 4,873 (0.5%) received at least one dose too soon after a prior live vaccine (revaccination cost, $786,413) with a median conflict interval of 16 days. Among 704,591 children who received at least one live vaccine dose from 2016-17, 1,001 (0.1%) received at least one dose too soon after a prior live vaccine (revaccination cost, $181,565) with a median conflict interval of 14 days. The live vaccine most frequently administered out-side of the recommended intervals was LAIV from 2014-15, and varicella from 2016-17.
   Conclusions: Live vaccine interval errors were rare (0.5%), indicating an adherence to recommendations. If all invalid doses were corrected by revaccination over the two time periods, the cost within the IIS Sentinel Sites would be nearly one million dollars. Provider awareness about live vaccine conflicts, especially with LAIV, could prevent errors, and utilization of clinical decision support functionality within IISs and Electronic Health Record Systems can facilitate better vaccination practices. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kirtland, Karen A.] Northrop Grumman Corp, Atlanta, GA USA.
   [Lin, Xia; Kroger, Andrew T.; Myerburg, Stuart; Rodgers, Loren] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP Kirtland, KA (reprint author), Northrop Grumman, 2800 Century Pkwy NE, Atlanta, GA 30345 USA.
EM kkirtland@cdc.gov
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX The IIS sentinel site project is funded by Centers for Disease Control
   and Prevention. We thank the following representatives from the IIS
   Sentinel Sites for reviewing the study proposal, manuscript, and
   providing vaccination records: Rachel Potter, DVM, MS1; Cristi Bramer,
   MPH1; Miriam Muscoplat, MPH2; Sydney Kuramoto, MPH2; Vikki Papadouka,
   PhD, MPH3; Alexandra Ternier, MPH3; Dominick Fitzsimmons4; Mary
   Woinarowicz, MA4; Andrew Osborn, MBA5; Aaron Dunn, MPH5; Danielle Sill,
   MSPH6, and Stephanie Schauer, PhD6.; 1Michigan Department of Health and
   Human Services.; 2Minnesota Department of Health.; 3North Dakota
   Department of Health.; 4New York City Department of Health and Mental
   Hygiene.; 5Oregon Health Authority.; 6Wisconsin Department of Health
   Services.
CR Bundy DG, 2009, VACCINE, V27, P3890, DOI 10.1016/j.vaccine.2009.04.005
   Cardemil C, 2013, MMWR-MORBID MORTAL W, V62, P1005
   Centers for Disease Control and Prevention, IMM INF SYST IIS Q A
   Centers for Disease Control and Prevention, 2014, ARCH CDC VACC PRIC L
   Centers for Disease Control and Prevention, 2018, REC IMM SCHED CHILDR
   Centers for Disease Control and Prevention, VACC YOUR CHILD IS S
   Centers for Disease Control and Prevention, COR DAT EL IIS FUNCT
   Centers for Disease Control and Prevention, IMM INF SYST IIS CLI
   Cullen KA, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6502a1
   ENGLUND JA, 1989, J PEDIATR-US, V114, P37, DOI 10.1016/S0022-3476(89)80598-0
   Grohskopf LA, 2018, MMWR-MORBID MORTAL W, V67, P643, DOI 10.15585/mmwr.mm6722a5
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Groom H, 2015, J PUBLIC HEALTH MAN, V21, P227, DOI 10.1097/PHH.0000000000000069
   Hamborsky J, 2015, EPIDEMIOLOGY PREVENT
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   High P., 2010, Morbidity and Mortality Weekly Report, V59, P125
   Hopkins DP, 2015, J PUBLIC HEALTH MAN, V21, P249, DOI 10.1097/PHH.0000000000000092
   Hulsey E, 2015, VACCINE, V33, P2546, DOI 10.1016/j.vaccine.2015.04.020
   Institute of Medicine, 2003, SETT COURS STRAT V 4
   Kroger AT, GEN BEST PRACTICES I
   Kroger AT, GEN RECOMMENDATIONS
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Marin Mona, 2010, Morbidity and Mortality Weekly Report, V59, P1
   McLean HQ, 2013, MMWR RECOMM REP, V62, P1
   Meyerhoff A, 2004, CLIN PEDIATR, V43, P87, DOI 10.1177/000992280404300112
   PETRALLI JK, 1965, NEW ENGL J MED, V273, P198, DOI 10.1056/NEJM196507222730405
   Poland GA, 2013, VACCINE, V31, P4689, DOI 10.1016/j.vaccine.2013.03.031
   Rodgers L, 2018, J PEDIATR-US, V193, P164, DOI 10.1016/j.jpeds.2017.09.057
   Stokley S, 2004, AM J PREV MED, V26, P34, DOI 10.1016/j.amepre.2003.09.002
   Ventola C Lee, 2016, P T, V41, P426
   Verstraeten T, 2003, PEDIATRICS, V112, pE98, DOI 10.1542/peds.112.2.e98
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6868
EP 6873
DI 10.1016/j.vaccine.2019.09.058
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000002
PM 31563283
DA 2020-05-12
ER

PT J
AU Biggerstaff, M
   Cohen, C
   Reed, C
   Tempia, S
   McMorrow, ML
   Walaza, S
   Moyes, J
   Treurnicht, FK
   Cohen, AL
   Hutchinson, P
   Stoecker, C
   Steinberg, J
AF Biggerstaff, Matthew
   Cohen, Cheryl
   Reed, Carrie
   Tempia, Stefano
   McMorrow, Meredith L.
   Walaza, Sibongile
   Moyes, Jocelyn
   Treurnicht, Florette K.
   Cohen, Adam L.
   Hutchinson, Paul
   Stoecker, Charles
   Steinberg, Joni
TI A cost-effectiveness analysis of antenatal influenza vaccination among
   HIV-infected and HIV-uninfected pregnant women in South Africa
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Pregnant; Maternal; Cost effectiveness; Infant
ID RESPIRATORY SYNCYTIAL VIRUS; SEASONAL INFLUENZA; PANDEMIC INFLUENZA;
   MATERNAL INFLUENZA; IMMUNIZATION; ILLNESSES; HEALTH; METAANALYSIS;
   BURDEN; AGE
AB Background: Pregnant women and infants are at increased risk of severe disease from influenza. Antenatal influenza vaccination is safe and can reduce the risk of illness for women and their infants. We evaluated for South Africa the health effects of antenatal influenza vaccination among pregnant women and their infants aged <6 months old and assessed its cost-effectiveness.
   Methods: We constructed a decision tree model to simulate the population of pregnant women and infants aged <6 months in South Africa using TreeAge Pro Suite 2015. The model evaluated the change in societal costs and outcomes associated with a vaccination campaign that prioritized HIV-infected over HIV-uninfected pregnant women compared with no vaccination. We also examined the impacts of a campaign without prioritization. Upper and lower 90% uncertainty intervals (90% UI) were generated using probabilistic sensitivity analysis on 10000 Monte Carlo simulations. The cost-effectiveness threshold was set to the 2015 per capita gross domestic product of South Africa, US$5724.
   Results: Antenatal vaccination with prioritization averted 9070 (90% UI: 7407-11217) total cases of influenza among pregnant women and infants, including 411 (90% UI: 305-546) hospitalizations and 30 (90% UI: 22-40) deaths. This corresponds to an averted fraction of 13.5% (90% Ul: 9.0-20.5%). Vaccinating without prioritization averted 7801 (90% UI: 6465-9527) cases of influenza, including 335 (90% UI: 254-440) hospitalizations and 24 (90% UI: 18-31) deaths. This corresponds to an averted fraction of 11.6% (90% UI: 7.8-17.4%). Vaccinating the cohort of pregnant women with prioritization had societal cost of $4689 (90% UI: $3128-$7294) per Quality Adjusted Life Year (QALY) gained while vaccinating without prioritization had a cost of $5924 (90% UI: $3992-$9056) per QALY.
   Conclusions: Antenatal influenza vaccination campaigns in South Africa would reduce the impact of influenza and could be cost-effective. Published by Elsevier Ltd.
C1 [Biggerstaff, Matthew; Reed, Carrie; Tempia, Stefano; McMorrow, Meredith L.; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA.
   [Cohen, Cheryl; Tempia, Stefano; Walaza, Sibongile; Moyes, Jocelyn; Treurnicht, Florette K.] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr Resp Dis & Meningitis, Johannesburg, South Africa.
   [Cohen, Cheryl; Walaza, Sibongile; Moyes, Jocelyn] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa.
   [Tempia, Stefano; McMorrow, Meredith L.; Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa.
   [Tempia, Stefano] MassGenics, Duluth, GA USA.
   [McMorrow, Meredith L.; Cohen, Adam L.] US PHS, Rockville, MD USA.
   [Treurnicht, Florette K.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa.
   [Cohen, Adam L.] WHO, Dept Immunizat Vaccines & Biol, Expanded Programme Immunizat, Geneva, Switzerland.
   [Hutchinson, Paul] Tulane Univ, Sch Publ Hlth & Trop Med, Global Community Hlth & Behav Sci, New Orleans, LA USA.
   [Stoecker, Charles; Steinberg, Joni] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Hlth Policy & Management, New Orleans, LA USA.
RP Biggerstaff, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS H24-7, Atlanta, GA 30329 USA.
EM mbiggerstaff@cdc.gov
RI Moyes, Jocelyn/AAF-7882-2019
OI Cohen, Cheryl/0000-0003-0376-2302; Biggerstaff,
   Matthew/0000-0001-5108-8311; McMorrow, Meredith/0000-0001-6363-4033;
   Tempia, Stefano/0000-0003-4395-347X
FU World Health OrganizationWorld Health Organization [001]
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Baguelin M, 2010, VACCINE, V28, P2370, DOI 10.1016/j.vaccine.2010.01.002
   Beigi RH, 2009, CLIN INFECT DIS, V49, P1784, DOI 10.1086/649013
   Bilcke J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102634
   Blommaert A, 2014, VACCINE, V32, P6075, DOI 10.1016/j.vaccine.2014.08.085
   Centers for Disease Control and Prevention, 2016, DIS BURD INFL SEAS I
   Centers for Disease Control and Prevention, 2019, SEAS INFL VACC EFF 2
   Chow MYK, 2014, QUAL LIFE RES, V23, P1651, DOI 10.1007/s11136-013-0606-3
   Cohen C, 2018, CLIN INFECT DIS, V66, P95, DOI 10.1093/cid/cix740
   Department of Health/South Africa, 2007, S AFR DEM HLTH SURV
   Ding Y, 2012, OBSTET GYNECOL, V119, P306, DOI 10.1097/AOG.0b013e318242af27
   Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037
   Fell DB, 2017, VACCINE, V35, P2279, DOI 10.1016/j.vaccine.2017.03.056
   Goga AE, 2014, J EPIDEMIOL COMMUNIT
   Jit M, 2010, VACCINE, V29, P115, DOI 10.1016/j.vaccine.2010.08.078
   Johnson LF, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002468
   Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Knoema, 2017, GLOB HLTH OBS
   Madhi SA, 2017, CLIN INFECT DIS, V64, P1773, DOI 10.1093/cid/cix241
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   McMorrow ML, 2019, VACCINE, V37, P25, DOI 10.1016/j.vaccine.2018.11.048
   McMorrow ML, 2018, CLIN INFECT DIS
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Murray J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132078
   Myers ER, 2011, AM J OBSTET GYNECOL, V204, pS128, DOI 10.1016/j.ajog.2011.04.009
   Orenstein EW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171499
   Pillay Y, 2014, JOINT REV HIV TB PMT
   Prosser LA, 2011, VALUE HEALTH, V14, P135, DOI 10.1016/j.jval.2010.10.026
   Ramkrishna W., 2016, OPTIONS 9 CONTROL IN
   Roberts S, 2006, OBSTET GYNECOL, V107, P1323, DOI 10.1097/01.AOG.0000210225.45986.99
   Savitz DA, 2015, VACCINE, V33, P6430, DOI 10.1016/j.vaccine.2015.08.041
   Sinha A, 2012, PAEDIATR INT CHILD H, V32, P65, DOI 10.1179/2046905512Y.0000000010
   Skedgel C, 2011, CAN J PUBLIC HEALTH, V102, P445, DOI 10.1007/BF03404197
   South Africa National Department of Health, 2017, NAT INFL POL STRAT P
   Statistics South Africa, 2015, REC LIV BIRTHS
   Statistics South Africa, 2018, STAT S AFR PUBL, VP0141
   Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9
   Sukumaran L, 2015, OBSTET GYNECOL, V126, P1069, DOI 10.1097/AOG.0000000000001066
   Tapia MD, 2016, LANCET INFECT DIS
   Tempia S, 2018, INFLUENZA OTHER RESP, V12, P360, DOI 10.1111/irv.12529
   Tempia S, 2015, CLIN INFECT DIS, V61, P1063, DOI 10.1093/cid/civ448
   Tempia S, 2014, CLIN INFECT DIS, V58, P1241, DOI 10.1093/cid/ciu095
   Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300
   The Centre for Respiratory Diseases and Meningitis National Institute for Communicable Diseases National Health Laboratory Service South African National Department of Health., 2016, HEALTHC WORK HDB INF
   Thompson MG, 2018, CLIN INFECT DIS
   United Nations Inter-agency Group for Child Mortality Estimation, 2014, LEV TRENDS CHILD MOR
   Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096
   Wong KKL, 2018, PAN AFR MED J, V30, DOI 10.11604/pamj.2018.30.271.14477
   World Bank, 2017, GDP PER CAP CURR US
   World Health Organization, 2017, WHO FLUNET
   World Health Organization, 2014, WHO TABL THRESH VAL
   World Health Organization Regional Office for Europe, 2015, REV VACC PRIC DAT
   Xu J, 2016, VACCINE, V34, P3149, DOI 10.1016/j.vaccine.2016.04.057
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6874
EP 6884
DI 10.1016/j.vaccine.2019.09.059
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000003
PM 31575494
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wang, B
   Afzali, HHA
   Giles, L
   Marshall, H
AF Wang, Bing
   Afzali, Hossein Haji Ali
   Giles, Lynne
   Marshall, Helen
TI Lifetime costs of invasive meningococcal disease: A Markov model
   approach
SO VACCINE
LA English
DT Article
DE Meningococcal disease; Costs; Markov model
ID ECONOMIC-EVALUATION; B DISEASE; INTRODUCING VACCINATION; EPIDEMIOLOGIC
   IMPACT; SEVERE MENINGITIS; STUMP OVERGROWTH; OUTCOMES; ADOLESCENTS;
   PREVALENCE; CHILDREN
AB Introduction: Invasive meningococcal disease (IMD) is an uncommon but life-threatening infectious disease associated with high sequelae rates in young children and an increased risk of mortality in adolescents and young adults. Funding decisions to reject inclusion of new meningococcal serogroup B vaccines on national immunisation schedules have been criticised by IMD patients, their families, paediatricians and charity organisations. We aim to estimate the lifetime costs of IMD with the best available evidence to inform cost-effectiveness analyses.
   Methods: A Markov model was developed taking healthcare system and societal perspectives. A range of data including age-specific mortality rates, and probabilities of IMD-related sequelae were derived from a systematic review and meta-analysis. All currencies were inflated to year 2017 prices by using consumer price indexes in local countries and converted to US dollars by applying purchasing power parities conversion rates. Expert panels were used to inform the model development process including key structural choices and model validations.
   Results: The estimated lifetime societal cost is US$319,896.74 per IMD case including the direct health-care cost of US$65,035.49. Using a discount rate of 5%, the costs are US$54,278.51 and US$13,968.40 respectively. Chronic renal failure and limb amputation result in the highest direct healthcare costs per patient. Patients aged < 5 years incur the higher healthcare expenditure compared with other age groups. The costing results are sensitive to the discount rate, disease incidence, acute admission costs, and sequelae rates and costs of brain injuries and epilepsy.
   Conclusions: IMD can result in substantial costs to the healthcare system and society. Understanding the costs of care can assist decision-making bodies in evaluating cost-effectiveness of new vaccine programs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Bing; Marshall, Helen] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Wang, Bing; Giles, Lynne; Marshall, Helen] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Wang, Bing; Afzali, Hossein Haji Ali; Giles, Lynne; Marshall, Helen] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.
   [Wang, Bing; Marshall, Helen] Womens & Childrens Hosp, VIRTU, Adelaide, SA, Australia.
RP Marshall, H (reprint author), Womens & Childrens Hosp, VIRTU, Adelaide, SA, Australia.
EM bing.wang@adelaide.edu.au; hossein.hajialiafzali@adelaide.edu.au;
   lynne.giles@adelaide.edu.au; helen.marshall@adelaide.edu.au
FU National Health and Medical Research Council of Australia: Career
   Development FellowshipNational Health and Medical Research Council of
   Australia [1084951]
FX Professor Helen Marshall acknowledges support from the National Health
   and Medical Research Council of Australia: Career Development Fellowship
   (1084951). Authors would like to thank Dr Nigel Crawford, Prof Robert
   Booy, Dr David Thomas, Dr James Rice, Dr David Shaw, Dr Celia Cooper, Dr
   Brain Conway, Dr Nan Vasilunas, Mr Stephen Cox, Ms Jenny Faulks, Dr
   Lachlan Farmer, A/Prof Ann Koehler and Ms Emma Denehy for kindly
   providing valuable advice on model structure and inputs.
CR ABRAHAM E, 1986, J PEDIATR ORTHOPED, V6, P66, DOI 10.1097/01241398-198601000-00014
   Afzali HHA, 2018, PHARMACOECONOMICS, V36, P1309, DOI 10.1007/s40273-018-0693-7
   Afzali HHA, 2012, PHARMACOECONOMICS, V30, P461, DOI 10.2165/11590500-000000000-00000
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bache CE, 2006, J PEDIATR ORTHOPED, V26, P135, DOI 10.1097/01.bpo.0000187991.71645.e7
   Benard S, 2016, J INFECT PUBLIC HEAL, V9, P339, DOI 10.1016/j.jiph.2015.10.016
   Borg J, 2009, PEDIATRICS, V123, pe502, DOI 10.1542/peds.2008-0581
   Caro JJ, 2012, VALUE HEALTH, V15, P796, DOI 10.1016/j.jval.2012.06.012
   Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004
   Christensen H, 2013, VACCINE, V31, P2638, DOI 10.1016/j.vaccine.2013.03.034
   Darba J, 2014, VACCINE, V32, P5006, DOI 10.1016/j.vaccine.2014.07.019
   Davis KL, 2011, HUM VACCINES, V7, P458, DOI 10.4161/hv.7.4.14434
   Davis KL, 2011, HUM VACCINES, V7, P96, DOI 10.4161/hv.7.1.13692
   De Wals P, 2007, VACCINE, V25, P5433, DOI 10.1016/j.vaccine.2007.04.071
   De Wals P, 2017, PEDIATR INFECT DIS J, V36, pE203, DOI 10.1097/INF.0000000000001512
   Delea TE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175721
   Drummond Michael F., 2015, METHODS EC EVALUATIO
   Gasparini R, 2016, HUM VACC IMMUNOTHER, V12, P2148, DOI 10.1080/21645515.2016.1160177
   Gottfredsson M, 2011, CLIN INFECT DIS, V53, pE117, DOI 10.1093/cid/cir500
   Haji Ali Afzali H, 2014, ENCY HLTH EC, P340
   Hanquet GC, 2014, KCE REPORTS, V231
   Hepkema H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065036
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Jo C, 2014, CLIN MOL HEPATOL, V20, P327, DOI 10.3350/cmh.2014.20.4.327
   Karve S, 2011, HLTH OUTCOMES RES ME, V2, pe215, DOI DOI 10.1016/J.EHRM.2011.08.001
   Kigozi J, 2016, EUR J HEALTH ECON, V17, P31, DOI 10.1007/s10198-014-0652-y
   Klimisch J, 2011, J PEDIATR ORTHOPED, V31, P216, DOI 10.1097/BPO.0b013e3182074769
   KOOPMANSCHAP MA, 1995, J HEALTH ECON, V14, P171, DOI 10.1016/0167-6296(94)00044-5
   Lecocq H, 2016, VACCINE, V34, P2240, DOI 10.1016/j.vaccine.2016.03.020
   Martinon-Torres F, 2016, J ADOLESCENT HEALTH, V59, pS12, DOI 10.1016/j.jadohealth.2016.03.041
   Mensch A, 2018, PHARMACOECONOMICS, V36, P987, DOI 10.1007/s40273-018-0651-4
   Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017
   Molinier L, 2008, VALUE HEALTH, V11, P878, DOI 10.1111/j.1524-4733.2008.00327.x
   Nelson Kliegman R, 2011, TXB PEDIAT
   Organisation for Economic Co-operation and Development (OECD), PURCH POW PAR PPP IN
   PELLICORE RJ, 1974, INTER-CLIN INFO BULL, V13, P1
   Pharmaceutical Benefits Advisory Committee, 2016, GUID PREP SUBM PHARM
   Pouwels KB, 2013, HUM VACC IMMUNOTHER, V9, P1129, DOI 10.4161/hv.23888
   Rice D P, 2000, Inj Prev, V6, P177, DOI 10.1136/ip.6.3.177
   Roberts M, 2012, VALUE HEALTH, V15, P804, DOI 10.1016/j.jval.2012.06.016
   Roed C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009662
   Sadarangani M, 2015, CLIN INFECT DIS, V60, pE27, DOI 10.1093/cid/civ028
   Scholz S, 2019, VACCINE, V37, P1692, DOI 10.1016/j.vaccine.2019.01.013
   Severens JL, 2004, VALUE HEALTH, V7, P397, DOI 10.1111/j.1524-4733.2004.74002.x
   Shemilt I, 2010, EVID POLICY, V6, P51, DOI 10.1332/174426410X482999
   Tirani M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123383
   Tooms RE, 1992, ATLAS LIMB PROSTHETI
   Tu HAT, 2014, VACCINE, V32, P5436, DOI 10.1016/j.vaccine.2014.07.096
   van den Hout WB, 2010, ANN RHEUM DIS, V69, P89, DOI 10.1136/ard.2009.117150
   Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1
   Vyse A, 2013, EXPERT REV ANTI-INFE, V11, P597, DOI [10.1586/ERI.13.42, 10.1586/eri.13.42]
   Wang B, 2019, VACCINE, V37, P2768, DOI 10.1016/j.vaccine.2019.04.020
   Wang B, 2014, VACCINE, V32, P4791, DOI 10.1016/j.vaccine.2014.05.069
   Wright C, 2013, PEDIATR DRUGS, V15, P49, DOI 10.1007/s40272-012-0006-0
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6885
EP 6893
DI 10.1016/j.vaccine.2019.09.060
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000004
PM 31594708
DA 2020-05-12
ER

PT J
AU Okenwa, UJ
   Dairo, MD
   Uba, B
   Ajumobi, O
AF Okenwa, Uchechukwu Joel
   Dairo, Magbagbeola David
   Uba, Belinda
   Ajumobi, Olufemi
TI Maternal reasons for non-receipt of valid Hepatitis B birth dose among
   mother-infant pairs attending routine immunization clinics, South-east,
   Nigeria
SO VACCINE
LA English
DT Article
DE Hepatitis B valid-birth-dose; Immunization; Maternal; Nigeria
ID VIRUS INFECTION; TRANSMISSION; PREVENTION
AB Background: Hepatitis B vaccine (HepB) is an effective tool in prevention of hepatitis B virus (HBV) infection. When administered at birth, it prevents mother-to-child transmission of acute and chronic HBV infection. However, despite a decade and half of implementation of HepB birth dose (HepB-BD), uptake has remained persistently low in Enugu State, Nigeria. We assessed the uptake of valid HepB-BD and the reasons given by mothers of infants for not receiving the HepB-BD in Enugu State, South-east Nigeria.
   Methods: An hospital-based cross-sectional survey was conducted among mother-infant pairs attending immunization clinics at randomly selected health facilities in Enugu State, Nigeria. Overall, 344 mothers and their infant children in this study were interviewed using structured questionnaire. Data on maternal reasons for non-receipt of valid HepB-BD by their infants and their recommendations on ways to improve valid HepB-BD uptake, were collected. We defined valid birth dose as the receipt of first dose of HepB within 24 h of birth.
   Results: Overall, 254 (73.8%) infants did not receive valid HepB-BD. Major reasons for its non-receipt were vaccine not available at place of delivery (91.3%, n = 232), delivery did not take place on immunization day (75.6%, n = 192), lack of awareness on timing of valid HepB-BD (72.8%, n = 185), long distance from the health facility (5.1%, n = 13) and fee payment for immunization (6.3%, n = 16). Of the 384 maternal recommendations, 143 (37.2%) emphasized female literacy while 87 (22.7%) indicated pre-positioning the vaccines at labor rooms to improve valid HepB-BD uptake.
   Conclusion: The low receipt of valid HepB-BD among infants attending routine immunization clinics, found in this study were attributed to lack of maternal awareness on timing of HepB-BD and poor integration of child delivery and immunization services. We recommend educating mothers on benefits of a timely HepB-BD and pre-positioning the vaccines at the labor rooms. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Okenwa, Uchechukwu Joel; Uba, Belinda; Ajumobi, Olufemi] Nigeria Field Epidemiol & Lab Training Program, Abuja, Nigeria.
   [Okenwa, Uchechukwu Joel; Dairo, Magbagbeola David] Univ Ibadan, Fac Publ Hlth, Dept Epidemiol & Med Stat, Ibadan, Nigeria.
   [Uba, Belinda; Ajumobi, Olufemi] Nigeria Country Off, African Field Epidemiol Network, Abuja, Nigeria.
RP Okenwa, UJ (reprint author), Nigeria Field Epidemiol & Lab Training Program, Abuja, Nigeria.; Okenwa, UJ (reprint author), Univ Ibadan, Fac Publ Hlth, Dept Epidemiol & Med Stat, Ibadan, Nigeria.
EM okexta@yahoo.com
FU United States Centers for Disease Control and Prevention through African
   Field Epidemiology NetworkUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA [NU2GGH001876]
FX This study was supported by Cooperative Agreement Number NU2GGH001876
   funded by the United States Centers for Disease Control and Prevention
   through African Field Epidemiology Network to the Nigeria Field
   Epidemiology and Laboratory Training Programme (NFELTP). Its contents
   are solely the responsibility of the authors and do not necessarily
   represent the official views of the United States Centers for Disease
   Control and Prevention or the Department of Health and Human Services.
CR ADEDIRE EB, 2016, BMC PUBLIC HEALTH, V16, P1, DOI DOI 10.1186/S12913-015-1014
   Andersson MI, 2015, LANCET GLOB HEALTH, V3, pE358, DOI 10.1016/S2214-109X(15)00056-X
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P405
   Babalola S, 2011, J PAEDIATR CHILD H, V47, P276, DOI 10.1111/j.1440-1754.2010.01956.x
   Downing S. G., 2008, Papua New Guinea Medical Journal, V51, P47
   Federal Ministry of Health NNH-A and StiCP, 2015, THE NATIONAL POLICY
   Franco E, 2012, WORLD J HEPATOL, V4, P74, DOI 10.4254/wjh.v4.i3.74
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Musa BM, 2015, NIGER J CLIN PRACT, V18, P163, DOI 10.4103/1119-3077.151035
   National Primary Health Care Development Agency and National Bureau of Statistics, 2016, NIG NAT IMM COV SURV, V4, P1
   National Programme on Immunization (NPI), 2004, BAS GUID ROUT IMM SE
   Odusanya OO, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-381
   Odutola A, 2015, BMC HEALTH SERV RES, P1, DOI [10.1186/S12913-015-1014, DOI 10.1186/S12913-015-1014]
   Organization WH, 2017, GLOBAL HEPATITIS REP
   Patel MK, 2014, VACCINE, V32, P5140, DOI 10.1016/j.vaccine.2013.11.097
   Sage W., 2016, MEETING OF THE STRAT, V2016
   *WHO, 2006, PREV CHEM HUM HELM C, P1
   World Health Organization, 2012, World Health Organ Tech Rep Ser, P1
   World Health Organization, 2016, CURR ZIK PROD PIP, P1
   Xeuatvongsa A, 2013, MMWR-MORBID MORTAL W, V62, P587
   Zhang L, 2014, HUM VACC IMMUNOTHER, V10, P2755, DOI 10.4161/hv.29648
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6894
EP 6899
DI 10.1016/j.vaccine.2019.09.056
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000005
PM 31562005
DA 2020-05-12
ER

PT J
AU Napolitano, F
   Bianco, A
   D'Alessandro, A
   Papadopoli, R
   Angelillo, IF
AF Napolitano, Francesco
   Bianco, Aida
   D'Alessandro, Alessia
   Papadopoli, Rosa
   Angelillo, Italo Francesco
TI Healthcare workers' knowledge, beliefs, and coverage regarding
   vaccinations in critical care units in Italy
SO VACCINE
LA English
DT Article
DE Critical care units; Healthcare workers; Hospital; Recommended
   vaccinations; Survey; Vaccinations coverage
ID INFLUENZA VACCINATION; ATTITUDES; INTERVENTIONS; PHYSICIANS; INFECTION;
   STATES; RISK
AB Background: Low rates of vaccine coverage have resulted in a resurgence of several vaccine-preventable diseases in many European countries. Routine vaccination of healthcare workers (HCWs) is important to reduce disease transmission, and to promote vaccine awareness and acceptance in the population. The objectives of this cross-sectional study were to investigate knowledge and beliefs about vaccines and to evaluate self-reported immunization coverage with vaccines recommended for HCWs. Additionally, the effects of several factors on these outcomes have been evaluated.
   Methods: A survey was conducted between September and November 2018 among a random sample of HCWs in cardiac, adult, and neonatal critical care units of 8 randomly selected hospitals across the Campania and Calabria Regions in Italy. Multivariate logistic and linear regression analysis has been performed.
   Results: A total 531 HCWs returned the questionnaire for a response rate of 54.9%. Based on a vaccination knowledge score ranging from 0 to 9, more than half of the participants (55.4%) knew few of the vaccines recommended for HCWs (<= 3 correct answers), 16.2% knew some vaccines (4-6 correct answers), and 28.4% knew most vaccines (>= 7 correct answers), and only 13.2% knew all the vaccines recommended for HCWs. However, two-thirds (62.2%) knew that hepatitis B and influenza vaccines were recommended, and this knowledge was significantly higher among females (p < 0.001), among HCWs aged between 50 and 59 years (p = 0.01) compared with those aged < 30 years, and in those who search for information about recommended vaccines for HCWs (p = 0.012). The vaccine knowledge was significantly lower among nurses and nursing supporting staff compared with physicians (p = 0.032). Approximately two-thirds (62.7%) of HCWs considered themselves at risk of contracting vaccine-preventable infectious diseases during their professional practice. High rates of coverage were self-reported for hepatitis B (96.3%), tetanus and pertussis (93.7%), whereas they were lower for measles/mumps/rubella (80.5%), chickenpox (65.3%), and influenza (35.8%). Only 9.2% of HCWs reported prior receipt of all recommended vaccines. Male HCWs were less likely to report prior receipt of all recommended vaccines (p = 0.011). HCWs aged between 30 and 39 years compared with those aged < 30 years (p = 0.001) and those who knew some (p < 0.001) and most (p = 0.007) of all vaccines recommended for HCWs were more likely to self-report to be immunized.
   Conclusions: Additional training about the vaccinations is needed to improve HCWs knowledge and to address specific concerns which may lead to better uptake among this group. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Napolitano, Francesco; D'Alessandro, Alessia; Angelillo, Italo Francesco] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy.
   [Bianco, Aida; Papadopoli, Rosa] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Via T Campanella 115, I-88100 Catanzaro, Italy.
RP Angelillo, IF (reprint author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Via L Armanni 5, I-80138 Naples, Italy.
EM italof.angelillo@unicampania.it
CR Adamo G, 2017, ANN IG MED PREV COMU, V29, P1, DOI 10.7416/ai.2017.2128
   Adamo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205147
   Adamo Giovanna, 2017, Ig Sanita Pubbl, V73, P429
   Albano L, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-208
   Awali RA, 2014, AM J INFECT CONTROL, V42, P649, DOI 10.1016/j.ajic.2014.02.025
   Betsch C, 2014, VACCINE, V32, P4478, DOI 10.1016/j.vaccine.2014.06.046
   Bianco A, 2014, HUM VACC IMMUNOTHER, V10, P2536, DOI 10.4161/21645515.2014.969614
   Bianco A, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-76
   Bianco A, 2013, AM J INFECT CONTROL, V41, P107, DOI 10.1016/j.ajic.2012.02.038
   Blank DL, 2010, VACCINE, V28, P4668, DOI 10.1016/j.vaccine.2010.04.066
   Boey L, 2018, VACCINE, V36, P3351, DOI 10.1016/j.vaccine.2018.04.044
   Burls A, 2006, VACCINE, V24, P4212, DOI 10.1016/j.vaccine.2005.12.043
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9
   Centers for Disease Control and Prevention, REC VACC HEALTHC WOR
   Costantino C, 2014, HUM VACC IMMUNOTHER, V10, P1204, DOI 10.4161/hv.28081
   D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809
   Fortunato F, 2015, HUM VACC IMMUNOTHER, V11, P133, DOI 10.4161/hv.34415
   Harrison N, 2016, HUM VACC IMMUNOTHER, V12, P2459, DOI 10.1080/21645515.2016.1168959
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Jaiyeoba O, 2014, AM J INFECT CONTROL, V42, P69, DOI 10.1016/j.ajic.2013.06.020
   Jiang CH, 2018, VACCINE, V36, P214, DOI 10.1016/j.vaccine.2017.11.071
   Little KE, 2015, PUBLIC HEALTH, V129, P755, DOI 10.1016/j.puhe.2015.02.031
   Liu Y, 2018, VACCINE, V36, P2307, DOI 10.1016/j.vaccine.2018.03.018
   Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039
   Loulergue P, 2016, AM J INFECT CONTROL, V44, P1080, DOI 10.1016/j.ajic.2016.02.030
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P66, DOI 10.1016/j.ajic.2012.01.028
   Martinello RA, 2003, INFECT CONT HOSP EP, V24, P845, DOI 10.1086/502147
   Ministero della Salute, PIAN NAZ PREV VACC P
   Moskosky S. B., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Mytton OT, 2013, OCCUP MED-OXFORD, V63, P189, DOI 10.1093/occmed/kqt002
   Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943
   Napolitano F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194920
   Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2
   Napolitano F, 2016, HUM VACC IMMUNOTHER, V12, P1504, DOI 10.1080/21645515.2016.1156271
   O'Halloran AC, 2018, AM J PREV MED, V54, P119, DOI 10.1016/j.amepre.2017.09.017
   Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087
   To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003
   Tuckerman JL, 2015, HUM VACC IMMUNOTHER, V11, P704, DOI 10.1080/21645515.2015.1008886
   WHO, 2017, WHO POSITION PAPERS
NR 39
TC 2
Z9 2
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6900
EP 6906
DI 10.1016/j.vaccine.2019.09.053
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000006
PM 31564452
DA 2020-05-12
ER

PT J
AU Chow, EPF
   Tabrizi, SN
   Fairley, CK
   Wigan, R
   Machalek, DA
   Regan, DG
   Hocking, JS
   Garland, SM
   Cornall, AM
   Atchison, S
   Bradshaw, CS
   McNulty, A
   Owen, L
   Marshall, L
   Russell, DB
   Kaldor, JM
   Chen, MY
AF Chow, Eric P. F.
   Tabrizi, Sepehr N.
   Fairley, Christopher K.
   Wigan, Rebecca
   Machalek, Dorothy A.
   Regan, David G.
   Hocking, Jane S.
   Garland, Suzanne M.
   Cornall, Alyssa M.
   Atchison, Steph
   Bradshaw, Catriona S.
   McNulty, Anna
   Owen, Louise
   Marshall, Lewis
   Russell, Darren B.
   Kaldor, John M.
   Chen, Marcus Y.
TI Prevalence of human papillomavirus in teenage heterosexual males
   following the implementation of female and male school-based vaccination
   in Australia: 2014-2017
SO VACCINE
LA English
DT Article
DE Human papillomavirus; HPV; Vaccine; Vaccination; Heterosexual; Male;
   Australia; Prevention; Control
ID HPV VACCINATION; HERD-IMMUNITY; GENITAL WARTS; POPULATION; COVERAGE;
   MEN; INFECTIONS; PROGRAM; LEVEL; WOMEN
AB Background: Australia introduced a school-based human papillomavirus (HPV) vaccination program for females aged 12-13 years in 2007, with a three-year catch-up to age 26; and for boys aged 12-13 from 2013, with a two-year catch-up to age 15. This study aimed to compare the prevalence of penile HPV between teenage heterosexual males in cohorts eligible or non-eligible for the school-based male vaccination program.
   Methods: Between 2014 and 2017, sexually active heterosexual males aged 17-19 were recruited from sexual health centres and community sources across Australia. Males provided a self-collected penile swab for 37 HPV genotypes using Roche Linear Array and completed a questionnaire. We calculated adjusted prevalence ratios (aPR) of HPV between males in two periods: 2014-2015 (preceding implementation of school-based male vaccination) and 2016-2017 (eligible for school-based male vaccination). Self-reported vaccine doses were confirmed with doses reported to the National HPV Vaccination Program Register.
   Results: Overall, 152 males were recruited in 2014-2015 and 146 in 2016-2017. Numbers of female sex partners and condom use did not differ between the two periods. The prevalence of quadrivalent vaccine-preventable [4vHPV] genotypes (6/11/16/18) was low in both periods (2.6% [2014-15] versus 0.7% [2016-17]; p = 0.371; aPR 0.28 [95% CI: 0.03-2.62]). Compared with men in 2014-2015, men in 2016-2017 had a lower prevalence of any of the 37 HPV genotypes tested (21.7% versus 11.6%; aPR 0.62 [95% CI: 0.36-1.07]) and any of the 13 high-risk genotypes tested (15.8% versus 7.5%; aPR 0.59 [95% CI: 0.30-1.19]). Prevalence of low-risk HPV genotypes did not differ between the two periods. Of the males recruited in 2016-2017, 55% had received >= 1 vaccine dose.
   Conclusion: The prevalence of 4vHPV genotypes among teenage heterosexual males in both cohorts was low, presumably due to herd protection from the female-only vaccination program. Further studies are required to determine the impact of universal HPV vaccination on HPV prevalence in males. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chow, Eric P. F.; Fairley, Christopher K.; Wigan, Rebecca; Bradshaw, Catriona S.; Chen, Marcus Y.] Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia.
   [Chow, Eric P. F.; Fairley, Christopher K.; Bradshaw, Catriona S.; Chen, Marcus Y.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia.
   [Tabrizi, Sepehr N.; Garland, Suzanne M.; Cornall, Alyssa M.] Univ Melbourne, Dept Obstet Gynaecol, Parkville, Vic, Australia.
   [Tabrizi, Sepehr N.; Machalek, Dorothy A.; Garland, Suzanne M.; Cornall, Alyssa M.; Atchison, Steph] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Machalek, Dorothy A.; Hocking, Jane S.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Parkville, Vic, Australia.
   [Machalek, Dorothy A.; Garland, Suzanne M.; Cornall, Alyssa M.; Atchison, Steph] Royal Womens Hosp, Ctr Womens Infect Dis, Parkville, Vic, Australia.
   [Regan, David G.; Kaldor, John M.] UNSW Sydney, Kirby Inst, Kensington, NSW, Australia.
   [McNulty, Anna] Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW, Australia.
   [McNulty, Anna] UNSW Sydney, Sch Publ Hlth & Community Med, Kensington, NSW, Australia.
   [Owen, Louise] Statewide Sexual Hlth Serv Tasmania, Hobart, Tas, Australia.
   [Marshall, Lewis] Fremantle Hosp, South Terrace Clin, Perth, WA, Australia.
   [Russell, Darren B.] Queensland Hlth, Cairns Sexual Hlth Serv, Cairns, Qld, Australia.
   [Russell, Darren B.] James Cook Univ, Coll Med & Dent, Cairns, Qld, Australia.
RP Chow, EPF (reprint author), Alfred Hlth, Melbourne Sexual Hlth Ctr, 580 Swanston St, Carlton, Vic 3053, Australia.
EM eric.chow@monash.edu; CFairley@mshc.org.au; RWigan@mshc.org.au;
   dorothy.machalek@thewomens.org.au; Dregan@kirby.unsw.edu.au;
   j.hocking@unimelb.edu.au; Suzanne.Garland@thewomens.org.au;
   alyssa.cornall@mcri.edu.au; steph.atchison@mcri.edu.au;
   catriona.bradshaw@monash.edu; Anna.McNulty@health.nsw.gov.au;
   louise.owen@ths.tas.gov.au; Lewis.Marshall@health.wa.gov.au;
   Darren.Russell@health.qld.gov.au; jkaldor@kirby.unsw.edu.au;
   mchen@mshc.org.au
RI Chow, Eric P.F./W-6684-2019
OI Chow, Eric P.F./0000-0003-1766-0657; Machalek,
   Dorothy/0000-0002-4101-8085; Cornall, Alyssa/0000-0003-0806-8475; Regan,
   David/0000-0002-2893-0969; Tabrizi, Sepehr/0000-0002-5556-4175
FU Merck Co.Merck & Company [50939]; Australian Government Department of
   HealthAustralian GovernmentDepartment of Health & Ageing [H1314G010]
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:;
   This study was funded by Merck & Co. (50939) and Australian Government
   Department of Health (HPV Surveillance Fund H1314G010).
CR Ali H, 2013, BMJ-BRIT MED J, V346, P12032
   Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9
   Brotherton J, 2011, COMMUN DIS INTELL, V35, P197
   Brotherton JML, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100177
   Brotherton JML, 2014, J PAEDIATR CHILD H, V50, P959, DOI 10.1111/jpc.12627
   Brotherton JML, 2014, VACCINE, V32, P592, DOI 10.1016/j.vaccine.2013.11.075
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Chow EP, 2016, SEXUAL HLTH
   Chow EPF, 2019, VACCINE, V37, P6271, DOI 10.1016/j.vaccine.2019.08.066
   Chow EPF, 2017, LANCET INFECT DIS, V17, P68, DOI 10.1016/S1473-3099(16)30116-5
   Chow EPF, 2016, SEX HEALTH, V13, P451, DOI 10.1071/SH16055
   Chow EPF, 2015, LANCET INFECT DIS, V15, P1314, DOI 10.1016/S1473-3099(15)00055-9
   Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813
   Collyer A, 2018, AUST J GEN PRACT, V47, P376, DOI 10.31128/AJGP-01-18-4446
   Draper E, 2011, VACCINE, V29, P8585, DOI 10.1016/j.vaccine.2011.09.021
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   Feiring B, 2018, J INFECT DIS, V218, P1900, DOI 10.1093/infdis/jiy432
   Gertig DM, 2011, SEX HEALTH, V8, P171, DOI 10.1071/SH10001
   Giuliano AR, 2007, J INFECT DIS, V196, P1146, DOI 10.1086/521629
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Howell-Jones R, 2012, VACCINE, V30, P3867, DOI 10.1016/j.vaccine.2012.04.006
   Kemp TJ, 2011, VACCINE, V29, P2011, DOI 10.1016/j.vaccine.2011.01.001
   Korostil IA, 2013, SEX TRANSM DIS, V40, P833, DOI 10.1097/OLQ.0000000000000030
   LaytonHenry J, 1996, INT J GYNECOL CANCER, V6, P193, DOI 10.1046/j.1525-1438.1996.06030193.x
   Lehtinen M, 2018, INT J CANCER, V142, P949, DOI 10.1002/ijc.31119
   Leinonen M, 2008, INT J CANCER, V123, P1344, DOI 10.1002/ijc.23670
   Machalek DA, 2017, J INFECT DIS, V215, P202, DOI 10.1093/infdis/jiw530
   Mesher D, 2016, EMERG INFECT DIS, V22, P1732, DOI 10.3201/eid2210.160675
   National HPV Vaccination Program Register, 2019, HPV VACC COV DOS 201
   National HPV Vaccination Program Register, NAT AUSTR HPV 3 DOS
   Ogilvie GS, 2009, SEX TRANSM INFECT, V85, P221, DOI 10.1136/sti.2008.033068
   Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737
   RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477
   Smith MA, 2011, VACCINE, V29, P9112, DOI 10.1016/j.vaccine.2011.02.091
   Soderlund-Strand A, 2013, CANCER EPIDEM BIOMAR, V22, P242, DOI 10.1158/1055-9965.EPI-12-1003
   Stevens MP, 2008, J CLIN MICROBIOL, V46, P3813, DOI 10.1128/JCM.01169-08
   Stevens MR, 2008, J VIROL METHODS, V147, P290, DOI 10.1016/j.jviromet.2007.09.018
   Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2
   Wadham E, 2019, SEX HEALTH, V16, P101, DOI 10.1071/SH18127
   Zhang L, 2017, VACCINE, V35, P4923, DOI 10.1016/j.vaccine.2017.07.078
   Zou HC, 2015, LANCET INFECT DIS, V15, P65, DOI 10.1016/S1473-3099(14)70994-6
   Zou HC, 2014, J INFECT DIS, V209, P642, DOI 10.1093/infdis/jit626
NR 42
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6907
EP 6914
DI 10.1016/j.vaccine.2019.09.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000007
PM 31562001
DA 2020-05-12
ER

PT J
AU Villena, R
   Valenzuela, MT
   Bastias, M
   Santolaya, ME
AF Villena, R.
   Valenzuela, M. T.
   Bastias, M.
   Santolaya, M. E.
TI Meningococcal invasive disease by serogroup W and use of ACWY conjugate
   vaccines as control strategy in Chile
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Meningococcal invasive disease; Meningococcal
   serogroup W; Meningococcal conjugate vaccines; Mass vaccination
ID CARRIAGE; CHILDREN; IMMUNIZATION; PREVALENCE; EMERGENCE; EPIDEMIC;
   COMPLEX; IMPACT
AB Background: Serogroup causing invasive meningococcal disease (IMD) can change abruptly, as it occurred in Chile when serogroup predominance switched from MenB to MenW in 2012. As a response, a national vaccination strategy was implemented since 2012 using tetravalent meningococcal-conjugate vaccines (MCV-ACWY) in children 9 months through 4 years of age. The aim of this study was to describe IMD cases by MenW in Chile 2009-2016, and to analyse its trend after the introduction of MCV-ACWY.
   Methods: Descriptive study of IMD cases in Chile, period 2009-2016. Cumulative incidence and mortality rate per 100,000 inhabitants, and case fatality rate (CRF) were used for descriptive analysis. Linear regression was used for post-intervention trend analysis.
   Results: In 2012, MenW, mainly ST-11 cc, became predominant. MenW incidence rose from 0.01/100,000 inhabitants in 2009 to a maximum of 0.6/100,000 in 2015. Infants and adults 80 years of age and older were mostly affected, with an incidence peak of 9.7/100,000 and 1.6/100,000, respectively, in 2015. In the group of children from 1 to 4 years of age MenW incidence declined from 1.3/100,000 in 2012 to 0.1/100,000 in 2016, a 92.3% reduction after vaccination implementation. In the same period and age-cohort, CFR decreased from 23% to 0%. High mortality rates concentrated in infants and adults 80 years of age and over.
   Conclusion: MenW became predominant in Chile since 2012. IMD cases increased steadily from 2009 to 2016, with higher incidence, CFR and mortality concentrating in infants and people 80 years of age and older. MCV-ACWY provided direct protection against MenW, reducing its incidence after mass meningococcal vaccine implementation. Indirect effects of vaccination are not yet observed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Villena, R.; Santolaya, M. E.] Univ Chile, Fac Med, Dept Pediat, Santiago, Chile.
   [Villena, R.] Hosp Ninos Dr Exequiel Gonzalez Cortes, Infect Dis Unit, San Miguel, Chile.
   [Valenzuela, M. T.] Univ los Andes, Fac Med, Dept Publ Hlth & Epidemiol, Santiago, Chile.
   [Santolaya, M. E.] Hosp Ninos Dr Luis Calvo Mackenna, Infect Dis Unit, Providencia, Chile.
RP Villena, R (reprint author), Univ Chile, Fac Med, Gran Ave Jose Miguel Carrera 3300, Santiago, Chile.
EM rvillena@uchile.cl
OI Bastias, Magdalena/0000-0002-7298-4884
CR Abad R, 2014, EPIDEMIOL INFECT, V142, P2461, DOI 10.1017/S0950268814001149
   Andrade AL, 2017, VACCINE, V35, P2025, DOI 10.1016/j.vaccine.2017.03.010
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1391
   [Anonymous], 2019, INV MEN DIS ANN EP R
   Araya P, 2015, EMERG INFECT DIS, V21, P339, DOI 10.3201/eid2102.140746
   Araya P, 2014, REV CHIL INFECTOL, V31, P377, DOI 10.4067/S0716-10182014000400001
   Arnold R, 2011, VACCINE, V29, P7100, DOI 10.1016/j.vaccine.2011.06.120
   Barra GN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066006
   Black SB, 2012, VACCINE, V30, pB37, DOI 10.1016/j.vaccine.2011.12.074
   Campbell H, 2009, VACCINE, V27, pB20, DOI 10.1016/j.vaccine.2009.04.067
   Daugla DM, 2014, LANCET, V383, P40, DOI 10.1016/S0140-6736(13)61612-8
   De Wals P, 2017, CLIN INFECT DIS, V64, P1263, DOI 10.1093/cid/cix154
   Diaz J, 2016, J INFECT PUBLIC HEAL, V9, P506, DOI 10.1016/j.jiph.2015.12.011
   do Macedo LE, 2018, HUM VACC IMMUNOTHER, V14, P1131, DOI 10.1080/21645515.2017.1415682
   Gallegos D, 2010, SITUATION EPIDEMIOLO
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Izquierdo G, 2015, HUM VACC IMMUNOTHER, V11, P875, DOI 10.1080/21645515.2015.1010885
   Kelly C, 2007, AM J EPIDEMIOL, V166, P817, DOI 10.1093/aje/kwm147
   Ladhani SN, 2015, CLIN INFECT DIS, V60, P578, DOI 10.1093/cid/ciu881
   Ministerio de Salud de Chile Subsecretaria de Salud Publica Departamento de Epidemiologia., B51N08 MIN SAL CHIL
   Moreno G, 2013, REV CHIL INFECTOL, V30, P350, DOI 10.4067/S0716-10182013000400002
   Nadel S, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00321
   Olea A, 2017, EMERG INFECT DIS, V23, P1070, DOI 10.3201/eid2307.160129
   Rodriguez P, 2014, VACCINE, V32, P5677, DOI 10.1016/j.vaccine.2014.08.015
   Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807
   Rouphael NG, 2012, METHODS MOL BIOL, V799, P1, DOI 10.1007/978-1-61779-346-2_1
   Valenzuela MT, 2019, REV MED CHILE, V147, P776, DOI 10.4067/S0034-98872019000600776
   Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4
   Trotter CL, 2009, EXPERT REV VACCINES, V8, P851, DOI 10.1586/ERV.09.48
   Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1
   Valenzuela MT, 2013, REV MED CHILE, V141, P959, DOI 10.4067/S0034-98872013000800001
   Villena R, 2018, HUM VACC IMMUNOTHER, V14, P1042, DOI 10.1080/21645515.2018.1458175
   Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1
   Wang B, 2014, VACCINE, V32, P4791, DOI 10.1016/j.vaccine.2014.05.069
   Wilhelm J, 2012, REV CHIL PEDIATR-CHI, V83, P533, DOI 10.4067/S0370-41062012000600002
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6915
EP 6921
DI 10.1016/j.vaccine.2019.09.050
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000008
PM 31585728
DA 2020-05-12
ER

PT J
AU Liu, ZZ
   Behloul, N
   Baha, S
   Wei, WJ
   Shi, RH
   Meng, JH
AF Liu, Zhenzhen
   Behloul, Nouredine
   Baha, Sarra
   Wei, Wenjuan
   Shi, Ruihua
   Meng, Jihong
TI Design and immunogenicity analysis of the combined vaccine against
   zoonotic hepatitis E and foot-and-mouth disease
SO VACCINE
LA English
DT Article
DE Hepatitis E virus; Foot-and-mouth disease virus; Combined vaccine;
   Immunogenicity; Zoonosis
ID E-VIRUS; CELL-CULTURE; PROTEINS; HEV; SEROPREVALENCE; NEUTRALIZATION;
   PROTECTION; CHALLENGE; INFECTION; ENDOTOXIN
AB Aim: Design and immunogenicity assessment of the combined vaccine candidate against zoonotic hepatitis E virus (HEV) and foot-and-mouth disease virus (FMDV).
   Methods: Using the molecular cloning technology, we produced and purified 9 HEV ORF2-truncated proteins (HEV genotype 4). Then, we compared their thermal stability, antigenicity, and immunogenicity to select the best HEV immunogen. Next, we used the adjuvant Montanide 1SA-206 to prepare different formulations of HEV vaccine alone, FMDV vaccine alone and HEV-FMDV combined vaccine. The formulations were injected into mice and the induced humoral immune responses were monitored up 12 weeks post-immunization.
   Results: The HEV p222 protein could self-assemble into VLPs (similar to 34 nm) and showed higher stability and better antigenicity/immunogenicity than the other HEV antigens, thus it was selected as the best HEV immunogen. Mice immunization with the FMDV vaccine alone induced high FMDV-specific antibody titers in a dose-dependent manner; the HEV p222 protein also induced high levels of anti-HEV antibodies but in a dose-independent manner. The HEV-FMDV combination induced anti-FMDV antibody titers 7-16-fold higher than the titers induced by the FMDV vaccine alone, and HEV-specific antibody titers 2.4-fold higher than those induced by the HEV p222 antigen alone.
   Conclusion: Herein, we proposed a new approach for the control of zoonotic HEV infection through its control in its main host (pig). We also designed the first HEV-FMDV combined vaccine and the preliminary analyses revealed a synergistic effect on the immunogenicity of both HEV and FMDV antigens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Zhenzhen; Baha, Sarra; Wei, Wenjuan; Shi, Ruihua; Meng, Jihong] Southeast Univ, Zhongda Hosp, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China.
   [Behloul, Nouredine; Meng, Jihong] Shanghai Univ Med & Hlth Sci, Coll Basic Med, Shanghai, Peoples R China.
RP Shi, RH; Meng, JH (reprint author), Southeast Univ, Nanjing 210009, Jiangsu, Peoples R China.; Meng, JH (reprint author), Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China.
EM ruihuashi@126.com; jihongmeng@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31770998]
FX This study was supported by the National Natural Science Foundation of
   China (31770998).
CR Behloul N, 2015, INFECT GENET EVOL, V34, P211, DOI 10.1016/j.meegid.2015.06.026
   Bouvet J, 2018, VET IMMUNOL IMMUNOP, V205, P93, DOI 10.1016/j.vetimm.2018.11.001
   Cai C, 2014, PREV VET MED, V115, P94, DOI 10.1016/j.prevetmed.2014.03.020
   Cai W, 2016, SCI REP-UK, V6, DOI 10.1038/srep25141
   Cao YM, 2018, J VIROL METHODS, V262, P26, DOI 10.1016/j.jviromet.2018.09.008
   Cao YM, 2013, ANTIVIR RES, V97, P145, DOI 10.1016/j.antiviral.2012.11.009
   Cao YM, 2012, J VIROL METHODS, V185, P124, DOI 10.1016/j.jviromet.2012.03.036
   Cao YF, 2017, VACCINE, V35, P5073, DOI 10.1016/j.vaccine.2017.05.072
   Caruso C, 2017, TRANSBOUND EMERG DIS, V64, P1443, DOI 10.1111/tbed.12533
   Dai X, 2013, EMERG INFECT DIS, V19, P1528, DOI 10.3201/eid1909.130013
   Dalton HR, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032144
   Dong C, 2012, HEPAT MON, V12, P386, DOI 10.5812/hepatmon.6194
   Dong Chen, 2006, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V22, P339
   Emerson SU, 2006, J GEN VIROL, V87, P697, DOI 10.1099/vir.0.81545-0
   Hewitt PE, 2014, LANCET, V384, P1766, DOI 10.1016/S0140-6736(14)61034-5
   Huang WJ, 2008, J MED VIROL, V80, P824, DOI 10.1002/jmv.21140
   Kulkarni SP, 2016, VACCINE, V34, P5895, DOI 10.1016/j.vaccine.2016.10.046
   Lee SY, 2016, VACCINE, V34, P3731, DOI 10.1016/j.vaccine.2016.06.008
   Li D, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-215
   Liu C, 2019, VIRUSES, V11
   Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0
   Ma ZR, 2010, INFECT GENET EVOL, V10, P614, DOI 10.1016/j.meegid.2010.04.003
   Mahapatra M, 2018, EXPERT REV VACCINES, V17, P577, DOI 10.1080/14760584.2018.1492378
   Meng J, 1997, J CLIN MICROBIOL, V35, P1373, DOI 10.1128/JCM.35.6.1373-1377.1997
   Meng JH, 2001, VIROLOGY, V288, P203, DOI 10.1006/viro.2001.1093
   Mughini-Gras L, 2017, EPIDEMIOL INFECT, V145, P3375, DOI 10.1017/S0950268817002485
   Pavio N, 2015, CURR OPIN VIROL, V10, P34, DOI 10.1016/j.coviro.2014.12.006
   Reichelt P, 2006, PROTEIN EXPRES PURIF, V46, P483, DOI 10.1016/j.pep.2005.09.027
   Sanford BJ, 2012, VACCINE, V30, P6249, DOI 10.1016/j.vaccine.2012.08.013
   Sanford BJ, 2011, VIRUS RES, V159, P17, DOI 10.1016/j.virusres.2011.04.010
   Shirazi R, 2018, EUROPEAN COMMUNICABL, V23
   Smith DB, 2014, J GEN VIROL, V95, P2223, DOI 10.1099/vir.0.068429-0
   Sridhar S, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.107
   Suin V, 2019, EUROPEAN COMMUNICABL, V24
   Thom K, 2018, EUROPEAN COMMUNICABL, V23
   Tsarev SA, 1997, VACCINE, V15, P1834, DOI 10.1016/S0264-410X(97)00145-X
   Valdazo-Gonzalez B, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-76
   Vidor E, 2007, J COMP PATHOL, V137, pS62, DOI 10.1016/j.jcpa.2007.04.014
   Wei WJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20137-2
   Wen JY, 2016, ANTIVIR RES, V128, P36, DOI 10.1016/j.antiviral.2016.02.002
   WHO, 2010, GLOB PREV HEP E VIR
   Xu H, 2017, VET MICROBIOL, V205, P46, DOI 10.1016/j.vetmic.2017.04.023
   Zhang J, 2015, NEW ENGL J MED, V372, P2265, DOI 10.1056/NEJMc1504302
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 31
PY 2019
VL 37
IS 46
BP 6922
EP 6930
DI 10.1016/j.vaccine.2019.09.036
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JL4HG
UT WOS:000495491000009
PM 31604580
DA 2020-05-12
ER

PT J
AU Agrawal, S
   Singh, RK
AF Agrawal, Saurabh
   Singh, Rajesh Kr
TI Analyzing disposition decisions for sustainable reverse logistics:
   Triple Bottom Line approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Reverse logistics; Disposition decision; Circular economy; Structural
   equation modelling; Performance; Indian electronics industry
ID PARTIAL LEAST-SQUARES; LOOP SUPPLY CHAIN; MANAGEMENT-PRACTICES; PRODUCT
   RETURNS; PERFORMANCE; FRAMEWORK; NETWORK; DESIGN; IMPACT; IDENTIFICATION
AB In last few decades, circular economy concepts have gained a lot of consideration because of its focus towards sustainability. Reverse logistics play an important role in the adoption and implementation of circular economy concepts in supply chains. It is defined as "sequence of activities required to collect the used product from the customers for their disposition to either reuse or repair or re-manufacture or recycle or dispose of it". Disposition is one of the crucial decisions which may greatly affect the reverse logistics performance from sustainability perspective. It also plays an important role in improving the operational efficiency of the reverse logistics. The objective of this study is to explore the reverse logistics in context of Indian electronics industry and examine the effect of disposition decisions on Triple Bottom Line (TBL) i.e. economic, environmental, and social performance of reverse logistics. Hypotheses related to disposition decisions and TBL performance was developed. A survey instrument was prepared and was sent to seven hundred organizations from the Indian electronics sector. Over all 208 responses were found suitable for the research. All the necessary statistical analysis was carried out to ensure the reliability and validity of the questionnaire. Partial least square path modelling technique of structural equation modeling has been used for testing the research hypothesis. Measurement model had shown sufficient data fit for the modelling. Partial least square path modelling results reveal that effectiveness of disposition decisions is positively associated with TBL performance. The article contributes to the few studies available on improving the reverse logistics performance. Findings will be useful for managers in managing reverse logistics in effective manner.
C1 [Agrawal, Saurabh] Delhi Technol Univ, Delhi, India.
   [Singh, Rajesh Kr] Management Dev Inst, Gurgaon, India.
RP Singh, RK (reprint author), Management Dev Inst, Gurgaon, India.
EM rajesh.singh@mdi.ac.in
CR Abd Razak N, 2016, WORLD J ENTREP MANAG, V12, P35, DOI 10.1108/WJEMSD-05-2015-0026
   Agrawal S, 2016, RESOUR CONSERV RECY, V108, P41, DOI 10.1016/j.resconrec.2016.01.004
   Agrawal S, 2015, RESOUR CONSERV RECY, V97, P76, DOI 10.1016/j.resconrec.2015.02.009
   [Anonymous], 2008, 15392 ISO
   Ardeshirilajimi A, 2015, INT J ADV MANUF TECH, V77, P1767, DOI 10.1007/s00170-014-6509-9
   Attia A, 2015, INT J BUS MANAG, V109, P143
   Balde C.P., 2015, GLOBAL E WASTE MONIT
   Barsky N. P, 2001, STRATEG FINAN, V827, P32
   Bell JE, 2013, INT J PHYS DISTR LOG, V43, P351, DOI 10.1108/IJPDLM-03-2012-0092
   Benyus J.M., 2002, BIOMIMICRY
   Bouzon M, 2016, RESOUR CONSERV RECY, V108, P182, DOI 10.1016/j.resconrec.2015.05.021
   Chaudhary K, 2020, ENVIRON DEV SUSTAIN, V22, P173, DOI 10.1007/s10668-018-0189-9
   Chin WW, 2003, INFORM SYST RES, V14, P189, DOI 10.1287/isre.14.2.189.16018
   Chin WW, 1998, QUANT METH SER, P295
   Chung CJ, 2011, INT J PROD ECON, V129, P195, DOI 10.1016/j.ijpe.2010.09.033
   Clauss T, 2016, R&D MANAGE, V46, P1044, DOI 10.1111/radm.12202
   Cohen J., 1988, STAT POWER ANAL BEHA
   Devika K, 2014, EUR J OPER RES, V235, P594, DOI 10.1016/j.ejor.2013.12.032
   Dixit S, 2016, RESOUR CONSERV RECY, V107, P115, DOI 10.1016/j.resconrec.2015.11.021
   Dowlatshahi S, 2005, INT J PROD RES, V43, P3455, DOI 10.1080/00207540500118118
   Dubey R, 2015, INT J ADV MANUF TECH, V80, P427, DOI 10.1007/s00170-015-6967-8
   Dutta D., 2017, ADV SOLID HAZARDOUS, P249, DOI 10.1007/978-3-319
   Elkington John, 1997, CANNIBALS FORKS TRIP
   Ellen MacArthur Foundation (EMF), 2013, CIRCULAR EC, V1
   Esposito V.V., 2010, HDB PARTIAL LEAST SQ
   Falk R.F., 1992, PRIMER SOFT MODELING
   Figge F, 2002, BUS STRATEG ENVIRON, V11, P269, DOI [10.1002/bse.339, DOI 10.1002/BSE.339]
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Gefen D., 2000, COMMUN AIS, V4, P1, DOI DOI 10.17705/1CAIS.00407
   Geisendorf S, 2018, THUNDERBIRD INT BUS, V60, P771, DOI 10.1002/tie.21924
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   GEISSER S, 1974, BIOMETRIKA, V61, P101, DOI 10.2307/2334290
   Gobbi C, 2011, INT J PHYS DISTR LOG, V41, P768, DOI 10.1108/09600031111166429
   Govindan K, 2017, ANN OPER RES, P1
   Govindan K, 2017, J CLEAN PROD, V142, P371, DOI 10.1016/j.jclepro.2016.03.126
   Govindan K, 2013, J CLEAN PROD, V47, P345, DOI 10.1016/j.jclepro.2012.04.014
   Graedel T.E., 1995, IND ECOLOGY
   Guide VD, 2008, OPER MANAGE RES, V1, P6, DOI DOI 10.1007/S12063-007-0001-8
   Guide VDR, 2001, PROD OPER MANAG, V10, P142
   Gurtu A, 2019, HDB SUSTAINABLE SUPP, P410
   Hair J.F., 2006, MULTIVARIATE DATA AN
   Hazen Benjamin T., 2011, International Journal of Logistics Systems and Management, V10, P275, DOI 10.1504/IJLSM.2011.043118
   Hazen BT, 2012, INT J PHYS DISTR LOG, V42, P244, DOI 10.1108/09600031211225954
   Henriques A, 2013, TRIPLE BOTTOM LINE D
   Henseler J, 2009, ADV INT MARKETING, V20, P277, DOI 10.1108/S1474-7979(2009)0000020014
   Hollos D, 2012, INT J PROD RES, V50, P2968, DOI 10.1080/00207543.2011.582184
   Huang RH, 2012, J STAT MANAG SYST, V15, P323, DOI 10.1080/09720510.2012.10701629
   Jack EP, 2010, INT J PHYS DISTR LOG, V40, P228, DOI 10.1108/09600031011035100
   Jamal AMM, 2004, COMPUT IND ENG, V47, P77, DOI 10.1016/j.cie.2004.03.001
   Janse B, 2010, INT J ADV MANUF TECH, V47, P495, DOI 10.1007/s00170-009-2333-z
   Johnston P, 2007, ENVIRON SCI POLLUT R, V14, P60, DOI 10.1065/espr2007.01.375
   Kaplan D, 2008, STRUCTURAL EQUATION
   Khor K. S, 2012, J SUPPLY CHAIN CUSTO, V1
   Kumar BM, 2014, APPL MECH MATER, V592-594, P2677, DOI 10.4028/www.scientific.net/AMM.592-594.2677
   Lambert S, 2011, COMPUT IND ENG, V61, P561, DOI 10.1016/j.cie.2011.04.012
   Lasi H, 2014, BUS INFORM SYST ENG+, V6, P239, DOI 10.1007/s12599-014-0334-4
   Leimeister S, 2009, INT J INFORM MANAGE, V29, P37, DOI 10.1016/j.ijinfomgt.2008.05.006
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Lyle J.T., 1994, REGENERATIVE DESIGN
   Malhotra MK, 1998, J OPER MANAG, V16, P407, DOI 10.1016/S0272-6963(98)00021-7
   Mangla S. K, 2019, RESOUR CONSER RECYCL, V142, P277
   Mangla SK, 2016, J CLEAN PROD, V129, P608, DOI 10.1016/j.jclepro.2016.03.124
   McDonough W., 2002, CRADLE CRADLE REMAKI
   Mckenzie S., 2004, SOCIAL SUSTAINABILIT
   McWilliams A, 2016, BUS STRATEG ENVIRON, V25, P193, DOI 10.1002/bse.1867
   Morgan TR, 2018, INT J PHYS DISTR LOG, V48, P164, DOI 10.1108/IJPDLM-02-2017-0068
   Narayana SA, 2014, INT J LOGIST MANAG, V25, P379, DOI 10.1108/IJLM-08-2012-0073
   Nunnally J.C., 1978, PSYCHOMETRIC THEORY
   Paksoy T, 2011, TRANSPORT RES E-LOG, V47, P532, DOI 10.1016/j.tre.2010.12.001
   Parvadavardini S, 2016, TOTAL QUAL MANAG BUS, V27, P507, DOI 10.1080/14783363.2015.1015411
   Pauli G., 2010, BLUE EC 10 YEARS 100
   Peng DX, 2012, J OPER MANAG, V30, P467, DOI 10.1016/j.jom.2012.06.002
   Prahinski C, 2006, OMEGA-INT J MANAGE S, V34, P519, DOI 10.1016/j.omega.2005.01.003
   Ravi V, 2005, INT J PRODUCT PERFOR, V54, P239, DOI 10.1108/17410400510593802
   Ravi V, 2015, BENCHMARKING, V22, P874, DOI 10.1108/BIJ-06-2013-0066
   Reinartz W, 2009, INT J RES MARK, V26, P332, DOI 10.1016/j.ijresmar.2009.08.001
   Richey RG, 2005, IND MARKET MANAG, V34, P830, DOI 10.1016/j.indmarman.2005.01.003
   Rubio S, 2008, COMPUT IND ENG, V55, P234, DOI 10.1016/j.cie.2007.12.009
   Sabharwal S, 2013, INT J PROD ECON, V144, P521, DOI 10.1016/j.ijpe.2013.04.003
   Sarkis J, 2010, CORP SOC RESP ENV MA, V17, P337, DOI 10.1002/csr.220
   Savaskan RC, 2004, MANAGE SCI, V50, P239, DOI 10.1287/mnsc.1030.0186
   Savitz A, 2013, TRIPLE BOT LINE TODA
   Segarra-Ona M, 2014, ENG MANAG J, V26, P31, DOI 10.1080/10429247.2014.11432002
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Shaharudin MR, 2019, J CLEAN PROD, V211, P233, DOI 10.1016/j.jclepro.2018.11.035
   Shaik MN, 2018, COMPUT IND ENG, V123, P9, DOI 10.1016/j.cie.2018.06.007
   Sharma V, 2016, J CLEAN PROD, V112, P1882, DOI 10.1016/j.jclepro.2014.11.082
   Shih LH, 2001, RESOUR CONSERV RECY, V32, P55, DOI 10.1016/S0921-3449(00)00098-7
   Singh RK, 2018, MANAG ENVIRON QUAL, V29, P427, DOI 10.1108/MEQ-12-2017-0177
   Skinner LR, 2008, INT J PHYS DISTR LOG, V38, P518, DOI 10.1108/09600030810900932
   Slomski Valmor, 2018, Environmental Quality Management, V27, P73, DOI 10.1002/tqem.21530
   Sroufe R, 2003, PROD OPER MANAG, V12, P416
   Stahel WR, 2010, PERFORMANCE ECONOMY, 2ND EDITION, P1, DOI 10.1057/9780230274907
   Stock J, 2002, HARVARD BUSINESS REV
   STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x
   Subramanian N, 2014, INT J SUST DEV WORLD, V21, P235, DOI 10.1080/13504509.2014.906003
   Sudarto S, 2017, INT J PROD ECON, V184, P179, DOI 10.1016/j.ijpe.2016.12.013
   Tan A. W. K., 2006, International Journal of Logistics Management, V17, P331, DOI 10.1108/09574090610717518
   THIERRY M, 1995, CALIF MANAGE REV, V37, P114, DOI 10.2307/41165792
   Tibben-Lembke R.S., 2002, SUPPLY CHAIN MANAG, V7, P271, DOI DOI 10.1108/13598540210447719
   Vahabzadeh AH, 2015, RESOUR CONSERV RECY, V103, P125, DOI 10.1016/j.resconrec.2015.05.023
   Wath SB, 2011, ENVIRON MONIT ASSESS, V172, P249, DOI 10.1007/s10661-010-1331-9
   WERTS CE, 1974, EDUC PSYCHOL MEAS, V34, P25, DOI 10.1177/001316447403400104
   Xie Y, 2012, SUPPLY CHAIN MANAG, V17, P40, DOI 10.1108/13598541211212195
   Zhu QH, 2007, J CLEAN PROD, V15, P1041, DOI 10.1016/j.jclepro.2006.05.021
NR 105
TC 3
Z9 3
U1 12
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104448
DI 10.1016/j.resconrec.2019.104448
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000043
DA 2020-05-12
ER

PT J
AU Ahmed, W
   Sarkar, B
AF Ahmed, Waqas
   Sarkar, Biswajit
TI Management of next-generation energy using a triple bottom line approach
   under a supply chain framework
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainable supply chain management; Second-generation biofuel; Triple
   bottom line; Carbon emissions; Social impact; Augmented
   epsilon-constraint
ID EPSILON-CONSTRAINT METHOD; MULTIOBJECTIVE OPTIMIZATION; RESIDUAL
   BIOMASS; CARBON EMISSION; NETWORK DESIGN; TRANSPORTATION; BIOFUELS;
   SYSTEM; PERFORMANCE; TECHNOLOGY
AB Researchers have raised concerns that it is very essential to concentrate on sustainable and renewable energy resources to control the elevated level of global warming, which is a result of the enormous usage of fossil fuels. Biofuel is considered as an alternative solution for non-renewable sources for energy production. The assurance of this supply relies on a sustainable and efficient supply chain. For this study, a multi-objective model is proposed to structure a sustainable supply chain for second-generation biofuel under a triple bottom line approach. The proposed model captures a trade-off among conflicting objectives. The multiple agricultural regions, multiple biorefineries, transportation, and multiple markets are considered. The yield of residual biomass, the expense at agricultural regions, and the demand of markets are assumed uncertain and denoted by fuzzy numbers. The carbon tax and cap are incorporated into the supply chain model. The improved augmented epsilon-constraint approach is employed to solve the proposed multi-objective optimization model. The objective of developed research is to design a sustainable supply chain framework which minimizes the total carbon emissions and total cost and maximizes the amount of new jobs opportunities in a second-generation biofuel. A numerical experiment is conducted, and the finding shows that the production cost of biofuel in the biorefineries contains a major proportion of the total cost. The transportation section is the predominant source for carbon emissions and a maximum number of jobs is accrued in rural areas. In-depth sensitivity analysis of this study is also performed to examine its actual application.
C1 [Ahmed, Waqas] Natl Univ Sci & Technol, NUST Business Sch, H-12, Islamabad 44000, Pakistan.
   [Sarkar, Biswajit] Yonsei Univ, Dept Ind Engn, 50 Yonsei Ro, Seoul 03722, South Korea.
RP Sarkar, B (reprint author), Yonsei Univ, Dept Ind Engn, 50 Yonsei Ro, Seoul 03722, South Korea.
EM bsbiswajitsarkar@gmail.com
RI Sarkar, Biswajit/AAJ-7089-2020; Ahmed, Waqas/U-4937-2019
OI Sarkar, Biswajit/0000-0002-6583-8416; Ahmed, Waqas/0000-0002-4707-6454
CR Ahmed W, 2018, J CLEAN PROD, V186, P807, DOI 10.1016/j.jclepro.2018.02.289
   Akgul O, 2012, COMPUT CHEM ENG, V42, P101, DOI 10.1016/j.compchemeng.2012.01.012
   Allaoui H, 2016, COMPUT OPER RES
   Asif S, 2017, IND CROP PROD, V108, P336, DOI 10.1016/j.indcrop.2017.06.046
   Balaman SY, 2018, J CLEAN PROD, V172, P2594, DOI 10.1016/j.jclepro.2017.11.150
   Balaman SY, 2014, ENERGY, V74, P928, DOI 10.1016/j.energy.2014.07.073
   Carter CR, 2008, INT J PHYS DISTR LOG, V38, P360, DOI 10.1108/09600030810882816
   Chaabane A, 2012, INT J PROD ECON, V135, P37, DOI 10.1016/j.ijpe.2010.10.025
   Cherubini F, 2010, APPL ENERG, V87, P47, DOI 10.1016/j.apenergy.2009.08.024
   Chuah LF, 2017, J CLEAN PROD, V146, P181, DOI 10.1016/j.jclepro.2016.05.017
   Chuah LF, 2016, J CLEAN PROD, V112, P4505, DOI 10.1016/j.jclepro.2015.06.112
   Ding HP, 2016, EUR J OPER RES, V255, P463, DOI 10.1016/j.ejor.2016.05.003
   Dyllick T, 2002, BUSINESS STRATEGY EN, V11.2, P130, DOI DOI 10.1002/BSE.323
   Murillo-Alvarado PE, 2015, J CLEAN PROD, V108, P422, DOI 10.1016/j.jclepro.2015.08.052
   Eksioglu SD, 2009, COMPUT IND ENG, V57, P1342, DOI 10.1016/j.cie.2009.07.003
   El-Halwagi AM, 2013, AICHE J, V59, P2427, DOI 10.1002/aic.14030
   Elkington J., 1997, CANNIBALS FORKS TRIP, P73
   Escobar JC, 2009, RENEW SUST ENERG REV, V13, P1275, DOI 10.1016/j.rser.2008.08.014
   Eskandarpour M, 2015, OMEGA-INT J MANAGE S, V54, P11, DOI 10.1016/j.omega.2015.01.006
   Gent S., 2017, THEORETICAL APPL ASP
   Ghaderi H, 2018, J CLEAN PROD
   Habib MS, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050716
   Ji X, 2016, RENEW SUST ENERG REV, V61, P41, DOI 10.1016/j.rser.2016.03.026
   Kemausuor F, 2014, RESOUR CONSERV RECY, V86, P28, DOI 10.1016/j.resconrec.2014.01.007
   Kleindorfer PR, 2005, PROD OPER MANAG, V14, P482
   Koizumi T, 2015, RENEW SUST ENERG REV, V52, P829, DOI 10.1016/j.rser.2015.06.041
   Manganaro J, 2011, ENERG FUEL, V25, P2711, DOI 10.1021/ef200327e
   Mavrotas G, 2009, APPL MATH COMPUT, V213, P455, DOI 10.1016/j.amc.2009.03.037
   Moazzam M, 2018, PROD PLAN CONTROL, V29, P1258, DOI 10.1080/09537287.2018.1522847
   Mohammadi M, 2014, TRANSPORT RES E-LOG, V62, P89, DOI 10.1016/j.tre.2013.12.005
   Mota B, 2015, J CLEAN PROD, V105, P14, DOI 10.1016/j.jclepro.2014.07.052
   Olojede MA, 2018, COGENT ENG, V5, P1, DOI 10.1080/23311916.2018.1538491
   Omair M, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050714
   Palak G, 2014, INT J PROD ECON, V154, P198, DOI 10.1016/j.ijpe.2014.04.019
   Pishvaee MS, 2012, APPL MATH MODEL, V36, P3433, DOI 10.1016/j.apm.2011.10.007
   Roberts JJ, 2015, RENEW SUST ENERG REV, V41, P568, DOI 10.1016/j.rser.2014.08.066
   Roni MS, 2017, ANN OPER RES, V249, P351, DOI 10.1007/s10479-015-2102-3
   Sarkar B, 2019, COMPUT IND ENG
   Sarkar B, 2019, J CLEAN PROD, V218, P896, DOI 10.1016/j.jclepro.2019.01.078
   Sarkar B, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10124761
   Sarkar B, 2018, J CLEAN PROD, V185, P421, DOI 10.1016/j.jclepro.2018.02.215
   Sarkar B, 2017, COMPUT IND ENG, V111, P148, DOI 10.1016/j.cie.2017.07.003
   Sarkar B, 2016, TRANSPORT RES E-LOG, V91, P112, DOI 10.1016/j.tre.2016.03.018
   Sarkar B, 2015, MATH PROBL ENG, DOI 10.1155/2015/469486
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Teuteberg F., 2010, MULTIKONFERENZ WIRTS, V2010, P203
   Tiwari S, 2018, J CLEAN PROD, V204, P82, DOI 10.1016/j.jclepro.2018.08.181
   Tsao YC, 2018, J CLEAN PROD, V174, P1550, DOI 10.1016/j.jclepro.2017.10.272
   Validi S, 2014, INT J PROD ECON, V152, P71, DOI 10.1016/j.ijpe.2014.02.003
   Ye F, 2018, RESOUR CONSERV RECY, V128, P306, DOI 10.1016/j.resconrec.2016.11.023
   You FQ, 2011, IND ENG CHEM RES, V50, P10102, DOI 10.1021/ie200850t
   Zhang WH, 2014, EUR J OPER RES, V234, P15, DOI 10.1016/j.ejor.2013.09.001
   Zhou ZY, 2000, COMPUT CHEM ENG, V24, P1151, DOI 10.1016/S0098-1354(00)00496-8
NR 53
TC 1
Z9 1
U1 19
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104431
DI 10.1016/j.resconrec.2019.104431
PG 20
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000029
DA 2020-05-12
ER

PT J
AU Arowosola, A
   Gaustad, G
AF Arowosola, Ayomipo
   Gaustad, Gabrielle
TI Estimating increasing diversity and dissipative loss of critical metals
   in the aluminum automotive sector
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Critical metals; Aluminum; Lightweight
ID FUTURE; ALLOYS; FLOWS
AB As the demand for and consumption of products and services grow in the US, so does the concern for sustainable material usage. In the automotive industry, major sustainability issues revolve around advocating for improved fuel economy and the incorporation of materials with higher recyclability in order to reduce greenhouse gas (GHG) emissions. A popular strategy to achieve this in the automotive industry is light-weighting. Many studies in this field are focused on the environmental benefits of light-weighting, that is, how replacement of traditional steel in the automotive industry with aluminum, for instance, will help reduce the amount of CO2-eq emissions in the environment. The increasing use of aluminum in the industry for differing automotive applications broadens the range of alloying elements. Unfortunately, many of these elements are dissipatively lost and also deemed critical. Furthermore, some of the alloying elements accumulate as tramp (unwanted) elements in the secondary aluminum stream, hence posing as a barrier to effective recycling, thus leading to material and economic losses. We quantified the material losses and analyzed the economic losses attributed to the dissipation of critical metals and also examined the attendant accumulation of tramp elements in the recycled aluminum stream. Our results indicate that to achieve a more circular economy requires investment and further development of a) operational blending and batching strategies that comprehend alloying additions and the inherent variability of their actual composition, and b) economically feasible material identification and sorting technologies that will help in abating these material losses and associated economic losses.
C1 [Arowosola, Ayomipo] Rochester Inst Technol, Golisano Inst Sustainabil, Rochester, NY 14623 USA.
   [Gaustad, Gabrielle] Alfred Univ, Inamori Sch Engn, Alfred, NY 14802 USA.
RP Gaustad, G (reprint author), Alfred Univ, Inamori Sch Engn, Alfred, NY 14802 USA.
EM gaustad@alfred.edu
FU National Science Foundation (NSF), through CBET awardNational Science
   Foundation (NSF) [1454166]; Golisano Institute for Sustainability (GIS)
   at the Rochester Institute of Technology
FX The authors would like to acknowledge funding from the National Science
   Foundation (NSF), through CBET award #1454166 and support from the
   Golisano Institute for Sustainability (GIS) at the Rochester Institute
   of Technology. They also acknowledge feedbacks on the original draft of
   this paper from Dr Callie Babbit (GIS), Dr Roger Chen (GIS) and Dr Anju
   Gupta (Department of Chemical Engineering) of Rochester Institute of
   Technology.
CR Alonso E, 2012, ENVIRON SCI TECHNOL, V46, P12986, DOI 10.1021/es301110e
   Barnhart J, 1997, REGUL TOXICOL PHARM, V26, pS3, DOI 10.1006/rtph.1997.1132
   Bayliss C, 2019, MINERALS METALS MAT
   Boon J. E., 2000, J IND ECOL, V4, P117
   Brooker A. D, 2013, SAE 2013 WORLD C EXH
   Brooks L, 2019, WASTE MANAGE, V85, P519, DOI 10.1016/j.wasman.2018.12.043
   Chappuis LB, MAT SPECIFICATION RE
   Cheah L., 2016, ENERG POLICY, V39, P454
   Cheah LW, 2010, CARS DIET MAT ENERGY
   Ciacci L, 2015, ENVIRON SCI TECHNOL, V49, P9443, DOI 10.1021/es505515z
   Cui JR, 2010, T NONFERR METAL SOC, V20, P2057, DOI 10.1016/S1003-6326(09)60417-9
   Ducker Worldwide, 2017, AL CONT N AM LIGHT V
   European Aluminium, AL AUT MAN
   European Aluminium Association, 2002, MAT ALL CONST AL AUT
   European Commission, 2017, LIST CRIT RAW MAT EU
   Fridlyander IN, 2002, MET SCI HEAT TREAT+, V44, P365, DOI 10.1023/A:1021901715578
   Gaustad G, 2009, SUSTAINABLE MAT USAG
   Gaustad G, 2007, RESOUR CONSERV RECY, V52, P180, DOI 10.1016/j.resconrec.2007.03.005
   Gaustad G, 2010, J IND ECOL, V14, P286, DOI 10.1111/j.1530-9290.2010.00229.x
   Graedel TE, 2011, J IND ECOL, V15, P355, DOI 10.1111/j.1530-9290.2011.00342.x
   Hatayama H, 2015, MATER TRANS, V56, P229, DOI 10.2320/matertrans.M2014380
   Kim HJ, 2010, J IND ECOL, V14, P929, DOI 10.1111/j.1530-9290.2010.00283.x
   Laner D, 2016, LCA COMPEND, P293, DOI 10.1007/978-94-017-7610-3_7
   Miller WS, 2000, MAT SCI ENG A-STRUCT, V280, P37, DOI 10.1016/S0921-5093(99)00653-X
   Modaresi R, 2012, ENVIRON SCI TECHNOL, V46, P8587, DOI 10.1021/es300648w
   Moss R., 2013, 25994 JRC EUR
   Nansai K, 2014, ENVIRON SCI TECHNOL, V48, P1391, DOI 10.1021/es4033452
   Nassar NT, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400180
   National Research Council, 2008, CRIT MIN MIN CRIT MI
   Nuss P, 2014, ENVIRON SCI TECHNOL, V48, P4171, DOI 10.1021/es405044w
   Petit S, 2018, N AM LIGHT VEHICLE P
   Restrepo E, 2017, ENVIRON SCI TECHNOL, V51, P1129, DOI 10.1021/acs.est.6b05743
   Staley J. T, 2018, ENCY BRITANNICA
   Staley J. T, 1993, J PHYS IV, V3
   Talens Peiro L, 2013, ENVIRON SCI TECHNOL, V47, P2939, DOI 10.1021/es301519c
   U.S. Geological Survey, 2018, MINERAL COMMODITY SU, DOI [10.3133/70194932, DOI 10.3133/70194932]
   US Environmental Protection Agency, 2018, 2018 EPA AUT TRENDS
   US Office of the Secretary of the Department of the Interior, 2018, FED REGISTER, V83, P23295
   USEPA, 2018, SOURC GREENH GAS EM
   USEPA, 2018, TRENDS GREENH GAS EM
   USEPA, 2018, INV US GREENH GAS EM
   Wagstaff S. R, 2018, IMPACT RECYCLING MEC
   Zimmermann T, 2013, SCI TOTAL ENVIRON, V461, P774, DOI 10.1016/j.scitotenv.2013.05.040
NR 43
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104382
DI 10.1016/j.resconrec.2019.06.016
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000006
DA 2020-05-12
ER

PT J
AU Cruz, NC
   Silva, FC
   Tarelho, LAC
   Rodrigues, SM
AF Cruz, Nuno C.
   Silva, Flavio C.
   Tarelho, Luis A. C.
   Rodrigues, Sonia M.
TI Critical review of key variables affecting potential recycling
   applications of ash produced at large-scale biomass combustion plants
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Biomass ash; Recycling; Soil application; Soil remediation; LIFE
   No_Waste Project
ID WOOD FLY-ASH; CHEMICAL-COMPOSITION; ORAL BIOACCESSIBILITY;
   PHYSICAL-PROPERTIES; INORGANIC ELEMENTS; ORGANIC POLLUTANTS;
   ENERGY-PRODUCTION; POWER-GENERATION; FOREST RESIDUES; TOXIC ELEMENTS
AB Growing quantities of biomass ash are produced worldwide due to an increasing use of biomass for heat and electricity generation. Physical-chemical properties and elemental composition of ash at industrial biomass thermal power plants show significant variations. Experimental methods to characterize ashes are time-consuming and difficult to implement on a routine basis, posing severe limitations to the selection of most appropriate recycling options for these waste materials at the ash production stage.
   This review focused on relevant biomass ash properties that must be evaluated prior to environmental applications and recycling and on the identification of key process variables that determine such properties. A database characterizing 77 biomass ashes collected at large-scale industrial facilities was compiled. Ash type (bottom ash (BA) or fly ash (FA)) are distinguished by their pH and electrical conductivity ranges. Ash chemical composition was largely influenced by the type of biomass fuel burnt, and to a lesser extent by the technology and temperature of combustion.
   Ash from combustion of contaminated biomass, as well as the smallest fraction of FA particles (< 0.200 mu m) show constraints for use in soils or construction materials due to high potentially toxic elements concentrations, soluble salts, and/or chloride contents posing both environmental and technical concerns. Both BA and FA generated by combustion of wood and biomass mixtures, regardless of the combustion technology, were found suitable for soil application as well as for incorporation in road or cementitious materials, provided that technical and risk assessment protocols to regulate their use are produced and standardized.
C1 [Cruz, Nuno C.; Silva, Flavio C.; Tarelho, Luis A. C.; Rodrigues, Sonia M.] Univ Aveiro, Ctr Environm & Marine Studies, Campus Univ Santiago, P-3810193 Aveiro, Portugal.
   [Cruz, Nuno C.; Rodrigues, Sonia M.] Univ Aveiro, Dept Chem, Campus Univ Santiago, P-3810193 Aveiro, Portugal.
   [Silva, Flavio C.; Tarelho, Luis A. C.] Univ Aveiro, Dept Environm & Planning, Campus Univ Santiago, P-3810193 Aveiro, Portugal.
RP Cruz, NC (reprint author), Univ Aveiro, Ctr Environm & Marine Studies, Campus Univ Santiago, P-3810193 Aveiro, Portugal.; Cruz, NC (reprint author), Univ Aveiro, Dept Chem, Campus Univ Santiago, P-3810193 Aveiro, Portugal.
EM nmcc@ua.pt
RI Rodrigues, Sonia M/A-5407-2012; Silva, Flavio GCS/A-6505-2008; da Cruz
   Tarelho, Luis Antonio/A-8278-2013; Cruz, Nuno/W-3601-2018
OI Rodrigues, Sonia M/0000-0002-3969-0972; Silva, Flavio
   GCS/0000-0001-7025-0601; da Cruz Tarelho, Luis
   Antonio/0000-0003-0385-5621; Cruz, Nuno/0000-0003-3439-1241
FU CESAM, by FCT/MCTES [UID/AMB/50017/2019]; project NanoFertil by
   FCT/MCTES [POCI- 01-0145-FEDER-016749-PTDC/AGR-PRO/6262/2014]; FEDER,
   within the PT2020 Partnership Agreement; FEDER, within Compete
   2020European Union (EU); FCTPortuguese Foundation for Science and
   Technology [SRFH/BD/115115/2016]; European Commission through Project
   LIFE No_Waste [LIFE14 ENV/PT/000369]
FX Thanks are due for the financial support to CESAM (UID/AMB/50017/2019),
   by FCT/MCTES through national funds. S.M. Rodrigues acknowledges funding
   to project NanoFertil (POCI-
   01-0145-FEDER-016749-PTDC/AGR-PRO/6262/2014) by FCT/MCTES through
   national funds, and the co-funding by the FEDER, within the PT2020
   Partnership Agreement and Compete 2020. N.C. Cruz acknowledges Ph.D.
   financial support from FCT (Grant SRFH/BD/115115/2016). Authors also
   acknowledge the financial support of the European Commission through
   Project LIFE No_Waste (LIFE14 ENV/PT/000369).
CR Ahmaruzzaman M, 2009, ENERG FUEL, V23, P1494, DOI 10.1021/ef8002697
   Al-Mansour F, 2010, BIOMASS BIOENERG, V34, P620, DOI 10.1016/j.biombioe.2010.01.004
   [Anonymous], 45012012 BS EN
   Augusto L, 2008, PLANT SOIL, V306, P181, DOI 10.1007/s11104-008-9570-z
   Barbosa R, 2013, FUEL PROCESS TECHNOL, V109, P124, DOI 10.1016/j.fuproc.2012.09.048
   Berra M, 2015, CONSTR BUILD MATER, V76, P286, DOI 10.1016/j.conbuildmat.2014.11.052
   Bogush AA, 2018, FUEL, V211, P712, DOI 10.1016/j.fuel.2017.09.103
   Caillat S, 2013, WOODHEAD PUBL SER EN, P189, DOI 10.1533/9780857097439.3.189
   Cheah Chee Ban, 2014, American Journal of Applied Sciences, V11, P1369, DOI 10.3844/ajassp.2014.1369.1378
   Cruz NC, 2017, ENVIRON SCI POLLUT R, V24, P14770, DOI 10.1007/s11356-017-9013-6
   Liao CP, 2007, FUEL PROCESS TECHNOL, V88, P149, DOI 10.1016/j.fuproc.2005.06.008
   Dahl O, 2010, FUEL PROCESS TECHNOL, V91, P1634, DOI 10.1016/j.fuproc.2010.06.012
   Dahl O, 2009, FUEL PROCESS TECHNOL, V90, P871, DOI 10.1016/j.fuproc.2009.04.013
   de la Gree GCHD, 2016, WASTE MANAGE, V49, P96, DOI 10.1016/j.wasman.2015.12.023
   De Rossi A, 2019, MATER LETT, V236, P644, DOI 10.1016/j.matlet.2018.11.016
   Demirbas A, 2006, ENERG SOURCE PART A, V28, P779, DOI 10.1080/00908310600718742
   EC (European Commission), 2016, CALL APPL MEMB OBS T
   EC (European Commission), 2011, COM11131912011 EC
   Ellabban O, 2014, RENEW SUST ENERG REV, V39, P748, DOI 10.1016/j.rser.2014.07.113
   ETIEGNI L, 1991, BIORESOURCE TECHNOL, V37, P173, DOI 10.1016/0960-8524(91)90207-Z
   Freire M, 2015, WASTE MANAGE, V46, P304, DOI 10.1016/j.wasman.2015.08.036
   Giron RP, 2013, FUEL, V114, P71, DOI 10.1016/j.fuel.2012.04.042
   Groenier J, 2006, MISCELLANEOUS PUBLIC, V44
   Hanne O, 2006, MINER ENG, V19, P1596, DOI 10.1016/j.mineng.2006.07.002
   Huotari N, 2015, FOREST ECOL MANAG, V348, P226, DOI 10.1016/j.foreco.2015.03.008
   Huygens D., 2017, DRAFT STRUBIAS TECHN
   Jacobs DE, 2002, ENVIRON HEALTH PERSP, V110, pA599, DOI 10.1289/ehp.021100599
   James AK, 2012, ENERGIES, V5, P3856, DOI 10.3390/en5103856
   Jaworek A, 2018, PROG ENERG COMBUST, V67, P206, DOI 10.1016/j.pecs.2018.03.003
   Jaworek A, 2013, J ELECTROSTAT, V71, P165, DOI 10.1016/j.elstat.2013.01.009
   Jenkins BM, 1998, FUEL PROCESS TECHNOL, V54, P17, DOI 10.1016/S0378-3820(97)00059-3
   Kabata-Pendias Alina, 2010, P1
   Kahl JS, 1996, J ENVIRON QUAL, V25, P220, DOI 10.2134/jeq1996.00472425002500020003x
   Khan AA, 2009, FUEL PROCESS TECHNOL, V90, P21, DOI 10.1016/j.fuproc.2008.07.012
   Kilpimaa S, 2013, BIORESOURCES, V8, P1011
   Klinghoffer NB, 2013, WOODHEAD PUBL SER EN, P3, DOI 10.1533/9780857096364.1.3
   Knapp BA, 2011, RECYCLING OF BIOMASS ASHES, P1, DOI 10.1007/978-3-642-19354-5_1
   Kulshrestha A, 2009, SCI TOTAL ENVIRON, V407, P6196, DOI 10.1016/j.scitotenv.2009.08.050
   Lanzerstorfer C, 2015, J ENVIRON SCI-CHINA, V30, P191, DOI 10.1016/j.jes.2014.08.021
   Laohaprapanon S, 2010, CLEAN-SOIL AIR WATER, V38, P1055, DOI 10.1002/clen.201000105
   Li LM, 2012, J HAZARD MATER, V233, P41, DOI 10.1016/j.jhazmat.2012.06.053
   Liu QM, 2017, ENERG FUEL, V31, P3525, DOI 10.1021/acs.energyfuels.7b00258
   Lopez R, 2018, SCI TOTAL ENVIRON, V625, P1013, DOI 10.1016/j.scitotenv.2017.12.263
   Masto RE, 2015, FUEL PROCESS TECHNOL, V132, P139, DOI 10.1016/j.fuproc.2014.12.036
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P37, DOI 10.1016/S0960-8524(01)00118-3
   McKendry P, 2002, BIORESOURCE TECHNOL, V83, P47, DOI 10.1016/S0960-8524(01)00119-5
   MISRA MK, 1993, BIOMASS BIOENERG, V4, P103, DOI 10.1016/0961-9534(93)90032-Y
   Modolo RCE, 2013, CONSTR BUILD MATER, V45, P275, DOI 10.1016/j.conbuildmat.2013.03.093
   Nable RO, 1997, PLANT SOIL, V193, P181, DOI 10.1023/A:1004272227886
   Niu YQ, 2013, BIORESOURCE TECHNOL, V129, P642, DOI 10.1016/j.biortech.2012.12.065
   Niu YQ, 2010, BIORESOURCE TECHNOL, V101, P9373, DOI 10.1016/j.biortech.2010.06.144
   NORDIN A, 1994, BIOMASS BIOENERG, V6, P339, DOI 10.1016/0961-9534(94)E0031-M
   Novais RM, 2019, J CLEAN PROD, V207, P350, DOI 10.1016/j.jclepro.2018.09.265
   Nunes LJR, 2017, RENEW SUST ENERG REV, V71, P373, DOI 10.1016/j.rser.2016.12.067
   Obernberger I, 2004, BIOMASS BIOENERG, V27, P653, DOI 10.1016/j.biombioe.2003.07.006
   Obernberger I, 1997, BIOMASS BIOENERG, V12, P211, DOI 10.1016/S0961-9534(96)00051-7
   Obernberger I, 2006, BIOMASS BIOENERG, V30, P973, DOI 10.1016/j.biombioe.2006.06.011
   OLANDERS B, 1995, BIOMASS BIOENERG, V8, P105, DOI 10.1016/0961-9534(95)00004-Q
   Pandey J, 2009, ENVIRON MONIT ASSESS, V148, P61, DOI 10.1007/s10661-007-0139-8
   Panwar NL, 2011, RENEW SUST ENERG REV, V15, P1513, DOI 10.1016/j.rser.2010.11.037
   Pitman RM, 2006, FORESTRY, V79, P563, DOI 10.1093/forestry/cpl041
   Poykio R, 2009, J HAZARD MATER, V162, P1059, DOI 10.1016/j.jhazmat.2008.05.140
   Poykio R, 2009, P EST ACAD SCI, V58, P247, DOI 10.3176/proc.2009.4.06
   Quirantes M, 2016, COMMUN SOIL SCI PLAN, V47, P2271, DOI 10.1080/00103624.2016.1243702
   Reijnders L, 2005, RESOUR CONSERV RECY, V43, P313, DOI 10.1016/j.resconrec.2004.06.007
   Reimann C, 2008, SCI TOTAL ENVIRON, V393, P191, DOI 10.1016/j.scitotenv.2008.01.015
   Rodrigues SM, 2018, SCI TOTAL ENVIRON, V635, P188, DOI 10.1016/j.scitotenv.2018.04.063
   Rodrigues SM, 2014, SCI TOTAL ENVIRON, V496, P649, DOI 10.1016/j.scitotenv.2014.06.115
   Saidur R, 2011, RENEW SUST ENERG REV, V15, P2262, DOI 10.1016/j.rser.2011.02.015
   Saqib N, 2016, FUEL, V172, P105, DOI 10.1016/j.fuel.2016.01.010
   Sarenbo S, 2009, BIOMASS BIOENERG, V33, P1212, DOI 10.1016/j.biombioe.2009.05.007
   Schirmer J, 2012, J OCCUP ENVIRON HYG, V9, P280, DOI 10.1080/15459624.2012.668489
   Schultz E, 2004, SCI TOTAL ENVIRON, V326, P71, DOI 10.1016/j.scitotenv.2003.12.008
   Sharma SK, 2016, ATMOS POLLUT RES, V7, P110, DOI 10.1016/j.apr.2015.08.002
   Sigvardsen NM, 2019, RESOUR CONSERV RECY, V145, P230, DOI 10.1016/j.resconrec.2019.02.034
   Silva FC, 2019, J CLEAN PROD, V214, P112, DOI 10.1016/j.jclepro.2018.12.268
   Steenari BM, 1999, FUEL, V78, P249, DOI 10.1016/S0016-2361(98)00137-9
   Steenari BM, 1997, BIOMASS BIOENERG, V13, P39, DOI 10.1016/S0961-9534(97)00024-X
   Tarelho LAC, 2015, ENERGY, V90, P387, DOI 10.1016/j.energy.2015.07.036
   Teixeira ER, 2019, RESOUR CONSERV RECY, V145, P292, DOI 10.1016/j.resconrec.2019.02.028
   Thy P, 2006, FUEL, V85, P783, DOI 10.1016/j.fuel.2005.08.020
   Trivedi NS, 2016, ENVIRON SCI POLLUT R, V23, P20243, DOI 10.1007/s11356-016-7227-7
   van der Drift A, 2001, BIOMASS BIOENERG, V20, P45, DOI 10.1016/S0961-9534(00)00045-3
   Van Herck P, 2001, WASTE MANAGE, V21, P685, DOI 10.1016/S0956-053X(01)00011-3
   Van Loo S, 2008, THE HANDBOOK OF BIOM
   Vassilev SV, 2014, FUEL, V129, P292, DOI 10.1016/j.fuel.2014.04.001
   Vassilev SV, 2013, FUEL, V105, P40, DOI 10.1016/j.fuel.2012.09.041
   Vassilev SV, 2013, FUEL, V105, P19, DOI 10.1016/j.fuel.2012.10.001
   Vassilev SV, 2010, FUEL, V89, P913, DOI 10.1016/j.fuel.2009.10.022
   Wang GL, 2012, ENERG FUEL, V26, P102, DOI 10.1021/ef201134m
   Wenni Li, 2013, Applied Mechanics and Materials, V260-261, P217, DOI 10.4028/www.scientific.net/AMM.260-261.217
   Werkelin J, 2011, BIOMASS BIOENERG, V35, P725, DOI 10.1016/j.biombioe.2010.10.010
   Wolf JP, 2013, WOODHEAD PUBL SER EN, P3, DOI 10.1533/9780857097439.1.3
   Zhang LH, 2010, ENERG CONVERS MANAGE, V51, P969, DOI 10.1016/j.enconman.2009.11.038
   Zhao MY, 2013, ENERG FUEL, V27, P898, DOI 10.1021/ef301715p
NR 95
TC 2
Z9 2
U1 11
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104427
DI 10.1016/j.resconrec.2019.104427
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000024
DA 2020-05-12
ER

PT J
AU Davenport, ML
   Qi, DY
   Roe, BE
AF Davenport, Megan L.
   Qi, Danyi
   Roe, Brian E.
TI Food-related routines, product characteristics, and household food waste
   in the United States: A refrigerator-based pilot study
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Food-related routines; Food labeling; Refrigerated foods
AB U.S. households waste a substantial quantity of food and are advised to better manage purchasing and storage of perishable foods as a means to reduce food waste. However, little research exists concerning the contents and management of home refrigerators, which are central to most advice regarding home food waste reduction. We survey U.S. consumers about their home refrigerator inventories to assess the relationship between food-related routines and important considerations in the food discarding decision process, as well as the influence of food related routines and product characteristics on the utilization of refrigerated foods. Our pilot study reveals that physical and institutional signals of food safety and quality drive consumer decision making about discarding food. We also find that refrigerator cleaning frequency, grocery shopping duration and frequently checking nutrition labels are among food-related routines that affect the utilization of refrigerated food. Additionally, "best by", "use by" and ambiguous date labeling significantly decrease the odds that food items are fully utilized.
C1 [Davenport, Megan L.; Roe, Brian E.] Ohio State Univ, Dept Agr Environm & Dev Econ, Agr Adm Bldg,2120 Fyffe Rd, Columbus, OH 43210 USA.
   [Qi, Danyi] Louisiana State Univ, Dept Agr Econ & Agribusiness, Martin D Woodin Hall, Baton Rouge, LA 70803 USA.
RP Davenport, ML (reprint author), Ohio State Univ, Dept Agr Environm & Dev Econ, Agr Adm Bldg,2120 Fyffe Rd, Columbus, OH 43210 USA.
EM davenport.209@osu.edu
RI Roe, Brian E/A-7386-2009
OI Roe, Brian E/0000-0003-4228-2889; Davenport, Megan/0000-0002-7558-3832
FU Ohio State University's Decision Sciences Collaborative; Ohio State
   University's Van Buren Program; Ohio Agricultural Research and
   Development Center
FX The authors recognize funding from Ohio State University's Decision
   Sciences Collaborative, Ohio State University's Van Buren Program, and
   the Ohio Agricultural Research and Development Center.
CR Buzby J, 2014, EC INFORM B
   Food and Agriculture Organization of the United Nations (FAO), 2014, WORKING PAPER
   Gunders D, 2012, IP1206B NRDC
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Hoover D, 2017, R1709B NAT RES DEF C
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Leib E. B., 2016, CONSUMER PERCEPTIONS
   Leib E. B, 2013, R1309A NRDC HARV FOO
   Neff RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127881
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Qi DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159250
   ReFED, 2016, ROADM RED US FOOD WA
   Roe BE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191813
   Rose D, 2002, J NUTR, V132, P3235
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Stenmarck A., 2016, ESTIMATES EUROPEAN F
   U. S. Census Bureau, 2018, CURR POP SURV ANN SO
   United Nations General Assembly, 2015, TRANSF OUR WORLD 203
   United States Environmental Protection Agency (EPA), 2016, 530F16014A EPA
   Wansink B., 2000, J FAM CONSUM SCI, V92, P104
   Wilson NLW, 2018, J FOOD PROD MARK, V24, P611, DOI 10.1080/10454446.2018.1472700
   Yu Y, 2018, SSRN ELECT J, DOI [10.2139/ssrn.3257535, DOI 10.2139/SSRN.3257535]
NR 24
TC 5
Z9 5
U1 14
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104440
DI 10.1016/j.resconrec.2019.104440
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000030
DA 2020-05-12
ER

PT J
AU Ding, GY
   Xu, J
   Wei, Y
   Chen, R
   Li, X
AF Ding, Guoyu
   Xu, Juan
   Wei, Yue
   Chen, Rui
   Li, Xu
TI Engineered reclamation fill material created from excavated soft
   material and granulated blast furnace slag
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Ground granulated blast; Furnace slag (GGBFS); Excavated soft soil;
   Engineered reclamation fill material; Lime
ID PARTIAL SUBSTITUTION; STRENGTH PROPERTIES; SOIL STABILIZATION; LIME;
   GGBS; CONSOLIDATION; CEMENT
AB Due to the rapid development and population growth, many coastal areas and countries are in shortage of land space. Large amount soft soil generated from excavation work has been used as an alternative recently, which is also a challenge because of its poor engineering properties. In this study, ground granulated blast furnace slag (GGBFS), a byproduct of steel industry, was employed to stabilize the excavated soft soil (ESS). Toxicity evaluation shows that the prepared engineering reclamation fill (ERF) materials possessed little impacts on marine ecology. Binder is essential to activate GGBFS. Lime was a better binder than cement. After 7 d curing, the unconfined compressive strength (UCS) of the ERF prepared with GGBFS (24%) and lime (1%) increased up to about 1.5 times of ESS, and the friction angle increased from about 15 degrees to 40 degrees. The addition of GGBFS activated by lime inhibits the swelling of ERF samples and increased the coefficient of consolidation tremendously. After soaking in simulated sea water for 113 d, only ERFs with lime/GGBFS/ESS dry ratios of 1/24/75 and 1/16/83 stood still with UCS of 4718 kPa and 3133 kPa, about 7 and 5 times of ESS, respectively. Scanning electron microscopy images further confirmed the formation of hydration products such as calcium aluminates, calcium silicate hydrates and calcium aluminum silicate hydrates responsible to the enhancement of the ERFs mechanical properties. The prepared ERF sample with GGBFS (24%) and lime (1%) has been proved to be a potential economic and environmental friendly alternative for land reclamation.
C1 [Ding, Guoyu; Xu, Juan; Wei, Yue; Chen, Rui; Li, Xu] Beijing Jiaotong Univ, Sch Civil Engn, Beijing 100044, Peoples R China.
   [Ding, Guoyu; Xu, Juan; Wei, Yue; Chen, Rui] Beijing Key Lab Aqueous Typ Pollutants Control &, Beijing 100044, Peoples R China.
RP Chen, R; Li, X (reprint author), Beijing Jiaotong Univ, Sch Civil Engn, Beijing 100044, Peoples R China.
EM rchen@bjtu.edu.cn; xuli@bjtu.edu.cn
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019BM094]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities, No. 2019BM094. We are grateful to Dr. Lee Heng
   Poon and Mr. Kok June Chow from ecoWise Holdings Limited, Singapore for
   their constructive critique and useful suggestions.
CR American Society for Testing and Materials, 2007, D114000 ASTM INT
   American Society for Testing and Materials, 2007, D216616 ASTM INT
   American Society for Testing and Materials, 2007, D285003A ASTM INT
   American Society for Testing and Materials, 2008, D454608 ASTM INT
   American Society for Testing and Materials, 2011, D2435D2435M11 ASTM I
   [Anonymous], 2009, NAT PRIM DRINK WAT R
   [Anonymous], 2012, D155712 ASTM INT
   [Anonymous], 2010, D85410 ASTM INT
   ASTM, 2007, D42263 ASTM INT
   ASTM, 2010, D431810 ASTM INT
   ASTM International, 2012, D69812 ASTM INT
   Chen YM, 2008, GEOTEXT GEOMEMBRANES, V26, P164, DOI 10.1016/j.geotexmem.2007.05.004
   Chu J, 2005, CAN GEOTECH J, V42, P528, DOI 10.1139/t04-114
   Chu J, 2015, 15 AS REG C SOIL MEC, P1790
   Higgins D, 2007, PROC INST CIV ENG-CO, V160, P99, DOI 10.1680/coma.2007.160.3.99
   Higgins D. D., 2005, SOIL STABILISATION G
   Keramatikerman M, 2016, APPL CLAY SCI, V132, P722, DOI 10.1016/j.clay.2016.08.029
   Kinuthia JM, 2012, APPL CLAY SCI, V59-60, P131, DOI 10.1016/j.clay.2012.02.021
   Maritime and Port Authority of Singapore, 2014, GEN GUID REQ APPL DR
   Ministry of Ecology and Environment of the People's Republic of China, 2015, 7802015 HJ MIN EC EN
   Nidzam RM, 2010, PROC INST CIV ENG-CO, V163, P157, DOI 10.1680/coma.2010.163.3.157
   Obuzor GN, 2012, ENG GEOL, V151, P112, DOI 10.1016/j.enggeo.2012.09.010
   Oti JE, 2009, P I CIVIL ENG-ENG SU, V162, P229, DOI 10.1680/ensu.2009.162.4.229
   Oti JE, 2008, PROC INST CIV ENG-CO, V161, P147, DOI 10.1680/coma.2008.161.4.147
   Oti JE, 2008, P I CIVIL ENG-ENG SU, V161, P211, DOI 10.1680/ensu.2008.161.4.211
   Oti JE, 2009, ENG GEOL, V107, P130, DOI 10.1016/j.enggeo.2009.05.002
   Saravanan R, 2017, INT C CIV ENG INFR I
   Sato T, 2002, INT S UND TECHN
   Sekhar DC, 2017, INDIAN GEOTECH J, V47, P384, DOI 10.1007/s40098-017-0228-8
   Tang M, 2000, GEOTECHNIQUE, V50, P613, DOI 10.1680/geot.2000.50.6.613
   US EPA, 1992, 1311 US EPA
   Vindula SK, 2019, INT J GEOTECH ENG, V13, P377, DOI 10.1080/19386362.2017.1359901
   Watabe Y, 2015, AS REG C SOIL MECH G, V2, P1784, DOI [10.3208/jgssp.TC217-04, DOI 10.3208/JGSSP.TC217-04]
   Wild S, 1998, ENG GEOL, V51, P37, DOI 10.1016/S0013-7952(98)00039-8
   Wild S, 1999, ENG GEOL, V51, P257, DOI 10.1016/S0013-7952(98)00069-6
   Yi YL, 2015, APPL CLAY SCI, V103, P71, DOI 10.1016/j.clay.2014.11.005
NR 36
TC 1
Z9 1
U1 9
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104428
DI 10.1016/j.resconrec.2019.104428
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000018
DA 2020-05-12
ER

PT J
AU Dong, F
   Li, JY
   Zhang, SN
   Wang, Y
   Sun, ZY
AF Dong, Feng
   Li, Jingyun
   Zhang, Shengnan
   Wang, Yue
   Sun, Ziyuan
TI Sensitivity analysis and spatial-temporal heterogeneity of CO2 emission
   intensity: Evidence from China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE CO2 emission intensity; LMDI; Sensitivity analysis; GTWR
ID ENERGY-RELATED CO2; CARBON INTENSITY; DECOMPOSITION ANALYSIS;
   EMPIRICAL-ANALYSIS; REDUCTION EVIDENCE; ECONOMIC-GROWTH; URBANIZATION;
   PERSPECTIVE; CONSUMPTION; ABATEMENT
AB Due to the Chinese reduction targets of CO2 emission intensity (CEI), it is of great significance to explore its determinants and mechanism. Therefore, the purpose of this study is to find how to effectively reduce CEI. At the national level, we investigate the influencing factors of CEI by using the Logarithmic Mean Divisia Index method (LMDI). Then, this study examines the sensitivity of CEI change to various factors. At the regional level, we study the spatial-temporal heterogeneity of the influencing factors through Geographically and Temporally Weighted Regress (GTWR). The main results are as follows. (1) At the national level, the positive contribution of the energy mix is the largest. The energy intensity of the production sector is the main negative driving factor in the early stage, and in the later stage, the principal negative contribution comes from the combined action of the CO2 emission coefficient and economic structure. (2) A dynamic change is observed in the sensitivity of CEI to various factors. (3) At the regional level, various determinants of CEI show spatial-temporal heterogeneity based on GTWR. For example, in analysing the impact of energy intensity in the industrial sector on CEI in various regions, Shandong Province has the largest coefficient. The findings are of considerable interest for China's policy makers to effectively formulate more appropriate emission-reduction measures for each region.
C1 [Dong, Feng; Li, Jingyun; Zhang, Shengnan; Wang, Yue; Sun, Ziyuan] China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
RP Dong, F; Sun, ZY (reprint author), China Univ Min & Technol, Sch Management, Xuzhou 221116, Jiangsu, Peoples R China.
EM dongfeng2008@126.com; zycumt@126.com
OI Dong, Feng/0000-0002-5177-6453
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71573254]; Humanities and Social Sciences Special
   Research Fund of Ministry of Education in China [19JDGC011]; Jiangsu
   Funds for Social Science [17JDB004]; Jiangsu Education Science Project
   [B-b/2015/01/027]; Key Project of Postgraduate Education and Teaching
   Reform in Jiangsu Province [JGZZ18047]; National Social Science Fund
   Later Funding Project of China [18FGL019]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 71573254), Humanities and Social Sciences Special
   Research Fund of Ministry of Education in China (Research on Talents
   Training for Engineering Science and Technology, Grant No. 19JDGC011),
   Jiangsu Funds for Social Science (Grant No. 17JDB004), Jiangsu Education
   Science Project (Grant No. B-b/2015/01/027), Key Project of Postgraduate
   Education and Teaching Reform in Jiangsu Province (JGZZ18047), and
   National Social Science Fund Later Funding Project of China (No.
   18FGL019). The authors thank Professor Huang Bo in the Chinese
   University of Hong Kong for providing GTWR software. The authors also
   would like to thank the anonymous reviewers for their valuable
   suggestions on the earlier draft of this study, and upon which the
   content have been improved.
CR Ang BW, 2007, ENERG POLICY, V35, P238, DOI 10.1016/j.enpol.2005.11.001
   Ang BW, 2005, ENERG POLICY, V33, P867, DOI 10.1016/j.enpol.2003.10.010
   Ang BW, 2004, ENERG POLICY, V32, P1131, DOI 10.1016/S0301-4215(03)00076-4
   ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x
   Chen SY, 2011, WORLD ECON, V34, P1148, DOI 10.1111/j.1467-9701.2011.01370.x
   Chen WD, 2017, RESOUR CONSERV RECY, V117, P264, DOI 10.1016/j.resconrec.2016.10.008
   Cheng YQ, 2014, J GEOGR SCI, V24, P631, DOI 10.1007/s11442-014-1110-6
   de Freitas LC, 2011, ENERG POLICY, V39, P1495, DOI 10.1016/j.enpol.2010.12.023
   Dhakal S, 2009, ENERG POLICY, V37, P4208, DOI 10.1016/j.enpol.2009.05.020
   Dong F, 2019, SCI TOTAL ENVIRON, V685, P631, DOI 10.1016/j.scitotenv.2019.05.269
   Dong F, 2019, J CLEAN PROD, V222, P768, DOI 10.1016/j.jclepro.2019.03.105
   Dong F, 2019, J CLEAN PROD, V223, P759, DOI 10.1016/j.jclepro.2019.03.152
   Dong F, 2019, RESOUR CONSERV RECY, V141, P61, DOI 10.1016/j.resconrec.2018.10.010
   Dong F, 2019, SCI TOTAL ENVIRON, V653, P565, DOI 10.1016/j.scitotenv.2018.10.395
   Dong F, 2018, RESOUR CONSERV RECY, V134, P206, DOI 10.1016/j.resconrec.2018.02.009
   Dong F, 2018, RESOUR CONSERV RECY, V130, P31, DOI 10.1016/j.resconrec.2017.11.011
   Dong F, 2018, RESOUR CONSERV RECY, V129, P187, DOI 10.1016/j.resconrec.2017.10.035
   Dong F, 2016, NAT HAZARDS, V82, P1375, DOI 10.1007/s11069-016-2248-6
   Dong M, 2018, J FINANC EC THEORY, V1, P1
   Guo P, 2014, SCI TECHNOL MANAG RE, V307, P220
   He LY, 2011, SOFT SCI, V25, P94
   Hoekstra R, 2003, ENERG ECON, V25, P39, DOI 10.1016/S0140-9883(02)00059-2
   Hu CZ, 2008, CHINA POPUL RESOUR E, V18, P38, DOI DOI 10.1016/S1872-583X(09)60006-1
   Huang B, 2009, INT J GEOGR INF SCI, V23, P379, DOI 10.1080/13658810802119685
   IPCC, 2006, GUID NAT GREENH GAS, V2
   IPCC, 2014, GREENH GAS INV IPCC
   Kaya Y., 1989, IMPACT CARBON DIOXID
   Kurniawan R, 2018, J CLEAN PROD, V201, P334, DOI 10.1016/j.jclepro.2018.08.051
   Li N, 2017, RESOUR CONSERV RECY, V121, P11, DOI 10.1016/j.resconrec.2016.03.016
   Li W, 2018, SCI TOTAL ENVIRON, V637, P91, DOI 10.1016/j.scitotenv.2018.04.419
   Li W, 2017, RESOUR CONSERV RECY, V126, P162, DOI 10.1016/j.resconrec.2017.07.043
   Li Z. K, 2014, CHINA COMMUN NEWS
   Liu N, 2015, ENERG POLICY, V87, P28, DOI 10.1016/j.enpol.2015.08.035
   Luo GI., 2015, ENERGY CHINA, V7, P43
   Ma XJ, 2019, SCI TOTAL ENVIRON, V648, P1411, DOI 10.1016/j.scitotenv.2018.08.183
   National Development and Reform Commission, 2013, EN CONS RED PLAN 12
   Pan XF, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8030271
   Qian Y, 2012, ATMOS CHEM PHYS, V12, P1785, DOI 10.5194/acp-12-1785-2012
   Shuai CY, 2019, SCI TOTAL ENVIRON, V646, P524, DOI 10.1016/j.scitotenv.2018.07.045
   Su B, 2015, APPL ENERG, V154, P13, DOI 10.1016/j.apenergy.2015.04.101
   Wang CJ, 2014, SUSTAINABILITY-BASEL, V6, P8164, DOI 10.3390/su6118164
   Wang F., 2010, EC RES J, V2, P123, DOI DOI 10.3969/J.ISSN.1002-5502.2010.002.013
   Wang HS, 2014, ENERG POLICY, V68, P482, DOI 10.1016/j.enpol.2013.12.066
   Wang Y, 2018, ATMOS POLLUT RES, V9, P15, DOI 10.1016/j.apr.2017.06.002
   Wang ZH, 2016, RENEW SUST ENERG REV, V55, P34, DOI 10.1016/j.rser.2015.10.077
   Weng ZX, 2018, RESOUR CONSERV RECY, V133, P157, DOI 10.1016/j.resconrec.2018.01.032
   Wu CB, 2018, J CLEAN PROD, V172, P466, DOI 10.1016/j.jclepro.2017.10.216
   Xiao H. W, 2014, STAT INFORM FORUM, V29, P83
   [徐国泉 XU Guoquan], 2006, [中国人口·资源与环境, China Population·Resources and Environment], V16, P158
   [张松林 ZHANG Songlin], 2007, [中山大学学报. 自然科学版, Acta Scientiarum Naturalium Universitatis Sunyatseni], V46, P93
   Zhang W, 2016, ENERG POLICY, V92, P369, DOI 10.1016/j.enpol.2016.02.026
   Zhang YJ, 2017, ENERG POLICY, V100, P18, DOI 10.1016/j.enpol.2016.10.005
   Zheng S, 2018, RESOUR CONSERV RECY, V137, P145, DOI 10.1016/j.resconrec.2018.06.004
   Zhou CS, 2018, RESOUR CONSERV RECY, V130, P1, DOI 10.1016/j.resconrec.2017.11.007
   Zhu ZS, 2014, APPL ENERG, V113, P808, DOI 10.1016/j.apenergy.2013.07.062
NR 55
TC 6
Z9 6
U1 24
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104398
DI 10.1016/j.resconrec.2019.06.032
PG 19
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000002
DA 2020-05-12
ER

PT J
AU Ertz, M
   Leblanc-Proulx, S
   Sarigollu, E
   Morin, V
AF Ertz, Myriam
   Leblanc-Proulx, Sebastien
   Sarigollu, Emine
   Morin, Vincent
TI Advancing quantitative rigor in the circular economy literature: New
   methodology for product lifetime extension business models
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Quantitative rigor; Taxonomy; Classification; Circular economy; Business
   model; Product lifetime extension
ID COLLABORATIVE CONSUMPTION; CAPTURING VALUE; BIG DATA; SUSTAINABILITY;
   FRAMEWORK; CONSUMERS; STRATEGY
AB Research on product lifetime extension (PLE) is of emerging interest in the circular economy (CE), but the extant literature is deficient in various aspects. First, it lacks a systematic analysis of the structure which underlies organizational efforts to PLE. Second, the literature has overlooked the role of two key agents in circular economy, namely, businesses and consumers. Third, the literature lacks a systematic study of the product lifetime extension strategies. Fourth, although several studies have proposed taxonomies of organizations in the circular economy, they lack quantitative rigor, ecological validity, and generalizability. The purpose of this study is to address these deficiencies in the circular economy literature. Specifically, this article develops and empirically validates a methodology to classify a specific type of circular business model, namely product lifetime extension business models, involving organizations and consumers, to bring quantitative rigor to conduct and presentation of taxonomy research in the field of the circular economy.
C1 [Ertz, Myriam; Leblanc-Proulx, Sebastien] Univ Quebec Chicoutimi, Dept Econ & Adm Sci, LaboNFC, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
   [Sarigollu, Emine] McGill Univ, Desautels Fac Management, LaboNFC, 1001 Rue Sherbrooke Ouest, Montreal, PQ H3A 1G5, Canada.
   [Morin, Vincent] Univ Quebec Chicoutimi, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
RP Ertz, M (reprint author), Univ Quebec Chicoutimi, Dept Econ & Adm Sci, LaboNFC, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
EM Myriam_Ertz@uqac.ca; Sebastien_Leblanc-Proulx@uqac.ca;
   emine.sarigollu@mcgill.ca; Vincent_Morin@uqac.ca
OI Leblanc-Proulx, Sebastien/0000-0002-5270-7396; Ertz,
   Myriam/0000-0001-9959-2779
FU International Fund of the Department of Economics and Administrative
   Sciences
FX This study w;1;as supported by the International Fund of the Department
   of Economics and Administrative Sciences and the LaboNFC.
CR Adivar B, 2019, J RETAIL CONSUM SERV, V48, P257, DOI 10.1016/j.jretconser.2019.02.024
   Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Bakker C., 2014, PRODUCTS LAST PRODUC
   Bardhi F, 2012, J CONSUM RES, V39, P881, DOI 10.1086/666376
   Belk R, 2014, J BUS RES, V67, P1595, DOI 10.1016/j.jbusres.2013.10.001
   Biloslavo R, 2018, J CLEAN PROD, V174, P746, DOI 10.1016/j.jclepro.2017.10.281
   Bocken NMP, 2016, ENVIRON INNOV SOC TR, V18, P41, DOI 10.1016/j.eist.2015.07.010
   Bocken NMP, 2014, J CLEAN PROD, V65, P42, DOI 10.1016/j.jclepro.2013.11.039
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   Chesbrough H, 2002, IND CORP CHANGE, V11, P529, DOI 10.1093/icc/11.3.529
   Choi S.S., 2010, J SYST CYBERN INF, V8, P43
   Cooper H. M., 1988, KNOWLEDGE SOC, V1, P104, DOI DOI 10.1007/BF03177550
   Cooper T., 2016, LONGER LASTING PRODU
   Cooper T, 2018, LONGER LASTING PRODU, P3
   Cox J, 2013, RESOUR CONSERV RECY, V79, P21, DOI 10.1016/j.resconrec.2013.05.003
   Dekker H, 2019, IND MARKET MANAG, V77, P143, DOI 10.1016/j.indmarman.2018.11.010
   Ellen MacArthur Foundation, 2015, CIRCULAR EC BUSINESS
   Erevelles S, 2016, J BUS RES, V69, P897, DOI 10.1016/j.jbusres.2015.07.001
   Ertz M, 2017, J PROMOT MANAG, P1
   Ertz M, 2018, J CONSUM MARK, V35, P392, DOI 10.1108/JCM-09-2016-1941
   Ertz M, 2018, INT REV RETAIL DISTR, V28, P92, DOI 10.1080/09593969.2017.1334692
   Ertz M, 2017, INT J MARKET RES, V59, P725, DOI 10.2501/IJMR-2017-040
   Ertz M, 2017, J CONSUM MARK, V34, P108, DOI 10.1108/JCM-07-2015-1491
   Everitt B. S., 2011, CLUSTER ANAL, P71, DOI DOI 10.1002/9780470977811.CH4
   Fastoso F, 2010, J INT MANAG, V16, P32, DOI 10.1016/j.intman.2009.02.005
   Flyvbjerg B, 2006, QUAL INQ, V12, P219, DOI 10.1177/1077800405284363
   Gaiardelli P, 2014, J CLEAN PROD, V66, P507, DOI 10.1016/j.jclepro.2013.11.032
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Gioia DA, 2013, ORGAN RES METHODS, V16, P15, DOI 10.1177/1094428112452151
   Hair J.F., 2006, MULTIVARIATE DATA AN
   HAMBRICK DC, 1984, J MANAGE, V10, P27, DOI 10.1177/014920638401000104
   Han J, 2012, MOR KAUF D, P1
   Hartmann PM, 2016, INT J OPER PROD MAN, V36, P1382, DOI 10.1108/IJOPM-02-2014-0098
   Hazen BT, 2017, BUS STRATEG ENVIRON, V26, P451, DOI 10.1002/bse.1929
   Heiskanen E, 1996, NATL CONSUMER RES CT, V22
   Johnson R. B., 1997, EDUCATION, V118, P282
   Karray S, 2018, ELECTRON COMMER R A, V27, P11, DOI 10.1016/j.elerap.2017.11.001
   Kaufman L, 1990, FINDING GROUPS DATA
   Ketchen DJ, 1996, STRATEGIC MANAGE J, V17, P441, DOI 10.1002/(SICI)1097-0266(199606)17:6<441::AID-SMJ819>3.0.CO;2-G
   Khan MA, 2018, J CLEAN PROD, V204, P1154, DOI 10.1016/j.jclepro.2018.08.329
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Lamberton CP, 2012, J MARKETING, V76, P109, DOI 10.1509/jm.10.0368
   Lincoln Y., 1985, NATURALISTIC INQUIRY
   Lincoln Y. S., 1994, HDB QUALITATIVE RES, P105, DOI DOI 10.1093/INTQHC/MZM042
   Liu Y, 2009, J OPER MANAG, V27, P294, DOI 10.1016/j.jom.2008.09.004
   Ludeke-Freund F, 2018, SUSTAIN PROD CONSUMP, V15, P145, DOI 10.1016/j.spc.2018.06.004
   Ludeke-Freund F, 2017, J CLEAN PROD, V168, P1668, DOI 10.1016/j.jclepro.2017.08.093
   Manninen K, 2018, J CLEAN PROD, V171, P413, DOI 10.1016/j.jclepro.2017.10.003
   Martin CJ, 2016, ECOL ECON, V121, P149, DOI 10.1016/j.ecolecon.2015.11.027
   Matzler Kurt, 2015, ADAPTING SHARING EC
   Milligan G. W., 1996, CLUSTERING CLASSIFIC, P341, DOI DOI 10.1142/9789812832153_0010
   Mooi E, 2011, CONCISE GUIDE TO MARKET RESEARCH: THE PROCESS, DATA, AND METHODS USING IBM SPSS STATISTICS, P1, DOI 10.1007/978-3-642-12541-6_1
   Muranko Z, 2018, RESOUR CONSERV RECY, V135, P132, DOI 10.1016/j.resconrec.2017.12.017
   Naude P, 2019, IND MARK MANAG
   Nussholz J. L. K, 2017, P PLATE 2017 NOV 201
   Nussholz JLK, 2018, J CLEAN PROD, V197, P185, DOI 10.1016/j.jclepro.2018.06.112
   Nussholz JLK, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101810
   Osterwalder A., 2004, THESIS
   Osterwalder A., 2010, BUSINESS MODEL GENER
   Owyang J, 2016, COLLABORATIVE EC HON
   Palmer R, 2007, J BUS IND MARK, V22, P439, DOI 10.1108/08858620710828827
   Perren R, 2018, J MARKETING, V82, P20, DOI 10.1509/jm.14.0250
   Pham D. T, 2005, P I MECH ENG C
   PwC, 2015, SHAR EC
   ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7
   Schor JB, 2015, HDB RES SUSTAINABLE, P410, DOI DOI 10.4337/9781783471270.00039
   Sundararajan A, 2016, SHARING EC END EMPLO
   Tashakkori A, 2002, HDB MIXED METHODS SO, P101
   Teece DJ, 2010, LONG RANGE PLANN, V43, P172, DOI 10.1016/j.lrp.2009.07.003
   The Ellen MacArthur Foundation, 2017, DEL CIRC EC TOOLK PO
   Tuffery S., 2011, DATA MINING STAT DEC
   Urbinati A, 2017, J CLEAN PROD, V168, P487, DOI 10.1016/j.jclepro.2017.09.047
   Whalen K, 2016, ELECT GOES GREEN 201
   Whalen K, 2017, P PLATE 2017
   Whalen KA, 2018, RESOUR CONSERV RECY, V135, P335, DOI 10.1016/j.resconrec.2017.06.021
   Wirtz BW, 2016, LONG RANGE PLANN, V49, P36, DOI 10.1016/j.lrp.2015.04.001
   World Bank, 2018, WHAT WASTE 2 0 GLOBA
   Zarbakhshnia N, 2019, J CLEAN PROD, V208, P1304, DOI 10.1016/j.jclepro.2018.10.138
   Zervas G, 2017, J MARKETING RES, V54, P687, DOI 10.1509/jmr.15.0204
NR 79
TC 2
Z9 2
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104437
DI 10.1016/j.resconrec.2019.104437
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000041
DA 2020-05-12
ER

PT J
AU Faubert, P
   Belisle, CL
   Bertrand, N
   Bouchard, S
   Chantigny, MH
   Pare, MC
   Rochette, P
   Ziadi, N
   Villeneuve, C
AF Faubert, Patrick
   Belisle, Catherine Lemay
   Bertrand, Normand
   Bouchard, Sylvie
   Chantigny, Martin H.
   Pare, Maxime C.
   Rochette, Philippe
   Ziadi, Noura
   Villeneuve, Claude
TI Land application of pulp and paper mill sludge may reduce greenhouse gas
   emissions compared to landfilling
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biosolid; Paper mill sludge; Greenhouse gases; Landfilling; Land
   application; Fertilization
ID NITROUS-OXIDE EMISSIONS; AGRICULTURAL SOILS; N2O EMISSIONS;
   DENITRIFICATION; WATER; CROP; AMENDMENTS; BIOSOLIDS; METHANE; CARBON
AB Land application of pulp and paper mill sludge (PPMS) may replace landfilling in certain jurisdictions. However, the consequences of this change in management on greenhouse gas (GHG) emissions from PPMS are unknown. Land application may also entail temporary storage by landfilling due to a timing mismatch between PPMS production and application. We quantified direct GHG emissions from landfilled PPMS (pilot scale; N-rich and N-poor types) over two snow-free seasons, and after application of previously landfilled PPMS (LPPMS; < 6-month landfilled) to a clay loam soil cropped to wheat over one snow-free season. Landfilling of N-rich PPMS induced the highest GHG emission factor (EF; 0.26 Mg CO2-equivalent Mg-1 dry PPMS) and generated substantial N2O emissions (2% of landfilled N), which are neglected by the current assessment methods. Landfilling of N-rich PPMS also resulted in the highest CH4 emissions (0.6% of landfilled C). Replacing urea with LPPMS to fulfill wheat N requirements did not change field N2O-N EFs (1.1-3.5% of applied N) and did not generate CH4. Shortterm (1-2 years) GHG (CO2-equivalent) EFs with landfilled N-rich PPMS were 0.54 to 4.48 times the EFs reported in the literature for land-applied PPMS. Long-term EF estimates suggest that landfilled PPMS may increase GHG emissions by up to three times compared to land application. Further research at the industrial scale is warranted to reduce uncertainty on GHG emissions from PPMS landfill sites, fulfill sustainable development goals and determine accurate carbon credits associated with changes in PPMS management practices.
C1 [Faubert, Patrick; Belisle, Catherine Lemay; Bouchard, Sylvie; Pare, Maxime C.; Villeneuve, Claude] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Chaire Ecoconseil, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
   [Bertrand, Normand; Chantigny, Martin H.; Rochette, Philippe; Ziadi, Noura] Agr & Agri Food Canada, Quebec Res & Dev Ctr, 2560 Hochelaga Blvd, Quebec City, PQ G1V 2J3, Canada.
   [Pare, Maxime C.] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Lab Ecol Vegetale & Anim, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
RP Faubert, P (reprint author), Univ Quebec Chicoutimi, Dept Sci Fondamentales, Chaire Ecoconseil, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
EM patrick1_faubert@uqac.ca
OI Pare, Maxime/0000-0003-3482-4828; Faubert, Patrick/0000-0003-0237-3188
FU Ministere du Developpement durable, de l'Environnement et de la Lutte
   contre les changements climatiques of Quebec; Ministere de
   l'Agriculture, des Pecheries et de l'Alimentation of Quebec (Program
   Innov'Action agroalimentaire); Fonds vert (Viridis); Fonds vert
   (Sanexen); Fonds vert (Serro); Mitacs Elevate program
FX This study was funded by the Ministere du Developpement durable, de
   l'Environnement et de la Lutte contre les changements climatiques of
   Quebec, Ministere de l'Agriculture, des Pecheries et de l'Alimentation
   of Quebec (Program Innov'Action agroalimentaire) and Fonds vert
   (Viridis, Sanexen and Serro) in research grants attributed to the Chaire
   en eco-conseil, Universite du Quebec a Chicoutimi. We are also grateful
   for the collaborative support from the Quebec Forest Industry Council
   and ZIP Saguenay. A research fellowship from the Mitacs Elevate program
   was awarded to Patrick Faubert. We thank our operational collaborators:
   Resolute Forest Products - Kenogami and Alma mills, Agrinova and College
   d'Alma. We thank Steeve Duchesne, landlord of the site for LPPMS
   application. We also thank Philippe Cournoyer Farley, Pascal Dufour,
   Simon Durocher, Claire Fournier, Olivier Fradette, Frederic Gagnon,
   Jean-Guy Girard, Stephanie Girard, Sylvie Michaud, Annie Robichaud,
   Nicolas St-Pierre, Pascal Tremblay and Denis Walsh for their assistance
   in field and laboratory work.
CR AAFC (Agriculture and Agri-Food Canada), 2018, PED REG CHIC
   Baggs EM, 2002, AGR ECOSYST ENVIRON, V90, P109, DOI 10.1016/S0167-8809(01)00175-X
   Bakken LR, 2012, PHILOS T R SOC B, V367, P1226, DOI 10.1098/rstb.2011.0321
   Bogner JE, 1999, J ENVIRON QUAL, V28, P278, DOI 10.2134/jeq1999.00472425002800010034x
   Bouwman AF, 1996, NUTR CYCL AGROECOSYS, V46, P53, DOI 10.1007/BF00210224
   Brown S, 2010, ENVIRON SCI TECHNOL, V44, P9509, DOI 10.1021/es101210k
   BUSWELL AM, 1952, IND ENG CHEM, V44, P550, DOI 10.1021/ie50507a033
   Camberato JJ, 2006, CAN J SOIL SCI, V86, P641, DOI 10.4141/S05-120
   CANMET E.T.C., 2005, 340173E4791 CANMET E, P152
   Chantigny MH, 2013, J ENVIRON QUAL, V42, P30, DOI 10.2134/jeq2012.0196
   Chantigny MH, 1998, CAN J SOIL SCI, V78, P589, DOI 10.4141/S98-009
   Charles A, 2017, AGR ECOSYST ENVIRON, V236, P88, DOI 10.1016/j.agee.2016.11.021
   CRAAQ, 2010, GUID REF FERT
   Eggleston H.S., 2006, 2006 IPCC GUIDELINES
   Environment and Climate Change Canada, 2018, CAN SUBM UN FRAM CON, P260
   Faubert P, 2017, AGR ECOSYST ENVIRON, V250, P102, DOI 10.1016/j.agee.2017.07.040
   Faubert P, 2017, J ENVIRON QUAL, V46, P950, DOI 10.2134/jeq2017.03.0119
   Faubert P, 2016, RESOUR CONSERV RECY, V108, P107, DOI 10.1016/j.resconrec.2016.01.007
   Faubert P, 2012, PLANT SOIL, V352, P199, DOI 10.1007/s11104-011-0989-2
   Gouvernement du Quebec, 2012, QUEB ACT GREEN 2020, P55
   Hao X., 2008, SOIL SAMPLING METHOD, P743
   Heath LS, 2010, ENVIRON SCI TECHNOL, V44, P3999, DOI 10.1021/es902723x
   IRDA, 2018, CART PED 22D07201
   Jensen J. E, 2002, BACKGROUND PAPERS, P419
   Le Mer J, 2001, EUR J SOIL BIOL, V37, P25, DOI 10.1016/S1164-5563(01)01067-6
   Likon M., 2012, RECENT ADV PAPER MIL, P73
   Likon M, 2012, MACROMOL SYMP, V320, P50, DOI 10.1002/masy.201251006
   LINN DM, 1984, SOIL SCI SOC AM J, V48, P1267, DOI 10.2136/sssaj1984.03615995004800060013x
   Liu BB, 2010, FEMS MICROBIOL ECOL, V72, P407, DOI 10.1111/j.1574-6941.2010.00856.x
   Luedeling E, 2012, AGR FOREST METEOROL, V158, P43, DOI 10.1016/j.agrformet.2011.10.020
   MDDELCC (Ministere du Developpement durable de l'Environnement et de la Lutte contre les changements climatiques), 2016, BIL ANN CONF ENV 201, P86
   MDDEP (Ministere du Developpement durable de l'Environnement et des Parcs), 2011, QUEB RES MAT MAN POL, P13
   MELCC (Ministere de l'Environnement et de la Lutte contre les changements climatiques), 2019, BIL ANN CONF ENV SEC
   NCASI, 2013, ICFPA NCASI SPREADSH
   NCASI (National Council for Air and Stream Improvement), 2005, CALC TOOLS EST GREEN, P140
   Pachauri R.K., 2007, CLIMATE CHANGE 2007
   Pelster DE, 2012, J ENVIRON QUAL, V41, P427, DOI 10.2134/jeq2011.0261
   Petersen SO, 2008, SOIL BIOL BIOCHEM, V40, P967, DOI 10.1016/j.soilbio.2007.11.017
   Rinne J, 2005, ENVIRON SCI TECHNOL, V39, P7790, DOI 10.1021/es048416q
   Rochette P, 2001, CAN J SOIL SCI, V81, P515, DOI 10.4141/S00-044
   Rochette P., 2008, SOIL SAMPLING METHOD, P851, DOI DOI 10.1201/9781420005271.CH65
   Rochette P, 2008, CAN J SOIL SCI, V88, P641, DOI 10.4141/CJSS07025
   Rochette P, 2018, AGR ECOSYST ENVIRON, V254, P69, DOI 10.1016/j.agee.2017.10.021
   Serrano-Silva N, 2014, PEDOSPHERE, V24, P291, DOI 10.1016/S1002-0160(14)60016-3
   Thangarajan R, 2013, SCI TOTAL ENVIRON, V465, P72, DOI 10.1016/j.scitotenv.2013.01.031
   USEPA (United States Environmental Protection Agency), 2018, ANN INV US GHG EM SI, P529
   USEPA (United States Environmental Protection Agency), 2018, INV US GREENH GAS EM, P655
   WEIER KL, 1993, SOIL SCI SOC AM J, V57, P66, DOI 10.2136/sssaj1993.03615995005700010013x
   Wold S, 1995, CHEMOMETRIC METHODS, V17, P195, DOI DOI 10.1002/9783527615452
   Zhang HH, 2008, J ENVIRON SCI, V20, P189, DOI 10.1016/S1001-0742(08)60030-3
NR 50
TC 0
Z9 0
U1 8
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104415
DI 10.1016/j.resconrec.2019.104415
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000014
DA 2020-05-12
ER

PT J
AU Gillman, A
   Campbell, DC
   Spang, ES
AF Gillman, Anne
   Campbell, David C.
   Spang, Edward S.
TI Does on-farm food loss prevent waste? Insights from California produce
   growers
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food loss and waste; Environmental impact; Agriculture; Food supply
   chain
ID SUPPLY CHAIN; GENERATION; MANAGEMENT
AB Significant quantities of edible produce are lost at the farm level. Amidst growing concern about the environmental impacts of food loss and waste, advocates have invested in exploring farm-level interventions that might reduce the environmental footprint of food. Farmers are obvious stakeholders in such efforts, yet their voices are often missing from the discussion. Drawing on interviews with 25 fresh produce growers in California, we show how on-farm losses are driven by efforts to mitigate economic risk within food supply chains. Buyers minimize risk by demanding consistent volumes of perfect produce, and growers in turn minimize their financial risks by holding back "imperfect" and surplus food. If food is likely to be rejected further down the chain, growers abandon it on the farm. Using the EPA food recovery hierarchy and the tools of life cycle analysis (LCA), we then compare the environmental impact of farm-level loss to downstream alternatives. While landfill disposal is common at retail and consumer levels, food lost at the farm level is tilled back into the soil or sold as animal feed. We conclude that some on-farm losses may prevent more environmentally harmful "waste," defined here as landfilled food, further down the supply chain. Our analysis argues for an approach to remedying on-farm food loss that is both ambitious and cautious one that recognizes the structural causes of loss and that considers how environmental risks can increase as food moves downstream.
C1 [Gillman, Anne; Campbell, David C.] Univ Calif Davis, Dept Human Ecol, Davis, CA USA.
   [Spang, Edward S.] Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA.
RP Spang, ES (reprint author), Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA.
EM esspang@ucdavis.edu
OI Spang, Edward/0000-0001-9883-078X
FU Foundation for Food and Agriculture Research [510953]; Walmart
   Foundation [29991673]
FX This research was made possible by a grant administered by the World
   Wildlife Foundation and funded by the Foundation for Food and
   Agriculture Research (Award #510953) and the Walmart Foundation (Award
   #29991673), both institutions are located in the United States.
CR Alexander P, 2017, AGR SYST, V153, P190, DOI 10.1016/j.agsy.2017.01.014
   Babbie E.R., 2015, PRACTICE SOCIAL RES
   Baker G, RESOURCES CONSERVATI
   Beausang C, 2017, RESOUR CONSERV RECY, V126, P177, DOI 10.1016/j.resconrec.2017.07.042
   Bellemare M. F, 2017, AM J AGR EC
   Berkenkamp J., 2015, BEAUTY OPPORTUNITIES
   Bernstad AK, 2017, WASTE MANAGE RES, V35, P29, DOI 10.1177/0734242X16666945
   Boehlje M, 1999, AM J AGR ECON, V81, P1028, DOI 10.2307/1244080
   Bosona T, 2013, FOOD CONTROL, V33, P32, DOI 10.1016/j.foodcont.2013.02.004
   Brautigam KR, 2014, WASTE MANAGE RES, V32, P683, DOI 10.1177/0734242X14545374
   Buzby JC, 2014, ESTIMATED AMOUNT VAL
   California Department of Food and Agriculture, 2018, CAL AGR STAT REV
   Canning P, 2010, 94 USDA EC RES SERV
   Carman H. F, 2003, CALIFORNIA AGR DIMEN, P89, DOI [10.1111/j.1549-0831.2001.tb00072.x, DOI 10.1111/J.1549-0831.2001.TB00072.X]
   Cook Roberta L, 2011, FUNDAMENTAL FORCES A, V26
   Dou ZX, 2016, GLOB FOOD SECUR-AGR, V8, P19, DOI 10.1016/j.gfs.2016.02.001
   Duffy R., 2003, British Food Journal, V105, P682, DOI 10.1108/00070700310506236
   Edwards J, 2018, BIORESOURCE TECHNOL, V248, P156, DOI 10.1016/j.biortech.2017.06.070
   Eriksson M, 2017, RESOUR CONSERV RECY, V122, P83, DOI 10.1016/j.resconrec.2017.02.006
   FUSIONS, FOOD WAST DEF
   Gao A., 2017, ENERGY PROCEDIA, V105, P3915, DOI DOI 10.1016/J.EGYPR0.2017.03.811
   Gille Z, 2012, SOCIOL REV, V60, P27, DOI 10.1111/1467-954X.12036
   Gunders D., 2012, WASTED AM IS LOSING
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Hammer D, 1993, CRAFTWAYS ORG SCHOLA
   Hartikainen H, 2018, WASTE MANAGE, V71, P502, DOI 10.1016/j.wasman.2017.10.026
   Heller MC, 2015, J IND ECOL, V19, P391, DOI 10.1111/jiec.12174
   Hendrickson M, 2008, 1337273 SSRN
   Hoover D., 2017, ESTIMATING QUANTITIE
   Howard Philip H., 2016, CONCENTRATION POWER
   Johnson LK, 2018, AGR SYST, V167, P136, DOI 10.1016/j.agsy.2018.09.008
   Johnson LK, 2018, RESOUR CONSERV RECY, V137, P243, DOI 10.1016/j.resconrec.2018.05.017
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   MacDonald J., 2011, EC INFORM B, V72
   Mata-Alvarez J, 2000, BIORESOURCE TECHNOL, V74, P3, DOI 10.1016/S0960-8524(00)00023-7
   Mena C, 2011, RESOUR CONSERV RECY, V55, P648, DOI 10.1016/j.resconrec.2010.09.006
   Milepost Consulting, 2012, LEFT OUT INV CAUS QU
   Minor T, 2019, CHOICES, V34
   Neff RA, 2018, J AGRIC FOOD SYST CO, V8, P39, DOI 10.5304/jafscd.2018.082.006
   Pelletier N, 2011, ANNU REV ENV RESOUR, V36, P223, DOI 10.1146/annurev-environ-081710-161014
   Scherhaufer S., 2015, CRITERIA BASELINE AS
   Takata M, 2012, SCI TOTAL ENVIRON, V432, P309, DOI 10.1016/j.scitotenv.2012.05.049
   Thyberg KL, 2015, ENVIRON SCI TECHNOL, V49, P13946, DOI 10.1021/acs.est.5b03880
   US EPA O, 2015, SUST MAN FOOD BAS OV
   van der Werf P, 2017, PROC INST CIV ENG-WA, V170, P66, DOI 10.1680/jwarm.16.00026
   WRAP, 2011, FRUIT VEG RES MAPS M
   WRAP, 2017, FOOD WAST PRIM PROD
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
NR 48
TC 2
Z9 2
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104408
DI 10.1016/j.resconrec.2019.104408
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000026
DA 2020-05-12
ER

PT J
AU Glick, DM
   Goldfarb, JL
   Heiger-Bernays, W
   Kriner, DL
AF Glick, David M.
   Goldfarb, Jillian L.
   Heiger-Bernays, Wendy
   Kriner, Douglas L.
TI Public knowledge, contaminant concerns, and support for recycled Water
   in the United States
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Recycled water; Public opinion; Knowledge gap; Contaminant concern;
   Water insecurity
ID WASTE-WATER; DONT KNOW; POLITICAL KNOWLEDGE; CLIMATE-CHANGE; REUSE;
   PERCEPTIONS; ACCEPTANCE; RESPONSES; OPINION; POLARIZATION
AB Water recycling is one potential solution to meeting the growing global demand for water in an age of dwindling freshwater supplies. However, public opposition has played a key role historically in blunting the broad implementation of water recycling technologies across the United States. Addressing public concerns and overcoming this opposition is critical to the political viability of water recycling programs as a response to growing water insecurity. This analysis builds on existing research on Americans' attitudes toward water recycling in three ways. First, it explores public understanding of basic elements of water recycling and identifies important gaps in public knowledge. Second, it examines the factors that most concern Americans about water recycling. Finally, it investigates how knowledge, specific concerns, and a range of other factors, including Americans' environmental priorities, local context, partisan leanings, and demographic characteristics, combine to influence attitudes toward recycled water. The results identify several promising targets for future educational outreach efforts to build public support for water recycling projects. Policy-relevant knowledge is the single most important predictor of support for water recycling. Yet, there is a stark knowledge gap between a highly informed few and an unaware majority. Bridging this gap could greatly increase support for water recycling. Concerns about sewage contamination were most corrosive to support for water recycling, making them a prime target for further outreach. Finally, our results suggest that future educational campaigns may seek to decouple water scarcity and climate change in the public mind to avoid exacerbating existing cleavages.
C1 [Glick, David M.] Boston Univ, Dept Polit Sci, 232 Bay State Rd, Boston, MA 02215 USA.
   [Glick, David M.; Goldfarb, Jillian L.; Heiger-Bernays, Wendy] Boston Univ, Pardee Ctr Study Longer Range Future, 67 Bay State Rd, Boston, MA 02215 USA.
   [Goldfarb, Jillian L.] Cornell Univ, Dept Biol & Environm Engn, 226 Riley Robb Hall, Ithaca, NY 14853 USA.
   [Heiger-Bernays, Wendy] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St 4W, Boston, MA 02118 USA.
   [Kriner, Douglas L.] Cornell Univ, Dept Govt, 209 White Hall, Ithaca, NY 14853 USA.
RP Goldfarb, JL (reprint author), Boston Univ, Pardee Ctr Study Longer Range Future, 67 Bay State Rd, Boston, MA 02215 USA.; Goldfarb, JL (reprint author), Cornell Univ, Dept Biol & Environm Engn, 226 Riley Robb Hall, Ithaca, NY 14853 USA.
EM Goldfarb@cornell.edu
OI Heiger-Bernays, Wendy/0000-0002-0091-9629
FU Boston University Pardee Center for the Study of the Longer Range
   Future; National Science Foundation Design of Materials Program
   [1727316]
FX The authors thank the generous support of the Boston University Pardee
   Center for the Study of the Longer Range Future. This work was partially
   supported by the National Science Foundation Design of Materials Program
   under grant number 1727316.
CR Ansolabehere S, 2014, POLIT ANAL, V22, P285, DOI 10.1093/pan/mpt025
   Bischel HN, 2012, ENVIRON SCI TECHNOL, V46, P180, DOI 10.1021/es202725e
   Bolsen T, 2015, J COMMUN, V65, P745, DOI 10.1111/jcom.12171
   Bridgeman J, 2004, WATER ENVIRON J, V18, P150, DOI 10.1111/j.1747-6593.2004.tb00517.x
   BRUVOLD WH, 1988, J WATER POLLUT CON F, V60, P45
   Bruvold William H., 1972, CONTRIBUTION N DAKOT, V137
   Christenson D. P., 2017, ENERGY POLICY, V105
   Dean AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159063
   Dolnicar S, 2006, DESALINATION, V187, P203, DOI 10.1016/j.desal.2005.04.080
   Dolnicar S, 2009, J ENVIRON MANAGE, V90, P888, DOI 10.1016/j.jenvman.2008.02.003
   Dolnicar S, 2011, WATER RES, V45, P933, DOI 10.1016/j.watres.2010.09.030
   Dunlap RE, 2016, ENVIRONMENT, V58, P4, DOI 10.1080/00139157.2016.1208995
   GAO, 2014, FRESHW SUPPL CONT UN
   Garcia-Cuerva L, 2016, RESOUR CONSERV RECY, V113, P106, DOI 10.1016/j.resconrec.2016.06.006
   Goodwin D., 2018, INFORMING PUBLIC ATT
   Gosling SN, 2016, CLIMATIC CHANGE, V134, P371, DOI 10.1007/s10584-013-0853-x
   Haddad Brent M., 2009, PSYCHOL WATER RECLAM
   Harris-Lovett SR, 2015, ENVIRON SCI TECHNOL, V49, P7552, DOI 10.1021/acs.est.5b00504
   Hart PS, 2012, COMMUN RES, V39, P701, DOI 10.1177/0093650211416646
   Hartley TW, 2006, DESALINATION, V187, P115, DOI 10.1016/j.desal.2005.04.072
   Hurlimann A, 2008, J ENVIRON MANAGE, V88, P1221, DOI 10.1016/j.jenvman.2007.06.002
   Jansen HP, 2007, WATER SCI TECHNOL, V55, P357, DOI 10.2166/wst.2007.001
   Jansen H. P., 2005, DEVELOPMENT OF INDIR
   KASPERSON R E, 1977, P238
   Krosnick JA, 2002, PUBLIC OPIN QUART, V66, P371
   Laugksch RC, 2000, SCI EDUC, V84, P71, DOI 10.1002/(SICI)1098-237X(200001)84:1<71::AID-SCE6>3.0.CO;2-C
   Luskin RC, 2011, J POLIT, V73, P547, DOI 10.1017/S0022381611000132
   McCright AM, 2011, GLOBAL ENVIRON CHANG, V21, P1163, DOI 10.1016/j.gloenvcha.2011.06.003
   MCKAY J, 2003, WATER J AUSTR WATER, V30, P45
   Menegaki AN, 2007, ECOL ECON, V62, P7, DOI 10.1016/j.ecolecon.2007.01.008
   Menegaki AN, 2009, J ECON PSYCHOL, V30, P285, DOI 10.1016/j.joep.2008.08.007
   Miller J. D., 1998, PUBLIC UNDERST SCI
   Miller J. D., 1983, DAEDALUS
   Miller MK, 2008, PUBLIC OPIN QUART, V72, P768, DOI 10.1093/poq/nfn057
   MONDAK JJ, 1999, POLIT ANAL, V0008
   Mondak JJ, 2001, POLIT BEHAV, V23, P199, DOI 10.1023/A:1015015227594
   National Science Board, 2016, SCIENCE AND ENGINEER
   Nijhawan A, 2013, RESOUR CONSERV RECY, V70, P20, DOI 10.1016/j.resconrec.2012.11.001
   Ormerod KJ, 2013, SCI TECHNOL HUM VAL, V38, P351, DOI 10.1177/0162243912444736
   Po Murni, 2003, CSIRO LAND WATER LIT
   Robinson KG, 2005, WA SCI TECHNOL, V5, P59
   Rock C, 2012, J WATER SUPPLY RES T, V61, P506, DOI 10.2166/aqua.2012.070
   Ross VL, 2014, J ENVIRON MANAGE, V137, P61, DOI 10.1016/j.jenvman.2014.01.039
   Rozin P, 2015, JUDGM DECIS MAK, V10, P50
   Russell S, 2009, WATER POLICY, V11, P21, DOI 10.2166/wp.2009.007
   Sedlak DL, 2000, ENVIRON SCI TECHNOL, V34, p509A, DOI 10.1021/es003513e
   SIMS JH, 1974, WATER RESOUR RES, V10, P659, DOI 10.1029/WR010i004p00659
   Smith HM, 2018, J ENVIRON MANAGE, V207, P43, DOI 10.1016/j.jenvman.2017.11.021
   Sturgis P, 2008, PUBLIC OPIN QUART, V72, P90, DOI 10.1093/poq/nfm032
   SYME GJ, 1993, WATER RESOUR RES, V29, P4003, DOI 10.1029/93WR01933
   Tourangeau R, 2016, PUBLIC OPIN QUART, V80, P741, DOI 10.1093/poq/nfw009
   Tsagarakis KP, 2007, ENVIRON SCI TECHNOL, V41, P6901, DOI 10.1021/es0627491
   Velasquez D, 2015, J WATER REUSE DESAL, V5, P344, DOI 10.2166/wrd.2015.126
   Wu XQ, 2015, SCI TOTAL ENVIRON, V536, P655, DOI 10.1016/j.scitotenv.2015.07.129
   Wuebbles Donald J., 2014, Eos, Transactions American Geophysical Union, V95, P149, DOI 10.1002/2014EO180001
   WWAP (United Nations World Water Assessment Programme), 2015, UN WORLD WAT DEV REP
NR 56
TC 0
Z9 0
U1 8
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104419
DI 10.1016/j.resconrec.2019.104419
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000019
DA 2020-05-12
ER

PT J
AU Gonzalez-Garcia, S
   Ferro, FS
   Silva, DAL
   Feijoo, G
   Lahr, FAR
   Moreira, MT
AF Gonzalez-Garcia, Sara
   Ferro, Fabiane Salles
   Lopes Silva, Diogo Aparecido
   Feijoo, Gumersindo
   Rocco Lahr, Francisco Antonio
   Moreira, Maria Teresa
TI Cross-country comparison on environmental impacts of particleboard
   production in Brazil and Spain
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Urea formaldehyde resin; Comparative LCA; Environmental hotspots;
   Medium-Density particleboard; Wood-based products
ID LIFE-CYCLE ASSESSMENT; WOOD WASTE; INVENTORY; ALLOCATION; EMISSIONS;
   ENERGY; LCA; SUSTAINABILITY; PERFORMANCE; RESOURCES
AB Remarkable differences can be found between Brazilian and Spanish production of wood-based products. The purpose of this study is to analyze and compare the environmental performance of particleboard production in both countries. The results showed that the greatest impacts in four impact categories correspond to Brazilian particleboards, because of the use of heavy fuel-oil and virgin wood as energy source and raw material respectively, as well as uncontrolled formaldehyde emissions. On the contrary, Spanish production reports worse results in other impacts (eutrophication and toxicity related categories) mostly due to the large demand of diesel in the mobile chipping machine. A sensitivity analysis based on the variation of scenarios considering multi functionality issues to produce particleboards in Brazil and Spain was conducted. The allocation approach (economic and mass) showed a relevant influence for all impact categories for the Brazilian scenarios in order to reduce most of the environmental impacts, however, it has increased most of the impacts for the Spanish ones due to the change of perspective in the hypothesis that wooden residues are free of environmental burden. The use of the substitution method to address the multifunctional processes displayed the lowest values for almost all impact categories, and especially for Spain, where the avoided impacts from wooden waste were so high that they covered all the life cycle impacts of the particleboards life cycle on many occasions, meaning that there was a net benefit, as the overall environmental impacts were more than offset by the avoided impacts.
C1 [Gonzalez-Garcia, Sara; Feijoo, Gumersindo; Moreira, Maria Teresa] Univ Santiago de Compostela, Inst Technol, Dept Chem Engn, Santiago De Compostela 15782, Spain.
   [Ferro, Fabiane Salles; Rocco Lahr, Francisco Antonio] Univ Sao Paulo, Engn Sch Sao Carlos, Dept Struct Engn, BR-13566590 Sao Carlos, SP, Brazil.
   [Lopes Silva, Diogo Aparecido] Univ Fed Sao Carlos, Sch Management & Technol, Dept Prod Engn, BR-18052780 Sorocaba, Brazil.
RP Gonzalez-Garcia, S (reprint author), Univ Santiago de Compostela, Inst Technol, Dept Chem Engn, Santiago De Compostela 15782, Spain.
EM sara.gonzalez@usc.es
RI Silva, Diogo/B-5981-2013
OI Silva, Diogo/0000-0002-7514-7467; Feijoo,
   Gumersindo/0000-0001-6231-3887; Moreira, Maria
   Teresa/0000-0001-9354-3298; Gonzalez-Garcia, Sara/0000-0002-2553-0863
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/03816-6, 2013/06736-9]; European
   project WooBAdh - Environmental-friendly bio-adhesives from renewable
   resources [PCI2018-092866]; Xunta de GaliciaXunta de Galicia [ED431 F
   2016/001]; Galician Competitive Research Group [GRC 2013-032]; CRETUS
   [AGRUP2015/02]; Xunta de GaliciaXunta de Galicia; FEDER (EU)European
   Union (EU); Spanish Ministry of Economy and Competitiveness
   [RYC-2014-14984]
FX D. A. L. Silva, F. S. Ferro, F. A. Roco Lahr are grateful for the
   financial support provided by The Sao Paulo Research Foundation (FAPESP)
   for the grants 2011/03816-6 and2013/06736-9. This research was partially
   supported by the European project WooBAdh - Environmental-friendly
   bio-adhesives from renewable resources (PCI2018-092866) as well as by a
   project granted by Xunta de Galicia (project ref. ED431 F 2016/001). S.
   Gonzalez-Garcia, G. Feijoo and M.T. Moreira belong to the Galician
   Competitive Research Group GRC 2013-032 as well as to CRETUS
   (AGRUP2015/02), co-funded by Xunta de Galicia and FEDER (EU). Dr. S.
   Gonzalez-Garcia would like to express her gratitude to the Spanish
   Ministry of Economy and Competitiveness (Grant reference RYC-2014-14984)
   for financial support.
CR [ABRAF Brazilian Association of Forest Plantation Producers], 2014, YB STAT ABRAF BAS YE
   Altoé Leandra, 2017, Estud. av., V31, P285, DOI 10.1590/s0103-40142017.31890022
   [Anonymous], 14040 ISO
   [Anonymous], 2014, AV INF SIST EL ESP 2
   [Anonymous], 14044 ISO
   Baumann H., 2004, HITCH HIKERS GUIDE L
   Benetto E, 2009, ENVIRON SCI TECHNOL, V43, P6003, DOI 10.1021/es900707u
   Biazus A, 2010, BNDES SETORIAL, V32, P49
   Bousios S, 2017, RESOUR CONSERV RECY, V125, P218, DOI 10.1016/j.resconrec.2017.06.020
   Chehebe J. R. B., 1998, ANALISE CICLO VIDA P
   Chen S., 2009, THESIS
   Cherubini E, 2018, INT J LIFE CYCLE ASS, V23, P2055, DOI 10.1007/s11367-017-1432-6
   Curran MA, 2007, ENVIRON SCI TECHNOL, V41, P7145, DOI 10.1021/es070033f
   DEFRA (UK Department for Environment Food and Rural Affairs), 2012, WOOD WAST SHORT REV
   Earles JM, 2011, ENVIRON SCI TECHNOL, V45, P9743, DOI 10.1021/es202180m
   European Commission Joint Research Centre JRC, 2011, EUR COMM INT REF LIF
   Factfish, 2018, PART BOARD PROD VOL
   [FAO Food and Agriculture Organization of United Nations], 2017, FOR PROD STAT 2016 G
   Feijoo S, 2017, J CLEAN PROD, V165, P204, DOI 10.1016/j.jclepro.2017.07.076
   Ferro FS, 2018, SCI TOTAL ENVIRON, V640, P599, DOI 10.1016/j.scitotenv.2018.05.262
   Ferro FS, 2018, J CLEAN PROD, V183, P710, DOI 10.1016/j.jclepro.2018.02.174
   Ferro FS, 2015, SCI FOR, V43, P313
   Finnveden G, 2009, J ENVIRON MANAGE, V91, P1, DOI 10.1016/j.jenvman.2009.06.018
   Garcia R, 2014, J CLEAN PROD, V66, P199, DOI 10.1016/j.jclepro.2013.11.073
   Gasol CM, 2008, INT J LIFE CYCLE ASS, V13, P421, DOI 10.1007/s11367-008-0005-0
   Global Particle Board Market, 2018, WHICH COUNTR IMP MOS
   Goedkoop M., 2008, RECIPE 2008 LIFE CYC
   Gonzalez-Garcia S, 2014, SCI TOTAL ENVIRON, V472, P324, DOI 10.1016/j.scitotenv.2013.11.034
   Gonzalez-Garcia S, 2011, J IND ECOL, V15, P568, DOI 10.1111/j.1530-9290.2011.00354.x
   Gonzalez-Garcia S, 2011, J CLEAN PROD, V19, P445, DOI 10.1016/j.jclepro.2010.10.016
   Gonzalez-Garcia S, 2009, INT J LIFE CYCLE ASS, V14, P456, DOI 10.1007/s11367-009-0099-z
   Gonzalez-Garcia S, 2009, INT J LIFE CYCLE ASS, V14, P340, DOI 10.1007/s11367-009-0089-1
   Gonzalez-Garcia S, 2009, SCAND J FOREST RES, V24, P160, DOI 10.1080/02827580902773462
   Guinee J. B., 2001, LIFE CYCLE ASSESSMEN
   Hauschild MZ, 2008, ENVIRON SCI TECHNOL, V42, P7032, DOI 10.1021/es703145t
   Hossain MU, 2018, CONSTR BUILD MATER, V173, P474, DOI 10.1016/j.conbuildmat.2018.04.066
   Hussain M, 2017, ENVIRON RES, V155, P385, DOI 10.1016/j.envres.2017.02.024
   IPCC, 2006, ENERGY, V2
   Iritani DR, 2015, J CLEAN PROD, V96, P308, DOI 10.1016/j.jclepro.2014.05.029
   IWAKIRI S., 2005, PAINEIS MADEIRA RECO
   Jonsson A, 1997, BUILD ENVIRON, V32, P245
   Jungmeier G, 2002, INT J LIFE CYCLE ASS, V7, P369, DOI 10.1065/lca2002.08.091.2
   Katcher J, 2017, RESOUR CONSERV RECY, V123, P143, DOI 10.1016/j.resconrec.2016.09.001
   Laschi A, 2016, ENERGY, V103, P469, DOI 10.1016/j.energy.2016.02.165
   Laser M, 2009, BIOFUEL BIOPROD BIOR, V3, P247, DOI 10.1002/bbb.136
   Lippke B, 2006, FOREST PROD J, V56, P58
   Silva DAL, 2015, J CLEAN PROD, V93, P222, DOI 10.1016/j.jclepro.2015.01.030
   Silva DAL, 2015, J CLEAN PROD, V96, P299, DOI 10.1016/j.jclepro.2014.03.007
   Silva DAL, 2014, INT J LIFE CYCLE ASS, V19, P1767, DOI 10.1007/s11367-014-0776-4
   Silva DAL, 2013, INT J LIFE CYCLE ASS, V18, P1404, DOI 10.1007/s11367-013-0583-3
   Modahl IS, 2015, J CLEAN PROD, V94, P247, DOI 10.1016/j.jclepro.2015.01.054
   Nebel B, 2006, INT J LIFE CYCLE ASS, V11, P172, DOI 10.1065/lca2004.10.187
   Nielsen PH, 2007, INT J LIFE CYCLE ASS, V12, P514, DOI 10.1065/lca2006.08.265.2
   Petersen AK, 2003, CAN J FOREST RES, V33, P1061, DOI [10.1139/x03-020, 10.1139/X03-020]
   Puettmann M. E, 2004, GLUED LAMINATED BEAM
   Rivela B, 2006, INT J LIFE CYCLE ASS, V11, P106, DOI 10.1065/lca2005.05.206
   Rivela B, 2007, INT J LIFE CYCLE ASS, V12, P143, DOI 10.1065/lca2006.12.290
   Rosenbaum RK, 2008, INT J LIFE CYCLE ASS, V13, P532, DOI 10.1007/s11367-008-0038-4
   Ruiz E. Moreno, 2018, DOCUMENTATION CHANGE
   Salazar J, 2008, SCAND J FOREST RES, V23, P121, DOI 10.1080/02827580801906981
   Saravia-Cortez AM, 2013, J CLEAN PROD, V52, P301, DOI 10.1016/j.jclepro.2013.02.006
   SCP-HAT, 2019, HOTSP AN TOOL SUST C
   Silva D. A. L., 2015, LIFE CYCLE ASSESSMEN, P143
   Sommerhuber PF, 2017, RESOUR CONSERV RECY, V117, P235, DOI 10.1016/j.resconrec.2016.10.012
   Souza AM, 2018, J CLEAN PROD, V193, P549, DOI 10.1016/j.jclepro.2018.05.087
   Taylor J., 2003, REV ENVIRONMENTALIMP
   Teixeira CE, 2010, INT J LIFE CYCLE ASS, V15, P212, DOI 10.1007/s11367-009-0138-9
   Thoemen H., 2010, WOOD BASED PANELS IN
   USEPA, 2011, GUID DET BEST AV CON
   Werner F, 2001, LIFE CYCLE ASSESSMEN
   Widsten P, 2008, ENZYME MICROB TECH, V42, P293, DOI 10.1016/j.enzmictec.2007.12.003
   Wilson JB, 2010, WOOD FIBER SCI, V42, P107
   Wilson JB, 2010, WOOD FIBER SCI, V42, P90
   Wilson JB, 2005, WOOD FIBER SCI, V37, P58
   Zeng XL, 2016, BIORESOURCES, V11, P4332
NR 75
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104434
DI 10.1016/j.resconrec.2019.104434
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000020
DA 2020-05-12
ER

PT J
AU Hait, A
   Powers, SE
AF Hait, Amy
   Powers, Susan E.
TI The value of reusable feminine hygiene products evaluated by comparative
   environmental life cycle assessment
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Lifecycle assessment; Feminine hygiene products; Reusable; Solid waste;
   Resource depletion; Menstrual cup
ID HEALTH
AB New options for feminine hygiene products could greatly reduce solid waste impacts and have other environmental benefits. As a group of widely used but rarely examined consumer products, feminine hygiene products offer great potential for impact reduction if alternative products are used or conventional products improved. Through a comparative life cycle assessment (LCA) of three menstrual products: disposable tampons and sanitary pads, and reusable menstrual cups, this study details the mid-point impacts of each product. Data from the Ecoinvent database and literature were used to complete the assessment. Disposable tampons and sanitary pads had far greater impacts across each category than the re-useable menstrual cup. Between the two disposable options, sanitary pads were the most impactful product, though the quantitative differences between the two disposable products is within uncertainty associated with variable use habits among women. The use of wood pulp as a component of the absorbent material in sanitary pads has substantial benefit for reducing greenhouse gas emissions. However, that benefit is coupled with increased toxicity, mostly due to the potential for dioxin generation during bleaching. For tampons, removing the applicator from the product substantially reduced several of the impacts and generally made them a better choice than a sanitary pad. The impacts of the reusable menstrual cup used for one year were less than 1.5% the environmental impacts of the disposable products and approximately only 10% of the cost. Thereby clearly demonstrating the overall value of the reusable option in a class of highly used and important consumer products.
C1 [Hait, Amy] Clarkson Univ, Dept Civil & Environm Engn, Potsdam, NY USA.
   [Powers, Susan E.] Clarkson Univ, Inst Sustainable Environm, Potsdam, NY 13699 USA.
RP Powers, SE (reprint author), Clarkson Univ, Inst Sustainable Environm, Potsdam, NY 13699 USA.
EM spowers@clarkson.edu
OI Powers, Susan/0000-0003-3529-9084
CR Abrams AJ, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.01052-15
   [Anonymous], NY TIMES, pA18
   [Anonymous], 2008, MAT DAT SAF SHEET SO
   Ashley R, 2005, J ENVIRON ENG-ASCE, V131, P206, DOI 10.1061/(ASCE)0733-9372(2005)131:2(206)
   Bae J, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10114146
   Barman A, 2019, OVERVIEW SANITARY NA
   Barman A, 2017, J TEXTILE SCI ENG, V7, P308, DOI DOI 10.4172/2165-8064
   Bobel C., 2010, NEW BLOOD 3 WAVE FEM
   Bobel C, 2006, SEX ROLES, V54, P331, DOI 10.1007/s11199-006-9001-7
   Borowski A, 2011, THESIS
   Branch F, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0043-6
   Bushak L, 2016, BRIEF HIST MENSTRUAL
   Cayman Chemical, MAT SAFT DAT SHEET A
   Cordella M, 2015, J CLEAN PROD, V95, P322, DOI 10.1016/j.jclepro.2015.02.040
   Davidson A, 2012, B SCI TECHNOL SOC, V32, P56, DOI DOI 10.1177/0270467612444579
   DeVito MJ, 2002, ENVIRON HEALTH PERSP, V110, P23, DOI 10.1289/ehp.0211023
   Diva International Inc, 2015, QUAL STAND
   DOW Coming, 2015, 2015 CORP SUST REP
   Ecoinvent, 2019, EC DAT
   EDANA The Absorbent Hygiene Products Manufacturers Committee, 2008, SUST REP 2007 2008 A
   European Commission, 2012, INT REFERENCE LIFE C, DOI [10.2788/85727, DOI 10.2788/85727]
   European Commission-Joint Research Centre, 2016, DEV ILCD COMPL NORM
   European Commission-Joint Research Centre (EC-JRC), 2010, INT REF LIF CYCL DAT, DOI [10.2788/38479, DOI 10.2788/38479]
   Fetters A, 2015, ATLANTIC
   Follows S.B., 2000, EUR J MARKETING, V34, P723, DOI DOI 10.1108/03090560010322009
   Kane J, 2015, HERES HOW MUCH A WOM
   Karazi S, 2010, YORK SCHOLAR, V7, P24
   Kimberly-Clark, 2019, U KOT INGR
   Meyer Z, 2017, US TODAY
   Nicole W, 2014, ENVIRON HEALTH PERSP, V122, pA70, DOI 10.1289/ehp.122-A70
   North BB, 2011, J WOMENS HEALTH, V20, P303, DOI 10.1089/jwh.2009.1929
   Office on Women's Health, 2019, MENSTRUAL CYCLE
   Oster E, 2011, AM ECON J-APPL ECON, V3, P91, DOI 10.1257/app.3.1.91
   Powers S. E, 2019, MENDELEY DATA, V2, DOI [10.17632/vj6ztpt96d.2, DOI 10.17632/VJ6ZTPT96D.2]
   Procter and Gamble, 2016, WHATS ALW PADS
   SCA, 2014, SUST REP
   Scranton A, 2013, CHEM FATALE POTENTIA
   Smil V, 2000, ANNU REV ENERG ENV, V25, P53, DOI 10.1146/annurev.energy.25.1.53
   Statista, 2019, FEM HYG MARK
   Tampax, 2019, TAMP TAMP INGR WHATS
   Thinkstep, 2016, GABI ED VERS 6 3
   U.S. EPA, 2019, IND AC
   U.S. EPA, 1984, EPA450484007 US EPA
   U.S. EPA, 2017, LEARN DIOX
   U.S. EPA, 2000, CHROM COMP HAZ SUMM
   U.S. EPA, 2014, EM GEN RES INT DAT E
   WebMD, 2019, WHATS MENSTR CUP
   Weir C. S, 2015, THESIS
   Woeller KE, 2015, REGUL TOXICOL PHARM, V73, P419, DOI 10.1016/j.yrtph.2015.07.028
NR 49
TC 1
Z9 1
U1 19
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104422
DI 10.1016/j.resconrec.2019.104422
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000036
DA 2020-05-12
ER

PT J
AU Hu, M
AF Hu, Ming
TI Building impact assessment-A combined life cycle assessment and multi
   criteria decision analysis framework
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Life cycle assessment; Multi-criteria decision analysis; Building impact
   assessment
ID ZERO-ENERGY BUILDINGS; EMBODIED ENERGY; CARBON EMISSIONS; WATER
   ANALYSIS; PERFORMANCE; CONSUMPTION; MANAGEMENT; QUALITY
AB In recent years, net zero energy building has becoming a trend in the building industry, with the aim to reach a carbon-neutral goal by 2050. Building codes, regulations, directives, and design guidelines have primarily focused on a building's performance-particularly on energy performance. Meanwhile, there is increasing interest in the co-benefits of a building's energy efficiency, such as human health and water conservation, which are less addressed in building performance assessments. To respond to these critics and the research gap in the current energy-centric building performance assessment framework, this paper presents a methodological framework to assess a building's impact on energy, environment (smog, global warming, ozone depletion), water (acidification, eutrophication) and human health. This integrated assessment framework is based on life cycle assessment (LCA) and multi-criteria decision analysis (MCDA). The aim of this proposed framework is to: (1) shift the mindset from performance to impact when assessing building design solutions; (2) provide a broader building assessment framework that integrates energy, water, the environment, and health; and (3) demonstrate the feasibility of the proposed integrated assessment framework. This paper first outlines the two missing components of the current net zero energy building assessment method, followed by a description of other building impacts that should be included in building. More precisely, three additional impact categories were identified: the environment, water, and human health. Within each impact category, multiple impact criteria were included. Then, a multi-criteria analysis was applied to rank the design alternatives. Lastly, a case study was used to demonstrate the validity of this proposed framework, the original building and three alternatives were evaluated. The results show current single criteria (energy-centric) approach is not adequate since 3 different alternatives performed differently in variety impact categories. In general, design alternatives with low-impact materials generate less human health impact, while not always correlate with life cycle energy saving. The findings approved that the proposed assessment framework can be applied to the whole building as well as to individual building components or assemblies.
C1 [Hu, Ming] Univ Maryland, Sch Architecture Planning & Preservat, College Pk, MD 20742 USA.
RP Hu, M (reprint author), Univ Maryland, Sch Architecture Planning & Preservat, College Pk, MD 20742 USA.
EM mhu2008@umd.edu
RI Hu, Ming/I-4311-2019
OI Hu, Ming/0000-0003-2583-1161
CR Allen Joseph G, 2015, Curr Environ Health Rep, V2, P250, DOI 10.1007/s40572-015-0063-y
   Anastasiou EK, 2015, RESOUR CONSERV RECY, V101, P1, DOI 10.1016/j.resconrec.2015.05.009
   [Anonymous], 2019, ENCY BRITANNICA
   [Anonymous], 2019, 350 CENTC
   Antipova E, 2014, ENERG BUILDINGS, V82, P92, DOI 10.1016/j.enbuild.2014.07.001
   AYRES RU, 1995, RESOUR CONSERV RECY, V14, P199, DOI 10.1016/0921-3449(95)00017-D
   Bare J, 2011, CLEAN TECHNOL ENVIR, V13, P687, DOI 10.1007/s10098-010-0338-9
   Benoit V, 2003, INT J LIFE CYCLE ASS, V8, P74, DOI 10.1007/BF02978430
   Cai YP, 2016, RESOUR CONSERV RECY, V108, P21, DOI 10.1016/j.resconrec.2016.01.008
   Cao XD, 2016, ENERG BUILDINGS, V128, P198, DOI 10.1016/j.enbuild.2016.06.089
   Cedeno-Laurent JG, 2018, ANNU REV PUBL HEALTH, V39, P291, DOI 10.1146/annurev-publhealth-031816-044420
   Cellura M, 2014, ENERG BUILDINGS, V72, P371, DOI 10.1016/j.enbuild.2013.12.046
   Chastas P, 2016, BUILD ENVIRON, V105, P267, DOI 10.1016/j.buildenv.2016.05.040
   Chau CK, 2015, APPL ENERG, V143, P395, DOI 10.1016/j.apenergy.2015.01.023
   Chen K, 2015, INT J PROJ MANAG, V33, P1405, DOI 10.1016/j.ijproman.2015.03.006
   Chester MV, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/2/024008
   Collinge W., 2013, INDOOR
   Collinge W, 2013, BUILD ENVIRON, V62, P182, DOI 10.1016/j.buildenv.2013.01.015
   Crawford R. H, 2003, P 8 INT IBPSA C
   Crawford RH, 2011, BUILD RES INF, V39, P589, DOI 10.1080/09613218.2011.584212
   D'Agostino D, 2017, ENERGIES, V10, DOI 10.3390/en10010117
   Dixit MK, 2012, RENEW SUST ENERG REV, V16, P3730, DOI 10.1016/j.rser.2012.03.021
   Elmisalami T. E, 2001, DEV MULTIATTRIBUTE U
   Environmental Protection Agency, 2008, GROUND LEV OZ POLL
   Erdmann C. A., 2002, INDOOR CARBON DIOXID
   Fantke P, 2015, INT J LIFE CYCLE ASS, V20, P276, DOI 10.1007/s11367-014-0822-2
   Fawcett T, 2019, J CLEAN PROD, V210, P1171, DOI 10.1016/j.jclepro.2018.11.026
   Geoffrion A. M., 1972, Journal of Optimization Theory and Applications, V10, P237, DOI 10.1007/BF00934810
   Ghaffarianhoseini A, 2018, ARCHIT SCI REV, V61, P99, DOI 10.1080/00038628.2018.1461060
   Hu M, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10093287
   Huppes G, 2012, INT J LIFE CYCLE ASS, V17, P876, DOI 10.1007/s11367-012-0415-x
   International living future institute, 2019, LIV BUILD BAS
   Jacobs DE, 2009, ENVIRON HEALTH PERSP, V117, P597, DOI 10.1289/ehp.0800086
   Rivero AJ, 2016, RESOUR CONSERV RECY, V108, P171, DOI 10.1016/j.resconrec.2016.01.014
   Khasreen Mohamad Monkiz, 2009, Sustainability, V1, P674, DOI 10.3390/su1030674
   Leon D. A, 2008, CITIES URBANIZATION
   MacNaughton P, 2015, INT J ENV RES PUB HE, V12, P14709, DOI 10.3390/ijerph121114709
   Angelo ACM, 2017, J CLEAN PROD, V143, P744, DOI 10.1016/j.jclepro.2016.12.049
   Marszal AJ, 2011, ENERG BUILDINGS, V43, P971, DOI 10.1016/j.enbuild.2010.12.022
   Medineckiene M, 2011, ENVIRONMENTAL ENGINEERING, VOLS 1-3, P957
   Mihelcic M, 2017, CENT EUR J OPER RES, V25, P627, DOI 10.1007/s10100-016-0451-x
   Motuziene V, 2016, J CLEAN PROD, V112, P532, DOI 10.1016/j.jclepro.2015.08.103
   Nosperger S., 2015, ECEEE 2015 SUMMER ST
   Prado V., 2015, STOCHASTIC MULTIATTR
   Pullen S., 2006, P P AUSTR NZ ARCH SC
   Ramesh T, 2010, ENERG BUILDINGS, V42, P1592, DOI 10.1016/j.enbuild.2010.05.007
   Ravishankara AR, 2009, SCIENCE, V326, P123, DOI 10.1126/science.1176985
   Rocchi L, 2018, ENERG BUILDINGS, V173, P281, DOI 10.1016/j.enbuild.2018.05.032
   Rogers K, 2008, NATO SCI PEACE SECUR, P305
   Saaty TL, 2014, WILEY STATSREF STAT
   Salcido JC, 2016, BUILD ENVIRON, V96, P22, DOI 10.1016/j.buildenv.2015.11.010
   Sarul L. S, 2016, EUR J INTERDISCIP ST, V2, P183
   Shove E, 2018, BUILD RES INF, V46, P779, DOI 10.1080/09613218.2017.1361746
   Si J, 2016, SUSTAIN CITIES SOC, V27, P106, DOI 10.1016/j.scs.2016.06.013
   Soares N, 2017, RENEW SUST ENERG REV, V77, P845, DOI 10.1016/j.rser.2017.04.027
   Stek E., 2011, STRUCT C 2011 STRUCT, P483
   Stephan A, 2016, APPL ENERG, V161, P445, DOI 10.1016/j.apenergy.2015.10.023
   Stephan A, 2014, BUILD RES INF, V42, P685, DOI 10.1080/09613218.2014.921764
   Stephan A, 2014, ARCHIT SCI REV, V57, P39, DOI 10.1080/00038628.2013.837814
   Szalay AZZ, 2007, BUILD ENVIRON, V42, P1761, DOI 10.1016/j.buildenv.2005.12.003
   Teng JY, 2019, SUSTAIN CITIES SOC, V44, P215, DOI 10.1016/j.scs.2018.09.038
   U. S. Energy Information Administration, 2019, MAR STAT PROF EN EST
   U. S. Environmental Protection Agency, 2019, OZ LAYER PROT
   U. S. Environmental Protection Agency, 2019, HDB PLANN SUST WAT W
   U. S. Environmental Protection Agency, 2019, VOL ORG COMP IMP IND
   U. S Environmental Protection Agency, 2019, IND AIR QUAL
   U.S. Environmental Protection Agency (US EPA), 2019, PART MATT PM BAS
   Verbeke S., 2018, SUPPORT SETTING SMAR
   Zhang X, 2017, INDOOR AIR, V27, P47, DOI 10.1111/ina.12284
   Zhang XC, 2016, BUILD ENVIRON, V104, P188, DOI 10.1016/j.buildenv.2016.05.018
   Zheng GZ, 2011, CIV ENG ENVIRON SYST, V28, P123, DOI 10.1080/10286608.2010.482655
   Zhou ZH, 2016, APPL ENERG, V177, P716, DOI 10.1016/j.apenergy.2016.05.093
   Zuo J, 2014, RENEW SUST ENERG REV, V30, P271, DOI 10.1016/j.rser.2013.10.021
NR 73
TC 1
Z9 1
U1 13
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104410
DI 10.1016/j.resconrec.2019.104410
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000034
DA 2020-05-12
ER

PT J
AU Kamil, M
   Ramadan, KM
   Olabi, AG
   Shanableh, A
   Ghenai, C
   Al Naqbi, AK
   Awad, OI
   Ma, X
AF Kamil, Mohammed
   Ramadan, Khalid M.
   Olabi, Abdul Ghani
   Shanableh, Abdallah
   Ghenai, Chaouki
   Al Naqbi, Amna K.
   Awad, Omar I.
   Ma, Xiao
TI Comprehensive evaluation of the life cycle of liquid and solid fuels
   derived from recycled coffee waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biodiesel; Life cycle evaluation; Spent coffee grounds; Tailpipe
   emissions; Brake power; Energy balance
ID BIODIESEL PRODUCTION; COOKING OIL; GROUNDS; PERFORMANCE; EXTRACTION;
   EMISSIONS; ECONOMICS; PRODUCTS; CARBONS
AB In this study, the potential advantages of fuels derived from coffee waste were evaluated and quantified over the entire life cycle. Life cycle evaluation is important for achieving robust understanding because it covers the entire sequence of stages of fuel production and utilization. Coffee waste collection and transport, oil extraction, and biodiesel production and transport are the stages covered under the first life phase, called "well-to-pump." Extensive engine tests were also conducted to assess the second life phase, "pump-to-wheel." Environmental, economic, energetic, and technical criteria were encapsulated within the frame of each phase, and various evaluation tools that fit each life stage were adopted. The results showed that coffee biodiesel contributes to an 80.5% reduction in CO2 emissions compared with the hydrocarbon diesel during its life cycle. Moreover, the conversion efficiency of the raw material energy to fuel energy in the case of coffee biodiesel was 10% higher than that of the petro-diesel. An energy amount of 3.45 MJ is associated with coffee biodiesel for each 1 MJ consumed in its life cycle. The economic viability of coffee biodiesel was found to be very sensitive to the price of the coffee solid fuel (biomass pellets). The entire project is feasible only when the price of pellets is 40% of that of wood pellets or higher. Substantial reduction of tailpipe emissions was attained for CO, CO2, and HC, with 45.3%, 5.7%, and 23.6% reductions, respectively, for B20. Reductions of 10.3% and 7.5% were observed in the brake thermal efficiency and brake power, respectively. Thus, coffee biodiesel has significant advantages and potential, and its technological development merits further research.
C1 [Kamil, Mohammed; Ramadan, Khalid M.] Univ Sharjah, Mech & Nucl Engn Dept, POB 27272, Sharjah, U Arab Emirates.
   [Kamil, Mohammed; Ghenai, Chaouki] Univ Sharjah, Sustainable Energy Dev Res Grp, RISE, POB 27272, Sharjah, U Arab Emirates.
   [Olabi, Abdul Ghani; Ghenai, Chaouki] Univ Sharjah, Dept Sustainable & Renewable Energy Engn, Sharjah, U Arab Emirates.
   [Olabi, Abdul Ghani] Aston Univ, Mech Engn & Design, Sch Engn & Appl Sci, Birmingham B4 7ET, W Midlands, England.
   [Shanableh, Abdallah] Univ Sharjah, Dept Civil & Environm Engn, Sharjah, U Arab Emirates.
   [Shanableh, Abdallah] Univ Sharjah, RISE, Sharjah, U Arab Emirates.
   [Al Naqbi, Amna K.] Beeah Environm Management Co, Waste Energy Dept, POB 20248, Sharjah, U Arab Emirates.
   [Awad, Omar I.; Ma, Xiao] Tsinghua Univ, State Key Lab Automot Safety & Energy, Beijing 100084, Peoples R China.
RP Kamil, M (reprint author), Univ Sharjah, Mech & Nucl Engn Dept, POB 27272, Sharjah, U Arab Emirates.
EM mmohammed@sharjah.ac.ae
RI KAMIL, MOHAMMED/L-9442-2019; Awad, Omar I./H-5039-2018
OI KAMIL, MOHAMMED/0000-0003-3129-303X; Awad, Omar I./0000-0001-7453-6690;
   Shanableh, Abdallah/0000-0002-9808-4120
FU University of Sharjah [V.C.R.G./R.1285/2017]; Lootah Biofuels LLC (UAE);
   Bureau Veritas-Inspectorate (UAE); Materials Laboratory (UAE); GHP
   Testing & Calibration Laboratory (UAE); Dubai Central Laboratory (Food
   and Environment Laboratory Section)
FX The authors would like to express their gratitude to the following
   institutions, laboratories, and inspection bodies for their support to
   this project: the University of Sharjah, Lootah Biofuels LLC (UAE),
   Bureau Veritas-Inspectorate (UAE), Materials Laboratory (UAE), GHP
   Testing & Calibration Laboratory (UAE), and Dubai Central Laboratory
   (Food and Environment Laboratory Section). This research was supported
   in part by the University of Sharjah under fund award
   V.C.R.G./R.1285/2017.
CR Akasaka H, 2011, INT J HYDROGEN ENERG, V36, P580, DOI 10.1016/j.ijhydene.2010.09.102
   Al-Hamamre Z, 2012, FUEL, V96, P70, DOI 10.1016/j.fuel.2012.01.023
   ALSTROM S, 1992, J PHYTOPATHOL, V136, P329, DOI 10.1111/j.1439-0434.1992.tb01315.x
   Apostolakou AA, 2009, FUEL PROCESS TECHNOL, V90, P1023, DOI 10.1016/j.fuproc.2009.04.017
   Aydin H, 2010, RENEW ENERG, V35, P588, DOI 10.1016/j.renene.2009.08.009
   Bio-bean, 2019, COFF CONS UK
   Bravo J, 2012, J AGR FOOD CHEM, V60, P12565, DOI 10.1021/jf3040594
   Campos-Vega R, 2015, TRENDS FOOD SCI TECH, V45, P24, DOI 10.1016/j.tifs.2015.04.012
   Center for Transportation Research, 2016, GREET LIF CYCL MOD U
   Charles C., 2013, BIOFUELS WHAT COST R
   Cholakov G., 2013, J CHEM TECHNOL METAL, V48, P497
   Ciesielczuk T, 2015, J ECOL ENG, V16, P133, DOI 10.12911/22998993/59361
   Davis M. L, 2013, INTRO ENV ENG
   Dias M, 2015, LETT APPL MICROBIOL, V61, P588, DOI 10.1111/lam.12498
   Dimian A.C., 2008, CHEM PROCESS DESIGN
   Duncan J., 2003, COSTS BIODIESEL PROD
   Espindola-Gonzalez A, 2010, NANOSCALE RES LETT, V5, P1408, DOI 10.1007/s11671-010-9654-6
   Figueroa G. A, 2016, AUSTIN FOOD SCI, V1, P1
   Gama NV, 2015, MATER DESIGN, V76, P77, DOI 10.1016/j.matdes.2015.03.032
   Gebremariam SN, 2018, ENERG CONVERS MANAGE, V168, P74, DOI 10.1016/j.enconman.2018.05.002
   Giller C., 2017, COFFEE BIOFUELS
   GIVENS DI, 1986, AGR WASTES, V18, P69, DOI 10.1016/0141-4607(86)90108-3
   Goncalves M, 2013, IND ENG CHEM RES, V52, P2832, DOI 10.1021/ie303072d
   Honeywell International, 2017, UNISIM DES US GUID
   International Coffee Organization (ICO), 2018, COFF MARK REP MAY 20
   Kamil M, 2019, SCI TOTAL ENVIRON, V675, P13, DOI 10.1016/j.scitotenv.2019.04.156
   Karmee SK, 2015, INT J MOL SCI, V16, P4362, DOI 10.3390/ijms16034362
   Kondamudi N, 2008, J AGR FOOD CHEM, V56, P11757, DOI 10.1021/jf802487s
   Kookos IK, 2018, RESOUR CONSERV RECY, V134, P156, DOI 10.1016/j.resconrec.2018.02.002
   Korbitz W., 2004, BEST CASE STUDIES BI
   Kyzas GZ, 2012, MATERIALS, V5, P1826, DOI 10.3390/ma5101826
   Limousy L, 2013, FUEL, V107, P323, DOI 10.1016/j.fuel.2012.10.019
   Low JH, 2015, J CLEAN PROD, V101, P222, DOI 10.1016/j.jclepro.2015.03.094
   McManus M. C, 2011, P WORLD REN EN C SWE, P455, DOI [10.3384/ecp11057455, DOI 10.3384/ECP11057455]
   Methanex, 2019, METH METH PRIC SHEET
   Murillo S, 2007, FUEL, V86, P1765, DOI 10.1016/j.fuel.2006.11.031
   Murthy PS, 2012, FOOD BIOPROCESS TECH, V5, P657, DOI [10.1007/s11947-010-0331-7, 10.1007/s11947-010-0363-z]
   Mussatto SI, 2011, FOOD BIOPROCESS TECH, V4, P661, DOI 10.1007/s11947-011-0565-z
   Mussatto SI, 2011, CARBOHYD POLYM, V83, P368, DOI 10.1016/j.carbpol.2010.07.063
   Nabais JMV, 2008, FUEL PROCESS TECHNOL, V89, P262, DOI 10.1016/j.fuproc.2007.11.030
   National Renewable Energy Laboratory (NREL), 1995, LIF CYCL ASS PETR BA
   Perry R.H., 2008, PERRYS CHEM ENG HDB
   Peters M.S., 2004, PLANT DESIGN EC CHEM
   Pflunger R.A., 1975, SOLID WASTES ORIGIN
   Qingdao Echemi Technology, 2019, SOD HYDR PRIC AN 201
   Rani MU, 2013, J FOOD SCI TECH MYS, V50, P755, DOI 10.1007/s13197-011-0401-5
   Reis KC, 2015, MATER RES-IBERO-AM J, V18, P546, DOI 10.1590/1516-1439.318114
   Ribeiro H, 2013, EUR J LIPID SCI TECH, V115, P330, DOI 10.1002/ejlt.201200239
   Rufford TE, 2008, ELECTROCHEM COMMUN, V10, P1594, DOI 10.1016/j.elecom.2008.08.022
   Sheehan J., 1998, LIFE CYCLE INVENTORY
   Shemekite F, 2014, WASTE MANAGE, V34, P642, DOI 10.1016/j.wasman.2013.11.010
   Silva MA, 1998, BIOMASS BIOENERG, V14, P457, DOI 10.1016/S0961-9534(97)10034-4
   Sinnott RK, 2005, COULSON RICHARDSONS
   Skarlis S, 2012, J CLEAN PROD, V20, P20, DOI 10.1016/j.jclepro.2011.08.011
   Somnuk Krit, 2017, Agriculture and Natural Resources, V51, P181, DOI 10.1016/j.anres.2017.01.003
   Utlu Z, 2008, RENEW ENERG, V33, P1936, DOI 10.1016/j.renene.2007.10.006
   Zhang Y, 2003, BIORESOURCE TECHNOL, V90, P229, DOI 10.1016/S0960-8524(03)00150-0
NR 57
TC 1
Z9 1
U1 8
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104446
DI 10.1016/j.resconrec.2019.104446
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000035
DA 2020-05-12
ER

PT J
AU Kirchherr, J
   Piscicelli, L
AF Kirchherr, Julian
   Piscicelli, Laura
TI Towards an Education for the Circular Economy (ECE): Five Teaching
   Principles and a Case Study
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Sustainable development; Education for sustainable
   development (ESD); Education for the circular economy (ECE); Teaching;
   Higher education
ID SUSTAINABLE DEVELOPMENT; BARRIERS; CHINA
AB The circular economy (CE) concept is seen by many as a novel pathway to sustainable development. A few scholars have started outlining educational approaches and tools that lecturers can use to accelerate the transition towards a circular economy. This paper aims to contribute to this nascent body of literature on education for the circular economy (ECE) by describing and critically discussing a course designed to introduce undergraduates to the CE concept. The course design adopted the pedagogical principles of constructive alignment and problem-based learning, as well as interactivity, non-dogmatism, and reciprocity. Seven exercises were developed for it: a drill game, buzzword bingo, a teardown lab, an eco-industrial park simulation, policy instruments, a circular party and circular futures. The course received an excellent rating by the participating students (with feedback collected for each module at the end of every module as well as for the entire course at the end of the course). The ECE approach outlined in this paper can be utilized and further developed by lecturers keen to incorporate the CE concept into their teaching. Overall, this paper hopes to encourage lecturers to share additional best practices regarding CE teaching with the intention of fostering a discussion on how to best approach ECE.
C1 [Kirchherr, Julian; Piscicelli, Laura] Univ Utrecht, Copernicus Inst Sustainable Dev, Utrecht, Netherlands.
RP Kirchherr, J (reprint author), Univ Utrecht, Copernicus Inst Sustainable Dev, Innovat Studies Grp, Utrecht, Netherlands.
EM j.kirchherr@uu.nl
OI Piscicelli, Laura/0000-0001-7501-4608
CR Alwi SRW, 2014, J CLEAN PROD, V71, P1, DOI 10.1016/j.jclepro.2014.03.013
   Anderberg E., 2009, INT J SUST HIGHER ED, V10, P368, DOI DOI 10.1108/14676370910990710
   Anderson L. W., 2001, A TAXONOMY FOR LEARN
   Andrews D, 2015, LOCAL ECON, V30, P305, DOI 10.1177/0269094215578226
   Au O., 2009, LECTURE NOTES IN COM, V5685
   Barth M., 2007, INT J SUST HIGHER ED, V8, P416, DOI [10.1108/14676370710823582, DOI 10.1108/14676370710823582]
   Barth M, 2013, INT J SUST HIGHER ED, V14, P160, DOI 10.1108/14676371311312879
   Bastein T., 2013, ENERGIES, V1, DOI [10.3390/en1030105, DOI 10.3390/EN1030105]
   Berryman T, 2016, J ENVIRON EDUC, V47, P104, DOI 10.1080/00958964.2015.1092934
   Biggs J., 2011, TEACHING FOR QUALITY
   BISWAS MR, 1982, ENVIRON CONSERV, V9, P125, DOI 10.1017/S0376892900020038
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   Bocken NMP, 2017, J IND ECOL, V21, P487, DOI 10.1111/jiec.12605
   Boulding K. E, 1966, THE ECONOMICS OF THE
   Broecks KPF, 2016, ENVIRON SCI POLICY, V59, P58, DOI 10.1016/j.envsci.2016.02.004
   Brumagim AL, 2012, J EDUC BUS, V87, P303, DOI 10.1080/08832323.2011.598886
   Chertow MR, 2005, ENVIRON SCI TECHNOL, V39, P6535, DOI 10.1021/es050050+
   Chertow MR, 2000, ANNU REV ENERG ENV, V25, P313, DOI 10.1146/annurev.energy.25.1.313
   Cortese A. D., 1999, EDUCATION FOR SUSTAI
   D'Amato D, 2017, J CLEAN PROD, V168, P716, DOI 10.1016/j.jclepro.2017.09.053
   De Groene Zaak Ethica, 2015, BOOSTING CIRCULAR DE
   de Jesus A, 2018, ECOL ECON, V145, P75, DOI 10.1016/j.ecolecon.2017.08.001
   DoF, 2017, THE WEIGHTED SCORING
   Duch B. J., 2001, THE POWER OF PROBLEM
   EC, 2015, CIRCULAR ECONOMY
   ELKINGTON J, 1997, CANNIBALS FORKS
   Ellen MacArthur Foundation, 2016, INTELLIGENT ASSETS U
   Ellen MacArthur Foundation, 2015, GROWTH WITHIN A CIRC
   Ellen MacArthur Foundation, 2018, TEACHING LEARNING RE
   Engelman R., 2013, STATE WORLD 2013 IS, P3, DOI DOI 10.5822/978-1-61091-458-1_1
   Fang YP, 2007, J ENVIRON MANAGE, V83, P315, DOI 10.1016/j.jenvman.2006.03.007
   Figueiro PS, 2015, J CLEAN PROD, V106, P22, DOI 10.1016/j.jclepro.2015.04.118
   Fulton S. C, 2012, UN C SUST DEV P ANN, P91
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Geng Y, 2009, J IND ECOL, V13, P978, DOI 10.1111/j.1530-9290.2009.00184.x
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Government of the Netherland, 2016, A CIRCULAR ECONOMY I
   Heeres RR, 2004, J CLEAN PROD, V12, P985, DOI 10.1016/j.jclepro.2004.02.014
   Hein A. M., 2015, 20TH DESIGN FOR MANU, V4, DOI 10.1115/DETC2015-46322
   Heshmati A, 2015, A REVIEW OF THE CIRC
   Huckle J, 2012, ENVIRON EDUC RES, V18, P845, DOI 10.1080/13504622.2012.665851
   IJSHE, 2017, INT J SUSTAIN HIGH E
   Jackson M., 2012, ENCYCLOPEDIA OF THE
   Jackson M, 2014, RESOURCES-BASEL, V3, P516, DOI 10.3390/resources3030516
   Jiang Y, 2014, ECON DEV CULT CHANGE, V63, P155, DOI 10.1086/677739
   Jickling B, 2016, J ENVIRON EDUC, V47, P128, DOI 10.1080/00958964.2015.1080653
   Johnston A, 2007, HIGHER EDUCATION FOR
   Juarez-Najera M, 2006, J CLEAN PROD, V14, P1028, DOI 10.1016/j.jclepro.2005.11.049
   Kevany KD, 2007, INT J SUSTAINABILITY, V8, P107, DOI DOI 10.1108/14676370710726580
   Kilkis S, 2017, J CLEAN PROD, V167, P1084, DOI 10.1016/j.jclepro.2017.03.178
   Kirchherr J., 2014, CREATING GROWTH CLUS
   Kirchherr J, 2018, ECOL ECON, V150, P264, DOI 10.1016/j.ecolecon.2018.04.028
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Knudby T, 2017, PROCEEDINGS OF THE 4
   Kopnina H, 2017, HANDBOOK OF ENGAGED
   Kopnina H, 2018, J INTEGR ENVIRON SCI, V15, P123, DOI 10.1080/1943815X.2018.1471724
   Kopnina H, 2015, ENVIRON DEV, V15, P120, DOI 10.1016/j.envdev.2015.03.005
   Kopnina H, 2015, ENVIRON DEV SUSTAIN, V17, P987, DOI 10.1007/s10668-014-9584-z
   Kopnina H, 2014, J ENVIRON EDUC, V45, P217, DOI 10.1080/00958964.2014.941783
   Leube M, 2017, DES J, V20, pS492, DOI 10.1080/14606925.2017.1352999
   Lewandowski M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010043
   Lieder M, 2016, J CLEAN PROD, V115, P36, DOI 10.1016/j.jclepro.2015.12.042
   Liu Y, 2014, RESOUR CONSERV RECY, V87, P145, DOI 10.1016/j.resconrec.2014.04.002
   Lozano R, 2015, J CLEAN PROD, V108, P1, DOI 10.1016/j.jclepro.2014.09.048
   Lozano R, 2010, J CLEAN PROD, V18, P637, DOI 10.1016/j.jclepro.2009.07.005
   McDowall W, 2017, J IND ECOL, V21, P651, DOI 10.1111/jiec.12597
   Moreno M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8090937
   Naude M., 2011, CORPORATE OWNERSHIP, V8, P352
   Ormazabal M, 2018, MEMORIA, P99
   Palmer G, 1992, LAW REV, V70
   Pandey N, 2009, INT J ENVIRON SUSTAI, V9, DOI [10.1504/IJESD.2010, DOI 10.1504/IJESD.2010]
   Pang M, 2009, J TEACH INT BUS, V20, P106, DOI 10.1080/08975930902827825
   Perella M, 2015, CIRCULAR ECONOMY INS
   Persons O, 2012, J EDUC BUS, V87, P63, DOI 10.1080/08832323.2011.562933
   Pitt J., 2015, DESIGN TECHNOLOGY ED, P245
   Potting J., 2017, CIRCULAR ECONOMY MEA
   Reid A, 2006, HIGH EDUC, V51, P105, DOI 10.1007/s10734-004-6379-4
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Rochman CM, 2016, ENVIRON RES LETT, V11, DOI 10.1088/1748-9326/11/4/041001
   Rosano M., 2015, PROG IND ECOL INT J, V9, P82, DOI [10.1504/PIE.2015.069844, DOI 10.1504/PIE.2015.069844]
   Sakr D, 2011, J CLEAN PROD, V19, P1158, DOI 10.1016/j.jclepro.2011.01.001
   Sanchez M., 2005, INT J SUSTAINABILITY, V6, P383, DOI DOI 10.1108/14676370510623865
   Sanchez-Romaguera V., 2016, ENG EDU SUSTAIN DEVE
   Santasalo-Aarnio A., 2017, 45TH SEFI CONFERENCE
   Sauve S, 2016, ENVIRON DEV, V17, P48, DOI 10.1016/j.envdev.2015.09.002
   Sitra, 2018, CIRCULAR ECONOMY TEA
   Skene KR, 2018, SUSTAIN SCI, V13, P479, DOI 10.1007/s11625-017-0443-3
   Stegeman H., 2015, THE POTENTIAL OF THE
   Tam M, 2014, QUAL ASSUR EDUC, V22, P158, DOI 10.1108/QAE-09-2011-0059
   Three C, 2015, CREATING COMPETENCES
   Tukker A, 2015, J CLEAN PROD, V97, P76, DOI 10.1016/j.jclepro.2013.11.049
   UNEP, 2011, TOWARDS A GREEN ECON
   Universiteit Utrecht, 2017, SOCIALE GEOGRAFIE EN
   Universiteit Utrecht, 2017, BUSINESS SUSTAINABIL
   Universiteit Utrecht, 2017, ENVIRONMENTAL SCIENC
   Urbinati A, 2017, J CLEAN PROD, V168, P487, DOI 10.1016/j.jclepro.2017.09.047
   Valenzuela-Venegas G, 2016, J CLEAN PROD, V133, P99, DOI 10.1016/j.jclepro.2016.05.113
   van Buren N, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070647
   Vanaga R, 2015, ENRGY PROCED, V72, P307, DOI 10.1016/j.egypro.2015.06.044
   Whalen KA, 2018, RESOUR CONSERV RECY, V135, P335, DOI 10.1016/j.resconrec.2017.06.021
   Wu YCJ, 2016, INT J SUST HIGHER ED, V17, P633, DOI 10.1108/IJSHE-01-2015-0004
   Zenelaj E, 2013, EUR J SUSTAIN DEV, V2, P227
   Zhu DJ, 2008, CHIN J POPUL RESOUR, V6, P3, DOI 10.1080/10042857.2008.10684889
   Zhu QH, 2015, J IND ECOL, V19, P457, DOI 10.1111/jiec.12176
   ZWS, 2016, CIRCULAR ECONOMY
NR 105
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104406
DI 10.1016/j.resconrec.2019.104406
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000001
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Kuenzel, C
   Ranjbar, N
AF Kuenzel, Carsten
   Ranjbar, Navid
TI Dissolution mechanism of fly ash to quantify the reactive
   aluminosilicates in geopolymerisation
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Fly ash; Reactivity; Geopolymers; Aluminosilicates; Characterization
ID QUANTITATIVE-DETERMINATION; MICROSTRUCTURAL ANALYSIS;
   CONDENSATION-REACTIONS; COMPRESSIVE STRENGTH; VOLCANIC ASH; PART I;
   KINETICS; GEOPOLYMERIZATION; CENOSPHERES; WORKABILITY
AB Predicting of fly ash (FA) performance in alkali environment is difficult due to its heterogeneous nature. This paper investigates the dissolution process of FA in NaOH-activated geopolymers toward quantification of its reactivity. Dissolution rates were influenced much more by temperature (25-145 degrees C) and time (2-24 h) than by NaOH molarity (8-16 M). Higher temperatures increased the kinetic energy of the system, thus increasing the effectiveness of solute molecular bond breakage by solvent molecules and intermolecular attraction. Analysis by FTIR, ICP, XRD and SEM-EDS implies that FA consists of reactive materials, partially reactive materials, and inert materials. The reactive materials dissolve rapidly during geopolymerisation. The partially reactive materials are cenospheres, whose outer vitreous Si shell dissolves gradually, while the inert materials remain un-reacted. To avoid overestimating or underestimating the reactive material content in FA, it is proposed to modify the dissolution method to match the intended curing temperature and to set the dissolution test duration fitting with the initial setting time of the geopolymer paste at the curing temperature of interest. It is not only the quantity of reactive material that is important but also the Si/Al ratio of the reactive material. Consequently, it is recommended that quantification of reactive material be analysed by ICP dissolution rather than EDS analyses of the undissolved material.
C1 [Kuenzel, Carsten] Imperial Coll London, Dept Civil & Environm Engn, London, England.
   [Ranjbar, Navid] Tech Univ Denmark, Dept Mech Engn, DK-2800 Lyngby, Denmark.
   [Ranjbar, Navid] Tech Univ Denmark, Dept Hlth Technol, DK-2800 Lyngby, Denmark.
   [Ranjbar, Navid] UCL, Dept Civil Environm & Geomat Engn, London WC1E 6BT, England.
RP Ranjbar, N (reprint author), Tech Univ Denmark, Dept Mech Engn, DK-2800 Lyngby, Denmark.
EM naran@mek.dtu.dk
RI Ranjbar, Navid/L-4274-2018
OI Ranjbar, Navid/0000-0002-1485-3931
FU European UnionEuropean Union (EU) [713683]
FX This project has received funding from the European Union's Horizon 2020
   research and innovation program under the Marie Sklodowska-Curie grant
   agreement no. 713683 (COFUNDfellowsDTU). Furthermore, the authors would
   like to acknowledge the contribution of Dr. Shane Donatello and Dr. Jean
   Noel Yankwa Djobo for fruitful discussions.
CR Aredes FGM, 2015, CERAM INT, V41, P7302, DOI 10.1016/j.ceramint.2015.02.022
   Aughenbaugh K. L, 2013, FLY ASH BASED GEOPOL
   Aughenbaugh KL, 2013, MATER STRUCT, V46, P869, DOI 10.1617/s11527-012-9939-6
   Brouwers HJH, 2002, J MATER SCI, V37, P2129, DOI 10.1023/A:1015206305942
   Chen-Tan NW, 2009, J AM CERAM SOC, V92, P881, DOI 10.1111/j.1551-2916.2009.02948.x
   Cheng TW, 2003, MINER ENG, V16, P205, DOI 10.1016/S0892-6875(03)00008-6
   Chindaprasirt P, 2007, CEMENT CONCRETE COMP, V29, P224, DOI 10.1016/j.cemconcomp.2006.11.002
   Criado M, 2007, MICROPOR MESOPOR MAT, V106, P180, DOI 10.1016/j.micromeso.2007.02.055
   Davidovits J., 2008, GEOPOLYMER CHEM APPL
   De Silva P, 2007, CEMENT CONCRETE RES, V37, P512, DOI 10.1016/j.cemconres.2007.01.003
   Djobo JNY, 2016, J AM CERAM SOC, V99, P3159, DOI 10.1111/jace.14332
   Djobo JNY, 2016, RSC ADV, V6, P39106, DOI 10.1039/c6ra03667h
   Donahue R.J, 2004, GEOL SOC LOND SPEC P, V236, P641
   Fang GH, 2018, CONSTR BUILD MATER, V172, P476, DOI 10.1016/j.conbuildmat.2018.04.008
   Fernandez-Jimenez A, 2005, CEMENT CONCRETE RES, V35, P1984, DOI 10.1016/j.cemconres.2005.03.003
   Fernandez-Jimenez A, 2005, CEMENT CONCRETE RES, V35, P1204, DOI 10.1016/j.cemconres.2004.08.021
   Fomenko EV, 2015, ENERG FUEL, V29, P5390, DOI 10.1021/acs.energyfuels.5b01022
   FRAAY ALA, 1989, CEMENT CONCRETE RES, V19, P235, DOI 10.1016/0008-8846(89)90088-4
   GHOSAL S, 1995, FUEL, V74, P522, DOI 10.1016/0016-2361(95)98354-H
   GUTTERIDGE WA, 1979, CEMENT CONCRETE RES, V9, P319, DOI 10.1016/0008-8846(79)90124-8
   Hajimohammadi A, 2010, J AM CHEM SOC, V22
   Hardjito D, 2004, ACI MATER J, V101, P467
   Komnitsas K, 2007, MINER ENG, V20, P1261, DOI 10.1016/j.mineng.2007.07.011
   Kuenzel C, 2013, APPL CLAY SCI, V83-84, P308, DOI 10.1016/j.clay.2013.08.023
   Kuenzel C, 2012, J AM CERAM SOC, V95, P3270, DOI 10.1111/j.1551-2916.2012.05380.x
   LI SQ, 1985, CEMENT CONCRETE RES, V15, P1079, DOI 10.1016/0008-8846(85)90100-0
   Li Y, 2013, ENERG FUEL, V27, P811, DOI 10.1021/ef3020553
   LUKE K, 1987, CEMENT CONCRETE RES, V17, P273, DOI 10.1016/0008-8846(87)90110-4
   Mo BH, 2014, APPL CLAY SCI, V99, P144, DOI 10.1016/j.clay.2014.06.024
   OGAWA K, 1980, CEMENT CONCRETE RES, V10, P683, DOI 10.1016/0008-8846(80)90032-0
   OHSAWA S, 1985, CEMENT CONCRETE RES, V15, P357, DOI 10.1016/0008-8846(85)90047-X
   Pietersen H. S, 1989, MAT RES SOC S P
   Provis JL, 2007, CHEM ENG SCI, V62, P2318, DOI 10.1016/j.ces.2007.01.028
   Provis JL, 2009, WOODHEAD PUBL MATER, P1, DOI 10.1533/9781845696382
   Provis JL, 2007, CHEM ENG SCI, V62, P2309, DOI 10.1016/j.ces.2007.01.027
   Ranjbar N, 2018, CEMENT CONCRETE COMP, V86, P1, DOI 10.1016/j.cemconcomp.2017.11.004
   Ranjbar N, 2017, CEMENT CONCRETE RES, V100, P14, DOI 10.1016/j.cemconres.2017.05.010
   Ranjbar N, 2017, FUEL, V207, P1, DOI 10.1016/j.fuel.2017.06.059
   Ranjbar N, 2017, J AM CERAM SOC, V100, P3165, DOI 10.1111/jace.14848
   Ranjbar N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147546
   Ranjbar N, 2014, CONSTR BUILD MATER, V65, P114, DOI 10.1016/j.conbuildmat.2014.04.064
   Ranjbar N, 2014, MATER DESIGN, V59, P532, DOI 10.1016/j.matdes.2014.03.037
   Ruiz-Santaquiteria C, 2011, 13 INT C CHEM CEM MA
   Sagoe-Crentsil K, 2007, J MATER SCI, V42, P3007, DOI 10.1007/s10853-006-0818-9
   Sarkar A, 2007, ENERG SOURCE PART A, V30, P271
   Sokol EV, 2000, FUEL PROCESS TECHNOL, V67, P35, DOI 10.1016/S0378-3820(00)00084-9
   Swanepoel JC, 2002, APPL GEOCHEM, V17, P1143, DOI 10.1016/S0883-2927(02)00005-7
   Tchadjie LN, 2016, CERAM INT, V42, P3046, DOI 10.1016/j.ceramint.2015.10.091
   Vassilev SV, 2004, FUEL, V83, P585, DOI 10.1016/j.fuel.2003.10.003
   Wang HL, 2005, COLLOID SURFACE A, V268, P1, DOI 10.1016/j.colsurfa.2005.01.016
   Weng L, 2007, J MATER SCI, V42, P2997, DOI 10.1007/s10853-006-0820-2
   Zuhua Z, 2009, APPL CLAY SCI, V43, P218, DOI 10.1016/j.clay.2008.09.003
NR 52
TC 5
Z9 5
U1 7
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104421
DI 10.1016/j.resconrec.2019.104421
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000022
DA 2020-05-12
ER

PT J
AU Lam, MML
   Wong, CWY
   Chan, WTY
   Leung, CH
   Cheung, MC
AF Lam, Magnum M. L.
   Wong, Christina W. Y.
   Chan, Winslet T. Y.
   Leung, Chi-hong
   Cheung Mei-chun
TI Effects of institutional environmental forces on participation in
   environmental initiatives
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Institutional theory; Institutional environmental forces; Customer
   participation; Environmental behavior; Environmental initiatives;
   Multi-method
ID GENDER-DIFFERENCES; REVERSE LOGISTICS; ASYMMETRY; RESPONSIBILITY;
   LEGITIMATION; MANAGEMENT; PRESSURES; EMOTION; IMPACT
AB This paper extends the environmental management literature by theorizing on and empirically validating the impacts of three different institutional environmental forces (IEFs): coercive, normative, and mimetic institutional environmental forces. We use a multi-method research design with two studies to examine the impacts of these forces by first investigating the environmental behaviors of individuals when they encounter these forces in their daily life, then examining their response towards environmental messages that reflect these three different forces. Specifically, we examine in Study 1 how these forces affect the environmental behaviors of individuals in terms of their participation in sorting and reducing waste, and other environmental activities through a mass survey. In Study 2, we investigate how the environmental messages of firms based on their environmental initiatives are emotionally received by individuals through electroencephalography (EEG). The findings suggest the importance of using normative and mimetic IEFs in addition to coercive IEFs to motivate participation in environmental initiatives.
C1 [Lam, Magnum M. L.; Wong, Christina W. Y.] Hong Kong Polytech Univ, Inst Text & Clothing, Business Div, Hong Kong, Peoples R China.
   [Chan, Winslet T. Y.; Leung, Chi-hong] Hong Kong Polytech Univ, Dept Management & Mkt, Hong Kong, Peoples R China.
   [Cheung Mei-chun] Chinese Univ Hong Kong, Dept Social Work, Hong Kong, Peoples R China.
RP Wong, CWY (reprint author), Hong Kong Polytech Univ, Inst Text & Clothing, Business Div, Hong Kong, Peoples R China.
EM tcchris@polyu.edu.hk
RI Cheung, Mei Chun/A-1261-2014
OI Cheung, Mei Chun/0000-0002-0210-0772
FU Research Grants Council of Hong Kong Special Administration Region,
   China (RGC/Gov) [35000017]; Hong Kong Polytechnic UniversityHong Kong
   Polytechnic University [1-ZVLF]
FX The authors thank the editor-in-chief, Prof. Ming Xu, and the three
   anonymous reviewers for their constructive comments and suggestions on
   the earlier versions of the paper. This research was partially supported
   by the Research Grants Council of Hong Kong Special Administration
   Region, China (RGC/Gov No.: 35000017) and the Hong Kong Polytechnic
   University account code 1-ZVLF.
CR Allen JJB, 2004, PSYCHOPHYSIOLOGY, V41, P269, DOI 10.1111/j.1469-8986.2003.00149.x
   ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411
   [Anonymous], 2008, CHINA BANS FREE PLAS
   ARMSTRONG JS, 1977, J MARKETING RES, V14, P396, DOI 10.2307/3150783
   Arnocky S., 2010, CURRENT RES SOCIAL P, V16
   BAGOZZI RP, 1982, J MARKETING RES, V19, P562, DOI 10.2307/3151727
   Baxter J, 2016, RESOUR CONSERV RECY, V109, P96, DOI 10.1016/j.resconrec.2016.02.012
   Berger P. L., 1967, SOCIAL CONSTRUCTION
   Bergsma E, 2012, RESOUR CONSERV RECY, V64, P13, DOI 10.1016/j.resconrec.2012.03.006
   Berkman ET, 2010, J COGNITIVE NEUROSCI, V22, P1970, DOI 10.1162/jocn.2009.21317
   Bitner MJ, 2008, BUS HORIZONS, V51, P39, DOI 10.1016/j.bushor.2007.09.003
   Bohner G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104086
   Brown B. B., 1974, THE ALPHA SYLLABUS A
   Campbell JL, 2007, ACAD MANAGE REV, V32, P946
   Carver CS, 2009, PSYCHOL BULL, V135, P183, DOI 10.1037/a0013965
   Chan R. Y. K., 2000, INT J ADVERT, V19, P349
   Chan TY, 2016, PROD OPER MANAG, V25, P432, DOI 10.1111/poms.12407
   Chan TY, 2012, J FASH MARK MANAG, V16, P193, DOI 10.1108/13612021211222824
   Cheung MC, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00014
   Cheung MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174906
   Cheung MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115112
   Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015
   Cicourel A, UNDERSTANDING EVERYD
   Coan JA, 2004, BIOL PSYCHOL, V67, P7, DOI 10.1016/j.biopsycho.2004.03.002
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Collins A, 2018, J CLEAN PROD, V174, P1000, DOI 10.1016/j.jclepro.2017.11.024
   Delmas M, 2004, BUSINESS STRATEGY EN, V13, P209, DOI DOI 10.1002/BSE.409
   Dietz T, 2002, SOC SCI QUART, V83, P353, DOI 10.1111/1540-6237.00088
   DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   FRIJDA NH, 1989, J PERS SOC PSYCHOL, V57, P212, DOI 10.1037/0022-3514.57.2.212
   GERBING DW, 1988, J MARKETING RES, V25, P186, DOI 10.2307/3172650
   Gustafson PE, 1998, RISK ANAL, V18, P805, DOI 10.1111/j.1539-6924.1998.tb01123.x
   Harmon-Jones E, 2010, BIOL PSYCHOL, V84, P451, DOI 10.1016/j.biopsycho.2009.08.010
   Harris CR, 2006, JUDGM DECIS MAK, V1, P48
   Harwood T, 2003, MARKETING REV, V3, P479, DOI DOI 10.1362/146934703771910080
   Hopkins MS, 2009, MIT SLOAN MANAGE REV, V50, P87
   Humphreys A, 2010, J CONSUM RES, V37, P490, DOI 10.1086/652464
   Huy QN, 1999, ACAD MANAGE REV, V24, P325, DOI 10.2307/259085
   Lai KH, 2014, INT J PROD ECON, V147, P284, DOI 10.1016/j.ijpe.2013.06.028
   Lai KH, 2013, INT J PROD ECON, V146, P106, DOI 10.1016/j.ijpe.2013.03.005
   Lai KH, 2012, TECHNOL FORECAST SOC, V79, P766, DOI 10.1016/j.techfore.2011.10.004
   Lai KH, 2011, RESOUR CONSERV RECY, V55, P631, DOI 10.1016/j.resconrec.2010.12.004
   Lai KH, 2010, CALIF MANAGE REV, V52, P6, DOI 10.1525/cmr.2010.52.2.6
   Liang HG, 2007, MIS QUART, V31, P59
   Liu Y, 2018, WASTE MANAGE, V76, P431, DOI 10.1016/j.wasman.2018.02.028
   Lu YJ, 2018, RESOUR CONSERV RECY, V139, P27, DOI 10.1016/j.resconrec.2018.07.002
   Maxwell JS, 2007, PSYCHOL SCI, V18, P1113, DOI 10.1111/j.1467-9280.2007.02033.x
   Morgeson FP, 1999, ACAD MANAGE REV, V24, P249, DOI 10.2307/259081
   Neuendorf K. A., 2002, CONTENT ANAL GUIDEBO
   Nunnally J., 1984, PSYCHOMETRIC THEORY
   Pisano I, 2017, ENVIRON BEHAV, V49, P31, DOI 10.1177/0013916515600494
   Powell W., 1991, NEW I ORG ANAL
   Price TF, 2012, MOTIV EMOTION, V36, P27, DOI 10.1007/s11031-011-9258-1
   Rhodes RE, 2014, RESOUR CONSERV RECY, V90, P1, DOI 10.1016/j.resconrec.2014.04.008
   Rutherford HJV, 2011, EMOT REV, V3, P333, DOI 10.1177/1754073911402392
   Ryoo Y, 2017, J ADVERTISING, V46, P536, DOI 10.1080/00913367.2017.1396514
   Sancha C, 2016, J CLEAN PROD, V112, P1849, DOI 10.1016/j.jclepro.2014.09.026
   Schultz PW, 2007, PSYCHOL SCI, V18, P429, DOI 10.1111/j.1467-9280.2007.01917.x
   Scott W. R, 2001, I ENV ORG
   Scott W. R, 1987, ORG RATIONAL NATURAL
   Sternthal B., 1974, ADV CONSUM RES, V1, P488
   Tanriverdi H, 2006, MIS QUART, V30, P57
   Teplan M., 2002, MEASUREMENT SCI REV, V2, P1, DOI DOI 10.1021/PR070350L
   Wang Y, 2017, ENVIRON BEHAV, V49, P1128, DOI 10.1177/0013916516680264
   Wong C. W. Y., 2016, J BUS ETHICS, V144, P1
   Wong CWY, 2012, INT J PROD ECON, V135, P584, DOI 10.1016/j.ijpe.2011.05.009
   Wraas A, 2009, INT J ORGAN ANAL, V17, P84, DOI 10.1108/19348830910948940
   Ye F, 2013, INT J PROD ECON, V143, P132, DOI 10.1016/j.ijpe.2012.12.021
   Zelezny LC, 2000, J SOC ISSUES, V56, P443, DOI 10.1111/0022-4537.00177
   Zhang ZJ, 2019, RESOUR CONSERV RECY, V143, P45, DOI 10.1016/j.resconrec.2018.12.018
   Zucker L. G., RES SOCIOLOGY ORG
NR 72
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104402
DI 10.1016/j.resconrec.2019.06.036
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000007
DA 2020-05-12
ER

PT J
AU Law, KP
   Pagilla, KR
AF Law, Kam P.
   Pagilla, Krishna R.
TI Reclaimed phosphorus commodity reserve from water resource recovery
   facilities-A strategic regional concept towards phosphorus recovery
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Phosphorus recovery; Commodity P reserve; Present worth analysis; Sludge
   liquor; Sludge ashes; Biosolids
ID WASTE-WATER; MUNICIPAL; BIOSOLIDS; SUSTAINABILITY; AGRICULTURE;
   PHOSPHATE; REMOVAL; RELEASE; SLUDGE; FLOW
AB Despite all the right reasons for phosphorus (P) recovery, many water resource recovery facilities (WRRFs), especially for small WRRFs, cannot afford to implement P recovery technologies. This work systematically evaluated cost impacts of recovering P into fertilizer form from 80 major WRRFs in the Chicagoland area. Using a 20-year present worth analysis, results indicate that it would cost US$21 billion for all 80 major WRRFs to recover P into struvite fertilizer form. Based on unit cost analysis ($ per kg P recovered), P recovery from biosolids is cost-prohibitive due to high energy demand. P recovery from sludge liquor is economically viable but only up to 30% of the influent P load can be recovered. P recovery from sludge ashes is comparable with P recovery from sludge liquor or de-facto P recovery by biosolids land application from a cost perspective but it has the highest P recovery potential (up to 90% of the influent P loads) and lessens the increasing concern of transferring emerging contaminants from biosolids to crops through land application. This leads to a novel approach of a centralized, regional P recovery facility where WRRFs of all sizes can "dispose" of their biosolids for incineration and that P can be recovered as calcium phosphate from the sludge ashes and stored in a monofill as a commodity reserve for future use. This paper proved that the concept of building a commodity P reserve through a centralized P recovery facility is economically justifiable for all WRRFs within the region.
C1 [Law, Kam P.] Univ Nevada, Reno, NV 89557 USA.
   [Pagilla, Krishna R.] Univ Nevada, Dept Civil & Environm Engn, Reno, NV 89557 USA.
RP Law, KP (reprint author), Univ Nevada, Reno, NV 89557 USA.
EM klaw@nevada.unr.edu
CR Alvarez J, 2018, SCI TOTAL ENVIRON, V612, P995, DOI 10.1016/j.scitotenv.2017.08.299
   Amann A, 2018, RESOUR CONSERV RECY, V130, P127, DOI 10.1016/j.resconrec.2017.11.002
   [Anonymous], 2019, COST EST CLASS SYST
   Bi DS, 2013, WATER SCI TECHNOL, V67, P1953, DOI 10.2166/wst.2013.045
   Brandt RC, 2004, WATER ENVIRON RES, V76, P121, DOI 10.2175/106143004X141645
   Childers DL, 2011, BIOSCIENCE, V61, P117, DOI 10.1525/bio.2011.61.2.6
   Cohen Y., 2011, INTEGRATED WASTE MAN, VII, P247
   Cordell D, 2011, CHEMOSPHERE, V84, P747, DOI 10.1016/j.chemosphere.2011.02.032
   Cornel P, 2009, WATER SCI TECHNOL, V59, P1069, DOI 10.2166/wst.2009.045
   Desmidt E, 2015, CRIT REV ENV SCI TEC, V45, P336, DOI 10.1080/10643389.2013.866531
   Egle L, 2016, SCI TOTAL ENVIRON, V571, P522, DOI 10.1016/j.scitotenv.2016.07.019
   Egle L, 2015, RESOUR CONSERV RECY, V105, P325, DOI 10.1016/j.resconrec.2015.09.016
   Elser JJ, 2013, PHOSPHORUS FOOD OUR, P20
   Gable J., 2017, P ANN SUST SEM
   Haghi E., 2015, THE FIRST SUSTAINABL
   Jacobs B, 2017, ENVIRON SCI POLICY, V77, P151, DOI 10.1016/j.envsci.2017.08.009
   Ju LK, 2005, WATER ENVIRON RES, V77, P553, DOI 10.2175/106143005X67476
   Kinney CA, 2006, ENVIRON SCI TECHNOL, V40, P7207, DOI 10.1021/es0603406
   Law KP, 2018, WATER ENVIRON RES, V90, P840, DOI 10.2175/106143017X15131012188006
   Le Corre KS, 2009, CRIT REV ENV SCI TEC, V39, P433, DOI 10.1080/10643380701640573
   Lu Q., 2012, APPL ENVIRON SOIL SC, DOI DOI 10.1155/2012/201462
   Lwin CM, 2017, RESOUR CONSERV RECY, V122, P94, DOI 10.1016/j.resconrec.2017.01.017
   Mayer BK, 2016, ENVIRON SCI TECHNOL, V50, P6606, DOI 10.1021/acs.est.6b01239
   MENAR AB, 1970, ENVIRON SCI TECHNOL, V4, P1115, DOI 10.1021/es60047a005
   Mew MC, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10041087
   Moller K, 2018, ADV AGRON, V147, P159, DOI 10.1016/bs.agron.2017.10.004
   Mohapatra DP, 2016, WATER AIR SOIL POLL, V227, DOI 10.1007/s11270-016-2768-4
   Molinos-Senante M, 2011, AMBIO, V40, P408, DOI 10.1007/s13280-010-0101-9
   Nattorp A, 2017, WATER SCI TECHNOL, V76, P413, DOI 10.2166/wst.2017.212
   North East Biosolids and Residuals Association, 2007, FINAL REPORT
   O'Dette R. G., 1996, P 10 ANN RES BIOS MA
   Peng LH, 2018, WATER AIR SOIL POLL, V229, DOI 10.1007/s11270-018-3706-4
   Petzet S, 2013, ISS ENVIRON SCI TECH, V37, P110
   Petzet S, 2012, WATER ENVIRON RES, V84, P220, DOI 10.2175/106143012X13347678384125
   Riesman A., 2012, BOSTON GLOBE
   Rittmann BE, 2011, CHEMOSPHERE, V84, P846, DOI 10.1016/j.chemosphere.2011.02.001
   Roy ED, 2017, ECOL ENG, V98, P213, DOI 10.1016/j.ecoleng.2016.10.076
   Sartorius C, 2012, WATER ENVIRON RES, V84, P313, DOI 10.2175/106143012X13347678384440
   Sarvajayakesavalu S, 2018, ECOSYST HEALTH SUST, V4, P48, DOI 10.1080/20964129.2018.1460122
   Scholz RW, 2019, J IND ECOL, V23, P313, DOI 10.1111/jiec.12750
   Smil V, 2000, ANNU REV ENERG ENV, V25, P53, DOI 10.1146/annurev.energy.25.1.53
   Steen I., 2004, PHOSPHORUS ENV TECHN, P339
   Suh S, 2011, CHEMOSPHERE, V84, P806, DOI 10.1016/j.chemosphere.2011.01.051
   Tchobanoglous G., 2003, WASTEWATER ENG TREAT
   Tyagi VK, 2016, ENVIRONMENTAL MATERIALS AND WASTE: RESOURCE RECOVERY AND POLLUTION PREVENTION, P221, DOI 10.1016/B978-0-12-803837-6.00010-X
   United Nations (UN), 2015, WORLD POP PROJ REACH
   United States Census Bureau, 2012, TOP 20 CIT
   United States Environmental Protection Agency, 2000, 832F00064 EPA
   United States Environmental Protection Agency, 2003, 832F03013 EPA
   United States Environmental Protection Agency, 2013, EPA821R13001
   Wu XQ, 2015, SCI TOTAL ENVIRON, V536, P655, DOI 10.1016/j.scitotenv.2015.07.129
   Wuana RA, 2011, ISRN ECOL, V402647, P1, DOI [10.5402/2011/402647, DOI 10.5402/2011/402647]
   Ye YY, 2017, SCI TOTAL ENVIRON, V576, P159, DOI 10.1016/j.scitotenv.2016.10.078
   Yoshida H., 2013, PHOSPHORUS FOOD OUR, P112
   Zhou KX, 2017, J ENVIRON SCI, V52, P151, DOI 10.1016/j.jes.2016.04.010
NR 55
TC 0
Z9 0
U1 6
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104429
DI 10.1016/j.resconrec.2019.104429
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000015
DA 2020-05-12
ER

PT J
AU Leverenz, D
   Moussawel, S
   Maurer, C
   Hafner, G
   Schneider, F
   Schmidt, T
   Kranert, M
AF Leverenz, Dominik
   Moussawel, Salua
   Maurer, Claudia
   Hafner, Gerold
   Schneider, Felicitas
   Schmidt, Thomas
   Kranert, Martin
TI Quantifying the prevention potential of avoidable food waste in
   households using a self-reporting approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste prevention; Self-reporting; Kitchen diary; Consumer behavior;
   Behavioral changes; Sustainable Development Goals (SDG 12.3)
ID BEHAVIOR; BARRIERS
AB The prevention of avoidable food waste at consumer level is an issue of increasing importance, yet persists with no evident solution. Recently the Sustainable Development Goals of the United Nations (SDG) set a new challenge to overcome in sustainable consumption, namely the target 12.3 to halve food waste by 2030 at retail and consumer level. This paper aims to show that it is indeed possible for households to achieve this target using an approach that builds on positive effects of interventions and kitchen diaries. We present an intervention method that is not only beneficial to gather data regarding avoidable food waste in households, but also contributes to reduce it. In this context, we compared the short-term impacts of two different types of self-reporting and coaching methods to reduce avoidable food waste in households. Therefore we implemented in two separate panels of households in the same area once an offline-system and once a web-based online-system. The study outcomes are based on experimental data collected in these two sets of household panels demonstrating a clear improvement in the participant's behavior regarding food purchase and waste production. The main finding of our study is a reduction of avoidable food waste by more than 50% of fresh mass for both panels, showing that households can achieve this part of the SDG 12.3. Based on the method's effectiveness, we encourage its wider use and further development.
C1 [Leverenz, Dominik; Moussawel, Salua; Maurer, Claudia; Hafner, Gerold; Kranert, Martin] Univ Stuttgart, Inst Sanit Engn Water Qual & Solid Waste Manageme, Bandtale 2, D-70569 Stuttgart, Germany.
   [Schneider, Felicitas; Schmidt, Thomas] Fed Res Inst Rural Areas Forestry & Fisheries, Thunen Inst, Bundesallee 63, D-38116 Braunschweig, Germany.
RP Leverenz, D (reprint author), Univ Stuttgart, Inst Sanit Engn Water Qual & Solid Waste Manageme, Bandtale 2, D-70569 Stuttgart, Germany.
EM dominik.leverenz@iswa.uni-stuttgart.de;
   salua.moussawel@iswa.uni-stuttgart.de;
   claudia.maurer@iswa.uni-stuttgart.de;
   gerold.hafner@iswa.uni-stuttgart.de; felicitas.schneider@thuenen.de;
   thomas.schmidt@thuenen.de; martin.kranert@iswa.uni-stuttgart.de
RI Maurer, Claudia/AAF-7085-2020
OI Maurer, Claudia/0000-0003-3804-671X
FU European UnionEuropean Union (EU)
FX We greatly acknowledge the European Union for the financial support of
   the GreenCook project through the INTERREG IVB NWE Programme as part of
   its drive to find new ways to achieve more sustainable food and waste
   management throughout the European Union. We thank the
   Abfallverwertungsgesellschaft des Landkreises Ludwigsburg (AVL) for the
   collaboration during the entire process of data collection and for the
   support during operational processes. We also thank Ms. Dominika Gusia
   and Mr. Jakob Barabosz for their important work as part of their master
   theses and during their time at University of Stuttgart conducting
   experiments and evaluating data.
CR Alexandratos N., 2012, 1203 ESA FAO
   Corrado S, 2018, WASTE MANAGE, V79, P120, DOI 10.1016/j.wasman.2018.07.032
   Delley M, 2018, BRIT FOOD J, V120, P1504, DOI 10.1108/BFJ-09-2017-0486
   Delley M, 2017, RESOUR CONSERV RECY, V122, P172, DOI 10.1016/j.resconrec.2017.02.008
   DESTATIS, 2013, AUFK HAUSH DEUTSCHL
   Elimelech E, 2018, WASTE MANAGE, V76, P68, DOI 10.1016/j.wasman.2018.03.031
   Falcon J., 2008, LOVE FOOD CHAMPIONS
   Gelbmann U., 2018, VORTRAGE KONF 14 REC, P407
   Gobel Christine, 2012, VERRINGERUNG LEBENSM
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Hafner Gerold, 2012, ERMITTLUNG WEGGEWORF
   Hanssen OJ, 2016, RESOUR CONSERV RECY, V109, P146, DOI 10.1016/j.resconrec.2016.03.010
   Hebrok M, 2017, J CLEAN PROD, V151, P380, DOI 10.1016/j.jclepro.2017.03.069
   Hubsch Helmut, 2017, TAGEBUCH ZEITRAU JUL
   Jorissen J, 2015, SUSTAINABILITY-BASEL, V7, P2695, DOI 10.3390/su7032695
   Katajajuuri JM, 2014, J CLEAN PROD, V73, P322, DOI 10.1016/j.jclepro.2013.12.057
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Ogwueleka TC, 2013, RESOUR CONSERV RECY, V77, P52, DOI 10.1016/j.resconrec.2013.05.011
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Quested T., 2009, HOUSEHOLD FOOD DRINK
   Richter B, 2017, RESOUR CONSERV RECY, V125, P181, DOI 10.1016/j.resconrec.2017.06.006
   Russell SV, 2017, RESOUR CONSERV RECY, V125, P107, DOI 10.1016/j.resconrec.2017.06.007
   Schneider F., 2016, THESIS
   Shaw Peter J., 2018, Recycling, V3, DOI 10.3390/recycling3020024
   Smith M. M., P SUM 2014 2 S URB M
   Statistik-BW, 2018, HAUSH DURCHSCHN HAUS
   Statistik-BW, 2018, BEV NACH NAT VIERT 2
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   Stenmarck A., 2016, ESTIMATES EUROPEAN F
   Thaler RH, 2009, NUDGE IMPROVING DECI
   Vanham D, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084008
   Visschers VHM, 2016, J ENVIRON PSYCHOL, V45, P66, DOI 10.1016/j.jenvp.2015.11.007
   Williams H, 2012, J CLEAN PROD, V24, P141, DOI 10.1016/j.jclepro.2011.11.044
   Young W, 2017, RESOUR CONSERV RECY, V117, P195, DOI 10.1016/j.resconrec.2016.10.016
NR 35
TC 1
Z9 1
U1 9
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104417
DI 10.1016/j.resconrec.2019.104417
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000010
OA Other Gold
DA 2020-05-12
ER

PT J
AU Li, Y
   Ding, RG
   Cui, L
   Lei, ZM
   Mou, J
AF Li, Ying
   Ding, Ronggui
   Cui, Li
   Lei, Zhimei
   Mou, Jian
TI The impact of sharing economy practices on sustainability performance in
   the Chinese construction industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sharing economy; Sustainability performance; Construction projects;
   Digital platform; Structural equation modelling
ID STRUCTURAL EQUATION MODELS; SOCIAL-RESPONSIBILITY; CORPORATE; FRAMEWORK;
   PROJECTS; PATHWAY; JUSTICE
AB The sharing economy is gradually reshaping the construction industry. This study identifies the use of digital platforms, internal sharing practices with project stakeholders, and external sharing practices with unfamiliar companies as three critical elements of sharing economy practices from a socio-technical perspective. The impacts of these three elements on sustainability performance, including economic performance, environmental performance and social performance, are investigated. Based on a survey of the Chinese construction industry, proposed hypotheses are tested using structural equation modelling. The results indicate that the use of digital platforms can promote both internal and external sharing practices in the construction industry. While internal sharing practices have positive impacts on the three dimensions of sustainability performance, external sharing practices can positively influence only environmental performance. The findings enhance the understanding of sharing economy practices and provide empirical evidence of the relationships between sharing economy practices and sustainability performance in the construction sector.
C1 [Li, Ying; Ding, Ronggui] Shandong Univ, Sch Management, 27 Shanda Nan Rd, Jinan 250100, Shandong, Peoples R China.
   [Cui, Li] Dalian Univ Technol, Sch Business, 2 Dagong Rd, Panjin 124010, Peoples R China.
   [Lei, Zhimei] Chongqing Univ, Coll Mech Engn, 174 Shazhengjie, Chongqing 400044, Peoples R China.
   [Mou, Jian] Xidian Univ, Sch Econ & Management, 266 Xinglong Sect,Xifeng Rd, Xian 710126, Shaanxi, Peoples R China.
RP Lei, ZM (reprint author), Chongqing Univ, Coll Mech Engn, 174 Shazhengjie, Chongqing 400044, Peoples R China.
EM zhimeilei@cqu.edu.cn
CR Acquier A, 2017, TECHNOL FORECAST SOC, V125, P1, DOI 10.1016/j.techfore.2017.07.006
   Aibinu AA, 2011, CONSTR MANAG ECON, V29, P463, DOI 10.1080/01446193.2011.564195
   ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411
   Belk R, 2007, ANN AM ACAD POLIT SS, V611, P126, DOI 10.1177/0002716206298483
   Belk R, 2014, ANTHROPOLOGIST, V18, P7
   Belk R, 2010, J CONSUM RES, V36, P715, DOI 10.1086/612649
   Black C., 2000, INT J PROJ MANAG, V18, P423, DOI DOI 10.1016/S0263-7863(99)00046-0
   Botsman Rachel, 2010, WHATS MINE IS YOURS
   Braglia M, 2014, INT J PROJ MANAG, V32, P18, DOI 10.1016/j.ijproman.2012.12.003
   Carter CR, 2002, TRANSPORT RES E-LOG, V38, P37, DOI 10.1016/S1366-5545(01)00008-4
   Chang Y, 2018, RESOUR CONSERV RECY, V139, P259, DOI 10.1016/j.resconrec.2018.08.025
   Cheng MM, 2016, INT J HOSP MANAG, V57, P60, DOI 10.1016/j.ijhm.2016.06.003
   Comrey A. L, 1973, J R STAT SOC, V43, P332
   Casanovas-Rubio MD, 2017, RESOUR CONSERV RECY, V126, P107, DOI 10.1016/j.resconrec.2017.07.035
   Eriksson PE, 2015, J PURCH SUPPLY MANAG, V21, P38, DOI 10.1016/j.pursup.2014.08.003
   Fang B, 2016, ANN TOURISM RES, V57, P264, DOI 10.1016/j.annals.2015.11.018
   Firnkorn J, 2011, ECOL ECON, V70, P1519, DOI 10.1016/j.ecolecon.2011.03.014
   FORNELL C, 1982, J MARKETING RES, V19, P440, DOI 10.2307/3151718
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fraccascia L, 2018, RESOUR CONSERV RECY, V136, P473, DOI 10.1016/j.resconrec.2018.03.009
   Frenken K, 2017, ANN TOURIS RES, V23
   Gong MF, 2018, RESOUR CONSERV RECY, V128, P155, DOI 10.1016/j.resconrec.2016.11.001
   Govindan K, 2013, J CLEAN PROD, V47, P345, DOI 10.1016/j.jclepro.2012.04.014
   Gregory A, 2016, PUBLIC RELAT REV, V43
   Haas C, 2017, IMPACT SHARING GIG E
   Habibi M. R., 2016, J ASS CONSUMER RES, V1, P277, DOI DOI 10.1086/684685
   Habibi MR, 2017, BUS HORIZONS, V60, P113, DOI 10.1016/j.bushor.2016.09.007
   Hair JF, 1998, MULTIVARIATE DATA AN
   Hair Jr JF, 2016, PRIMER PARTIAL LEAST
   Hall J, 2016, ALAN KRUEGER, V71
   Hamari J, 2016, J ASSOC INF SCI TECH, V67, P2047, DOI 10.1002/asi.23552
   Heinrichs H, 2013, GAIA, V22, P228, DOI 10.14512/gaia.22.4.5
   Henseler J, 2015, J ACAD MARKET SCI, V43, P115, DOI 10.1007/s11747-014-0403-8
   Keeble JJ, 2003, J BUS ETHICS, V44, P149, DOI 10.1023/A:1023343614973
   Kim SY, 2018, PROD PLAN CONTROL, V29, P170, DOI 10.1080/09537287.2017.1398846
   Kumar V, 2018, IND MARKET MANAG, V69, P147, DOI 10.1016/j.indmarman.2017.08.021
   Kupriyanovsky V, 2017, INT J OPEN INFORM TE, V5, P56
   Larson E, 1997, IEEE T ENG MANAGE, V44, P188, DOI 10.1109/17.584926
   Lim BTH, 2017, INT J PROJ MANAG, V35, P95, DOI 10.1016/j.ijproman.2016.10.016
   Lindner J.R., 2001, J AGR ED, V42, P43, DOI DOI 10.5032/JAE.2001.04043
   Mair J, 2017, TECHNOL FORECAST SOC, V125, P11, DOI 10.1016/j.techfore.2017.05.023
   Malhotra A, 2014, COMMUN ACM, V57, P24, DOI 10.1145/2668893
   Martin CJ, 2016, ECOL ECON, V121, P149, DOI 10.1016/j.ecolecon.2015.11.027
   Miao CL, 2017, RESOUR CONSERV RECY, V126, P153, DOI 10.1016/j.resconrec.2017.07.019
   Morioka SN, 2016, J CLEAN PROD, V136, P134, DOI 10.1016/j.jclepro.2016.01.104
   Munoz P, 2017, TECHNOL FORECAST SOC, V125, P21, DOI 10.1016/j.techfore.2017.03.035
   Nunnally J.C., 1978, PSYCHOMETRIC THEORY
   PODSAKOFF PM, 1986, J MANAGE, V12, P531, DOI 10.1177/014920638601200408
   Ranchordas S, 2015, DOES SHARING MEAN CA
   Srineck N, 2016, PLATFORM CAPITALISM
   Suprapto M, 2016, INT J PROJ MANAG, V34, P1071, DOI 10.1016/j.ijproman.2015.08.003
   ul Musawir A, 2017, INT J PROJ MANAG, V35, P1658, DOI 10.1016/j.ijproman.2017.07.007
   Wang G, 2017, INT J PROJ MANAG, V35, P1402, DOI 10.1016/j.ijproman.2017.04.008
   Weber TA, 2014, J MANAGE INFORM SYST, V31, P35, DOI 10.1080/07421222.2014.995520
   Wong JKW, 2015, AUTOMAT CONSTR, V57, P156, DOI 10.1016/j.autcon.2015.06.003
   Wu CL, 2015, J CLEAN PROD, V107, P185, DOI 10.1016/j.jclepro.2015.04.143
   Zervas G, 2013, RISE SHARING EC ESTI
   Zhang LY, 2017, INT J PROJ MANAG, V35, P516, DOI 10.1016/j.ijproman.2016.12.003
   Zhao XB, 2016, J MANAGE ENG, V32, DOI 10.1061/(ASCE)ME.1943-5479.0000434
NR 59
TC 0
Z9 0
U1 16
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104409
DI 10.1016/j.resconrec.2019.104409
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000009
DA 2020-05-12
ER

PT J
AU Liu, Y
   Wang, SJ
   Qiao, ZX
   Wang, YH
   Ding, YY
   Miao, CH
AF Liu, Yong
   Wang, Shaojian
   Qiao, Zengxuan
   Wang, Yunhao
   Ding, Yinying
   Miao, Changhong
TI Estimating the dynamic effects of socioeconomic development on
   industrial SO2 emissions in Chinese cities using a DPSIR causal
   framework
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE SO2 emissions; DPSIR framework; Variation effects; Weighted Least
   squares model; China
ID ENVIRONMENTAL KUZNETS CURVE; FOREIGN DIRECT-INVESTMENT; URBAN
   AIR-QUALITY; POLLUTANT EMISSIONS; ENERGY-CONSUMPTION; CO2 EMISSIONS;
   DECOMPOSITION ANALYSIS; TEMPORAL VARIATION; ECONOMIC-GROWTH; IMPACT
AB Much of the previous literature has identified limited influencing factors in relation to industrial SO2 emissions while ignoring the dynamic trends of these factors. Therefore, this paper promotes a Drivers-Pressures-State Impact-Response (DPSIR) framework to investigate the critical socioeconomic influencing factors of SO2 emissions in China at the city level. To solve the heteroscedasticity of the data, this paper analyzes multiple time points (two-year periods) from 2004 to 2016 based on the WLS model to capture the variations of these factors. The empirical results reveal that, during the study period, the urbanization process continuously contributes to the reduction of SO2 emissions in China through the scale effect of population aggregation; the positive contribution made by economic growth has steadily risen; and the optimization of the industrial structure has gradually decreased emissions, demonstrating the benefits of implementing effective desulfurization policies. The positive contribution of industrial land-use intensity is shown to have gradually decreased due to improvements in energy efficiency. The current government policies such as command-controlled environmental regulation and biased government technical input are found to have increased SO2 emissions. Improvements at the corporate level are shown to have helped to improve environmental pollution. The positive contribution effect of markets on SO2 emissions shows a decreasing trend with a degree of fluctuation. These findings provide a comprehensive insight into the task of understanding the key socioeconomic impact factors of industrial SO2 emissions and their dynamics against the backdrop of sustainable development.
C1 [Liu, Yong; Qiao, Zengxuan; Ding, Yinying; Miao, Changhong] Henan Univ, Key Res Inst Yellow River Civilizat & Sustainable, Kaifeng 475004, Peoples R China.
   [Liu, Yong; Qiao, Zengxuan; Ding, Yinying; Miao, Changhong] Henan Univ, Collaborat Innovat Ctr Urban Rural Coordinated De, Kaifeng 475004, Peoples R China.
   [Liu, Yong; Miao, Changhong] Henan Univ, Coll Environm & Planning, Kaifeng 475004, Peoples R China.
   [Wang, Shaojian] Sun Yat Sen Univ, Guangdong Prov Key Lab Urbanizat & Geosimulat, Sch Geog & Planning, Guangzhou 510275, Guangdong, Peoples R China.
   [Wang, Yunhao] Northeast Normal Univ, Sch Econ, Changchun 130117, Jilin, Peoples R China.
RP Miao, CH (reprint author), Henan Univ, Key Res Inst Yellow River Civilizat & Sustainable, Kaifeng 475004, Peoples R China.; Miao, CH (reprint author), Henan Univ, Collaborat Innovat Ctr Urban Rural Coordinated De, Kaifeng 475004, Peoples R China.; Wang, SJ (reprint author), Sun Yat Sen Univ, Guangdong Prov Key Lab Urbanizat & Geosimulat, Sch Geog & Planning, Guangzhou 510275, Guangdong, Peoples R China.
EM wanghj8@mail.sysu.edu.cn; chhmiao@henu.edu.cn
OI Wang, Yunhao/0000-0002-1242-7023
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41701129, 41430637]; Soft Science Research of
   Technology Development Projects of Henan Province [192400410253,
   192400410083]; Guangdong Special Support Program; Pearl River S&T Nova
   Program of Guangzhou [201806010187]; China Scholarship CouncilChina
   Scholarship Council [201806385014]
FX This work was supported by National Natural Science Foundation of China
   (41701129; 41430637), Soft Science Research of Technology Development
   Projects of Henan Province (192400410253; 192400410083), the Guangdong
   Special Support Program, Pearl River S&T Nova Program of Guangzhou
   (201806010187), and China Scholarship Council (201806385014).
CR Bar R, 2015, ENVIRON SCI POLICY, V46, P57, DOI 10.1016/j.envsci.2014.04.008
   Bidone ED, 2004, REG ENVIRON CHANGE, V4, P5, DOI 10.1007/s10113-003-0059-2
   Brook RD, 2018, AM J HYPERTENS, V31, P1, DOI 10.1093/ajh/hpx109
   Cash DW, 2003, P NATL ACAD SCI USA, V100, P8086, DOI 10.1073/pnas.1231332100
   Chang M, 2018, J CLEAN PROD, V189, P240, DOI 10.1016/j.jclepro.2018.02.111
   Cole MA, 2004, POPUL ENVIRON, V26, P5, DOI 10.1023/B:POEN.0000039950.85422.eb
   COMMONER B, 1971, ENVIRONMENT, V13, P2, DOI 10.1080/00139157.1971.9930577
   Copeland BR, 2004, J ECON LIT, V42, P7, DOI 10.1257/002205104773558047
   Dean JM, 2009, J DEV ECON, V90, P1, DOI 10.1016/j.jdeveco.2008.11.007
   Diab RD, 2007, S AFR GEOGR J, V89, P22, DOI 10.1080/03736245.2007.9713869
   Dinda S, 2004, ECOL ECON, V49, P431, DOI 10.1016/j.ecolecon.2004.02.011
   Dong L, 2015, J CLEAN PROD, V90, P345, DOI 10.1016/j.jclepro.2014.10.101
   Edith S, 1999, ENVIRONMENTAL INDICA
   EHRLICH PR, 1971, SCIENCE, V171, P1212, DOI 10.1126/science.171.3977.1212
   Fang CL, 2015, SUSTAINABILITY-BASEL, V7, P15570, DOI 10.3390/su71115570
   Fosten J, 2012, ECOL ECON, V76, P25, DOI 10.1016/j.ecolecon.2012.01.023
   Guariso G, 2016, ENVIRON SCI POLICY, V65, P3, DOI 10.1016/j.envsci.2016.05.001
   Han LJ, 2014, ENVIRON POLLUT, V194, P163, DOI 10.1016/j.envpol.2014.07.022
   Hao Y, 2018, J CLEAN PROD, V188, P966, DOI 10.1016/j.jclepro.2018.04.003
   He CF, 2014, STOCH ENV RES RISK A, V28, P767, DOI 10.1007/s00477-013-0736-8
   He CF, 2012, URBAN STUD, V49, P1767, DOI 10.1177/0042098011415719
   He J, 2010, ECOL ECON, V69, P868, DOI 10.1016/j.ecolecon.2009.10.012
   He J, 2009, ENVIRON DEV ECON, V14, P227, DOI 10.1017/S1355770X0800452X
   He QC, 2015, CHINA ECON REV, V36, P86, DOI 10.1016/j.chieco.2015.08.010
   Hu XH, 2018, J CLEAN PROD, V186, P997, DOI 10.1016/j.jclepro.2018.03.144
   Huang JT, 2018, J CLEAN PROD, V175, P431, DOI 10.1016/j.jclepro.2017.12.001
   Jaffe AB, 2005, ECOL ECON, V54, P164, DOI 10.1016/j.ecolecon.2004.12.027
   Jiang ZJ, 2012, ENERG POLICY, V49, P608, DOI 10.1016/j.enpol.2012.07.002
   Jiao JL, 2017, J CLEAN PROD, V164, P1455, DOI 10.1016/j.jclepro.2017.07.060
   Li Q, 2014, STOCH ENV RES RISK A, V28, P429, DOI 10.1007/s00477-013-0762-6
   Li SK, 2017, J CLEAN PROD, V163, pS359, DOI 10.1016/j.jclepro.2015.10.127
   Liddle B, 2014, POPUL ENVIRON, V35, P286, DOI 10.1007/s11111-013-0198-4
   Lin BQ, 2018, J CLEAN PROD, V188, P312, DOI 10.1016/j.jclepro.2018.03.293
   Lin T, 2007, COAST MANAGE, V35, P289, DOI 10.1080/08920750601169592
   List JA, 2000, J ENVIRON ECON MANAG, V40, P1, DOI 10.1006/jeem.1999.1095
   Liu C, 2018, ENERG POLICY, V121, P300, DOI 10.1016/j.enpol.2018.06.039
   Liu JG, 2005, NATURE, V435, P1179, DOI 10.1038/4351179a
   Liu QL, 2017, SCI TOTAL ENVIRON, V574, P1104, DOI 10.1016/j.scitotenv.2016.08.176
   Liu QL, 2015, ECOL ECON, V113, P39, DOI 10.1016/j.ecolecon.2015.02.026
   Liu QL, 2013, ENVIRON SCI POLICY, V33, P405, DOI 10.1016/j.envsci.2013.08.003
   Liu SX, 2017, CLEAN TECHNOL ENVIR, V19, P2327, DOI 10.1007/s10098-017-1407-0
   Liu YS, 2015, APPL ENERG, V155, P904, DOI 10.1016/j.apenergy.2015.06.051
   Lorek S, 2014, J CLEAN PROD, V63, P33, DOI 10.1016/j.jclepro.2013.08.045
   Lu Z, 2010, ATMOS CHEM PHYS, V10, P6311, DOI 10.5194/acp-10-6311-2010
   PORTER ME, 1995, J ECON PERSPECT, V9, P97, DOI 10.1257/jep.9.4.97
   Relvas H, 2018, AIR QUAL ATMOS HLTH, V11, P1069, DOI 10.1007/s11869-018-0609-x
   Gari SR, 2015, OCEAN COAST MANAGE, V103, P63, DOI 10.1016/j.ocecoaman.2014.11.013
   SELDEN TM, 1994, J ENVIRON ECON MANAG, V27, P147, DOI 10.1006/jeem.1994.1031
   Sinha A, 2017, ECOL INDIC, V72, P881, DOI 10.1016/j.ecolind.2016.09.018
   [孙雪丽 Sun Xueli], 2016, [环境科学学报, Acta Scientiae Circumstantiae], V36, P4253
   Wagner UJ, 2009, ENVIRON RESOUR ECON, V43, P231, DOI 10.1007/s10640-008-9236-6
   Wang Q, 2016, RENEW SUST ENERG REV, V54, P1563, DOI 10.1016/j.rser.2015.10.090
   Wang SJ, 2019, RENEW SUST ENERG REV, V103, P140, DOI 10.1016/j.rser.2018.12.046
   Wang SJ, 2018, APPL ENERG, V228, P1693, DOI 10.1016/j.apenergy.2018.06.155
   Wang SJ, 2018, J CLEAN PROD, V203, P143, DOI 10.1016/j.jclepro.2018.08.249
   Wang SJ, 2017, J CLEAN PROD, V142, P1800, DOI 10.1016/j.jclepro.2016.11.104
   Wang Y, 2016, RENEW SUST ENERG REV, V54, P1182, DOI 10.1016/j.rser.2015.10.143
   Yang X, 2018, ENVIRON POLLUT, V241, P172, DOI 10.1016/j.envpol.2018.05.052
   Yang X, 2017, J CLEAN PROD, V167, P824, DOI 10.1016/j.jclepro.2017.08.215
   Yang X, 2016, APPL ENERG, V184, P714, DOI 10.1016/j.apenergy.2016.11.013
   Yao XL, 2018, ENVIRON IMPACT ASSES, V71, P70, DOI 10.1016/j.eiar.2018.04.005
   York R, 2003, ECOL ECON, V46, P351, DOI 10.1016/S0921-8009(03)00188-5
   Zhang CH, 2011, ECOL ECON, V70, P2369, DOI 10.1016/j.ecolecon.2011.07.019
   Zhang XP, 2009, ECOL ECON, V68, P2706, DOI 10.1016/j.ecolecon.2009.05.011
   Zhang Y, 2018, J CLEAN PROD, V188, P763, DOI 10.1016/j.jclepro.2018.04.013
   Zhou GH, 2015, HABITAT INT, V50, P289, DOI 10.1016/j.habitatint.2015.09.001
   Zhou Y, 2017, HABITAT INT, V60, P10, DOI 10.1016/j.habitatint.2016.12.002
   Zhu L, 2017, J CLEAN PROD, V166, P189, DOI 10.1016/j.jclepro.2017.08.032
NR 68
TC 3
Z9 3
U1 17
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104450
DI 10.1016/j.resconrec.2019.104450
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000037
DA 2020-05-12
ER

PT J
AU Merciai, S
AF Merciai, Stefano
TI An input-output model in a balanced multi-layer framework
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Input-output model; Hybrid input-output tables; Integrated economic and
   environmental model; Structural economics; Mass flow analysis
ID LIFE-CYCLE ASSESSMENT; CHOICE; CONSTRUCTION; ALLOCATION; ISSUES; TABLES
AB Production or consumption processes can be seen as a transformation of inputs into outputs. Some of these flows may have a market value, therefore they have a price and can be accounted in monetary units. Some others, for example, might only be accounted in mass units, or in energy units or even in some other metrics, such as hours,items and so forth. Therefore, a framework that uses many metrics is necessary for describing the complexity of reality.
   Secondly, there are unquestionable laws that rule our world, such as the laws of Thermodynamics. Production or consumption processes also obey to these laws. In practice, this means that for any input there must always be outputs that obey these laws.
   Given these preconditions, the paper introduces a multi-layer supply and use framework, where each layer is balanced and accounted in a single metric. Then an input-output model is built upon this multi-layer framework. The model adopts the Stone's method, which is more known as the by-product technology assumption. Furthermore, endogenous matrices of technical coefficients are presented. This means that technical coefficients are not predetermined and kept fixed when running a simulation. Rather, they are endogenous variables that change according to the implemented analysis. Finally, the model makes use of linear programming techniques instead of implementing the Leontief inverse.
C1 [Merciai, Stefano] Rendsburggade 14, DK-9000 Aalborg, Denmark.
RP Merciai, S (reprint author), Rendsburggade 14, DK-9000 Aalborg, Denmark.
EM stefano.merciai@lca-net.com
CR Commission European, 2010, INT REF LIF CYCL DAT, DOI [10.2788/38479, DOI 10.2788/38479]
   Duchin F., 2005, ECON SYST RES, V17, P141, DOI DOI 10.1080/09535310500114903
   Duchin F, 2011, ECON SYST RES, V23, P281, DOI 10.1080/09535314.2011.571238
   EC IMF OECD UN WB, 2008, SYST NAT ACC 2008, P1, DOI [10.1057/ukna.2008.3, DOI 10.1057/UKNA.2008.3, 10. 1057/ukna. 2008. 3]
   Hawkins T, 2007, ENVIRON SCI TECHNOL, V41, P1024, DOI 10.1021/es060871u
   Hoekstra R, 2005, THESIS
   Hoekstra R, 2006, ECOL ECON, V59, P375, DOI 10.1016/j.ecolecon.2005.11.005
   Kondo Y, 2005, ECON SYST RES, V17, P393, DOI DOI 10.1080/09535310500283526
   LEONTIEF W, 1970, REV ECON STAT, V52, P262, DOI 10.2307/1926294
   LEONTIEF W, 1941, STRUCTURE AM EC 1919
   Luenberger D. G., 2008, LINEAR NONLINEAR PRO
   Majeau-Bettez G, 2016, ECOL ECON, V126, P188, DOI 10.1016/j.ecolecon.2016.02.017
   Majeau-Bettez G, 2016, J IND ECOL, V20, P67, DOI 10.1111/jiec.12273
   Merciai S, 2016, FP7 EU DESIRE
   Merciai S, 2010, 18 INT INP OUTP C 20
   Merciai S, 2018, J IND ECOL, V22, P516, DOI 10.1111/jiec.12713
   Merciai S, 2014, ECOL ECON, V102, P69, DOI 10.1016/j.ecolecon.2014.03.016
   Miller R. E, 2008, INPUT OUTPUT ANAL FD
   Nakamura S, 2009, ECO-EFFIC IND SCI, V26, P1
   Pauliuk S, 2015, J IND ECOL, V19, P728, DOI 10.1111/jiec.12306
   Rueda-Cantuche JM, 2009, ECON SYST RES, V21, P363, DOI 10.1080/09535310903208344
   Schmidhuber J, 2010, LECT NOTES ARTIF INT, V6321, P6, DOI 10.1007/978-3-642-15880-3_6
   Schmidt J. H, 2012, RECOMMENDATION TERMI
   Springer NP, 2018, RESOUR CONSERV RECY, V138, P231, DOI 10.1016/j.resconrec.2018.07.034
   Stadler K, 2018, J IND ECOL, V22, P502, DOI 10.1111/jiec.12715
   Stahmer C, 2000, 13 INT C INP OUTP TE
   Stone R., 1961, INPUT OUTPUT NATL AC
   Suh S, 2010, J IND ECOL, V14, P335, DOI 10.1111/j.1530-9290.2010.00235.x
   United Nations, 1969, SYST NAT ACC 1968
   Weidema B., 2009, GUIDELINES APPL DEEP
   Weidema B.P., 2013, OVERVIEW METHODOLOGY
   Weidema BP, 2010, J IND ECOL, V14, P192, DOI 10.1111/j.1530-9290.2010.00236.x
   Weidema BP, 2018, INT J LIFE CYCLE ASS, V23, P1839, DOI 10.1007/s11367-017-1398-4
   Weisz H, 2006, ECOL ECON, V57, P534, DOI 10.1016/j.ecolecon.2005.05.011
   YU M, 2018, J EC STRUCTURES, V7, P33, DOI DOI 10.1186/S40008-018-0131-1
NR 35
TC 0
Z9 0
U1 4
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104403
DI 10.1016/j.resconrec.2019.06.037
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000040
DA 2020-05-12
ER

PT J
AU Millette, S
   Williams, E
   Hull, CE
AF Millette, Sherwyn
   Williams, Eric
   Hull, Clyde Eirikur
TI Materials flow analysis in support of circular economy development:
   Plastics in Trinidad and Tobago
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Material flow analysis; Circular economy; Plastic flows; Developing
   economy; Recycling
ID ALTERNATIVE FUELS; CEMENT INDUSTRY; SOLID-WASTE; CONCRETE; CHINA; STEEL;
   IRON; PVC
AB Can material flow analysis (MFA) support strategic decisions necessary for the development of circular economy (CE) in a developing country? MFA can be an essential tool in providing necessary data inputs for decisions related to the development of CE. Data-poor environments in developing economies, however, e.g. lack of data on physical flows in manufacturing, pose challenges to doing MFA. Other data however, in particular trade statistics accounting for shipment mass, are often available. We undertake a case study to characterize plastic flows in Trinidad and Tobago (T&T) for 2016, demonstrating how leveraging such data enables MFA. A notable result from the MFA is that much (48%) of the landfilled plastic in T&T comes from plastic packaging for imported products rather than intentional domestic use. This is an example of what is probably a typical CE challenge for island nations: Importing materials with limited domestic demand at end-of-life. We use the MFA results to propose suggestions for a more circular flow of plastics in T&T. First, there is potential to divert plastic waste (including packaging plastic) for use as feedstock in a local cement plant. Second, the scale of PET plastic flows is of sufficient scale (26,000 metric tons annually) to make domestic recycle feasible. Techno-economic studies are needed to properly develop and evaluate these proposals, the role of the MFA here is to identify promising directions.
C1 [Millette, Sherwyn; Williams, Eric] Rochester Inst Technol, Golisano Inst Sustainabil, 190 Lomb Mem Dr, Rochester, NY 14623 USA.
   [Hull, Clyde Eirikur] Rochester Inst Technol, Saunders Coll Business, 190 Lomb Mem Dr, Rochester, NY 14623 USA.
   [Millette, Sherwyn] Pierre Rd Connector, Chaguanas, Trinid & Tobago.
RP Millette, S (reprint author), Rochester Inst Technol, Golisano Inst Sustainabil, 190 Lomb Mem Dr, Rochester, NY 14623 USA.; Millette, S (reprint author), Pierre Rd Connector, Chaguanas, Trinid & Tobago.
EM sm2004@rit.edu; exwgis@rit.edu; chull@saunders.rit.edu
CR Achilias DS, 2007, J HAZARD MATER, V149, P536, DOI 10.1016/j.jhazmat.2007.06.076
   Allong M., 2018, RE QUALITY HLTH SAFE
   Bao Z., 2010, REV MAT FLOW ANAL
   Barlow CY, 2013, RESOUR CONSERV RECY, V78, P74, DOI 10.1016/j.resconrec.2013.07.003
   Beckles D. M., 2016, IMPACT CONTAMINANTS
   Beston Henan M. C. L., 2018, WASTE PLASTIC RECYCL
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   CBCL, 2010, TRIN SOL WAST MAN PR
   Central Statistical Office of Trinidad and Tobago, 2018, POP MID EST
   Chatziaras N, 2016, MANAG ENVIRON QUAL, V27, P178, DOI 10.1108/MEQ-01-2015-0012
   Chen WQ, 2012, ENVIRON SCI TECHNOL, V46, P8574, DOI 10.1021/es3010333
   Chertow M, 2008, REG STUD, V42, P1299, DOI 10.1080/00343400701874123
   Ciacci L, 2017, RESOUR CONSERV RECY, V123, P108, DOI 10.1016/j.resconrec.2016.08.008
   D'Amato D, 2017, J CLEAN PROD, V168, P716, DOI 10.1016/j.jclepro.2017.09.053
   Dahlstrom K, 2006, ECOL ECON, V58, P507, DOI 10.1016/j.ecolecon.2005.07.024
   Danius L, 2001, REGIONAL MAT FLOW AN, P10
   Deschenes P.J, 2004, J ENVIRON PLANN MAN, V47, P201, DOI DOI 10.1080/0964056042000209102
   Dhawan R, 2019, PROCESS SAF ENVIRON, V124, P299, DOI 10.1016/j.psep.2019.02.018
   Fischer-Kowalski M, 2011, J IND ECOL, V15, P855, DOI 10.1111/j.1530-9290.2011.00366.x
   FROSCH RA, 1989, SCI AM, V261, P144, DOI 10.1038/scientificamerican0989-144
   Garg A, 2009, WASTE MANAGE, V29, P2289, DOI 10.1016/j.wasman.2009.03.031
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   GILJUM S, 2004, J IND ECOL, V8, P241, DOI DOI 10.1162/1088198041269418
   Government of The Republic of Trinidad and Tobago, 2017, CONS MONTHL B JAN DE
   [Government of Trinidad and Tobago Ministry of Trade and Industry], 2007, T T HSTARIFF07 FIN
   [Government of Trinidad & Tobago Ministry of Planning and Development], 2015, NAT WAST REC POL
   He ZG, 2015, ENVIRON INT, V77, P85, DOI 10.1016/j.envint.2015.01.004
   Hicks A, 2018, SUSTAIN J REC, V11, P29
   Hopewell J, 2009, PHILOS T R SOC B, V364, P2115, DOI 10.1098/rstb.2008.0311
   [International Monetary Fund Fund I. M.], 2018, M01 INT FIN STAT IFS
   Kahhat R, 2009, ENVIRON SCI TECHNOL, V43, P6010, DOI 10.1021/es8035835
   Krausmann F, 2014, J IND ECOL, V18, P294, DOI 10.1111/jiec.12100
   Kuczenski B, 2010, RESOUR CONSERV RECY, V54, P1161, DOI 10.1016/j.resconrec.2010.03.013
   Lamas WD, 2013, RENEW SUST ENERG REV, V19, P200, DOI 10.1016/j.rser.2012.11.015
   Laner D, 2016, J IND ECOL, V20, P1050, DOI 10.1111/jiec.12326
   Lassen C., 2000, PARADIGM SUBSTANCE F
   Littlemore J, 2013, REV ESP LINGUIST APL, P23
   MacArthur E., 2013, J IND ECOL, V2, P23
   Marzolf N. C., 2015, UNIQUE APPROACH SUST
   Mckinsey, 2012, CIRC EC EC BUS RAT A
   Menges G, 1996, PURE APPL CHEM, V68, P1809, DOI 10.1351/pac199668091809
   Mokrzycki E, 2003, APPL ENERG, V74, P95, DOI 10.1016/S0306-2619(02)00135-6
   MPD, 2019, GOV APPR BAN STYR T
   Murray A, 2008, USE ALTERNATIVE FUEL
   Mutha NH, 2006, RESOUR CONSERV RECY, V47, P222, DOI 10.1016/j.resconrec.2005.09.003
   Nakem S., 2016, COMPUTER AIDED CHEM
   Ness D, 2008, INT J SUST DEV WORLD, V15, P288, DOI 10.3843/SusDev.15.4:2
   Office C. S, 2016, TRAD DAT 2016
   Owens EL, 2011, J ENVIRON ENG-ASCE, V137, P937, DOI 10.1061/(ASCE)EE.1943-7870.0000399
   Park JA, 2011, RESOUR CONSERV RECY, V55, P456, DOI 10.1016/j.resconrec.2010.12.007
   Pauliuk S, 2013, RESOUR CONSERV RECY, V71, P22, DOI 10.1016/j.resconrec.2012.11.008
   Pratt K, 2016, CARBON BAL MANAGE, V11, DOI 10.1186/s13021-016-0063-8
   Rahman A, 2015, FUEL, V145, P84, DOI 10.1016/j.fuel.2014.12.029
   Rahman A, 2013, PROCEDIA ENGINEER, V56, P393, DOI 10.1016/j.proeng.2013.03.138
   Rajkumar W., 2011, STAT ENV REP
   Saikia N, 2012, CONSTR BUILD MATER, V34, P385, DOI 10.1016/j.conbuildmat.2012.02.066
   Sarkar S, 2011, J IND ECOL, V15, P300, DOI 10.1111/j.1530-9290.2010.00323.x
   Siddique R, 2008, WASTE MANAGE, V28, P1835, DOI 10.1016/j.wasman.2007.09.011
   Themelis N. J., 2011, ENERGY EC VALUE NONR
   UNSD (United Nations Statistic Division), 2016, UN COMM TRAD STAT DA
   Van Eygen E, 2017, RESOUR CONSERV RECY, V117, P183, DOI 10.1016/j.resconrec.2016.10.017
   WBCSD/ IEA, 2009, CEM TECHN ROADM 2009
   Yellishetty M, 2010, RESOUR CONSERV RECY, V54, P1084, DOI 10.1016/j.resconrec.2010.03.003
   Zhou YC, 2013, RESOUR CONSERV RECY, V73, P33, DOI 10.1016/j.resconrec.2012.12.016
NR 64
TC 1
Z9 1
U1 17
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104436
DI 10.1016/j.resconrec.2019.104436
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000046
DA 2020-05-12
ER

PT J
AU Noll, D
   Wiedenhofer, D
   Miatto, A
   Singh, SJ
AF Noll, Dominik
   Wiedenhofer, Dominik
   Miatto, Alessio
   Singh, Simron Jit
TI The expansion of the built environment, waste generation and EU
   recycling targets on Samothraki, Greece: An island's dilemma
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Island sustainability; Material flow analysis (MFA); Circular economy
   (CE); Waste management; Economic development; Lifestyles; Remote islands
ID MATERIAL STOCK ACCUMULATION; MATERIAL FLOW-ANALYSIS; SOLID-WASTE;
   DEMOLITION WASTE; MANAGEMENT-SYSTEMS; SOCIAL METABOLISM; CONSTRUCTION;
   SUSTAINABILITY; CHALLENGES; DYNAMICS
AB Connectivity and affluence provide communities on small islands with opportunities and challenges. Both factors drive the expansion of material stocks which in turn determines future waste generation. For islands with limited waste treatment options an effective waste management strategy is inevitable. For the Greek island of Samothraki, construction and demolition waste (CDW) represents a new phenomenon. The advent of tourism, EU funding, labor migration and the construction of a new port in the 1960s led to an expansion of the built environment unprecedented on the island. As a consequence, new types and expanding quantities of CDW put the island community increasingly in the need for action. The European Waste Framework Directive, reinforced in 2018 with the Circular Economy Package, demands from EU member states at least 70% recycling and recovery rate of CDW until 2020.
   In this study, a mixed methods approach enabled the integration of data from official statistics, field surveys and interviews into a dynamic stock-driven model for different infrastructure and buildings types on Samothraki from 1971 to 2016. Our results show that the material stock expanded from 175 t/cap to 350 t/cap in the given period, leading to a 15-fold increase of annual CDW generation. With a recycling rate of only 14%, the island is currently far away from meeting the recycling and recovery targets of the EU-WFD. This study provides a systematic and dynamic analysis for developing policy and management options on reducing, re-using and recycling of CDW on islands where waste treatment options are limited.
C1 [Noll, Dominik; Wiedenhofer, Dominik] Univ Nat Resources & Life Sci BOKU, Inst Social Ecol SEC, Schottenfeldgasse 29, A-1070 Vienna, Austria.
   [Miatto, Alessio] Yale Univ, Sch Forestry & Environm Studies, 195 Prospect S4, New Haven, CT 06511 USA.
   [Singh, Simron Jit] Univ Waterloo, Sch Environm Enterprise & Dev, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
RP Noll, D (reprint author), Univ Nat Resources & Life Sci BOKU, Inst Social Ecol SEC, Schottenfeldgasse 29, A-1070 Vienna, Austria.
EM dominik.noll@boku.ac.at
RI Wiedenhofer, Dominik/AAA-5678-2020; Miatto, Alessio/R-9972-2019
OI Wiedenhofer, Dominik/0000-0001-7418-3477; Miatto,
   Alessio/0000-0001-7541-9330; Noll, Dominik/0000-0001-5118-8005
FU Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P27951, P27590];
   Austrian Academy of Sciences (OEAW): SamoMAB; European Research Council
   (ERC): MAT STOCKSEuropean Research Council (ERC) [741950]; Municipality
   of Samothraki
FX The authors gratefully acknowledge funding from the Austrian Science
   Fund (FWF): SUSAKI (P27951) and MISO (P27590), the Austrian Academy of
   Sciences (OEAW): SamoMAB, and the European Research Council (ERC): MAT
   STOCKS (741950). We wish to thank Lazaros Xenidis for his preparatory
   research efforts, Giorgos Maskalidis, Carlota Maranon, Panos Petridis,
   Evgenia Tsianou and all participants of the summer schools 2012, 2014,
   2016, and 2017 for their assistance during data collection. Further we
   want to thank Prof. Marina Fischer Kowalski for her advice and provision
   of required resources for conducting this study. Finally, we want to
   thank the Municipality of Samothraki for their collaboration and
   support.
CR Augiseau V, 2017, RESOUR CONSERV RECY, V123, P153, DOI 10.1016/j.resconrec.2016.09.002
   Biel B, 2014, FLORA SAMOTHRAKI
   Camilleri-Fenech M, 2018, J CLEAN PROD, V195, P1609, DOI 10.1016/j.jclepro.2017.07.057
   Chen MC, 2005, RESOUR CONSERV RECY, V45, P31, DOI 10.1016/j.resconrec.2004.12.005
   Chertow Marian, 2013, HUMAN ENV INTERACTIO, V2
   Deschenes P.J, 2004, J ENVIRON PLANN MAN, V47, P201, DOI DOI 10.1080/0964056042000209102
   Dzubur N, 2018, J IND ECOL, V22, P1156, DOI 10.1111/jiec.12654
   Eckelman MJ, 2014, J IND ECOL, V18, P306, DOI 10.1111/jiec.12113
   Eckelman MJ, 2009, J IND ECOL, V13, P758, DOI 10.1111/j.1530-9290.2009.00159.x
   ELSTAT, 2017, POP CENS YEARS 1991
   ELSTAT, 2016, BUILD CENS YEARS 197
   ELSTAT, 2017, ESYE YB
   ELSTAT, 2016, CONSTR DEM ACT YEARS
   European Commission, 2018, CIRC EC
   European Commission, 2011, WAST CONSTR DEM WAST
   European Commission, 2008, EU COH POL 1988 2008
   European Commission, 2015, FIN REP CONSTR DEM W
   European Commission, 2016, EU CONSTR DEM WAST P
   Fatta D, 2003, RESOUR CONSERV RECY, V40, P81, DOI 10.1016/S0921-3449(03)00035-1
   Fischer-Kowalski M, 2011, GAIA, V20, P181, DOI 10.14512/gaia.20.3.9
   Fishman T, 2015, ECOL ECON, V113, P76, DOI 10.1016/j.ecolecon.2015.03.001
   Fishman T, 2014, J IND ECOL, V18, P407, DOI 10.1111/jiec.12114
   Foolmaun RK, 2011, RESOUR CONSERV RECY, V55, P966, DOI 10.1016/j.resconrec.2011.05.004
   Gidarakos E, 2006, WASTE MANAGE, V26, P668, DOI 10.1016/j.wasman.2005.07.018
   Gowdy JM, 1999, LAND ECON, V75, P333, DOI 10.2307/3147015
   Haberl H, 2004, LAND USE POLICY, V21, P199, DOI 10.1016/j.landusepol.2003.10.013
   Haberl H, 2019, NAT SUSTAIN, V2, P173, DOI 10.1038/s41893-019-0225-2
   Haberl H, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9071049
   Hof A, 2011, LAND USE POLICY, V28, P792, DOI 10.1016/j.landusepol.2011.01.007
   IIED, 2002, BREAK NEW GROUND MIN
   Kelle U, 2017, KOLNER Z SOZIOL SOZ, V69, P39, DOI 10.1007/s11577-017-0451-4
   Kourmpanis B, 2008, WASTE MANAGE RES, V26, P267, DOI 10.1177/0734242X07083344
   Krausmann F, 2018, GLOBAL ENVIRON CHANG, V52, P131, DOI 10.1016/j.gloenvcha.2018.07.003
   Krausmann F, 2017, P NATL ACAD SCI USA, V114, P1880, DOI 10.1073/pnas.1613773114
   Krausmann Fridolin, 2014, RES US SMALL ISL STA, DOI [10.1111/jiec.12100/full, DOI 10.1111/JIEC.12100/FULL]
   Luijendijk A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24630-6
   Menegaki M, 2018, CURR OPIN GREEN SUST, V13, P8, DOI 10.1016/j.cogsc.2018.02.010
   Miatto A, 2019, RESOUR CONSERV RECY, V142, P245, DOI 10.1016/j.resconrec.2018.12.011
   Miatto A, 2017, RESOUR CONSERV RECY, V127, P168, DOI 10.1016/j.resconrec.2017.08.024
   Mohee R, 2015, WASTE MANAGE, V43, P539, DOI 10.1016/j.wasman.2015.06.012
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Muller DB, 2006, ECOL ECON, V59, P142, DOI 10.1016/j.ecolecon.2005.09.025
   Municipality of Samothraki, 2015, LOC WAST MAN PLAN MU
   Nemry F., 2008, ENV IMPROVEMENT POTE
   Papatzani S, 2015, 5 INT C ENV MAN ENG
   Pauliuk S, 2014, GLOBAL ENVIRON CHANG, V24, P132, DOI 10.1016/j.gloenvcha.2013.11.006
   Petridis P, 2016, SOCIAL ECOLOGY ANAL
   Petridis P, 2017, HUMAN ENVIRON INTERA, V7, P263, DOI 10.1007/978-3-319-69236-4_9
   Petridis P, 2017, ISL STUD J, V12, P115, DOI 10.24043/isj.8
   Saito O, 2013, J IND ECOL, V17, P578, DOI 10.1111/jiec.12007
   Schebek L, 2017, RESOUR CONSERV RECY, V123, P24, DOI 10.1016/j.resconrec.2016.06.001
   Singh SJ, 2001, POPUL ENVIRON, V23, P71, DOI 10.1023/A:1017564309651
   Skordilis A, 2004, RESOUR CONSERV RECY, V41, P243, DOI 10.1016/j.resconrec.2003.10.007
   Symmes R, 2020, J IND ECOL, V24, P369, DOI 10.1111/jiec.12853
   Tanikawa H, 2015, J IND ECOL, V19, P778, DOI 10.1111/jiec.12284
   Wiedenhofer D, 2019, ECOL ECON, V156, P121, DOI 10.1016/j.ecolecon.2018.09.010
   Wiedenhofer Dominik, 2015, J IND ECOL, DOI [10.1111/jiec.12216/abstract, DOI 10.1111/JIEC.12216/ABSTRACT]
NR 57
TC 3
Z9 3
U1 11
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104405
DI 10.1016/j.resconrec.2019.104405
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000003
DA 2020-05-12
ER

PT J
AU Polverini, D
   Miretti, U
AF Polverini, Davide
   Miretti, Ugo
TI An approach for the techno-economic assessment of circular economy
   requirements under the Ecodesign Directive
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Ecodesign; Material efficiency; Techno-economic
   assessment
ID MATERIAL EFFICIENCY; ENERGY EFFICIENCY; PRODUCT; INCENTIVES
AB At European Union level, the 2015 Circular Economy Action Plan establishes challenging yet achievable policy objectives. In this context, it is expected that a key role could be played by the Ecodesign Directive, among the most renowned legislative initiatives addressing the environmental impact of products. This policy has the potential to implement the circular economy principles into actual requirements at product level. To this extent, improvements are needed to the supporting analytical tool, the Methodology for Ecodesign of Energy-related Products. This paper focuses on the techno-economic aspects of this methodology, devising improvements such as the systematic inclusion of a) externalities (by proposing to account them as environmental fees to be added in the consumer life cycle costing), b) lifetime (by proposing to switch from the life cycle cost to the 'equivalent annual cost') and c) material consumption aspects (by proposing to determine the life cycle cost as a function of energy and material). These methodological improvements are expected to contribute enhancing the uptake of circular economy requirements in the Ecodesign policy, notably on product durability, on product reparability and capability to be refurbished, on spare parts availability, on product recyclability and on the reuse of secondary raw materials and/or components.
C1 [Polverini, Davide] European Commiss, DG Internal Market Ind Entrepreneurship & SMEs, Brussels, Belgium.
   [Miretti, Ugo] ITRB Consulting, Brussels, Belgium.
RP Polverini, D (reprint author), European Commiss, DG Internal Market Ind Entrepreneurship & SMEs, Brussels, Belgium.
EM davide.polverini@ec.europa.eu
CR Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Bakker C, 2014, J CLEAN PROD, V69, P10, DOI 10.1016/j.jclepro.2014.01.028
   Bobba S, 2015, TECHNICAL SUPPORT EN, DOI [10.2788/563222, DOI 10.2788/563222]
   Bracquene E., 2018, REPAIRABILITY CRITER
   BRE, 2016, STUD OV CONS HOUS CO
   Bundgaard AM, 2017, J CLEAN PROD, V144, P358, DOI 10.1016/j.jclepro.2016.12.144
   Byggeth S, 2006, J CLEAN PROD, V14, P1420, DOI 10.1016/j.jclepro.2005.03.024
   Chen C, 2014, INT J PROD ECON, V147, P666, DOI 10.1016/j.ijpe.2013.04.016
   Dalhammar C., 2014, REV OPPORTUNITIES BA, DOI [10.6027/TN2014-511, DOI 10.6027/TN2014-511]
   De Menna Fabio, 2016, METHODOLOGY EVALUATI
   EC, 2016, COM2016773 EC
   EC, 2015, COM20150614 EC
   European Commission (EC), 2017, COM20170490 EC
   European Environmental Agency, 2011, 152011 EEA
   Gu F, 2017, SCI TOTAL ENVIRON, V601, P1192, DOI 10.1016/j.scitotenv.2017.05.278
   Hinchliffe D, 2017, J CLEAN PROD, V168, P1603, DOI 10.1016/j.jclepro.2017.03.091
   Hunkeler D., 2008, ENV LIFE CYCLE COSTI
   Kasaeian A, 2018, RENEW SUST ENERG REV, V96, P91, DOI 10.1016/j.rser.2018.07.033
   Kemna R., 2011, METHODOLOGY ECODESIG
   Kemna R, 2016, ECODESIGN IMPACTS AC
   Kourkoumpas DS, 2018, APPL ENERG, V231, P380, DOI 10.1016/j.apenergy.2018.09.043
   Lazarevic D, 2010, RESOUR CONSERV RECY, V55, P246, DOI 10.1016/j.resconrec.2010.09.014
   LUND RT, 1978, MANAG REV, V67, P17
   MILLIMAN SR, 1989, J ENVIRON ECON MANAG, V17, P247, DOI 10.1016/0095-0696(89)90019-3
   Mudgal S., 2013, MAT EFFICIENCY ECODE
   OECD (Organisation for Economic Co-operation and Development), 2004, EC ASP EXT PROD RESP, DOI [DOI 10.1787/9789264105270-EN, 10.1787/9789264105270-en]
   PEARCE D, 1989, EC NATURAL RESOURCES
   Perman R., 2011, NATURAL RESOURCE ENV
   Poluerini D, 2018, COMPUT SECUR, V76, P295, DOI 10.1016/j.cose.2017.12.001
   Polverini D, 2016, ELECT GOES GREEN, DOI [10.1109/EGG.2016.7829861, DOI 10.1109/EGG.2016.7829861]
   Polverini D, 2018, COMPUT STAND INTER, V55, P116, DOI 10.1016/j.csi.2017.06.003
   Saidani M, 2019, J CLEAN PROD, V207, P542, DOI 10.1016/j.jclepro.2018.10.014
   Sauve S, 2016, ENVIRON DEV, V17, P48, DOI 10.1016/j.envdev.2015.09.002
   Schneider L, 2015, INT J LIFE CYCLE ASS, V20, P709, DOI 10.1007/s11367-015-0864-0
   Siderius HP, 2013, ENERG POLICY, V59, P762, DOI 10.1016/j.enpol.2013.04.032
   Smith M., 2016, BENEFITS ECODESIGN E
   Soderholm P, 2012, RESOUR CONSERV RECY, V61, P75, DOI 10.1016/j.resconrec.2012.01.003
   Stahel W.R., 1976, POTENTIAL SUBSTITUTI
   Sultan AM, 2017, J CLEAN PROD, V154, P51, DOI 10.1016/j.jclepro.2017.03.201
   vanZomeren A, 2017, ECNE17060
   WORRELL E, 1995, RESOUR CONSERV RECY, V13, P215, DOI 10.1016/0921-3449(94)00050-F
NR 41
TC 2
Z9 2
U1 4
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104425
DI 10.1016/j.resconrec.2019.104425
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000028
DA 2020-05-12
ER

PT J
AU Qiu, Y
   Suh, S
AF Qiu, Yang
   Suh, Sangwon
TI Economic feasibility of recycling rare earth oxides from end-of-life
   lighting technologies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Rare earth elements; Efficient lighting technologies; Dynamic material
   flow analysis; Learning curve approach; Recycling; Economic feasibility
ID EXTENDED PRODUCER RESPONSIBILITY; POTENTIAL ENVIRONMENTAL IMPACTS;
   FLUORESCENT LAMPS; FLOW-ANALYSIS; STOCK; ELEMENTS
AB Transition to efficient lighting technologies, such as fluorescent and LED lamps, is an important strategy to mitigate climate change. However, it also increases the demand for critical materials such as rare earth oxides (REOs). While recycling can alleviate the dependence on primary REOs, recycling these materials from lighting technologies is currently economically infeasible, limiting its adoption. As more REOs will become available for recycling, the economy of scale is expected to reduce the cost, therefore improving their circularity. Here we analyze the effects that the scale of recycling operation and REO prices have on the economic feasibility of REO recycling using dynamic material flow analysis and technology learning curve approaches. Our results show that end-of-life REOs from lighting technologies are expected to peak between 2020 and 2027. Increasing recycling plant capacity can reduce cost from about $7200/t REO phosphors at 100 t/yr capacity to about $2500/t REO phosphors at 1500 t/yr capacity. Nevertheless, we found that REO recycling would not be economically feasible under 2018 REO prices, irrespective of scale. For a plant at 800 t/yr capacity, recycling becomes profitable only after a threefold increase from 2018 REO prices. The break-even point can be further reduced at a larger scale. Our results suggest that scaling-up recycling plants in the course of growing volume of end-of-life lighting technologies alone will not automatically increase REO recycling under current market conditions. Significant improvement of REO recycling rate in lighting technologies would therefore require substantially higher REO prices or commensurate policy interventions.
C1 [Qiu, Yang; Suh, Sangwon] Univ Calif Santa Barbara, Bren Sch Environm Sci & Management, Bren Hall,2400 Univ Calif, Santa Barbara, CA 93117 USA.
RP Suh, S (reprint author), Univ Calif Santa Barbara, Bren Sch Environm Sci & Management, Bren Hall,2400 Univ Calif, Santa Barbara, CA 93117 USA.
EM suh@bren.ucsb.edu
FU US Environmental Protection AgencyUnited States Environmental Protection
   Agency [83557907]; UCSB Mellichamp Sustainability Fellowship
FX We would like to acknowledge the financial support from the US
   Environmental Protection Agency via Science to Achieve Results Program
   Grant No. 83557907. We also acknowledge the UCSB Mellichamp
   Sustainability Fellowship for the additional financial aid for YQ. We
   thank Dr. Runsheng Song for his assistance in computer programming used
   in this study.
CR Amato A, 2019, RENEW SUST ENERG REV, V106, P41, DOI 10.1016/j.rser.2019.02.029
   ARGOTE L, 1990, SCIENCE, V247, P920, DOI 10.1126/science.247.4945.920
   Asari M, 2008, SCI TOTAL ENVIRON, V393, P1, DOI 10.1016/j.scitotenv.2007.08.062
   Ashe M., 2010, US LIGHTING MARKET C
   Bardsley N. B. S., 2015, SOLID STATE LIGHTING
   Beolchini Francesca, 2013, ENV ENG MANAGE J, V5
   Bergesen JD, 2016, APPL ENERG, V169, P721, DOI 10.1016/j.apenergy.2016.02.013
   Binder K., 1993, COMPUT PHYS, V7, P156, DOI DOI 10.1063/1.4823159
   Binnemans K, 2013, JOM-US, V65, P846, DOI 10.1007/s11837-013-0639-7
   Binnemans K, 2018, J SUSTAIN METALL, V4, P126, DOI 10.1007/s40831-018-0162-8
   Binnemans K, 2013, J CLEAN PROD, V51, P1, DOI 10.1016/j.jclepro.2012.12.037
   Brunner P. H., 2004, INT J LIFE CYCLE ASS, V9, P337, DOI DOI 10.1007/BF02979426
   Castilloux R, 2014, EMERGING END USES RE
   Ciacci L, 2018, RESOURCES-BASEL, V7, DOI 10.3390/resources7030059
   Cucchiella F, 2016, RENEW SUST ENERG REV, V64, P749, DOI 10.1016/j.rser.2016.06.057
   De Almeida Anibal, 2013, ACCELERATING DEPLOYM
   Elshkaki A, 2005, ENERGY, V30, P1353, DOI 10.1016/j.energy.2004.02.019
   EU Commission, 2014, REP CRIT RAW MAT EU
   Fan KS, 2005, J AIR WASTE MANAGE, V55, P574, DOI 10.1080/10473289.2005.10464647
   GRUBER H, 1992, APPL ECON, V24, P885, DOI 10.1080/00036849200000056
   Hatayama H, 2010, ENVIRON SCI TECHNOL, V44, P6457, DOI 10.1021/es100044n
   Hatch NW, 1998, MANAGE SCI, V44, P1461, DOI 10.1287/mnsc.44.11.1461
   Heidari M, 2018, ENERG BUILDINGS, V158, P536, DOI 10.1016/j.enbuild.2017.08.091
   Innocenti V, 2017, J TAIWAN INST CHEM E, V80, P769, DOI 10.1016/j.jtice.2017.09.019
   Innocenzi V, 2016, AD ENVIRON RES, V5, P125, DOI 10.12989/aer.2016.5.2.125
   IRWIN DA, 1994, J POLIT ECON, V102, P1200, DOI 10.1086/261968
   Jaber M. Y., 2016, LEARNING CURVES THEO
   Kleijn R, 2000, ECOL ECON, V32, P241, DOI 10.1016/S0921-8009(99)00090-7
   Kouvaritakis N., 2000, INT J GLOBAL ENERGY, V14, P104, DOI DOI 10.1504/IJGEI.2000.004384
   Lim SR, 2013, ENVIRON SCI TECHNOL, V47, P1040, DOI 10.1021/es302886m
   Lim SR, 2011, ENVIRON SCI TECHNOL, V45, P320, DOI 10.1021/es101052q
   Machacek E, 2015, RESOUR CONSERV RECY, V104, P76, DOI 10.1016/j.resconrec.2015.09.005
   Mancheri NA, 2015, RESOUR POLICY, V46, P262, DOI 10.1016/j.resourpol.2015.10.009
   Mandil C., 2006, ENERGY WORLD, V343, P14
   Massari S, 2013, RESOUR POLICY, V38, P36, DOI 10.1016/j.resourpol.2012.07.001
   McDonald A, 2001, ENERG POLICY, V29, P255, DOI 10.1016/S0301-4215(00)00122-1
   McKinsey & Company, 2012, LIGHT WAY PERSP GLOB
   Melo MT, 1999, RESOUR CONSERV RECY, V26, P91, DOI 10.1016/S0921-3449(98)00077-9
   MOORE FT, 1959, Q J ECON, V73, P232, DOI 10.2307/1883722
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Muller DB, 2006, ECOL ECON, V59, P142, DOI 10.1016/j.ecolecon.2005.09.025
   *OECD, 2001, EXT PROD RESP GUID M
   Peng LH, 2014, J AIR WASTE MANAGE, V64, P1299, DOI 10.1080/10962247.2014.944285
   Penning J, 2016, TECH REP
   Richter JL, 2016, J CLEAN PROD, V123, P167, DOI 10.1016/j.jclepro.2015.06.131
   Rollat A, 2016, WASTE MANAGE, V49, P427, DOI 10.1016/j.wasman.2016.01.011
   Setlur Anant A, 2009, ELECTROCHEM SOC INTE, V5
   Silveira GTR, 2011, WASTE MANAGE RES, V29, P656, DOI 10.1177/0734242X10383744
   Solvay, 2014, LOOP LIF PROJ
   Song RS, 2017, ENVIRON SCI TECHNOL, V51, P12424, DOI 10.1021/acs.est.7b01907
   Strauss Mark Lawrence, 2016, RECOVERY RARE EARTH
   SudOuest.fr, 2016, SUDOUEST
   Tan QY, 2015, CRIT REV ENV SCI TEC, V45, P749, DOI 10.1080/10643389.2014.900240
   U.S. Geological Survey (USGS), 2019, MIN COMM SUMM 2019, DOI [10.3133/70202434, DOI 10.3133/70202434]
   UNEP, 2012, ACH GLOB TRANS EN EF
   UNEP, 2017, ACC GLOB AD EN EFF L
   UNEP, 2014, GREEN PAP POL OPT AC
   van der Voet E, 2002, ECOL ECON, V41, P223, DOI 10.1016/S0921-8009(02)00028-9
   Waide Paul, 2010, IEA ENERGY PAPERS
   Walk W, 2009, WASTE MANAGE, V29, P945, DOI 10.1016/j.wasman.2008.07.012
   Wang F, 2013, WASTE MANAGE, V33, P2397, DOI 10.1016/j.wasman.2013.07.005
   Wilburn David R, 2012, BYPRODUCT METALS RAR
   Wright T. P., 1936, J AERONAUT SCI, V3, P122, DOI [10.2514/8.155, DOI 10.2514/8.155]
   Wu YF, 2014, RESOUR CONSERV RECY, V88, P21, DOI 10.1016/j.resconrec.2014.04.007
   Zeng XL, 2018, ENVIRON SCI TECHNOL, V52, P4835, DOI 10.1021/acs.est.7b04909
NR 65
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104432
DI 10.1016/j.resconrec.2019.104432
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000016
DA 2020-05-12
ER

PT J
AU Salim, HK
   Stewart, RA
   Sahin, O
   Dudley, M
AF Salim, Hengky K.
   Stewart, Rodney A.
   Sahin, Oz
   Dudley, Michael
TI End-of-life management of solar photovoltaic and battery energy storage
   systems: A stakeholder survey in Australia
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Solar photovoltaic; Battery energy storage system; End-of-life; Product
   stewardship; Stakeholder survey; Australia
ID PRODUCT STEWARDSHIP; WASTE MANAGEMENT; DRIVERS; POLICY; WATER
AB In this study, a preliminary list of drivers, barriers, and enablers to end-of-life management of photovoltaic panels and battery energy storage systems obtained from a systematic literature review was firstly evaluated and then expanded through an iterative expert review process. Subsequently, a questionnaire survey was administered in Australia to elicit stakeholder perceptions on each driver, barrier, and enabler factor. A total of 57 complete responses was obtained. A two-step cluster analysis was performed to compare the perceived drivers, barriers, and enablers between four stakeholder categories including research/education institutions, product stewardship arrangement (PSA) parties, governments, and consultants. Findings indicated that there is a high degree of agreement among stakeholders on various drivers, barriers, and enablers; however, some factors exhibited differences. It appeared that all stakeholders were driven to address triple bottom line issues, however, research/education institutions put more emphasis on the economic and environmental drivers. Stakeholders reported the lack of profitability, unavailability of regulations and incentives, as well as a lack of awareness of safe disposal options, as being the most significant barriers. Only government respondents recognised the current lack of on-shore recycling infrastructures as a critical barrier. Introducing a product stewardship scheme, implementing business models for collection, economic incentives, as well as developing recycling technologies and infrastructures were regarded as the most important enablers. Policy and practice implications and recommendations were also discussed in this study.
C1 [Salim, Hengky K.; Stewart, Rodney A.; Sahin, Oz] Griffith Univ, Sch Engn & Built Environm, Southport, Qld 4222, Australia.
   [Salim, Hengky K.; Stewart, Rodney A.; Sahin, Oz] Griffith Univ, Cities Res Inst, Southport, Qld 4222, Australia.
   [Sahin, Oz] Griffith Univ, Griffith Climate Change Response Program, Southport, Qld 4222, Australia.
   [Dudley, Michael] Sustainabil Victoria, Melbourne, Vic 3000, Australia.
RP Stewart, RA (reprint author), Griffith Univ, Sch Engn & Built Environm, Southport, Qld 4222, Australia.
EM r.stewart@griffith.edu.au
RI Stewart, Rodney/H-5561-2018; Salim, Hengky K/L-5744-2017
OI Stewart, Rodney/0000-0002-6013-3505; Salim, Hengky
   K/0000-0002-5388-2460; Sahin, Oz/0000-0002-1914-5379
FU Sustainability Victoria; Griffith University through the Griffith
   University Postgraduate Research Scholarship (GUPRS)
FX The authors would like to acknowledge Sustainability Victoria for
   contributing and supporting this research project. The authors would
   also like to thank anonymous expert review panel as well as survey
   respondents in which this research would not have been possible without
   their valuable insights. Finally, Hengky K. Salim would like to
   acknowledge Griffith University for funding this research project
   through the Griffith University Postgraduate Research Scholarship
   (GUPRS).
CR AEMO, 2018, AGGR PRIC DEM DAT HI
   Anctil A, 2013, PROG PHOTOVOLTAICS, V21, P1253, DOI [10.1002/pip.2226, 10.1002/pip.2308]
   APVI, 2018, PV POSTC DAT
   Besiou M, 2016, J IND ECOL, V20, P929, DOI 10.1111/jiec.12297
   Buysse K, 2003, STRATEGIC MANAGE J, V24, P453, DOI 10.1002/smj.299
   Chaplin L., 2018, PHOTOVOLTAIC STEWARD
   Corder GD, 2015, MINER ENG, V76, P2, DOI 10.1016/j.mineng.2014.11.004
   Davis G, 2008, RESOUR CONSERV RECY, V52, P1031, DOI 10.1016/j.resconrec.2008.04.001
   Davis G, 2010, WASTE MANAGE RES, V28, P705, DOI 10.1177/0734242X09343008
   Dias P, 2019, J CLEAN PROD, V209, P846, DOI 10.1016/j.jclepro.2018.10.306
   Dominguez A, 2017, RESOUR CONSERV RECY, V127, P29, DOI 10.1016/j.resconrec.2017.08.013
   Faircloth CC, 2019, RESOUR CONSERV RECY, V143, P260, DOI 10.1016/j.resconrec.2019.01.008
   Florin N., 2016, PV SYSTEMS STEWARDSH
   Frinsdorf O, 2014, INT J PROJ MANAG, V32, P803, DOI 10.1016/j.ijproman.2013.10.008
   Fthenakis VM, 2000, ENERG POLICY, V28, P1051, DOI 10.1016/S0301-4215(00)00091-4
   Gerardi W, 2017, PROJECTIONS UPTAKE S
   Giurco D, 2015, RESOURCES-BASEL, V4, P3, DOI 10.3390/resources4010003
   Golev A, 2017, MINER ENG, V107, P81, DOI 10.1016/j.mineng.2016.10.021
   Hafezi M, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10114100
   Heelan J, 2016, JOM-US, V68, P2632, DOI 10.1007/s11837-016-1994-y
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Katsanevakis M, 2017, J ENERGY STORAGE, V14, P329, DOI 10.1016/j.est.2017.07.022
   Katsanevakis M, 2017, RENEW SUST ENERG REV, V75, P719, DOI 10.1016/j.rser.2016.11.050
   Khan O, 2008, INT J PHYS DISTR LOG, V38, P412, DOI 10.1108/09600030810882834
   King S., 2018, LITHIUM BATTERY RECY
   Lane R, 2012, GEOFORUM, V43, P1254, DOI 10.1016/j.geoforum.2012.03.012
   Lapko Y, 2019, J IND ECOL, V23, P182, DOI 10.1111/jiec.12741
   Ledoux L, 2005, LAND USE POLICY, V22, P129, DOI 10.1016/j.landusepol.2004.03.001
   Liang X, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101927
   Lunardi MM, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8081396
   Luyet V, 2012, J ENVIRON MANAGE, V111, P213, DOI 10.1016/j.jenvman.2012.06.026
   Mahmoudi S, 2019, RESOUR CONSERV RECY, V146, P192, DOI 10.1016/j.resconrec.2019.03.039
   Marwede M, 2012, RESOUR CONSERV RECY, V69, P35, DOI 10.1016/j.resconrec.2012.09.003
   Massari S, 2013, RESOUR POLICY, V38, P36, DOI 10.1016/j.resourpol.2012.07.001
   Monier V, 2011, STUDY PHOTOVOLTAIC P
   Morris A, 2016, J ENVIRON MANAGE, V181, P218, DOI 10.1016/j.jenvman.2016.06.013
   Nicol S, 2007, WASTE MANAGE RES, V25, P227, DOI 10.1177/0734242X07079152
   PwC Hyder Consulting, 2009, DEC REG IMP STAT TEL
   Randell P, 2017, VICTORIAN E WASTE MF
   Sahin O, 2016, ENVIRON MODELL SOFTW, V75, P348, DOI 10.1016/j.envsoft.2014.05.018
   Salim HK, 2019, J CLEAN PROD, V211, P537, DOI 10.1016/j.jclepro.2018.11.229
   Santos JD, 2018, J CLEAN PROD, V196, P1613, DOI 10.1016/j.jclepro.2018.05.252
   Savic DA, 2016, WATER-SUI, V8, DOI 10.3390/w8100456
   Smart Energy Council, 2018, AUSTR EN STOR MARK A
   Umstattd MR, 2012, J PHYS ACT HEALTH, V9, P724, DOI 10.1123/jpah.9.5.724
   West C, 2017, WATER RES, V120, P133, DOI 10.1016/j.watres.2017.04.077
   Yu M, 2015, SUSTAINABILITY-BASEL, V7, P1213, DOI 10.3390/su7021213
NR 47
TC 3
Z9 3
U1 5
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104444
DI 10.1016/j.resconrec.2019.104444
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000033
DA 2020-05-12
ER

PT J
AU Schraven, D
   Bukvic, U
   Di Maio, F
   Hertogh, M
AF Schraven, Daan
   Bukvic, Uros
   Di Maio, Francesco
   Hertogh, Marcel
TI Circular transition: Changes and responsibilities in the Dutch stony
   material supply chain
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Supply chain; Stony materials; Social network
   analysis; Diffusion of responsibility; Recycling
ID ECONOMY; MANAGEMENT
AB Recent literature has recognized the difficulty of implementing Circular Economy (CE) in supply chains. This has not yet led to a clear understanding of the reasons. This is critical to address, because the difficulty stalls the CE transition and suspends its benefits. Therefore, this paper investigates the reasons for the difficulty of implementing CE in supply chains. In so doing the Dutch stony materials supply chain is used as empirical case. Through a literature review, the role of changes and responsibilities in CE implementations inside the supply chain, has been gained. Based on these insights, a Social Network Analysis approach for capturing and analysing perceptions of supply chain actors on the CE changes was developed. The findings show that the diffusion of responsibility and differences of perceptions are underlying reasons of the difficulty to implement CE in supply chains. The main reasons for these two developments consists of: (1) Lack of incentives for the supply chain actors to make a change towards circularity; (3) Lack of mutual interests between supply chain actors; (2) High uncertainties and risks and (4) Clashes of perceptions on all levels in supply chains. It was found that the observed diffusion of responsibility was due to the individual pursuance of the changes that benefit individual business models and making parties responsible for these changes if they have the biggest impact on their business. As long as supply chains are voluntarily changing, this will stall the transition, some obligatory outside influence can refine the incentives to change.
C1 [Schraven, Daan; Bukvic, Uros; Di Maio, Francesco; Hertogh, Marcel] Delft Univ Technol, Stevinweg 1, NL-2628 CN Delft, Netherlands.
RP Schraven, D (reprint author), Delft Univ Technol, Stevinweg 1, NL-2628 CN Delft, Netherlands.
EM d.f.j.schraven@tudelft.nl
OI Di Maio, Francesco/0000-0001-6018-1227
CR ABN AMRO & Circle Economy, 2015, CIRC CONSTR FDN REN
   Adams KT, 2017, PROC INST CIV ENG-WA, V170, P15, DOI 10.1680/jwarm.16.00011
   Allard-Poesi F, 1998, SCAND J MANAG, V14, P395, DOI DOI 10.1016/S09565221(98)000189
   Aminoff A, 2016, SMART INNOV SYST TEC, V52, P61, DOI 10.1007/978-3-319-32098-4_6
   BAM & ARUP, 2017, CIRC BUS MOD BUILT E
   Barlas Y, 1996, SYST DYNAM REV, V12, P183, DOI 10.1002/(SICI)1099-1727(199623)12:3<183::AID-SDR103>3.0.CO;2-4
   Borgatti S. P., 2011, SAGE HDB SOCIAL NETW, P417, DOI DOI 10.4135/9781446294413.N28
   Bressanelli G., 2018, P SUMM SCH FRANC TUR, P171
   Cai N., 2014, ADV MAT RES, V933, P1004
   CBS PBI & Wageningen UR, 2017, WAST GEN TREATM SECT
   CCICED, 2008, CIRC EC PROM LAW PEO
   Cohen D., 2006, QUALITATIVE RES GUID
   Cossu R, 2015, WASTE MANAGE, V45, P1, DOI 10.1016/j.wasman.2015.09.040
   De Angelis R, 2018, PROD PLAN CONTROL, V29, P425, DOI 10.1080/09537287.2018.1449244
   De Nooy W, 2018, EXPLORATORY SOCIAL N
   Di Maio F., 2015, J ENV PROT, V06, P1095, DOI DOI 10.4236/JEP.2015.610096
   Di Maio F, 2017, RESOUR CONSERV RECY, V122, P163, DOI 10.1016/j.resconrec.2017.02.009
   Dubey R., 2018, MANAGEMENT DECISION
   Elia V, 2017, J CLEAN PROD, V142, P2741, DOI 10.1016/j.jclepro.2016.10.196
   Ellen MacArthur Foundation (EMF), 2015, DEL CIRC EC TOOLK PO
   EMF (Ellen MacArthur Foundation), 2015, CIRC IND APPR MEAS C
   European Commission, 2015, CLOS LOOP ACT PLAN C
   European Commission, 2016, EU CONSTR DEM WAST P
   Fischer A, 2017, J CLEAN PROD, V155, P17, DOI 10.1016/j.jclepro.2016.12.038
   Fischer C., 2009, 2 EUR CTR RES WAST M
   Gaustad G, 2018, RESOUR CONSERV RECY, V135, P24, DOI 10.1016/j.resconrec.2017.08.002
   Geisendorf S, 2018, THUNDERBIRD INT BUS, V60, P771, DOI 10.1002/tie.21924
   Geissdoerfer M, 2018, J CLEAN PROD, V190, P712, DOI 10.1016/j.jclepro.2018.04.159
   Genovese A, 2017, OMEGA-INT J MANAGE S, V66, P344, DOI 10.1016/j.omega.2015.05.015
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   GINSBERG A, 1990, ACAD MANAGE REV, V15, P514, DOI 10.2307/258021
   Govindan K, 2018, INT J PROD RES, V56, P278, DOI 10.1080/00207543.2017.1402141
   Homrich AS, 2018, J CLEAN PROD, V175, P525, DOI 10.1016/j.jclepro.2017.11.064
   Howard M., 2018, INT J PROD RES
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Leising E, 2018, J CLEAN PROD, V176, P976, DOI 10.1016/j.jclepro.2017.12.010
   Liu JJ, 2018, INT J PHYS DISTR LOG, V48, P794, DOI 10.1108/IJPDLM-01-2017-0049
   Lopez FJD, 2019, ECOL ECON, V155, P20, DOI 10.1016/j.ecolecon.2018.03.009
   Maass O, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10041125
   Marinkovic S, 2010, WASTE MANAGE, V30, P2255, DOI 10.1016/j.wasman.2010.04.012
   Masi D, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9091602
   Mendoza J. M. F., 2017, J IND ECOL
   Ministry of Infrastructure and the Environment, 2016, CIRC EC NETH 2050 GO
   Mulders L., 2013, HIGH QUALITY RECYCLI
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   MVO Nederland, 2016, BET
   Nasir MHA, 2017, INT J PROD ECON, V183, P443, DOI 10.1016/j.ijpe.2016.06.008
   Preston F., 2012, GLOBAL REDESIGN SHAP
   Rijkswaterstaat & National Institute for Public Health and the Environment, 2015, CIRC EC DUTCH CONSTR
   Schraven DFJ, 2015, ORGAN RES METHODS, V18, P326, DOI 10.1177/1094428114562284
   Scott J, 2017, SOCIAL NETWORK ANAL
   Sharma Y. K, 2019, MANAGEMENT DECISION
   Tisserant A, 2017, J IND ECOL, V21, P628, DOI 10.1111/jiec.12562
   Tsolakis N, 2018, OPER MANAGE RES, V11, P83, DOI 10.1007/s12063-018-0134-y
   Turner DW, 2010, QUAL REP, V15, P754
   Wasserman S., 1994, SOCIAL NETWORK ANAL, V8
   Zeng HX, 2017, J CLEAN PROD, V155, P54, DOI 10.1016/j.jclepro.2016.10.093
NR 58
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104359
DI 10.1016/j.resconrec.2019.05.035
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000005
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Senan-Salinas, J
   Garcia-Pacheco, R
   Landaburu-Aguirre, J
   Garcia-Calvo, E
AF Senan-Salinas, Jorge
   Garcia-Pacheco, Raquel
   Landaburu-Aguirre, Junkal
   Garcia-Calvo, Eloy
TI Recycling of end-of-life reverse osmosis membranes: Comparative LCA and
   cost-effectiveness analysis at pilot scale
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Circular economy; Life Cycle Assessment; Reverse Osmosis; Recycling;
   Open-loop
ID CYCLE ASSESSMENT; CIRCULAR ECONOMY; WATER; DESALINATION
AB Reverse Osmosis (RO) is the most extended desalination technology implemented worldwide. However, RO desalination has some environmental challenges that must be resolved in order to comply with the circular economy principles. RO membranes have a short service life of 5-10 years, generating 14,000 tonnes annually of membrane waste that is landfilled yearly. In this work two pilot designs for recycling end-of-life (EoL) RO membranes are evaluated with LCA and cost effectiveness analysis. The study includes different types of transformations depending on: i) EoL RO membrane type (brackish water (BW) or sea water (SW)) and ii) recycling product (nanofiltration (NF) or ultrafiltration (UF)). Substitutability formulas were adapted to membrane technology and service life data gap. Therefore, two new indicators (minimum service life and service life ratio) were developed and estimated from the ILCD-Midpoint impact results of the recycling process and the avoided products. Cluster analysis was applied in contribution profiles for category grouping. LCA results show that the recycling process using the passive system (PS) has lower environmental performance than the active system (AS) in all the categories. The most environmentally interesting transformations are the BWRO into NF and UF and from SWRO into NF. The transformation from SWRO to UF does not seem to be technically competitive due to the low recycled membrane permeability evidenced during the LIFE-TRANSFOMEM project. Cluster analysis shows that the most relevant flows were NaClO, bisulphite and electricity use. The cost of the recycling process with the PS is (sic)25.9-41.5/module, whilst using the AS is (sic)54.5-73.75/module.
C1 [Senan-Salinas, Jorge; Garcia-Pacheco, Raquel; Landaburu-Aguirre, Junkal; Garcia-Calvo, Eloy] IMDEA Water Inst, Ave Punto Com 2, Madrid 28805, Spain.
   [Senan-Salinas, Jorge; Garcia-Calvo, Eloy] Univ Alcala De Henares, Chem Engn Dept, Ctra Madrid Barcelona Km 33-600, Madrid 28871, Spain.
   [Garcia-Pacheco, Raquel] Univ Girona, Inst Environm, Lab Chem & Environm Engn LEQUIA, Girona 17003, Spain.
   [Garcia-Pacheco, Raquel] Univ New South Wales, Sch Chem Engn, UNESCO Ctr Membrane Sci & Technol, Sydney, NSW 2052, Australia.
RP Senan-Salinas, J (reprint author), IMDEA Water Inst, Ave Punto Com 2, Madrid 28805, Spain.
EM Jorge.senan@imdea.org
RI Calvo, Eloy Garcia/K-3627-2017
OI Calvo, Eloy Garcia/0000-0001-8795-3880; Senan-Salinas,
   Jorge/0000-0001-8127-5425
FU LIFE program [LIFE13 ENV/ES/000751]; project INREMEM
   [CTM2015-65348-C2-1-R]
FX The authors acknowledge the financial support to the LIFE program for
   funding the TRANSFOMEM project (LIFE13 ENV/ES/000751) and to the project
   INREMEM - CTM2015-65348-C2-1-R (MINECO/FEDER). To Carlos Mario for his
   advises to assess the economic analysis and to Sacyr & Sacyr Agua
   Servicios staff, in particular to Patricia Terrero for collaborating
   within the inventory collection data.
CR Beltran FJ, 2009, J HAZARD MATER, V169, P532, DOI 10.1016/j.jhazmat.2009.03.127
   Bonton A, 2012, DESALINATION, V284, P42, DOI 10.1016/j.desal.2011.08.035
   Brinkmann T., 2016, 28112 EUR EN, DOI [10.2791/37535, DOI 10.2791/37535]
   Brinkmann T, 2014, 26844 EUR EN JOINT R, DOI [10.2791/13138, DOI 10.2791/13138]
   Caduff M, 2014, J IND ECOL, V18, P393, DOI 10.1111/jiec.12122
   EEA, 2016, CIRC EC EUR DEV KNOW, DOI [10.2800/51444, DOI 10.2800/51444]
   European Commission, 2011, INT REF LIF CYCL DAT
   European Commission Commission E, 2010, CONSTRAINTS, DOI [10.2788/38479, DOI 10.2788/38479]
   Garcia-Pacheco R, 2017, COMPREHENSIVE MEMBRA
   Garcia-Pacheco R, 2018, DESALINATION, V433, P199, DOI 10.1016/j.desal.2017.12.034
   Garcia-Pacheco R, 2015, J MEMBRANE SCI, V495, P305, DOI 10.1016/j.memsci.2015.08.025
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Huijbregts M., 1998, INT J LIFE CYCLE ASS, V3, P273, DOI DOI 10.1007/BF02979835
   IDA-Desalination, 2019, YB 2018 2019
   JRC-IPTS-EIPPCB, 2009, REF DOC BEST AV TECH
   JRC-IPTS-EIPPCB, 2007, REF DOC BEST AV TECH
   JRC-IPTS-EIPPCB, 2006, REF DOC BEST AV TECH
   Judd SJ, 2017, WATER RES, V122, P1, DOI 10.1016/j.watres.2017.05.027
   Kinani A, 2016, TRAC-TREND ANAL CHEM, V85, P273, DOI 10.1016/j.trac.2016.06.008
   Landaburu-Aguirre J, 2016, DESALINATION, V393, P16, DOI 10.1016/j.desal.2016.04.002
   Lattemann S, 2010, SUSTAIN SCI ENG, V2, P7, DOI 10.1016/S1871-2711(09)00202-5
   Lawler W., 2015, ASSESSMENT END OF LI
   Lawler W, 2015, DESALINATION, V357, P45, DOI 10.1016/j.desal.2014.10.013
   Market Reports, 2017, MARKET REPORTS
   Millipore Corporation, 2008, ULTR MEMBR
   Molina S, 2018, POLYM DEGRAD STABIL, V150, P46, DOI 10.1016/j.polymdegradstab.2018.02.012
   Piccinno F, 2016, J CLEAN PROD, V135, P1085, DOI 10.1016/j.jclepro.2016.06.164
   Terrero P, 2017, IDA WORLD C 2017, P305, DOI [10.1016/j.memsci.2015.08.025, DOI 10.1016/J.MEMSCI.2015.08.025]
   Veza JA, 2003, DESALINATION, V157, P65, DOI 10.1016/S0011-9164(03)00384-9
   Wernet G, 2016, INT J LIFE CYCLE ASS, V21, P1218, DOI 10.1007/s11367-016-1087-8
   Zhou J, 2011, DESALINATION, V283, P227, DOI 10.1016/j.desal.2011.04.066
NR 31
TC 0
Z9 0
U1 22
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104423
DI 10.1016/j.resconrec.2019.104423
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000017
DA 2020-05-12
ER

PT J
AU Singh, J
   Sung, K
   Cooper, T
   West, K
   Mont, O
AF Singh, Jagdeep
   Sung, Kyungeun
   Cooper, Tim
   West, Katherine
   Mont, Oksana
TI Challenges and opportunities for scaling up upcycling businesses - The
   case of textile and wood upcycling businesses in the UK
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Upcycling; Scaling up; Circular economy; Challenges and success factors;
   Group model building; System interventions
ID DESIGN; WASTE
AB Upcycling is a process in which used or waste products and materials are repaired, reused, repurposed, refurbished, upgraded and remanufactured in a creative way to add value to the compositional elements. It has been part of human life throughout history, and the past few years have seen its revival, driven by multiple factors including growing concern for the environment and resource scarcity. Upcycling increases quality and lifetimes of materials and products, reduces wastes, creates employment opportunities, and encourages sustainable consumer behaviour. Despite such benefits and increasing interest, upcycling is largely considered as a niche practice. One of the important gaps in the current state of knowledge on upcycling is a lack of systemic understanding about challenges and success factors relating to scaling up upcycling businesses. This paper aims to address this gap by employing a broad range of methods for reaching its goal, including literature review, stakeholder analysis, semi-structured interviews, group model building, development of causal loop diagrams, and a workshop with stakeholders and experts to validate causal loop diagrams and discuss promising interventions and how to proceed. The results identified potential actors for the success of upcycling businesses, key challenges and success factors, causal linkages among the challenges and success factors, key system mechanisms, and interventions for scaling up upcycling businesses. Collaboration across the upcycling value chain involving a wide range of actors is also discussed.
C1 [Singh, Jagdeep; Mont, Oksana] Lund Univ, IIIEE, POB 196, S-22100 Lund, Sweden.
   [Singh, Jagdeep; Sung, Kyungeun; Cooper, Tim; West, Katherine] Nottingham Trent Univ, Sch Architecture Design & Built Environm, 50 Shakespeare St, Nottingham NG1 4FQ, England.
   [Sung, Kyungeun] De Montfort Univ, Gateway House, Leicester LE1 9BH, Leics, England.
RP Singh, J (reprint author), Lund Univ, IIIEE, POB 196, S-22100 Lund, Sweden.
EM jagdeep.singh@iiiee.lu.se; kyungeun.sung@dmu.ac.uk;
   t.h.cooper@ntu.ac.uk; katherine@bigdifferencecompany.co.uk;
   oksana.mont@iiiee.lu.se
RI ; Singh, Jagdeep/C-4913-2018
OI Sung, Kyungeun/0000-0001-9570-7225; Singh, Jagdeep/0000-0002-9215-0166
FU Engineering and Physical Sciences Research Council (EPSRC)Engineering &
   Physical Sciences Research Council (EPSRC) [EP/N022645/1]; Urban
   Reconomy [Formas211-2014-1440]; Associate Dean for Research and
   Innovation in the faculty of Arts, Design and Humanities at De Montfort
   University
FX The authors acknowledge the Engineering and Physical Sciences Research
   Council (EPSRC) funded Centre for Industrial Energy, Materials and
   Products, grant reference EP/N022645/1 for financial support. Dr.
   Kyungeun Sung acknowledges Materials Seed-Corn Fund from Nottingham
   Trent University for data collection, and VC2020 Fund from Associate
   Dean for Research and Innovation in the faculty of Arts, Design and
   Humanities for sponsoring the workshop with experts and Research and
   Innovation Allowance at De Montfort University. Miss Katherine West
   acknowledges Sustainable Future from Nottingham Trent University for
   organising the workshop with experts. Dr. Jagdeep Singh and Prof. Oksana
   Mont acknowledge the financial support of Urban Reconomy by
   Formas211-2014-1440. Special thanks to Stuart Lawson and Deborah
   Cartmell for supporting the research. Any shortcomings are our own
   responsibility.
CR Andersen DF, 2007, J OPER RES SOC, V58, P691, DOI 10.1057/palgrave.jors.2602339
   Aus R, 2011, THESIS
   Bridgens B, 2018, J CLEAN PROD, V189, P145, DOI 10.1016/j.jclepro.2018.03.317
   Cassidy T. D, 2017, UPCYCLING FASHION MA, P148
   Coote A, 2010, 21 HOURS WHY SHORTER, P40
   Das D, 2015, INT J PROD RES, V53, P141, DOI 10.1080/00207543.2014.942007
   Dissanayake G, 2015, RESOUR CONSERV RECY, V104, P94, DOI 10.1016/j.resconrec.2015.09.008
   Earley R, 2011, UPCYCLING TEXTILES A
   EMF, 2013, CIRC EC, V1, P98
   Farrant L, 2010, INT J LIFE CYCLE ASS, V15, P726, DOI 10.1007/s11367-010-0197-y
   Fletcher K., 2012, FASHION SUSTAINABILI
   Fletcher K, 2013, SUSTAINABILITY IN FASHION AND TEXTILES: VALUES, DESIGN, PRODUCTION AND CONSUMPTION, pIX
   Fromm E., 1976, HAVE BE
   Gangola S, 2018, ADV ENV ENG GREEN TE, P1, DOI 10.4018/978-1-5225-3126-5.ch001
   Gardetti MA, 2017, SUSTAINABILITY FASHI
   Goldsmith B, 2009, TRASH TREASURE UPCYC
   Guiot D, 2010, J RETAILING, V86, P355, DOI 10.1016/j.jretai.2010.08.002
   Han S, 2015, PLATE PROD LIF ENV C
   Harris F, 2016, INT J CONSUM STUD, V40, P309, DOI 10.1111/ijcs.12257
   Hawkins G., 2001, INT J CULTURAL STUD, V4, P5
   Hirscher AL, 2018, J CLEAN PROD, V172, P4544, DOI 10.1016/j.jclepro.2017.11.020
   Hjelmgren D, 2015, WASTE MANAGEMENT SUS, P187
   Janigo KA, 2015, FASHION PRACT, V7, P75, DOI 10.2752/175693815X14182200335736
   Kamleitner B, 2017, ACR N AM ADV
   Khan A, 2018, DES TECHNOL ED, V23
   Larsson M, 2018, CIRCULAR BUSINESS MO, P163
   Laurenti R, 2016, SYST RES BEHAV SCI, V33, P381, DOI 10.1002/sres.2330
   Okoli C, 2015, COMMUNICATIONS ASS I, P37
   Paras MK, 2018, RES J TEXT APPAR, V22, P46, DOI 10.1108/RJTA-03-2017-0011
   Robson C., 2011, REAL WORLD RES RESOU
   Salvia G, 2015, PLATE PRODUCT LIFETI
   Seravalli Anna., 2016, MAKING UPCYCLING STA
   Silver C., 2014, USING SOFTWARE QUALI
   Sung K, 2017, PRODUCT LIFETIMES AND THE ENVIRONMENT (PLATE), P397, DOI 10.3233/978-1-61499-820-4-397
   Sung K., 2015, ICEES, P28
   Sung K, 2017, 18 EUR ROUNDT SUST C
   Sung Kyungeun., 2017, THESIS
   Vennix J.A.M, 1996, GROUP MODEL BUILDING
   Vennix JAM, 1999, SYST DYNAM REV, V15, P379, DOI 10.1002/(SICI)1099-1727(199924)15:4<379::AID-SDR179>3.0.CO;2-E
   Wang L, 2018, CONSTR BUILD MATER, V159, P54, DOI 10.1016/j.conbuildmat.2017.10.107
   Woollard M, 2010, PRE-HOSPITAL OBSTETRIC EMERGENCY TRAINING: THE PRACTICAL APPROACH, P136
   Zhao J, 2013, MATH PROBL ENG, DOI 10.1155/2013/619564
NR 42
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104439
DI 10.1016/j.resconrec.2019.104439
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000031
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Thomas, D
   Mulville, M
   Hare, B
AF Thomas, David
   Mulville, Mark
   Hare, Billy
TI The identification of the domestic waste collection system associated
   with the least operative musculoskeletal disorders using human Resource
   absence data
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Epidemiology; Musculoskeletal disorder (MSD); Recycling and waste
   collection; Ill health; Absence
ID OCCUPATIONAL-HEALTH; HOUSEHOLD; EFFICIENCY; WORKERS; SAFETY; IMPACT;
   LIFE
AB With increasing pressures around public sector costs, UK Local Authorities (LAs) and waste collection companies, are under pressure to reduce absence rates due to ill health. The identification of the 'safest' method of waste collection in the UK has been largely unresolved with many different types of waste and recycling receptacles used and deemed acceptable. The purpose of the study was to investigate the relationships between domestic waste collection methods and absence due to Musculoskeletal Disorders (MSDs) through the comparison of absence rates for different activity. Studies based upon ergonomic theory had suggested the use of wheeled bins is better than the use of boxes, but this has not been tested empirically. Absence data was obtained from 15 LAs who allocated a more detailed activity role to their records, allowing for activity absence rates to be calculated. The outputs were collated and analysed using SPSS to identify statistically significant relationships between types of waste collection services. The results confirm that wheeled bins are associated with less proxy measures of MSD than boxes, baskets and sacks with even lower absence rates associated with 1100 L capacity bins, when handled by two workers. Findings also indicates that there is a level where MSD absence interventions are unlikely to be sustainable.
   In conclusion these findings should help LAs better understand some critical factors regarding waste collection strategies and MSD absence and inform HSE enforcement strategies. Employers should interrogate their own ill health data and seek to move to systems that create less MSDs.
C1 [Thomas, David; Mulville, Mark; Hare, Billy] Univ Greenwich, London SE10 9LS, England.
RP Thomas, D (reprint author), Univ Greenwich, London SE10 9LS, England.
EM david.thomas@gre.ac.uk
OI Mulville, Mark/0000-0001-7466-4377; Thomas, David/0000-0003-1209-7025
CR An H, 1999, WASTE MANAGE RES, V17, P369, DOI 10.1034/j.1399-3070.1999.00058.x
   Anastasi K, 2013, COMMUNICATION   0612, P2013
   [Anonymous], 2016, VEOLIA ROLLS OUT SOU
   [Anonymous], 2013, DEFR SEP GLASS COLL
   Bartolacci F, 2019, RESOUR CONSERV RECY, V148, P124, DOI 10.1016/j.resconrec.2019.05.019
   Bees AD, 2017, WASTE MANAGE, V70, P222, DOI 10.1016/j.wasman.2017.09.004
   Black C., 2011, HLTH WORK INDEPENDEN
   Bomel, 2004, MAPP HLTH SAF STAND
   Bomel, 2009, UPDA MAPP HLTH SAF S
   Burton AK, 2006, EUR SPINE J, V15, pS136, DOI 10.1007/s00586-006-1070-3
   CIPD, 2018, HLTH WELL BEING WORK
   Feuerstein M, 2003, PAIN, V102, P51, DOI 10.1016/S0304-3959(02)00339-1
   Fisher T, 2017, AM J OCCUP THER, V71, DOI 10.5014/ajot.2017.022871
   Froggett M, 2010, POLICY MANAGING MUSC
   Garrido MV, 2015, J OCCUP MED TOXICOL, V10, DOI 10.1186/s12995-015-0065-6
   Handcock MS, 2011, SOCIOL METHODOL, V41, P367, DOI 10.1111/j.1467-9531.2011.01243.x
   Henry M, 2010, SICKNESS ABSENCE SUR
   Hollett N, 2009, HLTH SAFETY STUDY KE
   Holmes E., 2009, REV SICKNESS ABSENCE
   HSE, 2018, HLTH SAF WORK SUMM S
   HSE, 2013, MUSCULOSKELETAL DISO
   HSE, 2012, HLTH SAF STAT WAST M
   HSE, 2015, MAN HLTH SAF WORKPL
   HSE, 2009, 23 HSE WISH
   HSE, 2011, SORT PROC WAST HLTH
   Hughes A, 2018, RECYCLING CHANGES BI
   IOSH, 2015, SYST FOC GUID OCC SA
   Jeong BY, 2016, HUM FACTOR ERGON MAN, V26, P608, DOI 10.1002/hfm.20680
   Jeong BY, 2016, SAF HEALTH WORK-KR, V7, P138, DOI 10.1016/j.shaw.2015.11.008
   Kuijer P. P. F. M., 2002, EFFECTIVENESS INTERV
   Kuijer PPFM, 2007, INT J IND ERGONOM, V37, P855, DOI 10.1016/j.ergon.2007.07.011
   Kuijer PPFM, 2010, AM J IND MED, V53, P1040, DOI 10.1002/ajim.20870
   Lamb G., 2013, HLTH SAFETY ASSESSME
   Lund Research Ltd, 2012, CONV SAMPL
   Mason S, 2013, SICKNESS ABSENCE MAN
   McGill SM, 1997, J BIOMECH, V30, P465, DOI 10.1016/S0021-9290(96)00172-8
   McHugh M., 2001, INT J PUBLIC SECTOR, V14, P43, DOI DOI 10.1108/09513550110387066
   Meng XY, 2019, RESOUR CONSERV RECY, V140, P224, DOI 10.1016/j.resconrec.2018.09.021
   Mills C, 2009, FOOD WASTE COLLECTIO
   Naylor S, 2014, NATL SURVEY BURDEN S
   NZGov, 2018, UND INT BOX PLOTS
   Oldfield A, 2008, SICKNESS ABSENCE PER
   Oxley L, 2006, MANUAL HANDLING KERB
   Parry P., 2008, KERBSIDE RECYCLING C
   Pillastrini P, 2010, APPL ERGON, V41, P436, DOI 10.1016/j.apergo.2009.09.008
   Pinder A, 2019, COMP ANAL MANUAL HAN
   Pinder A, 2002, MANUAL HANDLING REFU
   POULSEN OM, 1995, SCI TOTAL ENVIRON, V168, P33, DOI 10.1016/0048-9697(95)04521-2
   Qureshi Zahid H, 2007, 2007 IEEE International Conference on Industrial Engineering and Engineering Management, P1883, DOI 10.1109/IEEM.2007.4419519
   Read C., 2013, COMMUNICATION
   Romano G, 2019, RESOUR CONSERV RECY, V146, P256, DOI 10.1016/j.resconrec.2019.03.030
   Saranga O, 2017, J BUS MANAG, V19, P6
   Slow E, 2019, BEXLEY PLANS BOXES B
   Thomas D, 2006, BOX BASKET WEIGHT TR
   Thomas D, 2018, POLICY PRACT HLTH SA, P1
   Toyer M., 2015, LOCAL AUTHORITIES HI
   UKG, 2019, GOV SETS OUT PLANS O
   van der Beek AJ, 1999, INT J IND ERGONOM, V24, P417, DOI 10.1016/S0169-8141(99)00008-6
   Wai EK, 2010, SPINE J, V10, P76, DOI 10.1016/j.spinee.2009.06.005
   Walker D, 2012, ASSESSMENT PROS CONS
   Warburton N, 2019, COUNCIL WEIGHS SMALL
   Westgaard RH, 1997, INT J IND ERGONOM, V20, P463, DOI 10.1016/S0169-8141(96)00076-5
   Widanarko B, 2011, INT J IND ERGONOM, V41, P561, DOI 10.1016/j.ergon.2011.06.002
   Williams ID, 2013, SCI TOTAL ENVIRON, V445, P29, DOI 10.1016/j.scitotenv.2012.12.024
   Woon KS, 2016, RESOUR CONSERV RECY, V107, P104, DOI 10.1016/j.resconrec.2015.11.020
   Yang CY, 2001, ENVIRON RES, V85, P195, DOI 10.1006/enrs.2000.4235
   Ziaei M, 2018, INDIVIDUAL PHYS ORG
NR 67
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104424
DI 10.1016/j.resconrec.2019.104424
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000012
DA 2020-05-12
ER

PT J
AU Tian, X
   Hu, YY
   Yin, HT
   Geng, Y
   Bleischwitz, R
AF Tian, Xu
   Hu, Yunyi
   Yin, Haitao
   Geng, Yong
   Bleischwitz, Raimund
TI Trade impacts of China's Belt and Road Initiative: From resource and
   environmental perspectives
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE The Belt and Road Initiative; Trade; Environment; Resource; Governance
ID DIFFERENCE-IN-DIFFERENCES; VIRTUAL WATER TRADE; INTERNATIONAL-TRADE;
   COUNTRIES; PRODUCTS; NATIONS; GROWTH; FLOWS
AB China's 'Belt and Road Initiative' (BRI) is a major global initiative with severe implications for economies, policies and societies; yet its impacts on environment and natural resource use have received little attention. This paper fills such a gap by assessing environmental and resource impacts of China's international trade with those BRI countries after the start of the BRI in 2013. Despite potential concerns on problem shifting, we find that China's net export growth after the BRI is concentrated in pollution-intensive and resource-intensive industries, compared to what would happen otherwise, and therefore increases China's domestic environmental and resource burden. This alleviates the concern over a migration of pollution and resource exploitation from China to other BRI countries and provides valuable insights to the Chinese policy makers. Several policy recommendations are raised in order to improve the overall sustainability of China's BRI.
C1 [Tian, Xu; Geng, Yong] Shanghai Jiao Tong Univ, Sch Int & Publ Affairs, Shanghai 200240, Peoples R China.
   [Bleischwitz, Raimund] UCL, Bartlett Sch Environm Energy & Resources, Inst Sustainable Resources, Cent House,14 Upper Woburn Pl, London WC1H 0NN, England.
   [Hu, Yunyi; Yin, Haitao] Shanghai Jiao Tong Univ, Antai Coll Econ & Management, Shanghai 200030, Peoples R China.
   [Geng, Yong] Shanghai Jiao Tong Univ, China Inst Urban Governance, Shanghai 200240, Peoples R China.
   [Geng, Yong] Shanghai Inst Pollut Control & Ecol Secur, Shanghai 200092, Peoples R China.
RP Geng, Y (reprint author), Shanghai Jiao Tong Univ, Sch Int & Publ Affairs, Shanghai 200240, Peoples R China.; Bleischwitz, R (reprint author), UCL, Bartlett Sch Environm Energy & Resources, Inst Sustainable Resources, Cent House,14 Upper Woburn Pl, London WC1H 0NN, England.; Yin, HT (reprint author), Shanghai Jiao Tong Univ, Antai Coll Econ & Management, Shanghai 200030, Peoples R China.
EM haitao.yin@gmail.com; ygeng@sjtu.edu.cn; r.bleischwitz@ucl.ac.uk
RI Geng, Yong/B-6310-2018
OI Geng, Yong/0000-0002-2284-1375; Tian, Xu/0000-0003-3265-5725
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [71704104, 71774100, 71690241, 71810107001]; Fundamental
   Research Funds for the China postdoctoral Science Foundation; Shanghai
   Municipal Government [17XD1401800]; Shanghai Jiao Tong University
   [SJTU-2019UGBD-03]; University College London (UCL)
FX This study is supported by the Natural Science Foundation of China
   (71704104, 71774100, 71690241, 71810107001), the Fundamental Research
   Funds for the China postdoctoral Science Foundation, the Shanghai
   Municipal Government (17XD1401800), and the big data project funded by
   Shanghai Jiao Tong University (SJTU-2019UGBD-03). Tian Xu values a
   visiting scholarship at University College London (UCL). The authors are
   grateful for the comments from the anonymous reviewers of this paper.
CR Abadie A, 2005, REV ECON STUD, V72, P1, DOI 10.1111/0034-6527.00321
   Bleischwitz R, 2018, NAT SUSTAIN, V1, P737, DOI 10.1038/s41893-018-0173-2
   Bringezu S, 2004, ECOL ECON, V51, P97, DOI 10.1016/j.ecolecon.2004.04.010
   Bruckner M., 2012, GLOB ENV CHANG, V22, P568
   Cai X, 2018, J CLEAN PROD, V198, P624, DOI 10.1016/j.jclepro.2018.06.291
   CCSY, 2018, CHIN CUST STAT YB GE
   Chatham House analysis of BP, 2015, STAT REV WORLD ENERG
   Chen Y. J, 2018, EC HDB ONE BELT ONE
   Dalin C, 2012, P NATL ACAD SCI USA, V109, P5989, DOI 10.1073/pnas.1203176109
   Donald SG, 2007, REV ECON STAT, V89, P221, DOI 10.1162/rest.89.2.221
   Du JL, 2018, CHINA ECON REV, V47, P189, DOI 10.1016/j.chieco.2017.05.010
   Duan F, 2018, J CLEAN PROD, V170, P535, DOI 10.1016/j.jclepro.2017.09.152
   Duan YW, 2017, ECOL ECON, V132, P31, DOI 10.1016/j.ecolecon.2016.10.001
   Fischer-Kowalski M, 2015, REPORT INT RESOURCE
   Geng Y, 2019, NATURE, V565, P153, DOI 10.1038/d41586-019-00017-z
   GROSSMAN GM, 1995, Q J ECON, V110, P353, DOI 10.2307/2118443
   Hu RW, 2017, LANCET GLOB HEALTH, V5, pE752, DOI 10.1016/S2214-109X(17)30250-4
   Jian WY, 2015, LANCET, V386, P26
   Li JX, 2018, PHYSICA A, V509, P1140, DOI 10.1016/j.physa.2018.06.059
   Lin LG, 2014, PROD OPER MANAG, V23, P525, DOI 10.1111/poms.12087
   Liu CH, 2018, NAT RESOUR RES, V27, P257, DOI 10.1007/s11053-017-9342-7
   Liu YY, 2018, SCI TOTAL ENVIRON, V645, P674, DOI 10.1016/j.scitotenv.2018.07.062
   Peters GP, 2011, P NATL ACAD SCI USA, V108, P8903, DOI 10.1073/pnas.1006388108
   Shuai J, 2018, ENERG POLICY, V120, P559, DOI 10.1016/j.enpol.2018.05.042
   Slaughter M. J, 1998, AM ECON REV, P194
   Tao H. U, 2011, ENV SUSTAIN DEV, V3, P21
   Tian X, 2018, RESOUR CONSERV RECY, V131, P148, DOI 10.1016/j.resconrec.2018.01.002
   Tian X, 2017, RESOUR CONSERV RECY, V126, P1, DOI 10.1016/j.resconrec.2017.07.017
   Zhai F, 2018, J ASIAN ECON, V55, P84, DOI 10.1016/j.asieco.2017.12.006
   Zhang N, 2017, SCIENCE, V357, P1107, DOI 10.1126/science.aao6621
   Zhang Y, 2018, SCI TOTAL ENVIRON, V622, P988, DOI 10.1016/j.scitotenv.2017.11.351
NR 31
TC 0
Z9 0
U1 46
U2 61
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104430
DI 10.1016/j.resconrec.2019.104430
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000021
DA 2020-05-12
ER

PT J
AU Urrutia, I
   Dias, GM
   Clapp, J
AF Urrutia, Isabel
   Dias, Goretty M.
   Clapp, Jennifer
TI Material and visceral engagements with household food waste: Towards
   opportunities for policy interventions
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste drivers; Visceral-material assessment
ID TIME-SCARCITY; CONSUMER; GEOGRAPHIES; CONTEXTS; OBESITY; HEALTH; MEALS
AB Current policies and programs to reduce consumer food waste are largely based on changing behaviours rather than addressing the underlying drivers of these behaviours. This article builds on previous structural approaches to understand underlying motivations of food waste-related behaviours. Our findings suggest that efforts to address food waste at the household level must be integrated with broader policies relating to food access and food insecurity, particularly those that seek to address food insecurity at the systems level. We use a visceral material framework to analyze and interpret data from thirteen households, with seventeen participants, in Ontario, Canada, including interviews, participant observation, and food waste measurements. We demonstrate that a visceral-material framework is useful in highlighting complex drivers of household food waste that are often missed in other studies: Although this work confirms previously identified barriers to reduce household food waste (e.g. identity, food packaging, low food literacy), we also draw out multi-scalar and interacting drivers of food waste, such as differing spatial access to food, and complex relationships with food due to past experiences of food abundance or food insecurity.
C1 [Urrutia, Isabel] Univ Toronto, Dept Geog & Planning, 27 Kings Coll Cir, Toronto, ON M5S, Canada.
   [Dias, Goretty M.] Univ Waterloo, Sch Environm Enterprise & Dev, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
   [Clapp, Jennifer] Univ Waterloo, Sch Environm Resources & Sustainabil, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.
RP Urrutia, I (reprint author), Univ Toronto, Dept Geog & Planning, 27 Kings Coll Cir, Toronto, ON M5S, Canada.
EM isabel.urrutiaschroeder@mail.utoronto.ca; gdias@uwaterloo.ca;
   jclapp@uwaterloo.ca
CR [Anonymous], 2018, SUST DEV GOALS REP 2, DOI [10.18356/7d014b41-en, DOI 10.18356/7D014B41-EN]
   Bio Intelligence Service, 2010, PREPARATORY STUDY FO, DOI [10.2779/85947, DOI 10.2779/85947]
   Bridgwater E, 2009, EVALUATION WRAP SEPA
   Bridgwater E, 2011, SYNTHESIS FOOD WASTE
   Brinkmann S, 2012, QUALITATIVE INQUIRY, P11
   Cappellini B, 2014, CONSUMP MARK CULT, V17, P71, DOI 10.1080/10253866.2012.701893
   Celnik D, 2012, TRENDS FOOD SCI TECH, V27, P4, DOI 10.1016/j.tifs.2012.06.001
   Clive H, 2005, WASTEFUL CONSUMPTION
   Cloke J, 2013, GEOGR COMPASS, V7, P622, DOI 10.1111/gec3.12068
   Coffey A., 1996, MAKING SENSE QUALITA, P26
   Cox J, 2007, FOOD BEHAV CONSUMER
   Cox J, 2010, WASTE MANAGE RES, V28, P193, DOI 10.1177/0734242X10361506
   Djupegot IL, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4408-3
   Evans D, 2012, SOCIOL REV, V60, P5, DOI 10.1111/1467-954X.12035
   Evans D, 2012, ENVIRON PLANN D, V30, P1123, DOI 10.1068/d22210
   Evans D, 2011, CRIT PUBLIC HEALTH, V21, P429, DOI 10.1080/09581596.2011.608797
   FAO, 2013, FOOD WAST FOOTPR IMP
   Fehr M., 2001, Environment, Development and Sustainability, V3, P253, DOI 10.1023/A:1012773330384
   FSRWR, 2019, FOOD SYST ROUNDT WAT
   FUSIONS, 2016, REC GUID COMM EUR FO
   Gille Z, 2012, SOCIOL REV, V60, P27, DOI 10.1111/1467-954X.12036
   Glanz R., 2008, CAUSES FOOD WASTE GE
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Gunson JS, 2017, CRIT PUBLIC HEALTH, V27, P407, DOI 10.1080/09581596.2016.1234709
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   Halkier B, 2011, QUAL INQ, V17, P787, DOI 10.1177/1077800411423194
   Hayes-Conroy A, 2008, GENDER PLACE CULT, V15, P461, DOI 10.1080/09663690802300803
   Hayes-Conroy A, 2017, GEOFORUM, V82, P51, DOI 10.1016/j.geoforum.2017.03.017
   Hayes-Conroy A, 2010, T I BRIT GEOGR, V35, P269, DOI 10.1111/j.1475-5661.2009.00374.x
   Hayes-Conroy J, 2013, EMOT SPACE SOC, V6, P81, DOI 10.1016/j.emospa.2011.11.003
   Hayes-Conroy J, 2010, GEOGR COMPASS, V4, P1273, DOI 10.1111/j.1749-8198.2010.00373.x
   HLPE, 2014, FOOD LOSS WAST CONT
   Jabs J, 2006, APPETITE, V47, P196, DOI 10.1016/j.appet.2006.02.014
   Koivupuro HK, 2012, INT J CONSUM STUD, V36, P183, DOI 10.1111/j.1470-6431.2011.01080.x
   Kremer S, 2016, CONSUMPTION LIFE CYC
   Lazell J, 2016, J CONSUM BEHAV, V15, P430, DOI 10.1002/cb.1581
   Lee KCL, 2018, J CLEAN PROD, V172, P325, DOI 10.1016/j.jclepro.2017.10.085
   MCCARTHY JR, 2003, INT J SOC RES METHOD, V6, P1, DOI DOI 10.1080/13645570110057933
   Meah A, 2014, CRIT PUBLIC HEALTH, V24, P88, DOI 10.1080/09581596.2013.791387
   Miles M, 2014, QUALITATIVE DATA ANA
   Moller H., 2014, REPORT REV FOOD WAST
   Morisaki I, 2011, PATTERN FOOD LOSSES
   Ofei KT, 2014, APPETITE, V83, P49, DOI 10.1016/j.appet.2014.08.001
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Pham T. M. H., 2011, FOOD WASTE RECYCLING
   Probyn E., 2000, CARNAL APPETITES FOO
   Roodhuyzen DMA, 2017, TRENDS FOOD SCI TECH, V68, P37, DOI 10.1016/j.tifs.2017.07.009
   Saldana J., 2017, QUALITATIVE RES ANAL
   Sandover R, 2015, GEOGRAPHY, V100, P152
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Schneider F, 2013, PROC INST CIV ENG-WA, V166, DOI 10.1680/warm.13.00016
   Soma T, 2017, LOCAL ENVIRON, V22, P1444, DOI 10.1080/13549839.2017.1357689
   Stefan V., 2011, ROMANIAN CONSUMERS P
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Stenvoll D, 2011, QUAL RES, V11, P570, DOI 10.1177/1468794111413242
   Strazdins L, 2011, ENVIRON PLANN A, V43, P545, DOI 10.1068/a4360
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Urrutia I., 2014, FOOD WASTAGE REGION
   van Geffen L, 2016, PROJECT REPORT
   van Herpen E, 2016, BEST PRACTICE MEASUR
   Waitt G, 2016, SOC CULT GEOGR, V17, P359, DOI 10.1080/14649365.2015.1075580
   Watson M, 2012, SOCIOL REV, V60, P102, DOI 10.1111/1467-954X.12040
   Williams H, 2012, J CLEAN PROD, V24, P141, DOI 10.1016/j.jclepro.2011.11.044
   WRAP, 2007, UND FOOD WAST
NR 64
TC 3
Z9 3
U1 4
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104435
DI 10.1016/j.resconrec.2019.104435
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000023
DA 2020-05-12
ER

PT J
AU Valenzuela-Levi, N
AF Valenzuela-Levi, Nicolas
TI Factors influencing municipal recycling in the Global South: The case of
   Chile
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Municipal solid waste; Waste management; Recycling rate; Waste policy;
   Local authorities; Circular economy
ID SEPARATE WASTE COLLECTION; SOLID-WASTE; EMPIRICAL-EVIDENCE; MANAGEMENT;
   DETERMINANTS; INEQUALITY; CHALLENGES; DISPOSAL; SANTIAGO; POLITICS
AB One of the targets from the Sustainable Development Goals is by 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse. The indicators defined to measure progress are the recycling rate and Tons of material recycled. Paradoxically, very little is known about these indicators and the factors influencing them outside rich countries, where recycling has been long ago adopted. This study provides the first analysis of factors linked to separate collection rates and kilograms recycled per capita from actually existing municipal recycling services in a Latin American country. Thanks to primary data collection, it is possible to characterise and analyse the Chilean case. By 2018, barely above half of the 345 local governments had implemented recycling. Furthermore, even among municipalities that have been recycling for at least 5 years, separate collection is much lower than in any OECD country with available data. Econometric models are used to test nine different hypotheses about factors influencing municipal recycling. Existence of kerbside separate collection, duration of recycling programs and per capita spending on waste management are found to be positively and significantly linked to separate collection rates. Collection frequency of landfill waste is significant and negatively linked to higher separate collection rates within municipalities, but the same link is not significant between local governments. Four of the Chilean regions are found to be significantly lagging behind compared to the Santiago Metropolitan Region. Variables that are not significant are existence of organic recycling, population density, total population and poverty rate.
C1 [Valenzuela-Levi, Nicolas] Univ Cambridge, Dept Land Econ, 19 Silver St, Cambridge CB3 9EP, England.
RP Valenzuela-Levi, N (reprint author), Univ Cambridge, Dept Land Econ, 19 Silver St, Cambridge CB3 9EP, England.
EM nv284@cam.ac.uk
OI Valenzuela-Levi, Nicolas/0000-0003-1174-9976
FU CONICYT PFCHA/DOCTORADO BECAS CHILE/2016 [72170123]
FX This research was possible thanks to the Becas Chile Program from the
   Chilean National Commission for Science and Technology (Conicyt). This
   work was funded by CONICYT PFCHA/DOCTORADO BECAS CHILE/2016 - 72170123.
CR Abbott A, 2011, ECOL ECON, V70, P2214, DOI 10.1016/j.ecolecon.2011.06.028
   Agovino M, 2019, ECOL INDIC, V98, P297, DOI 10.1016/j.ecolind.2018.11.003
   Agovino M, 2017, ENVIRON DEV SUSTAIN, V19, P589, DOI 10.1007/s10668-015-9754-7
   Agovino M, 2016, J CLEAN PROD, V124, P30, DOI 10.1016/j.jclepro.2016.02.082
   Besen GR, 2016, DISP, V52, P45, DOI 10.1080/02513625.2016.1195583
   Magni AAC, 2014, SAUDE SOC-SAO PAULO, V23, P99, DOI 10.1590/S0104-12902014000100011
   Callan SJ, 2006, E ECON J, V32, P221
   Carvalho P, 2014, WASTE MANAGE, V34, P12, DOI 10.1016/j.wasman.2013.10.004
   Challcharoenwattana A, 2016, J CLEAN PROD, V137, P1118, DOI 10.1016/j.jclepro.2016.07.208
   Chamizo-Gonzalez J, 2016, RESOUR CONSERV RECY, V107, P65, DOI 10.1016/j.resconrec.2015.12.006
   Chen CC, 2010, INT J ENVIRON SCI TE, V7, P447, DOI 10.1007/BF03326154
   Chen CC, 2008, J CLEAN PROD, V16, P59, DOI 10.1016/j.jclepro.2006.07.027
   Alfaia RGDM, 2017, WASTE MANAGE RES, V35, P1195, DOI 10.1177/0734242X17735375
   Chaves GDD, 2014, WASTE MANAGE RES, V32, P19, DOI 10.1177/0734242X14541987
   European Environment Agency, 2016, MUN WAST MAN EUR COU
   Ferronato N, 2019, ENVIRON DEV, V29, P94, DOI 10.1016/j.envdev.2019.01.002
   Gallardo A, 2012, WASTE MANAGE RES, V30, P859, DOI 10.1177/0734242X12443584
   Garreton M, 2017, CITIES, V65, P32, DOI 10.1016/j.cities.2017.02.005
   Giovannini M, 2017, LOCAL ENVIRON, V22, P1497, DOI 10.1080/13549839.2017.1363727
   Greco G, 2015, J CLEAN PROD, V106, P364, DOI 10.1016/j.jclepro.2014.07.011
   GROSSMAN GM, 1993, MEXICO-U.S. FREE TRADE AGREEMENT, P13
   Guibrunet L, 2019, WASTE MANAGE, V86, P13, DOI 10.1016/j.wasman.2019.01.021
   Guibrunet L, 2017, GEOFORUM, V85, P353, DOI 10.1016/j.geoforum.2016.10.011
   Intendencia Region Metropolitana de Santiago, 2019, IN NOV EST SEP REC R
   Jara-Samaniego J, 2017, J CLEAN PROD, V141, P1349, DOI 10.1016/j.jclepro.2016.09.178
   Jenkins RR, 2003, J ENVIRON ECON MANAG, V45, P294, DOI 10.1016/S0095-0696(02)00054-2
   Kaseva ME, 2005, HABITAT INT, V29, P353, DOI 10.1016/j.habitatint.2003.12.003
   Lakhan C, 2014, RESOUR CONSERV RECY, V92, P222, DOI 10.1016/j.resconrec.2014.07.006
   Lavee D, 2010, WASTE MANAGE, V30, P2204, DOI 10.1016/j.wasman.2010.03.032
   Lee S, 2011, BUILD ENVIRON, V46, P1159, DOI 10.1016/j.buildenv.2010.12.005
   Livert F, 2018, REG STUD, V52, P403, DOI 10.1080/00343404.2017.1309013
   Matsumoto S, 2011, RESOUR CONSERV RECY, V55, P325, DOI 10.1016/j.resconrec.2010.10.005
   Mendez AP, 2008, RENEW SUST ENERG REV, V12, P752, DOI 10.1016/j.rser.2006.10.025
   Hare P, 2019, DIALECT ANTHROPOL, V43, P31, DOI 10.1007/s10624-018-9533-6
   Ordonez I, 2013, RESOUR CONSERV RECY, V72, P108, DOI 10.1016/j.resconrec.2013.01.002
   Martinez CIP, 2017, ENVIRON DEV SUSTAIN, V19, P1067, DOI 10.1007/s10668-016-9782-y
   Passarini F, 2011, WASTE MANAGE, V31, P785, DOI 10.1016/j.wasman.2010.11.021
   PERETZ JH, 2005, [No title captured], V48, P627, DOI DOI 10.1080/0964056050018170
   Rehren A, 1996, CRIME LAW SOCIAL CH, V25, P323, DOI 10.1007/BF00572513
   Rojas CA, 2018, RESOURCES-BASEL, V7, DOI 10.3390/resources7010018
   Rosa E, 2018, ENVIRON PLANN A, V50, P1407, DOI 10.1177/0308518X18781083
   Sidique SF, 2010, RESOUR CONSERV RECY, V54, P242, DOI 10.1016/j.resconrec.2009.08.006
   Slavik J, 2013, RESOUR CONSERV RECY, V70, P68, DOI 10.1016/j.resconrec.2012.09.013
   Sorroche S, 2017, REV ESTUD SOC, P58, DOI 10.7440/res61.2017.05
   Starr J, 2015, RESOUR CONSERV RECY, V99, P7, DOI 10.1016/j.resconrec.2015.03.009
   Subsecretaria de Desarrollo Regional, 2019, SIST NAC INF MUN
   Tadesse T, 2009, RESOUR CONSERV RECY, V53, P183, DOI 10.1016/j.resconrec.2008.11.009
   Thorpe N., 2013, INDEPENDENT STUDY PR, P1806
   United Nations, 2016, SUST DEV GOALS REP 2
   Valenzuela-Levi N, 2019, J CLEAN PROD, V213, P440, DOI 10.1016/j.jclepro.2018.12.195
   Vasconi P, 2004, RESIDUOS SOLIDOS DOM
   Vasquez OC, 2014, RESOUR CONSERV RECY, V82, P94, DOI 10.1016/j.resconrec.2013.11.006
   Vasquez OC, 2011, REV INT CONTAM AMBIE, V27, P347
   Vergara SE, 2016, J IND ECOL, V20, P107, DOI 10.1111/jiec.12257
   Xevgenos D, 2015, WASTE BIOMASS VALORI, V6, P657, DOI 10.1007/s12649-015-9389-9
NR 55
TC 0
Z9 0
U1 12
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104441
DI 10.1016/j.resconrec.2019.104441
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000025
DA 2020-05-12
ER

PT J
AU Wang, CY
   Lin, L
   Olsson, G
   Liu, Y
   Xu, M
AF Wang, Chunyan
   Lin, Lu
   Olsson, Gustaf
   Liu, Yi
   Xu, Ming
TI The scope and understanding of the water-electricity nexus
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Water-electricity nexus; Electricity generation; Household end-use;
   Spatial mismatch; Integrated management
ID ENERGY-FOOD NEXUS; POWER-GENERATION; RESIDENTIAL WATER; INTEGRATED
   MODEL; CLIMATE-CHANGE; FRESH-WATER; CHINA; DEMAND; CONSUMPTION;
   FOOTPRINT
AB The water use associated with electricity generation and consumption has been the focus of research for decades. This study provides an overview of the water-electricity nexus from the perspectives of electricity production and consumption. In terms of production, the electricity generation and associated water use for various regions are summarized and compared. The spatial mismatch between water resource and electricity generation is highlighted and analyzed. It is estimated that the water use will be a vital constraint for future electricity generation in some regions. The technological water saving potential is evaluated to address this issue. In terms of consumption, space cooling/heating and water heating are identified as the most significant nexus-related coupled nodes at the household end-use level. Gaps in the theoretical nexus concept and practical policymaking are summarized herein. Existing policies in the US and Europe related to the water-electricity nexus are also reviewed. This study highlights that the generation and cooling technologies greatly influence the water consumption and withdrawal for electricity generation; tremendous spatial disparities of local water resources and electricity generation exist; residential behavior and household appliances have an impact on the household water-electricity nexus; and comprehensive management of the couplings between water and energy is lacking and urgently required.
C1 [Wang, Chunyan; Liu, Yi] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
   [Wang, Chunyan; Xu, Ming] Univ Michigan, Sch Environm & Sustainabil, Ann Arbor, MI 48109 USA.
   [Lin, Lu] China Univ Petr, Sch Econ & Management, Acad Chinese Energy Strategy, Beijing 102249, Peoples R China.
   [Olsson, Gustaf] Lund Univ, Ind Elect Engn & Automat, S-22100 Lund, Sweden.
   [Xu, Ming] Univ Michigan, Civil & Environm Engn, Ann Arbor, MI 48109 USA.
RP Liu, Y (reprint author), Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
EM wangchunyan@mail.tsinghua.edu.cn; linlu26@hotmail.com;
   gustaf.olsson@iea.lth.se; yi.liu@tsinghua.edu.cn; mingxu@umich.edu
RI Xu, Ming/F-3653-2010
OI Xu, Ming/0000-0002-7106-8390
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71774096, 71974110]; "12th Five -Year" Major
   Science and Technology Program for Water Pollution Control and
   Treatment- "Integration of urban water pollution control and water
   treatment technology" [2014ZX07323001]
FX This study was supported by the National Natural Science Foundation of
   China (No. 71774096 and No. 71974110) and "12th Five -Year" Major
   Science and Technology Program for Water Pollution Control and
   Treatment- "Integration of urban water pollution control and water
   treatment technology" (No. 2014ZX07323001).
CR Abdallah AM, 2014, J WATER RES PLAN MAN, V140, P288, DOI 10.1061/(ASCE)WR.1943-5452.0000340
   Ackerman F, 2013, ENERG POLICY, V59, P235, DOI 10.1016/j.enpol.2013.03.027
   Agrawal N, 2018, APPL ENERG, V216, P558, DOI 10.1016/j.apenergy.2018.02.116
   Ahjum F, 2018, ENVIRON PROG SUSTAIN, V37, P132, DOI 10.1002/ep.12837
   Akpinar A, 2012, RENEW SUST ENERG REV, V16, P1146, DOI 10.1016/j.rser.2011.11.015
   Albrecht TR, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aaa9c6
   Ali B, 2017, ENERG CONVERS MANAGE, V150, P201, DOI 10.1016/j.enconman.2017.08.019
   Ali B, 2017, ENERG CONVERS MANAGE, V143, P470, DOI 10.1016/j.enconman.2017.04.028
   Averyt K, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/015001
   Bakken TH, 2016, WATER POLICY, V18, P932, DOI 10.2166/wp.2016.009
   Balat H, 2008, RENEW SUST ENERG REV, V12, P1652, DOI 10.1016/j.rser.2007.03.001
   Bartos MD, 2014, ENVIRON SCI TECHNOL, V48, P2139, DOI 10.1021/es4033343
   Behrens P, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.114
   Binks AN, 2017, J CLEAN PROD, V157, P177, DOI 10.1016/j.jclepro.2017.04.128
   Binks AN, 2016, J CLEAN PROD, V135, P892, DOI 10.1016/j.jclepro.2016.06.091
   Brierley M., 2014, RE UK POWER STATIONS
   Bromwich B, 2015, INT J WATER RESOUR D, V31, P375, DOI 10.1080/07900627.2015.1030495
   Byers EA, 2014, GLOBAL ENVIRON CHANG, V25, P16, DOI 10.1016/j.gloenvcha.2014.01.005
   Carrillo AMR, 2009, ENERG POLICY, V37, P4303, DOI 10.1016/j.enpol.2009.05.074
   Carter N. T., 2010, ENERGYS WATER DEMAND
   Castillo RM, 2019, J CLEAN PROD, V214, P52, DOI 10.1016/j.jclepro.2018.12.264
   Chini CM, 2018, NAT ENERGY, V3, P1115, DOI 10.1038/s41560-018-0266-1
   Chini CM, 2016, ENVIRON SCI TECHNOL, V50, P9003, DOI 10.1021/acs.est.6b01559
   Clemmer S, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/015004
   Cominola A, 2018, J CLEAN PROD, V172, P1607, DOI 10.1016/j.jclepro.2017.10.203
   Dai JY, 2018, APPL ENERG, V210, P393, DOI 10.1016/j.apenergy.2017.08.243
   Dale AT, 2014, SUSTAIN ENERGY TECHN, V7, P237, DOI 10.1016/j.seta.2014.02.006
   DeOreo W. B., 2016, RESIDENTIAL END USES
   Dhaubanjar S, 2017, WATER-SUI, V9, DOI 10.3390/w9030162
   Dodder RS, 2014, CURR OPIN CHEM ENG, V5, P7, DOI 10.1016/j.coche.2014.03.004
   DOE (Department of Energy U. S.), 2009, CONC SOL POW COMM AP
   Endo A, 2015, J HYDROL REGION STUD, V11, P20, DOI DOI 10.1016/J.EJRH.2015.11.010
   Energy I, 2019, PAN 2011 WAT EL
   Escriva-Bou A, 2015, ENVIRON SCI POLICY, V50, P270, DOI 10.1016/j.envsci.2015.03.005
   Feng K, 2014, RENEW SUST ENERG REV, V39, P342, DOI 10.1016/j.rser.2014.07.080
   FENG Y, 2018, WATER-SUI, V10, DOI DOI 10.3390/W10030308
   Fthenakis V, 2010, RENEW SUST ENERG REV, V14, P2039, DOI 10.1016/j.rser.2010.03.008
   Gilron J, 2014, CLEAN TECHNOL ENVIR, V16, P1471, DOI 10.1007/s10098-014-0853-1
   GLEICK PH, 1994, ANNU REV ENERG ENV, V19, P267, DOI 10.1146/annurev.eg.19.110194.001411
   Grubert E, 2018, ENVIRON SCI TECHNOL, V52, P6695, DOI 10.1021/acs.est.8b00139
   Grubert EA, 2016, ADV WATER RESOUR, V96, P88, DOI 10.1016/j.advwatres.2016.07.004
   Grubert EA, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/4/045801
   Gu A, 2014, ENERG CONVERS MANAGE, V85, P630, DOI 10.1016/j.enconman.2014.04.054
   Hadian S, 2013, SUSTAINABILITY-BASEL, V5, P4674, DOI 10.3390/su5114674
   Hamiche AM, 2016, RENEW SUST ENERG REV, V65, P319, DOI 10.1016/j.rser.2016.07.020
   HARTE J, 1978, SCIENCE, V199, P623, DOI 10.1126/science.199.4329.623
   Hussien WA, 2017, ENVIRON MODELL SOFTW, V93, P366, DOI 10.1016/j.envsoft.2017.03.034
   International Energy Agency (IEA), 2016, WAT EN NEX
   Jack MW, 2018, APPL ENERG, V211, P104, DOI 10.1016/j.apenergy.2017.11.044
   Jiang DQ, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/2/024015
   Jin Y, 2017, RESOUR CONSERV RECY, V127, P206, DOI 10.1016/j.resconrec.2017.09.004
   Karatasou S, 2018, ENERG BUILDINGS, V170, P107, DOI 10.1016/j.enbuild.2018.04.019
   Kenway SJ, 2011, J WATER CLIM CHANGE, V2, P247, DOI 10.2166/wcc.2011.005
   Kenway SJ, 2011, WATER SCI TECHNOL, V63, P1983, DOI 10.2166/wst.2011.070
   Kenway SJ, 2016, ENERG BUILDINGS, V131, P21, DOI 10.1016/j.enbuild.2016.09.008
   Kenway SJ, 2013, ENERG BUILDINGS, V58, P378, DOI 10.1016/j.enbuild.2012.08.035
   Koulouri A, 2014, SAVING WATER WIND EN
   Kumar P, 2014, URBAN CLIM, V10, P846, DOI 10.1016/j.uclim.2014.07.004
   Lechon Y, 2018, ENERGIES, V11, DOI 10.3390/en11051203
   Leck H, 2015, GEOGR COMPASS, V9, P445, DOI 10.1111/gec3.12222
   Leitner Arnold, 2002, FUEL SKY SOLAR POWER
   Li MQ, 2017, APPL ENERG, V208, P580, DOI 10.1016/j.apenergy.2017.09.096
   Li X, 2019, APPL ENERG, V235, P827, DOI 10.1016/j.apenergy.2018.10.097
   Li X, 2012, ENERG POLICY, V45, P440, DOI 10.1016/j.enpol.2012.02.054
   Liao XW, 2019, J ENVIRON MANAGE, V231, P989, DOI 10.1016/j.jenvman.2018.10.109
   Liao XW, 2018, APPL ENERG, V226, P252, DOI 10.1016/j.apenergy.2018.05.132
   Liao XW, 2016, GLOBAL ENVIRON CHANG, V41, P142, DOI 10.1016/j.gloenvcha.2016.09.007
   LIN L, 2018, SUSTAINABILITY-BASEL, V10, DOI DOI 10.3390/SU10010030
   Liu JG, 2015, SCI REP-UK, V5, DOI 10.1038/srep11446
   Liu L, 2015, TECHNOL FORECAST SOC, V94, P318, DOI 10.1016/j.techfore.2014.11.004
   Lofman D, 2002, INT J WATER RESOUR D, V18, P73, DOI 10.1080/07900620220121666
   Lubega WN, 2014, APPL ENERG, V135, P142, DOI 10.1016/j.apenergy.2014.07.101
   Lubega WN, 2013, 2013 8TH INTERNATIONAL CONFERENCE ON SYSTEM OF SYSTEMS ENGINEERING (SOSE), P76, DOI 10.1109/SYSoSE.2013.6575246
   Macknick J, 2012, ENVIRON RES LETT, V7, DOI 10.1088/1748-9326/7/4/045803
   Mannan M, 2018, J CLEAN PROD, V193, P300, DOI 10.1016/j.jclepro.2018.05.050
   Marsh D, 2008, THESIS
   Matos C, 2018, SCI TOTAL ENVIRON, V642, P421, DOI 10.1016/j.scitotenv.2018.06.062
   Matos C, 2017, SCI TOTAL ENVIRON, V586, P536, DOI 10.1016/j.scitotenv.2017.02.008
   Mekonnen MM, 2011, HYDROL EARTH SYST SC, V15, P1577, DOI 10.5194/hess-15-1577-2011
   Mekonnen MM, 2015, ENVIRON SCI-WAT RES, V1, P285, DOI [10.1039/c5ew00026b, 10.1039/C5EW00026B]
   Meldrum J, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/015031
   Mercure JF, 2019, RENEW SUST ENERG REV, V105, P230, DOI 10.1016/j.rser.2019.01.045
   Mielke E, 2010, WATER CONSUMPTION EN
   Mostafavi N, 2018, ENERG BUILDINGS, V158, P1683, DOI 10.1016/j.enbuild.2017.12.005
   Mouratiadou I, 2018, CLIMATIC CHANGE, V147, P91, DOI 10.1007/s10584-017-2117-7
   Murrant D, 2017, ENERG POLICY, V108, P844, DOI 10.1016/j.enpol.2017.05.011
   Murrant D, 2017, ENERG POLICY, V108, P859, DOI 10.1016/j.enpol.2017.03.047
   Nair S, 2018, WATER-SUI, V10, DOI 10.3390/w10060810
   NCSL (National Conference of State Legislatures), 2014, OV WAT EN NEX US
   Nouri N, 2019, APPL ENERG, V248, P196, DOI 10.1016/j.apenergy.2019.04.023
   Okadera T, 2015, ENERG POLICY, V78, P148, DOI 10.1016/j.enpol.2014.12.029
   Olsson G., 2012, WAT EN THREATS OPP, P190
   Olsson G., 2018, CLEAN WATER SUING SL
   Olsson G., 2015, WATER ENERGY THREATS
   Olsson G, 2013, FRONT ENV SCI ENG, V7, P787, DOI 10.1007/s11783-013-0526-z
   Pang MY, 2015, ENERG POLICY, V76, P112, DOI 10.1016/j.enpol.2014.10.009
   Parkinson SC, 2018, APPL ENERG, V210, P477, DOI 10.1016/j.apenergy.2016.12.142
   Paul P., 2016, INT J ENV RES PUBLIC, V13
   Peng W, 2018, NAT SUSTAIN, V1, P693, DOI 10.1038/s41893-018-0174-1
   Perrone D, 2011, ENVIRON SCI TECHNOL, V45, P4228, DOI 10.1021/es103230n
   Pfister S, 2011, INT J LIFE CYCLE ASS, V16, P580, DOI 10.1007/s11367-011-0284-8
   Ramaswami A, 2017, ENVIRON RES LETT, V12, DOI 10.1088/1748-9326/aa5556
   Retamal M., 2009, WATER ENERGY NEXUS L
   Rubbelke D, 2011, ENVIRON SCI POLICY, V14, P53, DOI 10.1016/j.envsci.2010.10.007
   Rulli MC, 2013, P NATL ACAD SCI USA, V110, P892, DOI 10.1073/pnas.1213163110
   Sanders KT, 2015, ENVIRON SCI TECHNOL, V49, P51, DOI 10.1021/es504293b
   Santin OG, 2009, ENERG BUILDINGS, V41, P1223, DOI 10.1016/j.enbuild.2009.07.002
   Scott CA, 2011, ENERG POLICY, V39, P6622, DOI 10.1016/j.enpol.2011.08.013
   Martin DS, 2017, ECOL ECON, V140, P146, DOI 10.1016/j.ecolecon.2017.04.032
   [沈恬 Shen Tian], 2015, [资源科学, Resources Science], V37, P744
   Siddiqi A, 2011, ENERG POLICY, V39, P4529, DOI 10.1016/j.enpol.2011.04.023
   Smart A, 2009, WATER ELECT GENERATI
   Sovacool BK, 2009, ENERG POLICY, V37, P2763, DOI 10.1016/j.enpol.2009.03.012
   Spang ES, 2014, ENVIRON RES LETT, V9, DOI 10.1088/1748-9326/9/10/105002
   Srinivasan S, 2018, APPL ENERG, V210, P673, DOI 10.1016/j.apenergy.2017.04.079
   Statistics Canada, 2019, DEM WAT CAN
   Stillwell AS, 2015, J WATER RES PLAN MAN, V141, DOI 10.1061/(ASCE)WR.1943-5452.0000522
   Tan CP, 2016, ENRGY PROCED, V88, P277, DOI 10.1016/j.egypro.2016.06.154
   Tidwell V, 2016, ENVIRON RES LETT, V11, DOI 10.1088/1748-9326/11/9/094008
   Tidwell VC, 2012, J WATER RES PL-ASCE, V138, P491, DOI 10.1061/(ASCE)WR.1943-5452.0000222
   Tiefenbeck V, 2019, NAT ENERGY, V4, P35, DOI 10.1038/s41560-018-0282-1
   Topi C, 2016, ENVIRON SCI POLICY, V58, P74, DOI 10.1016/j.envsci.2016.01.001
   United States Department of Energy (DOE), 2006, EN DEM WAT RES REP C
   van der Zwaan B, 2018, ENERGY STRATEG REV, V19, P19, DOI 10.1016/j.esr.2017.11.001
   Venghaus S, 2018, ENVIRON SCI POLICY, V90, P183, DOI 10.1016/j.envsci.2017.12.014
   Wang CY, 2019, APPL ENERG, V238, P413, DOI 10.1016/j.apenergy.2019.01.120
   Wang CY, 2018, ENERG POLICY, V115, P291, DOI 10.1016/j.enpol.2018.01.035
   Wang RR, 2017, ENVIRON SCI TECHNOL, V51, P9899, DOI 10.1021/acs.est.7b01942
   WEC, 2010, WAT EN
   Weitz N, 2017, GLOBAL ENVIRON CHANG, V45, P165, DOI 10.1016/j.gloenvcha.2017.06.006
   Whitaker MB, 2013, ENVIRON SCI TECHNOL, V47, P5896, DOI 10.1021/es400821x
   Wicaksono A, 2017, WATER POLICY, V19, P440, DOI 10.2166/wp.2017.214
   Wichelns D, 2017, ENVIRON SCI POLICY, V69, P113, DOI 10.1016/j.envsci.2016.12.018
   Widen J, 2009, ENERG BUILDINGS, V41, P753, DOI 10.1016/j.enbuild.2009.02.013
   Woldeyesus T A, 2012, THESIS
   Wu XD, 2017, APPL ENERG, V195, P125, DOI 10.1016/j.apenergy.2017.03.029
   Xie XM, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0778-0
   Yu BY, 2011, ENERG POLICY, V39, P4168, DOI 10.1016/j.enpol.2011.04.024
   Zhang C, 2018, NAT ENERGY, V3, P792, DOI 10.1038/s41560-018-0236-7
   Zhang C, 2017, APPL ENERG, V187, P438, DOI 10.1016/j.apenergy.2016.11.052
   Zhang C, 2013, ENVIRON SCI TECHNOL, V47, P14459, DOI 10.1021/es402556x
   Zhang PP, 2019, RESOUR CONSERV RECY, V142, P215, DOI 10.1016/j.resconrec.2018.11.018
   Zhang XX, 2017, J CLEAN PROD, V161, P1171, DOI 10.1016/j.jclepro.2017.04.040
   Zhu XJ, 2015, APPL ENERG, V151, P345, DOI 10.1016/j.apenergy.2015.04.082
NR 144
TC 0
Z9 0
U1 11
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104453
DI 10.1016/j.resconrec.2019.104453
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000042
DA 2020-05-12
ER

PT J
AU Wang, HC
   Cui, D
   Han, JL
   Cheng, HY
   Liu, WZ
   Peng, YZ
   Chen, ZB
   Wang, AJ
AF Wang, Hong-Cheng
   Cui, Dan
   Han, Jing-Long
   Cheng, Hao-Yi
   Liu, Wen-Zong
   Peng, Yong-Zhen
   Chen, Zhao-Bo
   Wang, Ai-Jie
TI A(2)O-MBR as an efficient and profitable unconventional water treatment
   and reuse technology: A practical study in a green building residential
   community
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Unconventional water; Reuse and recycling; Anaerobic-Anoxic-Oxic
   membrane bioreactor (A(2)O-MBR); Green building residential community;
   Cost-Benefit analysis
ID MUNICIPAL WASTE-WATER; SCALE MEMBRANE BIOREACTOR; ANAEROBIC SLUDGE
   BLANKET; TREATMENT PLANTS; HYBRID TREATMENT; CONSTRUCTED WETLAND;
   SANITARY-LANDFILL; NUTRIENT REMOVAL; TREATMENT SYSTEM; COST
AB Unconventional water reclamation, recycling, and reuse have been identified as the major approaches for addressing water scarcity in China. The aim of this study was to evaluate the technical and economic feasibility of water reclamation plants (WRP) based on an anaerobic-anoxic-oxic membrane bioreactor (A(2)O-MBR) system for unconventional water resource (domestic wastewater and rainwater) treatment and reuse in green building residential community. During a year operation and evaluation process, average chemical oxygen demand (COD), biochemical oxygen demand (BOD5), total nitrogen (TN) and total phosphorus (TP) removal efficiencies averaged 83.7 +/- 3.2%, 91.6 +/- 2.6%, 69.0 +/- 6.5% and 74.5 +/- 5.5%, respectively. The effluent quality of wastewater treated by the A(2)O-MBR system complied with the water quality standards for reuse for green building residential community or for direct discharge. Typical seasonal fluctuations of temperature, COD loading rate, BOD5/COD and COD/TN were the key factors affecting pollutants removal efficiencies, and the membrane fouling rate was accelerated at low temperatures. The total cost of capital and operation was 0.406 $/m(3), a cost-benefit analysis incorporating both capital and operating expenditures showed that more than 60% of the reclaimed water is reused in the green building, and the full-scale WRP exhibits a positive net present value. These results demonstrated that A(2)O-MBR is an efficient and profitable technology for nontraditional water resource recycling in green building residential communities in terms of technical and economic feasibility.
C1 [Wang, Hong-Cheng; Han, Jing-Long; Cheng, Hao-Yi; Liu, Wen-Zong; Wang, Ai-Jie] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, Key Lab Environm Biotechnol, Beijing 100085, Peoples R China.
   [Cui, Dan; Peng, Yong-Zhen] Beijing Univ Technol, Natl Engn Lab Adv Municipal Wastewater Treatment, Beijing 100124, Peoples R China.
   [Chen, Zhao-Bo] Dalian Minzu Univ, Coll Environm & Resources, Dalian 116600, Peoples R China.
RP Wang, AJ (reprint author), Chinese Acad Sci, Res Ctr Ecoenvironm Sci, Key Lab Environm Biotechnol, Beijing 100085, Peoples R China.
EM ajwang@rcees.ac.cn
OI Han, Jing-Long/0000-0002-2465-5904; Wang, Hong-Cheng/0000-0002-6555-1722
FU Ministry of Ecological Environment of the People's Republic of China
   (Major Science and Technology Program for Water Pollution Control and
   Treatment) [2017ZX07602-004]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [51778114, 51508551,
   31700432]; Beijing Natural Science FoundationBeijing Natural Science
   Foundation [8182011]
FX We gratefully acknowledge the financial support by the Ministry of
   Ecological Environment of the People's Republic of China (Major Science
   and Technology Program for Water Pollution Control and Treatment, No.
   2017ZX07602-004), National Natural Science Foundation of China
   (No.51778114, No. 51508551 and No.31700432); Beijing Natural Science
   Foundation (No.8182011).
CR Alderson MP, 2015, ECOL ENG, V82, P6, DOI 10.1016/j.ecoleng.2015.04.081
   Andreo-Martinez P, 2017, BIORESOURCE TECHNOL, V233, P236, DOI 10.1016/j.biortech.2017.02.123
   [Anonymous], 2005, STANDARD METHODS EXA
   Chang Y, 2018, RESOUR CONSERV RECY, V139, P259, DOI 10.1016/j.resconrec.2018.08.025
   Chen YZ, 2015, BIOCHEM ENG J, V93, P235, DOI 10.1016/j.bej.2014.10.005
   Cheng HF, 2009, ENVIRON SCI TECHNOL, V43, P240, DOI 10.1021/es801934a
   ChristovaBoal D, 1996, DESALINATION, V106, P391, DOI 10.1016/0011-9164(96)00134-8
   Nguyen XC, 2018, J ENVIRON MANAGE, V222, P378, DOI 10.1016/j.jenvman.2018.05.085
   De Luca G, 2013, BIORESOURCE TECHNOL, V129, P526, DOI 10.1016/j.biortech.2012.11.113
   Diaz-Elsayed N, 2019, RESOUR CONSERV RECY, V145, P94, DOI 10.1016/j.resconrec.2018.12.035
   Nguyen DD, 2016, ECOL ENG, V89, P24, DOI 10.1016/j.ecoleng.2015.11.054
   Nguyen DD, 2014, BIORESOURCE TECHNOL, V169, P52, DOI 10.1016/j.biortech.2014.06.087
   Nguyen DD, 2014, BIORESOURCE TECHNOL, V153, P116, DOI 10.1016/j.biortech.2013.11.048
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Ersahin ME, 2014, WATER RES, V48, P420, DOI 10.1016/j.watres.2013.09.054
   Ferrer J, 2015, SEP PURIF TECHNOL, V141, P378, DOI 10.1016/j.seppur.2014.12.018
   Gao DW, 2014, CHEM ENG J, V240, P362, DOI 10.1016/j.cej.2013.12.012
   Gao DW, 2011, BIORESOURCE TECHNOL, V102, P5626, DOI 10.1016/j.biortech.2011.02.039
   Guo TJ, 2014, WATER SCI TECHNOL, V69, P223, DOI 10.2166/wst.2013.734
   Hatamoto M, 2016, BIORESOURCE TECHNOL, V204, P171, DOI 10.1016/j.biortech.2015.12.052
   He L, 2018, RESOUR CONSERV RECY, V133, P206, DOI 10.1016/j.resconrec.2018.02.015
   Hochstrat R, 2007, WATER SCI TECHNOL, V56, P175, DOI 10.2166/wst.2007.570
   Nguyen HT, 2017, RESOUR CONSERV RECY, V127, P8, DOI 10.1016/j.resconrec.2017.08.012
   Huang Z, 2011, WATER RES, V45, P705, DOI 10.1016/j.watres.2010.08.035
   Jenssen PD, 2010, ECOL ENG, V36, P1651, DOI 10.1016/j.ecoleng.2010.07.004
   Jeong J, 2006, WATER RES, V40, P1127, DOI 10.1016/j.watres.2005.12.045
   Jiang T, 2005, WATER SCI TECHNOL, V51, P19
   Jiang Y, 2009, J ENVIRON MANAGE, V90, P3185, DOI 10.1016/j.jenvman.2009.04.016
   Kalkan C, 2011, DESALINATION, V265, P266, DOI 10.1016/j.desal.2010.07.060
   Kim JH, 2008, PROCESS BIOCHEM, V43, P154, DOI 10.1016/j.procbio.2007.11.005
   Krzeminski P, 2012, J MEMBRANE SCI, V423, P348, DOI 10.1016/j.memsci.2012.08.032
   Liang B, 2019, WATER RES, V148, P398, DOI 10.1016/j.watres.2018.10.073
   Lin HJ, 2011, DESALINATION, V280, P120, DOI 10.1016/j.desal.2011.06.058
   Liu QL, 2010, DESALINATION, V250, P605, DOI 10.1016/j.desal.2009.09.033
   Malamis S, 2009, BIORESOURCE TECHNOL, V100, P3350, DOI 10.1016/j.biortech.2009.01.053
   Maurer M, 2009, WATER RES, V43, P2121, DOI 10.1016/j.watres.2009.02.008
   Molinos-Senante M, 2011, J ENVIRON MANAGE, V92, P3091, DOI 10.1016/j.jenvman.2011.07.023
   Molinos-Senante M, 2010, SCI TOTAL ENVIRON, V408, P4396, DOI 10.1016/j.scitotenv.2010.07.014
   Pintilie L, 2016, J CLEAN PROD, V139, P1, DOI 10.1016/j.jclepro.2016.07.209
   Pirsaheb M., 2017, SCI REP, V7
   Pirsaheb M, 2019, SEP PURIF TECHNOL, V211, P618, DOI 10.1016/j.seppur.2018.10.041
   Pirsaheb M, 2018, ENVIRON TECHNOL, V39, P2724, DOI 10.1080/09593330.2017.1365939
   Pirsaheb M, 2015, KOREAN J CHEM ENG, V32, P1340, DOI 10.1007/s11814-014-0365-z
   Purnell S, 2016, WATER RES, V100, P20, DOI 10.1016/j.watres.2016.05.013
   Rashidi H, 2015, RENEW SUST ENERG REV, V49, P845, DOI 10.1016/j.rser.2015.04.104
   Ribarova I, 2017, RESOUR CONSERV RECY, V116, P152, DOI 10.1016/j.resconrec.2016.10.003
   Santasmasas C, 2013, RESOUR CONSERV RECY, V72, P102, DOI 10.1016/j.resconrec.2013.01.004
   Shin C, 2014, BIORESOURCE TECHNOL, V159, P95, DOI 10.1016/j.biortech.2014.02.060
   dos Santos IFS, 2018, RESOUR CONSERV RECY, V136, P376, DOI 10.1016/j.resconrec.2018.05.011
   Silva TFCV, 2016, CHEM ENG J, V283, P76, DOI 10.1016/j.cej.2015.07.063
   Singh NK, 2015, WATER SCI TECHNOL, V71, P468, DOI 10.2166/wst.2014.413
   Sumino H, 2007, BIORESOURCE TECHNOL, V98, P177, DOI 10.1016/j.biortech.2005.10.020
   Verrecht B, 2012, J ENVIRON ENG, V138, P594, DOI 10.1061/(ASCE)EE.1943-7870.0000505
   Verrecht B, 2010, WATER RES, V44, P5274, DOI 10.1016/j.watres.2010.06.054
   Weiss S, 2008, WATER RES, V42, P3837, DOI 10.1016/j.watres.2008.05.019
   Wu CY, 2011, WATER SCI TECHNOL, V64, P1511, DOI 10.2166/wst.2011.140
   Wu F, 2018, RESOUR CONSERV RECY, V131, P305, DOI 10.1016/j.resconrec.2017.10.024
   Xiao K, 2014, FRONT ENV SCI ENG, V8, P805, DOI 10.1007/s11783-014-0756-8
   Xu RL, 2016, J ENVIRON SCI, V48, P59, DOI 10.1016/j.jes.2015.12.031
   Xue WC, 2010, WATER RES, V44, P5999, DOI 10.1016/j.watres.2010.07.052
   Ye L, 2013, RENEW ENERG, V53, P220, DOI 10.1016/j.renene.2012.11.022
   Zeng SY, 2017, RESOUR CONSERV RECY, V120, P157, DOI 10.1016/j.resconrec.2016.12.005
   Zheng X, 2012, J MEMBRANE SCI, V403, P129, DOI 10.1016/j.memsci.2012.02.051
NR 63
TC 0
Z9 0
U1 38
U2 45
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104418
DI 10.1016/j.resconrec.2019.104418
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000013
DA 2020-05-12
ER

PT J
AU Wang, Y
   Chen, B
   Guan, CH
   Zhang, B
AF Wang, Ying
   Chen, Bin
   Guan, ChengHe
   Zhang, Bo
TI Evolution of methane emissions in global supply chains during 2000-2012
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Methane emissions; Global supply chains; International trade;
   Multi-regional input-output analysis; Consumption-based accounting
ID INTERNATIONAL-TRADE; ENERGY-CONSUMPTION; CARBON EMISSIONS;
   URBAN-ECONOMY; CHINA; FLOWS; DRIVERS; CH4; FOOTPRINT; TRENDS
AB Reduction of methane emissions (CH4) plays an important role in addressing global climate change. Most previous studies have focused on the direct CH4 emissions of economies, but overlooked the upstream CH4 emissions along global supply chains induced by the final consumption of economies. Using a global multi-regional input-output analysis, this study aims to explore the evolution of CH4 emissions embodied in international trade and final consumption in major economies during 2000-2012. The results show that China, the EU, USA, India and Brazil were the top five economies with high volumes of consumption-based CH4 emissions from 2000 to 2012. In particular, China's consumption-based CH4 emissions showed an observable growth trend, while the EU, the USA and Japan showed a downward trend. It's estimated that growing amounts of CH4 emissions (i.e., the volume increase from 77.1 Mt in 2000 to 95.9 Mt in 2012) were transferred globally via international trade, primarily as exports from China, Russia and other large developing economies to consumers in major developed economies. Russia EU, China USA and China EU formed the main bilateral trading pairs of embodied emission flows. Further analysis found that per capita consumption-based CH4 emissions was closely related to their per capita GDP. Quantifying the CH4 emissions embodied in trade and final demand of major economies can provide important basis for understanding economy-wide emission drivers to design global and regional CH4 reduction scheme from a consumer perspective.
C1 [Wang, Ying; Zhang, Bo] China Univ Min & Technol Beijing, Sch Management, Beijing 100083, Peoples R China.
   [Chen, Bin] Peking Univ, Coll Engn, Lab Syst Ecol & Sustainabil Sci, Beijing 100871, Peoples R China.
   [Guan, ChengHe] New York Univ Shanghai, Sch Arts & Sci, Shanghai 200122, Peoples R China.
   [Guan, ChengHe; Zhang, Bo] Harvard Univ, Harvard China Project, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Zhang, B (reprint author), China Univ Min & Technol Beijing, Sch Management, Beijing 100083, Peoples R China.; Chen, B (reprint author), Peking Univ, Coll Engn, Lab Syst Ecol & Sustainabil Sci, Beijing 100871, Peoples R China.
RI Chen, Bin/E-1760-2017; Guan, ChengHe/AAM-9581-2020
OI Chen, Bin/0000-0001-8326-4551; Guan, ChengHe/0000-0002-5997-418X; zhang,
   bo/0000-0002-5783-6138
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71774161]; China University of Mining & Technology
   (Beijing)
FX This study has been supported by the National Natural Science Foundation
   of China (Grant no. 71774161), and the Yue Qi Young Scholar Project,
   China University of Mining & Technology (Beijing).
CR Andreoni V, 2016, ENERGY, V103, P27, DOI 10.1016/j.energy.2016.02.096
   Arto I, 2014, ENVIRON SCI TECHNOL, V48, P5388, DOI 10.1021/es5005347
   Bajzelj B, 2014, NAT CLIM CHANGE, V4, P924, DOI [10.1038/nclimate2353, 10.1038/NCLIMATE2353]
   Barrett J, 2013, CLIM POLICY, V13, P451, DOI 10.1080/14693062.2013.788858
   Bastianoni S, 2004, ECOL ECON, V49, P253, DOI 10.1016/j.ecolecon.2004.01.018
   Caro D, 2017, J CLEAN PROD, V147, P142, DOI 10.1016/j.jclepro.2017.01.106
   Caro D, 2014, CLIMATIC CHANGE, V126, P203, DOI 10.1007/s10584-014-1197-x
   Chen B, 2019, SCI TOTAL ENVIRON, V670, P87, DOI 10.1016/j.scitotenv.2019.03.215
   Chen B, 2018, APPL ENERG, V210, P98, DOI 10.1016/j.apenergy.2017.10.113
   Chen B, 2017, ENERG POLICY, V110, P69, DOI 10.1016/j.enpol.2017.08.010
   Chen B, 2018, SCI TOTAL ENVIRON, V613, P931, DOI 10.1016/j.scitotenv.2017.09.138
   Chen SQ, 2019, EARTHS FUTURE, V7, P197, DOI 10.1029/2018EF000811
   Chen SQ, 2016, ENVIRON SCI TECHNOL, V50, P4731, DOI 10.1021/acs.est.5b06299
   Cohen MA, 2012, ENERG ECON, V34, pS53, DOI 10.1016/j.eneco.2012.08.032
   Davis SJ, 2010, P NATL ACAD SCI USA, V107, P5687, DOI 10.1073/pnas.0906974107
   Dlugokencky EJ, 2011, PHILOS T R SOC A, V369, P2058, DOI 10.1098/rsta.2010.0341
   Du M., 2018, EARTHS FUTURE
   Fan J. L., 2016, APPL ENERGY, V184
   Fan J. L., 2016, APPL ENERG, V184
   Ferng JJ., ALLOCATING RESPONSIB
   Fu F, 2014, ENERG CONVERS MANAGE, V85, P573, DOI 10.1016/j.enconman.2014.05.046
   Ghosh A, 2015, ATMOS CHEM PHYS, V15, P2595, DOI 10.5194/acp-15-2595-2015
   Han MY, 2019, J CLEAN PROD, V210, P276, DOI 10.1016/j.jclepro.2018.11.018
   Hausmann P., 2016, ATMOS CHEM PHYS, V15, P35991
   He K, 2019, RESOUR CONSERV RECY, V145, P190, DOI 10.1016/j.resconrec.2019.02.016
   Hoglund-Isaksson L, 2017, ENVIRON RES LETT, V12, DOI 10.1088/1748-9326/aa583e
   IPCC, 2014, CLIMATE CHANGE 2014
   Ipcc, 2006, IPCC GUIDELINES NATL
   Janssens-Maenhout G., 2017, EDGAR V4 3 2 GLOBAL
   Kan SY, 2019, APPL ENERG, V250, P1235, DOI 10.1016/j.apenergy.2019.05.104
   Kirschke S, 2013, NAT GEOSCI, V6, P813, DOI [10.1038/NGEO1955, 10.1038/ngeo1955]
   Kondo Y., 2019, CO2 EMISSIONS JAPAN
   LENZEN M, 2004, ECON SYST RES, V16, P391, DOI DOI 10.1080/0953531042000304272
   Li JS, 2017, J CLEAN PROD, V140, P1470, DOI 10.1016/j.jclepro.2016.10.002
   Li JS, 2018, APPL ENERG, V226, P1076, DOI 10.1016/j.apenergy.2018.06.004
   Liang S, 2015, ENVIRON SCI TECHNOL, V49, P3566, DOI 10.1021/es503977y
   Liu J., 2016, P MATH PHYS ENG SCI, V472
   Long Y, 2018, ENERG POLICY, V119, P339, DOI 10.1016/j.enpol.2018.04.052
   Lybbert TJ, 2012, FOOD POLICY, V37, P114, DOI 10.1016/j.foodpol.2011.11.001
   Ma XJ, 2019, SCI TOTAL ENVIRON, V648, P1411, DOI 10.1016/j.scitotenv.2018.08.183
   Madrazo J, 2018, SCI TOTAL ENVIRON, V631-632, P934, DOI 10.1016/j.scitotenv.2018.03.094
   Meng J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04337-y
   Mi ZF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01820-w
   Montzka SA, 2011, NATURE, V476, P43, DOI 10.1038/nature10322
   Munksgaard J, 2001, ENERG POLICY, V29, P327, DOI 10.1016/S0301-4215(00)00120-8
   Munksgaard J, 2005, INT J GLOBAL ENERGY, V23, P324, DOI 10.1504/IJGEI.2005.006950
   Nisbet EG, 2016, GLOBAL BIOGEOCHEM CY, V30, P1356, DOI 10.1002/2016GB005406
   Oita A, 2016, NAT GEOSCI, V9, DOI 10.1038/ngeo2635
   PBL Netherlands Environmental Assessment Agency, 2018, TRENDS GLOB CO2 TOT
   Peng S. S., 2016, ATMOS CHEM PHYS, P1
   Peters GP, 2008, ECOL ECON, V65, P13, DOI 10.1016/j.ecolecon.2007.10.014
   Peters GP, 2008, ENVIRON SCI TECHNOL, V42, P1401, DOI 10.1021/es072023k
   Peters GP, 2008, CLIMATIC CHANGE, V86, P51, DOI 10.1007/s10584-007-9280-1
   Peters GP, 2006, GLOBAL ENVIRON CHANG, V16, P379, DOI 10.1016/j.gloenvcha.2006.03.001
   Saunois M, 2016, ENVIRON RES LETT, V11, DOI 10.1088/1748-9326/11/12/120207
   Tian X, 2014, APPL ENERG, V123, P19, DOI 10.1016/j.apenergy.2014.02.016
   Tian X, 2018, RESOUR CONSERV RECY, V131, P148, DOI 10.1016/j.resconrec.2018.01.002
   Zhang B, 2018, EARTHS FUTURE, V6, P1349, DOI 10.1029/2018EF000917
   Zhang B, 2016, APPL ENERG, V184, P1184, DOI 10.1016/j.apenergy.2016.04.088
   Zhang B, 2014, RENEW SUST ENERG REV, V29, P11, DOI 10.1016/j.rser.2013.08.060
NR 60
TC 2
Z9 2
U1 12
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104414
DI 10.1016/j.resconrec.2019.104414
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000038
DA 2020-05-12
ER

PT J
AU Wesana, J
   Gellynck, X
   Dora, MK
   Pearce, D
   De Steur, H
AF Wesana, Joshua
   Gellynck, Xavier
   Dora, Manoj K.
   Pearce, Darian
   De Steur, Hans
TI Measuring food and nutritional losses through value stream mapping along
   the dairy value chain in Uganda
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food loss and waste; Nutritional loss; Value stream mapping; FLW
   standard; Milk products; Uganda
ID LIFE-CYCLE ASSESSMENT; SUPPLY CHAIN; FRESH-CUT; UNITED-STATES; REDUCE
   FOOD; WASTE; FRAMEWORK; SECURITY; QUALITY; MILK
AB The growing burden of food losses has intensified the need for reliable and comparable data. This study extends the application of lean manufacturing practices and uses Value Stream Mapping (VSM) analysis with the Food Loss and Waste (FLW) Accounting and Reporting Standard to identify hotspots and analyze the magnitude of both food and nutritional losses in the food value chain. A case study on the dairy value chain in Uganda is utilized to understand the production configuration (primary production, processing and distribution). Through linking hotspots where food loss in milk production takes place to specific salient reasons, this case provides an estimation of the magnitude of losses occurring in yogurt and UHT milk production lines. Findings reaffirm the processing stage as a principle hotspot for discarding yogurt as well as UHT milk products. Throughout processing, from start to finish, food losses at chain level are estimated to be in the magnitude of up to 14%. This also translates to a substantial nutritional value disappearing from the food system, which compromises the ability of people to meet their nutrient recommendations. The case study represents a pragmatic assessment that combines the mapping advantages of VSM with accounting and reporting guidelines of FLW Accounting and Reporting Standard to contribute to a detailed assessment of food and nutritional losses. Thereby, reinforcing initiation of evidence-based and targeted reduction strategies along food supply chains.
C1 [Wesana, Joshua; Gellynck, Xavier; Pearce, Darian; De Steur, Hans] Univ Ghent, Fac Biosci Engn, Dept Agr Econ, Ghent, Belgium.
   [Wesana, Joshua] Mt Moon Univ, Sch Agr & Environm Sci, Ft Portal, Uganda.
   [Dora, Manoj K.] Brunel Univ, Brunel Business Sch, Coll Business Arts & Social Sci, London, England.
RP Wesana, J (reprint author), Univ Ghent, Dept Agr Econ, Coupure Links 653, B-9000 Ghent, Belgium.
EM Joshua.Wesana@UGent.be
OI De Steur, Hans/0000-0003-1340-0882; Wesana, Joshua/0000-0003-1970-6241
CR Affognon H, 2015, WORLD DEV, V66, P49, DOI 10.1016/j.worlddev.2014.08.002
   [Anonymous], 2018, STAT FOOD SEC NUTR W
   Aschemann-Witzel J, 2017, J CLEAN PROD, V155, P33, DOI 10.1016/j.jclepro.2016.11.173
   Atila Y, 2015, RES J AGR FORESTRY S, V3, P14
   Atungulu GG, 2014, ANN NY ACAD SCI, V1324, P15, DOI 10.1111/nyas.12492
   Balikowa D., 2011, DAIRY DEV UGANDA
   Barrett DM, 2010, CRIT REV FOOD SCI, V50, P369, DOI 10.1080/10408391003626322
   Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Bibi F, 2017, TRENDS FOOD SCI TECH, V62, P91, DOI 10.1016/j.tifs.2017.01.013
   Bogahawaththa D, 2018, INNOV FOOD SCI EMERG, V47, P301, DOI 10.1016/j.ifset.2018.03.016
   Boor KJ, 2017, J DAIRY SCI, V100, P9933, DOI 10.3168/jds.2017-12969
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Castro A, 2012, J DAIRY SCI, V95, P929, DOI 10.3168/jds.2010-3912
   Chaboud G, 2017, RESOUR CONSERV RECY, V125, P188, DOI 10.1016/j.resconrec.2017.06.008
   Chaboud G, 2017, GLOB FOOD SECUR-AGR, V12, P1, DOI 10.1016/j.gfs.2016.11.004
   Chen JC, 2013, INT J ADV MANUF TECH, V69, P531, DOI 10.1007/s00170-013-5016-8
   Cooper KA, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00019
   Corrado S, 2017, J CLEAN PROD, V140, P847, DOI 10.1016/j.jclepro.2016.06.050
   De Brabandere AG, 1999, J FOOD ENG, V41, P221, DOI 10.1016/S0260-8774(99)00096-5
   De Steur H, 2016, WASTE MANAGE, V58, P359, DOI 10.1016/j.wasman.2016.08.025
   de Treville S, 2004, J OPER MANAG, V21, P613, DOI 10.1016/j.jom.2003.10.001
   Dora M, 2014, BRIT FOOD J, V116, P125, DOI 10.1108/BFJ-05-2012-0107
   Ekou J., 2014, African Journal of Agricultural Research, V9, P881
   Elimelech E, 2018, WASTE MANAGE, V76, P68, DOI 10.1016/j.wasman.2018.03.031
   Engelund E. H., 2009, Journal of Foodservice, V20, P4, DOI 10.1111/j.1748-0159.2008.00109.x
   FAO, 2016, CAS STUD SMALL SCAL
   Francis GA, 2012, CRIT REV FOOD SCI, V52, P595, DOI 10.1080/10408398.2010.503685
   Garrone P, 2016, J CLEAN PROD, V137, P1076, DOI 10.1016/j.jclepro.2016.07.145
   Garrone P, 2014, FOOD POLICY, V46, P129, DOI 10.1016/j.foodpol.2014.03.014
   Gil MI, 2006, J AGR FOOD CHEM, V54, P4284, DOI 10.1021/jf060303y
   Godfray HCJ, 2010, SCIENCE, V327, P812, DOI 10.1126/science.1185383
   Gobel C, 2015, SUSTAINABILITY-BASEL, V7, P1429, DOI 10.3390/su7021429
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   Halloran A, 2014, FOOD POLICY, V49, P294, DOI 10.1016/j.foodpol.2014.09.005
   Hanson C., 2017, CHAMPIONS, V12, P3
   Hines P, 2004, INT J OPER PROD MAN, V24, P994, DOI 10.1108/01443570410558049
   Hines P, 1997, INT J OPER PROD MAN, V17, P46, DOI 10.1108/01443579710157989
   Kaipia R, 2013, INT J PHYS DISTR LOG, V43, P262, DOI 10.1108/IJPDLM-11-2011-0200
   Love DC, 2015, GLOBAL ENVIRON CHANG, V35, P116, DOI 10.1016/j.gloenvcha.2015.08.013
   Lukmanji Z., 2008, TANZANIA FOOD COMPOS
   Lyonnet B, 2014, PROD PLAN CONTROL, V25, P346, DOI 10.1080/09537287.2012.702867
   Mackelprang AW, 2010, J OPER MANAG, V28, P283, DOI 10.1016/j.jom.2009.10.002
   Malmbrandt M, 2013, INT J OPER PROD MAN, V33, P1131, DOI 10.1108/IJOPM-05-2011-0175
   Manzini R, 2013, J FOOD ENG, V115, P251, DOI 10.1016/j.jfoodeng.2012.10.026
   Mena C, 2014, INT J PROD ECON, V152, P144, DOI 10.1016/j.ijpe.2014.03.012
   Meyers L. D, 2006, DIETARY REFERENCE IN
   Morgan E. H., 2018, J HUNGER ENV NUTR, P1
   Munesue Y, 2015, ENVIRON ECON POLICY, V17, P43, DOI 10.1007/s10018-014-0083-0
   Muriana C, 2017, WASTE MANAGE, V68, P557, DOI 10.1016/j.wasman.2017.06.047
   Pangaribowo EH, 2013, FOOD NUTR SECURITY I
   Panwar A, 2015, PROD PLAN CONTROL, V26, P564, DOI 10.1080/09537287.2014.936532
   Papargyropoulou E, 2014, J CLEAN PROD, V76, P106, DOI 10.1016/j.jclepro.2014.04.020
   Paredes-Belmar G, 2017, COMPUT ELECTRON AGR, V134, P109, DOI 10.1016/j.compag.2017.01.015
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Parmar A, 2017, NJAS-WAGEN J LIFE SC, V80, P65, DOI 10.1016/j.njas.2016.12.002
   Phalan B, 2011, SCIENCE, V333, P1289, DOI 10.1126/science.1208742
   Qi PX, 2015, J DAIRY SCI, V98, P2884, DOI 10.3168/jds.2014-8920
   Redlingshofer B, 2017, J CLEAN PROD, V164, P703, DOI 10.1016/j.jclepro.2017.06.173
   Richter B, 2016, WASTE MANAGE, V48, P423, DOI 10.1016/j.wasman.2015.11.039
   Rivera L, 2007, ROBOT CIM-INT MANUF, V23, P684, DOI 10.1016/j.rcim.2007.02.013
   Rodenburg J, 2017, J DAIRY SCI, V100, P7729, DOI 10.3168/jds.2016-11715
   Roy P, 2009, J FOOD ENG, V90, P1, DOI 10.1016/j.jfoodeng.2008.06.016
   Rutten M. M., 2013, AGR FOOD SECURITY, V2, P1, DOI DOI 10.1186/2048-7010-2-13
   Sawaya W. N, 2017, WATER ENERGY FOOD SU, P361
   Schneider F, 2013, WASTE MANAGE, V33, P755, DOI 10.1016/j.wasman.2012.10.025
   Shafiee-Jood M, 2016, ENVIRON SCI TECHNOL, V50, P8432, DOI 10.1021/acs.est.6b01993
   Shewfelt R. L, 2017, DEFENSE PROCESSED FO, P107
   Silvennoinen K, 2015, WASTE MANAGE, V46, P140, DOI 10.1016/j.wasman.2015.09.010
   Simons D, 2005, BRIT FOOD J, V107, P192, DOI 10.1108/00070700510589495
   Smith P, 2013, GLOB FOOD SECUR-AGR, V2, P18, DOI 10.1016/j.gfs.2012.11.008
   Soukoulis C, 2007, J DAIRY SCI, V90, P2641, DOI 10.3168/jds.2006-802
   Spiker ML, 2017, J ACAD NUTR DIET, V117, P1031, DOI 10.1016/j.jand.2017.03.015
   Taylor DH, 2009, SUPPLY CHAIN MANAG, V14, P379, DOI 10.1108/13598540910980297
   TechnoServe, 2008, DAIR VAL CHAIN UG
   Tostivint C, 2017, J CLEAN PROD, V145, P221, DOI 10.1016/j.jclepro.2016.12.081
   Wesana J, 2018, J CLEAN PROD, V182, P46, DOI 10.1016/j.jclepro.2018.02.021
   West PC, 2014, SCIENCE, V345, P325, DOI 10.1126/science.1246067
   Willersinn C, 2015, WASTE MANAGE, V46, P120, DOI 10.1016/j.wasman.2015.08.033
   Womack JP, 2006, MANUF ENG, V136, P145
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
   Zokaei K., 2006, INT FOOD AGRIBUS MAN, V9, P30
NR 81
TC 0
Z9 0
U1 12
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104416
DI 10.1016/j.resconrec.2019.104416
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000011
DA 2020-05-12
ER

PT J
AU Wu, HY
   Zuo, J
   Yuan, HP
   Zillante, G
   Wang, JY
AF Wu, Huanyu
   Zuo, Jian
   Yuan, Hongping
   Zillante, George
   Wang, Jiayuan
TI A review of performance assessment methods for construction and
   demolition waste management
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Review
DE Construction and demolition waste; Waste management; Performance
   assessment methods; System thinking; Life cycle assessment
ID LIFE-CYCLE ASSESSMENT; ENVIRONMENTAL PERFORMANCE; ECOLOGICAL FOOTPRINT;
   ECONOMIC-FEASIBILITY; IMPACT ASSESSMENT; CARBON EMISSION; MODEL;
   STRATEGIES; SIMULATION; INDICATORS
AB Significant efforts have been devoted to assessing construction and demolition waste management (CDWM). However, there is little knowledge to understand the utilisation of the developed models for assessing CDWM performance, thus limiting the comparison and generalization of recognized methods and tools. By reviewing the prior published literature, this study assesses the current research methods, in particular, data collection. It also reviews the range of critical indicators for CDWM performance assessment considered by the literature and put forwards a new framework for better assessing CDWM performance. The proposed framework summarises the system boundary, research scale and performance assessment aspects documented by previous studies, and further integrate an integrated framework with procedures for better assessing CDWM performance. The literature review found that while some studies adopt a system thinking and life cycle thinking to assess CDWM performance, other research they adopt a sustainability based model to finalize CDWM performance assessment. The results also demonstrate that compared with environmental and economic aspects, the social aspect has attracted less attention. Social factors, however are crucial in CDWM. The findings about current performance assessment practices in CDWM and the proposed procedures are possible to implement for researchers and practitioners to develop sound CDWM approaches.
C1 [Wu, Huanyu; Zuo, Jian; Zillante, George] Univ Adelaide, Sch Architecture & Built Environm, Adelaide, SA 5001, Australia.
   [Zuo, Jian; Wang, Jiayuan] Shenzhen Univ, Coll Civil & Transportat Engn, Shenzhen 518060, Peoples R China.
   [Yuan, Hongping] Guangzhou Univ, Sch Management, Guangzhou 510006, Guangdong, Peoples R China.
RP Yuan, HP (reprint author), Guangzhou Univ, Sch Management, Guangzhou 510006, Guangdong, Peoples R China.
EM hpyuan2005@gmail.com
OI Zuo, Jian/0000-0002-8279-9666; Yuan, Hongping/0000-0002-2383-4249
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71573216]; Shenzhen Science and Technology Plan
   [JCYJ20160520173631894]
FX The authors wish to acknowledge the financial support from the National
   Natural Science Foundation of China (Grant number: 71573216) and the
   Shenzhen Science and Technology Plan (No. JCYJ20160520173631894). The
   authors also would like to appreciate Mrs. Gillian Armstrong for her
   language editing of the manuscript.
CR Ajayi SO, 2015, RESOUR CONSERV RECY, V102, P101, DOI 10.1016/j.resconrec.2015.06.001
   Begum RA, 2006, RESOUR CONSERV RECY, V48, P86, DOI 10.1016/j.resconrec.2006.01.004
   BENOIT N, 2011, INT J LIFE CYCLE ASS, V16, P682, DOI DOI 10.1007/S11367-011-0301-Y
   Bohne RA, 2008, J IND ECOL, V12, P52, DOI 10.1111/j.1530-9290.2008.00013.x
   Butera S, 2015, WASTE MANAGE, V44, P196, DOI 10.1016/j.wasman.2015.07.011
   Chau CK, 2017, APPL ENERG, V185, P1595, DOI 10.1016/j.apenergy.2016.01.019
   Chung SS, 2003, RESOUR CONSERV RECY, V37, P119, DOI 10.1016/S0921-3449(02)00075-7
   da Rocha CG, 2009, RESOUR CONSERV RECY, V54, P104, DOI 10.1016/j.resconrec.2009.07.004
   Dahlbo H, 2015, J CLEAN PROD, V107, P333, DOI 10.1016/j.jclepro.2015.02.073
   Dejkovski N, 2016, WASTE MANAGE, V56, P359, DOI 10.1016/j.wasman.2016.07.016
   Merino MD, 2010, WASTE MANAGE RES, V28, P118, DOI 10.1177/0734242X09103841
   Ding ZK, 2016, J CLEAN PROD, V133, P1136, DOI 10.1016/j.jclepro.2016.06.054
   Ding ZK, 2016, WASTE MANAGE, V51, P130, DOI 10.1016/j.wasman.2016.03.001
   Duran X, 2006, RESOUR CONSERV RECY, V46, P302, DOI 10.1016/j.resconrec.2005.08.003
   Penteado CSG, 2016, WASTE MANAGE RES, V34, P1026, DOI 10.1177/0734242X16657605
   Goedkoop M., 2008, INTRO LCA SIMAPRO 7
   Gomes CFS, 2008, OMEGA-INT J MANAGE S, V36, P395, DOI 10.1016/j.omega.2006.07.009
   Jung JS, 2015, KSCE J CIV ENG, V19, P1248, DOI 10.1007/s12205-015-0708-2
   Klang A, 2003, RESOUR CONSERV RECY, V38, P317, DOI 10.1016/S0921-3449(02)00167-2
   Kucukvar M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010089
   Lu M, 2009, J CONSTR ENG M, V135, P448, DOI 10.1061/(ASCE)0733-9364(2009)135:6(448)
   Manowong E, 2012, WASTE MANAGE RES, V30, P56, DOI 10.1177/0734242X10387012
   Marrero M, 2017, RESOUR CONSERV RECY, V117, P160, DOI 10.1016/j.resconrec.2016.10.020
   Marzouk M, 2014, RESOUR CONSERV RECY, V82, P41, DOI 10.1016/j.resconrec.2013.10.015
   McDougall Forbes R, 2008, INTEGRATED SOLID WAS
   Mercante IT, 2012, INT J LIFE CYCLE ASS, V17, P232, DOI 10.1007/s11367-011-0350-2
   Ortiz O, 2010, WASTE MANAGE, V30, P646, DOI 10.1016/j.wasman.2009.11.013
   Poon CS, 2013, J CONSTR ENG M, V139, P466, DOI 10.1061/(ASCE)CO.1943-7862.0000631
   Roussat N, 2009, WASTE MANAGE RES, V27, P159, DOI 10.1177/0734242X08089839
   Shen LY, 2009, RESOUR CONSERV RECY, V53, P145, DOI 10.1016/j.resconrec.2008.11.001
   Simion IM, 2013, ENVIRON ENG MANAG J, V12, P779
   Srour IM, 2013, WASTE MANAGE RES, V31, P1170, DOI 10.1177/0734242X13479430
   Stenis J, 2005, WASTE MANAGE RES, V23, P13, DOI 10.1177/0734242X05050184
   Tam VWY, 2008, WASTE MANAGE, V28, P1072, DOI 10.1016/j.wasman.2007.04.007
   Tam VWY, 2014, WASTE MANAGE RES, V32, P441, DOI 10.1177/0734242X14527636
   Tam VWY, 2010, WASTE MANAGE, V30, P291, DOI 10.1016/j.wasman.2009.09.044
   Saez PV, 2013, RESOUR CONSERV RECY, V75, P52, DOI 10.1016/j.resconrec.2013.03.009
   Wang JY, 2018, J CLEAN PROD, V172, P3154, DOI 10.1016/j.jclepro.2017.11.087
   Wang JY, 2004, WASTE MANAGE, V24, P989, DOI 10.1016/j.wasman.2004.07.010
   Wu HY, 2015, J MATER CYCLES WASTE, V17, P637, DOI 10.1007/s10163-015-0404-9
   Ye G, 2012, RESOUR CONSERV RECY, V62, P56, DOI 10.1016/j.resconrec.2012.01.010
   Yuan F, 2011, WASTE MANAGE, V31, P2503, DOI 10.1016/j.wasman.2011.07.001
   Yuan H., 2018, J MANAGE ENG, V34
   Yuan HP, 2013, ECOL INDIC, V24, P476, DOI 10.1016/j.ecolind.2012.07.022
   Yuan HP, 2012, WASTE MANAGE, V32, P1218, DOI 10.1016/j.wasman.2012.01.028
   Zambrana-Vasquez D, 2016, J CLEAN PROD, V130, P143, DOI 10.1016/j.jclepro.2016.02.048
   Zhao W, 2011, RESOUR CONSERV RECY, V55, P933, DOI 10.1016/j.resconrec.2011.04.011
   Zhao W, 2010, RESOUR CONSERV RECY, V54, P377, DOI 10.1016/j.resconrec.2009.09.003
   Zheng LN, 2017, CONSTR BUILD MATER, V136, P405, DOI 10.1016/j.conbuildmat.2017.01.055
NR 49
TC 0
Z9 0
U1 22
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104407
DI 10.1016/j.resconrec.2019.104407
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000004
DA 2020-05-12
ER

PT J
AU Zhang, SY
   Li, HX
   Zhang, Q
   Tian, X
   Shi, F
AF Zhang, Shaoying
   Li, Haoxin
   Zhang, Qi
   Tian, Xin
   Shi, Feng
TI Uncovering the impacts of industrial transformation on low-carbon
   development in the Yangtze River Delta
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Industrial transformation; CO2 emissions; Industrialization; Structural
   decomposition analysis
ID INPUT-OUTPUT-ANALYSIS; STRUCTURAL DECOMPOSITION ANALYSIS; CO2 EMISSIONS;
   DIOXIDE EMISSIONS; ENERGY; CHINA; REDUCTION; CITY; DRIVERS; TRADE
AB In China, industrial transformation have received attention as an effective means of CO2 emissions abatement. In our study, industrial transformation has a more generalized meaning including investment structure, trade structure, final demand structure, intensity structure and production structure. We built up a comprehensive analysis framework to evaluate how the industrial transformation process impact on CO2 emissions from the sectoral perspective, and applied it to the Yangtze River Delta, which is a leading region in terms of economy, industrial, and relatively low-carbon development within China. The results indicate the Yangtze River Delta has gradually developed toward an industrialization structure dominated by the service and advanced manufacturing sectors such as machinery manufacturing, leading to a slow growth in CO2 emissions during 2002-2012. The improvement of CO2 intensity and production structure in the service and construction sectors, and in machinery manufacturing particularly, has mainly led to this slow growth. Moreover, substantial CO2 emissions were avoided by imports from resource-related manufacturing and mining sectors. Within this region, the differences in improvement of CO2 intensity and production structure in machinery manufacturing, services sectors led to the gap in CO2 emissions between Shanghai and Zhejiang from 2002 to 2012. Meanwhile, swift investment, exports and inconspicuous improvement of CO2 intensity and production structure in machinery manufacturing and construction sectors widened the gap in CO2 emissions between Jiangsu and two other regions. Further, optimizing CO2 intensity and production structure is a feasible way to realize regional low carbon development.
C1 [Zhang, Shaoying; Li, Haoxin; Zhang, Qi; Tian, Xin] Beijing Normal Univ, Sch Environm, Beijing 100875, Peoples R China.
   [Tian, Xin] Beijing Normal Univ, State Key Lab Water Environm Simulat, Beijing 100875, Peoples R China.
   [Shi, Feng] Qilu Univ Technol, Shandong Acad Sci, Inst Sci & Technol Dev Shandong, Jinan 250014, Shandong, Peoples R China.
RP Tian, X (reprint author), Beijing Normal Univ, Beijing 100875, Peoples R China.
EM tianx@bnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71704012]; Taishan Scholar Program of Shandong
   Province, China
FX This work was jointly supported by the National Natural Science
   Foundation of China (No. 71704012), and the Taishan Scholar Program of
   Shandong Province, China.
CR Chen SY, 2011, CHINA ECON REV, V22, P133, DOI 10.1016/j.chieco.2010.10.003
   China Statistics Press, 2008, CHINESE REGIONAL INP
   China Statistics Press, 2011, CHINESE REGIONAL INP
   China Statistics Press, 2016, CHINESE REGIONAL INP
   Dietzenbacher E., 1998, ECON SYST RES, V10, P307, DOI DOI 10.1080/09535319800000023
   Geng Y, 2013, ENERG POLICY, V60, P820, DOI 10.1016/j.enpol.2013.05.054
   Guan D, 2008, GLOBAL ENVIRON CHANG, V18, P626, DOI 10.1016/j.gloenvcha.2008.08.001
   JPPG (Jiangsu Provincial People's Government), 2016, NOTICE OF THE JIANGS
   JSDRC (Jiangsu Development and Reform Commission), 2006, OUTL 11 5 YEAR PLAN
   JSDRC (Jiangsu Development and Reform Commission), 2011, OUTL 12 5 YEAR PLAN
   Lenzen M., 2003, Structural Change and Economic Dynamics, V14, P1, DOI 10.1016/S0954-349X(02)00025-5
   Li HA, 2015, ENERGY, V83, P438, DOI 10.1016/j.energy.2015.02.041
   Li ZL, 2017, J CLEAN PROD, V162, P61, DOI 10.1016/j.jclepro.2017.05.200
   Liang S, 2011, ENERG POLICY, V39, P7078, DOI 10.1016/j.enpol.2011.08.014
   Liu Z, 2015, NATURE, V524, P335, DOI 10.1038/nature14677
   Ma C., 2012, COMPETITIVE ANAL HIG
   Martin G, 2017, NAT CLIM CHANGE, V7, P912, DOI 10.1038/s41558-017-0001-0
   Mi ZF, 2015, J CLEAN PROD, V103, P455, DOI 10.1016/j.jclepro.2014.06.011
   Miller R.E., 2009, INPUT OUTPUT ANAL FD
   National Development and Reform Commission(NDRC), 2015, ENH ACT CLIM CHANG C
   NBS (National Bureau of Statistics of the People's Republic of China), 2011, 47542011 GBT NBS
   NDRC (National Development and Reform Commission), 2011, NOT STAT COUNC ISS C
   NDRC (National Development and Reform Commission), 2007, OUTL 11 5 YEAR PLAN
   NDRC (National Development and Reform Commission), 2007, NOT STAT COUNC ISS C
   NDRC (National Development and Reform Commission), 2016, NOT DEV PLANN URB AG
   NDRC (National Development and Reform Commission), 2010, NOT ISS REG PLANN YA
   NDRC (National Development and Reform Commission), 2012, NOT IMPL PLAN NAT AC
   NDRC (National Development and Reform Commission), 2016, NOT STAT COUNC ISS C
   NDRC (National Development and Reform Commission), 2011, OUTL 12 5 YEAR PLAN
   O' Mahony T, 2012, ENERG POLICY, V44, P256, DOI 10.1016/j.enpol.2012.01.049
   Parikh J, 2009, ENERGY, V34, P1024, DOI 10.1016/j.energy.2009.02.014
   Peters G., 2007, REPORTS WORK PAP NOR, P1
   Shen LY, 2018, J CLEAN PROD, V174, P343, DOI 10.1016/j.jclepro.2017.10.333
   Shindell D, 2018, NAT CLIM CHANGE, V8, P291, DOI 10.1038/s41558-018-0108-y
   SHMDRC (Shanghai Municipal Development and Reform Commission), 2011, OUTL 12 5 YEAR PLAN
   SHMDRC (Shanghai Municipal Development and Reform Commission), 2006, OUTL 11 5 YEAR PLAN
   SMPG (Shanghai Municipal People's Government, 2016, OUTL 13 5 YEAR PLAN
   SMPG (Shanghai Municipal People's Government), 2011, OFF MUN GOV TRANSM G
   SMPG (Shanghai Municipal People's Government, 2016, NOT MUN GOV ISS 13 5
   STDZJ (Science Technology Development of Zhejaing Province, 2006, OUTL 11 5 YEAR PLAN
   Su B, 2013, ENERG POLICY, V56, P83, DOI 10.1016/j.enpol.2013.01.041
   Su B, 2013, ECOL ECON, V88, P119, DOI 10.1016/j.ecolecon.2013.01.017
   Su B, 2012, ENERG ECON, V34, P177, DOI 10.1016/j.eneco.2011.10.009
   Tan XC, 2016, APPL ENERG, V162, P1345, DOI 10.1016/j.apenergy.2015.06.071
   Tian X, 2019, J ENVIRON MANAGE, V233, P728, DOI 10.1016/j.jenvman.2018.11.078
   Tian X, 2017, J CLEAN PROD, V142, P2114, DOI 10.1016/j.jclepro.2016.11.072
   Tian X, 2014, ENVIRON SCI POLICY, V37, P243, DOI 10.1016/j.envsci.2013.10.001
   Wang H, 2017, ENERG POLICY, V107, P585, DOI 10.1016/j.enpol.2017.05.034
   Wang KY, 2019, RESOUR POLICY, V60, P203, DOI 10.1016/j.resourpol.2019.01.001
   Wang M, 2017, APPL ENERG, V190, P772, DOI 10.1016/j.apenergy.2017.01.007
   Wang PP, 2005, EJC SUPPL, V3, P381
   Wang SJ, 2017, APPL ENERG, V200, P204, DOI 10.1016/j.apenergy.2017.05.085
   Wang ZH, 2012, APPL ENERG, V100, P277, DOI 10.1016/j.apenergy.2012.05.038
   Wu LB, 2005, ENERG POLICY, V33, P319, DOI 10.1016/j.enpol.2003.08.003
   Wu YL, 2018, J CLEAN PROD, V199, P518, DOI 10.1016/j.jclepro.2018.07.139
   Yamakawa A, 2011, ECON SYST RES, V23, P303, DOI 10.1080/09535314.2010.549461
   Zhang M, 2012, ENERGY, V44, P515, DOI 10.1016/j.energy.2012.05.050
   Zhao M, 2010, ENERGY, V35, P2505, DOI 10.1016/j.energy.2010.02.049
   Zhou XY, 2013, ENERG POLICY, V57, P43, DOI 10.1016/j.enpol.2012.07.017
   ZJDRC (Zhejiang Province Development and Reform Commission, 2012, REPORT ON THE OUTLIN
   ZPPG (People's Government of Zhejiang Province, 2016, NOT ZHEJ PROV GOV IS
   Zuo L, 2002, VALUE CONVERSION MOD
NR 62
TC 1
Z9 1
U1 12
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104442
DI 10.1016/j.resconrec.2019.104442
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000039
DA 2020-05-12
ER

PT J
AU Zhang, WS
   Jiang, L
   Cui, YZ
   Xu, Y
   Wang, C
   Yu, J
   Streets, DG
   Lin, BQ
AF Zhang, Weishi
   Jiang, Lei
   Cui, Yuanzheng
   Xu, Ying
   Wang, Can
   Yu, Jian
   Streets, David G.
   Lin, Boqiang
TI Effects of urbanization on airport CO2 emissions: A geographically
   weighted approach using nighttime light data in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Nighttime light data; China; Airport CO2 emissions; Geographically
   weighted regression
ID FOREIGN DIRECT-INVESTMENT; CARBON EMISSIONS; ENERGY-CONSUMPTION;
   SPATIOTEMPORAL DYNAMICS; REGRESSION; TRANSPORT; INDUSTRY; SYSTEM;
   MITIGATION; PATTERNS
AB Regional disparities in carbon dioxide (CO2) emissions from airports at the city level are of increasing importance for low-carbon development of the civil aviation sector. However, CO2 emissions from airport operations have rarely been estimated and discussed. We investigate the main driving forces of airport CO2 emissions by using Ordinary Least Square (OLS) and Geographically Weighted Regression (GWR) models, separately, to investigate whether urbanization drives airport CO2 emissions and to investigate spatial heterogeneity at the city level. Nighttime light (NTL) data from satellite observations are adopted as a proxy for urbanization. We obtained energy consumption data by end-use purpose for 70 airports in China and calculated the CO2 emissions from on-ground airport operations. The median CO2 emissions of the 70 sample airports are estimated to be 15.9 million tonnes for 2015. Results from the GWR model indicate that airport CO2 emissions are affected by five main factors: urbanization, foreign direct investment, the share of tertiary industry in gross domestic output, passenger turnover of civil aviation and passenger turnover of railways. The elasticity of urbanization shows an increasing trend from the east of China to the west. The spatial heterogeneity of the CO2 emissions of the five airport clusters that are located in five urban agglomerations is discussed. In order to achieve effective reductions of CO2 emissions from airports, policy-makers should consider the spatial heterogeneity of the major driving factors of carbon emissions in different regions to avoid carbon lock-in.
C1 [Zhang, Weishi] Tianjin Normal Univ, Sch Geog & Environm Sci, Tianjin 300387, Peoples R China.
   [Zhang, Weishi; Yu, Jian] Civil Aviat Univ China, Res Ctr Environm & Sustainable Dev China Civil Av, Tianjin 300300, Peoples R China.
   [Jiang, Lei] Zhejiang Univ Finance & Econ, Sch Econ, Hangzhou 310018, Zhejiang, Peoples R China.
   [Cui, Yuanzheng] Zhejiang Univ Finance & Econ, Inst Land & Urban Rural Dev, Hangzhou 310018, Zhejiang, Peoples R China.
   [Xu, Ying] Chinese Univ Hong Kong, Dept Geog & Resource Management, Hong Kong, Peoples R China.
   [Wang, Can] Tsinghua Univ, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China.
   [Wang, Can] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
   [Streets, David G.] Argonne Natl Lab, Energy Syst Div, Argonne, IL 60439 USA.
   [Lin, Boqiang] Xiamen Univ, Sch Management, China Inst Studies Energy Policy, Collaborat Innovat Ctr Energy Econ & Energy Polic, Xiamen 361005, Fujian, Peoples R China.
RP Cui, YZ (reprint author), Zhejiang Univ Finance & Econ, Inst Land & Urban Rural Dev, Hangzhou 310018, Zhejiang, Peoples R China.; Lin, BQ (reprint author), Xiamen Univ, Sch Management, China Inst Studies Energy Policy, Collaborat Innovat Ctr Energy Econ & Energy Polic, Xiamen 361005, Fujian, Peoples R China.
EM ryancuiyz@zufe.edu.cn; bqlin@xmu.edu.cn
RI Lin, Boqiang/G-3960-2010
OI Lin, Boqiang/0000-0002-1308-400X
FU National Key Research and Development Project: Study on Regional System
   of Joint Control of Regional Air Pollution Joint Defense in China
   [2018YFC0213600]; National Key Research and Development Project
   [2017YFB0503902]; Office of Biological and Environmental Research in the
   U.S. Department of Energy (U.S. DOE), Office of ScienceUnited States
   Department of Energy (DOE); U.S. DOEUnited States Department of Energy
   (DOE) [DE-AC02-06CH11357]
FX This work is funded by the National Key Research and Development
   Project: Study on Regional System of Joint Control of Regional Air
   Pollution Joint Defense in China (2018YFC0213600). This work is funded
   by the National Key Research and Development Project (2017YFB0503902).;
   Part of this work was performed at Argonne National Laboratory under the
   support of the Office of Biological and Environmental Research in the
   U.S. Department of Energy (U.S. DOE), Office of Science. Argonne
   National Laboratory is operated by UChicago Argonne, LLC, under Contract
   No. DE-AC02-06CH11357 with U.S. DOE.
CR Alexander L., 2013, WORKING GROUP 1 CONT
   Andersen O, 2010, ENERG POLICY, V38, P5790, DOI 10.1016/j.enpol.2010.05.030
   [Anonymous], 2016, CHIN CIT STAT YB 201
   Anselin L., 1988, PAP REG SCI ASSOC, DOI [10.1111/j.1435-5597.1988.tb01155.x, DOI 10.1111/j.1435-5597.1988.tb01155.x]
   Bai XM, 2014, NATURE, V509, P158, DOI 10.1038/509158a
   Bai Y, 2016, REMOTE SENS-BASEL, V8, DOI 10.3390/rs8030262
   Boeh KK, 2012, J INT BUS STUD, V43, P525, DOI 10.1057/jibs.2012.10
   Brunsdon C, 1996, GEOGR ANAL, V28, P281, DOI 10.1111/j.1538-4632.1996.tb00936.x
   Bu ML, 2019, ENERG ECON, V80, P366, DOI 10.1016/j.eneco.2019.01.003
   CAAC, 2016, CIV AV ADM CHIN STAT
   Chiaramonti D, 2014, APPL ENERG, V136, P767, DOI 10.1016/j.apenergy.2014.08.065
   Cui YZ, 2019, APPL ENERG, V241, P245, DOI 10.1016/j.apenergy.2019.03.060
   Cui YZ, 2019, RESOUR CONSERV RECY, V142, P59, DOI 10.1016/j.resconrec.2018.11.015
   Das D, 2016, J AIR TRANSP MANAG, V57, P89, DOI 10.1016/j.jairtraman.2016.07.013
   Delaplace M., 2016, REV BELGE GEOGRAPHIE
   Dornburg V, 2006, RESOUR CONSERV RECY, V46, P377, DOI 10.1016/j.resconrec.2005.08.006
   Du YY, 2018, J CLEAN PROD, V190, P72, DOI 10.1016/j.jclepro.2018.03.290
   Edwards HA, 2016, APPL ENERG, V164, P553, DOI 10.1016/j.apenergy.2015.11.058
   Enzler HB, 2017, J TRANSP GEOGR, V61, P1, DOI 10.1016/j.jtrangeo.2017.03.014
   Fan W., 2010, ATMOS ENVIRON, V56, P52
   Fotheringham AS, 1996, INT J GEOGR INF SYST, V10, P605, DOI 10.1080/02693799608902100
   Fotheringham AS, 2003, GEOGRAPHICALLY WEIGH
   Gao CK, 2019, RESOUR CONSERV RECY, V143, P184, DOI 10.1016/j.resconrec.2018.12.032
   Goldblatt R, 2018, REMOTE SENS ENVIRON, V205, P253, DOI 10.1016/j.rse.2017.11.026
   Grossman G., 1991, NBER WORK PAP, V1991, P3914, DOI DOI 10.3386/W3914
   Hattori R, 2014, RESOUR CONSERV RECY, V83, P229, DOI 10.1016/j.resconrec.2013.11.007
   Huang B, 2010, INT J GEOGR INF SCI, V24, P383, DOI 10.1080/13658810802672469
   International Civil Aviation Organization (ICAO), 2014, ICAO ENV REP
   Jiao P., 2005, J TRANSP SYST ENG IN, V5
   Kasimu A, 2009, 2009 JOINT URBAN REMOTE SENSING EVENT, VOLS 1-3, P458
   Letu H, 2015, ENVIRON SCI TECHNOL, V49, P10503, DOI 10.1021/acs.est.5b02471
   Letu H, 2014, ENVIRON SCI TECH LET, V1, P259, DOI 10.1021/ez500093s
   Letu H, 2010, INT J REMOTE SENS, V31, P4443, DOI 10.1080/01431160903277464
   Li FY, 2019, ENERGY, V174, P562, DOI 10.1016/j.energy.2019.02.179
   Li W, 2018, ENERG POLICY, V115, P434, DOI 10.1016/j.enpol.2018.01.005
   Li X, 2019, REMOTE SENS LETT, V10, P526, DOI 10.1080/2150704X.2019.1577573
   Liang HW, 2017, RESOUR CONSERV RECY, V123, P11, DOI 10.1016/j.resconrec.2016.04.001
   Liu HJ, 2019, SCI TOTAL ENVIRON, V648, P871, DOI 10.1016/j.scitotenv.2018.07.407
   Liu SJ, 2016, TIJDSCHR ECON SOC GE, V107, P468, DOI 10.1111/tesg.12169
   Liu YL, 2019, TRANSPORT RES E-LOG, V125, P388, DOI 10.1016/j.tre.2019.03.017
   Liu ZF, 2012, LANDSCAPE URBAN PLAN, V106, P62, DOI 10.1016/j.landurbplan.2012.02.013
   Liu Z, 2015, NATURE, V524, P335, DOI 10.1038/nature14677
   Ma T, 2012, REMOTE SENS ENVIRON, V124, P99, DOI 10.1016/j.rse.2012.04.018
   Meng LN, 2014, ENERGY, V71, P468, DOI 10.1016/j.energy.2014.04.103
   Mills S, 2013, PROC SPIE, V8866, DOI 10.1117/12.2023107
   NCSC, 2012, EM FACT 6 POW GRIDS
   Peng TD, 2018, APPL ENERG, V222, P313, DOI 10.1016/j.apenergy.2018.03.139
   Ru XJ, 2018, RESOUR CONSERV RECY, V134, P91, DOI 10.1016/j.resconrec.2018.03.001
   Shan YL, 2018, SCI DATA, V5, DOI 10.1038/sdata.2017.201
   Shan YL, 2016, APPL ENERG, V184, P742, DOI 10.1016/j.apenergy.2016.03.073
   Shao Shuai, 2008, JINGJI YANJIU, V4, P147, DOI DOI 10.1007/s11459-009-0008-1
   Sheng JC, 2017, J CLEAN PROD, V153, P362, DOI 10.1016/j.jclepro.2016.06.055
   Staples MD, 2018, ENERG POLICY, V114, P342, DOI 10.1016/j.enpol.2017.12.007
   Sutton P, 2001, INT J REMOTE SENS, V22, P3061, DOI 10.1080/01431160010007015
   Tenerelli P, 2016, ECOL INDIC, V64, P237, DOI 10.1016/j.ecolind.2015.12.042
   Uno I, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003252
   Wang P, 2013, APPL ENERG, V106, P65, DOI 10.1016/j.apenergy.2013.01.036
   Wu JS, 2018, J CLEAN PROD, V182, P872, DOI 10.1016/j.jclepro.2018.02.060
   Xu B, 2018, J CLEAN PROD, V175, P109, DOI 10.1016/j.jclepro.2017.12.022
   Xu B, 2017, J CLEAN PROD, V166, P628, DOI 10.1016/j.jclepro.2017.08.052
   Xu B, 2017, ENERG POLICY, V104, P404, DOI 10.1016/j.enpol.2017.02.011
   Xu S., 2016, ANN REPORT DEV CHINA
   Xu SC, 2014, APPL ENERG, V127, P182, DOI 10.1016/j.apenergy.2014.03.093
   Yang HR, 2018, J TRANSP GEOGR, V68, P233, DOI 10.1016/j.jtrangeo.2018.03.015
   Yu B, 2019, TRANSPORT RES E-LOG, V125, P203, DOI 10.1016/j.tre.2019.03.013
   Zhang QL, 2011, REMOTE SENS ENVIRON, V115, P2320, DOI 10.1016/j.rse.2011.04.032
   Zhang WS, 2018, ATMOS ENVIRON, V176, P158, DOI 10.1016/j.atmosenv.2017.12.029
   Zhang WS, 2018, ATMOS ENVIRON, V174, P122, DOI 10.1016/j.atmosenv.2017.11.050
   Zhang WS, 2017, J CLEAN PROD, V165, P734, DOI 10.1016/j.jclepro.2017.07.172
   Zhou WJ, 2016, APPL ENERG, V175, P100, DOI 10.1016/j.apenergy.2016.05.004
NR 70
TC 1
Z9 1
U1 18
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD NOV
PY 2019
VL 150
AR UNSP 104454
DI 10.1016/j.resconrec.2019.104454
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JA8ZY
UT WOS:000488141000044
DA 2020-05-12
ER

PT J
AU Kote, S
   Faktor, J
   Dapic, I
   Mayordomo, MY
   Kocikowski, M
   Kagansky, A
   Goodlett, D
   Vojtesek, B
   Hupp, T
   Wilcockson, D
   Piper, R
AF Kote, Sachin
   Faktor, Jakub
   Dapic, Irena
   Mayordomo, Marcos Yebenes
   Kocikowski, Mikolaj
   Kagansky, Alexander
   Goodlett, David
   Vojtesek, Borivoj
   Hupp, Ted
   Wilcockson, David
   Piper, Ross
TI Analysis of venom sac constituents from the solitary, aculeate wasp
   Cerceris rybyensis
SO TOXICON
LA English
DT Article
DE Venom sac; Mass spectrometry; Proteomics; Cerceris; Hymenoptera
ID PROTEINS; TREHALOSE
AB Solitary aculeate wasps are abundant and diverse hymenopteran insects that disable prey using venom. The venom may possess neuromodulation, immunomodulatory, metabolic-modulatory and antimicrobial functions. Venom analysis of transcriptomes and proteomes has been previously performed in social and parasitoid wasp species. We develop methodologies including mass spectrometry-based shotgun proteomics to analyse the protein constituents from venom sacs of the solitary aculeate wasp Cerceris tybyensis. The venom sac constituents of C. rybyensis are discussed with respect to other wasp species.
C1 [Kote, Sachin; Dapic, Irena; Mayordomo, Marcos Yebenes; Kocikowski, Mikolaj; Goodlett, David; Hupp, Ted] Univ Gdansk, Int Ctr Canc Vaccine Sci, Ul Wita Stwosza 63, PL-80308 Gdansk, Poland.
   [Faktor, Jakub; Vojtesek, Borivoj; Hupp, Ted] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno 65653, Czech Republic.
   [Kagansky, Alexander] Far Eastern Fed Univ, Sch Biomed, Ctr Genom & Regenerat Med, Vladivostok, Russia.
   [Goodlett, David] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Mayordomo, Marcos Yebenes; Kocikowski, Mikolaj; Hupp, Ted] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Wilcockson, David] Aberystwyth Univ, IBERS, Aberystwyth SY23 3FL, Dyfed, Wales.
   [Piper, Ross] Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.
   [Goodlett, David] Univ Maryland, Dept Microbial Pathogenesis, Baltimore, MD 21201 USA.
RP Piper, R (reprint author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.
EM ross_piper@yahoo.com
OI Kocikowski, Mikolaj/0000-0001-7396-9005
FU Ministry of Education Youth and Sports (MEYS)Ministry of Education,
   Youth & Sports - Czech Republic [NPS I -L01413]; Ministry of Health
   Czech Republic (MH CZ) - DRO (MMCI) [00209805]; International Centre for
   Cancer Vaccine Science project - European Union under the European
   Regional Development Fund
FX This work was supported by Ministry of Education Youth and Sports (MEYS)
   - NPS I -L01413, Ministry of Health Czech Republic (MH CZ) - DRO (MMCI,
   00209805). MYM and MK are part of the Bio2Bio study group aimed at
   classifying natural medicines within the PhD Doctoral Training Centre
   funded by the International Centre for Cancer Vaccine Science project
   carried out within the International Research Agendas programme of the
   Foundation for Polish Science co-financed by the European Union under
   the European Regional Development Fund.
CR Banks B.E.C., 1986, VENOMS HYMENOPTERA, P330
   Colinet D, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-342
   Danneels EL, 2010, TOXINS, V2, P494, DOI 10.3390/toxins2040494
   Fabre J.-H., 1916, HUNTING WASPS
   Kaushik JK, 2003, J BIOL CHEM, V278, P26458, DOI 10.1074/jbc.M300815200
   Konno K, 2016, TOXINS, V8, DOI 10.3390/toxins8040114
   Liu K, 2013, P NATL ACAD SCI USA, V110, P17504, DOI 10.1073/pnas.1316709110
   Moreau SJM, 2015, TOXINS, V7, P2385, DOI 10.3390/toxins7072385
   Mrinalini, 2015, METABOLOMICS, V11, P350, DOI 10.1007/s11306-014-0697-z
   Nakajima T., 1986, P309
   Nation JL, 2008, INSECT PHYSL BIOCH
   Parkinson NM, 2003, COMP BIOCHEM PHYS C, V134, P513, DOI 10.1016/S1532-0456(03)00041-3
   RIVERS DB, 1994, J INSECT PHYSIOL, V40, P121, DOI 10.1016/0022-1910(94)90083-3
   Shukla E, 2015, GLYCOBIOLOGY, V25, P357, DOI 10.1093/glycob/cwu125
   Tinbergen N., 1932, Zeitschrift fuer Vergleichende Physiologie Berlin, V16, P305
   Walker A.A., 2018, ENTOMO VENOMICS EVOL, DOI [10.1016/j.toxicon.2018.09.004, DOI 10.1016/J.TOXICON.2018.09.004]
   Way L, 2016, PROTEOMICS, V16, P2327, DOI 10.1002/pmic.201500501
   WILLMER PG, 1985, ECOL ENTOMOL, V10, P469, DOI 10.1111/j.1365-2311.1985.tb00745.x
   Zhu JY, 2010, ARCH INSECT BIOCHEM, V75, P28, DOI 10.1002/arch.20380
NR 19
TC 0
Z9 0
U1 3
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 1
EP 4
DI 10.1016/j.toxicon.2019.07.012
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800001
PM 31352010
DA 2020-05-12
ER

PT J
AU Rincon-Cortes, CA
   Olamendi-Portugal, T
   Carcamo-Noriega, EN
   Sandllan, EG
   Zuniga, FZ
   Reyes-Montano, EA
   Castro, NAV
   Possani, LD
AF Andrea Rincon-Cortes, Clara
   Olamendi-Portugal, Timoteo
   Norberto Carcamo-Noriega, Edson
   Gonzalez Sandllan, Edmundo
   Zamudio Zuniga, Fernando
   Antonio Reyes-Montano, Edgar
   Vega Castro, Nohora Angelica
   Domingos Possani, Lourival
TI Structural and functional characterization of toxic peptides purified
   from the venom of the Colombian scorpion Tityus macrochirus
SO TOXICON
LA English
DT Article
DE Amino acid sequence; Sodium-channels; Scorpion toxin; Phylogenetic tree;
   Tityus macrochirus
ID PROTEOMIC ANALYSIS; CHANNELS; BUTHIDAE; CURRENTS; MODEL
AB The soluble venom of the scorpion Tityus macrochirus was separated by chromatographic procedures and three homogeneous peptides were obtained and their primary structures were determined. They were called: Tma1-Tma3, from the abbreviated name of the scorpion. Tma1 is a peptide containing 65 amino acids with four disulfide linkages and a molecular weight of 7386.2 Da. It is a mammalian toxin, shown to affect human sodium-channels sub-types hNav1.6 and hNav1.4. Tma2 and Tma3 are peptides containing 69 amino acids linked by four disulfide bonds, molecular weights 7819.7 and 7830.0 Da, respectively. They do not affect human sodium-channels but are lethal to insects (crickets). A phylogenic analysis of the three peptides and those of other toxic peptides isolated from the genus Tityus and Centruroides were grouped together and analyzed, permitting to obtain a topology with two main clades, one includes most sodium-channel anti-insect scorpion toxins and others includes mostly sodium-channel scorpion toxins anti-mammalian. Tma1 segregates among a group of well-studied beta-class toxins of other Tityus species such as T. discrepans, T. obscurus and T. pachyurus. Tma2 and Tma3 are associated with anti-insect toxins, particularly with one of T. obscurus. This phylogenetic analysis confirms and enforces our experimental results obtained with these three new sodium-channel scorpion toxins.
C1 [Andrea Rincon-Cortes, Clara; Antonio Reyes-Montano, Edgar; Vega Castro, Nohora Angelica] Univ Nacl Colombia, Dept Quim, Grp Invest Prot, Bogota, DC, Colombia.
   [Andrea Rincon-Cortes, Clara] Univ Ciencias Aplicadas & Ambientales, UDCA, Bogota, DC, Colombia.
   [Olamendi-Portugal, Timoteo; Norberto Carcamo-Noriega, Edson; Gonzalez Sandllan, Edmundo; Zamudio Zuniga, Fernando; Domingos Possani, Lourival] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.
RP Possani, LD (reprint author), UNAM, Inst Biotechnol, Cuernavaca, Morelos, Mexico.
EM possani@ibt.unam.mx
RI Santillan, Edmundo Gonzalez/B-7648-2014
OI Santillan, Edmundo Gonzalez/0000-0003-1340-068X; Rincon Cortes, Clara
   Andrea/0000-0002-7236-7456
FU Direccicin General de Asuntos del Personal Academico (DGPA-UNAM)
   [IN202619]; Departamento Administrativo de Ciencia y Tecnologia,
   Colciencias (Colombia)Departamento Administrativo de Ciencia, Tecnologia
   e Innovacion Colciencias [646-2018]; Universidad Nacional de Colombia
   [646-2018]
FX This work was partially financed by grant IN202619 from Direccicin
   General de Asuntos del Personal Academico (DGPA-UNAM) awarded to LDP,
   and grant by Departamento Administrativo de Ciencia y Tecnologia,
   Colciencias (Colombia) and Universidad Nacional de Colombia,
   interadministrative contract 646-2018, Project: "Analisis Venomico y
   evaluacion de la actividad biologica de peptidos y/o lectinas del veneno
   de Tityus macrochirus (Buthidae), Pterois volitans y Crotalus durissus
   cumanensis".
CR Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Rincon-Cortes CA, 2017, BIOMEDICA, V37, P238, DOI 10.7705/biomedica.v37i3.3265
   Barona J, 2006, BBA-PROTEINS PROTEOM, V1764, P76, DOI 10.1016/j.bbapap.2005.08.010
   Batista CVF, 2018, TOXICON, V143, P51, DOI 10.1016/j.toxicon.2018.01.006
   Batista CVF, 2006, PROTEOMICS, V6, P3718, DOI 10.1002/pmic.200500525
   Batista CVF, 2002, TOXICON, V40, P557, DOI 10.1016/S0041-0101(01)00252-5
   Benkhadir K, 2004, PEPTIDES, V25, P151, DOI 10.1016/j.peptides.2004.01.009
   Bohorquez-Gomez R.M., 2016, REVISION TAXONOMICA, P128
   Borges A, 2006, COMP BIOCHEM PHYS C, V142, P240, DOI 10.1016/j.cbpc.2005.10.011
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   D'Suze G, 1999, FEBS LETT, V456, P146, DOI 10.1016/S0014-5793(99)00947-3
   Diniz C.R., 1978, HDB EXPT PHARM, P379
   Fet Victor, 2005, Euscorpius, V31, P1
   Guerrero-Vargas JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030478
   Jan Ove Rein M.S., 2019, SCORPION FILES REV S
   Lanfear R, 2017, MOL BIOL EVOL, V34, P772, DOI 10.1093/molbev/msw260
   Miller M. A., 2010, GAT COMP ENV WORKSH, P1, DOI [10.1109/GCE.2010.5676129, DOI 10.1109/GCE.2010.5676129]
   Olamendi-Portugal T, 2017, PEPTIDES, V87, P34, DOI 10.1016/j.peptides.2016.11.008
   Escalona MP, 2013, FRONT BIOSCI-LANDMRK, V18, P572, DOI 10.2741/4121
   Perafan C., 2013, C COL ENT 40 C SOC S, P479
   Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   RAMIREZ AN, 1994, TOXICON, V32, P479, DOI 10.1016/0041-0101(94)90300-X
   Ramirez-Dominguez ME, 2002, J EXP BIOL, V205, P869
   Restano-Cassulini R, 2017, TOXINS, V9, DOI 10.3390/toxins9030074
   Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029
   Rozewicki J., 2017, MAFFT ONLINE SERVICE
   Vandendriessche T, 2010, TOXICON, V56, P613, DOI 10.1016/j.toxicon.2010.06.008
   Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851
   Yacioob R, 2016, PAK J ZOOL, V48, P265
   ZHANG L, 1995, J PHYSIOL-LONDON, V488, P647, DOI 10.1113/jphysiol.1995.sp020997
   Zhang ZQ, 2011, ZOOTAXA, P7, DOI 10.11646/zootaxa.3703.1.1
NR 33
TC 0
Z9 0
U1 5
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 5
EP 11
DI 10.1016/j.toxicon.2019.07.013
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800002
PM 31402191
DA 2020-05-12
ER

PT J
AU Park, JE
   Shamim, EA
   Panyakaew, P
   Mathew, P
   Toro, C
   Sackett, J
   Karp, B
   Lungu, C
   Alter, K
   Wu, TX
   Ahmad, OF
   Villegas, M
   Auh, S
   Hallett, M
AF Park, Jung E.
   Shamim, Ejaz A.
   Panyakaew, Pattamon
   Mathew, Pawan
   Toro, Camilo
   Sackett, Jonathan
   Karp, Barbara
   Lungu, Codrin
   Alter, Katharine
   Wu, Tianxia
   Ahmad, Omar F.
   Villegas, Monica
   Auh, Sungyoung
   Hallett, Mark
TI Botulinum toxin and occupational therapy for Writer's cramp
SO TOXICON
LA English
DT Article
DE Writer's cramp; Dystonia; Focal; Hand; Botulinum; Toxin; Occupational;
   Therapy
ID FOCAL HAND; GRIP
AB Background: Writer's cramp (WC) is a form of focal hand dystonia, for which focal botulinum neurotoxin (BoNT) injections are the current best therapy. Past studies have shown that some types of rehabilitative therapy can be useful. We hypothesized that BoNT together with a specific type of occupational therapy would be better than BoNT alone for treating WC patients comparing the effects with a patient-rated subjective scale.
   Methods: Twelve WC patients were randomized to two groups. Six received only BoNT therapy and 6 received BoNT & occupational therapy. The occupational therapy involved specific exercises of finger movements in the direction opposite to the dystonic movements during writing. BoNT was injected by movement disorders neurologists in the affected muscles under electromyography-guidance. The primary outcome was the patient-rated subjective scale at 20 weeks. Secondary exploratory outcomes included the writer's cramp rating scale (WCRS), writer's cramp impairment scale (WCIS), the writer's cramp disability scale (WCDS), handgrip strength and kinetic parameters.
   Results: The patient-rated subjective scale scores at 20 weeks were not significantly different between the two groups. Significant objective improvement was noted in the BoNT & occupational therapy group, as noted by the decrease (28%) in WCIS scores.
   Conclusions: Improvement of the primary outcome measure, the patient-rated subjective scale, was not achieved. However, significant improvement was found in the BoNT & occupational therapy group in a secondary measure of impairment. Our hypothesis-driven study results are likely limited by small sample size, and further large-scale studies of occupational therapy methods to improve the efficacy of BoNT seems worthwhile.
C1 [Park, Jung E.] Dongguk Univ, Dept Neurol, Ilsan Hosp, Goyang, South Korea.
   [Park, Jung E.; Shamim, Ejaz A.; Mathew, Pawan; Sackett, Jonathan; Ahmad, Omar F.; Villegas, Monica; Hallett, Mark] NINDS, Human Motor Control Sect, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Panyakaew, Pattamon] Chulalongkorn Univ, Chulalongkorn Ctr Excellence Parkinson Dis & Rela, Fac Med, Dept Med, Bangkok, Thailand.
   [Panyakaew, Pattamon] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand.
   [Toro, Camilo] NHGRI, NIH, Bethesda, MD 20892 USA.
   [Karp, Barbara] NINDS, Combined Neurosci Inst Review Board, Off Clin Director, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Lungu, Codrin] NINDS, Div Clin Res, NIH, Rockville, MD USA.
   [Alter, Katharine] NIH, Funct & Appl Biomech Sect, Rehabil Med, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Wu, Tianxia] NINDS, Clin Neurosci Program, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Ahmad, Omar F.] Mt Carmel Neurol, Westerville, OH USA.
   [Auh, Sungyoung] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Hallett, M (reprint author), 10 Ctr Dr MSC 1428, Bethesda, MD 20892 USA.
EM hallettm@ninds.nih.gov
FU Merz North America; National Institute of Neurological Disorders and
   Stroke (NINDS)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS)
FX This study was funded by Merz North America and the National Institute
   of Neurological Disorders and Stroke (NINDS).
CR Baur B, 2009, ARCH PHYS MED REHAB, V90, P867, DOI 10.1016/j.apmr.2008.10.015
   Berger HJ, 2007, PARKINSONISM RELAT D, V13, P170, DOI 10.1016/j.parkreldis.2006.09.003
   Classen J, 1998, J NEUROPHYSIOL, V79, P1117
   Comella CL, 2018, PARKINSONISM RELAT D, V46, pS66, DOI 10.1016/j.parkreldis.2017.06.025
   Das CP, 2006, EUR J NEUROL, V13, P55, DOI 10.1111/j.1468-1331.2006.01446.x
   Hallett M, 2006, HUM MOVEMENT SCI, V25, P454, DOI 10.1016/j.humov.2006.05.004
   Hallett M, 2009, TOXICON, V54, P628, DOI 10.1016/j.toxicon.2008.12.008
   Hedera P, 2013, PARKINSONISM RELAT D, V19, P684, DOI 10.1016/j.parkreldis.2013.03.010
   Horisawa S, 2013, ANN NEUROL, V74, P648, DOI 10.1002/ana.23877
   Karp BI, 2012, TOXINS, V4, P1404, DOI 10.3390/toxins4111404
   Lungu C, 2011, MOVEMENT DISORD, V26, P750, DOI 10.1002/mds.23504
   Pekmezovic T, 2009, CLIN NEUROL NEUROSUR, V111, P161, DOI 10.1016/j.clineuro.2008.09.023
   Schneider AS, 2014, CLIN NEUROPHYSIOL, V125, P786, DOI 10.1016/j.clinph.2013.09.043
   Wissel J, 1996, J NEUROL NEUROSUR PS, V61, P172, DOI 10.1136/jnnp.61.2.172
   Zenner KE, 2007, MOVEMENT DISORD, V22, P1102, DOI 10.1002/mds.21294
   Zeuner KE, 2005, MOVEMENT DISORD, V20, P335, DOI 10.1002/mds.20314
   Zeuner KE, 2002, ANN NEUROL, V51, P593, DOI 10.1002/ana.10174
   Zeuner KE, 2008, MOVEMENT DISORD, V23, P2319, DOI 10.1002/mds.22222
NR 18
TC 0
Z9 0
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 12
EP 17
DI 10.1016/j.toxicon.2019.07.010
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800003
PM 31351085
DA 2020-05-12
ER

PT J
AU Sakuragui, MM
   Paulino, MG
   Souza, NEDE
   Tavares, D
   Terezan, AP
   Pesenti, E
   Giani, A
   Fernandes, JB
   Cestari, MM
   Fernandes, MN
AF Sakuragui, Marise Margareth
   Paulino, Marcelo Gustavo
   da Silva e Souza, Naiara Elisabete
   Tavares, Driele
   Terezan, Ana Paula
   Pesenti, Emanuele
   Giani, Alessandra
   Fernandes, Joao Batista
   Cestari, Marta Margarete
   Fernandes, Marisa Narciso
TI Crude extract of cyanobacterium Radiocystis fernandoi strain R28 induces
   anemia and oxidative stress in fish erythrocytes
SO TOXICON
LA English
DT Article
DE Antioxidant enzymes; Genotoxicity; Hematology; Lipid peroxidation;
   Microcystins
ID MICROCYSTIN-LR; HOPLIAS-MALABARICUS; RESPIRATORY RESPONSES; COMET ASSAY;
   TOXICITY; GLUTATHIONE; TOXINS; BLOOD; BIOMARKERS; DAMAGE
AB The cyanobacterium Radiocystis fernandoi has been frequently identified in cyanobacterial blooms in Brazil. Recently, R. fernandoi strain R28, which produces microcystin (MC)-RR and MC-YR, was isolated from the Furnas reservoir, Minas Gerais, Brazil. The present study evaluated the hematological variables and erythrocyte antioxidant responses, lipid peroxidation (LPG), and genotoxicity in a neotropical fish (Hoplias malabaricus) after acute and subchronic exposure to a crude extract (CE) of R. fernandoi strain R28. Acute exposure (12 or 96 h) consisted of a single intraperitoneal (i.p.) CE injection, and subchronic exposure consisted of one i.p. CE injection every 72 h for 30 days. After acute exposure, fish exhibited macrocytic anemia (12 h post-injection) followed by normocytic anemia (96 h post-injection). The increased activity of superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, and the glutathione level in the erythrocytes did not prevent oxidative stress, manifested as lipid peroxidation and elevated DNA damage after acute exposure. After subchronic exposure, the hematological variables recovered, and the absence of erythrocyte oxidative stress suggests possible modulation by other biological factors, including a possible decrease in MC uptake by the cells and/or increasing detoxification efficiency that precludes erythrocyte damage.
C1 [Sakuragui, Marise Margareth; Paulino, Marcelo Gustavo; da Silva e Souza, Naiara Elisabete; Tavares, Driele; Fernandes, Marisa Narciso] Univ Fed Sao Carlos, Dept Ciencias Fisiol, Rodovia Washington Luiz Km 235, BR-13565905 Sao Carlos, SP, Brazil.
   [Terezan, Ana Paula; Fernandes, Joao Batista] Univ Fed Sao Carlos, Dept Quim, Rodovia Washington Luiz Km 235, BR-13565905 Sao Carlos, SP, Brazil.
   [Pesenti, Emanuele; Cestari, Marta Margarete] Univ Fed Parana, Dept Genet, POB 19071, BR-81531990 Curitiba, Parana, Brazil.
   [Giani, Alessandra] Univ Fed Minas Gerais, Dept Bot, Av Pres Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [Sakuragui, Marise Margareth] Univ Estadual Minas Gerais, Campus Passos,Av Juca Stockler 1130, BR-37900106 Passos, MG, Brazil.
   [Paulino, Marcelo Gustavo] Univ Fed Tocantins, Setor Cimba, Campus Araguaina,Av Paraguai S-N, BR-77824838 Araguaina, TO, Brazil.
RP Fernandes, MN (reprint author), Univ Fed Sao Carlos, Dept Ciencias Fisiol, Via Washington Luis,Km 235, BR-13565905 Sao Carlos, SP, Brazil.
EM dmnf@ufscar.br
RI Paulino, Marcelo/AAF-5065-2020; Giani, Alessandra/H-9764-2012
OI Giani, Alessandra/0000-0002-2524-8534; Terezan, Ana
   Paula/0000-0002-6864-887X; Paulino, Marcelo Gustavo/0000-0003-0464-6848;
   Tavares, Driele/0000-0003-4486-5463
FU Companhia Energetica de Minas Gerais (CEMIG) [GT 346]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES)CAPES
   [2276/2011]; CAPES/PNDP [2276/2011]; CEMIG [GT 346]; Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2012/00728-1]
FX This study was supported by Companhia Energetica de Minas Gerais (CEMIG,
   Proc GT 346) to A. Giani and Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior, Brazil (CAPES, Proc. 2276/2011) to M.N. Fernandes.
   M.M. Sakuragui acknowledges CAPES/PNDP Proc. 2276/2011, N.E.S. Souza, D.
   Tavares and A.P. Terezan acknowledge CEMIG (Proc GT 346), and M.G.
   Paulino acknowledges CEMIG (Proc GT 346) and Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP, Proc. 2012/00728-1) for a
   scholarship.
CR Amado LL, 2010, ENVIRON INT, V36, P226, DOI 10.1016/j.envint.2009.10.010
   Aranda-Rodriguez R, 2005, ENVIRON TOXICOL, V20, P390, DOI 10.1002/tox.20116
   Beutler E, 1975, RED CELL METABOLISM, P89
   BEUTLER E, 1984, RED CELL METABOLISM, P74
   Borges Paul Aparecida Federiche, 2008, Acta Scientiarum Biological Sciences, V30, P57
   CARMICHAEL WW, 1988, TOXICON, V26, P971, DOI 10.1016/0041-0101(88)90195-X
   Carvalho M.C., 2013, MANUAL CIANOBACTERIA
   Cazenave J, 2006, ENVIRON TOXICOL, V21, P22, DOI 10.1002/tox.20151
   Cazenave J, 2006, AQUAT TOXICOL, V76, P1, DOI 10.1016/j.aquatox.2005.08.011
   Chellappa NT, 2008, BRAZ ARCH BIOL TECHN, V51, P833, DOI 10.1590/S1516-89132008000400022
   Chen L, 2016, J HAZARD MATER, V301, P381, DOI 10.1016/j.jhazmat.2015.08.041
   Christian J.A., 2000, SCHALMS VET HEMATOLO
   Collier HB, 1944, CAN MED ASSOC J, V50, P550
   Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO;2-I
   dos Anjos FM, 2006, TOXICON, V48, P239, DOI 10.1016/j.toxicon.2006.05.006
   Ernst B, 2001, ENVIRON TOXICOL, V16, P483, DOI 10.1002/tox.10006
   FALCONER IR, 2005, CYANOBACTERIAL TOXIN
   Fonseca Irauza Arroteia, 2011, Acta Scientiarum Biological Sciences, V33, P319, DOI 10.4025/actascibiolsci.v33i3.6802
   Ruas CBG, 2008, ECOTOX ENVIRON SAFE, V71, P86, DOI 10.1016/j.ecoenv.2007.08.018
   GUILLARD RR, 1972, J PHYCOL, V8, P10, DOI 10.1111/j.0022-3646.1972.00010.x
   Gupta N, 2003, TOXICOLOGY, V188, P285, DOI 10.1016/S0300-483X(03)00112-4
   Habig W H, 1981, Methods Enzymol, V77, P398
   Halliwell B., 2015, FREE RADICALS BIOL M
   Jacinavicius FR, 2018, BRAZ J BOT, V41, P675, DOI 10.1007/s40415-018-0490-8
   JACOB HS, 1966, J BIOL CHEM, V241, P4243
   Jiang JL, 2011, ECOTOXICOLOGY, V20, P1000, DOI 10.1007/s10646-011-0646-9
   JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N
   Koprucu SS, 2006, PESTIC BIOCHEM PHYS, V86, P99, DOI 10.1016/j.pestbp.2006.02.001
   Li W, 2014, AQUAT TOXICOL, V147, P18, DOI 10.1016/j.aquatox.2013.12.001
   Li XY, 2003, TOXICON, V42, P85, DOI 10.1016/S0041-0101(03)00104-1
   Lima CF, 2006, LIFE SCI, V79, P2056, DOI 10.1016/j.lfs.2006.06.042
   Livingstone DR, 2001, MAR POLLUT BULL, V42, P656, DOI 10.1016/S0025-326X(01)00060-1
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Merel S, 2013, ENVIRON INT, V59, P303, DOI 10.1016/j.envint.2013.06.013
   Metcalf JS, 2000, FEMS MICROBIOL LETT, V189, P155, DOI 10.1016/S0378-1097(00)00270-6
   MISRA HP, 1972, J BIOL CHEM, V247, P6960
   Moron SE, 2003, J EXP ZOOL PART A, V298A, P93, DOI 10.1002/jez.a.10259
   Nagasaka R, 2004, COMP BIOCHEM PHYS C, V139, P259, DOI 10.1016/j.cca.2004.12.001
   Pandey KB, 2011, BIOMED PAP, V155, P131, DOI 10.5507/bp.2011.027
   Pandey S, 2003, SCI TOTAL ENVIRON, V309, P105, DOI 10.1016/S0048-9697(03)00006-8
   Paskerova H, 2012, ENVIRON SCI POLLUT R, V19, P2024, DOI 10.1007/s11356-012-0960-7
   Paulino MG, 2017, AQUAT TOXICOL, V182, P91, DOI 10.1016/j.aquatox.2016.11.012
   Paulino MG, 2017, CHEMOSPHERE, V175, P431, DOI 10.1016/j.chemosphere.2017.02.089
   Pereira DA, 2015, AQUAT MICROB ECOL, V74, P205, DOI 10.3354/ame01739
   Pereira DA, 2014, FEMS MICROBIOL ECOL, V88, P175, DOI 10.1111/1574-6941.12281
   Pereira DA, 2012, MICROBIOL RES, V167, P413, DOI 10.1016/j.micres.2012.02.007
   Pflugmacher S, 1998, BBA-GEN SUBJECTS, V1425, P527, DOI 10.1016/S0304-4165(98)00107-X
   Pflugmacher S, 2001, ENVIRON TOXICOL CHEM, V20, P846, DOI [10.1002/etc.5620200421, 10.1897/1551-5028(2001)020&lt;0846:UEAMOC&gt;2.0.CO;2]
   Pouria S, 1998, LANCET, V352, P21, DOI 10.1016/S0140-6736(97)12285-1
   Prieto AI, 2006, AQUAT TOXICOL, V77, P314, DOI 10.1016/j.aquatox.2005.12.012
   Puddick J, 2014, MAR DRUGS, V12, P5372, DOI 10.3390/md12115372
   RANTIN FT, 1992, J FISH BIOL, V41, P805, DOI 10.1111/j.1095-8649.1992.tb02708.x
   Rios FS, 2006, J COMP PHYSIOL B, V176, P721, DOI 10.1007/s00360-006-0098-3
   Rios FS, 2005, COMP BIOCHEM PHYS A, V140, P281, DOI 10.1016/j.cbpb.2004.12.006
   Rios V, 2014, TOXINS, V6, P1062, DOI 10.3390/toxins6031062
   Sakuragui MM, 2003, J COMP PHYSIOL B, V173, P309, DOI 10.1007/s00360-003-0337-9
   Sant'Anna Celia L., 2008, Algological Studies, V126, P251, DOI 10.1127/1864-1318/2008/0126-0251
   Sedan D, 2013, TOXICON, V68, P9, DOI 10.1016/j.toxicon.2013.03.002
   Sicinska P, 2006, TOXICON, V47, P387, DOI 10.1016/j.toxicon.2005.12.006
   Sk UH, 2006, ENVIRON TOXICOL PHAR, V22, P298, DOI 10.1016/j.etap.2006.04.004
   Sotton B, 2012, ECOTOXICOLOGY, V21, P1788, DOI 10.1007/s10646-012-0913-4
   Speit G, 1999, METH MOL B, V113, P203
   Vajcova V, 1998, ACTA VET BRNO, V67, P281, DOI 10.2754/avb199867040281
   Weng D, 2007, TOXICOLOGY, V232, P15, DOI 10.1016/j.tox.2006.12.010
   White CC, 2003, ANAL BIOCHEM, V318, P175, DOI 10.1016/S0003-2697(03)00143-X
   Wu LY, 2010, J CHROMATOGR A, V1217, P1455, DOI 10.1016/j.chroma.2009.12.068
   Yonezawa LA, 2005, J VET MED A, V52, P292, DOI 10.1111/j.1439-0442.2005.00732.x
   Zhang XZ, 2007, TOXICON, V49, P1150, DOI 10.1016/j.toxicon.2007.02.009
NR 68
TC 0
Z9 0
U1 6
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 18
EP 24
DI 10.1016/j.toxicon.2019.08.002
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800004
PM 31421159
DA 2020-05-12
ER

PT J
AU Melo, FG
   Ocarino, NM
   Reis, AMS
   Gomes, LA
   Cardoso, KMM
   Gimeno, EJ
   Massone, AR
   Melo, MM
   Botelho, AFM
   Serakides, R
AF Melo, Fabricio Gomes
   Ocarino, Natalia Melo
   Sena Reis, Amanda Maria
   Gomes, Lorenna Alves
   Magalhaes Cardoso, Kenia Mara
   Gimeno, Eduardo Juan
   Massone, Adriana Raquel
   Melo, Marilia Martins
   Machado Botelho, Ana Flavia
   Serakides, Rogeria
TI Rat mesenchymal stem cell cultures as a model to elucidate the cellular
   and molecular pathogenesis of bone metaplasia induced by Solanum
   glaucophyllum intoxication
SO TOXICON
LA English
DT Article
DE Enzootic calcinosis; Osteogenic differentiation; Stem cell; Calcinogenic
   plant
ID OSTEOGENIC DIFFERENTIATION; ENZOOTIC CALCINOSIS; NIEREMBERGIA-VEITCHII;
   OSTEOBLAST PHENOTYPE; STROMAL CELLS; ADIPOSE-TISSUE; IN-VITRO; MARROW;
   MALACOXYLON; SHEEP
AB The hypothesis of this experiment is that mesenchymal stem cells (MSCs) are involved in the genesis of the bone metaplasia caused by Solanum glaucophyllum intoxication. We determined using liquid chromatography that 1 mL of plant extract contained 3.8 mu l of 1,25(OH)(2)D-3. The ability of 100 mu L, 1 mL and 5 mL of extract/L, containing 1 nM (0.4 mu g/L), 10 nM (4 mu g/L) and 50 nM (20 mu g/L) of 1,25(OH)(2)D-3, respectively, in inducing the osteogenic differentiation in bone marrow MSCs from rats was tested. At the concentrations of 1 and 5 mL of extract/L of culture medium without osteogenesis-inducing factors, the plant extract induced the osteogenic differentiation of the MSCs, as was evidenced by the greater synthesis of mineralized matrix. At the higher concentration (5 mL of extract/L), an increase in the relative expression of BMP-2 gene was observed. It was concluded that rat bone marrow MSC culture is a good model for studying the effects of the S. glaucophyllum extract on the osteogenic differentiation of undifferentiated cells. Also, S. glaucophyllum extracts containing 10 nM (4 mu g/L) and 50 nM (20 mu g/L) of 1,25(OH)(2)D-3 induce the osteogenic differentiation of MSCs, suggesting that this is one of the mechanisms by which S. glaucophyllum causes bone metaplasia.
C1 [Melo, Fabricio Gomes; Ocarino, Natalia Melo; Gomes, Lorenna Alves; Magalhaes Cardoso, Kenia Mara; Melo, Marilia Martins; Serakides, Rogeria] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Sena Reis, Amanda Maria] Univ Estadual Santa Cruz, Ilheus, BA, Brazil.
   [Gimeno, Eduardo Juan; Massone, Adriana Raquel] Univ La Plata, La Plata, Buenos Aires, Argentina.
   [Machado Botelho, Ana Flavia] Univ Fed Goias, Goiania, Go, Brazil.
RP Serakides, R (reprint author), Univ Fed Minas Gerais, Escola Vet, Dept Clin & Cirurgia Vet, Ave Antonio Carlos 6627,Caixa Postal 567, BR-31270901 Belo Horizonte, MG, Brazil.
EM serakidesufmg@gmail.com
RI Serakides, Rogeria/C-7571-2016
OI Serakides, Rogeria/0000-0001-5374-6242
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrasilNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), BrasilCAPES
FX This work was supported by grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Brasil and Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brasil.
CR Alves EGL, 2016, PESQUI VET BRASIL, V36, P21, DOI 10.1590/S0100-736X201600130004
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926-003-0071-z
   ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   Bachmann H, 2013, BRIT POULTRY SCI, V54, P642, DOI 10.1080/00071668.2013.825692
   Barros SS, 2000, J COMP PATHOL, V123, P270, DOI 10.1053/jcpa.2000.0415
   Blair HC, 2017, TISSUE ENG PART B-RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Boeloni JN, 2009, HORM RES, V72, P88, DOI 10.1159/000232161
   Boeloni JN, 2013, PATHOL RES PRACT, V209, P44, DOI 10.1016/j.prp.2012.10.004
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Dobereiner J., 1971, Pesquisa Agropecuaria Brasileira, Serie Veterinaria, V6, P91
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   DONE SH, 1976, BRIT VET J, V132, P28, DOI 10.1016/S0007-1935(17)34785-1
   Gili V, 2016, STEROIDS, V109, P7, DOI 10.1016/j.steroids.2016.03.002
   Guedes KMR, 2011, PESQUISA VET BRASIL, V31, P643, DOI 10.1590/S0100-736X2011000800002
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   Kato H, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.140201
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou Y.R, 2017, SCI REP, V7, P1
   Mathisa G.A, 2013, J STEROID BIOCHEM, V144, P40
   Micheloud J. F., 2012, REVA MED VET, V93, P59
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ocarino NM, 2008, NITRIC OXIDE-BIOL CH, V19, P320, DOI 10.1016/j.niox.2008.08.004
   Odriozola ER, 2018, J VET DIAGN INVEST, V30, P286, DOI 10.1177/1040638717746447
   OKADA KA, 1977, ECON BOT, V31, P225, DOI 10.1007/BF02866593
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   PETERLIK M, 1975, FED PROC, V34, P887
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posa F, 2016, STEM CELLS INT, P1
   PUCHE RC, 1974, CALC TISS RES, V16, P219, DOI 10.1007/BF02008229
   RAPPAPORTT I, 1977, PHYTOCHEMISTRY, V16, P1115, DOI 10.1016/S0031-9422(00)86765-5
   RIETCORREA F, 1981, PESQUI AGROPECU BRAS, V16, P727
   RIETCORREA F, 1987, PESQUISA VET BRASIL, V7, P85
   Rissi Daniel Ricardo, 2007, Cienc. Rural, V37, P1393, DOI 10.1590/S0103-84782007000500027
   Santos Carlos E.P. dos, 2011, Pesq. Vet. Bras., V31, P1053, DOI 10.1590/S0100-736X2011001200003
   Reis AMS, 2016, CONNECT TISSUE RES, V57, P131, DOI 10.3109/03008207.2015.1117075
   Reis AMS, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0467-8
   Stefkova K, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/628368
   Tokarnia C. H., 1974, Pesquisa Agropecuaria Brasileira, Serie Veterinaria, V9, P53
   Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761
   Vasconcelos RO, 1998, PESQUISA VET BRASIL, V18, P9, DOI 10.1590/S0100-736X1998000100002
   Vasuri Francesco, 2014, World J Stem Cells, V6, P540, DOI 10.4252/wjsc.v6.i5.540
   WASSERMAN RH, 1976, SCIENCE, V194, P853, DOI 10.1126/science.982048
   WORKER NA, 1967, NATURE, V215, P72, DOI 10.1038/215072a0
   Xu RS, 2018, BONE, V109, P134, DOI 10.1016/j.bone.2017.08.025
   Zhou Y, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0029-6
   Zhou YS, 2006, CHINESE MED J-PEKING, V119, P1278, DOI 10.1097/00029330-200608010-00008
NR 50
TC 0
Z9 0
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 25
EP 33
DI 10.1016/j.toxicon.2019.08.003
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800005
PM 31421160
DA 2020-05-12
ER

PT J
AU Witharana, EWRA
   Gnanathasan, A
   Dissanayake, AS
   Wijesinghe, SKJ
   Kadahetti, SCL
   Rajapaksha, RMJK
AF Witharana, E. W. R. A.
   Gnanathasan, A.
   Dissanayake, A. S.
   Wijesinghe, S. K. J.
   Kadahetti, S. C. L.
   Rajapaksha, R. M. J. K.
TI Sri Lankan green pit viper (Trimeresurus trigonocephalus) bites in
   Deniyaya: A clinico-epidemiological study
SO TOXICON
LA English
DT Article
DE Green pit viper; Trimeresurus trigonocephalus; Extensive limb swelling;
   Hemorrhagic blisters; Coagulopathy
ID SNAKE BITE; ALBOLABRIS; MACROPS; ASIA
AB Green pit viper (Trimeresurus trigonocephalus) is endemic to Sri Lanka and bites are reported from tropical rain forest and plantation areas. As scant data exists on clinico-epidemiological features of Sri Lankan green pit viper bite, objective of this study was to address this knowledge gap. A prospective observational study was conducted in Base Hospital Deniyaya from October 2013 to September 2015. Green pit viper as the offending snake was identified when the victims brought live or dead specimens. When the specimen was not available, green pit viper was identified by the victim pointing to preserved specimens and photographs of green pit viper and different similar appearing snakes. Clinical details were recorded during the hospital stay. Twenty four green pit viper bite patients (17-68 years) were studied. All cases were daytime bites despite green pit viper being a nocturnally active snake. Sixteen patients (67%) were bitten while they were working in tea plantation. Hands (42%), feet, (33%), forearms (8%), legs (8%), thighs (4%) and shoulders (4%) were the sites of bites. Thirteen (54%) had extensive limb swelling. Nine (38%) had local swelling and two had no swelling. Three (12.5%) developed haemorrhagic blisters. Four (17%) had regional lymphadenopathy. Two (8%) developed non clotting blood by the TWBCT.
   Green pit viper bites caused substantial morbidity. Risk factors included day time outdoor activities in bordering villages of tropical rain forests and occupation. Pain, extensive limb swelling and bite site swelling were prominent clinical features. However haemorrhagic blisters, regional lymphadenopathy and coagulopathy were reported. Nephrotoxicity and neurotoxicity were notably absent.
C1 [Witharana, E. W. R. A.; Wijesinghe, S. K. J.; Kadahetti, S. C. L.; Rajapaksha, R. M. J. K.] Base Hosp, Deniyaya, Sri Lanka.
   [Gnanathasan, A.] Univ Colombo, Dept Clin Med, Colombo, Sri Lanka.
   [Dissanayake, A. S.] Univ Ruhuna, Dept Clin Med, Galle, Sri Lanka.
RP Witharana, EWRA (reprint author), Base Hosp, Deniyaya, Sri Lanka.
EM elapathawitharana@gmail.com
CR Alirol E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000603
   [Anonymous], 1999, Southeast Asian J Trop Med Public Health, V30 Suppl 1, P1
   Ariaratnam CA, 2008, AM J TROP MED HYG, V79, P458, DOI 10.4269/ajtmh.2008.79.458
   Ariaratnam CA, 2009, AM J TROP MED HYG, V81, P725, DOI 10.4269/ajtmh.2009.09-0225
   de Silva A., 1983, Ceylon Medical Journal, V28, P118
   de Silva A., 1983, Ceylon Medical Journal, V28, P144
   Ediriweera DS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004813
   HUTTON RA, 1990, T ROY SOC TROP MED H, V84, P866, DOI 10.1016/0035-9203(90)90111-Q
   Kasturiratne A., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P733
   Kularatne SAM, 2002, POSTGRAD MED J, V78, P276, DOI 10.1136/pmj.78.919.276
   Rathnayaka RMMKN, 2017, TOXICON, V137, P99, DOI 10.1016/j.toxicon.2017.07.017
   Rathnayaka RMMKN, 2017, TOXICON, V129, P95, DOI 10.1016/j.toxicon.2017.02.011
   Rojnuckarin P, 1999, TOXICON, V37, P743, DOI 10.1016/S0041-0101(98)00214-1
   Sarmin S, 2013, ASIA PACIFIC J MED T, V2, P96
   VISUDHIPHAN S, 1989, AM J TROP MED HYG, V41, P570, DOI 10.4269/ajtmh.1989.41.570
NR 15
TC 2
Z9 2
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 34
EP 37
DI 10.1016/j.toxicon.2019.07.011
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800006
PM 31348933
DA 2020-05-12
ER

PT J
AU Abderrahim, LA
   Taibi, K
   Abderrahim, NA
   Alomery, AM
   Abdellah, F
   Alhazmi, AS
   Aljassabi, S
AF Abderrahim, Leila Ait
   Taibi, Khaled
   Abderrahim, Nawel Ait
   Alomery, Anas M.
   Abdellah, Fatiha
   Alhazmi, Ayman Saeed
   Aljassabi, Saad
TI Protective effects of melatonin and N-acetyl cysteine against oxidative
   stress induced by microcystin-LR on cardiac muscle tissue
SO TOXICON
LA English
DT Article
DE Microcystin-LR; Oxidative stress; Antioxidants; Melatonin; N-acetyl
   cysteine; Cardiac muscle tissue
ID ACETYLCYSTEINE; DAMAGE; ANTIOXIDANT; EXPOSURE; TOXICITY; HEART; RAT;
   ATTENUATION; PREVENTION; INDUCTION
AB Microcystin Leucine-Arginine (MC-LR) is a toxin produced by the cyanobacteria Microcystis aeruginosa. It is the most encountered and toxic type of cyanotoxins. Oxidative stress was shown to play a role in the pathogenesis of microcystin LR by the induction of intracellular reactive oxygen species (ROS) formation that oxidize and damage cellular macromolecules. In the present study we examined the effect of acute MC-LR dose on the cardiac muscle of BALB/c mice. Afterwards, melatonin and N-acetyl cysteine (NAC) were assayed and evaluated as potential protective and antioxidant agents against damages generated by MC-LR. For this purpose, thirty mice were assigned into six groups of five mice each. The effect of MC-LR was first compared to the control group supplied with distilled water, then compared to the other groups supplied with melatonin and NAC. The experiment lasted 10 days after which animals were euthanized. Biomarkers of toxicity such as alkaline phosphatase activity, lipid peroxidation, protein carbonyl content, reduced glutathione content, serum lactate dehydrogenase and serum sorbitol dehydrogenase were assayed. Results showed that toxin treated mice have experienced significant oxidative damage in their myocardial tissue as revealed by noticeable levels of oxidative stress biomarkers and by the reduction in alkaline phosphatase activity. Whereas, melatonin and NAC treated mice manifested lesser oxidative damages. Our findings suggest a potential therapeutic use of melatonin and N-acetyl cysteine as antioxidant protective agents against oxidative damage induced by MC-LR.
C1 [Abderrahim, Leila Ait; Taibi, Khaled] Ibn Khaldoun Univ, Fac Life & Nat Sci, Karman Campus, Tiaret 14000, Algeria.
   [Abderrahim, Nawel Ait] Univ Montpellier, Fac Sci, Montpellier, France.
   [Alomery, Anas M.; Alhazmi, Ayman Saeed] Taif Univ, Fac Appl Med Sci, Clin Lab Dept, At Taif, Saudi Arabia.
   [Abdellah, Fatiha] Ibn Khaldoun Univ, Lab Res Local Anim Prod, Tiaret, Algeria.
   [Aljassabi, Saad] Univ Malaya, Inst Biol Sci, Kuala Lumpur, Malaysia.
RP Abderrahim, LA (reprint author), Ibn Khaldoun Univ, Fac Life & Nat Sci, Karman Campus, Tiaret 14000, Algeria.
EM aitleila-biog@hotmail.com
RI ; TAIBI, Khaled/L-7670-2016
OI /0000-0003-0049-6117; TAIBI, Khaled/0000-0003-1640-5638
CR Akcay YD, 2005, CELL MOL BIOL LETT, V10, P321
   Akin-Oriola G. A., 2005, African Journal of Science and Technology, V6, P1
   Al-Jassabi S, 2006, BIOCHEMISTRY-MOSCOW+, V71, P1115, DOI 10.1134/S0006297906100099
   Albendea CD, 2007, J TRACE ELEM MED BIO, V21, P261, DOI 10.1016/j.jtemb.2007.04.002
   Anisimov VN, 2003, INT J CANCER, V103, P300, DOI 10.1002/ijc.10827
   Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   BESSEY OA, 1946, J BIOL CHEM, V164, P321
   Billam M, 2006, THESIS
   Blokhina O, 2003, ANN BOT-LONDON, V91, P179, DOI 10.1093/aob/mcf118
   Botha N, 2004, TOXICON, V43, P85, DOI 10.1016/j.toxicon.2003.10.025
   Butler N., 2009, OEHHA ECOTOXICOL, P1
   Campos A, 2010, INT J MOL SCI, V11, P268, DOI 10.3390/ijms11010268
   Chen T, 2005, MOL CELL PROTEOMICS, V4, P958, DOI 10.1074/mcp.M400185-MCP200
   Cornelissen G, 2000, AM J MED, V109, P343
   Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x
   Dawson RM, 1998, TOXICON, V36, P953, DOI 10.1016/S0041-0101(97)00102-5
   Dekhuijzen PNR, 2004, EUR RESPIR J, V23, P629, DOI 10.1183/09031936.04.00016804
   Ding WX, 1998, ENVIRON RES, V78, P12, DOI 10.1006/enrs.1998.3843
   Ding WX, 2001, BIOCHEM BIOPH RES CO, V285, P1155, DOI 10.1006/bbrc.2001.5309
   Fawell JK, 1999, HUM EXP TOXICOL, V18, P162, DOI 10.1191/096032799678839842
   Fishbane S, 2004, J AM SOC NEPHROL, V15, P251, DOI 10.1097/01.ASN.0000107562.68920.92
   Gerlach U., 1974, METHODS ENZYMATIC AN, VII
   Guzman RE, 2002, VET PATHOL, V39, P17, DOI 10.1354/vp.39-1-17
   Hoger S.J., 2003, THESIS
   Izaguirre G, 2007, WATER RES, V41, P492, DOI 10.1016/j.watres.2006.10.012
   Jiang JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055729
   Jovanovic P, 2010, BOSNIAN J BASIC MED, V10, P83
   Jungblut AD, 2006, TOXICON, V47, P271, DOI 10.1016/j.toxicon.2005.11.002
   Kannan M, 2004, EXP BIOL MED, V229, P553
   Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553
   Laurent T, 1996, CHEST, V109, P163, DOI 10.1378/chest.109.1.163
   Lee S, 2009, J PINEAL RES, V46, P43, DOI 10.1111/j.1600-079X.2008.00607.x
   Liu S., 2018, ONCOMEDICINE, V3, P37, DOI [10.7150/oncm.25566, DOI 10.7150/ONCM.25566]
   Lone Y, 2015, TOXICOL REP, V2, P289, DOI 10.1016/j.toxrep.2015.01.008
   Mak S, 2001, CHEST, V120, P2035, DOI 10.1378/chest.120.6.2035
   Manage P. M., 2009, INTERDISCIPLINARY ST, P277
   Martins ND, 2011, CHEMOSPHERE, V84, P154, DOI 10.1016/j.chemosphere.2011.02.016
   Milutnovic A, 2006, FOLIA BIOL-PRAGUE, V52, P116
   Moore CE, 2016, MAR DRUGS, V14, DOI 10.3390/md14030054
   Nhoato A., 2001, Online Journal of Veterinary Research, V5, P172
   Okutan Huseyin, 2004, Interact Cardiovasc Thorac Surg, V3, P519, DOI 10.1016/j.icvts.2004.05.005
   Olofsson AC, 2003, APPL ENVIRON MICROB, V69, P4814, DOI 10.1128/AEM.69.8.4814-4822.2003
   Prieto AI, 2007, AQUAT TOXICOL, V84, P337, DOI 10.1016/j.aquatox.2007.06.012
   Rudnicki M, 2007, FOOD CHEM TOXICOL, V45, P656, DOI 10.1016/j.fct.2006.10.022
   Schmidt JR, 2014, TOXINS, V6, P3354, DOI 10.3390/toxins6123354
   Solter PF, 1998, TOXICOL SCI, V44, P87, DOI 10.1006/toxs.1998.2478
   Sprong RC, 1998, AM J RESP CRIT CARE, V157, P1283
   Stetinova V, 2002, GEN PHYSIOL BIOPHYS, V21, P153
   Sun H, 2016, CURR OPIN LIPIDOL, V27, P408, DOI 10.1097/MOL.0000000000000314
   Tabassum H, 2006, CLIN CHIM ACTA, V370, P129, DOI 10.1016/j.cca.2006.02.006
   Teixeira KC, 2008, PULM PHARMACOL THER, V21, P309, DOI 10.1016/j.pupt.2007.07.006
   Tomas-Zapico C, 2007, RECENT PATENTS ENDOC, V1, P63, DOI 10.2174/187221407779814561
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299
   Wang Q, 2008, TOXICON, V52, P721, DOI 10.1016/j.toxicon.2008.08.004
   WHO, 2003, WHOSDEWSH030439
   Xu YH, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0115-z
   Yoshida Toshinori, 1997, Natural Toxins, V5, P91, DOI 10.1002/nt.1
   Zegura B, 2006, MUTAT RES-GEN TOX EN, V611, P25, DOI 10.1016/j.mrgentox.2006.06.038
   Zhao F, 2008, CHEM PHYS LIPIDS, V151, P77, DOI 10.1016/j.chemphyslip.2007.10.002
   Zisapel N, 2018, BRIT J PHARMACOL, V175, P3190, DOI 10.1111/bph.14116
NR 61
TC 2
Z9 2
U1 6
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 38
EP 44
DI 10.1016/j.toxicon.2019.08.005
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800007
PM 31465783
DA 2020-05-12
ER

PT J
AU Nystrom, GS
   Ward, MJ
   Ellsworth, SA
   Rokyta, DR
AF Nystrom, Gunnar S.
   Ward, Micaiah J.
   Ellsworth, Schyler A.
   Rokyta, Darin R.
TI Sex-based venom variation in the eastern bark centipede (Hemiscolopendra
   marginata)
SO TOXICON
LA English
DT Article
DE Centipede; Venom; Proteome; Transcriptome
ID RNA-SEQ; GLAND TRANSCRIPTOMICS; DIMORPHISM; SCORPION; EVOLUTION;
   PROTEOMICS; PROTEIN; PEPTIDES; SEQUENCE; BEHAVIOR
AB Sexually dimorphic traits are widespread across metazoans and are often the result of sex-specific inheritance or sex-based differences in gene expression. Intersexual differences have even been observed in invertebrate venoms, although the identification of these differences has been limited to the more well-studied groups, such as scorpions and spiders, where sex-based differences in morphology and behavior are apparent. Recent studies on centipede venom have identified evidence of intraspecific variation, but intersexual differences have not been reported. To investigate the potential for sex-based differences in centipede venom composition, we performed reversed-phase high performance liquid chromatography (RP-HPLC) analyses on five male and 15 female eastern bark centipedes (Hemiscolopendra marginata) from the Apalachicola National Forest in northern Florida. After detecting a significant sex-based difference in H. marginata venom composition, we completed a high-throughput venom-gland transcriptomic and venom proteomic analysis of one male and one female to determine the genetic basis for differences in venom composition. We identified 47 proteomically confirmed toxins and 717 nontoxin transcripts in H. marginata venom-glands. Of these proteomically confirmed toxins, the most abundantly expressed in the male venom included ion channel-modulating toxins and toxins so divergent from any characterized homologs that they could not be given a functional classification, whereas the most abundantly expressed in the female venom were gamma-glutamyl transferases and CAPs (cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins). These differences were then confirmed by performing replicate LC-MS/MS analyses on the venom from an additional three male and three female H. marginata. Our RP-HPLC and high-throughput transcriptomic and proteomic approach resulted in not only an in-depth characterization of H. marginata venom, but represents the first example of sex-based variation in centipede venoms.
C1 [Nystrom, Gunnar S.; Ward, Micaiah J.; Ellsworth, Schyler A.; Rokyta, Darin R.] Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.
RP Rokyta, DR (reprint author), Florida State Univ, Dept Biol Sci, 319 Stadium Dr, Tallahassee, FL 32306 USA.
EM drokyta@bio.fsu.edu
RI Ellsworth, Schyler/AAH-8776-2019
OI Ward, Micaiah/0000-0001-9474-8615
FU National Science FoundationNational Science Foundation (NSF) [NSF
   DEB-1145978, NSF DEB 1638902, 1449440]; Florida State University Council
   on Research and Creativity
FX This material is based upon work supported by the National Science
   Foundation Graduate Research Fellowship Program under Grant No. 1449440.
   Any opinions, findings, and conclusions or recommendations expressed in
   this material are those of the authors and do not necessarily reflect
   the views of the National Science Foundation. Funding for this work was
   provided by the National Science Foundation (NSF DEB-1145978 and NSF DEB
   1638902) and the Florida State University Council on Research and
   Creativity. We thank Rakesh Singh of the Florida State University
   College of Medicine Translational Science Laboratory for advice and
   assistance with proteomic analyses and Margaret Seavy of the Florida
   State Molecular Core Facility for her guidance on RP-HPLC parameters. We
   also thank Michael Hogan for specimen photographs.
CR Abdel-Rahman MA, 2011, COMP BIOCHEM PHYS C, V154, P318, DOI 10.1016/j.cbpc.2011.06.019
   Aitchison J., 1986, STAT ANAL COMPOSITIO
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Binford GJ, 2016, TOXICON, V114, P45, DOI 10.1016/j.toxicon.2016.02.015
   Bonato L, 2010, ZOOKEYS, P17, DOI 10.3897/zookeys.69.737
   Booncham U, 2007, NU SCI J, V4, P42
   Carlson BE, 2009, J ARACHNOL, V37, P321, DOI 10.1636/Hi09-06.1
   Carlson BE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097648
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Cooper AM, 2014, ZOOLOGY, V117, P398, DOI 10.1016/j.zool.2014.06.007
   COURTAY C, 1992, BIOCHEM PHARMACOL, V43, P2527, DOI 10.1016/0006-2952(92)90140-E
   D'Suze G, 2015, TOXICON, V108, P62, DOI 10.1016/j.toxicon.2015.09.034
   Dugon MM, 2012, J INSECT PHYSIOL, V58, P874, DOI 10.1016/j.jinsphys.2012.03.014
   Ellegren H, 2007, NAT REV GENET, V8, P689, DOI 10.1038/nrg2167
   Falabella P, 2007, INSECT BIOCHEM MOLEC, V37, P453, DOI 10.1016/j.ibmb.2007.02.005
   Gasteiger E., 2005, PROTEIN IDENTIFICATI
   Cupul-Magana FG, 2018, PAN-PAC ENTOMOL, V94, P1, DOI 10.3956/2018-94.1.1
   GLUCKSMANN A, 1974, BIOL REV, V49, P423, DOI 10.1111/j.1469-185X.1974.tb01171.x
   Gonzalez-Morales L, 2014, J PROTEOMICS, V111, P224, DOI 10.1016/j.jprot.2014.04.033
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Haas B, 2016, TRANSDECODER FIND CO
   Hakim MA, 2015, TOXINS, V7, P4832, DOI 10.3390/toxins7114832
   Herzig V, 2008, TOXICON, V51, P1167, DOI 10.1016/j.toxicon.2008.02.001
   Inceoglu B, 2003, P NATL ACAD SCI USA, V100, P922, DOI 10.1073/pnas.242735499
   Kalia J, 2015, J MOL BIOL, V427, P158, DOI 10.1016/j.jmb.2014.07.027
   Krueger F., 2015, TRIM GALORE
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lewis J, 2006, BIOL CENTIPEDES
   LEWIS J. G. E., 1968, J LINN SOC LONDOIN ZOOL, V47, P315
   Li H., 2013, ARXIV13033997
   Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Liu JT, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004772
   Liu ZC, 2012, J PROTEOME RES, V11, P6197, DOI 10.1021/pr300881d
   Luo L, 2018, P NATL ACAD SCI US
   Mank JE, 2009, AM NAT, V173, P141, DOI 10.1086/595754
   Marcais G, 2011, BIOINFORMATICS, V27, P764, DOI 10.1093/bioinformatics/btr011
   McMonigle O, 2014, CENTIPEDES CAPTIVITY
   Moran Y, 2013, MAR BIOTECHNOL, V15, P329, DOI 10.1007/s10126-012-9491-y
   Nisani Z, 2012, TOXICON, V60, P315, DOI 10.1016/j.toxicon.2012.04.343
   Carcamo-Noriega EN, 2019, TOXICON, V157, P87, DOI 10.1016/j.toxicon.2018.11.305
   Oksanen J, 2013, PACKAGE VEGAN COMMUN, V2, P1, DOI DOI 10.4135/9781412971874.N145
   Owens IPF, 1998, P ROY SOC B-BIOL SCI, V265, P397, DOI 10.1098/rspb.1998.0308
   PARKER GA, 1992, J FISH BIOL, V41, P1, DOI 10.1111/j.1095-8649.1992.tb03864.x
   Paszkiewicz KH, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00157
   Peichoto ME, 2009, COMP BIOCHEM PHYS C, V150, P79, DOI 10.1016/j.cbpc.2009.03.002
   Peng ZY, 2012, NAT BIOTECHNOL, V30, P253, DOI 10.1038/nbt.2122
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Rehm P, 2014, MOL PHYLOGENET EVOL, V77, P25, DOI 10.1016/j.ympev.2014.04.007
   Rice P, 2000, EMBOSS EUROPEAN MOL
   Rokyta DR, 2017, TOXICON, V128, P23, DOI 10.1016/j.toxicon.2017.01.014
   Rokyta DR, 2015, G3-GENES GENOM GENET, V5, P2375, DOI 10.1534/g3.115.020578
   Rokyta DR, 2015, TOXICON, V98, P34, DOI 10.1016/j.toxicon.2015.02.015
   Rokyta DR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-312
   ROTENBERG D, 1971, BIOCHEM J, V121, P609, DOI 10.1042/bj1210609
   Shelley R.M, 2002, SYNOPSIS N AM CENTIP
   Shelley Rowland M., 2008, International Journal of Myriapodology, V1, P171, DOI 10.1163/187525408X395931
   Smith JJ, 2018, TOXINS, V10, DOI 10.3390/toxins10030096
   Templ M, 2011, ROBCOMPOSITIONS ROBU
   Tragust S, 2013, CURR BIOL, V23, P76, DOI 10.1016/j.cub.2012.11.034
   Undheim EAB, 2015, TOXINS, V7, P679, DOI 10.3390/toxins7030679
   Undheim EAB, 2014, MOL BIOL EVOL, V31, P2124, DOI 10.1093/molbev/msu162
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   VOLLRATH F, 1992, NATURE, V360, P156, DOI 10.1038/360156a0
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Ward MJ, 2018, TOXICON, V152, P137, DOI 10.1016/j.toxicon.2018.07.026
   Ward MJ, 2018, TOXICON, V152, P121, DOI 10.1016/j.toxicon.2018.07.030
   Ward MJ, 2018, TOXICON, V142, P14, DOI 10.1016/j.toxicon.2017.12.042
   Whitfield JB, 2001, CRIT REV CL LAB SCI, V38, P263, DOI 10.1080/20014091084227
   Wong ESW, 2012, MOL CELL PROTEOMICS, V11, P1354, DOI 10.1074/mcp.M112.017491
   Xie YL, 2014, BIOINFORMATICS, V30, P1660, DOI 10.1093/bioinformatics/btu077
   Yang S, 2012, MOL CELL PROTEOMICS, V11, P640, DOI 10.1074/mcp.M112.018853
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
NR 73
TC 1
Z9 1
U1 3
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 45
EP 58
DI 10.1016/j.toxicon.2019.08.001
PG 14
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800008
PM 31445069
DA 2020-05-12
ER

PT J
AU Kuniyoshi, AK
   Kodama, RT
   Cajado-Carvalho, D
   Iwai, LK
   Kitano, E
   da Silva, CCF
   Duzzi, B
   da Silva, WD
   Portaro, FC
AF Kuniyoshi, Alexandre Kazuo
   Kodama, Roberto Tadashi
   Cajado-Carvalho, Daniela
   Iwai, Leo Kei
   Kitano, Eduardo
   Fernandes da Silva, Cristiane Castilho
   Duzzi, Bruno
   da Silva, Wilmar Dias
   Portaro, Fernanda Calheta
TI Experimental antivenom against serine proteases from the Bothrops
   jararaca venom obtained in mice, and its comparison with the
   antibothropic serum from the Butantan Institute
SO TOXICON
LA English
DT Article
DE Bothrops jararaca; Serine protease; Venom; Antivenom
ID LATIN-AMERICAN COUNTRIES; SNAKE-VENOM; PRECLINICAL ASSESSMENT;
   NEUTRALIZING CAPACITY; PROTEINASES; CLEAVAGE
AB In Brazil, snakes from the Bothrops genus are responsible for thousands of accidents, and their venoms are mainly made up of proteolytic enzymes. Although the antibothropic serum produced by the Butantan Institute is remarkable in saving lives, studies show that some symptoms observed in cases of envenoming are not efficiently neutralized. Moreover, our group has shown that the commercial antivenom does not fully neutralize in vitro some serine proteases present in the Bothrops jararaca venom. Therefore, this study focuses on a new method in the production of specific immunoglobulins capable of neutralizing the activities of these enzymes in vitro. For this, a pool of serine proteases that was not inhibited by the commercial antivenom, made up of four enzymes (KN-BJ2, BjSP, HS112 and BPA) from the B. jararaca venom was obtained through two chromatographic steps (DEAE-HPLC and C8-RP-HPLC). The identities of these proteases were confirmed by SDS-PAGE, followed by tryptic digestion and mass spectrometry analysis. This pool was inoculated into BALB/c and C57BL/6 mice, using SBA-15 as adjuvant, and the produced IgGs were purified by affinity chromatography. The sera were characterized by ELISA, avidity and proteolytic neutralization assays. Both animal models responded to the immunization, producing higher IgGs titers when compared to the commercial antivenom. The experimental serum from BALB/c mice presented a better hydrolysis inhibition of the selective fluorescent substrate for serine proteases (similar to 80%) when compared to C57BL/6 (similar to 25%) and the commercial antivenom ( < 1%) at the dose of 500:1 (weight of antivenom:weight of venom). These results show that a different immunization method using isolated serine proteases improves the toxins neutralizing efficacy and could lead to a better end product to be used as a supplemental medicine to the currently used immunotherapy.
C1 [Kuniyoshi, Alexandre Kazuo; Kodama, Roberto Tadashi; Cajado-Carvalho, Daniela; Fernandes da Silva, Cristiane Castilho; Duzzi, Bruno; da Silva, Wilmar Dias; Portaro, Fernanda Calheta] Butantan Inst, Immunochem Lab, Av Prof Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Iwai, Leo Kei; Kitano, Eduardo] Butantan Inst, Ctr Toxins Immune Response & Cell Signaling CeTIS, Special Lab Appl Toxinol, Sao Paulo, SP, Brazil.
RP Portaro, FC (reprint author), Butantan Inst, Immunochem Lab, Av Prof Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM fernanda.portaro@butantan.gov.br
RI ; Iwai, Leo/M-1734-2013
OI Portaro, Fernanda/0000-0002-9582-4699; Iwai, Leo/0000-0002-1571-7763
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2015/15364-3, 2013/15344-7,
   2015/13124-5, 2013/07467-1, 2012/06677-00]; CAPESCAPES
FX This study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo [Project 2015/15364-3, Project 2013/15344-7, Project
   2015/13124-5, Project 2013/07467-1 and Project 2012/06677-00] and CAPES.
CR Battellino C, 2003, TOXICON, V41, P583, DOI 10.1016/S0041-0101(02)00389-6
   Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097
   Bryan MA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000733
   CARDOSO JLC, 1993, Q J MED, V86, P315
   Carone SEI, 2018, TOXICOL APPL PHARM, V357, P50, DOI 10.1016/j.taap.2018.08.018
   da Saude Ministerio, 2017, GUIA VIGILANCIA EPID
   da Silva NMV, 2007, TOXICON, V50, P196, DOI 10.1016/j.toxicon.2007.03.010
   da Silva WD, 2011, TOXICON, V57, P1109, DOI 10.1016/j.toxicon.2011.03.022
   De Franco M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002862
   Ferreira RS, 2010, J TOXICOL ENV HEAL A, V73, P926, DOI 10.1080/15287391003745069
   Fox JW, 2008, FEBS J, V275, P3016, DOI 10.1111/j.1742-4658.2008.06466.x
   Goncalves-Machado L, 2016, J PROTEOMICS, V135, P73, DOI 10.1016/j.jprot.2015.04.029
   HENRIQUES OB, 1958, BIOCHEM J, V68, P597, DOI 10.1042/bj0680597
   Kuniyoshi AK, 2017, TOXICON, V137, P114, DOI 10.1016/j.toxicon.2017.07.020
   Kuniyoshi AK, 2012, TOXICON, V59, P124, DOI 10.1016/j.toxicon.2011.11.001
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leme AFP, 2008, J THROMB HAEMOST, V6, P1363, DOI 10.1111/j.1538-7836.2008.02995.x
   Li PW, 2017, TOXINS, V9, DOI 10.3390/toxins9050172
   Markland FS, 2013, TOXICON, V62, P3, DOI 10.1016/j.toxicon.2012.09.004
   Menaldo DL, 2013, INT IMMUNOPHARMACOL, V15, P764, DOI 10.1016/j.intimp.2013.02.023
   Nascimento NG, 2010, TOXICON, V55, P343, DOI 10.1016/j.toxicon.2009.08.009
   Nicolau CA, 2017, J PROTEOMICS, V151, P214, DOI 10.1016/j.jprot.2016.06.029
   Picolo G, 2002, BRAZ J MED BIOL RES, V35, P1221, DOI 10.1590/S0100-879X2002001000016
   Quimby FW, 2007, MOUSE BIOMEDICAL RES, P171
   Saguchi K, 2005, TOXICON, V46, P72, DOI 10.1016/j.toxicon.2005.03.011
   Saravia-Otten P, 2007, J INFECT DIS, V196, P748, DOI 10.1086/520537
   Segura A, 2010, TOXICON, V56, P980, DOI 10.1016/j.toxicon.2010.07.001
   Serrano SMT, 2005, TOXICON, V45, P1115, DOI 10.1016/j.toxicon.2005.02.020
   Serrano SMT, 1998, EUR J BIOCHEM, V251, P845, DOI 10.1046/j.1432-1327.1998.2510845.x
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Vlkova M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001719
   World Health Organization, 2017, WHO SNAK ANT IMM
   Zychar BC, 2010, TOXICON, V55, P227, DOI 10.1016/j.toxicon.2009.07.025
NR 33
TC 0
Z9 0
U1 4
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 59
EP 67
DI 10.1016/j.toxicon.2019.09.001
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800009
PM 31494207
DA 2020-05-12
ER

PT J
AU Monteiro, WM
   Gomes, J
   Fe, N
   da Silva, IM
   Lacerda, M
   Alencar, A
   de Farias, AS
   Val, F
   Sampaio, VD
   de Melo, GC
   Pardal, P
   da Silva, AM
   Bernarde, PS
   Ferreire, LCD
   Gutierrez, JM
   Sachett, JDG
   Fan, HW
AF Monteiro, Wuelton Marcelo
   Gomes, Jacimara
   Fe, Nelson
   da Silva, Iran Mendonca
   Lacerda, Marcus
   Alencar, Aristoteles
   de Farias, Altair Seabra
   Val, Fernando
   Sampaio, Vanderson de Souza
   de Melo, Gisely Cardoso
   Pardal, Pedro
   da Silva, Ageane Mota
   Bernarde, Paulo Sergio
   de Lima Ferreire, Luiz Carlos
   Maria Gutierrez, Jose
   Goncalves Sachett, Jacqueline de Almeida
   Fan, Hui Wen
TI Perspectives and recommendations towards evidence-based health care for
   scorpion sting envenoming in the Brazilian Amazon: A comprehensive
   review
SO TOXICON
LA English
DT Review
DE Amazon; Antivenom; Arachnida; Public health; Scorpion; Scorpion stings
ID TITYUS-CAMBRIDGEI; MANAUS REGION; CLINICAL CONSEQUENCES; OBSCURUS;
   FAUNA; STATE; ENVENOMATION; TOXIN; VENOM; MANIFESTATIONS
AB Although underreported across the Amazon region, scorpion stings are very prevalent in some areas and can be potentially life-threatening, especially in children. The most vulnerable populations are those living in locations far from the capitals, hence having limited access to the health system where the appropriate structure for the treatment of severe cases is found. An abundant and diverse fauna of scorpions is found in the region, but few studies have been conducted to decipher the clinical characteristics and therapeutic response of the available antivenoms in envenomings caused by the various species. Antivenom underdosage as well as delayed medical assistance are common among indigenous populations, resulting in poor outcome rates. An in depth understanding of the epidemiological, clinical and therapeutic aspects of scorpion sting envenomings in the Amazon is necessary to improve the outcome of these cases.
C1 [Monteiro, Wuelton Marcelo; Gomes, Jacimara; Fe, Nelson; da Silva, Iran Mendonca; Lacerda, Marcus; Alencar, Aristoteles; de Farias, Altair Seabra; Val, Fernando; Sampaio, Vanderson de Souza; de Melo, Gisely Cardoso; de Lima Ferreire, Luiz Carlos; Goncalves Sachett, Jacqueline de Almeida] Fundacao Med Trop Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Monteiro, Wuelton Marcelo; Gomes, Jacimara; da Silva, Iran Mendonca; de Farias, Altair Seabra; de Melo, Gisely Cardoso; Goncalves Sachett, Jacqueline de Almeida] Univ Estado Amazonas, Escola Super Ciencias Saude, Manaus, Amazonas, Brazil.
   [Lacerda, Marcus] Inst Leonidas & Maria Deane, Fundacao Oswaldo Cruz, Manaus, Amazonas, Brazil.
   [Alencar, Aristoteles; de Lima Ferreire, Luiz Carlos] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Sampaio, Vanderson de Souza] Fundacao Vigilancia Saude, Manaus, Amazonas, Brazil.
   [Pardal, Pedro] Univ Fed Para, Belem, Para, Brazil.
   [da Silva, Ageane Mota] Inst Fed Acre, Cruzeiro Do Sul, Acre, Brazil.
   [Bernarde, Paulo Sergio] Univ Fed Acre, Campus Floresta, Cruzeiro Do Sul, Acre, Brazil.
   [Maria Gutierrez, Jose] Univ Costa Rica, Sch Microbiol, Inst Clodomiro Picado, San Jose, Costa Rica.
   [Goncalves Sachett, Jacqueline de Almeida] Fundacao Alfredo Matta, Manaus, Amazonas, Brazil.
   [Fan, Hui Wen] Inst Butantan, Sao Paulo, SP, Brazil.
RP Monteiro, WM (reprint author), Fundacao Med Trop Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
EM wucltonmm@gmail.com
RI Sampaio, Vanderson/M-4337-2015; Fan, Hui Wen/F-8649-2015
OI Sampaio, Vanderson/0000-0001-7307-8851; Fan, Hui
   Wen/0000-0002-8191-559X; Val, Fernando/0000-0001-9995-0249
CR AMARAL CFS, 1994, TOXICON, V32, P211, DOI 10.1016/0041-0101(94)90110-4
   Asano ME, 1996, REV SOC BRASILEIRA M, V29, P243
   Batista CVF, 2018, TOXICON, V143, P51, DOI 10.1016/j.toxicon.2018.01.006
   Batista CVF, 2004, J CHROMATOGR B, V803, P55, DOI 10.1016/j.jchromb.2003.09.002
   Batista CVF, 2002, TOXICON, V40, P557, DOI 10.1016/S0041-0101(01)00252-5
   Batista CVF, 2002, BBA-PROTEINS PROTEOM, V1601, P123, DOI 10.1016/S1570-9639(02)00458-2
   Batista CVF, 2000, FEBS LETT, V486, P117, DOI 10.1016/S0014-5793(00)02253-5
   Benmosbah M, 2013, TOXICON, V73, P56, DOI 10.1016/j.toxicon.2013.05.025
   Borges A, 2016, TOXINOLOGY, P81, DOI 10.1007/978-94-007-6416-3_36
   Borja-Oliveira CR, 2009, COMP BIOCHEM PHYS C, V149, P404, DOI 10.1016/j.cbpc.2008.09.014
   Bortoluzzi L.R., 2007, NOTAS OCORRENCIA TIT, V7, P5
   Boyer LV, 2013, TOXICON, V76, P377, DOI 10.1016/j.toxicon.2013.07.014
   Brasileira A. de M.I, 2016, CENSO AMIB 2016
   Bucaretchi F, 2014, TOXICON, V89, P17, DOI 10.1016/j.toxicon.2014.06.022
   Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021
   Chowell G, 2006, TOXICON, V47, P753, DOI 10.1016/j.toxicon.2006.02.004
   Coelho JS, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0079-2
   Cupo P, 2007, INT J CARDIOL, V116, P98, DOI 10.1016/j.ijcard.2006.02.015
   da Silva E.P., 2018, J HUM GROWTH DEV, V28, P290, DOI [10.7322/jhgd.152178, DOI 10.7322/JHGD.152178]
   Dabo A, 2011, TOXICON, V58, P154, DOI 10.1016/j.toxicon.2011.05.004
   de Mello-Leitao C., 1945, ESCORPIOES SUL AM
   de Oliveira UC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193739
   de Roodt AR, 2003, TOXICON, V41, P971, DOI 10.1016/S0041-0101(03)00066-7
   DEREZENDE NA, 1995, AM J TROP MED HYG, V52, P277, DOI 10.4269/ajtmh.1995.52.277
   Duque HM, 2017, PEPTIDES, V95, P106, DOI 10.1016/j.peptides.2017.07.010
   Fan HW, 2018, TOXICON, V151, P15, DOI 10.1016/j.toxicon.2018.06.070
   Guerrero-Vargas JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030478
   Isbister GK, 2014, NEW ENGL J MED, V371, P457, DOI 10.1056/NEJMra1401108
   da Silva BAJ, 2017, REV SOC BRAS MED TRO, V50, P427, DOI 10.1590/0037-8682-0490-2016
   Khattabi A, 2011, T ROY SOC TROP MED H, V105, P364, DOI 10.1016/j.trstmh.2011.03.007
   Lourenco WR, 2007, AMAZONIANA, V19, P77
   LOURENCO W R, 1979, Bulletin du Museum National d'Histoire Naturelle Section A Zoologie Biologie et Ecologie Animales, V1, P95
   LOURENCO W R, 1981, Revista Brasileira de Biologia, V41, P797
   LOURENCO W R, 1984, Bulletin du Museum National d'Histoire Naturelle Section A Zoologie Biologie et Ecologie Animales, V6, P349
   Lourenco W.R., 2002, SCORPIONS OF BRAZIL
   Lourenco W.R., 1981, B MUS NATL HIST NAT, V3, P841
   Lourenco W.R., 2008, OCCASIONAL PUBLICATI, P1, DOI 10.18590/euscorpius.2008.vo12008.iss75.1
   Lourenco W.R., 1996, FONDATION MARCEL MER, P49
   Lourenco Wilson R., 2006, Boletin de la SEA, V39, P55
   Lourenco Wilson R., 2004, Revista Iberica de Aracnologia, V10, P285
   Lourenco WR, 2016, J VENOM ANIM TOXINS, V22, DOI 10.1186/s40409-016-0075-6
   Lourenco WR, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0016-9
   Lourenco Wilson R., 2008, Boletin de la SEA, V43, P75
   Lourenco Wilson R., 2006, Boletin de la S.E.A., P117
   Lourenco Wilson R., 2002, AMAZONIAN ARACHNIDA, P399
   LOURENCO WR, 1988, AMAZONIANA, V10, P327
   LOURENCO WR, 1986, AMAZONIANA, V9, P559
   Lourenco WR, 2005, AMAZONIANA, V18, P241
   Lourenco WR, 2005, AMAZONIANA, V18, P203
   Lourenco WR, 2002, AMAZONIANA, V17, P177
   Lourenco WR, 2002, REV SUISSE ZOOL, V109, P127, DOI 10.5962/bhl.part.79582
   Lourenco WR, 1997, REV SUISSE ZOOL, V104, P587, DOI 10.5962/bhl.part.80012
   Lourenco WR, 2017, RIV ARACNOLOGICA ITA, V12, P2
   Martins MA, 2002, REV PARA MED, V16, P34
   Ministerio da Saude do Brasil-Fundacao National de Saude (FUNASA), 2001, MAN DIAGN TRAT AC AN
   Ministerio da Saude/SVS, 2019, NOT REG SIST INF AGR
   Monteiro WM, 2016, TOXICON, V119, P266, DOI 10.1016/j.toxicon.2016.06.015
   Osnaya-Romero N, 2001, TOXICON, V39, P781, DOI 10.1016/S0041-0101(00)00204-X
   Otero R, 2004, T ROY SOC TROP MED H, V98, P742, DOI 10.1016/j.trstmh.2003.12.018
   Pardal PPO, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-3
   Pardal Pedro Pereira de Oliveira, 2003, Rev Soc Bras Med Trop, V36, P349
   Pardal PPO, 2014, REV PAN-AMAZ SAUDE, V5, P65, DOI DOI 10.5123/S2176-62232014000300008
   Pinto-da-Rocha Ricardo, 2000, Revue Arachnologique, V13, P187
   Queiroz AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128819
   Rezende NA, 1998, TOXICON, V36, P1507, DOI 10.1016/S0041-0101(98)00141-X
   Ribeiro L.A., 2001, REV PATOL TROP, V30, P83
   Santos-da-Silva AD, 2017, TOXICON, V126, P51, DOI 10.1016/j.toxicon.2016.12.008
   Costa CLSD, 2016, REV SOC BRAS MED TRO, V49, P376, DOI 10.1590/0037-8682-0377-2015
   Souza ARB, 1995, REV SOC BRAS MED TRO, V28, P167
   Tibery DV, 2019, BBA-BIOMEMBRANES, V1861, P142, DOI 10.1016/j.bbamem.2018.08.005
   Torrez PPQ, 2015, TOXICON, V96, P68, DOI 10.1016/j.toxicon.2014.12.012
   Wen FH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003701
NR 72
TC 2
Z9 2
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 68
EP 80
DI 10.1016/j.toxicon.2019.09.003
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800010
PM 31494205
DA 2020-05-12
ER

PT J
AU Rogowska, A
   Pomastowski, P
   Rafinska, K
   Railean-Plugaru, V
   Zloch, M
   Walczak, J
   Buszewski, B
AF Rogowska, Agnieszka
   Pomastowski, Pawel
   Rafinska, Katarzyna
   Railean-Plugaru, Viorica
   Zloch, Michal
   Walczak, Justyna
   Buszewski, Boguslaw
TI A study of zearalenone biosorption and metabolisation by prokaryotic and
   eukaryotic cells
SO TOXICON
LA English
DT Article
DE Zearalenone; Biotransformation; Neutralization; Prokaryotic cell;
   Eukaryotic cell
ID IN-VITRO; SACCHAROMYCES-CEREVISIAE; MYCOTOXIN ZEARALENONE; PROBIOTIC
   BACTERIA; ALPHA-ZEARALENOL; AFLATOXIN B-1; METABOLITES; STRAINS;
   BINDING; SPECTROSCOPY
AB A study of the mechanism responsible for the zearalenone (ZEA) neutralization by lactic acid bacteria Lactococcus laths 56 and L929 cell line was carried out by determination of the kinetics of the binding process. In the case of prokaryotic cells the biosorption process was non-linear and three steps were identified. The maximum efficiency of zearalenone binding to L. lactic was almost 30% and no metabolites were observed. In turn, for eukaryotic cells only two steps of the binding process were differentiated, and the efficiency of zearalenone binding was 53.99%. Furthermore, L929 cell line metabolizes zearalenone to alpha-ZOL and beta-ZOL. Additionally, Fourier transform infrared spectroscopy (FTIR) was used for description of the structural changes at the protein and lipid level, while Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF-MS) was applied to detect changes at the molecular level.
C1 [Rogowska, Agnieszka; Rafinska, Katarzyna; Railean-Plugaru, Viorica; Walczak, Justyna; Buszewski, Boguslaw] Nicolaus Copernicus Univ, Fac Chem, Dept Environm Chem & Bioanalyt, Gagarina 7 St, PL-87100 Torun, Poland.
   [Rogowska, Agnieszka; Pomastowski, Pawel; Rafinska, Katarzyna; Railean-Plugaru, Viorica; Zloch, Michal; Walczak, Justyna; Buszewski, Boguslaw] Nicolaus Copernicus Univ, Interdisciplinary Ctr Modern Technol, Wilenska 4, PL-87100 Torun, Poland.
RP Buszewski, B (reprint author), Nicolaus Copernicus Univ, Fac Chem, Dept Environm Chem & Bioanalyt, Gagarina 7 St, PL-87100 Torun, Poland.
EM bbusz@chem.umk.pl
OI , Justyna/0000-0001-9038-0470
FU Maestro-6 from the National Science Centre, Poland
   [2014/14/A/ST4/00641]; Foundation for Polish Science, Poland "START"
   [068.2017]
FX This work was supported by Maestro-6, No. 2014/14/A/ST4/00641
   (2015-2018) from the National Science Centre, Poland and by Foundation
   for Polish Science, Poland "START" No. 068.2017; subsidy (2017/2018). We
   acknowledge Mariusz Wrobel, MSc for technical assistance in sample
   preparation and FTIR analysis.
CR Abid-Essefi S, 2003, TOXICOLOGY, V192, P237, DOI 10.1016/S0300-483X(03)00329-9
   Aksglaede L, 2006, HUM REPROD UPDATE, V12, P341, DOI 10.1093/humupd/dml018
   Alleva E., 1988, TOXICOL IND HEALTH, V14, P1
   Ayed Y, 2011, MUTAT RES-GEN TOX EN, V726, P42, DOI 10.1016/j.mrgentox.2011.08.003
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003
   Bordin K, 2017, FOOD CHEM, V217, P648, DOI 10.1016/j.foodchem.2016.09.044
   Buszewski B., 2015, J ANAL BIOANAL TECH, V6, P232, DOI [10.4172/2155-9872.1000232, DOI 10.4172/2155-9872.1000232]
   Cho KJ, 2010, BIOTECHNOL LETT, V32, P1921, DOI 10.1007/s10529-010-0373-y
   Cvek D., 2012, Croatian Journal of Food Technology, Biotechnology and Nutrition, V7, P49
   Dalie DKD, 2010, FOOD CONTROL, V21, P370, DOI 10.1016/j.foodcont.2009.07.011
   Daston GP, 1997, REPROD TOXICOL, V11, P465, DOI 10.1016/S0890-6238(97)00014-2
   El-Nezami H, 2004, J AGR FOOD CHEM, V52, P4577, DOI 10.1021/jf049924m
   El-Nezami H, 2002, APPL ENVIRON MICROB, V68, P3545, DOI 10.1128/AEM.68.7.3545-3549.2002
   Emidio ES, 2015, J CHROMATOGR A, V1391, P1, DOI 10.1016/j.chroma.2015.02.067
   Fijan S, 2014, INT J ENV RES PUB HE, V11, P4745, DOI 10.3390/ijerph110504745
   Gadzala-Kopciuch R, 2011, ANAL BIOANAL CHEM, V401, P2069, DOI 10.1007/s00216-011-5206-x
   Ghaffar T, 2014, J RADIAT RES APPL SC, V7, P222, DOI 10.1016/j.jrras.2014.03.002
   Gratz S, 2004, APPL ENVIRON MICROB, V70, P6306, DOI 10.1128/AEM.70.10.6306-6308.2004
   Jiang W, 2004, LANGMUIR, V20, P11433, DOI 10.1021/la049043+
   Keller L, 2015, TOXINS, V7, P3297, DOI 10.3390/toxins7083297
   KIESSLING KH, 1978, ACTA PHARMACOL TOX, V43, P285
   Kleinova M, 2002, J AGR FOOD CHEM, V50, P4769, DOI 10.1021/jf020160p
   Kriszt R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043608
   Krol A, 2018, ANAL BIOANAL CHEM, V410, P943, DOI 10.1007/s00216-017-0555-8
   Maragos CM, 2010, WORLD MYCOTOXIN J, V3, P369, DOI 10.3920/WMJ2010.1240
   Naumann D, 2001, APPL SPECTROSC REV, V36, P239, DOI 10.1081/ASR-100106157
   OLSEN M, 1981, ACTA PHARMACOL TOX, V48, P157
   Ouwehand AC, 1999, FEMS MICROBIOL LETT, V177, P35, DOI 10.1111/j.1574-6968.1999.tb13710.x
   Pajewska M, 2018, ANAL BIOANAL CHEM, V410, P1571, DOI 10.1007/s00216-017-0807-7
   Pfeiffer E, 2010, MOL NUTR FOOD RES, V54, P1468, DOI 10.1002/mnfr.200900524
   Sangsila A, 2016, FOOD CONTROL, V62, P187, DOI 10.1016/j.foodcont.2015.10.031
   Schaut A, 2008, J APPL TOXICOL, V28, P966, DOI 10.1002/jat.1362
   Shetty PH, 2006, TRENDS FOOD SCI TECH, V17, P48, DOI 10.1016/j.tifs.2005.10.004
   Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417
   Sunita P, 2011, Pharmacogn Rev, V5, P41, DOI 10.4103/0973-7847.79098
   Tatay E, 2014, TOXICOL IN VITRO, V28, P95, DOI 10.1016/j.tiv.2013.06.025
   Videmann B, 2008, FOOD CHEM TOXICOL, V46, P3279, DOI 10.1016/j.fct.2008.07.011
   Zhao L., 2005, FOOD CONTROL, V54, P158
   Zhou HY, 2017, FOOD CHEM TOXICOL, V103, P18, DOI 10.1016/j.fct.2017.02.017
   Zinedine A., 2005, International Journal of Agriculture and Biology, V7, P67
   Zoghi A, 2014, MINI-REV MED CHEM, V14, P84, DOI 10.2174/1389557513666131211105554
NR 42
TC 0
Z9 0
U1 8
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 81
EP 90
DI 10.1016/j.toxicon.2019.09.008
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800011
PM 31493420
DA 2020-05-12
ER

PT J
AU Tang, ELH
   Tan, NH
   Fung, SY
   Tan, CH
AF Tang, Esther Lai Har
   Tan, Nget Hong
   Fung, Shin Yee
   Tan, Choo Hock
TI Comparative proteomes, immunoreactivities and neutralization of
   procoagulant activities of Calloselasma rhodostoma (Malayan pit viper)
   venoms from four regions in Southeast Asia
SO TOXICON
LA English
DT Article
DE Venomics; Antivenom; Immunoreactivity; Antigenicity; Malayan pit viper
ID PLATELET-AGGREGATION INHIBITOR; AMINO-ACID OXIDASE; NAJA-NAJA;
   BOTHROPS-ASPER; INTRASPECIFIC VARIATION; BIOLOGICAL-ACTIVITIES;
   PHOSPHOLIPASES A(2); SPECTACLED COBRA; SNAKE VENOMICS; PROTEIN
AB The intraspecific geographical venom variations of Calloselasma rhodostoma from Malaysia (CR-M), Indonesia (CR-I), Thailand (CR-T) and Vietnam (CR-V) were investigated through 10 SDS-PAGE and nano-ESI-LCMS/MS. The venom antigenicity, procoagulant activities and neutralization using Thai C. rhodostoma Monovalent Antivenom (CRMAV) were also investigated. SDS-PAGE patterns of the venoms were relatively similar with minor variations. Proteomic analysis revealed that snake venom metalloproteinases (SVMPs, particularly P-I class), serine proteases (SVSPs) and snaclecs dominated the venom protein composition (68.96-81.80%), followed by L-amino acid oxidase (LAAO) and phospholipase A(2) (PLA(2)) (7.37-11.08% and 5.18-13.81%, respectively), corroborating C. rhodostoma envenoming effects (hemorrhage, consumptive coagulopathy, thrombocytopenia and local tissue necrosis). Other proteins of lower abundances (2.82-9.13%) identified include cysteinerich secretory proteins (CRISP), phospholipase B, phosphodiesterase, nerve growth factor, 5'-nucleotidase, aminopeptidase and hyaluronidase. All four venoms exhibited strong procoagulant effects which were neutralized by CRMAV to different extents. CRMAV immunoreactivity was high toward venoms of CR-M, CR-I and CR-T but relatively low for CR-V venom. Among the venom samples from different locales, CR-V venom proteome has the smallest SVMP composition while SVSP, PLA(2) and phosphodiesterase were more abundant in the venom. These variations in C. rhodostoma venom protein composition could partly explain the differences seen in immunoreactivity.
C1 [Tang, Esther Lai Har; Tan, Nget Hong; Fung, Shin Yee] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia.
   [Tan, Choo Hock] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
RP Tan, CH (reprint author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
EM tanchoohock@gmail.com
RI FUNG, SHIN YEE/AAJ-3690-2020; Tan, Choo Hock/B-9905-2010
OI FUNG, SHIN YEE/0000-0002-9288-7328; Tan, Choo Hock/0000-0003-1416-077X
FU Fundamental Research Grant Scheme from the Government of Malaysia
   [FP028-2014A]; University of MalayaUniversiti Malaya [RFOO7C-2018]
FX The study was supported by Fundamental Research Grant Scheme
   (FP028-2014A) from the Government of Malaysia and research grant
   (RFOO7C-2018) from the University of Malaya.
CR Aird SD, 2002, TOXICON, V40, P335, DOI 10.1016/S0041-0101(01)00232-X
   Aird SD, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-790
   Alape-Giron A, 2008, J PROTEOME RES, V7, P3556, DOI 10.1021/pr800332p
   Ali SA, 2013, J PROTEOMICS, V91, P338, DOI 10.1016/j.jprot.2013.07.020
   Ande SR, 2006, APOPTOSIS, V11, P1439, DOI 10.1007/s10495-006-7959-9
   AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A
   Bonfim VL, 2008, BIOLOGICALS, V36, P168, DOI 10.1016/j.biologicals.2007.10.004
   Cajado-Carvalho D, 2016, TOXINS, V8, DOI 10.3390/toxins8120348
   Calvete JJ, 2018, EXPERT REV PROTEOMIC, V15, P555, DOI 10.1080/14789450.2018.1500904
   Calvete JJ, 2011, J PROTEOMICS, V74, P510, DOI 10.1016/j.jprot.2011.01.003
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chong HP, 2019, TOXINS, V11, DOI 10.3390/toxins11020104
   Daltry JC, 1998, J HERPETOL, V32, P198, DOI 10.2307/1565297
   Daltry JC, 1996, TOXICON, V34, P67, DOI 10.1016/0041-0101(95)00122-0
   Dhananjaya BL, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1, DOI 10.1134/S0006297910010013
   Dhananjaya BL, 2010, CELL BIOCHEM FUNCT, V28, P171, DOI 10.1002/cbf.1637
   Dutta S, 2017, J PROTEOMICS, V156, P29, DOI 10.1016/j.jprot.2016.12.018
   Eichberg S, 2015, EXPERT REV PROTEOMIC, V12, P557, DOI 10.1586/14789450.2015.1073590
   ESNOUF MP, 1967, BRIT J HAEMATOL, V13, P581, DOI 10.1111/j.1365-2141.1967.tb00765.x
   Faisal T., 2018, J PROT
   Fox JW, 2013, TOXICON, V62, P75, DOI 10.1016/j.toxicon.2012.09.009
   Fox JW, 2005, TOXICON, V45, P969, DOI 10.1016/j.toxicon.2005.02.012
   GLOYD HK, 1990, SNAKES AGKISTRODON C
   Goncalves-Machado L, 2016, J PROTEOMICS, V135, P73, DOI 10.1016/j.jprot.2015.04.029
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Gutierrez JA, 2009, PAHCE: 2009 PAN AMERICAN HEALTH CARE EXCHANGES, P115
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Herrera C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003731
   HO M, 1986, AM J TROP MED HYG, V35, P579, DOI 10.4269/ajtmh.1986.35.579
   Hsu CC, 2007, MOL PHARMACOL, V72, P984, DOI 10.1124/mol.107.038018
   HUANG TF, 1993, BIOCHIM BIOPHYS ACTA, V1158, P293, DOI 10.1016/0304-4165(93)90028-7
   HUANG TF, 1987, BIOCHIM BIOPHYS ACTA, V925, P248, DOI 10.1016/0304-4165(87)90189-9
   Ismail AK, 2015, TOXINOLOGY, P71, DOI 10.1007/978-94-007-6386-9_54
   Jamaiah I., 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P962
   Kalita B, 2017, J PROTEOME RES, V16, P583, DOI 10.1021/acs.jproteome.6b00693
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Kemparaju K, 2006, CELL BIOCHEM FUNCT, V24, P7, DOI 10.1002/cbf.1261
   Kunalan S, 2018, TOXINS, V10, DOI 10.3390/toxins10110434
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lodovicho ME, 2017, TOXICOL LETT, V265, P156, DOI 10.1016/j.toxlet.2016.12.003
   LOOAREESUWAN S, 1988, T ROY SOC TROP MED H, V82, P930, DOI 10.1016/0035-9203(88)90046-6
   Loria GD, 2003, ARCH BIOCHEM BIOPHYS, V418, P13, DOI 10.1016/S0003-9861(03)00385-0
   Mackessy S.P., 2009, HDB VENOMS TOXINS RE
   Maduwage K, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003220
   Margres MJ, 2016, TOXICON, V119, P28, DOI 10.1016/j.toxicon.2016.05.005
   Gutierrez JM, 2009, TOXICON, V54, P976, DOI 10.1016/j.toxicon.2009.01.039
   O'Leary MA, 2010, J PHARMACOL TOX MET, V61, P27, DOI 10.1016/j.vascn.2009.06.004
   Oh AMF, 2019, J PROTEOMICS, V193, P243, DOI 10.1016/j.jprot.2018.10.016
   Oh AMF, 2017, J PROTEOMICS, V164, P1, DOI [10.1016/j.jrot.2017.04.018, 10.1016/j.jprot.2017.04.018]
   Paloschi MV, 2018, CURR MED CHEM, V25, P2520, DOI 10.2174/0929867324666171109114125
   PONNUDURAI G, 1993, TOXICON, V31, P997, DOI 10.1016/0041-0101(93)90259-L
   REID HA, 1963, LANCET, V1, P621
   Sakurai Y, 2001, TOXICON, V39, P1827, DOI 10.1016/S0041-0101(01)00133-7
   Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516
   Sunagar K, 2016, J PROTEOMICS, V135, P62, DOI 10.1016/j.jprot.2015.09.015
   Tan C, 2016, SCI REP, V6
   Tan C. H., 2015, SNAKE VENOMS, P1, DOI DOI 10.1007/978-94-007-6648-8_13-1
   Tan CH, 2019, TOXINS, V11, DOI 10.3390/toxins11020095
   Tan Choo Hock, 2019, Methods Mol Biol, V1871, P83, DOI 10.1007/978-1-4939-8814-3_5
   Tan CH, 2017, TOXICON, V140, P32, DOI 10.1016/j.toxicon.2017.10.014
   Tan CH, 2016, J PROTEOMICS, V132, P1, DOI 10.1016/j.jprot.2015.11.014
   Tan CH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1828-2
   Tan CH, 2015, TOXICON, V93, P164, DOI 10.1016/j.toxicon.2014.11.231
   Tan KY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25955-y
   Tan KY, 2017, PEERJ, V5, DOI 10.7717/peerj.3142
   Tan KY, 2015, J PROTEOMICS, V120, P105, DOI 10.1016/j.jprot.2015.02.012
   Tan N.-H., 1991, Tropical Biomedicine, V8, P91
   Tan NH, 2015, J PROTEOMICS, V128, P403, DOI 10.1016/j.jprot.2015.08.017
   TAN NH, 1986, TOXICON, V24, P626, DOI 10.1016/0041-0101(86)90186-8
   TAN NH, 1990, COMP BIOCHEM PHYS B, V95, P577, DOI 10.1016/0305-0491(90)90024-N
   Tang ELH, 2016, J PROTEOMICS, V148, P44, DOI 10.1016/j.jprot.2016.07.006
   Tsai IH, 2001, ARCH BIOCHEM BIOPHYS, V387, P257, DOI 10.1006/abbi.2000.2229
   Tsai IH, 2000, EUR J BIOCHEM, V267, P6684, DOI 10.1046/j.1432-1327.2000.01766.x
   TU AT, 1983, COMP BIOCHEM PHYS B, V76, P377, DOI 10.1016/0305-0491(83)90086-X
   Vejayan J, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-6
   Villalta M, 2012, J PROTEOMICS, V75, P5628, DOI 10.1016/j.jprot.2012.08.008
   VIRAVAN C, 1992, T ROY SOC TROP MED H, V86, P100, DOI 10.1016/0035-9203(92)90463-M
   Wang DN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02534-1
   WARRELL DA, 1986, AM J TROP MED HYG, V35, P1235, DOI 10.4269/ajtmh.1986.35.1235
   WARRELL DA, 1986, NATURAL TOXINS ANIMA, P25
   Warrell DA, 2010, LANCET, V375, P77, DOI 10.1016/S0140-6736(09)61754-2
   *WHO, 2010, WHO GUID PROD CONTR
   Wong KY, 2018, J PROTEOMICS, V175, P156, DOI 10.1016/j.jprot.2017.12.012
   Wong KY, 2016, AM J TROP MED HYG, V94, P1392, DOI 10.4269/ajtmh.15-0871
   Wongtongkam N, 2005, MIL MED, V170, P342, DOI 10.7205/MILMED.170.4.342
   World Health Organization, 2016, GUID MAN SNAK
   World Health Organization W, 2005, GUIDELINES CLIN MANA
   Wuster W, 2008, MOL PHYLOGENET EVOL, V49, P445, DOI 10.1016/j.ympev.2008.08.019
   Yamazaki Y, 2004, TOXICON, V44, P227, DOI 10.1016/j.toxicon.2004.05.023
   Yang ZM, 2015, TOXICON, V107, P175, DOI 10.1016/j.toxicon.2015.08.010
   Yap MKK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002890
   You WK, 2006, BIOCHEM BIOPH RES CO, V339, P964, DOI 10.1016/j.bbrc.2005.11.083
   You WK, 2003, J BIOCHEM, V134, P739, DOI 10.1093/jb/mvg202
   Ziganshin RH, 2015, TOXICON, V107, P197, DOI 10.1016/j.toxicon.2015.08.026
NR 94
TC 0
Z9 0
U1 5
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 91
EP 102
DI 10.1016/j.toxicon.2019.08.004
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800012
PM 31445943
DA 2020-05-12
ER

PT J
AU Huang, YP
   Pan, HY
   Liu, HG
   Xi, Y
   Ren, D
AF Huang, Yingping
   Pan, Hongyu
   Liu, Huigang
   Xi, Ying
   Ren, Dong
TI Characteristics of growth and microcystin production of Microcystis
   aeruginosa exposed to low concentrations of naphthalene and phenanthrene
   under different pH values
SO TOXICON
LA English
DT Article
DE Microcystin; Naphthalene; Phenanthrene; pH value; Microcystis aeruginosa
ID ENVIRONMENTAL-FACTORS; GREEN-ALGAE; TAIHU LAKE; CYANOBACTERIA;
   BIOSYNTHESIS; LR; DISTRIBUTIONS; PURIFICATION; SEDIMENTS; SHALLOW
AB Here, Microcystis aeruginosa (M. aeruginosa) was studied to analyze the effects of 0.5 mg L-1 naphthalene and 0.05 mg L-1 phenanthrene on profiles of cell growth, chlorophyll-a content and Microcystin-LR (MC-LR) production at different pH values. The results indicated that for both the naphthalene and phenanthrene treatments, the specific growth rates were higher in pH 10.0 than in either pH 7.0 or pH 5.0. In the presence of low concentrations of naphthalene or phenanthrene, chlorophyll-a in medium increased significantly more in pH 10.0 than pH 5.0. chlorophyll-a in cell was significantly lowered when exposed to naphthalene in both pH 10.0 and pH 7.0, and was higher when exposed to phenanthrene in pH 10.0 than pH 5.0. HPLC analysis revealed that the extracellular MC Lit concentrations in M. aeruginosa exposed to either naphthalene or phenanthrene were lower than in control M. aeruginosa at pH 5.0. The intracellular MC-LR levels in toxic M. aeruginosa cells exposed to naphthalene or phenanthrene were higher than in the controls at pH 10.0. Our study suggests that the MC-LR production of M. aeruginosa was affected by the pH value when low concentrations of either naphthalene or phenanthrene were present in the water. These results indicate that the pH value should not be ignored when evaluating the risk of chemicals that promote MC LR production in eutrophic waters.
C1 [Huang, Yingping; Pan, Hongyu] China Three Gorges Univ, Coll Biol & Pharm, Yichang 443002, Hubei, Peoples R China.
   [Huang, Yingping; Pan, Hongyu; Liu, Huigang; Xi, Ying; Ren, Dong] China Three Gorges Univ, Farmland Environm Monitoring Engn Technol Ctr Hub, Yichang 443002, Hubei, Peoples R China.
   [Huang, Yingping; Pan, Hongyu; Liu, Huigang; Xi, Ying; Ren, Dong] China Three Gorges Univ, Minist Educ, Engn Res Ctr Ecoenvironm Gorges Reservoir Reg 3, Yichang 443002, Hubei, Peoples R China.
RP Liu, HG (reprint author), China Three Gorges Univ, Minist Educ, Engn Res Ctr Ecoenvironm Gorges Reservoir Reg 3, Yichang 443002, Hubei, Peoples R China.
EM chem_ctgu@126.com; 834721456@qq.com
FU Hubei Province Innovation Group Project [2015CFA021]; National Key
   Research and Development Program of China [2016YFD0800904]
FX This work was supported by the Hubei Province Innovation Group Project
   (2015CFA021) and the National Key Research and Development Program of
   China (No: 2016YFD0800904). We would also like to thank Elizabeth Tokarz
   at Yale University for her assistance with English language and
   grammatical editing.
CR Al-Ammar R, 2015, SENSOR ACTUAT B-CHEM, V209, P1070, DOI 10.1016/j.snb.2014.11.063
   Boopathi T, 2014, TOXINS, V6, P1951, DOI 10.3390/toxins6071951
   CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x
   CARMICHAEL WW, 1994, SCI AM, V270, P78, DOI 10.1038/scientificamerican0194-78
   Che FF, 2018, J ENVIRON SCI-CHINA, V66, P41, DOI 10.1016/j.jes.2017.05.041
   Chen C, 2016, ENVIRON POLLUT, V219, P649, DOI 10.1016/j.envpol.2016.06.043
   Chen J, 2005, ENVIRON POLLUT, V134, P423, DOI 10.1016/j.envpol.2004.09.014
   Chen RQ, 2016, CHIN J OCEANOL LIMN, V34, P1173, DOI 10.1007/s00343-016-5204-0
   Chen W, 2009, CHEMOSPHERE, V77, P1585, DOI 10.1016/j.chemosphere.2009.09.037
   Djomo JE, 2004, WATER RES, V38, P1817, DOI 10.1016/j.watres.2003.10.023
   Echeveste P, 2010, ENVIRON POLLUT, V158, P299, DOI 10.1016/j.envpol.2009.07.006
   Jahnichen S, 2011, HARMFUL ALGAE, V12, P95, DOI 10.1016/j.hal.2011.09.002
   Kaebernick M, 2000, APPL ENVIRON MICROB, V66, P3387, DOI 10.1128/AEM.66.8.3387-3392.2000
   Kuniyoshi TM, 2013, PLANT PHYSIOL BIOCH, V65, P120, DOI 10.1016/j.plaphy.2013.01.011
   Lankoff A, 2004, MUTAT RES-GEN TOX EN, V559, P131, DOI 10.1016/j.mrgentox.2004.01.004
   Li J, 2009, ENVIRON POLLUT, V157, P273, DOI 10.1016/j.envpol.2008.06.039
   Lin JL, 2018, J ENVIRON SCI-CHINA, V63, P147, DOI 10.1016/j.jes.2017.02.007
   Liu GQ, 2009, ENVIRON POLLUT, V157, P2994, DOI 10.1016/j.envpol.2009.05.056
   Lu GH, 2010, CHEMOSPHERE, V79, P588, DOI 10.1016/j.chemosphere.2010.01.053
   Neilan BA, 2013, ENVIRON MICROBIOL, V15, P1239, DOI 10.1111/j.1462-2920.2012.02729.x
   Pokora W, 2010, ECOTOX ENVIRON SAFE, V73, P1207, DOI 10.1016/j.ecoenv.2010.06.013
   Qiao M, 2006, ENVIRON INT, V32, P28, DOI 10.1016/j.envint.2005.04.005
   Sevilla E, 2008, ENVIRON MICROBIOL, V10, P2476, DOI 10.1111/j.1462-2920.2008.01663.x
   Song Lirong, 1998, Phycological Research, V46, P19, DOI 10.1046/j.1440-1835.1998.00120.x
   STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971
   Stewart AK, 2018, TOXICON, V144, P91, DOI 10.1016/j.toxicon.2018.01.021
   Sun XB, 2016, J ENVIRON SCI-CHINA, V45, P1, DOI 10.1016/j.jes.2015.11.027
   Tao M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032020
   Tillett D, 2000, CHEM BIOL, V7, P753, DOI 10.1016/S1074-5521(00)00021-1
   Tukaj S, 2010, J THERM BIOL, V35, P239, DOI 10.1016/j.jtherbio.2010.05.007
   Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317
   Verrhiest GJ, 2002, CHEMOSPHERE, V46, P187, DOI 10.1016/S0045-6535(01)00064-9
   Wang JX, 2007, ENVIRON RES, V103, P70, DOI 10.1016/j.envres.2006.05.013
   Wang LC, 2017, HARMFUL ALGAE, V61, P56, DOI 10.1016/j.hal.2016.11.010
   Wiedner C, 2003, APPL ENVIRON MICROB, V69, P1475, DOI 10.1128/AEM.69.3.1475-1481.2003
   Wu S, 2008, B ENVIRON CONTAM TOX, V80, P329, DOI 10.1007/s00128-008-9378-9
   YU SZ, 1995, J GASTROEN HEPATOL, V10, P674, DOI 10.1111/j.1440-1746.1995.tb01370.x
   Zhang DW, 2015, ECOTOXICOLOGY, V24, P19, DOI 10.1007/s10646-014-1349-9
   Zhang M, 2018, ECOTOX ENVIRON SAFE, V157, P134, DOI 10.1016/j.ecoenv.2018.03.052
   Zhu XZ, 2012, J HAZARD MATER, V237, P371, DOI 10.1016/j.jhazmat.2012.08.029
NR 40
TC 0
Z9 0
U1 14
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 103
EP 108
DI 10.1016/j.toxicon.2019.09.004
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800013
PM 31494204
DA 2020-05-12
ER

PT J
AU Agarwal, M
   Mondal, T
   Bose, B
AF Agarwal, Mahesh
   Mondal, Tanmay
   Bose, Biplab
TI Peptides derived from a short stretch of diphtheria toxin bind to
   heparin-binding epidermal growth factor-like growth factor
SO TOXICON
LA English
DT Article
DE Diphtheria toxin; HB-EGF; Peptide; Receptor binding
ID HB-EGF; SYNTHETIC PEPTIDES; BREAST-CANCER; CRYSTAL-STRUCTURE;
   ESCHERICHIA-COLI; CELLULAR GROWTH; RECEPTOR; CRM197; INHIBITOR; DOMAIN
AB Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) is the receptor for diphtheria toxin (DT). Mutated or truncated, non-toxic DT has been used earlier for HB-EGF-targeted drug delivery and to modulate HB-EGF signaling. In the present work, we have synthesized a peptide corresponding to a 26 amino acid long stretch of the receptor-binding domain of DT. This region of DT makes multiple contacts with HB-EGF and has residues critical for binding to HB-EGF. We show that this peptide and two of its mutants bind to HB-EGF. We have also created recombinant proteins by fusing Maltose-binding Protein (MBP) with these peptides. These recombinant MBP-tagged peptides bind to HB-EGF with affinities in the range of 10(-7) to 10(-8) M. We have observed that these MBP-tagged peptides can modulate molecular signaling of HB-EGF. Therefore, this 26 amino acid long stretch of DT can be considered as an independent functional segment for binding to HB-EGF. Peptides corresponding to this region may be used for HB-EGF targeted cellular delivery of molecular cargo or to modulate HB-EGF signaling.
C1 [Agarwal, Mahesh; Bose, Biplab] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, India.
   [Agarwal, Mahesh] Drexel Univ, Dept Biochem & Mol Biol, Coll Med, Philadelphia, PA 19102 USA.
   [Mondal, Tanmay] Indian Inst Technol Guwahati, Dept Chem, Gauhati 781039, India.
RP Bose, B (reprint author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, India.
EM biplabbose@iitg.ac.in
OI Bose, Biplab/0000-0002-7616-6838; Mondal, Tanmay/0000-0002-3056-1955
FU Science and Engineering Research Board (SERB), India, Department of
   Science & Technology, India, Government of India [EMR/2016/000573];
   Department of Biotechnology, Government of IndiaDepartment of
   Biotechnology (DBT) India [BT/PR13560/COE/34/44/2015]
FX We thank Science and Engineering Research Board (SERB), India,
   Department of Science & Technology, India, Government of India, for
   financial support through Project No. EMR/2016/000573. We are thankful
   to the DBT Programme Support Facility, at IIT Guwahati, funded by
   Department of Biotechnology, Government of India (Project no.
   BT/PR13560/COE/34/44/2015) for resources and facilities for conducting
   experiments.
CR Agarwal M, 2017, MOL PHARMACEUT, V14, P23, DOI 10.1021/acs.molpharmaceut.6b00480
   Akbari B, 2017, INT REV IMMUNOL, V36, P207, DOI 10.1080/08830185.2017.1284211
   ATASSI MZ, 1988, J PROTEIN CHEM, V7, P655, DOI 10.1007/BF01024881
   Auger A, 2015, MOL PHARMACEUT, V12, P2962, DOI 10.1021/acs.molpharmaceut.5b00233
   Buzzi S, 2004, CANCER IMMUNOL IMMUN, V53, P1041, DOI 10.1007/s00262-004-0546-4
   CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0
   Collier RJ, 2001, TOXICON, V39, P1793, DOI 10.1016/S0041-0101(01)00165-9
   Dateoka S, 2012, MED MOL MORPHOL, V45, P91, DOI 10.1007/s00795-011-0543-6
   Dev D, 2014, J ORG CHEM, V79, P5420, DOI 10.1021/jo500292m
   Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324
   Foss F M, 2000, Clin Lymphoma, V1, P110, DOI 10.3816/CLM.2000.n.009
   FOSS FM, 2000, CLIN LYMPHOMA, V1, P117
   Gillet D, 2017, U.S. Patent, Patent No. [US9758552B2, 9758552, 9,758,552]
   Gillet D, 2015, COMPREHENSIVE SOURCEBOOK OF BACTERIAL PROTEIN TOXINS, 4TH EDITION, P111, DOI 10.1016/B978-0-12-800188-2.00004-5
   GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987
   Hadfield TL, 2000, J INFECT DIS, V181, pS116, DOI 10.1086/315551
   Hobel S, 2011, PHARMACEUTICALS, V4, P1591, DOI 10.3390/ph4121591
   IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452
   Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668
   KIM JH, 2012, ANTIBODY ENG METHODS, P231
   Kumar A, 2014, MOL PHARMACEUT, V11, P208, DOI 10.1021/mp400378x
   Kunami N, 2011, ANTICANCER RES, V31, P2483
   Lee CW, 2004, APPL ENVIRON MICROB, V70, P4569, DOI 10.1128/AEM.70.8.4569-4574.2004
   LENTZ TL, 1987, PROTEINS, V2, P298, DOI 10.1002/prot.340020406
   Li M, 2017, ONCOTARGETS THER, V10, P3645, DOI 10.2147/OTT.S134584
   Lian CX, 2016, CANCER BIOTHER RADIO, V31, P85, DOI 10.1089/cbr.2015.1956
   Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Matsuda K, 2001, CANCER RES, V61, P5562
   MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015
   Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811
   Miyamoto S, 2006, CANCER SCI, V97, P341, DOI 10.1111/j.1349-7006.2006.00188.x
   Miyamoto S, 2007, ANTICANCER RES, V27, P3713
   Miyamoto S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3071-5
   Monnet C, 1999, J BIOL CHEM, V274, P3789, DOI 10.1074/jbc.274.6.3789
   MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nam SO, 2016, ANTICANCER RES, V36, P3651
   Nam SO, 2014, ANTICANCER RES, V34, P4615
   Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925
   Rip J, 2009, EXPERT OPIN DRUG DEL, V6, P227, DOI 10.1517/17425240902806383
   Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Schenk GJ, 2012, J CONTROL RELEASE, V158, P139, DOI 10.1016/j.jconrel.2011.09.091
   SHEN WH, 1994, J BIOL CHEM, V269, P29077
   Smith JW, 1995, J BIOL CHEM, V270, P30486, DOI 10.1074/jbc.270.51.30486
   Sorensen HP, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-1
   STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025
   Suzuki K, 2015, J BIOCHEM, V157, P331, DOI 10.1093/jb/mvu079
   Tang XH, 2012, BIOCHEM BIOPH RES CO, V422, P676, DOI 10.1016/j.bbrc.2012.05.052
   Tosi G, 2015, MOL PHARMACEUT, V12, P3672, DOI 10.1021/acs.molpharmaceut.5b00446
   Tsujioka H, 2011, ANTICANCER RES, V31, P2461
   Tsujioka H, 2011, CURR OPIN OBSTET GYN, V23, P24, DOI 10.1097/GCO.0b013e3283409c91
   Tsujioka H, 2010, ANTICANCER RES, V30, P3107
   Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999
   Wang LF, 2012, ANTI-CANCER DRUG, V23, P81, DOI 10.1097/CAD.0b013e32834b9b72
NR 55
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD NOV
PY 2019
VL 169
BP 109
EP 116
DI 10.1016/j.toxicon.2019.09.006
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA JC3PE
UT WOS:000489189800014
PM 31494209
DA 2020-05-12
ER

PT J
AU Akamatsu, Y
   Kubo, Y
   Chida, K
   Matsumoto, Y
   Ogasawara, K
AF Akamatsu, Yosuke
   Kubo, Yoshitaka
   Chida, Kohei
   Matsumoto, Yasushi
   Ogasawara, Kuniaki
TI Intraorbital Arteriovenous Fistula Presenting with Impaired Extraocular
   Movement After a Provocation Test at the Third Segment of the Ophthalmic
   Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extraocular movement; Intraorbital arteriovenous fistula; Ophthalmic
   artery; Provocation test
ID SUPERIOR ORBITAL FISSURE; TRANSARTERIAL EMBOLIZATION; ENDOVASCULAR
   TREATMENT; MANAGEMENT
AB BACKGROUND: Distal catheterization in the ophthalmic artery beyond the origin of the central retinal artery has been attempted to avoid visual complications in cases of transarterial embolization (TAE). Although avoiding visual complications is important, extraocular complications have been rarely reported and discussed. Here, we report a case of an intraorbital arteriovenous fistula (AVF) presenting with impaired extraocular movement after a provocation test and discuss the potential risks associated with TAE at the third segment of the ophthalmic artery.
   CASE DESCRIPTION: A 53-year-old man was referred to our hospital for a newly diagnosed vascular lesion on the left optic chiasm. A left internal carotid angiogram revealed an intraorbital AVF fed by distal branches of the left ophthalmic artery taking a recurrent course toward the proximal ophthalmic artery, and the anterior branches of the inferior lateral trunk draining into the tortuous basal vein of Rosenthal with a varix. Neither the cavernous sinus nor the superior ophthalmic vein was opacified as draining routes of this lesion. A provocation test was done for diagnostic and therapeutic purposes at the third segment of the ophthalmic artery. During the test, the patient developed a transient impaired adduction of the left eye without any visual field deficit; therefore, TAE was avoided. The patient made an uneventful recovery and was recommended a transcranial transvenous embolization for a radical treatment.
   CONCLUSIONS: In intraorbital hypervascular lesions, occlusion of the third segment of the ophthalmic artery is associated with a potential risk of extraocular complications.
C1 [Akamatsu, Yosuke; Kubo, Yoshitaka; Chida, Kohei; Ogasawara, Kuniaki] Iwate Med Univ, Dept Neurosurg, Morioka, Iwate, Japan.
   [Matsumoto, Yasushi] Kohnan Hosp, Dept Neuroendovasc Therapy, Sendai, Miyagi, Japan.
RP Akamatsu, Y (reprint author), Iwate Med Univ, Dept Neurosurg, Morioka, Iwate, Japan.
EM akamatsu@iwate-med.ac.jp
CR Caragine LP, 2006, NEUROSURGERY S, V58
   Deguchi J, 2005, J NEUROSURG, V103, P756, DOI 10.3171/jns.2005.103.4.0756
   Guedin P, 2010, J NEUROSURG, V112, P603, DOI 10.3171/2009.7.JNS08490
   HALBACH VV, 1989, AM J NEURORADIOL, V10, P143
   Hamada J, 2006, SURG NEUROL, V65, P55, DOI 10.1016/j.surneu.2005.03.043
   Hayreh S S, 1962, Br J Ophthalmol, V46, P212, DOI 10.1136/bjo.46.4.212
   HORTON JA, 1988, AM J NEURORADIOL, V9, P1167
   Katsaridis V, 2007, J NEURO-OPHTHALMOL, V27, P281, DOI 10.1097/WNO.0b013e31815b99ee
   Kiyosue H, 2015, AM J NEURORADIOL, V36, P1741, DOI 10.3174/ajnr.A4331
   Konstas AA, 2017, OPHTHAL PLAST RECONS, V33, pE63, DOI 10.1097/IOP.0000000000000753
   Lv M, 2015, INTERV NEURORADIOL, V21, P357, DOI 10.1177/1591019915582925
   Lv XL, 2008, NEURORADIOLOGY, V50, P433, DOI 10.1007/s00234-007-0346-6
   Mack WJ, 2011, INTERV NEURORADIOL, V17, P93, DOI 10.1177/159101991101700115
   Matsumaru Y, 1997, Interv Neuroradiol, V3, P239
   Reymond J, 2008, J CRANIO MAXILL SURG, V36, P346, DOI 10.1016/j.jcms.2008.02.004
   ROOTMAN J, 1992, OPHTHALMOLOGY, V99, P1440
   Sakata K, 2020, NEUROSURG REV, V43, P185, DOI 10.1007/s10143-018-1028-z
   Sato K, 2011, NEUROSURGERY, V68, P383, DOI 10.1227/NEU.0b013e31821522ec
   Tahon F, 2008, NEURORADIOLOGY, V50, P429, DOI 10.1007/s00234-007-0344-8
   Tsutsumi S, 2019, WORLD NEUROSURG, V122, P287, DOI 10.1016/j.wneu.2018.11.003
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 1
EP 5
DI 10.1016/j.wneu.2019.07.150
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300077
PM 31356978
DA 2020-05-12
ER

PT J
AU Mouchtouris, N
   Al Saiegh, F
   Sweid, A
   Amllay, A
   Tjoumakaris, S
   Gooch, R
   Rosenwasser, R
   Jabbour, PM
AF Mouchtouris, Nikolaos
   Al Saiegh, Fadi
   Sweid, Ahmad
   Amllay, Abdelaziz
   Tjoumakaris, Stavropoula
   Gooch, Reid
   Rosenwasser, Robert
   Jabbour, Pascal M.
TI Transradial Access for Newly Food and Drug Administration-Approved
   Devices for Endovascular Treatment of Cerebral Aneurysms: A Technical
   Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Endovascular embolization; Transradial access
AB BACKGROUND: Despite the recent increase of trans-radial access among neurointerventionalists, there is still a paucity of evidence in the neurosurgical literature. There are 3 newly Food and Drug Administration-approved devices-Woven EndoBridge (WEB), Surpass, and PulseRider-that significantly expand the options available for endovascular treatment of cerebral aneurysms. Our work reports the safety and feasibility of radial artery catheterization for the deployment of these new devices.
   METHODS: We performed a review of the first 10 patients with an unruptured cerebral aneurysm treated via a transradial cerebral angiogram. Seven patients underwent embolization with the WEB device, 1 patient underwent embolization with the PulseRider, and 2 patients underwent embolization with the Surpass device. We describe in detail our workflow and the devices used for transradial access.
   RESULTS: The aneurysms treated include internal carotid artery bifurcation, middle cerebral artery, anterior communicating artery, basilar tip, and posterior communicating artery. All patients underwent radial artery catheterization, and none of them had to be converted to femoral artery access. Of the 10 patients, 9 required a single attempt for accurate device deployment. One patient had unsuccessful placement of the WEB device and required coiling of the aneurysm because of device herniation into the parent vessel. None of the patients had any postoperative complications and were discharged the following day with the same modified Rankin scale score as preoperatively.
   CONCLUSIONS: Our experience with 10 patients revealed no limitations during catheterization and deployment of these devices. One patient had to be converted to coil embolization, which was feasible through the same vascular access. None of the patients had vascular complications postoperatively with minimal wrist discomfort.
C1 [Mouchtouris, Nikolaos; Al Saiegh, Fadi; Sweid, Ahmad; Amllay, Abdelaziz; Tjoumakaris, Stavropoula; Gooch, Reid; Rosenwasser, Robert; Jabbour, Pascal M.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
RP Jabbour, PM (reprint author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
EM pascal.jabbour@jefferson.edu
OI Mouchtouris, Nikolaos/0000-0001-9495-9391; Sweid,
   Ahmad/0000-0002-2652-2451
CR Pierot L, 2017, AM J NEURORADIOL, V38, P1151, DOI 10.3174/ajnr.A5178
   Satti Sudhakar R, 2017, J Vasc Interv Neurol, V9, P1
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P493, DOI 10.1136/neurintsurg-2017-013295
   Spiotta AM, 2017, NEUROSURGERY, V81, P56, DOI 10.1093/neuros/nyx085
   Wakhloo AK, 2015, AM J NEURORADIOL, V36, P98, DOI 10.3174/ajnr.A4078
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 6
EP 9
DI 10.1016/j.wneu.2019.07.149
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300078
PM 31356971
DA 2020-05-12
ER

PT J
AU Luzzi, S
   Zoia, C
   Rampini, AD
   Elia, A
   Del Maestro, M
   Carnevale, S
   Morbini, P
   Galzio, R
AF Luzzi, Sabino
   Zoia, Cesare
   Rampini, Angela Dele
   Elia, Angela
   Del Maestro, Mattia
   Carnevale, Sergio
   Morbini, Patrizia
   Galzio, Renato
TI Lateral Transorbital Neuroendoscopic Approach for Intraconal Meningioma
   of the Orbital Apex: Technical Nuances and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Ectopic meningiomas; Endoscopic orbitotomy; Intraconal meningiomas;
   Lateral orbitotomy; Orbital approaches; TONE approach
ID EXTRADURAL INTRAORBITAL MENINGIOMA; ECTOPIC MENINGIOMA; ANEURYSMS
AB BACKGROUND: Surgical approaches to orbital apex lesions involve the medial and lateral corridors. The transorbital neuroendoscopic (TONE) approach has been recently proposed as an elegant, bone-sparing, and minimally invasive alternative for tumors of the lateral orbital compartment. However, its effectiveness compared with the standard lateral orbitotomy approach still requires confirmation. The aim of the present report was to describe the key technical aspects of the lateral trans-eyebrow TONE approach and to review the relevant reported data on the surgical management of ectopic orbital intraconal meningiomas.
   CASE DESCRIPTION: The TONE approach was used in a 63-year-old man with a diagnosis of a left ectopic intraconal meningioma of the orbital apex involving the lateral compartment. The TONE approach involves performing a lateral 3-cm eyebrow skin incision. A subperiosteal dissection of the periorbita permits intermittent medialization of the eyeball and extracapsular access to the orbital apex region. A lateral periorbital incision under full endoscopic view allows for early access to 2 different intermuscular corridors that do not require mechanical retraction of the oculomotor muscles. The reported data included studies of 23 cases of intraconal meningioma, which were usually benign, although the meningothelial variant has been associated with a greater recurrence rate.
   CONCLUSIONS: In our limited experience, the lateral TONE approach proved to be an effective, feasible, versatile, and minimally invasive promising alternative to resect orbital apex meningiomas involving the lateral compartment. Its technical strengths include increased illumination and magnification of the surgical field and an unparalleled lateral view of the orbital apex.
C1 [Luzzi, Sabino; Rampini, Angela Dele; Elia, Angela; Galzio, Renato] Univ Pavia, Neurosurg Unit, Pavia, Italy.
   [Del Maestro, Mattia] Univ Pavia, PhD Sch Expt Med, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy.
   [Luzzi, Sabino; Zoia, Cesare; Del Maestro, Mattia; Galzio, Renato] Fdn IRCCS Policlin San Matteo, Dept Surg Sci, Neurosurg Unit, Pavia, Italy.
   [Carnevale, Sergio; Morbini, Patrizia] Fdn IRCCS Policlin San Matteo, Dept Pathol, Pavia, Italy.
RP Luzzi, S (reprint author), Univ Pavia, Neurosurg Unit, Pavia, Italy.; Luzzi, S (reprint author), Fdn IRCCS Policlin San Matteo, Dept Surg Sci, Neurosurg Unit, Pavia, Italy.
EM sabino.luzzi@unipv.it
RI ; Zoia, Cesare/B-8463-2015; Morbini, Patrizia/AAC-2658-2019
OI Luzzi, Sabino/0000-0002-1381-8528; Carnevale,
   Sergio/0000-0002-9679-4540; Zoia, Cesare/0000-0001-7304-6120; Morbini,
   Patrizia/0000-0001-5012-5790
CR Arai H, 1997, BRIT J NEUROSURG, V11, P560
   Baldi I, 2018, NEUROCHIRURGIE, V64, P5, DOI 10.1016/j.neuchi.2014.05.006
   Bellantoni G, 2019, eNeurologicalSci, V14, P31, DOI 10.1016/j.ensci.2018.11.021
   Campbell AA, 2015, MIDDLE EAST AFR J OP, V22, P435, DOI 10.4103/0974-9233.164613
   Castelnuovo P, 2006, RHINOLOGY, V44, P2
   Choi Kevin J, 2018, Int Ophthalmol Clin, V58, P85, DOI 10.1097/IIO.0000000000000222
   Ciappetta P, 2009, J NEUROSURG SCI, V53, P147
   CRAIG WM, 1949, AM J OPHTHALMOL, V32, P1663, DOI 10.1016/S0002-9394(49)90807-7
   DALENA PR, 1964, ARCH OPHTHALMOL-CHIC, V71, P832
   De Tommasi A, 2008, NEUROSURGERY, V63, P976, DOI 10.1227/01.NEU.0000327699.93146.CD
   Decock CE, 2009, OPHTHAL PLAST RECONS, V25, P57, DOI 10.1097/IOP.0b013e3181936811
   Dehcordi SR, 2017, WORLD NEUROSURG, V105, P895, DOI 10.1016/j.wneu.2017.05.099
   Del Maestro M, 2018, ACTA NEUROCHIR SUPPL, V129, P109, DOI 10.1007/978-3-319-73739-3_16
   Farah SE, 1999, OPHTHAL PLAST RECONS, V15, P463, DOI 10.1097/00002341-199911000-00021
   Gallieni M, 2018, ACTA NEUROCHIR SUPPL, V129, P19, DOI 10.1007/978-3-319-73739-3_3
   Gunduz K, 2014, SURV OPHTHALMOL, V59, P643, DOI 10.1016/j.survophthal.2014.01.009
   JOHNSON TE, 1993, J PEDIATR OPHTHALMOL, V30, P43
   LLOYD GAS, 1982, CLIN RADIOL, V33, P181, DOI 10.1016/S0009-9260(82)80057-3
   Luzzi S, 2019, TURK NEUROSURG, V29, P875, DOI 10.5137/1019-5149.JTN.26052-19.2
   Luzzi S, 2019, WORLD NEUROSURG, V127, P255, DOI 10.1016/j.wneu.2019.04.056
   Luzzi Sabino, 2019, Asian J Neurosurg, V14, P193, DOI 10.4103/ajns.AJNS_279_17
   Luzzi S, 2018, OPER NEUROSURG, V15, pE92
   Luzzi S, 2019, WORLD NEUROSURG, V124, pE769, DOI 10.1016/j.wneu.2019.01.016
   Luzzi S, 2018, ACTA NEUROCHIR SUPPL, V129, P25, DOI 10.1007/978-3-319-73739-3_4
   Luzzi S, 2018, WORLD NEUROSURG, V116, pE340, DOI 10.1016/j.wneu.2018.04.203
   Luzzi Sabino, 2018, Surg Neurol Int, V9, P19, DOI 10.4103/sni.sni_369_17
   MACMICHAEL IM, 1969, BRIT J OPHTHALMOL, V53, P169, DOI 10.1136/bjo.53.3.169
   Moe KS, 2010, NEUROSURGERY, V67, P16, DOI 10.1227/01.NEU.0000373431.08464.43
   Murchison AP, 2011, LARYNGOSCOPE, V121, P463, DOI 10.1002/lary.21357
   Palumbo P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123010
   Palumbo P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092801
   Paluzzi A, 2015, J NEUROL SURG PART B, V76, P12, DOI 10.1055/s-0033-1360580
   Pushker N, 2013, INT OPHTHALMOL, V33, P707, DOI 10.1007/s10792-012-9708-0
   Ricci Alessandro, 2017, Surg Neurol Int, V8, P117, DOI 10.4103/sni.sni_50_17
   Spraul CW, 1996, KLIN MONATSBL AUGENH, V209, P322, DOI 10.1055/s-2008-1035328
   Srinivasan Archana, 2018, Int Ophthalmol Clin, V58, P101, DOI 10.1097/IIO.0000000000000224
   Stokken J, 2016, LARYNGOSCOPE, V126, P20, DOI 10.1002/lary.25539
   TAKAHASHM, 1973, NEURORADIOLOGY, V5, P95
   TAN KK, 1965, BRIT J OPHTHALMOL, V49, P377, DOI 10.1136/bjo.49.7.377
   Tendler Irwin, 2017, Ophthalmic Plast Reconstr Surg, V33, pS99, DOI 10.1097/IOP.0000000000000578
   WOLTER JR, 1976, ARCH OPHTHALMOL-CHIC, V94, P1920
   Yeh Steven, 2004, Curr Opin Ophthalmol, V15, P490, DOI 10.1097/01.icu.0000144387.12739.9c
   Yesiltas YS, 2018, J NEUROSURG-PEDIATR, V22, P151, DOI 10.3171/2018.1.PEDS17557
   Yokoyama T, 1999, SKULL BASE SURG, V9, P47, DOI 10.1055/s-2008-1058172
   Zoia Cesare, 2019, Surg Neurol Int, V10, P76, DOI 10.25259/SNI-132-2019
   Zoia Cesare, 2018, J Neurosurg Sci, DOI 10.23736/S0390-5616.18.04333-3
NR 46
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 10
EP 17
DI 10.1016/j.wneu.2019.07.152
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300079
PM 31356977
DA 2020-05-12
ER

PT J
AU Lu, D
   Chen, L
   Kang, XY
   He, YK
   Xu, B
   Bai, WX
AF Lu, Dan
   Chen, Lei
   Kang, Xiaoyu
   He, Yingkun
   Xu, Bin
   Bai, Weixing
TI The Application of Copernic RC Balloon in Endovascular Treatment of
   Complex Intracranial Dural Arteriovenous Fistula of the Transverse
   Sigmoid Sinus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Copernic RC balloon; Dural arteriovenous fistula; Onyx tunnel technique;
   Sinus protection
ID TRANSARTERIAL ONYX EMBOLIZATION; PROTECTION
AB BACKGROUND: During endovascular treatment of complex intracranial dural arteriovenous fistulas (DAVFs) of the transverse sigmoid sinus, it can be difficult to preserve the patency of the dural sinus. We have described the details of the transvenous balloon-assisted technique using Copernic RC balloon as a treatment option for patients with complex DAVFs of the transverse sigmoid sinus.
   CASE DESCRIPTION: In these 2 cases, the Copernic RC balloon was navi-ed into the internal jugular vein and placed at the distal end of the DAVFs in the transverse sinus. After the balloon was fully inflated, a transarterial glue embolization or transvenous Onyx tunnel technique was performed, with cony plete exclusion of the fistula and patency of the transverse sigmoid sinus. No immediate or delayed postoperative complications occurred.
   CONCLUSION: Transvenous Copernic RC balloon-assisted embolization of DAVFs in the transverse and sigmoid sinuses is safe and can offer complete occlusion of DAVFs and remission of clinical symptoms.
C1 [Lu, Dan; Chen, Lei] Xian Int Med Ctr, Dept Neurosurg, Xian, Shaanxi, Peoples R China.
   [Kang, Xiaoyu; He, Yingkun; Xu, Bin; Bai, Weixing] Henan Prov Peoples Hosp, Dept Neurointervent, Zhengzhou, Henan, Peoples R China.
RP Bai, WX (reprint author), Henan Prov Peoples Hosp, Dept Neurointervent, Zhengzhou, Henan, Peoples R China.
EM 13526678722@126.com
CR Alturki AY, 2018, WORLD NEUROSURG, V109, P398, DOI 10.1016/j.wneu.2017.10.083
   Chiu AHY, 2014, J NEUROINTERV SURG, V6, P400, DOI 10.1136/neurintsurg-2013-010768
   Choi BJ, 2009, NEUROSURGERY, V65, P994, DOI 10.1227/01.NEU.0000351772.45417.92
   Ertl Lorenz, 2017, J Neurosurg, V126, P360, DOI 10.3171/2016.2.JNS152081
   Hu YC, 2011, J NEUROINTERV SURG, V3, P5, DOI 10.1136/jnis.2010.003707
   Jittapiromsak P, 2013, NEURORADIOLOGY, V55, P345, DOI 10.1007/s00234-012-1107-8
   Kerolus MG, 2018, J NEUROSURG, V129, P922, DOI 10.3171/2017.5.JNS17287
   Kortman H, 2019, INTERV NEURORADIOL, V25, P315, DOI 10.1177/1591019918819187
   Kubo M, 2002, AM J NEURORADIOL, V23, P787
   Piechowiak E, 2017, AM J NEURORADIOL, V38, P1984, DOI 10.3174/ajnr.A5333
   Piippo A, 2013, J NEUROSURG, V119, P164, DOI 10.3171/2013.3.JNS121547
   Shi ZS, 2009, J NEUROSURG, V110, P921, DOI 10.3171/2008.10.JNS08119
   Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485
   Webb S, 2013, WORLD NEUROSURG, V80, P47, DOI 10.1016/j.wneu.2012.04.018
   Zhang YX, 2015, INTERV NEURORADIOL, V21, P94, DOI 10.15274/INR-2014-10098
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 21
EP 26
DI 10.1016/j.wneu.2019.07.159
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300082
PM 31362106
DA 2020-05-12
ER

PT J
AU Sharma, A
   Mobasheri, R
   Russo, S
AF Sharma, Aadhar
   Mobasheri, Reza
   Russo, Salvatore
TI Posttraumatic C5 Palsy After Application of Hard Collar in Ankylosing
   Spondylitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; C5 palsy; Cervical fracture; Cervical orthosis
ID CERVICAL-SPINE; FRACTURES
AB BACKGROUND: Ankylosing spondylitis (AS) is a systemic enthesopathy. In its presence, spinal fractures are often unstable. Acknowledging the preinjury level of kyphosis is key in the management of cervical fractures, and placement into a hard collar has been shown to result in life-threatening spinal cord complications.
   CASE DESCRIPTION: This report presents the unique case of a patient with AS who developed a unilateral C5 palsy after the application of a hard collar for a C5/6 fracture, to our knowledge the first such case presented to date. The patient subsequently went on to an anterior fixation and partially recovered from the C5 palsy/injury. After the case report is an examination of the currently available literature and evidence exploring the factors that may contribute to C5 palsy after the application of a collar for acute fracture in AS.
   CONCLUSIONS: We described the first case in the literature of a posttraumatic C5 palsy after application of a hard collar in AS. This report and literature review should act to underscore the importance of respecting a preexisting rigid kyphotic deformity in cervical fractures but also to stimulate further thoughts and investigations into what may contribute to a posttraumatic C5 palsy.
C1 [Sharma, Aadhar; Mobasheri, Reza; Russo, Salvatore] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Spinal Trauma Unit, Praed St, London, England.
RP Sharma, A (reprint author), Imperial Coll Healthcare NHS Trust, St Marys Hosp, Spinal Trauma Unit, Praed St, London, England.
EM aadhar.sharma@nhs.net
CR An SB, 2014, J KOREAN NEUROSURG S, V56, P108, DOI 10.3340/jkns.2014.56.2.108
   Chaudhary SB, 2011, ISRN RHEUMATOL
   Clarke A, 2010, ACTA ORTHOP BELG, V76, P413
   Elgafy H, 2011, J SPINAL DISORD TECH, V24, P469, DOI 10.1097/BSD.0b013e318204da02
   Guerrero AI, 2018, NEUROCIRUGIA, V29, P116, DOI 10.1016/j.neucir.2017.11.001
   Longo UG, 2015, BRIT MED BULL, V115, P57, DOI 10.1093/bmb/ldv010
   Lubelski D, 2014, SPINE J, V14, P1895, DOI 10.1016/j.spinee.2013.10.038
   McMaster MJ, 1997, J BONE JOINT SURG BR, V79B, P197, DOI 10.1302/0301-620X.79B2.7095
   Papadopoulos MC, 1999, BRIT MED J, V319, P171, DOI 10.1136/bmj.319.7203.171
   Reinhold M, 2018, GLOB SPINE J, V8, p56S, DOI 10.1177/2192568217736268
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 27
EP 31
DI 10.1016/j.wneu.2019.07.158
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300083
PM 31356975
DA 2020-05-12
ER

PT J
AU Giordano, M
   Gallieni, M
   Zaed, I
   Samii, A
AF Giordano, Mario
   Gallieni, Massimo
   Zaed, Ismail
   Samii, Amir
TI Use of Frameless Stereotactic Navigation System Combined with
   Intraoperative Magnetic Resonance Imaging and 5-Aminolevulinic Acid
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-Aminolevulinic acid; Frameless biopsy; Glioma; Intraoperative MRI
ID BRAIN BIOPSY PROCEDURES; ACCURACY; LOCALIZATION; ADVANTAGES; MORBIDITY;
   PHANTOM
AB OBJECTIVE: We have described the integrated use of a neuronavigation-guided system for frameless stereotaxy (VarioGuide [Brainlab AG, Munich, Germany]) with intra-operative magnetic resonance imaging (iMRI) and 5-aminolevulinic acid (5-ALA) and report the advantages and disadvantages that the use of these tools together can have in the treatment of various types of intracerebral lesions.
   METHODS: After the skin incision, creation of a burr .._.e at the entry point, and dura opening, the VarioGuide procedure was started. Initially, the wizard software will require positioning of the stereotactic arm over the burr hole and provides feedback regarding the correct position. The procedure is performed in an iMRI theater furnished with a surgical microscope (Kinevo [Carl Zeiss AG, Ober-kochen, Germany]) supplied with a violet-blue excitation light for 5-ALA fluorescence. At the end of the surgery, iMRI was performed. We present 2 exemplary cases to describe the application and workflow of these tools.
   RESULTS: When used for traditional biopsy, the possibility of performing a new iMRI scan could be of paramount importance because the brain shift can be compensated for and an alternative trajectory can be calculated from the new images and fiber tracking reconstruction. The fluorescence of the tissue sample examined under the microscope filter can provide immediate information about the nature of the lesion, allowing for the possibility of converting the procedure to open craniotomy and tumor removal.
   CONCLUSION: The use of combination frameless stereotax with iMRI and 5-ALA has shown benefits in terms of safety and precision. Moreover, the use of these tools can simplify tumor removal after simple biopsy, widening the spectrum of indications.
C1 [Giordano, Mario; Gallieni, Massimo; Samii, Amir] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Zaed, Ismail] Humanitas Univ, Rozzano, Italy.
   [Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
RP Gallieni, M (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
EM drgallieni@gmail.com
RI Zaed, Ismail/AAF-3433-2019
OI Gallieni, Massimo/0000-0002-5314-8581; zaed, ismail/0000-0003-3506-4111
CR Amin DV, 2011, J NEUROSURG, V114, P1414, DOI 10.3171/2010.7.JNS091493
   Barnett GH, 1999, J NEUROSURG, V91, P569, DOI 10.3171/jns.1999.91.4.0569
   Bekelis K, 2012, J NEUROSURG, V116, P1002, DOI 10.3171/2012.1.JNS111746
   Budke M, 2018, OPER NEUROSURG, V15, P302, DOI 10.1093/ons/opx192
   Dorward N L, 1997, Comput Aided Surg, V2, P180, DOI 10.1002/(SICI)1097-0150(1997)2:3/4<180::AID-IGS5>3.0.CO;2-V
   Dorward NL, 1999, J NEUROSURG, V90, P160, DOI 10.3171/jns.1999.90.1.0160
   Dorward NL, 2002, BRIT J NEUROSURG, V16, P110, DOI 10.1080/02688690220131705
   Fukaya C, 2010, STEREOT FUNCT NEUROS, V88, P163, DOI 10.1159/000313868
   GALLOWAY R L JR, 1991, Biomedical Instrumentation and Technology, V25, P457
   Germano I M, 1998, Comput Aided Surg, V3, P33, DOI 10.3109/10929089809148126
   Gralla J, 2003, ZBL NEUROCHIR, V64, P166
   Hall WA, 2000, NEUROSURGERY, V46, P502, DOI 10.1097/00006123-200002000-00051
   Henderson JM, 2004, STEREOT FUNCT NEUROS, V82, P135, DOI 10.1159/000081345
   MACIUNAS RJ, 1994, NEUROSURGERY, V35, P682, DOI 10.1227/00006123-199410000-00015
   McGirt MJ, 2005, J NEUROSURG, V102, P897, DOI 10.3171/jns.2005.102.5.0897
   Paleologos TS, 2001, NEUROSURGERY, V49, P830, DOI 10.1097/00006123-200110000-00009
   Patil Arun Angelo, 2010, Surg Neurol Int, V1, P62, DOI 10.4103/2152-7806.70957
   Price R, 2003, BRIT J NEUROSURG, V17, P90, DOI 10.3109/02688690309177985
   Quinones-Hinojosa A, 2006, J NEURO-ONCOL, V76, P65, DOI 10.1007/s11060-005-2915-z
   Ringel F, 2009, NEUROSURGERY, V64, P365, DOI 10.1227/01.NEU.0000341532.15867.1C
   Smith JS, 2005, J NEURO-ONCOL, V73, P173, DOI 10.1007/s11060-004-4208-3
   Sutherland GR, 2013, NEUROSURGERY, V72, pA27, DOI 10.1227/NEU.0b013e318270da19
   Walton L, 1996, STEREOT FUNCT NEUROS, V66, P49, DOI 10.1159/000099700
   Walton L, 1997, NEUROSURGERY, V41, P131, DOI 10.1097/00006123-199707000-00027
   Woodworth GF, 2006, J NEUROSURG, V104, P233, DOI 10.3171/jns.2006.104.2.233
NR 25
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 32
EP 37
DI 10.1016/j.wneu.2019.07.171
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300084
PM 31369881
DA 2020-05-12
ER

PT J
AU Miyakoshi, N
   Hongo, M
   Kasukawa, Y
   Ishikawa, Y
   Kudo, D
   Shimada, Y
AF Miyakoshi, Naohisa
   Hongo, Michio
   Kasukawa, Yuji
   Ishikawa, Yoshinori
   Kudo, Daisuke
   Shimada, Yoichi
TI Intraoperative Visible Air Bubbling Recorded as a Sign of Massive Venous
   Air Embolism During Prone Position Surgery for Extensive Ossification of
   Spinal Ligaments: A Case Report with a Video Clip
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative visible air bubbling; Ossification of posterior
   longitudinal ligament; Ossification of ligamentum flavum; Prone
   position; Venous air embolism
ID FUSION; COMPLICATIONS; GIRL
AB BACKGROUND: Venous air embolism (VAE) is a rare but, frequently, fatal complication that can occur during surgery. Several reported studies have shown visible bubbling of air at the surgical site as the first clinical indication of VAE-induced cardiovascular collapse during prone-position spine surgery. However, to the best of our knowledge, video imaging of this phenomenon has not been previously reported.
   CASE DESCRIPTION: A 41-year-old man had undergone cervical laminoplasty for ossification of the posterior longitudinal ligament and thoracic laminectomy for ossification of the posterior longitudinal ligament and ossification of the ligamentum flavum in the prone position. The entire surgery was recorded with video imaging. Before cardiac arrest due to the massive VAE, visible air bubbling had been observed at the operated site of the thoracic laminectomy, and this phenomenon had been incidentally recorded with the video. The patient recovered with cardiopulmonary resuscitation and intensive treatment against severe acute respiratory distress syndrome due to pulmonary damage.
   CONCLUSIONS: The present case report offers the first video imaging evidence of intraoperative visible air bubbling as a sign of a massive VAE during prone-position spine surgery. To the best of our knowledge, this is also the first report of intraoperative VAE in a patient with extensive ossification of the spinal ligaments.
C1 [Miyakoshi, Naohisa; Hongo, Michio; Kasukawa, Yuji; Ishikawa, Yoshinori; Kudo, Daisuke; Shimada, Yoichi] Akita Univ, Dept Orthoped Surg, Grad Sch Med, Akita, Japan.
RP Miyakoshi, N (reprint author), Akita Univ, Dept Orthoped Surg, Grad Sch Med, Akita, Japan.
EM miyakosh@doc.med.akita-u.ac.jp
OI Kasukawa, Yuji/0000-0001-7008-675X
CR ALBIN MS, 1991, ANESTH ANALG, V73, P346
   Brown J, 2001, RESUSCITATION, V50, P233, DOI 10.1016/S0300-9572(01)00362-8
   Brull SJ, 2017, J CRIT CARE, V42, P255, DOI 10.1016/j.jcrc.2017.08.010
   Cruz AS, 2016, J NEUROSURG-SPINE, V25, P681, DOI 10.3171/2016.5.SPINE16109
   De-Giorgio F, 2012, BRAIN PATHOL, V22, P571, DOI 10.1111/j.1750-3639.2012.00606.x
   Despond O, 1997, CAN J ANAESTH, V44, P410, DOI 10.1007/BF03014463
   Dumont TM, 2010, SPINE, V35, pE1238, DOI 10.1097/BRS.0b013e3181f62600
   Ganslandt O, 2013, ACTA NEUROCHIR, V155, P1887, DOI 10.1007/s00701-013-1822-x
   Himes BT, 2017, J NEUROSURG, V127, P182, DOI 10.3171/2016.5.JNS152328
   Homma S, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.86
   HORLOCKER TT, 1992, ANESTH ANALG, V75, P152, DOI 10.1213/00000539-199207000-00045
   Lee-Archer PF, 2017, A A CASE REP, V8, P307, DOI 10.1213/XAA.0000000000000498
   MCCARTHY RE, 1990, J SPINAL DISORD, V3, P1
   McDouall SF, 2007, EUR J ANAESTH, V24, P803, DOI 10.1017/S0265021506002201
   Mirski MA, 2007, ANESTHESIOLOGY, V106, P164, DOI 10.1097/00000542-200701000-00026
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Pham Dang Charles, 2002, Spine (Phila Pa 1976), V27, pE291, DOI 10.1097/00007632-200206010-00025
   Rodriguez RA, 2001, SPINE, V26, P1719, DOI 10.1097/00007632-200108010-00017
   Sutherland RW, 1997, ACTA ANAESTH SCAND, V41, P1073, DOI 10.1111/j.1399-6576.1997.tb04839.x
   Wills J, 2005, SPINE, V30, pE629, DOI 10.1097/01.brs.0000182347.85827.0c
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 38
EP 42
DI 10.1016/j.wneu.2019.07.166
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300085
PM 31369880
DA 2020-05-12
ER

PT J
AU Tan, DCH
   Vaughan, KA
   Koeck, H
AF Tan, David Chi Hau
   Vaughan, Kerry A.
   Koeck, Helge
TI Endoscopic-Assisted Spinal Arachnoiditis Adhesiolysis and Placement of a
   Spinal Cysto-Subarachnoid Shunt
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adhesiolysis; Endoscopic; Spinal arachnoid cyst; Spinal arachnoiditis;
   Spinal cysto-arachnoid shunt
ID ADHESIVE ARACHNOIDITIS; ANESTHESIA
AB BACKGROUND: Spinal arachnoiditis and associated arachnoid adhesions can cause debilitating neurological symptoms due to nerve root and spinal cord compression or tethering. Adhesiolysis using a microscopic approach has traditionally been used for this condition. This procedure has been further refined in recent years with the use of flexible endoscopes.
   CASE DESCRIPTION: We report the case of a patient with progressive thoracic myelopathy secondary to arachnoid adhesions associated with arachnoiditis. A minimally invasive technique of adhesiolysis and placement of a cysto-arachnoid shunt was performed with the assistance of a flexible endoscope.
   CONCLUSIONS: The present case report has highlighted the advantages of using a flexible endoscope to treat spinal arachnoiditis adhesiolysis and placement of a cysto-arachnoid shunt, including a smaller skin incision and extended visualization.
C1 [Tan, David Chi Hau; Vaughan, Kerry A.; Koeck, Helge] Wellington Reg Hosp, Dept Neurosurg, Capital & Coast Dist Hlth Board, Wellington, New Zealand.
   [Vaughan, Kerry A.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Koeck, H (reprint author), Wellington Reg Hosp, Dept Neurosurg, Capital & Coast Dist Hlth Board, Wellington, New Zealand.
EM Helge.Koeck@ccdhb.org.nz
CR Demerdash A, 2017, BRIT J NEUROSURG, V31, P28, DOI 10.1080/02688697.2016.1245848
   Gnanalingham Kanna K, 2006, Eur Spine J, V15 Suppl 5, P661, DOI 10.1007/s00586-006-0204-y
   Greenberg MS, 2016, HDB NEUROSURGERY
   Hirai T, 2012, SPINE, V37, pE195, DOI 10.1097/BRS.0b013e31822ba817
   Kashcheev A A, 2013, Zh Vopr Neirokhir Im N N Burdenko, V77, P44
   Killeen T, 2012, ANAESTHESIA, V67, P1386, DOI 10.1111/anae.12017
   Mauer UM, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10291
   Torres-Corzo J, 2016, NEUROENDOSCOPIC SURG
   Vaughan D, 2012, BRIT J NEUROSURG, V26, P555, DOI 10.3109/02688697.2012.663516
   Waldman SD, 2019, ATLAS COMMON PAIN SY, P328
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 43
EP 46
DI 10.1016/j.wneu.2019.07.160
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300086
PM 31362104
DA 2020-05-12
ER

PT J
AU Echt, M
   Holland, R
   Gelfand, Y
   Chin, S
   Weidenheim, KM
   Yassari, R
   Kinon, MD
AF Echt, Murray
   Holland, Ryan
   Gelfand, Yaroslav
   Chin, Steven
   Weidenheim, Karen M.
   Yassari, Reza
   Kinon, Merritt D.
TI Extradural Dumbbell-Shaped Tuberculoma Masquerading as Nerve Sheath
   Tumor: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dumbbell-shaped tumor; Neural-foraminal widening; Spinal tuberculosis;
   Tuberculoma
ID INTRADURAL EXTRAMEDULLARY TUBERCULOMA; ULNAR NERVE; EPIDURAL
   TUBERCULOMA; CERVICAL-SPINE; OPTIC-NERVE; MIMICKING; GRANULOMA
AB BACKGROUND: Spinal tuberculosis has been listed as a rare cause of neuroforaminal widening with only 2 previous reports in the literature. Here, we report the third case of an extradural tuberculoma extending through and expanding the neural foramen closely masquerading as a nerve sheath tumor including, to the best of our knowledge, the first description of magnetic resonance imaging, operative, and histopathology findings.
   CASE DESCRIPTION: A 65-year-old Nigerian man presented with signs and symptoms of worsening thoracic myeloradiculopathy for the past month. Imaging found an extradural dumbbell-shaped lesion involving the spinal canal, neural foramen, and paraspinal area with a combination of solid and cystic components causing bony remodeling of the pedicle and vertebral body, as well as enlargement of the neural foramen. Surgery was performed to resect the mass, and pathology postoperatively demonstrated caseating granulomas, rare thin elongated organisms on Ziehl-Neelsen staining, and involvement of nerve fascicles.
   CONCLUSIONS: This case illustrates that a tuberculoma can have many of the features of a benign neoplasm, such as encapsulation, appearance of a slow rate of growth, and development of necrosis or even cystic degeneration. With the specific findings of entrapped nerve fascicles, we postulate that the lesion represents a nerve sheath tuberculoma rather than spinal tuberculosis of the pedicle or posterior elements. Furthermore, only a lesion of the nerve sheath would have the characteristic dumbbell appearance as it extends through the foramen.
C1 [Echt, Murray; Holland, Ryan; Gelfand, Yaroslav; Yassari, Reza; Kinon, Merritt D.] Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.
   [Echt, Murray; Holland, Ryan; Gelfand, Yaroslav; Yassari, Reza; Kinon, Merritt D.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
   [Chin, Steven; Weidenheim, Karen M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA.
RP Echt, M (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.; Echt, M (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
EM murrayecht@gmail.com
OI Echt, Murray/0000-0002-4504-4918
CR Arts MP, 2011, NEUROSURGERY, V69, P135, DOI 10.1227/NEU.0b013e318214a98c
   BABHULKAR SS, 1984, J BONE JOINT SURG BR, V66, P239
   Batirel A, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.07.013
   Bloom B.R., 2017, DIS CONTROL PRIORITI, P233, DOI DOI 10.1596/978-1-4648-0426-7
   BORNE G, 1968, J NEUROSURG, V28, P480, DOI 10.3171/jns.1968.28.5.0480
   Chandra VVR, 2013, J NEUROSURG-PEDIATR, V11, P100, DOI 10.3171/2012.9.PEDS12172
   Chatterjee D, 2015, NEUROL INDIA, V63, P268, DOI 10.4103/0028-3886.156305
   CHIN D, 1983, SURG NEUROL, V19, P428, DOI 10.1016/0090-3019(83)90140-4
   COMPTON JS, 1984, J NEUROSURG, V60, P200, DOI 10.3171/jns.1984.60.1.0200
   Dastur H M, 1983, Neurosurg Rev, V6, P111, DOI 10.1007/BF01742762
   Gul S, 2010, TURK NEUROSURG, V20, P561, DOI 10.5137/1019-5149.JTN.1112-08.6
   HAMADA J, 1991, NEUROSURGERY, V28, P161, DOI 10.1227/00006123-199101000-00025
   JAKOBY RK, 1961, J NEUROSURG, V18, P557, DOI 10.3171/jns.1961.18.4.0557
   Kalita J, 2014, INT J TUBERC LUNG D, V18, P486, DOI 10.5588/ijtld.13.0556
   Khanna K, 2019, SPINE J, V19, P1858, DOI 10.1016/j.spinee.2019.05.002
   Kim HJ, 2014, INT J INFECT DIS, V24, P37, DOI 10.1016/j.ijid.2014.03.1383
   Kivrak AS, 2009, EUR J RADIOL, V71, P29, DOI 10.1016/j.ejrad.2008.03.020
   Kolakshyapati M, 2018, NEUROSPINE, V15, P277, DOI 10.14245/ns.1836034.017
   Kumar R, 2007, PEDIATR NEUROSURG, V43, P541, DOI 10.1159/000108805
   Kumar S, 2007, CLIN ORTHOP RELAT R, P62, DOI 10.1097/BLO.0b013e318065b73c
   LANAPEIXOTO MA, 1980, ARCH NEUROL-CHICAGO, V37, P186, DOI 10.1001/archneur.1980.00500520084020
   Ledermann HP, 2003, RADIOLOGY, V228, P506, DOI 10.1148/radiol.2282020752
   Lima MA, 2012, ARCH NEUROL-CHICAGO, V69, P138, DOI 10.1001/archneurol.2011.720
   MANTZOROS CS, 1993, CLIN INFECT DIS, V17, P1032, DOI 10.1093/clinids/17.6.1032
   Marais S, 2018, CLIN INFECT DIS, V67, P89, DOI 10.1093/cid/ciy020
   NUCCI F, 1988, NEUROSURGERY, V22, P906, DOI 10.1227/00006123-198805000-00017
   OHAEGBULAM SC, 1977, TUBERCLE, V58, P97, DOI 10.1016/0041-3879(77)90036-8
   Orrell RW, 2002, J NEUROL NEUROSUR PS, V73, P769, DOI 10.1136/jnnp.73.6.769
   Ozek E, 2009, NEUROL INDIA, V57, P211, DOI 10.4103/0028-3886.51300
   Parry AH, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20180342
   RAGLAND RL, 1990, AM J NEURORADIOL, V11, P612
   Ramachandran R, 2017, J NEUROL SCI, V381, P256, DOI 10.1016/j.jns.2017.08.3258
   Rao B D, 1965, Neurol India, V13, P89
   RAO SB, 1971, J NEUROSURG, V35, P488
   REICHENTHAL E, 1981, SURG NEUROL, V15, P178, DOI 10.1016/0090-3019(81)90134-8
   Satyarthee GD, 2017, J PEDIATR NEUROSCI, V12, P180, DOI 10.4103/jpn.JPN_173_16
   SCHLERNITZAUER DA, 1971, ARCH OPHTHALMOL-CHIC, V85, P75
   Schoekler B, 2011, J NEUROL NEUROSUR PS, V82, P1217, DOI 10.1136/jnnp-2011-300034
   Shim DM, 2010, CLIN ORTHOP SURG, V2, P260, DOI 10.4055/cios.2010.2.4.260
   Sinha MK, 2010, J INFECTION, V60, P458, DOI 10.1016/j.jinf.2010.03.013
   Song MZ, 2016, J CLIN NEUROSCI, V32, P130, DOI 10.1016/j.jocn.2015.12.047
   Tumorunu B, 2015, TURK NEUROSURG, P2014
   Uthukumar NAM, 2007, SPINE, V6, P169
   Zibis AH, 2000, EUR RADIOL, V10, P144, DOI 10.1007/s003300050022
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 47
EP 51
DI 10.1016/j.wneu.2019.07.173
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300087
PM 31369884
DA 2020-05-12
ER

PT J
AU Sato, M
   Fujio, S
   Takajo, T
   Kamimura, K
   Hiraki, T
   Yamahata, H
   Arita, K
   Yoshimoto, K
AF Sato, Masanori
   Fujio, Shingo
   Takajo, Tomoko
   Kamimura, Kiyohisa
   Hiraki, Tsubasa
   Yamahata, Hitoshi
   Arita, Kazunori
   Yoshimoto, Koji
TI Large Intraosseous Schwannoma in Petrous Apex Presenting with
   Intratumoral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraosseoous schwannoma; Intratumoral hemorrhage; Petrous apex
ID NEURILEMOMA
AB BACKGROUND: Intracranial schwannomas are rarely confined to the skull. We here report a large schwannoma localized in the petrous apex that presented with intratumoral hemorrhage.
   CASE DESCRIPTION: A 35-year-old woman with mild hearing disturbance and ear fullness underwent computed tomography scan and magnetic resonance imaging, which demonstrated a tumor accompanied with intratumoral hematoma in the right petrous apex. Bone marrow was totally destroyed, but the bone cortex was relatively preserved. Pathologic specimen showed that the tumor was composed of proliferation of elongated neoplastic cells and positive for S-100 protein. It showed a nuclear palisading pattern, compatible with schwannoma. The lack of any cranial nerve signs and relative preservation of canals through which cranial nerves pass suggested the neurilemma cells surrounded vessels or mismigrated fetal neurilemma cells in the petrous apex as origin of the tumor. Benign nature of the tumor and total disappearance of the symptoms, supposedly due to the spontaneous absorption of the hematoma, made the patient choose a wait-and-watch approach. Magnetic resonance imaging studied 7 years after the diagnosis showed significant decrease of the tumor volume and disappearance of the hematoma.
   CONCLUSIONS: Although it is a large intraosseous schwannoma in the petrous apex, it has a benign nature, its size is reduced due to the hematoma absorption, and the patient is asymptomatic. We observed the patients for 7 years after the diagnosis.
C1 [Sato, Masanori; Fujio, Shingo; Takajo, Tomoko; Yamahata, Hitoshi; Yoshimoto, Koji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
   [Kamimura, Kiyohisa] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Radiol, Kagoshima, Japan.
   [Hiraki, Tsubasa] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pathol, Kagoshima, Japan.
   [Arita, Kazunori] Izumi Reg Med Ctr, Dept Neurosurg, Akune, Japan.
RP Fujio, S (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima, Japan.
EM ofuji@m2.kufm.kagoshima-u.ac.jp
OI Kamimura, Kiyohisa/0000-0003-4191-9358
CR Amita R, 2014, NEUROL INDIA, V62, DOI 10.4103/0028-3886.132447
   Celli P, 1998, NEUROSURG REV, V21, P158, DOI 10.1007/BF02389323
   De Paulis Danilo, 2011, Surg Neurol Int, V2, P60, DOI 10.4103/2152-7806.80352
   El-Bahy K, 2004, ACTA NEUROCHIR, V146, P1277, DOI 10.1007/s00701-004-0340-2
   Ersahin Y, 2000, CHILD NERV SYST, V16, P181, DOI 10.1007/s003810050490
   FAWCETT KJ, 1967, AM J CLIN PATHOL, V47, P759
   Goiney C, 2011, J RADIOL CASE REP, V5, P8, DOI 10.3941/jrcr.v5i11.859
   Goyal Richa, 2008, Orthopedics, V31, P281, DOI 10.3928/01477447-20080301-16
   HORN KL, 1995, SKULL BASE SURG, V5, P261, DOI 10.1055/s-2008-1058924
   KAWASE T, 1991, NEUROSURGERY, V28, P869, DOI 10.1227/00006123-199106000-00014
   Parikh PP, 2013, AM J OTOLARYNG, V34, P596, DOI 10.1016/j.amjoto.2013.02.003
   RAMAMURTHI B, 1958, J NEUROL NEUROSUR PS, V21, P92, DOI 10.1136/jnnp.21.2.92
   SAMTER TG, 1960, RADIOLOGY, V75, P215, DOI 10.1148/75.2.215
   SCHIFFER J, 1991, NEUROCHIRURGIA, V34, P178
   Sochart DH, 1995, FOOT, V5, P38
   Tamura R, 2015, J NEUROL SURG REP, V76, P135, DOI 10.1055/s-0035-1549312
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 53
EP 57
DI 10.1016/j.wneu.2019.07.179
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300089
PM 31376556
DA 2020-05-12
ER

PT J
AU Ziegler, AM
   Spencer, DA
   Nockels, RP
   Leonetti, JP
   Ibrahim, TF
AF Ziegler, Andrea M.
   Spencer, Drew A.
   Nockels, Russ P.
   Leonetti, John P.
   Ibrahim, Tarik F.
TI Tarik Syndrome: Reversible Postoperative Blindness Secondary to
   Occipital Seizures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Occipital seizures; Postoperative blindness; Postoperative
   complications; Skull base surgery
ID VISUAL-LOSS; SPINE SURGERY; COMPLICATIONS
AB BACKGROUND: Postoperative blindness is a devastating surgical complication. Although usually associated with prolonged cardiac and prone spinal operations, it may follow other procedures as well. Postoperative blindness is most commonly caused by a vascular etiology, but it can more rarely be caused by status epilepticus. We have previously reported a case of this phenomenon following a staged spinal deformity surgery.
   CASE DESCRIPTION: Here we report 2 additional cases following a skull base procedure and a single stage lumbar spine surgery. In all instances, rapid recognition that the patients' blindness was due to occipital seizures resulted in acute antiepileptiform treatment and full restoration of vision.
   CONCLUSIONS: Although a rare phenomenon, this syndrome, first recognized and described by Tarik F. Ibrahim, should be considered in any patient with postoperative visual impairment.
C1 [Ziegler, Andrea M.; Leonetti, John P.] Loyola Univ, Med Ctr, Dept Otolaryngol, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Spencer, Drew A.; Nockels, Russ P.; Ibrahim, Tarik F.] Loyola Univ, Med Ctr, Dept Neurosurg, 2160 S 1st Ave, Maywood, IL 60153 USA.
RP Ziegler, AM (reprint author), Loyola Univ, Med Ctr, Dept Otolaryngol, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM andrea.ziegler@lumc.edu
CR Adcock JE, 2012, J CLIN NEUROPHYSIOL, V29, P397, DOI 10.1097/WNP.0b013e31826c98fe
   Dewan MC, 2017, NEUROSURGERY, V80, P563, DOI 10.1093/neuros/nyw106
   Habibi Z, 2010, J PEDIATR NEUROSCI, V5, P36, DOI 10.4103/1817-1745.66661
   Ibrahim TF, 2017, J NEUROSURG-SPINE, V27, P63, DOI 10.3171/2016.12.SPINE16540
   Lee LA, 2006, ANESTHESIOLOGY, V105, P652, DOI 10.1097/00000542-200610000-00007
   Li A, 2015, WORLD NEUROSURG, V84, P2010, DOI 10.1016/j.wneu.2015.08.030
   Manaka S, 2003, NEUROL MED-CHIR, V43, P589, DOI 10.2176/nmc.43.589
   Tuan Huynh NN, 2013, TURK NEUROSURG, V23, P278, DOI 10.5137/1019-5149.JTN.4870-11.0
   Roth S, 2009, Br J Anaesth, V103 Suppl 1, pi31, DOI 10.1093/bja/aep295
   SHAW PJ, 1987, ACTA NEUROL SCAND, V76, P1, DOI 10.1111/j.1600-0404.1987.tb03535.x
   Shaw S, 2012, ARCH NEUROL-CHICAGO, V69, P1504, DOI 10.1001/archneurol.2012.317
   Shen Y, 2009, ANESTH ANALG, V109, P1534, DOI 10.1213/ane.0b013e3181b0500b
   Siatouni A, 2016, CLINICS PRACT, V6, P8, DOI 10.4081/cp.2016.840
   Stevens WR, 1997, SPINE, V22, P1319, DOI 10.1097/00007632-199706150-00008
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Youssoufa Maiga, 2013, BMC Res Notes, V6, P321, DOI 10.1186/1756-0500-6-321
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 58
EP 61
DI 10.1016/j.wneu.2019.07.186
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300090
PM 31376555
DA 2020-05-12
ER

PT J
AU Siddiqui, MI
   Hawksworth, SA
   Sun, DY
AF Siddiqui, Mehdi, I
   Hawksworth, Shane A.
   Sun, Derrick Y.
TI Removal of Migrating Lumbar Spine Bullet: Case Report and Surgical Video
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gunshot wound; Migrating bullet; Spinal cord and nerve root injury;
   Trauma
ID GUNSHOT INJURIES
AB BACKGROUND: Gunshot wounds to the spine are devastating injuries. Rarely, the bullet has been reported to migrate. Migration is associated with progressive neurologic deficits that often improve with bullet removal. The authors report a case of removal of a migrating lumbar spine bullet. This is supplemented by an operative video and a review of the literature.
   CASE DESCRIPTION: A 31-year-old man presented to the emergency department with multiple gunshot wounds and lower-extremity paresthesia. A ballistic injury occurred with an entry wound in the right posterior soft tissues, traversing the right paraspinal muscle and fracturing the left lumbar 5 pedicle and left lumbar 4 transverse process. The bullet was positioned within the spinal canal at the lumbar 3/4 interspace. His spinal injury was managed non-operatively due to his traumatic injuries and findings of minimal neurologic deficit without cerebrospinal fluid leak. The patient returned to the neurosurgery clinic a year later and was found to have worsening low back pain, decreased sensation throughout the left leg, and radiating pain throughout the right leg. Imaging demonstrated the bullet had migrated caudally to the midlumbar 5 vertebral body. Given the patient's progressive symptoms and migration of the bullet fragment, informed consent was obtained for a laminectomy and removal of the intradural bullet fragment.
   CONCLUSIONS: Neurosurgical treatment for gunshot wounds remains controversial. Cauda equina or lumbosacral level wounds are often incomplete and may improve with surgical decompression and bullet removal. Migrating bullet fragments throughout the spine and brain lead to worsened neurologic function, which can be reversed by removal. Movement of the bullet during surgery should be expected, and intraoperative fluoroscopy and patient positioning can help to properly localize the bullet and aid in its removal.
C1 [Siddiqui, Mehdi, I] Univ Texas Hlth Sci Ctr San Antonio, Long Sch Med, San Antonio, TX 78229 USA.
   [Sun, Derrick Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, San Antonio, TX 78229 USA.
   [Hawksworth, Shane A.] William Beaumont Army Med Ctr, Dept Neurosurg, El Paso, TX 79920 USA.
RP Hawksworth, SA (reprint author), William Beaumont Army Med Ctr, Dept Neurosurg, El Paso, TX 79920 USA.
EM hawksa3@gmail.com
OI Siddiqui, Mehdi/0000-0002-9432-5951
CR Baldawa S, 2017, EUR SPINE J, V26, pS128, DOI 10.1007/s00586-016-4913-6
   Bordon G, 2014, CASE REP ORTHOP, V2014
   Cheng JS, 2012, J NEUROSURG, V116, P921, DOI 10.3171/2011.12.JNS111047
   Choi Bryan D, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1485872
   de Barros TEP, 2014, SPINAL CORD, V52, P504, DOI 10.1038/sc.2014.56
   DESCHAMPS GT, 1991, J TRAUMA, V31, P293
   Farrugia A, 2010, J FORENSIC SCI, V55, P1371, DOI 10.1111/j.1556-4029.2010.01439.x
   Ghori SA, 2014, JCPSP-J COLL PHYSICI, V24, pS219, DOI 11.2014/JCPSP.S219S220
   Kafadar AM, 2006, SPINAL CORD, V44, P326, DOI 10.1038/sj.sc.3101808
   Kitchel SH, 2003, CLIN ORTHOP RELAT R, P115, DOI 10.1097/01.blo.0000053166.71678.86
   Moisi MD, 2015, GLOB SPINE J, V5, P523, DOI 10.1055/s-0035-1566231
   Rammo RA, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.06.015
   Sidhu GS, 2013, CLIN ORTHOP RELAT R, V471, P3945, DOI 10.1007/s11999-013-2901-2
   Singh Roop, 2010, Am J Orthop (Belle Mead NJ), V39, P116
   Vakil MT, 2017, EMERG RADIOL, V24, P301, DOI 10.1007/s10140-016-1477-z
   Yadav YR, 2006, NEUROL INDIA, V54, P453, DOI 10.4103/0028-3886.28138
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 62
EP 64
DI 10.1016/j.wneu.2019.07.151
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300091
PM 31356981
DA 2020-05-12
ER

PT J
AU Ghali, MGZ
   Srinivasan, VM
   Kan, P
AF Ghali, Michael George Zaki
   Srinivasan, Visish M.
   Kan, Peter
TI Focused Ultrasonography-Mediated Blood-Brain Barrier Disruption in the
   Enhancement of Delivery of Brain Tumor Therapies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Blood-brain barrier; Brain tumor; Chemotherapy; Disruption; Focused
   ultrasonography; Intra-arterial delivery; Microbubbles; Oncotherapy
ID NEUTRON-CAPTURE THERAPY; ULTRASOUND CONTRAST AGENT; TARGETED
   DRUG-DELIVERY; GLIOBLASTOMA-MULTIFORME; LIPOSOMAL DOXORUBICIN; MALIGNANT
   GLIOMA; RAT-BRAIN; GOLD NANOPARTICLES; MOUSE-BRAIN; TRANSCRANIAL
   ULTRASOUND
AB Glioblastoma is the most common intracranial malignancy in adults and carries a poor prognosis. Chemotherapeutic treatment figures prominently in the management of primary and recurrent disease. However, the blood-brain barrier presents a significant and formidable impediment to the entry of oncotherapeutic compounds to target tumor tissue. Several strategies have been developed to effect disruption of the blood-brain barrier and in turn enhance the efficacy of cytotoxic chemotherapy, as well as newly developed biologic agents. Focused ultrasonography is one such treatment modality, using acoustic cavitation of parenterally administered microbubbles to mechanically effect disruption of the vascular endothelium. We review and discuss the preclinical and clinical studies evaluating the biophysical basis for, and efficacy of, focused ultrasonography in the enhancement of oncotherapeutic agent delivery. Further, we provide some perspectives regarding future directions for the role of focused ultrasound in facilitating and improving the safe and effective delivery of oncotherapeutic agents in the treatment of glioblastoma.
C1 [Ghali, Michael George Zaki] Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.
   [Srinivasan, Visish M.; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Srinivasan, Visish M.; Kan, Peter] MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
RP Kan, P (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.; Kan, P (reprint author), MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
EM peter.kan@bcm.edu
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764
   Alkins R, 2013, CANCER RES, V73, P1892, DOI 10.1158/0008-5472.CAN-12-2609
   Alkins RD, 2013, NEURO-ONCOLOGY, V15, P1225, DOI 10.1093/neuonc/not052
   Alonso A, 2011, BRAIN RES, V1411, P9, DOI 10.1016/j.brainres.2011.07.006
   Alonso A, 2010, J CEREBR BLOOD F MET, V30, P1394, DOI 10.1038/jcbfm.2010.41
   Arvizo RR, 2013, P NATL ACAD SCI USA, V110, P6700, DOI 10.1073/pnas.1214547110
   Aryal M, 2015, J CONTROL RELEASE, V204, P60, DOI 10.1016/j.jconrel.2015.02.033
   Aryal M, 2015, PHYS MED BIOL, V60, P2511, DOI 10.1088/0031-9155/60/6/2511
   Barth RF, 2005, CLIN CANCER RES, V11, P3987, DOI 10.1158/1078-0432.CCR-05-0035
   Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044
   Barth RF, 2003, J NEURO-ONCOL, V62, P61
   Barth RF, 1997, CANCER RES, V57, P1129
   Bing KF, 2009, ULTRASOUND MED BIOL, V35, P1298, DOI 10.1016/j.ultrasmedbio.2009.03.012
   Black Keith L, 2004, Cancer Control, V11, P165
   Bodell WJ, 2007, NEURO-ONCOLOGY, V9, P12, DOI 10.1215/15228517-2006-014
   Bodell WJ, 2003, J NEURO-ONCOL, V62, P251, DOI 10.1023/A:1023383717833
   Boeckman HJ, 2005, MOL CANCER RES, V3, P277, DOI 10.1158/1541-7786.MCR-04-0032
   BROADWELL RD, 1982, SCIENCE, V217, P164, DOI 10.1126/science.7089551
   BURGER PC, 1987, MAYO CLIN PROC, V62, P527, DOI 10.1016/S0025-6196(12)65479-2
   Burgess A, 2012, SOC NEUROSCI, V876, P2
   Burgess A, 2014, RADIOLOGY, V273, P736, DOI 10.1148/radiol.14140245
   Burgess A, 2013, ACS CHEM NEUROSCI, V4, P519, DOI 10.1021/cn300191b
   Burgess A, 2012, J CONTROL RELEASE, V163, P125, DOI 10.1016/j.jconrel.2012.08.012
   Burgess A, 2012, PROC SPIE, V8226, DOI 10.1117/12.908826
   Burgess A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027877
   Butterworth KT, 2012, NANOSCALE, V4, P4830, DOI 10.1039/c2nr31227a
   Carpentier A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6086
   Caskey CF, 2007, J ACOUST SOC AM, V122, P1191, DOI 10.1121/1.2747204
   Chen SZ, 2015, ATOM SPECTROSC, V36, P153
   Choi JJ, 2011, J CEREBR BLOOD F MET, V31, P725, DOI 10.1038/jcbfm.2010.155
   Choi JJ, 2010, IEEE T BIO-MED ENG, V57, P145, DOI 10.1109/TBME.2009.2034533
   Chung YH, 2014, MOL PHARMACEUT, V11, P3904, DOI 10.1021/mp500296n
   Cloughesy TF, 1995, J NEURO-ONCOL, V26, P125, DOI 10.1007/BF01060218
   Coderre JA, 1999, RADIAT RES, V151, P1, DOI 10.2307/3579742
   Cohen-Inbar O, 2016, J THER ULTRASOUND, V4, DOI 10.1186/s40349-016-0046-y
   Coluccia D, 2018, NANOMED-NANOTECHNOL, V14, P1137, DOI 10.1016/j.nano.2018.01.021
   Coluccial D, 2014, J THER ULTRASOUND, V2, DOI [10.1186/2050-5736-217, 10.1186/2050-5736-2-17]
   Comenge J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047562
   CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627
   Czarnota GJ, 2012, P NATL ACAD SCI USA, V109, pE2033, DOI 10.1073/pnas.1200053109
   Dalecki D, 2004, ANNU REV BIOMED ENG, V6, P229, DOI 10.1146/annurev.bioeng.6.040803.140126
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Dean R L, 1999, Neuro Oncol, V1, P268, DOI 10.1093/neuonc/1.4.268
   Deng JM, 2012, J MOL NEUROSCI, V46, P677, DOI 10.1007/s12031-011-9629-9
   Detta A, 2009, CANCER RES, V69, P2126, DOI 10.1158/0008-5472.CAN-08-2345
   DEUTSCH M, 1989, INT J RADIAT ONCOL, V16, P1389, DOI 10.1016/0360-3016(89)90939-5
   Diaz AZ, 2003, J NEURO-ONCOL, V62, P101, DOI 10.1023/A:1023245123455
   Diaz RJ, 2014, NANOMED-NANOTECHNOL, V10, P1075, DOI 10.1016/j.nano.2013.12.006
   Doolittle ND, 2000, CANCER, V88, P637, DOI 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y
   Dreaden EC, 2012, THER DELIV, V3, P457, DOI 10.4155/TDE.12.21
   Elias WJ, 2012, AM ASS NEUR SURG 80
   Escoffre JM, 2011, MOL PHARMACEUT, V8, P799, DOI 10.1021/mp100397p
   Etame AB, 2012, NANOMED-NANOTECHNOL, V8, P1133, DOI 10.1016/j.nano.2012.02.003
   Ewing JR, 2006, J CEREBR BLOOD F MET, V26, P310, DOI 10.1038/sj.jcbfm.9600189
   Fan CH, 2019, ACS APPL MATER INTER, V11, P11144, DOI 10.1021/acsami.8b22468
   Fan CH, 2016, BIOMATERIALS, V106, P46, DOI 10.1016/j.biomaterials.2016.08.017
   Fan CH, 2013, BIOMATERIALS, V34, P2142, DOI 10.1016/j.biomaterials.2012.11.048
   Fan CH, 2012, ULTRASOUND MED BIOL, V38, DOI 10.1016/j.ultrasmedbio.2012.03.013
   Foye W. O., 1995, CANC CHEMOTHERAPEUTI
   GASPAR LE, 1992, INT J RADIAT ONCOL, V24, P55, DOI 10.1016/0360-3016(92)91021-E
   GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221
   GROOTHUIS DR, 1982, J NEUROPATH EXP NEUR, V41, P164, DOI 10.1097/00005072-198203000-00006
   Grossman SA, 2003, J CLIN ONCOL, V21, P1485, DOI 10.1200/JCO.2003.10.035
   GUMERLOCK MK, 1992, J NEURO-ONCOL, V12, P33
   HALPERIN EC, 1988, INT J RADIAT ONCOL, V15, P505, DOI 10.1016/S0360-3016(98)90036-0
   Hamstra DA, 2005, J NEURO-ONCOL, V73, P225, DOI 10.1007/s11060-004-5675-2
   HANIG JP, 1972, EUR J PHARMACOL, V18, P79, DOI 10.1016/0014-2999(72)90134-3
   Hansen S, 2018, J NEURO-ONCOL, V139, P479, DOI 10.1007/s11060-018-2892-7
   Henriksson R, 2008, RADIOTHER ONCOL, V88, P183, DOI 10.1016/j.radonc.2006.04.015
   Hong HY, 2008, J CELL MOL MED, V12, P2003, DOI 10.1111/j.1582-4934.2008.00189.x
   Hosseinkhah N, 2012, PHYS MED BIOL, V57, P785, DOI 10.1088/0031-9155/57/3/785
   Howles GP, 2010, MAGN RESON MED, V64, P995, DOI 10.1002/mrm.22411
   Huang Q, 2012, EXP NEUROL, V233, P350, DOI 10.1016/j.expneurol.2011.10.027
   Huang Y, 2011, INT SOC MAGN RESON M, P1738
   Huang YX, 2017, RADIOLOGY, V282, P123, DOI 10.1148/radiol.2016152154
   Husain SR, 1998, CANCER RES, V58, P3649
   Hynynen K, 2005, NEUROIMAGE, V24, P12, DOI 10.1016/j.neuroimage.2004.06.046
   Hynynen K, 2004, MAGN RESON MED, V52, P100, DOI 10.1002/mrm.20118
   Hynynen K, 2003, ACT NEUR S, V86, P555
   Hynynen K, 1998, ULTRASOUND MED BIOL, V24, P275, DOI 10.1016/S0301-5629(97)00269-X
   Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804
   Ivanov AI, 1998, J BIOL CHEM, V273, P14721, DOI 10.1074/jbc.273.24.14721
   Jacobs S, 2010, CANCER CHEMOTH PHARM, V65, P817, DOI 10.1007/s00280-009-1085-7
   Jalali S, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-114
   Jeanmonod D, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.10.FOCUS11248
   Joel DD, 1999, J NEURO-ONCOL, V41, P213, DOI 10.1023/A:1006176901713
   Joshi BH, 2001, CANCER RES, V61, P8058
   JUDY KD, 1995, J NEUROSURG, V82, P481, DOI 10.3171/jns.1995.82.3.0481
   Kang CS, 2009, TECHNOL CANCER RES T, V8, P61, DOI 10.1177/153303460900800108
   Kang JA, 2010, J ULTRAS MED, V29, P61, DOI 10.7863/jum.2010.29.1.61
   Khil MS, 2000, INT J RADIAT ONCOL, V47, P511, DOI 10.1016/S0360-3016(00)00428-4
   Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje
   Kim BYS, 2010, NEW ENGL J MED, V363, P2434, DOI 10.1056/NEJMra0912273
   Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103
   Kircher MF, 2012, NAT MED, V18, P829, DOI 10.1038/nm.2721
   Klotz AR, 2010, PHYS MED BIOL, V55, P1549, DOI 10.1088/0031-9155/55/6/001
   Kodama T, 1999, ULTRASOUND MED BIOL, V25, P977, DOI 10.1016/S0301-5629(99)00050-2
   Kovacs Z, 2014, J CONTROL RELEASE, V187, P74, DOI 10.1016/j.jconrel.2014.05.033
   Kovacs ZI, 2017, P NATL ACAD SCI USA, V114, pE75, DOI 10.1073/pnas.1614777114
   Krasovitski B, 2004, IEEE T ULTRASON FERR, V51, P973, DOI 10.1109/TUFFC.2004.1324401
   Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082
   Kumar A, 2014, ACS NANO, V8, P4205, DOI 10.1021/nn500152u
   Libutti SK, 2010, CLIN CANCER RES, V16, P6139, DOI 10.1158/1078-0432.CCR-10-0978
   Lidar Z, 2004, J NEUROSURG, V100, P472, DOI 10.3171/jns.2004.100.3.0472
   Liu HL, 2008, ULTRASOUND MED BIOL, V34, P598, DOI 10.1016/j.ultrasmedbio.2008.01.011
   Liu HL, 2016, RADIOLOGY, V281, P99, DOI 10.1148/radiol.2016152444
   Liu HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114311
   Liu HL, 2014, THERANOSTICS, V4, P432, DOI 10.7150/thno.8074
   Liu HL, 2010, P NATL ACAD SCI USA, V107, P15205, DOI 10.1073/pnas.1003388107
   Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699
   Lockman PR, 2010, CLIN CANCER RES, V16, P5664, DOI 10.1158/1078-0432.CCR-10-1564
   Luo ZM, 2017, ACS APPL MATER INTER, V9, P31612, DOI 10.1021/acsami.7b10866
   Marquet F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084310
   Matsukado K, 1998, BRAIN RES, V792, P10, DOI 10.1016/S0006-8993(97)01502-3
   McDannold N, 2005, ULTRASOUND MED BIOL, V31, P1527, DOI 10.1016/j.ultrasmedbio.2005.07.010
   Mcdannold N, 2008, ULTRASOUND MED BIOL, V34, P930, DOI 10.1016/j.ultrasmedbio.2007.11.009
   McDannold N, 2007, ULTRASOUND MED BIOL, V33, P584, DOI 10.1016/j.ultrasmedbio.2006.10.004
   McDannold N, 2012, CANCER RES, V72, P3652, DOI 10.1158/0008-5472.CAN-12-0128
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Meijering BDM, 2009, CIRC RES, V104, P679, DOI 10.1161/CIRCRESAHA.108.183806
   Mesiwala AH, 2002, ULTRASOUND MED BIOL, V28, P389, DOI 10.1016/S0301-5629(01)00521-X
   Mjos KD, 2014, CHEM REV, V114, P4540, DOI 10.1021/cr400460s
   Moffat BA, 2006, NEOPLASIA, V8, P259, DOI 10.1593/neo.05844
   Monteith S, 2013, J NEUROSURG, V118, P215, DOI 10.3171/2012.10.JNS12449
   Morris GM, 2004, APPL RADIAT ISOTOPES, V61, P917, DOI 10.1016/j.apradiso.2004.05.007
   Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861
   Netti PA, 1999, P NATL ACAD SCI USA, V96, P3137, DOI 10.1073/pnas.96.6.3137
   NEUWELT EA, 1982, P NATL ACAD SCI-BIOL, V79, P4420, DOI 10.1073/pnas.79.14.4420
   NEUWELT EA, 1986, NEUROSURGERY, V19, P573, DOI 10.1227/00006123-198610000-00011
   NEUWELT EA, 1985, CANCER RES, V45, P2827
   NEUWELT EA, 1986, CANCER, V58, P1609, DOI 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO;2-7
   NEWMAN WC, 2016, NEUROSURGERY, V79
   Nonaka M, 2009, ANTICANCER RES, V29, P943
   O'Reilly MA, 2012, INT J HYPERTHER, V28, P386, DOI 10.3109/02656736.2012.666709
   O'Reilly MA, 2012, RADIOLOGY, V263, P96, DOI 10.1148/radiol.11111417
   O'Reilly MA, 2011, ULTRASOUND MED BIOL, V37, P587, DOI 10.1016/j.ultrasmedbio.2011.01.008
   Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337
   Ohl CD, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.214502
   Ohmura T, 2011, ANTICANCER RES, V31, P2527
   Pan M, 2018, J BIOMED NANOTECHNOL, V14, P2031, DOI 10.1166/jbn.2018.2642
   Pardridge William M, 2005, NeuroRx, V2, P3
   Park J, 2012, J CONTROL RELEASE, V162, P134, DOI 10.1016/j.jconrel.2012.06.012
   Parney IF, 2005, J NEUROSURG, V102, P267, DOI 10.3171/jns.2005.102.2.0267
   Quadri SA, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.11.FOCUS17610
   Ragin AD, 2002, CHEM BIOL, V9, P943, DOI 10.1016/S1074-5521(02)00189-8
   Rainov NG, 2006, REV RECENT CLIN TRIA, V1, P119, DOI 10.2174/157488706776876454
   Sampson JH, 2007, NEUROSURGERY, V60, P89, DOI 10.1227/01.NEU.0000249256.09289.5F
   SHAPIRO WR, 1992, J NEUROSURG, V76, P772, DOI 10.3171/jns.1992.76.5.0772
   Sheikov N, 2004, ULTRASOUND MED BIOL, V30, P979, DOI 10.1016/j.ultrasmedbio.2004.04.010
   Sheikov N, 2008, ULTRASOUND MED BIOL, V34, P1093, DOI 10.1016/j.ultrasmedbio.2007.12.015
   Shen YY, 2016, ULTRASOUND MED BIOL, V42, P1499, DOI 10.1016/j.ultrasmedbio.2016.01.019
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Skold K, 2010, BRIT J RADIOL, V83, P596, DOI 10.1259/bjr/56953620
   Smith DR, 2001, CANCER RES, V61, P8179
   Strumberg D, 2002, ANN ONCOL, V13, P229, DOI 10.1093/annonc/mdf058
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Suehiro S, 2018, J NEUROSURG, V129, P1416, DOI 10.3171/2017.6.JNS162398
   Szerlip N, 2011, J NEURO-ONCOL, V103, P111, DOI 10.1007/s11060-010-0358-7
   Thevenot E, 2012, HUM GENE THER, V23, P1144, DOI 10.1089/hum.2012.013
   Timbie KF, 2017, J CONTROL RELEASE, V263, P120, DOI 10.1016/j.jconrel.2017.03.017
   Ting CY, 2012, BIOMATERIALS, V33, P704, DOI 10.1016/j.biomaterials.2011.09.096
   Tralins KS, 2002, J NUCL MED, V43, P1667
   Treat LH, 2007, INT J CANCER, V121, P901, DOI 10.1002/ijc.22732
   Treat LH, 2012, ULTRASOUND MED BIOL, V38, P1716, DOI 10.1016/j.ultrasmedbio.2012.04.015
   Urien S, 2004, BRIT J CLIN PHARMACO, V57, P756, DOI 10.1111/j.1365-2125.2004.02082.x
   van Wamel A, 2006, J CONTROL RELEASE, V112, P149, DOI 10.1016/j.jconrel.2006.02.007
   Vega Rafael A, 2016, Neurosurgery, V63 Suppl 1, P210, DOI 10.1227/01.neu.0000489858.08559.c8
   Vlachos F, 2011, MAGN RESON MED, V66, P821, DOI 10.1002/mrm.22848
   VYKHODTSEVA NI, 1995, ULTRASOUND MED BIOL, V21, P969, DOI 10.1016/0301-5629(95)00038-S
   WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303
   Wei KC, 2013, AM J NEURORADIOL, V34, P115, DOI 10.3174/ajnr.A3150
   Wei KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058995
   Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79
   White PJ, 2006, ULTRASOUND MED BIOL, V32, P1085, DOI 10.1016/j.ultrasmedbio.2006.03.015
   White PJ, 2006, PHYS MED BIOL, V51, P2293, DOI 10.1088/0031-9155/51/9/013
   Xie F, 2008, ULTRASOUND MED BIOL, V34, P2028, DOI 10.1016/j.ultrasmedbio.2008.05.004
   Yang FY, 2015, ONCOTARGET, V6, P36260, DOI 10.18632/oncotarget.5389
   Yang FY, 2013, IEEE ENG MED BIO, P6289, DOI 10.1109/EMBC.2013.6610991
   Yang FY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092910
   Yang FY, 2012, FUTURE ONCOL, V8, P1361, DOI [10.2217/FON.12.118, 10.2217/fon.12.118]
   Yang FY, 2012, J CONTROL RELEASE, V160, P652, DOI 10.1016/j.jconrel.2012.02.023
   Yang FY, 2012, INT J NANOMED, V7, P965, DOI 10.2147/IJN.S29229
   Yang FY, 2012, INT J NANOMED, V7, P723, DOI 10.2147/IJN.S28503
   Yang FY, 2011, IEEE T ULTRASON FERR, V58, P964, DOI 10.1109/TUFFC.2011.1897
   Yang FY, 2011, J NUCL MED, V52, P478, DOI 10.2967/jnumed.110.083071
   Yang FY, 2011, J CONTROL RELEASE, V150, P111, DOI 10.1016/j.jconrel.2010.10.038
   Yang FY, 2009, J ACOUST SOC AM, V126, P3344, DOI 10.1121/1.3242376
   Yang FS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037196
   Yoshida M, 2019, ULTRASOUND MED BIOL, V45, P526, DOI 10.1016/j.ultrasmedbio.2018.10.016
   Zhao GJ, 2018, CANCER LETT, V418, P147, DOI 10.1016/j.canlet.2018.01.035
   Zhao YL, 2018, J BIOL REG HOMEOS AG, V32, P655
NR 193
TC 1
Z9 1
U1 7
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 65
EP 75
DI 10.1016/j.wneu.2019.07.096
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300092
PM 31323404
DA 2020-05-12
ER

PT J
AU Wild, E
   Barry, J
   Sun, H
AF Wild, Elizabeth
   Barry, James
   Sun, Hai
TI Targeted Stereotactic Radiosurgery for Arteriovenous Malformation
   Downgrading Followed by Microsurgical Resection: A Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformation; Downgrade; Microsurgical; Radiosurgery;
   Resection; Stereotactic
ID BRAIN; HEMORRHAGE; ARUBA; RISK
AB BACKGROUND: An unruptured brain arteriovenous malformation (bAVM) is a pathological entity with the potential to lead to disabling or fatal intracranial hemorrhage. The treatment approaches for these lesions have included microsurgical resection, endovascular embolization, stereotactic radiosurgery (SRS), and medical management or any combination of these modalities. However, the optimal treatment approach for unruptured bAVMs has not yet been determined. In the present case, we used SRS strategically to down-tirade an AVM to allow for improved resectability.
   CASE DESCRIPTION: A 28-year-old woman had presented with 10 years of headches and was found to have a Spetzler-Martin grade IV AVM not amenable to resection. She underwent targeted SRS only of the deep portions of the AVM, resulting in a decrease of the AVM to grade III. Subsequent microsurgical resection was successful in complete removal of the AVM. At the 1-year follow up examination she had no deficits.
   CONCLUSIONS: We have proposed a protocol of using focused SRS to eliminate the portions of the AVM that confer an increased surgical risk. SRS, followed by microsurgical resection, could represent an optimal treatment strategy for high-grade AVMs with difficult surgical anatomy.
C1 [Wild, Elizabeth; Barry, James; Sun, Hai] Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Shreveport, LA 71105 USA.
RP Barry, J (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Shreveport, LA 71105 USA.
EM jamesbarrymd@gmail.com
OI Sun, Hai/0000-0001-8878-8776
CR Abla AA, 2015, J NEUROSURG, V122, P419, DOI 10.3171/2014.10.JNS1424
   Asgari S, 2010, NEUROSURG REV, V33, P53, DOI 10.1007/s10143-009-0216-2
   Firlik AD, 1998, NEUROSURGERY, V43, P1223, DOI 10.1097/00006123-199811000-00124
   Halim AX, 2004, STROKE, V35, P1697, DOI 10.1161/01.STR.0000130988.44824.29
   Laakso A, 2011, NEUROSURGERY, V68, P372, DOI 10.1227/NEU.0b013e3181ffe931
   Lang M, 2018, NEUROSURGERY, V83, P548, DOI 10.1093/neuros/nyx506
   Magro E, 2017, J NEUROSURG, V126, P486, DOI 10.3171/2015.6.JNS15619
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Morgan MK, 2017, ACTA NEUROCHIR, V159, P1457, DOI 10.1007/s00701-017-3217-x
   Patibandla MR, 2018, J NEUROSURG, V129, P498, DOI 10.3171/2017.3.JNS162635
   Rutledge WC, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14242
   Schramm J, 2017, J NEUROSURG, V126, P1056, DOI 10.3171/2016.4.JNS153017
   Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87
   Steinberg GK, 1996, J NEUROSURG, V84, P920, DOI 10.3171/jns.1996.84.6.0920
   Wong J, 2017, STROKE, V48, P136, DOI 10.1161/STROKEAHA.116.014660
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 82
EP 86
DI 10.1016/j.wneu.2019.07.170
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300096
PM 31369878
DA 2020-05-12
ER

PT J
AU de Souza, JM
   Aiex, CA
   Canedo, NHS
   Marques, SA
   Martinez, AMB
AF de Souza, Jorge Marcondes
   Aiex, Camilo Abud
   Silva Canedo, Nathalie Henriques
   Marques, Suelen Adriani
   Blanco Martinez, Ana Maria
TI Intraaxial and Extraaxial Cavernous Malformation with Venous Linkage:
   Immune Cellular Inflammation Associated with Aggressiveness
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral cavernous malformation; Immune response; Inflammation
AB BACKGROUND: Intraorbital and intracerebral cavernous malformation (CM)lesions are considered independent entities. Purely cerebral CMs have variable biology with recent evidence depicting inflammation as an important player and a risk factor for aggressiveness. We describe a case of concomitant left intra-axial and extraaxial CMs, linked by the ipsilateral basal vein, where the extraaxial component has developed an aggressive behavior.
   CASE DESCRIPTION: A 35-year-old female patient presented with a rapid and exophthalmos and loss of vision on the left eye. Cranial magnetic resonance and angiography examinations demonstrated a left craniofacial CM and large intraorbital component. The lesion was connected through a large basal vein to a cerebral intraventricular CM. Transconjunctival resection showed typical findings of CM. A complete histopathology and immunostaining analysis was performed and revealed a clear acute lymphomononuclear reaction with a predominant immune cellular inflammation.
   CONCLUSIONS: A case of intraorbital and extracranial cavernomatous mass, connected to a cerebral intraventricular CM through a large basal vein, has presented with an aggressive course. A complete histopathologic and immunohistochemical analysis of the orbital mass has pictured a clear immune-cellular inflammatory reaction adding to the amounting evidence of association between inflammation and site aggressiveness in the setting of CMs.
C1 [de Souza, Jorge Marcondes; Aiex, Camilo Abud] Univ Fed Rio de Janeiro, Dept Neurosurg, Neurosurg Serv HUCFF, Rio De Janeiro, Brazil.
   [de Souza, Jorge Marcondes; Aiex, Camilo Abud] Univ Fed Rio de Janeiro, Grad Program Surg Sci, Rio de Janeiro, Brazil.
   [Silva Canedo, Nathalie Henriques; Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Dept Pathol, HUCFF, Rio De Janeiro, Brazil.
   [Silva Canedo, Nathalie Henriques; Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Dept Pathol, Grad Program Pathol, Rio De Janeiro, Brazil.
   [Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Neurodegenerat & Repair Lab, Rio de Janeiro, Brazil.
   [Marques, Suelen Adriani] Univ Fed Fluminense, Grad Program Neurosci, Dept Neurobiol, Niteroi, RJ, Brazil.
RP de Souza, JM (reprint author), Univ Fed Rio de Janeiro, Dept Neurosurg, Neurosurg Serv HUCFF, Rio De Janeiro, Brazil.; de Souza, JM (reprint author), Univ Fed Rio de Janeiro, Grad Program Surg Sci, Rio de Janeiro, Brazil.
EM jormarcondes@gmail.com
RI MARTINEZ, Ana/AAE-8358-2019
CR Abdulrauf SI, 1999, NEUROSURGERY, V44, P41, DOI 10.1097/00006123-199901000-00020
   Batra S, 2009, NAT REV NEUROL, V5, P659, DOI 10.1038/nrneurol.2009.177
   Choudhri Omar, 2014, Surg Neurol Int, V5, pS148, DOI 10.4103/2152-7806.134810
   Dammann P, 2017, J NEUROSURG, V126, P570, DOI 10.3171/2016.2.JNS152322
   Girard R, 2018, CIRC RES, V122, P1716, DOI 10.1161/CIRCRESAHA.118.312680
   Hejazi N, 1999, NEUROSURG REV, V22, P28, DOI 10.1007/s101430050005
   Kumar S, 2019, J STROKE CEREBROVASC, V28, P1662, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.025
   Scheuerle AF, 2004, AM J OPHTHALMOL, V138, P237, DOI 10.1016/j.ajo.2004.03.011
   Shi C, 2007, J NEUROSURG, V107, P1023, DOI 10.3171/JNS-07/11/1023
   Shi CB, 2014, J NEUROIMMUNOL, V272, P67, DOI 10.1016/j.jneuroim.2014.04.016
   Shi CB, 2009, STROKE, V40, P1659, DOI 10.1161/STROKEAHA.108.538769
   Yan JH, 2014, J CRANIOFAC SURG, V25, pE348, DOI 10.1097/SCS.0000000000000774
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 87
EP 89
DI 10.1016/j.wneu.2019.07.145
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300097
PM 31356970
DA 2020-05-12
ER

PT J
AU Ricard, JA
   Cramer, SW
   Charles, R
   Tommee, CG
   Le, A
   Bell, WR
   Chen, CC
   Flanagan, ME
AF Ricard, Jocelyn A.
   Cramer, Samuel W.
   Charles, River
   Tommee, Carolina Gil
   Le, An
   Bell, W. Robert
   Chen, Clark C.
   Flanagan, Margaret E.
TI Intratentorial Glioblastoma Metastasis to Bone
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma multiforme; Isocitrate dehydrogenase (IDH1/IDH2);
   Metastasis; Spine
ID CENTRAL-NERVOUS-SYSTEM; INFRATENTORIAL GLIOBLASTOMA; EXTRANEURAL
   METASTASES; MULTIFORME; GLIOMAS; MUTATIONS; IDH1
AB BACKGROUND: Glioblastoma multiforme (GBM) is a rapid-growing central nervous system neoplasm. We report a case of GBM with extensive intra-medullary lumbar drop metastasis and highly unusual osseous spine metastasis from a primary infratentorial GBM occurring 10 years after the initial diagnosis, which to our knowledge has not been described previously.
   CASE DESCRIPTION: This 37-year-old man presented with new-onset head-aches of increasing severity. Brain magnetic resonance imaging (MRI) demonstrated a heterogeneously enhancing mass in the left superior temporal lobe with adjacent edema. The lesion was initially biopsied in December 2006 and diagnosed as GBM (World Health Organization grade IV) with characteristic features of a highly cellular infiltrating glial neoplasm with nuclear pleomorphism, abundant microvascular proliferation, and abundant necrosis with pseudopalisading nuclei. Ki-67 immunostaining revealed that 15%-20% tumor cell nuclei were positive, indicating a high proliferative index. Histologically, this neoplasm demonstrated characteristic "cell wrapping." Immunoreactivity was variably but strongly positive for glial fibrillary acidic protein in neoplastic cells. In 2018, additional MRI revealed disease throughout the spine and bone biopsy of the thoracic spine showed the same glial neoplasm with primitive neuroectodermal tumor-like components (GBM-PNET).
   CONCLUSIONS: This case is meant to highlight that, although rare, infratentorial GBM-PNET has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and may metastasize to the spine years after the initial diagnosis despite the likely better prognosis.
C1 [Ricard, Jocelyn A.; Charles, River; Tommee, Carolina Gil; Le, An; Bell, W. Robert; Flanagan, Margaret E.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [Cramer, Samuel W.; Chen, Clark C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Ricard, JA (reprint author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
EM ricar029@umn.edu
CR Alifieris C, 2015, PHARMACOL THERAPEUT, V152, P63, DOI 10.1016/j.pharmthera.2015.05.005
   Beauchesne Patrick, 2011, Cancers (Basel), V3, P461, DOI 10.3390/cancers3010461
   Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083
   Chen JR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002583
   Choi PP, 2006, CAN MED ASSOC J, V175, P475, DOI 10.1503/cmaj.060308
   Cohen AL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0345-4
   Davis L, 1928, Ann Surg, V87, P8
   deSouza RM, 2016, BRIT J CANCER, V114, pE20, DOI 10.1038/bjc.2016.134
   Goodwin CR, 2016, WORLD NEUROSURG, V89, P578, DOI 10.1016/j.wneu.2015.11.061
   HOFFMAN HJ, 1985, CANCER, V56, P1778, DOI 10.1002/1097-0142(19851001)56:7+<1778::AID-CNCR2820561309>3.0.CO;2-I
   KOPELSON G, 1982, INT J RADIAT ONCOL, V8, P999, DOI 10.1016/0360-3016(82)90167-5
   Kuo Keng-Liang, 2015, Asian J Neurosurg, V10, P268, DOI 10.4103/1793-5482.161170
   Lee SC, 2018, ARCH PATHOL LAB MED, V142, P804, DOI 10.5858/arpa.2017-0449-RA
   Lemonnier F, 2016, P NATL ACAD SCI USA, V113, P15084, DOI 10.1073/pnas.1617929114
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lun M, 2011, J NEURO-ONCOL, V105, P261, DOI 10.1007/s11060-011-0575-8
   NEWTON HB, 1992, CANCER, V69, P2149, DOI 10.1002/1097-0142(19920415)69:8<2149::AID-CNCR2820690822>3.0.CO;2-G
   Opstad KS, 2004, J MAGN RESON IMAGING, V20, P187, DOI 10.1002/jmri.20093
   Perry A, 2009, BRAIN PATHOL, V19, P81, DOI 10.1111/j.1750-3639.2008.00167.x
   Reifenberger G, 2014, INT J CANCER, V135, P1822, DOI 10.1002/ijc.28836
   Roy S, 2015, SOUTH ASIAN J CANCER, V4, P163, DOI 10.4103/2278-330X.175953
   Rulseh AM, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-220
   SILBERGELD DL, 1991, J NEURO-ONCOL, V10, P179, DOI 10.1007/BF00146880
   Sizoo EM, 2010, NEURO-ONCOLOGY, V12, P1162, DOI 10.1093/neuonc/nop045
   Tateishi K, 2017, NEUROSURGERY, V64, P134, DOI 10.1093/neuros/nyx247
   Wankowicz Pawel, 2014, Ann Acad Med Stetin, V60, P40
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 90
EP 94
DI 10.1016/j.wneu.2019.07.142
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300098
PM 31356980
DA 2020-05-12
ER

PT J
AU Oich, Y
   Toda, H
   Yamagishi, K
   Tsujimoto, Y
AF Oich, Yuki
   Toda, Hiroki
   Yamagishi, Koji
   Tsujimoto, Yoshitaka
TI Multiple Spinal Chronic Subdural Hematomas Associated with Thoracic
   Hematomyelia: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Chronic subdural hematoma; Hematomyelia; Spinal subdural
   hematoma; Warfarin
ID MIMICKING INTRADURAL TUMOR; RARE CAUSE; LUMBAR; CONCURRENT; PATIENT
AB BACKGROUND: Chronic subdural hematoma (CSDH) is uncommon in the spine. Most spinal CSDHs occur as solitary lesions in the lumbosacral region. We report a rare case of multiple spinal CSDHs associated with hematomyelia. The diagnostic and therapeutic management of these complex spinal CSDHs is reviewed as well as the pertinent literature.
   CASE DESCRIPTION: A 79-year-old woman on warfarin therapy presented with lower back pain and progressive lower extremity weakness that had developed in the previous 2 weeks. She subsequently developed paraplegia and urinary incontinence. Thoracolumbar magnetic resonance imaging showed a CSDH from T12-L3 compressing the cauda equina. Single-shot whole-spine magnetic resonance imaging showed another CSDH and hematomyelia at T2-3. She underwent L2-3 hemilaminectomy, which revealed a liquefied subdural hematoma. Delayed T2 laminectomy exposed an organized subdural hematoma and xanthochromic hematomyelia. After each surgery, the patient showed significant motor recovery. Finally, the patient could walk, and the urinary catheter was removed.
   CONCLUSIONS: Spinal CSDH may occur in multiple regions and may be associated with hematomyelia. Whole-spine magnetic resonance imaging is useful to examine the entire spine for CSDH accurately and thoroughly. Comprehensive surgical exploration of all symptomatic hematomas may restore neurologic functions even with delayed surgery.
C1 [Oich, Yuki; Toda, Hiroki; Tsujimoto, Yoshitaka] Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
   [Yamagishi, Koji] Fukui Red Cross Hosp, Dept Rehabil, Fukui, Japan.
RP Toda, H (reprint author), Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
EM htoda-nsu@umin.ac.jp
OI Toda, Hiroki/0000-0002-1596-4131
CR Abla AA, 2000, NEUROSURG CLIN N AM, V11, P465, DOI 10.1016/S1042-3680(18)30109-8
   Abuzayed B, 2009, TURK NEUROSURG, V19, P189
   Akiyama Y, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2016.11.128
   BRANDT RA, 1980, SURG NEUROL, V13, P121
   Braun P, 2007, EUR J RADIOL, V64, P119, DOI 10.1016/j.ejrad.2007.02.014
   CHAVES CJ, 1993, SURG NEUROL, V40, P435, DOI 10.1016/0090-3019(93)90227-R
   Cho DC, 2009, J SPINAL DISORD TECH, V22, P73, DOI 10.1097/BSD.0b013e31816d6546
   Diyora B, 2009, NEUROL MED-CHIR, V49, P310, DOI 10.2176/nmc.49.310
   Domenicucci M, 1999, J NEUROSURG, V91, P65, DOI 10.3171/spi.1999.91.1.0065
   Friday RY, 1999, J NATL MED ASSOC, V91, P289
   Golden N, 2019, WORLD NEUROSURG, V123, P343, DOI 10.1016/j.wneu.2018.12.053
   Hagihara N, 2010, NEUROL MED-CHIR, V50, P333, DOI 10.2176/nmc.50.333
   Hamaguchi Hiroyuki, 2008, Orthopedics, V31, P715
   Ichinose D, 2018, NEUROL MED-CHIR, V58, P178, DOI 10.2176/nmc.cr.2017-0177
   Ishikawa Y, 2016, GLOB SPINE J, V6, pE1, DOI 10.1055/s-0035-1549030
   Jain V, 2008, SINGAP MED J, V49, pE53
   Ji GY, 2013, J KOREAN NEUROSURG S, V54, P515, DOI 10.3340/jkns.2013.54.6.515
   Jibu KJ, 2012, J NEUROSCI RURAL PRA, V3, P97, DOI 10.4103/0976-3147.91977
   Jimbo H, 2006, SPINE, V31, pE184, DOI 10.1097/01.brs.0000202760.30257.88
   Kahraman S, 2003, J PAIN, V4, P471, DOI 10.1067/S1526-5900(03)00732-6
   Kanamaru H, 2016, CASE REP NEUROL, V8, P72, DOI 10.1159/000445709
   KHOSLA VK, 1985, J NEUROSURG, V63, P636, DOI 10.3171/jns.1985.63.4.0636
   Kim Hyeun Sung, 2017, Surg Neurol Int, V8, P231, DOI 10.4103/sni.sni_262_17
   Kim Hyun Gon, 2014, Korean J Neurotrauma, V10, P146, DOI 10.13004/kjnt.2014.10.2.146
   Kim K, 2010, NEUROL MED-CHIR, V50, P402, DOI 10.2176/nmc.50.402
   Kim MS, 2015, J KOREAN NEUROSURG S, V58, P397, DOI 10.3340/jkns.2015.58.4.397
   Kokubo R, 2014, J NEUROSURG-SPINE, V20, P157, DOI 10.3171/2013.10.SPINE13346
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   Kwon O Ik, 2015, Korean J Spine, V12, P207, DOI 10.14245/kjs.2015.12.3.207
   LANGMAYR JJ, 1995, J NEUROL NEUROSUR PS, V59, P442, DOI 10.1136/jnnp.59.4.442
   Leber KA, 1997, J NEUROSURG, V87, P644, DOI 10.3171/jns.1997.87.4.0644
   Lecouvet FE, 2003, J COMPUT ASSIST TOMO, V27, P530, DOI 10.1097/00004728-200307000-00013
   LEVY JM, 1990, AM J NEURORADIOL, V11, P780
   Lin JC, 2014, J EMERG MED, V47, P552, DOI 10.1016/j.jemermed.2014.06.030
   Ma HyunJin, 2012, Korean J Spine, V9, P41, DOI 10.14245/kjs.2012.9.1.41
   Ma Z, 2015, INT J CARDIOL, V195, P61, DOI 10.1016/j.ijcard.2015.05.083
   Matsumoto H, 2016, WORLD NEUROSURG
   Moon W, 2013, J KOREAN NEUROSURG S, V54, P68, DOI 10.3340/jkns.2013.54.1.68
   Morishige M, 2007, ACTA NEUROCHIR, V149, P1081, DOI 10.1007/s00701-007-1256-4
   Nagashima H, 2010, BRIT J NEUROSURG, V24, P537, DOI 10.3109/02688691003656119
   Panciani PP, 2014, BMJ CASE REP, V2014, P1
   Park DH, 2008, NEUROL MED-CHIR, V48, P231, DOI 10.2176/nmc.48.231
   REINSEL TE, 1993, J SPINAL DISORD, V6, P62
   RUSSELL NA, 1983, SURG NEUROL, V20, P133, DOI 10.1016/0090-3019(83)90464-0
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Shimada Y, 1996, SKELETAL RADIOL, V25, P477, DOI 10.1007/s002560050118
   Shimada Y, 2006, TOHOKU J EXP MED, V210, P83, DOI 10.1620/tjem.210.83
   Siddiqi F, 2005, J CLIN NEUROSCI, V12, P949, DOI 10.1016/j.jocn.2004.10.019
   Su YF, 2004, SPINAL CORD, V42, P717, DOI 10.1038/sj.sc.3101643
   Tillich M, 1999, NEURORADIOLOGY, V41, P137, DOI 10.1007/s002340050719
   Toda H, 2014, CLIN NEUROL NEUROSUR, V125, P75, DOI 10.1016/j.clineuro.2014.07.023
   Treister DS, 2014, CASE REP RADIOL, V2014
   Uto T, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012479
   Wang US, 2012, J KOREAN NEUROSURG S, V51, P237, DOI 10.3340/jkns.2012.51.4.237
   Wurm G, 1996, NEUROSURG REV, V19, P113, DOI 10.1007/BF00418081
   Yamaguchi S, 2005, NEUROL MED-CHIR, V45, P645, DOI 10.2176/nmc.45.645
   Yang MS, 2009, J FORMOS MED ASSOC, V108, P258, DOI 10.1016/S0929-6646(09)60061-9
NR 57
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 95
EP 103
DI 10.1016/j.wneu.2019.07.209
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300099
PM 31394354
DA 2020-05-12
ER

PT J
AU Dowd, RS
   Nail, TJ
   Arkun, K
   Kryzanski, J
   Soto, O
   Fogaren, T
   Harrington, K
   Patel, A
   Comenzo, R
   Riesenburger, RI
AF Dowd, Richard S.
   Nail, T. Jayde
   Arkun, Knarik
   Kryzanski, James
   Soto, Oscar
   Fogaren, Teresa
   Harrington, Kelly
   Patel, Ayan
   Comenzo, Raymond
   Riesenburger, Ron, I
TI Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with
   Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac
   Tissue with Bilateral Carpal Tunnel Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Amyloidosis; Cardiac amyloidosis; Carpal tunnel syndrome; Heart failure;
   Ligamentum flavum; Lumbar stenosis
ID LUMBAR; COMPLICATIONS
AB BACKGROUND: Transthyretin wild-type (ATTRwt) amyloidosis is a systemic process resulting in deposition of misfolded transthyretin protein in several different tissues throughout the body. It is known to be a cause of progressive, life-threatening cardiomyopathy and lumbar spinal stenosis and carpal tunnel syndrome.
   CASE DESCRIPTION: Here we present the case of a 71-year-old man who has clinical manifestations of all 3 entities over several years, providing a picture of the natural history of ATTRwt amyloidosis. This patient eventually underwent a heart transplant because of progressive cardiac amyloidosis (CA) resulting in end-stage heart failure. However, symptoms in carpal tunnel and lumbar spine manifested years before the symptoms of heart failure. ATTRwt amyloidosis may present as a clinical triad of lumbar stenosis, carpal tunnel syndrome, and heart failure. Recently developed medications have shown efficacy in slowing the progress of systemic and cardiac amyloidosis.
   CONCLUSIONS: Knowing that extracardiac symptoms may occur first, we propose that sending ligamentum flavum and flexor tenosynovium for pathologic evaluation may be a unique opportunity to screen and treat a population of patients at risk for developing CA and heart failure.
C1 [Dowd, Richard S.; Nail, T. Jayde; Kryzanski, James; Harrington, Kelly; Riesenburger, Ron, I] Tufts Med Ctr Boston, Dept Neurol Surg, Boston, MA 02111 USA.
   [Arkun, Knarik] Tufts Med Ctr Boston, Dept Pathol, Boston, MA USA.
   [Soto, Oscar] Tufts Med Ctr Boston, Dept Neurol, Boston, MA USA.
   [Fogaren, Teresa; Comenzo, Raymond] Tufts Med Ctr Boston, Dept Hematol & Oncol, Boston, MA USA.
   [Patel, Ayan] Tufts Med Ctr Boston, Dept Cardiol, Boston, MA USA.
RP Riesenburger, RI (reprint author), Tufts Med Ctr Boston, Dept Neurol Surg, Boston, MA 02111 USA.
EM rriesenburger@tuftsmedicalcenter.org
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   Benson MD, 2018, NEW ENGL J MED, V379, P22, DOI 10.1056/NEJMoa1716793
   Cyrille NB, 2014, AM J CARDIOL, V114, P1089, DOI 10.1016/j.amjcard.2014.07.026
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Karl JW, 2016, ORTHOP CLIN N AM, V47, P425, DOI 10.1016/j.ocl.2015.09.015
   Katz JN, 2008, NEW ENGL J MED, V358, P818, DOI 10.1056/NEJMcp0708097
   Maurer MS, 2018, NEW ENGL J MED, V379, P1007, DOI 10.1056/NEJMoa1805689
   Sekijima Y, 2018, AMYLOID, V25, P8, DOI 10.1080/13506129.2017.1409706
   Siddiqi OK, 2018, TRENDS CARDIOVAS MED, V28, P10, DOI 10.1016/j.tcm.2017.07.004
   Sperry BW, 2018, J AM COLL CARDIOL, V72, P2040, DOI 10.1016/j.jacc.2018.07.092
   Sueyoshi T, 2011, HUM PATHOL, V42, P1259, DOI 10.1016/j.humpath.2010.11.017
   Teerlink JR, 2017, HEART FAIL SOC AM SE
   Westermark P, 2014, UPSALA J MED SCI, V119, P223, DOI 10.3109/03009734.2014.895786
   Yanagisawa A, 2015, MODERN PATHOL, V28, P201, DOI 10.1038/modpathol.2014.102
   Yokoyama T, 2018, BIOL PHARM BULL, V41, P979, DOI 10.1248/bpb.b18-00166
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 104
EP 107
DI 10.1016/j.wneu.2019.07.172
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300100
PM 31369882
DA 2020-05-12
ER

PT J
AU Arslan, A
   Cavus, G
   Bilgin, E
   Okten, AI
   Gezercan, Y
   Atmis, A
   Celik, U
AF Arslan, Ali
   Cavus, Gokhan
   Bilgin, Emre
   Okten, Ali Ihsan
   Gezercan, Yurdal
   Atmis, Anil
   Celik, Umit
TI Brucella Case That Led to Atlantoaxial Spinal Instability in Childhood
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial; Brucella; Pediatrics; Spine; Surgical treatment;
   Tuberculosis
ID OSTEOARTICULAR COMPLICATIONS; EPIDURAL ABSCESS; SUBLUXATION; SECONDARY
AB BACKGROUND: Atlantoaxial subluxation caused by Brucella infection is rarely seen in children.
   CASE DESCRIPTION: C1-C2 dislocation, erosion in the odontoid bone, and compression to the brainstem were detected on cervical computed tomography and magnetic resonance imaging in a 6-year-old patient who suffered neck pain, deviation to the right in the neck, fever, and pain in his extremities. He was hospitalized in the Clinic of Pediatric Infectious Diseases. Positive Brucella agglutination tests were obtained, so C1-C2 stabilization and fusion were performed. Antibrucellosis antibiotic treatment was administered for 6 months. It was suggested that the dislocation was related to odontoid erosion and laxity of the atlantoaxial ligamentous structures during Brucella infection.
   CONCLUSIONS: Atlantoaxial dislocation and instability develops secondarily to paravertebral abscesses, only rarely. Like brucellosis of childhood, granulomatous infectious diseases rarely cause atlantoaxial subluxation or dislocation. Torticollis and neck pains should be taken seriously for the purpose of early diagnosis of patients at risk in endemic regions. Stabilization and fusion should be performed when instability is detected, and these patients should be assessed with both pediatric infectious diseases and neurosurgery clinics. Our case is the first one in the literature in which atlantoaxial instability developed due to Brucella infection and stabilization was performed.
C1 [Arslan, Ali; Cavus, Gokhan; Bilgin, Emre; Okten, Ali Ihsan; Gezercan, Yurdal] Adana City Training & Res Hosp, Dept Neurosurg, Adana, Turkey.
   [Atmis, Anil; Celik, Umit] Adana City Training & Res Hosp, Dept Pediat Infect Dis & Neurol, Adana, Turkey.
RP Cavus, G (reprint author), Adana City Training & Res Hosp, Dept Neurosurg, Adana, Turkey.
EM gokhanctf@yahoo.com
CR Alp E, 2008, INT J INFECT DIS, V12, P573, DOI 10.1016/j.ijid.2008.03.014
   Basaranoglu M, 1999, SCAND J INFECT DIS, V31, P214, DOI 10.1080/003655499750006353
   Bingol A, 1999, SURG NEUROL, V52, P570, DOI 10.1016/S0090-3019(99)00110-X
   Bouaziz MC, 2008, SKELETAL RADIOL, V37, P785, DOI 10.1007/s00256-007-0371-x
   Buzgan T, 2010, INT J INFECT DIS, V14, pE469, DOI 10.1016/j.ijid.2009.06.031
   COLMENERO JD, 1991, ANN RHEUM DIS, V50, P23, DOI 10.1136/ard.50.1.23
   Colmenero JD, 1997, ANN RHEUM DIS, V56, P709, DOI 10.1136/ard.56.12.709
   Dhaon BK, 2003, SPINE, V28, pE203, DOI 10.1097/00007632-200306010-00025
   Ekici MA, 2012, J KOREAN NEUROSURG S, V51, P383, DOI 10.3340/jkns.2012.51.6.383
   Fielding JW, 1991, SEMIN SPINE SURG, V3, P33
   Geyik MF, 2002, SWISS MED WKLY, V132, P98
   Gonzalez-Gay MA, 1999, J RHEUMATOL, V26, P141
   Gur A, 2003, YONSEI MED J, V44, P33
   Hantzidis Paraskevas, 2009, Cases J, V2, P6698, DOI 10.4076/1757-1626-2-6698
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hasanjani RMR, 2004, EPIDEMIOL INFECT, V132, P1109, DOI DOI 10.1017/S0950268804002833
   Lee Max C, 2004, Neurosurg Focus, V17, pE7
   Mandell GL, 2000, PRINCIPLES PRACTICE, P2669
   Morita T, 2001, AURIS NASUS LARYNX, V28, P177, DOI 10.1016/S0385-8146(00)00101-2
   Namiduru M, 2004, RHEUMATOL INT, V24, P125, DOI 10.1007/s00296-003-0339-7
   Nas K, 2007, EUR SPINE J, V16, pS255, DOI 10.1007/s00586-006-0252-3
   Pina MA, 2001, EUR NEUROL, V45, P249, DOI 10.1159/000052137
   POPE MH, 1985, SPINE, V10, P255, DOI 10.1097/00007632-198504000-00013
   Pourbagher A, 2006, AM J ROENTGENOL, V187, P873, DOI 10.2214/AJR.05.1088
   Simsek S, 2007, SURG NEUROL, V67, P207, DOI 10.1016/j.surneu.2006.06.061
   TEKKOK IH, 1993, NEUROSURGERY, V33, P838, DOI 10.1227/00006123-199311000-00008
   Tezer Mehmet, 2006, Spine J, V6, P321, DOI 10.1016/j.spinee.2005.10.019
   Welinder NR, 1997, EUR ARCH OTO-RHINO-L, V254, P251, DOI 10.1007/BF00874099
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 108
EP 111
DI 10.1016/j.wneu.2019.07.089
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300101
PM 31323407
DA 2020-05-12
ER

PT J
AU Lin, CH
   Lin, SM
   Lan, TY
   Pao, JL
AF Lin, Cheng-Han
   Lin, Shang-Ming
   Lan, Tsung-Yu
   Pao, Jwo-Luen
TI Pneumocephalus with Conscious Disturbance After Full Endoscopic Lumbar
   Diskectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural tear; Endoscopic diskectomy; Endoscopic spine surgery; Hyperbaric
   oxygen therapy; Pneumocephalus
ID THERAPY
AB BACKGROUND: Pneumocephalus is a rare complication after an elective lumbar spine surgery. Full endoscopic lumbar diskectomy (FELD) is an evolving minimally invasive surgical procedure gaining its popularity in the past decade. Although seizure was recognized as a possible complication, organic injury to the central nervous system such as pneumocephalus has not yet been reported after FELD.
   CASE DESCRIPTION: A 63-year-old man with L3-4 intervertebral disk herniation received FELD via the transforaminal approach under general anesthesia. A small dural tear about 2 mm was encountered. After the operation, the patient was unable to recover from anesthesia and failed to be extubated due to tachypnea and generalized tonic-clonic seizures. Emergent brain computed tomography (CT) revealed pneumocephalus in the subdural and subarachnoid space. Pure oxygen was given, and hyperbaric oxygen therapy (HBO2) was arranged immediately. Fortunately, he started to regain his consciousness 8 hours after the operation and had full recovery of consciousness on the next day. Follow-up brain CT showed nearly complete resolution of the pneumocephalus. He had no neurologic deficits at final follow-up.
   CONCLUSIONS: This case report highlights the risk of pneumocephalus with conscious disturbance when a dural tear occurs during FELD under general anesthesia. FELD is safer when performed under local anesthesia because the patient is awake to report his discomfort and thus possible to prevent serious neurologic sequels. An emergent brain CT is critical to obtain a prompt diagnosis and HBO2 is probably helpful for resolving the mass effect caused by the pneumocephalus.
C1 [Lin, Shang-Ming; Lan, Tsung-Yu; Pao, Jwo-Luen] Far Eastern Mem Hosp, Oriental Inst Technol, Dept Mat & Text, New Taipei, Taiwan.
   [Lin, Cheng-Han; Lan, Tsung-Yu; Pao, Jwo-Luen] Far Eastern Mem Hosp, Dept Orthoped Surg, New Taipei, Taiwan.
RP Pao, JL (reprint author), Far Eastern Mem Hosp, Oriental Inst Technol, Dept Mat & Text, New Taipei, Taiwan.; Pao, JL (reprint author), Far Eastern Mem Hosp, Dept Orthoped Surg, New Taipei, Taiwan.
EM jwoluenpao@gmail.com
OI Pao, Jwo-Luen/0000-0002-2000-5146
CR Andarcia-Banuelos C, 2015, Rev Esp Cir Ortop Traumatol, V59, P222, DOI 10.1016/j.recot.2014.04.007
   Baba M, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/1828461
   Choi G, 2017, J KOREAN NEUROSURG S, V60, P485, DOI 10.3340/jkns.2017.0203.004
   Choi G, 2011, J SPINAL DISORD TECH, V24, P83, DOI 10.1097/BSD.0b013e3181ddf124
   Dabdoub Carlos B, 2015, Surg Neurol Int, V6, P155, DOI 10.4103/2152-7806.166195
   Gader G, 2018, J SPINAL CORD MED, V23, P1
   Gauthe R, 2016, ORTHOP TRAUMATOL-SUR, V102, P251, DOI 10.1016/j.otsr.2015.12.006
   Gore PA, 2008, J NEUROSURG, V108, P926, DOI 10.3171/JNS/2008/108/5/0926
   Karavelioglu E, 2014, NEUROL MED-CHIR, V54, P405, DOI 10.2176/nmc.cr2013-0118
   Nowak R, 2011, J PEDIATR ORTHOP B, V20, P41, DOI 10.1097/BPB.0b013e32833f33d1
   Ozdemir Ugur, 2017, Korean J Neurotrauma, V13, P176, DOI 10.13004/kjnt.2017.13.2.176
   Paiva WS, 2014, THER CLIN RISK MANAG, V10, P769, DOI 10.2147/TCRM.S45220
   Pirris SM, 2013, CASE REP NEUROL MED, DOI 10.1155/2013/792168
   Yun JH, 2010, J KOREAN NEUROSURG S, V48, P288, DOI 10.3340/jkns.2010.48.3.288
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 112
EP 115
DI 10.1016/j.wneu.2019.07.200
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300102
PM 31382061
DA 2020-05-12
ER

PT J
AU Kawauchi, T
   Ikeda, H
   Miyakoshi, A
   Go, K
   Oichi, Y
   Sano, N
   Hayase, M
   Toda, H
AF Kawauchi, Takeshi
   Ikeda, Hiroyuki
   Miyakoshi, Akinori
   Go, Koichi
   Oichi, Yuki
   Sano, Noritaka
   Hayase, Makoto
   Toda, Hiroki
TI Occipital Sinus Dural Arteriovenous Fistula Presenting with Cerebellar
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellar hemorrhage; Dural arteriovenous fistula; Occipital sinus
ID NORMAL ANATOMY; MR VENOGRAPHY; CLASSIFICATION
AB BACKGROUND: Occipital sinus (OS) dural arteriovenous fistula (DAVF) is extremely rare, and we are aware of no case accompanied by cerebral hemorrhage. We present a case of OS DAVF presenting with cerebellar hemorrhage, treated successfully by transvenous embolization.
   CASE DESCRIPTION: A 62-year-old female presented with headache and nausea of recent onset. Computed tomography revealed left cerebellar hemorrhage with perihematomal edema. Angiography showed OS DAVF fed by bilateral occipital and posterior meningeal arteries, with drainage into the left inferior hemispheric vein and right transverse sinus receiving the shunt flow from OS. The caudal side of the OS was occluded. The inferior hemispheric vein was dilated with 2 varices, and the junction between the OS and right transverse sinus was narrowed. Because the OS was not involved in normal cerebellar drainage, transvenous embolization of the OS was performed. The microcatheter was advanced to the OS from the transverse sinus during balloon occlusion at the confluence of sinuses. Coils were placed in the OS from the caudal to cranial side, and complete occlusion of the shunt was obtained.
   CONCLUSIONS: This is the first report of OS DAVF presenting with cerebellar hemorrhage. Transvenous embolization of the affected OS appears ideal when transvenous access is feasible, and the OS is not involved in normal venous drainage of the cerebellum.
C1 [Kawauchi, Takeshi; Ikeda, Hiroyuki; Miyakoshi, Akinori; Go, Koichi; Oichi, Yuki; Sano, Noritaka; Hayase, Makoto; Toda, Hiroki] Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
RP Ikeda, H (reprint author), Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
EM rocky@kuhp.kyoto-u.ac.jp
OI Toda, Hiroki/0000-0002-1596-4131; Ikeda, Hiroyuki/0000-0001-5710-7456;
   Miyakoshi, Akinori/0000-0001-7547-2828
CR Ayanzen RH, 2000, AM J NEURORADIOL, V21, P74
   Beyrouti R, 2016, J STROKE CEREBROVASC, V25, pE71, DOI 10.1016/j.jstrokecerebrovasdis.2016.02.006
   Fukusumi A, 2010, ACAD RADIOL, V17, P1103, DOI 10.1016/j.acra.2010.04.020
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Gokce E, 2014, SURG RADIOL ANAT, V36, P527, DOI 10.1007/s00276-013-1223-0
   Kobayashi K, 2006, NEURORADIOLOGY, V48, P373, DOI 10.1007/s00234-006-0087-y
   Miller TR, 2015, STROKE, V46, P2017, DOI 10.1161/STROKEAHA.115.008228
   Mizutani K, 2018, NEURORADIOLOGY, V60, P325, DOI 10.1007/s00234-018-1980-x
   OKUDERA T, 1994, AM J NEURORADIOL, V15, P1871
   Reynolds MR, 2017, STROKE, V48, P1424, DOI 10.1161/STROKEAHA.116.012784
   Surendrababu N R S, 2006, Indian J Med Sci, V60, P135
   Takagi T, 2012, JNET, V6, P141
   Tanaka J, 2017, J STROKE CEREBROVASC, V26, pE62, DOI 10.1016/j.jstrokecerebrovasdis.2017.01.004
   Tanaka M, 2016, NEUROL MED-CHIR, V56, P544, DOI 10.2176/nmc.oa.2015-0313
   Widjaja E, 2004, AM J NEURORADIOL, V25, P1557
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 116
EP 119
DI 10.1016/j.wneu.2019.07.231
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300103
PM 31398518
DA 2020-05-12
ER

PT J
AU Mallepally, AR
   Karthik, Y
   Ansari, N
   Chhabra, HS
   Goel, SA
AF Mallepally, Abhinandan Reddy
   Karthik, Yelamarthy
   Ansari, Neshar
   Chhabra, Harvinder Singh
   Goel, Shakti Amar
TI Reversible Central Hypoventilation Syndrome in Basilar Invagination
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basilar invagination; Central hypoventilation; Occipitocervical fusion;
   Traction
ID TRACTION; ONDINE; CHIARI
AB BACKGROUND: A noninvasive approach for basilar invagination (BI) and moreover, cervical traction to reduce odontoid invagination, has not been thoroughly described in the literature. We report a case of BI with Arnold -Chiari malformation in which preoperative reduction using Gardner well cervical traction was attempted and the patient developed central hypoventilation syndrome.
   CASE DESCRIPTION: A 15-year-old boy presented with a 6-month history of progressive cervical myelopathy signs and symptoms, modified Japanese orthopedic association score 12 of 18. Radiology showed type A BI with occipitalization of atlas and a posterior arch defect of axis. A preoperative closed cervical traction followed by occipitocervical fusion via a posterior-only approach was planned. The patient developed 3 episodes of apnea on sleeping when on traction. Labeled as central hypoventilation, he was operated by foramen magnum decompression and occipitocervical fusion.
   CONCLUSIONS: Cervical traction followed by posterior fixation is an effective way to manage basilar invagination with Arnold-Chiari malformation and assimilated C1. However, patients should be monitored closely for respiratory dysfunction.
C1 [Mallepally, Abhinandan Reddy; Karthik, Yelamarthy; Ansari, Neshar; Chhabra, Harvinder Singh; Goel, Shakti Amar] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Mallepally, AR (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM mabhi28@gmail.com
RI Goel, Shakti/AAE-8363-2020
OI Goel, Shakti/0000-0002-1249-0647; mallepally, abhinandan
   reddy/0000-0001-8153-7499
CR Abd-El-Barr MM, 2016, J NEUROSURG-PEDIATR, V18, P724, DOI 10.3171/2016.5.PEDS16122
   Attali V, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0569-5
   Botelho RV, 2007, J NEUROSURG-SPINE, V7, P444, DOI 10.3171/SPI-07/10/444
   Botelho RV, 2000, NEUROSURG REV, V23, P151, DOI 10.1007/PL00011947
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Heckmann JG, 2014, J STROKE CEREBROVASC, V23, P390, DOI 10.1016/j.jstrokecerebrovasdis.2013.02.003
   Kc P, 2010, RESP PHYSIOL NEUROBI, V173, P213, DOI 10.1016/j.resp.2010.03.020
   Li P, 2017, CLIN NEUROL NEUROSUR, V162, P41, DOI 10.1016/j.clineuro.2017.09.003
   Manconi M, 2003, ARCH NEUROL-CHICAGO, V60, P1787, DOI 10.1001/archneur.60.12.1787
   Menezes AH, 1995, PEDIATR NEUROSURG, V23, P260, DOI 10.1159/000120969
   Rolak LA, 1996, J CHILD NEUROL, V11, P461, DOI 10.1177/088307389601100609
   Schafer Thorsten, 2006, GMS Curr Top Otorhinolaryngol Head Neck Surg, V5, pDoc01
   Shah A, 2016, J CRANIOVERTEBRAL JU, V7, P96, DOI 10.4103/0974-8237.181856
   Simsek S, 2006, SURG NEUROL, V66, P311, DOI 10.1016/j.surneu.2005.12.029
   Smith JS, 2010, NEUROSURGERY, V66, pA39, DOI 10.1227/01.NEU.0000365770.10690.6F
   Zaidi S, 2018, AUTON NEUROSCI-BASIC, V210, P1, DOI 10.1016/j.autneu.2017.11.003
NR 16
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 120
EP 125
DI 10.1016/j.wneu.2019.07.236
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300104
PM 31400526
DA 2020-05-12
ER

PT J
AU Ladak, AA
   Enam, SA
   Ibrahim, MT
AF Ladak, Asma Akbar
   Enam, Syed Ather
   Ibrahim, Muhammad Talal
TI A Review of the Molecular Mechanisms of Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cell death; Excitotoxicity; Molecular mechanisms; Neuroinflammation;
   Secondary brain injury; Traumatic brain injury
ID CELL-DEATH MECHANISMS; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; HEAD-INJURY;
   SPREADING DEPOLARIZATIONS; NEUROINFLAMMATION; DISEASE;
   NEURODEGENERATION; NEUROPROTECTION; EXCITOTOXICITY
AB Traumatic brain injury (TBI) refers to any insult to the brain resulting in primary (direct) and secondary (indirect) damage to the brain parenchyma. Secondary damage is often linked to the molecular mechanisms that occur post TBI and result in excitotoxicity, neuroinflammation and cytokine damage, oxidative damage, and eventual cell death as prominent mechanisms of cell damage. We present a review highlighting the relation of each of these mechanisms with TBI, their mode of damaging brain tissue, and therapeutic correlation. We also mention the long-term sequelae and their pathophysiology in relation to TBI focusing on Parkinson disease, Alzheimer disease, epilepsy, and chronic traumatic encephalopathy. Understanding of the molecular mechanisms is important in order to realize the secondary and long-term sequelae that follow primary TBI and to devise targeted therapy for quick recovery accordingly.
C1 [Ladak, Asma Akbar; Ibrahim, Muhammad Talal] Aga Khan Univ Hosp, Med Coll, Karachi, Pakistan.
   [Enam, Syed Ather] Aga Khan Univ Hosp, Sect Neurosurg, Karachi, Pakistan.
RP Enam, SA (reprint author), Aga Khan Univ Hosp, Sect Neurosurg, Karachi, Pakistan.
EM ather.enam@aku.edu
CR Moneim AEA, 2015, CURR ALZHEIMER RES, V12, P335, DOI 10.2174/1567205012666150325182702
   Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3
   Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830
   Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376
   Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312
   Angeloni C, 2014, BIOMED RES INT, DOI 10.1155/2014/238485
   Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062
   Arent AM, 2014, BIOMED RES INT, DOI 10.1155/2014/723060
   Ascenzi P, 2005, IUBMB LIFE, V57, P749, DOI 10.1080/15216540500380871
   Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168
   Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102
   Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605
   Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024
   Blaylock RL, 2011, SURG NEUROL INT, V2
   Bredesen DE, 2008, CURR MOL MED, V8, P173, DOI 10.2174/156652408784221315
   Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020
   Chen CH, 2019, CEREB CORTEX, V29, P54, DOI 10.1093/cercor/bhx303
   Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x
   Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8
   Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405
   Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628
   Dulla CG, 2016, NEUROSCIENTIST, V22, P295, DOI 10.1177/1073858415585108
   Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415
   Englander Jeffrey, 2014, Arch Phys Med Rehabil, V95, P1223, DOI 10.1016/j.apmr.2013.06.002
   Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183
   Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793
   Hebron ML, 2013, J BIOL CHEM, V288, P4103, DOI 10.1074/jbc.M112.419945
   Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5
   Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030
   Hinzman JM, 2016, J NEUROTRAUM, V33, P1775, DOI 10.1089/neu.2015.4226
   Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089
   Kohta M, 2009, NEUROSCI RES, V65, P393, DOI 10.1016/j.neures.2009.08.017
   Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268
   Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008
   Lambeth JD, 2014, ANNU REV PATHOL-MECH, V9, P119, DOI 10.1146/annurev-pathol-012513-104651
   Lorente L, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7110142
   Lorente L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0911-z
   Lorente L, 2014, THROMB RES, V134, P832, DOI 10.1016/j.thromres.2014.07.034
   Lorente L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094370
   Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815
   Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e
   Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4
   Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025
   McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248
   McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85
   Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364
   Mioni G, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00269
   Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001
   Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617
   Morrow SE, 2010, SEMIN PEDIATR SURG, V19, P279, DOI 10.1053/j.sempedsurg.2010.07.001
   Muradashvili N, 2013, BRAIN INJURY, V27, P1508, DOI 10.3109/02699052.2013.823562
   Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x
   Mutinati M, 2014, REPROD DOMEST ANIM, V49, P7, DOI 10.1111/rda.12230
   Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012
   Plotegher N, 2016, AGEING RES REV, V26, P62, DOI 10.1016/j.arr.2015.12.002
   Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125
   Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0
   Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005
   Rodrigues MCO, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/194720
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028
   Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6
   Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8
   Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023
   Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0
   Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292
   Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027
   Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350
   Tasker RC, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70084-4
   Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82
   Wang JW, 2014, J SURG RES, V186, P328, DOI 10.1016/j.jss.2013.08.027
   Wang K, 2016, FRONT BIOSCI-LANDMRK, V21, P890
   Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013
   Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026
   Xu HM, 2014, HEPATOB PANCREAT DIS, V13, P482, DOI 10.1016/S1499-3872(14)60305-2
   Yasuda T, 2013, MOL NEUROBIOL, V47, P466, DOI 10.1007/s12035-012-8327-0
   Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103
   Zauner A, 1996, ACT NEUR S, V67, P40
NR 78
TC 2
Z9 2
U1 10
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 126
EP 132
DI 10.1016/j.wneu.2019.07.039
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300105
PM 31301445
DA 2020-05-12
ER

PT J
AU Umana, GE
   Scalia, G
   Fagone, S
   Strano, G
   Tranchina, MG
   Raudino, G
   Cicero, S
AF Umana, Giuseppe Emmanuele
   Scalia, Gianluca
   Fagone, Saverio
   Strano, Giuseppe
   Tranchina, Maria Grazia
   Raudino, Giuseppe
   Cicero, Salvatore
TI Spontaneous Subgaleal Abscess Associated with Lung Adenocarcinoma: First
   Description of This Unusual Association
SO WORLD NEUROSURGERY
LA English
DT Article
DE De novo; Galea aponeurotica; Lung adenocarcinoma; Osteomyelitis;
   Spontaneous; Subgaleal abscess
AB BACKGROUND: Primary, spontaneous, or de novo subgaleal abscesses represent extremely rare lesions usually related to patients with risk factors and predisposing conditions for infections. They are associated with high morbidity, and a proper diagnosis can be misleading. To the best of our knowledge, this is the first reported case of a de novo subgaleal abscess not related to previous traumatic head injury and associated with lung adenocarcinoma.
   CASE DESCRIPTION: A 59-year-old man was admitted to our unit because he presented fever and a palpable subcutaneous right parietal mass. No history of traumatic head injury was mentioned. The patient underwent needle aspiration of the subgaleal lesion for microbiological, histological, and cytological examination, with negative response. Chest radiograph and then thoracic computed tomography scan revealed the presence of 2 lesions in the left lung. Complete removal with surgical debridement of the parietal bone lesion was performed due to the suspicion of an abscessualized skull metastasis from a primary lung adenocarcinoma.
   CONCLUSIONS: We strongly suggest a patient global assessment in the event of subgaleal abscess without history of traumatic head injury, to treat eventual associated findings as soon as possible.
C1 [Umana, Giuseppe Emmanuele; Fagone, Saverio; Cicero, Salvatore] Cannizzaro Hosp, Trauma Ctr, Gamma Knife Ctr, Dept Neurosurg, Catania, Italy.
   [Strano, Giuseppe] Cannizzaro Hosp, Dept Infectous Dis, Catania, Italy.
   [Tranchina, Maria Grazia] Cannizzaro Hosp, Dept Pathol Anat, Catania, Italy.
   [Scalia, Gianluca] Univ Messina, BIOMORF Dept, Div Neurosurg, Messina, Italy.
   [Raudino, Giuseppe] Monza Gen Hosp, Neurosurg, Monza, Italy.
RP Umana, GE (reprint author), Cannizzaro Hosp, Trauma Ctr, Gamma Knife Ctr, Dept Neurosurg, Catania, Italy.
EM umana.nch@gmail.com
OI Scalia, Gianluca/0000-0002-9465-2506
CR Chen CH, 2004, EUR J PEDIATR, V163, P565, DOI 10.1007/s00431-004-1481-2
   Dalugama Chamara, 2018, J Med Case Rep, V12, P115, DOI 10.1186/s13256-018-1643-x
   GOODMAN SJ, 1977, WESTERN J MED, V127, P169
   Schaefer J, 1992, Can J Infect Dis, V3, P30
   Wang WH, 2003, J FORMOS MED ASSOC, V102, P338
   WILEY JF, 1989, ANN EMERG MED, V18, P785, DOI 10.1016/S0196-0644(89)80021-6
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 133
EP 136
DI 10.1016/j.wneu.2019.07.233
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300106
PM 31400523
DA 2020-05-12
ER

PT J
AU Ogiwara, T
   Miyaoka, Y
   Nakamura, T
   Tsukada, K
   Yamazaki, D
   Ito, K
   Hanaoka, Y
   Koyama, JI
   Horiuchi, T
   Hongo, K
AF Ogiwara, Toshihiro
   Miyaoka, Yoshinari
   Nakamura, Takuya
   Tsukada, Keita
   Yamazaki, Daisuke
   Ito, Kiyoshi
   Hanaoka, Yoshiki
   Koyama, Jun-Ichi
   Horiuchi, Tetsuyoshi
   Hongo, Kazuhiro
TI Endoscopic Endonasal Odontoidectomy in the Hybrid Operating Room
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basilar invagination; Cone beam computed tomography scan; Endoscopic
   endonasal approach; Hybrid operating room; Odontoidectomy; Robotic
   angiography
AB BACKGROUND: The endoscopic endonasal approach for the craniovertebral junction (CVJ), instead of the microscopic transoral approach, has been widely adopted and accepted, especially in resection of the odontoid process for basilar invagination. However, there is concern regarding insufficient resection of odontoid and surgical complications, including vessel injuries, because this is a historically immature procedure. Here, we report a surgical case of endoscopic endonasal odontoidectomy (EEO) in the hybrid operating room (hOR) for improvement of its safety and reliability.
   CASE DESCRIPTION: A 70-year-old man presented with a 2-month history of myelopathic gait disturbance and swallowing disturbance. Neuroimaging analysis indicated medulla oblongata compression associated with basilar invagination. The patient underwent EEO in the hOR after posterior instrumented fixation. With the hOR, the extent of bone resection and anatomic orientation were confirmed intraoperatively. Postoperative course was uneventful, and symptoms were improved after surgery.
   CONCLUSIONS: The application of the hOR may make the EEO safe and precise for anterior decompression of the CVJ. To our knowledge, this is the first case report describing clinical experience of EEO in the hOR.
C1 [Ogiwara, Toshihiro; Miyaoka, Yoshinari; Nakamura, Takuya; Yamazaki, Daisuke; Ito, Kiyoshi; Hanaoka, Yoshiki; Koyama, Jun-Ichi; Horiuchi, Tetsuyoshi; Hongo, Kazuhiro] Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
   [Tsukada, Keita] Shinshu Univ, Dept Otorhinolaryngol, Sch Med, Matsumoto, Nagano, Japan.
RP Ogiwara, T (reprint author), Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
EM togiwara@shinshu-u.ac.jp
CR Aldea S, 2018, NEUROCHIRURGIE, V64, P194, DOI 10.1016/j.neuchi.2017.12.005
   Ponce-Gomez JA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14301
   Bai M, 2012, EUR J RADIOL, V81, P3577, DOI 10.1016/j.ejrad.2011.09.006
   Bohoun CA, 2019, NEUROSURG REV, V42, P417, DOI 10.1007/s10143-018-0977-6
   Goldschlager T, 2015, J NEUROSURG, V122, P511, DOI 10.3171/2014.9.JNS14733
   Gruter BE, 2018, WORLD NEUROSURG, V117, pE204, DOI 10.1016/j.wneu.2018.05.241
   Kassam AB, 2015, NEUROSURGERY S, V57, pE213
   Rossini Z, 2018, WORLD NEUROSURG, V110, P373, DOI 10.1016/j.wneu.2017.11.153
   Singh H, 2018, J NEUROSURG, V128, P1486, DOI 10.3171/2017.1.JNS162601
   Snyderman C, 2019, HEAD NECK SURG SKULL, P373
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 137
EP 140
DI 10.1016/j.wneu.2019.07.197
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300107
PM 31382069
DA 2020-05-12
ER

PT J
AU Somma, T
   Ius, T
   Certo, F
   Santi, L
   de Angelis, M
   Dones, F
   Cenzato, M
   Skrap, M
   Cappabianca, P
AF Somma, Teresa
   Ius, Tamara
   Certo, Francesco
   Santi, Laura
   de Angelis, Michelangelo
   Dones, Flavia
   Cenzato, Marco
   Skrap, Miran
   Cappabianca, Paolo
TI From the Champion to the Team: New Treatment Paradigms in Contemporary
   Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Multidisciplinary cooperation; Team; Treatment
ID ENDOSCOPIC ENDONASAL APPROACH; COMPUTER-BASED MODEL; QUALITY-OF-LIFE;
   EPILEPSY SURGERY; TRANSSPHENOIDAL SURGERY; PRESURGICAL EVALUATION;
   SURGICAL-TREATMENT; GENE-EXPRESSION; SKULL BASE; BRAIN
AB In our discipline, neurosurgery, the role of the leader has evolved and has been complemented by the collaboration of specific professionals of different disciplines, aiming at the overall result of curing people and defeating the disease. Indeed, the multidisciplinary cooperation and the innovative strength of a team composed of different specialists such as radiologists, anesthesiologists, pathologists, molecular biologists, geneticists, oncologists, psychologists, physiatrists, physiotherapists, neurologists, engineers, mathematics, statisticians, and economists, greatly has changed the way we see the patient and treat pathology: from a single to multiperspective vision, thus generating a synergy that improves the surgeon's and the overall work. An old African adage goes like this: "If you want to go fast, go alone. if you want to go far, go together," which in our opinion fully summarizes the sense of our contribution on the state of the art in neurosurgical contemporary practice.
C1 [Somma, Teresa; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
   [Ius, Tamara; Skrap, Miran] Santa Maria Misericordia Univ Hosp, Neurosurg Unit, Dept Neurosci, Udine, Italy.
   [Certo, Francesco] Policlin G Rodol Univ Hosp, Dept Neurosurg, Catania, Italy.
   [Santi, Laura] Sondrio ASST Valtellina & Alto Lario, Neurosurg Unit, Sondrio, Italy.
   [de Angelis, Michelangelo] IRCCS Neuromed, Dept Neurosurg, Pozzilli, IS, Italy.
   [Dones, Flavia; Cenzato, Marco] ASST Niguarda Hosp, Dept Neurosurg, Milan, Italy.
RP Somma, T (reprint author), Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
EM teresa.somma85@gmail.com
OI De Angelis, Michelangelo/0000-0002-4015-7446
CR Abla AA, 2015, J NEUROSURG, V122, P419, DOI 10.3171/2014.10.JNS1424
   Aquino D, 2017, J IMMUNOL RES, DOI 10.1155/2017/5813951
   Barbagallo GMV, 2015, NEUROSURG REV, V38, P343, DOI 10.1007/s10143-014-0589-8
   Bien CG, 2013, J NEUROL NEUROSUR PS, V84, P54, DOI 10.1136/jnnp-2011-301763
   Biermasz NR, 2004, J CLIN ENDOCR METAB, V89, P5369, DOI 10.1210/jc.2004-0669
   Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868
   Broersen LHA, 2018, PITUITARY, V21, P631, DOI 10.1007/s11102-018-0897-z
   Buslei R, 2007, ACTA NEUROPATHOL, V113, P585, DOI 10.1007/s00401-006-0184-3
   Cappabianca P, 2004, CHILD NERV SYST, V20, P796, DOI 10.1007/s00381-004-0933-3
   Cappabianca P, 2008, ADV TECH STAND NEURO, V33, P151, DOI 10.1007/978-3-211-72283-1_4
   Cappabianca P, 1999, NEUROSURGERY, V45, P392, DOI 10.1097/00006123-199908000-00041
   Cappabianca P, 2014, WORLD NEUROSURG, V82, pS3, DOI 10.1016/j.wneu.2014.07.019
   Cappabianca P, 2014, ACTA NEUROCHIR, V156, P2217, DOI 10.1007/s00701-014-2213-7
   Casanueva FF, 2006, CLIN ENDOCRINOL, V65, P265, DOI 10.1111/j.1365-2265.2006.02562.x
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Cenzato M, 2017, ACTA NEUROCHIR, V159, P1059, DOI 10.1007/s00701-017-3154-8
   Chaudhuri KR, 2015, PARKINSONISM RELAT D, V21, P287, DOI 10.1016/j.parkreldis.2014.12.031
   Colao A, 2003, NEW ENGL J MED, V349, P2023, DOI 10.1056/NEJMoa022657
   de Divitiis E, 2002, NEUROSURGERY, V51, P699, DOI 10.1097/00006123-200209000-00016
   de Divitiis E, 2002, NEUROSURGERY, V51, P705
   de Lara Danielle, 2012, Surg Neurol Int, V3, pS73, DOI 10.4103/2152-7806.95418
   De Notaris M, 2013, WORLD NEUROSURG, V79, pe19
   de Notaris M, 2011, WORLD NEUROSURG, V75, P106, DOI 10.1016/j.wneu.2010.09.033
   de Notaris M, 2010, CHILD NERV SYST, V26, P621, DOI 10.1007/s00381-010-1107-0
   Dewar SR, 2015, EPILEPSY BEHAV, V44, P171, DOI 10.1016/j.yebeh.2014.12.027
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Dusick JR, 2007, NEUROSURGERY, V60, P322, DOI 10.1227/01.NEU.0000255408.84269.A8
   Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097
   Fatemi N, 2008, NEUROSURGERY, V63, P709, DOI 10.1227/01.NEU.0000325725.77132.90
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   Ford E, 2012, NEURO-ONCOLOGY, V14, P392, DOI 10.1093/neuonc/nor229
   Frank G, 2002, NEUROSURGERY, V50, P675, DOI 10.1097/00006123-200203000-00059
   Galland F, 2010, ENDOCR-RELAT CANCER, V17, P361, DOI 10.1677/ERC-10-0018
   Garre ML, 2007, CURR OPIN PEDIATR, V19, P471, DOI 10.1097/MOP.0b013e3282495a22
   Ghaly Ramsis F, 2014, Surg Neurol Int, V5, P76, DOI 10.4103/2152-7806.133106
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169
   Giugno A, 2017, ACTA NEUROCHIR SUPPL, V124, P55, DOI 10.1007/978-3-319-39546-3_9
   Guadagno E, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0562-9
   Haneef Z, 2010, NEUROLOGY, V75, P699, DOI 10.1212/WNL.0b013e3181eee457
   Hendricks BK, 2019, J NEURO-ONCOL, V141, P13, DOI 10.1007/s11060-018-03026-6
   Herrlinger U, 2019, LANCET, V393, P678, DOI 10.1016/S0140-6736(18)31791-4
   Ius T, 2012, J NEUROSURG, V117, P1039, DOI 10.3171/2012.8.JNS12393
   Jane John A Jr, 2005, Neurosurg Focus, V19, pE2
   Jane John A Jr, 2003, Neurosurg Focus, V14, pe12
   Jenner P, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/2047-9158-4-3
   Jiang JL, 2019, TZU CHI MED J, V31, P107, DOI 10.4103/tcmj.tcmj_92_18
   Kang J, 2018, NEUROSPINE, V15, P353, DOI 10.14245/ns.1836086.043
   Labiner DM, 2010, EPILEPSIA, V51, P2322, DOI 10.1111/j.1528-1167.2010.02648.x
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Laws E R, 2001, Clin Neurosurg, V48, P306
   Laws ER, 2016, J NEUROSURG, V124, P1634, DOI 10.3171/2015.4.JNS142184
   Lawton MT, 2019, J NEUROSURG, V130, P1409, DOI 10.3171/2019.1.JNS182156
   Manjila S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10168
   Mann J, 2018, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00748
   Martinez-Gutierrez JC, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16325
   McGirt MJ, 2009, J NEUROSURG, V110, P583, DOI 10.3171/2008.5.17557
   McLaughlin N, 2012, NEUROSURGERY, V71, P916, DOI 10.1227/NEU.0b013e31826d5d06
   Melmed S, 2009, J CLIN ENDOCR METAB, V94, P1509, DOI 10.1210/jc.2008-2421
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Minniti G, 2018, PITUITARY, V21, P154, DOI 10.1007/s11102-018-0868-4
   Minniti G, 2016, REP PRACT ONCOL RADI, V21, P370, DOI 10.1016/j.rpor.2014.09.004
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Murayama Y, 2013, J NEUROINTERV SURG, V5, P489, DOI 10.1136/neurintsurg-2012-010382
   Nasrolahi A, 2019, REV NEUROSCIENCE, V30, P709, DOI 10.1515/revneuro-2018-0105
   O'Connor JPB, 2017, NAT REV CLIN ONCOL, V14, P169, DOI 10.1038/nrclinonc.2016.162
   Ohgaki Hiroko, 2009, V472, P323, DOI 10.1007/978-1-60327-492-0_14
   Palui R, 2018, J ENDOCRINOL INVEST, V41, P1445, DOI 10.1007/s40618-018-0936-7
   Pejrona M, 2018, SPINE J, V18, P1498, DOI 10.1016/j.spinee.2017.10.004
   Pittau F, 2012, NEUROLOGY, V78, P1479, DOI 10.1212/WNL.0b013e3182553bf7
   Rosenow F, 2001, BRAIN, V124, P1683, DOI 10.1093/brain/124.9.1683
   Roussouly P, 2010, EUR SPINE J, V19, P1824, DOI 10.1007/s00586-010-1476-9
   Ryvlin P, 2014, LANCET NEUROL, V13, P1114, DOI 10.1016/S1474-4422(14)70156-5
   Sanai N, 2011, REV NEUROL-FRANCE, V167, P648, DOI 10.1016/j.neurol.2011.07.004
   Sheehan JM, 2000, J NEUROSURG, V93, P738, DOI 10.3171/jns.2000.93.5.0738
   Shkarubo AN, 2019, WORLD NEUROSURG, V121, pE246, DOI 10.1016/j.wneu.2018.09.090
   Smith TR, 2015, J CLIN NEUROSCI, V22, P1785, DOI 10.1016/j.jocn.2015.06.001
   Solari D, 2019, WORLD NEUROSURG, V123, pE440, DOI 10.1016/j.wneu.2018.11.186
   Somma T, 2019, WORLD NEUROSURG, V125, P15, DOI 10.1016/j.wneu.2019.01.059
   Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   van Aken MO, 2005, J CLIN ENDOCR METAB, V90, P3279, DOI 10.1210/jc.2004-1375
   van der Eijk M, 2013, PARKINSONISM RELAT D, V19, P923, DOI 10.1016/j.parkreldis.2013.04.022
   van der Marck M A, 2009, Parkinsonism Relat Disord, V15 Suppl 3, pS219, DOI 10.1016/S1353-8020(09)70819-3
   Weller M, 2014, LANCET ONCOL, V15, pE395, DOI 10.1016/S1470-2045(14)70011-7
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Wijnenga MMJ, 2018, NEURO-ONCOLOGY, V20, P103, DOI 10.1093/neuonc/nox176
   Zada G, 2010, WORLD NEUROSURG, V74, P452, DOI 10.1016/j.wneu.2010.09.028
   Zoli M, 2018, ACTA NEUROCHIR, V160, P2349, DOI 10.1007/s00701-018-3708-4
   Zoli M, 2018, J NEUROSURG, V128, P329, DOI 10.3171/2016.11.JNS162082
   Zuckerberg M., 2017, PRIORITA NOSTRA GENE
NR 91
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 141
EP 148
DI 10.1016/j.wneu.2019.07.196
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300108
PM 31382066
DA 2020-05-12
ER

PT J
AU Haji, K
   Ishihara, H
   Oka, F
   Nishimoto, T
   Morikage, N
   Kubo, M
   Suzuki, M
AF Haji, Kohei
   Ishihara, Hideyuki
   Oka, Fumiaki
   Nishimoto, Takuma
   Morikage, Noriyasu
   Kubo, Makoto
   Suzuki, Michiyasu
TI Revascularization of Remaining Branch of Aorta in Advanced Takayasu
   Arteritis Protects Against Wide Range of Perfusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Subclavian artery stenosis; Takayasu arteritis
ID INTERVENTION; DISEASE
AB BACKGROUND: Stroke is a major factor of morbidity in the patients with Takayasu arteritis (TA). Restenosis is more common with endovascular intervention than after bypass surgery, but vascular anastomosis is difficult due to calcification involving the whole thickness of the arterial wall in the burned-out stage of TA. We report a case of advanced TA in which endovascular treatment of the left subclavian artery improved cerebral blood flow (CBF) over a wide range of perfusion in the posterior and anterior circulation.
   CASE DESCRIPTION: During medical treatment for TA, a 57-year-old male patient gradually developed ischemic symptoms of both upper limbs and dizziness. Angiography showed occlusion of the brachiocephalic artery and severe stenosis of the left common carotid artery and left subclavian artery. Preoperative single-photon emission computed tomography revealed reductions in the resting CBF and vascular reactivity in the area of the carotid artery and vertebral basilar artery. Chest computed tomography showed calcification of the aortic arch and its branches, and this advanced diffuse calcification indicated probable difficulties in bypass surgery. Therefore we performed percutaneous transluminal angioplasty and stenting for the left subclavian artery. Postoperative single-photon emission computed tomography showed increases in resting CBF in the area of the bilateral internal carotid artery, as well as the vertebrobasilar artery. The patient's various ischemic symptoms improved significantly.
   CONCLUSIONS: As collateral circulation is common in advanced TA, the ischemic area is large when the remaining proximal large vessels are occluded. Therefore revascularization of the remaining branch of the aorta in advanced TA may protect against a wide range of perfusion.
C1 [Haji, Kohei; Ishihara, Hideyuki; Oka, Fumiaki; Nishimoto, Takuma; Suzuki, Michiyasu] Yamaguchi Univ, Dept Neurosurg & Clin Neurosci, Sch Med, Yamaguchi, Japan.
   [Morikage, Noriyasu] Yamaguchi Univ, Dept Surg & Clin Sci, Grad Sch Med, Yamaguchi, Japan.
   [Kubo, Makoto] Yamaguchi Univ, Dept Med & Clin Sci, Grad Sch Med, Yamaguchi, Japan.
RP Ishihara, H (reprint author), Yamaguchi Univ, Dept Neurosurg & Clin Neurosci, Sch Med, Yamaguchi, Japan.
EM hishi@yamaguchi-u.ac.jp
OI Ishihara, Hideyuki/0000-0002-0208-2412
CR Couture P, 2018, J NEUROL, V265, P757, DOI 10.1007/s00415-018-8744-8
   de Souza AWS, 2010, CIRC J, V74, P1236, DOI 10.1253/circj.CJ-09-0905
   ISHIKAWA K, 1994, CIRCULATION, V90, P1855, DOI 10.1161/01.CIR.90.4.1855
   Jung JH, 2018, EUR J VASC ENDOVASC, V55, P888, DOI 10.1016/j.ejvs.2018.02.030
   Kang HS, 2007, AM J NEURORADIOL, V28, P222
   Maksimowicz-McKinnon K, 2007, ARTHRITIS RHEUM, V56, P1000, DOI 10.1002/art.22404
   Mehta Vimal, 2014, Indian Heart J, V66, P350, DOI 10.1016/j.ihj.2014.03.017
   Perera AH, 2014, BRIT J SURG, V101, P43, DOI 10.1002/bjs.9372
   Saadoun D, 2012, CIRCULATION, V125, P813, DOI 10.1161/CIRCULATIONAHA.111.058032
   Tsutsumi M, 2010, NEURORADIOLOGY, V52, P831, DOI 10.1007/s00234-009-0630-8
   Tyagi S, 1998, CARDIOVASC INTER RAD, V21, P219, DOI 10.1007/s002709900248
   Vaideeswar P, 2013, ANN PEDIAT CARDIOL, V6, P52, DOI 10.4103/0974-2069.107235
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 149
EP 153
DI 10.1016/j.wneu.2019.08.017
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300109
PM 31408749
DA 2020-05-12
ER

PT J
AU Gadiya, A
   Morassi, GL
   Badmus, O
   Marriot, A
   Shafafy, M
AF Gadiya, Akshay
   Morassi, Giuseppe Lambros
   Badmus, Olakunle
   Marriot, Ann
   Shafafy, Masood
TI Management of Catastrophic Proximal Junctional Failure Following Spinal
   Deformity Correction in an Adult with Osteogenesis Imperfecta: Case
   Report and Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity; Osteogenesis imperfect; Proximal junctional
   kyphosis; Scoliosis; Spinal fusion
ID SURGICAL-TREATMENT; RISK-FACTORS; KYPHOSIS; SURGERY; SCOLIOSIS;
   OUTCOMES; CLASSIFICATION; TRANSITION; FUSION
AB BACKGROUND: Proximal junctional failure (PJF) is a major and sometimes devastating problem following adult spinal deformity (ASD) correction surgery. Common consensus still lags on guidelines for preventing and managing these complications. Surgical treatment of scoliosis in the presence of osteogenesis imperfecta (OI) in the pediatric population is well described. The complication rates are unusually higher in this special subset of patients owing to poor quality of bone. There is a paucity of literature focusing on surgical techniques, strategies, and problems involved in the management of ASD associated with OI.
   CASE DESCRIPTION: We report a 59-year-old female with type 1 OI and adult scoliosis who underwent T10-to-pelvis fusion for ASD according to the principles of adult deformity correction. At a 1-year follow-up, she presented with asymptomatic proximal junctional kyphosis of 45 degrees and 2 weeks later had PJF along with spinal cord injury after a fall. On computed tomography scan, kyphosis was increased to 60 degrees at T9-T10. She underwent decompression and revision deformity correction using quadruple rods, with extension of instrumentation to T2 with soft landing using rib bands. At a 4-year follow-up, she had a good functional outcome after revision surgery.
   CONCLUSIONS: This is the first report of successful management of PJF following ASD correction in the presence of OI using this technique. Suboptimal hold of implants due to poor bone quality must be at the focus of any surgical planning for these patients. All possible strategies to prevent PJF must be considered when planning the deformity correction in adults with OI.
C1 [Gadiya, Akshay; Morassi, Giuseppe Lambros; Badmus, Olakunle; Marriot, Ann; Shafafy, Masood] Queens Med Ctr Nottingham Univ Hosp NHS Trust, Ctr Spinal Studies & Surg, Nottingham, England.
RP Gadiya, A (reprint author), Queens Med Ctr Nottingham Univ Hosp NHS Trust, Ctr Spinal Studies & Surg, Nottingham, England.
EM akshay.gadiya@nuh.nhs.uk
CR Antoniazzi F, 2000, Paediatr Drugs, V2, P465, DOI 10.2165/00128072-200002060-00005
   Arlet V, 2013, EUR SPINE J, V22, pS276, DOI 10.1007/s00586-013-2676-x
   BENSON DR, 1981, CLIN ORTHOP RELAT R, P147
   Bridwell KH, 2013, NEUROSURGERY, V72, P899, DOI 10.1227/NEU.0b013e31828bacd8
   Cahill PJ, 2012, SPINE, V37, pE687, DOI 10.1097/BRS.0b013e318246d4f2
   Cammarata M, 2014, SPINE, V39, pE500, DOI 10.1097/BRS.0000000000000222
   Gatti D, 2013, CALCIFIED TISSUE INT, V93, P448, DOI 10.1007/s00223-013-9770-2
   Glattes RC, 2005, SPINE, V30, P1643, DOI 10.1097/01.brs.0000169451.76359.49
   HANSCOM DA, 1992, J BONE JOINT SURG AM, V74A, P598, DOI 10.2106/00004623-199274040-00016
   Harrington J, 2014, PEDIATR CLIN N AM, V61, P1243, DOI 10.1016/j.pcl.2014.08.010
   Hart R, 2013, SPINE, V38, pE1223, DOI 10.1097/BRS.0b013e31829fedde
   Hart RA, 2008, SPINE J, V8, P875, DOI 10.1016/j.spinee.2008.01.015
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Kayanja MM, 2006, SPINE, V31, P769, DOI 10.1097/01.brs.0000207466.40955.31
   Kebaish KM, 2013, SPINE J, V13, P1897, DOI 10.1016/j.spinee.2013.06.039
   Kim HJ, 2014, SPINE, V39, pE576, DOI 10.1097/BRS.0000000000000246
   Kim HJ, 2012, SPINE, V37, pS144, DOI 10.1097/BRS.0b013e31826d611b
   Kocher M S, 1998, J Am Acad Orthop Surg, V6, P225
   Martin Elizabeth, 2007, Curr Osteoporos Rep, V5, P91
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   NORIMATSU H, 1982, CLIN ORTHOP RELAT R, P20
   Rauch Frank, 2006, Curr Osteoporos Rep, V4, P159, DOI 10.1007/BF02686963
   Smith MW, 2015, SPINE J, V15, P2142, DOI 10.1016/j.spinee.2015.05.028
   Thawrani DP, 2014, SPINE, V39, pE826, DOI 10.1097/BRS.0000000000000367
   Yagi M, 2012, SPINE, V37, P1479, DOI 10.1097/BRS.0b013e31824e4888
   Yagi M, 2011, SPINE, V36, pE60, DOI 10.1097/BRS.0b013e3181eeaee2
   Yilmaz G, 2014, J SPINAL DISORD TECH, V27, P174, DOI 10.1097/BSD.0b013e3182624b76
   YONGHING K, 1982, J BONE JOINT SURG BR, V64, P36
NR 28
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 154
EP 158
DI 10.1016/j.wneu.2019.07.230
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300110
PM 31398526
DA 2020-05-12
ER

PT J
AU Chidambaram, S
   Winston, GM
   Knisely, JPS
   Ramakrishna, R
   Juthani, R
   Salah, K
   McKenna, JT
   Jozsef, G
   Cardona, D
   Pannullo, SC
AF Chidambaram, Swathi
   Winston, Graham M.
   Knisely, Jonathan P. S.
   Ramakrishna, Rohan
   Juthani, Rupa
   Salah, Khaled
   McKenna, John T.
   Jozsef, Gabor
   Cardona, Danielle
   Pannullo, Susan C.
TI A Multidisciplinary Team Approach to Brain and Spine Stereotactic
   Radiosurgery Conferences: A Unique Institutional Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conference; Interdisciplinary; Multidisciplinary; Radiosurgery
ID PATIENT; MEETINGS; CANCER
AB OBJECTIVE: The use of multidisciplinary teams (MDTs) comprised of all members of the patient care team is becoming increasingly popular in the field of oncology. We present a single-center experience exploring the utility and uniqueness of an MDT in the care of patients undergoing brain and spine stereotactic radiosurgery (SRS).
   METHODS: The weekly SRS conference brought together neurosurgeons, radiation oncologists, neuroradiologists, physicists, dosimetrists, therapists, advanced practice providers, and trainees in these fields as well as researchers from a variety of disciplines with a goal of optimizing patient care. A survey of 20 conference attendees from 7 different facets of the MDT was conducted for feedback.
   RESULTS: The survey results revealed that most re-spondents believed the SRS conference increased educational opportunities, provided opportunities for research and collaborations, helped streamline patient care, and was beneficial to their practice.
   CONCLUSIONS: We present our institutional MDT model, framework and workflow that can be incorporated at other large academic centers. We believe that the SRS conference has educational, academic, and patient care value.
C1 [Chidambaram, Swathi; Winston, Graham M.; Ramakrishna, Rohan; Juthani, Rupa; Pannullo, Susan C.] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
   [Knisely, Jonathan P. S.; Salah, Khaled; McKenna, John T.; Jozsef, Gabor; Cardona, Danielle] Weill Cornell Med, Dept Radiat Oncol, New York, NY USA.
RP Pannullo, SC (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM scp2002@med.cornell.edu
CR Basta YL, 2017, ANN SURG ONCOL, V24, P2669, DOI 10.1245/s10434-017-5833-3
   Chinai N, 2013, CLIN RADIOL, V68, P780, DOI 10.1016/j.crad.2013.02.011
   Daveau C, 2015, EUR ARCH OTO-RHINO-L, V272, P3187, DOI 10.1007/s00405-014-3375-x
   Hahlweg P, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3768-5
   Hsu YH, 2016, HEALTH POLICY, V120, P674, DOI 10.1016/j.healthpol.2016.04.001
   Kostaras X, 2012, J CANCER EDUC, V27, P42, DOI 10.1007/s13187-011-0263-6
   Krishnan S, 2008, DIABETES CARE, V31, P99, DOI 10.2337/dc07-1178
   Monaghan J, 2005, CLIN REHABIL, V19, P194, DOI 10.1191/0269215505cr837oa
   MURPHY ML, 1975, CANCER, V35, P876, DOI 10.1002/1097-0142(197503)35:3+<876::AID-CNCR2820350705>3.0.CO;2-8
   Neligan A, 2013, EPILEPSIA, V54, pe62, DOI 10.1111/epi.12148
   Pillay B, 2016, CANCER TREAT REV, V42, P56, DOI 10.1016/j.ctrv.2015.11.007
   Reeves S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000072.pub3
   Snyder J, 2017, J NEURO-ONCOL, V133, P1, DOI 10.1007/s11060-017-2416-x
   Taylor C, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c951
NR 14
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 159
EP 162
DI 10.1016/j.wneu.2019.08.012
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300111
PM 31408748
DA 2020-05-12
ER

PT J
AU Chhabra, R
   Singh, A
   Salunke, P
   Virk, R
AF Chhabra, Rajesh
   Singh, Apinderpreet
   Salunke, Pravin
   Virk, Ramandeep
TI Unusual Presentation of Vasospasm Masking Underlying Pseudoaneurysm
   After Endoscopic Transsphenoidal Surgery in Pituitary Macroadenoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pseudoaneurysm; Transsphenoidal surgery; Vasospasm
ID COMPLICATIONS
AB BACKGROUND: Vascular complications during transsphenoidal surgery can be Devastating. Direct vascular injury during surgery can lead to various complications including pseudoaneurysm formation. Postoperative hematoma and direct vascular handling due to arachnoid tear can induce vasospasm. The vasospasm might present with varying clinical symptomatology and at times masks the underlying pathology as well.
   CASE DESCRIPTION: We present here a case of pituitary macroadenoma in whom the vasospasm caused vision loss and also concealed a developing pseudoaneurysm.
   CONCLUSIONS: Angiograms at regular intervals should be performed intervals where intraoperative vascular injury is suspected to detect such aneurysms and prevent catastrophe.
C1 [Chhabra, Rajesh; Singh, Apinderpreet; Salunke, Pravin] PGIMER, Dept Neurosurg, Chandigarh, India.
   [Virk, Ramandeep] PGIMER, Dept Otolaryngol, Chandigarh, India.
RP Singh, A (reprint author), PGIMER, Dept Neurosurg, Chandigarh, India.
EM apinderpreetsingh@gmail.com
CR Alzhrani G, 2018, WORLD NEUROSURG, V109, P233, DOI 10.1016/j.wneu.2017.09.192
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Mansouri A, 2012, CAN J NEUROL SCI, V39, P767, DOI 10.1017/S0317167100015596
   Singh A, 2017, WORLD NEUROSURG, V101, P208, DOI 10.1016/j.wneu.2017.01.115
   Yoon KW, 2014, J KOREAN NEUROSURG S, V55, P160, DOI 10.3340/jkns.2014.55.3.160
NR 5
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 163
EP 165
DI 10.1016/j.wneu.2019.07.176
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300112
PM 31376557
DA 2020-05-12
ER

PT J
AU Tanikawa, M
   Yamada, H
   Sakata, T
   Hayashi, Y
   Sasagawa, Y
   Watanabe, T
   Nagatani, T
   Mase, M
AF Tanikawa, Motoki
   Yamada, Hiroshi
   Sakata, Tomohiro
   Hayashi, Yasuhiko
   Sasagawa, Yasuo
   Watanabe, Tadashi
   Nagatani, Tetsuya
   Mase, Mitsuhito
TI Exclusive Endoscopic Occipital Transtentorial Approach for Pineal Region
   Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Occipital transtentorial approach; Pineal region tumor
ID INFRATENTORIAL; RESECTION; EXPERIENCE; MANAGEMENT
AB OBJECTIVE: Removal of pineal region tumors, which are deeply placed and encircled by intricate neurovascular structures, is challenging to neurosurgeons. The aim of this study was to present our experience with the exclusive endoscopic occipital transtentorial approach (EEOTA) used for removal of pineal region tumors.
   METHODS: A retrospective review was performed of patients who underwent surgery using the EEOTA to remove pineal region tumors from May 2016 to August 2018. The details of the EEOTA procedure were confirmed.
   RESULTS: Five patients underwent surgery via the EEOTA treatment of pineal region tumors. In all cases, it was possible to perform the EEOTA less invasively through a keyhole craniotomy approximately 2.0-2.5 cm in size. The EEOTA produced an excellent view and provided natural and automatic orientation. There was essentially no blind spot in this procedure, even for the floor or ipsilateral wall of the third ventricle. Gross total resection was achieved in 4 cases. In the patient with atypical teratoid rhabdoid tumor, we abandoned gross total resection because of a hardened adhesion to the tectum and the great cerebral vein and its tributaries. Two patients presented with transient upper gaze palsy immediately after surgery but experienced complete recovery during the follow-up period.
   CONCLUSIONS: The EEOTA is a very promising technique for removal of pineal region tumors and has the potential for extensive and routine application for surgeons familiar with endoscopic surgery.
C1 [Tanikawa, Motoki; Yamada, Hiroshi; Sakata, Tomohiro; Mase, Mitsuhito] Nagoya City Univ, Dept Neurosurg, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Hayashi, Yasuhiko; Sasagawa, Yasuo] Kanazawa Univ, Dept Neurosurg, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
   [Watanabe, Tadashi; Nagatani, Tetsuya] Japanese Red Cross Nagoya Daini Hosp, Dept Neurosurg, Nagoya, Aichi, Japan.
RP Tanikawa, M (reprint author), Nagoya City Univ, Dept Neurosurg, Grad Sch Med Sci, Nagoya, Aichi, Japan.
EM mtnkw@med.nagoya-cu.ac.jp
RI Watanabe, Tadashi/AAE-8965-2019
CR Azab Waleed A, 2014, Surg Neurol Int, V5, P39, DOI 10.4103/2152-7806.129430
   Bruce JN, 2004, J NEURO-ONCOL, V69, P221, DOI 10.1023/B:NEON.0000041885.09226.2d
   BRUCE JN, 1995, ACTA NEUROCHIR, V134, P130, DOI 10.1007/BF01417679
   Hart MG, 2013, ACTA NEUROCHIR, V155, P463, DOI 10.1007/s00701-012-1589-5
   Hernesniemi J, 2008, SURG NEUROL, V70, P576, DOI 10.1016/j.surneu.2008.07.019
   JAMIESON KG, 1971, J NEUROSURG, V35, P550, DOI 10.3171/jns.1971.35.5.0550
   Konovalov AN, 2003, SURG NEUROL, V59, P250, DOI 10.1016/S0090-3019(03)00080-6
   Little KM, 2001, J NEURO-ONCOL, V54, P287, DOI 10.1023/A:1012766902431
   Ma YY, 2013, WORLD NEUROSURG, V80, P183, DOI 10.1016/j.wneu.2012.03.007
   PLUCHINO F, 1989, ACTA NEUROCHIR, V96, P26, DOI 10.1007/BF01403491
   POPPEN JL, 1968, J NEUROSURG, V28, P357, DOI 10.3171/jns.1968.28.4.0357
   POPPEN JL, 1966, J NEUROSURG, V25, P706, DOI 10.3171/jns.1966.25.6.0706
   Qi ST, 2014, ACTA NEUROCHIR, V156, P2253, DOI 10.1007/s00701-014-2224-4
   REID WS, 1978, NEUROSURGERY, V3, P1
   Shahinian H, 2013, J NEUROL SURG PART B, V74, P114, DOI 10.1055/s-0033-1338165
   Sonabend AM, 2016, J NEURO-ONCOL, V130, P351, DOI 10.1007/s11060-016-2138-5
   STEIN BM, 1971, J NEUROSURG, V35, P197, DOI 10.3171/jns.1971.35.2.0197
   Tanikawa M, 2018, OPER NEUROSURG, V14, P206, DOI 10.1093/ons/opx089
   Tseng KY, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.05.035
   YAMAMOTO I, 1980, J NEUROSURG, V53, P205, DOI 10.3171/jns.1980.53.2.0205
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 167
EP 173
DI 10.1016/j.wneu.2019.08.038
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300114
PM 31421299
DA 2020-05-12
ER

PT J
AU La Rocca, G
   Sabatino, G
   Altieri, R
   Signorelli, F
   Ricciardi, L
   Gessi, M
   Della Pepa, GM
AF La Rocca, Giuseppe
   Sabatino, Giovanni
   Altieri, Roberto
   Signorelli, Francesco
   Ricciardi, Luca
   Gessi, Marco
   Della Pepa, Giuseppe Maria
TI Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of
   Cerebral Hemispheres
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffuse midline glioma; Glioblastoma; H3K27M-m; High-grade glioma;
   Histone mutation
ID K27M MUTATION; HISTONE H3.3
AB BACKGROUND: "Diffuse midline glioma H3K27M-mutant" (a mutation gene encoding H3 histone variants) represents a defined pathologic entity since the 2016 World Health Organization Central Nervous System classification and includes midline structures, namely the thalamus, brainstem, and spinal cord. H3K27M-mutant glioma responds more poorly and is associated with worse clinical outcome. Mutation detection is now diagnostic for "diffused midline gliomas." We report on a case arising in an atypical nonmidline localization with an exceedingly adverse course. The present case raises the question of the possible meaning of the H3K27M-mutation in high-grade gliomas arising from the cerebral hemispheres and its implications from prognostic and therapeutic views.
   CASE DESCRIPTION: A 48-year-old woman was admitted with a mass arising from the splenium of the corpus callosum with bilateral hemispheric extension, displaying magnetic resonance imaging characteristics typical of a high-grade glioma. Needle biopsy confirmed the diagnosis of "diffuse astrocytic neoplasm, World Health Organization grade IV." Immunostaining of the tumor revealed the H3K27M-mutant nuclear expression. The patient was referred to adjuvant therapy and died 3 months after biopsy.
   CONCLUSIONS: This experience highlights the possible negative prognostic impact of H3K27M-m and possibility that H3K27M-m could be a reliable prognostic indicator to be considered in not only diffuse midline gliomas but also gliomas from the cerebral hemispheres. Because of the rarity and limited knowledge of this specific mutation in this experience, reports should be encouraged.
C1 [La Rocca, Giuseppe; Sabatino, Giovanni; Signorelli, Francesco; Ricciardi, Luca; Della Pepa, Giuseppe Maria] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.
   [Altieri, Roberto] Univ Turin, Inst Neurosurg, Turin, Italy.
   [Gessi, Marco] Univ Cattolica Sacro Cuore, Inst Neuropathol, Rome, Italy.
RP Della Pepa, GM (reprint author), Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.
EM gdellapepa@hotmail.com
RI La Rocca, Giuseppe/AAG-3922-2019; Ricciardi, Luca/L-5405-2019;
   Signorelli, Francesco/Y-9746-2019; Pepa, Giuseppe Maria
   Della/AAC-1697-2019
OI La Rocca, Giuseppe/0000-0003-1830-4849; Ricciardi,
   Luca/0000-0001-5110-8386; Pepa, Giuseppe Maria
   Della/0000-0001-8698-3359; Altieri, Roberto/0000-0003-2671-4944
CR Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0
   Feng J, 2015, HUM PATHOL, V46, P1626, DOI 10.1016/j.humpath.2015.07.002
   Lopez G, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0440-x
   Pratt D, 2018, ACTA NEUROPATHOL, V135, P299, DOI 10.1007/s00401-018-1805-3
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833
NR 5
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 174
EP 176
DI 10.1016/j.wneu.2019.08.024
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300115
PM 31415896
DA 2020-05-12
ER

PT J
AU Labuschagne, JJ
   Hammer, N
AF Labuschagne, Jason John
   Hammer, Niels
TI Duplicated Vagus Nerve in Adolescence: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Duplication; Stimulation; Vagus nerve; VNS
ID NONRECURRENT LARYNGEAL NERVE; CAROTID-ARTERY SURGERY; VOCAL CORD
   PARALYSIS; ANSA CERVICALIS; PARTIAL SEIZURES; CRANIAL NERVES;
   STIMULATION; ANATOMY; EPILEPSY; GLOSSOPHARYNGEAL
AB BACKGROUND: Vagus nerve stimulation (VNS) has become an increasingly popular procedure for the treatment of epilepsy and depression. Significant complications or side effects associated with VNS surgery may result from either the inadvertent direct injury to the vagus nerve as part of the surgical approach, placement of the electrode, or the concomitant stimulation of vagal efferent fibers. To mitigate these effects, the recognition of anatomic variants that may place the nerve at increased risk is necessary.
   CASE DESCRIPTION: During microsurgical dissection of the carotid sheath for the implantation of a vagus nerve stimulator in a 17-year-old male patient with refractory epilepsy, additional nonidentified nerve tissue was found running parallel to the vagus nerve. These fibers were two thirds of the thickness of the vagus nerve and ran medial to it, from the most superior to the most inferior aspect of the carotid sheath dissection, found at a distance of at least 4 cm in a craniocaudal direction. This duplicated nerve did not appear to branch from the vagal trunk nor exit the sheath but rather paralleled the course of the vagus nerve. The parallel course and the proximity of the unidentified nerve make this structure likely to be a duplicated vagus nerve.
   CONCLUSIONS: This is the first reported case of cervical vagus nerve duplication presented in the literature. Surgeons performing VNS implantations should be cognizant of this potential anomaly in order to avoid inadvertent injury to the nerve.
C1 [Labuschagne, Jason John] Netcare Unitas Hosp, Centurion, South Africa.
   [Labuschagne, Jason John] Univ Witwatersrand, Dept Neurosurg, Johannesburg, South Africa.
   [Labuschagne, Jason John] Nelson Mandela Childrens Hosp, Dept Pediat Neurosurg, Johannesburg, South Africa.
   [Hammer, Niels] Univ Otago, Dept Anat, Dunedin, New Zealand.
   [Hammer, Niels] Univ Hosp Leipzig, Tepartment Trauma Orthoped & Plast Surg, Leipzig, Germany.
   [Hammer, Niels] Fraunhofer Inst Machine Tools & Forming Technol, Dresden, Germany.
RP Labuschagne, JJ (reprint author), Netcare Unitas Hosp, Centurion, South Africa.; Labuschagne, JJ (reprint author), Univ Witwatersrand, Dept Neurosurg, Johannesburg, South Africa.; Labuschagne, JJ (reprint author), Nelson Mandela Childrens Hosp, Dept Pediat Neurosurg, Johannesburg, South Africa.
EM Jason.labuschagne@icloud.com
CR Aalbers MW, 2009, AUTON NEUROSCI-BASIC, V147, P64, DOI 10.1016/j.autneu.2009.01.006
   Abu-Hijleh MF, 2005, ANN ANAT, V187, P121, DOI 10.1016/j.aanat.2004.06.002
   Al Omari AI, 2017, OTOLARYNGOL HEAD NEC, V38, P408
   Arakawa T, 2008, ANAT SCI INT, V83, P112, DOI 10.1111/j.1447-073X.2007.00183.x
   Banneheka S, 2008, ANAT SCI INT, V83, P145, DOI 10.1111/j.1447-073x.2007.00222.x
   Banneheka S, 2008, ANAT SCI INT, V83, P61, DOI 10.1111/j.1447-073x.2007.00202.x
   Bernard EJ, 2002, SURG NEUROL, V57, P94, DOI 10.1016/S0090-3019(01)00666-8
   Berthoud HR, 2000, AUTON NEUROSCI-BASIC, V85, P1, DOI 10.1016/S1566-0702(00)00215-0
   Binder D. K., 2010, CRANIAL NERVES ANATO
   Bonaz B, 2016, J PHYSIOL-LONDON, V594, P5781, DOI 10.1113/JP271539
   Caliot P, 1983, REV LARYNGOL OTOL RH, V104, P441
   Chakravarthy K, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0528-6
   Chhetri DK, 1997, LARYNGOSCOPE, V107, P1366, DOI 10.1097/00005537-199710000-00014
   Civelek E, 2007, J NEUROSURG-SPINE, V7, P669, DOI 10.3171/SPI-07/12/669
   Coady MA, 2000, J VASC SURG, V32, P192, DOI 10.1067/mva.2000.105680
   Ding P, 2011, COMPARATIVE MED, V61, P453
   Dionigi G, 2010, LANGENBECK ARCH SURG, V395, P893, DOI 10.1007/s00423-010-0693-3
   Elliott RE, 2011, EPILEPSY BEHAV, V20, P57, DOI 10.1016/j.yebeh.2010.10.017
   FERNANDO DA, 1994, ANN ANAT, V176, P333, DOI 10.1016/S0940-9602(11)80511-X
   Gopalakrishnan CV, 2015, J NEUROSURG-PEDIATR, V15, P535, DOI 10.3171/2014.10.PEDS14259
   Gurleyik E, 2015, TURK J SURG, V31, P182, DOI 10.5152/UCD.2015.2854
   Hammer N, 2018, SCI REP, V8, P1
   Hammer N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118006
   Hendrix P, 2014, CLIN ANAT, V27, P108, DOI 10.1002/ca.22318
   Hennessy MJ, 1998, NEUROLOGY, V51, P1224, DOI 10.1212/WNL.51.4.1224
   HENRY JF, 1988, SURGERY, V104, P977
   House PA, 2005, J NEUROSURG, V102, P390, DOI 10.3171/jns.2005.102.2.0390
   Iriarte J, 2001, NEUROLOGY, V57, P2319, DOI 10.1212/WNL.57.12.2319
   Kahlow H, 2013, SEIZURE-EUR J EPILEP, V22, P827, DOI 10.1016/j.seizure.2013.06.011
   Kang OC, 2010, EUR J RADIOL, V74, P359, DOI 10.1016/j.ejrad.2009.05.064
   Karunagaran B, 2013, J MED DENT SCI, V7, P52
   Kiray A, 2005, CLIN ANAT, V18, P179, DOI 10.1002/ca.20055
   Konschake M, 2016, SURGERY, V160, P161, DOI 10.1016/j.surg.2015.12.021
   Koulouris C, 2012, AM J SURG, V204, P49, DOI 10.1016/j.amjsurg.2011.05.011
   LANDY HJ, 1993, J NEUROSURG, V78, P26, DOI 10.3171/jns.1993.78.1.0026
   Loukas M., 2007, Folia Morphologica, V66, P120
   Lyons AJ, 1996, BR J ORAL MAXILLOFAC, V36, P180
   Mahmodlou R, 2013, INT J PREVENTIVE MED, V4, P237
   Martin JLR, 2012, EUR PSYCHIAT, V27, P147, DOI 10.1016/j.eurpsy.2011.07.006
   Mchonde GJ, 2017, INT J ANT RES, V5, P3731
   Morais M, 2015, EUR THYROID J, V4, P234, DOI 10.1159/000438751
   Morris GL, 2013, NEUROLOGY, V81, P1453, DOI 10.1212/WNL.0b013e3182a393d1
   Murphy JV, 1998, PEDIATR NEUROL, V19, P42, DOI 10.1016/S0887-8994(98)00013-7
   Mwachaka PM, 2010, FOLIA MORPHOL, V69, P160
   Ozveren MF, 2003, NEUROSURGERY, V52, P645, DOI 10.1227/01.NEU.0000048186.18741.3C
   Papagianni E, 2018, OTOLARYNGOLOGY, V2018
   PATEL JP, 2010, GUJARAT MED J, V65, P11
   Planitzer U, 2017, NEUROMODULATION, V20, P361, DOI 10.1111/ner.12557
   Qiabi M, 2011, CAN J NEUROL SCI, V38, P902, DOI 10.1017/S0317167100012506
   Quadros LS, 2013, INT J ANAT RES, V1, P69
   Raffaelli M, 2000, SURGERY, V128, P1082, DOI 10.1067/msy.2000.109966
   RAMSAY RE, 1994, EPILEPSIA, V35, P627, DOI 10.1111/j.1528-1157.1994.tb02483.x
   RATH G, 1994, SURG RADIOL ANAT, V16, P441, DOI 10.1007/BF01627669
   Rea P., 2014, CLIN ANATOMY CRANIAL, P104
   Revesz D, 2016, J NEUROSURG-PEDIATR, V18, P97, DOI 10.3171/2016.1.PEDS15534
   Rhoton AL, 2000, NEUROSURGERY, V47, pS93, DOI 10.1097/00006123-200009001-00013
   Robinson LC, 2015, J NEUROSURG, V122, P532, DOI 10.3171/2014.10.JNS14640
   Rosen CA, 2004, LARYNGOSCOPE, V114, P1549, DOI 10.1097/00005537-200409000-00009
   Rusu MC, 2011, SURG RADIOL ANAT, V33, P723, DOI 10.1007/s00276-011-0810-1
   Rychlicki F, 2006, NEUROSURG REV, V29, P103, DOI 10.1007/s10143-005-0005-5
   Sato I, 1997, J ANAT, V190, P147, DOI 10.1046/j.1469-7580.1997.19010147.x
   Saylam CY, 2009, CLIN ANAT, V22, P324, DOI 10.1002/ca.20764
   Seki A, 2014, HEART RHYTHM, V11, P1411, DOI 10.1016/j.hrthm.2014.04.032
   Shoja MM, 2014, CLIN ANAT, V27, P131, DOI 10.1002/ca.22342
   Spuck S, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f88867
   Toniato A, 2010, ACTA OTORHINOLARYNGO, V30, P107
   Tran Y, 2011, J NEUROL SCI, V304, P132, DOI 10.1016/j.jns.2011.02.022
   Vaughn BV, 2001, EPILEPTIC DISORD, V3, P75
   Vollala VR, 2005, NEUROANATOMY, V4, P8
   Williams PL, 1993, GRAYS ANATOMY
   Yuan H, 2016, HEADACHE, V56, P479, DOI 10.1111/head.12649
NR 71
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 180
EP 185
DI 10.1016/j.wneu.2019.08.014
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300117
PM 31408750
DA 2020-05-12
ER

PT J
AU Wong, AK
   Raviv, J
   Ciric, I
   Wong, RH
AF Wong, Andrew K.
   Raviv, Joseph
   Ciric, Ivan
   Wong, Ricky H.
TI Novel Use of Biodissolvable Stent in Treatment of Recurrent Rathke Cleft
   Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal surgery; Rathke cleft cyst; Recurrence; Stent
ID ALCOHOL CAUTERIZATION; OUTCOMES; SURGERY; ADVANCE
AB BACKGROUND: Rathke cleft cysts (RCCs) are benign cysts arising from the pars intermedia as a result of incomplete obliteration of the Rathke pouch during development of the pituitary gland. The most common presenting symptoms are headaches, visual disturbances, and endocrinopathies. Recurrence of RCCs after surgical treatment is a well-known phenomenon after surgery with reported recurrence rates as high as 30%. Various methods have been employed to reduce the rate of recurrence. Complete cyst wall resection has been associated with increased rates of perioperative cerebrospinal fluid leak, diabetes insipidus, and carotid injury, while inconsistently demonstrating reduced recurrence rates. Marsupialization, in which the cyst cavity is widely exposed and left open with or without a fat graft suspension, has similarly shown increased morbidity without clear improvement in outcomes. We report here the use of a steroid-eluting sinus stent to maintain patency of the cyst opening.
   CASE DESCRIPTION: A 39-year-old female presented with a symptomatic RCC. She underwent 4 different surgeries including cyst wall resection, marsupialization, and fat graft placement. She developed short-term symptomatic and radiographic recurrence within 3 months of each surgery. She then underwent placement of a steroid-eluting sinus stent. At 3 months, the patient remained symptom free, without radiographic recurrence and with patent cyst fenestration on nasal endoscopy.
   CONCLUSIONS: Recurrent RCCs are challenging to manage. Strategies to reduce recurrence are typically associated with higher risk and varying success. Stent placement represents a simple, low-risk method of potentially maintaining patency of cyst fenestration.
C1 [Wong, Andrew K.] Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
   [Raviv, Joseph; Ciric, Ivan; Wong, Ricky H.] Northshore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA.
RP Wong, RH (reprint author), Northshore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA.
EM rwong@northore.org
CR Aho CJ, 2005, J NEUROSURG, V102, P189, DOI 10.3171/jns.2005.102.2.0189
   Benveniste RJ, 2004, J NEUROSURG, V101, P577, DOI 10.3171/jns.2004.101.4.0577
   Forwith KD, 2011, LARYNGOSCOPE, V121, P2473, DOI 10.1002/lary.22228
   Han JK, 2014, INT FORUM ALLERGY RH, V4, P861, DOI 10.1002/alr.21426
   Han SJ, 2014, J NEURO-ONCOL, V117, P197, DOI 10.1007/s11060-013-1272-6
   Hsu HY, 2004, J NEUROSURG, V100, P1087, DOI 10.3171/jns.2004.100.6.1087
   Kinoshita Y, 2016, J NEUROSURG, V125, P1002, DOI 10.3171/2015.8.JNS151282
   Kuan EC, 2017, J NEUROL SURG PART B, V78, P112, DOI 10.1055/s-0036-1585088
   Larkin S, 2014, HAND CLINIC, V124, P255, DOI 10.1016/B978-0-444-59602-4.00017-4
   Lillehei KO, 2011, J NEUROSURG, V114, P310, DOI 10.3171/2010.7.JNS091793
   Lin M, 2019, J NEUROSURG, V130, P831, DOI 10.3171/2017.11.JNS171498
   Lu Victor M, 2019, Neurosurg Rev, DOI 10.1007/s10143-019-01107-2
   Luong A, 2018, JAMA OTOLARYNGOL, V144, P28, DOI 10.1001/jamaoto.2017.1859
   Marple BF, 2012, OTOLARYNG HEAD NECK, V146, P1004, DOI 10.1177/0194599811435968
   Mendelson ZS, 2014, J CLIN NEUROSCI, V21, P378, DOI 10.1016/j.jocn.2013.07.008
   Murr AH, 2011, INT FORUM ALLERGY RH, V1, P23, DOI 10.1002/alr.20020
   Raper DMS, 2009, J CLIN NEUROSCI, V16, P385, DOI 10.1016/j.jocn.2008.04.023
   Sala E, 2018, CLIN ENDOCRINOL, V89, P178, DOI 10.1111/cen.13744
   Wedemeyer MA, 2019, OPER NEUROSURG, V16, P675, DOI 10.1093/ons/opy258
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 186
EP 190
DI 10.1016/j.wneu.2019.08.035
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300118
PM 31421294
DA 2020-05-12
ER

PT J
AU Chiba, R
   Enatsu, R
   Ochi, S
   Yamada, S
   Sasagawa, A
   Suzuki, H
   Yokoyama, R
   Hirano, T
   Arihara, M
   Kuribara, T
   Mikuni, N
AF Chiba, Ryohei
   Enatsu, Rei
   Ochi, Satoko
   Yamada, Shoto
   Sasagawa, Ayaka
   Suzuki, Hime
   Yokoyama, Rintaro
   Hirano, Tsukasa
   Arihara, Masayasu
   Kuribara, Tomoyoshi
   Mikuni, Nobuhiro
TI Intraoperative Monitoring for Vagus Nerve Stimulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ansa cervicalis; Epilepsy; Intraoperative monitoring; Vagus nerve
   stimulation
ID COMPLICATIONS; EPILEPSY
AB BACKGROUND: Vagus nerve stimulation is a palliative treatment tor patients with refractory epilepsy; however, the misplacement of electrodes may cause complications and thus needs to be avoided.
   METHODS: We herein report an intraoperative monitoring technique to prevent the misplacement of electrodes. Endotracheal tube electrodes were inserted to record electromyographic activity from the vocal cords and identify the vagus nerve. Electromyography electrodes were placed on the sternomastoid muscle, sternohyoid muscle, geniohyoid muscle, and trapezius muscle to record muscle activities innervated by the ansa cervicalis. The vagus nerve and ansa cervicalis were electrically stimulated during surgery, and electromyography of the vocal cords and muscles innervated by the ansa cervicalis was recorded. The threshold of vagus nerve activation ranged between 0.05 and 0.75 mA.
   RESULTS: The vagus nerve was successfully identified and differentiated from the nerve root of the ansa cervicalis using this technique.
   CONCLUSIONS: Intraoperative monitoring of the vagus nerve and ansa cervicalis is useful for safe and effective vagus nerve stimulation.
C1 [Chiba, Ryohei; Enatsu, Rei; Ochi, Satoko; Sasagawa, Ayaka; Suzuki, Hime; Yokoyama, Rintaro; Hirano, Tsukasa; Arihara, Masayasu; Kuribara, Tomoyoshi; Mikuni, Nobuhiro] Sapporo Med Univ Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan.
   [Yamada, Shoto] Sapporo Med Univ Hosp, Div Clin Engn, Sapporo, Hokkaido, Japan.
RP Mikuni, N (reprint author), Sapporo Med Univ Hosp, Dept Neurosurg, Sapporo, Hokkaido, Japan.
EM mikunin@sapmed.ac.jp
CR Giordano F, 2017, EPILEPSIA, V58, P85, DOI 10.1111/epi.13678
   Gopalakrishnan CV, 2015, J NEUROSURG-PEDIATR, V15, P535, DOI 10.3171/2014.10.PEDS14259
   Iriarte J, 2001, NEUROLOGY, V57, P2319, DOI 10.1212/WNL.57.12.2319
   Kahlow H, 2013, SEIZURE-EUR J EPILEP, V22, P827, DOI 10.1016/j.seizure.2013.06.011
   Mikuni N, 2004, J NEUROSURG, V101, P536, DOI 10.3171/jns.2004.101.3.0536
   Rychlicki F, 2006, NEUROSURG REV, V29, P103, DOI 10.1007/s10143-005-0005-5
   Spuck S, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f88867
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 191
EP 193
DI 10.1016/j.wneu.2019.07.210
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300119
PM 31394364
DA 2020-05-12
ER

PT J
AU Kawasaki, T
   Fujitsu, K
   Ichikawa, T
   Miyahara, K
   Okada, T
   Tanino, S
   Uriu, Y
   Tanaka, Y
   Watanabe, N
   Yuda, K
AF Kawasaki, Taisuke
   Fujitsu, Kazuhiko
   Ichikawa, Teruo
   Miyahara, Kosuke
   Okada, Tomu
   Tanino, Shin
   Uriu, Yasuhiro
   Tanaka, Yusuke
   Watanabe, Nobuyuki
   Yuda, Kenji
TI Superior Oblique Myokymia: A Case Report of Surgical Treatment, Review
   of the Literature, and Consideration of Surgical Approach
SO WORLD NEUROSURGERY
LA English
DT Review
DE Microvascular decompression; Superior oblique myokymia; Surgical
   approach; Trochlear nerve
ID MICROVASCULAR DECOMPRESSION
AB BACKGROUND: Superior oblique myokymia (SOM) is a rare disorder characterized by episodic microtremor of the eyeball. in patients with SOM, inter mittent contraction of the superior oblique muscle causes irregular and rotatory eye movement, causing oscillopsia and diplopia. Microvascular decompression (MVD) of the trochlear nerve is potentially a definitive treatment method for SOM; however, owing to its rarity, this disorder is not well-known to neurosurgeons, and thus the optimal surgical approach has not yet been determined.
   CASE DESCRIPTION: A 77-year-old woman with left SOM had experienced oscillopsia for 2 years. MVD was performed via a left lateral superior cerebellar approach with the patient in the park-bench position. Her symptom resolved immediately after the surgery.
   CONCLUSIONS: We believe that MVD via a left lateral superior cerebellar approach can be safely performed to SOM in elderly patients like our patient. Therefore, MVD should be considered as the definitive treatment method for more patients with SOM.
C1 [Kawasaki, Taisuke; Fujitsu, Kazuhiko; Ichikawa, Teruo; Miyahara, Kosuke; Okada, Tomu; Tanino, Shin; Uriu, Yasuhiro; Tanaka, Yusuke; Watanabe, Nobuyuki] Natl Hosp Org, Yokohama Med Ctr, Dept Neurosurg, Yokohama, Kanagawa, Japan.
   [Yuda, Kenji] Kikuna Yuda Ophthalmol Clin, Yokohama, Kanagawa, Japan.
RP Kawasaki, T (reprint author), Natl Hosp Org, Yokohama Med Ctr, Dept Neurosurg, Yokohama, Kanagawa, Japan.
EM riviest11@gmail.com
CR BRINGEWALD PR, 1983, ARCH NEUROL-CHICAGO, V40, P526, DOI 10.1001/archneur.1983.04210070066021
   Duane A, 1906, Trans Am Ophthalmol Soc, V11, P63
   Fam MD, 2014, BRIT J NEUROSURG, V28, P552, DOI 10.3109/02688697.2013.869551
   Hashimoto M, 2004, J NEURO-OPHTHALMOL, V24, P237, DOI 10.1097/00041327-200409000-00012
   HOYT WF, 1970, ARCH OPHTHALMOL-CHIC, V84, P461, DOI 10.1001/archopht.1970.00990040463011
   Mikami T, 2005, ACTA NEUROCHIR, V147, P1005, DOI 10.1007/s00701-005-0582-7
   Ruttum MS, 2009, AM J OPHTHALMOL, V148, P563, DOI 10.1016/j.ajo.2009.05.010
   Samii M, 1998, J NEUROSURG, V89, P1020, DOI 10.3171/jns.1998.89.6.1020
   Sathyan S, 2017, MIDDLE EAST AFR J OP, V24, P162, DOI 10.4103/meajo.MEAJO_78_17
   Strupp M, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-016-0417-2
   Yousry I, 2002, RADIOLOGY, V223, P31, DOI 10.1148/radiol.2231010612
   Yousry I, 2002, ANN NEUROL, V51, P361, DOI 10.1002/ana.10118
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 197
EP 199
DI 10.1016/j.wneu.2019.07.024
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300122
PM 31299312
DA 2020-05-12
ER

PT J
AU D'Agostino, E
   Calnan, DR
   Whitson, W
   Stotland, M
   Bauer, DF
AF D'Agostino, Erin
   Calnan, Daniel R.
   Whitson, Wesley
   Stotland, Mitchell
   Bauer, David F.
TI The Use of Distraction Osteogenesis in the Treatment of
   Rickets-Associated Craniosynostosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniosynostosis; Distraction osteogenesis; Pediatric; Rickets
ID LINKED HYPOPHOSPHATEMIC RICKETS; SAGITTAL SYNOSTOSIS; CRANIAL EXPANSION;
   ANTACID USE; SECONDARY; INFANTS
AB BACKGROUND: Craniosynostosis has a known association with rickets. Because of abnormal bone development and a tendency for patients with rickets to present at an older age than most patients with craniosynostosis, repair may be complicated by inadequate cranial expansion and greater risk of sutural refusion. We present 2 cases of rickets-associated sagittal craniosynostosis and show the effectiveness of distraction osteogenesis in the surgical management of this condition.
   CASE DESCRIPTION: Two 3-year-old boys with rickets presented with sagittal synostosis and marked scaphocephalic deformity. Cranial osteotomies were performed followed by placement of 2 internal distractors. The devices were activated daily for 30 days to achieve a target transverse cranial distraction of 30 mm. A subsequent period of 10-12 weeks allowed for adequate bone consolidation. At the time of device removal, the final breadth of distraction and the quality of new bone formed was assessed. Distraction distance in both cases was verified intraoperatively to be 30 mm. Clinical examination confirmed that the distraction gaps were bridged by solid bone. The treatment protocol resulted in a significant improvement in cranial proportion in both patients, which was maintained at long-term follow-up. Estimated blood loss was high in both cases, presumably related to the hyperemic nature of rickets bone.
   CONCLUSIONS: Distraction osteogenesis promotes bone growth and cranial remodeling in patients with craniosynostosis caused by rickets. The technique allows for continuous incremental expansion of both bone and scalp tissue. We recommend consideration of distraction osteogenesis in the treatment of older children with severe deformity related to craniosynostosis, including those with rickets.
C1 [D'Agostino, Erin] Univ Vermont, Med Ctr, Sect Neurosurg, Burlington, VT USA.
   [Calnan, Daniel R.; Bauer, David F.] Dartmouth Hitchcock Med Ctr, Sect Neurosurg, Lebanon, NH 03766 USA.
   [Whitson, Wesley] Dartmouth Hitchcock Med Ctr, Sect Plast Surg, Lebanon, NH 03766 USA.
   [Stotland, Mitchell] Wenatchee Valley Hosp & Clin, Sect AlcurosurgoN, Wenatchee, WA USA.
RP Calnan, DR (reprint author), Dartmouth Hitchcock Med Ctr, Sect Neurosurg, Lebanon, NH 03766 USA.
EM Daniel.R.Calnan@hitchcock.org
OI Bauer, David/0000-0003-3548-0887
CR Collmann H, 2009, CHILD NERV SYST, V25, P217, DOI 10.1007/s00381-008-0708-3
   Currarino G, 2007, PEDIATR RADIOL, V37, P805, DOI 10.1007/s00247-007-0503-4
   Foster KA, 2008, PLAST RECONSTR SURG, V121, p70E, DOI 10.1097/01.prs.0000299393.36063.de
   Freudlsperger C, 2013, J CRANIO MAXILL SURG, V41, P842, DOI 10.1016/j.jcms.2013.01.039
   Garg R, 2010, INDIAN J ANAESTH, V54, P350, DOI 10.4103/0019-5049.68394
   Glass LRD, 2011, CASE REP OPHTHALM, V2, P376, DOI 10.1159/000334941
   Gough J, 2005, PEDIATR NEUROSURG, V41, P61, DOI 10.1159/000085158
   HARRISON HE, 1966, AM J PUBLIC HEALTH N, V56, P734, DOI 10.2105/AJPH.56.5.734
   Heschl M, 1873, VJSCHR PRAKT HEILK, V120, P135
   HUDGINS RJ, 1993, J NEUROSURG, V78, P199, DOI 10.3171/jns.1993.78.2.0199
   IMERSLUND O, 1951, Acta Paediatr, V40, P449, DOI 10.1111/j.1651-2227.1951.tb16509.x
   Inman PC, 2008, PLAST RECONSTR SURG, V121, p217E, DOI 10.1097/01.prs.0000305381.61117.2f
   Jaszczuk P, 2016, CHILD NERV SYST, V32, P887, DOI 10.1007/s00381-015-2934-9
   KANEV PM, 1995, J CRANIOFAC SURG, V6, P98, DOI 10.1097/00001665-199503000-00002
   Kosnik-Infinger L, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.2.FOCUS14847
   LITMAN NEIL N., 1957, CALIFORNIA MED, V86, P248
   Lowdon Jacqui, 2011, J Fam Health Care, V21, P25
   McCarthy J G, 1980, Ann Plast Surg, V4, P149, DOI 10.1097/00000637-198002000-00013
   MONCRIEFF MW, 1969, ARCH DIS CHILD, V44, P571, DOI 10.1136/adc.44.237.571
   Monnet P, 1962, SEM HOP PARIS, V38, P2617
   Murthy AS, 2009, J CRANIOFAC SURG, V20, P439, DOI 10.1097/SCS.0b013e31819b9868
   PIVNICK EK, 1995, CLIN PEDIATR, V34, P73, DOI 10.1177/000992289503400202
   REILLY BJ, 1964, J PEDIATR-US, V64, P396, DOI 10.1016/S0022-3476(64)80192-X
   Rowe PSN, 2005, BONE, V36, P33, DOI 10.1016/j.bone.2004.09.015
   Seruya M, 2013, J CRANIOFAC SURG, V24, P96, DOI 10.1097/SCS.0b013e318270fb83
   Shetty AK, 1998, ARCH PEDIAT ADOL MED, V152, P1243
   TAKADA M, 1992, EARLY HUM DEV, V29, P333, DOI 10.1016/0378-3782(92)90188-M
   Vega RA, 2016, J NEUROSURG-PEDIATR, V17, P694, DOI 10.3171/2015.10.PEDS15273
   Wang Page I, 2007, Radiol Case Rep, V2, P43, DOI 10.2484/rcr.v2i3.43
   Weisberg P, 2004, AM J CLIN NUTR, V80, p1697S, DOI 10.1093/ajcn/80.6.1697S
   Willis FR, 1997, J PAEDIATR CHILD H, V33, P78, DOI 10.1111/j.1440-1754.1997.tb00997.x
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 200
EP 206
DI 10.1016/j.wneu.2019.06.224
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300123
PM 31295604
DA 2020-05-12
ER

PT J
AU Higashi, E
   Hatano, T
   Ando, M
   Chihara, H
   Ogura, T
   Suzuki, K
   Yamagami, K
   Kondo, D
   Kamata, T
   Sakai, S
   Sakamoto, H
   Nagata, I
AF Higashi, Eiji
   Hatano, Taketo
   Ando, Mitsushige
   Chihara, Hideo
   Ogura, Takenori
   Suzuki, Keita
   Yamagami, Keitaro
   Kondo, Daisuke
   Kamata, Takahiko
   Sakai, Shota
   Sakamoto, Hiroki
   Nagata, Izumi
TI Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and
   Dissolved by Direct Factor Xa Inhibitor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Direct factor Xa inhibitor; Flow-diverter stent; Thrombosis
ID EMBOLIZATION DEVICE; RUPTURE
AB BACKGROUND: Antiplatelet agents are typically administered before and treatment using flow-diverter stents (FDS) to prevent thrombotic complications, but the effects of anticoagulants are unclear. We present a patient with a giant aneurysm treated with an FDS. The thrombus within the aneurysm was dissolved when a direct factor Xa inhibitor was administered to treat lower limb venous thrombosis that occurred secondary to steroid use.
   CASE DESCRIPTION: A 50-year-old woman with a 30-mm giant thrombosed aneurysm in the cavernous segment of the right internal carotid artery presenting with headache and right abducens nerve palsy was treated by placing an FDS. Diplopia and increased pain in her right eye appeared on postoperative day 7, and both were alleviated by continuous oral administration of prednisolone. Angiography 3 months postoperatively revealed that the aneurysm thrombosis had progressed, and there were signs of healing. However, at the same time, lower limb venous thrombosis occurred, which was treated by continuous edoxaban. Six months after surgery, her headaches worsened and angiography showed that the aneurysm was again contrast enhanced and that the thrombus within the aneurysm had dissolved. After discontinuing edoxaban 9 months after surgery, the aneurysmal thrombosis had again rapidly progressed.
   CONCLUSIONS: Administration of a direct factor Xa inhibitor during healing after placing an FDS may cause dissolution of an existing thrombus; therefore factor Xa inhibitors must be used with caution.
C1 [Higashi, Eiji; Hatano, Taketo; Ando, Mitsushige; Chihara, Hideo; Ogura, Takenori; Suzuki, Keita; Yamagami, Keitaro; Kondo, Daisuke; Kamata, Takahiko; Sakai, Shota; Sakamoto, Hiroki; Nagata, Izumi] Kokura Mem Hosp, Stroke Ctr, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
RP Higashi, E (reprint author), Kokura Mem Hosp, Stroke Ctr, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM eiji0016788@gmail.com
OI Higashi, Eiji/0000-0002-3461-9149; Chihara, Hideo/0000-0001-8767-6617
CR Berge J, 2011, AM J NEURORADIOL, V32, P1930, DOI 10.3174/ajnr.A2710
   Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da
   Gester K, 2016, AM J NEURORADIOL, V37, P490, DOI 10.3174/ajnr.A4555
   Hampton T, 2011, J NEUROINTERV SURG, V3, P167, DOI 10.1136/jnis.2010.002873
   Johannesdottir SA, 2013, JAMA INTERN MED, V173, P743, DOI 10.1001/jamainternmed.2013.122
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Kulcsar Z, 2011, AM J NEURORADIOL, V32, P20, DOI 10.3174/ajnr.A2370
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Sarrami-Foroushani A, 2019, J BIOMECH, V91, P7, DOI 10.1016/j.jbiomech.2019.04.045
   Touat Z, 2006, AM J PATHOL, V168, P1022, DOI 10.2353/ajpath.2006.050868
   Tritschler T, 2018, JAMA-J AM MED ASSOC, V320, P1583, DOI 10.1001/jama.2018.14346
   Tulamo R, 2010, J NEUROINTERV SURG, V2, P120, DOI 10.1136/jnis.2009.002055
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 209
EP 212
DI 10.1016/j.wneu.2019.08.053
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300125
PM 31442658
DA 2020-05-12
ER

PT J
AU Tabibkhooei, A
   Aslaninia, A
   Anousha, K
AF Tabibkhooei, Alireza
   Aslaninia, Asghar
   Anousha, Kiana
TI Childhood Transorbital Skull Base Penetrating Injury: Report of 2 Cases
   and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Penetrating eye injury; Pediatric; Stab wound; Transorbital
   brain injury
ID TRAUMATIC BRAIN-INJURY; OF-THE-LITERATURE; HEAD-INJURY; INTRACRANIAL
   INJURY; CASE SERIES; MANAGEMENT; EXPERIENCE; RECOVERY; REMOVAL; ADULT
AB BACKGROUND: A foreign object penetrating the brain via orbit is a rare occurrence. Accurate diagnosis and immediate intervention is essential to prevent ophthalmic or neurological deficits and to reduce chances of infection or hemorrhage.
   CASE DESCRIPTION: We report 2 cases of transorbital orbitocranial penetrating injury or metal objects in children. Computed tomography scan was obtained to assess the extent of the injury and to locate the objects. According to the trajectory, the best craniotomy approach was performed, and the objects were safely removed without any complication. Our cases are unique because of the absence of any neurological deficit on admission, before and after the removal.
   CONCLUSIONS: The importance of transorbital orbitocranial penetrating injury cannot be neglected because of possible orbital and intracranial damage. Therefore, in this report we aim to heighten awareness of the complexity and severity of transorbital penetrating brain injury.
C1 [Tabibkhooei, Alireza] Iran Univ Med Sci, Dept Neurosurg, Tehran, Iran.
   [Aslaninia, Asghar] Iran Univ Med Sci, Sch Med, Tehran, Iran.
   [Anousha, Kiana] Iran Univ Med Sci, Emergency Med Management Res Ctr, Tehran, Iran.
RP Anousha, K (reprint author), Iran Univ Med Sci, Emergency Med Management Res Ctr, Tehran, Iran.
EM Kiana.anousha@gmail.com
CR Agrawal A, 2016, CRANIOMAX TRAUM REC, V9, P145, DOI 10.1055/s-0035-1551545
   Ahmadi J, 2017, J SURG TRAUMA, V5, P39
   ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648
   Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293
   Bhatt AA, 2014, APPL RADIOL, V43, P10
   Borkar SA, 2014, CHILD NERV SYST, V30, P1441, DOI 10.1007/s00381-014-2364-0
   Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174
   Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006
   Chibbaro S, 2006, ACTA NEUROCHIR, V148, P937, DOI 10.1007/s00701-006-0794-5
   Dekker AP, 2014, CRANIOMAX TRAUM REC, V7, P310, DOI 10.1055/s-0034-1378178
   Erkutlu I, 2011, ULUS TRAVMA ACIL CER, V17, P79, DOI 10.5505/tjtes.2011.49092
   Estebanez G, 2015, CRANIOMAX TRAUM REC, V8, P356, DOI 10.1055/s-0035-1546813
   Farhadi MR, 2009, ACTA NEUROCHIR, V151, P685, DOI 10.1007/s00701-009-0221-9
   Fukushima T, 1991, Acta Neurochir Suppl (Wien), V53, P42
   Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc
   Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163
   Gutierrez-Gonzalez R, 2008, CLIN NEUROL NEUROSUR, V110, P207, DOI 10.1016/j.clineuro.2007.09.014
   Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155
   Ishisaka E, 2017, CHILD NERV SYST, V33, P2061, DOI 10.1007/s00381-017-3510-2
   Johnston MV, 2009, BRAIN DEV-JPN, V31, P1, DOI 10.1016/j.braindev.2008.03.014
   Joshi S, 2011, J CRANIOFAC SURG, V22, P1330, DOI 10.1097/SCS.0b013e31821c9365
   Liu DP, 2015, ACM TRANS MANAG INF, V6, DOI 10.1145/2764920
   LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409
   Mobaraki PD, 2016, J CRANIOFAC SURG, V27, P986, DOI 10.1097/SCS.0000000000002649
   MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063
   Mzimbiri JM, 2016, WORLD NEUROSURG, V87, P26, DOI 10.1016/j.wneu.2015.12.063
   Rana MA, 2014, CASE REP CRIT CARE, V2014
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Riley JP, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.09.083
   Rzaev D A, 2017, Zh Vopr Neirokhir Im N N Burdenko, V81, P77, DOI 10.17116/neiro201781277-87
   Sahuquillo J., 2006, COCHRANE DATABASE SY, V1
   Schreckinger M, 2011, J NEUROSURG, V114, P53, DOI 10.3171/2010.8.JNS10301
   Taniura S, 2004, AM J NEURORADIOL, V25, P871
   Turbin RE, 2006, SURV OPHTHALMOL, V51, P449, DOI 10.1016/j.survophthal.2006.06.008
   VILLIERS JCD, 1975, BRIT J OPHTHALMOL, V59, P52
   Zimmermann CE, 2005, INT J ORAL MAX SURG, V34, P823, DOI 10.1016/j.ijom.2005.06.015
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 213
EP 216
DI 10.1016/j.wneu.2019.06.234
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300126
PM 31295608
DA 2020-05-12
ER

PT J
AU Woo, PY
   Law, M
   Gai, X
   Ng, BF
   Ko, NMW
   Wong, HT
   Chan, KY
AF Woo, Peter Y. M.
   Law, Maggie
   Gai, Xin
   Ng, Ben C. F.
   Ko, Natalie M. W.
   Wong, Hoi-Tung
   Chan, Kwong-Yau
TI Novel Wavelength-Specific Blue Light-Emitting Headlamp for
   5-Aminolevulinic Acid Fluorescence-Guided Resection of Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-Aminolevulinic acid; Fluorescence-guided resection; Glioblastoma
ID HIGH-GRADE GLIOMAS; INTRAOPERATIVE MRI; COST-EFFECTIVENESS; SURGERY;
   MULTIFORME; CRANIOTOMY; SURVIVAL; CAMERA; EXTENT; AWAKE
AB OBJECTIVE: Extent of resection of glioblastoma is an important predictor for overall survival, and 5-aminolevulinic acid fluorescence-guided surgery can improve outcomes. However, the technique requires the installation of a blue light module on operative microscopes and may be cost prohibitive. A novel and economical blue light-emitting headlamp was designed, and its clinical utility was explored.
   METHODS: A remote-controlled dual light emitting diode headlamp system was constructed with 1 diode emitting white light and the other blue. Spectrographic analysis of the blue light emitted from a commercial operative microscope and the headlamp was performed. A comparative evaluation of the 2 illumination systems was conducted for 3 patients who underwent craniotomy for glioblastoma resection. Histologic examination of the fluorescing tissue detected by the headlamp was performed, and the extent of resection was assessed by postoperative day 1 magnetic resonance imaging.
   RESULTS: Spectrography of blue light emitted from the headlamp system was wavelength specific with a single emission peak at 416 nm and a linewidth of 35 nm. In contrast, blue light from the microscope (peak: 426 nm) had a wider linewidth of 54 nm and was not wavelength specific with additional infrared radiation detected. Gross or near-total resection of contrast-enhancing glioblastoma was performed for all 3 patients. Intraoperatively, comparable tumor fluorescence was observed under microscope and headlamp blue light illumination. Histologic examination of tissue fluorescing under headlamp blue light confirmed the presence of glioblastoma.
   CONCLUSIONS: This novel proof-of-concept blue light-emitting headlamp device may offer an opportunity for institutions with limited resources to implement 5-aminolevulinic acid fluorescence-guided glioblastoma resections.
C1 [Woo, Peter Y. M.; Ng, Ben C. F.; Ko, Natalie M. W.; Wong, Hoi-Tung; Chan, Kwong-Yau] Kwong Wah Hosp, Dept Neurosurg, Hong Kong, Peoples R China.
   [Law, Maggie] Hong Kong Acad Performing Arts, Sch Tech Arts Theater Lighting, Hong Kong, Peoples R China.
   [Gai, Xin] City Univ Hong Kong, Dept Elect Engn, Hong Kong, Peoples R China.
RP Woo, PY (reprint author), Kwong Wah Hosp, Dept Neurosurg, Hong Kong, Peoples R China.
EM wym307@ha.org.hk
OI GAI, Xin/0000-0003-4565-7279
CR Abraham P, 2019, RADIOLOGY
   Belloch JP, 2014, ACTA NEUROCHIR, V156, P653, DOI 10.1007/s00701-013-1976-6
   Belykh E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30247-6
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Eseonu CI, 2017, NEUROSURGERY, V81, P307, DOI 10.1093/neuros/nyx022
   Esteves S, 2015, NEUROSURGERY, V76, P552, DOI 10.1227/NEU.0000000000000673
   Haider SA, 2019, J NEURO-ONCOL, V141, P507, DOI 10.1007/s11060-018-03061-3
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Kubben PL, 2011, LANCET ONCOL, V12, P1062, DOI 10.1016/S1470-2045(11)70130-9
   Kuroiwa T, 2013, PHOTODIAGN PHOTODYN, V10, P379, DOI 10.1016/j.pdpdt.2013.03.004
   Lee B, 2015, BRIT J NEUROSURG, V29, P371, DOI 10.3109/02688697.2014.997664
   Lee CK, 2017, SPINE, V42, P275, DOI 10.1097/BRS.0000000000001719
   Molyadi AV, 2015, NEUROL INDIA, V63, P155
   Morshed RA, 2018, J NEUROSURG, V128, P1448, DOI 10.3171/2017.1.JNS161949
   Neira JA, 2017, J NEUROSURG, V127, P111, DOI 10.3171/2016.7.JNS16232
   Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029
   Rapp M, 2014, WORLD NEUROSURG, V82, pE277, DOI 10.1016/j.wneu.2013.07.002
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Slof J, 2015, NEUROLOGIA, V30, P163, DOI 10.1016/j.nrl.2013.11.002
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.NEU.0000297118.47076.5F, 10.1227/01.neu.0000317304.31579.17, 10.1227/01.NEU.0000346230.80425.3A]
   Stummer W, 2015, ACTA NEUROCHIR, V157, P2199, DOI 10.1007/s00701-015-2576-4
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Woo P, 2018, WORLD NEUROSURG, V115, pE375, DOI 10.1016/j.wneu.2018.04.059
NR 24
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 220
EP 226
DI 10.1016/j.wneu.2019.08.025
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300128
PM 31415891
DA 2020-05-12
ER

PT J
AU Sturda, C
   Steyn, C
   Olivi, A
   Visocchi, M
AF Sturda, Cosimo
   Steyn, Corlyze
   Olivi, Alessandro
   Visocchi, Massimiliano
TI Extraforaminal Vertebral Artery Until C2 Transverse Foramen in Down
   Syndrome Patient Affected by Atlantoaxial Subluxation: First Observation
   and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlantoaxial subluxation; Craniovertebral junction; Down syndrome;
   Transverse foramen; Vertebral artery
ID CERVICAL-SPINE; ABNORMALITIES; INSTABILITY; ANATOMY; SEGMENT
AB BACKGROUND: Patients with Down syndrome (DS) have an increased incidence of multisystem disorders, like cardiovascular, neurologic, gastrointestinal, respiratory, and musculoskeletal disorders. Craniovertebral junction instability is a common illness in DS patients, and they may often be affected by vertebral artery (VA) anomalies.
   CASE DESCRIPTION: In this paper we present neuroradiologic findings of a 34-year-old female patient affected by DS with atlantoaxial subluxation, scheduled for transoral decompression of C1-C2 and posterior occipitocervical fixation. The preoperative angio - computed tomography scan showed a peculiar anatomic variation in the entrance of the VA at the level of the C2 transverse foramen (TF). Normally, the segment of VA, named V2, becomes intraforaminal on average at the TF of C6.
   CONCLUSIONS: We reviewed the literature about the incidence of anatomic variations of the V2 segment in both the general population and the one affected by DS, and although numerous cases of anomalous course, none reported a C2 TF entry point. Ignoring such extremely rare anatomic variation during anterior, posterior, or lateral surgical approach to the cervical spine can lead to inadvertent injury and potentially serious complications like arterial dissection, thrombus, vascular spasm, fistula, pseudoaneurysm, cerebral ischemia, and death.
C1 [Sturda, Cosimo; Olivi, Alessandro; Visocchi, Massimiliano] Catholic Univ Largo F Vito, Fdn Policlin A Gemelli, Craniovertebral Junct Operat Unit, Rome, Italy.
   [Sturda, Cosimo; Olivi, Alessandro; Visocchi, Massimiliano] Catholic Univ Largo F Vito, Fdn Policlin A Gemelli, Master CVJ Surg Approach Res Ctr, Inst Neurosurg, Rome, Italy.
   [Steyn, Corlyze] Dept Neurosurg MMed Neurosurg & FC Neurosurg, Hennanus, South Africa.
   [Steyn, Corlyze] Catholic Univ, Rome, Italy.
RP Sturda, C (reprint author), Catholic Univ Largo F Vito, Fdn Policlin A Gemelli, Craniovertebral Junct Operat Unit, Rome, Italy.; Sturda, C (reprint author), Catholic Univ Largo F Vito, Fdn Policlin A Gemelli, Master CVJ Surg Approach Res Ctr, Inst Neurosurg, Rome, Italy.
EM cosimo88@icloud.com
CR Bruneau M, 2006, NEUROSURGERY, V59, P20, DOI 10.1227/01.NEU.0000219931.64378.B5
   Dodevski A, 2011, Prilozi, V32, P173
   Eskander MS, 2010, SPINE, V35, P2035, DOI 10.1097/BRS.0b013e3181c9f3d4
   Hankinson TC, 2010, NEUROSURGERY, V66, pA32, DOI 10.1227/01.NEU.0000365803.22786.F0
   Heary RF, 1996, SPINE, V21, P2074, DOI 10.1097/00007632-199609150-00004
   Inamasu J, 2005, ACTA NEUROL SCAND, V112, P349, DOI 10.1111/j.1600-0404.2005.00497.x
   Kajimoto Ben Hur Junitiro, 2007, Acta ortop. bras., V15, P84, DOI 10.1590/S1413-78522007000200005
   Matula C, 1997, SURG NEUROL, V48, P125
   Ranganatha Sastry V, 2006, ANN INDIAN ACAD NEUR, V9, P22
   RATHORE MH, 1989, AM J CARDIOL, V63, P1528, DOI 10.1016/0002-9149(89)90023-4
   SEMINE AA, 1978, J BONE JOINT SURG AM, V60, P649, DOI 10.2106/00004623-197860050-00010
   Shin HY, 2014, KOREAN J PAIN, V27, P266, DOI 10.3344/kjp.2014.27.3.266
   Standring S, 2008, GRAYS ANATOMY ANATOM
   TOUBOUL PJ, 1986, STROKE, V17, P921, DOI 10.1161/01.STR.17.5.921
   TREDWELL SJ, 1990, J PEDIATR ORTHOPED, V10, P602, DOI 10.1097/01241398-199009000-00006
   Ulusoy OL, 2016, KOREAN J RADIOL, V17, P554, DOI 10.3348/kjr.2016.17.4.554
   Yamazaki M, 2012, SPINE, V37, pE1389, DOI 10.1097/BRS.0b013e31826a0c9f
NR 17
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 230
EP 233
DI 10.1016/j.wneu.2019.08.043
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300130
PM 31425782
DA 2020-05-12
ER

PT J
AU Faltings, L
   Kulason, KO
   Patel, NV
   Wong, T
   Fralin, S
   Li, M
   Schneider, JR
   Filippi, CG
   Langer, DJ
   Ortiz, R
   Boockvar, JA
AF Faltings, Lukas
   Kulason, Kay O.
   Patel, Nitesh, V
   Wong, Tamika
   Fralin, Sherese
   Li, Mona
   Schneider, Julia R.
   Filippi, Christopher G.
   Langer, David J.
   Ortiz, Rafael
   Boockvar, John A.
TI Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab
   with Blood Brain-Barrier Disruption Results in Radiographic Response
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bevacizumab; Blood-brain barrier disruption; Glioblastoma;
   Intra-arterial; Recurrent GBM; Vascular endothelial growth factor
ID ANTIANGIOGENIC THERAPY; ADJUVANT TEMOZOLOMIDE; CEREBRAL INFUSION;
   MALIGNANT GLIOMA; RADIOTHERAPY; PROGRESSION; CONCOMITANT; IRINOTECAN;
   RESISTANT; SURVIVAL
AB BACKGROUND: High-dose bevacizumab delivered via super selective intraarterial cerebral infusion (SIACI) is one promising clinical trial combination for patients with glioblastoma (GBM). Although both continuous intravenous and intra-arterial administration of bevacizumab, and rechallenge with intravenous bevacizumab, have demonstrated improved survival, this is the first description of rechallenging GBM with SIACI of bevacizumab.
   CASE DESCRIPTION: We report a case of a 43-year-old woman with recurrent GBM who had received treatment from 3 clinical trials, including a rechallenge with SIACI of bevacizumab. First, she enrolled into a phase I/II trial for patients newly diagnosed with GBM (NCT01811498) and received 3 doses of SIACI bevacizumab over 180 days in addition to standard of care chemotherapy and radiation. Following progression, as indicated on her magnetic resonance imaging scan, she consented for a separate clinical trial for her disease and received 2 cycles of temozolomide with an investigational agent. The patient was removed from the study on tumor progression. Subsequently, she was rechallenged with SIACI of bevacizumab via a third clinical trial (NCT01269853) and then completed 3 intravenous infusions. After completing the third trial, her magnetic resonance imaging scan demonstrated improvement based on Response Assessment In Neuro-Oncology criteria.
   CONCLUSIONS: This is the first report to highlight the effect of rechallenging a patient with SIACI of bevacizumab following disease progression after initial bevacizumab treatment and subsequent alternate clinical trial failure. There is a need to conduct further clinical trials to evaluate the benefits of rechallenge with SIACI versus intravenous bevacizumab for GBM and further explore theories of bevacizumab resistance.
C1 [Faltings, Lukas; Kulason, Kay O.; Patel, Nitesh, V; Schneider, Julia R.; Langer, David J.; Ortiz, Rafael; Boockvar, John A.] Lenox Hill Hosp, Zucker Sch Med Hofstra Northwell, Dept Neurosurg, New York, NY 10021 USA.
   [Wong, Tamika; Fralin, Sherese; Li, Mona; Langer, David J.; Ortiz, Rafael; Boockvar, John A.] Lenox Hill Hosp, Dept Neurosurg, Brain Tumor Ctr, New York, NY 10021 USA.
   [Filippi, Christopher G.] Lenox Hill Hosp, Dept Radiol, Div Neuroradial, New York, NY 10021 USA.
   [Filippi, Christopher G.] Zucker Sch Med Hofstra Northwell, Dept Radiol, Manhasset, NY USA.
RP Boockvar, JA (reprint author), Lenox Hill Hosp, Zucker Sch Med Hofstra Northwell, Dept Neurosurg, New York, NY 10021 USA.; Boockvar, JA (reprint author), Lenox Hill Hosp, Dept Neurosurg, Brain Tumor Ctr, New York, NY 10021 USA.
EM jboockvar@northwell.edu
OI Faltings, Lukas/0000-0003-3208-3894
CR Balana C, 2017, NEURO-ONCOL PRACT, V4, P15, DOI 10.1093/nop/npw004
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bloch O, 2013, CLIN NEUROL NEUROSUR, V115, P1795, DOI 10.1016/j.clineuro.2013.04.017
   Boockvar JA, 2011, J NEUROSURG, V114, P624, DOI 10.3171/2010.9.JNS101223
   Bronnimann C, 2018, J NEURO-ONCOL, V138, P141, DOI 10.1007/s11060-018-2780-1
   Burkhardt JK, 2012, WORLD NEUROSURG, V77, P130, DOI 10.1016/j.wneu.2011.05.056
   Burkhardt Jan-Karl, 2011, J Exp Ther Oncol, V9, P183
   Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011
   Castro BA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14516
   Chakraborty S, 2016, J NEURO-ONCOL, V128, P405, DOI 10.1007/s11060-016-2099-8
   Chamberlain MC, 2011, CLIN MED INSIGHTS-ON, V5, P117, DOI 10.4137/CMO.S7232
   Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345
   Chinot OL, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0347-2
   Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390
   Dempsey MF, 2005, AM J NEURORADIOL, V26, P770
   ECKMAN WW, 1974, J PHARMACOKINET BIOP, V2, P257, DOI 10.1007/BF01059765
   Ellingson BM, 2017, NEUROTHERAPEUTICS, V14, P307, DOI 10.1007/s13311-016-0507-6
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Franceschi E, 2018, J NEURO-ONCOL, V139, P383, DOI 10.1007/s11060-018-2873-x
   Ghiaseddin Ashley, 2015, CNS Oncol, V4, P157, DOI 10.2217/cns.15.8
   Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281
   Jahangiri A, 2012, BBA-REV CANCER, V1825, P86, DOI 10.1016/j.bbcan.2011.10.004
   Jeon JY, 2012, AM J NEURORADIOL, V33, P2095, DOI 10.3174/ajnr.A3091
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158
   Narita Y, 2015, THER CLIN RISK MANAG, V11, P1759, DOI 10.2147/TCRM.S58289
   NEUWELT EA, 1979, J CLIN INVEST, V64, P684, DOI 10.1172/JCI109509
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   RAPOPORT SI, 1972, AM J PHYSIOL, V223, P323
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2014, NEURO-ONCOLOGY, V16, P765, DOI 10.1093/neuonc/nou092
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
   Wenger KJ, 2017, ONCOL LETT, V14, P1141, DOI 10.3892/ol.2017.6251
   Wick W, 2017, NEW ENGL J MED, V377, P1954, DOI 10.1056/NEJMoa1707358
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 234
EP 241
DI 10.1016/j.wneu.2019.07.137
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300131
PM 31351210
DA 2020-05-12
ER

PT J
AU Lu, VM
   George, ND
   Brown, DA
   Akinduro, OO
   Raghunathan, A
   Jentoft, M
   Quinones-Hinojosa, A
   Chaichana, KL
AF Lu, Victor M.
   George, Naveen D.
   Brown, Desmond A.
   Akinduro, Oluwaseun O.
   Raghunathan, Aditya
   Jentoft, Mark
   Quinones-Hinojosa, Alfredo
   Chaichana, Kaisorn L.
TI Confirming Diagnosis and Effective Treatment for Rare Epithelioid
   Glioblastoma Variant: An Integrated Survival Analysis of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE BRAF; Epithelioid; GBM; Glioblastoma; INI-1; Rhabdoid
ID BRAF V600E MUTATION; RHABDOID GLIOBLASTOMA; LOW-GRADE; PLEOMORPHIC
   XANTHOASTROCYTOMA; CONCOMITANT; FEATURES; SUBTYPE; ENTITY
AB BACKGROUND: Epithelioid glioblastoma (eGBM) is a very rare histologic variant of glioblastoma that has not been studied in isolation and, therefore, its optimal management has been largely assumed, but not confirmed. The aim of this study was to analyze all reported cases describing the presentation and clinical features to better understand the clinical significance of this histologic diagnosis.
   METHODS: A comprehensive literature search was conducted from 2005 to April 2019 identifying cases of eGBM that satisfied selection criteria for analysis. Survival was investigated using Kaplan-Meier estimations, and then univariate and multivariate logistic regression analyses for primary end point overall survival (OS) and second end point progression-free survival (PFS).
   RESULTS: A total cohort of 59 eGBM cases from 28 articles were included for final analysis. Median age of patients at diagnosis was 30 years, with 29 (46%) female patients. When reported, 100% (37/37) cases were IDH1-wild-type and 63% (19/30) were positive for the BRAFV600E mutation by immunohistochemistry. Median OS and PFS were estimated to be 11.0 months (95% confidence interval, 6.5-13.0) and 7.0 months (95% confidence interval, 3.0-10.0), respectively. Surgical extent of resection, radiation therapy, and chemotherapy all predicted superior OS and PFS on multivariate analysis (P < 0.05). No biomarkers prognosticated survival.
   CONCLUSIONS: These findings indicate that the histologic diagnosis of eGBM does not deviate from the clinical course of the broader glioblastoma diagnosis, despite being a unique histologic identity. These results argue against the temptation to deviate from the traditional management paradigm of surgery, radiation, and chemotherapy for glioblastoma based on this histology alone.
C1 [Lu, Victor M.; Brown, Desmond A.] Mayo Clin, Dept Neurosurg, Rochester, MN 55904 USA.
   [Raghunathan, Aditya] Mayo Clin, Dept Pathol, Rochester, MN USA.
   [George, Naveen D.] Univ Oxford, Magdalen Coll, Oxford, England.
   [Akinduro, Oluwaseun O.; Quinones-Hinojosa, Alfredo; Chaichana, Kaisorn L.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Jentoft, Mark] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA.
RP Lu, VM (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55904 USA.
EM lu.victor@mayo.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA183827,
   R01CA195503, R01CA216855, R01CA200399, R43CA221490]; Florida State
   Department of Health Research; William J. and Charles H. Mayo
   Professorship; Mayo Clinic
FX A.Q.H. is funded by the National Institutes of Health (R01CA183827,
   R01CA195503, R01CA216855, R01CA200399, and R43CA221490), Florida State
   Department of Health Research, the William J. and Charles H. Mayo
   Professorship, and the Mayo Clinic Clinician Investigator. The remaining
   authors have no conflicts to report.
CR Akimoto Jiro, 2005, Brain Tumor Pathol, V22, P21, DOI 10.1007/s10014-005-0173-6
   Alexandrescu S, 2016, BRAIN PATHOL, V26, P215, DOI 10.1111/bpa.12295
   Babu R, 2013, J NEUROSURG, V119, P412, DOI 10.3171/2013.3.JNS121773
   Brat DJ, 2018, ACTA NEUROPATHOL, V136, P805, DOI 10.1007/s00401-018-1913-0
   Broniscer A, 2014, NEUROPATH APPL NEURO, V40, P327, DOI 10.1111/nan.12093
   Byeon SJ, 2014, HUM PATHOL, V45, P611, DOI 10.1016/j.humpath.2013.08.024
   Ceccon G, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041090
   Chen SC, 2013, ACTA NEUROCHIR, V155, P1443, DOI 10.1007/s00701-013-1793-y
   Dai YT, 2016, MOL NEUROBIOL, V53, P1501, DOI 10.1007/s12035-015-9104-7
   Furuta T, 2018, NEUROPATHOLOGY, V38, P218, DOI 10.1111/neup.12459
   Gelal MF, 2016, CLIN NEURORADIOL, V26, P329, DOI 10.1007/s00062-014-0366-7
   Gramatzki D, 2016, CANCER-AM CANCER SOC, V122, P2206, DOI 10.1002/cncr.30023
   He MX, 2011, NEUROPATHOLOGY, V31, P421, DOI 10.1111/j.1440-1789.2010.01166.x
   Huang QL, 2019, WORLD NEUROSURG, V124, pE527, DOI 10.1016/j.wneu.2018.12.128
   Ida CM, 2015, BRAIN PATHOL, V25, P575, DOI 10.1111/bpa.12217
   Kanamori M, 2016, BRAIN TUMOR PATHOL, V33, P50, DOI 10.1007/s10014-015-0231-7
   KEPES JJ, 1987, CAN J NEUROL SCI, V14, P109
   Khanna G, 2018, PATHOL RES PRACT, V214, P679, DOI 10.1016/j.prp.2018.03.019
   Kleinschmidt-DeMasters BK, 2013, AM J SURG PATHOL, V37, P685, DOI 10.1097/PAS.0b013e31827f9c5e
   Kleinschmidt-DeMasters BK, 2010, AM J SURG PATHOL, V34, P341, DOI 10.1097/PAS.0b013e3181ce107b
   Koh Y, 2015, TRANSL ONCOL, V8, P279, DOI 10.1016/j.tranon.2015.05.003
   Korshunov A, 2018, BRAIN PATHOL, V28, P656, DOI 10.1111/bpa.12566
   Kuroda JI, 2016, NEUROPATHOLOGY, V36, P181, DOI 10.1111/neup.12258
   Lath R, 2003, J CLIN NEUROSCI, V10, P325, DOI 10.1016/S0967-5868(03)00030-4
   Le BH, 2018, CASE REP SURG, DOI 10.1155/2018/1285729
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Matsumura N, 2017, NEUROPATHOLOGY, V37, P58, DOI 10.1111/neup.12318
   Miyahara M, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.10.065
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Momota H, 2015, NAGOYA J MED SCI, V77, P321
   Momota H, 2011, BRAIN TUMOR PATHOL, V28, P65, DOI 10.1007/s10014-010-0010-4
   Nakajima N, 2018, BRAIN PATHOL, V28, P663, DOI 10.1111/bpa.12572
   Nitta N, 2018, WORLD NEUROSURG, V112, P257, DOI 10.1016/j.wneu.2018.01.200
   Nobusawa S, 2014, BRAIN PATHOL, V24, P239, DOI 10.1111/bpa.12114
   Pratt D, 2017, J NEUROPATH EXP NEUR, V76, P697, DOI 10.1093/jnen/nlx051
   PURVEY S, 2018, [No title captured], V36
   Rodriguez FJ, 2008, CANCER, V113, P2779, DOI 10.1002/cncr.23899
   ROSENBLUM MK, 1991, AM J SURG PATHOL, V15, P925, DOI 10.1097/00000478-199110000-00002
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sugimoto K, 2016, BRAIN TUMOR PATHOL, V33, P137, DOI 10.1007/s10014-015-0243-3
   Tanaka S, 2014, BRAIN TUMOR PATHOL, V31, P172, DOI 10.1007/s10014-014-0192-2
   Thuy MNT, 2015, J CLIN NEUROSCI, V22, P785, DOI 10.1016/j.jocn.2014.10.029
   Vaubel RA, 2018, BRAIN PATHOL, V28, P172, DOI 10.1111/bpa.12495
   Wang Y, 2018, MOL CLIN ONCOL, V9, P415, DOI 10.3892/mco.2018.1703
   Werner JM, 2019, WORLD NEUROSURG, V127, P213, DOI 10.1016/j.wneu.2019.04.025
   Willard N, 2015, CLIN NEUROPATHOL, V34, P330, DOI 10.5414/NP300882
   Woo PYM, 2019, ONCOTARGET, V10, P3818, DOI [10.18632/oncotarget.26932, DOI 10.18632/ONCOTARGET.26932]
   Wyatt-Ashmead J, 2001, CLIN NEUROPATHOL, V20, P248
   Yamamoto Y, 2016, DIAGN CYTOPATHOL, V44, P556, DOI 10.1002/dc.23474
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 243
EP +
DI 10.1016/j.wneu.2019.08.007
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300133
PM 31404694
DA 2020-05-12
ER

PT J
AU Gersey, Z
   Osiason, AD
   Bloom, L
   Shah, S
   Thompson, JW
   Bregy, A
   Agarwal, N
   Komotar, RJ
AF Gersey, Zachary
   Osiason, Adam D.
   Bloom, Laura
   Shah, Sumedh
   Thompson, John W.
   Bregy, Amade
   Agarwal, Nitin
   Komotar, Ricardo J.
TI Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain tumors; Glioblastoma; Notch; Notch proteins; Notch signaling;
   Targeted therapy
ID CANCER STEM-CELLS; NF-KAPPA-B; SELF-RENEWAL; SIGNALING ACTIVATION;
   INHIBITS GROWTH; HUMAN GLIOMAS; TUMOR-GROWTH; IN-VIVO; TEMOZOLOMIDE;
   EXPRESSION
AB BACKGROUND: Glioblastoma (GBM) is the most common and deadly form of brain tumor. After standard treatment of resection, radiotherapy, and chemotherapy, the 5-year survival is <5%. In recent years, research has uncovered several potential targets within the Notch signaling pathway, which may lead to improved patient outcomes.
   METHODS: A literature search was performed for articles containing the terms "Glioblastoma" and "Receptors, Notch" between 2003 and July 2015. Of the 62 articles retrieved, 46 met our criteria and were included in our review. Nine articles were identified from other sources and were subsequently included, leaving 55 articles reviewed.
   RESULTS: Of the 55 articles reviewed, 47 used established human GBM cell lines. Seventeen articles used human GBM surgical samples. Forty-five of 48 articles that assessed Notch activity showed increased expression in GBM cell lines. Targeting the Notch pathway was carried out through Notch knockdown and overexpression and targeting delta-like ligand, Jagged, gamma-secretase, ADAM10, ADAM17, and Mastermindlike protein 1. Arsenic trioxide, microRNAs, and several other compounds were shown to have an effect on the Notch pathway in GBM. Notch activity in GBM was also shown to be associated with hypoxia and certain cancer-related molecular pathways such as PI3K/AKT/mTOR and ERK/MAPK. Most articles concluded that Notch activity amplifies malignant characteristics in GBM and targeting this pathway can bring about amelioration of these effects.
   CONCLUSIONS: Recent literature suggests targeting the Notch pathway has great potential for future therapies for GBM.
C1 [Osiason, Adam D.; Bloom, Laura; Shah, Sumedh; Thompson, John W.; Bregy, Amade; Komotar, Ricardo J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Gersey, Zachary; Agarwal, Nitin] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA.
RP Komotar, RJ (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM RKomotar@med.miami.edu
OI Agarwal, Nitin/0000-0003-0256-3897
CR Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006
   Chen XR, 2013, NEUROSCI LETT, V537, P44, DOI 10.1016/j.neulet.2013.01.021
   Chigurupati S, 2010, CANCER RES, V70, P418, DOI 10.1158/0008-5472.CAN-09-2654
   Chu Q, 2013, CLIN CANCER RES, V19, P3224, DOI 10.1158/1078-0432.CCR-12-2119
   Clark PA, 2007, DEV DYNAM, V236, P3297, DOI 10.1002/dvdy.21381
   Dai L, 2011, PROTEOMICS, V11, P4529, DOI 10.1002/pmic.201000730
   Ding DC, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-31
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   El Hindy N, 2013, NEURO-ONCOLOGY, V15, P1366, DOI 10.1093/neuonc/not071
   Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254
   Fassl A, 2012, ONCOGENE, V31, P4698, DOI 10.1038/onc.2011.615
   Floyd DH, 2012, NEURO-ONCOLOGY, V14, P1215, DOI 10.1093/neuonc/nos157
   Gao X, 2007, J NEURO-ONCOL, V84, P147, DOI 10.1007/s11060-007-9364-9
   Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950
   Gilbert CA, 2010, CANCER RES, V70, P6870, DOI 10.1158/0008-5472.CAN-10-1378
   Gupta A, 2008, PROSTATE, V68, P50, DOI 10.1002/pros.20650
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hess S, 2007, J NEUROSURG, V107, P1060, DOI 10.3171/JNS-07/11/1060
   Hiddingh L, 2014, ONCOTARGET, V5, P363, DOI 10.18632/oncotarget.1620
   Hopfer O, 2005, BRIT J CANCER, V93, P709, DOI 10.1038/sj.bjc.6602719
   Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429
   Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0566-7
   Huber RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057793
   Hulleman E, 2009, J CELL MOL MED, V13, P136, DOI 10.1111/j.1582-4934.2008.00307.x
   Iacob Gabriel, 2009, J Med Life, V2, P386
   Jeon HM, 2008, GENE DEV, V22, P2028, DOI 10.1101/gad.1668708
   Jhanwar-Uniyal M, 2015, CANCERS, V7, P538, DOI 10.3390/cancers7020538
   Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kovall RA, 2017, DEV CELL, V41, P228, DOI 10.1016/j.devcel.2017.04.001
   Kristoffersen K, 2014, CANCER BIOL THER, V15, P862, DOI 10.4161/cbt.28876
   Kristoffersen K, 2013, CANCER BIOL THER, V14, P625, DOI 10.4161/cbt.24595
   Li AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541-7786.MCR-07-0280
   Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704
   Li WB, 2011, CANCER BIOL THER, V12, P477, DOI 10.4161/cbt.12.6.16300
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529
   Lim KJ, 2012, ANTICANCER RES, V32, P2689
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Lin H, 2011, ONCOL REP, V26, P925, DOI 10.3892/or.2011.1380
   Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134
   Liu FC, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/568634
   Margareto J, 2007, J MOL NEUROSCI, V32, P53, DOI 10.1007/s12031-007-0008-5
   Monticone M, 2009, MOL CANCER RES, V7, P1822, DOI 10.1158/1541-7786.MCR-09-0225
   Mullendore ME, 2009, CLIN CANCER RES, V15, P2291, DOI 10.1158/1078-0432.CCR-08-2004
   Pointer KB, 2014, NEUROCHEM INT, V71, P1, DOI 10.1016/j.neuint.2014.03.005
   Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95
   Qiang L, 2009, CANCER LETT, V279, P13, DOI 10.1016/j.canlet.2009.01.016
   Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187
   Raghu H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-130
   Rampazzo E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.32
   Reichrath S, 2010, J STEROID BIOCHEM, V121, P420, DOI 10.1016/j.jsbmb.2010.02.028
   Reisman SA, 2012, J AM SOC NEPHROL, V23, P1663, DOI 10.1681/ASN.2012050457
   Schreck KC, 2010, CLIN CANCER RES, V16, P6060, DOI 10.1158/1078-0432.CCR-10-1624
   Shao HW, 2012, ADV PHARMACOL, V65, P191, DOI 10.1016/B978-0-12-397927-8.00007-5
   Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526
   Sivasankaran B, 2009, CANCER RES, V69, P458, DOI 10.1158/0008-5472.CAN-08-2610
   Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865
   Sooman L, 2013, CANCER CHEMOTH PHARM, V72, P329, DOI 10.1007/s00280-013-2197-7
   Spratt DE, 2014, J NEURO-ONCOL, V116, P357, DOI 10.1007/s11060-013-1302-4
   Stepanenko AA, 2014, GENE, V540, P263, DOI 10.1016/j.gene.2014.02.053
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sun JC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002488
   Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488
   Tchorz JS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.65
   Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198
   Wan Y, 2013, IN VITRO CELL DEV-AN, V49, P599, DOI 10.1007/s11626-013-9644-y
   Wang H, 2014, J CLIN INVEST, V124, P4489, DOI 10.1172/JCI75284
   Wang JP, 2012, MOL BIOL REP, V39, P2497, DOI 10.1007/s11033-011-1001-1
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078-0432.CCR-12-2895
   Wu JN, 2013, TOXICOL LETT, V220, P61, DOI 10.1016/j.toxlet.2013.03.019
   Xu P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053654
   Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58
   Ying MY, 2011, STEM CELLS, V29, P20, DOI 10.1002/stem.561
   Ylivinkka I, 2013, J CELL SCI, V126, P2459, DOI 10.1242/jcs.120022
   Zhang XH, 2012, CANCER SCI, V103, P181, DOI 10.1111/j.1349-7006.2011.02154.x
   Zhen YB, 2010, CANCER LETT, V292, P64, DOI 10.1016/j.canlet.2009.11.005
   Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269
NR 80
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 252
EP +
DI 10.1016/j.wneu.2019.07.180
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300134
PM 31376551
DA 2020-05-12
ER

PT J
AU Head, J
   Mazza, J
   Sabourin, V
   Turpin, J
   Hoelscher, C
   Wu, CY
   Sharan, A
AF Head, Jeffery
   Mazza, Jacob
   Sabourin, Victor
   Turpin, Justin
   Hoelscher, Christian
   Wu, Chengyuan
   Sharan, Ashwini
TI Waves of Pain Relief: A Systematic Review of Clinical Trials in Spinal
   Cord Stimulation Waveforms for the Treatment of Chronic Neuropathic Low
   Back and Leg Pain
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic pain; Literature review; Low back pain; Randomized controlled
   trial; Spinal cord stimulation; Stimulation waveforms
ID CONVENTIONAL MEDICAL-MANAGEMENT; RANDOMIZED CONTROLLED-TRIAL;
   HIGH-FREQUENCY STIMULATION; 10-KHZ HIGH-FREQUENCY; SURGERY SYNDROME;
   DOUBLE-BLIND; MULTICENTER; OUTCOMES; EFFICACY
AB In the United States, chronic low back pain affects up to 37% of adults and is a multibillion dollar health care expenditure. Spinal cord simulation (SCS) has been established as an effective treatment alternative for chronic neuropathic low back and leg pain, especially for patients with failed back surgery syndrome or chronic regional pain syndrome. The field of SCS has rapidly advanced such that analgesia can now be achieved through numerous different waveforms, each claiming to offer improved outcomes. These waveforms include traditional paresthesia-based SCS (<100 Hz), paresthesia-free high-frequency SCS (5-10 kHz), burst SCS, and subperception SCS (1-5 kHz). Level 1 evidence critically evaluating the efficacy of these different waveforms is lacking. We conducted a systematic review of the literature in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify all randomized controlled trials of SCS in the treatment of chronic neuropathic low back and leg pain, failed back surgery syndrome, or chronic regional pain syndrome. Of 38 eligible studies reviewed, 13 randomized controlled trials were finally included in our systematic review. We reviewed evidence from randomized controlled trials in the field of SCS that have established paresthesia-based SCS, paresthesia-free high-frequency SCS, burst SCS, and subperception SCS as viable treatment options for chronic neuropathic low back and leg pain. We critically evaluated evidence that claims to support the use of one waveform over another and reviewed the literature on patient preference for different waveforms.
C1 [Head, Jeffery; Mazza, Jacob; Turpin, Justin] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   [Head, Jeffery; Mazza, Jacob; Sabourin, Victor; Turpin, Justin; Hoelscher, Christian; Wu, Chengyuan; Sharan, Ashwini] Thomas Jefferson Univ, Vicki & Jack Farber Inst Neurosci, Dept Neurosurg, Philadelphia, PA 19107 USA.
RP Sabourin, V (reprint author), Thomas Jefferson Univ, Vicki & Jack Farber Inst Neurosci, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM victor.sabourin@jefferson.edu
RI Wu, Chengyuan/AAE-2502-2020
OI Wu, Chengyuan/0000-0002-3954-2929
CR Al-Kaisy A, 2018, NEUROMODULATION, V21, P457, DOI 10.1111/ner.12771
   Al-Kaisy A, 2018, PAIN MED, V19, P1219, DOI 10.1093/pm/pnx237
   Al-Kaisy A, 2014, PAIN MED, V15, P347, DOI 10.1111/pme.12294
   Arle JE, 2016, NEUROMODULATION, V19, P385, DOI 10.1111/ner.12436
   Bicket MC, 2016, PAIN MED, V17, P2326, DOI 10.1093/pm/pnw156
   Burchiel KJ, 1996, SPINE, V21, P2786, DOI 10.1097/00007632-199612010-00015
   Chan CW, 2011, PAIN MED, V12, P577, DOI 10.1111/j.1526-4637.2011.01089.x
   Chou R, 2007, ANN INTERN MED, V147, P505, DOI 10.7326/0003-4819-147-7-200710020-00008
   De Andres J, 2017, PAIN MED, V18, P2401, DOI 10.1093/pm/pnx241
   De Ridder D, 2010, NEUROSURGERY, V66, P986, DOI 10.1227/01.NEU.0000368153.44883.B3
   Deer T, 2018, NEUROMODULATION, V21, P56, DOI 10.1111/ner.12698
   Duse G, 2019, NEUROMODULATION, V22, P200, DOI 10.1111/ner.12899
   Elsamadicy AA, 2017, NEUROMODULATION, V20, P354, DOI 10.1111/ner.12584
   Grider J, 2016, PAIN PHYSICIAN, V19, pE33
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Kapural L, 2016, NEUROSURGERY, V79, P667, DOI 10.1227/NEU.0000000000001418
   Kapural L, 2015, ANESTHESIOLOGY, V123, P851, DOI 10.1097/ALN.0000000000000774
   Kriek N, 2017, EUR J PAIN, V21, P507, DOI 10.1002/ejp.944
   Kumar K, 2005, NEUROMODULATION, V8, P213, DOI 10.1111/j.1525-1403.2005.00027.x
   Kumar K, 2008, NEUROSURGERY, V63, P762, DOI 10.1227/01.NEU.0000325731.46702.D9
   Kumar K, 2007, PAIN, V132, P179, DOI 10.1016/j.pain.2007.07.028
   Kumar V, 2018, NEUROMODULATION, V21, P466, DOI 10.1111/ner.12755
   Mekhail N, 2018, REGION ANESTH PAIN M, V43, P391, DOI 10.1097/AAP.0000000000000744
   Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1
   Mokdad AH, 2018, JAMA-J AM MED ASSOC, V319, P1444, DOI 10.1001/jama.2018.0158
   North JM, 2016, NEUROMODULATION, V19, P731, DOI 10.1111/ner.12441
   North RB, 2005, NEUROSURGERY, V56, P98, DOI 10.1227/01NEU.0000144839.65524.E0
   NORTH RB, 1994, STEREOT FUNCT NEUROS, V62, P267, DOI 10.1159/000098631
   NORTH RB, 1991, PAIN, V44, P119, DOI 10.1016/0304-3959(91)90125-H
   OCEBM Levels of Evidence Working Group, OXFORD 2011 LEVELS E
   Perruchoud C, 2013, NEUROMODULATION, V16, P363, DOI 10.1111/ner.12027
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Raslan AM, 2018, FUNCTIONAL NEUROSURG
   Schu S, 2014, NEUROMODULATION, V17, P443, DOI 10.1111/ner.12197
   Sherman SM, 2001, TRENDS NEUROSCI, V24, P122, DOI 10.1016/S0166-2236(00)01714-8
   Thomson SJ, 2018, NEUROMODULATION, V21, P67, DOI 10.1111/ner.12746
   Van Havenbergh T, 2015, NEUROMODULATION, V18, P9, DOI 10.1111/ner.12252
NR 37
TC 2
Z9 2
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 264
EP +
DI 10.1016/j.wneu.2019.07.167
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300135
PM 31369885
DA 2020-05-12
ER

PT J
AU You, E
   Bokhari, R
   Sirhan, D
AF You, Eunice
   Bokhari, Rakan
   Sirhan, Denis
TI Split-Pons Syndrome by Epidermoid Cyst: A Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brainstem; Epidermoid cyst; Infiltrating; Pons; Posterior fossa
ID BRAIN-STEM; MANAGEMENT; TUMORS
AB BACKGROUND: Epidermoid cysts are slow-growing extra-axial lesions that account for approximately 1% of all brain tumors. They rarely occur in the brain stem, and those possessing both intra-axial as well as extra-axial components represent an even smaller subset.
   CASE DESCRIPTION: We report the unusual manifestation of 2 adult male patients, whose recurrent posterior fossa epidermoid cysts progressively invaded the anterior surface of the pans. Over the years, the patients would present with various complaints of ataxia, diplopia, facial spasms, and hearing loss and underwent several interventions for recurrence. Eventually, the epidermoid cysts progressed to completely split the pons, forming a surgical corridor that was amenable to a posterior approach. We describe the patients' favorable clinical courses, pathologic and neuroradiologic findings, as well as review the literature for similar such cases.
   CONCLUSIONS: To the best of our knowledge, there are only 8 other cases of brainstem epidermoid lesions reported in the literature that are presumed to have originated extrinsically and thereafter transgressed the pons. However, we are the first to provide radiographic documentation confirming the progression of the lesions from extra-axial to intraparenchymal. Furthermore, although clinically subtle, we have decided to coin the term "split-pons syndrome" to better define this radiologic entity. Based on the evolution of the epidermoid's growth pattern, the authors propose a delayed posterior approach (telo-velotonsillar) to minimize morbidity.
C1 [You, Eunice] McGill Univ, Fac Med, Montreal, PQ, Canada.
   [Bokhari, Rakan] King Abdulaziz Univ, Fac Med, Dept Surg, Div Neurosurg, Jeddah, Saudi Arabia.
   [Bokhari, Rakan; Sirhan, Denis] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada.
RP Sirhan, D (reprint author), McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada.
EM denis.sirhan@mcgill.ca
OI Sirhan, Denis/0000-0002-0396-9103; You, Eunice/0000-0002-0860-3100
FU King Abdulaziz University; Saudi Arabian Cultural Bureau
FX R.B. is supported by a scholarship from King Abdulaziz University and
   the Saudi Arabian Cultural Bureau.
CR Abrey LE, 2011, FAST FACTS BRAIN TUM
   Ahmed I, 2009, J NEUROSURG-PEDIATR, V4, P91, DOI 10.3171/2009.4.PEDS08489
   BHATIA R, 1978, NEUROL INDIA, V26, P76
   Caldarelli M, 2004, J NEUROSURG, V100, P473, DOI 10.3171/ped.2004.100.5.0473
   DESOUZA CE, 1989, J NEUROL NEUROSUR PS, V52, P986, DOI 10.1136/jnnp.52.8.986
   Dutta M, 2013, INDIAN J OTOLARYNGOL, V65, pS14, DOI 10.1007/s12070-011-0363-y
   Gopalakrishnan CV, 2012, J CHILD NEUROL, V27, P105, DOI 10.1177/0883073811414709
   Hanna EY, 2009, COMPREHENSIVE MANAGE
   IIHARA K, 1989, SURG NEUROL, V32, P377, DOI 10.1016/0090-3019(89)90143-2
   Kachhara R, 2000, ACTA NEUROCHIR, V142, P97, DOI 10.1007/s007010050013
   Kuzeyli K, 1996, NEUROSURG REV, V19, P179, DOI 10.1007/BF00512049
   LEAL O, 1978, J NEUROSURG, V48, P811, DOI 10.3171/jns.1978.48.5.0811
   Malcolm GP, 1996, NEUROSURGERY, V38, P579, DOI 10.1097/00006123-199603000-00032
   Mask-Bull L, 2013, CLIN NEUROL NEUROSUR, V115, P1888, DOI 10.1016/j.clineuro.2013.05.002
   OBANA WG, 1991, J NEUROSURG, V74, P123, DOI 10.3171/jns.1991.74.1.0123
   Ouzek MM, 2015, POSTERIOR FOSSA TUMO
   Patibandla M R, 2016, Asian J Neurosurg, V11, P194, DOI 10.4103/1793-5482.145163
   Recinos PF, 2006, J NEUROSURG, V104, P285, DOI 10.3171/ped.2006.104.4.285
   Santos MV, 2013, NEUROCIRUGIA, V24, P135, DOI 10.1016/j.neucir.2012.09.007
   SCHWARTZ JF, 1978, NEUROLOGY, V28, P124, DOI 10.1212/WNL.28.2.124
   Takahashi M, 2007, NEUROL MED-CHIR, V47, P140, DOI 10.2176/nmc.47.140
   Talacchi A, 1998, NEUROSURGERY, V42, P242, DOI 10.1097/00006123-199802000-00020
   YASARGIL MG, 1989, NEUROSURGERY, V24, P561
   Zada G, 2016, ATLAS SELLAR PARASEL
   Zheng J, 2018, J NEURO-ONCOL, V138, P591, DOI 10.1007/s11060-018-2826-4
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 275
EP +
DI 10.1016/j.wneu.2019.07.072
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300136
PM 31306846
DA 2020-05-12
ER

PT J
AU Tomlinson, SB
   Hendricks, BK
   Cohen-Gadol, A
AF Tomlinson, Samuel B.
   Hendricks, Benjamin K.
   Cohen-Gadol, Aaron
TI Immersive Three-Dimensional Modeling and Virtual Reality for Enhanced
   Visualization of Operative Neurosurgical Anatomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D; The Neurosurgical Atlas; Operative anatomy; Resident education;
   Virtual reality
ID VENTRICULOSTOMY CATHETER PLACEMENT; STEREOTACTIC ATLAS; CRANIAL NERVES;
   TEMPORAL BONE; VISIBLE HUMAN; SURGICAL SIMULATION; INTERACTIVE ATLAS;
   NEXT-GENERATION; BRAIN ATLAS; HUMAN SKULL
AB Learning the endless intricacies of operative neurosurgical anatomy requires that surgeons complement their intraoperative experiences with a variety of educational resources. In the past 2 decades, rapid improvements in digital graphics and computing power have enabled a new generation of 3-dimensional (3D) virtual resources that overcome limitations of more traditional 2-dimensional materials. Today, dozens of immersive 3D visualization platforms exist for applications such as learning neuro-anatomy, simulating operative techniques, and planning surgical interventions with patient-specific models. The purpose of this article is to identify current applications of 3D digital modeling and virtual reality in neurosurgery. In addition, we showcase a new series of freely available 3D virtual-reality models created to assist in learning complex cranial anatomy. We anticipate these models to have a wide range of educational, clinical, and research applications. Three-dimensional visualization is poised to modernize the ways we learn and teach neurosurgical anatomy outside of the operating room. Future generations of neurosurgeons are expected to benefit from these technologies from the earliest stages of training.
C1 [Tomlinson, Samuel B.; Hendricks, Benjamin K.; Cohen-Gadol, Aaron] Neurosurg Atlas, Indianapolis, IN 46202 USA.
   [Tomlinson, Samuel B.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA.
   [Hendricks, Benjamin K.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Cohen-Gadol, Aaron] Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.
   [Cohen-Gadol, Aaron] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA.
RP Cohen-Gadol, A (reprint author), Neurosurg Atlas, Indianapolis, IN 46202 USA.; Cohen-Gadol, A (reprint author), Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.; Cohen-Gadol, A (reprint author), Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA.
EM acohenmd@gmail.com
RI Hendricks, Benjamin/AAI-6544-2020; Tomlinson, Samuel/AAE-7725-2020
OI Hendricks, Benjamin/0000-0002-7123-4387; 
FU Samerian Foundation
FX We acknowledge the generous support of the Samerian Foundation.
CR Ackerman MJ, 2001, STUD HEALTH TECHNOL, V84, P887
   Alaraj A, 2015, OPER NEUROSURG, V11, P52, DOI 10.1227/NEU.0000000000000583
   Allen LK, 2016, ANAT SCI EDUC, V9, P431, DOI 10.1002/ase.1604
   Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515
   Bernardo A, 2003, NEUROSURGERY, V52, P499, DOI 10.1227/01.NEU.0000047813.32607.68
   Bernardo A, 2017, WORLD NEUROSURG, V106, P991, DOI [10.1016/j.wneu.2017.06.160, 10.1016/J.WNEU.2017.06.160]
   Berney S, 2015, ANAT SCI EDUC, V8, P452, DOI 10.1002/ase.1524
   Bradley S W, 1995, Proc Annu Symp Comput Appl Med Care, P512
   Brewer Danielle N, 2012, Stud Health Technol Inform, V173, P85
   Brinkley JF, 1997, COMPUT BIOMED RES, V30, P472, DOI 10.1006/cbmr.1997.1461
   Choudhury Nusrat, 2013, World Neurosurg, V80, pe9, DOI 10.1016/j.wneu.2012.08.022
   Clark AD, 2017, J SURG EDUC, V74, P828, DOI 10.1016/j.jsurg.2017.02.007
   Cohen AR, 2013, CHILD NERV SYST, V29, P1235, DOI 10.1007/s00381-013-2139-z
   Davidson B, 2018, J SURG EDUC, V75, P1615, DOI 10.1016/j.jsurg.2018.05.001
   de Notaris M, 2013, WORLD NEUROSURG S, V79, pe9
   de Notaris M, 2014, WORLD NEUROSURG, V82, pS41, DOI 10.1016/j.wneu.2014.07.024
   Santos BFD, 2018, WORLD NEUROSURG, V110, pE864, DOI 10.1016/j.wneu.2017.11.123
   de Ribaupierre S, 2012, COMPUT BIOL MED, V42, P692, DOI 10.1016/j.compbiomed.2012.03.005
   Ferroli P, 2010, NEUROSURGERY, V67, P79, DOI 10.1227/01.NEU.0000383133.01993.96
   Gasco J, 2013, NEUROSURGERY, V73, P39, DOI 10.1227/NEU.0000000000000102
   Gmeiner M, 2018, WORLD NEUROSURG, V112, pE313, DOI 10.1016/j.wneu.2018.01.042
   Harput MV, 2014, OPER NEUROSURG, V10, P426, DOI 10.1227/NEU.0000000000000355
   Harrop J, 2013, NEUROSURGERY, V73, P25, DOI 10.1227/NEU.0000000000000101
   Hendricks BK, 2018, OPER NEUROSURG, V15, P613, DOI 10.1093/ons/opy283
   Hendricks BK, 2018, OPER NEUROSURG, V15, P368, DOI 10.1093/ons/opy166
   Hendricks BK, 2018, OPER NEUROSURG, V15, P365, DOI 10.1093/ons/opy167
   Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088
   Jastrow H, 2003, CLIN ANAT, V16, P44, DOI 10.1002/ca.10062
   Karmonik C, 2018, WORLD NEUROSURG, V119, pE617, DOI 10.1016/j.wneu.2018.07.222
   Khot Z, 2013, ANAT SCI EDUC, V6, P211, DOI 10.1002/ase.1355
   Kimura T, 2009, NEUROSURGERY, V65, P719, DOI 10.1227/01.NEU.0000354350.88899.07
   Kirkman MA, 2014, J NEUROSURG, V121, P228, DOI 10.3171/2014.5.JNS131766
   Kockro RA, 2000, NEUROSURGERY, V46, P118
   Kockro RA, 2009, NEUROSURGERY, V64, P216, DOI 10.1227/01.NEU.0000343744.46080.91
   Konakondla S, 2017, ADV MED EDUC PRACT, V8, P465, DOI 10.2147/AMEP.S113565
   Kuppersmith R B, 1997, Stud Health Technol Inform, V39, P180
   Lee C, 2019, J CLIN NEUROSCI, V62, P14, DOI 10.1016/j.jocn.2018.12.036
   Lemole M, 2009, NEUROL RES, V31, P430, DOI 10.1179/174313208X353695
   Locketz GD, 2017, OTOLARYNG HEAD NECK, V156, P1142, DOI 10.1177/0194599817691474
   Malone HR, 2010, NEUROSURGERY, V67, P1105, DOI 10.1227/NEU.0b013e3181ee46d0
   Marchenko Y, 2010, J DIGIT IMAGING, V23, P386, DOI 10.1007/s10278-009-9194-8
   Marinho P, 2014, SIMUL HEALTHC, V9, P370, DOI 10.1097/SIH.0000000000000056
   Mazur T, 2018, WORLD NEUROSURG, V110, P414, DOI 10.1016/j.wneu.2017.11.132
   Morone PJ, 2019, WORLD NEUROSURG, V122, pE1412, DOI 10.1016/j.wneu.2018.11.074
   Ng CL, 2015, OTOLARYNG HEAD NECK, V153, P832, DOI 10.1177/0194599815584600
   Nguyen N, 2014, ANAT SCI EDUC, V7, P280, DOI 10.1002/ase.1415
   Nicholson DT, 2006, MED EDUC, V40, P1081, DOI 10.1111/j.1365-2929.2006.02611.x
   Nowinski WL, 2013, NEURORADIOL J, V26, P252, DOI 10.1177/197140091302600302
   Nowinski WL, 2013, NEURORADIOL J, V26, P263, DOI 10.1177/197140091302600303
   Nowinski WL, 2013, NEURORADIOL J, V26, P56, DOI 10.1177/197140091302600110
   Nowinski WL, 2012, J NEUROSCI METH, V204, P44, DOI 10.1016/j.jneumeth.2011.10.021
   Nowinski WL, 2011, NEUROIMAGE, V55, P986, DOI 10.1016/j.neuroimage.2010.12.079
   Nowinski Wieslaw L, 2018, Brain Inform, V5, P1, DOI 10.1186/s40708-018-0082-1
   Nowinski WL, 2017, NEUROINFORMATICS, V15, P395, DOI 10.1007/s12021-017-9339-8
   Nowinski Wieslaw L, 2015, Brain Inform, V2, P65
   Nowinski WL, 2015, NEURORADIOL J, V28, P190, DOI 10.1177/1971400915576669
   Nowinski WL, 2015, J NEUROSCI METH, V246, P65, DOI 10.1016/j.jneumeth.2015.02.012
   Nowinski WL, 2013, J NEUROSCI METH, V215, P12, DOI 10.1016/j.jneumeth.2013.02.005
   Nowinski WL, 2012, J NEUROSCI METH, V206, P205, DOI 10.1016/j.jneumeth.2012.02.026
   Nowinski WL, 2012, NEUROINFORMATICS, V10, P33, DOI 10.1007/s12021-011-9118-x
   Nowinski WL, 2010, J NEUROSURG, V113, P1234, DOI 10.3171/2010.2.JNS091528
   Nowinski WL, 2009, ANAT SCI EDUC, V2, P244, DOI 10.1002/ase.106
   Nowinski WL, 2009, NEUROINFORMATICS, V7, P23, DOI 10.1007/s12021-008-9028-8
   Oishi M, 2013, J NEUROSURG, V119, P94, DOI 10.3171/2013.3.JNS121109
   Petersson H, 2009, ANAT SCI EDUC, V2, P61, DOI 10.1002/ase.76
   Phillips NI, 2000, NEUROSURGERY, V46, P933, DOI 10.1097/00006123-200004000-00031
   Pommert A, 2006, ACAD RADIOL, V13, P104, DOI 10.1016/j.acra.2005.08.034
   Preim B, 2018, COMPUT GRAPH-UK, V71, P132, DOI 10.1016/j.cag.2018.01.005
   Pujol S, 2016, ACAD RADIOL, V23, P507, DOI 10.1016/j.acra.2015.12.012
   Qian ZH, 2018, J CRANIOFAC SURG, V29, P163, DOI 10.1097/SCS.0000000000004046
   Randazzo Michael, 2016, Surg Neurol Int, V7, pS801
   Rosse C, 1998, J AM MED INFORM ASSN, V5, P17, DOI 10.1136/jamia.1998.0050017
   Ruisoto P, 2012, ANAT SCI EDUC, V5, P132, DOI 10.1002/ase.1275
   Schiemann T, 2000, COMPUT MED IMAG GRAP, V24, P127, DOI 10.1016/S0895-6111(00)00013-6
   Schubert R, 1997, ACTA ANAT, V160, P123
   Spicer MA, 2003, NEUROSURGERY, V52, P489, DOI 10.1227/01.NEU.0000047812.42726.56
   Spicer MA, 2003, NEUROSURGERY, V52, P496
   Spitzer VM, 2006, CLIN ANAT, V19, P192, DOI 10.1002/ca.20330
   Spitzer VM, 1998, ANAT REC, V253, P49, DOI 10.1002/(SICI)1097-0185(199804)253:2<49::AID-AR8>3.0.CO;2-9
   Stadie AT, 2008, J NEUROSURG, V108, P382, DOI 10.3171/JNS/2008/108/2/0382
   Stepan K, 2017, INT FORUM ALLERGY RH, V7, P1006, DOI 10.1002/alr.21986
   Trelease RB, 2016, ANAT SCI EDUC, V9, P583, DOI 10.1002/ase.1620
   Valera-Mele M, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0919-4
   Wang HB, 2006, OTOL NEUROTOL, V27, P452, DOI 10.1097/00129492-200606000-00004
   Wang SS, 2014, INT J CLIN EXP MED, V7, P3270
   Weinstock P, 2017, J NEUROSURG-PEDIATR, V20, P1, DOI 10.3171/2017.1.PEDS16568
   Xin BQ, 2019, WORLD NEUROSURG, V124, pE324, DOI 10.1016/j.wneu.2018.12.090
   Yammine K, 2015, ANAT SCI EDUC, V8, P525, DOI 10.1002/ase.1510
   Yao SJ, 2018, WORLD NEUROSURG, V113, pE499, DOI 10.1016/j.wneu.2018.02.069
   Yeung JC, 2012, J OTOLARYNGOL-HEAD N, V41, P426, DOI 10.2310/7070.2012.00049
   Yeung JC, 2011, ANAT SCI EDUC, V4, P92, DOI 10.1002/ase.190
   Zielinski P, 2001, Folia Morphol (Warsz), V60, P343
NR 92
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 313
EP 320
DI 10.1016/j.wneu.2019.06.081
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300161
PM 31658575
DA 2020-05-12
ER

PT J
AU Tomlinson, SB
   Hendricks, BK
   Torregrossa, F
   Grasso, G
   Cohen-Gadol, AA
AF Tomlinson, Samuel B.
   Hendricks, Benjamin K.
   Torregrossa, Fabio
   Grasso, Giovanni
   Cohen-Gadol, Aaron A.
TI Innovations in the Art of Microneurosurgery for Reaching Deep-Seated
   Cerebral Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Innovation; Microneurosurgery; The Neurosurgical Atlas; Operative
   technique; Surgical corridors
ID SUPRACEREBELLAR-TRANSTENTORIAL APPROACH; TRANSFALCINE TRANSPRECUNEUS
   APPROACH; OLFACTORY GROOVE MENINGIOMAS; MEDIOBASAL TEMPORAL REGION;
   LATERAL VENTRICLE; MICROSURGICAL RESECTION; ATRIUM; EXPAND; TUMORS
AB Deep-seated cerebral lesions have fascinated and frustrated countless surgical innovators since the dawn of the microneurosurgical era. To determine the optimal approach, the microneurosurgeon must take into account the characteristics and location of the pathological lesion as well as the operator's range of technical expertise. Increasingly, microneurosurgeons must select between multiple operative corridors that can provide access to the surgical target. Innovative trajectories have emerged for many indications that provide more flexible operative angles and superior exposure but result in longer working distances and more technically demanding maneuvers. In this article, we highlight 4 innovative surgical corridors and compare their strengths and weaknesses against those of more conventional approaches. Our goal is to use these examples to illustrate the following principles of microneurosurgical innovation: (1) discover more efficient and flexible exposures with superior working angles; (2) ensure maximal early protection of critical neurovascular structures; and (3) effectively handle target pathology with minimal disruption of normal tissues.
C1 [Tomlinson, Samuel B.; Hendricks, Benjamin K.; Cohen-Gadol, Aaron A.] Neurosurg Atlas, Indianapolis, IN 46202 USA.
   [Tomlinson, Samuel B.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA.
   [Torregrossa, Fabio; Grasso, Giovanni] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Sect Neurosurg, Palermo, Italy.
   [Cohen-Gadol, Aaron A.] Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46202 USA.
RP Cohen-Gadol, AA (reprint author), Neurosurg Atlas, Indianapolis, IN 46202 USA.; Cohen-Gadol, AA (reprint author), Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46202 USA.
EM acohenmd@gmail.com
RI Hendricks, Benjamin/AAI-6544-2020; Tomlinson, Samuel/AAE-7725-2020
OI Hendricks, Benjamin/0000-0002-7123-4387; 
FU Samerian Foundation
FX The authors acknowledge the support of the Samerian Foundation.
CR Ansari Shaheryar F, 2014, Surg Neurol Int, V5, P35, DOI 10.4103/2152-7806.128918
   Bitter AD, 2013, J NEUROL SURG PART B, V74, P97, DOI 10.1055/s-0033-1333618
   Bohnstedt BN, 2015, J NEUROSURG, V123, P1045, DOI 10.3171/2015.3.JNS14847
   Campero A, 2006, NEUROSURGERY, V59, P279, DOI 10.1227/NEU.0000223509.21474.2E
   Campero A, 2017, OPER NEUROSURG, V13, P113, DOI 10.1227/NEU.0000000000001239
   Chaddad-Neto F, 2019, OPER NEUROSURG, V16, pE83, DOI 10.1093/ons/opy294
   Cohen-Gadol AA, 2019, J NEUROSURG, V130, P1023, DOI 10.3171/2018.9.JNS182475
   de Oliveira JG, 2012, J NEUROSURG, V116, P764, DOI 10.3171/2011.12.JNS111256
   GOEL A, 1995, ACTA NEUROCHIR, V135, P210, DOI 10.1007/BF02187772
   Balanzar GG, 2011, WORLD NEUROSURG, V76, P255, DOI 10.1016/j.wneu.2011.04.011
   Kawashima M, 2006, SURG NEUROL, V65, P436, DOI 10.1016/j.surneu.2005.09.033
   Kodera T, 2011, J CLIN NEUROSCI, V18, P1481, DOI 10.1016/j.jocn.2011.02.035
   Kulwin C, 2016, J NEUROSURG, V124, P269, DOI 10.3171/2015.2.JNS142088
   La Pira B, 2017, ACTA NEUROCHIR, V159, P1529, DOI 10.1007/s00701-017-3196-y
   Little KM, 2001, J NEURO-ONCOL, V54, P287, DOI 10.1023/A:1012766902431
   Manilha R, 2018, OPER NEUROSURG, V15, P102, DOI 10.1093/ons/opx250
   Moftakhar R, 2008, NEUROSURGERY, V63, P1, DOI [10.1227/01.NEU.0000297030.82996.6E, 10.1227/01.neu.0000317367.61899.65]
   Pallini R, 2015, WORLD NEUROSURG, V83, P219, DOI 10.1016/j.wneu.2014.11.001
   Paterniti S, 1999, CLIN NEUROL NEUROSUR, V101, P235, DOI 10.1016/S0303-8467(99)00054-2
   Rey-Dios R, 2013, ACTA NEUROCHIR, V155, P1895, DOI 10.1007/s00701-013-1844-4
   STEIN BM, 1971, J NEUROSURG, V35, P197, DOI 10.3171/jns.1971.35.2.0197
   Ture U, 2012, J NEUROSURG, V116, P773, DOI 10.3171/2011.12.JNS11791
   Uchiyama N, 2001, NEUROSURGERY, V49, P1470, DOI 10.1097/00006123-200112000-00036
   VOIGT K, 1976, NEUROCHIRURGIA, V19, P59
   Wang S, 2010, J NEUROSURG, V113, P949, DOI 10.3171/2010.1.JNS091169
   Watanabe T, 2011, J NEUROSURG, V115, P49, DOI 10.3171/2011.2.JNS101759
   Xie T, 2015, OPER NEUROSURG, V11, P110, DOI 10.1227/NEU.0000000000000643
   Yasargil M. G., 1984, MICRONEUROSURGERY
   Yonekawa Y, 2001, J NEUROSURG, V94, P339, DOI 10.3171/jns.2001.94.2.0339
   Zhu W, 2013, WORLD NEUROSURG, V80, P167, DOI 10.1016/j.wneu.2012.08.010
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 321
EP 327
DI 10.1016/j.wneu.2019.06.210
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300162
PM 31284052
DA 2020-05-12
ER

PT J
AU Bush, NAO
   Hervey-Jumper, SL
   Berger, MS
AF Bush, Nancy Ann Oberheim
   Hervey-Jumper, Shawn L.
   Berger, Mitchel S.
TI Management of Glioblastoma, Present and Future
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioblastoma; Glioma; Immunotherapy; Pharmacology; Quality of life;
   Review; Targeted therapy; Treatment
ID QUALITY-OF-LIFE; POSITRON-EMISSION-TOMOGRAPHY; NEWLY-DIAGNOSED
   GLIOBLASTOMA; SINGLE-AGENT BEVACIZUMAB; GENOME-WIDE ASSOCIATION;
   HIGH-GRADE GLIOMA; RADIATION-THERAPY; RECURRENT GLIOBLASTOMA; PHASE-III;
   MALIGNANT GLIOMA
AB Glioblastomas are the most common malignant brain tumor and despite extensive research have a dismal prognosis. This review focuses on the current treatment paradigms of glioblastoma and highlights current advances in surgical approaches, imaging techniques, molecular diagnostics, and translational efforts. Several promising clinical trials in immunotherapy and personalized medicine are discussed and the importance of quality of life in the patients and their caregivers both during active treatment and survivorship is also commented on.
C1 [Bush, Nancy Ann Oberheim; Hervey-Jumper, Shawn L.] Univ Calif San Francisco, Dept Neurol Surg, Div Neurooncol, San Francisco, CA 94143 USA.
   [Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
RP Berger, MS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM Mitchel.Berger@ucsf.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K0812649025]; Robert Wood Johnson
   FoundationRobert Wood Johnson Foundation (RWJF) [74259]
FX This research work is supported by NIH grant number K0812649025
   (S.H.-J.) and the Robert Wood Johnson Foundation 74259 (S.H.-J.). The
   remaining authors have no conflicts to report.
CR Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1
   Alexander BM, 2018, CLIN CANCER RES, V24, P737, DOI 10.1158/1078-0432.CCR-17-0764
   Atkins I, 2019, CANCER RES, V79, P2065, DOI 10.1158/0008-5472.CAN-18-2888
   Barker FG, 1996, J NEUROSURG, V84, P442, DOI 10.3171/jns.1996.84.3.0442
   Barone R, 2014, FRONT MAR SCI, V1, DOI 10.3389/fmars.2014.00038
   Berman JI, 2004, J NEUROSURG, V101, P66, DOI 10.3171/jns.2004.101.1.0066
   Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741
   Boxerman JL, 2006, AM J NEURORADIOL, V27, P859
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Brown PD, 2006, J NEURO-ONCOL, V76, P283, DOI 10.1007/s11060-005-7020-9
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Buckner JC, 2001, CANCER-AM CANCER SOC, V92, P420, DOI 10.1002/1097-0142(20010715)92:2<420::AID-CNCR1338>3.0.CO;2-3
   Butowski Nicholas A, 2015, Continuum (Minneap Minn), V21, P301, DOI 10.1212/01.CON.0000464171.50638.fa
   Caccese M, 2019, CRIT REV ONCOL HEMAT, V135, P128, DOI 10.1016/j.critrevonc.2018.12.002
   Cella D F, 1996, Oncology (Williston Park), V10, P233
   Chapman CH, 2019, NEURO-ONCOL PRACT, V6, P364, DOI 10.1093/nop/npz017
   Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345
   Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7
   Crawford FW, 2009, J NEURO-ONCOL, V91, P337, DOI 10.1007/s11060-008-9719-x
   CURRAN WJ, 1992, J NEURO-ONCOL, V12, P219
   de Boer E, 2015, BRIT J SURG, V102, pE56, DOI 10.1002/bjs.9713
   Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435
   DINAPOLI RP, 1993, J CLIN ONCOL, V11, P1316, DOI 10.1200/JCO.1993.11.7.1316
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   DUNCAN GG, 1992, J NEURO-ONCOL, V13, P63
   Dunet V, 2012, J NUCL MED, V53, P207, DOI 10.2967/jnumed.111.096859
   Eseonu CI, 2017, NEUROSURGERY, V81, P481, DOI 10.1093/neuros/nyx023
   Eseonu CI, 2017, NEUROSURGERY, V81, P307, DOI 10.1093/neuros/nyx022
   Fabian D, 2019, CANCERS, V11, DOI 10.3390/cancers11020174
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Fujiwara N, 2004, NEUROIMAGE, V21, P1464, DOI 10.1016/j.neuroimage.2003.10.042
   Galldiks N, 2015, NEURO-ONCOLOGY, V17, P1293, DOI 10.1093/neuonc/nov088
   Galldiks N, 2015, EUR J NUCL MED MOL I, V42, P685, DOI 10.1007/s00259-014-2959-4
   Ganslandt O, 2004, CLIN NEUROL NEUROSUR, V107, P20, DOI 10.1016/j.clineuro.2004.02.027
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968
   Glaser SM, 2017, J NEURO-ONCOL, V134, P107, DOI 10.1007/s11060-017-2493-x
   Graves EE, 2000, NEUROSURGERY, V46, P319, DOI 10.1097/00006123-200002000-00011
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Heimans JJ, 2002, J NEUROL, V249, P955, DOI 10.1007/s00415-002-0839-5
   Herrlinger U, 2019, LANCET, V393, P678, DOI 10.1016/S0140-6736(18)31791-4
   Hervey-Jumper SL, 2014, NEUROSURGERY, V75, P491, DOI 10.1227/NEU.0000000000000486
   HOLLERHAGE HG, 1991, ACTA NEUROCHIR, V113, P31, DOI 10.1007/BF01402111
   HUBER A, 1993, NEUROCHIRURGIA, V36, P189
   Hyder R, 2015, IEEE ENG MED BIO, P626, DOI 10.1109/EMBC.2015.7318440
   JEREMIC B, 1994, J NEURO-ONCOL, V21, P177, DOI 10.1007/BF01052902
   Kalpathy-Cranner J, 2014, CANCER RES, V74, P4622, DOI 10.1158/0008-5472.CAN-14-0383
   Kaneko S, 2019, NEUROSURGERY, V85, pE739, DOI 10.1093/neuros/nyz129
   Kawaguchi T, 2016, J NEURO-ONCOL, V129, P505, DOI 10.1007/s11060-016-2201-2
   Kebir S, 2016, CLIN CANCER RES, V22, P2190, DOI 10.1158/1078-0432.CCR-15-1334
   Keles GE, 1999, SURG NEUROL, V52, P371, DOI 10.1016/S0090-3019(99)00103-2
   Keles GE, 2006, J NEUROSURG, V105, P34, DOI 10.3171/jns.2006.105.1.34
   Klein M, 2001, J CLIN ONCOL, V19, P4037, DOI 10.1200/JCO.2001.19.20.4037
   Kowalczuk A, 1997, NEUROSURGERY, V41, P1028, DOI 10.1097/00006123-199711000-00004
   Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055
   Krings T, 2002, ACTA NEUROCHIR, V144, P889, DOI 10.1007/s00701-002-0992-8
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Lamborn KR, 2004, NEURO-ONCOLOGY, V6, P227, DOI 10.1215/S1152851703000620
   Langen KJ, 2017, METHODS, V130, P124, DOI 10.1016/j.ymeth.2017.05.019
   Lau D, 2018, J NEUROSURG, V128, P1410, DOI 10.3171/2017.1.JNS161811
   Leroy HA, 2015, LASER SURG MED, V47, P441, DOI 10.1002/lsm.22359
   Levin VA, 2002, INT J RADIAT ONCOL, V53, P58, DOI 10.1016/S0360-3016(01)02819-X
   Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Melin BS, 2017, NAT GENET, V49, P789, DOI 10.1038/ng.3823
   NITTA T, 1995, CANCER-AM CANCER SOC, V75, P2727, DOI 10.1002/1097-0142(19950601)75:11<2727::AID-CNCR2820751115>3.0.CO;2-H
   Nomiya T, 2007, J NEUROSURG, V106, P575, DOI 10.3171/jns.2007.106.4.575
   Oppenlander ME, 2014, J NEUROSURG, V120, P846, DOI 10.3171/2013.12.JNS13184
   Osoba D, 2000, NEURO-ONCOLOGY, V2, P221, DOI 10.1093/neuonc/2.4.221
   Ostrom QT, 2015, CANCER TREAT RES, V163, P1, DOI 10.1007/978-3-319-12048-5_1
   Oszvald A, 2012, J NEUROSURG, V116, P357, DOI 10.3171/2011.8.JNS102114
   Ottenhausen M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14611
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977
   PHILLIPS TL, 1991, INT J RADIAT ONCOL, V21, P709, DOI 10.1016/0360-3016(91)90690-6
   Pirzkall A, 2001, INT J RADIAT ONCOL, V50, P915, DOI 10.1016/S0360-3016(01)01548-6
   Pirzkall A, 2009, NEURO-ONCOLOGY, V11, P842, DOI 10.1215/15228517-2009-005
   Pollyea DA, 2019, LEUKEMIA, V33, P2575, DOI 10.1038/s41375-019-0472-2
   Pope WB, 2005, AM J NEURORADIOL, V26, P2466
   PRADOS MD, 1992, INT J RADIAT ONCOL, V23, P3, DOI 10.1016/0360-3016(92)90537-R
   Puduvalli VK, 2003, ONCOLOGY-BASEL, V65, P259, DOI 10.1159/000074479
   Quinones-Hinojosa A, 2003, J NEUROSURG, V99, P311, DOI 10.3171/jns.2003.99.2.0311
   Rajaraman P, 2012, HUM GENET, V131, P1877, DOI 10.1007/s00439-012-1212-0
   Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062
   Roux FE, 1999, ACTA NEUROCHIR, V141, P71, DOI 10.1007/s007010050268
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   SANDBERGWOLLHEIM M, 1991, CANCER, V68, P22, DOI 10.1002/1097-0142(19910701)68:1<22::AID-CNCR2820680105>3.0.CO;2-2
   Schiffbauer H, 2002, J NEUROSURG, V97, P1333, DOI 10.3171/jns.2002.97.6.1333
   Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387
   SHIBAMOTO Y, 1990, RADIOTHER ONCOL, V18, P9, DOI 10.1016/0167-8140(90)90018-R
   SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8
   Southwell DG, 2016, J NEUROSURG, V124, P1460, DOI 10.3171/2015.5.JNS142833
   Stark AM, 2005, SURG NEUROL, V63, P162, DOI 10.1016/j.surneu.2004.01.028
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 2011, J NEUROSURG, V114, P613, DOI 10.3171/2010.3.JNS097
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669
   Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011
   Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6
   Tarapore PE, 2012, NEUROSURGERY, V71, P1012, DOI 10.1227/NEU.0b013e31826d2b78
   Ulmer JL, 2004, NEUROSURGERY, V55, P569, DOI 10.1227/01.NEU.0000134384.94749.B2
   Ushio Y, 2005, NEUROL MED-CHIR, V45, P454, DOI 10.2176/nmc.45.454
   Valtonen S, 1997, NEUROSURGERY, V41, P44, DOI 10.1097/00006123-199707000-00011
   van den Bent M, 2017, CANCER CHEMOTH PHARM, V80, P1209, DOI 10.1007/s00280-017-3451-1
   VECHT CJ, 1990, J NEUROL NEUROSUR PS, V53, P466, DOI 10.1136/jnnp.53.6.466
   Vogelbaum MA, 2015, NEURO-ONCOLOGY, V17, pII3, DOI 10.1093/neuonc/nou354
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Westphal M, 2006, ACTA NEUROCHIR, V148, P269, DOI 10.1007/s00701-005-0707-z
   Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79
   Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab
NR 112
TC 1
Z9 1
U1 8
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 328
EP 338
DI 10.1016/j.wneu.2019.01.044
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300163
PM 31658576
DA 2020-05-12
ER

PT J
AU Sharif, S
   Shaikh, MY
   Ali, SM
AF Sharif, Salman
   Shaikh, M. Yousuf
   Ali, S. Maroof
TI Novel Tool for Minimally Invasive Brain Surgery-Syringe Port System
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cylindrical port; Endoscope; Hematomas; Minimal access; Syringe port;
   Tubular retractor
ID INTRAPARENCHYMAL LESIONS; MICROSURGICAL APPROACH; HEMATOMA EVACUATION;
   SURGICAL EVACUATION; ENDOSCOPIC SURGERY; RETRACTOR SYSTEM; RESECTION;
   REMOVAL; SHEATH
AB Cylindrical tubular ports are among the most innovative dynamic tools added to the neurosurgery armamentarium. The rationale behind the use of tubular systems lies in the knowledge that damage to surrounding tissues is minimized with the equal pressure exerted by the walls of the cylinder. A microscope or an endoscope is used for visualization in the tubular ports. Neuronavigation is an essential adjuvant to ensure avoiding injury to essential brain tracts and parenchyma. In the present report, we focused on 3 commonly used cylindrical retractor systems, including the ViewSite, BrainPath, and syringe port. The custom-made syringe port system is used by us and is cost effective. It costs only the price of a syringe. The efficacy and safety of tubular port systems have been shown in limited studies. The complications associated with the port system have been minimal, and injury to the brain has been reduced by the equal pressure exerted by the walls of the port.
C1 [Sharif, Salman; Shaikh, M. Yousuf; Ali, S. Maroof] Liaquat Natl Hosp, Dept Neurosurg, Karachi, Pakistan.
RP Sharif, S (reprint author), Liaquat Natl Hosp, Dept Neurosurg, Karachi, Pakistan.
EM Sharifsalman73@gmail.com
CR Almenawer SA, 2013, NEUROSURG REV, V36, P321, DOI 10.1007/s10143-012-0442-x
   Almubarak AO, 2018, WORLD NEUROSURG, V117, P54, DOI 10.1016/j.wneu.2018.05.236
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Bakhsheshian J, 2019, OPER NEUROSURG, V16, P159, DOI 10.1093/ons/opy079
   Bander ED, 2016, J NEUROSURG, V124, P1053, DOI 10.3171/2015.4.JNS142576
   BENNETT MH, 1977, STROKE, V8, P487, DOI 10.1161/01.STR.8.4.487
   Bernardo A, 2015, WORLD NEUROSURG, V84, P132, DOI 10.1016/j.wneu.2015.02.042
   Buttrick SS, 2017, NEUROSURGERY, V64, P144, DOI 10.1093/neuros/nyx214
   Chaddad-Neto F, 2008, ARQ NEURO-PSIQUIAT, V66, P872, DOI 10.1590/S0004-282X2008000600018
   Chen CC, 2005, J CLIN NEUROSCI, V12, P937, DOI 10.1016/j.jocn.2005.04.006
   Engh JA, 2010, NEUROSURGERY, V67, P198, DOI 10.1227/01.NEU.0000382974.81828.F9
   GREENBERG IM, 1981, NEUROSURGERY, V8, P205, DOI 10.1227/00006123-198102000-00009
   Greenfield JP, 2008, NEUROSURGERY, V63, P334, DOI [10.1227/01.NEU.0000334741.61745.72, 10.1227/01.neu.0000334741.61745.72]
   Harris Anthony E, 2005, Neurosurgery, V56, P125
   Herrera Sebastian R, 2010, Surg Technol Int, V19, P47
   Hong CS, 2016, J NEUROSURG, V124, P799, DOI 10.3171/2015.1.JNS141113
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   Labib MA, 2017, NEUROSURGERY, V80, P515, DOI 10.1227/NEU.0000000000001316
   McLaughlin N, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.022
   Nishihara T, 2000, J NEUROSURG, V92, P1053, DOI 10.3171/jns.2000.92.6.1053
   Nishihara T, 2005, NEUROCRIT CARE, V2, P67, DOI 10.1385/NCC:2:1:067
   Ogura K, 2006, ACTA NEUROCHIR, V148, P779, DOI 10.1007/s00701-006-0768-7
   Prevedello DM, 2019, COMPREHENSIVE OVERVI, P465
   Raza SM, 2011, MINIM INVAS NEUROSUR, V54, P5, DOI 10.1055/s-0031-1273734
   Recinos PF, 2011, J NEUROSURG-PEDIATR, V7, P516, DOI 10.3171/2011.2.PEDS10515
   ROSENORN J, 1985, J NEUROSURG, V63, P608, DOI 10.3171/jns.1985.63.4.0608
   Shoakazemi A, 2015, J NEUROSURG, V122, P564, DOI 10.3171/2014.11.JNS14341
   Singh H, 2018, WORLD NEUROSURG, V114, P117, DOI 10.1016/j.wneu.2018.03.019
   Singh L, 2009, ACTA NEUROCHIR, V151, P1493, DOI 10.1007/s00701-009-0256-y
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Watanabe T, 2014, ACTA NEUROCHIR, V156, P1145, DOI 10.1007/s00701-014-2085-x
   White T, 2017, CUREUS, V9, DOI 10.7759/cureus.1012
   Yadav YR, 2011, NEUROL INDIA, V59, P74, DOI 10.4103/0028-3886.76870
   YASARGIL MG, 1974, SURG NEUROL, V2, P393
   YOKOH A, 1987, ACTA NEUROCHIR, V87, P134, DOI 10.1007/BF01476064
   Zammar SG, 2019, CUREUS, V11, DOI 10.7759/cureus.4272
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
NR 37
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 339
EP 345
DI 10.1016/j.wneu.2019.06.202
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300164
PM 31284061
DA 2020-05-12
ER

PT J
AU Torregrossa, F
   Aguennouz, M
   La Torre, D
   Sfacteria, A
   Grasso, G
AF Torregrossa, Fabio
   Aguennouz, M'hammed
   La Torre, Domenico
   Sfacteria, Alessandra
   Grasso, Giovanni
TI Role of Erythropoietin in Cerebral Glioma: An Innovative Target in
   Neuro-Oncology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Erythropoietin; Erythropoietin receptor; Glioma
ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; TUMOR-CELLS; RECEPTOR EXPRESSION;
   SIGNAL-TRANSDUCTION; ISCHEMIC-INJURY; DOUBLE-BLIND; GLIOBLASTOMA;
   CANCER; GROWTH; BRAIN
AB BACKGROUND: Erythropoietin (EPO) is a cytokine primarily involved in the regulation of erythropoiesis. In response to hypoxia-ischemia, hypoxia-inducible factor 1 induces EPO production, which, in turn, inhibits apoptosis of erythroid progenitor cells. By the same mechanism and acting through other signaling pathways, EPO exerts neuroprotective effects. Increased resistance to hypoxia and decreased apoptosis are thought to be important mechanisms for tumor progression, including malignant glioma. Because recent studies have demonstrated that EPO and its receptor (EPOR) are expressed in several tumors and can promote tumor growth, in the present study, we investigated EPO and EPOR expression in human glioma and the effect of EPO administration in a rat model of glioma implantation.
   METHODS: Using Western blotting and immunohistochemical analysis, we examined the expression of EPO, EPOR, platelet endothelial cell adhesion molecule, and Ki-67 in human glioma specimens and experimentally induced glioma in rats. In the experimental setting, a daily dose of recombinant human EPO (rHuEPO) or saline solution were administered for 21 days in Fischer rats subjected to 9L cell line implantation.
   RESULTS: In both human and animal specimens, we found an increase in EPOR expression as long as the lesion presented with an increasing malignant pattern. A significant direct correlation was found between the expression of EPOR and Ki-67 and EPOR and platelet endothelial cell adhesion molecule in low- and high-grade gliomas. The rats treated with rHuEPO presented with significantly larger tumor spread compared with the saline-treated rats.
   CONCLUSIONS: The results of our study have shown that the EPO/EPOR complex might play a significant role in the aggressive behavior of high-grade gliomas. The larger tumor spread in rHuEPO-treated rats suggests a feasible role for EPO in the aggressiveness and progression of malignant glioma.
C1 [Torregrossa, Fabio; Grasso, Giovanni] Univ Palermo, Neurosurg Unit, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
   [Aguennouz, M'hammed] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Sfacteria, Alessandra] Univ Messina, Dept Vet Sci, Messina, Italy.
   [La Torre, Domenico] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Neurosurg Unit, Catanzaro, Italy.
RP Torregrossa, F (reprint author), Univ Palermo, Neurosurg Unit, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
EM fabiotorregrossa00@gmail.com
RI Sfacteria, Alessandra/AAK-1839-2020
OI La Torre, Domenico/0000-0002-3918-8798
CR Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0
   Ahlqvist-Rastad J, 2007, MED ONCOL, V24, P267, DOI 10.1007/s12032-007-0037-5
   Alural B, 2017, VITAM HORM, V105, P249, DOI 10.1016/bs.vh.2017.03.002
   ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978
   Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40
   Aroca F, 1999, J NEURO-ONCOL, V43, P19, DOI 10.1023/A:1006233816724
   Barker FG, 1996, CANCER, V77, P1161, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1161::AID-CNCR24>3.0.CO;2-Z
   Batra S, 2003, LAB INVEST, V83, P1477, DOI 10.1097/01.LAB.0000090156.94795.48
   Belenkov AI, 2004, MOL CANCER THER, V3, P1525
   Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007
   Bittorf T, 2000, CELL SIGNAL, V12, P23, DOI 10.1016/S0898-6568(99)00063-7
   Blackwell KL, 2003, CANCER RES, V63, P6162
   Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101
   Buemi M, 2005, MED RES REV, V25, P245, DOI 10.1002/med.20012
   Buemi M, 2002, J NEPHROL, V15, P97
   Cao Yiting, 2010, Genes Cancer, V1, P50
   Cevik S, 2018, NIGER J CLIN PRACT, V21, P502, DOI 10.4103/njcp.njcp_126_17
   Chinot OL, 2014, NEW ENGL J MED, V370, P2049, DOI 10.1056/NEJMc1403303
   Crivellato E, 2004, LEUKEMIA, V18, P331, DOI 10.1038/sj.leu.2403246
   DASILVA JL, 1990, BLOOD, V75, P577
   Day BW, 2014, BRIT J CANCER, V111, P1255, DOI 10.1038/bjc.2014.73
   Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2
   Ebert BL, 1999, BLOOD, V94, P1864
   Farrell F, 2004, ONCOLOGIST, V9, P18, DOI 10.1634/theoncologist.9-90005-18
   Fischer I, 2005, BRAIN PATHOL, V15, P297
   Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450
   GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x
   Grasso G, 2006, J NEUROSURG ANESTH, V18, P91, DOI 10.1097/00008506-200604000-00001
   Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187
   Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565
   Grasso G, 2001, J Neurosurg Sci, V45, P7
   Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299
   Grasso G, 2007, J NEUROSURG-SPINE, V7, P645, DOI 10.3171/SPI-07/12/645
   Grasso G, 2019, WORLD NEUROSURG, V125, P529, DOI 10.1016/j.wneu.2019.02.086
   Grasso G, 2019, ANN THORAC SURG, V107, P988, DOI 10.1016/j.athoracsur.2018.05.092
   Grasso G, 2019, WORLD NEUROSURG, V123, P256, DOI 10.1016/j.wneu.2018.12.037
   Grasso G, 2018, J THORAC CARDIOV SUR, V156, P1795, DOI 10.1016/j.jtcvs.2018.05.029
   Grasso Giovanni, 2017, Surg Neurol Int, V8, P11, DOI 10.4103/2152-7806.198738
   Grasso G, 2016, JAMA ONCOL, V2, P1508, DOI 10.1001/jamaoncol.2016.3806
   Hardee ME, 2006, CLIN CANCER RES, V12, P332, DOI 10.1158/1078-0432.CCR-05-1771
   Hassouna I, 2008, INT J RADIAT ONCOL, V72, P927, DOI 10.1016/j.ijrobp.2008.06.1923
   Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9
   Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043
   Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814
   JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3
   Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115
   Kaushansky, 1997, STEM CELLS, V15, P112
   Lacombe C, 1998, HAEMATOLOGICA, V83, P724
   Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313
   Lesniak MS, 2005, ANTICANCER RES, V25, P3825
   Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150
   Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X
   Liu Zi-Li, 2018, Nan Fang Yi Ke Da Xue Xue Bao, V38, P395
   MITIAVILA MT, 1991, J CLIN INVEST, V88, P789, DOI 10.1172/JCI115378
   MIURA Y, 1994, J BIOL CHEM, V269, P29962
   Mohyeldin A, 2007, J NEUROSURG, V106, P338, DOI 10.3171/jns.2007.106.2.338
   Nakada M, 2011, NEURO-ONCOLOGY, V13, P1163, DOI 10.1093/neuonc/nor102
   Overgaard J, 2018, RADIOTHER ONCOL, V127, P12, DOI 10.1016/j.radonc.2018.02.018
   Peres EA, 2015, ONCOTARGET, V6, P2101, DOI 10.18632/oncotarget.2937
   Peres EA, 2011, EXP CELL RES, V317, P2321, DOI 10.1016/j.yexcr.2011.06.011
   Pinel S, 2004, INT J RADIAT ONCOL, V59, P250, DOI 10.1016/j.ijrobp.2003.12.022
   Pradeep S, 2015, CANCER CELL, V28, P610, DOI 10.1016/j.ccell.2015.09.008
   Salvati M, 1998, J NEURO-ONCOL, V36, P61, DOI 10.1023/A:1017926603341
   Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186
   Senger D, 2003, CANCER J, V9, P214, DOI 10.1097/00130404-200305000-00009
   Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165
   Sturiale A, 2007, NEPHROL DIAL TRANSPL, V22, P1484, DOI 10.1093/ndt/gfl769
   Tilbrook PA, 1999, INT J BIOCHEM CELL B, V31, P1001, DOI 10.1016/S1357-2725(99)00071-0
   Torp SH, 2002, CLIN NEUROPATHOL, V21, P252
   Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006
   Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166
   Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x
   Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673
   Wright JR, 2007, J CLIN ONCOL, V25, P1027, DOI 10.1200/JCO.2006.07.1514
   Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x
   Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060
   Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381
   Yin D, 2007, INT J ONCOL, V31, P1193
NR 79
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 346
EP 355
DI 10.1016/j.wneu.2019.06.221
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300165
PM 31658577
DA 2020-05-12
ER

PT J
AU Sparacia, G
   Parla, G
   Cannella, R
   Perri, A
   Lo Re, V
   Mamone, G
   Miraglia, R
   Torregrossa, F
   Grasso, G
AF Sparacia, Gianvincenzo
   Parla, Giuseppe
   Cannella, Roberto
   Perri, Alessandro
   Lo Re, Vincenzina
   Mamone, Giuseppe
   Miraglia, Roberto
   Torregrossa, Fabio
   Grasso, Giovanni
TI Resting-State Functional Magnetic Resonance Imaging for Brain Tumor
   Surgical Planning: Feasibility in Clinical Setting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood oxygen level-dependent (BOLD) technique; Magnetic resonance
   imaging; Resting-state functional magnetic resonance imaging (rest-fMRI)
ID CONNECTIVITY; NETWORK; FMRI; CORTEX
AB The aim of this study was to introduce resting-state functional magnetic resonance imaging (rest-fMRI) capability for brain tumor surgical planning. rest-fMRI is an emerging functional neuroimaging technique potentially able to provide new insights into brain physiology and to provide useful information regarding brain tumors in preoperative and postoperative settings. rest-fMRI evaluates low-frequency fluctuations in the blood oxygen level- dependent signal while the subject is at rest during magnetic resonance imaging examination. Multiple resting-state networks have been identified, including the somatosensory, language, and visual networks, which are of primary importance for surgical planning. We discuss the feasibility of rest-fMRI examination before and after surgical resection of brain tumors in routine clinical practice and the usefulness of the information obtained for surgical planning in brain tumor resection. rest-fMRI is particularly useful for patients who are unable to cooperate with the task-based paradigm, such as children or patients who are sedated, paretic, or aphasic. Although standardization and validation of rest-fMRI are still ongoing, this technique is feasible and valuable and can be implemented for routine clinical surgical planning.
C1 [Sparacia, Gianvincenzo; Cannella, Roberto; Perri, Alessandro] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Radiol Serv, Palermo, Italy.
   [Torregrossa, Fabio; Grasso, Giovanni] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Neurosurg Unit, Palermo, Italy.
   [Sparacia, Gianvincenzo; Parla, Giuseppe; Mamone, Giuseppe; Miraglia, Roberto] Mediterranean Inst Transplantat & Adv Specialized, Dept Diagnost & Therapeut Serv, Radiol Serv, Palermo, Italy.
   [Lo Re, Vincenzina] Mediterranean Inst Transplantat & Adv Specialized, Dept Diagnost & Therapeut Serv, Neurol Serv, Palermo, Italy.
RP Sparacia, G (reprint author), Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Radiol Serv, Palermo, Italy.; Sparacia, G (reprint author), Mediterranean Inst Transplantat & Adv Specialized, Dept Diagnost & Therapeut Serv, Radiol Serv, Palermo, Italy.
EM gianvincenzo.sparacia@unipa.it
RI Cannella, Roberto/U-7501-2019; Sparacia, Gianvincenzo/M-9458-2016
OI Cannella, Roberto/0000-0002-3808-0785; Sparacia,
   Gianvincenzo/0000-0002-4787-1634
CR Barkhof F, 2014, RADIOLOGY, V272, P28, DOI 10.1148/radiol.14132388
   Barnett A, 2017, NEUROIMAG CLIN N AM, V27, P697, DOI 10.1016/j.nic.2017.06.002
   Bassett DS, 2012, NEUROIMAGE, V59, P2196, DOI 10.1016/j.neuroimage.2011.10.002
   Beckmann CF, 2005, PHILOS T ROY SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634
   BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409
   Craddock RC, 2009, MAGN RESON MED, V62, P1619, DOI 10.1002/mrm.22159
   Dierker D, 2017, NEUROIMAG CLIN N AM, V27, P621, DOI 10.1016/j.nic.2017.06.011
   Duyn J, 2011, PROG BRAIN RES, V193, P295, DOI 10.1016/B978-0-444-53839-0.00019-3
   Fan LZ, 2016, CEREB CORTEX, V26, P3508, DOI 10.1093/cercor/bhw157
   Jiang LL, 2016, NEUROSCIENTIST, V22, P486, DOI 10.1177/1073858415595004
   Koch W, 2012, NEUROBIOL AGING, V33, P466, DOI 10.1016/j.neurobiolaging.2010.04.013
   Lang S, 2014, NEUROSURGERY, V74, P453, DOI 10.1227/NEU.0000000000000307
   Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263
   Lu JF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14248-5
   Lv H, 2018, AM J NEURORADIOL, V39, P1390, DOI 10.3174/ajnr.A5527
   Ma LS, 2011, NEUROIMAGE, V58, P226, DOI 10.1016/j.neuroimage.2011.06.014
   O'Neill TJ, 2017, NEUROIMAG CLIN N AM, V27, P685, DOI 10.1016/j.nic.2017.06.006
   Rosazza C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098860
   Sair HI, 2016, HUM BRAIN MAPP, V37, P913, DOI 10.1002/hbm.23075
   Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007
   Sestieri C, 2011, J NEUROSCI, V31, P4407, DOI 10.1523/JNEUROSCI.3335-10.2011
   Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011
   Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099
   Shurtleff H, 2010, J NEUROSURG-PEDIATR, V5, P500, DOI 10.3171/2009.11.PEDS09248
   Smith R, 2017, NEUROIMAGE, V159, P99, DOI 10.1016/j.neuroimage.2017.07.044
   Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100
   Takamura T, 2017, J NEURAL TRANSM, V124, P821, DOI 10.1007/s00702-017-1710-2
   Vergun S, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00440
   Wang DH, 2015, NAT NEUROSCI, V18, P1853, DOI 10.1038/nn.4164
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021-016-9299-4
   Zaca D, 2019, J NEUROSURG, V131, P764, DOI 10.3171/2018.4.JNS18474
   Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030
   Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002
   Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075
   Zou QH, 2008, J NEUROSCI METH, V172, P137, DOI 10.1016/j.jneumeth.2008.04.012
NR 35
TC 2
Z9 2
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 356
EP 363
DI 10.1016/j.wneu.2019.07.022
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300166
PM 31658578
DA 2020-05-12
ER

PT J
AU Rossi, M
   Nibali, MC
   Torregrossa, F
   Bello, L
   Grasso, G
AF Rossi, Marco
   Nibali, Marco Conti
   Torregrossa, Fabio
   Bello, Lorenzo
   Grasso, Giovanni
TI Innovation in Neurosurgery: The Concept of Cognitive Mapping
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognition; Eloquent areas; Glioma surgery; Neuropsychological tests
ID LOW-GRADE GLIOMAS; QUALITY-OF-LIFE; ARCUATE FASCICULUS; SURGERY;
   RESECTION; RADIOTHERAPY; STIMULATION; NETWORK; EXTENT; SURVIVAL
AB In recent years, advances in cortical-subcortical mapping, intraoperative neurophysiology, and neuropsychology have increased the ability to remove intrinsic brain tumors, expanding indications and maximizing the extent of resection. This has provided a significant improvement in progression-free survival, time of malignant transformation fin low-grade gliomas), and overall survival. Although current techniques enable preservation of language and motor functions during surgery, the maintenance of a complex set of functions defined with the term cognition is not always achievable. Cognition is defined as every neural process underlying a high human function and includes motor haptic and visuospatial functions, memory, social interactions, empathy, and emotions. In this regard, an extensive preoperative and postoperative neuropsychological evaluation is strongly suggested to assess cognitive impairment due to tumor growth, to assess surgical result, and to plan cognitive rehabilitation. This article discusses the main recent innovations introduced for cognitive mapping with the aim to preserve cognitive functions, which are essential to maintain a high quality of life.
C1 [Rossi, Marco; Nibali, Marco Conti; Bello, Lorenzo] Univ Milan, Neurosurg Oncol Unit, Dept Oncol & Hematooncol, Milan, Italy.
   [Rossi, Marco; Nibali, Marco Conti; Bello, Lorenzo] Humanitas Res Hosp, Ist Ric & Cura Carattere Sci, Milan, Italy.
   [Torregrossa, Fabio; Grasso, Giovanni] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Neurosurg Clin, Palermo, Italy.
RP Rossi, M (reprint author), Univ Milan, Neurosurg Oncol Unit, Dept Oncol & Hematooncol, Milan, Italy.; Rossi, M (reprint author), Humanitas Res Hosp, Ist Ric & Cura Carattere Sci, Milan, Italy.
EM rossi.marco@gmail.com
OI Rossi, Marco/0000-0002-0196-2370; Conti Nibali,
   Marco/0000-0003-2611-5685
CR Almairac F, 2014, NEUROSURG REV, V37, P513, DOI 10.1007/s10143-014-0530-1
   Beez T, 2013, ACTA NEUROCHIR, V155, P1301, DOI 10.1007/s00701-013-1759-0
   Bello L, 2014, NEURO-ONCOLOGY, V16, P1110, DOI 10.1093/neuonc/not327
   Borggraefe I, 2016, CLIN NEUROPHYSIOL, V127, P3314, DOI 10.1016/j.clinph.2016.08.001
   Buckner J, 2017, NAT REV NEUROL, V13, P340, DOI 10.1038/nrneurol.2017.54
   Conner AK, 2016, CUREUS, V8, DOI 10.7759/cureus.883
   CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627
   DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789
   Desmurget M, 2018, CURR BIOL, V28, P3303, DOI 10.1016/j.cub.2018.08.027
   Douw L, 2009, LANCET NEUROL, V8, P810, DOI 10.1016/S1474-4422(09)70204-2
   Duffau H, 2013, NEUROCHIRURGIE, V59, P2, DOI 10.1016/j.neuchi.2012.11.001
   Duffau H, 2016, ACTA NEUROCHIR, V158, P51, DOI 10.1007/s00701-015-2621-3
   Duffau H, 2015, NEURO-ONCOLOGY, V17, P332, DOI 10.1093/neuonc/nou153
   Duffau H, 2015, ACTA NEUROCHIR, V157, P165, DOI 10.1007/s00701-014-2303-6
   Duffau H, 2013, ACTA NEUROCHIR, V155, P951, DOI 10.1007/s00701-013-1653-9
   Fedorenko E, 2013, P NATL ACAD SCI USA, V110, P16616, DOI 10.1073/pnas.1315235110
   Grasso G, 2019, WORLD NEUROSURG, V123, P256, DOI 10.1016/j.wneu.2018.12.037
   Grasso G, 2016, JAMA ONCOL, V2, P1508, DOI 10.1001/jamaoncol.2016.3806
   Hamer PCD, 2012, J CLIN ONCOL, V30, P2559, DOI 10.1200/JCO.2011.38.4818
   Han SJ, 2019, J NEUROSURG, V131, P201, DOI 10.3171/2018.3.JNS172494
   Herbet G, 2017, BRAIN STRUCT FUNCT, V222, P1597, DOI 10.1007/s00429-016-1294-x
   Herbet G, 2015, BRAIN STRUCT FUNCT, V220, P2159, DOI 10.1007/s00429-014-0777-x
   Herbet G, 2014, BRAIN, V137, P944, DOI 10.1093/brain/awt370
   HOWARD D, 1992, PYRAMIDS PALM TREES
   Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5
   Langen M, 2012, CORTEX, V48, P183, DOI 10.1016/j.cortex.2011.05.018
   Lipszyc J, 2014, ARCH CLIN NEUROPSYCH, V29, P289, DOI 10.1093/arclin/acu004
   MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163
   Mandonnet E, 2017, NEUROSURG REV, V40, P29, DOI 10.1007/s10143-016-0723-x
   Naidich TP, 2001, NEUROIMAG CLIN N AM, V11, P305
   Nakajima R, 2018, NEUROPSYCHOLOGIA, V115, P179, DOI 10.1016/j.neuropsychologia.2018.01.024
   Papagno C, 2011, BRAIN, V134, P405, DOI 10.1093/brain/awq283
   Puglisi G, 2019, J NEUROSURG, V131, P474, DOI 10.3171/2018.4.JNS18393
   Rech F, 2019, BRAIN, V142, P952, DOI 10.1093/brain/awz021
   Rice GE, 2015, CEREB CORTEX, V25, P4374, DOI 10.1093/cercor/bhv024
   Rossi Marco, 2019, J Neurosurg, P1, DOI 10.3171/2019.2.JNS183408
   Rossi M, 2019, J NEUROSURG, V130, P17, DOI 10.3171/2017.7.JNS17357
   Rossi M, 2019, NEUROSURG CLIN N AM, V30, P55, DOI 10.1016/j.nec.2018.08.003
   Ruis C, 2018, J CLIN EXP NEUROPSYC, V40, P1081, DOI 10.1080/13803395.2018.1469602
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6
   Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285
   TAPHOORN MJB, 1994, ANN NEUROL, V36, P48, DOI 10.1002/ana.410360111
   Vallar G, 2014, HUM BRAIN MAPP, V35, P1334, DOI 10.1002/hbm.22257
   Vigano L, 2019, CORTEX, V113, P239, DOI 10.1016/j.cortex.2018.12.011
   Yordanova YN, 2019, NEUROIMAGE, V186, P628, DOI 10.1016/j.neuroimage.2018.11.046
   Zhao Y, 2012, J CLIN NEUROSCI, V19, P255, DOI 10.1016/j.jocn.2011.03.041
NR 47
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 364
EP 370
DI 10.1016/j.wneu.2019.06.177
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300167
PM 31658579
DA 2020-05-12
ER

PT J
AU Germano, A
   Raffa, G
   Conti, A
   Fiore, P
   Cardali, SM
   Esposito, F
   Scibilia, A
   Quattropani, MC
   Vinci, SL
   Marzano, G
   Pergolizzi, S
   Longo, M
   Angileri, FF
AF Germano, Antonino
   Raffa, Giovanni
   Conti, Alfredo
   Fiore, Patrizia
   Cardali, Salvatore Massimiliano
   Esposito, Felice
   Scibilia, Antonino
   Quattropani, Marina C.
   Vinci, Sergio Lucio
   Marzano, Giuseppina
   Pergolizzi, Stefano
   Longo, Marcello
   Angileri, Filippo Flavio
TI Modern Treatment of Brain Arteriovenous Malformations Using Preoperative
   Planning Based on Navigated Transcranial Magnetic Stimulation: A
   Revisitation of the Concept of Eloquence
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformations; Diffusion tensor imaging; Eloquent areas;
   Language areas; Motor area; Navigated transcranial magnetic stimulation
ID DTI FIBER TRACKING; AWAKE CRANIOTOMY; LANGUAGE PATHWAYS; GLIOMA SURGERY;
   MOTOR; TRACTOGRAPHY; DEFICITS; PATIENT; TUMORS; FMRI
AB BACKGROUND: Navigated transcranial magnetic stimulation (nTMS) provides a reliable identification of "eloquent" cortical brain areas. Moreover, it can be used for diffusion tensor imaging fiber tracking of eloquent subcortical tracts. We describe the use of nTMS-based cortical mapping and diffusion tensor imaging fiber tracking for defining the "eloquence" of areas surrounding brain arteriovenous malformations (BAVMs), aiming to improve patient stratification and treatment.
   METHODS: We collected data of BAVMs suspected to be in eloquent areas treated between 2017 and 2019, and submitted to nTMS-based reconstruction of motor, language, and visual pathways for the definition of the eloquence of the surrounding brain areas. We describe the nTMS-based approach and analyze its impact on patient stratification and allocation to treatment in comparison with the standard assessment of eloquence based on anatomical landmarks.
   RESULTS: Ten patients were included in the study. Preliminarily, 9 BAVMs were suspected to be located in an eloquent area. After nTMS-based mapping, only 5 BAVMs were confirmed to he close to eloquent structures, thus leading to a change of the score for eloquence and of the final BAVMs grading in 60% of patients. Treatment was customized according to nTMS information, and no cases of neurological worsening were observed. Radiological obliteration was complete in 7 cases microsurgically treated, and accounted for about 70% in the remaining 3 patients 1 year after radiosurgical treatment.
   CONCLUSIONS: The nTMS-based information allows an accurate stratification and allocation of patients with BAVMs to the most effective treatment according to a modern, customized, neurophysiological identification of the adjacent eloquent brain networks.
C1 [Germano, Antonino; Raffa, Giovanni; Conti, Alfredo; Fiore, Patrizia; Cardali, Salvatore Massimiliano; Esposito, Felice; Angileri, Filippo Flavio] Univ Messina, Div Neurosurg, BIOMORF Dept, Messina, Italy.
   [Quattropani, Marina C.; Marzano, Giuseppina] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Vinci, Sergio Lucio; Longo, Marcello] Univ Messina, Div Neuroradiol, BIOMORF Dept, Messina, Italy.
   [Pergolizzi, Stefano] Univ Messina, Div Radiotherapy, BIOMORF Dept, Messina, Italy.
   [Scibilia, Antonino] Univ Strasbourg, Dept Neurosurg, Strasbourg, France.
RP Raffa, G (reprint author), Univ Messina, Div Neurosurg, BIOMORF Dept, Messina, Italy.
EM giovanni.raffa@unime.it
RI Quattropani, Maria C./G-3504-2015; Raffa, Giovanni/K-7972-2016;
   Esposito, Felice/F-4238-2012; Angileri, Filippo/J-3533-2012
OI Quattropani, Maria C./0000-0003-0711-6412; Raffa,
   Giovanni/0000-0001-8623-4964; Esposito, Felice/0000-0003-1051-5924;
   Angileri, Filippo/0000-0002-1107-4115
FU PON Ricerca e Innovazione 2014-2020 [AIM 1839117 - 3]
FX This study has been partially funded by PON Ricerca e Innovazione
   2014-2020, Call AIM 1839117 - 3, Linea 1, Recipient: G. Raffa.
CR Bailey PD, 2015, J NEUROIMAGING, V25, P776, DOI 10.1111/jon.12273
   Bertani GA, 2018, WORLD NEUROSURG, V117, pE42, DOI 10.1016/j.wneu.2018.05.131
   Bette S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05767-2
   Bette S, 2016, ONCOTARGET, V7, P61945, DOI 10.18632/oncotarget.11482
   Borius PY, 2014, CLIN NEUROL NEUROSUR, V122, P87, DOI 10.1016/j.clineuro.2014.04.017
   Compston A, 2010, BRAIN, V133, P2835, DOI 10.1093/brain/awq274
   Conti A, 2014, OPER NEUROSURG, V10, P542, DOI 10.1227/NEU.0000000000000502
   Davis T, 2013, ANN NY ACAD SCI, V1296, P108, DOI 10.1111/nyas.12156
   De Benedictis A, 2011, NEUROSURGERY, V68, P1709, DOI 10.1227/NEU.0b013e3182124690
   Duffau H, 2014, WORLD NEUROSURG, V81, P56, DOI 10.1016/j.wneu.2013.01.116
   Duffau H, 2012, ACTA NEUROCHIR, V154, P575, DOI 10.1007/s00701-011-1216-x
   FITZ AG, 1992, ARCH CLIN NEUROPSYCH, V7, P243, DOI 10.1016/0887-6177(92)90166-K
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Gamble AJ, 2015, WORLD NEUROSURG, V84, P1394, DOI 10.1016/j.wneu.2015.06.059
   Gempt J, 2013, J NEUROSURG, V118, P801, DOI 10.3171/2012.12.JNS12125
   Germano A, 2013, NEUROSURG REV, V36, P123, DOI 10.1007/s10143-012-0408-z
   Giglhuber K, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0440-1
   Giglhuber K, 2017, BRAIN IMAGING BEHAV, V11, P17, DOI 10.1007/s11682-016-9506-9
   HOOPER H, 1958, HOOPER VISUAL ORG TE
   Ille S, 2018, ACTA NEUROCHIR, V160, P567, DOI 10.1007/s00701-018-3475-2
   Ille S, 2015, J NEUROSURG, V123, P314, DOI 10.3171/2014.10.JNS141582
   Jakola AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101805
   Kamiya-Matsuoka C, 2015, J NEURO-ONCOL, V125, P143, DOI 10.1007/s11060-015-1880-4
   Kato N, 2014, ACTA NEUROCHIR, V156, P885, DOI 10.1007/s00701-014-2043-7
   Kayama Takamasa, 2012, Neurol Med Chir (Tokyo), V52, P119
   Kim SS, 2009, NEUROSURGERY, V64, P836, DOI 10.1227/01.NEU.0000342405.80881.81
   Krieg SM, 2014, NEUROIMAGE, V100, P219, DOI 10.1016/j.neuroimage.2014.06.016
   Krieg SM, 2012, J NEUROSURG, V116, P994, DOI 10.3171/2011.12.JNS111524
   Lioumis P, 2012, J NEUROSCI METH, V204, P349, DOI 10.1016/j.jneumeth.2011.11.003
   Mangraviti A, 2013, NEUROL SCI, V34, P1551, DOI 10.1007/s10072-012-1283-7
   Merlo L, 2011, J NEUROTRAUM, V28, P2493, DOI 10.1089/neu.2010.1624
   Nossek E, 2013, J NEUROSURG, V118, P243, DOI 10.3171/2012.10.JNS12511
   Picht T, 2013, NEUROSURGERY, V72, P808, DOI 10.1227/NEU.0b013e3182889e01
   Picht T, 2011, NEUROSURGERY, V69, P581, DOI 10.1227/NEU.0b013e3182181b89
   Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59
   Raffa G, 2017, NAVIGATED TRANSCRANI, P97
   Raffa Giovanni, 2019, J Neurosurg, P1, DOI 10.3171/2019.3.JNS183411
   Raffa G, 2019, J NEUROSURG SCI, V63, P670, DOI 10.23736/S0390-5616.19.04710-6
   Raffa G, 2019, WORLD NEUROSURG, V128, pE378, DOI 10.1016/j.wneu.2019.04.158
   Raffa G, 2019, CLIN NEUROL NEUROSUR, V180, P7, DOI 10.1016/j.clineuro.2019.03.003
   Raffa G, 2018, CLIN NEUROL NEUROSUR, V168, P127, DOI 10.1016/j.clineuro.2018.03.009
   Raffa G, 2018, NEUROSURGERY, V83, P768, DOI 10.1093/neuros/nyx554
   Raffa G, 2017, ACTA NEUROCHIR SUPPL, V124, P251, DOI 10.1007/978-3-319-39546-3_37
   Raffa G, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00552
   Ringel F, 2015, J NEUROSURG SCI, V59, P129
   Rizzo V, 2014, NEUROSCI LETT, V583, P136, DOI 10.1016/j.neulet.2014.09.017
   Rosenstock T, 2017, J NEUROSURG, V126, P1227, DOI 10.3171/2016.4.JNS152896
   Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6
   Santini B, 2012, J NEUROSURG ANESTH, V24, P209, DOI 10.1097/ANA.0b013e3182464aec
   Scibilia A, 2018, NEUROL RES, V40, P241, DOI 10.1080/01616412.2018.1429203
   Scibilia A, 2017, ACTA NEUROCHIR SUPPL, V124, P263, DOI 10.1007/978-3-319-39546-3_38
   Scibilia A, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16141
   SHEWAN CM, 1980, J SPEECH HEAR DISORD, V45, P308, DOI 10.1044/jshd.4503.308
   Sollmann N, 2013, J NEUROSURG, V118, P175, DOI 10.3171/2012.9.JNS121053
   Spetzler RF, 2008, J NEUROSURG, V108, P186, DOI 10.3171/JNS/2008/108/01/0186
   Spetzler RF, 2011, J NEUROSURG, V114, P842, DOI 10.3171/2010.8.JNS10663
   Szelenyi A, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09237
   Takahashi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.1.FOCUS133
   Martinez GV, 2015, REV ESP ANEST REANIM, V62, P275, DOI 10.1016/j.redar.2014.09.009
   Wengenroth M, 2011, EUR RADIOL, V21, P1517, DOI 10.1007/s00330-011-2067-9
   Wowra B, 2009, NEUROSURGERY, V64, pA102, DOI 10.1227/01.NEU.0000339201.31176.C9
NR 61
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 371
EP 384
DI 10.1016/j.wneu.2019.06.119
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300168
PM 31247351
DA 2020-05-12
ER

PT J
AU Cherian, I
   Burhan, H
   Dashevskiy, G
   Motta, SJH
   Parthiban, J
   Wang, Y
   Tong, H
   Torregrossa, F
   Grasso, G
AF Cherian, Iype
   Burhan, Hira
   Dashevskiy, Gleb
   Motta, Shugar Jhamil Hinojosa
   Parthiban, Jutty
   Wang, Yonghong
   Tong, Haibo
   Torregrossa, Fabio
   Grasso, Giovanni
TI Cisternostomy: A Timely Intervention in Moderate to Severe Traumatic
   Brain Injuries: Rationale, Indications, and Prospects
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cisternostomy; Decompressive hemicraniectomy; Traumatic brain injury
ID DECOMPRESSIVE CRANIECTOMY; GLYMPHATIC PATHWAY; MECHANISMS
AB Traumatic brain injury (TBI) represents a major public health concern worldwide, with no significant change in its epidemiology over the last 30 years. After TBI, the primary injury induces irreversible brain damage, which is untreatable. The subsequent secondary injury plays a critical role in the clinical prognosis because without effective treatment it will provide additional tissue damage. The resulting scenario is the rise in intracranial pressure (ICP) with the development of progressive neurological deficits. Current optimal management is based on a progressive, target-driven approach combining both medical and surgical treatment strategies among which is decompressive hemicraniectomy. With the advent of technology, research in the glymphatic pathways, and advances in microscopic surgery, a novel surgical technique-the cisternostomy-has emerged that holds promise in managing rising ICP in TBI-affected patients. In this article we describe the rationale for cisternostomy, an emerging microneurosurgical approach for the management of moderate to severe TBI.
C1 [Cherian, Iype; Burhan, Hira; Dashevskiy, Gleb; Motta, Shugar Jhamil Hinojosa] Nobel Med Coll & Teaching Hosp, Inst Neurosci, Dept Neurosurg, Biratnagar, Nepal.
   [Parthiban, Jutty] Kovai Med Ctr & Hosp, Dept Neurosurg, Coimbatore, Tamil Nadu, India.
   [Wang, Yonghong; Tong, Haibo] Shanxi Dayi Hosp, Dept Neurosurg, Taiyuan, Shanxi, Peoples R China.
   [Torregrossa, Fabio; Grasso, Giovanni] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
RP Wang, Y (reprint author), Shanxi Dayi Hosp, Dept Neurosurg, Taiyuan, Shanxi, Peoples R China.
EM wyh200533@126.com
RI Burhan, Hira/AAI-9712-2020
CR Aaron G, 2014, OTOLARYNG HEAD NECK, V151, P1061, DOI 10.1177/0194599814551122
   Abdulqader MN, 2018, J ACUTE DIS, V7, P43, DOI 10.4103/2221-6189.228877
   Abode-Iyamah KO, 2018, WORLD NEUROSURG, V118, pE414, DOI 10.1016/j.wneu.2018.06.204
   Bothwell SW, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0129-6
   Cherian I, 2018, J NEUROSCI RES, V96, P744, DOI 10.1002/jnr.24145
   Cherian Iype, 2016, Surg Neurol Int, V7, pS711
   Cherian I, 2016, WORLD NEUROSURG, V89, P51, DOI 10.1016/j.wneu.2016.01.072
   Cherian I, 2016, CHIN J TRAUMATOL, V19, P7, DOI 10.1016/j.cjtee.2016.01.003
   Cherian Iype, 2013, Asian J Neurosurg, V8, P132, DOI 10.4103/1793-5482.121684
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352
   Dismuke Clara E, 2015, Glob J Health Sci, V7, P156, DOI 10.5539/gjhs.v7n6p156
   Eide PK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25666-4
   El-Fiki A, 2019, OPEN J MOD NEUROSURG, V9, P7
   Giammattei L, 2018, WORLD NEUROSURG, V116, P322, DOI 10.1016/j.wneu.2018.05.176
   Grasso Giovanni, 2016, Bull Emerg Trauma, V4, P119
   Grasso G, 2016, J NEUROSCI RES, V94, P825, DOI 10.1002/jnr.23803
   Grasso Giovanni, 2016, F1000Res, V5, P911, DOI 10.12688/f1000research.8723.1
   Grasso G, 2015, WORLD NEUROSURG, V84, P594, DOI 10.1016/j.wneu.2015.01.043
   Hoz SS, 2018, J NEUROSCI RURAL PRA, V9, P650, DOI 10.4103/jnrp.jnrp_92_18
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014
   Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748
   Lama S, 2014, J BIOL CHEM, V289, P20200, DOI 10.1074/jbc.M114.570978
   Masoudi Mohammad Sadegh, 2016, Bull Emerg Trauma, V4, P161
   Osborne C, 2014, J NEUROL NEUROSUR PS, V85, DOI 10.1136/jnnp-2014-309236.105
   Perez IP, 2019, NEUROCIRUGIA, V30, P77, DOI 10.1016/j.neucir.2018.11.003
   Rainey-Smith SR, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0094-x
   Rasmussen MK, 2018, LANCET NEUROL, V17, P1016, DOI 10.1016/S1474-4422(18)30318-1
   Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074
   Taniguchi D, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0997-9
   Taoka T, 2018, MAGN RESON MED SCI, V17, P111, DOI 10.2463/mrms.rev.2017-0116
   Zhang DF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08959-y
NR 33
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 385
EP 390
DI 10.1016/j.wneu.2019.007.082
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300169
PM 31658580
DA 2020-05-12
ER

PT J
AU Bassani, R
   Gregori, F
   Peretti, G
AF Bassani, Roberto
   Gregori, Fabrizio
   Peretti, Giuseppe
TI Evolution of the Anterior Approach in Lumbar Spine Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE ALIF; Evolution; Fusion; History; Lumbar spine; Retroperitoneal;
   Transperitoneal
ID INTERBODY FUSION; LAPAROSCOPIC APPROACH; INTERVERTEBRAL-DISK;
   COMPLICATIONS; EXPOSURE; OUTCOMES; L4-L5; ALIF; BERG
AB The anterior approach to lumbar spine fusion, termed anterior lumbar interbody fusion (ALIF), is becoming increasingly popular, with numerous recognized indications, well-defined advantages, and potential complications. From its first theoretical description in 1932 and the first operation published in 1933 to the more recently reported less invasive procedures, an anterior approach to the lumbar spine has many technical variations. Here we describe the evolution of the anterior approach to the lumbar spine, from a hugely invasive transperitoneal route to the current minimally invasive retroperitoneal approach Many advantages have been advocated for the ALIF approach, and some issues about intraoperative and postoperative complications need to be evaluated in a more specific and homogeneous manner.
C1 [Bassani, Roberto] IRCCS Ist Ortoped Galeazzi, Spine Surg 2, Milan, Italy.
   [Gregori, Fabrizio] Sapienza Univ, Dept Human Neurosci, Div Neurosurg, Rome, Italy.
   [Peretti, Giuseppe] IRCCS Ist Ortoped Galeazzi, Milan, Italy.
   [Peretti, Giuseppe] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.
RP Gregori, F (reprint author), Sapienza Univ, Dept Human Neurosci, Div Neurosurg, Rome, Italy.
EM fabr.gregori@gmail.com
RI Bassani, Roberto/AAC-9918-2020; Peretti, Giuseppe/K-6358-2016
OI Peretti, Giuseppe/0000-0001-9341-7187
CR Aebi M, 2000, EUR SPINE J, V9, pS44, DOI 10.1007/PL00010021
   Bassani R, 2018, EUR SPINE J, V27, P1956, DOI 10.1007/s00586-018-5659-0
   Brau Salvador A, 2002, Spine J, V2, P216, DOI 10.1016/S1529-9430(02)00184-5
   Burke PJ, 2011, RADIOL TECHNOL, V72, P423
   Burns BH, 1933, LANCET, V1, P1233
   Capener N, 1932, BRIT J SURG, V19, P374, DOI 10.1002/bjs.1800197505
   CHEN DY, 1995, SPINE, V20, P74, DOI 10.1097/00007632-199501000-00014
   CHOW SP, 1980, SPINE, V5, P452, DOI 10.1097/00007632-198009000-00010
   Choy W, 2017, GLOB SPINE J, V7, P141, DOI 10.1177/2192568217694009
   Cowles RK, 2000, SURGERY, V128, P589, DOI 10.1067/msy.2000.108055
   CROCK HV, 1982, CLIN ORTHOP RELAT R, P157
   DENNIS S, 1989, SPINE, V14, P876, DOI 10.1097/00007632-198908000-00019
   DeWald CJ, 1999, AM SURGEON, V65, P61
   FLYNN JC, 1979, J BONE JOINT SURG AM, V61, P1143, DOI 10.2106/00004623-197961080-00002
   Frantzides Constantine T, 2006, JSLS, V10, P488
   FRASER RD, 1982, J BONE JOINT SURG BR, V64, P44
   Gazzeri R, 2007, MINIM INVAS NEUROSUR, V50, P150, DOI 10.1055/s-2007-985144
   Giang G, 2017, WORLD NEUROSURG, V104, P259, DOI 10.1016/j.wneu.2017.05.011
   Goldner J L, 1971, Orthop Clin North Am, V2, P543
   Haid RW, 2002, NEUROSURGERY, V51, P1510
   Harmon P, 1960, CLIN ORTHOP RELAT R, P169
   Harmon P H, 1964, Clin Orthop Relat Res, V37, P130
   HARMON P H, 1963, Clin Orthop Relat Res, V26, P107
   Henry L G, 1997, JSLS, V1, P341
   HODGSON AR, 1968, CLIN ORTHOP RELAT R, P133
   Hosseini P, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.8.FOCUS17423
   Hsieh PC, 2007, J NEUROSURG-SPINE, V7, P379, DOI 10.3171/SPI-07/10/379
   Ikard RW, 2006, ARCH SURG-CHICAGO, V141, P1025, DOI 10.1001/archsurg.141.10.1025
   Inamasu J, 2005, MINIM INVAS NEUROSUR, V48, P340, DOI 10.1055/s-2005-915634
   INOUE S, 1984, CLIN ORTHOP RELAT R, P22
   IWAHARA T, 1963, Nihon Seikeigeka Gakkai Zasshi, V36, P1049
   Iwahara T., 1944, SURG JAPAN, V8, P271
   Jenkins JA, 1936, BRIT J SURG, V24, P80, DOI 10.1002/bjs.1800249312
   Kaiser MG, 2002, NEUROSURGERY, V51, P97, DOI 10.1097/00006123-200207000-00015
   Kerolus M, 2016, EXPERT REV MED DEVIC, V13, P1127, DOI 10.1080/17434440.2016.1254039
   LANE JD, 1948, ANN SURG, V127, P537, DOI 10.1097/00000658-194803000-00013
   Lieberman IH, 2000, SPINE, V25, P509, DOI 10.1097/00007632-200002150-00019
   Mahvi DM, 1996, ANN SURG, V224, P85, DOI 10.1097/00000658-199607000-00013
   MATHEWS HH, 1995, SPINE, V20, P1797, DOI 10.1097/00007632-199508150-00009
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Mayer HM, 2002, NEUROSURGERY, V51, pS159, DOI 10.1227/01.NEU.0000031090.42443.D7
   Mayer HM, 2000, EUR SPINE J, V9, pS35, DOI 10.1007/PL00010020
   Mehren C, 2010, OPER ORTHOP TRAUMATO, V22, P573, DOI 10.1007/s00064-010-8053-6
   Mercer Walter, 1936, Edinb Med J, V43, P545
   Mobbs RJ, 2013, ORTHOP SURG, V5, P153, DOI [10.1111/os.12048, 10.1111/j.1757-7861.2012.00185.x]
   Mummaneni PV, 2004, J NEUROSURG-SPINE, V1, P24, DOI 10.3171/spi.2004.1.1.0024
   Obenchain T G, 1991, J Laparoendosc Surg, V1, P145, DOI 10.1089/lps.1991.1.145
   Phan K, 2017, SPINE, V42, pE592, DOI 10.1097/BRS.0000000000001905
   Quraishi NA, 2013, EUR SPINE J, V22, pS16, DOI 10.1007/s00586-012-2616-1
   Regan JJ, 1999, SPINE, V24, P2171, DOI 10.1097/00007632-199910150-00018
   Sacks S, 1966, Clin Orthop Relat Res, V44, P163
   Saraph V, 2004, EUR SPINE J, V13, P425, DOI 10.1007/s00586-004-0722-4
   Shen FH, 2007, ORTHOP CLIN N AM, V38, P373, DOI 10.1016/j.ocl.2007.04.002
   Speed K, 1938, ARCH SURG-CHICAGO, V37, P175, DOI 10.1001/archsurg.1938.01200020003001
   Spiker WR, 2019, GLOB SPINE J, V9, P77, DOI 10.1177/2192568217712494
   STAUFFER RN, 1972, J BONE JOINT SURG AM, VA 54, P756, DOI 10.2106/00004623-197254040-00006
   Tay BBK, 2002, SEMIN NEUROL, V22, P221, DOI 10.1055/s-2002-36545
   Thalgott JS, 2000, EUR SPINE J, V9, pS51, DOI 10.1007/PL00010022
   Uribe JS, 2018, J NEUROSURG-SPINE, V29, P565, DOI 10.3171/2018.4.SPINE171206
   VANAKKERVEEKEN PF, 1993, ACTA ORTHOP SCAND, V64, P105, DOI 10.3109/17453679309160136
   Vazquez RM, 2003, SURG ENDOSC, V17, P268, DOI 10.1007/s00464-002-8827-5
   Bo W, 2009, SPINE, V34, pE298, DOI 10.1097/BRS.0b013e318195a87e
   Zdeblick TA, 2000, SPINE, V25, P2682, DOI 10.1097/00007632-200010150-00023
   ZUCHERMAN JF, 1995, SPINE, V20, P2029, DOI 10.1097/00007632-199509150-00015
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 391
EP 398
DI 10.1016/j.wneu.2019.07.023
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300170
PM 31658581
DA 2020-05-12
ER

PT J
AU Santoro, G
   Braidotti, P
   Gregori, F
   Santoro, A
   Domenicucci, M
AF Santoro, Giorgio
   Braidotti, Piero
   Gregori, Fabrizio
   Santoro, Antonio
   Domenicucci, Maurizio
TI Traumatic Sacral Fractures: Navigation Technique in Instrumented
   Stabilization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Classification; Fracture; Navigation; Pelvic; Sacral; Spinal; Traumatic
ID ILIOSACRAL SCREW INSERTION; ILIAC SCREWS; FIXATION; CLASSIFICATION;
   PLACEMENT; AOSPINE; INJURY; COMPLICATIONS; DEFORMITY; ACCURACY
AB BACKGROUND: Sacral fractures are a challenge regarding treatment and classification. Surgical techniques using spinal navigation systems can improve treatment, especially if used in collaboration among different specialists.
   METHODS: Between 2015 and 2017, we treated 25 consecutive cases of sacral fracture. Twelve patients (48%) underwent mechanical ventilation due to hypovolemic shock for severe thoracoabdominal trauma; bleeding was blocked with pelvic packing in 9 cases (36%) and trans-catheter embolization in 2 cases (8%). External fixation was used in 7 cases (28%). In 20 cases (80%) spinal fractures were associated. All patients were operated on using spinal navigation by a team of neurosurgeons and ortho-pedic surgeons.
   RESULTS: The mean time from first observation to surgery was 18 days (range 8-31). Surgical treatment consisted of iliosacral fixation in 19 cases (76%) and spinopelvic fixation in 6 cases (24%). The mean number of screws for spinopelvic fixation was 9.67 (range 6-17) with a mean operation time of 323.67 minutes (range 247-471); in iliosacral osteosynthesis the mean screw number was 1.37 (range 1-3) and mean surgical time was 78.93 minutes (range 61-130). Postoperative computed tomography showed the correct screw placement. Wound infection occurred in 2 cases (8%), managed with vacuum-assisted closure therapy; in 1 case (4%) a sacral screw was removed for decubitus.
   CONCLUSIONS: Navigation systems in instrumented spinopelvic and sacropelvic reconstruction provide greater safety, reducing learning times and malpositioning. Multi-disciplinary management allows us to achieve optimal results, especially when the sacral fracture is combined with spinal and pelvic lesions. The use of navigation systems could represent an important advancement.
C1 [Santoro, Giorgio; Gregori, Fabrizio; Santoro, Antonio; Domenicucci, Maurizio] Sapienza Univ Rome, UOD Emergency Orthopaed Traumatol, Dept Human Neurosci Neurosurg, Rome, Italy.
   [Braidotti, Piero] Sapienza Univ Rome, UOD Emergency Orthopaed Traumatol, Dept Emergency & Acceptance, Anesthesia & Crit Care Areas, Rome, Italy.
RP Gregori, F (reprint author), Sapienza Univ Rome, UOD Emergency Orthopaed Traumatol, Dept Human Neurosci Neurosurg, Rome, Italy.
EM fabr.gregori@gmail.com
CR Akesen B, 2008, SPINE, V33, P1423, DOI 10.1097/BRS.0b013e3181753c04
   Blum L, 2018, INT ORTHOP, V42, P2663, DOI 10.1007/s00264-018-3883-1
   Dayer R, 2012, CURR REV MUSCULOSKE, V5, P91, DOI 10.1007/s12178-012-9122-2
   Dorr LA, 2007, CLIN ORTHOP RELAT R, P92, DOI 10.1097/BLO.0b013e3181560c51
   Emami A, 2002, SPINE, V27, P776, DOI 10.1097/00007632-200204010-00017
   Gelalis ID, 2012, EUR SPINE J, V21, P247, DOI 10.1007/s00586-011-2011-3
   Hafez MA, 2006, CLIN ORTHOP RELAT R, P184, DOI 10.1097/01.blo.0000201148.06454.ef
   Helm PA, 2015, IEEE T MED IMAGING, V34, P1738, DOI 10.1109/TMI.2015.2391200
   Keating JF, 1999, J ORTHOP TRAUMA, V13, P107, DOI 10.1097/00005131-199902000-00007
   Kebaish KM, 2010, SPINE, V35, P2245, DOI 10.1097/BRS.0b013e3181f5cfae
   Laine T, 2000, EUR SPINE J, V9, P235, DOI 10.1007/s005860000146
   Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591
   Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432
   Papanastassiou ID, 2011, J SPINAL DISORD TECH, V24, P76, DOI 10.1097/BSD.0b013e3181df8e6b
   Robles LA, 2009, SPINE J, V9, P60, DOI 10.1016/j.spinee.2007.08.006
   Rodrigues-Pinto R, 2017, GLOB SPINE J, V7, P609, DOI 10.1177/2192568217701097
   Routt MLC, 1996, J ORTHOP TRAUMA, V10, P171
   Schroeder GD, 2016, GLOB SPINE J, V6, P686, DOI 10.1055/s-0036-1580611
   Shin JH, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e318230517a
   Takao M, 2018, ADV EXP MED BIOL, V1093, P289, DOI 10.1007/978-981-13-1396-7_22
   Takao M, 2013, J ORTHOP TRAUMA, V27, P716, DOI 10.1097/BOT.0b013e31828fc4a5
   Tian NF, 2009, INT ORTHOP, V33, P895, DOI 10.1007/s00264-009-0792-3
   Tile, 1996, J Am Acad Orthop Surg, V4, P143
   Tsuchiya K, 2006, SPINE, V31, P303, DOI 10.1097/01.brs.0000197193.81296.f1
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
   Vaccaro AR, 2013, SPINE, V38, P2028, DOI 10.1097/BRS.0b013e3182a8a381
   van den Bosch EW, 2002, J TRAUMA, V53, P44, DOI 10.1097/00005373-200207000-00009
   Yi CL, 2014, J ORTHOP TRAUMA, V28, P48, DOI 10.1097/BOT.0b013e318288c0c3
   Zheng ZM, 2009, SPINE, V34, pE565, DOI 10.1097/BRS.0b013e3181ac8fc4
   Ziran BH, 2007, J TRAUMA, V62, P347, DOI 10.1097/01.ta.0000229789.18211.85
   Zwingmann J, 2010, J TRAUMA, V69, P1501, DOI 10.1097/TA.0b013e3181d862db
   Zwingmann J, 2013, INJURY, V44, P1765, DOI 10.1016/j.injury.2013.08.008
   Zwingmann J, 2009, CLIN ORTHOP RELAT R, V467, P1833, DOI 10.1007/s11999-008-0632-6
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP 399
EP 407
DI 10.1016/j.wneu.2019.07.050
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300171
PM 31658582
DA 2020-05-12
ER

PT J
AU Acker, G
   Meinert, F
   Conti, A
   Kufeld, M
   Jelgersma, C
   Nguyen, P
   Kluge, A
   Lukas, M
   Loebel, F
   Pasemann, D
   Kaul, D
   Budach, V
   Vajkoczy, P
   Senger, C
AF Acker, Gueliz
   Meinert, Franziska
   Conti, Alfredo
   Kufeld, Markus
   Jelgersma, Claudius
   Nguyen, Phuong
   Kluge, Anne
   Lukas, Mathias
   Loebel, Franziska
   Pasemann, Diana
   Kaul, David
   Budach, Volker
   Vajkoczy, Peter
   Senger, Carolin
TI Image-Guided Robotic Radiosurgery for Treatment of Recurrent Grade II
   and III Meningiomas. A Single-Center Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE CyberKnife; Malignant meningiomas; Radiosurgery
ID GROSS-TOTAL RESECTION; CYBERKNIFE STEREOTACTIC RADIOSURGERY; GAMMA-KNIFE
   RADIOSURGERY; ATYPICAL MENINGIOMAS; ANAPLASTIC MENINGIOMAS; ADJUVANT
   RADIOTHERAPY; MALIGNANT MENINGIOMA; PROGNOSTIC-FACTORS; OUTCOMES;
   RADIATION
AB OBJECTIVE: Stereotactic radiosurgery (SRS) has been increasingly applied for malignant meningiomas as an alternative to conventionally fractioned radiation therapy. We performed a retrospective analysis of an institutional patient cohort with malignant meningiomas treated by image-guided SRS.
   METHODS: All patients with atypical or anaplastic meningiomas who were treated by SRS using CyberKnife (CK) were identified. Local failure and regional and/or distant recurrences were evaluated together with toxicity and overall survival.
   RESULTS: We identified 127 treated lesions (105 atypical and 22 anaplastic) in 35 patients. The mean time interval between the last surgery and subsequent CK-SRS was 30.8 +/- 24.5 months. Most lesions (83.5%) were treated using single-fraction CK-SRS. The median planning target volume of all 127 lesions was 1.71 cm(3) (range, 0.06-22.5 cm(3)). The median follow-up period was 23 months (range, 2.1-60.3 months). The estimated local control rates were 97%, 77%, and 67% at 12, 36, and 60 months, respectively, in atypical meningiomas and 66% each at 12 and 24 months in anaplastic meningiomas. The regional progression-free survival was 93%, 73%, and 59% at 12, 36, and 60 months, respectively, in atypical lesions and 93% and 46% at 12 and 24 months in anaplastic lesions. The estimated distant tumor progression-free interval in atypical lesions was 80%, 44%, and 44% at 12, 36, and 60 months, respectively, and 49% and 24% at 12 and 24 months, respectively, in anaplastic lesions. Age was identified as a risk factor for local failure.
   CONCLUSIONS: Although the real boundaries of efficacy of SRS have to be further evaluated in a prospective trial, it seems that aggressive treatment by high-dose single or multisession SRS of recurring malignant meningiomas provides satisfactory local control rates.
C1 [Acker, Gueliz; Meinert, Franziska; Conti, Alfredo; Jelgersma, Claudius; Nguyen, Phuong; Loebel, Franziska; Vajkoczy, Peter] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany.
   [Acker, Gueliz; Meinert, Franziska; Conti, Alfredo; Jelgersma, Claudius; Nguyen, Phuong; Loebel, Franziska; Vajkoczy, Peter] Charite Univ Med Berlin, Ctr Stroke Res Berlin CSB, Berlin, Germany.
   [Acker, Gueliz; Meinert, Franziska; Conti, Alfredo; Kufeld, Markus; Jelgersma, Claudius; Nguyen, Phuong; Kluge, Anne; Loebel, Franziska; Pasemann, Diana; Budach, Volker; Vajkoczy, Peter; Senger, Carolin] Charite Univ Med Berlin, Charite CyberKnife Ctr, Berlin, Germany.
   [Kluge, Anne; Pasemann, Diana; Kaul, David; Budach, Volker; Senger, Carolin] Charite Univ Med Berlin, Dept Radiat Oncol, Berlin, Germany.
   [Lukas, Mathias] Charite Univ Med Berlin, Dept Nucl Med, Berlin, Germany.
   [Lukas, Mathias] Free Univ Berlin, Berlin, Germany.
   [Lukas, Mathias] Humboldt Univ, Berlin, Germany.
   [Acker, Gueliz; Lukas, Mathias] Berlin Inst Hlth, Berlin, Germany.
   [Conti, Alfredo] Univ Messina, Dept Neurosurg, Messina, Italy.
RP Conti, A (reprint author), Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany.; Conti, A (reprint author), Charite Univ Med Berlin, Ctr Stroke Res Berlin CSB, Berlin, Germany.; Conti, A (reprint author), Charite Univ Med Berlin, Charite CyberKnife Ctr, Berlin, Germany.; Conti, A (reprint author), Univ Messina, Dept Neurosurg, Messina, Italy.
EM alfredo.conti@charite.de
FU Charite Universitatsmedizin Berlin; Berlin Institute of Health
FX G.A. is a participant of the BIH-Charite Clinician Scientist Program
   funded by the Charite Universitatsmedizin Berlin and the Berlin
   Institute of Health.
CR Aboukais R, 2015, J NEUROSURG, V122, P1157, DOI 10.3171/2014.9.JNS14233
   Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Albert Ashley, 2018, Adv Radiat Oncol, V3, P280, DOI 10.1016/j.adro.2018.04.004
   Atkinson T, 2016, SUPPORT CARE CANCER, V24, P3669, DOI 10.1007/s00520-016-3297-9
   Attia A, 2012, J NEURO-ONCOL, V108, P179, DOI 10.1007/s11060-012-0828-1
   Barnett GH, 2007, J NEUROSURG, V106, P1, DOI 10.3171/jns.2007.106.1.1
   Champeaux C, 2017, NEUROCHIRURGIE, V63, P273, DOI 10.1016/j.neuchi.2017.03.004
   Choi CYH, 2010, NEUROSURGERY, V67, P1180, DOI 10.1227/NEU.0b013e3181f2f427
   Conti A, 2017, WORLD NEUROSURG, V103, P702, DOI 10.1016/j.wneu.2017.04.102
   Conti A, 2016, CUREUS, V8, DOI 10.7759/cureus.605
   Conti A, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0804-2
   Conti A, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12414
   Conti A, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09-157
   Di Franco R, 2018, NEURORADIOL J, V31, DOI 10.1177/1971400917744885
   El-Khatib M, 2011, ACTA NEUROCHIR, V153, P1761, DOI 10.1007/s00701-011-1073-7
   Fatima N, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.3.FOCUS1970
   Ferraro DJ, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-38
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   Graffeo CS, 2017, WORLD NEUROSURG, V103, P655, DOI 10.1016/j.wneu.2017.04.095
   Hammouche S, 2014, ACTA NEUROCHIR, V156, P1475, DOI 10.1007/s00701-014-2156-z
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   Harris AE, 2003, SURG NEUROL, V60, P298, DOI 10.1016/S0090-3019(03)00320-3
   Harrison G, 2016, J NEUROSURG, V124, P146, DOI 10.3171/2014.12.JNS141341
   Hwang KL, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.06.09
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Kim JW, 2012, STEREOT FUNCT NEUROS, V90, P316, DOI 10.1159/000338253
   Kim M, 2017, CLIN NEUROL NEUROSUR, V153, P93, DOI 10.1016/j.clineuro.2016.12.014
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Kuhn EN, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13283
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Mattozo CA, 2007, J NEUROSURG, V106, P846, DOI 10.3171/jns.2007.106.5.846
   Mori Yoshimasa, 2013, Acta Neurochir Suppl, V116, P85, DOI 10.1007/978-3-7091-1376-9_13
   Ojemann SG, 2000, J NEUROSURG, V93, P62, DOI 10.3171/jns.2000.93.supplement_3.0062
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Pearson BE, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/5/E3
   Pollock BE, 2012, CANCER-AM CANCER SOC, V118, P1048, DOI 10.1002/cncr.26362
   Refaat T, 2017, J NEUROL SURG PART B, V78, P288, DOI 10.1055/s-0036-1597834
   Rogers L, 2018, J NEUROSURG, V129, P35, DOI 10.3171/2016.11.JNS161170
   Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644
   Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001
   Sun SQ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14757
   Valery CA, 2016, J NEUROSURG, V125, P89, DOI 10.3171/2016.7.GKS161521
   Willis J, 2005, NEUROPATH APPL NEURO, V31, P141, DOI 10.1111/j.1365-2990.2004.00621.x
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Zhang M, 2016, WORLD NEUROSURG, V91, P574, DOI 10.1016/j.wneu.2016.04.019
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E96
EP E107
DI 10.1016/j.wneu.2019.07.058
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300013
PM 31306844
DA 2020-05-12
ER

PT J
AU Amano, Y
   Fujimoto, A
   Ichikawa, N
   Sato, K
   Baba, S
   Nishimura, M
   Enoki, H
   Okanishi, T
AF Amano, Yuki
   Fujimoto, Ayataka
   Ichikawa, Naoki
   Sato, Keishiro
   Baba, Shimpei
   Nishimura, Mitsuyo
   Enoki, Hideo
   Okanishi, Tohru
TI Cranioplasty with Titanium Might Be Suitable for Adult Epilepsy Surgery
   After Subdural Placement Surgery To Avoid Surgical Site Infection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bioresorbable; Cranioplasty; Epilepsy surgery; Surgical site infection;
   Titanium
ID BONE; COMPLICATIONS; FIXATION; IMPLANTATION; ELECTRODES; EXPERIENCE;
   PLATES
AB BACKGROUND: The purpose of the present study was to compare the surgical site infection (SSI) rates between resorbable plates and titanium plates used for adult patients with intractable epilepsy who had undergone epilepsy surgery after subdural electrode placement.
   METHODS: We performed subdural electrode surgery, followed by epilepsy surgery, for 87 adult patients with intractable epilepsy. The epilepsy surgery included 75 focus resections and 12 corpus callosotomies. We compared the SSI rates between patients who had undergone cranioplasty with titanium and resorbable plates after epilepsy surgery.
   RESULTS: Of the 87 patients, 43 had undergone cranioplasty with resorbable plates (group A) and 44 had undergone cranioplasty with titanium plates (group B). The frequency of SSI was significantly greater in group A (7 patients; 16.3%) than in group B (1 patient; 2.3%; P = 0.03, Fisher's exact test). Univariate regression analysis also showed a significantly greater infection rate with the resorbable plates (P = 0.024).
   CONCLUSION: For epilepsy surgery of adult patients after subdural electrode placement surgery, the SSI rate for cranioplasty was greater with resorbable plates than with titanium plates.
C1 [Amano, Yuki; Fujimoto, Ayataka; Ichikawa, Naoki; Sato, Keishiro; Baba, Shimpei; Nishimura, Mitsuyo; Enoki, Hideo; Okanishi, Tohru] Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Hamamatsu, Shizuoka, Japan.
RP Fujimoto, A (reprint author), Seirei Hamamatsu Gen Hosp, Comprehens Epilepsy Ctr, Hamamatsu, Shizuoka, Japan.
EM afujimotoscienceacademy@gmail.com
CR Ahmad N, 2008, J CRANIOFAC SURG, V19, P855, DOI 10.1097/SCS.0b013e31816ae358
   An JG, 2015, J CRANIO MAXILL SURG, V43, P515, DOI 10.1016/j.jcms.2015.03.002
   An YH, 1998, J BIOMED MATER RES, V43, P338, DOI 10.1002/(SICI)1097-4636(199823)43:3<338::AID-JBM16>3.0.CO;2-B
   Bock RM, 2017, J BIOMED MATER RES A, V105, P1521, DOI 10.1002/jbm.a.35987
   Branch LG, 2017, J CRANIOFAC SURG, V28, P26, DOI 10.1097/SCS.0000000000003166
   Elsner JJ, 2009, ACTA BIOMATER, V5, P2872, DOI 10.1016/j.actbio.2009.04.007
   Emil A, 2015, INFECT DIS-NOR, V47, P761, DOI 10.3109/23744235.2015.1055587
   Hersh EH, 2013, J NEUROSURG, V119, P48, DOI 10.3171/2013.3.JNS121489
   Jin SW, 2018, TURK NEUROSURG, V28, P882, DOI 10.5137/1019-5149.JTN.21333-17.2
   Katsikogianni M, 2004, Eur Cell Mater, V8, P37
   Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313
   MEYER HGW, 1994, APMIS, V102, P538, DOI 10.1111/j.1699-0463.1994.tb05203.x
   Nguyen DC, 2017, J CRANIOFAC SURG, V28, P88, DOI 10.1097/SCS.0000000000003216
   Ozaki M, 2017, J CRANIOFAC SURG, V28, P888, DOI 10.1097/SCS.0000000000003507
   Park CH, 2011, ARCH OTOLARYNGOL, V137, P125, DOI 10.1001/archoto.2010.241
   PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786
   Renner LD, 2011, MRS BULL, V36, P347, DOI 10.1557/mrs.2011.65
   Ribeiro Marta, 2012, Biomatter, V2, P176, DOI 10.4161/biom.22905
   Saganuwan Saganuwan A., 2018, Central Nervous System Agents in Medicinal Chemistry, V18, P32, DOI 10.2174/1871524917666170821115748
   Scheuerman TR, 1998, J COLLOID INTERF SCI, V208, P23, DOI 10.1006/jcis.1998.5717
   Ueki K, 2009, J ORAL MAXIL SURG, V67, P1062, DOI 10.1016/j.joms.2008.11.016
   Weinand M E, 1993, Seizure, V2, P133, DOI 10.1016/S1059-1311(05)80117-7
   Wittwer G, 2006, ORAL SURG ORAL MED O, V101, P419, DOI 10.1016/j.tripleo.2005.07.026
   Wui SH, 2016, WORLD NEUROSURG, V91, P43, DOI 10.1016/j.wneu.2016.03.066
   Yang LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067449
   Yoshioka I, 2012, J ORAL MAXIL SURG, V70, P919, DOI 10.1016/j.joms.2011.02.136
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E503
EP E507
DI 10.1016/j.wneu.2019.07.201
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300062
PM 31382070
DA 2020-05-12
ER

PT J
AU Azad, TD
   Varshneya, K
   Ho, AL
   Veeravagu, A
   Sciubba, DM
   Ratliff, JK
AF Azad, Tej D.
   Varshneya, Kunal
   Ho, Allen L.
   Veeravagu, Anand
   Sciubba, Daniel M.
   Ratliff, John K.
TI Laminectomy Versus Corpectomy for Spinal Metastatic
   Disease-Complications, Costs, and Quality Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Corpectomy; Epidural spinal cord compression; Laminectomy; Spine
   metastasis
ID SURGICAL-TREATMENT; READMISSION RATES; CORD COMPRESSION; TUMORS;
   MANAGEMENT; RESECTION; SURGERY; RECONSTRUCTION; VERTEBRECTOMY; ANTERIOR
AB BACKGROUND: The landmark Patchell trial established surgical decompression followed by adjuvant radiotherapy as standard-of-care for patients with spinal cord compression caused by metastatic cancer. However, little comparative evidence exists with regard to the choice of specific surgical approaches for these patients. We sought to conduct a comparative analysis of outcomes of surgical options for spinal metastatic disease.
   METHODS: This was an epidemiologic study using national administrative data from the MarketScan database. We queried the MarketScan database (2007-2016), identifying patients with a diagnosis of spinal metastasis treated with surgical decompression (N = 1054). We used descriptive statistics and hypothesis testing to compare baseline characteristics, complications, quality metrics, and costs.
   RESULTS: We identified patients with spinal metastases undergoing laminectomy (N = 760), corpectomy (N = 193), or both combined procedures (laminectomy and corpectomy, N = 101). No significant differences in baseline demographics, follow-up time, or primary tumor histology were observed. We found a greater 30-day postoperative complication rate among patients undergoing corpectomy (P < 0.0001), driven by increased rate of postoperative anemia and pulmonary complications. Length of stay and 30-day readmission rates did not vary between surgical approaches. Total index hospitalization and 30-day payments were greatest among patients undergoing combined procedures and lowest for patients undergoing laminectomy alone.
   CONCLUSIONS: Our findings highlight distinct complication profiles and quality outcomes associated with selection of surgical approach for patients with spinal metastases. These findings must be interpreted with a clear understanding of the limitations.
C1 [Azad, Tej D.; Varshneya, Kunal; Ho, Allen L.; Veeravagu, Anand; Ratliff, John K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Sciubba, Daniel M.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA.
RP Ratliff, JK (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM jratliff@stanford.edu
CR Abu-Bonsrah N, 2017, WORLD NEUROSURG, V101, P695, DOI 10.1016/j.wneu.2017.02.065
   Akinduro OO, 2019, OPER NEUROSURG, V17, pE101, DOI 10.1093/ons/opy379
   Azad TD, 2018, SPINE J, V18, P2232, DOI 10.1016/j.spinee.2018.05.008
   Barzilai O, 2019, OPER NEUROSURG, V16, P310, DOI 10.1093/ons/opy137
   De la Garza-Ramos R, 2016, J CLIN NEUROSCI, V24, P43, DOI 10.1016/j.jocn.2015.08.008
   Elsamadicy Aladine A, 2018, J Spine Surg, V4, P304, DOI 10.21037/jss.2018.05.14
   HAMMERBERG KW, 1992, SPINE, V17, P1148, DOI 10.1097/00007632-199210000-00004
   Idowu OA, 2017, SPINE, V42, pE1429, DOI 10.1097/BRS.0000000000002180
   Kelly ML, 2014, CANCER-AM CANCER SOC, V120, P901, DOI 10.1002/cncr.28497
   Lau D, 2016, J NEUROSURG-SPINE, V25, P366, DOI 10.3171/2016.2.SPINE15954
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Li AY, 2017, CLIN SPINE SURG, V30, pE1392, DOI [10.1097/BSD.0000000000000450, 10.1097/BSD.0000000000000437]
   MAURER PK, 1993, NEUROSURGERY, V33, P533
   Molina C, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16129
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Patil CG, 2007, CANCER, V110, P625, DOI 10.1002/cncr.22819
   Schairer WW, 2014, SPINE, V39, P1801, DOI 10.1097/BRS.0000000000000517
   Sciubba DM, 2010, J NEUROSURG-SPINE, V13, P94, DOI 10.3171/2010.3.SPINE09202
   Spratt DE, 2017, LANCET ONCOL, V18, pE720, DOI 10.1016/S1470-2045(17)30612-5
   Street J, 2007, J SPINAL DISORD TECH, V20, P509, DOI 10.1097/BSD.0b013e3180335bf7
   SUNDARESAN N, 1991, NEUROSURGERY, V29, P645, DOI 10.1227/00006123-199111000-00001
   Ugiliweneza B, 2014, SPINE, V39, P1235, DOI 10.1097/BRS.0000000000000378
   Xu RS, 2009, J NEUROSURG-SPINE, V11, P272, DOI 10.3171/2009.3.SPINE08621
   Yang Joo Chul, 2013, Korean J Spine, V10, P149, DOI 10.14245/kjs.2013.10.3.149
   Yoshihara H, 2014, SPINE J, V14, P1844, DOI 10.1016/j.spinee.2013.11.029
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E468
EP E473
DI 10.1016/j.wneu.2019.07.206
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300057
PM 31404695
DA 2020-05-12
ER

PT J
AU Baek, J
   Malik, AT
   Khan, I
   Yu, E
   Kim, J
   Khan, SN
AF Baek, Jae
   Malik, Azeem Tariq
   Khan, Inamullah
   Yu, Elizabeth
   Kim, Jeffery
   Khan, Safdar N.
TI Orthopedic versus Neurosurgery-Understanding 90-Day Complications and
   Costs in Patients Undergoing Elective 1-Level to 2-Level Posterior
   Lumbar Fusions by Different Specialties
SO WORLD NEUROSURGERY
LA English
DT Article
DE Costs; Humana; Lumbar fusions; Neurosurgery; Orthopedic surgery;
   Outcomes; PearlDiver; Specialty
ID SURGEON SELECTION CRITERIA; SPINAL-FUSION; OUTCOMES
AB BACKGROUND: Lumbar fusions are routinely performed by either orthopedic or neurologic spine surgeons. Controversy still exists as to whether a provider's specialty (orthopedic vs. neurosurgery) influences outcomes.
   METHODS: The 2007-201502 Humana Commercial Database was queried using Current Procedural Terminology codes (22612, 22614, 22630, 22632, 22633 and 22634) to identify patients undergoing elective 1-to-2 level posterior lumbar fusions (PLFs) with active enrollment up to 90 days after procedure. Ninety-day complication rates were calculated for the 2 specialties. The surgical and 90-day resource utilization costs for the 2 groups were compared, by studying average reimbursements for acute-care and post-acute-care categories. Ninety-day complications and costs were compared using multivariable logistic and linear regression analyses.
   RESULTS: A total of 10,509 patients (5523 orthopedic and 4986 neurosurgery) underwent an elective 1-to-2 level PLF during the period. With the exception of a significantly lower odds of wound complications (odds ratio, 0.81) and a higher odds of dural tears (odds ratio, 1.29) in elective PLFs performed by orthopedic surgeons, no statistically strong differences were seen in 90-day complication rates between the 2 groups. Total 90-day costs were also similar between orthopedic surgeons and neurosurgeons, with the only exception being that surgeon reimbursement was lower for orthopedic surgery versus neurosurgery ($1202 vs. $1372; P < 0.001).
   CONCLUSIONS: It seems that a provider's specialty does not largely influence 90-day surgical outcomes and costs after elective PLFs. The results of the study promote the formation and acceptance of dual training pathways for entry into spine surgery.
C1 [Baek, Jae; Malik, Azeem Tariq; Yu, Elizabeth; Kim, Jeffery; Khan, Safdar N.] Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
   [Khan, Inamullah] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA.
RP Khan, SN (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
EM Safdar.Khan@osumc.edu
OI Khan, Inamullah/0000-0002-1519-8940
CR Arnold Paul M, 2009, Am J Orthop (Belle Mead NJ), V38, pE156
   Bronheim RS, 2018, WORLD NEUROSURG, V120, pE221, DOI 10.1016/j.wneu.2018.08.034
   Chee TT, 2016, CIRCULATION, V133, P2197, DOI 10.1161/CIRCULATIONAHA.115.010268
   Cowan JA, 2006, NEUROSURGERY, V59, P15, DOI 10.1227/01.NEU.0000219836.54861.CD
   Daniels AH, 2015, SPINE J, V15, P1513, DOI 10.1016/j.spinee.2014.08.452
   Daniels AH, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01562
   Deng Hansen, 2019, J Neurosurg Sci, DOI 10.23736/S0390-5616.19.04647-2
   Deyo RA, 2005, SPINE, V30, P1441, DOI 10.1097/01.brs.0000166503.37969.8a
   Dvorak MF, 2006, SPINE, V31, P831, DOI 10.1097/01.brs.0000207238.48446.ce
   Friedberg Mark W, 2015, Rand Health Q, V5, P8
   Grauer JN, 2004, SPINE, V29, P685, DOI 10.1097/01.BRS.0000115137.11276.0E
   Hijji FY, 2018, CLIN SPINE SURG, V31, pE127, DOI 10.1097/BSD.0000000000000576
   Kim BD, 2014, SPINE, V39, pE919, DOI 10.1097/BRS.0000000000000394
   Mabud T, 2017, CLIN SPINE SURG, V30, pE1376, DOI 10.1097/BSD.0000000000000426
   Manning BT, 2016, SPINE, V41, pE814, DOI 10.1097/BRS.0000000000001385
   Martin BI, 2019, SPINE, V44, P369, DOI 10.1097/BRS.0000000000002822
   McCutcheon BA, 2015, SPINE, V40, P1122, DOI 10.1097/BRS.0000000000000599
   Minhas SV, 2014, SPINE, V39, P1648, DOI 10.1097/BRS.0000000000000499
   Oro FB, 2011, ARTHROSCOPY, V27, P1219, DOI 10.1016/j.arthro.2011.04.008
   Post AF, 2019, WORLD NEUROSURG, V122, pE147, DOI 10.1016/j.wneu.2018.09.152
   Seicean A, 2014, SPINE, V39, P1605, DOI 10.1097/BRS.0000000000000489
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E447
EP E453
DI 10.1016/j.wneu.2019.07.194
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300054
PM 31415887
DA 2020-05-12
ER

PT J
AU Beynon, C
   Olivares, A
   Gumbinger, C
   Younsi, A
   Zweckberger, K
   Unterberg, AW
AF Beynon, Christopher
   Olivares, Arturo
   Gumbinger, Christoph
   Younsi, Alexander
   Zweckberger, Klaus
   Unterberg, Andreas W.
TI Management of Spinal Emergencies in Patients on Direct Oral
   Anticoagulants
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anticoagulants; Hemorrhage; Hemostasis; Spine
ID EPIDURAL HEMATOMA; SUBDURAL-HEMATOMA; RIVAROXABAN
AB OBJECTIVE: Spine surgeons increasingly encounter acute spinal pathologies in patients treated with direct oral anticoagulants (DOACs), but only limited data on the management of these patients are currently available.
   METHODS: We retrospectively analyzed patients who presented to our department with acute spinal pathology during treatment with DOAC and who required urgent surgical therapy. Patient characteristics and treatment modalities were studied, with specific focus on the management of hemostasis and surgical therapy. Furthermore, we analyzed 19 cases of spinal emergencies during DOAC treatment reported in the literature.
   RESULTS: A total of 12 patients were identified and included in the present analysis. Patients suffered from acute spinal cord compression caused by spinal tumor manifestation (n = 5), empyema (n = 4), degenerative spinal stenosis (n = 1), hematoma (n = 1), and vertebral body fracture/dislocation (n = 2). All patients underwent emergency surgical treatment. Prohemostatic substances were administered perioperatively in 10 patients (83%) and included administration of prothrombin complex concentrates (83%), tranexamic acid (17%), and transfusion of platelets (8%). A total of 9 patients (75%) showed postoperative improvement of neurologic symptoms, and the in-hospital mortality in this patient cohort was 17%.
   CONCLUSIONS: Emergency spine surgery is feasible and should be considered in patients on treatment with DOAC. The (low) risk of intraoperative bleeding complications has to be weighed against the risk of permanent disability if surgical decompression is delayed. Administration of prothrombin complex concentrates and tranexamic acid may improve the coagulation before surgery, especially in cases of unavailable specific antidotes.
C1 [Beynon, Christopher; Olivares, Arturo; Younsi, Alexander; Zweckberger, Klaus; Unterberg, Andreas W.] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
   [Gumbinger, Christoph] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany.
RP Beynon, C (reprint author), Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
EM christopher.beynon@med.uni-heidelberg.de
CR Bamps S, 2015, WORLD NEUROSURG, V83, P257, DOI 10.1016/j.wneu.2014.10.012
   Bang WS, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e40
   Beynon C, 2014, ACTA NEUROCHIR, V156, P741, DOI 10.1007/s00701-014-2032-x
   Bourassa-Moreau E, 2013, J NEUROTRAUM, V30, P1596, DOI 10.1089/neu.2013.2957
   CAPUTO AM, 2013, JBJS CASE CONNECT, V3, pE64, DOI DOI 10.2106/JBJS.CC.M.00011
   Castillo JM, 2015, AM J CASE REP, V16, P377, DOI 10.12659/AJCR.893320
   Colell A, 2018, CASE REP HEMATOL, DOI 10.1155/2018/4507638
   Croci DM, 2019, WORLD NEUROSURG, V125, pE1034, DOI 10.1016/j.wneu.2019.01.236
   Culbreth SE, 2019, AM J HEMATOL, V94, pE21, DOI 10.1002/ajh.25326
   Dargazanli C, 2016, EUR SPINE J, V25, pS100, DOI 10.1007/s00586-015-4160-2
   De Vlieger J, 2017, RES PRACT THROMB HAE, V1, P296, DOI 10.1002/rth2.12035
   Goldfine Charlotte, 2018, Clin Pract Cases Emerg Med, V2, P151, DOI 10.5811/cpcem.2018.2.37096
   Ismail R, 2017, J EMERG MED, V53, P536, DOI 10.1016/j.jemermed.2017.06.005
   Jaeger M, 2012, Eur Spine J, V21 Suppl 4, pS433, DOI 10.1007/s00586-011-2003-3
   Kircelli A, 2018, AM J CARDIOL, V121, pe13
   Mathais Q, 2018, WORLD NEUROSURG, V112, P264, DOI 10.1016/j.wneu.2018.01.199
   Mchaourab Ahmad, 2019, BMJ Case Rep, V12, DOI 10.1136/bcr-2018-227311
   Mukerji N, 2013, BRIT J NEUROSURG, V27, P712, DOI 10.3109/02688697.2013.793289
   Ozel O, 2016, ORTHOPEDICS, V39, pE558, DOI 10.3928/01477447-20160414-01
   Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000
   Radcliff KE, 2014, ORTHOP SURG, V6, P69, DOI 10.1111/os.12085
   Sarwal G, 2016, UBC MED J, V8, P134
   Steffel J, 2018, EUR HEART J, V39, P1330, DOI 10.1093/eurheartj/ehy136
   Truumees E, 2012, SPINE, V37, pE863, DOI 10.1097/BRS.0b013e31824ee320
   Wolfe Allen R, 2017, Radiol Case Rep, V12, P257, DOI 10.1016/j.radcr.2017.02.004
   Zaarour M, 2015, CASE REP HEMATOL, DOI 10.1155/2015/275380
NR 26
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E570
EP E578
DI 10.1016/j.wneu.2019.07.234
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300071
PM 31400524
DA 2020-05-12
ER

PT J
AU Brunozzi, D
   Theiss, P
   Andrews, A
   Amin-Hanjani, S
   Charbel, FT
   Alaraj, A
AF Brunozzi, Denise
   Theiss, Peter
   Andrews, Amanda
   Amin-Hanjani, Sepideh
   Charbel, Fady T.
   Alaraj, Ali
TI Correlation Between Laminar Wall Shear Stress and Growth of Unruptured
   Cerebral Aneurysms: In Vivo Assessment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flow; Hemodynamics; Parent vessel; Unruptured cerebral aneurysm; Wall
   shear stress
ID INTRACRANIAL ANEURYSMS; CAROTID-ARTERY; HEMODYNAMICS; RISK
AB BACKGROUND: Cerebral aneurysm growth is significantly associated with aneurysm rupture, but risk factors for aneurysm growth are not well characterized. It is believed that altered intracranial hemodynamics may contribute to the pathophysiology of aneurysm growth, but these mechanisms are not fully understood.
   OBJECTIVE: Here, we assess the correlation between growth of unruptured cerebral aneurysms over time and average laminar shear stress on the wall of the parent vessel proximal to the aneurysm.
   METHODS: Patients with unruptured, untreated cerebral aneurysms followed over time at our institution between 2005 and 2017 were retrospectively reviewed. Patients were included if at least 1 quantitative magnetic resonance angiography study was performed at baseline and followup. The nonparametric Wilcoxon-Mann-Whitney test was used to compare mean parent vessel - laminar wall shear stress (PV-LWSS) proximal to the aneurysm in growing versus stable aneurysms. Change in PV-LWSS over time was evaluated using the 1-way repeated measures analysis of variance test.
   RESULTS: Thirty-three patients with 45 total aneurysms were included (63% female, mean age 60 years). Four patients presented with aneurysm growth over time. Unstable aneurysms had significantly higher PV-LWSS compared with stable aneurysms at the time of first diagnosis (29.3 vs. 13.1 dynes/cm(2), P = 0.02) and at 1-year follow-up (25.8 vs. 12.3 dynes/cm(2), P = 0.05).
   CONCLUSIONS: The subset of unruptured cerebral aneurysms that demonstrate growth over time has a significantly higher mean PV-LWSS than stable aneurysms, as measured by quantitative magnetic resonance angiography. This information at the time of diagnosis may help predict future aneurysm growth, stratify rupture risk, and identify those aneurysms that should undergo prophylactic treatment.
C1 [Brunozzi, Denise; Theiss, Peter; Andrews, Amanda; Amin-Hanjani, Sepideh; Charbel, Fady T.; Alaraj, Ali] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
RP Alaraj, A (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM alaraj@uic.edu
OI Amin-Hanjani, Sepideh/0000-0002-1289-4596
CR Boussel L, 2008, STROKE, V39, P2997, DOI 10.1161/STROKEAHA.108.521617
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P615, DOI 10.3174/ajnr.A4575
   Calderon-Arnulphi M, 2011, AM J NEURORADIOL, V32, P1552, DOI 10.3174/ajnr.A2546
   Cebral JR, 2011, AM J NEURORADIOL, V32, P145, DOI 10.3174/ajnr.A2419
   Cebral JR, 2011, AM J NEURORADIOL, V32, P264, DOI 10.3174/ajnr.A2274
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Farnoush A, 2014, J CLIN NEUROSCI, V21, P1514, DOI 10.1016/j.jocn.2013.12.021
   LARSON JJ, 1995, NEUROSURGERY, V36, P23, DOI 10.1227/00006123-199501000-00002
   Matsumoto K, 2013, ACTA NEUROCHIR, V155, P211, DOI 10.1007/s00701-012-1566-z
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Munarriz PM, 2016, WORLD NEUROSURG, V88, P311, DOI 10.1016/j.wneu.2016.01.031
   Sadasivan C, 2013, ANN BIOMED ENG, V41, P1347, DOI 10.1007/s10439-013-0800-z
   Sforza DM, 2016, J NEUROINTERV SURG, V8, P407, DOI 10.1136/neurintsurg-2014-011339
   Zhang X, J NEUROSURG, DOI [10.3171/2018, DOI 10.3171/2018]
   Zhao M, 2000, MAGN RESON IMAGING, V18, P697, DOI 10.1016/S0730-725X(00)00157-0
   Zhao XX, 2015, J NEUROIMAGING, V25, P403, DOI 10.1111/jon.12133
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E599
EP E605
DI 10.1016/j.wneu.2019.08.005
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300075
PM 31404691
DA 2020-05-12
ER

PT J
AU Catapano, JS
   Rubel, NC
   Veljanoski, D
   Farber, SH
   Whiting, AC
   Morgan, CD
   Brigeman, S
   Lawton, MT
   Zabramski, JM
AF Catapano, Joshua S.
   Rubel, Nicolas C.
   Veljanoski, Damjan
   Farber, S. Harrison
   Whiting, Alexander C.
   Morgan, Clinton D.
   Brigeman, Scott
   Lawton, Michael T.
   Zabramski, Joseph M.
TI Standardized Ventriculostomy Protocol without an Occlusive Dressing:
   Results of an Observational Study in Patients with Aneurysmal
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF culture; External ventricular drain; Ruptured intracranial aneurysm;
   Ventriculostomy-associated infections
ID INTENSIVE-CARE-UNIT; CEREBROSPINAL-FLUID; INFECTION-RATES; RISK-FACTORS;
   DRAINAGE; VENTRICULITIS; PREVENTION; CATHETERS; HYDROCEPHALUS;
   MANAGEMENT
AB BACKGROUND: Catheter-related infections are a potentially life-threatening complication of having an external ventricular drain (EVD). Patients with aneurysmal subarachnoid hemorrhage (aSAH) are at increased risk of infection associated with prolonged ventricular drainage, with a reported mean infection rate of 6%. We report the EVD-associated infection rate among patients with aSAH managed with a unique standardized treatment protocol without an occlusive EVD dressing.
   METHODS: Patients with aSAH admitted from August 2015 through August 2017 were retrospectively analyzed for EVD placement. Cerebrospinal fluid (CSF) samples were obtained twice weekly for culture and routine studies. EVD-associated infection was defined as growth of CSF cultures.
   RESULTS: During the 2-year study period, 122 patients presented with an aSAH, with 91 (74.6%) having EVD placement. In patients with EVDs, the mean age was 57.9 years (68% women); 88% of aSAHs were Fisher grade In or IV. Mean duration of EVD was 14 days, and 13% of patients required EVD replacement. Endovascular coiling and surgical clipping were performed in 34 (37%) and 53 (58%) patients with EVD, respectively. A total of 347 CSF studies were performed with no EVD-associated infections. There were 3 CSF samples with false-positive Gram stain results but no growth on concurrent or multiple repeat cultures.
   CONCLUSIONS: Using a standardized protocol for placement and management of EVDs in patients with aSAH is associated with low risk of CSF infection. Our study demonstrates that occlusive EVD dressings are not necessary and that routine CSF sampling in patients with EVD may lead to false-positive findings and unnecessary antibiotic administration.
C1 [Catapano, Joshua S.; Rubel, Nicolas C.; Veljanoski, Damjan; Farber, S. Harrison; Whiting, Alexander C.; Morgan, Clinton D.; Brigeman, Scott; Lawton, Michael T.; Zabramski, Joseph M.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Zabramski, JM (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM neuropub.zabramski@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219; Farber, S.
   Harrison/0000-0002-0171-6516; Rubel, Nicolas/0000-0003-3674-029X
CR Abla AA, 2011, NEUROSURGERY, V68, P437, DOI 10.1227/NEU.0b013e3182039a14
   Bari Muhammad E, 2017, Surg Neurol Int, V8, P124, DOI 10.4103/sni.sni_440_16
   Bayston R, 2016, J NEUROSURG, V124, P375, DOI 10.3171/2014.12.JNS141900
   Avila SC, 2016, J ACUTE DIS, V5, P143, DOI 10.1016/j.joad.2015.12.001
   Chatzi M, 2014, CRIT CARE MED, V42, P66, DOI 10.1097/CCM.0b013e31829a70a5
   Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901
   Di Russo Paolo, 2020, J Neurosurg Sci, V64, P181, DOI 10.23736/S0390-5616.19.04641-1
   dos Santos SC, 2017, WORLD NEUROSURG, V99, P580, DOI 10.1016/j.wneu.2016.12.071
   Flint AC, 2017, WORLD NEUROSURG, V99, P518, DOI 10.1016/j.wneu.2016.12.042
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Gigante P, 2010, BRIT J NEUROSURG, V24, P625, DOI 10.3109/02688697.2010.505989
   Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025
   Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6
   Hirashima Y, 2005, NEUROL MED-CHIR, V45, P177, DOI 10.2176/nmc.45.177
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Honda H, 2010, INFECT CONT HOSP EP, V31, P1078, DOI 10.1086/656377
   Kim JH, 2012, WORLD NEUROSURG, V77, P135, DOI 10.1016/j.wneu.2011.04.017
   Kirmani Altaf Rehman, 2015, Surg Neurol Int, V6, P188, DOI 10.4103/2152-7806.172533
   Korinek AM, 2005, ACTA NEUROCHIR, V147, P39, DOI 10.1007/s00701-004-0416-z
   Kubilay Z, 2013, J NEUROSURG, V118, P514, DOI 10.3171/2012.11.JNS121336
   Lewis A, 2017, NEUROHOSPITALIST, V7, P15, DOI 10.1177/1941874416663281
   Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.neu.0000316273.35833.7c, 10.1227/01.NEU.0000017465.78245.6C]
   Murthy SB, 2016, NEUROCRIT CARE, V24, P389, DOI 10.1007/s12028-015-0199-5
   Park YK, 2018, ACTA NEUROCHIR, V160, P1407, DOI 10.1007/s00701-018-3560-6
   Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929
   Poblete R, 2017, WORLD NEUROSURG, V99, P599, DOI 10.1016/j.wneu.2016.12.073
   Sam Jo Ee, 2018, Asian J Neurosurg, V13, P250, DOI 10.4103/ajns.AJNS_150_16
   Sieg EP, 2018, WORLD NEUROSURG, V115, pE53, DOI 10.1016/j.wneu.2018.03.160
   Strahm C, 2018, WORLD NEUROSURG, V111, pE270, DOI 10.1016/j.wneu.2017.12.062
   Tamburrini G, 2008, ACTA NEUROCHIR, V150, P1049, DOI 10.1007/s00701-008-0022-6
   Thompson DR, 2018, ACTA NEUROCHIR, V160, P1089, DOI 10.1007/s00701-018-3508-x
   Tunkel AR, 2017, CLIN INFECT DIS, V64, P701, DOI 10.1093/cid/cix152
   Widen J, 2017, ACTA NEUROCHIR, V159, P317, DOI 10.1007/s00701-016-3039-2
   Williams TA, 2011, J NEUROSURG, V115, P1040, DOI 10.3171/2011.6.JNS11167
   Wong GKC, 2010, J NEUROL NEUROSUR PS, V81, P1064, DOI 10.1136/jnnp.2009.198523
   Yu H, 2014, J CRANIOFAC SURG, V25, P902, DOI 10.1097/SCS.0000000000000561
   Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E433
EP E440
DI 10.1016/j.wneu.2019.07.183
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300052
PM 31376558
DA 2020-05-12
ER

PT J
AU Chen, HX
   Lai, R
   Tang, XP
   Liu, ZY
   Xu, JG
AF Chen, Hongxu
   Lai, Rui
   Tang, Xinpu
   Liu, Zhiyong
   Xu, Jianguo
TI Lateral Intraventricular Anaplastic Meningioma: A Series of 5 Patients
   at a Single Institution and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anaplastic meningioma; Clinical and radiologic features; Lateral
   ventricle; Prognosis; Treatment
ID MALIGNANT MENINGIOMA; CONSECUTIVE SERIES; CLINICAL-FEATURES; SPINAL
   METASTASIS; MR; MANAGEMENT; TRANSFORMATION; RADIOSURGERY; EXPERIENCE;
   SURVIVAL
AB OBJECTIVE: Lateral intraventricular anaplastic meningiomas (LIAMs) are rare lesions. The aim of this study is to clarify clinical and radiologic characteristics and the optimal treatment strategies of LIAMs with long-term follow-up.
   METHODS: From September 2008 to September 2017, 5 patients with LIAM were enrolled in our study. The clinical profiles, radiologic features, treatment strategies, and outcomes were retrospectively analyzed.
   RESULTS: Five patients (all female; mean age, 48.8 years; range, 33-61 years) were included in this study. The most frequent symptoms were those related to increased intracranial pressure. Mean duration of symptoms was 6.7 months (range, 2 weeks-2 years). The average tumor size was 4.98 cm at the maximal diameter (range, 3.0-6.2 cm). All were confirmed with a diagnosis of anaplastic meningioma. Gross total resection was achieved in all 5 patients. All patients experienced improvement of symptoms. Recurrence and progression were identified in only 2 patients. At the last follow-up, the mean recurrence-free survival was 13 months (range, 7-21 months) and the mean overall survival was 16.25 months (range, 8-21 months). One patient was lost to follow-up.
   CONCLUSIONS: Female and right trigone area predominance were found in our case series. Shorter duration of symptoms, irregular tumor shape, peritumoral edema, and heterogeneous enhancement may indicate an aggressive feature. Maximal safe resection followed by radiation therapy may be the best strategy for patients with LIAM. Long-term clinical follow-up and serial imaging are recommended.
C1 [Chen, Hongxu; Tang, Xinpu; Liu, Zhiyong; Xu, Jianguo] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Lai, Rui] Peoples Hosp Deyang City, Dept Anesthesiol, Deyang, Sichuan, Peoples R China.
RP Xu, JG (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM jianguo_1229@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81602190]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81602190).
CR Balasubramanian SK, 2017, J NEURO-ONCOL, V131, P555, DOI 10.1007/s11060-016-2321-8
   Bertalanffy A, 2006, NEUROSURG REV, V29, P30, DOI 10.1007/s10143-005-0414-5
   Bhatoe Harjinder S, 2006, Neurosurg Focus, V20, pE9, DOI 10.3171/foc.2006.20.3.10
   Chamberlain MC, 2012, J NEURO-ONCOL, V107, P315, DOI 10.1007/s11060-011-0741-z
   Chen NF, 2003, J CLIN NEUROSCI, V10, P616, DOI 10.1016/S0967-5868(03)00135-8
   CRISCUOLO GR, 1986, ACTA NEUROCHIR, V83, P83, DOI 10.1007/BF01402383
   Darwish B, 2004, J CLIN NEUROSCI, V11, P787, DOI 10.1016/j.jocn.2004.02.008
   Dziuk TW, 1998, J NEURO-ONCOL, V37, P177, DOI 10.1023/A:1005853720926
   El-Khatib M, 2011, ACTA NEUROCHIR, V153, P1761, DOI 10.1007/s00701-011-1073-7
   Eom KS, 2009, J KOREAN NEUROSURG S, V45, P256, DOI 10.3340/jkns.2009.45.4.256
   Erman Tahsin, 2003, Neurosurg Focus, V15, pECP2
   Fujimaki M, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0611-6
   Garcia-Conde M, 2009, NEUROCIRUGIA, V20, P541
   GREENBERG SB, 1993, AM J ROENTGENOL, V160, P1111, DOI 10.2214/ajr.160.5.8470588
   Grujicic D, 2017, WORLD NEUROSURG, V97, P178, DOI 10.1016/j.wneu.2016.09.068
   Gupta V, 2007, J NEUROSURG, V106, P455, DOI 10.3171/jns.2007.106.3.455
   Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794
   JELINEK J, 1990, AM J ROENTGENOL, V155, P365, DOI 10.2214/ajr.155.2.2115270
   KAMIYA K, 1989, SURG NEUROL, V32, P213, DOI 10.1016/0090-3019(89)90181-X
   Kim EY, 2009, CLIN IMAG, V33, P175, DOI 10.1016/j.clinimag.2008.09.005
   Li Xue-zhen, 2006, Zhonghua Yi Xue Za Zhi, V86, P2321
   Li ZC, 2018, NEUROSURG REV, V41, P525, DOI 10.1007/s10143-017-0884-2
   Liu M, 2006, NEUROSURG REV, V29, P36, DOI 10.1007/s10143-005-0418-1
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma J, 2014, WORLD NEUROSURG, V82, P757, DOI 10.1016/j.wneu.2014.05.026
   Majos C, 1999, AM J NEURORADIOL, V20, P882
   Mattozo CA, 2007, J NEUROSURG, V106, P846, DOI 10.3171/jns.2007.106.5.846
   Menon G, 2009, BRIT J NEUROSURG, V23, P297, DOI 10.1080/02688690902721862
   Milosevic MF, 1996, INT J RADIAT ONCOL, V34, P817, DOI 10.1016/0360-3016(95)02166-3
   Moliterno J, 2015, J NEUROSURG, V123, P23, DOI 10.3171/2014.10.JNS14502
   Nanda A, 2017, J NEUROSURG, V126, P201, DOI 10.3171/2016.1.JNS151842
   Nayak L, 2012, J NEURO-ONCOL, V109, P187, DOI 10.1007/s11060-012-0886-4
   Odegaard KM, 2013, NEUROSURG REV, V36, P57, DOI 10.1007/s10143-012-0410-5
   PEH WCG, 1995, BRIT J RADIOL, V68, P428, DOI 10.1259/0007-1285-68-808-428
   Pollock BE, 2012, CANCER-AM CANCER SOC, V118, P1048, DOI 10.1002/cncr.26362
   ROCKHILL J, 2007, NEUROSURG FOCUS, V23, pE1, DOI DOI 10.3171/FOC-07/10/E1
   Rosenberg LA, 2009, INT J RADIAT ONCOL, V74, P427, DOI 10.1016/j.ijrobp.2008.08.018
   Sanverdi SE, 2012, EUR J RADIOL, V81, P2389, DOI 10.1016/j.ejrad.2011.06.031
   Shintaku M, 2007, NEUROPATHOLOGY, V27, P448, DOI 10.1111/j.1440-1789.2007.00786.x
   Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001
   Sughrue ME, 2010, J NEUROSURG, V113, P202, DOI 10.3171/2010.1.JNS091114
   Tao CY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-238
   Vuckovic N, 2010, J NEUROIMAGING, V20, P294, DOI 10.1111/j.1552-6569.2008.00345.x
   Wang X, 2007, MINIM INVAS NEUROSUR, V50, P346, DOI 10.1055/s-2007-993205
   Zhang WH, 2015, J HUAZHONG U SCI-MED, V35, P742, DOI 10.1007/s11596-015-1500-8
NR 45
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E1
EP E11
DI 10.1016/j.wneu.2018.11.184
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300002
PM 30500581
DA 2020-05-12
ER

PT J
AU Chen, W
   Liu, FJ
   Chen, J
   Ma, L
   Li, GP
   You, C
AF Chen, Wei
   Liu, Fujun
   Chen, Jing
   Ma, Lu
   Li, Guoping
   You, Chao
TI Timing and Outcomes of Tracheostomy in Patients with Hemorrhagic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemorrhagic stroke; Intracerebral hemorrhage; Outcome; Subarachnoid
   hemorrhage; Tracheostomy; Tracheostomy timing
ID ANEURYSMAL SUBARACHNOID HEMORRHAGE; MECHANICAL VENTILATION; TRACHEOTOMY;
   INTUBATION
AB OBJECTIVE: In the present study, we sought to evaluate the timing and outcomes in patients with hemorrhagic stroke who received tracheostomy.
   METHODS: A retrospective database search was undertaken to identify patients with hemorrhagic stroke between January 2010 and December 2018. Clinical data on basic demographics, clinical features, and outcomes were extracted. The primary outcome was in-hospital mortality and secondary outcomes were hospital stay s and hospital costs. Univariate and multivariate analyses were used to compare the characteristics and outcomes between patients with hemorrhagic stroke who underwent tracheostomy early (days 1-6) and late (days 7 or later).
   RESULTS: A total of 425 patients were identified, 74.4% (n = 316) received an early tracheostomy during the hospitalization. Patients with hemorrhagic stroke who received early tracheostomy had a higher rate of neurosurgical operation (odds ratio, 2.77; 95% confidence interval, 1.54-4.99; P = 0.001) and different types of hemorrhagic stroke (P = 0.001) in comparison with the late tracheostomy patients. In addition, early tracheostomy was associated with shorter hospital stays (odds ratio, 1.02; 95% confidence interval, 1.01-1.03; P = 0.003) and reduced hospital costs (P < 0.001) than with late tracheostomy. However, no significant difference was observed with regard to in-hospital mortality between early and late tracheostomy groups (P = 0.744).
   CONCLUSIONS: In our cohort, early tracheostomy in patients with hemorrhagic stroke may help reduce stays and hospital costs, but not in-hospital mortality. Future prospective multicenter studies are warranted to validate these findings.
C1 [Chen, Wei; Liu, Fujun; Chen, Jing; Ma, Lu; Li, Guoping; You, Chao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP You, C (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM chao_y2019@126.com
FU Support Project Funding of Science and Technology Department of Sichuan
   Province [2016FZ0119, 2010FZ0045]
FX This study was funded by the Support Project Funding of Science and
   Technology Department of Sichuan Province (grant no. 2016FZ0119 and
   2010FZ0045).
CR Alsherbini K, 2019, NEUROCRIT CARE, V30, P185, DOI 10.1007/s12028-018-0596-7
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   Blot F, 2008, INTENS CARE MED, V34, P1779, DOI 10.1007/s00134-008-1195-4
   Bosel J, 2017, STROKE, V48, P2638, DOI 10.1161/STROKEAHA.117.017794
   Bosel J, 2013, STROKE, V44, P21, DOI 10.1161/STROKEAHA.112.669895
   Combes A, 2007, CRIT CARE MED, V35, P802, DOI 10.1097/01.CCM.0000256721.60517.B1
   Cox CE, 2004, CRIT CARE MED, V32, P2219, DOI 10.1097/01.CCM.0000145232.46143.40
   Durbin CG, 2010, RESP CARE, V55, P1056
   Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44
   Freeman BD, 2012, CRIT CARE MED, V40, P2890, DOI 10.1097/CCM.0b013e31825bc948
   Gessler F, 2015, CRIT CARE MED, V43, P2429, DOI 10.1097/CCM.0000000000001195
   Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0
   Gross BA, 2019, JAMA-J AM MED ASSOC, V321, P1295, DOI 10.1001/jama.2019.2413
   Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407
   Lawton MT, 2017, NEW ENGL J MED, V377, P257, DOI 10.1056/NEJMcp1605827
   Lee YC, 2015, RESP CARE, V60, P651, DOI 10.4187/respcare.03652
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   MacIntyre N, 2007, CHEST, V132, P1049, DOI 10.1378/chest.06-2862
   Modi S, 2019, CLIN NEUROL NEUROSUR, V182, P167, DOI 10.1016/j.clineuro.2019.05.018
   Nielsen PB, 2017, JAMA INTERN MED, V177, P563, DOI 10.1001/jamainternmed.2016.9369
   Qureshi AI, 2000, CRIT CARE MED, V28, P1383, DOI 10.1097/00003246-200005000-00020
   Rabinstein AA, 2004, CEREBROVASC DIS, V18, P325, DOI 10.1159/000080771
   Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6
   Seder DB, 2009, NEUROCRIT CARE, V10, P264, DOI 10.1007/s12028-008-9174-8
   Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732
   Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447
   Villwock JA, 2014, J STROKE CEREBROVASC, V23, P1069, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.008
   Yaghi S, 2013, CLIN NEUROL NEUROSUR, V115, P695, DOI 10.1016/j.clineuro.2012.08.010
   Yoon S, 2019, STROKE, V50, P199, DOI 10.1161/STROKEAHA.118.023079
   Young D, 2013, JAMA-J AM MED ASSOC, V309, P2121, DOI 10.1001/jama.2013.5154
NR 30
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E606
EP E613
DI 10.1016/j.wneu.2019.08.013
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300076
PM 31408751
DA 2020-05-12
ER

PT J
AU Cheng, Q
   Li, ZY
   Wang, RZ
   Zhang, HF
   Cao, H
   Chen, FG
   Li, HB
   Xia, ZW
   Feng, SS
   Zhang, H
   Rui, YH
   Fan, F
AF Cheng, Quan
   Li, Zhenyan
   Wang, Ruizhe
   Zhang, Hongfu
   Cao, Hui
   Chen, Fenghua
   Li, Huangbao
   Xia, Zhiwei
   Feng, Songshan
   Zhang, Hao
   Rui, Yuhua
   Fan, Fan
TI Genetic Profiles Related to Pathogenesis in Sporadic Intracranial
   Aneurysm Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bioinformatics; Intracranial aneurysm; Pathogenesis
ID VASCULAR SMOOTH-MUSCLE; PHENOTYPIC MODULATION; EXPRESSION; PROTEIN;
   CELLS; PROLIFERATION; CONTRACTILITY; REGULATOR; MYOCARDIN; CALPONIN
AB BACKGROUND: Intracranial aneurysm (IA) represents a cerebrovascular disorder that featured by dilation or bulging of the weakened blood vessel wall. When it ruptures, an IA leads to subarachnoid hemorrhage with high disability and mortality rates. Despite the numerous studies focusing on IA ruptures, little research on IA pathogenesis has been reported. In this study, we aimed to reveal key genes related to IA formation.
   METHODS: Four datasets from Gene Expression Omnibus data were downloaded, normalized, and separated into the IA group and the normal vessel control group for analyses. We screened for differentially expressed genes (DEGs) between groups and conducted functional enrichment, pathway enrichment, and gene set enrichment analysis analyses among significant DEGs.
   RESULTS: according to our analyses, significant DEGs majorly associate with smooth muscle system and the complement system. Among all DEGs, 5 down-regulated genes (MYH11, CNN1, MYOCD, ACTA1, and LMOD1) and 3 up-regulated genes (C1QB, C3AR1, and VSIG4) are most relevant in IA formation.
   CONCLUSIONS: Key DEGs identified in this study are related to IA pathogenesis. Among identified DEGs, LMOD1 is the most significant and merits more attention.
C1 [Cheng, Quan; Li, Zhenyan; Chen, Fenghua; Feng, Songshan; Zhang, Hao; Fan, Fan] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.
   [Fan, Fan] Cent S Univ, Ctr Med Genet, Changsha, Hunan, Peoples R China.
   [Fan, Fan] Cent S Univ, Hunan Prov Key Lab Med Genet, Sch Life Sci, Changsha, Hunan, Peoples R China.
   [Wang, Ruizhe] Cent S Univ, Xiangya Hosp, Dept Urinary Surg, Changsha, Hunan, Peoples R China.
   [Zhang, Hongfu] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Neurosurg, Peoples Hosp, Zhengzhou, Henan, Peoples R China.
   [Cao, Hui] Hunan Univ Chinese Med, Dept Psychiat, Peoples Hosp 2, Changsha, Hunan, Peoples R China.
   [Li, Huangbao] Jiaxing Univ, Dept Hepatobiliary & Pancreat Surg, Hosp 1, Jiaxing, Zhejiang, Peoples R China.
   [Xia, Zhiwei] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Rui, Yuhua] Cent S Univ, Xiangya Hosp, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Cheng, Quan] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.
RP Fan, F (reprint author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.; Fan, F (reprint author), Cent S Univ, Ctr Med Genet, Changsha, Hunan, Peoples R China.; Fan, F (reprint author), Cent S Univ, Hunan Prov Key Lab Med Genet, Sch Life Sci, Changsha, Hunan, Peoples R China.
EM fanfan@csu.edu.cn
OI Zhang, Hao/0000-0002-7344-3457
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81703622, 81873756]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018M633002]; Hunan
   Provincial Natural Science Foundation of ChinaNatural Science Foundation
   of Hunan Province [2018JJ3838]
FX This work was supported by the National Natural Science Foundation of
   China (NO.81703622; NO.81873756), China Postdoctoral Science Foundation
   (NO. 2018M633002), and Hunan Provincial Natural Science Foundation of
   China (NO.2018JJ3838).
CR Alexander MR, 2012, ANNU REV PHYSIOL, V74, P13, DOI 10.1146/annurev-physiol-012110-142315
   Ali MS, 2013, J CEREBR BLOOD F MET, V33, P1564, DOI 10.1038/jcbfm.2013.109
   BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q
   Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84
   Chen L, 2014, GENET MOL RES, V13, P758, DOI 10.4238/2014.January.31.2
   Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501
   Feng J, 2016, EUR J HISTOCHEM, V60, P239, DOI 10.4081/ejh.2016.2711
   Gauthier J, 2015, EUR J HUM GENET, V23, P1266, DOI 10.1038/ejhg.2014.256
   Halim D, 2017, P NATL ACAD SCI USA, V114, pE2739, DOI 10.1073/pnas.1620507114
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002
   Huang F, 2016, ONCOTARGETS THER, V9, P3415, DOI 10.2147/OTT.S104972
   Huang JH, 2015, P NATL ACAD SCI USA, V112, P4447, DOI 10.1073/pnas.1420363112
   Jeon TY, 2011, KOREAN J RADIOL, V12, P547, DOI 10.3348/kjr.2011.12.5.547
   Keedy Alexander, 2006, Mcgill J Med, V9, P141
   Kilic T, 2005, NEUROSURGERY, V57, P997, DOI 10.1227/01.NEU.0000180812.77621.6C
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Luo J, 2016, MED SCI MONITOR, V22, P4247, DOI 10.12659/MSM.897511
   Nakajima N, 2000, ACTA NEUROPATHOL, V100, P475, DOI 10.1007/s004010000220
   Pera J, 2010, STROKE, V41, P224, DOI 10.1161/STROKEAHA.109.562009
   Ravindra VM, 2016, J NEUROSURG-PEDIATR, V18, P463, DOI 10.3171/2016.5.PEDS16115
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X
   SELLAR GC, 1991, BIOCHEM J, V274, P481, DOI 10.1042/bj2740481
   Sibon I, 2008, J NEUROSURG, V108, P558, DOI 10.3171/JNS/2008/108/3/0558
   Starke RM, 2014, TRANSL STROKE RES, V5, P338, DOI 10.1007/s12975-013-0290-1
   Starke RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071954
   Tai S, 2016, INT J CARDIOL, V211, P1, DOI 10.1016/j.ijcard.2016.02.128
   TAKAHASHI K, 1988, J HYPERTENS, V6, pS40, DOI 10.1097/00004872-198812040-00008
   Vogt L, 2006, J CLIN INVEST, V116, P2817, DOI 10.1172/JCI25673
   Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499
   Xia ZW, 2017, WORLD NEUROSURG, V98, P411, DOI 10.1016/j.wneu.2016.11.032
   Yang P, 2016, SCI REP-UK, V6, DOI 10.1038/srep35444
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan LQ, 2018, J VASC ACCESS, V19, P153, DOI 10.5301/jva.5000804
   Yuan SM, 2015, REV BRAS CIR CARDIOV, V30, P644, DOI 10.5935/1678-9741.20150081
   Zhang MM, 2015, J NEUROPATH EXP NEUR, V74, P411, DOI 10.1097/NEN.0000000000000185
   Zhang SF, 2014, ACTA HAEMATOL-BASEL, V132, P193, DOI 10.1159/000356681
NR 38
TC 0
Z9 0
U1 4
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E23
EP E31
DI 10.1016/j.wneu.2019.06.110
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300004
PM 31238169
DA 2020-05-12
ER

PT J
AU Choque-Velasquez, J
   Resendiz-Nieves, J
   Jahromi, BR
   Colasanti, R
   Raj, R
   Vehvilainen, J
   Tynninen, O
   Collan, J
   Niemela, M
   Hernesniemi, J
AF Choque-Velasquez, Joham
   Resendiz-Nieves, Julio
   Jahromi, Behnam Rezai
   Colasanti, Roberto
   Raj, Rahul
   Vehvilainen, Juho
   Tynninen, Olli
   Collan, Juhani
   Niemela, Mika
   Hernesniemi, Juha
TI Extent of Resection and Long-Term Survival of Pineal Region Tumors in
   Helsinki Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microneurosurgery; Multidisciplinary management; Pineal region lesions;
   Pineal tumors; Radiochemotherapy; Sitting position; Supracerebellar
   infratentorial approach
ID PRESERVING NORMAL ANATOMY; PRINCIPLES; EXPERIENCE
AB BACKGROUND: Pineal region tumors represent challenging surgical lesions with wide ranges of survival reported in different surgical series. In this article, we emphasize the role of complete microsurgical resection (CMR) to obtain a favorable long-term outcome of pineal region tumors.
   METHODS: We report a retrospective study of pineal region tumors operated on in Helsinki Neurosurgery between 1997 and 2015. Information was obtained from the hospital records, and an evaluation of the Finnish population register was conducted in July 2018 to determine the current status of the patients.
   RESULTS: A total of 76 pineal region tumors were operated on. The survival was 62% at a mean follow-up of 125 +/- 105 months (range, 0-588 months), and the disease-related mortality was limited to 14 patients (18.4%). Up to July 2018, 29 patients had died. Two patients died 1 and 3 months after surgery of delayed thalamic infarctions, 12 patients of disease progression, and 15 had non-disease-related deaths. Only 1 patient was lost in the long-term follow-up. Ten of 14 disease-related deaths occurred during the first 5 years of follow-up: 5 diffuse gliomas, 3 germ cell tumors, 1 grade II-III pineal parenchymal tumor of intermediate differentiation, and 1 meningioma. CMR was linked to better tumor-free survival and long-term survival, with the exception of diffuse gliomas.
   CONCLUSIONS: CMR, in the setting of a multidisciplinary management of pineal region tumors, correlates with favorable survival and with minimal mortality. Surgically treated grade II-IV gliomas constitute a particular group with high mortality within the first 5 years independently of the microsurgical resection.
C1 [Choque-Velasquez, Joham; Resendiz-Nieves, Julio; Jahromi, Behnam Rezai; Raj, Rahul; Vehvilainen, Juho; Niemela, Mika] Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
   [Colasanti, Roberto] Univ Politecn Marche, Dept Neurosurg, Umberto I Gen Hosp, Ancona, Italy.
   [Colasanti, Roberto] Osped Riuniti Marche Nord, Dept Neurosurg, Pesaro, Italy.
   [Tynninen, Olli] Univ Helsinki, Dept Pathol, Helsinki, Finland.
   [Tynninen, Olli] Helsinki Univ Hosp, HUSLAB, Helsinki, Finland.
   [Collan, Juhani] Univ Helsinki, Canc Ctr, Dept Radiat Oncol, Cent Hosp, Helsinki, Finland.
   [Hernesniemi, Juha] Henan Prov Peoples Hosp, Juha Hernesniemi Int Ctr Neurosurg, Zhengzhou, Henan, Peoples R China.
RP Choque-Velasquez, J (reprint author), Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
EM johchove@hotmail.com
RI Raj, Rahul/K-7693-2012
OI Raj, Rahul/0000-0003-4243-9591; Rezai Jahromi,
   Behnam/0000-0003-3937-2816; Choque-Velasquez, Joham/0000-0001-5220-1216
CR Al-Hussaini M, 2009, J NEURO-ONCOL, V94, P351, DOI 10.1007/s11060-009-9881-9
   CASTELLANO F, 1953, Acta Radiol Suppl, V104, P1
   Choque Velasquez J, 2016, J NEUROSURG SCI, V60, P44
   Choque-Velasquez Joham, 2019, Surg Neurol Int, V10, P103, DOI 10.25259/SNI-180-2019
   Choque-Velasquez Joham, 2018, Surg Neurol Int, V9, P162, DOI 10.4103/sni.sni_164_18
   Choque-Velasquez Joham, 2018, Surg Neurol Int, V9, P160, DOI 10.4103/sni.sni_128_18
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V117, pE669, DOI 10.1016/j.wneu.2018.06.110
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V117, P144, DOI 10.1016/j.wneu.2018.06.020
   Choque-Velasquez J, 2018, WORLD NEUROSURG, V113, pE604, DOI 10.1016/j.wneu.2018.02.107
   Choque-Velasquez Joham, 2017, Surg Neurol Int, V8, P188, DOI 10.4103/sni.sni_158_17
   Choque-Velasquez J, 2017, WORLD NEUROSURG, V105, P534, DOI 10.1016/j.wneu.2017.06.007
   Dho Yun-Sik, 2017, Brain Tumor Res Treat, V5, P16, DOI 10.14791/btrt.2017.5.1.16
   Hernesniemi J, 2005, SURG NEUROL, V64, P195, DOI 10.1016/j.surneu.2005.04.031
   Hernesniemi Juha, 2006, Surg Technol Int, V15, P305
   Iacoangeli M, 2017, ACTA NEUROCHIR, V159, P645, DOI 10.1007/s00701-017-3117-0
   Iorio-Morin C, 2017, WORLD NEUROSURG, V107, P974, DOI 10.1016/j.wneu.2017.07.097
   Konovalov AN, 1996, J NEUROSURG, V85, P586, DOI 10.3171/jns.1996.85.4.0586
   Konovalov AN, 2003, SURG NEUROL, V59, P250, DOI 10.1016/S0090-3019(03)00080-6
   Lindroos AC, 2010, WORLD NEUROSURG, V74, P505, DOI 10.1016/j.wneu.2010.09.026
   Magrini S, 2013, J NEURO-ONCOL, V115, P103, DOI 10.1007/s11060-013-1200-9
   Moon Kyung-Sub, 2008, J Med Case Rep, V2, P288, DOI 10.1186/1752-1947-2-288
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P223, DOI 10.1016/j.neuchi.2014.02.006
   Nakazato Y, 2007, WHO CLASSIFICATION T, P126
   Nowak A, 2014, NEUROL NEUROCHIR POL, V48, P397, DOI 10.1016/j.pjnns.2014.09.009
   Parikh KA, 2017, NEUROSURGERY, V81, P120, DOI 10.1093/neuros/nyx005
   Pendl G, 2002, NEUROSURG QUART, V12, P279, DOI 10.1097/00013414-200212000-00002
   Shibui S, 2009, PROG NEUROL SURG, V23, P1, DOI 10.1159/000210049
   Tate M, 2012, CANCER-AM CANCER SOC, V118, P173, DOI 10.1002/cncr.26300
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E379
EP E391
DI 10.1016/j.wneu.2019.07.169
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300046
PM 31369883
DA 2020-05-12
ER

PT J
AU Dallas, J
   Mummareddy, N
   Yengo-Kahn, AM
   Dambrino, RJ
   Lopez, AM
   Chambless, LB
   Berkman, R
   Chitale, RV
   Bonfield, CM
   Offodile, RS
   Durham, S
   Wellons, JC
   Thompson, RC
   Zuckerman, SL
AF Dallas, Jonathan
   Mummareddy, Nishit
   Yengo-Kahn, Aaron M.
   Dambrino, Robert J.
   Lopez, Alexander M.
   Chambless, Lola B.
   Berkman, Richard
   Chitale, Rohan, V
   Bonfield, Christopher M.
   Offodile, Regina S.
   Durham, Susan
   Wellons, John C., III
   Thompson, Reid C.
   Zuckerman, Scott L.
TI Neurosurgery Elective for Preclinical Medical Students with and without
   a Home Neurosurgery Program
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medical education; Neurosurgery elective; Preclinical course;
   Recruitment
ID SURGERY
AB BACKGROUND: Preclinical neurosurgery electives have been shown to increase student familiarity with neurosurgery, yet the impact on students without a home neurosurgery program is unknown. We conducted a preclinical neurosurgery elective in a mixed cohort of students with and without home neurosurgery programs to 1) evaluate changes in neurosurgery perceptions, 2) discern differences between cohorts, and 3) identify important factors in those considering neurosurgery.
   METHODS: A yearly elective was offered to students at Vanderbilt University School of Medicine (VUSM; home program) or Meharry Medical College (MMC; no home program) from 2017 to 2018. Each class included a student-led presentation, faculty academic lecture, and faculty round-table discussion. Precourse and postcourse surveys were completed.
   RESULTS: Thirty-two students completed the course. VUSM students (n = 15) showed no changes in initial perceptions, whereas MMC students (a = 17) had multiple improved perceptions, including collegiality (P = 0.001) and family achievability (P = 0.010), and believed residency to be less rigorous than their initial perceptions (P = 0.046). Fourteen students (44%) showed an increase in the likelihood of considering a neurosurgical career; eight (57%) were MMC students. These 14 students had improved perceptions of neurosurgery as less emotionally draining (P = 0.042), with favorable collegiality (P = 0.003) and work/life balance (P = 0.001) but did not believe residency to be less difficult (P = 0.102) or have added financial security (P = 0.380).
   CONCLUSIONS: Early exposure to neurosurgery at medical schools without home programs through preclinical electives may improve students' perceptions of neurosurgery, provide valuable information about the benefits and rigors of neurosurgery, and allow students to make informed decisions about further pursuit of neurosurgery.
C1 [Dallas, Jonathan] Vanderbilt Univ, Sch Med, Eskind Biomed Lib & Learning Ctr, Nashville, TN 37212 USA.
   [Mummareddy, Nishit; Yengo-Kahn, Aaron M.; Dambrino, Robert J.; Chambless, Lola B.; Berkman, Richard; Chitale, Rohan, V; Bonfield, Christopher M.; Wellons, John C., III; Thompson, Reid C.; Zuckerman, Scott L.] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37212 USA.
   [Lopez, Alexander M.; Offodile, Regina S.] George Hubbard Hosp, Meharry Med Coll, Nashville, TN USA.
   [Durham, Susan] Univ Vermont, Div Neurosurg, Larner Coll Med, Burlington, VT USA.
RP Zuckerman, SL (reprint author), Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37212 USA.
EM zuckerman.scott@gmail.com
CR Agarwal Nitin, 2013, World Neurosurg, V80, P745, DOI 10.1016/j.wneu.2013.08.027
   Day CS, 2010, J BONE JOINT SURG AM, V92A, P2328, DOI 10.2106/JBJS.I.01482
   Kashkoush A, 2017, WORLD NEUROSURG, V108, P101, DOI 10.1016/j.wneu.2017.08.125
   Knight J, 2017, BRIT J NEUROSURG, V31, P727, DOI 10.1080/02688697.2017.1335856
   Mummareddy N, 2018, WORLD NEUROSURG, V110, P504, DOI 10.1016/j.wneu.2017.10.131
   Okike Kanu, 2011, J Bone Joint Surg Am, V93, pe107, DOI 10.2106/JBJS.K.00108
   Shantharam G, 2019, UROLOGY, V127, P36, DOI 10.1016/j.urology.2018.10.061
   Weiss J, 2016, CLIN ORTHOP RELAT R, V474, P1943, DOI 10.1007/s11999-016-4923-z
   Zuckerman SL, 2017, NEUROSURGERY, V81, pE5, DOI 10.1093/neuros/nyx132
   Zuckerman SL, 2016, WORLD NEUROSURG, V86, P120, DOI 10.1016/j.wneu.2015.08.081
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E201
EP E210
DI 10.1016/j.wneu.2019.07.112
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300024
PM 31330335
DA 2020-05-12
ER

PT J
AU Feler, J
   Tan, A
   Sammann, A
   Matouk, C
   Hwang, DY
AF Feler, Joshua
   Tan, Amy
   Sammann, Amanda
   Matouk, Charles
   Hwang, David Y.
TI Decision Making Among Patients with Unruptured Aneurysms: A Qualitative
   Analysis of Online Patient Forum Discussions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medical decision making; Qualitative research; Risk communication;
   Unruptured intracranial aneurysm
ID INTRACRANIAL ANEURYSMS; THEMATIC ANALYSIS; LIVED-EXPERIENCE; MANAGEMENT;
   INTERNET; NARRATIVES; EXPLORE; DISEASE; STROKE; BLOGS
AB BACKGROUND: Deciding to treat unruptured intracranial aneurysms (UIA) involves discussion with patients about outcomes data and personal attitudes toward risk of rupture versus procedural complication risk. We performed a qualitative analysis of online interpatient discussions to investigate perspectives on medical decision making.
   METHODS: On an aneurysm-specific forum, we identified patient conversation threads created between December 3, 2016 and December 3, 2018 containing discussion of medical decision making. These threads were analyzed using an adapted grounded-theory approach. Two researchers coded each thread and discussed discrepancies until consensus was reached. Coded content was analyzed to identify emergent themes.
   RESULTS: We analyzed 40 threads from a foundation-sponsored intracranial aneurysm-specific patient forum in the public domain. There were 110 user accounts, contributing 527 posts of average length 108 words. Fifty-seven users described diagnosis of UIA without history of rupture, and 20 described presentation with rupture. Patients 1) felt fortunate for diagnosis with UIA but were challenged by decision making and concern for rupture, 2) desired treatment by providers with large case volumes, clear communication, and an unbiased approach to decision making, 3) acted on qualitative understandings of individual risk, 4) considered psychological, social, and clinical factors in forming preferences for management, 5) sought information for purposes other than informing decision making, and 6) regained control through decision-making processes.
   CONCLUSIONS: This is the first ethnographic account of decision making among patients with UIAs. Newly diagnosed patients explored treatment options using online forums. They faced ambiguity in identifying optimal management, creating apprehension and decisional conflict. Further research is required to improve risk communication and individualized decision making for patients with UIAs.
C1 [Feler, Joshua] Yale Univ, Sch Med, New Haven, CT USA.
   [Tan, Amy; Sammann, Amanda] Univ Calif San Francisco, Dept Surg, Div Gen Surg, San Francisco, CA USA.
   [Matouk, Charles] Yale Univ, Dept Neurosurg, Sch Med, New Haven, CT USA.
   [Hwang, David Y.] Yale Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, New Haven, CT 06510 USA.
   [Hwang, David Y.] Yale Sch Med, Ctr Neuroepidemiol & Clin Neurol Res, Dept Neurol, New Haven, CT 06510 USA.
RP Hwang, DY (reprint author), Yale Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, New Haven, CT 06510 USA.; Hwang, DY (reprint author), Yale Sch Med, Ctr Neuroepidemiol & Clin Neurol Res, Dept Neurol, New Haven, CT 06510 USA.
EM david.hwang@yale.edu
RI Matouk, Charles/AAF-7694-2019
OI Feler, Joshua/0000-0002-9206-6394
CR Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1037, DOI 10.1001/jama.281.11.1037
   Braun V., 2012, APA HDB RES METHODS, V2, P57, DOI DOI 10.1037/13620-004
   Darsaut TE, 2014, J NEUROSURG, V120, P618, DOI 10.3171/2013.11.JNS131366
   Etminan N, 2016, NAT REV NEUROL, V12, P699, DOI 10.1038/nrneurol.2016.150
   Garbett K, 2017, J HEALTH PSYCHOL, V22, P1755, DOI 10.1177/1359105316638549
   Hepokosi M, 2017, ANN INTERN MED, V166, pW20, DOI 10.7326/M17-0138
   Holtz P, 2012, J MEDIA PSYCHOL-GER, V24, P55, DOI 10.1027/1864-1105/a000062
   Kannaley K, 2018, DEMENTIA
   Keim-Malpass J, 2014, INT J NURS STUD, V51, P1686, DOI 10.1016/j.ijnurstu.2014.06.003
   Keim-Malpass J, 2012, ONCOL NURS FORUM, V39, P373, DOI 10.1188/12.ONF.373-378
   King JT, 2005, J NEUROL NEUROSUR PS, V76, P550, DOI 10.1136/jnnp.2004.051649
   Malhotra A, 2018, JAMA NEUROL, V75, P27, DOI 10.1001/jamaneurol.2017.3232
   Malik SH, 2008, J REPROD INFANT PSYC, V26, P18, DOI 10.1080/02646830701759777
   Moloney MF, 2003, ADV NURS SCI, V26, P274, DOI 10.1097/00012272-200310000-00005
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105
   Ryan C, 2015, COMPUTER INTERNET US, P10
   Sandman L, 2009, THEOR MED BIOETH, V30, P289, DOI 10.1007/s11017-009-9114-4
   Shapira AL, 2017, ISR MED ASSOC J, V19, P685
   King JS, 2006, AM J LAW MED, V32, P429, DOI 10.1177/009885880603200401
   Thomas CM, 2018, J ADV NURS, V74, P579, DOI 10.1111/jan.13457
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E371
EP E378
DI 10.1016/j.wneu.2019.07.161
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300045
PM 31362103
DA 2020-05-12
ER

PT J
AU Fu, CH
   Wang, N
   Chen, HY
   Chen, QX
AF Fu, Chuhua
   Wang, Ning
   Chen, Huayun
   Chen, Qianxue
TI A Novel Simple Puncture Positioning and Guidance System for
   Intracerebral Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Guided puncture; Intracerebral hematoma; Surgery
ID HEMORRHAGE; SURGERY
AB BACKGROUND: Minimally invasive surgical techniques may have beneficial effects on spontaneous intracerebral hemorrhage. Accurate localization of the hematoma and real-time guided puncture are more important in minimally invasive surgical procedures than in traditional craniotomy. Here, we introduce a novel simple puncture positioning and guidance system for intracerebral hematoma and demonstrate its utility for hematoma puncture surgery in a simulation experiment and series of patients.
   METHODS: We describe the device and use of the technique for hematoma puncture surgery in basal ganglia hematomas and report on the precision of the simulation experiments compared to that of freehand puncture, as well as its clinical application in 16 cases.
   RESULTS: The accuracy of this technique was superior to that of freehand puncture. All 16 patients underwent successful puncturing of the hematoma cavity or ventricles only once without any related complications.
   CONCLUSIONS: We demonstrate a novel simple puncture positioning and guidance system that has the advantages of simplicity, low-cost, device availability, and individual real-time guidance. We believe this system may be useful in resource-limited centers where navigation is not available.
C1 [Fu, Chuhua; Chen, Qianxue] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Wang, Ning; Chen, Huayun] Hubei Univ Med, Xiangyang Peoples Hosp 1, Dept Neurosurg, Xiangyang, Peoples R China.
RP Chen, QX (reprint author), Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM chenqianxue666@163.com
CR Abdu E, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11362
   Awad IA, 2019, NEUROSURGERY, V84, P1157, DOI 10.1093/neuros/nyz077
   Beijnum JV, 2008, BRAIN, V2, P537
   Cai Q, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008435
   Chen XN, 2011, BRIT J NEUROSURG, V25, P369, DOI 10.3109/02688697.2010.520765
   Fiorella D, 2016, CURR NEUROL NEUROSCI, V18, P34
   Fiorella D, 2015, WORLD NEUROSURG, V84, P1136, DOI 10.1016/j.wneu.2015.05.063
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hou YZ, 2016, WORLD NEUROSURG, V94, P480, DOI 10.1016/j.wneu.2016.07.047
   Hwang SC, 2016, WORLD NEUROSURG, V90, P268, DOI 10.1016/j.wneu.2016.03.001
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Ma LC, 2017, WORLD NEUROSURG, V101, P57, DOI 10.1016/j.wneu.2017.01.072
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Ochalski P, 2014, J NEUROL SURG PART A, V75, P195, DOI 10.1055/s-0033-1348348
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Yan YF, 2015, EUR REV MED PHARMACO, V19, P2614
   Yuwono AH, 2010, INT J TECHNOL, V1, P11
   Zhou XY, 2012, STROKE, V43, P2923, DOI 10.1161/STROKEAHA.112.667535
NR 20
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E562
EP E569
DI 10.1016/j.wneu.2019.07.235
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300070
PM 31400527
DA 2020-05-12
ER

PT J
AU Gagliardi, F
   Piloni, M
   Ballo, M
   Gragnaniello, C
   Boari, N
   Donofrio, CA
   Barzaghi, LR
   Capitanio, JF
   Caputy, AJ
   Mortini, P
AF Gagliardi, Filippo
   Piloni, Martina
   Ballo, Michele
   Gragnaniello, Cristian
   Boari, Nicola
   Donofrio, Carmine A.
   Barzaghi, Lina R.
   Capitanio, Jody F.
   Caputy, Anthony J.
   Mortini, Pietro
TI Anatomic Study on Neuroendoportal Transcortical Approach to Lateral
   Ventricles
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain retraction; Endoscopy; Minimally invasive neurosurgery; Tubular
   surgery; Ventricular surgery
ID BRAIN RETRACTOR PRESSURE; COLLOID CYSTS; MICROSURGICAL REMOVAL;
   RESECTION; 3RD-VENTRICLE; LESIONS; TUMORS; TRANSCALLOSAL; EXPERIENCE;
   SYSTEM
AB BACKGROUND: Resection of intraventricular lesions remains a challenge for modern neurosurgery. Endoscopy has provided great advantages in ventricular surgery, even if limited in terms of operability, due to the restricted working channel and impossibility for bimanual surgical manipulation. Tubular approaches have been considered as an option, enabling the use of microsurgical techniques, minimizing violation of brain tissue. The aim of our study was to describe and critically evaluate the use of portal surgery to access lateral ventricles in terms of surgical exposure and operability.
   METHODS: A microanatomic laboratory cadaver study was conducted with a stepwise description of the surgical technique. The operability score was applied for quantitative analysis of surgical operability, and an illustrative case is reported.
   RESULTS: Through the anterior approach, the neuroport provides maximal operability at the foramen of Monro and the posterior aspect of the frontal horn, while through the posterior approach maximal operability is achieved in the paratrigonal area. Endoscopic assistance does not affect operability but provides adjunctive exposure in blind spots, as the roof of the frontal horn, the most anterior aspect of the temporal and occipital horn.
   CONCLUSIONS: Ventricular tubular systems provide adequate visualization, with minimal brain retraction, improving operability as compared with endoscopy. Endoscopic assistance critically widens surgical exposure in blind spots without providing concomitant significant advantage in terms of surgical operability.
C1 [Gagliardi, Filippo; Piloni, Martina; Ballo, Michele; Boari, Nicola; Donofrio, Carmine A.; Barzaghi, Lina R.; Capitanio, Jody F.; Mortini, Pietro] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
   [Gragnaniello, Cristian; Caputy, Anthony J.] George Washington Univ, Dept Neurol Surg, Washington, DC USA.
RP Gagliardi, F (reprint author), Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
EM gagliardi.filippo@hsr.it
RI ; Bailo, Michele/M-3599-2016
OI Donofrio, Carmine Antonio/0000-0002-9123-8158; Bailo,
   Michele/0000-0003-4151-2873
CR Abdou MS, 1998, J NEUROSURG, V89, P1062, DOI 10.3171/jns.1998.89.6.1062
   ABERNATHEY CD, 1989, J NEUROSURG, V70, P525, DOI 10.3171/jns.1989.70.4.0525
   Albin MS, 2003, ANESTH ANALG, V96, P306, DOI 10.1097/00000539-200301000-00070
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Barlas O, 2004, ACTA NEUROCHIR, V146, P1199, DOI 10.1007/s00701-004-0367-4
   Cohen-Gadol AA, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2011.03.045
   Decq P, 1998, NEUROSURGERY, V42, P1288, DOI 10.1097/00006123-199806000-00051
   DONAGHY RMP, 1972, AM J SURG, V123, P429, DOI 10.1016/0002-9610(72)90195-X
   Francois PM, 2017, COMPUT METHOD BIOMEC, V20, P79, DOI 10.1080/10255842.2017.1382871
   Gagliardi F, 2014, J CRANIO MAXILL SURG, V42, P1000, DOI 10.1016/j.jcms.2014.01.024
   GREENBERG IM, 1981, NEUROSURGERY, V8, P205, DOI 10.1227/00006123-198102000-00009
   Harris AE, 2008, NEUROSURGERY, V62, P622, DOI [10.1227/01.NEU.0000146227.75138.08, 10.1227/01.neu.0000316266.97714.da]
   Hellwig D, 2008, NEUROSURGERY, V62, P1101, DOI [10.1227/01.NEU.0000047671.27057.55, 10.1227/01.neu.0000333776.89187.0e]
   Horn EM, 2008, NEUROSURGERY, V62, P1076, DOI [10.1227/01.NEU.0000255409.61398.EA, 10.1227/01.neu.0000333773.43445.7b]
   Kehler U, 2001, MINIM INVAS NEUROSUR, V44, P121, DOI 10.1055/s-2001-18122
   Kelly P J, 1989, J Neurosurg Sci, V33, P149
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   KELLY PJ, 1987, APPL NEUROPHYSIOL, V50, P107
   LEWIS AI, 1994, J NEUROSURG, V81, P174, DOI 10.3171/jns.1994.81.2.0174
   Milligan BD, 2010, NEUROSURGERY, V67, P1483, DOI 10.1227/NEU.0b013e3181f7eb68
   MORITA A, 1993, NEUROSURGERY, V32, P920, DOI 10.1227/00006123-199306000-00006
   Mortini P, 2017, ENDOCRINE, V57, P138, DOI 10.1007/s12020-016-1102-7
   Mortini P, 2013, WORLD NEUROSURG, V80, P160, DOI 10.1016/j.wneu.2012.06.042
   Moshel YA, 2007, NEUROSURGERY, V61, P66, DOI 10.1227/01.neu.0000279725.13521.a3
   Ogura K, 2006, ACTA NEUROCHIR, V148, P779, DOI 10.1007/s00701-006-0768-7
   Raza SM, 2011, MINIM INVAS NEUROSUR, V54, P5, DOI 10.1055/s-0031-1273734
   Recinos PF, 2011, J NEUROSURG-PEDIATR, V7, P516, DOI 10.3171/2011.2.PEDS10515
   Rodziewicz GS, 2000, NEUROSURGERY, V46, P655, DOI 10.1097/00006123-200003000-00025
   ROSENORN J, 1985, J NEUROSURG, V63, P608, DOI 10.3171/jns.1985.63.4.0608
   ROSENORN J, 1982, J NEUROSURG, V56, P826, DOI 10.3171/jns.1982.56.6.0826
   Solaroglu I, 2004, NEUROSURG REV, V27, P89, DOI 10.1007/s10143-003-0309-2
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E255
EP E264
DI 10.1016/j.wneu.2019.07.132
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300030
PM 31351205
DA 2020-05-12
ER

PT J
AU Ge, J
   Cheng, X
   Li, P
   Yang, H
   Zou, J
AF Ge, Jun
   Cheng, Xiaoqiang
   Li, Peng
   Yang, Huilin
   Zou, Jun
TI The Clinical Effect of Kyphoplasty Using the Extrapedicular Approach in
   the Treatment of Thoracic Osteoporotic Vertebral Compression Fracture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extrapedicular; Kyphoplasty; Osteoporosis; Vertebral compression
   fracture
ID CEMENT VOLUME; PERCUTANEOUS VERTEBROPLASTY; BILATERAL KYPHOPLASTY;
   BALLOON KYPHOPLASTY; SCREW FIXATION; SPINE; PLACEMENT
AB BACKGROUND: To evaluate the clinical effect of kyphoplasty with the extrapedicular approach in the treatment of thoracic osteoporotic compression fractures, including upper, middle, and lower thoracic.
   METHODS: From April 2014 to December 2016, 50 cases (55 vertebrae) of thoracic osteoporotic fractures were treated with balloon kyphoplasty using the extrapedicular approach. Symptomatic levels ranged from T3 to T12 and were confirmed based on medical history, physical examination, and medical imaging. Pain relief, restoration of vertebral anterior and median height, and kyphosis correction were retrospectively compared before and after operation by using the visual analogue scale and radiography, respectively. In addition, bone cement leakage location and complications were recorded.
   RESULTS: Operations were successfully performed in all the cases, with an average surgery time of 77 minutes and follow-up period of 15 months (range, 6-36 months). The visual analogue scale scores at 3 days after operation and final follow-up were significantly reduced (P < 0.05). The vertebral anterior margin and median height on radiography after surgery were significantly improved (P < 0.05), and the kyphosis was significantly corrected. Four cases had cement leakage but no other adverse events. No blood vessel or spinal cord puncture injury during surgery or blood vessel embolism, pulmonary embolism, or fat embolism after surgery was found.
   CONCLUSIONS: Extrapedicular kyphoplasty is safe and effective in treating thoracic osteoporotic vertebral compression fractures. It can rapidly relieve backache, restore the body height of the fractured thoracic vertebra, and correct kyphosis. In addition, it can improve patient quality of life.
C1 [Ge, Jun; Cheng, Xiaoqiang; Li, Peng; Yang, Huilin; Zou, Jun] Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
RP Zou, J (reprint author), Soochow Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Suzhou, Jiangsu, Peoples R China.
EM jzou@suda.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81472132, 81572183, 81672220, 91849114]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD)
FX This study was supported by National Natural Science Foundation of China
   (81472132, 81572183, 81672220, and 91849114), Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD).
CR Belkoff SM, 2001, SPINE, V26, P1537, DOI 10.1097/00007632-200107150-00007
   Chen YC, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1003-1
   Ding WB, 2014, EUR SPINE J, V23, P395, DOI 10.1007/s00586-013-3100-2
   DVORAK M, 1993, SPINE, V18, P1689, DOI 10.1097/00007632-199309000-00018
   Frankel BM, 2007, SPINE J, V7, P575, DOI 10.1016/j.spinee.2006.10.020
   Garnier L, 2012, ORTHOP TRAUMATOL-SUR, V98, pS112, DOI 10.1016/j.otsr.2012.03.018
   Ge ZH, 2013, ORTHOPEDICS, V36, pE1020, DOI 10.3928/01477447-20130724-17
   Han KR, 2005, ACTA RADIOL, V46, P280, DOI 10.1080/02841850510021058
   Heo DH, 2011, J KOREAN NEUROSURG S, V49, P131, DOI 10.3340/jkns.2011.49.2.131
   Husted DS, 2003, SPINE, V28, P2324, DOI 10.1097/01.BRS.0000085361.32600.63
   Iba K, 2006, J ORTHOP SCI, V11, P446, DOI 10.1007/s00776-006-1050-9
   Kaufmann TJ, 2006, AM J NEURORADIOL, V27, P1933
   Kumar K, 2010, NEUROSURGERY, V67, P171, DOI 10.1227/01.NEU.0000380936.00143.11
   Ledlie JT, 2006, SPINE, V31, P57
   LEECH JA, 1990, AM REV RESPIR DIS, V141, P68, DOI 10.1164/ajrccm/141.1.68
   Liebschner MAK, 2001, SPINE, V26, P1547, DOI 10.1097/00007632-200107150-00009
   Lovi A, 2009, EUR SPINE J, V18, pS95, DOI 10.1007/s00586-009-0986-9
   Luthman S, 2018, OSTEOPOROSIS INT, V29, P793, DOI 10.1007/s00198-017-4348-x
   McLain RF, 2002, SPINE, V27, P2467, DOI 10.1097/00007632-200211150-00009
   Ryu KS, 2007, J SPINAL DISORD TECH, V20, P392, DOI 10.1097/BSD.0b013e31802da846
   Sun H, 2016, PAIN PHYSICIAN, V19, P551
   Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140-6736(09)60010-6
   Xiang GH, 2018, PAIN PHYSICIAN, V21, P209
   Yang LY, 2013, PAIN PHYSICIAN, V16, P277
NR 24
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E284
EP E289
DI 10.1016/j.wneu.2019.07.133
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300034
PM 31351209
DA 2020-05-12
ER

PT J
AU Goertz, L
   Hamisch, C
   Pflaeging, M
   Kabbasch, C
   Borggrefe, J
   Timmer, M
   Stravrinou, P
   Goldbrunner, R
   Brinker, G
   Mpotsaris, A
   Krischek, B
AF Goertz, Lukas
   Hamisch, Christina
   Pflaeging, Muriel
   Kabbasch, Christoph
   Borggrefe, Jan
   Timmer, Marco
   Stravrinou, Pantelis
   Goldbrunner, Roland
   Brinker, Gerrit
   Mpotsaris, Anastasios
   Krischek, Boris
TI Angiographic Characteristics of Lobulated Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Angiography; Lobulated; Ruptured; Shape; Unruptured
ID UNRUPTURED CEREBRAL ANEURYSMS; RISK-FACTORS; PERIANEURYSMAL ENVIRONMENT;
   NATURAL-HISTORY; IRREGULAR SHAPE; PHASES SCORE; RUPTURE; GROWTH;
   BIFURCATION; PREDICTION
AB OBJECTIVE: Previous studies have indicated that lobulated aneurysms are more susceptible to rupture than are single-sac aneurysms. We aimed to determine the angiographic characteristics related to the lobulated shape of unruptured intracranial aneurysms (UIAs) and ruptured (RIAs) intracranial aneurysms.
   METHODS: This is a retrospective analysis of consecutive patients with UIAs (n = 143) and RIAs in = 190) who underwent digital subtraction angiography at our institution between 2010 and 2017. Patient and aneurysm characteristics were compared between lobulated and regular single-sac aneurysms.
   RESULTS: Patients with lobulated UIAs were significantly older than were patients with regular aneurysms (56.5 +/- 10.7 years vs. 49.3 +/- 13.0 years; P = 0.003). In the multivariate analysis, lobulated morphology was significantly related to bifurcation location (69.5% vs. 27.3%; odds ratio [OR], 3.0, 95% confidence interval [CI], 1.2-7.5; P = 0.019), aneurysm size (8.1 +/- 3.2 mm vs. 4.9 +/- 3.0 mm; OR, 5.4; 95% CI, 1.7-17.8; P = 0.005), and inflow angle (145 +/- 27 vs. 114 +/- 27 ; OR, 2.8; 95% CI, 1.1-7.2; P = 0.031). Bifurcation location (P = 0.031) and larger aneurysm size (P < 0.001) were confirmed as independent characteristics for lobulation in the RIA group. Compared with regular aneurysms, lobulated UIAs were more often allocated to treatment (86.6% vs. 60.3%; P < 0.001) and treated by microsurgical clipping (39.4% vs. 16.4%; P = 0.002).
   CONCLUSIONS: Bifurcation location, an increased aneurysm size, and a straighter aneurysm inflow angle are independently associated with lobulated aneurysms.
C1 [Goertz, Lukas; Hamisch, Christina; Pflaeging, Muriel; Timmer, Marco; Stravrinou, Pantelis; Goldbrunner, Roland; Brinker, Gerrit; Krischek, Boris] Univ Cologne, Fac Med, Ctr Neurosurg, Cologne, Germany.
   [Goertz, Lukas; Hamisch, Christina; Pflaeging, Muriel; Timmer, Marco; Stravrinou, Pantelis; Goldbrunner, Roland; Brinker, Gerrit; Krischek, Boris] Univ Cologne, Univ Hosp, Ctr Neurosurg, Cologne, Germany.
   [Kabbasch, Christoph; Borggrefe, Jan] Univ Hosp Cologne, Dept Neuroradiol, Cologne, Germany.
   [Mpotsaris, Anastasios] Rhein Westfal TH Aachen, Univ Hosp, Dept Diagnost & Intervent Neuroradiol, Aachen, Germany.
RP Goertz, L (reprint author), Univ Cologne, Fac Med, Ctr Neurosurg, Cologne, Germany.; Goertz, L (reprint author), Univ Cologne, Univ Hosp, Ctr Neurosurg, Cologne, Germany.
EM lukas.goertz@uk-koela.de
RI Borggrefe, Jan/N-6549-2018
OI Borggrefe, Jan/0000-0003-2908-7560; Kabbasch,
   Christoph/0000-0003-3712-2258
CR Abboud T, 2017, WORLD NEUROSURG, V99, P610, DOI 10.1016/j.wneu.2016.12.053
   Backes D, 2017, NEUROLOGY, V88, P1600, DOI 10.1212/WNL.0000000000003865
   Backes D, 2016, STROKE, V47, P951, DOI 10.1161/STROKEAHA.115.012162
   Backes D, 2015, STROKE, V46, P1221, DOI 10.1161/STROKEAHA.114.008198
   Baharoglu MI, 2010, STROKE, V41, P1423, DOI 10.1161/STROKEAHA.109.570770
   Beck J, 2003, ACTA NEUROCHIR, V145, P861, DOI 10.1007/s00701-003-0124-0
   Borggrefe J, 2016, WORLD NEUROSURG, V91, P483, DOI 10.1016/j.wneu.2016.04.091
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P615, DOI 10.3174/ajnr.A4575
   Brinjikji W, 2009, AM J NEURORADIOL, V30, P831, DOI 10.3174/ajnr.A1444
   Cebral JR, 2010, AM J NEURORADIOL, V31, P304, DOI 10.3174/ajnr.A1819
   Cebral JR, 2005, AM J NEURORADIOL, V26, P2550
   Chmayssani M, 2011, NEUROSURGERY, V68, P1164, DOI 10.1227/NEU.0b013e31820edbd3
   Dhar S, 2008, NEUROSURGERY, V63, P185, DOI 10.1227/01.NEU.0000316847.64140.81
   Etminan N, 2015, NEUROLOGY, V85, P881, DOI 10.1212/WNL.0000000000001891
   Etminan N, 2014, STROKE, V45, P1523, DOI 10.1161/STROKEAHA.114.004519
   Feng X, 2017, WORLD NEUROSURG, V107, P255, DOI 10.1016/j.wneu.2017.07.063
   Forbes G, 1996, AM J NEURORADIOL, V17, P1407
   Goertz Lukas, 2019, J Neurosurg, P1, DOI 10.3171/2019.1.JNS183193
   Goertz L, 2018, ACTA NEUROCHIR, V160, P2169, DOI 10.1007/s00701-018-3675-9
   Goertz L, 2018, WORLD NEUROSURG, V120, pE1163, DOI 10.1016/j.wneu.2018.09.026
   Goertz L, 2018, WORLD NEUROSURG, V118, pE806, DOI 10.1016/j.wneu.2018.07.058
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Hademenos GJ, 1998, NEURORADIOLOGY, V40, P755, DOI 10.1007/s002340050679
   Her Yunsuk, 2017, Radiol Case Rep, V12, P146, DOI 10.1016/j.radcr.2016.10.024
   Ho AL, 2015, NEUROSURGERY, V77, P59, DOI 10.1227/NEU.0000000000000735
   Hoh BL, 2007, NEUROSURGERY, V61, P716, DOI 10.1227/01.NEU.0000298899.77097.BF
   Jamous MA, 2005, J NEUROSURG, V103, P1046, DOI 10.3171/jns.2005.103.6.1046
   Juvela S, 2002, ACTA NEUROCHIR SUPPL, V82, P27
   Kwon OK, 2002, AM J NEURORADIOL, V23, P693
   Lall RR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0921
   Lindgren AE, 2016, STROKE, V47, P1219, DOI 10.1161/STROKEAHA.115.012404
   Matsubara S, 2004, J NEUROSURG, V101, P908, DOI 10.3171/jns.2004.101.6.0908
   Matsukawa H, 2018, WORLD NEUROSURG, V111, pE243, DOI 10.1016/j.wneu.2017.12.031
   Matsukawa H, 2013, J NEUROSURG, V118, P978, DOI 10.3171/2012.11.JNS121210
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Mercado Marcos, 2003, P R Health Sci J, V22, P405
   Mocco J, 2017, NEUROSURGERY, V82, P491
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Oh SY, 2013, ACTA NEUROCHIR, V155, P1493, DOI 10.1007/s00701-013-1794-x
   Ruiz DS, 2006, AM J NEURORADIOL, V27, P504
   Sforza DM, 2012, AM J NEURORADIOL, V33, P1115, DOI 10.3174/ajnr.A2908
   Song JP, 2017, NEUROSURGERY, V81, P779, DOI 10.1093/neuros/nyx093
   Wang J, 2014, AM J NEURORADIOL, V35, P1805, DOI 10.3174/ajnr.A3926
   Wang JT, 2014, J CHIN MED ASSOC, V77, P544, DOI 10.1016/j.jcma.2010.09.002
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Xiang JP, 2011, STROKE, V42, P144, DOI 10.1161/STROKEAHA.110.592923
NR 47
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E353
EP E361
DI 10.1016/j.wneu.2019.07.163
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300043
PM 31362105
DA 2020-05-12
ER

PT J
AU Goertz, L
   Hof, M
   Timmer, M
   Schulte, AP
   Kabbasch, C
   Krischek, B
   Stavrinou, P
   Reiner, M
   Goldbrunner, R
   Brinker, G
AF Goertz, Lukas
   Hof, Marion
   Timmer, Marco
   Schulte, Andre Pascal
   Kabbasch, Christoph
   Krischek, Boris
   Stavrinou, Pantelis
   Reiner, Michael
   Goldbrunner, Roland
   Brinker, Gerrit
TI Application of Intraoperatiye FLOW 800 Indocyanine Green
   Videoangiography Color-Coded Maps for Microsurgical Clipping of
   Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cerebral infarction; Clipping; FLOW 800; ICG
ID CEREBRAL-BLOOD-FLOW; TRANSCRANIAL DOPPLER; VIDEO ANGIOGRAPHY; SURGERY;
   VASOSPASM
AB OBJECTIVE: Indocyanine green (ICG) videoangiography (VAG) is an established method for assessment of cerebral blood flow during microsurgical clipping of intracranial aneurysms. FLOW 800 is a surgical microscope-integrated software program that shows the cerebral blood flow in color-coded maps, thus providing semi-quantitative and real-time analysis of ICG data. We aimed to establish reference values for FLOW 800 parameters before and after microsurgical clipping of intracranial aneurysms and to evaluate the potential of FLOW 800 to guide intraoperative decisions.
   METHODS: We retrospectively reviewed 54 patients (mean age, 53.6 +/- 11.6 years) who underwent microsurgical clipping for 60 aneurysms and intraoperative evaluation of ICG fluorescence dynamics using FLOW 800 color-coded maps. FLOW 800 data were correlated with patient characteristics, clinical outcomes, and intraoperative decision making.
   RESULTS: There were no significant differences in FLOW 800 data between ruptured and unruptured aneurysms (P> 0.05). Likewise, the hemodynamic parameters were not significantly different before and after definite clip placement (P> 0.05). However, in 2 cases, analysis of transit times by FLOW 800 analysis showed a hemodynamically significant clip stenosis that might have been missed by conventional ICG-VAG and resulted in adjustment of the clip position. Overall, there was 1 cerebral infarction, which was not related to clip placement.
   CONCLUSIONS: FLOW 800 is a useful adjunct to ICG-VAG for intraoperative assessment of cerebral perfusion and may help to identify hemodynamically relevant clip stenosis. The beneficial impact of FLOW 800 on clinical outcome after microsurgical clipping needs to be confirmed by comparative studies.
C1 [Goertz, Lukas; Hof, Marion; Timmer, Marco; Krischek, Boris; Stavrinou, Pantelis; Reiner, Michael; Goldbrunner, Roland; Brinker, Gerrit] Univ Cologne, Fac Med & Univ Hosp, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
   [Kabbasch, Christoph] Univ Hosp Cologne, Dept Neuroradiol, Cologne, Germany.
   [Schulte, Andre Pascal] Krankenhaus Augustinerinnen, Orthoped Spine Surg, Cologne, Germany.
RP Goertz, L (reprint author), Univ Cologne, Fac Med & Univ Hosp, Ctr Neurosurg, Dept Gen Neurosurg, Cologne, Germany.
EM lukas.goertz@uk-koeln.de
OI Kabbasch, Christoph/0000-0003-3712-2258
CR de Oliveira JG, 2008, NEUROSURGERY, V62, P1300, DOI [10.1227/01.NEU.0000279982.48426.A1, 10.1227/01.neu.0000333795.21468.d4]
   Ferroli P, 2011, WORLD NEUROSURG, V75, P122, DOI 10.1016/j.wneu.2010.09.011
   Fukuda K, 2015, WORLD NEUROSURG, V83, P203, DOI 10.1016/j.wneu.2014.07.012
   Goertz L, 2018, WORLD NEUROSURG, V120, pE1163, DOI 10.1016/j.wneu.2018.09.026
   GROSSET DG, 1992, STROKE, V23, P674, DOI 10.1161/01.STR.23.5.674
   Hardesty DA, 2014, J CLIN NEUROSCI, V21, P1377, DOI 10.1016/j.jocn.2014.02.006
   Imizu S, 2008, MINIM INVAS NEUROSUR, V51, P199, DOI 10.1055/s-2008-1080916
   Jing ZT, 2010, J CLIN NEUROSCI, V17, P26, DOI 10.1016/j.jocn.2009.03.034
   Kalyvas J, 2015, WORLD NEUROSURG, V83, P147, DOI 10.1016/j.wneu.2014.09.010
   Kamp MA, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822f7d7c
   Klopfenstein JD, 2004, J NEUROSURG, V100, P230, DOI 10.3171/jns.2004.100.2.0230
   Kunz M, 2013, J NEUROL, V260, P1304, DOI 10.1007/s00415-012-6795-9
   Li MG, 2018, NEUROSURG REV, V41, P675, DOI 10.1007/s10143-017-0913-1
   Ohkuma H, 2000, STROKE, V31, P1621, DOI 10.1161/01.STR.31.7.1621
   Raabe A, 2005, ZBL NEUROCHIR, V66, P1, DOI 10.1055/s-2004-836223
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Roessler K, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13475
   Schubert GA, 2012, NEUROSURGERY, V71, P260, DOI 10.1227/NEU.0b013e318265a3fb
   Shah KJ, 2019, WORLD NEUROSURG, V122, pE186, DOI 10.1016/j.wneu.2018.09.195
   Viski S, 2017, J CRIT CARE MED, V3, P99, DOI 10.1515/jccm-2017-0021
   Washington CW, 2013, J NEUROSURG, V118, P420, DOI 10.3171/2012.10.JNS11818
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yao PS, 2017, WORLD NEUROSURG, V103, P241, DOI 10.1016/j.wneu.2017.04.007
NR 23
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E192
EP E200
DI 10.1016/j.wneu.2019.07.113
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300023
PM 31330337
DA 2020-05-12
ER

PT J
AU Grassner, L
   Wutte, C
   Zimmermann, G
   Grillhosl, A
   Schmid, K
   Weiss, T
   Maier, W
   Hauck, S
   Hollerith, T
   Vogel, M
   Bierschneider, M
   Vastmans, J
   Thome C
   Gonschorek, O
   Strowitzki, M
AF Grassner, Lukas
   Wutte, Christof
   Zimmermann, Georg
   Grillhoesl, Andreas
   Schmid, Katharina
   Weiss, Thomas
   Maier, Walter
   Hauck, Stefan
   Hollerith, Tobias
   Vogel, Matthias
   Bierschneider, Michael
   Vastmans, Jan
   Thome, Claudius
   Gonschorek, Oliver
   Strowitzki, Martin
TI Influence of Preoperative Magnetic Resonance Imaging on Surgical
   Decision Making for Patients with Acute Traumatic Cervical Spinal Cord
   Injury: A Survey Among Experienced Spine Surgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute care; Cervical spine; Magnetic resonance imaging; Outcome; Spinal
   cord injury; Trauma
ID INTRAMEDULLARY LESION EXPANSION; COMPUTED-TOMOGRAPHY; DECOMPRESSION;
   MRI; IMPAIRMENT; MANAGEMENT; UTILITY; DELAYS
AB OBJECTIVE: Early decompression after acute spinal cord injury (SCI) is recommended. Acute care is crucial, but optimal management is unclear. The aim of this study was to investigate the role of preoperative magnetic resonance imaging (MRI) in addition to computed tomography (CT) in surgical decision making for acute cervical SCI.
   METHODS: All patients with cervical SCI between 2008 and 2016 who had preoperative CT and MRI (n = 63) at the Trauma Center Murnau, Germany, were included. We administered a survey to 10 experienced spine surgeons (5 neurosurgeons, 5 trauma surgeons) regarding the surgical management. First, the surgeons were shown clinical information and CT scans. Two months later, the survey was repeated with additional MRI. Corresponding percentages of change and agreement were obtained for each rater and survey item. Finally, results from both parts of the survey were compared with the definitive treatment option (i.e., real-world decision).
   RESULTS: MRI modified surgical timing in a median of 41% of patients (interquartile range 38%-56%). In almost every fifth patient (17%), no surgery would have been indicated with CT alone. The advocated surgical approach was changed in almost half of patients (median 48%, interquartile range 33%-49%). Surgically addressed levels were changed in a median of 57% of patients (interquartile range 56%-60%). MRI led to higher agreement with the real-world decision concerning addressed levels (median 35% vs. 73%), timing (median 51% vs. 57%), and approach ( median 44% vs. 65%).
   CONCLUSIONS: Preoperative MRI influenced surgical decision making substantially in our cohort and has become a new standard for patients with cervical SCI in our institution if medically possible.
C1 [Grassner, Lukas; Schmid, Katharina; Maier, Walter; Hollerith, Tobias; Bierschneider, Michael; Strowitzki, Martin] BG Trauma Ctr Murnau, Dept Neurosurg, Murnau, Germany.
   [Weiss, Thomas; Hauck, Stefan; Gonschorek, Oliver] BG Trauma Ctr Murnau, Dept Spine Surg, Murnau, Germany.
   [Grassner, Lukas; Wutte, Christof; Vogel, Matthias; Vastmans, Jan] BG Trauma Ctr Murnau, Ctr Spinal Cord Injuries, Murnau, Germany.
   [Grillhoesl, Andreas] BG Trauma Ctr Murnau, Dept Neuroradiol, Murnau, Germany.
   [Grassner, Lukas] Paracelsus Med Univ, Inst Mol Regenerat Med, Salzburg, Austria.
   [Zimmermann, Georg] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr Salzbur, Salzburg, Austria.
   [Zimmermann, Georg] Paracelsus Med Univ, Dept Neurol, Christian Doppler Med Ctr, Salzburg, Austria.
   [Zimmermann, Georg] Paracelsus Med Univ, Ctr Cognit Neurosci, Salzburg, Austria.
   [Grassner, Lukas; Thome, Claudius] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
RP Grassner, L (reprint author), BG Trauma Ctr Murnau, Dept Neurosurg, Murnau, Germany.; Grassner, L (reprint author), BG Trauma Ctr Murnau, Ctr Spinal Cord Injuries, Murnau, Germany.; Grassner, L (reprint author), Paracelsus Med Univ, Inst Mol Regenerat Med, Salzburg, Austria.; Grassner, L (reprint author), Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
EM Lukas.grassner@googlemail.com
OI Zimmermann, Georg/0000-0002-8282-1034
CR Aarabi B, 2019, J NEUROTRAUM, V36, P862, DOI 10.1089/neu.2018.5834
   Aarabi B, 2012, J NEUROSURG-SPINE, V17, P243, DOI 10.3171/2012.6.SPINE12122
   Awad BI, 2015, WORLD NEUROSURG, V84, P69, DOI 10.1016/j.wneu.2015.02.029
   Brinckman MA, 2015, SPINE J, V15, P454, DOI 10.1016/j.spinee.2014.09.032
   Fehlings MG, 2017, GLOB SPINE J, V7, p221S, DOI 10.1177/2192568217703089
   Furlan JC, 2013, J NEUROTRAUM, V30, P487, DOI 10.1089/neu.2012.2539
   Grassner L, 2018, J NEUROTRAUM, V35, P403, DOI 10.1089/neu.2017.5215
   Grassner L, 2017, EUR SPINE J, V26, P20, DOI 10.1007/s00586-016-4769-9
   Grassner L, 2016, J NEUROTRAUM, V33, P1658, DOI 10.1089/neu.2015.4325
   Jug M, 2015, J NEUROTRAUM, V32, P1385, DOI 10.1089/neu.2014.3767
   Khurana B, 2019, SPINE J, V19, P403, DOI 10.1016/j.spinee.2018.08.010
   Koyanagi I, 2000, J NEUROSURG, V93, P15, DOI 10.3171/spi.2000.93.1.0015
   Kurpad S, 2017, GLOB SPINE J, V7, p151S, DOI 10.1177/2192568217703666
   Lau BPH, 2018, EUR SPINE J, V27, P1028, DOI 10.1007/s00586-017-5317-y
   Le E, 2015, J NEUROSURG-SPINE, V22, P611, DOI 10.3171/2014.10.SPINE14576
   Mabray MC, 2016, J NEUROTRAUM, V33, P954, DOI 10.1089/neu.2015.4093
   Martinez-Perez R, 2017, WORLD NEUROSURG, V99, P192, DOI 10.1016/j.wneu.2016.12.005
   Mascarenhas D, 2016, AM J ROENTGENOL, V206, P1292, DOI 10.2214/AJR.15.15492
   Morais DF, 2014, EUR SPINE J, V23, P1457, DOI 10.1007/s00586-013-3047-3
   Nouri A, 2017, WORLD NEUROSURG, V105, P864, DOI 10.1016/j.wneu.2017.06.025
   Oichi T, 2016, EUR SPINE J, V25, P96, DOI 10.1007/s00586-015-4142-4
   R Development Core Team, 2017, R A LANGUAGE AND ENV
   Raslan AM, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/417834
   Rutges JPHJ, 2017, EUR SPINE J, V26, P2324, DOI 10.1007/s00586-017-5097-4
   Samuel AM, 2015, SPINE, V40, P992, DOI 10.1097/BRS.0000000000000883
   Schoenfeld AJ, 2010, J TRAUMA, V68, P113, DOI DOI 10.1097/TA.0B013E3181C0B67A
   Schoenfeld AJ, 2018, SPINE, V43, P179, DOI 10.1097/BRS.0000000000002285
   Schoenfeld AJ, 2010, J TRAUMA, V68, P109, DOI 10.1097/TA.0b013e3181c0b67a
   Sliker CW, 2005, RADIOLOGY, V234, P733, DOI 10.1148/radiol.2343031768
   Spinal cord injury (SCI), 2016, J SPINAL CORD MED, V39, P493, DOI DOI 10.1080/10790268.2016.1210925
   Talbott JF, 2015, J NEUROSURG-SPINE, V23, P495, DOI 10.3171/2015.1.SPINE141033
   Vedantam A, 2015, WORLD NEUROSURG, V83, P824, DOI 10.1016/j.wneu.2013.09.017
   Vedantam A, 2014, NEUROSURGERY, V74, P1, DOI 10.1227/NEU.0000000000000171
   Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f
   Wilson JR, 2017, GLOB SPINE J, V7, p95S, DOI 10.1177/2192568217701716
   Wutte C, 2019, J NEUROTRAUM, V36, P2020, DOI 10.1089/neu.2018.6146
NR 36
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E586
EP E592
DI 10.1016/j.wneu.2019.08.009
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300073
PM 31404692
DA 2020-05-12
ER

PT J
AU Hanaoka, Y
   Koyama, J
   Ogiwara, T
   Miyaoka, Y
   Fujii, Y
   Nakamura, T
   Horiuchi, T
   Hongo, K
AF Hanaoka, Yoshiki
   Koyama, Jun-ichi
   Ogiwara, Toshihiro
   Miyaoka, Yoshinari
   Fujii, Yu
   Nakamura, Takuya
   Horiuchi, Tetsuyoshi
   Hongo, Kazuhiro
TI Usefulness of a Novel Technique to Make Up for a Deficiency in
   Transradial Neurointervention with a 6Fr Simmonds Guiding Sheath:
   Original Experience with the Subclavian Artery Anchoring Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenting; Cerebral aneurysm coiling; Neuroendovascular
   treatment; Simmonds guiding sheath; Transradial approach; Vascular
   access
ID PERCUTANEOUS CORONARY INTERVENTION; INITIAL-EXPERIENCE; RADIAL ARTERY;
   ACCESS; ANGIOGRAPHY; COST
AB BACKGROUND: The benefits of the right transradial approach for anterior circulation lesions using a 6F Simmonds guiding sheath have been reported. However, this technique can he anatomically challenging in the type I aortic arch. Furthermore, to the best of our knowledge, no studies have reported on neurointervention using a Simmonds guiding sheath and the left transradial approach. We devised a novel technique using the contralateral subclavian artery as an "anchor" to reform the Simmonds curve, named the subclavian artery anchoring technique (SCAT). The purpose of the present study was to evaluate the feasibility, safety, and usefulness of neurointervention with the SCAT for patients with a type I aortic arch treated with the right transradial approach and patients treated with the left transradial approach.
   METHODS: Ten consecutive patients treated from June 2018 to January 2019 were included in the present study. We retrospectively analyzed: 1) the success rate for reforming the Simmonds curve using the SCAT; 2) the success rate for introducing the 6F Simmonds guiding sheath into the target common carotid artery; 3) the success rate for completing the procedure; 4) periprocedural complications; and 5) vascular access site complications.
   RESULTS: In all 10 patients, the Simmonds curve was reformed, and a 6F Simmonds guiding sheath was introduced into the target common carotid artery. The procedure was successfully achieved for all 10 patients without periprocedural or vascular access site complications.
   CONCLUSIONS: The results of the present study have shown that this technique is a feasible, safe, and useful method for patients with type I aortic arch treated with a right transradial approach or a left transradial approach. SCAT makes up for a deficiency in the transradial approach with a 6F Simmonds guiding sheath.
C1 [Hanaoka, Yoshiki; Ogiwara, Toshihiro; Miyaoka, Yoshinari; Fujii, Yu; Nakamura, Takuya; Horiuchi, Tetsuyoshi; Hongo, Kazuhiro] Shinshu Univ Hosp, Dept Neurosurg, Matsumoto, Nagano, Japan.
   [Koyama, Jun-ichi] Shinshu Univ Hosp, Neurointervent Ctr, Matsumoto, Nagano, Japan.
RP Horiuchi, T (reprint author), Shinshu Univ Hosp, Dept Neurosurg, Matsumoto, Nagano, Japan.
EM tetuyosi@shinshu-u.ac.jp
CR Bakhshi F, 2014, J NURS RES, V22, P45, DOI 10.1097/jnr.0000000000000020
   Casserly IP, 2005, MANUAL PERIPHERAL VA
   Castriota F, 1999, J ENDOVASC SURG, V6, P385, DOI 10.1583/1074-6218(1999)006<0385:CSURAA>2.0.CO;2
   Cooper CJ, 1999, AM HEART J, V138, P430, DOI 10.1016/S0002-8703(99)70143-2
   Etxegoien N, 2012, CATHETER CARDIO INTE, V80, P1081, DOI 10.1002/ccd.24503
   Fang HY, 2010, ANN VASC SURG, V24, P670, DOI 10.1016/j.avsg.2009.12.001
   Folmar J, 2007, CATHETER CARDIO INTE, V69, P355, DOI 10.1002/ccd.21049
   Goland Javier, 2017, Surg Neurol Int, V8, P73, DOI 10.4103/sni.sni_393_16
   Hanaoka Y, 2018, J NEUROENDOVASC THER, V12, P532
   Heenan SD, 1996, CLIN RADIOL, V51, P205, DOI 10.1016/S0009-9260(96)80324-2
   Kiemeneij F, 1997, J AM COLL CARDIOL, V29, P1269, DOI 10.1016/S0735-1097(97)00064-8
   Le Corvoisier P, 2013, CATHETER CARDIO INTE, V81, P15, DOI 10.1002/ccd.24545
   Lee MS, 2014, CATHETER CARDIO INTE, V84, P62, DOI 10.1002/ccd.25435
   Louvard Y, 2001, CATHETER CARDIO INTE, V52, P181, DOI 10.1002/1522-726X(200102)52:2<181::AID-CCD1044>3.0.CO;2-G
   Mann T, 1998, J AM COLL CARDIOL, V32, P572, DOI 10.1016/S0735-1097(98)00288-5
   Mendiz OA, 2011, VASC ENDOVASC SURG, V45, P499, DOI 10.1177/1538574411405547
   Patel T, 2010, CATHETER CARDIO INTE, V75, P268, DOI 10.1002/ccd.22159
   Peitz Geoffrey W, 2017, J Vasc Interv Neurol, V9, P42
   Pinter L, 2007, J VASC SURG, V45, P1136, DOI 10.1016/j.jvs.2007.02.035
   Ruzsa Z, 2014, EUROINTERVENTION, V10, P381, DOI 10.4244/EIJV10I3A64
   Shah SS, 2018, WORLD NEUROSURG, V120, P415, DOI 10.1016/j.wneu.2018.09.095
   Sur S, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.1.FOCUS16525
   Yokoyama N, 2000, CATHETER CARDIO INTE, V49, P357, DOI 10.1002/(SICI)1522-726X(200004)49:4<357::AID-CCD1>3.0.CO;2-Z
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E362
EP E370
DI 10.1016/j.wneu.2019.07.162
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300044
PM 31362101
DA 2020-05-12
ER

PT J
AU He, Y
   Wang, L
   Chen, HM
   Ou, YB
   Zhang, P
   Guo, DS
   Giuseppe, LZ
AF He, Yue
   Wang, Ling
   Chen, Hanmin
   Ou, Yibo
   Zhang, Po
   Guo, Dongsheng
   Giuseppe, Lanzino
TI Progressive Pure Arterial Malformations of the Anterior Cerebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial malformation; Developmental arterial anomaly; Dilative
   arteriopathy; Intracranial arterial dissection; Intracranial arterial
   dolichoectasia; Vascular disorder
ID DOLICHOECTASIA; ANEURYSMS; ECTASIA
AB BACKGROUND: Pure arterial malformations (PAMs) are rare intracranial vascular anomalies. As recently reported, PAMs have a benign natural history and can be treated conservatively. However, their etiology, natural history, and treatment have not yet been fully elucidated.
   METHODS: We present a rare case of the progression of a PAM involving the anterior cerebral artery. Magnetic resonance imaging showed a mass located in the suprasellar region associated with obstructive hydrocephalus. Digital subtraction angiography showed evolution of the arterial anomaly with progression compared with the studies 3 years earlier. Surgical trapping of the parent artery with electrophysiological monitoring was performed. Combined with previous data, the clinical features and therapeutic strategies for this unusual entity are discussed.
   RESULTS: The patient recovered uneventfully after surgery. Postoperative digital subtraction angiography confirmed complete obliteration of the lesion. Axial computed tomography also showed shrinkage of the aneurysm, with improvement of the hydrocephalus. Our review of the reported data showed only 4 patients with a definite or probable PAM who had undergone surgery. To the best of our knowledge, the present case represents the first report of changes in the vascular architecture of a PAM during the follow-up period.
   CONCLUSION: Whether the aneurysmal component of PAMs merits invasive treatment has remained controversial. The findings from our case raises the possibility of evolution for some patients with PAMs and stresses the importance of scheduled follow-up noninvasive imaging studies to rule out progression of these nosological entities, especially PAMs with an "aneurysm-like" component.
C1 [He, Yue; Chen, Hanmin; Ou, Yibo; Zhang, Po; Guo, Dongsheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Wang, Ling] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Operating Room, Wuhan, Hubei, Peoples R China.
   [Giuseppe, Lanzino] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
RP Guo, DS (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM Tjguodongshong@163.com
CR Abe T, 1997, AM J NEURORADIOL, V18, P144
   Araki Y, 2017, CHILD NERV SYST, V33, P1405, DOI 10.1007/s00381-017-3451-9
   Beringer W, 2004, AM J NEURORADIOL, V25, P1197
   Bikmaz K, 2007, CLIN NEUROL NEUROSUR, V109, P589, DOI 10.1016/j.clineuro.2007.04.002
   Brinjikji W, 2018, J NEUROSURG, V129, P91, DOI 10.3171/2017.2.JNS1744
   Del Brutto VJ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00344
   DORAN SE, 1995, AM J NEURORADIOL, V16, P1548
   Gutierrez J, 2011, NAT REV NEUROL, V7, P41, DOI 10.1038/nrneurol.2010.181
   HANAKITA J, 1986, NEUROSURGERY, V19, P271, DOI 10.1227/00006123-198608000-00017
   Jabbarli R, 2018, STROKE, V49, P848, DOI 10.1161/STROKEAHA.117.020342
   Kandemirli SG, 2018, AM J NEURORADIOL, V39, P1662, DOI 10.3174/ajnr.A5746
   Kanemoto Y, 1998, NEUROL MED-CHIR, V38, P40, DOI 10.2176/nmc.38.40
   KRYSTWIDZGOWSKA T, 1980, EUR J NUCL MED, V5, P387, DOI 10.1007/BF00445628
   Lanterna LA, 2014, J NEUROSURG, V121, P1007, DOI 10.3171/2014.5.JNS14999
   Lanzino G, 2014, J NEUROSURG, V120, P575, DOI 10.3171/2013.7.JNS131478
   McConnell FK, 2017, IEEE T BIO-MED ENG, V64, P1793, DOI 10.1109/TBME.2016.2623710
   McLaughlin N, 2013, J NEUROSURG, V119, P655, DOI 10.3171/2013.4.JNS121374
   Mitsuhara T, 2018, NEUROSURG REV, V41, P409, DOI 10.1007/s10143-017-0841-0
   SACKS JG, 1969, JOHNS HOPKINS MED J, V125, P95
   Sako T, 2016, NEURORADIOL J, V29, P283, DOI 10.1177/1971400916643339
   Shankar JJS, 2009, CAN J NEUROL SCI, V36, P757, DOI 10.1017/S0317167100008398
   Sikkema T, 2014, EUR J NEUROL, V21, P820, DOI 10.1111/ene.12384
   Sikkema T, 2015, NEUROSURGERY, V76, P663, DOI 10.1227/NEU.0000000000000696
   Sorenson TJ, 2018, J NEUROSURG-PEDIATR, V22, P261, DOI 10.3171/2018.4.PEDS18135
   THOMPSON JR, 1976, J NEUROSURG, V44, P509, DOI 10.3171/jns.1976.44.4.0509
   TSUKAMOTO Y, 1985, NEURORADIOLOGY, V27, P271, DOI 10.1007/BF00344500
   WOLPERT SM, 1972, AM J ROENTGENOL, V115, P92, DOI 10.2214/ajr.115.1.92
   Xu K, 2016, INT J MED SCI, V13, P432, DOI 10.7150/ijms.14934
   YAMADA K, 1985, SURG NEUROL, V23, P19, DOI 10.1016/0090-3019(85)90154-5
NR 29
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E52
EP E64
DI 10.1016/j.wneu.2019.07.020
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300008
PM 31295621
DA 2020-05-12
ER

PT J
AU Hoogmoed, J
   Manoel, ALD
   Coert, BA
   Marotta, TR
   Macdonald, RL
   Vandertop, WP
   Verbaan, D
   Germans, MR
AF Hoogmoed, Jantien
   Manoel, Airton L. de Oliveira
   Coert, Bert A.
   Marotta, Thomas R.
   Macdonald, R. Loch
   Vandertop, W. Peter
   Verbaan, Dagmar
   Germans, Menno R.
TI Why Do Patients with Poor-Grade Suharachnoid Hemorrhage Die?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain death; Cause of death; Humans; Intensive care; Intracranial
   aneurysm; Subarachnoid hemorrhage; Withholding treatment
ID ANEURYSMAL SUBARACHNOID HEMORRHAGE; DELAYED CEREBRAL-ISCHEMIA; RISK;
   WITHDRAWAL; MORTALITY; IMPACT
AB BACKGROUND: Poor-grade subarachnoid hemorrhage (SAH) has been associated with a high case fatality, either in the acute phase or in the later stages. The exact causes of death in these patients are unknown.
   METHODS: We performed a retrospective study of all consecutive patients with SAH with World Federation of Neurosurgical Societies grade IV or V on admission from 2009 to 2013 at 2 tertiary referral centers in Amsterdam, the Netherlands, and Toronto, Ontario, Canada, who had died during their hospital stay.
   RESULTS: Of 357 patients, 152 (43%) had died. Of these 152 patients, 87 (24%) had not undergone aneurysm treatment. The median interval to death was 3 days (interquartile range, 1-12 days) after initial hemorrhage. The major cause of death in both centers was withdrawal of life support (107 patients [71%]; 74 of 94 [79%] in Amsterdam and 33 of 58 [58%] in Toronto; P < 0.01), followed by brain death in 23 (15%; 16 of 58 [28%] in Amsterdam vs. 7 of 94 [7%] in Toronto; P < 0.01). The remaining causes of death represented <15%.
   CONCLUSIONS: The decision to withdraw life support was the major reason for death of patients with poor-grade SAH for an overwhelming majority of the patients. The exact reasons for withdrawal of life support, other than cultural and referral differences, were undetermined. Insight into the reasons of death should be prospectively studied to improve the care and clinical outcomes of patients with poor-grade SAH.
C1 [Hoogmoed, Jantien; Coert, Bert A.; Vandertop, W. Peter; Verbaan, Dagmar] Univ Amsterdam, Neurosurg Ctr Amsterdam, Dept Neurosurg, Med Ctr, Amsterdam, Netherlands.
   [Manoel, Airton L. de Oliveira] Univ Fed Sao Paulo, Neurol & Neurosurg Dept, Sao Paulo, Brazil.
   [Manoel, Airton L. de Oliveira; Macdonald, R. Loch] Univ Toronto, Dept Crit Care Med, Trauma & Neurosurg Intens Care Unit, Toronto, ON, Canada.
   [Manoel, Airton L. de Oliveira; Marotta, Thomas R.] Univ Toronto, Dept Med Imaging, Div Intervent Neuroradiol, Toronto, ON, Canada.
   [Manoel, Airton L. de Oliveira; Marotta, Thomas R.] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Neurosci Res Program, Toronto, ON, Canada.
   [Macdonald, R. Loch] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Germans, Menno R.] Univ Hosp Zurich, Dept Neurosurg, Zurich, Switzerland.
   [Germans, Menno R.] Univ Hosp Zurich, Clin Neurosci Ctr, Zurich, Switzerland.
RP Hoogmoed, J (reprint author), Univ Amsterdam, Neurosurg Ctr Amsterdam, Dept Neurosurg, Med Ctr, Amsterdam, Netherlands.
EM j.hoogmoed@amc.nl
RI Germans, Menno/AAI-8211-2020
CR BAILES JE, 1990, J NEUROSURG, V72, P559, DOI 10.3171/jns.1990.72.4.0559
   Bruder N, 2011, NEUROCRIT CARE, V15, P257, DOI 10.1007/s12028-011-9598-4
   Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   de Oliveira Manoel AL, 2016, NEUROCRIT CARE, V25, P338, DOI 10.1007/s12028-016-0305-3
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   Geurts M, 2014, LANCET NEUROL, V13, P515, DOI 10.1016/S1474-4422(14)70030-4
   Hemphill JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5687
   Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009
   Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca
   Hoogmoed J, 2017, EUR J NEUROL, V24, P82, DOI 10.1111/ene.13134
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P105
   Laidlaw JD, 2003, NEUROSURGERY, V53, P1275, DOI 10.1227/01.NEU.0000093199.74960.FF
   Laidlaw JD, 2002, J NEUROSURG, V97, P250, DOI 10.3171/jns.2002.97.2.0250
   Laidlaw JD, 2002, J NEUROSURG, V97, P248
   Lantigua H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1036-0
   Luo YC, 2015, NEURORADIOLOGY, V57, P205, DOI 10.1007/s00234-014-1454-8
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1193-9
   Milhorat TH, 2002, NEUROSURGERY, V51, P525, DOI 10.1097/00006123-200208000-00053
   Mitra D, 2015, AM J NEURORADIOL, V36, P116, DOI 10.3174/ajnr.A4061
   Naidech AM, 2005, ARCH NEUROL-CHICAGO, V62, P410, DOI 10.1001/archneur.62.3.410
   ROSENORN J, 1987, J NEUROSURG, V67, P329, DOI 10.3171/jns.1987.67.3.0329
   SAVELAND H, 1992, J NEUROSURG, V76, P729, DOI 10.3171/jns.1992.76.5.0729
   Shemie SD, 2006, CAN MED ASSOC J, V175, pS1, DOI 10.1503/cmaj.060895
   SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506
   Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786
   van den Berg JW, 2011, CRIT CARE MED, V39, P126, DOI 10.1097/CCM.0b013e3181fa3a93
   van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   Vergouwen MDI, 2016, NEUROLOGY, V86, P59, DOI 10.1212/WNL.0000000000002239
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35
   Wijdicks EFM, 2004, CRIT CARE MED, V32, P2332, DOI 10.1097/01.CCM.0000145949.34618.E1
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E508
EP E513
DI 10.1016/j.wneu.2019.07.221
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300063
PM 31398522
DA 2020-05-12
ER

PT J
AU Huang, KT
   Harary, M
   Abd-El-Barr, MM
   Chi, JH
AF Huang, Kevin T.
   Harary, Maya
   Abd-El-Barr, Muhammad M.
   Chi, John H.
TI Crossing the Cervicothoracic Junction in Posterior Cervical
   Decompression and Fusion: A Cohort Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Cervicothoracic junction; Cohort study;
   Posterior cervical decompression and fusion; Postoperative complications
ID PEDICLE SCREW FIXATION; NONTRAUMATIC LESIONS; SPINE SURGERY; TRENDS;
   COMPLICATIONS; INSTABILITY
AB BACKGROUND: The cervicothoracic junction (CTJ) has often been identified as an area of biomechanical vulnerability; however, few studies have examined the relative merits of extending fusions across this area. In this study, we sought to investigate the tradeoffs involved in fusing across the CTJ in cases of elective posterior cervical laminectomy and fusion.
   METHODS: We conducted a single-institution retrospective cohort study of patients undergoing elective, multilevel, posterior cervical decompression and fusion for degenerative cervical stenosis. Data were collected on baseline clinical and radiographic variables as well any subsequent complications or reoperations. Outcomes measures were compared between those who received fusion stopping at C7 with those who received fusion crossing the CTJ, with multivariate logistic regression used to adjust for any known confounders.
   RESULTS: Patients whose fusion crossed the CTJ were found to have more levels fused (mean: 5.8 vs. 3.5 levels, P < 0.0001), longer surgical times (mean: 216 vs. 149 minutes, P < 0.0001), and higher estimated blood losses (mean: 475 vs. 116 ml, P< 0.0001) despite no significant differences in number of levels decompressed (mean: 4.2 vs. 4.3 levels, P = 0.63). The groups did not differ in overall reoperation rate (10.8% vs. 9.4%, P = 1.00), but crossing the CTJ was associated with a higher rate of wound dehiscence (7.8% vs. 0%, P = 0.03). This difference persisted in multivariate analysis (P < 0.001).
   CONCLUSIONS: Crossing the CTJ was associated with increased surgical time, estimated blood loss, and the rates of wound dehiscence. These tradeoffs should be considered in planning posterior cervical decompression and fusion procedures.
C1 [Huang, Kevin T.; Harary, Maya; Chi, John H.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Abd-El-Barr, Muhammad M.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
RP Chi, JH (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
EM jchi@bwh.harvard.edu
RI Harary, Maya/AAG-9361-2019
OI Harary, Maya/0000-0002-9962-8900
FU Daniel J. Sandman PhD Memorial Fund
FX This work was supported in part by the Daniel J. Sandman PhD Memorial
   Fund, an internal funding grant within our institute made possible by
   philanthropic donations.
CR Abumi K, 2000, SPINE, V25, P962, DOI 10.1097/00007632-200004150-00011
   Abumi K, 1997, SPINE, V22, P1853, DOI 10.1097/00007632-199708150-00010
   AN HS, 1994, SPINE, V19, P2557, DOI 10.1097/00007632-199411001-00011
   An HS, 1999, J SPINAL DISORD, V12, P519
   Boockvar JA, 2001, J NEUROSURG, V94, P12, DOI 10.3171/spi.2001.94.1.0012
   Chapman JR, 1996, J NEUROSURG, V84, P552, DOI 10.3171/jns.1996.84.4.0552
   FEHLINGS MG, 1994, J NEUROSURG, V81, P341, DOI 10.3171/jns.1994.81.3.0341
   Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
   Johnston Todd L, 2006, Spine J, V6, P667
   Jones EL, 1997, SPINE, V22, P977, DOI 10.1097/00007632-199705010-00009
   Kreshak JL, 2002, SPINE, V27, P2763, DOI 10.1097/00007632-200212150-00005
   Marquez-Lara A, 2014, SPINE, V39, P476, DOI 10.1097/BRS.0000000000000165
   Nakashima H, 2012, J NEUROSURG-SPINE, V16, P238, DOI 10.3171/2011.11.SPINE11102
   Oglesby M, 2013, SPINE, V38, P1226, DOI 10.1097/BRS.0b013e31828be75d
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Rhee JM, 2005, SPINE, V30, pE636, DOI 10.1097/01.brs.0000184750.80067.a1
   Schroeder GD, 2016, SPINE, V41, P1845, DOI 10.1097/BRS.0000000000001864
   Steinmetz MP, 2006, J NEUROSURG-SPINE, V4, P278, DOI 10.3171/spi.2006.4.4.278
   Wang MC, 2009, SPINE, V34, P955, DOI 10.1097/BRS.0b013e31819e2fd5
   Xu RS, 2010, J NEUROSURG-SPINE, V13, P688, DOI 10.3171/2010.5.SPINE09712
   Yukawa Y, 2006, J NEUROSURG-SPINE, V5, P488, DOI 10.3171/spi.2006.5.6.488
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E514
EP E520
DI 10.1016/j.wneu.2019.07.219
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300064
PM 31394365
DA 2020-05-12
ER

PT J
AU Hudson, JS
   Zanaty, M
   Wadman, V
   Nakagawa, D
   Ishii, D
   Roa, JA
   Al Kasabz, S
   Limaye, K
   Rossen, JD
   Jabbour, P
   Adams, HP
   Samaniego, EA
   Hasan, DM
AF Hudson, Joseph S.
   Zanaty, Mario
   Wadman, Victoria
   Nakagawa, Daichi
   Ishii, Daizo
   Roa, Jorge A.
   Al Kasabz, Sami
   Limaye, Kaustubh
   Rossen, James D.
   Jabbour, Pascal
   Adams, Harold P., Jr.
   Samaniego, Edgar A.
   Hasan, David M.
TI Bradycardia and Asystole in Patients Undergoing Symptomatic Chronically
   Occluded Internal Carotid Artery Recanalization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Arrhythmias; Autonomic nervous system; Cerebrovascular
   procedures; Hemodynamics; Physiology; Stenosis
ID ENDOVASCULAR RECANALIZATION; HYPOTENSION; PREDICTORS; ANGIOPLASTY;
   OCCLUSION; BYPASS
AB BACKGROUND: Reports have emerged describing the successful endovascular recanalization of the chronically occluded internal carotid artery (COICA). The impact this restoration of flow has on the sensitive carotid sinus baroreceptors has not been previously described. In this manuscript, we present the largest COICA surgical series to date, with a specific focus on perioperative heart rate abnormalities.
   METHODS: Patient demographics were obtained, and the COICAs were radiographically classified based on the anatomic distribution of the stenosis and collateral flow. Thirty-six patients had a total of 37 COICA revascularization procedures.
   RESULTS: A total of 23 patients had intraprocedural bradycardia during balloon angioplasty. Three patients went into transient asystole during the procedure, and 2 of these patients had symptomatic bradycardia with ischemic cerebral changes, 1 of which required permanent pacemaking. All other patients had immediate resolution of their bradycardia, asystole, and neurologic symptoms immediately following balloon deflation and pharmaceutical management. There was a statistically significant difference in the observed proportion of bradycardic patients among COICA classifications (P = 0.014). There was no statistically significant difference in mean age between patients with bradycardia and those without (aged 63.36 vs. 67.71 years, P = 0.2265).
   CONCLUSIONS: Bradycardia associated with angioplasty of the carotid bulb was observed in the majority of patients receiving COICA revascularization. A small percentage of these patients were symptomatic. Our results suggest that carotid sinus baroreceptors remain active while residing in a complete arterial occlusion, and close monitoring is necessary during balloon angioplasty of the proximal COICA.
C1 [Hudson, Joseph S.; Zanaty, Mario; Ishii, Daizo; Roa, Jorge A.; Samaniego, Edgar A.; Hasan, David M.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Roa, Jorge A.; Al Kasabz, Sami; Limaye, Kaustubh; Adams, Harold P., Jr.; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
   [Rossen, James D.] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA.
   [Wadman, Victoria] Univ Nebraska Med Ctr, Coll Med, Omaha, NE USA.
   [Nakagawa, Daichi] Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
   [Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
RP Hasan, DM (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM david-hasan@uiowa.edu
OI Roa, Jorge/0000-0003-4987-8853; Ishii, Daizo/0000-0002-7139-695X;
   Limaye, Kaustubh/0000-0002-7280-7407
CR Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002
   Cao QQ, 2014, INTERV NEUROL, V3, P13, DOI 10.1159/000366231
   Cayne NS, 2005, J VASC SURG, V41, P956, DOI 10.1016/j.jvs.2005.02.038
   Dangas G, 2000, RADIOLOGY, V215, P677, DOI 10.1148/radiology.215.3.r00jn04677
   Fan YL, 2014, VASC ENDOVASC SURG, V48, P305, DOI 10.1177/1538574414525863
   Galkin P, 2017, J NEUROSURG SCI, V61, P22, DOI 10.23736/S0390-5616.16.03234-3
   Gupta R, 2006, J AM COLL CARDIOL, V47, P1538, DOI 10.1016/j.jacc.2005.08.079
   Hasan D, 2019, J NEUROSURG, V130, P1468, DOI 10.3171/2018.1.JNS172858
   Kanamaru K, 2011, ACTA NEUROCHIR SUPPL, V112, P55, DOI 10.1007/978-3-7091-0661-7_10
   Kao HL, 2007, J AM COLL CARDIOL, V49, P765, DOI 10.1016/j.jacc.2006.11.029
   Kim Won Ho, 2010, Korean Circ J, V40, P288, DOI 10.4070/kcj.2010.40.6.288
   Lavoie P, 2008, AM J NEURORADIOL, V29, P1942, DOI 10.3174/ajnr.A1258
   Leisch F, 2003, CATHETER CARDIO INTE, V58, P516, DOI 10.1002/ccd.10483
   Lin MS, 2008, CIRC-CARDIOVASC INTE, V1, P119, DOI 10.1161/CIRCINTERVENTIONS.108.772350
   Mlekusch W, 2003, J ENDOVASC THER, V10, P851, DOI 10.1583/1545-1550(2003)010<0851:HABAEC>2.0.CO;2
   Namba K, 2012, INTERV NEURORADIOL, V18, P288, DOI 10.1177/159101991201800307
   Pappada G, 2006, ACTA NEUROCHIR, V148, P639, DOI 10.1007/s00701-006-0752-2
   Persoon S, 2011, J NEUROL NEUROSUR PS, V82, P521, DOI 10.1136/jnnp.2010.208330
   Persoon S, 2009, J NEUROL, V256, P1728, DOI 10.1007/s00415-009-5194-3
   Trocciola SM, 2006, J VASC SURG, V43, P714, DOI 10.1016/j.jvs.2005.12.008
   Zanaty M, 2020, J NEUROSURG, V132, P1158, DOI 10.3171/2019.1.JNS183337
   Zanaty M, 2019, WORLD NEUROSURG, V121, P137, DOI 10.1016/j.wneu.2018.09.230
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E211
EP E217
DI 10.1016/j.wneu.2019.07.125
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300025
PM 31349074
DA 2020-05-12
ER

PT J
AU Jang, HD
   Won, SH
   Kim, DW
   Kim, EH
   Lee, JC
   Choi, SW
   Park, SS
   Goo, W
   Shin, BJ
AF Jang, Hae-Dong
   Won, Sung Hun
   Kim, Dae Woong
   Kim, Eung-Ha
   Lee, Jae Chul
   Choi, Sung-Woo
   Park, Seong San
   Goo, Woonhoe
   Shin, Byung-Joon
TI Magnetic Resonance Imaging Characteristics and Age-Related Changes in
   the Psoas Muscle: Analysis of 164 Patients with Back Pain and Balanced
   Lumbar Sagittal Alignment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative lumbar; Direct lateral lumbar interbody fusion; Lateral
   lumbar spinal surgery; Psoas muscle; Sarcopenia; Transpsoas approach
ID QUANTITATIVE-ANALYSIS; PARASPINAL MUSCLES; FATTY DEGENERATION;
   SARCOPENIA; MRI; MORPHOMETRY; MUSCULARITY; MORTALITY; KYPHOSIS; ANATOMY
AB OBJECTIVE: The psous muscle (PS), 1 of the para-vertebral core muscles, is associated with sarcopenia. It also has clinical relevance in lateral-access spinal surgery (LASS) as a determinant structure affecting the operative window. We aimed to identify age-related patterns of PS degeneration, and we propose that our results be used to evaluate the operative window in LASS.
   METHODS: We included 164 participants with back pain, no leg symptoms or claudication, and normal lumbar lordosis and sagittal balance. We evaluated the cross-sectional morphology of the PS on magnetic resonance imaging, specifically assessing the anterior to posterior (AP)/medial to lateral (ML) ratio and the cross-sectional area (CSA). We assessed the locational relationship of the PS and the intervertebral disc using the anterior margin gap (AMG; the distance between the anterior margins of the PS and the intervertebral disc) and the center gap, and compared all measurements by surgical level, sex, and age group.
   RESULTS: At the L2-3 to L4-5 levels, the PS showed a decreased AP/ML ratio, increased CSA, ventral retraction of the anterior margin without center shift, and decreased operative window length. The degeneration patterns were decreased ML width and CSA and dorsal retraction of the anterior margin. Youth, male sex, and lower lumbar level were associated with higher AMGs, indicating an increased need for the transpsoas approach in LASS.
   CONCLUSIONS: In patients without sagittal imbalance, the PS showed significant imaging characteristics. Our detailed data may aid the identification of degeneration patterns and specific preoperative planning regarding the operative window for LASS.
C1 [Jang, Hae-Dong; Kim, Eung-Ha; Park, Seong San] Soonchunhyang Univ, Dept Orthopaed Surg, Bucheon Hosp, Gyeonggi Do, South Korea.
   [Won, Sung Hun; Kim, Dae Woong; Lee, Jae Chul; Choi, Sung-Woo; Shin, Byung-Joon] Soonchunhyang Univ, Dept Orthopaed Surg, Seoul Hosp, Seoul, South Korea.
   [Goo, Woonhoe] Incheon Natl Univ, Mech Engn Appl Bioengn Lab, Incheon, South Korea.
RP Shin, BJ (reprint author), Soonchunhyang Univ, Dept Orthopaed Surg, Seoul Hosp, Seoul, South Korea.
EM schsbj@gmail.com
FU Soonchunhyang University Research Fund
FX Supported by the Soonchunhyang University Research Fund.
CR Arbanas J, 2013, EUR SPINE J, V22, P1965, DOI 10.1007/s00586-013-2749-x
   Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520
   Bokshan SL, 2016, ORTHOPEDICS, V39, pE295, DOI 10.3928/01477447-20160222-02
   Buckland AJ, 2018, ASIAN SPINE J, V12, P29, DOI 10.4184/asj.2018.12.1.29
   Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389
   Davis TT, 2011, J BONE JOINT SURG AM, V93A, P1482, DOI 10.2106/JBJS.J.00962
   Demoulin C, 2007, JOINT BONE SPINE, V74, P9, DOI 10.1016/j.jbspin.2006.02.013
   Drudi LM, 2016, EUR J VASC ENDOVASC, V52, P764, DOI 10.1016/j.ejvs.2016.09.011
   GOEL VK, 1993, SPINE, V18, P1531
   Hyun SJ, 2016, SPINE J, V16, P1095, DOI 10.1016/j.spinee.2016.05.008
   Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x
   Janssen I, 2000, J APPL PHYSIOL, V89, P81
   Kang CH, 2007, CLIN RADIOL, V62, P479, DOI 10.1016/j.crad.2006.12.002
   Kepler CK, 2011, EUR SPINE J, V20, P550, DOI 10.1007/s00586-010-1593-5
   Kim H, 2013, EUR SPINE J, V22, P1332, DOI 10.1007/s00586-013-2740-6
   LECAM L, 1965, P NATL ACAD SCI USA, V54, P354, DOI 10.1073/pnas.54.2.354
   Lee JC, 2008, SPINE, V33, P318, DOI 10.1097/BRS.0b013e318162458f
   Lee SH, 2017, SPINE J, V17, P81, DOI 10.1016/j.spinee.2016.08.001
   Lee SJ, 2017, CANCER NURS, V40, P479, DOI 10.1097/NCC.0000000000000454
   Liu LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163452
   Min SH, 2009, ASIAN SPINE J, V3, P89, DOI 10.4184/asj.2009.3.2.89
   Modi H, 2008, ASIAN SPINE J, V2, P38, DOI 10.4184/asj.2008.2.1.38
   PARKKOLA R, 1992, J SPINAL DISORD, V5, P86, DOI 10.1097/00002517-199203000-00011
   SAVAGE RA, 1991, EUR J APPL PHYSIOL O, V63, P265, DOI 10.1007/BF00233859
   Shachar SS, 2016, EUR J CANCER, V57, P58, DOI 10.1016/j.ejca.2015.12.030
   Sun X, 2006, CALCIFIED TISSUE INT, V79, P43, DOI 10.1007/s00223-006-0041-3
   Thakar S, 2016, J NEUROSURG-SPINE, V24, P679, DOI 10.3171/2015.9.SPINE15705
   Thakar S, 2014, J NEUROSURG-SPINE, V21, P223, DOI 10.3171/2014.4.SPINE13627
   Valentin S, 2015, J BACK MUSCULOSKELET, V28, P181, DOI 10.3233/BMR-140552
   Voyadzis JM, 2014, J NEUROSURG-SPINE, V20, P531, DOI 10.3171/2014.1.SPINE13153
   Wallace JD, 2017, J TRAUMA ACUTE CARE, V82, P65, DOI 10.1097/TA.0000000000001297
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Yen CP, 2016, SPINE, V41, P152
NR 34
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E88
EP E95
DI 10.1016/j.wneu.2019.07.048
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300012
PM 31302267
DA 2020-05-12
ER

PT J
AU Kamp, MA
   Knipps, J
   Neumann, LM
   Mijderwijk, HJ
   Dibue-Adjei, M
   Steiger, HJ
   Slotty, PJ
   Rapp, M
   Cornelius, JF
   Sabel, M
AF Kamp, Marcel A.
   Knipps, Johannes
   Neumann, Lisa Margarete
   Mijderwijk, Hendrik-Jan
   Dibue-Adjei, Maxine
   Steiger, Hans-Jakob
   Slotty, Philipp J.
   Rapp, Marion
   Cornelius, Jan-Frederick
   Sabel, Michael
TI Is the Intensity of 5-Aminolevulinic Acid-Derived Fluorescence Related
   to the Light Source?
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-ALA; 5-Aminolevulinic acid; Fluorescence; Glioma; Light source;
   Metastasis; Quantification
ID GUIDED SURGERY; RESECTION; MENINGIOMAS; GLIOMA; IMPACT
AB OBJECTIVE: With the introduction of the 5-aminolevulimic acid (5-ALA) technique, surgical neuro-oncology has made a major advance. 5-ALA fluorescence-guided resection of malignant glioma results in more complete surgical resections and subsequently prolonged survival. However, it remains uncertain how light intensities of the blue light source and 5-ALA-derived fluorescence intensities of the illuminated tissue are connected. The aim of the present study was to compare light intensities of different blue light sources and protoporphyrin (PpIX) fluorescence intensities of PpIX solutions with defined concentrations after illumination with different light sources.
   MATERIAL AND METHODS: The light spectrum of 7 different blue light sources and the fluorescence intensity of 2 PpIX solutions (0.15 mu g/mL and 5 mu g/mL) were quantified after illumination. We compared the Zeiss OPMI Pentero microscope, the Zeiss OPMI Pentero 900 microscope, the Leica M530 OH6 microscope, an endoscope equipped with the 5-ALA technique, a mini-spectrometer equipped with a mufti-channel light-emitting diode (LED) source emitting monochromatic light, a modified commercially available LED head lamp, and a commercially available unmodified UV-LED lamp. PpIX fluorescence was quantified in a standardized setup using a mini-spectrometer.
   RESULTS: Maximum light intensities of the evaluated light sources were reached at different wavelengths. All tested devices were able to detect PpIX-induced fluorescence. However, the intensity of PpIX fluorescence of the differently concentrated PpIX solutions (0.15 mu g/mL and 5 mu g/mL) was significantly dependent on the light source used.
   CONCLUSIONS: Intensity of the 5-ALA-derived fluorescence is related to the light source used.
C1 [Kamp, Marcel A.; Knipps, Johannes; Neumann, Lisa Margarete; Mijderwijk, Hendrik-Jan; Dibue-Adjei, Maxine; Steiger, Hans-Jakob; Slotty, Philipp J.; Rapp, Marion; Cornelius, Jan-Frederick; Sabel, Michael] Heinrich Heine Univ, Med Fac, Dept Neurosurg, Dusseldorf, Germany.
RP Kamp, MA (reprint author), Heinrich Heine Univ, Med Fac, Dept Neurosurg, Dusseldorf, Germany.
EM MarcelAlexander.Kamp@med.uni-duesseldorf.de
OI Kamp, Marcel/0000-0002-1252-2944; Mijderwijk,
   Hendrik-Jan/0000-0002-9516-8257
CR Cornelius JF, 2017, PHOTODIAGN PHOTODYN, V17, P147, DOI 10.1016/j.pdpdt.2016.12.007
   Cornelius JF, 2014, PHOTODIAGN PHOTODYN, V11, P481, DOI 10.1016/j.pdpdt.2014.07.008
   Cornelius JF, 2013, J NEUROL SURG PART B, V74, P211, DOI 10.1055/s-0033-1342918
   Evers G, 2017, WORLD NEUROSURG, V98, P375, DOI 10.1016/j.wneu.2016.11.011
   Ewelt C, 2015, J PHOTOCH PHOTOBIO B, V148, P302, DOI 10.1016/j.jphotobiol.2015.05.002
   Kamp MA, 2018, NEUROSURG REV, V41, P3, DOI 10.1007/s10143-016-0745-4
   Kamp MA, 2016, ONCOTARGET, V7, P66776, DOI 10.18632/oncotarget.11488
   Kamp MA, 2012, ACTA NEUROCHIR, V154, P223, DOI 10.1007/s00701-011-1200-5
   Knipps J, 2017, WORLD NEUROSURG, V108, P118, DOI 10.1016/j.wneu.2017.08.140
   Marbacher S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.12.FOCUS13464
   Millesi M, 2016, J NEUROSURG, V125, P1408, DOI 10.3171/2015.12.JNS151513
   Rapp M, 2014, WORLD NEUROSURG, V82, pE277, DOI 10.1016/j.wneu.2013.07.002
   Slotty PJ, 2013, ACTA NEUROCHIR, V155, P959, DOI 10.1007/s00701-013-1693-1
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 1998, J PHOTOCH PHOTOBIO B, V45, P160, DOI 10.1016/S1011-1344(98)00176-6
   Stummer W, 2000, J NEUROSURG, V93, P1003, DOI 10.3171/jns.2000.93.6.1003
   Stummer W, 2014, NEUROSURGERY, V74, P310, DOI 10.1227/NEU.0000000000000267
   Stummer W, 2009, CURR OPIN NEUROL, V22, P645, DOI 10.1097/WCO.0b013e3283320165
   Valdes PA, 2014, OPER NEUROSURG, V10, P74, DOI 10.1227/NEU.0000000000000117
   Valdes PA, 2011, J NEUROSURG, V115, P11, DOI 10.3171/2011.2.JNS101451
   Valdes PA, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3646916
   Yamamoto T, 2015, PHOTOCHEM PHOTOBIOL, V91, P1452, DOI 10.1111/php.12510
NR 22
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E271
EP E276
DI 10.1016/j.wneu.2019.07.136
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300032
PM 31351208
DA 2020-05-12
ER

PT J
AU Katzir, M
   Lefkowitz, JJ
   Ben-Reuven, D
   Fuchs, SJ
   Hussein, K
   Sviri, GE
AF Katzir, Miki
   Lefkowitz, Jason J.
   Ben-Reuven, Daniel
   Fuchs, Steven J.
   Hussein, Khetam
   Sviri, Gill E.
TI Decreasing External Ventricular Drain-Related Infection Rates with
   Duration-Independent, Clinically Indicated Criteria for Drain Revision:
   A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acinetobacter baumannii; Cerebrospinal fluid; EVD; External ventricular
   drain; Meningitis; Ventriculitis; Ventriculostomy-related infection
ID INTRACRANIAL-PRESSURE MONITORS; RISK-FACTORS; COMPLICATIONS; MENINGITIS;
   EXCHANGE
AB OBJECTIVE: To lower external ventricular drain (EVD)-related infection rates, in April 2013, our institution enacted a major protocol change, switching from routine EVD replacement every 5 days to EVD replacement only when clinically indicated. In the present study, we evaluated the effect of this change on nosocomial EVD-related infections.
   METHODS: We performed a retrospective cohort study to compare the EVD-related infection rates between 2 groups (group A, elective EVD replacement; group B, clinically indicated EVD replacement). We analyzed the data from 142 patients (group A, n = 43; group B, n = 99), with a total of 227 EVDs for 5 years and 3 months (1721 catheter days).
   RESULTS: The overall EVD-related infection rates were elevated in group A (0.14; 32% of patients) compared with group B (0.08; 8%; P = 0.001). The median hospital stay (33 vs. 24 days; P = 0.001) and neurosurgical intensive care unit stay (30.5 vs. 17 days; P < 0.0001) were also longer for group A. The requirement for multiple EVDs was an independent risk factor (P = 0.003), with a 4.6 times greater risk in group A (odds ratio, 4.64; 95% confidence interval, 1.7-12.6).
   CONCLUSIONS: The findings from our study strengthen an increasing body of evidence suggesting the importance of inoculation of skin flora as a critical risk factor for EVD- related infections, underscoring the importance of drain changes only when clinically indicated and that, as soon as clinically permitted, catheters should be removed.
C1 [Katzir, Miki; Sviri, Gill E.] Rambam Maimonides Hlth Care Campus, Dept Neurosurg, Haifa, Israel.
   [Hussein, Khetam] Rambam Maimonides Hlth Care Campus, Infect Dis Inst, Haifa, Israel.
   [Lefkowitz, Jason J.; Ben-Reuven, Daniel; Fuchs, Steven J.] Technion Israel Inst Technol, Technion Amer Med Sch, Bruce & Ruth Rappaport Fac Med, Haifa, Israel.
   [Katzir, Miki] Univ Washington, Dept Neurol Surg, Harborview Med Ctr, Seattle, WA 98195 USA.
RP Sviri, GE (reprint author), Rambam Maimonides Hlth Care Campus, Dept Neurosurg, Haifa, Israel.
EM g_sviri@rambam.health.gov.il
OI Katzir MD, Miki/0000-0002-7503-557X
CR Alleyne CH, 2000, NEUROSURGERY, V47, P1124, DOI 10.1097/00006123-200011000-00020
   AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4
   BADER MK, 1995, HEART LUNG, V24, P166, DOI 10.1016/S0147-9563(05)80012-3
   BOGDAHN U, 1992, NEUROSURGERY, V31, P898, DOI 10.1227/00006123-199211000-00011
   Bookland MJ, 2014, J NEUROSURG, V121, P189, DOI 10.3171/2013.12.JNS13700
   BUCKWOLD FJ, 1977, J NEUROSURG, V46, P494, DOI 10.3171/jns.1977.46.4.0494
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Centers for Disease Control and Prevention, CDC NHSN SURV DEF SP
   CLARK WC, 1989, NEUROSURGERY, V25, P20
   Cui ZW, 2015, AM J INFECT CONTROL, V43, pE23, DOI 10.1016/j.ajic.2015.03.015
   FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662
   Guyot LL, 1998, ACT NEUR S, V71, P47
   Hagel S, 2014, Interdiscip Perspect Infect Dis, V2014, P708531, DOI 10.1155/2014/708531
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419
   Hussein K, 2019, ACTA NEUROCHIR, V161, P517, DOI 10.1007/s00701-019-03801-y
   KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012
   Khan SH, 1998, ACT NEUR S, V71, P50
   KHANNA RK, 1995, J NEUROSURG, V83, P791, DOI 10.3171/jns.1995.83.5.0791
   KIM DK, 1995, J NEUROL NEUROSUR PS, V58, P444, DOI 10.1136/jnnp.58.4.444
   Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378
   Luerssen TG, 1993, INTRACRANIAL PRESSUR
   LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1
   Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492
   MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903
   Neuberger A, 2016, CLIN MICROBIOL INFEC, V22, pe1
   Omar MA, 2010, MALAYS J MED SCI, V17, P48
   Paramore CG, 1984, ACTA NEUROCHIR WIEN, V127, P79
   Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929
   Poon WS, 1998, ACT NEUR S, V71, P146
   Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381
   Rossi S, 1998, ACT NEUR S, V71, P91
   Shofty B, 2016, CLIN MICROBIOL INFEC, V22, P66, DOI 10.1016/j.cmi.2015.09.023
   Stevens EA, 2010, J NEUROSURG, V113, P86, DOI 10.3171/2009.10.JNS09565
   Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603
   VOLDBY B, 1982, J NEUROSURG, V56, P186, DOI 10.3171/jns.1982.56.2.0186
   WINFIELD JA, 1993, NEUROSURGERY, V33, P424
   Wong GKC, 2002, J NEUROL NEUROSUR PS, V73, P759, DOI 10.1136/jnnp.73.6.759
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E474
EP E481
DI 10.1016/j.wneu.2019.07.205
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300058
PM 31382072
DA 2020-05-12
ER

PT J
AU Kawabata, S
   Imamura, H
   Tani, S
   Adachi, H
   Tokunaga, S
   Funatsu, T
   Suzuki, K
   Adachi, H
   Sasaki, N
   Matsui, Y
   Akiyama, R
   Horiuchi, K
   Sakai, C
   Sakai, N
AF Kawabata, Shuhei
   Imamura, Hirotoshi
   Tani, Shoichi
   Adachi, Hidemitsu
   Tokunaga, So
   Funatsu, Takayuki
   Suzuki, Keita
   Adachi, Hiromasa
   Sasaki, Natsuhi
   Matsui, Yuichi
   Akiyama, Ryo
   Horiuchi, Kazufumi
   Sakai, Chiaki
   Sakai, Nobuyuki
TI Effect of Direct Neurologic Evaluation on Outcomes During Treatment of
   Unruptured Intracranial Aneurysms Under Local Anesthesia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anesthesia; Aneurysm; Coil embolization; Complication
ID ENDOVASCULAR TREATMENT; CONSCIOUS SEDATION; PERIPROCEDURAL
   COMPLICATIONS; COIL EMBOLIZATION; ASSISTED COILING; SAFETY; FEASIBILITY;
   BALLOON
AB OBJECTIVE: The greatest advantage of local anesthesia (LA) in endovascular treatment (EVT) of unruptured intracranial aneurysms (UIAs) is that direct neurologic evaluation can be performed during the procedure, unlike with general anesthesia. However, the usefulness of such direct evaluation has not been established. In this study, we attempted to assess the effects of direct neurologic evaluation by identifying the causes, management, and outcomes of clinical symptoms during the procedure and procedure-related events during EVT under LA.
   METHODS: We retrospectively evaluated the medical and radiologic data of 1000 patients (1015 UIAs) who had undergone coil embolization under LA from 2008 to 2016.
   RESULTS: Clinical symptoms were identified in 62 patients (6.2%) during the procedure. The symptoms improved during the procedure in 27 of these patients (44%) and after the procedure in another 28 (45%). One month after the procedure, 55 patients (89%) had good outcomes and 7 (11%) had poor outcomes. Procedure-related events occurred in 67 patients (6.7%); of these 67 events, 39 were symptomatic and 28 were asymptomatic. Thirty-five of the 39 symptomatic events (90%) [13 of 13 (100%) ruptures, 6 of 10 (60%) thrombus formations, and 16 of 16 (100%) thromboembolisms] were detected on the basis of clinical symptoms before angiographic changes were identified, and they were managed promptly. All 28 patients with asymptomatic events were managed safely without further complications before symptoms developed.
   CONCLUSIONS: We demo crated that appropriate management of clinical symptoms and procedure-related events under LA led to favorable outcomes of EVT of UIAs.
C1 [Kawabata, Shuhei; Imamura, Hirotoshi; Tani, Shoichi; Adachi, Hidemitsu; Tokunaga, So; Funatsu, Takayuki; Suzuki, Keita; Adachi, Hiromasa; Sasaki, Natsuhi; Matsui, Yuichi; Akiyama, Ryo; Horiuchi, Kazufumi; Sakai, Chiaki; Sakai, Nobuyuki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
RP Imamura, H (reprint author), Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
EM i-hiro@zg7.so-net.ne.jp
CR Adeeb N, 2017, STROKE, V48, P1098, DOI 10.1161/STROKEAHA.116.016521
   Fiehler J, 2009, CLIN NEURORADIOL, V19, P73, DOI 10.1007/s00062-009-8029-9
   Hassan AE, 2013, AM J NEURORADIOL, V34, P1375, DOI 10.3174/ajnr.A3385
   Kan P, 2013, NEUROSURGERY, V72, P216, DOI [10.1227/NEU.0b013e31827b9183, 10.1227/NEU.0b013e31827b93ea]
   Kawabata S, 2018, J NEUROINTERV SURG, V10, P362, DOI 10.1136/neurintsurg-2017-013156
   Kwon SC, 2014, ACTA NEUROCHIR, V156, P847, DOI 10.1007/s00701-014-2033-9
   Layton KF, 2007, AM J NEURORADIOL, V28, P1172, DOI 10.3174/ajnr.A0490
   Ogilvy CS, 2011, J NEUROSURG, V114, P120, DOI 10.3171/2010.3.JNS091384
   Park SH, 2008, J KOREAN NEUROSURG S, V43, P270, DOI 10.3340/jkns.2008.43.6.270
   Park Soo-Dong, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P215, DOI 10.7461/jcen.2016.18.3.215
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Pierot L, 2009, RADIOLOGY, V251, P846, DOI 10.1148/radiol.2513081056
   Qureshi AI, 2001, J NEUROSURG, V94, P880, DOI 10.3171/jns.2001.94.6.0880
   Rangel-Castilla L, 2015, OPER NEUROSURG, V11, P426, DOI 10.1227/NEU.0000000000000864
   Shapiro M, 2008, AM J NEURORADIOL, V29, P1777, DOI 10.3174/ajnr.A1216
   Shigematsu T, 2013, STROKE, V44, P2735, DOI 10.1161/STROKEAHA.111.000609
   Song J, 2017, WORLD NEUROSURG, V104, P694, DOI 10.1016/j.wneu.2017.05.077
   Spiotta AM, 2011, STROKE, V42, P1051, DOI 10.1161/STROKEAHA.110.602276
   Takigawa T, 2014, NEURORADIOLOGY, V56, P1079, DOI 10.1007/s00234-014-1421-4
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E593
EP E598
DI 10.1016/j.wneu.2019.08.006
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300074
PM 31404688
DA 2020-05-12
ER

PT J
AU Kearns, KN
   Chen, CJ
   Yagmurlu, K
   Capek, S
   Buell, TJ
   Taylor, DG
   Pomeraniec, IJ
   Park, MS
   Kalani, MY
AF Kearns, Kathryn N.
   Chen, Ching-Jen
   Yagmurlu, Kaan
   Capek, Stepan
   Buell, Thomas J.
   Taylor, Davis G.
   Pomeraniec, I. Jonathan
   Park, Min S.
   Kalani, M. Yashar
TI Hemorrhage Risk of Untreated Isolated Cerebral Cavernous Malformations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernoma; Cavernous malformation; Hemorrhage; Risk
ID CENTRAL-NERVOUS-SYSTEM; NATURAL-HISTORY; BRAIN-STEM; CLINICAL-COURSE;
   EXPERIENCE; MANAGEMENT; MIDBRAIN
AB OBJECTIVE: Predicting future hemorrhage risk may allow better selection of patients with cerebral cavernous malformations (CCMs) who will likely benefit from treatment. In this study, we sought to identify predictors of CCM hemorrhage, and to compare subsequent symptomatic hemorrhage risks between patients with and without previous hemorrhage.
   METHODS: We performed a retrospective review of consecutive CCM patients at our institution between 1982 and 2017. Patients with diffuse or familial CCM syndromes, and those without follow-up data were excluded. The primary endpoint was acute symptomatic hemorrhage causing transient or permanent neurological symptoms. Primary endpoint incidences were compared between patients with and without previous hemorrhage.
   RESULTS: The study cohort comprised 84 patients with 90 CCMs. Previous hemorrhage was the only significant predictor for the primary endpoint (P = 0.003). CCMs with previous hemorrhage had a higher risk of symptomatic hemorrhage in follow-up than those without previous hemorrhage (26.9 vs. 1.5 symptomatic hemorrhages per 1000 CCM-months, P < 0.001). CCMs with and without previous hemorrhage had annual hemorrhage rates of 2.7% and 0.15%, respectively. Symptomatic hemorrhage-free survival rates were significantly lower in CCMs with previous hemorrhage (log-rank test, P < 0.001). Actuarial hemorrhage-free survival rates for CCMs with previous hemorrhage were 75%, 60%, 60%, and 60% at 1, 2, 3, and 4 years, respectively, compared with rates of 95%, 95%, 95%, and 84% for CCMs without previous hemorrhage.
   CONCLUSIONS: Previous hemorrhage is a predictor of subsequent symptomatic hemorrhage in CCMs. Compared with CCMs without previous hemorrhage, those with prior hemorrhage have a significantly higher risk of future symptomatic hemorrhage.
C1 [Kearns, Kathryn N.; Chen, Ching-Jen; Yagmurlu, Kaan; Capek, Stepan; Buell, Thomas J.; Taylor, Davis G.; Pomeraniec, I. Jonathan; Park, Min S.; Kalani, M. Yashar] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.
RP Kalani, MY (reprint author), Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.
EM YK6Z@hscmail.mcc.virginia.edu
RI Chen, Ching-Jen/F-5976-2013
OI Chen, Ching-Jen/0000-0002-7830-9273
CR Abdulrauf SI, 1999, NEUROSURGERY, V44, P41, DOI 10.1097/00006123-199901000-00020
   Acciarri N, 2009, PEDIATR NEUROSURG, V45, P81, DOI 10.1159/000209283
   Al-Shahi SR, 2012, LANCET NEUROL, V11, P217, DOI DOI 10.1016/S1474-4422(12)70004-2
   ALVAREZSABIN J, 1991, J NEUROL NEUROSUR PS, V54, P843, DOI 10.1136/jnnp.54.9.843
   Awad Issam, 2006, Neurosurg Focus, V21, pe7
   Batra S, 2009, NAT REV NEUROL, V5, P659, DOI 10.1038/nrneurol.2009.177
   Cantu C, 2005, NEUROL RES, V27, P314, DOI 10.1179/016164105X39914
   DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702
   Flemming KD, 2012, NEUROLOGY, V78, P632, DOI 10.1212/WNL.0b013e318248de9b
   Flemming KD, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0931-1
   Flemming KD, 2015, J CLIN NEUROSCI, V22, P969, DOI 10.1016/j.jocn.2015.01.007
   FRITSCHI JA, 1994, ACTA NEUROCHIR, V130, P35, DOI 10.1007/BF01405501
   GIOMBINI S, 1978, ACTA NEUROCHIR, V40, P61, DOI 10.1007/BF01773116
   Goldberg J, 2019, J NEUROSURG, V130, P1931, DOI 10.3171/2017.12.JNS172404
   Gross BA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1165
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Labauge P, 2001, NEUROLOGY, V57, P1825, DOI 10.1212/WNL.57.10.1825
   MARAIRE JN, 1995, NEUROSURGERY, V37, P591, DOI 10.1227/00006123-199510000-00001
   MCCORMICK WF, 1984, INTRACRANIAL ARTERIO, P44
   Moriarity JL, 1999, NEUROSURG CLIN N AM, V10, P411, DOI 10.1016/S1042-3680(18)30175-X
   Nakase K, 2017, NEUROSURGERY, V80, pE257, DOI 10.1093/neuros/nyx065
   Negoto T, 2017, CEREBROVASC DIS
   Nikoubashman O, 2015, AM J NEURORADIOL, V36, P2177, DOI 10.3174/ajnr.A4427
   OTTEN P, 1989, NEUROCHIRURGIE, V35, P82
   de la Pena PPG, 2013, SEMIN ULTRASOUND CT, V34, P113, DOI 10.1053/j.sult.2013.01.002
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050
   Ren YM, 2017, WORLD NEUROSURG, V107, P753, DOI 10.1016/j.wneu.2017.08.117
   RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605
   Robinson J, 1998, SURG CRANIOVERTEBRAL
   ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709
   Sawarkar DP, 2017, CHILD NERV SYST, V33, P1525, DOI 10.1007/s00381-017-3429-7
   Tian KB, 2017, J NEUROSURG, V127, P480, DOI 10.3171/2016.8.JNS16934
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
   Xie MG, 2018, WORLD NEUROSURG, V110, P55, DOI 10.1016/j.wneu.2017.10.121
   Zabramski J, 2003, TXB NEUROLOGICAL SUR
   ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422
   Zabramski JM, 2011, YOUMANS NEUROLOGICAL, P4114
   Zaidi HA, 2017, NEUROSURGERY, V81, P620, DOI 10.1093/neuros/nyw139
NR 40
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E557
EP E561
DI 10.1016/j.wneu.2019.07.222
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300069
PM 31400525
DA 2020-05-12
ER

PT J
AU Knio, ZO
   Schallmo, MS
   Hsu, W
   Corona, BT
   Lackey, JT
   Marquez-Lara, A
   Luo, TD
   Medda, S
   Wham, BC
   O'Gara, TJ
AF Knio, Ziyad O.
   Schallmo, Michael S.
   Hsu, Wesley
   Corona, Benjamin T.
   Lackey, Justin T.
   Marquez-Lara, Alejandro
   Luo, Tianyi D.
   Medda, Suman
   Wham, Bradley C.
   O'Gara, Tadhg J.
TI Unilateral Laminotomy with Bilateral Decompression: A Case Series
   Studying One- and Two-Year Outcomes with Predictors of Minimal Clinical
   Improvement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar nerve decompression; Lumbar spinal stenosis; Minimally invasive
   surgery; Spinal decompression; Tubular decompression; ULBD
ID LUMBAR SPINAL STENOSIS; PARASPINAL MUSCLES; SMOKING-CESSATION; LOCAL
   DENERVATION; SURGERY; LAMINECTOMY; COMPLICATIONS; MANAGEMENT; ATROPHY;
   FUSION
AB OBJECTIVE: To assess factors that may predict failure to improve at 12 and 24 months after unilateral laminotomy with bilateral decompression (ULBD) for the management of lumbar spinal stenosis.
   METHODS: A database of 255 patients who underwent microdecompression surgery by a single orthopedic spine surgeon between 2014 and 2018 was queried. Patients who underwent primary single-level ULBD of the lumbar spine were included. Visual analog scale (VAS) for back pain and leg pain and Oswestry Disability Index (ODI) results were collected preoperatively and at 12 and 24 months post-operatively. Demographic, radiographic, and operative factors were assessed for associations with failure to improve. Clinically important improvement was defined as reaching or surpassing the previously established minimum clinically important difference for ODI (12.8) and not requiring revision.
   RESULTS: A total of 68 patients were included. Compared with preoperative values for back pain, leg pain, and ODI (7.32, 7.53, and 51.22, respectively), there were significant improvements on follow-up at 12 months (2.89, 2.23, and 22.40, respectively; P< 0.001) and 24 months (2.80, 2.11, 20.32, respectively; P < 0.001). Based on the defined criteria, 50 patients showed clinically important improvement after ULBD. Of the 18 patients who failed to improve, 12 required revision. Independent predictors of failure to improve included female sex (adjusted odds ratio, 5.06; 95% confidence interval, 1.49-21.12; P = 0.014) and current smoker status (adjusted odds ratio, 5.39; 95% confidence interval, 1.39-23.97; P = 0.018).
   CONCLUSIONS: ULBD for the management of lumbar spinal stenosis leads to clinically important improvement that is maintained over a 24-month follow-up period. Female sex and tobacco smoking are associated with poorer outcomes.
C1 [Knio, Ziyad O.; Schallmo, Michael S.; Hsu, Wesley; Corona, Benjamin T.; Lackey, Justin T.; Marquez-Lara, Alejandro; Luo, Tianyi D.; Medda, Suman; Wham, Bradley C.; O'Gara, Tadhg J.] Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC 27101 USA.
   [Hsu, Wesley; O'Gara, Tadhg J.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
RP O'Gara, TJ (reprint author), Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC 27101 USA.; O'Gara, TJ (reprint author), Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
EM togara@wakehealth.edu
OI Knio, Ziyad/0000-0001-5696-873X
CR Alimi M, 2014, OPER NEUROSURG, V10, P436, DOI 10.1227/NEU.0000000000000358
   Alimi M, 2015, J NEUROSURG-SPINE, V22, P339, DOI 10.3171/2014.11.SPINE13597
   Amundsen T, 2000, SPINE, V25, P1424, DOI 10.1097/00007632-200006010-00016
   Anderson DG, 2011, SPINE, V36, pE320, DOI 10.1097/BRS.0b013e3181db1dfb
   Atlas SJ, 2005, SPINE, V30, P936, DOI 10.1097/01.brs.0000158953.57966.c0
   Bresnahan LE, 2017, CLIN SPINE SURG, V30, pE162, DOI 10.1097/BSD.0000000000000038
   Ciol MA, 1996, J AM GERIATR SOC, V44, P285, DOI 10.1111/j.1532-5415.1996.tb00915.x
   Copay AG, 2008, SPINE J, V8, P968, DOI 10.1016/j.spinee.2007.11.006
   Costa F, 2007, J NEUROSURG-SPINE, V7, P579, DOI 10.3171/SPI-07/12/579
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Dohzono S, 2013, J NEUROSURG-SPINE, V18, P472, DOI 10.3171/2013.2.SPINE12633
   Du Bois M, 2012, EUR SPINE J, V21, P2693, DOI 10.1007/s00586-012-2381-1
   Elsamadicy AA, 2017, WORLD NEUROSURG, V107, P952, DOI 10.1016/j.wneu.2017.07.082
   Englund Jon, 2007, Curr Sports Med Rep, V6, P50, DOI 10.1007/s11932-007-0012-0
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Giannadakis C, 2015, WORLD NEUROSURG, V84, P1227, DOI 10.1016/j.wneu.2015.06.020
   Glassman SD, 2000, SPINE, V25, P2608, DOI 10.1097/00007632-200010150-00011
   Heo DH, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.2.FOCUS197
   Iguchi T, 2000, SPINE, V25, P1754, DOI 10.1097/00007632-200007150-00003
   Jackson KL, 2016, GLOB SPINE J, V6, P695, DOI 10.1055/s-0036-1571285
   Jansson KA, 2003, EUR SPINE J, V12, P535, DOI 10.1007/s00586-003-0544-9
   Kim DY, 2005, SPINE, V30, P123, DOI 10.1097/01.brs.0000148999.21492.53
   Kim S, 2012, SPINE J, V12, P44, DOI 10.1016/j.spinee.2011.10.004
   Kleeman TJ, 2000, SPINE, V25, P865, DOI 10.1097/00007632-200004010-00016
   Kovacs FM, 2011, SPINE, V36, pE1335, DOI 10.1097/BRS.0b013e31820c97b1
   Machado GC, 2016, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858
   Macnab I, 1977, SPINE, V69, P109
   Malmivaara A, 2007, SPINE, V32, P1, DOI 10.1097/01.brs.0000251014.81875.6d
   Matsumura A, 2010, J NEUROSURG-SPINE, V13, P758, DOI 10.3171/2010.5.SPINE091001
   McCulloch J. A., 1998, ESSENTIALS SPINAL MI, P453
   Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420
   Musluman AM, 2012, J NEUROSURG-SPINE, V16, P68, DOI 10.3171/2011.7.SPINE11222
   Nerland US, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1603
   Overdevest GM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010036.pub2
   Palmer Sylvain, 2012, Surg Neurol Int, V3, P41, DOI 10.4103/2152-7806.94294
   Pao JL, 2014, J SPINAL DISORD TECH, V27, pE318, DOI 10.1097/BSD.0000000000000126
   Pao JL, 2009, EUR SPINE J, V18, P672, DOI 10.1007/s00586-009-0903-2
   Papavero L, 2009, NEUROSURGERY, V65, P182, DOI 10.1227/01.NEU.0000341906.65696.08
   Parikh K, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E14
   Phan K, 2017, ORTHOP SURG, V9, P241, DOI 10.1111/os.12335
   Pochon L, 2016, EUR SPINE J, V25, P235, DOI 10.1007/s00586-015-4062-3
   POLETTI CE, 1995, NEUROSURGERY, V37, P343, DOI 10.1227/00006123-199508000-00025
   Porter S E, 2001, J Am Acad Orthop Surg, V9, P9
   Sasai K, 2008, J NEUROSURG-SPINE, V9, P554, DOI 10.3171/SPI.2008.8.08122
   Schmitz MA, 1999, CLIN ORTHOP RELAT R, P184, DOI 10.1097/00003086-199908000-00024
   Scholler K, 2016, ACTA NEUROCHIR, V158, P1103, DOI 10.1007/s00701-016-2804-6
   SIHVONEN T, 1993, SPINE, V18, P575, DOI 10.1097/00007632-199304000-00009
   Sloan A, 2010, SURG-J R COLL SURG E, V8, P111, DOI 10.1016/j.surge.2009.10.014
   Spetzger U, 1997, ACTA NEUROCHIR, V139, P392, DOI 10.1007/BF01808872
   Storzer B, 2016, EUR SPINE J, V25, pS270, DOI 10.1007/s00586-016-4479-3
   Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136
   WILLIAMS RW, 1991, MT SINAI J MED, V58, P139
   Zoidl G, 2003, CLIN NEUROPATHOL, V22, P71
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E290
EP E297
DI 10.1016/j.wneu.2019.07.144
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300035
PM 31356984
DA 2020-05-12
ER

PT J
AU Kolakshyapati, M
   Hashizume, A
   Ochi, K
   Ueno, H
   Kaichi, Y
   Takayasu, T
   Takano, M
   Karlowee, V
   Akiyama, Y
   Awai, K
   Maruyama, H
   Sugiyama, K
   Kurisu, K
   Yamasaki, F
AF Kolakshyapati, Manish
   Hashizume, Akira
   Ochi, Kazuhide
   Ueno, Hiroki
   Kaichi, Yoko
   Takayasu, Takeshi
   Takano, Motoki
   Karlowee, Vega
   Akiyama, Yuji
   Awai, Kazuo
   Maruyama, Hirofumi
   Sugiyama, Kazuhiko
   Kurisu, Kaoru
   Yamasaki, Fumiyuki
TI Usefulness of Histogram-Profile Analysis in Ring-Enhancing Intracranial
   Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Differentiation; Histogram-profile analysis; Ring-enhancement;
   T2-hypointensity
ID APPEARING WHITE-MATTER; MULTIPLE-SCLEROSIS; GRAY-MATTER; LOW SIGNAL;
   DIFFUSION; GLIOMA; TUMOR; DIFFERENTIATION; GLIOBLASTOMA; MAPS
AB BACKGROUND: Several intracranial pathologies present as a ring-enhancing lesion on conventional magnetic resonance imaging (MRI), creating diagnostic difficulty. We studied the characteristics of the anatomical border of gadolinium enhancement on T1-weighted imaging (WI) and hypointensity on T2WI to employ a simple technique of histogram-profile analysis of MRI for differentiation of various ring-enhancing intracranial lesions.
   METHODS: After approval from the institutional review board, preoperative MRI (T2WI, postcontrast T1WI) scans were analyzed retrospectively in 18 patients with histologically confirmed brain abscess, 66 glioblastomas, 46 brain-metastases, and 16 tumefactive multiple sclerosis (MS). T2WI and postcontrast T1WI were overlapped, and histogram-profile analysis was performed with in-house image-fusion software. The pattern of differential-peaks in histogram-profile was assessed visually. Kaplan-Meier survival analysis incorporating histogram-profile patterns was performed in patients with glioblastoma.
   RESULTS: The histogram-profile study revealed 4 distinct patterns. Pattern 1 showed no differential T2-hypointensity trough, pattern 2 had T2-hypointensity trough inside, whereas pattern 3 had T2-hypointensity trough overlapping the enhanced margin. Pattern 4 had T2-hypointensity trough immediately external to the enhanced margin. Pattern 1 was specific for tumefactive MS (93.3%), whereas pattern 4 was specific for glioblastoma (40.7%). Pattern 4 glioblastoma was subdivided into rim (T2-hypointensity .50% of circumference of contrast-enhanced tumor) and arc (T2-hypointensity <50% of circumference of contrast-enhanced tumor). Pattern 4 glioblastoma was further subdivided into group A (edema: T2-hyperintensity 513 degrees/0 of circumference of contrast-enhanced tumor) and group B (less edema: T2-hyperintensity <50% of circumference of contrast-enhanced tumor). Patients with pattern 3 glioblastoma (37.6%) had better survival compared with others (P = 0.0341) and pattern 4B had decreased survival compared with pattern 4A (P = 0.0001) and others (P = 0.0003).
   CONCLUSIONS: Tumefactive MS and a subset of glioblastomas show specific patterns in histogram-profile analysis. The difference in anatomical border also determines difference in survival in glioblastoma. Histogram-profile analysis is a simple and efficient technique to differentiate these pathologies.
C1 [Kolakshyapati, Manish; Hashizume, Akira; Takayasu, Takeshi; Takano, Motoki; Karlowee, Vega; Kurisu, Kaoru; Yamasaki, Fumiyuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
   [Ochi, Kazuhide; Ueno, Hiroki; Maruyama, Hirofumi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Clin Neurosci & Therapeut, Hiroshima, Japan.
   [Kaichi, Yoko; Awai, Kazuo] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Diagnost Radiol, Hiroshima, Japan.
   [Akiyama, Yuji] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Clin Radiol, Hiroshima, Japan.
   [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan.
   [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan.
RP Yamasaki, F (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM fyama@hiroshima-u.ac.jp
RI Maruyama, Hirofumi/B-9333-2011
OI Maruyama, Hirofumi/0000-0001-7613-8717
CR Armao D, 2000, AM J NEURORADIOL, V21, P1470
   BRITT RH, 1981, J NEUROSURG, V55, P590, DOI 10.3171/jns.1981.55.4.0590
   Emblem KE, 2008, AM J NEURORADIOL, V29, P1664, DOI 10.3174/ajnr.A1182
   Emblem KE, 2008, RADIOLOGY, V247, P808, DOI 10.1148/radiol.2473070571
   Ge YL, 2003, AM J NEURORADIOL, V24, P1935
   Ge YL, 2002, J COMPUT ASSIST TOMO, V26, P62, DOI 10.1097/00004728-200201000-00009
   Ge YL, 2001, AM J NEURORADIOL, V22, P470
   Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4
   HAIMES AB, 1989, AM J ROENTGENOL, V152, P1073, DOI 10.2214/ajr.152.5.1073
   He J, 2001, AM J NEURORADIOL, V22, P664
   Kang Y, 2011, RADIOLOGY, V261, P882, DOI 10.1148/radiol.11110686
   Karlowee V, 2019, PATHOBIOLOGY, V86, P152, DOI 10.1159/000496691
   Kolakshyapati M, 2018, J NEUROSURG, V128, P667, DOI 10.3171/2016.10.JNS161694
   Law M, 2007, AM J NEURORADIOL, V28, P761
   Louis DN, 2016, WHO CLASSIFICATION C
   Ma JH, 2010, AM J NEURORADIOL, V31, P235
   Pavlisa G, 2009, CLIN IMAG, V33, P96, DOI 10.1016/j.clinimag.2008.06.035
   Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Pope WB, 2009, RADIOLOGY, V252, P182, DOI 10.1148/radiol.2521081534
   Price SJ, 2006, AM J NEURORADIOL, V27, P1969
   Schwartz KM, 2006, NEURORADIOLOGY, V48, P143, DOI 10.1007/s00234-005-0024-5
   Toh CH, 2012, AM J NEURORADIOL, V33, P1534, DOI 10.3174/ajnr.A2986
   Tsuchiya K, 2005, BRIT J RADIOL, V78, P533, DOI 10.1259/bjr/68749637
   Warakaulle DR, 2003, CLIN RADIOL, V58, P922, DOI 10.1016/S0009-9260(03)00268-X
   WATANABE M, 1992, NEURORADIOLOGY, V34, P463, DOI 10.1007/BF00598951
   Yamasaki F, 2010, EUR J RADIOL, V73, P532, DOI 10.1016/j.ejrad.2009.01.013
   Young RJ, 2006, J MAGN RESON IMAGING, V24, P709, DOI 10.1002/jmri.20704
   Zhou LQ, 2004, AM J NEURORADIOL, V25, P1234
   Zimny A, 2015, POL J RADIOL, V80, P40, DOI 10.12659/PJR.892146
   Zimny A, 2011, J NEURO-ONCOL, V103, P777, DOI 10.1007/s11060-010-0445-9
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E226
EP E236
DI 10.1016/j.wneu.2019.07.123
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300027
PM 31349079
DA 2020-05-12
ER

PT J
AU Li, ML
   Luan, L
   Liu, Q
   Liu, Y
   Lan, XQ
   Li, ZZ
   Liu, W
AF Li, Maolei
   Luan, Lei
   Liu, Qing
   Liu, Yang
   Lan, Xiaoquan
   Li, Zuozhen
   Liu, Wei
TI MiRNA-199a-5p Protects Against Cerebral Ischemic Injury by
   Down-Regulating DDR1 in Rats
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral ischemic injury; DDR1; miR-199a-5p; Neuronal apoptosis;
   Neuronal damage; Proinflammatory cytokines
ID DOMAIN RECEPTOR 1; ISCHEMIA/REPERFUSION INJURY; INFLAMMATORY CYTOKINES;
   COLLAGEN RECEPTOR; OXIDATIVE STRESS; CELL-SURVIVAL; FIBROSIS;
   ATTENUATION; INHIBITION; MICRORNAS
AB OBJECTIVE: To assess the effects of miR-199a-5p on cerebral ischemic injury and its underlying mechanisms.
   METHODS: Infarct volume, neurologic deficit scores, and brain water content were evaluated after 24 hours of reperfusion. The histopathological damage in cortical neurons was assayed by hematoxylin and eosin staining. Neuronal apoptosis was evaluated by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. The regulatory effect of miR-199a-5p on discoidin domain receptor 1 (DDR1) was investigated using a dual luciferase reporter gene assay. Expression levels of miR-199a-5p and DDR1 were detected by real-time fluorogenic polymerase chain reaction and Western blot analysis. Expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-beta and IL-6 were investigated by enzyme-linked immunosorbent assay.
   RESULTS: Our results suggest that DDR1 is the target gene of miR-199a-5p. The expression levels of miR-199a-5p and DDR1 were significantly down-regulated and upregulated in the rats with cerebral ischemia compared with the control and sham groups, respectively. Moreover, infarct volume, neurologic score, brain water content, neuronal damage, and neuronal apoptosis were significantly decreased in the mimics group, siRNA DDR1 siDDR1) group, and especially the mimics + siDDR1 group. The results also confirmed significantly weakened expression levels of proinflammatory cytokines (TNF-alpha, IL-6, and IL-1 beta) in mimics, siDDR1, and especially mimics + siDDR1 rats. In addition, DDR1 silencing attenuated the effects of the miR-199a-5p inhibitor on neurologic function, infarct volume, brain water content, and proinflammatory cytokine expressions after middle cerebral artery occlusion in rats.
   CONCLUSIONS: miR-199a-5p may protect against cerebral ischemic injury by down-regulating DDR1 in rats.
C1 [Li, Maolei; Luan, Lei; Liu, Yang] Qingdao Chengyang Dist Peoples Hosp, Dept Neurosurg, Qingdao, Shandong, Peoples R China.
   [Liu, Qing] Qingdao Chengyang Dist Peoples Hosp, Hemodialysis Unit, Qingdao, Shandong, Peoples R China.
   [Lan, Xiaoquan] Qingdao Chengyang Dist Peoples Hosp, 3D Printing Ctr, Qingdao, Shandong, Peoples R China.
   [Li, Zuozhen] Qingdao Chengyang Dist Peoples Hosp, Clin Lab, Qingdao, Shandong, Peoples R China.
   [Liu, Wei] Qingdao Univ, Affiliated Hosp, Dept Neurosurg, Qingdao, Shandong, Peoples R China.
RP Liu, W (reprint author), Qingdao Univ, Affiliated Hosp, Dept Neurosurg, Qingdao, Shandong, Peoples R China.
EM liuwei201998@163.com
FU Qingdao Science and Technology Bureau project "Clinical Study on
   Endoscopic Treatment of Cerebral Hemorrhage Through a Superior Frontal
   Sulcus Approach" [2016-WJZD123]
FX This research was supported by the Qingdao Science and Technology Bureau
   project "Clinical Study on Endoscopic Treatment of Cerebral Hemorrhage
   Through a Superior Frontal Sulcus Approach" (2016-WJZD123).
CR Anwar MA, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00098
   Bao N, 2018, CELL MOL NEUROBIOL, V38, P1293, DOI 10.1007/s10571-018-0597-2
   BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472
   Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Dorison A, 2017, NEPHRON, V137, P212, DOI 10.1159/000479119
   Guerrot D, 2011, AM J PATHOL, V179, P83, DOI 10.1016/j.ajpath.2011.03.023
   Henriksson KM, 2012, INT J STROKE, V7, P276, DOI 10.1111/j.1747-4949.2011.00706.x
   Jiang Y, 2015, J NEUROCHEM, V134, P173, DOI 10.1111/jnc.13097
   Kong LL, 2014, NEUROCHEM INT, V76, P91, DOI 10.1016/j.neuint.2014.07.004
   Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037
   Lakhan SE, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00202
   Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li SJ, 2012, MOLECULES, V17, P13403, DOI 10.3390/molecules171113403
   Liang Y, 2018, CELL PHYSIOL BIOCHEM, V45, P1818, DOI 10.1159/000487873
   Ma J., 2017, PLOS ONE, V12
   Ma MJ, 2013, BRAIN RES, V1519, P87, DOI 10.1016/j.brainres.2013.04.040
   Ma YK, 2014, J PHARMACOL SCI, V125, P320, DOI 10.1254/jphs.14102FP
   Mata R, 2016, ONCOTARGET, V7, P7683, DOI 10.18632/oncotarget.6524
   Minami M, 2006, J PHARMACOL SCI, V100, P461, DOI 10.1254/jphs.CRJ06005X
   Mukhopadhyay P, 2012, FREE RADICAL BIO MED, V53, P1123, DOI 10.1016/j.freeradbiomed.2012.05.036
   Okuno S, 2001, NEUROL RES, V23, P657, DOI 10.1179/016164101101198983
   Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573
   Ram R, 2006, J NEURO-ONCOL, V76, P239, DOI 10.1007/s11060-005-6874-1
   Sarady-Andrews JK, 2005, AM J PHYSIOL-LUNG C, V289, pL1131, DOI 10.1152/ajplung.00458.2004
   Shen QL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-227
   Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895
   Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078-0432.CCR-11-1686
   Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001
   Wang Y, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20177319, 10.1590/1414-431x20177319]
   Weng HC, 2011, BIOMED RES-TOKYO, V32, P135, DOI 10.2220/biomedres.32.135
   Yao Y, 2014, INT J MOL SCI, V15, P20913, DOI 10.3390/ijms151120913
   Yu D, 2014, J MOL NEUROSCI, V53, P242, DOI 10.1007/s12031-014-0293-8
   Zhang DL, 2019, EUR REV MED PHARMACO, V23, P740, DOI 10.26355/eurrev_201901_16888
   Zhou JS, 2014, MOL MED REP, V10, P971, DOI 10.3892/mmr.2014.2245
   Zhou XQ, 2008, NEUROSCI LETT, V447, P31, DOI 10.1016/j.neulet.2008.09.064
   Zhu MX, 2015, NEUROSCI RES, V96, P14, DOI 10.1016/j.neures.2015.01.004
   Zille M, 2012, J CEREBR BLOOD F MET, V32, P213, DOI 10.1038/jcbfm.2011.150
NR 40
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E486
EP E494
DI 10.1016/j.wneu.2019.07.203
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300060
PM 31382062
DA 2020-05-12
ER

PT J
AU Li, SH
   Jiang, RF
   Zhang, J
   Su, CL
   Chen, XW
   Zhang, JX
   Jiang, JJ
   Zhu, WZ
AF Li, Shi-Hui
   Jiang, Ri-Feng
   Zhang, Ju
   Su, Chang-Liang
   Chen, Xiao-Wei
   Zhang, Jia-Xuan
   Jiang, Jing-Jing
   Zhu, Wen-Zhen
TI Application of Neurite Orientation Dispersion and Density Imaging in
   Assessing Glioma Grades and Cellular Proliferation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cellular proliferation; Glioma; Ki-67; Neurite orientation dispersion
   and density imaging
ID MULTISHELL DIFFUSION MRI; WHITE-MATTER; NODDI; DIFFERENTIATION;
   MICROSTRUCTURE; TUMORS
AB OBJECTIVE: To explore the performance of neurite orientation dispersion and density imaging (NODDI) in grading gliomas and to evaluate the cellular proliferation.
   METHODS: NODDI and diffusion-weighted imaging were performed on 79 patients with histopathologically proven gliomas. Parameter maps of intracellular volume fraction (ICVF), orientation dispersion index (0D1), and apparent diffusion coefficient (ADC) were calculated. Regions of interest were placed in the most solid part of the tumor. These metrics were normalized to the contralateral normal-appearing white matter and correlated with Ki-67 expression.
   RESULTS: ICVF and ODI increased as tumor grades increased, whereas ADC decreased with the increase of tumor grades. Significant differences in normalized ICVF and ODI were observed between low-grade gliomas and high-grade gliomas (ICVF: 0.208 +/- 0.104 vs. 0.718 +/- 0.234; ODI: 0.952 +/- 0.428 vs. 1.767 +/- 0.636, P < 0.001, respectively) and between grades II and III (ICVF: 0.208 1 0.104 vs. 0.603 1 0.253; ODI: 0.952 +/- 0.428 vs. 1.762 +/- 0.542, P < 0.001, respectively). Normalized ICVF was also significantly different between grades III and IV (0.603 +/- 0.253 vs. 0.803 +/- 0.182, P = 0.004). Ki-67 labeling index was positively correlated with normalized ICVF and ODI (r = 0. 755 and 0.572, P < 0.001, respectively), and negatively correlated with normalized ADC (r = - 0.709, P < 0.001).
   CONCLUSIONS: NODDI is a promising method in grading gliomas and predicting cellular proliferation. These results may be of great significance for the clinical diagnosis and treatment of gliomas.
C1 [Li, Shi-Hui; Zhang, Ju; Su, Chang-Liang; Chen, Xiao-Wei; Zhang, Jia-Xuan; Jiang, Jing-Jing; Zhu, Wen-Zhen] Huazhong Univ Sci & Technol, Dept Radiol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Jiang, Ri-Feng] Fujian Med Univ, Union Hosp, Dept Radiol, Fuzhou, Fujian, Peoples R China.
RP Zhu, WZ (reprint author), Huazhong Univ Sci & Technol, Dept Radiol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM zhuwenzhen8612@163.com
FU National Program of the Ministry of Science and Technology of China
   [2011BAI08B10]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81171308, 81401389, 81570462];
   Natural Science Foundation of Fujian ProvinceNatural Science Foundation
   of Fujian Province [2018J05135]; Joint Funds for the Innovation of
   Science and Technology, Fujian Province [2017Y9024]; Fundamental
   Research Funds for the Central Universities, HUSTFundamental Research
   Funds for the Central Universities [2019JYCXJJ044]
FX This work was supported by grants from the National Program of the
   Ministry of Science and Technology of China during the "12th Five-Year
   Plan" grant number 2011BAI08B10); National Natural Science Foundation of
   China (grant numbers 81171308, 81401389, and 81570462); Natural Science
   Foundation of Fujian Province (grant number 2018J05135); Joint Funds for
   the Innovation of Science and Technology, Fujian Province (grant number
   2017Y9024), and the Fundamental Research Funds for the Central
   Universities, HUST (grant number 2019JYCXJJ044).
CR Alexiou GA, 2010, J CLIN NEUROSCI, V17, P1233, DOI 10.1016/j.jocn.2010.03.021
   Arevalo-Perez J, 2015, J NEUROIMAGING, V25, P792, DOI 10.1111/jon.12239
   Beaulieu C, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P105, DOI 10.1016/B978-0-12-374709-9.00006-7
   Billiet T, 2014, NEUROIMAGE-CLIN, V4, P649, DOI 10.1016/j.nicl.2014.04.005
   Caverzasi E, 2016, J NEUROIMAGING, V26, P494, DOI 10.1111/jon.12359
   Cha S, 2006, AM J NEURORADIOL, V27, P475
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Goebell E, 2006, RADIOLOGY, V239, P217, DOI 10.1148/radiol.2383050059
   Grussu F, 2015, NEUROIMAGE, V111, P590, DOI 10.1016/j.neuroimage.2015.01.045
   Hempel JM, 2017, J NEURO-ONCOL, V131, P93, DOI 10.1007/s11060-016-2272-0
   Jiang RF, 2015, ONCOTARGET, V6, P42380, DOI 10.18632/oncotarget.5675
   Johannessen AL, 2006, PATHOL ONCOL RES, V12, P143, DOI 10.1007/BF02893360
   Kodiweera C, 2016, NEUROIMAGE, V128, P180, DOI 10.1016/j.neuroimage.2015.12.033
   Kunz N, 2014, NEUROIMAGE, V96, P288, DOI 10.1016/j.neuroimage.2014.03.057
   Lee EJ, 2008, AM J NEURORADIOL, V29, P1872, DOI 10.3174/ajnr.A1254
   Li FY, 2016, CLIN NEUROL NEUROSUR, V151, P120, DOI 10.1016/j.clineuro.2016.10.018
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma L, 2013, CLIN NEUROL NEUROSUR, V115, P2489, DOI 10.1016/j.clineuro.2013.10.003
   Magnollay L, JOINT ANN M ISMRM ES
   Maier SE, 2010, NMR BIOMED, V23, P849, DOI 10.1002/nbm.1544
   Maximov II, 2017, PHYS MEDICA, V40, P24, DOI 10.1016/j.ejmp.2017.07.002
   Papageorgiou TS, 2015, PHYS MEDICA, V31, P767, DOI 10.1016/j.ejmp.2015.03.010
   Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209
   Raab P, 2010, RADIOLOGY, V254, P876, DOI 10.1148/radiol.09090819
   Raja R, 2016, NEURORADIOLOGY, V58, P1217, DOI 10.1007/s00234-016-1758-y
   Rostampour M, 2018, PHYS MEDICA, V48, P47, DOI 10.1016/j.ejmp.2018.03.005
   Schneider T, 2014, P INT SOC MAGN RESON
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Server A, 2014, EUR J RADIOL, V83, pE156, DOI 10.1016/j.ejrad.2013.12.023
   Sone D, 2018, NEUROIMAGE-CLIN, V20, P772, DOI 10.1016/j.nicl.2018.09.017
   Van Cauter S, 2012, RADIOLOGY, V263, P492, DOI 10.1148/radiol.12110927
   Wen QT, 2015, NEUROIMAGE-CLIN, V9, P291, DOI 10.1016/j.nicl.2015.08.017
   Winston GP, 2014, EPILEPSY RES, V108, P336, DOI 10.1016/j.eplepsyres.2013.11.004
   Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072
NR 34
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E247
EP E254
DI 10.1016/j.wneu.2019.07.121
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300029
PM 31349073
DA 2020-05-12
ER

PT J
AU Li, W
   Chae, R
   Rubio, RR
   Benet, A
   Meybodi, AT
   Feng, XQ
   Huang, GL
   El-Sayed, IH
AF Li, Wei
   Chae, Ricky
   Rubio, Roberto Rodriguez
   Benet, Arnau
   Meybodi, Ali Tayebi
   Feng, Xuequan
   Huang, Guanglong
   El-Sayed, Ivan H.
TI Characterization of Anatomical Landmarks for Exposing the internal
   Carotid Artery in the Infratemporal Fossa Through an Endoscopic
   Transmasticator Approach: A Morphometric Cadaveric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Infratemporal fossa; Internal carotid artery; Surgical
   simulation; Sphenoid spine; Transmasticator approach; Tympanic crest
ID TRANSPTERYGOID APPROACH; EUSTACHIAN-TUBE; ENDONASAL; TRANSNASAL;
   FRACTURES; SURGERY
AB BACKGROUND: The Eustachian tube and sphenoid spine have been previously described as landmarks for endonasal surgical identification of the most distal segment of the parapharyngeal internal carotid artery (PhICA). However, the intervening space between the sphenoid spine and PhICA allows for error during exposure of the artery. In the present study, we have characterized endoscopic endonasal transmasticator exposure of the PhICA using the sphenoid spine, vaginal process of the tympanic bone, and the "tympanic crest" as useful anatomical landmarks.
   METHODS: Endonasal dissection was performed in 13 embalmed latex-injected cadaveric specimens. Two open lateral dissections and osteologic analysis of 10 dry skulls were also performed.
   RESULTS: A novel and palpable bony landmark, the inferomedial edge of the tympanic bone, referred to as the tympanic crest, was identified, leading from the sphenoid spine to the lateral carotid canal. Additionally, the vaginal process of the tympanic bone, viewed endoscopically, was a guide to the PhICA. The sphenoid spine was bifurcate in 20% of the skulls, with an average length of 5.98 mm (range, 3.9-8.2 mm), width of 5.81 mm (range, 3.0-10.6 mm), and distance to the carotid canal of 4.48 mm (range, 2.5-6.1 mm).
   CONCLUSION: The sphenoid spine and pericarotid space has variable anatomy. Using an endoscopic transmasticator approach to the infratemporal fossa, we found that the closest landmarks leading to the PhICA were the tympanic crest, sphenoid spine, and vaginal process of the tympanic bone.
C1 [Li, Wei; Rubio, Roberto Rodriguez; Huang, Guanglong; El-Sayed, Ivan H.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94110 USA.
   [Chae, Ricky; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
   [Chae, Ricky; Rubio, Roberto Rodriguez; Benet, Arnau; Meybodi, Ali Tayebi; Feng, Xuequan; Huang, Guanglong; El-Sayed, Ivan H.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94110 USA.
   [Li, Wei] China Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Shenyang, Liaoning, Peoples R China.
   [Benet, Arnau; Meybodi, Ali Tayebi] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Feng, Xuequan] Tianjin First Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China.
RP El-Sayed, IH (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94110 USA.; El-Sayed, IH (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94110 USA.
EM ivan.el-sayed@ucsf.edu
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X; Chae,
   Ricky/0000-0001-5014-9303
FU Departments of Neurological Surgery and Otolaryngology-Head and Neck
   Surgery, University of California, San Francisco, San Francisco,
   California, USAUniversity of California System; Stryker Inc. (Kalamazoo,
   Michigan, USA)
FX The present study was funded by departmental funds from the Departments
   of Neurological Surgery and Otolaryngology-Head and Neck Surgery,
   University of California, San Francisco, San Francisco, California, USA;
   the anatomy laboratory equipment resources were supported in part by an
   educational grant from Stryker Inc. (Kalamazoo, Michigan, USA). Ivan
   El-Sayed is a consultant for Stryker Inc.
CR Barges-Coll J, 2010, NEUROSURGERY, V67, P144, DOI 10.1227/01.NEU.0000370892.11284.EA
   Battaglia P, 2014, OTOLARYNG HEAD NECK, V150, P696, DOI 10.1177/0194599813520290
   Benet A, 2015, CUREUS, V7, DOI 10.7759/cureus.285
   Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Bolger WE, 2005, OTOLARYNG HEAD NECK, V133, P20, DOI 10.1016/j.otohns.2005.03.063
   Castelnuovo P, 2013, SURG ANATOMY INTERNA
   de Lara D, 2014, WORLD NEUROSURG, V82, pS121, DOI 10.1016/j.wneu.2014.07.036
   DePowell JJ, 2014, WORLD NEUROSURG, V82, pS66, DOI 10.1016/j.wneu.2014.07.028
   El-Sayed I, 2011, LARYNGOSCOPE, V121, P694, DOI 10.1002/lary.21469
   Falcon RT, 2011, LARYNGOSCOPE, V121, P31, DOI 10.1002/lary.21341
   Fernandez-Miranda JC, 2014, J NEUROSURG, V121, P91, DOI 10.3171/2014.3.JNS131865
   Fortes FSG, 2012, LARYNGOSCOPE, V122, P445, DOI 10.1002/lary.22395
   Gallia GL, 2010, J CLIN NEUROSCI, V17, P1423, DOI 10.1016/j.jocn.2010.04.013
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   Ho B, 2014, LARYNGOSCOPE, V124, P1995, DOI 10.1002/lary.24601
   Hofstetter CP, 2010, J NEUROSURG, V113, P967, DOI 10.3171/2009.10.JNS09157
   Kassam AB, 2008, J NEUROSURG, V108, P177, DOI 10.3171/JNS/2008/108/01/0177
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   Komune N, 2015, J LARYNGOL OTOL, V129, pS12, DOI 10.1017/S0022215114002321
   Labib MA, 2014, OPER NEUROSURG, V10, P448, DOI 10.1227/NEU.0000000000000362
   Land TJ, 2014, RES MATH EDUC, P3, DOI 10.1007/978-3-319-02562-9_1
   Little A, 2015, J NEUROL SURG PART B, V76
   Liu JF, 2014, LARYNGOSCOPE, V124, P2655, DOI 10.1002/lary.24808
   Mason E, 2014, LARYNGOSCOPE, V124, P1988, DOI 10.1002/lary.24594
   Rubio RR, 2019, WORLD NEUROSURG, V126, P359, DOI 10.1016/j.wneu.2019.03.099
   Sherif C, 2012, NEUROSURG REV, V35, P227, DOI 10.1007/s10143-011-0352-3
   Taylor RJ, 2014, LARYNGOSCOPE, V124, P2443, DOI 10.1002/lary.24638
   Vescan AD, 2007, LARYNGOSCOPE, V117, P1338, DOI 10.1097/MLG.0b013e31806146cd
   Visocchi M., 2015, J NEUROSURG SCI
   von Ludinghausen M, 2006, SURG RADIOL ANAT, V28, P284, DOI 10.1007/s00276-006-0078-z
   Wood CP, 2014, AM J NEURORADIOL, V35, P186, DOI 10.3174/ajnr.A3609
   Wu J, 2016, HEAD NECK PATHOL, V10, P213, DOI 10.1007/s12105-015-0632-2
   Zimmer LA, 2009, AMJ RHINOL ALLERGY, V23, P192, DOI 10.2500/ajra.2009.23.3292
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E415
EP E424
DI 10.1016/j.wneu.2019.07.185
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300050
PM 31376554
DA 2020-05-12
ER

PT J
AU Li, ZH
   Liu, P
   Zhang, CL
   Xu, G
   Zhang, Y
   Chang, A
   Liu, MZ
   Hou, SX
AF Li, Zhonghai
   Liu, Peng
   Zhang, Chunli
   Xu, Gang
   Zhang, Yu
   Chang, Yvang
   Liu, Mozhen
   Hou, Shuxun
TI Incidence, Prevalence, and Analysis of Risk Factors for Surgical Site
   Infection After Lumbar Fusion Surgery: >= 2-Year Follow-Up Retrospective
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Infection; Risk factor; Spinal fusion; Surgical site infection; Wound
   complication
ID SPINAL DEFORMITY SURGERY; URINARY-TRACT-INFECTION; COMPLICATION RATES;
   OUTCOMES; COST; MULTICENTER; PREDICTORS; DUROTOMY; OBESITY; IMPACT
AB PURPOSE: Surgical site infection (SSI) in spine surgery remains a significant cause of morbidity and prolonged hospitalization. We intended to document our experience in our center and to highlight possible factors influencing SSI in posterior lumbar fusion surgery.
   METHODS: Between June 2015 and March 2017, 448 consecutive patients with lumbar degenerative disease who underwent classic open transforaminal lumbar interbody fusion were enrolled in the study. We divided the patients into the SSI group and the non-SSI group and compared their patient-specific and procedure-specific factors. Univariate and multiple logistic regression analyses were performed to determine risk factors.
   RESULTS: There was a significant difference between groups in age (P = 0.001), body mass index (P < 0.001), subcutaneous fat thickness (P < 0.001), preoperative American Society of Anesthesiologists (ASA) score (P < 0.001), postoperative hemoglobin (P = 0.003), preoperative serum albumin (P < 0.001), operative time (P < 0.001), operated levels (P < 0.001), postoperative drainage (P = 0.004), time of draining (P< 0.001) and late-presenting dural tear (P = 0.008). Logistic regression analysis of these differences showed that thicker subcutaneous fat thickness, higher preoperative ASA score, lower preoperative serum albumin, and longer time of draining were significantly related to SSI (P < 0.05).
   CONCLUSIONS: The risk factors for SSI after lumbar fusion surgery are multifactorial. These data should provide a step toward the development of quality improvement measures aimed at reducing complications in high-risk patients. These factors may prove useful for patient counseling and for surgical planning.
C1 [Li, Zhonghai; Xu, Gang; Zhang, Yu; Chang, Yvang; Liu, Mozhen] Dalian Med Univ, Dept Orthopaed, Affiliated Hosp 1, Dalian, Peoples R China.
   [Li, Zhonghai; Xu, Gang; Zhang, Yu; Chang, Yvang; Liu, Mozhen] Key Lab Mol Mech Repair & Remodeling Orthopaed Di, Shenyang, Liaoning, Peoples R China.
   [Liu, Peng] Peoples Hosp Ningxia Hui Autonomous Reg, Dept Orthopaed, Yinchuan, Peoples R China.
   [Zhang, Chunli; Hou, Shuxun] Peoples Liberat Army Gen Hosp, Dept Orthopaed, Med Ctr 4, Beijing, Peoples R China.
RP Li, ZH (reprint author), Dalian Med Univ, Dept Orthopaed, Affiliated Hosp 1, Dalian, Peoples R China.; Li, ZH (reprint author), Key Lab Mol Mech Repair & Remodeling Orthopaed Di, Shenyang, Liaoning, Peoples R China.
EM lizhonghaispine@126.com
RI Li, Zhonghai/N-6670-2018
OI Li, Zhonghai/0000-0003-4735-1193
FU LiaoNing Revitalization Talents Program [XLYC1807131]; Natural Science
   Foundation of Liaoning ProvinceNatural Science Foundation of Liaoning
   Province [20170540294]; Basic Scientific Research Projects of the
   Universities in Liaoning Province [LQ2017022]
FX Supported by LiaoNing Revitalization Talents Program (XLYC1807131), the
   Natural Science Foundation of Liaoning Province (20170540294) and Basic
   Scientific Research Projects of the Universities in Liaoning Province
   (LQ2017022).
CR Abdul-Jabbar A, 2012, SPINE, V37, P1340, DOI 10.1097/BRS.0b013e318246a53a
   Adogwa O, 2014, SPINE J, V14, P1828, DOI 10.1016/j.spinee.2013.10.023
   Ahmed R, 2012, J SPINAL DISORD TECH, V25, P299, DOI 10.1097/BSD.0b013e31821fbf72
   Ando M, 2014, EUR SPINE J, V23, P854, DOI 10.1007/s00586-014-3202-5
   Blood AG, 2017, SURG INFECT, V18, P234, DOI 10.1089/sur.2016.183
   Blumberg TJ, 2018, SPINE J, V18, P300, DOI 10.1016/j.spinee.2017.07.173
   Boston KM, 2009, INFECT CONT HOSP EP, V30, P884, DOI 10.1086/605323
   Browne JA, 2007, SPINE, V32, P2214, DOI 10.1097/BRS.0b013e31814b1bc0
   Chaichana KL, 2014, J NEUROSURG-SPINE, V20, P45, DOI 10.3171/2013.10.SPINE1364
   Chen S, 2009, CLIN ORTHOP RELAT R, V467, P1670, DOI 10.1007/s11999-009-0740-y
   Cheng CW, 2019, SPINE J, V19, P602, DOI 10.1016/j.spinee.2018.09.014
   Djurasovic M, 2008, SPINE, V33, P1789, DOI 10.1097/BRS.0b013e31817b8f6f
   Ezzati M, 2017, LANCET, V390, P2627, DOI 10.1016/S0140-6736(17)32129-3
   Fang A, 2005, SPINE, V30, P1460, DOI 10.1097/01.brs.0000166532.58227.4f
   Fei Q, 2016, WORLD NEUROSURG, V95, P507, DOI 10.1016/j.wneu.2015.05.059
   Gruskay J, 2012, SPINE, V37, P1170, DOI 10.1097/BRS.0b013e3182407859
   Gu WF, 2018, AM J INFECT CONTROL, V46, P8, DOI 10.1016/j.ajic.2017.09.025
   Habiba S, 2017, ACTA NEUROCHIR, V159, P1113, DOI 10.1007/s00701-017-3184-2
   Kalanithi PA, 2012, SPINE, V37, P982, DOI 10.1097/BRS.0b013e31823bbeef
   Kasliwal MK, 2012, J NEUROSURG-SPINE, V17, P128, DOI 10.3171/2012.4.SPINE12130
   Koutsoumbelis S, 2011, J BONE JOINT SURG AM, V93A, P1627, DOI 10.2106/JBJS.J.00039
   Kurtz SM, 2012, J NEUROSURG-SPINE, V17, P342, DOI 10.3171/2012.7.SPINE12203
   Lee NJ, 2017, GLOB SPINE J, V7, P417, DOI 10.1177/2192568217699378
   Lieber B, 2016, WORLD NEUROSURG, V89, P517, DOI 10.1016/j.wneu.2015.12.085
   Liu JM, 2018, SPINE, V43, P732, DOI 10.1097/BRS.0000000000002419
   Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X
   Maragakis LL, 2009, ANESTHESIOLOGY, V110, P556, DOI 10.1097/ALN.0b013e3181974be7
   Mehta AI, 2012, SPINE, V37, P1652, DOI 10.1097/BRS.0b013e318241b186
   Nunez-Pereira S, 2014, CLIN MICROBIOL INFEC, V20, P768, DOI 10.1111/1469-0691.12527
   Ogihara S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205539
   Olsen MA, 2008, J BONE JOINT SURG AM, V90A, P62, DOI 10.2106/JBJS.F.01515
   Piper Keaton F, 2017, Surg Neurol Int, V8, P269, DOI 10.4103/sni.sni_306_17
   Puvanesarajah V, 2017, SPINE, V42, P770, DOI 10.1097/BRS.0000000000001895
   Sansur CA, 2011, SPINE, V36, pE593, DOI 10.1097/BRS.0b013e3182059bfd
   Schimmel JJP, 2010, EUR SPINE J, V19, P1711, DOI 10.1007/s00586-010-1421-y
   Singla A, 2019, SPINE, V44, pE408, DOI 10.1097/BRS.0000000000002864
   Smith JS, 2011, SPINE, V36, P958, DOI 10.1097/BRS.0b013e3181eabb26
   Somani S, 2017, GLOB SPINE J, V7, P719, DOI 10.1177/2192568217700106
   Takenaka S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013970
   ter Gunne AFP, 2010, EUR SPINE J, V19, P982, DOI 10.1007/s00586-009-1269-1
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Tominaga H, 2016, EUR SPINE J, V25, P3908, DOI 10.1007/s00586-016-4674-2
   Veeravagu A, 2009, SPINE, V34, P1869, DOI 10.1097/BRS.0b013e3181adc989
NR 43
TC 1
Z9 1
U1 7
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E460
EP E467
DI 10.1016/j.wneu.2019.07.207
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300056
PM 31394358
DA 2020-05-12
ER

PT J
AU Ma, J
   Tian, K
   Wang, L
   Wang, K
   Du, J
   Li, D
   Wu, Z
   Zhang, J
AF Ma, Junpeng
   Tian, Kaibing
   Wang, Liang
   Wang, Ke
   Du, Jiang
   Li, Da
   Wu, Zhen
   Zhang, Junting
TI High Expression of TGF-beta 1 Predicting Tumor Progression in Skull Base
   Chordomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Oncology; Prognosis; Progression; Skull base; TGF-beta 1
ID PROGNOSTIC-FACTORS; TGF-BETA; SURVIVAL; CONSISTENCY
AB OBJECTIVE: To investigate the expression characteristics and prognostic value of transforming growth factor beta 1 (TGF-beta 1) in primary skull base chordomas (SBCs).
   METHODS: The mRNA expression levels of TGF-beta 1 were measured in 57 frozen samples from patients with primary SBCs. Clinical data collection, follow-up, correlations, and survival analyses were performed.
   RESULTS: In the series of 57 patients (29 men and 28 women) with primary SBCs, the mean value of TGF-beta 1 mRNA was 1.713 with a median of 0.904. Twenty-four SBCs were soft type and 33 were hard type. The Mann-Whitney U test revealed that the expression level of TGF-beta 1 mRNA in hard type SBCs was significantly higher than the expression level found in the soft type (P = 0.03). The independent-samples median test suggested that the expression level of TGF-beta 1 mRNA in female patients' SBCs was significantly higher than that in male patients' SBCs (P = 0.01). Expression differences of TGF-beta 1 were not seen among different pathological subtypes, tumor blood supply, or degree of resection. The Spearman rank correlation coefficient clarified that TGF-beta 1 mRNA levels were not correlated with tumor diameter, preoperative Karnofsky Performance Status (KPS), postoperative KPS, follow-up KPS, age, or intraoperative blood loss. The multivariate Cox analysis revealed that pathological subtype (P = 0.008), expression level of TGF-beta 1 mRNA (P = 0.01), and tumor texture (P = 0.03) were all independent prognostic factors for tumor progression.
   CONCLUSIONS: SBCs in female patients and SBCs with hard texture were prone to have high TGF-beta 1 mRNA expression. High expression of TGF-beta 1, hard tumor texture, and conventional subtype were all independent risk factors for tumor progression.
C1 [Ma, Junpeng; Tian, Kaibing; Wang, Liang; Wang, Ke; Li, Da; Wu, Zhen; Zhang, Junting] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Junpeng; Tian, Kaibing; Wang, Liang; Wang, Ke; Li, Da; Wu, Zhen; Zhang, Junting] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Ma, Junpeng; Tian, Kaibing; Wang, Liang; Wang, Ke; Li, Da; Wu, Zhen; Zhang, Junting] Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.
   [Ma, Junpeng; Tian, Kaibing; Wang, Liang; Wang, Ke; Li, Da; Wu, Zhen; Zhang, Junting] Beijing Key Lab Brian Tumor, Beijing, Peoples R China.
   [Du, Jiang] Capital Med Univ, Beijing Neurosurg Inst, Dept Neuropathol, Beijing, Peoples R China.
RP Zhang, J (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, J (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Zhang, J (reprint author), Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.; Zhang, J (reprint author), Beijing Key Lab Brian Tumor, Beijing, Peoples R China.
EM Zhangjunting2003@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672506, 81802683, 81472370]; National High
   Technology Research and Development Program of China (863
   program)National High Technology Research and Development Program of
   China [2014AA020610]; Major State Basic Research Development Program of
   China (973 program)National Basic Research Program of China
   [2014CB542006]
FX This work was supported by the National Natural Science Foundation of
   China (grant no. 81672506, 81802683, and 81472370), the National High
   Technology Research and Development Program of China (863 program, grant
   no. 2014AA020610), and the Major State Basic Research Development
   Program of China (973 program, grant no. 2014CB542006).
CR Akhurst RJ, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022301
   Alimohamadi M, 2014, ACTA NEUROCHIR, V156, P2245, DOI 10.1007/s00701-014-2259-6
   Bakker SH, 2018, EUR SPINE J, V27, P3043, DOI 10.1007/s00586-018-5764-0
   Chambers KJ, 2014, LARYNGOSCOPE, V124, P1097, DOI 10.1002/lary.24420
   Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177
   Cote GM, 2018, INT J RADIAT ONCOL, V102, P1496, DOI 10.1016/j.ijrobp.2018.07.2013
   Lee IJ, 2017, WORLD NEUROSURG, V104, P346, DOI 10.1016/j.wneu.2017.04.118
   Li MX, 2018, J NEURO-ONCOL, V137, P139, DOI 10.1007/s11060-017-2706-3
   Lichtman MK, 2016, WOUND REPAIR REGEN, V24, P215, DOI 10.1111/wrr.12398
   Lin YS, 2009, DIS MARKERS, V27, P23, DOI [10.1155/2009/529253, 10.3233/DMA-2009-0643]
   Long C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066676
   Malgulwar PB, 2017, BRAIN TUMOR PATHOL, V34, P155, DOI 10.1007/s10014-017-0295-7
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Mima M, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130512
   OCONNELL JX, 1994, CANCER-AM CANCER SOC, V74, P2261, DOI 10.1002/1097-0142(19941015)74:8<2261::AID-CNCR2820740809>3.0.CO;2-0
   Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501
   Romano A, 2017, PITUITARY, V20, P201, DOI 10.1007/s11102-016-0760-z
   SALISBURY JR, 1993, J PATHOL, V171, P253, DOI 10.1002/path.1711710404
   Shen XH, 2018, INT J SURG, V58, P37, DOI 10.1016/j.ijsu.2018.08.004
   Shiroishi MS, 2016, NEUROSURG CLIN N AM, V27, P145, DOI 10.1016/j.nec.2015.11.007
   Stacchiotti S, 2018, CANCER-AM CANCER SOC, V124, P4056, DOI 10.1002/cncr.31685
   Tam A, 2016, AM J RESP CRIT CARE, V193, P825, DOI 10.1164/rccm.201503-0487OC
   Thieblemont C, 1995, EUR J CANCER, V31A, P2255, DOI 10.1016/0959-8049(95)00458-0
   Tian KB, 2017, WORLD NEUROSURG, V101, P396, DOI 10.1016/j.wneu.2017.02.012
   Tian KB, 2017, WORLD NEUROSURG, V97, P39, DOI 10.1016/j.wneu.2016.09.055
   Wang K, 2016, J CLIN NEUROSCI, V27, P147, DOI 10.1016/j.jocn.2015.05.073
   Wang L, 2016, CANCER MED-US, V5, P2368, DOI 10.1002/cam4.834
   Wu Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119523
   Zhang Y, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022145
   Zhou JH, 2017, NEUROSURGERY, V81, P812, DOI 10.1093/neuros/nyx081
   Zhou JP, 2018, WORLD NEUROSURG, V117, P46, DOI 10.1016/j.wneu.2018.05.209
   Zhou YB, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012207
   Zou MX, 2018, WORLD NEUROSURG, V109, P307, DOI 10.1016/j.wneu.2017.10.010
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E265
EP E270
DI 10.1016/j.wneu.2019.07.128
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300031
PM 31349076
DA 2020-05-12
ER

PT J
AU Mallepally, AR
   Rustagi, T
   Chhabra, HS
   Gupta, A
AF Mallepally, Abhinandan Reddy
   Rustagi, Tarush
   Chhabra, Harvinder Singh
   Gupta, Anuj
TI Sensorineural Deafness After Spine Surgery: Case Series and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Corticosteroids; Hearing loss; SNHL; Spine surgery
ID SUDDEN HEARING-LOSS; NITROUS-OXIDE; ANESTHESIA; PRESSURE
AB BACKGROUND: Sudden sensorineural hearing loss (SNHL) after nonotologic surgery is unusual, with most occurrences reported in patients having cardiopulmonary bypass. Reports of SNHL after nonotologic noncardiac surgery are rare, particularly after spine surgery. In patients undergoing subarachnoid anesthesia or intradural surgery, loss of cerebrospinal fluid pressure can result in hearing loss and cranial nerve palsy.
   METHODS: A 70-year-old male patient had ankylosing spondylitis with an Anderson lesion T11-12 with diabetes mellitus, hypertension, and American Spinal Injury Association Impairment Scale-A neurology. He underwent posterior stabilization of T10-11 and developed a profound, painless, left-sided hearing deficit shortly afterward. An otorhinolaryngology consultation confirmed SNHL. An 82-year-old male reported claudication with L4-5 LCS and type 2 diabetes mellitus. Post L4-5 transforaminal lumbar interbody fusion, he complained of hearing loss in his left ear, confirmed by an otolaryngologist. A 72-year-old diabetic male had tuberculous spondylodiskitis of D2-3 with an epidural abscess. An emergent decompression and stabilization C7-D5 bone grafting at D2-3 was done. In the early postoperative period, the patient complained of marked hearing impairment on the right side. Audiometry indicated SNHL in his right ear.
   RESULTS: A course of intravenous corticosteroids was instituted in the first and second patients for severe hearing loss. Steroids were not given to the third patient in view of his Pott spine. No improvement in hearing impairment occurred until the latest follow-up in all patients.
   CONCLUSIONS: Sudden-onset hearing loss post spine surgery is disastrous with multiple etiologies and remains poorly understood. Timely evaluation by an otolaryngologist and audiologist is recommended. The role of corticosteroids in treating SNHL is still unclear.
C1 [Mallepally, Abhinandan Reddy; Rustagi, Tarush; Chhabra, Harvinder Singh; Gupta, Anuj] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Mallepally, AR (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM mabhi28@gmail.com
OI mallepally, abhinandan reddy/0000-0001-8153-7499; Rustagi,
   Tarush/0000-0001-9950-3780
CR Chen CY, 2003, OTOL NEUROTOL, V24, P728, DOI 10.1097/00129492-200309000-00006
   Cox AJ, 1997, ARCH OTOLARYNGOL, V123, P994
   Eisenman DJ, 2000, ARCH OTOLARYNGOL, V126, P1161, DOI 10.1001/archotol.126.9.1161
   Girardi FP, 2001, J SPINAL DISORD, V14, P180, DOI 10.1097/00002517-200104000-00014
   Mak PHK, 2003, CAN J ANAESTH, V50, P519, DOI 10.1007/BF03021068
   Malhotra SK, 2002, EUR J ANAESTH, V19, P69
   Park P, 2006, SURG NEUROL, V66, P415, DOI 10.1016/j.surneu.2005.12.026
   PERREAULT L, 1982, CAN ANAESTH SOC J, V29, P428, DOI 10.1007/BF03009404
   PLASSE HM, 1980, J THORAC CARDIOV SUR, V79, P822
   PLASSE HM, 1981, LARYNGOSCOPE, V91, P101
   Schaffartzik W, 2000, ANESTH ANALG, V91, P1466, DOI 10.1097/00000539-200012000-00032
   SEGAL S, 1984, AM J OTOL, V5, P308
   Sprung J, 2003, ANESTHESIOLOGY, V98, P241
   WANG LP, 1986, ACTA ANAESTH SCAND, V30, P412, DOI 10.1111/j.1399-6576.1986.tb02441.x
   WAUN JE, 1967, ANESTHESIOLOGY, V28, P846, DOI 10.1097/00000542-196709000-00015
   WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772
NR 16
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E482
EP E485
DI 10.1016/j.wneu.2019.07.204
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300059
PM 31382067
DA 2020-05-12
ER

PT J
AU Masalha, W
   Heiland, DH
   Delev, D
   Fennell, JT
   Franco, P
   Scheiwe, C
   Mercas, BI
   Mader, I
   Schnell, O
   Grauvogel, J
AF Masalha, Waseem
   Heiland, Dieter Henrik
   Delev, Daniel
   Fennell, Jamina Tara
   Franco, Pamela
   Scheiwe, Christian
   Mercas, Bianca-Ioana
   Mader, Irina
   Schnell, Oliver
   Grauvogel, Juergen
TI Survive and Prognostic Predictors of Anaplastic Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjuvant radiotherapy; Anaplastic meningiomas; Meningiomas; Surgery
ID MALIGNANT MENINGIOMAS; ADJUVANT RADIOTHERAPY; GRADE; EXPERIENCE;
   MANAGEMENT; RADIATION; KI-67; EFFICACY; SURGERY; BENIGN
AB BACKGROUND: Anaplastic meningiomas are rare tumors with a poor prognosis, even after complete surgical resection and radiotherapy. There has been limited evidence with respect to the clinical factors and their effects on the course of the disease. Various retrospective studies have not been able to provide clear evidence of standardized treatment, usually presenting contradictory results. The aim of this study was to evaluate the prognostic factors influencing the progression-free survival (PFS) and overall survival (OS) of anaplastic meningiomas, with a particular focus on the roles of the extent of resection and postoperative adjuvant radiotherapy.
   METHODS: Between October 2001 and March 2016, 36 patients with anaplastic meningiomas were treated in our Department of Neurosurgery, of whom 11 underwent gross total resection (GTR) and 18 subtotal resection. Twenty-one patients received postoperative adjuvant radiotherapy, and 8 were treated with surgery alone. GTR (Simpson grades I and II) was associated with significantly improved PFS (P = 0.01) and OS (P = 0.004). Furthermore, adjuvant radiotherapy showed an improvement in PFS (P = 0.01) but not in OS (P = 0.16).
   CONCLUSIONS: The extent of resection in anaplastic meningiomas is correlated with a better outcome. However, resection alone is not sufficient for the long-term control of anaplastic meningiomas. Adjuvant radiotherapy is an essential component in the adjuvant treatment of anaplastic meningiomas, including for patients undergoing GTR. Further investigations through which to improve adjuvant therapy options are necessary to improve meningioma therapy.
C1 [Masalha, Waseem; Heiland, Dieter Henrik; Delev, Daniel; Franco, Pamela; Scheiwe, Christian; Mercas, Bianca-Ioana; Schnell, Oliver; Grauvogel, Juergen] Univ Freiburg, Dept Neurosurg, Med Ctr, Freiburg, Germany.
   [Fennell, Jamina Tara] Univ Freiburg, Dept Radiat Oncol, Med Ctr, Freiburg, Germany.
   [Mader, Irina] Univ Freiburg, Dept Neuroradiol, Med Ctr, Freiburg, Germany.
   [Masalha, Waseem; Heiland, Dieter Henrik; Delev, Daniel; Fennell, Jamina Tara; Franco, Pamela; Scheiwe, Christian; Mercas, Bianca-Ioana; Mader, Irina; Schnell, Oliver; Grauvogel, Juergen] Univ Freiburg, Fac Med, Freiburg, Germany.
   [Fennell, Jamina Tara] German Canc Consortium DKTK, Partner Site Freiburg, Freiburg, Germany.
RP Masalha, W (reprint author), Univ Freiburg, Dept Neurosurg, Med Ctr, Freiburg, Germany.; Masalha, W (reprint author), Univ Freiburg, Fac Med, Freiburg, Germany.
EM waseem.masalha@uniklinik-freiburg.de
CR Abramovich CM, 1998, HUM PATHOL, V29, P1420, DOI 10.1016/S0046-8177(98)90010-7
   Adeberg S, 2012, INT J RADIAT ONCOL, V83, P859, DOI 10.1016/j.ijrobp.2011.08.010
   Balasubramanian SK, 2017, J NEURO-ONCOL, V131, P555, DOI 10.1007/s11060-016-2321-8
   Bruna J, 2007, NEUROPATHOLOGY, V27, P114, DOI 10.1111/j.1440-1789.2007.00750.x
   Cain SA, 2015, J CLIN NEUROSCI, V22, P1742, DOI 10.1016/j.jocn.2015.03.054
   Cao XY, 2015, J CLIN NEUROSCI, V22, P828, DOI 10.1016/j.jocn.2014.11.022
   Champeaux C, 2016, NEUROCHIRURGIE, V62, P203, DOI 10.1016/j.neuchi.2016.05.001
   Choi Y, 2014, J NEURO-ONCOL, V119, P405, DOI 10.1007/s11060-014-1507-1
   Colli BO, 2015, ARQ NEURO-PSIQUIAT, V73, P770, DOI 10.1590/0004-282X20150106
   Detti B, 2013, J NEURO-ONCOL, V115, P421, DOI 10.1007/s11060-013-1239-7
   Ding D, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13364
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Dziuk TW, 1998, J NEURO-ONCOL, V37, P177, DOI 10.1023/A:1005853720926
   GOLDSMITH BJ, 1994, J NEUROSURG, V80, P195, DOI 10.3171/jns.1994.80.2.0195
   Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Kane AJ, 2011, CANCER-AM CANCER SOC, V117, P1272, DOI 10.1002/cncr.25591
   Kaur G, 2014, NEURO-ONCOLOGY, V16, P628, DOI 10.1093/neuonc/nou025
   Kayaselcuk F, 2004, J NEURO-ONCOL, V67, P209, DOI 10.1023/B:NEON.0000021823.05163.2c
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5
   Moliterno J, 2015, J NEUROSURG, V123, P23, DOI 10.3171/2014.10.JNS14502
   Orton A, 2018, J NEUROSURG, V128, P1684, DOI 10.3171/2017.2.JNS162282
   Paldor I, 2016, J CLIN NEUROSCI, V31, P37, DOI 10.1016/j.jocn.2016.03.014
   Palma L, 1997, J NEUROSURG, V86, P793, DOI 10.3171/jns.1997.86.5.0793
   Perry A, 1998, CANCER-AM CANCER SOC, V82, P2262, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.3.CO;2-O
   Peyre M, 2018, NEURO-ONCOLOGY, V20, P1113, DOI 10.1093/neuonc/nox231
   Piscevic I, 2015, WORLD NEUROSURG, V83, P987, DOI 10.1016/j.wneu.2015.02.021
   Rosenberg LA, 2009, INT J RADIAT ONCOL, V74, P427, DOI 10.1016/j.ijrobp.2008.08.018
   Roser F, 2004, ACTA NEUROCHIR, V146, P37, DOI 10.1007/s00701-003-0173-4
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sughrue ME, 2010, J NEUROSURG, V113, P202, DOI 10.3171/2010.1.JNS091114
   Sun SQ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14757
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Zhang GJ, 2018, CLIN NEUROL NEUROSUR, V170, P13, DOI 10.1016/j.clineuro.2018.03.028
   Zhao P, 2015, NEUROSURG REV, V38, P101, DOI 10.1007/s10143-014-0558-2
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E321
EP E328
DI 10.1016/j.wneu.2019.07.148
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300039
PM 31356972
DA 2020-05-12
ER

PT J
AU Miura, M
   Shindo, S
   Nakajima, M
   Namitome, S
   Wada, K
   Nagao, Y
   Sugimura, Y
   Terasaki, T
   Ando, Y
AF Miura, Masatomo
   Shindo, Seigo
   Nakajima, Makoto
   Namitome, Satoshi
   Wada, Kuniyasu
   Nagao, Yoichiro
   Sugimura, Yusuke
   Terasaki, Tadashi
   Ando, Yukio
TI Stent Retriever-Assisted Continuous Aspiration for Distal Intracranial
   Vessel Embolectomy: The Distal Combined Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Combined technique; Distal intracranial artery occlusion; Stroke;
   Surgical technique; Thrombectomy
ID MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC-STROKE; MECHANICAL THROMBECTOMY;
   MICROSURGICAL ANATOMY; M2 OCCLUSION; EXPERIENCE; SEGMENT
AB OBJECTIVE: We investigated the efficacy of a combined approach with stent retriever-assisted aspiration catheter for distal intracranial vessel occlusion (distal combined technique [DCT]).
   METHODS: We evaluated consecutive patients with acute ischemic stroke with distal occlusion in anterior circulation, including occlusions of the M2/M3 or A2/A3 segments, who received endovascular therapy (EVT) in a single center. Modified Thrombolysis in Cerebral Infraction (mTICI) score including TICI 2C category, processing time from puncture to reperfusion, proportion of a favorable clinical outcome at discharge (modified Rankin Scale [mRS] score <= 2), and incidence of symptomatic intracranial hemorrhage (sICH) were compared between the DCT and single device approach technique (non-DCT) groups.
   RESULTS: Of 65 patients, 28 were treated with EVT using the DCT and 37 were treated with EVT with a single device approach (non-DCT). In the DCT group, a higher reperfusion rate at the first pass (mTICI score >= 2B, 92% vs. 54%; P = 0.0008; mTICI score >= 2C,71% vs. 16%; P < 0.0001; mTICI score 3, 57% vs. 14%; P = 0.0004) and shorter time from puncture to successful reperfusion (median, 31 vs. 43 minutes; P = 0.0006) were achieved, respectively. The final successful reperfusion rate was also higher in the DCT group than in the non-DCT group (mTICI score >= 2C, 85% vs. 51%; P = 0.004; mTICI score 3, 75% vs. 43%; P = 0.012), respectively. sICH occurred in 2 patients in the non-DCT group. Patients with mRS score <= 2 at discharge were more prevalent in the DCT than in the non-DCT group (57 degrees/a vs. 27%, respectively; P = 0.021).
   CONCLUSIONS: This retrospective analysis indicated that the OCT is a useful and safe strategy for patients with distal anterior intracranial vessel occlusion.
C1 [Miura, Masatomo; Shindo, Seigo; Namitome, Satoshi; Wada, Kuniyasu; Terasaki, Tadashi] Japanese Red Cross Kumamoto Hosp, Dept Neurol, Kumamoto, Japan.
   [Miura, Masatomo; Nakajima, Makoto; Nagao, Yoichiro; Sugimura, Yusuke; Ando, Yukio] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan.
   [Nagao, Yoichiro] Hyogo Coll Med, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
RP Shindo, S (reprint author), Japanese Red Cross Kumamoto Hosp, Dept Neurol, Kumamoto, Japan.
EM seigoshindou@yahoo.co.jp
CR Almekhlafi MA, 2014, INTERV NEURORADIOL, V20, P21, DOI 10.15274/INR-2014-10004
   Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Chen CJ, 2017, WORLD NEUROSURG, V107, P684, DOI 10.1016/j.wneu.2017.08.108
   GIBO H, 1981, J NEUROSURG, V54, P151, DOI 10.3171/jns.1981.54.2.0151
   Gory B, 2018, STROKE, V49, P461, DOI 10.1161/STROKEAHA.117.019598
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Grossberg JA, 2018, STROKE, V49, P1662, DOI 10.1161/STROKEAHA.118.020567
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Kim BJ, 2018, J STROKE, V20, P140, DOI 10.5853/jos.2017.02915
   Kim YW, 2017, J NEUROINTERV SURG, V9, P626, DOI 10.1136/neurintsurg-2016-012466
   Kuhn AL, 2017, J NEUROINTERV SURG, V9, P541, DOI 10.1136/neurintsurg-2016-012454
   Massari F, 2016, INTERV NEURORADIOL, V22, P325, DOI 10.1177/1591019916632369
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   McTaggart RA, 2017, J NEUROINTERV SURG, V9, P1154, DOI 10.1136/neurintsurg-2016-012838
   Miura M, 2019, J NEUROINTERV SURG, V11, P964, DOI 10.1136/neurintsurg-2018-014627
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Nikoubashman O, 2017, J NEUROINTERV SURG, V9, P459, DOI 10.1136/neurintsurg-2016-012319
   PERLMUTTER D, 1978, J NEUROSURG, V49, P204, DOI 10.3171/jns.1978.49.2.0204
   Phan Kevin, 2018, Neurointervention, V13, P100, DOI 10.5469/neuroint.2018.00997
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Sarraj A, 2016, JAMA NEUROL, V73, P1291, DOI 10.1001/jamaneurol.2016.2773
   Shirakawa M, 2017, J STROKE CEREBROVASC, V26, P1732, DOI 10.1016/j.jstrokecerebrovasdis.2017.03.038
   Turk AS, 2014, J NEUROINTERV SURG, V6, P231, DOI 10.1136/neurintsurg-2013-010713
   von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E495
EP E502
DI 10.1016/j.wneu.2019.07.202
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300061
PM 31382073
DA 2020-05-12
ER

PT J
AU Mizutani, K
   Arai, N
   Toda, M
   Akiyama, T
   Fujiwara, H
   Jinzaki, M
   Yoshida, K
AF Mizutani, Katsuhiro
   Arai, Nobuhiko
   Toda, Masahiro
   Akiyama, Takenori
   Fujiwara, Hirokazu
   Jinzaki, Masahiro
   Yoshida, Kazunari
TI A Novel Flow Dynamics Study of the Intracranial Veins Using Whole Brain
   Four-Dimensional Computed Tomography Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE 4D-CTA; Flow direction; Flow dynamics; Flow velocity; Intracranial vein
ID DURAL ARTERIOVENOUS-FISTULAS; VENOUS-BLOOD FLOW; VELOCITY
AB BACKGROUND: The flow dynamics of the intracranial venous channels are fundamentally important for understanding intracranial physiology and pathophysiology. However, the method clinically applicable to the evaluation of the flow dynamics of the intracranial venous system has not been well described in the reported data. We have developed a new method to evaluate intracranial venous flow direction and velocity using 4-dimensional (4D) computed tomography angiography (CTA). The aim of the present study was to verify the accuracy and validity of 4D-CTA in a clinical setting.
   METHODS: We retrospectively analyzed 97 veins from 26 patients (16 cases of arteriovenous shunt disease, 9 intracranial tumor cases, and 1 cerebral aneurysm case) who had undergone both 4D-CTA and conventional digital subtraction angiography (DSA). Using 4D-CTA, we analyzed the time-density curve with gamma distribution extrapolation and obtained the direction of the flow and flow velocity of each vein. The direction of the flow in 4D-CTA was also collated with that obtained using conventional DSA to verify the experimental method.
   RESULTS: The direction of the flow determined by 4D-CTA was consistent with that of conventional DSA in 94.8% of cases. The average venous flow velocity was 64.3 mm/ second and 81.8 mm/second, respectively, in the antegrade and retrograde channels affected by arteriovenous shunts.
   CONCLUSIONS: The present flow analysis using 4D-CTA enabled us to evaluate the direction and velocity of intracranial venous flow. Other than some limitations, the presented method is reliable and its potential for application in clinical settings is promising.
C1 [Mizutani, Katsuhiro; Arai, Nobuhiko; Toda, Masahiro; Akiyama, Takenori; Yoshida, Kazunari] Keio Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
   [Mizutani, Katsuhiro] Hop Foch, Serv Neuroradiol Diagnost & Therapeut, Suresnes, France.
   [Fujiwara, Hirokazu; Jinzaki, Masahiro] Keio Univ, Dept Radiol, Sch Med, Tokyo, Japan.
RP Mizutani, K (reprint author), Keio Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.; Mizutani, K (reprint author), Hop Foch, Serv Neuroradiol Diagnost & Therapeut, Suresnes, France.
EM katsu512@yahoo.co.jp
RI Akiyama, Takenori/L-3453-2013
OI Akiyama, Takenori/0000-0003-2795-7411; Mizutani,
   Katsuhiro/0000-0002-3158-0189; Toda, Masahiro/0000-0003-2700-1620; Arai,
   Nobuhiko/0000-0003-4434-7551
CR Connolly F, 2018, J NEUROSURG, V129, P1136, DOI 10.3171/2017.5.JNS17232
   D'Orazio F, 2014, NEURORADIOL J, V27, P710, DOI 10.15274/NRJ-2014-10096
   DAVENPORT R, 1983, J NUCL MED, V24, P945
   Dawkins AA, 2007, NEURORADIOLOGY, V49, P753, DOI 10.1007/s00234-007-0252-y
   Fujiwara H, 2013, NEURORADIOLOGY, V55, P837, DOI 10.1007/s00234-013-1181-6
   Harrer JU, 2005, STROKE, V36, P976, DOI 10.1161/01.STR.0000162586.55769.fb
   Holling M, 2013, NEUROSURGERY, V73, P93, DOI 10.1227/NEU.0b013e31828772a4
   Hope MD, 2009, AM J NEURORADIOL, V30, P362, DOI 10.3174/ajnr.A1138
   Kilic Turker, 2008, Front Neurol Neurosci, V23, P4
   Kortman HGJ, 2015, AM J NEURORADIOL, V36, P1026, DOI 10.3174/ajnr.A4162
   MADSEN MT, 1992, PHYS MED BIOL, V37, P1597, DOI 10.1088/0031-9155/37/7/010
   Maduri R, 2016, ACTA NEUROCHIR, V158, P1387, DOI 10.1007/s00701-016-2812-6
   Mehta NR, 2000, AM J ROENTGENOL, V175, P221, DOI 10.2214/ajr.175.1.1750221
   Mizutani K, 2018, CLIN NEUROL NEUROSUR, V167, P11, DOI 10.1016/j.clineuro.2018.02.007
   Niesen WD, 2004, STROKE, V35, P1873, DOI 10.1161/01.STR.0000132195.17366.2b
   Schaller B, 2004, BRAIN RES REV, V46, P243, DOI 10.1016/j.brainresrev.2004.04.005
   Shen QM, 1999, J CLIN MONIT COMPUT, V15, P179, DOI 10.1023/A:1009925811965
   STARMER CF, 1970, J APPL PHYSIOL, V28, P219
   Tsai LK, 2008, J MED ULTRASOUND, V16, P57, DOI 10.1016/S0929-6441(08)60006-5
   Valdueza JM, 1999, ARCH NEUROL-CHICAGO, V56, P229, DOI 10.1001/archneur.56.2.229
   Valdueza JM, 1996, STROKE, V27, P1221, DOI 10.1161/01.STR.27.7.1221
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E176
EP E185
DI 10.1016/j.wneu.2019.07.109
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300021
PM 31330333
DA 2020-05-12
ER

PT J
AU Muller, SJ
   Freimann, FB
   von Der Brelie, C
   Rohde, V
   Schatlo, B
AF Mueller, Sebastian J.
   Freimann, Florian B.
   von Der Brelie, Christian
   Rohde, Veit
   Schatlo, Bawarjan
TI Test-Retest Reliability of Outpatient Telemetric Intracranial Pressure
   Measurements in Shunt-Dependent Patients with Hydrocephalus and
   Idiopathic Intracranial Hypertension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Intracranial pressure; Shunt failure; Telemetric
   measurement
ID ICP; SENSOR
AB BACKGROUND: Some patients with hydrocephalus and idiopathic intracranial hypertension treated for elevated intracranial pressure (ICP) with a cerebrospinal fluid shunt may continue to experience symptoms or develop new symptoms despite valve adjustments. Use of telemetric ICP measurements may help confirm clinical suspicion of cerebrospinal fluid underdrainage or overdrainage in these patients. However, point in time, duration, and activity during the measurements have never been standardized. We devised a simple, repeatable maneuver for outpatient telemetric ICP recording and evaluated its test-retest reliability.
   METHODS: Data of patients who underwent ven-triculoperitoneal or ventriculoatrial shunt placement and subsequent telemetric ICP sensor implantation were retrospectively reviewed. Telemetric ICP recordings in patients were conducted in a standardized manner: The standing-supine-sitting paradigm requires postural changes in 10-minute intervals over 30 minutes. First, the patient is requested to walk; second, to lay down; third, to sit down with a headrest elevation of 60 degrees. ICP data (in mmHg) were reported as mean +/- SD values. Test-retest validity was assessed using Pearson correlation analysis.
   RESULTS: We evaluated 66 ICP datasets obtained repeatedly with a time difference of at least 24 hours. Overall test-retest reliability was excellent (Pearson correlation coefficient 0.99, P < 0.001), as were the scores for individual postures: standing (correlation 0.98, P < 0.001), supine (correlation 0.98, P< 0.001), and sitting (correlation 0.99, P < 0.001). The sum of square differences of the test-retest measures reflected a comparable validity of all tested positions.
   CONCLUSIONS: We confirmed high test-retest reliability of the standing-supine-sitting paradigm for telemetric ICP measurements in the outpatient setting. High test-retest reliability should be considered as prerequisite for clinical decision making.
C1 [Mueller, Sebastian J.; Freimann, Florian B.; von Der Brelie, Christian; Rohde, Veit; Schatlo, Bawarjan] Georg August Univ, Univ Med Gottingen, Dept Neurosurg, Gottingen, Germany.
RP Schatlo, B (reprint author), Georg August Univ, Univ Med Gottingen, Dept Neurosurg, Gottingen, Germany.
EM Bawarjan.schatlo@med.uni-goettingen.de
OI Mueller, Sebastian Johannes/0000-0003-2147-9797
CR Andresen M, 2015, ACTA NEUROCHIR, V157, P109, DOI 10.1007/s00701-014-2250-2
   Antes S, 2016, WORLD NEUROSURG, V91, P133, DOI 10.1016/j.wneu.2016.03.096
   Antes S, 2014, ACTA NEUROCHIR, V156, P1009, DOI 10.1007/s00701-013-1991-7
   Antes S, 2014, CHILD NERV SYST, V30, P331, DOI 10.1007/s00381-013-2269-3
   Citerio G, 2004, ACTA NEUROCHIR, V146, P1221, DOI 10.1007/s00701-004-0351-z
   Citerio G, 2008, NEUROSURGERY, V63, P1152, DOI 10.1227/01.NEU.0000335148.87042.D7
   Eide PK, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-75
   Freimann FB, 2014, CHILD NERV SYST, V30, P689, DOI 10.1007/s00381-013-2324-0
   Freimann FB, 2013, PEDIATR NEUROSURG, V49, P29, DOI 10.1159/000355561
   Frim DM, 2000, PEDIATR NEUROSURG, V33, P237, DOI 10.1159/000055961
   Golz Leonie, 2013, Surg Neurol Int, V4, P140, DOI 10.4103/2152-7806.119879
   Kiefer Michael, 2012, Acta Neurochir Suppl, V114, P111, DOI 10.1007/978-3-7091-0956-4_20
   Kiefer M, 2011, IEEE ENG MED BIO, P2246, DOI 10.1109/IEMBS.2011.6090426
   Lemcke J, 2013, J NEUROL NEUROSUR PS, V84, P850, DOI 10.1136/jnnp-2012-303936
   Petersen LG, 2016, AM J PHYSIOL-REG I, V310, pR100, DOI 10.1152/ajpregu.00302.2015
NR 15
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E74
EP E80
DI 10.1016/j.wneu.2019.07.014
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300010
PM 31295619
DA 2020-05-12
ER

PT J
AU Ogawa, Y
   Tominaga, T
AF Ogawa, Yoshikazu
   Tominaga, Teiji
TI Partial Reconstitution of the Hypothalamo-Pituitary Axes After Pituitary
   Stalk Sectioning and Specific Magnetic Resonance Imaging Findings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diabetes insipidus; Hypothalamus; Magnetic resonance imaging; Pituitary
   stalk sectioning; Reconstitution; Recovery
ID DIABETES-INSIPIDUS; CRANIOPHARYNGIOMA; COLOCALIZATION; HYPOTHALAMUS;
   VASOPRESSIN; RESECTION; OXYTOCIN; CHILDREN; NEURONS; RISK
AB BACKGROUND: Pituitary stalk sectioning is only essential in cases of craniopharyngioma originating from the stalk or metastatic tumor to the stalk. Some patients can discontinue postoperative antidiuretic hormone (ADH) supplementation with special conditions.
   METHODS: Sixty-three patients with craniopharyngiomas who were treated by surgery with pituitary stalk sectioning were included in this study. Great care was taken to preserve the fine arteries running along the lateral walls of the third ventricle. Removal rates, change of endocrinologic status, and magnetic resonance imaging (MRI) findings were investigated.
   RESULTS: Total removal was achieved in 52 of 54 patients in initial surgery (96.3%), and in 5 of 9 patients in retreatment (55.6%). ADH supplementation was required in all patients from the day of surgery, but was discontinued in 29 of 54 patients among the initial surgery group (53.7%) and in 2 of 9 patients among the retreatment group (22.2%). Preservation of thyroid hormone secretion was observed in 24 of 31 patients who could discontinue ADH (77.4%), but only in 12 of 32 patients who could not discontinue ADH (37.5%). Recovery from diabetes insipidus (DI) was significantly associated with preservation of thyroid function (P < 0.01). Postoperative MRI showed that part of the hypothalamus was enhanced in patients with recovery from DI.
   CONCLUSIONS: Total removal was achieved in 91% of all cases. Half of the patients could discontinue ADH supplementation, which was associated with preservation of thyroid function. The findings of hypothalamic enhancement on postoperative MRI may be associated with recovery from DI.
C1 [Ogawa, Yoshikazu] Kohnan Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Tominaga, Teiji] Tohoku Univ, Dept Neurosurg, Grad Sch Med, Sendai, Miyagi, Japan.
RP Ogawa, Y (reprint author), Kohnan Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
EM yogawa@kohnan-sendai.or.jp
CR Arima H, 2014, ENDOCR J, V61, P143, DOI 10.1507/endocrj.EJ13-0368
   Bacova Z, 2006, CELL MOL NEUROBIOL, V26, P1047, DOI 10.1007/s10571-006-9013-4
   Bengtsson D, 2017, J CLIN ENDOCR METAB, V102, P3928, DOI 10.1210/jc.2017-01401
   Brodal A., 1989, NEUROLOGICAL ANATOMY
   Cheng J, 2017, J CRANIOFAC SURG, V28, pE591, DOI 10.1097/SCS.0000000000003920
   Cuesta M, 2017, PITUITARY, V20, P372, DOI 10.1007/s11102-016-0784-4
   Di Iorgi N, 2014, J CLIN ENDOCR METAB, V99, P1264, DOI 10.1210/jc.2013-3724
   Fernandez-Lopez B, 2017, J ANAT, V231, P776, DOI 10.1111/joa.12674
   Habu M, 2015, J NEUROSURG, V123, P998, DOI 10.3171/2014.12.JNS14870
   Kandel ER, 1981, PRINCIPALS NEURAL SC
   Kassam AB, 2008, J NEUROSURG, V108, P715, DOI 10.3171/JNS/2008/108/4/0715
   Kohno D, 2008, ENDOCRINOLOGY, V149, P1295, DOI 10.1210/en.2007-1276
   Langrand-Escure J, 2016, Rev Med Liege, V71, P332
   Muller HL, 2017, PITUITARY, V20, P267, DOI 10.1007/s11102-016-0751-0
   Nagata Y, 2018, WORLD NEUROSURG, V114, pE1225, DOI 10.1016/j.wneu.2018.03.180
   Nishizawa S, 2006, NEUROL MED-CHIR, V46, P126, DOI 10.2176/nmc.46.126
   Ogawa Y, 2017, ACTA NEUROCHIR, V159, P865, DOI 10.1007/s00701-017-3112-5
   Ogawa Y, 2015, ACTA NEUROCHIR, V157, P1731, DOI 10.1007/s00701-015-2519-0
   Ogawa Y, 2014, CLIN NEUROL NEUROSUR, V125, P41, DOI 10.1016/j.clineuro.2014.07.014
   Otero-Garcia M, 2016, BRAIN STRUCT FUNCT, V221, P3445, DOI 10.1007/s00429-015-1111-y
   Romanova I V, 2017, Dokl Biol Sci, V472, P11, DOI 10.1134/S0012496617010082
   Salvatore B, 2018, CLIN NUCL MED, V43, P363, DOI 10.1097/RLU.0000000000002037
   WORDINGER RJ, 1977, AM J VET RES, V38, P449
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E81
EP E87
DI 10.1016/j.wneu.2019.07.057
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300011
PM 31306837
DA 2020-05-12
ER

PT J
AU Ozoner, B
   Cakir, T
   Kayaci, S
   Aydin, MD
   Aydin, S
   Demirci, E
AF Ozoner, Baris
   Cakir, Tayfun
   Kayaci, Selim
   Aydin, Mehmet Dumlu
   Aydin, Seckin
   Demirci, Elif
TI Effect of Vasa Vasorum on Basilar Artery Vasospasm Following
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basilar artery; Degeneration; Subarachnoid hemorrhage; Vasa vasorum;
   Vasospasm
ID CEREBRAL VASOSPASM; EXPERIMENTAL-MODEL
AB BACKGROUND: A well-documented association exists between the vasa vasorum and vasopathologies, including atherosclerosis. However, information on the role of the vasa vasorum during vascular degenerative changes of vasospasm after subarachnoid hemorrhage (SAH) is insufficient.
   METHODS: In this study, 34 rabbits were divided into 3 groups: basal group (N = 8), sham group (N = 8), and SAH group (N = 18). Experimental SAH was formed using a double-injection model. During follow-up, the neurologic status of the rabbits was observed. All rabbits were euthanized after 2 weeks, and the vasopathologic degeneration was categorized as normal, mild, moderate, and severe according to the changes in the basilar arteries. The numbers, locations, and spasms of the vasa vasorum and their relation to the vasodegenerative changes of the basilar artery were investigated.
   RESULTS: The basilar arteries were graded as normal in the basal and sham groups. In the SAH group, 6 rabbits had mild, 7 had moderate, and 5 had severe degeneration. Neurologic deficits were prominent in the SAH group, and deficit grades correlated with vascular degeneration. The number of the vasa vasorum were significantly higher in the SAH group, and an enhanced formation of the vasa vasorum was noted in which severe degenerative changes were present. Moreover, the vasospasm index of the vasa vasorum, which increased with the aggravation of vascular degenerative changes, was significantly higher in the SAH group.
   CONCLUSIONS: The vasa vasorum and their vasospasm play a crucial role in the pathogenesis of basilar artery degeneration in the vasospasm following SAH.
C1 [Ozoner, Baris; Cakir, Tayfun; Kayaci, Selim] Erzincan Binali Yildirim Univ, Sch Med, Dept Neurosurg, Erzincan, Turkey.
   [Aydin, Mehmet Dumlu] Ataturk Univ, Sch Med, Dept Neurosurg, Erzurum, Turkey.
   [Aydin, Seckin] Univ Med Sci, Okmeydani Res & Educ Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Demirci, Elif] Firat Univ, Sch Med, Dept Pathol, Elazig, Turkey.
RP Aydin, MD (reprint author), Ataturk Univ, Sch Med, Dept Neurosurg, Erzurum, Turkey.
EM nmda11@hotmail.com
RI aydin, seckin/F-8538-2015
OI CAKIR, TAYFUN/0000-0002-9979-9291; Ozoner, Baris/0000-0003-0534-2766
CR Al-Mufti F, 2017, WORLD NEUROSURG, V107, P148, DOI [10.1016/J.WNEU.2017.07.114, 10.1016/j.wneu.2017.07.114]
   BARKER SGE, 1992, J ANAT, V180, P225
   Cahill J, 2006, STROKE, V37, P1868, DOI 10.1161/01.STR.0000226995.27230.96
   Connolly ES, 1996, NEUROSURGERY, V38, P789, DOI 10.1227/00006123-199604000-00031
   ENDO S, 1988, STROKE, V19, P1420, DOI 10.1161/01.STR.19.11.1420
   ESPINOSA F, 1986, NEUROSURGERY, V19, P935, DOI 10.1227/00006123-198612000-00007
   FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Guvenc Y, 2017, J NEUROL SURG PART A, V78, P124, DOI 10.1055/s-0036-1584906
   HUGHES JT, 1978, J NEUROSURG, V48, P515, DOI 10.3171/jns.1978.48.4.0515
   Inagawa T, 2016, WORLD NEUROSURG, V85, P56, DOI 10.1016/j.wneu.2015.08.052
   Kamp MA, 2013, ACTA NEUROCHIR, V155, P255, DOI 10.1007/s00701-012-1559-y
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Kayaci S, 2011, AUTON NEUROSCI-BASIC, V165, P163, DOI 10.1016/j.autneu.2011.06.008
   Kikkawa Y., 2014, ACTA NEUROCHIR S, V120, P331
   LISZCZAK TM, 1984, AM J ANAT, V170, P223, DOI 10.1002/aja.1001700207
   LISZCZAK TM, 1983, J NEUROSURG, V58, P18, DOI 10.3171/jns.1983.58.1.0018
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   MARTIN JF, 1991, EUR J CLIN INVEST, V21, P355, DOI 10.1111/j.1365-2362.1991.tb01382.x
   Mayberg M R, 1990, Neurosurg Clin N Am, V1, P417
   MAYBERG MR, 1990, J NEUROSURG, V72, P626, DOI 10.3171/jns.1990.72.4.0626
   Mulligan-Kehoe MJ, 2014, CIRCULATION, V129, P2557, DOI 10.1161/CIRCULATIONAHA.113.007189
   Nishimiya K, 2016, CIRC J, V80, P2252, DOI 10.1253/circj.CJ-16-0580
   Pahl FH, 2016, WORLD NEUROSURG, V85, DOI 10.1016/j.wneu.2015.09.103
   Reilly C, 2004, J NEUROSURG, V101, P255, DOI 10.3171/jns.2004.101.2.0255
   Ritman EL, 2007, CARDIOVASC RES, V75, P649, DOI 10.1016/j.cardiores.2007.06.020
   Sviri GE, 2006, STROKE, V37, P2738, DOI 10.1161/01.STR.0000244765.29502.85
   Takaba M, 1998, ACTA NEUROCHIR, V140, P411, DOI 10.1007/s007010050118
   Turkmenoglu O, 2014, ASIAN J NEUROSURG, V12, P22
   van Lieshout JH, 2018, NEUROSURG REV, V41, P917, DOI 10.1007/s10143-017-0827-y
   YAMASHIMA T, 1983, J NEUROSURG, V58, P843, DOI 10.3171/jns.1983.58.6.0843
   ZERVAS NT, 1982, J NEUROSURG, V56, P475, DOI 10.3171/jns.1982.56.4.0475
   Zheng L, 2018, J STROKE, V20, P342, DOI 10.5853/jos.2018.01263
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E218
EP E225
DI 10.1016/j.wneu.2019.02.124
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300026
PM 31349081
DA 2020-05-12
ER

PT J
AU Park, CK
   Lee, SH
   Park, BJ
AF Park, Chang Kyu
   Lee, Seung Hwan
   Park, Bong Jin
TI Surgical Outcomes of Revision Microvascular Decompression for Persistent
   or Recurrent Hemifacial Spasm After Surgery: Analysis of Radiologic and
   Intraoperative Findings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Failed surgery; Hemifacial spasm; Microvascular decompression; Recurrent
   hemifacial spasm; Teflon granuloma
ID TRIGEMINAL NEURALGIA; TEFLON GRANULOMA; REOPERATION
AB OBJECTIVES: Microvascular decompression (MVD) is the treatment of choice for hemifacial spasm (HFS), due to the high rate of complete resolution associated with MVD. However, some patients experience recurrent or persistent symptoms after surgery. In this study, we evaluated the causes of recurrence or failure based on our surgical experience with revision of MVD for HFS and analyzed the relationship between surgical outcomes and radiologic and intraoperative findings.
   METHODS: Among more than 2500 patients who underwent MVD surgery for HFS, 23 patients received a second MVD in our hospital from January 2002 to December 2017. Three-dimensional time-of-flight magnetic resonance angiography and reconstructed imaging were used to identify the culprit vessel and its conflict on the root exit zone (REZ) of the facial nerve. We reviewed patients' medical records and operation videos to identify the missing points of first surgery.
   RESULTS: In our experience with revision of MVD, 8 patients had incomplete decompression, such as singlevessel decompression of multiple offending vessels. Teflon was not detected at the REZ but was found in other locations in 12 patients. Three patients had severe adhesion with previous Teflon around the REZ. Nineteen patients had excellent surgical outcomes at immediate postoperative evaluation; 20 patients showed spasm disappearance at 1 year after surgery and 3 patients showed persistent symptoms. Neurovascular contacts around the REZ of the facial nerve were revealed on magnetic resonance imaging of incomplete decompression and Teflon malposition patient groups. There were no clear neurovascular contacts in the patients with severe Teflon adhesion.
   CONCLUSIONS: The decision regarding secondary MVD for persistent or recurrent spasm is troubling. However, if neurovascular contact was observed in the MRI of the patient and there were offending vessels, the surgical outcome might be favorable.
C1 [Park, Chang Kyu; Lee, Seung Hwan; Park, Bong Jin] Kyung Hee Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Park, BJ (reprint author), Kyung Hee Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM hyunsong@khu.ac.kr
OI Park, Chang Kyu/0000-0002-5935-8264
FU Kyung Hee University [KHU-20182176]
FX This work was supported by a grant from Kyung Hee University in 2018
   (KHU-20182176). The authors declare that the article content was
   composed in the absence of any commercial or financial relationships
   that could be construed as a potential conflict of interest.
CR BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Chen JF, 2000, SURG NEUROL, V53, P281, DOI 10.1016/S0090-3019(00)00169-5
   Deep NL, 2017, LARYNGOSCOPE, V127, P715, DOI 10.1002/lary.26126
   Fan Zhao-min, 2009, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V44, P364
   Goto Y, 2002, NEUROL RES, V24, P296, DOI 10.1179/016164102101199774
   JANNETTA PJ, 1977, J NEUROSURG, V47, P321, DOI 10.3171/jns.1977.47.3.0321
   Jo KW, 2013, NEUROSURG REV, V36, P297, DOI 10.1007/s10143-012-0420-3
   Kim JP, 2008, J KOREAN NEUROSURG S, V44, P131, DOI 10.3340/jkns.2008.44.3.131
   Kureshi SA, 1998, NEUROSURGERY, V43, P1111, DOI 10.1097/00006123-199811000-00061
   Li CS, 2005, ACTA NEUROCHIR, V147, P617, DOI 10.1007/s00701-005-0492-8
   Ma QF, 2014, J CRANIOFAC SURG, V25, P1810, DOI 10.1097/SCS.0000000000000990
   Oda K, 2017, NEUROSURG REV, V40, P513, DOI 10.1007/s10143-017-0865-5
   Park YS, 2006, NEUROSURGERY, V58, P1162, DOI 10.1227/01.NEU.0000215954.97948.B3
   Ravina K, 2019, J NEUROL SURG PART B, V80, P31, DOI 10.1055/s-0038-1661348
   Wang XH, 2013, NEUROSURG REV, V36, P637, DOI 10.1007/s10143-013-0480-z
   Xia L, 2015, J CRANIOFAC SURG, V26, P408, DOI 10.1097/SCS.0000000000001406
   YAMAKI T, 1992, ACTA NEUROCHIR, V115, P1, DOI 10.1007/BF01400583
   Yuan Yue, 2003, Zhonghua Wai Ke Za Zhi, V41, P362
   Zhong J, 2014, NEUROL RES, V36, P882, DOI 10.1179/1743132814Y.0000000344
   Zhong J, 2010, ACTA NEUROCHIR, V152, P2119, DOI 10.1007/s00701-010-0794-3
NR 20
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E454
EP E459
DI 10.1016/j.wneu.2019.07.191
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300055
PM 31382068
DA 2020-05-12
ER

PT J
AU Park, HR
   Park, SQ
   Park, HK
   Im, SB
   Yoon, SM
   Kim, BT
AF Park, Hye Ran
   Park, Sukh Que
   Park, Hyung Ki
   Im, Soo-Bin
   Yoon, Seok Mann
   Kim, Bum-Tae
TI Current Training Status of Neurosurgical Residents in South Korea: A
   Nationwide Multicenter Survey
SO WORLD NEUROSURGERY
LA English
DT Article
DE Education; Neurosurgery; Surveys and questionnaires
AB BACKGROUND: In South Korea, special legislation was introduced in December 2016 to limit residents' training time to a maximum of 80 hours per week. The aim of this study was to survey the current training system and environment of neurosurgical residents and to find ways to improve the quality of neurosurgical training.
   METHODS: The questionnaire survey included 373 neurosurgical residents at 66 training hospitals nationwide, who were members of the Korean Neurosurgical Society. The survey method included a questionnaire link through a text message and was carried out anonymously. The survey was conducted for 7 days and targeted a total of 106 residents (28.4%).
   RESULTS: Most respondents selected "excessive training time" as a reason for dissatisfaction with the training environment (n = 61, 57.5%), followed by "limited number of opportunities for surgery" (n = 50, 47.2%), and "little experience for research" (n = 42, 39.6%). Respondents still believe that they have to work excessively longer, even after 80 hours of training per week.
   CONCLUSIONS: The major reason that neurosurgical residents are dissatisfied with the current training system and environment is the excessive time spent on it. These survey results are expected to be used as the basis for improvement of the residents' training system and work environment in South Korea.
C1 [Park, Hye Ran; Park, Sukh Que; Park, Hyung Ki] Soonchunhyang Univ, Dept Neurosurg, Seoul Hosp, Seoul, South Korea.
   [Im, Soo-Bin; Kim, Bum-Tae] Soonchunhyang Univ, Dept Neurosurg, Bucheon Hosp, Buecheon, South Korea.
   [Yoon, Seok Mann] Soonchunhyang Univ, Dept Neurosurg, Cheonan Hosp, Cheonan, South Korea.
RP Kim, BT (reprint author), Soonchunhyang Univ, Dept Neurosurg, Bucheon Hosp, Buecheon, South Korea.
EM bumtkim@gmail.com
OI bag, hyelan/0000-0003-0506-4882
CR BURKE RJ, 1990, PSYCHOL REP, V67, P1335
   Immerman Igor, 2007, Am J Orthop (Belle Mead NJ), V36, pE172
   Jagsi R, 2005, ARCH INTERN MED, V165, P2607, DOI 10.1001/archinte.165.22.2607
   Johns MME, 2009, RESIDENT DUTY HOURS
   Kim BT, 2016, J KOREAN NEUROSURG S, V59, P325, DOI 10.3340/jkns.2016.59.3.325
   Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406
   Lee KS, 2018, J KOREAN NEUROSURG S, V61, P474, DOI 10.3340/jkns.2017.0404.012
   Lee SW, 2012, HLTH POLICY FORUM, V10, P50
   Murguia-Fuentes R, 2018, WORLD NEUROSURG, V120, pE1079, DOI 10.1016/j.wneu.2018.08.232
   Park HR, 2018, J KOREAN NEUROSURG S, V61, P105, DOI 10.3340/jkns.2017.0303.006
   Park J, 2017, J KOREAN NEUROSURG S, V60, P385, DOI 10.3340/jkns.2017.0101.007
   Stienen MN, 2017, J NEUROL SURG PART A, V78, P337, DOI 10.1055/s-0036-1594012
   Temple J, 2010, TIME TRAINING REV IM
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E329
EP E338
DI 10.1016/j.wneu.2019.07.147
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300040
PM 31356983
DA 2020-05-12
ER

PT J
AU Park, JH
   Hong, JT
   Lee, JB
   Kim, IS
AF Park, Jong-Hyeok
   Hong, Jae Taek
   Lee, Jong Beom
   Kim, Il Sup
TI Clinical Analysis of Radiologic Measurements in Patients with Basilar
   Invagination
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial fusion; Basilar invagination; Correlation; Modified Ranawat
   method; Occipitocervical fusion; Redlund-Johnell method
ID RHEUMATOID-ARTHRITIS; VERTICAL TRANSLOCATION; CERVICAL-SPINE;
   DISTRACTION; RELIABILITY; INDEX
AB OBJECTIVE: To investigate correlations between radiologic measurements and clinical outcomes in patients with basilar invagination (BI).
   METHODS: The medical records and radiologic data of 46 patients (27 women) who had undergone posterior atlantoaxial fusion or occipitocervical fusion for BI from January 2010 to June 2018 were retrospectively analyzed. Patients under 15 years old or with a polytraumatic, tumorous, or infectious pathology were excluded. The modified Ranawat method (MRM) and the Redlund-Johnell method (RJM) were used to obtain radiographic measurements of basilar invagination preoperatively, subacute postoperatively, and at 3-month and last follow-up. Visual analogue scale, Neck Disability Index, and Japanese Orthopedic Association (JOA) scores were also assessed. Correlations between MRM and RJM measurements and clinical outcomes were evaluated.
   RESULTS: Mean age of patients was 59.9 + 16.5 years, mean body mass index was 23.5 +/- 4.6 kg/m(2), and mean follow-up was 37.9 +/- 23.8 months. Postoperative radiologic measurements increased about 36% of preoperative radiologic measurements. Subsidence at the C1-2 joint occurred in most patients at 3 months postoperatively, but clinical outcomes did not deteriorate. JOA scores were linearly correlated with percentage increases in both radiologic measurements subacute postoperatively (P < 0.05), hut this significance was not maintained until the last follow-up. Occipital numbness and neuralgia were most common postoperative complications. One case of neurovascular injury and 3 cases of postoperative dysphagia occurred postoperatively.
   CONCLUSIONS: The subacute postoperative neurological outcomes of BI patients are significantly related to the amount of vertical reduction.
C1 [Park, Jong-Hyeok] Catholic Univ Korea, Incheon St Marys Hosp, Dept Neurosurg, Incheon, South Korea.
   [Hong, Jae Taek] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Lee, Jong Beom; Kim, Il Sup] Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.
RP Hong, JT (reprint author), Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM jatagi@daum.net
CR BODEN SD, 1993, J BONE JOINT SURG AM, V75A, P1282, DOI 10.2106/00004623-199309000-00004
   Casey ATH, 1997, J NEUROSURG, V87, P863, DOI 10.3171/jns.1997.87.6.0863
   Casey ATH, 1997, J NEUROSURG, V87, P856, DOI 10.3171/jns.1997.87.6.0856
   Chandra PS, 2014, OPER NEUROSURG, V10, P621, DOI 10.1227/NEU.0000000000000470
   Donnally III CJ, 2018, BASILAR INVAGINATION
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Han MH, 2017, SPINE, V42, P966, DOI 10.1097/BRS.0000000000001942
   Hong J, 2017, NEW ENGL J MED, V376, pE46, DOI 10.1056/NEJMicm1610752
   Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8
   Jian FZ, 2010, NEUROSURGERY, V66, P678, DOI 10.1227/01.NEU.0000367632.45384.5A
   Joaquim AF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14664
   Kersten RFMR, 2015, SPINE J, V15, P1446, DOI 10.1016/j.spinee.2013.08.030
   Kim CH, 2015, EUR SPINE J, V24, P671, DOI 10.1007/s00586-015-3791-7
   Kim DH, 2005, J AM ACAD ORTHOP SUR, V13, P463, DOI 10.5435/00124635-200511000-00006
   Klekamp J, 2014, EUR SPINE J, V23, P1656, DOI 10.1007/s00586-014-3423-7
   Kulkarni AG, 2008, J SPINAL DISORD TECH, V21, P4, DOI 10.1097/BSD.0b013e31804856d7
   Kwong Y, 2011, AM J ROENTGENOL, V196, pW421, DOI 10.2214/AJR.10.5339
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee HJ, 2013, J KOREAN NEUROSURG S, V54, P275, DOI 10.3340/jkns.2013.54.4.275
   Matsumoto M, 2008, SPINE, V33, P1034, DOI 10.1097/BRS.0b013e31816c913b
   RANAWAT CS, 1979, J BONE JOINT SURG AM, V61, P1003, DOI 10.2106/00004623-197961070-00006
   REDLUNDJOHNELL I, 1984, ACTA RADIOL DIAGN, V25, P23, DOI 10.1177/028418518402500105
   REDLUNDJOHNELL I, 1984, ACTA RADIOL DIAGN, V25, P133, DOI 10.1177/028418518402500209
   Riew KD, 2001, J BONE JOINT SURG AM, V83A, P194, DOI 10.2106/00004623-200102000-00006
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E108
EP E115
DI 10.1016/j.wneu.2019.07.080
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300014
PM 31323410
DA 2020-05-12
ER

PT J
AU Perry, A
   Graffeo, CS
   Meyer, J
   Carlstrom, LP
   Oushy, S
   Driscoll, CLW
   Meyer, FB
AF Perry, Avital
   Graffeo, Christopher S.
   Meyer, Jenna
   Carlstrom, Lucas P.
   Oushy, Soliman
   Driscoll, Colin L. W.
   Meyer, Fredric B.
TI Beyond the Learning Curve: Comparison of Microscopic and Endoscopic
   Incidences of Internal Carotid Injury in a Series of Highly Experienced
   Operators
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrovascular; Complications; Internal carotid artery; Transsphenoidal
   resection; Vascular injury
ID SKULL BASE SURGERY; TRANSSPHENOIDAL PITUITARY SURGERY; SIMULATION
   TRAINING MODEL; ENDONASAL APPROACH; ARTERY INJURIES; ADENOMAS;
   COMPLICATIONS; MICROSURGERY; TRANSNASAL; OUTCOMES
AB BACKGROUND: As the endoscopic endonasal approach (EEA) has gained popularity as an alternative to microsurgery (MS) for transsphenoidal resection (TSR), numerous studies have attempted to assess the differential risk of internal carotid artery (ICA) injury between the techniques, yet results have been equivocal and contradictory. The aim of this study was to evaluate ICA injury in MS versus EEA among highly experienced neurosurgeons.
   METHODS: We performed a systematic literature review of publications from 2002-2017 reporting ICA injury outcomes in >= 250 cases using MS or EEA.
   RESULTS: Seventeen series reporting 11,149 patients were included: 3 MS series, 13 EEA series, and 1 series with adequate samples for each. ICA injury incidences were 0.0%-1.6% in cohorts of 275-3000. MS series documented 5 ICA injuries in 2672 operations, for an overall incidence of 0.2% (range, 0.0%-0.4%), and EEA series reported 30 ICA injuries in 8477 operations, for a 0.4% injury rate (range, 0.0%-1.6%); the difference was nonsignificant (P = 0.25). Increased operative experience was associated with decreased incidence of ICA injury, a finding preserved in the overall study cohort and within discretely examined MS and EEA subgroups (overall r(2) = 0.08, MS r(2) = 0.23, EEA r(2) = 0.07).
   CONCLUSIONS: ICA injury is the most serious complication of TSR of pituitary neoplasms. Operator inexperience may be a more important risk factor than choice of surgical technique, given the comparably low rates of injury obtained by highly experienced surgeons independent of technique. This emphasizes the need for consolidated care in pituitary centers of excellence, improvement of high-fidelity simulators, and skull base mentorship between senior and junior staff.
C1 [Perry, Avital; Graffeo, Christopher S.; Meyer, Jenna; Carlstrom, Lucas P.; Oushy, Soliman; Meyer, Fredric B.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Driscoll, Colin L. W.] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN USA.
RP Meyer, FB (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM Meyer.Fredric@mayo.edu
OI Oushy, Soliman/0000-0001-6343-6950
CR Ammirati M, 2013, J NEUROL NEUROSUR PS, V84, P843, DOI 10.1136/jnnp-2012-303194
   Simal-Julian JA, 2014, NEUROCIRUGIA, V25, P170, DOI 10.1016/j.neucir.2013.12.001
   Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926
   Asemota AO, 2017, NEUROSURGERY, V81, P458, DOI 10.1093/neuros/nyx350
   Barker FG, 2003, J CLIN ENDOCR METAB, V88, P4709, DOI 10.1210/jc.2003-030461
   Barr J, 2016, J SURG EDUC, V73, P466, DOI 10.1016/j.jsurg.2015.11.014
   Baskaran V, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00069
   Bastos RVS, 2016, ARCH ENDOCRIN METAB, V60, P411, DOI 10.1590/2359-3997000000204
   Berker M, 2012, PITUITARY, V15, P288, DOI 10.1007/s11102-011-0368-2
   Bokhari AR, 2013, BRIT J NEUROSURG, V27, P44, DOI 10.3109/02688697.2012.709554
   Cheng RX, 2011, J INT MED RES, V39, P1985, DOI 10.1177/147323001103900545
   Christian EA, 2018, J NEUROSURG, V129, P792, DOI 10.3171/2017.5.JNS162982
   D'Haens J, 2009, SURG NEUROL, V72, P336, DOI 10.1016/j.surneu.2009.04.012
   Dehdashti AR, 2008, NEUROSURGERY, V62, P1006, DOI 10.1227/01.neu.0000325862.83961.12
   Carmen A, 2017, OPER NEUROSURG, V13, P138, DOI 10.1227/NEU.0000000000001180
   Dusick JR, 2007, NEUROSURGERY, V60, P322, DOI 10.1227/01.NEU.0000255408.84269.A8
   EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713
   Eseonu CI, 2017, WORLD NEUROSURG, V97, P317, DOI 10.1016/j.wneu.2016.09.120
   Esquenazi Y, 2017, WORLD NEUROSURG, V101, P186, DOI 10.1016/j.wneu.2017.01.110
   Frank G, 2006, NEUROENDOCRINOLOGY, V83, P240, DOI 10.1159/000095534
   Gao Y, 2016, J CRANIOFAC SURG, V27, pE157, DOI 10.1097/SCS.0000000000002401
   Gao Y, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-94
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   Gondim JA, 2011, PITUITARY, V14, P174, DOI 10.1007/s11102-010-0280-1
   Goudakos JK, 2011, CLIN OTOLARYNGOL, V36, P212, DOI 10.1111/j.1749-4486.2011.02331.x
   Graffeo CS, 2014, PITUITARY, V17, P349, DOI 10.1007/s11102-013-0508-y
   Grantcharov TP, 2003, AM J SURG, V185, P146, DOI 10.1016/S0002-9610(02)01213-8
   Guvenc G, 2016, J CRANIOFAC SURG, V27, P1015, DOI 10.1097/SCS.0000000000002684
   Halvorsen H, 2014, ACTA NEUROCHIR, V156, P441, DOI 10.1007/s00701-013-1959-7
   Han ZL, 2008, CLIN NEUROL NEUROSUR, V110, P570, DOI 10.1016/j.clineuro.2008.02.017
   Har-El G, 2005, OTOLARYNG CLIN N AM, V38, P723, DOI 10.1016/j.otc.2005.01.004
   Hu YY, 2017, JAMA SURG, V152, P318, DOI 10.1001/jamasurg.2016.4619
   Hu YY, 2012, J AM COLL SURGEONS, V214, P115, DOI 10.1016/j.jamcollsurg.2011.10.009
   Huang GD, 2016, J CRANIOFAC SURG, V27, pE648, DOI 10.1097/SCS.0000000000003000
   HUGHES GB, 1991, LARYNGOSCOPE, V101, P1280, DOI 10.1002/lary.5541011205
   Jane JA, 2002, NEUROSURGERY, V51, P435, DOI 10.1097/00006123-200208000-00025
   Jang JH, 2016, WORLD NEUROSURG, V96, P545, DOI 10.1016/j.wneu.2016.09.051
   Jho HD, 1996, ACTA NEUROCHIR, V138, P1416, DOI 10.1007/BF01411120
   Kabil MS, 2005, MINIM INVAS NEUROSUR, V48, P348, DOI 10.1055/s-2005-915635
   Kalinin P L, 2013, Zh Vopr Neirokhir Im N N Burdenko, V77, P28
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Kenan K, 2006, NEUROSURG REV, V29, P298, DOI 10.1007/s10143-006-0033-9
   Khan I, 2017, J PAK MED ASSOC, V67, P1777
   Komotar RJ, 2012, PITUITARY, V15, P150, DOI 10.1007/s11102-011-0359-3
   Kshettry VR, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16292
   Laws ER, 2013, J NEUROL NEUROSUR PS, V84, P829, DOI 10.1136/jnnp-2012-304541
   Laws ER, 1999, ENDOCRIN METAB CLIN, V28, P119, DOI 10.1016/S0889-8529(05)70059-1
   Lawton MT, 2002, NEUROSURGERY, V50, P1
   LEKAWA M, 1995, SURG LAPAROSC ENDOSC, V5, P455
   Magro E, 2016, WORLD NEUROSURG, V89, P442, DOI 10.1016/j.wneu.2016.02.059
   Meyer J, 2019, J NEUROL SURG PART B, DOI [10.1055/s-0039-1692484, DOI 10.1055/S-0039-1692484]
   Mortini P, 2005, NEUROSURGERY, V56, P1222, DOI 10.1227/01.NEU.0000159647.64275.9D
   O'Malley BW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E10
   Oldfield EH, 2013, J NEUROL NEUROSUR PS, V84, P827, DOI 10.1136/jnnp-2012-304583
   Paluzzi A, 2014, PITUITARY, V17, P307, DOI 10.1007/s11102-013-0502-4
   Prevedello DM, 2007, J NEUROSURG, V107, P206, DOI 10.3171/JNS-07/07/0206
   Qureshi T, 2016, BRIT J NEUROSURG, V30, P637, DOI 10.1080/02688697.2016.1199786
   Razak AA, 2013, BRIT J NEUROSURG, V27, P40, DOI 10.3109/02688697.2012.703353
   Rotenberg B, 2010, LARYNGOSCOPE, V120, P1292, DOI 10.1002/lary.20949
   Sander IM, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8020013
   Schaberg MR, 2010, CURR OPIN OTOLARYNGO, V18, P8, DOI 10.1097/MOO.0b013e328334db5b
   Sheehan MT, 1999, MAYO CLIN PROC, V74, P661, DOI 10.4065/74.7.661
   Shen J, 2018, OPER NEUROSURG, V15, P231, DOI 10.1093/ons/opx262
   Snyderman C, 2007, LARYNGOSCOPE, V117, P699, DOI 10.1097/mlg.0b013e318031c817
   Strychowsky J, 2011, J OTOLARYNGOL-HEAD N, V40, P175, DOI 10.2310/7070.2011.100118
   Sylvester PT, 2016, J NEUROSURG, V125, P1256, DOI 10.3171/2015.6.JNS142483
   Weinstock P, 2017, J NEUROSURG-PEDIATR, V20, P1, DOI 10.3171/2017.1.PEDS16568
   WILSON CB, 1978, J NEUROSURG, V48, P13, DOI 10.3171/jns.1978.48.1.0013
   Zada G, 2018, OPER NEUROSURG, V14, P72, DOI 10.1093/ons/opx074
   Zaidi HA, 2016, J NEUROSURG, V124, P596, DOI 10.3171/2015.4.JNS15102
NR 70
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E128
EP E135
DI 10.1016/j.wneu.2019.07.074
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300016
PM 31319187
DA 2020-05-12
ER

PT J
AU Raman, T
   Passias, PG
   Kebaish, KM
AF Raman, Tina
   Passias, Peter G.
   Kebaish, Khaled M.
TI Asymmetric Three-Column Osteotomy for Coronal Malalignment in Adult
   Patients with Prior Thoracic Fusion for Adolescent Idiopathic Scoliosis:
   Three-Year Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity; Asymmetric pedicle subtraction osteotomy;
   Coronal malalignment; Pedicle subtraction osteotomy; Revision spinal
   deformity surgery
ID SPINAL BALANCE; INSTRUMENTATION; COMPLICATIONS; PARAMETERS; IMBALANCE;
   ALIGNMENT; OUTCOMES; SURGERY; PAIN
AB OBJECTIVE: In the setting of a previous proximal fusion, an asymmetric 3-column osteotomy (3CO) can provide tremendous deformity correction. Our goal was to evaluate outcomes and complications of asymmetric 3CO through the proximal fusion mass, for coronal malalignment in patients with previous long thoracic fusion for adolescent idiopathic scoliosis.
   METHODS: This was a retrospective case series. Thirteen individuals with a history of a long thoracic fusion underwent asymmetric 3CO for persistent coronal malalignment. Clinical chart review was conducted to determine perioperative complications and radiographs evaluated for alignment.
   RESULTS: Thirteen patients (age: 57.8 +/- 12.2 years; 0 male, 13 female) completed a mean follow-up of 42.4 months. There was significant improvement in coronal and sagittal alignment, and pelvic incidence-lumbar lordosis postoperatively (P < 0.05). One patient developed lower-extremity weakness requiring revision decompression 72 hours postoperatively; the weakness subsequently resolved. One patient had a foot drop postoperatively. At final follow-up, 12 of 13 patients had grade 1 fusion at the osteotomy site; 1 patient had a grade 2 fusion. None of the patients developed a pseudarthrosis, or superficial or deep infections.
   CONCLUSIONS: Patients with a history of previous thoracic fusion for adolescent idiopathic scoliosis and coronal malalignment may develop painful degeneration of the segments caudal to the fusion as adults. In this setting, extension of fusion to the sacropelvis alone may worsen the patient's coronal alignment. An asymmetric 3CO may be considered at the proximal fusion mass to achieve realignment objectives, with an acceptable complication rate and an expected improvement in outcomes.
C1 [Raman, Tina; Passias, Peter G.] NYU, Dept Orthopaed Surg, Langone Orthoped Hosp, New York, NY 10003 USA.
   [Kebaish, Khaled M.] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA.
RP Raman, T (reprint author), NYU, Dept Orthopaed Surg, Langone Orthoped Hosp, New York, NY 10003 USA.
EM tina.raman@nyumc.org
CR Ames CP, 2012, J NEUROSURG-SPINE, V16, P547, DOI 10.3171/2012.2.SPINE11320
   Bartie BJ, 2009, SPINE, V34, pE873, DOI 10.1097/BRS.0b013e3181aa7d53
   Bridwell KH, 2010, SPINE, V35, P1849, DOI 10.1097/BRS.0b013e3181efa06a
   COCHRAN T, 1983, SPINE, V8, P576, DOI 10.1097/00007632-198309000-00003
   CONNOLLY PJ, 1995, J BONE JOINT SURG AM, V77A, P1210, DOI 10.2106/00004623-199508000-00011
   Cook S, 2000, SPINE, V25, P463, DOI 10.1097/00007632-200002150-00012
   Diebo BG, 2018, NEUROSURGERY, V83, P69, DOI 10.1093/neuros/nyx338
   Glassman SD, 2005, SPINE, V30, P682, DOI 10.1097/01.brs.0000155425.04536.f7
   Gupta MC, 2013, SPINE J, V13, P9
   Hu Z, 2014, SPINE J, V14, P122
   Iyer S, 2016, ASIAN SPINE J, V10, P601, DOI 10.4184/asj.2016.10.3.601
   Jain A, 2015, SPINE J, V15, P148
   Lafage R, 2016, SPINE, V41, P62, DOI 10.1097/BRS.0000000000001171
   Mac-Thiong JM, 2009, SPINE, V34, P519
   Miller DJ, 2010, STUD HEALTH TECHNOL, V158, P141, DOI 10.3233/978-1-60750-573-0-141
   Plais N, 2017, SPINE J, V17, P182
   Ploumis A, 2015, J SPINAL DISORD TECH, V28, P341, DOI 10.1097/BSD.0b013e3182aab2ff
   Rose PS, 2009, SPINE, V34, P785, DOI 10.1097/BRS.0b013e31819d0c86
   Schwab F, 2010, SPINE, V35, P2224, DOI 10.1097/BRS.0b013e3181ee6bd4
   Schwab F, 2009, SPINE, V34, P1828, DOI 10.1097/BRS.0b013e3181a13c08
   Schwab FJ, 2008, SPINE, V33, P2243, DOI 10.1097/BRS.0b013e31817d1d4e
   Shetty Ajoy Prasad, 2017, J Spine Surg, V3, P541, DOI 10.21037/jss.2017.09.04
   Smith JS, 2017, SPINE J, V17, P188
   Smith JS, 2011, SPINE, V36, P817, DOI 10.1097/BRS.0b013e3181e21783
   Thambiraj S, 2012, EUR SPINE J, V21, pS225, DOI 10.1007/s00586-012-2171-9
   Toyone T, 2012, SPINE, V37, P1847, DOI 10.1097/BRS.0b013e31825bf644
   Videbaek TS, 2011, SPINE, V36, P183, DOI 10.1097/BRS.0b013e3181cd9ee5
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E441
EP E446
DI 10.1016/j.wneu.2019.07.199
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300053
PM 31382065
DA 2020-05-12
ER

PT J
AU Ramos, MB
   Falavigna, A
   Abduljabbar, F
   Rabau, O
   Ferland, CE
   Weber, MH
   Ouellet, JA
   Teles, AR
AF Ramos, Miguel Bertelli
   Falavigna, Asdrubal
   Abduljabbar, Fahad
   Rabau, Oded
   Ferland, Catherine E.
   Weber, Michael H.
   Ouellet, Jean A.
   Teles, Alisson R.
TI Assessing Publication Rate of Abstracts Presented in Spine Conferences
   as a Quality Benchmark: The Example of the Canadian Spine Society Annual
   Meetings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Abstract; Neurosurgery; Orthopedics; Publication rate; PubMed; Spine
ID PEDIATRIC ORTHOPEDIC SOCIETY; CITED ARTICLES; INFLUENTIAL PUBLICATIONS;
   PODIUM PRESENTATIONS; AMERICAN ACADEMY; TOP 50; PAPER
AB BACKGROUND: Publication rate can indirectly assess the quality of research presented at scientific meetings. Considering presentations at orthopedic surgery and neurosurgery meetings, 10.5%-66% of abstracts are published in scientific journals. The publication rate of abstracts presented at Canadian Spine Society (CSS) meetings is unknown. The objective of this study was to evaluate the publication rate of abstracts presented at the CSS annual meetings from 2005 to 2014.
   METHODS: In October 2018, a systematic PubMed search was performed using title and authors of all abstracts presented at CSS meetings from 2005 to 2014. The following information was retrieved from the articles and abstracts: year, type of presentation, publication in PubMed, time from presentation to final publication, journal name, and journal impact factor (IF).
   RESULTS: A total of 621 abstracts were presented at CSS meetings from 2005 to 2014. The publication rate in PubMed was 54.8% (340/621). Oral presentations were more likely to be published than poster presentations (63.8% vs. 44.0%, respectively; odds ratio, 1.45; 95% confidence interval, 1.20-1.75; P < 0.0001). The mean time from presentation to publication was 1.76 +/- 1.93 years. The 340 identified articles were published in 87 different journals. The most common journals were Spine (n = 75; 22.1%), The Spine Journal (n = 40; 11.8%), and Journal of Neurosurgery: Spine (n = 28; 8.2%). The IF ranged from 0.18 to 47.66 (mean, 3.73 +/- 4.68). The IF of articles presented orally was higher than those presented as posters (P = 0.038).
   CONCLUSIONS: The CSS scientific meetings maintain a steady rate of high-quality research presentations as manifested by the significant publication rate (54.8%) in medical journals with a mean IF of 3.73. In comparison with other spine scientific meetings, the publication rates of abstracts presented at CSS meetings is among the highest.
C1 [Ramos, Miguel Bertelli; Falavigna, Asdrubal] Univ Caxias do Sul, Dept Neurosurg, Caxias Do Sul, RS, Brazil.
   [Abduljabbar, Fahad] King Abdulaziz Univ, Dept Orthoped Surg, Jeddah, Saudi Arabia.
   [Rabau, Oded; Ferland, Catherine E.; Weber, Michael H.; Ouellet, Jean A.; Teles, Alisson R.] McGill Univ, McGill Scoliosis & Spine Grp, Montreal, PQ, Canada.
RP Teles, AR (reprint author), McGill Univ, McGill Scoliosis & Spine Grp, Montreal, PQ, Canada.
EM alisson.r.teles@gmail.com
RI Abduljabbar, Fahad/AAL-9905-2020; falavigna, asdrubal/H-5123-2012
OI falavigna, asdrubal/0000-0002-0016-3198
CR Abicht BP, 2012, J FOOT ANKLE SURG, V51, P45, DOI 10.1053/j.jfas.2011.05.009
   Al-Hourani K, 2017, SICOT-J, V3, DOI 10.1051/sicotj/2017019
   Alan N, 2017, J CLIN NEUROSCI, V42, P19, DOI 10.1016/j.jocn.2017.02.019
   Amirhamzeh Daniel, 2012, J Pediatr Orthop, V32, pe6, DOI 10.1097/BPO.0b013e3182468c6b
   Ankomah F, 2018, WORLD NEUROSURG, V118, DOI 10.1016/j.wneu.2018.07.022
   Badhiwala JH, 2018, SPINE, V43, P1746, DOI 10.1097/BRS.0000000000002735
   Bovonratwet P, 2018, INT J SPINE SURG, V12, P713, DOI 10.14444/5089
   Czorlich P, 2016, J NEUROL SURG PART A, V77, P46, DOI 10.1055/s-0035-1558822
   Daluiski A, 1998, J ORTHOPAED RES, V16, P645, DOI 10.1002/jor.1100160603
   De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V24, P810, DOI 10.3171/2015.8.SPINE15674
   DeMola PM, 2009, CLIN ORTHOP RELAT R, V467, P1629, DOI 10.1007/s11999-008-0474-2
   Donegan DJ, 2010, CLIN ORTHOP RELAT R, V468, P1428, DOI 10.1007/s11999-009-1171-5
   Eksi MS, 2017, TURK NEUROSURG, V27, P142, DOI 10.5137/1019-5149.JTN.14862-15.1
   Frost Chelsea, 2015, Spine Deform, V3, P528, DOI 10.1016/j.jspd.2015.04.009
   Gavazza JB, 1996, J HAND SURG-AM, V21A, P742, DOI 10.1016/S0363-5023(96)80185-7
   Huang WM, 2016, SPINE, V41, P1683, DOI 10.1097/BRS.0000000000001736
   Jamjoom AA, 2014, NEUROSCIENCES, V19, P60
   Janssen T, 2016, EUR SPINE J, V25, P2311, DOI 10.1007/s00586-016-4404-9
   Jasko JJ, 2003, CLIN ORTHOP RELAT R, P98, DOI 10.1097/01.blo.0000093902.12372.76
   Kleine-Konig MT, 2014, J PEDIATR ORTHOPED, V34, pE33, DOI 10.1097/BPO.0000000000000140
   Larsen PO, 2010, SCIENTOMETRICS, V84, P575, DOI 10.1007/s11192-010-0202-z
   Narain AS, 2017, SPINE, V42, P1723, DOI 10.1097/BRS.0000000000002203
   Nguyen V, 1998, J ORTHOP TRAUMA, V12, P457, DOI 10.1097/00005131-199809000-00004
   Ohtori S, 2018, SPINE, V43, P1347, DOI 10.1097/BRS.0000000000002620
   Okafor L, 2015, SPINE, V40, P699, DOI 10.1097/BRS.0000000000000838
   Pallot JM, 2018, BRIT J NEUROSURG, V32, P231, DOI 10.1080/02688697.2018.1464120
   Patel AJ, 2011, J NEUROSURG, V115, P1258, DOI 10.3171/2011.7.JNS101538
   Raudenbush B, 2018, GLOB SPINE J, V8, P273, DOI 10.1177/2192568217713732
   Ruegsegger N, 2016, SPINE, V41, P538, DOI 10.1097/BRS.0000000000001261
   Scherer RW, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000005.pub3
   Scherer RW, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000005.pub4
   Scherer RW, 2015, J CLIN EPIDEMIOL, V68, P803, DOI 10.1016/j.jclinepi.2015.01.027
   Schoenfeld Andrew J, 2012, J Surg Orthop Adv, V21, P204
   Schulte TL, 2012, EUR SPINE J, V21, P2105, DOI 10.1007/s00586-012-2211-5
   Skovrlj Branko, 2014, Spine Deform, V2, P241, DOI 10.1016/j.jspd.2014.04.004
   Steinberger J, 2015, SPINE, V40, P740, DOI 10.1097/BRS.0000000000000847
   Toroser D, 2017, CURR MED RES OPIN, V33, P1183, DOI 10.1080/03007995.2016.1271778
   Varghese RA, 2011, J PEDIATR ORTHOPED, V31, P334, DOI 10.1097/BPO.0b013e31820f8783
   Virk SS, 2017, SPINE, V42, P513, DOI 10.1097/BRS.0000000000001797
   Wang JC, 1999, SPINE, V24, P425, DOI 10.1097/00007632-199903010-00002
   Whitehouse MR, 2009, ORTHOPEDICS, V32, P407, DOI 10.3928/01477447-20090511-13
   Zhou JJ, 2017, SPINE, V42, P336, DOI 10.1097/BRS.0000000000001860
NR 42
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E339
EP E345
DI 10.1016/j.wneu.2019.07.146
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300041
PM 31356976
DA 2020-05-12
ER

PT J
AU Rosenblum, JS
   Neto, M
   Essayed, WI
   Bi, WL
   Patel, NJ
   Aziz-Sultan, MA
   Heiss, JD
   Al-Mefty, O
AF Rosenblum, Jared S.
   Neto, Mateus
   Essayed, Walid, I
   Bi, Wenya Linda
   Patel, Nirav J.
   Aziz-Sultan, Mohammad A.
   Heiss, John D.
   Al-Mefty, Ossama
TI Tentorial Venous Anatomy: Cadaveric and Radiographic Study with
   Discussion of Origin and Surgical Significance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver; Development; Tentorial sinuses; Transtentorial approaches;
   Venous anatomy
ID DURAL SINUS PRESSURE; MICROSURGICAL ANATOMY; STRAIGHT SINUS; VEINS;
   INNERVATION; TRIBUTARIES; SYSTEM
AB BACKGROUND: Described variations of tentorial venous anatomy impact surgical sectioning of the tentorium in skull base approaches; however, described configurations do not consistently explain postoperative complications. To understand the outcomes of 2 clinical cases we studied the tentorial venous anatomy of 2 cadavers.
   METHODS: The venous anatomy of the tentorium isolated in 2 uninjected fresh cadaver head specimens with preserved bridging veins was observed by transillumination before and after methylene blue injection of the dural sinuses and tentorial veins. Our findings in cadavers were applied to explain the clinical and radiologic (magnetic resonance imaging and computed tomographic venography) findings in the 2 cases presented.
   RESULTS: A consistent transtentorial venous system, arising from transverse and straight sinuses, communicating with supra- and infratentorial bridging veins was seen in the cadaver and patient radiography (magnetic resonance imaging and computed tomographic venography). Our first patient had a cerebellar venous infarct from compromise of the venous drainage from the adjacent brain after ligation of a temporal lobe bridging vein to the tentorium. Our second patient suffered no clinical effects from bilateral transverse sinus occlusion due to drainage through the accessory venous system within the tentorium.
   CONCLUSIONS: Herein, we elaborate on transtentorial venous anatomy. These veins, previously reported to obliterate in completed development of the tentorium, remain patent with consistent observed configuration. The same transtentorial venous system was observed in both cases and provided insight to their outcomes. These findings emphasize the importance of the transtentorial venous system physiologically and in surgical approaches.
C1 [Rosenblum, Jared S.; Essayed, Walid, I; Bi, Wenya Linda; Patel, Nirav J.; Aziz-Sultan, Mohammad A.; Al-Mefty, Ossama] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Rosenblum, Jared S.; Heiss, John D.] NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Rosenblum, Jared S.] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA.
   [Neto, Mateus] Hosp Beneficencia Portuguesa Sao Paulo, Inst Neurol Sci Sao Paulo Bela Vista, Dept Neurosurg, Sao Paulo, Brazil.
RP Rosenblum, JS (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Rosenblum, JS (reprint author), NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.; Rosenblum, JS (reprint author), NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA.
EM Jared.rosenblum@nih.gov
OI Reghin Neto, Mateus/0000-0003-4448-8231; Rosenblum,
   Jared/0000-0001-5941-9082
FU Intramural Research Programs of the National Institute of Neurological
   Disorders and StrokeUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS); National Cancer Institute at
   the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI)
FX This study was supported, in part, by the Intramural Research Programs
   of the National Institute of Neurological Disorders and Stroke and
   National Cancer Institute at the National Institutes of Health.
CR al-Mefty O, 1991, Acta Neurochir Suppl (Wien), V53, P166
   Apra C, 2017, J NEUROSURG, V126, P8, DOI 10.3171/2015.11.JNS151881
   BROWDER J, 1976, J NEUROSURG, V44, P55, DOI 10.3171/jns.1976.44.1.0055
   Browder J, 1975, Surg Neurol, V3, P37
   Chung JI, 2005, INTERV NEURORADIOL, V11, P123, DOI 10.1177/159101990501100202
   Grapin-Botton A, 1999, MECH DEVELOP, V84, P41, DOI 10.1016/S0925-4773(99)00069-6
   Hildebrand M., 1968, ANATOMICAL PREPARATI, V6, P66
   Horsfield K., 1990, MODELS LUNG DIS MICR, V47, P267
   Huang YP, 1997, MT SINAI J MED, V64, P197
   Huang YP, 1974, RADIOLOGY SKULL BRAI, VII, P2155
   IWABUCHI T, 1983, NEUROSURGERY, V12, P203, DOI 10.1227/00006123-198302000-00012
   Jin SW, 2016, J KOREAN NEUROSURG S, V59, P192, DOI 10.3340/jkns.2016.59.3.192
   KAPLAN HA, 1976, J NEUROSURG, V45, P166, DOI 10.3171/jns.1976.45.2.0166
   KAPLAN HA, 1975, RADIOLOGY, V115, P641, DOI 10.1148/15.3.641
   KAWASE T, 1994, ACTA NEUROCHIR, V129, P113, DOI 10.1007/BF01406489
   Kemp WJ, 2012, WORLD NEUROSURG, V78, P505, DOI 10.1016/j.wneu.2011.10.045
   Kida Katsumi, 1996, Hokkaido Journal of Medical Science, V71, P205
   Lasjaunias P, 2006, SURG NEUROANGRIOGRAP, P109
   Lee SH, 2017, J ANAT, V231, P683, DOI 10.1111/joa.12659
   Lv XL, 2014, NEURORADIOL J, V27, P293, DOI 10.15274/NRJ-2014-10052
   Malis LI, 1985, NEUROSURGERY, VI, P1011
   Maroto M, 2012, DEVELOPMENT, V139, P2453, DOI 10.1242/dev.069310
   MATSUSHIMA T, 1989, J NEUROSURG, V71, P923, DOI 10.3171/jns.1989.71.6.0923
   Merill LK, 1940, CHEM ENG NEWS, V18, P496
   Miabi Z, 2004, AM J NEURORADIOL, V25, P1181
   Mitsuhashi Y, 2016, NEUROL MED-CHIR, V56, P326, DOI 10.2176/nmc.ra.2015-0346
   Amato MCM, 2016, J NEUROSURG, V125, P494, DOI 10.3171/2015.6.JNS15584
   OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003
   OKUDERA T, 1994, AM J NEURORADIOL, V15, P1871
   OKUDERA T, 1984, CEREBRAL VENOUS SYST, P93
   PADGET DH, 1956, AM J ANAT, V98, P307, DOI 10.1002/aja.1000980302
   RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711
   Sankar L., 2010, ANATOMICAL VARIATION, P1
   Scoffings DJ, 2007, J NEUROL NEUROSUR PS, V78, P911, DOI 10.1136/jnnp.2006.111765
   SHULMAN K, 1964, ARCH NEUROL-CHICAGO, V10, P575, DOI 10.1001/archneur.1964.00460180041003
   Streeter GL, 1921, CONTRIBUTIONS EMBRYO
   Ture U, 2012, J NEUROSURG, V116, P773, DOI 10.3171/2011.12.JNS11791
   Ueyama T, 1998, NEUROSURGERY, V43, P1137, DOI 10.1097/00006123-199811000-00068
   VELUT S, 1987, NEUROCHIRURGIE, V33, P258
   Wilson MH, 2016, J CEREBR BLOOD F MET, V36, P1338, DOI 10.1177/0271678X16648711
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E38
EP E45
DI 10.1016/j.wneu.2019.06.232
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300006
PM 31295599
DA 2020-05-12
ER

PT J
AU Rosinski, CL
   Chaker, AN
   Zakrzewski, J
   Geever, B
   Patel, S
   Chiu, RG
   Rosenberg, DM
   Parola, R
   Shah, K
   Behbahani, M
   Mehta, AI
AF Rosinski, Clayton L.
   Chaker, Anisse N.
   Zakrzewski, Jack
   Geever, Brett
   Patel, Saavan
   Chiu, Ryan G.
   Rosenberg, David M.
   Parola, Rown
   Shah, Koral
   Behbahani, Mandana
   Mehta, Ankit, I
TI Autologous Bone Cranioplasty: A Retrospective Comparative Analysis of
   Frozen and Subcutaneous Bone Flap Storage Methods
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autologous bone; Cranioplasty; Frozen; Infection; Subcutaneous
ID SURGICAL SITE INFECTION; DECOMPRESSIVE CRANIECTOMY; COMPLICATIONS;
   PRESERVATION; PREDICTORS; OUTCOMES
AB OBJECTIVE: The use of autologous hone for cranioplasty offers superior cosmesis and cost-effectiveness compared with synthetic materials. The choice between 2 common autograft storage mechanisms (subcutaneous vs. frozen) remains controversial and dictated by surgeon preference. We compared surgical outcomes after autologous bone cranioplasty between patients with cryopreserved and subcutaneously stored autografts.
   METHODS: Ten-year retrospective comparative analysis of patients undergoing cranioplasty with autologous bone stored subcutaneously or frozen at a tertiary academic medical center.
   RESULTS: Ninety-four patients were studied, with 34 (36.2%) bone flaps stored subcutaneously and 59 (62.8%) frozen. The 2 groups were similar in demographics, comorbidities, and craniectomy indication, with only body mass index and race differing statistically. The mean operation time was greater within the subcutaneous group (P < 0.001), which also had a greater number of ventriculoperitoneal shunt (VPS) placements (P = 0.02). There were no significant differences in complications, read-missions, unplanned reoperations, or length of stay between the 2 groups. VPS placement during cranioplasty increased length of stay (P < 0.001), and placement prior to cranioplasty increased both length of stay (P = 0.009) and incidence of hospital-acquired infection (P = 0.03).
   CONCLUSIONS: Subcutaneous and frozen storage of autologous bone result in similar surgical risk profiles. Cryopreservation may be preferred because of shorter operation time and avoidance of complications with the abdominal pocket, whereas the portability of subcutaneous storage remains favorable for patients undergoing cranioplasty at a different institution. VPS placement prior to cranioplasty should be avoided, if possible, due to the increased risk of hospital-acquired infection.
C1 [Rosinski, Clayton L.; Chaker, Anisse N.; Zakrzewski, Jack; Geever, Brett; Patel, Saavan; Chiu, Ryan G.; Rosenberg, David M.; Parola, Rown; Shah, Koral; Behbahani, Mandana; Mehta, Ankit, I] Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
RP Mehta, AI (reprint author), Univ Illinois, Dept Neurosurg, Chicago, IL 60607 USA.
EM ankitm@uic.edu
RI Mehta, Ankit/AAL-3851-2020
OI Zakrzewski, Jack/0000-0002-9824-8148; Chiu, Ryan/0000-0001-8666-9001;
   behbahani, mandana/0000-0003-3882-8658; Rosenberg,
   David/0000-0003-4914-3195
CR Andrabi Syed M, 2017, Surg Neurol Int, V8, P91, DOI 10.4103/sni.sni_45_17
   Baldo S, 2010, WORLD NEUROSURG, V73, P552, DOI 10.1016/j.wneu.2010.02.018
   Cheng Cheng-Hsin, 2014, Clin Neurol Neurosurg, V124, P85, DOI 10.1016/j.clineuro.2014.06.029
   Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782
   Choban PS, 1997, J AM COLL SURGEONS, V185, P593, DOI 10.1016/S1072-7515(97)00109-9
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Corliss B, 2016, WORLD NEUROSURG, V96, P510, DOI 10.1016/j.wneu.2016.09.025
   Ernst G, 2018, J NEUROSURG, V129, P1604, DOI 10.3171/2017.6.JNS17943
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007
   Inamasu J, 2010, J TRAUMA, V68, P183, DOI 10.1097/TA.0b013e3181c45384
   Lee S. H., 2014, J NEUROTRAUM, V10, P10, DOI [1410.13004/kjnt.2014.10.1.1027169026, DOI 10.13004/KJNT.2014.10.1.10]
   MAYONWHITE RT, 1988, J HOSP INFECT, V11, P43, DOI 10.1016/0195-6701(88)90164-8
   Morton RP, 2018, J NEUROSURG, V128, P1648, DOI 10.3171/2016.11.JNS161917
   Morton RP, 2016, J NEUROSURG, V125, P766, DOI 10.3171/2015.8.JNS151390
   Mustroph CM, 2017, WORLD NEUROSURG, V103, P686, DOI 10.1016/j.wneu.2017.04.066
   Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014
   Shibahashi K, 2017, WORLD NEUROSURG, V101, P20, DOI 10.1016/j.wneu.2017.01.106
   Sperling CD, 2018, UROLOGY, V121, P104, DOI 10.1016/j.urology.2018.08.002
   Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
   Zingale A, 2003, J Neurosurg Sci, V47, P137
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E312
EP E320
DI 10.1016/j.wneu.2019.07.139
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300038
PM 31351936
DA 2020-05-12
ER

PT J
AU Sass, B
   Bopp, M
   Nimsky, C
   Carl, B
AF Sass, Benjamin
   Bopp, Miriam
   Nimsky, Christopher
   Carl, Barbara
TI Navigated 3-Dimensional Intraoperative Ultrasound for Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D ultrasound; Intraoperative ultrasound; Low-dose intraoperative
   computed tomography; Navigated ultrasound; Registration; Spine surgery
ID PEDICLE SCREW PLACEMENT; CORD TUMOR SURGERY; 3D ULTRASOUND;
   NEURONAVIGATION; REGISTRATION; ULTRASONOGRAPHY; CT
AB OBJECTIVE: To integrate 3-dimensional (3D) intra-operative ultrasound (iUS) data in spinal navigation.
   METHODS: In 11 patients with intradural spinal tumors, 3D-iUS was performed before and after tumor resection. Intraoperative computed tomography (iCT) was used for automatic patient registration for spinal navigation; fiducial-based registration was performed in 1 case. The outlines of the vertebra were defined in preoperative image data by automatic mapping; risk and target structures were segmented manually; all these data were rigidly and if necessary non-rigidly registered with iCT. For 3D-iUS acquisition, tracked convex-shaped transducers (contact surface: 29 x 10 mm; scanning frequency: 10-3.8 MHz or 13-5 MHz) were used.
   RESULTS: Navigated 3D-iUS was successfully implemented in all cases; 3D-iUS datasets were acquired and could be used as 3D image data for further navigation after iUS scanning. The 3D objects defined in preoperative image data, outlining the vertebra, target and risk structures, could be visualized in the 3D-iUS data. Navigated 3D-iUS allowed to reliably evaluate the extent of resection in all cases and updating of navigation, ensuring high navigational accuracy. The target registration error applying iCT-based automatic registration was 0.78 +/- 0.23 mm. The effective dose for iCT was 0.11 +/- 0.077 mSv for cervical and 1.75 +/- 0.72 mSv for thoracic scans.
   CONCLUSIONS: Using 3D-iUS can be successfully integrated in spinal navigation. Automatic registration applying low-dose iCT and non-linear image registration offers displaying preoperative images in the same orientation as the 3D-iUS scan, as well as visualizing segmented structures in the navigated 3D-iUS data. This greatly facilitates image interpretation. Navigated 3D-iUS provides a possibility for navigation updating and immediate online quality control.
C1 [Sass, Benjamin; Bopp, Miriam; Nimsky, Christopher; Carl, Barbara] Univ Marburg, Dept Neurosurg, Marburg, Germany.
   [Bopp, Miriam; Nimsky, Christopher] MCMBB, Marburg, Germany.
RP Nimsky, C (reprint author), Univ Marburg, Dept Neurosurg, Marburg, Germany.; Nimsky, C (reprint author), MCMBB, Marburg, Germany.
EM nimsky@med.uni-marburg.de
RI Nimsky, Christopher/E-3702-2014
OI Nimsky, Christopher/0000-0002-8216-9410; Sass,
   Benjamin/0000-0003-2855-3443; Bopp, Miriam H. A./0000-0003-1574-7572;
   Carl, Barbara/0000-0003-3661-9908
CR Al-Habib A, 2018, J NEUROSURG-SPINE, V29, P461, DOI 10.3171/2018.2.SPINE171195
   Bonsanto MM, 2005, ACTA NEUROCHIR, V147, P533, DOI 10.1007/s00701-005-0505-7
   Carl B, 2019, WORLD NEUROSURG, V128, pE541, DOI 10.1016/j.wneu.2019.04.192
   Choi G, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-14
   Coburger J, 2014, WORLD NEUROSURG, V82, P366, DOI 10.1016/j.wneu.2014.05.025
   Cui LG, 2011, CLIN NEUROL NEUROSUR, V113, P173, DOI 10.1016/j.clineuro.2010.10.011
   Della Pepa GM, 2018, ACTA NEUROCHIR, V160, P1259, DOI 10.1007/s00701-018-3541-9
   Dhaliwal PPS, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.020
   Fanti Z, 2018, J HEALTHC ENG, DOI 10.1155/2018/2365178
   Ganau M, 2018, QUANT IMAG MED SURG, V8, P261, DOI 10.21037/qims.2018.04.02
   Goodkin R, 1996, J NEUROSURG, V84, P702, DOI 10.3171/jns.1996.84.4.0702
   Gronningsaeter A, 2000, NEUROSURGERY, V47, P1373, DOI 10.1097/00006123-200012000-00021
   Haciyakupoglu E, 2019, TURK NEUROSURG, V29, P237, DOI 10.5137/1019-5149.JTN.23296-18.3
   Harel R, 2016, EUR SPINE J, V25, P865, DOI 10.1007/s00586-015-4222-5
   Ivanov M, 2017, WORLD NEUROSURG, V97, P104, DOI 10.1016/j.wneu.2016.09.097
   Jakubovic R, 2018, ULTRASOUND MED BIOL, V44, P2379, DOI 10.1016/j.ultrasmedbio.2018.05.003
   Jodicke A, 2004, ACTA NEUROCHIR, V146, P1211, DOI 10.1007/s00701-004-0352-y
   KOIVUKANGAS J, 1986, ANN CLIN RES, V18, P25
   KOIVUKANGAS J, 1993, J NEUROSURG, V79, P36, DOI 10.3171/jns.1993.79.1.0036
   Kolstad F, 2006, J NEUROSURG-SPINE, V5, P264, DOI 10.3171/spi.2006.5.3.264
   Ma LF, 2017, INT J COMPUT ASS RAD, V12, P2205, DOI 10.1007/s11548-017-1652-z
   Meinig H, 2015, EUR SPINE J, V24, P864, DOI 10.1007/s00586-014-3596-0
   Nagpal S, 2015, INT J COMPUT ASS RAD, V10, P1371, DOI 10.1007/s11548-015-1247-5
   Nishimura Y, 2014, J NEUROSURG-SPINE, V21, P568, DOI 10.3171/2014.6.SPINE13682
   Prada F, 2018, ACTA NEUROCHIR, V160, P1869, DOI 10.1007/s00701-018-3626-5
   Prada F, 2017, WORLD NEUROSURG, V100, DOI 10.1016/j.wneu.2017.01.045
   Prada F, 2014, J ULTRASOUND, V17, P195, DOI 10.1007/s40477-014-0102-9
   Regelsberger J, 2005, ULTRASOUND MED BIOL, V31, P593, DOI 10.1016/j.ultrasmedbio.2005.01.016
   Shamov T, 2013, TURK NEUROSURG, V23, P329, DOI 10.5137/1019-5149.JTN.6639-12.2
   Tatsui CE, 2017, J NEUROSURG-SPINE, V26, P605, DOI 10.3171/2016.9.SPINE16475
   Tirakotai W, 2006, NEUROSURGERY, V58, P710, DOI 10.1227/01.NEU.0000204454.52414.7A
   Toktas ZO, 2013, TURK NEUROSURG, V23, P600, DOI 10.5137/1019-5149.JTN.7199-12.1
   Toossi A, 2018, J NEUROSURG-SPINE, V29, P292, DOI 10.3171/2018.1.SPINE17903
   Ungi T., 2015, SPINAL IMAGING IMAGE, P469, DOI DOI 10.1007/978-3-319-12508-4_15
   Ungi T, 2013, CLIN ORTHOP RELAT R, V471, P4047, DOI 10.1007/s11999-013-3239-5
   Unsgaard G, 2005, ACTA NEUROCHIR, V147, P1259, DOI 10.1007/s00701-005-0624-1
   Unsgaard Geirmund, 2005, Neurosurgery, V56, P281, DOI 10.1227/01.NEU.0000157005.51053.41
   Vasudeva VS, 2017, GLOB SPINE J, V7, P648, DOI 10.1177/2192568217700100
   Vetrano IG, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15162
   Winter S, 2009, ULTRASOUND MED BIOL, V35, P1773, DOI 10.1016/j.ultrasmedbio.2009.06.1089
   Yan CXB, 2012, INT J COMPUT ASS RAD, V7, P601, DOI 10.1007/s11548-011-0666-1
   Zhao JW, 2018, SPINE, V43, pE1329, DOI 10.1097/BRS.0000000000002704
   Zhou HY, 2011, CLIN NEUROL NEUROSUR, V113, P531, DOI 10.1016/j.clineuro.2011.03.006
NR 43
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E155
EP E169
DI 10.1016/j.wneu.2019.07.188
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300019
PM 31376550
DA 2020-05-12
ER

PT J
AU Sharma, M
   Ugiliweneza, B
   Boakye, M
   Andaluz, N
   Williams, BJ
AF Sharma, Mayur
   Ugiliweneza, Beatrice
   Boakye, Maxwell
   Andaluz, Noberto
   Williams, Brian J.
TI Feasibility of Bundled Payments in Anterior, Middle, and Posterior
   Cranial Fossa Skull Base Meningioma Surgery: MarketScan Analysis of
   Health Care Utilization and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior; Bundled payment; Health care utilization; Meningioma; Middle
   and posterior cranial fossa; Surgery
ID PETROCLIVAL MENINGIOMAS; TUMOR-CONTROL; EXPERIENCE; RADIOSURGERY;
   MORBIDITY; RESECTION
AB BACKGROUND: The aim of our study was to compare the health care utilization and outcomes after surgery for anterior cranial fossa skull base meningioma (AFM), middle cranial fossa skull base meningioma (MFM), and posterior cranial fossa skull base meningioma (PFM) across the United States.
   METHODS: We queried the MarketScan database using International Classification of Diseases, Ninth Revision and Current Procedural Terminology 4, from 2000 to 2016. We included adult patients who had at least 24 months of enrollment after the surgical procedure. The outcome of interest was length of hospital stay, disposition, complications, and reoperation after the procedure.
   RESULTS: A cohort of 1191 patients was identified from the database. Less than half of patients (43.66%) were in the AFM cohort, 32.24% were in the MFM cohort, and only 24.1% were in the PFM cohort. Patients who underwent surgery for PFM had longer hospital stay (P = 0.0009), high complication rate (P = 0.0011), and less likely to be discharged home (P = 0.0013) during index hospitalization. There were no differences in overall payments at 12 months and 24 months among the cohorts. There was no significant difference in 90-day median payments among the groups ($66,212 [AFM] vs. $65,602 [MFM] and $71,837 [PFMJ; P = 0.198). Male gender, commercial insurance (compared with Medicare), and higher comorbidity scores (score 3 compared with score 0) were associated with higher 90-day payments in the PFM cohort.
   CONCLUSIONS: Overall payments (at 12 months and 24 months) and 90-day payments were not different among the cohorts. Patients with PFM had longer hospital stay and higher complication rate and were less likely to be discharged home with higher utilization of outpatient services at 12 months and 24 months.
C1 [Sharma, Mayur; Ugiliweneza, Beatrice; Boakye, Maxwell; Andaluz, Noberto; Williams, Brian J.] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
RP Williams, BJ (reprint author), Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
EM Brian.Williams@ulp.org
RI Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819
CR Alhourani A, 2019, NEUROSURGERY
   Almefty R, 2014, J NEUROSURG, V120, P40, DOI 10.3171/2013.8.JNS13535
   Ambekar S, 2013, J NEURO-ONCOL, V114, P299, DOI 10.1007/s11060-013-1183-6
   [Anonymous], 2012, Hosp Case Manag, V20, P113
   [Anonymous], 2011, HOSP CASE MANAG, V19, P148
   Connolly ID, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00259
   Dietz N, 2019, WORLD NEUROSURG, V123, P177, DOI 10.1016/j.wneu.2018.12.001
   Dubey A, 2009, SURG NEUROL, V72, P369, DOI 10.1016/j.surneu.2009.04.001
   Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Hansen LG, 2012, HLTH RES DATA REAL W
   Kondziolka D, 1998, NEUROSURGERY, V43, P405, DOI 10.1097/00006123-199809000-00001
   LITTELL RC, 2002, SAS LINEAR MODELS
   Little KM, 2005, NEUROSURGERY, V56, P546, DOI 10.1227/01.NEU.0000153906.12640.62
   Matsui T, 2012, NEUROL MED-CHIR, V52, P704, DOI 10.2176/nmc.52.704
   Nanda A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.10.FOCUS13350
   Nanda A, 2011, J NEUROSURG, V114, P1268, DOI 10.3171/2010.11.JNS10326
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Parikh AA, 2014, J SURG ONCOL, V110, P227, DOI 10.1002/jso.23627
   Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Roberti F, 2001, SURG NEUROL, V56, P8, DOI 10.1016/S0090-3019(01)00479-7
   Sharma M, 2019, SPINE, V44, P280, DOI 10.1097/BRS.0000000000002794
   Sharma M, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.2.FOCUS17764
   Sharma M, 2018, WORLD NEUROSURG, V115, pE664, DOI 10.1016/j.wneu.2018.04.131
   STOKES ME, 2000, CATEGORICAL DATA ANA
   Sullivan R, 2017, CURR REV MUSCULOSKE, V10, P218, DOI 10.1007/s12178-017-9405-8
   Trahan J, 2011, WORLD NEUROSURG, V75, P145, DOI 10.1016/j.wneu.2010.09.015
   VanLare JM, 2012, NEW ENGL J MED, V367, P292, DOI 10.1056/NEJMp1204939
   VERTREES JC, 2013, MED MED RES REV, V3, pE1
   Zachenhofer I, 2006, NEUROSURGERY, V58, P28, DOI 10.1227/01.NEU.0000190654.82265.A3
NR 31
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E116
EP E127
DI 10.1016/j.wneu.2019.07.078
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300015
PM 31323403
DA 2020-05-12
ER

PT J
AU Shen, JG
   Shen, J
   Zhu, KC
   Zhou, HH
   Tian, HP
   Yu, GJ
AF Shen, Jianguo
   Shen, Jian
   Zhu, Kuncan
   Zhou, Haihang
   Tian, Heping
   Yu, Gongjie
TI Efficacy of Statins in Cerebral Vasospasm, Mortality, and Delayed
   Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage: A
   Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysmal subarachnoid hemorrhage; Delayed cerebral ischemia;
   Mortality; Statins; Vasospasm
ID HIGH-DOSE SIMVASTATIN; DOUBLE-BLIND; RAT; AUTOREGULATION; NEUROGENESIS;
   ANGIOGENESIS; MULTICENTER; OUTCOMES
AB BACKGROUND: Aneurysmal subarachnoid hemorrhage (aSAH) is an acute cerebrovascular disease with frequent cerebral vasospasm and delayed cerebral ischemia (DCI). The use of statins for patients with aSAH is controversial. The present study evaluated the efficacy of statins in aSAH-induced vasospasm, DCI, delayed ischemic neurological deficit (DIND), mortality, and other outcomes.
   METHODS: A literature search was performed in PubMed, EMBASE, and the Cochrane Library. English reports of patients with aSAH who had been treated with statins without combination were included. The outcomes, including cerebral vasospasm, DIND, DCI, mortality, disability, and creatine kinase/alanine aminotransferase/aspartic transaminase elevation, were extracted for meta-analysis.
   RESULTS: A total of 13 studies, with 776 versus 821 patients treated with statins versus placebo, were retained for the statistical meta-analysis. The results showed that statin administration significantly reduced the frequency of vasospasm (relative risk [RR], 0.76; 95% confidence interval [CI], 0.63-0.91; P = 0.003), DIND (RR, 0.76; 95% CI, 0.63-0.91; P = 0.003), vasospasm-DCI (RR, 0.49; 95% CI, 0.32-0.74; P = 0.0008), and mortality (RR, 0.73; 95% CI, 0.54-0.98; P = 0.03). Statins showed insignificant efficacy in the prevention of disability (RR, 0.92; 95% CI, 0.71-1.20), a neurological poor prognosis (RR, 0.75; 95% CI, 0.45-1.27), and creatine kinase/alanine aminotransferase/aspartic transaminase elevation (RR, 1.90; 95% CI, 0.55-6.50).
   CONCLUSIONS: Statins significantly reduced the incidence of vasospasm, DIND, DCI, and mortality in individuals with aSAH, suggesting its efficacy in aSAH.
C1 [Shen, Jianguo; Shen, Jian; Zhu, Kuncan; Zhou, Haihang; Tian, Heping; Yu, Gongjie] Jiaxing Univ, Dept Neurosurg, Affiliated Hosp 2, Jiaxing, Peoples R China.
RP Yu, GJ (reprint author), Jiaxing Univ, Dept Neurosurg, Affiliated Hosp 2, Jiaxing, Peoples R China.
EM yugongjie2008@126.com
FU Science and Technology Program of Jiaxing, China [2018AD32016]
FX The present study was supported by the Science and Technology Program of
   Jiaxing, China (grant 2018AD32016).
CR Atangana E, 2017, TRANSL STROKE RES, V8, P144, DOI 10.1007/s12975-016-0485-3
   Badjatia N, 2015, NEUROLOGY, V84, P680, DOI 10.1212/WNL.0000000000001259
   Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555
   Chou SHY, 2008, STROKE, V39, P2891, DOI 10.1161/STROKEAHA.107.505875
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diringer MN, 2017, SEMIN RESP CRIT CARE, V38, P760, DOI 10.1055/s-0037-1607990
   Diringer MN, 2016, NEUROCRIT CARE, V25, P56, DOI 10.1007/s12028-015-0233-7
   Galea J, 2018, J NEUROSURG, V128, P515, DOI 10.3171/2016.9.JNS16615
   Gallia GL, 2006, NEUROL RES, V28, P750, DOI 10.1179/016164106X152025
   Garg K, 2013, BRIT J NEUROSURG, V27, P181, DOI 10.3109/02688697.2012.757293
   Hafeez S, 2019, NEUROCRIT CARE, P1
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jaschinski U, 2008, CRITICAL CARE S2, V12, P112
   Kirkpatrick PJ, 2014, LANCET NEUROL, V13, P666, DOI 10.1016/S1474-4422(14)70084-5
   Leclerc JL, 2015, P NATL ACAD SCI USA, V112, P1155, DOI 10.1073/pnas.1412833112
   Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288
   Lucke-Wold BP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040497
   Lynch JR, 2006, STORKE, V36, P2024
   Macedo S, 2009, CRIT CARE, V13, P103
   Macedo S, 2009, CRIT CARE S1, V13, pP96
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Mason RP, 2018, BIOMED PHARMACOTHER, V103, P1231, DOI 10.1016/j.biopha.2018.04.118
   McMahon CJ, 2013, J NEUROINTERV SURG, V5, P512, DOI 10.1136/neurintsurg-2012-010386
   Moher David, 2009, Open Med, V3, pe123
   Naraoka M, 2018, J CEREBR BLOOD F MET, V38, P1190, DOI 10.1177/0271678X17724682
   Ogilvy C, 2006, CRIT CARE MED, V34, pA80, DOI 10.1097/00003246-200612002-00275
   Pluta RM, 1996, J NEUROSURG, V84, P648, DOI 10.3171/jns.1996.84.4.0648
   Pradilla G, 2010, NEUROSURG CLIN N AM, V21, P365, DOI 10.1016/j.nec.2009.10.008
   Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4
   Shen J, 2016, J NEUROSURG, V127, P1
   Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732
   Sugawara T, 2008, ACTA NEUROCHIR SUPPL, V102, P391, DOI 10.1007/978-3-211-85578-2_76
   Sugawara T, 2008, J NEUROSCI RES, V86, P3635, DOI 10.1002/jnr.21807
   Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d
   Vergouwen MDI, 2009, J CEREBR BLOOD F MET, V29, P1444, DOI 10.1038/jcbfm.2009.59
   Wang D, 2016, J NEUROL SCI, V362, P91, DOI 10.1016/j.jns.2016.01.017
   Wong GKC, 2013, NEUROSURGERY, V72, P840, DOI 10.1227/NEU.0b013e31828ab413
   Yang Dongmei, 2013, World J Neurosci, V3, P69
   Zumofen DW, 2018, NEUROSURG REV, V41, P1059, DOI 10.1007/s10143-018-0952-2
NR 40
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E65
EP E73
DI 10.1016/j.wneu.2019.07.016
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300009
PM 31295598
DA 2020-05-12
ER

PT J
AU Silva, MA
   Patel, J
   Kavouridis, V
   Gallerani, T
   Beers, A
   Chang, K
   Hoebel, KV
   Brown, J
   See, AP
   Gormley, WB
   Aziz-Sultan, MA
   Kalpathy-Cramer, J
   Arnaout, O
   Patel, NJ
AF Silva, Michael A.
   Patel, Jay
   Kavouridis, Vasileios
   Gallerani, Troy
   Beers, Andrew
   Chang, Ken
   Hoebel, Katharina, V
   Brown, James
   See, Alfred P.
   Gormley, William B.
   Aziz-Sultan, Mohammad Ali
   Kalpathy-Cramer, Jayashree
   Arnaout, Omar
   Patel, Nirav J.
TI Machine Learning Models can Detect Aneurysm Rupture and Identify
   Clinical Features Associated with Rupture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Aneurysm rupture; Artificial intelligence; Machine learning;
   Subarachnoid hemorrhage
ID UNRUPTURED INTRACRANIAL ANEURYSMS; HEMODYNAMIC CHARACTERISTICS;
   NATURAL-HISTORY
AB BACKGROUND: Machine learning (ML) has been increasingly used in medicine and neurosurgery. We sought to determine whether ML models can distinguish ruptured from unruptured aneurysms and identify features associated with rupture.
   METHODS: We performed a retrospective review of patients with intracranial aneurysms detected on vascular imaging at our institution between 2002 and 2018. The dataset was used to train 3 ML models (random forest, linear support vector machine [SVM], and radial basis function kernel SVM). Relative contributions of individual predictors were derived from the linear SVM model.
   RESULTS: Complete data were available for 845 aneurysms in 615 patients. Ruptured aneurysms (n = 309, 37%) were larger (mean 6.51 mm vs. 5.73 mm; P = 0.02) and more likely to be in the posterior circulation (20% vs. 11%; P < 0.001) than unruptured aneurysms. Area under the receiver operating curve was 0.77 for the linear SVM, 0.78 for the radial basis function kernel SVM models, and 0.81 for the random forest model. Aneurysm location and size were the 2 features that contributed most significantly to the model. Posterior communicating artery, anterior communicating artery, and posterior inferior cerebellar artery locations were most highly associated with rupture, whereas paraclinoid and middle cerebral artery locations had the strongest association with unruptured status.
   CONCLUSIONS: ML models are capable of accurately distinguishing ruptured from unruptured aneurysms and identifying features associated with rupture. Consistent with prior studies, location and size show the strongest association with aneurysm rupture.
C1 [Kavouridis, Vasileios; Gallerani, Troy; See, Alfred P.; Gormley, William B.; Aziz-Sultan, Mohammad Ali; Arnaout, Omar; Patel, Nirav J.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Kavouridis, Vasileios; Gallerani, Troy; See, Alfred P.; Gormley, William B.; Aziz-Sultan, Mohammad Ali; Arnaout, Omar; Patel, Nirav J.] Brigham & Womens Hosp, Computat Neurosci Outcomes Ctr, 75 Francis St, Boston, MA 02115 USA.
   [Patel, Jay; Beers, Andrew; Chang, Ken; Hoebel, Katharina, V; Brown, James; Kalpathy-Cramer, Jayashree] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martins Ctr Biomed Imaging, Charlestown, MA USA.
   [Silva, Michael A.] Jackson Mem Hosp, Dept Neurosurg, Miami, FL 33136 USA.
RP Patel, NJ (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Patel, NJ (reprint author), Brigham & Womens Hosp, Computat Neurosci Outcomes Ctr, 75 Francis St, Boston, MA 02115 USA.
EM npatel40@bwh.harvard.edu
CR Aranda A, 2018, MACHINE LEARN APPL I, V5
   Bender MT, 2018, NEUROSURGERY, V83, P692, DOI 10.1093/neuros/nyx484
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bzdok Danilo, 2018, Nat Methods, V15, P233, DOI 10.1038/nmeth.4642
   Can A, 2016, NEUROSURGERY, V78, P510, DOI 10.1227/NEU.0000000000001083
   Chien A, 2018, AM J NEURORADIOL, V39, P500, DOI 10.3174/ajnr.A5531
   Chung BJ, 2017, AM J NEURORADIOL, V38, P2111, DOI 10.3174/ajnr.A5358
   Dasenbrock HH, 2018, J NEUROSURG, V129, P446, DOI 10.3171/2016.10.JNS16748
   Doddasomayajula R, 2017, AM J NEURORADIOL, V38, P2301, DOI 10.3174/ajnr.A5397
   Hu P, 2016, NEURORADIOLOGY, V58, P979, DOI 10.1007/s00234-016-1729-3
   Juvela S, 2000, J NEUROSURG, V93, P379, DOI 10.3171/jns.2000.93.3.0379
   Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838
   Korja M, 2014, STROKE, V45, P1958, DOI 10.1161/STROKEAHA.114.005318
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565
   Paliwal N, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.8.FOCUS18332
   Rahman M, 2010, STROKE, V41, P916, DOI 10.1161/STROKEAHA.109.574244
   Ramos LA, 2019, J NEUROINTERV SURG, V11, P497, DOI 10.1136/neurintsurg-2018-014258
   Senders JT, 2018, NEUROSURGERY, V83, P181, DOI 10.1093/neuros/nyx384
   Senders JT, 2018, WORLD NEUROSURG, V109, P476, DOI 10.1016/j.wneu.2017.09.149
   Skodvin TO, 2019, NEUROSURGERY, V84, P132, DOI 10.1093/neuros/nyy010
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   Ueda D, 2019, RADIOLOGY, V290, P187, DOI 10.1148/radiol.2018180901
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 24
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E46
EP E51
DI 10.1016/j.wneu.2019.06.231
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300007
PM 31295616
DA 2020-05-12
ER

PT J
AU Sivakumar, W
   Barkhoudarian, G
   Lobo, BM
   Zhang, X
   Zhao, F
   Eisenberg, A
   Kesari, S
   Krauss, H
   Cohan, P
   Griffiths, C
   Wollman, R
   Chaiken, L
   Kelly, DF
AF Sivakumar, Walavan
   Barkhoudarian, Garni
   Lobo, Bjorn M.
   Zhang, Xin
   Zhao, Fan
   Eisenberg, Amy
   Kesari, Santosh
   Krauss, Howard
   Cohan, Pejman
   Griffiths, Chester
   Wollman, Robert
   Chaiken, Lisa
   Kelly, Daniel F.
TI Strategy and Technique of Endonasal Endoscopic Bony Decompression and
   Selective Tumor Removal in Symptomatic Skull Base Meningiomas of the
   Cavernous Sinus and Meckel's Cave
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial neuropathy; Double vision; Endocrinopathy; Endonasal approach;
   Endoscopic; Meningioma; Neurosurgery; Tumor
ID GAMMA-KNIFE RADIOSURGERY; TERM-FOLLOW-UP; STEREOTACTIC RADIOSURGERY;
   INTRACRANIAL MENINGIOMAS; SURGERY; MANAGEMENT; RADIOTHERAPY;
   IMPROVEMENT; EXPERIENCE; AVOIDANCE
AB BACKGROUND: Parasellar meningiomas involving the cavernous sinus and Meckel's cave pose a management challenge because of invasion around neurovascular structures and the pituitary gland. The management options range from aggressive resection to focused radiotherapy alone. We present a strategy for these tumors that includes endonasal bony decompression, partial tumor removal, and stereotactic radiotherapy (SRT) in select cases.
   METHODS: The tumor location, previous treatments, cranial neuropathies, pituitary dysfunction, tumor control rates, use of stereotactic radiosurgery, SRT, and complications were retrospectively evaluated.
   RESULTS: Twenty patients (age range, 43-81 years; 65% women; 90% with World Health Organization grade I; median follow-up, 57 months; 14 without previous debulking and RT; 6 with previous debulking and RT) underwent endonasal bony decompression and partial tumor removal. The most common tumor locations were cavernous sinus (95%), Meckel's cave (95%), sella (75%), petroclival (60%), and optic canal/orbit (30%). Three patients with large meningiomas underwent staged transcranial and endonasal debulking. Of the 14 patients without previous debulking and RT, 11 had undergone postoperative SRT, with tumor shrinkage in 3 (27%). At the last follow-up examination, for these 14 patients and the 6 patients who had undergone previous surgery and RT, tumor control was 100% and 33% (P< 0.001) and the cranial neuropathies had improved in 57% and 33%, respectively. Major complications occurred in 2 patients: a permanent sixth cranial nerve palsy and cerebrospinal fluid leakage requiring reoperation.
   CONCLUSIONS: Endonasal bony decompression and selective tumor removal, followed by SRT, appears to be a reasonable treatment option for most previously untreated parasellar meningiomas. For patients who have undergone previous debulking and RT, new targeted treatment strategies are needed.
C1 [Sivakumar, Walavan; Barkhoudarian, Garni; Lobo, Bjorn M.; Zhang, Xin; Zhao, Fan; Eisenberg, Amy; Kesari, Santosh; Krauss, Howard; Cohan, Pejman; Griffiths, Chester; Wollman, Robert; Chaiken, Lisa; Kelly, Daniel F.] Providence St Johns Hlth Ctr, Pacific Neurosci Inst, John Wayne Canc Inst, Santa Monica, CA 90401 USA.
   [Sivakumar, Walavan] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA.
RP Kelly, DF (reprint author), Providence St Johns Hlth Ctr, Pacific Neurosci Inst, John Wayne Canc Inst, Santa Monica, CA 90401 USA.
EM kellyd@jwci.org
CR Abdel-Aziz KM, 2004, NEUROSURGERY, V54, P1383
   Akutsu H, 2009, NEUROSURGERY, V65, P54, DOI 10.1227/01.NEU.0000348016.69726.A6
   Aziz KMA, 2004, NEUROSURGERY, V54, P1375, DOI 10.1227/01.NEU.0000125542.00834.6D
   Banerjee J, 2009, NEURO-ONCOLOGY, V11, P543, DOI 10.1215/15228517-2008-122
   Conger A, 2019, J NEUROSURG, V130, P861, DOI 10.3171/2017.11.JNS172141
   Conti M, 2008, CLIN NEUROL NEUROSUR, V110, P682, DOI 10.1016/j.clineuro.2008.04.007
   Couldwell WT, 2006, J NEUROSURG, V105, P148, DOI 10.3171/jns.2006.105.1.148
   de Keizer RJW, 2004, EYE, V18, P954, DOI 10.1038/sj.eye.6701370
   DEMONTE F, 1994, J NEUROSURG, V81, P245, DOI 10.3171/jns.1994.81.2.0245
   DiBiase SJ, 2004, INT J RADIAT ONCOL, V60, P1515, DOI 10.1016/j.ijrobp.2004.05.073
   Dusick JR, 2007, NEUROSURGERY, V60, P322, DOI 10.1227/01.NEU.0000255408.84269.A8
   Elsamadicy AA, 2015, WORLD NEUROSURG, V83, P530, DOI 10.1016/j.wneu.2014.12.009
   Fernandez A, 2009, ENDOCR-RELAT CANCER, V16, P733, DOI 10.1677/ERC-08-0231
   Griffiths CF, 2014, ACTA NEUROCHIR, V156, P1393, DOI 10.1007/s00701-014-2107-8
   HAAK HR, 1990, LANCET, V336, P124
   Han JN, 2014, AM J CLIN ONCOL-CANC, V37, P255, DOI 10.1097/COC.0b013e318271b36a
   Iwai Y, 2003, NEUROSURGERY, V52, P517, DOI 10.1227/01.NEU.0000047814.18819.9F
   Kaley T, 2014, NEURO-ONCOLOGY, V16, P829, DOI 10.1093/neuonc/not330
   Kano H, 2013, NEUROSURGERY, V73, P401, DOI 10.1227/01.neu.0000431471.64289.3d
   Kassam AB, 2009, NEUROSURGERY, V64, pS71, DOI 10.1227/01.NEU.0000335162.36862.54
   Lee JYK, 2002, J NEUROSURG, V97, P65, DOI 10.3171/jns.2002.97.1.0065
   Lobo B, 2015, NEUROSURG CLIN N AM, V26, P389, DOI 10.1016/j.nec.2015.03.004
   Lou E, 2012, J NEURO-ONCOL, V109, P63, DOI 10.1007/s11060-012-0861-0
   Ly KI, 2015, J NEURO-OPHTHALMOL, V35, P382, DOI 10.1097/WNO.0000000000000253
   Metellus P, 2005, NEUROSURGERY, V57, P873, DOI 10.1227/01.NEU.0000179924.76551.cd
   Correa SFM, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-27
   Nicolato A, 2002, INT J RADIAT ONCOL, V53, P992, DOI 10.1016/S0360-3016(02)02802-X
   OSullivan MG, 1997, NEUROSURGERY, V40, P238, DOI 10.1097/00006123-199702000-00003
   Pamir MN, 2005, SURG NEUROL, V64, P58, DOI 10.1016/j.surneu.2005.07.053
   Puchner MJA, 2010, ANN ONCOL, V21, P2445, DOI 10.1093/annonc/mdq634
   Roche PH, 2000, J NEUROSURG, V93, P68, DOI 10.3171/jns.2000.93.supplement_3.0068
   Santacroce A, 2012, NEUROSURGERY, V70, P32, DOI 10.1227/NEU.0b013e31822d408a
   Sheehan JP, 2014, J NEUROSURG, V120, P1268, DOI 10.3171/2014.2.JNS13139
   Sindou M, 2007, J NEUROSURG, V107, P937, DOI 10.3171/JNS-07/11/0937
   Skeie BS, 2010, NEUROSURGERY, V66, P661, DOI 10.1227/01.NEU.0000366112.04015.E2
   Touat M, 2014, ACTA NEUROCHIR, V156, P1831, DOI 10.1007/s00701-014-2188-4
NR 36
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E12
EP E22
DI 10.1016/j.wneu.2019.06.073
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300003
PM 31226453
DA 2020-05-12
ER

PT J
AU Sriamornrattanakul, K
   Wongsuriyanan, S
   Akharathammachote, N
AF Sriamornrattanakul, Kitiporn
   Wongsuriyanan, Somkiat
   Akharathammachote, Nasaeng
TI Anterior Temporal Approach for Clipping of Upper Basilar Artery
   Aneurysms: Surgical Techniques and Treatment Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior temporal approach; Basilar bifurcation aneurysm; Basilar tip
   aneurysm; Ruptured aneurysm; Superior cerebellar artery aneurysm; Upper
   basilar artery aneurysm
ID POSTERIOR CIRCULATION ANEURYSMS; ENDOVASCULAR COILING; APEX ANEURYSMS;
   TIP ANEURYSMS; RISK-FACTORS; COMPLEX; TERM
AB BACKGROUND: Upper basilar artery (BA) aneurysms, which consist of basilar tip and BA-superior cerebellar artery aneurysms, are challenging to treat with microsurgical clipping. The anterior temporal approach is one surgical approach used to treat aneurysms in this region. Most previous reports on this approach have consisted of unruptured cases. Assessing mostly ruptured cases in this study, we describe the surgical technique, patient characteristics, and surgical outcomes.
   METHODS: Twenty-three patients with aneurysms arising from the upper BA who received aneurysm clipping via an anterior temporal approach between December 2015 and January 2019 were retrospectively evaluated.
   RESULTS: The location of the aneurysms was the basilar tip in 15 patients (65.2%) and the BA-superior cerebellar artery junction in 8 patients (34.8%). Twenty-one patients (91.3%) presented with subarachnoid hemorrhage. Good outcomes (modified Rankin Scale score 0-2) at 3 months were achieved in 55.6% of all patients and in 80% of good-grade patients (World Federation of Neurosurgical Societies grades I-III) and patients with unruptured aneurysms. For patients with subarachnoid hemorrhage, a good outcome was achieved in 75% of good-grade patients. Postoperative transient oculomotor nerve palsy and thalamic infarctions were detected in 7 patients (30.4%) and 2 patients (8.7%), respectively.
   CONCLUSIONS: With appropriate case selection, the anterior temporal approach was effective and safe for clipping of upper BA aneurysms, especially under subarachnoid hemorrhage conditions.
C1 [Sriamornrattanakul, Kitiporn; Wongsuriyanan, Somkiat; Akharathammachote, Nasaeng] Navamindradhiraj Univ, Fac Med, Dept Surg, Div Neurosurg,Vajira Hosp, Bangkok, Thailand.
RP Sriamornrattanakul, K (reprint author), Navamindradhiraj Univ, Fac Med, Dept Surg, Div Neurosurg,Vajira Hosp, Bangkok, Thailand.
EM kitiporn6823@gmail.com
CR ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Bendok BR, 2004, NEUROSURGERY, V55, P174, DOI 10.1227/01.NEU.0000126948.21288.AF
   DEOLIVEIRA E, 1995, ACTA NEUROCHIR, V136, P204, DOI 10.1007/BF01410627
   DRAKE CG, 1961, J NEUROSURG, V18, P230, DOI 10.3171/jns.1961.18.2.0230
   Drake CG, 1978, NEUROSURGERY, V3, P140
   Goehre F, 2016, WORLD NEUROSURG, V86, P490, DOI [10.1016/j.wneu.2015.09.068, 10.1016/J.WNEU.2015.09.068]
   Goehre F, 2016, WORLD NEUROSURG, V86, P497, DOI 10.1016/j.wneu.2015.09.053
   Hafez Ahmad, 2017, Oper Neurosurg (Hagerstown), V13, P702, DOI 10.1093/ons/opx075
   Henkes H, 2005, J NEUROSURG, V103, P990, DOI 10.3171/jns.2005.103.6.0990
   HEROS RC, 1993, NEUROSURGERY, V33, P244
   Jin Sung-Chul, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P29, DOI 10.7461/jcen.2012.14.1.29
   Jin SC, 2009, J KOREAN NEUROSURG S, V45, P224, DOI 10.3340/jkns.2009.45.4.224
   Katsuno Makoto, 2015, Surg Neurol Int, V6, P10, DOI 10.4103/2152-7806.149843
   Katsuno Makoto, 2013, No Shinkei Geka, V41, P311
   Kazumata K, 2003, SURG CEREBRAL STROKE, V31, P431
   Krisht AF, 2005, NEUROSURGERY, V56, P1361, DOI 10.1227/01.NEU.0000159715.47962.C4
   Krisht AF, 2007, NEUROSURGERY, V60, P242, DOI 10.1227/01.NEU.0000249265.88203.DF
   Kulcsar Z, 2010, STROKE, V41, P1690, DOI 10.1161/STROKEAHA.110.580308
   Lawton MT, 2002, NEUROSURGERY, V50, P1
   Lozier AP, 2004, NEUROSURGERY, V54, P286, DOI 10.1227/01.NEU.0000103222.13642.00
   Lusseveld E, 2002, J NEUROL NEUROSUR PS, V73, P591, DOI 10.1136/jnnp.73.5.591
   Matsukawa H, 2017, ACTA NEUROCHIR, V159, P1633, DOI 10.1007/s00701-017-3239-4
   Matsukawa H, 2015, WORLD NEUROSURG, V84, P475, DOI 10.1016/j.wneu.2015.03.060
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   PANDEY AS, 2007, NEUROSURGERY, V60, P636, DOI DOI 10.1227/01.NEU.0000255433.47044.8F
   Pandley AS, 2007, NEUROSURGERY, V60, P626, DOI 10.1227/NEU.0000255433.47044.8F
   Peluso JPP, 2008, J NEUROL NEUROSUR PS, V79, P706, DOI 10.1136/jnnp.2007.127480
   Post Nicholas, 2005, Neurosurgery, V56, P274, DOI 10.1227/01.NEU.0000156542.31517.70
   Sanai N, 2008, NEUROSURGERY, V62, P1236, DOI 10.1227/01.neu.0000333295.59738.de
   Sano K, 1980, Neurol Res, V2, P361
   Sekhar LN, 2013, NEUROSURGERY, V72, P284, DOI 10.1227/NEU.0b013e3182797952
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Takeuchi Satoru, 2015, Surg Neurol Int, V6, P95, DOI 10.4103/2152-7806.157949
   Tjahjadi Mardjono, 2018, Surg Neurol Int, V9, P44, DOI 10.4103/sni.sni_311_17
   Tjahjadi M, 2016, NEUROSURGERY, V78, P181, DOI 10.1227/NEU.0000000000001021
   Yamamoto J, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FocusVid.14624
   Yasargil M G, 1976, Surg Neurol, V6, P83
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E530
EP E542
DI 10.1016/j.wneu.2019.07.211
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300066
PM 31394359
DA 2020-05-12
ER

PT J
AU Tacconi, L
   Giordan, E
AF Tacconi, Leonello
   Giordan, Enrico
TI A Novel Hybrid Endoscopic Approach for Anterior Cervical Discectomy and
   Fusion and a Meta-Analysis of the Literature
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical discectomy; Endoscopic; Endoscopic discectomy; Fusion;
   Percutaneous
ID DECOMPRESSION
AB BACKGROUND: We describe our experience in the endoscopic treatment of cervical spondylosis. We present a "hybrid" technique that is similar to an open anterior cervical discectomy with fusion but is performed endoscopically. We also analyzed data from studies on endoscopic cervical discectomies published in the past 2 decades.
   METHODS: We prospectively collected and analyzed data on all patients who underwent endoscopic cervical discectomy and fusion from January 2017 to January 2019. Data included age, sex, location, diagnosis, arm pain, degree of myelopathy and disability, and adverse events. Also, several databases were explored from January 1998 to December 2018, and 11 studies describing data about the anterior endoscopic treatment of cervical spondylosis, with and without fusion, were retrieved. We pooled these studies into a meta-analysis.
   RESULTS: Arm pain decreased from a preoperative mean visual analogue scale value of 7 to a postoperative value of 2.1, and Nurick grade improved from a mean value of 3.1 to 1.8 at 12 months. 36-Item Short Form Survey scores increased from a mean preoperative value of 67 to 83.2, whereas the mean Oswestry Disability Index score decreased from 65.7 to a final mean value of 23.1 at 12 months. Median hospitalization time was 36 hours. Our meta-analysis found a satisfactory outcome in 88% of patients at last follow-up, an overall recurrence rate of 3%, and a revision rate of 5%.
   CONCLUSIONS: We described the feasibility and safety of anterior hybrid endoscopic cervical discectomy, over-coming some of the limitations of the previously described percutaneous discectomies and shifting the standard open technique into an endoscopic procedure.
C1 [Tacconi, Leonello; Giordan, Enrico] Univ Hosp Trieste, Dept Neurosurg, Trieste, Italy.
RP Giordan, E (reprint author), Univ Hosp Trieste, Dept Neurosurg, Trieste, Italy.
EM enrico.giordan@aulss2.veneto.it
OI Giordan, Enrico/0000-0002-8863-116X
CR Ahn Y, 2016, EXPERT REV MED DEVIC, V13, P601, DOI 10.1080/17434440.2016.1180245
   BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160
   Bucknall V, 2018, J ORTHOP SURG, V26, P1
   Chiu JC, 2000, MT SINAI J MED, V67, P278
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Deukmedjian Ara J, 2012, Surg Neurol Int, V3, P142, DOI 10.4103/2152-7806.103884
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106
   Hadley M N, 1993, Neurosurg Clin N Am, V4, P45
   Haufe SMW, 2004, J CLIN LASER MED SUR, V22, P57, DOI 10.1089/104454704773660985
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Lee JH, 2014, PHOTOMED LASER SURG, V32, P663, DOI 10.1089/pho.2014.3806
   León Jorge Felipe Ramírez, 2017, Coluna/Columna, V16, P261, DOI 10.1590/s1808-185120171604182181
   Lyson T, 2013, J NEUROL SURG PART A, V74, pE100, DOI 10.1055/s-0032-1326942
   Middleton SD, 2017, EFORT OPEN REV, V2, P317, DOI 10.1302/2058-5241.2.160087
   Murad Mohammad Hassan, 2018, BMJ Evid Based Med, V23, P60, DOI 10.1136/bmjebm-2017-110853
   Nadkarni SM, 2017, INDIAN J ORTHOP, V51, P653, DOI 10.4103/ortho.IJOrtho_283_16
   NURICK S, 1972, BRAIN, V95, P87
   Oh HS, 2017, WORLD NEUROSURG, V102, P583, DOI 10.1016/j.wneu.2017.03.056
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Quillo-Olvera J, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.02.09
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Ruetten S, 2009, INT ORTHOP, V33, P1677, DOI 10.1007/s00264-008-0684-y
   Tacconi L, 2019, WORLD NEUROSURG, V121, pE940, DOI 10.1016/j.wneu.2018.10.023
   Tzaan WC, 2011, J SPINAL DISORD TECH, V24, P421, DOI 10.1097/BSD.0b013e31820ef328
   Yadav YR, 2014, NEUROL INDIA, V62, P417, DOI 10.4103/0028-3886.141287
   Yang JS, 2017, PAIN PHYSICIAN, V20, pE1123
   Yang JS, 2014, SPINE, V39, P1743, DOI 10.1097/BRS.0000000000000508
   Yao NZ, 2011, EUR SPINE J, V20, P899, DOI 10.1007/s00586-010-1642-0
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E237
EP E246
DI 10.1016/j.wneu.2019.07.122
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300028
PM 31349080
DA 2020-05-12
ER

PT J
AU Terakado, T
   Marushima, A
   Koyama, Y
   Tsuruta, W
   Takigawa, T
   Ito, Y
   Hino, T
   Sato, M
   Hayakawa, M
   Ishikawa, E
   Inoue, Y
   Matsumaru, Y
   Matsumura, A
AF Terakado, Toshitsugu
   Marushima, Aiki
   Koyama, Yasuaki
   Tsuruta, Wataro
   Takigawa, Tomoji
   Ito, Yoshiro
   Hino, Tenyu
   Sato, Masayuki
   Hayakawa, Mikito
   Ishikawa, Eiichi
   Inoue, Yoshiaki
   Matsumaru, Yuji
   Matsumura, Akira
TI Effectiveness of Near-Infrared Spectroscopy (NIRO-200NX, Pulse Mode) for
   Risk Management in Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenting; Hyperperfusion; Near-infrared spectroscopy;
   Tissue oxygenation index
ID CEREBRAL HYPERPERFUSION SYNDROME; TRANSCRANIAL DOPPLER; ENDARTERECTOMY;
   INDEX; ANGIOPLASTY; ISCHEMIA
AB BACKGROUND: Near-infrared spectroscopy (NIRS) is an alternative monitoring method during carotid artery stenting (CAS). NIRS has been reported to be effective in emergency care; however, it is unknown whether it can predict intraoperative ischemic intolerance and cerebral hyperperfusion during CAS. Perioperative ischemic intolerance and cerebral hyperperfusion are potential events during CAS for carotid artery stenosis. We evaluated whether perioperative monitoring of the tissue oxygenation index (TOI) using NIRS with the NIRO system can predict the occurrence of ischemic intolerance and cerebral hyperperfusion.
   METHODS: The TOI of 27 patients was measured during CAS. The relationship between the TOI and ischemic intolerance or cerebral hyperperfusion was analyzed, and the cutoff TOI was calculated to predict their occurrence.
   RESULTS: Ischemic intolerance occurred in 5 patients during balloon protection. The TOI in the presence of ischemic intolerance was significantly lower than that without ischemic intolerance. The cutoff TOI to detect ischemic intolerance was 50% and that of the TOI change rate before and after balloon protection was 80%. The ischemic symptoms in all patients had resolved immediately after balloon deflation. The cerebral hyperperfusion phenomenon was detected using single-photon emission computed tomography in 4 patients. These patients showed a transient increase in the TOI immediately after CAS; however, none of these patients showed symptomatic cerebral hyperperfusion phenomenon. The cutoff TOI to detect cerebral hyperperfusion was 109% compared with the TOI before CAS.
   CONCLUSION: Monitoring of the TOI using the NIRO system could be useful for the detection of ischemic intolerance and cerebral hyperperfusion during CAS and to prevent perioperative adverse events.
C1 [Terakado, Toshitsugu; Marushima, Aiki; Tsuruta, Wataro; Takigawa, Tomoji; Ito, Yoshiro; Hino, Tenyu; Sato, Masayuki; Hayakawa, Mikito; Ishikawa, Eiichi; Inoue, Yoshiaki; Matsumaru, Yuji; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
   [Marushima, Aiki; Koyama, Yasuaki] Univ Tsukuba, Fac Med, Dept Emergency & Crit Care Med, Tsukuba, Ibaraki, Japan.
RP Marushima, A (reprint author), Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.; Marushima, A (reprint author), Univ Tsukuba, Fac Med, Dept Emergency & Crit Care Med, Tsukuba, Ibaraki, Japan.
EM aiki.marushima@md.tsukuba.ac.jp
FU Japanese Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [JP17K10819]; Agency for Medical Research and
   Development [JP17ek0210099h0001]
FX The present study was supported by the Japanese Society for the
   Promotion of Science Grant-in-Aid for Scientific Research (grant
   JP17K10819) and Agency for Medical Research and Development (grant
   JP17ek0210099h0001).
CR Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae
   Ansel GM, 2010, CATHETER CARDIO INTE, V76, P1, DOI 10.1002/ccd.22439
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Dalman JE, 1999, EUR J VASC ENDOVASC, V18, P222, DOI 10.1053/ejvs.1999.0846
   Davie SN, 2012, ANESTHESIOLOGY, V116, P834, DOI 10.1097/ALN.0b013e31824c00d7
   Dunne VG, 2001, J CLIN NEUROSCI, V8, P140, DOI 10.1054/jocn.2000.0752
   Guay J, 2013, CAN J ANESTH, V60, P266, DOI 10.1007/s12630-012-9876-4
   HALSEY JH, 1992, STROKE, V23, P1583, DOI 10.1161/01.STR.23.11.1583
   ITOH T, 1993, STROKE, V24, P1192, DOI 10.1161/01.STR.24.8.1192
   Iwata T, 2011, NEUROSURGERY, V68, P649, DOI 10.1227/NEU.0b013e3182077ed8
   Kaku Y, 2004, AM J NEURORADIOL, V25, P1403
   Komoribayashi N, 2006, J CEREBR BLOOD F MET, V26, P878, DOI 10.1038/sj.jcbfm.9600244
   Koyama Y, 2018, AM J EMERG MED, V36, DOI 10.1016/j.ajem.2017.11.029
   Koyama Y, 2017, INTERNAL MED, V56, P2451, DOI 10.2169/internalmedicine.7826-16
   Matsumoto S, 2009, NEUROLOGY, V72, P1512, DOI 10.1212/WNL.0b013e3181a2e846
   Ogasawara K, 2003, NEUROSURGERY, V53, P309, DOI 10.1227/01.NEU.0000073547.86747.F3
   Ogasawara K, 2007, J NEUROSURG, V107, P1130, DOI 10.3171/JNS-07/12/1130
   Park HS, 2017, WORLD NEUROSURG, V99, P548, DOI 10.1016/j.wneu.2016.12.062
   Pennekamp CWA, 2013, EUR J VASC ENDOVASC, V46, P397, DOI 10.1016/j.ejvs.2013.07.007
   Pennekamp CWA, 2012, CEREBROVASC DIS, V34, P314, DOI 10.1159/000343229
   Pinkerton JA, 2002, ANN VASC SURG, V16, P756, DOI 10.1007/s10016-001-0208-3
   Uchino H, 2012, WORLD NEUROSURG, V78, P651, DOI 10.1016/j.wneu.2011.10.039
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yoshimura S, 2009, NEUROSURGERY, V64, pS122, DOI 10.1227/01.NEU.0000334046.41985.BB
   Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E425
EP E432
DI 10.1016/j.wneu.2019.07.184
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300051
PM 31376552
DA 2020-05-12
ER

PT J
AU Tomonori, T
   Fumihiro, M
   Michio, Y
   Akio, M
AF Tomonori, Tamaki
   Fumihiro, Matano
   Michio, Yamazaki
   Akio, Morita
TI Prevention of Back Bleeding During Carotid Endarterectomy: Analysis of
   Clamping Techniques
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerosis; Carotid endarterectomy; Common carotid artery
ID ARTERY; STROKE; CALCIFICATION; PATHOLOGY; OCCLUSION; CT
AB OBJECTIVE: Complete control of back bleeding during carotid endarterectomy (CEA) is important. We investigated the causes of back bleeding during CEA and techniques for the control of bleeding.
   METHODS: A retrospective review was performed of 214 CEA procedures. We assessed the results of routine preoperative examinations, instruments used for arterial clamping (vessel loop and crude or bulldog clamps), and severity of carotid artery stenosis and arterial wall calcification. The study end point was incomplete control of back bleeding before arteriotomy. Factors associated with back bleeding were identified by univariate analysis. The culprit artery and intraoperative technique used in patients with back bleeding were also determined.
   RESULTS: Transient back bleeding occurred in 19 CEA procedures (8.9%). Back bleeding was from the ascending pharyngeal artery in 9 cases, common carotid artery in 8 cases, and external carotid artery in 2 cases. Univariate analysis identified the following factors as being related to incomplete control of back bleeding: moderate carotid artery stenosis (20 mm thick) and use of bulldog clamps.
   CONCLUSIONS: Transient back bleeding during CEA was uncommon, with the risk factors being severe carotid calcification and moderate carotid stenosis. Transient back bleeding was managed by clamping an undetected ascending pharyngeal artery or by additional clamping of the common carotid or external carotid artery. The vessel loop and crude were superior to the bulldog clamp for clamping the carotid artery.
C1 [Tomonori, Tamaki; Fumihiro, Matano; Michio, Yamazaki] Tamanagayama Hosp, Nippon Med Sch, Dept Neurol Surg, Tokyoto, Japan.
   [Akio, Morita] Nippon Med Sch, Dept Neurol Surg, Tokyoto, Japan.
RP Tomonori, T (reprint author), Tamanagayama Hosp, Nippon Med Sch, Dept Neurol Surg, Tokyoto, Japan.
EM tamakito@nms.ac.jp
CR ATKINSON JLD, 1990, NEUROSURGERY, V26, P80, DOI 10.1227/00006123-199001000-00011
   Cao QQ, 2014, INTERV NEUROL, V3, P13, DOI 10.1159/000366231
   Catalog M., 2007, CHILDREN, P18034
   Cavalcanti D, 2008, SKULL BASE S2, V17, P1
   Cortes-Franco S, 2013, ANN VASC SURG, V27, DOI 10.1016/j.avsg.2012.10.003
   Cosar M, 2008, SURG NEUROL, V69, P483, DOI 10.1016/j.surneu.2007.01.053
   Ferguson GG, 1999, STROKE, V30, P1751, DOI 10.1161/01.STR.30.9.1751
   Fisher M, 2005, STROKE, V36, P253, DOI 10.1161/01.STR.0000152336.71224.21
   Fukuda I, 2013, GEN THORAC CARDIOVAS, V61, P301, DOI 10.1007/s11748-013-0203-y
   Ha SK, 2009, J KOREAN NEUROSURG S, V46, P31, DOI 10.3340/jkns.2009.46.1.31
   Hayashi N, 2005, NEUROL MED-CHIR, V45, P25, DOI 10.2176/nmc.45.25
   Maki Y, 2018, ANN VASC SURG, V53, DOI 10.1016/j.avsg.2018.05.073
   Marrocco-trischitta MM, 2006, J VASC SURG, V58, P136
   Michalinos A, 2016, ANAT RES INT, V2016, P1
   Miralles M, 2006, EUR J VASC ENDOVASC, V32, P561, DOI 10.1016/j.ejvs.2006.02.019
   Nandalur KR, 2006, AM J ROENTGENOL, V186, P547, DOI 10.2214/AJR.04.1216
   Ooka K, 1997, NEUROSURGERY, V40, P318, DOI 10.1097/00006123-199702000-00016
   Ozgur Z, 2008, SURG RADIOL ANAT, V30, P475, DOI 10.1007/s00276-008-0351-4
   Sidani Charif A, 2015, Avicenna J Med, V5, P98, DOI 10.4103/2231-0770.160251
   SUGITA K, 1976, J NEUROSURG, V44, P723, DOI 10.3171/jns.1976.44.6.0723
   Thirumala PD, 2016, NEUROL RES, V38, P698, DOI 10.1080/01616412.2016.1200707
   Umeoka K, 2014, TURK NEUROSURG, V24, P546, DOI 10.5137/1019-5149.JTN.9527-13.0
   Ustunsoz B, 2007, CARDIOVASC INTER RAD, V30, P116, DOI 10.1007/s00270-006-0060-5
   Wilson PWF, 2001, CIRCULATION, V103, P1529, DOI 10.1161/01.cir.103.11.1529
   Yahagi K, 2017, ARTERIOSCL THROM VAS, V37, P191, DOI 10.1161/ATVBAHA.116.306256
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E186
EP E191
DI 10.1016/j.wneu.2019.07.114
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300022
PM 31336174
DA 2020-05-12
ER

PT J
AU Tripathi, M
   Rekhapalli, R
   Batish, A
   Kumar, N
   Oinam, AS
   Ahuja, CK
   Deora, H
   Aggarwal, A
   Mohindra, S
   Kaur, P
   Kaur, R
   Bhatt, S
   Gurnani, J
AF Tripathi, Manjul
   Rekhapalli, Rajashekhar
   Batish, Aman
   Kumar, Narendra
   Oinam, Arun S.
   Ahuja, Chirag K.
   Deora, Harsh
   Aggarwal, Ashish
   Mohindra, Sandeep
   Kaur, Parwinder
   Kaur, Rupinder
   Bhatt, Sandeep
   Gurnani, Jenil
TI Safety and Efficacy of Primary Multisession Dose Fractionated Gamma
   Knife Radiosurgery for Jugular Paragangliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial neuropathy; Dose fractionated Gamma Knife radiosurgery; Jugular
   paraganglioma; Linear quadratic model; Radiosurgery
ID STEREOTACTIC RADIOSURGERY; GLOMUS TUMORS; MANAGEMENT; SINGLE; SURGERY
AB BACKGROUND: While multisession dose fractionated Gamma Knife radiosurgery (DFGKS) is common, its use has never been described for jugular paragangliomas (JP), which are notoriously difficult to treat.
   OBJECTIVE: To define efficacy, safety, and complication profile of DFGKS in 2 or 3 consecutive sessions for the treatment of a cohort of 10 cases of JP.
   METHODS: Between 2012 and 2017, 10 patients with JP were treated with DFGKS in 2 or 3 sessions, because it was not safe to treat the lesion in a single session because of the large volume or proximity to organs at risk. The small to medium-sized JP are treated with 16-22 Gy radiation, but the large-volume JP were treated with 23-25 Gy radiation dose. The Leksell G frame was kept in situ during the whole procedure. The tumor volumes on pretreatment and posttreatment imaging were compared, using the Leksell Gamma Plan treatment plan software to assess tumor progression. The patients were regularly evaluated for their clinical outcome with radiologic correlation.
   RESULTS: The mean radiologic follow-up was 39 months (range, 12-78 months). The mean marginal dose for 3 fractions and 2 fractions was 7.64 Gy at 50% and 11.2 Gy at 50%, respectively. The mean tumor size was 29.9 cm(3) (range, 9.95-47.63 cm(3)) at treatment and 21.9 cm(3) (range, 8.83-37.5 cm(3)) at follow-up (suggestive of 26.7% reduction). Tumor control was achieved in all patients (100%). Of 110 potential neurologic problems (signs/symptoms) evaluated (11 in each patient), 56 (50.9%) were present preoperatively. Of them, 27 (48.2%) improved and 29 (51.8%) stabilized after treatment. There were 2 new-onset neurologic problems (of 110, 1.8%) attributable to treatment (new-onset headache and spinal accessory paresis). No patient had any permanent neurologic deterioration.
   CONCLUSIONS: DFGKS for large-volume JP leads to acceptable progression-free survival, tumor control rate, and symptomatic improvement. It may be preferred to surgery or fractionated radiotherapy given its better safety, efficacy, and complication profile.
C1 [Tripathi, Manjul; Rekhapalli, Rajashekhar; Batish, Aman; Aggarwal, Ashish; Mohindra, Sandeep; Kaur, Parwinder; Kaur, Rupinder; Gurnani, Jenil] Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
   [Kumar, Narendra; Oinam, Arun S.] Post Grad Inst Med Educ & Res, Dept Radiotherapy, Chandigarh, India.
   [Ahuja, Chirag K.; Bhatt, Sandeep] Post Grad Inst Med Educ & Res, Dept Radiodiag, Chandigarh, India.
   [Deora, Harsh] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
RP Tripathi, M (reprint author), Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India.
EM drmanjultripathi@gmail.com
RI DEORA, HARSH/A-5817-2019; Tripathi, Manjul/AAE-7128-2019
OI DEORA, HARSH/0000-0003-3247-1117; Tripathi, Manjul/0000-0002-5679-3439;
   Rekapalli, Rajasekhar/0000-0003-0428-5042; batish,
   aman/0000-0003-3257-9443
CR ALFORD BOB R., 1962, LARYNGOSCOPE, V72, P765
   Chen PG, 2010, LARYNGOSCOPE, V120, P1856, DOI 10.1002/lary.21073
   Chhabra R, 2017, ANN NEUROSCI, V24, P181, DOI 10.1159/000477183
   Common Terminology Criteria for Adverse Events (CTCAE, VERS 4 03
   DEANDRADE EM, 2013, SURG NEUROL INT S6, V4, P429, DOI DOI 10.4103/2152-7806
   Dobberpuhl MR, 2016, OTOL NEUROTOL, V37, P1406, DOI 10.1097/MAO.0000000000001160
   El Majdoub F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129057
   Feigl GC, 2006, J NEUROSURG, V105, P161, DOI 10.3171/sup.2006.105.7.161
   Gigliotti MJ, 2018, J RADIOSURGERY SBRT, V5, P183
   Gottfried Oren N, 2004, Neurosurg Focus, V17, pE4
   Greer J A, 1976, J Otolaryngol, V5, P391
   Guss ZD, 2011, INT J RADIAT ONCOL, V81, pE497, DOI 10.1016/j.ijrobp.2011.05.006
   Hafez RFA, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0779-7
   Hall EJ, 2012, RADIOBIOLOGY RADIOLO, P25
   Hurmuz P, 2013, TECHNOL CANCER RES T, V12, P109, DOI 10.7785/tcrt.2012.500303
   Ibrahim R, 2017, J NEUROSURG, V126, P1488, DOI 10.3171/2016.4.JNS152667
   Ivan ME, 2011, J NEUROSURG, V114, P1299, DOI 10.3171/2010.9.JNS10699
   Lieberson RE, 2012, WORLD NEUROSURG, V77, P745, DOI 10.1016/j.wneu.2011.03.026
   Gandia-Gonzalez ML, 2014, J NEUROSURG, V121, P1158, DOI 10.3171/2014.5.JNS131880
   Mukherjee KK, 2017, NEUROL INDIA, V65, P826, DOI 10.4103/neuroindia.NI_220_17
   Mukherjee KK, 2016, ACTA NEUROCHIR, V158, P2237, DOI 10.1007/s00701-016-2964-4
   Martin AN, 2010, CLIN TRANSL ONCOL, V12, P55, DOI 10.1007/s12094-010-0467-y
   Patel NS, 2019, J NEUROSURG, V130, P379, DOI 10.3171/2017.10.JNS17764
   Pollock Bruce E, 2004, Neurosurg Focus, V17, pE10
   Rowe J, 2007, NEUROSURGERY, V60, P60, DOI 10.1227/01.NEU.0000255492.34063.32
   Sager Omer, 2015, CNS Oncol, V4, P105, DOI 10.2217/cns.14.56
   Sager O, 2014, TUMORI, V100, P184, DOI 10.1700/1491.16409
   Schuster D, 2016, AM J OTOLARYNG, V37, P255, DOI 10.1016/j.amjoto.2016.01.002
   Sheehan JP, 2012, J NEUROSURG, V117, P246, DOI 10.3171/2012.4.JNS11214
   Suarez C, 2013, HEAD NECK-J SCI SPEC, V35, P1195, DOI 10.1002/hed.22976
   TRIPATHI M, 2018, J NEUROSURG, V28, P1
   Tripathi M, 2018, NEUROL INDIA, V66, P1469, DOI 10.4103/0028-3886.241362
   Tripathi M, 2016, ACTA NEUROCHIR, V158, P1691, DOI 10.1007/s00701-016-2878-1
   Tse V, 2017, J RADIOSURGERY SBRT, V5, P73
   Tuniz F, 2009, NEUROSURGERY, V65, P898, DOI 10.1227/01.NEU.0000359316.34041.A8
   VANDERMEY AGL, 1989, LANCET, V2, P1291
   Zhong J, 2018, NEUROSURGERY, V83, P850, DOI 10.1093/neuros/nyy145
NR 37
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E136
EP E148
DI 10.1016/j.wneu.2019.07.090
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300017
PM 31323416
DA 2020-05-12
ER

PT J
AU Varshneya, K
   Pendharkar, AV
   Azad, TD
   Ratliff, JK
   Veeravagu, A
AF Varshneya, Kunal
   Pendharkar, Arjun, V
   Azad, Tej D.
   Ratliff, John K.
   Veeravagu, Anand
TI A Descriptive Analysis of Spinal Cord Arteriovenous Malformations:
   Clinical Features, Outcomes, and Trends in Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; MarketScan; Outcomes; Spinal cord AVM
ID ENDOVASCULAR TREATMENT; VASCULAR MALFORMATIONS; FISTULAS; EMBOLIZATION
AB BACKGROUND: Spinal arteriovenous malformations (AVM) are an abnormal interconnection of vasculature in the spine than can lead to significant neurologic deficit if left untreated.
   OBJECTIVE: The objective of this study was to characterize how patients with spinal AVM initially presented, what treatment options were used, and their overall outcomes on a national scale.
   METHODS: The MarketScan database was queried to identify adult patients diagnosed with a spinal AVM from 2007 to 2015. Trends in management, postoperative complication rates, and costs were determined.
   RESULTS: In total, 976 patients were identified with having a diagnosis of a spinal AVM. Patients were more commonly treated with an open incision than an embolization (40.1% vs. 15.4%). The overall complication rate was 33.61%. Spinal AVM admissions have been stable over the past decade, and mean cost of hospitalization has risen from of $48,700 in 2007 to $71,292 in 2015. Patients who underwent open surgery had a greater complication rate than those treated with embolization (31.15% vs. 18.25%, P < 0.005); however, this may be strongly influenced by complexity of spinal AVM pathology and not treatment modality.
   CONCLUSIONS: Costs of spinal AVM management continue to rise, even when treatment modalities have reduced length of stay significantly. Open surgery may lead to more postoperative complications and a greater length of stay than endovascular approaches. Further studies should look to identify the efficacy of endovascular approaches for spinal cord AVMs, particularly in complex spinal AVM traditionally treated with open surgery and to isolate factors leading to the elevated hospitalization costs.
C1 [Varshneya, Kunal; Pendharkar, Arjun, V; Azad, Tej D.; Ratliff, John K.; Veeravagu, Anand] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
RP Veeravagu, A (reprint author), Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
EM anandv2@stanford.edu
CR AMINOFF MJ, 1974, J NEUROL SCI, V23, P255, DOI 10.1016/0022-510X(74)90229-9
   AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211
   Andres RH, 2008, NEURORADIOLOGY, V50, P869, DOI 10.1007/s00234-008-0425-3
   Bao YH, 1997, NEUROSURGERY, V40, P75, DOI 10.1097/00006123-199701000-00017
   da Costa L, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.1.E6
   Detwiler PW, 1999, NEUROSURG CLIN N AM, V10, P89, DOI 10.1016/S1042-3680(18)30212-2
   Endo T, 2016, NEUROL MED-CHIR, V56, P457, DOI 10.2176/nmc.ra.2015-0327
   Ferch RD, 2001, J CLIN NEUROSCI, V8, P299, DOI 10.1054/jocn.2000.0914
   Gokhale Sankalp, 2014, Surg Neurol Int, V5, P7, DOI 10.4103/2152-7806.125628
   HORTON JA, 1986, AM J NEURORADIOL, V7, P113
   HUFFMANN BC, 1995, ACTA NEUROCHIR, V135, P44, DOI 10.1007/BF02307413
   Jellema K, 2005, J NEUROSURG-SPINE, V2, P580, DOI 10.3171/spi.2005.2.5.0580
   Kataoka H, 2001, NEUROSURGERY, V48, P1224, DOI 10.1097/00006123-200106000-00004
   Koch MJ, 2017, J NEUROSURG-SPINE, V26, P519, DOI 10.3171/2016.9.SPINE16394
   Krings T, 2005, EUR RADIOL, V15, P267, DOI 10.1007/s00330-004-2510-2
   Lad Shivanand P, 2009, Neurosurg Focus, V26, P1, DOI 10.3171/FOC.2009.26.1.E10
   Lee YJ, 2014, STROKE, V45, P2606, DOI 10.1161/STROKEAHA.114.006087
   Patsalides A, 2011, AM J NEURORADIOL, V32, P798, DOI 10.3174/ajnr.A2190
   RICHE MC, 1983, AM J NEURORADIOL, V4, P378
   ROSENBLUM B, 1987, J NEUROSURG, V67, P795, DOI 10.3171/jns.1987.67.6.0795
   Sasamori T, 2016, EUR SPINE J, V25, P748, DOI 10.1007/s00586-015-3887-0
   THERON J, 1986, RADIOLOGY, V158, P163, DOI 10.1148/radiology.158.1.3940375
NR 23
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E579
EP E585
DI 10.1016/j.wneu.2019.08.010
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300072
PM 31404690
DA 2020-05-12
ER

PT J
AU Wan, YF
   Xie, DJ
   Xue, ZL
   Xie, JX
   Song, ZF
   Wang, YR
   Yang, SX
AF Wan, Yingfeng
   Xie, Dajiang
   Xue, Zhaoliang
   Xie, Jixi
   Song, Zhengfei
   Wang, Yirong
   Yang, Shuxu
TI Single Versus Double Burr Hole Craniostomy in Surgical Treatment of
   Chronic Subdural Hematoma: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Craniostomy; Double burr hole craniostomy;
   Meta-analysis; Single burr hole craniostomy
ID DRAINAGE; MANAGEMENT; QUALITY; NUMBER; SCALE
AB BACKGROUND: Chronic subdural hematoma (cSDH) is one of the most common illnesses seen in neurosurgery departments worldwide. For surgical treatment, some neurosurgeons prefer single burr hole craniostomy (SBHC), whereas others prefer double burr hole craniostomy (DBHC). We performed a meta-analysis to investigate whether DBHC is associated with increased risks of recurrence, complications and mortality compared with SBHC in patients with cSDH.
   METHODS: Retrospective observational trial or randomized controlled trial (RCT) studies concerning burr hole craniostomy to treat cSDH were systematically identified through a search of electronic databases: PubMed, Web of Science, Embase, and Cochrane. Inclusion and exclusion criteria were defined for the eligible studies. The random fixed-effects model was used when heterogeneity was indicated; otherwise, a fixed-effects model was adopted.
   RESULTS: This meta-analysis included 12 studies, 3 of which were RCTs. Our findings can be summarized as follows. First, SBHC did not increase the risk of recurrence compared with DBHC in patients with cSDH (odds ratio [OR], 1.28; 95% confidence interval [CI], 0.92-1.78; P = 0.07). Second, DBHC was not associated with an increased complication rate compared with SBHC in patients with cSDH (OR, 0.74; 95% CI, 0.20-2.76; P = 0.11). Third, DBHC did not increase mortality compared with SBHC in patients with cSDH (OR, 1.38; 95% CI, 0.55-3.46; P = 0.58).
   CONCLUSIONS: This meta-analysis demonstrates that there are no significant differences in recurrence rate, complication rate, and morbidity between SBHC and DBHC in the treatment of patients with cSDH.
C1 [Wan, Yingfeng; Xie, Dajiang; Xue, Zhaoliang; Xie, Jixi; Song, Zhengfei; Wang, Yirong; Yang, Shuxu] Zhejiang Univ, Sir Run Run Shaw Hosp, Affiliated Hosp, Dept Neurosurg,Med Coll, Hangzhou, Zhejiang, Peoples R China.
RP Yang, SX (reprint author), Zhejiang Univ, Sir Run Run Shaw Hosp, Affiliated Hosp, Dept Neurosurg,Med Coll, Hangzhou, Zhejiang, Peoples R China.
EM 3195019@zju.edu.cn
CR Agrawal Y, 2017, INDIAN J NEUROTRAUM, V14, P59, DOI 10.1055/s-0037-1606210
   Baschera D, 2018, WORLD NEUROSURG, V116, pE983, DOI 10.1016/j.wneu.2018.05.145
   Belkhair S, 2013, CAN J NEUROL SCI, V40, P56, DOI 10.1017/S0317167100012956
   Chen JCT, 2000, NEUROSURG CLIN N AM, V11, P399, DOI 10.1016/S1042-3680(18)30101-3
   D'oria Salvatore, 2020, J Neurosurg Sci, V64, P216, DOI 10.23736/S0390-5616.18.04577-0
   De Bonis P, 2018, CLIN NEUROL NEUROSUR, V170, P88, DOI 10.1016/j.clineuro.2018.05.002
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Fomchenko EI, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0518-1
   Han HJ, 2009, J KOREAN NEUROSURG S, V46, P87, DOI 10.3340/jkns.2009.46.2.87
   HARDERS A, 1982, NEUROCHIRURGIA, V25, P147
   Heringer LC, 2017, ARQ NEURO-PSIQUIAT, V75, P809, DOI [10.1590/0004-282X20170136, 10.1590/0004-282x20170136]
   Jang Kyoung-Min, 2015, Korean J Neurotrauma, V11, P75, DOI 10.13004/kjnt.2015.11.2.75
   Kansal R, 2010, J CLIN NEUROSCI, V17, P428, DOI 10.1016/j.jocn.2009.07.109
   Lee JK, 2009, J KOREAN NEUROSURG S, V46, P210, DOI 10.3340/jkns.2009.46.3.210
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Motiei-Langroudi R, 2018, J NEUROSURG, V129, P1143, DOI 10.3171/2017.6.JNS17130
   Nayil K, 2014, TURK NEUROSURG, V24, P246, DOI 10.5137/1019-5149.JTN.8465-13.0
   Oremus M, 2001, DEMENT GERIATR COGN, V12, P232, DOI 10.1159/000051263
   Ou YW, 2019, CLIN NEUROL NEUROSUR, V178, P63, DOI 10.1016/j.clineuro.2019.01.018
   Pahatouridis D, 2013, NEUROSURG REV, V36, P151, DOI 10.1007/s10143-012-0412-3
   Rafi AN, 2018, EURASIAN J ANAL CHEM, V13, DOI 10.20933/ejac/85017
   Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182
   Sahyouni R, 2017, WORLD NEUROSURG, V108, P948, DOI 10.1016/j.wneu.2017.09.064
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Taussky P, 2008, BRIT J NEUROSURG, V22, P279, DOI 10.1080/02688690701818885
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   Xu CS, 2017, EUR REV MED PHARMACO, V21, P809
NR 27
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E149
EP E154
DI 10.1016/j.wneu.2019.07.097
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300018
PM 31323397
DA 2020-05-12
ER

PT J
AU Wang, HG
   Wu, ZH
AF Wang, Honggang
   Wu, Zenghui
TI Association Between Irregular Alteration of Facet Orientation and
   Degenerative Lumbar Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative lumbar spondylolisthesis; Facet joint; Facet orientation;
   Risk factor
ID JOINT ORIENTATION; DISC HERNIATION; SURGERY; TROPISM; STENOSIS
AB BACKGROUND: Numerous studies have reported that irregular alteration of facet orientation (IAFO) is associated with lumbar disc herniation (LDH) in adolescents. The present study investigated the association between IAFO and degenerative lumbar spondylolisthesis (DLS) at the L4-5 segment.
   METHODS: Forty-two adults with DLS were enrolled in this study. Facet angles were measured in the bone window of the computed tomography scan. Large-small-large (LSL) was defined as a type of IAFO that includes the angle of facet joints at L4-5, which is smaller than that in L3-4 and L5-S1 segments. Fifty subjects with LDH at L4-5 served as controls. Data were analyzed using logistic regression analysis.
   RESULTS: In the 42 patients and 50 controls, the facet angle was measured at 276 levers from L3-4 to L5-S1. The mean included angles of L3-4, L4-5, and L5-S1 were 71.5 +/- 19.97 degrees, 51.79 +/- 21.43 degrees, and 102.89 +/- 20.37 degrees, respectively, in the DLS group and 77.48 +/- 17.24 degrees, 91.00 +/- 17.24, and 102.94 +/- 19.75 degrees, respectively, in the control group. LSL was detected in 38 of 42 subjects (90.5%) in the DLS group, compared with 9 of 50 (18.0%) in the controls. The sagittal orientation facet joint in L4-5 was associated with DLS (odds ratio [OR], 26.24; 95% confidence interval [CI], 13.30-155.35; P = 0.000). The facet in L3-4 with a more coronal orientation than that in L4-5 was also correlated with DLS (OR, 33.68; 95% CI, 9.86-115.06; P = 0.000). There was no correlation between the facet in L5-S1 and DLS in L4-5 (P = 0.999), but there was a strong relationship between LSL in L3-5 and DLS in L4-5 (OR, 43.278; 95% CI, 12.303-152.232; P = 0.000).
   CONCLUSIONS: The data presented here demonstrate that LSL, which is an irregular alteration of facet joint orientation, is associated with the degenerative lumbar spondylolisthesis at L4-5.
C1 [Wang, Honggang; Wu, Zenghui] Gen Hosp Southern Theatre Command PLA, Dept Spinal Surg, Guangzhou, Guangdong, Peoples R China.
RP Wu, ZH (reprint author), Gen Hosp Southern Theatre Command PLA, Dept Spinal Surg, Guangzhou, Guangdong, Peoples R China.
EM Zenghuiwu_1@163.com
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M643892]
FX This research was supported by a grant from the China Postdoctoral
   Science Foundation (2018M643892).
CR Abdu WA, 2018, SPINE, V43, P1619, DOI 10.1097/BRS.0000000000002682
   Austevoll IM, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-018-2386-y
   Boden SD, 1996, J BONE JOINT SURG AM, V78A, P403, DOI 10.2106/00004623-199603000-00012
   Chadha M, 2013, EUR SPINE J, V22, P1045, DOI 10.1007/s00586-012-2612-5
   Desai A, 2012, SPINE, V37, P406, DOI 10.1097/BRS.0b013e3182349bc5
   Fardon DF, 2014, SPINE J, V14, P2525, DOI 10.1016/j.spinee.2014.04.022
   GHAILANE S, 2018, SPINE DEFORM, V6, P358, DOI DOI 10.1016/J.JSPD.2017.12.001
   GROBLER JL, 1993, SPINE, V18, P80
   Hrabalek L, 2014, ACTA CHIR ORTHOP TR, V81, P323
   Ikuta K, 2016, SPINE, V41, pE1434, DOI 10.1097/BRS.0000000000001813
   Jaumard NV, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004493
   Liu ZY, 2017, CLIN NEUROL NEUROSUR, V161, P41, DOI 10.1016/j.clineuro.2017.08.005
   Mahato NK, 2011, SPINE, V36, pE569, DOI [10.1097/BRS.0b013e3181f6ecb2, 10.1097/BRS.0b013e318206bdf7]
   Mooney V, 2000, J BONE JOINT SURG BR, V82B, P307
   Murphy HA, 2018, SPINE, V43, P805, DOI 10.1097/BRS.0000000000002459
   Pichaisak Witchate, 2015, Journal of the Medical Association of Thailand, V98, P373
   Rihn JA, 2015, J BONE JOINT SURG AM, V97A, P177, DOI 10.2106/JBJS.N.00313
   ROSENBERG NJ, 1975, J BONE JOINT SURG AM, VA 57, P467, DOI 10.2106/00004623-197557040-00004
   Samartzis D, 2016, GLOB SPINE J, V6, P414, DOI 10.1055/s-0035-1564417
   Sclafani JA, 2016, PM&R, V8, pS160
   Wang HG, 2016, WORLD NEUROSURG, V86, P321, DOI 10.1016/j.wneu.2015.09.029
   Yao Q, 2013, J SPINAL DISORD TECH, V26, pE19, DOI 10.1097/BSD.0b013e31827a254f
   Zencica P, 2010, ACTA CHIR ORTHOP TR, V77, P124
NR 23
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E298
EP E302
DI 10.1016/j.wneu.2019.07.141
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300036
PM 31356974
DA 2020-05-12
ER

PT J
AU Wang, XQ
   Chong, Z
   Guo, X
   Liu, DG
   Sun, ZG
   Chen, YQ
   Gao, LY
   Chen, YG
AF Wang, Xiaoqiang
   Chong, Zhen
   Guo, Xiang
   Liu, Deguo
   Sun, Zhanguo
   Chen, Yueqin
   Gao, Lingyun
   Chen, Yuge
TI Evaluation of Hemodynamics Before and After Revascularization in
   Hemorrhagic Moyamoya Disease: A Computed Tomography Perfusion Imaging
   Case Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Hemorrhage; Moyamoya disease; Perfusion;
   Revascularization
ID SUPERFICIAL TEMPORAL ARTERY; ANGIOGRAPHIC FEATURES; ANASTOMOSIS;
   HYPERPERFUSION; VOLUME
AB OBJECTIVE: To explore the feasibility of computed tomography perfusion imaging (CTP) for evaluating hemo-dynamics in hemorrhagic moyamoya disease (MMD).
   METHODS: The retrospective analysis included 25 patients with hemorrhagic MMD who underwent brain CTP examination. Two experienced radiologists manually delineated regions of interest (ROIs) in the bilateral frontal lobe, temporal lobe, brain tissue adjacent to the hemorrhagic foci, and brainstem as a control region. The perfusion values for all ROls were extracted, including cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), and time to peak (UP). Subsequently, the differences in perfusion values for different brain tissues were compared between the hemorrhagic side and the nonhemorrhagic side. For patients who underwent revascularization surgery, differences in perfusion values from before to after surgery were determined in brain tissues on the ipsilateral side.
   RESULTS: CBF in the area around the hematoma and the lateral temporal lobe on the hemorrhage hemisphere was lower than that on the contralateral side, whereas UP and MIT were higher. Among the 14 patients who underwent revascularization, CBF and CBV in the postoperative temporal lobes were higher than the preoperative values, whereas UP and MTT were lower. CBF and CBV in the frontal lobe were higher after the operation.
   CONCLUSIONS: Hemorrhagic MMD results in cerebral ischemia, and CTP could be used to localize such ischemic brain tissue and objectively evaluate the changes in cerebral hemodynamics with revascularization.
C1 [Wang, Xiaoqiang; Chong, Zhen; Guo, Xiang; Liu, Deguo; Sun, Zhanguo; Chen, Yueqin; Gao, Lingyun; Chen, Yuge] Jining Med Univ, Dept Med Imaging, Affiliated Hosp, Jining, Peoples R China.
RP Chen, YQ (reprint author), Jining Med Univ, Dept Med Imaging, Affiliated Hosp, Jining, Peoples R China.
EM sdjnchenyueqin@163.com
FU Shandong Provincial Development Program of Medical Science and
   Technology [2016WS0185]; Jining Key Research and Development Program
   [2017SMNS012]
FX This study was supported by Shandong Provincial Development Program of
   Medical Science and Technology (No. 2016WS0185), Jining Key Research and
   Development Program (No. 2017SMNS012).
CR Baba T, 2008, J NEUROL NEUROSUR PS, V79, P900, DOI 10.1136/jnnp.2007.130666
   Chen YQ, 2016, EUR RADIOL, V26, P254, DOI 10.1007/s00330-015-3802-4
   Derdeyn CP, 2002, BRAIN, V125, P595, DOI 10.1093/brain/awf047
   Ding JY, 2018, WORLD NEUROSURG, V117, pE557, DOI 10.1016/j.wneu.2018.06.076
   Fainardi E, 2008, NEURORADIOLOGY, V50, P729, DOI 10.1007/s00234-008-0402-x
   Fu J, 2015, NEURORADIOLOGY, V57, P179, DOI 10.1007/s00234-014-1456-6
   Fujimura M, 2007, SURG NEUROL, V67, P273, DOI 10.1016/j.surneu.2006.07.017
   Furuya K, 2004, J NEUROSURG, V100, P128, DOI 10.3171/jns.2004.100.1.0128
   Ha Mahnjeong, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P239, DOI 10.7461/jcen.2016.18.3.239
   Hayashi K, 2014, CLIN NEUROL NEUROSUR, V124, P1, DOI 10.1016/j.clineuro.2014.06.010
   Jang DK, 2014, AM J NEURORADIOL, V35, P1124, DOI 10.3174/ajnr.A3819
   Jo KI, 2016, J KOREAN NEUROSURG S, V59, P117, DOI 10.3340/jkns.2016.59.2.117
   Liu P, 2016, STROKE, V47, P240, DOI 10.1161/STROKEAHA.115.010512
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Rosand J, 2002, CEREBROVASC DIS, V14, P214, DOI 10.1159/000065681
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Serrone JC, 2014, J NEUROL SURG PART B, V75, P371, DOI 10.1055/s-0034-1373658
   Smith ER, 2012, J NEUROSURG-PEDIATR, V9, P353, DOI 10.3171/2011.12.PEDS1172
   Su IC, 2008, J NEUROSURG, V109, P1049, DOI 10.3171/JNS.2008.109.12.1049
   Xie AM, 2015, INT J CLIN EXP MED, V8, P21351
   Zhang WG, 2016, WORLD NEUROSURG, V93, P365, DOI 10.1016/j.wneu.2016.06.063
NR 21
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E277
EP E283
DI 10.1016/j.wneu.2019.07.135
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300033
PM 31351211
DA 2020-05-12
ER

PT J
AU Wang, Y
   Jin, H
   Gong, S
   Yang, XW
   Sun, X
   Xu, MT
   Liu, Y
   Wang, SM
   Song, WL
   Tao, YQ
AF Wang, Yu
   Jin, Hai
   Gong, Shun
   Yang, Xingwang
   Sun, Xiao
   Xu, Mengting
   Liu, Yang
   Wang, Shimiao
   Song, Weilong
   Tao, Yingqun
TI Efficacy Analysis of Robot-Assisted Minimally Invasive Surgery for
   Small-Volume Spontaneous Thalamic Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Efficacy; Hematoma volume; Spontaneous thalamic hemorrhage
ID INTRACEREBRAL HEMORRHAGE; PERIHEMATOMAL EDEMA
AB OBJECTIVE: To test whether robot-assisted surgery can improve prognosis of small-volume thalamic hemorrhage and to provide a surgical basis for treatment of small-volume thalamic hemorrhage.
   METHODS: This retrospective study included patients with thalamic hemorrhage and hematoma volume of 5-15 ml treated from December 2015 to December 2018. Patients were divided into an operation group and a nonoperation group. General data, types of hematoma, incidence of complications, Scandinavian Stroke Scale score, and modified Rankin Scale score were recorded and analyzed.
   RESULTS: Retrospectively, 84 cases met inclusion criteria: 35 cases in operation group and 49 cases in nonoperation group. At 90 days after onset, mortality was 11.4% in the operation group and 4.1% in the nonoperation group (P> 0.05). The Scandinavian Stroke Scale score in the operation group (43.3 +/- 8.5) was higher than in the nonoperation group (36.1 +/- 10.0) (P < 0.05). The modified Rankin Scale score in the operation group (2.9 +/- 0.3) was lower than in the nonoperation group (3.7 +/- 0.2) (P < 0.05). The incidence of pneumonia (8.6%) and renal dysfunction (14.3%) was lower in the operation group than in the nonoperation group (28.6% and 34.7%, respectively) (P < 0.05). There was no significant difference between the 2 groups in the incidence of central fever (5.7% vs. 12.2%), stress ulcer (11.4% vs. 16.3%), and ion balance disturbance (20.0% vs. 26.5%) (P > 0.05).
   CONCLUSIONS: Robot-assisted drainage of thalamic hemorrhage can improve prognosis and reduce the incidence of pneumonia and renal dysfunction.
C1 [Wang, Yu; Jin, Hai; Gong, Shun; Yang, Xingwang; Sun, Xiao; Xu, Mengting; Liu, Yang; Wang, Shimiao; Song, Weilong; Tao, Yingqun] Original Gen Hosp Shenyang Mil Area Command, Gen Hosp Northern Theater Command, Dept Neurosurg, PLA Inst Neurol, Shenyang, Liaoning, Peoples R China.
RP Tao, YQ (reprint author), Original Gen Hosp Shenyang Mil Area Command, Gen Hosp Northern Theater Command, Dept Neurosurg, PLA Inst Neurol, Shenyang, Liaoning, Peoples R China.
EM yingquntao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81870890]; Program of Scientific Natural Funding of
   Liaoning Province [20170540935, 20170520307]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81870890) and Program of Scientific Natural Funding of
   Liaoning Province (Grant No. 20170540935, 20170520307).
CR Alves PN, 2017, EUR NEUROL, V77, P75, DOI 10.1159/000454764
   Babi MA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00645
   Dastur CK, 2017, STROKE VASC NEUROL, V2, P21, DOI 10.1136/svn-2016-000047
   Han WY, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.864
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Kim H, 2016, WORLD NEUROSURG, V94, P32, DOI 10.1016/j.wneu.2016.06.093
   Li YQ, 2018, WORLD NEUROSURG, V109, pE136, DOI 10.1016/j.wneu.2017.09.121
   Neisewander BL, 2018, WORLD NEUROSURG, V116, pE525, DOI 10.1016/j.wneu.2018.05.026
   Osawa A, 2016, NEUROL SCI, V37, P565, DOI 10.1007/s10072-016-2476-2
   Otite FO, 2017, STROKE, V48, P596, DOI 10.1161/STROKEAHA.116.015746
   Scaggiante J, 2018, STROKE, V49, P2612, DOI 10.1161/STROKEAHA.118.020688
   [孙霄 Sun Xiao], 2018, [中华神经外科杂志, Chinese Journal of Neurosurgery], V34, P674
   Wu TY, 2017, STROKE, V48, P873, DOI 10.1161/STROKEAHA.116.014416
   Xu F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS1815
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E543
EP E549
DI 10.1016/j.wneu.2019.07.224
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300067
PM 31398520
DA 2020-05-12
ER

PT J
AU Wu, WJ
   Diao, WB
   Yang, S
   Guo, Y
   Yan, M
   Luo, F
AF Wu, Wenjie
   Diao, Wenbo
   Yang, Sen
   Guo, Yang
   Yan, Ming
   Luo, Fei
TI The Effect of Using Visual Trepan to Treat Single-Segment Ossification
   of Ligamentum Flavum Under the Endoscope
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompression; Endoscope; Ossification of ligamentum flavum; Thoracic
   spinal; Visual trepan
ID SURGERY
AB OBJECTIVES: To evaluate the surgical outcome of using a trepan to treat single-segment ossification of ligamentum flavum under endoscopy and the clinical value of the new surgical treatment.
   MATERIALS AND METHODS: Patients who underwent surgery for single-segment ossification of ligamentum flavum from January 2015 to June 2018 were included in a retrospective analysis. Endoscopic visual trepan decompression was performed in 26 patients and posterior spinal canal resection and decompression was performed in 11 patients. Japanese Orthopaedic Association scores, Japanese Orthopaedic Association improvement rate, and visual analog scale scores of both groups were recorded during follow-up. Computed tomography was used to evaluate patients' residual area ratio of the vertebral canal. Operative time, length of stay, amount of bleeding, and hospital cost in both groups were recorded.
   RESULTS: Average follow-up time was 8.9 +/- 2.7 months. Average operative time was 100.6 1 35.0 minutes in the experimental group and 140.5 +/- 28.3 minutes in the control group. At the final follow-up, the average improvement rate of Japanese Orthopaedic Association score was 78.3% in the experimental group and 84.2% in the control group. The average residual area ratio of the vertebral canal, which was <50% before the operation in both groups, recovered to 100% in both groups after the operation. Visual analog scale score of all patients was significantly (P < 0.05) reduced at the final follow-up.
   CONCLUSIONS: The visual trepan technique using a spinal endoscope can be used to treat single-segment ossification of ligamentum flavum. Advantages include less trauma, faster recovery, and lower cost. However, more cases and long-term follow-up are required to further evaluate the clinical effectiveness and safety of this surgical method.
C1 [Wu, Wenjie; Yang, Sen; Luo, Fei] Third Mil Med Univ, Southwest Hosp, Dept Orthopaed, Chongqing, Peoples R China.
   [Diao, Wenbo] Zhoukou Xiehe Orthopaed Hosp, Zhoukou, Henan, Peoples R China.
   [Guo, Yang; Yan, Ming] Jilin Univ, Affiliated Hosp 1, Dept Orthopaed, Changchun, Jilin, Peoples R China.
RP Luo, F (reprint author), Third Mil Med Univ, Southwest Hosp, Dept Orthopaed, Chongqing, Peoples R China.
EM luofeispine@126.com
CR Aizawa T, 2006, J NEUROSURG-SPINE, V5, P514, DOI 10.3171/spi.2006.5.6.514
   Chen HP, 2018, J CERVICODYNIA LUMBO, V1, P5
   Eun SS, 2018, SPINE J, V18, P1286, DOI 10.1016/j.spinee.2018.02.021
   Ha KY, 2012, EUR SPINE J, V21, P2443, DOI 10.1007/s00586-012-2413-x
   Ju JH, 2018, SPINE J, V18, P747, DOI 10.1016/j.spinee.2017.09.006
   Kepler CK, 2013, SPINE J, V13, P489, DOI 10.1016/j.spinee.2012.10.034
   Li M, 2012, SPINE J, V12, P1093, DOI 10.1016/j.spinee.2012.10.022
   Li XC, 2016, PAIN PHYSICIAN, V19, P103
   Li Z, 2016, SPINAL CORD, V54, P188, DOI 10.1038/sc.2015.139
   Ouyang CJ, 2017, ADV SOC SCI EDUC HUM, V105, P108
   Park BC, 2007, JOINT BONE SPINE, V74, P600, DOI 10.1016/j.jbspin.2007.01.033
   Shepard NA, 2015, SPINE J, V15, pE9, DOI 10.1016/j.spinee.2014.12.011
   Sun C, 2012, SPINE J S, V12, pS116
   Tang CY, 2017, MALAYS J LIBR INF SC, V22, P1, DOI 10.22452/mjlis.vol22no3.1
   Yu SZ, 2013, ACTA NEUROCHIR, V155, P1169, DOI 10.1007/s00701-013-1694-0
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E550
EP E556
DI 10.1016/j.wneu.2019.07.223
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300068
PM 31398521
DA 2020-05-12
ER

PT J
AU Xie, HT
   Yin, J
   Duan, YX
   Wu, H
   Xia, Y
   Zhang, ZQ
AF Xie, Hengtao
   Yin, Jing
   Duan, Yixuan
   Wu, Huan
   Xia, Yang
   Zhang, Zhaoqing
TI Bibliometric Analysis of Scientific Publications on Spinal Cord
   Stimulation in the Past Two Decades
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometric analysis; Co-occurrence; Key words; Spinal cord
   stimulation; VOSviewer software
ID PAIN; SAFETY
AB BACKGROUND: Spinal cord stimulation (SCS), a common invasive neuromodulation technique, induces pain relief via electrical stimulation of the dorsal column of the spinal cord. To present an overview of research publications on SCS, a bibliometric analysis of scientific publications from 1998 to 2017 was performed.
   METHODS: The relevant data were obtained from the Web of Science and PubMed database. These articles were classified into several categories, such as total number, countries, institutions, authors, and citations reports. The analysis of co-occurrence key words was handled by VOSviewer software.
   RESULTS: We found that there existed an increasing trend in the number of publications on SCS between 1998 and 2017. Among these countries, the United States published the largest number of papers in the past 20 years. Case Western Reserve University in the United States contributed the most publications. Among all research categories, neuroscience neurology was the most common area. In addition, regarding article types, basic research comprised a great proportion of the total papers on SCS in the PubMed database. The author V. Reggie Edgerton from the United States was the most-frequent contributor among the authors. The results showed that "spinal cord," "stimulation," and "pain" were the most common key words in the past 20 years.
   CONCLUSIONS: This bibliometric analysis first provides a basic overview of research publications on SCS published during the last 2 decades. Considering the expanded indications of SCS, there are a lot of things to do, and various countries should increase support to complete high-quality SCS studies.
C1 [Xie, Hengtao; Yin, Jing; Duan, Yixuan; Wu, Huan; Xia, Yang; Zhang, Zhaoqing] Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Pain & Rehabil Med, Wuhan, Hubei, Peoples R China.
RP Zhang, ZQ (reprint author), Wuhan Univ, Wuhan Hosp 3, Tongren Hosp, Dept Pain & Rehabil Med, Wuhan, Hubei, Peoples R China.
EM zhang110@protonmail.com
FU Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2017CFB388]
FX This work was supported by the Natural Science Foundation of Hubei
   Province (grant no: 2017CFB388).
CR de Andrade EM, 2016, NEUROSURG REV, V39, P27, DOI 10.1007/s10143-015-0651-1
   Eldabe S, 2016, PAIN MED, V17, P325, DOI 10.1093/pm/pnv025
   Farber SH, 2017, PAIN PHYSICIAN, V20, pE796
   Gao Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184869
   Huang Q, 2019, NEUROSCI BULL, V35, P527, DOI 10.1007/s12264-018-0320-9
   Levy R, 2019, NEUROMODULATION, V22, P317, DOI 10.1111/ner.12932
   Liang YD, 2017, J PAIN RES, V10, P951, DOI 10.2147/JPR.S132808
   Liu XX, 2019, THER CLIN RISK MANAG, V15, P1, DOI 10.2147/TCRM.S163881
   Mekhail N, 2018, REGION ANESTH PAIN M, V43, P391, DOI 10.1097/AAP.0000000000000744
   Novik Y, 2019, WORLD NEUROSURG, V122, P278, DOI 10.1016/j.wneu.2018.10.215
   O'Connor EM, 2017, IRISH J MED SCI, V186, P371, DOI 10.1007/s11845-016-1485-8
   Oakley JC, 2002, SPINE, V27, P2574, DOI 10.1097/00007632-200211150-00034
   Provenzano DA, 2019, NEUROMODULATION, V22, P302, DOI 10.1111/ner.12939
   Robert C, 2017, CEPHALALGIA, V37, P1299, DOI 10.1177/0333102416678636
   Walsh KM, 2015, SPINE J, V15, P1864, DOI 10.1016/j.spinee.2015.04.043
   Wong SSC, 2017, HONG KONG MED J, V23, P517, DOI 10.12809/hkmj176288
   Xie GH, 2016, ANESTH ANALG, V122, P1640, DOI 10.1213/ANE.0000000000001225
   Ye B, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004201
   Ye JS, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0941-4
NR 19
TC 0
Z9 0
U1 12
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E521
EP E529
DI 10.1016/j.wneu.2019.07.216
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300065
PM 31394362
DA 2020-05-12
ER

PT J
AU Yang, WC
   Song, JT
   Liang, M
   Cui, H
   Chen, HY
   Yang, JY
AF Yang, Wencheng
   Song, Jiangtao
   Liang, Ming
   Cui, Hao
   Chen, Hengyi
   Yang, Jianyi
TI Functional Outcomes and New Vertebral Fractures in Percutaneous
   Vertebroplasty and Conservative Treatment of Acute Symptomatic
   Osteoporotic Vertebral Compression Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conservative treatment; New vertebral fracture; Osteoporosis;
   Osteoporotic vertebral compression fracture; OVCF; Vertebroplasty
ID RANDOMIZED-TRIAL; BODY FRACTURE; RISK-FACTOR; METAANALYSIS; EFFICACY;
   KYPHOPLASTY; SAFETY; RECOMPRESSION; MULTICENTER; THERAPY
AB OBJECTIVE: The present study compared the clinical functional outcomes and new vertebral compression fractures (NVCFs) between percutaneous vertebroplasty (PVP) and conservative treatment (CT) in patients with severe pain due to acute osteoporotic vertebral compression fractures (OVCFs). PVP has been increasingly used for the treatment of pain in patients with OVCFs. However, the effectiveness of the procedure and whether it causes NVCFs has remained controversial.
   METHODS: A total of 544 eligible patients with OVCFs found on spinal radiographs and intractable back pain for <= 6 weeks were recruited from September 2012 to February 2018 and assigned to PVP (n = 280; 392 levels) or CT (n = 264; 366 levels). The visual analog scale and Oswestry Disability Index scores were determined before the intervention and at the 1-week and 1-, 3-, 6-, 12-, and 24-month follow-up examinations. In addition, monthly telephone follow-up interviews were performed. In the case of a sudden increase in back pain, the patient returned to the hospital for medical and magnetic resonance imaging examinations for NVCF detection.
   RESULTS: The PVP group had significantly lower visual analog scale and Oswestry Disability Index scores than those for the CT group at 1 week and 1, 3, and 6 months (P < 0.05). However, the differences after 6 months were not statistically statistically significant (P > 0.05). Similar numbers of NVCFs (total and adjacent fractures) were found at 24 months in both groups (P> 0.05).
   CONCLUSIONS: Compared with CT, PVP provided a rapid decrease in pain and an early return to daily life activities, without an increase in the incidence of NVCFs.
C1 [Yang, Wencheng; Song, Jiangtao; Liang, Ming; Cui, Hao; Chen, Hengyi; Yang, Jianyi] Zhengzhou Univ, Zhengzhou Cent Hosp, Zhengzhou City, Peoples R China.
RP Yang, WC (reprint author), Zhengzhou Univ, Zhengzhou Cent Hosp, Zhengzhou City, Peoples R China.
EM 15121093750@163.com
FU key scientific research project of Henan Province [19B320037]
FX The present research was supported by a key scientific research project
   of Henan Province (grant 19B320037).
CR Al-Nakshabandi NA, 2011, ANN SAUDI MED, V31, P294, DOI 10.4103/0256-4947.81542
   Anderson PA, 2013, J BONE MINER RES, V28, P372, DOI 10.1002/jbmr.1762
   Balkarli H, 2015, INT J CLIN EXP MED, V8, P16287
   Blasco J, 2012, J BONE MINER RES, V27, P1159, DOI 10.1002/jbmr.1564
   Boszczyk Bronek, 2015, Evid Based Med, V20, P181, DOI 10.1136/ebmed-2015-110233
   Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429
   Capozzi A, 2017, CLIN CASES MINER BON, V14, P161, DOI 10.11138/ccmbm/2017.14.1.161
   Clark W, 2016, LANCET, V388, P1408, DOI 10.1016/S0140-6736(16)31341-1
   Comstock BA, 2013, RADIOLOGY, V269, P224, DOI 10.1148/radiol.13120821
   DePalma MJ, 2011, SPINE, V36, P277, DOI 10.1097/BRS.0b013e3181cf8a37
   Farrokhi MR, 2011, J NEUROSURG-SPINE, V14, P561, DOI 10.3171/2010.12.SPINE10286
   Han SL, 2015, OSTEOPOROSIS INT, V26, P113, DOI 10.1007/s00198-014-2848-5
   Hulme PA, 2006, SPINE, V31, P1983, DOI 10.1097/01.brs.0000229254.89952.6b
   Macias-Hernandez SI, 2015, REV INVEST CLIN, V67, P98
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4
   Kallmes DF, 2009, NEW ENGL J MED, V361, P569, DOI 10.1056/NEJMoa0900563
   Klazen CAH, 2010, AM J NEURORADIOL, V31, P1447, DOI 10.3174/ajnr.A2148
   Klazen CAH, 2010, LANCET, V376, P1085, DOI 10.1016/S0140-6736(10)60954-3
   Komemushi A, 2006, CARDIOVASC INTER RAD, V29, P580, DOI 10.1007/s00270-005-0138-5
   Leali PT, 2016, CLIN CASES MINER BON, V13, P234, DOI 10.11138/ccmbm/2016.13.3.234
   Li LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138126
   Lin Hua, 2010, Orthop Surg, V2, P119, DOI 10.1111/j.1757-7861.2010.00074.x
   Lindsay R, 2001, JAMA-J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Liu JT, 2013, PAIN PHYSICIAN, V16, P455
   Luthman S, 2018, OSTEOPOROSIS INT, V29, P793, DOI 10.1007/s00198-017-4348-x
   Mattie R, 2016, J BONE JOINT SURG AM, V98, P1041, DOI 10.2106/JBJS.15.00425
   Rachelle B, 2015, COCHRANE DB SYST REV, V4
   Rousing Rikke, 2009, Spine (Phila Pa 1976), V34, P1349, DOI 10.1097/BRS.0b013e3181a4e628
   Savage JW, 2014, J AM ACAD ORTHOP SUR, V22, P653, DOI 10.5435/JAAOS-22-10-653
   Shi MM, 2012, CLIN ORTHOP RELAT R, V470, P2785, DOI 10.1007/s11999-012-2404-6
   Staples MP, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3952
   Tian J, 2014, INT J SURG, V12, P1249, DOI 10.1016/j.ijsu.2014.10.027
   Uppin AA, 2003, RADIOLOGY, V226, P119, DOI 10.1148/radiol.2261011911
   Xie L, 2017, INT J SURG, V47, P25, DOI 10.1016/j.ijsu.2017.09.021
   Yang EZ, 2016, SPINE, V41, P653, DOI 10.1097/BRS.0000000000001298
   Yi XD, 2014, ARCH ORTHOP TRAUM SU, V134, P21, DOI 10.1007/s00402-013-1886-3
   Zhang L, 2017, CLIN INTERV AGING, V12, P431, DOI 10.2147/CIA.S113240
   Zou J, 2012, PAIN PHYSICIAN, V15, pE515
NR 38
TC 0
Z9 0
U1 5
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E346
EP E352
DI 10.1016/j.wneu.2019.07.153
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300042
PM 31356973
DA 2020-05-12
ER

PT J
AU Yang, XY
   Bartels, RHMA
   Donk, R
   Depreitere, B
   Walraevens, J
   Zhai, ZW
   Vleggeert-Lankamp, CLA
AF Yang, Xiaoyu
   Bartels, Ronald H. M. A.
   Donk, Roland
   Depreitere, Bart
   Walraevens, Joris
   Zhai, Zhiwei
   Vleggeert-Lankamp, Carmen L. A.
TI Does Heterotopic Ossification in Cervical Arthroplasty Affect Clinical
   Outcome?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arthroplasty; Heterotopic cervical discectomy; Neck pain; Ossification;
   Range of motion
ID NECK DISABILITY INDEX; TERM-FOLLOW-UP; DISC REPLACEMENT; INTERVERTEBRAL
   DISC; FUSION; DISKECTOMY; DISEASE; DECOMPRESSION; MULTICENTER;
   RELIABILITY
AB OBJECTIVE: To investigate the occurrence and progression of heterotopic ossification (HO) in patients treated by anterior cervical discectomy with arthroplasty. It was evaluated if HO affects clinical outcome and range of motion (ROM). Risk factors of HO was studied as well.
   METHODS: Patients who underwent anterior cervical discectomy with arthroplasty for a cervical radiculopathy because of a herniated disc from the NECK and PROCON trial were analyzed for HO at 12 and 24 months post-operatively. HO was scored according to the McAfee-Mehren classification. The index ROM was defined by a custom developed image analysis tool, and global cervical ROM was measured by Cobb's angle. Clinical outcome was evaluated by means of the Neck Disability Index and the 36-Item Short Form Health Survey.
   RESULTS: The occurrence of HO was 60% at 1 year, and it increased to 76% at 2-year follow-up. A total of 31% of patients were scored as high-grade HO at 1-year follow-up, and this percentage increased to 50% at 2-year follow-up. Clinical outcome does not correlate to HO grade, and no risk factor for high-grade HO could be identified. The ROM at the index level was significantly higher in low-grade HO group than those patients with high-grade HO, but in 15%-38% HO grade does not correspond to ROM.
   CONCLUSIONS: HO occurs in three fourths of the patients at 2 years after surgery, but does not necessarily correspond to clinical outcome, nor loss or preservation of ROM. The McAfee-Mehren classification should he combined with ROM evaluation to properly study HO.
C1 [Yang, Xiaoyu; Vleggeert-Lankamp, Carmen L. A.] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
   [Zhai, Zhiwei] Radboud Univ Nijmegen Med Ctr, Dept Radiol, Med Ctr, Div Image Proc, Nijmegen, Netherlands.
   [Bartels, Ronald H. M. A.] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, Nijmegen, Netherlands.
   [Donk, Roland] Via Sana Clin, Dept Orthopaed Surg, Mill, Netherlands.
   [Depreitere, Bart] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium.
   [Walraevens, Joris] Katholieke Univ Leuven, Div Biomech & Engn Design, Heverlee, Belgium.
RP Yang, XY (reprint author), Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
EM X.Yang@lumc.nl
RI Depreitere, Bart/AAA-9846-2020; Bartels, R.H.M.A./L-4184-2015
OI Depreitere, Bart/0000-0002-7458-0648; Bartels,
   R.H.M.A./0000-0002-8638-4660
FU China Scholarship CouncilChina Scholarship Council; Department of
   Neurosurgery, Leiden University Medical Centre, the
   NetherlandsNetherlands Government; B. Braun Medical; Department of
   Neurosurgery of the Leiden University Medical Centre, the
   NetherlandsNetherlands Government
FX This work was supported by China Scholarship Council and the Department
   of Neurosurgery, Leiden University Medical Centre, the Netherlands. The
   NECK trial was sponsored by B. Braun Medical and the Department of
   Neurosurgery of the Leiden University Medical Centre, the Netherlands.
CR Arts MP, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-122
   Bartels Ronald H M A, 2005, Neurosurgery, V57, pE194, DOI 10.1227/01.NEU.0000163419.59635.78
   Bartels RHMA, 2018, J NEUROSURG-SPINE, V28, P395, DOI 10.3171/2017.7.SPINE17182
   Bartels RHMA, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-85
   Baskin DS, 2003, SPINE, V28, P1219, DOI 10.1097/00007632-200306150-00003
   CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602
   Coric D, 2013, J NEUROSURG-SPINE, V18, P36, DOI 10.3171/2012.9.SPINE12555
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Heidecke V, 2008, ACTA NEUROCHIR, V150, P453, DOI 10.1007/s00701-008-1552-7
   Heller JG, 2009, SPINE, V34, P101, DOI 10.1097/BRS.0b013e31818ee263
   Hou Y, 2016, BONE JOINT J, V98B, P829, DOI 10.1302/0301-620X.98B6.36381
   Janssen ME, 2015, J BONE JOINT SURG AM, V97A, P1738, DOI 10.2106/JBJS.N.01186
   Leung C, 2005, NEUROSURGERY, V57, P759, DOI 10.1227/01.NEU.0000175856.31210.58
   McAfee PC, 2003, J SPINAL DISORD TECH, V16, P384, DOI 10.1097/00024720-200308000-00010
   Mehren C, 2006, SPINE, V31, P2802, DOI 10.1097/01.brs.0000245852.70594.d5
   Mummaneni PV, 2007, J NEUROSURG-SPINE, V6, P198, DOI 10.3171/spi.2007.6.3.198
   Park JH, 2008, J KOREAN NEUROSURG S, V44, P217, DOI 10.3340/jkns.2008.44.4.217
   Park JH, 2013, J SPINAL DISORD TECH, V26, P141, DOI 10.1097/BSD.0b013e31823ba071
   Parkinson JF, 2005, J NEUROSURG-SPINE, V2, P377, DOI 10.3171/spi.2005.2.3.0377
   Pietrobon B, 2002, SPINE, V27, P515, DOI 10.1097/00007632-200203010-00012
   Pimenta Luiz, 2004, Spine J, V4, p315S, DOI 10.1016/j.spinee.2004.07.024
   Pimenta L, 2013, NEUROSURG QUART, V23, P1, DOI 10.1097/WNQ.0b013e3182592fd7
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Suchomel P, 2010, EUR SPINE J, V19, P307, DOI 10.1007/s00586-009-1259-3
   Sundseth J, 2016, EUR SPINE J, V25, P2271, DOI 10.1007/s00586-016-4549-6
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   Vos CJ, 2006, EUR SPINE J, V15, P1729, DOI 10.1007/s00586-006-0119-7
   Walraevens J, 2010, NEUROSURGERY, V67, P679, DOI 10.1227/01.NEU.0000377039.89725.F3
   Yi S, 2014, SPINE, V39, P2078, DOI 10.1097/BRS.0000000000000640
   Yi S, 2010, SPINE, V35, P1556, DOI 10.1097/BRS.0b013e3181c6526b
   Zhang HX, 2014, INT ORTHOP, V38, P2533, DOI 10.1007/s00264-014-2497-5
   Zhou HH, 2015, SPINE, V40, pE332, DOI 10.1097/BRS.0000000000000776
NR 32
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E408
EP E414
DI 10.1016/j.wneu.2019.07.187
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300049
PM 31376560
DA 2020-05-12
ER

PT J
AU Yilmaz, E
   von Glinski, A
   Ishak, B
   Abdul-Jabbar, A
   Blecher, R
   O'Lynnger, T
   Alonso, F
   Benca, E
   Chapman, JR
   Oskouian, R
AF Yilmaz, Emre
   von Glinski, Alexander
   Ishak, Basem
   Abdul-Jabbar, Amir
   Blecher, Ronan
   O'Lynnger, Thomas
   Alonso, Fernando
   Benca, Eric
   Chapman, Jens R.
   Oskouian, Rod J.
TI Outcome After Extreme Lateral Transpsoas Approach: Corpectomies Versus
   Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Corpectomy; Interbody fusion; Lateral transposes approach
ID 2-YEAR COMPARATIVE OUTCOMES; MINIMALLY INVASIVE SURGERY; MINI-OPEN;
   LUMBAR SPINE; ANTERIOR; COMPLICATIONS
AB INTRODUCTION: The lateral transpsoas approach (LTPA) has gained popularity in thoracolumbar spine surgery procedures; however, there is an insufficient amount of data pertaining to motor and sensory complications that arise when a corpectomy is performed through the LTPA approach.
   METHODS: Patients who underwent a corpectomy through a LTPA at a single institution between 2006 and 2016 were analyzed. Demographics, neurological outcomes, and complications were recorded. The minimum follow-up was 6 months. Univariate analysis was performed to compare demographics, surgical characteristics, complications, and outcome scores. To compare categorical variables, the chi(2) test was used. For continuous outcomes, simple linear regression was used. Statistical significance was set at P < 0.05.
   RESULTS: A total of 166 patients were included. The patients were divided into 2 groups; LTPA without corpectomy (n = 112) versus LTPA with corpectomy (n = 54). Patients without corpectomy showed a significantly lower rate of postoperative infections compared with patients with corpectomy (3.6% vs. 22.2%; P< 0.000). A higher percentage of postoperative complications was found in patients with corpectomy (31.5% vs. 13.4%; P = 0.006). The rate of neurologic complications at the 6-month follow-up and the reoperation rate (22.7% vs. 32.4%; P = 0.256) were higher in the corpectomy group (8.9% vs. 7.4%; P = 0.741), no significant difference was found between the groups.
   CONCLUSION: Patients who underwent an LTPA corpectomy have a higher risk to suffer from postoperative complications. The results at the 6-month follow-up did not significantly differ between the groups.
C1 [Yilmaz, Emre; von Glinski, Alexander; Ishak, Basem; Abdul-Jabbar, Amir; Blecher, Ronan; O'Lynnger, Thomas; Alonso, Fernando; Benca, Eric; Chapman, Jens R.; Oskouian, Rod J.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98122 USA.
   [Yilmaz, Emre; von Glinski, Alexander; Ishak, Basem; Abdul-Jabbar, Amir; Blecher, Ronan; O'Lynnger, Thomas; Alonso, Fernando; Benca, Eric] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Yilmaz, Emre; von Glinski, Alexander] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Burkle de la Camp Pl 1, Bochum, Germany.
   [Ishak, Basem] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
   [von Glinski, Alexander] Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98122 USA.
RP von Glinski, A (reprint author), Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Burkle de la Camp Pl 1, Bochum, Germany.; von Glinski, A (reprint author), Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98122 USA.
EM AlexandervonGlinski@icloud.com
CR Baaj AA, 2012, J CLIN NEUROSCI, V19, P1265, DOI 10.1016/j.jocn.2012.01.026
   Bendersky M, 2015, EUR SPINE J, V24, P1051, DOI 10.1007/s00586-015-3801-9
   Bergey DL, 2004, SPINE, V29, P1681, DOI 10.1097/01.BRS.0000133643.75795.EF
   Berjano P, 2015, EUR SPINE J, V24, pS369, DOI 10.1007/s00586-015-3929-7
   Brau Salvador A, 2002, Spine J, V2, P216, DOI 10.1016/S1529-9430(02)00184-5
   Buric J, 2015, INT J SPINE SURG, V9, DOI 10.14444/2027
   Cahill KS, 2012, J NEUROSURG-SPINE, V17, P227, DOI 10.3171/2012.5.SPINE1288
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Dakwar E, 2011, J NEUROSURG-SPINE, V14, P290, DOI 10.3171/2010.10.SPINE10395
   Dakwar E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09282
   Hartl R, 2016, EUR SPINE J, V25, P1484, DOI 10.1007/s00586-016-4407-6
   Hrabalek L, 2014, BIOMED PAP, V158, P127, DOI 10.5507/bp.2012.079
   Isaacs RE, 2016, SPINE, V41, pS133, DOI 10.1097/BRS.0000000000001472
   Isaacs RE, 2010, SPINE, V35, pS322, DOI 10.1097/BRS.0b013e3182022e04
   Khajavi K, 2015, EUR SPINE J, V24, pS322, DOI 10.1007/s00586-015-3840-2
   Knight RQ, 2009, J SPINAL DISORD TECH, V22, P34, DOI 10.1097/BSD.0b013e3181679b8a
   Malham GM, 2014, SPINE J, V14, pS54, DOI 10.1016/j.spinee.2014.08.141
   Malham GM, 2015, J NEUROL SURG PART A, V76, P240, DOI 10.1055/s-0034-1368094
   Mandelli C, 2016, EUR SPINE J, V25, P4155, DOI 10.1007/s00586-016-4617-y
   Nakamura H, 2000, J AM COLL SURGEONS, V191, P686, DOI 10.1016/S1072-7515(00)00716-X
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Ozgur Burak M, 2010, SAS J, V4, P41, DOI 10.1016/j.esas.2010.03.005
   Pumberger M, 2012, EUR SPINE J
   Rodgers JA, 2013, J SPINE NEUROSURG, V2, P1
   Rodgers W B, 2010, SAS J, V4, P63, DOI 10.1016/j.esas.2010.03.001
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Saraph V, 2004, EUR SPINE J, V13, P425, DOI 10.1007/s00586-004-0722-4
   Sembrano JN, 2016, SPINE, V41, pS123, DOI 10.1097/BRS.0000000000001471
   Smith WD, 2016, SPINE, V41, pS106, DOI 10.1097/BRS.0000000000001479
   Smith WD, 2012, J CLIN NEUROSCI, V19, P673, DOI 10.1016/j.jocn.2011.09.010
   Smith WD, 2010, SPINE, V35, pS338, DOI 10.1097/BRS.0b013e3182023113
   Tormenti MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09263
   Tubbs RI, 2017, SPINE J, V17, P1012, DOI 10.1016/j.spinee.2017.03.011
   Uribe JS, 2015, EUR SPINE J, V24, pS378, DOI 10.1007/s00586-015-3871-8
   Wang MY, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09286
   Winder Mark J, 2016, J Spine Surg, V2, P2, DOI 10.21037/jss.2015.12.01
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
NR 38
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E170
EP E175
DI 10.1016/j.wneu.2019.07.102
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300020
PM 31330334
DA 2020-05-12
ER

PT J
AU Zhang, JJY
   Wang, S
   Foo, ASC
   Yang, M
   Quah, BL
   Sun, IS
   Ng, ZX
   Teo, K
   Pang, BC
   Yang, EW
   Lwin, S
   Chou, N
   Low, SW
   Yeo, TT
   Santarius, T
   Nga, VDW
AF Zhang, John J. Y.
   Wang, Shilin
   Foo, Aaron Song Chuan
   Yang, Ming
   Quah, Boon Leong
   Sun, Ira Siyang
   Ng, Zhi Xu
   Teo, Kejia
   Pang, Boon Chuan
   Yang, Eugene Weiren
   Lwin, Sein
   Chou, Ning
   Low, Shiong Wen
   Yeo, Tseng Tsai
   Santarius, Thomas
   Nga, Vincent Diong Weng
TI Outcomes of Subdural Versus Subperiosteal Drain After Burr-Hole
   Evacuation of Chronic Subdural Hematoma: A Multicenter Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burr hole; Chronic subdural hematoma; Outcome; Recurrence; Subdural
   drain; Subgaleal drain; Subperiosteal drain
ID SURGICAL-TREATMENT; MANAGEMENT; RECURRENCE; COMPLICATIONS; TREPANATION;
   CRANIOSTOMY; SYSTEM
AB BACKGROUND: Although the use of a postoperative drain after burr-hole evacuation of chronic subdural hematoma (CSDH) is known to improve surgical outcomes, the superiority of subdural over subperiosteal drains has not been firmly established. Evidence comparing these 2 drain types is largely restricted to single-center series with limited numbers. Using a multicenter cohort study, we aimed to show noninferiority of subperiosteal drains vis-avis subdural drains after burr-hole evacuation of CSDH.
   METHODS: We performed a retrospective analysis of all consecutive patients with CSDH aged 21 years and older who had undergone burr-hole craniostomy across 3 tertiary hospitals from 2010 to 2017. Primary outcome measures included CSDH recurrence and modified Rankin Scale (mRS) score at 6 months. Outcomes of patients in the subdural and subperiosteal drain groups were analyzed and confounders were adjusted for using multivariate logistic regression.
   RESULTS: Of the 570 cases analyzed, 329 (57.7%) received a subdural drain and 241 (42.3%) received a subperiosteal drain. There was no significant difference between the 2 drain groups in CSDH recurrence (13.1% in the subdural group vs. 11.2% in the subperiosteal group; P = 0.502) or 6-month mRS score (27.2% with mRS 4-6 in the subdural group vs. 20.4% in the subperiosteal group; P = 0.188). Independent predictors of CSDH recurrence identified on multivariate analysis included premorbid mRS score 0-3 (P = 0.021), separated CSDH type on preoperative computed tomography scan (P = 0.002), and postoperative pneumocephalus of >= 15 mm (P = 0.005).
   CONCLUSIONS: Outcomes of subdural and subperiosteal drains after burr-hole craniostomy for CSDH are largely equivalent based on our findings.
C1 [Zhang, John J. Y.; Wang, Shilin; Teo, Kejia; Lwin, Sein; Chou, Ning; Low, Shiong Wen; Yeo, Tseng Tsai; Nga, Vincent Diong Weng] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Foo, Aaron Song Chuan; Teo, Kejia; Lwin, Sein; Chou, Ning; Yeo, Tseng Tsai; Nga, Vincent Diong Weng] Natl Univ Singapore Hosp, Dept Surg, Div Neurosurg, Jurong Hlth Campus, Singapore, Singapore.
   [Sun, Ira Siyang; Low, Shiong Wen] Natl Univ Hlth Syst, Ng Teng Fong Gen Hosp, Neurosurg Serv, Jurong Hlth Campus, Singapore, Singapore.
   [Yang, Ming; Quah, Boon Leong; Ng, Zhi Xu; Pang, Boon Chuan; Yang, Eugene Weiren] Alexandra Hlth Private Ltd, Khoo Teck Puat Hosp, Dept Surg, Div Neurosurg, Singapore, Singapore.
   [Santarius, Thomas] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge, England.
RP Zhang, JJY (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
EM zhangjohnjy@gmail.com
OI Zhang, John J Y/0000-0002-8567-3807
CR Bellut D, 2012, WORLD NEUROSURG, V77, P111, DOI 10.1016/j.wneu.2011.05.036
   Cenic A, 2005, CAN J NEUROL SCI, V32, P501, DOI 10.1017/S0317167100004510
   Chan KW, 2000, SURG NEUROL, V54, P444, DOI 10.1016/S0090-3019(00)00323-2
   Chari A, 2017, YOUMANS NEUROLOGICAL, P310
   Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9
   Gazzeri R, 2007, ACTA NEUROCHIR, V149, P487, DOI 10.1007/s00701-007-1139-8
   Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015
   Glancz LJ, 2019, NEUROSURGERY, V85, P486, DOI 10.1093/neuros/nyy366
   Kaliaperumal C, 2012, ACTA NEUROCHIR, V154, P2083, DOI 10.1007/s00701-012-1483-1
   Kim SU, 2017, J KOREAN NEUROSURG S, V60, P701, DOI 10.3340/jkns.2016.1010.003
   KINSELLA K, 2001, US CENSUS BUREAU SER
   KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207
   Lee Hyun Seok, 2018, Korean J Neurotrauma, V14, P68, DOI 10.13004/kjnt.2018.14.2.68
   Lind CRP, 2003, J NEUROSURG, V99, P44, DOI 10.3171/jns.2003.99.1.0044
   MCKISSOCK W, 1960, LANCET, V1, P1365
   Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371
   Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256
   Neuberger J, 2008, LANCET, V371, P1743, DOI 10.1016/S0140-6736(08)60748-5
   Pavlov Vladislav, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.12.2011.5397
   Ramachandran R, 2007, SURG NEUROL, V67, P367, DOI 10.1016/j.surneu.2006.07.022
   Ro HW, 2016, ACTA NEUROCHIR, V158, P135, DOI 10.1007/s00701-015-2625-z
   ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263
   Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182
   Santarius T, 2008, BRIT J NEUROSURG, V22, P529, DOI 10.1080/02688690802195381
   Santarius T, 2004, BRIT J NEUROSURG, V18, P328, DOI 10.1080/02688690400004845
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Stanisic M, 2017, NEUROSURGERY, V81, P752, DOI 10.1093/neuros/nyx090
   Uno M, 2017, NEUROL MED-CHIR, V57, P402, DOI 10.2176/nmc.ra.2016-0337
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   Zumofen D, 2009, NEUROSURGERY, V64, P1116, DOI 10.1227/01.NEU.0000345633.45961.BB
NR 30
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E392
EP E401
DI 10.1016/j.wneu.2019.07.168
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300047
PM 31369879
DA 2020-05-12
ER

PT J
AU Zhang, S
   Li, Q
   Ju, Y
AF Zhang, Si
   Li, Qiang
   Ju, Yan
TI Spontaneous Regression in Intracranial Germinoma: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Germinoma; latrogenic; Spontaneous regression
ID GERM-CELL TUMORS
AB BACKGROUND: Spontaneous regression in intracranial germ cell tumors (GCTs) is an extremely rare phenomenon with only 9 cases reported. The mechanism and natural history of this phenomenon are still equivocal.
   METHODS: A 12-year-old boy presented with a lesion in the suprasellar region with involvement of basal ganglia and corpus callosum. After 1 month, his symptoms were relieved, and magnetic resonance imaging demonstrated a remarkable regression of the lesion. Three months later, the boy's symptoms deteriorated, and magnetic resonance imaging revealed regrowth and enlargement of the lesion. Diagnosis of germinoma was confirmed via biopsy, and radiation therapy achieved complete response. We performed a systematic literature review of spontaneous regression of intracranial GCTs. The natural history of these cases was analyzed, and hypotheses in the studies were discussed.
   RESULTS: Spontaneous regression is extremely rare with only 10 cases reported, including the present case. There were 9 male patients and 1 female patient with mean age 22.1 +/- 10.3 years (range, 12-43 years). Nine cases were diagnosed as germinoma, and 4 cases included an episode of regression followed by regrowth. The mechanism of tumor regression in intracranial GCTs remains unclear. Four hypotheses were proposed, including radiation exposure, surgical procedures, effects of steroids, and immune reaction triggered by intervention.
   CONCLUSIONS: Tumor regression in intracranial GCTs could be a iatrogenic transient phenomenon, caused by complex immune reactions triggered by interventions.
C1 [Zhang, Si; Li, Qiang; Ju, Yan] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Ju, Y (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM juyan4022@sina.com
FU Science and Technology Support Plan of Sichuan province [2018sz0043]
FX This work was supported by Science and Technology Support Plan of
   Sichuan province (Grant No. 2018sz0043).
CR Astigueta JC, 2018, ECANCERMEDICALSCIENC, V12, DOI 10.3332/ecancer.2018.888
   AYDIN F, 1992, CANCER, V69, P2322, DOI 10.1002/1097-0142(19920501)69:9<2322::AID-CNCR2820690920>3.0.CO;2-8
   Balzer BL, 2006, AM J SURG PATHOL, V30, P858, DOI 10.1097/01.pas.0000209831.24230.56
   COLE WH, 1981, J SURG ONCOL, V17, P201, DOI 10.1002/jso.2930170302
   EVERSON TC, 1959, JAMA-J AM MED ASSOC, V169, P1758, DOI 10.1001/jama.1959.03000320060014
   Fujimaki T, 1999, J NEURO-ONCOL, V41, P65, DOI 10.1023/A:1006155120191
   Ide M, 1997, CANCER, V79, P558, DOI 10.1002/(SICI)1097-0142(19970201)79:3<558::AID-CNCR19>3.0.CO;2-2
   Mascalchi M, 1998, J NEUROL NEUROSUR PS, V64, P670, DOI 10.1136/jnnp.64.5.670
   Masoudi A, 2008, PEDIATR BLOOD CANCER, V50, P1079, DOI 10.1002/pbc.21421
   Matsutani M, 1997, J NEUROSURG, V86, P446, DOI 10.3171/jns.1997.86.3.0446
   Murai Y, 2000, J NEUROSURG, V93, P884, DOI 10.3171/jns.2000.93.5.0884
   Ono H, 2011, J NEURO-ONCOL, V103, P755, DOI 10.1007/s11060-010-0432-1
   PARK SK, 1971, LANCET, V1, P53
   SHANBROM E, 1962, NEW ENGL J MED, V266, P1354, DOI 10.1056/NEJM196206282662603
   Si SJ, 2010, PEDIATR HEMAT ONCOL, V27, P237, DOI 10.3109/08880010903544866
   SLATER GS, 1955, JAMA-J AM MED ASSOC, V157, P911, DOI 10.1001/jama.1955.02950280035010e
   Woo Peter Y M, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1519110
   Yoneoka Yuichiro, 2011, J Med Case Rep, V5, P39, DOI 10.1186/1752-1947-5-39
   Zapka P, 2018, J NEUROPATH EXP NEUR, V77, P119, DOI 10.1093/jnen/nlx106
NR 19
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E32
EP E37
DI 10.1016/j.wneu.2019.06.220
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300005
PM 31295590
DA 2020-05-12
ER

PT J
AU Zheng, WJ
   Li, LM
   Zhu, YH
   Hu, ZH
   Liao, W
   Lin, QC
   Lin, WB
   Zhu, ZK
   Su, JH
   Lin, SH
AF Zheng, Wen-Jian
   Li, Liang-Ming
   Zhu, Yong-Hua
   Hu, Zi-Hui
   Liao, Wei
   Lin, Qi-Chang
   Lin, Wei-Biao
   Zhu, Zheng-Kai
   Su, Jia-Hao
   Lin, Shao-Hua
TI Impact of Surgeon Experience on Postoperative Rehemorrhage in
   Spontaneous Basal Ganglia Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Postoperative rehemorrhage; Spontaneous intracerebral
   hemorrhage; Surgical technique
ID HEMATOMA GROWTH; RISK-FACTORS; SIGN
AB BACKGROUND: Spontaneous Irtracerebral hemorrhage (SIGH) is of high mortality and morbidity. SICH in the basal ganglia is usually attributed to chronic hypertension. Postoperative rehemorrhage is a severe complication, and it is relative to surgical techniques.
   METHODS: A retrospective survey was conducted on 123 patients with basal ganglia SICH who received surgery from January 2015 to January 2019. Postoperative rehemorrhage within 24 hours was recorded. Preoperative clinical parameters, surgeon experience (<10 and >20 years), operation time, surgical approach, and hemostasis technique were recorded and analyzed.
   RESULTS: The total postoperative rehemorrhage rate was 12.2% (15/123). The univariable analysis showed general surgeons had a higher postoperative rehemorrhage rate than experienced surgeons (30.4% vs. 8.6%, respectively; P = 0.068). The operation time (minutes) in experienced surgeons was significantly longer (164.9 +/- 53.5 vs. 137.7 +/- 30.8, P = 0.016), but they had a higher chance to locate the responsible vessel (74.2% vs. 40.0%, P = 0.001), respectively. Logistic analysis indicated that experienced surgeons significantly reduced the risk of rehemorrhage (odds ratio [013], 0.242; P = 0.021). Transsylvian approach was a protective factor for postoperative rehemorrhage (OR, 0.291; P = 0.045).
   CONCLUSIONS: Surgeons' experience plays the most important role in postoperative rehemorrhage. Surgeons with rich experience were willing to spend more time to achieve definitive hemostasis in operation. The use of a transsylvian approach can significantly reduce the rehemorrhage rate. Packing hemostasis with gelatin sponge may increase complications.
C1 [Zheng, Wen-Jian; Li, Liang-Ming; Zhu, Yong-Hua; Hu, Zi-Hui; Liao, Wei; Lin, Qi-Chang; Lin, Wei-Biao; Zhu, Zheng-Kai; Su, Jia-Hao; Lin, Shao-Hua] Zhongshan City Peoples Hosp, Dept Neurosurg, Zhongshan, Peoples R China.
RP Zheng, WJ (reprint author), Zhongshan City Peoples Hosp, Dept Neurosurg, Zhongshan, Peoples R China.
EM 297229614@qq.com
RI zheng, wenjian/W-2471-2019
OI zheng, wenjian/0000-0001-5490-3852
CR Chen T, 2015, EUR REV MED PHARMACO, V19, P795
   Gao ZB, 2016, WORLD NEUROSURG, V95, P341, DOI 10.1016/j.wneu.2016.08.030
   Ge JW, 2009, J CRANIOFAC SURG, V20, P1097, DOI 10.1097/SCS.0b013e3181abbf09
   Guan J, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00187
   Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   McCracken DJ, 2019, NEUROSURGERY, V84, P741, DOI 10.1093/neuros/nyy193
   Morgan TC, 2013, STROKE, V44, P635, DOI 10.1161/STROKEAHA.112.670653
   Morgenstern LB, 2001, NEUROLOGY, V56, P1294, DOI 10.1212/WNL.56.10.1294
   Qureshi AI, 2018, J CEREBR BLOOD F MET, V38, P1551, DOI 10.1177/0271678X17725431
   Ren YM, 2018, J KOREAN NEUROSURG S, V61, P35, DOI 10.3340/jkns.2017.0199
   Shen ZK, 2018, WORLD NEUROSURG, V120, pE153, DOI 10.1016/j.wneu.2018.07.256
   Tang YP, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1138-9
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wang WJ, 2017, WORLD NEUROSURG, V105, P348, DOI 10.1016/j.wneu.2017.05.158
   Wang XH, 2013, ACTA CIR BRAS, V28, P112, DOI 10.1590/S0102-86502013000200005
   Ye ZPP, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007876
   Zhang YH, 2011, J CRANIOFAC SURG, V22, P1626, DOI 10.1097/SCS.0b013e31822e5f07
   Zheng J, 2017, STROKE, V48, P216, DOI 10.1161/STROKEAHA.116.014285
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E402
EP E407
DI 10.1016/j.wneu.2019.07.182
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300048
PM 31376559
DA 2020-05-12
ER

PT J
AU Bartley, PM
   Burrells, A
   Benavides, J
   Canton, G
   Garcia, JL
   Thomson, J
   Chianini, F
   Innes, EA
   Katzer, F
AF Bartley, Paul M.
   Burrells, Alison
   Benavides, Julio
   Canton, German
   Garcia, Joao L.
   Thomson, Jackie
   Chianini, Fransesca
   Innes, Elisabeth A.
   Katzer, Frank
TI Cell mediated and innate immune responses in pigs following vaccination
   and challenge with Toxoplasma parasites
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Toxoplasma gondii; Porcine; Vaccination; Cell mediated immunity
ID GONDII; INFECTION; IMMUNIZATION; LYMPHOCYTES; CYTOKINE
AB Toxoplasma gondii has a worldwide distribution and can infect almost all warm blooded animals including pigs and humans. This study aims to examine the immune responses induced in pigs following vaccination (live S48 tachyzoites) and/or challenge with T. gondii oocysts, through the examination of changes in levels of transcription in CD4, CD8 alpha, IFN-gamma, IL-12p35, CXCR3, MyD88. The experiment involved four groups of animals; pigs in group 1 (Challenged) (Chal) were challenged orally with (1 x 10(3) oocysts) on day 28 of the experiment. Pigs in group 2 (Vaccinated /Challenged) (Vac/Chal) were vaccinated (S48 isolate tachyzoites) on day 0, then challenged on day 28. The group 3 (Vaccinated) (Vac) animals were vaccinated (S48 isolate tachyzoites) on day 0 of the experiment. Finally the group 4 (control) pigs remained non-vaccinated and non-challenged. All animals were culled 6 weeks post challenge. At post mortem samples of retropharyngeal lymph node (RLN), mesenteric LN (MLN) and spleen were collected, RNA was extracted and cDNA synthesised. The results showed significant increases in IFN-gamma expression in samples from groups 1 (Chal) and 2 (Vac/Chal) (RLN) and groups 1, 2 and 3 (Vac) (spleen) and in MyD88 expression (RLN) in samples from groups 1, 2 and 3 compared to the group 4 (control) animals. Significant increases were also observed in CD8 alpha expression in group 1 (Chal) (RLN) and groups 1 and 2 (Vac/Chal) (RLN and MLN) compared against group 4 (control) and group 3 (Vac) respectively. Conversely, significant down regulation of CD4 and/or IL-12p35 transcription was found in at least one sample from groups 1 (Chal), 2 (Vac/Chal) and 3 (Vac) compared to group 4 (control) pigs. This study demonstrates that cell mediated and innate immune responses are generated in pigs following exposure to T. gondii parasites (oocysts or tachyzoites), key amongst them appear to be IFN-gamma, MyD88 and CD8 alpha.
C1 [Bartley, Paul M.; Burrells, Alison; Benavides, Julio; Canton, German; Garcia, Joao L.; Thomson, Jackie; Chianini, Fransesca; Innes, Elisabeth A.; Katzer, Frank] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
   [Benavides, Julio] Inst Ganaderia Montana CSIC ULE, Leon, Spain.
   [Canton, German] EEA Balcarce, Inst Nacl Tecnol Agr INTA, Balcarce, Buenos Aires, Argentina.
   [Garcia, Joao L.] Univ Londrina, Lab Protozool, Londrina, Parana, Brazil.
RP Bartley, PM (reprint author), Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
EM paul.bartley@moredun.ac.uk
RI Katzer, Frank/AAG-2042-2020; Chianini, Francesca/K-1451-2013; Canton,
   German/C-1975-2014; Benavides, Julio/D-5299-2014
OI Katzer, Frank/0000-0001-5902-4136; Chianini,
   Francesca/0000-0001-9962-446X; Canton, German/0000-0003-3494-8193;
   Garcia, JL/0000-0002-5736-7511; Benavides, Julio/0000-0001-9706-100X
FU Scottish Government's Rural and Environment Science and Analytical
   Services Division (RESAS) - European Union [FP7-228394]
FX The authors would like to thank Scottish Government's Rural and
   Environment Science and Analytical Services Division (RESAS) for
   supporting this work and all of the members of the clinical department
   at the Moredun Research Institute who assisted with the experiment. This
   project was partially funded by a transnational access project funded
   through the European Union Seventh Framework Network of Animal Disease
   Infectiology Research Facilities (NADIR; reference number FP7-228394)
CR Aguilar GIS, 2001, INT J PARASITOL, V31, P187, DOI 10.1016/S0020-7519(00)00159-4
   Bartley PM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-91
   Burrells A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0177-0
   Cook AJC, 2000, BRIT MED J, V321, P142, DOI 10.1136/bmj.321.7254.142
   Dawson HD, 2005, INFECT IMMUN, V73, P1116, DOI 10.1128/IAI.73.2.1116-1128.2005
   Dawson HD, 2004, VET IMMUNOL IMMUNOP, V100, P105, DOI 10.1016/j.vetimm.2004.03.006
   de Groot J, 2005, IMMUNOLOGY, V115, P495, DOI 10.1111/j.1365-2567.2005.02184.x
   Dotiwala F, 2016, NAT MED, V22, P210, DOI 10.1038/nm.4023
   Dubey JP, 2008, J EUKARYOT MICROBIOL, V55, P467, DOI 10.1111/j.1550-7408.2008.00345.x
   DUBEY JP, 1994, J AM VET MED ASSOC, V205, P1593
   FRENKEL JK, 1970, SCIENCE, V167, P893, DOI 10.1126/science.167.3919.893
   Garcia JL, 2005, VET PARASITOL, V129, P209, DOI 10.1016/j.vetpar.2005.01.006
   Jones JL, 2001, OBSTET GYNECOL SURV, V56, P296, DOI 10.1097/00006254-200105000-00025
   Jungersen G, 1999, INT J PARASITOL, V29, P1307, DOI 10.1016/S0020-7519(99)00078-8
   Katzer F, 2014, VET PARASITOL, V205, P46, DOI 10.1016/j.vetpar.2014.07.003
   Kringel H, 2004, VET PARASITOL, V123, P55, DOI 10.1016/j.vetpar.2004.01.021
   Mair KH, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-13
   Mair KH, 2012, EUR J IMMUNOL, V42, P1261, DOI 10.1002/eji.201141989
   PINCKNEY RD, 1994, J PARASITOL, V80, P438, DOI 10.2307/3283415
   Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997
   Solano-Aguilar GI, 2002, VET IMMUNOL IMMUNOP, V89, P133, DOI 10.1016/S0165-2427(02)00205-2
   Wang YH, 2013, PARASITOL RES, V112, P3835, DOI 10.1007/s00436-013-3571-4
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108963
DI 10.1016/j.vetpar.2019.108963
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700012
PM 31669836
DA 2020-05-12
ER

PT J
AU Camino, E
   Dorrego, A
   Carvajal, KA
   Buendia-Andres, A
   de Juan, L
   Dominguez, L
   Cruz-Lopez, F
AF Camino, Eliazar
   Dorrego, Abel
   Carvajal, Kelly Alejandra
   Buendia-Andres, Aranzazu
   de Juan, Lucia
   Dominguez, Lucas
   Cruz-Lopez, Fatima
TI Serological, molecular and hematological diagnosis in horses with
   clinical suspicion of equine piroplasmosis: Pooling strengths
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Equine piroplasmosis; Clinical signs; Hematology; Real-time PCR;
   Competitive ELISA
ID BABESIA-CABALLI INFECTIONS; THEILERIA-EQUI; QUANTITATIVE DETECTION;
   IDENTIFICATION; PREVALENCE
AB Equine piroplasmosis (EP) is a tick-borne protozoan disease caused by Theileria equi and/or Babesia caballi. Clinical signs (fever, pale mucosal membranes, jaundice), anemia and hyperbilirubinemia have been associated with the disease. EP is widespread, has a significant economic impact on the equine industry and remains endemic in Spain. This study was carried out with samples belonging to 140 horses residing in Spain and showing common clinical signs of EP. A blood smear microscopic examination and a comparison between the different results obtained by competitive Enzyme-Linked Immunosorbent Assay (cELISA), real-time Polymerase Chain Reaction (PCR) and hematological and biochemical (direct and total bilirubin) screening were conducted. EP positivity rates by cELISA and PCR were 50.7% and 42.9%, respectively, whereas only 9% of the horses were positive in the microscopic analysis. A significantly higher number of B. caballi-positive horses were detected by cELISA than PCR, and Kappa value was higher for T. equi (k = 0.575) than for B. caballi (k = 0.401). For the first time, an association between a high ELISA inhibition percentage (IP) and a positive PCR result for B. caballi was determined. Although most authors have described T. equi as more pathogenic than B. caballi, we found that horses parasitized by B. caballi showed a more severe hemolytic anemia, whereas T. equi infections were mostly associated with leukocytosis. The hemogram and clinical chemistry could guide the veterinary surgeon towards the diagnosis of T. equi or B. caballi since horses showed a significant leukocytosis or anemia and hyperbilirubinemia, respectively; however PCR would be the test of choice in order to confirm the diagnosis. Information about the importance of a correct diagnosis of EP using a combination of techniques is essential in order to allow the early detection of cases and prevent the spread of the disease, as well as to avoid the common practice of treating horses without a laboratory diagnosis.
C1 [Camino, Eliazar; Dorrego, Abel; Carvajal, Kelly Alejandra; Buendia-Andres, Aranzazu; de Juan, Lucia; Dominguez, Lucas; Cruz-Lopez, Fatima] Univ Complutense, VISAVET Hlth Surveillance Ctr, Madrid, Spain.
   [Camino, Eliazar; de Juan, Lucia; Dominguez, Lucas] Univ Complutense, Fac Vet, Anim Hlth Dept, Madrid, Spain.
RP Cruz-Lopez, F (reprint author), Univ Complutense, VISAVET Hlth Surveillance Ctr, Madrid, Spain.
EM fatimacr@ucm.es
RI ; de Juan Ferre, Lucia/I-6465-2016; Cruz, Fatima/P-5858-2014
OI Dorrego, Abel/0000-0003-1088-8261; de Juan Ferre,
   Lucia/0000-0002-7070-6872; Cruz, Fatima/0000-0002-1142-3944
FU Complutense University of Madrid [CT27/16]
FX Camino, E. was supported by the Grants for Predoctoral Researchers of
   the Complutense University of Madrid (CT27/16). We are grateful to the
   technicians and the IT department at the VISAVET Health Surveillance
   Centre, Universidad Complutense, Madrid, Spain, for their help in the
   processing of the samples and the editing of the figure included in the
   manuscript, respectively. We are also grateful to all the veterinary
   surgeons and stud farm owners that participated in this study.
CR Bhoora R, 2010, VET PARASITOL, V168, P201, DOI 10.1016/j.vetpar.2009.11.011
   Bruning A, 1996, BRIT VET J, V152, P139, DOI 10.1016/S0007-1935(96)80070-4
   Butler CM, 2012, VET J, V193, P381, DOI 10.1016/j.tvjl.2011.12.014
   Camacho AT, 2005, TROP ANIM HEALTH PRO, V37, P293, DOI 10.1007/s11250-005-5691-z
   Camino E, 2018, J EQUINE VET SCI, V67, P81, DOI 10.1016/j.jevs.2018.03.012
   Coultous RM, 2019, VET REC, V184, DOI 10.1136/vr.104855
   DEWAAL DT, 1992, BRIT VET J, V148, P6, DOI 10.1016/0007-1935(92)90061-5
   Friedhoff K T, 1990, Rev Sci Tech, V9, P1187
   Garcia-Bocanegra I, 2013, VET J, V195, P172, DOI 10.1016/j.tvjl.2012.06.012
   Grause JF, 2013, VET J, V196, P541, DOI 10.1016/j.tvjl.2012.10.025
   Hailat NQ, 1997, VET PARASITOL, V69, P1, DOI 10.1016/S0304-4017(96)01100-4
   HOLMAN PJ, 1993, J CLIN MICROBIOL, V31, P698, DOI 10.1128/JCM.31.3.698-701.1993
   Homer MJ, 2000, CLIN MICROBIOL REV, V13, P451, DOI 10.1128/CMR.13.3.451-469.2000
   Ionita M, 2018, PARASITOL RES, V117, P2333, DOI 10.1007/s00436-018-5899-2
   Kappmeyer LS, 1999, J CLIN MICROBIOL, V37, P2285, DOI 10.1128/JCM.37.7.2285-2290.1999
   Katz J, 2000, J VET DIAGN INVEST, V12, P46, DOI 10.1177/104063870001200108
   Kim C, 2008, VET PARASITOL, V151, P158, DOI 10.1016/j.vetpar.2007.10.023
   Knowles D, 1996, BRIT VET J, V152, P123, DOI 10.1016/S0007-1935(96)80066-2
   KNOWLES DP, 1992, J CLIN MICROBIOL, V30, P3122, DOI 10.1128/JCM.30.12.3122-3126.1992
   Kumar S, 2002, VET PARASITOL, V107, P295, DOI 10.1016/S0304-4017(02)00161-9
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Leblond A, 2019, VET REC, V184, P92, DOI 10.1136/vr.l16
   Elisa BDL, 2016, TICKS TICK-BORNE DIS, V7, P462, DOI 10.1016/j.ttbdis.2016.01.011
   Mahmoud MS, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1539-9
   Malekifard Farnaz, 2014, Veterinary Research Forum, V5, P129
   MAURER FD, 1962, J AM VET MED ASSOC, V141, P699
   Mehlhorn H, 1998, PARASITOL RES, V84, P467, DOI 10.1007/s004360050431
   Mierzejewskal EJ, 2014, ANN AGR ENV MED, V21, P500, DOI 10.5604/12321966.1120590
   Moretti A, 2010, VET J, V184, P346, DOI 10.1016/j.tvjl.2009.03.021
   Munkhjargal T, 2013, INFECT GENET EVOL, V16, P178, DOI 10.1016/j.meegid.2013.02.005
   Posada-Guzman Maria Fernanda, 2015, Vet Med Int, V2015, P236278, DOI 10.1155/2015/236278
   Rothschild CM, 2013, J EQUINE VET SCI, V33, P497, DOI 10.1016/j.jevs.2013.03.189
   Schwint ON, 2009, ANTIMICROB AGENTS CH, V53, P4327, DOI 10.1128/AAC.00404-09
   Scoles GA, 2015, ANNU REV ENTOMOL, V60, P561, DOI 10.1146/annurev-ento-010814-021110
   Short MA, 2012, JAVMA-J AM VET MED A, V240, P588, DOI 10.2460/javma.240.5.588
   TAYLOR WM, 1969, J AM VET MED ASSOC, V155, P915
   VMRD, 2017, VET DIAGN TEST KITS, P3
   Wise LN, 2013, J VET INTERN MED, V27, P1334, DOI 10.1111/jvim.12168
   Wise LN, 2014, VET CLIN N AM-EQUINE, V30, P677, DOI 10.1016/j.cveq.2014.08.008
   Ybanez AP, 2018, TICKS TICK-BORNE DIS, V9, P1125, DOI 10.1016/j.ttbdis.2018.04.010
   Zobba R, 2008, J EQUINE VET SCI, V28, P301, DOI 10.1016/j.jevs.2008.03.005
NR 41
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108928
DI 10.1016/j.vetpar.2019.108928
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700005
PM 31605935
DA 2020-05-12
ER

PT J
AU Carlis, MSD
   Feboli, A
   de Laurentiz, AC
   Filardi, RD
   de Oliveira, AHP
   Silva, MLAE
   dos Anjos, LA
   Magalhaes, LG
   de Laurentiz, RD
AF de Paula Carlis, Matheus Souza
   Feboli, Aline
   de Laurentiz, Antonio Carlos
   Filardi, Rosemeire da Silva
   Prizantelli de Oliveira, Anna Helena
   Andrade e Silva, Marcio Luis
   dos Anjos, Luciano Alves
   Magalhaes, Lizandra Guidi
   de Laurentiz, Rosangela da Silva
TI In vitro anthelmintic activity of the crude hydroalcoholic extract of
   Piper cubeba fruits and isolated natural products against
   gastrointestinal nematodes in sheep
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cubebin; Hinokinin; Dihydrocubebin; Larval migration test; Egg hatch
   test; Larval development test
ID HAEMONCHUS-CONTORTUS; ESSENTIAL OIL; RESISTANCE; (-)-CUBEBIN;
   MONEPANTEL; EFFICACY; DRUG
AB This study describes the in vitro anthelmintic activity of a hydroalcoholic extract from the fruit of Piper cubeba and its major isolated components against the eggs and larvae of gastrointestinal nematodes obtained from naturally-infected ovines. In vitro anthelmintic activity was evaluated using the egg hatch test (EHT), larval development test (LDT) and L3 migration inhibition test (LMT). The extract showed ovicidal and larvicidal activity, with an EC50 of 200 mu g/mL and 83.00 mu g/mL in the EHT and LDT, respectively. The extract inhibited 100% of larval migration at the lowest tested concentration (95 mu g/mL). The crude extract was purified using successive silica gel chromatographic columns, which revealed the lignans hinokinin, cubebin and dihydrocubebin as the major compounds that were present, which were then used in in vitro tests. Cubebin, dihydrocubebin and hinokinin showed higher activity than the crude extract, with an EC50 for ovicidal activity of 150.00 mu g/mL, 186.70 mu g/mL and 68.38 mu g/mL, respectively. In the LDT, cubebin presented an EC50 of 14.89 mu g/mL and dihydrocubebin of 30.75 mu g/mL. Hinokinin inhibited 100% the larval development at all concentrations evaluated. In the LMT, dihydrocubebin inhibited 100% the larval migration in all concentrations evaluated while cubebin and hinokinin showed EC50 values of 0.89 mu g/mL and 0.34 mu g/mL, respectively. P. cubeba extract is rich in several classes of active compounds, but here we demonstrate that the described anthelmintic activity may be related to the presence of these lignans, which are present in larger concentrations than other components of the extract. Our results demonstrate for first time the anthelmintic activity against gastrointestinal nematodes in sheep for this class of special metabolites that are present in P. cubeba fruit. However, future detailed studies are needed to evaluate the effectiveness of P. cubeba fruits extract and active lignans in in vivo tests.
C1 [Feboli, Aline; de Laurentiz, Rosangela da Silva] Univ Estadual Paulista, Fac Engn IIha Solteira, Dept Fis & Quim, Av Brasil 56, BR-15385000 Sao Paulo, SP, Brazil.
   [de Paula Carlis, Matheus Souza; de Laurentiz, Antonio Carlos; Filardi, Rosemeire da Silva; dos Anjos, Luciano Alves] Univ Estadual Paulista, Fac Engn IIha Solteira, Dept Biol & Zootecnia, Rua Moncao 226, BR-15385000 Sao Paulo, SP, Brazil.
   [Prizantelli de Oliveira, Anna Helena; Andrade e Silva, Marcio Luis; Magalhaes, Lizandra Guidi] Univ Franca, Nucleo Pesquisa Ciencias Exatas & Tecnol, Av Salesde Oliveira 201,Parque Univ, BR-14404600 Sao Paulo, SP, Brazil.
RP de Laurentiz, RD (reprint author), Univ Estadual Paulista, Fac Engn IIha Solteira, Dept Fis & Quim, Av Brasil 56, BR-15385000 Sao Paulo, SP, Brazil.
EM rosangela@dfq.feis.unesp.br
RI da Silva de Laurentiz, Rosangela/F-2413-2012; de Paula Carlis, Matheus
   Sousa/AAC-3535-2019
OI da Silva de Laurentiz, Rosangela/0000-0002-5240-4870; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2016/17270-9]; CAPESCAPES
FX The authors thank FAPESP (process 2016/17270-9) and CAPES for
   scholarships.
CR Abidi A, 2018, VET PARASITOL, V263, P59, DOI 10.1016/j.vetpar.2018.10.003
   Adate P. S., 2012, Pharmacognosy Journal, V4, P61, DOI 10.5530/pj.2012.29.10
   Gainza YA, 2016, REV BRAS PARASITOL V, V25, P383, DOI [10.1590/S1984-29612016073, 10.1590/s1984-29612016073]
   Alonso-Diaz MA, 2008, VET PARASITOL, V153, P313, DOI 10.1016/j.vetpar.2008.01.042
   AlSaid M, 2015, BIOMED RES INT, P1
   Andre WPP, 2016, VET PARASITOL, V218, P52, DOI 10.1016/j.vetpar.2016.01.001
   Besier RB, 2016, ADV PARASIT, V93, P181, DOI 10.1016/bs.apar.2016.02.024
   Chan-Perez JI, 2016, VET PARASITOL, V217, P53, DOI 10.1016/j.vetpar.2015.11.001
   CHOPRA RN, 1956, GLOSSARY INDIAN MED
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   da Silva R, 2005, BIOORG MED CHEM LETT, V15, P1033, DOI 10.1016/j.bmcl.2004.12.035
   de Araujo JV, 2018, IND CROP PROD, V124, P294, DOI 10.1016/j.indcrop.2018.07.059
   de Lima RG, 2018, CHEMISTRYOPEN, V7, P180, DOI 10.1002/open.201700182
   Demessie Y., 2016, WJAS, V12, P245
   Elfahmi, 2007, BIOCHEM SYST ECOL, V35, P397, DOI 10.1016/j.bse.2007.01.003
   Esperandim VR, 2013, PLANTA MED, V79, P1653, DOI 10.1055/s-0033-1351022
   Esperandim VR, 2013, EXP PARASITOL, V133, P442, DOI 10.1016/j.exppara.2012.12.005
   Feboli A, 2016, VET PARASITOL, V226, P65, DOI 10.1016/j.vetpar.2016.06.030
   Macedo ITF, 2015, REV BRAS PARASITOL V, V24, P268, DOI 10.1590/S1984-29612015059
   Gayatri Nahak, 2011, Journal of Applied Pharmaceutical Science, V1, P153
   Graidist P, 2015, NUTRIENTS, V7, P2707, DOI 10.3390/nu7042707
   Jabbar A, 2006, LIFE SCI, V79, P2413, DOI 10.1016/j.lfs.2006.08.010
   Katiki LM, 2017, VET PARASITOL, V243, P47, DOI 10.1016/j.vetpar.2017.06.008
   Katiki L.M., 2013, VET PARASITOL, V18, P192
   Koorse K. G., 2018, Pharmacognosy Journal, V10, P333, DOI 10.5530/pj.2018.2.57
   Kotze AC, 2016, ADV PARASIT, V93, P397, DOI 10.1016/bs.apar.2016.02.012
   Lacey E., 1995, INT J PARASITOL, V25, P463
   Laing R, 2017, TRENDS PARASITOL, V33, P463, DOI 10.1016/j.pt.2017.02.004
   LAURENTIZ R.S., 2015, Rev. bras. plantas med., V17, P782, DOI 10.1590/1983-084X/14_085
   Lecova L, 2014, PARASITOLOGY, V141, P1686, DOI 10.1017/S0031182014001401
   Lucius R., 2017, BIOL PARASITES
   Magalhaes LG, 2012, PARASITOL RES, V110, P1747, DOI 10.1007/s00436-011-2695-7
   MANSFIELD LS, 1992, COMP BIOCHEM PHYS B, V103, P681, DOI 10.1016/0305-0491(92)90390-D
   Martinez-Ortiz-de-Montellano C, 2013, EXP PARASITOL, V133, P281, DOI 10.1016/j.exppara.2012.11.024
   Mengistu G, 2017, VET PARASITOL, V237, P110, DOI 10.1016/j.vetpar.2016.12.020
   Mouid M.G., 2016, WORLD J PHARM SCI, V4, P104
   Oliveira AF, 2017, VET PARASITOL, V236, P121, DOI 10.1016/j.vetpar.2017.02.005
   Paul A., 2018, CLIN PHYTOSCI, V4, P17
   Perazzo F. F., 2013, Pharmacognosy Journal, V5, P13
   Qi H, 2015, VET PARASITOL, V211, P223, DOI 10.1016/j.vetpar.2015.05.029
   RABEL B, 1994, INT J PARASITOL, V24, P671, DOI 10.1016/0020-7519(94)90119-8
   Ramos F, 2018, PESQUI VET BRASIL, V38, P48, DOI 10.1590/1678-5150-pvb-5188
   Rezende KCS, 2016, REV BRAS FARMACOGN, V26, P296, DOI 10.1016/j.bjp.2015.12.006
   Riou M, 2005, PARASITOL RES, V96, P142, DOI 10.1007/s00436-005-1345-3
   Silva MLA, 2007, PHYTOTHER RES, V21, P420, DOI 10.1002/ptr.2088
   van Wyk JA, 2013, ONDERSTEPOORT J VET, V80, DOI 10.4102/ojvr.v80i1.539
   Zenebe S, 2017, BIOMED RES INT, DOI 10.1155/2017/1905987
NR 47
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108932
DI 10.1016/j.vetpar.2019.108932
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700002
PM 31600614
DA 2020-05-12
ER

PT J
AU do Vale, B
   Lopes, AP
   Fontes, MD
   Silvestre, M
   Cardoso, L
   Coelho, AC
AF do Vale, Beatriz
   Lopes, Ana Patricia
   Fontes, Maria da Conceicao
   Silvestre, Mario
   Cardoso, Luis
   Coelho, Ana Claudia
TI Thelaziosis due to Thelazia callipaeda in Europe in the 21st century-A
   review
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Cat; Dog; Human; Phortica variegata; Red fox; Thelazia callipaeda;
   Zoonosis
ID CANINE OCULAR THELAZIOSIS; 1ST REPORT; PHORTICA-VARIEGATA; IMIDACLOPRID
   10-PERCENT; PARASITIC DISEASE; INTERMEDIATE HOST; RED FOXES; DOGS;
   INFECTION; SPIRURIDA
AB Thelazia callipaeda was first described at the beginning of the 20th century in Asia, but this eyeworm is now frequently reported in Europe in the 21st century. To date, thelaziosis has been described in the following European countries (in order of appearance): Italy, France, Germany, Switzerland, Spain, Portugal, Belgium, Bosnia and Herzegovina, Croatia, Serbia, Romania, Greece, Bulgaria, Hungary, Slovakia, the United Kingdom, Turkey and Austria. The infected vertebrate host species include domestic carnivores (dogs and cats), wild carnivores (red foxes, wolves, beech martens, wildcats and golden jackals), lagomorphs (brown hares and wild European rabbits) and humans. In Europe, 11 cases of human thelaziosis have been reported, the majority of which are autochthonous. However, some of them have been imported, a fact which highlights the importance of surveillance policies to restrict cross-border spread of the parasite. The objectives of this article are to review key aspects of the epidemiology of T. callipaeda, summarise animal and human cases in Europe and emphasise the importance of education and awareness among veterinarians, physicians (particularly ophthalmologists) and animal, in order to owners to tackle this zoonosis.
C1 [do Vale, Beatriz; Lopes, Ana Patricia; Fontes, Maria da Conceicao; Cardoso, Luis; Coelho, Ana Claudia] Univ Tras Os Montes & Alto Douro UTAD, Dept Vet Sci, Sch Agr & Vet Sci ECAV, Vila Real, Portugal.
   [Lopes, Ana Patricia; Fontes, Maria da Conceicao; Silvestre, Mario; Cardoso, Luis; Coelho, Ana Claudia] UTAD, Anim & Vet Res Ctr, Vila Real, Portugal.
   [Silvestre, Mario] UTAD, ECAV, Dept Zootech, Vila Real, Portugal.
RP Cardoso, L (reprint author), Univ Tras Os Montes & Alto Douro UTAD, Dept Ciencias Vet, P-5000801 Vila Real, Portugal.
EM lcardoso@utad.pt
RI ; Coelho, Ana/K-4740-2013; Cardoso, Luis/J-8310-2013
OI do Vale, Beatriz/0000-0001-8858-4829; Coelho, Ana/0000-0002-7196-4179;
   Cardoso, Luis/0000-0002-6145-7560; Lopes, Ana
   Patricia/0000-0002-8182-5674; Fontes, Maria da
   Conceicao/0000-0002-8913-5504
FU Portuguese Science and Technology Foundation (FCT)Portuguese Foundation
   for Science and Technology [UID/CVT/00772/2019]
FX This work was funded by the project UID/CVT/00772/2019 supported by the
   Portuguese Science and Technology Foundation (FCT).
CR Akhanda A H, 2013, Mymensingh Med J, V22, P581
   Anderson RC, 2000, NEMATODE PARASITES V, P672
   Baneth G, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-55
   Beugnet F., 2018, TXB CLIN PARASITOLOG, P200
   Bianciardi P, 2005, VET PARASITOL, V129, P89, DOI 10.1016/j.vetpar.2004.12.020
   Bradbury RS, 2018, AM J TROP MED HYG, V98, P1171, DOI 10.4269/ajtmh.17-0870
   BURNETT HS, 1957, J PARASITOL, V43, P433, DOI 10.2307/3274668
   Cabanova V, 2018, ACTA PARASITOL, V63, P160, DOI 10.1515/ap-2018-0018
   Cabanova V, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2128-2
   Calero-Bernal R, 2014, VET PARASITOL, V200, P203, DOI 10.1016/j.vetpar.2013.12.014
   Calero-Bernal R, 2013, J WILDLIFE DIS, V49, P458, DOI 10.7589/2012-10-268
   Caron Y, 2013, J SMALL ANIM PRACT, V54, P205, DOI 10.1111/jsap.12003
   Chermette R., 2004, VET REC, V248
   Colella V, 2016, EMERG INFECT DIS, V22, P1513, DOI 10.3201/eid2208.160792
   Colwell DD, 2011, VET PARASITOL, V182, P14, DOI 10.1016/j.vetpar.2011.07.012
   Diakou A, 2017, VET REC, V181, P344, DOI 10.1136/vr.j4454
   Diakou A, 2015, PARASITOL RES, V114, P2771, DOI 10.1007/s00436-015-4457-4
   Dorchies P, 2007, VET PARASITOL, V149, P294, DOI 10.1016/j.vetpar.2007.08.005
   Dumitrache MO, 2018, PARASITOL RES, V117, P4037, DOI 10.1007/s00436-018-6122-1
   Eser M., 2018, KAFKAS UNIV VET FAK, V25, P131
   Farkas R, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2925-2
   FAUST ERNEST CARROLL, 1928, JOUR PARASITOL, V15, P75, DOI 10.2307/3271341
   Ferroglio E, 2008, VET PARASITOL, V154, P351, DOI 10.1016/j.vetpar.2008.03.011
   Fuentes I, 2012, EMERG INFECT DIS, V18, P2073, DOI 10.3201/eid1812.120472
   Gajic B, 2014, ACTA VET-BEOGRAD, V64, P447, DOI 10.2478/acve-2014-0042
   Gama A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1526-1
   Graham-Brown J, 2017, VET REC, V181, DOI 10.1136/vr.104378
   Deltell JG, 2019, REV ESP QUIM, V32, P286
   Hammond A, 2018, VET REC, V183, DOI 10.1136/vr.k4340
   Hermosilla C, 2004, VET REC, V154, P568, DOI 10.1136/vr.154.18.568
   Hodzic A, 2019, PARASITOL RES, V118, P1321, DOI 10.1007/s00436-019-06275-0
   Hodzic A, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-352
   Hossain M I, 2011, Mymensingh Med J, V20, P128
   Ionica AM, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3631-4
   Ionica AM, 2018, J WILDLIFE DIS, V54, P829, DOI 10.7589/2017-10-251
   Ionita M, 2016, VECTOR-BORNE ZOONOT, V16, P172, DOI 10.1089/vbz.2015.1919
   Lebon W, 2019, PARASITE, V26, DOI 10.1051/parasite/2019001
   Lechat C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0696-6
   Lia R., 2000, Acta Parasitologica, V45, P178
   Lia RP, 2004, VET REC, V154, P143, DOI 10.1136/vr.154.5.143
   Medrano RL, 2015, MED CLIN-BARCELONA, V145, P317, DOI 10.1016/j.medcli.2015.02.014
   Maca J, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0516-4
   Magnis J, 2010, PARASITOL RES, V106, P715, DOI 10.1007/s00436-009-1678-4
   Maia C, 2016, TRANSBOUND EMERG DIS, V63, P416, DOI 10.1111/tbed.12284
   Malacrida F, 2008, VET PARASITOL, V157, P321, DOI 10.1016/j.vetpar.2008.07.029
   Marino V, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2773-0
   McGarry JW, 2017, LANCET INFECT DIS, V17, P1115, DOI [10.1016/S1473-3099(17)30573-X, 10.1016/S1473-3099(17)30580-7]
   Merindol I, 2018, VET PARASITOL, V253, P26, DOI 10.1016/j.vetpar.2018.02.021
   Mihalca AD, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1628-9
   Mihalca AD, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0663-2
   Miro G, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-148
   Motta B, 2014, VET PARASITOL, V203, P287, DOI 10.1016/j.vetpar.2014.04.009
   Motta B, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-85
   De NV, 2012, KOREAN J PARASITOL, V50, P221, DOI 10.3347/kjp.2012.50.3.221
   Otranto D, 2006, MED VET ENTOMOL, V20, P358, DOI 10.1111/j.1365-2915.2006.00643.x
   Otranto D, 2006, INT J PARASITOL, V36, P1167, DOI 10.1016/j.ijpara.2006.06.006
   Otranto D, 2005, PARASITOLOGY, V131, P847, DOI 10.1017/S0031182005008395
   Otranto D, 2005, MOL CELL PROBE, V19, P306, DOI 10.1016/j.mcp.2005.05.001
   Otranto D, 2005, MED VET ENTOMOL, V19, P135, DOI 10.1111/j.0269-283X.2005.00554.x
   Otranto D, 2005, TRENDS PARASITOL, V21, P1, DOI 10.1016/j.pt.2004.10.008
   Otranto D, 2004, PARASITOLOGY, V129, P627, DOI 10.1017/S0031182004006018
   Otranto D, 2003, VET PARASITOL, V116, P315, DOI 10.1016/j.vetpar.2003.07.022
   Otranto D, 2008, EMERG INFECT DIS, V14, P647, DOI 10.3201/eid1404.071205
   Otranto D, 2008, TRENDS PARASITOL, V24, P116, DOI 10.1016/j.pt.2007.12.005
   Otranto D, 2007, J WILDLIFE DIS, V43, P508, DOI 10.7589/0090-3558-43.3.508
   Otranto D, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-018-3262-1
   Otranto D, 2016, VET PARASITOL, V227, P118, DOI 10.1016/j.vetpar.2016.07.035
   Otranto D, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0881-7
   Otranto D, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-16
   Otranto D, 2012, J VECTOR ECOL, V37, P458, DOI 10.1111/j.1948-7134.2012.00251.x
   Otranto D, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-41
   Otranto D, 2009, VET PARASITOL, V166, P262, DOI 10.1016/j.vetpar.2009.08.027
   Palfreyman J, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2842-4
   Papadopoulos E, 2018, TRANSBOUND EMERG DIS, V65, P248, DOI 10.1111/tbed.12626
   Paradzik MT, 2016, WIEN KLIN WOCHENSCHR, V128, P221, DOI 10.1007/s00508-015-0889-1
   Pavlovi I, 2017, BALKAN J WILDLIFE RE, V4, P1, DOI [10.15679/bjwr.v4i1.31, DOI 10.15679/BJWR.V4I1.31]
   Pimenta P, 2013, VET OPHTHALMOL, V16, P312, DOI 10.1111/j.1463-5224.2012.01074.x
   Rodrigues FT, 2012, J FELINE MED SURG, V14, P952, DOI 10.1177/1098612X12459645
   Roggero C, 2010, VET PARASITOL, V171, P58, DOI 10.1016/j.vetpar.2010.03.012
   ROSSI L, 1989, Parassitologia (Rome), V31, P167
   Ruytoor P, 2010, EMERG INFECT DIS, V16, P1943, DOI 10.3201/eid1612.100872
   Ryu Sukhyun, 2017, J Prev Med Public Health, V50, P411, DOI 10.3961/jpmph.17.097
   Sah R, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy237
   Sargo R, 2014, J ZOO WILDLIFE MED, V45, P458, DOI 10.1638/2013-0294R.1
   Seixas F, 2018, VET PARASITOL, V252, P163, DOI 10.1016/j.vetpar.2018.02.007
   Sharma M, 2019, INDIAN J OPHTHALMOL, V67, P282, DOI 10.4103/ijo.IJO_1110_18
   Shen JL, 2006, J PARASITOL, V92, P872, DOI 10.1645/GE-823R.1
   Soares C, 2013, VET PARASITOL, V196, P528, DOI 10.1016/j.vetpar.2013.03.029
   Stull JW, 2015, CAN MED ASSOC J, V187, P736, DOI 10.1503/cmaj.141020
   Stull JW, 2014, J PEDIATR-US, V165, P348, DOI 10.1016/j.jpeds.2014.04.045
   Tasic-Otasevic S, 2016, COMP IMMUNOL MICROB, V45, P20, DOI 10.1016/j.cimid.2016.01.003
   Tudor P, 2016, PARASITOL RES, V115, P1741, DOI 10.1007/s00436-016-4964-y
   Vieira L, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-124
   Zhang X, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006165
NR 94
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108957
DI 10.1016/j.vetpar.2019.108957
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700001
PM 31630050
DA 2020-05-12
ER

PT J
AU Fang, SF
   Gu, XL
   El-Ashram, S
   Li, XW
   Yu, XJ
   Guo, B
   Li, HF
   Liu, NX
   Liu, XY
   Cui, P
   Suo, X
AF Fang, Sufang
   Gu, Xiaolong
   El-Ashram, Saeed
   Li, Xiwang
   Yu, Xiaojie
   Guo, Bing
   Li, Huifeng
   Liu, Nanxing
   Liu, Xianyong
   Cui, Ping
   Suo, Xun
TI Immune protection provided by a precocious line trivalent vaccine
   against rabbit Eimeria
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Rabbit; Eimeria; Precocious line; Precocious line vaccine
ID SELECTION; COCCIDIOSIS; INFECTIONS; MAGNA; MEDIA
AB A pilot study was conducted to evaluate the pathogenicity and immunogenicity of vaccinated rabbits with different doses of oocysts (5 x 10(2), 1 x 10(3), 1 x 10(4), and 5 x 10(4)) of a precocious line, including Eimeria magna, E. intestinalis or E. media following the challenge with their corresponding parent strains. Our results showed that each precocious line had weak pathogenicity but good immunogenicity in terms of clinical symptoms, average daily weight gains (ADGs), and oocyst outputs. Therefore, a precocious line trivalent vaccine, including E. magna, E. intestinalis, and E. media was formulated. A total of sixty 40-day-old coccidia-free rabbits were allocated to ten treatments with a 2 x 3 factorial arrangement that included 2 vaccination doses (5 x 10(2) or 1 x 10(3) oocysts of the precocious line). Groups Ito VIII and Unimmunized Challenged Control group were challenged with mixed oocysts of their corresponding parent strains (1 x 10(4) oocysts of each parent strain) 14 days after vaccination. No clinical symptoms were observed in the immunized groups after vaccination. Average daily weight gains (ADGs) were similar to those of unimmunized unchallenged controls (P > 0.05) after vaccination or after challenge. Oocyst outputs in the vaccinated challenged groups were significantly different from those of unimmunized challenged controls (P < 0.01) after challenge. These results indicated that the trivalent vaccine could provide immune protection against coccidiosis and therefore, it could be used as a candidate vaccine.
C1 [Fang, Sufang; Gu, Xiaolong; Li, Xiwang; Yu, Xiaojie; Guo, Bing; Li, Huifeng; Cui, Ping] Hebei North Univ, Coll Anim Sci & Technol, Zhangjiakou 075000, Hebei, Peoples R China.
   [Gu, Xiaolong; Liu, Nanxing; Liu, Xianyong; Suo, Xun] China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
   [El-Ashram, Saeed] Foshan Univ, Sch Life Sci & Engn, Foshan 528231, Guangdong, Peoples R China.
   [El-Ashram, Saeed] Kafrelsheikh Univ, Fac Sci, Kafrelsheikh, Egypt.
RP Cui, P (reprint author), Hebei North Univ, Coll Anim Sci & Technol, Zhangjiakou 075000, Hebei, Peoples R China.; Suo, X (reprint author), China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
EM dkyjsc@126.com; suoxun@cau.edu.cn
FU National Rabbit Industry Technology System Programme [CARS-44]; Ministry
   of Agriculture, ChinaMinistry of Agriculture, China; Major Project of
   Hebei North University, Hebei, China [ZD201308]
FX This work was supported by the National Rabbit Industry Technology
   System Programme (CARS-44), the Ministry of Agriculture, China and by
   the Major Project of Hebei North University (Grant No.ZD201308), Hebei,
   China
CR Akpo Y, 2012, VET PARASITOL, V184, P73, DOI 10.1016/j.vetpar.2011.08.012
   Duszynski DW, 2013, BIOLOGY AND IDENTIFICATION OF THE COCCIDIA (APICOMPLEXA) OF RABBITS OF THE WORLD, P121, DOI 10.1016/B978-0-12-397899-8.00006-8
   JEFFERS TK, 1975, J PARASITOL, V61, P1083, DOI 10.2307/3279381
   Jing F, 2012, PARASITOL RES, V110, P1495, DOI 10.1007/s00436-011-2653-4
   LICOIS D, 1994, PARASITOL RES, V80, P48, DOI 10.1007/BF00932623
   LICOIS D, 1995, VET PARASITOL, V60, P27, DOI 10.1016/0304-4017(94)00768-8
   LICOIS D, 1990, PARASITOL RES, V76, P192, DOI 10.1007/BF00930814
   Pakandl M, 2006, VET PARASITOL, V137, P351, DOI 10.1016/j.vetpar.2006.01.012
   Pakandl M, 2008, PARASITOL RES, V103, P1265, DOI 10.1007/s00436-008-1123-0
   Pakandl M, 2008, FOLIA PARASIT, V55, P1
NR 10
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108927
DI 10.1016/j.vetpar.2019.108927
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700008
PM 31639571
DA 2020-05-12
ER

PT J
AU Ferraz, CM
   Sobral, SA
   Senna, CC
   Fidelis, O
   Moreira, TF
   Tobias, FL
   Soares, FED
   Genier, HLA
   Vilela, VLR
   Lima, JAC
   de Araujo, JV
   Braga, FR
AF Ferraz, Carolina Magri
   Sobral, Samilla Alves
   Senna, Caio Colodette
   Fidelis Junior, Otavio
   Moreira, Tiago Facury
   Tobias, Fernando Luiz
   de Freitas Soares, Filippe Elias
   Andre Genier, Hugo Leonardo
   Ribeiro Vilela, Vinicius Longo
   Correia Lima, Jose Antonio
   de Araujo, Jackson Victor
   Braga, Fabio Ribeiro
TI Combined use of ivermectin, dimethyl sulfoxide, mineral oil and
   nematophagous fungi to control Rhabditis spp.
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Nematophagous fungi; Biological control; Parasitic otitis
ID BOVINE PARASITIC OTITIS; DUDDINGTONIA-FLAGRANS; IN-VITRO;
   GASTROINTESTINAL NEMATODES; MONACROSPORIUM-THAUMASIUM;
   METARHIZIUM-ANISOPLIAE; COMPATIBILITY; PENETRATION; CONIDIA; TICKS
AB Rhabditis spp., is a nematode known to cause otitis externa, an infection difficult to control, in cattle reared within tropical regions. The objective of this study was to assess the combined use of ivermectin 1%, dimethyl sulfoxide 1% and mineral oil 100% containing nematophagous fungi of both Duddingtonia fiagrans (AC001) and Monacrosporium thaumasium (NF34) species to control in vitro Rhabditis spp. Thus, 12 experimental groups were designed with eight replicates each: G1 (nematodes + AC001); G2 (nematodes + NF34); G3 (nematodes + ivermectin 1%/positive control); G4 (nematodes + dimethyl sulfoxide 1%/positive control); G5 (nematodes + mineral oil 100%/positive control); G6 (nematodes + AC001 + ivermectin 1%); G7 (nematodes + NF34 + ivermectin 1%); G8 (nematodes + AC001 + mineral oil 100%); G9 (nematodes + NF34 + mineral oil 100%); G10 (nematodes + AC001 + dimethyl sulfoxide 1%); G1 1 (nematode + NF34 + di methyl sulfoxide 1%); G12 (nematode + distilled water/negative control). The results demonstrated that all experimentally treated groups differed statistically (p < 0.01) from the control group. In the present study, the use of dimethyl sulfoxide 1% and mineral oil 100% in conjunction with conidia fungi portrayed noteworthy outcomes, which represents a future premise for the combined use of nematophagous fungi within these vehicles in both controlling Rhabditis spp.
C1 [Ferraz, Carolina Magri; Sobral, Samilla Alves; Senna, Caio Colodette; Correia Lima, Jose Antonio; Braga, Fabio Ribeiro] Univ Vila Velha, Lab Expt Parasitol & Biol Control, Vila Velha, ES, Brazil.
   [Fidelis Junior, Otavio; Moreira, Tiago Facury; Tobias, Fernando Luiz] Univ Vila Velha, Dept Vet Med, Vila Velha, ES, Brazil.
   [de Freitas Soares, Filippe Elias] Univ Fed Goias, Inst Trop Pathol & Hlth, Goiania, Go, Brazil.
   [Andre Genier, Hugo Leonardo] Fed Inst Espirito Santo IFES, Vitoria, ES, Brazil.
   [Ribeiro Vilela, Vinicius Longo] Fed Inst Paraiba IFPB, Joao Pessoa, Paraiba, Brazil.
   [de Araujo, Jackson Victor] Univ Fed Vicosa, Dept Vet Med, Vicosa, MG, Brazil.
RP Braga, FR (reprint author), Univ Vila Velha, Lab Expt Parasitol & Biol Control, Vila Velha, ES, Brazil.
EM fabio.braga@uvv.br
RI Moreira, Tiago/AAK-4190-2020
OI Longo Ribeiro Vilela, Vinicius/0000-0001-9891-7842
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)CAPES
   [001]; CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq)
FX The authors acknowledge the CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior) for the scholarship grant - Finance Code 001
   to the author Carolina Magri Ferraz; as well as the CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico)for the author
   Fabio Ribeiro Braga's productivity grant. Moreover, they thank to the
   FAPES (Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo) and
   Fapemig (Fundacao de Amparo Pesquisa de Minas Gerais).
CR Anhalt FA, 2010, BRAZ J BIOL, V70, P931, DOI 10.1590/S1519-69842010000500003
   Aradjo J.V., 2002, CIEN ANIM, V12, P129
   Arafijo J.V., 1993, J HELMINTHOL, V67, P136
   AYRES M, 2003, BIOESTAT 3 0 APLICAC
   Barbosa JD, 2016, PESQUI VET BRASIL, V36, P605, DOI 10.1590/S0100-736X2016000700008
   Braga FR, 2014, APPL MICROBIOL BIOT, V98, P71, DOI 10.1007/s00253-013-5366-z
   Braga FR, 2013, REV SOC BRAS MED TRO, V46, P108, DOI 10.1590/0037-86829612013
   Camargo MG, 2012, VET PARASITOL, V188, P140, DOI 10.1016/j.vetpar.2012.03.012
   Campos Artur Kanadani, 2004, Cienc. Rural, V34, P465, DOI 10.1590/S0103-84782004000200020
   Chaparro Jenny J, 2017, Vet Parasitol Reg Stud Reports, V10, P29, DOI 10.1016/j.vprsr.2017.07.005
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   Leite PVB, 2013, PESQUISA VET BRASIL, V33, P319, DOI 10.1590/S0100-736X2013000300008
   Luns F.D., 2018, BIOMED RES INT, V2018, P1
   Mangia SH, 2014, PESQUI VET BRASIL, V34, P449, DOI 10.1590/S0100-736X2014000500011
   Manjunath P., 2013, INT J MOL VET RES, V3
   Mendoza-de Gives P, 2018, VET PARASITOL, V263, P66, DOI 10.1016/j.vetpar.2018.10.001
   MENDOZADEGIVES P, 1994, VET PARASITOL, V55, P197, DOI 10.1016/0304-4017(93)00646-G
   Mota MA, 2003, WORLD J MICROB BIOT, V19, P913, DOI 10.1023/B:WIBI.0000007314.76357.00
   MSOLLA P, 1985, TROP ANIM HEALTH PRO, V17, P166, DOI 10.1007/BF02355877
   MSOLLA P, 1986, TROP ANIM HEALTH PRO, V18, P51, DOI 10.1007/BF02359660
   MSOLLA P, 1993, TROP ANIM HEALTH PRO, V25, P15, DOI 10.1007/BF02236880
   Mukhtar T., 2003, INT J AGRIC BIOL, V4, P576
   Patzelt A, 2012, SKIN RES TECHNOL, V18, P364, DOI 10.1111/j.1600-0846.2011.00578.x
   Picoli T., 2015, Science and Animal Health, V3, P159
   Vilela VLR, 2018, REV BRAS PARASITOL V, V27, P27, DOI [10.1590/s1984-296120180011, 10.1590/S1984-296120180011]
   Round M. C., 1962, Journal of Helminthology, V36, P375, DOI 10.1017/S0022149X00019453
   Sanyal PK, 2004, VET RES COMMUN, V28, P375, DOI 10.1023/B:VERC.0000034997.50332.77
   Silva AR, 2011, J HELMINTHOL, V85, P138, DOI 10.1017/S0022149X10000362
   Simon LS, 2009, PAIN, V143, P238, DOI 10.1016/j.pain.2009.03.008
   Soares F. B., 2011, Arquivos do Instituto Biologico Sao Paulo, V78, P385
   Sobral SA, 2019, REV BRAS PARASITOL V, V28, P333, DOI [10.1590/S1984-29612019020, 10.1590/s1984-29612019020]
   Verocai GG, 2009, PESQUISA VET BRASIL, V29, P910, DOI 10.1590/S0100-736X2009001100008
   Vieira FT, 2018, PESQUI VET BRASIL, V38, P519, DOI [10.1590/1678-5150-PVB-5112, 10.1590/1678-5150-pvb-5112]
   Vieira JN, 2017, BRAZ J BIOL, V77, P476, DOI 10.1590/1519-6984.15715
   Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025
NR 35
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108924
DI 10.1016/j.vetpar.2019.108924
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700009
PM 31630049
DA 2020-05-12
ER

PT J
AU Gowrishankar, S
   Latha, BR
   Sreekumar, C
   Leela, V
AF Gowrishankar, S.
   Latha, Bhaskaran Ravi
   Sreekumar, C.
   Leela, V
TI Innovative way to dispense pheromones for off-host control of
   Rhipicephalus sanguineus sensu lato ticks
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Rhipicephalus sanguineus; Vapour patch; Sex pheromone; Assembly
   pheromone; Petri dish bioassay; Bamboo sticky tick trap
ID ASSEMBLY PHEROMONE; 2,6-DICHLOROPHENOL; SEMIOCHEMICALS; IDENTIFICATION;
   ATTRACTION; BIOASSAY; DOGS
AB Vapour patches dispensing pheromones were evaluated as lures to increase the attractiveness of sticky tick traps for Rhipicephalus sanguineus sensu lato (s.l.). Sex pheromone (SP), assembly pheromone (AP) and a combination of SP + AP at optimal concentrations were impregnated in vapour patches. The responses of the different stages of R. sanguineus s.l. (i.e. larvae, nymphs and adults) to the pheromones were evaluated using a Petri dish bioassay. The impregnated vapour patches were retained as such for a period of two mo and their efficacy was reassessed. In a subsequent field trial, pheromone impregnated vapour patches were placed as lures in bamboo (Bambusa vulgaris) sticky traps designed for the control of ticks in dog kennels. In vitro AP impregnated vapour patches were effective in attracting the different life stages of R. sanguineus s.l. whereas SP was effective in attracting the unfed and fed male stages of R. sanguineus s.l. The field trial revealed that questing and engorged larvae, nymphs and females of R. sanguineus s.l. were attracted more towards AP impregnated vapour patches than SP and AP + SP impregnated vapour patches. Fed and unfed male ticks were lured effectively by SP alone. The combination of SP + AP revealed no potent additive or synergistic effect.
C1 [Gowrishankar, S.; Latha, Bhaskaran Ravi; Leela, V] Tamil Nadu Vet & Anim Sci Univ, Madras Vet Coll, Dept Vet Parasitol, Chennai 600007, Tamil Nadu, India.
   [Sreekumar, C.] Tamil Nadu Vet & Anim Sci Univ, Madras Vet Coll, Dept Wildlife Sci, Chennai 600007, Tamil Nadu, India.
RP Gowrishankar, S (reprint author), Tamil Nadu Vet & Anim Sci Univ, Madras Vet Coll, Dept Vet Parasitol, Chennai 600007, Tamil Nadu, India.
EM bhaskaranravilatha@tanuvas.ac.in
CR Anish RK, 2017, VET PARASITOL, V235, P57, DOI 10.1016/j.vetpar.2017.01.005
   Anish R.K., 2016, THESIS
   Baneth G, 2001, J PARASITOL, V87, P606, DOI 10.1645/0022-3395(2001)087[0606:TOHCTD]2.0.CO;2
   Bhoopathy D., 2016, REV BRAS PARASITOL V, V30, P81
   Bhoopathy Dhivya, 2016, Journal of Parasitic Diseases, V40, P1392, DOI 10.1007/s12639-015-0697-6
   Louly CCB, 2008, MEM I OSWALDO CRUZ, V103, P60, DOI 10.1590/S0074-02762008000100009
   Louly Carla Cristina Braz, 2007, Cienc. Rural, V37, P464, DOI 10.1590/S0103-84782007000200026
   Carde R.T., 1984, P355
   Carnohan LP, 2017, TICKS TICK-BORNE DIS, V8, P226, DOI 10.1016/j.ttbdis.2016.11.003
   Carr AL, 2016, PESTIC BIOCHEM PHYS, V131, P60, DOI 10.1016/j.pestbp.2015.12.009
   Coles TB, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-8
   Dantas-Torres F, 2011, EXP APPL ACAROL, V53, P389, DOI 10.1007/s10493-010-9406-4
   de la Fuente J., 2008, FRONT BIOSCI, V13, P38
   Dhivya B., 2013, THESIS
   Dusbabek F, 1998, FOLIA PARASIT, V45, P62
   GOTHE R, 1987, ONDERSTEPOORT J VET, V54, P439
   Haggart D.A., 1981, J INSECT PHYSL, V26, P51
   HAMILTON JGC, 1992, PARASITOL TODAY, V8, P130, DOI 10.1016/0169-4758(92)90284-9
   Heuskin S, 2011, BIOTECHNOL AGRON SOC, V15, P459
   KOSHY TJ, 1983, CHEIRON, V12, P337
   Kulkarni M.P., 2018, INT J ADV SCI RES DE, V3, P127
   Borges LMF, 2007, VET PARASITOL, V147, P155, DOI 10.1016/j.vetpar.2007.02.037
   NORVAL RAI, 1991, EXP APPL ACAROL, V11, P233, DOI 10.1007/BF01246095
   OTIENO DA, 1985, INSECT SCI APPL, V6, P667, DOI 10.1017/S1742758400002873
   Parola P, 2001, CLIN MICROBIOL INFEC, V7, P80, DOI 10.1046/j.1469-0691.2001.00200.x
   Patton, 1984, TXB MED ENTOMOLOGY, P598
   Peter RJ, 2005, VET PARASITOL, V132, P205, DOI 10.1016/j.vetpar.2005.07.004
   Ranju R.S., 2012, Journal of Parasitic Diseases, V36, P155, DOI 10.1007/s12639-012-0140-1
   Ranju R.S., 2011, THESIS
   Sonenshine DE, 2006, ANNU REV ENTOMOL, V51, P557, DOI 10.1146/annurev.ento.51.110104.151150
   Sonenshine DE, 2004, PARASITOLOGY, V129, pS405, DOI 10.1017/S003118200400486X
   SONENSHINE DE, 1985, ANNU REV ENTOMOL, V30, P1, DOI 10.1146/annurev.en.30.010185.000245
   Sonensine D.E., 1991, BIOL TICKS, V1, P449
   Yoder JA, 2000, EXP APPL ACAROL, V24, P159, DOI 10.1023/A:1006419203251
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108936
DI 10.1016/j.vetpar.2019.108936
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700013
PM 31669835
DA 2020-05-12
ER

PT J
AU Pyziel, AM
   Demiaszkiewicz, AW
   Klich, D
   Laskowski, Z
AF Pyziel, Anna M.
   Demiaszkiewicz, Aleksander W.
   Klich, Daniel
   Laskowski, Zdzislaw
TI A morphological and molecular comparison of Eimeria bovis-like oocysts
   (Apicomplexa: Eimeriidae) from European bison, Bison bonasus L., and
   cattle, Bos taurus L., and the development of two multiplex PCR assays
   for their identification
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Protozoa; Oocysts; Eimeria bovis; Wisent; Wildlife
ID COCCIDIA
AB The European bison, Bison bonasus is the largest terrestrial mammal in Europe; it is also on the red list, being recognized as vulnerable to extinction by the International Union for Conservation of Nature. The species suffers from low genetic variability, rendering it vulnerable to various environmental and biological threats.
   This study presents the first molecular confirmation of Eimeria bovis infection in European bison, and details a 1708 bp nucleotide sequence of the 18S rRNA gene in European bison -derived E. bovis (GenBank: MK691697). It also describes two multiplex PCR assays based on 18S rRNA gene for identifying Eimeria bovis oocysts and developmental stages in European bison and cattle. These yielded DNA banding patterns common for those of Eimeria spp. (250 bp for the first assay and 305 bp for the second assay) and species-specific E. bovis DNA in positive samples (344 bp and 586 bp, respectively). Both multiplex PCRs yielded bands characteristic of Eimeria spp. and E. bovis in samples containing DNA of oocysts from both bison and cattle. Moreover, convergent results were obtained for the DNA of the wall of colon in both assays, indicating the presence of developmental stages of Eimeria spp. other than E. bovis. Despite displaying the same sporulation time (four days), and similar general morphological features, the E. bovis oocysts derived from European bison were significantly narrower than those obtained from cattle (t = -6.19, p < 0.001), with a significantly higher shape index (length/width ratio) (t = 3.94, p < 0.001).
   The result provides further evidence for infection of European bison with a highly-pathogenic bovine protozoan, E. bovis.
C1 [Pyziel, Anna M.] Warsaw Univ Life Sci SGGW, Fac Vet Med, Dept Food Hyg & Publ Hlth Protect, Nowoursynowska 159, PL-02776 Warsaw, Poland.
   [Demiaszkiewicz, Aleksander W.; Laskowski, Zdzislaw] Polish Acad Sci, Stefanski Inst Parasitol, Twarda 51-55, PL-00818 Warsaw, Poland.
   [Klich, Daniel] Warsaw Univ Life Sci SGGW, Dept Genet & Anim Breeding, Fac Anim Sci, Ciszewskiego 8, PL-02786 Warsaw, Poland.
RP Pyziel, AM (reprint author), Warsaw Univ Life Sci SGGW, Fac Vet Med, Dept Food Hyg & Publ Hlth Protect, Nowoursynowska 159, PL-02776 Warsaw, Poland.
EM anna_pyziel@sggw.pl
RI Klich, Daniel/AAD-7611-2020; Laskowski, Zdzislaw/V-5682-2018
OI Laskowski, Zdzislaw/0000-0001-8542-6307; Pyziel, Anna
   Maria/0000-0002-8149-7412
CR Barta JR, 1997, J PARASITOL, V83, P262, DOI 10.2307/3284453
   Chibunda RT, 1997, PREV VET MED, V31, P191, DOI 10.1016/S0167-5877(96)01131-2
   Duszynski DW, 1997, J PARASITOL, V83, P333, DOI 10.2307/3284470
   Ellis JT, 2000, PROTIST, V151, P329, DOI 10.1078/S1434-4610(04)70031-0
   Ferenci T., 2009, P CHALL AN EC BUS SO, P1343
   Golemansky Vassil, 2003, Acta Zoologica Bulgarica, V55, P49
   Hnida JA, 1999, PARASITOLOGY, V119, P349, DOI 10.1017/S0031182099004849
   Karbowiak G, 2014, ACTA PARASITOL, V59, P363, DOI 10.2478/s11686-014-0252-0
   Kita J., 2006, HLTH THREATS EUROPEA
   Klockiewicz M, 2007, PARASITOL RES, V101, pS121, DOI 10.1007/s00436-007-0619-3
   Krasinska M., 2007, THE NATURE MONOGRAPH
   Nicholas K.B., 1997, EMBNET NEWS, V4, P1
   Pandit A.B., 2009, VETSCAN, V4, P16
   PENZHORN BL, 1994, J WILDLIFE DIS, V30, P267, DOI 10.7589/0090-3558-30.2.267
   Pyziel AM, 2015, FOLIA PARASIT, V62
   Pyziel AM, 2014, VET PARASITOL, V202, P138, DOI 10.1016/j.vetpar.2014.03.014
   Pyziel AM, 2013, PARASITOL RES, V112, P2083, DOI 10.1007/s00436-012-3262-6
   Rind Rahmatullah, 2000, Pakistan Veterinary Journal, V20, P113
   Sommer C, 1998, PARASITOLOGY, V116, P21, DOI 10.1017/S003118209700187X
   Taylor M.A., 2007, VET PARASITOL, P798
   Zarlenga DS, 2001, VET PARASITOL, V101, P215, DOI 10.1016/S0304-4017(01)00568-4
   Zhao XM, 2001, J MICROBIOL METH, V44, P131, DOI 10.1016/S0167-7012(00)00249-9
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108917
DI 10.1016/j.vetpar.2019.08.011
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700014
PM 31473050
DA 2020-05-12
ER

PT J
AU Redman, E
   Queiroz, C
   Bartley, DJ
   Levy, M
   Avramenko, RW
   Gilleard, JS
AF Redman, Elizabeth
   Queiroz, Camila
   Bartley, David J.
   Levy, Michel
   Avramenko, Russell W.
   Gilleard, John Stuart
TI Validation of ITS-2 rDNA nemabiome sequencing for ovine gastrointestinal
   nematodes and its application to a large scale survey of UK sheep farms
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Nemabiome; Deep-sequencing; Amplicon assay; ITS-2; PCR bias; Correction
   factors; Sheep
ID SPECIES-DIVERSITY; IDENTIFICATION; PARASITES; ECOLOGY; LARVAE; BEEF
AB We have validated ITS-2 rDNA nemabiome next-generation amplicon sequencing to determine relative species abundance of gastrointestinal nematode species in ovine fecal samples. In order to determine species representation biases, ITS-2 rDNA amplicon sequencing was applied to mock communities or field populations with known proportions of L3 for eight of the major ovine gastrointestinal nematode species: Teladorsagia circumcincta, Trichostrongylus vitrinus, Haemonchus contortus, Cooperia curticei, Trichostrongylus axei, Trichostrongylus colubriformis, Chabertia ovina and Oesophagostumum venulosum. Correction factors, calculated from this data, were shown to reduce species representation biases when applied to an independent set of field samples of known composition. We compared ITS-2 rDNA amplicon sequencing data that was generated from harvested eggs, freshly hatched L1 or L3 larvae following fecal culture and no statistically significant differences were found for the more abundant parasite species. We then applied the validated ITS-2 rDNA nemabiome amplicon sequencing assay to a set of archived L1 gastrointestinal nematode populations, collected in 2008 from fecal samples from 93 groups of 20 ewes and 61 groups of 20 lambs derived from 99 UK sheep farms. The presence of the major gastrointestinal nematode species had previously been determined on this large sample set by species-specific PCR. We show how the ITS-2rDNA amplicon sequencing data provided much more detailed information on species abundance than the previous species-specific PCR. This new data represents the most comprehensive overview of the relative abundance of the major gastrointestinal nematode species across UK sheep farms to date. Substantial variance in the relative abundance of both T. circumcincta and T. vitrinus between farms was revealed with the former species being of statistically significantly higher abundance in all three regions sampled (England, Scotland and Wales). The data also revealed that the relative abundance of T. circumcinta was statistically significantly higher in ewes than in lambs with the opposite pattern being the case for T. vitrinus. The nemabiome sequencing data also clearly illustrated the sporadic nature and skewed distribution of H. controtus across UK sheep farms as well as a higher relative abundance on farms from England compared to Wales and Scotland. The nemabiome survey also provides the first widescale data on the relative abundance of the two major large intestinal nematodes C. ovine and O. venulosum. This work validates ITS-2 rDNA nemabiome sequencing for use in sheep and illustrates the power of the approach for large scale surveillance of ovine gastrointestinal nematodes.
C1 [Redman, Elizabeth; Queiroz, Camila; Levy, Michel; Avramenko, Russell W.; Gilleard, John Stuart] Univ Calgary, Dept Comparat Biol & Expt Med, Host Parasite Interact Program, Fac Vet Med, 3330 Hosp Dr, Calgary, AB T2N 4N2, Canada.
   [Bartley, David J.] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
RP Gilleard, JS (reprint author), Univ Calgary, Dept Comparat Biol & Expt Med, Host Parasite Interact Program, Fac Vet Med, 3330 Hosp Dr, Calgary, AB T2N 4N2, Canada.
EM libbyredman@hotmail.co.uk; camila.dequeiroz@ucalgary.ca;
   dave.bartley@moredun.ac.uk; mlevy@ucalgary.ca; rwavrame@ucalgary.ca;
   jsgillea@ucalgary.ca
OI Bartley, David/0000-0002-8543-9244; Avramenko,
   Russell/0000-0002-0638-1700; Gilleard, John/0000-0002-6787-4699
FU CEDFAS BBRSC grant
FX The UK samples were originally collected as part of a CEDFAS BBRSC
   grant, (2008-2012).
CR Agneessens J, 1997, VET PARASITOL, V69, P65, DOI 10.1016/S0304-4017(96)01116-8
   Avramenko RW, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2880-y
   Avramenko RW, 2017, INT J PARASITOL, V47, P893, DOI 10.1016/j.ijpara.2017.06.006
   Avramenko RW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143559
   Besier RB, 2016, ADV PARASIT, V93, P95, DOI 10.1016/bs.apar.2016.02.022
   Bisset SA, 2014, VET PARASITOL, V200, P117, DOI 10.1016/j.vetpar.2013.12.002
   Blaxter M, 2015, PARASITOLOGY, V142, pS26, DOI 10.1017/S0031182014000791
   Burgess CGS, 2012, VET PARASITOL, V189, P299, DOI 10.1016/j.vetpar.2012.04.009
   Elmahalawy ST, 2018, VET PARASITOL, V261, P1, DOI 10.1016/j.vetpar.2018.07.008
   GASSER RB, 1994, INT J PARASITOL, V24, P291, DOI 10.1016/0020-7519(94)90041-8
   Gasser RB, 2008, BIOTECHNOL ADV, V26, P325, DOI 10.1016/j.biotechadv.2008.03.003
   Giudici C, 1999, VET RES, V30, P573
   Learmount J, 2009, VET PARASITOL, V166, P268, DOI 10.1016/j.vetpar.2009.08.017
   McMurtry LW, 2000, VET PARASITOL, V90, P73, DOI 10.1016/S0304-4017(00)00230-2
   O'Connor LJ, 2006, VET PARASITOL, V142, P1, DOI 10.1016/j.vetpar.2006.08.035
   Redman E, 2008, INT J PARASITOL, V38, P111, DOI 10.1016/j.ijpara.2007.06.008
   Redman E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003494
   Roeber F, 2011, INFECT GENET EVOL, V11, P849, DOI 10.1016/j.meegid.2011.01.013
   SANGSTER NC, 1980, RES VET SCI, V29, P26, DOI 10.1016/S0034-5288(18)32680-8
   Sargison ND, 2007, VET PARASITOL, V147, P326, DOI 10.1016/j.vetpar.2007.04.011
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09
   Stromberg BE, 2015, CAN J VET RES, V79, P290
   van Wyk JA, 2004, VET PARASITOL, V119, P277, DOI 10.1016/j.vetpar.2003.11.012
   VLASSOFF A, 1976, New Zealand Journal of Experimental Agriculture, V4, P281
NR 24
TC 2
Z9 2
U1 3
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108933
DI 10.1016/j.vetpar.2019.108933
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700007
PM 31606485
DA 2020-05-12
ER

PT J
AU Rojas, A
   Baneth, G
AF Rojas, Alicia
   Baneth, Gad
TI Secretome of the carcinogenic helminth Spirocerca lupi reveals specific
   parasite proteins associated with its different life stages
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Spirocerca lupi; Spirocercosis; Helminth; Products of
   excretion-secretion; Secretome
ID ONCHOCERCA-VOLVULUS; PARTIAL PROTECTION; THIOREDOXIN PEROXIDASE; ANNEXIN
   A6; INFECTION; NEMATODE; DOG; VACCINATION; PRODUCTS; ORGANIZATION
AB Spirocerca lupi is a parasitic and carcinogenic nematode of canids distributed in tropical and subtropical regions around the world. The excretion-secretion proteins (PES) of S. lupi have been suggested to play a role in the pathogenesis of its infection. We aimed to identify the PES of different stages of S. lupi and search for proteins that would be useful for diagnostic, therapeutic and vaccination purposes as well as understand their functions. A nano-UPLC mass spectrometry de novo analysis was performed on proteins collected from cultures of S. lupi L3 larvae, L4 females, adult females and adult males from naturally infected hosts. A total of 211 proteins were identified in all cultures. Accordingly, 117, 130, 99 and 116 proteins were detected in L3 larva, L4 females, adult females and adult males, respectively, with a strong correlation in the biological replicates (Pearson coefficients > 0.73). Fourty-four proteins were detected in all developmental stages, 64 were stage-specific and 49 were exclusively identified in L4 females. Cell compartment enrichment analysis revealed that proteins common to all stages were cytoplasmatic (p < 9.x10(-6)), whereas L4 unique proteins were in collagen trimers, and macromolecular complexes (p < 0.00001). Functional enrichment analysis of proteins showed significant enrichment in lipid metabolism in L3-unique proteins (p < 0.00005), in mannose metabolism and protein deglycosylation for L4-unique proteins (p < 0.00004), and in phosphorus metabolism in proteins shared by all stages (p < 2.1 x10(-9)). Interestingly, annexin 6, associated with cancer in humans, was detected in all life stages, but in a larger abundance in L4 females and adults. These findings indicate that S. lupi establishes complex interactions with its hosts by an arsenal of proteins expressed in different patterns in each life stage which influence the pathogenesis and oncogenesis of S. lupi and may be used as potential targets for diagnostic assays, drug targets or vaccine candidates.
C1 [Rojas, Alicia; Baneth, Gad] Hebrew Univ Jerusalem, Koret Sch Vet Med, Fac Agr Food & Environm, Rehovot, Israel.
RP Rojas, A (reprint author), Hebrew Univ Jerusalem, Alicia Rojas Koret Sch Vet Med, POB 12, IL-7610001 Rehovot, Israel.
EM alicia.rojas@mail.huji.ac.il
OI Baneth, Gad/0000-0002-7549-1305; Rojas, Alicia/0000-0003-2007-7198
FU University of Costa Rica
FX The authors thank Drs. Daniel Yasur-Landau and Alex Markovics for the
   provision of live S. lupi worms, and Dr. Alon Savidor for his assistance
   in the peptide analysis. This study was funded by internal sources of
   Prof. Baneth's laboratory, and a stipend from the University of Costa
   Rica granted to Alicia Rojas.
CR Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1
   Anderson JP, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004168
   Barroso FG, 2014, AQUACULTURE, V422, P193, DOI 10.1016/j.aquaculture.2013.12.024
   Becker AC, 2017, MOL BIOCHEM PARASIT, V216, P39, DOI 10.1016/j.molbiopara.2017.06.008
   Bercher M, 2001, J CELL BIOL, V154, P415, DOI 10.1083/jcb.200103035
   Bradley JE, 2001, TRENDS PARASITOL, V17, P471, DOI 10.1016/S1471-4922(01)02036-0
   Cantacessi C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02893
   Chai O, 2018, VET PARASITOL, V253, P16, DOI 10.1016/j.vetpar.2018.02.025
   Chen MX, 2011, J PARASITOL, V97, P721, DOI 10.1645/GE-2590.1
   Coghlan A, 2019, NAT GENET, V51, P163, DOI 10.1038/s41588-018-0262-1
   Coskun S. Z., 1995, Turkiye Parazitoloji Dergisi, V19, P541
   Cuesta-Astroz Y, 2017, INT J PARASITOL, V47, P529, DOI 10.1016/j.ijpara.2017.01.007
   da Silva MB, 2018, VET PARASITOL, V259, P25, DOI 10.1016/j.vetpar.2018.06.015
   de la Torre-Escudero E, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007087
   Donnelly S, 2005, INFECT IMMUN, V73, P166, DOI 10.1128/IAI.73.1.166-173.2005
   Dvir E, 2011, PARASITE IMMUNOL, V33, P545, DOI 10.1111/j.1365-3024.2011.01316.x
   Dvir E, 2010, VET PARASITOL, V168, P71, DOI 10.1016/j.vetpar.2009.10.023
   Dvir E, 2001, VET RADIOL ULTRASOUN, V42, P119, DOI 10.1111/j.1740-8261.2001.tb00914.x
   Dvir E, 2008, VET PARASITOL, V155, P80, DOI 10.1016/j.vetpar.2008.04.006
   Dvir E, 2007, J VET INTERN MED, V21, P860, DOI 10.1892/0891-6640(2007)21[860:SIASLM]2.0.CO;2
   Dvorak J, 2016, BIOCHIMIE, V122, P99, DOI 10.1016/j.biochi.2015.09.025
   Eichenberger RM, 2018, IMMUNOL CELL BIOL, V96, P704, DOI 10.1111/imcb.12171
   Fischer P., 1974, Anais de Escola de Agronomia e Veterinaria, V4, P53
   Floudas A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006012
   Francia G, 1996, CANCER RES, V56, P3855
   Garg G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S7-S8
   GARG UK, 1989, INDIAN VET J, V66, P1073
   GEORGI ME, 1980, CORNELL VET, V70, P43
   Gozdzik K, 2012, RES VET SCI, V93, P813, DOI 10.1016/j.rvsc.2011.09.016
   Han KK, 2012, VET IMMUNOL IMMUNOP, V149, P177, DOI 10.1016/j.vetimm.2012.06.016
   Hao LM, 2006, DEV DYNAM, V235, P1469, DOI 10.1002/dvdy.20721
   Harnett W, 2014, MOL BIOCHEM PARASIT, V195, P130, DOI 10.1016/j.molbiopara.2014.03.007
   Harrus S, 1996, J AM ANIM HOSP ASSOC, V32, P125, DOI 10.5326/15473317-32-2-125
   Herrera LA, 2001, TRENDS PARASITOL, V17, P172, DOI 10.1016/S1471-4922(00)01942-5
   Hetherington S, 2011, DEV BIOL, V350, P267, DOI 10.1016/j.ydbio.2010.11.025
   Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008
   Ignatchenko V, 2015, PROTEOMICS, V15, P1239, DOI 10.1002/pmic.201400320
   Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200
   Ito K, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.56
   Jex AR, 2019, TRENDS PARASITOL, V35, P72, DOI 10.1016/j.pt.2018.09.010
   KAPUR J, 1987, Angewandte Parasitologie, V28, P211
   Kim JY, 2010, MOL BIOCHEM PARASIT, V174, P53, DOI 10.1016/j.molbiopara.2010.06.014
   Lagatie O, 2018, AM J TROP MED HYG, V98, P779, DOI 10.4269/ajtmh.17-0756
   Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734
   Lomnytska MI, 2011, BRIT J CANCER, V104, P110, DOI 10.1038/sj.bjc.6605992
   Lu WH, 1998, MOL BIOCHEM PARASIT, V91, P221, DOI 10.1016/S0166-6851(97)00230-2
   Ma GX, 2015, ACTA TROP, V149, P148, DOI 10.1016/j.actatropica.2015.05.026
   Ma GX, 2014, EXP PARASITOL, V141, P55, DOI 10.1016/j.exppara.2014.03.019
   Mazaki-Tovi M, 2002, VET PARASITOL, V107, P235, DOI 10.1016/S0304-4017(02)00118-8
   Mehrdana F, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028-017-0310-3
   Melendez RD, 2001, TRENDS PARASITOL, V17, P516, DOI 10.1016/S1471-4922(01)02081-5
   Moreno Y, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000326
   Mullen GP, 1999, MOL BIOL CELL, V10, P3205, DOI 10.1091/mbc.10.10.3205
   Nisbet AJ, 2013, VACCINE, V31, P4017, DOI 10.1016/j.vaccine.2013.05.026
   Page AP, 2014, INT J PARASITOL-DRUG, V4, P133, DOI 10.1016/j.ijpddr.2014.05.003
   PROUDFOOT L, 1990, ACTA TROP, V47, P323, DOI 10.1016/0001-706X(90)90033-V
   Qi HB, 2015, ONCOL LETT, V10, P1947, DOI 10.3892/ol.2015.3498
   Rehman AA, 2013, J CELL PHYSIOL, V228, P1665, DOI 10.1002/jcp.24266
   Riddle DL, 1997, C ELEGANS
   Rojas A, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3202-0
   Rojas A, 2017, VET PARASITOL, V242, P71, DOI 10.1016/j.vetpar.2017.05.026
   Sako K, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1162-9
   Sakwe AM, 2011, EXP CELL RES, V317, P823, DOI 10.1016/j.yexcr.2010.12.008
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   SEN K, 1971, Journal of Helminthology, V45, P123
   Shears RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22783-y
   Smith DL, 2002, MOL CELL PROTEOMICS, V1, P876, DOI 10.1074/mcp.M200035-MCP200
   Smout MJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000611
   Sotillo J, 2017, TRENDS PARASITOL, V33, P875, DOI 10.1016/j.pt.2017.06.011
   Sperotto RL, 2017, MOL BIOCHEM PARASIT, V211, P39, DOI 10.1016/j.molbiopara.2016.09.002
   Steisslinger V, 2015, VACCINE, V33, P5861, DOI 10.1016/j.vaccine.2015.07.110
   STEPHENS LC, 1983, J AM VET MED ASSOC, V182, P496
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Team R. C., 2013, R LANG ENV STAT COMP
   THANIKACHALAM M, 1984, CHEIRON, V13, P220
   Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Tritten L, 2016, VET PARASITOL, V232, P1, DOI 10.1016/j.vetpar.2016.11.005
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]
   van der Merwe LL, 2008, VET J, V176, P294, DOI 10.1016/j.tvjl.2007.02.032
   Wang X, 2013, AM J TRANSL RES, V5, P555
   Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314
   Wilson I.B.H., 2015, ESSENTIALS GLYCOBIOL, P321
   Wilson N.O., 2016, PLOS NEGLECT TROP D, V10, P15
   Yang ZS, 2018, VACCINE, V36, P248, DOI 10.1016/j.vaccine.2017.11.048
   Yanming S, 2007, PARASITE IMMUNOL, V29, P319, DOI 10.1111/j.1365-3024.2007.00949.x
   Zhan B, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006772
   Zhao L., 2018, FASEB J
   Zottler EM, 2017, VET PARASITOL, V235, P75, DOI 10.1016/j.vetpar.2017.01.015
NR 89
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108935
DI 10.1016/j.vetpar.2019.108935
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700010
PM 31704657
DA 2020-05-12
ER

PT J
AU Singh, A
   Kumari, P
   Singh, SK
   Soman, SP
   Choudhury, S
   Srivastava, A
   Nigam, R
   Garg, SK
AF Singh, Alok
   Kumari, Priyambada
   Singh, Shanker K.
   Soman, Sandeep P.
   Choudhury, Soumen
   Srivastava, Ashish
   Nigam, Rajesh
   Garg, Satish K.
TI Pre- and post-therapy circulating immuno-stimulatory and
   immuno-suppressive cytokines in dogs with juvenile-onset generalized
   demodecosis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Amitraz; Demodex; Immunosuppression; Interleukin-10; IFN-gamma;
   TNF-alpha
ID BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; DEMODICOSIS; CANIS;
   IMMUNOSUPPRESSION; SKIN
AB Overproliferation of Demodex mites in dogs with compromised immunity attributed to the development of canine demodecosis. Whether clinical signs of canine demodecosis are triggered by genetically-mediated specific immunodeficiency in dogs or the Demodex mites induce lesions in hair follicles and result in compromised immunity is yet to be fully explored. To unravel the concealments of immunosuppression in canine demodecosis the present study was aimed to estimate the levels of circulating cytokines, pre- and post-therapy in nine dogs with juvenile-onset generalized demodecosis. At day 60 post-therapy of recommended amitraz rinse, significant (p <= 0.02) reduction in circulating IL-10 level was observed compared to its level before the start of the therapy (day 0). However, significant alterations in circulating levels of TNF-alpha and IFN-gamma were not observed in these dogs at day 60 post-therapy as compared to their day 0 levels. A strong positive correlation between circulating level of IL-10 and mites population was observed both on day 0 (r(2) = 0.656; p <= 0.005) and day 60 post-therapy (r(2) = 0.575; p <= 0.018). Therefore, our findings suggest that Demodex mites induce immunosuppression in dogs during clinical disease and mites burden seems to be responsible for the development of generalized demodecosis.
C1 [Singh, Alok; Singh, Shanker K.; Soman, Sandeep P.; Srivastava, Ashish] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Coll Vet Sci & Anim Husb, Dept Vet Med, Mathura 281001, UP, India.
   [Kumari, Priyambada; Nigam, Rajesh] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Coll Biotechnol, Mathura 281001, UP, India.
   [Choudhury, Soumen; Garg, Satish K.] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Coll Vet Sci & Anim Husb, Dept Vet Pharmacol & Toxicol, Mathura 281001, UP, India.
RP Singh, SK (reprint author), UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Coll Vet Sci & Anim Husb, Dept Vet Med, Mathura 281001, UP, India.
EM pshankervet@gmail.com
RI Singh, Shanker K/AAH-1258-2020
OI Singh, Shanker/0000-0002-0326-4226
FU Indian Council of Agricultural Research, New Delhi, IndiaIndian Council
   of Agricultural Research (ICAR)
FX This study was undertaken with the financial assistance from Indian
   Council of Agricultural Research, New Delhi, India under "Development
   Grant" to the University. Laboratory facilities in CIL provided by the
   Head, Department of Veterinary Pharmacology and Toxicology are
   thankfully acknowledged.
CR BARRIGA OO, 1992, VET IMMUNOL IMMUNOP, V32, P37, DOI 10.1016/0165-2427(92)90067-Z
   Caswell JL, 1997, VET PATHOL, V34, P279, DOI 10.1177/030098589703400403
   De Bosschere H, 2007, VET J, V174, P665, DOI 10.1016/j.tvjl.2006.10.015
   Felix AOC, 2013, VET PARASITOL, V193, P312, DOI 10.1016/j.vetpar.2012.11.012
   Ferrer L, 2014, VET DERMATOL, V25, P427, DOI 10.1111/vde.12136
   Forton FMN, 2012, J EUR ACAD DERMATOL, V26, P19, DOI 10.1111/j.1468-3083.2011.04310.x
   Gasparetto ND, 2018, VET PARASITOL, V257, P1, DOI 10.1016/j.vetpar.2018.05.003
   It V, 2010, TISSUE ANTIGENS, V76, P67, DOI 10.1111/j.1399-0039.2010.01463.x
   Kumari P, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12509
   Kumari P, 2017, PARASITOLOGY, V144, P1412, DOI 10.1017/S0031182017000774
   Mason IS, 1996, VET DERMATOL, V7, P119, DOI 10.1111/j.1365-3164.1996.tb00237.x
   Miller W.H., 2013, SMALL ANIMAL DERMATO, P304
   Paterson TE, 2009, VET DERMATOL, V20, P447, DOI 10.1111/j.1365-3164.2009.00803.x
   Ravera I, 2013, VET DERMATOL, V24, P168, DOI 10.1111/j.1365-3164.2012.01099.x
   Richter KR, 2018, VET PATHOL, V55, P53, DOI 10.1177/0300985817725388
   Scott D.W., 2001, SMALL ANIMAL DERMATO, P457
   Singh SK, 2010, PARASITOLOGY, V137, P1921, DOI 10.1017/S0031182010000879
   Singh SK, 2014, VET PARASITOL, V206, P253, DOI 10.1016/j.vetpar.2014.10.024
   Singh SK, 2014, VET PARASITOL, V203, P1, DOI 10.1016/j.vetpar.2014.03.008
   Singh SK, 2011, VET IMMUNOL IMMUNOP, V144, P487, DOI 10.1016/j.vetimm.2011.08.008
   Souza CP, 2018, VET DERMATOL, V29, P482, DOI 10.1111/vde.12681
   Tani K, 2002, J VET MED SCI, V64, P513, DOI 10.1292/jvms.64.513
NR 22
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108954
DI 10.1016/j.vetpar.2019.108954
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700015
PM 31634689
DA 2020-05-12
ER

PT J
AU Snak, A
   Serighelli, G
   Pilati, GV
   Kroetz, CC
   Consoni, W
   Cristani, J
   de Moura, AB
AF Snak, Alessandra
   Serighelli Junior, Gilberto
   Pilati, Giulia Von Tonnemann
   Kroetz, Carlos Czpak
   Consoni, Wagner
   Cristani, Jose
   de Moura, Anderson Barbosa
TI Does Neospora caninum cause reproductive problems in pigs?
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Gilts; Mummified; Neosporosis; Piglets
ID FLUORESCENT-ANTIBODY TEST; TOXOPLASMA-GONDII; SLAUGHTERED PIGS;
   DAIRY-CATTLE; SUS-SCROFA; INFECTION; DIAGNOSIS; PREVALENCE; SWINE;
   SEROPREVALENCE
AB Neospora caninum is known to cause reproductive disturbances in several animal species, such as cattle, sheep, and goats. However, research on the effects of N. caninum on reproduction in pigs is limited. The objective of this study was to verify the transplacental transmission of N. caninum in pigs during several gestational stages. Twelve healthy Toxoplasma gondii and N. caninum seronegative female pigs were selected and separated into four groups of three animals each. Group A was maintained as a control group. Groups B, C, and D were inoculated intravenously with 2.9 x 10(7) tachyzoites of the N. caninum strain Ncl, 30 days before conception and at 45 and 90 days of gestation, respectively. Blood samples were collected from females periodically through IFAT for IgG and IgM screening to confirm the infection. At birth, after blood samples were collected from the piglets, they were then euthanized for the collection of the brain, heart, lung, liver, and diaphragm, which were then subjected to PCR. All inoculated gilts seroconverted (IgG) from the seventh day after inoculation. Nine of the 12 females expelled 24 mummified fetuses at the time of delivery, two in group A (eight), two in group B (four), three in group C (nine), and two in group D (three). Of the 24 mummified fetuses, nine were positive for N. caninum (one (25%) fetus of group B, seven (77.8%) of group C, and one (33.3%) of group D). A total of 126 live piglets were born. When the organs of the piglets from the inoculated females were analyzed by PCR for N. caninum, 88 (93.61%) were positive. All gilts inoculated produced at least one positive piglet. This demonstrates that there is transplacental transmission of N. caninum in all phases of gestation, regardless of the time of infection.
C1 [Snak, Alessandra; Serighelli Junior, Gilberto; Pilati, Giulia Von Tonnemann; Kroetz, Carlos Czpak; Consoni, Wagner; Cristani, Jose; de Moura, Anderson Barbosa] Univ Estado Santa Catarina, Ctr Ciencias Agrovet, Blvd Luiz de Camoes 2090, BR-88520000 Lagos, SC, Brazil.
RP Snak, A (reprint author), Univ Estado Santa Catarina, Ctr Ciencias Agrovet, Blvd Luiz de Camoes 2090, BR-88520000 Lagos, SC, Brazil.
EM alessandra.snak@hotmail.com
OI Pilati, Giulia/0000-0001-9689-0279
FU Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina
   (FAPESC) [779/2017]
FX This work was supported by Fundacao de Amparo a Pesquisa e Inovacao do
   Estado de Santa Catarina (FAPESC) -Public call 01/2016 Granting
   Agreement 779/2017.
CR Amaral RLG, 2012, PESQUI VET BRASIL, V32, P963, DOI 10.1590/S0100-736X2012001000002
   Antonello Ana Maria, 2015, Ciênc. anim. bras., V16, P553, DOI 10.1590/1089-6891v16i428127
   Bartova E, 2011, PARASITOLOGY, V138, P1369, DOI 10.1017/S0031182011001041
   Basso W, 2015, PARASITOL INT, V64, P157, DOI 10.1016/j.parint.2014.11.017
   Bortoletto C., 2014, REV CIENT MED VET, V23, P1
   Buxton D, 1998, J COMP PATHOL, V118, P267, DOI 10.1016/S0021-9975(07)80003-X
   Camillo G, 2010, ARQ BRAS MED VET ZOO, V62, P1511, DOI 10.1590/S0102-09352010000600033
   Canton GJ, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-11
   Cavalcante G.T., 2010, THESIS
   Cedillo CJR, 2008, VET PARASITOL, V154, P151, DOI 10.1016/j.vetpar.2008.02.025
   Cerqueira-Cezar CK, 2016, VET PARASITOL, V226, P35, DOI 10.1016/j.vetpar.2016.06.023
   Costa RC, 2018, VET PARASITOL, V249, P70, DOI 10.1016/j.vetpar.2017.11.009
   de Azevedo SS, 2010, REV BRAS PARASITOL V, V19, P80, DOI 10.1590/S1984-29612010000200002
   Dubey JP, 1996, AM J VET RES, V57, P329
   Feitosa TF, 2014, VET PARASITOL, V202, P305, DOI 10.1016/j.vetpar.2014.03.015
   Helmick B, 2002, RES VET SCI, V73, P187, DOI 10.1016/S0034-5288(02)00093-0
   Ho MSY, 1997, J PARASITOL, V83, P508, DOI 10.2307/3284418
   Jensen L, 1998, APMIS, V106, P475, DOI 10.1111/j.1699-0463.1998.tb01374.x
   Kamga-Waladjo AR, 2009, ASIAN J ANIM VET ADV, V4, P263, DOI 10.3923/ajava.2009.263.266
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lopes MG, 2018, J ZOO WILDLIFE MED, V49, P656, DOI 10.1638/2017-0084.1
   McAllister MM, 2016, VET CLIN N AM-FOOD A, V32, P443, DOI 10.1016/j.cvfa.2016.01.012
   Muller N, 1996, J CLIN MICROBIOL, V34, P2850
   Ooi HK, 2000, VET PARASITOL, V90, P47, DOI 10.1016/S0304-4017(00)00211-9
   Padilha J. B., 2017, Nucleus Animalium, V9, P7
   PARE J, 1995, J VET DIAGN INVEST, V7, P273, DOI 10.1177/104063879500700222
   Pescador CA, 2010, PESQUISA VET BRASIL, V30, P1058, DOI 10.1590/S0100-736X2010001200010
   Razmi Gh, 2017, Arch Razi Inst, V72, P265, DOI 10.22092/ari.2017.113304
   Sharma R. N., 2015, Open Journal of Veterinary Medicine, V5, P138, DOI 10.4236/ojvm.2015.56019
   Sheather A. L., 1923, Journal of Comparative Pathology and Therapeutics, V36, P266
   SILVA MRH, 2017, THESIS
   Sinkora M, 2016, DEV COMP IMMUNOL, V58, P1, DOI 10.1016/j.dci.2015.12.003
   Sinnott FA, 2017, VET PARASITOL, V239, P19, DOI 10.1016/j.vetpar.2017.04.008
   Snak A, 2018, REV BRAS PARASITOL V, V27, P52, DOI [10.1590/S1984-29612018001, 10.1590/s1984-29612018001]
   Soares Herbert Sousa, 2016, Brazilian Journal of Veterinary Research and Animal Science, V53, P112, DOI 10.11606/issn.1678-4456.v53i1p112-116
   Sobestiansky J., 2007, DOENCAS SUINOS
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108934
DI 10.1016/j.vetpar.2019.108934
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700004
PM 31600613
DA 2020-05-12
ER

PT J
AU Stehr, M
   Grashorn, M
   Dannenberger, D
   Tuchscherer, A
   Gauly, M
   Metges, CC
   Das, G
AF Stehr, Manuel
   Grashorn, Michael
   Dannenberger, Dirk
   Tuchscherer, Armin
   Gauly, Matthias
   Metges, Cornelia C.
   Das, Gurbuz
TI Resistance and tolerance to mixed nematode infections in relation to
   performance level in laying hens
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Egg production; Multi-species infection; Dual purpose chicken;
   Susceptibility; Egg quality; Fatty acid profile
ID ASCARIDIA-GALLI INFECTION; GASTROINTESTINAL HELMINTH INFECTIONS;
   FREE-RANGE; EGG-PRODUCTION; FATTY-ACID; HETERAKIS-GALLINARUM;
   IMMUNE-RESPONSE; CHICKENS; PREVALENCE; QUALITY
AB Modem chickens have been genetically developed to perform high under optimal conditions. We hypothesized that high-performance is associated with a higher sensitivity to environmental challenges in laying hens. By using nematode infections as an environmental stressor, we assessed performance-level associated host responses in a high (i.e. Lohmann Brown Plus, LB) and in a lower performing, a so-called dual-purpose chicken genotype (i.e. Lohmann Dual, LD). The hens were infected with 1000 eggs of Ascaridia galli and Heterakis gallinarum at 24 weeks of age. Hen performance parameters, humoral immune responses in plasma and egg yolks and worm burdens were assessed at several occasions over a period of 18 weeks post infection (wpi).
   While infections had no significant effect on feed intake (P = 0.130) and body weight in both genotypes (P = 0.392), feed conversion efficiency was negatively affected by infections (P = 0.017). Infections reduced both laying rate and egg weight and thereby per capita egg mass in both genotypes (P < 0.05). While laying rate in infected LB hens decreased significantly (P < 0.05) in the early infection period (i.e. by 3 wpi), the decrease in LD hens appeared much later (i.e. by 14 wpi). Worm burdens resulting from the experimental infection were not different between the genotypes for both worm species (P > 0.05), whereas LB hens were more susceptible (P < 0.05) to re-infections than LD hens. Changes in humoral immune responses (i.e. ascaridspecific IgY antibodies in plasma and egg yolks) of the two genotypes over time reflected closely the corresponding changes in larval counts of the hens, descending from both experimental and subsequent natural infections in both genotypes. Infections caused a shift in egg size classes, leading to smaller frequency of larger eggs in both genotypes. Infections reduced egg weight (P = 0.018) and led to a reduced fat content in the egg yolks (P = 0.045). The proportion of poly-unsaturated fatty acids (PUFA), especially n-6-PUFA, was also lower in egg yolks of the infected hens (P = 0.032).
   We conclude that tolerance to nematode infections in laying hens is dependent on host-performance level. The impairment in host tolerance was both genotype and time dependent, likely due to differences in genetic programming for production peak and persistency of the two genotypes. The two genotypes exhibited similar levels of resistance after a fully controlled experimental infection, but the high performing hens were more susceptible to subsequent natural infections. Infections negatively affected economically important egg-quality traits, including egg weight, fat content and fatty acid profiles in egg yolks.
C1 [Stehr, Manuel; Metges, Cornelia C.; Das, Gurbuz] Leibniz Inst Farm Anim Biol, Inst Nutr Physiol Oskar Kellner, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.
   [Grashorn, Michael] Univ Hohenheim, Inst Anim Sci, Emil Wolff Str 10, D-70593 Stuttgart, Germany.
   [Dannenberger, Dirk] Leibniz Inst Farm Anim Biol, Inst Muscle Biol & Growth, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.
   [Tuchscherer, Armin] Leibniz Inst Farm Anim Biol, Inst Genet & Biometry, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.
   [Gauly, Matthias] Free Univ Bozen Bolzano, Fac Sci & Technol, Univ Pl 5, I-39100 Bolzano, Italy.
RP Das, G (reprint author), Leibniz Inst Farm Anim Biol, Inst Nutr Physiol Oskar Kellner, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.
EM gdas@fbn-dummerstorf.de
RI Das, Gurbuz/A-8403-2011
OI Das, Gurbuz/0000-0001-6690-0050
FU German Government's Special Purpose Fund at Landwirtschaftliche
   Rentenbank [28RZ3-72.051]
FX This work is an outcome of a sub-project of the Integhof Consortium
   (Germany) supported by the funds from the German Government's Special
   Purpose Fund held at Landwirtschaftliche Rentenbank (Grant no.
   28RZ3-72.051). We are deeply grateful to B. Mielenz for her invaluable
   assistance throughout the animal experiment and following laboratory
   analysis of the samples. We also thank Dr. S. Gors, K. Karpati, U.
   Ludtke, E. Wunsche, K. Grot, K. Hass and R. Gaeth for their support with
   laboratory analyses, sample collection and animal feeding as well as the
   other valuable qualified staff of the Leibniz Institute for Farm Animal
   Biology (FBN, Germany) for assisting with animal care and performing
   necropsies. We further thank Prof. Dr. S. Rautenschlein (Clinic for
   Poultry, University of Veterinary Medicine Hannover, Foundation,
   Germany) and Dr. C. Surie (Farm for Education and Research Ruthe,
   University of Veterinary Medicine Hannover, Foundation, Germany) and
   Lohmann Tierzucht GmbH (Cuxhaven, Germany) for the animal supply.
CR Anderson KE, 2011, POULTRY SCI, V90, P1600, DOI 10.3382/ps.2010-01289
   Bain MM, 2016, BRIT POULTRY SCI, V57, P330, DOI 10.1080/00071668.2016.1161727
   Barash G., 2019, PLOS ONE, V14
   Bruijnis MRN, 2015, J AGR ENVIRON ETHIC, V28, P939, DOI 10.1007/s10806-015-9566-7
   Butler MW, 2013, J EXP BIOL, V216, P2632, DOI 10.1242/jeb.082982
   Cherian G, 2015, J ANIM SCI BIOTECHNO, V6, DOI 10.1186/s40104-015-0029-9
   Colditz IG, 2008, PARASITE IMMUNOL, V30, P63, DOI 10.1111/j.1365-3024.2007.00964.x
   Danicke S, 2009, BRIT POULTRY SCI, V50, P512, DOI 10.1080/00071660903124530
   Dahl C, 2002, VET MICROBIOL, V86, P313, DOI 10.1016/S0378-1135(02)00015-9
   Damme K, 2003, WORLD POULTRY SCI J, V59, P50
   Das G, 2012, PARASITOLOGY, V139, P110, DOI 10.1017/S0031182011001636
   Das G, 2014, VET PARASITOL, V205, P606, DOI 10.1016/j.vetpar.2014.08.008
   Das G, 2011, VET PARASITOL, V178, P121, DOI 10.1016/j.vetpar.2010.12.027
   Das G, 2010, VET PARASITOL, V170, P238, DOI 10.1016/j.vetpar.2010.02.026
   Das G, 2018, VET PARASITOL, V255, P10, DOI 10.1016/j.vetpar.2018.03.021
   Das G, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2121-9
   Ferdushy T, 2012, PARASITOL RES, V111, P2273, DOI 10.1007/s00436-012-3079-3
   Gauly M, 2007, VET PARASITOL, V146, P271, DOI 10.1016/j.vetpar.2007.03.005
   Gauly M, 2002, VET PARASITOL, V103, P99, DOI 10.1016/S0304-4017(01)00587-8
   Giersberg MF, 2017, ANIMALS, V7, DOI 10.3390/ani7120097
   Golden JB, 2012, J APPL POULTRY RES, V21, P95, DOI 10.3382/japr.2011-00370
   Grafl B, 2017, BRIT POULTRY SCI, V58, P209, DOI 10.1080/00071668.2017.1280723
   Grashorn M, 2016, WOODHEAD PUBL FOOD S, V295, P283, DOI 10.1016/B978-0-08-100371-8.00014-2
   Grashorn M.A., 2018, GEFLUGELJAHRBUCH 201
   Habig C, 2013, BRIT POULTRY SCI, V54, P413, DOI 10.1080/00071668.2013.792405
   Herdmann A, 2010, J AGR FOOD CHEM, V58, P8314, DOI 10.1021/jf101145y
   Hinrichsen LK, 2016, VET REC, V179, DOI 10.1136/vr.103614
   Julian RJ, 2005, VET J, V169, P350, DOI 10.1016/j.tvjl.2004.04.015
   Kalbe C, 2019, J ANIM PHYSIOL AN N, V103, P574, DOI 10.1111/jpn.13037
   Katakam K.K., 2014, PARASITOLOGY, V14, P1
   Katakam KK, 2010, AVIAN PATHOL, V39, P81, DOI 10.1080/03079451003599284
   Kaufmann F., 2013, 64 EAAP ANN M EUR FE, P178
   Kaufmann F, 2011, LIVEST SCI, V141, P182, DOI 10.1016/j.livsci.2011.05.015
   Kaufmann F, 2011, VET PARASITOL, V176, P250, DOI 10.1016/j.vetpar.2010.11.007
   Kaufmann J., 1996, PARASITIC INFECT DOM, P423
   Krautwald-Junghanns ME, 2018, POULTRY SCI, V97, P749, DOI 10.3382/ps/pex389
   Kringel H, 2002, ACTA VET SCAND, V43, P185
   Laudadio V, 2014, POULTRY SCI, V93, P1868, DOI 10.3382/ps.2013-03831
   Lawrence CE, 2003, PARASITE IMMUNOL, V25, P271, DOI 10.1046/j.1365-3024.2003.00630.x
   Leenstra F, 2011, ANIM WELFARE, V20, P37
   Leeson S, 2007, J APPL POULTRY RES, V16, P121, DOI 10.1093/japr/16.1.121
   Lensing M, 2012, POULTRY SCI, V91, P1590, DOI 10.3382/ps.2011-01508
   Lesic T., 2017, Croatian Journal of Food Science and Technology, V9, P158, DOI [10.17508/CJFST.2017.9.2.12, 10.17508/cjfst.2017.9.2.12]
   Liebhart D, 2013, AVIAN PATHOL, V42, P79, DOI 10.1080/03079457.2012.760841
   LTZ, 2015, LOHMANN INFORM, V49
   Lucas A, 2014, J EXP BIOL, V217, P1253, DOI 10.1242/jeb.098004
   Luna-Olivares LA, 2015, PARASITOL RES, V114, P2507, DOI 10.1007/s00436-015-4450-y
   Malchow J., 2019, POULTRY SCI, V98, P129
   Marcos-Atxutegi C, 2009, VET PARASITOL, V161, P69, DOI 10.1016/j.vetpar.2008.12.011
   Maurelli MP, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-356
   MCDOUGALD LR, 1990, AVIAN DIS, V34, P485, DOI 10.2307/1591441
   Mueller S, 2018, POULTRY SCI, V97, P3325, DOI 10.3382/ps/pey172
   Mullens BA, 2009, VET PARASITOL, V160, P116, DOI 10.1016/j.vetpar.2008.10.076
   Oliveira DD, 2010, POULTRY SCI, V89, P2484, DOI 10.3382/ps.2009-00522
   Permin A, 1998, BRIT POULTRY SCI, V39, P441, DOI 10.1080/00071669889033
   Permin A, 2001, VET PARASITOL, V102, P101, DOI 10.1016/S0304-4017(01)00525-8
   Permin A, 1999, BRIT POULTRY SCI, V40, P439, DOI 10.1080/00071669987179
   QUINN JP, 1956, POULTRY SCI, V35, P3, DOI 10.3382/ps.0350003
   Rahimian S, 2016, VET PARASITOL, V215, P29, DOI 10.1016/j.vetpar.2015.10.026
   Ramadan H.H., 1991, J KAU SCI, V4, P87
   Rauw Wendy M., 2012, Frontiers in Genetics, V3, P267, DOI 10.3389/fgene.2012.00267
   Rauw WM, 1998, LIVEST PROD SCI, V56, P15, DOI 10.1016/S0301-6226(98)00147-X
   Rodenburg TB, 2008, ANIM WELFARE, V17, P363
   Schwarz A, 2011, DEV COMP IMMUNOL, V35, P774, DOI 10.1016/j.dci.2011.02.012
   Sepp T, 2011, EXP PARASITOL, V127, P651, DOI 10.1016/j.exppara.2010.12.004
   Sharma N, 2018, POULTRY SCI, V97, P494, DOI 10.3382/ps/pex347
   Sharma N, 2018, VET PARASITOL, V256, P9, DOI 10.1016/j.vetpar.2018.04.009
   Shini A, 2019, AVIAN PATHOL, V48, P25, DOI 10.1080/03079457.2018.1538550
   Siekmann L., 2018, EUROP POULT SCI, V82, P12
   Silva J.R., 2018, WOUND HEALING OMEGA, DOI [10.1155/2018/2503950, DOI 10.1155/2018/2503950]
   Simons P., 2017, PRACTICAL GUIDE IMPR
   Speake BK, 1998, PROG LIPID RES, V37, P1, DOI 10.1016/S0163-7827(97)00012-X
   Stehr M, 2019, INT J PARASITOL, V49, P579, DOI 10.1016/j.ijpara.2019.03.001
   Stehr M, 2018, INT J PARASITOL, V48, P1003, DOI 10.1016/j.ijpara.2018.05.014
   Tarbiat B, 2015, VET PARASITOL, V209, P101, DOI 10.1016/j.vetpar.2015.01.024
   Thapa S, 2017, PARASITOLOGY, V144, P1243, DOI 10.1017/S0031182017000555
   Thapa S, 2015, VET PARASITOL, V214, P118, DOI 10.1016/j.vetpar.2015.10.009
   Urban J., 2018, EUROP POULT SCI, V82
   VATNE RD, 1965, POULTRY SCI, V44, P1079, DOI 10.3382/ps.0441079
   Vezzoli G, 2016, POULTRY SCI, V95, P1042, DOI 10.3382/ps/pew027
   Wongrak K, 2015, BRIT POULTRY SCI, V56, P15, DOI 10.1080/00071668.2014.981147
   Wongrak K, 2014, BERL MUNCH TIERARZTL, V127, P314, DOI 10.2376/0005-9366-127-314
   Wuthijaree K, 2017, BRIT POULTRY SCI, V58, P649, DOI 10.1080/00071668.2017.1379049
   Yazwinski TA, 2003, VET PARASITOL, V116, P159, DOI 10.1016/S0304-4017(03)00264-4
   Zuidhof MJ, 2014, POULTRY SCI, V93, P2970, DOI 10.3382/ps.2014-04291
NR 85
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108925
DI 10.1016/j.vetpar.2019.108925
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700003
PM 31605937
DA 2020-05-12
ER

PT J
AU Vazquez, AA
   de Vargas, M
   Alba, A
   Sanchez, J
   Alda, P
   Sabourin, E
   Vittecoq, M
   Alarcon-Elbal, PM
   Pointier, JP
   Hurtrez-Bousses, S
AF Vazquez, Antonio A.
   de Vargas, Mercedes
   Alba, Annia
   Sanchez, Jorge
   Alda, Pilar
   Sabourin, Emeline
   Vittecoq, Marion
   Alarcon-Elbal, Pedro M.
   Pointier, Jean-Pierre
   Hurtrez-Bousses, Sylvie
TI Reviewing Fasciola hepatica transmission in the West Indies and novel
   perceptions from experimental infections of sympatric vs. allopatric
   snail/fluke combinations
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Fasciola hepatica; Lymnaeidae; Caribbean; Parasite transmission;
   Experimental infections
ID PSEUDOSUCCINEA-COLUMELLA; INTERMEDIATE HOSTS; GALBA-TRUNCATULA;
   BIOGEOGRAPHY; POPULATION; LYMNAEIDAE; CUBENSIS; DIGENEA; IDENTIFICATION;
   GASTROPODA
AB Fasciolosis is an important food-borne parasitic disease affecting over two million people worldwide with economic losses related to cattle production of up to US$ 3 billion annually. Despite the long known presence of Fasciola hepatica in the Caribbean islands its transmission is not well known. This study reviews historical and recent data on fasciolosis in the West Indies, revealing for the first time the outcomes of sympatric and allopatric fluke/snail interactions in the area by exploring the susceptibility of four lymnaeid species after exposure to F. hepatica isolates from Cuba, the Dominican Republic and France. Overall, Galba cubensis showed a mean prevalence of 71.8% and appears to be the most suitable intermediate host species irrespective of the isolate used. Sympatric combinations (snail and parasite from the same country) were generally more compatible (higher susceptibility, parasite intensity and snail survival post-exposure) and only the allopatric interaction of French G. truncatula/Cuban F. hepatica attained 100% prevalence and mean intensity over 33 rediae/snail. However, certain Dominican populations of Pseudosuccinea columella showed high parasite intensities ( > 30 rediae/snail) when infected with Cuban flukes, highlighting the potential risks of biological introductions. Overall, high compatibility in most sympatric combinations compared to low or moderate compatibility in allopatric ones, suggests the existence of local adaptation from a long sustained interaction that has led to high rates of transmission. Interestingly, attempts to infect G. schirazensis with sympatric and allopatric flukes failed and coupled with the lowest survival rates which supposes a low risk of fasciolosis transmission in areas where this is the only snail species. Although there are significant gaps in the actual status of fasciolosis transmission from several islands in the West Indies these results show a permanent risk. We conclude that fasciolosis transmission is high in areas where the local snail, G. cubensis, occurs, and will be even higher in the presence of the invasive P. columella.
C1 [Vazquez, Antonio A.; Alda, Pilar; Sabourin, Emeline; Vittecoq, Marion; Hurtrez-Bousses, Sylvie] Univ Montpellier, MIVEGEC, CNRS, IRD, Montpellier, France.
   [Vazquez, Antonio A.; Alba, Annia; Sanchez, Jorge] Inst Trop Med Pedro Kouri, Lab Malacol, Havana, Cuba.
   [de Vargas, Mercedes] Inst Tecnol Santo Domingo, Santo Domingo, Dominican Rep.
   [Alda, Pilar] Univ Nacl Sur, Dept Biol Bioquim & Farm, Lab Zool Invertebrados 1, San Juan 670,B80001CN, Bahia Blanca, Buenos Aires, Argentina.
   [Alda, Pilar] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Sabourin, Emeline; Vittecoq, Marion] Inst Rech Tour Valat, Arles, France.
   [Alarcon-Elbal, Pedro M.] Univ Iberoamer UNIBE, Inst Med Trop & Salud Global IMTSAG, Santo Domingo, Dominican Rep.
   [Pointier, Jean-Pierre] Univ Perpignan, CRIOBE, PSL Res Univ, USR 3278,CNRS,EPHE, Perpignan, France.
   [Hurtrez-Bousses, Sylvie] Univ Montpellier, Fac Sci, Dept Biol Ecol, Montpellier, France.
RP Vazquez, AA (reprint author), Univ Montpellier, MIVEGEC, CNRS, IRD, Montpellier, France.
EM applesnail@hotmail.fr
OI Vazquez, Antonio A./0000-0002-0894-1708
FU Institute of Tropical Medicine "Pedro Kouri" (IPKMINSAP, Cuba);
   FONDOCYT-MESCyT (Dominican Republic); Ecos-Sud program [A16B02]; Labex
   CeMeb; Muse (project REPAS) [170544IA, ANR-IDEX-0006]; Tour du Valat;
   IRD; CNRSCentre National de la Recherche Scientifique (CNRS); University
   of Montpellier
FX We would like to thanks Iannis Hurtrez, Mathieu Baudoin and Thomas
   Gandou for facilitating the transport of samples for experimental
   infection and molecular identification. We also thank all the students
   of INTEC in the Dominican Republic, which helped us in the field. We are
   in debt to veterinary authorities and technical personnel from abattoirs
   in Cuba (Candelaria), Dominican Republic (Dajabon) and France (Tarascon)
   for their help in obtaining fluke samples. We are most thankful to the
   anonymous reviewers for their valuable suggestions and the editor for
   all the comments that greatly improved the final version of the
   manuscript. We also thank Dr. Suzanne Mills for smoothing the English
   writing. These studies have been partially supported by the Institute of
   Tropical Medicine "Pedro Kouri" (IPKMINSAP, Cuba), FONDOCYT-MESCyT
   (Dominican Republic), Ecos-Sud program A16B02, Labex CeMeb, Muse
   (project REPAS: grant n 170544IA, n ANR-IDEX-0006), Tour du Valat, IRD,
   CNRS and University of Montpellier.
CR Abdel-Hamid AHZ, 2006, MEM I OSWALDO CRUZ, V101, P863, DOI 10.1590/S0074-02762006000800007
   Agnamey P, 2012, J Parasitol Res, V2012, P751951, DOI 10.1155/2012/751951
   Aguayo C., 1938, SISTEMATICA MEM SO 2, V12, P253
   Alba A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50894-7
   Alba A, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3155-3
   Alba A, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1303-1
   Alda P, 2018, VET PARASITOL, V251, P101, DOI 10.1016/j.vetpar.2018.01.006
   Andrews SJ, 1999, FASCIOLOSIS, P1
   BARNISH G, 1980, BRIT VET J, V136, P299
   BENDEZU P, 1988, J AGR U PUERTO RICO, V72, P405
   BENDEZU P, 1982, J PARASITOL, V68, P297, DOI 10.2307/3281190
   Bundy D. A. P., 1984, Boletin de la Oficina Sanitaria Panamericana, V96, P1
   Caron Y, 2008, PARASITOL RES, V103, P735, DOI 10.1007/s00436-008-1086-1
   Caron Y, 2017, PARASITE, V24, DOI 10.1051/parasite/2017026
   Chen M. G., 1990, Tropical Diseases Bulletin, V87, pR1
   CLENCH W. J., 1963, BULL MUS COMP ZOOL HARVARD, V128, P393
   Correa AC, 2017, INFECT GENET EVOL, V55, P186, DOI 10.1016/j.meegid.2017.09.012
   Correa AC, 2011, INFECT GENET EVOL, V11, P1978, DOI 10.1016/j.meegid.2011.09.003
   Correa AC, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-381
   Cowie RH, 2006, J BIOGEOGR, V33, P193, DOI 10.1111/j.1365-2699.2005.01383.x
   de Kock KN, 2003, J S AFR VET ASSOC, V74, P117
   Dobsinsky O., 1969, HELMINTHOLOGIA, V2, P167
   Bargues MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024567
   Dreyfuss G, 2015, J HELMINTHOL, V89, P720, DOI 10.1017/S0022149X14000509
   Estoup A., 1996, MARQUEURS MICROSATEL
   FRAME AD, 1978, J PARASITOL, V64, P136, DOI 10.2307/3279624
   GENTILINI M., 1964, BULL SOC PATHOL EXOTIQUE, V57, P299
   GOMEZ JD, 1986, NAUTILUS, V100, P130
   Gretillat S., 1967, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V20, P279
   GRETILLAT S, 1966, CR ACAD SCI D NAT, V262, P2736
   Gutierrez A, 2003, EXP PARASITOL, V105, P211, DOI 10.1016/j.exppara.2003.12.006
   Gutierrez A, 2011, J HELMINTHOL, V85, P109, DOI 10.1017/S0022149X10000350
   Gutierrez A, 2002, PARASITOL RES, V88, P535, DOI 10.1007/s00436-002-0625-4
   Harry H. W., 1964, Annual Report American Malacological Union, V31, P4
   HUBENDICK BENGT, 1951, K SVENSKA VETENSKAPSAKAD HANDL, V3, P1
   IBRAHIM MS, 1987, MED VET ENTOMOL, V1, P329, DOI 10.1111/j.1365-2915.1987.tb00363.x
   JabbourZahab R, 1997, ACTA TROP, V64, P191, DOI 10.1016/S0001-706X(96)00631-6
   Jones RA, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1271-x
   Khan MK, 2013, PARASITOL RES, V112, P2421, DOI 10.1007/s00436-013-3464-6
   Lotfy WM, 2008, AM J TROP MED HYG, V79, P248, DOI 10.4269/ajtmh.2008.79.248
   Lounnas M, 2017, MOL ECOL, V26, P887, DOI 10.1111/mec.13984
   Malek E., 1980, SNAIL TRANSMITTED PA
   Mas-Coma S, 2018, PARASITOLOGY, V145, P1665, DOI [10.1017/S0031182018000914, 10.1017/s0031182018000914]
   Mas-Coma S, 2009, ADV PARASIT, V69, P41, DOI 10.1016/S0065-308X(09)69002-3
   Meunier C, 2001, MOL ECOL, V10, P1333, DOI 10.1046/j.1365-294X.2001.01284.x
   Pointier J.-P., 2008, GUIDE FRESHWATER MOL
   Pointier J.P., 1974, B MUSEUM NATL HIST N, V3, P905
   Reiczigel J, 2019, TRENDS PARASITOL, V35, P277, DOI 10.1016/j.pt.2019.01.003
   Robart G., 1977, REV AGR, V2, P20
   Rojas L, 2010, TRENDS PARASITOL, V26, P26, DOI 10.1016/j.pt.2009.10.005
   Rondelaud D, 2006, BIOL CONTROL, V39, P290, DOI 10.1016/j.biocontrol.2006.07.015
   Rondelaud D, 2013, PARASITE, V20, DOI 10.1051/parasite/2013034
   Sanchez Ricardo, 1995, Revista Cubana de Medicina Tropical, V47, P71
   Sorensen RE, 2001, PARASITOLOGY, V123, pS3, DOI 10.1017/S0031182001007843
   Theron A, 2005, J HELMINTHOL, V79, P187, DOI 10.1079/JOH2005299
   Toet H, 2014, INT J PARASITOL, V44, P915, DOI 10.1016/j.ijpara.2014.07.011
   Vazquez A., 2018, CAB REV, V13, P62, DOI [10.1079/PAVSNNR201813062, DOI 10.1079/PAVSNNR201813062]
   Vazquez AA, 2016, J HELMINTHOL, V90, P719, DOI 10.1017/S0022149X15001029
   Vazquez AA, 2014, J HELMINTHOL, V88, P434, DOI 10.1017/S0022149X13000382
   Vazquez AA, 2015, PARASITOL RES, V114, P4205, DOI 10.1007/s00436-015-4653-2
   Wesselingh FP, 1999, GEOL MIJNBOUW-N J G, V78, P165, DOI 10.1023/A:1003766516646
NR 61
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108955
DI 10.1016/j.vetpar.2019.108955
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700011
PM 31648107
DA 2020-05-12
ER

PT J
AU Wei, ZK
   Zhao, YC
   Zhang, N
   Han, Z
   Liu, X
   Jiang, AM
   Zhang, Y
   Wang, CQ
   Gong, PT
   Li, JH
   Zhang, XC
   Yang, ZT
AF Wei, Zhengkai
   Zhao, Yingchi
   Zhang, Nan
   Han, Zhen
   Liu, Xiao
   Jiang, Aimin
   Zhang, Yong
   Wang, Chaoqun
   Gong, Pengtao
   Li, Jianhua
   Zhang, Xichen
   Yang, Zhengtao
TI Eimeria tenella induces the release of chicken heterophil extracellular
   traps
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Eimeria tenella; Chicken; Heterophil; Cells; Extracellular traps
ID NADPH OXIDASE
AB Avian coccidiosis makes a great threat and economic loss to the poultry industry, and fully understanding the innate immune response of chicken against E. tenella infection will play a significant role in avian coccidiosis prevention and treatment. Extracellular traps have been reported as a novel defense mechanism of host against pathogens infection. However, the interaction between chicken heterophil extracellular traps and E. tenella has remained not well known. Thus, this study aims to investigate the effects of E. tenella on chicken heterophil extracellular traps (ETs), and try to clarify the regulatory mechanisms in this process. E. tenella-triggered chicken heterophil ETs structures were analyzed by using scanning electron microscopy (SEM) and scanning confocal microscope. Inhibitors and Pico Green (R) were used to quantify E. tenella - triggered chicken heterophil ETs release. The results showed that E. tenella sporozoites significantly induced chicken heterophil ETs-like structures release, and histone and elastin co-existed with DNA in these structures of chicken heterophil ETs. Furthermore, it was also demonstrated that NADPH, p38 or Racl signaling pathways participated in E. tenella sporozoitesinduced chicken heterophil ETs release, but more key molecules or signaling pathways involved in this process still needed to be further investigated. Taken together, this study reports that E. tenella sporozoites could induce chicken heterophil ETs formation via NADPH, p38 and Racl signaling pathways, which further suggests the critical role of heterophil ETs in the process of chicken against E. tenella infection.
C1 [Wei, Zhengkai; Yang, Zhengtao] Foshan Univ, Coll Life Sci & Engn, Foshan 528225, Guangdong, Peoples R China.
   [Wei, Zhengkai; Zhao, Yingchi; Zhang, Nan; Han, Zhen; Liu, Xiao; Jiang, Aimin; Zhang, Yong; Wang, Chaoqun; Gong, Pengtao; Li, Jianhua; Zhang, Xichen; Yang, Zhengtao] Jilin Univ, Coll Vet Med, Key Lab, Minist Educ, Changchun 130062, Jilin, Peoples R China.
RP Yang, ZT (reprint author), Foshan Univ, Coll Life Sci & Engn, Foshan 528225, Guangdong, Peoples R China.; Zhang, XC; Yang, ZT (reprint author), Jilin Univ, Coll Vet Med, Key Lab, Minist Educ, Changchun 130062, Jilin, Peoples R China.
EM xczhang@jlu.edu.cn; yangzhengtao01@sina.com
FU Jilin Key Scientific and Technological Development Program
   [20190301089NY, 20170204036NY]
FX This work was funded by the grants from Jilin Key Scientific and
   Technological Development Program (Nos. 20190301089NY and
   20170204036NY).
CR Abdallah DSA, 2012, INFECT IMMUN, V80, P768, DOI 10.1128/IAI.05730-11
   Barr FD, 2018, MUCOSAL IMMUNOL, V11, P1420, DOI 10.1038/s41385-018-0045-0
   Blake DP, 2014, TRENDS PARASITOL, V30, P12, DOI 10.1016/j.pt.2013.10.003
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Bussiere FI, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2622-1
   Chuammitri P, 2009, VET IMMUNOL IMMUNOP, V129, P126, DOI 10.1016/j.vetimm.2008.12.013
   del Cacho E, 2016, VET PARASITOL, V224, P1, DOI 10.1016/j.vetpar.2016.04.043
   del Cacho E, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-25
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Guo AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064236
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P209, DOI 10.1016/j.vetimm.2006.07.007
   Jin XM, 2016, MOL VIS, V22, P944
   Laurent F, 2001, INFECT IMMUN, V69, P2527, DOI 10.1128/IAI.69.4.2527-2534.2001
   McDonald V, 2009, PARASITOLOGY, V136, P1477, DOI 10.1017/S0031182009006349
   Munoz-Caro T, 2015, DEV COMP IMMUNOL, V52, P245, DOI 10.1016/j.dci.2015.05.007
   Munoz-Caro T, 2015, VET RES, V46, DOI 10.1186/s13567-015-0155-6
   Perez D, 2016, VET PARASITOL, V227, P143, DOI 10.1016/j.vetpar.2016.07.028
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   Silva LMR, 2014, PARASITOL RES, V113, P2797, DOI 10.1007/s00436-014-3939-0
   Suo X, 2006, VET PARASITOL, V142, P63, DOI 10.1016/j.vetpar.2006.06.020
   Urban C.F., 2018, SEMIN CELL DEV BIOL
   Villagra-Blanco R, 2017, INT J PARASITOL-PAR, V6, P287, DOI 10.1016/j.ijppaw.2017.09.002
   Wei ZK, 2018, VET PARASITOL, V258, P1, DOI 10.1016/j.vetpar.2018.06.002
   Wei ZK, 2018, CHEMOSPHERE, V196, P297, DOI 10.1016/j.chemosphere.2017.12.175
   Wei ZK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00436
   Witcombe DM, 2014, PARASITOLOGY, V141, P1379, DOI 10.1017/S0031182014000195
   Yang ZT, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02016
NR 27
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD NOV
PY 2019
VL 275
AR UNSP 108931
DI 10.1016/j.vetpar.2019.108931
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA JU3YX
UT WOS:000501615700006
PM 31605936
DA 2020-05-12
ER

PT J
AU Zhou, H
   Bai, HX
   Chan, LL
   Zhang, PJ
   Karakousis, G
   Huang, R
   Xiao, B
   Yang, L
AF Zhou, Hao
   Bai, Harrison X.
   Chan, Lilian
   Zhang, Paul J.
   Karakousis, Giorgos
   Huang, Raymond
   Xiao, Bo
   Yang, Li
TI Survival Benefit of Adjuvant Radiotherapy in Elderly Patients with WHO
   Grade III Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Overall survival; Radiotherapy; WHO grade III meningiomas
ID ANAPLASTIC MENINGIOMAS; MALIGNANT MENINGIOMAS; CONTROVERSIES; OUTCOMES;
   SURGERY
AB BACKGROUND: The benefit of adjuvant radiotherapy (RT) is uncertain in elderly patients diagnosed with World Health Organization (WHO) grade III meningiomas.
   METHODS: The US National Cancer Database was used to identify elderly patients (aged over 60) with histologically confirmed WHO grade III meningiomas who underwent surgery with or without adjuvant external beam RT. Overall survival (OS) was evaluated by Kaplan-Meier analysis, multivariable Cox proportional hazard models, and propensity score-matched analysis.
   RESULTS: Among the 254 patients who met inclusion criteria, 151 (58.4%) underwent surgery followed by RT and 103 (41.6%) surgery without RT. The 5-year relative survival rate was 57.8% (95% confidence interval [CI]. 38.7%-85.4%) in the adjuvant RT group and 38.1% (95% CI, 21.9%-55.9%) in the group without RT when compared with age- and gender-matched US population. Adjuvant RT was associated with longer OS on both univariate (P = 0.011) and multivariable analyses (adjusted hazard ratio [AHR], 0.663; 95% CI, 0.449-0.978; P = 0.038). However, adjuvant RT did not significantly improve OS in a propensity score-matched analysis (P = 0.271) after matching the 2 cohorts on age, race, comorbidity, extent of resection, and tumor size. In patients who underwent subtotal resection or biopsy (n = 106), adjuvant RT significantly benefited OS on univariate analysis (P = 0.023), but did not show statistically significant benefit on multivariate analysis (AHR, 0.594; 95% CI, 0.337-1.046; P = 0.071). Adjuvant RT was not associated with improved OS in the elderly patients who underwent gross total resection (AHR, 0.764; 95% CI, 0.434-1.344; P = 0.350).
   CONCLUSION: Adjuvant external beam RT may not provide any survival benefit for elderly patients with WHO grade III meningioma after gross total resection.
C1 [Yang, Li] Second Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Zhou, Hao; Xiao, Bo] Cent S Univ, Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
   [Bai, Harrison X.] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Zhang, Paul J.] Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA.
   [Karakousis, Giorgos] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Huang, Raymond] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
   [Chan, Lilian] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Yang, L (reprint author), Second Xiangya Hosp, Dept Neurol, Changsha, Hunan, Peoples R China.
EM yangli762@csu.edu.cn
OI Huang, Raymond/0000-0001-7661-797X; Zhou, Hao/0000-0001-5648-0574
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81301988]; ShenghuaYuying Project of Central South University;
   Natural Science Foundation of Hunan Province for Young Scientists,
   ChinaNatural Science Foundation of Hunan Province [2018JJ3709]; RSNA
   [RF1802]; SIR Foundation; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [818580410556]
FX This work was supported by the Natural Science Foundation of China
   (81301988 to L.Y.), ShenghuaYuying Project of Central South University
   to L.Y., and the Natural Science Foundation of Hunan Province for Young
   Scientists, China (Grant No.: 2018JJ3709 to L.Y.). This project was
   supported by the RSNA research fellow grant to H.X.B. (RF1802), SIR
   Foundation resident research grant to H.X.B., and Research Fund for
   International Young Scientist by the National Natural Science Foundation
   of China (818580410556 to H.X.B.).
CR Balasubramanian SK, 2017, J NEURO-ONCOL, V131, P555, DOI 10.1007/s11060-016-2321-8
   Dickman PW, 2015, STATA J, V15, P186, DOI 10.1177/1536867X1501500112
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Dziuk TW, 1998, J NEURO-ONCOL, V37, P177, DOI 10.1023/A:1005853720926
   Garzon-Muvdi T, 2017, J NEURO-ONCOL, V133, P321, DOI 10.1007/s11060-017-2436-6
   Hanft S, 2010, J NEURO-ONCOL, V99, P433, DOI 10.1007/s11060-010-0348-9
   Kaur G, 2014, NEURO-ONCOLOGY, V16, P628, DOI 10.1093/neuonc/nou025
   Maclean J, 2014, CLIN ONCOL-UK, V26, P51, DOI 10.1016/j.clon.2013.10.001
   Milosevic MF, 1996, INT J RADIAT ONCOL, V34, P817, DOI 10.1016/0360-3016(95)02166-3
   Minniti G, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0841-9
   Modha A, 2005, NEUROSURGERY, V57, P538, DOI 10.1227/01.NEU.0000170980.47582.A5
   Moon Kyung-Sub, 2017, Brain Tumor Research and Treatment, V5, P54
   O'Connor KP, 2019, WORLD NEUROSURG, V130, pE558, DOI 10.1016/j.wneu.2019.06.152
   Paldor I, 2016, J CLIN NEUROSCI, V31, P37, DOI 10.1016/j.jocn.2016.03.014
   Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
   Shan BY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007385
   Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439
   Sughrue ME, 2010, J NEUROSURG, V113, P202, DOI 10.3171/2010.1.JNS091114
   Sun SQ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14757
   Vulto AJCM, 2006, CANCER-AM CANCER SOC, V106, P2734, DOI 10.1002/cncr.21934
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Zhao P, 2015, NEUROSURG REV, V38, P101, DOI 10.1007/s10143-014-0558-2
NR 22
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD NOV
PY 2019
VL 131
BP E303
EP E311
DI 10.1016/j.wneu.2019.07.140
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JG3GV
UT WOS:000491963300037
PM 31356979
DA 2020-05-12
ER

PT J
AU Sun, BJ
   Liu, Z
   Wang, ZY
   Chen, LT
   Li, H
   Duan, WG
AF Sun, Baojiang
   Liu, Zheng
   Wang, Zhiyuan
   Chen, Litao
   Li, Hao
   Duan, Wenguang
TI Experimental and modeling investigations into hydrate shell growth on
   suspended bubbles considering pore updating and surface collapse
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrate shell; Surface collapse; Mass transfer; Pore updating; System
   supercooling
ID CLATHRATE-HYDRATE; GAS-HYDRATE; FILM GROWTH; CO2 DROPLET; LIQUID CO2;
   HIGH-PRESSURE; WATER; INTERFACE; KINETICS; SEAWATER
AB Modeling of hydrate behaviors on the bubble surface is important for accurately evaluating the global budgets of greenhouse gas released from the deep ocean. Current mass-transfer models for hydrate shell growth mainly consider the inward and outward hydrate growth. However, the pore updating inside the hydrate shell and hydrate surface collapse may also play a significant role in hydrate growth. In this work, sustained visual observations on the morphological variation of hydrate shell on suspended methane bubbles in supersaturated water were conducted. The observed new insights and data processing results indicate that the dynamic growth of hydrate shell has successively experienced three stages: rapid development, continuous collapse and growth stagnation. Based on the surface characteristics of hydrated bubbles at different stages, a new mechanistic model of hydrate shell growth on bubble surface is developed, which considers the intercoupling of multiple hydrate-forming reactions, multiphase mass transfer processes, and hydrate collapse mechanical properties. This model not only characterizes the hydrate growth on both sides of hydrate shell, but also first presents a quantitative description of capillary pore updating inside the hydrate shell. Moreover, the relationship between the critical collapse pressure of hydrate shell and the dynamic pressure inside the hydrated bubble was investigated. Combining with experimental measurements from the literature, the efficiency of gas diffusion through the hydrate shell was determined, and correspondingly the time evolution of intergranular pore structure at different supercoolings was also performed. Using the proposed model, the variation rules of hydrate growth characterization parameters in different initial conditions were simulated and analyzed. Furthermore, the influence of the surface collapse behavior on hydrate shell thickening growth was also discussed. This work provides further insights into the growth characteristics of hydrated bubble accompanied with interphase mass transfer and surface morphological change. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Baojiang; Liu, Zheng; Chen, Litao; Li, Hao; Duan, Wenguang] China Univ Petr East China, Sch Petr Engn, Qingdao 266580, Shandong, Peoples R China.
   [Wang, Zhiyuan] China Univ Petr East China, Offshore Petr Engn Res Ctr, Qingdao 266580, Shandong, Peoples R China.
RP Sun, BJ; Liu, Z (reprint author), China Univ Petr East China, Sch Petr Engn, Qingdao 266580, Shandong, Peoples R China.
EM sunbj1128@126.com; wangzy1209@126.com
FU National Natural Science Foundation-Outstanding Youth Foundation
   [51622405]; National Key Basic Research Program of ChinaNational Basic
   Research Program of China [2015CB251200]; Shandong Natural Science funds
   for Distinguished Young Scholar [JQ201716]; National Key Research and
   Development Program of China [2017YFC0307304]; Program for Changjiang
   ScholarsProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [IRT_14R58, Q2016135]
FX The authors acknowledge the supports of the National Natural Science
   Foundation-Outstanding Youth Foundation (51622405), the National Key
   Basic Research Program of China (No. 2015CB251200), the Shandong Natural
   Science funds for Distinguished Young Scholar (JQ201716), the National
   Key Research and Development Program of China (2017YFC0307304), the
   Program for Changjiang Scholars (No. IRT_14R58, Q2016135).
CR Aliev AM, 2011, THEOR FOUND CHEM EN+, V45, P185, DOI 10.1134/S0040579511020023
   Arakawa M, 1997, COLD REG SCI TECHNOL, V26, P215, DOI 10.1016/S0165-232X(97)00018-9
   Aya I., 1992, AM SOC MECH ENG, V215, P17
   BALLARD AL, 2002, J SUPRAMOL CHEM, V2, P385, DOI DOI 10.1016/S1472-7862(03)00063-7
   Bigalke NK, 2008, ENVIRON SCI TECHNOL, V42, P5241, DOI 10.1021/es800228j
   Bonath V., 2013, AUST FAM PHYSICIAN, V35, P745
   Chen L. T., 2013, J CHEM ENG DATA, V59, P261
   Davies SR, 2010, J PETROL SCI ENG, V72, P302, DOI 10.1016/j.petrol.2010.03.031
   DHARMAWARDHANA PB, 1980, IND ENG CHEM FUND, V19, P410, DOI 10.1021/i160076a015
   Egorov AV, 2014, GEOFLUIDS, V14, P430, DOI 10.1111/gfl.12085
   Freer EM, 2001, FLUID PHASE EQUILIBR, V185, P65, DOI 10.1016/S0378-3812(01)00457-5
   Fu WQ, 2019, ENERG FUEL, V33, P2176, DOI 10.1021/acs.energyfuels.9b00132
   Gabitto J, 2006, ENERG CONVERS MANAGE, V47, P494, DOI 10.1016/j.enconman.2005.05.016
   Han S, 2017, DESALINATION, V404, P132, DOI 10.1016/j.desal.2016.11.016
   Hao WF, 2008, ENERG CONVERS MANAGE, V49, P2546, DOI 10.1016/j.enconman.2008.05.016
   HARRISON WJ, 1995, APPL GEOCHEM, V10, P461, DOI 10.1016/0883-2927(95)00018-F
   Hirai S, 1996, ENERG CONVERS MANAGE, V37, P1073, DOI 10.1016/0196-8904(95)00300-2
   Holder GD, 1996, AM CHEM SOC DIV FUEL, V41, P1452
   Kishimoto M, 2012, ENERGIES, V5, P92, DOI 10.3390/en5010092
   Li CJ, 2016, OCEAN ENG, V112, P16, DOI 10.1016/j.oceaneng.2015.12.002
   Li H, 2017, EXP THERM FLUID SCI, V88, P554, DOI 10.1016/j.expthermflusci.2017.07.009
   Li SL, 2015, CHEM ENG SCI, V135, P412, DOI 10.1016/j.ces.2015.01.057
   Li SL, 2014, CHEM ENG SCI, V116, P109, DOI 10.1016/j.ces.2014.04.009
   Li SL, 2013, AICHE J, V59, P2145, DOI 10.1002/aic.13987
   Liu Z, 2018, ENERG FUEL, V32, P2053, DOI 10.1021/acs.energyfuels.7b03530
   LUND PC, 1994, INT J CHEM KINET, V26, P289, DOI 10.1002/kin.550260207
   Makogon Y. F, 1981, HYDRATES NATURAL GAS, P85
   MASUTANI SM, 1993, ENERG CONVERS MANAGE, V34, P865, DOI 10.1016/0196-8904(93)90030-E
   Mochizuki T, 2006, J CRYST GROWTH, V290, P642, DOI 10.1016/j.jcrysgro.2006.01.036
   Mori YH, 1997, CHEM ENG SCI, V52, P3613, DOI 10.1016/S0009-2509(97)00169-3
   Mori YH, 1998, ENERG CONVERS MANAGE, V39, P1537, DOI 10.1016/S0196-8904(98)00029-6
   Ning FL, 2010, J NAT GAS CHEM, V19, P234, DOI 10.1016/S1003-9953(09)60077-3
   Ohmura R, 2016, CRYST GROWTH DES, V5, P1
   Peng BZ, 2007, J PHYS CHEM B, V111, P12485, DOI 10.1021/jp074606m
   Rehder G, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013966
   Salamatin AN, 1998, J CRYST GROWTH, V193, P197, DOI 10.1016/S0022-0248(98)00488-6
   Sato Y., 2013, J MMIJ, V129, P124
   Shi BH, 2011, CHEM ENG J, V171, P1308, DOI 10.1016/j.cej.2011.05.029
   Shindo Y, 1996, ENERG CONVERS MANAGE, V37, P485, DOI 10.1016/0196-8904(95)00198-0
   Sloan ED, 2003, NATURE, V426, P353, DOI 10.1038/nature02135
   Sugaya M, 1996, CHEM ENG SCI, V51, P3505, DOI 10.1016/0009-2509(95)00404-1
   Sun XH, 2018, CHEM ENG J, V331, P221, DOI 10.1016/j.cej.2017.08.105
   Taheri Z, 2014, J NAT GAS SCI ENG, V21, P846, DOI 10.1016/j.jngse.2014.09.026
   Tajima H, 2004, ENERGY, V29, P1713, DOI 10.1016/j.energy.2004.03.003
   Takeya S, 2006, CHEM ENG SCI, V61, P2670, DOI 10.1016/j.ces.2005.11.049
   Taylor CJ, 2007, CHEM ENG SCI, V62, P6524, DOI 10.1016/j.ces.2007.07.038
   Teng H, 1996, CHEM ENG SCI, V51, P4979, DOI 10.1016/0009-2509(96)00358-2
   TENG H, 1995, CHEM ENG SCI, V50, P559, DOI 10.1016/0009-2509(94)00438-W
   TOPHAM DR, 1984, CHEM ENG SCI, V39, P1613, DOI 10.1016/0009-2509(84)80088-3
   Turner DJ, 2009, CHEM ENG SCI, V64, P3996, DOI 10.1016/j.ces.2009.05.051
   Uchida T, 1997, ENERGY, V22, P357, DOI 10.1016/S0360-5442(96)00112-0
   Uchida T, 1999, J CRYST GROWTH, V204, P348, DOI 10.1016/S0022-0248(99)00178-5
   Warzinski RP, 2014, GEOPHYS RES LETT, V41, P6841, DOI 10.1002/2014GL061665
   Yapa PD, 2004, J HYDRAUL ENG, V130, P540, DOI 10.1061/(ASCE)0733-9429(2004)130:6(540)
   Zhang WX, 2017, ENERG CONVERS MANAGE, V146, P43, DOI 10.1016/j.enconman.2017.04.091
NR 55
TC 2
Z9 2
U1 24
U2 94
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1
EP 16
DI 10.1016/j.ces.2019.06.004
PG 16
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300001
DA 2020-05-12
ER

PT J
AU Ji, BQ
   Song, Q
   Wang, A
   Yao, Q
AF Ji, Bingqiang
   Song, Qiang
   Wang, Ao
   Yao, Qiang
TI Critical sinking of hydrophobic micron particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micron particles; Impact; Liquid surface; Sinking; Criterion
ID WATER ENTRY; DYNAMICS; BEHAVIOR; SPHERE; FLOW
AB Particle impacting on a liquid surface is frequently observed in natural and industrial processes. This study numerically investigates the critical sinking behaviour after the impact of hydrophobic micron particles on liquid surfaces. The effects of contact angle theta, density ratio D, and the Reynolds number Re on the motions of the particle and TPCL are analyzed. The dimensionless penetration depth of the particle increases with increasing theta and D, whereas the effect of Re is negligible. The relationship between the TPCL position on the particles and the normalised particle displacement is only determined by theta and almost unaffected by Re and D. For the critical sinking of hydrophobic micron particles, both fluid force and surface tension play important roles in the conversion of particle kinetic energy. A dimensionless energy conservation equation is constructed, based on which a simple criterion of critical sinking is proposed. The expression of this criterion is obtained based on the semi-empirical expressions describing the relationships of each dimensionless accumulated work with Re, theta, and D obtained from simulation results. Compared with existing criteria, the proposed criterion is more accurate because it considers the fluid force, TPCL movement, and other factors reasonably. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ji, Bingqiang; Song, Qiang; Wang, Ao; Yao, Qiang] Tsinghua Univ, Dept Energy & Power Engn, Minist Educ, Key Lab Thermal Sci & Power Engn, Beijing 100084, Peoples R China.
RP Song, Q (reprint author), Tsinghua Univ, Dept Energy & Power Engn, Minist Educ, Key Lab Thermal Sci & Power Engn, Beijing 100084, Peoples R China.
EM qsong@tsinghua.edu.cn
OI Song, Qiang/0000-0002-5484-3594
FU National Key Research and Development Program of China [2017YFC0210704];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51576109]
FX This work was supported by funds from the National Key Research and
   Development Program of China (2017YFC0210704) and the National Natural
   Science Foundation of China (51576109).
CR Abraham J, 2014, OCEAN ENG, V76, P1, DOI 10.1016/j.oceaneng.2013.11.015
   ANSYS Inc, 2012, ANSYS FLUENT 14 5 TH
   Aristoff JM, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3309454
   Aristoff JM, 2009, J FLUID MECH, V619, P45, DOI 10.1017/S0022112008004382
   Bae SY, 2010, J AEROSOL SCI, V41, P266, DOI 10.1016/j.jaerosci.2009.11.006
   Bormashenko E, 2016, J COLLOID INTERF SCI, V463, P8, DOI 10.1016/j.jcis.2015.10.031
   Bormashenko E, 2013, LANGMUIR, V29, P10700, DOI 10.1021/la4018823
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Bush JWM, 2006, ANNU REV FLUID MECH, V38, P339, DOI 10.1146/annurev.fluid.38.050304.092157
   Carlson A, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3275853
   Ding H, 2015, J FLUID MECH, V783, P504, DOI 10.1017/jfm.2015.574
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Jaworek A, 2006, ENVIRON SCI TECHNOL, V40, P6197, DOI 10.1021/es0605927
   Ji B., 2017, PHYS FLUIDS, V29, P3627
   Johnson TA, 1999, J FLUID MECH, V378, P19, DOI 10.1017/S0022112098003206
   Kaptay G, 1996, MATER SCI FORUM, V215, P467, DOI 10.4028/www.scientific.net/MSF.215-216.467
   Kaptay G, 2001, INTERFACIAL ASPECTS
   Kim SJ, 2017, APPL PHYS LETT, V111, DOI 10.1063/1.4991361
   Kintea DM, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4939285
   Lee DG, 2008, LANGMUIR, V24, P142, DOI 10.1021/la702437c
   Lee DG, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3614536
   Liu D, 2010, ADV POWDER TECHNOL, V21, P401, DOI 10.1016/j.apt.2010.04.004
   Liu DM, 2012, ADV MATER RES-SWITZ, V361-363, P320, DOI 10.4028/www.scientific.net/AMR.361-363.320
   Maria SF, 2005, ENVIRON SCI TECHNOL, V39, P4793, DOI 10.1021/es0491679
   Mitra S, 2015, ADV POWDER TECHNOL, V26, P280, DOI 10.1016/j.apt.2014.10.008
   Mouchacca AN, 1996, POWDER TECHNOL, V88, P95, DOI 10.1016/0032-5910(96)86778-7
   Nguyen A. V, 1993, COLLOIDAL SCI FLOTAT
   Park SH, 2005, J AEROSOL SCI, V36, P1444, DOI 10.1016/j.jaerosci.2005.03.012
   Richter A, 2012, INT J HEAT MASS TRAN, V55, P1343, DOI 10.1016/j.ijheatmasstransfer.2011.09.005
   Truscott TT, 2014, ANNU REV FLUID MECH, V46, P355, DOI 10.1146/annurev-fluid-011212-140753
   Vella D, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2747235
   Vella D, 2015, ANNU REV FLUID MECH, V47, P115, DOI 10.1146/annurev-fluid-010814-014627
   Verezub O, 2005, MATER SCI FORUM, V473-474, P429, DOI 10.4028/www.scientific.net/MSF.473-474.429
   Wang A., 2016, THESIS
   Wang A, 2017, POWDER TECHNOL, V311, P408, DOI 10.1016/j.powtec.2017.02.003
   Wang A, 2015, ATMOS ENVIRON, V115, P1, DOI 10.1016/j.atmosenv.2015.05.053
   Youngs D., 1982, NUMERICAL METHODS FL, P273, DOI DOI 10.1007/S11433-009-0265-0
NR 37
TC 1
Z9 1
U1 7
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 17
EP 29
DI 10.1016/j.ces.2019.06.009
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300002
DA 2020-05-12
ER

PT J
AU Cao, XP
   Zhou, M
   Jia, SK
   Yuan, XG
   Yu, KT
AF Cao, Xuepu
   Zhou, Mi
   Jia, Shengkun
   Yuan, Xigang
   Yu, Kuo-Tsong
TI Maxwell-Stefan diffusion coefficient model derived from entropy
   generation minimization principle for binary liquid mixtures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Maxwell-Stefan diffusion coefficient; Entropy generation minimization;
   Molar excess internal energy; Local surface area fraction
ID MUTUAL-DIFFUSION; NONIDEAL MIXTURES; PREDICTION; DIFFUSIVITIES; FLUXES
AB A new model for the Maxwell-Stefan (MS) diffusion coefficient was developed in this study. The entropy generation minimization principle was used to derive the expression of the MS diffusion coefficient, which has a similar form as Eyring's model. Molar excess internal energy based on two-liquid theory was derived to correct the error induced by the linear mixing rule. The local surface area fraction was used to replace the bulk fraction by considering the intermolecular friction force exerting on the molecular surfaces. The new model was applied to calculate the Fick diffusion coefficients for four binary systems, which were measured experimentally by digital holographic interferometry. Comparison of the experimental and calculation results indicated that the proposed model has a good performance for calculating the diffusion coefficients for the mentioned binary systems. (C) 2019 Published by Elsevier Ltd.
C1 [Cao, Xuepu; Zhou, Mi; Jia, Shengkun; Yuan, Xigang; Yu, Kuo-Tsong] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Yuan, Xigang; Yu, Kuo-Tsong] Tianjin Univ, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Yuan, Xigang] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP Jia, SK; Yuan, XG (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM jiask@tju.edu.cn; yuanxg@tju.edu.cn
OI Jia, Shengkun/0000-0003-4524-0588
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834303]
FX This work was supported by National Natural Science Foundation of China
   [grant number 91834303].
CR Allie-Ebrahim T., 2018, PREDICTIVE MODEL DIF
   ANDERSON DK, 1958, J PHYS CHEM-US, V62, P404, DOI 10.1021/j150562a006
   Bosse D, 2006, IND ENG CHEM RES, V45, P1822, DOI 10.1021/ie0487989
   Boudin L, 2017, NONLINEAR ANAL-THEOR, V159, P40, DOI 10.1016/j.na.2017.01.010
   Bringuier SA, 2017, IND ENG CHEM RES, V56, P3713, DOI 10.1021/acs.iecr.7b00159
   CARRINGTON CG, 1991, INT J HEAT MASS TRAN, V34, P2767, DOI 10.1016/0017-9310(91)90235-7
   CULLINAN HT, 1965, J PHYS CHEM-US, V69, P3941, DOI 10.1021/j100895a050
   CULLINAN HT, 1966, IND ENG CHEM FUND, V5, P281, DOI 10.1021/i160018a021
   D'Agostino C, 2012, CHEM ENG SCI, V74, P105, DOI 10.1016/j.ces.2012.02.025
   D'Agostino C, 2011, CHEM ENG SCI, V66, P3898, DOI 10.1016/j.ces.2011.05.014
   DARKEN LS, 1948, T AM I MIN MET ENG, V175, P184
   Glansdorff P., 1971, THERMODYNAMIC THEORY
   Glasstone S., 1941, THEORY RATE PROCESSE
   Gmehling J., 1996, MANUAL DORTMUND DATA
   Guevara-Carrion G, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4943395
   HAMMOND BR, 1953, T FARADAY SOC, V49, P890, DOI 10.1039/tf9534900890
   Hirschfelder J. O., 1964, MOL THEORY GASES LIQ
   Hsu YD, 1998, FLUID PHASE EQUILIBR, V152, P149, DOI 10.1016/S0378-3812(98)00375-6
   Hsu YD, 2000, FLUID PHASE EQUILIBR, V173, P1, DOI 10.1016/S0378-3812(00)00389-7
   Janzen T, 2018, IND ENG CHEM RES, V57, P16508, DOI 10.1021/acs.iecr.8b04385
   Kelly C. M., 1971, Journal of Physical Chemistry, V75, P3293, DOI 10.1021/j100690a015
   KRISHNA R, 1978, CHEM ENG SCI, V33, P765, DOI 10.1016/0009-2509(78)80055-4
   Kubaczka A, 2018, J MEMBRANE SCI, V546, P111, DOI 10.1016/j.memsci.2017.08.074
   LEFFLER J, 1970, IND ENG CHEM FUND, V9, P88, DOI 10.1021/i160033a014
   Li J, 2001, FLUID PHASE EQUILIBR, V187, P193, DOI 10.1016/S0378-3812(01)00535-0
   Liu X, 2013, INT J THERMOPHYS, V34, P1169, DOI 10.1007/s10765-013-1482-3
   Maxwell J. C., 1972, PHILOS MAG, V157, P49
   MCCALL DW, 1967, J PHYS CHEM-US, V71, P987, DOI 10.1021/j100863a035
   Onsager L, 1931, PHYS REV, V37, P405, DOI 10.1103/PhysRev.37.405
   Prausnitz J. M., 1998, PEARSON ED
   Prigogine I., 1947, ETUDE THERMODYNAMIQU
   RAO SS, 1971, AICHE J, V17, P75, DOI 10.1002/aic.690170117
   SANNI SA, 1973, J CHEM ENG DATA, V18, P317, DOI 10.1021/je60058a028
   SHUCK FO, 1963, J PHYS CHEM-US, V67, P540, DOI 10.1021/j100797a002
   Stefan J., 2007, GLEICHGEWICHT BEWEGU
   Szydlowska J., 1982, J PHYS D, V30, P136
   TAYLOR R, 1993, MULTICOMPONENT MASS
   VIGNES A, 1966, IND ENG CHEM FUND, V5, P189, DOI 10.1021/i160018a007
   Zhou M, 2013, IND ENG CHEM RES, V52, P10845, DOI 10.1021/ie4010157
   Zhu QY, 2015, CHEM ENG SCI, V132, P250, DOI 10.1016/j.ces.2015.04.021
NR 40
TC 1
Z9 1
U1 16
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 30
EP 38
DI 10.1016/j.ces.2019.06.011
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300003
DA 2020-05-12
ER

PT J
AU Moliner, C
   Marchelli, F
   Ong, L
   Martinez-Felipe, A
   Van der Dominic, A
   Arato, E
AF Moliner, Cristina
   Marchelli, Filippo
   Ong, Laura
   Martinez-Felipe, Alfonso
   Van der Dominic, A.
   Arato, Elisabetta
TI Sensitivity analysis and validation of a Two Fluid Method (TFM) model
   for a spouted bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Two fluid model; Multiphase flows;
   Granular materials; Ansys Fluent
ID THERMAL EXPLOITATION; KINETIC-THEORY; FLOW PATTERNS; SOLID FLOW;
   PARTICLE; EQUATIONS; HYDRODYNAMICS; SIMULATION; PROFILES; DYNAMICS
AB A spouted bed has been simulated through a Computational Fluid Dynamic model using the Two Fluid Method and validated against experimental data. A sensitivity analysis has assessed the influence of the characteristic parameters on the solution. Among them, the accurate selection of the drag law seems to have the strongest influence on the results. In order to extend the capabilities of Ansys Fluent, Di Felice's drag law was also considered through a User Defined Function. The assessment of the granular phase and its kinetic, collisional and frictional forces, is highly relevant to achieve a correct prediction of the particle velocity profile. The specularity coefficient appears to be more influencing than the restitution coefficient, but both parameters are useful to optimise the model. Overall, the prediction of the particle vertical velocity is accurate whereas the height of the fountain is slightly over-predicted. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moliner, Cristina; Arato, Elisabetta] Univ Genoa, Dept Civil Chem & Environm Engn, Via Opera Pia 15A, I-16145 Genoa, Italy.
   [Marchelli, Filippo] Free Univ Bozen Bolzano, Fac Sci & Technol, Piazza Univ 5, I-39100 Bolzano, Italy.
   [Ong, Laura; Martinez-Felipe, Alfonso] Univ Aberdeen, Kings Coll, Sch Engn, Chem & Mat Engn Grp, Aberdeen AB24 3UE, Scotland.
   [Van der Dominic, A.] Univ Aberdeen, Kings Coll, Sch Engn, Mech Fluids Soils & Struct Res Grp, Aberdeen AB24 3UE, Scotland.
RP Marchelli, F (reprint author), Free Univ Bozen Bolzano, Fac Sci & Technol, Piazza Univ 5, I-39100 Bolzano, Italy.
EM filippo.marchelli@natec.unibz.it
RI Marchelli, Filippo/I-7470-2019; van der A, Dominic/J-5104-2017
OI Marchelli, Filippo/0000-0003-4189-391X; van der A,
   Dominic/0000-0003-1025-9465; ARATO, ELISABETTA/0000-0002-0481-2175
FU LIFE LIBERNITRATE project [LIFE16 ENV/ES/000419]; Erasmus+ grant
   [2017-1-UK01-KA103-035896]
FX This work was funded through the LIFE LIBERNITRATE project (LIFE16
   ENV/ES/000419) in the framework of the LIFE+ funding programme. EA and
   AMF acknowledge the traineeship Erasmus+ grant
   (2017-1-UK01-KA103-035896) for Laura Ong.
CR AHMADI G, 1990, INT J MULTIPHAS FLOW, V16, P323, DOI 10.1016/0301-9322(90)90062-N
   ANSYS, 2018, ANSYS FLUENT THEOR G
   ANSYS, 2018, FLUENT THEOR GUID
   Arregi A, 2017, ENERG CONVERS MANAGE, V136, P192, DOI 10.1016/j.enconman.2017.01.008
   Bove D, 2019, CAN J CHEM ENG, V97, P59, DOI 10.1002/cjce.23223
   BRUNELLO G, 1974, CAN J CHEM ENG, V52, P201, DOI 10.1002/cjce.5450520211
   Campbell CS, 2006, POWDER TECHNOL, V162, P208, DOI 10.1016/j.powtec.2005.12.008
   Chen WY, 2015, PROCEDIA ENGINEER, V102, P1144, DOI 10.1016/j.proeng.2015.01.238
   Dalla Valle J.M., 1943, MICROMERITICS TECHNO
   Dan S., 2010, CHEM ENG SCI, V65, P2635, DOI DOI 10.1016/J.CES.2009.12.042
   DIFELICE R, 1994, INT J MULTIPHAS FLOW, V20, P153, DOI 10.1016/0301-9322(94)90011-6
   Erkiaga A, 2013, FUEL PROCESS TECHNOL, V116, P292, DOI 10.1016/j.fuproc.2013.07.008
   Gidaspow D, 1992, FLUIDIZATION, P75
   Golshan S, 2017, CHEM ENG RES DES, V121, P315, DOI 10.1016/j.cherd.2017.03.022
   HE YL, 1994, CAN J CHEM ENG, V72, P229, DOI 10.1002/cjce.5450720208
   He YL, 1997, CHEM ENG SCI, V52, P329, DOI 10.1016/S0009-2509(96)00378-8
   HE YL, 1994, CAN J CHEM ENG, V72, P561, DOI 10.1002/cjce.5450720402
   Hosseini SH, 2015, POWDER TECHNOL, V279, P301, DOI 10.1016/j.powtec.2015.04.013
   Hosseini SH, 2013, POWDER TECHNOL, V246, P303, DOI 10.1016/j.powtec.2013.05.016
   Hosseini SH, 2010, ENERG FUEL, V24, P6086, DOI 10.1021/ef100612r
   Iddir H, 2005, AICHE J, V51, P1620, DOI 10.1002/aic.10429
   JOHNSON PC, 1990, J FLUID MECH, V210, P501, DOI 10.1017/S0022112090001380
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Kechagiopoulos PN, 2007, CATAL TODAY, V127, P246, DOI 10.1016/j.cattod.2007.05.018
   Li TW, 2010, POWDER TECHNOL, V203, P447, DOI 10.1016/j.powtec.2010.06.005
   Liu GQ, 2008, CHEM ENG SCI, V63, P1131, DOI 10.1016/j.ces.2007.11.013
   Lu HL, 2004, CHEM ENG SCI, V59, P865, DOI 10.1016/j.ces.2003.10.018
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Machado MVC, 2017, POWDER TECHNOL, V311, P341, DOI 10.1016/j.powtec.2017.01.076
   Makibar J, 2015, FUEL PROCESS TECHNOL, V137, P283, DOI 10.1016/j.fuproc.2015.03.011
   Marchelli F, 2019, POWDER TECHNOL, V353, P409, DOI 10.1016/j.powtec.2019.05.035
   Marchelli F, 2017, POWDER TECHNOL, V321, P119, DOI 10.1016/j.powtec.2017.08.032
   MATHUR KB, 1955, AICHE J, V1, P157, DOI 10.1002/aic.690010205
   MATHUR KB, 1974, CAN J CHEM ENG, V52, P129, DOI 10.1002/cjce.5450520201
   Moliner C, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.11.164
   Moliner C, 2019, PARTICUOLOGY, V43, P193, DOI 10.1016/j.partic.2018.01.003
   Moliner C, 2017, ENERGIES, V10, DOI 10.3390/en10111729
   Mollick PK, 2015, CHEM ENG SCI, V128, P44, DOI 10.1016/j.ces.2015.01.065
   OGAWA S, 1980, Z ANGEW MATH PHYS, V31, P483, DOI 10.1007/BF01590859
   OLAZAR M, 1993, IND ENG CHEM RES, V32, P2826, DOI 10.1021/ie00023a053
   Rong LW, 2010, J HYDRODYN, V22, P351, DOI 10.1016/S1001-6058(09)60064-0
   San Jose MJ, 2014, CHEM ENG J, V238, P227, DOI 10.1016/j.cej.2013.09.073
   Jose MJS, 2013, FUEL, V110, P178, DOI 10.1016/j.fuel.2012.10.039
   SCHAEFFER DG, 1987, J DIFFER EQUATIONS, V66, P19, DOI 10.1016/0022-0396(87)90038-6
   Syamlal M., 1993, NTISDE9400087, V1
   Yang JS, 2018, POWDER TECHNOL, V334, P151, DOI 10.1016/j.powtec.2018.04.067
   Zhao XL, 2008, POWDER TECHNOL, V184, P205, DOI 10.1016/j.powtec.2007.11.044
NR 47
TC 5
Z9 5
U1 5
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 39
EP 53
DI 10.1016/j.ces.2019.06.008
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300004
DA 2020-05-12
ER

PT J
AU Zhang, X
   Xiong, S
   Liu, CX
   Shen, L
   Ding, C
   Guan, CY
   Wang, Y
AF Zhang, Xuan
   Xiong, Shu
   Liu, Chu-Xuan
   Shen, Liang
   Ding, Chun
   Guan, Chen-Yu
   Wang, Yan
TI Confining migration of amine monomer during interfacial polymerization
   for constructing thin-film composite forward osmosis membrane with low
   fouling propensity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polyvinylidene fluoride (PVDF); Internal concentration polarization
   (ICP); Polyamide (PA); Phosphorylated titanium dioxide (p-TiO2); Forward
   osmosis (FO)
ID INTERNAL CONCENTRATION POLARIZATION; HOLLOW-FIBER MEMBRANES;
   INCORPORATED POLYSULFONE SUBSTRATE; PVDF ULTRAFILTRATION MEMBRANE;
   HIGH-PERFORMANCE; SURFACE MODIFICATION; NANOCOMPOSITE MEMBRANES;
   SEPARATION PERFORMANCE; TIO2 NANOPARTICLES; SUPPORT LAYER
AB Forward osmosis (FO) membrane is paramount to the progress and implementation of FO process. However, typical FO membranes are confronted with many unsatisfactory issues, including the low water flux, high fouling propensity and the poor long-term operation stability in most cases, which confines the practical application of FO process to a large extent. This study proposes a feasible way to mitigate the internal concentration polarization (ICP) and optimize the polyamide (PA) layer structure of as-fabricated thin-film composite forward osmosis (TFC-FO) membranes simultaneously by incorporating phosphorylated titanium dioxide (p-TiO2) in polyvinylidene fluoride (PVDF) substrate. P-TiO2 nanoparticies with abundant phosphate groups were prepared through a chemical absorption approach followed by the thermal post-treatment. Superior water flux and the better antifouling properties of the resultant PVDF/p-TiO2 TFC-FO membrane was achieved, taking advantage of the more compact and smoother PA layer as a result of the confined migration of amine monomer during interfacial polymerization (IP). In addition, effects of p-TiO2 content on morphological changes and physicochemical properties of modified substrates and the construction of top PA layer are studied and elaborated systemically via many characterizations as well as the permeation tests. As a result, the water flux decline of PVDF/p-TiO2 TFC membrane is much lower (16.0%) than that (similar to 31.3%) of the pristine TFC membrane, in the long-term (20 h) dynamic fouling test against 500 ppm humic acid (HA) solution. Therefore, PVDF/p-TiO2 TFC-FO membrane with improved water flux and low fouling tendency is beneficial for wastewater treatment and desalination process, especially for the treatment of brackish water with high fouling tendency or under harsh conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Yan] Huazhong Univ Sci & Technol, Minist Educ, Key Lab Mat Chem Energy Convers & Storage, Wuhan 430074, Hubei, Peoples R China.
   Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Hubei Key Lab Mat Chem & Serv Failure, Wuhan 430074, Hubei, Peoples R China.
RP Wang, Y (reprint author), Huazhong Univ Sci & Technol, Minist Educ, Key Lab Mat Chem Energy Convers & Storage, Wuhan 430074, Hubei, Peoples R China.
EM wangyan@hust.edu.cn
OI Shen, Liang/0000-0001-6569-5649; Wang, Yan/0000-0002-5268-776X
FU Free Exploring Fundamental Research Project from Shenzhen Research
   Council, China [JCYJ20160408173516757]
FX This study was supported by the Free Exploring Fundamental Research
   Project from Shenzhen Research Council, China (no.
   JCYJ20160408173516757). The authors would also like to acknowledge the
   assistance from the Analysis and Testing Center, the Analysis and
   Testing Center in School of Chemistry and Chemical Engineering, as well
   as the State Key Laboratory of Materials Processing and Die & Mould
   Technology, in Huazhong University of Science and Technology for their
   help with material measurements and characterizations.
CR Bell EA, 2016, J MEMBRANE SCI, V517, P1, DOI 10.1016/j.memsci.2016.06.014
   Chang XJ, 2014, APPL SURF SCI, V316, P537, DOI 10.1016/j.apsusc.2014.07.202
   Chen YQ, 2016, J MEMBRANE SCI, V505, P53, DOI 10.1016/j.memsci.2016.01.030
   Di Vona ML, 2011, J MEMBRANE SCI, V369, P536, DOI 10.1016/j.memsci.2010.12.044
   Dudasova D, 2008, J DISPER SCI TECHNOL, V29, P139, DOI 10.1080/01932690701688904
   Duong PHH, 2015, ACS APPL MATER INTER, V7, P3960, DOI 10.1021/am508387d
   Emadzadeh D, 2015, CHEM ENG J, V281, P243, DOI 10.1016/j.cej.2015.06.035
   Emadzadeh D, 2014, DESALINATION, V348, P82, DOI 10.1016/j.desal.2014.06.008
   Emadzadeh D, 2014, CHEM ENG J, V237, P70, DOI 10.1016/j.cej.2013.09.081
   EMSLEY J, 1973, J CHEM SOC DALTON, P1576, DOI 10.1039/dt9730001576
   Ghanbari M, 2016, DESALINATION, V377, P152, DOI 10.1016/j.desal.2015.09.019
   Ghanbari M, 2015, DESALINATION, V371, P104, DOI 10.1016/j.desal.2015.06.007
   Ghosh AK, 2009, J MEMBRANE SCI, V336, P140, DOI 10.1016/j.memsci.2009.03.024
   Gopal B, 2013, APPL CATAL A-GEN, V462, P262, DOI 10.1016/j.apcata.2013.04.036
   Han G, 2017, J MEMBRANE SCI, V523, P497, DOI 10.1016/j.memsci.2016.10.022
   Han G, 2012, CHEM ENG SCI, V80, P219, DOI 10.1016/j.ces.2012.05.033
   Hancock NT, 2013, J MEMBRANE SCI, V445, P34, DOI 10.1016/j.memsci.2013.04.056
   Huang LW, 2015, J MEMBRANE SCI, V483, P25, DOI 10.1016/j.memsci.2015.01.025
   Ingole PG, 2014, CHEM ENG J, V243, P137, DOI 10.1016/j.cej.2013.12.094
   Jiang K, 2015, ANGEW CHEM INT EDIT, V54, P5360, DOI 10.1002/anie.201501193
   Jones KL, 2001, J MEMBRANE SCI, V193, P163, DOI 10.1016/S0376-7388(01)00492-6
   Kamada T, 2014, J MEMBRANE SCI, V453, P489, DOI 10.1016/j.memsci.2013.11.028
   Klaysom C, 2013, J MEMBRANE SCI, V445, P25, DOI 10.1016/j.memsci.2013.05.037
   Kuang W, 2016, J MEMBRANE SCI, V497, P485, DOI 10.1016/j.memsci.2015.06.052
   Kumar M, 2016, J MEMBRANE SCI, V506, P38, DOI 10.1016/j.memsci.2016.02.005
   Lau WJ, 2012, DESALINATION, V287, P190, DOI 10.1016/j.desal.2011.04.004
   Le NL, 2016, J MEMBRANE SCI, V505, P157, DOI 10.1016/j.memsci.2016.01.027
   Lim WG, 2018, KOREAN J CHEM ENG, V35, P579, DOI 10.1007/s11814-017-0302-z
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Liu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep19593
   Loeb S, 1997, J MEMBRANE SCI, V129, P243, DOI 10.1016/S0376-7388(96)00354-7
   Lu P, 2016, RSC ADV, V6, P56599, DOI 10.1039/c6ra10080e
   Luo YB, 2009, ACTA MATER, V57, P3182, DOI 10.1016/j.actamat.2009.03.022
   Madaeni SS, 2011, J MEMBRANE SCI, V380, P155, DOI 10.1016/j.memsci.2011.07.006
   Mi B, 2008, J MEMBRANE SCI, V320, P292, DOI 10.1016/j.memsci.2008.04.036
   Morales-Torres S, 2016, J MEMBRANE SCI, V520, P326, DOI 10.1016/j.memsci.2016.07.009
   Obaid M, 2016, ACS APPL MATER INTER, V8, P4561, DOI 10.1021/acsami.5b09945
   Park MJ, 2015, J MEMBRANE SCI, V493, P496, DOI 10.1016/j.memsci.2015.06.053
   Peyravi M, 2014, CHEM ENG J, V241, P155, DOI 10.1016/j.cej.2013.12.024
   Rastgar M, 2017, DESALINATION, V421, P179, DOI 10.1016/j.desal.2017.01.040
   Salehi H, 2018, J MEMBRANE SCI, V548, P641, DOI 10.1016/j.memsci.2017.10.044
   She QH, 2016, J MEMBRANE SCI, V499, P201, DOI 10.1016/j.memsci.2015.10.040
   Shen L, 2019, J MEMBRANE SCI, V570, P112, DOI 10.1016/j.memsci.2018.10.014
   Shen L, 2018, J MEMBRANE SCI, V563, P284, DOI 10.1016/j.memsci.2018.05.071
   Shen L, 2018, CHEM ENG SCI, V178, P82, DOI 10.1016/j.ces.2017.12.026
   Shen L, 2017, J MEMBRANE SCI, V537, P186, DOI 10.1016/j.memsci.2017.05.035
   Shen L, 2017, J MEMBRANE SCI, V534, P46, DOI 10.1016/j.memsci.2017.04.008
   Shen L, 2016, CHEM ENG SCI, V143, P194, DOI 10.1016/j.ces.2015.12.029
   Shi H, 2016, J MEMBRANE SCI, V506, P60, DOI 10.1016/j.memsci.2016.01.053
   Shi L, 2011, J MEMBRANE SCI, V382, P116, DOI 10.1016/j.memsci.2011.07.045
   Shi MQ, 2018, J MEMBRANE SCI, V555, P157, DOI 10.1016/j.memsci.2018.03.025
   Shi Q, 2017, J MATER CHEM A, V5, P13610, DOI 10.1039/c7ta02552a
   Sukitpaneenit P, 2014, J MEMBRANE SCI, V450, P124, DOI 10.1016/j.memsci.2013.08.047
   Sukitpaneenit P, 2012, ENVIRON SCI TECHNOL, V46, P7358, DOI 10.1021/es301559z
   Sukitpaneenit P, 2012, IND ENG CHEM RES, V51, P978, DOI 10.1021/ie202116h
   Tang CYY, 2010, J MEMBRANE SCI, V354, P123, DOI 10.1016/j.memsci.2010.02.059
   Tiraferri A, 2011, J MEMBRANE SCI, V367, P340, DOI 10.1016/j.memsci.2010.11.014
   Wang YQ, 2015, J MEMBRANE SCI, V476, P330, DOI 10.1016/j.memsci.2014.11.025
   Wang YQ, 2015, J MEMBRANE SCI, V475, P281, DOI 10.1016/j.memsci.2014.10.028
   Wang YQ, 2013, DESALINATION, V330, P70, DOI 10.1016/j.desal.2013.09.028
   Weng YJ, 2008, APPL SURF SCI, V254, P2712, DOI 10.1016/j.apsusc.2007.10.107
   Widjojo N, 2013, CHEM ENG J, V220, P15, DOI 10.1016/j.cej.2013.01.007
   Woods AS, 2008, J PROTEOME RES, V7, P3423, DOI 10.1021/pr8001595
   Wu HP, 2007, LANGMUIR, V23, P7880, DOI 10.1021/la700555y
   Xiong S, 2019, J MEMBRANE SCI, V572, P281, DOI 10.1016/j.memsci.2018.11.012
   Xu GR, 2017, DESALINATION, V417, P19, DOI 10.1016/j.desal.2017.05.011
   Xu J, 2017, J MEMBRANE SCI, V541, P174, DOI 10.1016/j.memsci.2017.06.057
   Yao ZK, 2018, DESALINATION, V436, P1, DOI 10.1016/j.desal.2018.01.039
   Yeow ML, 2004, J APPL POLYM SCI, V92, P1782, DOI 10.1002/app.20141
   Yuan W, 2000, ENVIRON SCI TECHNOL, V34, P5043, DOI 10.1021/es0012366
   Zhang GL, 2013, J MEMBRANE SCI, V436, P163, DOI 10.1016/j.memsci.2013.02.009
   Zhang XY, 2016, J MEMBRANE SCI, V520, P529, DOI 10.1016/j.memsci.2016.08.005
   Zhang X, 2018, J MEMBRANE SCI, V564, P328, DOI 10.1016/j.memsci.2018.07.043
   Zhang X, 2017, J MEMBRANE SCI, V535, P188, DOI 10.1016/j.memsci.2017.04.038
   Zhang X, 2015, RSC ADV, V5, P21532, DOI 10.1039/c5ra00926j
   Zhang X, 2014, J MEMBRANE SCI, V469, P458, DOI 10.1016/j.memsci.2014.07.009
   Zhao D, 2008, J PHYS CHEM C, V112, P5993, DOI 10.1021/jp712049c
   Zhao SF, 2012, J MEMBRANE SCI, V396, P1, DOI 10.1016/j.memsci.2011.12.023
   Zhao XZ, 2017, DESALINATION, V408, P102, DOI 10.1016/j.desal.2017.01.021
   Zhao XZ, 2015, ACS APPL MATER INTER, V7, P17947, DOI 10.1021/acsami.5b04648
NR 80
TC 2
Z9 2
U1 35
U2 98
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 54
EP 68
DI 10.1016/j.ces.2019.06.010
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300005
DA 2020-05-12
ER

PT J
AU Flach, F
   Breitung-Faes, S
   Kwade, A
AF Flach, Frederik
   Breitung-Faes, Sandra
   Kwade, Arno
TI Tailoring product formulation properties to reduce grinding media wear
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Stirred media milling; Colloidal stability; Grinding media wear; Organic
   particles
ID SUBMICRON PARTICLES; STRESS INTENSITY; MILLS; STABILIZATION;
   OPTIMIZATION; MOTION; BEADS; COMMINUTION; SUSPENSIONS; INTERFACES
AB The generation of grinding media wear during wet stirred media milling of organic particles was studied in dependence of product formulation parameters. It was shown that targeted product formulation leads to the reduction of ceramic grinding media wear for a certain product quality. Solids concentration and agglomerate size of product particles were identified as key parameters. Both influence the effective stress intensity of grinding media which has a significant impact on the generation of grinding media wear. Moreover, the reduction of grinding media wear can be attributed to the damping properties of comparatively soft organic particles. Their potential to protect ceramic grinding media from abrasion can be increased by tailoring formulation properties. Therefore, especially the increase of solids concentration was identified as most practical formulation variable which affects also grinding efficiency and production capacity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Flach, Frederik; Breitung-Faes, Sandra; Kwade, Arno] Tech Univ Carolo Wilhelmina Braunschweig, Inst Particle Technol, Volkmaroder Str 5, D-38104 Braunschweig, Germany.
RP Flach, F (reprint author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Particle Technol, Volkmaroder Str 5, D-38104 Braunschweig, Germany.
EM f.flach@tu-braunschweig.de
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [KW 9/18]
FX The Deutsche Forschungsgemeinschaft (DFG) is gratefully acknowledged for
   funding this research work (grant: KW 9/18).
CR Becker M, 1999, POWDER TECHNOL, V105, P374, DOI 10.1016/S0032-5910(99)00161-8
   Bernhardt C, 1999, POWDER TECHNOL, V105, P357, DOI 10.1016/S0032-5910(99)00159-X
   Blecher L, 1996, POWDER TECHNOL, V86, P59, DOI 10.1016/0032-5910(95)03038-7
   Breitung-Faes S, 2017, MINER ENG, V103, P33, DOI 10.1016/j.mineng.2016.08.008
   Breitung-Faes S, 2011, POWDER TECHNOL, V212, P383, DOI 10.1016/j.powtec.2011.06.018
   Breitung-Faes S, 2008, CHEM ENG RES DES, V86, P390, DOI 10.1016/j.cherd.2007.11.006
   Breitung-Faes S, 2014, CHEM ENG TECHNOL, V37, P819, DOI 10.1002/ceat.201300686
   Derjaguin B. V, 1941, ACTA PHYSIOCHEM USS, V14, P632
   EINARSON MB, 1993, J COLLOID INTERF SCI, V155, P165, DOI 10.1006/jcis.1993.1022
   ELWORTHY PH, 1971, J COLLOID INTERF SCI, V35, P34, DOI 10.1016/0021-9797(71)90181-0
   Farber BY, 2009, MINER ENG, V22, P704, DOI 10.1016/j.mineng.2008.12.011
   Flach F, 2017, COLLOID SURFACE A, V522, P140, DOI 10.1016/j.colsurfa.2017.02.071
   Flach F, 2016, ADV POWDER TECHNOL, V27, P2507, DOI 10.1016/j.apt.2016.09.026
   Flach F, 2016, CHEM-ING-TECH, V88, P850, DOI 10.1002/cite.201500159
   Gers R, 2010, CHEM ENG SCI, V65, P2052, DOI 10.1016/j.ces.2009.12.003
   Hennart SLA, 2010, POWDER TECHNOL, V198, P56, DOI 10.1016/j.powtec.2009.10.014
   IARC, 2013, IARC MONOGR, V101, P41
   Joost B, 1996, CHEM-ING-TECH, V68, P713, DOI 10.1002/cite.330680615
   Juhnke M, 2006, ENTWICKLUNG PLANETEN
   Juhnke M, 2012, EUR J PHARM BIOPHARM, V81, P214, DOI 10.1016/j.ejpb.2012.01.005
   Knieke C, 2010, CHEM ENG TECHNOL, V33, P1401, DOI 10.1002/ceat.201000105
   Konnerth C, 2016, POWDER TECHNOL, V294, P71, DOI 10.1016/j.powtec.2016.02.016
   Kotze H, 2015, INT J MINER PROCESS, V136, P45, DOI 10.1016/j.minpro.2014.09.009
   Kudin KN, 2008, J AM CHEM SOC, V130, P3915, DOI 10.1021/ja077205t
   Kwade A, 2004, INT J MINER PROCESS, V74, pS93, DOI 10.1016/j.minpro.2004.07.027
   Kwade A, 2003, CHEM ENG TECHNOL, V26, P199, DOI 10.1002/ceat.200390029
   Kwade A, 1996, POWDER TECHNOL, V86, P69, DOI 10.1016/0032-5910(95)03039-5
   Kwade A., 1996, THESIS
   Li M, 2015, CHEM ENG SCI, V130, P207, DOI 10.1016/j.ces.2015.03.020
   Marinova KG, 1996, LANGMUIR, V12, P2045, DOI 10.1021/la950928i
   Mende G, 2004, INT C PART TECHN NUR
   Mende S, 2004, J MATER SCI, V39, P5223, DOI 10.1023/B:JMSC.0000039214.12131.58
   Mende S, 2003, POWDER TECHNOL, V132, P64, DOI 10.1016/S0032-5910(03)00042-1
   Steiner D, 2016, ADV POWDER TECHNOL, V27, P1700, DOI 10.1016/j.apt.2016.05.034
   Stender H.-H, 2001, INT C PART TECHN NUR
   Sugimoto S, 2012, INT J PHARMACEUT, V426, P162, DOI 10.1016/j.ijpharm.2012.01.007
   Tadros T.F., 2010, RHEOLOGY DISPERSIONS
   Theuerkauf J, 1999, POWDER TECHNOL, V105, P406, DOI 10.1016/S0032-5910(99)00165-5
   Verwey E.J.W., 1948, THEORY STABILITY LYO
   YAMAMOTO T, 1994, WEAR, V174, P21, DOI 10.1016/0043-1648(94)90082-5
   Zimmermann R, 2001, J PHYS CHEM B, V105, P8544, DOI 10.1021/jp004051u
NR 41
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 69
EP 78
DI 10.1016/j.ces.2019.06.007
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300006
DA 2020-05-12
ER

PT J
AU Ghafurian, MM
   Niazmand, H
   Dastjerd, FT
   Mahian, O
AF Ghafurian, Mohammad Mustafa
   Niazmand, Hamid
   Dastjerd, Fateme Tavakoli
   Mahian, Omid
TI A study on the potential of carbon-based nanomaterials for enhancement
   of evaporation and water production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Steam generation; Carbon nanomaterials; Nanofluid; Solar simulator;
   Experimental study
ID SOLAR STEAM-GENERATION; HEAT-TRANSFER; VAPOR GENERATION; TURBULENT-FLOW;
   NANOFLUIDS; NANOPARTICLES; EFFICIENCY; CONVECTION
AB In the present study, the performance of water based-nanofluids containing four different types of carbon nanostructures for solar vapor generation has experimentally been investigated. The considered nanofluids are multi-walled carbon nanotube, single-walled carbon nanotube, graphene nanoplate and graphene oxide. Nanofluids with three nanoparticle mass concentrations of 0.001%, 0.002%, and 0.004% were prepared and their evaporation characteristics were investigated for solar radiation intensities in the range of 1.5 and 3.5 Suns. The results indicated that the multi-walled carbon nanotube nanofluid with a mass concentration of 0.004% provides the highest evaporation rate with the maximum total efficiency of 94% at 3.5 Suns. The total efficiencies for nanofluids containing the single-walled carbon nanotube, graphene nanoplate and graphene oxide at similar conditions and that of pure water, respectively, are about 91%, 90%, 81% and, 54%. Furthermore, it is observed that for the mass concentration of 0.004%, the evaporation rate with respect to water increases to about 72%, 63%, 58% and 36%, respectively, for the multi-walled carbon nanotube, the single-walled carbon nanotube, graphene nanoplate and graphene oxide nanofluids. As far as the sensible heat is concerned, graphene oxide shows the most considerable sensible heating efficiency at the mass concentration of 0.004% with the maximum fluid bulk temperature rise of 20.5 degrees C, which is 40% higher than that of water. Finally, it was found that increasing the radiation intensity from 1.5 to 3.5 Suns improves the evaporation rate; however, the sensible heat efficiency is more influenced such that the evaporation efficiency declines. The quality of the produced water from a seawater sample is also examined and it was shown that it is well below the limitations of the drinking water standards. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ghafurian, Mohammad Mustafa; Niazmand, Hamid; Dastjerd, Fateme Tavakoli] Ferdowsi Univ Mashhad, Dept Mech Engn, Mashhad, Razavi Khorasan, Iran.
   [Mahian, Omid] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
   [Mahian, Omid] Ouchan Univ Technol, Dept Mech Engn, Ouchan, Iran.
RP Niazmand, H (reprint author), Ferdowsi Univ Mashhad, Dept Mech Engn, Mashhad, Razavi Khorasan, Iran.; Mahian, O (reprint author), Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
EM niazmand@um.ac.ir; omid.mahian@xjtu.edu.cn
RI Niazmand, Hamid/AAA-6000-2020; Mahian, Omid/AAA-4550-2019
OI Niazmand, Hamid/0000-0002-1638-4075; 
FU Ferdowsi University of Mashhad [46870]
FX The authors gratefully acknowledge the Ferdowsi University of Mashhad
   for the financial support (contract No. 46870) and The VIRA Equipment
   Unique Engineering Co. for providing useful information and advice on
   various technical issues.
CR Alzahrani S, 2013, DESALINATION, V315, P18, DOI 10.1016/j.desal.2012.12.004
   Amani M, 2017, CHEM ENG SCI, V167, P135, DOI 10.1016/j.ces.2017.03.065
   Amjad M, 2017, APPL ENERG, V206, P393, DOI 10.1016/j.apenergy.2017.08.144
   Brongersma ML, 2015, NAT NANOTECHNOL, V10, P25, DOI [10.1038/NNANO.2014.311, 10.1038/nnano.2014.311]
   Fu Y, 2017, APPL THERM ENG, V114, P961, DOI 10.1016/j.applthermaleng.2016.12.054
   Ghafurian M. M., 2018, AMIRKABIR J ME UNPUB, DOI [10.22060/MEJ.2018.13852.5730, DOI 10.22060/MEJ.2018.13852.5730]
   Ghafurian M. M., 2019, MODARES MECH ENG
   Ghafurian M. M., 2019, J SOLID FLUID MECH
   Ghafurian MM, 2019, J THERM ANAL CALORIM, V135, P1443, DOI 10.1007/s10973-018-7496-0
   Hjerrild NE, 2017, PHYS TODAY, V70, P40, DOI 10.1063/PT.3.3790
   Jin HC, 2016, NANO ENERGY, V28, P397, DOI 10.1016/j.nanoen.2016.08.011
   Li HR, 2017, APPL THERM ENG, V121, P617, DOI 10.1016/j.applthermaleng.2017.04.102
   Liu X, 2018, APPL ENERG, V220, P302, DOI 10.1016/j.apenergy.2018.03.097
   Mahian O, 2019, PHYS REP, V790, P1, DOI 10.1016/j.physrep.2018.11.004
   Mahian O, 2019, PHYS REP, V791, P1, DOI 10.1016/j.physrep.2018.11.003
   Mahian O, 2013, INT J HEAT MASS TRAN, V57, P582, DOI 10.1016/j.ijheatmasstransfer.2012.10.037
   Minea AA, 2017, CHEM ENG SCI, V174, P13, DOI 10.1016/j.ces.2017.08.028
   Negishi N, 2019, WATER RES, V150, P40, DOI 10.1016/j.watres.2018.11.047
   Neumann O, 2013, ACS NANO, V7, P42, DOI 10.1021/nn304948h
   Ni G, 2015, NANO ENERGY, V17, P290, DOI 10.1016/j.nanoen.2015.08.021
   Nielsen G, 2018, WATER RES, V140, P268, DOI 10.1016/j.watres.2018.04.035
   Oka PA, 2017, WATER RES, V115, P287, DOI 10.1016/j.watres.2017.02.065
   Sekrani G, 2018, CHEM ENG SCI, V176, P205, DOI 10.1016/j.ces.2017.10.044
   Sharafeldin MA, 2017, ENERGY, V141, P2436, DOI 10.1016/j.energy.2017.11.068
   Sheikholeslami M, 2019, J CLEAN PROD, V215, P963, DOI 10.1016/j.jclepro.2019.01.122
   Sheikholeslami M, 2017, CHEM ENG SCI, V174, P326, DOI 10.1016/j.ces.2017.09.026
   Shi L, 2017, ENERG CONVERS MANAGE, V149, P401, DOI 10.1016/j.enconman.2017.07.044
   Subramani J, 2018, RENEW ENERG, V119, P19, DOI 10.1016/j.renene.2017.11.079
   Swinehart D.F., 1962, J CHEM EDUC, V39, P333, DOI DOI 10.1021/ED039P333
   Taylor RA, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-225
   Wang J, 2017, ADV MATER, V29, DOI 10.1002/adma.201603730
   Wang XQ, 2016, ACS APPL MATER INTER, V8, P9194, DOI 10.1021/acsami.6b02071
   Wang XZ, 2017, SOL ENERGY, V157, P35, DOI 10.1016/j.solener.2017.08.015
   Wang XZ, 2017, POWDER TECHNOL, V321, P276, DOI 10.1016/j.powtec.2017.08.027
   Wang XZ, 2016, ENERG CONVERS MANAGE, V130, P176, DOI 10.1016/j.enconman.2016.10.049
   WHO, 2011, GUID DRINK WAT QUAL, V38, P104
   World Health Organization, 2011, WHOHSEWSH1103
   Xu HJ, 2019, CHEM ENG SCI, V195, P462, DOI 10.1016/j.ces.2018.09.045
   Zeiny A, 2018, RENEW ENERG, V122, P443, DOI 10.1016/j.renene.2018.01.043
   Zhang XW, 2018, CHEM ENG SCI, V180, P95, DOI 10.1016/j.ces.2017.11.044
NR 40
TC 6
Z9 6
U1 25
U2 81
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 79
EP 90
DI 10.1016/j.ces.2019.05.043
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300007
DA 2020-05-12
ER

PT J
AU Caballero, KV
   Guerrero-Amaya, H
   Baldovino-Medrano, VG
AF Caballero, Karen, V
   Guerrero-Amaya, Hernando
   Baldovino-Medrano, Victor G.
TI Revisiting glycerol esterification with acetic acid over Amberlyst-35
   via statistically designed experiments: Overcoming transport limitations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Glycerol esterification; Acetic acid; Liquid phase; Amberlyst-35;
   Sequential experiment design; Mass and heat transport limitations;
   Turnover rates
ID SELECTIVE ESTERIFICATION; CATALYTIC ACETYLATION; ISOAMYL ALCOHOL;
   KINETICS; VALORIZATION; ADDITIVES; PROGRESS; PRODUCT
AB The market is overflooded by unrefined glycerol with the production of biodiesel from vegetable oils. A recurrently studied alternative for its valorization is the production of acetins via esterification with acetic acid over acid catalysts in liquid phase. However, most of the published literature uses experimental methodologies that prevent a proper kinetic analysis of the reaction. This work revisits glycerol esterification with acetic acid catalyzed by Amberlyst-35 applying sequential statistically designed experiments. Following such approach, statistically meaningful data were collected providing insight into the catalytic reaction. Experiments were designed to test the influence of the quantity of active sites; assumed herein as the number of surface SO3H+ sites on Amberlyst-35, temperature, and the acetic acid to glycerol molar ratio over the turnover frequency of the catalyst. The collected evidence shows that, under the typical conditions employed in most open literature, heat and mass transport artifacts should not be neglected. In the present case, these limitations were overcome by reducing the particle size of the solid. Under such conditions, a straightforward relationship between the concentration of surface SO3H+ active sites and the glycerol turnover rates was established. Meanwhile, it was shown that the reaction temperature has a rather weak effect on the catalytic turnover. This trend concurred with the thermodynamic equilibrium of the reaction. Likewise, the already established effect of the acetic acid to glycerol molar ratio was also confirmed. Overall, the performed study serves a double purpose. First, it is a methodological guide to collect kinetically relevant information in liquid phase. Second, it reports intrinsic kinetic rates for the esterification reaction over the studied catalyst hence paving the way for a rigorous kinetic modeling. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Caballero, Karen, V; Guerrero-Amaya, Hernando; Baldovino-Medrano, Victor G.] Univ Ind Santander, PTG, CMN, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.
   [Caballero, Karen, V; Guerrero-Amaya, Hernando; Baldovino-Medrano, Victor G.] Univ Ind Santander, PTG, Ctr Invest Catalisis CICAT, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.
   [Baldovino-Medrano, Victor G.] Univ Ind Santander, PTG, Lab Ciencia Superficies SurfLab, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.
RP Baldovino-Medrano, VG (reprint author), Univ Ind Santander, PTG, CMN, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.; Baldovino-Medrano, VG (reprint author), Univ Ind Santander, PTG, Ctr Invest Catalisis CICAT, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.; Baldovino-Medrano, VG (reprint author), Univ Ind Santander, PTG, Lab Ciencia Superficies SurfLab, Km 2 Via El Refugio, Piedecuesta 681011, Santander, Colombia.
EM vicbaldo@uis.edu.co
OI Guerrero- Amaya, Hernando/0000-0002-7722-3080
FU Vicerrectoria de Investigacion y Extension UIS [1319]
FX Authors thanks Vicerrectoria de Investigacion y Extension UIS for
   funding within the frame of the project No. 1319: "Obtencion de
   productos de alto valor agregado a partir de la glicerina cruda" and
   also for funding within the frame of the program: "Programa de Movilidad
   VIE-UIS: 2017."
CR Bedogni GA, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2167-y
   Ali SH, 2011, BIORESOURCE TECHNOL, V102, P10094, DOI 10.1016/j.biortech.2011.08.033
   Altiokka MR, 2003, APPL CATAL A-GEN, V239, P141, DOI 10.1016/S0926-860X(02)00381-2
   Balaraju M, 2010, FUEL PROCESS TECHNOL, V91, P249, DOI 10.1016/j.fuproc.2009.10.005
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Bonet J, 2009, FOOD BIOPROD PROCESS, V87, P171, DOI 10.1016/j.fbp.2009.06.003
   Boudart M., 1991, KINETICS CHEM PROCES
   Box G. E., 2005, STAT EXPT DESIGN INN, DOI [10.1017/S1742170510000062, DOI 10.1017/S1742170510000062]
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   CID R, 1985, APPL CATAL, V14, P15, DOI 10.1016/S0166-9834(00)84340-7
   Dosuna-Rodriguez I, 2012, CATAL TODAY, V195, P14, DOI 10.1016/j.cattod.2012.04.031
   Dosuna-Rodriguez I, 2011, CATAL TODAY, V167, P56, DOI 10.1016/j.cattod.2010.11.057
   Faria RPV, 2013, IND ENG CHEM RES, V52, P1538, DOI 10.1021/ie302935w
   Ferreira P, 2011, CATAL COMMUN, V12, P573, DOI 10.1016/j.catcom.2010.11.022
   Fogler HS, 1999, ELEMENTS CHEM REACTI
   FREDENSLUND A, 1975, AICHE J, V21, P1086, DOI 10.1002/aic.690210607
   Gelosa D, 2003, IND ENG CHEM RES, V42, P6536, DOI 10.1021/ie030292n
   Goncalves VLC, 2008, CATAL TODAY, V133, P673, DOI 10.1016/j.cattod.2007.12.037
   Gonzalez-Garay A, 2017, ACS SUSTAIN CHEM ENG, V5, P5723, DOI 10.1021/acssuschemeng.7b00286
   HABER J, 1991, PURE APPL CHEM, V63, P1227, DOI 10.1351/pac199163091227
   Hasabnis A, 2010, IND ENG CHEM RES, V49, P9058, DOI 10.1021/ie100937p
   Hung SK, 2014, IND ENG CHEM RES, V53, P11989, DOI 10.1021/ie500346w
   Izci A, 2007, REACT FUNCT POLYM, V67, P1458, DOI 10.1016/j.reactfunctpolym.2007.07.019
   Jagadeeswaraiah K, 2010, APPL CATAL A-GEN, V386, P166, DOI 10.1016/j.apcata.2010.07.046
   Khayoon MS, 2014, CHEM ENG J, V243, P473, DOI 10.1016/j.cej.2014.01.027
   Khayoon MS, 2011, BIORESOURCE TECHNOL, V102, P9229, DOI 10.1016/j.biortech.2011.07.035
   Khder AS, 2008, CATAL COMMUN, V9, P769, DOI 10.1016/j.catcom.2007.08.022
   Kim I, 2014, APPL CATAL B-ENVIRON, V148, P295, DOI 10.1016/j.apcatb.2013.11.008
   KIMBALL AW, 1951, ANN MATH STAT, V22, P600, DOI 10.1214/aoms/1177729552
   Kirumakki SR, 2006, APPL CATAL A-GEN, V299, P185, DOI 10.1016/j.apcata.2005.10.033
   KOROS RM, 1967, CHEM ENG SCI, V22, P470, DOI 10.1016/0009-2509(67)80134-9
   Kozuch S, 2012, ACS CATAL, V2, P2787, DOI 10.1021/cs3005264
   Kutner M. H., 2005, APPL LINEAR STAT MOD, DOI [10.2307/2984653, DOI 10.2307/2984653]
   Liao XY, 2010, APPL CATAL B-ENVIRON, V94, P64, DOI 10.1016/j.apcatb.2009.10.021
   Liao XY, 2009, FUEL PROCESS TECHNOL, V90, P988, DOI 10.1016/j.fuproc.2009.03.015
   Lilja J, 2002, J MOL CATAL A-CHEM, V182, P555, DOI 10.1016/S1381-1169(01)00495-2
   Liu JJ, 2013, IND ENG CHEM RES, V52, P3742, DOI 10.1021/ie400050v
   LOFTUS GR, 1978, MEM COGNITION, V6, P312, DOI 10.3758/BF03197461
   MADON RJ, 1982, IND ENG CHEM FUND, V21, P438, DOI 10.1021/i100008a022
   Montgomery D.C., 2013, APPL STAT PROBABILIT
   Mufrodi Z., 2012, INT J CHEM, V4, P101, DOI DOI 10.5539/IJC.V4N2P101
   Nanda MR, 2014, FUEL, V117, P470, DOI 10.1016/j.fuel.2013.09.066
   Okoye PU, 2017, RENEW SUST ENERG REV, V74, P387, DOI 10.1016/j.rser.2017.02.017
   Orjuela A, 2012, CHEM ENG J, V188, P98, DOI 10.1016/j.cej.2012.01.103
   Osorio-Viana W, 2013, CHEM ENG SCI, V101, P755, DOI 10.1016/j.ces.2013.07.009
   Pappu VKS, 2013, BIORESOURCE TECHNOL, V130, P793, DOI 10.1016/j.biortech.2012.12.087
   Patel A, 2014, FUEL, V118, P358, DOI 10.1016/j.fuel.2013.11.005
   Pico MP, 2012, IND ENG CHEM RES, V51, P9500, DOI 10.1021/ie300481d
   Quinn G.P., 2002, EXPT DESIGN DATA ANA
   Rahmat N, 2010, RENEW SUST ENERG REV, V14, P987, DOI 10.1016/j.rser.2009.11.010
   Rane SA, 2016, CHEM BIOCHEM ENG Q, V30, P33, DOI 10.15255/CABEQ.2014.2093
   Rastegari H, 2015, IND ENG CHEM RES, V54, P3279, DOI 10.1021/acs.iecr.5b00234
   Reddy PS, 2012, J IND ENG CHEM, V18, P648, DOI 10.1016/j.jiec.2011.11.063
   Reddy PS, 2010, CATAL COMMUN, V11, P1224, DOI 10.1016/j.catcom.2010.07.006
   Rohm Haas, 2006, AMBERLYST 35DRY IND, P1
   ROSNOW RL, 1995, PSYCHOL SCI, V6, P3, DOI 10.1111/j.1467-9280.1995.tb00297.x
   Sanchez JA, 2011, APPL CATAL A-GEN, V405, P55, DOI 10.1016/j.apcata.2011.07.027
   Santacesaria E, 1997, CATAL TODAY, V34, P393, DOI 10.1016/S0920-5861(96)00061-2
   Sievers C, 2016, ACS CATAL, V6, P8286, DOI 10.1021/acscatal.6b02532
   Silva LN, 2010, CATAL COMMUN, V11, P1036, DOI 10.1016/j.catcom.2010.05.007
   Smith J. M., 2005, INTRO CHEM ENG THERM
   Teo HTR, 2004, J CATAL, V228, P174, DOI 10.1016/j.jcat.2004.08.018
   Thommes M, 2015, PURE APPL CHEM, V87, P1051, DOI 10.1515/pac-2014-1117
   Vannice M. A., 2005, KINETICS CATALYTIC R, DOI [10.1007/b136380, DOI 10.1007/B136380]
   Veluturla Sravanthi, 2017, Resource-Efficient Technologies, V3, P337, DOI 10.1016/j.reffit.2017.02.005
   Wagenmakers EJ, 2012, MEM COGNITION, V40, P145, DOI 10.3758/s13421-011-0158-0
   WEISZ PB, 1954, ADV CATAL, V6, P143, DOI 10.1016/S0360-0564(08)60390-9
   Wu CFJ, 2009, EXPT PLANNING ANAL O, P2
   Wulfers MJ, 2015, APPL CATAL A-GEN, V505, P394, DOI 10.1016/j.apcata.2015.08.016
   Zhou LM, 2012, FUEL PROCESS TECHNOL, V104, P310, DOI 10.1016/j.fuproc.2012.06.001
NR 70
TC 2
Z9 2
U1 13
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 91
EP 104
DI 10.1016/j.ces.2019.06.003
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300008
DA 2020-05-12
ER

PT J
AU Dass, A
   Gedupudi, S
AF Dass, Akhil
   Gedupudi, Sateesh
TI 1-D semi-analytical modeling and parametric study of a single phase
   rectangular Coupled Natural Circulation Loop
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Natural Circulation Loop; 1-D mathematical model; Coupled system
ID CLOSED-LOOP; STEADY-STATE; OSCILLATORY INSTABILITY; BEHAVIOR; FLOW
AB The study of heat exchangers with both the hot and cold fluid sides driven by buoyancy forces is an area of considerable interest due to their inherent passivity and non-existence of moving parts. The current study aims to study such heat exchange devices employing the basic Coupled Natural Circulation Loop (CNCL) systems. A one dimensional (1-D) Fourier series based semi-analytical model of the basic CNCL system is proposed. A 3-D CFD validation is performed to validate the developed 1-D model. The non-dimensional numbers such as Grashof number, Fourier number, Stanton number and Reynolds number, which determine the system behavior are identified and a detailed parametric study is performed. Both vertical and horizontal CNCL systems are considered along with the parallel and counter flow configurations. The heater-cooler location greatly influences the behavior of CNCL system. The vertical CNCL always exhibits counter flow configuration whereas the horizontal CNCL system may exhibit parallel or counter flow arrangement depending on the heater-cooler location and initial flow conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dass, Akhil; Gedupudi, Sateesh] IIT Madras, Dept Mech Engn, Heat Transfer & Thermal Power Lab, Chennai 600036, Tamil Nadu, India.
RP Gedupudi, S (reprint author), IIT Madras, Dept Mech Engn, Heat Transfer & Thermal Power Lab, Chennai 600036, Tamil Nadu, India.
EM sateeshg@iitm.ac.in
OI Dass D, Akhil/0000-0003-4480-8071
CR Basu DN, 2007, APPL THERM ENG, V27, P1432, DOI 10.1016/j.applthermaleng.2006.10.004
   Basu DN, 2014, NUCL ENG DES, V280, P326, DOI 10.1016/j.nucengdes.2014.09.011
   Borgohain A, 2011, PROG NUCL ENERG, V53, P308, DOI 10.1016/j.pnucene.2010.10.004
   Cammi A, 2017, CHEM ENG SCI, V166, P220, DOI 10.1016/j.ces.2017.03.036
   CHEN K, 1985, J HEAT TRANS-T ASME, V107, P826, DOI 10.1115/1.3247510
   Crawford NM, 2007, P I MECH ENG E-J PRO, V221, P77, DOI 10.1243/0954408JPME84
   Darby R, 2001, CHEM ENG FLUID MECH
   DAVIS SH, 1987, PHYSICA D, V24, P226, DOI 10.1016/0167-2789(87)90077-7
   Desrayaud G, 2013, APPL THERM ENG, V50, P187, DOI 10.1016/j.applthermaleng.2012.06.003
   Devia F, 2012, INT J THERM SCI, V59, P195, DOI 10.1016/j.ijthermalsci.2012.03.006
   Duffey RB, 2016, WOODHEAD PUBL SER EN, P455, DOI 10.1016/B978-0-08-100149-3.00016-1
   EDWARDS MF, 1985, CHEM ENG RES DES, V63, P43
   Ehrhard P, 1988, THESIS
   Fichera A, 2003, INT J HEAT MASS TRAN, V46, P2425, DOI 10.1016/S0017-9310(02)00543-4
   GORDON M, 1987, INT J HEAT FLUID FL, V8, P177, DOI 10.1016/0142-727X(87)90025-7
   GREIF R, 1988, J HEAT TRANS-T ASME, V110, P1243, DOI 10.1115/1.3250624
   HART JE, 1984, INT J HEAT MASS TRAN, V27, P125, DOI 10.1016/0017-9310(84)90244-8
   Kudariyawar JY, 2016, INT J THERM SCI, V101, P193, DOI 10.1016/j.ijthermalsci.2015.11.003
   Louisos WF, 2013, INT J HEAT MASS TRAN, V61, P565, DOI 10.1016/j.ijheatmasstransfer.2013.02.015
   Luzzi L, 2017, CHEM ENG SCI, V162, P262, DOI 10.1016/j.ces.2016.12.058
   Marchitto A, 2018, MATH MODELL ENG PROB
   Misale M, 2016, INT J HEAT MASS TRAN, V99, P782, DOI 10.1016/j.ijheatmasstransfer.2016.04.036
   Misale M, 2012, APPL THERM ENG, V40, P64, DOI 10.1016/j.applthermaleng.2012.01.053
   Misale M, 2011, INT J HEAT FLUID FL, V32, P413, DOI 10.1016/j.ijheatfluidflow.2010.12.003
   Misale M, 1999, INT COMMUN HEAT MASS, V26, P597, DOI 10.1016/S0735-1933(99)00046-9
   Misale M, 2010, P 20 NAT 9 INT ISHMT, P4
   Pini A, 2016, CHEM ENG SCI, V145, P108, DOI 10.1016/j.ces.2016.01.014
   Rodriguez-Bernal A, 1998, SIAM J APPL MATH, V58, P1072, DOI 10.1137/S0036139996304184
   Salazar O., 1988, J THERMOPHYS HEAT TR, V2, P180
   Satoh A, 1998, CHAOS SOLITON FRACT, V9, P1575, DOI 10.1016/S0960-0779(97)00117-3
   Satou A, 2001, EXP THERM FLUID SCI, V25, P429, DOI 10.1016/S0894-1777(01)00092-9
   Srivastava AK, 2016, APPL THERM ENG, V98, P513, DOI 10.1016/j.applthermaleng.2015.12.065
   Tolstov G.P, 2012, FOURIER SERIES
   Vijayan PK, 2007, EXP THERM FLUID SCI, V31, P925, DOI 10.1016/j.expthermflusci.2006.10.003
   Vijayan PK, 2002, NUCL ENG DES, V215, P139, DOI 10.1016/S0029-5493(02)00047-X
   VIJAYAN PK, 1995, NUCL ENG DES, V155, P623, DOI 10.1016/0029-5493(94)00972-2
   WELANDER P, 1967, J FLUID MECH, V29, P17, DOI 10.1017/S0022112067000606
   Yunus AC, 2006, FLUID MECH FUNDAMENT
   Zhang X, 2015, ATOM ENERGY SCI TECH, V3
   ZVIRIN Y, 1982, NUCL ENG DES, V67, P203, DOI 10.1016/0029-5493(82)90142-X
NR 40
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 105
EP 129
DI 10.1016/j.ces.2019.05.050
PG 25
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300009
DA 2020-05-12
ER

PT J
AU Ledema, PD
   Schambock, V
   Boonen, H
   van der Linden, MN
   Willemse, R
AF Ledema, P. D.
   Schambock, V
   Boonen, H.
   van der Linden, M. N.
   Willemse, R.
TI Photocuring of di-acrylate in presence of oxygen
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Photocuring; Modeling; Acrylate; Oxygen inhibition; Kinetics
ID RADICAL PHOTOPOLYMERIZATION; CROSS-LINKING; KINETICS; INHIBITION
AB A model is presented for photocuring of a hexanediol diacrylate (HDDA) film, where in the presence of oxygen liquid monomer cures into a solid polymer network. The model is based on an earlier version (ledema et al., 2018) that has been validated in absence of oxygen. The oxygen from ambient air inhibits the polymerization in the top part of the film causing conversion gradients across the film, which is a problem in the manufacture of large scale prints. In the current work results of the curing of thin HDDA films (10 mu m) exposed to ambient air with initiator Irgacure 819, bis(acylphosphine oxide) under irradiation intensity varying in a range of 1000-6000 W.m(2) are presented. The average conversion of vinyl groups in bulk of the films was registered by real-time Fourier Transformed Infrared (FTIR) in transmission mode, while simultaneously the conversion in the non-exposed bottom part was measured by real-time FTIR with attenuated transmission reflectance (ATR). The bulk data were used to estimate the kinetic and transport parameters of the model, which enables it to correctly describe the bulk and bottom cure as measured by FTIR. The model accounts for local swelling and shrinking of the created polymer due to the conversion gradient. By Raman spectroscopy the conversion gradient after the photocuring process was also directly measured, again confirming the considerable conversion difference between top and bottom of the film predicted by the model as caused by oxygen inhibition. Initially dissolved small amounts oxygen throughout the whole film turns out to be a negligable role. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ledema, P. D.; Schambock, V] Univ Amsterdam, Amsterdam, Netherlands.
   [Boonen, H.; van der Linden, M. N.; Willemse, R.] Oce Technol, Venlo, Netherlands.
RP Ledema, PD (reprint author), Univ Amsterdam, Amsterdam, Netherlands.
CR Bisschops MAT, 1998, IND ENG CHEM RES, V37, P3312, DOI 10.1021/ie9800389
   Boonen HAL, 2017, APPL SPECTROSC, V71, P2699, DOI 10.1177/0003702817718203
   Bowman CN, 2008, AICHE J, V54, P2775, DOI 10.1002/aic.11678
   Caspers P, 2003, RAMAN MICROSPECTROSC
   Caspers PJ, 2000, J RAMAN SPECTROSC, V31, P813, DOI 10.1002/1097-4555(200008/09)31:8/9<813::AID-JRS573>3.0.CO;2-7
   Courtecuisse F, 2016, PROG ORG COAT, V92, P1, DOI 10.1016/j.porgcoat.2015.11.020
   Debroy D, 2018, J COLLOID INTERF SCI, V510, P334, DOI 10.1016/j.jcis.2017.09.081
   Elliott JE, 1999, MACROMOLECULES, V32, P8621, DOI 10.1021/ma990797i
   Goodner MD, 2002, CHEM ENG SCI, V57, P887, DOI 10.1016/S0009-2509(01)00287-1
   Iedema PD, 2018, CHEM ENG SCI, V176, P491, DOI 10.1016/j.ces.2017.11.009
   Ligon SC, 2014, CHEM REV, V114, P557, DOI 10.1021/cr3005197
   Ligon-Auer SC, 2016, POLYM CHEM-UK, V7, P257, DOI 10.1039/c5py01631b
   Mueller JB, 2014, ADV MATER, V26, P6566, DOI 10.1002/adma.201402366
   O'Brien AK, 2006, MACROMOLECULES, V39, P2501, DOI 10.1021/ma051863l
   O'Brien AK, 2006, MACROMOL THEOR SIMUL, V15, P176, DOI 10.1002/mats.200500056
   Oakley L., 2015, APPL PHYS A, V121
   Orlova Y, 2018, COMPUT CHEM ENG, V112, P37, DOI 10.1016/j.compchemeng.2018.01.022
   Pilkenton M, 2011, J APPL POLYM SCI, V119, P2359, DOI 10.1002/app.32650
   POTUCEK F, 1986, CHEM ENG SCI, V41, P3223, DOI 10.1016/0009-2509(86)85061-8
   Safranski DL, 2008, POLYMER, V49, P4446, DOI 10.1016/j.polymer.2008.07.060
   Scherzer T, 1999, VIB SPECTROSC, V19, P385, DOI 10.1016/S0924-2031(98)00070-8
   Scherzer T, 2005, MACROMOL CHEM PHYSIC, V206, P240, DOI 10.1002/macp.200400300
   Skomorokhov IV, 2004, RUSS J APPL CHEM+, V77, P88, DOI 10.1023/B:RJAC.0000024583.75610.50
   Taki K, 2014, MACROMOLECULES, V47, P1906, DOI 10.1021/ma402437q
   Torres-Knoop A, 2018, SOFT MATTER, V14, P3404, DOI 10.1039/c8sm00451j
   Yagci Y, 2010, MACROMOLECULES, V43, P6245, DOI 10.1021/ma1007545
   Yao KZ, 2003, POLYM REACT ENG, V11, P563, DOI 10.1081/PRE-120024426
   Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z
   Zhao Z, 2016, EXTREME MECH LETT, V9, P108, DOI 10.1016/j.eml.2016.05.012
NR 29
TC 1
Z9 1
U1 15
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 130
EP 144
DI 10.1016/j.ces.2019.05.056
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300010
DA 2020-05-12
ER

PT J
AU Makeev, IV
   Popov, IY
   Abiev, RS
AF Makeev, Ilya, V
   Popov, Igor Yu
   Abiev, Rufat Sh
TI Analytical solution of Taylor circulation in a prolate ellipsoid droplet
   in the frame of 2D Stokes equations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microreactor; Taylor flow; Taylor vortices; 2D Stokes equations; Exact
   solution
ID SLUG FLOW; SEGMENTED FLOW; BUBBLES; REACTORS; INTENSIFICATION; SHAPE
AB Exact solutions for the biharmonic Stokes equation for the stream function of the Stokes flow were obtained for the prolate ellipsoid which mimics the shape of an elongated Taylor bubble or droplet in two-phase gas-liquid or liquid-liquid flow in microchannels. The Obtained results demonstrate good qualitative agreement with data available in the published papers: two main vortices along the droplet plus two secondary vortices near both ends of the droplet. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Makeev, Ilya, V; Popov, Igor Yu] St Petersburg Natl Res Univ Informat Technol, ITMO Univ, Fac Control Syst & Robot, Mech & Opt, Kronverkskiy 49, St Petersburg 197101, Russia.
   [Abiev, Rufat Sh] St Petersburg State Inst Technol Tech Univ, Dept Optimizat Chem & Biotechnol Equipment, Moskovskii Pr 26, St Petersburg 190013, Russia.
RP Abiev, RS (reprint author), St Petersburg State Inst Technol Tech Univ, Dept Optimizat Chem & Biotechnol Equipment, Moskovskii Pr 26, St Petersburg 190013, Russia.
EM rufat.abiev@gmail.com
RI Abiev, Rufat Sh/J-4139-2013; Popov, Igor/A-7604-2014
OI Abiev, Rufat Sh/0000-0003-3571-5770; Popov, Igor/0000-0002-5251-5327
FU Government of the Russian Federation [08-08, 16-11-10330]; Russian
   Science FoundationRussian Science Foundation (RSF); Russian Foundation
   for Basic ResearchRussian Foundation for Basic Research (RFBR)
   [18-03-00206-a]
FX This work was partially financially supported by the Government of the
   Russian Federation (grant 08-08), grant 16-11-10330 of Russian Science
   Foundation, and by Russian Foundation for Basic Research according to
   the research project No 18-03-00206-a.
CR Abiev RS, 2008, THEOR FOUND CHEM EN+, V42, P105, DOI 10.1134/S0040579508020012
   Abiev RS, 2017, CHEM ENG SCI, V174, P403, DOI 10.1016/j.ces.2017.09.041
   Abiev RS, 2009, THEOR FOUND CHEM EN+, V43, P298, DOI 10.1134/S0040579509030099
   Arad M., 1997, NUMER METH PART D E, V13, P375, DOI [10.1002/(SICI)1098-2426(199707)13:4<lessthan>375::AID-NUM5<greaterthan>3.0.CO;2-I, DOI 10.1002/(SICI)1098-2426(199707)13:4<375::AID-NUM5>3.0.CO;2-I]
   Bauer T, 2006, RUSS J APPL CHEM+, V79, P1047, DOI 10.1134/S107042720607019
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Cherukumudi A, 2015, MICROFLUID NANOFLUID, V19, P1221, DOI 10.1007/s10404-015-1641-x
   Choblet G, 2005, J COMPUT PHYS, V205, P269, DOI 10.1016/j.jcp.2004.11.005
   Dore V, 2012, CHEM ENG SCI, V80, P334, DOI 10.1016/j.ces.2012.06.030
   Driesen CH, 1998, J ENG MATH, V34, P3, DOI 10.1023/A:1004235021527
   Driesen CH, 2000, COMPUT MECH, V25, P501, DOI 10.1007/s004660050497
   Falconi CJ, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4939498
   Gurcan F, 2003, P I MECH ENG C-J MEC, V217, P353, DOI 10.1243/095440603762870018
   Hessel V, 2005, CHEMICAL MICRO PROCESS ENGINEERING: PROCESSING AND PLANTS, P1, DOI 10.1002/3527603581
   HIGDON JJL, 1985, J FLUID MECH, V159, P195, DOI 10.1017/S0022112085003172
   Kashid MN, 2007, J COMPUT APPL MATH, V203, P487, DOI 10.1016/j.cam.2006.04.010
   Kashid MN, 2008, ASIA-PAC J CHEM ENG, V3, P151, DOI 10.1002/apj.127
   Klaseboer E, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4868257
   Krasnopolskaya TS, 1996, Q J MECH APPL MATH, V49, P593, DOI 10.1093/qjmam/49.4.593
   Kreutzer MT, 2005, CHEM ENG SCI, V60, P5895, DOI 10.1016/j.ces.2005.03.022
   Li Q., 2017, CHEM ENG J, V15, P17
   Marchisio DL, 2006, AICHE J, V52, P1877, DOI 10.1002/aic.10786
   Marschall H, 2017, ADV MATH FLUID MECH, P663, DOI 10.1007/978-3-319-56602-3_23
   Meyer C, 2014, INT J MULTIPHAS FLOW, V67, P140, DOI 10.1016/j.ijmultiphaseflow.2014.07.004
   Nightingale AM, 2013, ADV MATER, V25, P1813, DOI 10.1002/adma.201203252
   Popov AI, 2015, NANOSYST-PHYS CHEM M, V6, P140, DOI 10.17586/2220-8054-2015-6-1-140-145
   Popov AI, 2014, NANOSYST-PHYS CHEM M, V5, P391
   Popov IY, 2014, SOLID EARTH, V5, P461, DOI 10.5194/se-5-461-2014
   Popova EA, 2014, CHEM BIOCHEM ENG Q, V28, P241, DOI 10.15255/CABEQ.2013.1936
   SAATDJIAN E, 1994, PHYS FLUIDS, V6, P3833, DOI 10.1063/1.868375
   Stankiewicz AI, 2000, CHEM ENG PROG, V96, P22
   Tosi N, 2007, GEOPHYS J INT, V170, P1015, DOI 10.1111/J.1365-246X.2007.03482.X
   van der Woude D, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2742679
NR 33
TC 0
Z9 0
U1 10
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 145
EP 152
DI 10.1016/j.ces.2019.06.015
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300011
DA 2020-05-12
ER

PT J
AU Amani, A
   Balcazar, N
   Castro, J
   Oliva, A
AF Amani, Ahmad
   Balcazar, Nestor
   Castro, Jesus
   Oliva, Assensi
TI Numerical study of droplet deformation in shear flow using a
   conservative level-set method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Simple shear flow; Droplet deformation and breakup; Conservative
   Level-set method; Viscosity ratio; Critical confinement ratio
ID LATTICE BOLTZMANN SIMULATIONS; REYNOLDS-NUMBER MOTION; VISCOUS DROPS;
   VISCOELASTIC DROP; VISCOSITY RATIO; POLYMER BLENDS; BREAKUP; FLUID;
   SINGLE; MICROFLUIDICS
AB This paper is concerned with a numerical study on the behavior of a single Newtonian droplet suspended in another Newtonian fluid, all subjected to a simple shear flow. Conservative finite-volume approximation on a collocated three-dimensional grid along with a conservative Level-set method are used to solve the governing equations. Four parameters of capillary number (Ca), Viscosity ratio (lambda), Reynolds number (Re) and walls confinement ratio are used to physically define the problem. The main focus of the current study is to investigate the effect of viscosity on walls critical confinement ratio. In this paper, the phrase critical is used to specify a state of governing parameters in which divides the parameter space into the subcritical and supercritical regions where droplets attain a steady shape or breakup, respectively. To do so, first, we validate the ability of proposed method on capturing the physics of droplet deformation including: steady-state subcritical deformation of non-confined droplet, breakup of supercritical conditioned droplet, steady-state deformation of moderate confined droplet, subcritical oscillation of highlyconfined droplet, and the effect of viscosity ratio on deformation of the droplet. The extracted results are compared with available experimental, analytical and numerical data from the literature. Afterward, for a constant capillary number of 0.3 and a low Reynolds number of 1.0, subcritical (steady-state) and supercritical (breakup) deformations of the droplet for a wide range of walls confinement in different viscosity ratios are studied. The results indicate the existence of two steady-state regions in a viscosity ratio-walls confinement ratio graph which are separated by a breakup region. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Amani, Ahmad; Castro, Jesus; Oliva, Assensi] Univ Politecn Cataluna, Barcelona Tech, ESEIAAT, Heat & Mass Transfer Technol Ctr CTTC, Colom 11, Tenassa 08222, Barcelona, Spain.
   [Balcazar, Nestor] Termo Fluids SL, Avda Jacquard 97 1-E, Terrassa 08222, Barcelona, Spain.
RP Amani, A; Oliva, A (reprint author), Univ Politecn Cataluna, Barcelona Tech, ESEIAAT, Heat & Mass Transfer Technol Ctr CTTC, Colom 11, Tenassa 08222, Barcelona, Spain.
EM ahmad@cttc.upc.edu.com; nestor@cttc.upc.edu; jesus@cttc.upc.edu;
   oliva@cttc.upc.edu
RI Castro, Jesus/L-8564-2014; Balcazar, Nestor/Y-9985-2018
OI Castro, Jesus/0000-0002-8943-2402; Balcazar, Nestor/0000-0003-0776-2086
FU Ministerio de Economia y Competitividad, Secretaria de Estado de
   Investigacion, Desarrollo e Innovacion, Spain [ENE2015-70672-P]; FI
   research scholarship by the Agencia de Gestio d'Ajuts Universitaris i de
   Recerca (AGAUR) of Generalitat de Catalunya [2016 FI_B 01059]; Programa
   Torres Quevedo [PTQ-14-07186]; Instituto de Fisica de Cantabria -
   Universidad de Cantabria [RES-FI-2018-3-0045]
FX This work has been financially supported by the Ministerio de Economia y
   Competitividad, Secretaria de Estado de Investigacion, Desarrollo e
   Innovacion, Spain (ENE2015-70672-P). A. Amani acknowledges the financial
   support of an FI research scholarship by the Agencia de Gestio d'Ajuts
   Universitaris i de Recerca (AGAUR) of Generalitat de Catalunya (2016
   FI_B 01059). N. Balcazar acknowledges the financial support of the
   Programa Torres Quevedo (PTQ-14-07186). The authors thankfully
   acknowledge the computer resources at Altamira and the technical support
   provided by Instituto de Fisica de Cantabria - Universidad de Cantabria
   (RES-FI-2018-3-0045).
CR Abou-Hassan A, 2010, ANGEW CHEM INT EDIT, V49, P6268, DOI 10.1002/anie.200904285
   Amani A., 2018, 6 EUR C COMP MECH EC
   Amani A, 2019, CHEM ENG J, V370, P477, DOI 10.1016/j.cej.2019.03.188
   Armfield S, 2002, INT J NUMER METH FL, V38, P255, DOI 10.1002/fld.217
   Balcazar N, 2017, PROCEDIA COMPUT SCI, V108, P2008, DOI 10.1016/j.procs.2017.05.076
   Balcazar N, 2016, INT J HEAT FLUID FL, V62, P324, DOI 10.1016/j.ijheatfluidflow.2016.09.015
   Balcazar N, 2016, COMPUT FLUIDS, V124, P12, DOI 10.1016/j.compfluid.2015.10.005
   Balcazar N, 2015, INT J HEAT FLUID FL, V56, P91, DOI 10.1016/j.ijheatfluidflow.2015.07.004
   Balcazar N, 2015, INT J MULTIPHAS FLOW, V74, P125, DOI 10.1016/j.ijmultiphaseflow.2015.04.009
   Balcazar N, 2014, INT J MULTIPHAS FLOW, V64, P55, DOI 10.1016/j.ijmultiphaseflow.2014.04.008
   BENTLEY BJ, 1986, J FLUID MECH, V167, P241, DOI 10.1017/S0022112086002811
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   CHORIN AJ, 1968, MATH COMPUT, V22, P745, DOI 10.2307/2004575
   COX RG, 1969, J FLUID MECH, V37, P601, DOI 10.1017/S0022112069000759
   Cristini V, 2006, FLUID DYN MATER PROC, V2, P77
   Felten FN, 2006, J COMPUT PHYS, V215, P465, DOI 10.1016/j.jcp.2005.11.009
   Gottlieb S, 1998, MATH COMPUT, V67, P73, DOI 10.1090/S0025-5718-98-00913-2
   Gounley J, 2016, J FLUID MECH, V791, P464, DOI 10.1017/jfm.2016.39
   GRACE HP, 1982, CHEM ENG COMMUN, V14, P225, DOI 10.1080/00986448208911047
   Gutierrez E, 2018, CHEM ENG J, V349, P662, DOI 10.1016/j.cej.2018.05.110
   Hsu AS, 2009, J NON-NEWTON FLUID, V160, P176, DOI 10.1016/j.jnnfm.2009.03.004
   Ioannou N, 2017, MICROMACHINES-BASEL, V8, DOI 10.3390/mi8020057
   Janssen PJA, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2715621
   Janssen PJA, 2010, J RHEOL, V54, P1047, DOI 10.1122/1.3473924
   KENNEDY MR, 1994, COMPUT FLUIDS, V23, P251, DOI 10.1016/0045-7930(94)90040-X
   Khismatullin DB, 2003, PHYS FLUIDS, V15, P1351, DOI 10.1063/1.1564825
   KIM J, 1985, J COMPUT PHYS, V59, P308, DOI 10.1016/0021-9991(85)90148-2
   Komrakova AE, 2014, INT J MULTIPHAS FLOW, V59, P24, DOI 10.1016/j.ijmultiphaseflow.2013.10.009
   Kwak S, 1998, J COMPUT PHYS, V145, P61, DOI 10.1006/jcph.1998.6030
   Li J, 2000, PHYS FLUIDS, V12, P269, DOI 10.1063/1.870305
   Li L, 2010, MICROFLUID NANOFLUID, V8, P789, DOI 10.1007/s10404-009-0512-8
   Marks C. R, 1998, DROP BREAKUP DEFORMA
   Mason TG, 1997, LANGMUIR, V13, P4600, DOI 10.1021/la9700580
   Minale M, 2008, RHEOL ACTA, V47, P667, DOI 10.1007/s00397-007-0237-0
   Mukherjee S, 2009, J NON-NEWTON FLUID, V160, P104, DOI 10.1016/j.jnnfm.2009.03.007
   Olsson E, 2005, J COMPUT PHYS, V210, P225, DOI 10.1016/j.jcp.2005.04.007
   Pozrikidis C., 1992, CAMBRIDGE TEXTS APPL
   RALLISON JM, 1984, ANNU REV FLUID MECH, V16, P45, DOI 10.1146/annurev.fl.16.010184.000401
   Renardy Y, 2002, INT J MULTIPHAS FLOW, V28, P1125, DOI 10.1016/S0301-9322(02)00022-8
   Renardy YY, 2001, PHYS FLUIDS, V13, P7, DOI 10.1063/1.1331321
   RHIE CM, 1983, AIAA J, V21, P1525, DOI 10.2514/3.8284
   RICHARDSON S, 1968, J FLUID MECH, V33, P475, DOI 10.1017/S0022112068001461
   Roths T, 2002, RHEOL ACTA, V41, P211, DOI 10.1007/s003970100189
   Rowat AC, 2009, P NATL ACAD SCI USA, V106, P18149, DOI 10.1073/pnas.0903163106
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   SHAN XW, 1993, PHYS REV E, V47, P1815, DOI 10.1103/PhysRevE.47.1815
   SHAPIRA M, 1990, INT J MULTIPHAS FLOW, V16, P305, DOI 10.1016/0301-9322(90)90061-M
   SHAPIRA M, 1988, INT J MULTIPHAS FLOW, V14, P483, DOI 10.1016/0301-9322(88)90024-9
   Sibillo V, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.054502
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   STONE HA, 1994, ANNU REV FLUID MECH, V26, P65, DOI 10.1146/annurev.fluid.26.1.65
   Taylor GI, 1932, P R SOC LOND A-CONTA, V138, P41, DOI 10.1098/rspa.1932.0169
   Taylor GI, 1934, P R SOC LOND A-CONTA, V146, P0501, DOI 10.1098/rspa.1934.0169
   Theberge AB, 2010, ANGEW CHEM INT EDIT, V49, P5846, DOI 10.1002/anie.200906653
   TOOSE EM, 1995, J NON-NEWTON FLUID, V60, P129, DOI 10.1016/0377-0257(95)01386-3
   Tufano C, 2008, LANGMUIR, V24, P4494, DOI 10.1021/la7036636
   van der Sman RGM, 2008, COMPUT PHYS COMMUN, V178, P492, DOI 10.1016/j.cpc.2007.11.009
   Vananroye A, 2006, LANGMUIR, V22, P2273, DOI 10.1021/la0527893
   Vananroye A, 2006, LANGMUIR, V22, P3972, DOI 10.1021/la060442+
   Vananroye A, 2008, J RHEOL, V52, P1459, DOI 10.1122/1.2978956
   Verhulst K, 2009, J NON-NEWTON FLUID, V156, P29, DOI 10.1016/j.jnnfm.2008.06.007
   Vyawahare S, 2010, CHEM BIOL, V17, P1052, DOI 10.1016/j.chembiol.2010.09.007
   Xi HW, 1999, PHYS REV E, V59, P3022, DOI 10.1103/PhysRevE.59.3022
NR 63
TC 1
Z9 1
U1 15
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 153
EP 171
DI 10.1016/j.ces.2019.06.014
PG 19
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300012
DA 2020-05-12
ER

PT J
AU Wang, YN
   Liu, ZZ
   Cao, LL
   Blanpain, B
   Guo, MX
AF Wang, Yannan
   Liu, Zhuangzhuang
   Cao, Lingling
   Blanpain, Bart
   Guo, Muxing
TI Simulation of particle migration during viscosity measurement of
   solid-bearing slag using a spindle rotational type viscometer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Viscosity measurement; Particle migration; Critical shear time;
   Operational condition; Discrete phase model; Discrete element method
ID HETEROGENEOUS SILICATE MELTS; CONCENTRATED SUSPENSIONS; RHEOLOGY;
   COUETTE; LIFT; DRAG
AB A Discrete Phase Model (DPM) is adopted to investigate the particle behavior during viscosity measurement of solid-bearing slags. The particle-particle interaction is interpreted by the Discrete Element Method (DEM). The results show that the particle migration is a function of shear time, leading to continuous changes in variable viscosity before a critical shear time. The critical shear time and therefore the viscosity measurement depend on the operational conditions through the particle migration behavior that is influenced by the shear time, rotational speed, gap width and particle content, shape and size. The study of particle size indicates a size segregation of the initially homogeneous system. Based on our results a number of guidelines are formulated to assist in developing more reproducible viscosity measurement methodologies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Yannan; Liu, Zhuangzhuang; Blanpain, Bart; Guo, Muxing] Katholieke Univ Leuven, Dept Mat Engn, B-3000 Leuven, Belgium.
   [Cao, Lingling] Univ Sci & Technol Beijing, State Key Lab Adv Met, Beijing 100083, Peoples R China.
RP Liu, ZZ (reprint author), Katholieke Univ Leuven, Dept Mat Engn, B-3000 Leuven, Belgium.
EM zhoangzhuang.liu@kuleuven.be
FU China Scholarship Council (CSC)China Scholarship Council [IWT 140514]
FX The financial grant IWT 140514 (Belgium) is highly acknowledged. The
   authors, Y. Wang, L. Cao and Z. Liu, would like to give their thanks to
   the China Scholarship Council (CSC).
CR ABBOTT JR, 1991, J RHEOL, V35, P773, DOI 10.1122/1.550157
   ANSYS Inc, 2015, ANS THEOR GUID 16 2
   Chen X, 2004, COMP MATER SCI, V30, P223, DOI 10.1016/j.commatsci.2004.03.010
   CHOW AW, 1994, PHYS FLUIDS, V6, P2561, DOI 10.1063/1.868147
   Chu KW, 2011, CHEM ENG SCI, V66, P834, DOI 10.1016/j.ces.2010.11.026
   Crowe C., 1998, MULTIPHASE FLOWS DRO
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   GADALAMARIA F, 1980, J RHEOL, V24, P799, DOI 10.1122/1.549584
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   HUSBAND DM, 1994, RHEOL ACTA, V33, P185, DOI 10.1007/BF00437303
   JINESCU VV, 1974, INT CHEM ENG, V14, P397
   KERR RC, 1991, J GEOL, V99, P457, DOI 10.1086/629506
   LEIGHTON D, 1987, J FLUID MECH, V181, P415, DOI 10.1017/S0022112087002155
   Liu Z, 2016, P 10 INT C MOLT SLAG, P439
   Liu ZZ, 2018, ISIJ INT, V58, P1972, DOI 10.2355/isijinternational.ISIJINT-2018-176
   Liu ZZ, 2018, METALL MATER TRANS B, V49, P2469, DOI 10.1007/s11663-018-1374-9
   Liu ZZ, 2018, METALL MATER TRANS B, V49, P2649, DOI 10.1007/s11663-018-1324-6
   Liu ZZ, 2016, 7TH INTERNATIONAL SYMPOSIUM ON HIGH-TEMPERATURE METALLURGICAL PROCESSING, P263
   Liu ZZ, 2018, J NON-CRYST SOLIDS, V493, P65, DOI 10.1016/j.jnoncrysol.2018.04.042
   Liu ZZ, 2017, ISIJ INT, V57, P1895, DOI 10.2355/isijinternational.ISIJINT-2017-288
   Liu ZZ, 2017, METALL MATER TRANS B, V48, P3027, DOI 10.1007/s11663-017-1075-9
   Marshall JS, 2009, J COMPUT PHYS, V228, P1541, DOI 10.1016/j.jcp.2008.10.035
   Mewis J, 2012, COLLOIDAL SUSPENSION
   MIKAMI HM, 1963, T METALL SOC AIME, V227, P1229
   MORSI SA, 1972, J FLUID MECH, V55, P193, DOI 10.1017/S0022112072001806
   PHILLIPS RJ, 1992, PHYS FLUIDS A-FLUID, V4, P30, DOI 10.1063/1.858498
   Rao RR, 2002, CHEM ENG COMMUN, V189, P1, DOI 10.1080/00986440211827
   SAFFMAN PG, 1965, J FLUID MECH, V22, P385, DOI 10.1017/S0022112065000824
   Sato H, 2005, J MINER PETROL SCI, V100, P133, DOI 10.2465/jmps.100.133
   Seok SH, 2007, ISIJ INT, V47, P1090, DOI 10.2355/isijinternational.47.1090
   Sridhar S, 2000, IRONMAK STEELMAK, V27, P238, DOI 10.1179/030192300677534
   Wadell H, 1933, J GEOL, V41, P310, DOI 10.1086/624040
   Wright S, 2000, METALL MATER TRANS B, V31, P97, DOI 10.1007/s11663-000-0134-8
   Wright S, 2001, J NON-CRYST SOLIDS, V282, P15, DOI 10.1016/S0022-3093(01)00324-6
   Zastawny M, 2012, INT J MULTIPHAS FLOW, V39, P227, DOI 10.1016/j.ijmultiphaseflow.2011.09.004
   Zhen YL, 2015, METALL MATER TRANS B, V46, P155, DOI 10.1007/s11663-014-0169-x
NR 36
TC 0
Z9 0
U1 9
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 172
EP 180
DI 10.1016/j.ces.2019.06.022
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300013
DA 2020-05-12
ER

PT J
AU Hopley, A
   Doyle, BJ
   Roberge, DM
   Macchi, A
AF Hopley, Alexandra
   Doyle, Brendon J.
   Roberge, Dominique M.
   Macchi, Arturo
TI Residence time distribution in coil and plate micro-reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micro-reactor; Residence time distribution; Mixer geometry; Mixer
   spacing; Dispersion; Scaling
ID LAMINAR-FLOW; AXIAL-DISPERSION; HEAT-TRANSFER; SCALE-UP; EXOTHERMIC
   REACTIONS; MASS-TRANSFER; DESIGN; RTD; MICROREACTORS; DIFFUSION
AB Micro-reactors, enabling continuous processes at small scales, have been of growing interest due to their advantages over batch. These advantages include better scaling, as well as improved mass and heat transfer, though many new challenges arise due to the small scales involved such as non-negligible entrance effects and significant pressure losses. The flow in coils, rectangular channel serpentine plates, mix-andreside plates, and liquid-liquid (LL) mixing plates was investigated and characterized using residence time distribution (RTD) tests. A pulse test was used to determine the RTD curve of these reactors at flowrates ranging from 15 to 100 g/min of water. A semi-empirical, multi-parameter model was used to describe the asymmetrical curves, while the axial dispersion model was used to describe the symmetrical ones. The Peclet number is given in function of the Reynolds number for the LL plates that were found to be near-plug flow (Pe > 100). In a plate with continuous LL micro-mixers, the Pe ranged from 193 to 467 with Pe increasing as Re increased. Importantly, the effect of straight channel segments interspaced between mixers is also evaluated as a method of volume gain for scale-up of micro-reactors. For a given average energy dissipation rate, the Pe number was maintained for the shorter channel segments between LL micro-mixers whereas longer spacing lengths likely lead to the development of unidirectional laminar flow and resulting in the observed increased axial dispersion and tailing in the RTD. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hopley, Alexandra; Doyle, Brendon J.; Macchi, Arturo] Univ Ottawa, Ctr Catalysis Res & Innovat, Dept Chem & Biol Engn, Ottawa, ON K1N 6N5, Canada.
   [Roberge, Dominique M.] Lonza AG, Chem Mfg Technol, CH-3930 Visp, Switzerland.
RP Macchi, A (reprint author), Univ Ottawa, Ctr Catalysis Res & Innovat, Dept Chem & Biol Engn, Ottawa, ON K1N 6N5, Canada.; Roberge, DM (reprint author), Lonza AG, Chem Mfg Technol, CH-3930 Visp, Switzerland.
EM dominique.roberge@lonza.com; arturo.mac-chi@uottawa.ca
FU Natural Sciences and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada; CREATE program in
   Continuous Flow Science, and Lonza
FX The authors would like to thank the Natural Sciences and Engineering
   Research Council of Canada, including the CREATE program in Continuous
   Flow Science, and Lonza for their financial contribution. Also, Ehrfeld
   Mikrotechnik is acknowledged for the reactor manufacturing.
CR Aider AA, 2005, J PHYS CONF SER, V14, P118, DOI 10.1088/1742-6596/14/1/015
   Boskovic D, 2008, CHEM ENG J, V135, pS138, DOI 10.1016/j.cej.2007.07.058
   Bothe D, 2010, HEAT MASS TRANSF, P265, DOI 10.1007/978-3-642-04549-3_15
   Casalini T, 2011, J PHYS CHEM B, V115, P12896, DOI 10.1021/jp207459k
   CHENG KC, 1976, J FLUID ENG-T ASME, V98, P41, DOI 10.1115/1.3448205
   Cybulski A., 2001, FINE CHEM MANUFACTUR, P193, DOI 10.1016/B978-044482202-4/50005-5
   Davis M. E., 2003, FUNDAMENTALS CHEM RE, P260
   Deng QL, 2017, CHEM ENG J, V313, P1577, DOI 10.1016/j.cej.2016.11.035
   Donaldson AA, 2011, INT J MULTIPHAS FLOW, V37, P429, DOI 10.1016/j.ijmultiphaseflow.2010.10.003
   Ehgartner J, 2016, SENSOR ACTUAT B-CHEM, V228, P748, DOI 10.1016/j.snb.2016.01.050
   Falk L, 2010, CHEM ENG SCI, V65, P405, DOI 10.1016/j.ces.2009.05.045
   Fogler H. S, 2006, ELEMENTS CHEM REACTI, P867
   Fogler H. S., 2006, ELEMENTS CHEM REACTI, P945
   Georget E, 2013, J FOOD ENG, V116, P910, DOI 10.1016/j.jfoodeng.2013.01.041
   Gobert SRL, 2017, ORG PROCESS RES DEV, V21, P531, DOI 10.1021/acs.oprd.6b00359
   Gutierrez CGCC, 2010, J FOOD ENG, V98, P248, DOI 10.1016/j.jfoodeng.2010.01.004
   Ham JH, 2004, CHEM ENG TECHNOL, V27, P1172, DOI 10.1002/ceat.200407038
   Han L S, 1960, J APPL MECH, V27, P403, DOI DOI 10.1115/1
   Hessel V, 2005, CHEM ENG SCI, V60, P2479, DOI 10.1016/j.ces.2004.11.033
   Holvey CP, 2011, CHEM ENG PROCESS, V50, P1069, DOI 10.1016/j.cep.2011.05.016
   Howell PB, 2004, LAB CHIP, V4, P663, DOI 10.1039/b407170k
   Kalaga DV, 2017, CHEM ENG SCI, V170, P332, DOI 10.1016/j.ces.2017.02.022
   Kalaga DV, 2012, CHEM ENG J, V191, P475, DOI 10.1016/j.cej.2012.02.091
   KANDLIKAR SG, 2006, HEAT TRANSFER FLUID, P87, DOI DOI 10.1016/B978-008044527-4/50005-0
   Klutz S, 2015, CHEM ENG RES DES, V95, P22, DOI 10.1016/j.cherd.2015.01.003
   Kockmann N., 2013, MICROPROCESS ENG, P41, DOI [10.1002/9783527631445.ch2, DOI 10.1002/9783527631445.CH2]
   Kuan B. T., 2014, P 19 AUSTR FLUID MEC, P1
   Kurt SK, 2017, IND ENG CHEM RES, V56, P11320, DOI 10.1021/acs.iecr.7b02240
   Kurt SK, 2015, CHEM ENG TECHNOL, V38, P1122, DOI 10.1002/ceat.201400515
   Levenspiel O, 1999, CHEM REACTION ENG, P257, DOI DOI 10.1021/IE990488G
   LIGRANI PM, 1988, PHYS FLUIDS, V31, P3605, DOI 10.1063/1.866877
   Mielke E, 2018, CHEM ENG J, V352, P682, DOI 10.1016/j.cej.2018.07.043
   Mielke E, 2017, REACT CHEM ENG, V2, P763, DOI 10.1039/c7re00085e
   Mielke E, 2016, J FLOW CHEM, V6, P279, DOI 10.1556/1846.2016.00026
   Ni XW, 2001, CAN J CHEM ENG, V79, P444, DOI 10.1002/cjce.5450790318
   Nieuwland PJ, 2011, ORG PROCESS RES DEV, V15, P783, DOI 10.1021/op100338z
   Nieves-Remacha MJ, 2015, IND ENG CHEM RES, V54, P6649, DOI 10.1021/acs.iecr.5b00480
   Plouffe P, 2016, CHEM ENG J, V300, P9, DOI 10.1016/j.cej.2016.04.072
   Plouffe P, 2014, ORG PROCESS RES DEV, V18, P1286, DOI 10.1021/op5001918
   Rossetti I, 2016, CHEM ENG J, V296, P56, DOI 10.1016/j.cej.2016.02.119
   SAXENA AK, 1984, AICHE J, V30, P363, DOI 10.1002/aic.690300303
   Saxena AK, 1983, CHEM ENG COMMUN, V23, P277, DOI 10.1080/00986448308940479
   Schwolow S, 2016, CHEM ENG SCI, V141, P356, DOI 10.1016/j.ces.2015.11.022
   Sharma L, 2017, CHEM ENG SCI, V160, P227, DOI 10.1016/j.ces.2016.11.034
   SITTEL CN, 1968, IND ENG CHEM FUND, V7, P39, DOI 10.1021/i160025a007
   Torres AP, 1998, J FOOD ENG, V35, P147, DOI 10.1016/S0260-8774(98)00007-7
   Trambouze P., 2004, CHEM REACTORS
   TRIVEDI RN, 1975, CHEM ENG SCI, V30, P317, DOI 10.1016/0009-2509(75)80081-9
   Vaccaro L., 2017, SUSTAINABLE FLOW CHE
   Wellsandt T, 2015, CHEM-ING-TECH, V87, P150, DOI 10.1002/cite.201300184
NR 50
TC 0
Z9 0
U1 7
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 181
EP 193
DI 10.1016/j.ces.2019.06.016
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300014
DA 2020-05-12
ER

PT J
AU Fu, ZJ
   Zhu, ES
   Barghi, S
   Zhao, YM
   Luo, ZF
   Duan, CL
AF Fu, Zhijie
   Zhu, Jesse
   Barghi, Shahzad
   Zhao, Yuemin
   Luo, Zhenfu
   Duan, Chenlong
TI Minimum fluidization velocity of binary mixtures of medium particles in
   the Air Dense medium fluidized bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Minimum fluidization velocity; Air dense medium fluidized bed; Binary
   mixtures
ID DRY BENEFICIATION; PRESSURE-DROP; COAL; PACKING; SEGREGATION; SOLIDS;
   SEPARATION; BIOMASS; MODEL; SIZE
AB Minimum fluidization velocity of binary mixtures is one of the most important parameters when applying an Air Dense Medium Fluidized Bed for dry coal beneficiation. Measurements of minimum fluidization velocities were carried out for binary mixtures of magnetite and sand/gangue/coal particles. The experimental results showed that the minimum fluidization velocity of binary mixtures remained almost unchanged when the volume fraction of magnetite particles was above 50%, whereas it varied significantly when the volume fraction of magnetite particles was below 50%. A general correlation based on the Cheung equation has been developed for predicting the minimum fluidization velocity of binary mixtures in terms of particle size ratio, volumetric composition and incipient fluidization velocity of each component. The extended Cheung equation is in reasonable agreement with almost all the available experimental data in the present work and the literature, and it can be used to estimate accurately the minimum fluidization velocity of binary mixtures of medium particles for the ADMFB and other similar fluidized bed operations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fu, Zhijie; Zhu, Jesse; Barghi, Shahzad] Western Univ, London, ON N6A 5B9, Canada.
   [Fu, Zhijie; Zhu, Jesse; Zhao, Yuemin; Luo, Zhenfu; Duan, Chenlong] China Univ Min & Technol, Xuzhou 221116, Jiangsu, Peoples R China.
RP Zhu, ES (reprint author), Western Univ, London, ON N6A 5B9, Canada.; Zhu, ES; Zhao, YM (reprint author), China Univ Min & Technol, Xuzhou 221116, Jiangsu, Peoples R China.
EM jzhu@uwo.ca; ymzhao_paper@126.com
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917; Fu, Zhijie/0000-0003-2403-9738
FU Natural Sciences and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [51620105001]
FX The authors are grateful to the financial support by Natural Sciences
   and Engineering Research Council of Canada, and National Natural Science
   Foundation of China (No. 51620105001).
CR ASIF M, 2010, INT J CHEM MOL NUCL, V4, P243
   Asif M, 2012, POWDER TECHNOL, V217, P361, DOI 10.1016/j.powtec.2011.10.049
   Asif M, 2011, PARTICUOLOGY, V9, P101, DOI 10.1016/j.partic.2010.11.001
   CARSKY M, 1987, POWDER TECHNOL, V51, P237, DOI 10.1016/0032-5910(87)80024-4
   CHEN JLP, 1975, CAN J CHEM ENG, V53, P395, DOI 10.1002/cjce.5450530407
   Chen QR, 2003, COAL PREP, V23, P3, DOI 10.1080/07349340302266
   CHEUNG L, 1974, CHEM ENG SCI, V29, P1301
   CHIBA S, 1979, POWDER TECHNOL, V22, P255, DOI 10.1016/0032-5910(79)80031-5
   Choung J, 2006, COAL PREP, V26, P1, DOI 10.1080/07349340600619345
   CHYANG CS, 1989, CAN J CHEM ENG, V67, P344, DOI 10.1002/cjce.5450670222
   Dwari RK, 2007, MINER PROCESS EXTR M, V28, P177, DOI 10.1080/08827500601141271
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Firdaus M, 2012, INT J COAL PREP UTIL, V32, P276, DOI 10.1080/19392699.2012.716801
   Formisani B, 2008, POWDER TECHNOL, V185, P97, DOI 10.1016/j.powtec.2007.10.003
   Formisani B, 2013, AICHE J, V59, P729, DOI 10.1002/aic.13876
   Formisani B, 2011, AICHE J, V57, P2325, DOI 10.1002/aic.12450
   FORMISANI B, 1991, POWDER TECHNOL, V66, P259, DOI 10.1016/0032-5910(91)80039-L
   Franks GV, 2015, INT J MINER PROCESS, V137, P43, DOI 10.1016/j.minpro.2015.03.001
   Goossens W.R.A., 1971, CHEM ENG PROGR S SER, V67, P38
   Jena HM, 2008, CHEM ENG J, V145, P16, DOI 10.1016/j.cej.2008.02.013
   Kumoro A. C., 2014, INT J APPL ENG RES, V9, P21561
   Li ZY, 2005, CHEM ENG COMMUN, V192, P918, DOI 10.1080/009864490510950
   LOCKETT MJ, 1973, CHEM ENG SCI, V28, P666, DOI 10.1016/0009-2509(73)80072-7
   Marzocchella A, 2000, AICHE J, V46, P2175, DOI 10.1002/aic.690461110
   Mohanta S, 2013, PARTICUL SCI TECHNOL, V31, P16, DOI 10.1080/02726351.2011.629285
   Mohanta S, 2012, PART PART SYST CHAR, V29, P228, DOI 10.1002/ppsc.201100020
   Mohanta S, 2011, IND ENG CHEM RES, V50, P10865, DOI 10.1021/ie201548r
   NODA K, 1986, POWDER TECHNOL, V46, P149, DOI 10.1016/0032-5910(86)80021-3
   OBATA E, 1982, J CHEM ENG JPN, V15, P23, DOI 10.1252/jcej.15.23
   Olivieri G, 2004, AICHE J, V50, P3095, DOI 10.1002/aic.10340
   Oshitani J, 2012, ADV POWDER TECHNOL, V23, P120, DOI 10.1016/j.apt.2011.08.002
   Oshitani J, 2011, MINER ENG, V24, P70, DOI 10.1016/j.mineng.2010.10.010
   OTERO AR, 1971, AN QUIM-INT, V67, P1207
   Paudel B, 2013, POWDER TECHNOL, V237, P134, DOI 10.1016/j.powtec.2013.01.031
   Rao TR, 2001, ENERGY, V26, P633
   Reina J, 2000, POWDER TECHNOL, V111, P245, DOI 10.1016/S0032-5910(00)00226-6
   RINCON J, 1994, J CHEM ENG JPN, V27, P177, DOI 10.1252/jcej.27.177
   ROWE PN, 1975, CHEM ENG SCI, V30, P1365, DOI 10.1016/0009-2509(75)85066-4
   Sahu AK, 2009, INT J COAL PREP UTIL, V29, P216, DOI 10.1080/19392690903113847
   Sekito T, 2006, WASTE MANAGE, V26, P1422, DOI 10.1016/j.wasman.2005.10.015
   STOVALL T, 1986, POWDER TECHNOL, V48, P1, DOI 10.1016/0032-5910(86)80058-4
   Tang LG, 2009, INT J COAL PREP UTIL, V29, P265, DOI 10.1080/19392690903411977
   Turrado S, 2018, POWDER TECHNOL, V338, P608, DOI 10.1016/j.powtec.2018.07.057
   Uchida S., 1983, J CHIN INST CHEM ENG, V14, P257
   VAID RP, 1978, CAN J CHEM ENG, V56, P292, DOI 10.1002/cjce.5450560304
   Wei LB, 2003, COAL PREP, V23, P21, DOI 10.1080/07349340302269
   Weintraub M., 1979, RI PMTC, V4, P12
   WEN CY, 1966, AICHE J, V12, P610, DOI 10.1002/aic.690120343
   Yoshida M, 2010, ADV POWDER TECHNOL, V21, P69, DOI 10.1016/j.apt.2009.11.002
   Yoshida M, 2008, KONA POWDER PART J, V26, P227, DOI 10.14356/kona.2008020
   YU AB, 1991, IND ENG CHEM RES, V30, P1372, DOI 10.1021/ie00054a045
   ZALTZMAN A, 1983, T ASAE, V26, P987
   Zhao Y.M., 2011, MINING SCI TECHNOLOG, V21, P547, DOI DOI 10.1016/j.mstc.2011.06.015
   Zhao YM, 2012, SEP SCI TECHNOL, V47, P2256, DOI 10.1080/01496395.2012.669805
NR 54
TC 3
Z9 3
U1 23
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 194
EP 201
DI 10.1016/j.ces.2019.06.005
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300015
DA 2020-05-12
ER

PT J
AU Li, ZZ
   Wang, HY
   Jing, K
   Wang, LM
   Li, Y
   Zhang, XW
   Liu, GZ
AF Li, Zaizheng
   Wang, Hongyan
   Jing, Kai
   Wang, Limin
   Li, Yu
   Zhang, Xiangwen
   Liu, Guozhu
TI Kinetics and modeling of supercritical pyrolysis of endothermic
   hydrocarbon fuels in regenerative cooling channels
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Endothermic hydrocarbon fuels; Pyrolysis; Supercritical; Kinetic;
   Modeling
ID THERMAL-DECOMPOSITION KINETICS; HEAT-TRANSFER; N-DECANE; CRACKING;
   MANAGEMENT; PRESSURE; OLEFINS; COKING; ENERGY
AB Endothermic hydrocarbon fuel (EHF) is used as on-board coolant quenching the combustors of advanced aircrafts through sensible and endothermic pyrolysis reactions. The supercritical pyrolysis of EHFs was experimentally investigated under conditions (3.5 MPa, 525-600 degrees C) in a stainless steel mini-tubular reactor heated by a fluidized sand bath system. A simplified molecular reaction kinetic model (16 species and 11 reactions) was proposed based on the primary/secondary pyrolysis mechanism and the residence time estimation using computational fluid dynamics simulations. The experimental and predicted results using the developed kinetics model agree very well with the errors less than 10% under the conversion up to 70%. The pyrolysis model was also used in modeling EHF flowing and pyrolysis in an electrically heated tube showing the conversion prediction errors less than 15% and the fuel and wall temperature prediction deviations less than 20 K, which is a significant improvement on the previous model (Energy Fuels 2013, 27, 2563). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Zaizheng; Wang, Hongyan; Jing, Kai; Zhang, Xiangwen; Liu, Guozhu] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
   [Zhang, Xiangwen; Liu, Guozhu] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Li, Yu] Beijing Power Machinery Res Inst, Beijing 100074, Peoples R China.
   [Wang, Limin] Tianjin Univ, Binhai Ind Res Inst Co Ltd, Tianjin 300072, Peoples R China.
RP Liu, GZ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
EM gliu@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21522605, 21776210]; Tianjin Natural Science
   Foundation (Distinguish Young Scientist Program) [18JCJQJC46800]
FX This work was supported by the research funds from the National Natural
   Science Foundation of China (Grant No. 21522605 and 21776210) and the
   Tianjin Natural Science Foundation (Distinguish Young Scientist Program,
   Grant No. 18JCJQJC46800).
CR Belohlav Z, 2003, CHEM ENG PROCESS, V42, P461, DOI 10.1016/S0255-2701(02)00062-4
   Bunker CE, 2018, ENERG FUEL, V32, P3391, DOI 10.1021/acs.energyfuels.8b00232
   Chen Y, 2018, AICHE J, V64, P2781, DOI 10.1002/aic.16086
   Dahm KD, 2004, J ANAL APPL PYROL, V71, P865, DOI 10.1016/j.jaap.2003.11.005
   Edwards T, 2003, AIAA INT AIR SPAC S, P2611
   FABUSS BM, 1964, IND ENG CHEM PROC DD, V3, P33, DOI 10.1021/i260009a009
   FROMENT G, 1961, CHEM ENG SCI, V13, P180, DOI 10.1016/0009-2509(61)80009-2
   Gascoin N, 2008, FUEL PROCESS TECHNOL, V89, P1416, DOI 10.1016/j.fuproc.2008.07.004
   Hougen O. A, 1959, CHEM PROCESS PRINCIP, P884
   Huang H, 2004, J ENG GAS TURB POWER, V126, P284, DOI 10.1115/1.1689361
   HUANG H, 1994, ENERG FUEL, V8, P1310, DOI 10.1021/ef00048a020
   Jia ZJ, 2014, ENERG FUEL, V28, P6019, DOI 10.1021/ef5009314
   Jiang RP, 2013, ENERG FUEL, V27, P2563, DOI 10.1021/ef400367n
   Jin BT, 2017, J ANAL APPL PYROL, V125, P117, DOI 10.1016/j.jaap.2017.04.010
   KUMAR P, 1985, IND ENG CHEM PROC DD, V24, P774, DOI 10.1021/i200030a043
   MacDonald ME, 2011, J PROPUL POWER, V27, P981, DOI 10.2514/1.B34204
   McMasters B. P, 2014, EFFECT FUEL CHEM COM
   Qin J, 2013, ENERGY, V49, P459, DOI 10.1016/j.energy.2012.10.050
   Sadrameli SM, 2015, FUEL, V140, P102, DOI 10.1016/j.fuel.2014.09.034
   SAVAGE PE, 1995, AICHE J, V41, P1723, DOI 10.1002/aic.690410712
   Shi XP, 2017, FUEL, V200, P395, DOI 10.1016/j.fuel.2017.03.073
   Sobel D. R, 1995, ASME 1995 INT GAS TU
   Striebich RC, 2014, ENERG FUEL, V28, P5696, DOI 10.1021/ef500813x
   Taddeo L, 2016, P 52 AIAA SAE ASEE J, P5071
   VANDAMME PS, 1981, IND ENG CHEM PROC DD, V20, P366, DOI 10.1021/i200013a029
   Ward TA, 2005, J PROPUL POWER, V21, P344, DOI 10.2514/1.6863
   Ward TA, 2004, J PROPUL POWER, V20, P394, DOI 10.2514/1.10380
   Wauters S, 2001, CHEM ENG J, V82, P267, DOI 10.1016/S1385-8947(00)00354-5
   WENDER L, 1958, AICHE J, V4, P15, DOI 10.1002/aic.690040104
   Widegren JA, 2008, IND ENG CHEM RES, V47, P4342, DOI 10.1021/ie8000666
   Widegren JA, 2013, ENERG FUEL, V27, P5138, DOI 10.1021/ef401677g
   Widegren JA, 2009, IND ENG CHEM RES, V48, P654, DOI 10.1021/ie8008988
   Xu KK, 2018, INT J THERM SCI, V124, P212, DOI 10.1016/j.ijthermalsci.2017.10.019
   Xu KK, 2015, ENERG FUEL, V29, P4137, DOI 10.1021/acs.energyfuels.5b00097
   Zhou H, 2017, APPL THERM ENG, V112, P403, DOI 10.1016/j.applthermaleng.2016.10.057
   Zhou WX, 2014, CHEM ENG J, V243, P127, DOI 10.1016/j.cej.2013.12.081
   Zhu YH, 2014, ENERG FUEL, V28, P466, DOI 10.1021/ef401924s
NR 37
TC 1
Z9 1
U1 39
U2 109
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 202
EP 214
DI 10.1016/j.ces.2019.06.019
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300016
DA 2020-05-12
ER

PT J
AU Liu, PY
   Yan, X
   Yao, J
   Sun, SY
AF Liu, Piyang
   Yan, Xia
   Yao, Jun
   Sun, Shuyu
TI Modeling and analysis of the acidizing process in carbonate rocks using
   a two-phase thermal-hydrologic-chemical coupled model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbonate acidizing; Wormhole; Two-phase flow; T-H-C coupled; Reactive
   flow
ID WORMHOLE FORMATION; REACTIVE-DISSOLUTION; POROUS-MEDIA; PORE-SCALE;
   NUMERICAL-SIMULATION; PHASE SATURATION; CONTINUUM MODEL; FLUID-FLOW;
   PROPAGATION; ACID
AB We present a two-phase thermal-hydrologic-chemical coupled model for simulating the dissolution process during the acidization of carbonate rocks. In particular, we develop a new model to describe the change in irreducible water saturation, residual oil saturation, and the maximum relative permeability of oil and water phases with dissolution proceeding. We also present a new method for the generation of the initial porosity field with controllable correlation length. In numerical calculation, the sequential iteration approach is adopted to solve the presented model, and the operator splitting method is used to deal with the reaction relevant equations. The involved equations are discretized using the finite-volume method, where the convection term is discretized by the MINMOD scheme which can prevent overshoot/undershoot of the numerical solution. Additionally, sensitivity analysis of the dissolution process concerning rock properties, the exothermic heat of reaction, and two-phase flow, is carried out. Based on the predicted results, several recommendations for the carbonate acidizing operation are given, and the potential extensions of the current work are summarized. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Piyang; Yan, Xia; Yao, Jun] China Univ Petr East China, Sch Petr Engn, Qingdao 266580, Shandong, Peoples R China.
   [Liu, Piyang; Sun, Shuyu] King Abdullah Univ Sci & Technol, Div Phys Sci & Engn PSE, Computat Transport Phenomena Lab, Thuwal 239556900, Saudi Arabia.
RP Sun, SY (reprint author), King Abdullah Univ Sci & Technol, Div Phys Sci & Engn PSE, Computat Transport Phenomena Lab, Thuwal 239556900, Saudi Arabia.
EM shuyu.sun@kaust.edu.sa
RI Sun, Shuyu/G-9910-2013
OI Sun, Shuyu/0000-0002-3078-864X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874262, 51774317]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2019M652508]
FX The authors gratefully acknowledge the support from the National Natural
   Science Foundation of China (No. 51804325), China Postdoctoral Science
   Foundation (No. 2019M652508), and the National Natural Science
   Foundation of China (Nos. 51874262, 51774317).
CR Al-Obied M. A, 2012, SPE INT S EXH FORM D, P1
   Al-Shemmeri T., 2012, ENG FLUID MECH
   Babaei M, 2018, CHEM ENG SCI, V177, P39, DOI 10.1016/j.ces.2017.10.046
   Bastami A, 2016, J ENERG RESOUR-ASME, V138, DOI 10.1115/1.4032728
   Bazin B, 2001, SPE PROD FACIL, V16, P22, DOI 10.2118/66566-PA
   Chen J, 2014, ADV MECH ENG, DOI 10.1155/2014/871021
   Chen L, 2014, INT J HEAT MASS TRAN, V75, P483, DOI 10.1016/j.ijheatmasstransfer.2014.03.074
   Cheng HN, 2017, ACS SYM SER, V1257, P1
   Cohen CE, 2008, CHEM ENG SCI, V63, P3088, DOI 10.1016/j.ces.2008.03.021
   DACCORD G, 1987, PHYS REV LETT, V58, P479, DOI 10.1103/PhysRevLett.58.479
   DACCORD G, 1993, CHEM ENG SCI, V48, P169, DOI 10.1016/0009-2509(93)80293-Y
   DAINES MJ, 1994, GEOPHYS RES LETT, V21, P145, DOI 10.1029/93GL03052
   De Oliveira T. J. L, 2012, SPE INT S EXH FORM D, P1
   Dong K, 2014, STRUCT BOND, V151, P1, DOI 10.1007/978-3-642-38619-0_1
   Economides M. J., 1989, RESERVOIR STIMULATIO, V2
   Fredd CN, 1999, SPE J, V4, P196, DOI 10.2118/56995-PA
   Fredd C.N., 1996, INT S FORM DAM CONTR, DOI [10.2118/31074-MS, DOI 10.2118/31074-MS]
   Fredd CN, 1998, AICHE J, V44, P1933, DOI 10.1002/aic.690440902
   Frick T., 1994, SPE INT S FORM DAM C, P577
   Golfier F, 2002, J FLUID MECH, V457, P213, DOI 10.1017/S0022112002007735
   Huang ZQ, 2014, COMMUN COMPUT PHYS, V16, P799, DOI 10.4208/cicp.050413.170314a
   Jensen J, 2000, FORBES, P26
   JOURNEL AG, 1974, ECON GEOL, V69, P673, DOI 10.2113/gsecongeo.69.5.673
   Kalia N., 2009, EUR FORM DAM C SOC P, P1
   Kalia N., 2009, SPE PROD OP C EXH SO, P1
   Kalia N, 2007, CHEM ENG SCI, V62, P919, DOI 10.1016/j.ces.2006.10.021
   Kalia N, 2009, CHEM ENG SCI, V64, P376, DOI 10.1016/j.ces.2008.10.026
   Kang QJ, 2005, FUEL PROCESS TECHNOL, V86, P1647, DOI 10.1016/j.fuproc.2005.02.001
   Karale C., 2016, OFFSH TECHN C AS OFF, P1
   Karrech A, 2013, J MECH PHYS SOLIDS, V61, P819, DOI 10.1016/j.jmps.2012.10.015
   Kelemen PB, 1997, PHILOS T R SOC A, V355, P283, DOI 10.1098/rsta.1997.0010
   KELEMEN PB, 1995, J GEOPHYS RES-SOL EA, V100, P475, DOI 10.1029/94JB02544
   Kolditz O, 2012, ENVIRON EARTH SCI, V67, P589, DOI 10.1007/s12665-012-1546-x
   Kumar R, 2014, STRATEGIES OF BANKS AND OTHER FINANCIAL INSTITUTIONS: THEORIES AND CASES, P1
   Li JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123894
   Li YM, 2018, J PETROL SCI ENG, V170, P932, DOI 10.1016/j.petrol.2018.06.050
   Li YM, 2017, J NAT GAS SCI ENG, V42, P120, DOI 10.1016/j.jngse.2017.02.048
   Liu M, 2012, J PETROL SCI ENG, V94-95, P28, DOI 10.1016/j.petrol.2012.06.021
   Liu P., 2018, COMPUT GEOSCI, P1
   Liu PL, 2016, J NAT GAS SCI ENG, V32, P81, DOI 10.1016/j.jngse.2016.04.014
   Liu PY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18095-2
   Liu PY, 2017, CHEM ENG SCI, V172, P143, DOI 10.1016/j.ces.2017.06.027
   Liu PY, 2017, J PETROL SCI ENG, V154, P284, DOI 10.1016/j.petrol.2017.04.040
   Machado A., 2013, 13 INT C BRAZ GEOPH, P1159
   Machado AC, 2015, APPL RADIAT ISOTOPES, V96, P129, DOI 10.1016/j.apradiso.2014.10.027
   Maheshwari P, 2016, SPE PROD OPER, V31, P103, DOI 10.2118/171731-PA
   Maheshwari P, 2013, SPE PROD OPER, V28, P402, DOI 10.2118/164517-PA
   Maheshwari P, 2013, CHEM ENG SCI, V90, P258, DOI 10.1016/j.ces.2012.12.032
   Mahmoodi A, 2018, J PETROL SCI ENG, V166, P679, DOI 10.1016/j.petrol.2018.03.072
   McDermott C, 2015, ENVIRON EARTH SCI, V74, P7837, DOI 10.1007/s12665-015-4769-9
   McDuff D., 2010, SPE ANN TECHN C EXH, P1
   Oliver DS, 1995, MATH GEOL, V27, P939, DOI 10.1007/BF02091660
   Panga MKR, 2005, AICHE J, V51, P3231, DOI 10.1002/aic.10574
   Ratnakar R., 2012, SPE INT PROD OP C EX, P1
   Ratnakar RR, 2013, CHEM ENG SCI, V90, P179, DOI 10.1016/j.ces.2012.12.019
   Safari A, 2016, J NAT GAS SCI ENG, V30, P539, DOI 10.1016/j.jngse.2016.02.036
   Shukla S, 2006, SPE J, V11, P273, DOI 10.2118/82273-PA
   Siddiqui S, 2006, J PETROL SCI ENG, V54, P93, DOI 10.1016/j.petrol.2006.08.005
   Steefel CI, 2015, COMPUTAT GEOSCI, V19, P445, DOI 10.1007/s10596-014-9443-x
   Taron J, 2009, INT J ROCK MECH MIN, V46, P842, DOI 10.1016/j.ijrmms.2009.01.008
   Thomas HR, 2012, GEOTECH GEOL ENG, V30, P841, DOI 10.1007/s10706-012-9502-9
   Tiab D, 2015, PETROPHYSICS THEORY
   Upadhyay VK, 2015, J GEOPHYS RES-SOL EA, V120, P6102, DOI 10.1002/2015JB012233
   Wang Y., 1993, SPE, P675
   Wei W, 2017, SPE J, V22, P2067
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Wu YQ, 2015, COMPUT GEOTECH, V69, P564, DOI 10.1016/j.compgeo.2015.06.021
   Xu TF, 2006, COMPUT GEOSCI-UK, V32, P145, DOI 10.1016/j.cageo.2005.06.014
   Yan X, 2019, ADV WATER RESOUR, V126, P137, DOI 10.1016/j.advwatres.2019.02.013
   Yao Jun, 2017, Earth Science, V42, P1263, DOI 10.3799/dqkx.2017.546
   [姚军 Yao Jun], 2017, [中国科学. 技术科学, Scientia Sinica Technologica], V47, P692
   Yeh GT, 2010, COMPUTAT GEOSCI, V14, P149, DOI 10.1007/s10596-009-9140-3
   Yow JL, 2002, INT J ROCK MECH MIN, V39, P143, DOI 10.1016/S1365-1609(02)00064-3
   Yuan T, 2016, TRANSPORT POROUS MED, V114, P747, DOI 10.1007/s11242-016-0742-7
   Zhang RL, 2016, GREENH GASES, V6, P370, DOI 10.1002/ghg.1571
   Zhu GP, 2019, APPL MATH MODEL, V70, P82, DOI 10.1016/j.apm.2018.12.017
   Ziauddin M. E, 2007, SPE MIDDL E OIL GAS, P1
NR 77
TC 1
Z9 1
U1 11
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 215
EP 234
DI 10.1016/j.ces.2019.06.017
PG 20
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300017
DA 2020-05-12
ER

PT J
AU Xiao, ZR
   Hou, F
   Li, YT
   Zhang, RR
   Shen, GQ
   Wang, L
   Zhang, XW
   Wang, QF
   Li, GZ
AF Xiao, Zhourong
   Hou, Fang
   Li, Yueting
   Zhang, Rongrong
   Shen, Guoqiang
   Wang, Li
   Zhang, Xiangwen
   Wang, Qingfa
   Li, Guozhu
TI Confinement of Fe2O3 nanoparticles in the shell of N-doped carbon hollow
   microsphere for efficient oxygen reduction reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxygen reduction reaction; N-doped carbon coated iron oxide; Hollow
   microsphere; Silica protection; Density functional theory
ID NONPRECIOUS METAL-CATALYSTS; INITIO MOLECULAR-DYNAMICS; TOTAL-ENERGY
   CALCULATIONS; FUEL-CELLS; FE-N/C; ELECTROCATALYSTS; GRAPHENE; SPHERES;
   TRANSITION; DURABILITY
AB Fe2O3 nanoparticles is confined in the mesoporous shell of N-doped carbon microsphere for oxygen reduction reaction (ORR). A series of hollow catalysts together with corresponding control samples have been constructed, characterized and evaluated. The structure, composition and state of the as-prepared catalysts were characterized by Scanning electron microscope, Transmission electron microscope, X-Ray diffraction, X-Ray photoelectron spectroscopy, Raman and nitrogen adsorption-desorption. The electrochemical activity and selectivity of Fe2O3-based catalyst toward the 4e pathway has been greatly improved (E-onset of -50 mV, E-1/2 of -150 mV and average electron transfer number of 3.87). The current density is 18.5% higher than that of commercial 20 wt% Pt/C. Density functional theory calculations reveal that the confinement of Fe2O3 nanoparticles in the interlayer of N-doped graphite can significantly promote the activity of N-doped graphitic surface in alkaline media for ORR, due to facilitated O-2 adsorption and reduced energy of OOH formation which is the rate-determining step of ORR. Such a confinement strategy provides a general and effective route to push the limit of transition metal oxides to a higher level for ORR and realize the controllable construction of highly active non-noble-metal catalysts with well-defined mechanism understanding. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xiao, Zhourong; Hou, Fang; Li, Yueting; Zhang, Rongrong; Shen, Guoqiang; Wang, Li; Zhang, Xiangwen; Wang, Qingfa; Li, Guozhu] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
   [Wang, Li; Zhang, Xiangwen; Wang, Qingfa; Li, Guozhu] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP Li, GZ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
EM gzli@tju.edu.cn
RI wang, qingfa/G-4787-2016
OI wang, qingfa/0000-0002-0665-7586
FU National Key Research and Development Program of China [2016YFB0600305];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21306132]
FX Zhourong Xiao and Fang Hou contributed equally to this work. This work
   was supported by the research fund of the National Key Research and
   Development Program of China (2016YFB0600305) and National Natural
   Science Foundation of China (21306132). The calculations were performed
   on TianHe-1(A) at National Supercomputer Center in Tianjin. We thank Mr.
   Gang Yuan and Miss. Miaolun Jiao for helpful discussion.
CR Banham D, 2015, J POWER SOURCES, V285, P334, DOI 10.1016/j.jpowsour.2015.03.047
   Bashyam R, 2006, NATURE, V443, P63, DOI 10.1038/nature05118
   Bezerra CWB, 2008, ELECTROCHIM ACTA, V53, P4937, DOI 10.1016/j.electacta.2008.02.012
   Borup R, 2007, CHEM REV, V107, P3904, DOI 10.1021/cr050182l
   Cai SC, 2017, APPL CATAL B-ENVIRON, V217, P477, DOI 10.1016/j.apcatb.2017.06.008
   Chen Z, 2010, CHEM COMMUN, V46, P6524, DOI 10.1039/c0cc01786h
   Chen ZW, 2011, ENERG ENVIRON SCI, V4, P3167, DOI 10.1039/c0ee00558d
   Choi IA, 2017, APPL CATAL B-ENVIRON, V211, P235, DOI 10.1016/j.apcatb.2017.04.039
   Dai LM, 2015, CHEM REV, V115, P4823, DOI 10.1021/cr5003563
   Dhavale VM, 2015, NANOSCALE, V7, P20117, DOI 10.1039/c5nr04929f
   Gao YY, 2018, INT J HYDROGEN ENERG, V43, P7893, DOI 10.1016/j.ijhydene.2018.03.043
   Gong KP, 2009, SCIENCE, V323, P760, DOI 10.1126/science.1168049
   Guo S., 2012, ANGEW CHEM, V124, P11940
   HADIDI L, 2017, NANOTECHNOLOGY, V28, DOI DOI 10.1088/1361-6528/AA5716
   He JA, 2017, J MATER SCI, V52, P10938, DOI 10.1007/s10853-017-1192-5
   Hu F, 2017, SMALL, V13, DOI 10.1002/smll.201602507
   Hu J, 2011, CHEM SOC REV, V40, P5472, DOI 10.1039/c1cs15103g
   Huo KF, 2016, J POWER SOURCES, V324, P233, DOI 10.1016/j.jpowsour.2016.05.084
   Jaouen F, 2011, ENERG ENVIRON SCI, V4, P114, DOI 10.1039/c0ee00011f
   Jiang YY, 2014, NANOSCALE, V6, P15066, DOI 10.1039/c4nr04295f
   KRESSE G, 1994, PHYS REV B, V49, P14251, DOI 10.1103/PhysRevB.49.14251
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   Lai LF, 2012, ENERG ENVIRON SCI, V5, P7936, DOI 10.1039/c2ee21802j
   Lefevre M, 2009, SCIENCE, V324, P71, DOI 10.1126/science.1170051
   Li B, 2016, NANOSCALE, V8, P5067, DOI 10.1039/c5nr06538k
   Li YG, 2012, NAT NANOTECHNOL, V7, P394, DOI [10.1038/NNANO.2012.72, 10.1038/nnano.2012.72]
   Li Y, 2012, ADV FUNCT MATER, V22, P4634, DOI 10.1002/adfm.201200591
   Liang HW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5973
   Liu C, 2016, DALTON T, V45, P10954, DOI 10.1039/c6dt01437b
   Liu G, 2009, APPL CATAL B-ENVIRON, V93, P156, DOI 10.1016/j.apcatb.2009.09.025
   Liu J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15938
   Liu S, 2017, CATAL SCI TECHNOL, V7, P4007, DOI 10.1039/c7cy00491e
   Liu YY, 2017, NANO RES, V10, P1213, DOI 10.1007/s12274-016-1300-x
   Liu YL, 2015, J POWER SOURCES, V283, P389, DOI 10.1016/j.jpowsour.2015.02.151
   Norskov JK, 2004, J PHYS CHEM B, V108, P17886, DOI 10.1021/jp047349j
   Parlett CMA, 2013, CHEM SOC REV, V42, P3876, DOI 10.1039/c2cs35378d
   Peng Z., 2012, SCIENCE
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Qin W, 2013, APPL SURF SCI, V266, P350, DOI 10.1016/j.apsusc.2012.12.023
   Sa YJ, 2016, J AM CHEM SOC, V138, P15046, DOI 10.1021/jacs.6b09470
   Shao MH, 2016, CHEM REV, V116, P3594, DOI 10.1021/acs.chemrev.5b00462
   Song P, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700802
   Steele BCH, 2001, NATURE, V414, P345, DOI 10.1038/35104620
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Sun M, 2014, J MATER CHEM A, V2, P13635, DOI 10.1039/c4ta02172j
   Sun TT, 2016, APPL CATAL B-ENVIRON, V193, P1, DOI 10.1016/j.apcatb.2016.04.006
   Suntivich J, 2011, NAT CHEM, V3, P546, DOI 10.1038/nchem.1069
   Tang HL, 2017, APPL CATAL B-ENVIRON, V202, P550, DOI 10.1016/j.apcatb.2016.09.062
   Wang HT, 2017, ACS APPL MATER INTER, V9, P10610, DOI 10.1021/acsami.6b15392
   Wang HT, 2017, ACS APPL MATER INTER, V9, P335, DOI 10.1021/acsami.6b11608
   Wang H, 2017, ELECTROCHIM ACTA, V232, P114, DOI 10.1016/j.electacta.2017.02.144
   Wang M, 2016, UNITED EUROPEAN GAST, V4, P1
   Wang MQ, 2014, ACS CATAL, V4, P3928, DOI 10.1021/cs500673k
   Winter M, 2004, CHEM REV, V104, P4245, DOI 10.1021/cr020730k
   Yang F, 2017, NANO RES, V10, P97, DOI 10.1007/s12274-016-1269-5
   Yang ZK, 2016, J MATER CHEM A, V4, P19037, DOI 10.1039/c6ta08050b
   Yang ZK, 2016, SMALL, V12, P5710, DOI 10.1002/smll.201601887
   You CH, 2016, J POWER SOURCES, V324, P134, DOI 10.1016/j.jpowsour.2016.05.077
   Yu L, 2011, J CATAL, V282, P183, DOI 10.1016/j.jcat.2011.06.015
   Yu YM, 2012, FUEL CELLS, V12, P506, DOI 10.1002/fuce.201100111
   Zhang MW, 2017, J MATER CHEM A, V5, P20789, DOI 10.1039/c7ta06204d
   Zhang ZY, 2017, J MATER CHEM A, V5, P10876, DOI 10.1039/c7ta00710h
   Zheng Y, 2012, SMALL, V8, P3550, DOI 10.1002/smll.201200861
   Zhou D, 2015, NANOSCALE, V7, P1501, DOI 10.1039/c4nr06366j
   Zhu CZ, 2016, CHEM SOC REV, V45, P517, DOI 10.1039/c5cs00670h
NR 67
TC 2
Z9 2
U1 68
U2 247
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 235
EP 246
DI 10.1016/j.ces.2019.06.029
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300018
DA 2020-05-12
ER

PT J
AU Zong, SY
   Wang, JK
   Xiao, Y
   Sakoth, B
   Wu, H
   Liu, Q
   Zhou, YN
   Huang, X
   Hao, HX
AF Zong, Shuyi
   Wang, Jingkang
   Xiao, Yan
   Sakoth, Brang
   Wu, Hao
   Liu, Qi
   Zhou, Yanan
   Huang, Xin
   Hao, Hongxun
TI Thermodynamic and population balance models for solvent-mediated phase
   transformation of lansoprazole
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Lansoprazole; Solvent-mediated transformation; The ternary phase
   diagram; The population balance model; Kinetics
ID CRYSTALLIZING DRUG PHASE; PLUS WATER MIXTURES; POLYMORPHIC
   TRANSFORMATION; SOLUBILITY; NUCLEATION; GROWTH; ACID; AGGREGATION;
   DISSOLUTION; KINETICS
AB In this work, two new polymorphs (monohydrate and ethanol solvate) of lansoprazole were first discovered and fully characterized. The transformation between two polymorphs of lansoprazole was investigated both experimentally and theoretically. The ternary phase diagram of the two polymorphic forms of lansoprazole in the binary solvent mixtures of ethanol and water at 15 degrees C, 25 degrees C and 35 degrees C was determined and the thermodynamic model was established. Raman spectroscopy was used to in situ monitor the solvent-mediated transformation from monohydrate to ethanol solvate of lansoprazole, while the solution concentration was measured by UV spectroscopy. The population balance models were established to analyze and compare the dissolution, nucleation and crystal growth process during polymorphic transformation. By combining the experimental and simulation results, the rate-controlling step, the changing profiles of the suspension density and the solid compositions of both polymorphs were investigated and discussed. Furthermore, the effect of temperature on the transformation process was also analyzed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zong, Shuyi; Wang, Jingkang; Xiao, Yan; Sakoth, Brang; Wu, Hao; Liu, Qi; Zhou, Yanan; Huang, Xin; Hao, Hongxun] Tianjin Univ, Sch Chem Engn & Technol, Natl Engn Res Ctr Ind Crystallizat Technol, Tianjin 300072, Peoples R China.
   [Zong, Shuyi; Wang, Jingkang; Huang, Xin; Hao, Hongxun] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP Hao, HX (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Natl Engn Res Ctr Ind Crystallizat Technol, Tianjin 300072, Peoples R China.
EM hongxunhao@tju.edu.cn
FU Major National Scientific Instrument Development Project [21527812]
FX This research is financially supported by Major National Scientific
   Instrument Development Project (No. 21527812).
CR BARRADELL LB, 1992, DRUGS, V44, P225, DOI 10.2165/00003495-199244020-00007
   Bobrovs R, 2015, CRYSTENGCOMM, V17, P5237, DOI 10.1039/c4ce02484b
   Brittain HG, 2011, J PHARM SCI-US, V100, P1260, DOI 10.1002/jps.22386
   Chaudhury A, 2016, METHOD PHARMACOL TOX, P43, DOI 10.1007/978-1-4939-2996-2_2
   Dang LP, 2009, ORG PROCESS RES DEV, V13, P1301, DOI 10.1021/op900134w
   Dharmayat S, 2008, CRYST GROWTH DES, V8, P2205, DOI 10.1021/cg0706215
   GARSIDE J, 1980, CHEM ENG COMMUN, V4, P393, DOI 10.1080/00986448008935918
   Herbrink M, 2016, J CONTROL RELEASE, V239, P118, DOI 10.1016/j.jconrel.2016.08.036
   Hermanto MW, 2009, AICHE J, V55, P122, DOI 10.1002/aic.11644
   HOUNSLOW MJ, 1988, AICHE J, V34, P1821, DOI 10.1002/aic.690341108
   HULBURT HM, 1964, CHEM ENG SCI, V19, P555, DOI 10.1016/0009-2509(64)85047-8
   Jiang SF, 2010, CRYST GROWTH DES, V10, P2541, DOI 10.1021/cg901257s
   John V, 2009, CHEM ENG SCI, V64, P733, DOI 10.1016/j.ces.2008.05.004
   Kitamura M, 2002, J CRYST GROWTH, V237, P2205, DOI 10.1016/S0022-0248(01)02277-1
   KURIHARA K, 1993, J CHEM ENG DATA, V38, P446, DOI 10.1021/je00011a031
   Liu JQ, 2013, J CHEM ENG DATA, V58, P2414, DOI 10.1021/je400188h
   Mahony M. A. O., 2012, CRYST GROWTH DES, V12, P1925
   Mangin D., 2009, STP PHARM PRATIQUES, V13, P1
   MARCHAL P, 1988, CHEM ENG SCI, V43, P59, DOI 10.1016/0009-2509(88)87126-4
   Marchisio DL, 2003, J COLLOID INTERF SCI, V258, P322, DOI 10.1016/S0021-9797(02)00054-1
   Nagy ZK, 2011, CRYST GROWTH DES, V11, P2205, DOI 10.1021/cg101555u
   Ono T, 2004, CRYST GROWTH DES, V4, P1161, DOI 10.1021/cg0497694
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Randolph A.D., 1998, THEORY PARTICULATE P
   RAWLINGS JB, 1993, IND ENG CHEM RES, V32, P1275, DOI 10.1021/ie00019a002
   Scholl J, 2006, CRYST GROWTH DES, V6, P881, DOI 10.1021/cg0503402
   Scott Lesley J, 2003, Paediatr Drugs, V5, P57
   Shen YM, 2015, J CHEM THERMODYN, V80, P128, DOI 10.1016/j.jct.2014.08.026
   Tandon P, 1999, J COLLOID INTERF SCI, V213, P273, DOI 10.1006/jcis.1998.6036
   Trifkovic M, 2008, IND ENG CHEM RES, V47, P1586, DOI 10.1021/ie071125g
   Tung H.-H., 2008, CRYSTALLIZATION ORGA, P137
   Vippagunta SR, 2001, ADV DRUG DELIVER REV, V48, P3, DOI 10.1016/S0169-409X(01)00097-7
   Wang YT, 2017, J COLLOID INTERF SCI, V485, P91, DOI 10.1016/j.jcis.2016.09.003
   Wantha L, 2013, CHEM ENG TECHNOL, V36, P1313, DOI 10.1002/ceat.201300034
   Weinstein RD, 2007, J CHEM ENG DATA, V52, P256, DOI 10.1021/je0603729
   Zhang J, 2014, J CHEM THERMODYN, V79, P61, DOI 10.1016/j.jct.2014.07.011
   Zhu HJ, 1996, INT J PHARM, V139, P33, DOI 10.1016/0378-5173(96)04570-X
   Zhu HJ, 1996, INT J PHARM, V135, P151, DOI 10.1016/0378-5173(95)04466-3
   Zong SY, 2017, J MOL LIQ, V241, P399, DOI 10.1016/j.molliq.2017.06.037
NR 39
TC 1
Z9 1
U1 19
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 247
EP 257
DI 10.1016/j.ces.2019.06.020
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300019
DA 2020-05-12
ER

PT J
AU Rehage, H
   Nikq, F
   Kind, M
AF Rehage, H.
   Nikq, F.
   Kind, M.
TI Experimental investigation of a two-zone model for semi-batch
   precipitation in stirred-tank reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Precipitation; Zone model; Barium sulfate; Semi-batch
ID BARIUM-SULFATE PRECIPITATION; SCALE-UP; SIMULATION; DYNAMICS; QUALITY;
   GROWTH
AB A zone model for the semi-batch precipitation process of sparingly soluble salts in stirred-tank reactors is presented. The low product solubility of these substances leads to high levels of supersaturation during the process. Consequently, nucleation and growth rates are fast and solids formation only takes place in a part of the reactor close to the feed pipe. The presented local mixing environment (LME) model extends an existing model for semi-batch processes, which consists of two zones. In the mixing zone, a steady-state plug-flow reactor (PFR) is used to imitate the local flow environment of the feed. The tank is approximated as a well-mixed storage tank outside the mixing zone. Exchange streams between the two zones are estimated by dimensional analysis considering stirrer type, size and rotational speed. The correctness of the two-zone hypothesis and the accuracy of the LME model is validated by barium sulfate precipitation in an experimental comparison setup using different stirrer types, rotational speeds and feed rates. The PFR is represented in the experiments as a pipe-in-pipe reactor in jet-in-cross-flow (JICF) or coaxial-flow (COAX) arrangement. The experimental results show that the semi-batch precipitation of sparingly soluble salts in stirred-tanks can be successfully simplified by the assumption of a PFR mixing zone. The LME model is simple to implement, scalable and reaches acceptable results in the experimental validation. It is therefore a promising model for future application in process simulation of industrial precipitation processes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rehage, H.; Nikq, F.; Kind, M.] Karlsruhe Inst Technol, Inst Thermal Proc Engn, Karlsruhe, Germany.
RP Kind, M (reprint author), Karlsruhe Inst Technol, Inst Thermal Proc Engn, Karlsruhe, Germany.
EM matthias.kind@kit.edu
OI Kind, Matthias/0000-0002-7203-1776; Rehage, Hendrik/0000-0001-5298-4556
FU German Research Foundation (DFG)German Research Foundation (DFG)
   [SPP1679, KI 709/26-3]
FX The authors would like to thank the German Research Foundation (DFG) for
   financial support under the Priority Program SPP1679 "Dynamic simulation
   of interconnected solid processes" (KI 709/26-3). Furthermore, we thank
   R. Lavrenev for experimental support. We thank the laboratory for
   Electron Microscopy (LEM) at Karlsruhe Institute of Technology for
   providing the particle SEM pictures.
CR Alexopoulos AH, 2002, CHEM ENG SCI, V57, P1735, DOI 10.1016/S0009-2509(02)00053-2
   Alopaeus V, 1999, CHEM ENG SCI, V54, P5887, DOI 10.1016/S0009-2509(99)00170-0
   BALDYGA J, 1995, CHEM ENG SCI, V50, P1281, DOI 10.1016/0009-2509(95)98841-2
   Baldyga J, 2005, IND ENG CHEM RES
   BALDYGA J, 1999, TURBULENT MIXING CHE
   BOURNE JR, 1994, IND ENG CHEM RES, V33, P41, DOI 10.1021/ie00025a007
   FOX RO, 2003, COMPUTATIONAL MODELS
   GOSELE W, 1991, CHEM-ING-TECH, V63, P59, DOI 10.1002/cite.330630113
   Gradl J, 2006, CHEM ENG PROCESS, V45, P908, DOI 10.1016/j.cep.2005.11.012
   Ingham John, 2008, CHEM ENG DYNAMICS IN
   Jones A, 2005, COMPUT CHEM ENG, V29, P1159, DOI 10.1016/j.compchemeng.2005.02.022
   Judat B, 2004, J COLLOID INTERF SCI, V269, P341, DOI 10.1016/j.jcis.2003.07.047
   Kawabata T, 2006, APPL CATAL A-GEN, V308, P82, DOI 10.1016/j.apcata.2006.04.032
   Kim WS, 1996, CHEM ENG COMMUN, V146, P33, DOI 10.1080/00986449608936480
   Kucher M, 2006, CHEM ENG PROCESS, V45, P900, DOI 10.1016/j.cep.2005.12.006
   Kugler RT, 2015, CHEM ENG SCI, V133, P140, DOI 10.1016/j.ces.2014.12.024
   Marchisio DL, 2006, AICHE J, V52, P1877, DOI 10.1002/aic.10786
   Marchisio DL, 2002, AICHE J, V48, P2039, DOI 10.1002/aic.690480917
   Metzger L, 2017, CHEM ENG SCI, V169, P284, DOI 10.1016/j.ces.2016.07.006
   Metzger L, 2016, CHEM ENG RES DES, V109, P464, DOI 10.1016/j.cherd.2016.02.019
   Metzger L, 2016, CHEM ENG RES DES, V108, P176, DOI 10.1016/j.cherd.2016.01.009
   Monnin C, 1999, CHEM GEOL, V153, P187, DOI 10.1016/S0009-2541(98)00171-5
   Oncul AA, 2009, IND ENG CHEM RES, V48, P999, DOI 10.1021/ie800364k
   PITZER KS, 1973, J PHYS CHEM-US, V77, P268, DOI 10.1021/j100621a026
   Rogers TL, 2004, PHARM RES, V21, P2048, DOI 10.1023/B:PHAM.0000048196.61887.e5
   Schwarzer HC, 2006, CHEM ENG SCI, V61, P167, DOI 10.1016/j.ces.2004.11.064
   VanLeeuwen MLJ, 1996, CHEM ENG SCI, V51, P2595, DOI 10.1016/0009-2509(96)00120-0
   Vicum L, 2004, CHEM ENG SCI, V59, P1767, DOI 10.1016/j.ces.2004.01.032
   Villermaux J, 1989, AM I CHEM ENG ANN M, P114
   Zauner R, 2000, CHEM ENG RES DES, V78, P894, DOI 10.1205/026387600527969
   Zlokarnik M., 2001, STIRRING THEORY PRAC
NR 31
TC 0
Z9 0
U1 8
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 258
EP 270
DI 10.1016/j.ces.2019.06.024
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300020
DA 2020-05-12
ER

PT J
AU Chen, P
   Liu, F
   Chen, S
   Guo, JK
   Shen, S
   Chen, L
   Au, CT
   Yin, SF
AF Chen, Peng
   Liu, Fan
   Chen, Sheng
   Guo, Jun-Kang
   Shen, Sheng
   Chen, Lang
   Au, Chak-Tong
   Yin, Shuang-Feng
TI A novel and efficient route for aryl ketones generation over
   Co3O4/Ag@C3N4 photocatalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aryl ketones; Photocatalysis; Porous C3N4; Supramolecular self-assembly;
   C-H activation
ID MESOPOROUS CARBON NITRIDE; C-H BOND; SELECTIVE OXIDATION; HETEROGENEOUS
   PHOTOCATALYSIS; PALLADIUM; ETHOXYCARBONYLATION; NANOSTRUCTURES;
   CYCLOHEXANE; COCATALYSTS; ACTIVATION
AB Aryl ketones are ubiquitous structural motifs in organic synthesis. Nonetheless, the traditional methods for their generation are often costly and not environment-friendly. Herein we report a novel and efficient route for the preparation of aryl ketones by photocatalysis at mild conditions. Porous C3N4 nanorods decorated with spatially separated Ag and Co3O4 nanoparticles on the interior and exterior surface of C(3)N(4)( )hollow sphere (Co3O4/Ag@C3N4) fabricated by a facile method of supramolecular self-assembly. Using this porous material as photocatalyst and O-2 as oxidant, aryl ketones could efficiently generate (with a yield up to 75.7% and selectivity to 97%) via toluene and halobenzene under visible-light irradiation at room temperature. The present study not only provides an inexpensive strategy for aryl ketones generation but also an effective tactic for activation of sp(3 )C-H bonds under mild conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Peng; Liu, Fan; Chen, Sheng; Guo, Jun-Kang; Shen, Sheng; Chen, Lang; Yin, Shuang-Feng] Hunan Univ, Coll Chem & Chem Engn, Prov Hunan Key Lab Cost Effect Utilizat Fossil Fu, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
   [Au, Chak-Tong] Hunan Inst Engn, Coll Chem & Chem Engn, Xiangtan 411104, Hunan, Peoples R China.
RP Chen, L; Yin, SF (reprint author), Hunan Univ, Coll Chem & Chem Engn, Prov Hunan Key Lab Cost Effect Utilizat Fossil Fu, State Key Lab Chemo Biosensing & Chemometr, Changsha 410082, Hunan, Peoples R China.
EM huagong042cl@163.com; sf_yin@hnu.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [21725602, 21776064, 21671062, 21476065]; Innovative
   Research Groups of Hunan Province [2019JJ10001]
FX This project was financially supported by the National Nature Science
   Foundation of China (Grants 21725602, 21776064, 21671062 and 21476065),
   Innovative Research Groups of Hunan Province (Grant 2019JJ10001). C. T.
   Au thanks the HNU for an adjunct professorship.
CR Ahlburg A, 2013, J ORG CHEM, V78, P10310, DOI 10.1021/jo401696c
   Bielejewska AG, 2001, J AM CHEM SOC, V123, P7518, DOI 10.1021/ja010664o
   Cerdan K, 2019, CHEM ENG SCI, V194, P78, DOI 10.1016/j.ces.2018.04.001
   Che W, 2017, J AM CHEM SOC, V139, P3021, DOI 10.1021/jacs.6b11878
   Chen L, 2019, APPL CATAL B-ENVIRON, V242, P379, DOI 10.1016/j.apcatb.2018.10.025
   Chenniappan VK, 2018, ACS CATAL, V8, P4539, DOI 10.1021/acscatal.8b00244
   Chu LL, 2015, ANGEW CHEM INT EDIT, V54, P7929, DOI 10.1002/anie.201501908
   Dai B, 2015, CHEM ENG SCI, V135, P472, DOI 10.1016/j.ces.2014.12.017
   ECHAVARREN AM, 1988, J AM CHEM SOC, V110, P1557, DOI 10.1021/ja00213a032
   Fei JB, 2015, ADV MATER, V27, P314, DOI 10.1002/adma.201404007
   Fei JB, 2013, SMALL, V9, P1021, DOI 10.1002/smll.201202299
   Goubert-Renaudin S, 2007, TETRAHEDRON LETT, V48, P2113, DOI 10.1016/j.tetlet.2007.01.119
   Guo SE, 2016, ANGEW CHEM INT EDIT, V55, P1830, DOI 10.1002/anie.201508505
   He WW, 2014, J AM CHEM SOC, V136, P750, DOI 10.1021/ja410800y
   Hong TT, 2017, APPL CATAL B-ENVIRON, V202, P454, DOI 10.1016/j.apcatb.2016.09.053
   Hsieh JC, 2012, ORG LETT, V14, P1282, DOI 10.1021/ol300153f
   Jun YS, 2013, ADV FUNCT MATER, V23, P3661, DOI 10.1002/adfm.201203732
   Lan X, 2016, ADV MATER, V28, P10499, DOI 10.1002/adma.201600697
   Lei J, 2017, CHEM ENG SCI, V171, P404, DOI 10.1016/j.ces.2017.05.021
   Li HY, 2015, APPL CATAL B-ENVIRON, V170, P206, DOI 10.1016/j.apcatb.2015.01.043
   Li LL, 2015, J AM CHEM SOC, V137, P5272, DOI 10.1021/jacs.5b01092
   Li RG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2401
   Li XH, 2012, ACS CATAL, V2, P2082, DOI 10.1021/cs300413x
   Li XH, 2011, J AM CHEM SOC, V133, P8074, DOI 10.1021/ja200997a
   Li ZY, 2015, ORG LETT, V17, P4866, DOI 10.1021/acs.orglett.5b02422
   Liu J, 2014, GREEN CHEM, V16, P4559, DOI 10.1039/c4gc01126k
   Liu Y, 2016, CHEM COMMUN, V52, P1274, DOI 10.1039/c5cc07586f
   Monneyron P, 2003, CHEM ENG SCI, V58, P971, DOI 10.1016/S0009-2509(02)00637-1
   Neumann H, 2008, CHEM-EUR J, V14, P3645, DOI 10.1002/chem.200800001
   Parrino F, 2018, ACS CATAL, V8, P11191, DOI 10.1021/acscatal.8b03093
   Patra TK, 2015, CHEM ENG SCI, V121, P16, DOI 10.1016/j.ces.2014.09.023
   Peng F, 2016, SCI REP-UK, V6, DOI 10.1038/srep39502
   Ruan JW, 2008, J AM CHEM SOC, V130, P10510, DOI 10.1021/ja804351z
   Serrano B, 2007, CHEM ENG SCI, V62, P5160, DOI 10.1016/j.ces.2007.01.026
   Song LN, 2017, CHEM COMMUN, V53, P6480, DOI 10.1039/c7cc02890c
   Suchand B, 2016, J ORG CHEM, V81, P6409, DOI 10.1021/acs.joc.6b01064
   Takemiya A., 2007, J AM CHEM SOC, V38, P14800
   Toh QY, 2013, J AM CHEM SOC, V135, P3772, DOI 10.1021/ja400051d
   Wang DA, 2013, ANGEW CHEM INT EDIT, V52, P11252, DOI 10.1002/anie.201303693
   Wang J, 2018, CHEM ENG SCI, V181, P237, DOI 10.1016/j.ces.2018.02.009
   Wang Y, 2010, ANGEW CHEM INT EDIT, V49, P3356, DOI 10.1002/anie.201000120
   Wonner P, 2017, ANGEW CHEM INT EDIT, V56, P12009, DOI 10.1002/anie.201704816
   Wu XF, 2010, ANGEW CHEM INT EDIT, V49, P7316, DOI 10.1002/anie.201003895
   Wu XF, 2010, ANGEW CHEM INT EDIT, V49, P5284, DOI 10.1002/anie.201002155
   Yu WY, 2008, J AM CHEM SOC, V130, P3304, DOI 10.1021/ja710555g
   Zhang JK, 2017, ANGEW CHEM INT EDIT, V56, P816, DOI 10.1002/anie.201611137
   Zheng DD, 2016, ANGEW CHEM INT EDIT, V55, P11512, DOI 10.1002/anie.201606102
   Zheng Y, 2017, J AM CHEM SOC, V139, P3336, DOI 10.1021/jacs.6b13100
   Zheng Y, 2014, ANGEW CHEM INT EDIT, V53, P11926, DOI 10.1002/anie.201407319
   Zhu Z, 2016, APPL CATAL B-ENVIRON, V182, P115, DOI 10.1016/j.apcatb.2015.09.029
NR 50
TC 3
Z9 3
U1 55
U2 133
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 271
EP 279
DI 10.1016/j.ces.2019.06.027
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300021
DA 2020-05-12
ER

PT J
AU Adloo, H
   L'Heureux, I
   Kharaghani, A
AF Adloo, Hadi
   L'Heureux, Ivan
   Kharaghani, Abdolreza
TI Effects of correlated morphological and topological heterogeneity of
   pore network on effective transport and reaction parameters
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalytic reaction; Renormalized Thiele modulus; Effective diffusivity;
   Pore topology and morphology; Porous media
ID QUANTITATIVE IMAGE-ANALYSIS; FINITE POROUS-MEDIA; GROUNDWATER-FLOW;
   REGULAR NETWORKS; DIFFUSION; MODEL; PERCOLATION; TORTUOSITY; CONDUCTION;
   SIMULATION
AB The effective diffusivity and the effective Thiele modulus of reactive porous matrices are determined by using a hybrid discrete and continuum model. The model describes static heterogeneity with weak noise on both morphology and topology of the matrix. Variations in diffusivity with respect to pore size (radius and length) and network connectivity up to second order are analyzed to assess the effect of stochastic media on catalytic reaction and transition of a single species. The porous medium is simulated by several building blocks (BB) which are regular in topology and morphology. A methodology is presented to construct a BB such that it fits the true matrix. Permutation of several regular pore networks in series constructs the porous media. Local mass balances over each BB yields model equations for reaction and transport in the matrix. Correlated random walk theory is used in each BB in order to relate the diffusivity to the coordination number.
   The Gaussian correlation function is assumed to model the autocorrelation of independent variables which are used to characterize the correlated porous media. The contribution of the fluctuating parameters in the mass conservation of the matrix yields a new closure equation in which ensemble average concentration of the reactant depends on different cross-correlations. The model is stable as long as the Thiele modulus at the correlation length scale is small. It predicts that geometrical heterogeneities lead to correction in effective diffusivity while the reaction rate is unaffected due to small Thiele modulus at correlation length scale. The model is verified by assessing the Thiele modulus of a pore network under Knudsen regime during a first order catalytic reaction; a good agreement was found especially for moderate Thiele modulus of correlated network. However, it fails to simulate random networks. Our systematic study revealed that the pore radius statistics impact significantly the diffusivity and the Thiele modulus while the topological parameters are important in weakly connected networks. The model predictions show that the diffusion constant decreases sharply as pore radius variance increases but increases smoothly with Thiele modulus. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Adloo, Hadi] Islamic Azad Univ, Shiraz Branch, Young Researchers & Elite Club, Shiraz 7473171987, Iran.
   [L'Heureux, Ivan] Univ Ottawa, Dept Phys, 150 Louis Pasteur, Ottawa, ON K1N 6N5, Canada.
   [Kharaghani, Abdolreza] Otto von Guericke Univ, Thermal Proc Engn, Magdeburg, Germany.
RP Adloo, H (reprint author), Islamic Azad Univ, Shiraz Branch, Young Researchers & Elite Club, Shiraz 7473171987, Iran.
EM h.adloo@ce.iut.ac.ir
RI Kharaghani, Abdolreza/AAM-7292-2020
CR Adler P. M., 1992, POROUS MEDIA, P83
   Adloo H, 2014, CAN J CHEM ENG, V92, P1059, DOI 10.1002/cjce.21960
   Andrade JE, 2008, INT J NUMER ANAL MET, V32, P1147, DOI 10.1002/nag.652
   Armatas GS, 2006, CHEM ENG SCI, V61, P4662, DOI 10.1016/j.ces.2006.02.036
   Arns JY, 2004, TRANSPORT POROUS MED, V55, P21, DOI 10.1023/B:TIPM.0000007252.68488.43
   BACHMAT Y, 1986, TRANSPORT POROUS MED, V1, P213, DOI 10.1007/BF00238181
   BEECKMAN JW, 1990, CHEM ENG SCI, V45, P2603, DOI 10.1016/0009-2509(90)80148-8
   BHATIA SK, 1986, CHEM ENG SCI, V41, P1311, DOI 10.1016/0009-2509(86)87104-4
   BRYANT SL, 1993, AICHE J, V39, P387, DOI 10.1002/aic.690390303
   BRYANT SL, 1993, TRANSPORT POROUS MED, V11, P53, DOI 10.1007/BF00614635
   BURGANOS VN, 1987, AICHE J, V33, P1678, DOI 10.1002/aic.690331011
   Cai Q, 2008, CHEM ENG SCI, V63, P3319, DOI 10.1016/j.ces.2008.03.032
   da Luz C, 2018, CHEM ENG SCI, V184, P285, DOI 10.1016/j.ces.2018.02.047
   Dadvar M, 2007, CHEM ENG SCI, V62, P1466, DOI 10.1016/j.ces.2006.12.002
   DAGAN G, 1982, WATER RESOUR RES, V18, P813, DOI 10.1029/WR018i004p00813
   DAVIS MW, 1987, MATH GEOL, V19, P91
   DEEPAK PD, 1994, CHEM ENG SCI, V49, P245, DOI 10.1016/0009-2509(94)80042-1
   Dong H, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.036307
   EDWARDS DA, 1993, PHYS FLUIDS A-FLUID, V5, P837, DOI 10.1063/1.858631
   Fathi E, 2009, TRANSPORT POROUS MED, V80, P281, DOI 10.1007/s11242-009-9359-4
   FREEZE RA, 1975, WATER RESOUR RES, V11, P725, DOI 10.1029/WR011i005p00725
   FRIEDMAN SP, 1995, CHEM ENG SCI, V50, P897, DOI 10.1016/0009-2509(94)00220-L
   Gao SY, 2012, INT J NUMER ANAL MET, V36, P1954, DOI 10.1002/nag.1134
   GARCIAOCHOA F, 1994, CHEM ENG SCI, V49, P3091, DOI 10.1016/0009-2509(94)E0124-9
   Ghanbarian B, 2013, SOIL SCI SOC AM J, V77, P1461, DOI 10.2136/sssaj2012.0435
   Guo JW, 2015, TRANSPORT POROUS MED, V109, P541, DOI 10.1007/s11242-015-0535-4
   Hilfer R., 2000, STAT PHYS SPATIAL ST
   HOLLEWAND MP, 1992, CHEM ENG SCI, V47, P1761, DOI 10.1016/0009-2509(92)85023-5
   HOLLEWAND MP, 1992, J PHYS-CONDENS MAT, V4, P5757, DOI 10.1088/0953-8984/4/26/009
   Ioannidis MA, 2000, J COLLOID INTERF SCI, V229, P323, DOI 10.1006/jcis.2000.7055
   IOANNIDIS MA, 1993, WATER RESOUR RES, V29, P1777, DOI 10.1029/93WR00385
   JERAULD GR, 1984, J PHYS C SOLID STATE, V17, P3429, DOI 10.1088/0022-3719/17/19/017
   JERAULD GR, 1984, J PHYS C SOLID STATE, V17, P1519, DOI 10.1088/0022-3719/17/9/010
   Kharaghani A, 2013, COMPUT CHEM ENG, V52, P46, DOI 10.1016/j.compchemeng.2012.12.003
   KIRKPATRICK S, 1973, REV MOD PHYS, V45, P574, DOI 10.1103/RevModPhys.45.574
   Knackstedt MA, 2001, ADV WATER RESOUR, V24, P257, DOI 10.1016/S0309-1708(00)00057-9
   L'Heureux I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.180602
   L'Heureux I, 2018, PHYSICA A, V491, P425, DOI 10.1016/j.physa.2017.09.010
   MACDONALD IF, 1986, J MICROSC-OXFORD, V144, P277, DOI 10.1111/j.1365-2818.1986.tb02807.x
   MACDONALD IF, 1986, J MICROSC-OXFORD, V144, P297, DOI 10.1111/j.1365-2818.1986.tb02808.x
   Meyers JJ, 1998, J CHROMATOGR A, V827, P197, DOI 10.1016/S0021-9673(98)00658-X
   Muljadi BP, 2016, ADV WATER RESOUR, V95, P329, DOI 10.1016/j.advwatres.2015.05.019
   Naseri AT, 2015, CHEM ENG SCI, V138, P499, DOI 10.1016/j.ces.2015.08.028
   OTANI S, 1966, J CATAL, V5, P332, DOI 10.1016/S0021-9517(66)80016-7
   Pathak P., 1982, SPE ANN TECHN C EXH, P20
   PISMEN LM, 1974, CHEM ENG SCI, V29, P1227, DOI 10.1016/0009-2509(74)80122-3
   Roberts AP, 1997, PHYS REV E, V56, P3203, DOI 10.1103/PhysRevE.56.3203
   SAHIMI M, 1994, J PHYS I, V4, P1263, DOI 10.1051/jp1:1994107
   SAHIMI M, 1983, J CHEM PHYS, V78, P6849, DOI 10.1063/1.444631
   Sahimi M, 1997, IND ENG CHEM RES, V36, P3043, DOI 10.1021/ie960602k
   SAHIMI M, 1988, CHEM ENG SCI, V43, P2981, DOI 10.1016/0009-2509(88)80051-4
   Sahimi M., 2011, FLOW TRANSPORT POROU, P253
   Sahimi M., 2011, FLOW TRANSPORT POROU, DOI [10.1002/9783527636693, DOI 10.1002/9783527636693]
   Sahimi M., 2011, FLOW TRANSPORT POROU, P39
   SEATON NA, 1991, CHEM ENG SCI, V46, P1895, DOI 10.1016/0009-2509(91)80151-N
   SHARRATT PN, 1987, CHEM ENG SCI, V42, P1565, DOI 10.1016/0009-2509(87)80161-6
   Shen L, 2007, CHEM ENG SCI, V62, P3748, DOI 10.1016/j.ces.2007.03.041
   Sok RM, 2002, TRANSPORT POROUS MED, V46, P345, DOI 10.1023/A:1015034924371
   Tahmasebi P, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.066709
   Valdes-Parada FJ, 2011, CHEM ENG SCI, V66, P2177, DOI 10.1016/j.ces.2011.02.016
   Valdes-Parada FJ, 2010, CHEM ENG SCI, V65, P4100, DOI 10.1016/j.ces.2010.03.040
   Valdes-Parada FJ, 2017, INT J CHEM REACT ENG, V15, DOI 10.1515/ijcre-2017-0086
   Wang Q., 2012, GENERATE MULTIVARIAT
   Whitaker S, 1999, METHOD VOLUME AVERAG
   Yang RY, 2000, PHYS REV E, V62, P3900, DOI 10.1103/PhysRevE.62.3900
   ZHANG L, 1994, CHEM ENG SCI, V49, P41, DOI 10.1016/0009-2509(94)85032-1
NR 66
TC 0
Z9 0
U1 8
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 280
EP 304
DI 10.1016/j.ces.2019.05.029
PG 25
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300022
DA 2020-05-12
ER

PT J
AU Cheng, LW
   Liao, K
   Li, Z
   Cui, JL
   Liu, B
   Li, FG
   Chen, GJ
   Sun, CY
AF Cheng, Liwei
   Liao, Kai
   Li, Zhi
   Cui, Jinlong
   Liu, Bei
   Li, Fengguang
   Chen, Guangjin
   Sun, Changyu
TI The invalidation mechanism of kinetic hydrate inhibitors under high
   subcooling conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molecular dynamics; Kinetic hydrate inhibitors; Hydrate nucleation; High
   subcooling condition
ID ETHYLENE-GLYCOL; SIMULATIONS; NUCLEATION; PHASE; METHANOL; GROWTH; WATER
AB Vinyl lactam-based polymers have been shown to be excellent kinetic hydrate inhibitors (KHIs), inhibiting the formation and growth of methane hydrate under low subcooling conditions. However, under moderate/high subcooling conditions, they lose their inhibitory effect and can even be converted into hydrate promoters. In this work, molecular dynamics simulations were employed to explore the invalidation mechanism of two vinyl lactam-based KHIs, namely, PVP-A and PVP, under high subcooling conditions. By analyzing the nucleation and growth trajectories of methane hydrate in the absence/presence of KHIs, we found that the addition of KHIs could shorten the nucleation time of methane hydrate by reducing the mass transfer resistance of methane and water molecules and accelerating the formation of the hydrate precursor. Additionally, KHIs can facilitate the formation and survival of sII hydrate by improving the kinetic superiority of the methane-water homogeneous solution. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cheng, Liwei; Liao, Kai; Cui, Jinlong; Liu, Bei; Chen, Guangjin; Sun, Changyu] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Li, Zhi; Li, Fengguang] QiLu Univ Technol, Shandong Acad Sci, Shandong Prov Key Lab Mol Engn, Jinan 250353, Shandong, Peoples R China.
RP Liu, B (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.; Li, Z (reprint author), QiLu Univ Technol, Shandong Acad Sci, Shandong Prov Key Lab Mol Engn, Jinan 250353, Shandong, Peoples R China.
EM liz@qlu.edu.cn; liub@cup.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776301]; Science Foundation of China University
   of Petroleum, Beijing [2462018BJC004]
FX The financial support received from the National Natural Science
   Foundation of China (21776301) and the Science Foundation of China
   University of Petroleum, Beijing (2462018BJC004) are gratefully
   acknowledged.
CR Abascal J. L. F, 2005, J CHEM PHYS, V122, P268
   Abay H. K, 2011, 7 INT C GAS HYDR ED
   Anderson BJ, 2005, J AM CHEM SOC, V127, P17852, DOI 10.1021/ja0554965
   Calero S, 2004, J AM CHEM SOC, V126, P11377, DOI 10.1021/ja0476056
   Chen GJ, 1998, CHEM ENG J, V71, P145, DOI 10.1016/S1385-8947(98)00126-0
   Chen GJ, 1996, FLUID PHASE EQUILIBR, V122, P43, DOI 10.1016/0378-3812(96)03032-4
   Chen J, 2015, ENERG FUEL, V29, P122, DOI 10.1021/ef5022413
   Cooper TG, 2004, LANGMUIR, V20, P3984, DOI 10.1021/la049796w
   Dauber-Osguthorpe P, 2010, PROTEINS, V4, P31
   de Leeuw NH, 2004, CRYST GROWTH DES, V4, P123, DOI 10.1021/cg0341003
   Eslamimanesh A, 2011, CHEM ENG SCI, V66, P5439, DOI 10.1016/j.ces.2011.06.062
   Hammerschmidt EG, 1934, IND ENG CHEM, V26, P851, DOI 10.1021/ie50296a010
   Hockney R. W, 1981, COMPUTER SIMULATION, V76
   Jacobson LC, 2009, J PHYS CHEM B, V113, P10298, DOI 10.1021/jp903439a
   Jimenez-Angeles F, 2014, J PHYS CHEM C, V118, P11310, DOI 10.1021/jp5002012
   Kamal MS, 2016, RENEW SUST ENERG REV, V60, P206, DOI 10.1016/j.rser.2016.01.092
   Karig SP, 2014, CHEM ENG SCI, V116, P817, DOI 10.1016/j.ces.2014.04.035
   Ke W, 2016, ENERG FUEL, V30, P7646, DOI 10.1021/acs.energyfuels.6b01321
   Kuznetsova T, 2010, MACROMOL SYMP, V287, P168, DOI 10.1002/masy.201050124
   Kvamme B, 2005, J MOL GRAPH MODEL, V23, P524, DOI 10.1016/j.jmgm.2005.04.001
   Lederhos JP, 1996, CHEM ENG SCI, V51, P1221, DOI 10.1016/0009-2509(95)00370-3
   Li XS, 2006, IND ENG CHEM RES, V45, P2131, DOI 10.1021/ie051204x
   Li Z, 2017, CHEM ENG SCI, V164, P307, DOI 10.1016/j.ces.2017.02.029
   Liu JX, 2017, ENERGY, V120, P698, DOI 10.1016/j.energy.2016.11.120
   Makogon T. Y, 1997, THESIS
   Mohammadi AH, 2010, IND ENG CHEM RES, V49, P8865, DOI 10.1021/ie100908d
   Moon C, 2007, FARADAY DISCUSS, V136, P367, DOI 10.1039/b618194p
   Perrin A, 2013, CHEM SOC REV, V42, P1996, DOI 10.1039/c2cs35340g
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Rodger PM, 1996, FLUID PHASE EQUILIBR, V116, P326, DOI 10.1016/0378-3812(95)02903-6
   Schicks JM, 2004, ANGEW CHEM INT EDIT, V43, P3310, DOI 10.1002/anie.200453898
   Sloan ED, 2008, CHEM IND-SER, V119, pXIX
   Vatamanu J, 2006, J AM CHEM SOC, V128, P15588, DOI 10.1021/ja066515t
   Walsh MR, 2009, SCIENCE, V326, P1095, DOI 10.1126/science.1174010
   Wu M, 2007, J NAT GAS CHEM, V16, P81, DOI 10.1016/S1003-9953(07)60031-0
NR 35
TC 0
Z9 0
U1 14
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 305
EP 316
DI 10.1016/j.ces.2019.06.032
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300023
DA 2020-05-12
ER

PT J
AU v Kameke, A
   Kastens, S
   Ruttinger, S
   Herres-Pawlis, S
   Schluter, M
AF v Kameke, A.
   Kastens, S.
   Ruettinger, S.
   Herres-Pawlis, S.
   Schlueter, M.
TI How coherent structures dominate the residence time in a bubble wake: An
   experimental example
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble wake; Local residence time; Lagrangian coherent structures;
   Competitive consecutive reaction; Reaction timescale
ID MASS-TRANSFER; ENCOUNTER VOLUME; SIMULATION; BEHAVIOR
AB Timescales and residence times in reactive multiphase flows are essential for product selectivity. For instance when a gas species is consumed, e.g., by a competitive consecutive reaction with moderate reaction kinetics where reaction timescales are comparable to relevant mixing timescales. To point out the importance of the details of the fluid flow, we analyze experimental velocity data from a Taylor bubble wake by means of Lagrangian methods. By adjusting the channel diameter in which the Taylor bubble rises, and thus the rise velocity, we obtain three different wake regimes. Remarkably, the residence times of passive particles advected in the bubble wake's velocity field show a peak for intermediate rise velocities. This observation seems unintuitive at first glance because one expects a faster removal of passive tracers for a faster overall flow rate. However, the details of the flow topology analyzed using Finite Time Lyapunov Exponent (FTLE) fields and Lagrangian Coherent Structures (LCS) reveal the existence of a coherent vortical pattern in the bubble wake which explains the long residence times. The increased residence times within the vortical structure in combination with the close bubble interface acting as a constant gas species source could enhance side product generation of a hypothetical competitive consecutive reaction, where the first reaction with the gas species forms the desired product and the second the side product. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [v Kameke, A.; Kastens, S.; Ruettinger, S.; Schlueter, M.] Hamburg Univ Technol, Inst Multiphase Flows, Hamburg, Germany.
   [Herres-Pawlis, S.] Rhein Westfal TH Aachen, Inst Inorgan Chem, Aachen, Germany.
RP v Kameke, A (reprint author), Hamburg Univ Technol, Inst Multiphase Flows, Hamburg, Germany.
EM alexandra.vonkameke@tuhh.de
RI Schlueter, Michael/AAK-5967-2020; Herres-Pawlis, Sonja/P-3928-2014
OI Herres-Pawlis, Sonja/0000-0002-4354-4353; von Kameke,
   Alexandra/0000-0002-1913-774X; Schluter, Michael/0000-0001-5969-2150
FU German Research Foundation (DFG) within the Priority Program Reactive
   Bubbly FlowsGerman Research Foundation (DFG) [SPP 1740, SCHL 617/12-2,
   HE 5480/10-2]
FX The authors gratefully acknowledge the financial support provided by the
   German Research Foundation (DFG) within the Priority Program Reactive
   Bubbly Flows, SPP 1740 (SCHL 617/12-2 and HE 5480/10-2,
   http://www.dfg-spp1740.de/).We thank Dr. Marko Hoffmann for his advice
   with regard to the mixing measures and Dr. Florian Huhn for proofreading
   of the revised manuscript.
CR Balasuriya S, 2018, PHYSICA D, V372, P31, DOI 10.1016/j.physd.2018.01.011
   BALDYGA J, 1999, TURBULENT MIXING CHE
   BozorgMagham AE, 2015, COMMUN NONLINEAR SCI, V22, P964, DOI 10.1016/j.cnsns.2014.07.011
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   d'Ovidio F, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020328
   Falcone M, 2018, CHEM ENG SCI, V177, P523, DOI 10.1016/j.ces.2017.11.024
   Fitzer E., 1995, TECHNISCHE CHEM
   Haller G, 2000, PHYSICA D, V147, P352, DOI 10.1016/S0167-2789(00)00142-1
   Haller G, 2018, P NATL ACAD SCI USA, V115, P9074, DOI 10.1073/pnas.1720177115
   Haller G, 2015, ANNU REV FLUID MECH, V47, P137, DOI 10.1146/annurev-fluid-010313-141322
   Hayashi K, 2011, INT J MULTIPHAS FLOW, V37, P241, DOI 10.1016/j.ijmultiphaseflow.2010.10.008
   Kastens S, 2017, CHEM ENG TECHNOL, V40, P1494, DOI 10.1002/ceat.201700047
   Kastens S, 2015, CHEM ENG TECHNOL, V38, P1925, DOI 10.1002/ceat.201500065
   KOMASAWA I, 1980, J CHEM ENG JPN, V13, P103, DOI 10.1252/jcej.13.103
   Koudella CR, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.026307
   Neufeld Z., 2010, CHEM BIOL PROCESSES
   Onu K, 2015, J COMPUT SCI-NETH, V7, P26, DOI 10.1016/j.jocs.2014.12.002
   Ottino J.M., 1989, KINEMATICS MIXING ST
   Paul M, 2018, EUR J INORG CHEM, P2101, DOI 10.1002/ejic.201800146
   Raben SG, 2014, EXP FLUIDS, V55, DOI 10.1007/s00348-014-1824-3
   Raben SG, 2014, EXP FLUIDS, V55, DOI 10.1007/s00348-013-1638-8
   Roessler A, 2001, CHEM UNSERER ZEIT, V35, P314, DOI 10.1002/1521-3781(200110)35:5<314::AID-CIUZ314>3.3.CO;2-4
   Rypina II, 2018, NONLINEAR PROC GEOPH, V25, P267, DOI 10.5194/npg-25-267-2018
   Rypina II, 2017, NONLINEAR PROC GEOPH, V24, P189, DOI 10.5194/npg-24-189-2017
   SCHLUTER S, 1992, CHEM ENG PROCESS, V31, P97, DOI 10.1016/0255-2701(92)85004-L
   Schulzke T, 1998, COMPUT CHEM ENG, V22, pS667, DOI 10.1016/S0098-1354(98)00120-3
   SHAH SIA, 2012, INT J CHEM ENG, DOI DOI 10.1155/2012/750162
   Sulman MHM, 2013, PHYSICA D, V258, P77, DOI 10.1016/j.physd.2013.05.005
   Szalai E. S., 2004, HDB IND MIXING, DOI [10.1002/0471451452.ch3, DOI 10.1002/0471451452.CH3]
   Timmermann J, 2016, CHEM ENG TECHNOL, V39, P1955, DOI 10.1002/ceat.201600299
   Wang JE, 2017, CHAOS, V27, DOI 10.1063/1.5004649
   Weiner Andre, 2019, Chemical Engineering Science: X, V1, P59, DOI 10.1016/j.cesx.2019.100007
   WHITE ET, 1962, CHEM ENG SCI, V17, P351, DOI 10.1016/0009-2509(62)80036-0
NR 33
TC 1
Z9 1
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 317
EP 326
DI 10.1016/j.ces.2019.06.033
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300024
DA 2020-05-12
ER

PT J
AU Liu, Y
   Guo, FY
   Hu, J
   Liu, HL
   Hu, Y
AF Liu, Yu
   Guo, Fangyuan
   Hu, Jun
   Liu, Honglai
   Hu, Ying
TI Time-dependent density functional theory for the freezing/melting
   transition in interfacial systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Freezing; Time-dependent density functional theory; Interface;
   Nano-droplet; Crystal
ID SIMPLE CLASSICAL FLUIDS; EQUATION-OF-STATE; CRYSTALLIZATION
AB We propose a three-dimensional time-dependent density functional theory (TDDFT) to investigate the freezing/melting of Lennard-Jones fluids in interfacial systems including flat interfaces and nano-droplets. The theory is based on a modified fundamental measure theory (MFMT) for the hard-sphere reference system plus mean field theory (MFT) for the attractive contributions plus an additional weighted density approximation (WDA) contribution to enforce that bulk liquid equation of state is that of modified Benedict, Webb and Rubin (MBWR). By using different initial states, our theory generated a series of equilibrium structures including crystals and polyhedral particles. The non-linear effect and the irreversibility of the freezing/melting process were captured. The profiles for free energy and the order parameter indicate that the free energy barrier existing in the freezing/melting process is caused by the break in symmetry. Additionally, the time-dependent properties were also examined, and provided insight into the mechanism of the freezing process. (C) 2019 Published by Elsevier Ltd.
C1 [Liu, Yu; Guo, Fangyuan; Hu, Jun; Liu, Honglai; Hu, Ying] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Liu, Yu] East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
   [Guo, Fangyuan; Hu, Jun; Liu, Honglai; Hu, Ying] East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
RP Liu, Y (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Liu, Y (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
EM liuyu@ecust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776070, 91534202, 91834301]; Shanghai Rising Star
   Program [19QA1402400]
FX Yu Liu and Fangyuan Guo contributed equally to this work. This work is
   sponsored by the National Natural Science Foundation of China (No.
   21776070, 91534202, 91834301), and the Shanghai Rising Star Program
   (19QA1402400).
CR Agrawal KV, 2017, NAT NANOTECHNOL, V12, P267, DOI [10.1038/nnano.2016.254, 10.1038/NNANO.2016.254]
   Archer AJ, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.012324
   Archer AJ, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3054633
   BARKER JA, 1967, J CHEM PHYS, V47, P4714, DOI 10.1063/1.1701689
   Bharadwaj AS, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.032120
   Bharadwaj AS, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4931376
   CARNAHAN NF, 1969, J CHEM PHYS, V51, P635, DOI 10.1063/1.1672048
   Chan GKL, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.183001
   Delfau JB, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.042120
   EBNER C, 1976, PHYS REV A, V14, P2264, DOI 10.1103/PhysRevA.14.2264
   EBNER C, 1979, PHYS REV A, V19, P856, DOI 10.1103/PhysRevA.19.856
   Frigo M, 2005, P IEEE, V93, P216, DOI 10.1109/JPROC.2004.840301
   Hartel A, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.226101
   Hasan M, 2018, AICHE J, V64, P200, DOI 10.1002/aic.15885
   Jaiswal A, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.012309
   Jiang J, 2014, J PHYS-CONDENS MAT, V26, DOI 10.1088/0953-8984/26/28/284102
   JOHNSON JK, 1993, MOL PHYS, V78, P591, DOI 10.1080/00268979300100411
   Khrapak SA, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.255003
   Khrapak SA, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.052101
   Kruger M, 2011, EPL-EUROPHYS LETT, V96, DOI 10.1209/0295-5075/96/68006
   Li ZD, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1886685
   Liu Y, 2016, PHYS CHEM CHEM PHYS, V18, P13158, DOI 10.1039/c6cp01610c
   Liu Y, 2009, J PHYS CHEM B, V113, P12326, DOI 10.1021/jp904872f
   Lutsko JF, 2018, PHYS REV E, V98, DOI 10.1103/PhysRevE.98.012604
   LUTSKO JF, 1990, PHYS REV A, V41, P6647, DOI 10.1103/PhysRevA.41.6647
   Marin AG, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.054301
   Martin TP, 1996, PHYS REP, V273, P199, DOI 10.1016/0370-1573(95)00083-6
   Meister K, 2013, P NATL ACAD SCI USA, V110, P1617, DOI 10.1073/pnas.1214911110
   Nazir S, 2008, AICHE J, V54, P2999, DOI 10.1002/aic.11602
   Oettel M, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.021404
   RAMAKRISHNAN TV, 1979, PHYS REV B, V19, P2775, DOI 10.1103/PhysRevB.19.2775
   Scacchi A, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.062616
   Scacchi A, 2018, J PHYS-CONDENS MAT, V30, DOI 10.1088/1361-648X/aaaa10
   Singh SL, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.051506
   Subramanian P, 2016, PHYS REV LETT, V117, DOI 10.1103/PhysRevLett.117.075501
   Tang YP, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.011201
   Turci F, 2014, EUR PHYS J-SPEC TOP, V223, P421, DOI 10.1140/epjst/e2014-02100-8
   Walters MC, 2018, PHYS REV E, V98, DOI 10.1103/PhysRevE.98.012606
   Wang W, 2015, AICHE J, V61, P2048, DOI 10.1002/aic.14769
   Yoshimori A, 2004, J THEOR COMPUT CHEM, V3, P117, DOI 10.1142/S0219633604000878
   Yoshimori A, 2011, J PHYS SOC JPN, V80, DOI 10.1143/JPSJ.80.034801
   Yu YX, 2002, J CHEM PHYS, V117, P10156, DOI 10.1063/1.1520530
NR 42
TC 0
Z9 0
U1 9
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 327
EP 333
DI 10.1016/j.ces.2019.06.038
PG 7
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300025
DA 2020-05-12
ER

PT J
AU Hu, YH
   Yang, YL
   Lin, KF
   Hao, DY
   Qiu, LL
   Wang, DK
   Fan, RQ
   Xia, DB
AF Hu, Yinghui
   Yang, Yulin
   Lin, Kaifeng
   Hao, Dongyu
   Qiu, Lele
   Wang, Dakang
   Fan, Ruiqing
   Xia, Debin
TI Ammonium perchlorate encapsulating nanothermites as high energetic
   composites: Preparation, thermal decomposition and combustion properties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Encapsulated; Nanothermites/AP; Energetic composites; EISA; Combustion
ID CATALYTIC-ACTIVITY; CUO; PERFORMANCE; PARTICLES; NANOCOMPOSITES;
   MICROSPHERES; FABRICATION; MECHANISM
AB In this study, various nanothermites, such as nCuO/nano Al (nAl), nMoO(3)/nAl, nBi(2)O(3)/nAl, nFe(2)O(3) /nAl, nNiO/nAl and nMgO/nAl, were encapsulated into ammonium perchlorate (AP) by the evaporation induced self-assembly (EISA) method. The obtained composites showed superior properties in decreasing the decomposition temperature of AP, increasing heat of release and ignition and combustion properties than the corresponding physically-mixed ones. The mechanism for such high-quality composites prepared by EISA was due to not only more intimate interaction between AP and nanothermites but also less agglomeration of nanothermites. nAl/nCuO/AP showed the lowest decomposition temperature of AP, highest heat of release and best ignition and combustion properties among all the obtained composites by EISA. This was because of effective conversion of NH3 to N2O with less NO production, as proved by the real-time FT-IR. This work demonstrated that EISA was an effective approach with high compatibility for obtaining various AP-nanothermites-based energetic materials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hu, Yinghui; Yang, Yulin; Lin, Kaifeng; Hao, Dongyu; Qiu, Lele; Wang, Dakang; Fan, Ruiqing; Xia, Debin] Harbin Inst Technol, Sch Chem & Chem Engn, MIIT Key Lab Crit Mat Technol New Energy Convers, Harbin 150001, Heilongjiang, Peoples R China.
RP Yang, YL; Lin, KF (reprint author), Harbin Inst Technol, Sch Chem & Chem Engn, MIIT Key Lab Crit Mat Technol New Energy Convers, Harbin 150001, Heilongjiang, Peoples R China.
EM ylyang@hit.edu.cn; linkaifeng@hit.edu.cn
OI Lin, Kaifeng/0000-0002-3458-7829
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21571042, 21873025, 51603055]; Natural Science
   Foundation of Heilongjiang ProvinceNatural Science Foundation of
   Heilongjiang Province [QC2017055]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2016M601424,
   2017T100236]; Postdoctoral Foundation of Heilongjiang Province
   [LBH-Z16059]; Key Laboratory of Functional Inorganic Material Chemistry
   (Heilongjiang University), Ministry of Education; SFAC [6141B0626020201,
   6141B0626020101]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 21571042, 21873025, 51603055), SFAC (Grant No.
   6141B0626020201, 6141B0626020101), the Natural Science Foundation of
   Heilongjiang Province (Grant No. QC2017055), the China Postdoctoral
   Science Foundation (Grant No. 2016M601424, 2017T100236), the
   Postdoctoral Foundation of Heilongjiang Province (Grant No. LBH-Z16059)
   and Key Laboratory of Functional Inorganic Material Chemistry
   (Heilongjiang University), Ministry of Education.
CR Ayoman E, 2016, J THERM ANAL CALORIM, V123, P1213, DOI 10.1007/s10973-015-5059-1
   Chatragadda K, 2017, COMBUST FLAME, V182, P28, DOI 10.1016/j.combustflame.2017.04.007
   Cheng ZP, 2016, CERAM INT, V42, P3876, DOI 10.1016/j.ceramint.2015.11.053
   Dai J, 2018, J PHYS CHEM C, V122, P10240, DOI 10.1021/acs.jpcc.8b01514
   Dai J, 2018, MATER DESIGN, V143, P93, DOI 10.1016/j.matdes.2018.01.056
   Dong QQ, 2018, EUR J PHARM SCI, V119, P147, DOI 10.1016/j.ejps.2018.04.001
   Elbasuney S, 2017, FUEL, V208, P296, DOI 10.1016/j.fuel.2017.07.020
   Gao K, 2014, J THERM ANAL CALORIM, V118, P43, DOI 10.1007/s10973-014-3955-4
   Gnanaprakash K, 2017, COMBUST FLAME, V182, P64, DOI 10.1016/j.combustflame.2017.04.024
   He W., 2018, ADV MATER, V30
   He W, 2019, CHEM ENG J, V369, P1093, DOI 10.1016/j.cej.2019.03.165
   Hu YH, 2019, VACUUM, V159, P105, DOI 10.1016/j.vacuum.2018.10.020
   Huang C, 2015, ADV ENG MATER, V17, P95, DOI 10.1002/adem.201400151
   Hung CT, 2008, CHEM ENG SCI, V63, P1997, DOI 10.1016/j.ces.2008.01.002
   Liu LL, 2018, J HAZARD MATER, V342, P477, DOI 10.1016/j.jhazmat.2017.08.055
   Luo AM, 2019, J COLLOID INTERF SCI, V534, P205, DOI 10.1016/j.jcis.2018.08.114
   Luo Y., 2015, NOVEL ENERGETIC MAT, P102
   Lv T, 2019, CHEM ENG J, V356, P580, DOI 10.1016/j.cej.2018.09.031
   Lyu JY, 2019, CHEM ENG J, V368, P129, DOI 10.1016/j.cej.2019.02.170
   Ma ZC, 2018, LANGMUIR, V34, P5712, DOI 10.1021/acs.langmuir.7b04190
   Marothiya G, 2017, COMBUST FLAME, V182, P114, DOI 10.1016/j.combustflame.2017.04.010
   Paulose S, 2017, J IND ENG CHEM, V53, P155, DOI 10.1016/j.jiec.2017.04.020
   Pichot V, 2015, J HAZARD MATER, V300, P194, DOI 10.1016/j.jhazmat.2015.06.039
   Reddy KR, 2017, J MOL STRUCT, V1150, P553, DOI 10.1016/j.molstruc.2017.09.005
   Saceleanu F, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00465
   Shen JP, 2018, THERMOCHIM ACTA, V666, P60, DOI 10.1016/j.tca.2018.06.005
   Shim HM, 2017, J IND ENG CHEM, V54, P434, DOI 10.1016/j.jiec.2017.06.024
   Shim HM, 2016, IND ENG CHEM RES, V55, P10227, DOI 10.1021/acs.iecr.6b01558
   Shim HM, 2015, CENT EUR J ENERG MAT, V12, P703
   Singh S., 2014, J THERM ANAL CALORIM, V119, P309
   Slocik JM, 2013, NANO LETT, V13, P2535, DOI 10.1021/nl400590k
   Sui HT, 2018, ADV ENG MATER, V20, DOI 10.1002/adem.201700822
   Tang G, 2014, CRYSTENGCOMM, V16, P570, DOI 10.1039/c3ce41435c
   Terry BC, 2016, J HAZARD MATER, V317, P259, DOI 10.1016/j.jhazmat.2016.05.067
   Wang HY, 2017, COMBUST FLAME, V180, P175, DOI 10.1016/j.combustflame.2017.02.036
   Wang HY, 2013, ACS APPL MATER INTER, V5, P6797, DOI 10.1021/am401238t
   Weir C, 2013, J ELECTROSTAT, V71, P77, DOI 10.1016/j.elstat.2012.10.002
   Zeng CC, 2018, J MATER SCI, V53, P12091, DOI 10.1007/s10853-018-2503-1
   Zhang YF, 2016, J ALLOY COMPD, V674, P259, DOI 10.1016/j.jallcom.2016.03.071
   Zhang ZK, 2011, J COLLOID INTERF SCI, V357, P95, DOI 10.1016/j.jcis.2011.01.102
   Zhao K, 2018, REP PROG PHYS, V81, DOI 10.1088/1361-6633/aad1a7
   Zhao NN, 2014, J SOLID STATE CHEM, V219, P67, DOI 10.1016/j.jssc.2014.06.039
   Zhao WY, 2016, J IND ENG CHEM, V38, P73, DOI 10.1016/j.jiec.2016.04.005
   Zhao WY, 2016, RSC ADV, V6, P71223, DOI 10.1039/c6ra08150a
NR 44
TC 2
Z9 2
U1 26
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 334
EP 343
DI 10.1016/j.ces.2019.06.041
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300026
DA 2020-05-12
ER

PT J
AU Constales, D
   Fang, ZT
   Kunz, MR
   Yablonsky, G
   Fushimi, R
AF Constales, Denis
   Fang, Zongtang
   Kunz, M. Ross
   Yablonsky, Gregory
   Fushimi, Rebecca
TI Methods for determining the intrinsic kinetic characteristics of
   irreversible adsorption processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas adsorption; Active sites; Platinum oxidation; Temporal analysis of
   products; TAP reactor
ID TEMPORAL ANALYSIS; TURNOVER RATES; TAP; CHEMISORPTION; CATALYST;
   PLATINUM; HYDROGEN; OXYGEN
AB To benchmark the performance of a different of catalytic materials it is essential to know the adsorption characteristics such as the kinetic order of adsorption, the apparent rate constant and the total number of active sites. It is advantageous to normalize the reaction rate to the number of active sites; a quantity commonly referred to as the turnover frequency (TOF). Methods such as chemisorption and SSITKA (steady state isotopic transient kinetic analysis) are conventionally used to quantify the number of active sites, both have advantages and drawbacks. The TAP (Temporal Analysis of Products) pulse response technique provides a distinct method for precise (10 nmol) quantification of active sites at elevated temperatures. Using irreversible reaction processes, mathematical techniques for analysis of pulsed active site titration are described herein. Whereas previous methods simply consider the total capacity for gas adsorption, these new methods take into account the dynamics and interdependence of the conversion, the number of available sites and the adsorption rate as they change over the course of the titration experiment. Moreover, these methods enable an independent fitting of the kinetic order and stoichiometry of the adsorption process directly from experimental data. In comparison with experimental data for the incremental oxidation of a reduced platinum, we found the analytical method of linear rectification was most robust and efficient. In fitting the kinetic order to experimental data collected between 125 and 175 degrees C we found a clear indication over the range of 45-95% conversion of a second order rate dependence and 2:1 balance between active sites and O-2. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Constales, Denis] Univ Ghent, Dept Math Anal, Galglaan 2, B-9000 Ghent, Belgium.
   [Fang, Zongtang; Kunz, M. Ross; Fushimi, Rebecca] Idaho Natl Lab, Biol & Chem Proc Dept, POB 1626, Idaho Falls, ID 83415 USA.
   [Yablonsky, Gregory] Washington Univ, Dept Energy Environm & Chem Engn, Campus Box 1198,One Brookings Dr, St Louis, MO 63130 USA.
RP Fushimi, R (reprint author), Idaho Natl Lab, Biol & Chem Proc Dept, POB 1626, Idaho Falls, ID 83415 USA.
EM denis.constales@ugent.be; zongtang.fang@inl.gov; ross.kunz@inl.gov;
   gy@che.wustl.edu; rebecca.fushimi@inl.gov
RI Kunz, Matthew/E-2974-2017
OI Kunz, Matthew/0000-0001-8878-8274
FU U.S. Department of Energy (USDOE), Office of Energy Efficiency and
   Renewable Energy (EERE), Advanced Manufacturing Office Next Generation
   RD ProjectsUnited States Department of Energy (DOE) [DE-AC07-05ID14517]
FX R.F. acknowledges this work was supported by U.S. Department of Energy
   (USDOE), Office of Energy Efficiency and Renewable Energy (EERE),
   Advanced Manufacturing Office Next Generation R&D Projects under
   contract No. DE-AC07-05ID14517.
CR BENNETT CO, 1982, ACS SYM SER, V178, P1
   BILOEN P, 1983, J MOL CATAL, V21, P17, DOI 10.1016/0304-5102(93)80108-7
   Bond G. C., 2005, METAL CATALYSED REAC
   Bond GC, 2008, CATAL REV, V50, P532, DOI 10.1080/01614940802480338
   BOUDART M, 1966, J CATAL, V6, P92, DOI 10.1016/0021-9517(66)90113-8
   BOUDART M, 1995, CHEM REV, V95, P661, DOI 10.1021/cr00035a009
   BOUDART M, 1984, KINETICS HETEROGENEO
   Che M, 2012, CHARACTERIZATION SOL
   FREEL J, 1972, J CATAL, V25, P149, DOI 10.1016/0021-9517(72)90212-6
   Gleaves JT, 2010, J MOL CATAL A-CHEM, V315, P108, DOI 10.1016/j.molcata.2009.06.017
   GLEAVES JT, 1988, CATAL REV, V30, P49, DOI 10.1080/01614948808078616
   Goodwin J.G., 2004, CATALYSIS, V17, P320, DOI DOI 10.1039/9781847553294-00320
   GRUBER HL, 1962, J PHYS CHEM-US, V66, P48, DOI 10.1021/j100807a010
   HAPPEL J, 1978, CHEM ENG SCI, V33, P1567, DOI 10.1016/0009-2509(78)85214-2
   HAPPEL J, 1982, J CATAL, V75, P314, DOI 10.1016/0021-9517(82)90214-7
   Ledesma C, 2014, ACS CATAL, V4, P4527, DOI 10.1021/cs501264f
   Marin G., 2011, KINETICS CHEM REACTI
   Morgan K, 2017, CATAL SCI TECHNOL, V7, P2416, DOI 10.1039/c7cy00678k
   Perez-Ramirez J, 2007, CATAL TODAY, V121, P160, DOI 10.1016/j.cattod.2007.01.001
   Redekop EA, 2013, IND ENG CHEM RES, V52, P15417, DOI 10.1021/ie400677b
   Redekop EA, 2011, CHEM ENG SCI, V66, P6441, DOI 10.1016/j.ces.2011.08.055
   Ribeiro FH, 1997, CATAL REV, V39, P49, DOI 10.1080/01614949708006468
   SHANNON SL, 1995, CHEM REV, V95, P677, DOI 10.1021/cr00035a011
   Shekhtman SO, 2008, J CATAL, V253, P303, DOI 10.1016/j.jcat.2007.10.028
   Shekhtman SO, 1999, CHEM ENG SCI, V54, P4371, DOI 10.1016/S0009-2509(98)00534-X
   Taylor HS, 1925, P R SOC LOND A-CONTA, V108, P105, DOI 10.1098/rspa.1925.0061
   WILSON GR, 1970, J CATAL, V17, P190, DOI 10.1016/0021-9517(70)90091-6
   Yablonsky GS, 2007, CHEM ENG SCI, V62, P6754, DOI 10.1016/j.ces.2007.04.050
NR 28
TC 0
Z9 0
U1 4
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 344
EP 351
DI 10.1016/j.ces.2019.06.026
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300027
DA 2020-05-12
ER

PT J
AU Yan, LF
   Wang, H
   Bai, L
   Fu, YH
   Cheng, Y
AF Yan, Lifang
   Wang, Hao
   Bai, Lin
   Fu, Yuhang
   Cheng, Yi
TI Suzuki-Miyura cross-coupling reaction in droplet-based microreactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet-based microreactor; Ionic liquid; Suzuki-Miyaura reaction;
   Process intensification; Reaction performance
ID IONIC LIQUIDS; HETEROGENEOUS CATALYST; LIGANDLESS
AB An ionic liquid (IL)-based Suzuki-Miyaura cross-coupling reaction was implemented successfully in a droplet-based microreactor. FC-40 fluorocarbon-based liquid was introduced as the continuous phase to disperse reactants into uniform droplets. The negligible effect of the existence of FC-40 on reaction and product analysis was clarified, and then the reaction performance within droplets was investigated under different operating conditions. The application of droplet-based microreactor not only solved the clogging problem in a microchannel due to high viscosity of ionic liquids, but also improved the reaction yield by intensifying mixing. Compared with a batch reactor, the yield in the droplet-based microreactor improved evidently, i.e., from 59.4% to 68.7% at 83 degrees C with the reaction time at 10 min. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yan, Lifang; Wang, Hao; Fu, Yuhang; Cheng, Yi] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
   [Bai, Lin] China Natl BlueStar Grp Co Ltd, Beijing 100029, Peoples R China.
RP Cheng, Y (reprint author), Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
EM yicheng@tsinghua.edu.cn
FU National Natural Science FoundationNational Natural Science Foundation
   of China [21576151]
FX We thank the financial support from National Natural Science Foundation
   (No. 21576151).
CR Bai L, 2017, J FLOW CHEM, V7, P52, DOI 10.1556/1846.2017.00002
   Bellina F, 2004, SYNTHESIS-STUTTGART, P2419, DOI 10.1055/s-2004-831223
   Bellina F, 2010, MOLECULES, V15, P2211, DOI 10.3390/molecules15042211
   Chiappe C, 2004, GREEN CHEM, V6, P33, DOI 10.1039/b313221h
   Davies IW, 2001, J AM CHEM SOC, V123, P10139, DOI 10.1021/ja016877v
   Eremin DB, 2017, COORDIN CHEM REV, V346, P2, DOI 10.1016/j.ccr.2016.12.021
   Ghorbani-Vaghei R, 2018, CR CHIM, V21, P644, DOI 10.1016/j.crci.2018.03.004
   Kaur A, 2015, TETRAHEDRON LETT, V56, P1128, DOI 10.1016/j.tetlet.2015.01.055
   LeBlond CR, 2001, ORG LETT, V3, P1555, DOI 10.1021/ol015850d
   Li LY, 2012, CHEM-EUR J, V18, P7842, DOI 10.1002/chem.201103631
   Lu J, 2009, CHEM REV, V109, P815, DOI 10.1021/cr8004444
   Martin R, 2008, ACCOUNTS CHEM RES, V41, P1461, DOI 10.1021/ar800036s
   Mathews CJ, 2000, CHEM COMMUN, P1249, DOI 10.1039/b002755n
   McLachlan F, 2003, ORGANOMETALLICS, V22, P5350, DOI 10.1021/om034075y
   Myung-Jong J., 2010, ANGEW CHEM, V122, P1137, DOI DOI 10.1002/ange.200905626
   Noel T, 2011, CHEM SOC REV, V40, P5010, DOI 10.1039/c1cs15075h
   Paul S, 2003, GREEN CHEM, V5, P635, DOI 10.1039/b306097g
   Soomro SS, 2010, J CATAL, V273, P138, DOI 10.1016/j.jcat.2010.05.007
   Wong HT, 2006, GREEN CHEM, V8, P373, DOI 10.1039/b516778g
   Yu K, 2010, ADV SYNTH CATAL, V347, P161
   Yuan B., 2010, ANGEW CHEM, V122, P4148
NR 21
TC 1
Z9 1
U1 15
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 352
EP 357
DI 10.1016/j.ces.2019.06.031
PG 6
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300028
DA 2020-05-12
ER

PT J
AU Qin, ZY
   Zhou, Q
   Wang, JW
AF Qin, Zhiyuan
   Zhou, Quan
   Wang, Junwu
TI An EMMS drag model for coarse grid simulation of polydisperse gas-solid
   flow in circulating fluidized bed risers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Clustering structure; EMMS drag model; Meso scale
   structure; Particle size distribution
ID GROUP-B PARTICLES; LATTICE-BOLTZMANN SIMULATIONS; CLUSTER
   CHARACTERISTICS; MESOSCALE STRUCTURES; EULERIAN SIMULATION; BIDISPERSE
   ARRAYS; SIZE DISTRIBUTION; BINARY-MIXTURES; 2-FLUID MODEL; CFB RISERS
AB Polydisperse gas-solid systems are more common in both industry and the natural world than their monodisperse counterparts. This paper aims to investigate the hydrodynamics of polydisperse gas-solid flow systems by extending the energy minimization multiscale (EMMS) drag model. The continuous particle size is discretized into several characteristic sizes, by which the polydisperse particles are classified into several discrete groups. A polydisperse EMMS drag model is then developed by treating these particle groups as solid phases. Finally, the proposed drag model is coupled with the multifluid model to simulate the hydrodynamics of polydisperse gas-solid flow in CFB risers. Extensive simulations are conducted to validate the effectiveness of the polydisperse EMMS drag model and investigate the effects of gas-particle drag models, kinetic theories, and particle-particle drag models on the simulation results. It was found that (i) the polydisperse EMMS drag model can predict the concentration and particle size distribution of polydisperse gas-solid flows better than the traditional drag model; (ii) the particle-particle drag force has an important influence on the mixing and segregation of different particles whereas the particulate phase stress has only a very minor effect, especially when the superficial gas velocity is low. The second finding highlights the need for a suitable particle-particle drag model that considers the effects of mesoscale structures, which will be the topic of our future study. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qin, Zhiyuan; Zhou, Quan; Wang, Junwu] Chinese Acad Sci, Inst Proc Engn, Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.
   [Qin, Zhiyuan; Wang, Junwu] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.
RP Wang, JW (reprint author), Chinese Acad Sci, Inst Proc Engn, Key Lab Multiphase Complex Syst, Beijing 100190, Peoples R China.
EM jwwang@ipe.ac.cn
RI Wang, Junwu/C-6591-2009; Wang, Junwu/P-5040-2019
OI Wang, Junwu/0000-0003-3988-1477; Wang, Junwu/0000-0003-3988-1477
FU Innovation Academy for Green Manufacture, Chinese Academy of Sciences
   [IAGM-2019-A13]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [91834303, 91334106]; Key Research
   Program of Frontier Science, Chinese Academy of Sciences
   [QYZDJ-SSW-JSC029]; "Transformational Technologies for Clean Energy and
   Demonstration", Strategic Priority Research Program of the Chinese
   Academy of Sciences [XDA21030700]
FX This study was financially supported by the Innovation Academy for Green
   Manufacture, Chinese Academy of Sciences (IAGM-2019-A13), National
   Natural Science Foundation of China (91834303 and 91334106), Key
   Research Program of Frontier Science, Chinese Academy of Sciences
   (QYZDJ-SSW-JSC029), and the "Transformational Technologies for Clean
   Energy and Demonstration", Strategic Priority Research Program of the
   Chinese Academy of Sciences (XDA21030700).
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Ahmad N, 2019, CHINESE J CHEM ENG, V27, P54, DOI 10.1016/j.cjche.2018.04.011
   Andrews MJ, 1996, INT J MULTIPHAS FLOW, V22, P379, DOI 10.1016/0301-9322(95)00072-0
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Benyahia S, 2012, AICHE J, V58, P427, DOI 10.1002/aic.12603
   Berger KJ, 2014, POWDER TECHNOL, V264, P627, DOI 10.1016/j.powtec.2014.04.096
   BI HT, 1992, CHEM ENG SCI, V47, P3113, DOI 10.1016/0009-2509(92)87011-E
   Chen XZ, 2011, AICHE J, V57, P3351, DOI 10.1002/aic.12548
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   Chen XZ, 2013, CHEM ENG J, V234, P173, DOI 10.1016/j.cej.2013.08.108
   Chew JW, 2011, CHEM ENG J, V178, P348, DOI 10.1016/j.cej.2011.10.020
   Chew JW, 2012, CHEM ENG SCI, V68, P82, DOI 10.1016/j.ces.2011.09.011
   Chew JW, 2011, POWDER TECHNOL, V214, P89, DOI 10.1016/j.powtec.2011.07.040
   Chew JW, 2011, CHEM ENG SCI, V66, P4595, DOI 10.1016/j.ces.2011.06.031
   FAN LS, 1983, POWDER TECHNOL, V36, P290, DOI 10.1016/0032-5910(83)85017-7
   Fan R, 2004, POWDER TECHNOL, V139, P7, DOI 10.1016/j.powtec.2003.10.005
   Fan R, 2008, CHEM ENG SCI, V63, P272, DOI 10.1016/j.ces.2007.09.038
   Feng YQ, 2004, AICHE J, V50, P1713, DOI 10.1002/aic.10169
   Ge W, 2019, CHEM ENG SCI, V198, P198, DOI 10.1016/j.ces.2018.12.037
   GELDART D, 1983, POWDER TECHNOL, V34, P95, DOI 10.1016/0032-5910(83)87034-X
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   GORDON RG, 1968, J MATH PHYS, V9, P655, DOI 10.1063/1.1664624
   Grace J. R, 1997, CIRCULATING FLUIDIZE, P1
   GRACE JR, 1991, CAN J CHEM ENG, V69, P1126, DOI 10.1002/cjce.5450690512
   Hirschberg B, 1998, AICHE J, V44, P25, DOI 10.1002/aic.690440105
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li J., 2013, MULTISCALE MODELING
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Mathiesen V, 1999, AICHE J, V45, P2503, DOI 10.1002/aic.690451206
   Mazzei L, 2012, AICHE J, V58, P3054, DOI 10.1002/aic.13714
   Murray JA, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4744987
   Nelson MJ, 2017, ENGINEERING, V3, P330, DOI 10.1016/J.ENG.2017.03.021
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4089, DOI 10.1016/j.ces.2010.03.053
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4080, DOI 10.1016/j.ces.2010.03.054
   Popoff B., 2007, INT C MULT FLOW LEIP
   Qin Z, 2017, CFD STUDY MIXING SEG
   Qin ZY, 2019, CAN J CHEM ENG, V97, P793, DOI 10.1002/cjce.23160
   ROWE PN, 1976, POWDER TECHNOL, V15, P141, DOI 10.1016/0032-5910(76)80042-3
   Sarkar S, 2009, CHEM ENG SCI, V64, P2683, DOI 10.1016/j.ces.2009.02.045
   SATIJA S, 1985, CHEM ENG SCI, V40, P259, DOI 10.1016/0009-2509(85)80065-8
   Snider DM, 2001, J COMPUT PHYS, V170, P523, DOI 10.1006/jcph.2001.6747
   Syamlal M, 1993, 94 NASA STIRECON
   Syamlal M, 1987, PARTICLE PARTICLE DR, P25
   Tagami N, 2009, PARTICUOLOGY, V7, P9, DOI 10.1016/j.partic.2008.11.008
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   Wang JW, 2008, CHEM ENG SCI, V63, P1553, DOI 10.1016/j.ces.2007.11.023
   Wang JW, 2009, IND ENG CHEM RES, V48, P5567, DOI 10.1021/ie900247t
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Werther J, 1994, AICHE S SER, V301, P31
   [肖海涛 Xiao Haitao], 2003, [化工学报, Journal of Chemical Industry and Engineering (China)], V54, P311
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Yin XL, 2009, AICHE J, V55, P1352, DOI 10.1002/aic.11800
   Zhang DZ, 2002, INT J MULTIPHAS FLOW, V28, P805, DOI 10.1016/S0301-9322(02)00005-8
   Zhang Y, 2019, RENEW ENERG, V136, P193, DOI 10.1016/j.renene.2018.12.121
   Zhou Q, 2016, INT J MINER PROCESS, V151, P40, DOI 10.1016/j.minpro.2016.04.005
   Zhou Q, 2015, CHEM ENG SCI, V122, P637, DOI 10.1016/j.ces.2014.10.025
NR 60
TC 4
Z9 4
U1 13
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 358
EP 378
DI 10.1016/j.ces.2019.06.037
PG 21
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300029
DA 2020-05-12
ER

PT J
AU Cloete, JH
   Cloete, S
   Radl, S
   Amini, S
AF Cloete, Jan Hendrik
   Cloete, Schalk
   Radl, Stefan
   Amini, Shahriar
TI On the choice of closure complexity in anisotropic drag closures for
   filtered Two Fluid Models
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidized bed; Computational fluid dynamics; Filtered two fluid model;
   Coarse-grid simulations; Drag; Verification
ID GRID INDEPENDENCE BEHAVIOR; GAS-SOLID FLUIDIZATION; PARTICLE FLOWS;
   2-FLUID MODELS; WALL FRICTION; BED; SIMULATION; RISER; HYDRODYNAMICS;
   VALIDATION
AB Filtered Two Fluid Models (fTFMs) aim to enable accurate industrial-scale simulations of fluidized beds by means of closures accounting for the effects of bubbles and clusters. The present study aims to improve anisotropic closures for the drift velocity, which is the primary sub-grid effect altering the filtered drag force, by deriving increasingly complex closures by considering additional independent variables (markers). Three different anisotropic closures, as well as an isotropic closure, are evaluated. A priori tests revealed a significant increase in the predictive capability of the closures as the complexity, in terms of the number of markers considered, increases. However, this improvement is relatively small when compared to the effect of considering anisotropy. Next, a posteriori tests were completed by comparing coarse-grid simulations of bubbling, turbulent and core-annular fluidization against benchmark resolved TFM simulations. This analysis shows good performance of all anisotropic closures, with negligible to minor effects of increasing the drag closure's complexity by considering additional markers. On the other hand, the isotropic closure lacks generality and shows poor grid independence behaviour. It is therefore concluded that it is essential to include important physical effects, such as anisotropy, in fTFM closures, while complexity in terms of the number of markers considered is of lesser importance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cloete, Jan Hendrik; Amini, Shahriar] Norwegian Univ Sci & Technol NTNU, Dept Energy & Proc Engn, NO-7491 Trondheim, Norway.
   [Cloete, Schalk; Amini, Shahriar] SINTEF Ind, Flow Technol Res Grp, NO-7465 Trondheim, Norway.
   [Radl, Stefan] Graz Univ Technol, Inst Proc & Particle Engn, Inffeldgasse 13-3, A-8010 Graz, Austria.
RP Amini, S (reprint author), SINTEF Ind, SP Andersens Vei 15, N-7031 Trondheim, Norway.
EM shahriar.amini@sintef.no
RI Cloete, Jan Hendrik/Y-9555-2019
OI Cloete, Jan Hendrik/0000-0002-7854-1662; Cloete,
   Schalk/0000-0001-9641-2939
FU NanoSim - European Commission [604656]; GaSTech - Research Council of
   Norway [271511]; European CommissionEuropean Commission Joint Research
   Centre [691712]
FX The authors would like to express their gratitude for the financial
   support in the following projects: NanoSim (project number: 604656),
   funded by the European Commission, and GaSTech (project number: 271511),
   funded by the Research Council of Norway and co-funded by the European
   Commission under the Horizon 2020 programme, ACT Grant Agreement No
   691712. We would further like to acknowledge the computational resources
   provided at NTNU by UNINETT Sigma2 AS, https://www.sigma2.no.
CR Bakshi A, 2016, POWDER TECHNOL, V299, P185, DOI 10.1016/j.powtec.2016.05.029
   BI HT, 1995, INT J MULTIPHAS FLOW, V21, P1229, DOI 10.1016/0301-9322(95)00037-X
   Cloete J. H., 2018, DEV ANISOTROPIC FILT
   Cloete J. H., 2017, AICHE ANN M
   Cloete JH, 2018, CHEM ENG SCI, V192, P930, DOI 10.1016/j.ces.2018.06.041
   Cloete JH, 2018, CHEM ENG SCI, V192, P906, DOI 10.1016/j.ces.2018.06.040
   Cloete JH, 2017, POWDER TECHNOL, V316, P265, DOI 10.1016/j.powtec.2016.11.064
   Cloete JH, 2016, POWDER TECHNOL, V303, P156, DOI 10.1016/j.powtec.2016.07.009
   Cloete S., 2016, AICHE ANN M
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   Cloete S, 2016, POWDER TECHNOL, V289, P65, DOI 10.1016/j.powtec.2015.11.011
   Cloete S, 2015, POWDER TECHNOL, V283, P85, DOI 10.1016/j.powtec.2015.04.060
   Cloete S, 2015, POWDER TECHNOL, V269, P153, DOI 10.1016/j.powtec.2014.08.055
   Cloete S, 2013, POWDER TECHNOL, V235, P735, DOI 10.1016/j.powtec.2012.11.041
   Cloete S, 2011, POWDER TECHNOL, V210, P6, DOI 10.1016/j.powtec.2011.02.003
   Ellis N, 2011, IND ENG CHEM RES, V50, P4697, DOI 10.1021/ie101141f
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Gidaspow D, 1992, FLUIDIZATION, P75
   Hamidouche Z, 2019, CHEM ENG SCI, V193, P102, DOI 10.1016/j.ces.2018.08.032
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Jiang Y., 2018, POWDER TECHNOL
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Leonard B. P., 1990, 12568ICOMP9012 NASA
   Lu HL, 2003, CHEM ENG SCI, V58, P3777, DOI 10.1016/S0009-2509(03)00238-0
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Municchi F, 2016, COMPUT PHYS COMMUN, V207, P400, DOI 10.1016/j.cpc.2016.05.026
   Ostermeier P, 2017, POWDER TECHNOL, V312, P89, DOI 10.1016/j.powtec.2017.02.015
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Ozel A, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.5000516
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   POPE SB, 2000, TUBULENT FLOWS
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   SCHAEFFER DG, 1987, J DIFFER EQUATIONS, V66, P19, DOI 10.1016/0022-0396(87)90038-6
   Schneiderbauer S., 2016, 9 INT C MULT FLOW FI
   Schneiderbauer S, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5017004
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Tricomi L., FRONT BIOENG BIOTECH, V5
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
NR 44
TC 8
Z9 8
U1 4
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 379
EP 396
DI 10.1016/j.ces.2019.06.006
PG 18
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300030
DA 2020-05-12
ER

PT J
AU Siebler, F
   Lapin, A
   Hermann, M
   Takors, R
AF Siebler, Flora
   Lapin, Alexey
   Hermann, Maria
   Takors, Ralf
TI The impact of CO gradients on C. ljungdahlii in a 125 m(3) bubble
   column: Mass transfer, circulation time and lifeline analysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pseudo-stationary gas gradient; Two-phase Euler-Euler simulation;
   Lagrange trajectories; Bubble column reactor; Computational fluid
   dynamics (CFD)
ID POPULATION BALANCE MODEL; ESCHERICHIA-COLI; SCALE-UP; BIOREACTORS; GAS;
   LIQUID; COMPARTMENT; DYNAMICS; SYNGAS
AB Successful scale-up of biological fermentations requires the prevention of any performance losses from lab to production scale. Modelling large-scale conditions, in particular, so-called lifeline analysis, is a proper approach to unravel potential risks and to guide the way for preventing non-wanted underperformance. This study focuses on synthesis gas fermentations in bubble columns which are particularly challenging because of poor carbon (C) -source solubility and low bacterial energy availability under such anaerobic conditions. As a model case, Clostridium ljungdahlii DSM 13528 is studied in a 125 m(3) bubble column reactor investigating bacterial motion patterns, circulation time, short- and long-term responses. A pseudo-stationary gas gradient respectively fermentations 'snap-shot' was conducted with computational fluid dynamics in an Euler-Euler approach while the movement of the microorganism was simulated as Lagrangian massless particles. Cells were assigned uptake and product formation kinetics. Statistical lifeline analysis revealed that 97% of all cells experienced substrate limitations, whereas 84% were likely to undergo transcriptional changes after exposure in stress-inducing zone longer than 70 s. Bacteria movements predominately occurred between low and moderate product biomass yield regions with longer residence times in the latter. The circulation time derived from mixing time analysis is similar to the mean circulation time of a single bacterium. The latter was deduced from regime transition studies. Maximum residence times over 100 s as minimum regime crossing times of 10 s could also be identified. These findings show the high potential of Lagrange trajectories analysis in bubble column gas gradients which can be used for performance prediction and therefore risk minimization in scale-up. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Siebler, Flora; Hermann, Maria; Takors, Ralf] Univ Stuttgart, Inst Biochem Engn, Allmandring 31, D-70569 Stuttgart, Germany.
   [Lapin, Alexey] Univ Stuttgart, Stuttgart Res Ctr Syst Biol, Nobelstr 15, D-70569 Stuttgart, Germany.
RP Takors, R (reprint author), Univ Stuttgart, Inst Biochem Engn, Allmandring 31, D-70569 Stuttgart, Germany.
EM takors@uni-stuttgart.de
FU Federal Ministry of Education and Research (BMBF)Federal Ministry of
   Education & Research (BMBF) [FKZ031A468B]
FX At this point, we want to thank Maike Kuschel, Andreas Ulmer and Julia
   Zieringer for their inspiring discussion and support during the
   simulation process. This work was supported by the Federal Ministry of
   Education and Research (BMBF; FKZ031A468B).
CR AKITA K, 1973, IND ENG CHEM PROC DD, V12, P76, DOI 10.1021/i260045a015
   ANTAL SP, 1991, INT J MULTIPHAS FLOW, V17, P635, DOI 10.1016/0301-9322(91)90029-3
   Burns A. D., 2004, EULERIAN MULTIPHASE, V4, P1
   Chen J, 2015, BIOTECHNOL BIOFUELS, V8, DOI 10.1186/s13068-015-0272-5
   Clift R., 1978, BUBBLES DROPS PARTIC
   Daniell J, 2012, ENERGIES, V5, P5372, DOI 10.3390/en5125372
   DECKWER WD, 1980, IND ENG CHEM PROC DD, V19, P699, DOI 10.1021/i260076a032
   Enfors SO, 2001, J BIOTECHNOL, V85, P175, DOI 10.1016/S0168-1656(00)00365-5
   Gomez JA, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/s12859-014-0409-8
   GRACE JR, 1973, T I CHEM ENG-LOND, V51, P116
   Haringa C, 2016, ENG LIFE SCI, P1
   Haringa C, 2018, CHEM ENG RES DES, V136, P886, DOI 10.1016/j.cherd.2018.06.007
   Haringa C, 2017, CHEM ENG SCI, V170, P653, DOI 10.1016/j.ces.2017.01.014
   Haringa C, 2017, CHEM ENG SCI, V157, P159, DOI 10.1016/j.ces.2016.07.031
   Heins AL, 2015, J CHEM TECHNOL BIOT, V90, P324, DOI 10.1002/jctb.4532
   Henson MA, 2003, CURR OPIN BIOTECH, V14, P460, DOI 10.1016/S0958-1669(03)00104-6
   Higbie R, 1935, T AM INST CHEM ENG, V31, P365
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Kopke M, 2010, P NATL ACAD SCI USA, V107, P13087, DOI 10.1073/pnas.1004716107
   Krishna R, 2000, FUEL PROCESS TECHNOL, V64, P73, DOI 10.1016/S0378-3820(99)00128-9
   Kuschel Maike, 2017, Bioengineering-Basel, V4, DOI 10.3390/bioengineering4020027
   Lapin A, 2004, IND ENG CHEM RES, V43, P4647, DOI 10.1021/ie030786k
   Lapin A, 2006, CHEM ENG SCI, V61, P4783, DOI 10.1016/j.ces.2006.03.003
   Larsson G, 1996, BIOPROCESS ENG, V14, P281
   Lee YH, 2014, SCI WORLD J, DOI 10.1155/2014/951216
   Lehr F., 2002, AICHE J, V42, P1225, DOI DOI 10.1002/AIC.690481103
   Loeffler M, 2016, METAB ENG, V38, P73, DOI 10.1016/j.ymben.2016.06.008
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Luo H., 1993, COALESCENCE BREAKUP
   Mantzaris NV, 1999, J BIOTECHNOL, V71, P157, DOI 10.1016/S0168-1656(99)00020-6
   Michalowski A, 2017, METAB ENG, V40, P93, DOI 10.1016/j.ymben.2017.01.005
   Morchain J, 2014, AICHE J, V60, P27, DOI 10.1002/aic.14238
   Nagarajan H, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-118
   Abubackar HN, 2011, BIOFUEL BIOPROD BIOR, V5, P93, DOI 10.1002/bbb.256
   Nauha EK, 2018, CHEM ENG J, V334, P2319, DOI 10.1016/j.cej.2017.11.182
   Noorman H., 1993, BHR GR C SER PUBL, V5, P241
   PANDIT AB, 1983, CHEM ENG SCI, V38, P1189, DOI 10.1016/0009-2509(83)80040-2
   Philp J., 2018, N BIOTECHNOL A, V40, P25
   Pigou M, 2015, CHEM ENG SCI, V126, P267, DOI 10.1016/j.ces.2014.11.035
   Sato Y, 1975, INT J MULTIPHAS FLOW, V2, P97
   Schmalzriedt S, 2003, ADV BIOCH ENG BIOTEC
   Takors R, 2012, J BIOTECHNOL, V160, P3, DOI 10.1016/j.jbiotec.2011.12.010
   Takors R, 2018, MICROB BIOTECHNOL, V11, P606, DOI 10.1111/1751-7915.13270
   TANNER RS, 1993, INT J SYST BACTERIOL, V43, P232, DOI 10.1099/00207713-43-2-232
   Taymaz-Nikerel H, 2010, BIOTECHNOL BIOENG, V107, P369, DOI 10.1002/bit.22802
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Vrabel P, 2001, CHEM ENG J, V84, P463, DOI 10.1016/S1385-8947(00)00271-0
NR 47
TC 3
Z9 3
U1 14
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 410
EP 423
DI 10.1016/j.ces.2019.06.018
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300032
DA 2020-05-12
ER

PT J
AU Yin, CF
   Liu, GL
AF Yin, Changfang
   Liu, Guilian
TI Automatic identification of the optimal distillation sequence based on
   its integration with reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Distillation sequence; Reaction; Non-key components; Optimization;
   Integration
ID REACTION/DISTILLATION MATRIX; HEURISTIC DESIGN; OPTIMIZATION; FRAMEWORK
AB A systematical method is proposed for integrating the reaction and separation system and automatically identifying the optimal distillation sequence. Based on the regularity of each component as a non-key component, the non-key component matrix is constructed to illustrate the difference between distillation sequences. With the marginal minimum vapor rate of non-key components used to evaluate distillation sequences and the relation between reactor and distillation sequences considered, procedure is developed for automatically identifying the optimal distillation sequence and reactor parameters. The proposed method can be used for systems with simple columns performing sharp splits and the separated mixture can be taken as ideal mixtures. The reaction and distillation systems of the propylene oxide production process and styrene production process are analyzed, and the optimal distillation sequences generated by the proposed method are in good agreement with that identified by the systematical analyzation and rigorous simulation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yin, Changfang; Liu, Guilian] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
RP Liu, GL (reprint author), Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
EM guilianliui@mail.xjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21736008, U1662126]
FX Financial supports provided by the National Natural Science Foundation
   of China (21736008) and (U1662126) are gratefully acknowledged.
CR Adams TA, 2009, CHEM ENG RES DES, V87, P263, DOI 10.1016/j.cherd.2008.09.008
   An WZ, 2009, COMPUT CHEM ENG, V33, P199, DOI 10.1016/j.compchemeng.2008.08.001
   Caballero JA, 2014, COMPUT CHEM ENG, V61, P118, DOI 10.1016/j.compchemeng.2013.10.015
   Fox JA, 2013, AICHE J, V59, P3714, DOI 10.1002/aic.14116
   GOMEZM A, 1976, AICHE J, V22, P970, DOI 10.1002/aic.690220604
   Hentschel B, 2014, CHEM ENG SCI, V115, P69, DOI 10.1016/j.ces.2013.09.046
   Khalili-Garakani A, 2016, KOREAN J CHEM ENG, V33, P1134, DOI 10.1007/s11814-015-0273-x
   KOEHLER J, 1992, GAS SEP PURIF, V6, P153
   [李慧 Li Hui], 2017, [化学工程, Chemical Engineering (China)], V45, P55
   Li Y., 2014, THESIS
   Linke P, 2003, COMPUT CHEM ENG, V27, P733, DOI 10.1016/S0098-1354(02)00253-3
   Luyben WL, 2011, IND ENG CHEM RES, V50, P4788, DOI 10.1021/ie101896v
   Luyben WL, 2010, IND ENG CHEM RES, V49, P11564, DOI 10.1021/ie101509w
   MODI AK, 1992, IND ENG CHEM RES, V31, P839, DOI 10.1021/ie00003a028
   Nezhadfard M, 2018, CHEM ENG RES DES, V139, P259, DOI 10.1016/j.cherd.2018.09.029
   Nezhadfard M, 2018, COMPUT CHEM ENG, V117, P268, DOI 10.1016/j.compchemeng.2018.06.025
   Ondrey G, 2006, CHEM ENG, V6, P14
   Ozcelik Y, 2016, CHEM BIOCHEM ENG Q, V30, P305, DOI 10.15255/CABEQ.2015.2202
   PAULES GE, 1988, COMPUT CHEM ENG, V12, P267, DOI 10.1016/0098-1354(88)85038-5
   Recker S, 2015, COMPUT CHEM ENG, V81, P260, DOI 10.1016/j.compchemeng.2015.03.014
   Robin S, 2005, CHEM PROCESS DESIGN
   Ryll O, 2014, CHEM ENG SCI, V109, P284, DOI 10.1016/j.ces.2014.01.024
   SARGENT RWH, 1976, OPTIMIZATION ACTION
   THOMPSON RW, 1972, AICHE J, V18, P941, DOI 10.1002/aic.690180510
   Yeomans H, 1999, COMPUT CHEM ENG, V23, P1135, DOI 10.1016/S0098-1354(99)00279-3
   Yeomans H, 1999, COMPUT CHEM ENG, V23, P709, DOI 10.1016/S0098-1354(99)00003-4
   Zakharov MK, 2017, THEOR FOUND CHEM EN+, V51, P610, DOI 10.1134/S0040579517040157
   Zhang L, 2010, CHEM ENG TECHNOL, V33, P44, DOI 10.1002/ceat.200900312
   Zhang X, 2018, COMPUT CHEM ENG, V111, P16, DOI 10.1016/j.compchemeng.2017.12.013
   [赵基钢 ZHAO Jigang], 2007, [华东理工大学学报. 自然科学版, Journal of East China University of Science and Technoloy. Natural Sciences Edition], V33, P23
   Zhou GQ, 2014, INT ARCH PHOTOGRAMM, V40-8, P493, DOI 10.5194/isprsarchives-XL-8-493-2014
NR 31
TC 0
Z9 0
U1 5
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 424
EP 440
DI 10.1016/j.ces.2019.06.021
PG 17
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300033
DA 2020-05-12
ER

PT J
AU Nie, GK
   Dai, YY
   Liu, YN
   Xie, JJ
   Gong, S
   Afzal, N
   Zhang, XW
   Pan, L
   Zou, JJ
AF Nie, Genkuo
   Dai, Yiying
   Liu, Yanan
   Xie, Junjian
   Gong, Si
   Afzal, Nisha
   Zhang, Xiangwen
   Pan, Lun
   Zou, Ji-Jun
TI High yield one-pot synthesis of high density and low freezing point
   jet-fuel-ranged blending from bio-derived phenol and cyclopentanol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Biofuel; Phenol; Cyclopentanol; Alkylation; Hydrodeoxygenation;
   Jet-fuel-ranged blending
ID CATALYZED ISOMERIZATION; LIGNIN DEPOLYMERIZATION; ACIDIC RESIN;
   CONVERSION; DIESEL; 2-METHYLFURAN; ALKANES; HYDROALKYLATION;
   DEOXYGENATION; CYCLOALKANES
AB Synthesizing high performance jet fuel from biomass provides potential way to convert low-cost biomass to valuable fuels and meets the requirements of sustainable development. Here, we report a one-pot synthesis of high density and low freezing point jet-fuel-ranged blending from bio-derived phenol and cyclopentanol, which is with high yield, simple and low-cost for scale-up. With the co-presence of acid catalyst like H beta and metal catlayst like Pd/C, the alkylation first happens to produce bi-and tri-cyclic compounds under N-2 atomphere, then in H-2 atmosphere the remained reactant is partly hydrogenated and takes part in alkylation again to produce cyclic compounds, finally hydrodeoxygenation happens to convert all the compounds to cyclic hydrocarbons. A jet-fuel-blending containing bi- and tri-cyclic alkanes is obtained at high molar yield of 83.9% from the starting reactant, which shows high density of 0.89 g/mL, freezing point lower than -75 degrees C. Especially, the major component, i.e. cyclopentylcyclohexane shows much better low-temperature properties compared with reported hydrocarbons with similar molecular structure. This result provides a simple, low-cost way to synthesize high performance jet fuel from biomass. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nie, Genkuo; Dai, Yiying; Liu, Yanan; Xie, Junjian; Gong, Si; Afzal, Nisha; Zhang, Xiangwen; Pan, Lun; Zou, Ji-Jun] Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
   [Nie, Genkuo; Zhang, Xiangwen; Pan, Lun; Zou, Ji-Jun] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP Zou, JJ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Minist Educ, Key Lab Green Chem Technol, Tianjin 300072, Peoples R China.
EM jj_zou@tju.edu.cn
OI Pan, Lun/0000-0002-3083-4693
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808162]; National Postdoctoral Program for
   Innovative Talents [BX20180212]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018M631743]
FX The authors appreciate the supports from the National Natural Science
   Foundation of China (21808162); National Postdoctoral Program for
   Innovative Talents (BX20180212) and China Postdoctoral Science
   Foundation (2018M631743).
CR Arias KS, 2015, ENERG ENVIRON SCI, V8, P317, DOI 10.1039/c4ee03194f
   Bond JQ, 2010, SCIENCE, V327, P1110, DOI 10.1126/science.1184362
   BRUGEL W, 1967, J MOL STRUCT, V1, P61, DOI 10.1016/0022-2860(67)80007-3
   Bu Q, 2012, BIORESOURCE TECHNOL, V108, P274, DOI 10.1016/j.biortech.2011.12.125
   Chen S, 2018, CHEM REV, V118, P11023, DOI 10.1021/acs.chemrev.8b00134
   Chung HS, 1999, ENERG FUEL, V13, P641, DOI 10.1021/ef980195k
   Corma A, 2011, CHEMSUSCHEM, V4, P1574, DOI 10.1002/cssc.201100296
   Corson BB, 1937, J AM CHEM SOC, V59, P645, DOI 10.1021/ja01283a014
   Deng Q, 2015, GREEN CHEM, V17, P4473, DOI [10.1039/c5gc01287b, 10.1039/C5GC01287B]
   Gollis M.H., 1962, J CHEM ENG DATA, V7, P311
   Harvey BG, 2010, ENERG ENVIRON SCI, V3, P352, DOI 10.1039/b924004g
   He JY, 2012, J AM CHEM SOC, V134, P20768, DOI 10.1021/ja309915e
   Jia XK, 2017, ENERG FUEL, V31, P8023, DOI 10.1021/acs.energyfuels.7b01128
   Kang SM, 2013, RENEW SUST ENERG REV, V27, P546, DOI 10.1016/j.rser.2013.07.013
   Li GY, 2014, ENERG FUEL, V28, P5112, DOI 10.1021/ef500676z
   Li SS, 2017, CHEMSUSCHEM, V10, P711, DOI 10.1002/cssc.201601727
   Li SS, 2015, GREEN CHEM, V17, P3644, DOI 10.1039/c5gc00372e
   Ma QS, 2006, J PHYS CHEM A, V110, P2246, DOI 10.1021/jp0560213
   Meylemans HA, 2013, ENERG FUEL, V27, P883, DOI 10.1021/ef301608z
   Nakagawa Y, 2013, ACS CATAL, V3, P2655, DOI 10.1021/cs400616p
   Nie GK, 2017, CHEM ENG SCI, V173, P91, DOI 10.1016/j.ces.2017.07.034
   Nie GK, 2017, CHEM ENG SCI, V158, P64, DOI 10.1016/j.ces.2016.10.003
   Nie GK, 2014, CATAL TODAY, V234, P271, DOI 10.1016/j.cattod.2013.12.003
   Olcay H, 2013, ENERG ENVIRON SCI, V6, P205, DOI [10.1039/c2ee23316a, 10.1039/C2EE23316A]
   Pandey MP, 2011, CHEM ENG TECHNOL, V34, P29, DOI 10.1002/ceat.201000270
   Pholjaroen B, 2014, IND ENG CHEM RES, V53, P13618, DOI 10.1021/ie5016365
   Sheng XR, 2016, AICHE J, V62, P2754, DOI 10.1002/aic.15248
   Shu RY, 2018, CHEM ENG J, V338, P457, DOI 10.1016/j.cej.2018.01.002
   Song W., 2018, ACS CATAL, P259
   Sun ZH, 2018, NAT CATAL, V1, P82, DOI 10.1038/s41929-017-0007-z
   Van de Vyver S, 2011, ENERG ENVIRON SCI, V4, P3601, DOI 10.1039/c1ee01418h
   Wang L, 2009, ENERG FUEL, V23, P2383, DOI 10.1021/ef801139h
   Wang W, 2017, ACS SUSTAIN CHEM ENG, V5, P1812, DOI 10.1021/acssuschemeng.6b02554
   Wright ME, 2008, ENERG FUEL, V22, P3299, DOI 10.1021/ef800380b
   Wu LQ, 2014, GREEN CHEM, V16, P3935, DOI [10.1039/c4gc00311j, 10.1039/C4GC00311J]
   Xing R, 2010, GREEN CHEM, V12, P1933, DOI 10.1039/c0gc00263a
   Yang FF, 2017, J CATAL, V349, P84, DOI 10.1016/j.jcat.2017.01.001
   Yang FJ, 2008, J CHEM ENG DATA, V53, P2237, DOI 10.1021/je800348s
   Yang JF, 2014, CHEM COMMUN, V50, P2572, DOI 10.1039/c3cc46588h
   Zhang XW, 2017, AICHE J, V63, P680, DOI 10.1002/aic.15410
   Zhao C, 2012, ACS CATAL, V2, P2714, DOI 10.1021/cs300418a
   Zhao C, 2012, J CATAL, V288, P92, DOI 10.1016/j.jcat.2012.01.005
   Zhao C, 2012, CHEMCATCHEM, V4, P64, DOI 10.1002/cctc.201100273
   Zhao C, 2009, ANGEW CHEM INT EDIT, V48, P3987, DOI 10.1002/anie.200900404
   Zhou MH, 2014, J ENERGY CHEM, V23, P91, DOI 10.1016/S2095-4956(14)60109-1
NR 45
TC 1
Z9 1
U1 31
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 441
EP 447
DI 10.1016/j.ces.2019.06.050
PG 7
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300034
DA 2020-05-12
ER

PT J
AU Zheng, PY
   Zhang, WH
   Li, C
   Wang, NX
   Li, J
   Qin, ZP
   An, QF
AF Zheng, Pei-Yao
   Zhang, Wen-Hai
   Li, Chong
   Wang, Nai-Xin
   Li, Jie
   Qin, Zhen-Ping
   An, Quan-Fu
TI Efficient bio-ethanol recovery by non-contact vapor permeation process
   using membranes with tailored pore size and hydrophobicity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polyacrylonitrile; Hydrolysis; Hydrophobically modification; Vapor
   permeation; Bio-ethanol
ID NANOFILTRATION MEMBRANE; HYBRID MEMBRANES; PERVAPORATION; WATER;
   FERMENTATION; POLYACRYLONITRILE; PERFORMANCE; DISTILLATION; REMOVAL
AB Vapor permeation seems to be a more suitable separation process than pervaporation in bio-ethanol recovery from fermentation broth because of its non-direct contact trait. The unsatisfactory flux and selectivity of polymeric membranes limit their utilization in industrial application. Here, we tailored the physical and chemical structure of commercial available polyacrylonitrile (PAN) ultrafiltration membrane to serve in vapor permeation. The membrane porosity was reduced till dense enough for separation while preserving an ultra-high flux by hydrolyzing in alkali. The hydrophilicity/hydrophobicity was controlled by grafting fluoroalkyl chains to ensure an acceptable ethanol selectivity. The changes of physical structure and chemical property were systematically characterized by Fourier transform infrared-attenuated total reflectance (ATR-FTIR), X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM), water contact angle and pure water permeance. Tested at 60 degrees C, the optimized membrane exhibited a high flux of ca. 10.5 kg m(-2) h(-1) and a permeate ethanol content similar to vapor-liquid equilibrium curve, which outstripped most polymeric membranes (applied in pervaporation or vapor permeation) in both flux and selectivity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wen-Hai; Li, Chong; Wang, Nai-Xin; Li, Jie; Qin, Zhen-Ping; An, Quan-Fu] Beijing Univ Technol, Coll Environm & Energy Engn, Beijing Key Lab Green Catalysis & Separat, Beijing 100124, Peoples R China.
   [Zheng, Pei-Yao; An, Quan-Fu] Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou 310027, Zhejiang, Peoples R China.
RP An, QF (reprint author), Beijing Univ Technol, Coll Environm & Energy Engn, Beijing Key Lab Green Catalysis & Separat, Beijing 100124, Peoples R China.
EM anqf@bjut.edu.cn
RI An, Quan-Fu/T-4717-2017; Wang, Naixin/AAI-7142-2020
OI An, Quan-Fu/0000-0002-6574-9368; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706003, 21376206]; Importation and Development of
   High-Caliber Talents Project of Beijing Municipal Institutions [CIT
   TCD20170305]
FX This research was financially supported by the National Natural Science
   Foundation of China (No. 21706003, 21376206) and the Importation and
   Development of High-Caliber Talents Project of Beijing Municipal
   Institutions (CIT& TCD20170305).
CR Al-Gharabli S, 2018, J MEMBRANE SCI, V556, P214, DOI 10.1016/j.memsci.2018.04.012
   An QF, 2013, J MEMBRANE SCI, V431, P171, DOI 10.1016/j.memsci.2012.12.043
   Baker R.W., 2004, MEMBRANE TECHNOLOGY
   Dahiya D, 2018, AIMS ENERGY, V6, P979, DOI 10.3934/energy.2018.6.979
   [邓兆龙 Deng Zhaolong], 2016, [化工新型材料, New Chemical Materials], V44, P58
   Garcia V, 2011, RENEW SUST ENERG REV, V15, P964, DOI 10.1016/j.rser.2010.11.008
   Gaykawad SS, 2017, BIOCHEM ENG J, V124, P54, DOI 10.1016/j.bej.2017.04.010
   Gmehling J., 1977, CHEM DATA SERIES, VI
   Guo YS, 2018, SEP PURIF TECHNOL, V206, P59, DOI 10.1016/j.seppur.2018.05.048
   Hu S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09428
   KATAOKA T, 1991, J CHEM ENG JPN, V24, P334, DOI 10.1252/jcej.24.334
   Kujawski W, 2016, J MEMBRANE SCI, V499, P442, DOI 10.1016/j.memsci.2015.10.067
   Lai CL, 2015, J MEMBRANE SCI, V490, P275, DOI 10.1016/j.memsci.2015.05.008
   Liu GP, 2011, J MEMBRANE SCI, V373, P121, DOI 10.1016/j.memsci.2011.02.042
   Liu HC, 2018, MACROMOL CHEM PHYS, V219, DOI 10.1002/macp.201700558
   Liu Q, 2013, J MATER CHEM A, V1, P11970, DOI 10.1039/c3ta12001e
   Mai TK, 2018, J MEMBRANE SCI, V551, P180, DOI 10.1016/j.memsci.2018.01.046
   Mohd Azhar Siti Hajar, 2017, Biochem Biophys Rep, V10, P52, DOI 10.1016/j.bbrep.2017.03.003
   Novita FJ, 2018, CHEM ENG SCI, V190, P297, DOI 10.1016/j.ces.2018.06.024
   Oh NW, 2001, J APPL POLYM SCI, V80, P1854, DOI 10.1002/app.1282
   Ong YK, 2016, PROG POLYM SCI, V57, P1, DOI 10.1016/j.progpolymsci.2016.02.003
   Pan FS, 2019, CHEM ENG SCI, V195, P609, DOI 10.1016/j.ces.2018.10.003
   QURESHI N, 1992, BIOTECHNOL PROGR, V8, P382, DOI 10.1021/bp00017a002
   SANDER U, 1991, J MEMBRANE SCI, V61, P113, DOI 10.1016/0376-7388(91)80010-4
   Sukitpaneenit P, 2011, J MEMBRANE SCI, V374, P67, DOI 10.1016/j.memsci.2011.03.016
   Tian Y, 2013, NAT MATER, V12, P291, DOI 10.1038/nmat3610
   Van der Bruggen B, 2014, CURR OPIN CHEM ENG, V4, P47, DOI 10.1016/j.coche.2014.01.005
   Van Hecke W, 2012, BIORESOURCE TECHNOL, V111, P368, DOI 10.1016/j.biortech.2012.02.043
   Vane LM, 2005, J CHEM TECHNOL BIOT, V80, P603, DOI 10.1002/jctb.1265
   Verhoef A, 2008, SEP PURIF TECHNOL, V60, P54, DOI 10.1016/j.seppur.2007.07.044
   Vogler EA, 1998, ADV COLLOID INTERFAC, V74, P69, DOI 10.1016/S0001-8686(97)00040-7
   Wang MR, 2018, CHEM ENG SCI, V178, P273, DOI 10.1016/j.ces.2017.12.021
   WERBER JR, 2016, NAT REV MATER, V1
   WU CR, 1986, SYNTHETIC MET, V16, P147, DOI 10.1016/0379-6779(86)90107-4
   Zheng PY, 2018, J MEMBRANE SCI, V548, P215, DOI 10.1016/j.memsci.2017.11.015
   Zheng PY, 2019, CHINESE J CHEM ENG, V27, P1296, DOI 10.1016/j.cjche.2018.09.025
   Zhu M, 2018, J MEMBRANE SCI, V554, P264, DOI 10.1016/j.memsci.2018.01.055
   Zuo J, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.45086
NR 38
TC 1
Z9 1
U1 19
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 448
EP 455
DI 10.1016/j.ces.2019.06.047
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300035
DA 2020-05-12
ER

PT J
AU Sun, JJ
   Liu, ZP
   Cao, DP
AF Sun, Jingjing
   Liu, Zhiping
   Cao, Dapeng
TI A permeation model of shale gas in cylindrical-like kerogen pores at
   geological conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shale gas; Diffusion and permeation; Grand canonical molecular dynamics
   simulation; Kerogen; Cylindrical pores; Confined fluids
ID MOLECULAR-DYNAMICS SIMULATION; CARBON-DIOXIDE; NATURAL-GAS; WATER
   TRANSPORT; FORCE-FIELD; METHANE; FLOW; DIFFUSION; ADSORPTION; STORAGE
AB Understanding the diffusion and permeation behavior of shale gas at geological depths is significantly important to exploration of shale gas, while the permeation mechanism of shale gas in shale gas reservoir is closely related to the confined fluid behavior at mesoscopic scale and cannot be described by traditional Fick or Knudsen diffusion models. In this work, we use the dual control volume grand canonical molecular dynamics method to systematically investigate the permeation processes of shale gas in cylindrical -like kerogen pores represented by the carbon nanotube at different geological depths, and hundreds of simulation data in different pressures, temperatures and pore diameter are obtained. By analyzing these simulated data, we propose a new permeation model to describe the permeability of shale gas in cylindrical-like kerogen pores at geological depths. The new model can satisfactorily reproduce the extrapolation testing data of permeability of shale gas, and perfectly bridge the gap between macroscopic Fick model and microscopic Knudsen model, which provides a useful guidance and reference for exploration of shale gas. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Jingjing; Liu, Zhiping; Cao, Dapeng] Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
RP Cao, DP (reprint author), Beijing Univ Chem Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
EM caodp@mail.buct.edu.cn
FU National Natural Science Foundation of China for Distinguished Young
   ScholarsNational Natural Science Foundation of ChinaNational Science
   Fund for Distinguished Young Scholars [21625601]; Outstanding Talents
   Plan from BUCT
FX This work is supported by National Natural Science Foundation of China
   for Distinguished Young Scholars (No. 21625601) and Outstanding Talents
   Plan from BUCT.
CR Al Hinai A, 2014, J UNCONV OIL GAS RES, V8, P1, DOI 10.1016/j.juogr.2014.06.002
   Aljamaan H, 2017, ENERG FUEL, V31, P1193, DOI 10.1021/acs.energyfuels.6b02286
   Ambrose RJ, 2012, SPE J, V17, P219, DOI 10.2118/131772-PA
   Burnham A, 2012, ENVIRON SCI TECHNOL, V46, P619, DOI 10.1021/es201942m
   Cao DP, 2003, J PHYS CHEM B, V107, P13286, DOI 10.1021/jp036094r
   Chen H, 2016, J ENVIRON MANAGE, V170, P152, DOI 10.1016/j.jenvman.2016.01.023
   Chen JH, 2019, J NAT GAS SCI ENG, V66, P18, DOI 10.1016/j.jngse.2019.03.015
   Clark C., 2012, HYDRAULIC FRACTURING, P1
   Clarkson CR, 2016, J NAT GAS SCI ENG, V31, P612, DOI 10.1016/j.jngse.2016.01.041
   Collell J, 2015, J PHYS CHEM C, V119, P22587, DOI 10.1021/acs.jpcc.5b07242
   Connor J. A, 2015, SPE LATIN AM CARIBBE, P1123
   Corma A, 1997, CHEM REV, V97, P2373, DOI 10.1021/cr960406n
   Corry B, 2008, J PHYS CHEM B, V112, P1427, DOI 10.1021/jp709845u
   CRACKNELL RF, 1995, PHYS REV LETT, V74, P2463, DOI 10.1103/PhysRevLett.74.2463
   Curtis JB, 2002, AAPG BULL, V86, P1921, DOI 10.1306/61eeddbe-173e-11d7-8645000102c1865d
   Cygan RT, 2004, J PHYS CHEM B, V108, P1255, DOI 10.1021/jp0363287
   Dayhoff GW, 2017, MOL SIMULAT, V43, P467, DOI 10.1080/08927022.2016.1273524
   Firouzi M, 2014, INT J COAL GEOL, V123, P62, DOI 10.1016/j.coal.2013.09.006
   Firouzi M, 2012, MICROPOR MESOPOR MAT, V158, P195, DOI 10.1016/j.micromeso.2012.02.045
   Furukawa S, 2000, J MEMBRANE SCI, V178, P107, DOI 10.1016/S0376-7388(00)00483-X
   Gasparik M, 2012, ENERG FUEL, V26, P4995, DOI 10.1021/ef300405g
   Guan WH, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/12/122001
   Heller R, 2014, AAPG BULL, V98, P975, DOI 10.1306/09231313023
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hu YA, 2016, J NAT GAS SCI ENG, V33, P1078, DOI 10.1016/j.jngse.2016.06.014
   Hu YN, 2015, SPE J, V20, P112
   Humplik T, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/29/292001
   Javadpour F, 2009, J CAN PETROL TECHNOL, V48, P16, DOI 10.2118/09-08-16-DA
   Ji LM, 2012, APPL GEOCHEM, V27, P2533, DOI 10.1016/j.apgeochem.2012.08.027
   Jin ZH, 2016, SPE J, V21, P190, DOI 10.2118/176015-PA
   Jin ZH, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4930006
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kang SM, 2011, SPE J, V16, P842, DOI 10.2118/134583-PA
   Kazemi M, 2016, SPE W REG M
   Kazemi M, 2016, J NAT GAS SCI ENG, V33, P1087, DOI 10.1016/j.jngse.2016.05.068
   Kerr RA, 2010, SCIENCE, V328, P1624, DOI 10.1126/science.328.5986.1624
   Kowalczyk P, 2012, J PHYS CHEM C, V116, P13640, DOI 10.1021/jp302776z
   Krogulec E, 2015, EPISODES, V38, P9, DOI 10.18814/epiiugs/2015/v38i1/002
   Lan JH, 2010, LANGMUIR, V26, P220, DOI 10.1021/la9020383
   Li Yu-xi, 2009, Natural Gas Industry, V29, P115, DOI 10.3787/j.issn.1000-0976.2009.12.034
   MacElroy JMD, 1999, CHEM ENG J, V74, P85, DOI 10.1016/S1385-8947(99)00056-X
   Makrodimitris K, 2001, J PHYS CHEM B, V105, P777, DOI 10.1021/jp002866x
   Martin CR, 2001, J PHYS CHEM B, V105, P1925, DOI 10.1021/jp003486e
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   Ning Y, 2015, J NAT GAS SCI ENG, V26, P345, DOI 10.1016/j.jngse.2015.06.015
   Nyakairu GWA, 2001, GEOCHEM J, V35, P13, DOI 10.2343/geochemj.35.13
   Obliger A, 2018, LANGMUIR, V34, P13766, DOI 10.1021/acs.langmuir.8b02534
   Ozcan A, 2017, CHEM SCI, V8, P3858, DOI 10.1039/c6sc04978h
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Rahm BG, 2014, ENVIRON SCI-PROC IMP, V16, P1400, DOI 10.1039/c4em00018h
   Ren YQ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/19/195707
   Riewchotisakul S, 2015, SPE J, V21, P1
   Samuel B, 2013, NANOTECHNOLOGY, V24
   Savatorova VL, 2016, COMPOS-MECH COMPUT A, V7, P45, DOI 10.1615/CompMechComputApplIntJ.v7.i1.40
   Shaffer DL, 2013, ENVIRON SCI TECHNOL, V47, P9569, DOI 10.1021/es401966e
   Shuai H, 2016, SPE LOW PERM S
   Small MJ, 2014, ENVIRON SCI TECHNOL, V48, P8289, DOI 10.1021/es502111u
   Striolo A, 2006, NANO LETT, V6, P633, DOI 10.1021/nl052254u
   Tan JQ, 2014, FUEL, V129, P204, DOI 10.1016/j.fuel.2014.03.064
   Tao JB, 2018, CHEM ENG SCI, V192, P1252, DOI 10.1016/j.ces.2018.05.018
   Thomas JA, 2008, NANO LETT, V8, P2788, DOI 10.1021/nl8013617
   Titiloye JO, 2005, J COLLOID INTERF SCI, V282, P422, DOI 10.1016/j.jcis.2004.08.131
   Tong TX, 2018, AICHE J, V64, P1059, DOI 10.1002/aic.15982
   Wang F. P, 2009, SPE INT, V8
   Wang H, 2016, J PHYS CHEM C, V120, P8986, DOI 10.1021/acs.jpcc.6b01660
   Wang H, 2014, J MATER CHEM A, V2, P11341, DOI 10.1039/c3ta14973k
   Yao CQ, 2017, AICHE J, V63, P1727, DOI 10.1002/aic.15536
   Zhai ZQ, 2014, ENERG FUEL, V28, P7467, DOI 10.1021/ef5023434
   Zhang HB, 2017, J NAT GAS SCI ENG, V39, P82, DOI 10.1016/j.jngse.2017.01.024
   Zhang HB, 2016, CHEM ENG SCI, V156, P121, DOI 10.1016/j.ces.2016.09.002
   Zhang XL, 2015, PETROL SCI, V12, P96, DOI 10.1007/s12182-014-0004-7
   Zhao SL, 2017, AICHE J, V63, P1704, DOI 10.1002/aic.15535
NR 72
TC 1
Z9 1
U1 8
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 457
EP 463
DI 10.1016/j.ces.2019.06.048
PG 7
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300037
DA 2020-05-12
ER

PT J
AU Azizi, F
AF Azizi, Fouad
TI On the pressure drop of fluids through woven screen meshes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Woven mesh; Pressure drop; Friction factor; Screen; Wire gauze; Flow
   resistance
ID INTENSIFYING MASS-TRANSFER; GRID-GENERATED TURBULENCE; FLOW RESISTANCE;
   STATIC MIXERS; HEAT-TRANSFER; LIQUID FLOW; HYDRODYNAMICS
AB Quantifying pressure drop for fluids passing through woven screen meshes has been the subject of numerous investigations. All of them rely on one of two major theories that explain the pressure losses in terms of a conceptualized nature of the flow. This paper attempts to compare the two approaches using a large number of new experimental measurements conducted using water flowing through circular conduits in which equidistant woven meshes are inserted. The work was also compared against a large number of measurements extracted from the open literature and obtained using single gauzes and/or tightly packed gauzes.
   In contrast to earlier works that focused on narrow ranges of Re and/or accurately predicting their respective experimental measurements, this investigation considers, in total, a set of more than a thousand data points. Two universal correlations, each corresponding to a different theory, were derived using data that spans 60 different screen geometries with fraction open areas ranging between 0.21 and 0.84. These correlations were found to predict the pressure drop over a wide range of Reynolds numbers at an acceptable accuracy. Furthermore, it was found that both theoretical approaches render similar outputs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Azizi, Fouad] Amer Univ Beirut, M Semaan Fac Engn & Architecture, B&W Bassatne Dept Chem Engn & Adv Energy, Beirut 11072020, Lebanon.
RP Azizi, F (reprint author), Amer Univ Beirut, M Semaan Fac Engn & Architecture, B&W Bassatne Dept Chem Engn & Adv Energy, Beirut 11072020, Lebanon.
EM fouad.azizi@aub.edu.lb
RI Azizi, Fouad/F-8128-2015
OI Azizi, Fouad/0000-0001-8002-5184
FU Lebanese National Council for Scientific Research (CNRS-L); University
   Research Board at the American University of Beirut
FX The author would like to acknowledge the financial support of the
   Lebanese National Council for Scientific Research (CNRS-L) and the
   University Research Board at the American University of Beirut.
CR Abou Hweij K, 2015, CHEM ENG J, V279, P948, DOI 10.1016/j.cej.2015.05.100
   Al Taweel AM, 2007, CHEM ENG RES DES, V85, P760, DOI 10.1205/cherd06180
   Al Taweel AM, 2013, CHEM ENG PROCESS, V72, P51, DOI 10.1016/j.cep.2013.08.009
   Al Taweel AM, 2005, CHEM ENG SCI, V60, P6378, DOI 10.1016/j.ces.2005.03.011
   AlTaweel AM, 1996, CHEM ENG RES DES, V74, P445
   Annand W. J. D., 1953, J ROYAL AERONAUTICAL, V57, P141
   ARMOUR JC, 1968, AICHE J, V14, P415, DOI 10.1002/aic.690140315
   Azizi F, 2007, CHEM ENG SCI, V62, P7436, DOI 10.1016/j.ces.2007.08.083
   Azizi F, 2015, IND ENG CHEM RES, V54, P11635, DOI 10.1021/acs.iecr.5b01078
   Azizi F, 2011, CHEM ENG COMMUN, V198, P726, DOI 10.1080/00986445.2011.532748
   Azizi F, 2011, CHEM ENG J, V166, P715, DOI 10.1016/j.cej.2010.11.050
   Bailey BJ, 2003, BIOSYST ENG, V86, P217, DOI 10.1016/S1537-5110(03)00115-6
   BENNANI A, 1985, AICHE J, V31, P1157, DOI 10.1002/aic.690310714
   BOURNE JR, 1991, CHEM ENG J BIOCH ENG, V47, P155, DOI 10.1016/0300-9467(91)85021-M
   BRUNDRETT E, 1993, J FLUID ENG-T ASME, V115, P239, DOI 10.1115/1.2910130
   Bussiere W, 2017, INT J HEAT FLUID FL, V65, P60, DOI 10.1016/j.ijheatfluidflow.2017.02.008
   Carman P.C., 1956, FLOW GASES POROUS ME
   Castellano S, 2016, BIOSYST ENG, V150, P131, DOI 10.1016/j.biosystemseng.2016.07.007
   Chen C, 1996, DISPERSION COALESCEN
   Costa SC, 2014, ENERG CONVERS MANAGE, V79, P255, DOI 10.1016/j.enconman.2013.11.055
   Cowdrey C. F, 1945, BR ARC           AUG
   Davies R. M., 1944, AERONAUT RES COUNC R
   de Vahl Davis G, 1964, HYDRAULICS FLUID MEC, P191
   Drevon D, 2017, BEHAV MODIF, V41, P323, DOI 10.1177/0145445516673998
   Ehrhardt G., 1983, INT CHEM ENG, V23, P455
   El-Ali M. S, 2001, PERFORMANCE CHARACTE
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Gerstmann J, 2013, GASEOUS CRYOGENIC FL, P1
   Grootenhuis P, 1954, P I MECH ENG, V168, P837, DOI 10.1243/PIME_PROC_1954_168_076_02
   GROTH J, 1988, J FLUID MECH, V197, P139, DOI 10.1017/S0022112088003209
   Ingmanson W. L., 1961, TAPPI, V44, P47
   Kolodziej A, 2012, INT J HEAT FLUID FL, V33, P101, DOI 10.1016/j.ijheatfluidflow.2011.11.006
   Kolodziej A, 2009, CHEM ENG COMMUN, V196, P932, DOI 10.1080/00986440902743851
   Kolodziej A, 2009, CHEM ENG PROCESS, V48, P816, DOI 10.1016/j.cep.2008.10.009
   Kolodziej A, 2009, AICHE J, V55, P264, DOI 10.1002/aic.11646
   Kurian T, 2009, FLUID DYN RES, V41, DOI 10.1088/0169-5983/41/2/021403
   LAWS EM, 1978, ANNU REV FLUID MECH, V10, P247, DOI 10.1146/annurev.fl.10.010178.001335
   Li HZ, 1997, CHEM ENG RES DES, V75, P792, DOI 10.1205/026387697524461
   MUNSON BR, 1988, J FLUID ENG-T ASME, V110, P462, DOI 10.1115/1.3243578
   Okolo PN, 2019, EUR J MECH B-FLUID, V76, P259, DOI 10.1016/j.euromechflu.2019.03.001
   Pfluger F., 1942, LUFTFAHRTFORSCHUNG, V18
   PINKER RA, 1967, J MECH ENG SCI, V9, P11, DOI 10.1243/JMES_JOUR_1967_009_004_02
   ROACH PE, 1987, INT J HEAT FLUID FL, V8, P82, DOI 10.1016/0142-727X(87)90001-4
   Schubauer G. B., 1950, AERODYNAMIC CHARACTE
   Teitel M, 2009, BIOSYST ENG, V104, P404, DOI 10.1016/j.biosystemseng.2009.07.006
   Teitel M, 2010, BIOSYST ENG, V105, P172, DOI 10.1016/j.biosystemseng.2009.10.005
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968
   Theron F, 2011, INT J MULTIPHAS FLOW, V37, P488, DOI 10.1016/j.ijmultiphaseflow.2011.01.004
   Valera DL, 2005, ACTA HORTIC, P441, DOI 10.17660/ActaHortic.2005.691.53
   Wakeland RS, 2003, J FLUID ENG-T ASME, V125, P851, DOI 10.1115/1.1601254
   WIEGHARDT KEG, 1953, AERONAUT QUART, V4, P186, DOI 10.1017/S0001925900000871
   Wu WT, 2005, INT J HEAT MASS TRAN, V48, P3008, DOI 10.1016/j.ijheatmasstransfer.2005.01.038
NR 52
TC 0
Z9 0
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 464
EP 478
DI 10.1016/j.ces.2019.06.046
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300038
DA 2020-05-12
ER

PT J
AU Zhong, C
   Gong, JK
   Tan, LG
   Liu, WQ
   Liu, GL
   Zhang, ZQ
AF Zhong, Chao
   Gong, Jinke
   Tan, Ligang
   Liu, Weiqiang
   Liu, Guanlin
   Zhang, Zhiqing
TI Modeling intraphase and interphase mass transfer limitations for NH3-SCR
   over Cu-ZSM-5
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE NH3-SCR; Copper zeolites; Pore diffusion; deNOx efficiency; Mass
   transfer limitation
ID SELECTIVE CATALYTIC-REDUCTION; FLUID-SOLID REACTIONS; RANDOM PORE MODEL;
   DIFFUSION-COEFFICIENTS; ZEOLITE CATALYST; ACTIVE-SITES; TRANSPORT; SCR;
   TORTUOSITY; NOX
AB A model describing NH3 selective catalytic reduction (NH3-SCR) over Cu-ZSM-5 to investigate the effects of intraphase and interphase mass transfer on standard SCR reaction is developed and further verified with the synthetic gas bench. The correlation between tortuosity and porosity has been analyzed by least squares method and applied to the sinuousoidal capillary bundle model. The effects of washcoat thicknesses, lengths, cell densities and channel widths on the standard SCR reaction are analyzed in temperature range of 150-500 degrees C. It is found that deNOx efficiency is affected by intraphase diffusion limitations at 200-500 degrees C and by interphase mass transfer limitation at intermediate (250-400 degrees C) and high temperatures (400-500 degrees C). As the temperature increases, the reaction is firstly controlled by kinetics, with the kinetics resistance decreasing and then increasing until the maximum among three processes. Furthermore, intake flow rates (GHSVs) play an important role impacting NO conversion on NH3-SCR. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhong, Chao; Gong, Jinke; Liu, Weiqiang] Hunan Univ, State Key Lab Adv Design & Mfg Vehicle Body, Changsha 410082, Hunan, Peoples R China.
   [Zhong, Chao; Gong, Jinke; Tan, Ligang; Liu, Weiqiang; Liu, Guanlin; Zhang, Zhiqing] Hunan Univ, Coll Mech & Vehicle Engn, Changsha 410082, Hunan, Peoples R China.
   [Zhong, Chao; Gong, Jinke; Tan, Ligang; Liu, Weiqiang; Liu, Guanlin; Zhang, Zhiqing] Hunan Univ, Inst New Energy & Energy Saving & Emiss Reduct Te, Changsha 410082, Hunan, Peoples R China.
   [Liu, Weiqiang] Univ Waterloo, Mech & Mechatron Engn, Waterloo, ON N2L 3G1, Canada.
RP Gong, JK; Tan, LG (reprint author), Hunan Univ, Coll Mech & Vehicle Engn, Changsha 410082, Hunan, Peoples R China.
EM gongjinke@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [551776062, 91541121]
FX The authors thank the financial support of National Natural Science
   Foundation of China (Nos. 551776062 and 91541121).
CR Auvray X, 2015, APPL CATAL B-ENVIRON, V163, P393, DOI 10.1016/j.apcatb.2014.08.003
   Auvray X, 2012, APPL CATAL B-ENVIRON, V126, P144, DOI 10.1016/j.apcatb.2012.07.019
   Aziz K., 1979, PETROLEUM RESERVOIR, P476
   Baleta J, 2015, J CLEAN PROD, V88, P280, DOI 10.1016/j.jclepro.2014.06.042
   Becker J, 2011, INT J HEAT MASS TRAN, V54, P1360, DOI 10.1016/j.ijheatmasstransfer.2010.12.003
   BEECKMAN JW, 1990, CHEM ENG SCI, V45, P2603, DOI 10.1016/0009-2509(90)80148-8
   Bendrich M, 2018, APPL CATAL B-ENVIRON, V222, P76, DOI 10.1016/j.apcatb.2017.09.069
   BHATIA SK, 1980, AICHE J, V26, P379, DOI 10.1002/aic.690260308
   BHATIA SK, 1981, AICHE J, V27, P247, DOI 10.1002/aic.690270211
   Bhatia SK, 2011, PHYS CHEM CHEM PHYS, V13, P15350, DOI 10.1039/c1cp21166h
   Boudreau BP, 1996, GEOCHIM COSMOCHIM AC, V60, P3139, DOI 10.1016/0016-7037(96)00158-5
   Chatterjee D., 2007, SAE TECHNICAL PAPER, V2007-01-1136
   Colombo M, 2012, CATAL TODAY, V197, P243, DOI 10.1016/j.cattod.2012.09.002
   De-La-Torre U, 2017, CATAL TODAY, V296, P95, DOI 10.1016/j.cattod.2017.04.011
   EPSTEIN N, 1989, CHEM ENG SCI, V44, P777, DOI 10.1016/0009-2509(89)85053-5
   Guan B, 2014, APPL THERM ENG, V66, P395, DOI 10.1016/j.applthermaleng.2014.02.021
   Hawthorn R. D., 1974, AICHE S SERIES 137, V70, P428
   Hayes RE, 2000, APPL CATAL B-ENVIRON, V25, P93, DOI 10.1016/S0926-3373(99)00122-8
   Hu XQ, 2016, J CATAL, V341, P55, DOI 10.1016/j.jcat.2016.05.022
   IVERSEN N, 1993, GEOCHIM COSMOCHIM AC, V57, P571, DOI 10.1016/0016-7037(93)90368-7
   Joshi SY, 2018, APPL CATAL B-ENVIRON, V226, P565, DOI 10.1016/j.apcatb.2017.12.076
   Joshi SY, 2010, CHEM ENG SCI, V65, P1729, DOI 10.1016/j.ces.2009.11.021
   Karadag H. G., 2018, ENERG ENV DIMENS, P961
   Kong W, 2012, J POWER SOURCES, V206, P171, DOI 10.1016/j.jpowsour.2012.01.107
   Lanfrey PY, 2010, CHEM ENG SCI, V65, P1891, DOI 10.1016/j.ces.2009.11.011
   Lietti L, 1998, CATAL TODAY, V45, P85, DOI 10.1016/S0920-5861(98)00253-3
   Low P. F., 1981, CHEM SOIL ENV, P31
   Matyka M, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.026306
   Metkar PS, 2011, CHEM ENG SCI, V66, P5192, DOI 10.1016/j.ces.2011.07.014
   Millo F, 2017, FUEL, V198, P183, DOI 10.1016/j.fuel.2016.11.082
   Nakasaka Y, 2019, CATAL TODAY, V332, P64, DOI 10.1016/j.cattod.2018.06.056
   Nikitsin VI, 2013, INT J HEAT MASS TRAN, V56, P30, DOI 10.1016/j.ijheatmasstransfer.2012.09.021
   Nova I, 2011, IND ENG CHEM RES, V50, P299, DOI 10.1021/ie1015409
   Ochonska-Kryca J, 2013, CATAL TODAY, V216, P135, DOI 10.1016/j.cattod.2013.05.018
   Olsson L, 2008, APPL CATAL B-ENVIRON, V81, P203, DOI 10.1016/j.apcatb.2007.12.011
   Popovicova J, 1997, J CONTAM HYDROL, V28, P157, DOI 10.1016/S0169-7722(97)00014-4
   Rutkowska M, 2017, MICROPOR MESOPOR MAT, V246, P193, DOI 10.1016/j.micromeso.2017.03.017
   Santos A, 1996, APPL CATAL B-ENVIRON, V8, P299, DOI 10.1016/0926-3373(95)00056-9
   Shakya BM, 2015, CHEM ENG J, V278, P374, DOI 10.1016/j.cej.2014.11.029
   Shen L, 2007, CHEM ENG SCI, V62, P3748, DOI 10.1016/j.ces.2007.03.041
   Shibata G, 2019, CATAL TODAY, V332, P59, DOI 10.1016/j.cattod.2018.06.023
   Sjovall H, 2006, APPL CATAL B-ENVIRON, V64, P180, DOI 10.1016/j.apcatb.2005.12.003
   SWEERTS JPRA, 1991, LIMNOL OCEANOGR, V36, P335, DOI 10.4319/lo.1991.36.2.0335
   TOMADAKIS MM, 1993, J CHEM PHYS, V98, P616, DOI 10.1063/1.464604
   ULLMAN WJ, 1982, LIMNOL OCEANOGR, V27, P552, DOI 10.4319/lo.1982.27.3.0552
   WAKAO N, 1962, CHEM ENG SCI, V17, P825, DOI 10.1016/0009-2509(62)87015-8
   Wang T, 2018, APPL SURF SCI, V457, P187, DOI 10.1016/j.apsusc.2018.06.216
   WEIBEL J, 1965, NEUROLOGY, V15, P7, DOI 10.1212/WNL.15.1.7
   WEISSBERG HL, 1963, J APPL PHYS, V34, P2636, DOI 10.1063/1.1729783
   WEISZ PB, 1954, ADV CATAL, V6, P143, DOI 10.1016/S0360-0564(08)60390-9
   Wheeler A., 1955, CATALYSIS
   Yang GP, 2018, MICROPOR MESOPOR MAT, V266, P223, DOI 10.1016/j.micromeso.2018.01.034
   Yuan J, 2005, DEV HEAT TRANSFER, V19, P133
   Yuan JL, 2014, INT J HEAT MASS TRAN, V69, P358, DOI 10.1016/j.ijheatmasstransfer.2013.10.032
   Zhang F, 2004, CHEM ENG RES DES, V82, P481, DOI 10.1205/026387604323050191
NR 55
TC 0
Z9 0
U1 11
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 479
EP 489
DI 10.1016/j.ces.2019.06.052
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300039
DA 2020-05-12
ER

PT J
AU Hamidi, M
   Wheeler, VM
   Kreider, P
   Catchpole, K
   Weimer, AW
AF Hamidi, Marziyeh
   Wheeler, Vincent M.
   Kreider, Peter
   Catchpole, Kylie
   Weimer, Alan W.
TI Effective thermal conductivity of a bed packed with granular
   iron-manganese oxide for thermochemical energy storage
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heat transfer modelling; Packed-bed reactor; Thermal radiation; High
   temperature thermochemical energy storage; Iron-manganese oxide;
   Effective thermal conductivity
ID CONCENTRATED SOLAR POWER; HEAT-TRANSFER; REDOX MATERIALS; REACTORS;
   KINETICS
AB Heat transfer is studied in a lab-scale tubular reactor packed with spherical 0.5-1 mm iron-manganese oxide particles with an Fe/Mn molar ratio of 2:1. A two-dimensional transient heat transfer model considering conduction, convection and radiation heat transfer is developed to simulate the temperature profile in the reactor. The effective thermal conductivity of the packed bed as well as the wall heat transfer coefficient are determined based on the experimental data and a steady-state model. The validity of calculated effective parameters is checked by employing the parameters in a transient model and comparing the predicted temperature profile with transient experimental data and by comparison with existing correlations found in the literature. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hamidi, Marziyeh; Wheeler, Vincent M.; Kreider, Peter; Catchpole, Kylie; Weimer, Alan W.] Australian Natl Univ, Res Sch Engn, Canberra, ACT 2601, Australia.
   [Wheeler, Vincent M.] Univ Wisconsin Stout, Dept Engn & Technol, Menomonie, WI 54751 USA.
   [Weimer, Alan W.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.
RP Wheeler, VM (reprint author), Univ Wisconsin Stout, Dept Engn & Technol, Menomonie, WI 54751 USA.; Weimer, AW (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA.
RI Kreider, Peter/O-3583-2019; Catchpole, Kylie/AAE-5973-2019
OI Catchpole, Kylie/0000-0003-4858-1820; Hamidi,
   Marziyeh/0000-0002-1144-1085; Wheeler, Vincent/0000-0002-2331-4905;
   WEIMER, ALAN/0000-0002-2471-349X
FU Australian Renewable Energy Agency (ARENA)Australian Renewable Energy
   Agency (ARENA) [2014/RND005]
FX This work was supported by the Australian Renewable Energy Agency
   (ARENA) via Grant 2014/RND005. The authors would like to thank Prof.
   Wojciech Lipinski for the use of his laboratories, and also Assoc. Prof.
   Takuya Tsuzuki, Dr. John Pye and Dr. Charles-Alexis Asselineau for their
   valuable advice. The authors thank Mr. Mark Wallace of the University of
   Colorado for his support fabricating the spherical iron-manganese oxide
   particles used in this study.
CR Abanades S, 2006, SOL ENERGY, V80, P1611, DOI 10.1016/j.solener.2005.12.005
   Al-Shankiti IA, 2019, SOL ENERGY, V183, P17, DOI 10.1016/j.solener.2019.02.071
   BREITBACH G, 1980, NUCL TECHNOL, V49, P392, DOI 10.13182/NT80-A17687
   Castillo-Araiza CO, 2007, IND ENG CHEM RES, V46, P7426, DOI 10.1021/ie070097z
   Cheng GJ, 2013, IND ENG CHEM RES, V52, P12202, DOI 10.1021/ie3033137
   Chueh WC, 2010, SCIENCE, V330, P1797, DOI 10.1126/science.1197834
   Chung JD, 1999, KSME INT J, V13, P762, DOI 10.1007/BF03184454
   Deissler R., 1958, ASME T, V80, P1417
   Furler P, 2012, ENERG FUEL, V26, P7051, DOI 10.1021/ef3013757
   Hamidi M, 2019, CHEM ENG SCI, V201, P74, DOI 10.1016/j.ces.2019.02.012
   Jorge LMM, 1999, BRAZ J CHEM ENG, V16, P407, DOI 10.1590/S0104-66321999000400009
   Keunecke M, 2004, CHEM ENG SCI, V59, P2695, DOI 10.1016/j.ces.2004.03.019
   Kim SJ, 2002, INT J HEAT MASS TRAN, V45, P3885, DOI 10.1016/S0017-9310(02)00109-6
   KUNII D, 1960, AICHE J, V6, P71, DOI 10.1002/aic.690060115
   Pan ZH, 2017, ENERGY, V130, P155, DOI 10.1016/j.energy.2017.04.102
   Preisner NC, 2018, ENERGY TECHNOL-GER, V6, P2154, DOI 10.1002/ente.201800211
   Prieto C, 2016, RENEW SUST ENERG REV, V60, P909, DOI 10.1016/j.rser.2015.12.364
   Romero M, 2012, ENERG ENVIRON SCI, V5, P9234, DOI 10.1039/c2ee21275g
   van Antwerpen W, 2010, NUCL ENG DES, V240, P1803, DOI 10.1016/j.nucengdes.2010.03.009
   Wen DS, 2006, CHEM ENG SCI, V61, P3532, DOI 10.1016/j.ces.2005.12.027
   Wokon M, 2017, SOL ENERGY, V153, P200, DOI 10.1016/j.solener.2017.05.034
   Zanganeh G, 2012, SOL ENERGY, V86, P3084, DOI 10.1016/j.solener.2012.07.019
NR 22
TC 0
Z9 0
U1 23
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 490
EP 494
DI 10.1016/j.ces.2019.06.035
PG 5
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300040
DA 2020-05-12
ER

PT J
AU Liu, X
   Zhang, X
   Min, JC
AF Liu, Xin
   Zhang, Xuan
   Min, Jingchun
TI Spreading of droplets impacting different wettable surfaces at a Weber
   number close to zero
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet spreading; Low Weber number; Surface wettability; Advancing
   contact angle
ID LIQUID DROPLETS; CONTACT-ANGLE; SOLID-SURFACE; DYNAMICS; WETTABILITY;
   SIMULATIONS; DROPS; MODEL; TIME
AB Six different surfaces ranging from superhydrophilic to superhydrophobic were fabricated. Droplet impact experiments were conducted on these surfaces with water droplets 2.25 mm in diameter at a Weber number close to zero to study the effects of surface wettability on the impact process and postimpact oscillation. Droplet impact on all surfaces, except for superhydrophobic surfaces, is dominated by a spreading stage and no evident retraction is observed. Using the inertia-capillarity time t(c) = root rho R-0(3)/sigma as characteristic time, the spreading stage on all surfaces at We < 0.5 was calculated to be 2.25 +/- 0.11t(c); further, it could be divided into inertial and viscous spreading stages at 1 +/- 0.11t(c) based on droplet height evolution. A semi-empirical correlation for calculating the evolution of spreading factors on different surfaces was fitted by a piecewise exponential function using experimental data, and a deviation of +/- 20% was observed between the fitted and experimental data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Xin; Min, Jingchun] Tsinghua Univ, Dept Engn Mech, Minist Educ, Key Lab Thermal Sci & Power Engn, Beijing 100084, Peoples R China.
   [Zhang, Xuan] Tsinghua Univ, Key Lab Thermal Sci & Power Engn, Minist Educ,Dept Energy & Power Engn, Beijing Key Lab CO2 Utilizat & Reduct Technol, Beijing 100084, Peoples R China.
RP Min, JC (reprint author), Tsinghua Univ, Dept Engn Mech, Minist Educ, Key Lab Thermal Sci & Power Engn, Beijing 100084, Peoples R China.
EM minjc@mail.tsinghua.edu.cn
RI Zhang, Xuan/AAB-1249-2020
OI Zhang, Xuan/0000-0002-4999-7361
FU National Key Basic Research Program of ChinaNational Basic Research
   Program of China [2015CB755800]
FX This research was funded by the National Key Basic Research Program of
   China (No. 2015CB755800).
CR Bartolo D, 2005, J FLUID MECH, V545, P329, DOI 10.1017/S0022112005007184
   Biance AL, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.016301
   Bird JC, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.234501
   CAZABAT AM, 1986, J PHYS CHEM-US, V90, P5845, DOI 10.1021/j100280a075
   CHANDRA S, 1991, P R SOC-MATH PHYS SC, V432, P13, DOI 10.1098/rspa.1991.0002
   Cheng YP, 2018, INT J HEAT MASS TRAN, V121, P402, DOI 10.1016/j.ijheatmasstransfer.2018.01.026
   Chu FQ, 2016, APPL SURF SCI, V371, P322, DOI 10.1016/j.apsusc.2016.02.208
   Cui WJ, 2019, APPL SURF SCI, V466, P503, DOI 10.1016/j.apsusc.2018.10.042
   de Ruiter R, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.043602
   DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827
   Dupuy PM, 2010, CHEM ENG SCI, V65, P5320, DOI 10.1016/j.ces.2010.07.006
   Farshchian B, 2018, MICROELECTRON ENG, V195, P50, DOI 10.1016/j.mee.2018.03.019
   Gao LC, 2006, LANGMUIR, V22, P6234, DOI 10.1021/la060254j
   GOOD RJ, 1992, J ADHES SCI TECHNOL, V6, P1269, DOI 10.1163/156856192X00629
   Healy WM, 2001, INT J HEAT MASS TRAN, V44, P235, DOI 10.1016/S0017-9310(00)00097-1
   Huang HM, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5006439
   Josserand C, 2016, ANNU REV FLUID MECH, V48, P365, DOI 10.1146/annurev-fluid-122414-034401
   Kompinsky E, 2013, CHEM ENG SCI, V98, P186, DOI 10.1016/j.ces.2013.04.047
   Leopoldes J, 2003, LANGMUIR, V19, P9818, DOI 10.1021/la0353069
   Lin SJ, 2018, J COLLOID INTERF SCI, V516, P86, DOI 10.1016/j.jcis.2017.12.086
   Lunkad SF, 2007, CHEM ENG SCI, V62, P7214, DOI 10.1016/j.ces.2007.07.036
   Mao T, 1997, AICHE J, V43, P2169, DOI 10.1002/aic.690430903
   Pasandideh-Fard M, 2002, J THERM SPRAY TECHN, V11, P206, DOI 10.1361/105996302770348862
   PasandidehFard M, 1996, PHYS FLUIDS, V8, P650, DOI 10.1063/1.868850
   Perez M, 1999, EUROPHYS LETT, V47, P189, DOI 10.1209/epl/i1999-00371-6
   Rioboo R, 2002, EXP FLUIDS, V33, P112, DOI [10.1007/s00348-002-0431-X, 10.1007/s00348-002-0431-x]
   Roisman IV, 2018, J FLUID MECH, V842, P87, DOI 10.1017/jfm.2018.123
   Roisman IV, 2002, P ROY SOC A-MATH PHY, V458, P1411, DOI 10.1098/rspa.2001.0923
   Schiaffino S, 1997, PHYS FLUIDS, V9, P3172, DOI 10.1063/1.869434
   Sikalo S, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1928828
   Sikalo S, 2006, EXP THERM FLUID SCI, V31, P97, DOI 10.1016/j.expthermflusci.2006.03.028
   Sikalo S, 2005, EXP THERM FLUID SCI, V29, P795, DOI 10.1016/j.expthermflusci.2005.03.006
   Sikalo S, 2002, EXP THERM FLUID SCI, V25, P503, DOI 10.1016/S0894-1777(01)00109-1
   Singh DP, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4811751
   Tan H, 2016, CHEM ENG SCI, V153, P93, DOI 10.1016/j.ces.2016.07.015
   Tang CL, 2017, INT J MULTIPHAS FLOW, V96, P56, DOI 10.1016/j.ijmultiphaseflow.2017.07.002
   Thomson W. T, 2003, THEORY VIBRATION APP
   Vadillo DC, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3276259
   Wang FJ, 2019, LANGMUIR, V35, P3204, DOI 10.1021/acs.langmuir.8b03748
   Wang FJ, 2018, EXP THERM FLUID SCI, V98, P420, DOI 10.1016/j.expthermflusci.2018.06.013
   Werner SRL, 2007, CHEM ENG SCI, V62, P2336, DOI 10.1016/j.ces.2006.12.024
   Wu ZL, 2018, ADV COLLOID INTERFAC, V256, P23, DOI 10.1016/j.cis.2018.05.005
   Yang C, 2002, EXP FLUIDS, V33, P728, DOI [10.1007/S00348-002-0430-Y, 10.1007/s00348-002-0430-y]
   Yarin AL, 2006, ANNU REV FLUID MECH, V38, P159, DOI 10.1146/annurev.fluid.38.050304.092144
   Yokoi K, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3158468
   Zhang X, 2017, INT J HEAT MASS TRAN, V104, P510, DOI 10.1016/j.ijheatmasstransfer.2016.08.086
   Zhao P, 2018, CHEM ENG SCI, V190, P232, DOI 10.1016/j.ces.2018.06.030
NR 47
TC 3
Z9 4
U1 17
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 495
EP 503
DI 10.1016/j.ces.2019.06.058
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300041
DA 2020-05-12
ER

PT J
AU John, TP
   Panesar, JS
   Kowalski, A
   Rodgers, TL
   Fonte, CP
AF John, T. P.
   Panesar, J. S.
   Kowalski, A.
   Rodgers, T. L.
   Fonte, C. P.
TI Linking power and flow in rotor-stator mixers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotor-stator; Mixing; Power number; Flow number; CFD
ID ENERGY-DISSIPATION; DROP SIZES; DISPERSION; VELOCITY; BATCH; SHEAR
AB The relationship between power and flow characteristics of batch rotor-stator mixers has been studied using CFD simulations with experimental power validation. The mixer studied was the Silverson L5M batch mixer with the standard emulsor head. The size of the holes in the screen and the constriction of the base hole were changed in small increments. The MRF technique was used to model rotor rotation. A model is developed in this study which links the power and flow numbers of the mixer. Since power is easy to measure experimentally, one can use this model to predict the flow number by measuring torque. A second model is also developed which allows one to predict the flow number using solely the geometry of the mixing head. This study greatly enhances our understanding of the relationship between power, flow and mixer geometry in rotor-stator mixers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [John, T. P.; Rodgers, T. L.; Fonte, C. P.] Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
   [Panesar, J. S.; Kowalski, A.] Unilever R&D, Port Sunlight Lab, Quarry Rd East, Wirral CH63 3JW, Merseyside, England.
   [Panesar, J. S.] CentDS Ltd, Nexus, Discovery Way, Leeds LS2 3AA, W Yorkshire, England.
RP Fonte, CP (reprint author), Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
EM claudio.fonte@manchester.ac.uk
OI John, Thomas/0000-0001-6687-0007
CR Atiemo-Obeng V. A, 2004, HDB IND MIXING SCI P, P479, DOI DOI 10.1002/0471451452.CH8
   Barailler F, 2006, CHEM ENG SCI, V61, P2888, DOI 10.1016/j.ces.2005.10.064
   CALABRESE RV, 1986, AICHE J, V32, P657, DOI 10.1002/aic.690320416
   Carrillo De Hert S., 2017, THESIS
   Cooke M, 2012, AICHE J, V58, P1683, DOI 10.1002/aic.12703
   DAVIES JT, 1987, CHEM ENG SCI, V42, P1671, DOI 10.1016/0009-2509(87)80172-0
   DAVIES JT, 1985, CHEM ENG SCI, V40, P839, DOI 10.1016/0009-2509(85)85036-3
   Espinoza CJU, 2018, CHEM ENG RES DES, V132, P989, DOI 10.1016/j.cherd.2018.01.028
   Ghaderzadeh K, 2018, THESIS
   Hakansson A, 2018, PROCESSES, V6, DOI 10.3390/pr6040032
   Hakansson A, 2017, CAN J CHEM ENG, V95, P806, DOI 10.1002/cjce.22718
   Hall S, 2011, CAN J CHEM ENG, V89, P1040, DOI 10.1002/cjce.20556
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Jasinska M, 2015, CHEM ENG PROCESS, V91, P43, DOI 10.1016/j.cep.2015.03.015
   John TP, 2019, CHEM ENG SCI, V202, P481, DOI 10.1016/j.ces.2019.03.015
   Kowalski AJ, 2011, CHEM ENG SCI, V66, P241, DOI 10.1016/j.ces.2010.10.010
   Kowalski AJ, 2009, CHEM ENG PROCESS, V48, P581, DOI 10.1016/j.cep.2008.04.002
   Malavasi S, 2012, FLOW MEAS INSTRUM, V28, P57, DOI 10.1016/j.flowmeasinst.2012.07.006
   Minnick BA, 2018, CHEM ENG RES DES, V136, P477, DOI 10.1016/j.cherd.2018.05.015
   Mortensen HH, 2018, CHEM ENG SCI, V177, P340, DOI 10.1016/j.ces.2017.11.037
   Mortensen HH, 2017, CHEM ENG RES DES, V121, P245, DOI 10.1016/j.cherd.2017.03.016
   Mortensen HH, 2011, CAN J CHEM ENG, V89, P1076, DOI 10.1002/cjce.20587
   Ozcan-Taskin G, 2011, CAN J CHEM ENG, V89, P1005, DOI 10.1002/cjce.20553
   Padron Gustavo A., 2001, THESIS
   Rielly C. D, 2009, COMPUTATIONAL FLUID, DOI [10.1002/9781444312928.ch8, DOI 10.1002/9781444312928.CH8]
   Rodgers TL, 2012, CHEM ENG RES DES, V90, P323, DOI 10.1016/j.cherd.2011.07.018
   Utomo A, 2009, CHEM ENG RES DES, V87, P533, DOI 10.1016/j.cherd.2008.12.011
   Utomo AT, 2008, CHEM ENG RES DES, V86, P1397, DOI 10.1016/j.cherd.2008.07.012
NR 28
TC 0
Z9 0
U1 10
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 504
EP 515
DI 10.1016/j.ces.2019.06.039
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300042
DA 2020-05-12
ER

PT J
AU Sun, Y
   Gao, JP
   Liu, Y
   Kang, HY
   Xie, MH
   Wu, FM
   Qiu, HX
AF Sun, Yu
   Gao, Jianping
   Liu, Yu
   Kang, Huiying
   Xie, Minhui
   Wu, Fuming
   Qiu, Haixia
TI Copper sulfide-macroporous polyacrylamide hydrogel for solar steam
   generation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solar steam generation; Photothermal conversion; CuS nanoparticles;
   Macroporous polyacrylamide hydrogel; Nano composites
ID CUS HOLLOW NANOSPHERES; PHOTOTHERMAL ABLATION; CONVERSION EFFICIENCY;
   WATER EVAPORATION; CARBON-BLACK; DESALINATION; HEAT; NANOPARTICLES;
   PERFORMANCE; SYSTEM
AB The use of abundant solar energy to produce clean water by a solar steam generation device is a promising strategy to solve the long-term water and energy shortage. The development and application of photothermal materials are an effective way to improve solar photothermal conversion efficiency of the device. Herein, an inorganic-organic light-absorbing material, copper sulfide-macroporous polyacrylamide hydrogel (CuS-m-PAM), is reported for the first time. The CuS-m-PAM was prepared by in-situ synthesis method via loading CuS nanoparticles into macroporous polyacrylamide hydrogel (m-PAM). CuS-m-PAM forms a heating zone at the air-water interface and CuS nanoparticles can efficiently convert the strongly absorbed light into localized heat, thus reducing the heat loss in the transfer process. The results demonstrate that the solar photothermal conversion efficiency of CuS-m-PAM-0.05 is the highest and can reach 92% under one sun illumination (1000 W m(-2)). The rough surface of m-PAM and the plasma resonance effect of CuS nanoparticles improve the absorb ability to sunlight. The open macroporous structure of m-PAM also makes a great contribution to the water vapor escape of solar steam generation device. Moreover, the formation of N-Cu bond in CuS-m-PAM makes CuS nanoparticles more stabilization, and the solar photothermal conversion efficiency of CuS-m-PAM-0.05 remains 87.5% after 50 cycles of tests. CuS-m-PAM, as a novel light-absorbing material, can comprehensively optimize the solar steam generation device in light absorption, thermal insulation, water replenishment and steam exhaust, and thus provides a new practical method for maximum utilization of solar steam generation device. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Yu; Gao, Jianping; Liu, Yu; Kang, Huiying; Xie, Minhui; Wu, Fuming; Qiu, Haixia] Tianjin Univ, Sch Sci, Dept Chem, Tianjin 300350, Peoples R China.
RP Gao, JP; Liu, Y; Qiu, HX (reprint author), Tianjin Univ, Sch Sci, Dept Chem, Tianjin 300350, Peoples R China.
EM haixiaqiutg@163.com
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China [51573126]
FX This work was supported by the National Science Foundation of China
   (51573126).
CR Alam A, 2017, COMPOS PART A-APPL S, V93, P1, DOI 10.1016/j.compositesa.2016.11.001
   Cai LY, 2015, RSC ADV, V5, P98136, DOI 10.1039/c5ra18563g
   Chandrashekara M, 2017, RENEW SUST ENERG REV, V67, P1308, DOI 10.1016/j.rser.2016.08.058
   Elimelech M, 2011, SCIENCE, V333, P712, DOI 10.1126/science.1200488
   Evingur GA, 2009, CHEM ENG PROCESS, V48, P600, DOI 10.1016/j.cep.2008.07.003
   Lima MCFS, 2016, CARBON, V109, P290, DOI 10.1016/j.carbon.2016.08.021
   Gao MM, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201800711
   Ghasemi H, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5449
   Haddeland I, 2014, P NATL ACAD SCI USA, V111, P3251, DOI 10.1073/pnas.1222475110
   Hu XZ, 2017, ADV MATER, V29, DOI 10.1002/adma.201604031
   Kara S, 2001, J APPL POLYM SCI, V80, P1898, DOI 10.1002/app.1287
   Kashyap V, 2019, SUSTAIN ENERG FUELS, V3, P272, DOI 10.1039/c8se00546j
   Li B, 2014, NANOSCALE, V6, P3274, DOI 10.1039/c3nr06242b
   Li M, 2018, J MACROMOL SCI B, V57, P21, DOI 10.1080/00222348.2017.1406742
   Li XQ, 2016, P NATL ACAD SCI USA, V113, P13953, DOI 10.1073/pnas.1613031113
   Li YB, 2010, NANOMEDICINE-UK, V5, P1161, DOI 10.2217/NNM.10.85
   Lin JM, 2007, REACT FUNCT POLYM, V67, P489, DOI 10.1016/j.reactfunctpolym.2007.02.002
   Liu GH, 2017, NANO ENERGY, V41, P269, DOI 10.1016/j.nanoen.2017.09.005
   Liu KK, 2017, ACS APPL MATER INTER, V9, P7675, DOI 10.1021/acsami.7b01307
   Liu YM, 2015, ADV MATER, V27, P2768, DOI 10.1002/adma.201500135
   Liu YM, 2015, ACS APPL MATER INTER, V7, P13645, DOI 10.1021/acsami.5b03435
   Ma QL, 2018, ELECTROCHIM ACTA, V283, P1154, DOI 10.1016/j.electacta.2018.07.026
   Makaya K, 2009, J BIOSCI BIOENG, V108, P68, DOI 10.1016/j.jbiosc.2009.02.015
   Mekonnen MM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1500323
   Meng XY, 2013, CRYSTENGCOMM, V15, P5144, DOI 10.1039/c3ce40195b
   Nekouei F, 2018, MAT SCI ENG C-MATER, V90, P576, DOI 10.1016/j.msec.2018.05.001
   Neumann O, 2013, P NATL ACAD SCI USA, V110, P11677, DOI 10.1073/pnas.1310131110
   Orozco-Guareno E, 2010, J COLLOID INTERF SCI, V349, P583, DOI 10.1016/j.jcis.2010.05.048
   Ren HY, 2017, ADV MATER, V29, DOI 10.1002/adma.201702590
   Sharma A, 2014, APPL SURF SCI, V313, P624, DOI 10.1016/j.apsusc.2014.06.034
   Sharon H, 2015, RENEW SUST ENERG REV, V41, P1080, DOI 10.1016/j.rser.2014.09.002
   Song WC, 2014, CHEM ENG J, V246, P268, DOI 10.1016/j.cej.2014.02.101
   Sun W, 2017, ANGEW CHEM INT EDIT, V56, P6329, DOI 10.1002/anie.201701321
   Tanveer M, 2014, CRYSTENGCOMM, V16, P5290, DOI 10.1039/c4ce00090k
   Tian QW, 2011, ACS NANO, V5, P9761, DOI 10.1021/nn203293t
   [王彩 Wang Cai], 2014, [功能材料, Journal of Functional Materials], V45, P2059
   Wang C, 2016, APPL CATAL B-ENVIRON, V188, P351, DOI 10.1016/j.apcatb.2016.02.017
   Wang JJ, 2017, J MATER CHEM A, V5, P6860, DOI 10.1039/c7ta00882a
   Wang J, 2017, ADV MATER, V29, DOI 10.1002/adma.201603730
   Wang QZ, 2013, INT J HYDROGEN ENERG, V38, P10739, DOI 10.1016/j.ijhydene.2013.02.131
   Wang ZH, 2014, SMALL, V10, P3234, DOI 10.1002/smll.201401071
   Xie X, 2016, MACROMOLECULES, V49, P972, DOI 10.1021/acs.macromol.5b02477
   Xu Y, 2019, CHEM ENG J, V356, P869, DOI 10.1016/j.cej.2018.09.070
   Xue GB, 2017, ACS APPL MATER INTER, V9, P15052, DOI 10.1021/acsami.7b01992
   Yang K, 2009, CARBON, V47, P1723, DOI 10.1016/j.carbon.2009.02.029
   Yang SH, 2015, SENSOR ACTUAT B-CHEM, V212, P1, DOI 10.1016/j.snb.2015.01.124
   Yao JD, 2017, NANOSCALE, V9, P16396, DOI 10.1039/c7nr04374k
   Yin XY, 2018, ACS APPL MATER INTER, V10, P10998, DOI 10.1021/acsami.8b01629
   Zeng Y, 2014, CHEM ENG SCI, V116, P704, DOI 10.1016/j.ces.2014.05.057
   Zhang H, 2014, SOL ENERGY, V100, P141, DOI 10.1016/j.solener.2013.12.004
   Zhang PP, 2017, ACS NANO, V11, P5087, DOI 10.1021/acsnano.7b01965
   Zhang YP, 2017, SCI TOTAL ENVIRON, V580, P776, DOI 10.1016/j.scitotenv.2016.12.024
   Zhou L, 2016, NAT PHOTONICS, V10, P393, DOI [10.1038/nphoton.2016.75, 10.1038/NPHOTON.2016.75]
   Zhou M, 2010, J AM CHEM SOC, V132, P15351, DOI 10.1021/ja106855m
NR 54
TC 2
Z9 2
U1 72
U2 193
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 516
EP 526
DI 10.1016/j.ces.2019.06.044
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300043
DA 2020-05-12
ER

PT J
AU Panda, A
   Pati, AR
   Saha, B
   Kumar, A
   Mohapatra, SS
AF Panda, Anita
   Pati, A. R.
   Saha, B.
   Kumar, A.
   Mohapatra, S. S.
TI The role of viscous and capillary forces in the prediction of critical
   conditions defining super-hydrophobic and hydrophilic characteristics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Spreading; Recoiling; Hydrophobicity; Hydrophilicity
ID SLIP BOUNDARY-CONDITION; HEAT-TRANSFER RATE; SUPERHYDROPHOBIC SURFACES;
   SUPERWETTING SURFACES; SILICA NANOPARTICLES; ALUMINUM SURFACES; IMPACT
   DYNAMICS; DROPLETS; WATER; FABRICATION
AB The prediction of the superhydrophobic/superhydrophilic behavior from the characteristics of post impinged droplet on a surface with the alteration of physical properties of fluid or the surface properties has gained much interest for the development of anti-fogging glass, gradient surface and anti-corrosion surfaces. The abovementioned characteristics are well described by the spreading, recoiling, rolling, and bouncing behaviors of the post impinged droplet and these phenomena are controlled by viscous and capillary forces. The proper combination of the capillary and viscous forces of a fluid leads to various levels of recoiling and spreading. However, in terms of the discussed forces, the conditions to attain superhydrophobicity/superhydrophilicity are not reported. Therefore, in the current work, an attempt has been made to predict critical conditions for the attainment of both superhydrophobic and superhydrophilic characteristics in terms of fluid and surface properties defining the post impingement behavior. The analysis of droplet dynamics reveals that the ratio of viscous force to capillary force (V-F/C-F) is considered as the defining parameters for super-hydrophobic and hydrophilic characteristics. For the attainment of superhydrophilic characteristics, V-F/C- (F) ratio must be greater than 30 x 10(-4) and value below 2.9 x 10(-4) generates superhydrophobicity. Furthermore, the role of viscosity and surface tension in droplet dynamics were also investigated by using Central Composite Design (CCD) analysis methodology and it confirms the existence of strong interaction between the viscosity and surface tension. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Panda, Anita; Pati, A. R.; Saha, B.; Mohapatra, S. S.] Natl Inst Technol Rourkela, Dept Chem Engn, Rourkela 769008, India.
   [Kumar, A.] Indian Inst Technol Dhanbad, Dept Chem Engn, Dhanbad 826004, Bihar, India.
RP Mohapatra, SS (reprint author), NIT Rourkela, Dept Chem Engn, Spray Boiling Heat Transfer Lab, Rourkela 769008, India.
EM mohapatras@nitrkl.ac.in
RI Kumar, Aditya/AAB-8521-2020
OI Kumar, Aditya/0000-0001-7550-8034
CR Amin S, 2016, INT J CURRENT TRENDS, V2, P556
   Antonini C, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4757122
   Bhatt NH, 2017, INT J HEAT MASS TRAN, V110, P330, DOI 10.1016/j.ijheatmasstransfer.2017.02.094
   Bhushan B, 2008, LOTUS EFFECT ROUGHNE, P995
   Bhushan B, 2010, LANGMUIR, V26, P8207, DOI 10.1021/la904585j
   Bhushan B, 2009, PHILOS T R SOC A, V367, P1631, DOI 10.1098/rsta.2009.0014
   Chen LQ, 2018, MACROMOLECULES, V51, P7817, DOI 10.1021/acs.macromol.8b01589
   Drelich J, 2011, SOFT MATTER, V7, P9804, DOI 10.1039/c1sm05849e
   Drelich J, 2010, LANGMUIR, V26, P18621, DOI 10.1021/la1039893
   Fedorchenko AI, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2038367
   Feng L, 2008, LANGMUIR, V24, P4114, DOI 10.1021/la703821h
   Guo J, 2018, APPL PHYS LETT, V113
   Hikita M, 2005, LANGMUIR, V21, P7299, DOI 10.1021/la050901r
   Huang KT, 2015, ACS APPL MATER INTER, V7, P21021, DOI 10.1021/acsami.5b07362
   Jia W, 2003, EXP THERM FLUID SCI, V27, P829, DOI 10.1016/S0894-1777(03)00015-3
   Laan N, 2014, PHYS REV APPL, V2, DOI 10.1103/PhysRevApplied.2.044018
   Latthe SS, 2014, MOLECULES, V19, P4256, DOI 10.3390/molecules19044256
   Lee JB, 2016, J FLUID MECH, V786, DOI 10.1017/jfm.2015.620
   Li MY, 2014, APPL SURF SCI, V297, P147, DOI 10.1016/j.apsusc.2014.01.105
   Lin SJ, 2018, J COLLOID INTERF SCI, V516, P86, DOI 10.1016/j.jcis.2017.12.086
   Liu GM, 2010, FARADAY DISCUSS, V146, P141, DOI 10.1039/b924965f
   Marmur A, 2004, LANGMUIR, V20, P3517, DOI 10.1021/la036369u
   McHale G, 2004, J APPL PHYS, V95, P373, DOI 10.1063/1.1630373
   Nosonovsky Michael, 2009, Functional Properties of Bio-Inspired Surfaces Characterization and Technological Applications, P43, DOI 10.1142/9789812837028_0003
   Nosonovsky M, 2007, NANO LETT, V7, P2633, DOI 10.1021/nl071023f
   Otitoju TA, 2017, J IND ENG CHEM, V47, P19, DOI 10.1016/j.jiec.2016.12.016
   Panda A, 2018, CARBOHYD POLYM, V181, P1052, DOI 10.1016/j.carbpol.2017.11.044
   PasandidehFard M, 1996, PHYS FLUIDS, V8, P650, DOI 10.1063/1.868850
   Pati AR, 2018, INT J THERM SCI, V127, P335, DOI 10.1016/j.ijthermalsci.2018.01.028
   Pati A. R, 2018, INVERSE PROBL SCI EN, V27, P1
   Qian BT, 2005, LANGMUIR, V21, P9007, DOI 10.1021/la051308c
   Ravi V, 2010, 22 ANN C LIQ AT SPRA
   Roisman I. V, 2009, PHYS FLUIDS, V21
   Samaha MA, 2012, CR MECANIQUE, V340, P18, DOI 10.1016/j.crme.2011.11.002
   Saranadhi D, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600686
   Satapathy M, 2017, CELLULOSE, V24, P4405, DOI 10.1007/s10570-017-1420-9
   Sedai BR, 2016, APPL SURF SCI, V386, P178, DOI 10.1016/j.apsusc.2016.06.009
   Takeuchi M, 2005, J PHYS CHEM B, V109, P15422, DOI 10.1021/jp058075i
   Ukiwe C, 2005, LANGMUIR, V21, P666, DOI 10.1021/la0481288
   Varshney P, 2018, TRIBOL INT, V119, P38, DOI 10.1016/j.triboint.2017.10.033
   Varshney P, 2016, INT J SMART NANO MAT, V7, P248, DOI 10.1080/19475411.2016.1272502
   Vinogradova OI, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.045302
   Wang YJ, 2017, J MATER CHEM A, V5, P3759, DOI 10.1039/c6ta10474f
   Yang SC, 2005, MOL SIMULAT, V31, P971, DOI 10.1080/08927020500423778
   Yonemoto Y, 2017, SCI REP, V2362, P1
   Zang DY, 2013, SOFT MATTER, V9, P394, DOI 10.1039/c2sm26759d
   Zhang M., 2016, BIOTRIBOLOGY, V5, P31, DOI DOI 10.1016/J.BI0TRI.2015.08.002
   Zhao BY, 2017, LANGMUIR, V33, P144, DOI 10.1021/acs.langmuir.6b03862
   Zhu YX, 2002, LANGMUIR, V18, P10058, DOI 10.1021/la026016f
NR 49
TC 0
Z9 0
U1 21
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 527
EP 541
DI 10.1016/j.ces.2019.06.013
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300044
DA 2020-05-12
ER

PT J
AU Wu, XX
   Gong, Y
   Guo, QH
   Xue, ZC
   Yu, GS
AF Wu, Xiaoxiang
   Gong, Yan
   Guo, Qinghua
   Xue, Zhicun
   Yu, Guangsuo
TI Experimental study on the atomization and particle evolution
   characteristics in an impinging entrained-flow gasifier
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Entrained-flow gasifier; Coal water slurry (CWS); Atomization;
   Visualization
ID COAL-WATER SLURRY; AIR; JET; BREAKUP; PERFORMANCE
AB Based on the bench-scale opposed multi-burner (OMB) impinging entrained-flow gasifier and advanced visualization apparatus, studies on the coal water slurry (CWS) atomization process in gasifier were carried out. Morphological classification of the CWS atomization was discussed in detail. The particle size distribution of CWS after atomization was obtained by image processing algorithm and statistical method. The primary atomization modes in gasifier can be divided into: Rayleigh-type breakup and superpulsating breakup. Besides, the spray angle and breakup length are negatively correlated with the oxygen-CWS relative velocity. The secondary atomization modes can be divided into: no breakup, tensile breakup, shear breakup and synergistic breakup. The statistical analysis shows that the particle size of the CWS after atomization show a negative correlation with the oxygen-CWS relative velocity. The greater the difference in relative velocity between oxygen and CWS, the better the atomization effect, but excessive oxygen velocity results in reduced gasification efficiency. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Xiaoxiang; Gong, Yan; Guo, Qinghua; Xue, Zhicun; Yu, Guangsuo] East China Univ Sci & Technol, Inst Clean Coal Technol, Shanghai 200237, Peoples R China.
   [Yu, Guangsuo] Ningxia Univ, Coll Chem & Chem Engn, State Key Lab High Efficiency Coal Utilizat & Gre, Yinchuan 750021, Peoples R China.
RP Guo, QH; Yu, GS (reprint author), East China Univ Sci & Technol, Inst Clean Coal Technol, Shanghai 200237, Peoples R China.
EM gqh@ecust.edu.cn; gsyu@ecust.edu.cn
RI Xue, Zhicun/AAD-9867-2020
FU National Key R&D Program of China [2017YFB0602601]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21761132034]
FX The research was supported by the National Key R&D Program of China
   (2017YFB0602601) and National Natural Science Foundation of China
   (21761132034).
CR Addo-Yobo FO, 2011, AICHE J, V57, P2007, DOI 10.1002/aic.12441
   Baillot F, 2009, J FLUID MECH, V640, P305, DOI 10.1017/S002211200999139X
   Chigier N., 1992, ATOMIZATION SPRAY, V2, P137
   Cui TM, 2015, ENERG FUEL, V29, P6231, DOI 10.1021/acs.energyfuels.5b01289
   Dumouchel C, 2008, EXP FLUIDS, V45, P371, DOI 10.1007/s00348-008-0526-0
   Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601
   Gad HM, 2018, EXP THERM FLUID SCI, V99, P211, DOI 10.1016/j.expthermflusci.2018.07.006
   Gong Y, 2017, APPL ENERG, V206, P1184, DOI 10.1016/j.apenergy.2017.10.037
   Gong Y, 2017, APPL ENERG, V205, P1091, DOI 10.1016/j.apenergy.2017.08.095
   Gong Y, 2014, CHEM ENG SCI, V117, P93, DOI 10.1016/j.ces.2014.05.053
   Gong Y, 2012, IND ENG CHEM RES, V51, P7828, DOI 10.1021/ie2028602
   Guildenbecher DR, 2009, EXP FLUIDS, V46, P371, DOI 10.1007/s00348-008-0593-2
   Guo QH, 2019, J ENERGY INST, V92, P578, DOI 10.1016/j.joei.2018.04.001
   Lasheras JC, 2000, ANNU REV FLUID MECH, V32, P275, DOI 10.1146/annurev.fluid.32.1.275
   Leroux B, 2007, ATOMIZATION SPRAY, V17, P381, DOI 10.1615/AtomizSpr.v17.i5.10
   Li YB, 2011, CHEM ENG SCI, V66, P788, DOI 10.1016/j.ces.2010.11.045
   Liu HF, 2012, POWDER TECHNOL, V225, P206, DOI 10.1016/j.powtec.2012.04.011
   Liu HF, 2006, CHEM ENG SCI, V61, P1741, DOI 10.1016/j.ces.2005.10.012
   Marmottant PH, 2004, J FLUID MECH, V498, P73, DOI 10.1017/S0022112003006529
   Paprika MJ, 2013, ENERG FUEL, V27, P5488, DOI 10.1021/ef400875q
   Rayleigh L., 1879, P LOND MATH SOC, V10, P4, DOI DOI 10.1112/PLMS/S1-10.1.4
   REITZ RD, 1982, PHYS FLUIDS, V25, P1730, DOI 10.1063/1.863650
   Salinero J, 2016, CHEM ENG J, V288, P441, DOI 10.1016/j.cej.2015.11.098
   Senneca O, 2013, FUEL, V104, P253, DOI 10.1016/j.fuel.2012.09.026
   Strasser W, 2019, CHEM ENG SCI, V196, P214, DOI 10.1016/j.ces.2018.10.055
   Wang Fuchen, 2007, Frontiers of Energy and Power Engineering in China, V1, P251, DOI 10.1007/s11708-007-0035-5
   Wang YJ, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.154502
   Xue ZC, 2019, FUEL, V244, P40, DOI 10.1016/j.fuel.2019.01.186
   Xue ZC, 2018, CHEM ENG SCI, V190, P248, DOI 10.1016/j.ces.2018.06.039
   Yu HL, 2008, ENERG FUEL, V22, P1170, DOI 10.1021/ef700553s
   Yu Z. H., 2011, U.S. Patent, Patent No. [7,862,632B2, 7862632]
   Zhang Q, 2017, CHEM ENG SCI, V162, P104, DOI 10.1016/j.ces.2016.12.072
   Zhang WG, 2014, FUEL PROCESS TECHNOL, V119, P1, DOI 10.1016/j.fuproc.2013.10.006
   Zhao H, 2014, J NON-NEWTON FLUID, V211, P1, DOI 10.1016/j.jnnfm.2014.06.007
   Zhao H, 2014, AICHE J, V60, P2335, DOI 10.1002/aic.14414
   Zhao H, 2012, CHEM ENG SCI, V78, P63, DOI 10.1016/j.ces.2012.05.007
   Zhao H, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3659495
NR 37
TC 0
Z9 0
U1 11
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 542
EP 555
DI 10.1016/j.ces.2019.06.055
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300045
DA 2020-05-12
ER

PT J
AU Dadvand, A
   Hosseini, S
   Aghebatandish, S
   Khoo, BC
AF Dadvand, Abdolrahman
   Hosseini, Soheil
   Aghebatandish, Saharnaz
   Khoo, Boo Cheong
TI Enhancement of heat and mass transfer in a microchannel via passive
   oscillation of a flexible vortex generator
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluid-structure interaction; Arbitrary Lagrangian-Eulerian; Passive
   oscillation; Flexible vortex generator; Neo-Hookean model
ID MIXING ENHANCEMENT; CHANNEL; FLOW; NANOFLUIDS; DEFORMATION; SIMULATION;
   FLAGS
AB The advantages of both the passive and active heat and mass transfer enhancement techniques are used. A beam (rigid or flexible) as vortex generator (VG) is placed downstream of a cylindrical obstacle on the lower wall of a microchannel. The governing equations are solved using ALE approach. The elastic beam oscillates due to the forces exerted by the periodic flow behind the obstacle on it leading to the formation and separation of periodic vortices from the tip of the beam. These vortices disrupt the thermal boundary layer and prevent it from re-growing and hence increase the heat transfer rate dramatically. The total Nu number increases 18.46%, the Darcy friction factor experiences a decrease of 42.33%, the thermal performance factor increases 42% and the mixing index increases 16.86% with respect to the rigid beam case. Finally, the flexible beam used here would not experience failure in the laminar flow regime. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dadvand, Abdolrahman; Hosseini, Soheil; Aghebatandish, Saharnaz] Urmia Univ Technol, Fac Mech Engn, Orumiyeh, Iran.
   [Khoo, Boo Cheong] Natl Univ Singapore, Dept Mech Engn, Singapore, Singapore.
RP Dadvand, A (reprint author), Urmia Univ Technol, Fac Mech Engn, Orumiyeh, Iran.
EM a.dadvand@mee.uut.ac.ir
OI Dadvand, Abdolrahman/0000-0002-6642-6122
CR Ahmed HE, 2012, RENEW SUST ENERG REV, V16, P5951, DOI 10.1016/j.rser.2012.06.003
   Ali S, 2017, CHEM ENG SCI, V162, P152, DOI 10.1016/j.ces.2016.12.039
   Ali S, 2015, INT J HEAT MASS TRAN, V85, P250, DOI 10.1016/j.ijheatmasstransfer.2015.01.122
   ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6
   Attard MM, 2003, INT J SOLIDS STRUCT, V40, P4353, DOI 10.1016/S0020-7683(03)00217-8
   Babar H, 2019, J MOL LIQ
   Becker S, 2002, J WIND ENG IND AEROD, V90, P265, DOI 10.1016/S0167-6105(01)00209-4
   Bejan A, 2003, HEAT TRANSFER HDB
   Bower A.F., 2009, APPL MECH SOLIDS
   Bruus H., 2008, THEORETICAL MICROFLU
   Celik IB, 2008, J FLUID ENG-T ASME, V130, DOI 10.1115/1.2960953
   Depaiwa N, 2010, ENERGY SUSTAIN DEV, V2010, P1
   DONEA J, 2004, ENCY COMPUTATIONAL M, V1, P14, DOI DOI 10.1002/0170091355.ECM009
   Fiebig M, 1998, CHEM ENG RES DES, V76, P108, DOI 10.1205/026387698524686
   Fu WS, 2002, INT J HEAT MASS TRAN, V45, P3033, DOI 10.1016/S0017-9310(02)00016-9
   Gao YC, 1997, THEOR APPL FRACT MEC, V26, P155, DOI 10.1016/S0167-8442(96)00044-4
   Gent AN, 1996, RUBBER CHEM TECHNOL, V69, P59, DOI 10.5254/1.3538357
   Habchi C, 2010, CHEM ENG PROCESS, V49, P1066, DOI 10.1016/j.cep.2010.08.007
   Habchi C, 2010, J TURBUL, V11, P1, DOI 10.1080/14685248.2010.510841
   Holzapfel A.G., 2000, NONLINEAR SOLID MECH
   Kakac S., 1987, HDB SINGLE PHASE CON
   Karniadakis G, 2006, MICROFLOWS NANOFLOWS
   Khatavkar VV, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2762206
   Khattak Z, 2019, INT J HEAT MASS TRAN, V130, P141, DOI 10.1016/j.ijheatmasstransfer.2018.08.048
   Lambert RA, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3410268
   Lee JB, 2018, INT J HEAT MASS TRAN, V116, P1003, DOI 10.1016/j.ijheatmasstransfer.2017.09.094
   Lee JB, 2017, INT J HEAT MASS TRAN, V107, P391, DOI 10.1016/j.ijheatmasstransfer.2016.11.057
   Li Z., 2017, ASME 2017 HEAT TRANS
   Ma J, 2010, NUCL ENG DES, V240, P92, DOI 10.1016/j.nucengdes.2009.10.015
   Meis M, 2010, INT J HEAT MASS TRAN, V53, P29, DOI 10.1016/j.ijheatmasstransfer.2009.10.013
   Mirzaee H, 2012, J ENHANC HEAT TRANSF, V19, P199, DOI 10.1615/JEnhHeatTransf.2012002747
   Mohebbi R, 2018, INT J HEAT MASS TRAN, V117, P1291, DOI 10.1016/j.ijheatmasstransfer.2017.10.063
   Morand H.J., 1992, FLUID STRUCTURE INTE
   Park SG, 2017, INT J HEAT MASS TRAN, V110, P20, DOI 10.1016/j.ijheatmasstransfer.2017.03.012
   Peskin CS, 2002, ACT NUMERIC, V11, P479, DOI 10.1017/S0962492902000077
   RIVLIN RS, 1951, PHILOS TR R SOC S-A, V243, P251, DOI 10.1098/rsta.1951.0004
   Sajid MU, 2019, RENEW SUST ENERG REV, V103, P556, DOI 10.1016/j.rser.2018.12.057
   Sharipov F, 2011, J PHYS CHEM REF DATA, V40, DOI 10.1063/1.3580290
   Shoele K, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4903793
   Soti AK, 2015, INT J HEAT MASS TRAN, V84, P1070, DOI 10.1016/j.ijheatmasstransfer.2015.01.048
   STORAKERS B, 1986, J MECH PHYS SOLIDS, V34, P125, DOI 10.1016/0022-5096(86)90033-5
   Tauseef-ur-Rehman, 2019, INT J HEAT MASS TRAN, V135, P649, DOI 10.1016/j.ijheatmasstransfer.2019.02.001
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968
   Turek S., 2006, PROPOSAL NUMERICAL B, P371
   van Loon R, 2007, COMPUT STRUCT, V85, P833, DOI 10.1016/j.compstruc.2007.01.010
   Webb R.L., 2005, ENHANCED HEAT TRANSF
   Yang YT, 2008, INT J HEAT MASS TRAN, V51, P1603, DOI 10.1016/j.ijheatmasstransfer.2007.07.010
   Yu YL, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5022723
   Zdravkovich M., 1997, FLOW CIRCULAR CYLIND, V1
NR 49
TC 2
Z9 2
U1 22
U2 61
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 556
EP 580
DI 10.1016/j.ces.2019.06.045
PG 25
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300046
DA 2020-05-12
ER

PT J
AU Perazzo, A
   Sicignano, L
   Tomaiuolo, G
   Marotta, R
   Andreozzi, R
   Guido, S
AF Perazzo, Antonio
   Sicignano, Luca
   Tomaiuolo, Giovanna
   Marotta, Raffaele
   Andreozzi, Roberto
   Guido, Stefano
TI Tuning crystal structure in a micro-scale reactive flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE In situ crystallization; Microfluidics; Shear flow; Surface fouling
ID CRYSTALLIZATION; MICROFLUIDICS; AGGREGATION; NUCLEATION; DEPOSITION;
   DISPERSION; PARTICLES; DYNAMICS; VELOCITY; KINETICS
AB In many industrial applications, ranging from chemical reactions to transport of suspensions, colloids can be produced and deposited within the processing equipment leading to significant fouling and clogging issues. Here, a continuous-flow reactor for the production of pharmaceutically relevant arylamines through the Buchwald-Hartwig synthesis is coupled to a microfluidic channel to investigate the complex interplay among fluid dynamics, crystallization, reaction and surface chemistry. The process of wall deposition and crystal formation under flow is studied in situ by fragmenting to the micron-scale the particles coming from the reactor and using glass microchannels. Tuning the flow rate, a dramatic change in crystal morphology and composition is found, from dendritic needle-like potassium tert-pentoxide structures to irregular colloidal clusters mainly made of potassium bromide. The results are characterized in terms of dimensionless parameters and provide novel insights for an improved understanding and control of fouling and crystal growth under flow. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Perazzo, Antonio; Sicignano, Luca; Tomaiuolo, Giovanna; Marotta, Raffaele; Andreozzi, Roberto; Guido, Stefano] Univ Napoli Federico II, Dipartimento Ingn Chim Mat & Prod Ind, Ple V Tecchio 80, I-80125 Naples, Italy.
   [Perazzo, Antonio] Princeton Univ, Dept Mech & Aerosp Engn, Olden St, Princeton, NJ 08544 USA.
RP Tomaiuolo, G (reprint author), Univ Napoli Federico II, Dipartimento Ingn Chim Mat & Prod Ind, Ple V Tecchio 80, I-80125 Naples, Italy.
EM g.tomaiuolo@unina.it
OI Tomaiuolo, Giovanna/0000-0003-3012-0356; Marotta,
   Raffaele/0000-0002-0548-7087
FU European CommunityEuropean Community (EC) [NMP2-LA-2010-246461];
   European network action "Smart and green interfaces -from single bubbles
   and drops to industrial, environmental, and biomedical applications"
   [COST MP1106]; European network action "Colloidal aspects of nanoscience
   for innovative processes and materials" [COST CM1101]; European network
   action "Flowing Matter" [COST MP1305]
FX The research leading to these results has received funding from the
   European Community Seventh Framework Programme [FP7/2007-2013] within
   the SYNFLOW project under Grant agreement No. NMP2-LA-2010-246461. This
   study is related to the activity of the European network action COST
   MP1106 "Smart and green interfaces -from single bubbles and drops to
   industrial, environmental, and biomedical applications", COST CM1101
   "Colloidal aspects of nanoscience for innovative processes and
   materials" and COST MP1305 "Flowing Matter".
CR Abkarian M, 2004, J AM CHEM SOC, V126, P5978, DOI 10.1021/ja049775o
   Bradley D.C., 2001, ALKOXO ARYLOXO DERIV
   Cejas CM, 2017, LANGMUIR, V33, P6471, DOI 10.1021/acs.langmuir.7b01394
   Chartoire A, 2012, CHEM-EUR J, V18, P4517, DOI 10.1002/chem.201104009
   Chen DL, 2005, J AM CHEM SOC, V127, P9672, DOI 10.1021/ja052279v
   Chen WQ, 2017, LAB CHIP, V17, P3051, DOI 10.1039/c7lc00645d
   Conchuir BO, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.032310
   Dennis JM, 2018, J AM CHEM SOC, V140, P4721, DOI 10.1021/jacs.8b01696
   Dressaire E, 2017, SOFT MATTER, V13, P37, DOI 10.1039/c6sm01879c
   Dutta D, 2006, MICROFLUID NANOFLUID, V2, P275, DOI 10.1007/s10404-005-0070-7
   Falss S, 2016, ORG PROCESS RES DEV, V20, P558, DOI 10.1021/acs.oprd.5b00350
   Flatt RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5823
   Frungieri G, 2017, CAN J CHEM ENG, V95, P1768, DOI 10.1002/cjce.22843
   Gai Y, 2016, P NATL ACAD SCI USA, V113, P12082, DOI 10.1073/pnas.1606601113
   Gardner CR, 2004, NAT REV DRUG DISCOV, V3, P926, DOI 10.1038/nrd1550
   GREGORY J, 1981, CHEM ENG SCI, V36, P1789, DOI 10.1016/0009-2509(81)80126-1
   Griffiths IM, 2012, EPL-EUROPHYS LETT, V97, DOI 10.1209/0295-5075/97/58005
   Gudipaty T, 2011, MICROFLUID NANOFLUID, V10, P661, DOI 10.1007/s10404-010-0700-6
   Hansen C, 2003, CURR OPIN STRUC BIOL, V13, P538, DOI 10.1016/j.sbi.2003.09.010
   Harshe YM, 2016, J PHYS CHEM B, V120, P7244, DOI 10.1021/acs.jpcb.6b03220
   Jain P, 2019, LANGMUIR, V35, P3949, DOI 10.1021/acs.langmuir.8b04307
   Jensen KF, 2017, AICHE J, V63, P858, DOI 10.1002/aic.15642
   Kang LF, 2008, DRUG DISCOV TODAY, V13, P1, DOI 10.1016/j.drudis.2007.10.003
   Kong YL, 2015, LANGMUIR, V31, P12560, DOI 10.1021/acs.langmuir.5b03443
   Lazzari S, 2016, ADV COLLOID INTERFAC, V235, P1, DOI 10.1016/j.cis.2016.05.002
   Lazzari S, 2018, LANGMUIR, V34, P3307, DOI 10.1021/acs.langmuir.8b00076
   LEIGHTON D, 1987, J FLUID MECH, V181, P415, DOI 10.1017/S0022112087002155
   Leng J, 2009, LAB CHIP, V9, P24, DOI 10.1039/b807653g
   Li SB, 2017, SMALL, V13, DOI 10.1002/smll.201702154
   Li YH, 2017, SMALL, V13, DOI 10.1002/smll.201604125
   Liu Y, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.036102
   Miller A.P., 1941, LANGES HDB CHEM
   Mizukami M, 2002, J AM CHEM SOC, V124, P12889, DOI 10.1021/ja027141g
   Mura F, 2016, PHYS REV E, V93, DOI 10.1103/PhysRevE.93.042803
   Noel T, 2011, CHEM SCI, V2, P287, DOI 10.1039/c0sc00524j
   Pal S, 2019, CHEM ENG SCI, V199, P88, DOI 10.1016/j.ces.2019.01.015
   Pal S, 2016, CHEM ENG SCI, V153, P344, DOI 10.1016/j.ces.2016.07.012
   Perazzo A, 2015, RSC ADV, V5, P63786, DOI 10.1039/c5ra10971j
   Pommella A, 2013, CHEM ENG J, V223, P578, DOI 10.1016/j.cej.2013.03.070
   Qazi MJ, 2017, LANGMUIR, V33, P4260, DOI 10.1021/acs.langmuir.7b00244
   Qu G, 2016, ACCOUNTS CHEM RES, V49, P2756, DOI 10.1021/acs.accounts.6b00445
   Rusconi R, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.254502
   Sassoni E, 2018, CORROS SCI, V136, P255, DOI 10.1016/j.corsci.2018.03.019
   Scherer GW, 2004, CEMENT CONCRETE RES, V34, P1613, DOI 10.1016/j.cemconres.2003.12.034
   Schiro M, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.265503
   Shahzad K, 2016, CHEM ENG J, V303, P202, DOI 10.1016/j.cej.2016.05.134
   Shi HH, 2017, LAB CHIP, V17, P2167, DOI 10.1039/c6lc01225f
   Shim JU, 2007, CRYST GROWTH DES, V7, P2192, DOI 10.1021/cg700688f
   Sicignano L, 2018, CHEM ENG J, V341, P639, DOI 10.1016/j.cej.2018.02.037
   Sizaret S, 2006, GEOPHYS J INT, V167, P1027, DOI 10.1111/j.1365-246X.2006.03165.x
   Soos M, 2010, LANGMUIR, V26, P10, DOI 10.1021/la903982n
   Stamm MT, 2011, MICROFLUID NANOFLUID, V11, P395, DOI 10.1007/s10404-011-0805-6
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Stone HA, 1999, IND ENG CHEM RES, V38, P851, DOI 10.1021/ie980355f
   Trofa M, 2019, CHEM ENG J, V358, P91, DOI 10.1016/j.cej.2018.09.207
   Vaccaro L., 2016, SUSTAINABLE FLOW CHE
   van Dinther AMC, 2012, ADV COLLOID INTERFAC, V173, P23, DOI 10.1016/j.cis.2012.02.003
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Wyss HM, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.061402
   Zhang P, 2018, CHEM-EUR J, V24, P2776, DOI 10.1002/chem.201706004
NR 60
TC 0
Z9 0
U1 13
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 581
EP 587
DI 10.1016/j.ces.2019.06.060
PG 7
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300047
DA 2020-05-12
ER

PT J
AU Sharma, P
AF Sharma, Pooja
TI Spectroscopic analysis of Jet A-1 heteroatomic components
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Jet fuel; Deposit; Heteroatomic; Antioxidant; Lichen; Additives
ID ADSORPTIVE DESULFURIZATION; RUBBER TIRES; DIESEL FUEL; CARBON;
   HYDRODESULFURIZATION; DIBENZOTHIOPHENE; NANOPARTICLES; OPTIMIZATION;
   LUBRICITY; LICHENS
AB This article presents the chemical analysis of jet fuel (Jet A-1) heteroatomic components generated as a result of thermal stressing. Jet A-1 was thermally stressed by flow and static tests in a single tube heat exchanger in the autoxidation regime (150-300 degrees C). Jet A-1 samples were analyzed by electrospray ion mass spectrometry (ESI-MS), Fourier transform infrared (FTIR) and C-13 nuclear magnetic resonance (NMR) spectroscopy. Mass spectra of Jet A-1 recorded higher molecular weight components in the mass range 300-1000 Da. FTIR spectra revealed absorption bands for oxygen-containing species such as alcohol, phenol, and ether. Jet A-1 NMR spectra recorded heteroatomic alkoxy species. A lichen substance, gyrophoric acid was identified as Jet A-1 component. ESI-MS, FTIR and NMR spectra of unstressed jet fuel recorded peaks corresponding with gyrophoric acid. Natural products polyphenols and lichen derived compounds are excellent antioxidants, and their advantages as potential fuel additives are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sharma, Pooja] Univ Toronto, Aerosp Studies, Toronto, ON M3H 5T6, Canada.
RP Sharma, P (reprint author), Univ Toronto, Aerosp Studies, Toronto, ON M3H 5T6, Canada.
EM poojaa.sharma@mail.utoronto.ca
CR Adams RK, 2013, ENERG FUEL, V27, P2390, DOI 10.1021/ef3015298
   AL-Hammadi SA, 2018, CHEM ENG J, V345, P242, DOI 10.1016/j.cej.2018.03.106
   Anastopoulos G, 2013, FRICTION, V1, P271, DOI 10.1007/s40544-013-0025-z
   Banerjee S, 2012, INT J ANAL CHEM, DOI 10.1155/2012/282574
   Behera BC, 2009, FOOD TECHNOL BIOTECH, V47, P7
   Bentil Addison Joseph, 1985, ANALYST, V110
   Black Bruce H, 1989, LUBRICITY PROPERTI 1
   BOHMAN G, 1969, ACTA CHEM SCAND, V23, P2241, DOI 10.3891/acta.chem.scand.23-2241
   Bonny S, 2011, ANAL CHIM ACTA, V707, P69, DOI 10.1016/j.aca.2011.09.009
   Bucukoglu TZ, 2013, J FOOD PROCESS PRES, V37, P1103, DOI 10.1111/j.1745-4549.2012.00811.x
   Burlando B, 2009, PLANTA MED, V75, P607, DOI 10.1055/s-0029-1185329
   Choudhary MI, 2011, SCI CHINA CHEM, V54, P1926, DOI 10.1007/s11426-011-4436-2
   Commodo M, 2011, ENERG FUEL, V25, P2142, DOI 10.1021/ef2002102
   Corporan E, 2011, ENERG FUEL, V25, P955, DOI 10.1021/ef101520v
   CULBERSON CF, 1969, CHEM BOT GUIDE LICHE
   Danmaliki GI, 2017, CHEM ENG J, V313, P993, DOI 10.1016/j.cej.2016.10.141
   Danmaliki GI, 2017, CHEM ENG J, V307, P914, DOI 10.1016/j.cej.2016.08.143
   HARDY DR, 1990, ENERG FUEL, V4, P270, DOI 10.1021/ef00021a009
   HAWKSWORTH DL, 1976, LICHENS POLLUTION MO
   HAZLETT RN, 1991, THERMAL OXIDATIVE ST
   Huneck S, 1996, SCI CHINA CHEM, V54, P1926
   Kosanic M, 2011, J FOOD SCI TECH MYS, V48, P584, DOI 10.1007/s13197-010-0174-2
   Kumar S, 1999, J NAT PROD, V62, P821, DOI 10.1021/np980378z
   Maass W. S. G, 1975, BRYOLOGIST, V78
   Rankovic Branislav, 2015, LICHENS POTENTIAL SO
   Saleh T. A., 2017, ADV NANOMATERIALS WA
   Saleh TA, 2018, TOP MINING METAL MAT, P1, DOI 10.1007/978-3-319-60630-9
   Saleh TA, 2015, APPL NANOTECHNOLOGY
   Saleh TA, 2018, J MOL LIQ, V272, P715, DOI 10.1016/j.molliq.2018.09.118
   Saleh TA, 2018, J CLEAN PROD, V172, P2123, DOI 10.1016/j.jclepro.2017.11.208
   Saleh TA, 2017, J CLEAN PROD, V154, P401, DOI 10.1016/j.jclepro.2017.03.169
   Saleh TA, 2016, PROCESS SAF ENVIRON, V102, P9, DOI 10.1016/j.psep.2016.02.005
   Saleh TA, 2016, J TAIWAN INST CHEM E, V60, P460, DOI 10.1016/j.jtice.2015.11.008
   Sharma P, 2019, CHEM ENG SCI, V206, P335, DOI 10.1016/j.ces.2019.05.045
   Silverstein Robert M, 2015, SPECTROMETRIC IDENTI
   Totten G.E., 2003, FUELS LUBRICANTS HDB
   WEI DP, 1986, WEAR, V111, P217
   White PAS, 2014, MOLECULES, V19, P14496, DOI 10.3390/molecules190914496
NR 38
TC 0
Z9 0
U1 7
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 588
EP 599
DI 10.1016/j.ces.2019.06.059
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300048
DA 2020-05-12
ER

PT J
AU Jabbari, Y
   Tsotsas, E
   Kirsch, C
   Kharaghani, A
AF Jabbari, Yasaman
   Tsotsas, Evangelos
   Kirsch, Christoph
   Kharaghani, Abdolreza
TI Determination of the moisture transport coefficient from pore network
   simulations of spontaneous imbibition in capillary porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Spontaneous imbibition; Pore network models; Richards equation;
   Parameter identification; Scale transition
ID INTERFACIAL AREA; 2-PHASE FLOW; OIL-RECOVERY; DYNAMICS; PRESSURE; MODEL;
   PERMEABILITY; HYSTERESIS; EQUATION; LIQUIDS
AB The Richards model for spontaneous imbibition of a wetting liquid into a porous medium is revisited. Two methods are presented to determine the effective parameter in the Richards equation, i.e. the saturation-dependent moisture transport coefficient D(S), from pore network simulations: The first method employs a quasi-static pore network model (QPNM), whereas the second method uses a dynamic pore network model (DPNM) to estimate D(S) in an inverse approach. The DPNM simulation results serve as a reference to assess the quality of these two parameter estimation methods. It is found that the solution of the Richards equation is very sensitive to D(S), especially when the porous medium is close to fully saturated. While the saturation levels over time obtained from solving the Richards equation with D(S) calculated from the inverse method match well with those from the DPNM, some discrepancy is observed when the QPNM is used to estimate D(S) instead. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jabbari, Yasaman; Tsotsas, Evangelos; Kharaghani, Abdolreza] Otto von Guericke Univ, Thermal Proc Engn, Magdeburg, Germany.
   [Kirsch, Christoph] Zurich Univ Appl Sci, Inst Computat Phys, Winterthur, Switzerland.
RP Kharaghani, A (reprint author), Otto von Guericke Univ, Thermal Proc Engn, Magdeburg, Germany.
EM abdolreza.kharaghani@ovgu.de
RI Kharaghani, Abdolreza/AAM-7292-2020; Tsotsas, Evangelos/E-6610-2013
OI Tsotsas, Evangelos/0000-0001-9575-1138
FU German Research Foundation (DFG)German Research Foundation (DFG)
FX This work was financially supported by the German Research Foundation
   (DFG) within the framework of the Graduate School 1554
   "Micro-Macro-Interactions in Structured Media and Particulate Systems".
   The authors are grateful to the anonymous reviewers for their
   constructive comments.
CR Ahrenholz B, 2008, ADV WATER RESOUR, V31, P1151, DOI 10.1016/j.advwatres.2008.03.009
   Arabjamaloei R, 2014, INT S SOC COR AN, P62
   Ashari A, 2009, CHEM ENG SCI, V64, P2067, DOI 10.1016/j.ces.2009.01.048
   Blunt MJ, 2002, ADV WATER RESOUR, V25, P1069, DOI 10.1016/S0309-1708(02)00049-0
   Bosanquet CH, 1923, PHILOS MAG, V45, P525, DOI 10.1080/14786442308634144
   Brooks R. H., 1964, HYDROL PAP
   BURDINE NT, 1953, T AM I MIN MET ENG, V198, P71
   Cai JC, 2011, TRANSPORT POROUS MED, V89, P251, DOI 10.1007/s11242-011-9767-0
   Chapman EM, 2013, ENRGY PROCED, V37, P3680, DOI 10.1016/j.egypro.2013.06.262
   Chen YJ, 2015, J PHYS CHEM C, V119, P12508, DOI 10.1021/acs.jpcc.5b03157
   Dai CL, 2017, ENERG FUEL, V31, P2663, DOI 10.1021/acs.energyfuels.6b03244
   Darcy Henry, 1856, RECHERCHE, V647, DOI DOI 10.2516/OGST
   David C, 2017, J GEOPHYS RES-SOL EA, V122, P4948, DOI 10.1002/2017JB014193
   Deng BQ, 2017, APPL MATH MODEL, V50, P39, DOI 10.1016/j.apm.2017.05.021
   Dernaika M. R., 2012, SOC PETROPHYS WELL L
   Dube M, 2000, EUR PHYS J B, V15, P691, DOI 10.1007/s100510051174
   FATT I, 1956, T AM I MIN MET ENG, V207, P144
   Fries N, 2008, J COLLOID INTERF SCI, V320, P259, DOI 10.1016/j.jcis.2008.01.009
   Geromichalos D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.104503
   Ghaedi M., 2015, IRAN J OIL GAS SCI T, V4, P1, DOI [10.22050/ijogst.2015.10364, DOI 10.22050/IJOGST.2015.10364]
   Ghassemzadeh J, 2004, CHEM ENG SCI, V59, P2281, DOI 10.1016/j.ces.2004.01.058
   Groen JC, 2003, MICROPOR MESOPOR MAT, V60, P1, DOI 10.1016/S1387-1811(03)00339-1
   Gruener S, 2012, P NATL ACAD SCI USA, V109, P10245, DOI 10.1073/pnas.1119352109
   GUMMERSON RJ, 1979, NATURE, V281, P56, DOI 10.1038/281056a0
   Hatiboglu CU, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.066311
   Huinink H, 2016, FLUIDS IN POROUS MEDIA: TRANSPORT AND PHASE CHANGES, P1, DOI 10.1088/978-1-6817-4297-7
   JERAULD GR, 1990, TRANSPORT POROUS MED, V5, P103, DOI 10.1007/BF00144600
   Joekar-Niasar V, 2010, J FLUID MECH, V655, P38, DOI 10.1017/S0022112010000704
   Landeryou M, 2005, J FLUID MECH, V529, P173, DOI 10.1017/S0022112005003356
   Lev J, 2017, INT AGROPHYS, V31, P475, DOI 10.1515/intag-2016-0072
   Li J, 2017, ADV WATER RESOUR, V107, P191, DOI 10.1016/j.advwatres.2017.06.017
   Lucas R, 1918, KOLLOID Z, V23, P15, DOI 10.1007/BF01461107
   Martic G, 2002, LANGMUIR, V18, P7971, DOI 10.1021/la020068n
   Miranda AM, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.086101
   Moghaddam AA, 2017, WATER RESOUR RES, V53, P10433, DOI 10.1002/2017WR021162
   Nimmo J. R., 2004, ENCY SOILS ENV
   Oak M. J., 1990, P SPE DOE 7 S ENH OI
   PEL L, 1995, J PHYS D APPL PHYS, V28, P675, DOI 10.1088/0022-3727/28/4/009
   Perez-Cruz A, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-1937-0
   PURCELL WR, 1949, T AM I MIN MET ENG, V186, P39
   Reeves PC, 1996, WATER RESOUR RES, V32, P2345, DOI 10.1029/96WR01105
   Richards LA, 1931, PHYSICS-J GEN APPL P, V1, P318, DOI 10.1063/1.1745010
   Rieger H, 2015, J PHYS CONF SER, V638, DOI 10.1088/1742-6596/638/1/012007
   Roychaudhuri B, 2013, J PETROL SCI ENG, V111, P87, DOI 10.1016/j.petrol.2013.10.002
   Sahimi M, 1995, FLOW TRANSPORT POROU
   Standnes DC, 2004, COLLOID SURFACE A, V251, P93, DOI 10.1016/j.colsurfa.2004.09.013
   Sun Y, 2016, CHEM ENG SCI, V150, P41, DOI 10.1016/j.ces.2016.04.055
   Sun Y, 2015, TRANSPORT POROUS MED, V107, P449, DOI 10.1007/s11242-014-0448-7
   Sylte A., 2004, INT S SOC COR AN
   Thompson KE, 2002, AICHE J, V48, P1369, DOI 10.1002/aic.690480703
   Tora G, 2012, TRANSPORT POROUS MED, V92, P145, DOI 10.1007/s11242-011-9895-6
   VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892, DOI 10.2136/sssaj1980.03615995004400050002x
   Wang X, 2017, ENERGIES, V10, DOI 10.3390/en10040506
   Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273
   WILKINSON D, 1983, J PHYS A-MATH GEN, V16, P3365, DOI 10.1088/0305-4470/16/14/028
   Witelski TP, 1997, TRANSPORT POROUS MED, V27, P121, DOI 10.1023/A:1006513009125
   Zarandi MAF, 2018, AICHE J, V64, P306, DOI [10.1002/aic.15865, 10.1002/aic.15856]
NR 57
TC 0
Z9 0
U1 12
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 600
EP 610
DI 10.1016/j.ces.2019.07.002
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300049
DA 2020-05-12
ER

PT J
AU Zhang, HX
   Liu, Y
   Jiang, H
   Deng, ZN
   Liu, HL
   Li, CZ
AF Zhang, Haoxuan
   Liu, Yu
   Jiang, Hao
   Deng, Zongnan
   Liu, Honglai
   Li, Chunzhong
TI Macroporous MoS2/carbon hybrid film with superior ion/electron
   conductivity for superhigh areal capacity Li-ion batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Macroporous hybrid film; Ion transfer; Areal specific capacity; Flexible
   electrode; Lithium-ion battery
ID LITHIUM; STORAGE; ENERGY; CATHODE
AB The development of flexible lithium-ion batteries (LIBs) with very high areal capacity becomes extremely important in achieving precision medicine due to the limited area of the involved LIB devices. However, the improvement of areal capacity using well-known conventional strategies unavoidably engenders serious polarization and gravimetric specific capacity fading. Herein, we report an entirely new insight into constructing superhigh areal-specific-capacity LIBs by designing an electron/ion dual-conductive macroporous MoS2/C hybrid film. A four-film stacked electrode even with a high mass loading of similar to 12.0 mg cm(2) can deliver an unprecedented high areal specific capacity of 7.21 mA h cm (2), almost double that of best material reported to date (4 mA h cm(2)). Such film electrode unexpectedly shows a positive linear increase of areal specific capacity versus layer number, but no gravimetric capacity (high value of similar to 600 mA h g(1)) change. The electrode kinetics studies reveal that such superhigh arealspecific-capacity lithium storage is mainly attributed to excellent ion transport (10(8) -10(9) cm(2) s(1)) and electron transfer (21.3 S cm(1)) of three-dimensional macroporous MoS2/C hybrid film. This work demonstrates a new concept of dual-conductive film electrode for the development and application of LIBs with tailorable areal specific capacity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Haoxuan; Liu, Yu; Jiang, Hao; Liu, Honglai; Li, Chunzhong] East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.
   [Jiang, Hao; Deng, Zongnan; Li, Chunzhong] East China Univ Sci & Technol, Sch Mat Sci & Engn, Shanghai Engn Res Ctr Hierarch Nanomat, Shanghai 200237, Peoples R China.
RP Jiang, H (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.; Jiang, H (reprint author), East China Univ Sci & Technol, Sch Mat Sci & Engn, Shanghai Engn Res Ctr Hierarch Nanomat, Shanghai 200237, Peoples R China.
EM jianghao@ecust.edu.cn
RI Li, Chunzhong/B-1103-2015
OI Li, Chunzhong/0000-0001-7897-5850
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51672082, 91534202, 91834301]; Basic Research
   Program of Shanghai [17JC1402300]; Shanghai Scientific and Technological
   Innovation Project [18JC1410500, 18DZ2252400]; National Program for
   Support of Top-Notch Young Professionals; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [222201718002]
FX This work was supported by the National Natural Science Foundation of
   China (51672082, 91534202 and 91834301), the Basic Research Program of
   Shanghai (17JC1402300), the Shanghai Scientific and Technological
   Innovation Project (18JC1410500 and 18DZ2252400), the National Program
   for Support of Top-Notch Young Professionals, and the Fundamental
   Research Funds for the Central Universities (222201718002).
CR Alighaleh S, 2017, P ANN INT IEEE EMBS, P2181, DOI 10.1109/EMBC.2017.8037287
   Bai WB, 2018, ADV MATER, V30, DOI 10.1002/adma.201801584
   Billaud J, 2016, NAT ENERGY, V1, DOI [10.1038/nenergy.2016.97, 10.1038/NENERGY.2016.97]
   Chae S, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700071
   Chao Y. F., 2017, ADV FUNCT MATER, V27, P10
   Chen MH, 2018, J ALLOY COMPD, V735, P2022, DOI 10.1016/j.jallcom.2017.12.006
   Chen XZ, 2019, ENERG ENVIRON SCI, V12, P938, DOI 10.1039/c8ee02617c
   Chiu H. C., 2017, ADV ENERGY MATER, V7, P10
   Choi J, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar3921
   Deng ZN, 2017, ADV MATER, V29, DOI 10.1002/adma.201603020
   Ding N, 2009, SOLID STATE IONICS, V180, P222, DOI 10.1016/j.ssi.2008.12.015
   Fang Y, 2016, ADV MATER, V28, P9385, DOI 10.1002/adma.201602210
   Feiner R., 2018, NAT REV MATER, V3, P16
   Frackowiak E, 2002, CARBON, V40, P1775, DOI 10.1016/S0008-6223(02)00045-3
   Jiang ZY, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201801433
   Kang SK, 2018, ACCOUNTS CHEM RES, V51, P988, DOI 10.1021/acs.accounts.7b00548
   Kim SJ, 2015, ELECTROCHIM ACTA, V163, P246, DOI 10.1016/j.electacta.2015.02.132
   Lei T, 2017, P NATL ACAD SCI USA, V114, P5107, DOI 10.1073/pnas.1701478114
   Li N, 2012, P NATL ACAD SCI USA, V109, P17360, DOI 10.1073/pnas.1210072109
   Li XL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5105
   Li YZ, 2016, NAT ENERGY, V1, DOI 10.1038/NENERGY.2015.29
   Liu N, 2014, NAT NANOTECHNOL, V9, P187, DOI [10.1038/nnano.2014.6, 10.1038/NNANO.2014.6]
   Liu W, 2017, ADV MATER, V29, DOI 10.1002/adma.201603436
   Ma K, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804306
   Mao L. J., 2017, ADV ENERGY MATER, V7, P19
   Ning HL, 2015, P NATL ACAD SCI USA, V112, P6573, DOI 10.1073/pnas.1423889112
   Rui XH, 2011, SOLID STATE IONICS, V187, P58, DOI 10.1016/j.ssi.2011.02.013
   Shan YL, 2019, CHEM ENG SCI, V200, P38, DOI 10.1016/j.ces.2019.01.043
   Shang H, 2018, ADV MATER, V30, DOI 10.1002/adma.201801459
   Share K, 2016, CHEM ENG SCI, V154, P3, DOI 10.1016/j.ces.2016.05.034
   Shi LR, 2017, NANO LETT, V17, P3681, DOI 10.1021/acs.nanolett.7b00906
   Sun HT, 2017, SCIENCE, V356, P599, DOI 10.1126/science.aam5852
   Wang G, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201702254
   Wang HY, 2017, CHEM ENG SCI, V174, P104, DOI 10.1016/j.ces.2017.09.007
   Wang JX, 2018, NANO ENERGY, V44, P272, DOI 10.1016/j.nanoen.2017.11.079
   Wang L, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201704858
   Wang S., 2017, ADV OPT MAT, V5, DOI DOI 10.1002/ADOM.201700023
   Wang SH, 2018, NATURE, V555, P83, DOI 10.1038/nature25494
   Wang XF, 2016, CHEM SOC REV, V45, P1308, DOI 10.1039/c5cs00708a
   Wang XH, 2014, NANO ENERGY, V5, P91, DOI 10.1016/j.nanoen.2014.02.005
   Wen KC, 2019, CHEM ENG SCI, V200, P80, DOI 10.1016/j.ces.2019.01.062
   Xu Q, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201601481
   Yu YF, 2013, SCI REP-UK, V3, DOI 10.1038/srep01866
   Zhang QH, 2018, ADV MATER, V30, DOI 10.1002/adma.201801435
   Zou MC, 2016, J MATER CHEM A, V4, P7398, DOI 10.1039/c6ta01071g
NR 45
TC 3
Z9 3
U1 51
U2 160
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 611
EP 618
DI 10.1016/j.ces.2019.06.043
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300050
DA 2020-05-12
ER

PT J
AU Yerrayya, A
   Natarajan, U
   Vinu, R
AF Yerrayya, Attada
   Natarajan, Upendra
   Vinu, R.
TI Fast pyrolysis of guaiacol to simple phenols: Experiments, theory and
   kinetic model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Guaiacol; Fast pyrolysis; Kinetics; Rate parameters; Density functional
   theory; Phenols
ID BOND-DISSOCIATION ENTHALPIES; DENSITY-FUNCTIONAL THEORY;
   THERMAL-DECOMPOSITION; REACTION PATHWAYS; LIGNIN DIMER; MECHANISM;
   COMBUSTION; CONVERSION; LINKAGES; RADICALS
AB This study is focused on both experimental and theoretical analysis of fast pyrolysis of guaiacol, a major pyrolysate and a model monomeric compound of lignin. Fast pyrolysis experiments were performed in an analytical pyrolyzer coupled with gas chromatograph/mass spectrometer in the temperature range of 450-650 degrees C. Thermodynamics and kinetics of 19 elementary reactions of 17 species were investigated using quantum chemical density functional theory calculations. Reaction pathways for the formation of four major phenols, viz. phenol, catechol, o-hydroxybenzaldehyde and o-cresol, were proposed. The homolytic cleavage of O-CH3 bond, with low bond dissociation energy of 57.7 kcal/mol, is shown to be the primary reaction for the generation of free radicals. The generation of o-hydroxyphenyl radical is found to be vital for the formation of phenol and cresol, while o-hydroxybenzyloxy radical is the key intermediate for the formation of o-hydroxybenzaldehyde. Multiple pathways for the formation of catechol were evaluated. A kinetic model was developed using the elementary reactions and their Arrhenius rate parameters. The concentration of the major products at different temperatures obtained from the model reasonably matched the trends in product yields from the experiments. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yerrayya, Attada; Natarajan, Upendra; Vinu, R.] Indian Inst Technol Madras, Dept Chem Engn, Chennai 600036, Tamil Nadu, India.
   [Vinu, R.] Indian Inst Technol Madras, Natl Ctr Combust Res & Dev, Chennai 600036, Tamil Nadu, India.
RP Vinu, R (reprint author), Indian Inst Technol Madras, Dept Chem Engn, Chennai 600036, Tamil Nadu, India.
EM vinu@iitm.ac.in
RI venkataraman, natarajan/X-3411-2019; Vinu, Ravikrishnan/AAJ-4635-2020
OI YERRAYYA, ATTADA/0000-0001-6788-5059
FU Department of Science and Technology (DST), IndiaDepartment of Science &
   Technology (India)
FX The authors are grateful to IIT Madras for the computational facilities.
   The National Centre for Combustion Research and Development is funded by
   Department of Science and Technology (DST), India. The authors thank
   Prof. Eliseo Ranzi of Politecnico di Milano, Italy, for the valuable
   suggestions.
CR Amen-Chen C, 2001, BIORESOURCE TECHNOL, V79, P277, DOI 10.1016/S0960-8524(00)00180-2
   Asmadi M, 2011, J ANAL APPL PYROL, V92, P88, DOI 10.1016/j.jaap.2011.04.011
   BATT L, 1979, INT J CHEM KINET, V11, P977, DOI 10.1002/kin.550110905
   BAULCH DL, 1994, J PHYS CHEM REF DATA, V23, P847, DOI 10.1063/1.555953
   Beste A, 2008, J PHYS CHEM A, V112, P4982, DOI 10.1021/jp800767j
   Beste A, 2010, ENERG FUEL, V24, P2857, DOI 10.1021/ef1001953
   Beste A, 2009, J ORG CHEM, V74, P2837, DOI 10.1021/jo9001307
   Britt PF, 2000, J ORG CHEM, V65, P1376, DOI 10.1021/jo991479k
   Choi YS, 2016, GREEN CHEM, V18, P1762, DOI 10.1039/c5gc02268a
   Dorrestijn E, 1999, J CHEM SOC PERK T 2, P777, DOI 10.1039/a809619h
   Dorrestijn E, 2000, J ANAL APPL PYROL, V54, P153, DOI 10.1016/S0165-2370(99)00082-0
   Elder T, 2014, ENERG FUEL, V28, P5229, DOI 10.1021/ef5013648
   Frisch M.J., 2016, GAUSSIAN 09 REVISION
   Furutani Y, 2017, J PHYS CHEM A, V121, P8495, DOI 10.1021/acs.jpca.7b08112
   HE YZ, 1988, J PHYS CHEM-US, V92, P2196, DOI 10.1021/j100319a023
   Huang JB, 2015, J ANAL APPL PYROL, V113, P655, DOI 10.1016/j.jaap.2015.04.012
   Huang JB, 2015, COMPUT THEOR CHEM, V1054, P80, DOI 10.1016/j.comptc.2014.12.007
   Huang JB, 2014, J ANAL APPL PYROL, V109, P98, DOI 10.1016/j.jaap.2014.07.007
   Huang JB, 2013, J RENEW SUSTAIN ENER, V5, DOI 10.1063/1.4816497
   [黄金保 Huang Jinbao], 2013, [燃料化学学报, Journal of Fuel Chemistry and Technology], V41, P657
   Huang XL, 2011, COMPUT THEOR CHEM, V976, P51, DOI 10.1016/j.comptc.2011.08.001
   Ince A, 2017, AICHE J, V63, P2089, DOI 10.1002/aic.15588
   Kim S, 2011, J PHYS CHEM LETT, V2, P2846, DOI 10.1021/jz201182w
   Klein MT, 2008, ENERG FUEL, V22, P2175, DOI 10.1021/ef800285f
   Liu C, 2016, J ANAL APPL PYROL, V118, P123, DOI 10.1016/j.jaap.2016.01.007
   Liu C, 2014, FUEL PROCESS TECHNOL, V123, P159, DOI 10.1016/j.fuproc.2014.01.002
   Liu JY, 2003, J CHEM PHYS, V119, P7214, DOI 10.1063/1.1605938
   MULCAHY MFR, 1963, NATURE, V199, P761, DOI 10.1038/199761a0
   Mullen CA, 2010, FUEL PROCESS TECHNOL, V91, P1446, DOI 10.1016/j.fuproc.2010.05.022
   Nair V, 2016, J ANAL APPL PYROL, V119, P31, DOI 10.1016/j.jaap.2016.03.020
   Nowakowska M, 2018, J PHYS CHEM A, V122, P7894, DOI 10.1021/acs.jpca.8b06301
   Nowakowska M, 2014, COMBUST FLAME, V161, P1474, DOI 10.1016/j.combustflame.2013.11.024
   Nowakowski DJ, 2010, J ANAL APPL PYROL, V88, P53, DOI 10.1016/j.jaap.2010.02.009
   Parthasarathi R, 2011, J PHYS CHEM LETT, V2, P2660, DOI 10.1021/jz201201q
   Patwardhan PR, 2011, CHEMSUSCHEM, V4, P1629, DOI 10.1002/cssc.201100133
   Pelucchi M, 2019, REACT CHEM ENG, V4, P490, DOI 10.1039/c8re00198g
   Poutsma ML, 2000, J ANAL APPL PYROL, V54, P5, DOI 10.1016/S0165-2370(99)00083-2
   Proano-Aviles J, 2017, ENERGY TECHNOL-GER, V5, P189, DOI 10.1002/ente.201600279
   Resende FLP, 2008, ENERG FUEL, V22, P1328, DOI 10.1021/ef700574k
   Robichaud DJ, 2016, GREEN CHEM SUSTAIN T, P145, DOI 10.1007/978-981-287-769-7_8
   Verma AM, 2016, CHEMISTRYSELECT, V1, P6196, DOI 10.1002/slct.201601139
   Vinu R, 2012, ANNU REV CHEM BIOMOL, V3, P29, DOI 10.1146/annurev-chembioeng-062011-081108
   Wang M, 2016, J ANAL APPL PYROL, V117, P325, DOI 10.1016/j.jaap.2015.10.016
   WESTBROOK CK, 1977, J PHYS CHEM-US, V81, P2542, DOI 10.1021/j100540a036
   Windt M, 2009, J ANAL APPL PYROL, V85, P38, DOI 10.1016/j.jaap.2008.11.011
NR 45
TC 0
Z9 0
U1 14
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 619
EP 630
DI 10.1016/j.ces.2019.06.025
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300051
DA 2020-05-12
ER

PT J
AU Jia, HW
   Xiao, X
   Kang, YM
AF Jia, Hongwei
   Xiao, Xin
   Kang, Yanming
TI Investigation of bubble behavior with phase change under the effect of
   noncondensable gas
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Noncondensable gas (NCG); Bubble dynamics; Mass transfer; Condensation;
   Subcooled boiling
ID LAMINAR-FILM CONDENSATION; SINGLE VAPOR BUBBLE; MASS-TRANSFER; CFD
   SIMULATION; FLOW; EVAPORATION; STEAM; AIR; DYNAMICS; SHAPES
AB An Arbitrary-Lagrangian-Eulerian based numerical method is proposed to study the phase change bubble under the effect of noncondensable gas (NCG). In order to validate the underlying mathematical model, benchmark tests, including the bubble growth in quiescent superheated liquid and the condensation of rising bubble with NCG, are conducted. The numerical results by the phase change model, in which the mass transfer rate is directly determined by interfacial heat flux, is found to agree fairly well with analytical results, and the calculation of fluid flow and heat transfer by the present numerical approach is reasonable. Moreover, the numerical results of free rising bubble condensation with NCG are found to present good agreement with the experimental data on the evolution of bubble size, and the mass balance of the NCGs is proved to be achieved by the model. Finally, the subcooled boiling with NCG on a biphilic surface is numerically investigated, and the bubble behavior and internal distribution of the NCG are studied in detail. In the presence of NCG, the bubbles can even depart from the walls that are negatively superh yeated. The bubble keeps the bowl-shape for a long time before necking, which is consistent with the experimental observations. The contact line is found to stay at the boundary between the hydrophilic and hydrophobic surfaces. The results also show that the local accumulation of the NCG near the bubble surface decreases the local apparent saturation temperature and inhibits the condensation, and the growth and departure of bubbles is thus promoted. In addition, the amount of NCG in the bubble is found to determine whether the bubble in the subcooled boiling is detached or not. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jia, Hongwei; Kang, Yanming] Donghua Univ, Sch Environm Sci & Engn, Shanghai 201620, Peoples R China.
   [Xiao, Xin] Univ Hull, Sch Engn & Comp Sci, Kingston Upon Hull HU6 7RX, N Humberside, England.
RP Kang, YM (reprint author), Donghua Univ, Sch Environm Sci & Engn, Shanghai 201620, Peoples R China.
EM ymkang@dhu.edu.cn
OI jia, hongwei/0000-0001-7726-1370
FU Shanghai Sailing Program [18YF1400700]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018M641892]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51578121]; Fundamental Research Funds for the Central
   Universities of ChinaFundamental Research Funds for the Central
   Universities [2232018D3-37]
FX This work was supported by the Shanghai Sailing Program [Grant No.
   18YF1400700]; the China Postdoctoral Science Foundation [Grant No.
   2018M641892]; the National Natural Science Foundation of China [Grant
   No. 51578121]; the Fundamental Research Funds for the Central
   Universities of China [Grant No. 2232018D3-37]. The authors are very
   grateful to Dr. B. Shen for providing selfless detailed experimental
   data for the comparison and analysis.
CR Aktinol E, 2014, INT J HEAT MASS TRAN, V79, P251, DOI 10.1016/j.ijheatmasstransfer.2014.08.014
   Antoine C., 1888, CR HEBD ACAD SCI, V107, P681
   Collier J., 1981, CONVECTIVE BOILING C
   Esmaeeli A, 2004, INT J HEAT MASS TRAN, V47, P5451, DOI 10.1016/j.ijheatmasstransfer.2004.07.027
   Falcone M, 2018, CHEM ENG SCI, V177, P523, DOI 10.1016/j.ces.2017.11.024
   FULLER EN, 1969, J PHYS CHEM-US, V73, P3679, DOI 10.1021/j100845a020
   GRACE JR, 1973, T I CHEM ENG-LOND, V51, P116
   Gusarov AV, 2002, PHYS FLUIDS, V14, P4242, DOI 10.1063/1.1516211
   Hampson H, 1951, CONDENSATION STEAM M, P58
   Huang J, 2015, APPL THERM ENG, V89, P469, DOI 10.1016/j.applthermaleng.2015.06.040
   ISENBERG J, 1970, INT J HEAT MASS TRAN, V13, P997, DOI 10.1016/0017-9310(70)90166-3
   Jafari R, 2016, APPL MATH COMPUT, V272, P593, DOI 10.1016/j.amc.2015.03.042
   Jeon SS, 2011, CHEM ENG SCI, V66, P5899, DOI 10.1016/j.ces.2011.08.011
   Jia HW, 2015, APPL THERM ENG, V88, P248, DOI 10.1016/j.applthermaleng.2014.09.022
   Jia HW, 2019, INT J HEAT MASS TRAN, V137, P545, DOI 10.1016/j.ijheatmasstransfer.2019.03.117
   Kalman H, 2003, INT J HEAT MASS TRAN, V46, P3451, DOI 10.1016/S0017-9310(03)00128-5
   Kalman H, 1999, J FLUID ENG-T ASME, V121, P496, DOI 10.1115/1.2822236
   Kalman H, 2002, CHEM ENG J, V85, P197, DOI 10.1016/S1385-8947(01)00150-4
   Kalman H, 1987, J HEAT TRANSF, V109, P241
   Kamei S, 1990, EXP HEAT TRANSFER, V3, P173, DOI 10.1080/08916159008946385
   Kunkelmann C, 2009, NUMER HEAT TR A-APPL, V56, P631, DOI 10.1080/10407780903423908
   LEE K, 1968, INT J HEAT MASS TRAN, V11, P1013, DOI 10.1016/0017-9310(68)90007-0
   LERNER Y, 1987, J HEAT TRANS-T ASME, V109, P509, DOI 10.1115/1.3248112
   Magnini M, 2012, CFD MODELING 2 PHASE
   Marek R, 2001, INT J HEAT MASS TRAN, V44, P39, DOI 10.1016/S0017-9310(00)00086-7
   Marek R, 2001, INT J HEAT MASS TRAN, V44, P619, DOI 10.1016/S0017-9310(00)00124-1
   Oh S, 2006, INT J HEAT MASS TRAN, V49, P2523, DOI 10.1016/j.ijheatmasstransfer.2006.01.021
   Othmer DF, 1929, IND ENG CHEM, V21, P576, DOI 10.1021/ie50234a018
   Pan LM, 2012, NUCL ENG DES, V248, P126, DOI 10.1016/j.nucengdes.2012.04.001
   PLESSET MS, 1954, J APPL PHYS, V25, P493, DOI 10.1063/1.1721668
   Poling B. E, 2004, PROPERTIES GASES LIQ, P644
   Qu XH, 2016, CHEM ENG SCI, V144, P216, DOI 10.1016/j.ces.2015.09.009
   Qu XH, 2016, NUCL ENG DES, V297, P44, DOI 10.1016/j.nucengdes.2015.11.011
   Revankar ST, 2005, APPL MATH MODEL, V29, P341, DOI 10.1016/j.apm.2004.09.010
   Sanjari E, 2013, INT J REFRIG, V36, P1327, DOI 10.1016/j.ijrefrig.2013.01.007
   Sato Y, 2013, J COMPUT PHYS, V249, P127, DOI 10.1016/j.jcp.2013.04.035
   SCRIVEN LE, 1959, CHEM ENG SCI, V10, P1, DOI 10.1016/0009-2509(59)80019-1
   Shang D, 2011, HEAT MASS TRANSF, P1, DOI 10.1007/978-3-642-12581-2
   Shen BA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02163-8
   SLEGERS L, 1970, INT J HEAT MASS TRAN, V13, P1941, DOI 10.1016/0017-9310(70)90094-3
   Tang JG, 2015, EXP THERM FLUID SCI, V61, P210, DOI 10.1016/j.expthermflusci.2014.11.009
   Tian WX, 2010, ANN NUCL ENERGY, V37, P5, DOI 10.1016/j.anucene.2009.10.011
   Ullmann A, 1989, J HEAT TRANS-T ASME, V111, P1060, DOI 10.1115/1.3250768
   Zeng QY, 2015, PROG NUCL ENERG, V83, P336, DOI 10.1016/j.pnucene.2015.04.011
   Zhang P, 2016, CHEM ENG J, V306, P978, DOI 10.1016/j.cej.2016.08.034
   Zheng SF, 2018, INT J HEAT MASS TRAN, V120, P879, DOI 10.1016/j.ijheatmasstransfer.2017.12.059
NR 46
TC 0
Z9 0
U1 10
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 631
EP 643
DI 10.1016/j.ces.2019.07.003
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300052
DA 2020-05-12
ER

PT J
AU Makeev, AG
   Peskov, NV
   Semendyaeva, NL
   Slinko, MM
   Bychkov, VY
   Korchak, VN
AF Makeev, Alexei G.
   Peskov, Nickolai, V
   Semendyaeva, Natalia L.
   Slinko, Marina M.
   Bychkov, Victor Yu
   Korchak, Vladimir N.
TI Mathematical modeling of oscillations during CO oxidation on Ni under
   reducing conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO oxidation; Ni catalyst; Mathematical modeling; Oscillations
ID PT-GROUP METALS; PRESSURES. 2. PALLADIUM; STICKING PROBABILITIES;
   ULTRAHIGH-VACUUM; CARBON-MONOXIDE; SURFACE; NICKEL; OXYGEN; OXIDE;
   TEMPERATURE
AB This paper presents the first mathematical model simulating the recently discovered oscillatory behavior during CO oxidation on a Ni foil in a continuous-flow catalytic reactor. These oscillations occur in the presence of excess CO; thus, the well-known Sales-Turner-Maple model, simulating oscillations in oxygen excess, cannot be applied. We suggest a modification of the Sales-Turner-Maple model by introducing the precursor-mediated adsorption of CO. This made it possible to simulate the oscillations under reducing conditions. The suggested microkinetic model coupled with a continuous-flow reactor model predicts that the oscillations proceed on the partially oxidized catalyst because of the periodic formation and reduction of the surface oxide. The introduction of oxygen diffusion into the subsurface layers allows the description of the experimentally observed variation in Ni color during the oscillatory cycle. The developed model successfully reproduces experimental data as the temperature range of the oscillations together with their shape and amplitudes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Makeev, Alexei G.; Peskov, Nickolai, V; Semendyaeva, Natalia L.] Lomonosov Moscow State Univ, Fac Computat Math & Cybernet, Moscow, Russia.
   [Slinko, Marina M.; Bychkov, Victor Yu; Korchak, Vladimir N.] Semenov Inst Chem Phys, Moscow, Russia.
RP Slinko, MM (reprint author), Semenov Inst Chem Phys, Moscow, Russia.
EM slinko@polymer.chph.ras.ru
RI Makeev, Alexei G/D-6993-2012
OI Makeev, Alexei G/0000-0002-2646-4538
FU Russian Science FoundationRussian Science Foundation (RSF) [N
   17-13-01057]
FX This work was supported by the Russian Science Foundation (grant N
   17-13-01057).
CR BEHM RJ, 1985, SURF SCI, V160, P387, DOI 10.1016/0039-6028(85)90782-4
   Bychkov VY, 2018, CATAL LETT, V148, P653, DOI 10.1007/s10562-017-2283-2
   BYKOV VI, 1981, SURF SCI, V107, pL334, DOI 10.1016/0167-2584(81)90536-3
   COLLINS NA, 1987, SURF SCI, V180, P136, DOI 10.1016/0039-6028(87)90040-9
   Dicke J, 2000, SURF SCI, V454, P352, DOI 10.1016/S0039-6028(00)00189-8
   Doedel E, 1991, INT J BIFURCAT CHAOS, V1, P493, DOI 10.1142/S0218127491000397
   ENGEL T, 1979, ADV CATAL, V28, P1
   Ertl G, 2000, ADV CATAL, V45, P1
   FEIGERLE CS, 1990, J CHEM PHYS, V93, P787, DOI 10.1063/1.459532
   Figueroa SJA, 2014, J CATAL, V312, P69, DOI 10.1016/j.jcat.2014.01.006
   Freund HJ, 2011, ANGEW CHEM INT EDIT, V50, P10064, DOI 10.1002/anie.201101378
   Gao F, 2009, J PHYS CHEM C, V113, P174, DOI 10.1021/jp8077985
   Gao F, 2010, J PHYS CHEM C, V114, P6874, DOI 10.1021/jp100134e
   Hendriksen BLM, 2010, NAT CHEM, V2, P730, DOI 10.1038/nchem.728
   Hendriksen BLM, 2005, CATAL TODAY, V105, P234, DOI 10.1016/j.cattod.2005.02.041
   HOLLOWAY PH, 1981, SURF SCI, V111, P300, DOI 10.1016/0039-6028(80)90710-4
   IMBIHL R, 1995, CHEM REV, V95, P697, DOI 10.1021/cr00035a012
   JOYNER RW, 1974, J CHEM SOC FARAD T 1, V70, P1819, DOI 10.1039/f19747001819
   KISLIUK P, 1957, J PHYS CHEM SOLIDS, V3, P95, DOI 10.1016/0022-3697(57)90054-9
   LABOHM F, 1983, SURF SCI, V135, P409, DOI 10.1016/0039-6028(83)90233-9
   Lund CD, 2000, SURF SCI, V459, P413, DOI 10.1016/S0039-6028(00)00482-9
   Makeev AG, 2019, APPL CATAL A-GEN, V571, P127, DOI 10.1016/j.apcata.2018.11.015
   McClure SM, 2009, CHEM PHYS LETT, V469, P1, DOI 10.1016/j.cplett.2008.12.066
   McEwen JS, 2009, J PHYS CHEM C, V113, P17045, DOI 10.1021/jp901975w
   Monnerat B, 2003, CHEM ENG SCI, V58, P4911, DOI 10.1016/j.ces.2002.11.006
   Nekhamkina O, 2003, J CHEM PHYS, V119, P2322, DOI 10.1063/1.1584651
   Noh MC, 2018, CHEMCATCHEM, V10, P2046, DOI 10.1002/cctc.201702002
   Peng GW, 2010, J PHYS CHEM C, V114, P21579, DOI 10.1021/jp108475e
   SALES BC, 1982, SURF SCI, V114, P381, DOI 10.1016/0039-6028(82)90692-6
   Singh J, 2010, CHEMCATCHEM, V2, P653, DOI 10.1002/cctc.201000061
   SLINKO MG, 1978, CATAL REV, V17, P119, DOI 10.1080/03602457808080880
   Slinko MM, 1994, STUD SURF SCI CATAL, V86, P1
   STUCKLESS JT, 1993, J CHEM PHYS, V99, P2202, DOI 10.1063/1.465282
   Stuckless JT, 1997, J CHEM PHYS, V106, P2012, DOI 10.1063/1.473308
   Yang WS, 2000, CATAL TODAY, V61, P237, DOI 10.1016/S0920-5861(00)00368-0
NR 35
TC 6
Z9 6
U1 5
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 644
EP 652
DI 10.1016/j.ces.2019.06.053
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300053
DA 2020-05-12
ER

PT J
AU Zhou, Y
   Zhu, J
AF Zhou, Yandaizi
   Zhu, Jesse
TI Group C+ particles: Enhanced flow and fluidization of fine powders with
   nano-modulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Group C+ particles; Nanoparticle modulation; Pseudo-particulate
   fluidization; Flowability; Bed expansion
ID COHESIVE PARTICLES; GAS; BEHAVIOR; SIZE; BEDS; FLOWABILITY; FORCES;
   IMPROVEMENT; VOIDAGE; BUBBLE
AB The main challenge in the flow and fluidization of Geldart Group C particles is their cohesive nature due to strong interparticle forces. The "nanoparticle modulation" technique is adopted to reduce the interparticle forces of Group C particles and thus significantly improve their flow and fluidization quality. Group C+ particles, a new type of fine particles with drastically reduced or insignificant interparticle forces, are created using the nano-modulation technique. Fundamental studies provided a comprehensive understanding of the flow and fluidization quality of Group C+ particles. Nano-modulation led to major enhancements to both the static and dynamic flowability of Group C+ particles. Moreover, Group C+ particles exhibited revolutionary advancements in fluidization, which enabled its pseudo-particulate fluidization over a wide range of operating gas velocities, up to 200-300% times that of bed expansion. The high bed expansion allows more gas to be retained in the bed and provides large volumes for gassolid interfacial contact, thus promoting chemical reactions, especially gas phase catalytic reactions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhou, Yandaizi; Zhu, Jesse] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
RP Zhu, J (reprint author), Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
EM jzhu@uwo.ca
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917
CR ABRAHAMSEN AR, 1980, POWDER TECHNOL, V26, P47, DOI 10.1016/0032-5910(80)85006-6
   American Society for Testing and Materials, 2008, COMM D18 SOIL ROCK S
   [Anonymous], 2006, D612806 ASTM
   BAERNS M, 1966, IND ENG CHEM FUND, V5, P508, DOI 10.1021/i160020a013
   BARRETO GF, 1983, CHEM ENG SCI, V38, P345, DOI 10.1016/0009-2509(83)80152-3
   Chen YH, 2008, AICHE J, V54, P104, DOI 10.1002/aic.11368
   CHIRONE R, 1993, CHEM ENG SCI, V48, P41, DOI 10.1016/0009-2509(93)80281-T
   CHIRONE R, 1994, CHEM ENG SCI, V49, P1185, DOI 10.1016/0009-2509(94)85089-5
   Dai WL, 2001, APPL SURF SCI, V177, P172, DOI 10.1016/S0169-4332(01)00229-X
   Donsi G., 1973, AICHE J, V18, P239
   Dutta A., 1990, AICHE S SER, V86, P26
   GELDART D, 1984, CHEM ENG SCI, V39, P1481, DOI 10.1016/0009-2509(84)80006-8
   GELDART D, 1978, POWDER TECHNOL, V19, P133, DOI 10.1016/0032-5910(78)80084-9
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   GELDART D, 1972, POWDER TECHNOL, V6, P201, DOI 10.1016/0032-5910(72)83014-6
   Han M Q., 2015, THESIS
   Hancock BC, 2004, J PHARMACEUT BIOMED, V35, P979, DOI 10.1016/j.jpba.2004.02.035
   Hierso JC, 1998, APPL ORGANOMET CHEM, V12, P161, DOI 10.1002/(SICI)1099-0739(199803)12:3<161::AID-AOC689>3.3.CO;2-Y
   Huang Q, 2010, PARTICUOLOGY, V8, P19, DOI 10.1016/j.partic.2009.05.007
   Jono K, 2000, POWDER TECHNOL, V113, P269, DOI 10.1016/S0032-5910(00)00310-7
   KAMATH S, 1993, POWDER TECHNOL, V76, P277, DOI 10.1016/S0032-5910(05)80009-9
   Kashu Seiichiro, 2012, SUPERFINE PARTICLE T
   Knowlton T. M., 1994, CHEM ENG PROGR US, V90
   Krantz M, 2009, POWDER TECHNOL, V194, P239, DOI 10.1016/j.powtec.2009.05.001
   Kuipers NJM, 1996, CHEM ENG SCI, V51, P2727, DOI 10.1016/0009-2509(96)00143-1
   LAUGA C, 1991, POWDER TECHNOL, V65, P461, DOI 10.1016/0032-5910(91)80208-Z
   Lepek D, 2010, AICHE J, V56, P54, DOI 10.1002/aic.11954
   MARRING E, 1994, POWDER TECHNOL, V79, P1, DOI 10.1016/0032-5910(94)02810-9
   Nakamura H, 2008, POWDER TECHNOL, V183, P324, DOI 10.1016/j.powtec.2008.01.007
   Quintanilla MAS, 2006, AICHE J, V52, P1715, DOI 10.1002/aic.10770
   ROWE PN, 1978, CHEM ENG SCI, V33, P133, DOI 10.1016/0009-2509(78)85079-9
   Sanguansri P, 2006, TRENDS FOOD SCI TECH, V17, P547, DOI 10.1016/j.tifs.2006.04.010
   SANJURJO A, 1991, SURF COAT TECH, V49, P110, DOI 10.1016/0257-8972(91)90040-4
   Sathish M, 2005, CHEM MATER, V17, P6349, DOI 10.1021/cm052047v
   SCHWEDES J, 1990, POWDER TECHNOL, V61, P59, DOI 10.1016/0032-5910(90)80066-8
   Shur J, 2008, PHARM RES-DORDR, V25, P1931, DOI 10.1007/s11095-008-9538-y
   TODA Y, 1989, CERAM INT, V15, P161, DOI 10.1016/0272-8842(89)90011-4
   Vidal BC, 2011, APPL BIOCHEM BIOTECH, V164, P1405, DOI 10.1007/s12010-011-9221-3
   VISSER J, 1989, POWDER TECHNOL, V58, P1, DOI 10.1016/0032-5910(89)80001-4
   Xie HY, 1997, POWDER TECHNOL, V94, P99, DOI 10.1016/S0032-5910(97)03270-1
   Xu C., 2006, 5 WORLD C PART TECHN
   Xu CB, 2005, CHEM ENG SCI, V60, P6529, DOI 10.1016/j.ces.2005.05.062
   Xu CC, 2009, CAN J CHEM ENG, V87, P403, DOI 10.1002/cjce.20179
   Yamamoto K, 2009, NAT CHEM, V1, P397, DOI [10.1038/NCHEM.288, 10.1038/nchem.288]
   Yang J, 2005, POWDER TECHNOL, V158, P21, DOI 10.1016/j.powtec.2005.04.032
   YATES JG, 1986, CHEM ENG SCI, V41, P801, DOI 10.1016/0009-2509(86)87160-3
   Zhou Q, 2011, POWDER TECHNOL, V207, P414, DOI 10.1016/j.powtec.2010.11.028
   Zhou T, 1999, POWDER TECHNOL, V102, P215, DOI 10.1016/S0032-5910(98)00211-3
   Zhu J, 2004, U.S. Patent, Patent No. [6,833,185, 6833185]
   Zhu J., 2003, GRANULAR MAT FUNDAME, P270
   Zhu J.-X., 2007, U.S. Patent, Patent No. 7240861
NR 51
TC 2
Z9 2
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 653
EP 662
DI 10.1016/j.ces.2019.06.056
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300054
DA 2020-05-12
ER

PT J
AU Peng, C
   Kong, B
   Zhou, J
   Sun, B
   Passalacqua, A
   Subramaniam, S
   Fox, RO
AF Peng, C.
   Kong, B.
   Zhou, J.
   Sun, B.
   Passalacqua, A.
   Subramaniam, S.
   Fox, R. O.
TI Implementation of pseudo-turbulence closures in an Eulerian-Eulerian
   two-fluid model for non-isothermal gas-solid flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Pseudo-turbulent heat flux; Two-fluid
   model; Gas-solid flow
ID DIRECT NUMERICAL-SIMULATION; FICTITIOUS DOMAIN METHOD; BIOMASS FAST
   PYROLYSIS; HEAT-TRANSFER; PARTICULATE FLOWS; BIDISPERSE ARRAYS; DRAG
   LAW; MONODISPERSE; SUSPENSIONS; ASSEMBLIES
AB The Eulerian-Eulerian two-fluid model is widely used for computational fluid dynamics simulations of gas-solid flows. For non-isothermal flows, the averaged conservation equations solved in the two-fluid model require closures for drag, gas-solid heat transfer, pseudo-turbulent velocity fluctuations and the pseudo-turbulent heat flux (PTHF). However, the pseudo-turbulence terms are usually neglected in two-fluid simulations due to the lack of accurate correlations. With the increase in computational power, closures for these terms are now available from particle-resolved direct-numerical simulation (PR-DNS). Here, the PTHF closure as well as the heat-transfer closure (i.e., the Nusselt number) extracted from PR-DNS are implemented in the two-fluid thermal energy equation in OpenFOAM. The implementation is validated by comparing the simulation results with the PR-DNS data for the temperature profiles. Based on the analysis of the thermal energy budget, the PTHF can have a significant contribution and neglecting it can lead to large errors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Peng, C.; Fox, R. O.] Iowa State Univ, Dept Chem & Biol Engn, 618 Bissell Rd, Ames, IA 50011 USA.
   [Kong, B.] US DOE, Ames Lab, Ames, IA 50011 USA.
   [Zhou, J.; Sun, B.; Passalacqua, A.; Subramaniam, S.] Iowa State Univ, Dept Mech Engn, Ames, IA 50011 USA.
   [Peng, C.; Kong, B.; Zhou, J.; Sun, B.; Passalacqua, A.; Subramaniam, S.; Fox, R. O.] Iowa State Univ, Ctr Multiphase Flow Res & Educ CoMFRE, Ames, IA 50011 USA.
RP Peng, C (reprint author), Iowa State Univ, Dept Chem & Biol Engn, 618 Bissell Rd, Ames, IA 50011 USA.
EM cpeng@iastate.edu; kongbo@iastate.edu; jiazhong@liastate.edu;
   bo.sun@ansys.com; albertop@iastate.edu; shankar@iastate.edu;
   rofox@iastate.edu
RI Kong, Bo/AAL-2011-2020
OI Kong, Bo/0000-0001-6160-7517; Fox, Rodney/0000-0003-1944-1861
FU U.S. National Science FoundationNational Science Foundation (NSF)
   [CBET-1336941, ACI-1440443]
FX The authors gratefully acknowledge support from the U.S. National
   Science Foundation through grant CBET-1336941 and ACI-1440443.
CR ADRIAN RJ, 1991, ANNU REV FLUID MECH, V23, P261, DOI 10.1146/annurev.fluid.23.1.261
   Adrian RJ, 2005, EXP FLUIDS, V39, P159, DOI 10.1007/s00348-005-0991-7
   ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007
   Bagchi P, 2003, PHYS FLUIDS, V15, P3496, DOI 10.1063/1.1616031
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Burton TM, 2005, J FLUID MECH, V545, P67, DOI 10.1017/S0022112005006889
   Crimaldi JP, 2008, EXP FLUIDS, V44, P851, DOI 10.1007/s00348-008-0496-2
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Deen NG, 2012, CHEM ENG SCI, V81, P329, DOI 10.1016/j.ces.2012.06.055
   Drew D.A., 1998, THEORY MULTICOMPONEN
   Feng ZG, 2009, INT J HEAT MASS TRAN, V52, P777, DOI 10.1016/j.ijheatmasstransfer.2008.07.023
   Fox RO, 2006, ADV CHEM ENG, V31, P231, DOI DOI 10.1016/S0065-2377(06)31004-6
   FOX RO, 2003, COMPUTATIONAL MODELS
   Gvozdic B, 2018, J FLUID MECH, V845, P226, DOI 10.1017/jfm.2018.213
   Haeri S, 2013, J COMPUT PHYS, V237, P21, DOI 10.1016/j.jcp.2012.11.050
   Hill RJ, 2001, J FLUID MECH, V448, P213, DOI 10.1017/S0022112001005948
   Homann H, 2010, J FLUID MECH, V651, P81, DOI 10.1017/S0022112010000923
   Kashiwa B., 2003, LAUR031295 LOS AL NA
   Kidanemariam AG, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/2/025031
   Lu J., 2018, THESIS
   Lucci F, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3553279
   Marchisio DL, 2007, CISM COUR L, P41
   Mehrabadi M, 2015, J FLUID MECH, V770, P210, DOI 10.1017/jfm.2015.146
   Naso A, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/3/033040
   Passalacqua A, 2018, CHEM ENG SCI, V176, P306, DOI 10.1016/j.ces.2017.10.043
   Risso F, 2018, ANNU REV FLUID MECH, V50, P25, DOI 10.1146/annurev-fluid-122316-045003
   Subramaniam S, 2014, STUDYING TURBULENCE, P5
   Sun B, 2015, INT J HEAT MASS TRAN, V86, P898, DOI 10.1016/j.ijheatmasstransfer.2015.03.046
   Sun B, 2016, THESIS
   Sun B, 2016, J FLUID MECH, V798, P299, DOI 10.1017/jfm.2016.290
   Sun J, 2007, J FLUID ENG-T ASME, V129, P1394, DOI 10.1115/1.2786530
   Syamlal M, 2006, DOENETL20071259
   Syamlal M., 1993, DOEMETC951013 NAT EN
   Syamlal M, 2006, COLLABORATORY MULTIP
   Tavanashad V., 2018, ACTA MECH, P1
   Tavassoli H, 2013, INT J MULTIPHAS FLOW, V57, P29, DOI 10.1016/j.ijmultiphaseflow.2013.06.009
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Tenneti S, 2011, INT J MULTIPHAS FLOW, V37, P1072, DOI 10.1016/j.ijmultiphaseflow.2011.05.010
   Tenneti S, 2010, POWDER TECHNOL, V203, P57, DOI 10.1016/j.powtec.2010.03.042
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   Uhlmann M, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2912459
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   VANCRUYNINGEN I, 1990, EXP FLUIDS, V10, P41, DOI 10.1007/BF00187871
   Xu Y, 2010, FLOW TURBUL COMBUST, V85, P735, DOI 10.1007/s10494-010-9298-8
   Xue Q, 2012, FUEL, V97, P757, DOI 10.1016/j.fuel.2012.02.065
   Xue Q, 2011, CHEM ENG SCI, V66, P2440, DOI 10.1016/j.ces.2011.03.010
   Yin XL, 2009, IND ENG CHEM RES, V48, P227, DOI 10.1021/ie800171p
   Yu ZS, 2006, J COMPUT PHYS, V217, P424, DOI 10.1016/j.jcp.2006.01.016
NR 49
TC 1
Z9 1
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 663
EP 671
DI 10.1016/j.ces.2019.06.054
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300055
DA 2020-05-12
ER

PT J
AU Shi, HB
   Li, MD
   Nikrityuk, P
   Liu, QX
AF Shi, Hongbo
   Li, Mingda
   Nikrityuk, Petr
   Liu, Qingxia
TI Experimental and numerical study of cavitation flows in venturi tubes:
   From CFD to an empirical model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cavitation; Experiments; Benchmark; CFD; Scale up
ID HYDRODYNAMIC CAVITATION; VALIDATION; PARTICLES; DESIGN
AB This work is devoted to experimental and numerical studies of cavitation phenomena in Venturi tubes with different geometries. A two-phase mixture model has been validated against experimental data. The numerical results showed good agreement with the experimental data. Experimental studies have been carried out for two different Venturi tubes with convergent angles of 19 degrees and 45 degrees, respectively. The effect of the convergent angle on the cavitation performance was investigated experimentally and numerically. Both the numerical and experimental studies reveal that the change in the convergent angle has significant effects on flow characteristics and the generation of cavitation. It was shown that a 45 degrees convergent angle enhances cavitation in comparison with 19 degrees angle. A scaled-up study of the Venturi geometry has been conducted using CFD-based numerical simulations. Finally, a semi-empirical model enabling the prediction of cavitation in Venturi tubes has been developed and validated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Hongbo; Li, Mingda; Nikrityuk, Petr; Liu, Qingxia] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
RP Nikrityuk, P (reprint author), Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
EM nikrityu@ualberta.ca
FU Natural Science and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Canadian Centre for Clean Coal/Carbon and the Mineral Processing
   Technologies (C5MPT); Canadian Mining Industry Research Organization
   (CAMIRO)
FX Financial support from the Natural Science and Engineering Research
   Council of Canada (NSERC), the Canadian Centre for Clean Coal/Carbon and
   the Mineral Processing Technologies (C5MPT) and Canadian Mining Industry
   Research Organization (CAMIRO) is greatly appreciated.
CR Ashrafizadeh SM, 2015, FLOW MEAS INSTRUM, V42, P6, DOI 10.1016/j.flowmeasinst.2014.12.007
   Bashir TA, 2011, CAN J CHEM ENG, V89, P1366, DOI 10.1002/cjce.20500
   Brennen CE, 2014, CAVITATION AND BUBBLE DYNAMICS, P1
   Chen BX, 2018, COMPUT FLUIDS, V162, P1, DOI 10.1016/j.compfluid.2017.12.002
   Chung J, 2009, SER OPER SUPP CH MAN, V3, P7
   Gagol M, 2018, CHEM ENG J, V338, P599, DOI 10.1016/j.cej.2018.01.049
   Hosseininejad Seyed Shaham Aldin, 2016, THESIS
   Inc Ansys, 2011, ANSYS FLUENT THEOR G, P794
   Jangir N, 2017, CHEM ENG PROCESS, V122, P128, DOI 10.1016/j.cep.2017.10.008
   Knapp R. T., 1970, CAVITATION
   Kumar KS, 2007, CHEM ENG SCI, V62, P2698, DOI 10.1016/j.ces.2007.02.010
   LEONARD BP, 1979, COMPUT METHOD APPL M, V19, P59, DOI 10.1016/0045-7825(79)90034-3
   Li DH, 2018, INT COMMUN HEAT MASS, V97, P17, DOI 10.1016/j.icheatmasstransfer.2018.06.001
   Li H., 2014, THESIS
   Li H, 2008, KEY ENG MATER, V385-387, P413, DOI 10.4028/www.scientific.net/KEM.385-387.413
   Liu HL, 2013, WATER SCI ENG, V6, P331, DOI 10.3882/j.issn.1674-2370.2013.03.009
   Margot X, 2012, ENG APPL COMP FLUID, V6, P15, DOI 10.1080/19942060.2012.11015399
   MATLAB User's Guide, 1998, MATLAB US GUID, V5, P333
   Mendenhall W., 1996, 2 COURSE STAT REGRES, V5
   Oliveira H, 2018, MINER ENG, V116, P32, DOI 10.1016/j.mineng.2017.10.020
   Rahman A, 2014, INT J MIN SCI TECHNO, V24, P559, DOI 10.1016/j.ijmst.2014.05.021
   SCHEFFE H, 1947, J AM STAT ASSOC, V42, P425, DOI 10.2307/2280545
   Schnerr G.H., 2001, 4 INT C MULT FLOW NE, V1
   Shi HB, 2019, POWDER TECHNOL, V343, P479, DOI 10.1016/j.powtec.2018.11.043
   Srinivasan V, 2010, CHEM ENG SCI, V65, P2782, DOI 10.1016/j.ces.2010.01.006
   Tao D, 2004, SEPAR SCI TECHNOL, V39, P741, DOI 10.1081/SS-120028444
   THOMSON GW, 1946, CHEM REV, V38, P1, DOI 10.1021/cr60119a001
   YOON R H, 1986, COAL PREP, V2, P179
   Yoon RH, 1997, J COLLOID INTERF SCI, V185, P363, DOI 10.1006/jcis.1996.4583
   Zhang JX, 2017, AIP ADV, V7, DOI 10.1063/1.4991441
   Zhao Liang, 2019, INT J MULTIPHASE FLO
   Zhou WG, 2016, INT J MINER PROCESS, V157, P236, DOI 10.1016/j.minpro.2016.11.003
   Zhou ZA, 1997, INT J MINER PROCESS, V51, P139, DOI 10.1016/S0301-7516(97)00026-4
NR 33
TC 3
Z9 3
U1 31
U2 64
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 672
EP 687
DI 10.1016/j.ces.2019.07.004
PG 16
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300056
DA 2020-05-12
ER

PT J
AU Zhang, WL
   Mao, JC
   Yang, XJ
   Zhang, H
   Zhao, JZ
   Tian, JZ
   Lin, C
   Mao, JH
AF Zhang, Wenlong
   Mao, Jincheng
   Yang, Xiaojiang
   Zhang, Heng
   Zhao, Jinzhou
   Tian, Jizhen
   Lin, Chong
   Mao, Jinhua
TI Development of a sulfonic gemini zwitterionic viscoelastic surfactant
   with high salt tolerance for seawater-based clean fracturing fluid
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Viscoelastic surfactant; Salt-tolerance; Seawater; Clean fracturing
   fluid
ID AGGREGATION BEHAVIOR; WORMLIKE MICELLES; PERFORMANCE; RHEOLOGY; DESIGN
AB In this study, a gemini zwitterionic viscoelastic surfactant with a sulfonic group, named VES-S, was synthesized. The surface activity properties of VES-S were found to show an ultra-low sensitivity to the salt concentration compared to those of cationic gemini surfactants, meaning that the packing parameter of VES-S varies little with increasing salinity. Through laboratory measurements, it was found that the addition of salt can enhance the viscoelasticity of the VES-S solution by tightening the net-work structure even at a high NaCl concentration (8 wt%), which indicated that VES-S was a viscoelastic surfactant with high salt tolerance. A series of laboratory evaluations showed that the clean fracturing fluids prepared by VES-S and simulated seawaters fulfilled the requirements for hydraulic fracturing operations, which proved that VES-S was an excellent and reliable viscoelastic surfactant with a high salt tolerance that can be used to prepare seawater-based clean fracturing fluids. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wenlong; Mao, Jincheng; Yang, Xiaojiang; Zhang, Heng; Zhao, Jinzhou; Tian, Jizhen; Lin, Chong; Mao, Jinhua] Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
RP Mao, JC; Yang, XJ; Zhang, H (reprint author), Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
EM Jcmao@swpu.edu.cn
OI Zhang, Yang/0000-0002-4010-8660
FU Sichuan Youth Science & Technology Foundation [2017JQ0010]; National
   High Technology Research & Development Program [2016ZX05053]; Key Fund
   Project of Educational Commission of Sichuan Province [16CZ0008];
   Explorative Project Fund of State Key Laboratory of Oil and Gas
   Reservoir Geology and Exploitation (Southwest Petroleum University)
   [G201601]; Major Program of the National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [51490653]; 973
   ProgramNational Basic Research Program of China [2013CB228004]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M650250]
FX The research is partly supported by Sichuan Youth Science & Technology
   Foundation (2017JQ0010), National High Technology Research & Development
   Program (2016ZX05053), Key Fund Project of Educational Commission of
   Sichuan Province (16CZ0008), Explorative Project Fund (G201601) of State
   Key Laboratory of Oil and Gas Reservoir Geology and Exploitation
   (Southwest Petroleum University), the Major Program of the National
   Natural Science Foundation of China (51490653), 973 Program
   (2013CB228004) and China Postdoctoral Science Foundation (2019M650250).
CR Acharya DP, 2004, J PHYS CHEM B, V108, P1790, DOI 10.1021/jp036096b
   Akram M, 2015, J PHYS CHEM B, V119, P3499, DOI 10.1021/jp5097822
   Alimohammadi MH, 2012, J CHEM THERMODYN, V44, P107, DOI 10.1016/j.jct.2011.08.007
   Alohaly M, 2016, KINGD SAUD AR TECHN
   And S.R.R., 2007, LANGMUIR, V17, P300
   ANDREAS R, 2010, CHEM ERDE-GEOCHEM, V70, P107, DOI DOI 10.1016/J.CHEMER.2010.05.016
   Chu ZL, 2013, CHEM SOC REV, V42, P7174, DOI 10.1039/c3cs35490c
   Chu ZL, 2013, ACS SUSTAIN CHEM ENG, V1, P75, DOI 10.1021/sc300037e
   Chu ZL, 2010, LANGMUIR, V26, P7783, DOI 10.1021/la904582w
   CREWS JB, 2005, [No title captured], DOI DOI 10.2118/93449-MS
   Dogon D, 2016, J UNCONV OIL GAS RES, V14, P12, DOI 10.1016/j.juogr.2016.01.003
   Dreiss CA, 2007, SOFT MATTER, V3, P956, DOI 10.1039/b705775j
   Fan HM, 2018, J SURFACTANTS DETERG, V21, P475, DOI 10.1002/jsde.12042
   Fan HM, 2017, RSC ADV, V7, P53290, DOI 10.1039/c7ra11687j
   Ghosh SK, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3373404
   Hansen J.E., 2017, SPE MIDDL E OIL GAS
   Khair EMM, 2011, J PETROL SCI ENG, V78, P131, DOI 10.1016/j.petrol.2011.05.011
   LOWE DK, 1966, J PETROL TECHNOL, V18, P1102
   Lu T, 2012, J COLLOID INTERF SCI, V377, P222, DOI 10.1016/j.jcis.2012.03.044
   Mao JC, 2018, J IND ENG CHEM, V60, P133, DOI 10.1016/j.jiec.2017.10.048
   Mao JC, 2016, RSC ADV, V6, P88426, DOI 10.1039/c6ra17823e
   Menger FM, 2000, ANGEW CHEM INT EDIT, V39, P1907
   Nagarajan R, 2002, LANGMUIR, V18, P31, DOI 10.1021/la010831y
   Oda R, 1998, LANGMUIR, V14, P4364, DOI 10.1021/la971369d
   PERKINS TK, 1961, T SOC PETROL EN AIME, V222, P937
   Rodriguez A, 2006, LANGMUIR, V22, P9519, DOI 10.1021/la062225e
   Samuel M, 1997, SPE ANN TECHN C EXH, DOI [10.2118/59478-PA, DOI 10.2118/59478-PA]
   SINCLAIR AR, 1970, J PETROL TECHNOL, V22, P711, DOI 10.2118/2623-PA
   Sullivan P. F, 2006, SPE INT S EXH FORM D
   Vo L. K, 2016, SPE AS PAC HYDR FRAC
   Yang C, 2017, J APPL POLYM SCI, V134
   Zana R, 2002, ADV COLLOID INTERFAC, V97, P205, DOI 10.1016/S0001-8686(01)00069-0
   Zanten V, 2011, SPE DRILL COMPLET, V26
   Zhang W. L, 2019, JOURNEY SURFACTANTS, V22
   Zhang WL, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10111215
   Zhang Y, 2018, CHEM ENG J, V354, P913, DOI 10.1016/j.cej.2018.08.021
   Zhang YM, 2015, RSC ADV, V5, P19135, DOI 10.1039/c4ra16772d
   Zhao JZ, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10050535
   Zhu JY, 2019, COLLOID SURFACE A, V572, P88, DOI 10.1016/j.colsurfa.2019.03.087
NR 39
TC 4
Z9 4
U1 19
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 688
EP 701
DI 10.1016/j.ces.2019.06.061
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300057
DA 2020-05-12
ER

PT J
AU Kalo, L
   Kamalanathan, P
   Pant, HJ
   Cassanello, MC
   Upadhyay, RK
AF Kalo, Lipika
   Kamalanathan, Premkumar
   Pant, Harish J.
   Cassanello, Miryan C.
   Upadhyay, Rajesh K.
TI Mixing and regime transition analysis of liquid-solid conical fluidized
   bed through RPT technique
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Radioactive particle tracking; Liquid-solid conical fluidized bed;
   Binary bed; Time series analysis; Chaos analysis
ID RADIOACTIVE PARTICLE TRACKING; HYDRODYNAMICS; DISTRIBUTIONS; DYNAMICS;
   BEHAVIOR; SIZE
AB The current work focuses on the hydrodynamic study of liquid-solid mono and binary conical fluidized bed using the radioactive particle tracking technique. Two different sizes 0.6 and 1 mm diameter glass beads were used for the experiment. Two different bed compositions, mono dispersed (100 wt% of each solid) and 50 wt% mixture of the solids, were studied. A rich data base, including instantaneous velocities, mean and RMS velocities, granular temperature, etc., were calculated by suitable post-processing. Further, Hurst exponent, autocorrelation function, segregation index, Kolmogorov entropy, and correlation dimension were calculated using time series data to understand the mixing and chaotic nature of the fluidized bed for each set of data. Good degree of mixing was observed even at a low velocity of 0.07 m/s. Kolmogorov entropy and correlation dimension indicate regime change at liquid inlet velocity of 0.1 m/s for both mono and 50 wt% binary bed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kalo, Lipika; Kamalanathan, Premkumar; Upadhyay, Rajesh K.] Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
   [Pant, Harish J.] Bhabha Atom Res Ctr, Isotope & Radiat Applicat Div, Mumbai 400085, Maharashtra, India.
   [Cassanello, Miryan C.] Univ Buenos Aires, Dept Ind, Buenos Aires, DF, Argentina.
RP Upadhyay, RK (reprint author), Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
EM rkupadhyay@iitg.ac.in
OI Kamalanathan, Premkumar/0000-0001-9425-8675; Upadhyay,
   Rajesh/0000-0001-9629-8814; Cassanello, Miryan/0000-0001-8233-3797
CR Bhusarapu S, 2005, THESIS
   CASSANELLO M, 1995, IND ENG CHEM RES, V34, P2971, DOI 10.1021/ie00048a007
   Chavan PV, 2008, IND ENG CHEM RES, V47, P8458, DOI 10.1021/ie800504z
   Dathrika S. K., 2011, INT J PHARM SCI RES, V2, P91
   DAW CS, 1990, PHYS REV A, V41, P1179, DOI 10.1103/PhysRevA.41.1179
   DAW CS, 1991, P 11 INT C FLUID BED, V1, P777
   DIFELICE R, 1995, CHEM ENG SCI, V50, P1213, DOI 10.1016/0009-2509(95)98838-6
   FAN LS, 1985, CHEM ENG COMMUN, V37, P141, DOI 10.1080/00986448508911277
   FAN LT, 1993, AICHE J, V39, P513, DOI 10.1002/aic.690390314
   HAM JM, 1990, INT J MULTIPHAS FLOW, V16, P171, DOI 10.1016/0301-9322(90)90052-K
   HANDLEY D, 1966, TRANS INST CHEM ENG, V44, pT260
   Jain S, 2014, J RADIOANAL NUCL CH, V302, P1309, DOI 10.1007/s10967-014-3547-6
   Jain V, 2017, PARTICUOLOGY, V33, P112, DOI 10.1016/j.partic.2016.07.011
   Kalo L, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.08.193
   Kang Y., 1988, PARTICUL SCI TECHNOL, V6, P133
   Kiared K, 1997, IND ENG CHEM RES, V36, P4695, DOI 10.1021/ie970161k
   Kim HG, 2000, ISIJ INT, V40, P16, DOI 10.2355/isijinternational.40.16
   KMIEC A, 1978, CHEM ENG J BIOCH ENG, V15, P1, DOI 10.1016/0300-9467(78)80032-X
   KOLAR V, 1963, COLLECT CZECH CHEM C, V28, P1224, DOI 10.1135/cccc19631224
   KOLOINI T, 1973, CAN J CHEM ENG, V51, P499, DOI 10.1002/cjce.5450510416
   KWANT G, 1995, POWDER TECHNOL, V82, P279, DOI 10.1016/0032-5910(94)02937-J
   LARACHI F, 1994, NUCL INSTRUM METH A, V338, P568, DOI 10.1016/0168-9002(94)91343-9
   LATIF BAJ, 1972, CHEM ENG SCI, V27, P1933, DOI 10.1016/0009-2509(72)87052-0
   Limtrakul S, 2005, CHEM ENG SCI, V60, P1889, DOI 10.1016/j.ces.2004.11.026
   MARUYAMA T, 1984, J CHEM ENG JPN, V17, P132, DOI 10.1252/jcej.17.132
   Morooka S., 1980, INT CHEM ENG, V20, P433
   Padhi RK, 2016, COGENT ENG, V3, DOI 10.1080/23311916.2016.1181821
   Peng YM, 1997, CHEM ENG SCI, V52, P2277, DOI 10.1016/S0009-2509(97)00061-4
   Reddy RK, 2013, CHEM ENG SCI, V92, P1, DOI 10.1016/j.ces.2012.11.017
   Roy S, 2005, AICHE J, V51, P802, DOI 10.1002/aic.10447
   Roy S., 2000, THESIS
   Schouten JC, 1996, CHEM ENG SCI, V51, P1991, DOI 10.1016/0009-2509(96)00056-5
   SCOTT CD, 1976, BIOTECHNOL BIOENG, V18, P1393, DOI 10.1002/bit.260181006
   SHI YF, 1984, IND ENG CHEM FUND, V23, P484, DOI 10.1021/i100016a018
   Shin MK, 2007, IND ENG CHEM RES, V46, P1408, DOI 10.1021/ie061098e
   Talapuru S., 2010, 13 INT C FLUID NEW P, P1
   Upadhyay R. K., 2010, THESIS
   Upadhyay RK, 2010, CAN J CHEM ENG, V88, P601, DOI 10.1002/cjce.20334
   VANDENBLEEK CM, 1993, CHEM ENG SCI, V48, P2367, DOI 10.1016/0009-2509(93)81058-4
   Venkatesh RD, 1996, POWDER TECHNOL, V89, P179
   Volpicelli G., 1966, CHEM ENG PROG S SER, V62, P42
   Wormsbecker M, 2009, POWDER TECHNOL, V194, P115, DOI 10.1016/j.powtec.2009.03.036
   Yang JZ, 2003, CHEM ENG J, V92, P7, DOI 10.1016/S1385-8947(02)00084-0
   YUTANI N, 1983, AICHE J, V29, P101, DOI 10.1002/aic.690290114
   Zbib H, 2018, IND ENG CHEM RES, V57, P16944, DOI 10.1021/acs.iecr.8b03369
NR 45
TC 0
Z9 0
U1 6
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 702
EP 712
DI 10.1016/j.ces.2019.07.005
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300058
DA 2020-05-12
ER

PT J
AU Wei, XY
   Zhu, J
AF Wei, Xiaoyang
   Zhu, Jesse
TI Capturing the instantaneous flow structure in gas-solid circulating
   fluidized bed using high-speed imaging and fiber optic sensing
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aggregation; Macro-fluctuation; Instantaneous flow structure; High-speed
   imaging; Fiber optic sensing; Gas-solid circulating fluidized bed
ID GROUP-B PARTICLES; RECTANGULAR CFB RISER; CLUSTER CHARACTERISTICS;
   HEAT-TRANSFER; WALL; IDENTIFICATION; HYDRODYNAMICS; DISTRIBUTIONS;
   HOLDUP; MOTION
AB Knowing the instantaneous flow structure in a gas-solid circulating fluidized bed (CFB) is extremely crucial for the understanding of fast fluidization and the development of numerical models. Up to now, numerous studies have been reported on the instantaneous flow structure, but essential information, such as phase classification, solids holdup mapping, macro-scale fluctuation and much more, remains insufficient for a thorough understanding. In this work, the instantaneous flow structure was captured in large-scale CFBs using high-speed imaging and fiber optic sensing. The instantaneous solids holdup mapping across the riser is first computed from images with a verified calibration between solids holdup and grayscale. Based on the solids holdup characteristics, the gas-solid flow in a CFB riser is classified into distinctive phases. Macroscopically, there is a trough phase having continuous low solids holdup and a crest phase having continuous high solids holdup, causing the mean solids holdup across the riser to fluctuate significantly. Within the trough phase, there are trough clusters (particle aggregations) surrounded by dispersed particles (dilute atmosphere). Within the crest phase, there are crest clusters (particle aggregations) surrounded by coalesced particles (dense atmosphere). The above flow structure is further verified with the instantaneous solids holdup obtained using fiber optic sensing in terms of solids holdup characteristics and phase dimensions. Collectively, this study deepens the understanding of fast fluidization, prepares for further phase characterization, and contributes to the development of numerical modeling. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wei, Xiaoyang; Zhu, Jesse] Univ Western Ontario, Dept Chem & Biochem Engn, Particle Technol Res Ctr, London, ON N6A 5B9, Canada.
RP Zhu, J (reprint author), Univ Western Ontario, Dept Chem & Biochem Engn, Particle Technol Res Ctr, London, ON N6A 5B9, Canada.
EM jzhu@uwo.ca
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917
FU National Science and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada; China Scholarship
   CouncilChina Scholarship Council
FX The authors are grateful to the financial support from National Science
   and Engineering Research Council of Canada, and the sponsorship of the
   China Scholarship Council.
CR Anantharaman A, 2016, IND ENG CHEM RES, V55, P8659, DOI 10.1021/acs.iecr.6b00956
   Bi X, 1993, P 6 CHIN C FLUID WUH, P162
   Breault RW, 2008, POWDER TECHNOL, V182, P137, DOI 10.1016/j.powtec.2007.08.018
   Breault RW, 2012, POWDER TECHNOL, V220, P151, DOI 10.1016/j.powtec.2011.09.002
   Breault RW, 2012, POWDER TECHNOL, V220, P79, DOI 10.1016/j.powtec.2011.09.024
   Breault RW, 2009, POWDER TECHNOL, V190, P385, DOI 10.1016/j.powtec.2008.08.021
   Breault RW, 2005, POWDER TECHNOL, V149, P68, DOI 10.1016/j.powtec.2004.11.003
   Brown RC, 2001, POWDER TECHNOL, V119, P68, DOI 10.1016/S0032-5910(00)00419-8
   Cahyadi A, 2017, CHEM ENG SCI, V158, P70, DOI 10.1016/j.ces.2016.10.002
   Chew JW, 2011, CHEM ENG J, V178, P348, DOI 10.1016/j.cej.2011.10.020
   Chew JW, 2012, CHEM ENG SCI, V68, P82, DOI 10.1016/j.ces.2011.09.011
   Chew JW, 2012, CHEM ENG SCI, V68, P72, DOI 10.1016/j.ces.2011.09.012
   Johnsson F, 1997, CIRCUL FUID BED TECH, V652
   LI HZ, 1991, POWDER TECHNOL, V66, P231, DOI 10.1016/0032-5910(91)80035-H
   LI HZ, 2004, CHINA PART, V2, P101
   Lim KS, 1995, INT J MULTIPHAS FLOW, V21, P141, DOI 10.1016/0301-9322(95)00038-Y
   Manyele SV, 2002, CHEM ENG J, V88, P151, DOI 10.1016/S1385-8947(01)00299-6
   Noymer PD, 1998, INT J HEAT MASS TRAN, V41, P147, DOI 10.1016/S0017-9310(97)00065-3
   Ren JQ, 2001, CHEM ENG SCI, V56, P981, DOI 10.1016/S0009-2509(00)00313-4
   RHODES M, 1992, POWDER TECHNOL, V70, P207, DOI 10.1016/0032-5910(92)80055-2
   Shaffer F, 2013, POWDER TECHNOL, V242, P86, DOI 10.1016/j.powtec.2013.01.012
   Shi HL, 2008, PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND INFORMATION TECHNOLOGY, P102, DOI 10.1109/ICCSIT.2008.52
   Soong C.H., 1994, CIRCULATING FLUIDIZE, P615
   Takeuchi H, 1991, CIRCULATING FLUIDIZE, VIII, P177
   Takeuchi H., 1996, CIRCULATING FLUIDIZE, P164
   Wang Chao, 2013, THESIS
   Wang CX, 2014, CHEM ENG SCI, V108, P233, DOI 10.1016/j.ces.2013.12.042
   WU RL, 1991, INT J HEAT MASS TRAN, V34, P2019, DOI 10.1016/0017-9310(91)90213-X
   Xu J, 2011, CHEM ENG SCI, V66, P5064, DOI 10.1016/j.ces.2011.06.057
   Xu J, 2010, CHEM ENG SCI, V65, P5447, DOI 10.1016/j.ces.2010.07.015
   Yang JS, 2015, PARTICUOLOGY, V23, P16, DOI 10.1016/j.partic.2014.12.004
   Yang JS, 2015, POWDER TECHNOL, V273, P76, DOI 10.1016/j.powtec.2014.12.020
   Yang JS, 2014, CAN J CHEM ENG, V92, P2202, DOI 10.1002/cjce.22059
   Yang JS, 2014, POWDER TECHNOL, V254, P407, DOI 10.1016/j.powtec.2014.01.015
   Yang TY, 2009, AICHE J, V55, P612, DOI 10.1002/aic.11758
   YANG YL, 1992, POWDER TECHNOL, V73, P67, DOI 10.1016/0032-5910(92)87008-X
   YERUSHALMI J, 1976, IND ENG CHEM PROC DD, V15, P47, DOI 10.1021/i260057a010
   Zhang H, 1998, POWDER TECHNOL, V100, P260, DOI 10.1016/S0032-5910(98)00147-8
   Zhu JX, 2005, CONTEMP PERSPECT EAR, P55
   ZOU B, 1994, POWDER TECHNOL, V78, P173, DOI 10.1016/0032-5910(93)02786-A
NR 40
TC 2
Z9 2
U1 8
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 713
EP 724
DI 10.1016/j.ces.2019.05.036
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300059
DA 2020-05-12
ER

PT J
AU Lee, K
   Ghosh, T
   Bakshi, BR
AF Lee, Kyuha
   Ghosh, Tapajyoti
   Bakshi, Bhavik R.
TI Toward multiscale consequential sustainable process design: Including
   the effects of economy and resource constraints with application to
   green urea production in a watershed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Consequential modeling approach; Multiple technology choices; Market
   effects; Multiscale optimization; Supply chain network design; Green
   urea production
ID LIFE-CYCLE ASSESSMENT; SUPPLY CHAIN; CONCEPTUAL-FRAMEWORK; HYDROGEN
   STORAGE; ASSESSMENT LCA; UNITED-STATES; INPUT; OPTIMIZATION; BIOENERGY;
   PLANET
AB Decisions made by approaches that only consider the environmental domain could result in unexpected outcomes due to burdens shifting to economic and social domains. These consequences could occur through the entire supply chain at multiple spatial scales. In this work, the process-to-planet (P2P) multiscale modeling framework is integrated with the rectangular choice-of-technology (RCOT) consequential approach. The resulting RCOT-P2P multiscale technology choice modeling framework takes account of market effects, such as economic resource constraints, as a consequential approach for designing engineering systems and their supply chain networks. The integrated modeling framework can represent different stakeholders' interests by considering engineering, environmental, and economic dimensions. The case study focuses on installation of a new green urea production system in a watershed where there are limited supplies of resources, such as water and land area. We identify how the adoption of new technologies could change and be limited by market constraints, as the urea demand increases. This multiscale consequential framework is useful for modeling substitution effects of emerging technologies while considering market effects. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Kyuha; Ghosh, Tapajyoti; Bakshi, Bhavik R.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
RP Bakshi, BR (reprint author), Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
EM bakshi.2@osu.edu
FU Ohio Water Resources Institute
FX Partial funding for this work was provided by the Ohio Water Resources
   Institute.
CR [Anonymous], 2013, LEV COST NEW GEN RES
   Argonne National Laboratory, 2018, GREENHOUSE GASES REG
   Bakshi BR, 2018, ACS SUSTAIN CHEM ENG, V6, P3632, DOI 10.1021/acssuschemeng.7b03953
   Bakshi BR, 2015, ENVIRON SCI TECHNOL, V49, P1752, DOI 10.1021/es5041442
   Biegler L.T., 1997, SYSTEMATIC METHODS C
   Blass V, 2018, J IND ECOL, V22, P18, DOI 10.1111/jiec.12550
   Boulay AM, 2018, INT J LIFE CYCLE ASS, V23, P368, DOI 10.1007/s11367-017-1333-8
   Brander M., 2008, TECHNICAL PAPER CONS
   Brouwer Mark, 2009, THERMODYNAMICS UREA
   Callahan Charles C., 1979, PRINCIPLES WATER RIG
   Choi JK, 2016, APPL ENERG, V184, P830, DOI 10.1016/j.apenergy.2016.05.033
   Choi JK, 2010, ENERG POLICY, V38, P3527, DOI 10.1016/j.enpol.2010.02.029
   COLBY BG, 1990, AM J AGR ECON, V72, P1184, DOI 10.2307/1242530
   Cook Lucien H., 1968, US Patent, Patent No. [3,370,090, 3370090]
   Deutch J, 2011, FOREIGN AFF, V90, P82
   Dilekli N, 2016, J IND ECOL, V20, P120, DOI 10.1111/jiec.12291
   Duchin F., 2012, J EC STRUCT, V1, P1, DOI [10.1186/2193-2409-1-3, DOI 10.1186/2193-2409-1-3]
   Duchin F, 2011, ECON SYST RES, V23, P281, DOI 10.1080/09535314.2011.571238
   Earles JM, 2011, INT J LIFE CYCLE ASS, V16, P445, DOI 10.1007/s11367-011-0275-9
   Engro Corporation Limited, 2018, WORLDS LARG UR PLANT
   Falano T, 2014, BIOTECHNOL J, V9, P753, DOI 10.1002/biot.201300246
   FRAUZEM R, 2015, COMPUT AIDED CHEM EN, V36, P175
   Frischknecht R, 2005, INT J LIFE CYCLE ASS, V10, P3, DOI 10.1065/lca2004.10.181.1
   Ghosh T, 2019, COMPUT CHEM ENG, V126, P113, DOI 10.1016/j.compchemeng.2019.03.041
   Ghosh T, 2017, THEOR FOUND CHEM EN+, V51, P936, DOI 10.1134/S0040579517060045
   Gong J, 2017, ACS SUSTAIN CHEM ENG, V5, P5887, DOI 10.1021/acssuschemeng.7b00631
   Govindan K, 2013, J CLEAN PROD, V47, P345, DOI 10.1016/j.jclepro.2012.04.014
   Hanes RJ, 2015, AICHE J, V61, P3332, DOI 10.1002/aic.14919
   Hanes RJ, 2015, AICHE J, V61, P3320, DOI 10.1002/aic.14918
   Heffer Patrick, 2016, INT NITR IN C MELB A
   Hendrickson C, 1998, ENVIRON SCI TECHNOL, V32, p184A, DOI 10.1021/es983471i
   Horowitz Karen J., 2006, CONCEPTS METHODS INP
   Jacquemin L, 2012, INT J LIFE CYCLE ASS, V17, P1028, DOI 10.1007/s11367-012-0432-9
   James H, 2018, ANNU REV FINANC ECON, V10, P219, DOI 10.1146/annurev-financial-110217-022625
   Katelhon A, 2016, ENVIRON SCI TECHNOL, V50, P12575, DOI 10.1021/acs.est.6b04270
   Klerke A, 2008, J MATER CHEM, V18, P2304, DOI 10.1039/b720020j
   KOCIS GR, 1989, COMPUT CHEM ENG, V13, P307, DOI 10.1016/0098-1354(89)85008-2
   Kongpanna P, 2015, CHEM ENG RES DES, V93, P496, DOI 10.1016/j.cherd.2014.07.013
   Lan R, 2012, INT J HYDROGEN ENERG, V37, P1482, DOI 10.1016/j.ijhydene.2011.10.004
   Larrea-Gallegos G, 2019, J IND ECOL, V23, P601, DOI 10.1111/jiec.12812
   LEONTIEF W, 1970, REV ECON STAT, V52, P262, DOI 10.2307/1926294
   Leontief WW, 1936, REV ECON STATISTICS, V18, P105, DOI 10.2307/1927837
   Liu Xinyu, 2018, J IND ECOL
   Liu Xinyu, 2018, J CLEANER PROD
   Loiseau E, 2018, J CLEAN PROD, V176, P474, DOI 10.1016/j.jclepro.2017.12.169
   Lund H, 2010, INT J LIFE CYCLE ASS, V15, P260, DOI 10.1007/s11367-010-0164-7
   Martin M, 2013, IND ENG CHEM RES, V52, P3044, DOI 10.1021/ie2030213
   Martinez-Frias J, 2003, INT J HYDROGEN ENERG, V28, P483, DOI 10.1016/S0360-3199(02)00135-0
   Marvuglia A, 2013, RENEW SUST ENERG REV, V25, P768, DOI 10.1016/j.rser.2013.04.031
   Mueller-Langer F, 2007, INT J HYDROGEN ENERG, V32, P3797, DOI 10.1016/j.ijhydene.2007.05.027
   National Renewable Energy Laboratory (NREL), 2018, US LIF CYCL INV DAT
   Pagani Giorgio, 1997, US Patent, Patent No. [5,684,194, 5684194]
   Papageorgiou LG, 2009, COMPUT CHEM ENG, V33, P1931, DOI 10.1016/j.compchemeng.2009.06.014
   Pascual-Gonzalez J, 2016, AICHE J, V62, P3639, DOI 10.1002/aic.15376
   Pieragostini C, 2012, J ENVIRON MANAGE, V96, P43, DOI 10.1016/j.jenvman.2011.10.014
   Reinhard J, 2009, J CLEAN PROD, V17, pS46, DOI 10.1016/j.jclepro.2009.05.003
   Seaber P. R., 1987, HYDROLOGIC UNIT MAPS
   Seider WD, 2008, PRODUCT PROCESS DESI
   Seuring S, 2008, J CLEAN PROD, V16, P1699, DOI 10.1016/j.jclepro.2008.04.020
   Seuring S, 2013, DECIS SUPPORT SYST, V54, P1513, DOI 10.1016/j.dss.2012.05.053
   Springer NP, 2017, SCI TOTAL ENVIRON, V577, P319, DOI 10.1016/j.scitotenv.2016.10.190
   Suh S, 2004, ECOL ECON, V48, P451, DOI 10.1016/j.ecolecon.2003.10.013
   U. S. Bureau of Economic Analysis, 2018, INT ACC IND EC ACC D
   U. S. Census Bureau, 2018, N AM IND CLASS SYST
   U.S. Energy Information Administration(EIA), 2018, LEV COST LEV AV COST
   U. S. Energy Information Administration (USEIA), 2018, EL FORM EIA 923
   U. S. Environmental Protection Agency (USEPA), 2018, ENVIROATLAS INT MAP
   U. S. Environmental Protection Agency (USEPA), 2014, NAT EM INV NEI REP
   USEPA, 2018, INV US GREENH GAS EM
   Vazquez-Rowe I, 2014, SCI TOTAL ENVIRON, V472, P78, DOI 10.1016/j.scitotenv.2013.10.097
   Vazquez-Rowe I, 2013, INT J LIFE CYCLE ASS, V18, P1593, DOI 10.1007/s11367-013-0604-2
   Voll A, 2012, COMPUT-AIDED CHEM EN, V31, P850
   Yang Y, 2017, J CLEAN PROD, V158, P308, DOI 10.1016/j.jclepro.2017.04.150
   Yue DJ, 2016, ENVIRON SCI TECHNOL, V50, P1501, DOI 10.1021/acs.est.5b04279
   Yue DJ, 2014, COMPUT CHEM ENG, V66, P36, DOI 10.1016/j.compchemeng.2013.11.016
NR 75
TC 2
Z9 2
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 725
EP 743
DI 10.1016/j.ces.2019.06.028
PG 19
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300060
DA 2020-05-12
ER

PT J
AU Savchenko, VI
   Nikitin, AV
   Sedov, IV
   Ozerskii, AV
   Arutyunov, VS
AF Savchenko, V., I
   Nikitin, A., V
   Sedov, I., V
   Ozerskii, A., V
   Arutyunov, V. S.
TI The role of homogeneous steam reforming of acetylene in the partial
   oxidation of methane to syngas in matrix type converters
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Natural gas; Syngas; Matrix conversion; Acetylene
ID NATURAL-GAS
AB The conversion of natural gas to syngas is a key and most expensive stage of modern gas chemical technologies. As a promising alternative to existing technologies, a non-catalytic matrix conversion of natural gas to syngas was proposed. However, the reaction products, in addition to CO and H-2, also contain unreacted methane, CO2 and acetylene. The latter is the most problem impurity, as it is a precursor of soot and other heavy products. In this work, the kinetic analysis of changes in the composition of the products during the matrix conversion of rich methane-air mixtures up to the establishment of the thermodynamic equilibrium was carried out. Three characteristic stages of the process were identified. The first stage of fast reactions involving oxygen is completed in a very short time (similar to 10 (2)s at 1500 K) with almost complete oxygen consumption and the formation of CO, H-2, CO2, H2O and some minor products of methane pyrolysis, mainly acetylene, but at their ratio, far from equilibrium. At the second stage, slow reactions of steam reforming of the formed products significantly increase the amount of hydrogen. The ratio [CO2][HO2]/[CO][H2O] reaches an equilibrium value, but not the concentration of individual products due to incomplete conversion of acetylene and methane. At the third and longest stage, the system reaches equilibrium, and acetylene is not among the equilibrium products. The results of kinetic modeling and experimental study of partial oxidation of methane in matrix-type reformers have shown the important role of acetylene steam conversion in the post-flame zone. This reaction leads to a substantial decrease of methane and acetylene with a simultaneous increase in the yields of hydrogen and CO. (C) 2019 Published by Elsevier Ltd.
C1 [Savchenko, V., I; Nikitin, A., V; Sedov, I., V; Ozerskii, A., V; Arutyunov, V. S.] Russian Acad Sci, Inst Problems Chem Phys, Chernogolovka, Russia.
   [Nikitin, A., V; Ozerskii, A., V; Arutyunov, V. S.] Russian Acad Sci, Semenov Inst Chem Phys, Moscow, Russia.
RP Savchenko, VI (reprint author), Russian Acad Sci, Inst Problems Chem Phys, Chernogolovka, Russia.
EM vsavch@icp.ac.ru
RI Arutyunov, Vladimir/A-4978-2014; Savchenko, Valery/AAD-1165-2019; Sedov,
   Igor/F-1114-2011; Nikitin, Alexey/I-8994-2014
OI Arutyunov, Vladimir/0000-0003-0339-0297; Savchenko,
   Valery/0000-0001-9823-6844; Ozerskii, Aleksei/0000-0002-6765-1401;
   Sedov, Igor/0000-0001-9648-4895; Nikitin, Alexey/0000-0002-8236-3854
FU Institute of Problems of Chemical Physics, Russian Academy of Sciences
   [0089-2019-0018]; Semenov Institute of Chemical Physics, Russian Academy
   of Sciences [0082-2014-0004]
FX This work was performed in terms of the Program for Basic Research of
   State Academies of Sciences for 2013-2020, theme codes No.
   0089-2019-0018 (Institute of Problems of Chemical Physics, Russian
   Academy of Sciences) and 0082-2014-0004 (Semenov Institute of Chemical
   Physics, Russian Academy of Sciences).
CR Arutyunov VS, 2015, CHEM ENG J, V282, P206, DOI 10.1016/j.cej.2015.02.082
   Arutyunov VS, 2011, CHEM ENG J, V176, P291, DOI 10.1016/j.cej.2011.03.084
   Arutyunov VS, 2014, IND ENG CHEM RES, V53, P1754, DOI 10.1021/ie4022489
   Callaghan CA, 2006, KINETICS CATALYSIS W
   Chen TW, 2017, CHEM ENG J, V329, P238, DOI 10.1016/j.cej.2017.04.016
   Constales D, 2017, ADVANCED DATA ANALYSIS AND MODELLING IN CHEMICAL ENGINEERING, P9, DOI 10.1016/B978-0-444-59485-3.00002-3
   Dybkjaer I, 2016, CAN J CHEM ENG, V94, P607, DOI 10.1002/cjce.22453
   Healy D, 2010, ENERG FUEL, V24, P1521, DOI 10.1021/ef9011005
   Lanza R, 2011, SPR-CATAL, V23, P50, DOI 10.1039/9781849732772-00050
   Li CE, 2018, CHEM ENG SCI, V187, P189, DOI 10.1016/j.ces.2018.04.070
   Li QX, 2012, CHEM ENG J, V207, P235, DOI 10.1016/j.cej.2012.06.093
   Liu YF, 2017, COMBUST SCI TECHNOL, V189, P908, DOI 10.1080/00102202.2016.1256879
   Masuda M, 2003, J MOL CATAL A-CHEM, V199, P175, DOI 10.1016/S1381-1169(03)00033-5
   Nikitin A. V., 2018, COMB EXPL, V11, P19
   Nikitin A, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2019.01.162
   Parmon V. N., 2015, TERMODINAMIKA NERAVN, P127
   Trusov B. G., 2002, 14 INT S CHEM THERM, P483
   Wernicke H., 2008, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.a01_097.pub3, DOI 10.1002/14356007.A01_097.PUB3]
   Zhang O, 2016, IND ENG CHEM RES, V55, P8383, DOI 10.1021/acs.iecr.6b00817
NR 19
TC 0
Z9 0
U1 7
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 744
EP 751
DI 10.1016/j.ces.2019.07.012
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300061
DA 2020-05-12
ER

PT J
AU Fernandes, RR
   Oevermann, D
   Wilson, DI
AF Fernandes, R. R.
   Oevermann, D.
   Wilson, D., I
TI Cleaning insoluble viscoplastic soil layers using static and moving
   coherent impinging water jets
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cleaning; Impinging jet; Viscoplastic fluid; Moving jet; Modelling
ID VISCOUS FILM; LIQUID JET; REMOVAL; FLOW; STRESS; WALLS; PERFORMANCE;
   SURFACES; DEPOSITS; SHEAR
AB Impinging liquid jets are widely employed in cleaning operations to remove residual soiling layers from walls and other surfaces of process vessels. Insoluble viscoplastic soiling layers represent challenging soils to clean as removal is primarily by hydraulic forces. The rheological behaviour of a commercial petroleum jelly was investigated and shown to exhibit significant creep below its critical stress. The removal of thin (<1 mm) layers of petroleum jelly from glass and Perspex surfaces by coherent water jets impinging normally on vertical walls were studied experimentally. The jet clears a roughly circular area, forming a berm of removed material at the cleaning front. The shape of the berm was measured and found to depend on the ratio of the height of the water film and the initial thickness of the soil layer. The data were compared with the adhesive removal of viscoplastic soils proposed by Glover et al. (2016) with the momentum flow rate calculated using the results in Bhagat and Wilson (2016). The asymptotic approach to a cleaning limit observed in experiments with static nozzles required modification of the model: a semi-empirical term which represents the transition to a creeping regime is presented. The modified model allowed results obtained using static nozzles to predict the shape of the region cleaned by a jet from a similar nozzle moving across a soiled plate. The influence of process conditions on model parameters is discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fernandes, R. R.; Wilson, D., I] Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
   [Oevermann, D.] Tech Univ Dresden, Fac Mech Sci & Engn, Inst Nat Mat Technol, Bergstr 120, D-01062 Dresden, Germany.
RP Wilson, DI (reprint author), Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM diw11@cam.ac.uk
RI Fernandes, Rubens R./AAE-9815-2019
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; European UnionEuropean Union (EU)
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior -Brasil (CAPES) - Finance Code 001, by the
   provision of a PhD studentship for RRF. ERASMUS funding for DO from the
   European Union, as well as helpful discussions with Rajesh Bhagat and
   Melissa Chee, are also gratefully acknowledged.
CR Barnes HA, 1999, J NON-NEWTON FLUID, V81, P133, DOI 10.1016/S0377-0257(98)00094-9
   Bhagat RK, 2017, FOOD BIOPROD PROCESS, V102, P31, DOI 10.1016/j.fbp.2016.11.011
   Bhagat RK, 2016, CHEM ENG SCI, V152, P606, DOI 10.1016/j.ces.2016.06.011
   Bhagat RK, 2018, J FLUID MECH, V851, DOI 10.1017/jfm.2018.558
   Bonn D, 2017, REV MOD PHYS, V89, DOI 10.1103/RevModPhys.89.035005
   Chang C, 1998, IND ENG CHEM RES, V37, P1551, DOI 10.1021/ie970588r
   Chee MWL, 2019, FOOD BIOPROD PROCESS, V113, P142, DOI 10.1016/j.fbp.2018.10.005
   Coussot P, 2002, J RHEOL, V46, P573, DOI 10.1122/1.1459447
   Cuckston GL, 2019, J FOOD ENG, V243, P22, DOI 10.1016/j.jfoodeng.2018.08.018
   Da Cruz F, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.051305
   Damkjaer NF, 2017, FOOD BIOPROD PROCESS, V101, P145, DOI 10.1016/j.fbp.2016.11.001
   DEWAELE A, 1949, NATURE, V163, P774, DOI 10.1038/163774a0
   Dimitriou CJ, 2011, ENERG FUEL, V25, P3040, DOI 10.1021/ef2002348
   Dinkgreve M, 2018, J RHEOL, V62, P773, DOI 10.1122/1.5016034
   Dumouchel C, 2008, EXP FLUIDS, V45, P371, DOI 10.1007/s00348-008-0526-0
   Ewoldt RH, 2017, RHEOL ACTA, V56, P195, DOI 10.1007/s00397-017-1001-8
   Ewoldt RH, 2010, RHEOL ACTA, V49, P191, DOI 10.1007/s00397-009-0403-7
   Fernandes RR, 2016, J NON-NEWTON FLUID, V231, P6, DOI 10.1016/j.jnnfm.2016.02.003
   Fryer PJ, 2009, TRENDS FOOD SCI TECH, V20, P255, DOI 10.1016/j.tifs.2009.03.005
   Glover HW, 2016, J FOOD ENG, V178, P95, DOI 10.1016/j.jfoodeng.2015.12.021
   Hsu TYT, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3567215
   Hyun K, 2011, PROG POLYM SCI, V36, P1697, DOI 10.1016/j.progpolymsci.2011.02.002
   KAYE PL, 1995, WEAR, V186, P413, DOI 10.1016/0043-1648(95)07152-0
   Kohler H, 2015, FOOD BIOPROD PROCESS, V93, P327, DOI 10.1016/j.fbp.2014.09.010
   Macosko CW, 1994, RHEOLOGY PRINCIPLES
   Mewis J, 2009, ADV COLLOID INTERFAC, V147-48, P214, DOI 10.1016/j.cis.2008.09.005
   MICKAILY ES, 1993, AICHE J, V39, P885, DOI 10.1002/aic.690390517
   Micro-Epsilon, 2018, CONFOCALDT CAT
   Murcek R, 2019, FOOD BIOPROD PROCESS, V113, P86, DOI 10.1016/j.fbp.2018.11.009
   Oevermann D, 2019, WEAR, V422, P27, DOI 10.1016/j.wear.2018.12.056
   Park EK, 2010, KOREA-AUST RHEOL J, V22, P279
   Rodgers A, 2019, FOOD BIOPROD PROCESS, V113, P118, DOI 10.1016/j.fbp.2018.11.003
   Walker TW, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4752765
   WATSON EJ, 1964, J FLUID MECH, V20, P481, DOI 10.1017/S0022112064001367
   Wilson DI, 2015, CHEM ENG SCI, V123, P450, DOI 10.1016/j.ces.2014.11.006
   Wilson DI, 2014, CHEM ENG SCI, V109, P183, DOI 10.1016/j.ces.2014.01.034
   Wilson DI, 2012, CHEM ENG SCI, V68, P449, DOI 10.1016/j.ces.2011.10.003
   Yang JF, 2019, FOOD BIOPROD PROCESS, V113, P154, DOI 10.1016/j.fbp.2018.10.007
   YECKEL A, 1987, CHEM ENG COMMUN, V50, P165, DOI 10.1080/00986448708911823
   YOSHIMURA A, 1988, J RHEOL, V32, P53, DOI 10.1122/1.549963
NR 40
TC 0
Z9 0
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 752
EP 768
DI 10.1016/j.ces.2019.06.034
PG 17
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300062
DA 2020-05-12
ER

PT J
AU Tavangarrad, AH
   Mohebbi, B
   Qin, CZ
   Hassanizadeh, SM
   Rosati, R
   Claussen, J
   Blumich, B
AF Tavangarrad, Amir Hossein
   Mohebbi, Behzad
   Qin, Chaozhong
   Hassanizadeh, S. Majid
   Rosati, Rodrigo
   Claussen, Jan
   Bluemich, Bernhard
TI Continuum-scale modeling of water infiltration into a stack of two thin
   fibrous layers and their inter-layer space
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thin porous media; Liquid infiltration; Low-field NMR; Fibrous layer;
   Richards model; Reduced Continua Model
ID MORPHOLOGY
AB Unsaturated water flow through thin porous layers plays an important role in many applications such as water management in hydrogen fuel cells and hygiene products. It is well known that void spaces between adjacent thin layers (i.e., layer-layer interfaces) considerably impact through-plane water infiltration. Therefore, it is essential to account for this fact in the model development. Recently, we reported Nuclear Magnetic Resonance (NMR) measurements of water infiltration into a stack of two thin porous layers of 43-gsm polyester and showed crucial effect of the inter-layer space on the transfer of liquid from one layer to the other. In this work, we aim to test two numerical models of water infiltration into two (partially dry) thin porous layers. One is the standard Richards model for unsaturated flow and the other is Reduced Continua Model (RCM). The latter model is based on thickness-averaged properties and does not provide through-plane distribution of saturation in the layers. Layer-scale material properties are experimentally measured. Sub-layer material properties, which are used in the Richards model, are obtained by pore-morphology modeling of micro-CT images. Our results show that the RCM is superior to the Richards model. It can predict NMR measurements of temporal evolutions of water contents in the two layers quite well. Moreover, it is computationally much more efficient. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tavangarrad, Amir Hossein; Hassanizadeh, S. Majid] Univ Utrecht, Dept Earth Sci, Environm Hydrogeol Grp, Princetonlaan 8a, NL-3584 CB Utrecht, Netherlands.
   [Mohebbi, Behzad; Rosati, Rodrigo; Claussen, Jan] Procter & Gamble Serv GmbH, Sulzbacher Str 40, D-65824 Schwalbach, Germany.
   [Mohebbi, Behzad; Bluemich, Bernhard] Rhein Westfal TH Aachen, Inst Tech & Makromol Chem, D-52056 Aachen, Germany.
   [Qin, Chaozhong] Eindhoven Univ Technol, Dept Mech Engn, Eindhoven, Netherlands.
RP Tavangarrad, AH (reprint author), Univ Utrecht, Dept Earth Sci, Environm Hydrogeol Grp, Princetonlaan 8a, NL-3584 CB Utrecht, Netherlands.
EM A.H.Tavangarrad@uu.nl
FU European Research Council under the European UnionEuropean Research
   Council (ERC) [341225]; Procter Gamble
FX The research leading to these results has received funding from the
   European Research Council under the European Union's Seventh Framework
   Program (FP/2007-2013)/ERC Grant Agreement no. 341225 and from Procter &
   Gamble.
CR Albrecht W, 2003, NONWOVEN FABRICS RAW
   Birrfelder P, 2013, TEXT RES J, V83, P1477, DOI 10.1177/0040517512460296
   Carrere P, 2019, INT J HEAT MASS TRAN, V129, P1043, DOI 10.1016/j.ijheatmasstransfer.2018.10.004
   Diersch H. J. G, 2011, T POROUS MEDIA, V86
   Garcia-Salaberri PA, 2018, INT J HEAT MASS TRAN, V127, P687, DOI 10.1016/j.ijheatmasstransfer.2018.07.030
   Hao L, 2016, J ELECTROCHEM SOC, V163, pF744, DOI 10.1149/2.1461607jes
   Hazlett R. D, 1995, T POROUS MEDIA, P20
   Hilpert M, 2001, ADV WATER RESOUR, V24, P243, DOI 10.1016/S0309-1708(00)00056-7
   Hizir FE, 2010, J POWER SOURCES, V195, P3463, DOI 10.1016/j.jpowsour.2009.11.032
   JACKSON GW, 1986, CAN J CHEM ENG, V64, P364, DOI 10.1002/cjce.5450640302
   Leisen J., 2009, FLUID DISTRIBUTION M
   MILLER B, 1994, J COLLOID INTERF SCI, V162, P163, DOI 10.1006/jcis.1994.1021
   Mohebbi B., 2019, J MAGN RESON IMAGING
   Mohebbi B, 2018, J MAGN RESON, V294, P16, DOI 10.1016/j.jmr.2018.06.014
   Prat M, 2015, HDB POROUS MEDIA
   Qin C, 2019, CHEM ENG SCI
   Qin CZ, 2015, INT J HYDROGEN ENERG, V40, P3348, DOI 10.1016/j.ijhydene.2015.01.035
   Qin CZ, 2014, INT J HEAT MASS TRAN, V70, P693, DOI 10.1016/j.ijheatmasstransfer.2013.11.059
   Sweijen T, 2017, ADV WATER RESOUR, V107, P22, DOI 10.1016/j.advwatres.2017.06.001
   Tafreshi H. V., 2013, WICKING POROUS MAT, P131
   Tavangarrad AH, 2019, THESIS
   Tavangarrad AH, 2019, TEXT RES J, V89, P4906, DOI 10.1177/0040517519844209
   Tavangarrad AH, 2018, TRANSPORT POROUS MED, V122, P203, DOI 10.1007/s11242-018-0999-0
   VANGENUCHTEN MT, 1980, SOIL SCI SOC AM J, V44, P892, DOI 10.2136/sssaj1980.03615995004400050002x
   Zhuang Q, 2002, TEXT RES J, V72, P727, DOI 10.1177/004051750207200813
NR 25
TC 0
Z9 0
U1 6
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 769
EP 779
DI 10.1016/j.ces.2019.07.001
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300063
DA 2020-05-12
ER

PT J
AU Blakemore, DM
   Govender, I
   McBride, AT
   Mainza, AN
AF Blakemore, D. M.
   Govender, I
   McBride, A. T.
   Mainza, A. N.
TI Multiple particle tracking in PEPT using Voronoi tessellations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PEPT; Nuclear imaging; Voronoi; Clustering
ID TARGET TRACKING; FLOW; SIMULATIONS; ALGORITHM; MOTION
AB Many complex flow phenomena encountered in chemical engineering lack fundamental understanding. Central to this problem is the lack of non-invasive, in situ measurement tools that can simultaneously track the motion and dynamics of different particle species across the entire phase space of the flow. To this end, a novel algorithm was developed for simultaneously tracking multiple particles using a Positron Emission Tomography scanner. The algorithm discretizes the back-to-back gamma rays emanating from multiple radio-labelled particles, and uses a Voronoi tessellation to create a density map of the points. The locations of the tracers are determined using a clustering technique. A series of experiments was performed to test the precision, robustness, and performance of the algorithm. Twenty tracers were successfully tracked, limited only by the amount of available sodium-22 isotope. The presented algorithm resulted in a RMSE of 1.26 mm. The precision was found to be dependent on the level of discretization, and is robust in that the loss of a tracer (due to exiting the field of view, high acceleration, or tracer collision) is handled internally, with no need for human correction. The proposed algorithm can also be easily parallelized. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Govender, I] Univ KwaZulu Natal, Sch Engn, ZA-4041 Durban, South Africa.
   [Blakemore, D. M.] Univ KwaZulu Natal, Sch Clin Med, ZA-4041 Durban, South Africa.
   [Mainza, A. N.] Univ Cape Town, Ctr Minerals Res, ZA-7701 Rondebosch, South Africa.
   [McBride, A. T.] Univ Glasgow, Div Infrastruct & Environm, Glasgow, Lanark, Scotland.
RP Govender, I (reprint author), Univ KwaZulu Natal, Sch Engn, ZA-4041 Durban, South Africa.
EM indresan.govender@gmail.com
OI McBride, Andrew/0000-0001-7153-3777
FU Centre for Minerals Research
FX The authors would like to thank the Centre for Minerals Research for
   funding the research.
CR AURENHAMMER F, 1991, COMPUT SURV, V23, P345
   Bickell M, 2012, NUCL INSTRUM METH A, V682, P36, DOI 10.1016/j.nima.2012.04.037
   Blackman SS, 2004, IEEE AERO EL SYS MAG, V19, P5, DOI 10.1109/MAES.2004.1263228
   Borak J, 2007, GHOST MAP STORY LOND
   Breunig MM, 2000, SIGMOD REC, V29, P93, DOI 10.1145/335191.335388
   Chang YF, 2011, CHEM ENG SCI, V66, P4203, DOI 10.1016/j.ces.2011.06.001
   Ester M., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226
   Fangary YS, 2000, CHEM ENG SCI, V55, P5969, DOI 10.1016/S0009-2509(00)00176-7
   Govender I, 2017, J PHYS D APPL PHYS, V50, DOI 10.1088/1361-6463/aa5125
   Govender I, 2013, CHEM ENG SCI, V97, P162, DOI 10.1016/j.ces.2013.04.023
   Govender I, 2017, AICHE J, V63, P903, DOI 10.1002/aic.15453
   Gundogdu O, 2004, NUCL INSTRUM METH A, V534, P562, DOI 10.1016/j.nima.2004.06.162
   HAWKESWORTH MR, 1991, NUCL INSTRUM METH A, V310, P423, DOI 10.1016/0168-9002(91)91073-5
   Hill K. H, 2016, HDB GRANULAR MAT
   Hoomans BPB, 2001, POWDER TECHNOL, V116, P166, DOI 10.1016/S0032-5910(00)00391-0
   Hue C, 2002, IEEE T SIGNAL PROCES, V50, P309, DOI 10.1109/78.978386
   Li H, 2012, PROC SPIE, V8290, DOI 10.1117/12.907371
   MacQueen J, 1967, P 5 BERK S MATH STAT, V1, P14, DOI DOI 10.1234/12345678
   MITCHELL T., 1997, MACHINE LEARNING
   Ni R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3704
   Oh S, 2004, IEEE DECIS CONTR P, P735, DOI 10.1109/CDC.2004.1428740
   Ouellette NT, 2006, EXP FLUIDS, V40, P301, DOI 10.1007/s00348-005-0068-7
   Pal P, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.011111
   Parker DJ, 1997, CHEM ENG SCI, V52, P2011, DOI 10.1016/S0009-2509(97)00030-4
   PARKER DJ, 1993, NUCL INSTRUM METH A, V326, P592, DOI 10.1016/0168-9002(93)90864-E
   Sanchez-Gutierrez D, 2016, EMBO J, V35, P77, DOI 10.15252/embj.201592374
   Sarkka S, 2007, INFORM FUSION, V8, P2, DOI 10.1016/j.inffus.2005.09.009
   Springel V, 2010, MON NOT R ASTRON SOC, V401, P791, DOI 10.1111/j.1365-2966.2009.15715.x
   SWEET WH, 1951, NEW ENGL J MED, V245, P875, DOI 10.1056/NEJM195112062452301
   Wildman RD, 2000, PHYS REV E, V62, P3826, DOI 10.1103/PhysRevE.62.3826
   WRENN FR, 1951, SCIENCE, V113, P525, DOI 10.1126/science.113.2940.525
   Yang Z, 2007, NUCL INSTRUM METH A, V577, P585, DOI 10.1016/j.nima.2007.01.089
   Yang Z, 2006, NUCL INSTRUM METH A, V564, P332, DOI 10.1016/j.nima.2006.04.054
NR 33
TC 0
Z9 0
U1 4
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 780
EP 789
DI 10.1016/j.ces.2019.06.057
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300064
DA 2020-05-12
ER

PT J
AU Zhao, WQ
   Yang, J
   Guo, HS
   Xu, T
   Li, QS
   Wen, CY
   Sui, XJ
   Lin, CG
   Zhang, JW
   Zhang, L
AF Zhao, Weiqiang
   Yang, Jing
   Guo, Hongshuang
   Xu, Tong
   Li, Qingsi
   Wen, Chiyu
   Sui, Xiaojie
   Lin, Cunguo
   Zhang, Jinwei
   Zhang, Lei
TI Slime-resistant marine anti-biofouling coating with PVP-based copolymer
   in PDMS matrix
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Anti-biofouling coatings; Slime-resistant; Fouling-release; PDMS; PVP
ID POLY(ETHYLENE GLYCOL); ANTIFOULING COATINGS; PROTEIN ADSORPTION;
   CHAIN-LENGTH; SURFACE; POLYMERS; ADHESION; FILMS; HYDROGELS; NETWORKS
AB Poly(dimethylsiloxane) (PDMS) has been widely used as the fouling-release coatings due to its low surface energy. However, for marine anti-biofouling applications, current PDMS-based materials with hydrophobic property still suffer from marine slime attachment. Therefore, the design of novel amphiphilic coatings by modifying PDMS with hydrophilic polymers has been widely explored. In this work, based on poly(N-vinylpyrrolidone) (PVP), a novel hydrophilicity-active poly(N-vinyl-2-pyrrolidone-co-methyl methacrylate-co-butyl acrylate-co- 2-hydroxyethyl methacrylate) (PNMBH) was synthesized using a robust free radical polymerization method. Next, amphiphilic coatings were prepared by crosslinking different amounts of PNMBH with PDMS at room temperature. The resultant PNMBH-PDMS coatings were characterized with water contact angle tests, presenting their increased hydrophilicity and the optimal PNMBH content (10%). Moreover, the anti-biofouling performance of these coatings was evaluated using proteins (bovine serum albumin and fibrinogen), bacteria (Gram-negative Escherichia coli and Grampositive Staphylococcus aureus), and marine diatom (Navicula parva). Compared with pristine PDMS coating, PNMBH-PDMS coatings could reduce similar to 82% adhesion of fibrinogen, similar to 97% adhesion of Staphylococcus aureus, and similar to 97% adhesion of diatom, the major composition of marine slime. More importantly, PNMBH-PDMS coatings were also tested in the marine field, and results showed their excellent antibiofouling performance for at least 4 months in the ocean. This work developed a novel amphiphilic coating with appealing marine anti-biofouling performance and might provide new opportunities for marine coating applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Weiqiang; Yang, Jing; Guo, Hongshuang; Xu, Tong; Li, Qingsi; Wen, Chiyu; Sui, Xiaojie; Zhang, Lei] Tianjin Univ, Sch Chem Engn & Technol, Dept Biochem Engn, Tianjin 300072, Peoples R China.
   [Zhao, Weiqiang; Yang, Jing; Guo, Hongshuang; Xu, Tong; Li, Qingsi; Wen, Chiyu; Sui, Xiaojie; Zhang, Lei] Tianjin Univ, Sch Chem Engn & Technol, Frontier Sci Ctr Synthet Biol, Tianjin 300350, Peoples R China.
   [Zhao, Weiqiang; Yang, Jing; Guo, Hongshuang; Xu, Tong; Li, Qingsi; Wen, Chiyu; Sui, Xiaojie; Zhang, Lei] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Syst Bioengn MOE, Tianjin 300350, Peoples R China.
   [Zhao, Weiqiang; Yang, Jing; Guo, Hongshuang; Xu, Tong; Li, Qingsi; Wen, Chiyu; Sui, Xiaojie; Zhang, Lei] Tianjin Univ, Qingdao Inst Marine Technol, Qingdao 266235, Shandong, Peoples R China.
   [Zhao, Weiqiang; Yang, Jing; Guo, Hongshuang; Xu, Tong; Li, Qingsi; Wen, Chiyu; Sui, Xiaojie; Zhang, Lei] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Lin, Cunguo; Zhang, Jinwei] LSMRI, State Key Lab Marine Corros & Protect, Qingdao 266101, Shandong, Peoples R China.
RP Zhang, L (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Dept Biochem Engn, Tianjin 300072, Peoples R China.; Zhang, JW (reprint author), LSMRI, State Key Lab Marine Corros & Protect, Qingdao 266101, Shandong, Peoples R China.
EM zhangjw725@163.com; lei_zhang@tju.edu.cn
RI Zhang, Lei/H-5729-2013
FU Qingdao National Laboratory for Marine Science and Technology
   [QNLM2016ORP0407]; National Natural Science Funds for Innovation
   Research Groups [21621004]; National Natural Science Funds for Excellent
   Young Scholars [21422605]; Tianjin Natural Science FoundationNatural
   Science Foundation of Tianjin [18JCYBJC29500]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2019M651041]
FX The authors acknowledge the financial support from the Qingdao National
   Laboratory for Marine Science and Technology (QNLM2016ORP0407), the
   National Natural Science Funds for Innovation Research Groups
   (21621004), the National Natural Science Funds for Excellent Young
   Scholars (21422605), the Tianjin Natural Science Foundation
   (18JCYBJC29500) and the China Postdoctoral Science Foundation
   (2019M651041).
CR Banerjee I, 2011, ADV MATER, V23, P690, DOI 10.1002/adma.201001215
   Bi HY, 2006, LAB CHIP, V6, P769, DOI 10.1039/b600326e
   Bodkhe RB, 2015, PROG ORG COAT, V78, P369, DOI 10.1016/j.porgcoat.2014.07.011
   Callow JA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1251
   Cao B, 2016, CHEM SCI, V7, P1976, DOI 10.1039/c5sc03887a
   Cao B, 2013, ADV HEALTHC MATER, V2, P1096, DOI 10.1002/adhm.201200359
   Cao B, 2013, BIOMATERIALS, V34, P7592, DOI 10.1016/j.biomaterials.2013.06.063
   Cao ZQ, 2012, NANO TODAY, V7, P404, DOI 10.1016/j.nantod.2012.08.001
   Chambers LD, 2006, SURF COAT TECH, V201, P3642, DOI 10.1016/j.surfcoat.2006.08.129
   Ciriminna R, 2015, ACS SUSTAIN CHEM ENG, V3, P559, DOI 10.1021/sc500845n
   Dickenson NC, 2017, BIOFOULING, V33, P955, DOI 10.1080/08927014.2017.1393803
   Gallardo A, 2017, BIOMACROMOLECULES, V18, P1521, DOI 10.1021/acs.biomac.7b00073
   Galli G, 2017, MACROMOL RAPID COMM, V38, DOI 10.1002/marc.201600704
   Guo HS, 2019, CHEM ENG J, V374, P1353, DOI 10.1016/j.cej.2019.06.025
   HAAF F, 1985, POLYM J, V17, P143, DOI 10.1295/polymj.17.143
   Hawkins ML, 2014, BIOFOULING, V30, P247, DOI 10.1080/08927014.2013.862235
   Holland R, 2004, BIOFOULING, V20, P323, DOI 10.1080/08927010400029031
   Iguerb O, 2008, LANGMUIR, V24, P12272, DOI 10.1021/la801814u
   Jiang JX, 2017, APPL SURF SCI, V412, P1, DOI 10.1016/j.apsusc.2017.03.117
   Jiang SY, 2010, ADV MATER, V22, P920, DOI 10.1002/adma.200901407
   Keefe AJ, 2012, BIOMACROMOLECULES, V13, P1683, DOI 10.1021/bm300399s
   Kingshott P, 2002, BIOMATERIALS, V23, P2043, DOI 10.1016/S0142-9612(01)00334-9
   Landoulsi J, 2011, BIOFOULING, V27, P1105, DOI 10.1080/08927014.2011.629043
   Laukkanen A, 2004, MACROMOLECULES, V37, P2268, DOI 10.1021/ma035124l
   Lejars M, 2012, CHEM REV, V112, P4347, DOI 10.1021/cr200350v
   Liu XL, 2010, COLLOID SURFACE B, V79, P452, DOI 10.1016/j.colsurfb.2010.05.011
   Magin CM, 2010, MATER TODAY, V13, P36, DOI 10.1016/S1369-7021(10)70058-4
   Martinelli E, 2012, BIOFOULING, V28, P571, DOI 10.1080/08927014.2012.697897
   Mochida K, 2006, ENVIRON TOXICOL CHEM, V25, P3058, DOI 10.1897/05-688R.1
   Occhipinti-Ambrogi A, 2003, MAR POLLUT BULL, V46, P542, DOI 10.1016/S0025-326X(02)00363-6
   Occhipinti-Ambrogi A, 2007, MAR POLLUT BULL, V55, P342, DOI 10.1016/j.marpolbul.2006.11.014
   Omae I, 2003, APPL ORGANOMET CHEM, V17, P81, DOI 10.1002/aoc.396
   Ran F, 2011, ACTA BIOMATER, V7, P3370, DOI 10.1016/j.actbio.2011.05.026
   Roosjen A, 2004, LANGMUIR, V20, P10949, DOI 10.1021/la048469l
   Stafslien SJ, 2015, BIOFOULING, V31, P135, DOI 10.1080/08927014.2014.1003295
   Sulek MW, 2012, IND ENG CHEM RES, V51, P14700, DOI 10.1021/ie301431v
   Telford AM, 2010, ACS APPL MATER INTER, V2, P2399, DOI 10.1021/am100406j
   Thomas KV, 2010, BIOFOULING, V26, P73, DOI 10.1080/08927010903216564
   Wang HF, 2018, ACS APPL MATER INTER, V10, P37609, DOI 10.1021/acsami.8b10450
   Wu ZQ, 2012, COLLOID SURFACE B, V96, P37, DOI 10.1016/j.colsurfb.2012.03.016
   Wu ZQ, 2009, LANGMUIR, V25, P2900, DOI 10.1021/la8037523
   Yang WJ, 2014, PROG POLYM SCI, V39, P1017, DOI 10.1016/j.progpolymsci.2014.02.002
   Yang WJ, 2016, ACTA BIOMATER, V40, P92, DOI 10.1016/j.actbio.2016.05.035
   Yang WF, 2017, ACS APPL MATER INTER, V9, P18295, DOI 10.1021/acsami.7b04079
   Yasani BR, 2014, BIOFOULING, V30, P387, DOI 10.1080/08927014.2013.878864
   Zhang JW, 2013, PROG ORG COAT, V76, P1430, DOI 10.1016/j.porgcoat.2013.05.002
   Zhang Z, 2006, LANGMUIR, V22, P10072, DOI 10.1021/la062175d
   Zhou ZL, 2014, BIOFOULING, V30, P589, DOI 10.1080/08927014.2014.897335
   Zhu YN, 2017, J MATER CHEM B, V5, P8451, DOI 10.1039/c7tb02477k
NR 49
TC 2
Z9 2
U1 51
U2 106
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 790
EP 798
DI 10.1016/j.ces.2019.06.042
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300065
DA 2020-05-12
ER

PT J
AU Shaw, DD
   Pease, LF
AF Shaw, David D.
   Pease, Leonard F., III
TI Release of pharmaceutical cocktails from small polymeric micelles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiple drug solubilization; Combination therapy; Polymeric micelle;
   Mass transfer through non-ideal solutions; Triolimus
ID BLOCK-COPOLYMER MICELLES; DRUG-DELIVERY; ACID) MICELLES;
   17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; PACLITAXEL; RAPAMYCIN; DESIGN;
   MTOR
AB Here we model release of multidrug cocktails from small micelles. As most emerging anticancer agents remain sparingly soluble in water, they require carriers such as poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) micelles to enhance their delivery. These micelles have been used as vectors for multidrug cocktails (e.g., the hydrophobic anticancer agents paclitaxel, 17-allylamino-17-demethoxy geldanamycin, and rapamycin). Empirically determined agent release takes hours and half-lives depend on oil-water partition coefficients, a representative thermodynamic parameter. This contrasts with the assertion that the cocktail release rate is diffusion controlled, with diffusion time scales less than a millisecond. Here we resolve this inconsistency in mechanism using a "lumped capacitance" method. The two parameter equation that results provides excellent agreement with experimental release profiles. Model time scales depend on the micelle radius, external mass transfer coefficient, and lumped partition coefficient. These findings enable tuning of release rates of multidrug mixtures from micelles, which will become increasingly important because many new drug candidates remain hydrophobic. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shaw, David D.; Pease, Leonard F., III] Univ Utah, Dept Chem Engn, Salt Lake City, UT 84112 USA.
   [Pease, Leonard F., III] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [Pease, Leonard F., III] Univ Utah, Dept Pharmaceut, Salt Lake City, UT 84112 USA.
   [Pease, Leonard F., III] Univ Utah, Dept Pharmaceut Chem, Salt Lake City, UT 84112 USA.
RP Pease, LF (reprint author), 50 S Cent Campus Dr,3290 MEB, Salt Lake City, UT 84112 USA.
EM Pease@eng.utah.edu
FU American Partnership For Eosinophilic Disorders (APFED); Utah Technology
   Commercialization Program (TCP)
FX The authors gratefully acknowledge the generous provision of data by
   Glen S. Kwon and Ho-chul Shin and helpful discussions with Richard L.
   Raun, Gerald J. Gleich, Kathryn A. Peterson, John D. McLennan, and
   Philip J. Smith. Dr. Shaw wishes to express appreciation to the American
   Partnership For Eosinophilic Disorders (APFED) and the Utah Technology
   Commercialization Program (TCP) for partial support of his dissertation
   and to the National Science Foundation (NSF) for travel support to
   present intial results through which insightful comments were received.
CR Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007
   Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t
   Bergman T. L., 2011, FUNDAMENTALS HEAT MA
   Bird R. B., 2002, TRANSPORT PHENOMENA
   Dancey JE, 2006, CANCER BIOL THER, V5, P1065, DOI 10.4161/cbt.5.9.3175
   Deen W.M., 2012, ANAL TRANSPORT PHENO
   FREDENSLUND A, 1975, AICHE J, V21, P1086, DOI 10.1002/aic.690210607
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898
   GRIJPMA DW, 1994, COLLOID POLYM SCI, V272, P1068, DOI 10.1007/BF00652375
   Hasenstein JR, 2012, MOL CANCER THER, V11, P2233, DOI 10.1158/1535-7163.MCT-11-0987
   Henton D. E., 2005, POLYLACTIC ACID TECH, P527
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Kang JW, 2011, FLUID PHASE EQUILIBR, V309, P68, DOI 10.1016/j.fluid.2011.07.001
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20
   Kwon GS, 1996, ADV DRUG DELIVER REV, V21, P107, DOI 10.1016/S0169-409X(96)00401-2
   Kwon GS, 1998, CRIT REV THER DRUG, V15, P481
   Lavasanifar A, 2002, ADV DRUG DELIVER REV, V54, P169, DOI 10.1016/S0169-409X(02)00015-7
   Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Poon WCK, 2006, SCOT GRAD SER, P1
   Roforth MM, 2008, ANTI-CANCER DRUG, V19, P681, DOI 10.1097/CAD.0b013e3283067681
   SAVJANI K.T., 2012, ISRN PHARM, V2012
   Shin HC, 2012, J CONTROL RELEASE, V163, P93, DOI 10.1016/j.jconrel.2012.04.024
   Shin HC, 2011, MOL PHARMACEUT, V8, P1257, DOI 10.1021/mp2000549
   Shin HC, 2009, J CONTROL RELEASE, V140, P294, DOI 10.1016/j.jconrel.2009.04.024
   Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004
   Smith J. M., 2005, INTRO CHEM ENG THERM
   Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007
   TAYLOR R, 1993, MULTICOMPONENT MASS
   Torchilin VP, 2002, ADV DRUG DELIVER REV, V54, P235, DOI 10.1016/S0169-409X(02)00019-4
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI 10.2217/NNM.10.10
   Wen SN, 2018, J NANOMATER, DOI 10.1155/2018/5818592
   Wittig R, 2003, IND ENG CHEM RES, V42, P183, DOI 10.1021/ie020506l
NR 38
TC 0
Z9 0
U1 5
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 799
EP 804
DI 10.1016/j.ces.2019.05.052
PG 6
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300066
DA 2020-05-12
ER

PT J
AU Xie, XZ
   Schenkendorf, R
AF Xie, Xiangzhong
   Schenkendorf, Rene
TI Robust optimization of a pharmaceutical freeze-drying process under
   non-Gaussian parameter uncertainties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Robust optimization; Freeze-drying; Point estimate method; Gaussian
   mixture distribution; Uncertainty quantification;
   Expectation-maximization
ID DESIGN SPACE; DYNAMIC OPTIMIZATION; QUANTIFICATION; TRANSFORMATION;
   SYSTEMS; MODEL; WATER
AB Model-based design of pharmaceutical manufacturing processes has received much interest in academia and industry. Model parameter uncertainties, however, might deteriorate the predicted process performance. Probability-based robust process design concepts as a countermeasure against uncertainties might be implemented. Here, parameter uncertainties are typically limited to Gaussian parameter distributions. However, parameter uncertainties derived with experimental data can be correlated and arbitrarily distributed. In our previous work, transformation techniques were combined with the point estimate method (PEM) to address non-Gaussian and correlated parameter distributions, but at the cost of additional nonlinearities and approximation errors. In this work, we take advantage of Gaussian mixture distributions (GMD) and decompose the parameter distribution into a finite set of Gaussian distributions using the Expectation-Maximization approach. Combining the GMD with the PEM ensures a proper and effective uncertainty quantification. The improved PEM algorithm is applied to a freezedrying process (lyophilization) aiming for high-quality products with minimum processing time. Results obtained suggest that the novel GMD-PEM algorithm has the potential to outperform conventional robustification concepts regarding credibility and efficiency. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xie, Xiangzhong; Schenkendorf, Rene] Tech Univ Carolo Wilhelmina Braunschweig, Inst Energy & Proc Syst Engn, Franz Liszt Str 35, D-38106 Braunschweig, Germany.
   [Xie, Xiangzhong; Schenkendorf, Rene] Tech Univ Carolo Wilhelmina Braunschweig, Ctr Pharmaceut Engn PVZ, Franz Liszt Str 35a, D-38106 Braunschweig, Germany.
RP Schenkendorf, R (reprint author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Energy & Proc Syst Engn, Franz Liszt Str 35, D-38106 Braunschweig, Germany.
EM r.schenkendorf@tu-braunschweig.de
FU "Promotionsprogramm mu-Props" by MWK Niedersachsen; International Max
   Planck Research School for Advanced Methods in Process and Systems
   Engineering, MPI Magdeburg
FX X. Xie acknowledges funding from the "Promotionsprogramm mu-Props" by
   MWK Niedersachsen and the support from the International Max Planck
   Research School for Advanced Methods in Process and Systems Engineering,
   MPI Magdeburg.
CR Amorij JP, 2007, VACCINE, V25, P6447, DOI 10.1016/j.vaccine.2007.06.054
   Andersson J., 2012, RECENT ADV ALGORITHM, V87, P297, DOI DOI 10.1007/978-3-642-30023-3_
   Beal MJ, 2003, BAYESIAN STATISTICS 7, P453
   Benyahia B, 2012, IND ENG CHEM RES, V51, P15393, DOI 10.1021/ie3006319
   Beyer HG, 2007, COMPUT METHOD APPL M, V196, P3190, DOI 10.1016/j.cma.2007.03.003
   Biegler LT, 2007, CHEM ENG PROCESS, V46, P1043, DOI 10.1016/j.cep.2006.06.021
   Biegler LT, 2010, NONLINEAR PROGRAMMIN
   Bishop C., 2006, PATTERN RECOGNITION
   Botev ZI, 2010, ANN STAT, V38, P2916, DOI 10.1214/10-AOS799
   Bulmer MG., 1979, PRINCIPLES STAT
   Carullo A, 2012, MEASUREMENT, V45, P1706, DOI 10.1016/j.measurement.2012.04.017
   Duff IS, 2004, ACM T MATH SOFTWARE, V30, P118, DOI 10.1145/992200.992202
   EDGAR TF, 2001, OPTIMIZATION CHEM PR
   Emery AF, 1998, MEAS SCI TECHNOL, V9, P864, DOI 10.1088/0957-0233/9/6/003
   Fisher R. A., 1959, STAT METHODS SCI INF
   Fissore D, 2011, J PHARM SCI-US, V100, P4922, DOI 10.1002/jps.22668
   Fissore D, 2011, DRY TECHNOL, V29, P73, DOI 10.1080/07373937.2010.482715
   GROSSMANN IE, 1978, AICHE J, V24, P1021, DOI 10.1002/aic.690240612
   Gupta U. D., 2010, INT J ENG TECHNOLOGY, V2, P340
   ICH, 2009, ICH HARMON TRIPART G, V8, P1
   Joshi M, 2006, METAB ENG, V8, P447, DOI 10.1016/j.ymben.2006.04.003
   Kaiser NM, 2016, COMPUT CHEM ENG, V94, P45, DOI 10.1016/j.compchemeng.2016.06.008
   Kalyanaraman J, 2015, COMPUT CHEM ENG, V81, P376, DOI 10.1016/j.compchemeng.2015.04.028
   Kasper JC, 2013, EUR J PHARM BIOPHARM, V85, P162, DOI 10.1016/j.ejpb.2013.05.019
   Kleinbaum D. G., 2010, MAXIMUM LIKELIHOOD T
   Krishna K, 1999, IEEE T SYST MAN CY B, V29, P433, DOI 10.1109/3477.764879
   Lebrun R, 2009, PROBABILIST ENG MECH, V24, P172, DOI 10.1016/j.probengmech.2008.05.001
   Lerner U.N., 2002, THESIS
   Liu YK, 2017, J MANUF SCI E-T ASME, V139, DOI 10.1115/1.4034667
   Luyben W.L., 1989, PROCESS MODELING SIM
   Maussner J, 2018, CHEM ENG SCI, V183, P329, DOI 10.1016/j.ces.2018.02.002
   Mesbah Ali, 2014, 2014 American Control Conference, P2413, DOI 10.1109/ACC.2014.6858851
   Moon TK, 1996, IEEE SIGNAL PROC MAG, V13, P47, DOI 10.1109/79.543975
   Mooney C. Z., 1997, MONTE CARLO SIMULATI
   Mortier STFC, 2016, EUR J PHARM BIOPHARM, V103, P71, DOI 10.1016/j.ejpb.2016.03.015
   Murphy DM, 2005, Q J ROY METEOR SOC, V131, P1539, DOI 10.1256/qj.04.94
   Nelsen R.B, 2007, INTRO COPULAS
   Ng S. K., 2012, EM ALGORITHM
   Nimmegeers P, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0328-6
   Noh Y, 2009, STRUCT MULTIDISCIP O, V38, P1, DOI 10.1007/s00158-008-0277-9
   Oladyshkin S, 2012, RELIAB ENG SYST SAFE, V106, P179, DOI 10.1016/j.ress.2012.05.002
   Pisano R, 2013, PHARM DEV TECHNOL, V18, P280, DOI 10.3109/10837450.2012.734512
   Roffel Brian, 2007, PROCESS DYNAMICS CON
   Rossner N., 2014, THESIS
   Sahinidis NV, 2004, COMPUT CHEM ENG, V28, P971, DOI 10.1016/j.compchemeng.2003.09.017
   Schenkendorf R., 2014, 2 EUR C PROGN HLTH M
   Schenkendorf R., 2014, THESIS
   Schenkendorf R, 2018, PROCESSES, V6, DOI 10.3390/pr6040027
   Searles J., 2004, AM PHARM REV, V7, P58
   Sheehan P, 1998, BIOTECHNOL BIOENG, V60, P712, DOI 10.1002/(SICI)1097-0290(19981220)60:6<712::AID-BIT8>3.0.CO;2-4
   Shi J, 2016, COMPUT CHEM ENG, V95, P260, DOI 10.1016/j.compchemeng.2016.08.002
   Shi XQ, 2014, WATER RESOUR RES, V50, P4416, DOI 10.1002/2013WR013755
   Smith R. C, 2013, UNCERTAINTY QUANTIFI, V12
   Srinivasan B, 2003, COMPUT CHEM ENG, V27, P27, DOI 10.1016/S0098-1354(02)00117-5
   Tang XL, 2004, PHARM RES-DORDR, V21, P191, DOI 10.1023/B:PHAM.0000016234.73023.75
   Telen D, 2015, J PROCESS CONTR, V33, P140, DOI 10.1016/j.jprocont.2015.06.011
   Vallerio M, 2016, CHEM ENG SCI, V140, P201, DOI 10.1016/j.ces.2015.09.012
   Vallerio M, 2015, EXPERT SYST APPL, V42, P7710, DOI 10.1016/j.eswa.2015.05.038
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Xie XZ, 2018, IFAC PAPERSONLINE, V51, P427, DOI 10.1016/j.ifacol.2018.03.073
   Xu T, 2016, WATER RESOUR RES, V52, P6111, DOI 10.1002/2016WR019011
   Zhao YG, 2001, STRUCT SAF, V23, P47, DOI 10.1016/S0167-4730(00)00027-8
NR 62
TC 2
Z9 2
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 805
EP 819
DI 10.1016/j.ces.2019.06.023
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300067
DA 2020-05-12
ER

PT J
AU Song, Y
   Liu, SE
   Wang, BY
   Shang, MJ
   Lin, LL
   Su, YH
AF Song, Yang
   Liu, Saier
   Wang, Baoyi
   Shang, Minjing
   Lin, Liangliang
   Su, Yuanhai
TI Continuous and controllable preparation of polyaniline with different
   reaction media in microreactors for supercapacitor applications
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polyaniline; Conductive polymers; Supercapacitor; Chemical oxidative
   polymerization; Microreactor; Solubility
ID INTERFACIAL POLYMERIZATION; OXIDATIVE POLYMERIZATION; CHEMICAL
   POLYMERIZATION; CONDUCTING POLYMER; ANILINE; NANOSTRUCTURES;
   PERFORMANCE; NANOFIBERS; MECHANISM; MICROPARTICLES
AB Polyaniline (PANI) particles were prepared via chemical oxidative polymerization in microreactors within the liquid-liquid slug flow regime. The effect of co-solvent (methanol, glycol or glycerol) on the morphology, chemical structure, thermal stability and electrochemical performance of final polymer products was investigated. Hansen's solubility parameters and Flory-Huggins model were introduced to explicate the microstructure variation of PANI particles synthesized with different media. The characteristic dimension of PANI particles tended to be smaller with the decrease of the Flory parameter of the reaction medium. Electrochemical measurement indicated that the specific capacitance of PANI could be improved by adding an organic co-solvent into the reaction medium. The maximum specific capacitance of 426F/g was achieved at the current density of 1 A/g with the voltage window ranging from -0.2 to 0.8 V (vs. Ag/AgCl) in 1 M H2SO4 solution. The maximum energy density reached 59.2 Wh/kg with the power density of 500 W/kg. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Song, Yang; Liu, Saier; Wang, Baoyi; Shang, Minjing; Su, Yuanhai] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, Shanghai 200240, Peoples R China.
   [Lin, Liangliang] Jiangnan Univ, Sch Chem & Mat Engn, 1800 Lihu Rd, Wuxi 214122, Jiangsu, Peoples R China.
   [Su, Yuanhai] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Thin Film & Microfabricat, Shanghai 200240, Peoples R China.
RP Shang, MJ; Su, YH (reprint author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, Shanghai 200240, Peoples R China.
EM mshang@sjtu.edu.cn; y.su@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676164, 21706157]; Science and Technology
   Commission of Shanghai MunicipalityScience & Technology Commission of
   Shanghai Municipality (STCSM) [18520743500]
FX We would like to acknowledge financial support from the National Natural
   Science Foundation of China (Nos. 21676164 and 21706157) and the Science
   and Technology Commission of Shanghai Municipality (No. 18520743500).
CR Bhadra S, 2009, PROG POLYM SCI, V34, P783, DOI 10.1016/j.progpolymsci.2009.04.003
   Blaha M, 2017, MATER CHEM PHYS, V194, P206, DOI 10.1016/j.matchemphys.2017.03.028
   Choi YK, 2017, MACROMOLECULES, V50, P3164, DOI 10.1021/acs.macromol.6b02586
   Dendukuri D, 2009, ADV MATER, V21, P4071, DOI 10.1002/adma.200803386
   Deng JX, 2017, COLLOID SURFACE A, V521, P247, DOI 10.1016/j.colsurfa.2016.09.016
   [邓楠楠 Deng Nannan], 2015, [中国科学. 化学, Scientia Sinica Chimica], V45, P7
   Duay J, 2012, PHYS CHEM CHEM PHYS, V14, P3329, DOI 10.1039/c2cp00019a
   FU YP, 1994, CHEM MATER, V6, P671, DOI 10.1021/cm00041a018
   Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013
   Guan H, 2010, ELECTROCHIM ACTA, V56, P964, DOI 10.1016/j.electacta.2010.09.078
   He Y, 2017, ACS APPL MATER INTER, V9, P7804, DOI 10.1021/acsami.6b15791
   Huang JX, 2004, J AM CHEM SOC, V126, P851, DOI 10.1021/ja0371754
   HUANG WS, 1986, J CHEM SOC FARAD T 1, V82, P2385, DOI 10.1039/f19868202385
   Jin DD, 2018, J SOLID STATE ELECTR, V22, P1227, DOI 10.1007/s10008-017-3866-y
   Kong XZ, 2009, MACROMOL RAPID COMM, V30, P909, DOI 10.1002/marc.200800772
   Lei W, 2014, J POWER SOURCES, V266, P347, DOI 10.1016/j.jpowsour.2014.05.064
   Li D, 2009, ACCOUNTS CHEM RES, V42, P135, DOI 10.1021/ar800080n
   Li R, 2019, RSC ADV, V9, P1679, DOI 10.1039/c8ra09043b
   Lin YF, 2011, ACS NANO, V5, P1541, DOI 10.1021/nn103525b
   Liu L, 2013, SYNTHETIC MET, V170, P57, DOI 10.1016/j.synthmet.2013.02.026
   Liu Y, 2013, J AM CHEM SOC, V135, P4765, DOI 10.1021/ja3122608
   Long YZ, 2011, PROG POLYM SCI, V36, P1415, DOI 10.1016/j.progpolymsci.2011.04.001
   MACDIARMID AG, 1985, MOL CRYST LIQ CRYST, V121, P173, DOI 10.1080/00268948508074857
   Nisisako T, 2007, ADV MATER, V19, P1489, DOI 10.1002/adma.200700272
   Nuraje N, 2008, ACS NANO, V2, P502, DOI 10.1021/nn7001536
   Odian G., 2004, PRINCIPLES POLYM
   Oueiny C, 2016, PHYS CHEM CHEM PHYS, V18, P3504, DOI 10.1039/c5cp06473b
   Qiu BW, 2017, J POLYM SCI POL CHEM, V55, P3357, DOI 10.1002/pola.28707
   Qiu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13060
   Russum JP, 2005, IND ENG CHEM RES, V44, P2484, DOI 10.1021/ie040136w
   Sapurina I, 2008, POLYM INT, V57, P1295, DOI 10.1002/pi.2476
   Singh P, 2012, SYNTHETIC MET, V162, P2193, DOI 10.1016/j.synthmet.2012.10.017
   Song Y, 2018, IND ENG CHEM RES, V57, P10922, DOI 10.1021/acs.iecr.8b02314
   Song Y, 2018, CHEM ENG J, V353, P769, DOI 10.1016/j.cej.2018.07.166
   Stejskal J, 2010, PROG POLYM SCI, V35, P1420, DOI 10.1016/j.progpolymsci.2010.07.006
   Su YH, 2014, CHEM-EUR J, V20, P10562, DOI 10.1002/chem.201400283
   Tonhauser C, 2012, MACROMOLECULES, V45, P9551, DOI 10.1021/ma301671x
   Tran HD, 2011, J MATER CHEM, V21, P3534, DOI 10.1039/c0jm02699a
   TZOU K, 1992, SYNTHETIC MET, V47, P267, DOI 10.1016/0379-6779(92)90367-R
   Wallace G., 2009, CONDUCTIVE ELECTROAC
   Wang K, 2017, CHEM ENG SCI, V169, P18, DOI 10.1016/j.ces.2016.10.025
   Yadav AK, 2011, MACROMOL REACT ENG, V5, P69, DOI 10.1002/mren.201000030
   Yang YH, 2007, NANO LETT, V7, P3879, DOI 10.1021/nl071849h
   Zeng FX, 2015, PROG NAT SCI-MATER, V25, P512, DOI 10.1016/j.pnsc.2015.10.002
   Zhao JY, 2015, PROG NAT SCI-MATER, V25, P316, DOI 10.1016/j.pnsc.2015.07.003
   Zhao YF, 2015, SMALL, V11, P1310, DOI 10.1002/smll.201401922
NR 46
TC 3
Z9 3
U1 30
U2 111
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 820
EP 828
DI 10.1016/j.ces.2019.07.008
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300068
DA 2020-05-12
ER

PT J
AU Bao, YY
   Jiang, ZC
   Tong, SF
   Huang, XB
   Cai, ZQ
   Gao, ZM
AF Bao, Yuyun
   Jiang, Zhichao
   Tong, Shuaifei
   Huang, Xiongbin
   Cai, Ziqi
   Gao, Zhengming
TI Reactive mass transfer of single O-2 bubbles in a turbulent flow chamber
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactive mass transfer coefficients; Single bubble; Turbulent vortex;
   Enhancement factor; Slip velocity
ID DIFFUSION-COEFFICIENTS; LIQUID; GAS; VISUALIZATION; CONTAMINATION;
   SURFACE; IMPACT; PHASE; WATER; CO2
AB A non-intrusive measurement method was used to quantify the mass transfer between an oxygen bubble (with a spherical equivalent diameter in the range 2-4 mm) and the turbulent sodium sulfite solution in which the bubble was driven to circulate. The variations of the position, size, and velocity of the single bubble with time were derived from the images recorded by a high-speed camera, and the average reactive mass transfer coefficients were calculated from the reduction of the volume of the bubble. The enhancement factors under various flow conditions caused by the catalyzed chemical reaction were provided. The flow field in the chamber was measured by 2D particle image velocimetry (PIV). The single-phase instantaneous flow field was compared with the multi-phase flow field in terms of the effect of the single bubble. A correlation of the bubble Sherwood number with the bubble Reynolds number was obtained under different liquid Reynolds numbers. We found that the slip velocity has a high capacity to keep the bubble surface mobile. Both the bubble Reynolds number based on the bubble slip velocity and liquid Reynolds number contributed to the mass transfer in the turbulent chamber. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bao, Yuyun; Jiang, Zhichao; Tong, Shuaifei; Huang, Xiongbin; Cai, Ziqi; Gao, Zhengming] Beijing Univ Chem Technol, Sch Chem Engn, State Key Lab Chem Resource Engn, Beijing 100029, Peoples R China.
RP Cai, ZQ; Gao, ZM (reprint author), Beijing Univ Chem Technol, Sch Chem Engn, Mailbox 230, Beijing 100029, Peoples R China.
EM caiziqi@mail.buct.edu.cn; gaozm@mail.buct.edu.cn
FU National Key R&D Program of China [2017YFB0306701, 2017YFB0306703];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676007]; Fundamental Research Funds for the
   Central Universities of ChinaFundamental Research Funds for the Central
   Universities [XK1802-1]
FX Financial supports from the National Key R&D Program of China
   (2017YFB0306701, 2017YFB0306703), the National Natural Science
   Foundation of China (No. 21676007) and the Fundamental Research Funds
   for the Central Universities of China (XK1802-1) are gratefully
   acknowledged.
CR Alves SS, 2006, CHEM ENG SCI, V61, P1334, DOI 10.1016/j.ces.2005.08.001
   Alves SS, 2005, CHEM ENG SCI, V60, P1, DOI 10.1016/j.ces.2004.07.053
   Alves SS, 2004, CHEM ENG PROCESS, V43, P823, DOI 10.1016/S0255-2701(03)00100-4
   Alves SS, 2002, CHEM ENG SCI, V57, P487, DOI 10.1016/S0009-2509(01)00400-6
   Aoki J, 2017, INT J HEAT MASS TRAN, V108, P1991, DOI 10.1016/j.ijheatmasstransfer.2017.01.058
   Bork O, 2005, CAN J CHEM ENG, V83, P658
   CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Clift R., 1978, BUBBLES DROPS PARTIC
   Dietrich N, 2013, CHEM ENG SCI, V100, P172, DOI 10.1016/j.ces.2013.03.041
   Dietrich N, 2018, HEAT MASS TRANSFER, V54, P2163, DOI 10.1007/s00231-018-2297-3
   Francois J, 2011, CHEM ENG SCI, V66, P3328, DOI 10.1016/j.ces.2011.01.049
   Green D. W., 2007, PERRYS CHEM ENG HDB
   GRIFFITH RM, 1960, CHEM ENG SCI, V12, P198, DOI 10.1016/0009-2509(60)85006-3
   Higbie R, 1935, T AM INST CHEM ENG, V31, P365
   Hosoda S, 2014, INT J HEAT MASS TRAN, V69, P215, DOI 10.1016/j.ijheatmasstransfer.2013.10.031
   Huang J, 2017, CHEM ENG SCI, V157, P182, DOI 10.1016/j.ces.2016.05.013
   Jamnongwong M, 2010, CHEM ENG J, V165, P758, DOI 10.1016/j.cej.2010.09.040
   Jimenez M, 2013, CHEM ENG SCI, V100, P160, DOI 10.1016/j.ces.2013.01.036
   Jimenez M, 2014, WATER RES, V58, P111, DOI 10.1016/j.watres.2014.03.065
   KAWASE Y, 1992, BIOTECHNOL BIOENG, V39, P1133, DOI 10.1002/bit.260391109
   Kherbeche A., 2019, CHEM ENG J
   Kong G, 2018, EXP THERM FLUID SCI, V93, P186, DOI 10.1016/j.expthermflusci.2017.12.032
   Kordac M, 2011, CHEM ENG J, V167, P314, DOI 10.1016/j.cej.2010.12.075
   Kuck UD, 2018, CHEM ENG SCI, V187, P367, DOI 10.1016/j.ces.2018.04.031
   Kuck UD, 2012, J CHEM ENG JPN, V45, P708
   LAMONT JC, 1970, AICHE J, V16, P513, DOI 10.1002/aic.690160403
   Li GH, 2018, AICHE J, V64, P389, DOI 10.1002/aic.15924
   Li ZP, 2013, AICHE J, V59, P3986, DOI 10.1002/aic.14117
   Linek V, 2004, CHEM ENG PROCESS, V43, P1511, DOI 10.1016/j.cep.2004.02.009
   LOCHIEL AC, 1964, CHEM ENG SCI, V19, P471, DOI 10.1016/0009-2509(64)85074-0
   Madhavi T, 2007, CHEM ENG J, V128, P95, DOI 10.1016/j.cej.2006.10.019
   Martinodotn M., 2011, Bubble Science, Engineering & Technology, V3, P48, DOI 10.1179/1758897911Y.0000000006
   Merker D, 2017, CHEM ENG TECHNOL, V40, P1391, DOI 10.1002/ceat.201600715
   Moreno VC, 2017, CHEM ENG SCI, V170, P77, DOI 10.1016/j.ces.2017.01.050
   Nock WJ, 2016, CHEM ENG SCI, V140, P171, DOI 10.1016/j.ces.2015.10.001
   Olsen JE, 2017, CHEM ENG SCI, V161, P308, DOI 10.1016/j.ces.2016.12.047
   Pan X, 2018, CHEM ENG SCI, V176, P343, DOI 10.1016/j.ces.2017.10.054
   PRASHER BD, 1973, IND ENG CHEM PROC DD, V12, P351, DOI 10.1021/i260047a023
   Saito T, 2015, CHEM ENG J, V265, P164, DOI 10.1016/j.cej.2014.12.039
   Solsvik J, 2018, CHEM ENG SCI, V190, P370, DOI 10.1016/j.ces.2018.06.002
   Vasconcelos JMT, 2002, AICHE J, V48, P1145, DOI 10.1002/aic.690480603
   Wang GC, 2017, MINER ENG, V102, P58, DOI 10.1016/j.mineng.2016.11.013
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Xu FS, 2018, IND ENG CHEM RES, V57, P15181, DOI 10.1021/acs.iecr.8b03617
   Xu FS, 2017, CHEM ENG SCI, V170, P68, DOI 10.1016/j.ces.2017.02.043
   Yang L, 2017, CHEM ENG SCI, V165, P192, DOI 10.1016/j.ces.2017.03.007
   Yang LX, 2016, CHEM ENG SCI, V143, P364, DOI 10.1016/j.ces.2016.01.013
   Zhang JJ, 2017, CHEM ENG SCI, V170, P464, DOI 10.1016/j.ces.2017.02.002
   Zhang JJ, 2016, CHINESE J CHEM ENG, V24, P703, DOI 10.1016/j.cjche.2015.12.008
   Zhao B, 2003, CHEM ENG J, V96, P23, DOI 10.1016/j.cej.2003.08.010
NR 50
TC 0
Z9 0
U1 5
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 829
EP 843
DI 10.1016/j.ces.2019.07.006
PG 15
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300069
DA 2020-05-12
ER

PT J
AU Rocha, KD
   Marques, CMP
   Bueno, JMC
AF Rocha, Kleper de Oliveira
   Paula Marques, Clelia Mara
   Correa Bueno, Jose Maria
TI Effect of Au doping of Ni/Al2O3 catalysts used in steam reforming of
   methane: Mechanism, apparent activation energy, and compensation effect
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Steam reforming of methane; Ni/Al2O3 catalysts; Compensation effect;
   Apparent activation energy; Au-promoted Ni catalysts
ID WATER-GAS SHIFT; SUPPORTED NI CATALYSTS; CHEMICAL CONVERSION; CO
   OXIDATION; INFRARED-SPECTROSCOPY; KINETIC ASSESSMENT; SITE REQUIREMENTS;
   REACTION PATHWAYS; NICKEL-CATALYSTS; CARBON
AB Investigation was made of the effect of addition of Au to 15%Ni/Al2O3 catalysts used in the steam reforming of methane. The addition of Au was performed by impregnation of reduced Ni catalysts. The catalysts were characterized by X-ray diffraction (XRD) and diffuse reflectance infrared Fourier transform spectroscopy of adsorbed CO (DRIFTS-CO). DRIFTS-CO showed that Au modified the surface structure of Ni. Au blocked the low coordination Ni sites with high electron density and high activity for CH4 activation. Furthermore, it modified the high coordination Ni, causing geometric and electronic effects, changing the CO adsorption from bridge to linear form, and increasing the electron density of Ni-Au, relative to Ni at sites such as Ni(1 1 1). Addition of Au to the Ni catalysts had a strong influence on the activation of CH4. A compensation effect was observed between the apparent activation energy (E-a(app)) and the natural logarithm of the pre-exponential factor (In(k(0))), obtained by fitting of the Arrhenius equation to the rate of the overall reaction. Greater Au addition decreased the catalytic activity, with linear increase of E-a(app) with increase of ln(k(0)). These results suggested that the intermediates formed by decomposition of CH4, in the step determining the overall velocity, presented low interaction with the Ni surface. The proposed mechanisms also suggested that the activation of CH4 required two Ni neighbor sites. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rocha, Kleper de Oliveira] Sao Paulo State Univ UNESP, Sci Fac, Dept Chem, Av Engn Luiz Edmundo Carrijo Coube 14-01, BR-17033360 Bauru, SP, Brazil.
   [Paula Marques, Clelia Mara] Fed Univ Sao Carlos UFSCar, Dept Chem, CP 676, BR-13565905 Sao Carlos, SP, Brazil.
   [Correa Bueno, Jose Maria] Fed Univ Sao Carlos UFSCar, Dept Chem Engn, CP 676, BR-13565905 Sao Carlos, SP, Brazil.
RP Rocha, KD (reprint author), Sao Paulo State Univ UNESP, Sci Fac, Dept Chem, Av Engn Luiz Edmundo Carrijo Coube 14-01, BR-17033360 Bauru, SP, Brazil.
EM kleper.rocha@unesp.br; clelia@ufscar.br; jmcb@ufscar.br
RI Rocha, Kleper/K-7010-2012
OI Rocha, Kleper/0000-0001-7887-9113
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2018/012585]; CNPQNational Council for Scientific
   and Technological Development (CNPq) [301027/2018-8]
FX The authors thank Sao Paulo Research Foundation for financial support
   (process 2018/012585) and CNPQ (Project No 301027/2018-8).
CR Bengaard HS, 2002, J CATAL, V209, P365, DOI 10.1006/jcat.2002.3579
   Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913
   BLACKMOND DG, 1985, J CATAL, V96, P210, DOI 10.1016/0021-9517(85)90374-4
   Bligaard T, 2004, J CATAL, V224, P206, DOI 10.1016/j.jcat.2004.02.034
   Bligaard T, 2003, J PHYS CHEM B, V107, P9325, DOI 10.1021/jp034447g
   Boudjeloud M, 2019, INT J HYDROGEN ENERG, V44, P9906, DOI 10.1016/j.ijhydene.2019.01.140
   Choudhary TV, 2000, J MOL CATAL A-CHEM, V163, P9, DOI 10.1016/S1381-1169(00)00395-2
   Christensen A, 1997, PHYS REV B, V56, P5822, DOI 10.1103/PhysRevB.56.5822
   Christensen KO, 2006, APPL CATAL A-GEN, V314, P9, DOI 10.1016/j.apcata.2006.07.028
   EISCHENS RP, 1956, J PHYS CHEM-US, V60, P194, DOI 10.1021/j150536a015
   El Kolli N, 2013, J CATAL, V297, P79, DOI 10.1016/j.jcat.2012.09.022
   Froment G. F., 2011, CHEM REACTOR ANAL DE
   GARLAND CW, 1965, J PHYS CHEM-US, V69, P1188, DOI 10.1021/j100888a016
   Hinojosa-Reyes M, 2016, APPL SURF SCI, V368, P224, DOI 10.1016/j.apsusc.2016.01.285
   Holmblad PM, 1996, J CHEM PHYS, V104, P7289, DOI 10.1063/1.471395
   Hu CW, 1996, J MOL CATAL A-CHEM, V110, P163, DOI 10.1016/1381-1169(96)00044-1
   Hyldtoft Kokkedal Jens, 1999, Patent No. [US5997835A, 5997835]
   Hyldtoft Kokkedal Jens, 1998, Patent No. [US5997835A, 5997835]
   Jones G, 2008, J CATAL, V259, P147, DOI 10.1016/j.jcat.2008.08.003
   Karolyi J, 2018, J IND ENG CHEM, V58, P189, DOI 10.1016/j.jiec.2017.09.024
   KUBELKOVA L, 1993, APPL CATAL A-GEN, V95, P87, DOI 10.1016/0926-860X(93)80199-Z
   Leba A, 2012, CATAL COMMUN, V29, P6, DOI 10.1016/j.catcom.2012.09.010
   Lee SM, 2019, FUEL PROCESS TECHNOL, V188, P197, DOI 10.1016/j.fuproc.2019.02.023
   Lonergan WW, 2010, J CATAL, V271, P239, DOI 10.1016/j.jcat.2010.01.019
   Malaibari ZO, 2015, APPL CATAL A-GEN, V490, P80, DOI 10.1016/j.apcata.2014.11.002
   Malyala RV, 2000, APPL CATAL A-GEN, V193, P71, DOI 10.1016/S0926-860X(99)00442-1
   Mohsenzadeh A, 2016, SURF SCI, V644, P53, DOI 10.1016/j.susc.2015.09.014
   Molenbroek AM, 2001, J PHYS CHEM B, V105, P5450, DOI 10.1021/jp0043975
   NIELSEN LP, 1993, PHYS REV LETT, V71, P754, DOI 10.1103/PhysRevLett.71.754
   Norskov JK, 2002, J CATAL, V209, P275, DOI 10.1006/jcat.2002.3615
   Parizotto NV, 2007, APPL CATAL A-GEN, V330, P12, DOI 10.1016/j.apcata.2007.06.022
   Park YS, 2018, J POWER SOURCES, V397, P318, DOI 10.1016/j.jpowsour.2018.07.025
   Pashchenko D, 2019, AICHE J, V65, DOI 10.1002/aic.16558
   Pashchenko D, 2019, INT J HYDROGEN ENERG, V44, P7073, DOI 10.1016/j.ijhydene.2019.01.250
   Pawelec B, 2005, APPL SURF SCI, V242, P380, DOI 10.1016/j.apsusc.2004.09.004
   PERI JB, 1984, J CATAL, V86, P84, DOI 10.1016/0021-9517(84)90350-6
   Poncelet G, 2005, APPL CATAL A-GEN, V288, P232, DOI 10.1016/j.apcata.2005.04.052
   PRIMET M, 1977, J CATAL, V46, P25, DOI 10.1016/0021-9517(77)90132-4
   Riguetto BA, 2004, J PHYS CHEM B, V108, P5349, DOI 10.1021/jp031167s
   ROSTRUPNIELSEN JR, 1984, J CATAL, V85, P31, DOI 10.1016/0021-9517(84)90107-6
   Ruban A, 1997, J MOL CATAL A-CHEM, V115, P421, DOI 10.1016/S1381-1169(96)00348-2
   Ruban AV, 1999, PHYS REV B, V59, P15990, DOI 10.1103/PhysRevB.59.15990
   Saw ET, 2014, J CATAL, V314, P32, DOI 10.1016/j.jcat.2014.03.015
   Shirasuka K., 1976, Yogyo-Kyokai-Shi, V84, P610
   SKIBSTED LH, 1974, ACTA CHEM SCAND A, VA 28, P740, DOI 10.3891/acta.chem.scand.28a-0740
   Theofanidis SA, 2018, APPL CATAL B-ENVIRON, V239, P502, DOI 10.1016/j.apcatb.2018.08.042
   Trimm DL, 1997, CATAL TODAY, V37, P233, DOI 10.1016/S0920-5861(97)00014-X
   Trimm DL, 1999, CATAL TODAY, V49, P3, DOI 10.1016/S0920-5861(98)00401-5
   Wei JM, 2004, PHYS CHEM CHEM PHYS, V6, P3754, DOI 10.1039/b400934g
   Wei JM, 2004, J CATAL, V225, P116, DOI 10.1016/j.jcat.2003.09.030
   Wei JM, 2004, J PHYS CHEM B, V108, P7253, DOI 10.1021/jp030783l
   Wei JM, 2004, J CATAL, V224, P370, DOI 10.1016/j.jcat.2004.02.032
   Wei JM, 2004, J PHYS CHEM B, V108, P4094, DOI 10.1021/jp036985z
   Widmann D, 2010, J CATAL, V276, P292, DOI 10.1016/j.jcat.2010.09.023
   Wu HJ, 2013, CATALYSTS, V3, P563, DOI 10.3390/catal3020563
   XU JG, 1989, AICHE J, V35, P88, DOI 10.1002/aic.690350109
   Xu Y, 2018, INT J HYDROGEN ENERG, V43, P15975, DOI 10.1016/j.ijhydene.2018.06.175
   Yang KW, 2017, APPL SURF SCI, V399, P255, DOI 10.1016/j.apsusc.2016.12.073
   YATES JT, 1961, J PHYS CHEM-US, V65, P617, DOI 10.1021/j100822a007
   Zhang C, 2007, CATAL TODAY, V126, P345, DOI 10.1016/j.cattod.2007.06.010
NR 60
TC 4
Z9 4
U1 23
U2 76
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 844
EP 852
DI 10.1016/j.ces.2019.06.049
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300070
DA 2020-05-12
ER

PT J
AU Fleck, S
   Rzehak, R
AF Fleck, Sebastian
   Rzehak, Roland
TI Investigation of bubble plume oscillations by Euler-Euler simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble columns; Dispersed gas liquid multiphase flow; Euler-Euler two
   fluid model; Closure relations; CFD simulation; Model validation
ID GAS-LIQUID FLOWS; MULTIPHASE CFD-SIMULATION; MASS-TRANSFER;
   NUMERICAL-SIMULATION; REACTIVE ABSORPTION; ASPECT RATIO; COLUMN; MODEL;
   DYNAMICS; NAOH
AB For practical applications the Euler-Euler two-fluid model relies on suitable closure relations describing interfacial exchange processes. An ongoing effort at HZDR has led to a validated set of closures for adiabatic bubbly flows that is applicable under a rather broad range of conditions including flows in pipes and bubble columns. Up to now, however, only flows with stationary mean values have been considered. The present contribution extends the model validation to dynamic flow phenomena by considering a periodically oscillating bubble plume. Consequently, the turbulence model then runs in URANS mode. Literature data for a partially aerated flat rectangular bubble column are used for comparison. In particular, results for the plume oscillation period show good agreement between simulation and experiment. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fleck, Sebastian; Rzehak, Roland] Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
   [Fleck, Sebastian] Tech Univ Dresden, Chair Chem React Engn & Proc Plant, Munchnerpl 3, D-01062 Dresden, Germany.
RP Rzehak, R (reprint author), Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
EM r.rzehak@hzdr.de
CR Becker S, 1999, CHEM ENG SCI, V54, P4929, DOI 10.1016/S0009-2509(99)00214-6
   Burns A.D., 2004, P 5 INT C MULT FLOW
   Buwa VV, 2006, INT J MULTIPHAS FLOW, V32, P864, DOI 10.1016/j.ijmultiphaseflow.2006.02.017
   Buwa VV, 2005, CHEM ENG COMMUN, V192, P1129, DOI 10.1080/009864490522704
   Buwa VV, 2002, CHEM ENG SCI, V57, P4715, DOI 10.1016/S0009-2509(02)00274-9
   Buwa VV, 2004, AICHE J, V50, P2394, DOI 10.1002/aic.10199
   Cachaza EM, 2011, CHEM ENG SCI, V66, P4047, DOI 10.1016/j.ces.2011.05.036
   Darmana D, 2007, CHEM ENG SCI, V62, P2556, DOI 10.1016/j.ces.2007.01.065
   Delnoij E, 1997, CHEM ENG SCI, V52, P3759, DOI 10.1016/S0009-2509(97)00222-4
   Diaz ME, 2008, CHEM ENG J, V139, P363, DOI 10.1016/j.cej.2007.08.015
   Drew D.A., 1998, THEORY MULTICOMPONEN
   Diaz ME, 2006, IND ENG CHEM RES, V45, P7301, DOI 10.1021/ie060466b
   Gupta A, 2013, CHEM ENG J, V225, P818, DOI 10.1016/j.cej.2012.11.012
   Hosokawa S., 2002, P ASME JOINT US EUR
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   Ishii M, 2011, THERMO-FLUID DYNAMICS OF TWO-PHASE FLOW, SECOND EDITION, P1, DOI 10.1007/978-1-4419-7985-8
   Julia JE, 2007, CHEM ENG SCI, V62, P6361, DOI 10.1016/j.ces.2007.07.055
   Krauss M, 2018, CHEM ENG SCI, V181, P199, DOI 10.1016/j.ces.2018.01.009
   Krauss M, 2017, CHEM ENG SCI, V166, P193, DOI 10.1016/j.ces.2017.03.029
   Laupsien D, 2017, CHEM ENG TECHNOL, V40, P1484, DOI 10.1002/ceat.201600690
   Liao J, 2016, J CHEM TECHNOL BIOT, V91, P2904, DOI 10.1002/jctb.4917
   Liao YX, 2015, CHEM ENG SCI, V122, P336, DOI 10.1016/j.ces.2014.09.042
   Lin TJ, 1996, AICHE J, V42, P301, DOI 10.1002/aic.690420202
   Liu L., 2019, CHEM ENG SCI
   Parekh J, 2018, INT J MULTIPHAS FLOW, V99, P231, DOI 10.1016/j.ijmultiphaseflow.2017.10.012
   Pfleger D, 1999, CHEM ENG SCI, V54, P5091, DOI 10.1016/S0009-2509(99)00261-4
   Rensen J, 2001, INT J MULTIPHAS FLOW, V27, P1431, DOI 10.1016/S0301-9322(01)00012-X
   Rzehak R, 2017, INT J MULTIPHAS FLOW, V89, P299, DOI 10.1016/j.ijmultiphaseflow.2016.09.024
   Rzehak R, 2017, CHEM ENG SCI, V157, P147, DOI 10.1016/j.ces.2016.04.056
   Rzehak R, 2016, CHEM ENG SCI, V155, P459, DOI 10.1016/j.ces.2016.08.036
   Rzehak R, 2016, CHEM ENG SCI, V151, P139, DOI 10.1016/j.ces.2016.05.024
   Rzehak R, 2015, CHEM ENG TECHNOL, V38, P1972, DOI 10.1002/ceat.201500118
   Rzehak R, 2015, NUCL ENG DES, V287, P108, DOI 10.1016/j.nucengdes.2015.03.005
   Rzehak R, 2015, INT J MULTIPHAS FLOW, V68, P135, DOI 10.1016/j.ijmultiphaseflow.2014.09.005
   Rzehak R, 2013, INT J MULTIPHAS FLOW, V55, P138, DOI 10.1016/j.ijmultiphaseflow.2013.04.007
   Rzehak R, 2013, NUCL ENG DES, V258, P57, DOI 10.1016/j.nucengdes.2013.02.008
   Shi PY, 2018, CHEM ENG SCI, V190, P419, DOI 10.1016/j.ces.2018.06.001
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Upadhyay RK, 2013, CHEM ENG SCI, V96, P152, DOI 10.1016/j.ces.2013.03.045
   Yeoh GH, 2010, COMPUTATIONAL TECHNIQUES FOR MULTI-PHASE FLOWS: BASICS AND APPLICATIONS, P1
   Ziegenhein T, 2017, CAN J CHEM ENG, V95, P170, DOI 10.1002/cjce.22647
   Ziegenhein T, 2013, CHEM-ING-TECH, V85, P1080, DOI 10.1002/cite.201200223
NR 42
TC 0
Z9 0
U1 8
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 853
EP 861
DI 10.1016/j.ces.2019.07.011
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300071
DA 2020-05-12
ER

PT J
AU Tripodi, A
   Ripamonti, D
   Martinazzo, R
   Folco, F
   Tabanelli, T
   Cavani, F
   Rossetti, I
AF Tripodi, Antonio
   Ripamonti, Davide
   Martinazzo, Rocco
   Folco, Federico
   Tabanelli, Tommaso
   Cavani, Fabrizio
   Rossetti, Ilenia
TI Kinetic model for the ammoxidation of ethanol to acetonitrile
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Acetonitrile; Ethanol; Ammoxidation; Kinetic modeling; Biorefinery
ID DENSITY-FUNCTIONAL THEORY; OXIDATIVE DEHYDROGENATION; SELECTIVE
   OXIDATION; FLAMMABILITY LIMITS; PROPANE AMMOXIDATION; CATALYSTS;
   VANADIUM; ETHYLENE; DISTILLATION; PURE
AB A comprehensive kinetic study, based on V-based catalysts (Vanadium Pyro-Phosphate, VPP, VOx/TiO2 and VOx/ZrO2), was modeled to retrieve the surface reaction mechanism and kinetic parameters for the ammoxidation of ethanol to acetonitrile. In all the cases, the catalysts showed a moderate to good acetonitrile selectivity, that in turn resulted correlated primarily to the reaction temperature, while the byproducts distribution was more influenced by the thermodynamic stability of the reacting mixture.
   A large and comprehensive collection of data on ammoxidation of C2 substrates for acetonitrile production was analysed and 5 groups of experiments on VOx-based catalysts (operating in the temperature range 250-450 degrees C) were selected. The base reactant was ethanol and ammonia and oxygen were fed in optimal ratios of 1:3-1:4 mol/mol.
   A kinetic model was then derived applying the Langmuir-Hinshelwood-Hougen-Watson (LHHW) approach to accepted catalytic oxidation mechanisms: for every catalytic material, eight to ten reactions with rates described by the Arrhenius formula were employed. Fixing the reaction orders according to the mechanistic assumption and adjusting only the kinetic and adsorption parameters, the calculated molar fractions of ethanol, ammonia, acetonitrile and ethylene resulted in good agreement with the extensive collection of experimental data available. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tripodi, Antonio; Ripamonti, Davide; Martinazzo, Rocco; Rossetti, Ilenia] Univ Milan, Dipartimento Chim, Chem Plants & Ind Chem Grp, INSTM Milano Univ Unit,CNR ISTM, Via Golgi 19, I-20133 Milan, MI, Italy.
   [Folco, Federico; Tabanelli, Tommaso; Cavani, Fabrizio] Alma Mater Studiorum Univ Bologna, Dipartimento Chim Ind Toso Montanari, Viale Risorgimento 4, I-40136 Bologna, Italy.
RP Rossetti, I (reprint author), Univ Milan, Dipartimento Chim, Chem Plants & Ind Chem Grp, INSTM Milano Univ Unit,CNR ISTM, Via Golgi 19, I-20133 Milan, MI, Italy.
EM ileina.rossetti@unimi.it
RI Tabanelli, Tommaso/AAL-1300-2020; Martinazzo, Rocco/B-5192-2011;
   Rossetti, Ilenia/O-8929-2016
OI Tabanelli, Tommaso/0000-0003-0616-8990; Martinazzo,
   Rocco/0000-0002-1077-251X; Rossetti, Ilenia/0000-0001-5882-5011
CR ACS Office of Public Outreach, 1996, SOH ACR PROC
   Afandizadeh S, 2001, APPL THERM ENG, V21, P669, DOI 10.1016/S1359-4311(00)00072-7
   Alexopoulos K, 2016, J CATAL, V339, P173, DOI 10.1016/j.jcat.2016.04.020
   Ayari F, 2012, APPL CATAL A-GEN, V415, P132, DOI 10.1016/j.apcata.2011.12.021
   Ballarini N, 2006, TOP CATAL, V38, P147, DOI 10.1007/s11244-006-0080-z
   Ballarini N, 2004, CATAL TODAY, V91-2, P99, DOI 10.1016/j.cattod.2004.03.016
   Belov VV, 2016, RUSS J APPL CHEM+, V89, P414, DOI 10.1134/S1070427216030113
   Bharadwaj SS, 1996, IND ENG CHEM RES, V35, P1524, DOI 10.1021/ie950520g
   Bondareva VM, 2006, REACT KINET CATAL L, V87, P377, DOI 10.1007/s11144-006-0051-1
   Bredow T, 2004, RES CHEM INTERMEDIAT, V30, P65, DOI 10.1163/156856704322798052
   Bulanek R, 2002, APPL CATAL A-GEN, V235, P181, DOI 10.1016/S0926-860X(02)00263-6
   CARD RJ, 1981, J ORG CHEM, V46, P754, DOI 10.1021/jo00317a020
   CAVALLI P, 1987, IND ENG CHEM RES, V26, P804, DOI 10.1021/ie00064a031
   CAVALLI P, 1987, IND ENG CHEM RES, V26, P639, DOI 10.1021/ie00064a001
   Cavani F, 1997, APPL CATAL A-GEN, V157, P195, DOI 10.1016/S0926-860X(97)00052-5
   Cavani F., 1987, J CATAL, V106
   Chen KD, 1999, J CATAL, V186, P325, DOI 10.1006/jcat.1999.2510
   Chieregato A, 2015, COORDIN CHEM REV, V301, P3, DOI 10.1016/j.ccr.2014.12.003
   Corker EC, 2013, GREEN CHEM, V15, P928, DOI 10.1039/c3gc36513a
   Coronado CJR, 2012, J HAZARD MATER, V241, P32, DOI 10.1016/j.jhazmat.2012.09.035
   Costine A, 2005, APPL CATAL A-GEN, V290, P9, DOI 10.1016/j.apcata.2005.05.032
   Creaser D, 1999, J CATAL, V182, P264, DOI 10.1006/jcat.1998.2336
   Evans B., 1991, ULLMANNS ENCY IND CH
   Fang ZT, 2015, J PHYS CHEM C, V119, P23413, DOI 10.1021/acs.jpcc.5b05887
   Fattahi M, 2014, J IND ENG CHEM, V20, P2236, DOI 10.1016/j.jiec.2013.09.056
   Feng C, 2011, CATAL LETT, V141, P168, DOI 10.1007/s10562-010-0468-z
   Folco F, 2017, CATAL SCI TECHNOL, V7, P200, DOI 10.1039/c6cy01275b
   Galanov SI, 2014, PROCEDIA CHEM, V10, P108, DOI 10.1016/j.proche.2014.10.020
   Grabowski R, 2004, APPL CATAL A-GEN, V270, P37, DOI 10.1016/j.apcata.2004.04.021
   GRASSELLI RK, 1986, J CHEM EDUC, V63, P216, DOI 10.1021/ed063p216
   Grasselli RK, 1999, CATAL TODAY, V49, P141, DOI 10.1016/S0920-5861(98)00418-0
   Hamill C, 2015, APPL CATAL A-GEN, V506, P261, DOI 10.1016/j.apcata.2015.09.030
   Harris G. F. P., 1964, I CHEM ENG S SER, V49, P29
   Hinz A, 1999, CHEM ENG SCI, V54, P4407, DOI 10.1016/S0009-2509(99)00138-4
   Hu YF, 2012, REACT KINET MECH CAT, V106, P127, DOI 10.1007/s11144-011-0415-z
   Huang YP, 2015, CATAL SCI TECHNOL, V5, P1093, DOI 10.1039/c4cy01205d
   HUMMEL AA, 1993, J CATAL, V139, P392, DOI 10.1006/jcat.1993.1035
   Kagyrmanova AP, 2007, CHEM ENG J, V134, P228, DOI 10.1016/j.cej.2007.03.035
   Khodakov A, 1999, J CATAL, V181, P205, DOI 10.1006/jcat.1998.2295
   Kim S, 2015, J PHYS CHEM A, V119, P3604, DOI 10.1021/jp513024z
   Kulkarni S. J., 1994, J CHEM SOC CHEM COMM, V3
   Li YJ, 1998, J CATAL, V176, P495, DOI 10.1006/jcat.1998.2089
   Liao B, 2001, CHEM ENG J, V84, P581, DOI 10.1016/S1385-8947(01)00175-9
   Malmusi A, 2019, APPL CATAL A-GEN, V570, P139, DOI 10.1016/j.apcata.2018.11.013
   Mannei E, 2017, MICROPOR MESOPOR MAT, V241, P246, DOI 10.1016/j.micromeso.2016.12.021
   McConvey IF, 2012, ORG PROCESS RES DEV, V16, P612, DOI 10.1021/op2003503
   Mendiburu AZ, 2017, ENERGY, V118, P414, DOI 10.1016/j.energy.2016.12.036
   Mies MJM, 2007, CHEM ENG SCI, V62, P5097, DOI 10.1016/j.ces.2006.12.018
   Oehlert GW, 2003, AM STAT, V57, P66, DOI DOI 10.1198/TAS.2003.S210
   Oishi T, 2010, TOP CATAL, V53, P479, DOI 10.1007/s11244-010-9475-y
   Pan WC, 2005, REACT KINET CATAL L, V86, P67, DOI 10.1007/s11144-005-0296-0
   Reddy B. M., 1993, J CHEM SOC CHEM COMM
   Rhimi B, 2016, J MOL CATAL A-CHEM, V416, P127, DOI 10.1016/j.molcata.2016.02.028
   Rojas E, 2013, CATAL SCI TECHNOL, V3, P3173, DOI 10.1039/c3cy00415e
   Rojas E, 2012, J PHYS CHEM C, V116, P9132, DOI 10.1021/jp3017437
   Rojas E, 2009, CATAL COMMUN, V10, P1555, DOI 10.1016/j.catcom.2009.04.016
   Sanati M, 1998, CATAL TODAY, V42, P325, DOI 10.1016/S0920-5861(98)00109-6
   Schuster BG, 2013, BIOENERG RES, V6, P416, DOI 10.1007/s12155-012-9278-z
   Sun J, 2014, ACS CATAL, V4, P1078, DOI 10.1021/cs4011343
   Tanganelli F., 2011, THESIS
   TOLLEFSON EL, 1970, CAN J CHEM ENG, V48, P219, DOI 10.1002/cjce.5450480223
   Tripodi A, 2018, ACS SUSTAIN CHEM ENG, V6, P5441, DOI 10.1021/acssuschemeng.8b00215
   Tripodi A, 2018, J IND ENG CHEM, V59, P35, DOI 10.1016/j.jiec.2017.10.003
   Tripodi A, 2017, CHEM ENG RES DES, V127, P92, DOI 10.1016/j.cherd.2017.09.018
   Vedrine JC, 2002, TOP CATAL, V21, P97, DOI 10.1023/A:1020560200125
   Velasquez EIG, 2017, FUEL, V210, P410, DOI 10.1016/j.fuel.2017.08.089
   Zhang D, 2011, CHEM ENG RES DES, V89, P2147, DOI 10.1016/j.cherd.2011.01.029
   Zhang YN, 2009, CATAL COMMUN, V10, P1454, DOI 10.1016/j.catcom.2009.03.019
NR 68
TC 1
Z9 1
U1 6
U2 52
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 862
EP 875
DI 10.1016/j.ces.2019.07.015
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300072
DA 2020-05-12
ER

PT J
AU Yang, CH
   Peng, X
   Zhao, YJ
   Wang, X
   Cheng, L
   Wang, F
   Li, YD
   Li, PL
AF Yang, Chaohuan
   Peng, Xin
   Zhao, Yajing
   Wang, Xin
   Cheng, Lan
   Wang, Fang
   Li, Yingdong
   Li, Pingli
TI Experimental study on VMD and its performance comparison with AGMD for
   treating copper-containing solution
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Copper-containing solution; Vacuum membrane distillation; Air gap
   membrane distillation; Membrane concentration; Membrane module
   parameters
ID VACUUM MEMBRANE DISTILLATION; RADIOACTIVE WASTE-WATER; HOLLOW-FIBER;
   DIRECT-CONTACT; NUMERICAL-SIMULATION; DESALINATION; RECOVERY; REMOVAL;
   MODULE; DCMD
AB This study investigated the performance of VMD and AGMD system for separating water from copper-containing solution. The impacts of various operating parameters and module parameters on VMD performance were studied in terms of permeate flux, rejection rate, total water production, specific thermal (electric) energy consumption, pressure drop and thermal efficiency. A relatively stable VMD performance with high rejection rate was achieved due to the chemical stability and the sponge-like structure of membrane. It was found that enhancing membrane length would increase thermal consumption and pressure drop simultaneously. Moreover, the membrane module with high packing density performed better in utilizing lower thermal energy. The maximum permeate flux and the minimum specific thermal energy consumption of VMD was 21.82 kg/m(2)-h and 674.5 kWh/m(3) respectively. Meanwhile, AGMD was superior for energy saving compared with VMD. In this study, VMD and AGMD process have shown the potential to treat copper-containing solution. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Chaohuan; Zhao, Yajing; Wang, Xin; Cheng, Lan; Wang, Fang; Li, Yingdong; Li, Pingli] Tianjin Univ, Chem Engn Res Ctr, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Peng, Xin] Tianjin Univ, Sch Life Sci, Tianjin 300350, Peoples R China.
   [Yang, Chaohuan; Zhao, Yajing; Wang, Xin; Cheng, Lan; Wang, Fang; Li, Yingdong; Li, Pingli] Tianjin State Key Lab Membrane Sci & Desalinat Te, Tianjin 300350, Peoples R China.
   [Yang, Chaohuan] Qingdao Guoxin Blue Valley Dev Co Ltd, Qingdao 266000, Shandong, Peoples R China.
RP Li, PL (reprint author), Tianjin Univ, Chem Engn Res Ctr, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM lipingli@tju.edu.cn
OI Peng, Xin/0000-0003-1654-2130
CR Ahmad AL, 2006, SEP PURIF TECHNOL, V47, P162, DOI 10.1016/j.seppur.2005.07.016
   Ahmed IM, 2011, HYDROMETALLURGY, V110, P62, DOI 10.1016/j.hydromet.2011.08.007
   Alsalhy QF, 2017, CHEM ENG PROCESS, V120, P68, DOI 10.1016/j.cep.2017.06.011
   Aryapratama R, 2016, DESALINATION, V385, P58, DOI 10.1016/j.desal.2016.01.005
   Attia H, 2017, DESALINATION, V420, P318, DOI 10.1016/j.desal.2017.07.022
   Cheng LH, 2009, IND ENG CHEM RES, V48, P4948, DOI 10.1021/ie800832z
   Chou YH, 2018, SEP PURIF TECHNOL, V198, P113, DOI 10.1016/j.seppur.2017.02.008
   Csefalvay E, 2009, DESALINATION, V240, P132, DOI 10.1016/j.desal.2007.11.070
   Curcio E, 2005, SEP PURIF REV, V34, P35, DOI 10.1081/SPM-200054951
   Davarnejad R, 2016, SEP PURIF TECHNOL, V158, P286, DOI 10.1016/j.seppur.2015.12.018
   Dong Y, 2017, J HAZARD MATER, V321, P307, DOI 10.1016/j.jhazmat.2016.08.034
   Eykens L, 2017, DESALINATION, V422, P91, DOI 10.1016/j.desal.2017.08.018
   Fan HW, 2012, CHEM ENG SCI, V79, P94, DOI 10.1016/j.ces.2012.05.052
   Geng HX, 2014, DESALINATION, V344, P55, DOI 10.1016/j.desal.2014.03.016
   Guan YS, 2015, DESALINATION, V355, P110, DOI 10.1016/j.desal.2014.10.005
   Guo YX, 2018, MATER LETT, V228, P239, DOI 10.1016/j.matlet.2018.06.028
   Hu HM, 2017, J ENVIRON MANAGE, V203, P1, DOI 10.1016/j.jenvman.2017.07.066
   Jia F, 2017, ANN NUCL ENERGY, V110, P1148, DOI 10.1016/j.anucene.2017.07.024
   Kim YD, 2018, WATER RES, V132, P23, DOI 10.1016/j.watres.2017.12.066
   Kim YD, 2013, J MEMBRANE SCI, V427, P345, DOI 10.1016/j.memsci.2012.10.008
   Lawson KW, 1997, J MEMBRANE SCI, V124, P1, DOI 10.1016/S0376-7388(96)00236-0
   Lee JG, 2013, DESALINATION, V331, P46, DOI 10.1016/j.desal.2013.10.022
   Lefers R, 2018, SEP PURIF TECHNOL, V199, P57, DOI 10.1016/j.seppur.2018.01.042
   Leitch ME, 2016, ENVIRON SCI TECH LET, V3, P85, DOI 10.1021/acs.estlett.6b00030
   Li B, 2005, J MEMBRANE SCI, V257, P60, DOI 10.1016/j.memsci.2004.08.040
   Li L, 2017, J MEMBRANE SCI, V523, P225, DOI 10.1016/j.memsci.2016.09.028
   Li ZH, 2014, APPL SURF SCI, V317, P338, DOI 10.1016/j.apsusc.2014.07.080
   Liu C, 2018, CHEMOSPHERE, V208, P530, DOI 10.1016/j.chemosphere.2018.06.013
   Liu HY, 2013, J HAZARD MATER, V261, P307, DOI 10.1016/j.jhazmat.2013.07.045
   Liu J, 2017, CHEM ENG RES DES, V119, P12, DOI 10.1016/j.cherd.2017.01.013
   Liu ZY, 2017, DESALINATION, V414, P63, DOI 10.1016/j.desal.2017.03.031
   Liu ZY, 2016, DESALINATION, V396, P48, DOI 10.1016/j.desal.2016.04.025
   Na HN, 2011, J APPL POLYM SCI, V122, P774, DOI 10.1002/app.33964
   Ozbey-Unal B, 2018, DESALINATION, V433, P141, DOI 10.1016/j.desal.2018.01.033
   Pal P, 2010, WATER RES, V44, P5750, DOI 10.1016/j.watres.2010.05.031
   Pangarkar B. L., 2011, International Journal of ChemTech Research, V3, P1816
   Phattaranawik J, 2003, J MEMBRANE SCI, V215, P75, DOI 10.1016/S0376-7388(02)00603-8
   Shen JY, 2017, BIOELECTROCHEMISTRY, V114, P1, DOI 10.1016/j.bioelechem.2016.11.002
   Singh D, 2012, J MEMBRANE SCI, V421, P172, DOI 10.1016/j.memsci.2012.07.007
   Sun AC, 2014, J MEMBRANE SCI, V455, P131, DOI 10.1016/j.memsci.2013.12.055
   Tao HC, 2011, BIORESOURCE TECHNOL, V102, P10334, DOI 10.1016/j.biortech.2011.08.116
   Wang P, 2011, WATER RES, V45, P5489, DOI 10.1016/j.watres.2011.08.012
   Wen X, 2016, NUCL TECHNOL, V194, P379, DOI 10.13182/NT15-74
   Woldemariam D, 2018, RENEW ENERG, V128, P484, DOI 10.1016/j.renene.2017.06.009
   Wu D, 2016, J POWER SOURCES, V307, P705, DOI 10.1016/j.jpowsour.2016.01.022
   Xu JL, 2016, J MEMBRANE SCI, V512, P73, DOI 10.1016/j.memsci.2016.04.010
   Yao K, 2013, AICHE J, V59, P1278, DOI 10.1002/aic.13892
   Zhang JH, 2013, J MEMBRANE SCI, V442, P31, DOI 10.1016/j.memsci.2013.04.028
   Zhang XM, 2016, DESALINATION, V385, P117, DOI 10.1016/j.desal.2016.01.021
   Zhang YG, 2016, CHEM ENG SCI, V152, P172, DOI 10.1016/j.ces.2016.05.040
   Zoungrana A, 2016, CHEM PAP, V70, P1185, DOI 10.1515/chempap-2016-0066
NR 51
TC 1
Z9 1
U1 8
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 876
EP 891
DI 10.1016/j.ces.2019.07.013
PG 16
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300073
DA 2020-05-12
ER

PT J
AU Ma, HY
   Gong, PJ
   Zhai, S
   Huang, YJ
   Niu, YH
   Park, CB
   Li, GX
AF Ma, Haoyu
   Gong, Pengjian
   Zhai, Shuo
   Huang, Yajiang
   Niu, Yanhua
   Park, Chul B.
   Li, Guangxian
TI Multi-dimensional analysis of micro-/nano-polymeric foams by confocal
   laser scanning microscopy and foam simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Confocal laser scanning microscopy; Fluorescence; Multi-dimensional foam
   morphology; Supercritical CO2 foaming; Micro-/nano-cellular foams
ID THERMAL-INSULATION; GRAPHENE FOAM; HEAT-TRANSFER; PERFORMANCE;
   EVOLUTION; PRESSURE; CO2; MORPHOLOGY; ELECTRODE; COMPOSITE
AB Multi-dimensional foam structure analysis is critical to identify the properties of supercritical CO2 (scCO(2)) foamed materials, but most applied analysis only focus on two-dimensional (2D) foam morphology. A novel method of confocal laser scanning microscopy (CLSM), a powerful technique for material structure characterization, is then successfully applied for the first time to construct the multidimensional (including 2D and 3D) foam structure obtained in scCO(2) foaming. In CLSM characterization, fluorescent dye is the key point to enhance polymeric foams' fluorescence intensity so that the multidimensional foam structure is clearly observed. In the multi-dimensional analysis, it is noticed that the statistical cell size via 2D characterization is only 0.79 of that via 3D characterization. This specific conversion coefficient among multi-dimensional foam morphology is further verified in theoretical analysis via micro-/nano-cellular foam simulation. The universal specific conversion coefficient (2D/3D_(cell size) = 0.79 and 2D/3D_(cell density) = 1.2) then enables a 3D foam construction for polymeric foams made from scCO(2) foaming with only 2D foam characterization data no matter the foam has a micro- or nano-cellular structure. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ma, Haoyu; Gong, Pengjian; Zhai, Shuo; Huang, Yajiang; Niu, Yanhua; Li, Guangxian] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, 24 Yihuan Rd, Chengdu 610065, Sichuan, Peoples R China.
   [Gong, Pengjian; Park, Chul B.] Univ Toronto, Dept Mech & Ind Engn, Microcellular Plast Mfg Lab, 5 Kings Coll Rd, Toronto, ON M5S 3G8, Canada.
RP Gong, PJ (reprint author), Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, 24 Yihuan Rd, Chengdu 610065, Sichuan, Peoples R China.
EM pgong@scu.edu.cn
OI Ma, Haoyu/0000-0002-9327-8196
FU National Natural Science Foundation for the Youth of ChinaNational
   Natural Science Foundation of China [51703146]; National Natural Science
   FoundationNational Natural Science Foundation of China [51721091]; State
   Key Lab of Polymer Materials Engineering [sklpme2018-3-02]; Sichuan
   University Starting funds [YJ201657]
FX The authors are grateful to the National Natural Science Foundation for
   the Youth of China (No. 51703146) for their financial support of this
   project. We are also thankful to the support from National Natural
   Science Foundation (No. 51721091), State Key Lab of Polymer Materials
   Engineering (No. sklpme2018-3-02), Sichuan University Starting funds
   (No. YJ201657).
CR [Anonymous], 2010, D357604 ASTM INT
   Berglund LA, 2018, ADV MATER, V30, DOI 10.1002/adma.201704285
   Carpio LR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3273
   Chen YC, 2018, CHEM ENG SCI, V192, P488, DOI 10.1016/j.ces.2018.07.051
   Cherukupally P, 2017, ENVIRON SCI TECHNOL, V51, P8552, DOI 10.1021/acs.est.7b01255
   del Rey R, 2012, APPL ACOUST, V73, P604, DOI 10.1016/j.apacoust.2011.12.009
   Dubois C., 2003, MACROMOL S
   Ferkl P, 2018, CHEM ENG SCI, V176, P50, DOI 10.1016/j.ces.2017.10.024
   Ferkl P, 2017, CHEM ENG SCI, V172, P323, DOI 10.1016/j.ces.2017.06.035
   Ferrando M, 2005, J MEMBRANE SCI, V250, P283, DOI 10.1016/j.memsci.2004.10.043
   Ge CB, 2017, CHEM ENG SCI, V174, P337, DOI 10.1016/j.ces.2017.09.011
   Gendron R, 2004, J CELL PLAST, V40, P131, DOI 10.1177/0021955X04041959
   Gmoser R, 2017, EUR FOOD RES TECHNOL, V243, P115, DOI 10.1007/s00217-016-2728-7
   Gong PJ, 2018, IND ENG CHEM RES, V57, P5464, DOI 10.1021/acs.iecr.7b05023
   Gong PJ, 2017, CARBON, V120, P1, DOI 10.1016/j.carbon.2017.05.029
   Gong PJ, 2015, CARBON, V93, P819, DOI 10.1016/j.carbon.2015.06.003
   Gong PJ, 2012, J POLYM SCI POL PHYS, V50, P1173, DOI 10.1002/polb.23099
   Guo XM, 2019, CHEM ENG SCI, V194, P54, DOI 10.1016/j.ces.2018.04.072
   Gwon JG, 2016, MATER DESIGN, V89, P448, DOI 10.1016/j.matdes.2015.10.017
   Hamidinejad M, 2018, ACS APPL MATER INTER, V10, P19987, DOI 10.1021/acsami.8b03777
   Han J, 2018, INT J FOOD PROP, V21, P593, DOI 10.1080/10942912.2018.1437630
   He YQ, 2013, J HAZARD MATER, V260, P796, DOI 10.1016/j.jhazmat.2013.06.042
   Hwang HJ, 2016, NAT MATER, V15, P1031, DOI [10.1038/nmat4663, 10.1038/NMAT4663]
   Ilcikova M, 2016, EUR POLYM J, V79, P187, DOI 10.1016/j.eurpolymj.2016.02.015
   Ji LJ, 2009, CARBON, V47, P2733, DOI 10.1016/j.carbon.2009.05.031
   Lee JWS, 2017, CHEM ENG SCI, V167, P105, DOI 10.1016/j.ces.2017.04.005
   Lee J, 2012, J APPL POLYM SCI, V123, P2384, DOI 10.1002/app.34755
   Lee K, 2017, ACS APPL MATER INTER, V9, P22502, DOI 10.1021/acsami.7b04777
   Lee KM, 2009, J CELL PLAST, V45, P539, DOI 10.1177/0021955X09343632
   Li ZQ, 2013, NUMER HEAT TR A-APPL, V64, P1038, DOI 10.1080/10407782.2013.811159
   Lin DC, 2018, ADV MATER, V30, DOI 10.1002/adma.201802661
   Ling JQ, 2013, ACS APPL MATER INTER, V5, P2677, DOI 10.1021/am303289m
   Ma HB, 2019, CHEM ENG SCI, V194, P10, DOI 10.1016/j.ces.2018.05.019
   Mantaranon N, 2016, POLYMER, V96, P54, DOI 10.1016/j.polymer.2016.05.001
   Marroquin M, 2011, J MEMBRANE SCI, V379, P504, DOI 10.1016/j.memsci.2011.06.024
   Mauko A, 2009, MATER CHARACT, V60, P603, DOI 10.1016/j.matchar.2009.01.008
   Muller E, 2017, ADV MATER, V29, DOI 10.1002/adma.201703489
   Nachtrab S, 2011, ADV MATER, V23, P2633, DOI 10.1002/adma.201004094
   Nilsson G, 2015, THESIS
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Palmer WM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13492
   Patil SP, 2017, J PHYS CHEM B, V121, P5660, DOI 10.1021/acs.jpcb.7b03184
   Perez-Tamarit S., 2018, EUR POLYM J
   Pinto J, 2013, J CELL PLAST, V49, P555, DOI 10.1177/0021955X13503847
   Ray SS, 2002, NANO LETT, V2, P423, DOI 10.1021/nl020284g
   Shaayegan V, 2016, CHEM ENG SCI, V155, P27, DOI 10.1016/j.ces.2016.07.040
   Shah AA, 2015, NAT MATER, V14, P117, DOI [10.1038/nmat4111, 10.1038/NMAT4111]
   Song JW, 2018, NATURE, V554, P224, DOI 10.1038/nature25476
   Tobushi H, 2004, SMART MATER STRUCT, V13, P881, DOI 10.1088/0964-1726/13/4/026
   Wang GL, 2017, EUR POLYM J, V95, P382, DOI 10.1016/j.eurpolymj.2017.08.025
   Wang L, 2017, ACS APPL MATER INTER, V9, P35419, DOI 10.1021/acsami.7b10565
   Wang XL, 2010, BIOMATERIALS, V31, P3920, DOI 10.1016/j.biomaterials.2010.01.118
   Wei DX, 2018, ADV MATER, V30, DOI 10.1002/adma.201802273
   Xiao F, 2016, COMPUT MATH APPL, V72, P328, DOI 10.1016/j.camwa.2015.09.009
   Xu CX, 2018, ACS SUSTAIN CHEM ENG, V6, P3358, DOI 10.1021/acssuschemeng.7b03542
   Xu YC, 2017, CHEM ENG SCI, V171, P650, DOI 10.1016/j.ces.2017.05.031
   Yu H, 2016, ACS APPL MATER INTER, V8, P2505, DOI 10.1021/acsami.5b09030
   Zalucky J, 2017, CHEM ENG SCI, V168, P480, DOI 10.1016/j.ces.2017.05.011
   Zhang HB, 2011, ACS APPL MATER INTER, V3, P918, DOI 10.1021/am200021v
   Zhang QQ, 2017, ADV MATER, V29, DOI 10.1002/adma.201605506
   Zhang SM, 2017, ACS APPL MATER INTER, V9, P34497, DOI 10.1021/acsami.7b11315
   Zhang XY, 2017, MECH MATER, V104, P73, DOI 10.1016/j.mechmat.2016.10.007
   Zhao BA, 2019, J MATER CHEM A, V7, P133, DOI 10.1039/c8ta05556d
   Zhao XN, 2011, APPL SURF SCI, V257, P3612, DOI 10.1016/j.apsusc.2010.11.088
   Zhao Y, 2013, ADV MATER, V25, P591, DOI 10.1002/adma.201203578
NR 65
TC 0
Z9 0
U1 16
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 892
EP 902
DI 10.1016/j.ces.2019.07.007
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300074
DA 2020-05-12
ER

PT J
AU Zhang, Y
   Yang, LM
   Pramoda, KP
   Gai, WX
   Zhang, S
AF Zhang, Yu
   Yang, Liming
   Pramoda, Kumari Pallathadka
   Gai, Wenxiao
   Zhang, Sui
TI Highly permeable and fouling-resistant hollow fiber membranes for
   reverse osmosis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Membrane; Reverse osmosis; Fouling; Hollow fiber; Zwitterionic
ID INTERFACIAL POLYMERIZATION; SEAWATER DESALINATION; POLYAMIDE MEMBRANES;
   WATER-TREATMENT; SURFACES; DESIGN; ROBUST; TRANSPORT; ENERGY
AB This paper reports a fast, cost-effective and environmental-friendly method to engineer the membrane structure, and simultaneously enhance the permeance and fouling resistance in reverse osmosis (RO). By free radical polymerization in water, copolymers containing fouling-resistant zwitterionic and hydroxyl-based anchoring groups are synthesized and quickly bonded to the polyamide membrane surface. The copolymer also functions as the molecular engine to reduce the thickness of the polyamide layer and drill nanopores, thereby re-shaping its 3D structure for higher permeability. It is revealed that by design of the size and functionality of the copolymer, the water permeability and salt rejection may be simultaneously increased. Our membrane demonstrates a pure water permeability of 10.5 L m(2) h(1) bar(1), NaCl rejection of 98.1%, and superior fouling resistance towards various foulants and realistic feed. This paper provides a new perspective for the development of highly permeable, fouling-resistance membranes not only for RO, but also nanofiltration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yu; Yang, Liming; Gai, Wenxiao; Zhang, Sui] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117586, Singapore.
   [Pramoda, Kumari Pallathadka] Agcy Sci Technol & Res, Inst Mat Res & Engn, Singapore 138634, Singapore.
RP Zhang, S (reprint author), Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117586, Singapore.
EM chezhasu@nus.edu.sg
FU Public Utility Board of Singapore, Singapore [R-279-000-571-279]
FX The authors acknowledge the Public Utility Board of Singapore, Singapore
   for funding support with grant number R-279-000-571-279, and highly
   appreciate Prof. Neal Chung Tai-Shung for his advice and support for the
   project.
CR Banerjee I, 2011, ADV MATER, V23, P690, DOI 10.1002/adma.201001215
   Cai T, 2016, J MEMBRANE SCI, V497, P142, DOI 10.1016/j.memsci.2015.09.037
   Chen SF, 2005, J AM CHEM SOC, V127, P14473, DOI 10.1021/ja054169u
   Chen SF, 2010, POLYMER, V51, P5283, DOI 10.1016/j.polymer.2010.08.022
   Chowdhury MR, 2018, SCIENCE, V361, P682, DOI 10.1126/science.aar2122
   Cohen-Tanugi D, 2014, ENERG ENVIRON SCI, V7, P1134, DOI 10.1039/c3ee43221a
   Elimelech M, 2011, SCIENCE, V333, P712, DOI 10.1126/science.1200488
   Jiang SY, 2010, ADV MATER, V22, P920, DOI 10.1002/adma.200901407
   Jiang ZW, 2018, ADV MATER, V30, DOI 10.1002/adma.201705973
   Kang GD, 2012, WATER RES, V46, P584, DOI 10.1016/j.watres.2011.11.041
   Karan S, 2015, SCIENCE, V348, P1347, DOI 10.1126/science.aaa5058
   Khorshidi B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22069
   Lee KP, 2011, J MEMBRANE SCI, V370, P1, DOI 10.1016/j.memsci.2010.12.036
   Li D, 2010, J MATER CHEM, V20, P4551, DOI 10.1039/b924553g
   Liu CH, 2017, ENVIRON SCI TECHNOL, V51, P2161, DOI 10.1021/acs.est.6b05992
   Ma XH, 2018, ENVIRON SCI TECH LET, V5, P117, DOI 10.1021/acs.estlett.7b00566
   Mezher T, 2011, DESALINATION, V266, P263, DOI 10.1016/j.desal.2010.08.035
   Nikkola J, 2013, J MEMBRANE SCI, V444, P192, DOI 10.1016/j.memsci.2013.05.032
   Park H. B., 2017, SCIENCE, V356, P1137
   Qi SR, 2016, J MEMBRANE SCI, V508, P94, DOI 10.1016/j.memsci.2016.02.013
   Schlenoff JB, 2014, LANGMUIR, V30, P9625, DOI 10.1021/la500057j
   Shao Q, 2015, ADV MATER, V27, P15, DOI 10.1002/adma.201404059
   Sun HG, 2018, J MEMBRANE SCI, V563, P22, DOI 10.1016/j.memsci.2018.05.046
   Tan Z, 2018, SCIENCE, V360, P518, DOI 10.1126/science.aar6308
   Van der Bruggen B, 2003, ENVIRON PROG, V22, P46, DOI 10.1002/ep.670220116
   Vorosmarty CJ, 2010, NATURE, V467, P555, DOI 10.1038/nature09440
   Wan CF, 2015, J MEMBRANE SCI, V479, P148, DOI 10.1016/j.memsci.2014.12.036
   Wang HL, 2013, J MEMBRANE SCI, V434, P130, DOI 10.1016/j.memsci.2013.01.031
   Wang ZY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04467-3
   Xu P, 2006, J MEMBRANE SCI, V279, P165, DOI 10.1016/j.memsci.2005.12.001
   Yang R, 2014, ADV MATER, V26, P1711, DOI 10.1002/adma.201304386
   Yang R, 2011, CHEM MATER, V23, P1263, DOI 10.1021/cm1031392
   Yang XB, 2018, ACS APPL MATER INTER, V10, P29982, DOI 10.1021/acsami.8b09218
   Yu HY, 2014, J MEMBRANE SCI, V449, P50, DOI 10.1016/j.memsci.2013.08.022
   Zeng RC, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.41041
   Zhang S, 2014, CHEM ENG J, V241, P457, DOI 10.1016/j.cej.2013.10.063
   Zhang Y, 2017, CARBON, V123, P193, DOI 10.1016/j.carbon.2017.07.054
   Zhao Y, 2012, J MEMBRANE SCI, V423, P422, DOI 10.1016/j.memsci.2012.08.039
NR 38
TC 4
Z9 4
U1 27
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 903
EP 910
DI 10.1016/j.ces.2019.07.014
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300075
DA 2020-05-12
ER

PT J
AU Liang, MC
   Gao, YH
   Luo, L
   Xiao, BQ
   Pang, MH
   Wang, ZK
AF Liang, Mingchao
   Gao, Yinhao
   Luo, Liang
   Xiao, Boqi
   Pang, Minghua
   Wang, Zhankui
TI A study on the permeability for the tree-like branching network with
   polygonal loops based on the fractal network of leaf vein
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Leaf-vein-like fractal network; Polygonal loop; Permeability; Damage
ID KOZENY-CARMAN CONSTANT; HEAT-TRANSFER; POROUS-MEDIA; MICROCHANNEL
   NETWORKS; FLOW; MODEL; PRINCIPLE; DIFFUSION
AB A novel tree-like branching network with polygonal loops is designed based on the network of leaf vein. In this study, analytical models are presented for the effective permeabilities through the undamaged and damaged tree-like branching networks with polygonal loops based on Hagen-Poiseuille equation and Darcy's law. These effective permeability models are explicitly related to the structural parameters and the damaged number (or points) of the tree-like branching networks. We have discussed quantitatively the influences of the length and diameter ratios of channels, Y-shaped bifurcation angle, total branching level number, and damaged number (or points) on the effective permeability. Besides, numerical simulations are performed, and compared with the model predictions. Good agreement indicates that the present models for the permeability are reasonable. These analyses of the networks may provide a basis for scientific and engineering applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liang, Mingchao; Gao, Yinhao; Pang, Minghua; Wang, Zhankui] Henan Inst Sci & Technol, Sch Mech & Elect Engn, Xinxiang 453003, Henan, Peoples R China.
   [Luo, Liang] Wuhan Inst Technol, Sch Mech & Elect Engn, Wuhan 430205, Hubei, Peoples R China.
   [Luo, Liang] Hunan Inst Sci & Technol, Coll Phys & Elect, Yueyang 414000, Peoples R China.
   [Xiao, Boqi] Sanming Univ, Sch Mech & Elect Engn, Sanming 365004, Peoples R China.
RP Luo, L; Xiao, BQ (reprint author), Wuhan Inst Technol, Sch Mech & Elect Engn, Wuhan 430205, Hubei, Peoples R China.
EM luoliang@hnist.edu.cn; mr.boqi-xiao@connect.polyu.hk
OI xiao, boqi/0000-0001-7243-1676
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11602078, 51576114, U1804142]; Key Scientific
   Research Project of Higher Education of Henan Province of China
   [17A130005]; Hubei Provincial Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [2018CFA066]; High
   Level Talent Research Start Project of Henan Institute of Science and
   Technology of Henan Province of China; Landmark Innovation Project of
   Henan Institute of Science and Technology of Henan Province of China
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 11602078, 51576114 and U1804142), the Key Scientific
   Research Project of Higher Education of Henan Province of China (No.
   17A130005), the Hubei Provincial Natural Science Foundation of China
   (No. 2018CFA066), and the Landmark Innovation Project and High Level
   Talent Research Start Project of Henan Institute of Science and
   Technology of Henan Province of China.
CR Afrin N, 2011, INT J HEAT MASS TRAN, V54, P2419, DOI 10.1016/j.ijheatmasstransfer.2011.02.020
   Alalaimi M, 2015, INT J HEAT MASS TRAN, V90, P259, DOI 10.1016/j.ijheatmasstransfer.2015.06.042
   Bejan A, 1997, INT J HEAT MASS TRAN, V40, P799, DOI 10.1016/0017-9310(96)00175-5
   Bejan A., 2000, SHAPE STRUCTURE ENG
   Bejan A, 2013, J APPL PHYS, V113, DOI 10.1063/1.4798429
   Cai JC, 2018, MAR PETROL GEOL, V98, P437, DOI 10.1016/j.marpetgeo.2018.08.040
   Cai RJ, 2018, INT J ENG SCI, V123, P143, DOI 10.1016/j.ijengsci.2017.11.006
   Deng T, 2019, APPL THERM ENG, V150, P1186, DOI 10.1016/j.applthermaleng.2019.01.065
   Durand M, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.046125
   Durand M, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016116
   Guo RW, 2019, CHEM ENG J, V373, P1203, DOI 10.1016/j.cej.2019.05.124
   Hess WR, 1917, PFLUG ARCH GES PHYS, V168, P439, DOI 10.1007/BF01681580
   Jing DL, 2018, INT J HEAT MASS TRAN, V125, P749, DOI 10.1016/j.ijheatmasstransfer.2018.04.115
   Jing DL, 2018, BEILSTEIN J NANOTECH, V9, P482, DOI 10.3762/bjnano.9.46
   Karimi-Fard M, 2004, SPE J, V9, P227, DOI 10.2118/88812-PA
   Kou JL, 2014, PHYSICA A, V393, P527, DOI 10.1016/j.physa.2013.08.029
   Kwak Y, 2009, INT J HEAT FLUID FL, V30, P868, DOI 10.1016/j.ijheatfluidflow.2009.03.014
   Li L, 2014, INT J THERM SCI, V86, P219, DOI 10.1016/j.ijthermalsci.2014.07.006
   Liang MC, 2019, INT J HEAT MASS TRAN, V137, P365, DOI 10.1016/j.ijheatmasstransfer.2019.03.141
   Liang MC, 2018, INT J HYDROGEN ENERG, V43, P17880, DOI 10.1016/j.ijhydene.2018.07.186
   Liang MC, 2018, FRACTALS, V26, DOI 10.1142/S0218348X18500378
   Liu WY, 2015, APPL THERM ENG, V91, P731, DOI 10.1016/j.applthermaleng.2015.08.075
   Luo L, 2018, INT J HEAT MASS TRAN, V116, P813, DOI 10.1016/j.ijheatmasstransfer.2017.09.056
   Luo LA, 2010, INT J HEAT MASS TRAN, V53, P5022, DOI 10.1016/j.ijheatmasstransfer.2010.06.003
   Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT
   Miao TJ, 2018, INT J HEAT MASS TRAN, V127, P278, DOI 10.1016/j.ijheatmasstransfer.2018.06.053
   Miao TJ, 2016, INT J THERM SCI, V102, P89, DOI 10.1016/j.ijthermalsci.2015.10.040
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Murray CD, 1926, J GEN PHYSIOL, V9, P835, DOI 10.1085/jgp.9.6.835
   Peng Y, 2019, INT J HEAT MASS TRAN, V129, P801, DOI 10.1016/j.ijheatmasstransfer.2018.09.121
   Peng Y, 2014, INT J HEAT MASS TRAN, V71, P79, DOI 10.1016/j.ijheatmasstransfer.2013.11.051
   Peng Y, 2013, INT J HEAT MASS TRAN, V63, P120, DOI 10.1016/j.ijheatmasstransfer.2013.02.021
   Pia G, 2014, INT J ENG SCI, V82, P196, DOI 10.1016/j.ijengsci.2014.05.013
   Rismanian M, 2019, CHEM ENG SCI, V195, P120, DOI 10.1016/j.ces.2018.11.041
   Sandve TH, 2012, J COMPUT PHYS, V231, P3784, DOI 10.1016/j.jcp.2012.01.023
   SHERMAN TF, 1981, J GEN PHYSIOL, V78, P431, DOI 10.1085/jgp.78.4.431
   Shou DH, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.053007
   Shui LQ, 2018, J MECH SCI TECHNOL, V32, P937, DOI 10.1007/s12206-018-0144-y
   Shui LQ, 2017, PROCEEDINGS OF THE ASME TURBO EXPO: TURBINE TECHNICAL CONFERENCE AND EXPOSITION, 2017, VOL 5A
   Tan XH, 2015, INT J MOD PHYS B, V29, DOI 10.1142/S0217979215501350
   Wang G, 2019, CHEM ENG SCI, V195, P250, DOI 10.1016/j.ces.2018.07.021
   Wang XQ, 2007, J APPL PHYS, V102, DOI 10.1063/1.2794379
   Wechsatol W, 2005, INT J HEAT MASS TRAN, V48, P573, DOI 10.1016/j.ijheatmasstransfer.2004.08.020
   Wei W, 2018, FUEL, V234, P1373, DOI 10.1016/j.fuel.2018.08.012
   WEST BJ, 1990, FRACTAL PHYSL CHAOS
   Xiao BQ, 2019, FRACTALS, V27, DOI 10.1142/S0218348X19500129
   Xiao BQ, 2019, FRACTALS, V27, DOI 10.1142/S0218348X19500622
   Xiao BQ, 2019, POWDER TECHNOL, V349, P92, DOI 10.1016/j.powtec.2019.03.028
   Xu P, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2221861
   Xu P, 2016, APPL MECH REV, V68, DOI 10.1115/1.4033966
   Xu P, 2016, FRACTALS, V24, DOI 10.1142/S0218348X16500183
   Xu P, 2015, FRACTALS, V23, DOI 10.1142/S0218348X15300019
   Yang SS, 2017, FRACTALS, V25, DOI 10.1142/S0218348X17500086
   Zhang CP, 2015, INT J HEAT MASS TRAN, V85, P723, DOI 10.1016/j.ijheatmasstransfer.2015.01.118
NR 54
TC 1
Z9 1
U1 13
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 911
EP 928
DI 10.1016/j.ces.2019.07.010
PG 18
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300076
DA 2020-05-12
ER

PT J
AU Shao, SY
   Li, C
   Hong, JR
AF Shao, Siyao
   Li, Cheng
   Hong, Jiarong
TI A hybrid image processing method for measuring 3D bubble distribution
   using digital inline holography
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Image analysis; Bubbly flow; Particle size distribution; Digital inline
   holography
ID SIZE DISTRIBUTIONS; MASS-TRANSFER; FLOWS; SELECTION; VELOCITY;
   COALESCENCE; FRACTION; MODELS; PIPE
AB The paper presents a hybrid bubble hologram processing approach for measuring the size and 3D distribution of bubbles over a wide range of size and shape. The proposed method consists of five major steps, including image enhancement, digital reconstruction, small bubble segmentation, large bubble/cluster segmentation, and post-processing. Two different segmentation approaches are proposed to extract the size and the location of bubbles in different size ranges from the 3D reconstructed optical field. Specifically, a small bubble is segmented based on the presence of the prominent intensity minimum in its longitudinal intensity profile, and its depth is determined by the location of the minimum. In contrast, a large bubble/cluster is segmented using a modified watershed segmentation algorithm and its depth is measured through a wavelet-based focus metric. Our processing approach also determines the inclination angle of a large bubble with respect to the hologram recording plane based on the depth variation along its edge on the plane. The accuracy of our processing approach on the measurements of object size and 3D distributions are assessed through synthetic bubble holograms and oil droplet holograms from an experiment separately. In addition, we evaluate the ability of this algorithm to estimate the bubble inclination with respect to the hologram recording plane through measuring a 3D-printed physical target of pillars with different inclination angles. The holographic measurement technique is further implemented to capture the fluctuation of instantaneous gas leakage rate from a ventilated supercavity generated in a water tunnel experiment. Overall, our paper introduces an inexpensive and compact solution for high resolution characterization of bubbles and other particles in multiphase flows from a broad range of applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shao, Siyao; Li, Cheng; Hong, Jiarong] Univ Minnesota, St Anthony Falls Lab, 2 3rd AVE SE, Minneapolis, MN 55414 USA.
   [Shao, Siyao; Hong, Jiarong] Univ Minnesota, Dept Mech Engn, 111 Church St SE, Minneapolis, MN 55414 USA.
RP Hong, JR (reprint author), Univ Minnesota, Dept Mech Engn, 111 Church St SE, Minneapolis, MN 55414 USA.
EM jhong@umn.edu
OI Hong, Jiarong/0000-0001-7860-2181
FU Office of Naval ResearchOffice of Naval Research [N000141612755];
   University of MinnesotaUniversity of Minnesota System
FX This work is supported by the Office of Naval Research (Program Manager,
   Dr. Thomas Fu) under grant No. N000141612755 and the start-up funding
   received by Prof. Jiarong Hong from University of Minnesota. We would
   like to thank the help from Mr. Santosh Kumar for assisting the
   ventilated supercavitation bubbly wake experiments. The authors also
   gratefully acknowledge the discussion of the algorithm with Mr. Kevin
   Mallery, and the oil droplet hologram and the corresponding manual
   analysis results provided by Prof. Joseph Katz research group from Johns
   Hopkins University.
CR Bonifazi G., 1999, Proceedings of the Second International Conference on Intelligent Processing and Manufacturing of Materials. IPMM'99 (Cat. No.99EX296), P465, DOI 10.1109/IPMM.1999.792524
   Brucker C., 2000, LECT SERIES, P1
   Da Silva MJ, 2007, MEAS SCI TECHNOL, V18, P2245, DOI 10.1088/0957-0233/18/7/059
   Estevadeordal J., 2005, 43 AIAA AER SCI M EX
   Felder S, 2015, EXP THERM FLUID SCI, V61, P66, DOI 10.1016/j.expthermflusci.2014.10.009
   Gao J.H., 2014, THESIS
   Gao J, 2014, APPL OPTICS, V53, pG130, DOI 10.1364/AO.53.00G130
   Gonzalez R.C., 2009, DIGITAL IMAGE PROCES
   GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761
   Guildenbecher DR, 2013, APPL OPTICS, V52, P3790, DOI 10.1364/AO.52.003790
   Haralick R.M., 1992, COMPUTER ROBOT VISIO
   Hernandez-Alvarado F, 2018, INT J MULTIPHAS FLOW, V102, P119, DOI 10.1016/j.ijmultiphaseflow.2018.02.002
   Honkanen M, 2010, FLOW MEAS INSTRUM, V21, P25, DOI 10.1016/j.flowmeasinst.2009.11.001
   Huang QM, 2005, PATTERN RECOGN LETT, V26, P801, DOI 10.1016/j.patrec.2004.09.035
   Junker B, 2006, BIOPROC BIOSYST ENG, V29, P185, DOI 10.1007/s00449-006-0070-3
   Kamp AM, 2001, INT J MULTIPHAS FLOW, V27, P1363, DOI 10.1016/S0301-9322(01)00010-6
   Karn A, 2016, J FLUID MECH, V789, P259, DOI 10.1017/jfm.2015.680
   Karn A, 2015, INT J HEAT MASS TRAN, V87, P512, DOI 10.1016/j.ijheatmasstransfer.2015.04.021
   Karn A, 2015, CHEM ENG SCI, V122, P240, DOI 10.1016/j.ces.2014.09.036
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   Katz J, 2010, ANNU REV FLUID MECH, V42, P531, DOI 10.1146/annurev-fluid-121108-145508
   Khanam T, 2011, CHEM ENG SCI, V66, P2699, DOI 10.1016/j.ces.2011.03.026
   Laakkonen M, 2005, CHEM ENG RES DES, V83, P50, DOI 10.1205/cherd.04122
   Lau YM, 2013, CHEM ENG SCI, V94, P20, DOI 10.1016/j.ces.2013.02.043
   Li C, 2017, J GEOPHYS RES-OCEANS, V122, P7938, DOI 10.1002/2017JC013193
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Lin B, 2008, MINER ENG, V21, P539, DOI 10.1016/j.mineng.2007.11.004
   Liu HY, 2013, CHIN OPT LETT, V11, DOI 10.3788/COL201311.123301
   LIU TJ, 1993, INT J HEAT MASS TRAN, V36, P1061, DOI 10.1016/S0017-9310(05)80290-X
   MEYER F, 1994, SIGNAL PROCESS, V38, P113, DOI 10.1016/0165-1684(94)90060-4
   Olson E, 2011, J GXP COMPLIANCE, V15, P85
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pertuz S, 2013, PATTERN RECOGN, V46, P1415, DOI 10.1016/j.patcog.2012.11.011
   Roesler T.C., 1989, INT J TURBO JET ENG, V6, P221
   SABERI S, 1995, CAN J CHEM ENG, V73, P253, DOI 10.1002/cjce.5450730213
   Sahoo P, 1997, PATTERN RECOGN, V30, P71, DOI 10.1016/S0031-3203(96)00065-9
   Sentis MPL, 2018, OPT LETT, V43, P2945, DOI 10.1364/OL.43.002945
   SHAO SY, 2018, PHYS FLUIDS, V30
   Smith JS, 1996, IND ENG CHEM RES, V35, P1700, DOI 10.1021/ie950366y
   SOILLE P, 2003, MORPHOLOGICAL IMAGE
   Sotiriadis AA, 2005, CHEM ENG SCI, V60, P5917, DOI 10.1016/j.ces.2005.05.046
   Talapatra S, 2012, PROC SPIE, V8372, DOI 10.1117/12.920570
   Tian L, 2010, APPL OPTICS, V49, P1549, DOI 10.1364/AO.49.001549
   Toloui M, 2015, OPT EXPRESS, V23, P27159, DOI 10.1364/OE.23.027159
   Weeks M, 2010, DIGITAL SIGNAL PROCE
   Wosnik M, 2013, J FLUID ENG-T ASME, V135, DOI 10.1115/1.4023193
   Wu YC, 2014, APPL OPTICS, V53, P556, DOI 10.1364/AO.53.000556
   Wu Y, 2019, J FLUID MECH, V862, P1135, DOI 10.1017/jfm.2018.1006
   Zhang YG, 2006, OPT ENG, V45, DOI 10.1117/1.2227074
NR 50
TC 3
Z9 3
U1 12
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 929
EP 941
DI 10.1016/j.ces.2019.07.009
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300077
DA 2020-05-12
ER

PT J
AU Menbari, A
   Hashemnia, K
AF Menbari, Amir
   Hashemnia, Kamyar
TI Effect of vibration characteristics on the performance of mixing in a
   vertically vibrated bed of a binary mixture of spherical particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Discrete element modeling; Fluidization; Granular media; Mixing;
   Vibration
ID FLOW; FLUIDIZATION; SEGREGATION; SIMULATION; INDEX
AB The uniform mixing is necessary in many processes such as those used in pharmaceutical, chemical and petrochemical industries. The present work studies the influence of vibration characteristics on mixing of binary mixtures of spheres produced in a vibrationally fluidized bed by using discrete element method. Solid-like flow pattern was observed in low frequencies and amplitudes, while as the vibration got stronger, particles behaved fluid-like, and convection rolls were generated. The generation and movement of convection rolls played a fundamental role in mixing within vibrated beds. It was realized that mixing was generally improved by increasing the vibration amplitude. In contrast, an optimal frequency was found in each amplitude, by which the best mixing occurred. The particles average velocity always increased by amplitude at a fixed frequency, while the mixing was not necessarily improved. It was found that the results were in qualitative agreement with some previous experimental and numerical studies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Menbari, Amir; Hashemnia, Kamyar] Shiraz Univ, Sch Mech Engn, Molla Sadra St, Shiraz, Iran.
RP Hashemnia, K (reprint author), Shiraz Univ, Sch Mech Engn, Molla Sadra St, Shiraz, Iran.
EM khashmenia@shirazu.ac.ir
RI Hashemnia, Kamyar/AAN-2671-2020
CR Amiri Z, 2017, POWDER TECHNOL, V320, P637, DOI 10.1016/j.powtec.2017.07.097
   [Anonymous], 2019, TUMBL MED VIBR FIN
   Asmar BN, 2002, GRANUL MATTER, V4, P129, DOI 10.1007/s10035-002-0112-8
   Badawy SI, 2000, AAPS PHARMSCITECH, V1, P55, DOI DOI 10.1208/PT010433
   Banfai B, 2007, J CHROMATOGR A, V1156, P206, DOI 10.1016/j.chroma.2006.10.067
   Basinskas G, 2016, POWDER TECHNOL, V301, P815, DOI 10.1016/j.powtec.2016.07.017
   Brennan W, 2008, POWDER TECHNOL, V181, P178, DOI 10.1016/j.powtec.2006.12.002
   Busciglio A, 2012, POWDER TECHNOL, V231, P21, DOI 10.1016/j.powtec.2012.07.033
   Cano-Pleite E, 2017, POWDER TECHNOL, V316, P101, DOI 10.1016/j.powtec.2017.01.007
   Chandratilleke GR, 2012, CHEM ENG SCI, V79, P54, DOI 10.1016/j.ces.2012.05.010
   Cho M, 2017, POWDER TECHNOL, V319, P434, DOI 10.1016/j.powtec.2017.07.011
   Di Renzo A, 2005, CHEM ENG SCI, V60, P1303, DOI 10.1016/j.ces.2004.10.004
   Eshuis P, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2815745
   Feng YQ, 2007, CHEM ENG SCI, V62, P256, DOI 10.1016/j.ces.2006.08.015
   Freeman Maisha Kelly, 2012, Consult Pharm, V27, P421, DOI 10.4140/TCP.n.2012.421
   Gerhart P. M., 2016, MUNSON YOUNG OKIISHI
   Gooding D. E. M, 1993, QUASISTATIC COMPRESS
   Halidan M, 2018, POWDER TECHNOL, V325, P92, DOI 10.1016/j.powtec.2017.11.009
   Halidan M, 2014, CHEM ENG SCI, V120, P37, DOI 10.1016/j.ces.2014.08.048
   Hashemnia K, 2018, POWDER TECHNOL, V327, P335, DOI 10.1016/j.powtec.2017.12.097
   Hashemnia K, 2015, CHEM ENG SCI, V129, P91, DOI 10.1016/j.ces.2015.02.025
   Hashemnia K, 2014, CHEM ENG SCI, V109, P123, DOI 10.1016/j.ces.2014.01.027
   Hou QF, 2012, CHEM ENG SCI, V84, P449, DOI 10.1016/j.ces.2012.08.051
   HUNT ML, 1994, J FLUID ENG-T ASME, V116, P785, DOI 10.1115/1.2911850
   Lacey P. M. C., 2010, J CHEM TECHNOL BIOT, V4, P257, DOI DOI 10.1002/JCTB.5010040504
   Li X, 2010, POWDER TECHNOL, V197, P25, DOI 10.1016/j.powtec.2009.08.016
   Lu LS, 2008, POWDER TECHNOL, V184, P31, DOI 10.1016/j.powtec.2007.07.036
   Maciel LD, 2018, GRANUL MATTER, V20, DOI 10.1007/s10035-018-0831-0
   Mizonov V, 2017, ADV POWDER TECHNOL, V28, P3049, DOI 10.1016/j.apt.2017.09.016
   Namdarkedenji R, 2018, ADV POWDER TECHNOL, V29, P3527, DOI 10.1016/j.apt.2018.09.033
   Nienow A.W., 1997, MIXING PROCESS IND
   Norouzi H.R., 2016, COUPLED CFD DEM MODE
   Qi FL, 2017, POWDER TECHNOL, V308, P334, DOI 10.1016/j.powtec.2016.12.043
   Rao A, 2011, AICHE J, V57, P1446, DOI 10.1002/aic.12371
   Sakai M, 2015, CHEM ENG J, V279, P821, DOI 10.1016/j.cej.2015.04.130
   Silbert LE, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.051302
   Tai SC, 2009, POWDER TECHNOL, V194, P159, DOI 10.1016/j.powtec.2009.04.001
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Zhang FW, 2014, PHYS LETT A, V378, P1303, DOI 10.1016/j.physleta.2014.03.001
NR 39
TC 0
Z9 0
U1 15
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 942
EP 957
DI 10.1016/j.ces.2019.07.026
PG 16
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300078
DA 2020-05-12
ER

PT J
AU Hubble, R
   York, APE
   Dennis, JS
AF Hubble, R.
   York, A. P. E.
   Dennis, J. S.
TI Modelling reaction and diffusion in a wax-filled hollow cylindrical
   pellet of Fischer Tropsch catalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Modelling; Fischer Tropsch catalyst; Cylindrical geometry; Reaction and
   diffusion
ID ALPHA-OLEFIN READSORPTION; PRODUCT DISTRIBUTIONS; TRANSPORT; IRON;
   OPTIMIZATION; SELECTIVITY; LIMITATIONS; KINETICS; SHAPE
AB Previous modelling of fixed-bed, Fischer-Tropsch (FT) reactors has demonstrated the advantages relative to spherical pellets of using cylindrical and shaped pellets to provide improved transport attributes under conditions relevant to industrial operation. However, mass transport models have focussed on the investigation of transport within pellets with spherical symmetry, whilst detailed investigations of more complex shapes have not been undertaken. Here, a pseudo-isothermal, steady-state, two-dimensional model was investigated for catalyst pellets of cylindrical form, both solid and hollow. A cobalt-based catalyst was considered at conditions where the rate of condensable hydrocarbon generation is large enough to result in the accumulation of liquid hydrocarbons in the pores of a catalyst. It was found that effectiveness factors were bounded by those of sphere and slab above and below Thiele moduli of similar to 0.75 and similar to 1.15, respectively, for the conditions examined, with the effectiveness factors exceeding those of both sphere and slab models between these moduli. Here, comparisons were made on the basis of the characteristic diffusion length, the catalyst particle's volume divided by its external surface area. However, values of the FT chain growth parameter, alpha, between these values of Thiele modulus were lower than those of both sphere and slab geometry, and thus under these conditions hollow cylinders gave the greatest methane selectivity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hubble, R.; Dennis, J. S.] Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
   [York, A. P. E.] Johnson Matthey Technol Ctr, Blounts Court Rd, Reading RG4 9NH, Berks, England.
RP Dennis, JS (reprint author), Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM jsd3@cam.ac.uk
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC)
FX R. A. H. would like to thank the EPSRC for provision of a Doctoral
   Training Grant.
CR Akgerman A, 1987, DEAC2284PC701132
   Akgerman A., 1984, DOEPC70032T2
   ANDERSON RB, 1952, IND ENG CHEM, V44, P391, DOI 10.1021/ie50506a052
   ARIS R, 1957, CHEM ENG SCI, V6, P262, DOI 10.1016/0009-2509(57)85028-3
   Atashi H, 2012, KOREAN J CHEM ENG, V29, P304, DOI 10.1007/s11814-011-0189-z
   Becker H, 2016, CATAL SCI TECHNOL, V6, P275, DOI 10.1039/c5cy00957j
   Becker H, 2014, CHEM-ING-TECH, V86, P544, DOI 10.1002/cite.201300142
   BISCHOFF KB, 1965, AICHE J, V11, P351, DOI 10.1002/aic.690110229
   Brunner KM, 2015, IND ENG CHEM RES, V54, P2902, DOI 10.1021/ie503174v
   CAREY GF, 1975, CHEM ENG SCI, V30, P587, DOI 10.1016/0009-2509(75)80031-5
   de Deugd RM, 2003, CHEM ENG SCI, V58, P583, DOI 10.1016/S0009-2509(02)00583-3
   Dry ME, 2002, CATAL TODAY, V71, P227, DOI 10.1016/S0920-5861(01)00453-9
   ERKEY C, 1990, ENERG FUEL, V4, P275, DOI 10.1021/ef00021a010
   Gardezi SA, 2015, IND ENG CHEM RES, V54, P8080, DOI 10.1021/acs.iecr.5b01288
   Gaube J, 2008, J MOL CATAL A-CHEM, V283, P60, DOI 10.1016/j.molcata.2007.11.028
   Hallac BB, 2015, CHEM ENG J, V263, P268, DOI 10.1016/j.cej.2014.10.108
   HUFF GA, 1985, IND ENG CHEM PROC DD, V24, P986, DOI 10.1021/i200031a015
   HUFF GA, 1984, J CATAL, V85, P370, DOI 10.1016/0021-9517(84)90226-4
   IGLESIA E, 1991, J CATAL, V129, P238, DOI 10.1016/0021-9517(91)90027-2
   Jess A, 2009, CHEM ENG TECHNOL, V32, P1164, DOI 10.1002/ceat.200900131
   Kaiser P, 2014, CHEM ENG TECHNOL, V37, P964, DOI 10.1002/ceat.201300815
   Kaskes B, 2016, CHEM ENG J, V283, P1465, DOI 10.1016/j.cej.2015.08.078
   Keyser MJ, 2000, IND ENG CHEM RES, V39, P48, DOI 10.1021/ie990236f
   Kuipers EW, 1996, J CATAL, V158, P288, DOI 10.1006/jcat.1996.0028
   KUIPERS EW, 1995, J CATAL, V152, P137, DOI 10.1006/jcat.1995.1068
   Leckel D, 2009, ENERG FUEL, V23, P2342, DOI 10.1021/ef900064c
   MADON RJ, 1994, J CATAL, V149, P428, DOI 10.1006/jcat.1994.1309
   Makrodimitri ZA, 2011, J PHYS CHEM B, V115, P1429, DOI 10.1021/jp1063269
   Mandic M, 2017, IND ENG CHEM RES, V56, P2733, DOI 10.1021/acs.iecr.7b00053
   Marano JJ, 1997, IND ENG CHEM RES, V36, P2409, DOI 10.1021/ie9605140
   Marano JJ, 1997, IND ENG CHEM RES, V36, P2399, DOI 10.1021/ie9605138
   Marano JJ, 1997, FLUID PHASE EQUILIBR, V138, P1, DOI 10.1016/S0378-3812(97)00166-0
   Maretto C, 1999, CATAL TODAY, V52, P279, DOI 10.1016/S0920-5861(99)00082-6
   Masuku CM, 2011, CHEM ENG SCI, V66, P6254, DOI 10.1016/j.ces.2011.09.005
   Mills P. L., 2015, P 2015 COMSOL C BOST
   NOVAK S, 1981, J CHEM PHYS, V74, P6083, DOI 10.1063/1.441051
   Pohlmann F, 2016, CATAL TODAY, V275, P172, DOI 10.1016/j.cattod.2015.09.032
   POST MFM, 1989, AICHE J, V35, P1107, DOI 10.1002/aic.690350706
   RODDEN JB, 1988, J CHEM ENG DATA, V33, P344, DOI 10.1021/je00053a034
   Sanchez-Lopez J. R. G., 2016, REV CHEM ENG, V33, P1
   Sehabiague L., 2012, THESIS
   Sehabiague L., 2013, INT J CHEM REACT ENG, V11, P309
   Shi BC, 2005, CATAL TODAY, V106, P129, DOI 10.1016/j.cattod.2005.07.159
   Smith DS, 2013, J MATER RES, V28, P2260, DOI 10.1557/jmr.2013.179
   SNEL R, 1987, CATAL REV, V29, P361, DOI 10.1080/01614948708078612
   Vervloet D, 2012, CATAL SCI TECHNOL, V2, P1221, DOI 10.1039/c2cy20060k
   Wang YN, 2001, IND ENG CHEM RES, V40, P4324, DOI 10.1021/ie010080v
   Wijngaarden R.J., 1998, IND CATALYSIS OPTIMI
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   YATES IC, 1991, ENERG FUEL, V5, P168, DOI 10.1021/ef00025a029
NR 50
TC 0
Z9 0
U1 7
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 958
EP 969
DI 10.1016/j.ces.2019.06.051
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300079
DA 2020-05-12
ER

PT J
AU Basu, S
   Sarkar, J
AF Basu, Surita
   Sarkar, Jayati
TI Selective adsorption of oil on self-organized surface patterns formed
   over soft thin PDMS films
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Self-organization; Contact instability; Patterns; RMS roughness; Oil
   adsorption
ID ELASTIC FILMS; CONTACT INSTABILITY; WASTE-WATER; ADHESION; SPILL;
   MINIATURIZATION; ABSORPTION; EFFICIENCY; RECOVERY; REMOVAL
AB A new, simple, cost effective and facile method of adsorption of oil from oil - water mixture on self-organized patterns formed over a soft thin elastic film has been developed, which is of great ecological importance. Surface corrugations (such as columns, labyrinths and cavities evolved spontaneously due to instability on the surfaces of a thin soft elastic PDMS film in adhesive contact with a contactor) along with the oleophilic nature of the film help in selective adsorption of the oil from the oil-water mixture into the intervening surface spaces. The increase in RMS surface roughness brought about either by increase in adsorbent weight or by formation of a columnar structure (instead of cavities or labyrinths) was found to have a significant incremental effect on the true surface area creation by formation of increased number of oil adsorption sites: leading to higher oil penetration and thus, higher oil adsorption. For 0.3 wt% of adsorbent, adsorption was found to be maximum for columnar structures at 23%, followed by cavities at 15% and minimum with labyrinth at around 12%. The ratio (d(p)/d(d)) of the substrate pore size dimension (d(p)) to the surface oil droplet dimension (d(d)) in crude oil, motor oil, diesel and petrol were found to be progressively lower and hence the maximum adsorption and penetration in the columnar patterns was recognized in case of crude oil. The different oil morphology on adsorption can be greatly used as a marker to identify different category of oil. The surface columns fabricated by self-organization was found to adsorb double the weight of the adsorbent, and moreover the quantity of the polymeric material required in the present case was much less than that for bulk adsorbents, and also does not involve any additional functionalization or use of any external template material, making this method a very suitable one for selective oil adsorption. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Basu, Surita; Sarkar, Jayati] Indian Inst Technol, Dept Chem Engn, New Delhi, India.
RP Sarkar, J (reprint author), Indian Inst Technol, Dept Chem Engn, New Delhi, India.
EM jayati@chemical.iitd.ac.in
CR Aggelis G, 2003, WATER RES, V37, P3897, DOI 10.1016/S0043-1354(03)00313-0
   Annepu H, 2014, LANGMUIR, V30, P12278, DOI 10.1021/la502933c
   Annepu H, 2014, MODEL SIMUL MATER SC, V22, DOI 10.1088/0965-0393/22/5/055003
   Annepu H, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051604
   Arun N, 2007, J ADHESION, V83, P513, DOI 10.1080/00218460701453486
   Arun N, 2006, ADV MATER, V18, P660, DOI 10.1002/adma.200502199
   Basu S, 2019, CHEM ENG SCI, V197, P195, DOI 10.1016/j.ces.2018.12.012
   Bayat A, 2005, CHEM ENG TECHNOL, V28, P1525, DOI 10.1002/ceat.200407083
   Bodas D, 2007, SENSOR ACTUAT B-CHEM, V123, P368, DOI 10.1016/j.snb.2006.08.037
   Bolong N, 2009, DESALINATION, V239, P229, DOI 10.1016/j.desal.2008.03.020
   Broje V, 2006, ENVIRON SCI TECHNOL, V40, P7914, DOI 10.1021/es061842m
   Buist I, 2011, COLD REG SCI TECHNOL, V67, P3, DOI 10.1016/j.coldregions.2011.02.004
   Carmody O, 2007, J COLLOID INTERF SCI, V305, P17, DOI 10.1016/j.jcis.2006.09.032
   Choi SJ, 2011, ACS APPL MATER INTER, V3, P4552, DOI 10.1021/am201352w
   Chuah YJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep18162
   Chung JY, 2006, EUR PHYS J E, V20, P47, DOI 10.1140/epje/i2005-10080-0
   Deblonde T, 2011, INT J HYG ENVIR HEAL, V214, P442, DOI 10.1016/j.ijheh.2011.08.002
   Feng L., 2003, ANGEW CHEM, V115, P824, DOI DOI 10.1002/ANGE.200390181
   Forsberg PSH, 2010, LANGMUIR, V26, P860, DOI 10.1021/la902296d
   Fu Y, 2011, APPL CLAY SCI, V53, P634, DOI 10.1016/j.clay.2011.05.014
   Ghatak A, 2000, PHYS REV LETT, V85, P4329, DOI 10.1103/PhysRevLett.85.4329
   Ghatak A, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.041601
   Ghatak A, 2004, P ROY SOC A-MATH PHY, V460, P2725, DOI 10.1098/rspa.2004.1313
   Ghatak A, 2003, LANGMUIR, V19, P2621, DOI 10.1021/la026932t
   Gonuguntla M., 2006, PHYS REV LETT, V97, P1
   Gonuguntla M, 2006, LANGMUIR, V22, P7066, DOI 10.1021/la0600696
   Head IM, 2006, NAT REV MICROBIOL, V4, P173, DOI 10.1038/nrmicro1348
   Kabiri S, 2014, CARBON, V80, P523, DOI 10.1016/j.carbon.2014.08.092
   Karan CP, 2011, OIL SPILL CLEANUP ST
   Kujawinski EB, 2011, ENVIRON SCI TECHNOL, V45, P1298, DOI 10.1021/es103838p
   Li HL, 2010, NAT GEOSCI, V3, P96, DOI 10.1038/NGEO749
   Mark JE, 2004, ACCOUNTS CHEM RES, V37, P946, DOI 10.1021/ar030279z
   Mishra S, 2017, INT J ADHES ADHES, V79, P102, DOI 10.1016/j.ijadhadh.2017.09.013
   Mukherjee R, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2752499
   Mukherjee R, 2007, ADV FUNCT MATER, V17, P2356, DOI 10.1002/adfm.200600896
   Nishi Y, 2002, WATER RES, V36, P5029, DOI 10.1016/S0043-1354(02)00225-7
   Noble PF, 2004, J AM CHEM SOC, V126, P8092, DOI 10.1021/ja047808u
   Nonomura Y, 2016, LANGMUIR, V32, P6328, DOI 10.1021/acs.langmuir.6b01509
   Rajakovic V, 2007, J HAZARD MATER, V143, P494, DOI 10.1016/j.jhazmat.2006.09.060
   Sarkar J, 2005, J ADHESION, V81, P271, DOI 10.1080/00218460590944558
   Sarkar J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.018302
   Sarkar J, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031607
   Sarkar J, 2005, LANGMUIR, V21, P1457, DOI 10.1021/la048061o
   Sarkar J, 2016, PERUSAL OF THE FINITE ELEMENT METHOD, P163, DOI 10.5772/65357
   Sarkar J, 2011, J ADHESION, V87, P214, DOI 10.1080/00218464.2011.557332
   Sarkar J, 2010, LANGMUIR, V26, P8464, DOI 10.1021/la9049007
   Sarkar J, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031604
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Shenoy V, 2002, J MECH PHYS SOLIDS, V50, P1155, DOI 10.1016/S0022-5096(01)00109-0
   Shenoy V, 2001, PHYS REV LETT, V86, P119, DOI 10.1103/PhysRevLett.86.119
   Tran DNH, 2015, ENVIRON SCI-WAT RES, V1, P298, DOI [10.1039/c5ew00035a, 10.1039/C5EW00035A]
   Trantidou T, 2017, MICROSYST NANOENG, V3, DOI 10.1038/micronano.2016.91
   Vuong T, 1998, LANGMUIR, V14, P4880, DOI 10.1021/la980033g
   Wolf A. T, 1999, RILEM PUBLICATIONS, V21
   Wu J, 2012, ACS APPL MATER INTER, V4, P3207, DOI 10.1021/am300544d
   Xue ZX, 2014, J MATER CHEM A, V2, P2445, DOI 10.1039/c3ta13397d
   Yuan JK, 2008, NAT NANOTECHNOL, V3, P332, DOI 10.1038/nnano.2008.136
   Zhang YL, 2009, NANO TODAY, V4, P135, DOI 10.1016/j.nantod.2009.02.010
   Zhao X, 2014, J MATER CHEM A, V2, P18281, DOI 10.1039/c4ta04406a
   Zhu K, 2013, FRONT MATER SCI, V7, P170, DOI 10.1007/s11706-013-0200-1
NR 60
TC 0
Z9 0
U1 3
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 970
EP 979
DI 10.1016/j.ces.2019.07.021
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300080
DA 2020-05-12
ER

PT J
AU Zhong, C
   Gong, JK
   Liu, WN
   Liu, GL
AF Zhong, Chao
   Gong, Jinke
   Liu, Weicnang
   Liu, Guanlin
TI Low temperature, medium temperature and high temperature performance of
   the continuous regenerative diesel particulate filter assisted by
   electric regeneration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Continuous regeneration; Electric regeneration; Balance point
   temperature; Thermal response; Outlet temperature
ID SOOT OXIDATION; THERMAL REGENERATION; CARBON-BLACK; NO2; SIMULATION;
   FILTRATION; COMBUSTION; DEPOSITION; MECHANISM; DYNAMICS
AB A model is established to investigate low temperature (<300 degrees C), medium temperature (300-550 degrees C) and high temperature (>550 degrees C) performance of the continuous regenerative diesel particulate filter (CR-DPF) assisted by electric regeneration regarding to balance point temperature, regeneration speed and outlet temperature respectively and relevant influencing factors. Results show that inlet PM concentration and inlet flow rate are positively correlated to balance point temperature and vice versa for initial soot loading and intake NOx concentration. Increasing intake NOx concentration and flow rate increase rapid continuous regeneration speed. At low and medium temperatures, rapid thermal response tends to increase passive regeneration speed and the trend is more with decreasing wall thickness and channel density. In the high temperature range, outlet temperature increases and temperature gradients presented in the early stage of regeneration become steeper with decreasing channel density and wall thickness. However, "L/D" has limited impact on low, medium and high temperature performance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhong, Chao; Gong, Jinke; Liu, Weicnang] Hunan Univ, State Key Lab Adv Design & Mfg Vehicle Body, Changsha 410082, Hunan, Peoples R China.
   [Zhong, Chao; Gong, Jinke; Liu, Weicnang; Liu, Guanlin] Hunan Univ, Coll Mech & Vehicle Engn, Changsha 410082, Hunan, Peoples R China.
   [Zhong, Chao; Gong, Jinke; Liu, Weicnang; Liu, Guanlin] Hunan Univ, Inst New Energy & Energy Saving & Emiss Reduct Te, Changsha 410082, Hunan, Peoples R China.
   [Liu, Weicnang] Univ Waterloo, Mech & Mechatron Engn, Waterloo, ON N2L 3G1, Canada.
RP Gong, JK (reprint author), Hunan Univ, State Key Lab Adv Design & Mfg Vehicle Body, Changsha 410082, Hunan, Peoples R China.; Gong, JK (reprint author), Hunan Univ, Coll Mech & Vehicle Engn, Changsha 410082, Hunan, Peoples R China.; Gong, JK (reprint author), Hunan Univ, Inst New Energy & Energy Saving & Emiss Reduct Te, Changsha 410082, Hunan, Peoples R China.
EM gongjinke@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [551776062, 51776062]
FX The authors thank the financial support of National Natural Science
   Foundation of China (Nos. 551776062 and 51776062).
CR Allansson R., 2002, 0428 SAE
   Arai M, 2007, INT J ENGINE RES, V8, P477, DOI 10.1243/14680874JER01507
   Arvajova A, 2016, APPL CATAL B-ENVIRON, V181, P644, DOI 10.1016/j.apcatb.2015.08.004
   Bach E., 1998, SAE T, P771
   Baik Doo S, 2004, 2004013041 SAE
   Ball Bill, 2004, 2004010078 SAE
   Bensaid S, 2010, CHEM ENG SCI, V65, P357, DOI 10.1016/j.ces.2009.06.051
   BISSETT EJ, 1984, CHEM ENG SCI, V39, P1233, DOI 10.1016/0009-2509(84)85084-8
   Choo J, 2008, SCI TOTAL ENVIRON, V405, P396, DOI 10.1016/j.scitotenv.2008.07.028
   Di Sarli V, 2018, AICHE J, V64, P1714, DOI 10.1002/aic.16047
   Di Sarli V, 2017, AICHE J, V63, P3442, DOI 10.1002/aic.15688
   Di Sarli V, 2016, IND ENG CHEM RES, V55, P11052, DOI 10.1021/acs.iecr.6b02521
   Di Sarli V, 2015, CHEM ENG SCI, V137, P69, DOI 10.1016/j.ces.2015.06.011
   Dudak M, 2014, APPL CATAL B-ENVIRON, V150, P446, DOI 10.1016/j.apcatb.2013.12.018
   E JQ, 2016, ATMOS POLLUT RES, V7, P9, DOI 10.1016/j.apr.2015.06.012
   He C, 2015, J ENVIRON SCI-CHINA, V35, P55, DOI 10.1016/j.jes.2015.02.009
   Heibel A, 2010, HEAV DUT DIES EM CON
   HOFFMANN U, 1991, CHEM ENG SCI, V46, P1101, DOI 10.1016/0009-2509(91)85103-5
   Horiuchi M., 1990, SAE T, P1268
   Jeguirim M, 2004, J ANAL APPL PYROL, V72, P171, DOI 10.1016/j.jaap.2004.03.008
   Jeguirim M, 2005, FUEL, V84, P1949, DOI 10.1016/j.fuel.2005.03.026
   Jiang JH, 2016, J AEROSOL SCI, V95, P73, DOI 10.1016/j.jaerosci.2016.01.009
   Jinke G., 2011, 2011 INT C EL INF CO, P5297
   Kamm S, 2004, COMBUST FLAME, V138, P353, DOI 10.1016/j.combustflame.2004.06.008
   Kandylas IP, 2002, IND ENG CHEM RES, V41, P5372, DOI 10.1021/ie020379t
   Kato H, 2011, INT J ENGINE RES, V12, P1, DOI 10.1243/14680874JER594
   Koltsakis GC, 1996, AICHE J, V42, P1662, DOI 10.1002/aic.690420618
   Konstandopoulos AG, 2000, COMBUST FLAME, V121, P488, DOI 10.1016/S0010-2180(99)00156-X
   Kostoglou M, 2003, CHEM ENG SCI, V58, P3273, DOI 10.1016/S0009-2509(03)00178-7
   Kotrba A., 2013, 0520 SAE
   Lee KO, 2013, P COMBUST INST, V34, P3057, DOI 10.1016/j.proci.2012.06.121
   Lee SJ, 2008, INT J AUTO TECH-KOR, V9, P659, DOI 10.1007/s12239-008-0078-6
   Lupse J, 2016, CHEM ENG SCI, V151, P36, DOI 10.1016/j.ces.2016.05.008
   Matarrese R, 2017, CHEM ENG SCI, V173, P560, DOI 10.1016/j.ces.2017.08.017
   OH SH, 1982, IND ENG CHEM PROD RD, V21, P29, DOI 10.1021/i300005a006
   Peters B. J., 2004, 2004011132 SAE
   Presti M., 2013, 2013240158 SAE
   Schejbal M, 2009, CHEM ENG J, V154, P219, DOI 10.1016/j.cej.2009.04.056
   Schejbal M, 2009, COMPUT-AIDED CHEM EN, V26, P803
   Shrivastava M, 2010, ENVIRON SCI TECHNOL, V44, P4796, DOI 10.1021/es903672y
   Stanmore BR, 2008, FUEL, V87, P131, DOI 10.1016/j.fuel.2007.04.012
   Tang T, 2014, J ENVIRON SCI, V26, P2434, DOI 10.1016/j.jes.2014.04.004
   Tighe CJ, 2012, COMBUST FLAME, V159, P77, DOI 10.1016/j.combustflame.2011.06.009
   Triana A. P., 2003, 2003013176 SAE
   Wang-Hansen C, 2013, J PHYS CHEM C, V117, P522, DOI 10.1021/jp307789r
   Yukio Miyairi, 2001, SAE TECHNICAL PAPER
   Zhang B, 2016, APPL ENERG, V181, P14, DOI 10.1016/j.apenergy.2016.08.051
   Zouaoui N, 2014, CR CHIM, V17, P672, DOI 10.1016/j.crci.2013.09.004
NR 48
TC 0
Z9 0
U1 4
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 980
EP 992
DI 10.1016/j.ces.2019.07.024
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300081
DA 2020-05-12
ER

PT J
AU Egger, T
   Fieg, G
AF Egger, Torben
   Fieg, Georg
TI Operation, validation and model comparison for a reactive dividing wall
   column
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactive dividing wall column; Mathematical modeling; Non-equilibrium
   stage model; Process integration; Distillation; Enzyme
ID MASS-TRANSFER; DISTILLATION-COLUMNS; STRUCTURED PACKINGS; COMPREHENSIVE
   MODEL; PERFORMANCE; SIMULATION; SCALE; STAGE
AB The reactive dividing wall column (RDWC) is a highly integrated apparatus that combines the features of reactive distillation and dividing wall column technology. The high degree of integration results in complex interactions between vapour-liquid equilibrium, chemical reaction and component distribution. This leads to a considerably more complex column design and operation than for conventional distillation columns. Therefore, precise simulation models are a prerequisite for a successful implementation and operation of this technology. A newly developed rate-based (NEQ) RDWC model for packed columns is presented and a detailed investigation on the influence of separation modeling was carried out. Comprehensive experimental RDWC data are presented for the reference system of the butyl acetate transesterification with hexanol and employed for a model validation. The validation results for the NEQ model are compared to the well-known equilibrium stage (EQ) approach. The rate-based model is shown to predict the inner flows and concentrations of the column with higher precision. Furthermore, an analysis of the validation results enhances the understanding of the interactions between separation, chemical reaction and reactant conversion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Egger, Torben; Fieg, Georg] Hamburg Univ Technol, Inst Proc & Plant Engn, Am Schwarzenberg Campus 4, D-21073 Hamburg, Germany.
RP Egger, T (reprint author), Hamburg Univ Technol, Inst Proc & Plant Engn, Am Schwarzenberg Campus 4, D-21073 Hamburg, Germany.
EM Torben.Egger@tuhh.de
CR Baur R, 2000, CHEM ENG J, V76, P33, DOI 10.1016/S1385-8947(99)00114-X
   Behrens M, 2006, CHEM ENG RES DES, V84, P381, DOI 10.1205/cherd05067
   Behrens M., 2006, THESIS
   BRAVO JL, 1985, HYDROCARB PROCESS, V64, P91
   Brunazzi E., 2006, DIST ABS S 2006 DIST
   Dejanovic I, 2010, CHEM ENG PROCESS, V49, P559, DOI 10.1016/j.cep.2010.04.001
   Egger T, 2018, CHEM ENG SCI, V178, P324, DOI 10.1016/j.ces.2017.12.050
   Egger T, 2018, CHEM ENG SCI, V179, P284, DOI 10.1016/j.ces.2017.12.011
   Egger T, 2017, AICHE J, V63, P2198, DOI 10.1002/aic.15598
   Ehlers C., 2017, EXPT SIMULATIVE ANAL
   Ehlers C, 2017, AICHE J, V63, P1036, DOI 10.1002/aic.15435
   Feng SY, 2016, IND ENG CHEM RES, V55, P11305, DOI 10.1021/acs.iecr.6b02824
   GLINOS K, 1988, CHEM ENG RES DES, V66, P229
   Hernandez S, 2009, CHEM ENG PROCESS, V48, P250, DOI 10.1016/j.cep.2008.03.015
   Hiller C., 2015, MODELLIERUNG UNTERSU
   Hiller C, 2010, HEAT MASS TRANSFER, V46, P1209, DOI 10.1007/s00231-010-0686-3
   Kaibel G., 1987, CHEM ENG TECHNOL, V10, P92, DOI DOI 10.1002/CEAT.270100112
   Keller T, 2013, COMPUT CHEM ENG, V48, P74, DOI 10.1016/j.compchemeng.2012.07.015
   Kenig EY, 2008, CHEM ENG RES DES, V86, P1059, DOI 10.1016/j.cherd.2008.04.011
   Kiss AA, 2012, COMPUT CHEM ENG, V38, P74, DOI 10.1016/j.compchemeng.2011.11.012
   Kloker M, 2005, CHEM ENG PROCESS, V44, P617, DOI 10.1016/j.cep.2003.12.011
   Muller I, 2010, CHEM-ING-TECH, V82, P2109, DOI 10.1002/cite.201000084
   Muller I., 2010, THEORETISCHE UNTERSU
   Pelkonen S., 1997, MULTICOMPONENT MASS
   ROCHA JA, 1993, IND ENG CHEM RES, V32, P641, DOI 10.1021/ie00016a010
   Rocha JA, 1996, IND ENG CHEM RES, V35, P1660, DOI 10.1021/ie940406i
   Ryll O., 2009, THERMODYNAMISCHE ANA
   Schroder M, 2016, CHEM ENG TECHNOL, V39, P2323, DOI 10.1002/ceat.201500722
   Schroder M, 2016, CHEM ENG TECHNOL, V39, P2265, DOI 10.1002/ceat.201600134
   Steinigeweg S, 2003, IND ENG CHEM RES, V42, P3612, DOI 10.1021/ie020925i
   Taylor R, 2000, CHEM ENG SCI, V55, P5183, DOI 10.1016/S0009-2509(00)00120-2
   TAYLOR R, 1993, MULTICOMPONENT MASS
   Taylor R, 2007, IND ENG CHEM RES, V46, P4349, DOI 10.1021/ie061626m
   Tsai RE, 2011, AICHE J, V57, P1173, DOI 10.1002/aic.12345
   Viva A, 2011, FLOW MEAS INSTRUM, V22, P279, DOI 10.1016/j.flowmeasinst.2011.03.008
   Wang GQ, 2005, IND ENG CHEM RES, V44, P8715, DOI 10.1021/ie050017w
   Weinfeld JA, 2018, CHEM ENG PROCESS, V123, P20, DOI 10.1016/j.cep.2017.10.019
   Wierschem M, 2017, CHEM ENG J, V312, P106, DOI 10.1016/j.cej.2016.11.127
NR 38
TC 1
Z9 1
U1 14
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 993
EP 1006
DI 10.1016/j.ces.2019.07.032
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300082
DA 2020-05-12
ER

PT J
AU Yamamoto, T
   Komarov, SV
AF Yamamoto, Takuya
   Komarov, Sergey, V
TI Single-bubble fragmentation in a mechanically stirred liquid bath under
   trailing vortex conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mechanical stirring; Volume of fluid method; OpenFOAM; Bubble
   fragmentation; Large eddy simulation
ID SIZE DISTRIBUTION; BREAKUP PROCESS; DROP BREAKAGE; THEORETICAL-MODEL;
   ENERGY-SPECTRUM; FLOW; DISPERSION; COALESCENCE; VALIDATION; TANK
AB We investigated the mechanism of single-bubble fragmentation during mechanical stirring under different trailing vortex conditions. Experiments and numerical simulations using the LES-VOF method were carried out under different bubble sizes and locations of bubble injection. We found that the following three phenomena can cause bubble fragmentation: collision with impeller blade; shear stress in the boundary layer ahead of the impeller blade; and interaction between trailing vortices and the bubble. In the last case, the mechanism of fragmentation can be categorized into six types, which are determined by the relationship between the bubble behavior and the trailing vortices. Thus, we clarified the relationship between trailing vortices and bubble fragmentation for the first time in a stirred vessel. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yamamoto, Takuya; Komarov, Sergey, V] Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9808579, Japan.
RP Yamamoto, T (reprint author), Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9808579, Japan.
EM t-yamamoto@tohoku.ac.jp
FU Initiative on Promotion of Supercomputing for Young or Women
   Researchers, Supercomputing Division, Information Technology Center, The
   University of Tokyo; Aluminium research grant from the Japan Aluminium
   Association
FX This work was supported partly by the Initiative on Promotion of
   Supercomputing for Young or Women Researchers, Supercomputing Division,
   Information Technology Center, The University of Tokyo, and partly by
   Aluminium research grant from the Japan Aluminium Association.
CR ALVAREZ J, 1994, CHEM ENG SCI, V49, P99, DOI 10.1016/0009-2509(94)85037-2
   Alves SS, 2002, CHEM ENG J, V89, P109, DOI 10.1016/S1385-8947(02)00008-6
   Andersson R, 2006, AICHE J, V52, P2031, DOI 10.1002/aic.10832
   [Anonymous], 2018, OPENFOAM USER GUIDE
   Ashar M, 2018, CHEM ENG SCI, V181, P186, DOI 10.1016/j.ces.2018.02.021
   BERKMAN PD, 1988, AICHE J, V34, P602, DOI 10.1002/aic.690340409
   Bilodeau JF, 2001, LIGHT MET, P1009
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   BROWN DE, 1974, CHEM ENG SCI, V29, P345, DOI 10.1016/0009-2509(74)80042-4
   Bujalski W, 2004, CHEM ENG TECHNOL, V27, P310, DOI 10.1002/ceat.200401982
   CHEN HT, 1967, AICHE J, V13, P989, DOI 10.1002/aic.690130529
   Chisti Y, 2002, BIOCHEM ENG J, V10, P143, DOI 10.1016/S1369-703X(01)00174-7
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Cui YQ, 1998, BIOTECHNOL BIOENG, V57, P409, DOI 10.1002/(SICI)1097-0290(19980220)57:4<409::AID-BIT4>3.0.CO;2-Q
   Han LC, 2015, AICHE J, V61, P2147, DOI 10.1002/aic.14830
   Han LC, 2014, CHEM ENG SCI, V117, P55, DOI 10.1016/j.ces.2014.06.018
   Han LC, 2013, CHEM ENG SCI, V102, P186, DOI 10.1016/j.ces.2013.06.046
   Han LC, 2011, CHEM ENG SCI, V66, P766, DOI 10.1016/j.ces.2010.11.041
   Hasan BO, 2018, EXP THERM FLUID SCI, V96, P48, DOI 10.1016/j.expthermflusci.2018.02.013
   Hasan BO, 2017, INT J MULTIPHAS FLOW, V97, P94, DOI 10.1016/j.ijmultiphaseflow.2017.08.006
   Hasan BO, 2017, CHINESE J CHEM ENG, V25, P698, DOI 10.1016/j.cjche.2017.03.008
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   ISSA RI, 1986, J COMPUT PHYS, V62, P40, DOI 10.1016/0021-9991(86)90099-9
   KONNO M, 1983, J CHEM ENG JPN, V16, P312, DOI 10.1252/jcej.16.312
   KONNO M, 1980, J CHEM ENG JPN, V13, P67, DOI 10.1252/jcej.13.67
   KUMAR S, 1991, CHEM ENG SCI, V46, P2483, DOI 10.1016/0009-2509(91)80041-V
   Laakkonen M, 2006, CHEM ENG SCI, V61, P218, DOI 10.1016/j.ces.2004.11.066
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Lovick J, 2004, CHEM ENG SCI, V59, P3105, DOI 10.1016/j.ces.2004.04.035
   Maass S, 2007, CHEM ENG RES DES, V85, P703, DOI 10.1205/cherd06187
   Maass S, 2012, CHEM ENG SCI, V70, P146, DOI 10.1016/j.ces.2011.08.027
   Mancilla E, 2017, CHEM ENG RES DES, V118, P158, DOI 10.1016/j.cherd.2016.11.031
   Martin M, 2008, IND ENG CHEM RES, V47, P6251, DOI 10.1021/ie800063v
   NISHIKAWA M, 1987, J CHEM ENG JPN, V20, P82, DOI 10.1252/jcej.20.82
   Paul E.L., 2004, HDB IND MIXING SCI P
   Roger W. A, 1956, CHEM ENGNG PROG, V52, P515
   Rusche H., 2002, THESIS
   Shimizu K, 1999, CHEM ENG J, V72, P117, DOI 10.1016/S1385-8947(98)00150-8
   Solsvik J, 2016, IND ENG CHEM RES, V55, P2872, DOI 10.1021/acs.iecr.6b00591
   Solsvik J, 2015, INT J CHEM REACT ENG, V13, P477, DOI 10.1515/ijcre-2014-0154
   Solsvik J, 2015, CHEM ENG SCI, V131, P219, DOI 10.1016/j.ces.2015.03.059
   Solsvik J, 2013, REV CHEM ENG, V29, P241, DOI 10.1515/revce-2013-0009
   Song J.L., 2003, P 3 INT C CFD MIN PR, P65
   SPROW FB, 1967, CHEM ENG SCI, V22, P435, DOI 10.1016/0009-2509(67)80130-1
   Sun Z, 2009, AICHE J, V55, P2646, DOI 10.1002/aic.11871
   VALENTAS KJ, 1966, IND ENG CHEM FUND, V5, P533, DOI 10.1021/i160020a018
   VAN LEER B, 1974, J COMPUT PHYS, V14, P361
   Yamamoto T, 2019, CHEM ENG J, V367, P25, DOI 10.1016/j.cej.2019.02.130
   Yamamoto T, 2019, CHEM ENG SCI, V197, P26, DOI 10.1016/j.ces.2018.12.007
   Yamamoto T, 2018, J MATER PROCESS TECH, V261, P164, DOI 10.1016/j.jmatprotec.2018.06.012
   Yamamoto T, 2017, INT J NUMER METH FL, V83, P223, DOI 10.1002/fld.4267
   Zhou GW, 1998, CHEM ENG SCI, V53, P2063, DOI 10.1016/S0009-2509(97)00438-7
NR 52
TC 0
Z9 0
U1 7
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1007
EP 1016
DI 10.1016/j.ces.2019.07.019
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300083
DA 2020-05-12
ER

PT J
AU Wang, ZQ
   Chang, MZ
   Kong, FY
   Yun, K
AF Wang, Zhenqing
   Chang, Mengzhou
   Kong, Fangyun
   Yun, Kumchol
TI Optimization of thermo-mechanical properties of shape memory polymer
   composites based on a network model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shape memory polymer; Thermo-mechanical property; Network; Polymer
   composite
ID VISCOELASTIC CONSTITUTIVE MODEL; NANOCOMPOSITES; POLYURETHANES
AB In this paper, thermo-mechanical responses of shape memory polymers and their composites are investigated for improving the shape memory effect. First, a chain model composed of thermal and mechanical parts has been proposed. The properties of thermal and mechanical parts are considered by way of analogy with thermo-mechanical responses in macro-scope. Subsequently, the instantaneous elastic modulus of chain system under different temperatures is examined to calibrate the material's parameters by adjusting several variables: chain length, chain number, and distribution function. Next, numerical simulations of polyurethane composites are performed and compared with experimental data to validate the applicability of the model. Furthermore, the shape memory processes of polymer composites are optimized by changing the structure of the chain system: geometry, cross link, and internal filler. From the results, it can be concluded that the shape memory effect of polymer composite can be improved by increasing cross link density. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Zhenqing; Chang, Mengzhou; Kong, Fangyun] Harbin Engn Univ, Coll Aerosp & Civil Engn, Harbin 150001, Heilongjiang, Peoples R China.
   [Yun, Kumchol] Kim II Sung Univ, Fac Mech, Pyongyang, North Korea.
RP Chang, MZ (reprint author), Harbin Engn Univ, Coll Aerosp & Civil Engn, Harbin 150001, Heilongjiang, Peoples R China.
EM changmengzhou@hrbeu.edu.cn
OI Yun, Kumchol/0000-0002-5380-2467
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11872157, 11532013, 11472086]
FX The authors gratefully acknowledge the financial support of the National
   Natural Science Foundation of China within the project with Grant Nos.
   11872157, 11532013 and 11472086.
CR Abishera R, 2017, COMPOS SCI TECHNOL, V141, P145, DOI 10.1016/j.compscitech.2017.01.020
   ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6
   Behniafar H, 2015, INT J POLYM MATER PO, V64, P1, DOI 10.1080/00914037.2014.886237
   Brinson LC, 1993, J INTELLIGENT MATERI, V4, P229, DOI DOI 10.1177/1045389X9300400213
   CHANG LC, 1951, JOM-J MIN MET MAT S, V3, P47
   Chang MZ, 2018, POLYMER, V149, P192, DOI 10.1016/j.polymer.2018.06.063
   Chang MZ, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10040426
   Chen HM, 2014, POLYM CHEM-UK, V5, P5168, DOI 10.1039/c4py00474d
   Chen L, 2016, COMPOS PART B-ENG, V91, P75, DOI 10.1016/j.compositesb.2016.01.019
   Chen W, 2016, POLYM CHEM-UK, V7, P6789, DOI 10.1039/c6py01638c
   Chen YC, 2008, J MECH PHYS SOLIDS, V56, P1766, DOI 10.1016/j.jmps.2007.12.004
   Chen YC, 2008, J MECH PHYS SOLIDS, V56, P1752, DOI 10.1016/j.jmps.2007.12.005
   Gu JP, 2017, MECH MATER, V111, P1, DOI 10.1016/j.mechmat.2017.04.008
   Guo JM, 2017, J ALLOY COMPD, V705, P146, DOI 10.1016/j.jallcom.2017.02.142
   Habault D, 2013, CHEM SOC REV, V42, P7244, DOI 10.1039/c3cs35489j
   Hornbogen E, 2006, ADV ENG MATER, V8, P101, DOI 10.1002/adem.200500193
   Ji SZ, 2017, J APPL POLYM SCI, V134, DOI [10.1002/app.44405, 10.1002/APP.44405]
   Jiang J, 2017, MACROMOL REACT ENG, V11, DOI 10.1002/mren.201770016
   Lan X, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.45978
   Lee WJ, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.45910
   Leng JS, 2011, PROG MATER SCI, V56, P1077, DOI 10.1016/j.pmatsci.2011.03.001
   Li JJ, 2012, ACS APPL MATER INTER, V4, P598, DOI 10.1021/am201727a
   Li YX, 2017, INT J PLASTICITY, V91, P300, DOI 10.1016/j.ijplas.2017.04.004
   Linder C, 2011, J MECH PHYS SOLIDS, V59, P2134, DOI 10.1016/j.jmps.2011.05.005
   Liu YJ, 2009, COMPOS SCI TECHNOL, V69, P2064, DOI 10.1016/j.compscitech.2008.08.016
   Liu YP, 2006, INT J PLASTICITY, V22, P279, DOI 10.1016/j.ijplas.2005.03.004
   Lu HB, 2016, SMART MATER STRUCT, V25, DOI 10.1088/0964-1726/25/6/065004
   Manosa L, 2010, NAT MATER, V9, P478, DOI [10.1038/NMAT2731, 10.1038/nmat2731]
   Moon S, 2016, J APPL MECH-T ASME, V83, DOI 10.1115/1.4033380
   Moon S, 2015, INT J ENG SCI, V96, P86, DOI 10.1016/j.ijengsci.2015.06.003
   Ogden RW, 1997, NONLINEAR ELASTIC DE
   Prasad HC, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.44389
   Rahman AA, 2017, FIBER POLYM, V18, P979, DOI 10.1007/s12221-017-6687-9
   Ramirez-Hernandez A, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4936878
   Tey SJ, 2001, SMART MATER STRUCT, V10, P321, DOI 10.1088/0964-1726/10/2/318
   Tobushi H, 2001, MECH MATER, V33, P545, DOI 10.1016/S0167-6636(01)00075-8
   Tobushi H, 1997, J INTEL MAT SYST STR, V8, P711, DOI 10.1177/1045389X9700800808
   Khiem VN, 2016, J MECH PHYS SOLIDS, V95, P254, DOI 10.1016/j.jmps.2016.05.030
   Wang Z, 2017, COORDIN CHEM REV, V350, P68, DOI 10.1016/j.ccr.2017.06.003
   Weems AC, 2017, ACTA BIOMATER, V59, P33, DOI 10.1016/j.actbio.2017.06.030
   Xiao R, 2013, J MECH PHYS SOLIDS, V61, P1612, DOI 10.1016/j.jmps.2013.02.005
   YEOH OH, 1990, RUBBER CHEM TECHNOL, V63, P792, DOI 10.5254/1.3538289
   Zhao Q., 2016, MAT SCI, V2, P1
NR 43
TC 1
Z9 1
U1 20
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1017
EP 1029
DI 10.1016/j.ces.2019.07.022
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300084
DA 2020-05-12
ER

PT J
AU Abushammala, O
   Hreiz, R
   Lemaitre, C
   Favre, E
AF Abushammala, Omran
   Hreiz, Rainier
   Lemaitre, Cecile
   Favre, Eric
TI Laminar flow friction factor in highly curved helical pipes: Numerical
   investigation, predictive correlation and experimental validation using
   a 3D-printed model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 3D printing; CFD; Correlation; Dean vortices; Friction factor; Helical
   pipe
ID PRESSURE-DROP CORRELATIONS; MEMBRANE CONTACTORS; DEAN VORTICES;
   HEAT-TRANSFER; FLUID
AB Highly curved helical pipes offer attracting potentialities for intensified mass/heat transfer performances as they generate intense Dean-type vortices. The evaluation of friction factor in such geometries is necessary for assessing the trade-offs between the increase of transfer efficiency and the associated specific energy requirement. Unfortunately, such data are lacking for highly curved helixes, probably due to the difficulty to manufacture these geometries through traditional manufacturing techniques.
   In this paper, CFD simulations are carried out for determining the laminar flow friction factor in helical pipes, particularly highly curved ones. For an experimental validation of the numerical results, a highly curved helix was built by 3D-printing. Existing correlations are shown to fail for the accurate prediction of the friction factor in highly curved helixes. A new correlation is thus proposed. An excellent agreement is obtained between the experimental pressure drop measurements and the proposed correlation predictions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abushammala, Omran; Hreiz, Rainier; Lemaitre, Cecile; Favre, Eric] Univ Lorraine, Lab React & Genie Proc, CNRS, F-54000 Nancy, France.
RP Hreiz, R (reprint author), Univ Lorraine, Lab React & Genie Proc, CNRS, ENSIC, 1 Rue Grandville, F-54001 Nancy, France.
EM rainier.hreiz@univ.lorraine.fr
FU French ministry of higher education and research
FX The authors gratefully thank the 'French ministry of higher education
   and research' for funding this study, Mrs. Maude Ferrari for the MRI
   measurements and Mr. Philippe Marchal for the rheological experiments.
CR Abdel-Aziz MH, 2010, CHEM ENG PROCESS, V49, P643, DOI 10.1016/j.cep.2009.06.004
   Abushammala O., 2019, 6 INT C FLUID FLOW H
   Ali S, 2001, FLUID DYN RES, V28, P295, DOI 10.1016/S0169-5983(00)00034-4
   Cardone M, 2018, ENRGY PROCED, V148, P932, DOI 10.1016/j.egypro.2018.08.092
   De Amicis J, 2014, PROG NUCL ENERG, V76, P206, DOI 10.1016/j.pnucene.2014.05.019
   Dean WR, 1928, PHILOS MAG, V5, P673
   Dean WR, 1927, PHILOS MAG, V4, P208
   Ghidossi R, 2006, CHEM ENG PROCESS, V45, P437, DOI 10.1016/j.cep.2005.11.002
   Ghobadi M, 2016, HEAT TRANSFER ENG, V37, P815, DOI 10.1080/01457632.2015.1089735
   Gill J, 2018, INT J REFRIG, V86, P228, DOI 10.1016/j.ijrefrig.2017.11.001
   HART J, 1988, CHEM ENG SCI, V43, P775, DOI 10.1016/0009-2509(88)80072-1
   Kaufhold D, 2012, J MEMBRANE SCI, V423, P342, DOI 10.1016/j.memsci.2012.08.035
   Liu YF, 2019, APPL THERM ENG, V147, P167, DOI 10.1016/j.applthermaleng.2018.10.072
   Low ZX, 2017, J MEMBRANE SCI, V523, P596, DOI 10.1016/j.memsci.2016.10.006
   Mansour M, 2017, CHEM ENG SCI, V172, P250, DOI 10.1016/j.ces.2017.06.015
   Mendez DLM, 2017, J MEMBRANE SCI, V530, P20, DOI 10.1016/j.memsci.2017.02.016
   MISHRA P, 1979, IND ENG CHEM PROC DD, V18, P130, DOI 10.1021/i260069a017
   Moll R, 2007, J MEMBRANE SCI, V288, P307, DOI 10.1016/j.memsci.2006.11.030
   Pioro I., 2016, HDB GENERATION
   Przybyl S, 2001, EUR PHYS J E, V4, P445, DOI 10.1007/s101890170099
   SCHMIDT EF, 1967, CHEM-ING-TECH, V39, P781, DOI 10.1002/cite.330391302
   Srinivasan P., 1968, CHEM ENG, V218, pCE113
   White CM, 1929, P R SOC LOND A-CONTA, V123, P645, DOI 10.1098/rspa.1929.0089
   Yasuo M, 1965, INT J HEAT MASS TRAN, V8, P67, DOI [10.1016/0017-9310(65)90098-0, DOI 10.1016/0017-9310(65)90098-0]
NR 24
TC 0
Z9 0
U1 9
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1030
EP 1039
DI 10.1016/j.ces.2019.07.018
PG 10
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300085
DA 2020-05-12
ER

PT J
AU Nawada, SH
   Aalbers, T
   Schoenmakers, PJ
AF Nawada, Suhas H.
   Aalbers, Tom
   Schoenmakers, Peter J.
TI Freeze-thaw valves as a flow control mechanism in spatially complex
   3D-printed fluidic devices
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 3D-printing; Fluidic valves; Selective laser melting; Lab-on-a-chip
ID PHASE LIQUID-CHROMATOGRAPHY; TEMPERATURE; COLUMNS; REACTIONWARE;
   APPARATUS; CHIP; ICE
AB In this paper, we demonstrate a proof-of-principle of a freeze-thaw valve (FTV) created in a 3D-printed fluidic device. Portions of channels are enveloped by cooling and heating jackets, and a heat transfer liquid is recirculated through the two jackets. A frozen plug is created in selected portions of the target-channel and the heating jacket ensures that a selected temperature is maintained in the rest of the channel. An FTV can be 3D-printed in a wide variety of materials as single piece devices with no moving parts without high resolution requirements of the printing process. Such valves can therefore be incorporated in devices for liquid chromatography or multi-step synthesis process.
   Computational fluid dynamic simulations of a prototype T-junction piece show the two zones to be well defined at coolant and heating jacket flow-rates greater than 1 mL/min, with power consumptions of 1-3 W. The prototype was printed in Titanium 6Al-4V using selective laser melting and the frozen plug was shown to withstand 20 MPa of pressure. Switching times between states 1 (with a frozen section) and 2 (with both sections thawed) were 0.2-3 min in computational and experimental tests. The scalability of the freeze-thaw system was demonstrated using a multi-gate valve containing 33 junctions without a proportionate increase in operational complexity or switching times. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nawada, Suhas H.; Aalbers, Tom; Schoenmakers, Peter J.] Univ Amsterdam, Vant Hoff Inst Mol Sci, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.
RP Nawada, SH (reprint author), Univ Amsterdam, Vant Hoff Inst Mol Sci, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.
EM s.h.nawada@uva.nl
FU European Research Council (ERC)European Research Council (ERC) [C.
   2322.0340]
FX The STAMP project is funded under Horizon 2020-Excellent
   Science-European Research Council (ERC), Project C. 2322.0340. The sole
   responsibility of this publication lies with the authors. The European
   Union is not responsible for any use that may be made of the information
   contained therein. The authors would like to thank Universiteit van
   Amsterdam's FNWI Technical Center for their support in building the
   experimental setup.
CR Abueidda DW, 2017, MATER DESIGN, V122, P255, DOI 10.1016/j.matdes.2017.03.018
   Adamski K, 2016, PROCEDIA ENGINEER, V168, P1454, DOI 10.1016/j.proeng.2016.11.416
   BEVAN CD, 1995, J CHROMATOGR A, V697, P541, DOI 10.1016/0021-9673(94)00954-8
   Bhargava KC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15609
   Bhargava KC, 2014, P NATL ACAD SCI USA, V111, P15013, DOI 10.1073/pnas.1414764111
   BOHNE D, 1984, BER BUNSEN PHYS CHEM, V88, P739, DOI 10.1002/bbpc.19840880813
   Chen ZY, 2005, LAB CHIP, V5, P1277, DOI 10.1039/b508275g
   Chockalingam K, 2006, RAPID PROTOTYPING J, V12, P106, DOI 10.1108/13552540610652456
   COLE LA, 1992, ANAL CHEM, V64, P1324, DOI 10.1021/ac00037a005
   Comina G, 2015, MICROMACHINES-BASEL, V6, P437, DOI 10.3390/mi6040437
   Costan A, 2011, OPTOELECTRON ADV MAT, V5, P92
   Edwards P, 2014, MAT SCI ENG A-STRUCT, V598, P327, DOI 10.1016/j.msea.2014.01.041
   Facchini L, 2010, RAPID PROTOTYPING J, V16, P450, DOI 10.1108/13552541011083371
   Gaiteri JC, 2017, ANAL CHEM, V89, P5999, DOI 10.1021/acs.analchem.7b00556
   Gerhardt G. C., 2003, Fluid flow control freeze/thaw valve for narrow bore capillaries or microfluidic devices, Patent No. [US6557575, 6557575]
   Gogia AK, 2005, DEFENCE SCI J, V55, P149, DOI 10.14429/dsj.55.1979
   Gritti F, 2006, ANAL CHEM, V78, P4642, DOI 10.1021/ac0602017
   Groskreutz SR, 2017, J CHROMATOGR A, V1523, P193, DOI 10.1016/j.chroma.2017.07.015
   Groskreutz SR, 2016, J CHROMATOGR A, V1474, P95, DOI 10.1016/j.chroma.2016.10.062
   Gui L, 2004, J MICROMECH MICROENG, V14, P242, DOI 10.1088/0960-1317/14/2/011
   Gupta V, 2018, ANAL CHEM, V90, P1186, DOI 10.1021/acs.analchem.7b03778
   Gupta V, 2016, ANAL CHIM ACTA, V910, P84, DOI 10.1016/j.aca.2016.01.012
   Hassan MF, 2010, MEAS SCI TECHNOL, V21, DOI 10.1088/0957-0233/21/7/075701
   Keating SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160624
   Kim S, 2016, INT J PRECIS ENG MAN, V17, P937, DOI 10.1007/s12541-016-0114-9
   Kitson PJ, 2018, SCIENCE, V359, P314, DOI 10.1126/science.aao3466
   Kranz J, 2015, J LASER APPL, V27, DOI 10.2351/1.4885235
   Lee YS, 2018, LAB CHIP, V18, P1207, DOI [10.1039/c8lc00001h, 10.1039/C8LC00001H]
   Novotny J, 2017, HPLC 2017
   Pervier MLA, 2019, ENG FRACT MECH, V214, P212, DOI 10.1016/j.engfracmech.2019.01.039
   Prikryl J, 2014, ANAL CHEM, V86, P11951, DOI 10.1021/ac503678n
   Quintana R, 2010, INT J ADV MANUF TECH, V46, P201, DOI 10.1007/s00170-009-2066-z
   Radebaugh R, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/16/164219
   Reytier M, 2002, AIP CONF PROC, V614, P76
   Rogers CI, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4905840
   Rumble J., 2017, CRC HDB CHEM PHYS
   Schutz R. W, 2005, ALLOYS CORROS MAT, DOI [10.31399/asm.hb.v13b.a0003822, DOI 10.31399/ASM.HB.V13B.A0003822]
   Si CR, 2017, SCI REP-UK, V7, DOI 10.1038/srep40570
   Sinnott R. K., 2005, CHEM ENG DESIGN, V6, P634
   Soltis J, 2015, AIAA J, V53, P654, DOI 10.2514/1.J053208
   Symes MD, 2012, NAT CHEM, V4, P349, DOI [10.1038/NCHEM.1313, 10.1038/nchem.1313]
   Tesar V, 2001, J VISUAL-JAPAN, V4, P51, DOI 10.1007/BF03182455
   Vanhoutte DJD, 2011, ANAL CHIM ACTA, V701, P92, DOI 10.1016/j.aca.2011.06.004
   Vonk RJ, 2015, J CHROMATOGR A, V1401, P60, DOI 10.1016/j.chroma.2015.05.003
   Vonk RJ, 2014, J CHROMATOGR A, V1359, P162, DOI 10.1016/j.chroma.2014.07.039
   Waheed S, 2016, LAB CHIP, V16, P1993, DOI 10.1039/c6lc00284f
   Wessarges Y, 2014, BIOMED ENG-BIOMED TE, V59, pS385, DOI 10.1515/bmt-2014-4175
   Wouters B, 2015, LAB CHIP, V15, P4415, DOI 10.1039/c5lc01169h
NR 48
TC 3
Z9 3
U1 3
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1040
EP 1048
DI 10.1016/j.ces.2019.07.036
PG 9
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300086
DA 2020-05-12
ER

PT J
AU Son, Y
   Lee, S
   Heo, S
AF Son, Yongho
   Lee, Sangyoon
   Heo, Seongmin
TI Evaluation of the ship motion effects on the NaOH/air absorption system
   performance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Packed column; Offshore column; CO2 absorption; NaOH/air system;
   Reduction factor
ID MASS-TRANSFER AREA; STRUCTURED-PACKING; CARBON-DIOXIDE; LIQUID
   DISTRIBUTION; SURFACE-TENSION; PACKED-COLUMN; KINETICS; SOLUBILITY;
   VISCOSITY; TILT
AB In this study, the effects of ship motion on the CO2 absorption performance of the offshore columns (i.e., the separation columns installed on offshore floating units) are investigated. Specifically, a pilot scale column with 0.4 m diameter and 4 m packed height is used, and NaOH/air system is implemented to measure the CO2 absorption performance of the column under both vertical and offshore conditions. The experimental results obtained from the vertical conditions are used to validate the mathematical model which can compute the effective surface area of the separation columns. Then, such model is used to produce the reference values for the experimental results obtained from the various offshore conditions, where tilt angle, roll motion conditions, liquid load, gas factor, liquid surface tension and liquid viscosity are used as the design variables. The reduction factor is proposed, which can describe the change in the absorption performance of the offshore columns with respect to the important factors. From our study, the tilt angle was shown to be the most important factor, and the mass transfer efficiency was reduced by 8.4% in average (compared to the value obtained under the vertical condition) when the tilt angle was 6 degrees. It was also shown that the roll motion can enhance the absorption performance of offshore columns under certain operating conditions, and the maximum improvement (6.7%) in the mass transfer efficiency was achieved when the liquid load, roll motion amplitude and period were 14 m(3)/m(2) hr, 8 degrees and 45 s, respectively. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Son, Yongho; Heo, Seongmin] Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, 291 Daehak Ro, Daejeon 34141, South Korea.
   [Lee, Sangyoon] Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul 04107, South Korea.
RP Heo, S (reprint author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, 291 Daehak Ro, Daejeon 34141, South Korea.
EM smheo@kaist.ac.kr
OI Heo, Seongmin/0000-0003-4658-2141
FU Program of KAIA - Ministry of Land, Infrastructure and Transport of the
   Korean government [08 GASPLANT F03]
FX This research was supported by a grant from the Program of KAIA funded
   by the Ministry of Land, Infrastructure and Transport of the Korean
   government (08 GASPLANT F03).
CR BAKER SA, 1992, CHEM ENG RES DES, V70, P509
   Barrett P. V. L, 1969, GAS ABSORPTION SIEVE
   Billingham JE, 2002, CHEM ENG RES DES, V80, P373, DOI 10.1205/026387602317446416
   Bishnoi S, 2000, CHEM ENG SCI, V55, P5531, DOI 10.1016/S0009-2509(00)00182-2
   Cullinane J. T, 2011, EFFECTS TOWER MOTION
   Danckwerts P.V., 1970, J ELECTROCHEM SOC, V117, p369C, DOI DOI 10.1149/1.2407312
   Di XN, 2018, CHEM ENG SCI, V177, P27, DOI 10.1016/j.ces.2017.11.008
   Di XN, 2019, CHEM ENG SCI, V203, P302, DOI 10.1016/j.ces.2019.03.056
   du Nouy PL, 1925, J GEN PHYSIOL, V7, P625, DOI 10.1085/jgp.7.5.625
   Gauthier P, 2016, INT PETR TECHN C
   Haubrock J, 2005, INT J CHEM REACT ENG, V3
   He TB, 2018, CHEM ENG RES DES, V132, P89, DOI 10.1016/j.cherd.2018.01.002
   HOERNER BK, 1982, CHEM ENG PROG, V78, P47
   Kucka L, 2002, IND ENG CHEM RES, V41, P5952, DOI 10.1021/ie020452f
   Kvamsdal HM, 2009, CHEM ENG PROCESS, V48, P135, DOI 10.1016/j.cep.2008.03.002
   Lawal A, 2009, FUEL, V88, P2455, DOI 10.1016/j.fuel.2008.11.009
   Liu HL, 2019, CHEM ENG SCI, V203, P86, DOI 10.1016/j.ces.2019.03.073
   Liu H, 2019, FUEL, V249, P61, DOI 10.1016/j.fuel.2019.02.088
   MONIUK W, 1991, HUNG J IND CHEM, V19, P175
   PERRY D, 1990, CHEM ENG PROG, V86, P30
   POHORECKI R, 1988, CHEM ENG SCI, V43, P1677, DOI 10.1016/0009-2509(88)85159-5
   Son Y, 2017, CHEM ENG SCI, V166, P168, DOI 10.1016/j.ces.2017.03.044
   Tan LS, 2012, J IND ENG CHEM, V18, P1874, DOI 10.1016/j.jiec.2012.05.013
   TSAI R., 2010, THESIS
   Tsai RE, 2008, IND ENG CHEM RES, V47, P1253, DOI 10.1021/ie070780l
   Tsai RE, 2011, AICHE J, V57, P1173, DOI 10.1002/aic.12345
   Tsai RE, 2009, ENRGY PROCED, V1, P1197, DOI 10.1016/j.egypro.2009.01.157
   Weiss C, 2014, OFFSH TECHN C
   Won W, 2014, KOREAN J CHEM ENG, V31, P732, DOI 10.1007/s11814-014-0047-x
   Yuan Y, 2019, INT J GREENH GAS CON, V84, P82, DOI 10.1016/j.ijggc.2019.03.013
   Yuan Y, 2018, CHEM ENG SCI, V182, P56, DOI 10.1016/j.ces.2018.02.026
NR 31
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1049
EP 1059
DI 10.1016/j.ces.2019.07.028
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300087
DA 2020-05-12
ER

PT J
AU Zhao, JX
   Shi, RN
   Quan, YH
   Liu, JJ
   Wang, J
   Pei, YL
   Wang, XH
   Li, Z
   Ren, J
AF Zhao, Jinxian
   Shi, Ruina
   Quan, Yanhong
   Liu, Junjie
   Wang, Juan
   Pei, Yongli
   Wang, Xuhui
   Li, Zhong
   Ren, Jun
TI Highly efficient synthesis of dimethyl carbonate over copper catalysts
   supported on resin-derived carbon microspheres
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon microspheres; Cu nanoparticles; Ion exchange resin; Sulfonic acid
   groups; Dimethyl carbonate
ID PHASE OXIDATIVE CARBONYLATION; FISCHER-TROPSCH SYNTHESIS; ACTIVATED
   CARBON; CU/AC CATALYST; IONIC LIQUID; NANOPARTICLES; METHANOL; CU; ACID;
   XPS
AB An effective approach to improve catalytic performance of a Cu-based catalyst for the synthesis of dimethyl carbonate (DMC) is to minimize particle size and to increase the dispersion of active Cu species. Here, highly dispersed Cu nanoparticles (NPs) supported on carbon microspheres (CMs) catalyst has been fabricated through a multi-step process involving cationic ion-exchange, high-temperature carbonization and H-2 reduction. The Cu NPs size shows a volcanic curve versus the heat-treatment temperature. Cu/CMs catalyst calcined at 500 degrees C with mean Cu NP size of 5.5 nm, displayed the highest catalytic activity, with a methanol conversion of 5.0%, DMC selectivity of 100% and space time yield of DMC of 3770 mg/(gh). The sulfonic acid groups on the IR 120 resin endows its strong anchoring ability for copper precursors, leading to a decrease in particle size and better dispersion of Cu active species, which plays a key role in promoting the catalytic performance of Cu/CMs catalyst. However, a calcination temperature higher than 500 degrees C was proved to be detrimental because of extensive damage of the sulfonic acid groups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhao, Jinxian; Shi, Ruina; Quan, Yanhong; Wang, Juan; Pei, Yongli; Wang, Xuhui; Li, Zhong; Ren, Jun] Taiyuan Univ Technol, Minist Educ & Shanxi Prov, Key Lab Coal Sci & Technol, Taiyuan 030024, Shanxi, Peoples R China.
   [Liu, Junjie] Natl Inst Metrol, Div Nanoscale Measurement & Adv Mat, Beijing 100029, Peoples R China.
RP Ren, J (reprint author), 79 Yingze West St, Taiyuan 030024, Shanxi, Peoples R China.
EM renjun@tyut.edu.cn
OI , Jun/0000-0001-8589-3810; Li, Zhong/0000-0001-6087-6854
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808154, 21776194, 21376159]; Key Research and
   Development Program of Shanxi Province [201703D121022-1]
FX This work has been supported by a grant from the National Natural
   Science Foundation of China (21808154, 21776194, and 21376159) and Key
   Research and Development Program of Shanxi Province (201703D121022-1).
   The authors would like to thank Prof. Yongfeng Hu from Canadian Light
   Source for his help with XANES analysis.
CR Aksoylu AE, 2001, CARBON, V39, P175, DOI 10.1016/S0008-6223(00)00102-0
   Ali SW, 2015, HYDROMETALLURGY, V157, P82, DOI 10.1016/j.hydromet.2015.07.013
   Amrollahi P, 2014, J SUPERCOND NOV MAGN, V27, P481, DOI 10.1007/s10948-013-2286-1
   Bell AT, 2003, SCIENCE, V299, P1688, DOI 10.1126/science.1083671
   Cao Y, 2003, CHEM COMMUN, P908, DOI 10.1039/b301375h
   Cui HY, 2004, J SUPERCRIT FLUID, V30, P63, DOI 10.1016/S0896-8446(03)00164-5
   Curnutt G. A., 1986, US Pat, Patent No. 4625044A
   Delledonne D, 2001, APPL CATAL A-GEN, V221, P241, DOI 10.1016/S0926-860X(01)00796-7
   Ding XS, 2014, CHEM ENG J, V240, P221, DOI 10.1016/j.cej.2013.11.079
   Dong WS, 2008, APPL CATAL A-GEN, V334, P100, DOI 10.1016/j.apcata.2007.09.040
   DUBOIS MA, 1995, J ANAL APPL PYROL, V31, P129, DOI 10.1016/0165-2370(94)00817-K
   Espinos JP, 2002, J PHYS CHEM B, V106, P6921, DOI 10.1021/jp014618m
   Farhadi S, 2016, MATER RES BULL, V83, P345, DOI 10.1016/j.materresbull.2016.06.030
   Fiorilli S, 2011, J SOL-GEL SCI TECHN, V60, P260, DOI 10.1007/s10971-011-2484-x
   Fleet ME, 2005, SURF SCI, V584, P133, DOI 10.1016/j.susc.2005.03.048
   Fu TJ, 2017, CARBON, V115, P363, DOI 10.1016/j.carbon.2017.01.004
   Garcia-Dieguez M, 2010, J CATAL, V270, P136, DOI 10.1016/j.jcat.2009.12.010
   Garcia-Herrero I, 2016, ACS SUSTAIN CHEM ENG, V4, P2088, DOI 10.1021/acssuschemeng.5b01515
   Gawande MB, 2016, CHEM REV, V116, P3722, DOI 10.1021/acs.chemrev.5b00482
   Gong MX, 2014, ACS APPL MATER INTER, V6, P7301, DOI 10.1021/am500656j
   Gross MS, 2015, APPL CATAL A-GEN, V501, P1, DOI 10.1016/j.apcata.2015.04.026
   Han MS, 2001, J MOL CATAL A-CHEM, V170, P225, DOI 10.1016/S1381-1169(01)00073-5
   Hao PP, 2016, CHEM ENG J, V283, P1295, DOI 10.1016/j.cej.2015.08.069
   Huang SY, 2015, CHEM SOC REV, V44, P3079, DOI 10.1039/c4cs00374h
   Keller N, 2010, J MOL CATAL A-CHEM, V317, P1, DOI 10.1016/j.molcata.2009.10.027
   KOLARZ BN, 1994, J POLYM SCI POL PHYS, V32, P1977, DOI 10.1002/polb.1994.090321204
   Kuwahara Y, 2017, ACS SUSTAIN CHEM ENG, V5, P1141, DOI 10.1021/acssuschemeng.6b02464
   Li Q, 2012, CATAL COMMUN, V17, P8, DOI 10.1016/j.catcom.2011.10.008
   Li Y, 2008, J MEMBRANE SCI, V308, P128, DOI 10.1016/j.memsci.2007.09.053
   Li Z, 2009, CHEM J CHINESE U, V30, P2024
   Lin CJ, 2005, CHEMOSPHERE, V59, P1299, DOI 10.1016/j.chemosphere.2004.11.064
   Liu FJ, 2012, J MATER CHEM, V22, P5495, DOI 10.1039/c2jm16608a
   Lu CH, 2010, SOL ENERG MAT SOL C, V94, P1622, DOI 10.1016/j.solmat.2010.05.005
   Malik DJ, 2008, CARBON, V46, P310, DOI 10.1016/j.carbon.2007.11.041
   MATSUDA M, 1987, J POLYM SCI POL CHEM, V25, P669, DOI 10.1002/pola.1987.080250218
   Mo WL, 2006, J MOL CATAL A-CHEM, V247, P227, DOI 10.1016/j.molcata.2005.11.051
   Mohammadipour M, 2017, MONATSH CHEM, V148, P1075, DOI 10.1007/s00706-016-1876-6
   Nieto-Marquez A, 2010, APPL CATAL A-GEN, V373, P192, DOI 10.1016/j.apcata.2009.11.013
   Pacheco MA, 1997, ENERG FUEL, V11, P2, DOI 10.1021/ef9600974
   Qiu LM, 2013, APPL SURF SCI, V266, P230, DOI 10.1016/j.apsusc.2012.11.156
   Raimondi F, 2002, APPL SURF SCI, V189, P59, DOI 10.1016/S0169-4332(01)01045-5
   Ren J, 2017, CHEM ENG J, V328, P673, DOI 10.1016/j.cej.2017.07.101
   Ren J, 2015, J THERM ANAL CALORIM, V120, P1929, DOI 10.1007/s10973-015-4519-y
   Ren J, 2014, APPL CATAL A-GEN, V472, P47, DOI 10.1016/j.apcata.2013.12.006
   Ren MJ, 2016, CHEMCATCHEM, V8, P861, DOI 10.1002/cctc.201501182
   Shi RN, 2018, APPL SURF SCI, V459, P707, DOI 10.1016/j.apsusc.2018.08.032
   Sun YF, 2012, CHEMOSPHERE, V88, P895, DOI 10.1016/j.chemosphere.2012.03.099
   Teo JJ, 2006, LANGMUIR, V22, P7369, DOI 10.1021/la060439q
   Tomishige K, 1999, APPL CATAL A-GEN, V181, P95, DOI 10.1016/S0926-860X(98)00386-X
   Wang H, 2009, FUEL PROCESS TECHNOL, V90, P1198, DOI 10.1016/j.fuproc.2009.05.020
   Wang J, 2018, J MATER SCI, V53, P1833, DOI 10.1007/s10853-017-1639-8
   Wang J, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671-017-2258-7
   Wang RY, 2010, CHINESE J CATAL, V31, P851, DOI 10.3724/SP.J.1088.2010.00102
   Wang WZ, 2002, ADV MATER, V14, P67, DOI 10.1002/1521-4095(20020104)14:1<67::AID-ADMA67>3.0.CO;2-Z
   Xiong HF, 2014, J CATAL, V311, P80, DOI 10.1016/j.jcat.2013.11.007
   Xiong HF, 2011, J CATAL, V278, P26, DOI 10.1016/j.jcat.2010.11.010
   Xiong HF, 2010, APPL CATAL A-GEN, V388, P168, DOI 10.1016/j.apcata.2010.08.039
   Zhang B, 2015, CATAL SCI TECHNOL, V5, P1683, DOI 10.1039/c4cy01382d
   Zhang GQ, 2016, APPL SURF SCI, V390, P68, DOI 10.1016/j.apsusc.2016.08.054
   Zhang GQ, 2015, APPL CATAL B-ENVIRON, V179, P95, DOI 10.1016/j.apcatb.2015.05.001
   Zhang L, 2014, ACS CATAL, V4, P1546, DOI 10.1021/cs500071c
   Zhang LL, 2013, GREEN CHEM, V15, P2680, DOI 10.1039/c3gc41117f
   Zhang YH, 2006, J CATAL, V244, P219, DOI 10.1016/j.jcat.2006.09.002
NR 63
TC 0
Z9 0
U1 21
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1060
EP 1071
DI 10.1016/j.ces.2019.07.039
PG 12
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300088
DA 2020-05-12
ER

PT J
AU Ye, JX
   Xu, YX
   Song, XF
   Yu, JG
AF Ye, Junxiang
   Xu, Yanxia
   Song, Xingfu
   Yu, Jianguo
TI Numerical modelling and multi-objective optimization of the novel
   hydrocyclone for ultra-fine particles classification
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Novel hydrocyclone; Computational fluid dynamics; Support vector
   machine; Radial basis function neural network; Multi-objective
   optimization
ID SUPPORT VECTOR MACHINE; LARGE-EDDY SIMULATION; SEPARATION PERFORMANCE;
   CYCLONE SEPARATORS; MULTIPHASE FLOW; PRESSURE-DROP; AIR-CORE; CFD;
   DESIGN; ENHANCEMENT
AB A novel hydrocyclone with arc inlet and convex cone is proposed to obtain the higher particles classification sharpness than the conventional design. The classification of the micron scale manganese dioxide particle is taken as a study case, and various methods are used to perform the modelling and optimization of the novel geometrical structure. Two performance indexes have been taken into consideration in the multi-objective optimization which are the classification sharpness, S-s and total pressure drop, Delta P. The numerical experiments designed via response surface methodology are carried out using computation fluid dynamics simulations of Eulerian-Eulerian strategy. The obtained data sets are utilized for modelling the performance indexes by support vector machine (SVM) and radial basis function neural network (RBFNN) approaches. The optimal structure with the classification sharpness of 0.956 is searched using the genetic algorithm (GA) in contrast to the conventional design of 0.849. Flow field analysis illustrates that the extended radial space, strengthened centrifugal field and inlet pre-classification effect of the optimal design improve the classification sharpness. However, the narrower inlet cross area leads to a higher pressure drop. The Pareto front of the multi-objective optimization is obtained using the NSGA-II algorithm to provide alternatives for the optimal performance of the novel hydrocyclone. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ye, Junxiang; Xu, Yanxia; Song, Xingfu; Yu, Jianguo] East China Univ Sci & Technol, Sch Resources & Environm Engn, Natl Engn Res Ctr Integrated Utilizat Salt Lake R, Shanghai 200237, Peoples R China.
RP Xu, YX; Yu, JG (reprint author), East China Univ Sci & Technol, Sch Resources & Environm Engn, Natl Engn Res Ctr Integrated Utilizat Salt Lake R, Shanghai 200237, Peoples R China.
EM xyx@ecust.edu.cn; jgyu@ecust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51504098]
FX The funds for this research were provided by the National Natural
   Science Foundation of China [51504098].
CR Banerjee C, 2016, CHEM ENG SCI, V152, P724, DOI 10.1016/j.ces.2016.06.037
   Bergstrom J, 2007, SEP PURIF TECHNOL, V53, P8, DOI 10.1016/j.seppur.2006.09.019
   BOX GEP, 1951, J R STAT SOC B, V13, P1, DOI 10.1111/j.2517-6161.1951.tb00067.x
   Bradley D.A., 1965, HYDROCYCLONE
   Brar LS, 2018, SEP PURIF TECHNOL, V207, P269, DOI 10.1016/j.seppur.2018.06.013
   Brar LS, 2017, POWDER TECHNOL, V311, P465, DOI 10.1016/j.powtec.2017.02.004
   Broomhead D. S., 1988, Complex Systems, V2, P321
   Camps-Valls G., 2009, KERNEL METHODS REMOT
   Chen J, 2012, MINER ENG, V31, P59, DOI 10.1016/j.mineng.2011.11.010
   Chen W, 2000, CHEM ENG J, V80, P295, DOI 10.1016/S1383-5866(00)00105-2
   Chu KW, 2012, CHEM ENG SCI, V73, P123, DOI 10.1016/j.ces.2012.01.007
   Chu KW, 2011, CHEM ENG SCI, V66, P834, DOI 10.1016/j.ces.2010.11.026
   Chu KW, 2009, MINER ENG, V22, P893, DOI 10.1016/j.mineng.2009.04.008
   Chu LY, 2000, SEP PURIF TECHNOL, V21, P71, DOI 10.1016/S1383-5866(00)00192-1
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1023/A:1022627411411
   Cui BY, 2017, POWDER TECHNOL, V322, P114, DOI 10.1016/j.powtec.2017.09.010
   Delgadillo J.A., 2006, THESIS
   Dueck J, 2010, MINER ENG, V23, P289, DOI 10.1016/j.mineng.2010.01.002
   Dueck J, 2014, MINER ENG, V62, P25, DOI 10.1016/j.mineng.2013.10.004
   Elsayed K, 2015, SEP PURIF TECHNOL, V142, P274, DOI 10.1016/j.seppur.2015.01.010
   Elsayed K, 2014, APPL MATH COMPUT, V236, P325, DOI 10.1016/j.amc.2014.03.082
   Elsayed K, 2013, APPL MATH MODEL, V37, P5680, DOI 10.1016/j.apm.2012.11.010
   Evans WK, 2008, CHEM ENG J, V143, P51, DOI 10.1016/j.cej.2007.12.023
   Fu PB, 2017, ENVIRON SCI TECHNOL, V51, P1587, DOI 10.1021/acs.est.6b04418
   Fu PB, 2016, SEP PURIF TECHNOL, V158, P357, DOI 10.1016/j.seppur.2015.12.044
   Funk PA, 2014, J AEROSOL SCI, V74, P26, DOI 10.1016/j.jaerosci.2014.04.001
   Ghodrat M, 2016, MINER ENG, V90, P55, DOI 10.1016/j.mineng.2016.03.017
   Ghodrat M, 2014, MINER ENG, V63, P125, DOI 10.1016/j.mineng.2014.02.003
   Ghodrat M, 2014, MINER ENG, V62, P74, DOI 10.1016/j.mineng.2013.12.003
   Ghodrat M, 2013, IND ENG CHEM RES, V52, P16019, DOI 10.1021/ie402267b
   Gong HF, 2018, SEP PURIF TECHNOL, V207, P124, DOI 10.1016/j.seppur.2018.06.049
   Hsieh K.T., 1988, THESIS
   Huang L, 2018, IND ENG CHEM RES, V57, P7613, DOI 10.1021/acs.iecr.8b00137
   Huang L, 2017, CHEM ENG SCI, V172, P107, DOI 10.1016/j.ces.2017.06.030
   Hwang KJ, 2017, SEP PURIF TECHNOL, V172, P76, DOI 10.1016/j.seppur.2016.08.005
   Hwang KJ, 2013, CHEM ENG SCI, V85, P62, DOI 10.1016/j.ces.2011.12.046
   Ji L, 2019, SEP PURIF TECHNOL, V211, P141, DOI 10.1016/j.seppur.2018.09.073
   Ji L, 2018, IND ENG CHEM RES, V57, P9641, DOI 10.1021/acs.iecr.8b01699
   Jia SK, 2017, CHEM ENG RES DES, V125, P422, DOI 10.1016/j.cherd.2017.07.028
   Kraipech W, 2006, INT J MINER PROCESS, V80, P100, DOI 10.1016/j.minpro.2005.02.005
   Kuang SB, 2012, MINER ENG, V31, P17, DOI 10.1016/j.mineng.2012.01.003
   Kuang SB, 2014, MINER ENG, V62, P43, DOI 10.1016/j.mineng.2013.10.012
   Kyriakidis YN, 2018, POWDER TECHNOL, V338, P645, DOI 10.1016/j.powtec.2018.07.064
   Motin A, 2017, SEP PURIF TECHNOL, V185, P41, DOI 10.1016/j.seppur.2017.05.015
   Narasimha M, 2014, INT J MINER PROCESS, V133, P1, DOI 10.1016/j.minpro.2014.08.006
   Ni L, 2019, SEP PURIF REV, V48, P30, DOI 10.1080/15422119.2017.1421558
   Perez D, 2018, MINER ENG, V123, P71, DOI 10.1016/j.mineng.2018.04.008
   Qi Z, 2015, INT J MINER PROCESS, V142, P35, DOI 10.1016/j.minpro.2015.05.006
   Razmi H, 2019, SEP PURIF TECHNOL, V209, P851, DOI 10.1016/j.seppur.2018.06.073
   Reeves C. R., 2002, GENETIC ALGORITHMS P
   Safikhani H, 2011, COMPUT CHEM ENG, V35, P1064, DOI 10.1016/j.compchemeng.2010.07.017
   Safikhani H, 2016, ADV POWDER TECHNOL, V27, P2277, DOI 10.1016/j.apt.2016.08.017
   Sgrott OL, 2015, POWDER TECHNOL, V277, P11, DOI 10.1016/j.powtec.2015.02.039
   Siadaty M, 2017, J AEROSOL SCI, V114, P219, DOI 10.1016/j.jaerosci.2017.09.015
   Silva DO, 2015, CHEM ENG TECHNOL, V38, P319, DOI 10.1002/ceat.201300464
   Silva NKG, 2015, POWDER TECHNOL, V286, P305, DOI 10.1016/j.powtec.2015.08.036
   Sun X, 2017, POWDER TECHNOL, V320, P51, DOI 10.1016/j.powtec.2017.06.065
   Tang B, 2015, CHEM ENG J, V278, P504, DOI 10.1016/j.cej.2014.11.022
   Tian JY, 2018, SEP PURIF TECHNOL, V206, P268, DOI 10.1016/j.seppur.2018.06.015
   Vakamalla TR, 2017, SEP PURIF TECHNOL, V176, P23, DOI 10.1016/j.seppur.2016.11.049
   Vakamalla TR, 2017, SEP PURIF TECHNOL, V175, P481, DOI 10.1016/j.seppur.2016.10.026
   Vapnik V, 1997, ADV NEUR IN, V9, P281
   Vega-Garcia D, 2018, CHEM ENG J, V350, P653, DOI 10.1016/j.cej.2018.06.016
   Vieira LGM, 2011, CAN J CHEM ENG, V89, P655, DOI 10.1002/cjce.20461
   Wang B, 2006, MINER ENG, V19, P1022, DOI 10.1016/j.mineng.2006.03.016
   Wang B, 2010, AICHE J, V56, P1703, DOI 10.1002/aic.12114
   Wang B, 2009, MINER ENG, V22, P931, DOI 10.1016/j.mineng.2009.03.019
   Wang CC, 2018, SEP PURIF TECHNOL, V198, P60, DOI 10.1016/j.seppur.2017.04.034
   Xu YX, 2013, IND ENG CHEM RES, V52, P5470, DOI 10.1021/ie302081v
   Xu YX, 2012, IND ENG CHEM RES, V51, P443, DOI 10.1021/ie201147e
   Yang Q, 2013, SEP PURIF TECHNOL, V102, P15, DOI 10.1016/j.seppur.2012.09.018
   Yang QA, 2010, SEP PURIF TECHNOL, V74, P271, DOI 10.1016/j.seppur.2010.06.014
   Ye JX, 2019, CHEM ENG RES DES, V144, P135, DOI 10.1016/j.cherd.2019.02.006
   Yoshida H, 2004, POWDER TECHNOL, V140, P1, DOI 10.1016/j.powtec.2003.12.006
   Yoshida H, 2012, POWDER TECHNOL, V219, P29, DOI 10.1016/j.powtec.2011.12.002
   Zhang CE, 2017, POWDER TECHNOL, V319, P279, DOI 10.1016/j.powtec.2017.06.064
   Zhang C, 2017, POWDER TECHNOL, V305, P156, DOI 10.1016/j.powtec.2016.10.002
   Zhang YH, 2011, IND ENG CHEM RES, V50, P8176, DOI 10.1021/ie100210c
   Zhao B. T., 2018, SEP PURIF REV, P1
   Zhao BT, 2010, CHEM ENG RES DES, V88, P606, DOI 10.1016/j.cherd.2009.11.010
   Zhao BT, 2009, CHEM ENG SCI, V64, P4131, DOI 10.1016/j.ces.2009.06.017
NR 81
TC 0
Z9 0
U1 18
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1072
EP 1084
DI 10.1016/j.ces.2019.07.031
PG 13
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300089
DA 2020-05-12
ER

PT J
AU Liu, J
   Li, WY
   Feng, J
   Gao, X
   Luo, ZY
AF Liu, Juan
   Li, Wen-ying
   Feng, Jie
   Gao, Xiang
   Luo, Zhong-yang
TI Promotional effect of TiO2 on quinoline hydrodenitrogenation activity
   over Pt/gamma-Al2O3 catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrodenitrogenation; Quinoline; Pt/gamma-Al2O3 catalysts; Titania;
   Dibenzothiophene; Hydrodesulfurization
ID SUPPORT BRONSTED ACIDITY; SULFIDE CATALYSTS; MESOPOROUS SILICA;
   PARTICLE-SIZE; HYDRODESULFURIZATION; HYDROGENATION; HDN; PERFORMANCE;
   ALUMINA; SELECTIVITY
AB The structural and electronic properties of Pt/gamma-Al2O3 catalysts catalysts for quinoline hydrodenitrogenation were modified by introducing TiO2. The results indicated that the addition of TiO2 enhanced the reducibility of PtOx species, which increased the number of metallic Pt active sites. TiO2 facilitated quinoline hydrodenitrogenation over Pt/gamma-Al2O3 catalysts catalysts, with an increase in activity from 80.6% to 91.5% at 340 degrees C and 3 MPa when the TiO2 content was 16.3 wt%; and improved resistance to the inhibiting effects of sulfur species, therefore the hydrodenitrogenation activity decreased less sharply. High activity in dibenzothiophene hydrodesulfurization, i.e., above 91%, was maintained with different sulfur concentrations. Density functional theory calculations confirmed that dibenzothiophene and quinoline had comparable adsorption energies on a metallic Pt surface. We propose that the partially reduced TiO2 mitigated inhibition by dibenzothiophene and enhanced the hydrogenation of quinoline via the formation of electron-rich Pt species. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Juan; Li, Wen-ying; Gao, Xiang; Luo, Zhong-yang] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
   [Li, Wen-ying; Feng, Jie] Taiyuan Univ Technol, Training Base State Key Lab Coal Sci & Technol Jo, Taiyuan 030024, Shanxi, Peoples R China.
RP Li, WY (reprint author), Taiyuan Univ Technol, Training Base State Key Lab Coal Sci & Technol Jo, Taiyuan 030024, Shanxi, Peoples R China.
EM ying@tyut.edu.cn
FU National Key Research and Development Program of China [2016YFB0600305]
FX The authors gratefully acknowledge financial support by the National Key
   Research and Development Program of China (Grant No. 2016YFB0600305).
CR Baldovino-Medrano VG, 2008, FUEL, V87, P1917, DOI 10.1016/j.fuel.2007.12.008
   Caballero M, 2018, CATAL TODAY, DOI [10.1016/j.cattod.2018.05.024, DOI 10.1016/J.CATTOD.2018.05.024]
   Chattopadhyay S, 2017, J MATER CHEM A, V5, P17341, DOI 10.1039/c7ta04702a
   Chen SY, 2014, APPL CATAL B-ENVIRON, V148, P344, DOI 10.1016/j.apcatb.2013.11.009
   Cinibulk J, 1999, APPL CATAL A-GEN, V180, P15, DOI 10.1016/S0926-860X(98)00354-8
   Colman RD, 2010, J PHYS CHEM C, V114, P18501, DOI 10.1021/jp104698s
   Cui WG, 2017, ENERG FUEL, V31, P3768, DOI 10.1021/acs.energyfuels.6b03390
   Duan XP, 2010, CATAL TODAY, V149, P11, DOI 10.1016/j.cattod.2009.04.014
   EIJSBOUTS S, 1991, J CATAL, V127, P619, DOI 10.1016/0021-9517(91)90187-9
   Ferri D, 2001, J AM CHEM SOC, V123, P12074, DOI 10.1021/ja011769u
   Gonzalez C, 2015, ENERG FUEL, V29, P8208, DOI 10.1021/acs.energyfuels.5b02112
   Gulkova D, 2009, APPL CATAL B-ENVIRON, V87, P171, DOI 10.1016/j.apcatb.2008.09.004
   Guo K, 2018, APPL CATAL B-ENVIRON, V239, P433, DOI 10.1016/j.apcatb.2018.08.041
   Gutierrez OY, 2014, ACS CATAL, V4, P1487, DOI 10.1021/cs500034d
   Han W, 2017, CATAL TODAY, V292, P58, DOI 10.1016/j.cattod.2016.11.049
   Han W, 2016, J CATAL, V339, P135, DOI 10.1016/j.jcat.2016.04.005
   Infantes-Molina A, 2013, J CATAL, V305, P101, DOI 10.1016/j.jcat.2013.05.001
   Jian M, 1998, J CATAL, V179, P18, DOI 10.1006/jcat.1998.2181
   Jiang BL, 2017, IND ENG CHEM RES, V56, P12038, DOI 10.1021/acs.iecr.7b02018
   Kabe T, 2000, J CATAL, V190, P191, DOI 10.1006/jcat.1999.2742
   Kale MJ, 2016, ACS CATAL, V6, P5599, DOI 10.1021/acscatal.6b01128
   Kim MS, 2013, APPL CATAL B-ENVIRON, V142, P354, DOI 10.1016/j.apcatb.2013.05.033
   Kuhn JN, 2008, J AM CHEM SOC, V130, P14026, DOI 10.1021/ja805050c
   Ledesma BC, 2016, APPL CATAL B-ENVIRON, V192, P220, DOI 10.1016/j.apcatb.2016.03.066
   Li GC, 2012, APPL CATAL A-GEN, V437, P79, DOI 10.1016/j.apcata.2012.06.017
   Li N, 2010, ENERG FUEL, V24, P5539, DOI 10.1021/ef1007598
   Li X, 2008, J PHYS CHEM C, V112, P16584, DOI 10.1021/jp803676v
   Li X, 2012, APPL CATAL A-GEN, V417, P19, DOI 10.1016/j.apcata.2011.12.014
   Li XH, 2013, J CATAL, V300, P9, DOI 10.1016/j.jcat.2012.12.007
   Liu XM, 2012, APPL CATAL B-ENVIRON, V121, P50, DOI 10.1016/j.apcatb.2012.03.024
   Ma Z, 2004, J MOL CATAL A-CHEM, V216, P199, DOI 10.1016/j.molcata.2004.03.012
   Meng Q, 2018, CATAL SCI TECHNOL, V8, P5062, DOI 10.1039/c8cy01060a
   Nguyen MT, 2017, APPL CATAL A-GEN, V530, P132, DOI 10.1016/j.apcata.2016.11.015
   Narayanan S, 1998, APPL CATAL A-GEN, V168, P373, DOI 10.1016/S0926-860X(97)00368-2
   Pan HY, 2017, J CATAL, V354, P24, DOI 10.1016/j.jcat.2017.07.026
   Paulino PN, 2016, APPL CATAL B-ENVIRON, V185, P362, DOI 10.1016/j.apcatb.2015.12.037
   Peeters E, 2008, CATAL TODAY, V133, P299, DOI 10.1016/j.cattod.2007.12.127
   Prins R, 2001, ADV CATAL, V46, P399, DOI 10.1016/S0360-0564(02)46025-7
   Pushkarev VV, 2012, J CATAL, V292, P64, DOI 10.1016/j.jcat.2012.04.022
   Saih Y, 2005, APPL CATAL A-GEN, V295, P11, DOI 10.1016/j.apcata.2005.07.024
   Suresh C, 2012, ACS CATAL, V2, P127, DOI 10.1021/cs200385y
   Temperton RH, 2019, PHYS CHEM CHEM PHYS, V21, P1393, DOI 10.1039/c8cp06912c
   Nguyen TT, 2018, ENERG FUEL, V32, P1665, DOI 10.1021/acs.energyfuels.7b03781
   Vaiano V, 2016, APPL CATAL B-ENVIRON, V188, P134, DOI 10.1016/j.apcatb.2016.02.001
   Valles VA, 2017, CATAL TODAY, V282, P111, DOI 10.1016/j.cattod.2016.07.004
   Wan GF, 2009, ENERG FUEL, V23, P81, DOI 10.1021/ef8006905
   Wu QF, 2016, J COLLOID INTERF SCI, V463, P75, DOI 10.1016/j.jcis.2015.10.026
   Xie KC, 2010, ENERGY, V35, P4349, DOI 10.1016/j.energy.2009.05.029
   Zepeda TA, 2016, APPL CATAL B-ENVIRON, V180, P569, DOI 10.1016/j.apcatb.2015.07.013
NR 49
TC 1
Z9 1
U1 24
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1085
EP 1095
DI 10.1016/j.ces.2019.07.040
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300090
DA 2020-05-12
ER

PT J
AU Zheng, JN
   Jiang, LL
   Wang, PF
   Zhou, H
   Yang, MJ
AF Zheng, Jia-nan
   Jiang, Lanlan
   Wang, Pengfei
   Zhou, Hang
   Yang, Mingjun
TI MRI observation of CO2-C3H8 hydrate-induced water migration in glass
   sand
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas hydrate; Water migration; Carbon dioxide; Propane
ID CARBON-DIOXIDE; PHASE-EQUILIBRIUM; POROUS-MEDIA; GAS-MIXTURES; FLUE-GAS;
   CAPTURE; CO2; SEPARATION; HYDROGEN; PROPANE
AB Hydrate-induced water migration is an unusual behaviour that occurs in certain hydrate formation processes, such as in the formation of propane-containing hydrate. This study is the first to investigate the continuous, staged processes of constant-volume formation, constant-pressure reformation and exhaust dissociation of CO2-C3H8 hydrates using the magnetic resonance imaging (MRI) technique. Real-time MRI images indicate that the formation of CO2-C3H8 hydrates draw water from its surroundings, causing the local water saturation to increase. As the concentrated water can further form hydrates and extend to the gas phase, the water appears as though it climbs upward through the glass sand and hydrate zone towards the gas phase. Experiments under different formation pressures indicate that the locations of hydrate-induced water migration are uncertain and depend on hydrate nucleation. The evolution processes of hydrate-induced water migration under different initial pressures have good similarity. In addition, water migration will still occur during the reformation stage. The initial pressure has great effects on both the formation and dissociation of hydrate. In addition, faster dissociation may make the water move upward due to strong gas release. The findings in this study are significant to future research on propane-containing hydrate, especially for hydrate-based seawater desalination applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zheng, Jia-nan; Jiang, Lanlan; Wang, Pengfei; Zhou, Hang; Yang, Mingjun] Dalian Univ Technol, Minist Educ, Key Lab Ocean Energy Utilizat & Energy Conservat, Dalian 116024, Peoples R China.
RP Yang, MJ (reprint author), Dalian Univ Technol, Minist Educ, Key Lab Ocean Energy Utilizat & Energy Conservat, Dalian 116024, Peoples R China.
EM yangmj@dlut.edu.cn
OI Zheng, Jia-nan/0000-0003-4022-3017; Yang, Mingjun/0000-0001-6336-7617
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51436003, 51822603, 51576025]; National Key
   Research and Development Plan of China [2017YFC0307303, 2016YFC0304001];
   Fok Ying-Tong Education Foundation for Young Teachers in the Higher
   Education Institutions of ChinaFok Ying Tung Education Foundation
   [161050]; Fundamental Research Funds for the Central Universities of
   ChinaFundamental Research Funds for the Central Universities
   [DUT18ZD403]
FX This study was financially supported by grants from the National Natural
   Science Foundation of China (51436003, 51822603 and 51576025), the
   National Key Research and Development Plan of China (2017YFC0307303 and
   2016YFC0304001), the Fok Ying-Tong Education Foundation for Young
   Teachers in the Higher Education Institutions of China (161050) and the
   Fundamental Research Funds for the Central Universities of China
   (DUT18ZD403).
CR Babu P, 2014, CHEM ENG SCI, V117, P342, DOI 10.1016/j.ces.2014.06.044
   Babu P, 2013, J CHEM THERMODYN, V61, P58, DOI 10.1016/j.jct.2013.02.003
   Bagherzadeh SA, 2011, ENERG FUEL, V25, P3083, DOI 10.1021/ef200399a
   Chong ZR, 2017, APPL ENERG, V204, P1513, DOI 10.1016/j.apenergy.2017.04.031
   ENGLEZOS P, 1993, IND ENG CHEM RES, V32, P1251, DOI 10.1021/ie00019a001
   Eslamimanesh A, 2012, J CHEM THERMODYN, V46, P62, DOI 10.1016/j.jct.2011.10.006
   Fan SS, 2009, ENERG FUEL, V23, P4202, DOI 10.1021/ef9003329
   Gholinezhad J, 2011, CHEM ENG RES DES, V89, P1747, DOI 10.1016/j.cherd.2011.03.008
   Herslund PJ, 2012, J CHEM THERMODYN, V48, P13, DOI 10.1016/j.jct.2011.12.039
   Ho LC, 2013, ENERGY, V63, P252, DOI 10.1016/j.energy.2013.10.031
   KUPERMAN V, 2000, MAGNETIC RESONANCE I
   Li XS, 2010, IND ENG CHEM RES, V49, P11614, DOI 10.1021/ie100851u
   Li XS, 2010, ENERGY, V35, P3902, DOI 10.1016/j.energy.2010.06.009
   Li XS, 2011, J NAT GAS CHEM, V20, P647, DOI 10.1016/S1003-9953(10)60254-X
   Lim YA, 2013, CRYST GROWTH DES, V13, P2047, DOI 10.1021/cg400118p
   Liu Y, 2015, MAGN RESON IMAGING, V33, P918, DOI 10.1016/j.mri.2015.04.010
   Nambiar A, 2015, CAN J CHEM, V93, P808, DOI 10.1139/cjc-2014-0547
   Song YC, 2015, FUEL, V140, P126, DOI 10.1016/j.fuel.2014.09.086
   Veluswamy HP, 2015, J CHEM ENG DATA, V60, P228, DOI 10.1021/je500489d
   Wang PF, 2017, CHEMISTRYSELECT, V2, P6030, DOI 10.1002/slct.201700754
   Wang PF, 2017, CHEM ENG SCI, V168, P344, DOI 10.1016/j.ces.2017.04.036
   Yang MJ, 2018, APPL ENERG, V221, P374, DOI 10.1016/j.apenergy.2018.03.187
   Yang MJ, 2017, RENEW SUST ENERG REV, V74, P1346, DOI 10.1016/j.rser.2016.11.161
   Yang MJ, 2017, APPL ENERG, V187, P180, DOI 10.1016/j.apenergy.2016.10.029
   Yoslim J, 2010, J CRYST GROWTH, V313, P68, DOI 10.1016/j.jcrysgro.2010.10.009
   Zhang Y, 2015, IND ENG CHEM RES, V54, P2627, DOI 10.1021/ie5042885
   Zhao YC, 2011, IND ENG CHEM RES, V50, P4707, DOI 10.1021/ie1013019
   Zheng JJ, 2018, ACS SUSTAIN CHEM ENG, V6, P11913, DOI 10.1021/acssuschemeng.8b02187
NR 28
TC 2
Z9 2
U1 8
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1096
EP 1106
DI 10.1016/j.ces.2019.07.038
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300091
DA 2020-05-12
ER

PT J
AU Li, JG
   Agarwal, RK
   Zhou, L
   Yang, BL
AF Li, Jiageng
   Agarwal, Ramesh K.
   Zhou, Ling
   Yang, Bolun
TI Investigation of a bubbling fluidized bed methanation reactor by using
   CFD-DEM and approximate image processing method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD-DEM; Fluidized-bed methanation; Approximate image processing; Bubble
   properties; MFiX
ID CHEMICAL LOOPING COMBUSTION; BIOMASS GASIFICATION; NUMERICAL-SIMULATION;
   GAS; FLOW; MODEL; PARTICLES; EXPANSION; SCALE
AB Computational fluid dynamics and discrete element method (CFD-DEM) integrated with a new localstructure-dependent (LSD) drag model and modified reaction kinetics are used to simulate the bubbling fluidized bed methanation process. The nonlinear Hertzian model is employed to describe the particleparticle collision process. An approximate image processing method (AIPM) is developed to investigate the bubble properties in the reactive gas-solid fluidized bed, by which the bubbles can be located, measured, and tracked from the CFD-DEM results. The results of the bubble properties and reaction behavior are in good agreement with the correlations in the literature and the experimental data, respectively. The sensitivity study of particles Young's modulus indicates that this parameter has a minor influence on the simulation results but the simulation efficiency can be significantly improved by reducing this parameter. The feasibility of the isothermal flow assumption is also validated for simulations of the fluidized bed methanation process by the CFD-DEM method. In addition, the comparison between CFD-DEM and the two-fluid model (TFM) results shows that both models gave similar results for the reactor performance but the TFM provides smaller bubble size. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Jiageng; Yang, Bolun] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Shaanxi Key Lab Energy Chem Proc Intensificat, Xian 710049, Shaanxi, Peoples R China.
   [Li, Jiageng; Agarwal, Ramesh K.; Zhou, Ling] Washington Univ, Sch Engn & Appl Sci, St Louis, MO 63130 USA.
   [Zhou, Ling] Jiangsu Univ, Res Ctr Fluid Machinery Engn & Technol, Zhenjiang 212013, Jiangsu, Peoples R China.
RP Yang, BL (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Shaanxi Key Lab Energy Chem Proc Intensificat, Xian 710049, Shaanxi, Peoples R China.; Agarwal, RK (reprint author), Washington Univ, Sch Engn & Appl Sci, St Louis, MO 63130 USA.
EM blunyang@mail.xjtu.edu.cn
RI Li, Jiageng/AAC-1913-2019; Zhou, Ling/C-5721-2014
OI Agarwal, Ramesh/0000-0002-9642-1023; Zhou, Ling/0000-0001-9868-2561
FU Major Research Plan of National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [91334101]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [U1662117]; China Scholarship Council (CSC)China Scholarship
   Council [201806280146]
FX This work was supported by the Major Research Plan of National Natural
   Science Foundation of China (No. 91334101), and the National Natural
   Science Foundation of China (No. U1662117). Jiageng Li also supported by
   the China Scholarship Council (CSC) (No. 201806280146).
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Banerjee S, 2015, APPL ENERG, V160, P552, DOI 10.1016/j.apenergy.2015.10.013
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Fernandez XR, 2013, CHEM ENG SCI, V94, P7, DOI 10.1016/j.ces.2013.02.039
   Garg R., 2010, DOCUMENTATION OPEN S
   Hamidouche Z, 2019, CHEM ENG SCI, V193, P102, DOI 10.1016/j.ces.2018.08.032
   Hepbasli A, 1998, INT J ENERG RES, V22, P1365, DOI 10.1002/(SICI)1099-114X(199812)22:15<1365::AID-ER456>3.0.CO;2-Z
   Hilligardt K., 1986, GER CHEM ENG, V9, P215
   HORIO M, 1987, AICHE J, V33, P1865, DOI 10.1002/aic.690331113
   Jing L, 2019, POWDER TECHNOL, V345, P532, DOI 10.1016/j.powtec.2019.01.029
   Karimipour S, 2011, POWDER TECHNOL, V205, P1, DOI 10.1016/j.powtec.2010.09.016
   Kopyscinski J, 2010, J CATAL, V271, P262, DOI 10.1016/j.jcat.2010.02.008
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Li JG, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.08.204
   Li JG, 2019, AICHE J, V65, DOI 10.1002/aic.16561
   Li JG, 2017, CHEM ENG J, V329, P100, DOI 10.1016/j.cej.2017.05.164
   Li TW, 2012, POWDER TECHNOL, V220, P70, DOI 10.1016/j.powtec.2011.09.025
   Liu H, 2016, INT J HYDROGEN ENERG, V41, P11974, DOI 10.1016/j.ijhydene.2016.04.205
   Liu PY, 2016, CHEM ENG SCI, V145, P266, DOI 10.1016/j.ces.2016.02.024
   Liu YF, 2014, IND ENG CHEM RES, V53, P9348, DOI 10.1021/ie500774s
   Loha C, 2014, CHEM ENG SCI, V109, P53, DOI 10.1016/j.ces.2014.01.017
   MATSEN JM, 1969, CHEM ENG SCI, V24, P1743, DOI 10.1016/0009-2509(69)87018-1
   Nikolopoulos A, 2017, CHEM ENG SCI, V163, P189, DOI 10.1016/j.ces.2017.01.052
   Rong D., 1999, 2 INT C CFD MIN PROC, P65
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   Sun L, 2017, ENERG FUEL, V31, P10267, DOI 10.1021/acs.energyfuels.7b01781
   Varas AEC, 2017, IND ENG CHEM RES, V56, P5558, DOI 10.1021/acs.iecr.7b00366
   Zhang YL, 2015, POWDER TECHNOL, V275, P199, DOI 10.1016/j.powtec.2015.01.064
   Zhou ZY, 2009, AICHE J, V55, P868, DOI 10.1002/aic.11823
   Zhuang YQ, 2014, COMPUT CHEM ENG, V60, P1, DOI 10.1016/j.compchemeng.2013.08.007
NR 32
TC 0
Z9 0
U1 16
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1107
EP 1120
DI 10.1016/j.ces.2019.07.016
PG 14
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300092
DA 2020-05-12
ER

PT J
AU Choudhury, MD
   Das, S
   Roy, B
   Sengupta, S
   Tarafdar, S
   Karmakar, S
AF Choudhury, Moutushi Dutta
   Das, Saptarshi
   Roy, Biswajit
   Sengupta, Subhamita
   Tarafdar, Sujata
   Karmakar, Sanat
TI Salt crystal growth in interacting drops of a complex biopolymer:
   Statistical characterization using FESEM images
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drop-drying; Pattern formation; Crystal growth; Interacting drops; FESEM
   feature; Fractal analysis; Image texture analysis
ID CRACK FORMATION; PATTERNS; NANOPARTICLES; DROPLETS; IMPACT;
   ENCAPSULATION; EVAPORATION; FILMS
AB A simple colloidal drop generally forms ring like patterns after drying. The deposition morphology of the dried drop changes significantly when such a drop dries in the vicinity of another similar drop. Here we present an observational study and statistical analysis of the patterns formed inside an isolated as well as interacting drops of gelatin containing sodium sulfate (Na2SO4). In all the cases, multiple concentric regions of solute particles combined with the polymer gel appear as the drops dry up. Needle crystals of sulfur and coacervates of salt and gelatin are visible in some regions. The outer region becomes non-uniform, so does the size distribution of the needle crystals and coacervates. The non-uniformity increases with proximity of the drops. Here we propose a novel mechanism of growing patterns inside the single drop during drying and correlate that with the results obtained for interacting drops. This study and the proposed mechanism provide insights into the future studies of drying drops under different physical conditions. Further we explore the statistical characteristics of the single and interacting drops using the field emission scanning electron microscopy (FESEM) images. Next, we report fractal and image texture analyses along with object shape statistics of the drop FESEM images, under various experimental conditions. Several statistical hypothesis tests have been carried out to identify the most significant features. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Choudhury, Moutushi Dutta; Roy, Biswajit; Sengupta, Subhamita; Tarafdar, Sujata; Karmakar, Sanat] Jadavpur Univ, Condensed Matter Phys Res Ctr, Dept Phys, Kolkata 700032, India.
   [Das, Saptarshi] Univ Exeter, Coll Engn Math & Phys Sci, Dept Math, Penryn Campus, Penryn TR10 9FE, England.
   [Choudhury, Moutushi Dutta] Indian Inst Sci Educ & Res IISER Mohali, Mohali, Punjab, India.
   [Roy, Biswajit] Chakdaha Coll, Nadia 741223, W Bengal, India.
   [Sengupta, Subhamita] SN Bose Natl Ctr Basic Sci, Dept Condensed Matter Phys & Mat Sci, JD Block,Sect 3, Kolkata 700106, India.
RP Das, S (reprint author), Univ Exeter, Coll Engn Math & Phys Sci, Dept Math, Penryn Campus, Penryn TR10 9FE, England.
EM moutushi@iisermohali.ac.in; saptarshi.das@ieee.org
RI Das, Saptarshi/AAB-4003-2019
OI Das, Saptarshi/0000-0002-8394-5303
FU SERB, India [PDF/2016/001151/PMS]; DST, Govt. of IndiaDepartment of
   Science & Technology (India) [SR/S2/CMP-127/2012]; DSTDepartment of
   Science & Technology (India)
FX MDC thanks SERB, India for providing national post-doctoral fellowship
   (PDF/2016/001151/PMS). BR is grateful to DST, Govt. of India for funding
   this research through project No. SR/S2/CMP-127/2012. BR thanks DST for
   providing a Junior Research fellowship.
CR Alvarez-Puebla RA, 2011, P NATL ACAD SCI USA, V108, P8157, DOI 10.1073/pnas.1016530108
   Arifin AZ, 2006, PATTERN RECOGN LETT, V27, P1515, DOI 10.1016/j.patrec.2006.02.022
   Bradley Derek, 2007, Journal of Graphics Tools, V12, P13
   Brutin D, 2011, J FLUID MECH, V667, P85, DOI 10.1017/S0022112010005070
   Chatterjee SK, 2017, SENSOR ACTUAT B-CHEM, V249, P278, DOI 10.1016/j.snb.2017.04.071
   Chen LF, 2009, LANGMUIR, V25, P11299, DOI 10.1021/la902918m
   Choudhury MD, 2016, COLLOID SURFACE A, V492, P47, DOI 10.1016/j.colsurfa.2015.12.007
   Choudhury MD, 2015, SOFT MATTER, V11, P6938, DOI 10.1039/c5sm00742a
   Choudhury MD, 2013, COLLOID SURFACE A, V432, P110, DOI 10.1016/j.colsurfa.2013.04.064
   Deegan RD, 1997, NATURE, V389, P827, DOI 10.1038/39827
   Dong AG, 2010, NATURE, V466, P474, DOI 10.1038/nature09188
   Dutta T, 2013, COLLOID SURFACE A, V432, P127, DOI 10.1016/j.colsurfa.2013.04.040
   Edwards C, 2015, LANGMUIR, V31, P11020, DOI 10.1021/acs.langmuir.5b02148
   Fan JA, 2010, SCIENCE, V328, P1135, DOI 10.1126/science.1187949
   Feder J., 2013, FRACTALS
   Field A, 2012, DISCOVERING STAT USI
   Gibbons J.D., 2010, NONPARAMETRIC STAT I
   Haracz S, 2015, CRYST RES TECHNOL, V50, P791, DOI 10.1002/crat.201500091
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   He L, 2003, INT J PHARM, V250, P45, DOI 10.1016/S0378-5173(02)00478-7
   He R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5327
   Hu H, 2006, J PHYS CHEM B, V110, P7090, DOI 10.1021/jp0609232
   Huang XL, 2017, FOOD HYDROCOLLOID, V64, P157, DOI 10.1016/j.foodhyd.2016.10.029
   Jiao YC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7420
   Jing JP, 1998, P NATL ACAD SCI USA, V95, P8046, DOI 10.1073/pnas.95.14.8046
   Khatun T, 2013, LANGMUIR, V29, P15535, DOI 10.1021/la404297k
   Layani M, 2009, ACS NANO, V3, P3537, DOI 10.1021/nn901239z
   Lewandowski W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7590
   Loeb J, 1921, J GEN PHYSIOL, V4, P187, DOI 10.1085/jgp.4.2.187
   Maity D, 2011, J APPL POLYM SCI, V122, P2189, DOI 10.1002/app.34266
   Mal D, 2006, FRACTALS, V14, P283, DOI 10.1142/S0218348X06003301
   Nakanishi H, 2009, NATURE, V460, P371, DOI 10.1038/nature08131
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   PAPPAS TN, 1992, IEEE T SIGNAL PROCES, V40, P901, DOI 10.1109/78.127962
   Park J, 2006, LANGMUIR, V22, P3506, DOI 10.1021/la053450j
   Pradhan TK, 2016, COLLOID SURFACE A, V500, P154, DOI 10.1016/j.colsurfa.2016.03.073
   Pradhan TK, 2015, COLLOID SURFACE A, V482, P562, DOI 10.1016/j.colsurfa.2015.07.013
   Roy A, 1999, EUR PHYS J B, V12, P1, DOI 10.1007/s100510050966
   Roy B, 2015, APPL SURF SCI, V357, P1000, DOI 10.1016/j.apsusc.2015.09.085
   Rozin MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8325
   Sefiane K, 2014, ADV COLLOID INTERFAC, V206, P372, DOI 10.1016/j.cis.2013.05.002
   Shahidzadeh-Bonn N, 2008, LANGMUIR, V24, P8599, DOI 10.1021/la8005629
   Sinha S, 2009, IND ENG CHEM RES, V48, P8837, DOI 10.1021/ie801836r
   Sinha SD, 2017, IND ENG CHEM RES, V56, P9496, DOI 10.1021/acs.iecr.7b01106
   Tamas V., 1992, FRACTAL GROWTH PHENO
   Tao A, 2007, NAT NANOTECHNOL, V2, P435, DOI 10.1038/nnano.2007.189
   Tarafdar S, 2008, IND ENG CHEM RES, V47, P6459, DOI 10.1021/ie071375x
   Tarasevich YY, 2016, EUR PHYS J E, V39, DOI 10.1140/epje/i2016-16026-5
   Theodoridis S., 2010, INTRO PATTERN RECOGN
   Wang QQ, 2007, NANO LETT, V7, P723, DOI 10.1021/nl062964f
   Wong TS, 2011, ANAL CHEM, V83, P1871, DOI 10.1021/ac102963x
   Wong TW, 2011, J PHARM PHARMACOL, V63, P1497, DOI 10.1111/j.2042-7158.2011.01347.x
   Yakhno T, 2008, J COLLOID INTERF SCI, V318, P225, DOI 10.1016/j.jcis.2007.10.020
   Yoon B, 2014, NAT MATER, V13, P807, DOI [10.1038/NMAT3923, 10.1038/nmat3923]
   Zang DY, 2019, PHYS REP, V804, P1, DOI 10.1016/j.physrep.2019.01.008
   Zhang ZP, 2017, FOOD HYDROCOLLOID, V67, P85, DOI 10.1016/j.foodhyd.2017.01.005
   Zijlstra P, 2009, NATURE, V459, P410, DOI 10.1038/nature08053
NR 57
TC 0
Z9 0
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1121
EP 1139
DI 10.1016/j.ces.2019.07.037
PG 19
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300093
DA 2020-05-12
ER

PT J
AU Lee, HW
   Song, S
   Kim, HT
AF Lee, Hong Woon
   Song, Sinae
   Kim, Hee Taik
TI Improvement of pulverization efficiency for micro-sized particles
   grinding by uncooled high-temperature air jet mill using a computational
   simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microsizer; Grinding; Mill system; Jet mill; Uncooled type air jet mill;
   Pulverization
ID FLUIDIZED-BED; SILICA
AB The high-temperature-uncooled-developed air jet mill system (AJMS) is one of the most effective grinding technologies for uniformed particle size. AJMS is the core technology in raw material manufacturing technology to grind and classify materials efficiently with a classifier that crushes raw materials by high-pressure compressible nozzles at high temperature into micro size particles and separates them by the desired size by using the centrifugal force of the rotor. However, the characteristics of grinding and classifying are affected by internal factors with occurring of complexed physical phenomena. To overcome the challenge, we used a discrete element model (DEM) and Computational fluid dynamics (CFD) simulation to clarify the relationship of the correlation with the actual design variables by predicted the motion of particles with the operating conditions and obtained optimized conditions. This research is described pulverization models of the AJMS with particle-structure interactions through optimized design value from DEM. Based on these results, we suggest a design method of AJMS to grinding the ceramic particles 2.86 mu m of an average and 1.32 mu m of a standard deviation from 14,000 rpm of the classifying rotor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Hong Woon] Daega Powder Syst Co Ltd, Head Off & Seoul Factory, 22-31,Buil Ro 1Na Gil, Seoul Si, South Korea.
   [Lee, Hong Woon; Kim, Hee Taik] Hanyang Univ, Dept Mat Sci & Chem Engn, 1271 Sa 3 Dong, Ansan 426791, Gyeonggi Do, South Korea.
   [Song, Sinae; Kim, Hee Taik] Hanyang Univ, Dept Adv Mat Sci Engn, 1271 Sa 3 Dong, Ansan 426791, Gyeonggi Do, South Korea.
RP Kim, HT (reprint author), Hanyang Univ, Dept Mat Sci & Chem Engn, 1271 Sa 3 Dong, Ansan 426791, Gyeonggi Do, South Korea.
EM khtaik@hanyang.ac.kr
CR Berthiaux H, 1999, POWDER TECHNOL, V106, P88, DOI 10.1016/S0032-5910(99)00050-9
   Brosh T, 2014, POWDER TECHNOL, V257, P104, DOI 10.1016/j.powtec.2014.02.043
   Brosh T, 2011, GRANUL MATTER, V13, P765, DOI 10.1007/s10035-011-0286-z
   Godet-Morand L, 2002, POWDER TECHNOL, V128, P306, DOI 10.1016/S0032-5910(02)00172-9
   Jabbar A, 2016, IND CROP PROD, V84, P230, DOI 10.1016/j.indcrop.2015.12.052
   Kalman H, 2009, GRANUL MATTER, V11, P253, DOI 10.1007/s10035-009-0140-8
   Klimanek A, 2015, FUEL, V152, P131, DOI 10.1016/j.fuel.2014.10.058
   Levy E K, 2006, USE COAL DRYING REDU
   Mishra BK, 2003, INT J MINER PROCESS, V71, P73, DOI 10.1016/S0301-7516(03)00032-2
   Nykamp G, 2002, INT J PHARM, V242, P79, DOI 10.1016/S0378-5173(02)00150-3
   Palaniandy S, 2008, J MATER PROCESS TECH, V205, P119, DOI 10.1016/j.jmatprotec.2007.11.086
   Palaniandy S, 2008, MINER ENG, V21, P380, DOI 10.1016/j.mineng.2007.10.011
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Xu BH, 1997, CHEM ENG SCI, V52, P2785, DOI 10.1016/S0009-2509(97)00081-X
   Zhao QQ, 2002, POWDER TECHNOL, V122, P129, DOI 10.1016/S0032-5910(01)00408-9
   Zhao XY, 2009, J TAIWAN INST CHEM E, V40, P337, DOI 10.1016/j.jtice.2008.10.001
NR 16
TC 0
Z9 0
U1 7
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1140
EP 1147
DI 10.1016/j.ces.2019.07.025
PG 8
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300094
DA 2020-05-12
ER

PT J
AU Enzmann, F
   Holtmann, D
AF Enzmann, Franziska
   Holtmann, Dirk
TI Rational Scale-Up of a methane producing bioelectrochemical reactor to
   50 L pilot scale
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Scale-Up; Bioelectromethanogenesis; Bioelectrochemical systems;
   Microbial electrosynthesis; Similarity theory
ID MICROBIAL FUEL-CELLS; WASTE-WATER; MASS-TRANSFER; HYDROGEN;
   ELECTROSYNTHESIS; PERFORMANCE; CO2; OPTIMIZATION; PARAMETERS; DESIGN
AB The field of microbial electrosynthesis gained much attention since it allows the conversion of electrical energy into valuable chemicals. The technology is now on the turning point from lab scale to first industrial applications. We show a rational Scale-Up using similarity theory from a 1-L reactor to a 50-L reactor for the production of methane via bioelectromethanogenesis. Pure culture experiments with Methanococcus maripaludis were carried out. Since this was the largest pure culture bioelectromethanogenesis experiment shown so far, also the total methane production rate of 11.7 mmol/d was the highest reported. However, the space time yield was with 0.23 mmol/l*d only 16% of the yield reached in the lab scale reactor. The Coulombic and energy efficiency were much higher than in lab scale. Different reasons for this gap, especially inhibition by reactor material and low current densities, are discussed to avoid such losses in performance in future research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Enzmann, Franziska; Holtmann, Dirk] DECHEMA Res Inst, Ind Biotechnol, Theodor Heuss Allee 25, D-60486 Frankfurt, Germany.
RP Holtmann, D (reprint author), DECHEMA Res Inst, Ind Biotechnol, Theodor Heuss Allee 25, D-60486 Frankfurt, Germany.
EM holtmann@dechema.de
FU BMBFFederal Ministry of Education & Research (BMBF) [FKZ: 033RC013A]
FX The authors thank the BMBF for funding the project "MIKE Methanation of
   CO<INF>2</INF> from biogas by microbial electrosynthesis (FKZ:
   033RC013A) and all project partners for fruitful discussions.
CR AKITA K, 1974, IND ENG CHEM PROC DD, V13, P84, DOI 10.1021/i260049a016
   Andricacos P. C, 1999, ELECTROCHEMICAL PROC
   Babanova S, 2017, J ELECTROCHEM SOC, V164, pH3015, DOI 10.1149/2.0051703jes
   Beese-Vasbender PF, 2015, BIOELECTROCHEMISTRY, V102, P50, DOI 10.1016/j.bioelechem.2014.11.004
   Bensmann A, 2014, APPL ENERG, V134, P413, DOI 10.1016/j.apenergy.2014.08.047
   Bhandari H, 2012, NANOCOMPOSITES NEW T
   Blasco-Gomez R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040874
   Brown RK, 2014, BIORESOURCE TECHNOL, V163, P206, DOI 10.1016/j.biortech.2014.04.044
   Burkhardt M, 2013, APPL ENERG, V111, P74, DOI 10.1016/j.apenergy.2013.04.080
   Cheng SA, 2009, ENVIRON SCI TECHNOL, V43, P3953, DOI 10.1021/es803531g
   Choi O, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0426-0
   Cusick RD, 2011, APPL MICROBIOL BIOT, V89, P2053, DOI 10.1007/s00253-011-3130-9
   Deutzmann JS, 2015, MBIO, V6, DOI 10.1128/mBio.00496-15
   Durst F, 2008, FLUID MECH INTRO THE, P193, DOI [10.1007/978-3-540-71343-2_7, DOI 10.1007/978-3-540-71343-2_]
   Enzmann F, 2019, ENG LIFE SCI, V19, P121, DOI 10.1002/elsc.201800160
   Enzmann F, 2019, CHEM ENG SCI, V193, P133, DOI 10.1016/j.ces.2018.08.056
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   Giddings CGS, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00468
   Gil-Carrera L, 2011, BIORESOURCE TECHNOL, V102, P9593, DOI 10.1016/j.biortech.2011.08.026
   Gildemyn S, 2017, BIORESOURCE TECHNOL, V224, P358, DOI 10.1016/j.biortech.2016.11.088
   GUNTHER B, 1975, PHYSIOL REV, V55, P659
   Harnisch F, 2010, CHEM SOC REV, V39, P4433, DOI 10.1039/c003068f
   He Z, 2009, ENERG ENVIRON SCI, V2, P215, DOI 10.1039/b814914c
   Heidrich ES, 2014, BIORESOURCE TECHNOL, V173, P87, DOI 10.1016/j.biortech.2014.09.083
   Hiegemann H, 2016, BIORESOURCE TECHNOL, V218, P115, DOI 10.1016/j.biortech.2016.06.052
   Holtmann D, 2019, ADV BIOCHEM ENG BIOT, V167, P395, DOI 10.1007/10_2018_75
   Janicek A, 2014, BIOFUELS-UK, V5, P79, DOI [10.4155/bfs.13.69, 10.4155/BFS.13.69]
   Kadier A, 2016, ALEX ENG J, V55, P427, DOI 10.1016/j.aej.2015.10.008
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Kitching M, 2017, ENZYME MICROB TECH, V96, P1, DOI 10.1016/j.enzmictec.2016.09.002
   Krieg T, 2019, ADV BIOCHEM ENG BIOT, V167, P231, DOI 10.1007/10_2017_40
   Krieg T, 2018, ANGEW CHEM INT EDIT, V57, P1879, DOI 10.1002/anie.201711302
   Krieg T, 2017, APPL ENERG, V195, P942, DOI 10.1016/j.apenergy.2017.03.101
   Liang P, 2018, WATER RES, V141, P1, DOI 10.1016/j.watres.2018.04.066
   Logan BE, 2006, ENVIRON SCI TECHNOL, V40, P5181, DOI 10.1021/es0605016
   Logan BE, 2010, APPL MICROBIOL BIOT, V85, P1665, DOI 10.1007/s00253-009-2378-9
   Lohner ST, 2014, ISME J, V8, P1673, DOI 10.1038/ismej.2014.82
   Marques MPC, 2010, J CHEM TECHNOL BIOT, V85, P1184, DOI 10.1002/jctb.2387
   Mayer F, 2019, BIORESOURCE TECHNOL, V289, DOI 10.1016/j.biortech.2019.121706
   Meier K, 2013, POLYM TEST, V32, P1064, DOI 10.1016/j.polymertesting.2013.06.004
   Montes FJ, 1999, CHEM ENG SCI, V54, P3127, DOI 10.1016/S0009-2509(98)00314-5
   Nicolopoulou E. P, 2013, 18 INT S HIGH VOLT E, P434
   Recio-Garrido D, 2016, CHEM ENG J, V289, P180, DOI 10.1016/j.cej.2015.11.112
   Rosa LFM, 2017, ENG LIFE SCI, V17, P77, DOI 10.1002/elsc.201600105
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Strong PJ, 2015, ENVIRON SCI TECHNOL, V49, P4001, DOI 10.1021/es504242n
   Sulaymon A. H, 2012, ELECTROLYSIS, P111, DOI [10.5772/48728, DOI 10.5772/48728]
   ter Heijne A, 2019, ADV BIOCHEM ENG BIOT, V167, P203, DOI 10.1007/10_2017_15
   Vassilev I, 2018, ACS SUSTAIN CHEM ENG, V6, P8485, DOI 10.1021/acssuschemeng.8b00739
   Villano M, 2010, BIORESOURCE TECHNOL, V101, P3085, DOI 10.1016/j.biortech.2009.12.077
   WATANO S, 1995, CHEM PHARM BULL, V43, P1227
   Xu H, 2014, BIORESOURCE TECHNOL, V173, P392, DOI 10.1016/j.biortech.2014.09.127
   Zhang YM, 2010, INT J HYDROGEN ENERG, V35, P12020, DOI 10.1016/j.ijhydene.2010.08.064
NR 53
TC 3
Z9 3
U1 8
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1148
EP 1158
DI 10.1016/j.ces.2019.07.051
PG 11
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300095
DA 2020-05-12
ER

PT J
AU Kang, LX
   Jiang, YH
   Liu, YZ
AF Kang, Lixia
   Jiang, Yinghua
   Liu, Yongzhong
TI Impacts of synthesis schemes on economy and flexibility of hydrogen
   networks
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogen network; Synthesis scheme; Direct reuse/recycle; Purification
   reuse/recycle; Hydrogen header; Multiperiod operation
ID OPTIMAL-DESIGN; FLOW-RATE; OPTIMIZATION
AB This paper addresses impacts of three synthesis schemes, i.e. the direct scheme, the indirect scheme and the hybrid scheme on the economic and operational performances of hydrogen networks through a comprehensive comparative analysis. The synthesis models, flexibility analysis models and flexible design models for hydrogen networks with the three schemes are presented. The effects of different synthesis schemes on the network complexity, hydrogen consumption, total annual cost and operational flexibility of hydrogen network with single period operation and multiple period operation are studied. Results show that the direct scheme can always obtain a hydrogen network with the least connections and the highest total annual cost, whereas the other two schemes enable to generate hydrogen networks with the lower hydrogen costs and similar total annual costs. In a single period operation, the operational flexibility of the network can be improved to a certain extent, which depends strongly on the utilization efficiency of hydrogen sources and the amount of hydrogen utilities available. However, in a multiperiod operation, the hydrogen networks with indirect scheme are superior to the hydrogen networks with other two schemes in enhancing the operational flexibility due to the increases of the actual capacity redundancy and additional control variables. This work is also expected to provide a useful guidance for optimal synthesis of hydrogen networks with the desired economic and operational performances. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kang, Lixia; Jiang, Yinghua; Liu, Yongzhong] Xi An Jiao Tong Univ, Dept Chem Engn, Xian 710049, Shaanxi, Peoples R China.
   [Liu, Yongzhong] Minist Educ, Key Lab Thermofluid Sci & Engn, Xian 710049, Shaanxi, Peoples R China.
   [Kang, Lixia; Liu, Yongzhong] Shaanxi Key Lab Energy Chem Proc Intensificat, Xian 710049, Shaanxi, Peoples R China.
RP Liu, YZ (reprint author), Xi An Jiao Tong Univ, Dept Chem Engn, Xian 710049, Shaanxi, Peoples R China.
EM yzliu@mail.xjtu.edu.cn
OI Liu, Yongzhong/0000-0001-6624-7549
FU National Natural Science Foundation of China (NSFC), China's
   Post-doctoral Science Fund [21808179, 21878240, 21676211]; Key Research
   and Development Program of Shaanxi Province, China [2018 M633518]; 
   [2019GY-139];  [2018GY-072]
FX The authors gratefully acknowledge the funding by the projects (No.
   21808179, No. 21878240, and No. 21676211) sponsored by the National
   Natural Science Foundation of China (NSFC), China's Post-doctoral
   Science Fund (No. 2018 M633518), Key Research and Development Program of
   Shaanxi Province, China (No. 2019GY-139 and No. 2018GY-072)
CR Ahmad MI, 2010, J CLEAN PROD, V18, P889, DOI 10.1016/j.jclepro.2010.01.003
   Alves JJ, 2002, IND ENG CHEM RES, V41, P5759, DOI 10.1021/ie010558v
   Bandyopadhyay S, 2006, CHEM ENG J, V125, P99, DOI 10.1016/j.cej.2006.08.007
   Birjandi MRS, 2017, CHEM ENG RES DES, V117, P83, DOI 10.1016/j.cherd.2016.10.017
   Chiang YC, 2014, IND ENG CHEM RES, V53, P6006, DOI 10.1021/ie404068p
   Deng C, 2017, INT J HYDROGEN ENERG, V42, P19984, DOI 10.1016/j.ijhydene.2017.06.199
   Deng C, 2015, ENERGY, V90, P68, DOI 10.1016/j.energy.2015.05.054
   Deng C, 2014, APPL THERM ENG, V70, P1162, DOI 10.1016/j.applthermaleng.2014.04.036
   Deng C, 2014, INT J HYDROGEN ENERG, V39, P13049, DOI 10.1016/j.ijhydene.2014.06.129
   Foo DCY, 2006, IND ENG CHEM RES, V45, P5986, DOI 10.1021/ie051322k
   GROSSMANN IE, 1987, COMPUT CHEM ENG, V11, P675, DOI 10.1016/0098-1354(87)87011-4
   Hallale N, 2001, ADV ENVIRON RES, V6, P81, DOI 10.1016/S1093-0191(01)00112-5
   Jagannath A, 2017, AICHE J, V63, P3925, DOI 10.1002/aic.15771
   Jagannath A, 2014, IND ENG CHEM RES, V53, P19715, DOI 10.1021/ie5011004
   Jagannath A, 2014, IND ENG CHEM RES, V53, P16948, DOI 10.1021/ie5005042
   Jia N, 2011, ENERGY, V36, P4663, DOI 10.1016/j.energy.2011.03.040
   Jiao YQ, 2012, CHEM ENG RES DES, V90, P1553, DOI 10.1016/j.cherd.2012.02.016
   Jiao YQ, 2012, CONTROL ENG PRACT, V20, P1075, DOI 10.1016/j.conengprac.2012.04.010
   Jiao YQ, 2011, CHINESE J CHEM ENG, V19, P990
   Kang LX, 2018, INT J HYDROGEN ENERG, V43, P16638, DOI 10.1016/j.ijhydene.2018.07.044
   Kang LX, 2018, INT J HYDROGEN ENERG, V43, P861, DOI 10.1016/j.ijhydene.2017.11.032
   Li AH, 2018, CLEAN TECHNOL ENVIR, V20, P477, DOI 10.1007/s10098-018-1484-8
   Liang XQ, 2017, IND ENG CHEM RES, V56, P10733, DOI 10.1021/acs.iecr.7b01174
   Liang XQ, 2016, IND ENG CHEM RES, V55, P2574, DOI 10.1021/acs.iecr.5b04120
   [梁肖强 Liang Xiaoqiang], 2014, [化工进展, Chemical Industry and Engineering Progress], V33, P577
   Liao ZW, 2011, CHEM ENG SCI, V66, P821, DOI 10.1016/j.ces.2010.10.019
   Liao ZW, 2011, CHEM ENG SCI, V66, P813, DOI 10.1016/j.ces.2010.10.018
   Liao ZW, 2016, INT J HYDROGEN ENERG, V41, P5243, DOI 10.1016/j.ijhydene.2016.01.104
   Liu GL, 2013, CHEM ENG SCI, V88, P33, DOI 10.1016/j.ces.2012.11.010
   Lou JY, 2014, INT J HYDROGEN ENERG, V39, P1210, DOI 10.1016/j.ijhydene.2013.11.024
   Marques JP, 2017, INT J HYDROGEN ENERG, V42, P376, DOI 10.1016/j.ijhydene.2016.09.179
   Saw SY, 2011, CLEAN TECHNOL ENVIR, V13, P347, DOI 10.1007/s10098-010-0305-5
   Short M, 2018, CHEM ENG SCI, V178, P118, DOI 10.1016/j.ces.2017.12.019
   Wang XF, 2015, CHINESE J CHEM ENG, V23, P1536, DOI 10.1016/j.cjche.2015.04.004
   Wei LL, 2017, IND ENG CHEM RES, V56, P6703, DOI 10.1021/acs.iecr.7b00882
   Wu L, 2018, J CLEAN PROD, V192, P542, DOI 10.1016/j.jclepro.2018.05.014
   [张亮 Zhang Liang], 2010, [计算机与应用化学, Computers and Applied Chemistry], V27, P1361
   Zhou L, 2013, INT J HYDROGEN ENERG, V38, P2937, DOI 10.1016/j.ijhydene.2012.12.084
   Zhou L, 2012, INT J HYDROGEN ENERG, V37, P18163, DOI 10.1016/j.ijhydene.2012.08.151
NR 39
TC 1
Z9 1
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV 2
PY 2019
VL 207
BP 1159
EP 1174
DI 10.1016/j.ces.2019.07.041
PG 16
WC Engineering, Chemical
SC Engineering
GA IR7TR
UT WOS:000481644300096
DA 2020-05-12
ER

EF